Caloric	O
restriction	O
or	O
telmisartan	O
control	O
dyslipidemia	O
and	O
nephropathy	O
in	O
obese	O
diabetic	O
Zücker	O
rats	O
Zücker	O
diabetic	O
fatty	O
rat	O
;	O
Type	O
II	O
diabetes	O
;	O
Dyslipidaemia	O
;	O
Caloric	O
restriction	O
;	O
Telmisartan	O
;	O
Mildly	O
oxidized	O
LDL	O
The	O
obese	O
Zücker	O
diabetic	O
fatty	O
male	O
rat	O
(	O
ZDF	O
:	O
[UNK]	O
-	O
fa	O
)	O
is	O
an	O
animal	O
model	O
of	O
type	O
II	O
diabetes	O
associated	O
with	O
obesity	O
and	O
related	O
metabolic	O
disturbances	O
like	O
dyslipidaemia	O
and	O
diabetic	O
nephropathy	O
.	O
In	O
addition	O
,	O
diabetic	O
dyslipidaemia	O
has	O
been	O
linked	O
to	O
vascular	O
and	O
glomerular	O
damage	O
too	O
.	O
Dietary	O
fat	O
restriction	O
is	O
a	O
current	O
strategy	O
to	O
tackle	O
obesity	O
and	O
,	O
telmisartan	O
,	O
as	O
a	O
renoprotective	O
agent	O
,	O
may	O
mediate	O
cholesterol	O
efflux	O
by	O
activating	O
PPARγ	O
.	O
To	O
test	O
the	O
hypothesis	O
that	O
both	O
therapeutical	O
alternatives	O
may	O
influence	O
dyslipidaemia	O
and	O
nephropathy	O
in	O
the	O
ZDF	O
rat	O
,	O
we	O
studied	O
their	O
effect	O
on	O
development	O
of	O
diabetes	O
.	O
Male	O
Zücker	O
Diabetic	O
Fatty	O
(	O
ZDF	O
)	O
rats	O
received	O
a	O
low	O
-	O
calorie	O
diet	O
,	O
vehicle	O
or	O
telmisartan	O
for	O
9	O
weeks	O
.	O
Blood	O
samples	O
were	O
obtained	O
for	O
analyses	O
of	O
lipids	O
and	O
lipoproteins	O
,	O
LDL	O
-	O
oxidisability	O
,	O
HDL	O
structural	O
and	O
functional	O
properties	O
.	O
Urinalysis	O
was	O
carried	O
out	O
to	O
estimate	O
albumin	O
loss	O
.	O
At	O
the	O
end	O
of	O
the	O
experimental	O
period	O
,	O
rats	O
were	O
sacrificed	O
,	O
liver	O
extracted	O
and	O
APOA1	O
mRNA	O
quantified	O
.	O
Results	O
indicated	O
that	O
low	O
-	O
calorie	O
diet	O
and	O
telmisartan	O
can	O
slower	O
the	O
onset	O
of	O
overt	O
hyperglycaemia	O
and	O
renal	O
damage	O
assessed	O
as	O
albuminuria	O
.	O
Both	O
interventions	O
decreased	O
the	O
oxidative	O
susceptibility	O
of	O
LDL	O
and	O
hepatic	O
APOA1	O
mRNA	O
expression	O
but	O
only	O
dietary	O
restriction	O
lowered	O
hyperlipidaemia	O
.	O
Either	O
a	O
dietary	O
or	O
pharmacologic	B-methodology
interventions	I-methodology
with	O
telmisartan	O
have	O
important	O
beneficial	O
effects	O
in	O
terms	O
of	O
LDL	O
oxidative	O
susceptibility	O
and	O
progression	O
of	O
albuminuria	O
in	O
obesity	O
related	O
type	O
II	O
diabetes	O
.	O
Incidence	O
and	O
prevalence	O
of	O
obesity	O
and	O
diabetes	O
have	O
increased	O
considerably	O
in	O
recent	O
years	O
[	O
1	O
,	O
2	O
]	O
.	O

They	O
both	O
represent	O
a	O
major	O
public	O
health	O
concern	O
in	O
terms	O
of	O
morbidity	O
and	O
mortality	O
,	O
due	O
to	O
their	O
association	O
with	O
cardiovascular	O
disorders	O
,	O
resulting	O
from	O
metabolic	O
disturbances	O
(	O
atherogenic	O
dyslipidaemia	O
and	O
hyperglycaemia	O
)	O
,	O
inflammatory	O
status	O
and	O
endothelial	O
dysfunction	O
that	O
led	O
to	O
atherosclerosis	O
[	O
3	O
,	O
4	O
]	O
.	O
Zücker	O
obese	O
and	O
diabetic	O
rat	O
(	O
ZDF	O
/	O
Gmi	O
-	O
fa	O
)	O
is	O
an	O
animal	O
model	O
frequently	O
used	O
to	O
study	O
obesity	O
and	O
related	O
metabolic	O
disturbances	O
like	O
dyslipidaemia	O
and	O
non	O
-	O
insulin	O
dependent	O
diabetes	O
[	O
5	O
]	O
.	O
They	O
also	O
develop	O
diabetic	O
nephropathy	O
with	O
proteinuria	O
and	O
focal	O
glomerulosclerosis	O
that	O
end	O
in	O
renal	O
insufficiency	O
[	O
6	O
]	O
.	O
Low	O
serum	O
levels	O
of	O
HDL	O
cholesterol	O
(	O
HDL	O
-	O
c	O
)	O
are	O
consistently	O
associated	O
with	O
increased	O
risk	O
for	O
all	O
forms	O
of	O
atherosclerotic	O
disease	O
and	O
its	O
clinical	O
sequelae	O
,	O
including	O
myocardial	O
infarction	O
,	O
stroke	O
,	O
and	O
sudden	O
death	O
.	O
HDL	O
particles	O
have	O
been	O
studied	O
in	B-methodology
vitro	I-methodology
,	O
in	O
animal	B-methodology
models	I-methodology
,	O
and	O
in	O
humans	O
.	O
The	O
classical	O
function	O
of	O
HDL	O
is	O
reverse	O
cholesterol	O
transport	O
from	O
macrophages	O
.	O
However	O
,	O
HDL	O
particles	O
inhibit	O
many	O
inflammatory	O
activities	O
,	O
inhibit	O
oxidation	O
of	O
lipoproteins	O
and	O
cell	O
membranes	O
,	O
and	O
help	O
to	O
maintain	O
endothelial	O
function	O
and	O
integrity	O
too	O
.	O
They	O
also	O
exert	O
anticoagulant	O
effects	O
by	O
inhibiting	O
coagulation	O
proteins	O
and	O
platelet	O
aggregation	O
.	O
Furthermore	O
,	O
HDL	O
has	O
been	O
found	O
to	O
improve	O
beta	O
cell	O
survival	O
and	O
insulin	O
secretion	O
in	O
diabetic	O
patients	O
and	O
to	O
reduce	O
insulin	O
resistance	O
in	O
muscle	O
and	O
adipose	O
tissues	O
[	O
7	O
]	O
.	O
HDL	O
particles	O
are	O
very	O
heterogeneous	O
;	O
they	O
differ	O
in	O
shape	O
and	O
size	O
.	O
APOA1	O
plays	O
a	O
key	O
role	O
for	O
cholesterol	O
efflux	O
,	O
but	O
there	O
are	O
other	O
components	O
of	O
the	O
HDL	O
particle	O
such	O
as	O
apolipoproteins	O
,	O
antioxidant	O
enzymes	O
or	O
lipids	O
besides	O
cholesterol	O
that	O
confer	O
HDL	O
its	O
beneficial	O
properties	O
[	O
8	O
]	O
.	O

In	O
patients	O
with	O
certain	O
diseases	O
(	O
diabetes	O
,	O
cardiovascular	O
diseases	O
,	O
etc	O
.	O
)	O
,	O
the	O
different	O
proteins	O
and	O
lipids	O
commonly	O
found	O
in	O
HDL	O
particles	O
may	O
undergo	O
modifications	O
such	O
as	O
amino	O
acid	O
oxidation	O
,	O
protein	O
loss	O
,	O
proteolytic	O
degradation	O
,	O
protein	O
glycation	O
,	O
and	O
many	O
other	O
harmful	O
modifications	O
that	O
interfere	O
with	O
HDL	O
function	O
[	O
9	O
,	O
10	O
]	O
.	O
There	O
is	O
a	O
beneficial	O
effect	O
of	O
dietary	O
restriction	O
and	O
weight	O
reduction	O
on	O
the	O
hyperglycaemia	O
of	O
patients	O
with	O
obesity	O
-	O
associated	O
non	O
-	O
insulin	O
-	O
dependent	O
diabetes	O
mellitus	O
(	O
NIDDM	O
)	O
.	O
A	O
low	O
-	O
energy	O
diet	O
recommended	O
for	O
the	O
treatment	O
of	O
obesity	O
should	O
be	O
low	O
fat	O
(	O
25	O
-	O
35	O
%	O
total	O
energy	O
)	O
,	O
high	O
carbohydrate	O
,	O
high	O
protein	O
,	O
and	O
high	O
fiber	O
[	O
11	O
,	O
12	O
]	O
.	O
Caloric	O
restriction	O
in	O
obese	O
pre	O
-	O
diabetic	O
rats	O
prevents	O
hyperglycaemia	O
,	O
beta	O
-	O
cell	O
depletion	O
,	O
loss	O
of	O
beta	O
-	O
cell	O
GLUT	O
2	O
and	O
glucose	O
incompetence	O
[	O
21	O
]	O
.	O
Nuclear	O
PPARγ	O
receptor	O
is	O
a	O
transcription	O
factor	O
regulating	O
many	O
genes	O
related	O
to	O
adipogenesis	O
,	O
lipid	O
metabolism	O
and	O
insulin	O
sensitivity	O
[	O
13	O
]	O
.	O
Mainly	O
known	O
for	O
its	O
angiotensin	O
II	O
receptor	O
blocker	O
(	O
ARB	O
)	O
and	O
anti	O
-	O
hypertensive	O
action	O
,	O
telmisartan	O
is	O
also	O
a	O
partial	O
PPARγ	O
agonist	O
[	O
14	O
,	O
15	O
]	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
PPARγ	O
modulation	O
using	O
telmisartan	O
,	O
or	O
caloric	O
restriction	O
on	O
plasma	O
lipoprotein	O
profile	O
,	O
plasma	O
APOA1	O
and	O
its	O
hepatic	O
expression	O
,	O
in	O
an	O
early	O
stage	O
of	O
vascular	O
disease	O
(	O
with	O
or	O
without	O
albuminuria	O
)	O
in	O
obese	O
and	O
diabetic	O
Zücker	O
rats	O
.	O
Male	O
Zücker	O
obese	O
(	O
fa	O
/	O
fa	O
)	O
and	O
Male	O
Zücker	O
Diabetic	O
Fatty	O
(	O
ZDF	O
)	O
rats	O
,	O
weighing	O
250	O
–	O
300	O
g	O
(	O
purchased	O
at	O
8	O
weeks	O
of	O
age	O
from	O
Charles	O
River	O
,	O
Barcelona	O
,	O
Spain	O
)	O
,	O
were	O
used	O
for	O
experiments	O
.	O
Rats	O
,	O
housed	O
in	O
sterile	O
filter	O
-	O
top	O
cages	O
,	O
were	O
acclimatized	O
in	O
a	O
room	O
maintained	O
at	O
20°C	O
with	O
a	O
12	O
-	O
h	O
light	O
–	O
dark	O
cycle	O
for	O
10	O
days	O
,	O
allowed	O
ad	O
libitum	O
access	O
to	O
water	O
and	O
standard	O
chow	O
diet	O
(	O
Purina	O
LabDiet®	O
5008	O
diet	O
;	O
Purina	O
S	O
.	O
A	O
.	O
Spain	O
)	O
.	O

ZDF	O
rats	O
were	O
randomly	B-methodology
assigned	I-methodology
to	O
three	O
groups	O
of	O
eight	O
animals	O
each	O
:	O
a	O
low	O
-	O
calorie	O
diet	O
(	O
ZDFD	O
)	O
,	O
vehicle	O
(	O
ZDFV	O
)	O
or	O
treatment	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
telmisartan	O
,	O
ZDFT	O
)	O
.	O
In	O
addition	O
,	O
male	O
Zücker	O
rats	O
(	O
n	O
=	O
5	O
)	O
were	O
used	O
as	O
control	O
to	O
observe	O
the	O
early	O
effects	O
of	O
obesity	O
related	O
diabetes	O
.	O
Animals	O
in	O
the	O
hypocaloric	O
diet	O
were	O
fed	O
with	O
a	O
30	O
%	O
low	O
-	O
calorie	O
diet	O
(	O
Purina	O
LabDiet®	O
5008	O
diet	O
)	O
.	O
Telmisartan	O
(	O
Boehringer	O
Ingelheim	O
Pharma	O
KG	O
,	O
Ingelheim	O
,	O
Germany	O
)	O
was	O
dissolved	O
in	O
1	O
N	O
NaOH	O
and	O
then	O
in	O
water	O
,	O
and	O
the	O
solution	O
adjusted	O
at	O
pH	O
7	O
.	O
4	O
.	O
Telmisartan	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
)	O
or	O
the	O
vehicle	O
were	O
orally	O
administered	O
once	O
daily	O
in	O
the	O
morning	O
from	O
weeks	O
10	O
to	O
19	O
.	O
The	O
animals	O
were	O
handled	O
and	O
killed	O
always	O
observing	O
criteria	O
from	O
the	O
European	O
Union	O
for	O
care	O
and	O
use	O
of	O
laboratory	O
animals	O
in	O
research	O
,	O
and	O
the	O
protocol	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
for	O
Animal	O
Research	O
of	O
the	O
University	O
of	O
Zaragoza	O
.	O
Blood	O
samples	O
were	O
obtained	O
from	O
tail	O
vein	O
at	O
weeks	O
10	O
(	O
after	O
2	O
-	O
week	O
quarantine	O
)	O
,	O
14	O
,	O
and	O
19	O
,	O
after	O
an	O
18	O
h	O
-	O
fasting	O
period	O
.	O
Blood	O
samples	O
were	O
collected	O
in	O
heparin	O
coated	O
capillary	O
tubes	O
and	O
centrifuged	O
at	O
2000	O
g	O
for	O
5	O
min	O
.	O
At	O
the	O
moment	O
of	O
sacrifice	O
(	O
18	O
h	O
after	O
the	O
feeding	O
)	O
,	O
rats	O
were	O
anesthetized	O
with	O
1	O
ml	O
of	O
8	O
%	O
Avertine	O
(	O
Aldrich	O
Chemical	O
Co	O
.	O
,	O
Madrid	O
,	O
Spain	O
)	O
in	O
0	O
.	O
1	O
M	O
phosphate	O
,	O
pH	O
7	O
.	O
2	O
,	O
and	O
blood	O
drawn	O
from	O
hearts	O
.	O
Blood	O
was	O
collected	O
in	O
tubes	O
containing	O
1	O
g	O
/	O
l	O
sodium	O
EDTA	O
.	O
Liver	O
was	O
removed	O
and	O
quickly	O
frozen	O
in	O
liquid	O
N2	O
until	O
total	O
RNA	O
was	O
extracted	O
.	O
Twenty	O
-	O
four	O
-	O
hour	O
urine	O
samples	O
were	O
collected	O
from	O
all	O
animals	O
using	O
metabolic	O
cages	O
while	O
providing	O
food	O
and	O
water	O
.	O
After	O
urine	O
volume	O
was	O
measured	O
,	O
the	O
samples	O
were	O
centrifuged	O
at	O
1500	O
rpm	O
for	O
5	O
minutes	O
at	O
room	O
temperature	O
in	O
order	O
to	O
separate	O
the	O
supernatant	O
from	O
the	O
residue	O
.	O

Urinary	O
albumin	O
was	O
measured	O
with	O
an	O
immunoenzymatic	O
assay	O
method	O
Rat	O
Albumin	O
EIA	O
kit	O
(	O
SPI	O
bio	O
,	O
France	O
)	O
.	O
In	O
all	O
animals	O
,	O
plasma	O
creatinine	O
was	O
assayed	O
using	O
[UNK]	O
Creatinine	O
Assay	O
Kit	O
(	O
DICT	O
-	O
500	O
)	O
(	O
BioAssay	O
Hayward	O
,	O
CA	O
,	O
USA	O
)	O
,	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
and	O
glucose	O
were	O
determined	O
using	O
Vetscan	O
(	O
Abaxis	O
,	O
Inc	O
.	O
,	O
USA	O
)	O
,	O
analyzer	O
.	O
Total	O
plasma	O
cholesterol	O
,	O
triglyceride	O
(	O
corrected	O
for	O
free	O
glycerol	O
)	O
and	O
non	O
-	O
esterified	O
fatty	O
acids	O
(	O
NEFA	O
)	O
concentrations	O
were	O
quantified	O
enzymatically	O
in	O
a	O
microtiter	O
assay	O
using	O
commercial	O
kits	O
(	O
Thermo	O
scientific	O
,	O
Madrid	O
,	O
Spain	O
)	O
and	O
(	O
Wako	O
,	O
Madrid	O
,	O
Spain	O
)	O
.	O
Cardiolipid	O
(	O
Sigma	O
)	O
was	O
used	O
as	O
quality	B-methodology
control	I-methodology
.	O
Plasma	O
lipoprotein	O
profile	O
was	O
determined	O
in	O
100	O
μl	O
of	O
plasma	O
samples	O
by	O
fast	O
protein	O
liquid	O
chromatography	O
(	O
FPLC	O
)	O
gel	O
filtration	O
using	O
a	O
Superose	O
6B	O
column	O
(	O
Amersham	O
Pharmacia	O
,	O
Barcelona	O
,	O
Spain	O
)	O
,	O
and	O
the	O
total	O
cholesterol	O
in	O
each	O
fraction	O
was	O
measured	O
using	O
a	O
fluorometric	O
method	O
(	O
Amplex	O
Red	O
,	O
Molecular	O
Probes	O
,	O
USA	O
)	O
.	O
Apolipoprotein	O
,	O
APOA1	O
,	O
was	O
quantified	O
by	O
ELISA	O
using	O
specific	O
polyclonal	O
antibodies	O
(	O
Biodesign	O
,	O
Saco	O
,	O
ME	O
,	O
USA	O
)	O
,	O
as	O
previously	O
described	O
[	O
16	O
]	O
.	O
LDL	O
oxidisability	O
was	O
assessed	O
using	O
modified	O
procedures	O
of	O
Navab	O
et	O
al	O
.	O
[	O
17	O
]	O
to	O
determine	O
the	O
presence	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
by	O
measuring	O
the	O
conversion	O
of	O
2	O
’	O
,	O
7	O
’	O
-	O
dichlorofluorescein	O
diacetate	O
(	O
DCFH	O
-	O
DA	O
)	O
into	O
fluorescent	O
dichlorofluorescein	O
(	O
DCF	O
)	O
.	O
Briefly	O
,	O
the	O
FPLC	O
-	O
separated	O
LDL	O
fractions	O
(	O
5	O
μg	O
of	O
cholesterol	O
)	O
were	O
incubated	O
,	O
at	O
37°C	O
with	O
2	O
microg	O
of	O
DCFH	O
-	O
DA	O
,	O
in	O
25	O
μl	O
of	O
0	O
.	O
1	O
%	O
sodium	O
azide	O
and	O
100	O
μl	O
of	O
PBS	O
,	O
up	O
to	O
a	O
total	O
volume	O
of	O
150	O
μl	O
.	O

The	O
fluorescence	O
was	O
measured	O
after	O
3	O
h	O
of	O
incubation	O
at	O
485	O
nm	O
excitation	O
and	O
535	O
nm	O
emission	O
wavelengths	O
.	O
The	O
ability	O
of	O
HDL	O
to	O
inactivate	O
LDL	O
ROS	O
was	O
also	O
tested	O
.	O
RNA	O
from	O
each	O
liver	O
was	O
isolated	O
using	O
Tri	O
reagent	O
(	O
Sigma	O
)	O
.	O
DNA	O
contaminants	O
were	O
removed	O
by	O
TURBO	O
DNAse	O
treatment	O
using	O
the	O
DNA	O
removal	O
kit	O
from	O
AMBION	O
(	O
Austin	O
,	O
TX	O
,	O
USA	O
)	O
.	O
RNA	O
was	O
quantified	O
by	O
absorbance	O
at	O
260	O
and	O
280	O
nm	O
.	O
The	O
A260	O
/	O
280	O
ratio	O
did	O
not	O
vary	O
significantly	O
among	O
groups	O
.	O
The	O
integrity	O
of	O
the	O
28S	O
and	O
18S	O
ribosomal	O
RNAs	O
was	O
verified	O
by	O
1	O
%	O
agarose	O
gel	O
electrophoresis	O
of	O
500	O
ng	O
of	O
total	O
RNA	O
.	O
Ethidium	O
-	O
bromide	O
stained	O
gels	O
were	O
exposed	O
to	O
UV	O
light	O
and	O
images	O
were	O
captured	O
(	O
BioRad	O
,	O
Madrid	O
,	O
SpA	O
-	O
In	O
)	O
.	O
Intensity	O
of	O
bands	O
for	O
each	O
condition	O
was	O
calculated	O
using	O
Quantity	O
One®	O
software	O
version	O
4	O
.	O
5	O
.	O
0	O
(	O
BioRad	O
)	O
.	O
The	O
28S	O
/	O
18S	O
ratio	O
did	O
not	O
differ	O
among	O
groups	O
.	O
RNA	O
integrity	O
number	O
(	O
RIN	O
)	O
from	O
samples	O
was	O
obtained	O
by	O
RNA	O
nano	O
kit	O
using	O
an	O
Agilent	O
2100	O
Bioanalyzer	O
.	O
RIN	O
values	O
were	O
not	O
significantly	O
different	O
among	O
tested	O
groups	O
.	O
The	O
mRNA	O
expression	O
was	O
analysed	O
by	O
reverse	O
transcriptase	O
and	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
qPCR	O
)	O
.	O
Equal	O
amounts	O
of	O
DNA	O
-	O
free	O
RNA	O
from	O
each	O
sample	O
of	O
each	O
animal	O
were	O
used	O
.	O
First	O
-	O
strand	O
cDNA	O
synthesis	O
and	O
the	O
PCRs	O
were	O
performed	O
using	O
the	O
SuperScript	O
II	O
Platinum	O
Two	O
-	O
Step	O
RT	O
-	O
qPCR	O
Kit	O
with	O
SYBR	O
Green	O
(	O
Invitrogen	O
,	O
Madrid	O
,	O
Spain	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
and	O
as	O
previously	O
described	O
[	O
18	O
]	O
.	O
Primers	O
were	O
designed	O
by	O
Primer	O
Express®	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
and	O
checked	O
by	O
BLAST	O
analysis	O
(	O
NCBI	O
)	O
to	O
verify	O
specificity	O
and	O
selective	O
amplification	O
of	O
the	O
target	O
gene	O
as	O
well	O
as	O
to	O
get	O
amplification	O
of	O
the	O
cDNA	O
and	O
not	O
of	O
genomic	O
DNA	O
.	O
The	O
sequences	O
have	O
been	O
published	O
[	O
19	O
]	O
.	O

Real	O
time	O
PCRs	O
were	O
performed	O
in	O
an	O
ABI	O
PRISM	O
7700	O
Sequence	O
Detector	O
(	O
Applied	O
Biosystems	O
)	O
following	O
the	O
standard	O
procedure	O
.	O
The	O
specificity	O
of	O
the	O
PCR	O
was	O
confirmed	O
by	O
observing	O
a	O
single	O
dissociation	O
curve	O
and	O
no	O
template	O
controls	O
were	O
carried	O
out	O
to	O
reject	O
unintended	O
amplification	O
.	O
Each	O
sample	O
was	O
analyzed	O
in	O
duplicate	O
obtaining	O
an	O
average	O
Cq	O
for	O
sample	O
.	O
The	O
relative	O
amount	O
of	O
all	O
mRNAs	O
was	O
calculated	O
using	O
the	O
comparative	O
2	O
-	O
ΔΔCq	O
method	O
and	O
normalized	O
to	O
the	O
reference	O
Rn18s	O
mRNA	O
expression	O
[	O
17	O
]	O
.	O
The	O
results	O
are	O
expressed	O
as	O
means	O
±	O
SD	O
.	O
Comparisons	O
were	O
made	O
using	O
one	O
-	O
way	O
ANOVA	O
and	O
the	O
Tukey	O
-	O
Kramer	O
multiple	O
comparison	O
test	O
(	O
post	O
hoc	O
)	O
when	O
the	O
distribution	O
of	O
the	O
variables	O
was	O
normal	O
.	O
When	O
the	O
variables	O
did	O
not	O
show	O
such	O
a	O
distribution	O
(	O
according	O
to	O
the	O
Shapiro	O
-	O
Wilk	O
test	O
)	O
,	O
or	O
failed	O
to	O
show	O
homology	O
of	O
variance	O
,	O
comparisons	O
were	O
calculated	O
by	O
the	O
Mann	O
–	O
Whitney	O
U	O
-	O
test	O
.	O
Correlations	O
between	O
variables	O
were	O
sought	O
using	O
the	O
Pearson	O
or	O
Spearman	O
correlation	O
coefficients	O
.	O
SPSS	O
version	O
15	O
.	O
0	O
(	O
SPSS	O
Inc	O
,	O
Chicago	O
,	O
IL	O
)	O
were	O
used	O
for	O
calculations	O
.	O
Significance	O
was	O
set	O
at	O
P	O
<	O
0	O
.	O
05	O
.	O
As	O
shown	O
in	O
Table	O
1	O
,	O
mean	O
body	O
weight	O
increased	O
progressively	O
during	O
study	O
period	O
in	O
all	O
animals	O
with	O
a	O
trend	O
to	O
a	O
slower	O
weight	O
gain	O
in	O
the	O
obese	O
and	O
diabetic	O
Zücker	O
rats	O
when	O
no	O
treatment	O
was	O
administered	O
(	O
vehicle	O
)	O
.	O
At	O
19	O
weeks	O
of	O
age	O
,	O
mean	O
body	O
weight	O
was	O
only	O
slightly	O
greater	O
in	O
that	O
vehicle	O
group	O
.	O
The	O
greater	O
weight	O
increase	O
is	O
statistically	O
significant	O
in	O
the	O
non	O
-	O
diabetic	O
and	O
the	O
diabetic	O
groups	O
subjected	O
to	O
caloric	O
restriction	O
versus	O
the	O
vehicle	O
group	O
.	O
Conversely	O
we	O
clearly	O
see	O
a	O
marked	O
increase	O
in	O
hyperglycaemia	O
in	O
that	O
vehicle	O
group	O
over	O
time	O
,	O
with	O
statistically	O
significant	O
differences	O
versus	O
the	O
other	O
obese	O
and	O
diabetic	O
animals	O
that	O
were	O
subjected	O
to	O
any	O
of	O
the	O
interventions	O
.	O
Urinary	O
excretion	O
of	O
albumin	O
gradually	O
increased	O
in	O
all	O
groups	O
as	O
shown	O
in	O
Table	O
2	O
.	O

At	O
19	O
weeks	O
,	O
non	O
-	O
diabetic	O
obese	O
Zücker	O
rats	O
showed	O
only	O
a	O
slight	O
increase	O
in	O
urinary	O
excretion	O
,	O
ranging	O
from	O
traces	O
to	O
microalbuminuria	O
,	O
whereas	O
the	O
urinary	O
excretion	O
of	O
albumin	O
in	O
the	O
vehicle	O
group	O
at	O
the	O
completion	O
of	O
the	O
experiment	O
was	O
10	O
times	O
higher	O
and	O
only	O
3	O
to	O
4	O
times	O
in	O
the	O
other	O
two	O
groups	O
of	O
diabetic	O
rats	O
(	O
telmisartan	O
and	O
calorie	O
-	O
restricted	O
diet	O
)	O
.	O
The	O
increase	O
in	O
urinary	O
albumin	O
excretion	O
was	O
significantly	O
higher	O
in	O
the	O
vehicle	O
group	O
versus	O
telmisartan	O
and	O
diet	O
restricted	O
groups	O
.	O
No	O
statistically	O
significant	O
difference	O
between	O
caloric	O
-	O
restricted	O
and	O
telmisartan	O
-	O
treated	O
animals	O
was	O
observed	O
despite	O
a	O
trend	O
towards	O
a	O
slower	O
increase	O
in	O
the	O
urinary	O
albumin	O
excretion	O
in	O
the	O
drug	O
group	O
.	O
Renal	O
function	O
and	O
plasma	O
creatinine	O
values	O
did	O
not	O
experience	O
any	O
significant	O
change	O
.	O
NEFA	O
,	O
triglycerides	O
,	O
total	O
cholesterol	O
and	O
HDL	O
-	O
cholesterol	O
values	O
are	O
summarized	O
in	O
Table	O
3	O
.	O
No	O
statistically	O
significant	O
differences	O
were	O
found	O
in	O
circulating	O
NEFA	O
,	O
whereas	O
a	O
marked	O
and	O
similar	O
increase	O
in	O
plasma	O
triglycerides	O
was	O
shown	O
in	O
the	O
groups	O
of	O
obese	O
and	O
diabetic	O
rats	O
that	O
there	O
were	O
not	O
on	O
a	O
restricted	O
diet	O
regardless	O
of	O
they	O
received	O
vehicle	O
or	O
telmisartan	O
treatment	O
.	O
Values	O
in	O
the	O
non	O
-	O
diabetic	O
and	O
the	O
diabetic	O
with	O
caloric	O
restriction	O
groups	O
were	O
only	O
slightly	O
different	O
(	O
lower	O
in	O
the	O
first	O
one	O
)	O
,	O
and	O
both	O
significantly	O
different	O
from	O
drug	O
-	O
or	O
-	O
vehicle	O
-	O
treated	O
animals	O
(	O
Figure	O
1	O
)	O
.	O
At	O
the	O
end	O
of	O
experimental	B-methodology
intervention	I-methodology
,	O
hyperlipidaemia	O
in	O
all	O
groups	O
was	O
mainly	O
due	O
to	O
elevated	O
triglycerides	O
with	O
modest	O
increases	O
in	O
total	O
cholesterol	O
,	O
particularly	O
HDL	O
cholesterol	O
levels	O
,	O
with	O
the	O
exception	O
of	O
the	O
low	O
-	O
calorie	O
diet	O
group	O
in	O
which	O
total	O
cholesterol	O
and	O
its	O
HDL	O
fraction	O
were	O
significantly	O
less	O
than	O
a	O
half	O
than	O
the	O
others	O
.	O
Moderate	O
correlation	O
between	O
serum	O
triglyceride	O
concentration	O
and	O
albumin	O
urinary	O
excretion	O
at	O
week	O
19	O
was	O
also	O
found	O
(	O
R	O
=	O
0	O
.	O
530	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
Plasma	O
APOA1	O
concentration	O
and	O
its	O
mRNA	O
hepatic	O
expression	O
are	O
shown	O
in	O
Table	O
3	O
.	O

Plasma	O
levels	O
in	O
the	O
non	O
-	O
diabetic	O
rats	O
were	O
significantly	O
lower	O
than	O
the	O
others	O
regardless	O
of	O
cholesterol	O
and	O
HDL	O
-	O
cholesterol	O
concentration	O
.	O
In	O
contrast	O
,	O
the	O
obese	O
and	O
diabetic	O
rats	O
showed	O
a	O
trend	O
towards	O
higher	O
plasma	O
concentration	O
.	O
Either	O
in	O
the	O
telmisartan	O
or	O
in	O
the	O
low	O
-	O
calorie	O
groups	O
plasma	O
APOA1	O
levels	O
were	O
lower	O
than	O
in	O
the	O
vehicle	O
group	O
(	O
diet	O
vs	O
vehicle	O
,	O
p	O
=	O
0	O
.	O
05	O
)	O
.	O
APOA1	O
hepatic	O
mRNA	O
expression	O
showed	O
statistically	O
significant	O
differences	O
between	O
the	O
obese	O
and	O
diabetic	O
animals	O
that	O
were	O
on	O
restricted	O
diet	O
compared	O
to	O
the	O
vehicle	O
ones	O
,	O
in	O
which	O
values	O
were	O
higher	O
(	O
Figure	O
2	O
)	O
.	O
LDL	O
and	O
LDL	O
+	O
HDL	O
from	O
each	O
group	O
were	O
incubated	O
and	O
oxidation	O
was	O
tested	O
with	O
the	O
DCF	O
method	O
[	O
17	O
]	O
.	O
Results	O
are	O
summarized	O
in	O
Table	O
4	O
.	O
ROS	O
content	O
in	O
LDL	O
was	O
markedly	O
lower	O
in	O
the	O
diet	O
restricted	O
group	O
,	O
suggesting	O
less	O
oxidation	O
of	O
this	O
lipoprotein	O
,	O
whereas	O
higher	O
signals	O
were	O
obtained	O
from	O
de	O
non	O
-	O
diabetic	O
and	O
the	O
diabetic	O
with	O
vehicle	O
treatment	O
obese	O
groups	O
.	O
After	O
incubating	O
LDL	O
of	O
each	O
group	O
with	O
its	O
own	O
HDL	O
,	O
very	O
little	O
fluorescent	O
signal	O
change	O
was	O
found	O
for	O
all	O
groups	O
with	O
the	O
exception	O
of	O
the	O
obese	O
and	O
diabetic	O
rats	O
receiving	O
vehicle	O
,	O
where	O
the	O
signal	O
decreased	O
substantially	O
.	O
At	O
the	O
end	O
of	O
the	O
study	O
in	O
a	O
bivariate	O
analyses	O
,	O
we	O
found	O
significant	O
correlations	O
between	O
the	O
increase	O
in	O
the	O
urinary	O
albumin	O
excretion	O
and	O
the	O
glycaemia	O
(	O
R	O
=	O
0	O
.	O
74	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
APOA1	O
also	O
showed	O
a	O
positive	O
correlation	O
with	O
the	O
urinary	O
albumin	O
excretion	O
(	O
R	O
=	O
0	O
.	O
66	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
while	O
body	O
weight	O
increase	O
was	O
inversely	O
correlated	O
(	O
R	O
=	O
-	O
0	O
.	O
73	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
Results	O
of	O
the	O
correlation	O
between	O
LDL	O
oxidisability	O
using	O
DCF	O
test	O
with	O
and	O
without	O
HDL	O
,	O
its	O
average	O
fluorescent	O
signal	O
of	O
the	O
difference	O
,	O
and	O
media	O
of	O
urinary	O
albumin	O
excretion	O
are	O
depicted	O
in	O
Figure	O
3	O
.	O
Good	O
correlations	O
were	O
also	O
found	O
between	O
DCF	O
signal	O
difference	O
between	O
LDL	O
and	O
LDL	O
+	O
HDL	O
and	O
the	O
increase	O
in	O
the	O
urinary	O
albumin	O
excretion	O
(	O
R	O
=	O
0	O
.	O
63	O
)	O
and	O
inversely	O
body	O
weight	O
increase	O
(	O
R	O
=	O
-	O
0	O
.	O
64	O
)	O
.	O

The	O
ZDF	O
rat	O
is	O
an	O
inbred	O
rat	B-methodology
model	I-methodology
obtained	O
through	O
selective	O
breeding	O
(	O
fa	O
mutation	O
)	O
that	O
results	O
in	O
shortened	O
leptin	O
receptor	O
which	O
does	O
not	O
effectively	O
interact	O
with	O
leptin	O
and	O
is	O
phenotypically	O
expressed	O
as	O
obesity	O
with	O
high	O
levels	O
of	O
leptin	O
in	O
the	O
blood	O
.	O
When	O
fed	O
with	O
a	O
diet	O
of	O
Purina	O
5008	O
,	O
homozygote	O
recessive	O
males	O
(	O
fa	O
/	O
fa	O
)	O
develop	O
obesity	O
,	O
hyperlipidemia	O
,	O
fasting	O
hyperglycaemia	O
and	O
non	O
-	O
insulin	O
dependent	O
diabetes	O
(	O
NIDDM	O
)	O
.	O
We	O
observed	O
a	O
trend	O
towards	O
high	O
glucose	O
plasma	O
concentration	O
in	O
all	O
groups	O
since	O
the	O
first	O
time	O
point	O
.	O
At	O
week	O
10	O
,	O
hyperglycaemia	O
was	O
modestly	O
higher	O
in	O
the	O
vehicle	O
group	O
in	O
which	O
diabetes	O
seems	O
to	O
develop	O
earlier	O
whereas	O
low	O
-	O
calorie	O
diet	O
could	O
delay	O
the	O
onset	O
of	O
a	O
diabetic	O
state	O
similar	O
to	O
obese	O
non	O
-	O
diabetic	O
Zücker	O
rats	O
.	O
Nine	O
weeks	O
later	O
,	O
the	O
plasma	O
glucose	O
level	O
in	O
the	O
vehicle	O
group	O
was	O
up	O
to	O
three	O
times	O
higher	O
than	O
in	O
the	O
non	O
-	O
diabetic	O
one	O
,	O
and	O
almost	O
two	O
times	O
than	O
in	O
the	O
diet	O
restricted	O
group	O
.	O
This	O
rapid	O
increase	O
in	O
glucose	O
level	O
in	O
the	O
vehicle	O
group	O
due	O
to	O
an	O
overt	O
diabetic	O
state	O
was	O
partially	O
controlled	O
by	O
both	O
interventions	O
with	O
telmisartan	O
or	O
low	O
-	O
calorie	O
diet	O
.	O
On	O
the	O
contrary	O
,	O
greater	O
weight	O
increase	O
rate	O
was	O
found	O
in	O
the	O
non	O
-	O
diabetic	O
animals	O
and	O
minor	O
in	O
the	O
diabetic	O
vehicle	O
group	O
,	O
whereas	O
rats	O
subjected	O
to	O
caloric	O
restriction	O
or	O
telmisartan	O
showed	O
moderate	O
increase	O
during	O
experiment	O
.	O
In	O
work	O
by	O
Corsetti	O
et	O
al	O
.	O
as	O
hyperglycaemia	O
developed	O
with	O
a	O
higher	O
dietary	O
fat	O
-	O
content	O
weight	O
increased	O
slower	O
[	O
20	O
]	O
.	O
Ohneda	O
et	O
al	O
.	O
also	O
showed	O
that	O
when	O
ZDF	O
rats	O
are	O
fed	O
with	O
an	O
unrestricted	O
diet	O
they	O
became	O
hyperglycaemic	O
by	O
8	O
weeks	O
of	O
age	O
,	O
whereas	O
all	O
diet	O
-	O
matched	O
rats	O
remained	O
euglycaemic	O
despite	O
the	O
fact	O
that	O
at	O
18	O
weeks	O
of	O
age	O
their	O
mean	O
body	O
weight	O
equalled	O
that	O
of	O
obese	O
rats	O
on	O
an	O
unrestricted	O
diet	O
[	O
21	O
]	O
.	O

As	O
we	O
could	O
see	O
,	O
rats	O
on	O
a	O
moderate	O
caloric	O
restriction	O
diet	O
with	O
a	O
well	O
-	O
adjusted	O
nutrient	O
content	O
showed	O
a	O
normal	O
growth	O
whereas	O
animals	O
on	O
an	O
unrestricted	O
diet	O
had	O
only	O
a	O
markedly	O
increase	O
in	O
body	O
fat	O
content	O
but	O
weight	O
increase	O
was	O
hindered	O
by	O
the	O
severe	O
catabolic	O
state	O
associated	O
with	O
earlier	O
and	O
more	O
severe	O
diabetes	O
as	O
it	O
was	O
suggested	O
by	O
Corsetti	O
and	O
colleagues	O
.	O
Telmisartan	O
can	O
modulate	O
PPARγ	O
by	O
improving	O
insulin	O
sensitivity	O
without	O
fluid	O
retention	O
[	O
14	O
]	O
.	O
Upton	O
et	O
al	O
.	O
demonstrated	O
that	O
ZDF	O
rats	O
treated	O
with	O
experimental	O
thiazolidinedione	O
MCC	O
-	O
555	O
improved	O
metabolic	O
status	O
and	O
insulin	O
sensitivity	O
,	O
and	O
had	O
a	O
small	O
but	O
significant	O
increase	O
in	O
body	O
weight	O
gain	O
during	O
experimental	O
period	O
whereas	O
vehicle	O
-	O
treated	O
animals	O
did	O
not	O
[	O
22	O
]	O
.	O
Despite	O
the	O
marked	O
hyperphagia	O
in	O
diabetic	O
ZDF	O
rats	O
,	O
they	O
do	O
not	O
continue	O
to	O
gain	O
weight	O
after	O
15	O
–	O
20	O
weeks	O
of	O
age	O
due	O
to	O
heavy	O
losses	O
of	O
energy	O
as	O
glycosuria	O
and	O
higher	O
catabolism	O
.	O
The	O
body	O
weight	O
gain	O
in	O
diabetic	O
ZDF	O
rats	O
following	O
telmisartan	O
treatment	O
is	O
probably	O
the	O
result	O
of	O
increase	O
glucose	O
entry	O
into	O
adipose	O
tissue	O
and	O
the	O
conversion	O
into	O
triglycerides	O
.	O
Urinary	O
loss	O
of	O
albumin	O
in	O
the	O
vehicle	O
treated	O
diabetic	O
group	O
was	O
significantly	O
higher	O
than	O
groups	O
on	O
caloric	O
restricted	O
diet	O
or	O
telmisartan	O
treatment	O
at	O
week	O
19	O
,	O
but	O
also	O
since	O
week	O
14	O
(	O
data	O
not	O
shown	O
)	O
,	O
as	O
well	O
as	O
the	O
increase	O
in	O
albuminuria	O
since	O
the	O
starting	O
point	O
at	O
the	O
experimental	O
period	O
.	O
Albuminuria	O
correlates	O
with	O
endothelial	O
dysfunction	O
and	O
predicts	O
cardiovascular	O
outcomes	O
by	O
its	O
predisposition	O
to	O
systemic	O
atherosclerosis	O
[	O
23	O
]	O
.	O
With	O
increasing	O
age	O
,	O
fa	O
/	O
fa	O
-	O
rats	O
spontaneously	O
develop	O
proteinuria	O
and	O
focal	O
segmental	O
glomerulosclerosis	O
(	O
FSGS	O
)	O
,	O
eventually	O
leading	O
to	O
renal	O
failure	O
[	O
24	O
]	O
.	O
The	O
development	O
of	O
proteinuria	O
and	O
/	O
or	O
FSGS	O
in	O
fa	O
/	O
fa	O
-	O
rats	O
can	O
be	O
ameliorated	O
by	O
treatment	O
with	O
a	O
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methyl	O
-	O
glutaryl	O
-	O
coenzyme	O
A	O
(	O
HMG	O
-	O
CoA	O
)	O
reductase	O
inhibitor	O
[	O
25	O
]	O
.	O

When	O
studying	O
diabetic	O
ZDF	O
,	O
Coimbra	O
et	O
al	O
.	O
showed	O
that	O
the	O
animals	O
exhibited	O
pronounced	O
hyperinsulinemia	O
and	O
hyperlipidaemia	O
at	O
6	O
weeks	O
and	O
became	O
diabetic	O
after	O
14	O
weeks	O
of	O
age	O
.	O
Significant	O
FSGS	O
nephropathy	O
was	O
first	O
noted	O
in	O
18	O
-	O
week	O
-	O
old	O
fa	O
/	O
fa	O
-	O
rats	O
and	O
tubulointerstitial	O
damage	O
and	O
proteinuria	O
in	O
40	O
-	O
week	O
-	O
old	O
fa	O
/	O
fa	O
-	O
rats	O
but	O
progressive	O
glomerular	O
hypertrophy	O
was	O
already	O
detected	O
in	O
diabetic	O
fa	O
/	O
fa	O
rats	O
after	O
10	O
.	O
They	O
suggested	O
that	O
early	O
progressive	O
podocyte	O
damage	O
and	O
macrophage	O
infiltration	O
was	O
associated	O
with	O
type	O
II	O
diabetes	O
mellitus	O
but	O
also	O
with	O
hyperlipidaemia	O
[	O
26	O
]	O
.	O
Noda	O
et	O
al	O
.	O
[	O
27	O
]	O
examined	O
the	O
role	O
of	O
angiotensin	O
II	O
in	O
obese	O
Zücker	O
rats	O
and	O
suggested	O
that	O
angiotensin	O
II	O
is	O
the	O
main	O
cause	O
of	O
diabetic	O
nephropathy	O
as	O
is	O
the	O
case	O
in	O
diabetic	O
patients	O
.	O
Increase	O
in	O
proteinuria	O
and	O
albuminuria	O
are	O
inhibited	O
by	O
ACE	O
-	O
I	O
or	O
ARB	O
in	O
animals	O
[	O
28	O
]	O
.	O
Therefore	O
,	O
as	O
in	O
the	O
work	O
by	O
Ohmura	O
et	O
al	O
.	O
[	O
29	O
]	O
,	O
it	O
is	O
possible	O
that	O
the	O
renoprotective	O
effect	O
of	O
telmisartan	O
may	O
be	O
induced	O
at	O
least	O
in	O
part	O
by	O
inhibition	O
of	O
the	O
renal	O
hypertensive	O
effect	O
of	O
angiotensin	O
II	O
based	O
on	O
the	O
antagonistic	O
activity	O
to	O
the	O
AT1	O
receptor	O
,	O
but	O
also	O
by	O
its	O
non	O
-	O
hemodynamic	O
effects	O
in	O
relation	O
to	O
cell	O
proliferation	O
,	O
renal	O
sclerosis	O
and	O
fibrosis	O
stimulated	O
by	O
angiotensin	O
II	O
[	O
30	O
]	O
.	O
They	O
showed	O
that	O
even	O
at	O
low	O
doses	O
,	O
telmisartan	O
inhibited	O
the	O
increase	O
in	O
albuminuria	O
and	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
the	O
progression	O
of	O
glomerulosclerosis	O
.	O
Our	O
findings	O
are	O
consistent	O
with	O
their	O
conclusions	O
regarding	O
those	O
renal	O
changes	O
.	O
Our	O
results	O
suggest	O
that	O
a	O
low	O
-	O
calorie	O
diet	O
can	O
prevent	O
urinary	O
loss	O
of	O
albumin	O
and	O
therefore	O
early	O
renal	O
damage	O
probably	O
by	O
its	O
lipid	O
lowering	O
effect	O
and	O
slowing	O
the	O
rapid	O
decline	O
in	O
insulin	O
sensitivity	O
.	O
Works	O
by	O
Sparks	O
-	O
Corsetti	O
et	O
al	O
.	O
showed	O
a	O
significant	O
increase	O
over	O
time	O
in	O
serum	O
cholesterol	O
concentration	O
in	O
the	O
higher	O
dietary	O
fat	O
diet	O
relative	O
to	O
the	O
lowest	O
fat	O
-	O
content	O
diet	O
and	O
triglycerides	O
concentration	O
in	O
male	O
ZDF	O
rats	O
.	O

Previously	O
that	O
group	O
had	O
reported	O
an	O
extensive	O
characterization	O
of	O
the	O
diabetic	O
dyslipidaemia	O
in	O
obese	O
ZDF	O
rats	O
that	O
was	O
initially	O
due	O
to	O
triglyceride	O
and	O
free	O
fatty	O
acids	O
but	O
followed	O
by	O
an	O
additionally	O
rise	O
in	O
serum	O
total	O
cholesterol	O
(	O
LDL	O
and	O
HDL	O
cholesterol	O
)	O
in	O
the	O
insulinopenic	O
state	O
,	O
by	O
20	O
weeks	O
of	O
age	O
[	O
20	O
,	O
31	O
]	O
.	O
In	O
this	O
study	O
,	O
telmisartan	O
did	O
not	O
show	O
the	O
same	O
effect	O
as	O
with	O
restricted	O
diet	O
,	O
probably	O
due	O
to	O
low	O
dose	O
of	O
treatment	O
and	O
short	O
experimental	O
period	O
.	O
According	O
to	O
Ohmura	O
et	O
al	O
.	O
telmisartan	O
did	O
only	O
inhibit	O
the	O
increase	O
in	O
blood	O
cholesterol	O
and	O
triglycerides	O
with	O
higher	O
doses	O
of	O
telmisartan	O
and	O
longer	O
treatment	O
periods	O
[	O
26	O
]	O
.	O
We	O
also	O
found	O
moderate	O
correlation	O
between	O
serum	O
triglyceride	O
concentration	O
and	O
albumin	O
urinary	O
excretion	O
.	O
As	O
mentioned	O
above	O
,	O
treatment	O
of	O
hyperlipidaemia	O
can	O
reduce	O
glomerular	O
injury	O
in	O
obese	O
Zücker	O
rats	O
.	O
Work	O
by	O
Joles	O
et	O
al	O
.	O
[	O
32	O
]	O
showed	O
that	O
analbuminemic	O
rats	O
with	O
hypertriglyceridemia	O
developed	O
podocyte	O
injury	O
and	O
glomerulosclerosis	O
,	O
and	O
that	O
hypertriglyceridemia	O
,	O
proteinuria	O
,	O
and	O
the	O
increase	O
in	O
desmin	O
staining	O
(	O
podocyte	O
injury	O
)	O
were	O
largely	O
prevented	O
by	O
ovariectomy	O
.	O
Regarding	O
APOA1	O
either	O
in	O
serum	O
or	O
in	O
hepatic	O
tissue	O
,	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
on	O
plasma	O
APOA1	O
concentration	O
and	O
hepatic	O
mRNA	O
expression	O
in	O
ZDF	O
rats	O
subjected	O
to	O
low	O
-	O
calorie	O
diet	O
or	O
telmisartan	O
.	O
Current	O
data	O
shows	O
a	O
trend	O
towards	O
higher	O
plasma	O
APOA1	O
concentration	O
as	O
well	O
as	O
mRNA	O
hepatic	O
expression	O
when	O
animals	O
are	O
not	O
treated	O
with	O
telmisartan	O
and	O
are	O
fed	O
a	O
normal	O
chow	O
.	O
A	O
study	O
by	O
Sparks	O
et	O
al	O
.	O
[	O
31	O
]	O
in	O
hyperinsulinemic	O
and	O
insulinopenic	O
Zücker	O
diabetic	O
fatty	O
rats	O
showed	O
increases	O
both	O
APOA1	O
and	O
APOA4	O
levels	O
more	O
than	O
doubled	O
between	O
10	O
and	O
20	O
weeks	O
in	O
ZDF	O
rats	O
as	O
hyperglycaemia	O
and	O
hypercholesterolemia	O
developed	O
.	O

In	O
our	O
experiment	O
conditions	O
,	O
the	O
effect	O
of	O
PPAR	O
modulation	O
with	O
low	O
dose	O
telmisartan	O
and	O
caloric	O
restriction	O
seems	O
to	O
be	O
independent	O
of	O
serum	O
cholesterol	O
levels	O
since	O
there	O
were	O
no	O
differences	O
between	O
vehicle	O
and	O
telmisartan	O
-	O
treated	O
group	O
.	O
This	O
could	O
be	O
explained	O
by	O
the	O
non	O
-	O
linear	O
relationship	O
between	O
HDL	O
and	O
APOA1	O
levels	O
depending	O
on	O
the	O
type	O
of	O
HDL	O
-	O
particle	O
analysed	O
[	O
33	O
]	O
.	O
A	O
good	O
correlation	O
between	O
serum	O
APOA1	O
levels	O
and	O
the	O
increase	O
in	O
glycaemia	O
was	O
observed	O
in	O
the	O
present	O
study	O
.	O
Murao	O
et	O
al	O
.	O
[	O
34	O
]	O
showed	O
that	O
transcriptional	O
activity	O
of	O
the	O
rat	O
APOA1	O
promoter	O
in	O
HepG2	O
cells	O
paralleled	O
the	O
endogenous	O
mRNA	O
expression	O
,	O
and	O
this	O
activity	O
was	O
dependent	O
on	O
the	O
dose	O
of	O
glucose	O
or	O
insulin	O
:	O
glucose	O
decreases	O
and	O
insulin	O
increases	O
APOA1	O
promoter	O
activity	O
,	O
respectively	O
.	O
We	O
found	O
that	O
endogenous	O
mRNA	O
expression	O
paralleled	O
serum	O
apolipoprotein	O
concentration	O
.	O
However	O
,	O
animals	O
with	O
marked	O
hyperglycaemia	O
and	O
severe	O
diabetes	O
showed	O
higher	O
serum	O
APOA1	O
concentration	O
suggesting	O
a	O
positive	O
regulation	O
in	B-methodology
vivo	I-methodology
.	O
Oxidation	O
of	O
LDL	O
is	O
thought	O
to	O
contribute	O
to	O
the	O
development	O
of	O
atherosclerosis	O
.	O
Using	O
the	O
dichlorofluorescein	O
analysis	O
(	O
DCF	O
)	O
,	O
the	O
high	O
fluorescent	O
signal	O
generated	O
by	O
LDL	O
-	O
oxidized	O
-	O
phospholipids	O
in	O
the	O
vehicle	O
group	O
suggests	O
a	O
greater	O
pro	O
-	O
inflammatory	O
and	O
pro	O
-	O
atherosclerosis	O
state	O
in	O
the	O
obese	O
and	O
diabetic	O
animal	O
group	O
than	O
the	O
others	O
.	O
On	O
the	O
contrary	O
,	O
LDL	O
from	O
calorie	O
-	O
restricted	O
diet	O
resulted	O
in	O
low	O
fluorescent	O
signal	O
.	O
Navab	O
et	O
al	O
.	O
demonstrated	O
that	O
normal	O
HDL	O
inhibited	O
the	O
fluorescent	O
signal	O
generated	O
by	O
oxidized	O
phospholipids	O
in	O
the	O
cell	O
-	O
free	O
assay	O
using	O
dichlorofluorescein	O
,	O
whereas	O
patient	O
(	O
with	O
definite	O
coronary	O
atherosclerosis	O
)	O
HDL	O
did	O
not	O
.	O
In	O
our	O
study	O
when	O
incubating	O
this	O
oxidized	O
LDL	O
from	O
vehicle	O
group	O
with	O
its	O
own	O
HDL	O
,	O
we	O
saw	O
a	O
decrease	O
in	O
the	O
fluorescent	O
signal	O
,	O
suggesting	O
intact	O
beneficial	O
properties	O
of	O
HDL	O
in	O
this	O
early	O
setting	O
when	O
preventing	O
the	O
formation	O
or	O
inactivating	O
oxidized	O
phospholipids	O
.	O

As	O
mentioned	O
above	O
good	O
correlations	O
were	O
also	O
found	O
between	O
the	O
DCF	O
signal	O
difference	O
between	O
LDL	O
and	O
LDL	O
+	O
HDL	O
incubation	O
and	O
the	O
increase	O
in	O
the	O
urinary	O
albumin	O
excretion	O
,	O
suggesting	O
that	O
either	O
LDL	O
oxidisability	O
or	O
the	O
properties	O
of	O
HDL	O
in	O
this	O
animal	O
model	O
of	O
type	O
II	O
diabetes	O
could	O
be	O
used	O
as	O
marker	O
of	O
albuminuria	O
and	O
endothelial	O
dysfunction	O
.	O
The	O
low	O
calorie	O
diet	O
lowered	O
total	O
serum	O
cholesterol	O
,	O
although	O
no	O
dietary	O
manipulations	O
were	O
made	O
in	O
fatty	O
acid	O
content	O
that	O
could	O
increase	O
the	O
LDL	O
oxidative	O
resistance	O
.	O
The	O
relative	O
content	O
in	O
monounsaturated	O
(	O
MUFA	O
)	O
and	O
polyunsaturated	O
fatty	O
acids	O
(	O
PUFA	O
)	O
were	O
the	O
same	O
in	O
both	O
the	O
normal	O
chow	O
and	O
the	O
30	O
%	O
-	O
less	O
calorie	O
diet	O
.	O
Nevertheless	O
,	O
we	O
have	O
clearly	O
shown	O
an	O
inhibition	O
of	O
oxidative	O
LDL	O
signal	O
in	O
the	O
restrictive	O
dietary	O
group	O
compared	O
with	O
the	O
others	O
.	O
This	O
would	O
be	O
in	O
agreement	O
with	O
the	O
results	O
of	O
Hargrove	O
et	O
al	O
.	O
[	O
35	O
]	O
who	O
showed	O
differences	O
in	O
LDL	O
oxidative	O
susceptibility	O
between	O
different	O
diets	O
(	O
although	O
the	O
objective	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
diets	O
high	O
in	O
MUFA	O
from	O
different	O
food	O
sources	O
on	O
LDL	O
oxidative	O
susceptibility	O
)	O
.	O
They	O
compared	O
these	O
effects	O
with	O
those	O
of	O
a	O
Step	O
II	O
blood	O
cholesterol	O
-	O
lowering	O
diet	O
(	O
25	O
%	O
total	O
fat	O
,	O
7	O
%	O
saturated	O
)	O
as	O
well	O
as	O
a	O
higher	O
fat	O
average	O
American	O
diet	O
(	O
35	O
%	O
total	O
fat	O
,	O
15	O
%	O
saturated	O
)	O
.	O
As	O
regard	O
to	O
the	O
two	O
last	O
diets	O
,	O
they	O
showed	O
that	O
the	O
average	O
American	O
diet	O
tended	O
to	O
cause	O
the	O
shortest	O
to	O
LDL	O
-	O
oxidation	O
lag	O
time	O
compared	O
with	O
the	O
Step	O
II	O
diet	O
.	O
Telmisartan	O
may	O
mediate	O
cholesterol	O
efflux	O
by	O
activating	O
PPAR	O
.	O
In	O
this	O
regard	O
,	O
Matsumura	O
et	O
al	O
.	O
[	O
36	O
]	O
demonstrated	O
that	O
telmisartan	O
increased	O
the	O
expression	O
of	O
CD36	O
,	O
ABCA1	O
and	O
ABCG1	O
,	O
all	O
PPAR	O
-	O
responsive	O
genes	O
,	O
and	O
the	O
activation	O
of	O
LXR	O
,	O
a	O
transcription	O
factor	O
that	O
also	O
regulates	O
ABCA1	O
and	O
ABCG1	O
gene	O
transcription	O
in	O
macrophages	O
.	O

This	O
finding	O
corroborated	O
previous	O
reports	O
that	O
telmisartan	O
activated	O
PPARγ	O
target	O
genes	O
including	O
CD36	O
in	O
monocytes	O
[	O
37	O
]	O
and	O
that	O
telmisartan	O
increased	O
cholesterol	O
efflux	O
via	O
PPARγ	O
-	O
dependent	O
ABCA1	O
and	O
ABCG1	O
expression	O
in	O
macrophages	O
[	O
38	O
]	O
.	O
In	O
conclusion	O
,	O
this	O
is	O
the	O
first	O
study	O
in	O
which	O
LDL	O
oxidative	O
susceptibility	O
and	O
response	O
to	O
HDL	O
incubation	O
,	O
serum	O
APOA1	O
as	O
well	O
as	O
mRNA	O
hepatic	O
expression	O
and	O
urinary	O
albumin	O
excretion	O
are	O
analysed	O
in	O
an	O
obesity	O
related	O
type	O
II	O
diabetes	O
rat	B-methodology
model	I-methodology
subjected	O
to	O
either	O
a	O
dietary	B-methodology
intervention	I-methodology
or	O
a	O
pharmacologic	O
modulation	O
of	O
PPAR	O
gamma	O
with	O
telmisartan	O
.	O
Our	O
results	O
suggest	O
important	O
beneficial	O
effects	O
of	O
both	O
interventions	O
in	O
terms	O
of	O
LDL	O
oxidative	O
susceptibility	O
and	O
progression	O
of	O
albuminuria	O
in	O
obesity	O
related	O
type	O
II	O
diabetes	O
.	O
ABCA	O
1	O
:	O
ATP	O
binding	O
cassette	O
transporter	O
A1	O
;	O
ABCG	O
1	O
:	O
ATP	O
binding	O
cassette	O
transporter	O
G1	O
;	O
ACE	O
-	O
I	O
:	O
Angiotensin	O
II	O
converting	O
enzyme	O
inhibitor	O
;	O
APOA1	O
:	O
Apolipoprotein	O
A1	O
;	O
ARB	O
:	O
Angiotensin	O
receptor	O
blocker	O
;	O
AT	O
-	O
1	O
:	O
Angiotensin	O
1	O
;	O
DCF	O
:	O
Dichlorofluorescein	O
;	O
GLUT	O
-	O
1	O
:	O
Glucose	O
transporter	O
1	O
;	O
FSGS	O
:	O
Focal	O
segmental	O
glomerulosclerosis	O
;	O
HDL	O
:	O
High	O
density	O
lipoprotein	O
;	O
LDL	O
:	O
Low	O
density	O
lipoprotein	O
;	O
LXR	O
:	O
Liver	O
X	O
receptor	O
;	O
MUFA	O
:	O
Monounsaturated	O
fatty	O
acids	O
;	O
NIDM	O
:	O
Non	O
-	O
insulin	O
-	O
dependent	O
diabetes	O
mellitus	O
;	O
PPAR	O
:	O
Peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
;	O
PUFA	O
:	O
Polyunsaturated	O
fatty	O
acids	O
;	O
mRNA	O
:	O
Messenger	O
ribonucleic	O
acid	O
;	O
TG	O
:	O
Triglycerides	O
;	O
Z	O
:	O
Zücker	O
;	O
ZDF	O
:	O
Zücker	O
diabetic	O
fatty	O
.	O
No	O
competing	O
financial	O
or	O
non	O
-	O
financial	O
interests	O
exist	O
.	O
AML	O
participated	O
in	O
the	O
animal	O
handling	O
and	O
biochemical	O
laboratory	O
assays	O
.	O

CB	O
was	O
involved	O
in	O
the	O
plasma	O
lipid	O
and	O
apolipoprotein	O
assays	O
,	O
prepared	O
RNA	O
and	O
quantified	O
mRNA	O
.	O
EJL	O
participated	O
in	O
the	O
analysis	O
and	O
interpretation	O
of	O
the	O
data	O
,	O
the	O
statistical	O
analysis	O
and	O
preparation	O
of	O
the	O
manuscript	O
.	O
IG	O
was	O
involved	O
in	O
the	O
conception	O
and	O
design	O
of	O
the	O
study	O
.	O
JO	O
contributed	O
to	O
the	O
design	O
of	O
the	O
study	O
,	O
supervised	O
the	O
lipid	O
and	O
apolipoprotein	O
assays	O
and	O
preparation	O
of	O
the	O
manuscript	O
.	O
PI	O
was	O
involved	O
in	O
the	O
conception	O
and	O
design	O
of	O
the	O
study	O
and	O
participated	O
in	O
the	O
animal	O
manipulation	O
and	O
biochemical	O
laboratory	O
assays	O
.	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Dietary	O
fructose	O
feeds	O
hepatic	O
lipogenesis	O
via	O
microbiota	O
-	O
derived	O
acetate	O
Fructose	O
consumption	O
has	O
risen	O
dramatically	O
in	O
recent	O
decades	O
due	O
to	O
use	O
of	O
sucrose	O
and	O
high	O
fructose	O
corn	O
syrup	O
in	O
beverages	O
and	O
processed	O
foods1	O
,	O
contributing	O
to	O
rising	O
rates	O
of	O
obesity	O
and	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
2	O
–	O
4	O
.	O
Fructose	O
intake	O
triggers	O
hepatic	O
de	O
novo	O
lipogenesis	O
(	O
DNL	O
)	O
4	O
–	O
6	O
,	O
which	O
is	O
initiated	O
from	O
acetyl	O
-	O
CoA	O
.	O
ATP	O
-	O
citrate	O
lyase	O
(	O
ACLY	O
)	O
cleaves	O
cytosolic	O
citrate	O
to	O
generate	O
acetyl	O
-	O
CoA	O
and	O
is	O
upregulated	O
upon	O
carbohydrate	O
consumption7	O
.	O
Ongoing	O
clinical	B-methodology
trials	I-methodology
are	O
pursuing	O
ACLY	O
inhibition	O
for	O
treatment	O
of	O
metabolic	O
diseases8	O
.	O
Nevertheless	O
,	O
the	O
route	O
from	O
dietary	O
fructose	O
to	O
hepatic	O
acetyl	O
-	O
CoA	O
and	O
lipids	O
remains	O
unproven	O
.	O
Here	O
we	O
show	O
,	O
using	O
in	B-methodology
vivo	I-methodology
isotope	O
tracing	O
,	O
that	O
liver	O
-	O
specific	O
deletion	O
of	O
Acly	O
fails	O
to	O
suppress	O
fructose	O
-	O
induced	O
DNL	O
in	O
mice	O
.	O
Dietary	O
fructose	O
is	O
converted	O
by	O
the	O
gut	O
microbiome	O
into	O
acetate9	O
,	O
which	O
supplies	O
lipogenic	O
acetyl	O
-	O
CoA	O
independently	O
of	O
ACLY10	O
.	O
Depletion	O
of	O
the	O
microbiome	O
or	O
silencing	O
of	O
hepatic	O
ACSS2	O
,	O
which	O
generates	O
acetyl	O
-	O
CoA	O
from	O
acetate	O
,	O
potently	O
suppresses	O
conversion	O
of	O
a	O
fructose	O
bolus	O
into	O
hepatic	O
acetyl	O
-	O
CoA	O
and	O
fatty	O
acids	O
,	O
bypassing	O
ACLY	O
.	O
When	O
fructose	O
is	O
consumed	O
more	O
gradually	O
to	O
facilitate	O
its	O
absorption	O
in	O
the	O
small	O
intestine	O
,	O
both	O
citrate	O
cleavage	O
and	O
microbial	O
acetate	O
contribute	O
to	O
lipogenesis	O
.	O
The	O
DNL	O
transcriptional	O
program	O
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
activated	O
in	O
response	O
to	O
fructose	O
in	O
a	O
manner	O
independent	O
of	O
acetyl	O
-	O
CoA	O
metabolism	O
.	O
These	O
data	O
reveal	O
a	O
two	O
-	O
pronged	O
mechanism	O
regulating	O
hepatic	O
DNL	O
,	O
in	O
which	O
fructolysis	O
within	O
hepatocytes	O
provides	O
a	O
signal	O
to	O
promote	O
DNL	O
gene	O
expression	O
,	O
while	O
microbial	O
acetate	O
generation	O
feeds	O
lipogenic	O
acetyl	O
-	O
CoA	O
pools	O
.	O

Since	O
ACLY	O
links	O
carbohydrate	O
and	O
lipid	O
metabolism	O
(	O
Extended	O
Data	O
Fig	O
.	O
1a	O
)	O
,	O
we	O
hypothesized	O
that	O
genetic	O
deletion	O
of	O
Acly	O
in	O
hepatocytes	O
would	O
protect	O
mice	O
against	O
fructose	O
-	O
induced	O
lipid	O
accumulation	O
.	O
While	O
whole	O
body	O
Acly	O
knockout	O
is	O
embryonic	O
lethal11	O
,	O
liver	O
-	O
specific	O
Acly	O
knockout	O
(	O
LAKO	O
)	O
mice	O
were	O
grossly	O
indistinguishable	O
from	O
wild	O
-	O
type	O
(	O
WT	O
)	O
littermate	O
controls	O
,	O
with	O
similar	O
body	O
weights	O
and	O
organ	O
sizes	O
between	O
genotypes	O
on	O
either	O
standard	O
chow	O
or	O
a	O
high	O
-	O
fructose	O
(	O
60	O
%	O
)	O
diet	O
(	O
HFrD	O
)	O
(	O
Extended	O
Data	O
Fig	O
.	O
1b	O
–	O
c	O
)	O
.	O
Fructose	O
consumption	O
triggered	O
mild	O
hepatic	O
lipid	O
accumulation	O
,	O
without	O
fibrosis	O
or	O
excess	O
glycogen	O
accumulation	O
,	O
in	O
both	O
WT	O
and	O
LAKO	O
mice	O
(	O
Fig	O
.	O
1a	O
,	O
Extended	O
Data	O
Fig	O
.	O
1d	O
–	O
e	O
)	O
.	O
Metabolomic	O
and	O
lipidomic	O
analyses	O
revealed	O
striking	O
diet	O
-	O
dependent	O
changes	O
,	O
and	O
relatively	O
modest	O
genotype	O
-	O
dependent	O
differences	O
(	O
Extended	O
Data	O
Fig	O
.	O
2a	O
–	O
b	O
,	O
3a	O
–	O
c	O
,	O
Supplementary	O
Tables	O
1	O
and	O
2	O
)	O
.	O
Consistent	O
with	O
loss	O
of	O
ACLY	O
activity	O
,	O
accumulation	O
of	O
citrate	O
and	O
its	O
downstream	O
metabolite	O
aconitate	O
was	O
observed	O
in	O
LAKO	O
livers	O
(	O
Extended	O
Data	O
Fig	O
.	O
2c	O
)	O
.	O
These	O
data	O
demonstrate	O
that	O
ACLY	O
deficiency	O
,	O
surprisingly	O
,	O
neither	O
dramatically	O
impacts	O
global	O
hepatic	O
metabolite	O
levels	O
nor	O
prevents	O
fructose	O
-	O
induced	O
accumulation	O
of	O
triglyceride	O
.	O
To	O
further	O
investigate	O
the	O
role	O
of	O
hepatic	O
ACLY	O
in	O
fructose	O
-	O
induced	O
steatosis	O
without	O
altering	O
the	O
overall	O
diet	O
,	O
we	O
fed	O
mice	O
standard	O
chow	O
diets	O
with	O
either	O
normal	O
drinking	O
water	O
(	O
H2O	O
)	O
or	O
drinking	O
water	O
containing	O
a	O
1	O
:	O
1	O
mixture	O
of	O
fructose	O
and	O
glucose	O
(	O
15	O
%	O
each	O
,	O
Fruc	O
:	O
Gluc	O
)	O
(	O
Extended	O
Data	O
Fig	O
.	O
4a	O
–	O
c	O
)	O
.	O
Similar	O
to	O
HFrD	O
,	O
WT	O
and	O
LAKO	O
mice	O
drinking	O
Fruc	O
:	O
Gluc	O
for	O
4	O
weeks	O
developed	O
mild	O
hepatic	O
steatosis	O
(	O
Extended	O
Data	O
Fig	O
.	O
4d	O
)	O
.	O

Moreover	O
,	O
deuterated	O
water	O
(	O
D2O	O
)	O
tracing	O
revealed	O
that	O
Fruc	O
:	O
Gluc	O
consumption	O
increases	O
hepatic	O
DNL	O
to	O
a	O
similar	O
extent	O
in	O
WT	O
and	O
LAKO	O
mice	O
(	O
Fig	O
.	O
1b	O
)	O
.	O
Thus	O
,	O
deletion	O
of	O
Acly	O
from	O
liver	O
does	O
not	O
prevent	O
DNL	O
in	O
response	O
to	O
fructose	O
consumption	O
.	O
Given	O
this	O
unexpected	O
result	O
,	O
we	O
directly	O
tested	O
the	O
impact	O
of	O
ACLY	O
deficiency	O
on	O
fructose	O
conversion	O
into	O
nascent	O
fatty	O
acids	O
.	O
WT	O
and	O
LAKO	O
mice	O
were	O
gavaged	O
with	O
1	O
:	O
1	O
fructose	O
:	O
glucose	O
,	O
with	O
either	O
glucose	O
or	O
fructose	O
13C	O
-	O
labeled	O
(	O
Extended	O
Data	O
Fig	O
.	O
4e	O
)	O
.	O
Strikingly	O
,	O
fructose	O
carbons	O
were	O
incorporated	O
into	O
fatty	O
acids	O
in	O
LAKO	O
and	O
WT	O
mice	O
to	O
a	O
similar	O
extent	O
,	O
while	O
glucose	O
carbons	O
were	O
barely	O
used	O
(	O
Fig	O
.	O
1c	O
,	O
Extended	O
Data	O
Fig	O
.	O
4f	O
)	O
.	O
These	O
data	O
indicate	O
that	O
,	O
in	O
contrast	O
with	O
existing	O
models	O
of	O
fructose	O
metabolism	O
,	O
the	O
use	O
of	O
fructose	O
carbons	O
for	O
hepatic	O
DNL	O
does	O
not	O
require	O
ACLY	O
.	O
We	O
next	O
investigated	O
the	O
mechanisms	O
of	O
how	O
fructose	O
carbons	O
are	O
used	O
for	O
fatty	O
acid	O
synthesis	O
in	O
an	O
ACLY	O
-	O
independent	O
manner	O
.	O
It	O
has	O
been	O
previously	O
shown	O
that	O
the	O
hepatic	O
DNL	O
program	O
is	O
activated	O
in	O
response	O
to	O
carbohydrate	O
consumption	O
by	O
ChREBP12	O
,	O
13	O
.	O
Upon	O
chronic	O
high	O
fructose	O
consumption	O
,	O
livers	O
of	O
both	O
WT	O
and	O
LAKO	O
mice	O
upregulated	O
the	O
highly	O
active	O
ChREBP	O
-	O
β	O
isoform14	O
,	O
along	O
with	O
lipogenic	O
genes	O
(	O
Acaca	O
and	O
Fasn	O
)	O
and	O
other	O
ChREBP	O
target	O
genes	O
,	O
aldolase	O
B	O
(	O
AldoB	O
)	O
,	O
and	O
ketohexokinase	O
(	O
Khk	O
)	O
15	O
(	O
Extended	O
Data	O
Fig	O
.	O
5a	O
–	O
b	O
)	O
.	O
WT	O
mice	O
also	O
exhibited	O
upregulation	O
of	O
Acly	O
on	O
HFrD	O
(	O
Extended	O
Data	O
Fig	O
.	O
5a	O
)	O
.	O
The	O
induction	O
of	O
the	O
DNL	O
program	O
was	O
also	O
robust	O
at	O
the	O
protein	O
level	O
,	O
with	O
residual	O
ACLY	O
protein	O
in	O
fructose	O
-	O
fed	O
LAKO	O
livers	O
in	O
cells	O
other	O
than	O
hepatocytes	O
(	O
Fig	O
.	O
1d	O
,	O
Extended	O
Data	O
Fig	O
.	O

5c	O
–	O
d	O
)	O
.	O
Acyl	O
-	O
CoA	O
synthetase	O
short	O
chain	O
family	O
member	O
2	O
(	O
ACSS2	O
)	O
,	O
which	O
converts	O
acetate	O
into	O
acetyl	O
-	O
CoA	O
,	O
was	O
notably	O
upregulated	O
in	O
fructose	O
-	O
consuming	O
LAKO	O
mice	O
(	O
Fig	O
.	O
1d	O
,	O
Extended	O
Data	O
Fig	O
.	O
5b	O
–	O
c	O
)	O
.	O
Moreover	O
,	O
the	O
Acss2	O
genomic	O
locus	O
showed	O
increased	O
histone	O
H3K27	O
acetylation	O
after	O
Fruc	O
:	O
Gluc	O
drinking	O
(	O
Extended	O
Data	O
Fig	O
.	O
5e	O
)	O
.	O
ChREBP	O
binding	O
to	O
the	O
Acss2	O
locus	O
was	O
identified	O
in	O
a	O
published	O
ChIP	O
-	O
Seq	O
dataset16	O
(	O
Extended	O
Data	O
Fig	O
.	O
5f	O
)	O
.	O
Acss2	O
is	O
also	O
a	O
target	O
of	O
SREBP	O
transcription	O
factors	O
,	O
which	O
are	O
activated	O
in	O
response	O
to	O
fructose	O
consumption17	O
–	O
19	O
.	O
These	O
data	O
suggest	O
that	O
ACSS2	O
is	O
a	O
component	O
of	O
the	O
hepatic	O
response	O
to	O
fructose	O
consumption	O
.	O
Since	O
acetate	O
conversion	O
to	O
acetyl	O
-	O
CoA	O
by	O
ACSS2	O
can	O
support	O
de	O
novo	O
lipogenesis	O
in	O
the	O
absence	O
of	O
ACLY10	O
,	O
we	O
hypothesized	O
that	O
acetate	O
might	O
be	O
an	O
important	O
source	O
of	O
acetyl	O
-	O
CoA	O
for	O
DNL	O
in	O
the	O
context	O
of	O
fructose	O
feeding	O
(	O
Fig	O
.	O
2a	O
)	O
.	O
Acetate	O
can	O
be	O
generated	O
within	O
mammalian	O
cells	O
through	O
several	O
mechanisms20	O
–	O
22	O
,	O
prompting	O
us	O
to	O
investigate	O
if	O
fructose	O
is	O
converted	O
to	O
acetate	O
in	O
a	O
cell	O
autonomous	O
manner	O
in	O
hepatocytes	O
.	O
Incubation	O
of	O
murine	O
hepatocytes	O
with	O
25	O
mM	O
13C	O
-	O
fructose	O
labeled	O
fructolytic	O
intermediates	O
(	O
Fig	O
.	O
2b	O
)	O
,	O
but	O
only	O
minimally	O
labeled	O
acetyl	O
-	O
CoA	O
and	O
malonyl	O
-	O
CoA	O
,	O
the	O
core	O
DNL	O
substrates	O
(	O
Fig	O
.	O
2c	O
)	O
.	O
In	O
contrast	O
,	O
1	O
mM	O
13C	O
-	O
acetate	O
was	O
readily	O
used	O
for	O
synthesis	O
of	O
acetyl	O
-	O
CoA	O
and	O
malonyl	O
-	O
CoA	O
,	O
as	O
well	O
as	O
HMG	O
-	O
CoA	O
,	O
an	O
intermediate	O
in	O
the	O
mevalonate	O
pathway	O
downstream	O
of	O
acetyl	O
-	O
CoA	O
(	O
Fig	O
.	O
2c	O
)	O
.	O

Therefore	O
,	O
even	O
when	O
ACLY	O
is	O
intact	O
,	O
exogenous	O
acetate	O
directly	O
feeds	O
into	O
lipogenic	O
acetyl	O
-	O
CoA	O
pools	O
in	O
hepatocytes	O
.	O
We	O
thus	O
investigated	O
the	O
possibility	O
that	O
fructose	O
is	O
converted	O
to	O
acetate	O
prior	O
to	O
reaching	O
the	O
liver	O
to	O
feed	O
hepatic	O
DNL	O
by	O
performing	O
a	O
13C	O
-	O
fructose	O
tracing	O
time	O
course	O
in	O
mice	O
.	O
Orally	O
administered	O
13C	O
-	O
fructose	O
labeled	O
fructose	O
-	O
1	O
-	O
phosphate	O
(	O
F1P	O
)	O
and	O
pyruvate	O
in	O
the	O
liver	O
with	O
peaks	O
between	O
15	O
–	O
30	O
min	O
post	O
-	O
gavage	B-methodology
,	O
indicative	O
of	O
rapid	O
fructose	O
absorption	O
and	O
hepatic	O
fructolysis	O
(	O
Fig	O
.	O
2d	O
)	O
.	O
Hepatic	O
acetyl	O
-	O
CoA	O
labeling	O
was	O
much	O
slower	O
,	O
peaking	O
at	O
60	O
–	O
90	O
min	O
(	O
Fig	O
.	O
2d	O
)	O
.	O
The	O
slower	O
kinetic	O
of	O
acetyl	O
-	O
CoA	O
labeling	O
was	O
closely	O
aligned	O
with	O
the	O
appearance	O
of	O
labeled	O
acetate	O
in	O
the	O
portal	O
circulation	O
(	O
Fig	O
.	O
2d	O
)	O
.	O
Labeling	O
of	O
hepatic	O
fatty	O
acids	O
followed	O
that	O
of	O
acetyl	O
-	O
CoA	O
,	O
peaking	O
at	O
120	O
–	O
180	O
min	O
(	O
Fig	O
.	O
2d	O
)	O
,	O
consistent	O
with	O
fructose	O
feeding	O
hepatic	O
acetyl	O
-	O
CoA	O
and	O
fatty	O
acid	O
production	O
indirectly	O
via	O
acetate	O
.	O
We	O
next	O
sought	O
to	O
determine	O
the	O
source	O
of	O
fructose	O
-	O
derived	O
acetate	O
.	O
While	O
fructose	O
is	O
mainly	O
taken	O
up	O
by	O
the	O
small	O
intestine	O
,	O
unabsorbed	O
fructose	O
reaches	O
the	O
colon	O
where	O
the	O
microbiome	O
converts	O
fructose	O
into	O
short	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
,	O
including	O
acetate9	O
.	O
To	O
test	O
if	O
the	O
microbiome	O
is	O
important	O
for	O
hepatic	O
DNL	O
,	O
we	O
depleted	O
it	O
with	O
an	O
antibiotic	O
cocktail	O
(	O
Extended	O
Data	O
Fig	O
.	O
6a	O
–	O
d	O
)	O
.	O
Antibiotic	O
treatment	O
slightly	O
enhanced	O
the	O
appearance	O
of	O
labeled	O
fructose	O
and	O
fructose	O
-	O
derived	O
glucose	O
in	O
the	O
portal	O
vein	O
following	O
an	O
oral	O
administration	O
of	O
13C	O
-	O
fructose	O
(	O
Extended	O
Data	O
Fig	O
.	O
6e	O
–	O
f	O
)	O
.	O
The	O
induction	O
of	O
hepatic	O
DNL	O
genes	O
following	O
fructose	O
consumption	O
is	O
thought	O
to	O
be	O
dependent	O
on	O
fructolytic	O
and	O
/	O
or	O
glycolytic	O
intermediates12	O
,	O
23	O
.	O

Consistent	O
with	O
normal	O
passage	O
of	O
fructose	O
from	O
the	O
intestine	O
to	O
the	O
liver	O
,	O
DNL	O
gene	O
expression	O
remained	O
intact	O
after	O
antibiotic	O
treatment	O
(	O
Extended	O
Data	O
Fig	O
.	O
6g	O
)	O
,	O
as	O
did	O
labeling	O
of	O
F1P	O
,	O
pyruvate	O
and	O
citrate	O
in	O
the	O
liver	O
(	O
Fig	O
.	O
3a	O
,	O
Extended	O
Data	O
Fig	O
.	O
7a	O
)	O
.	O
In	O
contrast	O
,	O
microbiome	O
depletion	O
dramatically	O
reduced	O
the	O
labeling	O
from	O
13C	O
-	O
fructose	O
of	O
hepatic	O
acetyl	O
-	O
CoA	O
and	O
palmitate	O
,	O
as	O
well	O
as	O
fatty	O
acids	O
within	O
circulating	O
lipids	O
(	O
Fig	O
.	O
3a	O
–	O
b	O
,	O
Extended	O
Data	O
Fig	O
.	O
7a	O
–	O
b	O
)	O
.	O
This	O
reduction	O
was	O
well	O
matched	O
with	O
depleted	O
portal	O
and	O
cecal	O
labeling	O
of	O
acetate	O
and	O
other	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
Fig	O
.	O
3a	O
,	O
Extended	O
Data	O
Fig	O
.	O
7a	O
,	O
8a	O
–	O
b	O
)	O
.	O
Antibiotic	O
treatment	O
also	O
reduced	O
total	O
hepatic	O
triglycerides	O
(	O
Extended	O
Data	O
Fig	O
.	O
8c	O
)	O
,	O
consistent	O
with	O
prior	O
observations24	O
,	O
25	O
.	O
Thus	O
,	O
depletion	O
of	O
the	O
microbiome	O
suppresses	O
hepatic	O
DNL	O
from	O
13C	O
-	O
fructose	O
,	O
without	O
impairing	O
small	O
intestinal	O
or	O
hepatic	O
fructose	O
metabolism	O
,	O
or	O
the	O
induction	O
of	O
DNL	O
gene	O
expression	O
.	O
We	O
next	O
investigated	O
if	O
acetate	O
is	O
a	O
key	O
microbial	O
product	O
supporting	O
DNL	O
.	O
To	O
assess	O
whether	O
fructose	O
intake	O
led	O
to	O
an	O
appreciable	O
increase	O
in	O
portal	O
acetate	O
concentrations	O
,	O
we	O
measured	O
acetate	O
in	O
portal	O
and	O
systemic	O
blood	O
after	O
gavage	B-methodology
.	O
Portal	O
vein	O
acetate	O
concentrations	O
increased	O
approximately	O
twofold	O
over	O
baseline	O
(	O
to	O
>	O
1	O
mM	O
)	O
at	O
60	O
–	O
90	O
minutes	O
after	O
fructose	O
gavage	B-methodology
(	O
Extended	O
Data	O
Fig	O
.	O
8d	O
)	O
,	O
corresponding	O
with	O
acetate	O
labeling	O
from	O
fructose	O
(	O
Fig	O
.	O
2d	O
)	O
.	O
The	O
rise	O
in	O
portal	O
acetate	O
was	O
absent	O
in	O
antibiotic	O
treated	O
animals	O
(	O
Extended	O
Data	O
Fig	O
.	O
8d	O
)	O
.	O
Acetate	O
concentrations	O
in	O
systemic	O
circulation	O
were	O
lower	O
than	O
that	O
in	O
the	O
portal	O
vein	O
and	O
did	O
not	O
markedly	O
fluctuate	O
after	O
fructose	O
consumption	O
,	O
suggesting	O
clearance	O
by	O
the	O
liver	O
(	O
Extended	O
Data	O
Fig	O
.	O
8d	O
)	O
.	O

Next	O
,	O
to	O
assess	O
whether	O
acetate	O
supports	O
DNL	O
downstream	O
of	O
microbial	O
metabolism	O
,	O
mice	O
were	O
gavaged	O
with	O
13C	O
-	O
acetate	O
,	O
along	O
with	O
1	O
:	O
1	O
fructose	O
:	O
glucose	O
.	O
DNL	O
from	O
13C	O
-	O
acetate	O
,	O
in	O
contrast	O
to	O
that	O
from	O
13C	O
-	O
fructose	O
,	O
was	O
not	O
impacted	O
by	O
antibiotic	O
treatment	O
(	O
Fig	O
.	O
3c	O
)	O
.	O
Finally	O
,	O
to	O
test	O
if	O
hepatic	O
ACSS2	O
is	O
required	O
for	O
fructose	O
to	O
feed	O
DNL	O
,	O
ACSS2	O
in	O
the	O
liver	O
was	O
silenced	O
using	O
an	O
adeno	O
-	O
associated	O
viral	O
hairpin	O
targeting	O
Acss226	O
(	O
Extended	O
Data	O
Fig	O
.	O
8e	O
–	O
g	O
)	O
.	O
Depletion	O
of	O
hepatic	O
ACSS2	O
strongly	O
suppressed	O
the	O
labeling	O
of	O
fatty	O
acids	O
in	O
circulating	O
lipids	O
from	O
13C	O
-	O
fructose	O
(	O
Fig	O
.	O
3d	O
)	O
.	O
Altogether	O
,	O
these	O
data	O
point	O
to	O
a	O
two	O
-	O
pronged	O
mechanism	O
of	O
DNL	O
upon	O
consumption	O
of	O
a	O
fructose	O
bolus	O
,	O
in	O
which	O
sugar	O
metabolism	O
in	O
hepatocytes	O
triggers	O
the	O
DNL	O
transcriptional	O
program	O
,	O
but	O
microbiome	O
-	O
dependent	O
acetate	O
production	O
serves	O
as	O
the	O
major	O
fructose	O
-	O
derived	O
lipogenic	O
substrate	O
,	O
after	O
conversion	O
to	O
acetyl	O
-	O
CoA	O
by	O
hepatic	O
ACSS2	O
(	O
Extended	O
Data	O
Fig	O
.	O
10a	O
)	O
.	O
Microbiome	O
-	O
dependent	O
acetate	O
production	O
from	O
fructose	O
occurs	O
when	O
rate	O
of	O
ingestion	O
exceeds	O
small	O
intestinal	O
uptake	O
capacity9	O
.	O
Thus	O
,	O
if	O
fructose	O
is	O
consumed	O
gradually	O
,	O
its	O
contribution	O
to	O
DNL	O
might	O
occur	O
to	O
a	O
greater	O
extent	O
via	O
ACLY	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
via	O
microbial	O
acetate	O
production	O
.	O
Still	O
,	O
upon	O
providing	O
Fruc	O
:	O
Gluc	O
in	O
the	O
drinking	O
water	O
,	O
DNL	O
was	O
comparably	O
stimulated	O
in	O
the	O
presence	O
or	O
absence	O
of	O
ACLY	O
(	O
Fig	O
.	O
1b	O
)	O
.	O
To	O
explore	O
this	O
further	O
,	O
mice	O
were	O
given	O
13C	O
-	O
labeled	O
fructose	O
or	O
glucose	O
in	O
drinking	O
water	O
for	O
24	O
hours	O
(	O
Fig	O
.	O
4a	O
)	O
.	O

Fructose	O
-	O
derived	O
carbons	O
provided	O
a	O
substantial	O
contribution	O
to	O
hepatic	O
lipid	O
pools	O
,	O
with	O
greater	O
than	O
20	O
%	O
of	O
total	O
liver	O
fatty	O
acid	O
carbons	O
being	O
labeled	O
from	O
13C	O
-	O
fructose	O
after	O
24	O
hours	O
of	O
Fruc	O
:	O
Gluc	O
drinking	O
,	O
while	O
13C	O
-	O
glucose	O
contributed	O
less	O
(	O
Fig	O
.	O
4b	O
)	O
.	O
In	O
this	O
context	O
,	O
ACLY	O
deficiency	O
reduced	O
13C	O
-	O
fructose	O
and	O
-	O
glucose	O
labeling	O
of	O
fatty	O
acids	O
(	O
Fig	O
.	O
4b	O
)	O
.	O
Nevertheless	O
,	O
total	O
DNL	O
as	O
measured	O
by	O
D2O	O
labeling	O
was	O
not	O
different	O
between	O
genotypes	O
(	O
Fig	O
.	O
4c	O
)	O
,	O
indicating	O
sufficient	O
availability	O
of	O
other	O
two	O
-	O
carbon	O
donors	O
.	O
One	O
possibility	O
is	O
assimilation	O
of	O
acetate	O
from	O
other	O
sources	O
(	O
e	O
.	O
g	O
.	O
fiber	O
fermentation	O
)	O
.	O
To	O
test	O
this	O
,	O
we	O
supplemented	O
Fruc	O
:	O
Gluc	O
drinking	O
water	O
with	O
13C	O
-	O
acetate	O
upon	O
initial	O
exposure	O
(	O
naïve	O
)	O
and	O
after	O
2	O
weeks	O
on	O
Fruc	O
:	O
Gluc	O
water	O
(	O
conditioned	O
)	O
(	O
Extended	O
Data	O
Fig	O
.	O
9a	O
)	O
.	O
Fatty	O
acid	O
labeling	O
from	O
13C	O
-	O
acetate	O
was	O
higher	O
in	O
LAKO	O
mice	O
at	O
baseline	O
(	O
Fig	O
.	O
4d	O
)	O
.	O
After	O
fructose	O
conditioning	O
,	O
acetate	O
contribution	O
to	O
DNL	O
increased	O
in	O
WT	O
animals	O
,	O
and	O
this	O
was	O
further	O
enhanced	O
in	O
LAKO	O
mice	O
(	O
Fig	O
.	O
4d	O
)	O
,	O
consistent	O
with	O
increased	O
hepatic	O
ACSS2	O
expression	O
in	O
LAKO	O
mice	O
following	O
fructose	O
feeding	O
,	O
which	O
preceded	O
the	O
onset	O
of	O
steatosis	O
(	O
Extended	O
Data	O
Fig	O
.	O
9b	O
–	O
c	O
)	O
.	O
We	O
next	O
assessed	O
the	O
contribution	O
of	O
microbiome	O
-	O
derived	O
acetate	O
from	O
all	O
dietary	O
sources	O
in	O
the	O
context	O
of	O
gradual	O
fructose	O
consumption	O
.	O
Antibiotic	O
treatment	O
suppressed	O
total	O
hepatic	O
DNL	O
in	O
LAKO	O
mice	O
(	O
Fig	O
.	O
4e	O
,	O
Extended	O
Data	O
Fig	O
.	O
9d	O
)	O
.	O
ChREBPβ	O
and	O
DNL	O
gene	O
expression	O
were	O
confirmed	O
to	O
be	O
upregulated	O
by	O
Fruc	O
:	O
Gluc	O
drinking	O
in	O
all	O
groups	O
,	O
indicating	O
that	O
their	O
regulation	O
in	O
response	O
to	O
fructose	O
consumption	O
is	O
independent	O
of	O
acetyl	O
-	O
CoA	O
metabolism	O
(	O
Fig	O
.	O
4f	O
)	O
.	O

Finally	O
,	O
we	O
examined	O
DNL	O
in	O
Fruc	O
:	O
Gluc	O
-	O
drinking	O
mice	O
following	O
silencing	O
of	O
hepatic	O
ACSS2	O
,	O
finding	O
that	O
in	O
the	O
context	O
of	O
gradual	O
fructose	O
consumption	O
via	O
drinking	O
water	O
,	O
loss	O
of	O
both	O
ACLY	O
and	O
ACSS2	O
is	O
necessary	O
to	O
suppress	O
DNL	O
(	O
Fig	O
.	O
4g	O
)	O
.	O
These	O
data	O
indicate	O
that	O
when	O
fructose	O
is	O
consumed	O
gradually	O
to	O
reduce	O
its	O
passage	O
into	O
the	O
colon	O
,	O
the	O
rate	O
of	O
DNL	O
is	O
established	O
by	O
signaling	O
mechanisms	O
(	O
i	O
.	O
e	O
.	O
,	O
sugar	O
-	O
driven	O
ChREBP	O
activation	O
)	O
,	O
and	O
DNL	O
is	O
suppressed	O
only	O
when	O
acetyl	O
-	O
CoA	O
production	O
by	O
both	O
ACLY	O
and	O
ACSS2	O
is	O
inhibited	O
(	O
Extended	O
Data	O
Fig	O
.	O
10b	O
)	O
.	O
This	O
study	O
demonstrates	O
that	O
bolus	O
fructose	O
consumption	O
triggers	O
hepatic	O
DNL	O
independent	O
of	O
liver	O
ACLY	O
but	O
dependent	O
on	O
fructose	O
metabolism	O
to	O
acetate	O
by	O
gut	O
microbiota	O
,	O
which	O
reaches	O
the	O
liver	O
via	O
the	O
portal	O
vein	O
.	O
The	O
induction	O
of	O
the	O
DNL	O
transcriptional	O
program	O
in	O
the	O
liver	O
,	O
however	O
,	O
appears	O
to	O
be	O
independent	O
of	O
both	O
ACLY	O
and	O
the	O
microbiome	O
,	O
consistent	O
with	O
evidence	O
that	O
hexose	O
-	O
phosphate	O
metabolites	O
are	O
important	O
for	O
ChREBP	O
activation19	O
,	O
27	O
.	O
This	O
likely	O
explains	O
why	O
KHK	O
knockout	O
mice	O
are	O
protected	O
from	O
fructose	O
-	O
induced	O
fatty	O
liver28	O
,	O
29	O
.	O
Thus	O
,	O
we	O
propose	O
a	O
revised	O
model	O
of	O
fructose	O
-	O
dependent	O
DNL	O
induction	O
,	O
in	O
which	O
hepatic	O
fructose	O
metabolism	O
provides	O
a	O
signal	O
to	O
transcriptionally	O
promote	O
DNL	O
while	O
microbial	O
fructose	O
metabolism	O
provides	O
acetate	O
to	O
feed	O
DNL	O
(	O
Extended	O
Data	O
Fig	O
.	O
10a	O
)	O
.	O
These	O
dual	O
mechanisms	O
may	O
also	O
explain	O
higher	O
lipogenic	O
potential	O
of	O
fructose	O
as	O
compared	O
to	O
glucose30	O
,	O
at	O
least	O
in	O
the	O
context	O
of	O
high	O
dose	O
sugar	O
consumption	O
,	O
in	O
that	O
the	O
small	O
intestine	O
rapidly	O
absorbs	O
even	O
large	O
loads	O
of	O
glucose	O
,	O
whereas	O
fructose	O
reaches	O
the	O
gut	O
microbiome	O
,	O
which	O
generates	O
acetate9	O
.	O
When	O
consumed	O
more	O
gradually	O
,	O
fructose	O
can	O
feed	O
DNL	O
in	O
an	O
ACLY	O
-	O
dependent	O
manner	O
.	O
However	O
,	O
acetate	O
from	O
other	O
sources	O
is	O
also	O
readily	O
available	O
to	O
the	O
liver	O
,	O
rendering	O
ACLY	O
dispensable	O
for	O
DNL	O
even	O
when	O
fructose	O
is	O
gradually	O
consumed	O
(	O
Extended	O
Data	O
Fig	O
.	O

10b	O
)	O
.	O
Of	O
note	O
,	O
acetate	O
is	O
likely	O
insufficient	O
to	O
trigger	O
DNL	O
in	O
the	O
absence	O
of	O
the	O
sugar	O
-	O
derived	O
lipogenic	O
signal	O
.	O
Thus	O
,	O
it	O
will	O
be	O
important	O
in	O
the	O
future	O
to	O
define	O
how	O
fructose	O
interacts	O
with	O
dietary	O
sources	O
of	O
acetate	O
such	O
as	O
ethanol	O
and	O
fermentable	O
fibers	O
.	O
Understanding	O
the	O
fundamental	O
pathways	O
involved	O
in	O
hepatic	O
DNL	O
is	O
important	O
for	O
the	O
development	O
of	O
new	O
therapeutic	O
interventions	O
for	O
metabolic	O
diseases	O
.	O
In	O
addition	O
to	O
acetate	O
,	O
the	O
microbiome	O
also	O
produces	O
other	O
SCFAs	O
such	O
as	O
butyrate	O
and	O
propionate	O
.	O
Butyrate	O
has	O
been	O
shown	O
to	O
contribute	O
to	O
hepatic	O
lipogenesis31	O
,	O
but	O
likely	O
feeds	O
extra	O
-	O
mitochondrial	O
acetyl	O
-	O
CoA	O
pools	O
in	O
an	O
ACLY	O
-	O
dependent	O
manner32	O
.	O
Diet	O
and	O
microbiome	O
could	O
potentially	O
impact	O
the	O
efficacy	O
of	O
ACLY	O
inhibitors	O
,	O
currently	O
in	O
clinical	B-methodology
trials	I-methodology
for	O
hypercholesterolemia33	O
.	O
Prior	O
studies	O
of	O
RNAi	O
-	O
mediated	O
ACLY	O
deficiency	O
report	O
decreased	O
hepatic	O
lipid	O
in	O
db	O
/	O
db	O
mice	O
and	O
mice	O
fed	O
a	O
high	O
-	O
fat	O
,	O
high	O
sucrose	O
diet	O
,	O
but	O
increased	O
hepatic	O
lipid	O
in	O
mice	O
fed	O
a	O
high	O
fat	O
diet	O
only34	O
,	O
35	O
,	O
36	O
.	O
In	O
our	O
own	O
data	O
,	O
principal	O
component	O
analysis	O
of	O
hepatic	O
triglycerides	O
separated	O
LAKO	O
mice	O
from	O
WT	O
mice	O
on	O
HFrD	O
but	O
not	O
on	O
chow	O
(	O
Extended	O
Data	O
Fig	O
.	O
3c	O
)	O
,	O
supportive	O
of	O
the	O
notion	O
that	O
ACLY	O
may	O
play	O
distinct	O
roles	O
depending	O
on	O
diet	O
.	O
The	O
current	O
data	O
elucidate	O
a	O
previously	O
unappreciated	O
interplay	O
between	O
diet	O
,	O
the	O
gut	O
microbiome	O
,	O
and	O
host	O
organ	O
metabolism	O
that	O
contributes	O
to	O
fructose	O
-	O
induced	O
NAFLD	O
.	O
Generation	O
of	O
Aclyf	O
/	O
f	O
mice	O
on	O
a	O
C57Bl6	O
/	O
J	O
background	O
was	O
previously	O
described10	O
.	O
To	O
generate	O
hepatocyte	O
-	O
specific	O
Acly	O
knockouts	O
,	O
Aclyf	O
/	O
f	O
mice	O
were	O
crossed	O
to	O
albumin	O
-	O
Cre	O
transgenic	O
mice	O
(	O
B6	O
.	O
Cg	O
-	O
Tg	O
(	O
Alb	O
-	O
Cre	O
)	O
21Mgn	O
/	O
J	O
,	O
Jackson	O
Laboratory	O
)	O
37	O
.	O
Genotyping	O
of	O
the	O
recombined	O
Acly	O
allele	O
was	O
confirmed	O
as	O
previously	O
described10	O
.	O

Genotyping	O
of	O
the	O
Albumin	O
-	O
Cre	O
allele	O
was	O
confirmed	O
with	O
the	O
following	O
primer	O
sequences	O
:	O
AlbCre	O
-	O
5	O
’	O
F	O
(	O
CCTGCCAGCATGGATATAA	O
)	O
,	O
AlbCre	O
-	O
3	O
’	O
R	O
(	O
GTTGTCCTTTGTGCTGCTGA	O
)	O
,	O
Alb	O
-	O
TSP3	O
(	O
GAAGCAGAAGCTTAGGAAGATGG	O
)	O
,	O
and	O
the	O
following	O
cycling	O
conditions	O
:	O
1	O
cycle	O
-	O
94°	O
×	O
5	O
min	O
.	O
35	O
cycles	O
-	O
94°	O
×	O
45	O
sec	O
.	O
,	O
58°	O
×	O
45	O
sec	O
.	O
,	O
72°	O
×	O
1	O
min	O
.	O
1	O
cycle	O
-	O
72°	O
×	O
10	O
min	O
,	O
hold	O
at	O
4°C	O
.	O
All	O
animal	O
protocols	O
in	O
this	O
study	O
were	O
approved	O
by	O
the	O
University	O
of	O
Pennsylvania	O
’	O
s	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
(	O
IACUC	O
)	O
and	O
Princeton	O
University	O
’	O
s	O
IACUC	O
.	O
For	O
diet	B-methodology
studies	I-methodology
,	O
4	O
-	O
week	O
-	O
old	O
male	O
mice	O
were	O
placed	O
on	O
either	O
a	O
regular	O
chow	O
diet	O
(	O
Lab	O
Diet	O
5010	O
)	O
or	O
a	O
high	O
-	O
fructose	O
chow	O
diet	O
(	O
Teklad	O
TD	O
.	O
89247	O
)	O
for	O
indicated	O
lengths	O
of	O
time	O
.	O
Weights	O
of	O
mice	O
kept	O
on	O
each	O
diet	O
were	O
taken	O
weekly	O
.	O
For	O
drinking	O
water	O
studies	O
,	O
mice	O
were	O
provided	O
with	O
regular	O
tap	O
water	O
(	O
filtered	O
through	O
a	O
0	O
.	O
22	O
μm	O
filter	O
)	O
or	O
a	O
15	O
%	O
(	O
w	O
/	O
v	O
)	O
fructose	O
:	O
15	O
%	O
(	O
w	O
/	O
v	O
)	O
glucose	O
(	O
Sigma	O
F3510	O
,	O
G8270	O
)	O
in	O
tap	O
water	O
(	O
filtered	O
through	O
a	O
0	O
.	O
22	O
μm	O
filter	O
)	O
.	O
To	O
deplete	O
the	O
gut	O
microbiome	O
,	O
mice	O
were	O
given	O
a	O
daily	O
10	O
μL	O
/	O
g	O
body	O
weight	O
oral	O
gavage	B-methodology
consisting	O
of	O
1	O
mg	O
/	O
mL	O
ampicillin	O
,	O
1	O
mg	O
/	O
mL	O
gentamicin	O
,	O
0	O
.	O
5	O
mg	O
/	O
mL	O
vancomycin	O
,	O
1	O
mg	O
/	O
mL	O
neomycin	O
,	O
1	O
mg	O
/	O
ml	O
metronidazole	O
in	O
a	O
0	O
.	O
9	O
%	O
NaCl	O
solution	O
for	O
7	O
–	O
10	O
days	O
.	O
Studies	O
were	O
controlled	O
to	O
mice	O
given	O
the	O
same	O
0	O
.	O
9	O
%	O
NaCl	O
solution	O
without	O
antibiotics	O
.	O

To	O
knockdown	O
Acss2	O
,	O
6	O
–	O
8	O
week	O
-	O
old	O
male	O
mice	O
were	O
injected	O
via	O
tail	O
vein	O
with	O
2	O
.	O
0	O
×	O
1011	O
GC	O
/	O
mouse	O
AAV8	O
.	O
U6	O
.	O
shAcss2	O
.	O
CMV	O
.	O
eGFP	O
.	O
SV40	O
(	O
University	O
of	O
Pennsylvania	O
Vector	O
Core	O
)	O
or	O
AAV8	O
.	O
CMV	O
.	O
PI	O
.	O
eGFP	O
.	O
WPRE	O
.	O
bGH	O
(	O
Addgene	O
)	O
as	O
control	O
;	O
experiments	O
were	O
performed	O
1	O
week	O
after	O
injection	O
.	O
For	O
H	O
&	O
E	O
,	O
Periodic	O
Acid	O
Shiff	O
,	O
Trichrome	O
staining	O
:	O
tissues	O
were	O
fixed	O
in	O
formalin	O
overnight	O
,	O
dehydrated	O
by	O
titrating	O
in	O
ethanol	O
(	O
50	O
%	O
,	O
75	O
%	O
,	O
95	O
%	O
)	O
,	O
and	O
submitted	O
to	O
the	O
Molecular	O
Pathology	O
and	O
Imaging	O
Core	O
at	O
the	O
University	O
of	O
Pennsylvania	O
for	O
paraffin	O
embedding	O
,	O
sectioning	O
,	O
and	O
staining	O
.	O
For	O
Oil	O
Red	O
O	O
staining	O
:	O
tissues	O
were	O
fixed	O
in	O
formalin	O
overnight	O
,	O
dehydrated	O
by	O
titrating	O
in	O
sucrose	O
(	O
10	O
%	O
,	O
20	O
%	O
,	O
30	O
%	O
)	O
,	O
and	O
embedded	O
in	O
Richard	O
-	O
Allan	O
Scientific	O
NEG	O
-	O
50	O
frozen	O
section	O
medium	O
(	O
ThermoFisher	O
Scientific	O
6502	O
)	O
by	O
freezing	O
in	O
2	O
-	O
methylbutane	O
that	O
was	O
cooled	O
using	O
dry	O
ice	O
.	O
Tissues	O
frozen	O
in	O
NEG	O
-	O
50	O
were	O
submitted	O
to	O
the	O
Molecular	O
Pathology	O
and	O
Imaging	O
Core	O
at	O
the	O
University	O
of	O
Pennsylvania	O
for	O
cryosectioning	O
and	O
staining	O
.	O
Images	O
were	O
acquired	O
on	O
a	O
Keyence	O
BZ	O
-	O
X710	O
microscope	O
.	O
Cecal	O
contents	O
were	O
collected	O
,	O
snap	O
frozen	O
,	O
and	O
weighed	O
before	O
storage	O
in	O
−80C	O
until	O
use	O
.	O
DNA	O
was	O
extracted	O
from	O
cecal	O
contents	O
using	O
a	O
Fecal	O
DNA	O
extraction	O
kit	O
(	O
IBI	O
scientific	O
IB47821	O
)	O
according	O
to	O
manufacturer	O
instructions	O
.	O
Samples	O
were	O
diluted	O
1	O
:	O
1000	O
prior	O
to	O
use	O
for	O
RT	O
-	O
PCR	O
.	O
To	O
establish	O
a	O
bacterial	O
DNA	O
standard	O
,	O
genomic	O
DNA	O
was	O
extracted	O
from	O
Stbl3	O
E	O
.	O
coli	O
cells	O
.	O
A	O
standard	O
curve	O
was	O
generated	O
using	O
a	O
1	O
:	O
4	O
serial	O
dilution	O
starting	O
with	O
10	O
ng	O
of	O
E	O
.	O
coli	O
DNA	O
.	O
RT	O
-	O
PCR	O
was	O
performed	O
as	O
described	O
,	O
using	O
previously	O
published	O
universal	O
16s	O
primers	O
(	O
Forward	O
:	O
TCCTACGGGAGGCAGCAGT	O
,	O
Reverse	O
:	O
GGACTACCAGGGTATCTAATCCTGTT	O
)	O
38	O
.	O

Relative	O
bacterial	O
load	O
was	O
calculated	O
by	O
normalizing	O
DNA	O
content	O
to	O
initial	O
cecal	O
content	O
weight	O
.	O
Protein	O
extraction	O
from	O
tissue	O
was	O
performed	O
by	O
re	O
-	O
suspending	O
frozen	O
tissue	O
in	O
0	O
.	O
5	O
mL	O
of	O
RIPA	O
buffer	O
(	O
1	O
%	O
NP	O
-	O
40	O
,	O
0	O
.	O
5	O
%	O
Deoxycholate	O
,	O
0	O
.	O
1	O
%	O
SDS	O
,	O
150	O
mM	O
NaCl	O
,	O
50	O
mM	O
Tris	O
plus	O
protease	O
and	O
phosphatase	O
inhibitors	O
)	O
,	O
and	O
lysed	O
using	O
a	O
tissue	O
lyser	O
(	O
Qiagen	O
)	O
twice	O
for	O
30	O
seconds	O
at	O
20	O
Hz	O
.	O
Following	O
lysis	O
,	O
samples	O
were	O
incubated	O
on	O
ice	O
for	O
10	O
minutes	O
,	O
then	O
spun	O
down	O
at	O
15	O
,	O
000	O
RCF	O
for	O
5	O
minutes	O
in	O
4°C	O
.	O
Supernatant	O
was	O
collected	O
and	O
stored	O
in	O
−80°C	O
until	O
immunoblotting	O
.	O
Antibodies	O
used	O
in	O
this	O
study	O
:	O
ATP	O
-	O
Citrate	O
Lyase	O
(	O
Proteintech	O
15421	O
–	O
1	O
-	O
AP	O
)	O
,	O
Acyl	O
-	O
CoA	O
Synthetase	O
Family	O
Member	O
2	O
(	O
Cell	O
Signaling	O
Technology	O
3658S	O
)	O
,	O
Acetyl	O
-	O
CoA	O
Carboxylase	O
(	O
Cell	O
Signaling	O
Technology	O
3676S	O
)	O
,	O
Fatty	O
Acid	O
Synthase	O
(	O
Cell	O
Signaling	O
Technology	O
3189S	O
)	O
,	O
Catalase	O
(	O
Cell	O
Signaling	O
Technology	O
14097S	O
)	O
,	O
Ribosomal	O
Protein	O
S6	O
(	O
Cell	O
Signaling	O
Technology	O
2217S	O
)	O
,	O
IRDye800CW	O
Goat	O
Anti	O
-	O
Rabbit	O
(	O
LI	O
-	O
COR	O
926	O
–	O
32211	O
)	O
.	O
Immunoblots	O
were	O
developed	O
using	O
a	O
LI	O
-	O
COR	O
Odyssey	O
Clx	O
.	O
RNA	O
extraction	O
from	O
tissue	O
was	O
performed	O
by	O
re	O
-	O
suspending	O
frozen	O
tissue	O
in	O
1	O
mL	O
Trizol	O
(	O
Life	O
Technologies	O
)	O
,	O
and	O
lysed	O
using	O
a	O
tissue	O
lyser	O
(	O
Qiagen	O
)	O
for	O
60	O
seconds	O
at	O
30	O
Hz	O
,	O
followed	O
by	O
manufacturer	O
protocol	O
for	O
Trizol	O
RNA	O
extraction	O
.	O
cDNA	O
was	O
synthesized	O
using	O
high	O
-	O
capacity	O
RNA	O
-	O
to	O
-	O
cDNA	O
master	O
mix	O
(	O
Applied	O
Biosystems	O
4368814	O
)	O
,	O
as	O
per	O
the	O
kit	O
instructions	O
.	O
cDNA	O
was	O
diluted	O
1	O
:	O
20	O
and	O
amplified	O
using	O
PowerUp	O
SYBR	O
Green	O
Master	O
Mix	O
(	O
Applied	O
Biosystems	O
A25778	O
)	O
on	O
the	O
ViiA	O
-	O
7	O
Real	O
-	O
Time	O
PCR	O
system	O
.	O

Fold	O
change	O
in	O
expression	O
was	O
calculated	O
using	O
ΔCt	O
,	O
with	O
18S	O
reference	O
gene	O
as	O
an	O
endogenous	O
control	O
.	O
Primer	O
sequences	O
for	O
RT	O
-	O
qPCR	O
are	O
:	O
Aldob	O
(	O
Forward	O
:	O
GAAACCGCCTGCAAAGGATAA	O
,	O
Reverse	O
:	O
GAGGGTCTCGTGGAAAAGGAT	O
)	O
,	O
Khk	O
(	O
Forward	O
:	O
ATGTGGTGGACAAATACCCAGA	O
,	O
Reverse	O
:	O
CAAGCAAGGAAAGGACAGTGC	O
)	O
,	O
Acly	O
(	O
Forward	O
:	O
TTCGTCAAACAGCACTTCC	O
,	O
Reverse	O
:	O
ATTTGGCTTCTTGGAGGTG	O
)	O
,	O
Acss2	O
(	O
Forward	O
:	O
GCTTCTTTCCCATTCTTCGGT	O
,	O
Reverse	O
:	O
CCCGGACTCATTCAGGATTG	O
)	O
,	O
Chrebpα	O
(	O
Forward	O
:	O
CGACACTCACCCACCTCTTC	O
,	O
Reverse	O
:	O
TTGTTCAGCCGGATCTTGTC	O
)	O
,	O
Chrebpβ	O
(	O
Forward	O
:	O
TCTGCAGATCGCGTGGAG	O
,	O
Reverse	O
:	O
CTTGTCCCGGCATAGCAAC	O
)	O
,	O
Fasn	O
(	O
Forward	O
:	O
ATTGGTGGTGTGGACATGGTC	O
,	O
Reverse	O
:	O
CCCAGCCTTCCATCTCCTG	O
)	O
,	O
Acc1	O
(	O
Forward	O
:	O
ACAGTGGAGCTAGAATTGGAC	O
,	O
Reverse	O
:	O
ACTTCCCGACCAAGGACTTTG	O
)	O
.	O
To	O
assess	O
total	O
lipogenesis	O
,	O
mice	O
were	O
provided	O
with	O
50	O
%	O
(	O
v	O
/	O
v	O
)	O
deuterated	O
water	O
(	O
Sigma	O
151882	O
)	O
mixed	O
into	O
15	O
%	O
fructose	O
:	O
15	O
%	O
glucose	O
drinking	O
water	O
for	O
24	O
hours	O
.	O
Systemic	O
blood	O
was	O
collected	O
by	O
cardiac	O
puncture	O
,	O
allowed	O
to	O
coagulate	O
on	O
ice	O
for	O
10	O
minutes	O
,	O
and	O
spun	O
down	O
at	O
15	O
,	O
000	O
×	O
RCF	O
for	O
10	O
minutes	O
at	O
4°C	O
to	O
collect	O
serum	O
.	O
To	O
account	O
for	O
differences	O
in	O
drinking	O
water	O
consumption	O
,	O
calculated	O
deuterium	O
enrichment	O
labeling	O
in	O
serum	O
water	O
was	O
used	O
to	O
normalize	O
labeling	O
into	O
fatty	O
acids	O
.	O
To	O
assess	O
lipogenesis	O
from	O
dietary	O
carbohydrates	O
,	O
on	O
day	O
of	O
experiment	O
,	O
mice	O
were	O
weighed	O
and	O
fasted	O
from	O
10	O
a	O
.	O
m	O
.	O

until	O
3	O
p	O
.	O
m	O
.	O
,	O
when	O
they	O
were	O
given	O
an	O
oral	O
gavage	B-methodology
consisting	O
of	O
a	O
1	O
:	O
1	O
mixture	O
of	O
glucose	O
and	O
fructose	O
in	O
a	O
0	O
.	O
9	O
%	O
NaCl	O
saline	O
.	O
Doses	O
used	O
in	O
this	O
study	O
ranged	O
from	O
1	O
.	O
0	O
g	O
/	O
kg	O
or	O
2	O
.	O
0	O
g	O
/	O
kg	O
of	O
each	O
hexose	O
.	O
[	O
U	O
-	O
13C	O
]	O
-	O
glucose	O
(	O
CLM	O
-	O
1396	O
–	O
1	O
)	O
or	O
[	O
U	O
-	O
13C	O
]	O
-	O
fructose	O
(	O
CLM	O
-	O
1553	O
–	O
1	O
)	O
were	O
provided	O
with	O
the	O
corresponding	O
unlabeled	O
hexose	O
.	O
Six	O
hours	O
following	O
gavage	B-methodology
,	O
systemic	O
blood	O
was	O
collected	O
by	O
tail	O
bleeding	O
the	O
mice	O
and	O
incubating	O
the	O
blood	O
on	O
ice	O
for	O
15	O
minutes	O
before	O
spinning	O
down	O
at	O
15	O
,	O
000	O
×	O
RCF	O
for	O
10	O
minutes	O
at	O
4°C	O
to	O
collect	O
serum	O
.	O
Tissues	O
were	O
collected	O
using	O
a	O
clamp	O
pre	O
-	O
cooled	O
with	O
liquid	O
nitrogen	O
.	O
The	O
frozen	O
liver	O
samples	O
were	O
ground	O
at	O
liquid	O
nitrogen	O
temperature	O
with	O
a	O
Cryomill	O
(	O
Retsch	O
,	O
Newtown	O
,	O
PA	O
)	O
.	O
Saponification	O
of	O
lipids	O
and	O
LC	O
-	O
MS	O
analysis	O
were	O
performed	O
as	O
previously	O
described39	O
.	O
Briefly	O
,	O
serum	O
(	O
5	O
μL	O
)	O
or	O
liver	O
powder	O
(	O
10	O
mg	O
)	O
was	O
incubated	O
with	O
1	O
mL	O
of	O
0	O
.	O
3	O
M	O
KOH	O
in	O
90	O
%	O
methanol	O
at	O
80°C	O
for	O
1	O
hour	O
in	O
a	O
2	O
mL	O
glass	O
vial	O
.	O
Formic	O
acid	O
(	O
0	O
.	O
1	O
mL	O
)	O
was	O
then	O
added	O
for	O
neutralization	O
.	O
The	O
saponified	O
fatty	O
acids	O
were	O
extracted	O
by	O
adding	O
0	O
.	O
5	O
mL	O
of	O
hexane	O
,	O
vortexing	O
,	O
and	O
transferring	O
the	O
top	O
hexane	O
layer	O
to	O
a	O
new	O
glass	O
vial	O
.	O
Samples	O
were	O
then	O
dried	O
under	O
a	O
stream	O
of	O
N2	O
and	O
dissolved	O
in	O
100	O
μL	O
(	O
for	O
serum	O
)	O
or	O
1	O
mL	O
(	O
for	O
liver	O
)	O
of	O
isopropanol	O
:	O
methanol	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
solution	O
for	O
LC	O
-	O
MS	O
analysis	O
.	O
Separation	O
was	O
performed	O
by	O
reversed	O
-	O
phase	O
ion	O
-	O
pairing	O
chromatography	O
on	O
a	O
C8	O
column	O
coupled	O
to	O
negative	O
-	O
ion	O
mode	O
,	O
full	O
-	O
scan	O
LC	O
-	O
MS	O
at	O
1	O
-	O
Hz	O
scan	O
time	O
and	O
100	O
,	O
000	O
resolving	O
power	O
(	O
stand	O
-	O
alone	O
orbitrap	O
;	O
Thermo	O
Fischer	O
Scientific	O
)	O
.	O
Data	O
analysis	O
with	O
MAVEN	O
software	O
and	O
natural	O
isotope	O
correction	O
were	O
performed	O
as	O
previously	O
described40	O
.	O

Hepatocytes	O
were	O
isolated	O
using	O
a	O
two	O
-	O
step	O
collagenase	O
/	O
DNAse	O
digestion	O
protocol41	O
and	O
plated	O
in	O
M199	O
media	O
containing	O
5	O
mM	O
glucose	O
,	O
10	O
%	O
FBS	O
,	O
500	O
nM	O
dexamethasone	O
and	O
1	O
nM	O
insulin	O
.	O
Following	O
attachment	O
,	O
cells	O
were	O
changed	O
to	O
M199	O
media	O
containing	O
5	O
mM	O
glucose	O
,	O
500	O
nM	O
dexamethasone	O
and	O
incubated	O
overnight	O
.	O
Cells	O
were	O
switched	O
to	O
M199	O
containing	O
5	O
mM	O
glucose	O
,	O
10	O
%	O
FBS	O
,	O
500	O
nM	O
dexamethasone	O
,	O
100	O
nM	O
insulin	O
and	O
respective	O
fructose	O
and	O
acetate	O
supplementation	O
for	O
6	O
hours	O
on	O
day	O
of	O
experiment	O
.	O
Evidence	O
that	O
high	O
concentrations	O
of	O
glucose	O
are	O
required	O
to	O
induce	O
the	O
DNL	O
gene	O
program	O
in	O
primary	O
hepatocytes42	O
informed	O
our	O
use	O
of	O
25	O
mM	O
fructose	O
.	O
Acyl	O
-	O
CoA	O
measurements	O
in	O
primary	O
hepatocytes	O
were	O
performed	O
by	O
liquid	O
chromatograpy	O
-	O
mass	O
spectrometry	O
/	O
high	O
-	O
resolution	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
HRMS	O
)	O
as	O
previously	O
described43	O
.	O
Briefly	O
,	O
primary	O
hepatocytes	O
were	O
isolated	O
and	O
cultured	O
as	O
described	O
above	O
in	O
6	O
-	O
well	O
plates	O
.	O
At	O
harvest	O
,	O
culture	O
media	O
was	O
completely	O
aspirated	O
before	O
harvesting	O
cells	O
in	O
0	O
.	O
5	O
mL	O
ice	O
-	O
cold	O
10	O
%	O
trichloroacetic	O
acid	O
/	O
well	O
of	O
a	O
6	O
-	O
well	O
dish	O
using	O
a	O
cell	O
lifter	O
.	O
Samples	O
were	O
then	O
sonicated	O
for	O
10	O
×	O
0	O
.	O
5	O
second	O
pulses	O
to	O
completely	O
disrupt	O
cellular	O
membranes	O
,	O
and	O
incubated	O
on	O
ice	O
to	O
precipitate	O
proteins	O
.	O
Protein	O
was	O
pelleted	O
at	O
16	O
,	O
000	O
×	O
RCF	O
for	O
10	O
minutes	O
at	O
4°C	O
.	O
Supernatant	O
was	O
collected	O
and	O
purified	O
by	O
solid	O
-	O
phase	O
extraction	O
using	O
Oasis	O
HLB	O
1cc	O
(	O
30	O
mg	O
)	O
SPE	O
columns	O
(	O
Waters	O
)	O
.	O
Eluate	O
was	O
evaporated	O
to	O
dryness	O
under	O
nitrogen	O
gas	O
and	O
re	O
-	O
suspended	O
in	O
50	O
μL	O
of	O
5	O
%	O
5	O
-	O
sulfosalicylic	O
acid	O
(	O
w	O
/	O
v	O
)	O
for	O
injection	O
.	O
Samples	O
were	O
analyzed	O
by	O
an	O
Ultimate	O
3000	O
autosampler	O
coupled	O
to	O
a	O
Thermo	O
Q	O
-	O
Exactive	O
Plus	O
instrument	O
in	O
positive	O
electrospray	O
ionization	O
(	O
ESI	O
)	O
mode	O
.	O

For	O
isotopic	O
tracer	O
analysis	O
,	O
isotopic	O
enrichment	O
from	O
[	O
U	O
-	O
13C	O
]	O
-	O
fructose	O
(	O
Cambridge	O
Isotope	O
Laboratories	O
,	O
CLM	O
-	O
1553	O
)	O
or	O
[	O
U	O
-	O
13C	O
]	O
-	O
acetate	O
(	O
Cambridge	O
Isotope	O
Laboratories	O
,	O
CLM	O
-	O
440	O
–	O
1	O
)	O
was	O
calculated	O
to	O
compensate	O
for	O
the	O
non	O
-	O
linearity	O
of	O
isotopic	O
enrichment	O
using	O
the	O
FluxFix	O
calculator44	O
.	O
For	O
fructolytic	O
intermediate	O
measurements	O
in	O
primary	O
hepatocytes	O
,	O
culture	O
media	O
was	O
completely	O
aspirated	O
before	O
harvesting	O
cells	O
in	O
0	O
.	O
5	O
mL	O
of	O
cold	O
80	O
:	O
20	O
methanol	O
:	O
water	O
/	O
well	O
of	O
a	O
6	O
-	O
well	O
dish	O
using	O
a	O
cell	O
lifter	O
.	O
Samples	O
were	O
then	O
sonicated	O
for	O
10	O
×	O
0	O
.	O
5	O
second	O
pulses	O
to	O
completel	O
disrupt	O
cellular	O
membranes	O
,	O
and	O
incubated	O
on	O
ice	O
.	O
Samples	O
were	O
then	O
spun	O
down	O
at	O
16	O
,	O
000	O
×	O
RCF	O
for	O
10	O
minutes	O
at	O
4°C	O
.	O
Supernatant	O
was	O
collected	O
and	O
dried	O
under	O
nitrogen	O
gas	O
flow	O
in	O
preparation	O
for	O
water	O
-	O
soluble	O
metabolomic	O
analysis	O
.	O
For	O
H3K27ac	O
-	O
ChIP	O
qPCR	O
studies	O
,	O
WT	O
male	O
mice	O
were	O
provided	O
with	O
Fruc	O
:	O
Gluc	O
drinking	O
water	O
for	O
24	O
hours	O
,	O
and	O
orally	O
gavaged	O
with	O
2	O
.	O
0	O
g	O
/	O
kg	O
fructose	O
+	O
2	O
.	O
0	O
g	O
/	O
kg	O
glucose	O
1	O
hour	O
prior	O
to	O
sacrifice	O
.	O
ChIP	O
was	O
performed	O
as	O
previously	O
described45	O
with	O
adjustments	O
to	O
start	O
from	O
liver	O
tissue	O
.	O
Liver	O
tissues	O
were	O
harvested	O
from	O
mice	O
90	O
minutes	O
following	O
gavage	B-methodology
,	O
and	O
100	O
mg	O
of	O
tissue	O
was	O
weighed	O
out	O
.	O
Tissues	O
were	O
homogenized	O
by	O
mincing	O
briefly	O
with	O
razor	O
blades	O
followed	O
by	O
resuspension	O
in	O
5	O
mL	O
of	O
ice	O
-	O
cold	O
1X	O
PBS	O
and	O
several	O
passages	O
through	O
a	O
16	O
gauge	O
syringe	O
needle	O
into	O
15	O
mL	O
conical	O
tubes	O
.	O
Samples	O
were	O
crosslinked	O
with	O
2	O
%	O
formaldehyde	O
for	O
10	O
minutes	O
at	O
room	O
temperature	O
.	O
The	O
reactions	O
were	O
quenched	O
with	O
0	O
.	O
25	O
M	O
glycine	O
.	O
The	O
cells	O
were	O
then	O
washed	O
with	O
1X	O
PBS	O
and	O
resuspended	O
in	O
cell	O
lysis	O
buffer	O
(	O
10	O
mM	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
1	O
,	O
10	O
mM	O
NaCl	O
,	O
1	O
.	O
5	O
mM	O
MgCl2	O
,	O
0	O
.	O
5	O
%	O
NP	O
-	O
40	O
)	O
,	O
supplemented	O
with	O
protease	O
inhibitors	O
(	O
Roche	O
)	O
.	O

The	O
cell	O
pellet	O
was	O
resuspended	O
in	O
0	O
.	O
5	O
mL	O
of	O
nuclear	O
lysis	O
buffer	O
(	O
50	O
mM	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
1	O
,	O
5	O
mM	O
EDTA	O
,	O
1	O
%	O
SDS	O
)	O
supplemented	O
with	O
protease	O
inhibitors	O
.	O
The	O
chromatin	O
was	O
fragmented	O
with	O
a	O
Diagenode	O
Bioruptor	O
Pico	O
(	O
12	O
cycles	O
of	O
30	O
s	O
on	O
followed	O
by	O
30	O
s	O
off	O
,	O
at	O
4°C	O
)	O
.	O
Samples	O
were	O
incubated	O
with	O
protein	O
G	O
magnetic	O
beads	O
(	O
Millipore	O
-	O
Sigma	O
16	O
–	O
662	O
)	O
and	O
H3K27ac	O
(	O
Abcam	O
ab4729	O
)	O
,	O
ChREBP	O
(	O
Novus	O
Biologicals	O
NB400	O
–	O
135	O
)	O
,	O
or	O
Normal	O
Rabbit	O
IgG	O
(	O
Cell	O
Signalling	O
Technology	O
2729S	O
)	O
antibody	O
overnight	O
at	O
4°C	O
.	O
The	O
next	O
day	O
,	O
samples	O
were	O
washed	O
5	O
times	O
with	O
decreasingly	O
stringent	O
buffers	O
.	O
ChIP	O
DNA	O
was	O
eluted	O
off	O
the	O
beads	O
by	O
incubating	O
beads	O
in	O
125	O
μL	O
elution	O
buffer	O
for	O
10	O
minutes	O
at	O
65°C	O
.	O
The	O
combined	O
supernatant	O
was	O
then	O
incubated	O
overnight	O
at	O
65°C	O
to	O
reverse	O
crosslinks	O
and	O
proteinase	O
K	O
treated	O
for	O
1	O
hour	O
the	O
next	O
morning	O
.	O
Samples	O
were	O
purified	O
using	O
Macherey	O
-	O
Nagel	O
DNA	O
purification	O
kit	O
,	O
with	O
NTB	O
binding	O
buffer	O
.	O

Samples	O
were	O
diluted	O
1	O
:	O
5	O
in	O
nuclease	O
-	O
free	O
water	O
prior	O
to	O
RT	O
-	O
qPCR	O
reactions	O
,	O
which	O
were	O
performed	O
as	O
described	O
above	O
with	O
the	O
following	O
primers	O
:	O
Mlxipl	O
p1	O
(	O
Forward	O
:	O
CGCACCCGGTCTACAGTTT	O
,	O
Reverse	O
:	O
GTGCCTCCTTCTCTCCTTAGC	O
)	O
,	O
Mlxipl	O
p2	O
(	O
Forward	O
:	O
GCCATCCACGTGCTAAGGA	O
,	O
Reverse	O
:	O
GGCTTTTAGACTGGGGTGTGG	O
)	O
,	O
Pklr	O
p1	O
(	O
Forward	O
:	O
GGGAAGGATGCCCACTACAG	O
,	O
Reverse	O
:	O
TGGAAGCCTTGTACACTGGG	O
)	O
,	O
Pklr	O
p2	O
(	O
Forward	O
:	O
CCCAGTGTACAAGGCTTCCAT	O
,	O
Reverse	O
:	O
CTCTGCCTTTGTCAGTGGGA	O
)	O
,	O
Acss2	O
p1	O
(	O
Forward	O
:	O
ATTGGATGCCTAGAGCACGG	O
,	O
Reverse	O
:	O
CGCATCAAGTTCCGAACACC	O
)	O
,	O
Acss2	O
p2	O
(	O
Forward	O
:	O
TCAGGACAGTTTAGGGTGCAA	O
,	O
Reverse	O
:	O
TTACAAAGACCTGCCTCTGCC	O
)	O
.	O
Triglyceride	O
measurements	O
were	O
performed	O
using	O
a	O
Triglyceride	O
Colorimetric	O
Assay	O
Kit	O
(	O
Cayman	O
Chemical	O
10010303	O
)	O
as	O
per	O
manufacturer	O
instructions	O
.	O
Water	O
-	O
soluble	O
metabolite	O
extraction	O
was	O
performed	O
as	O
previously	O
described9	O
.	O
For	O
serum	O
samples	O
,	O
100	O
μL	O
−20°C	O
methanol	O
was	O
added	O
to	O
5	O
μL	O
of	O
serum	O
sample	O
and	O
incubated	O
on	O
ice	O
for	O
10	O
min	O
,	O
followed	O
by	O
vortexing	O
and	O
centrifugation	O
at	O
16	O
,	O
000	O
×	O
g	O
for	O
10	O
min	O
at	O
4°C	O
.	O
The	O
supernatant	O
(	O
first	O
extract	O
)	O
was	O
transferred	O
to	O
a	O
new	O
tube	O
.	O
Then	O
,	O
50	O
μL	O
methanol	O
was	O
added	O
to	O
resuspend	O
the	O
pellet	O
,	O
followed	O
by	O
vortexing	O
and	O
centrifugation	O
at	O
16	O
,	O
000	O
×	O
g	O
for	O
10	O
min	O
at	O
4°C	O
.	O
The	O
supernatant	O
(	O
second	O
extract	O
)	O
was	O
combined	O
with	O
the	O
first	O
extract	O
.	O
Then	O
,	O
3	O
μL	O
of	O
the	O
150	O
μL	O
extract	O
was	O
loaded	O
to	O
LC	O
-	O
MS	O
.	O
For	O
tissue	O
samples	O
,	O
frozen	O
tissue	O
samples	O
were	O
ground	O
at	O
liquid	O
nitrogen	O
temperature	O
with	O
a	O
Cryomill	O
(	O
Retsch	O
,	O
Newtown	O
,	O
PA	O
)	O
.	O

The	O
resulting	O
tissue	O
powder	O
was	O
weighed	O
(	O
[UNK]	O
mg	O
)	O
.	O
The	O
extraction	O
was	O
then	O
done	O
by	O
adding	O
−20°C	O
40	O
:	O
40	O
:	O
20	O
methanol	O
:	O
acetonitrile	O
:	O
water	O
to	O
the	O
powder	O
and	O
incubating	O
in	O
−20°C	O
overnight	O
,	O
followed	O
by	O
vortexing	O
and	O
centrifugation	O
at	O
16	O
,	O
000	O
×	O
g	O
for	O
10	O
min	O
at	O
4°C	O
.	O
The	O
volume	O
of	O
the	O
extraction	O
solution	O
(	O
μL	O
)	O
was	O
40	O
×	O
the	O
weight	O
of	O
tissue	O
(	O
mg	O
)	O
to	O
make	O
an	O
extract	O
of	O
25	O
mg	O
tissue	O
per	O
mL	O
solvent	O
.	O
Serum	O
and	O
tissue	O
extracts	O
were	O
analyzed	O
by	O
LC	O
-	O
MS	O
,	O
using	O
two	O
different	O
LC	O
-	O
MS	O
methods	O
chosen	O
for	O
optimal	O
separation	O
of	O
glucose	O
and	O
fructose	O
(	O
in	O
serum	O
)	O
and	O
of	O
hexose	O
phosphate	O
species	O
(	O
from	O
tissues	O
)	O
.	O
Serum	O
extracts	O
were	O
analyzed	O
(	O
without	O
drying	O
)	O
using	O
a	O
quadrupole	O
-	O
orbitrap	O
mass	O
spectrometer	O
(	O
Q	O
Exactive	O
,	O
Thermo	O
Fisher	O
Scientific	O
,	O
San	O
Jose	O
,	O
CA	O
)	O
operating	O
in	O
negative	O
ion	O
mode	O
,	O
coupled	O
to	O
hydrophilic	O
interaction	O
chromatography	O
via	O
electrospray	O
ionization	O
and	O
used	O
to	O
scan	O
from	O
m	O
/	O
z	O
70	O
to	O
1000	O
at	O
1	O
Hz	O
and	O
75	O
,	O
000	O
resolution	O
.	O
LC	O
separation	O
was	O
on	O
a	O
XBridge	O
BEH	O
Amide	O
column	O
(	O
2	O
.	O
1	O
mm	O
×	O
150	O
mm	O
,	O
2	O
.	O
5	O
μm	O
particle	O
size	O
,	O
130	O
Å	O
pore	O
size	O
)	O
using	O
a	O
gradient	O
of	O
solvent	O
A	O
(	O
20	O
mM	O
ammonium	O
acetate	O
,	O
20	O
mM	O
ammonium	O
hydroxide	O
in	O
95	O
:	O
5	O
water	O
:	O
acetonitrile	O
,	O
pH	O
9	O
.	O
45	O
)	O
and	O
solvent	O
B	O
(	O
acetonitrile	O
)	O
.	O
Flow	O
rate	O
was	O
150	O
μl	O
/	O
min	O
.	O

The	O
LC	O
gradient	O
was	O
:	O
0	O
min	O
,	O
85	O
%	O
B	O
;	O
2	O
min	O
,	O
85	O
%	O
B	O
;	O
3	O
min	O
,	O
80	O
%	O
B	O
;	O
5	O
min	O
,	O
80	O
%	O
B	O
;	O
6	O
min	O
,	O
75	O
%	O
B	O
;	O
7	O
min	O
,	O
75	O
%	O
B	O
;	O
8	O
min	O
,	O
70	O
%	O
B	O
;	O
9	O
min	O
,	O
70	O
%	O
B	O
;	O
10	O
min	O
,	O
50	O
%	O
B	O
;	O
12	O
min	O
,	O
50	O
%	O
B	O
;	O
13	O
min	O
,	O
25	O
%	O
B	O
;	O
16	O
min	O
,	O
25	O
%	O
B	O
;	O
18	O
min	O
,	O
0	O
%	O
B	O
;	O
23	O
min	O
,	O
0	O
%	O
B	O
;	O
24	O
min	O
,	O
85	O
%	O
B	O
;	O
30	O
min	O
,	O
85	O
%	O
B	O
.	O
Autosampler	O
temperature	O
was	O
5°C	O
,	O
and	O
injection	O
volume	O
was	O
3	O
μL	O
.	O
Tissue	O
extracts	O
were	O
dried	O
under	O
nitrogen	O
gas	O
flow	O
and	O
re	O
-	O
dissolved	O
in	O
LC	O
-	O
MS	O
grade	O
water	O
.	O
Metabolites	O
were	O
analyzed	O
via	O
reverse	O
-	O
phase	O
ion	O
-	O
pairing	O
chromatography	O
coupled	O
to	O
an	O
Exactive	O
Orbitrap	O
mass	O
spectrometer	O
(	O
Thermo	O
Fisher	O
Scientific	O
,	O
San	O
Jose	O
,	O
CA	O
)	O
.	O
The	O
mass	O
spectrometer	O
was	O
operated	O
in	O
negative	O
ion	O
mode	O
with	O
resolving	O
power	O
of	O
100	O
,	O
000	O
at	O
m	O
/	O
z	O
200	O
and	O
scan	O
range	O
of	O
m	O
/	O
z	O
75	O
–	O
1000	O
.	O
The	O
LC	O
method	O
was	O
modified	O
from	O
an	O
earlier	O
method	O
(	O
Lu	O
et	O
al	O
.	O
,	O
2010	O
)	O
,	O
using	O
an	O
Atlantis	O
T3	O
column	O
(	O
150	O
mm	O
×	O
2	O
.	O
1	O
mm	O
,	O
3	O
μm	O
particle	O
size	O
,	O
100	O
Å	O
pore	O
size	O
)	O
,	O
with	O
a	O
gradient	O
of	O
solvent	O
A	O
(	O
97	O
:	O
3	O
water	O
:	O
methanol	O
with	O
10	O
mM	O
tributylamine	O
and	O
15	O
mM	O
acetic	O
acid	O
)	O
and	O
solvent	O
B	O
(	O
methanol	O
)	O
.	O
The	O
LC	O
gradient	O
was	O
0	O
min	O
,	O
0	O
%	O
B	O
,	O
200	O
μl	O
/	O
min	O
;	O
2	O
min	O
,	O
0	O
%	O
B	O
,	O
200	O
μl	O
/	O
min	O
;	O
4	O
min	O
,	O
20	O
%	O
B	O
,	O
200	O
μl	O
/	O
min	O
;	O
13	O
min	O
,	O
80	O
%	O
B	O
,	O
200	O
μl	O
/	O
min	O
;	O
17	O
min	O
,	O
100	O
%	O
B	O
,	O
200	O
μl	O
/	O
min	O
;	O
17	O
.	O
5	O
min	O
,	O
100	O
%	O
B	O
,	O
300	O
μl	O
/	O
min	O
;	O
20	O
min	O
,	O
100	O
%	O
B	O
,	O
300	O
μl	O
/	O
min	O
;	O
20	O
.	O
5	O
min	O
,	O
0	O
%	O
B	O
,	O
300	O
μl	O
/	O
min	O
;	O
24	O
min	O
,	O
0	O
%	O
B	O
,	O
300	O
μl	O
/	O
min	O
;	O
25	O
min	O
,	O
0	O
%	O
B	O
,	O
200	O
μl	O
/	O
min	O
.	O

Other	O
LC	O
parameters	O
,	O
common	O
to	O
both	O
methods	O
,	O
were	O
column	O
temperature	O
25°C	O
,	O
autosampler	O
temperature	O
5°C	O
,	O
and	O
injection	O
volume	O
10	O
μL	O
.	O
Data	O
analysis	O
with	O
MAVEN	O
software	O
and	O
natural	O
isotope	O
correction	O
were	O
performed	O
as	O
previously	O
described40	O
.	O
Volcano	O
plot	O
and	O
principle	O
component	O
analysis	O
of	O
metabolomics	O
data	O
were	O
generated	O
using	O
Metaboanalyst46	O
.	O
Acetate	O
was	O
derivatized	O
and	O
measured	O
by	O
LC	O
-	O
MS	O
.	O
The	O
derivatizing	O
reagent	O
was	O
12	O
mM	O
EDC	O
,	O
15	O
mM	O
3	O
-	O
Nitrophenylhydrazine	O
and	O
pyridine	O
(	O
2	O
%	O
v	O
/	O
v	O
)	O
in	O
methanol	O
.	O
Reaction	O
was	O
stopped	O
with	O
quenching	O
reagent	O
consisting	O
of	O
0	O
.	O
5	O
mM	O
beta	O
-	O
mercaptoethanol	O
in	O
water	O
.	O
Serum	O
(	O
5	O
μL	O
)	O
was	O
mixed	O
with	O
derivatizing	O
reagent	O
(	O
100	O
μL	O
)	O
and	O
incubated	O
for	O
1	O
hour	O
at	O
4°C	O
.	O
Then	O
,	O
the	O
samples	O
were	O
centrifuged	O
at	O
16	O
,	O
000	O
×	O
g	O
for	O
10	O
min	O
at	O
4°C	O
,	O
and	O
20	O
μL	O
of	O
supernatant	O
was	O
mixed	O
with	O
200	O
μL	O
of	O
the	O
quenching	O
reagent	O
.	O
After	O
centrifugation	O
at	O
16	O
,	O
000	O
×	O
g	O
for	O
10	O
min	O
at	O
4°C	O
,	O
supernatants	O
were	O
collected	O
for	O
LC	O
-	O
MS	O
analysis	O
.	O
A	O
quadrupole	O
-	O
time	O
of	O
flight	O
mass	O
spectrometer	O
(	O
Q	O
-	O
TOF	O
,	O
Agilent	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
operating	O
in	O
negative	O
ion	O
mode	O
was	O
coupled	O
to	O
C18	O
chromatography	O
via	O
electrospray	O
ionization	O
and	O
used	O
to	O
scan	O
from	O
m	O
/	O
z	O
100	O
to	O
300	O
at	O
1	O
Hz	O
and	O
15	O
,	O
000	O
resolution	O
.	O
LC	O
separation	O
was	O
on	O
an	O
Acquity	O
UPLC	O
BEH	O
C18	O
column	O
(	O
2	O
.	O
1	O
mm	O
×	O
100	O
mm	O
,	O
1	O
.	O
7	O
5	O
μm	O
particle	O
size	O
,	O
130	O
Å	O
pore	O
size	O
;	O
Waters	O
,	O
Milford	O
,	O
MA	O
)	O
using	O
a	O
gradient	O
of	O
solvent	O
A	O
(	O
0	O
.	O
01	O
%	O
formic	O
acid	O
in	O
water	O
)	O
and	O
solvent	O
B	O
(	O
0	O
.	O
01	O
%	O
formic	O
acid	O
in	O
isopropanol	O
)	O
.	O
Flow	O
rate	O
was	O
400	O
μL	O
/	O
min	O
,	O
except	O
that	O
from	O
6	O
min	O
to	O
8	O
min	O
flow	O
rate	O
was	O
increased	O
to	O
700	O
μL	O
/	O
min	O
.	O

The	O
LC	O
gradient	O
was	O
:	O
0	O
min	O
,	O
10	O
%	O
B	O
;	O
2	O
min	O
,	O
15	O
%	O
B	O
;	O
5	O
min	O
,	O
25	O
%	O
B	O
;	O
6	O
min	O
,	O
100	O
%	O
B	O
;	O
8	O
min	O
,	O
100	O
%	O
B	O
;	O
8	O
.	O
6	O
min	O
,	O
10	O
%	O
B	O
;	O
10	O
.	O
5	O
min	O
,	O
10	O
%	O
B	O
.	O
Autosampler	O
temperature	O
was	O
5°C	O
,	O
and	O
injection	O
volume	O
was	O
10	O
μL	O
.	O
Ion	O
masses	O
for	O
derivatized	O
acetate	O
was	O
194	O
.	O
Lipidomics	O
was	O
performed	O
as	O
previously	O
described47	O
,	O
with	O
some	O
modifications	O
on	O
an	O
extraction	O
step	O
.	O
Briefly	O
,	O
serum	O
samples	O
(	O
10	O
μL	O
)	O
was	O
dissolved	O
in	O
100	O
μL	O
of	O
isopropanol	O
.	O
After	O
centrifugation	O
at	O
14	O
,	O
000	O
g	O
at	O
4°C	O
for	O
10	O
min	O
,	O
supernatant	O
was	O
transferred	O
to	O
a	O
glass	O
MS	O
vial	O
and	O
injected	O
into	O
a	O
1290	O
Infinity	O
UHPLC	O
system	O
coupled	O
to	O
Agilent	O
6550	O
iFunnel	O
Q	O
-	O
TOF	O
mass	O
spectrometer	O
.	O
To	O
cover	O
both	O
the	O
positive	O
charged	O
and	O
negative	O
charged	O
species	O
,	O
each	O
sample	O
was	O
analyzed	O
twice	O
using	O
the	O
same	O
LC	O
gradient	O
but	O
with	O
different	O
mass	O
spectrometer	O
ionization	O
modes	O
.	O
The	O
LC	O
separation	O
was	O
performed	O
on	O
an	O
Agilent	O
Poroshell	O
120	O
EC	O
-	O
C18	O
column	O
(	O
150	O
×	O
2	O
.	O
1	O
mm	O
,	O
2	O
.	O
7	O
μm	O
particle	O
size	O
)	O
with	O
a	O
flow	O
rate	O
of	O
150	O
μL	O
/	O
min	O
.	O
Solvent	O
A	O
was	O
1	O
mM	O
ammonium	O
acetate	O
+	O
0	O
.	O
2	O
%	O
acetic	O
acid	O
in	O
water	O
/	O
methanol	O
(	O
90	O
:	O
10	O
)	O
.	O
Solvent	O
B	O
was	O
1	O
mM	O
ammonium	O
acetate	O
+	O
0	O
.	O
2	O
%	O
acetic	O
acid	O
in	O
methanol	O
/	O
2	O
-	O
propanol	O
(	O
2	O
:	O
98	O
)	O
.	O
The	O
solvent	O
gradient	O
in	O
volume	O
ratios	O
was	O
as	O
follows	O
:	O
0	O
–	O
2	O
min	O
,	O
25	O
%	O
B	O
;	O
2	O
–	O
4	O
min	O
,	O
25	O
to	O
65	O
%	O
B	O
;	O
4	O
–	O
16	O
min	O
,	O
65	O
to	O
100	O
%	O
B	O
;	O
16	O
–	O
20	O
min	O
,	O
100	O
%	O
B	O
;	O
20	O
–	O
21	O
min	O
,	O
100	O
to	O
25	O
%	O
B	O
;	O
21	O
–	O
27	O
min	O
,	O
25	O
%	O
B	O
.	O
Principle	O
component	O
analysis	O
was	O
generated	O
using	O
Metaboanalyst46	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
metaboanalyst	O
.	O
ca	O
)	O
and	O
heatmap	O
of	O
lipidomics	O
data	O
was	O
generated	O
using	O
Morpheus	O
(	O
https	O
:	O
/	O
/	O
software	O
.	O
broadinstitute	O
.	O
org	O
/	O
morpheus	O
)	O
.	O

This	O
work	O
was	O
supported	O
by	O
grant	O
R01CA174761	O
,	O
R01CA228339	O
,	O
and	O
R01DK116005	O
to	O
K	O
.	O
E	O
.	O
W	O
.	O
S	O
.	O
Z	O
.	O
is	O
supported	O
by	O
pre	O
-	O
doctoral	O
fellowship	O
F99CA222741	O
.	O
C	O
.	O
J	O
.	O
is	O
supported	O
by	O
the	O
American	O
Diabetes	O
Association	O
through	O
post	O
-	O
doctoral	O
fellowship	O
1	O
-	O
17	O
-	O
PDF	O
-	O
076	O
.	O
K	O
.	O
U	O
.	O
is	O
supported	O
by	O
NIAMS	O
training	O
grant	O
T32AR053461	O
.	O
L	O
.	O
I	O
.	O
is	O
supported	O
by	O
NIGMS	O
training	O
grant	O
T32GM07229	O
.	O
S	O
.	O
T	O
.	O
is	O
supported	O
by	O
the	O
American	O
Diabetes	O
Association	O
through	O
post	O
-	O
doctoral	O
fellowship	O
1	O
-	O
18	O
-	O
PDF	O
-	O
144	O
.	O
S	O
.	O
F	O
.	O
is	O
supported	O
through	O
the	O
Penn	O
-	O
PORT	O
IRACDA	O
grant	O
K12	O
GM081259	O
.	O
P	O
.	O
M	O
.	O
T	O
.	O
is	O
supported	O
by	O
K01DK111715	O
.	O
N	O
.	O
W	O
.	O
S	O
.	O
is	O
supported	O
by	O
the	O
NIH	O
grant	O
R03HD092630	O
and	O
R01GM132261	O
.	O
J	O
.	O
D	O
.	O
R	O
.	O
is	O
supported	O
by	O
the	O
NIH	O
Pioneer	O
Award	O
1DP1DK113643	O
and	O
Diabetes	O
Research	O
Center	O
P30	O
DK019525	O
.	O
We	O
thank	O
Dr	O
.	O
Shelley	O
Berger	O
and	O
Dr	O
.	O
Phillip	O
Mews	O
for	O
providing	O
the	O
AAV	O
.	O
U6	O
.	O
shAcss2	O
.	O
CMV	O
.	O
eGFP	O
.	O
SV40	O
vector	O
.	O
We	O
thank	O
Dr	O
.	O
Gary	O
Wu	O
and	O
Dr	O
.	O
Yedidya	O
Saimon	O
for	O
helpful	O
discussions	O
on	O
the	O
microbiome	O
.	O
J	O
.	O
D	O
.	O
R	O
.	O
is	O
a	O
consultant	O
to	O
Pfizer	O
and	O
to	O
Colorado	O
Research	O
Partners	O
.	O
All	O
other	O
authors	O
declare	O
no	O
conflicts	O
of	O
interest	O
.	O
Data	O
Availability	O
:	O
All	O
data	O
generated	O
or	O
analysed	O
during	O
this	O
study	O
are	O
included	O
in	O
this	O
published	O
article	O
(	O
and	O
its	O
supplementary	O
information	O
files	O
)	O
.	O

Impaired	O
CPT1A	O
Gene	O
Expression	O
Response	O
to	O
Retinoic	O
Acid	O
Treatment	O
in	O
Human	O
PBMC	O
as	O
Predictor	O
of	O
Metabolic	O
Risk	O
blood	O
cells	O
;	O
biomarkers	O
;	O
retinoic	O
acid	O
;	O
obesity	O
;	O
HDL	O
-	O
cholesterol	O
Ex	B-methodology
vivo	I-methodology
human	O
peripheral	O
blood	O
mononuclear	O
cell	O
(	O
PBMC	O
)	O
systems	O
offer	O
the	O
possibility	O
to	O
test	O
transcriptomic	O
effects	O
of	O
food	O
bioactive	O
compounds	O
with	O
potential	O
health	O
effects	O
.	O
We	O
investigated	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
effect	O
on	O
mRNA	O
expression	O
of	O
key	O
lipid	O
metabolism	O
and	O
inflammatory	O
genes	O
in	O
PBMCs	O
from	O
normal	O
-	O
weight	O
(	O
NW	O
)	O
and	O
overweight	O
-	O
obese	O
(	O
OW	O
-	O
OB	O
)	O
men	O
with	O
different	O
metabolic	O
syndrome	O
-	O
related	O
features	O
.	O
PBMCs	O
were	O
incubated	O
with	O
10	O
µM	O
ATRA	O
and	O
mRNA	O
levels	O
of	O
selected	O
genes	O
were	O
analyzed	O
using	O
real	O
-	O
time	O
RT	O
-	O
qPCR	O
.	O
Human	O
ex	B-methodology
vivo	I-methodology
PBMCs	O
responded	O
to	O
ATRA	O
treatment	O
,	O
but	O
the	O
response	O
for	O
some	O
genes	O
was	O
dependent	O
on	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
with	O
a	O
lower	O
response	O
in	O
PBMC	O
from	O
OW	O
-	O
OB	O
than	O
from	O
NW	O
donors	O
.	O
Moreover	O
,	O
gene	O
expression	O
response	O
was	O
affected	O
by	O
circulating	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
-	O
cholesterol	O
levels	O
.	O
Particularly	O
,	O
the	O
response	O
to	O
ATRA	O
of	O
CPT1A	O
,	O
previously	O
reported	O
as	O
a	O
sensitive	O
metabolic	O
risk	O
predictive	O
biomarker	O
,	O
was	O
dependent	O
on	O
HDL	O
levels	O
and	O
not	O
on	O
BMI	O
,	O
being	O
impaired	O
in	O
those	O
individuals	O
with	O
lower	O
HDL	O
levels	O
,	O
specifically	O
in	O
OW	O
-	O
OB	O
.	O
Thus	O
,	O
PBMCs	O
’	O
insensitivity	O
to	O
ATRA	O
,	O
which	O
can	O
be	O
considered	O
as	O
indicative	O
of	O
impaired	O
metabolism	O
,	O
was	O
observed	O
in	O
individuals	O
with	O
higher	O
metabolic	O
risk	O
(	O
OW	O
-	O
OB	O
with	O
low	O
HDL	O
levels	O
)	O
.	O
In	O
conclusion	O
,	O
an	O
ex	B-methodology
vivo	I-methodology
human	O
PBMC	O
system	O
indicates	O
that	O
ATRA	O
response	O
could	O
be	O
influenced	O
by	O
metabolic	O
syndrome	O
features	O
.	O
Moreover	O
,	O
our	O
study	O
reinforces	O
the	O
role	O
of	O
CPT1A	O
as	O
a	O
marker	O
of	O
metabolic	O
risk	O
and	O
points	O
to	O
plasmatic	O
HDL	O
-	O
cholesterol	O
levels	O
as	O
a	O
parameter	O
to	O
take	O
into	O
consideration	O
when	O
the	O
effects	O
of	O
nutritional	O
factors	O
and	O
/	O
or	O
dietary	B-methodology
interventions	I-methodology
on	O
humans	O
are	O
under	O
study	O
.	O
Further	O
studies	O
including	O
women	O
are	O
required	O
to	O
detect	O
potential	O
gender	O
differences	O
in	O
the	O
observed	O
effects	O
.	O

In	O
recent	O
years	O
,	O
metabolic	O
-	O
related	O
health	O
problems	O
have	O
emerged	O
as	O
a	O
result	O
of	O
the	O
increasing	O
incidence	O
of	O
obesity	O
and	O
metabolic	O
alterations	O
linked	O
to	O
metabolic	O
syndrome	O
[	O
1	O
]	O
.	O
Both	O
obesity	O
and	O
metabolic	O
syndrome	O
play	O
a	O
crucial	O
role	O
in	O
the	O
origin	O
of	O
type	O
2	O
diabetes	O
and	O
cardiometabolic	O
diseases	O
[	O
2	O
]	O
.	O
Nowadays	O
,	O
the	O
available	O
treatments	O
against	O
these	O
metabolic	O
abnormalities	O
are	O
poorly	O
effective	O
;	O
therefore	O
,	O
prevention	O
strategies	O
are	O
those	O
that	O
should	O
receive	O
more	O
attention	O
.	O
In	O
this	O
sense	O
,	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
,	O
a	O
subset	O
of	O
blood	O
cells	O
consisting	O
of	O
lymphocytes	O
and	O
monocytes	O
,	O
are	O
being	O
consolidated	O
as	O
a	O
biological	O
tool	O
for	O
the	O
search	O
of	O
health	O
metabolic	O
biomarkers	O
as	O
they	O
are	O
easy	O
to	O
obtain	O
and	O
their	O
gene	O
expression	O
is	O
representative	O
of	O
whole	O
metabolic	O
status	O
[	O
3	O
,	O
4	O
]	O
.	O
Our	O
group	O
previously	O
reported	O
that	O
PBMCs	O
could	O
reflect	O
the	O
response	O
to	O
nutritional	O
interventions	O
,	O
metabolic	O
alterations	O
or	O
other	O
pathophysiological	O
conditions	O
related	O
to	O
obesity	O
at	O
level	O
of	O
gene	O
expression	O
both	O
in	O
human	O
and	O
animal	B-methodology
models	I-methodology
[	O
5	O
,	O
6	O
,	O
7	O
,	O
8	O
,	O
9	O
,	O
10	O
]	O
.	O
Moreover	O
,	O
we	O
have	O
shown	O
that	O
human	O
PBMCs	O
maintained	O
ex	B-methodology
vivo	I-methodology
represent	O
an	O
interesting	O
tool	O
to	O
test	O
the	O
effects	O
of	O
food	O
bioactive	O
compounds	O
and	O
to	O
discern	O
the	O
differential	O
transcriptomic	O
response	O
to	O
those	O
compounds	O
related	O
to	O
increased	O
body	O
weight	O
[	O
11	O
]	O
.	O
Previous	O
studies	O
from	O
our	O
group	O
showed	O
that	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
the	O
active	O
metabolite	O
of	O
vitamin	O
A	O
,	O
reduces	O
body	O
weight	O
and	O
adiposity	O
[	O
12	O
,	O
13	O
,	O
14	O
]	O
and	O
ameliorates	O
glucose	O
tolerance	O
,	O
insulin	O
sensitivity	O
,	O
dyslipidemia	O
,	O
and	O
hepatic	O
steatosis	O
in	O
diet	O
-	O
induced	O
obese	O
mice	O
[	O
15	O
,	O
16	O
,	O
17	O
]	O
.	O
It	O
is	O
known	O
that	O
a	O
large	O
part	O
of	O
these	O
beneficial	O
effects	O
is	O
mediated	O
through	O
the	O
action	O
of	O
RA	O
on	O
adipose	O
tissue	O
,	O
a	O
key	O
tissue	O
whose	O
expansion	O
has	O
been	O
related	O
to	O
the	O
development	O
of	O
obesity	O
and	O
other	O
metabolic	O
disorders	O
.	O
The	O
role	O
of	O
RA	O
regarding	O
metabolism	O
of	O
adipose	O
tissue	O
has	O
been	O
generally	O
proven	O
in	B-methodology
vitro	I-methodology
.	O
It	O
has	O
been	O
demonstrated	O
that	O
RA	O
is	O
involved	O
in	O
the	O
control	O
of	O
adiposity	O
,	O
affects	O
adaptive	O
thermogenesis	O
,	O
and	O
promotes	O
increased	O
fatty	O
acid	O
oxidative	O
metabolism	O
[	O
18	O
,	O
19	O
]	O
.	O

However	O
,	O
apart	O
from	O
animal	B-methodology
studies	I-methodology
,	O
evidences	O
suggesting	O
a	O
potential	O
role	O
of	O
RA	O
in	O
the	O
control	O
of	O
adiposity	O
and	O
other	O
factors	O
related	O
to	O
metabolic	O
abnormalities	O
in	O
human	O
populations	O
are	O
very	O
limited	O
.	O
In	O
fact	O
,	O
contradictory	O
data	O
appear	O
on	O
the	O
effect	O
of	O
vitamin	O
A	O
and	O
its	O
derivatives	O
on	O
humans	O
[	O
20	O
]	O
.	O
However	O
,	O
although	O
evidences	O
exist	O
pointing	O
to	O
a	O
connection	O
of	O
vitamin	O
A	O
or	O
RA	O
and	O
metabolic	O
risk	O
,	O
human	B-methodology
studies	I-methodology
do	O
not	O
provide	O
consistent	O
associations	O
with	O
obesity	O
or	O
insulin	O
resistance	O
[	O
20	O
,	O
21	O
]	O
.	O
Moreover	O
,	O
the	O
majority	O
of	O
preclinical	O
and	O
clinical	B-methodology
studies	I-methodology
agree	O
that	O
an	O
adequate	O
vitamin	O
A	O
/	O
RA	O
status	O
has	O
a	O
preventive	O
role	O
on	O
cardiovascular	O
health	O
,	O
while	O
an	O
excess	O
or	O
deficiency	O
can	O
increase	O
the	O
cardiovascular	O
risk	O
[	O
22	O
]	O
.	O
Interestingly	O
,	O
although	O
only	O
a	O
few	O
studies	O
exist	O
on	O
RA	O
,	O
it	O
has	O
been	O
shown	O
to	O
be	O
inversely	O
correlated	O
with	O
metabolic	O
syndrome	O
and	O
cardiovascular	O
risk	O
[	O
20	O
,	O
23	O
]	O
.	O
Thus	O
,	O
there	O
is	O
a	O
need	O
of	O
additional	O
research	O
to	O
clarify	O
RA	O
’	O
s	O
role	O
on	O
health	O
,	O
and	O
its	O
mechanisms	O
of	O
action	O
.	O
The	O
possibility	O
to	O
have	O
an	O
ex	B-methodology
vivo	I-methodology
system	O
of	O
human	O
PBMCs	O
whose	O
gene	O
expression	O
are	O
representative	O
of	O
whole	O
metabolic	O
status	O
would	O
be	O
extremely	O
useful	O
to	O
test	O
the	O
effects	O
of	O
RA	O
without	O
the	O
need	O
of	O
administering	O
it	O
(	O
avoiding	O
potential	O
problems	O
of	O
toxicity	O
)	O
.	O
It	O
is	O
well	O
known	O
that	O
RA	O
exerts	O
its	O
biological	O
effects	O
in	O
large	O
part	O
by	O
controlling	O
gene	O
expression	O
.	O
RA	O
acts	O
through	O
the	O
binding	O
and	O
activation	O
of	O
members	O
of	O
the	O
nuclear	O
receptor	O
family	O
including	O
retinoic	O
acid	O
receptors	O
(	O
RARs	O
)	O
and	O
retinoid	O
X	O
receptors	O
(	O
RXRs	O
)	O
,	O
both	O
existing	O
in	O
different	O
isoforms	O
[	O
18	O
]	O
.	O
In	O
addition	O
,	O
RXRs	O
serve	O
as	O
obligate	O
heterodimeric	O
partners	O
for	O
other	O
nuclear	O
receptors	O
,	O
including	O
peroxisome	O
proliferator	O
-	O
activated	O
receptors	O
(	O
PPARs	O
)	O
deeply	O
involved	O
in	O
the	O
control	O
of	O
lipid	O
metabolism	O
[	O
18	O
]	O
.	O
The	O
activation	O
of	O
these	O
receptors	O
elicits	O
a	O
modulation	O
of	O
key	O
inflammation	O
and	O
metabolic	O
pathways	O
related	O
to	O
lipid	O
metabolism	O
,	O
two	O
processes	O
linked	O
to	O
the	O
development	O
of	O
obesity	O
and	O
metabolic	O
-	O
related	O
abnormalities	O
.	O
Both	O
retinoid	O
receptors	O
and	O
PPARs	O
are	O
expressed	O
in	O
PBMCs	O
[	O
24	O
,	O
25	O
]	O
.	O

Considering	O
the	O
usefulness	O
of	O
PBMCs	O
to	O
obtain	O
biomarkers	O
related	O
to	O
nutrition	O
and	O
obesity	O
[	O
4	O
]	O
,	O
here	O
we	O
investigated	O
the	O
action	O
of	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
on	O
the	O
expression	O
of	O
key	O
inflammatory	O
and	O
lipid	O
metabolism	O
genes	O
on	O
an	O
ex	B-methodology
vivo	I-methodology
system	O
of	O
PBMCs	O
from	O
normal	O
-	O
weight	O
and	O
overweight	O
-	O
obese	O
humans	O
and	O
its	O
relation	O
with	O
metabolic	O
syndrome	O
-	O
related	O
features	O
.	O
Our	O
first	O
aim	O
was	O
to	O
determine	O
the	O
usefulness	O
of	O
this	O
surrogate	O
system	O
to	O
study	O
ATRA	O
effect	O
analyzing	O
potential	O
differential	O
outcomes	O
depending	O
on	O
body	O
weight	O
.	O
When	O
analyzing	O
the	O
data	O
,	O
we	O
realized	O
that	O
the	O
effect	O
of	O
ATRA	O
on	O
gene	O
expression	O
was	O
not	O
dependent	O
only	O
on	O
body	O
mass	O
index	O
but	O
on	O
the	O
circulating	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
-	O
cholesterol	O
levels	O
.	O
Results	O
obtained	O
for	O
CPT1A	O
expression	O
,	O
previously	O
reported	O
as	O
a	O
biomarker	O
of	O
diet	O
-	O
related	O
metabolic	O
alterations	O
[	O
7	O
,	O
26	O
]	O
,	O
appeared	O
of	O
particular	O
interest	O
.	O
Thus	O
,	O
subsequently	O
,	O
additional	O
subgroups	O
were	O
made	O
based	O
on	O
circulating	O
HDL	O
levels	O
of	O
the	O
PBMC	O
donors	O
and	O
of	O
the	O
degree	O
of	O
CPT1A	O
response	O
to	O
ATRA	O
treatment	O
,	O
to	O
find	O
out	O
biomarkers	O
of	O
metabolic	O
risk	O
beyond	O
the	O
typical	O
ones	O
in	O
order	O
to	O
provide	O
more	O
personalized	O
diagnostic	O
tools	O
.	O
Experiments	O
were	O
performed	O
with	O
blood	O
samples	O
collected	O
from	O
volunteers	O
of	O
the	O
NUTRI	O
-	O
BLOOD	O
study	O
.	O
Informed	O
consent	O
to	O
participate	O
in	O
the	O
study	O
was	O
obtained	O
from	O
all	O
volunteers	O
.	O
The	O
study	O
was	O
conducted	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
,	O
and	O
the	O
protocol	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
Research	O
of	O
the	O
Balearic	O
Islands	O
(	O
CEI	O
-	O
IB	O
)	O
(	O
NUTRI	O
-	O
BLOOD	O
study	O
,	O
no	O
.	O
IB	O
2114	O
/	O
13	O
PI	O
)	O
.	O
Eighteen	O
apparently	O
healthy	O
men	O
aged	O
19	O
–	O
36	O
years	O
were	O
divided	O
into	O
two	O
groups	O
according	O
to	O
their	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
:	O
normal	O
-	O
weight	O
(	O
NW	O
)	O
group	O
(	O
BMI	O
<	O
25	O
kg	O
/	O
m2	O
)	O
and	O
overweight	O
-	O
obese	O
(	O
OW	O
-	O
OB	O
)	O
group	O
(	O
BMI	O
≥25	O
kg	O
/	O
m2	O
)	O
composed	O
of	O
9	O
subjects	O
each	O
.	O
The	O
number	O
of	O
individuals	O
per	O
group	O
was	O
selected	O
based	O
on	O
what	O
is	O
usual	O
in	O
previous	O
ex	O
vivo	O
experiments	O
performed	O
with	O
human	O
PBMCs	O
focused	O
on	O
gene	O
expression	O
analysis	O
(	O
e	O
.	O
g	O
.	O
,	O
[	O
27	O
,	O
28	O
]	O
)	O
,	O
as	O
well	O
as	O
on	O
our	O
own	O
preliminary	O
observations	O
.	O
NW	O
group	O
was	O
considered	O
as	O
the	O
control	B-methodology
group	I-methodology
.	O

The	O
inclusion	B-methodology
criteria	I-methodology
were	O
as	O
follows	O
:	O
men	O
aged	O
18	O
–	O
45	O
years	O
not	O
suffering	O
from	O
chronic	O
disease	O
,	O
not	O
taking	O
regular	O
medication	O
or	O
drugs	O
,	O
keeping	O
their	O
habitual	O
diet	O
,	O
and	O
non	O
-	O
smokers	O
.	O
The	O
study	O
was	O
performed	O
only	O
with	O
males	O
to	O
avoid	O
any	O
potential	O
interference	O
,	O
which	O
could	O
appear	O
due	O
to	O
menstrual	O
cycle	O
hormonal	O
fluctuations	O
occurring	O
in	O
women	O
.	O
Blood	O
was	O
obtained	O
after	O
nocturnal	O
fast	O
.	O
The	O
same	O
day	O
of	O
blood	O
collection	O
,	O
anthropometric	O
(	O
weight	O
,	O
height	O
,	O
BMI	O
,	O
kg	O
of	O
fat	O
,	O
%	O
of	O
fat	O
and	O
blood	O
pressure	O
)	O
and	O
blood	O
parameters	O
(	O
glucose	O
and	O
triglycerides	O
)	O
were	O
also	O
collected	O
.	O
Anthropometric	O
and	O
most	O
relevant	O
circulating	O
parameters	O
of	O
the	O
volunteers	O
were	O
previously	O
reported	O
[	O
11	O
]	O
.	O
In	O
brief	O
,	O
compared	O
to	O
NW	O
group	O
,	O
OW	O
-	O
OB	O
subjects	O
displayed	O
increased	O
body	O
weight	O
,	O
BMI	O
,	O
fat	O
content	O
,	O
and	O
higher	O
blood	O
pressure	O
(	O
both	O
systolic	O
and	O
diastolic	O
)	O
.	O
OW	O
-	O
OB	O
group	O
showed	O
glucose	O
,	O
triglycerides	O
,	O
total	O
and	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
-	O
cholesterol	O
levels	O
comparable	O
to	O
those	O
in	O
the	O
NW	O
group	O
.	O
However	O
,	O
they	O
presented	O
signs	O
of	O
insulin	O
resistance	O
,	O
such	O
as	O
increased	O
fasting	O
circulating	O
insulin	O
levels	O
and	O
a	O
trend	O
for	O
increased	O
homeostatic	O
model	O
assessment	O
for	O
insulin	O
resistance	O
(	O
HOMA	O
-	O
IR	O
)	O
index	O
(	O
p	O
<	O
0	O
.	O
1	O
)	O
,	O
as	O
well	O
as	O
lower	O
plasma	O
HDL	O
-	O
cholesterol	O
.	O
Moreover	O
,	O
the	O
proportion	O
of	O
lymphocytes	O
and	O
monocytes	O
in	O
PBMC	O
samples	O
was	O
not	O
different	O
between	O
both	O
groups	O
(	O
an	O
average	O
of	O
84	O
%	O
lymphocytes	O
and	O
16	O
%	O
monocytes	O
)	O
,	O
discarding	O
in	O
this	O
way	O
that	O
differences	O
in	O
gene	O
expression	O
when	O
analyzing	O
the	O
PBMC	O
samples	O
could	O
be	O
influenced	O
by	O
differences	O
in	O
the	O
amount	O
of	O
the	O
two	O
cell	O
types	O
.	O
During	O
the	O
process	O
of	O
data	O
analysis	O
,	O
subjects	O
were	O
divided	O
into	O
additional	O
groups	O
/	O
subgroups	O
.	O
On	O
one	O
hand	O
,	O
all	O
the	O
subjects	O
participating	O
in	O
the	O
study	O
were	O
separated	O
into	O
two	O
groups	O
considering	O
their	O
circulating	O
HDL	O
levels	O
(	O
low	O
or	O
high	O
)	O
.	O
The	O
low	O
HDL	O
group	O
was	O
composed	O
of	O
6	O
individuals	O
with	O
HDL	O
levels	O
<	O
40	O
mg	O
/	O
dL	O
,	O
using	O
as	O
cut	O
-	O
off	O
valuethat	O
established	O
in	O
the	O
National	O
Cholesterol	O
Treatment	O
Panel	O
guidelines	B-methodology
[	O
29	O
]	O
.	O

The	O
high	O
HDL	O
group	O
was	O
composed	O
of	O
12	O
individuals	O
with	O
HDL	O
levels	O
>	O
40	O
mg	O
/	O
dL	O
.	O
Moreover	O
,	O
subjects	O
of	O
the	O
NW	O
and	O
OW	O
-	O
OB	O
groups	O
were	O
divided	O
into	O
two	O
subgroups	O
considering	O
the	O
degree	O
of	O
CPT1A	O
gene	O
expression	O
response	O
of	O
their	O
PBMCs	O
treated	O
ex	B-methodology
vivo	I-methodology
with	O
ATRA	O
(	O
i	O
.	O
e	O
.	O
,	O
high	O
or	O
low	O
CPT1A	O
response	O
)	O
.	O
Median	O
CPT1A	O
response	O
to	O
ATRA	O
in	O
ex	B-methodology
vivo	I-methodology
PBMCs	O
from	O
all	O
donors	O
(	O
with	O
independence	O
of	O
their	O
range	O
of	O
body	O
weight	O
)	O
was	O
established	O
as	O
the	O
split	O
point	O
.	O
The	O
use	O
of	O
median	O
as	O
separating	O
threshold	O
value	O
to	O
dichotomize	O
subjects	O
into	O
high	O
vs	O
.	O
low	O
responders	O
is	O
commonly	O
used	O
in	O
basic	O
and	O
clinical	B-methodology
research	I-methodology
.	O
A	O
high	O
response	O
was	O
considered	O
when	O
CPT1A	O
expression	O
increased	O
16	O
%	O
over	O
the	O
baseline	O
value	O
.	O
In	O
this	O
way	O
,	O
four	O
different	O
subgroups	O
were	O
obtained	O
:	O
NW	O
with	O
high	O
(	O
n	O
=	O
4	O
)	O
or	O
low	O
(	O
n	O
=	O
5	O
)	O
CPT1A	O
response	O
and	O
OW	O
-	O
OB	O
with	O
high	O
(	O
n	O
=	O
5	O
)	O
or	O
low	O
(	O
n	O
=	O
4	O
)	O
CPT1A	O
response	O
.	O
The	O
sample	O
size	O
,	O
even	O
after	O
subgrouping	O
,	O
was	O
appropriated	O
for	O
ex	O
vivo	O
experiments	O
in	O
which	O
the	O
conditions	O
are	O
more	O
controlled	O
than	O
in	O
intervention	B-methodology
studies	I-methodology
.	O
ATRA	O
was	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
and	O
was	O
prepared	O
dissolved	O
in	O
absolute	O
ethanol	O
as	O
a	O
stock	O
solution	O
(	O
10	O
mM	O
)	O
,	O
stored	O
in	O
single	O
use	O
aliquots	O
at	O
−80	O
°C	O
to	O
prevent	O
repeated	O
freeze	O
thaw	O
cycles	O
and	O
protected	O
from	O
light	O
.	O
A	O
final	O
concentration	O
of	O
10	O
µM	O
ATRA	O
was	O
administered	O
to	O
human	O
PBMCs	O
maintained	O
ex	B-methodology
vivo	I-methodology
.	O
This	O
concentration	O
has	O
been	O
proven	O
non	O
-	O
toxic	O
in	O
other	O
studies	O
using	O
different	O
cell	O
types	O
,	O
including	O
PBMCs	O
[	O
30	O
]	O
.	O
We	O
tested	O
the	O
10	O
μM	O
dose	O
on	O
PBMCs	O
from	O
a	O
pool	O
of	O
two	O
overweight	O
-	O
obese	O
individuals	O
to	O
determine	O
%	O
of	O
cytotoxicity	O
of	O
ATRA	O
treatment	O
based	O
on	O
the	O
measurement	O
of	O
LDH	O
activity	O
released	O
from	O
damaged	O
cells	O
(	O
Roche	O
Diagnostics	O
,	O
Barcelona	O
,	O
Spain	O
)	O
.	O
The	O
toxicity	O
test	O
was	O
performed	O
twice	O
with	O
samples	O
coming	O
from	O
triplicate	O
cultures	O
of	O
ATRA	O
-	O
treated	O
and	O
non	O
-	O
treated	O
cells	O
.	O

In	O
one	O
of	O
the	O
tests	O
,	O
we	O
observed	O
up	O
to	O
a	O
maximum	O
of	O
15	O
%	O
cytotoxicity	O
(	O
lysis	O
)	O
in	O
10	O
µM	O
ATRA	O
-	O
treated	O
cells	O
.	O
However	O
,	O
the	O
average	O
results	O
from	O
both	O
tests	O
showed	O
no	O
difference	O
in	O
the	O
percentage	O
of	O
cytotoxicity	O
:	O
0	O
%	O
for	O
control	O
and	O
0	O
.	O
7	O
%	O
for	O
ATRA	O
-	O
treated	O
cells	O
.	O
The	O
maximum	O
LDH	O
release	O
(	O
i	O
.	O
e	O
.	O
,	O
positive	O
control	O
(	O
100	O
%	O
of	O
toxicity	O
)	O
)	O
was	O
obtained	O
by	O
adding	O
a	O
lysis	O
reagent	O
to	O
control	O
cells	O
.	O
Venous	O
blood	O
from	O
the	O
volunteers	O
was	O
collected	O
in	O
EDTA	O
tubes	O
and	O
diluted	O
1	O
:	O
1	O
with	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
1×	O
.	O
PBMC	O
isolation	O
was	O
performed	O
by	O
density	O
gradient	O
over	O
Ficoll	O
-	O
Paque	O
Plus	O
(	O
GE	O
Healthcare	O
Bio	O
Science	O
,	O
Barcelona	O
,	O
Spain	O
)	O
,	O
with	O
30	O
min	O
centrifugation	O
at	O
400×	O
g	O
,	O
25	O
°C	O
,	O
with	O
no	O
break	O
.	O
After	O
centrifugation	O
,	O
plasma	O
samples	O
were	O
obtained	O
(	O
top	O
layer	O
)	O
and	O
stored	O
at	O
−80	O
°C	O
.	O
The	O
PBMC	O
layer	O
was	O
then	O
collected	O
and	O
washed	O
with	O
PBS	O
1×	O
(	O
twice	O
)	O
by	O
centrifugation	O
for	O
10	O
min	O
at	O
300×	O
g	O
(	O
25	O
°C	O
)	O
.	O
Then	O
,	O
the	O
obtained	O
PBMCs	O
were	O
adjusted	O
to	O
4	O
×	O
106	O
cells	O
/	O
mL	O
using	O
sterile	O
RPMI	O
-	O
1640	O
culture	O
medium	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
1	O
%	O
L	O
-	O
glutamine	O
(	O
2	O
mM	O
)	O
,	O
100	O
unit	O
/	O
mL	O
penicillin	O
,	O
and	O
100	O
µg	O
/	O
mL	O
streptomycin	O
(	O
reagents	O
from	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O
A	O
final	O
concentration	O
of	O
1	O
×	O
106	O
cells	O
from	O
NW	O
and	O
OW	O
-	O
OB	O
donors	O
was	O
maintained	O
in	O
suspension	O
in	O
24	O
-	O
well	O
plates	O
.	O
Cells	O
were	O
activated	O
using	O
CD3	O
/	O
CD28	O
magnetic	O
beads	O
(	O
one	O
bead	O
each	O
two	O
cells	O
)	O
(	O
Life	O
Technologies	O
,	O
Madrid	O
,	O
Spain	O
)	O
.	O

Each	O
well	O
was	O
treated	O
with	O
ATRA	O
diluted	O
in	O
RPMI	O
-	O
1640	O
culture	O
medium	O
in	O
a	O
final	O
concentration	O
of	O
10	O
µM	O
.	O
The	O
original	O
ATRA	O
solution	O
stock	O
was	O
dissolved	O
in	O
ethanol	O
that	O
was	O
present	O
in	O
a	O
final	O
concentration	O
of	O
0	O
.	O
1	O
%	O
in	O
the	O
treated	O
wells	O
;	O
an	O
equivalent	O
dose	O
of	O
ethanol	O
was	O
added	O
to	O
control	O
cells	O
.	O
Additionally	O
,	O
PBMC	O
cultures	O
from	O
three	O
non	O
-	O
obese	O
participants	O
were	O
set	O
up	O
to	O
evaluate	O
the	O
dose	O
-	O
dependent	O
effects	O
of	O
ATRA	O
;	O
hence	O
,	O
1	O
and	O
10	O
µM	O
of	O
this	O
compound	O
were	O
assessed	O
.	O
The	O
dose	O
-	O
dependent	O
test	O
was	O
performed	O
directly	O
in	O
normal	O
-	O
weight	O
subjects	O
as	O
we	O
previously	O
reported	O
the	O
insensitivity	O
of	O
ex	B-methodology
vivo	I-methodology
PBMCs	O
to	O
food	O
bioactives	O
as	O
a	O
result	O
of	O
increased	O
body	O
weight	O
[	O
11	O
]	O
.	O
The	O
cultures	O
were	O
maintained	O
at	O
37	O
°C	O
in	O
an	O
atmosphere	O
of	O
5	O
%	O
CO2	O
for	O
48	O
h	O
.	O
The	O
48	O
h	O
incubation	O
period	O
was	O
chosen	O
based	O
on	O
our	O
previous	O
optimization	O
experiments	O
,	O
which	O
showed	O
a	O
maximum	O
effect	O
on	O
gene	O
expression	O
modulation	O
in	O
comparison	O
to	O
a	O
24	O
h	O
incubation	O
period	O
,	O
without	O
affecting	O
cell	O
viability	O
.	O
Total	O
RNA	O
was	O
isolated	O
from	O
human	O
PBMC	O
after	O
48	O
h	O
ex	B-methodology
vivo	I-methodology
incubation	O
with	O
ATRA	O
,	O
using	O
Direct	O
-	O
[UNK]	O
RNA	O
Mini	O
-	O
Prep	O
(	O
Zymo	O
Research	O
Corp	O
,	O
Irvine	O
,	O
CA	O
,	O
USA	O
)	O
.	O
RNA	O
integrity	O
was	O
confirmed	O
by	O
agarose	O
gel	O
electrophoresis	O
.	O
RNA	O
(	O
0	O
.	O
05	O
µg	O
)	O
was	O
transcribed	O
into	O
cDNA	O
using	O
an	O
[UNK]	O
cDNA	O
synthesis	O
kit	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
,	O
Madrid	O
,	O
Spain	O
)	O
in	O
an	O
Applied	O
Biosystems	O
2720	O
Thermal	O
Cycler	O
.	O
For	O
each	O
PBMC	O
sample	O
,	O
three	O
replicates	O
were	O
reverse	O
-	O
transcribed	O
,	O
and	O
real	O
-	O
time	O
qPCR	O
was	O
performed	O
for	O
each	O
RT	O
product	O
(	O
three	O
PCRs	O
per	O
sample	O
)	O
.	O
The	O
mRNA	O
expression	O
of	O
inflammatory	O
and	O
energy	O
metabolism	O
genes	O
of	O
interest	O
was	O
analyzed	O
.	O
Each	O
PCR	O
was	O
carried	O
out	O
as	O
previously	O
described	O
[	O
31	O
]	O
.	O
To	O
calculate	O
the	O
threshold	O
cycle	O
(	O
Ct	O
)	O
the	O
instrument	O
software	O
(	O
StepOne	O
Software	O
v2	O
.	O
0	O
,	O
from	O
Applied	O
Biosystems	O
)	O
was	O
used	O
.	O
The	O
relative	O
mRNA	O
expression	O
was	O
calculated	O
for	O
each	O
sample	O
as	O
a	O
percentage	O
referred	O
to	O
gene	O
expression	O
of	O
control	O
PBMC	O
from	O
NW	O
group	O
(	O
which	O
was	O
set	O
as	O
100	O
%	O
)	O
,	O
using	O
Livak	O
’	O
s	O
method	O
[	O
32	O
]	O
.	O

For	O
data	O
normalization	O
the	O
housekeeping	O
gene	O
ribosomal	O
protein	O
,	O
large	O
,	O
P0	O
(	O
RPLP0	O
)	O
/	O
human	O
acidic	O
ribosomal	O
protein	O
(	O
HuPO	O
)	O
,	O
which	O
was	O
selected	O
from	O
a	O
panel	O
of	O
tested	O
genes	O
due	O
to	O
its	O
higher	O
stability	O
among	O
groups	O
,	O
was	O
used	O
.	O
This	O
gene	O
has	O
been	O
previously	O
described	O
as	O
a	O
stable	O
reference	O
gene	O
for	O
isolated	O
human	O
PBMCs	O
[	O
33	O
,	O
34	O
]	O
.	O
Primers	O
were	O
obtained	O
from	O
Sigma	O
Genosys	O
(	O
Sigma	O
Aldrich	O
Química	O
SA	O
,	O
Madrid	O
,	O
Spain	O
)	O
,	O
and	O
are	O
shown	O
in	O
Table	O
1	O
.	O
Interleukin	O
6	O
(	O
IL6	O
)	O
and	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNFα	O
)	O
concentrations	O
were	O
analyzed	O
in	O
the	O
supernatants	O
of	O
the	O
cell	B-methodology
culture	I-methodology
wells	O
using	O
specific	O
sandwich	O
ELISAs	O
(	O
RayBiotech	O
,	O
Norcross	O
,	O
GA	O
,	O
USA	O
)	O
to	O
test	O
cytokine	O
released	O
by	O
PBMCs	O
maintained	O
ex	B-methodology
vivo	I-methodology
.	O
Measurements	O
were	O
performed	O
using	O
the	O
following	O
dilutions	O
:	O
1	O
/	O
50	O
for	O
IL6	O
,	O
and	O
1	O
/	O
8	O
and	O
1	O
/	O
10	O
(	O
culture	O
medium	O
from	O
NW	O
and	O
OW	O
-	O
OB	O
donors	O
,	O
respectively	O
)	O
for	O
TNFα	O
analysis	O
.	O
SPSS	O
for	O
windows	O
(	O
SPSS	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
was	O
used	O
to	O
perform	O
statistical	O
analysis	O
.	O
Shapiro	O
–	O
Wilk	O
test	O
and	O
Levene	O
test	O
were	O
used	O
to	O
test	O
normal	O
distribution	O
of	O
the	O
data	O
and	O
homogeneity	O
of	O
variances	O
,	O
respectively	O
.	O
For	O
statistical	O
comparison	O
of	O
anthropometric	O
and	O
serum	O
parameters	O
between	O
NW	O
and	O
OW	O
-	O
OB	O
subjects	O
,	O
unpaired	O
t	O
-	O
test	O
was	O
used	O
(	O
between	O
-	O
group	O
analysis	O
)	O
.	O
Paired	O
t	O
-	O
test	O
was	O
applied	O
to	O
compare	O
gene	O
expression	O
changes	O
between	O
ATRA	O
-	O
stimulated	O
PBMCs	O
and	O
baseline	O
,	O
in	O
NW	O
or	O
OW	O
-	O
OB	O
groups	O
(	O
within	O
-	O
group	O
analysis	O
)	O
.	O
The	O
same	O
statistical	O
analysis	O
was	O
applied	O
to	O
cytokine	O
released	O
to	O
culture	O
medium	O
.	O
Two	O
-	O
way	O
repeated	O
measures	O
ANOVA	O
was	O
used	O
to	O
compare	O
differences	O
of	O
ATRA	O
treatment	O
(	O
pre	O
-	O
and	O
post	O
-	O
treatment	O
)	O
of	O
ex	B-methodology
vivo	I-methodology
PBMCs	O
on	O
gene	O
expression	O
or	O
circulating	O
cytokines	O
depending	O
on	O
body	O
weight	O
.	O
Two	O
-	O
way	O
ANOVA	O
was	O
applied	O
to	O
determine	O
differences	O
between	O
normal	O
-	O
weight	O
and	O
overweight	O
-	O
obese	O
subjects	O
and	O
CPT1A	O
response	O
to	O
ATRA	O
regarding	O
the	O
cholesterol	O
levels	O
.	O

Pearson	O
correlations	O
were	O
performed	O
to	O
identify	O
associations	O
among	O
CPT1	O
response	O
and	O
HDL	O
-	O
cholesterol	O
levels	O
.	O
One	O
-	O
way	O
repeated	O
measures	O
ANOVA	O
followed	O
by	O
least	O
significant	O
difference	O
(	O
LSD	O
)	O
post	O
-	O
hoc	O
test	O
was	O
applied	O
to	O
evaluate	O
the	O
dose	O
effects	O
of	O
ATRA	O
on	O
gene	O
expression	O
.	O
If	O
variables	O
were	O
not	O
adjusted	O
to	O
parametric	O
criteria	O
,	O
they	O
were	O
log	O
transformed	O
to	O
perform	O
statistical	O
measures	O
.	O
Threshold	O
of	O
significance	O
was	O
defined	O
at	O
p	O
<	O
0	O
.	O
05	O
for	O
all	O
analyses	O
.	O
Detailed	O
explanation	O
of	O
the	O
statistical	O
analysis	O
used	O
is	O
present	O
in	O
the	O
figure	O
/	O
table	O
legends	O
.	O
We	O
wanted	O
to	O
test	O
whether	O
effects	O
of	O
ATRA	O
treatment	O
were	O
dose	O
-	O
dependent	O
.	O
To	O
this	O
purpose	O
,	O
we	O
studied	O
this	O
dose	O
-	O
response	O
effect	O
in	O
PBMCs	O
from	O
three	O
NW	O
participants	O
and	O
analyzed	O
the	O
gene	O
expression	O
of	O
MCP1	O
,	O
RXRα	O
,	O
and	O
SLC27A2	O
as	O
selected	O
genes	O
(	O
Figure	O
1	O
)	O
.	O
Results	O
show	O
that	O
the	O
effect	O
of	O
ATRA	O
treatment	O
on	O
PBMC	O
gene	O
expression	O
was	O
significant	O
for	O
both	O
doses	O
used	O
(	O
1	O
and	O
10	O
µM	O
)	O
.	O
The	O
effect	O
of	O
ATRA	O
tended	O
to	O
be	O
dose	O
-	O
dependent	O
on	O
MCP1	O
expression	O
but	O
statistical	O
significance	O
between	O
doses	O
was	O
not	O
reached	O
due	O
to	O
the	O
large	O
inter	O
-	O
individual	O
variability	O
in	O
gene	O
expression	O
response	O
.	O
Concerning	O
RXRα	O
and	O
SLC27A2	O
expression	O
,	O
the	O
effects	O
of	O
ATRA	O
were	O
similar	O
with	O
1	O
and	O
10	O
µM	O
.	O
As	O
shown	O
in	O
Figure	O
2	O
,	O
incubation	O
of	O
human	O
PBMCs	O
with	O
10	O
µM	O
of	O
ATRA	O
decreased	O
mRNA	O
levels	O
of	O
both	O
receptors	O
RXRα	O
and	O
RARα	O
in	O
NW	O
group	O
as	O
previously	O
reported	O
by	O
Bonet	O
et	O
al	O
.	O
[	O
35	O
]	O
in	O
cultured	O
brown	O
adipocytes	O
,	O
as	O
an	O
auto	O
-	O
regulatory	O
mechanism	O
of	O
the	O
retinoids	O
effects	O
.	O
However	O
,	O
RXRα	O
and	O
RARα	O
expression	O
remained	O
unchanged	O
in	O
the	O
OW	O
-	O
OB	O
group	O
.	O
Decreased	O
mRNA	O
levels	O
of	O
NFΚB	O
,	O
TLR2	O
,	O
and	O
TNFα	O
were	O
observed	O
in	O
NW	O
and	O
OW	O
-	O
OB	O
groups	O
(	O
Figure	O
3	O
)	O
.	O
On	O
the	O
contrary	O
,	O
the	O
exposure	O
to	O
ATRA	O
increased	O
the	O
transcriptomic	O
levels	O
of	O
MCP1	O
in	O
PBMCs	O
from	O
both	O
groups	O
of	O
participants	O
and	O
of	O
IL6	O
in	O
NW	O
group	O
(	O
Figure	O
3	O
)	O
.	O

However	O
,	O
the	O
increased	O
mRNA	O
levels	O
of	O
IL6	O
in	O
this	O
group	O
were	O
not	O
reflected	O
into	O
higher	O
levels	O
of	O
this	O
cytokine	O
in	O
the	O
culture	O
media	O
(	O
Figure	O
4	O
)	O
.	O
In	O
fact	O
,	O
the	O
release	O
of	O
IL6	O
and	O
TNFα	O
in	O
the	O
culture	O
media	O
was	O
lower	O
in	O
NW	O
subjects	O
,	O
as	O
well	O
as	O
TNFα	O
release	O
in	O
OW	O
-	O
OB	O
subjects	O
,	O
in	O
response	O
to	O
ATRA	O
treatment	O
(	O
Figure	O
4	O
)	O
.	O
The	O
mRNA	O
levels	O
of	O
the	O
key	O
lipogenic	O
gene	O
FASN	O
,	O
decreased	O
in	O
PBMCs	O
of	O
the	O
NW	O
group	O
after	O
incubation	O
with	O
ATRA	O
;	O
this	O
inhibitory	O
effect	O
was	O
not	O
observed	O
in	O
the	O
OW	O
-	O
OB	O
group	O
.	O
However	O
,	O
ATRA	O
treatment	O
did	O
not	O
affect	O
SREBP1C	O
expression	O
,	O
which	O
codes	O
for	O
a	O
key	O
lipogenic	O
transcription	O
factor	O
(	O
Figure	O
5A	O
)	O
.	O
We	O
also	O
analyzed	O
the	O
regulation	O
of	O
SLC27A2	O
,	O
whose	O
coded	O
protein	O
is	O
involved	O
in	O
fatty	O
acid	O
transport	O
,	O
which	O
facilitates	O
the	O
uptake	O
of	O
long	O
chain	O
fatty	O
acids	O
[	O
36	O
,	O
37	O
]	O
.	O
Interestingly	O
,	O
SLC27A2	O
expression	O
in	O
PBMCs	O
decreased	O
in	O
both	O
groups	O
of	O
participants	O
in	O
response	O
to	O
ATRA	O
treatment	O
(	O
Figure	O
5A	O
)	O
.	O
Regarding	O
the	O
key	O
gene	O
involved	O
in	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
,	O
CPT1A	O
,	O
no	O
effect	O
was	O
observed	O
in	O
PBMCs	O
after	O
ATRA	O
administration	O
either	O
in	O
NW	O
or	O
OW	O
-	O
OB	O
group	O
(	O
Figure	O
5A	O
)	O
.	O
Considering	O
the	O
previously	O
described	O
role	O
of	O
CPT1A	O
as	O
a	O
marker	O
of	O
the	O
metabolic	O
status	O
both	O
in	O
animals	O
and	O
humans	O
[	O
7	O
,	O
26	O
]	O
,	O
we	O
divided	O
subjects	O
considering	O
anthropometric	O
and	O
biochemical	O
parameters	O
related	O
to	O
metabolic	O
risk	O
in	O
order	O
to	O
analyze	O
possible	O
associations	O
between	O
these	O
parameters	O
and	O
CPT1A	O
response	O
.	O
Taking	O
into	O
account	O
fat	O
mass	O
content	O
,	O
circulating	O
triglycerides	O
,	O
total	O
and	O
LDL	O
-	O
cholesterol	O
,	O
glucose	O
and	O
insulin	O
levels	O
,	O
and	O
HOMA	O
-	O
IR	O
index	O
no	O
differences	O
were	O
detected	O
in	O
terms	O
of	O
CPT1A	O
expression	O
response	O
(	O
data	O
not	O
shown	O
)	O
.	O
Interestingly	O
,	O
when	O
we	O
divided	O
the	O
overall	O
group	O
of	O
subjects	O
by	O
their	O
plasma	O
HDL	O
levels	O
(	O
low	O
vs	O
.	O
high	O
)	O
,	O
we	O
found	O
that	O
subjects	O
with	O
high	O
HDL	O
levels	O
were	O
those	O
whose	O
PBMCs	O
showed	O
an	O
increased	O
expression	O
of	O
CPT1A	O
after	O
incubation	O
with	O
ATRA	O
(	O
Figure	O
5B	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
subjects	O
with	O
lower	O
levels	O
of	O
HDL	O
did	O
not	O
display	O
this	O
response	O
(	O
Figure	O
5B	O
)	O
.	O

To	O
further	O
examine	O
the	O
potential	O
interaction	O
between	O
CPT1A	O
response	O
to	O
ATRA	O
in	O
PBMCs	O
and	O
cholesterol	O
levels	O
of	O
volunteers	O
,	O
NW	O
and	O
OW	O
-	O
OB	O
groups	O
were	O
subdivided	O
into	O
categories	O
according	O
to	O
the	O
CPT1A	O
gene	O
expression	O
response	O
(	O
high	O
response	O
vs	O
.	O
low	O
response	O
,	O
taking	O
as	O
reference	O
the	O
median	O
response	O
of	O
all	O
the	O
individuals	O
)	O
(	O
Figure	O
5C	O
–	O
E	O
)	O
.	O
When	O
subjects	O
were	O
subdivided	O
on	O
the	O
basis	O
of	O
CPT1A	O
response	O
,	O
NW	O
group	O
did	O
not	O
exhibit	O
differences	O
in	O
HDL	O
levels	O
between	O
high	O
-	O
and	O
low	O
-	O
responder	O
subjects	O
(	O
Figure	O
5E	O
)	O
.	O
However	O
,	O
OW	O
-	O
OB	O
subjects	O
with	O
lower	O
CPT1A	O
gene	O
expression	O
response	O
to	O
ATRA	O
exhibited	O
lower	O
levels	O
of	O
HDL	O
-	O
cholesterol	O
compared	O
both	O
with	O
their	O
partners	O
with	O
higher	O
CPT1A	O
response	O
and	O
with	O
NW	O
group	O
(	O
Figure	O
5E	O
)	O
.	O
In	O
line	O
with	O
these	O
observations	O
,	O
we	O
found	O
a	O
positive	O
correlation	O
between	O
the	O
%	O
CPT1A	O
response	O
and	O
circulating	O
HDL	O
-	O
cholesterol	O
(	O
r	O
=	O
0	O
.	O
656	O
,	O
p	O
=	O
0	O
.	O
055	O
)	O
in	O
PBMCs	O
from	O
all	O
OW	O
-	O
OB	O
donors	O
,	O
confirming	O
a	O
lower	O
response	O
to	O
ATRA	O
treatment	O
in	O
those	O
OW	O
-	O
OB	O
subjects	O
with	O
lower	O
HDL	O
levels	O
.	O
No	O
correlation	O
between	O
CPT1A	O
response	O
and	O
HDL	O
levels	O
was	O
evident	O
when	O
considering	O
data	O
from	O
the	O
NW	O
group	O
(	O
r	O
=	O
−0	O
.	O
004	O
,	O
p	O
=	O
0	O
.	O
992	O
)	O
.	O
Likewise	O
,	O
no	O
associations	O
were	O
found	O
regarding	O
total	O
and	O
LDL	O
-	O
cholesterol	O
levels	O
in	O
any	O
of	O
the	O
subgroups	O
in	O
relation	O
to	O
their	O
CPT1A	O
response	O
to	O
ATRA	O
(	O
Figure	O
5C	O
,	O
D	O
)	O
.	O
Finally	O
,	O
these	O
correlations	O
observed	O
for	O
CPT1A	O
mRNA	O
expression	O
and	O
HDL	O
-	O
cholesterol	O
levels	O
were	O
not	O
observed	O
for	O
any	O
of	O
the	O
other	O
genes	O
analyzed	O
(	O
data	O
not	O
shown	O
)	O
,	O
reinforcing	O
the	O
specific	O
interest	O
of	O
this	O
gene	O
as	O
a	O
biomarker	O
in	O
studies	O
of	O
nutrition	O
and	O
obesity	O
.	O
There	O
is	O
a	O
wide	O
amount	O
of	O
information	O
showing	O
that	O
PBMCs	O
offer	O
an	O
accessible	O
source	O
of	O
transcriptomic	O
-	O
based	O
biomarkers	O
of	O
nutritional	O
and	O
metabolic	O
status	O
,	O
giving	O
the	O
possibility	O
to	O
show	O
the	O
metabolic	O
scenario	O
that	O
occur	O
in	O
other	O
tissues	O
,	O
such	O
as	O
liver	O
,	O
adipose	O
tissue	O
or	O
skeletal	O
muscle	O
[	O
4	O
,	O
38	O
]	O
.	O

Moreover	O
,	O
ex	B-methodology
vivo	I-methodology
assays	O
of	O
human	O
PBMCs	O
offer	O
a	O
plausible	O
model	O
to	O
test	O
the	O
efficacy	O
and	O
safety	O
of	O
food	O
bioactive	O
compounds	O
[	O
4	O
,	O
11	O
]	O
.	O
Food	O
bioactives	O
are	O
recently	O
receiving	O
an	O
increasing	O
attention	O
in	O
terms	O
of	O
their	O
possible	O
beneficial	O
effects	O
on	O
ameliorating	O
metabolic	O
and	O
physiological	O
alterations	O
related	O
to	O
obesity	O
and	O
its	O
co	O
-	O
morbidities	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
the	O
administration	O
of	O
ATRA	O
regulates	O
the	O
expression	O
of	O
key	O
inflammatory	O
and	O
lipid	O
metabolism	O
genes	O
in	O
isolated	O
human	O
PBMCs	O
maintained	O
ex	B-methodology
vivo	I-methodology
.	O
These	O
gene	O
expression	O
changes	O
may	O
be	O
modulated	O
in	O
part	O
by	O
nuclear	O
receptors	O
.	O
In	O
fact	O
,	O
RARα	O
and	O
RXRα	O
were	O
expressed	O
in	O
PBMCs	O
of	O
the	O
participants	O
as	O
stated	O
previously	O
by	O
Szabova	O
et	O
al	O
.	O
[	O
24	O
]	O
.	O
Moreover	O
,	O
we	O
describe	O
that	O
ATRA	O
response	O
in	O
PBMCs	O
is	O
impaired	O
depending	O
on	O
body	O
weight	O
of	O
the	O
donors	O
as	O
well	O
as	O
depending	O
on	O
metabolic	O
risk	O
factors	O
,	O
particularly	O
,	O
HDL	O
-	O
cholesterol	O
levels	O
.	O
The	O
effects	O
of	O
retinoic	O
acid	O
treatment	O
in	O
animals	O
are	O
well	O
studied	O
.	O
It	O
is	O
known	O
that	O
this	O
retinoid	O
is	O
able	O
to	O
ameliorate	O
the	O
negative	O
effects	O
associated	O
with	O
obesity	O
,	O
improving	O
different	O
processes	O
,	O
such	O
as	O
glucose	O
tolerance	O
,	O
insulin	O
sensitivity	O
,	O
and	O
serum	O
lipid	O
profile	O
[	O
13	O
,	O
14	O
,	O
15	O
]	O
.	O
In	O
fact	O
,	O
a	O
previous	O
study	O
from	O
our	O
group	O
using	O
mice	O
showed	O
that	O
whole	O
blood	O
(	O
that	O
includes	O
PBMCs	O
)	O
reflected	O
gene	O
expression	O
patterns	O
after	O
ATRA	O
treatment	O
that	O
occur	O
in	O
other	O
tissues	O
like	O
liver	O
or	O
adipose	O
tissue	O
[	O
39	O
]	O
.	O
However	O
,	O
in	O
humans	O
,	O
the	O
physiological	O
and	O
metabolic	O
effects	O
of	O
retinoic	O
acid	O
are	O
controversial	O
[	O
20	O
]	O
.	O
First	O
of	O
all	O
,	O
ATRA	O
is	O
a	O
minor	O
constituent	O
of	O
the	O
diet	O
and	O
represents	O
less	O
than	O
5	O
%	O
of	O
total	O
vitamin	O
A	O
in	O
the	O
tissues	O
of	O
healthy	O
animals	O
and	O
humans	O
[	O
40	O
]	O
.	O
In	O
fact	O
,	O
unlike	O
vitamin	O
A	O
or	O
carotenoids	O
,	O
ATRA	O
is	O
not	O
available	O
as	O
a	O
dietary	O
supplement	O
.	O
Therefore	O
,	O
exposure	O
to	O
ATRA	O
is	O
limited	O
,	O
for	O
all	O
practical	O
purposes	O
,	O
to	O
the	O
oral	O
or	O
topical	O
treatment	O
of	O
medical	O
disorders	O
.	O

The	O
use	O
of	O
ATRA	O
or	O
its	O
active	O
derivatives	O
at	O
pharmacological	O
doses	O
is	O
associated	O
to	O
a	O
wide	O
range	O
of	O
side	O
-	O
effects	O
,	O
such	O
as	O
disturbed	O
glucose	O
metabolism	O
,	O
impairment	O
of	O
insulin	O
sensitivity	O
,	O
and	O
increase	O
in	O
serum	O
levels	O
of	O
total	O
cholesterol	O
and	O
triglycerides	O
and	O
decrease	O
in	O
serum	O
levels	O
of	O
HDL	O
-	O
cholesterol	O
[	O
41	O
]	O
.	O
Therefore	O
,	O
the	O
subjects	O
receiving	O
treatment	O
with	O
retinoids	O
could	O
be	O
at	O
greater	O
risk	O
of	O
developing	O
metabolic	O
syndrome	O
in	O
later	O
life	O
.	O
However	O
,	O
numerous	O
studies	O
in	O
humans	O
have	O
described	O
an	O
inadequate	O
vitamin	O
A	O
status	O
in	O
overweight	O
and	O
obese	O
population	O
[	O
42	O
,	O
43	O
]	O
.	O
Despite	O
the	O
fact	O
that	O
the	O
concentration	O
of	O
ATRA	O
in	O
human	O
plasma	O
represents	O
only	O
a	O
small	O
part	O
of	O
all	O
-	O
trans	O
-	O
retinol	O
(	O
<	O
1	O
%	O
)	O
and	O
that	O
it	O
is	O
rapidly	O
metabolized	O
in	O
the	O
body	O
[	O
40	O
]	O
,	O
Liu	O
et	O
al	O
.	O
[	O
23	O
]	O
described	O
that	O
serum	O
levels	O
of	O
ATRA	O
in	O
humans	O
are	O
inversely	O
correlated	O
with	O
the	O
risk	O
of	O
metabolic	O
syndrome	O
,	O
regardless	O
of	O
adiposity	O
and	O
insulin	O
resistance	O
.	O
Hence	O
,	O
probably	O
the	O
doses	O
and	O
the	O
routes	O
through	O
which	O
vitamin	O
A	O
derivatives	O
are	O
taken	O
are	O
particularly	O
relevant	O
,	O
as	O
it	O
seems	O
there	O
is	O
a	O
delicate	O
balance	O
between	O
promoting	O
negative	O
effects	O
on	O
lipid	O
profile	O
and	O
ameliorating	O
lipid	O
metabolism	O
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
although	O
there	O
are	O
few	O
studies	O
analyzing	O
the	O
effects	O
of	O
RA	O
or	O
its	O
derivatives	O
on	O
energy	O
metabolism	O
and	O
inflammatory	O
response	O
in	O
animal	O
and	O
human	O
cell	O
lines	O
[	O
12	O
,	O
35	O
,	O
44	O
,	O
45	O
]	O
,	O
there	O
are	O
no	O
studies	O
analyzing	O
the	O
expression	O
of	O
lipid	O
metabolism	O
-	O
related	O
genes	O
in	O
PBMCs	O
after	O
ATRA	O
treatment	O
.	O
Moreover	O
,	O
none	O
of	O
either	O
in	B-methodology
vitro	I-methodology
or	O
in	B-methodology
vivo	I-methodology
studies	I-methodology
using	O
pharmacological	O
doses	O
of	O
RA	O
or	O
of	O
its	O
derivatives	O
directly	O
compare	O
the	O
differential	O
effects	O
of	O
retinoic	O
acid	O
treatment	O
taking	O
into	O
account	O
metabolic	O
syndrome	O
-	O
related	O
features	O
.	O
Regarding	O
the	O
effects	O
of	O
ATRA	O
administration	O
on	O
inflammation	O
,	O
our	O
results	O
point	O
towards	O
an	O
anti	O
-	O
inflammatory	O
profile	O
after	O
ATRA	O
administration	O
as	O
has	O
been	O
stated	O
in	O
different	O
cell	O
lines	O
[	O
45	O
,	O
46	O
]	O
and	O
in	O
animal	B-methodology
models	I-methodology
with	O
inflammatory	O
-	O
related	O
diseases	O
[	O
47	O
,	O
48	O
]	O
.	O
We	O
found	O
a	O
significant	O
reduction	O
in	O
the	O
expression	O
of	O
key	O
inflammatory	O
genes	O
(	O
NFKB	O
,	O
TNFα	O
,	O
and	O
TLR2	O
)	O
in	O
PBMCs	O
from	O
both	O
NW	O
and	O
OW	O
-	O
OB	O
subjects	O
after	O
ex	B-methodology
vivo	I-methodology
ATRA	O
treatment	O
.	O

Moreover	O
,	O
even	O
if	O
MCP1	O
(	O
a	O
chemotactic	O
protein	O
)	O
expression	O
was	O
increased	O
in	O
the	O
two	O
studied	O
groups	O
and	O
IL6	O
expression	O
was	O
increased	O
in	O
NW	O
subjects	O
,	O
the	O
released	O
IL6	O
and	O
TNFα	O
levels	O
in	O
the	O
culture	O
media	O
were	O
lower	O
in	O
PBMCs	O
from	O
NW	O
donors	O
,	O
as	O
well	O
as	O
TNFα	O
levels	O
in	O
PBMCs	O
from	O
OW	O
-	O
OB	O
donors	O
.	O
Although	O
the	O
analysis	O
of	O
inflammatory	O
genes	O
did	O
not	O
show	O
relevant	O
differences	O
between	O
NW	O
and	O
OW	O
-	O
OB	O
subjects	O
,	O
it	O
is	O
well	O
known	O
that	O
obesity	O
is	O
related	O
to	O
an	O
impaired	O
nutritional	O
response	O
at	O
gene	O
expression	O
level	O
in	O
key	O
metabolic	O
tissues	O
,	O
which	O
is	O
reflected	O
in	O
PBMCs	O
[	O
5	O
,	O
31	O
]	O
.	O
Moreover	O
,	O
we	O
previously	O
found	O
using	O
the	O
same	O
ex	B-methodology
vivo	I-methodology
system	O
of	O
human	O
PBMCs	O
that	O
subjects	O
with	O
higher	O
BMI	O
showed	O
up	O
an	O
impaired	O
response	O
either	O
of	O
key	O
lipid	O
metabolism	O
and	O
inflammatory	O
genes	O
to	O
long	O
chain	O
n	O
-	O
3	O
polyunsaturated	O
fatty	O
acids	O
[	O
11	O
]	O
.	O
In	O
fact	O
,	O
when	O
the	O
group	O
of	O
subjects	O
was	O
divided	O
by	O
their	O
BMI	O
,	O
we	O
found	O
that	O
there	O
was	O
a	O
reduction	O
in	O
mRNA	O
levels	O
of	O
both	O
retinoid	O
nuclear	O
receptors	O
in	O
PBMCs	O
of	O
the	O
NW	O
group	O
(	O
RARα	O
and	O
RXRα	O
)	O
.	O
Nevertheless	O
,	O
this	O
auto	O
-	O
regulatory	O
mechanism	O
of	O
the	O
retinoid	O
effects	O
was	O
impaired	O
in	O
the	O
OW	O
-	O
OB	O
group	O
.	O
Probably	O
,	O
these	O
nuclear	O
receptors	O
are	O
mediating	O
the	O
downstream	O
effects	O
of	O
ATRA	O
on	O
the	O
expression	O
of	O
energy	O
metabolism	O
-	O
related	O
genes	O
[	O
18	O
]	O
.	O
The	O
same	O
lack	O
of	O
response	O
was	O
seen	O
in	O
the	O
case	O
of	O
FASN	O
gene	O
expression	O
,	O
a	O
key	O
lipogenic	O
gene	O
,	O
whose	O
expression	O
decreased	O
in	O
the	O
NW	O
group	O
but	O
not	O
in	O
the	O
OW	O
-	O
OB	O
group	O
.	O
However	O
,	O
we	O
did	O
not	O
find	O
changes	O
in	O
CPT1A	O
in	O
response	O
to	O
ATRA	O
treatment	O
in	O
any	O
of	O
the	O
two	O
studied	O
groups	O
.	O
CPT1A	O
codes	O
for	O
a	O
rate	O
-	O
limiting	O
enzyme	O
of	O
fatty	O
acid	O
oxidation	O
,	O
and	O
it	O
is	O
described	O
in	O
animal	O
tissues	O
[	O
13	O
,	O
14	O
]	O
and	O
cell	O
lines	O
[	O
49	O
]	O
that	O
its	O
gene	O
expression	O
is	O
enhanced	O
by	O
ATRA	O
treatment	O
.	O
In	O
spite	O
of	O
the	O
fact	O
that	O
BMI	O
is	O
the	O
most	O
used	O
measure	O
to	O
classify	O
body	O
weight	O
and	O
obesity	O
,	O
it	O
is	O
well	O
known	O
that	O
it	O
is	O
not	O
the	O
best	O
predictor	O
of	O
metabolic	O
health	O
[	O
50	O
]	O
.	O
Thus	O
,	O
we	O
divided	O
the	O
gene	O
expression	O
response	O
to	O
ATRA	O
taking	O
into	O
account	O
other	O
metabolic	O
syndrome	O
-	O
related	O
features	O
collected	O
from	O
the	O
participants	O
.	O

By	O
doing	O
this	O
,	O
we	O
found	O
an	O
interesting	O
association	O
between	O
HDL	O
levels	O
and	O
CPT1A	O
response	O
to	O
ATRA	O
,	O
an	O
association	O
that	O
was	O
not	O
observed	O
either	O
for	O
total	O
or	O
LDL	O
-	O
cholesterol	O
levels	O
,	O
and	O
was	O
exclusive	O
for	O
CPT1A	O
,	O
not	O
being	O
observed	O
either	O
for	O
the	O
rest	O
of	O
the	O
genes	O
analyzed	O
.	O
We	O
have	O
shown	O
that	O
individuals	O
with	O
higher	O
levels	O
of	O
HDL	O
display	O
the	O
expected	O
enhanced	O
CPT1A	O
expression	O
in	O
PBMCs	O
after	O
ATRA	O
administration	O
.	O
Nevertheless	O
,	O
this	O
response	O
is	O
missing	O
in	O
subjects	O
with	O
levels	O
of	O
HDL	O
below	O
40	O
mg	O
/	O
dL	O
,	O
which	O
has	O
been	O
associated	O
to	O
an	O
increased	O
risk	O
of	O
coronary	O
risk	O
[	O
51	O
]	O
.	O
An	O
increasing	O
number	O
of	O
studies	O
show	O
the	O
importance	O
of	O
HDL	O
levels	O
by	O
themselves	O
as	O
a	O
risk	O
factor	O
of	O
cardiovascular	O
disease	O
and	O
HDL	O
is	O
considered	O
as	O
a	O
better	O
risk	O
predictor	O
than	O
LDL	O
[	O
52	O
,	O
53	O
,	O
54	O
]	O
.	O
Therefore	O
,	O
our	O
data	O
reinforce	O
the	O
importance	O
of	O
HDL	O
as	O
predictor	O
of	O
metabolic	O
disturbances	O
,	O
in	O
this	O
case	O
,	O
studied	O
as	O
a	O
lack	O
of	O
CPT1A	O
response	O
in	O
PBMC	O
to	O
ATRA	O
treatment	O
.	O
Moreover	O
,	O
our	O
data	O
suggest	O
an	O
association	O
may	O
exist	O
between	O
BMI	O
,	O
HDL	O
levels	O
,	O
and	O
CPT1A	O
response	O
to	O
ATRA	O
in	O
PBMCs	O
.	O
That	O
is	O
,	O
here	O
we	O
show	O
that	O
CPT1A	O
expression	O
after	O
ATRA	O
treatment	O
is	O
independent	O
of	O
HDL	O
levels	O
in	O
PBMCs	O
from	O
NW	O
subjects	O
but	O
not	O
in	O
the	O
OW	O
-	O
OB	O
group	O
.	O
Remarkably	O
,	O
the	O
OW	O
-	O
OB	O
participants	O
with	O
lower	O
levels	O
of	O
HDL	O
-	O
cholesterol	O
showed	O
an	O
attenuate	O
response	O
to	O
ATRA	O
regarding	O
CPT1A	O
expression	O
.	O
This	O
regulation	O
/	O
impaired	O
regulation	O
of	O
CPT1A	O
response	O
to	O
ATRA	O
,	O
more	O
related	O
to	O
HDL	O
than	O
to	O
BMI	O
is	O
of	O
interest	O
,	O
as	O
it	O
could	O
be	O
used	O
as	O
a	O
new	O
marker	O
to	O
diagnose	O
metabolic	O
risk	O
with	O
independence	O
of	O
the	O
presence	O
of	O
overweight	O
or	O
obesity	O
,	O
as	O
it	O
is	O
well	O
known	O
that	O
also	O
normal	O
-	O
weight	O
individuals	O
can	O
have	O
increased	O
metabolic	O
syndrome	O
risk	O
[	O
55	O
]	O
.	O
In	O
the	O
same	O
line	O
,	O
previous	O
data	O
from	O
our	O
group	O
described	O
the	O
utility	O
of	O
the	O
analysis	O
of	O
impaired	O
CPT1A	O
response	O
to	O
fasting	O
as	O
a	O
marker	O
of	O
metabolic	O
risk	O
(	O
liver	O
steatosis	O
and	O
insulin	O
resistance	O
)	O
in	O
metabolically	O
obese	O
but	O
normal	O
-	O
weight	O
rodents	O
[	O
26	O
]	O
.	O

Moreover	O
,	O
we	O
also	O
showed	O
,	O
in	O
humans	O
,	O
an	O
association	O
between	O
the	O
expression	O
levels	O
of	O
CPT1A	O
in	O
whole	O
blood	O
and	O
metabolic	O
alterations	O
associated	O
with	O
childhood	O
obesity	O
[	O
7	O
]	O
.	O
Concerning	O
potential	O
limitations	O
of	O
the	O
study	O
performed	O
,	O
they	O
could	O
be	O
more	O
related	O
to	O
the	O
PBMC	O
ex	B-methodology
vivo	I-methodology
system	O
per	O
se	O
.	O
PBMCs	O
express	O
a	O
large	O
amount	O
of	O
human	O
genome	O
,	O
but	O
some	O
specific	O
genes	O
of	O
interest	O
may	O
not	O
be	O
expressed	O
or	O
expressed	O
in	O
low	O
amounts	O
in	O
these	O
cells	O
.	O
Thus	O
,	O
even	O
though	O
we	O
demonstrated	O
the	O
usefulness	O
of	O
this	O
system	O
to	O
study	O
the	O
impact	O
of	O
ATRA	O
on	O
key	O
lipid	O
metabolism	O
and	O
inflammatory	O
genes	O
,	O
it	O
could	O
not	O
work	O
so	O
well	O
to	O
study	O
some	O
other	O
specific	O
pathways	O
.	O
Although	O
we	O
obtained	O
clear	O
results	O
and	O
the	O
sample	O
size	O
is	O
appropriate	O
for	O
a	O
controlled	O
ex	B-methodology
vivo	I-methodology
study	O
,	O
interindividual	O
variability	O
exists	O
,	O
and	O
the	O
use	O
of	O
a	O
higher	O
number	O
of	O
individuals	O
could	O
have	O
helped	O
to	O
get	O
additional	O
statistical	O
differences	O
in	O
our	O
study	O
.	O
Finally	O
,	O
our	O
study	O
was	O
limited	O
to	O
men	O
,	O
so	O
a	O
careful	O
consideration	O
about	O
gender	O
differences	O
should	O
be	O
considered	O
in	O
future	O
studies	O
,	O
including	O
women	O
,	O
as	O
well	O
as	O
individuals	O
from	O
different	O
ethnicities	O
,	O
in	O
order	O
to	O
better	O
represent	O
the	O
whole	O
population	O
.	O
An	O
ex	B-methodology
vivo	I-methodology
system	O
of	O
human	O
PBMCs	O
(	O
derived	O
from	O
men	O
)	O
is	O
able	O
to	O
respond	O
to	O
food	O
bioactive	O
compounds	O
,	O
in	O
this	O
case	O
to	O
ATRA	O
administration	O
,	O
providing	O
a	O
useful	O
,	O
secure	O
,	O
and	O
fast	O
tool	O
to	O
go	O
in	O
depth	O
on	O
the	O
effects	O
of	O
vitamin	O
A	O
derivatives	O
on	O
health	O
.	O
Moreover	O
,	O
PBMC	O
response	O
to	O
ATRA	O
can	O
be	O
influenced	O
/	O
impaired	O
by	O
the	O
presence	O
of	O
overweigh	O
-	O
obesity	O
but	O
also	O
by	O
other	O
metabolic	O
syndrome	O
features	O
,	O
such	O
as	O
low	O
circulating	O
HDL	O
levels	O
.	O
Particularly	O
,	O
CPT1A	O
response	O
to	O
ATRA	O
is	O
impaired	O
in	O
those	O
individuals	O
with	O
higher	O
metabolic	O
risk	O
(	O
overweight	O
-	O
obesity	O
and	O
low	O
HDL	O
levels	O
)	O
,	O
providing	O
additional	O
evidences	O
of	O
its	O
previously	O
reported	O
role	O
as	O
a	O
metabolic	O
risk	O
predictive	O
biomarker	O
.	O
Finally	O
,	O
our	O
data	O
point	O
to	O
plasmatic	O
levels	O
of	O
HDL	O
-	O
cholesterol	O
to	O
be	O
further	O
explored	O
as	O
a	O
parameter	O
to	O
take	O
into	O
account	O
per	O
se	O
,	O
independently	O
of	O
BMI	O
,	O
which	O
can	O
affect	O
the	O
response	O
to	O
nutritional	O
factors	O
and	O
/	O
or	O
dietary	B-methodology
interventions	I-methodology
on	O
humans	O
.	O

CIBER	O
de	O
Fisiopatología	O
de	O
la	O
Obesidad	O
y	O
Nutrición	O
is	O
an	O
initiative	O
of	O
the	O
ISCIII	O
.	O
The	O
Nutrigenomics	O
and	O
Obesity	O
Group	O
is	O
a	O
member	O
of	O
the	O
European	O
Research	O
Network	O
of	O
Excellence	O
NuGO	O
(	O
The	O
European	O
Nutrigenomics	O
Organization	O
,	O
EU	O
Contract	O
:	O
FOOD	O
-	O
CT	O
-	O
2004	O
-	O
506360	O
NUGO	O
)	O
.	O
Conceptualization	O
,	O
P	O
.	O
O	O
.	O
and	O
A	O
.	O
P	O
.	O
;	O
methodology	O
,	O
P	O
.	O
O	O
.	O
and	O
M	O
.	O
C	O
.	O
;	O
validation	O
,	O
M	O
.	O
C	O
.	O
;	O
formal	O
analysis	O
,	O
M	O
.	O
C	O
.	O
,	O
P	O
.	O
O	O
.	O
,	O
and	O
A	O
.	O
P	O
.	O
;	O
investigation	O
,	O
M	O
.	O
C	O
.	O
and	O
P	O
.	O
O	O
.	O
;	O
resources	O
,	O
M	O
.	O
C	O
.	O
and	O
P	O
.	O
O	O
.	O
;	O
data	O
curation	O
,	O
M	O
.	O
C	O
.	O
and	O
P	O
.	O
O	O
.	O
;	O
writing	O
—	O
original	O
draft	O
preparation	O
,	O
M	O
.	O
C	O
.	O
;	O
writing	O
—	O
review	O
and	O
editing	O
,	O
P	O
.	O
O	O
.	O
and	O
A	O
.	O
P	O
.	O
;	O
supervision	O
,	O
P	O
.	O
O	O
.	O
and	O
A	O
.	O
P	O
.	O
;	O
project	O
administration	O
,	O
P	O
.	O
O	O
.	O
and	O
A	O
.	O
P	O
.	O
;	O
funding	O
acquisition	O
,	O
A	O
.	O
P	O
.	O
and	O
P	O
.	O
O	O
.	O
All	O
authors	O
have	O
read	O
and	O
agreed	O
to	O
the	O
published	O
version	O
of	O
the	O
manuscript	O
.	O
This	O
research	O
was	O
funded	O
by	O
the	O
Spanish	O
Government	O
:	O
EPIMILK	O
-	O
AGL2012	O
-	O
33692	O
-	O
and	O
INTERBIOBES	O
-	O
AGL2015	O
-	O
67019	O
-	O
P	O
(	O
AEI	O
,	O
MINECO	O
/	O
FEDER	O
,	O
EU	O
)	O
,	O
and	O
by	O
the	O
University	O
of	O
the	O
Balearic	O
Islands	O
:	O
IBIFLEX	O
-	O
FA38	O
/	O
2016	O
-	O
.	O
M	O
.	O
C	O
.	O
was	O
funded	O
with	O
a	O
fellowship	O
from	O
the	O
Spanish	O
Government	O
.	O
Open	O
access	O
publication	O
was	O
funded	O
by	O
the	O
IdISBa	O
“	O
Liberi	O
”	O
program	O
.	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O

Dietary	O
effects	O
on	O
human	O
gut	O
microbiome	O
diversity	O
Microbiome	O
;	O
Diet	O
;	O
Gut	O
The	O
human	O
gut	O
harbours	O
diverse	O
and	O
abundant	O
microbes	O
,	O
forming	O
a	O
complex	O
ecological	O
system	O
that	O
interacts	O
with	O
host	O
and	O
environmental	O
factors	O
.	O
In	O
this	O
article	O
,	O
we	O
summarise	O
recent	O
advances	O
in	O
microbiome	O
studies	O
across	O
both	O
Western	O
and	O
non	O
-	O
Western	O
populations	O
,	O
either	O
in	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
or	O
longitudinal	B-methodology
surveys	I-methodology
,	O
and	O
over	O
various	O
age	O
groups	O
,	O
revealing	O
a	O
considerable	O
diversity	O
and	O
variability	O
in	O
the	O
human	O
gut	O
microbiome	O
.	O
Of	O
all	O
the	O
exogenous	O
factors	O
affecting	O
gut	O
microbiome	O
,	O
a	O
long	O
-	O
term	O
diet	O
appears	O
to	O
have	O
the	O
largest	O
effect	O
to	O
date	O
.	O
Recent	O
research	O
on	O
the	O
effects	O
of	O
dietary	B-methodology
interventions	I-methodology
has	O
shown	O
that	O
the	O
gut	O
microbiome	O
can	O
change	O
dramatically	O
with	O
diet	O
;	O
however	O
,	O
the	O
gut	O
microbiome	O
is	O
generally	O
resilient	O
,	O
and	O
short	O
-	O
term	O
dietary	B-methodology
intervention	I-methodology
is	O
not	O
typically	O
successful	O
in	O
treating	O
obesity	O
and	O
malnutrition	O
.	O
Understanding	O
the	O
dynamics	O
of	O
the	O
gut	O
microbiome	O
under	O
different	O
conditions	O
will	O
help	O
us	O
diagnose	O
and	O
treat	O
many	O
diseases	O
that	O
are	O
now	O
known	O
to	O
be	O
associated	O
with	O
microbial	O
communities	O
.	O
It	O
is	O
estimated	O
that	O
human	O
body	O
contains	O
as	O
many	O
as	O
1014	O
microbial	O
cells	O
(	O
1	O
)	O
,	O
and	O
our	O
appreciation	O
of	O
their	O
contribution	O
to	O
host	O
physiology	O
,	O
disease	O
and	O
behaviour	O
is	O
increasing	O
rapidly	O
(	O
2	O
–	O
5	O
)	O
.	O
This	O
complex	O
community	O
,	O
collectively	O
known	O
as	O
the	O
microbiota	O
(	O
their	O
genes	O
are	O
known	O
as	O
the	O
microbiome	O
)	O
,	O
contains	O
diverse	O
viruses	O
,	O
bacteria	O
,	O
archaea	O
and	O
eukaryotes	O
(	O
3	O
,	O
6	O
)	O
.	O
Recent	O
advances	O
in	O
high	O
-	O
throughput	O
sequencing	O
technology	O
,	O
together	O
with	O
the	O
development	O
of	O
bioinformatics	O
techniques	O
,	O
have	O
sparked	O
a	O
tremendous	O
explosion	O
of	O
culture	O
-	O
independent	O
microbiome	O
studies	O
(	O
i	O
.	O
e	O
.	O
studies	O
that	O
do	O
not	O
rely	O
on	O
culture	O
-	O
based	O
techniques	O
,	O
which	O
usually	O
capture	O
only	O
a	O
small	O
fraction	O
of	O
microbial	O
diversity	O
)	O
providing	O
a	O
profound	O
insight	O
into	O
the	O
role	O
of	O
the	O
microbiota	O
in	O
human	O
health	O
(	O
7	O
,	O
8	O
)	O
.	O
For	O
example	O
,	O
gut	O
microbes	O
train	O
the	O
immune	O
system	O
(	O
9	O
)	O
,	O
protect	O
against	O
opportunistic	O
pathogens	O
(	O
10	O
)	O
,	O
harvest	O
nutrients	O
and	O
energy	O
from	O
diet	O
(	O
11	O
)	O
,	O
and	O
ferment	O
non	O
-	O
digestible	O
carbohydrates	O
(	O
12	O
–	O
14	O
)	O
.	O

The	O
disruption	O
of	O
the	O
normal	O
gut	O
microbiota	O
(	O
dysbiosis	O
)	O
is	O
associated	O
with	O
obesity	O
(	O
15	O
,	O
16	O
)	O
,	O
diabetes	O
(	O
17	O
)	O
,	O
various	O
inflammatory	O
bowel	O
diseases	O
(	O
IBD	O
)	O
(	O
18	O
,	O
19	O
)	O
and	O
autoimmune	O
diseases	O
(	O
20	O
,	O
21	O
)	O
.	O
We	O
are	O
beginning	O
to	O
understand	O
the	O
baseline	O
states	O
for	O
a	O
healthy	O
microbiota	O
(	O
or	O
,	O
rather	O
,	O
for	O
the	O
diverse	O
array	O
of	O
healthy	O
microbiota	O
found	O
in	O
different	O
healthy	O
people	O
)	O
,	O
and	O
in	O
contrast	O
,	O
what	O
constitutes	O
a	O
bad	O
microbiota	O
,	O
by	O
studying	O
the	O
taxonomy	O
of	O
the	O
constituent	O
organisms	O
(	O
revealing	O
who	O
is	O
there	O
)	O
and	O
their	O
genes	O
(	O
revealing	O
what	O
they	O
are	O
capable	O
of	O
doing	O
)	O
.	O
Many	O
factors	O
,	O
either	O
exogenous	O
or	O
endogenous	O
,	O
affect	O
the	O
composition	O
of	O
the	O
gut	O
microbiota	O
.	O
These	O
factors	O
include	O
host	O
genotype	O
(	O
22	O
)	O
,	O
age	O
(	O
2	O
)	O
and	O
sex	O
(	O
23	O
)	O
.	O
However	O
,	O
of	O
all	O
the	O
environmental	O
factors	O
studied	O
to	O
date	O
,	O
diet	O
has	O
the	O
largest	O
known	O
impact	O
on	O
the	O
gut	O
microbiota	O
.	O
Revealing	O
the	O
complex	O
interactions	O
between	O
these	O
factors	O
and	O
microbiota	O
may	O
ultimately	O
help	O
us	O
modulate	O
our	O
microbiome	O
to	O
diagnose	O
and	O
treat	O
microbiome	O
-	O
associated	O
diseases	O
in	O
a	O
personalised	O
way	O
,	O
restoring	O
a	O
healthy	O
microbial	O
community	O
.	O
The	O
human	O
gut	O
microbiota	O
is	O
seeded	O
during	O
birth	O
and	O
mainly	O
develops	O
over	O
the	O
first	O
3	O
years	O
of	O
life	O
(	O
24	O
)	O
.	O
From	O
birth	O
,	O
neonates	O
are	O
exposed	O
to	O
microbes	O
from	O
a	O
variety	O
of	O
sources	O
,	O
and	O
the	O
initial	O
colonisation	O
of	O
their	O
guts	O
depends	O
on	O
the	O
microbes	O
first	O
encountered	O
.	O
The	O
initial	O
composition	O
of	O
the	O
gut	O
microbiota	O
depends	O
on	O
the	O
mode	O
of	O
delivery	O
:	O
babies	O
delivered	O
vaginally	O
harbour	O
gut	O
microbiota	O
resembling	O
microbial	O
communities	O
found	O
in	O
their	O
mothers	O
'	O
vaginas	O
,	O
whereas	O
those	O
born	O
via	O
Cesarean	O
section	O
apparently	O
acquire	O
microbes	O
from	O
the	O
skin	O
,	O
dominated	O
by	O
taxa	O
such	O
as	O
Propionibacterium	O
and	O
Staphylococcus	O
(	O
25	O
)	O
.	O
The	O
feeding	O
mode	O
also	O
influences	O
the	O
infant	O
gut	O
microbiota	O
.	O
Breast	O
milk	O
contains	O
nutrients	O
,	O
maternal	O
antibodies	O
and	O
also	O
diverse	O
commensal	O
maternal	O
bacteria	O
including	O
bifidobacteria	O
and	O
lactobacilli	O
(	O
26	O
)	O
.	O
Compared	O
with	O
formula	O
-	O
fed	O
infants	O
,	O
breast	O
-	O
fed	O
infants	O
have	O
lower	O
levels	O
of	O
Atopobium	O
and	O
higher	O
levels	O
of	O
Bifidobacterium	O
(	O
27	O
)	O
.	O
The	O
diversity	O
in	O
the	O
baby	O
'	O
s	O
gut	O
is	O
initially	O
low	O
and	O
increases	O
during	O
development	O
.	O

Over	O
the	O
first	O
3	O
years	O
of	O
life	O
,	O
the	O
composition	O
of	O
the	O
microbial	O
community	O
becomes	O
more	O
adult	O
-	O
like	O
,	O
and	O
major	O
microbial	O
shifts	O
are	O
associated	O
with	O
key	O
events	O
such	O
as	O
the	O
introduction	O
of	O
solid	O
food	O
(	O
24	O
)	O
.	O
Although	O
the	O
adult	O
gut	O
microbiota	O
are	O
relatively	O
stable	O
within	O
a	O
person	O
(	O
in	O
that	O
serial	O
samples	O
from	O
the	O
same	O
person	O
typically	O
resemble	O
each	O
other	O
more	O
closely	O
than	O
do	O
samples	O
from	O
different	O
people	O
)	O
and	O
are	O
typically	O
dominated	O
by	O
members	O
of	O
the	O
Bacteroidetes	O
,	O
Firmicutes	O
and	O
Actinobacteria	O
,	O
they	O
show	O
great	O
interpersonal	O
and	O
intrapersonal	O
variability	O
.	O
For	O
example	O
,	O
fewer	O
than	O
50	O
%	O
of	O
bacterial	O
taxa	O
are	O
shared	O
between	O
monozygotic	O
twins	O
at	O
the	O
species	O
level	O
(	O
28	O
)	O
.	O
We	O
are	O
starting	O
to	O
appreciate	O
this	O
variability	O
to	O
a	O
greater	O
extent	O
because	O
of	O
the	O
numerous	O
studies	O
facilitated	O
by	O
the	O
methods	O
developed	O
in	O
large	O
-	O
scale	O
projects	O
such	O
as	O
the	O
Human	O
Microbiome	O
Project	O
(	O
7	O
,	O
8	O
)	O
and	O
the	O
Metagenomics	O
of	O
the	O
Human	O
Intestinal	O
Tract	O
(	O
MetaHIT	O
)	O
(	O
29	O
)	O
.	O
It	O
has	O
been	O
argued	O
that	O
the	O
gut	O
microbiota	O
can	O
be	O
classified	O
into	O
three	O
broad	O
clusters	O
,	O
or	O
‘	O
enterotypes	O
’	O
,	O
based	O
on	O
the	O
dominant	O
presence	O
of	O
Bacteroides	O
,	O
Prevotella	O
or	O
Ruminococcus	O
genera	O
(	O
30	O
)	O
,	O
although	O
statistical	O
support	O
for	O
the	O
three	O
-	O
cluster	O
model	O
is	O
weak	O
and	O
has	O
generally	O
not	O
been	O
replicated	O
in	O
later	O
studies	O
.	O
The	O
idea	O
is	O
controversial	O
,	O
especially	O
because	O
the	O
model	O
of	O
discrete	O
clusters	O
has	O
a	O
clear	O
alternative	O
in	O
terms	O
of	O
continuous	O
gradients	O
in	O
the	O
major	O
taxa	O
that	O
are	O
well	O
supported	O
(	O
31	O
–	O
34	O
)	O
.	O
Intriguingly	O
,	O
despite	O
the	O
considerable	O
variability	O
in	O
the	O
composition	O
of	O
the	O
gut	O
microbiota	O
,	O
metagenomic	O
shotgun	O
sequencing	O
demonstrates	O
that	O
these	O
diverse	O
communities	O
share	O
a	O
core	O
set	O
of	O
gene	O
functions	O
in	O
the	O
microbiome	O
(	O
35	O
)	O
.	O
The	O
gut	O
microbial	O
community	O
changes	O
with	O
age	O
.	O
In	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
studies	I-methodology
,	O
we	O
see	O
an	O
apparently	O
smooth	O
change	O
in	O
the	O
gut	O
microbiota	O
in	O
the	O
first	O
3	O
years	O
of	O
life	O
,	O
followed	O
by	O
relatively	O
subtle	O
changes	O
thereafter	O
.	O
Although	O
few	O
studies	O
have	O
specifically	O
examined	O
the	O
gut	O
microbiota	O
in	O
old	O
age	O
,	O
recent	O
studies	O
on	O
elderly	O
population	O
confirm	O
that	O
they	O
harbour	O
distinct	O
gut	O
microbial	O
communities	O
from	O
younger	O
adults	O
(	O
36	O
)	O
,	O
and	O
the	O
composition	O
of	O
the	O
microbiota	O
in	O
the	O
elderly	O
subjects	O
correlates	O
significantly	O
with	O
measures	O
of	O
frailty	O
,	O
co	O
-	O
morbidity	O
and	O
nutrition	O
(	O
37	O
)	O
.	O

Lachnospiraceae	O
and	O
microbial	O
genes	O
involved	O
in	O
the	O
production	O
of	O
SCFA	O
were	O
enriched	O
in	O
elderly	O
subjects	O
living	O
in	O
the	O
community	O
compared	O
with	O
those	O
in	O
long	O
-	O
term	O
care	O
.	O
Another	O
study	O
performing	O
functional	O
profiling	O
of	O
the	O
gut	O
microbiota	O
found	O
an	O
increase	O
in	O
proteolytic	O
function	O
and	O
a	O
decrease	O
in	O
saccharolytic	O
function	O
,	O
in	O
addition	O
to	O
the	O
loss	O
of	O
genes	O
for	O
SCFA	O
production	O
associated	O
with	O
ageing	O
(	O
38	O
)	O
.	O
However	O
,	O
more	O
studies	O
,	O
and	O
especially	O
prospective	B-methodology
longitudinal	I-methodology
studies	I-methodology
,	O
are	O
needed	O
to	O
clarify	O
how	O
diet	O
and	O
the	O
gut	O
microbiota	O
affect	O
the	O
ageing	O
process	O
and	O
how	O
the	O
gut	O
microbiota	O
are	O
in	O
turn	O
affected	O
by	O
aging	O
itself	O
.	O
Understanding	O
the	O
variability	O
of	O
the	O
microbiota	O
between	O
people	O
and	O
over	O
time	O
is	O
a	O
prerequisite	O
to	O
discriminating	O
disease	O
states	O
from	O
normal	O
perturbations	O
.	O
Caporaso	O
et	O
al	O
.	O
(	O
39	O
)	O
densely	O
sampled	O
microbiota	O
from	O
three	O
body	O
sites	O
(	O
tongue	O
,	O
gut	O
and	O
skin	O
)	O
of	O
two	O
healthy	O
subjects	O
for	O
6	O
and	O
15	O
months	O
.	O
This	O
time	O
series	O
shows	O
the	O
remarkable	O
temporal	O
dynamics	O
of	O
the	O
gut	O
microbiota	O
of	O
individuals	O
.	O
Although	O
the	O
difference	O
between	O
gut	O
samples	O
from	O
an	O
individual	O
is	O
smaller	O
than	O
those	O
from	O
different	O
individuals	O
or	O
different	O
body	O
sites	O
,	O
there	O
seems	O
to	O
be	O
no	O
core	O
set	O
of	O
taxa	O
present	O
at	O
all	O
time	O
points	O
.	O
However	O
,	O
Faith	O
et	O
al	O
.	O
(	O
40	O
)	O
found	O
that	O
in	O
faecal	O
samples	O
sequenced	O
much	O
more	O
deeply	O
,	O
on	O
an	O
average	O
60	O
%	O
of	O
strains	O
in	O
the	O
gut	O
can	O
persist	O
over	O
a	O
long	O
period	O
up	O
to	O
5	O
years	O
when	O
only	O
a	O
few	O
time	O
points	O
are	O
evaluated	O
,	O
suggesting	O
that	O
either	O
the	O
dynamic	O
range	O
of	O
abundance	O
of	O
particular	O
taxa	O
is	O
large	O
(	O
requiring	O
very	O
deep	O
sequencing	O
to	O
recover	O
them	O
)	O
or	O
strains	O
can	O
be	O
lost	O
but	O
recolonise	O
the	O
host	O
.	O
This	O
temporal	O
consistency	O
assumes	O
that	O
other	O
factors	O
that	O
could	O
affect	O
the	O
microbiota	O
,	O
such	O
as	O
diet	O
and	O
disease	O
status	O
,	O
remain	O
relatively	O
constant	O
.	O
Most	O
studies	O
of	O
the	O
gut	O
microbiota	O
have	O
been	O
focused	O
on	O
Western	O
populations	O
in	O
Europe	O
,	O
the	O
USA	O
and	O
Canada	O
.	O
It	O
is	O
important	O
to	O
expand	O
these	O
studies	O
to	O
non	O
-	O
Western	O
diet	O
populations	O
in	O
order	O
to	O
fully	O
understand	O
the	O
range	O
of	O
variation	O
of	O
the	O
gut	O
microbiota	O
and	O
how	O
gut	O
microbes	O
have	O
co	O
-	O
evolved	O
with	O
humans	O
.	O

For	O
example	O
,	O
the	O
Japanese	O
population	O
has	O
a	O
unique	O
gene	O
coding	O
for	O
the	O
enzyme	O
porphyranase	O
in	O
the	O
gut	O
bacterium	O
Bacteroides	O
plebeius	O
,	O
potentially	O
transferred	O
from	O
marine	O
Bacteroides	O
spp	O
.	O
that	O
naturally	O
degrade	O
seaweed	O
,	O
to	O
facilitate	O
the	O
digestion	O
of	O
this	O
component	O
of	O
the	O
Japanese	O
,	O
but	O
not	O
,	O
historically	O
,	O
the	O
US	O
diet	O
(	O
41	O
)	O
.	O
Gut	O
microbiota	O
of	O
children	O
in	O
a	O
rural	O
African	O
village	O
in	O
Burkina	O
Faso	O
showed	O
an	O
increase	O
in	O
Bacteroidetes	O
and	O
a	O
decrease	O
in	O
Firmicutes	O
relative	O
to	O
European	O
children	O
(	O
12	O
)	O
.	O
This	O
pattern	O
was	O
also	O
found	O
in	O
a	O
broader	O
cross	O
-	O
cultural	O
comparison	O
of	O
the	O
gut	O
microbiota	O
of	O
people	O
living	O
in	O
the	O
Venezuelan	O
Amazon	O
,	O
rural	O
Malawi	O
and	O
the	O
USA	O
,	O
suggesting	O
that	O
carbohydrate	O
-	O
rich	O
diets	O
increase	O
the	O
amount	O
of	O
Prevotella	O
(	O
2	O
)	O
.	O
The	O
Hadza	O
hunter	O
-	O
gatherers	O
in	O
Tanzania	O
also	O
harbour	O
unique	O
compositions	O
of	O
microbiota	O
,	O
presumably	O
as	O
a	O
result	O
of	O
their	O
foraging	O
lifestyle	O
(	O
42	O
)	O
.	O
All	O
these	O
studies	O
demonstrate	O
the	O
heterogeneity	O
of	O
gut	O
microbiota	O
across	O
geographically	O
and	O
culturally	O
diverse	O
populations	O
,	O
although	O
to	O
date	O
not	O
enough	O
populations	O
have	O
been	O
studied	O
to	O
resolve	O
which	O
of	O
these	O
differences	O
are	O
due	O
to	O
diet	O
,	O
which	O
to	O
host	O
genetics	O
and	O
which	O
to	O
environmental	O
exposures	O
,	O
all	O
of	O
which	O
differ	O
among	O
these	O
populations	O
.	O
The	O
quantitative	O
contributions	O
of	O
host	O
genetics	O
,	O
environmental	O
factors	O
and	O
diet	O
to	O
shaping	O
the	O
gut	O
microbiota	O
remain	O
largely	O
unknown	O
.	O
Significant	O
associations	O
between	O
host	O
genotypes	O
and	O
their	O
gut	O
microbiota	O
composition	O
have	O
been	O
reported	O
in	O
both	O
human	O
and	O
mouse	O
studies	O
(	O
see	O
Spor	O
et	O
al	O
.	O
(	O
43	O
)	O
for	O
a	O
comprehensive	O
recent	O
review	O
)	O
.	O
The	O
environment	O
also	O
plays	O
an	O
important	O
role	O
in	O
establishing	O
and	O
modifying	O
the	O
gut	O
microbiota	O
.	O
For	O
example	O
,	O
the	O
close	O
physical	O
contact	O
between	O
humans	O
and	O
companion	O
animals	O
facilitates	O
the	O
acquisition	O
and	O
exchange	O
of	O
microbes	O
.	O
A	O
study	O
of	O
skin	O
,	O
oral	O
and	O
gut	O
microbiomes	O
showed	O
that	O
the	O
microbial	O
communities	O
of	O
cohabiting	O
family	O
members	O
resemble	O
each	O
other	O
and	O
that	O
adults	O
share	O
more	O
microbial	O
taxa	O
with	O
their	O
own	O
dogs	O
than	O
they	O
do	O
with	O
others	O
'	O
dogs	O
(	O
44	O
)	O
.	O
Having	O
a	O
dog	O
,	O
and	O
the	O
resulting	O
exposure	O
to	O
a	O
diverse	O
microbial	O
community	O
,	O
can	O
be	O
beneficial	O
.	O
Pet	O
ownership	O
in	O
the	O
early	O
,	O
but	O
not	O
later	O
,	O
years	O
of	O
life	O
(	O
45	O
)	O
is	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
the	O
risk	O
of	O
allergic	O
disease	O
(	O
46	O
)	O
.	O

As	O
discussed	O
earlier	O
,	O
dietary	O
effects	O
on	O
the	O
gut	O
microbiota	O
and	O
health	O
are	O
often	O
confounded	O
by	O
variation	O
in	O
host	O
genotypes	O
and	O
environmental	O
exposures	O
.	O
Nevertheless	O
,	O
accumulating	O
evidence	O
has	O
suggested	O
that	O
long	O
-	O
term	O
diet	O
is	O
a	O
primary	O
driver	O
of	O
the	O
gut	O
microbiota	O
.	O
As	O
an	O
extreme	O
example	O
,	O
two	O
co	O
-	O
evolution	O
studies	O
of	O
mammals	O
and	O
their	O
gut	O
microbiota	O
has	O
found	O
that	O
both	O
gut	O
microbiota	O
composition	O
and	O
functions	O
are	O
adapted	O
to	O
their	O
diet	O
(	O
herbivorous	O
,	O
carnivorous	O
and	O
omnivorous	O
)	O
(	O
47	O
,	O
48	O
)	O
.	O
In	O
another	O
more	O
recent	O
study	O
,	O
the	O
convergently	O
evolved	O
composition	O
of	O
the	O
gut	O
microbiome	O
in	O
ant	O
-	O
eating	O
mammals	O
,	O
despite	O
their	O
phylogenetic	O
diversity	O
,	O
strongly	O
suggests	O
that	O
diet	O
is	O
the	O
major	O
force	O
shaping	O
their	O
microbiota	O
(	O
49	O
)	O
.	O
Wu	O
et	O
al	O
.	O
(	O
31	O
)	O
showed	O
that	O
the	O
overall	O
structure	O
of	O
the	O
human	O
gut	O
microbiota	O
,	O
at	O
least	O
in	O
a	O
Western	O
population	O
,	O
seems	O
to	O
be	O
driven	O
mainly	O
by	O
long	O
-	O
term	O
dietary	O
effects	O
:	O
Prevotella	O
was	O
enriched	O
in	O
people	O
with	O
high	O
-	O
fibre	O
and	O
high	O
-	O
carbohydrate	O
diets	O
,	O
whereas	O
Bacteroides	O
was	O
associated	O
with	O
a	O
typical	O
‘	O
Western	O
’	O
diet	O
high	O
in	O
protein	O
and	O
fat	O
.	O
The	O
studies	O
highlighted	O
in	O
the	O
previous	O
section	O
also	O
suggest	O
that	O
differences	O
between	O
the	O
gut	O
microbial	O
communities	O
of	O
rural	O
populations	O
and	O
Westerners	O
are	O
largely	O
linked	O
to	O
differences	O
in	O
diet	O
(	O
2	O
,	O
12	O
,	O
42	O
)	O
.	O
Fortunately	O
,	O
we	O
can	O
examine	O
dietary	O
effects	O
more	O
directly	O
with	O
techniques	O
that	O
constrain	O
other	O
interacting	O
factors	O
.	O
Studies	O
of	O
the	O
faecal	O
microbiomes	O
of	O
human	O
monozygotic	O
and	O
dizygotic	O
twins	O
have	O
been	O
helpful	O
in	O
identifying	O
the	O
effects	O
of	O
diet	O
on	O
gut	O
microbiota	O
controlling	O
for	O
host	O
genetics	O
(	O
50	O
)	O
.	O
In	O
addition	O
,	O
gnotobiotic	O
mice	O
(	O
initially	O
germ	O
-	O
free	O
mice	O
colonised	O
with	O
either	O
a	O
defined	O
set	O
of	O
microbial	O
strains	O
or	O
with	O
a	O
donor	O
faecal	O
sample	O
)	O
provides	O
a	O
well	O
-	O
defined	O
,	O
powerful	O
animal	O
model	O
of	O
the	O
human	O
gut	O
ecosystem	O
to	O
elucidate	O
the	O
effects	O
of	O
nutrients	O
on	O
the	O
microbiome	O
,	O
including	O
taxonomic	O
composition	O
,	O
microbial	O
and	O
host	O
gene	O
expression	O
,	O
and	O
,	O
ultimately	O
,	O
host	O
physiological	O
status	O
in	O
response	O
to	O
controlled	O
changes	O
in	O
diet	O
(	O
15	O
,	O
51	O
)	O
.	O

Using	O
the	O
gnotobiotic	O
mouse	B-methodology
model	I-methodology
,	O
a	O
recent	O
study	O
found	O
that	O
obese	O
or	O
lean	O
phenotypes	O
can	O
be	O
transmitted	O
to	O
germ	O
-	O
free	O
mice	O
by	O
inoculating	O
them	O
with	O
the	O
gut	O
microbiota	O
from	O
human	O
twins	O
discordant	O
for	O
obesity	O
and	O
that	O
the	O
obese	O
phenotype	O
of	O
the	O
mouse	O
transplanted	O
with	O
the	O
obese	O
microbiota	O
can	O
be	O
rescued	O
by	O
the	O
invasion	O
of	O
a	O
particular	O
species	O
of	O
Bacteroidetes	O
from	O
the	O
mouse	O
transplanted	O
with	O
lean	O
microbiota	O
when	O
they	O
are	O
co	O
-	O
housed	O
(	O
14	O
)	O
.	O
This	O
rescue	O
and	O
invasion	O
is	O
diminished	O
when	O
the	O
mice	O
are	O
fed	O
with	O
a	O
diet	O
high	O
in	O
saturated	O
fats	O
and	O
low	O
in	O
vegetables	O
and	O
fruit	O
,	O
confirming	O
the	O
dependency	O
of	O
the	O
gut	O
microbiota	O
on	O
diet	O
.	O
Arguably	O
,	O
diet	O
is	O
among	O
the	O
most	O
easily	O
controlled	O
factors	O
that	O
can	O
potentially	O
manipulate	O
the	O
gut	O
microbiota	O
.	O
Studying	O
the	O
resilience	O
of	O
the	O
microbiota	O
and	O
its	O
patterns	O
of	O
change	O
,	O
during	O
and	O
after	O
dietary	B-methodology
intervention	I-methodology
,	O
could	O
allow	O
the	O
design	O
of	O
effective	O
nutrition	O
therapy	O
.	O
Ley	O
et	O
al	O
.	O
(	O
52	O
)	O
have	O
shown	O
that	O
the	O
ratio	O
of	O
Bacteroidetes	O
:	O
Firmicutes	O
increases	O
in	O
the	O
gut	O
microbiota	O
of	O
people	O
consuming	O
either	O
a	O
fat	O
-	O
restricted	O
or	O
a	O
carbohydrate	O
-	O
restricted	O
low	O
-	O
energy	O
diet	O
for	O
a	O
year	O
and	O
that	O
people	O
who	O
lost	O
more	O
weight	O
showed	O
larger	O
changes	O
in	O
the	O
ratios	O
of	O
these	O
taxa	O
.	O
Two	O
other	O
short	O
-	O
term	O
controlled	B-methodology
feeding	I-methodology
experiments	I-methodology
found	O
that	O
the	O
changes	O
in	O
microbiota	O
composition	O
can	O
be	O
rapid	O
(	O
within	O
24	O
h	O
)	O
,	O
reproducible	O
and	O
can	O
overwhelm	O
interpersonal	O
variability	O
with	O
a	O
sufficiently	O
extreme	O
diet	O
(	O
31	O
,	O
53	O
)	O
.	O
A	O
dietary	B-methodology
intervention	I-methodology
study	I-methodology
of	O
obese	O
or	O
overweight	O
individuals	O
found	O
that	O
the	O
gene	O
richness	O
(	O
the	O
number	O
of	O
gut	O
microbial	O
genes	O
)	O
is	O
increased	O
and	O
the	O
metabolic	O
status	O
is	O
improved	O
in	O
individuals	O
with	O
low	O
gut	O
microbial	O
gene	O
richness	O
,	O
after	O
a	O
6	O
-	O
week	O
low	O
-	O
energy	O
,	O
high	O
-	O
protein	O
diet	O
followed	O
by	O
another	O
6	O
-	O
week	O
weight	O
maintenance	O
diet	O
(	O
54	O
)	O
,	O
but	O
this	O
improvement	O
is	O
very	O
limited	O
for	O
individuals	O
with	O
already	O
high	O
gut	O
microbial	O
gene	O
richness	O
.	O
Dietary	B-methodology
interventions	I-methodology
in	O
malnourished	O
humans	O
are	O
not	O
always	O
successful	O
,	O
and	O
the	O
variation	O
may	O
be	O
explained	O
by	O
individual	O
differences	O
in	O
the	O
gut	O
microbiota	O
.	O

Studies	O
of	O
Malawian	O
and	O
Bangladeshi	O
subjects	O
with	O
severe	O
acute	O
malnutrition	O
have	O
shown	O
that	O
their	O
gut	O
microbiota	O
are	O
resilient	O
and	O
often	O
regress	O
back	O
to	O
the	O
state	O
before	O
the	O
food	O
intervention	O
(	O
50	O
,	O
55	O
)	O
,	O
suggesting	O
that	O
longer	O
intervention	O
or	O
a	O
repair	O
of	O
the	O
gut	O
microbiota	O
is	O
needed	O
to	O
effectively	O
treat	O
malnutrition	O
in	O
these	O
cases	O
.	O
It	O
remains	O
a	O
challenge	O
to	O
identify	O
the	O
key	O
pathogenic	O
microbiota	O
and	O
to	O
establish	O
a	O
causal	O
(	O
rather	O
than	O
associative	O
)	O
relationship	O
between	O
specific	O
microbes	O
or	O
community	O
states	O
and	O
a	O
given	O
physiological	O
or	O
disease	O
phenotype	O
(	O
5	O
)	O
.	O
Exactly	O
what	O
role	O
does	O
the	O
microbiota	O
play	O
in	O
obesity	O
,	O
diabetes	O
and	O
other	O
diseases	O
?	O
Is	O
the	O
microbiota	O
shift	O
a	O
result	O
of	O
changes	O
in	O
gut	O
environment	O
or	O
a	O
cause	O
?	O
Does	O
microbiota	O
initiate	O
the	O
effect	O
,	O
or	O
mediate	O
it	O
?	O
Can	O
we	O
design	O
therapeutic	O
food	O
interventions	O
or	O
faecal	O
transplantations	O
to	O
restore	O
a	O
healthy	O
microbiota	O
and	O
cure	O
diseases	O
that	O
stem	O
from	O
dysbiosis	O
?	O
These	O
questions	O
are	O
largely	O
unanswered	O
and	O
will	O
require	O
more	O
mechanistic	B-methodology
studies	I-methodology
of	O
the	O
gut	O
microbiota	O
.	O
Encouragingly	O
,	O
a	O
recent	O
randomised	B-methodology
clinical	I-methodology
trial	I-methodology
of	O
faecal	O
transplantation	O
demonstrated	O
that	O
it	O
is	O
much	O
more	O
effective	O
at	O
curing	O
recurring	O
infections	O
of	O
Clostridium	O
difficile	O
(	O
56	O
)	O
than	O
traditional	O
antibiotic	O
treatment	O
.	O
Vast	O
resources	O
have	O
been	O
invested	O
in	O
studies	O
of	O
mouse	O
and	O
human	O
microbiota	O
such	O
as	O
the	O
Human	O
Microbiome	O
Project	O
(	O
7	O
,	O
57	O
,	O
58	O
)	O
and	O
the	O
MetaHIT	O
project	O
(	O
29	O
,	O
59	O
)	O
.	O
These	O
projects	O
and	O
their	O
associated	O
technologies	O
have	O
led	O
to	O
a	O
greater	O
understanding	O
of	O
the	O
function	O
of	O
the	O
microbiome	O
.	O
Many	O
of	O
the	O
tools	O
developed	O
and	O
the	O
conclusions	O
reached	O
for	O
the	O
human	O
microbiome	O
can	O
be	O
readily	O
transferred	O
to	O
other	O
host	O
-	O
associated	O
studies	O
.	O
Similar	O
to	O
the	O
human	O
gut	O
microbiota	O
,	O
Firmicutes	O
and	O
Bacteroidetes	O
are	O
also	O
the	O
predominant	O
taxa	O
in	O
horses	O
(	O
60	O
)	O
,	O
guinea	O
pig	O
(	O
61	O
)	O
,	O
cats	O
and	O
dogs	O
(	O
62	O
)	O
.	O
Gastrointestinal	O
microbiome	O
dysbiosis	O
is	O
common	O
in	O
canine	O
and	O
feline	O
diseases	O
,	O
such	O
as	O
diarrhoea	O
and	O
IBD	O
,	O
and	O
the	O
alterations	O
in	O
the	O
bacterial	O
communities	O
of	O
dogs	O
and	O
cats	O
with	O
IBD	O
resemble	O
,	O
at	O
least	O
partially	O
,	O
the	O
dysbiosis	O
in	O
human	O
with	O
chronic	O
intestine	O
inflammation	O
(	O
63	O
)	O
.	O

For	O
example	O
,	O
Clostridium	O
clusters	O
XIVa	O
and	O
IV	O
,	O
which	O
produce	O
beneficial	O
SCFA	O
,	O
are	O
depleted	O
in	O
both	O
humans	O
and	O
dogs	O
with	O
IBD	O
(	O
64	O
)	O
.	O
The	O
interactions	O
of	O
host	O
genetics	O
,	O
diet	O
and	O
the	O
gut	O
microbiota	O
are	O
thus	O
convoluted	O
and	O
multi	O
-	O
faceted	O
.	O
In	O
many	O
cases	O
,	O
the	O
effect	O
size	O
may	O
be	O
small	O
compared	O
with	O
the	O
huge	O
variability	O
intrinsic	O
in	O
the	O
data	O
.	O
It	O
will	O
require	O
a	O
large	O
number	O
of	O
samples	O
to	O
reveal	O
such	O
small	O
effects	O
.	O
Citizen	O
science	O
projects	O
such	O
as	O
the	O
American	O
Gut	O
Project	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
microbio	O
.	O
me	O
/	O
americangut	O
/	O
)	O
launched	O
in	O
2013	O
provide	O
opportunities	O
for	O
the	O
general	O
public	O
to	O
participate	O
.	O
The	O
American	O
Gut	O
Project	O
is	O
one	O
of	O
the	O
largest	O
crowd	O
-	O
funded	O
citizen	O
science	O
projects	O
,	O
with	O
over	O
3600	O
participants	O
and	O
3800	O
samples	O
collected	O
to	O
date	O
.	O
Such	O
large	B-methodology
-	I-methodology
scale	I-methodology
studies	I-methodology
with	O
greater	O
statistical	O
power	O
will	O
allow	O
us	O
to	O
examine	O
the	O
subtle	O
contributions	O
of	O
diet	O
and	O
other	O
environmental	O
factors	O
on	O
the	O
gut	O
microbiota	O
from	O
an	O
integrated	O
perspective	O
.	O
This	O
work	O
is	O
supported	O
in	O
part	O
by	O
the	O
Howard	O
Hughes	O
Medical	O
Institute	O
and	O
the	O
National	O
Institutes	O
of	O
Health	O
.	O
The	O
authors	O
declare	O
no	O
competing	O
financial	O
interests	O
.	O
The	O
authors	O
'	O
contributions	O
are	O
as	O
follows	O
:	O
Z	O
.	O
X	O
.	O
wrote	O
the	O
manuscript	O
;	O
both	O
authors	O
conceived	O
and	O
edited	O
the	O
manuscript	O
.	O

Synbiotics	O
Easing	O
Renal	O
Failure	O
by	O
Improving	O
Gut	O
Microbiology	O
II	O
(	O
SYNERGY	O
II	O
)	O
:	O
A	O
Feasibility	O
Randomized	B-methodology
Controlled	I-methodology
Trial	I-methodology
synbiotic	O
;	O
gastrointestinal	O
microbiome	O
;	O
kidney	O
disease	O
;	O
randomized	B-methodology
controlled	I-methodology
trial	I-methodology
;	O
p	O
-	O
cresyl	O
sulphate	O
;	O
indoxyl	O
sulfate	O
Synbiotics	O
have	O
emerged	O
as	O
a	O
therapeutic	O
strategy	O
for	O
modulating	O
the	O
gut	O
microbiome	O
and	O
targeting	O
novel	O
cardiovascular	O
risk	O
factors	O
,	O
including	O
uremic	O
toxins	O
indoxyl	O
sulfate	O
(	O
IS	O
)	O
and	O
p	O
-	O
cresyl	O
sulfate	O
(	O
PCS	O
)	O
.	O
This	O
study	O
aims	O
to	O
evaluate	O
the	O
feasibility	O
of	O
a	O
trial	O
of	O
long	O
-	O
term	O
synbiotic	O
supplementation	O
in	O
adults	O
with	O
stage	O
3	O
–	O
4	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
.	O
Adult	O
participants	O
with	O
CKD	O
and	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
eGFR	O
)	O
of	O
15	O
–	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
)	O
were	O
recruited	O
between	O
April	O
2017	O
and	O
August	O
2018	O
to	O
a	O
feasibility	O
,	O
double	B-methodology
-	I-methodology
blind	I-methodology
,	I-methodology
placebo	I-methodology
-	O
controlled	O
,	O
randomized	B-methodology
trial	I-methodology
of	O
synbiotic	O
therapy	O
or	O
matched	O
identical	O
placebo	B-methodology
for	O
12	O
months	O
.	O
The	O
primary	O
outcomes	O
were	O
recruitment	O
and	O
retention	O
rates	O
as	O
well	O
as	O
acceptability	O
of	O
the	O
intervention	O
.	O
Secondary	O
outcomes	O
were	O
treatment	O
adherence	O
and	O
dietary	O
intake	O
.	O
Exploratory	O
outcomes	O
were	O
evaluation	O
of	O
the	O
cardiovascular	O
structure	O
and	O
function	O
,	O
serum	O
IS	O
and	O
PCS	O
,	O
stool	O
microbiota	O
profile	O
,	O
kidney	O
function	O
,	O
blood	O
pressure	O
,	O
and	O
lipid	O
profile	O
.	O
Of	O
166	O
potentially	O
eligible	O
patients	O
,	O
68	O
(	O
41	O
%	O
)	O
were	O
recruited	O
into	O
the	O
trial	O
(	O
synbiotic	O
n	O
=	O
35	O
,	O
placebo	B-methodology
n	O
=	O
33	O
)	O
.	O
Synbiotic	O
and	O
placebo	O
groups	O
had	O
acceptable	O
and	O
comparable	O
12	O
-	O
month	O
retention	O
rates	O
(	O
80	O
%	O
versus	O
85	O
%	O
,	O
respectively	O
,	O
p	O
=	O
0	O
.	O
60	O
)	O
.	O

Synbiotic	O
supplementation	O
altered	O
the	O
stool	O
microbiome	O
with	O
an	O
enrichment	O
of	O
Bifidobacterium	O
and	O
Blautia	O
spp	O
.	O
,	O
resulting	O
in	O
a	O
3	O
.	O
14	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
−6	O
.	O
23	O
to	O
−0	O
.	O
06	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
reduction	O
in	O
eGFR	O
and	O
a	O
20	O
.	O
8	O
µmol	O
/	O
L	O
(	O
95	O
%	O
CI	O
,	O
2	O
.	O
97	O
to	O
38	O
.	O
5	O
µmol	O
/	O
L	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
increase	O
in	O
serum	O
creatinine	O
concentration	O
.	O
No	O
between	O
-	O
group	O
differences	O
were	O
observed	O
in	O
any	O
of	O
the	O
other	O
secondary	O
or	O
exploratory	O
outcomes	O
.	O
Long	O
-	O
term	O
synbiotic	O
supplementation	O
was	O
feasible	O
and	O
acceptable	O
to	O
patients	O
with	O
CKD	O
,	O
and	O
it	O
modified	O
the	O
gastrointestinal	O
microbiome	O
.	O
However	O
,	O
the	O
reduction	O
in	O
kidney	O
function	O
with	O
synbiotics	O
warrants	O
further	O
investigation	O
.	O
Individuals	O
with	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
have	O
a	O
significantly	O
increased	O
risk	O
of	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
and	O
are	O
more	O
likely	O
to	O
die	O
from	O
cardiovascular	O
-	O
related	O
complications	O
than	O
progress	O
to	O
kidney	O
replacement	O
therapy	O
[	O
1	O
]	O
.	O
Framingham	O
risk	O
factors	O
only	O
partially	O
explain	O
this	O
elevated	O
cardiovascular	O
risk	O
[	O
2	O
]	O
,	O
leading	O
many	O
researchers	O
to	O
explore	O
novel	O
risk	O
factors	O
such	O
as	O
uremic	O
toxins	O
.	O
The	O
uremic	O
toxins	O
,	O
indoxyl	O
sulfate	O
(	O
IS	O
)	O
and	O
p	O
-	O
cresyl	O
sulfate	O
(	O
PCS	O
)	O
,	O
have	O
increasingly	O
been	O
associated	O
with	O
accelerated	O
kidney	O
disease	O
progression	O
and	O
cardiovascular	O
morbidity	O
and	O
mortality	O
[	O
3	O
,	O
4	O
,	O
5	O
]	O
.	O
These	O
toxins	O
are	O
produced	O
through	O
the	O
metabolism	O
of	O
the	O
dietary	O
amino	O
acids	O
,	O
tryptophan	O
(	O
IS	O
)	O
and	O
tyrosine	O
(	O
PCS	O
)	O
,	O
respectively	O
,	O
by	O
the	O
gut	O
microbiota	O
[	O
6	O
]	O
.	O
Both	O
IS	O
and	O
PCS	O
are	O
predominantly	O
bound	O
to	O
plasma	O
proteins	O
,	O
such	O
as	O
albumin	O
,	O
and	O
rely	O
on	O
kidney	O
excretion	O
.	O
An	O
altered	O
gut	O
microbiota	O
and	O
reduced	O
kidney	O
clearance	O
are	O
both	O
contributing	O
factors	O
to	O
increased	O
serum	O
toxin	O
concentrations	O
in	O
CKD	O
[	O
7	O
]	O
.	O
The	O
altered	O
gut	O
microbiota	O
seen	O
in	O
patients	O
with	O
CKD	O
may	O
be	O
therapeutically	O
modifiable	O
.	O

Synbiotic	O
supplementation	O
(	O
the	O
co	O
-	O
administration	O
of	O
prebiotics	O
and	O
probiotics	O
)	O
has	O
emerged	O
over	O
the	O
last	O
decade	O
as	O
a	O
reportedly	O
innocuous	O
intervention	O
targeting	O
the	O
microbial	O
generation	O
of	O
IS	O
and	O
PCS	O
.	O
The	O
key	O
hypothesis	O
is	O
that	O
controlling	O
toxin	O
generation	O
by	O
competitively	O
decreasing	O
protein	O
-	O
fermenting	O
intestinal	O
microbiota	O
can	O
slow	O
CKD	O
progression	O
and	O
reduce	O
associated	O
cardiovascular	O
complications	O
.	O
The	O
Synbiotics	O
Easing	O
Renal	O
Failure	O
by	O
Improving	O
Gut	O
Microbiology	O
(	O
SYNERGY	O
)	O
study	O
[	O
8	O
]	O
,	O
a	O
proof	B-methodology
-	I-methodology
of	I-methodology
-	I-methodology
concept	I-methodology
study	O
,	O
determined	O
that	O
synbiotic	O
supplementation	O
reduced	O
PCS	O
and	O
favorably	O
altered	O
the	O
gastrointestinal	O
microbiome	O
.	O
However	O
,	O
to	O
date	O
,	O
studies	O
of	O
synbiotic	B-methodology
interventions	I-methodology
in	O
CKD	O
have	O
been	O
limited	O
,	O
hampered	O
by	O
uncertain	O
or	O
high	O
risk	O
of	O
bias	O
and	O
conflicting	O
findings	O
[	O
9	O
]	O
.	O
Whilst	O
these	O
interventions	O
report	O
high	O
levels	O
of	O
adherence	O
and	O
minimal	O
side	O
effects	O
,	O
the	O
duration	O
of	O
supplementation	O
was	O
short	O
,	O
ranging	O
from	O
1	O
to	O
2	O
months	O
[	O
9	O
]	O
.	O
Dietary	B-methodology
interventions	I-methodology
are	O
exceptionally	O
challenging	O
with	O
up	O
to	O
60	O
%	O
of	O
participants	O
being	O
unable	O
to	O
adhere	O
to	O
recommended	O
dietary	O
changes	O
long	O
-	O
term	O
(	O
1	O
year	O
)	O
[	O
10	O
]	O
.	O
Meanwhile	O
,	O
medication	O
non	O
-	O
adherence	O
in	O
chronic	O
conditions	O
is	O
common	O
,	O
with	O
rates	O
averaging	O
50	O
%	O
and	O
higher	O
[	O
11	O
]	O
.	O
Further	O
,	O
adherence	O
to	O
nutrition	O
supplementation	O
in	O
the	O
chronic	O
disease	O
population	O
remains	O
largely	O
unexplored	O
.	O
Accordingly	O
,	O
this	O
study	O
aimed	O
to	O
evaluate	O
the	O
feasibility	O
and	O
acceptability	O
of	O
long	O
-	O
term	O
synbiotic	O
supplementation	O
in	O
people	O
with	O
stage	O
3	O
–	O
4	O
CKD	O
.	O
In	O
addition	O
,	O
this	O
study	O
explored	O
the	O
effect	O
of	O
synbiotic	O
supplementation	O
on	O
markers	O
of	O
cardiovascular	O
risk	O
,	O
microbial	O
-	O
derived	O
uremic	O
toxins	O
,	O
and	O
gastrointestinal	O
(	O
stool	O
)	O
microbiota	O
.	O
The	O
Synbiotics	O
Easing	O
Renal	O
Failure	O
by	O
Improving	O
Gut	O
Microbiology	O
II	O
(	O
SYNERGY	O
II	O
)	O
study	O
was	O
a	O
double	B-methodology
-	I-methodology
blind	I-methodology
,	I-methodology
placebo	I-methodology
-	O
controlled	O
,	O
randomized	B-methodology
controlled	I-methodology
trial	I-methodology
assessing	O
the	O
feasibility	O
and	O
acceptability	O
of	O
12	O
-	O
month	O
synbiotic	O
supplementation	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
CKD	O
.	O
Ethical	O
approval	O
was	O
granted	O
through	O
the	O
Metro	O
South	O
Human	B-methodology
Research	I-methodology
Ethics	O
Committee	O
(	O
HREC	O
/	O
16	O
/	O
QPAH	O
/	O
336	O
)	O
and	O
the	O
University	O
of	O
Queensland	O
Human	B-methodology
Research	I-methodology
Ethics	O
committee	O
,	O
and	O
the	O
study	O
adhered	O
to	O
the	O
Declaration	O
of	O
Helsinki	O
.	O
All	O
patients	O
provided	O
written	O
consent	O
prior	O
to	O
enrolment	O
and	O
participation	O
.	O

The	O
SYNERGY	O
II	O
study	O
was	O
registered	O
with	O
the	O
Australian	O
and	O
New	O
Zealand	O
Clinical	B-methodology
Trials	I-methodology
Registry	O
(	O
ACTRN12617000324314	O
)	O
.	O
Patients	O
from	O
two	O
tertiary	O
kidney	O
care	O
outpatient	O
departments	O
with	O
an	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
eGFR	O
)	O
between	O
15	O
and	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
,	O
aged	O
≥	O
18	O
years	O
of	O
age	O
were	O
eligible	O
for	O
inclusion	O
.	O
Exclusion	B-methodology
criteria	I-methodology
were	O
as	O
follows	O
:	O
anticipated	O
dialysis	O
commencement	O
within	O
12	O
months	O
or	O
anticipated	O
death	O
within	O
6	O
months	O
;	O
non	O
-	O
English	O
speaking	O
or	O
unable	O
to	O
give	O
informed	O
consent	O
;	O
a	O
clinically	O
significant	O
change	O
in	O
immunosuppressant	O
dose	O
within	O
6	O
months	O
;	O
receiving	O
or	O
had	O
received	O
radiation	O
to	O
the	O
bowel	O
or	O
had	O
a	O
large	O
bowel	O
resection	O
;	O
consumed	O
pre	O
-	O
,	O
probiotic	O
,	O
or	O
antibiotic	O
therapy	O
within	O
1	O
month	O
of	O
study	O
commencement	O
;	O
medically	O
diagnosed	O
and	O
active	O
irritable	O
bowel	O
syndrome	O
,	O
Crohn	O
’	O
s	O
disease	O
,	O
or	O
ulcerative	O
colitis	O
;	O
cirrhotic	O
liver	O
disease	O
;	O
or	O
severely	O
malnourished	O
(	O
Subjective	O
Global	O
Assessment	O
:	O
C	O
)	O
.	O
A	O
local	O
site	O
investigator	O
or	O
research	O
nurse	O
utilized	O
daily	O
outpatient	O
appointment	O
lists	O
and	O
relevant	O
hospital	O
databases	O
to	O
screen	O
potential	O
participants	O
for	O
eligibility	O
.	O
Participants	O
were	O
approached	O
and	O
invited	O
to	O
participate	O
following	O
discussion	O
with	O
their	O
treating	O
nephrologist	O
.	O
At	O
the	O
first	O
study	O
visit	O
,	O
participants	O
were	O
randomly	B-methodology
assigned	I-methodology
to	O
either	O
synbiotic	O
supplements	O
or	O
placebo	B-methodology
for	O
12	O
months	O
.	O
The	O
randomization	O
was	O
completed	O
by	O
a	O
computer	O
-	O
generated	O
random	O
number	O
(	O
1	O
:	O
1	O
ratio	O
,	O
blocks	O
of	O
4	O
,	O
stratified	O
by	O
CKD	O
stage	O
and	O
presence	O
of	O
diabetes	O
)	O
,	O
which	O
was	O
carried	O
out	O
by	O
an	O
independent	O
investigator	O
not	O
involved	O
in	O
the	O
recruitment	O
or	O
implementation	O
of	O
the	O
study	B-methodology
protocol	I-methodology
.	O
All	O
participants	O
received	O
face	O
-	O
to	O
-	O
face	O
or	O
telephone	O
dietary	O
education	O
and	O
counseling	O
with	O
a	O
qualified	O
dietitian	O
in	O
line	O
with	O
evidence	O
-	O
based	O
guidelines	B-methodology
[	O
12	O
,	O
13	O
]	O
at	O
their	O
commencement	O
in	O
the	O
trial	O
.	O
The	O
prebiotic	O
component	O
of	O
the	O
synbiotic	O
therapy	O
consisted	O
of	O
20	O
g	O
/	O
day	O
of	O
high	O
-	O
resistant	O
starch	O
fiber	O
supplement	O
(	O
Hi	O
-	O
Maize	O
260	O
,	O
50	O
%	O
resistant	O
starch	O
;	O
Ingredion	O
)	O
,	O
and	O
the	O
probiotic	O
component	O
provided	O
4	O
.	O
5	O
×	O
1011	O
colony	O
-	O
forming	O
units	O
(	O
CFU	O
)	O
/	O
day	O
of	O
nine	O
different	O
strains	O
from	O
three	O
different	O
genera	O
(	O
Bifidobacteria	O
,	O
Lactobacillus	O
,	O
and	O
Streptococcus	O
;	O
Swiss	O
Mendes	O
)	O
.	O

The	O
placebo	B-methodology
group	I-methodology
received	O
waxy	O
maize	O
powder	O
(	O
Ingredion	O
)	O
and	O
maltodextrin	O
(	O
Swiss	O
Mendes	O
)	O
in	O
lieu	O
of	O
the	O
prebiotic	O
and	O
probiotic	O
,	O
respectively	O
.	O
Both	O
prebiotics	O
and	O
probiotics	O
were	O
packaged	O
offsite	O
and	O
labeled	O
by	O
an	O
independent	O
investigator	O
.	O
The	O
prebiotic	O
component	O
in	O
this	O
present	O
study	O
differed	O
from	O
that	O
used	O
in	O
the	O
SYNERGY	O
study	O
[	O
8	O
]	O
,	O
which	O
used	O
15	O
g	O
/	O
day	O
across	O
fructooligosaccharide	O
(	O
FOS	O
)	O
,	O
galactooligosaccharide	O
(	O
GOS	O
)	O
,	O
and	O
inulin	O
.	O
Short	O
-	O
chain	O
carbohydrates	O
,	O
such	O
as	O
FOS	O
and	O
GOS	O
,	O
are	O
rapidly	O
fermented	O
in	O
the	O
proximal	O
colon	O
,	O
while	O
resistant	O
starch	O
is	O
slowly	O
fermented	O
and	O
can	O
reach	O
the	O
distal	O
parts	O
of	O
the	O
colon	O
,	O
yielding	O
a	O
greater	O
production	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFA	O
)	O
[	O
14	O
]	O
.	O
The	O
probiotic	O
component	O
in	O
this	O
present	O
study	O
had	O
identical	O
taxa	O
to	O
that	O
used	O
in	O
the	O
SYNERGY	O
study	O
[	O
8	O
]	O
;	O
however	O
,	O
it	O
had	O
a	O
higher	O
CFU	O
.	O
The	O
probiotic	O
contained	O
strains	O
from	O
the	O
Lactobacillus	O
(	O
L	O
.	O
acidophilus	O
,	O
L	O
.	O
plantarum	O
,	O
L	O
.	O
paracasei	O
,	O
L	O
.	O
delbrueckii	O
subsp	O
.	O
Bulgaricus	O
)	O
,	O
Bifidobacteria	O
(	O
B	O
.	O
breve	O
,	O
B	O
.	O
longum	O
,	O
B	O
.	O
infantis	O
)	O
and	O
Streptococcus	O
(	O
S	O
.	O
thermophilus	O
)	O
genera	O
,	O
which	O
have	O
limited	O
enzymatic	O
capacity	O
to	O
produce	O
uremic	O
toxins	O
and	O
competitively	O
decrease	O
bacteria	O
that	O
do	O
[	O
15	O
,	O
16	O
]	O
.	O
The	O
study	B-methodology
design	I-methodology
(	O
Figure	O
1	O
)	O
included	O
a	O
dose	O
escalation	O
to	O
avoid	O
potential	O
adverse	O
gastrointestinal	O
symptoms	O
.	O
In	O
both	O
arms	O
,	O
the	O
prebiotic	O
/	O
placebo	B-methodology
were	O
commenced	O
at	O
a	O
one	O
-	O
half	O
dose	O
for	O
the	O
first	O
2	O
weeks	O
,	O
consisting	O
of	O
10	O
g	O
(	O
one	O
level	O
scoop	O
)	O
of	O
the	O
prebiotic	O
/	O
placebo	B-methodology
powder	O
and	O
one	O
probiotic	O
/	O
placebo	B-methodology
sachet	O
.	O
This	O
was	O
taken	O
in	O
the	O
morning	O
with	O
food	O
.	O
Following	O
dose	O
escalation	O
,	O
participants	O
included	O
an	O
additional	O
prebiotic	O
/	O
placebo	B-methodology
dose	O
(	O
10	O
g	O
powder	O
)	O
with	O
their	O
evening	O
meal	O
.	O
A	O
qualified	O
dietitian	O
provided	O
telephone	O
consultations	O
fortnightly	O
for	O
the	O
first	O
2	O
months	O
and	O
then	O
monthly	O
for	O
the	O
remainder	O
of	O
the	O
intervention	O
to	O
verify	O
adherence	O
and	O
assess	O
adverse	O
events	O
.	O

If	O
the	O
participant	O
experienced	O
any	O
adverse	O
gastrointestinal	O
symptoms	O
associated	O
with	O
the	O
supplement	O
,	O
the	O
supplement	O
dose	O
was	O
modified	O
.	O
Throughout	O
the	O
intervention	O
,	O
participants	O
were	O
provided	O
individualized	O
and	O
tailored	O
dietary	O
advice	O
in	O
line	O
with	O
best	B-methodology
practice	I-methodology
guidelines	I-methodology
and	O
were	O
encouraged	O
to	O
maintain	O
a	O
stable	O
dietary	O
intake	O
,	O
focusing	O
on	O
not	O
altering	O
protein	O
and	O
fiber	O
intake	O
.	O
The	O
primary	O
outcome	O
was	O
the	O
feasibility	O
and	O
acceptability	O
of	O
long	O
-	O
term	O
synbiotic	O
supplementation	O
.	O
Feasibility	O
was	O
measured	O
through	O
recruitment	O
and	O
retention	O
rate	O
.	O
Recruitment	O
rate	O
was	O
collected	O
and	O
stored	O
in	O
a	O
password	O
-	O
protected	O
Microsoft	O
Excel	O
database	O
throughout	O
the	O
trial	O
.	O
Retention	O
rate	O
was	O
measured	O
in	O
both	O
groups	O
at	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
months	O
.	O
Successful	O
retention	O
was	O
defined	O
as	O
80	O
%	O
at	O
the	O
12	O
-	O
month	O
study	O
end	O
.	O
Acceptability	O
was	O
measured	O
through	O
gastrointestinal	O
symptoms	O
,	O
stool	O
frequency	O
,	O
and	O
stool	O
consistency	O
.	O
Gastrointestinal	O
symptoms	O
,	O
stool	O
frequency	O
,	O
and	O
stool	O
consistency	O
were	O
measured	O
at	O
baseline	O
,	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
months	O
.	O
Gastrointestinal	O
symptoms	O
were	O
measured	O
using	O
the	O
Gastrointestinal	O
Symptoms	O
Rating	O
Scale	O
(	O
GSRS	O
)	O
[	O
17	O
]	O
,	O
which	O
is	O
a	O
15	O
-	O
item	O
survey	O
that	O
combines	O
symptoms	O
into	O
5	O
clusters	O
:	O
reflux	O
,	O
abdominal	O
pain	O
,	O
indigestion	O
,	O
diarrhea	O
,	O
and	O
constipation	O
.	O
The	O
GSRS	O
has	O
a	O
7	O
-	O
point	O
Likert	O
scale	O
in	O
which	O
the	O
intensity	O
of	O
each	O
symptom	O
is	O
graded	O
from	O
1	O
to	O
7	O
,	O
with	O
a	O
higher	O
score	O
indicating	O
more	O
severe	O
symptoms	O
.	O
Stool	O
frequency	O
was	O
measured	O
by	O
a	O
single	O
question	O
asking	O
the	O
participant	O
the	O
number	O
of	O
times	O
their	O
bowels	O
had	O
opened	O
in	O
the	O
previous	O
24	O
h	O
period	O
.	O
The	O
Bristol	O
Stool	O
Score	O
(	O
BSS	O
)	O
[	O
18	O
]	O
,	O
a	O
7	O
-	O
point	O
scale	O
,	O
was	O
used	O
to	O
classify	O
stool	O
consistency	O
.	O
Secondary	O
outcomes	O
were	O
treatment	O
adherence	O
and	O
dietary	O
intake	O
.	O
Adherence	O
was	O
measured	O
by	O
sachet	O
count	O
and	O
powder	O
weight	O
,	O
and	O
it	O
was	O
defined	O
as	O
consuming	O
80	O
%	O
or	O
more	O
of	O
the	O
prescribed	O
pre	O
-	O
and	O
probiotics	O
.	O
Participants	O
’	O
dietary	O
intakes	O
were	O
assessed	O
using	O
a	O
7	O
-	O
day	O
food	O
record	O
at	O
baseline	O
and	O
at	O
the	O
final	O
study	O
visit	O
by	O
the	O
same	O
dietitian	O
.	O
Dietary	O
data	O
were	O
analyzed	O
using	O
Food	O
Works	O
9	O
(	O
Xyris	O
Software	O
;	O
Version	O
9	O
.	O
0	O
.	O
3932	O
)	O
.	O
All	O
adverse	O
and	O
serious	O
adverse	O
events	O
(	O
SAE	O
)	O
were	O
documented	O
and	O
reported	O
to	O
the	O
ethics	O
committee	O
for	O
review	O
.	O

The	O
validated	O
‘	O
Assessment	O
of	O
Quality	O
of	O
Life	O
’	O
questionnaire	O
(	O
AQoL	O
-	O
4D	O
)	O
,	O
a	O
12	O
-	O
item	O
instrument	O
,	O
was	O
used	O
to	O
assess	O
health	O
-	O
related	O
quality	O
of	O
life	O
[	O
19	O
]	O
.	O
The	O
AQoL	O
-	O
4D	O
instrument	O
measures	O
health	O
-	O
related	O
quality	O
of	O
life	O
across	O
4	O
measures	O
:	O
independent	O
living	O
,	O
social	O
relationships	O
,	O
senses	O
,	O
and	O
mental	O
health	O
.	O
The	O
AQoL	O
-	O
4D	O
uses	O
a	O
4	O
-	O
point	O
Likert	O
scale	O
in	O
which	O
each	O
response	O
is	O
graded	O
from	O
1	O
(	O
a	O
‘	O
good	O
’	O
health	O
state	O
)	O
to	O
4	O
(	O
the	O
‘	O
worst	O
’	O
health	O
state	O
)	O
.	O
Exploratory	O
outcome	O
measures	O
included	O
echocardiographic	O
measurements	O
of	O
global	O
longitudinal	O
strain	O
(	O
GLS	O
)	O
,	O
left	O
ventricular	O
mass	O
index	O
(	O
LVMI	O
)	O
and	O
ejection	O
fraction	O
,	O
serum	O
creatinine	O
,	O
eGFR	O
,	O
free	O
and	O
protein	O
-	O
bound	O
serum	O
concentrations	O
of	O
serum	O
IS	O
and	O
PCS	O
,	O
and	O
stool	O
microbiota	O
analysis	O
(	O
opt	O
-	O
in	O
)	O
.	O
Outcome	O
measures	O
were	O
collected	O
at	O
baseline	O
and	O
12	O
months	O
and	O
were	O
analyzed	O
using	O
validated	O
methods	O
detailed	O
in	O
Appendix	O
A	O
.	O
The	O
DNA	O
extraction	O
and	O
sequencing	O
methods	O
are	O
described	O
in	O
detail	O
in	O
Appendix	O
A	O
.	O
The	O
sample	O
size	O
of	O
68	O
participants	O
to	O
be	O
randomized	O
was	O
based	O
on	O
a	O
recruitment	O
rate	O
of	O
20	O
%	O
of	O
eligible	O
patients	O
to	O
within	O
a	O
95	O
%	O
confidence	O
interval	O
of	O
±10	O
%	O
.	O
The	O
recruitment	O
rate	O
of	O
20	O
%	O
is	O
based	O
on	O
the	O
previous	O
SYNERGY	O
trial	O
[	O
8	O
]	O
.	O
Summary	O
statistics	O
for	O
patients	O
’	O
characteristics	O
were	O
expressed	O
as	O
means	O
±	O
standard	O
deviations	O
for	O
normally	O
distributed	O
continuous	O
data	O
,	O
medians	O
(	O
interquartile	O
ranges	O
)	O
for	O
continuous	O
non	O
-	O
normally	O
distributed	O
data	O
,	O
and	O
frequencies	O
(	O
percentages	O
)	O
for	O
categorical	O
data	O
.	O
Baseline	O
differences	O
between	O
intervention	O
and	O
placebo	O
groups	O
were	O
evaluated	O
by	O
chi	O
-	O
square	O
or	O
Fisher	O
’	O
s	O
exact	O
tests	O
for	O
categorical	O
variables	O
and	O
Student	O
’	O
s	O
t	O
-	O
test	O
or	O
Mann	O
–	O
Whitney	O
test	O
,	O
for	O
normal	O
or	O
skewed	O
continuous	O
variables	O
,	O
respectively	O
.	O
Recruitment	O
,	O
retention	O
,	O
and	O
adherence	O
rates	O
were	O
estimated	O
using	O
simple	O
descriptive	O
statistics	O
(	O
counts	O
and	O
percentages	O
)	O
.	O
To	O
determine	O
the	O
difference	O
in	O
the	O
GSRS	O
and	O
BSS	O
between	O
the	O
two	O
study	B-methodology
groups	I-methodology
,	O
the	O
chi	O
-	O
square	O
test	O
was	O
used	O
.	O
The	O
secondary	O
outcome	O
analyses	O
were	O
undertaken	O
using	O
the	O
analysis	O
of	O
covariance	O
regression	O
method	O
,	O
i	O
.	O
e	O
.	O
,	O
adjusted	O
for	O
the	O
baseline	O
measure	O
of	O
the	O
variable	O
.	O
The	O
outcome	O
values	O
were	O
transformed	O
where	O
not	O
normally	O
distributed	O
.	O

All	O
analyses	O
followed	O
an	O
intention	O
-	O
to	O
-	O
treat	O
principle	O
;	O
however	O
,	O
a	O
sensitivity	O
analysis	O
was	O
performed	O
to	O
evaluate	O
additional	O
effects	O
of	O
eGFR	O
,	O
dietary	O
protein	O
/	O
fiber	O
ratio	O
,	O
and	O
antibiotics	O
.	O
The	O
analysis	O
was	O
conducted	O
in	O
Stata	O
(	O
Version	O
15	O
;	O
StataCorp	O
.	O
,	O
College	O
Station	O
,	O
TX	O
,	O
USA	O
)	O
with	O
the	O
significance	O
level	O
set	O
at	O
0	O
.	O
05	O
.	O
The	O
stool	O
microbiota	O
between	O
the	O
synbiotic	O
and	O
placebo	O
groups	O
were	O
compared	O
as	O
described	O
by	O
McFarlane	O
et	O
al	O
.	O
[	O
20	O
]	O
.	O
Briefly	O
,	O
the	O
richness	O
and	O
Shannon	O
index	O
values	O
were	O
compared	O
using	O
mixed	O
effect	O
linear	O
models	O
.	O
Data	O
/	O
sample	O
clustering	O
was	O
examined	O
using	O
both	O
unsupervised	O
analysis	O
(	O
Principal	O
Coordinates	O
Analysis	O
(	O
PCoA	O
)	O
of	O
Bray	O
–	O
Curtis	O
dissimilarity	O
metrics	O
)	O
and	O
supervised	O
analyses	O
(	O
redundancy	O
analysis	O
(	O
RDA	O
)	O
)	O
constrained	O
by	O
the	O
synbiotic	O
or	O
placebo	B-methodology
intervention	O
.	O
These	O
data	O
were	O
also	O
subjected	O
to	O
centered	O
-	O
log	O
ratio	O
transformation	O
to	O
support	O
multivariate	O
analyses	O
by	O
sparse	O
Partial	O
Least	O
Squares	O
Discriminant	O
Analysis	O
(	O
sPLS	O
-	O
DA	O
)	O
[	O
21	O
]	O
.	O
The	O
sPLS	O
-	O
DA	O
function	O
of	O
the	O
Mixomics	O
micMC	O
package	O
was	O
used	O
to	O
identify	O
discriminatory	O
taxa	O
[	O
22	O
]	O
.	O
Those	O
bacterial	O
taxa	O
considered	O
different	O
between	O
the	O
two	O
treatment	O
arms	O
were	O
further	O
tested	O
for	O
significance	O
and	O
after	O
adjustment	O
for	O
multiplicity	O
,	O
as	O
described	O
by	O
McFarlane	O
et	O
al	O
.	O
[	O
20	O
]	O
and	O
were	O
considered	O
statistically	O
significant	O
if	O
both	O
the	O
P	O
and	O
FDR	O
values	O
were	O
less	O
than	O
0	O
.	O
05	O
.	O
Participants	O
were	O
recruited	O
from	O
two	O
kidney	O
care	O
outpatient	O
departments	O
from	O
April	O
2017	O
to	O
August	O
2018	O
and	O
randomized	O
to	O
synbiotic	O
or	O
placebo	B-methodology
group	I-methodology
.	O
Of	O
the	O
68	O
participants	O
who	O
completed	O
their	O
baseline	O
visit	O
,	O
66	O
%	O
were	O
men	O
,	O
had	O
a	O
median	O
age	O
of	O
70	O
years	O
(	O
IQR	O
58	O
–	O
75	O
years	O
)	O
,	O
and	O
had	O
a	O
median	O
eGFR	O
of	O
34	O
.	O
0	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
(	O
IQR	O
27	O
.	O
0	O
–	O
41	O
.	O
0	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
)	O
(	O
Table	O
1	O
)	O
.	O
A	O
total	O
of	O
56	O
participants	O
completed	O
the	O
12	O
-	O
month	O
intervention	O
with	O
40	O
participants	O
completing	O
the	O
optional	O
fecal	O
sub	B-methodology
-	I-methodology
study	I-methodology
.	O
There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
the	O
demographic	O
,	O
clinical	O
,	O
dietary	O
,	O
and	O
biochemical	O
parameters	O
between	O
groups	O
at	O
baseline	O
.	O

The	O
flow	O
of	O
participants	O
through	O
the	O
SYNERGY	O
II	O
study	O
is	O
described	O
in	O
the	O
CONSORT	O
diagram	O
(	O
Figure	O
2	O
)	O
.	O
A	O
total	O
of	O
686	O
individuals	O
were	O
screened	O
,	O
of	O
whom	O
520	O
(	O
76	O
%	O
)	O
were	O
not	O
eligible	O
,	O
98	O
(	O
14	O
%	O
)	O
declined	O
to	O
participate	O
,	O
and	O
68	O
(	O
10	O
%	O
)	O
were	O
recruited	O
into	O
the	O
study	O
.	O
Of	O
the	O
eligible	O
participants	O
,	O
41	O
%	O
(	O
68	O
/	O
166	O
)	O
consented	O
to	O
participate	O
in	O
the	O
SYNERGY	O
II	O
trial	O
.	O
Of	O
the	O
98	O
individuals	O
who	O
declined	O
to	O
participate	O
,	O
‘	O
not	O
interested	O
’	O
was	O
the	O
most	O
common	O
reason	O
for	O
not	O
participating	O
(	O
82	O
,	O
84	O
%	O
)	O
,	O
which	O
was	O
followed	O
by	O
travel	O
burden	O
(	O
8	O
,	O
9	O
%	O
)	O
and	O
family	O
commitments	O
(	O
6	O
,	O
7	O
%	O
)	O
.	O
The	O
retention	O
rate	O
was	O
82	O
%	O
,	O
with	O
56	O
of	O
the	O
randomly	B-methodology
allocated	I-methodology
participants	O
completing	O
the	O
12	O
-	O
month	O
intervention	O
.	O
Twelve	O
(	O
18	O
%	O
)	O
participants	O
withdrew	O
from	O
the	O
study	O
with	O
no	O
difference	O
in	O
withdrawals	O
between	O
groups	O
(	O
synbiotic	O
:	O
7	O
,	O
placebo	B-methodology
:	O
5	O
;	O
p	O
=	O
0	O
.	O
60	O
)	O
.	O
Work	O
or	O
university	O
commitments	O
were	O
the	O
main	O
reason	O
for	O
withdrawal	O
(	O
5	O
,	O
42	O
%	O
)	O
followed	O
by	O
family	O
commitments	O
or	O
caregiver	O
responsibilities	O
(	O
4	O
,	O
33	O
%	O
)	O
.	O
One	O
participant	O
from	O
each	O
group	O
withdrew	O
at	O
week	O
2	O
and	O
cited	O
the	O
palatability	O
of	O
the	O
study	O
products	O
as	O
the	O
reason	O
for	O
withdrawal	O
.	O
The	O
majority	O
of	O
withdrawals	O
occurred	O
at	O
≥6	O
months	O
(	O
8	O
,	O
67	O
%	O
)	O
.	O
Table	O
2	O
shows	O
changes	O
in	O
the	O
acceptability	O
outcomes	O
between	O
the	O
two	O
groups	O
.	O
There	O
were	O
no	O
significant	O
changes	O
in	O
gastrointestinal	O
symptoms	O
or	O
stool	O
consistency	O
between	O
the	O
two	O
groups	O
.	O
Overall	O
,	O
adherence	O
was	O
excellent	O
in	O
both	O
placebo	B-methodology
and	O
synbiotic	O
groups	O
(	O
median	O
intake	O
92	O
%	O
(	O
86	O
–	O
95	O
%	O
)	O
versus	O
90	O
%	O
(	O
84	O
–	O
95	O
%	O
)	O
;	O
p	O
=	O
0	O
.	O
40	O
,	O
respectively	O
)	O
.	O
There	O
was	O
no	O
difference	O
in	O
adherence	O
to	O
prebiotics	O
(	O
median	O
intake	O
92	O
%	O
(	O
83	O
–	O
98	O
)	O
placebo	B-methodology
versus	O
89	O
%	O
(	O
83	O
–	O
92	O
)	O
synbiotic	O
group	O
;	O
p	O
=	O
0	O
.	O
40	O
)	O
or	O
probiotics	O
(	O
median	O
intake	O
91	O
%	O
(	O
88	O
–	O
98	O
)	O
placebo	B-methodology
versus	O
90	O
%	O
(	O
84	O
–	O
95	O
)	O
synbiotic	O
group	O
;	O
p	O
=	O
0	O
.	O
60	O
)	O
between	O
the	O
groups	O
.	O
There	O
were	O
no	O
significant	O
changes	O
in	O
dietary	O
intakes	O
of	O
energy	O
,	O
protein	O
,	O
fiber	O
,	O
and	O
protein	O
/	O
fiber	O
ratio	O
between	O
the	O
groups	O
(	O
Table	O
2	O
)	O
.	O

There	O
were	O
18	O
serious	O
adverse	O
events	O
(	O
SAE	O
)	O
in	O
total	O
:	O
seven	O
occurred	O
in	O
the	O
placebo	B-methodology
group	I-methodology
,	O
and	O
11	O
occurred	O
in	O
the	O
synbiotic	O
group	O
.	O
Initial	O
hospitalization	O
accounted	O
for	O
17	O
SAEs	O
.	O
One	O
participant	O
died	O
during	O
the	O
study	O
period	O
for	O
reasons	O
unrelated	O
to	O
the	O
study	O
(	O
Table	O
3	O
)	O
.	O
Table	O
4	O
shows	O
changes	O
in	O
exploratory	O
outcomes	O
between	O
groups	O
.	O
No	O
differences	O
in	O
cardiac	O
measures	O
of	O
GLS	O
,	O
LVMI	O
,	O
or	O
ejection	O
fraction	O
were	O
observed	O
between	O
groups	O
.	O
Furthermore	O
,	O
no	O
differences	O
were	O
observed	O
between	O
free	O
and	O
total	O
uremic	O
toxins	O
between	O
placebo	B-methodology
and	O
synbiotic	O
groups	O
.	O
Synbiotic	O
supplementation	O
resulted	O
in	O
a	O
3	O
.	O
14	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
(	O
95	O
%	O
CI	O
,	O
−6	O
.	O
23	O
to	O
−0	O
.	O
06	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
reduction	O
in	O
eGFR	O
and	O
a	O
20	O
.	O
8	O
µmol	O
/	O
L	O
(	O
95	O
%	O
CI	O
,	O
2	O
.	O
97	O
to	O
38	O
.	O
5	O
µmol	O
/	O
L	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
increase	O
in	O
serum	O
creatinine	O
concentration	O
.	O
Two	O
(	O
6	O
%	O
)	O
participants	O
in	O
the	O
synbiotic	O
group	O
had	O
a	O
>	O
40	O
%	O
decline	O
in	O
eGFR	O
over	O
12	O
months	O
.	O
Additional	O
adjustments	O
for	O
baseline	O
eGFR	O
,	O
dietary	O
protein	O
/	O
fiber	O
ratio	O
,	O
and	O
antibiotics	O
did	O
not	O
change	O
the	O
results	O
(	O
data	O
not	O
shown	O
)	O
.	O
The	O
coverage	O
of	O
the	O
microbiota	O
diversity	O
for	O
all	O
samples	O
was	O
high	O
with	O
a	O
rarefied	O
sequencing	O
depth	O
of	O
4	O
million	O
reads	O
with	O
298	O
species	O
identified	O
.	O
No	O
differences	O
were	O
observed	O
in	O
Richness	O
and	O
Shannon	O
’	O
s	O
index	O
between	O
synbiotic	O
or	O
placebo	O
groups	O
(	O
Supplemental	O
Figure	O
S1A	O
,	O
B	O
)	O
.	O
While	O
an	O
unsupervised	O
analysis	O
(	O
PCoA	O
)	O
revealed	O
no	O
discernible	O
clustering	O
,	O
a	O
supervised	O
analysis	O
(	O
sPLS	O
-	O
DA	O
)	O
at	O
the	O
species	O
level	O
identified	O
differential	O
taxa	O
between	O
groups	O
(	O
Figure	O
3a	O
)	O
.	O

Specifically	O
,	O
unclassified	O
members	O
of	O
Oscillospiraceae	O
and	O
Coprobacteraceae	O
families	O
,	O
Lachnospira	O
genus	O
,	O
Bifidobacterium	O
animalis	O
,	O
and	O
Ruminococcus	O
B	O
gnavus	O
were	O
discriminatory	O
taxa	O
for	O
the	O
synbiotic	O
group	O
(	O
Figure	O
3b	O
)	O
,	O
while	O
unclassified	O
members	O
of	O
Ruminococcus	O
A	O
,	O
Bacteroides	O
clarus	O
,	O
and	O
Escherichia	O
coli	O
were	O
taxa	O
that	O
were	O
discriminatory	O
for	O
the	O
placebo	B-methodology
group	I-methodology
.	O
The	O
most	O
noticeable	O
effect	O
of	O
synbiotic	O
therapy	O
was	O
a	O
2	O
.	O
4	O
-	O
fold	O
increased	O
relative	O
abundance	O
of	O
Bifidobacterium	O
animalis	O
(	O
p	O
<	O
0	O
.	O
001	O
,	O
FDR	O
=	O
0	O
.	O
04	O
,	O
Supplemental	O
Table	O
S1	O
)	O
and	O
unclassified	O
Blautia	O
spp	O
.	O
(	O
p	O
=	O
0	O
.	O
004	O
,	O
FDR	O
=	O
0	O
.	O
47	O
)	O
.	O
There	O
were	O
concordant	O
1	O
.	O
7	O
-	O
fold	O
decreases	O
in	O
Bacteroides	O
cellulosilyticus	O
and	O
an	O
unclassified	O
Ruminiclostridium	O
spp	O
.	O
(	O
both	O
p	O
<	O
0	O
.	O
05	O
,	O
FDR	O
=	O
0	O
.	O
47	O
)	O
,	O
although	O
significance	O
did	O
not	O
hold	O
once	O
adjusted	O
for	O
multiple	O
comparisons	O
.	O
The	O
RDA	O
demonstrated	O
that	O
17	O
%	O
of	O
the	O
variance	O
in	O
gastrointestinal	O
microbial	O
composition	O
could	O
be	O
explained	O
by	O
synbiotic	O
supplementation	O
(	O
F	O
=	O
1	O
.	O
43	O
,	O
p	O
=	O
0	O
.	O
001	O
,	O
Supplemental	O
Figure	O
S2	O
)	O
.	O
Supervised	O
analysis	O
(	O
sPLS	O
-	O
DA	O
)	O
showed	O
that	O
the	O
tricarboxylic	O
acid	O
(	O
TCA	O
)	O
cycle	O
,	O
carboxylate	O
degradation	O
,	O
acetyl	O
coenzyme	O
A	O
(	O
CoA	O
)	O
biosynthesis	O
,	O
and	O
amino	O
acid	O
degradation	O
were	O
the	O
most	O
discriminating	O
microbial	O
function	O
after	O
synbiotic	O
supplementation	O
,	O
while	O
protein	O
modification	O
was	O
the	O
most	O
discriminating	O
microbial	O
function	O
after	O
placebo	B-methodology
(	O
Supplemental	O
Figure	O
S3	O
)	O
.	O
The	O
most	O
pronounced	O
effect	O
observed	O
with	O
synbiotic	O
therapy	O
was	O
a	O
1	O
.	O
8	O
-	O
fold	O
increase	O
(	O
p	O
<	O
0	O
.	O
001	O
,	O
FDR	O
=	O
0	O
.	O
043	O
)	O
in	O
the	O
microbial	O
function	O
methane	O
oxidation	O
to	O
methanol	O
I	O
pathway	O
.	O
This	O
study	O
is	O
the	O
first	O
to	O
examine	O
the	O
feasibility	O
of	O
long	O
-	O
term	O
synbiotic	O
supplementation	O
in	O
patients	O
with	O
CKD	O
.	O
There	O
was	O
a	O
high	O
rate	O
of	O
recruitment	O
and	O
retention	O
,	O
with	O
41	O
%	O
of	O
eligible	O
people	O
consenting	O
to	O
be	O
involved	O
in	O
the	O
study	O
and	O
82	O
%	O
of	O
participants	O
completing	O
the	O
study	O
.	O

Furthermore	O
,	O
synbiotic	O
therapy	O
achieved	O
excellent	O
compliance	O
and	O
did	O
not	O
result	O
in	O
altered	O
gastrointestinal	O
symptoms	O
or	O
stool	O
consistency	O
.	O
Together	O
,	O
these	O
findings	O
indicate	O
a	O
good	O
uptake	O
and	O
acceptance	O
of	O
synbiotic	O
supplementation	O
in	O
people	O
with	O
CKD	O
.	O
Overall	O
,	O
there	O
has	O
been	O
limited	O
evidence	O
on	O
the	O
feasibility	O
and	O
acceptability	O
of	O
synbiotic	O
supplementation	O
in	O
CKD	O
or	O
other	O
chronic	O
conditions	O
.	O
The	O
rate	O
of	O
attrition	O
(	O
18	O
%	O
)	O
in	O
SYNERGY	O
II	O
was	O
comparable	O
to	O
that	O
in	O
other	O
synbiotic	B-methodology
interventions	I-methodology
[	O
8	O
,	O
23	O
]	O
with	O
durations	O
of	O
1	O
–	O
3	O
months	O
,	O
which	O
further	O
strengthens	O
feasibility	O
given	O
that	O
the	O
duration	O
of	O
SYNERGY	O
II	O
was	O
12	O
months	O
.	O
In	O
this	O
present	O
study	O
,	O
synbiotic	O
therapy	O
was	O
deemed	O
acceptable	O
by	O
study	O
participants	O
with	O
a	O
high	O
level	O
of	O
adherence	O
and	O
tolerance	O
to	O
treatment	O
.	O
Similar	O
findings	O
have	O
been	O
reported	O
in	O
other	O
synbiotic	B-methodology
interventions	I-methodology
with	O
adherence	O
ranging	O
from	O
82	O
to	O
94	O
%	O
[	O
8	O
,	O
24	O
,	O
25	O
]	O
,	O
with	O
minimal	O
gastrointestinal	O
side	O
effects	O
reported	O
[	O
26	O
]	O
.	O
The	O
present	O
study	O
observed	O
no	O
effect	O
on	O
echocardiographic	O
parameters	O
,	O
blood	O
pressure	O
,	O
and	O
lipid	O
profile	O
.	O
This	O
is	O
in	O
agreement	O
with	O
recent	O
meta	B-methodology
-	I-methodology
analyses	I-methodology
that	O
highlighted	O
that	O
supplementation	O
had	O
no	O
effect	O
on	O
serum	O
lipids	O
[	O
9	O
,	O
27	O
]	O
.	O
To	O
our	O
knowledge	O
,	O
no	O
prior	O
intervention	B-methodology
study	I-methodology
has	O
reported	O
data	O
on	O
GLS	O
,	O
LVMI	O
,	O
and	O
blood	O
pressure	O
after	O
synbiotic	O
supplementation	O
.	O
A	O
novel	O
and	O
unexpected	O
finding	O
of	O
the	O
SYNERGY	O
II	O
trial	O
was	O
that	O
participants	O
in	O
the	O
synbiotic	O
group	O
experienced	O
a	O
significant	O
decrease	O
in	O
our	O
exploratory	O
outcomes	O
eGFR	O
and	O
increase	O
in	O
serum	O
creatinine	O
compared	O
with	O
the	O
placebo	B-methodology
group	I-methodology
.	O
It	O
is	O
prudent	O
to	O
note	O
that	O
this	O
was	O
an	O
underpowered	O
exploratory	O
outcome	O
,	O
and	O
the	O
observed	O
difference	O
may	O
have	O
been	O
due	O
to	O
chance	O
with	O
the	O
numeric	O
increase	O
in	O
eGFR	O
in	O
the	O
placebo	B-methodology
group	I-methodology
.	O
However	O
,	O
this	O
finding	O
is	O
in	O
contrast	O
to	O
the	O
findings	O
of	O
previous	O
short	O
-	O
term	O
studies	O
that	O
have	O
shown	O
synbiotic	O
supplementation	O
to	O
have	O
no	O
effect	O
on	O
eGFR	O
[	O
8	O
,	O
23	O
]	O
or	O
serum	O
creatinine	O
concentration	O
[	O
23	O
]	O
.	O

In	O
the	O
SYNERGY	O
trial	O
[	O
8	O
]	O
,	O
a	O
proof	B-methodology
-	I-methodology
of	I-methodology
-	I-methodology
concept	I-methodology
study	O
,	O
the	O
daily	O
use	O
of	O
prebiotics	O
(	O
15	O
g	O
/	O
day	O
across	O
fructooligosaccharide	O
,	O
galactooligosaccharide	O
,	O
inulin	O
)	O
and	O
probiotics	O
(	O
4	O
.	O
5	O
×	O
1010	O
CFU	O
/	O
day	O
(	O
nine	O
strains	O
across	O
Lactobacillus	O
,	O
Bifidobacteria	O
,	O
Streptococcus	O
)	O
)	O
for	O
6	O
weeks	O
did	O
not	O
change	O
eGFR	O
.	O
However	O
,	O
a	O
significant	O
increase	O
in	O
albuminuria	O
,	O
a	O
marker	O
of	O
kidney	O
damage	O
,	O
was	O
reported	O
.	O
SYNERGY	O
II	O
,	O
a	O
pragmatically	O
designed	O
feasibility	B-methodology
study	I-methodology
,	O
did	O
not	O
routinely	O
collect	O
24	O
h	O
urine	O
samples	O
,	O
precluding	O
measurement	O
of	O
albuminuria	O
and	O
proteinuria	O
.	O
Similarly	O
,	O
Dehghani	O
et	O
al	O
.	O
[	O
23	O
]	O
reported	O
no	O
change	O
in	O
eGFR	O
or	O
serum	O
creatinine	O
after	O
6	O
weeks	O
of	O
supplementation	O
with	O
prebiotic	O
(	O
fructooligosaccharide	O
)	O
and	O
probiotic	O
(	O
seven	O
strains	O
across	O
Lactobacillus	O
,	O
Bifidobacteria	O
,	O
Streptococcus	O
)	O
.	O
A	O
systematic	B-methodology
review	I-methodology
and	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
of	O
16	O
studies	O
of	O
pre	O
-	O
,	O
pro	O
-	O
,	O
and	O
synbiotic	O
supplementation	O
involving	O
645	O
adult	O
participants	O
[	O
9	O
]	O
found	O
that	O
nutritional	O
supplementation	O
probably	O
made	O
little	O
or	O
no	O
difference	O
to	O
kidney	O
function	O
,	O
as	O
measured	O
by	O
eGFR	O
(	O
three	O
studies	O
,	O
132	O
participants	O
,	O
mean	O
difference	O
(	O
MD	O
)	O
0	O
.	O
34	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
,	O
p	O
=	O
0	O
.	O
79	O
,	O
I2	O
=	O
0	O
%	O
)	O
,	O
although	O
the	O
certainty	O
of	O
the	O
evidence	O
was	O
limited	O
by	O
imprecision	O
and	O
risk	O
of	O
bias	O
.	O
Conversely	O
,	O
a	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
of	O
13	O
studies	O
involving	O
721	O
participants	O
[	O
28	O
]	O
reported	O
that	O
the	O
consumption	O
of	O
prebiotics	O
,	O
probiotics	O
,	O
and	O
synbiotics	O
resulted	O
in	O
a	O
non	O
-	O
significant	O
reduction	O
in	O
eGFR	O
(	O
six	O
studies	O
,	O
376	O
participants	O
,	O
MD	O
−2	O
.	O
00	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
,	O
95	O
%	O
CI	O
−5	O
.	O
15	O
to	O
1	O
.	O
16	O
,	O
p	O
=	O
0	O
.	O
22	O
,	O
I2	O
=	O
89	O
%	O
)	O
.	O
These	O
findings	O
were	O
again	O
limited	O
by	O
risk	O
of	O
bias	O
,	O
imprecision	O
,	O
and	O
high	O
heterogeneity	O
.	O
Therefore	O
,	O
the	O
effects	O
of	O
pre	O
-	O
,	O
pro	O
-	O
,	O
and	O
synbiotics	O
on	O
kidney	O
function	O
remain	O
uncertain	O
.	O

Whether	O
pre	O
-	O
,	O
pro	O
-	O
,	O
and	O
synbiotics	O
(	O
or	O
at	O
least	O
certain	O
types	O
of	O
these	O
agents	O
)	O
may	O
have	O
a	O
deleterious	O
effect	O
on	O
kidney	O
function	O
requires	O
further	O
and	O
more	O
rigorous	O
investigation	O
.	O
Our	O
study	O
also	O
provides	O
new	O
insights	O
into	O
the	O
effect	O
of	O
synbiotic	O
therapy	O
on	O
gastrointestinal	O
microbiota	O
in	O
CKD	O
.	O
Increases	O
were	O
observed	O
in	O
bacterial	O
taxa	O
that	O
are	O
well	O
-	O
recognized	O
for	O
their	O
specialized	O
capabilities	O
in	O
terms	O
of	O
acetate	O
(	O
e	O
.	O
g	O
.	O
,	O
Bifidobacterium	O
spp	O
.	O
)	O
[	O
29	O
]	O
and	O
butyrate	O
formation	O
(	O
e	O
.	O
g	O
.	O
,	O
Blautia	O
spp	O
.	O
)	O
[	O
30	O
]	O
.	O
This	O
is	O
also	O
reflected	O
in	O
the	O
functional	O
categories	O
,	O
which	O
showed	O
that	O
the	O
TCA	O
cycle	O
and	O
acetyl	O
CoA	O
biosynthesis	O
were	O
discriminant	O
after	O
synbiotic	O
supplementation	O
.	O
Acetyl	O
CoA	O
biosynthesis	O
is	O
a	O
key	O
enzymatic	O
step	O
in	O
the	O
formation	O
of	O
butyrate	O
and	O
acetate	O
[	O
31	O
,	O
32	O
]	O
.	O
Both	O
acetate	O
and	O
butyrate	O
are	O
a	O
desirable	O
outcome	O
of	O
gut	O
fermentation	O
,	O
as	O
they	O
have	O
been	O
associated	O
with	O
improved	O
integrity	O
of	O
the	O
intestinal	O
epithelium	O
and	O
enhanced	O
anti	O
-	O
inflammatory	O
effects	O
[	O
33	O
]	O
.	O
The	O
shift	O
in	O
microbial	O
composition	O
after	O
synbiotic	O
supplementation	O
in	O
this	O
present	O
study	O
is	O
consistent	O
with	O
two	O
other	O
synbiotic	O
studies	O
that	O
used	O
combinations	O
of	O
Lactobacillus	O
,	O
Bifidobacterium	O
,	O
and	O
Streptococcus	O
spp	O
.	O
with	O
inulin	O
,	O
fructo	O
-	O
oligosaccharides	O
(	O
FOS	O
)	O
,	O
and	O
galacto	O
-	O
oligosaccharides	O
(	O
GOS	O
)	O
[	O
8	O
]	O
,	O
and	O
Lactobacillus	O
and	O
Bifidobacterium	O
spp	O
.	O
and	O
inulin	O
[	O
34	O
]	O
.	O
More	O
detailed	O
metabolomic	O
and	O
microbiome	O
studies	O
are	O
required	O
to	O
further	O
understand	O
the	O
effect	O
of	O
symbiotic	O
therapy	O
.	O
In	O
this	O
study	O
,	O
12	O
months	O
of	O
synbiotic	O
supplementation	O
was	O
found	O
to	O
have	O
no	O
effect	O
on	O
serum	O
concentrations	O
of	O
the	O
uremic	O
toxins	O
,	O
IS	O
and	O
PCS	O
.	O
This	O
is	O
supported	O
by	O
a	O
recent	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
that	O
reported	O
no	O
effect	O
on	O
IS	O
and	O
PCS	O
after	O
supplementation	O
[	O
9	O
]	O
.	O
However	O
,	O
this	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
was	O
limited	O
by	O
suboptimal	O
study	O
quality	O
and	O
heterogeneity	O
inclusive	O
of	O
study	O
duration	O
and	O
pre	O
-	O
and	O
probiotic	O
formulations	O
.	O

To	O
date	O
,	O
there	O
have	O
been	O
five	O
other	O
synbiotic	O
intervention	B-methodology
studies	I-methodology
:	O
three	O
controlled	B-methodology
trials	I-methodology
in	O
stage	O
3	O
and	O
4	O
CKD	O
[	O
8	O
,	O
23	O
,	O
35	O
]	O
and	O
two	O
controlled	B-methodology
trials	I-methodology
in	O
patients	O
on	O
hemodialysis	O
[	O
26	O
,	O
34	O
]	O
.	O
The	O
duration	O
of	O
supplementation	O
ranged	O
from	O
four	O
to	O
eight	O
weeks	O
.	O
Of	O
these	O
,	O
two	O
measured	O
uremic	O
toxins	O
[	O
8	O
,	O
35	O
]	O
.	O
In	O
contrast	O
to	O
our	O
findings	O
,	O
the	O
SYNERGY	O
trial	O
[	O
8	O
]	O
reported	O
a	O
mean	O
14	O
μmol	O
/	O
L	O
reduction	O
in	O
serum	O
PCS	O
after	O
six	O
weeks	O
of	O
prebiotics	O
(	O
15	O
g	O
/	O
day	O
across	O
fructooligosaccharide	O
,	O
galactooligosaccharide	O
,	O
inulin	O
)	O
and	O
probiotics	O
(	O
4	O
.	O
5	O
×	O
1010	O
CFU	O
/	O
day	O
(	O
nine	O
strains	O
across	O
Lactobacillus	O
,	O
Bifidobacteria	O
,	O
Streptococcus	O
)	O
)	O
supplementation	O
.	O
Similarly	O
,	O
Guida	O
et	O
al	O
.	O
[	O
35	O
]	O
determined	O
that	O
four	O
weeks	O
of	O
prebiotic	O
(	O
6	O
.	O
6	O
g	O
/	O
day	O
of	O
inulin	O
)	O
and	O
probiotic	O
(	O
5	O
.	O
7	O
×	O
1010	O
CFU	O
/	O
day	O
(	O
nine	O
strains	O
across	O
Lactobacillus	O
,	O
Bifidobacteria	O
,	O
Streptococcus	O
)	O
)	O
supplementation	O
reduced	O
plasma	O
p	O
-	O
cresol	O
,	O
which	O
is	O
a	O
precursor	O
of	O
PCS	O
.	O
Therefore	O
,	O
it	O
is	O
plausible	O
that	O
the	O
prebiotic	O
and	O
probiotic	O
formulation	O
,	O
dose	O
,	O
and	O
duration	O
of	O
treatment	O
are	O
critical	O
to	O
inducing	O
changes	O
in	O
uremic	O
toxin	O
concentrations	O
.	O
The	O
major	O
strengths	O
of	O
the	O
SYNERGY	O
II	O
study	O
include	O
its	O
robust	O
design	O
(	O
randomized	O
,	O
double	B-methodology
-	I-methodology
blind	I-methodology
,	I-methodology
placebo	I-methodology
-	O
controlled	O
)	O
and	O
the	O
provision	O
of	O
both	O
taxonomic	O
and	O
functional	O
understanding	O
of	O
the	O
gastrointestinal	O
microbiome	O
after	O
synbiotic	O
supplementation	O
.	O
To	O
our	O
knowledge	O
,	O
the	O
SYNERGY	O
II	O
study	O
is	O
the	O
longest	O
synbiotic	O
intervention	O
and	O
the	O
first	O
to	O
explore	O
the	O
feasibility	O
of	O
synbiotic	O
supplementation	O
in	O
the	O
CKD	O
population	O
.	O
Potential	O
dietary	O
confounders	O
were	O
controlled	O
for	O
by	O
using	O
validated	O
dietary	O
assessment	O
methods	O
by	O
a	O
qualified	O
dietitian	O
who	O
was	O
blinded	O
along	O
with	O
participants	O
to	O
the	O
intervention	O
.	O

However	O
,	O
balanced	O
against	O
these	O
strengths	O
,	O
the	O
SYNERGY	O
II	O
feasibility	B-methodology
study	I-methodology
was	O
limited	O
by	O
a	O
small	O
sample	O
size	O
that	O
has	O
limited	O
statistical	O
power	O
to	O
detect	O
significant	O
changes	O
in	O
secondary	O
clinical	O
outcomes	O
(	O
cardiovascular	O
risk	O
markers	O
and	O
uremic	O
toxins	O
)	O
and	O
use	O
of	O
surrogate	O
outcome	O
measures	O
(	O
uremic	O
toxins	O
and	O
stool	O
microbiome	O
)	O
.	O
Furthermore	O
,	O
our	O
study	O
population	O
was	O
limited	O
to	O
participants	O
with	O
an	O
eGFR	O
between	O
15	O
and	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
,	O
which	O
may	O
have	O
limited	O
the	O
generalizability	O
of	O
our	O
findings	O
to	O
other	O
CKD	O
patients	O
.	O
Finally	O
,	O
metabolomic	O
analysis	O
would	O
be	O
useful	O
in	O
future	O
studies	O
to	O
provide	O
further	O
insight	O
into	O
the	O
metabolite	O
performance	O
of	O
the	O
microbiome	O
.	O
In	O
summary	O
,	O
this	O
study	O
indicates	O
that	O
long	O
-	O
term	O
synbiotic	O
supplementation	O
is	O
feasible	O
and	O
acceptable	O
for	O
adults	O
with	O
stage	O
3	O
to	O
4	O
CKD	O
.	O
There	O
were	O
notable	O
alterations	O
in	O
the	O
gastrointestinal	O
microbiome	O
and	O
some	O
functional	O
groups	O
involved	O
in	O
the	O
gastrointestinal	O
microbiota	O
after	O
synbiotic	O
supplementation	O
.	O
However	O
,	O
the	O
reduction	O
in	O
kidney	O
function	O
observed	O
with	O
synbiotic	O
supplementation	O
warrants	O
further	O
investigation	O
.	O
The	O
authors	O
gratefully	O
acknowledge	O
Marguerite	O
Conley	O
,	O
Sarah	O
Guo	O
,	O
Andrea	O
Pollock	O
,	O
and	O
Gerald	O
Hilder	O
for	O
assistance	O
with	O
the	O
coordination	O
and	O
data	O
collection	O
in	O
this	O
study	O
.	O
Publisher	O
’	O
s	O
Note	O
:	O
MDPI	O
stays	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O
The	O
following	O
are	O
available	O
online	O
at	O
https	O
:	O
/	O
/	O
www	O
.	O
mdpi	O
.	O
com	O
/	O
article	O
/	O
10	O
.	O
3390	O
/	O
nu13124481	O
/	O
s1	O
,	O
Figure	O
S1	O
:	O
(	O
A	O
)	O
Richness	O
of	O
the	O
gastrointestinal	O
microbiota	O
,	O
by	O
species	O
.	O
(	O
B	O
)	O
Diversity	O
of	O
gastrointestinal	O
microbiota	O
,	O
by	O
species	O
,	O
Figure	O
S2	O
:	O
Redundancy	O
analysis	O
(	O
RDA	O
)	O
of	O
gut	O
microbiome	O
composition	O
by	O
condition	O
,	O
Figure	O
S3	O
:	O
Functional	O
groups	O
of	O
the	O
gastrointestinal	O
microbiota	O
differentiating	O
between	O
participants	O
after	O
placebo	B-methodology
or	O
synbiotic	O
supplementation	O
as	O
identified	O
by	O
sparse	O
Partial	O
Least	O
Squares	O
Discriminant	O
Analysis	O
(	O
sPLS	O
-	O
DA	O
)	O
,	O
Table	O
S1	O
:	O
Bacterial	O
taxa	O
,	O
by	O
relative	O
abundance	O
at	O
end	O
of	O
intervention	O
.	O

C	O
.	O
M	O
.	O
,	O
K	O
.	O
L	O
.	O
C	O
.	O
,	O
D	O
.	O
W	O
.	O
J	O
.	O
were	O
responsible	O
for	O
the	O
conception	O
and	O
study	B-methodology
design	I-methodology
;	O
C	O
.	O
M	O
.	O
,	O
E	O
.	O
S	O
.	O
were	O
responsible	O
for	O
the	O
data	O
acquisition	O
;	O
C	O
.	O
M	O
.	O
,	O
M	O
.	O
S	O
.	O
,	O
G	O
.	O
M	O
.	O
,	O
J	O
.	O
T	O
.	O
K	O
.	O
were	O
responsible	O
for	O
the	O
data	O
analysis	O
and	O
interpretation	O
;	O
C	O
.	O
M	O
.	O
drafted	O
the	O
manuscript	O
;	O
R	O
.	O
K	O
.	O
,	O
T	O
.	O
S	O
.	O
,	O
E	O
.	O
S	O
.	O
,	O
M	O
.	O
S	O
.	O
,	O
G	O
.	O
M	O
.	O
,	O
J	O
.	O
T	O
.	O
K	O
.	O
,	O
M	O
.	O
M	O
.	O
,	O
D	O
.	O
W	O
.	O
J	O
.	O
,	O
and	O
K	O
.	O
L	O
.	O
C	O
.	O
provided	O
critical	O
analysis	O
to	O
the	O
paper	O
.	O
All	O
authors	O
have	O
read	O
and	O
agreed	O
to	O
the	O
published	O
version	O
of	O
the	O
manuscript	O
.	O
This	O
study	O
was	O
funded	O
through	O
project	O
grants	O
from	O
the	O
Princess	O
Alexandra	O
Research	O
Foundation	O
;	O
Wishlist	O
Research	O
Grant	O
Scheme	O
,	O
Study	O
Education	O
and	O
Research	O
Trust	O
Fund	O
,	O
Sunshine	O
Coast	O
;	O
and	O
BEAT	O
-	O
CKD	O
via	O
Australasian	O
Kidney	O
Trial	O
Network	O
.	O
The	O
study	O
was	O
conducted	O
according	O
to	O
the	O
guidelines	B-methodology
of	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
approved	O
by	O
the	O
Metro	O
South	O
Human	B-methodology
Research	I-methodology
Ethics	O
Committee	O
(	O
HREC	O
/	O
16	O
/	O
QPAH	O
/	O
336	O
)	O
and	O
the	O
University	O
of	O
Queensland	O
Human	B-methodology
Research	I-methodology
Ethics	O
committee	O
.	O
The	O
study	O
was	O
registered	O
with	O
the	O
Australian	O
and	O
New	O
Zealand	O
Clinical	B-methodology
Trials	I-methodology
Registry	O
(	O
ACTRN12617000324314	O
)	O
.	O
Informed	O
consent	O
was	O
obtained	O
from	O
all	O
subjects	O
involved	O
in	O
the	O
study	O
.	O
Data	O
available	O
upon	O
written	O
request	O
to	O
corresponding	O
author	O
.	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O

Predictive	O
Capacity	O
of	O
Beat	O
-	O
to	O
-	O
Beat	O
Blood	O
Pressure	O
Variability	O
for	O
Cardioautonomic	O
and	O
Vascular	O
Dysfunction	O
in	O
Early	O
Metabolic	O
Challenge	O
blood	O
pressure	O
variability	O
;	O
approximate	O
entropy	O
;	O
self	O
-	O
correlation	O
;	O
metabolic	O
challenge	O
;	O
autonomic	O
dysfunction	O
Diabetic	O
patients	O
present	O
established	O
cardiovascular	O
disease	O
at	O
the	O
onset	O
of	O
diagnostic	O
metabolic	O
symptoms	O
.	O
While	O
premature	O
autonomic	O
and	O
vascular	O
deterioration	O
considered	O
risk	O
factors	O
for	O
major	O
cardiovascular	O
complications	O
of	O
diabetes	O
,	O
present	O
in	O
initial	O
stages	O
of	O
metabolic	O
impairment	O
,	O
their	O
early	O
detection	O
remains	O
a	O
significant	O
challenge	O
impeding	O
timely	O
intervention	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
examine	O
the	O
utility	O
of	O
beat	O
-	O
to	O
-	O
beat	O
blood	O
pressure	O
variability	O
(	O
BPV	O
)	O
parameters	O
in	O
capturing	O
subtle	O
changes	O
in	O
cardiac	O
autonomic	O
and	O
vascular	O
control	O
distinguishing	O
between	O
various	O
risk	O
categories	O
,	O
independent	O
of	O
the	O
average	O
BP	O
.	O
A	O
rat	B-methodology
model	I-methodology
of	O
mild	O
hypercaloric	O
(	O
HC	O
)	O
intake	O
was	O
used	O
to	O
represent	O
the	O
insidious	O
cardiovascular	O
changes	O
associated	O
with	O
early	O
metabolic	O
impairment	O
.	O
Invasive	O
hemodynamics	O
were	O
used	O
to	O
collect	O
beat	O
-	O
to	O
-	O
beat	O
BP	O
time	O
series	O
in	O
rats	O
of	O
either	O
sex	O
with	O
different	O
durations	O
of	O
exposure	O
to	O
the	O
HC	O
diet	O
.	O
Linear	O
(	O
standard	O
deviation	O
and	O
coefficient	O
of	O
variation	O
)	O
and	O
nonlinear	O
(	O
approximate	O
entropy	O
,	O
ApEn	O
,	O
and	O
self	O
-	O
correlation	O
of	O
detrended	O
fluctuation	O
analysis	O
,	O
α	O
)	O
BPV	O
parameters	O
were	O
calculated	O
to	O
assess	O
the	O
impact	O
of	O
early	O
metabolic	O
impairment	O
across	O
sexes	O
and	O
feeding	O
durations	O
.	O
HC	O
-	O
fed	O
male	O
,	O
but	O
not	O
female	O
,	O
rats	O
developed	O
increased	O
fat	O
:	O
lean	O
ratio	O
as	O
well	O
as	O
hyperinsulinemia	O
.	O
Unlike	O
linear	O
parameters	O
,	O
multivariate	O
analysis	O
showed	O
that	O
HC	O
-	O
fed	O
rats	O
possessed	O
lower	O
ApEn	O
and	O
higher	O
α	O
,	O
consistent	O
with	O
early	O
changes	O
in	O
heart	O
rate	O
variability	O
and	O
blunting	O
of	O
parasympathetic	O
baroreceptor	O
sensitivity	O
,	O
particularly	O
in	O
males	O
.	O
Moreover	O
,	O
logistic	O
regression	O
demonstrated	O
the	O
superiority	O
of	O
nonlinear	O
parameters	O
of	O
diastolic	O
BPV	O
in	O
predicting	O
a	O
prediabetic	O
disease	O
state	O
.	O
Our	O
findings	O
support	O
the	O
use	O
of	O
nonlinear	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
for	O
early	O
detection	O
of	O
cardiovascular	O
derangements	O
in	O
the	O
initial	O
stages	O
of	O
metabolic	O
impairment	O
.	O
Average	O
blood	O
pressure	O
(	O
BP	O
)	O
values	O
have	O
long	O
been	O
used	O
to	O
characterize	O
overt	O
changes	O
in	O
vascular	O
function	O
and	O
BP	O
control	O
mechanisms	O
associated	O
with	O
hypertension	O
.	O

However	O
,	O
a	O
recent	O
understanding	O
of	O
cardiovascular	O
signals	O
emphasizes	O
variability	O
in	O
cardiovascular	O
parameters	O
as	O
an	O
indicator	O
of	O
the	O
cardiovascular	O
and	O
autonomic	O
control	O
of	O
hemodynamics	O
(	O
Parati	O
et	O
al	O
.	O
,	O
2013a	O
)	O
.	O
BP	O
spontaneously	O
fluctuates	O
in	O
the	O
long	O
,	O
short	O
,	O
and	O
very	O
short	O
term	O
conferring	O
week	O
-	O
to	O
-	O
week	O
,	O
diurnal	O
and	O
beat	O
-	O
to	O
-	O
beat	O
BP	O
variability	O
(	O
BPV	O
)	O
,	O
respectively	O
(	O
Parati	O
et	O
al	O
.	O
,	O
2013b	O
)	O
.	O
Significantly	O
,	O
abnormal	O
long	O
-	O
and	O
short	O
-	O
term	O
BPV	O
are	O
reported	O
to	O
detect	O
hidden	O
and	O
early	O
changes	O
in	O
various	O
pathophysiological	O
states	O
,	O
establish	O
risk	O
stratification	O
within	O
the	O
same	O
condition	O
,	O
and	O
predict	O
prognosis	O
independent	O
of	O
mean	O
systolic	O
(	O
SBP	O
)	O
and	O
diastolic	O
BP	O
(	O
DBP	O
)	O
(	O
Hsu	O
et	O
al	O
.	O
,	O
2016	O
;	O
Chowdhury	O
et	O
al	O
.	O
,	O
2018	O
;	O
Palatini	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Continuous	O
BPV	O
captures	O
the	O
intricacies	O
of	O
BP	O
dynamics	O
which	O
are	O
not	O
otherwise	O
collected	O
by	O
intermittent	O
BP	O
monitoring	O
(	O
Webb	O
and	O
Rothwell	O
,	O
2014	O
;	O
Wei	O
et	O
al	O
.	O
,	O
2014	O
;	O
Webb	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
Linear	O
and	O
nonlinear	O
parameters	O
describe	O
different	O
aspects	O
of	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
.	O
Linear	O
time	O
-	O
domain	O
parameters	O
are	O
mainly	O
measures	O
of	O
dispersion	O
frequently	O
reported	O
to	O
increase	O
in	O
pathological	O
conditions	O
(	O
Parati	O
and	O
Ochoa	O
,	O
2019	O
)	O
.	O
Indeed	O
,	O
aberrant	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
is	O
associated	O
with	O
end	O
-	O
organ	O
damage	O
related	O
to	O
excursions	O
in	O
perfusion	O
(	O
Wei	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O
Alternatively	O
,	O
nonlinear	O
parameters	O
quantify	O
complexity	O
and	O
regularity	O
that	O
decreases	O
and	O
increases	O
in	O
disease	O
states	O
,	O
respectively	O
(	O
Bakkar	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
Despite	O
the	O
value	O
of	O
linear	O
parameters	O
of	O
variability	O
,	O
fluctuations	O
of	O
the	O
cardiovascular	O
system	O
are	O
described	O
as	O
nonhomogeneous	O
,	O
that	O
is	O
,	O
different	O
parts	O
of	O
the	O
signal	O
exhibit	O
distinctive	O
scaling	O
properties	O
,	O
and	O
are	O
thus	O
believed	O
to	O
be	O
better	O
quantified	O
using	O
nonlinear	O
parameters	O
(	O
Ivanov	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

Indeed	O
,	O
entropy	O
and	O
detrended	O
fluctuation	O
analysis	O
of	O
the	O
beat	O
-	O
to	O
-	O
beat	O
BP	O
time	O
series	O
are	O
shown	O
to	O
possess	O
superior	O
power	O
of	O
discriminating	O
among	O
patient	O
groups	O
compared	O
to	O
conventional	O
parameters	O
of	O
variability	O
and	O
average	O
BP	O
(	O
Bakkar	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
Research	O
on	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
remains	O
a	O
relatively	O
new	O
field	O
with	O
a	O
potential	O
early	O
diagnostic	O
value	O
for	O
premature	O
changes	O
prior	O
to	O
overt	O
symptomatic	O
manifestations	O
(	O
Wu	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
Particularly	O
,	O
studies	O
of	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
in	O
the	O
context	O
of	O
metabolic	O
diseases	O
remain	O
limited	O
(	O
Bakkar	O
et	O
al	O
.	O
,	O
2021	O
)	O
,	O
with	O
previous	O
studies	O
,	O
not	O
directly	O
measuring	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
,	O
in	O
adults	O
with	O
metabolic	O
syndrome	O
,	O
indicating	O
possible	O
changes	O
in	O
these	O
parameters	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Hence	O
,	O
it	O
is	O
prudent	O
to	O
study	O
continuous	O
BPV	O
in	O
transition	O
states	O
like	O
prediabetes	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2016	O
)	O
and	O
prehypertension	O
(	O
Pal	O
et	O
al	O
.	O
,	O
2015	O
)	O
and	O
its	O
sex	O
-	O
specific	O
evolution	O
over	O
time	O
.	O
In	O
this	O
regard	O
,	O
we	O
demonstrated	O
in	O
our	O
previous	O
work	O
that	O
12	O
weeks	O
of	O
mild	O
hypercaloric	O
(	O
HC	O
)	O
feeding	O
led	O
to	O
subtle	O
metabolic	O
impairment	O
characterized	O
by	O
hyperinsulinemia	O
,	O
hyperlipidemia	O
,	O
and	O
altered	O
body	O
composition	O
in	O
the	O
absence	O
of	O
hyperglycemia	O
,	O
hypertension	O
,	O
and	O
increased	O
body	O
weight	O
recapitulating	O
the	O
early	O
stages	O
of	O
prediabetes	O
(	O
Al	O
-	O
Assi	O
et	O
al	O
.	O
,	O
2018	O
;	O
Alaaeddine	O
et	O
al	O
.	O
,	O
2019	O
;	O
Elkhatib	O
et	O
al	O
.	O
,	O
2019	O
;	O
Fakih	O
et	O
al	O
.	O
,	O
2020	O
;	O
Hammoud	O
et	O
al	O
.	O
,	O
2021a	O
)	O
.	O
Such	O
metabolic	O
alterations	O
were	O
associated	O
with	O
cardiac	O
-	O
,	O
renal	O
-	O
,	O
and	O
cerebral	O
-	O
vascular	O
dysfunction	O
as	O
well	O
as	O
cardiac	O
autonomic	O
deterioration	O
only	O
discernible	O
upon	O
considerably	O
invasive	O
hemodynamic	O
interventions	O
.	O
Nevertheless	O
,	O
our	O
results	O
demonstrated	O
the	O
ability	O
of	O
nonlinear	O
metrics	O
of	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
to	O
describe	O
the	O
progression	O
from	O
prediabetes	O
to	O
type	O
2	O
diabetes	O
with	O
worsening	O
of	O
baroreflex	O
function	O
(	O
Bakkar	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O

We	O
also	O
showed	O
the	O
ability	O
of	O
nonlinear	O
metrics	O
to	O
discriminate	O
between	O
hypertensive	O
and	O
nonhypertensive	O
rats	O
switching	O
from	O
low	O
-	O
to	O
high	O
-	O
salt	O
diet	O
while	O
linear	O
parameters	O
remained	O
unchanged	O
across	O
groups	O
and	O
experimental	O
conditions	O
(	O
Fares	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Our	O
present	O
study	O
aimed	O
to	O
examine	O
the	O
role	O
of	O
BPV	O
as	O
a	O
novel	O
cardiovascular	O
risk	O
factor	O
discriminating	O
between	O
subjects	O
as	O
to	O
the	O
presence	O
or	O
absence	O
of	O
a	O
subtle	O
underlying	O
vascular	O
pathology	O
.	O
For	O
this	O
purpose	O
,	O
we	O
utilized	O
our	O
established	O
model	O
of	O
mild	O
metabolic	O
challenge	O
as	O
a	O
representation	O
of	O
the	O
transition	O
state	O
of	O
early	O
cardiometabolic	O
dysfunction	O
to	O
offer	O
the	O
much	O
-	O
needed	O
pathophysiological	O
insight	O
.	O
An	O
implied	O
hypothesis	O
is	O
that	O
rats	O
exposed	O
to	O
the	O
mild	O
HC	O
challenge	O
will	O
exhibit	O
different	O
BPV	O
profiles	O
evolving	O
disparately	O
with	O
sex	O
over	O
time	O
,	O
irrespective	O
of	O
mean	O
BP	O
.	O
We	O
also	O
aimed	O
to	O
compare	O
the	O
powers	O
of	O
linear	O
and	O
nonlinear	O
BPV	O
parameters	O
in	O
predicting	O
this	O
early	O
altered	O
metabolic	O
state	O
.	O
Experimental	O
procedures	O
were	O
performed	O
according	O
to	O
a	O
protocol	O
approved	O
by	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
at	O
the	O
American	O
University	O
of	O
Beirut	O
in	O
accordance	O
with	O
the	O
Guide	O
for	O
Care	O
and	O
Use	O
of	O
Laboratory	O
Animals	O
of	O
the	O
Institute	O
for	O
Laboratory	O
Animal	O
Research	O
of	O
the	O
National	O
Academy	O
of	O
Sciences	O
(	O
National	O
Research	O
Council	O
(	O
US	O
)	O
Committee	O
for	O
the	O
Update	O
of	O
the	O
Guide	O
for	O
the	O
Care	O
and	O
Use	O
of	O
Laboratory	O
Animals	O
,	O
2011	O
)	O
.	O
Beat	O
-	O
to	O
-	O
beat	O
BP	O
time	O
series	O
were	O
derived	O
from	O
two	O
groups	O
of	O
Sprague	O
–	O
Dawley	O
rats	O
:	O
a	O
control	B-methodology
group	I-methodology
(	O
N	O
=	O
28	O
)	O
fed	O
with	O
a	O
normal	O
chow	O
containing	O
3	O
kcal	O
/	O
g	O
and	O
HC	O
-	O
fed	O
group	O
(	O
N	O
=	O
23	O
)	O
receiving	O
a	O
HC	O
diet	O
providing	O
4	O
.	O
035	O
kcal	O
/	O
g	O
.	O

The	O
normal	O
chow	O
contained	O
32	O
%	O
of	O
calories	O
from	O
protein	O
,	O
14	O
%	O
from	O
fat	O
(	O
0	O
.	O
9	O
%	O
of	O
weight	O
saturated	O
fat	O
)	O
,	O
and	O
54	O
%	O
from	O
carbohydrates	O
,	O
while	O
the	O
HC	O
diet	O
was	O
prepared	O
in	O
-	O
house	O
,	O
as	O
described	O
previously	O
,	O
to	O
contain	O
15	O
.	O
66	O
%	O
of	O
calories	O
from	O
protein	O
(	O
15	O
.	O
8	O
%	O
by	O
weight	O
)	O
,	O
38	O
.	O
68	O
%	O
from	O
fat	O
(	O
18	O
.	O
06	O
%	O
by	O
weight	O
of	O
which	O
5	O
%	O
was	O
saturated	O
fat	O
)	O
,	O
and	O
45	O
.	O
73	O
%	O
from	O
carbohydrates	O
(	O
46	O
.	O
13	O
%	O
by	O
weight	O
)	O
(	O
Al	O
-	O
Assi	O
et	O
al	O
.	O
,	O
2018	O
;	O
Alaaeddine	O
et	O
al	O
.	O
,	O
2019	O
;	O
Elkhatib	O
et	O
al	O
.	O
,	O
2019	O
;	O
Fakih	O
et	O
al	O
.	O
,	O
2020	O
;	O
Hammoud	O
et	O
al	O
.	O
,	O
2021a	O
)	O
.	O
Rats	O
of	O
both	O
sexes	O
(	O
24	O
males	O
and	O
27	O
females	O
)	O
were	O
received	O
at	O
5	O
weeks	O
of	O
age	O
,	O
housed	O
individually	O
at	O
standard	O
temperature	O
and	O
humidity	O
conditions	O
with	O
a	O
12	O
-	O
h	O
dark	O
/	O
light	O
cycle	O
,	O
and	O
randomly	B-methodology
divided	I-methodology
into	O
control	O
and	O
HC	O
groups	O
fed	O
the	O
corresponding	O
diet	O
ad	O
libitum	O
for	O
a	O
duration	O
of	O
either	O
12	O
weeks	O
(	O
22	O
rats	O
)	O
or	O
24	O
weeks	O
(	O
29	O
rats	O
)	O
.	O
The	O
selection	O
of	O
feeding	O
duration	O
was	O
based	O
on	O
our	O
previous	O
results	O
where	O
the	O
end	O
of	O
week	O
12	O
was	O
the	O
earliest	O
time	O
point	O
at	O
which	O
manifestations	O
of	O
metabolic	O
dysfunction	O
,	O
which	O
mimic	O
prediabetes	O
,	O
started	O
to	O
appear	O
in	O
our	O
rat	B-methodology
model	I-methodology
(	O
Elkhatib	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Particularly	O
,	O
hyperinsulinemia	O
and	O
dyslipidemia	O
as	O
well	O
as	O
perivascular	O
adipose	O
tissue	O
inflammation	O
started	O
at	O
week	O
12	O
(	O
Al	O
-	O
Assi	O
et	O
al	O
.	O
,	O
2018	O
;	O
Elkhatib	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Signs	O
of	O
early	O
cardiovascular	O
(	O
Alaaeddine	O
et	O
al	O
.	O
,	O
2019	O
;	O
Elkhatib	O
et	O
al	O
.	O
,	O
2019	O
)	O
,	O
cerebrovascular	O
(	O
Fakih	O
et	O
al	O
.	O
,	O
2020	O
)	O
,	O
renovascular	O
(	O
Hammoud	O
et	O
al	O
.	O
,	O
2020	O
;	O
Al	O
-	O
Saidi	O
et	O
al	O
.	O
,	O
2021	O
)	O
deteriorations	O
,	O
as	O
well	O
as	O
cardiac	O
autonomic	O
neuropathy	O
(	O
Al	O
-	O
Assi	O
et	O
al	O
.	O
,	O
2018	O
)	O
,	O
were	O
also	O
evident	O
at	O
12	O
weeks	O
.	O

No	O
signs	O
of	O
overt	O
cardiac	O
or	O
vascular	O
dysfunction	O
manifested	O
up	O
to	O
12	O
weeks	O
of	O
HC	O
feeding	O
,	O
as	O
indicated	O
by	O
echocardiography	O
and	O
noninvasive	O
blood	O
pressure	O
monitoring	O
performed	O
biweekly	O
starting	O
from	O
baseline	O
(	O
Al	O
-	O
Assi	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
Starting	O
week	O
24	O
,	O
our	O
data	O
showed	O
that	O
fasting	O
and	O
random	O
blood	O
glucose	O
as	O
well	O
as	O
HbA1C	O
levels	O
begin	O
to	O
rise	O
gradually	O
,	O
possibly	O
marking	O
the	O
progression	O
to	O
type	O
2	O
diabetes	O
(	O
Elkhatib	O
et	O
al	O
.	O
,	O
2019	O
;	O
Fakih	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
As	O
such	O
,	O
we	O
have	O
chosen	O
these	O
two	O
time	O
points	O
to	O
represent	O
compensated	O
versus	O
decompensated	O
metabolic	O
disease	O
states	O
in	O
an	O
attempt	O
to	O
assess	O
the	O
diagnostic	O
,	O
and	O
rather	O
discriminatory	O
,	O
capacity	O
of	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
parameters	O
in	O
this	O
context	O
(	O
Bakkar	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Our	O
experimental	B-methodology
design	I-methodology
targeted	O
a	O
typical	O
group	O
size	O
of	O
5	O
–	O
7	O
animals	O
shown	O
to	O
yield	O
enough	O
statistical	O
power	O
and	O
an	O
allocation	O
strategy	O
described	O
in	O
detail	O
in	O
our	O
previous	O
work	O
(	O
Elkhatib	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
The	O
number	O
of	O
control	O
female	O
rats	O
fed	O
for	O
24	O
weeks	O
was	O
exceptionally	O
duplicated	O
due	O
to	O
an	O
ordering	O
error	O
that	O
occurred	O
during	O
the	O
period	O
of	O
pandemic	O
-	O
related	O
lockdowns	O
.	O
To	O
avoid	O
potential	O
selection	O
bias	O
,	O
their	O
results	O
were	O
added	O
.	O
At	O
the	O
end	O
of	O
the	O
designated	O
feeding	O
duration	O
,	O
the	O
control	B-methodology
group	I-methodology
comprised	O
12	O
male	O
rats	O
(	O
six	O
12	O
-	O
week	O
and	O
six	O
24	O
-	O
week	O
)	O
and	O
16	O
female	O
rats	O
(	O
five	O
12	O
-	O
week	O
and	O
eleven	O
24	O
-	O
week	O
)	O
,	O
while	O
the	O
HC	O
group	O
had	O
12	O
male	O
rats	O
(	O
six	O
12	O
-	O
week	O
and	O
six	O
24	O
-	O
week	O
)	O
and	O
11	O
female	O
rats	O
(	O
five	O
12	O
-	O
week	O
and	O
six	O
24	O
-	O
week	O
)	O
.	O
Calorie	O
intake	O
was	O
determined	O
for	O
each	O
rat	O
based	O
on	O
the	O
amount	O
of	O
food	O
consumed	O
daily	O
.	O
Anesthetized	O
rats	O
were	O
sacrificed	O
by	O
decapitation	O
after	O
12	O
(	O
age	O
=	O
17	O
weeks	O
)	O
or	O
24	O
weeks	O
(	O
age	O
=	O
29	O
weeks	O
)	O
of	O
feeding	O
(	O
Dwaib	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O

In	O
order	O
to	O
assess	O
the	O
heart	O
structure	O
and	O
function	O
,	O
echocardiography	O
along	O
the	O
parasternal	O
long	O
axis	O
M	O
-	O
and	O
B	O
-	O
modes	O
was	O
performed	O
1	O
day	O
before	O
sacrifice	O
using	O
SonixTouch	O
Q	O
+	O
ultrasound	O
(	O
BK	O
ultrasound	O
,	O
Peabody	O
,	O
MA	O
,	O
United	O
States	O
)	O
on	O
rats	O
sedated	O
with	O
a	O
mixture	O
of	O
ketamine	O
and	O
xylazine	O
(	O
80	O
%	O
of	O
1	O
.	O
5	O
mg	O
/	O
ml	O
/	O
kg	O
of	O
ketamine	O
followed	O
by	O
80	O
%	O
0	O
.	O
375	O
mg	O
/	O
ml	O
/	O
kg	O
of	O
xylazine	O
for	O
complete	O
sedation	O
)	O
.	O
Images	O
were	O
acquired	O
at	O
a	O
probe	O
frequency	O
of	O
20	O
.	O
0	O
MHz	O
.	O
For	O
structural	O
left	O
ventricular	O
(	O
LV	O
)	O
parameters	O
,	O
interventricular	O
septum	O
thickness	O
(	O
during	O
systole	O
and	O
diastole	O
)	O
,	O
posterior	O
wall	O
thickness	O
(	O
during	O
systole	O
and	O
diastole	O
)	O
,	O
and	O
LV	O
diameters	O
(	O
during	O
systole	O
and	O
diastole	O
)	O
were	O
measured	O
.	O
LV	O
end	O
systolic	O
volume	O
,	O
end	O
diastolic	O
volume	O
,	O
as	O
well	O
as	O
LV	O
mass	O
were	O
automatically	O
estimated	O
based	O
on	O
experts	O
’	O
recommendations	O
(	O
Belenkie	O
et	O
al	O
.	O
,	O
1973	O
;	O
Gibson	O
,	O
1973	O
;	O
Teichholz	O
et	O
al	O
.	O
,	O
1976	O
;	O
Oh	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O
All	O
structural	O
indices	O
were	O
normalized	O
to	O
body	O
weight	O
and	O
tibia	O
length	O
.	O
As	O
for	O
functional	O
parameters	O
,	O
the	O
device	O
automatically	O
calculates	O
ejection	O
fraction	O
(	O
EF	O
)	O
,	O
fractional	O
shortening	O
,	O
and	O
stroke	O
volume	O
,	O
according	O
to	O
standard	O
formulas	O
from	O
Terry	O
Reynold	O
’	O
s	O
The	O
Echocardiographer	O
’	O
s	O
Pocket	O
Reference	O
.	O
The	O
rat	O
fat	O
:	O
lean	O
ratio	O
was	O
measured	O
using	O
the	O
LF10	O
Minispec	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
machine	O
(	O
Bruker	O
,	O
MA	O
,	O
United	O
States	O
)	O
detecting	O
different	O
tissue	O
densities	O
as	O
previously	O
described	O
(	O
Fakih	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
similar	O
to	O
our	O
previous	O
work	O
(	O
Bakkar	O
et	O
al	O
.	O
,	O
2020	O
)	O
,	O
random	O
blood	O
glucose	O
levels	O
(	O
BGLs	O
)	O
were	O
measured	O
using	O
an	O
Accu	O
-	O
Chek	O
glucometer	O
(	O
Roche	O
Diagnostics	O
,	O
Basel	O
,	O
Switzerland	O
)	O
by	O
lateral	O
tail	O
vein	O
puncture	O
on	O
the	O
day	O
of	O
sacrifice	O
,	O
before	O
anesthesia	O
induction	O
for	O
the	O
surgical	O
procedure	O
.	O
Serum	O
insulin	O
concentrations	O
were	O
measured	O
using	O
ELISA	O
kit	O
(	O
Cat	O
.	O
no	O
.	O

ERINS	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
protocol	O
(	O
Thermo	O
Scientific	O
,	O
Walter	O
,	O
MA	O
,	O
United	O
States	O
)	O
.	O
Rats	O
were	O
anesthetized	O
and	O
instrumented	O
for	O
invasive	O
hemodynamic	O
monitoring	O
as	O
previously	O
described	O
(	O
Al	O
-	O
Assi	O
et	O
al	O
.	O
,	O
2018	O
;	O
Bakkar	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Briefly	O
,	O
rats	O
were	O
intraperitoneally	O
injected	O
with	O
thiopental	O
(	O
50	O
mg	O
/	O
kg	O
)	O
to	O
induce	O
light	O
anesthesia	O
,	O
followed	O
by	O
phenobarbital	O
(	O
10	O
mg	O
/	O
kg	O
)	O
for	O
maintenance	O
.	O
A	O
paw	O
pinch	O
test	O
was	O
performed	O
prior	O
to	O
surgical	O
intervention	O
to	O
confirm	O
total	O
loss	O
of	O
sensation	O
.	O
A	O
similar	O
dose	O
of	O
barbiturate	O
was	O
shown	O
to	O
preserve	O
mechanisms	O
of	O
cardiovascular	O
modulation	O
,	O
like	O
BPV	O
,	O
HRV	O
,	O
vasopressor	O
and	O
vasodepressor	O
responses	O
,	O
as	O
well	O
as	O
baroreceptor	O
sensitivity	O
(	O
BRS	O
)	O
(	O
Yang	O
et	O
al	O
.	O
,	O
1996	O
;	O
Bencze	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O
It	O
is	O
thus	O
believed	O
to	O
be	O
suitable	O
for	O
use	O
in	O
hemodynamic	O
experiments	O
(	O
Kuo	O
et	O
al	O
.	O
,	O
2005	O
;	O
Bencze	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O
Importantly	O
,	O
such	O
a	O
level	O
of	O
anesthesia	O
was	O
shown	O
to	O
maintain	O
BP	O
levels	O
within	O
the	O
same	O
range	O
previously	O
recorded	O
invasively	O
in	O
conscious	O
rats	O
of	O
the	O
same	O
model	O
using	O
the	O
same	O
experimental	O
setup	O
(	O
Elkhatib	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Prior	O
to	O
carotid	O
catheterization	O
,	O
tracheostomy	O
was	O
performed	O
in	O
order	O
to	O
facilitate	O
ventilation	O
and	O
prevent	O
overaccumulation	O
of	O
respiratory	O
secretions	O
(	O
Yang	O
et	O
al	O
.	O
,	O
1996	O
;	O
Kuo	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O
BP	O
signals	O
were	O
obtained	O
using	O
a	O
pressure	O
transducer	O
(	O
SP844	O
,	O
Cat	O
.	O
no	O
.	O
32030	O
,	O
MEMSCAP	O
,	O
Norway	O
)	O
connected	O
to	O
the	O
carotid	O
catheter	O
.	O
Acquiring	O
beat	O
-	O
to	O
-	O
beat	O
BP	O
signals	O
under	O
such	O
conditions	O
(	O
carotid	O
catheterization	O
of	O
anesthetized	O
rats	O
)	O
is	O
an	O
alternative	O
to	O
a	O
more	O
complex	O
and	O
elaborate	O
procedure	O
(	O
involving	O
tunneling	O
and	O
femoral	O
catheterization	O
)	O
requiring	O
extensive	O
manipulation	O
.	O
While	O
the	O
effect	O
of	O
anesthesia	O
on	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
cannot	O
be	O
underestimated	O
,	O
the	O
latter	O
puts	O
the	O
rat	O
under	O
increased	O
stress	O
and	O
infection	O
risk	O
,	O
two	O
factors	O
which	O
might	O
affect	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
and	O
introduce	O
confounders	O
to	O
its	O
analysis	O
.	O

PowerLab	O
(	O
Model	O
ML870	O
,	O
AD	O
Instruments	O
Ltd	O
.	O
,	O
Dunedin	O
,	O
New	O
Zealand	O
)	O
was	O
used	O
for	O
data	O
acquisition	O
and	O
LabChart	O
Pro	O
8	O
(	O
AD	O
Instruments	O
Ltd	O
.	O
,	O
Dunedin	O
,	O
New	O
Zealand	O
)	O
software	O
for	O
recording	O
.	O
After	O
stabilization	O
and	O
prior	O
to	O
BRS	O
assessment	O
,	O
25	O
min	O
of	O
signal	O
acquisition	O
was	O
conducted	O
.	O
Then	O
,	O
SBP	O
and	O
DBP	O
recordings	O
for	O
a	O
stable	O
5	O
-	O
min	O
time	O
series	O
were	O
acquired	O
at	O
a	O
sampling	O
rate	O
of	O
1	O
,	O
000	O
Hz	O
corresponding	O
to	O
approximately	O
300	O
,	O
000	O
data	O
points	O
.	O
At	O
such	O
a	O
sampling	O
rate	O
,	O
every	O
heart	O
beat	O
would	O
be	O
represented	O
by	O
150	O
–	O
200	O
data	O
points	O
.	O
BP	O
time	O
series	O
were	O
then	O
extracted	O
and	O
downsampled	O
by	O
20×	O
(	O
50	O
Hz	O
)	O
to	O
obtain	O
approximately	O
15	O
,	O
100	O
data	O
points	O
(	O
8	O
–	O
10	O
data	O
points	O
/	O
heart	O
beat	O
)	O
for	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
analysis	O
.	O
BRS	O
was	O
determined	O
using	O
the	O
vasoactive	O
method	O
as	O
described	O
previously	O
(	O
Al	O
-	O
Assi	O
et	O
al	O
.	O
,	O
2018	O
;	O
Bakkar	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
After	O
30	O
min	O
of	O
signal	O
stabilization	O
,	O
rats	O
were	O
intravenously	O
(	O
through	O
a	O
catheterized	O
jugular	O
vein	O
)	O
injected	O
with	O
increasing	O
doses	O
of	O
the	O
vasopressor	O
,	O
phenylephrine	O
(	O
ICN	O
Biochemicals	O
)	O
(	O
PE	O
0	O
.	O
25	O
,	O
0	O
.	O
5	O
,	O
0	O
.	O
75	O
,	O
1	O
,	O
and	O
2	O
μg	O
)	O
,	O
followed	O
by	O
increasing	O
doses	O
of	O
the	O
vasodepressor	O
,	O
sodium	O
nitroprusside	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
228710	O
-	O
5G	O
)	O
(	O
SNP	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
4	O
,	O
and	O
8	O
μg	O
)	O
,	O
in	O
order	O
to	O
assess	O
the	O
functionality	O
of	O
the	O
parasympathetic	O
and	O
the	O
sympathetic	O
arms	O
of	O
BRS	O
in	O
decreasing	O
and	O
increasing	O
HR	O
,	O
respectively	O
.	O
Changes	O
in	O
the	O
heart	O
rate	O
(	O
ΔHR	O
)	O
were	O
plotted	O
as	O
a	O
function	O
of	O
the	O
corresponding	O
changes	O
in	O
mean	O
arterial	O
pressure	O
(	O
ΔMAP	O
)	O
in	O
response	O
to	O
the	O
vasoactive	O
drugs	O
.	O
GraphPad	O
Prism	O
for	O
Mac	O
OS	O
version	O
8	O
was	O
used	O
to	O
calculate	O
the	O
BRS	O
of	O
the	O
parasympathetic	O
and	O
sympathetic	O
nervous	O
system	O
(	O
PSNS	O
and	O
SNS	O
,	O
respectively	O
)	O
as	O
the	O
best	O
-	O
fit	O
slope	O
of	O
the	O
linear	O
regression	O
of	O
ΔHR	O
vs	O
.	O
ΔMAP	O
in	O
response	O
to	O
PE	O
and	O
SNP	O
,	O
respectively	O
.	O

The	O
standard	O
deviation	O
(	O
SD	O
)	O
and	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
of	O
beat	O
-	O
to	O
-	O
beat	O
HR	O
and	O
BP	O
values	O
were	O
calculated	O
.	O
SD	O
was	O
determined	O
as	O
a	O
measure	O
of	O
dispersion	O
around	O
the	O
mean	O
,	O
while	O
CV	O
was	O
used	O
to	O
reduce	O
the	O
dependence	O
of	O
SD	O
on	O
the	O
mean	O
value	O
(	O
Di	O
Rienzo	O
et	O
al	O
.	O
,	O
1983	O
;	O
Jinadasa	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
Approximate	O
entropy	O
(	O
ApEn	O
)	O
was	O
computed	O
using	O
a	O
MATLAB	O
(	O
Mathworks	O
,	O
Natick	O
,	O
MA	O
,	O
United	O
States	O
)	O
code	O
derived	O
in	O
our	O
laboratory	O
.	O
ApEn	O
was	O
determined	O
as	O
a	O
measure	O
reflecting	O
system	O
complexity	O
or	O
self	O
-	O
similarity	O
in	O
a	O
time	O
series	O
(	O
Bakkar	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
By	O
definition	O
,	O
ApEn	O
is	O
the	O
negative	O
natural	O
logarithm	O
of	O
the	O
conditional	O
probability	O
that	O
a	O
sequence	O
similar	O
for	O
m	O
values	O
remains	O
similar	O
at	O
the	O
next	O
point	O
within	O
a	O
tolerance	O
r	O
(	O
Pincus	O
,	O
1991	O
;	O
Pincus	O
and	O
Goldberger	O
,	O
1994	O
)	O
.	O
ApEn	O
was	O
calculated	O
for	O
m	O
=	O
2	O
and	O
r	O
=	O
0	O
.	O
2	O
,	O
where	O
r	O
is	O
conventionally	O
recommended	O
to	O
be	O
in	O
the	O
range	O
of	O
(	O
0	O
.	O
1	O
–	O
0	O
.	O
25	O
)	O
times	O
the	O
standard	O
deviation	O
of	O
the	O
given	O
time	O
series	O
(	O
Pincus	O
,	O
1991	O
;	O
Chon	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O
In	O
our	O
control	O
rats	O
,	O
the	O
SD	O
of	O
the	O
systolic	O
and	O
diastolic	O
BP	O
time	O
series	O
ranged	O
from	O
[UNK]	O
.	O
5	O
to	O
4	O
,	O
thus	O
implicating	O
a	O
potential	O
r	O
value	O
ranging	O
from	O
0	O
.	O
15	O
to	O
1	O
.	O
Based	O
on	O
our	O
previous	O
work	O
(	O
Fares	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
we	O
expected	O
a	O
decrease	O
in	O
entropy	O
measures	O
in	O
disease	O
states	O
,	O
and	O
thus	O
we	O
opted	O
for	O
an	O
r	O
value	O
toward	O
the	O
lower	O
end	O
of	O
the	O
range	O
(	O
0	O
.	O
2	O
)	O
to	O
maximize	O
ApEn	O
value	O
and	O
increase	O
the	O
sensitivity	O
of	O
detection	O
of	O
differences	O
among	O
different	O
groups	O
.	O
Importantly	O
,	O
at	O
a	O
heart	O
rate	O
of	O
approximately	O
300	O
BPM	O
,	O
a	O
series	O
length	O
of	O
L	O
=	O
1	O
,	O
500	O
cardiac	O
beats	O
and	O
N	O
=	O
15	O
,	O
100	O
data	O
points	O
were	O
used	O
for	O
ApEn	O
calculations	O
.	O
It	O
is	O
worth	O
mentioning	O
that	O
the	O
use	O
of	O
such	O
a	O
lengthy	O
time	O
series	O
overcomes	O
the	O
potential	O
“	O
bias	O
toward	O
regularity	O
”	O
associated	O
with	O
ApEn	O
(	O
Bakkar	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O

Indeed	O
,	O
as	O
mentioned	O
by	O
Porta	O
et	O
al	O
.	O
(	O
2007	O
)	O
,	O
the	O
bias	O
of	O
counting	O
self	O
-	O
matches	O
is	O
particularly	O
a	O
concern	O
in	O
short	O
signals	O
consisting	O
of	O
a	O
“	O
few	O
hundreds	O
of	O
samples	O
”	O
or	O
around	O
300	O
beat	O
-	O
to	O
-	O
beat	O
samples	O
(	O
Porta	O
et	O
al	O
.	O
,	O
2007	O
)	O
,	O
which	O
is	O
far	O
below	O
the	O
number	O
of	O
samples	O
we	O
are	O
considering	O
.	O
As	O
such	O
,	O
the	O
contribution	O
of	O
self	O
-	O
matches	O
becomes	O
minimal	O
.	O
Detrended	O
fluctuation	O
analysis	O
(	O
DFA	O
)	O
is	O
a	O
measure	O
of	O
system	O
correlation	O
(	O
Peng	O
et	O
al	O
.	O
,	O
1995	O
)	O
on	O
varying	O
ranges	O
(	O
short	O
-	O
and	O
long	O
-	O
term	O
)	O
(	O
Fares	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Briefly	O
,	O
the	O
original	O
time	O
series	O
is	O
integrated	O
and	O
detrended	O
and	O
the	O
root	O
mean	O
square	O
fluctuation	O
of	O
the	O
detrended	O
time	O
series	O
is	O
calculated	O
over	O
different	O
box	O
sizes	O
(	O
n	O
)	O
.	O
A	O
correlation	O
coefficient	O
,	O
α	O
,	O
is	O
then	O
calculated	O
as	O
the	O
linear	O
slope	O
of	O
the	O
logarithm	O
of	O
root	O
mean	O
square	O
fluctuation	O
versus	O
the	O
logarithm	O
of	O
box	O
size	O
(	O
n	O
)	O
.	O
α	O
quantifies	O
fractal	O
scaling	O
of	O
beat	O
-	O
to	O
-	O
beat	O
signals	O
and	O
reflects	O
long	O
-	O
term	O
self	O
-	O
correlation	O
in	O
multicomponent	O
systems	O
(	O
Goldberger	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O
In	O
fact	O
,	O
fractal	O
scaling	O
emerges	O
from	O
complex	O
and	O
rather	O
nonlinear	O
coupling	O
processes	O
(	O
Goldberger	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O
As	O
such	O
,	O
the	O
fractal	O
scaling	O
exponent	O
,	O
α	O
,	O
assesses	O
temporal	O
characteristics	O
,	O
that	O
is	O
,	O
correlations	O
,	O
of	O
a	O
time	O
series	O
with	O
nonlinear	O
control	O
mechanisms	O
(	O
Ivanov	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O
Thus	O
,	O
while	O
α	O
in	O
itself	O
might	O
not	O
be	O
a	O
nonlinear	O
value	O
,	O
it	O
rather	O
depicts	O
changes	O
in	O
nonlinear	O
processes	O
,	O
the	O
assessment	O
of	O
which	O
in	O
the	O
context	O
of	O
early	O
metabolic	O
disease	O
was	O
the	O
intent	O
of	O
the	O
present	O
study	O
.	O
DFA	O
correlations	O
were	O
computed	O
,	O
for	O
the	O
same	O
series	O
length	O
of	O
1	O
,	O
500	O
cardiac	O
beats	O
(	O
5×300BPM	O
)	O
sampled	O
at	O
50	O
Hz	O
(	O
15	O
,	O
100	O
data	O
points	O
)	O
,	O
using	O
a	O
MATLAB	O
code	O
developed	O
in	O
our	O
laboratory	O
(	O
Fares	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Normality	O
was	O
tested	O
using	O
the	O
Shapiro	O
–	O
Wilk	O
test	O
.	O
Continuous	O
variables	O
and	O
variability	O
metrics	O
were	O
summarized	O
using	O
means	O
and	O
standard	O
errors	O
(	O
SEs	O
)	O
and	O
were	O
compared	O
univariately	O
across	O
groups	O
using	O
the	O
independent	O
samples	O
t	O
-	O
test	O
or	O
the	O
Mann	O
–	O
Whitney	O
U	O
test	O
.	O

Three	O
-	O
way	O
ANOVA	O
was	O
used	O
for	O
subgroup	O
analysis	O
to	O
compare	O
the	O
changes	O
in	O
different	O
parameters	O
across	O
dietary	O
groups	O
for	O
different	O
sexes	O
and	O
feeding	O
durations	O
.	O
Sidak	O
’	O
s	O
multiple	O
comparison	O
test	O
was	O
used	O
for	O
post	O
hoc	O
comparisons	O
.	O
Bootstrap	O
multivariable	O
linear	O
regression	O
models	O
were	O
conducted	O
to	O
determine	O
the	O
adjusted	O
associations	O
among	O
sex	O
,	O
diet	O
type	O
and	O
duration	O
,	O
and	O
average	O
BP	O
and	O
BPV	O
metrics	O
to	O
test	O
their	O
interactions	O
with	O
independent	O
variables	O
irrespective	O
of	O
the	O
average	O
BP	O
.	O
Due	O
to	O
the	O
small	O
sample	O
size	O
,	O
the	O
nonparametric	O
bootstrap	O
technique	O
was	O
used	O
to	O
estimate	O
SEs	O
,	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
,	O
and	O
p	O
-	O
values	O
for	O
the	O
regression	O
coefficients	O
.	O
In	O
the	O
bootstrap	O
analysis	O
,	O
1	O
,	O
000	O
samples	O
of	O
the	O
same	O
size	O
as	O
the	O
original	O
sample	O
were	O
drawn	O
,	O
with	O
replacement	O
from	O
the	O
original	O
data	O
set	O
.	O
Logistic	O
regression	O
was	O
carried	O
out	O
to	O
determine	O
and	O
compare	O
the	O
powers	O
of	O
BPV	O
parameters	O
in	O
predicting	O
disease	O
state	O
,	O
represented	O
by	O
the	O
presence	O
or	O
absence	O
of	O
HC	O
feeding	O
.	O
Odds	O
ratio	O
(	O
OR	O
)	O
,	O
SEs	O
,	O
and	O
95	O
%	O
CIs	O
were	O
reported	O
.	O
All	O
tests	O
were	O
two	O
-	O
tailed	O
,	O
and	O
p	O
-	O
values	O
<	O
0	O
.	O
05	O
were	O
considered	O
significant	O
.	O
Statistical	O
analyses	O
were	O
performed	O
using	O
Stata	O
version	O
13	O
.	O
1	O
for	O
Windows	O
and	O
GraphPad	O
Prism	O
for	O
iOS	O
.	O
As	O
expected	O
,	O
HC	O
feeding	O
for	O
different	O
durations	O
was	O
associated	O
with	O
increased	O
caloric	O
intake	O
compared	O
to	O
the	O
corresponding	O
rat	O
group	O
receiving	O
control	O
diet	O
,	O
albeit	O
being	O
generally	O
less	O
in	O
female	O
compared	O
to	O
male	O
rats	O
(	O
Figure	O
1A	O
)	O
.	O
Similar	O
to	O
our	O
previous	O
results	O
(	O
Al	O
-	O
Assi	O
et	O
al	O
.	O
,	O
2018	O
;	O
Elkhatib	O
et	O
al	O
.	O
,	O
2019	O
;	O
Fakih	O
et	O
al	O
.	O
,	O
2020	O
;	O
Hammoud	O
et	O
al	O
.	O
,	O
2021a	O
)	O
,	O
the	O
increased	O
calorie	O
intake	O
in	O
HC	O
-	O
fed	O
rats	O
was	O
not	O
associated	O
with	O
an	O
increase	O
in	O
neither	O
body	O
weight	O
(	O
Figure	O
1B	O
)	O
nor	O
random	O
blood	O
glucose	O
level	O
(	O
Figure	O
1C	O
)	O
,	O
yet	O
HC	O
-	O
fed	O
rats	O
generally	O
showed	O
altered	O
body	O
composition	O
as	O
depicted	O
by	O
an	O
increased	O
fat	O
:	O
lean	O
ratio	O
across	O
sexes	O
and	O
along	O
different	O
feeding	O
durations	O
(	O
Figure	O
1D	O
)	O
confirming	O
the	O
occurrence	O
of	O
the	O
previously	O
demonstrated	O
metabolic	O
impairment	O
.	O
Interestingly	O
,	O
commensurate	O
with	O
the	O
lower	O
caloric	O
intake	O
in	O
female	O
rats	O
,	O
both	O
their	O
body	O
weight	O
and	O
fat	O
:	O
lean	O
ratio	O
were	O
lower	O
than	O
those	O
of	O
the	O
male	O
rat	O
groups	O
(	O
Figures	O
1B	O
,	O
D	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
HC	O
feeding	O
was	O
globally	O
associated	O
with	O
hyperinsulinemia	O
,	O
mainly	O
driven	O
by	O
significant	O
increases	O
in	O
serum	O
insulin	O
levels	O
in	O
male	O
rats	O
fed	O
HC	O
diet	O
for	O
12	O
or	O
24	O
weeks	O
compared	O
to	O
their	O
NC	O
-	O
fed	O
counterparts	O
(	O
Figure	O
1E	O
)	O
.	O
Importantly	O
,	O
HC	O
-	O
fed	O
female	O
rats	O
exhibited	O
significantly	O
lower	O
serum	O
insulin	O
levels	O
than	O
their	O
male	O
counterparts	O
.	O
Similar	O
to	O
our	O
previous	O
studies	O
(	O
Al	O
-	O
Assi	O
et	O
al	O
.	O
,	O
2018	O
;	O
Bakkar	O
et	O
al	O
.	O
,	O
2020	O
)	O
,	O
no	O
changes	O
were	O
detected	O
in	O
baseline	O
hemodynamics	O
and	O
myocardial	O
structure	O
or	O
function	O
across	O
different	O
diet	O
groups	O
.	O
Indeed	O
,	O
Figure	O
2A	O
shows	O
the	O
representative	O
echocardiographic	O
images	O
without	O
alteration	O
in	O
ejection	O
fraction	O
(	O
Figure	O
2B	O
)	O
.	O
Similarly	O
,	O
there	O
was	O
no	O
difference	O
in	O
MAP	O
among	O
control	O
and	O
HC	O
rats	O
of	O
either	O
sex	O
or	O
feeding	O
duration	O
group	O
,	O
albeit	O
with	O
female	O
rats	O
showing	O
a	O
lower	O
MAP	O
(	O
Figure	O
2C	O
)	O
.	O
Significantly	O
,	O
an	O
impaired	O
cardiac	O
autonomic	O
activity	O
,	O
particularly	O
on	O
the	O
parasympathetic	O
side	O
,	O
was	O
revealed	O
following	O
a	O
hemodynamic	O
challenge	O
using	O
a	O
vasopressor	O
agent	O
.	O
This	O
was	O
observed	O
as	O
a	O
reduced	O
parasympathetic	O
BRS	O
following	O
HC	O
feeding	O
in	O
both	O
12	O
-	O
week	O
and	O
24	O
-	O
week	O
male	O
rats	O
,	O
but	O
not	O
in	O
female	O
rats	O
(	O
Figure	O
2D	O
)	O
,	O
and	O
not	O
in	O
the	O
sympathetic	O
arm	O
of	O
baroreflex	O
(	O
Figure	O
2E	O
)	O
.	O
Consistently	O
,	O
a	O
significant	O
interaction	O
appeared	O
between	O
sex	O
and	O
diet	O
(	O
p	O
=	O
0	O
.	O
0003	O
)	O
,	O
whereby	O
males	O
were	O
more	O
prone	O
to	O
the	O
effect	O
of	O
diet	O
on	O
parasympathetic	O
BRS	O
.	O
Examination	O
of	O
beat	O
-	O
to	O
-	O
beat	O
HR	O
tracing	O
revealed	O
that	O
female	O
rats	O
collectively	O
exhibited	O
significantly	O
lower	O
average	O
HR	O
than	O
males	O
(	O
Figure	O
3A	O
)	O
.	O
Particularly	O
,	O
healthy	O
female	O
rats	O
demonstrated	O
significantly	O
lower	O
average	O
HR	O
than	O
their	O
male	O
counterparts	O
(	O
NC	O
-	O
fed	O
for	O
12	O
weeks	O
)	O
.	O
Regarding	O
HRV	O
,	O
no	O
significant	O
differences	O
in	O
linear	O
fluctuations	O
of	O
HR	O
,	O
assessed	O
by	O
SD	O
and	O
CV	O
,	O
were	O
observed	O
among	O
rats	O
from	O
either	O
sex	O
,	O
on	O
either	O
diet	O
for	O
the	O
different	O
feeding	O
durations	O
(	O
Figure	O
3B	O
)	O
.	O
Interestingly	O
,	O
alterations	O
in	O
nonlinear	O
parameters	O
of	O
beat	O
-	O
to	O
-	O
beat	O
HRV	O
were	O
exclusively	O
observed	O
in	O
male	O
rats	O
on	O
HC	O
diet	O
for	O
12	O
weeks	O
,	O
reflected	O
by	O
a	O
decrease	O
in	O
ApEn	O
and	O
an	O
increase	O
in	O
α	O
of	O
DFA	O
with	O
respect	O
to	O
their	O
NC	O
-	O
fed	O
counterparts	O
(	O
Figures	O
3C	O
,	O
D	O
,	O
respectively	O
)	O
.	O

Additionally	O
,	O
HC	O
-	O
fed	O
rats	O
collectively	O
exhibited	O
higher	O
α	O
of	O
DFA	O
than	O
those	O
fed	O
an	O
NC	O
diet	O
(	O
Figure	O
3D	O
)	O
.	O
Importantly	O
,	O
significant	O
interactions	O
existed	O
between	O
feeding	O
duration	O
and	O
diet	O
for	O
ApEn	O
(	O
p	O
=	O
0	O
.	O
0004	O
)	O
and	O
α	O
(	O
p	O
=	O
0	O
.	O
014	O
)	O
of	O
HR	O
,	O
indicating	O
a	O
more	O
pronounced	O
decrease	O
and	O
increase	O
,	O
respectively	O
,	O
in	O
12	O
-	O
week	O
HC	O
-	O
fed	O
rats	O
.	O
Another	O
significant	O
interaction	O
was	O
found	O
between	O
sex	O
and	O
feeding	O
duration	O
for	O
α	O
of	O
HR	O
(	O
p	O
=	O
0	O
.	O
027	O
)	O
,	O
reflecting	O
a	O
stronger	O
effect	O
of	O
feeding	O
duration	O
on	O
males	O
.	O
Figure	O
4	O
depicts	O
BP	O
tracings	O
of	O
the	O
raw	O
(	O
Figures	O
4A	O
,	O
B	O
)	O
and	O
downsampled	O
signals	O
(	O
Figures	O
4C	O
,	O
D	O
)	O
.	O
Examination	O
of	O
beat	O
-	O
to	O
-	O
beat	O
BP	O
tracings	O
revealed	O
that	O
despite	O
equal	O
average	O
BP	O
values	O
,	O
rats	O
from	O
different	O
groups	O
might	O
demonstrate	O
disparate	O
variability	O
patterns	O
(	O
Figure	O
4	O
)	O
.	O
Whereas	O
female	O
rats	O
had	O
lower	O
average	O
and	O
linear	O
BPV	O
parameters	O
for	O
SBP	O
,	O
univariate	O
analysis	O
showed	O
that	O
the	O
average	O
beat	O
-	O
to	O
-	O
beat	O
SBP	O
,	O
SD	O
,	O
and	O
CV	O
did	O
not	O
differ	O
with	O
respect	O
to	O
diet	O
type	O
and	O
duration	O
(	O
Table	O
1	O
)	O
.	O
Other	O
than	O
an	O
increased	O
SD	O
of	O
DBP	O
in	O
HC	O
-	O
fed	O
rats	O
,	O
no	O
differences	O
were	O
observed	O
in	O
average	O
DBP	O
or	O
CV	O
for	O
DBP	O
by	O
univariate	O
analysis	O
across	O
sexes	O
or	O
with	O
diet	O
type	O
or	O
duration	O
(	O
Table	O
1	O
)	O
.	O
While	O
further	O
subgroup	O
analysis	O
using	O
three	O
-	O
way	O
ANOVA	O
confirmed	O
the	O
broad	O
changes	O
across	O
sexes	O
for	O
SBP	O
parameters	O
,	O
24	O
-	O
week	O
control	O
female	O
rats	O
had	O
lower	O
average	O
SBP	O
and	O
12	O
-	O
week	O
HC	O
-	O
fed	O
female	O
rats	O
showed	O
lower	O
values	O
for	O
SD	O
and	O
CV	O
than	O
their	O
male	O
counterparts	O
(	O
Figures	O
5A	O
,	O
C	O
,	O
E	O
)	O
.	O
No	O
differences	O
were	O
observed	O
for	O
the	O
average	O
DBP	O
or	O
SD	O
and	O
CV	O
values	O
for	O
DBP	O
across	O
sexes	O
,	O
diet	O
type	O
,	O
or	O
duration	O
(	O
Figures	O
5B	O
,	O
D	O
,	O
F	O
)	O
.	O
Univariate	O
examination	O
of	O
nonlinear	O
BPV	O
indices	O
revealed	O
a	O
lower	O
ApEn	O
for	O
SBP	O
and	O
α	O
for	O
both	O
SBP	O
and	O
DBP	O
in	O
female	O
rats	O
compared	O
to	O
their	O
male	O
counterparts	O
(	O
Table	O
2	O
)	O
.	O
Moreover	O
,	O
a	O
reduction	O
and	O
an	O
increase	O
in	O
ApEn	O
and	O
α	O
for	O
DBP	O
,	O
respectively	O
,	O
were	O
observed	O
in	O
HC	O
-	O
fed	O
rats	O
compared	O
to	O
those	O
receiving	O
the	O
control	O
chow	O
(	O
Table	O
2	O
)	O
.	O

Subgroup	O
analysis	O
confirmed	O
a	O
lower	O
ApEn	O
for	O
SBP	O
and	O
α	O
for	O
both	O
SBP	O
and	O
DBP	O
in	O
female	O
rats	O
(	O
Figures	O
6A	O
,	O
C	O
,	O
D	O
)	O
.	O
For	O
ApEn	O
,	O
while	O
HC	O
-	O
feeding	O
reduced	O
the	O
values	O
for	O
DBP	O
across	O
sex	O
and	O
feeding	O
duration	O
groups	O
,	O
12	O
-	O
week	O
HC	O
-	O
fed	O
rats	O
were	O
particularly	O
vulnerable	O
to	O
that	O
effect	O
for	O
both	O
SBP	O
and	O
DBP	O
(	O
Figures	O
6A	O
,	O
B	O
)	O
.	O
Indeed	O
,	O
there	O
was	O
a	O
significant	O
interaction	O
between	O
feeding	O
duration	O
and	O
diet	O
for	O
ApEn	O
of	O
both	O
SBP	O
and	O
DBP	O
(	O
p	O
=	O
0	O
.	O
0041	O
and	O
p	O
=	O
0	O
.	O
01	O
,	O
respectively	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
α	O
for	O
DBP	O
was	O
increased	O
for	O
HC	O
-	O
fed	O
rats	O
across	O
sex	O
and	O
feeding	O
duration	O
groups	O
without	O
a	O
specific	O
trend	O
in	O
one	O
subgroup	O
over	O
the	O
other	O
(	O
Figure	O
6D	O
)	O
.	O
Bootstrap	O
multivariable	O
linear	O
regression	O
models	O
were	O
conducted	O
to	O
determine	O
the	O
adjusted	O
associations	O
between	O
average	O
BP	O
,	O
sex	O
,	O
diet	O
type	O
and	O
duration	O
,	O
and	O
BPV	O
metrics	O
.	O
Interactions	O
among	O
sex	O
,	O
and	O
diet	O
type	O
and	O
duration	O
were	O
examined	O
to	O
determine	O
whether	O
the	O
associations	O
with	O
BPV	O
metrics	O
vary	O
across	O
the	O
different	O
rat	O
categories	O
,	O
while	O
that	O
with	O
average	O
BP	O
was	O
performed	O
to	O
examine	O
whether	O
these	O
parameters	O
are	O
affected	O
by	O
baseline	O
BP	O
.	O
For	O
the	O
linear	O
parameters	O
,	O
average	O
SBP	O
(	O
BSBP	O
=	O
0	O
.	O
03	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
sex	O
(	O
BSBP	O
=	O
0	O
.	O
63	O
,	O
p	O
=	O
0	O
.	O
014	O
)	O
were	O
significantly	O
associated	O
with	O
SD	O
of	O
the	O
SBP	O
and	O
resulted	O
in	O
an	O
adjusted	O
R	O
2	O
of	O
0	O
.	O
3	O
.	O
As	O
expected	O
by	O
the	O
subgroup	O
analysis	O
,	O
significantly	O
higher	O
values	O
of	O
SD	O
were	O
found	O
in	O
rats	O
with	O
higher	O
average	O
SBP	O
and	O
in	O
males	O
(	O
Figures	O
5A	O
,	O
C	O
)	O
,	O
while	O
no	O
such	O
associations	O
were	O
found	O
with	O
SD	O
of	O
the	O
DBP	O
.	O
On	O
the	O
other	O
hand	O
,	O
CV	O
of	O
the	O
SBP	O
series	O
showed	O
a	O
significant	O
interaction	O
with	O
feeding	O
duration	O
and	O
sex	O
resulting	O
in	O
an	O
increase	O
in	O
CV	O
in	O
males	O
only	O
in	O
the	O
12	O
-	O
week	O
rats	O
(	O
BSBP	O
=	O
0	O
.	O
74	O
,	O
p	O
=	O
0	O
.	O
008	O
)	O
,	O
possibly	O
driven	O
by	O
the	O
lower	O
CV	O
values	O
observed	O
in	O
young	O
HC	O
-	O
fed	O
females	O
(	O
Figure	O
5E	O
)	O
.	O
The	O
model	O
,	O
however	O
,	O
had	O
an	O
adjusted	O
R	O
2	O
of	O
0	O
.	O
19	O
only	O
.	O

Average	O
SBP	O
was	O
not	O
associated	O
with	O
CV	O
of	O
the	O
SBP	O
.	O
Alternatively	O
,	O
CV	O
of	O
the	O
DBP	O
was	O
associated	O
with	O
average	O
DBP	O
(	O
BDBP	O
=	O
−0	O
.	O
42	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
with	O
an	O
adjusted	O
R	O
2	O
of	O
0	O
.	O
4	O
.	O
Surprisingly	O
,	O
a	O
decrease	O
in	O
mean	O
DBP	O
was	O
associated	O
with	O
an	O
increase	O
in	O
CV	O
.	O
As	O
opposed	O
to	O
findings	O
related	O
to	O
SD	O
for	O
SBP	O
,	O
no	O
association	O
was	O
observed	O
for	O
any	O
of	O
the	O
nonlinear	O
parameters	O
with	O
average	O
BP	O
.	O
For	O
ApEn	O
regression	O
models	O
,	O
significant	O
interactions	O
were	O
found	O
with	O
diet	O
type	O
and	O
duration	O
for	O
both	O
SBP	O
and	O
DBP	O
series	O
(	O
p	O
=	O
0	O
.	O
005	O
and	O
p	O
=	O
0	O
.	O
005	O
,	O
respectively	O
)	O
.	O
Adjusted	O
R	O
2	O
for	O
the	O
overall	O
models	O
with	O
these	O
interactions	O
were	O
0	O
.	O
39	O
for	O
SBP	O
and	O
0	O
.	O
43	O
for	O
DBP	O
.	O
After	O
running	O
separate	O
models	O
for	O
12	O
-	O
week	O
and	O
24	O
-	O
week	O
rats	O
,	O
ApEn	O
was	O
found	O
to	O
decrease	O
in	O
12	O
-	O
week	O
HC	O
-	O
fed	O
rats	O
only	O
(	O
BSBP	O
=	O
−0	O
.	O
08	O
,	O
p	O
=	O
0	O
.	O
005	O
and	O
BDBP	O
=	O
−0	O
.	O
1	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
similar	O
to	O
observations	O
in	O
subgroup	O
analyses	O
(	O
Figures	O
6A	O
,	O
B	O
)	O
.	O
No	O
changes	O
in	O
ApEn	O
across	O
diets	O
and	O
sex	O
were	O
observed	O
in	O
the	O
24	O
-	O
week	O
rats	O
.	O
No	O
significant	O
interactions	O
were	O
found	O
with	O
α	O
of	O
both	O
BP	O
series	O
.	O
Adjusted	O
R	O
2	O
for	O
the	O
overall	O
models	O
were	O
0	O
.	O
36	O
for	O
SBP	O
and	O
0	O
.	O
23	O
for	O
DBP	O
.	O
α	O
was	O
higher	O
in	O
males	O
in	O
both	O
series	O
(	O
BSBP	O
=	O
0	O
.	O
13	O
,	O
p	O
=	O
0	O
.	O
001	O
and	O
BDBP	O
=	O
0	O
.	O
12	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
(	O
Figures	O
6C	O
,	O
D	O
)	O
and	O
in	O
DBP	O
for	O
HC	O
-	O
fed	O
rats	O
(	O
BDBP	O
=	O
0	O
.	O
07	O
,	O
p	O
=	O
0	O
.	O
039	O
)	O
(	O
Figure	O
6D	O
)	O
similar	O
to	O
what	O
was	O
concluded	O
from	O
the	O
subgroup	O
analysis	O
.	O
Since	O
ApEn	O
and	O
α	O
for	O
DBP	O
were	O
found	O
in	O
subgroup	O
analysis	O
and	O
bootstrap	O
regression	O
to	O
consistently	O
decrease	O
and	O
increase	O
,	O
respectively	O
,	O
in	O
different	O
rat	O
groups	O
following	O
HC	O
-	O
feeding	O
,	O
logistic	O
regression	O
was	O
carried	O
out	O
to	O
determine	O
and	O
compare	O
the	O
powers	O
of	O
BPV	O
parameters	O
in	O
predicting	O
a	O
prediabetic	O
disease	O
state	O
induced	O
by	O
HC	O
feeding	O
and	O
associated	O
with	O
subtle	O
yet	O
significant	O
cardiovascular	O
and	O
autonomic	O
impairment	O
.	O

The	O
overall	O
logistic	O
regression	O
model	O
was	O
significant	O
(	O
p	O
-	O
value	O
=	O
0	O
.	O
0159	O
,	O
Pseudo	O
R	O
2	O
=	O
17	O
.	O
4	O
%	O
)	O
.	O
As	O
expected	O
,	O
a	O
0	O
.	O
1	O
unit	O
increase	O
in	O
ApEn	O
or	O
α	O
of	O
DBP	O
was	O
associated	O
with	O
an	O
OR	O
of	O
0	O
.	O
27	O
±	O
0	O
.	O
16	O
(	O
CI	O
:	O
0	O
.	O
09	O
–	O
0	O
.	O
85	O
,	O
p	O
=	O
0	O
.	O
026	O
)	O
or	O
1	O
.	O
69	O
±	O
0	O
.	O
43	O
(	O
CI	O
:	O
1	O
.	O
03	O
–	O
2	O
.	O
79	O
,	O
p	O
=	O
0	O
.	O
040	O
)	O
,	O
respectively	O
,	O
for	O
the	O
incidence	O
of	O
early	O
cardiovascular	O
involvement	O
and	O
metabolic	O
impairment	O
associated	O
with	O
HC	O
feeding	O
(	O
Table	O
3	O
)	O
.	O
Linear	O
parameters	O
of	O
DBP	O
,	O
SD	O
and	O
CV	O
,	O
did	O
not	O
significantly	O
predict	O
disease	O
stage	O
with	O
ORs	O
of	O
1	O
.	O
2	O
±	O
0	O
.	O
77	O
(	O
CI	O
:	O
0	O
.	O
34	O
–	O
4	O
.	O
25	O
,	O
p	O
=	O
0	O
.	O
773	O
)	O
and	O
0	O
.	O
7	O
±	O
0	O
.	O
44	O
(	O
CI	O
:	O
0	O
.	O
21	O
–	O
2	O
.	O
4	O
,	O
p	O
=	O
0	O
.	O
574	O
)	O
for	O
a	O
0	O
.	O
1	O
unit	O
increase	O
in	O
SD	O
and	O
CV	O
of	O
DBP	O
,	O
respectively	O
.	O
Despite	O
significant	O
advances	O
in	O
care	O
for	O
diabetic	O
patients	O
in	O
the	O
past	O
decade	O
,	O
evidence	O
has	O
long	O
indicated	O
that	O
glycemic	O
control	O
was	O
not	O
sufficient	O
to	O
reduce	O
cardiovascular	O
complications	O
(	O
Giorgino	O
et	O
al	O
.	O
,	O
2013	O
;	O
Hayward	O
et	O
al	O
.	O
,	O
2015	O
;	O
Barer	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
Indeed	O
,	O
the	O
deleterious	O
process	O
culminating	O
in	O
overt	O
cardiovascular	O
dysfunction	O
as	O
diabetic	O
patients	O
progress	O
along	O
the	O
course	O
of	O
the	O
disease	O
appears	O
to	O
start	O
much	O
earlier	O
than	O
the	O
initial	O
diagnosis	O
of	O
hyperglycemia	O
,	O
extending	O
the	O
elevated	O
cardiovascular	O
risk	O
to	O
the	O
prediabetic	O
stage	O
(	O
Fowler	O
,	O
2008	O
;	O
DeFronzo	O
and	O
Abdul	O
-	O
Ghani	O
,	O
2011	O
;	O
Wasserman	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
In	O
this	O
regard	O
,	O
one	O
of	O
the	O
greatest	O
challenges	O
would	O
be	O
the	O
detection	O
of	O
changes	O
in	O
cardiovascular	O
function	O
triggered	O
by	O
early	O
metabolic	O
impairment	O
leading	O
to	O
increased	O
risk	O
of	O
morbidity	O
and	O
mortality	O
,	O
especially	O
since	O
many	O
of	O
these	O
changes	O
are	O
subtle	O
or	O
asymptomatic	O
,	O
and	O
an	O
onset	O
point	O
of	O
metabolic	O
impairment	O
lacks	O
an	O
unequivocal	O
definition	O
.	O
Here	O
,	O
we	O
propose	O
the	O
use	O
of	O
nonlinear	O
BPV	O
parameters	O
as	O
potential	O
predictors	O
of	O
the	O
earliest	O
signs	O
of	O
cardiovascular	O
involvement	O
in	O
the	O
course	O
of	O
metabolic	O
disease	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
ours	O
is	O
the	O
first	O
study	O
to	O
assess	O
the	O
impact	O
of	O
early	O
metabolic	O
challenge	O
on	O
linear	O
as	O
well	O
as	O
nonlinear	O
parameters	O
of	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
in	O
a	O
nonobese	O
prediabetic	O
model	O
.	O
While	O
our	O
experimental	O
method	O
collected	O
BP	O
data	O
series	O
using	O
an	O
invasive	O
technique	O
,	O
calculation	O
of	O
such	O
parameters	O
is	O
equally	O
feasible	O
using	O
noninvasive	O
recording	O
methods	O
(	O
Bakkar	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
In	O
this	O
context	O
,	O
we	O
measured	O
linear	O
and	O
nonlinear	O
BPV	O
parameters	O
in	O
control	O
and	O
HC	O
-	O
fed	O
rats	O
of	O
either	O
sex	O
exposed	O
to	O
different	O
feeding	O
durations	O
.	O
Indeed	O
,	O
12	O
weeks	O
of	O
mild	O
hypercaloric	O
challenge	O
were	O
shown	O
to	O
induce	O
an	O
early	O
state	O
of	O
nonobese	O
metabolic	O
dysfunction	O
characterized	O
by	O
hyperinsulinemia	O
associated	O
with	O
increased	O
fat	O
:	O
lean	O
ratio	O
and	O
localized	O
adipose	O
tissue	O
inflammation	O
in	O
male	O
rats	O
,	O
while	O
lacking	O
hyperglycemia	O
and	O
signs	O
of	O
systemic	O
inflammation	O
(	O
Al	O
-	O
Assi	O
et	O
al	O
.	O
,	O
2018	O
;	O
Alaaeddine	O
et	O
al	O
.	O
,	O
2019	O
;	O
Elkhatib	O
et	O
al	O
.	O
,	O
2019	O
;	O
Fakih	O
et	O
al	O
.	O
,	O
2020	O
;	O
Hammoud	O
et	O
al	O
.	O
,	O
2021a	O
)	O
.	O
While	O
these	O
rats	O
lacked	O
signs	O
of	O
gross	O
cardiovascular	O
dysfunction	O
,	O
with	O
no	O
hypertension	O
or	O
cardiac	O
remodeling	O
seen	O
with	O
echocardiography	O
,	O
renal	O
and	O
vascular	O
endothelial	O
,	O
cerebrovascular	O
,	O
and	O
parasympathetic	O
cardiac	O
autonomic	O
dysfunction	O
demonstrated	O
as	O
suppressed	O
measures	O
of	O
time	O
-	O
domain	O
and	O
frequency	O
-	O
domain	O
parameters	O
of	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
together	O
with	O
reduced	O
BRS	O
,	O
as	O
well	O
as	O
markers	O
of	O
cardiovascular	O
oxidative	O
stress	O
and	O
inflammation	O
,	O
were	O
seen	O
upon	O
molecular	O
profiling	O
(	O
Al	O
-	O
Assi	O
et	O
al	O
.	O
,	O
2018	O
;	O
Alaaeddine	O
et	O
al	O
.	O
,	O
2019	O
;	O
Elkhatib	O
et	O
al	O
.	O
,	O
2019	O
;	O
Fakih	O
et	O
al	O
.	O
,	O
2020	O
;	O
Hammoud	O
et	O
al	O
.	O
,	O
2021a	O
)	O
.	O
Thus	O
,	O
we	O
believe	O
that	O
HC	O
-	O
fed	O
rats	O
would	O
serve	O
as	O
a	O
reasonable	O
model	O
for	O
mild	O
metabolic	O
impairment	O
with	O
early	O
cardiovascular	O
involvement	O
lacking	O
baseline	O
gross	O
diagnostic	O
signs	O
.	O
Importantly	O
,	O
the	O
association	O
between	O
metabolic	O
syndrome	O
and	O
cardiac	O
autonomic	O
dysfunction	O
is	O
well	O
documented	O
and	O
thought	O
to	O
underlie	O
the	O
increased	O
risk	O
of	O
incidence	O
of	O
other	O
cardiovascular	O
disorders	O
(	O
Fowler	O
,	O
2008	O
)	O
.	O

In	O
this	O
regard	O
,	O
the	O
study	O
of	O
the	O
considerable	O
and	O
characteristic	O
degree	O
of	O
change	O
associated	O
with	O
various	O
physiological	O
signals	O
such	O
as	O
heart	O
rate	O
(	O
HR	O
)	O
and	O
BP	O
due	O
to	O
the	O
competitive	O
interaction	O
between	O
different	O
reflex	O
control	O
mechanisms	O
might	O
offer	O
a	O
means	O
of	O
detecting	O
autonomic	O
dysfunction	O
.	O
While	O
cardiorespiratory	O
and	O
baroreceptor	O
reflexes	O
reflect	O
as	O
variability	O
in	O
both	O
HR	O
and	O
BP	O
,	O
a	O
main	O
advantage	O
of	O
BPV	O
over	O
HRV	O
analysis	O
is	O
its	O
capacity	O
to	O
depict	O
an	O
integrative	O
view	O
of	O
vascular	O
and	O
autonomic	O
control	O
.	O
Specifically	O
,	O
vascular	O
properties	O
like	O
reactivity	O
(	O
Xu	O
et	O
al	O
.	O
,	O
2017	O
)	O
,	O
elasticity	O
,	O
and	O
compliance	O
(	O
Webb	O
and	O
Rothwell	O
,	O
2014	O
;	O
Xia	O
et	O
al	O
.	O
,	O
2017	O
)	O
,	O
together	O
with	O
autonomic	O
input	O
through	O
BRS	O
,	O
were	O
shown	O
to	O
affect	O
beat	O
-	O
to	O
-	O
beat	O
BP	O
dynamics	O
(	O
DeBoer	O
et	O
al	O
.	O
,	O
1987	O
;	O
Grilletti	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
As	O
such	O
,	O
it	O
became	O
prudent	O
to	O
investigate	O
the	O
capacity	O
of	O
BPV	O
parameters	O
to	O
reflect	O
and	O
predict	O
early	O
cardiovascular	O
dysfunction	O
in	O
a	O
prediabetic	O
disease	O
state	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Univariate	O
analysis	O
of	O
our	O
present	O
results	O
showed	O
that	O
changes	O
in	O
nonlinear	O
BPV	O
parameters	O
indicative	O
of	O
cardiovascular	O
pathology	O
occurred	O
in	O
HC	O
-	O
fed	O
rats	O
more	O
so	O
than	O
those	O
in	O
linear	O
parameters	O
.	O
Indeed	O
,	O
a	O
reduction	O
in	O
DBP	O
beat	O
-	O
to	O
-	O
beat	O
signal	O
complexity	O
,	O
manifested	O
as	O
a	O
lower	O
ApEn	O
,	O
and	O
increased	O
self	O
-	O
correlation	O
,	O
measured	O
as	O
a	O
higher	O
α	O
for	O
DBP	O
,	O
were	O
observed	O
in	O
HC	O
-	O
fed	O
rats	O
of	O
either	O
sex	O
at	O
different	O
feeding	O
durations	O
.	O
Only	O
an	O
increased	O
beat	O
-	O
to	O
-	O
beat	O
DBP	O
SD	O
was	O
observed	O
for	O
HC	O
-	O
fed	O
rats	O
.	O
Interestingly	O
,	O
multivariate	O
subgroup	O
analyses	O
revealed	O
that	O
these	O
changes	O
persisted	O
only	O
for	O
the	O
nonlinear	O
parameters	O
,	O
ApEn	O
and	O
α	O
,	O
but	O
not	O
for	O
SD	O
.	O
Moreover	O
,	O
adjusted	O
bootstrap	O
analysis	O
confirmed	O
that	O
,	O
unlike	O
linear	O
parameters	O
,	O
nonlinear	O
BPV	O
parameters	O
appeared	O
to	O
be	O
affected	O
by	O
intake	O
of	O
HC	O
diet	O
and	O
hence	O
early	O
metabolic	O
impairment	O
.	O
Our	O
results	O
are	O
in	O
line	O
with	O
observations	O
from	O
different	O
human	B-methodology
studies	I-methodology
revealing	O
that	O
various	O
pathological	O
conditions	O
are	O
associated	O
with	O
a	O
similar	O
trend	O
of	O
beat	O
-	O
to	O
-	O
beat	O
BP	O
aberrations	O
(	O
Bakkar	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O

Despite	O
the	O
fact	O
that	O
HRV	O
is	O
believed	O
to	O
be	O
more	O
complex	O
owing	O
to	O
cardiac	O
parasympathetic	O
innervation	O
and	O
antagonistic	O
firing	O
(	O
Porta	O
et	O
al	O
.	O
,	O
2012	O
)	O
,	O
the	O
paradigm	O
of	O
pathological	O
increase	O
in	O
signal	O
predictability	O
,	O
reflected	O
by	O
migration	O
of	O
ApEn	O
and	O
α	O
to	O
lower	O
and	O
higher	O
values	O
,	O
respectively	O
,	O
typically	O
observed	O
with	O
HRV	O
(	O
Goldberger	O
et	O
al	O
.	O
,	O
2002	O
)	O
,	O
seems	O
to	O
hold	O
for	O
BPV	O
.	O
In	O
fact	O
,	O
although	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
is	O
essentially	O
under	O
sympathetic	O
control	O
,	O
vagal	O
activity	O
was	O
found	O
to	O
have	O
an	O
indirect	O
effect	O
on	O
BPV	O
by	O
modulating	O
HRV	O
.	O
For	O
example	O
,	O
Castiglioni	O
et	O
al	O
.	O
(	O
2011	O
)	O
showed	O
that	O
parasympathetic	O
outflow	O
alters	O
BP	O
scaling	O
exponents	O
by	O
increasing	O
white	O
noise	O
in	O
HR	O
time	O
series	O
.	O
As	O
such	O
,	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
analysis	O
is	O
complementary	O
to	O
HRV	O
assessment	O
(	O
Porta	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O
Indeed	O
,	O
our	O
study	O
reveals	O
similar	O
HC	O
-	O
induced	O
changes	O
in	O
nonlinear	O
HRV	O
and	O
BPV	O
in	O
12	O
-	O
week	O
-	O
fed	O
male	O
rats	O
.	O
Interestingly	O
,	O
neither	O
ApEn	O
nor	O
α	O
seemed	O
to	O
be	O
affected	O
by	O
BP	O
as	O
opposed	O
to	O
SD	O
for	O
SBP	O
.	O
Given	O
the	O
lack	O
of	O
difference	O
in	O
BP	O
among	O
control	O
and	O
HC	O
-	O
fed	O
rats	O
observed	O
in	O
our	O
present	O
as	O
well	O
as	O
previous	O
studies	O
(	O
Al	O
-	O
Assi	O
et	O
al	O
.	O
,	O
2018	O
;	O
Alaaeddine	O
et	O
al	O
.	O
,	O
2019	O
;	O
Elkhatib	O
et	O
al	O
.	O
,	O
2019	O
;	O
Fakih	O
et	O
al	O
.	O
,	O
2020	O
;	O
Hammoud	O
et	O
al	O
.	O
,	O
2021a	O
)	O
,	O
this	O
latter	O
finding	O
suggests	O
that	O
nonlinear	O
parameters	O
might	O
be	O
a	O
more	O
reliable	O
reflection	O
of	O
the	O
cardiovascular	O
status	O
in	O
early	O
metabolic	O
impairment	O
.	O
Indeed	O
,	O
the	O
values	O
of	O
α	O
of	O
DFA	O
remained	O
approximately	O
equal	O
to	O
1	O
in	O
HC	O
-	O
fed	O
rats	O
indicating	O
the	O
presence	O
of	O
pink	O
noise	O
which	O
typically	O
describes	O
healthy	O
time	O
series	O
that	O
are	O
essentially	O
complex	O
with	O
a	O
degree	O
of	O
long	O
-	O
term	O
self	O
-	O
correlation	O
(	O
Peng	O
et	O
al	O
.	O
,	O
1995	O
;	O
Goldberger	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O
However	O
,	O
slight	O
yet	O
significant	O
differences	O
in	O
α	O
of	O
BPV	O
were	O
observed	O
between	O
the	O
different	O
groups	O
according	O
to	O
their	O
propensity	O
to	O
early	O
cardiovascular	O
impairment	O
.	O
Significantly	O
,	O
logistic	O
regression	O
indicated	O
a	O
solid	O
ability	O
of	O
nonlinear	O
diastolic	O
BPV	O
parameters	O
to	O
predict	O
the	O
cardiovascular	O
status	O
associated	O
with	O
the	O
mild	O
metabolic	O
impairment	O
triggered	O
by	O
the	O
HC	O
diet	O
.	O

A	O
0	O
.	O
1	O
unit	O
decrease	O
or	O
increase	O
in	O
DBP	O
ApEn	O
or	O
α	O
corresponded	O
to	O
an	O
increased	O
risk	O
of	O
such	O
a	O
state	O
by	O
73	O
%	O
or	O
69	O
%	O
,	O
respectively	O
.	O
This	O
was	O
not	O
the	O
case	O
with	O
DBP	O
SD	O
or	O
CV	O
as	O
linear	O
parameters	O
of	O
BPV	O
.	O
Such	O
an	O
outcome	O
would	O
not	O
be	O
surprising	O
since	O
nonlinear	O
parameters	O
are	O
based	O
on	O
the	O
postulation	O
that	O
erratic	O
cardiovascular	O
processes	O
stem	O
from	O
competitive	O
autonomic	O
signals	O
,	O
which	O
feed	O
into	O
a	O
system	O
whose	O
components	O
do	O
not	O
sum	O
up	O
to	O
the	O
whole	O
(	O
Subramaniam	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O
In	O
this	O
regard	O
,	O
it	O
is	O
plausible	O
that	O
the	O
altered	O
sympathovagal	O
balance	O
observed	O
in	O
HC	O
-	O
fed	O
rats	O
(	O
Al	O
-	O
Assi	O
et	O
al	O
.	O
,	O
2018	O
)	O
,	O
together	O
with	O
the	O
impaired	O
endothelial	O
function	O
(	O
Alaaeddine	O
et	O
al	O
.	O
,	O
2019	O
;	O
Fakih	O
et	O
al	O
.	O
,	O
2020	O
)	O
and	O
increased	O
sensitivity	O
to	O
vasoconstrictors	O
(	O
Elkhatib	O
et	O
al	O
.	O
,	O
2019	O
)	O
,	O
have	O
interacted	O
to	O
confer	O
these	O
changes	O
in	O
ApEn	O
and	O
α	O
.	O
Indeed	O
,	O
these	O
latter	O
observations	O
suggest	O
that	O
HC	O
-	O
fed	O
rats	O
are	O
prone	O
to	O
furnish	O
an	O
increased	O
peripheral	O
vascular	O
resistance	O
commonly	O
reflected	O
by	O
DBPV	O
as	O
a	O
surrogate	O
measure	O
(	O
Carrara	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
From	O
a	O
different	O
perspective	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
showed	O
that	O
females	O
exhibited	O
a	O
more	O
favorable	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
profile	O
compared	O
to	O
males	O
reflecting	O
the	O
sex	O
-	O
based	O
disparity	O
where	O
females	O
are	O
postulated	O
to	O
require	O
a	O
more	O
profound	O
metabolic	O
deterioration	O
prior	O
to	O
significant	O
cardiovascular	O
risk	O
involvement	O
(	O
de	O
Ritter	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Consistently	O
,	O
female	O
rats	O
seemed	O
resistant	O
to	O
diet	O
-	O
induced	O
hyperinsulinemia	O
and	O
fat	O
accumulation	O
and	O
thus	O
had	O
preserved	O
BRS	O
and	O
HRV	O
.	O
Univariate	O
analysis	O
revealed	O
that	O
females	O
possessed	O
lower	O
average	O
and	O
linear	O
fluctuations	O
(	O
SD	O
and	O
CV	O
)	O
of	O
SBP	O
and	O
a	O
lesser	O
degree	O
of	O
self	O
-	O
correlation	O
in	O
SBP	O
and	O
DBP	O
time	O
series	O
.	O
Particularly	O
,	O
on	O
subgroup	O
comparisons	O
,	O
24	O
-	O
week	O
control	O
female	O
rats	O
were	O
shown	O
to	O
possess	O
lower	O
average	O
SBP	O
than	O
males	O
of	O
the	O
same	O
group	O
.	O
Such	O
observations	O
could	O
be	O
possibly	O
attributed	O
to	O
vascular	O
and	O
/	O
or	O
autonomic	O
sex	O
-	O
specific	O
characteristics	O
.	O

On	O
the	O
vascular	O
level	O
,	O
α	O
-	O
adrenergic	O
vasoconstriction	O
was	O
shown	O
to	O
be	O
masked	O
by	O
β	O
-	O
adrenergic	O
vasodilation	O
in	O
females	O
(	O
Hart	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O
Additionally	O
,	O
vagal	O
activity	O
was	O
found	O
to	O
predominate	O
in	O
females	O
as	O
opposed	O
to	O
sympathetic	O
firing	O
in	O
males	O
(	O
Dart	O
et	O
al	O
.	O
,	O
2002	O
;	O
Du	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
sex	O
segregation	O
revealed	O
that	O
HC	O
-	O
induced	O
alterations	O
in	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
were	O
more	O
pronounced	O
in	O
males	O
.	O
Along	O
the	O
same	O
lines	O
,	O
diet	O
-	O
induced	O
sympathovagal	O
imbalance	O
in	O
response	O
to	O
HC	O
feeding	O
(	O
Al	O
-	O
Assi	O
et	O
al	O
.	O
,	O
2018	O
;	O
Hammoud	O
et	O
al	O
.	O
,	O
2021b	O
)	O
can	O
possibly	O
explain	O
sex	O
differences	O
in	O
propensity	O
to	O
aberrations	O
in	O
vascular	O
dynamics	O
(	O
Laitinen	O
et	O
al	O
.	O
,	O
1999	O
)	O
.	O
Indeed	O
,	O
augmented	O
sympathetic	O
activity	O
is	O
associated	O
with	O
increased	O
total	O
peripheral	O
resistance	O
in	O
men	O
but	O
not	O
in	O
women	O
(	O
Hart	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O
The	O
latter	O
is	O
concordant	O
with	O
the	O
observation	O
that	O
changes	O
in	O
diastolic	O
BPV	O
significantly	O
predicted	O
prediabetic	O
disease	O
state	O
.	O
Consistent	O
with	O
our	O
results	O
,	O
such	O
a	O
discrepancy	O
was	O
related	O
to	O
differential	O
fat	O
distribution	O
along	O
with	O
less	O
variable	O
glucose	O
homeostasis	O
and	O
kidney	O
function	O
in	O
women	O
(	O
Barajas	O
Martínez	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
Women	O
are	O
more	O
likely	O
to	O
store	O
fat	O
subcutaneously	O
and	O
on	O
their	O
lower	O
extremities	O
,	O
whereas	O
men	O
are	O
more	O
likely	O
to	O
store	O
fat	O
in	O
the	O
abdominal	O
region	O
(	O
Power	O
and	O
Schulkin	O
,	O
2008	O
)	O
.	O
Not	O
only	O
is	O
visceral	O
adiposity	O
associated	O
with	O
worse	O
metabolic	O
outcomes	O
(	O
Karelis	O
et	O
al	O
.	O
,	O
2004	O
)	O
,	O
but	O
it	O
was	O
also	O
correlated	O
to	O
increased	O
pro	O
-	O
inflammatory	O
cytokine	O
production	O
(	O
Beasley	O
et	O
al	O
.	O
,	O
2009	O
)	O
potentially	O
suggesting	O
a	O
worsened	O
inflammatory	O
-	O
driven	O
cardiovascular	O
outcome	O
in	O
males	O
.	O
Significantly	O
,	O
estrogen	O
receptor	O
α	O
deletion	O
in	O
mice	O
was	O
shown	O
to	O
increase	O
diet	O
-	O
induced	O
adipose	O
inflammation	O
,	O
to	O
which	O
control	O
mice	O
were	O
relatively	O
resistant	O
(	O
Ribas	O
et	O
al	O
.	O
,	O
2010	O
)	O
.	O
Moreover	O
,	O
estrogen	O
signaling	O
was	O
found	O
to	O
produce	O
antiadipogenic	O
and	O
anti	O
-	O
inflammatory	O
effects	O
in	O
perivascular	O
adipose	O
tissues	O
which	O
were	O
associated	O
with	O
amelioration	O
of	O
endothelial	O
function	O
(	O
Sun	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O

Interestingly	O
,	O
diet	O
-	O
induced	O
changes	O
in	O
BPV	O
parameters	O
appeared	O
to	O
be	O
driven	O
mainly	O
by	O
12	O
-	O
week	O
male	O
rats	O
despite	O
a	O
similar	O
decrease	O
in	O
parasympathetic	O
BRS	O
in	O
24	O
-	O
week	O
male	O
rats	O
compared	O
to	O
their	O
control	O
counterparts	O
.	O
This	O
suggests	O
that	O
while	O
BRS	O
reflects	O
cardiovascular	O
involvement	O
in	O
prediabetic	O
metabolic	O
dysfunction	O
,	O
it	O
correlates	O
weakly	O
with	O
beat	O
-	O
to	O
-	O
beat	O
BP	O
dynamics	O
with	O
increasing	O
age	O
.	O
This	O
could	O
be	O
attributed	O
to	O
age	O
-	O
dependent	O
increases	O
and	O
decreases	O
in	O
vascular	O
stiffness	O
and	O
reactivity	O
,	O
respectively	O
,	O
which	O
are	O
stronger	O
determinants	O
of	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
.	O
Results	O
from	O
our	O
study	O
show	O
that	O
different	O
linear	O
and	O
non	O
-	O
linear	O
parameters	O
of	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
possess	O
varying	O
sensitivities	O
to	O
sex	O
and	O
early	O
metabolic	O
impairment	O
.	O
Indeed	O
,	O
nonlinear	O
parameters	O
of	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
,	O
namely	O
ApEn	O
and	O
α	O
,	O
are	O
superior	O
in	O
predicting	O
the	O
early	O
signs	O
of	O
cardiovascular	O
and	O
autonomic	O
dysfunction	O
.	O
These	O
results	O
support	O
the	O
use	O
of	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
assessment	O
as	O
a	O
screening	O
tool	O
for	O
insidious	O
autonomic	O
and	O
vascular	O
dysfunction	O
in	O
early	O
stages	O
of	O
metabolic	O
conditions	O
including	O
prediabetes	O
.	O
Interestingly	O
,	O
our	O
previous	O
work	O
indicates	O
worsening	O
control	O
of	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
on	O
establishment	O
of	O
type	O
2	O
diabetes	O
in	O
the	O
same	O
rat	B-methodology
model	I-methodology
(	O
Bakkar	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Significantly	O
,	O
a	O
limitation	O
of	O
the	O
present	O
study	O
is	O
that	O
the	O
results	O
reflect	O
the	O
processing	O
of	O
data	O
collected	O
by	O
invasive	O
techniques	O
from	O
anesthetized	O
rats	O
.	O
Future	O
work	O
using	O
telemetry	O
recording	O
methods	O
has	O
the	O
potential	O
to	O
reveal	O
more	O
details	O
on	O
the	O
diurnal	O
changes	O
of	O
these	O
parameters	O
in	O
early	O
metabolic	O
dysfunction	O
and	O
thus	O
further	O
highlight	O
these	O
differences	O
.	O
Additionally	O
,	O
direct	O
assessment	O
of	O
sympathetic	O
nerve	O
activity	O
has	O
the	O
capacity	O
to	O
provide	O
insight	O
into	O
the	O
pathophysiological	O
determinants	O
of	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
changes	O
in	O
early	O
metabolic	O
disease	O
(	O
Kuo	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O
Yet	O
,	O
the	O
resilience	O
of	O
the	O
detected	O
differences	O
in	O
face	O
of	O
anesthesia	O
emphasizes	O
the	O
potential	O
diagnostic	O
value	O
of	O
the	O
nonlinear	O
BPV	O
metrics	O
.	O

Indeed	O
,	O
the	O
availability	O
of	O
noninvasive	O
methods	O
to	O
monitor	O
beat	O
-	O
to	O
-	O
beat	O
BP	O
in	O
patients	O
,	O
such	O
as	O
finger	O
plethysmography	O
and	O
tonometry	O
(	O
Kemmotsu	O
et	O
al	O
.	O
,	O
1991	O
)	O
,	O
makes	O
the	O
utility	O
of	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
attractive	O
,	O
especially	O
in	O
the	O
light	O
of	O
studies	O
indicating	O
the	O
validity	O
of	O
noninvasive	O
techniques	O
in	O
comparison	O
to	O
invasive	O
methods	O
(	O
Gibson	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Moreover	O
,	O
the	O
discrepant	O
effect	O
of	O
anesthesia	O
in	O
rats	O
with	O
different	O
fat	O
:	O
lean	O
ratios	O
secondary	O
to	O
HC	O
diet	O
feeding	O
cannot	O
be	O
precluded	O
.	O
Distribution	O
of	O
anesthesia	O
into	O
fat	O
tissues	O
can	O
alter	O
the	O
final	O
effective	O
concentration	O
in	O
HC	O
-	O
fed	O
rats	O
(	O
Brandon	O
and	O
Baggot	O
,	O
1981	O
)	O
.	O
However	O
,	O
in	O
our	O
hands	O
,	O
rats	O
from	O
the	O
different	O
groups	O
reached	O
the	O
same	O
sedative	O
levels	O
before	O
the	O
surgical	O
procedure	O
.	O
It	O
is	O
worth	O
mentioning	O
that	O
studies	O
have	O
indicated	O
that	O
invasive	O
,	O
perioperative	O
beat	O
-	O
to	O
-	O
beat	O
BPV	O
assessment	O
under	O
similar	O
conditions	O
(	O
anesthesia	O
and	O
arterial	O
catheterization	O
)	O
provides	O
valuable	O
information	O
for	O
risk	O
appraisal	O
,	O
making	O
such	O
an	O
assessment	O
reasonably	O
acceptable	O
(	O
Subramaniam	O
et	O
al	O
.	O
,	O
2014	O
;	O
Jinadasa	O
et	O
al	O
.	O
,	O
2018	O
;	O
Putowski	O
et	O
al	O
.	O
,	O
2022	O
)	O
.	O
Extensive	O
future	O
work	O
will	O
be	O
required	O
for	O
the	O
appropriate	O
translation	O
of	O
such	O
findings	O
to	O
clinical	B-methodology
practice	I-methodology
.	O

A	O
Short	O
-	O
Term	O
Feeding	O
of	O
Dietary	O
Casein	O
Increases	O
Abundance	O
of	O
Lactococcus	O
lactis	O
and	O
Upregulates	O
Gene	O
Expression	O
Involving	O
Obesity	O
Prevention	O
in	O
Cecum	O
of	O
Young	O
Rats	O
Compared	O
With	O
Dietary	O
Chicken	O
Protein	O
casein	O
;	O
chicken	O
;	O
Lactococcus	O
lactis	O
;	O
AdipoQ	O
;	O
Irs1	O
Casein	O
and	O
chicken	O
are	O
assessed	O
to	O
contain	O
high	O
quality	O
proteins	O
,	O
which	O
are	O
essential	O
for	O
human	O
health	O
.	O
Studies	O
have	O
shown	O
that	O
ingestion	O
of	O
the	O
two	O
dietary	O
proteins	O
resulted	O
in	O
distinct	O
effects	O
on	O
physiology	O
,	O
liver	O
transcriptome	O
and	O
gut	O
microbiota	O
.	O
However	O
,	O
its	O
underlying	O
mechanism	O
is	O
not	O
fully	O
understood	O
,	O
in	O
particular	O
for	O
a	O
crosstalk	O
between	O
gut	O
microbiota	O
and	O
host	O
under	O
a	O
specific	O
diet	B-methodology
intervention	I-methodology
.	O
We	O
fed	O
young	O
rats	O
with	O
a	O
casein	O
or	O
a	O
chicken	O
protein	O
-	O
based	O
diet	O
(	O
CHPD	O
)	O
for	O
7	O
days	O
,	O
and	O
characterized	O
cecal	O
microbiota	O
composition	O
and	O
cecal	O
gene	O
expression	O
.	O
We	O
found	O
that	O
a	O
short	O
-	O
term	O
intervention	O
with	O
a	O
casein	O
-	O
based	O
diet	O
(	O
CAD	O
)	O
induced	O
a	O
higher	O
relative	O
abundance	O
of	O
beneficial	O
bacterium	O
Lactococcus	O
lactis	O
as	O
well	O
as	O
Bifidobacterium	O
pseudolongum	O
,	O
which	O
upregulated	O
galactose	O
metabolism	O
of	O
the	O
microbiome	O
compared	O
with	O
a	O
CHPD	O
.	O
The	O
CAD	O
also	O
upregulated	O
gene	O
expression	O
involved	O
in	O
obesity	O
associated	O
pathways	O
(	O
e	O
.	O
g	O
.	O
,	O
Adipoq	O
and	O
Irs1	O
)	O
in	O
cecal	O
tissue	O
of	O
rats	O
.	O
These	O
genes	O
and	O
the	O
bacterial	O
taxon	O
were	O
reported	O
to	O
play	O
an	O
important	O
role	O
in	O
protecting	O
development	O
of	O
obesity	O
.	O
Furthermore	O
,	O
the	O
differentially	O
represented	O
bacterial	O
taxon	O
L	O
.	O
lactis	O
was	O
positively	O
associated	O
with	O
these	O
differentially	O
expressed	O
genes	O
in	O
the	O
gut	O
tissue	O
.	O
Our	O
results	O
provide	O
a	O
new	O
insight	O
into	O
the	O
crosstalk	O
between	O
gut	O
microbiota	O
and	O
host	O
in	O
response	O
to	O
dietary	O
proteins	O
,	O
indicating	O
a	O
potential	O
mechanism	O
of	O
obesity	O
prevention	O
function	O
by	O
casein	O
.	O
Meat	O
and	O
dairy	O
products	O
are	O
the	O
major	O
dietary	O
animal	O
protein	O
sources	O
for	O
human	O
nutrition	O
,	O
which	O
contain	O
high	O
quantities	O
and	O
balanced	O
proportions	O
of	O
amino	O
acids	O
relative	O
to	O
human	O
tissues	O
(	O
Li	O
et	O
al	O
.	O
,	O
2011	O
;	O
FAO	O
,	O
2013	O
)	O
.	O
Therefore	O
,	O
adequate	O
consumption	O
of	O
such	O
foods	O
is	O
essential	O
for	O
optimal	O
growth	O
,	O
development	O
,	O
and	O
human	O
health	O
(	O
Wu	O
,	O
2016	O
)	O
.	O
Chicken	O
consumption	O
has	O
grown	O
by	O
70	O
%	O
in	O
developed	O
countries	O
since	O
1990	O
and	O
it	O
becomes	O
one	O
of	O
the	O
most	O
widely	O
consumed	O
meat	O
,	O
indicating	O
its	O
increasing	O
effects	O
on	O
human	O
health	O
.	O

Casein	O
is	O
special	O
for	O
its	O
high	O
content	O
of	O
branched	O
chain	O
amino	O
acids	O
(	O
BCAAs	O
)	O
(	O
Rafiq	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
and	O
has	O
a	O
potential	O
to	O
reduce	O
body	O
mass	O
gain	O
and	O
diet	O
-	O
induced	O
obesity	O
(	O
Lillefosse	O
et	O
al	O
.	O
,	O
2013	O
;	O
Liisberg	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Although	O
chicken	O
protein	O
and	O
casein	O
were	O
assessed	O
as	O
high	O
quality	O
proteins	O
,	O
a	O
short	O
-	O
term	O
intervention	O
from	O
our	O
group	O
demonstrated	O
that	O
the	O
two	O
dietary	O
proteins	O
resulted	O
in	O
distinct	O
physiological	O
and	O
liver	O
transcriptomic	O
changes	O
in	O
young	O
rats	O
(	O
Song	O
et	O
al	O
.	O
,	O
2016b	O
)	O
.	O
A	O
number	O
of	O
studies	O
have	O
shown	O
that	O
there	O
is	O
a	O
close	O
association	O
among	O
obesity	O
,	O
high	O
fat	O
diet	O
and	O
gut	O
microbiota	O
(	O
Martinez	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
However	O
,	O
several	O
long	O
-	O
term	O
animal	B-methodology
studies	I-methodology
have	O
also	O
shown	O
that	O
casein	O
or	O
CHPDs	O
varied	O
in	O
their	O
effects	O
on	O
obesity	O
development	O
in	O
high	O
fat	O
diet	O
fed	O
mice	O
(	O
Liisberg	O
et	O
al	O
.	O
,	O
2016	O
)	O
and	O
gut	O
microbiota	O
in	O
normal	O
fat	O
diet	O
fed	O
rats	O
(	O
Zhu	O
et	O
al	O
.	O
,	O
2015	O
)	O
,	O
indicating	O
a	O
crucial	O
impact	O
of	O
the	O
protein	O
sources	O
.	O
Recently	O
,	O
gut	O
microbiota	O
has	O
been	O
shown	O
to	O
play	O
a	O
critical	O
role	O
in	O
human	O
health	O
by	O
affecting	O
physiology	O
,	O
energy	O
homeostasis	O
or	O
immune	O
system	O
(	O
Rooks	O
and	O
Garrett	O
,	O
2016	O
;	O
Smidt	O
et	O
al	O
.	O
,	O
2016	O
;	O
Gomes	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
Diet	O
intake	O
could	O
determine	O
the	O
diversity	O
and	O
metabolic	O
outputs	O
of	O
the	O
microbial	O
community	O
(	O
Zmora	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Taken	O
together	O
,	O
dietary	O
protein	O
-	O
associated	O
changes	O
in	O
the	O
gut	O
microbiota	O
could	O
be	O
causally	O
linked	O
with	O
host	O
metabolism	O
.	O
However	O
,	O
the	O
associations	O
between	O
gut	O
microbiota	O
and	O
host	O
in	O
response	O
to	O
dietary	O
proteins	O
are	O
less	O
investigated	O
.	O
Also	O
,	O
most	O
of	O
the	O
associated	O
analyses	O
on	O
gut	O
microbiota	O
were	O
conducted	O
based	O
on	O
16s	O
rRNA	O
sequencing	O
,	O
which	O
may	O
cause	O
a	O
bias	O
.	O
In	O
this	O
study	O
,	O
we	O
fed	O
young	O
rats	O
with	O
a	O
casein	O
or	O
a	O
CHPD	O
for	O
7	O
days	O
,	O
and	O
characterized	O
cecal	O
microbiota	O
composition	O
and	O
gene	O
expression	O
in	O
cecal	O
tissue	O
by	O
using	O
shotgun	O
metagenomics	O
and	O
transcriptome	O
sequencing	O
.	O
The	O
associations	O
among	O
gut	O
bacteria	O
,	O
gene	O
expression	O
in	O
cecum	O
tissue	O
and	O
physiological	O
responses	O
were	O
discussed	O
.	O

Protein	O
diets	O
were	O
prepared	O
by	O
Jiangsu	O
Xietong	O
,	O
Inc	O
.	O
,	O
according	O
to	O
the	O
AIN	O
-	O
93G	O
formulation	O
(	O
Reeves	O
et	O
al	O
.	O
,	O
1993	O
)	O
.	O
Casein	O
or	O
chicken	O
protein	O
was	O
included	O
in	O
the	O
diets	O
.	O
To	O
ensure	O
consistency	O
between	O
the	O
diets	O
,	O
most	O
diet	O
ingredients	O
were	O
purchased	O
from	O
Dyets	O
Inc	O
.	O
(	O
Bethlehem	O
,	O
PA	O
,	O
United	O
States	O
)	O
.	O
Chicken	O
protein	O
was	O
prepared	O
as	O
follows	O
.	O
Chicken	O
pectoralis	O
major	O
muscle	O
was	O
cooked	O
in	O
a	O
72°C	O
water	O
bath	O
till	O
a	O
center	O
temperature	O
of	O
70°C	O
.	O
The	O
cooked	O
meat	O
was	O
chilled	O
and	O
minced	O
.	O
Fat	O
was	O
removed	O
in	O
dichloromethane	O
and	O
methanol	O
mixture	O
(	O
1	O
:	O
2	O
,	O
v	O
:	O
v	O
)	O
.	O
Chicken	O
meat	O
powder	O
was	O
then	O
passed	O
through	O
a	O
25	O
screen	O
.	O
The	O
powder	O
consists	O
of	O
proteins	O
(	O
>	O
90	O
%	O
)	O
and	O
a	O
small	O
amount	O
of	O
mineral	O
and	O
other	O
micronutrients	O
.	O
The	O
detailed	O
information	O
of	O
the	O
diet	O
formula	O
was	O
listed	O
in	O
Supplementary	O
Table	O
S1	O
.	O
The	O
animal	B-methodology
experiment	I-methodology
has	O
been	O
previously	O
described	O
(	O
Song	O
et	O
al	O
.	O
,	O
2016b	O
)	O
,	O
and	O
all	O
the	O
experimental	B-methodology
protocols	I-methodology
were	O
approved	O
by	O
the	O
Animal	O
Care	O
Committee	O
of	O
Nanjing	O
Agricultural	O
University	O
.	O
In	O
brief	O
,	O
after	O
a	O
1	O
-	O
week	O
adaptation	O
period	O
,	O
4	O
-	O
week	O
-	O
old	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
fed	O
either	O
a	O
casein	O
-	O
based	O
or	O
a	O
CHPD	O
(	O
10	O
rats	O
each	O
group	O
)	O
.	O
After	O
7	O
days	O
feeding	O
,	O
rats	O
were	O
anesthetized	O
with	O
ether	O
inhalation	O
.	O
Cecal	O
contents	O
and	O
tissues	O
were	O
obtained	O
and	O
snap	O
-	O
frozen	O
separately	O
in	O
liquid	O
nitrogen	O
.	O
Three	O
of	O
the	O
10	O
samples	O
in	O
each	O
group	O
were	O
randomly	O
selected	O
for	O
metagenomic	O
sequencing	O
(	O
cecal	O
contents	O
)	O
and	O
transcriptome	O
(	O
cecal	O
tissues	O
)	O
analyses	O
.	O
Genomic	O
DNA	O
was	O
extracted	O
according	O
to	O
the	O
protocols	O
of	O
Zoetendal	O
et	O
al	O
.	O
(	O
2006	O
)	O
.	O
DNA	O
library	O
construction	O
was	O
performed	O
following	O
the	O
manufacturer	O
’	O
s	O
instruction	O
(	O
Illumina	O
Hiseq	O
2000	O
)	O
.	O
Paired	O
-	O
end	O
DNA	O
libraries	O
was	O
built	O
and	O
sequenced	O
with	O
100	O
bp	O
read	O
length	O
from	O
each	O
end	O
under	O
an	O
Illumina	O
Hiseq2000	O
platform	O
by	O
the	O
standard	O
pipelines	O
.	O
Data	O
filtration	O
was	O
done	O
using	O
in	O
-	O
house	O
scripts	O
according	O
to	O
MOCAT	O
pipeline	O
(	O
Kultima	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Adaptor	O
contamination	O
,	O
low	O
-	O
quality	O
reads	O
,	O
and	O
host	O
contaminating	O
reads	O
were	O
removed	O
from	O
the	O
raw	O
sequencing	O
reads	O
sets	O
.	O
Finally	O
,	O
high	O
-	O
quality	O
data	O
were	O
obtained	O
for	O
metagenomic	O
analysis	O
.	O
Known	O
bacterial	O
sequences	O
were	O
extracted	O
from	O
an	O
NT	O
database	O
,	O
and	O
then	O
,	O
filtered	O
reads	O
were	O
mapped	O
onto	O
these	O
sequences	O
by	O
SOAPaligner	O
(	O
version	O
2	O
.	O
21	O
)	O
(	O
Li	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O
Mapped	O
reads	O
were	O
classified	O
at	O
different	O
taxonomic	O
levels	O
(	O
including	O
phylum	O
,	O
class	O
,	O
order	O
,	O
family	O
,	O
genus	O
,	O
and	O
species	O
)	O
,	O
and	O
the	O
corresponding	O
abundance	O
was	O
summarized	O
.	O
Negative	O
binomial	O
distribution	O
difference	O
test	O
(	O
DEseq2	O
,	O
an	O
R	O
package	O
)	O
was	O
applied	O
for	O
differential	O
analysis	O
of	O
the	O
bacteria	O
between	O
the	O
two	O
dietary	O
groups	O
.	O
The	O
filtered	O
data	O
were	O
assembled	O
by	O
SOAPdenovo	O
(	O
Li	O
et	O
al	O
.	O
,	O
2008	O
)	O
(	O
Version	O
1	O
.	O
061	O
)	O
and	O
assembly	O
results	O
were	O
optimized	O
using	O
an	O
in	O
-	O
house	O
program	O
(	O
BGI	O
,	O
Shenzhen	O
)	O
.	O
MetaGeneMark	O
(	O
version	O
2	O
.	O
10	O
,	O
default	O
parameters2	O
)	O
software	O
was	O
used	O
to	O
predict	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
based	O
on	O
assembly	O
results	O
(	O
Zhu	O
et	O
al	O
.	O
,	O
2010	O
)	O
.	O
ORFs	O
from	O
all	O
samples	O
were	O
combined	O
without	O
redundancy	O
(	O
processed	O
by	O
software	O
cd	O
-	O
hit	O
,	O
4	O
.	O
6	O
.	O
13	O
)	O
(	O
Li	O
and	O
Godzik	O
,	O
2006	O
)	O
to	O
obtain	O
a	O
gene	O
catalog	O
.	O
Sequencing	O
reads	O
were	O
annotated	O
using	O
KEGG	O
Orthology	O
group	O
assignments	O
(	O
Version	O
59	O
)	O
.	O
A	O
DESeq2	O
R	O
package	O
was	O
applied	O
for	O
differential	O
analysis	O
of	O
KEGG	O
Orthology	O
(	O
KO	O
)	O
based	O
on	O
readcount	O
data	O
between	O
the	O
two	O
dietary	O
groups	O
.	O
Gene	O
set	O
enrichment	O
analysis	O
(	O
GSEA	O
)	O
was	O
applied	O
to	O
evaluate	O
changes	O
in	O
gene	O
expression	O
related	O
to	O
biological	O
processes	O
(	O
Subramanian	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O
Gene	O
sets	O
were	O
retrieved	O
from	O
the	O
expert	O
-	O
curated	O
KEGG	O
pathway	O
database4	O
.	O
Total	O
RNA	O
was	O
extracted	O
from	O
cecal	O
tissue	O
by	O
using	O
Takara	O
MiniBEST	O
universal	O
RNA	O
extraction	O
kit	O
(	O
Takara	O
,	O
Kusatsu	O
,	O
Japan	O
)	O
.	O
RNA	O
degradation	O
and	O
contamination	O
was	O
monitored	O
on	O
1	O
%	O
agarose	O
gels	O
.	O
RNA	O
purity	O
was	O
checked	O
using	O
a	O
NanoPhotometer®	O
spectrophotometer	O
(	O
IMPLEN	O
,	O
Los	O
Angeles	O
,	O
CA	O
,	O
United	O
States	O
)	O
.	O

RNA	O
concentration	O
was	O
measured	O
using	O
a	O
Qubit®	O
RNA	O
Assay	O
Kit	O
in	O
Qubit®	O
2	O
.	O
0	O
Fluorometer	O
(	O
Life	O
Technologies	O
,	O
Carlsbad	O
,	O
CA	O
,	O
United	O
States	O
)	O
.	O
RNA	O
integrity	O
was	O
assessed	O
using	O
a	O
RNA	O
Nano	O
6000	O
Assay	O
Kit	O
of	O
the	O
Bioanalyzer	O
2100	O
system	O
(	O
Agilent	O
Technologies	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
United	O
States	O
)	O
.	O
A	O
total	O
amount	O
of	O
3	O
μg	O
RNA	O
per	O
sample	O
was	O
used	O
as	O
input	O
material	O
for	O
the	O
RNA	O
sample	O
preparations	O
.	O
Sequencing	O
libraries	O
were	O
generated	O
using	O
NEBNext®	O
UltraTM	O
RNA	O
Library	O
Prep	O
Kit	O
for	O
Illumina®	O
(	O
NEB	O
,	O
United	O
States	O
)	O
following	O
manufacturer	O
’	O
s	O
recommendations	O
and	O
index	O
codes	O
were	O
added	O
to	O
attribute	O
sequences	O
to	O
each	O
sample	O
.	O
Briefly	O
,	O
mRNA	O
was	O
purified	O
from	O
total	O
RNA	O
using	O
poly	O
-	O
T	O
oligo	O
-	O
attached	O
magnetic	O
beads	O
.	O
Fragmentation	O
was	O
carried	O
out	O
using	O
divalent	O
cations	O
under	O
elevated	O
temperature	O
in	O
NEBNext	O
First	O
Strand	O
Synthesis	O
Reaction	O
Buffer	O
(	O
5X	O
)	O
.	O
First	O
strand	O
cDNA	O
was	O
synthesized	O
using	O
random	O
hexamer	O
primer	O
and	O
M	O
-	O
MuLV	O
Reverse	O
Transcriptase	O
(	O
RNase	O
H	O
–	O
)	O
.	O
Second	O
strand	O
cDNA	O
synthesis	O
was	O
subsequently	O
performed	O
using	O
DNA	O
Polymerase	O
I	O
and	O
RNase	O
H	O
–	O
.	O
Remaining	O
overhangs	O
were	O
converted	O
into	O
blunt	O
ends	O
via	O
exonuclease	O
/	O
polymerase	O
activities	O
.	O
After	O
adenylation	O
of	O
3	O
′	O
ends	O
of	O
DNA	O
fragments	O
,	O
NEBNext	O
Adaptor	O
with	O
hairpin	O
loop	O
structure	O
were	O
ligated	O
to	O
prepare	O
for	O
hybridization	O
.	O
In	O
order	O
to	O
select	O
cDNA	O
fragments	O
of	O
preferentially	O
[UNK]	O
bp	O
in	O
length	O
,	O
the	O
library	O
fragments	O
were	O
purified	O
with	O
AMPure	O
XP	O
system	O
(	O
Beckman	O
Coulter	O
,	O
Beverly	O
,	O
United	O
States	O
)	O
.	O
Then	O
3	O
μl	O
USER	O
Enzyme	O
(	O
NEB	O
,	O
United	O
States	O
)	O
was	O
used	O
with	O
size	O
-	O
selected	O
,	O
adaptor	O
-	O
ligated	O
cDNA	O
at	O
37°C	O
for	O
15	O
min	O
and	O
then	O
increased	O
to	O
95°C	O
and	O
kept	O
for	O
5	O
min	O
.	O
PCR	O
was	O
performed	O
with	O
Phusion	O
High	O
-	O
Fidelity	O
DNA	O
polymerase	O
,	O
Universal	O
PCR	O
primers	O
and	O
Index	O
(	O
X	O
)	O
Primer	O
.	O

Finally	O
,	O
PCR	O
products	O
were	O
purified	O
(	O
AMPure	O
XP	O
system	O
)	O
and	O
library	O
quality	O
was	O
assessed	O
on	O
the	O
Agilent	O
Bioanalyzer	O
2100	O
system	O
(	O
Agilent	O
Technologies	O
,	O
United	O
States	O
)	O
.	O
The	O
clustering	O
of	O
the	O
index	O
-	O
coded	O
samples	O
was	O
performed	O
on	O
a	O
cBot	O
Cluster	O
Generation	O
System	O
using	O
TruSeq	O
PE	O
Cluster	O
Kit	O
v3	O
-	O
cBot	O
-	O
HS	O
(	O
Illumia	O
,	O
United	O
States	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O
After	O
cluster	O
generation	O
,	O
the	O
library	O
preparations	O
were	O
sequenced	O
on	O
an	O
Illumina	O
Hiseq	O
platform	O
(	O
Illumina	O
,	O
United	O
States	O
)	O
and	O
125	O
bp	O
/	O
150	O
bp	O
paired	O
-	O
end	O
reads	O
were	O
generated	O
.	O
Raw	O
data	O
of	O
fastq	O
format	O
were	O
firstly	O
processed	O
through	O
in	O
-	O
house	O
perl	O
scripts	O
.	O
Clean	O
reads	O
were	O
obtained	O
by	O
removing	O
reads	O
containing	O
adapter	O
,	O
ploy	O
-	O
N	O
and	O
low	O
quality	O
reads	O
from	O
raw	O
data	O
.	O
Q20	O
,	O
Q30	O
,	O
and	O
GC	O
content	O
in	O
the	O
clean	O
data	O
were	O
calculated	O
.	O
All	O
the	O
downstream	O
analyses	O
were	O
based	O
on	O
the	O
clean	O
data	O
.	O
Reference	O
genome	O
and	O
gene	O
model	O
annotation	O
files	O
were	O
downloaded	O
from	O
genome	O
website	O
directly	O
.	O
Index	O
of	O
the	O
reference	O
genome	O
was	O
built	O
using	O
Bowtie	O
v2	O
.	O
2	O
.	O
3	O
(	O
Langmead	O
and	O
Salzberg	O
,	O
2012	O
)	O
and	O
paired	O
-	O
end	O
clean	O
reads	O
were	O
aligned	O
to	O
the	O
reference	O
genome	O
using	O
the	O
TopHat	O
v2	O
.	O
0	O
.	O
12	O
(	O
Trapnell	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O
Differential	O
expression	O
analysis	O
was	O
performed	O
on	O
the	O
basis	O
of	O
the	O
negative	O
binomial	O
distribution	O
model	O
using	O
the	O
DESeq2	O
R	O
package	O
(	O
1	O
.	O
24	O
.	O
0	O
)	O
.	O
The	O
resulting	O
P	O
values	O
were	O
adjusted	O
using	O
the	O
Benjamini	O
-	O
Hochberg	O
’	O
s	O
approach	O
for	O
controlling	O
the	O
false	O
discovery	O
rate	O
(	O
FDR	O
)	O
.	O
Genes	O
with	O
an	O
adjusted	O
P	O
value	O
<	O
0	O
.	O
05	O
were	O
assigned	O
as	O
differentially	O
expressed	O
genes	O
.	O
Gene	O
set	O
enrichment	O
analysis	O
was	O
applied	O
to	O
evaluate	O
changes	O
in	O
gene	O
expression	O
related	O
to	O
biological	O
processes	O
(	O
Subramanian	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O
GSEA	O
has	O
multiple	O
advantages	O
over	O
analyses	O
of	O
individual	O
genes	O
(	O
Abatangelo	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O
Gene	O
sets	O
were	O
retrieved	O
from	O
the	O
expert	O
-	O
curated	O
KEGG	O
pathway	O
database	O
(	O
see	O
text	O
footnote	O
4	O
)	O
.	O
Only	O
gene	O
sets	O
consisting	O
of	O
15	O
–	O
500	O
genes	O
were	O
taken	O
into	O
account	O
.	O
For	O
each	O
comparison	O
,	O
genes	O
were	O
ranked	O
on	O
their	O
t	O
-	O
values	O
that	O
were	O
calculated	O
by	O
the	O
empirical	O
Bayes	O
method	O
.	O

Statistical	O
significance	O
of	O
GSEA	O
results	O
was	O
determined	O
using	O
1	O
,	O
000	O
permutations	O
.	O
The	O
Enrichment	O
Map	O
v3	O
.	O
2	O
.	O
0	O
plugin	O
for	O
Cytoscape	O
v3	O
.	O
7	O
.	O
1	O
was	O
used	O
for	O
visualization	O
and	O
interpretation	O
of	O
the	O
GSEA	O
results	O
(	O
Merico	O
et	O
al	O
.	O
,	O
2010	O
)	O
.	O
Enrichment	O
maps	O
were	O
generated	O
with	O
gene	O
sets	O
that	O
passed	O
conservative	O
significance	O
thresholds	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
FDR	O
<	O
0	O
.	O
25	O
)	O
.	O
Total	O
RNA	O
was	O
extracted	O
from	O
cecum	O
tissue	O
using	O
a	O
TaKaRa	O
MiniBEST	O
Universal	O
RNA	O
Extraction	O
Kit	O
(	O
Takara	O
)	O
followed	O
by	O
reverse	O
transcription	O
into	O
cDNA	O
using	O
PrimeScriptTM	O
RT	O
Master	O
Mix	O
(	O
Perfect	O
Real	O
Time	O
)	O
(	O
Takara	O
,	O
Japan	O
)	O
.	O
Quantitative	O
real	O
-	O
time	O
PCR	O
was	O
performed	O
with	O
Applied	O
BiosystemsTM	O
QuantStudioTM	O
6	O
Flex	O
Real	O
-	O
Time	O
PCR	O
System	O
(	O
Life	O
Technologies	O
,	O
Waltham	O
,	O
MA	O
,	O
United	O
States	O
)	O
.	O
Data	O
analysis	O
was	O
according	O
to	O
2	O
–	O
ΔΔCt	O
method	O
(	O
Livak	O
and	O
Schmittgen	O
,	O
2001	O
)	O
.	O
The	O
casein	O
fed	O
group	O
was	O
set	O
as	O
the	O
control	B-methodology
group	I-methodology
.	O
The	O
primers	O
for	O
each	O
specific	O
genes	O
were	O
listed	O
in	O
Supplementary	O
Table	O
S2	O
.	O
Correlation	O
analysis	O
was	O
performed	O
between	O
gut	O
microbiota	O
and	O
host	O
gene	O
expression	O
using	O
mixOmics	O
R	O
package	O
(	O
version	O
6	O
.	O
1	O
.	O
15	O
)	O
(	O
Rohart	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
Correlation	O
coefficients	O
were	O
calculated	O
between	O
all	O
the	O
bacterial	O
species	O
and	O
the	O
top	O
250	O
differentially	O
expressed	O
genes	O
.	O
Bacterial	O
DNA	O
was	O
extracted	O
from	O
cecal	O
contents	O
of	O
rats	O
fed	O
casein	O
and	O
CHPD	O
for	O
7	O
days	O
.	O
DNA	O
was	O
sequenced	O
using	O
metagenome	O
sequencing	O
,	O
which	O
yielded	O
18	O
gigabases	O
(	O
Gb	O
)	O
of	O
high	O
-	O
quality	O
data	O
with	O
an	O
average	O
of	O
3	O
Gb	O
per	O
sample	O
(	O
Supplementary	O
Table	O
S3	O
)	O
.	O
The	O
K	O
-	O
mer	O
frequency	O
distribution	O
analysis	O
showed	O
that	O
the	O
sequencing	O
data	O
were	O
reliable	O
(	O
Supplementary	O
Figure	O
S1	O
)	O
.	O
Great	O
differences	O
were	O
observed	O
in	O
gut	O
microbiota	O
composition	O
in	O
cecum	O
of	O
rats	O
fed	O
with	O
CAD	O
and	O
CHPD	O
.	O
At	O
the	O
phylum	O
level	O
,	O
Firmicutes	O
and	O
Bacteroidetes	O
accounted	O
as	O
average	O
for	O
96	O
.	O
3	O
and	O
80	O
.	O
3	O
%	O
of	O
cecal	O
microbiota	O
in	O
CAD	O
and	O
CHPD	O
groups	O
(	O
Figure	O
1A	O
)	O
.	O

Principle	O
component	O
analysis	O
indicates	O
a	O
distinction	O
of	O
gut	O
microbiota	O
composition	O
in	O
CAD	O
-	O
fed	O
rats	O
from	O
that	O
of	O
CHPD	O
-	O
fed	O
rats	O
(	O
Figure	O
1B	O
)	O
.	O
A	O
negative	O
binomial	O
distribution	O
model	O
was	O
applied	O
to	O
explore	O
the	O
differential	O
microorganisms	O
between	O
the	O
two	O
groups	O
.	O
At	O
the	O
genus	O
level	O
,	O
23	O
bacteria	O
showed	O
significant	O
difference	O
with	O
P	O
values	O
less	O
than	O
0	O
.	O
05	O
(	O
Figure	O
1C	O
)	O
,	O
whereas	O
only	O
the	O
abundance	O
of	O
Lactococcus	O
was	O
found	O
significantly	O
higher	O
in	O
CAD	O
group	O
with	O
an	O
adjusted	O
P	O
value	O
less	O
than	O
0	O
.	O
05	O
(	O
Supplementary	O
Table	O
S4	O
)	O
.	O
At	O
the	O
species	O
level	O
,	O
12	O
bacteria	O
were	O
significantly	O
different	O
.	O
Among	O
these	O
species	O
,	O
Lactococcus	O
lactis	O
was	O
the	O
most	O
variable	O
microorganism	O
between	O
the	O
two	O
groups	O
(	O
Padj	O
<	O
0	O
.	O
05	O
,	O
Figure	O
1D	O
,	O
Supplementary	O
Table	O
S4	O
)	O
.	O
Core	O
microbiome	O
analysis	O
was	O
performed	O
at	O
the	O
species	O
level	O
using	O
MicrobiomeAnalyst	O
in	O
which	O
sample	O
prevalence	O
and	O
relative	O
abundance	O
cut	O
off	O
value	O
were	O
set	O
at	O
20	O
and	O
0	O
.	O
2	O
%	O
,	O
respectively	O
.	O
Thirteen	O
-	O
nine	O
species	O
were	O
identified	O
as	O
the	O
core	O
microbiome	O
.	O
Bacteroides	O
fragilis	O
,	O
which	O
belongs	O
to	O
genus	O
Bacteroides	O
,	O
was	O
the	O
most	O
dominant	O
species	O
among	O
all	O
the	O
samples	O
(	O
Figure	O
2	O
)	O
.	O
The	O
dominance	O
of	O
genus	O
Bacteroides	O
has	O
been	O
considered	O
biomarkers	O
of	O
human	O
diet	O
and	O
lifestyle	O
(	O
Gorvitovskaia	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Of	O
note	O
,	O
L	O
.	O
lactis	O
was	O
the	O
only	O
core	O
species	O
that	O
was	O
significantly	O
different	O
between	O
the	O
two	O
diet	O
groups	O
.	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
analysis	O
further	O
revealed	O
the	O
alteration	O
of	O
pathways	O
in	O
gut	O
microbiota	O
in	O
response	O
to	O
protein	O
diets	O
.	O
Most	O
of	O
the	O
mapped	O
genes	O
were	O
involved	O
in	O
the	O
carbohydrate	O
metabolism	O
,	O
membrane	O
transport	O
,	O
replication	O
and	O
repair	O
,	O
and	O
amino	O
acid	O
metabolism	O
(	O
Figure	O
3A	O
)	O
.	O
A	O
total	O
of	O
19	O
KOs	O
differed	O
between	O
CAD	O
and	O
CHPD	O
,	O
only	O
two	O
of	O
which	O
were	O
significantly	O
higher	O
in	O
CHPD	O
group	O
(	O
Supplementary	O
Table	O
S5	O
,	O
Padj	O
<	O
0	O
.	O
05	O
)	O
.	O
The	O
profile	O
of	O
enriched	O
pathways	O
was	O
analyzed	O
by	O
GSEA	O
to	O
get	O
the	O
differential	O
KEGG	O
pathways	O
in	O
CAD	O
and	O
CHPD	O
(	O
Supplementary	O
Table	O
S6	O
)	O
.	O

CHPD	O
showed	O
more	O
abundant	O
microbial	O
genomes	O
involved	O
in	O
the	O
citrate	O
cycle	O
pathway	O
as	O
compared	O
to	O
CAD	O
,	O
while	O
CAD	O
showed	O
more	O
abundant	O
microbial	O
genomes	O
involved	O
in	O
sulfur	O
,	O
methane	O
and	O
galactose	O
metabolism	O
pathways	O
(	O
Figures	O
3B	O
,	O
C	O
and	O
Supplementary	O
Figure	O
S2	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
RNA	O
was	O
extracted	O
from	O
rat	O
cecum	O
tissue	O
and	O
was	O
sequenced	O
on	O
Illumina	O
HiSeq	O
platform	O
to	O
identify	O
differentially	O
expressed	O
genes	O
.	O
A	O
total	O
of	O
49	O
.	O
88	O
Gb	O
high	O
quality	O
reads	O
were	O
obtained	O
.	O
The	O
quality	O
information	O
of	O
the	O
data	O
is	O
shown	O
in	O
Supplementary	O
Table	O
S7	O
.	O
The	O
samples	O
from	O
CAD	O
and	O
CHPD	O
fed	O
rats	O
were	O
well	O
separated	O
(	O
Figure	O
4A	O
)	O
.	O
There	O
were	O
2524	O
differential	O
expressed	O
genes	O
between	O
the	O
two	O
groups	O
,	O
of	O
which	O
871	O
genes	O
were	O
upregulated	O
in	O
the	O
CHPD	O
group	O
compared	O
with	O
the	O
CAD	O
group	O
(	O
Supplementary	O
Table	O
S8	O
and	O
Figure	O
4B	O
)	O
.	O
A	O
GSEA	O
based	O
on	O
KEGG	O
pathways	O
was	O
conducted	O
to	O
get	O
better	O
understanding	O
of	O
underlying	O
biological	O
processes	O
induced	O
by	O
protein	O
diets	O
.	O
We	O
observed	O
that	O
62	O
KEGG	O
pathways	O
were	O
differentially	O
regulated	O
by	O
diets	O
(	O
P	O
<	O
0	O
.	O
05	O
and	O
FDR	O
<	O
0	O
.	O
25	O
;	O
Figure	O
4C	O
and	O
Supplementary	O
Table	O
S9	O
)	O
.	O
Six	O
pathways	O
were	O
upregulated	O
and	O
56	O
pathways	O
were	O
downregulated	O
by	O
CHPD	O
compared	O
with	O
the	O
CAD	O
group	O
.	O
These	O
pathways	O
are	O
mainly	O
involved	O
in	O
regulation	O
of	O
obesity	O
and	O
lipolysis	O
,	O
including	O
AMPK	O
and	O
PPAR	O
signaling	O
pathways	O
.	O
Adipoq	O
(	O
adiponectin	O
,	O
C1Q	O
and	O
collagen	O
domain	O
containing	O
)	O
and	O
Irs1	O
(	O
Insulin	O
receptor	O
substrate	O
1	O
)	O
may	O
play	O
a	O
critical	O
role	O
in	O
these	O
signaling	O
pathways	O
.	O
Most	O
genes	O
in	O
AMPK	O
and	O
PPAR	O
signaling	O
pathways	O
were	O
downregulated	O
by	O
CHPD	O
,	O
while	O
all	O
differentially	O
expressed	O
genes	O
involving	O
oxidative	O
phosphorylation	O
were	O
upregulated	O
(	O
Figure	O
5	O
)	O
.	O
This	O
is	O
in	O
accordance	O
with	O
the	O
published	O
transcriptomic	O
results	O
in	O
liver	O
(	O
Song	O
et	O
al	O
.	O
,	O
2016b	O
)	O
.	O
Q	O
-	O
PCR	O
analyses	O
of	O
Adipoq	O
,	O
Irs1	O
,	O
Cd36	O
,	O
and	O
Pde3b	O
genes	O
confirmed	O
the	O
results	O
of	O
RNA	O
sequencing	O
.	O

In	O
particular	O
,	O
the	O
Adipoq	O
gene	O
was	O
more	O
highly	O
expressed	O
in	O
CAD	O
than	O
in	O
CHPD	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
Figure	O
6	O
)	O
.	O
Partial	O
least	O
squares	O
regression	O
was	O
applied	O
for	O
correlation	O
analysis	O
between	O
cecal	O
microbiota	O
and	O
gene	O
expression	O
of	O
cecum	O
tissue	O
.	O
Forty	O
-	O
nine	O
species	O
were	O
found	O
to	O
be	O
correlated	O
with	O
148	O
of	O
the	O
top	O
250	O
most	O
variable	O
genes	O
(	O
correlation	O
coefficients	O
were	O
greater	O
than	O
0	O
.	O
85	O
,	O
Supplementary	O
Table	O
S10	O
)	O
.	O
Interestingly	O
,	O
the	O
core	O
variable	O
species	O
L	O
.	O
lactis	O
was	O
positively	O
correlated	O
with	O
those	O
genes	O
such	O
as	O
AdipoQ	O
,	O
Irs1	O
,	O
Cd	O
36	O
,	O
and	O
Pde3b	O
(	O
Figure	O
7	O
)	O
involved	O
in	O
obesity	O
associated	O
pathways	O
.	O
The	O
cecum	O
is	O
a	O
major	O
site	O
for	O
microbial	O
fermentation	O
of	O
dietary	O
components	O
.	O
It	O
also	O
plays	O
a	O
critical	O
role	O
in	O
maintaining	O
intestinal	O
health	O
(	O
Brown	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
Here	O
we	O
reported	O
a	O
comprehensive	O
comparison	O
of	O
the	O
short	O
-	O
term	O
diet	O
effect	O
at	O
a	O
normal	O
dose	O
on	O
the	O
cecal	O
microbiota	O
and	O
gene	O
expression	O
in	O
cecum	O
tissue	O
of	O
young	O
rats	O
.	O
This	O
work	O
relates	O
to	O
several	O
previous	O
studies	O
on	O
the	O
effects	O
of	O
casein	O
and	O
CHPD	O
on	O
the	O
growth	O
performance	O
,	O
lipid	O
metabolism	O
and	O
gut	O
microbiota	O
(	O
Zhu	O
et	O
al	O
.	O
,	O
2015	O
;	O
Liisberg	O
et	O
al	O
.	O
,	O
2016	O
;	O
Song	O
et	O
al	O
.	O
,	O
2016a	O
,	O
b	O
)	O
.	O
However	O
,	O
it	O
is	O
little	O
known	O
how	O
the	O
gut	O
microbiota	O
and	O
gene	O
expression	O
of	O
gut	O
tissue	O
respond	O
to	O
a	O
short	O
-	O
term	O
intervention	O
of	O
dietary	O
proteins	O
.	O
The	O
samples	O
used	O
in	O
the	O
present	O
study	O
were	O
obtained	O
from	O
the	O
same	O
animals	O
as	O
previous	O
studies	O
that	O
focused	O
on	O
the	O
effects	O
of	O
dietary	O
protein	O
sources	O
on	O
the	O
physiology	O
and	O
liver	O
metabolism	O
(	O
Song	O
et	O
al	O
.	O
,	O
2016a	O
,	O
b	O
,	O
c	O
)	O
.	O
Here	O
,	O
the	O
composition	O
of	O
gut	O
microbiota	O
in	O
cecum	O
of	O
CHPD	O
-	O
fed	O
rats	O
was	O
found	O
to	O
be	O
different	O
from	O
that	O
of	O
CAD	O
-	O
fed	O
rats	O
after	O
a	O
short	B-methodology
-	I-methodology
term	I-methodology
diet	I-methodology
intervention	I-methodology
.	O
In	O
practice	O
,	O
diet	O
may	O
alter	O
the	O
gut	O
microbiota	O
within	O
2	O
-	O
day	O
intervention	O
(	O
Biddinger	O
et	O
al	O
.	O
,	O
2014	O
;	O
Zhao	O
et	O
al	O
.	O
,	O
2017	O
;	O
Zmora	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
At	O
the	O
genus	O
level	O
,	O
the	O
abundance	O
of	O
Lactococcus	O
was	O
higher	O
in	O
the	O
CAD	O
group	O
.	O

At	O
the	O
species	O
level	O
,	O
B	O
.	O
fragilis	O
and	O
Parabacteroides	O
distasonis	O
were	O
the	O
top	O
core	O
species	O
.	O
B	O
.	O
fragilis	O
is	O
an	O
important	O
obligate	O
anaerobe	O
that	O
colonizes	O
the	O
mammalian	O
lower	O
intestine	O
(	O
Moore	O
and	O
Holdeman	O
,	O
1974	O
)	O
.	O
P	O
.	O
distasonis	O
was	O
initially	O
classified	O
to	O
the	O
genus	O
Bacteroides	O
but	O
reclassified	O
to	O
genus	O
Parabacteroides	O
(	O
Sakamoto	O
and	O
Benn	O
,	O
2006	O
)	O
,	O
indicating	O
a	O
high	O
similarity	O
between	O
the	O
two	O
species	O
.	O
This	O
could	O
be	O
the	O
reason	O
why	O
they	O
acted	O
similarly	O
as	O
the	O
top	O
core	O
species	O
in	O
the	O
present	O
study	O
.	O
Lactococcus	O
lactis	O
was	O
also	O
identified	O
as	O
a	O
core	O
species	O
,	O
which	O
had	O
a	O
significantly	O
higher	O
abundance	O
in	O
the	O
CAD	O
group	O
.	O
However	O
,	O
in	O
a	O
relatively	O
long	O
term	O
intervening	O
study	O
,	O
we	O
did	O
not	O
characterize	O
the	O
species	O
L	O
.	O
lactis	O
as	O
an	O
indicator	O
for	O
the	O
CAD	O
group	O
(	O
Zhu	O
et	O
al	O
.	O
,	O
2015	O
)	O
.	O
This	O
inconsistence	O
could	O
be	O
due	O
to	O
different	O
sequencing	O
methods	O
.	O
A	O
shotgun	O
metagenomic	O
sequencing	O
was	O
applied	O
in	O
the	O
present	O
study	O
to	O
get	O
the	O
information	O
of	O
metagenomic	O
DNA	O
without	O
amplification	O
,	O
while	O
16S	O
rRNA	O
sequencing	O
contained	O
amplification	O
step	O
,	O
which	O
might	O
cause	O
a	O
bias	O
.	O
Animal	O
age	O
and	O
feeding	O
period	O
may	O
be	O
also	O
the	O
causes	O
for	O
such	O
an	O
inconsistence	O
.	O
In	O
the	O
previous	O
study	O
,	O
4	O
-	O
week	O
-	O
old	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
used	O
,	O
which	O
received	O
a	O
7	O
-	O
day	O
chow	O
diet	O
for	O
acclimatization	O
and	O
then	O
were	O
subjected	O
to	O
3	O
-	O
month	O
diet	B-methodology
intervention	I-methodology
.	O
In	O
the	O
present	O
study	O
,	O
3	O
-	O
week	O
-	O
old	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
used	O
and	O
received	O
7	O
-	O
day	O
chow	O
diet	O
for	O
acclimatization	O
and	O
another	O
7	O
-	O
day	O
diet	B-methodology
intervention	I-methodology
.	O
The	O
sampling	O
time	O
points	O
were	O
18	O
weeks	O
old	O
for	O
the	O
previous	O
study	O
and	O
5	O
weeks	O
old	O
for	O
the	O
present	O
study	O
.	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
analysis	O
revealed	O
the	O
difference	O
in	O
metabolism	O
functions	O
of	O
the	O
cecal	O
microbiota	O
of	O
rats	O
between	O
CAD	O
and	O
CHPD	O
groups	O
.	O
Genes	O
annotated	O
to	O
sulfur	O
metabolism	O
in	O
CAD	O
group	O
were	O
more	O
abundant	O
than	O
those	O
in	O
CHPD	O
group	O
(	O
Figure	O
3C	O
)	O
,	O
which	O
could	O
be	O
attributed	O
to	O
higher	O
content	O
of	O
sulfur	O
-	O
containing	O
amino	O
acid	O
in	O
casein	O
(	O
Supplementary	O
Table	O
S1	O
)	O
.	O

We	O
also	O
found	O
that	O
galactose	O
metabolism	O
was	O
upregulated	O
by	O
CAD	O
.	O
This	O
could	O
be	O
associated	O
with	O
higher	O
abundance	O
of	O
L	O
.	O
lactis	O
,	O
which	O
was	O
reported	O
to	O
utilize	O
lactose	O
(	O
Laroute	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
And	O
the	O
annotated	O
gene	O
lacE	O
(	O
encoding	O
lactose	O
-	O
specific	O
enzyme	O
II	O
of	O
the	O
PTS	O
system	O
,	O
K02787	O
)	O
involving	O
in	O
galactose	O
metabolism	O
widely	O
exists	O
in	O
L	O
.	O
lactis	O
substrains	O
(	O
Passerini	O
et	O
al	O
.	O
,	O
2010	O
;	O
Laroute	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
Although	O
,	O
lactose	O
does	O
not	O
exist	O
in	O
casein	O
,	O
there	O
are	O
some	O
glycoproteins	O
(	O
Gal	O
and	O
GalNAc	O
)	O
in	O
kappacasein	O
that	O
might	O
induce	O
such	O
kind	O
of	O
metabolism	O
(	O
Jollès	O
and	O
Fiat	O
,	O
1979	O
)	O
.	O
Lactococcus	O
lactis	O
is	O
commonly	O
associated	O
with	O
dairy	O
products	O
(	O
Song	O
et	O
al	O
.	O
,	O
2017	O
)	O
,	O
and	O
originated	O
from	O
plants	O
.	O
L	O
.	O
lactis	O
can	O
colonize	O
stably	O
in	O
the	O
intestinal	O
tract	O
because	O
it	O
has	O
mucus	O
/	O
mucin	O
binding	O
proteins	O
on	O
the	O
cell	O
surface	O
(	O
Mercier	O
-	O
Bonin	O
and	O
Chapot	O
-	O
Chartier	O
,	O
2017	O
)	O
.	O
Emerging	O
evidence	O
suggests	O
that	O
the	O
colonization	O
of	O
L	O
.	O
lactis	O
has	O
an	O
impact	O
on	O
gut	O
microbiota	O
and	O
further	O
on	O
host	O
health	O
(	O
Veiga	O
et	O
al	O
.	O
,	O
2014	O
;	O
Derrien	O
and	O
van	O
Hylckama	O
Vlieg	O
,	O
2015	O
)	O
.	O
For	O
example	O
,	O
L	O
.	O
lactis	O
was	O
reported	O
to	O
be	O
responsible	O
for	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
Bifidobacterium	O
cells	O
in	O
fecal	O
samples	O
(	O
Bernbom	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
abundance	O
of	O
Bifidobacterium	O
pseudolongum	O
was	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
the	O
CAD	O
group	O
,	O
which	O
could	O
be	O
induced	O
by	O
L	O
.	O
lactis	O
.	O
Several	O
natural	O
L	O
.	O
lactis	O
isolates	O
have	O
been	O
shown	O
beneficial	O
for	O
health	O
(	O
Mercier	O
-	O
Bonin	O
and	O
Chapot	O
-	O
Chartier	O
,	O
2017	O
;	O
Nakano	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O

Recombinant	O
L	O
.	O
lactis	O
has	O
also	O
been	O
proposed	O
as	O
a	O
delivery	O
vehicle	O
for	O
therapeutic	O
molecules	O
in	O
the	O
gastrointestinal	O
tract	O
(	O
Carvalho	O
et	O
al	O
.	O
,	O
2017	O
)	O
,	O
due	O
to	O
its	O
anti	O
-	O
inflammatory	O
(	O
Nishitani	O
et	O
al	O
.	O
,	O
2009	O
;	O
Bermudez	O
-	O
Humaran	O
et	O
al	O
.	O
,	O
2013	O
;	O
Luerce	O
et	O
al	O
.	O
,	O
2014	O
;	O
Ballal	O
et	O
al	O
.	O
,	O
2015	O
)	O
,	O
anti	O
-	O
cancer	O
(	O
Roeffen	O
et	O
al	O
.	O
,	O
2015	O
)	O
and	O
anti	O
-	O
diabetes	O
properties	O
(	O
Freudenberg	O
et	O
al	O
.	O
,	O
2013	O
;	O
Agarwal	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O
Transcriptome	O
analysis	O
indicated	O
that	O
the	O
casein	O
diet	O
upregulated	O
PPAR	O
signaling	O
pathway	O
,	O
AMPK	O
signaling	O
pathway	O
and	O
lipolysis	O
that	O
are	O
associated	O
with	O
obesity	O
.	O
In	O
addition	O
,	O
PLS	O
-	O
DA	O
analysis	O
showed	O
that	O
the	O
mRNA	O
levels	O
of	O
Adipoq	O
and	O
Irs1	O
were	O
correlated	O
positively	O
with	O
the	O
abundance	O
of	O
the	O
core	O
species	O
L	O
.	O
lactis	O
.	O
The	O
Adipoq	O
gene	O
encodes	O
adiponectin	O
,	O
which	O
modulates	O
a	O
number	O
of	O
metabolic	O
processes	O
,	O
including	O
glucose	O
regulation	O
and	O
fatty	O
acid	O
oxidation	O
(	O
Díez	O
and	O
Iglesias	O
,	O
2003	O
)	O
.	O
Irs1	O
encodes	O
insulin	O
receptor	O
substrate−1	O
,	O
which	O
is	O
a	O
substrate	O
of	O
the	O
insulin	O
receptor	O
tyrosine	O
kinase	O
and	O
plays	O
a	O
central	O
role	O
in	O
the	O
insulin	O
-	O
stimulated	O
signal	O
transduction	O
pathway	O
(	O
Kovacs	O
et	O
al	O
.	O
,	O
2003	O
)	O
.	O
The	O
mRNA	O
levels	O
of	O
these	O
two	O
genes	O
were	O
reported	O
to	O
be	O
inversely	O
correlated	O
with	O
body	O
mass	O
index	O
,	O
insulin	O
resistance	O
and	O
the	O
risk	O
of	O
type	O
2	O
diabetes	O
(	O
Hu	O
et	O
al	O
.	O
,	O
1996	O
;	O
Carvalho	O
et	O
al	O
.	O
,	O
1999	O
;	O
Ukkola	O
and	O
Santaniemi	O
,	O
2002	O
;	O
Kursawe	O
et	O
al	O
.	O
,	O
2010	O
;	O
Freudenberg	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O
L	O
.	O
lactis	O
,	O
Adipoq	O
and	O
Irs1	O
have	O
been	O
shown	O
negatively	O
correlated	O
with	O
obesity	O
development	O
,	O
however	O
,	O
we	O
found	O
strongly	O
positive	O
correlation	O
among	O
relevant	O
variables	O
and	O
its	O
underling	O
mechanism	O
needs	O
to	O
be	O
further	O
explored	O
.	O
Here	O
,	O
we	O
come	O
to	O
the	O
conclusion	O
that	O
the	O
differentially	O
expressed	O
genes	O
and	O
the	O
differentially	O
represented	O
bacterial	O
taxon	O
could	O
regulate	O
lipid	O
metabolism	O
more	O
strongly	O
by	O
CAD	O
than	O
by	O
CHPD	O
,	O
which	O
may	O
prevent	O
host	O
from	O
metabolic	O
diseases	O
.	O

In	O
fact	O
,	O
casein	O
has	O
already	O
been	O
reported	O
as	O
an	O
efficient	O
protein	O
source	O
in	O
preventing	O
against	O
obesity	O
than	O
meat	O
proteins	O
(	O
Smith	O
et	O
al	O
.	O
,	O
2015	O
;	O
Liisberg	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
This	O
could	O
be	O
related	O
to	O
high	O
levels	O
of	O
BCAAs	O
in	O
casein	O
,	O
including	O
valine	O
,	O
leucine	O
and	O
isoleucine	O
.	O
Previous	O
studies	O
indicated	O
that	O
supplementation	O
with	O
BCAAs	O
in	O
diet	O
increased	O
the	O
abundance	O
of	O
Bifidobacterium	O
in	O
gut	O
,	O
and	O
some	O
strains	O
including	O
B	O
.	O
pseudolongum	O
may	O
protect	O
against	O
diet	O
-	O
induced	O
obesity	O
(	O
An	O
et	O
al	O
.	O
,	O
2011	O
;	O
Moya	O
-	O
Pérez	O
et	O
al	O
.	O
,	O
2015	O
;	O
Wang	O
et	O
al	O
.	O
,	O
2015	O
;	O
Li	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
as	O
recently	O
shown	O
for	O
Akkermansia	O
muciniphila	O
(	O
Ottman	O
et	O
al	O
.	O
,	O
2017	O
)	O
and	O
Lactobacillus	O
plantarum	O
(	O
Heeney	O
et	O
al	O
.	O
,	O
2019	O
)	O
,	O
an	O
important	O
route	O
through	O
which	O
intestinal	O
bacteria	O
can	O
benefit	O
body	O
health	O
is	O
by	O
inducing	O
improvements	O
to	O
intestinal	O
epithelial	O
barrier	O
integrity	O
,	O
which	O
could	O
also	O
be	O
a	O
clue	O
for	O
the	O
mechanism	O
exploration	O
in	O
the	O
future	O
.	O
In	O
conclusion	O
,	O
casein	O
and	O
CHPD	O
have	O
a	O
substantial	O
influence	O
on	O
the	O
composition	O
of	O
gut	O
bacteria	O
and	O
gene	O
expression	O
in	O
cecum	O
tissue	O
.	O
A	O
short	O
-	O
term	O
intervention	O
with	O
CAD	O
induced	O
a	O
higher	O
relative	O
abundance	O
of	O
L	O
.	O
Lactis	O
,	O
B	O
.	O
pseudolongum	O
,	O
and	O
higher	O
mRNA	O
levels	O
of	O
genes	O
AdipoQ	O
and	O
Irs1	O
involved	O
in	O
obesity	O
associated	O
pathways	O
compared	O
with	O
CHPD	O
.	O
Further	O
work	O
is	O
required	O
to	O
explore	O
the	O
mechanism	O
of	O
how	O
dietary	O
proteins	O
regulate	O
gut	O
microbiota	O
and	O
gene	O
expression	O
,	O
and	O
confirm	O
the	O
potential	O
mechanism	O
of	O
obesity	O
prevention	O
.	O
The	O
sequencing	O
data	O
are	O
available	O
on	O
NCBI	O
.	O
The	O
shotgun	O
metagenomics	O
sequencing	O
accession	O
ID	O
is	O
PRJNA545455	O
.	O
The	O
transcriptome	O
sequencing	O
data	O
accession	O
ID	O
is	O
GSE131975	O
.	O
All	O
animal	O
experimental	O
protocols	O
were	O
approved	O
by	O
the	O
Animal	O
Care	O
Committee	O
of	O
Nanjing	O
Agricultural	O
University	O
,	O
and	O
the	O
animals	O
were	O
housed	O
in	O
an	O
SPF	O
animal	O
facility	O
(	O
reference	O
number	O
SYXK	O
(	O
Su	O
)	O
2011	O
-	O
0037	O
)	O
.	O
CL	O
,	O
GZ	O
and	O
XX	O
designed	O
the	O
study	O
.	O
FZ	O
and	O
SS	O
carried	O
out	O
the	O
animal	B-methodology
study	I-methodology
and	O
collected	O
samples	O
.	O
YM	O
conducted	O
the	O
RT	O
-	O
PCR	O
verification	O
experiment	O
.	O

FZ	O
performed	O
statistical	O
analyses	O
and	O
produced	O
the	O
figures	O
.	O
FZ	O
and	O
CL	O
wrote	O
the	O
manuscript	O
.	O
The	O
authors	O
declare	O
that	O
the	O
research	O
was	O
conducted	O
in	O
the	O
absence	O
of	O
any	O
commercial	O
or	O
financial	O
relationships	O
that	O
could	O
be	O
construed	O
as	O
a	O
potential	O
conflict	O
of	O
interest	O
.	O
Funding	O
.	O
This	O
work	O
was	O
supported	O
by	O
grants	O
31530054	O
(	O
NSFC	O
)	O
,	O
31471600	O
(	O
NSFC	O
)	O
,	O
PAPD	O
,	O
and	O
B14023	O
.	O

Genetic	O
Background	O
Shapes	O
Phenotypic	O
Response	O
to	O
Diet	O
for	O
Adiposity	O
in	O
the	O
Collaborative	O
Cross	O
collaborative	O
cross	O
;	O
diet	O
;	O
nutrigenomics	O
and	O
nutrigenetics	O
;	O
genetics	O
;	O
obesity	O
Defined	O
as	O
chronic	O
excessive	O
accumulation	O
of	O
adiposity	O
,	O
obesity	O
results	O
from	O
long	O
-	O
term	O
imbalance	O
between	O
energy	O
intake	O
and	O
expenditure	O
.	O
The	O
mechanisms	O
behind	O
how	O
caloric	O
imbalance	O
occurs	O
are	O
complex	O
and	O
influenced	O
by	O
numerous	O
biological	O
and	O
environmental	O
factors	O
,	O
especially	O
genetics	O
,	O
and	O
diet	O
.	O
Population	O
-	O
based	O
diet	O
recommendations	O
have	O
had	O
limited	O
success	O
partly	O
due	O
to	O
the	O
wide	O
variation	O
in	O
physiological	O
responses	O
across	O
individuals	O
when	O
they	O
consume	O
the	O
same	O
diet	O
.	O
Thus	O
,	O
it	O
is	O
necessary	O
to	O
broaden	O
our	O
understanding	O
of	O
how	O
individual	O
genetics	O
and	O
diet	O
interact	O
relative	O
to	O
the	O
development	O
of	O
obesity	O
for	O
improving	O
weight	O
loss	O
treatment	O
.	O
To	O
determine	O
how	O
consumption	O
of	O
diets	O
with	O
different	O
macronutrient	O
composition	O
alter	O
adiposity	O
and	O
other	O
obesity	O
-	O
related	O
traits	O
in	O
a	O
genetically	O
diverse	O
population	O
,	O
we	O
analyzed	O
body	O
composition	O
,	O
metabolic	O
rate	O
,	O
clinical	O
blood	O
chemistries	O
,	O
and	O
circulating	O
metabolites	O
in	O
22	O
strains	O
of	O
mice	O
from	O
the	O
Collaborative	O
Cross	O
(	O
CC	O
)	O
,	O
a	O
highly	O
diverse	O
recombinant	O
inbred	O
mouse	O
population	O
,	O
before	O
and	O
after	O
8	O
weeks	O
of	O
feeding	O
either	O
a	O
high	O
protein	O
or	O
high	O
fat	O
high	O
sucrose	O
diet	O
.	O
At	O
both	O
baseline	O
and	O
post	O
-	O
diet	O
,	O
adiposity	O
and	O
other	O
obesity	O
-	O
related	O
traits	O
exhibited	O
a	O
broad	O
range	O
of	O
phenotypic	O
variation	O
based	O
on	O
CC	O
strain	O
;	O
diet	O
-	O
induced	O
changes	O
in	O
adiposity	O
and	O
other	O
traits	O
also	O
depended	O
largely	O
on	O
CC	O
strain	O
.	O
In	O
addition	O
to	O
estimating	O
heritability	O
at	O
baseline	O
,	O
we	O
also	O
quantified	O
the	O
effect	O
size	O
of	O
diet	O
for	O
each	O
trait	O
,	O
which	O
varied	O
by	O
trait	O
and	O
experimental	O
diet	O
.	O
Our	O
findings	O
identified	O
CC	O
strains	O
prone	O
to	O
developing	O
obesity	O
,	O
demonstrate	O
the	O
genotypic	O
and	O
phenotypic	O
diversity	O
of	O
the	O
CC	O
for	O
studying	O
complex	O
traits	O
,	O
and	O
highlight	O
the	O
importance	O
of	O
accounting	O
for	O
genetic	O
differences	O
when	O
making	O
dietary	O
recommendations	O
.	O
Obesity	O
is	O
a	O
complex	O
disease	O
characterized	O
by	O
excessive	O
adipose	O
tissue	O
accumulation	O
and	O
has	O
become	O
one	O
of	O
the	O
leading	O
preventable	O
causes	O
of	O
death	O
in	O
both	O
developed	O
and	O
developing	O
countries	O
(	O
Bell	O
et	O
al	O
.	O
,	O
2005	O
;	O
Friedman	O
,	O
2015	O
;	O
WHO	O
,	O
2015	O
)	O
.	O
Fundamentally	O
,	O
obesity	O
results	O
from	O
a	O
chronic	O
imbalance	O
between	O
energy	O
intake	O
and	O
expenditure	O
(	O
Hill	O
et	O
al	O
.	O
,	O
2012	O
;	O
Romieu	O
et	O
al	O
.	O
,	O
2017	O
;	O
Swift	O
et	O
al	O
.	O
,	O
2018	O
;	O
Oussaada	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O

This	O
imbalance	O
is	O
caused	O
by	O
numerous	O
biological	O
factors	O
including	O
:	O
genetics	O
(	O
Bell	O
et	O
al	O
.	O
,	O
2005	O
;	O
Singh	O
et	O
al	O
.	O
,	O
2017	O
;	O
Loos	O
,	O
2018	O
)	O
,	O
metabolism	O
(	O
Timper	O
and	O
Brüning	O
,	O
2017	O
;	O
Speakman	O
,	O
2018	O
;	O
Fernández	O
-	O
Verdejo	O
et	O
al	O
.	O
,	O
2019	O
)	O
,	O
and	O
the	O
gut	O
microbiome	O
(	O
John	O
and	O
Mullin	O
,	O
2016	O
;	O
Martinez	O
et	O
al	O
.	O
,	O
2016	O
;	O
Torres	O
-	O
Fuentes	O
et	O
al	O
.	O
,	O
2017	O
)	O
,	O
as	O
well	O
as	O
environmental	O
factors	O
such	O
as	O
chemical	O
exposure	O
(	O
Janesick	O
and	O
Blumberg	O
,	O
2016	O
;	O
Heindel	O
and	O
Blumberg	O
,	O
2019	O
;	O
Shahnazaryan	O
et	O
al	O
.	O
,	O
2019	O
)	O
and	O
diet	O
,	O
particularly	O
in	O
the	O
context	O
of	O
overfeeding	O
relative	O
to	O
physical	O
activity	O
levels	O
(	O
Sims	O
,	O
1976	O
;	O
Danforth	O
,	O
1985	O
;	O
Schmidt	O
et	O
al	O
.	O
,	O
2012	O
;	O
Cuthbertson	O
et	O
al	O
.	O
,	O
2017	O
;	O
Creasy	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
Identification	O
of	O
the	O
underlying	O
genes	O
predisposing	O
an	O
individual	O
to	O
obesity	O
has	O
been	O
a	O
very	O
active	O
area	O
of	O
investigation	O
.	O
Large	O
-	O
scale	O
human	O
genome	B-methodology
-	I-methodology
wide	I-methodology
association	I-methodology
studies	I-methodology
(	O
GWAS	B-methodology
)	O
that	O
test	O
the	O
association	O
of	O
millions	O
of	O
genetic	O
variants	O
with	O
adiposity	O
,	O
body	O
mass	O
index	O
,	O
and	O
waist	O
-	O
to	O
-	O
hip	O
ratio	O
have	O
identified	O
>	O
300	O
genetic	O
loci	O
for	O
obesity	O
traits	O
,	O
such	O
as	O
the	O
FTO	O
,	O
TMEM18	O
,	O
CADM2	O
,	O
and	O
LYPLAL1	O
loci	O
,	O
among	O
others	O
(	O
Loos	O
et	O
al	O
.	O
,	O
2008	O
;	O
González	O
-	O
Muniesa	O
et	O
al	O
.	O
,	O
2017	O
;	O
Loos	O
,	O
2018	O
)	O
.	O
Complementing	O
approaches	O
in	O
humans	O
,	O
studies	O
in	O
mice	O
have	O
provided	O
fundamental	O
insights	O
into	O
the	O
genetic	O
regulation	O
of	O
adiposity	O
and	O
susceptibility	O
to	O
obesity	O
(	O
Coleman	O
and	O
Hummel	O
,	O
1974	O
;	O
Lu	O
et	O
al	O
.	O
,	O
1994	O
;	O
Carroll	O
et	O
al	O
.	O
,	O
2004	O
;	O
Attie	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
For	O
example	O
,	O
the	O
genes	O
that	O
encode	O
leptin	O
and	O
leptin	O
receptor	O
which	O
arose	O
as	O
spontaneous	O
deficiency	O
mutations	O
in	O
ob	O
/	O
ob	O
and	O
db	O
/	O
db	O
obese	O
mice	O
respectively	O
(	O
Ingalls	O
et	O
al	O
.	O
,	O
1950	O
;	O
Hummel	O
et	O
al	O
.	O
,	O
1966	O
)	O
were	O
shown	O
to	O
regulate	O
satiety	O
after	O
gene	O
cloning	O
was	O
possible	O
(	O
Zhang	O
et	O
al	O
.	O
,	O
1994	O
;	O
Tartaglia	O
et	O
al	O
.	O
,	O
1995	O
)	O
.	O

Similarly	O
,	O
the	O
link	O
between	O
the	O
FTO	O
gene	O
and	O
obesity	O
was	O
first	O
reported	O
in	O
mice	O
prior	O
to	O
the	O
identification	O
of	O
this	O
gene	O
'	O
s	O
association	O
with	O
obesity	O
in	O
humans	O
(	O
Fischer	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O
The	O
similar	O
biology	O
between	O
humans	O
and	O
mice	O
in	O
terms	O
of	O
physiology	O
,	O
morphology	O
,	O
and	O
genetics	O
,	O
and	O
the	O
ability	O
to	O
manipulate	O
the	O
mouse	O
genome	O
has	O
aided	O
our	O
understanding	O
of	O
the	O
underlying	O
mechanisms	O
affecting	O
energy	O
balance	O
and	O
obesity	O
(	O
Robinson	O
et	O
al	O
.	O
,	O
2000	O
;	O
Pomp	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O
Similarly	O
,	O
diet	O
is	O
among	O
the	O
most	O
studied	O
environmental	O
factors	O
,	O
as	O
it	O
remains	O
an	O
important	O
and	O
potentially	O
successful	O
focus	O
of	O
public	O
health	O
interventions	O
(	O
Wilborn	O
et	O
al	O
.	O
,	O
2005	O
;	O
Eknoyan	O
,	O
2006	O
;	O
Makris	O
and	O
Foster	O
,	O
2011	O
)	O
.	O
One	O
of	O
the	O
difficulties	O
identifying	O
the	O
optimal	O
dietary	O
recommendation	O
for	O
a	O
population	O
is	O
the	O
inter	O
-	O
individual	O
variation	O
observed	O
in	O
response	O
to	O
diet	O
(	O
Berry	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
At	O
a	O
certain	O
level	O
there	O
may	O
be	O
no	O
“	O
perfect	O
”	O
diet	O
that	O
works	O
universally	O
across	O
populations	O
to	O
mitigate	O
obesity	O
(	O
Dansinger	O
et	O
al	O
.	O
,	O
2005	O
;	O
Johnston	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O
Thus	O
,	O
in	O
spite	O
of	O
the	O
successes	O
of	O
GWAS	B-methodology
and	O
dietary	B-methodology
intervention	I-methodology
studies	I-methodology
,	O
there	O
still	O
remains	O
practical	O
public	O
health	O
challenges	O
for	O
understanding	O
and	O
preventing	O
obesity	O
.	O
Animal	B-methodology
models	I-methodology
often	O
solve	O
some	O
of	O
the	O
challenges	O
by	O
limiting	O
confounding	O
environmental	O
influences	O
to	O
gain	O
a	O
more	O
complete	O
understanding	O
of	O
the	O
etiology	O
of	O
obesity	O
.	O
Studies	O
performed	O
using	O
inbred	O
mouse	O
strains	O
suggest	O
that	O
phenotypic	O
response	O
to	O
diet	O
occurs	O
in	O
a	O
strain	O
-	O
dependent	O
manner	O
(	O
West	O
et	O
al	O
.	O
,	O
1992	O
,	O
1995	O
;	O
Barrington	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
Understanding	O
the	O
interaction	O
of	O
genetics	O
and	O
diet	O
offers	O
insight	O
into	O
how	O
“	O
precision	O
nutrition	O
”	O
could	O
improve	O
and	O
refine	O
our	O
dietary	O
recommendations	O
.	O

In	O
order	O
to	O
broaden	O
our	O
understanding	O
of	O
how	O
genetics	O
and	O
diet	O
impact	O
obesity	O
at	O
both	O
the	O
individual	O
and	O
population	O
levels	O
in	O
a	O
genetically	O
diverse	O
population	O
,	O
we	O
analyzed	O
how	O
consumption	O
of	O
diets	O
with	O
different	O
macronutrient	O
compositions	O
altered	O
adiposity	O
and	O
other	O
physiological	O
traits	O
in	O
22	O
strains	O
of	O
mice	O
from	O
the	O
Collaborative	O
Cross	O
(	O
CC	O
)	O
,	O
a	O
large	O
recombinant	O
inbred	O
mouse	O
population	O
generated	O
from	O
elaborate	O
intercrosses	O
of	O
C57BL	O
/	O
6J	O
,	O
A	O
/	O
J	O
,	O
NOD	O
/	O
ShiLtJ	O
,	O
NZO	O
/	O
HiLtJ	O
,	O
129S1	O
/	O
SvImJ	O
,	O
WSB	O
/	O
EiJ	O
,	O
CAST	O
/	O
EiJ	O
,	O
and	O
PWK	O
/	O
PhJ	O
,	O
mouse	O
strains	O
(	O
Churchill	O
et	O
al	O
.	O
,	O
2004	O
;	O
Iraqi	O
et	O
al	O
.	O
,	O
2008	O
;	O
Threadgill	O
and	O
Churchill	O
,	O
2012	O
)	O
.	O
The	O
tremendous	O
genetic	O
diversity	O
of	O
the	O
CC	O
population	O
(	O
Philip	O
et	O
al	O
.	O
,	O
2011	O
;	O
Collaborative	O
Cross	O
Consortium	O
,	O
2012	O
;	O
Srivastava	O
et	O
al	O
.	O
,	O
2017	O
;	O
Shorter	O
et	O
al	O
.	O
,	O
2019	O
)	O
facilitates	O
the	O
discernment	O
between	O
effects	O
caused	O
by	O
diet	O
from	O
effects	O
caused	O
by	O
genetic	O
variation	O
when	O
measuring	O
differences	O
and	O
changes	O
in	O
adiposity	O
and	O
other	O
metabolic	O
traits	O
across	O
multiple	O
genetic	O
“	O
replicates	O
”	O
in	O
each	O
strain	O
,	O
thereby	O
increasing	O
power	O
,	O
reproducibility	O
,	O
and	O
relevance	O
to	O
obesity	O
in	O
humans	O
(	O
Mathes	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O
Following	O
a	O
2	O
-	O
week	O
acclimation	O
period	O
on	O
standard	O
synthetic	O
diet	O
(	O
AIN	O
-	O
76A	O
)	O
to	O
determine	O
baseline	O
phenotypes	O
,	O
mice	O
between	O
8	O
and	O
11	O
weeks	O
of	O
age	O
were	O
randomized	O
and	O
put	O
on	O
experimental	O
diets	O
(	O
high	O
fat	O
high	O
sucrose	O
or	O
high	O
protein	O
)	O
for	O
8	O
weeks	O
,	O
followed	O
by	O
analysis	O
of	O
body	O
composition	O
,	O
metabolic	O
rate	O
,	O
clinical	O
blood	O
chemistries	O
,	O
and	O
circulating	O
metabolites	O
to	O
assess	O
the	O
effect	O
of	O
diet	O
on	O
each	O
trait	O
since	O
diets	O
with	O
higher	O
protein	O
,	O
low	O
glycemic	O
index	O
,	O
and	O
lower	O
fat	O
content	O
may	O
assist	O
in	O
maintaining	O
weight	O
loss	O
compared	O
to	O
diets	O
with	O
higher	O
carbohydrate	O
content	O
(	O
Abete	O
et	O
al	O
.	O
,	O
2010	O
;	O
Larsen	O
et	O
al	O
.	O
,	O
2010	O
;	O
Hu	O
et	O
al	O
.	O
,	O
2018	O
;	O
Myrmel	O
et	O
al	O
.	O
,	O
2019	O
;	O
San	O
-	O
Cristobal	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
While	O
both	O
genetics	O
and	O
diet	O
interact	O
to	O
influence	O
adiposity	O
and	O
other	O
phenotypes	O
,	O
health	O
outcomes	O
were	O
more	O
strongly	O
impacted	O
by	O
genetic	O
effects	O
than	O
diet	O
.	O

Furthermore	O
,	O
the	O
effect	O
of	O
diet	O
on	O
each	O
trait	O
varied	O
depending	O
on	O
CC	O
strain	O
,	O
indicating	O
that	O
genetics	O
determine	O
how	O
a	O
particular	O
diet	O
may	O
affect	O
body	O
composition	O
.	O
Female	O
mice	O
from	O
22	O
CC	O
strains	O
were	O
obtained	O
in	O
2016	O
from	O
University	O
of	O
North	O
Carolina	O
'	O
s	O
Systems	O
Genetics	O
Core	O
Facility	O
(	O
Welsh	O
et	O
al	O
.	O
,	O
2012	O
)	O
(	O
total	O
n	O
=	O
204	O
,	O
Figure	O
1	O
)	O
.	O
All	O
strains	O
used	O
are	O
listed	O
in	O
Supplementary	O
Table	O
1	O
.	O
Mice	O
were	O
then	O
acclimated	O
for	O
2	O
weeks	O
on	O
standard	O
synthetic	O
diet	O
(	O
AIN	O
-	O
76A	O
)	O
,	O
housed	O
three	O
mice	O
per	O
cage	O
at	O
22°C	O
with	O
non	O
-	O
irradiated	O
pine	O
bedding	O
,	O
and	O
provided	O
free	O
access	O
to	O
sterile	O
water	O
in	O
a	O
climate	O
-	O
controlled	O
facility	O
under	O
a	O
12	O
-	O
h	O
light	O
/	O
dark	O
cycle	O
.	O
Mice	O
were	O
put	O
on	O
experimental	O
diets	O
between	O
8	O
and	O
11	O
weeks	O
of	O
age	O
after	O
the	O
2	O
-	O
week	O
acclimation	O
period	O
,	O
randomized	O
into	O
different	O
cages	O
by	O
experimental	O
diet	O
(	O
Supplementary	O
Figure	O
1	O
,	O
Supplementary	O
Table	O
1	O
)	O
,	O
and	O
housed	O
under	O
the	O
same	O
conditions	O
.	O
After	O
randomization	O
,	O
mice	O
were	O
challenged	O
on	O
their	O
respective	O
diets	O
for	O
8	O
weeks	O
,	O
and	O
analysis	O
of	O
body	O
composition	O
,	O
metabolic	O
rate	O
,	O
and	O
physical	O
activity	O
were	O
performed	O
at	O
the	O
UNC	O
Animal	O
Metabolism	O
Phenotyping	O
Core	O
post	O
diet	B-methodology
challenge	I-methodology
(	O
methods	O
for	O
analysis	O
of	O
body	O
composition	O
,	O
metabolic	O
rate	O
,	O
and	O
physical	O
activity	O
described	O
below	O
)	O
followed	O
by	O
necropsy	O
and	O
tissue	O
collection	O
.	O
Because	O
only	O
a	O
limited	O
number	O
of	O
mice	O
were	O
available	O
at	O
one	O
time	O
,	O
experiments	O
spanning	O
11	O
weeks	O
(	O
2	O
weeks	O
of	O
acclimation	O
,	O
8	O
weeks	O
of	O
diet	B-methodology
challenge	I-methodology
,	O
post	O
-	O
diet	O
phenotype	O
assessments	O
)	O
for	O
each	O
“	O
batch	O
”	O
were	O
performed	O
in	O
7	O
batches	O
,	O
where	O
each	O
batch	O
contained	O
about	O
33	O
mice	O
on	O
average	O
,	O
except	O
for	O
batch	O
6	O
which	O
contained	O
14	O
mice	O
.	O
All	O
mice	O
were	O
maintained	O
on	O
their	O
respective	O
experimental	O
diets	O
for	O
the	O
remainder	O
of	O
the	O
study	O
using	O
protocols	O
in	O
accordance	O
with	O
the	O
University	O
of	O
North	O
Carolina	O
Institution	O
Animal	O
Care	O
and	O
Use	O
Committee	O
guidelines	B-methodology
.	O
All	O
maintenance	O
protocols	O
and	O
experimental	O
procedures	O
were	O
approved	O
by	O
the	O
IACUC	O
at	O
University	O
of	O
North	O
Carolina	O
(	O
UNC	O
)	O
Chapel	O
Hill	O
(	O
IACUC	O
Protocol	O
Number	O
:	O
13	O
-	O
103	O
)	O
.	O

During	O
the	O
2	O
-	O
week	O
acclimation	O
period	O
,	O
mice	O
were	O
maintained	O
on	O
the	O
defined	O
synthetic	O
diet	O
containing	O
20	O
.	O
8	O
%	O
kcal	O
protein	O
,	O
67	O
.	O
7	O
%	O
kcal	O
carbohydrate	O
,	O
and	O
11	O
.	O
5	O
%	O
kcal	O
fat	O
,	O
referred	O
to	O
as	O
AIN	O
-	O
76A	O
in	O
this	O
study	O
(	O
D10001	O
,	O
Research	O
Diets	O
,	O
New	O
Brunswick	O
,	O
NJ	O
;	O
Supplementary	O
Table	O
2	O
)	O
until	O
8	O
–	O
11	O
weeks	O
of	O
age	O
to	O
account	O
for	O
differences	O
due	O
to	O
variable	O
components	O
of	O
standard	O
chow	O
.	O
Subsequently	O
,	O
one	O
sibling	O
from	O
each	O
of	O
the	O
102	O
sibling	O
trios	O
was	O
randomly	B-methodology
assigned	I-methodology
to	O
each	O
experimental	O
diet	O
(	O
Supplementary	O
Table	O
1	O
)	O
.	O
One	O
hundred	O
and	O
two	O
mice	O
were	O
transferred	O
to	O
a	O
synthetic	O
high	O
fat	O
high	O
sucrose	O
diet	O
(	O
HS	O
)	O
containing	O
16	O
.	O
8	O
%	O
kcal	O
protein	O
,	O
51	O
.	O
4	O
%	O
kcal	O
carbohydrate	O
,	O
and	O
31	O
.	O
8	O
%	O
kcal	O
fat	O
,	O
and	O
102	O
mice	O
were	O
placed	O
on	O
a	O
high	O
protein	O
diet	O
(	O
HP	O
)	O
containing	O
40	O
%	O
kcal	O
protein	O
,	O
40	O
%	O
kcal	O
carbohydrate	O
and	O
20	O
%	O
kcal	O
fat	O
(	O
D12266B	O
and	O
D12083101	O
,	O
respectively	O
,	O
Supplementary	O
Table	O
2	O
;	O
Research	O
Diets	O
,	O
New	O
Brunswick	O
,	O
NJ	O
)	O
.	O
Body	O
composition	O
(	O
lean	O
and	O
fat	O
mass	O
)	O
was	O
assessed	O
in	O
all	O
cohorts	B-methodology
during	O
the	O
first	O
week	O
of	O
the	O
acclimation	O
phase	O
to	O
establish	O
baseline	O
phenotypes	O
,	O
as	O
well	O
as	O
after	O
8	O
weeks	O
of	O
the	O
experimental	O
diet	B-methodology
challenge	I-methodology
using	O
the	O
Echo	O
MRI	O
-	O
130	O
Body	O
Composition	O
Analyzer	O
(	O
EchoMRI	O
,	O
Houston	O
,	O
TX	O
,	O
USA	O
)	O
.	O
Body	O
fat	O
and	O
lean	O
mass	O
percentages	O
were	O
calculated	O
by	O
dividing	O
fat	O
mass	O
by	O
scale	O
weight	O
and	O
dividing	O
lean	O
mass	O
by	O
scale	O
weight	O
,	O
respectively	O
.	O
Mice	O
were	O
placed	O
into	O
individual	O
indirect	O
calorimetry	O
cages	O
(	O
Phenomaster	O
,	O
TSE	O
SYSTEMS	O
,	O
Chesterfield	O
,	O
MO	O
)	O
the	O
week	O
immediately	O
following	O
the	O
8	O
weeks	O
of	O
the	O
experimental	O
diet	B-methodology
challenge	I-methodology
for	O
~	O
3	O
days	O
and	O
two	O
nights	O
(	O
~	O
48	O
h	O
)	O
to	O
obtain	O
O2	O
consumption	O
and	O
CO2	O
production	O
,	O
activity	O
,	O
and	O
feed	O
and	O
water	O
consumption	O
measurements	O
.	O
After	O
an	O
8	O
-	O
h	O
acclimation	O
period	O
,	O
data	O
were	O
collected	O
for	O
two	O
complete	O
12	O
-	O
h	O
night	O
cycles	O
and	O
one	O
complete	O
12	O
-	O
h	O
day	O
cycle	O
every	O
42	O
min	O
(	O
Supplementary	O
Figure	O
2	O
)	O
.	O
Basal	O
activity	O
was	O
measured	O
in	O
three	O
dimensions	O
(	O
x	O
,	O
y	O
,	O
and	O
z	O
)	O
as	O
breaks	O
in	O
the	O
two	O
infrared	O
light	O
beam	O
frames	O
that	O
surrounded	O
each	O
cage	O
.	O

Rearing	O
was	O
detected	O
by	O
beam	O
breaks	O
in	O
the	O
z	O
axis	O
and	O
total	O
physical	O
activity	O
was	O
defined	O
as	O
the	O
sum	O
of	O
beam	O
breaks	O
in	O
all	O
three	O
axes	O
in	O
counts	O
.	O
Feed	O
and	O
water	O
were	O
available	O
ad	O
libitum	O
and	O
consumption	O
was	O
measured	O
by	O
weighing	O
sensors	O
that	O
held	O
containers	O
for	O
feed	O
and	O
water	O
,	O
respectively	O
,	O
and	O
recorded	O
the	O
amount	O
of	O
feed	O
or	O
water	O
consumed	O
.	O
Spilled	O
feed	O
and	O
water	O
were	O
caught	O
by	O
extended	O
attachments	O
on	O
the	O
feed	O
and	O
water	O
containers	O
suspended	O
from	O
the	O
weighing	O
sensors	O
,	O
so	O
spilled	O
feed	O
and	O
water	O
were	O
not	O
recorded	O
as	O
consumed	O
.	O
Heat	O
production	O
calculations	O
were	O
performed	O
two	O
ways	O
by	O
the	O
TSE	O
software	O
(	O
LabMaster	O
)	O
using	O
O2	O
consumption	O
and	O
CO2	O
production	O
measurements	O
:	O
(	O
1	O
)	O
for	O
the	O
computation	O
of	O
total	O
body	O
weight	O
(	O
kcal	O
/	O
h	O
/	O
kg	O
)	O
,	O
and	O
(	O
2	O
)	O
for	O
the	O
computation	O
of	O
an	O
exponent	O
lean	O
body	O
mass	O
assigned	O
to	O
total	O
body	O
weight	O
(	O
kcal	O
/	O
h	O
/	O
kg	O
)	O
.	O
From	O
the	O
exported	O
raw	O
data	O
,	O
energy	O
consumption	O
was	O
calculated	O
by	O
multiplying	O
feed	O
consumption	O
measurement	O
(	O
in	O
grams	O
)	O
by	O
the	O
calorie	O
(	O
kcal	O
)	O
content	O
per	O
gram	O
feed	O
for	O
each	O
diet	O
(	O
Supplementary	O
Table	O
2	O
)	O
.	O
Protein	O
,	O
carbohydrate	O
,	O
and	O
fat	O
consumption	O
were	O
calculated	O
by	O
multiplying	O
the	O
feed	O
consumption	O
measurement	O
(	O
in	O
grams	O
)	O
by	O
macronutrient	O
content	O
(	O
in	O
grams	O
)	O
per	O
total	O
gram	O
of	O
feed	O
.	O
For	O
example	O
,	O
the	O
average	O
protein	O
consumption	O
for	O
mice	O
on	O
the	O
high	O
protein	O
diet	O
was	O
calculated	O
by	O
multiplying	O
the	O
measured	O
feed	O
consumed	O
(	O
g	O
)	O
by	O
(	O
40	O
.	O
6	O
g	O
protein	O
/	O
90	O
.	O
3	O
g	O
feed	O
total	O
)	O
.	O
Individual	O
and	O
combined	O
diurnal	O
means	O
were	O
calculated	O
for	O
each	O
metabolic	O
measurement	O
using	O
data	O
collected	O
at	O
time	O
points	O
between	O
the	O
start	O
and	O
end	O
times	O
of	O
the	O
day	O
cycle	O
.	O
Likewise	O
,	O
individual	O
and	O
combined	O
nocturnal	O
means	O
were	O
calculated	O
for	O
each	O
metabolic	O
measurement	O
using	O
data	O
collected	O
at	O
time	O
points	O
between	O
the	O
start	O
and	O
end	O
times	O
of	O
the	O
night	O
cycle	O
(	O
Supplementary	O
Figure	O
2	O
)	O
.	O
Means	O
for	O
each	O
measure	O
were	O
also	O
calculated	O
by	O
date	O
,	O
e	O
.	O
g	O
.	O
,	O
mean	O
of	O
feed	O
consumption	O
for	O
both	O
light	O
and	O
dark	O
cycles	O
on	O
the	O
second	O
day	O
of	O
the	O
experiment	O
.	O
Tail	O
clippings	O
and	O
blood	O
samples	O
were	O
collected	O
immediately	O
before	O
putting	O
mice	O
on	O
experimental	O
diets	O
to	O
establish	O
baseline	O
values	O
.	O
To	O
collect	O
tail	O
clippings	O
,	O
tail	O
tips	O
were	O
cleaned	O
with	O
70	O
%	O
ethanol	O
,	O
and	O
up	O
to	O
5	O
mm	O
of	O
the	O
tail	O
tips	O
were	O
excised	O
with	O
sterile	O
scissors	O
and	O
placed	O
in	O
2	O
ml	O
screw	O
-	O
cap	O
tubes	O
.	O

After	O
8	O
weeks	O
on	O
experimental	O
diets	O
,	O
mice	O
were	O
anesthetized	O
via	O
isoflurane	O
inhalation	O
and	O
euthanized	O
using	O
cervical	O
dislocation	O
during	O
the	O
necropsy	O
following	O
a	O
4	O
-	O
h	O
fast	O
.	O
Blood	O
,	O
kidney	O
,	O
liver	O
,	O
subcutaneous	O
and	O
gonadal	O
fat	O
,	O
and	O
cecum	O
samples	O
were	O
collected	O
(	O
Figure	O
1	O
)	O
.	O
Blood	O
samples	O
were	O
collected	O
via	O
retro	O
-	O
orbital	O
bleed	O
with	O
heparinized	O
capillary	O
tubes	O
into	O
EDTA	O
tubes	O
,	O
placed	O
on	O
ice	O
,	O
and	O
centrifuged	O
at	O
6	O
,	O
000	O
rpm	O
for	O
10	O
min	O
at	O
4°C	O
for	O
plasma	O
collection	O
.	O
Plasma	O
was	O
then	O
transferred	O
to	O
1	O
.	O
5	O
ml	O
Eppendorf	O
tubes	O
.	O
Tissues	O
were	O
placed	O
in	O
2	O
ml	O
screw	O
-	O
cap	O
tubes	O
and	O
snap	O
frozen	O
in	O
liquid	O
nitrogen	O
.	O
All	O
plasma	O
,	O
frozen	O
tissues	O
,	O
and	O
previously	O
collected	O
samples	O
were	O
stored	O
at	O
−80°C	O
.	O
Additional	O
gonadal	O
fat	O
,	O
kidney	O
,	O
and	O
liver	O
tissues	O
were	O
fixed	O
in	O
capped	O
glass	O
vials	O
containing	O
10	O
%	O
formalin	O
and	O
stored	O
at	O
room	O
temperature	O
.	O
Cholesterol	O
,	O
triglyceride	O
(	O
TG	O
)	O
,	O
glucose	O
,	O
albumin	O
,	O
creatinine	O
,	O
urea	O
,	O
aspartate	O
transaminase	O
(	O
AST	O
)	O
,	O
and	O
alanine	O
transaminase	O
(	O
ALT	O
)	O
levels	O
were	O
quantified	O
using	O
the	O
Cobas	O
Integra	O
400	O
Plus	O
(	O
Roche	O
Diagnostics	O
,	O
Indianapolis	O
,	O
IN	O
)	O
,	O
according	O
to	O
manufacturer	O
'	O
s	O
instructions	O
.	O
An	O
internal	O
control	O
(	O
Human	O
UTAK	O
)	O
was	O
used	O
to	O
assess	O
run	O
variation	O
.	O
Baseline	O
and	O
post	O
-	O
diet	O
circulating	O
insulin	O
were	O
measured	O
using	O
ultrasensitive	O
mouse	O
insulin	O
ELISA	O
(	O
ALPCO	O
Diagnostics	O
,	O
Salem	O
,	O
NH	O
)	O
per	O
manufacturer	O
'	O
s	O
instructions	O
except	O
for	O
the	O
following	O
adjustment	O
:	O
15	O
μl	O
of	O
plasma	O
sample	O
dilutions	O
were	O
used	O
in	O
the	O
assay	O
and	O
back	O
calculations	O
were	O
performed	O
to	O
determine	O
actual	O
plasma	O
concentrations	O
.	O
Insulin	O
optical	O
density	O
(	O
OD	O
)	O
was	O
measured	O
at	O
450	O
nm	O
using	O
a	O
spectrophotometric	O
BioTek	O
Synergy	O
2	O
plate	O
reader	O
(	O
BioTek	O
Instruments	O
Inc	O
,	O
Winooski	O
,	O
VT	O
)	O
.	O
Insulin	O
concentrations	O
were	O
derived	O
from	O
measured	O
ODs	O
using	O
BioTek	O
'	O
s	O
Gen5	O
software	O
.	O

Baseline	O
and	O
post	O
-	O
diet	O
circulating	O
trimethylamine	O
N	O
-	O
oxide	O
(	O
TMAO	O
)	O
,	O
choline	O
,	O
phosphocholine	O
,	O
betaine	O
,	O
and	O
carnitine	O
were	O
quantified	O
using	O
liquid	O
chromatography	O
–	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
)	O
methods	O
described	O
by	O
Wang	O
et	O
al	O
.	O
(	O
2014	O
)	O
with	O
modifications	O
.	O
Standards	O
ranging	O
from	O
0	O
to	O
100	O
μM	O
of	O
non	O
-	O
deuterated	O
analytes	O
in	O
methanol	O
were	O
run	O
in	O
order	O
to	O
establish	O
analyte	O
standard	O
curves	O
.	O
Two	O
-	O
fold	O
serial	O
dilutions	O
of	O
a	O
100	O
μM	O
stock	O
solution	O
in	O
methanol	O
was	O
used	O
to	O
make	O
13	O
standards	O
.	O
5	O
μM	O
of	O
surrogate	O
standard	O
(	O
SSTD	O
)	O
were	O
prepared	O
comprising	O
of	O
deuterated	O
analytes	O
in	O
methanol	O
.	O
All	O
standards	O
were	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
.	O
All	O
reagent	O
solvents	O
were	O
mass	O
spectrometry	O
grade	O
and	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Waltham	O
,	O
MA	O
)	O
.	O
Details	O
of	O
the	O
protocol	O
are	O
contained	O
in	O
the	O
data	O
supplement	O
and	O
Supplementary	O
Table	O
3	O
.	O
All	O
phenotype	O
data	O
were	O
tested	O
for	O
normality	O
using	O
the	O
Shapiro	O
-	O
Wilk	O
test	O
in	O
the	O
statistical	O
programming	O
language	O
R	O
(	O
R	O
Core	O
Team	O
,	O
2019	O
)	O
.	O
Baseline	O
non	O
-	O
normal	O
data	O
were	O
transformed	O
using	O
power	O
transformation	O
or	O
rank	O
normalization	O
if	O
necessary	O
before	O
linear	O
fixed	O
models	O
were	O
fitted	O
using	O
CC	O
strain	O
and	O
mouse	O
batch	O
(	O
“	O
week	O
”	O
in	O
Supplementary	O
File	O
2	O
)	O
as	O
fixed	O
effects	O
to	O
test	O
for	O
significant	O
CC	O
strain	O
effects	O
on	O
phenotypic	O
variance	O
.	O
Post	O
-	O
diet	O
non	O
-	O
normal	O
data	O
were	O
also	O
normalized	O
using	O
these	O
methods	O
as	O
appropriate	O
for	O
fitting	O
linear	O
mixed	O
models	O
using	O
restricted	O
maximum	O
likelihood	O
(	O
REML	O
)	O
to	O
determine	O
the	O
significance	O
of	O
the	O
effect	O
of	O
diet	O
and	O
strain	O
/	O
diet	O
interactions	O
.	O
To	O
test	O
for	O
the	O
significance	O
of	O
the	O
effect	O
of	O
diet	O
underlying	O
phenotypic	O
variance	O
,	O
linear	O
mixed	O
model	O
analysis	O
of	O
the	O
relationship	O
between	O
diet	O
and	O
phenotypic	O
traits	O
was	O
performed	O
using	O
R	O
and	O
packages	O
lme4	O
(	O
Bates	O
et	O
al	O
.	O
,	O
2015	O
)	O
,	O
lmerTest	O
(	O
Kuznetsova	O
et	O
al	O
.	O
,	O
2017	O
)	O
,	O
and	O
car	O
(	O
Fox	O
and	O
Weisberg	O
,	O
2019	O
)	O
for	O
each	O
post	O
-	O
diet	O
phenotype	O
.	O

For	O
models	O
testing	O
diet	O
as	O
the	O
main	O
effect	O
,	O
fixed	O
effects	O
included	O
experimental	O
diet	O
and	O
mouse	O
batch	O
,	O
and	O
random	O
effects	O
(	O
intercepts	O
)	O
included	O
CC	O
strain	O
,	O
CC	O
strain	O
×	O
experimental	O
diet	O
,	O
randomization	O
cage	O
nested	O
within	O
experimental	O
diet	O
,	O
and	O
baseline	O
cage	O
nested	O
within	O
CC	O
strain	O
.	O
In	O
models	O
used	O
to	O
test	O
for	O
the	O
significance	O
of	O
the	O
effect	O
of	O
strain	O
/	O
diet	O
interactions	O
,	O
linear	O
mixed	O
models	O
were	O
fit	O
for	O
each	O
post	O
-	O
diet	O
phenotype	O
,	O
which	O
included	O
CC	O
strain	O
,	O
experimental	O
diet	O
,	O
CC	O
strain	O
×	O
experimental	O
diet	O
,	O
and	O
mouse	O
batch	O
as	O
fixed	O
effects	O
,	O
and	O
randomization	O
cage	O
nested	O
within	O
experimental	O
diet	O
and	O
baseline	O
cage	O
nested	O
within	O
CC	O
strain	O
as	O
random	O
effects	O
(	O
intercepts	O
)	O
.	O
Visual	O
inspection	O
of	O
residual	O
plots	O
did	O
not	O
reveal	O
obvious	O
deviations	O
from	O
homoscedasticity	O
or	O
normality	O
.	O
P	O
-	O
values	O
were	O
obtained	O
by	O
implementing	O
Satterthwaite	O
approximations	O
as	O
described	O
by	O
Luke	O
(	O
2016	O
)	O
.	O
Metabolic	O
health	O
scores	O
were	O
calculated	O
for	O
all	O
mice	O
at	O
baseline	O
and	O
9	O
weeks	O
post	O
-	O
diet	O
.	O
First	O
,	O
Z	O
scores	O
were	O
calculated	O
for	O
several	O
metabolic	O
risk	O
factors	O
(	O
circulating	O
glucose	O
,	O
insulin	O
,	O
glucose	O
/	O
insulin	O
ratio	O
,	O
cholesterol	O
,	O
TG	O
,	O
and	O
body	O
fat	O
%	O
)	O
measured	O
at	O
baseline	O
and	O
post	O
-	O
diet	O
for	O
each	O
mouse	O
;	O
the	O
distribution	O
used	O
to	O
calculate	O
the	O
Z	O
score	O
for	O
baseline	O
was	O
all	O
baseline	O
samples	O
,	O
while	O
samples	O
were	O
separated	O
by	O
diet	O
before	O
calculating	O
post	O
-	O
diet	O
Z	O
scores	O
.	O
Next	O
,	O
the	O
Z	O
scores	O
for	O
each	O
metabolic	O
risk	O
factor	O
were	O
added	O
together	O
,	O
and	O
then	O
multiplied	O
by	O
−1	O
so	O
that	O
decreased	O
health	O
is	O
reflected	O
by	O
a	O
lower	O
health	O
score	O
.	O
From	O
linear	O
models	O
fitted	O
using	O
baseline	O
normalized	O
data	O
with	O
CC	O
strain	O
and	O
mouse	O
batch	O
as	O
the	O
covariates	O
used	O
to	O
test	O
for	O
significant	O
CC	O
strain	O
effects	O
on	O
phenotypic	O
variance	O
(	O
described	O
above	O
)	O
,	O
broad	O
-	O
sense	O
heritability	O
(	O
H2	O
)	O
was	O
estimated	O
for	O
each	O
phenotype	O
by	O
calculating	O
the	O
intraclass	O
correlation	O
(	O
rI	O
)	O
and	O
the	O
coefficient	O
of	O
genetic	O
determination	O
(	O
g2	O
)	O
using	O
derived	O
values	O
for	O
mean	O
square	O
between	O
(	O
MSB	O
)	O
strains	O
and	O
mean	O
square	O
within	O
(	O
MSW	O
)	O
strains	O
(	O
Festing	O
,	O
1979	O
)	O
.	O

rI	O
may	O
be	O
interpreted	O
as	O
the	O
proportion	O
of	O
total	O
phenotypic	O
variation	O
that	O
is	O
accounted	O
for	O
by	O
differences	O
between	O
strains	O
,	O
while	O
g2	O
accounts	O
for	O
the	O
additive	O
genetic	O
variance	O
that	O
doubles	O
during	O
inbreeding	O
(	O
Festing	O
,	O
1979	O
;	O
Falconer	O
,	O
1989	O
;	O
Lightfoot	O
et	O
al	O
.	O
,	O
2001	O
)	O
,	O
so	O
g2	O
is	O
a	O
more	O
appropriate	O
estimate	O
for	O
broad	O
sense	O
heritability	O
in	O
this	O
study	O
.	O
However	O
,	O
other	O
studies	O
sometimes	O
only	O
provide	O
one	O
estimate	O
or	O
the	O
other	O
,	O
so	O
we	O
have	O
included	O
both	O
values	O
to	O
facilitate	O
comparisons	O
with	O
other	O
findings	O
in	O
the	O
literature	O
.	O
rI	O
and	O
g2	O
were	O
calculated	O
using	O
the	O
following	O
formulas	O
,	O
where	O
n	O
is	O
the	O
number	O
of	O
mice	O
per	O
strain	O
:	O
The	O
number	O
of	O
mice	O
per	O
strain	O
varies	O
in	O
this	O
study	O
,	O
so	O
n	O
was	O
calculated	O
as	O
:	O
where	O
a	O
is	O
the	O
number	O
of	O
strains	O
,	O
ni	O
is	O
the	O
number	O
of	O
mice	O
in	O
the	O
ith	O
strain	O
,	O
and	O
N	O
is	O
the	O
total	O
number	O
of	O
mice	O
(	O
samples	O
)	O
per	O
phenotype	O
.	O
Post	O
-	O
diet	O
broad	O
-	O
sense	O
heritability	O
estimates	O
(	O
H2	O
)	O
were	O
calculated	O
for	O
each	O
trait	O
to	O
contrast	O
the	O
proportion	O
of	O
relative	O
heritable	O
variation	O
attributed	O
to	O
genetics	O
or	O
diet	O
,	O
and	O
to	O
assess	O
whether	O
different	O
diet	O
“	O
environments	O
”	O
affect	O
heritability	O
.	O
Post	O
-	O
diet	O
intraclass	O
correlation	O
(	O
rI	O
)	O
values	O
and	O
the	O
coefficients	O
of	O
genetic	O
determination	O
(	O
g2	O
)	O
were	O
calculated	O
using	O
the	O
formulas	O
above	O
and	O
the	O
MSB	O
and	O
MSW	O
derived	O
from	O
four	O
different	O
linear	O
models	O
:	O
(	O
1	O
)	O
a	O
“	O
full	O
”	O
additive	O
model	O
with	O
strain	O
,	O
diet	O
,	O
and	O
week	O
as	O
variables	O
fitted	O
with	O
phenotype	O
data	O
from	O
both	O
experimental	O
diets	O
,	O
(	O
2	O
)	O
a	O
“	O
partial	O
”	O
additive	O
model	O
including	O
strain	O
and	O
week	O
as	O
variables	O
(	O
diet	O
excluded	O
)	O
fitted	O
with	O
phenotype	O
data	O
from	O
both	O
experimental	O
diets	O
,	O
(	O
3	O
)	O
a	O
“	O
HP	O
”	O
additive	O
model	O
including	O
strain	O
and	O
week	O
as	O
variables	O
fitted	O
with	O
phenotype	O
data	O
from	O
only	O
mice	O
fed	O
the	O
HP	O
diet	O
,	O
and	O
(	O
4	O
)	O
a	O
“	O
HS	O
”	O
additive	O
model	O
including	O
strain	O
and	O
week	O
as	O
variables	O
fitted	O
with	O
phenotype	O
data	O
from	O
only	O
mice	O
fed	O
the	O
HS	O
diet	O
.	O
H2	O
estimates	O
derived	O
from	O
models	O
fitted	O
with	O
data	O
from	O
all	O
mice	O
post	O
-	O
diet	O
compare	O
the	O
contribution	O
of	O
genetics	O
(	O
strain	O
)	O
and	O
diet	O
overall	O
to	O
heritable	O
phenotypic	O
variance	O
,	O
while	O
diet	O
-	O
specific	O
H2	O
estimates	O
were	O
calculated	O
to	O
discern	O
differences	O
in	O
heritability	O
affected	O
by	O
differences	O
in	O
macronutrient	O
composition	O
.	O

Linear	O
mixed	O
models	O
with	O
strain	O
,	O
diet	O
,	O
and	O
strain	O
x	O
diet	O
interactions	O
as	O
random	O
effects	O
(	O
intercepts	O
)	O
were	O
fitted	O
using	O
all	O
post	O
-	O
diet	O
phenotype	O
data	O
for	O
body	O
fat	O
%	O
and	O
obesity	O
-	O
related	O
traits	O
to	O
quantify	O
the	O
relative	O
heritable	O
variation	O
attributed	O
to	O
genetics	O
,	O
diet	O
,	O
and	O
gene	O
×	O
diet	O
interactions	O
based	O
on	O
the	O
variance	O
of	O
each	O
term	O
in	O
the	O
model	O
.	O
The	O
approximate	O
values	O
for	O
the	O
proportion	O
of	O
variance	O
for	O
strain	O
,	O
diet	O
,	O
and	O
interaction	O
were	O
calculated	O
by	O
dividing	O
the	O
variance	O
for	O
each	O
term	O
by	O
the	O
sum	O
of	O
the	O
variance	O
for	O
all	O
terms	O
in	O
the	O
model	O
(	O
including	O
residuals	O
)	O
.	O
To	O
quantify	O
size	O
effects	O
of	O
diet	O
on	O
each	O
trait	O
,	O
Hedges	O
'	O
g	O
values	O
for	O
the	O
HP	O
diet	O
were	O
calculated	O
by	O
using	O
the	O
baseline	O
-	O
specific	O
(	O
AIN	O
-	O
76A	O
)	O
mean	O
of	O
the	O
phenotype	O
minus	O
the	O
HP	O
-	O
specific	O
mean	O
of	O
the	O
phenotype	O
(	O
M1	O
-	O
M2	O
)	O
,	O
and	O
then	O
dividing	O
this	O
value	O
by	O
the	O
weighted	O
pooled	O
standard	O
deviation	O
(	O
SD	O
)	O
for	O
the	O
two	O
groups	O
(	O
Ellis	O
,	O
2009	O
)	O
:	O
The	O
weighted	O
pooled	O
SDs	O
was	O
calculated	O
using	O
the	O
following	O
equation	O
where	O
n1	O
=	O
the	O
number	O
of	O
samples	O
from	O
mice	O
on	O
the	O
AIN	O
-	O
76A	O
diet	O
and	O
n2	O
=	O
the	O
number	O
of	O
samples	O
from	O
mice	O
on	O
the	O
HP	O
diet	O
:	O
Calculations	O
for	O
Hedges	O
'	O
g	O
were	O
performed	O
using	O
the	O
following	O
function	O
from	O
the	O
effsize	O
package	O
in	O
R	O
(	O
Torchiano	O
,	O
2019	O
)	O
,	O
with	O
pooled	O
weighted	O
SD	O
,	O
unpaired	O
samples	O
,	O
removed	O
NA	O
entries	O
and	O
a	O
95	O
%	O
confidence	O
interval	O
,	O
where	O
d	O
=	O
phenotype	O
measurements	O
and	O
f	O
=	O
experimental	O
diets	O
:	O
cohen	O
.	O
d	O
(	O
d	O
,	O
f	O
,	O
pooled	O
=	O
TRUE	O
,	O
paired	O
=	O
FALSE	O
,	O
na	O
.	O
rm	O
=	O
TRUE	O
,	O
hedges	O
.	O
correction	O
=	O
TRUE	O
,	O
conf	O
.	O
level	O
=	O
0	O
.	O
95	O
)	O
.	O
Corrected	O
Hedges	O
'	O
g	O
effect	O
sizes	O
are	O
presented	O
as	O
standard	O
deviation	O
units	O
so	O
that	O
a	O
Hedges	O
'	O
g	O
value	O
of	O
1	O
indicates	O
that	O
the	O
baseline	O
diet	O
and	O
respective	O
experimental	O
diet	O
differ	O
by	O
1	O
standard	O
deviation	O
,	O
a	O
g	O
of	O
2	O
indicates	O
they	O
differ	O
by	O
2	O
standard	O
deviations	O
,	O
and	O
so	O
on	O
with	O
the	O
sign	O
indicating	O
the	O
direction	O
of	O
change	O
between	O
diets	O
.	O
Positive	O
Hedges	O
'	O
g	O
indicates	O
increased	O
phenotype	O
values	O
post	O
-	O
diet	O
compared	O
to	O
baseline	O
,	O
e	O
.	O
g	O
.	O
body	O
fat	O
%	O
was	O
increased	O
from	O
baseline	O
in	O
mice	O
after	O
feeding	O
them	O
the	O
HP	O
diet	O
.	O

Magnitude	O
descriptions	O
are	O
based	O
on	O
the	O
following	O
cut	O
-	O
offs	O
of	O
|	O
g	O
|	O
:	O
negligible	O
<	O
0	O
.	O
2	O
<	O
small	O
<	O
0	O
.	O
5	O
<	O
medium	O
<	O
0	O
.	O
8	O
<	O
large	O
.	O
Hedges	O
'	O
g	O
values	O
were	O
calculated	O
for	O
the	O
HS	O
diet	O
for	O
each	O
trait	O
using	O
the	O
same	O
method	O
.	O
To	O
further	O
quantify	O
the	O
effect	O
size	O
of	O
diet	O
,	O
we	O
also	O
calculated	O
the	O
intraclass	O
correlation	O
(	O
ICC	O
)	O
for	O
diet	O
using	O
the	O
mean	O
square	O
between	O
(	O
MSB	O
)	O
diets	O
and	O
mean	O
square	O
within	O
(	O
MSW	O
)	O
diets	O
derived	O
from	O
post	O
-	O
diet	O
linear	O
models	O
including	O
strain	O
,	O
diet	O
,	O
and	O
week	O
as	O
variables	O
,	O
using	O
the	O
following	O
formula	O
where	O
n	O
=	O
number	O
of	O
mice	O
on	O
each	O
diet	O
:	O
The	O
ICC	O
for	O
diet	O
can	O
be	O
interpreted	O
as	O
the	O
proportion	O
of	O
the	O
total	O
phenotypic	O
variation	O
that	O
is	O
accounted	O
for	O
by	O
differences	O
between	O
diet	O
.	O
Phenotype	O
data	O
for	O
metabolic	O
traits	O
were	O
viewed	O
in	O
histograms	O
to	O
check	O
for	O
normality	O
of	O
the	O
distributions	O
,	O
revealing	O
skewness	O
and	O
non	O
-	O
normality	O
.	O
Thus	O
,	O
Wilcoxon	O
signed	O
rank	O
tests	O
with	O
continuity	O
correction	O
were	O
performed	O
instead	O
of	O
student	O
'	O
s	O
t	O
-	O
tests	O
using	O
the	O
following	O
function	O
from	O
the	O
stats	O
package	O
in	O
R	O
(	O
R	O
Core	O
Team	O
,	O
2019	O
)	O
,	O
with	O
paired	O
samples	O
and	O
a	O
95	O
%	O
confidence	O
interval	O
,	O
where	O
day	O
=	O
diurnal	O
metabolic	O
trait	O
data	O
and	O
night	O
=	O
corresponding	O
nocturnal	O
metabolic	O
trait	O
data	O
:	O
wilcox	O
.	O
test	O
(	O
day	O
,	O
night	O
,	O
paired	O
=	O
TRUE	O
,	O
conf	O
.	O
int	O
=	O
TRUE	O
)	O
.	O
All	O
statistical	O
analyses	O
were	O
performed	O
in	O
R	O
(	O
R	O
Core	O
Team	O
,	O
2019	O
)	O
.	O
Summary	O
statistics	O
were	O
calculated	O
for	O
all	O
phenotypic	O
data	O
,	O
include	O
means	O
and	O
standard	O
error	O
(	O
SE	O
)	O
.	O
Spearman	O
'	O
s	O
correlations	O
were	O
performed	O
to	O
determine	O
significant	O
relationships	O
between	O
traits	O
at	O
baseline	O
and	O
post	O
-	O
diet	O
.	O
To	O
ascertain	O
the	O
magnitude	O
of	O
the	O
effect	O
of	O
diet	O
behind	O
gene	O
x	O
environmental	O
effects	O
found	O
for	O
each	O
trait	O
in	O
our	O
linear	O
mixed	O
models	O
,	O
Spearman	O
'	O
s	O
correlation	O
analysis	O
was	O
performed	O
between	O
the	O
F	O
-	O
statistic	O
of	O
the	O
gene	O
x	O
diet	O
interactions	O
of	O
our	O
models	O
and	O
Hedges	O
'	O
effect	O
size	O
for	O
both	O
diets	O
(	O
|	O
g	O
|	O
)	O
.	O

Each	O
trait	O
was	O
categorized	O
as	O
either	O
largely	O
affected	O
by	O
diet	O
(	O
|	O
g	O
|	O
>	O
0	O
.	O
8	O
)	O
or	O
not	O
(	O
|	O
g	O
|	O
<	O
0	O
.	O
8	O
)	O
,	O
and	O
significantly	O
affected	O
by	O
gene	O
x	O
diet	O
interactions	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
or	O
not	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
,	O
followed	O
by	O
Chi	O
square	O
analysis	O
of	O
whether	O
the	O
effect	O
size	O
of	O
diet	O
and	O
the	O
gene	O
x	O
environment	O
are	O
significantly	O
related	O
for	O
the	O
given	O
trait	O
.	O
Baseline	O
values	O
for	O
adiposity	O
(	O
synonymous	O
with	O
body	O
fat	O
%	O
in	O
this	O
study	O
)	O
,	O
clinical	O
blood	O
chemistries	O
,	O
and	O
circulating	O
metabolites	O
were	O
established	O
to	O
assess	O
the	O
degree	O
of	O
phenotypic	O
variation	O
due	O
to	O
genetic	O
background	O
of	O
the	O
CC	O
strain	O
(	O
see	O
Methods	O
and	O
Figure	O
1	O
)	O
.	O
Adiposity	O
and	O
circulating	O
metabolic	O
health	O
marker	O
levels	O
exhibited	O
wide	O
ranges	O
of	O
phenotypic	O
variation	O
by	O
CC	O
strain	O
(	O
Figure	O
2	O
)	O
and	O
there	O
was	O
a	O
wide	O
range	O
of	O
adiposity	O
in	O
the	O
CC	O
population	O
ranging	O
from	O
1	O
.	O
1	O
to	O
29	O
.	O
8	O
%	O
body	O
fat	O
,	O
with	O
strain	O
CC019	O
/	O
TauUnc	O
least	O
susceptible	O
to	O
obesity	O
(	O
average	O
body	O
fat	O
4	O
.	O
4	O
±	O
0	O
.	O
6	O
%	O
)	O
and	O
strain	O
CC028	O
/	O
GeniUnc	O
most	O
susceptible	O
(	O
average	O
body	O
fat	O
23	O
.	O
1	O
±	O
1	O
.	O
5	O
%	O
)	O
(	O
Figure	O
2A	O
)	O
.	O
Similarly	O
,	O
there	O
was	O
a	O
wide	O
range	O
in	O
average	O
weight	O
across	O
the	O
CC	O
lines	O
ranging	O
from	O
12	O
.	O
4	O
±	O
0	O
.	O
2	O
g	O
in	O
strain	O
CC019	O
/	O
TauUnc	O
to	O
23	O
.	O
7	O
±	O
1	O
.	O
0	O
g	O
in	O
line	O
CC011	O
/	O
Unc	O
(	O
Figure	O
2B	O
)	O
.	O
Within	O
CC	O
strains	O
,	O
CC040	O
/	O
TauUnc	O
had	O
the	O
highest	O
range	O
of	O
variability	O
in	O
adiposity	O
(	O
1	O
.	O
7	O
–	O
29	O
.	O
3	O
%	O
)	O
,	O
while	O
CC030	O
/	O
GeniUnc	O
had	O
the	O
lowest	O
range	O
of	O
variability	O
in	O
adiposity	O
(	O
7	O
.	O
6	O
–	O
12	O
.	O
6	O
%	O
)	O
.	O
CC040	O
/	O
TauUnc	O
had	O
the	O
highest	O
variability	O
in	O
weight	O
(	O
11	O
–	O
28	O
g	O
)	O
,	O
while	O
CC019	O
/	O
TauUnc	O
had	O
the	O
lowest	O
variability	O
in	O
weight	O
(	O
11	O
.	O
1	O
–	O
13	O
.	O
2	O
g	O
)	O
.	O

Linear	O
regression	O
analysis	O
was	O
performed	O
to	O
assess	O
the	O
significance	O
of	O
the	O
effect	O
of	O
strain	O
on	O
each	O
of	O
the	O
measured	O
traits	O
at	O
baseline	O
(	O
Supplementary	O
Table	O
4	O
)	O
,	O
and	O
strain	O
was	O
found	O
to	O
have	O
a	O
significant	O
effect	O
on	O
almost	O
all	O
traits	O
,	O
especially	O
body	O
fat	O
%	O
(	O
F	O
=	O
12	O
.	O
44	O
,	O
p	O
=	O
7	O
.	O
71	O
×10−25	O
)	O
and	O
weight	O
(	O
F	O
=	O
19	O
.	O
39	O
,	O
p	O
=	O
3	O
.	O
95	O
×	O
10−35	O
)	O
.	O
To	O
estimate	O
the	O
overall	O
health	O
of	O
the	O
mice	O
from	O
each	O
CC	O
strain	O
,	O
a	O
metabolic	O
health	O
score	O
was	O
calculated	O
using	O
the	O
sum	O
of	O
Z	O
scores	O
from	O
measurements	O
of	O
several	O
metabolic	O
risk	O
factors	O
(	O
circulating	O
glucose	O
,	O
insulin	O
,	O
glucose	O
/	O
insulin	O
ratio	O
,	O
cholesterol	O
,	O
TG	O
,	O
and	O
body	O
fat	O
%	O
)	O
.	O
While	O
the	O
health	O
score	O
includes	O
body	O
fat	O
%	O
as	O
one	O
of	O
the	O
components	O
,	O
the	O
phenotypes	O
exhibited	O
across	O
CC	O
strains	O
for	O
circulating	O
analytes	O
typically	O
used	O
as	O
markers	O
of	O
metabolic	O
health	O
(	O
circulating	O
glucose	O
,	O
insulin	O
,	O
glucose	O
/	O
insulin	O
ratio	O
,	O
cholesterol	O
,	O
TG	O
)	O
varied	O
so	O
that	O
although	O
one	O
strain	O
may	O
have	O
high	O
body	O
fat	O
%	O
,	O
it	O
may	O
simultaneously	O
have	O
low	O
levels	O
of	O
TG	O
or	O
glucose	O
,	O
such	O
as	O
CC040	O
/	O
TauUnc	O
at	O
baseline	O
.	O
Because	O
metabolic	O
health	O
is	O
determined	O
by	O
multiple	O
phenotypes	O
,	O
the	O
health	O
score	O
provides	O
a	O
way	O
to	O
estimate	O
overall	O
metabolic	O
health	O
for	O
each	O
CC	O
strain	O
in	O
a	O
way	O
that	O
accounts	O
for	O
these	O
differences	O
.	O
For	O
example	O
,	O
at	O
baseline	O
CC028	O
/	O
GeniUnc	O
had	O
the	O
highest	O
BF	O
%	O
but	O
its	O
health	O
score	O
was	O
close	O
to	O
0	O
,	O
so	O
it	O
was	O
not	O
exceedingly	O
unhealthy	O
relative	O
to	O
the	O
other	O
strains	O
in	O
this	O
study	O
despite	O
its	O
high	O
BF	O
%	O
,	O
since	O
this	O
strain	O
'	O
s	O
glucose	O
,	O
TG	O
,	O
and	O
cholesterol	O
levels	O
were	O
not	O
elevated	O
.	O
Similar	O
to	O
adiposity	O
and	O
circulating	O
analytes	O
(	O
Figures	O
2C	O
–	O
F	O
)	O
,	O
metabolic	O
health	O
also	O
showed	O
a	O
wide	O
range	O
of	O
phenotypic	O
variation	O
by	O
CC	O
strain	O
at	O
baseline	O
(	O
Figure	O
2G	O
)	O
,	O
where	O
most	O
strains	O
with	O
higher	O
adiposity	O
also	O
appeared	O
to	O
have	O
decreased	O
metabolic	O
health	O
(	O
Figures	O
2A	O
,	O
G	O
)	O
,	O
with	O
the	O
exception	O
of	O
CC028	O
/	O
GeniUnc	O
.	O
To	O
determine	O
whether	O
total	O
body	O
weight	O
predicts	O
susceptibility	O
to	O
increased	O
adiposity	O
,	O
body	O
fat	O
%	O
was	O
correlated	O
with	O
total	O
body	O
weight	O
.	O

Although	O
the	O
leanest	O
strain	O
overall	O
(	O
CC019	O
/	O
TauUnc	O
,	O
average	O
body	O
fat	O
4	O
.	O
41	O
±	O
0	O
.	O
56	O
%	O
)	O
was	O
on	O
average	O
also	O
the	O
smallest	O
strain	O
(	O
12	O
.	O
4	O
±	O
0	O
.	O
22	O
g	O
)	O
and	O
body	O
fat	O
%	O
was	O
positively	O
correlated	O
with	O
weight	O
overall	O
(	O
Figure	O
3B	O
,	O
rho	O
=	O
0	O
.	O
56	O
,	O
p	O
<	O
2	O
.	O
2	O
×	O
10−16	O
)	O
,	O
the	O
largest	O
average	O
CC	O
strain	O
was	O
not	O
necessarily	O
the	O
most	O
susceptible	O
to	O
developing	O
obesity	O
(	O
Figures	O
2A	O
,	O
B	O
,	O
Supplementary	O
Figure	O
3	O
)	O
.	O
For	O
example	O
,	O
the	O
CC	O
strains	O
with	O
the	O
highest	O
average	O
weight	O
(	O
23	O
.	O
4	O
±	O
0	O
.	O
97	O
g	O
in	O
CC011	O
/	O
Unc	O
,	O
22	O
.	O
4	O
±	O
1	O
.	O
08	O
g	O
in	O
CC028	O
/	O
GeniUnc	O
,	O
and	O
22	O
.	O
3	O
±	O
0	O
.	O
7	O
g	O
in	O
CC008	O
/	O
GeniUnc	O
)	O
did	O
not	O
necessarily	O
always	O
have	O
the	O
highest	O
body	O
fat	O
%	O
(	O
15	O
.	O
7	O
±	O
1	O
.	O
29	O
%	O
in	O
CC011	O
/	O
Unc	O
,	O
23	O
.	O
11	O
±	O
1	O
.	O
59	O
%	O
in	O
CC028	O
/	O
GeniUnc	O
,	O
and	O
15	O
.	O
00	O
±	O
1	O
.	O
39	O
%	O
in	O
CC008	O
/	O
GeniUnc	O
)	O
.	O
Excessive	O
adiposity	O
is	O
a	O
risk	O
factor	O
for	O
metabolic	O
dysfunction	O
and	O
thus	O
we	O
quantified	O
the	O
relationship	O
between	O
circulating	O
plasma	O
analyte	O
levels	O
and	O
body	O
fat	O
%	O
(	O
Figure	O
3	O
)	O
.	O
For	O
example	O
,	O
for	O
traits	O
associated	O
with	O
metabolic	O
syndrome	O
such	O
as	O
total	O
weight	O
,	O
circulating	O
glucose	O
,	O
insulin	O
,	O
TG	O
,	O
and	O
cholesterol	O
,	O
body	O
fat	O
%	O
was	O
significantly	O
correlated	O
with	O
weight	O
(	O
rho	O
=	O
0	O
.	O
56	O
,	O
p	O
<	O
2	O
.	O
2	O
×	O
10−16	O
)	O
,	O
insulin	O
(	O
rho	O
=	O
0	O
.	O
44	O
,	O
p	O
=	O
8	O
.	O
8	O
×	O
10−11	O
)	O
,	O
and	O
TG	O
(	O
rho	O
=	O
0	O
.	O
24	O
,	O
p	O
=	O
5	O
.	O
9	O
×	O
10−4	O
)	O
as	O
shown	O
in	O
Figures	O
3B	O
–	O
D	O
,	O
but	O
not	O
glucose	O
nor	O
cholesterol	O
.	O
In	O
terms	O
of	O
metabolites	O
associated	O
with	O
cardiovascular	O
health	O
,	O
adiposity	O
was	O
not	O
correlated	O
with	O
the	O
risk	O
factor	O
TMAO	O
but	O
was	O
moderately	O
associated	O
with	O
circulating	O
choline	O
(	O
rho	O
=	O
0	O
.	O
190	O
,	O
padj	O
=	O
0	O
.	O
012	O
)	O
,	O
carnitine	O
(	O
rho	O
=	O
0	O
.	O
17	O
,	O
padj	O
=	O
0	O
.	O
023	O
)	O
,	O
and	O
phosphocholine	O
(	O
rho	O
=	O
0	O
.	O
260	O
,	O
padj	O
=	O
0	O
.	O
001	O
;	O
Figure	O
3A	O
,	O
Supplementary	O
Table	O
5	O
)	O
.	O

We	O
next	O
calculated	O
broad	O
sense	O
heritability	O
(	O
H2	O
)	O
of	O
traits	O
at	O
baseline	O
to	O
quantify	O
the	O
degree	O
that	O
genetic	O
variation	O
influences	O
phenotypic	O
variation	O
compared	O
to	O
the	O
variation	O
of	O
environmental	O
factors	O
.	O
Linear	O
regression	O
analysis	O
was	O
performed	O
to	O
test	O
whether	O
strain	O
had	O
significant	O
effects	O
on	O
phenotypic	O
variation	O
.	O
Strain	O
was	O
a	O
significant	O
predictor	O
for	O
all	O
traits	O
at	O
baseline	O
except	O
for	O
circulating	O
non	O
-	O
esterified	O
fatty	O
acids	O
(	O
Supplementary	O
Table	O
4	O
)	O
.	O
Using	O
the	O
between	O
-	O
and	O
within	O
-	O
strain	O
mean	O
square	O
values	O
(	O
MSB	O
and	O
MSW	O
,	O
respectively	O
)	O
derived	O
from	O
these	O
linear	O
models	O
,	O
broad	O
sense	O
heritability	O
(	O
H2	O
)	O
was	O
estimated	O
by	O
calculating	O
the	O
intraclass	O
correlation	O
(	O
rI	O
)	O
and	O
coefficient	O
of	O
genetic	O
determination	O
(	O
g2	O
)	O
which	O
determine	O
the	O
proportion	O
of	O
phenotypic	O
variation	O
accounted	O
for	O
by	O
differences	O
between	O
strain	O
(	O
genetic	O
variation	O
)	O
(	O
Table	O
1	O
)	O
.	O
Estimates	O
of	O
H2	O
for	O
phenotypic	O
variation	O
based	O
on	O
g2	O
were	O
0	O
.	O
359	O
–	O
0	O
.	O
565	O
.	O
The	O
highest	O
and	O
lowest	O
estimates	O
of	O
H2	O
were	O
for	O
lean	O
mass	O
(	O
g2	O
=	O
0	O
.	O
565	O
)	O
and	O
circulating	O
non	O
-	O
esterified	O
fatty	O
acids	O
(	O
g2	O
=	O
0	O
.	O
029	O
)	O
.	O
Our	O
assessment	O
of	O
H2	O
demonstrates	O
that	O
genotypic	O
variation	O
accounts	O
for	O
a	O
large	O
proportion	O
of	O
phenotypic	O
variation	O
in	O
the	O
CC	O
for	O
all	O
body	O
composition	O
traits	O
and	O
a	O
medium	O
proportion	O
of	O
phenotypic	O
variation	O
for	O
traits	O
related	O
to	O
1	O
-	O
carbon	O
metabolism	O
.	O
We	O
note	O
that	O
not	O
all	O
analytes	O
were	O
highly	O
heritable	O
.	O
After	O
establishing	O
baseline	O
phenotype	O
values	O
to	O
examine	O
the	O
effect	O
of	O
strain	O
without	O
the	O
influence	O
of	O
diet	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
diet	O
in	O
the	O
CC	O
population	O
on	O
weight	O
gain	O
and	O
metabolic	O
health	O
.	O
To	O
accomplish	O
this	O
,	O
we	O
randomized	O
the	O
204	O
female	O
mice	O
from	O
22	O
CC	O
strains	O
to	O
one	O
of	O
two	O
diets	O
and	O
challenged	O
them	O
for	O
8	O
weeks	O
with	O
either	O
a	O
high	O
protein	O
(	O
n	O
=	O
102	O
)	O
or	O
high	O
fat	O
high	O
sucrose	O
diet	O
(	O
n	O
=	O
102	O
)	O
.	O
After	O
8	O
weeks	O
on	O
the	O
experimental	O
diets	O
,	O
we	O
assessed	O
whether	O
phenotypic	O
response	O
to	O
diet	O
differed	O
by	O
genetic	O
background	O
(	O
CC	O
strain	O
)	O
(	O
see	O
Methods	O
and	O
Figure	O
1	O
)	O
.	O
MRI	O
body	O
composition	O
analysis	O
of	O
the	O
CC	O
mice	O
after	O
8	O
weeks	O
on	O
the	O
diet	B-methodology
challenge	I-methodology
revealed	O
that	O
diet	O
influenced	O
susceptibility	O
to	O
adiposity	O
in	O
a	O
strain	O
-	O
dependent	O
manner	O
(	O
Figure	O
4A	O
)	O
.	O

Strain	O
CC028	O
/	O
GeniUnc	O
was	O
most	O
susceptible	O
to	O
increased	O
adiposity	O
on	O
the	O
high	O
fat	O
high	O
sucrose	O
(	O
HS	O
)	O
diet	O
(	O
35	O
.	O
7	O
±	O
2	O
.	O
0	O
%	O
)	O
and	O
strain	O
CC019	O
/	O
TauUnc	O
was	O
least	O
susceptible	O
(	O
4	O
.	O
68	O
±	O
0	O
.	O
5	O
%	O
)	O
(	O
Figure	O
4A	O
,	O
Supplementary	O
Figure	O
4	O
)	O
.	O
CC040	O
/	O
TauUnc	O
was	O
most	O
susceptible	O
to	O
increased	O
adiposity	O
on	O
the	O
high	O
protein	O
(	O
HP	O
)	O
diet	O
(	O
29	O
.	O
7	O
±	O
1	O
.	O
37	O
%	O
)	O
and	O
strain	O
CC019	O
/	O
TauUnc	O
was	O
least	O
susceptible	O
(	O
4	O
.	O
7	O
±	O
0	O
.	O
47	O
%	O
)	O
.	O
The	O
effect	O
of	O
diet	O
was	O
highly	O
variable	O
across	O
the	O
selected	O
strains	O
from	O
the	O
CC	O
.	O
For	O
example	O
,	O
CC028	O
/	O
GeniUnc	O
and	O
CC004	O
/	O
TauUnc	O
had	O
a	O
12	O
%	O
increase	O
in	O
adiposity	O
when	O
fed	O
the	O
HS	O
diet	O
compared	O
to	O
the	O
HP	O
diet	O
(	O
Supplementary	O
Figure	O
4	O
)	O
,	O
while	O
CC019	O
/	O
TauUnc	O
and	O
CC063	O
/	O
Unc	O
showed	O
negligible	O
differences	O
in	O
adiposity	O
when	O
fed	O
different	O
diets	O
(	O
0	O
.	O
05	O
and	O
0	O
.	O
54	O
%	O
)	O
.	O
Comparisons	O
of	O
phenotypic	O
differences	O
between	O
baseline	O
and	O
post	O
-	O
diet	O
body	O
fat	O
%	O
(	O
Supplementary	O
Figure	O
5A	O
)	O
by	O
strain	O
and	O
diet	O
further	O
emphasize	O
the	O
strain	O
-	O
dependent	O
response	O
of	O
body	O
fat	O
%	O
to	O
diet	O
in	O
the	O
CC	O
.	O
Similar	O
to	O
adiposity	O
,	O
total	O
weight	O
,	O
circulating	O
analyte	O
levels	O
,	O
and	O
metabolic	O
health	O
score	O
all	O
showed	O
phenotypic	O
variation	O
and	O
different	O
responses	O
to	O
diet	O
depending	O
on	O
CC	O
strain	O
(	O
Figure	O
4	O
)	O
,	O
though	O
to	O
a	O
lesser	O
degree	O
than	O
adiposity	O
.	O
As	O
shown	O
in	O
Figure	O
4G	O
,	O
strain	O
effects	O
account	O
for	O
the	O
inherent	O
phenotypic	O
variation	O
in	O
metabolic	O
health	O
illustrated	O
by	O
metabolic	O
health	O
score	O
,	O
as	O
well	O
as	O
the	O
varied	O
responses	O
to	O
diet	O
.	O
Certain	O
strains	O
such	O
as	O
CC059	O
/	O
TauUnc	O
and	O
CC008	O
/	O
GeniUnc	O
showed	O
very	O
little	O
responses	O
to	O
diet	O
in	O
terms	O
of	O
their	O
metabolic	O
health	O
score	O
,	O
while	O
other	O
strains	O
showed	O
improved	O
metabolic	O
health	O
on	O
either	O
the	O
HP	O
compared	O
to	O
the	O
HS	O
diet	O
(	O
CC032	O
/	O
GeniUnc	O
and	O
CC004	O
/	O
TauUnc	O
)	O
or	O
HS	O
compared	O
to	O
the	O
HP	O
diet	O
(	O
CC012	O
/	O
GeniUnc	O
and	O
CC030	O
/	O
GeniUnc	O
)	O
.	O

To	O
ascertain	O
whether	O
there	O
is	O
a	O
significant	O
effect	O
of	O
CC	O
strain	O
x	O
experimental	O
diet	O
interaction	O
on	O
adiposity	O
and	O
related	O
traits	O
,	O
linear	O
mixed	O
models	O
were	O
fitted	O
as	O
appropriate	O
for	O
each	O
trait	O
using	O
CC	O
strain	O
,	O
experimental	O
diet	O
,	O
and	O
CC	O
strain	O
×	O
experimental	O
diet	O
as	O
covariates	O
,	O
followed	O
by	O
application	O
of	O
the	O
Satterthwaite	O
approximations	O
for	O
degrees	O
of	O
freedom	O
for	O
evaluating	O
significance	O
(	O
Supplementary	O
Table	O
6	O
)	O
.	O
A	O
significant	O
effect	O
of	O
CC	O
strain	O
×	O
diet	O
interactions	O
was	O
found	O
for	O
adiposity	O
,	O
fat	O
mass	O
,	O
lean	O
mass	O
percentage	O
,	O
metabolic	O
health	O
score	O
,	O
and	O
circulating	O
TMAO	O
and	O
TG	O
.	O
The	O
models	O
for	O
each	O
phenotype	O
were	O
significant	O
with	O
the	O
range	O
of	O
significant	O
p	O
-	O
values	O
from	O
p	O
=	O
7	O
.	O
37	O
×	O
10−5	O
for	O
adiposity	O
to	O
p	O
=	O
0	O
.	O
03	O
for	O
metabolic	O
health	O
score	O
(	O
F	O
=	O
3	O
.	O
36	O
and	O
F	O
=	O
1	O
.	O
84	O
)	O
.	O
There	O
was	O
a	O
significant	O
effect	O
of	O
strain	O
on	O
circulating	O
cholesterol	O
,	O
glucose	O
,	O
and	O
insulin	O
(	O
Supplementary	O
Table	O
6	O
)	O
,	O
but	O
no	O
significant	O
effect	O
of	O
CC	O
strain	O
×	O
diet	O
interactions	O
which	O
suggests	O
that	O
genotypic	O
variation	O
is	O
largely	O
responsible	O
for	O
the	O
phenotypic	O
variation	O
of	O
these	O
traits	O
.	O
To	O
determine	O
the	O
magnitude	O
of	O
the	O
effect	O
of	O
diet	O
behind	O
gene	O
×	O
environmental	O
effects	O
found	O
for	O
each	O
trait	O
in	O
our	O
linear	O
mixed	O
models	O
,	O
we	O
performed	O
Spearman	O
'	O
s	O
correlation	O
analysis	O
between	O
the	O
F	O
-	O
statistic	O
of	O
the	O
gene	O
x	O
diet	O
interactions	O
of	O
our	O
models	O
and	O
Hedges	O
'	O
effect	O
size	O
for	O
both	O
diets	O
(	O
|	O
g	O
|	O
)	O
,	O
which	O
demonstrated	O
that	O
the	O
significance	O
of	O
gene	O
x	O
diet	O
interactions	O
were	O
not	O
significantly	O
affected	O
by	O
diet	O
for	O
either	O
diet	O
(	O
HP	O
p	O
=	O
0	O
.	O
96	O
,	O
HS	O
p	O
=	O
0	O
.	O
74	O
)	O
.	O
Furthermore	O
,	O
we	O
categorized	O
each	O
trait	O
as	O
either	O
largely	O
affected	O
by	O
diet	O
(	O
|	O
g	O
|	O
>	O
0	O
.	O
8	O
)	O
or	O
not	O
(	O
|	O
g	O
|	O
<	O
0	O
.	O
8	O
)	O
,	O
and	O
significantly	O
affected	O
by	O
gene	O
×	O
diet	O
interactions	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
or	O
not	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
,	O
followed	O
by	O
Chi	O
square	O
analysis	O
of	O
whether	O
the	O
effect	O
size	O
of	O
diet	O
and	O
the	O
gene	O
x	O
environment	O
are	O
significantly	O
related	O
.	O
The	O
results	O
of	O
the	O
Chi	O
square	O
analysis	O
(	O
p	O
>	O
0	O
.	O
99	O
)	O
were	O
consistent	O
with	O
the	O
results	O
of	O
the	O
Spearman	O
'	O
s	O
correlations	O
performed	O
between	O
the	O
F	O
-	O
statistic	O
of	O
the	O
gene	O
x	O
diet	O
interactions	O
models	O
and	O
Hedges	O
'	O
effect	O
size	O
for	O
both	O
diets	O
(	O
|	O
g	O
|	O
)	O
which	O
suggest	O
that	O
the	O
magnitude	O
of	O
the	O
effect	O
of	O
diet	O
is	O
not	O
a	O
significant	O
“	O
driver	O
”	O
of	O
gene	O
x	O
diet	O
interactions	O
.	O

Because	O
diet	O
is	O
an	O
important	O
environmental	O
factor	O
that	O
affects	O
the	O
manifestation	O
of	O
phenotypes	O
,	O
we	O
next	O
investigated	O
the	O
relative	O
effect	O
size	O
of	O
diet	O
on	O
clinical	O
traits	O
associated	O
with	O
adiposity	O
and	O
metabolic	O
health	O
.	O
To	O
accurately	O
quantify	O
the	O
effect	O
size	O
of	O
diet	O
on	O
each	O
phenotype	O
,	O
Hedges	O
'	O
g	O
was	O
calculated	O
for	O
each	O
trait	O
instead	O
of	O
Cohen	O
'	O
s	O
d	O
because	O
strain	O
groups	O
were	O
dissimilar	O
in	O
sample	O
size	O
for	O
various	O
traits	O
.	O
The	O
difference	O
in	O
n	O
by	O
strain	O
may	O
result	O
in	O
unequal	O
measures	O
of	O
variation	O
between	O
experimental	O
groups	O
,	O
which	O
needs	O
to	O
be	O
adjusted	O
for	O
so	O
that	O
the	O
standard	O
deviation	O
(	O
SD	O
)	O
used	O
to	O
calculate	O
effect	O
size	O
more	O
closely	O
reflects	O
the	O
SD	O
of	O
the	O
population	O
.	O
Hedges	O
'	O
g	O
uses	O
pooled	O
SD	O
weighted	O
by	O
sample	O
size	O
of	O
each	O
group	O
in	O
its	O
calculation	O
(	O
see	O
Methods	O
)	O
,	O
which	O
makes	O
it	O
a	O
more	O
appropriate	O
measure	O
of	O
effect	O
size	O
when	O
experimental	O
groups	O
are	O
dissimilar	O
in	O
sample	O
size	O
compared	O
to	O
Cohen	O
'	O
s	O
d	O
(	O
Ellis	O
,	O
2009	O
)	O
.	O
As	O
shown	O
in	O
Table	O
2	O
,	O
the	O
HS	O
diet	O
had	O
large	O
effects	O
on	O
circulating	O
choline	O
,	O
urea	O
and	O
non	O
-	O
esterified	O
fatty	O
acids	O
(	O
NEFAS	O
)	O
,	O
as	O
well	O
as	O
most	O
traits	O
associated	O
with	O
body	O
composition	O
(	O
|	O
g	O
|	O
>	O
0	O
.	O
8	O
)	O
;	O
medium	O
effects	O
on	O
adiposity	O
,	O
glucose	O
/	O
insulin	O
ratio	O
,	O
TMAO	O
,	O
and	O
albumin	O
(	O
0	O
.	O
8	O
>	O
|	O
g	O
|	O
>	O
0	O
.	O
5	O
)	O
;	O
and	O
small	O
to	O
negligible	O
on	O
all	O
other	O
phenotypes	O
(	O
|	O
g	O
|	O
<	O
0	O
.	O
5	O
)	O
.	O
In	O
contrast	O
,	O
the	O
HP	O
diet	O
only	O
had	O
large	O
effects	O
on	O
total	O
weight	O
(	O
|	O
g	O
|	O
>	O
0	O
.	O
8	O
)	O
;	O
medium	O
effects	O
on	O
glucose	O
/	O
insulin	O
ratio	O
,	O
circulating	O
choline	O
,	O
TMAO	O
,	O
NEFAS	O
,	O
albumin	O
,	O
urea	O
,	O
cholesterol	O
,	O
and	O
TG	O
,	O
as	O
well	O
as	O
all	O
phenotypes	O
associated	O
with	O
body	O
composition	O
;	O
and	O
small	O
to	O
negligible	O
on	O
all	O
other	O
phenotypes	O
(	O
|	O
g	O
|	O
<	O
0	O
.	O
5	O
)	O
.	O
Post	O
-	O
diet	O
values	O
for	O
body	O
fat	O
%	O
,	O
clinical	O
blood	O
chemistries	O
,	O
and	O
circulating	O
metabolites	O
were	O
established	O
for	O
each	O
diet	O
to	O
assess	O
the	O
degree	O
of	O
phenotypic	O
variation	O
due	O
to	O
differences	O
in	O
macronutrient	O
composition	O
of	O
diet	O
(	O
Figure	O
5	O
)	O
.	O

For	O
both	O
diets	O
,	O
there	O
was	O
a	O
wide	O
range	O
of	O
phenotypic	O
variation	O
within	O
each	O
diet	O
for	O
body	O
fat	O
%	O
(	O
HP	O
=	O
3	O
.	O
6	O
–	O
33	O
.	O
9	O
%	O
,	O
HS	O
=	O
3	O
.	O
17	O
–	O
41	O
.	O
7	O
%	O
)	O
,	O
total	O
weight	O
(	O
HP	O
=	O
14	O
.	O
1	O
–	O
35	O
.	O
5	O
g	O
,	O
HS	O
=	O
14	O
.	O
1	O
–	O
39	O
g	O
)	O
and	O
cholesterol	O
(	O
HP	O
=	O
64	O
.	O
8	O
–	O
199	O
.	O
5	O
mg	O
/	O
dL	O
,	O
HS	O
=	O
63	O
–	O
228	O
.	O
9	O
mg	O
/	O
dL	O
)	O
.	O
Means	O
per	O
diet	O
for	O
body	O
fat	O
%	O
(	O
HP	O
=	O
17	O
.	O
95	O
±	O
0	O
.	O
77	O
%	O
,	O
HS	O
=	O
20	O
.	O
31	O
±	O
0	O
.	O
97	O
%	O
)	O
,	O
total	O
body	O
weight	O
(	O
HP	O
=	O
21	O
.	O
78	O
±	O
0	O
.	O
42	O
g	O
,	O
HS	O
=	O
24	O
.	O
02	O
±	O
0	O
.	O
5	O
g	O
)	O
,	O
TG	O
(	O
HP	O
=	O
104	O
.	O
6	O
±	O
4	O
.	O
28	O
mg	O
/	O
dL	O
,	O
HS	O
=	O
113	O
.	O
65	O
±	O
4	O
.	O
73	O
mg	O
/	O
dL	O
)	O
,	O
cholesterol	O
(	O
HP	O
=	O
115	O
.	O
1	O
±	O
2	O
.	O
85	O
mg	O
/	O
dL	O
,	O
HS	O
=	O
139	O
.	O
51	O
±	O
3	O
.	O
3	O
mg	O
/	O
dL	O
)	O
,	O
glucose	O
(	O
HP	O
=	O
173	O
.	O
45	O
±	O
5	O
.	O
73	O
mg	O
/	O
dL	O
,	O
HS	O
=	O
184	O
.	O
63	O
±	O
6	O
.	O
42	O
mg	O
/	O
dL	O
)	O
,	O
and	O
insulin	O
(	O
1	O
.	O
03	O
±	O
0	O
.	O
05	O
ng	O
/	O
ml	O
,	O
HS	O
=	O
1	O
.	O
17	O
±	O
0	O
.	O
08	O
ng	O
/	O
ml	O
)	O
showed	O
slightly	O
elevated	O
values	O
for	O
each	O
trait	O
on	O
the	O
HS	O
diet	O
compared	O
to	O
the	O
HP	O
diet	O
(	O
Supplementary	O
Table	O
7	O
)	O
,	O
but	O
the	O
only	O
significant	O
increases	O
in	O
phenotype	O
were	O
for	O
total	O
weight	O
and	O
cholesterol	O
(	O
p	O
<	O
0	O
.	O
01	O
,	O
Student	O
'	O
s	O
t	O
-	O
test	O
)	O
,	O
not	O
body	O
fat	O
%	O
,	O
TG	O
,	O
glucose	O
,	O
insulin	O
,	O
nor	O
metabolic	O
health	O
score	O
(	O
Figure	O
5	O
)	O
.	O
Relative	O
to	O
mice	O
fed	O
the	O
HP	O
diet	O
,	O
mice	O
fed	O
the	O
HS	O
diet	O
showed	O
a	O
10	O
.	O
6	O
%	O
increase	O
in	O
total	O
weight	O
(	O
Figure	O
5B	O
)	O
and	O
a	O
21	O
.	O
2	O
%	O
increase	O
in	O
cholesterol	O
(	O
Figure	O
5D	O
)	O
,	O
suggesting	O
that	O
macronutrient	O
composition	O
had	O
a	O
stronger	O
effect	O
on	O
these	O
traits	O
compared	O
to	O
body	O
fat	O
%	O
,	O
TG	O
,	O
glucose	O
,	O
insulin	O
,	O
and	O
metabolic	O
health	O
score	O
.	O

To	O
further	O
assess	O
whether	O
diet	O
had	O
a	O
significant	O
effect	O
on	O
adiposity	O
and	O
related	O
phenotypes	O
,	O
linear	O
mixed	O
model	O
analysis	O
was	O
performed	O
(	O
Supplementary	O
Table	O
8	O
)	O
,	O
which	O
showed	O
that	O
experimental	O
diet	O
had	O
a	O
significant	O
effect	O
on	O
all	O
phenotypes	O
related	O
to	O
body	O
composition	O
,	O
except	O
post	O
-	O
diet	O
body	O
fat	O
%	O
for	O
which	O
diet	O
showed	O
a	O
suggestive	O
effect	O
(	O
F	O
=	O
3	O
.	O
98	O
,	O
p	O
=	O
0	O
.	O
057	O
)	O
.	O
Although	O
experimental	O
diet	O
alone	O
did	O
not	O
have	O
a	O
significant	O
effect	O
in	O
general	O
on	O
body	O
fat	O
%	O
,	O
TG	O
,	O
glucose	O
,	O
insulin	O
,	O
nor	O
metabolic	O
health	O
score	O
(	O
Figure	O
5	O
)	O
,	O
experimental	O
diet	O
did	O
have	O
significant	O
effects	O
on	O
total	O
weight	O
(	O
F	O
=	O
20	O
.	O
0	O
,	O
p	O
=	O
0	O
.	O
0002	O
)	O
and	O
cholesterol	O
(	O
F	O
=	O
43	O
.	O
8	O
,	O
p	O
=	O
6	O
.	O
22	O
×	O
10−7	O
)	O
.	O
Furthermore	O
,	O
experimental	O
diet	O
also	O
had	O
significant	O
effects	O
on	O
circulating	O
urea	O
,	O
betaine	O
,	O
TMAO	O
,	O
carnitine	O
,	O
and	O
phosphocholine	O
(	O
Supplementary	O
Table	O
8	O
)	O
,	O
indicating	O
that	O
diet	O
macronutrient	O
composition	O
still	O
plays	O
an	O
important	O
role	O
in	O
terms	O
of	O
metabolic	O
health	O
.	O
To	O
confirm	O
the	O
degree	O
to	O
which	O
genetic	O
background	O
mediates	O
weight	O
gain	O
,	O
adiposity	O
,	O
and	O
metabolic	O
health	O
in	O
response	O
to	O
diet	O
,	O
additional	O
linear	O
mixed	O
model	O
analyses	O
with	O
strain	O
,	O
diet	O
,	O
and	O
strain	O
×	O
diet	O
interactions	O
as	O
all	O
random	O
effects	O
were	O
performed	O
for	O
each	O
trait	O
to	O
estimate	O
the	O
relative	O
heritable	O
variation	O
that	O
can	O
be	O
attributed	O
to	O
genetics	O
,	O
environment	O
(	O
diet	O
)	O
,	O
and	O
gene	O
×	O
environmental	O
effects	O
.	O
From	O
the	O
results	O
of	O
these	O
models	O
,	O
we	O
calculated	O
the	O
variance	O
for	O
each	O
of	O
these	O
terms	O
(	O
Supplementary	O
Table	O
9	O
)	O
and	O
found	O
that	O
a	O
large	O
proportion	O
of	O
relative	O
phenotypic	O
variation	O
can	O
be	O
attributed	O
to	O
background	O
strain	O
for	O
most	O
traits	O
,	O
especially	O
body	O
fat	O
%	O
,	O
total	O
weight	O
,	O
and	O
TG	O
(	O
>	O
~	O
49	O
.	O
6	O
%	O
)	O
.	O
In	O
contrast	O
,	O
the	O
proportion	O
of	O
relative	O
phenotypic	O
variation	O
that	O
can	O
be	O
attributed	O
to	O
diet	O
varied	O
depending	O
on	O
the	O
trait	O
,	O
where	O
cholesterol	O
,	O
betaine	O
,	O
and	O
urea	O
/	O
BUN	O
were	O
the	O
traits	O
that	O
had	O
the	O
highest	O
proportion	O
of	O
heritable	O
variation	O
attributed	O
to	O
diet	O
(	O
>	O
~	O
21	O
%	O
)	O
.	O
The	O
degree	O
to	O
which	O
genetics	O
,	O
diet	O
,	O
and	O
gene	O
x	O
diet	O
interactions	O
influence	O
phenotypic	O
variation	O
differs	O
depending	O
on	O
the	O
trait	O
.	O

To	O
quantify	O
the	O
relative	O
heritable	O
phenotypic	O
variation	O
which	O
can	O
be	O
attributed	O
to	O
genetics	O
or	O
diet	O
for	O
body	O
fat	O
%	O
and	O
obesity	O
-	O
related	O
traits	O
,	O
we	O
calculated	O
heritability	O
using	O
the	O
mean	O
square	O
between	O
(	O
MSB	O
)	O
strains	O
and	O
mean	O
square	O
within	O
(	O
MSW	O
)	O
strains	O
derived	O
from	O
two	O
different	O
linear	O
models	O
for	O
post	O
-	O
diet	O
traits	O
(	O
a	O
“	O
full	O
”	O
additive	O
model	O
that	O
includes	O
strain	O
,	O
diet	O
,	O
and	O
week	O
as	O
variables	O
and	O
a	O
“	O
partial	O
”	O
model	O
that	O
excludes	O
diet	O
)	O
and	O
the	O
intraclass	O
correlation	O
(	O
ICC	O
)	O
for	O
diet	O
using	O
the	O
mean	O
square	O
between	O
(	O
MSB	O
)	O
diets	O
and	O
mean	O
square	O
within	O
(	O
MSW	O
)	O
diets	O
derived	O
from	O
the	O
“	O
full	O
”	O
model	O
(	O
Methods	O
)	O
.	O
Heritability	O
estimates	O
were	O
similar	O
for	O
most	O
traits	O
regardless	O
of	O
the	O
model	O
used	O
(	O
“	O
full	O
”	O
vs	O
.	O
“	O
partial	O
”	O
)	O
except	O
for	O
traits	O
where	O
the	O
ICCs	O
for	O
diet	O
were	O
relatively	O
high	O
,	O
such	O
as	O
total	O
weight	O
,	O
cholesterol	O
,	O
urea	O
/	O
BUN	O
,	O
and	O
betaine	O
,	O
demonstrating	O
the	O
robust	O
contribution	O
of	O
strain	O
to	O
heritable	O
variation	O
compared	O
to	O
diet	O
(	O
Table	O
2	O
)	O
.	O
The	O
relatively	O
high	O
diet	O
ICCs	O
for	O
total	O
weight	O
,	O
cholesterol	O
,	O
urea	O
/	O
BUN	O
,	O
and	O
betaine	O
suggest	O
that	O
diet	O
may	O
be	O
responsible	O
for	O
a	O
higher	O
proportion	O
of	O
heritable	O
variation	O
for	O
these	O
traits	O
compared	O
to	O
other	O
traits	O
,	O
which	O
is	O
consistent	O
with	O
the	O
results	O
of	O
our	O
linear	O
mixed	O
models	O
testing	O
the	O
significance	O
of	O
diet	O
that	O
also	O
show	O
diet	O
as	O
significantly	O
affecting	O
these	O
traits	O
(	O
Supplementary	O
Table	O
8	O
)	O
.	O
Traits	O
with	O
negative	O
or	O
close	O
to	O
zero	O
diet	O
ICCs	O
had	O
higher	O
within	O
-	O
diet	O
variation	O
than	O
between	O
-	O
diet	O
variation	O
.	O
Interestingly	O
,	O
with	O
the	O
exception	O
of	O
insulin	O
and	O
metabolic	O
health	O
score	O
,	O
most	O
post	O
-	O
diet	O
traits	O
had	O
higher	O
heritability	O
estimates	O
when	O
the	O
MSB	O
term	O
was	O
used	O
from	O
linear	O
models	O
that	O
included	O
diet	O
compared	O
to	O
the	O
models	O
excluding	O
diet	O
,	O
suggesting	O
that	O
accounting	O
for	O
the	O
effect	O
of	O
diet	O
improved	O
heritability	O
estimates	O
since	O
either	O
the	O
within	O
-	O
strain	O
variation	O
was	O
decreased	O
and	O
/	O
or	O
the	O
between	O
-	O
strain	O
variation	O
was	O
increased	O
.	O
Diet	O
-	O
specific	O
heritability	O
was	O
also	O
calculated	O
using	O
linear	O
models	O
fitted	O
only	O
including	O
mice	O
fed	O
HP	O
or	O
HS	O
diet	O
with	O
strain	O
and	O
week	O
as	O
covariates	O
to	O
compare	O
changes	O
in	O
heritability	O
for	O
each	O
experimental	O
diet	O
due	O
to	O
“	O
environmental	O
”	O
differences	O
(	O
Tables	O
1	O
,	O
2	O
)	O
.	O

One	O
caveat	O
of	O
comparing	O
baseline	O
heritability	O
and	O
diet	O
-	O
specific	O
post	O
-	O
diet	O
heritability	O
is	O
that	O
diet	O
-	O
specific	O
post	O
-	O
diet	O
heritability	O
values	O
were	O
calculated	O
using	O
half	O
the	O
number	O
of	O
mice	O
as	O
the	O
baseline	O
heritability	O
values	O
,	O
which	O
could	O
affect	O
the	O
within	O
-	O
strain	O
variance	O
component	O
of	O
the	O
heritability	O
calculations	O
.	O
Nonetheless	O
,	O
assuming	O
that	O
the	O
genotypic	O
variance	O
is	O
the	O
same	O
between	O
diets	O
and	O
time	O
points	O
(	O
baseline	O
vs	O
.	O
post	O
-	O
diet	O
)	O
,	O
we	O
can	O
still	O
identify	O
which	O
traits	O
may	O
be	O
more	O
strongly	O
affected	O
by	O
differences	O
in	O
macronutrient	O
composition	O
.	O
Indeed	O
,	O
after	O
calculating	O
the	O
heritability	O
estimates	O
for	O
each	O
of	O
the	O
traits	O
post	O
-	O
diet	O
on	O
the	O
respective	O
experimental	O
diets	O
,	O
we	O
found	O
that	O
the	O
different	O
“	O
environments	O
”	O
(	O
diets	O
)	O
resulted	O
in	O
slight	O
alterations	O
in	O
heritability	O
estimates	O
depending	O
on	O
the	O
trait	O
.	O
For	O
example	O
,	O
the	O
difference	O
in	O
macronutrient	O
composition	O
appears	O
to	O
have	O
a	O
bigger	O
impact	O
on	O
traits	O
such	O
as	O
cholesterol	O
,	O
insulin	O
,	O
and	O
glucose	O
with	O
larger	O
variation	O
in	O
heritability	O
(	O
Table	O
2	O
)	O
,	O
and	O
less	O
important	O
to	O
traits	O
such	O
as	O
metabolic	O
health	O
score	O
where	O
heritability	O
estimates	O
remain	O
consistent	O
(	O
baseline	O
g2	O
=	O
0	O
.	O
21	O
,	O
HP	O
g2	O
=	O
0	O
.	O
24	O
,	O
HS	O
g2	O
=	O
0	O
.	O
24	O
)	O
.	O
Obesity	O
is	O
characterized	O
by	O
the	O
excess	O
accumulation	O
of	O
body	O
fat	O
,	O
which	O
results	O
from	O
chronic	O
energy	O
imbalance	O
between	O
energy	O
intake	O
and	O
expenditure	O
.	O
Given	O
the	O
diverse	O
range	O
of	O
body	O
fat	O
accumulation	O
in	O
response	O
to	O
diet	O
across	O
strains	O
,	O
we	O
sought	O
to	O
elucidate	O
the	O
differences	O
in	O
metabolism	O
between	O
strains	O
on	O
each	O
diet	O
by	O
using	O
indirect	O
calorimetry	O
to	O
measure	O
the	O
following	O
traits	O
related	O
to	O
energy	O
balance	O
in	O
mice	O
after	O
8	O
weeks	O
on	O
the	O
experimental	O
diets	O
:	O
(	O
1	O
)	O
heat	O
expenditure	O
to	O
estimate	O
metabolism	O
levels	O
,	O
(	O
2	O
)	O
respiratory	O
exchange	O
rate	O
(	O
RER	O
)	O
to	O
estimate	O
substrate	O
utilization	O
(	O
carbohydrate	O
compared	O
to	O
fat	O
as	O
a	O
source	O
of	O
energy	O
)	O
,	O
(	O
3	O
)	O
food	O
intake	O
to	O
estimate	O
energy	O
consumption	O
,	O
and	O
(	O
4	O
)	O
basal	O
activity	O
.	O
Energy	O
consumption	O
was	O
calculated	O
by	O
multiplying	O
feed	O
consumption	O
measurement	O
(	O
in	O
grams	O
)	O
by	O
the	O
calorie	O
(	O
kcal	O
)	O
content	O
per	O
gram	O
feed	O
for	O
each	O
diet	O
.	O
Similar	O
to	O
other	O
phenotypes	O
reported	O
above	O
,	O
linear	O
mixed	O
model	O
analysis	O
was	O
performed	O
for	O
each	O
trait	O
to	O
test	O
whether	O
experimental	O
diet	O
,	O
CC	O
strain	O
,	O
and	O
/	O
or	O
CC	O
strain	O
x	O
experimental	O
diet	O
interactions	O
had	O
significant	O
effects	O
on	O
metabolic	O
traits	O
.	O

Heat	O
production	O
,	O
RER	O
,	O
energy	O
intake	O
,	O
and	O
basal	O
activity	O
phenotypes	O
varied	O
widely	O
by	O
CC	O
strain	O
(	O
Figure	O
6	O
,	O
Supplementary	O
Figures	O
6	O
,	O
7	O
,	O
Supplementary	O
Table	O
10	O
)	O
,	O
with	O
phenotype	O
measurements	O
higher	O
at	O
night	O
than	O
day	O
which	O
reflected	O
the	O
active	O
nocturnal	O
behavior	O
of	O
mice	O
.	O
Wilcoxon	O
signed	O
rank	O
tests	O
performed	O
comparing	O
the	O
day	O
and	O
night	O
measurements	O
for	O
each	O
trait	O
confirmed	O
the	O
differences	O
between	O
light	O
and	O
dark	O
cycles	O
for	O
all	O
strains	O
on	O
both	O
diets	O
(	O
p	O
<	O
2	O
.	O
2	O
×	O
10−16	O
for	O
all	O
traits	O
)	O
.	O
Overall	O
heat	O
production	O
while	O
accounting	O
for	O
total	O
weight	O
(	O
Heat1	O
)	O
was	O
highest	O
on	O
average	O
for	O
both	O
day	O
and	O
night	O
cycles	O
in	O
the	O
leanest	O
strain	O
,	O
CC019	O
/	O
TauUnc	O
on	O
the	O
HS	O
diet	O
(	O
21	O
.	O
4	O
±	O
0	O
.	O
64	O
and	O
27	O
.	O
6	O
±	O
0	O
.	O
87	O
kcal	O
/	O
h	O
/	O
kg	O
in	O
the	O
day	O
and	O
night	O
)	O
(	O
Figure	O
6A	O
,	O
Supplementary	O
Figure	O
6A	O
)	O
.	O
During	O
the	O
day	O
,	O
heat	O
production	O
was	O
lowest	O
in	O
CC030	O
/	O
GeniUnc	O
on	O
the	O
HP	O
diet	O
(	O
11	O
.	O
9	O
±	O
2	O
.	O
86	O
kcal	O
/	O
h	O
/	O
kg	O
)	O
even	O
though	O
CC030	O
/	O
GeniUnc	O
was	O
relatively	O
lean	O
compared	O
to	O
other	O
strains	O
on	O
the	O
same	O
diet	O
(	O
11	O
.	O
9	O
±	O
1	O
.	O
2	O
%	O
,	O
Figure	O
4A	O
)	O
,	O
while	O
heat	O
production	O
was	O
lowest	O
in	O
CC008	O
/	O
GeniUnc	O
during	O
the	O
night	O
on	O
the	O
HS	O
diet	O
(	O
15	O
.	O
4	O
±	O
0	O
.	O
30	O
kcal	O
/	O
h	O
/	O
kg	O
)	O
,	O
which	O
was	O
one	O
of	O
the	O
fatter	O
strains	O
compared	O
to	O
other	O
strains	O
in	O
the	O
same	O
diet	O
(	O
26	O
.	O
8	O
±	O
1	O
.	O
3	O
%	O
,	O
Figure	O
4A	O
)	O
.	O
Overall	O
heat	O
production	O
while	O
accounting	O
for	O
only	O
lean	O
mass	O
(	O
Heat2	O
)	O
(	O
Figure	O
6B	O
,	O
Supplementary	O
Figure	O
6B	O
)	O
was	O
highest	O
on	O
average	O
for	O
CC019	O
/	O
TauUnc	O
on	O
the	O
HS	O
diet	O
during	O
the	O
day	O
(	O
7	O
.	O
61	O
±	O
0	O
.	O
23	O
kcal	O
/	O
h	O
/	O
kg	O
)	O
and	O
CC004	O
/	O
TauUnc	O
on	O
the	O
HP	O
diet	O
at	O
night	O
(	O
10	O
.	O
2	O
±	O
0	O
.	O
56	O
kcal	O
/	O
h	O
/	O
kg	O
)	O
and	O
lowest	O
in	O
CC030	O
/	O
GeniUnc	O
on	O
the	O
HP	O
diet	O
(	O
4	O
.	O
35	O
±	O
1	O
.	O
06	O
and	O
5	O
.	O
81	O
±	O
0	O
.	O
94	O
kcal	O
/	O
h	O
/	O
kg	O
in	O
the	O
day	O
and	O
night	O
,	O
respectively	O
)	O
.	O
In	O
summary	O
,	O
variation	O
in	O
energy	O
production	O
was	O
much	O
larger	O
between	O
strains	O
than	O
diets	O
,	O
with	O
the	O
differences	O
in	O
phenotype	O
by	O
diet	O
depending	O
on	O
the	O
strain	O
(	O
Supplementary	O
Figure	O
6	O
)	O
.	O

Linear	O
mixed	O
model	O
analysis	O
showed	O
that	O
CC	O
strain	O
×	O
experimental	O
diet	O
interactions	O
had	O
significant	O
effects	O
on	O
energy	O
production	O
during	O
both	O
day	O
and	O
night	O
,	O
but	O
the	O
effect	O
of	O
CC	O
strain	O
was	O
much	O
stronger	O
and	O
may	O
be	O
driving	O
the	O
effects	O
of	O
CC	O
strain	O
×	O
experimental	O
diet	O
interactions	O
(	O
Supplementary	O
Table	O
6	O
)	O
.	O
In	O
linear	O
mixed	O
models	O
testing	O
the	O
effect	O
of	O
experimental	O
diet	O
alone	O
,	O
diet	O
had	O
a	O
significant	O
effect	O
on	O
Heat2	O
during	O
the	O
day	O
(	O
F	O
=	O
5	O
.	O
3	O
,	O
p	O
=	O
0	O
.	O
03	O
)	O
but	O
not	O
any	O
of	O
the	O
other	O
heat	O
production	O
measured	O
(	O
Supplementary	O
Table	O
8	O
)	O
,	O
suggesting	O
that	O
diet	O
may	O
have	O
a	O
different	O
effect	O
on	O
metabolism	O
during	O
the	O
day	O
for	O
lean	O
mass	O
compared	O
to	O
non	O
-	O
lean	O
mass	O
.	O
Similar	O
to	O
energy	O
production	O
,	O
the	O
wide	O
range	O
of	O
variation	O
in	O
substrate	O
utilization	O
(	O
RER	O
)	O
depended	O
on	O
CC	O
strain	O
and	O
were	O
all	O
higher	O
during	O
the	O
night	O
compared	O
to	O
the	O
day	O
for	O
mice	O
within	O
the	O
same	O
strain	O
on	O
either	O
diets	O
(	O
Figure	O
6C	O
,	O
Supplementary	O
Figure	O
7A	O
)	O
.	O
RER	O
levels	O
were	O
lowest	O
in	O
CC030	O
/	O
GeniUnc	O
during	O
the	O
day	O
and	O
CC012	O
/	O
GeniUnc	O
during	O
the	O
night	O
on	O
the	O
high	O
protein	O
diet	O
(	O
0	O
.	O
725	O
±	O
0	O
.	O
007	O
and	O
0	O
.	O
76	O
±	O
0	O
.	O
01	O
)	O
even	O
though	O
the	O
adiposity	O
of	O
CC012	O
/	O
GeniUnc	O
was	O
twice	O
the	O
adiposity	O
of	O
CC030	O
/	O
GeniUnc	O
(	O
24	O
.	O
1	O
±	O
1	O
.	O
8	O
%	O
and	O
11	O
.	O
9	O
±	O
1	O
.	O
2	O
%	O
,	O
Figure	O
4A	O
)	O
,	O
while	O
RER	O
levels	O
were	O
highest	O
in	O
CC071	O
during	O
the	O
day	O
and	O
CC019	O
/	O
TauUnc	O
during	O
the	O
night	O
on	O
the	O
HS	O
diet	O
(	O
0	O
.	O
825	O
±	O
0	O
.	O
019	O
and	O
0	O
.	O
943	O
±	O
0	O
.	O
013	O
)	O
despite	O
vastly	O
different	O
levels	O
of	O
adiposity	O
(	O
13	O
.	O
9	O
±	O
1	O
.	O
5	O
%	O
in	O
CC071	O
and	O
4	O
.	O
7	O
±	O
0	O
.	O
5	O
%	O
in	O
CC019	O
/	O
TauUnc	O
,	O
Figure	O
4A	O
)	O
.	O
Surprisingly	O
,	O
linear	O
mixed	O
model	O
analysis	O
revealed	O
that	O
both	O
CC	O
strain	O
and	O
experimental	O
diet	O
independently	O
had	O
significant	O
effects	O
on	O
RER	O
for	O
both	O
day	O
and	O
night	O
(	O
Supplementary	O
Tables	O
6	O
,	O
8	O
)	O
,	O
but	O
despite	O
CC	O
strain	O
having	O
a	O
stronger	O
effect	O
than	O
diet	O
,	O
the	O
effects	O
of	O
CC	O
strain	O
×	O
diet	O
interactions	O
were	O
not	O
significant	O
.	O
Our	O
indirect	O
calorimetry	O
assays	O
were	O
also	O
able	O
to	O
calculate	O
the	O
energy	O
intake	O
and	O
activity	O
of	O
the	O
mice	O
over	O
the	O
48	O
-	O
h	O
test	O
.	O

As	O
expected	O
,	O
there	O
were	O
significant	O
differences	O
between	O
night	O
and	O
day	O
cycles	O
in	O
both	O
of	O
these	O
behaviors	O
,	O
as	O
confirmed	O
by	O
the	O
results	O
of	O
Wilcoxon	O
signed	O
rank	O
tests	O
(	O
p	O
<	O
2	O
.	O
2	O
×	O
10−16	O
)	O
.	O
Energy	O
intake	O
was	O
lowest	O
in	O
the	O
lean	O
strain	O
CC041	O
/	O
TauUnc	O
on	O
the	O
HP	O
diet	O
for	O
both	O
day	O
and	O
night	O
(	O
0	O
.	O
579	O
±	O
0	O
.	O
110	O
kcal	O
/	O
h	O
and	O
2	O
.	O
68	O
±	O
0	O
.	O
915	O
kcal	O
/	O
h	O
)	O
(	O
Figure	O
6D	O
,	O
Supplementary	O
Figure	O
7B	O
)	O
.	O
Food	O
intake	O
was	O
highest	O
for	O
strain	O
CC024	O
/	O
GeniUnc	O
during	O
the	O
day	O
(	O
16	O
.	O
47	O
±	O
3	O
.	O
661	O
kcal	O
/	O
h	O
)	O
and	O
CC019	O
/	O
TauUnc	O
during	O
the	O
night	O
(	O
26	O
.	O
64	O
±	O
7	O
.	O
301	O
kcal	O
/	O
h	O
)	O
on	O
the	O
HS	O
diet	O
.	O
The	O
energy	O
consumption	O
was	O
variable	O
depending	O
on	O
the	O
diet	O
consumed	O
.	O
For	O
example	O
,	O
in	O
terms	O
of	O
mice	O
on	O
the	O
HS	O
diet	O
,	O
energy	O
intake	O
was	O
highest	O
in	O
CC024	O
/	O
GeniUnc	O
during	O
the	O
day	O
(	O
16	O
.	O
47	O
±	O
3	O
.	O
66	O
kcal	O
/	O
h	O
)	O
and	O
CC019	O
/	O
TauUnc	O
at	O
night	O
(	O
26	O
.	O
64	O
±	O
7	O
.	O
30	O
kcal	O
/	O
h	O
)	O
,	O
and	O
lowest	O
in	O
CC063	O
/	O
Unc	O
during	O
both	O
day	O
(	O
2	O
.	O
32	O
±	O
0	O
.	O
17	O
kcal	O
/	O
h	O
)	O
and	O
night	O
(	O
4	O
.	O
59	O
±	O
0	O
.	O
44	O
kcal	O
/	O
h	O
)	O
.	O
Additionally	O
,	O
energy	O
intake	O
for	O
CC063	O
/	O
Unc	O
was	O
extremely	O
variable	O
on	O
the	O
HP	O
diet	O
during	O
the	O
day	O
and	O
night	O
(	O
39	O
.	O
45	O
±	O
18	O
.	O
00	O
kcal	O
/	O
h	O
and	O
40	O
.	O
42	O
±	O
17	O
.	O
34	O
kcal	O
/	O
h	O
)	O
.	O
Because	O
of	O
this	O
high	O
variability	O
,	O
four	O
types	O
of	O
linear	O
mixed	O
models	O
were	O
fitted	O
for	O
both	O
day	O
and	O
night	O
energy	O
intake	O
:	O
(	O
1	O
)	O
model	O
testing	O
for	O
the	O
effect	O
of	O
diet	O
including	O
CC063	O
/	O
Unc	O
,	O
(	O
2	O
)	O
model	O
testing	O
for	O
the	O
effect	O
of	O
diet	O
excluding	O
CC063	O
/	O
Unc	O
,	O
(	O
3	O
)	O
model	O
testing	O
for	O
the	O
effect	O
of	O
CC	O
strain	O
×	O
diet	O
including	O
CC063	O
/	O
Unc	O
,	O
and	O
(	O
4	O
)	O
model	O
testing	O
for	O
the	O
effect	O
of	O
CC	O
strain	O
x	O
diet	O
excluding	O
CC063	O
/	O
Unc	O
.	O

For	O
energy	O
intake	O
both	O
day	O
and	O
night	O
,	O
both	O
experimental	O
diet	O
and	O
CC	O
strain	O
had	O
significant	O
effects	O
on	O
energy	O
intake	O
regardless	O
of	O
whether	O
CC063	O
/	O
Unc	O
was	O
included	O
,	O
but	O
the	O
CC	O
strain	O
×	O
diet	O
interaction	O
did	O
not	O
significantly	O
affect	O
energy	O
intake	O
when	O
CC063	O
/	O
Unc	O
was	O
excluded	O
(	O
Supplementary	O
Table	O
11	O
)	O
.	O
Although	O
we	O
could	O
not	O
identify	O
a	O
specific	O
error	O
with	O
the	O
collection	O
or	O
calculation	O
of	O
the	O
data	O
for	O
CC063	O
/	O
Unc	O
,	O
results	O
for	O
energy	O
intake	O
from	O
CC063	O
/	O
Unc	O
should	O
be	O
interpreted	O
with	O
caution	O
.	O
Basal	O
activity	O
exhibited	O
phenotypic	O
variation	O
depending	O
on	O
and	O
between	O
CC	O
strains	O
,	O
but	O
barely	O
any	O
difference	O
by	O
diet	O
(	O
Figure	O
6E	O
,	O
Supplementary	O
Figure	O
7C	O
)	O
.	O
Diurnal	O
basal	O
activity	O
was	O
lowest	O
in	O
CC030	O
/	O
GeniUnc	O
on	O
the	O
HP	O
diet	O
and	O
CC041	O
/	O
TauUnc	O
on	O
the	O
HS	O
diet	O
(	O
988	O
.	O
8	O
±	O
383	O
.	O
1	O
and	O
1	O
,	O
188	O
.	O
2	O
±	O
260	O
.	O
6	O
beam	O
breaks	O
/	O
h	O
)	O
,	O
and	O
highest	O
in	O
CC004	O
/	O
TauUnc	O
on	O
the	O
HP	O
diet	O
and	O
CC045	O
/	O
GeniUnc	O
on	O
the	O
HS	O
diet	O
(	O
4	O
,	O
328	O
.	O
1	O
±	O
985	O
.	O
7	O
and	O
3	O
,	O
322	O
.	O
5	O
±	O
988	O
.	O
8	O
beam	O
breaks	O
/	O
h	O
)	O
,	O
while	O
nocturnal	O
basal	O
activity	O
was	O
lowest	O
in	O
CC012	O
/	O
GeniUnc	O
on	O
the	O
both	O
HP	O
and	O
HS	O
diets	O
(	O
2	O
,	O
304	O
.	O
4	O
±	O
124	O
.	O
7	O
and	O
2	O
,	O
792	O
.	O
7	O
±	O
337	O
.	O
7	O
beam	O
breaks	O
/	O
h	O
)	O
,	O
and	O
highest	O
in	O
CC004	O
/	O
TauUnc	O
on	O
HP	O
and	O
CC045	O
/	O
GeniUnc	O
on	O
HS	O
diets	O
(	O
16	O
,	O
742	O
.	O
5	O
±	O
1	O
,	O
919	O
.	O
9	O
and	O
11	O
,	O
081	O
.	O
9	O
±	O
6	O
,	O
070	O
.	O
3	O
beam	O
breaks	O
/	O
h	O
)	O
.	O
Linear	O
mixed	O
model	O
analysis	O
confirmed	O
that	O
only	O
CC	O
strain	O
had	O
a	O
significant	O
effect	O
on	O
both	O
diurnal	O
and	O
nocturnal	O
basal	O
activity	O
;	O
the	O
effects	O
of	O
experimental	O
diet	O
and	O
CC	O
strain	O
x	O
experimental	O
diet	O
interactions	O
were	O
not	O
significant	O
(	O
Supplementary	O
Tables	O
6	O
,	O
8	O
)	O
.	O
Our	O
comprehensive	O
phenotyping	O
demonstrates	O
the	O
high	O
variability	O
among	O
metabolic	O
traits	O
.	O
Using	O
the	O
phenotyping	O
data	O
,	O
Spearman	O
'	O
s	O
correlations	O
between	O
body	O
composition	O
and	O
traits	O
related	O
to	O
energy	O
intake	O
or	O
expenditure	O
were	O
performed	O
.	O

Although	O
the	O
individual	O
phenotypes	O
are	O
variable	O
between	O
strains	O
there	O
are	O
several	O
notable	O
results	O
,	O
such	O
as	O
the	O
negative	O
correlations	O
between	O
body	O
fat	O
percentage	O
and	O
all	O
expenditure	O
phenotypes	O
except	O
for	O
basal	O
activity	O
and	O
diurnal	O
fat	O
intake	O
(	O
rho	O
<	O
−0	O
.	O
17	O
,	O
padj	O
<	O
0	O
.	O
02	O
)	O
.	O
Conversely	O
,	O
lean	O
mass	O
percentage	O
was	O
positively	O
correlated	O
with	O
all	O
energy	O
intake	O
/	O
expenditure	O
phenotypes	O
except	O
for	O
basal	O
activity	O
,	O
diurnal	O
fat	O
intake	O
,	O
and	O
diurnal	O
carbohydrate	O
intake	O
(	O
rho	O
>	O
0	O
.	O
16	O
,	O
padj	O
<	O
0	O
.	O
025	O
,	O
Figure	O
7	O
)	O
.	O
Total	O
body	O
weight	O
was	O
significantly	O
but	O
negatively	O
correlated	O
with	O
nocturnal	O
protein	O
intake	O
,	O
night	O
RER	O
,	O
and	O
heat	O
expenditure	O
(	O
rho	O
<	O
−0	O
.	O
17	O
,	O
padj	O
<	O
0	O
.	O
01	O
)	O
,	O
while	O
all	O
energy	O
intake	O
phenotypes	O
were	O
positively	O
correlated	O
with	O
RER	O
,	O
energy	O
expenditure	O
phenotypes	O
,	O
and	O
basal	O
activity	O
(	O
rho	O
>	O
0	O
.	O
19	O
,	O
padj	O
<	O
0	O
.	O
008	O
,	O
Figure	O
7	O
)	O
.	O
Body	O
fat	O
percentage	O
and	O
heat	O
production	O
(	O
accounting	O
for	O
total	O
weight	O
)	O
are	O
negatively	O
correlated	O
for	O
both	O
day	O
and	O
night	O
(	O
rho	O
=	O
−0	O
.	O
563	O
and	O
rho	O
=	O
−0	O
.	O
612	O
)	O
,	O
stronger	O
than	O
the	O
negative	O
correlations	O
between	O
body	O
fat	O
percentage	O
and	O
energy	O
intake	O
(	O
rho	O
=	O
−0	O
.	O
20	O
and	O
rho	O
=	O
−0	O
.	O
26	O
)	O
.	O
These	O
data	O
demonstrate	O
that	O
the	O
decrease	O
in	O
food	O
intake	O
as	O
body	O
fat	O
percentage	O
increases	O
is	O
not	O
enough	O
to	O
maintain	O
energy	O
balance	O
.	O
Coupled	O
with	O
average	O
adiposity	O
measurements	O
,	O
indirect	O
calorimetry	O
data	O
demonstrated	O
that	O
energy	O
expenditure	O
varies	O
tremendously	O
between	O
inbred	O
strains	O
of	O
similar	O
weight	O
,	O
specifically	O
strains	O
CC030	O
/	O
GeniUnc	O
and	O
CC019	O
/	O
TauUnc	O
(	O
Figure	O
8	O
)	O
.	O
Although	O
mice	O
from	O
these	O
two	O
strains	O
were	O
close	O
in	O
terms	O
of	O
average	O
total	O
body	O
weight	O
(	O
Figure	O
8A	O
)	O
,	O
the	O
average	O
body	O
fat	O
percentage	O
of	O
CC030	O
/	O
GeniUnc	O
was	O
more	O
than	O
twice	O
the	O
average	O
body	O
fat	O
percent	O
of	O
CC019	O
/	O
TauUnc	O
(	O
Figure	O
8B	O
)	O
.	O
CC019	O
/	O
TauUnc	O
stayed	O
consistently	O
lean	O
across	O
diets	O
,	O
while	O
CC030	O
/	O
GeniUnc	O
'	O
s	O
highest	O
average	O
post	O
-	O
diet	O
body	O
fat	O
percentage	O
paradoxically	O
decreased	O
with	O
increasing	O
dietary	O
fat	O
content	O
(	O
Figure	O
4A	O
)	O
.	O

Comparing	O
the	O
two	O
strains	O
of	O
mice	O
on	O
the	O
same	O
diet	O
,	O
CC019	O
/	O
TauUnc	O
mice	O
consistently	O
consumed	O
more	O
calories	O
than	O
CC030	O
/	O
GeniUnc	O
mice	O
during	O
both	O
day	O
and	O
night	O
(	O
Figure	O
8C	O
)	O
but	O
also	O
consistently	O
produced	O
more	O
heat	O
than	O
CC030	O
/	O
GeniUnc	O
and	O
importantly	O
,	O
produced	O
enough	O
heat	O
to	O
achieve	O
energy	O
balance	O
(	O
Figure	O
8D	O
)	O
.	O
In	O
addition	O
to	O
CC019	O
/	O
TauUnc	O
'	O
s	O
relatively	O
high	O
metabolism	O
,	O
the	O
difference	O
in	O
substrate	O
utilization	O
between	O
the	O
two	O
strains	O
could	O
help	O
to	O
explain	O
their	O
different	O
responses	O
to	O
diet	O
(	O
Figure	O
8E	O
)	O
;	O
during	O
the	O
night	O
,	O
the	O
average	O
RERs	O
of	O
CC019	O
/	O
TauUnc	O
are	O
0	O
.	O
943	O
and	O
0	O
.	O
926	O
on	O
the	O
HS	O
and	O
HP	O
diets	O
,	O
and	O
the	O
average	O
RERs	O
of	O
CC030	O
/	O
GeniUnc	O
are	O
0	O
.	O
82	O
and	O
0	O
.	O
798	O
on	O
the	O
HS	O
and	O
HP	O
diets	O
,	O
implying	O
that	O
CC019	O
/	O
TauUnc	O
mice	O
are	O
utilizing	O
carbohydrates	O
as	O
their	O
fuel	O
source	O
more	O
than	O
CC030	O
/	O
GeniUnc	O
mice	O
,	O
which	O
could	O
suggest	O
that	O
CC019	O
/	O
TauUnc	O
mice	O
are	O
more	O
active	O
than	O
CC030	O
/	O
GeniUnc	O
mice	O
.	O
Intriguingly	O
,	O
substrate	O
utilization	O
during	O
the	O
light	O
phase	O
was	O
quite	O
different	O
between	O
strains	O
.	O
The	O
average	O
RERs	O
of	O
CC019	O
/	O
TauUnc	O
across	O
diets	O
is	O
0	O
.	O
800	O
and	O
the	O
average	O
RERs	O
of	O
CC030	O
/	O
GeniUnc	O
are	O
0	O
.	O
746	O
and	O
0	O
.	O
725	O
on	O
the	O
HS	O
and	O
HP	O
diets	O
,	O
which	O
suggests	O
that	O
at	O
rest	O
CC030	O
/	O
GeniUnc	O
mice	O
preferentially	O
utilize	O
fat	O
as	O
an	O
energy	O
source	O
more	O
than	O
carbohydrate	O
as	O
compared	O
to	O
CC019	O
/	O
TauUnc	O
mice	O
(	O
Figure	O
8F	O
)	O
.	O
Given	O
the	O
variation	O
in	O
diet	O
-	O
driven	O
changes	O
in	O
adiposity	O
,	O
we	O
next	O
investigated	O
whether	O
there	O
were	O
alterations	O
in	O
metabolic	O
health	O
in	O
corresponding	O
fashion	O
.	O
We	O
correlated	O
body	O
fat	O
%	O
after	O
diet	O
feeding	O
with	O
other	O
traits	O
(	O
Figure	O
9	O
)	O
.	O
Broadly	O
,	O
body	O
fat	O
%	O
is	O
strongly	O
correlated	O
with	O
total	O
weight	O
(	O
Figure	O
9B	O
;	O
rho	O
>	O
0	O
.	O
579	O
,	O
p	O
<	O
3	O
.	O
91	O
×	O
10−10	O
)	O
,	O
and	O
moderately	O
correlated	O
with	O
insulin	O
levels	O
,	O
total	O
heat	O
production	O
,	O
and	O
total	O
RER	O
(	O
Supplementary	O
Table	O
12	O
)	O
.	O

Remarkably	O
,	O
the	O
significant	O
correlations	O
at	O
baseline	O
(	O
Figure	O
3	O
)	O
between	O
body	O
fat	O
%	O
and	O
TG	O
(	O
rho	O
=	O
0	O
.	O
24	O
,	O
padj	O
=	O
1	O
.	O
35	O
×	O
10−3	O
)	O
,	O
carnitine	O
(	O
rho	O
=	O
0	O
.	O
17	O
,	O
padj	O
=	O
0	O
.	O
036	O
)	O
,	O
and	O
choline	O
(	O
rho	O
=	O
0	O
.	O
19	O
,	O
padj	O
=	O
0	O
.	O
018	O
)	O
were	O
no	O
longer	O
significant	O
after	O
the	O
diet	B-methodology
challenge	I-methodology
(	O
Supplementary	O
Table	O
12	O
)	O
,	O
indicating	O
that	O
the	O
metabolic	O
effect	O
of	O
diet	O
varies	O
among	O
clinical	O
traits	O
.	O
Spearman	O
'	O
s	O
correlation	O
analysis	O
performed	O
between	O
metabolic	O
traits	O
and	O
other	O
traits	O
related	O
to	O
adiposity	O
(	O
Figure	O
9A	O
)	O
revealed	O
significant	O
correlations	O
between	O
metabolic	O
health	O
score	O
and	O
heat	O
production	O
accounting	O
for	O
total	O
weight	O
(	O
Heat1	O
)	O
(	O
rho	O
=	O
0	O
.	O
37	O
,	O
padj	O
=	O
2	O
.	O
61	O
×	O
10−7	O
)	O
,	O
heat	O
production	O
accounting	O
for	O
lean	O
mass	O
(	O
Heat2	O
)	O
(	O
rho	O
=	O
0	O
.	O
32	O
,	O
padj	O
=	O
9	O
.	O
12	O
×	O
10−6	O
)	O
,	O
feed	O
intake	O
(	O
rho	O
=	O
0	O
.	O
20	O
,	O
padj	O
=	O
0	O
.	O
009	O
)	O
,	O
energy	O
intake	O
(	O
rho	O
=	O
0	O
.	O
20	O
,	O
padj	O
=	O
0	O
.	O
009	O
)	O
,	O
and	O
RER	O
(	O
rho	O
=	O
0	O
.	O
36	O
,	O
padj	O
=	O
7	O
.	O
08	O
×	O
10−7	O
)	O
but	O
not	O
basal	O
activity	O
(	O
padj	O
=	O
0	O
.	O
76	O
)	O
.	O
These	O
relationships	O
are	O
heavily	O
driven	O
by	O
the	O
body	O
fat	O
%	O
component	O
of	O
metabolic	O
health	O
score	O
,	O
as	O
body	O
fat	O
%	O
was	O
also	O
significantly	O
correlated	O
with	O
these	O
traits	O
but	O
in	O
the	O
“	O
opposite	O
”	O
direction	O
(	O
Supplementary	O
Table	O
12	O
)	O
.	O
Of	O
all	O
circulating	O
analytes	O
and	O
1	O
-	O
carbon	O
metabolites	O
,	O
RER	O
was	O
moderately	O
correlated	O
with	O
albumin	O
(	O
rho	O
=	O
−0	O
.	O
29	O
,	O
padj	O
=	O
3	O
.	O
21	O
×	O
10−4	O
)	O
,	O
heat	O
production	O
accounting	O
for	O
total	O
body	O
weight	O
and	O
lean	O
mass	O
showed	O
a	O
slight	O
negative	O
correlation	O
with	O
albumin	O
(	O
rho	O
=	O
−0	O
.	O
19	O
,	O
padj	O
=	O
0	O
.	O
01	O
for	O
both	O
heat	O
production	O
estimations	O
)	O
,	O
and	O
feed	O
intake	O
was	O
positively	O
correlated	O
with	O
betaine	O
(	O
rho	O
=	O
0	O
.	O
21	O
,	O
padj	O
=	O
0	O
.	O
02	O
)	O
and	O
carnitine	O
(	O
rho	O
=	O
0	O
.	O
22	O
,	O
padj	O
=	O
9	O
.	O
12	O
×	O
10−3	O
)	O
.	O

Other	O
than	O
metabolic	O
traits	O
,	O
the	O
only	O
traits	O
which	O
total	O
basal	O
activity	O
showed	O
slight	O
correlations	O
with	O
were	O
insulin	O
(	O
rho	O
=	O
0	O
.	O
23	O
,	O
padj	O
=	O
3	O
.	O
31	O
×	O
10−3	O
)	O
and	O
glucose	O
/	O
insulin	O
ratio	O
(	O
rho	O
=	O
−0	O
.	O
19	O
,	O
padj	O
=	O
0	O
.	O
02	O
)	O
.	O
With	O
the	O
rapid	O
rise	O
in	O
the	O
global	O
prevalence	O
of	O
obesity	O
and	O
obesity	O
-	O
related	O
diseases	O
in	O
the	O
recent	O
decades	O
(	O
Flegal	O
,	O
2010	O
;	O
Ogden	O
et	O
al	O
.	O
,	O
2016	O
,	O
2018	O
)	O
,	O
there	O
is	O
a	O
crucial	O
need	O
to	O
improve	O
our	O
understanding	O
of	O
obesity	O
.	O
Individually	O
,	O
diet	O
and	O
genetics	O
are	O
known	O
to	O
be	O
critical	O
factors	O
in	O
the	O
development	O
of	O
obesity	O
,	O
but	O
our	O
understanding	O
of	O
how	O
diet	O
and	O
genetics	O
interact	O
to	O
affect	O
obesity	O
remain	O
to	O
be	O
fully	O
elucidated	O
.	O
Taken	O
at	O
the	O
individual	O
gene	O
level	O
,	O
this	O
is	O
a	O
daunting	O
task	O
.	O
There	O
are	O
hundreds	O
of	O
genes	O
associated	O
with	O
body	O
weight	O
and	O
BMI	O
reported	O
in	O
the	O
GWAS	B-methodology
catalog	O
and	O
these	O
can	O
interact	O
with	O
each	O
other	O
and	O
diet	O
,	O
increasing	O
the	O
complexity	O
of	O
obesity	O
(	O
Bell	O
et	O
al	O
.	O
,	O
2005	O
;	O
Rankinen	O
et	O
al	O
.	O
,	O
2006	O
;	O
Kunej	O
et	O
al	O
.	O
,	O
2013	O
;	O
Singh	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
Thus	O
,	O
the	O
complexity	O
and	O
heterogeneity	O
of	O
obesity	O
may	O
affect	O
dietary	O
recommendations	O
,	O
as	O
illustrated	O
by	O
the	O
lack	O
of	O
a	O
universally	O
“	O
perfect	O
”	O
diet	O
for	O
weight	O
loss	O
(	O
Dansinger	O
et	O
al	O
.	O
,	O
2005	O
;	O
Johnston	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O
Increasing	O
our	O
knowledge	O
of	O
how	O
genetics	O
and	O
environmental	O
factors	O
(	O
particularly	O
diet	O
)	O
interact	O
,	O
the	O
degree	O
to	O
which	O
these	O
interactions	O
impact	O
the	O
development	O
of	O
obesity	O
,	O
and	O
the	O
mechanisms	O
behind	O
these	O
effects	O
are	O
crucial	O
to	O
developing	O
successful	O
methods	O
for	O
mitigating	O
obesity	O
.	O
To	O
investigate	O
the	O
degree	O
that	O
genetics	O
,	O
diet	O
,	O
and	O
gene	O
-	O
by	O
-	O
diet	O
interactions	O
impact	O
phenotypic	O
variation	O
in	O
obesity	O
,	O
obesity	O
-	O
related	O
traits	O
,	O
and	O
metabolic	O
traits	O
,	O
we	O
performed	O
our	O
study	O
on	O
multiple	O
strains	O
of	O
mice	O
from	O
the	O
CC	O
genetic	O
reference	O
population	O
to	O
overcome	O
the	O
limitations	O
of	O
human	B-methodology
studies	I-methodology
,	O
especially	O
in	O
terms	O
of	O
controlling	O
genetic	O
background	O
,	O
diet	O
,	O
and	O
other	O
environmental	O
influences	O
.	O
The	O
CC	O
is	O
well	O
-	O
suited	O
for	O
investigating	O
genetic	O
vs	O
.	O
environmental	O
impacts	O
on	O
phenotypic	O
variation	O
due	O
to	O
its	O
high	O
genetic	O
diversity	O
and	O
ability	O
to	O
generate	O
genetic	O
“	O
replicates	O
”	O
which	O
enables	O
increased	O
accuracy	O
in	O
phenotypic	O
measurements	O
.	O

Indeed	O
,	O
the	O
CC	O
has	O
already	O
been	O
used	O
to	O
provide	O
a	O
genetic	O
framework	O
to	O
depict	O
the	O
relationship	O
between	O
body	O
weight	O
and	O
the	O
central	O
nervous	O
system	O
(	O
Mao	O
et	O
al	O
.	O
,	O
2015	O
)	O
,	O
high	O
fat	O
diet	O
and	O
fasting	O
glucose	O
levels	O
(	O
Atamni	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
and	O
hepatic	O
gene	O
expression	O
in	O
response	O
to	O
impaired	O
glucose	O
tolerance	O
(	O
Atamni	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
The	O
CC	O
has	O
also	O
been	O
used	O
as	O
a	O
model	O
to	O
study	O
exercise	O
-	O
induced	O
paradoxical	O
fat	O
response	O
(	O
McMullan	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
The	O
current	O
manuscript	O
adds	O
to	O
this	O
literature	O
by	O
examining	O
the	O
dietary	O
responses	O
of	O
the	O
CC	O
.	O
While	O
previous	O
studies	O
have	O
examined	O
subsets	O
of	O
obesity	O
-	O
related	O
traits	O
in	O
the	O
CC	O
and	O
energy	O
balance	O
traits	O
have	O
been	O
examined	O
in	O
pre	O
-	O
CC	O
lines	O
(	O
Mathes	O
et	O
al	O
.	O
,	O
2011	O
)	O
,	O
we	O
examined	O
the	O
unique	O
effect	O
of	O
diet	O
in	O
this	O
population	O
.	O
In	O
this	O
study	O
we	O
sought	O
to	O
elucidate	O
the	O
relationships	O
between	O
genetic	O
background	O
,	O
diet	O
,	O
adiposity	O
,	O
and	O
obesity	O
-	O
related	O
traits	O
.	O
Our	O
comprehensive	O
phenotyping	O
included	O
:	O
body	O
composition	O
,	O
circulating	O
analyte	O
and	O
metabolite	O
levels	O
,	O
and	O
metabolism	O
through	O
indirect	O
calorimetry	O
,	O
followed	O
by	O
the	O
integration	O
of	O
all	O
these	O
data	O
in	O
common	O
analyses	O
.	O
We	O
found	O
that	O
in	O
the	O
absence	O
of	O
dietary	O
perturbation	O
,	O
many	O
of	O
the	O
traits	O
phenotyped	O
in	O
this	O
manuscript	O
are	O
heritable	O
in	O
the	O
CC	O
.	O
Defined	O
as	O
the	O
proportion	O
of	O
phenotypic	O
variation	O
due	O
to	O
genetic	O
variation	O
for	O
a	O
specific	O
population	O
,	O
we	O
calculated	O
broad	O
sense	O
heritability	O
for	O
adiposity	O
and	O
other	O
traits	O
for	O
mice	O
on	O
the	O
synthetic	O
chow	O
diet	O
at	O
baseline	O
to	O
estimate	O
the	O
strength	O
of	O
genetic	O
contribution	O
.	O
Traits	O
related	O
to	O
body	O
composition	O
had	O
moderately	O
high	O
broad	O
sense	O
heritability	O
(	O
g2	O
)	O
at	O
baseline	O
ranging	O
between	O
0	O
.	O
359	O
and	O
0	O
.	O
565	O
,	O
with	O
the	O
broad	O
sense	O
heritability	O
estimate	O
of	O
total	O
body	O
weight	O
at	O
0	O
.	O
499	O
which	O
is	O
higher	O
than	O
a	O
previously	O
reported	O
estimate	O
in	O
the	O
CC	O
at	O
0	O
.	O
37	O
(	O
Atamni	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Given	O
that	O
H2	O
estimates	O
can	O
vary	O
among	O
studies	O
,	O
we	O
also	O
calculated	O
g2	O
for	O
baseline	O
body	O
fat	O
%	O
,	O
lean	O
%	O
,	O
and	O
total	O
weight	O
using	O
four	O
publicly	O
available	O
body	O
composition	O
data	O
sets	O
(	O
McMullan	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
The	O
range	O
of	O
g2	O
for	O
these	O
traits	O
across	O
the	O
4	O
data	O
sets	O
were	O
between	O
0	O
.	O
268	O
and	O
0	O
.	O
511	O
,	O
similar	O
to	O
the	O
estimates	O
in	O
this	O
study	O
.	O

The	O
average	O
baseline	O
g2	O
for	O
lean	O
%	O
in	O
the	O
McMullan	O
study	O
(	O
g2	O
=	O
0	O
.	O
358	O
)	O
and	O
the	O
current	O
study	O
(	O
g2	O
=	O
0	O
.	O
359	O
)	O
were	O
closer	O
than	O
the	O
average	O
g2	O
for	O
weight	O
in	O
the	O
McMullan	O
study	O
(	O
g2	O
=	O
0	O
.	O
357	O
)	O
and	O
the	O
current	O
study	O
(	O
g2	O
=	O
0	O
.	O
499	O
)	O
,	O
but	O
the	O
average	O
g2	O
for	O
body	O
fat	O
%	O
in	O
the	O
McMullan	O
study	O
and	O
the	O
current	O
study	O
was	O
the	O
same	O
(	O
g2	O
=	O
0	O
.	O
383	O
)	O
,	O
which	O
is	O
close	O
to	O
the	O
minimum	O
heritability	O
of	O
0	O
.	O
4	O
in	O
humans	O
as	O
indicated	O
by	O
twin	O
studies	O
(	O
Bell	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O
The	O
heritability	O
of	O
most	O
circulating	O
metabolites	O
in	O
the	O
CC	O
varied	O
between	O
12	O
and	O
46	O
%	O
,	O
similar	O
to	O
the	O
heritability	O
of	O
circulating	O
small	O
metabolites	O
and	O
amino	O
acids	O
in	O
humans	O
,	O
which	O
has	O
been	O
reported	O
to	O
vary	O
between	O
23	O
and	O
55	O
%	O
(	O
Dharuri	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O
Interestingly	O
,	O
broad	O
sense	O
heritability	O
for	O
circulating	O
insulin	O
(	O
0	O
.	O
153	O
)	O
was	O
much	O
lower	O
than	O
heritability	O
for	O
adiposity	O
(	O
0	O
.	O
383	O
)	O
,	O
which	O
implies	O
that	O
environmental	O
factors	O
such	O
as	O
diet	O
or	O
lifestyle	O
may	O
have	O
a	O
stronger	O
effect	O
on	O
attenuating	O
hyperinsulinemia	O
than	O
adiposity	O
.	O
Overall	O
,	O
these	O
data	O
suggest	O
similar	O
overall	O
metabolic	O
health	O
parameters	O
to	O
those	O
observed	O
in	O
humans	O
,	O
demonstrating	O
that	O
the	O
high	O
genetic	O
,	O
and	O
phenotypic	O
diversity	O
of	O
the	O
CC	O
make	O
this	O
mouse	O
panel	O
a	O
suitable	O
model	O
for	O
studying	O
obesity	O
,	O
a	O
trait	O
with	O
complex	O
etiology	O
.	O
Furthermore	O
,	O
we	O
have	O
identified	O
which	O
specific	O
strains	O
have	O
predispositions	O
for	O
increased	O
adiposity	O
accumulation	O
,	O
total	O
weight	O
,	O
circulating	O
analyte	O
levels	O
,	O
and	O
metabolic	O
phenotypes	O
.	O
Like	O
the	O
CC	O
,	O
the	O
relationship	O
between	O
weight	O
and	O
adiposity	O
is	O
not	O
always	O
uniform	O
within	O
humans	O
(	O
Hashimoto	O
et	O
al	O
.	O
,	O
2016	O
;	O
Verheggen	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
While	O
the	O
CC	O
mostly	O
showed	O
a	O
strong	O
positive	O
relationship	O
between	O
adiposity	O
and	O
weight	O
,	O
several	O
strains	O
such	O
as	O
CC011	O
/	O
Unc	O
,	O
CC008	O
/	O
GeniUnc	O
,	O
and	O
CC059	O
/	O
TauUnc	O
that	O
weighed	O
more	O
than	O
the	O
majority	O
of	O
other	O
strains	O
had	O
only	O
~	O
15	O
%	O
body	O
fat	O
,	O
compared	O
to	O
the	O
fattest	O
strains	O
with	O
20	O
–	O
23	O
%	O
body	O
fat	O
.	O

Similar	O
to	O
the	O
relationship	O
between	O
weight	O
and	O
adiposity	O
,	O
the	O
relationship	O
between	O
adiposity	O
and	O
overall	O
metabolic	O
health	O
can	O
vary	O
within	O
humans	O
(	O
Yaghootkar	O
et	O
al	O
.	O
,	O
2014	O
,	O
2016	O
;	O
Ding	O
et	O
al	O
.	O
,	O
2016	O
;	O
Gonçalves	O
et	O
al	O
.	O
,	O
2016	O
;	O
Iacobini	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
At	O
both	O
baseline	O
and	O
post	O
-	O
diet	O
,	O
significant	O
associations	O
between	O
body	O
fat	O
%	O
and	O
individual	O
markers	O
of	O
metabolic	O
health	O
were	O
only	O
detected	O
consistently	O
for	O
body	O
fat	O
%	O
and	O
insulin	O
,	O
and	O
body	O
fat	O
%	O
and	O
alanine	O
transaminase	O
(	O
ALT	O
)	O
.	O
One	O
possible	O
explanation	O
for	O
the	O
lack	O
of	O
associations	O
obtained	O
is	O
the	O
nocturnal	O
eating	O
pattern	O
of	O
mice	O
,	O
since	O
the	O
concentration	O
of	O
glucose	O
and	O
insulin	O
fluctuates	O
with	O
their	O
circadian	O
rhythms	O
(	O
Jensen	O
et	O
al	O
.	O
,	O
2013	O
)	O
,	O
though	O
the	O
number	O
of	O
hours	O
that	O
the	O
mice	O
were	O
fasted	O
prior	O
to	O
the	O
blood	O
draw	O
could	O
also	O
have	O
minor	O
effects	O
on	O
the	O
analytes	O
measured	O
.	O
By	O
estimating	O
the	O
average	O
metabolic	O
health	O
of	O
each	O
CC	O
strain	O
via	O
calculation	O
of	O
a	O
metabolic	O
health	O
score	O
,	O
we	O
identified	O
CC028	O
/	O
GeniUnc	O
and	O
CC040	O
/	O
TauUnc	O
as	O
two	O
of	O
the	O
fattest	O
strains	O
in	O
our	O
study	O
that	O
were	O
healthier	O
than	O
the	O
leaner	O
strains	O
CC030	O
/	O
GeniUnc	O
and	O
CC041	O
/	O
TauUnc	O
at	O
baseline	O
,	O
whose	O
body	O
fat	O
%	O
were	O
half	O
of	O
CC028	O
/	O
GeniUnc	O
and	O
CC040	O
/	O
TauUnc	O
,	O
mirroring	O
the	O
“	O
sub	O
-	O
phenotypes	O
”	O
within	O
obesity	O
of	O
metabolically	O
“	O
healthy	O
”	O
or	O
“	O
unhealthy	O
”	O
individuals	O
found	O
in	O
human	B-methodology
studies	I-methodology
(	O
Peppa	O
et	O
al	O
.	O
,	O
2013	O
;	O
Dobson	O
et	O
al	O
.	O
,	O
2015	O
;	O
Schulze	O
,	O
2019	O
)	O
.	O
After	O
the	O
8	O
-	O
week	O
diet	B-methodology
challenge	I-methodology
,	O
CC028	O
/	O
GeniUnc	O
and	O
CC040	O
/	O
TauUnc	O
remained	O
healthier	O
than	O
CC030	O
/	O
GeniUnc	O
,	O
while	O
CC041	O
/	O
TauUnc	O
was	O
both	O
leaner	O
and	O
healthier	O
than	O
these	O
three	O
strains	O
,	O
reflecting	O
the	O
strain	O
-	O
dependent	O
effect	O
of	O
diet	O
.	O
At	O
baseline	O
the	O
body	O
fat	O
%	O
measured	O
in	O
the	O
CC	O
mice	O
demonstrated	O
that	O
the	O
predisposition	O
to	O
developing	O
obesity	O
occurred	O
in	O
a	O
strain	O
-	O
dependent	O
manner	O
;	O
baseline	O
body	O
fat	O
%	O
also	O
highlighted	O
the	O
wide	O
phenotypic	O
variation	O
across	O
strains	O
and	O
minor	O
phenotypic	O
variation	O
within	O
strains	O
,	O
which	O
varied	O
by	O
trait	O
and	O
strain	O
.	O

For	O
most	O
traits	O
at	O
baseline	O
such	O
as	O
total	O
weight	O
,	O
TG	O
,	O
cholesterol	O
,	O
and	O
glucose	O
,	O
the	O
ranges	O
of	O
strain	O
coefficients	O
of	O
variation	O
(	O
CV	O
%	O
)	O
were	O
within	O
~	O
20	O
%	O
;	O
for	O
example	O
,	O
the	O
CV	O
%	O
of	O
total	O
weight	O
for	O
each	O
strain	O
was	O
4	O
.	O
91	O
–	O
23	O
.	O
2	O
%	O
where	O
CC030	O
/	O
GeniUnc	O
exhibited	O
the	O
lowest	O
within	O
-	O
strain	O
phenotypic	O
variation	O
(	O
CV	O
%	O
=	O
4	O
.	O
91	O
)	O
and	O
CC040	O
/	O
TauUnc	O
exhibited	O
the	O
highest	O
within	O
-	O
strain	O
phenotypic	O
variation	O
(	O
CV	O
%	O
=	O
23	O
.	O
2	O
%	O
)	O
.	O
The	O
range	O
of	O
strain	O
CV	O
%	O
for	O
baseline	O
body	O
fat	O
%	O
was	O
slightly	O
larger	O
(	O
13	O
.	O
9	O
–	O
44	O
.	O
7	O
%	O
)	O
,	O
demonstrating	O
that	O
certain	O
traits	O
may	O
be	O
more	O
sensitive	O
to	O
environmental	O
differences	O
such	O
as	O
being	O
housed	O
in	O
different	O
cages	O
which	O
could	O
lead	O
to	O
differences	O
in	O
microbiome	O
exposure	O
,	O
or	O
minor	O
genetic	O
differences	O
since	O
completed	O
CC	O
lines	O
are	O
at	O
least	O
98	O
%	O
homozygous	O
(	O
UNC	O
Systems	O
Genetics	O
Core	O
Facility	O
,	O
2012	O
)	O
but	O
not	O
necessarily	O
the	O
same	O
degree	O
of	O
homozygosity	O
across	O
individuals	O
.	O
By	O
analyzing	O
the	O
post	O
-	O
diet	O
metabolic	O
traits	O
measured	O
in	O
these	O
22	O
CC	O
strains	O
together	O
,	O
our	O
data	O
recapitulates	O
some	O
key	O
findings	O
in	O
humans	O
by	O
Sims	O
(	O
1976	O
)	O
.	O
As	O
expected	O
,	O
metabolic	O
rate	O
estimated	O
as	O
heat	O
production	O
had	O
the	O
strongest	O
inverse	O
relationship	O
with	O
post	O
-	O
diet	O
body	O
fat	O
%	O
,	O
which	O
implies	O
that	O
body	O
fat	O
%	O
increases	O
as	O
metabolic	O
rate	O
decreases	O
.	O
Body	O
fat	O
%	O
was	O
not	O
significantly	O
correlated	O
with	O
basal	O
activity	O
,	O
showing	O
that	O
spontaneous	O
physical	O
activity	O
alone	O
did	O
not	O
significantly	O
alter	O
the	O
degree	O
of	O
adiposity	O
accumulation	O
.	O
Remarkably	O
,	O
energy	O
intake	O
decreased	O
as	O
body	O
fat	O
%	O
increased	O
;	O
when	O
adjusted	O
for	O
total	O
body	O
weight	O
,	O
this	O
negative	O
correlation	O
increased	O
in	O
both	O
strength	O
and	O
significance	O
regardless	O
of	O
diet	O
(	O
Supplementary	O
Figure	O
8	O
)	O
,	O
suggesting	O
that	O
the	O
body	O
attempts	O
to	O
adjust	O
energy	O
consumption	O
and	O
maintain	O
energy	O
homeostasis	O
when	O
adiposity	O
is	O
in	O
excess	O
,	O
as	O
reflected	O
by	O
changes	O
in	O
hormone	O
levels	O
that	O
regulate	O
energy	O
consumption	O
such	O
as	O
increased	O
leptin	O
secretion	O
from	O
adipose	O
tissue	O
(	O
Caro	O
et	O
al	O
.	O
,	O
1996	O
;	O
Friedman	O
and	O
Halaas	O
,	O
1998	O
)	O
and	O
lower	O
levels	O
of	O
the	O
gut	O
satiety	O
-	O
related	O
peptide	O
tyrosine	O
-	O
tyrosine	O
(	O
PYY	O
)	O
found	O
in	O
obese	O
individuals	O
(	O
Simpson	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

As	O
body	O
fat	O
%	O
increases	O
,	O
the	O
secretion	O
of	O
the	O
satiety	O
hormone	O
leptin	O
from	O
adipocytes	O
also	O
increases	O
,	O
which	O
would	O
lead	O
to	O
a	O
decrease	O
in	O
appetite	O
and	O
therefore	O
a	O
decrease	O
in	O
feed	O
consumption	O
.	O
Because	O
the	O
HS	O
diet	O
contains	O
290	O
g	O
of	O
sucrose	O
for	O
1	O
,	O
042	O
.	O
8	O
g	O
of	O
HS	O
diet	O
and	O
the	O
HP	O
diet	O
contains	O
113	O
g	O
of	O
sucrose	O
for	O
1	O
,	O
000	O
.	O
1	O
g	O
of	O
HP	O
diet	O
,	O
another	O
potential	O
explanation	O
for	O
the	O
negative	O
correlation	O
between	O
energy	O
intake	O
and	O
body	O
fat	O
%	O
is	O
the	O
glucostatic	O
theory	O
,	O
which	O
states	O
that	O
glucose	O
availability	O
and	O
utilization	O
in	O
specific	O
regions	O
of	O
the	O
brain	O
may	O
affect	O
the	O
regulation	O
of	O
satiety	O
perception	O
and	O
short	O
-	O
term	O
regulation	O
of	O
appetite	O
(	O
Mayer	O
,	O
1953	O
)	O
.	O
Thus	O
,	O
for	O
two	O
mice	O
consuming	O
the	O
same	O
grams	O
of	O
experimental	O
diet	O
,	O
the	O
mouse	O
fed	O
the	O
HS	O
diet	O
would	O
consume	O
more	O
sucrose	O
than	O
the	O
mouse	O
fed	O
the	O
HP	O
diet	O
,	O
resulting	O
in	O
a	O
difference	O
in	O
the	O
availability	O
of	O
glucose	O
for	O
each	O
mouse	O
and	O
possible	O
differences	O
in	O
the	O
utilization	O
of	O
macronutrients	O
depending	O
on	O
the	O
strain	O
(	O
genetic	O
effects	O
)	O
.	O
For	O
example	O
,	O
the	O
night	O
RER	O
of	O
CC002	O
/	O
Unc	O
was	O
0	O
.	O
847	O
on	O
the	O
HP	O
diet	O
and	O
0	O
.	O
921	O
on	O
the	O
HS	O
diet	O
,	O
whereas	O
the	O
night	O
RER	O
of	O
CC008	O
/	O
GeniUnc	O
was	O
0	O
.	O
821	O
on	O
the	O
HP	O
diet	O
and	O
0	O
.	O
824	O
on	O
the	O
HS	O
diet	O
(	O
Supplementary	O
Table	O
10	O
)	O
.	O
Future	O
studies	O
using	O
isocaloric	O
diets	O
with	O
more	O
extreme	O
differences	O
only	O
in	O
fat	O
content	O
or	O
only	O
sucrose	O
content	O
would	O
help	O
determine	O
whether	O
the	O
stronger	O
negative	O
correlation	O
between	O
energy	O
intake	O
after	O
correcting	O
for	O
total	O
weight	O
and	O
body	O
fat	O
%	O
of	O
mice	O
fed	O
the	O
HS	O
diet	O
is	O
attributed	O
to	O
increased	O
fat	O
or	O
sucrose	O
content	O
.	O
As	O
accumulation	O
of	O
adiposity	O
increased	O
,	O
RER	O
decreased	O
which	O
implies	O
increased	O
utilization	O
of	O
fat	O
as	O
the	O
substrate	O
for	O
energy	O
expenditure	O
since	O
fat	O
is	O
in	O
excess	O
.	O
RER	O
was	O
strongly	O
positively	O
correlated	O
with	O
heat	O
production	O
,	O
illustrating	O
that	O
the	O
increase	O
in	O
metabolic	O
rate	O
shifts	O
substrate	O
utilization	O
toward	O
carbohydrates	O
and	O
away	O
from	O
fat	O
.	O
If	O
energy	O
expenditure	O
remains	O
unchanged	O
,	O
the	O
metabolic	O
flexibility	O
of	O
shifting	O
from	O
carbohydrate	O
utilization	O
toward	O
lipid	O
utilization	O
would	O
compensate	O
for	O
the	O
decrease	O
in	O
energy	O
consumption	O
(	O
Farias	O
et	O
al	O
.	O
,	O
2011	O
;	O
Goodpaster	O
and	O
Sparks	O
,	O
2017	O
)	O
.	O

Along	O
with	O
the	O
strong	O
positive	O
correlation	O
between	O
heat	O
production	O
and	O
energy	O
intake	O
,	O
the	O
relationships	O
between	O
metabolic	O
traits	O
reaffirm	O
the	O
implication	O
of	O
energy	O
balance	O
.	O
The	O
consistency	O
between	O
the	O
current	O
results	O
and	O
Sims	O
'	O
results	O
demonstrates	O
the	O
ability	O
of	O
the	O
CC	O
to	O
reliably	O
model	O
human	O
genotypic	O
and	O
phenotypic	O
variation	O
when	O
studying	O
complex	O
traits	O
.	O
After	O
8	O
weeks	O
of	O
feeding	O
the	O
CC	O
mice	O
either	O
the	O
HP	O
or	O
HS	O
diet	O
,	O
assessing	O
body	O
composition	O
in	O
the	O
CC	O
revealed	O
the	O
strains	O
'	O
different	O
responses	O
to	O
diet	O
in	O
terms	O
of	O
weight	O
gain	O
and	O
other	O
phenotypic	O
changes	O
in	O
obesity	O
-	O
related	O
traits	O
.	O
Consistent	O
with	O
the	O
findings	O
of	O
Barrington	O
et	O
al	O
.	O
(	O
2017	O
)	O
,	O
the	O
strength	O
of	O
the	O
effect	O
of	O
diet	O
depended	O
on	O
the	O
trait	O
examined	O
,	O
macronutrient	O
composition	O
,	O
and	O
subject	O
strain	O
(	O
genetic	O
background	O
)	O
.	O
For	O
example	O
,	O
certain	O
CC	O
strains	O
did	O
not	O
respond	O
to	O
differences	O
in	O
macronutrient	O
composition	O
,	O
either	O
remaining	O
persistently	O
fat	O
(	O
CC040	O
/	O
TauUnc	O
,	O
CC063	O
/	O
Unc	O
,	O
CC001	O
/	O
Unc	O
)	O
or	O
lean	O
(	O
CC019	O
/	O
TauUnc	O
)	O
regardless	O
of	O
experimental	O
diet	O
,	O
while	O
other	O
strains	O
clearly	O
accumulated	O
less	O
body	O
fat	O
%	O
on	O
the	O
HP	O
diet	O
compared	O
to	O
the	O
HS	O
diet	O
(	O
CC028	O
/	O
GeniUnc	O
,	O
CC004	O
/	O
TauUnc	O
,	O
CC006	O
/	O
TauUnc	O
)	O
.	O
Furthermore	O
,	O
experimental	O
diet	O
alone	O
did	O
not	O
have	O
a	O
significant	O
effect	O
in	O
general	O
on	O
circulating	O
glucose	O
,	O
insulin	O
,	O
nor	O
TG	O
based	O
on	O
the	O
results	O
of	O
the	O
linear	O
mixed	O
model	O
analysis	O
,	O
but	O
certain	O
CC	O
strains	O
showed	O
drastic	O
differences	O
in	O
phenotypic	O
response	O
to	O
diet	O
for	O
these	O
traits	O
,	O
such	O
as	O
CC036	O
/	O
Unc	O
,	O
CC002	O
,	O
and	O
CC004	O
/	O
TauUnc	O
for	O
TG	O
;	O
CC036	O
/	O
Unc	O
and	O
CC040	O
/	O
TauUnc	O
for	O
glucose	O
;	O
and	O
CC040	O
/	O
TauUnc	O
,	O
CC004	O
/	O
TauUnc	O
,	O
CC045	O
/	O
GeniUnc	O
,	O
and	O
CC032	O
/	O
GeniUnc	O
for	O
insulin	O
.	O
The	O
different	O
response	O
to	O
diet	O
by	O
CC	O
strain	O
suggests	O
that	O
variation	O
in	O
genetic	O
architecture	O
may	O
contribute	O
to	O
differences	O
in	O
individual	O
nutrient	O
need	O
and	O
substrate	O
utilization	O
,	O
which	O
should	O
be	O
taken	O
into	O
account	O
when	O
developing	O
weight	O
loss	O
strategies	O
.	O

Similar	O
to	O
the	O
findings	O
in	O
this	O
study	O
,	O
a	O
recent	O
large	O
-	O
scale	O
human	B-methodology
study	I-methodology
performed	O
by	O
Berry	O
et	O
al	O
.	O
(	O
2020	O
)	O
examining	O
postprandial	O
metabolic	O
response	O
to	O
food	O
relative	O
to	O
precision	O
nutrition	O
highlighted	O
large	O
inter	O
-	O
individual	O
variability	O
when	O
subjects	O
were	O
fed	O
identical	O
meals	O
,	O
and	O
found	O
that	O
genetic	O
background	O
and	O
environmental	O
factors	O
,	O
including	O
person	O
-	O
specific	O
factors	O
(	O
e	O
.	O
g	O
.	O
,	O
the	O
microbiome	O
)	O
and	O
meal	O
macronutrients	O
,	O
had	O
varying	O
degrees	O
of	O
influence	O
on	O
traits	O
assessed	O
.	O
Mirroring	O
the	O
broad	O
range	O
of	O
phenotypic	O
response	O
to	O
diet	O
in	O
the	O
CC	O
,	O
human	O
participants	O
in	O
the	O
DIETFITS	O
Randomized	B-methodology
Clinical	I-methodology
Trial	I-methodology
that	O
were	O
administered	O
either	O
a	O
low	O
-	O
fat	O
or	O
low	O
-	O
carbohydrate	O
diet	O
also	O
exhibited	O
a	O
wide	O
range	O
of	O
response	O
to	O
diet	O
in	O
terms	O
of	O
weight	O
loss	O
over	O
12	O
months	O
,	O
regardless	O
of	O
their	O
genotypes	O
defined	O
by	O
three	O
SNPs	O
(	O
Gardner	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
Due	O
to	O
the	O
complex	O
etiology	O
of	O
obesity	O
,	O
studies	O
in	O
humans	O
endeavoring	O
to	O
prove	O
direct	O
relationships	O
between	O
individual	O
SNPs	O
and	O
obesity	O
have	O
succeeded	O
in	O
finding	O
associations	O
between	O
genetic	O
loci	O
and	O
body	O
weight	O
(	O
Deeb	O
et	O
al	O
.	O
,	O
1998	O
;	O
Scuteri	O
et	O
al	O
.	O
,	O
2007	O
;	O
Speliotes	O
et	O
al	O
.	O
,	O
2010	O
;	O
Claussnitzer	O
et	O
al	O
.	O
,	O
2015	O
;	O
Hägg	O
et	O
al	O
.	O
,	O
2015	O
)	O
,	O
but	O
translational	O
application	O
of	O
these	O
associations	O
will	O
first	O
require	O
further	O
investigation	O
into	O
the	O
biological	O
function	O
of	O
novel	O
obesity	O
-	O
associated	O
genetic	O
loci	O
(	O
Loos	O
,	O
2018	O
)	O
and	O
elucidation	O
of	O
the	O
causes	O
behind	O
conflicting	O
findings	O
where	O
associations	O
between	O
genetic	O
loci	O
and	O
phenotypes	O
were	O
not	O
detected	O
(	O
Sørensen	O
et	O
al	O
.	O
,	O
2006	O
;	O
Drabsch	O
et	O
al	O
.	O
,	O
2018	O
;	O
Gardner	O
et	O
al	O
.	O
,	O
2018	O
;	O
Merino	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
Nevertheless	O
,	O
the	O
phenotypic	O
variation	O
in	O
adiposity	O
by	O
CC	O
strain	O
in	O
this	O
study	O
clearly	O
illustrate	O
the	O
genetic	O
predisposition	O
for	O
developing	O
obesity	O
,	O
concurrent	O
with	O
findings	O
in	O
humans	O
(	O
Stunkard	O
et	O
al	O
.	O
,	O
1986	O
;	O
Bouchard	O
and	O
Tremblay	O
,	O
1997	O
;	O
Viitasalo	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Therefore	O
,	O
effective	O
mitigation	O
of	O
obesity	O
using	O
personalized	O
nutrition	O
would	O
ideally	O
incorporate	O
information	O
regarding	O
an	O
individual	O
'	O
s	O
genetic	O
background	O
,	O
behavior	O
,	O
environmental	O
influences	O
,	O
physiological	O
response	O
to	O
diet	O
,	O
and	O
socioeconomic	O
situation	O
in	O
addition	O
to	O
their	O
genotype	O
in	O
terms	O
of	O
recommendations	O
for	O
alterations	O
in	O
diet	O
and	O
exercise	O
levels	O
(	O
Drabsch	O
and	O
Holzapfel	O
,	O
2019	O
)	O
.	O

One	O
caveat	O
of	O
our	O
study	B-methodology
design	I-methodology
is	O
that	O
we	O
cannot	O
assess	O
the	O
effect	O
of	O
aging	O
nor	O
whether	O
there	O
are	O
strain	O
specific	O
age	O
-	O
related	O
phenotypes	O
given	O
the	O
natural	O
variation	O
both	O
between	O
strains	O
and	O
between	O
individuals	O
within	O
strains	O
.	O
Similar	O
to	O
the	O
current	O
study	O
,	O
a	O
preprint	O
of	O
a	O
pending	O
manuscript	O
utilizing	O
B	O
×	O
D	O
mice	O
indicates	O
that	O
certain	O
age	O
-	O
related	O
phenotypes	O
such	O
as	O
longevity	O
and	O
weight	O
are	O
under	O
strong	O
genetic	O
regulation	O
and	O
are	O
also	O
affected	O
by	O
diet	O
and	O
gene	O
-	O
by	O
-	O
environmental	O
interactions	O
(	O
Roy	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Our	O
diet	B-methodology
challenge	I-methodology
and	O
age	O
are	O
confounded	O
and	O
we	O
cannot	O
assess	O
differences	O
in	O
genetic	O
susceptibility	O
that	O
are	O
age	O
dependent	O
.	O
Additional	O
investigations	O
using	O
a	O
modified	O
study	B-methodology
design	I-methodology
could	O
effectively	O
assess	O
the	O
effect	O
of	O
aging	O
on	O
metabolic	O
factors	O
in	O
CC	O
mice	O
.	O
Although	O
basal	O
activity	O
levels	O
were	O
assessed	O
,	O
one	O
limitation	O
of	O
this	O
study	O
is	O
the	O
lack	O
of	O
“	O
true	O
”	O
exercise	O
activity	O
(	O
e	O
.	O
g	O
.	O
,	O
wheel	O
running	O
)	O
,	O
since	O
increased	O
weight	O
loss	O
in	O
humans	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
increased	O
physical	O
activity	O
if	O
calorie	O
intake	O
is	O
controlled	O
(	O
Zemel	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O
Another	O
caveat	O
of	O
this	O
study	O
is	O
the	O
unavailability	O
of	O
metabolic	O
phenotype	O
data	O
for	O
the	O
mice	O
at	O
baseline	O
(	O
e	O
.	O
g	O
.	O
,	O
energy	O
expenditure	O
,	O
feed	O
intake	O
,	O
RER	O
,	O
basal	O
activity	O
)	O
,	O
which	O
limits	O
the	O
conclusions	O
that	O
can	O
be	O
made	O
regarding	O
the	O
effects	O
of	O
diet	O
compared	O
to	O
feed	O
intake	O
on	O
energy	O
balance	O
when	O
interpreting	O
these	O
data	O
.	O
Moreover	O
,	O
recent	O
studies	O
have	O
found	O
that	O
the	O
gut	O
microbiota	O
also	O
potentially	O
play	O
a	O
significant	O
role	O
in	O
the	O
development	O
of	O
obesity	O
(	O
Tilg	O
and	O
Kaser	O
,	O
2011	O
;	O
Pace	O
and	O
Crowe	O
,	O
2016	O
;	O
Lee	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
Further	O
studies	O
should	O
be	O
performed	O
with	O
multiple	O
genetically	O
diverse	O
populations	O
to	O
determine	O
which	O
diets	O
would	O
be	O
most	O
effective	O
for	O
weight	O
loss	O
by	O
individuals	O
according	O
to	O
their	O
genetic	O
background	O
and	O
to	O
examine	O
the	O
state	O
of	O
epigenetic	O
markers	O
and	O
transcript	O
expression	O
levels	O
in	O
specific	O
tissues	O
.	O
Raw	O
metabolomics	O
data	O
are	O
available	O
at	O
the	O
NIH	O
Common	O
Fund	O
'	O
s	O
National	O
Metabolomics	O
Data	O
Repository	O
(	O
NMDR	O
)	O
website	O
,	O
the	O
Metabolomics	O
Workbench	O
,	O
https	O
:	O
/	O
/	O
www	O
.	O
metabolomicsworkbench	O
.	O
org	O
,	O
where	O
it	O
has	O
been	O
assigned	O
Project	O
ID	O
PR001032	O
.	O
The	O
data	O
can	O
be	O
accessed	O
directly	O
via	O
its	O
Project	O
doi	O
:	O
10	O
.	O
21228	O
/	O
M89D63	O
.	O

The	O
animal	B-methodology
study	I-methodology
was	O
reviewed	O
and	O
approved	O
by	O
University	O
of	O
North	O
Carolina	O
Institution	O
Animal	O
Care	O
and	O
Use	O
Committee	O
.	O
PY	O
assisted	O
with	O
data	O
collection	O
,	O
analyzed	O
the	O
data	O
,	O
performed	O
the	O
statistical	O
analysis	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O
JA	O
and	O
MV	O
maintained	O
the	O
mice	O
,	O
performed	O
the	O
experiment	O
on	O
them	O
,	O
and	O
collected	O
data	O
.	O
EG	O
also	O
collected	O
and	O
processed	O
data	O
.	O
BB	O
conceived	O
of	O
and	O
designed	O
the	O
study	O
with	O
the	O
assistance	O
of	O
FP	O
-	O
M	O
.	O
BB	O
performed	O
analysis	O
and	O
interpretation	O
of	O
the	O
data	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O
All	O
authors	O
contributed	O
to	O
the	O
article	O
and	O
approved	O
the	O
submitted	O
version	O
.	O
The	O
authors	O
declare	O
that	O
the	O
research	O
was	O
conducted	O
in	O
the	O
absence	O
of	O
any	O
commercial	O
or	O
financial	O
relationships	O
that	O
could	O
be	O
construed	O
as	O
a	O
potential	O
conflict	O
of	O
interest	O
.	O
Funding	O
.	O
This	O
research	O
was	O
supported	O
in	O
part	O
by	O
in	O
part	O
by	O
grants	O
from	O
the	O
National	O
Institutes	O
of	O
Health	O
5R01HL128572	O
(	O
to	O
BB	O
)	O
,	O
P30DK056350	O
(	O
to	O
BB	O
)	O
,	O
a	O
pilot	O
grant	O
from	O
the	O
Nutrition	O
Research	O
Institute	O
(	O
to	O
BB	O
)	O
,	O
and	O
United	O
States	O
Department	O
of	O
Agriculture	O
(	O
USDA	O
)	O
/	O
Agricultural	O
Research	O
Service	O
(	O
ARS	O
)	O
/	O
Western	O
Human	O
Nutrition	O
Research	O
Center	O
project	O
funds	O
(	O
2032	O
-	O
51000	O
-	O
022	O
-	O
00D	O
)	O
.	O
The	O
USDA	O
is	O
an	O
equal	O
opportunity	O
employer	O
and	O
provider	O
.	O

Interplay	O
of	O
an	O
Obesity	O
-	O
Based	O
Genetic	O
Risk	O
Score	O
with	O
Dietary	O
and	O
Endocrine	O
Factors	O
on	O
Insulin	O
Resistance	O
insulin	O
resistance	O
;	O
obesity	O
;	O
genetic	O
risk	O
score	O
;	O
diet	O
;	O
metabolic	O
factors	O
;	O
personalized	O
nutrition	O
This	O
study	O
aimed	O
to	O
nutrigenetically	O
screen	O
gene	O
-	O
diet	O
and	O
gene	O
-	O
metabolic	O
interactions	O
influencing	O
insulin	O
resistance	O
(	O
IR	O
)	O
phenotypes	O
.	O
A	O
total	O
of	O
232	O
obese	O
or	O
overweight	O
adults	O
were	O
categorized	O
by	O
IR	O
status	O
:	O
non	O
-	O
IR	O
(	O
HOMA	O
-	O
IR	O
(	O
homeostatic	O
model	O
assessment	O
-	O
insulin	O
resistance	O
)	O
index	O
≤	O
2	O
.	O
5	O
)	O
and	O
IR	O
(	O
HOMA	O
-	O
IR	O
index	O
>	O
2	O
.	O
5	O
)	O
.	O
A	O
weighted	O
genetic	O
risk	O
score	O
(	O
wGRS	O
)	O
was	O
constructed	O
using	O
95	O
single	O
nucleotide	O
polymorphisms	O
related	O
to	O
energy	O
homeostasis	O
,	O
which	O
were	O
genotyped	O
by	O
a	O
next	O
generation	O
sequencing	O
system	O
.	O
Body	O
composition	O
,	O
the	O
metabolic	O
profile	O
and	O
lifestyle	O
variables	O
were	O
evaluated	O
,	O
where	O
individuals	O
with	O
IR	O
showed	O
worse	O
metabolic	O
outcomes	O
.	O
Overall	O
,	O
16	O
obesity	O
-	O
predisposing	O
genetic	O
variants	O
were	O
associated	O
with	O
IR	O
(	O
p	O
<	O
0	O
.	O
10	O
in	O
the	O
multivariate	O
model	O
)	O
.	O
The	O
wGRS	O
strongly	O
associated	O
with	O
the	O
HOMA	O
-	O
IR	O
index	O
(	O
adj	O
.	O
R	O
squared	O
=	O
0	O
.	O
2705	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O
Moreover	O
,	O
the	O
wGRS	O
positively	O
interacted	O
with	O
dietary	O
intake	O
of	O
cholesterol	O
(	O
P	O
int	O
.	O
=	O
0	O
.	O
002	O
)	O
,	O
and	O
with	O
serum	O
concentrations	O
of	O
C	O
-	O
reactive	O
protein	O
(	O
P	O
int	O
.	O
=	O
0	O
.	O
008	O
)	O
regarding	O
IR	O
status	O
,	O
whereas	O
a	O
negative	O
interaction	O
was	O
found	O
regarding	O
adiponectin	O
blood	O
levels	O
(	O
P	O
int	O
.	O
=	O
0	O
.	O
006	O
)	O
.	O
In	O
conclusion	O
,	O
this	O
study	O
suggests	O
that	O
interactions	O
between	O
an	O
adiposity	O
-	O
based	O
wGRS	O
with	O
nutritional	O
and	O
metabolic	O
/	O
endocrine	O
features	O
influence	O
IR	O
phenotypes	O
,	O
which	O
could	O
facilitate	O
the	O
prescription	O
of	O
personalized	O
nutrition	O
recommendations	O
for	O
precision	O
prevention	O
and	O
management	O
of	O
IR	O
and	O
diabetes	O
.	O
Obesity	O
usually	O
has	O
a	O
negative	O
metabolic	O
impact	O
associated	O
to	O
an	O
excessive	O
and	O
abnormal	O
adipose	O
tissue	O
deposition	O
and	O
function	O
[	O
1	O
]	O
,	O
which	O
affects	O
several	O
physiological	O
processes	O
such	O
as	O
glucose	O
homeostasis	O
and	O
insulin	O
sensitivity	O
[	O
2	O
]	O
.	O

Insulin	O
resistance	O
(	O
IR	O
)	O
is	O
characterized	O
by	O
complete	O
or	O
partial	O
insufficiency	O
of	O
insulin	O
action	O
on	O
target	O
tissues	O
,	O
being	O
one	O
of	O
the	O
first	O
physiological	O
abnormalities	O
that	O
precede	O
the	O
development	O
of	O
type	O
2	O
diabetes	O
(	O
T2D	O
)	O
and	O
being	O
usually	O
related	O
to	O
concomitant	O
metabolic	O
chronic	O
diseases	O
such	O
as	O
obesity	O
,	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
,	O
and	O
atherosclerosis	O
[	O
3	O
]	O
.	O
In	O
turn	O
,	O
this	O
condition	O
is	O
associated	O
with	O
concomitant	O
pathological	O
processes	O
including	O
hyperlipidemia	O
,	O
ectopic	O
lipid	O
accumulation	O
,	O
low	O
-	O
grade	O
inflammation	O
,	O
endoplasmic	O
reticulum	O
stress	O
,	O
and	O
oxidative	O
cell	O
damage	O
[	O
4	O
]	O
.	O
Given	O
the	O
high	O
heterogeneity	O
of	O
chronic	O
diseases	O
,	O
efforts	O
have	O
been	O
made	O
to	O
stratify	O
clinical	O
/	O
metabolic	O
outcomes	O
in	O
order	O
to	O
personalize	O
the	O
treatment	O
.	O
In	O
this	O
context	O
,	O
novel	O
subgroups	O
of	O
adult	O
-	O
onset	O
diabetes	O
with	O
variable	O
disease	O
progression	O
have	O
been	O
postulated	O
[	O
5	O
]	O
.	O
Studies	O
have	O
shown	O
that	O
body	O
fat	O
accumulation	O
in	O
the	O
android	O
or	O
gynoid	O
compartments	O
has	O
been	O
associated	O
with	O
different	O
cardiometabolic	O
risk	O
factors	O
,	O
including	O
IR	O
[	O
6	O
]	O
.	O
Additionally	O
,	O
metabolically	O
healthy	O
and	O
unhealthy	O
phenotypes	O
have	O
emerged	O
in	O
subjects	O
with	O
excessive	O
adiposity	O
[	O
7	O
]	O
.	O
Although	O
the	O
precise	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
onset	O
and	O
progression	O
of	O
IR	O
are	O
not	O
completely	O
understood	O
,	O
studies	O
suggest	O
that	O
genetic	O
and	O
environmental	O
factors	O
may	O
influence	O
IR	O
predisposition	O
[	O
8	O
]	O
.	O
Accordingly	O
,	O
candidate	O
,	O
linkage	O
and	O
genome	B-methodology
-	I-methodology
wide	I-methodology
association	I-methodology
studies	I-methodology
have	O
allowed	O
the	O
identification	O
of	O
a	O
number	O
of	O
genetic	O
variants	O
associated	O
with	O
IR	O
and	O
related	O
traits	O
[	O
9	O
]	O
.	O
Moreover	O
,	O
Westernized	O
food	O
patterns	O
in	O
conjunction	O
with	O
sedentary	O
behaviors	O
contribute	O
to	O
the	O
increased	O
risk	O
of	O
IR	O
and	O
T2D	O
[	O
10	O
]	O
.	O
Furthermore	O
,	O
potential	O
interactions	O
between	O
genetic	O
polymorphisms	O
and	O
nutritional	O
factors	O
have	O
been	O
pioneerly	O
proposed	O
to	O
modulate	O
the	O
risk	O
of	O
developing	O
IR	O
[	O
11	O
,	O
12	O
]	O
as	O
well	O
as	O
changes	O
in	O
IR	O
status	O
in	O
response	O
to	O
dietary	B-methodology
interventions	I-methodology
may	O
be	O
gene	O
-	O
dependent	O
[	O
13	O
,	O
14	O
]	O
.	O

Together	O
,	O
these	O
findings	O
highlight	O
the	O
importance	O
to	O
study	O
the	O
complex	O
interactions	O
between	O
the	O
genetic	O
background	O
and	O
lifestyles	O
underlying	O
IR	O
in	O
order	O
to	O
translate	O
this	O
information	O
into	O
innovative	O
strategies	O
aimed	O
to	O
the	O
early	O
detection	O
,	O
accurate	O
diagnosis	O
,	O
and	O
effective	O
clinical	O
management	O
of	O
IR	O
and	O
T2D	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
nutrigenetically	O
screen	O
gene	O
-	O
diet	O
and	O
gene	O
-	O
metabolic	O
interactions	O
influencing	O
IR	O
phenotypes	O
in	O
overweight	O
/	O
obese	O
subjects	O
.	O
This	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
study	I-methodology
included	O
232	O
Caucasian	O
non	O
-	O
consanguineous	O
overweight	O
(	O
BMI	O
:	O
25	O
–	O
29	O
.	O
9	O
kg	O
/	O
m2	O
)	O
or	O
obese	O
(	O
BMI	O
:	O
30	O
–	O
40	O
kg	O
/	O
m2	O
)	O
adults	O
from	O
the	O
Obekit	O
study	O
.	O
Major	O
exclusion	B-methodology
criteria	I-methodology
were	O
a	O
clinical	O
history	O
of	O
type	O
1	O
diabetes	O
or	O
cardiovascular	O
disease	O
;	O
T2D	O
patients	O
treated	O
with	O
insulin	O
;	O
pregnant	O
or	O
lactating	O
women	O
;	O
and	O
use	O
of	O
medication	O
that	O
could	O
affects	O
body	O
weight	O
or	O
lipid	O
/	O
glucose	O
levels	O
(	O
antipsychotic	O
and	O
antidepressant	O
drugs	O
,	O
or	O
corticosteroids	O
)	O
.	O
The	O
study	B-methodology
protocol	I-methodology
was	O
approved	O
by	O
the	O
Research	O
Ethics	O
Committee	O
of	O
the	O
University	O
of	O
Navarra	O
(	O
ref	O
.	O
132	O
/	O
2015	O
)	O
.	O
The	O
characteristics	O
of	O
this	O
research	O
project	O
including	O
study	B-methodology
design	I-methodology
,	O
and	O
registration	O
have	O
been	O
previously	O
reported	O
[	O
15	O
,	O
16	O
]	O
.	O
Approval	O
by	O
the	O
Research	O
Ethics	O
Committee	O
of	O
the	O
University	O
of	O
Navarra	O
(	O
ref	O
.	O
132	O
/	O
2015	O
)	O
was	O
obtained	O
,	O
and	O
the	O
ethical	O
principles	O
of	O
the	O
2013	O
Helsinki	O
Declaration	O
concerning	O
medical	O
research	O
involving	O
human	O
subjects	O
were	O
carefully	O
followed	O
.	O
In	O
addition	O
,	O
all	O
participants	O
signed	O
out	O
the	O
written	B-methodology
informed	I-methodology
consent	I-methodology
.	O
Demographic	O
characteristics	O
,	O
anthropometric	O
and	O
body	O
composition	O
measurements	O
,	O
the	O
metabolic	O
/	O
inflammatory	O
profile	O
,	O
and	O
the	O
lifestyle	O
(	O
including	O
dietary	O
intake	O
and	O
the	O
level	O
of	O
physical	O
activity	O
)	O
at	O
baseline	O
as	O
well	O
as	O
the	O
genotype	O
of	O
95	O
obesity	O
-	O
predisposing	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
were	O
retrieved	O
from	O
the	O
Obekit	O
database	O
.	O
Methodology	O
details	O
regarding	O
anthropometric	O
assessment	O
,	O
lifestyle	O
data	O
collection	O
,	O
and	O
blood	O
samples	O
processing	O
have	O
been	O
previously	O
provided	O
[	O
15	O
,	O
16	O
]	O
.	O
Additionally	O
,	O
the	O
selection	O
procedure	O
and	O
genomic	O
information	O
of	O
the	O
95	O
genetic	O
variants	O
have	O
been	O
recently	O
reported	O
[	O
17	O
]	O
.	O

The	O
homeostatic	O
model	O
assessment	O
-	O
insulin	O
resistance	O
(	O
HOMA	O
-	O
IR	O
(	O
homeostatic	O
model	O
assessment	O
-	O
insulin	O
resistance	O
)	O
)	O
index	O
was	O
calculated	O
according	O
to	O
the	O
Matthews	O
formula	O
:	O
fasting	O
insulin	O
(	O
µU	O
/	O
L	O
)	O
x	O
fasting	O
glucose	O
(	O
nmol	O
/	O
L	O
)	O
/	O
22	O
.	O
5	O
[	O
18	O
]	O
.	O
Subjects	O
were	O
categorized	O
by	O
IR	O
status	O
according	O
to	O
the	O
HOMA	O
-	O
IR	O
index	O
:	O
non	O
-	O
IR	O
(	O
NIR	O
)	O
(	O
HOMA	O
-	O
IR	O
index	O
≤	O
2	O
.	O
5	O
)	O
and	O
IR	O
(	O
HOMA	O
-	O
IR	O
index	O
>	O
2	O
.	O
5	O
)	O
following	O
accepted	O
criteria	O
[	O
19	O
]	O
.	O
The	O
triglyceride	O
-	O
glucose	O
index	O
(	O
TyG	O
index	O
)	O
was	O
estimated	O
as	O
:	O
TyG	O
index	O
=	O
(	O
ln	O
(	O
fasting	O
triglycerides	O
(	O
mg	O
/	O
dL	O
)	O
×	O
fasting	O
plasma	O
glucose	O
(	O
mg	O
/	O
dL	O
)	O
/	O
2	O
)	O
)	O
,	O
as	O
described	O
elsewhere	O
[	O
20	O
]	O
.	O
First	O
screening	O
consisted	O
of	O
comparing	O
the	O
frequency	O
of	O
IR	O
between	O
genotypes	O
of	O
the	O
95	O
SNPs	O
to	O
select	O
those	O
with	O
a	O
p	O
value	O
<	O
0	O
.	O
20	O
,	O
which	O
were	O
adjusted	O
by	O
BMI	O
,	O
waist	O
circumference	O
,	O
and	O
body	O
fat	O
in	O
order	O
to	O
rule	O
out	O
random	O
baseline	O
adiposity	O
differences	O
.	O
Next	O
,	O
genotypes	O
with	O
similar	O
non	O
-	O
significant	O
effects	O
were	O
clustered	O
in	O
a	O
single	O
group	O
and	O
coded	O
as	O
risk	O
and	O
non	O
-	O
risk	O
groups	O
.	O
A	O
risk	O
genotype	O
was	O
defined	O
as	O
that	O
associated	O
with	O
a	O
higher	O
frequency	O
of	O
IR	O
.	O
Then	O
,	O
SNPs	O
whose	O
risk	O
genotypes	O
presented	O
at	O
least	O
a	O
marginal	O
statistical	O
trend	O
(	O
p	O
<	O
0	O
.	O
10	O
in	O
the	O
multivariate	O
model	O
)	O
were	O
finally	O
selected	O
,	O
excluding	O
those	O
with	O
low	O
sample	O
(	O
<	O
10	O
%	O
)	O
in	O
either	O
NIR	O
and	O
IR	O
categories	O
or	O
due	O
to	O
collinearity	O
.	O
Using	O
these	O
SNPs	O
,	O
a	O
weighted	O
genetic	O
risk	O
score	O
(	O
wGRS	O
)	O
was	O
computed	O
by	O
multiplying	O
the	O
risk	O
genotypes	O
at	O
each	O
locus	O
for	O
the	O
corresponding	O
effect	O
sizes	O
(	O
β	O
-	O
coefficients	O
)	O
on	O
IR	O
,	O
and	O
then	O
summing	O
the	O
products	O
,	O
assuming	O
that	O
all	O
selected	O
SNPs	O
had	O
independent	O
effects	O
and	O
contributed	O
in	O
an	O
additive	O
manner	O
to	O
IR	O
,	O
as	O
previously	O
reported	O
[	O
21	O
]	O
.	O
The	O
distribution	O
(	O
normality	O
)	O
of	O
the	O
study	O
variables	O
was	O
assessed	O
by	O
the	O
Kolmogorov	O
-	O
Smirnov	O
test	O
.	O

All	O
main	O
variables	O
including	O
HOMA	O
-	O
IR	O
,	O
PCR	O
,	O
adiponectin	O
,	O
dietary	O
cholesterol	O
,	O
simple	O
carbohydrates	O
,	O
and	O
fiber	O
were	O
normally	O
distributed	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O
Continuous	O
and	O
categorical	O
variables	O
were	O
expressed	O
as	O
means	O
±	O
standard	O
errors	O
(	O
SE	O
)	O
and	O
as	O
numbers	O
and	O
percentages	O
,	O
respectively	O
.	O
Comparisons	O
of	O
body	O
composition	O
,	O
metabolic	O
,	O
and	O
dietary	O
intake	O
markers	O
by	O
IR	O
status	O
(	O
NIR	O
and	O
IR	O
)	O
were	O
carried	O
out	O
using	O
ANCOVA	O
tests	O
adjusted	O
by	O
age	O
,	O
sex	O
,	O
and	O
BMI	O
.	O
The	O
levels	O
of	O
these	O
markers	O
were	O
compared	O
by	O
dividing	O
the	O
population	O
into	O
two	O
genetic	O
categories	O
:	O
low	O
genetic	O
risk	O
score	O
(	O
LGRS	O
)	O
and	O
high	O
genetic	O
risk	O
score	O
(	O
HGRS	O
)	O
based	O
on	O
the	O
median	O
value	O
of	O
wGRS	O
(	O
4	O
.	O
850	O
)	O
.	O
Differences	O
in	O
the	O
proportions	O
of	O
risk	O
genotypes	O
between	O
NIR	O
and	O
IR	O
groups	O
were	O
assessed	O
using	O
chi	O
squared	O
tests	O
.	O
Mean	O
values	O
of	O
wGRS	O
according	O
to	O
NIR	O
and	O
IR	O
phenotypes	O
were	O
compared	O
by	O
Student	O
’	O
s	O
t	O
tests	O
.	O
Multiple	O
linear	O
regression	O
analyses	O
adjusted	O
by	O
age	O
,	O
sex	O
,	O
and	O
BMI	O
were	O
performed	O
to	O
evaluate	O
the	O
association	O
between	O
the	O
wGRS	O
and	O
the	O
HOMA	O
-	O
IR	O
index	O
.	O
Additionally	O
,	O
logistic	O
regression	O
tests	O
adjusted	O
by	O
the	O
same	O
covariates	O
were	O
run	O
to	O
assess	O
the	O
risk	O
of	O
develop	O
IR	O
in	O
genetically	O
susceptible	O
individuals	O
.	O
Multivariate	O
general	O
linear	O
models	O
were	O
applied	O
to	O
test	O
interactions	O
between	O
the	O
wGRS	O
with	O
dietary	O
and	O
metabolic	O
factors	O
in	O
relation	O
to	O
IR	O
after	O
adjustment	O
for	O
age	O
,	O
sex	O
,	O
and	O
BMI	O
.	O
Statistical	O
analyses	O
were	O
performed	O
in	O
the	O
statistical	O
program	O
Stata	O
12	O
(	O
StataCorp	O
LLC	O
,	O
College	O
Station	O
,	O
TX	O
,	O
USA	O
;	O
www	O
.	O
stata	O
.	O
com	O
)	O
.	O
Statistical	O
significance	O
was	O
established	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O
Figure	O
plots	O
were	O
created	O
using	O
the	O
GraphPad	O
Prism®	O
software	O
,	O
version	O
6	O
.	O
0C	O
(	O
La	O
Jolla	O
,	O
CA	O
,	O
USA	O
)	O
and	O
Stata	O
12	O
.	O
Hardy	O
–	O
Weinberg	O
equilibrium	O
(	O
HWE	O
)	O
and	O
the	O
analysis	O
of	O
molecular	O
variance	O
(	O
AMOVA	O
)	O
were	O
estimated	O
using	O
the	O
Arlequin	O
software	O
,	O
version	O
3	O
.	O
0	O
[	O
22	O
]	O
.	O
In	O
order	O
to	O
show	O
the	O
interactions	O
between	O
the	O
genes	O
where	O
significant	O
SNPs	O
are	O
present	O
,	O
a	O
multiprotein	O
network	O
was	O
performed	O
using	O
the	O
STRING	O
(	O
https	O
:	O
/	O
/	O
string	O
-	O
db	O
.	O
org	O
/	O
)	O
with	O
a	O
low	O
confidence	O
interaction	O
score	O
(	O
0	O
.	O
150	O
)	O
.	O

Functions	O
enriched	O
in	O
the	O
network	O
were	O
revealed	O
according	O
to	O
the	O
UniProt	O
database	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
uniprot	O
.	O
org	O
)	O
.	O
Anthropometrics	O
,	O
clinical	O
and	O
metabolic	O
characteristics	O
of	O
the	O
study	O
population	O
categorized	O
by	O
IR	O
are	O
reported	O
(	O
Table	O
1	O
)	O
.	O
The	O
prevalence	O
of	O
IR	O
was	O
22	O
.	O
8	O
%	O
in	O
this	O
sample	O
.	O
Participants	O
with	O
IR	O
were	O
older	O
,	O
had	O
greater	O
adiposity	O
and	O
worst	O
blood	O
lipid	O
profile	O
as	O
well	O
as	O
lower	O
levels	O
of	O
adiponectin	O
than	O
their	O
NIR	O
counterparts	O
.	O
Compatible	O
findings	O
were	O
found	O
when	O
comparing	O
HGRS	O
and	O
LGRS	O
individuals	O
,	O
where	O
HGRS	O
subjects	O
showed	O
more	O
clinically	O
adverse	O
phenotypes	O
(	O
Table	O
S1	O
)	O
.	O
Concerning	O
the	O
nutritional	O
profile	O
,	O
higher	O
intakes	O
of	O
simple	O
carbohydrates	O
and	O
dietary	O
cholesterol	O
as	O
well	O
as	O
lower	O
intakes	O
of	O
dietary	O
fiber	O
were	O
found	O
in	O
IR	O
individuals	O
than	O
those	O
exhibiting	O
a	O
NIR	O
phenotype	O
(	O
Table	O
2	O
)	O
.	O
No	O
additional	O
differences	O
were	O
found	O
between	O
LGRS	O
and	O
HGRS	O
groups	O
for	O
other	O
macronutrients	O
(	O
Table	O
S2	O
)	O
.	O
The	O
16	O
obesity	O
-	O
predisposing	O
genetic	O
variants	O
that	O
were	O
marginally	O
or	O
statistically	O
associated	O
with	O
IR	O
(	O
p	O
<	O
0	O
.	O
10	O
)	O
,	O
were	O
incorporated	O
into	O
the	O
wGRS	O
.	O
The	O
characteristics	O
and	O
genome	O
/	O
statistical	O
coding	O
of	O
each	O
of	O
these	O
SNPs	O
are	O
reported	O
(	O
Table	O
3	O
)	O
.	O
The	O
distribution	O
of	O
genotypes	O
of	O
the	O
16	O
SNPs	O
was	O
concordant	O
with	O
the	O
HWE	O
principle	O
.	O
Additionally	O
,	O
the	O
AMOVA	O
analyses	O
revealed	O
no	O
significant	O
genetic	O
differentiation	O
within	O
the	O
sample	O
(	O
p	O
>	O
0	O
05	O
)	O
.	O
The	O
following	O
SNPs	O
showed	O
best	O
association	O
with	O
IR	O
:	O
rs1800544	O
(	O
ADRA2A	O
)	O
,	O
rs7903146	O
(	O
TCF7L2	O
)	O
,	O
rs2289487	O
(	O
PLIN1	O
)	O
,	O
rs12255372	O
(	O
TCF7L2	O
)	O
,	O
rs894160	O
(	O
PLIN1	O
)	O
,	O
rs206936	O
(	O
NUDT3	O
)	O
,	O
rs1799883	O
(	O
FABP2	O
)	O
,	O
rs2734827	O
(	O
UCP3	O
)	O
,	O
rs10838738	O
(	O
MTCH2	O
)	O
,	O
rs519887	O
(	O
ABCB11	O
)	O
,	O
and	O
rs7799039	O
(	O
LEP	O
)	O
.	O

Ten	O
SNPs	O
were	O
excluded	O
from	O
the	O
analyses	O
by	O
low	O
n	O
sample	O
or	O
collinearity	O
:	O
rs8179183	O
(	O
LEPR	O
)	O
,	O
rs1516725	O
(	O
ETV5	O
)	O
,	O
rs10938397	O
(	O
GNPDA2	O
)	O
,	O
rs1685325	O
(	O
UCP3	O
)	O
,	O
rs1558902	O
(	O
FTO	O
)	O
,	O
rs17817449	O
(	O
FTO	O
)	O
,	O
rs8050136	O
(	O
FTO	O
)	O
,	O
rs3751812	O
(	O
FTO	O
)	O
,	O
rs9939609	O
(	O
FTO	O
)	O
,	O
rs17069904	O
(	O
TNFRSF11A	O
)	O
.	O
The	O
score	O
of	O
the	O
wGRS	O
ranged	O
from	O
1	O
.	O
23	O
to	O
9	O
.	O
75	O
.	O
The	O
results	O
showed	O
a	O
statistically	O
significant	O
protein	O
-	O
protein	O
interaction	O
(	O
PPI	O
)	O
enrichment	O
p	O
-	O
value	O
of	O
5	O
.	O
71	O
×	O
10−14	O
,	O
indicating	O
that	O
the	O
proteins	O
are	O
at	O
least	O
in	O
some	O
way	O
biologically	O
connected	O
,	O
as	O
a	O
group	O
(	O
Figure	O
S1	O
)	O
.	O
Functional	O
enrichment	O
analyses	O
revealed	O
two	O
functions	O
enriched	O
in	O
the	O
network	O
:	O
obesity	O
(	O
false	O
discovery	O
rate	O
=	O
0	O
.	O
0011	O
)	O
and	O
diabetes	O
(	O
false	O
discovery	O
rate	O
=	O
0	O
.	O
0226	O
)	O
.	O
Associations	O
between	O
the	O
wGRS	O
and	O
the	O
HOMA	O
-	O
IR	O
index	O
are	O
depicted	O
(	O
Figure	O
1	O
)	O
.	O
The	O
wGRS	O
positively	O
associated	O
with	O
the	O
HOMA	O
-	O
IR	O
index	O
(	O
Figure	O
1A	O
)	O
.	O
Comparisons	O
of	O
wGRS	O
mean	O
values	O
according	O
to	O
IR	O
status	O
are	O
plotted	O
(	O
Figure	O
1	O
)	O
.	O
Statistically	O
significant	O
higher	O
levels	O
of	O
wGRS	O
were	O
detected	O
in	O
the	O
IR	O
group	O
(	O
Figure	O
1B	O
)	O
.	O
Moreover	O
,	O
the	O
HOMA	O
-	O
IR	O
index	O
increased	O
0	O
.	O
36	O
units	O
by	O
each	O
unit	O
of	O
increase	O
of	O
the	O
wGRS	O
(	O
B	O
coefficient	O
=	O
0	O
.	O
36	O
,	O
CI	O
95	O
%	O
,	O
0	O
.	O
26	O
–	O
0	O
.	O
46	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
Additionally	O
,	O
HGRS	O
individuals	O
had	O
13	O
.	O
76	O
higher	O
risk	O
of	O
develop	O
IR	O
than	O
those	O
carrying	O
a	O
LGRS	O
(	O
OR	O
=	O
13	O
.	O
76	O
,	O
CI	O
95	O
%	O
,	O
5	O
.	O
18	O
–	O
36	O
.	O
54	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
Estimation	O
curves	O
of	O
gene	O
-	O
diet	O
and	O
gene	O
-	O
metabolic	O
interactions	O
concerning	O
IR	O
are	O
drawn	O
(	O
Figure	O
2	O
)	O
.	O

Interestingly	O
,	O
the	O
wGRS	O
positively	O
interacted	O
with	O
dietary	O
cholesterol	O
to	O
influence	O
IR	O
(	O
Figure	O
2A	O
)	O
.	O
Thus	O
,	O
an	O
increase	O
in	O
dietary	O
cholesterol	O
was	O
associated	O
with	O
higher	O
HOMA	O
-	O
IR	O
index	O
only	O
in	O
participants	O
carrying	O
a	O
HGRS	O
.	O
Similar	O
findings	O
were	O
raised	O
regarding	O
the	O
blood	O
concentrations	O
of	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
(	O
Figure	O
2B	O
)	O
.	O
However	O
,	O
an	O
opposite	O
effect	O
was	O
detected	O
in	O
HGRS	O
individuals	O
in	O
relation	O
to	O
serum	O
adiponectin	O
,	O
where	O
HOMA	O
index	O
decreased	O
as	O
adiponectin	O
levels	O
increased	O
(	O
Figure	O
2C	O
)	O
.	O
The	O
prevalence	O
of	O
IR	O
shows	O
important	O
variations	O
across	O
studies	O
,	O
mainly	O
due	O
to	O
the	O
use	O
of	O
different	O
diagnosis	O
tools	O
and	O
cut	O
-	O
off	O
points	O
as	O
well	O
as	O
inherent	O
differences	O
in	O
ethnicity	O
,	O
health	O
status	O
,	O
and	O
cultural	O
issues	O
[	O
19	O
]	O
.	O
In	O
this	O
investigation	O
,	O
IR	O
was	O
assessed	O
via	O
the	O
HOMA	O
-	O
IR	O
index	O
because	O
it	O
is	O
the	O
most	O
frequently	O
used	O
parameter	O
in	O
epidemiological	B-methodology
studies	I-methodology
[	O
23	O
]	O
,	O
being	O
considered	O
by	O
the	O
international	O
guidelines	B-methodology
for	O
the	O
screening	O
of	O
high	O
-	O
risk	O
groups	O
[	O
19	O
]	O
.	O
According	O
to	O
this	O
index	O
,	O
the	O
22	O
.	O
8	O
%	O
of	O
the	O
studied	O
population	O
had	O
IR	O
(	O
HOMA	O
IR	O
>	O
2	O
.	O
5	O
)	O
.	O
Higher	O
frequencies	O
have	O
been	O
reported	O
in	O
Asians	O
(	O
51	O
%	O
)	O
and	O
Europeans	O
(	O
49	O
%	O
)	O
using	O
similar	O
thresholds	O
[	O
24	O
,	O
25	O
]	O
.	O
These	O
findings	O
highlight	O
the	O
heterogeneity	O
of	O
IR	O
phenotypes	O
among	O
individuals	O
and	O
emphasize	O
the	O
importance	O
of	O
establishing	O
more	O
uniform	O
criteria	O
to	O
define	O
this	O
metabolic	O
feature	O
as	O
well	O
as	O
to	O
investigate	O
the	O
role	O
of	O
the	O
genetic	O
makeup	O
and	O
the	O
gene	O
-	O
diet	O
interactions	O
for	O
precision	O
management	O
.	O
IR	O
and	O
hyperglycemia	O
are	O
two	O
pathological	O
conditions	O
linked	O
to	O
obesity	O
,	O
aging	O
,	O
and	O
chronic	O
inflammation	O
,	O
which	O
are	O
major	O
risk	O
factors	O
for	O
the	O
development	O
of	O
metabolic	O
syndrome	O
and	O
T2D	O
[	O
26	O
]	O
.	O
Accordingly	O
,	O
IR	O
individuals	O
in	O
this	O
study	O
were	O
older	O
,	O
heavier	O
,	O
and	O
underwent	O
a	O
detrimental	O
metabolic	O
profile	O
characterized	O
by	O
increased	O
levels	O
of	O
blood	O
lipids	O
compared	O
with	O
normal	O
NIR	O
participants	O
,	O
being	O
these	O
outcomes	O
similar	O
to	O
previous	O
findings	O
reported	O
in	O
the	O
scientific	O
literature	O
[	O
3	O
,	O
4	O
]	O
.	O
Nutritional	O
factors	O
have	O
been	O
associated	O
with	O
IR	O
and	O
related	O
inflammatory	O
states	O
in	O
different	O
populations	O
[	O
27	O
,	O
28	O
]	O
.	O
In	O
the	O
studied	O
population	O
,	O
participants	O
with	O
IR	O
showed	O
significantly	O
higher	O
consumptions	O
of	O
simple	O
carbohydrates	O
and	O
dietary	O
cholesterol	O
and	O
low	O
intakes	O
of	O
dietary	O
fiber	O
than	O
their	O
NIR	O
counterparts	O
.	O

In	O
agreement	O
with	O
our	O
results	O
,	O
a	O
positive	O
correlation	O
between	O
carbohydrate	O
intake	O
and	O
HOMA	O
-	O
IR	O
index	O
was	O
found	O
in	O
an	O
Indian	O
cohort	B-methodology
[	O
27	O
]	O
.	O
Indeed	O
,	O
recent	O
human	B-methodology
studies	I-methodology
support	O
a	O
dose	O
response	O
link	O
between	O
the	O
consumption	O
of	O
simple	O
carbohydrates	O
and	O
adverse	O
metabolic	O
changes	O
,	O
particularly	O
when	O
it	O
is	O
accompanied	O
by	O
an	O
excessive	O
intake	O
of	O
calories	O
[	O
29	O
]	O
.	O
Nevertheless	O
,	O
findings	O
from	O
the	O
Inter99	O
nonpharmacological	O
intervention	B-methodology
study	I-methodology
revealed	O
a	O
lack	O
of	O
association	O
of	O
high	O
content	O
of	O
carbohydrates	O
,	O
including	O
simple	O
sugars	O
,	O
with	O
the	O
probability	O
of	O
having	O
IR	O
[	O
30	O
]	O
.	O
Moreover	O
,	O
although	O
dietary	O
cholesterol	O
has	O
been	O
identified	O
as	O
a	O
major	O
determinant	O
of	O
the	O
severity	O
of	O
metabolic	O
disorders	O
(	O
including	O
IR	O
)	O
in	O
animal	B-methodology
models	I-methodology
[	O
31	O
]	O
,	O
current	O
epidemiological	O
and	O
clinical	O
evidences	O
do	O
not	O
support	O
consistently	O
a	O
relationship	O
between	O
dietary	O
cholesterol	O
and	O
IR	O
or	O
T2D	O
risks	O
[	O
32	O
]	O
.	O
Regarding	O
dietary	O
fiber	O
,	O
large	O
prospective	B-methodology
cohort	I-methodology
studies	I-methodology
have	O
consistently	O
showed	O
associations	O
of	O
a	O
high	O
-	O
fiber	O
intake	O
with	O
a	O
reduction	O
in	O
the	O
risk	O
of	O
developing	O
IR	O
and	O
T2D	O
[	O
33	O
]	O
;	O
however	O
,	O
these	O
effects	O
may	O
vary	O
by	O
the	O
types	O
of	O
fiber	O
-	O
rich	O
foods	O
and	O
glycemic	O
index	O
,	O
which	O
were	O
not	O
analyzed	O
in	O
this	O
study	O
.	O
Therefore	O
,	O
further	O
investigation	O
analyzing	O
the	O
role	O
of	O
diet	O
in	O
glucose	O
homeostasis	O
and	O
insulin	O
sensitivity	O
is	O
warranted	O
.	O
Recent	O
progress	O
in	O
genome	O
sequencing	O
techniques	O
has	O
added	O
knowledge	O
about	O
the	O
involvement	O
of	O
the	O
genetic	O
makeup	O
in	O
the	O
susceptibility	O
for	O
developing	O
IR	O
[	O
34	O
]	O
.	O
In	O
this	O
study	O
,	O
16	O
obesity	O
-	O
related	O
genetic	O
polymorphisms	O
located	O
at	O
13	O
genes	O
were	O
associated	O
with	O
IR	O
.	O
These	O
genes	O
participate	O
in	O
relevant	O
physiological	O
pathways	O
such	O
as	O
lipid	O
metabolism	O
(	O
PLIN1	O
,	O
FABP2	O
,	O
ABCB11	O
,	O
NPC1	O
)	O
,	O
energy	O
balance	O
(	O
LEP	O
,	O
UCP3	O
)	O
,	O
presynaptic	O
transmitter	O
release	O
(	O
ADRA2A	O
)	O
,	O
cell	O
signal	O
transduction	O
(	O
TCF7L2	O
,	O
NUDT3	O
)	O
,	O
apoptosis	O
(	O
AGTR2	O
)	O
,	O
adipocyte	O
differentiation	O
(	O
MTCH2	O
)	O
,	O
antioxidant	O
response	O
(	O
NFE2L3	O
)	O
,	O
and	O
amino	O
acid	O
processing	O
(	O
MTHFR	O
)	O
according	O
to	O
human	O
gene	O
database	O
references	O
(	O
www	O
.	O
genecards	O
.	O
org	O
)	O
.	O

Also	O
,	O
multiprotein	O
network	O
analyses	O
revealed	O
partial	O
,	O
but	O
significant	O
interactions	O
between	O
these	O
proteins	O
.	O
These	O
results	O
support	O
a	O
link	O
between	O
genetics	O
,	O
obesity	O
and	O
glucose	O
homeostasis	O
,	O
as	O
reviewed	O
elsewhere	O
[	O
35	O
,	O
36	O
]	O
.	O
Furthermore	O
,	O
in	O
this	O
research	O
,	O
a	O
computed	O
obesity	O
-	O
based	O
wGRS	O
using	O
the	O
IR	O
-	O
related	O
alleles	O
positively	O
associated	O
with	O
the	O
HOMA	O
-	O
IR	O
index	O
,	O
which	O
was	O
independent	O
of	O
the	O
adiposity	O
degree	O
,	O
age	O
,	O
and	O
sex	O
.	O
Additionally	O
,	O
higher	O
levels	O
of	O
the	O
wGRS	O
were	O
directly	O
linked	O
to	O
IR	O
.	O
Moreover	O
,	O
individuals	O
with	O
a	O
HGRS	O
presented	O
a	O
more	O
adverse	O
metabolic	O
profile	O
compared	O
with	O
those	O
carrying	O
a	O
LGRS	O
.	O
Instead	O
,	O
no	O
differences	O
in	O
nutrient	O
intakes	O
between	O
HGRS	O
and	O
LGRS	O
groups	O
were	O
detected	O
.	O
According	O
to	O
our	O
results	O
,	O
the	O
genetic	O
makeup	O
is	O
an	O
important	O
contributor	O
to	O
the	O
pathogenesis	O
of	O
IR	O
and	O
related	O
metabolic	O
abnormalities	O
.	O
Consistently	O
,	O
an	O
obesity	O
GRS	O
predicted	O
the	O
risk	O
of	O
IR	O
in	O
a	O
Chinese	O
children	O
population	O
[	O
37	O
]	O
.	O
Moreover	O
,	O
an	O
adult	O
-	O
based	O
GRS	O
encompassing	O
53	O
SNPs	O
was	O
associated	O
with	O
the	O
HOMA	O
-	O
IR	O
index	O
,	O
metabolic	O
syndrome	O
traits	O
,	O
and	O
altered	O
fat	O
distribution	O
in	O
a	O
sample	O
of	O
Danish	O
children	O
and	O
adolescents	O
[	O
38	O
]	O
.	O
Complex	O
gene	O
-	O
environment	O
/	O
lifestyle	O
interactions	O
modulate	O
IR	O
status	O
and	O
metabolic	O
disease	O
risk	O
[	O
39	O
]	O
and	O
were	O
also	O
screened	O
in	O
this	O
investigation	O
.	O
Thus	O
,	O
interactions	O
between	O
the	O
wGRS	O
with	O
dietary	O
intake	O
of	O
cholesterol	O
and	O
the	O
serum	O
levels	O
of	O
CRP	O
and	O
adiponectin	O
in	O
relation	O
to	O
IR	O
were	O
found	O
.	O
On	O
the	O
one	O
hand	O
,	O
high	O
CRP	O
concentrations	O
were	O
associated	O
with	O
increased	O
IR	O
in	O
genetically	O
susceptible	O
individual	O
,	O
supporting	O
a	O
link	O
between	O
low	O
-	O
grade	O
chronic	O
inflammation	O
and	O
IR	O
[	O
40	O
]	O
.	O
On	O
the	O
other	O
hand	O
,	O
high	O
adiponectin	O
levels	O
were	O
accompanied	O
by	O
reduced	O
IR	O
,	O
indicating	O
a	O
protective	O
role	O
of	O
adiponectin	O
in	O
relation	O
to	O
IR	O
predisposition	O
[	O
41	O
]	O
.	O
In	O
addition	O
,	O
dietary	O
cholesterol	O
was	O
positively	O
associated	O
with	O
IR	O
,	O
especially	O
in	O
individuals	O
at	O
high	O
-	O
genetic	O
risk	O
.	O
A	O
similar	O
study	O
reported	O
that	O
the	O
association	O
between	O
a	O
GRS	O
for	O
glucose	O
-	O
stimulated	O
insulin	O
secretion	O
and	O
T2D	O
risk	O
was	O
stronger	O
in	O
individuals	O
with	O
high	O
energy	O
intakes	O
[	O
42	O
]	O
.	O

Similarly	O
,	O
the	O
risk	O
of	O
T2D	O
was	O
exacerbated	O
in	O
subjects	O
with	O
high	O
GRS	O
for	O
impaired	O
insulin	O
secretion	O
capacity	O
and	O
consuming	O
a	O
low	O
carbohydrate	O
Western	O
-	O
style	O
diet	O
[	O
43	O
]	O
.	O
In	O
addition	O
,	O
coffee	O
drinkers	O
(	O
more	O
than	O
10	O
cups	O
coffee	O
/	O
week	O
or	O
220	O
mg	O
caffeine	O
/	O
day	O
)	O
were	O
more	O
susceptible	O
to	O
IR	O
when	O
carrying	O
a	O
high	O
GRS	O
for	O
IR	O
than	O
those	O
with	O
a	O
low	O
GRS	O
[	O
44	O
]	O
.	O
The	O
strengths	O
of	O
this	O
study	O
include	O
the	O
screening	O
of	O
the	O
interplay	O
of	O
an	O
obesity	O
-	O
related	O
wGRS	O
with	O
lifestyle	O
data	O
and	O
metabolic	O
/	O
endocrine	O
features	O
influencing	O
IR	O
status	O
in	O
overweight	O
/	O
obese	O
individuals	O
.	O
These	O
analyses	O
were	O
adjusted	O
by	O
confounding	O
factors	O
affecting	O
glucose	O
homeostasis	O
,	O
such	O
as	O
age	O
,	O
sex	O
,	O
obesity	O
degree	O
,	O
and	O
total	O
calorie	O
intake	O
[	O
10	O
]	O
.	O
Additionally	O
,	O
the	O
possible	O
effect	O
of	O
population	O
stratification	O
in	O
our	O
results	O
was	O
minimized	O
due	O
to	O
the	O
enrollment	O
of	O
a	O
genetically	O
homogeneous	O
Caucasian	O
/	O
European	O
population	O
,	O
as	O
revealed	O
by	O
HWE	O
and	O
AMOVA	O
analyses	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
drawbacks	O
of	O
this	O
research	O
include	O
a	O
relatively	O
small	O
sample	O
and	O
the	O
fact	O
that	O
the	O
genetic	O
findings	O
of	O
this	O
investigation	O
may	O
not	O
be	O
generalizable	O
to	O
other	O
ethnic	O
groups	O
exposed	O
to	O
different	O
geographic	O
/	O
cultural	O
environments	O
.	O
Therefore	O
,	O
further	O
studies	O
analyzing	O
the	O
association	O
of	O
these	O
and	O
other	O
SNPs	O
with	O
IR	O
and	O
concomitant	O
metabolic	O
alterations	O
in	O
other	O
populations	O
are	O
required	O
in	O
order	O
to	O
evaluate	O
their	O
applicability	O
in	O
a	O
real	O
-	O
life	O
scenario	O
,	O
although	O
this	O
research	O
is	O
a	O
proof	O
-	O
of	O
-	O
principle	O
.	O
Moreover	O
,	O
given	O
the	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
design	O
of	O
this	O
study	O
,	O
no	O
causality	O
relationships	O
between	O
predictors	O
and	O
outcomes	O
can	O
be	O
set	O
.	O
Furthermore	O
,	O
type	O
I	O
and	O
type	O
II	O
errors	O
cannot	O
be	O
completely	O
ruled	O
out	O
despite	O
the	O
application	O
of	O
appropriate	O
statistical	O
settings	O
.	O
In	O
addition	O
,	O
although	O
the	O
HOMA	O
-	O
IR	O
index	O
is	O
a	O
widely	O
accepted	O
indirect	O
measurement	O
of	O
IR	O
,	O
the	O
gold	O
standard	O
technique	O
to	O
assess	O
this	O
parameter	O
could	O
provide	O
more	O
information	O
.	O
Furthermore	O
,	O
interactions	O
between	O
the	O
genetic	O
makeup	O
and	O
other	O
emerging	O
factors	O
affecting	O
the	O
host	O
metabolism	O
such	O
as	O
gut	O
microbiota	O
composition	O
and	O
epigenetic	O
signatures	O
also	O
need	O
to	O
be	O
explored	O
[	O
45	O
]	O
.	O
Novel	O
insights	O
have	O
emerged	O
regarding	O
the	O
importance	O
of	O
categorizing	O
disease	O
outcomes	O
with	O
the	O
aim	O
of	O
identifying	O
high	O
-	O
risk	O
individuals	O
and	O
customize	O
treatments	O
[	O
5	O
,	O
6	O
,	O
7	O
]	O
.	O

In	O
this	O
pioneer	O
study	O
,	O
relevant	O
differences	O
in	O
anthropometric	O
,	O
dietary	O
,	O
and	O
clinical	O
characteristics	O
were	O
evidenced	O
in	O
patients	O
with	O
overweight	O
and	O
obesity	O
depending	O
on	O
the	O
IR	O
status	O
,	O
where	O
interactions	O
with	O
the	O
genetic	O
background	O
(	O
wGRS	O
)	O
played	O
a	O
pivotal	O
role	O
.	O
This	O
information	O
supports	O
the	O
heterogeneity	O
of	O
IR	O
phenotypes	O
between	O
individuals	O
and	O
emphasizes	O
the	O
need	O
for	O
integrative	O
individualized	O
schemes	O
of	O
intervention	O
for	O
the	O
control	O
of	O
obesity	O
and	O
related	O
chronic	O
diseases	O
for	O
precision	O
nutrition	O
[	O
46	O
]	O
.	O
In	O
conclusion	O
,	O
this	O
study	O
suggests	O
that	O
interactions	O
between	O
the	O
genetic	O
makeup	O
(	O
exemplified	O
in	O
an	O
obesity	O
-	O
based	O
wGRS	O
)	O
and	O
nutritional	O
and	O
metabolic	O
features	O
influence	O
the	O
IR	O
phenotype	O
,	O
which	O
could	O
contribute	O
to	O
the	O
understanding	O
of	O
IR	O
pathogenesis	O
as	O
well	O
as	O
facilitate	O
the	O
prescription	O
of	O
personalized	O
nutrition	O
recommendations	O
for	O
the	O
early	O
prevention	O
of	O
T2D	O
through	O
the	O
improvement	O
of	O
current	O
therapeutic	O
decision	O
-	O
making	O
and	O
the	O
development	O
of	O
novel	O
strategies	O
using	O
precision	O
medicine	O
approaches	O
.	O
Authors	O
thank	O
Laura	O
Olazaran	O
and	O
Iosune	O
Zubieta	O
(	O
nutritionists	O
)	O
,	O
Ana	O
Lorente	O
(	O
technician	O
)	O
and	O
Blanca	O
Martinez	O
de	O
Morentin	O
(	O
physician	O
)	O
by	O
technical	O
support	O
.	O
The	O
support	O
from	O
CINFA	O
concerning	O
general	O
logistics	O
is	O
also	O
gratefully	O
acknowledged	O
.	O
The	O
following	O
are	O
available	O
online	O
at	O
https	O
:	O
/	O
/	O
www	O
.	O
mdpi	O
.	O
com	O
/	O
2072	O
-	O
6643	O
/	O
12	O
/	O
1	O
/	O
33	O
/	O
s1	O
,	O
Table	O
S1	O
:	O
Anthropometric	O
,	O
clinical	O
and	O
biochemical	O
characteristics	O
of	O
the	O
study	O
population	O
categorized	O
by	O
insulin	O
resistance	O
genetic	O
risk	O
categories	O
;	O
Table	O
S2	O
:	O
Nutritional	O
profile	O
and	O
physical	O
activity	O
patterns	O
of	O
the	O
study	O
subjects	O
according	O
to	O
insulin	O
resistance	O
genetic	O
risk	O
categories	O
;	O
Figure	O
S1	O
:	O
Multiprotein	O
network	O
showing	O
potential	O
interactions	O
between	O
the	O
13	O
genes	O
where	O
SNPs	O
are	O
present	O
.	O
PPI	O
enrichment	O
p	O
-	O
value	O
of	O
5	O
.	O
71	O
×	O
10−14	O
.	O

Conceptualization	O
,	O
J	O
.	O
A	O
.	O
M	O
.	O
;	O
formal	O
analysis	O
,	O
O	O
.	O
R	O
.	O
-	O
L	O
.	O
and	O
J	O
.	O
I	O
.	O
R	O
.	O
-	O
B	O
.	O
;	O
writing	O
—	O
original	O
draft	O
,	O
O	O
.	O
R	O
.	O
-	O
L	O
.	O
and	O
J	O
.	O
I	O
.	O
R	O
.	O
-	O
B	O
.	O
;	O
methodology	O
,	O
J	O
.	O
A	O
.	O
M	O
.	O
,	O
F	O
.	O
I	O
.	O
M	O
.	O
,	O
M	O
.	O
C	O
.	O
,	O
and	O
L	O
.	O
G	O
.	O
;	O
investigation	O
,	O
L	O
.	O
G	O
.	O
and	O
M	O
.	O
C	O
.	O
;	O
writing	O
—	O
review	O
and	O
editing	O
,	O
O	O
.	O
R	O
.	O
-	O
L	O
.	O
,	O
J	O
.	O
I	O
.	O
R	O
.	O
-	O
B	O
.	O
,	O
F	O
.	O
I	O
.	O
M	O
.	O
,	O
M	O
.	O
C	O
.	O
,	O
L	O
.	O
G	O
.	O
,	O
and	O
J	O
.	O
A	O
.	O
M	O
.	O
All	O
authors	O
have	O
read	O
and	O
agreed	O
to	O
the	O
published	O
version	O
of	O
the	O
manuscript	O
.	O
This	O
investigation	O
was	O
supported	O
by	O
grants	O
from	O
the	O
Gobierno	O
de	O
Navarra	O
(	O
Obekit	O
,	O
grant	O
number	O
PT024	O
;	O
Microbiota	O
,	O
grant	O
number	O
PI035	O
)	O
;	O
Centro	O
de	O
Investigación	O
Biomédica	O
en	O
Red	O
:	O
Fisiopatología	O
de	O
la	O
Obesidad	O
y	O
Nutrición	O
(	O
CIBERobn	O
,	O
grant	O
number	O
CB12	O
/	O
03	O
/	O
30002	O
)	O
;	O
Nutrición	O
personalizada	O
y	O
biomarcadores	O
nutrigenómicos	O
de	O
la	O
inflamación	O
asociada	O
a	O
la	O
dieta	O
y	O
la	O
obesidad	O
(	O
Nutrigenio	O
,	O
grant	O
number	O
AGL2013	O
–	O
45554	O
-	O
R	O
)	O
;	O
and	O
MINECO	O
(	O
AGL2013	O
-	O
45554	O
-	O
R	O
)	O
.	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
conflicts	O
of	O
interest	O
concerning	O
this	O
investigation	O
.	O

Effect	O
of	O
Differently	O
Fed	O
Farmed	O
Gilthead	O
Sea	O
Bream	O
Consumption	O
on	O
Platelet	O
Aggregation	O
and	O
Circulating	O
Haemostatic	O
Markers	O
among	O
Apparently	O
Healthy	O
Adults	O
:	O
A	O
Double	B-methodology
-	I-methodology
Blind	I-methodology
Randomized	I-methodology
Crossover	I-methodology
Trial	I-methodology
fish	O
;	O
olive	O
pomace	O
;	O
human	O
platelet	O
aggregation	O
;	O
sP	O
-	O
selectin	O
;	O
PAI	O
-	O
1	O
;	O
PAF	O
;	O
ADP	O
;	O
thrombin	O
Fish	O
consumption	O
beneficially	O
affects	O
coagulation	O
markers	O
.	O
Few	O
dietary	B-methodology
intervention	I-methodology
studies	I-methodology
have	O
investigated	O
differently	O
fed	O
farmed	O
fish	O
against	O
these	O
cardio	O
-	O
metabolic	O
risk	O
factors	O
in	O
humans	O
.	O
This	O
double	B-methodology
-	I-methodology
blind	I-methodology
randomized	I-methodology
crossover	I-methodology
trial	I-methodology
evaluated	O
differently	O
fed	O
farmed	O
gilthead	O
sea	O
bream	O
consumption	O
against	O
platelet	O
aggregation	O
and	O
circulating	O
haemostatic	O
markers	O
among	O
apparently	O
healthy	O
adults	O
.	O
Subjects	O
aged	O
30	O
–	O
65	O
years	O
,	O
with	O
a	O
body	O
mass	O
index	O
24	O
.	O
0	O
–	O
31	O
.	O
0	O
kg	O
/	O
m2	O
,	O
consuming	O
less	O
than	O
150	O
g	O
cooked	O
fish	O
per	O
week	O
,	O
were	O
recruited	O
in	O
Attica	O
,	O
Greece	O
.	O
Participants	O
were	O
randomized	O
(	O
n	O
=	O
38	O
,	O
1	O
:	O
1	O
)	O
to	O
one	O
of	O
two	O
sequences	O
;	O
consumption	O
of	O
fish	O
fed	O
with	O
fish	O
oil	O
diet	O
(	O
conventional	O
fish	O
,	O
CF	O
)	O
/	O
fish	O
fed	O
with	O
olive	O
pomace	O
-	O
enriched	O
diet	O
(	O
enriched	O
fish	O
,	O
EF	O
)	O
versus	O
EF	O
/	O
CF	O
.	O
The	O
primary	O
outcomes	O
were	O
ex	B-methodology
vivo	I-methodology
human	I-methodology
platelet	I-methodology
aggregation	I-methodology
and	O
circulating	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
and	O
P	O
-	O
selectin	O
(	O
sP	O
-	O
selectin	O
)	O
concentrations	O
.	O
EF	O
consumption	O
had	O
no	O
significant	O
effect	O
on	O
platelet	O
sensitivity	O
or	O
haemostatic	O
markers	O
compared	O
to	O
CF	O
.	O
Platelet	O
sensitivity	O
to	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
decreased	O
after	O
CF	O
consumption	O
during	O
the	O
second	O
period	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O
Plasma	O
PAI	O
-	O
1	O
and	O
sP	O
-	O
selectin	O
concentrations	O
increased	O
after	O
CF	O
consumption	O
during	O
both	O
periods	O
(	O
p	O
<	O
0	O
.	O
01	O
for	O
both	O
)	O
.	O
Based	O
on	O
current	O
findings	O
,	O
consumption	O
of	O
enriched	O
farmed	O
gilthead	O
sea	O
bream	O
had	O
no	O
greater	O
effect	O
on	O
coagulation	O
markers	O
in	O
adults	O
compared	O
to	O
the	O
conventionally	O
fed	O
fish	O
.	O
Fish	O
is	O
an	O
integral	O
part	O
of	O
a	O
diet	O
aiming	O
to	O
prevent	O
or	O
treat	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
.	O

Governing	O
bodies	O
worldwide	O
currently	O
recommend	O
consumption	O
of	O
fish	O
one	O
to	O
three	O
times	O
per	O
week	O
,	O
with	O
great	O
emphasis	O
being	O
placed	O
on	O
the	O
consumption	O
of	O
fatty	O
fish	O
to	O
increase	O
the	O
dietary	O
intake	O
of	O
long	O
-	O
chain	O
ω	O
-	O
3	O
polyunsaturated	O
fatty	O
acids	O
(	O
PUFAs	O
)	O
,	O
i	O
.	O
e	O
.	O
,	O
eicosapentaenoic	O
acid	O
(	O
EPA	O
)	O
and	O
docosahexaenoic	O
acid	O
(	O
DHA	O
)	O
[	O
1	O
]	O
.	O
In	O
healthy	O
subjects	O
,	O
fatty	O
fish	O
consumption	O
providing	O
a	O
minimum	O
of	O
2	O
g	O
EPA	O
plus	O
DHA	O
per	O
day	O
has	O
been	O
associated	O
with	O
beneficial	O
effects	O
on	O
CVD	O
risk	O
factors	O
,	O
i	O
.	O
e	O
.	O
,	O
decreased	O
circulating	O
triglyceride	O
levels	O
,	O
increased	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
-	O
cholesterol	O
levels	O
,	O
and	O
significant	O
reductions	O
in	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
and	O
diastolic	O
blood	O
pressure	O
(	O
DBP	O
)	O
[	O
2	O
]	O
.	O
Although	O
increased	O
fish	O
consumption	O
and	O
dietary	O
intake	O
of	O
long	O
-	O
chain	O
ω	O
-	O
3	O
PUFAs	O
were	O
associated	O
with	O
incidence	O
of	O
type	O
2	O
diabetes	O
mellitus	O
among	O
participants	O
in	O
the	O
Women	O
’	O
s	O
Health	O
Study	O
[	O
3	O
]	O
,	O
intervention	B-methodology
studies	I-methodology
among	O
healthy	O
participants	O
do	O
not	O
support	O
significant	O
effects	O
on	O
markers	O
of	O
glycaemic	O
control	O
[	O
2	O
]	O
.	O
Finally	O
,	O
fish	O
consumption	O
was	O
associated	O
with	O
improvements	O
in	O
several	O
CVD	O
related	O
markers	O
among	O
subjects	O
with	O
the	O
metabolic	O
syndrome	O
(	O
MetS	O
)	O
compared	O
to	O
consumption	O
of	O
no	O
fish	O
or	O
seafood	O
[	O
4	O
]	O
.	O
Platelets	O
play	O
a	O
critical	O
role	O
in	O
the	O
physiological	O
process	O
of	O
haemostasis	O
and	O
also	O
in	O
the	O
formation	O
of	O
pathological	O
thrombi	O
[	O
5	O
,	O
6	O
]	O
.	O
Platelets	O
also	O
contribute	O
to	O
the	O
fibrinolytic	O
system	O
since	O
platelets	O
constitute	O
the	O
main	O
storage	O
pool	O
for	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
[	O
7	O
,	O
8	O
]	O
.	O
Soluble	O
platelet	O
agonists	O
,	O
released	O
from	O
damaged	O
cells	O
(	O
e	O
.	O
g	O
.	O
,	O
adenosine	O
diphosphate	O
,	O
ADP	O
)	O
or	O
produced	O
during	O
coagulation	O
and	O
inflammation	O
(	O
e	O
.	O
g	O
.	O
,	O
thrombin	O
and	O
platelet	O
-	O
activating	O
factor	O
,	O
PAF	O
)	O
,	O
are	O
critical	O
factors	O
in	O
platelet	O
activation	O
and	O
thrombus	O
formation	O
.	O

Particularly	O
,	O
PAF	O
(	O
1	O
-	O
O	O
-	O
alkyl	O
-	O
2	O
-	O
acetyl	O
-	O
sn	O
-	O
glycerol	O
-	O
3	O
-	O
phosphocholine	O
)	O
[	O
9	O
]	O
is	O
the	O
most	O
potent	O
lipid	O
mediator	O
of	O
inflammation	O
and	O
the	O
majority	O
of	O
its	O
pro	O
-	O
inflammatory	O
effects	O
are	O
produced	O
by	O
binding	O
to	O
the	O
PAF	O
-	O
receptor	O
(	O
PAF	O
-	O
R	O
)	O
,	O
expressed	O
on	O
the	O
surface	O
of	O
effector	O
cells	O
of	O
the	O
immune	O
and	O
coagulation	O
systems	O
[	O
10	O
]	O
.	O
Subclinical	O
activation	O
of	O
platelets	O
,	O
especially	O
under	O
conditions	O
of	O
insulin	O
resistance	O
,	O
is	O
a	O
chronic	O
stimulus	O
for	O
endothelial	O
inflammation	O
,	O
atherothrombosis	O
,	O
dementia	O
and	O
cancer	O
[	O
11	O
,	O
12	O
]	O
.	O
Dietary	O
changes	O
alone	O
or	O
in	O
combination	O
with	O
established	O
antiplatelet	O
therapies	O
may	O
play	O
a	O
role	O
in	O
the	O
attenuation	O
of	O
platelet	O
activation	O
and	O
thus	O
reduce	O
the	O
CVD	O
risk	O
[	O
13	O
]	O
.	O
However	O
,	O
few	O
intervention	B-methodology
studies	I-methodology
have	O
assessed	O
the	O
effect	O
of	O
diet	O
on	O
platelet	O
functionality	O
so	O
far	O
.	O
Evidence	O
suggests	O
that	O
platelet	O
aggregation	O
may	O
be	O
beneficially	O
affected	O
by	O
fish	O
consumption	O
probably	O
due	O
to	O
the	O
presence	O
of	O
ω	O
-	O
3	O
fatty	O
acids	O
and	O
other	O
specific	O
polar	O
lipids	O
[	O
14	O
]	O
.	O
In	O
a	O
recently	O
published	O
review	O
[	O
2	O
]	O
,	O
data	O
from	O
intervention	B-methodology
studies	I-methodology
showed	O
that	O
platelet	O
aggregation	O
was	O
reduced	O
after	O
consumption	O
of	O
approximately	O
2	O
fish	O
meals	O
per	O
week	O
providing	O
an	O
EPA	O
plus	O
DHA	O
amount	O
as	O
low	O
as	O
0	O
.	O
40	O
g	O
per	O
day	O
.	O
Specifically	O
,	O
collagen	O
-	O
induced	O
aggregation	O
was	O
most	O
consistently	O
affected	O
by	O
fish	O
consumption	O
,	O
followed	O
by	O
ADP	O
,	O
PAF	O
and	O
arachidonic	O
acid	O
(	O
AA	O
)	O
,	O
whereas	O
thrombin	O
-	O
induced	O
aggregation	O
was	O
not	O
significantly	O
affected	O
.	O
Findings	O
from	O
a	O
small	O
number	O
of	O
studies	O
on	O
fibrinolysis	O
suggested	O
that	O
fatty	O
fish	O
consumption	O
providing	O
an	O
EPA	O
plus	O
DHA	O
intake	O
as	O
low	O
as	O
0	O
.	O
6	O
g	O
or	O
as	O
high	O
as	O
3	O
.	O
4	O
g	O
per	O
day	O
could	O
reduce	O
PAI	O
-	O
1	O
levels	O
or	O
activity	O
.	O
Part	O
of	O
the	O
ongoing	O
aquaculture	O
research	O
has	O
focused	O
on	O
plant	O
-	O
based	O
products	O
as	O
substitutes	O
for	O
raw	O
materials	O
of	O
marine	O
origin	O
,	O
and	O
although	O
many	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
different	O
fish	O
feeds	O
on	O
fish	O
growth	O
,	O
performance	O
and	O
mortality	O
,	O
few	O
studies	O
have	O
addressed	O
the	O
potential	O
benefit	O
of	O
modifying	O
fish	O
feed	O
for	O
human	O
health	O
[	O
15	O
]	O
.	O
Specifically	O
,	O
a	O
limited	O
number	O
of	O
dietary	B-methodology
intervention	I-methodology
studies	I-methodology
investigated	O
the	O
effects	O
of	O
differently	O
fed	O
farmed	O
fish	O
on	O
CVD	O
related	O
biomarkers	O
in	O
human	O
adults	O
[	O
16	O
,	O
17	O
,	O
18	O
]	O
.	O

These	O
biomarkers	O
were	O
mostly	O
serum	O
lipid	O
profile	O
,	O
but	O
one	O
study	O
also	O
included	O
circulating	O
levels	O
of	O
vascular	O
inflammation	O
markers	O
[	O
16	O
]	O
.	O
Several	O
PAF	O
-	O
inhibitors	O
of	O
natural	O
origin	O
have	O
been	O
identified	O
,	O
which	O
can	O
either	O
bind	O
to	O
the	O
PAF	O
-	O
R	O
or	O
inhibit	O
certain	O
processes	O
in	O
the	O
PAF	O
-	O
induced	O
signal	O
transduction	O
pathways	O
[	O
19	O
]	O
.	O
Among	O
these	O
inhibitors	O
,	O
an	O
olive	O
pomace	O
polar	O
lipid	O
extract	O
,	O
where	O
the	O
most	O
active	O
compound	O
has	O
been	O
chemically	O
characterized	O
as	O
a	O
glycerylether	O
-	O
sn	O
-	O
2	O
-	O
acetyl	O
glycolipid	O
,	O
was	O
found	O
to	O
stabilize	O
established	O
atheromatous	O
lesions	O
in	O
animal	B-methodology
models	I-methodology
of	O
atherosclerosis	O
,	O
and	O
these	O
effects	O
were	O
comparable	O
to	O
a	O
standard	O
chow	O
diet	O
supplemented	O
with	O
simvastatin	O
[	O
20	O
]	O
.	O
Nasopoulou	O
and	O
colleagues	O
(	O
2011	O
)	O
used	O
olive	O
pomace	O
(	O
OP	O
)	O
and	O
olive	O
pomace	O
oil	O
(	O
OPO	O
)	O
to	O
partly	O
replace	O
fish	O
oil	O
in	O
the	O
diet	O
of	O
farmed	O
gilthead	O
sea	O
bream	O
and	O
growth	O
performance	O
was	O
not	O
affected	O
.	O
Interestingly	O
,	O
the	O
total	O
lipids	O
extracted	O
from	O
the	O
muscles	O
of	O
fish	O
fed	O
the	O
OP	O
diet	O
had	O
a	O
higher	O
in	B-methodology
vitro	I-methodology
inhibitory	O
activity	O
against	O
PAF	O
-	O
induced	O
aggregation	O
of	O
washed	O
rabbit	O
platelets	O
in	O
comparison	O
with	O
the	O
gilthead	O
sea	O
bream	O
fed	O
the	O
fish	O
oil	O
(	O
FO	O
)	O
diet	O
,	O
suggesting	O
that	O
the	O
bioactive	O
compounds	O
from	O
the	O
OP	O
passed	O
to	O
the	O
fish	O
muscles	O
[	O
21	O
]	O
.	O
The	O
aim	O
of	O
the	O
study	O
presented	O
herein	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
consumption	O
of	O
fillets	O
from	O
differently	O
fed	O
farmed	O
gilthead	O
sea	O
bream	O
on	O
platelet	O
aggregation	O
and	O
circulating	O
haemostatic	O
markers	O
among	O
apparently	O
healthy	O
adults	O
.	O
Based	O
on	O
the	O
findings	O
of	O
the	O
in	B-methodology
vitro	I-methodology
experiments	I-methodology
on	O
the	O
inhibition	O
of	O
the	O
PAF	O
-	O
induced	O
aggregation	O
[	O
21	O
]	O
,	O
we	O
hypothesized	O
that	O
the	O
consumption	O
of	O
fillets	O
from	O
fish	O
fed	O
with	O
a	O
diet	O
where	O
fish	O
oil	O
in	O
the	O
grow	O
-	O
out	O
feed	O
of	O
gilthead	O
sea	O
bream	O
was	O
partly	O
replaced	O
with	O
olive	O
pomace	O
(	O
OP	O
diet	O
)	O
would	O
have	O
a	O
greater	O
impact	O
on	O
platelet	O
aggregation	O
and	O
circulating	O
haemostatic	O
markers	O
compared	O
to	O
consumption	O
of	O
fillets	O
from	O
fish	O
fed	O
the	O
typical	O
FO	O
diet	O
.	O
The	O
trial	O
was	O
a	O
double	B-methodology
-	I-methodology
blind	I-methodology
randomized	I-methodology
dietary	I-methodology
intervention	I-methodology
study	I-methodology
with	O
a	O
1	O
:	O
1	O
allocation	O
ratio	O
,	O
conducted	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
[	O
22	O
]	O
.	O

This	O
study	O
compared	O
two	O
treatments	O
,	O
i	O
.	O
e	O
.	O
,	O
farmed	O
fish	O
fed	O
with	O
olive	O
pomace	O
enriched	O
diet	O
(	O
enriched	O
fish	O
;	O
EF	O
)	O
versus	O
farmed	O
fish	O
fed	O
with	O
fish	O
oil	O
diet	O
(	O
conventional	O
fish	O
;	O
CF	O
)	O
,	O
using	O
a	O
crossover	B-methodology
design	I-methodology
.	O
A	O
crossover	B-methodology
design	I-methodology
was	O
chosen	O
for	O
this	O
study	O
to	O
account	O
for	O
potential	O
within	O
-	O
subjects	O
’	O
variation	O
and	O
confounding	O
.	O
The	O
study	O
lasted	O
22	O
weeks	O
;	O
treatment	O
period	O
one	O
(	O
8	O
weeks	O
,	O
mid	O
-	O
January	O
–	O
end	O
of	O
March	O
)	O
,	O
washout	B-methodology
period	I-methodology
(	O
6	O
weeks	O
)	O
,	O
and	O
treatment	O
period	O
two	O
(	O
8	O
weeks	O
,	O
mid	O
-	O
May	O
–	O
end	O
of	O
July	O
)	O
.	O
The	O
participants	O
were	O
equally	O
distributed	O
to	O
the	O
two	O
treatments	O
along	O
treatment	O
periods	O
.	O
Eligible	O
subjects	O
were	O
all	O
adults	O
aged	O
between	O
30	O
and	O
65	O
years	O
old	O
with	O
a	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
between	O
24	O
.	O
0	O
and	O
31	O
.	O
0	O
kg	O
/	O
m2	O
who	O
met	O
the	O
eligibility	O
criteria	O
for	O
habitual	O
fish	O
consumption	O
(	O
<	O
150	O
g	O
of	O
cooked	O
fish	O
per	O
week	O
)	O
.	O
Exclusion	B-methodology
criteria	I-methodology
were	O
pregnancy	O
,	O
current	O
or	O
recent	O
weight	O
loss	O
effort	O
,	O
use	O
of	O
dietary	O
supplements	O
and	O
being	O
under	O
treatment	O
for	O
any	O
medical	O
disorder	O
.	O
Subjects	O
were	O
allowed	O
to	O
use	O
medical	O
treatment	O
for	O
thyroid	O
gland	O
disorders	O
,	O
iron	O
or	O
folic	O
acid	O
supplements	O
,	O
contraceptives	O
or	O
hormone	O
replacement	O
therapy	O
(	O
HRT	O
)	O
for	O
women	O
,	O
provided	O
they	O
would	O
continue	O
receiving	O
their	O
medication	O
throughout	O
the	O
study	O
.	O
Eligible	O
subjects	O
were	O
recruited	O
from	O
the	O
community	O
by	O
word	O
of	O
mouth	O
,	O
and	O
were	O
all	O
living	O
in	O
the	O
Attica	O
area	O
,	O
Greece	O
.	O
The	O
study	O
was	O
carried	O
out	O
at	O
the	O
Laboratory	O
of	O
Nutrition	O
and	O
Dietetics	O
in	O
collaboration	O
with	O
the	O
Laboratory	O
of	O
Biology	O
,	O
Biochemistry	O
,	O
Physiology	O
and	O
Microbiology	O
of	O
Harokopio	O
University	O
,	O
Athens	O
,	O
Greece	O
.	O
Participants	O
were	O
randomly	B-methodology
assigned	I-methodology
to	O
one	O
of	O
two	O
fish	O
treatment	O
sequences	O
(	O
CF	O
/	O
EF	O
or	O
EF	O
/	O
CF	O
)	O
.	O
Participants	O
in	O
each	O
sequence	O
received	O
each	O
treatment	O
for	O
8	O
weeks	O
with	O
a	O
6	O
-	O
week	O
washout	B-methodology
period	I-methodology
between	O
treatment	O
periods	O
.	O
The	O
fish	O
species	O
studied	O
in	O
the	O
present	O
trial	O
was	O
gilthead	O
seabream	O
(	O
Sparus	O
aurata	O
L	O
.	O
)	O
,	O
and	O
the	O
two	O
types	O
of	O
fish	O
compared	O
were	O
farmed	O
fish	O
fed	O
with	O
fish	O
oil	O
diet	O
(	O
CF	O
)	O
and	O
farmed	O
fish	O
fed	O
with	O
olive	O
pomace	O
enriched	O
diet	O
(	O
EF	O
)	O
.	O
NIREUS	O
Aquaculture	O
S	O
.	O
A	O
.	O
provided	O
both	O
types	O
of	O
fish	O
.	O

The	O
production	O
method	O
of	O
fish	O
feed	O
enriched	O
with	O
olive	O
processing	O
byproducts	O
,	O
the	O
method	O
to	O
enrich	O
farmed	O
fish	O
and	O
the	O
effect	O
of	O
feed	O
on	O
the	O
fatty	O
acid	O
profile	O
and	O
total	O
polar	O
lipid	O
(	O
TPL	O
)	O
concentration	O
in	O
the	O
flesh	O
of	O
gilthead	O
sea	O
bream	O
,	O
are	O
described	O
in	O
detail	O
elsewhere	O
[	O
23	O
]	O
.	O
The	O
fatty	O
acid	O
composition	O
of	O
the	O
fish	O
consumed	O
in	O
the	O
study	O
was	O
not	O
specifically	O
analyzed	O
for	O
the	O
study	O
fish	O
fillets	O
.	O
Details	O
of	O
the	O
percent	O
fatty	O
acid	O
composition	O
of	O
the	O
fillets	O
were	O
as	O
follows	O
:	O
18	O
:	O
1ω	O
-	O
9	O
(	O
24	O
–	O
25	O
%	O
)	O
,	O
20	O
:	O
5ω	O
-	O
3	O
(	O
4	O
–	O
5	O
%	O
)	O
,	O
22	O
:	O
5ω	O
-	O
3	O
(	O
2	O
–	O
2	O
.	O
6	O
%	O
)	O
,	O
22	O
:	O
6ω	O
-	O
3	O
(	O
13	O
–	O
14	O
%	O
)	O
for	O
the	O
CF	O
,	O
and	O
18	O
:	O
1ω	O
-	O
9	O
(	O
23	O
–	O
23	O
.	O
8	O
%	O
)	O
,	O
20	O
:	O
5ω	O
-	O
3	O
(	O
2	O
.	O
2	O
–	O
2	O
.	O
6	O
%	O
)	O
,	O
22	O
:	O
5ω	O
-	O
3	O
(	O
1	O
.	O
7	O
–	O
1	O
.	O
9	O
%	O
)	O
and	O
22	O
:	O
6ω	O
-	O
3	O
(	O
7	O
–	O
7	O
.	O
8	O
%	O
)	O
for	O
the	O
EF	O
.	O
Every	O
week	O
during	O
each	O
treatment	O
period	O
,	O
participants	O
were	O
provided	O
with	O
two	O
portions	O
of	O
fresh	O
,	O
raw	O
,	O
gutted	O
and	O
scaled	O
gilthead	O
seabream	O
.	O
Each	O
portion	O
weighed	O
on	O
average	O
380	O
g	O
(	O
quantity	O
of	O
edible	O
fillet	O
approximately	O
170	O
g	O
)	O
.	O
Participants	O
were	O
instructed	O
to	O
consume	O
fish	O
twice	O
weekly	O
(	O
one	O
portion	O
at	O
a	O
time	O
)	O
on	O
the	O
days	O
of	O
their	O
choice	O
.	O
At	O
the	O
beginning	O
of	O
each	O
treatment	O
period	O
,	O
participants	O
were	O
given	O
oral	O
and	O
written	O
instructions	O
regarding	O
the	O
preparation	O
of	O
fish	O
.	O
Specifically	O
,	O
participants	O
were	O
asked	O
to	O
bake	O
or	O
grill	O
the	O
fish	O
,	O
and	O
were	O
allowed	O
to	O
add	O
seasonings	O
and	O
spices	O
of	O
their	O
choice	O
during	O
fish	O
preparation	O
and	O
consumption	O
.	O
Participants	O
were	O
also	O
asked	O
to	O
maintain	O
their	O
dietary	O
and	O
physical	O
activity	O
habits	O
throughout	O
the	O
study	O
and	O
to	O
refrain	O
from	O
any	O
weight	O
loss	O
effort	O
during	O
that	O
period	O
.	O
In	O
particular	O
,	O
participants	O
maintained	O
their	O
olive	O
oil	O
consumption	O
pattern	O
throughout	O
the	O
study	O
with	O
the	O
food	O
frequency	O
questionnaire	O
(	O
FFQ	O
)	O
data	O
showing	O
similar	O
levels	O
of	O
consumption	O
at	O
the	O
end	O
of	O
each	O
intervention	B-methodology
period	I-methodology
compared	O
to	O
the	O
beginning	O
of	O
the	O
study	O
(	O
30	O
±	O
14	O
vs	O
.	O
29	O
±	O
15	O
mL	O
/	O
day	O
(	O
CF	O
,	O
1st	O
period	O
)	O
;	O
30	O
±	O
13	O
vs	O
.	O
33	O
±	O
19	O
mL	O
/	O
day	O
(	O
CF	O
,	O
2nd	O
period	O
)	O
;	O
32	O
±	O
19	O
vs	O
.	O

33	O
±	O
19	O
mL	O
/	O
day	O
(	O
EF	O
,	O
1st	O
period	O
)	O
;	O
27	O
±	O
12	O
vs	O
.	O
29	O
±	O
15	O
mL	O
/	O
day	O
(	O
EF	O
,	O
2nd	O
period	O
)	O
;	O
pwithin	O
-	O
group	O
>	O
0	O
.	O
5	O
,	O
for	O
all	O
)	O
.	O
During	O
the	O
6	O
-	O
week	O
washout	B-methodology
period	I-methodology
,	O
participants	O
were	O
not	O
provided	O
with	O
any	O
fish	O
portion	O
and	O
were	O
advised	O
to	O
continue	O
their	O
long	O
-	O
standing	O
dietary	O
habits	O
.	O
The	O
primary	O
outcomes	O
were	O
circulating	O
concentrations	O
of	O
haemostatic	O
markers	O
(	O
i	O
.	O
e	O
.	O
,	O
PAI	O
-	O
1	O
;	O
sP	O
-	O
selectin	O
)	O
,	O
and	O
ex	B-methodology
vivo	I-methodology
assessment	O
of	O
human	O
platelet	O
aggregation	O
in	O
platelet	O
rich	O
plasma	O
(	O
PRP	O
)	O
.	O
All	O
assessments	O
were	O
performed	O
at	O
the	O
beginning	O
and	O
at	O
the	O
end	O
of	O
each	O
treatment	O
period	O
.	O
Anthropometric	O
assessment	O
:	O
Body	O
weight	O
of	O
participants	O
was	O
measured	O
with	O
digital	O
scale	O
(	O
Seca	O
robusta	O
813	O
,	O
Hamburg	O
,	O
Germany	O
)	O
to	O
the	O
nearest	O
100	O
g	O
,	O
and	O
body	O
height	O
was	O
measured	O
to	O
the	O
nearest	O
0	O
.	O
5	O
cm	O
.	O
BMI	O
was	O
calculated	O
as	O
weight	O
(	O
kg	O
)	O
divided	O
by	O
height	O
squared	O
(	O
m2	O
)	O
.	O
Waist	O
circumference	O
was	O
measured	O
to	O
the	O
nearest	O
0	O
.	O
1	O
cm	O
between	O
the	O
lowest	O
rib	O
and	O
the	O
superior	O
border	O
of	O
the	O
iliac	O
crest	O
at	O
the	O
end	O
of	O
normal	O
expiration	O
.	O
The	O
American	O
Heart	O
Association	O
/	O
National	O
Heart	O
,	O
Lung	O
,	O
and	O
Blood	O
Institute	O
criteria	O
were	O
used	O
to	O
define	O
increased	O
waist	O
circumference	O
among	O
study	O
subjects	O
(	O
i	O
.	O
e	O
.	O
,	O
≥102	O
cm	O
for	O
men	O
and	O
≥88	O
cm	O
for	O
women	O
)	O
.	O
SBP	O
and	O
DBP	O
of	O
subjects	O
were	O
measured	O
twice	O
,	O
2	O
min	O
apart	O
,	O
in	O
a	O
sitting	O
position	O
,	O
using	O
an	O
automated	O
Omron	O
M4	O
sphygmomanometer	O
and	O
the	O
average	O
of	O
the	O
two	O
measurements	O
was	O
calculated	O
and	O
recorded	O
.	O
Dietary	O
assessment	O
:	O
Participants	O
’	O
habitual	O
dietary	O
intake	O
over	O
the	O
last	O
month	O
was	O
assessed	O
with	O
a	O
semi	O
-	O
quantitative	O
76	O
-	O
item	O
FFQ	O
,	O
which	O
was	O
developed	O
and	O
tested	O
for	O
its	O
repeatability	O
and	O
relative	O
validity	O
in	O
the	O
Greek	O
population	O
[	O
24	O
]	O
.	O
Daily	O
energy	O
and	O
macronutrient	O
intake	O
were	O
calculated	O
based	O
on	O
the	O
FFQ	O
data	O
.	O
Dietary	O
intake	O
was	O
also	O
expressed	O
in	O
terms	O
of	O
daily	O
food	O
group	O
(	O
e	O
.	O
g	O
.	O
,	O
dairy	O
products	O
,	O
fruits	O
,	O
vegetables	O
)	O
and	O
individual	O
food	O
and	O
beverage	O
(	O
e	O
.	O
g	O
.	O
,	O
potatoes	O
,	O
olive	O
oil	O
,	O
coffee	O
)	O
consumption	O
as	O
described	O
in	O
the	O
dietary	B-methodology
guidelines	I-methodology
for	O
Greek	O
adults	O
[	O
25	O
]	O
.	O

The	O
Mediterranean	O
Diet	O
Score	O
(	O
MedDietScore	O
)	O
was	O
used	O
to	O
evaluate	O
the	O
level	O
of	O
adherence	O
to	O
the	O
Mediterranean	O
dietary	O
pattern	O
[	O
26	O
]	O
.	O
Physical	B-methodology
activity	I-methodology
assessment	I-methodology
:	O
Physical	O
activity	O
was	O
assessed	O
with	O
the	O
Athens	O
Physical	O
Activity	O
Questionnaire	O
(	O
APAQ	O
)	O
validated	O
for	O
the	O
Greek	O
population	O
[	O
27	O
]	O
.	O
This	O
questionnaire	O
was	O
used	O
to	O
calculate	O
total	O
daily	O
energy	O
expenditure	O
(	O
kcal	O
/	O
day	O
)	O
and	O
estimate	O
physical	O
activity	O
level	O
(	O
PAL	O
)	O
.	O
Smoking	O
assessment	O
:	O
Subjects	O
were	O
assessed	O
with	O
respect	O
to	O
smoking	O
status	O
(	O
non	O
-	O
smoker	O
,	O
former	O
smoker	O
,	O
and	O
current	O
smoker	O
)	O
,	O
duration	O
of	O
smoking	O
(	O
in	O
years	O
)	O
and	O
mean	O
number	O
of	O
cigarettes	O
smoked	O
per	O
day	O
(	O
for	O
current	O
smokers	O
)	O
.	O
Pack	O
-	O
years	O
of	O
smoking	O
were	O
calculated	O
based	O
on	O
the	O
following	O
formula	O
:	O
Number	O
of	O
pack−years	O
=	O
(	O
mean	O
number	O
of	O
cigarettes	O
smoked	O
per	O
day	O
/	O
20	O
)	O
×	O
number	O
of	O
years	O
smoked	O
Blood	O
sampling	O
:	O
The	O
subjects	O
were	O
asked	O
not	O
to	O
use	O
any	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
medication	O
,	O
antibiotics	O
or	O
analgesics	O
two	O
weeks	O
before	O
the	O
scheduled	O
time	O
of	O
blood	O
collection	O
.	O
The	O
subjects	O
were	O
also	O
instructed	O
to	O
avoid	O
vigorous	O
physical	O
activity	O
the	O
day	O
before	O
blood	O
sampling	O
and	O
refrain	O
from	O
smoking	O
in	O
the	O
morning	O
prior	O
to	O
blood	O
collection	O
.	O
Venous	O
blood	O
samples	O
were	O
drawn	O
after	O
a	O
10	O
-	O
h	O
overnight	O
fast	O
between	O
08	O
:	O
00	O
AM	O
and	O
10	O
:	O
00	O
AM	O
.	O
Serum	O
was	O
obtained	O
from	O
silicone	O
coated	O
tubes	O
(	O
BD	O
Vacutainer®	O
Plus	O
Plastic	O
Serum	O
Tubes	O
)	O
.	O
Blood	O
was	O
allowed	O
to	O
clot	O
at	O
room	O
temperature	O
for	O
60	O
min	O
until	O
centrifugation	O
(	O
1500×	O
g	O
,	O
10	O
min	O
,	O
20	O
°C	O
)	O
.	O
Plasma	O
was	O
obtained	O
from	O
EDTA	O
tubes	O
(	O
BD	O
Vacutainer®	O
spray	O
-	O
coated	O
K2EDTA	O
Tubes	O
)	O
.	O
Whole	O
blood	O
count	O
was	O
performed	O
on	O
a	O
BC	O
-	O
3000	O
Plus	O
Auto	O
Hematology	O
Analyzer	O
(	O
Shenzhen	O
Mindray	O
Bio	O
-	O
Medical	O
Electronics	O
C	O
.	O
,	O
Ltd	O
.	O
,	O
Shenzhen	O
518057	O
,	O
China	O
)	O
at	O
room	O
temperature	O
immediately	O
prior	O
to	O
plasma	O
collection	O
.	O
All	O
serum	O
and	O
plasma	O
aliquots	O
were	O
stored	O
at	O
−80	O
°C	O
until	O
biochemical	O
analysis	O
.	O

Blood	O
analyses	O
:	O
Commercially	O
available	O
kits	O
(	O
BIOSIS	O
,	O
Athens	O
,	O
Greece	O
)	O
based	O
on	O
enzymatic	O
methods	O
were	O
used	O
to	O
determine	O
glucose	O
(	O
mmol	O
/	O
L	O
)	O
(	O
glucose	O
oxidase	O
,	O
sensitivity	O
0	O
.	O
04	O
mmol	O
/	O
L	O
,	O
intra	O
-	O
assay	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
2	O
.	O
4	O
%	O
)	O
,	O
triacylglycerols	O
(	O
TAG	O
)	O
(	O
mmol	O
/	O
L	O
)	O
(	O
phospho	O
-	O
glycerol	O
oxidase	O
,	O
sensitivity	O
0	O
.	O
03	O
mmol	O
/	O
L	O
,	O
intra	O
-	O
assay	O
CV	O
1	O
.	O
3	O
%	O
)	O
,	O
total	O
cholesterol	O
(	O
mmol	O
/	O
L	O
)	O
(	O
cholesterol	O
esterase	O
/	O
cholesterol	O
oxidase	O
,	O
sensitivity	O
0	O
.	O
10	O
mmol	O
/	O
L	O
,	O
intra	O
-	O
assay	O
CV	O
1	O
.	O
6	O
%	O
)	O
.	O
High	O
density	O
lipoprotein	O
-	O
cholesterol	O
(	O
mmol	O
/	O
L	O
)	O
was	O
determined	O
using	O
the	O
same	O
method	O
as	O
that	O
used	O
for	O
total	O
cholesterol	O
,	O
after	O
precipitation	O
of	O
non	O
-	O
HDL	O
lipoproteins	O
with	O
phosphotungstic	O
acid	O
and	O
LDL	O
-	O
cholesterol	O
(	O
mmol	O
/	O
L	O
)	O
was	O
calculated	O
using	O
Friedewald	O
formula	O
.	O
Insulin	O
(	O
pmol	O
/	O
L	O
)	O
was	O
measured	O
with	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
[UNK]	O
,	O
human	O
Insulin	O
ELISA	O
,	O
intra	O
-	O
assay	O
CV	O
%	O
:	O
5	O
.	O
4	O
%	O
,	O
and	O
inter	O
-	O
assay	O
CV	O
%	O
:	O
8	O
.	O
5	O
;	O
Life	O
Technologies	O
Corporation	O
,	O
7335	O
Executive	O
Way	O
,	O
Frederick	O
,	O
MD	O
USA	O
21704	O
)	O
.	O
The	O
homeostasis	O
model	O
assessment	O
(	O
HOMA	O
)	O
method	O
was	O
used	O
to	O
assess	O
insulin	O
resistance	O
(	O
IR	O
)	O
from	O
basal	O
(	O
fasting	O
)	O
glucose	O
and	O
insulin	O
concentrations	O
;	O
HOMA	O
-	O
IR	O
was	O
calculated	O
according	O
to	O
the	O
formula	O
:	O
(	O
FPI	O
×	O
FPG	O
)	O
/	O
22	O
.	O
5	O
,	O
where	O
FPI	O
is	O
fasting	O
plasma	O
insulin	O
concentration	O
(	O
mU	O
/	O
L	O
)	O
and	O
FPG	O
is	O
fasting	O
plasma	O
glucose	O
(	O
mmol	O
/	O
L	O
)	O
.	O
The	O
concentrations	O
of	O
PAI	O
-	O
1	O
(	O
pg	O
/	O
mL	O
)	O
and	O
sP	O
-	O
selectin	O
(	O
ng	O
/	O
mL	O
)	O
were	O
measured	O
in	O
duplicate	O
in	O
plasma	O
.	O

Plasma	O
concentration	O
of	O
PAI	O
-	O
1	O
was	O
measured	O
with	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
[UNK]	O
,	O
human	O
PAI	O
-	O
1	O
ELISA	O
,	O
intra	O
-	O
assay	O
CV	O
%	O
:	O
4	O
.	O
7	O
,	O
and	O
inter	O
-	O
assay	O
CV	O
%	O
:	O
5	O
.	O
0	O
;	O
Life	O
Technologies	O
Corporation	O
,	O
7335	O
Executive	O
Way	O
,	O
Frederick	O
,	O
MD	O
USA	O
21704	O
)	O
.	O
Plasma	O
concentration	O
of	O
sP	O
-	O
selectin	O
was	O
measured	O
with	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
[UNK]	O
,	O
human	O
sP	O
-	O
selectin	O
ELISA	O
,	O
intra	O
-	O
assay	O
CV	O
%	O
:	O
7	O
.	O
8	O
,	O
and	O
inter	O
-	O
assay	O
CV	O
%	O
:	O
5	O
.	O
4	O
;	O
Life	O
Technologies	O
Corporation	O
,	O
7335	O
Executive	O
Way	O
,	O
Frederick	O
,	O
MD	O
USA	O
21704	O
)	O
.	O
Ex	B-methodology
vivo	I-methodology
assessment	O
of	O
human	O
platelet	O
aggregation	O
:	O
The	O
procedure	O
followed	O
has	O
been	O
previously	O
described	O
[	O
28	O
]	O
.	O
Briefly	O
,	O
blood	O
was	O
collected	O
in	O
trisodium	O
citrate	O
as	O
anticoagulant	O
,	O
and	O
platelet	O
-	O
rich	O
plasma	O
(	O
PRP	O
)	O
was	O
obtained	O
by	O
centrifugation	O
followed	O
by	O
centrifugation	O
of	O
the	O
residue	O
to	O
obtain	O
platelet	O
-	O
poor	O
plasma	O
(	O
PPP	O
)	O
.	O
The	O
aggregation	O
,	O
induced	O
by	O
various	O
concentrations	O
of	O
PAF	O
,	O
adenosine	O
diphosphate	O
(	O
ADP	O
)	O
and	O
thrombin	O
(	O
THR	O
)	O
,	O
was	O
determined	O
in	O
human	O
PRP	O
by	O
light	O
transmission	O
aggregometry	O
in	O
a	O
Chrono	O
-	O
Log	O
(	O
Havertown	O
,	O
PA	O
,	O
USA	O
)	O
aggregometer	O
(	O
model	O
440VS	O
)	O
.	O
The	O
aggregation	O
curve	O
of	O
maximum	O
-	O
reversible	O
platelet	O
aggregation	O
of	O
human	O
PRP	O
induced	O
by	O
an	O
agonist	O
was	O
determined	O
as	O
the	O
100	O
%	O
aggregation	O
of	O
platelets	O
.	O
Within	O
the	O
20	O
and	O
80	O
%	O
of	O
the	O
maximum	O
-	O
reversible	O
platelet	O
aggregation	O
of	O
human	O
PRP	O
,	O
there	O
exists	O
a	O
linear	O
association	O
(	O
linear	O
curve	O
)	O
between	O
the	O
concentrations	O
of	O
a	O
platelet	O
aggregation	O
agonist	O
and	O
percentage	O
of	O
aggregation	O
.	O
The	O
concentration	O
of	O
a	O
specific	O
agonist	O
needed	O
to	O
induce	O
50	O
%	O
of	O
platelet	O
aggregation	O
(	O
EC50	O
or	O
half	O
maximal	O
effective	O
concentration	O
)	O
can	O
be	O
calculated	O
from	O
the	O
linear	O
part	O
of	O
the	O
aggregation	O
curve	O
.	O
As	O
expected	O
,	O
the	O
lower	O
the	O
EC50	O
value	O
for	O
an	O
agonist	O
the	O
higher	O
the	O
potency	O
of	O
its	O
platelet	O
aggregation	O
effect	O
.	O

Bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
,	O
PAF	O
,	O
ADP	O
and	O
THR	O
were	O
obtained	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O
EC50	O
measurements	O
were	O
expressed	O
in	O
mM	O
(	O
for	O
ADP	O
and	O
PAF	O
)	O
or	O
in	O
U	O
/	O
mL	O
(	O
for	O
THR	O
)	O
.	O
A	O
priori	O
power	O
analysis	O
showed	O
that	O
a	O
sample	O
size	O
of	O
25	O
participants	O
was	O
adequate	O
to	O
achieve	O
statistical	O
power	O
equal	O
to	O
83	O
%	O
at	O
a	O
5	O
%	O
significance	O
level	O
of	O
two	O
-	O
sided	O
hypotheses	O
that	O
evaluated	O
1	O
standard	O
deviation	O
(	O
SD	O
)	O
difference	O
between	O
groups	O
based	O
on	O
the	O
EC50	O
values	O
of	O
platelet	O
aggregation	O
induced	O
by	O
PAF	O
.	O
Participants	O
were	O
randomly	B-methodology
allocated	I-methodology
to	O
each	O
sequence	O
group	O
using	O
a	O
computerized	O
random	O
number	O
generator	O
.	O
One	O
of	O
the	O
research	O
dietitians	O
was	O
solely	O
responsible	O
for	O
the	O
assignment	O
of	O
participants	O
to	O
the	O
treatment	O
sequences	O
,	O
whereas	O
all	O
other	O
team	O
investigators	O
were	O
kept	O
blinded	O
to	O
the	O
allocation	O
.	O
In	O
addition	O
,	O
the	O
participants	O
were	O
not	O
aware	O
of	O
the	O
fish	O
treatments	O
provided	O
since	O
there	O
was	O
no	O
obvious	O
difference	O
between	O
the	O
two	O
types	O
of	O
raw	O
fish	O
,	O
and	O
the	O
enriched	O
cooked	O
fish	O
had	O
similar	O
sensory	O
characteristics	O
(	O
i	O
.	O
e	O
.	O
,	O
odor	O
,	O
taste	O
and	O
aftertaste	O
)	O
to	O
the	O
conventional	O
one	O
[	O
29	O
]	O
.	O
During	O
the	O
fish	O
consumption	O
and	O
the	O
washout	O
periods	O
,	O
participants	O
were	O
asked	O
to	O
record	O
the	O
days	O
they	O
consumed	O
fish	O
,	O
and	O
the	O
use	O
of	O
any	O
medication	O
,	O
as	O
well	O
as	O
to	O
report	O
any	O
short	O
-	O
term	O
cold	O
.	O
All	O
records	O
were	O
collected	O
during	O
the	O
appointments	O
that	O
participants	O
had	O
with	O
the	O
research	O
dietitian	O
.	O
Moreover	O
,	O
in	O
the	O
middle	O
of	O
each	O
intervention	B-methodology
period	I-methodology
,	O
one	O
of	O
the	O
investigators	O
called	O
participants	O
to	O
explore	O
compliance	O
to	O
the	O
intervention	O
and	O
to	O
record	O
any	O
unexpected	O
conditions	O
(	O
e	O
.	O
g	O
.	O
,	O
illnesses	O
,	O
problems	O
with	O
fish	O
deliveries	O
,	O
loss	O
of	O
fish	O
servings	O
due	O
to	O
accidents	O
during	O
cooking	O
)	O
.	O
In	O
addition	O
,	O
participants	O
’	O
compliance	O
with	O
the	O
study	B-methodology
protocol	I-methodology
was	O
assessed	O
with	O
a	O
fatty	O
acid	O
analysis	O
(	O
FA	O
)	O
of	O
red	O
blood	O
cell	O
(	O
RBC	O
)	O
membranes	O
collected	O
at	O
the	O
beginning	O
and	O
the	O
end	O
of	O
each	O
fish	O
treatment	O
period	O
.	O
Red	O
blood	O
cell	O
isolation	O
and	O
FA	O
analysis	O
:	O
The	O
procedure	O
followed	O
has	O
been	O
recently	O
described	O
[	O
30	O
]	O
.	O
Briefly	O
,	O
red	O
blood	O
cell	O
pellet	O
was	O
prepared	O
from	O
EDTA	O
tubes	O
(	O
BD	O
Vacutainer®	O
spray	O
-	O
coated	O
K2EDTA	O
Tubes	O
)	O
after	O
plasma	O
collection	O
.	O

Fatty	O
acid	O
methyl	O
esters	O
(	O
FAME	O
)	O
were	O
produced	O
during	O
methanolysis	O
of	O
the	O
RBC	O
extracts	O
,	O
and	O
were	O
extracted	O
with	O
hexane	O
containing	O
internal	O
standard	O
,	O
i	O
.	O
e	O
.	O
,	O
methyl	O
nonanoate	O
,	O
and	O
BHT	O
.	O
Fatty	O
acid	O
methyl	O
esters	O
were	O
analyzed	O
with	O
gas	O
chromatography	O
using	O
an	O
Agilent	O
HP	O
-	O
6890	O
(	O
Avondale	O
,	O
PA	O
,	O
USA	O
)	O
gas	O
chromatograph	O
equipped	O
with	O
flame	O
ionization	O
detector	O
,	O
split	O
–	O
splitless	O
injector	O
,	O
and	O
an	O
HP	O
6890	O
autosampler	O
.	O
A	O
standard	O
FAME	O
mixture	O
was	O
used	O
for	O
the	O
identification	O
of	O
the	O
peaks	O
(	O
Sigma	O
L9405	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O
For	O
the	O
purposes	O
of	O
the	O
present	O
study	O
,	O
only	O
those	O
FAs	O
that	O
comprised	O
>	O
0	O
.	O
01	O
%	O
of	O
the	O
total	O
FAs	O
of	O
the	O
RBC	O
membranes	O
were	O
considered	O
for	O
data	O
analysis	O
,	O
i	O
.	O
e	O
.	O
,	O
34	O
FAs	O
out	O
of	O
a	O
total	O
of	O
46	O
FAs	O
identified	O
.	O
Trans	O
isomers	O
were	O
not	O
included	O
.	O
All	O
statistical	O
analyses	O
were	O
performed	O
using	O
Stata	O
Statistical	O
Software	O
,	O
Release	O
12	O
(	O
StataCorp	O
LP	O
:	O
College	O
Station	O
,	O
TX	O
,	O
USA	O
)	O
.	O
The	O
significance	O
(	O
α	O
)	O
level	O
was	O
set	O
to	O
0	O
.	O
05	O
for	O
all	O
tests	O
.	O
The	O
Shapiro	O
–	O
Wilk	O
test	O
and	O
normal	O
Q	O
–	O
Q	O
plots	O
were	O
used	O
to	O
test	O
normal	O
distribution	O
of	O
data	O
.	O
Data	O
were	O
analysed	O
based	O
on	O
the	O
per	O
-	O
protocol	O
principle	O
.	O
The	O
two	O
sequence	O
groups	O
(	O
CF	O
/	O
EF	O
vs	O
.	O
EF	O
/	O
CF	O
)	O
were	O
compared	O
for	O
demographic	O
,	O
anthropometric	O
,	O
biochemical	O
,	O
physical	O
activity	O
and	O
dietary	O
characteristics	O
assessed	O
at	O
the	O
beginning	O
of	O
the	O
study	O
.	O
Fisher	O
’	O
s	O
exact	O
test	O
was	O
used	O
to	O
assess	O
if	O
sex	O
and	O
smoking	O
status	O
were	O
uniformly	O
represented	O
between	O
the	O
two	O
groups	O
.	O
For	O
continuous	O
variables	O
,	O
two	O
-	O
independent	O
-	O
samples	O
t	O
-	O
test	O
or	O
the	O
nonparametric	O
Mann	O
–	O
Whitney	O
test	O
were	O
used	O
for	O
variables	O
following	O
a	O
normal	O
or	O
a	O
non	O
-	O
normal	O
distribution	O
,	O
respectively	O
.	O
Categorical	O
variables	O
(	O
sex	O
,	O
smoking	O
status	O
)	O
are	O
presented	O
as	O
frequencies	O
,	O
n	O
(	O
%	O
)	O
;	O
relative	O
frequency	O
(	O
%	O
)	O
is	O
expressed	O
as	O
percentage	O
of	O
all	O
participants	O
(	O
n	O
=	O
30	O
)	O
.	O
Continuous	O
variables	O
with	O
normal	O
distribution	O
are	O
presented	O
as	O
mean	O
±	O
standard	O
deviation	O
(	O
SD	O
)	O
,	O
whereas	O
continuous	O
variables	O
with	O
non	O
-	O
normal	O
distribution	O
are	O
presented	O
as	O
median	O
(	O
25th	O
,	O
75th	O
percentiles	O
)	O
.	O

p	O
-	O
values	O
are	O
presented	O
for	O
two	O
-	O
sided	O
two	O
-	O
independent	O
-	O
samples	O
tests	O
.	O
Paired	O
-	O
samples	O
t	O
tests	O
were	O
used	O
to	O
evaluate	O
whether	O
the	O
RBC	O
membrane	O
content	O
in	O
EPA	O
and	O
DHA	O
was	O
higher	O
after	O
fish	O
consumption	O
compared	O
to	O
the	O
content	O
before	O
fish	O
consumption	O
.	O
Comparisons	O
were	O
performed	O
by	O
period	O
and	O
treatment	O
.	O
Data	O
are	O
presented	O
as	O
mean	O
before	O
treatment	O
±	O
SD	O
,	O
mean	O
change	O
±	O
SD	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
of	O
the	O
change	O
,	O
and	O
p	O
-	O
value	O
for	O
one	O
-	O
sided	O
paired	O
-	O
samples	O
t	O
tests	O
.	O
For	O
each	O
primary	O
outcome	O
and	O
other	O
outcome	O
measure	O
,	O
sequence	O
,	O
carry	O
-	O
over	O
and	O
period	O
effects	O
were	O
evaluated	O
with	O
analysis	O
of	O
variance	O
for	O
a	O
2	O
×	O
2	O
crossover	B-methodology
design	I-methodology
(	O
pkcross	O
)	O
,	O
and	O
treatment	O
effect	O
was	O
estimated	O
with	O
linear	O
regression	O
(	O
regress	O
)	O
.	O
Input	O
data	O
were	O
expressed	O
as	O
relative	O
change	O
(	O
%	O
)	O
,	O
calculated	O
as	O
the	O
change	O
between	O
values	O
at	O
the	O
end	O
and	O
values	O
at	O
the	O
beginning	O
of	O
each	O
treatment	O
period	O
.	O
For	O
data	O
with	O
non	O
-	O
normal	O
distribution	O
,	O
the	O
natural	O
logarithm	O
(	O
ln	O
)	O
of	O
the	O
ratio	O
(	O
%	O
)	O
was	O
used	O
instead	O
of	O
the	O
relative	O
change	O
(	O
%	O
)	O
.	O
Linear	O
regression	O
models	O
were	O
fitted	O
for	O
each	O
of	O
the	O
outcomes	O
.	O
Treatment	O
was	O
used	O
as	O
the	O
main	O
exposure	O
,	O
and	O
the	O
CF	O
was	O
used	O
as	O
the	O
reference	O
group	O
.	O
Adjustments	O
were	O
made	O
for	O
the	O
period	O
of	O
treatment	O
,	O
i	O
.	O
e	O
.	O
,	O
1st	O
period	O
(	O
winter	O
)	O
versus	O
2nd	O
period	O
(	O
summer	O
)	O
.	O
Additional	O
adjustments	O
for	O
insulin	O
or	O
HOMA	O
-	O
IR	O
,	O
and	O
pack	O
-	O
years	O
of	O
smoking	O
did	O
not	O
alter	O
the	O
results	O
and	O
thus	O
are	O
not	O
presented	O
.	O
The	O
effect	O
of	O
treatment	O
is	O
presented	O
as	O
the	O
exponentiated	O
coefficient	O
(	O
standard	O
error	O
,	O
SE	O
)	O
and	O
95	O
%	O
CI	O
.	O
For	O
each	O
primary	O
outcome	O
and	O
other	O
outcome	O
measure	O
,	O
values	O
at	O
the	O
beginning	O
of	O
the	O
8	O
-	O
week	O
treatment	O
were	O
compared	O
to	O
the	O
values	O
at	O
the	O
end	O
of	O
treatment	O
,	O
separately	O
for	O
each	O
fish	O
treatment	O
.	O
Comparisons	O
were	O
also	O
performed	O
by	O
period	O
since	O
there	O
were	O
indications	O
for	O
period	O
effect	O
.	O
Two	O
-	O
paired	O
-	O
samples	O
t	O
tests	O
or	O
Wilcoxon	O
signed	O
-	O
rank	O
tests	O
were	O
used	O
for	O
this	O
analysis	O
.	O
p	O
-	O
values	O
are	O
presented	O
for	O
two	O
-	O
sided	O
paired	O
-	O
samples	O
tests	O
.	O
The	O
flow	O
diagram	O
of	O
the	O
study	O
is	O
shown	O
in	O
Figure	O
S1	O
.	O

No	O
significant	O
differences	O
were	O
found	O
for	O
anthropometric	O
indices	O
,	O
standard	O
biochemical	O
markers	O
,	O
circulating	O
haemostatic	O
markers	O
or	O
ex	B-methodology
vivo	I-methodology
platelet	I-methodology
aggregation	I-methodology
markers	O
between	O
the	O
CF	O
/	O
EF	O
and	O
the	O
EF	O
/	O
CF	O
groups	O
at	O
the	O
beginning	O
of	O
the	O
study	O
except	O
that	O
heart	O
rate	O
(	O
pulses	O
/	O
min	O
)	O
,	O
fasting	O
serum	O
insulin	O
concentration	O
(	O
pmol	O
/	O
L	O
)	O
and	O
HOMA	O
-	O
IR	O
were	O
higher	O
in	O
the	O
CF	O
/	O
EF	O
group	O
compared	O
to	O
the	O
EF	O
/	O
CF	O
group	O
(	O
Table	O
1	O
)	O
.	O
Furthermore	O
,	O
the	O
two	O
groups	O
did	O
not	O
differ	O
with	O
respect	O
to	O
physical	O
activity	O
and	O
dietary	O
characteristics	O
at	O
the	O
beginning	O
of	O
the	O
study	O
(	O
Table	O
S1	O
)	O
.	O
Participants	O
’	O
compliance	O
to	O
the	O
study	B-methodology
protocol	I-methodology
was	O
high	O
(	O
100	O
%	O
)	O
,	O
based	O
on	O
self	O
-	O
reporting	O
,	O
and	O
this	O
was	O
confirmed	O
by	O
the	O
RBC	O
membrane	O
content	O
(	O
%	O
)	O
in	O
EPA	O
and	O
DHA	O
,	O
which	O
was	O
found	O
to	O
be	O
higher	O
at	O
the	O
end	O
of	O
each	O
treatment	O
period	O
compared	O
to	O
the	O
content	O
at	O
the	O
beginning	O
.	O
Similar	O
results	O
were	O
obtained	O
for	O
the	O
consumption	O
of	O
the	O
CF	O
,	O
as	O
well	O
as	O
for	O
the	O
consumption	O
of	O
the	O
EF	O
during	O
both	O
treatment	O
periods	O
(	O
Table	O
2	O
)	O
.	O
No	O
significant	O
sequence	O
or	O
carry	O
-	O
over	O
effects	O
were	O
found	O
for	O
the	O
changes	O
in	O
any	O
of	O
the	O
primary	O
outcomes	O
or	O
other	O
outcome	O
measures	O
(	O
data	O
not	O
shown	O
)	O
.	O
In	O
contrast	O
,	O
there	O
was	O
a	O
period	O
(	O
seasonal	O
)	O
effect	O
on	O
some	O
of	O
the	O
primary	O
outcomes	O
and	O
other	O
outcome	O
measures	O
.	O
Specifically	O
,	O
the	O
period	O
of	O
treatment	O
affected	O
BMI	O
(	O
p	O
=	O
0	O
.	O
003	O
)	O
,	O
energy	O
intake	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
total	O
and	O
LDL	O
-	O
cholesterol	O
(	O
p	O
=	O
0	O
.	O
014	O
and	O
p	O
=	O
0	O
.	O
007	O
,	O
respectively	O
)	O
,	O
sP	O
-	O
selectin	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
EC50ADP	O
and	O
EC50PAF	O
(	O
p	O
=	O
0	O
.	O
035	O
and	O
p	O
=	O
0	O
.	O
009	O
,	O
respectively	O
)	O
.	O
In	O
particular	O
,	O
LDL	O
-	O
cholesterol	O
was	O
increased	O
in	O
the	O
first	O
period	O
,	O
whereas	O
energy	O
intake	O
was	O
decreased	O
in	O
the	O
second	O
period	O
,	O
regardless	O
of	O
treatment	O
(	O
data	O
not	O
shown	O
)	O
.	O
Treatment	O
effect	O
was	O
estimated	O
with	O
adjustments	O
made	O
for	O
the	O
period	O
of	O
treatment	O
.	O
Lipid	O
profile	O
and	O
markers	O
of	O
glucose	O
homeostasis	O
did	O
not	O
differ	O
between	O
the	O
two	O
fish	O
treatments	O
(	O
Table	O
S2	O
)	O
.	O

Ex	B-methodology
vivo	I-methodology
human	I-methodology
platelet	I-methodology
aggregation	I-methodology
against	O
all	O
agonists	O
used	O
,	O
as	O
well	O
as	O
PAI	O
-	O
1	O
and	O
sP	O
-	O
selectin	O
did	O
not	O
differ	O
between	O
the	O
two	O
treatments	O
(	O
Table	O
3	O
)	O
.	O
The	O
EC50	O
value	O
of	O
ADP	O
was	O
found	O
to	O
decrease	O
at	O
the	O
end	O
of	O
the	O
first	O
period	O
with	O
either	O
the	O
CF	O
or	O
the	O
EF	O
,	O
whereas	O
the	O
EC50	O
value	O
of	O
PAF	O
was	O
found	O
to	O
increase	O
at	O
the	O
end	O
of	O
the	O
second	O
period	O
with	O
the	O
CF	O
only	O
.	O
Plasma	O
concentrations	O
of	O
PAI	O
-	O
1	O
and	O
sP	O
-	O
selectin	O
were	O
found	O
to	O
increase	O
at	O
the	O
end	O
of	O
the	O
first	O
and	O
the	O
second	O
period	O
,	O
respectively	O
,	O
with	O
the	O
CF	O
only	O
(	O
Table	O
4	O
)	O
.	O
We	O
found	O
that	O
consumption	O
of	O
two	O
fish	O
meals	O
per	O
week	O
(	O
on	O
average	O
380	O
g	O
per	O
meal	O
)	O
for	O
a	O
period	O
of	O
eight	O
weeks	O
affected	O
platelet	O
aggregation	O
and	O
circulating	O
haemostatic	O
markers	O
among	O
apparently	O
healthy	O
adults	O
.	O
However	O
,	O
these	O
effects	O
were	O
mostly	O
period	O
(	O
season	O
)	O
-	O
specific	O
and	O
did	O
not	O
differentiate	O
between	O
gilthead	O
sea	O
bream	O
fed	O
the	O
olive	O
pomace	O
-	O
enriched	O
fish	O
diet	O
and	O
gilthead	O
sea	O
bream	O
fed	O
the	O
conventional	O
fish	O
diet	O
.	O
With	O
respect	O
to	O
platelet	O
aggregation	O
,	O
consumption	O
of	O
the	O
conventional	O
fish	O
increased	O
the	O
EC50	O
value	O
of	O
PAF	O
in	O
the	O
second	O
intervention	B-methodology
period	I-methodology
,	O
whereas	O
a	O
non	O
-	O
significant	O
increase	O
was	O
also	O
found	O
for	O
the	O
EC50	O
value	O
of	O
PAF	O
after	O
consumption	O
of	O
the	O
enriched	O
fish	O
during	O
the	O
same	O
period	O
.	O
In	O
contrast	O
,	O
human	O
platelets	O
were	O
more	O
responsive	O
to	O
ADP	O
after	O
either	O
fish	O
consumption	O
in	O
the	O
first	O
period	O
only	O
,	O
whereas	O
no	O
significant	O
changes	O
were	O
observed	O
in	O
the	O
second	O
period	O
.	O
Thrombin	O
-	O
induced	O
platelet	O
aggregation	O
was	O
not	O
significantly	O
affected	O
by	O
either	O
treatment	O
.	O
Previously	O
,	O
Mori	O
and	O
colleagues	O
found	O
that	O
fish	O
consumption	O
significantly	O
reduced	O
platelet	O
aggregation	O
response	O
to	O
PAF	O
stimulation	O
only	O
as	O
part	O
of	O
a	O
low	O
-	O
fat	O
diet	O
(	O
30	O
%	O
of	O
daily	O
energy	O
intake	O
)	O
[	O
31	O
]	O
.	O
This	O
finding	O
could	O
give	O
an	O
explanation	O
for	O
the	O
absence	O
of	O
consistent	O
effects	O
of	O
either	O
fish	O
treatment	O
on	O
PAF	O
-	O
induced	O
human	O
platelet	O
aggregation	O
in	O
our	O
study	O
where	O
dietary	O
fat	O
intake	O
remained	O
high	O
(	O
over	O
40	O
%	O
on	O
average	O
)	O
throughout	O
the	O
study	O
.	O

In	O
addition	O
,	O
in	O
a	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
of	I-methodology
randomized	I-methodology
controlled	I-methodology
trials	I-methodology
in	O
adults	O
,	O
supplementation	O
with	O
ω	O
-	O
3	O
PUFAs	O
(	O
α	O
-	O
linolenic	O
acid	O
,	O
EPA	O
,	O
DHA	O
)	O
did	O
not	O
significantly	O
affect	O
ADP	O
-	O
induced	O
platelet	O
aggregation	O
in	O
healthy	O
adults	O
[	O
32	O
]	O
.	O
Even	O
though	O
the	O
increased	O
ω	O
-	O
3	O
PUFA	O
and	O
the	O
decreased	O
ω	O
-	O
6	O
PUFA	O
,	O
especially	O
AA	O
,	O
content	O
of	O
platelet	O
phospholipids	O
could	O
partly	O
explain	O
the	O
favorable	O
effects	O
of	O
ω	O
-	O
3	O
PUFA	O
on	O
platelet	O
function	O
,	O
studies	O
found	O
no	O
significant	O
differences	O
among	O
equal	O
amounts	O
of	O
fish	O
and	O
plant	O
oils	O
,	O
providing	O
diverse	O
ω	O
-	O
6	O
to	O
ω	O
-	O
3	O
PUFA	O
ratios	O
,	O
with	O
respect	O
to	O
collagen	O
-	O
or	O
thrombin	O
-	O
induced	O
platelet	O
aggregation	O
[	O
33	O
]	O
.	O
In	O
addition	O
,	O
the	O
effect	O
of	O
gender	O
on	O
platelet	O
aggregation	O
and	O
on	O
ω	O
-	O
3	O
and	O
ω	O
-	O
6	O
metabolism	O
should	O
be	O
considered	O
[	O
34	O
,	O
35	O
]	O
since	O
the	O
ratio	O
of	O
men	O
to	O
women	O
differs	O
between	O
CF	O
and	O
EF	O
in	O
the	O
first	O
intervention	B-methodology
period	I-methodology
and	O
in	O
the	O
second	O
period	O
as	O
well	O
.	O
Our	O
data	O
revealed	O
that	O
EPA	O
and	O
DHA	O
,	O
both	O
expressed	O
as	O
per	O
cent	O
(	O
%	O
)	O
change	O
,	O
did	O
not	O
differentiate	O
between	O
men	O
and	O
women	O
irrespective	O
of	O
the	O
intervention	B-methodology
period	I-methodology
or	O
the	O
fish	O
type	O
consumed	O
(	O
p	O
>	O
0	O
.	O
4	O
for	O
all	O
)	O
.	O
Lastly	O
,	O
it	O
is	O
now	O
well	O
established	O
that	O
other	O
lipid	O
constituents	O
in	O
fish	O
and	O
fish	O
oils	O
have	O
biological	O
activities	O
which	O
are	O
not	O
limited	O
to	O
their	O
superior	O
incorporation	O
to	O
plasma	O
lipoproteins	O
and	O
cell	O
membranes	O
,	O
and	O
the	O
AA	O
/	O
eicosanoid	O
-	O
related	O
pathway	O
[	O
36	O
]	O
.	O
Polar	O
lipids	O
extracted	O
from	O
gilthead	O
sea	O
bream	O
inhibited	O
PAF	O
-	O
induced	O
aggregation	O
of	O
washed	O
rabbit	O
platelets	O
in	B-methodology
vitro	I-methodology
.	O
In	O
addition	O
,	O
fish	O
polar	O
lipids	O
added	O
in	O
a	O
cholesterol	O
-	O
rich	O
diet	O
and	O
fed	O
to	O
rabbits	O
for	O
45	O
days	O
were	O
shown	O
to	O
have	O
anti	O
-	O
PAF	O
and	O
antithrombotic	O
properties	O
[	O
37	O
]	O
.	O
With	O
respect	O
to	O
the	O
circulating	O
haemostatic	O
markers	O
,	O
plasma	O
PAI	O
-	O
1	O
concentration	O
significantly	O
increased	O
after	O
treatment	O
with	O
the	O
conventional	O
fish	O
in	O
the	O
first	O
period	O
.	O
Plasma	O
sP	O
-	O
selectin	O
concentration	O
significantly	O
increased	O
after	O
consumption	O
of	O
the	O
conventional	O
fish	O
in	O
the	O
second	O
period	O
and	O
tended	O
to	O
increase	O
after	O
consumption	O
of	O
the	O
enriched	O
fish	O
in	O
the	O
second	O
period	O
as	O
well	O
.	O

As	O
in	O
our	O
study	O
,	O
plasma	O
concentrations	O
of	O
soluble	O
markers	O
of	O
platelet	O
activation	O
,	O
CD40	O
ligand	O
and	O
P	O
-	O
selectin	O
,	O
were	O
not	O
significantly	O
affected	O
by	O
consumption	O
of	O
500	O
g	O
of	O
fatty	O
fish	O
per	O
week	O
for	O
four	O
weeks	O
among	O
healthy	O
adults	O
[	O
38	O
]	O
.	O
Previous	O
studies	O
with	O
purified	O
EPA	O
,	O
DHA	O
or	O
olive	O
oil	O
also	O
reported	O
no	O
significant	O
effects	O
on	O
serum	O
levels	O
of	O
tissue	O
-	O
plasminogen	O
activator	O
(	O
tPA	O
)	O
and	O
PAI	O
-	O
1	O
antigens	O
,	O
P	O
-	O
selectin	O
and	O
von	O
Willebrand	O
factor	O
(	O
vWf	O
)	O
[	O
39	O
]	O
.	O
Overall	O
,	O
our	O
findings	O
are	O
in	O
agreement	O
with	O
the	O
findings	O
from	O
the	O
few	O
previously	O
published	O
studies	O
which	O
investigated	O
the	O
effects	O
of	O
differently	O
fed	O
farmed	O
fish	O
on	O
CVD	O
related	O
biomarkers	O
,	O
mostly	O
blood	O
lipid	O
indices	O
.	O
We	O
found	O
no	O
significant	O
changes	O
in	O
fasting	O
serum	O
concentration	O
of	O
triglycerides	O
or	O
HDL	O
-	O
cholesterol	O
.	O
There	O
was	O
a	O
trend	O
towards	O
an	O
increase	O
in	O
fasting	O
serum	O
total	O
cholesterol	O
and	O
LDL	O
-	O
cholesterol	O
after	O
consumption	O
of	O
the	O
conventional	O
fish	O
in	O
the	O
first	O
period	O
,	O
and	O
an	O
increase	O
in	O
both	O
total	O
and	O
LDL	O
-	O
cholesterol	O
after	O
consumption	O
of	O
the	O
enriched	O
fish	O
in	O
the	O
first	O
period	O
,	O
as	O
well	O
(	O
data	O
not	O
shown	O
)	O
.	O
In	O
two	O
dietary	O
intervention	O
trials	O
,	O
apparently	O
healthy	O
adults	O
randomly	O
received	O
150	O
g	O
per	O
day	O
marine	O
trout	O
fillet	O
fed	O
a	O
100	O
%	O
marine	O
-	O
based	O
meal	O
or	O
a	O
100	O
%	O
vegetable	O
-	O
based	O
meal	O
for	O
eight	O
weeks	O
[	O
17	O
]	O
or	O
approximately	O
630	O
g	O
per	O
week	O
of	O
gilthead	O
sea	O
bream	O
fed	O
either	O
a	O
100	O
%	O
fishmeal	O
(	O
FM	O
)	O
or	O
50	O
%	O
fishmeal	O
plus	O
50	O
%	O
a	O
mixture	O
of	O
plant	O
protein	O
sources	O
(	O
PP	O
)	O
for	O
ten	O
weeks	O
[	O
18	O
]	O
.	O
No	O
significant	O
differences	O
in	O
fasting	O
plasma	O
triglyceride	O
,	O
total	O
,	O
LDL	O
-	O
or	O
HDL	O
-	O
cholesterol	O
concentrations	O
or	O
in	O
fasting	O
serum	O
concentrations	O
of	O
glucose	O
,	O
insulin	O
or	O
inflammation	O
markers	O
were	O
found	O
among	O
groups	O
in	O
the	O
first	O
trial	O
[	O
17	O
]	O
;	O
whereas	O
,	O
in	O
the	O
second	O
trial	O
,	O
significantly	O
decreased	O
fasting	O
serum	O
concentrations	O
of	O
total	O
cholesterol	O
,	O
LDL	O
-	O
cholesterol	O
and	O
triglycerides	O
,	O
as	O
well	O
as	O
markers	O
of	O
inflammation	O
(	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
)	O
were	O
found	O
among	O
those	O
participants	O
who	O
consumed	O
the	O
FM	O
fish	O
fillets	O
in	O
the	O
first	O
period	O
[	O
18	O
]	O
.	O
Fasting	O
serum	O
HDL	O
-	O
cholesterol	O
levels	O
were	O
not	O
significantly	O
changed	O
in	O
either	O
group	O
.	O

Overall	O
,	O
no	O
significant	O
changes	O
were	O
observed	O
at	O
the	O
end	O
of	O
the	O
second	O
period	O
[	O
18	O
]	O
.	O
A	O
direct	O
comparison	O
of	O
the	O
above	O
studies	O
cannot	O
be	O
made	O
as	O
the	O
effects	O
depend	O
on	O
the	O
characteristics	O
of	O
the	O
participants	O
,	O
as	O
well	O
as	O
on	O
the	O
dose	O
and	O
the	O
duration	O
of	O
the	O
treatment	O
.	O
In	O
the	O
present	O
study	O
,	O
fasting	O
serum	O
concentrations	O
of	O
glucose	O
and	O
insulin	O
,	O
as	O
well	O
as	O
HOMA	O
-	O
IR	O
were	O
not	O
significantly	O
affected	O
by	O
consumption	O
of	O
the	O
conventionally	O
fed	O
gilthead	O
sea	O
bream	O
in	O
the	O
first	O
or	O
the	O
second	O
period	O
.	O
Similarly	O
,	O
no	O
significant	O
changes	O
were	O
observed	O
after	O
consumption	O
of	O
the	O
gilthead	O
sea	O
bream	O
fed	O
the	O
olive	O
pomace	O
-	O
enriched	O
diet	O
in	O
the	O
first	O
period	O
(	O
data	O
not	O
shown	O
)	O
.	O
Our	O
results	O
are	O
in	O
accordance	O
with	O
previously	O
published	O
intervention	B-methodology
studies	I-methodology
where	O
even	O
high	O
intake	O
of	O
fish	O
oil	O
supplement	O
or	O
frequent	O
consumption	O
of	O
fatty	O
fish	O
did	O
not	O
improve	O
parameters	O
of	O
glucose	O
metabolism	O
[	O
40	O
,	O
41	O
]	O
.	O
With	O
respect	O
to	O
blood	O
pressure	O
,	O
we	O
found	O
that	O
DBP	O
significantly	O
decreased	O
at	O
the	O
end	O
of	O
the	O
first	O
period	O
after	O
consumption	O
of	O
the	O
conventionally	O
fed	O
gilthead	O
sea	O
bream	O
,	O
and	O
there	O
was	O
a	O
trend	O
towards	O
a	O
significant	O
decrease	O
in	O
DBP	O
at	O
the	O
end	O
of	O
the	O
same	O
period	O
after	O
the	O
consumption	O
of	O
gilthead	O
sea	O
bream	O
fed	O
the	O
olive	O
pomace	O
-	O
enriched	O
diet	O
.	O
However	O
,	O
no	O
significant	O
changes	O
were	O
observed	O
for	O
DBP	O
in	O
the	O
second	O
period	O
or	O
for	O
SBP	O
in	O
either	O
period	O
(	O
data	O
not	O
shown	O
)	O
.	O
In	O
a	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
of	I-methodology
randomized	I-methodology
controlled	I-methodology
trials	I-methodology
examining	O
the	O
effects	O
of	O
EPA	O
plus	O
DHA	O
intake	O
from	O
different	O
sources	O
,	O
including	O
food	O
sources	O
,	O
on	O
blood	O
pressure	O
,	O
found	O
that	O
adults	O
with	O
untreated	O
hypertension	O
benefited	O
most	O
from	O
the	O
EPA	O
plus	O
DHA	O
intake	O
,	O
although	O
significant	O
decreases	O
were	O
also	O
observed	O
in	O
normotensive	O
subjects	O
.	O
However	O
,	O
the	O
improvements	O
in	O
both	O
SBP	O
and	O
DBP	O
were	O
reported	O
for	O
the	O
supplements	O
,	O
but	O
not	O
for	O
the	O
dietary	O
intake	O
of	O
EPA	O
and	O
DHA	O
[	O
42	O
]	O
.	O

In	O
the	O
study	O
presented	O
herein	O
,	O
we	O
hypothesized	O
that	O
the	O
consumption	O
of	O
fillets	O
from	O
fish	O
fed	O
with	O
a	O
diet	O
where	O
fish	O
oil	O
in	O
the	O
grow	O
-	O
out	O
feed	O
of	O
gilthead	O
sea	O
bream	O
was	O
partly	O
replaced	O
with	O
olive	O
pomace	O
(	O
OP	O
diet	O
)	O
,	O
would	O
have	O
a	O
greater	O
impact	O
on	O
PAF	O
-	O
induced	O
platelet	O
aggregation	O
and	O
haemostatic	O
markers	O
compared	O
to	O
consumption	O
of	O
fillets	O
from	O
fish	O
fed	O
with	O
the	O
fish	O
oil	O
-	O
diet	O
,	O
based	O
on	O
the	O
findings	O
of	O
previous	O
experiments	O
on	O
the	O
inhibition	O
of	O
the	O
PAF	O
-	O
induced	O
aggregation	O
.	O
Specifically	O
,	O
the	O
OP	O
diet	O
contained	O
polar	O
lipid	O
extracts	O
of	O
olive	O
pomace	O
that	O
were	O
found	O
to	O
inhibit	O
PAF	O
-	O
induced	O
washed	O
rabbit	O
platelet	O
aggregation	O
[	O
43	O
]	O
.	O
Additionally	O
,	O
Nasopoulou	O
and	O
colleagues	O
(	O
2011	O
)	O
have	O
reported	O
that	O
gilthead	O
sea	O
bream	O
fed	O
an	O
olive	O
pomace	O
-	O
enriched	O
diet	O
(	O
8	O
%	O
olive	O
pomace	O
,	O
OP	O
)	O
had	O
a	O
different	O
fatty	O
acid	O
profile	O
in	O
muscles	O
compared	O
to	O
gilthead	O
sea	O
bream	O
fed	O
a	O
conventional	O
diet	O
(	O
100	O
%	O
fish	O
oil	O
,	O
FO	O
diet	O
)	O
.	O
With	O
respect	O
to	O
oleic	O
acid	O
(	O
18	O
:	O
1	O
cis	O
,	O
ω	O
-	O
9	O
)	O
and	O
linoleic	O
acid	O
(	O
18	O
:	O
2	O
,	O
ω	O
-	O
6	O
)	O
,	O
the	O
lower	O
levels	O
detected	O
in	O
the	O
muscle	O
of	O
fish	O
fed	O
the	O
OP	O
diet	O
reflected	O
the	O
lower	O
content	O
of	O
the	O
OP	O
diet	O
in	O
these	O
fatty	O
acids	O
compared	O
to	O
the	O
100	O
%	O
fish	O
oil	O
diet	O
.	O
Gilthead	O
sea	O
bream	O
fed	O
the	O
OP	O
diet	O
had	O
also	O
lower	O
EPA	O
and	O
DHA	O
levels	O
than	O
fish	O
fed	O
the	O
FO	O
diet	O
,	O
even	O
though	O
both	O
fish	O
diets	O
provided	O
comparable	O
amounts	O
of	O
these	O
fatty	O
acids	O
.	O
In	B-methodology
vitro	I-methodology
experiments	I-methodology
suggested	O
that	O
olive	O
pomace	O
reinforced	O
the	O
anti	O
-	O
PAF	O
biological	O
activity	O
of	O
gilthead	O
sea	O
bream	O
,	O
and	O
this	O
effect	O
should	O
be	O
attributed	O
to	O
components	O
other	O
than	O
the	O
long	O
-	O
chain	O
ω	O
-	O
3	O
fatty	O
acids	O
EPA	O
and	O
DHA	O
[	O
21	O
]	O
.	O
Lipidomic	O
analysis	O
of	O
fillets	O
from	O
gilthead	O
sea	O
bream	O
fed	O
the	O
OP	O
diet	O
identified	O
several	O
glycerophospholipids	O
of	O
olive	O
pomace	O
origin	O
that	O
could	O
inhibit	O
PAF	O
-	O
activity	O
in	B-methodology
vitro	I-methodology
[	O
44	O
]	O
.	O
Despite	O
the	O
promising	O
findings	O
from	O
the	O
in	B-methodology
vitro	I-methodology
studies	I-methodology
,	O
we	O
did	O
not	O
observe	O
any	O
beneficial	O
effect	O
on	O
platelet	O
aggregation	O
after	O
consumption	O
of	O
gilthead	O
sea	O
bream	O
fed	O
the	O
OP	O
diet	O
among	O
apparently	O
healthy	O
adults	O
.	O

Although	O
the	O
ex	B-methodology
vivo	I-methodology
assessment	O
of	O
human	O
platelet	O
aggregation	O
was	O
performed	O
under	O
controlled	O
experimental	O
conditions	O
,	O
the	O
dietary	O
assessment	O
carried	O
out	O
in	O
the	O
present	O
study	O
did	O
not	O
allow	O
to	O
draw	O
a	O
clear	O
distinction	O
between	O
the	O
effects	O
of	O
the	O
overall	O
diet	O
of	O
the	O
participants	O
and	O
the	O
fish	O
treatments	O
assigned	O
to	O
them	O
.	O
We	O
must	O
point	O
out	O
certain	O
limitations	O
and	O
strengths	O
of	O
the	O
present	O
study	O
to	O
facilitate	O
the	O
interpretation	O
of	O
the	O
findings	O
.	O
The	O
first	O
limitation	O
is	O
concerned	O
with	O
the	O
determination	O
of	O
sample	O
size	O
.	O
Power	O
calculation	O
was	O
based	O
on	O
the	O
EC50	O
value	O
of	O
PAF	O
after	O
treatment	O
with	O
respect	O
to	O
before	O
treatment	O
and	O
,	O
thus	O
,	O
the	O
study	O
may	O
not	O
be	O
sufficiently	O
powered	O
for	O
the	O
other	O
primary	O
outcomes	O
evaluated	O
.	O
A	O
second	O
limitation	O
is	O
the	O
seasonal	O
effect	O
on	O
anthropometric	O
and	O
biochemical	O
indices	O
that	O
may	O
have	O
an	O
impact	O
or	O
conceal	O
the	O
differences	O
in	O
the	O
primary	O
outcomes	O
.	O
Certain	O
strengths	O
were	O
also	O
identified	O
in	O
the	O
present	O
study	O
.	O
In	O
the	O
absence	O
of	O
previously	O
published	O
data	O
with	O
respect	O
to	O
the	O
effects	O
of	O
consumption	O
of	O
differently	O
fed	O
farmed	O
gilthead	O
sea	O
bream	O
on	O
platelet	O
aggregation	O
and	O
circulating	O
haemostatic	O
markers	O
among	O
apparently	O
healthy	O
adults	O
,	O
the	O
cross	B-methodology
-	I-methodology
over	I-methodology
design	I-methodology
of	O
the	O
study	O
is	O
an	O
important	O
strength	O
since	O
participant	O
serves	O
as	O
their	O
own	O
control	O
.	O
In	O
addition	O
,	O
the	O
absence	O
of	O
differences	O
between	O
the	O
two	O
sequence	O
groups	O
at	O
the	O
beginning	O
of	O
the	O
study	O
as	O
well	O
as	O
the	O
absence	O
of	O
carry	O
-	O
over	O
effects	O
with	O
respect	O
to	O
the	O
primary	O
outcomes	O
adds	O
to	O
the	O
value	O
of	O
the	O
study	O
findings	O
.	O
Finally	O
,	O
participants	O
’	O
compliance	O
with	O
fish	O
consumption	O
was	O
also	O
based	O
on	O
the	O
findings	O
from	O
the	O
fatty	O
acid	O
analysis	O
of	O
the	O
red	O
blood	O
cell	O
membranes	O
.	O
In	O
conclusion	O
,	O
consumption	O
of	O
fillets	O
from	O
gilthead	O
sea	O
bream	O
fed	O
with	O
a	O
diet	O
where	O
fish	O
oil	O
in	O
the	O
grow	O
-	O
out	O
fish	O
feed	O
was	O
partly	O
replaced	O
with	O
olive	O
pomace	O
did	O
not	O
have	O
a	O
greater	O
impact	O
on	O
platelet	O
aggregation	O
and	O
circulating	O
haemostatic	O
markers	O
compared	O
to	O
consumption	O
of	O
fillets	O
from	O
fish	O
fed	O
the	O
typical	O
fish	O
-	O
oil	O
diet	O
among	O
apparently	O
healthy	O
adults	O
.	O
It	O
should	O
be	O
pointed	O
out	O
that	O
the	O
intervention	O
was	O
performed	O
in	O
Greek	O
population	O
where	O
widespread	O
consumption	O
of	O
olive	O
oil	O
exists	O
and	O
for	O
that	O
reason	O
the	O
conclusion	O
cannot	O
be	O
generalized	O
to	O
different	O
populations	O
.	O
Clinical	B-methodology
trials	I-methodology
with	O
larger	O
number	O
of	O
participants	O
,	O
and	O
with	O
a	O
longer	O
-	O
term	O
intervention	O
evaluating	O
various	O
markers	O
of	O
cardiovascular	O
disease	O
could	O
distinguish	O
between	O
the	O
health	O
effects	O
of	O
a	O
conventionally	O
fed	O
gilthead	O
sea	O
bream	O
and	O
those	O
of	O
a	O
differently	O
fed	O
gilthead	O
sea	O
bream	O
.	O

Future	O
research	O
could	O
also	O
focus	O
on	O
the	O
enrichment	O
of	O
the	O
fish	O
feed	O
with	O
the	O
isolated	O
olive	O
pomace	O
polar	O
lipid	O
fraction	O
,	O
containing	O
the	O
bioactive	O
specific	O
PAF	O
-	O
receptor	O
antagonists	O
,	O
and	O
subsequent	O
dietary	B-methodology
intervention	I-methodology
studies	I-methodology
should	O
evaluate	O
the	O
effect	O
of	O
the	O
enriched	O
fish	O
on	O
coagulation	O
markers	O
in	O
humans	O
.	O
The	O
authors	O
would	O
like	O
to	O
thank	O
Antigoni	O
Tsiafitsa	O
for	O
technical	O
assistance	O
in	O
blood	O
sample	O
collection	O
;	O
Christos	O
Kokkalis	O
,	O
for	O
medical	O
supervision	O
throughout	O
the	O
study	O
;	O
Michael	O
Georgoulis	O
and	O
Nafsika	O
Tilleli	O
for	O
enrolling	O
and	O
carrying	O
out	O
the	O
dietary	O
assessment	O
of	O
the	O
participants	O
,	O
as	O
well	O
as	O
for	O
their	O
contribution	O
to	O
data	O
entry	O
.	O
Publisher	O
’	O
s	O
Note	O
:	O
MDPI	O
stays	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O
The	O
following	O
are	O
available	O
online	O
at	O
https	O
:	O
/	O
/	O
www	O
.	O
mdpi	O
.	O
com	O
/	O
2072	O
-	O
6643	O
/	O
13	O
/	O
2	O
/	O
286	O
/	O
s1	O
,	O
Figure	O
S1	O
:	O
CONSORT	O
flow	O
diagram	O
for	O
crossover	B-methodology
trials	I-methodology
;	O
Table	O
S1	O
:	O
Physical	O
activity	O
and	O
dietary	O
characteristics	O
of	O
participants	O
at	O
the	O
beginning	O
of	O
the	O
study	O
by	O
sequence	O
;	O
Table	O
S2	O
:	O
Estimation	O
of	O
the	O
effect	O
of	O
the	O
enriched	O
fish	O
versus	O
the	O
conventional	O
fish	O
on	O
dietary	O
characteristics	O
and	O
standard	O
biochemical	O
markers	O
;	O
CONSORT	O
2010	O
checklist	O
.	O
Conceptualization	O
,	O
S	O
.	O
A	O
.	O
;	O
methodology	O
,	O
S	O
.	O
A	O
.	O
,	O
E	O
.	O
F	O
.	O
,	O
M	O
.	O
D	O
.	O
K	O
.	O
,	O
T	O
.	O
N	O
.	O
;	O
validation	O
,	O
A	O
.	O
M	O
.	O
,	O
M	O
.	O
X	O
.	O
;	O
formal	O
analysis	O
,	O
D	O
.	O
P	O
.	O
,	O
A	O
.	O
N	O
.	O
;	O
investigation	O
,	O
A	O
.	O
M	O
.	O
,	O
M	O
.	O
X	O
.	O
Ν	O
.	O
Κ	O
.	O
;	O
resources	O
,	O
E	O
.	O
F	O
.	O
,	O
N	O
.	O
K	O
.	O
,	O
T	O
.	O
N	O
.	O
,	O
D	O
.	O
P	O
.	O
;	O
data	O
curation	O
,	O
S	O
.	O
A	O
.	O
,	O
E	O
.	O
F	O
.	O
,	O
M	O
.	O
D	O
.	O
K	O
.	O
,	O
N	O
.	O
K	O
.	O
,	O
T	O
.	O
N	O
.	O
;	O
writing	O
—	O
original	O
draft	O
preparation	O
,	O
A	O
.	O
N	O
.	O
;	O
writing	O
—	O
review	O
and	O
editing	O
,	O
S	O
.	O
A	O
.	O
,	O
E	O
.	O
F	O
.	O
,	O
M	O
.	O
D	O
.	O
K	O
.	O
,	O
T	O
.	O
N	O
.	O
;	O
visualization	O
,	O
A	O
.	O
N	O
.	O
;	O
supervision	O
,	O
S	O
.	O
A	O
.	O
;	O
project	O
administration	O
,	O
S	O
.	O
A	O
.	O
;	O
funding	O
acquisition	O
,	O
S	O
.	O
A	O
.	O
All	O
authors	O
have	O
read	O
and	O
agreed	O
to	O
the	O
published	O
version	O
of	O
the	O
manuscript	O
.	O

This	O
research	O
has	O
been	O
co	O
-	O
financed	O
by	O
the	O
European	O
Regional	O
Development	O
Fund	O
of	O
the	O
EU	O
and	O
Greek	O
national	O
funds	O
(	O
project	O
code	O
:	O
T1EDK	O
-	O
00687	O
)	O
and	O
was	O
partly	O
supported	O
by	O
NIREUS	O
Aquaculture	O
S	O
.	O
A	O
.	O
The	O
study	O
was	O
conducted	O
according	O
to	O
the	O
guidelines	B-methodology
of	O
the	O
Declaration	O
of	O
Helsinki	O
,	O
and	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
Harokopio	O
University	O
,	O
Athens	O
,	O
Greece	O
(	O
25	O
/	O
07	O
/	O
2012	O
)	O
.	O
Informed	O
consent	O
was	O
obtained	O
from	O
all	O
subjects	O
involved	O
in	O
the	O
study	O
.	O
The	O
data	O
presented	O
in	O
this	O
study	O
are	O
available	O
on	O
request	O
from	O
the	O
corresponding	O
author	O
.	O
The	O
data	O
are	O
not	O
publicly	O
available	O
for	O
the	O
following	O
reasons	O
.	O
The	O
study	O
was	O
conducted	O
while	O
the	O
approval	O
process	O
of	O
the	O
world	O
patent	O
,	O
described	O
in	O
reference	O
23	O
,	O
was	O
in	O
progress	O
.	O
Therefore	O
,	O
as	O
this	O
process	O
is	O
normally	O
time	O
-	O
consuming	O
,	O
the	O
data	O
were	O
prohibited	O
from	O
being	O
published	O
and	O
it	O
is	O
at	O
the	O
discretion	O
of	O
the	O
patent	O
holders	O
to	O
make	O
them	O
jointly	O
available	O
to	O
any	O
interested	O
party	O
.	O
S	O
.	O
Antonopoulou	O
holds	O
a	O
World	O
patent	O
for	O
the	O
production	O
method	O
of	O
fish	O
feed	O
enriched	O
with	O
polar	O
lipids	O
and	O
method	O
to	O
enrich	O
farmed	O
fishes	O
(	O
WO	O
2014	O
/	O
122571	O
A1	O
.	O
2014	O
August	O
14	O
)	O
.	O
All	O
other	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O
The	O
funders	O
had	O
no	O
role	O
in	O
the	O
design	O
of	O
the	O
study	O
;	O
in	O
the	O
collection	O
,	O
analyses	O
,	O
or	O
interpretation	O
of	O
data	O
;	O
in	O
the	O
writing	O
of	O
the	O
manuscript	O
,	O
or	O
in	O
the	O
decision	O
to	O
publish	O
the	O
results	O
.	O

Association	O
between	O
gastrointestinal	O
tract	O
infections	O
and	O
glycated	O
hemoglobin	O
in	O
school	O
children	O
of	O
poor	O
neighborhoods	O
in	O
Port	O
Elizabeth	O
,	O
South	O
Africa	O
Low	O
-	O
and	O
middle	O
-	O
income	O
countries	O
are	O
facing	O
a	O
dual	O
disease	O
burden	O
with	O
infectious	O
diseases	O
(	O
e	O
.	O
g	O
.	O
,	O
gastrointestinal	O
tract	O
infections	O
)	O
and	O
non	O
-	O
communicable	O
diseases	O
(	O
e	O
.	O
g	O
.	O
,	O
diabetes	O
)	O
being	O
common	O
.	O
For	O
instance	O
,	O
chronic	O
parasite	O
infections	O
lead	O
to	O
altered	O
immune	O
regulatory	O
networks	O
,	O
anemia	O
,	O
malnutrition	O
,	O
and	O
diarrhea	O
with	O
an	O
associated	O
shift	O
in	O
the	O
gut	O
microbiome	O
.	O
These	O
can	O
all	O
be	O
pathways	O
of	O
potential	O
relevance	O
for	O
insulin	O
resistance	O
and	O
diabetes	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
association	O
between	O
common	O
gastrointestinal	O
tract	O
infections	O
and	O
glycemia	O
in	O
children	O
from	O
non	O
-	O
fee	O
paying	O
schools	O
in	O
South	O
Africa	O
.	O
We	O
conducted	O
a	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
survey	I-methodology
among	O
9	O
-	O
to	O
14	O
-	O
year	O
-	O
old	O
school	O
children	O
in	O
Port	O
Elizabeth	O
.	O
Stool	O
and	O
urine	O
samples	O
were	O
collected	O
to	O
assess	O
infection	O
status	O
with	O
parasitic	O
worms	O
(	O
e	O
.	O
g	O
.	O
,	O
Ascaris	O
lumbricoides	O
,	O
Enterobius	O
vermicularis	O
,	O
and	O
Trichuris	O
trichiura	O
)	O
,	O
intestinal	O
protozoa	O
(	O
e	O
.	O
g	O
.	O
,	O
Cryptosporidium	O
parvum	O
and	O
Giardia	O
intestinalis	O
)	O
,	O
and	O
the	O
bacterium	O
Helicobacter	O
pylori	O
.	O
Glycated	O
hemoglobin	O
(	O
HbA1c	O
)	O
was	O
measured	O
in	O
finger	O
prick	O
derived	O
capillary	O
blood	O
.	O
All	O
children	O
at	O
schools	O
with	O
a	O
high	O
prevalence	O
of	O
helminth	O
infections	O
and	O
only	O
infected	O
children	O
at	O
the	O
schools	O
with	O
low	O
infection	O
rates	O
were	O
treated	O
with	O
albendazole	O
.	O
The	O
association	O
of	O
anthelmintic	O
treatment	O
with	O
changes	O
in	O
HbA1c	O
6	O
months	O
after	O
the	O
drug	O
intervention	O
was	O
also	O
investigated	O
.	O
A	O
high	O
prevalence	O
of	O
71	O
.	O
8	O
%	O
of	O
prediabetes	O
was	O
measured	O
in	O
this	O
group	O
of	O
children	O
,	O
with	O
only	O
27	O
.	O
8	O
%	O
having	O
HbA1c	O
in	O
the	O
normal	O
range	O
.	O
H	O
.	O
pylori	O
was	O
the	O
predominant	O
infectious	O
agent	O
and	O
showed	O
an	O
independent	O
positive	O
association	O
with	O
HbA1c	O
in	O
a	O
multivariable	O
regression	O
analysis	O
(	O
β	O
=	O
0	O
.	O
040	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0	O
.	O
006	O
–	O
0	O
.	O
073	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

No	O
association	O
of	O
HbA1c	O
with	O
either	O
any	O
other	O
infectious	O
agent	O
or	O
albendazole	O
administration	O
was	O
found	O
.	O
The	O
role	O
of	O
H	O
.	O
pylori	O
in	O
diabetes	O
needs	O
confirmation	O
in	O
the	O
context	O
of	O
longitudinal	B-methodology
treatment	I-methodology
interventions	I-methodology
.	O
The	O
specific	O
effect	O
of	O
other	O
gastrointestinal	O
tract	O
infections	O
on	O
glycemia	O
remains	O
unclear	O
.	O
Future	O
studies	O
should	O
integrate	O
the	O
measurement	O
of	O
biomarkers	O
,	O
including	O
immunological	O
parameters	O
,	O
to	O
shed	O
light	O
on	O
the	O
potential	O
mediating	O
mechanisms	O
between	O
parasite	O
infections	O
and	O
diabetes	O
.	O
Parasitic	O
worms	O
(	O
e	O
.	O
g	O
.	O
,	O
pinworm	O
,	O
roundworm	O
,	O
and	O
whipworm	O
)	O
,	O
intestinal	O
protozoa	O
(	O
e	O
.	O
g	O
.	O
,	O
Cryptosporidium	O
parvum	O
and	O
Giardia	O
intestinalis	O
)	O
,	O
and	O
the	O
bacterium	O
Helicobacter	O
pylori	O
persist	O
at	O
high	O
rates	O
in	O
the	O
gastrointestinal	O
tract	O
of	O
people	O
from	O
low	O
-	O
and	O
middle	O
-	O
income	O
countries	O
.	O
These	O
infectious	O
agents	O
are	O
increasingly	O
paralleled	O
by	O
high	O
rates	O
of	O
non	O
-	O
communicable	O
diseases	O
,	O
such	O
as	O
diabetes	O
.	O
We	O
studied	O
the	O
association	O
of	O
glycemia	O
,	O
measured	O
as	O
HbA1c	O
with	O
common	O
gastrointestinal	O
tract	O
infections	O
among	O
school	O
children	O
aged	O
9	O
–	O
14	O
years	O
from	O
disadvantaged	O
neighborhoods	O
in	O
Port	O
Elizabeth	O
,	O
South	O
Africa	O
.	O
Our	O
goal	O
was	O
to	O
deepen	O
the	O
understanding	O
of	O
whether	O
specific	O
gastrointestinal	O
tract	O
infections	O
might	O
be	O
early	O
life	O
determinants	O
of	O
elevated	O
HbA1c	O
levels	O
that	O
might	O
lead	O
to	O
diabetes	O
.	O
We	O
found	O
that	O
the	O
bacterium	O
H	O
.	O
pylori	O
was	O
very	O
common	O
among	O
our	O
group	O
of	O
children	O
with	O
a	O
positive	O
association	O
with	O
hyperglycemia	O
.	O
None	O
of	O
the	O
other	O
infectious	O
agents	O
showed	O
such	O
an	O
association	O
.	O
Additional	O
,	O
longitudinal	B-methodology
studies	I-methodology
are	O
needed	O
to	O
determine	O
whether	O
there	O
is	O
causality	O
for	O
the	O
observed	O
association	O
between	O
H	O
.	O
pylori	O
and	O
hyperglycemia	O
.	O
The	O
integration	O
of	O
biomarkers	O
will	O
allow	O
studying	O
mediating	O
mechanisms	O
.	O
In	O
low	O
-	O
and	O
middle	O
-	O
income	O
countries	O
(	O
LMICs	O
)	O
,	O
the	O
dual	O
disease	O
burden	O
stemming	O
from	O
infectious	O
diseases	O
(	O
IDs	O
)	O
and	O
non	O
-	O
communicable	O
diseases	O
(	O
NCDs	O
)	O
poses	O
a	O
challenge	O
to	O
population	O
health	O
and	O
the	O
health	O
systems	O
.	O
Soil	O
-	O
transmitted	O
helminths	O
and	O
schistosomes	O
are	O
estimated	O
to	O
infect	O
over	O
a	O
billion	O
individuals	O
in	O
LMICs	O
[	O
1	O
,	O
2	O
]	O
and	O
cause	O
abdominal	O
pain	O
,	O
diarrhea	O
,	O
poor	O
cognitive	O
development	O
,	O
malnutrition	O
,	O
and	O
anemia	O
.	O

As	O
a	O
consequence	O
of	O
such	O
symptoms	O
,	O
school	O
and	O
work	O
performance	O
is	O
affected	O
and	O
physical	O
activity	O
levels	O
compromised	O
[	O
3	O
]	O
.	O
Helminthiases	O
are	O
often	O
chronic	O
,	O
a	O
result	O
of	O
both	O
under	O
-	O
treatment	O
and	O
re	O
-	O
infection	O
.	O
Soil	O
-	O
transmitted	O
helminthiasis	O
,	O
schistosomiasis	O
,	O
and	O
intestinal	O
protozoa	O
infection	O
are	O
intimately	O
connected	O
with	O
poverty	O
,	O
partially	O
explained	O
by	O
lack	O
of	O
clean	O
water	O
,	O
sanitation	O
,	O
and	O
hygiene	O
[	O
4	O
]	O
.	O
NCDs	O
are	O
gaining	O
importance	O
,	O
also	O
in	O
LMICs	O
[	O
5	O
]	O
.	O
For	O
example	O
,	O
the	O
frequency	O
of	O
diabetes	O
mellitus	O
(	O
DM	O
)	O
is	O
rising	O
worldwide	O
,	O
and	O
South	O
Africa	O
is	O
among	O
the	O
top	O
five	O
countries	O
in	O
Africa	O
with	O
an	O
estimated	O
DM	O
prevalence	O
of	O
9	O
.	O
2	O
%	O
[	O
6	O
]	O
.	O
This	O
can	O
be	O
attributed	O
primarily	O
to	O
aging	O
,	O
population	O
growth	O
,	O
increasing	O
rates	O
of	O
unhealthy	O
dietary	O
habits	O
,	O
a	O
sedentary	O
lifestyle	O
,	O
and	O
obesity	O
.	O
While	O
NCDs	O
and	O
DM	O
particularly	O
affect	O
older	O
people	O
,	O
it	O
is	O
generally	O
accepted	O
that	O
early	O
life	O
exposures	O
contribute	O
to	O
the	O
accumulation	O
of	O
molecular	O
damage	O
and	O
a	O
higher	O
disease	O
risk	O
later	O
in	O
adulthood	O
[	O
7	O
]	O
.	O
Little	O
is	O
known	O
about	O
how	O
common	O
parasite	O
infections	O
affect	O
glucose	O
homeostasis	O
and	O
DM	O
etiology	O
,	O
particularly	O
at	O
young	O
age	O
.	O
It	O
is	O
conceivable	O
that	O
parasite	O
infections	O
influence	O
the	O
DM	O
risk	O
through	O
different	O
pathways	O
and	O
in	O
opposite	O
directions	O
[	O
8	O
]	O
.	O
On	O
the	O
one	O
hand	O
,	O
parasite	O
-	O
induced	O
alterations	O
of	O
immune	O
regulatory	O
networks	O
,	O
which	O
have	O
evolved	O
to	O
prolong	O
survival	O
in	O
the	O
human	O
intestines	O
,	O
may	O
stimulate	O
anti	O
-	O
inflammatory	O
pathways	O
and	O
decrease	O
the	O
risk	O
of	O
obesity	O
-	O
induced	O
insulin	O
resistance	O
.	O
Malnutrition	O
,	O
diarrhea	O
and	O
,	O
as	O
a	O
result	O
,	O
low	O
body	O
weight	O
related	O
to	O
chronic	O
helminth	O
infections	O
may	O
additionally	O
decrease	O
DM	O
risk	O
.	O
On	O
the	O
other	O
hand	O
,	O
a	O
sedentary	O
lifestyle	O
and	O
anemia	O
have	O
the	O
potential	O
to	O
increase	O
DM	O
risk	O
.	O
Additionally	O
,	O
the	O
mediating	O
role	O
of	O
helminth	O
-	O
induced	O
shifts	O
in	O
the	O
gut	O
microbiome	O
composition	O
remains	O
to	O
be	O
determined	O
[	O
9	O
]	O
.	O
A	O
limited	O
number	O
of	O
recently	O
reviewed	O
epidemiologic	B-methodology
studies	I-methodology
with	O
inconsistent	O
results	O
investigated	O
the	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
association	O
of	O
different	O
IDs	O
,	O
including	O
lymphatic	O
filariasis	O
[	O
10	O
,	O
11	O
]	O
,	O
schistosomiasis	O
[	O
12	O
]	O
,	O
strongyloidiasis	O
[	O
13	O
,	O
14	O
]	O
,	O
and	O
soil	O
-	O
transmitted	O
helminthiasis	O
[	O
15	O
,	O
16	O
]	O
with	O
DM	O
or	O
insulin	O
sensitivity	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
followed	O
up	O
on	O
these	O
observations	O
by	O
studying	O
the	O
association	O
of	O
gastrointestinal	O
tract	O
infections	O
due	O
to	O
helminths	O
,	O
intestinal	O
protozoa	O
,	O
and	O
the	O
bacterium	O
Helicobacter	O
pylori	O
with	O
glycated	O
hemoglobin	O
(	O
HbA1c	O
)	O
concentration	O
in	O
school	O
children	O
in	O
the	O
frame	O
of	O
the	O
“	O
Disease	O
,	O
Activity	O
and	O
Schoolchildren	O
’	O
s	O
Health	O
”	O
(	O
DASH	O
)	O
study	O
in	O
Port	O
Elizabeth	O
,	O
South	O
Africa	O
[	O
3	O
,	O
17	O
]	O
.	O
The	O
study	O
provided	O
detailed	O
information	O
on	O
physical	O
activity	O
,	O
fitness	O
,	O
and	O
socioeconomic	O
status	O
(	O
SES	O
)	O
to	O
consider	O
as	O
confounding	O
factors	O
on	O
gastrointestinal	O
tract	O
infection	O
status	O
,	O
and	O
intensity	O
of	O
helminth	O
infections	O
to	O
study	O
a	O
possible	O
dose	O
-	O
response	O
relationship	O
;	O
and	O
on	O
the	O
longitudinal	O
course	O
of	O
HbA1c	O
upon	O
selective	O
anthelmintic	O
treatment	O
.	O
Ethics	O
approval	O
was	O
obtained	O
from	O
ethics	O
committees	O
in	O
both	O
Switzerland	O
(	O
EKNZ	O
;	O
reference	O
no	O
.	O
2014	O
–	O
179	O
,	O
approval	O
date	O
:	O
17	O
June	O
2014	O
)	O
,	O
and	O
South	O
Africa	O
(	O
study	O
number	O
H14	O
-	O
HEA	O
-	O
HMS002	O
,	O
approval	O
date	O
:	O
4	O
July	O
2014	O
)	O
.	O
Written	B-methodology
informed	I-methodology
consent	I-methodology
from	O
the	O
parents	O
/	O
guardians	O
of	O
participating	O
children	O
as	O
well	O
as	O
oral	O
assent	O
from	O
the	O
children	O
were	O
obtained	O
prior	O
to	O
data	O
collection	O
.	O
A	O
total	O
of	O
1	O
,	O
009	O
grade	O
-	O
4	O
children	O
aged	O
9	O
–	O
14	O
years	O
from	O
eight	O
non	O
-	O
fee	O
paying	O
primary	O
schools	O
were	O
recruited	O
in	O
various	O
parts	O
of	O
Port	O
Elizabeth	O
in	O
the	O
south	O
-	O
eastern	O
part	O
of	O
South	O
Africa	O
,	O
as	O
described	O
before	O
[	O
3	O
,	O
17	O
]	O
.	O
The	O
study	O
was	O
part	O
of	O
the	O
2	O
-	O
year	O
longitudinal	O
DASH	O
study	O
that	O
consisted	O
of	O
three	O
cross	O
-	O
sectional	O
surveys	O
.	O
In	O
each	O
of	O
the	O
cross	O
-	O
sectional	O
surveys	O
,	O
children	O
’	O
s	O
gastrointestinal	O
infections	O
and	O
other	O
health	O
parameters	O
were	O
assessed	O
,	O
including	O
HbA1c	O
,	O
anthropometry	O
,	O
levels	O
of	O
physical	O
fitness	O
,	O
cognitive	O
performance	O
,	O
and	O
psychosocial	O
health	O
.	O
After	O
each	O
survey	O
,	O
helminth	O
-	O
infected	O
children	O
were	O
treated	O
with	O
a	O
single	O
400	O
mg	O
oral	O
dose	O
of	O
albendazole	O
.	O
In	O
schools	O
where	O
the	O
prevalence	O
of	O
helminth	O
infection	O
was	O
20	O
%	O
or	O
above	O
,	O
all	O
children	O
were	O
treated	O
regardless	O
of	O
infection	O
status	O
according	O
to	O
guidelines	B-methodology
put	O
forth	O
by	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
[	O
18	O
]	O
.	O

Children	O
with	O
other	O
infections	O
(	O
Cryptosporidium	O
spp	O
.	O
and	O
/	O
or	O
Giardia	O
intestinalis	O
)	O
in	O
combination	O
with	O
severe	O
symptoms	O
(	O
e	O
.	O
g	O
.	O
,	O
bloody	O
stool	O
,	O
diarrhea	O
,	O
abdominal	O
pain	O
,	O
and	O
any	O
abnormal	O
lung	O
sounds	O
)	O
were	O
referred	O
to	O
the	O
nearest	O
local	O
health	O
clinic	O
for	O
individual	O
management	O
.	O
The	O
baseline	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
survey	I-methodology
took	O
place	O
in	O
March	O
2015	O
.	O
The	O
current	O
study	O
considers	O
data	O
from	O
this	O
baseline	O
survey	O
and	O
the	O
anthelmintic	O
treatment	O
follow	O
-	O
up	O
examination	O
in	O
September	O
/	O
October	O
2015	O
.	O
Grade	O
-	O
4	O
primary	O
school	O
children	O
of	O
the	O
selected	O
schools	O
were	O
included	O
in	O
the	O
study	O
.	O
Children	O
with	O
severe	O
clinical	O
signs	O
and	O
symptoms	O
(	O
e	O
.	O
g	O
.	O
,	O
severe	O
fever	O
,	O
severe	O
headache	O
,	O
dizziness	O
,	O
nausea	O
,	O
skin	O
rashes	O
,	O
seizures	O
,	O
and	O
diarrhea	O
)	O
or	O
reported	O
serious	O
health	O
problems	O
,	O
such	O
as	O
Crohn	O
’	O
s	O
disease	O
,	O
liver	O
or	O
kidney	O
diseases	O
,	O
or	O
who	O
participated	O
in	O
any	O
other	O
study	O
were	O
excluded	O
.	O
Standardized	O
questionnaires	O
available	O
in	O
both	O
English	O
and	O
local	O
languages	O
(	O
Afrikaans	O
and	O
Xhosa	O
)	O
were	O
used	O
to	O
determine	O
the	O
SES	O
of	O
the	O
children	O
and	O
their	O
families	O
.	O
Volunteers	O
fluent	O
in	O
relevant	O
languages	O
were	O
trained	O
to	O
conduct	O
these	O
in	O
-	O
person	O
interviews	O
.	O
Experienced	O
nurses	O
obtained	O
a	O
detailed	O
medical	O
history	O
through	O
physical	O
examination	O
of	O
the	O
whole	O
body	O
and	O
evaluation	O
of	O
symptoms	O
to	O
assess	O
current	O
infections	O
,	O
anemia	O
,	O
jaundice	O
,	O
as	O
well	O
as	O
signs	O
and	O
symptoms	O
of	O
protein	O
energy	O
malnutrition	O
,	O
general	O
respiratory	O
and	O
gastrointestinal	O
problems	O
,	O
allergies	O
,	O
and	O
skin	O
infections	O
.	O
Body	O
temperature	O
was	O
measured	O
using	O
an	O
infrared	O
digital	O
ear	O
thermometer	O
(	O
TS7	O
,	O
Hi	O
-	O
Care	O
International	O
;	O
Cape	O
Town	O
,	O
South	O
Africa	O
)	O
.	O
Blood	O
pressure	O
was	O
measured	O
once	O
after	O
the	O
child	O
had	O
been	O
seated	O
for	O
5	O
min	O
using	O
validated	O
oscillometric	O
Omron	O
digital	O
blood	O
pressure	O
monitor	O
(	O
Omron	O
M6	O
AC	O
model	O
;	O
Hoofdoorp	O
,	O
Netherlands	O
)	O
.	O
For	O
the	O
anthropometric	O
measurements	O
,	O
shoes	O
and	O
sweaters	O
were	O
removed	O
before	O
standing	O
on	O
a	O
digital	O
weighting	O
scale	O
(	O
Micro	O
T7E	O
electronic	O
platform	O
scale	O
,	O
Optima	O
Electronics	O
;	O
George	O
,	O
South	O
Africa	O
)	O
.	O
Body	O
weight	O
was	O
measured	O
once	O
to	O
the	O
nearest	O
0	O
.	O
1	O
kg	O
.	O

Children	O
’	O
s	O
height	O
was	O
assessed	O
with	O
a	O
Seca	O
stadiometer	O
(	O
Surgical	O
SA	O
;	O
Johannesburg	O
,	O
South	O
Africa	O
)	O
,	O
whereby	O
the	O
child	O
was	O
standing	O
with	O
the	O
back	O
erect	O
,	O
heals	O
touching	O
the	O
wall	O
,	O
and	O
shoulders	O
relaxed	O
.	O
Body	O
height	O
was	O
taken	O
to	O
the	O
nearest	O
0	O
.	O
1	O
cm	O
.	O
A	O
sample	O
of	O
at	O
least	O
15	O
g	O
of	O
early	O
morning	O
stool	O
from	O
every	O
participant	O
was	O
collected	O
in	O
a	O
container	O
and	O
transferred	O
to	O
a	O
laboratory	O
of	O
the	O
Nelson	O
Mandela	O
University	O
(	O
NMU	O
)	O
in	O
Port	O
Elizabeth	O
for	O
diagnostic	O
work	O
-	O
up	O
.	O
Stool	O
samples	O
were	O
visually	O
examined	O
for	O
Taenia	O
spp	O
.	O
proglottids	O
,	O
signs	O
of	O
blood	O
,	O
mucus	O
,	O
and	O
diarrhea	O
.	O
Duplicate	O
41	O
.	O
7	O
mg	O
Kato	O
-	O
Katz	O
thick	O
smears	O
were	O
prepared	O
from	O
each	O
stool	O
sample	O
[	O
19	O
]	O
and	O
examined	O
under	O
a	O
microscope	O
by	O
two	O
experienced	O
laboratory	O
technicians	O
.	O
The	O
number	O
of	O
helminth	O
eggs	O
was	O
counted	O
and	O
recorded	O
for	O
each	O
species	O
separately	O
.	O
Helminth	O
egg	O
counts	O
were	O
multiplied	O
by	O
a	O
factor	O
of	O
24	O
to	O
obtain	O
a	O
proxy	O
for	O
infection	O
intensity	O
,	O
expressed	O
as	O
the	O
number	O
of	O
eggs	O
per	O
gram	O
of	O
stool	O
(	O
EPG	O
)	O
,	O
which	O
was	O
then	O
categorized	O
into	O
light	O
,	O
moderate	O
,	O
and	O
heavy	O
infections	O
using	O
readily	O
available	O
cut	O
-	O
offs	O
offered	O
by	O
WHO	O
[	O
20	O
]	O
.	O
For	O
the	O
detection	O
of	O
intestinal	O
protozoa	O
C	O
.	O
parvum	O
and	O
G	O
.	O
intestinalis	O
,	O
a	O
Crypto	O
-	O
Giardia	O
Duo	O
-	O
Strip	O
rapid	O
diagnostic	O
test	O
(	O
RDT	O
)	O
was	O
performed	O
on	O
the	O
stool	O
sample	O
[	O
21	O
]	O
.	O
For	O
the	O
discovery	O
of	O
the	O
bacterium	O
H	O
.	O
pylori	O
,	O
a	O
Pylori	O
-	O
Strip	O
RDT	O
was	O
applied	O
[	O
22	O
]	O
(	O
both	O
tests	O
are	O
from	O
CORIS	O
,	O
BioConcept	O
;	O
Gembloux	O
,	O
Belgium	O
)	O
.	O
Children	O
were	O
also	O
asked	O
to	O
provide	O
a	O
urine	O
sample	O
,	O
which	O
was	O
transferred	O
to	O
the	O
laboratory	O
and	O
analyzed	O
on	O
the	O
same	O
day	O
.	O
Visual	O
inspection	O
for	O
macrohematuria	O
was	O
followed	O
by	O
testing	O
for	O
blood	O
in	O
urine	O
using	O
Hemastix	O
strips	O
(	O
Siemens	O
Healthcare	O
Diagnostics	O
GmbH	O
;	O
Eschborn	O
,	O
Germany	O
)	O
,	O
as	O
a	O
proxy	O
for	O
Schistosoma	O
haematobium	O
infection	O
.	O

A	O
point	O
-	O
of	O
-	O
care	O
circulating	O
cathodic	O
antigen	O
(	O
POC	O
-	O
CCA	O
)	O
urine	O
cassette	O
test	O
(	O
Rapid	O
Medical	O
Diagnostics	O
;	O
Cape	O
Town	O
,	O
South	O
Africa	O
)	O
was	O
used	O
for	O
the	O
diagnosis	O
of	O
Schistosoma	O
mansoni	O
infection	O
[	O
23	O
]	O
.	O
The	O
infectious	O
agents	O
under	O
the	O
same	O
taxonomy	O
were	O
grouped	O
as	O
trematodes	O
(	O
S	O
.	O
mansoni	O
and	O
S	O
.	O
haematobium	O
)	O
,	O
nematodes	O
(	O
Ascaris	O
lumbricoides	O
,	O
Enterobius	O
vermicularis	O
,	O
and	O
Trichuris	O
trichiura	O
)	O
,	O
intestinal	O
protozoa	O
(	O
G	O
.	O
intestinalis	O
and	O
C	O
.	O
parvum	O
)	O
,	O
and	O
bacteria	O
(	O
H	O
.	O
pylori	O
)	O
in	O
the	O
statistical	O
analyses	O
.	O
HbA1c	O
reflects	O
plasma	O
glucose	O
concentrations	O
over	O
an	O
8	O
-	O
to	O
12	O
-	O
week	O
period	O
.	O
It	O
is	O
used	O
as	O
a	O
convenient	O
diagnostic	O
indicator	O
for	O
DM	O
,	O
as	O
no	O
fasting	O
is	O
required	O
to	O
measure	O
it	O
.	O
HbA1c	O
concentrations	O
were	O
obtained	O
by	O
using	O
the	O
POC	O
instrument	O
Afinion	O
(	O
Alere	O
Inc	O
.	O
Waltham	O
;	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
,	O
which	O
is	O
based	O
on	O
boronate	O
affinity	O
separation	O
and	O
the	O
use	O
of	O
fluorescence	O
quenching	O
,	O
with	O
results	O
available	O
after	O
3	O
min	O
.	O
This	O
method	O
meets	O
the	O
generally	O
accepted	O
performance	O
criteria	O
for	O
HbA1c	O
,	O
as	O
defined	O
by	O
the	O
U	O
.	O
S	O
.	O
National	O
Glycohemoglobin	O
Standardization	O
Program	O
(	O
NGSP	O
)	O
,	O
with	O
no	O
interference	O
from	O
HbC	O
,	O
HbS	O
,	O
HbE	O
,	O
and	O
HbD	O
traits	O
results	O
.	O
All	O
test	O
cartridges	O
for	O
the	O
Afinion	O
test	O
belonged	O
to	O
the	O
specific	O
lot	O
number	O
.	O
Test	O
cartridges	O
were	O
stored	O
at	O
4°C	O
during	O
the	O
study	O
and	O
were	O
removed	O
from	O
the	O
refrigerator	O
a	O
maximum	O
of	O
120	O
min	O
before	O
the	O
test	O
.	O
The	O
tests	O
were	O
run	O
when	O
the	O
temperature	O
of	O
the	O
cartridges	O
were	O
in	O
their	O
optimal	O
range	O
(	O
15	O
–	O
25°C	O
)	O
.	O
Ambient	O
room	O
temperature	O
was	O
measured	O
on	O
each	O
test	O
day	O
to	O
assure	O
absence	O
of	O
temperature	O
effects	O
on	O
HbA1c	O
test	O
results	O
as	O
a	O
means	O
of	O
quality	B-methodology
control	I-methodology
.	O
Patients	O
with	O
HbA1c	O
≥6	O
.	O
5	O
%	O
,	O
the	O
recommended	O
cut	O
-	O
off	O
for	O
diagnosing	O
DM	O
[	O
24	O
]	O
,	O
were	O
referred	O
to	O
DM	O
care	O
centers	O
for	O
confirmation	O
and	O
specific	O
management	O
.	O

Hb	O
concentration	O
was	O
measured	O
with	O
the	O
HemoCue	O
Hb	O
301	O
system	O
(	O
HemoCueAB	O
;	O
Ängelholm	O
,	O
Sweden	O
)	O
and	O
the	O
results	O
were	O
considered	O
to	O
the	O
nearest	O
0	O
.	O
1	O
g	O
/	O
l	O
.	O
The	O
SES	O
was	O
derived	O
from	O
housing	O
characteristics	O
and	O
household	O
assets	O
(	O
S1	O
Table	O
)	O
.	O
The	O
SES	O
score	O
of	O
the	O
households	O
was	O
categorized	O
as	O
poorest	O
,	O
poor	O
,	O
and	O
least	O
poor	O
using	O
the	O
scale	O
by	O
Filmer	O
and	O
Pritchett	O
to	O
disaggregate	O
the	O
distribution	O
of	O
the	O
scores	O
[	O
25	O
]	O
.	O
The	O
age	O
of	O
individuals	O
was	O
grouped	O
into	O
five	O
categories	O
(	O
8	O
–	O
9	O
,	O
10	O
,	O
11	O
,	O
12	O
and	O
>	O
12	O
years	O
)	O
,	O
according	O
to	O
the	O
age	O
distribution	O
of	O
the	O
population	O
in	O
the	O
study	O
.	O
The	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
was	O
calculated	O
as	O
kg	O
/	O
m2	O
based	O
on	O
the	O
measured	O
height	O
and	O
weight	O
.	O
For	O
physical	O
activity	O
,	O
we	O
used	O
questionnaires	O
on	O
the	O
frequency	O
and	O
duration	O
of	O
certain	O
activities	O
(	O
how	O
many	O
days	O
in	O
a	O
week	O
the	O
children	O
were	O
physically	O
active	O
for	O
a	O
total	O
of	O
at	O
least	O
60	O
min	O
,	O
the	O
traveling	O
time	O
from	O
home	O
to	O
school	O
,	O
and	O
numbers	O
of	O
exercising	O
days	O
and	O
intensity	O
of	O
exercise	O
in	O
children	O
’	O
s	O
leisure	O
time	O
)	O
.	O
The	O
scores	O
were	O
summed	O
up	O
and	O
equally	O
categorized	O
into	O
tertiles	O
:	O
active	O
,	O
fair	O
,	O
and	O
poor	O
physical	O
activity	O
level	O
according	O
to	O
the	O
distribution	O
of	O
scores	O
.	O
Cardiorespiratory	O
fitness	O
(	O
VO2	O
max	O
)	O
is	O
the	O
maximum	O
rate	O
of	O
oxygen	O
consumption	O
,	O
as	O
measured	O
during	O
incremental	O
exercise	O
.	O
We	O
estimated	O
the	O
individual	O
VO2	O
max	O
from	O
the	O
20	O
m	O
shuttle	O
run	O
test	O
,	O
which	O
is	O
the	O
most	O
widely	O
used	O
field	O
test	O
for	O
determining	O
cardiorespiratory	O
fitness	O
in	O
children	O
[	O
26	O
,	O
27	O
]	O
.	O
A	O
complete	B-methodology
case	I-methodology
analysis	I-methodology
was	O
applied	O
.	O
Forty	O
out	O
of	O
882	O
participants	O
at	O
baseline	O
moved	O
or	O
changed	O
schools	O
within	O
the	O
6	O
-	O
month	O
anthelmintic	O
treatment	O
follow	O
-	O
up	O
,	O
and	O
hence	O
,	O
did	O
not	O
participate	O
in	O
the	O
latter	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
survey	I-methodology
.	O
Statistical	O
analyses	O
were	O
performed	O
with	O
STATA	O
version	O
14	O
.	O
1	O
(	O
StataCorp	O
;	O
College	O
Station	O
,	O
TX	O
,	O
USA	O
)	O
.	O
Statistical	O
significance	O
was	O
defined	O
as	O
a	O
two	O
-	O
sided	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
.	O
Descriptive	O
statistics	O
include	O
counts	O
,	O
percentages	O
for	O
categorical	O
variables	O
and	O
,	O
means	O
,	O
and	O
standard	O
deviations	O
(	O
SD	O
)	O
for	O
continuous	O
variables	O
.	O
The	O
categorization	O
of	O
DM	O
status	O
by	O
sex	O
is	O
described	O
according	O
to	O
the	O
American	O
Diabetes	O
Association	O
cutoffs	O
for	O
HbA1c	O
.	O

The	O
baseline	O
prevalence	O
of	O
the	O
different	O
gastrointestinal	O
tract	O
infections	O
is	O
presented	O
for	O
the	O
different	O
schools	O
separately	O
.	O
The	O
characteristics	O
of	O
covariates	O
at	O
baseline	O
are	O
presented	O
stratified	O
for	O
infected	O
and	O
non	O
-	O
infected	O
children	O
.	O
To	O
assess	O
the	O
independent	O
association	O
between	O
gastrointestinal	O
tract	O
infections	O
and	O
HbA1c	O
measurement	O
(	O
treated	O
as	O
continuous	O
numerical	O
data	O
)	O
at	O
baseline	O
,	O
linear	O
mixed	O
regressions	O
models	O
with	O
random	O
intercepts	O
for	O
schools	O
were	O
computed	O
.	O
Models	O
were	O
a	O
priori	O
adjusted	O
for	O
factors	O
previously	O
shown	O
to	O
be	O
associated	O
with	O
infections	O
and	O
glycemia	O
or	O
diabetes	O
,	O
and	O
therefore	O
with	O
a	O
potential	O
role	O
as	O
confounders	O
:	O
age	O
,	O
sex	O
,	O
SES	O
,	O
Hb	O
,	O
height	O
,	O
weight	O
,	O
BMI	O
,	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
,	O
physical	O
activity	O
,	O
VO2	O
max	O
,	O
and	O
body	O
temperature	O
.	O
As	O
a	O
sensitivity	O
analysis	O
,	O
we	O
also	O
omitted	O
weight	O
,	O
BMI	O
,	O
physical	O
activity	O
,	O
VO2	O
max	O
,	O
anemia	O
and	O
blood	O
pressure	O
from	O
the	O
models	O
as	O
they	O
are	O
potential	O
mediators	O
of	O
infection	O
effects	O
on	O
glycemia	O
or	O
correlates	O
of	O
glycemia	O
.	O
All	O
models	O
were	O
run	O
(	O
i	O
)	O
by	O
adding	O
each	O
infection	O
separately	O
without	O
excluding	O
children	O
with	O
other	O
infections	O
;	O
(	O
ii	O
)	O
by	O
adding	O
each	O
infection	O
separately	O
and	O
excluding	O
children	O
with	O
other	O
infections	O
;	O
(	O
iii	O
)	O
by	O
adding	O
all	O
infection	O
variables	O
simultaneously	O
and	O
;	O
and	O
(	O
iv	O
)	O
by	O
adding	O
groups	O
of	O
infections	O
.	O
We	O
also	O
assessed	O
dose	O
-	O
response	O
effects	O
on	O
HbA1c	O
for	O
infectious	O
agents	O
,	O
especially	O
A	O
.	O
lumbricoides	O
,	O
where	O
data	O
on	O
intensity	O
of	O
infection	O
was	O
available	O
.	O
To	O
assess	O
the	O
independent	O
effect	O
of	O
anthelmintic	O
treatment	O
on	O
changes	O
in	O
HbA1c	O
level	O
between	O
baseline	O
and	O
the	O
6	O
-	O
month	O
anthelmintic	O
treatment	O
follow	O
-	O
up	O
among	O
children	O
from	O
schools	O
without	O
lifestyle	B-methodology
intervention	I-methodology
and	O
who	O
were	O
infected	O
at	O
baseline	O
,	O
linear	O
mixed	O
regression	O
models	O
with	O
random	O
intercepts	O
for	O
schools	O
were	O
built	O
.	O
Models	O
were	O
a	O
priori	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
SES	O
,	O
Hb	O
,	O
height	O
,	O
weight	O
,	O
BMI	O
,	O
diastolic	O
and	O
systolic	O
blood	O
pressure	O
,	O
physical	O
activity	O
,	O
VO2	O
max	O
,	O
and	O
body	O
temperature	O
,	O
considering	O
information	O
from	O
both	O
time	O
points	O
,	O
as	O
appropriate	O
.	O
Longitudinal	O
models	O
were	O
re	O
-	O
run	O
among	O
subjects	O
infected	O
at	O
baseline	O
but	O
not	O
at	O
follow	O
-	O
up	O
,	O
to	O
differentiate	O
between	O
the	O
effect	O
of	O
the	O
anthelmintic	O
treatment	O
itself	O
and	O
the	O
effect	O
of	O
resolved	O
infection	O
on	O
change	O
in	O
HbA1c	O
.	O

Models	O
were	O
also	O
run	O
for	O
children	O
infected	O
with	O
nematodes	O
and	O
for	O
children	O
with	O
any	O
gastrointestinal	O
tract	O
infection	O
separately	O
.	O
Complete	O
data	O
records	O
including	O
the	O
baseline	O
and	O
6	O
-	O
month	O
anthelmintic	O
treatment	O
follow	B-methodology
-	I-methodology
up	I-methodology
surveys	I-methodology
were	O
available	O
from	O
842	O
children	O
(	O
Fig	O
1	O
)	O
.	O
Fig	O
2	O
shows	O
the	O
distribution	O
of	O
HbA1c	O
at	O
baseline	O
and	O
at	O
the	O
6	O
-	O
month	O
follow	O
-	O
up	O
for	O
the	O
total	O
study	O
sample	O
of	O
842	O
children	O
irrespective	O
of	O
the	O
intervention	O
that	O
they	O
obtained	O
.	O
There	O
was	O
a	O
small	O
shift	O
towards	O
lower	O
HbA1c	O
levels	O
at	O
follow	O
-	O
up	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
reflecting	O
the	O
lifestyle	B-methodology
intervention	I-methodology
in	O
some	O
schools	O
.	O
The	O
results	O
of	O
quality	B-methodology
control	I-methodology
tests	O
underline	O
the	O
validity	O
of	O
the	O
HbA1c	O
data	O
.	O
First	O
,	O
HbA1c	O
results	O
did	O
not	O
depend	O
on	O
the	O
day	O
of	O
examination	O
(	O
p	O
=	O
0	O
.	O
222	O
)	O
,	O
body	O
temperature	O
(	O
p	O
=	O
0	O
.	O
327	O
)	O
,	O
or	O
ambient	O
temperature	O
(	O
p	O
=	O
0	O
.	O
217	O
)	O
(	O
S1	O
Fig	O
)	O
.	O
Second	O
,	O
results	O
from	O
the	O
weekly	O
calibration	O
with	O
identical	O
control	O
1	O
and	O
control	O
2	O
are	O
presented	O
in	O
S2	O
Table	O
.	O
At	O
baseline	O
,	O
the	O
overall	O
mean	O
HbA1c	O
level	O
of	O
participants	O
was	O
5	O
.	O
79	O
%	O
with	O
SD	O
of	O
0	O
.	O
25	O
.	O
The	O
prevalence	O
of	O
prediabetes	O
and	O
diabetes	O
according	O
to	O
baseline	O
is	O
presented	O
in	O
S3	O
Table	O
.	O
A	O
high	O
prevalence	O
of	O
preDM	O
was	O
observed	O
with	O
605	O
(	O
71	O
.	O
8	O
%	O
)	O
of	O
children	O
having	O
preDM	O
HbA1c	O
levels	O
.	O
Three	O
children	O
(	O
0	O
.	O
4	O
%	O
)	O
exhibited	O
HbA1c	O
results	O
≥6	O
.	O
5	O
%	O
at	O
baseline	O
and	O
were	O
offered	O
diagnostic	O
follow	O
-	O
up	O
for	O
DM	O
.	O
The	O
characteristics	O
of	O
the	O
study	O
population	O
and	O
its	O
univariate	O
association	O
with	O
HbA1c	O
are	O
presented	O
in	O
S4	O
Table	O
.	O
Table	O
1	O
shows	O
the	O
prevalence	O
of	O
gastrointestinal	O
tract	O
infections	O
in	O
the	O
study	O
schools	O
at	O
baseline	O
.	O
H	O
.	O
pylori	O
was	O
the	O
predominant	O
infection	O
(	O
416	O
children	O
with	O
a	O
positive	O
RDT	O
result	O
,	O
49	O
.	O
4	O
%	O
)	O
.	O
At	O
the	O
unit	O
of	O
the	O
school	O
,	O
the	O
prevalence	O
of	O
H	O
.	O
pylori	O
ranged	O
from	O
27	O
%	O
to	O
62	O
%	O
.	O
The	O
second	O
most	O
common	O
infections	O
were	O
the	O
soil	O
-	O
transmitted	O
helminths	O
A	O
.	O
lumbricoides	O
and	O
T	O
.	O
trichiura	O
.	O

Two	O
out	O
of	O
eight	O
schools	O
showed	O
very	O
high	O
prevalence	O
of	O
A	O
.	O
lumbricoides	O
infection	O
(	O
62	O
.	O
5	O
%	O
and	O
74	O
.	O
1	O
%	O
)	O
,	O
there	O
was	O
a	O
moderate	O
infection	O
prevalence	O
in	O
a	O
third	O
school	O
(	O
25	O
.	O
9	O
%	O
)	O
,	O
while	O
the	O
prevalence	O
in	O
the	O
five	O
remaining	O
schools	O
were	O
below	O
5	O
%	O
.	O
High	O
prevalence	O
of	O
T	O
.	O
trichiura	O
infection	O
was	O
observed	O
in	O
the	O
same	O
two	O
schools	O
where	O
the	O
prevalence	O
of	O
A	O
.	O
lumbricoides	O
prevalence	O
was	O
high	O
(	O
66	O
.	O
7	O
%	O
and	O
67	O
.	O
9	O
%	O
,	O
respectively	O
)	O
,	O
while	O
the	O
prevalence	O
of	O
T	O
.	O
trichiura	O
was	O
below	O
3	O
%	O
in	O
the	O
remaining	O
six	O
schools	O
.	O
In	O
all	O
schools	O
,	O
infection	O
rates	O
were	O
low	O
to	O
very	O
low	O
or	O
even	O
undetectable	O
for	O
intestinal	O
protozoa	O
(	O
Cryptosporidium	O
spp	O
.	O
1	O
–	O
5	O
%	O
;	O
G	O
.	O
intestinalis	O
6	O
–	O
17	O
%	O
)	O
,	O
the	O
nematode	O
E	O
.	O
vermicularis	O
(	O
1	O
–	O
5	O
%	O
)	O
,	O
and	O
the	O
trematodes	O
S	O
.	O
mansoni	O
(	O
1	O
–	O
3	O
%	O
;	O
detected	O
by	O
POC	O
-	O
CCA	O
urine	O
cassette	O
test	O
)	O
and	O
S	O
.	O
haematobium	O
(	O
0	O
%	O
)	O
.	O
Table	O
2	O
simply	O
compares	O
the	O
characteristics	O
of	O
participants	O
with	O
and	O
without	O
a	O
specific	O
gastrointestinal	O
tract	O
infection	O
.	O
Except	O
for	O
H	O
.	O
pylori	O
,	O
the	O
proportion	O
of	O
children	O
with	O
low	O
SES	O
was	O
higher	O
among	O
infected	O
children	O
compared	O
to	O
their	O
non	O
-	O
infected	O
counterparts	O
.	O
Infections	O
with	O
nematodes	O
and	O
G	O
.	O
intestinalis	O
were	O
more	O
common	O
in	O
males	O
,	O
whereas	O
C	O
.	O
parvum	O
infection	O
was	O
more	O
common	O
in	O
females	O
.	O
Infected	O
children	O
were	O
,	O
on	O
average	O
,	O
older	O
than	O
their	O
non	O
-	O
infected	O
peers	O
.	O
Nevertheless	O
,	O
children	O
with	O
an	O
A	O
.	O
lumbricoides	O
,	O
T	O
.	O
trichiura	O
,	O
and	O
E	O
.	O
vermicularis	O
infection	O
had	O
lower	O
height	O
,	O
weight	O
,	O
and	O
BMI	O
compared	O
to	O
non	O
-	O
infected	O
children	O
.	O
However	O
,	O
children	O
infected	O
with	O
A	O
.	O
lumbricoides	O
,	O
T	O
.	O
trichiura	O
,	O
and	O
H	O
.	O
pylori	O
reported	O
higher	O
physical	O
activity	O
,	O
but	O
did	O
not	O
differ	O
with	O
regard	O
to	O
cardiorespiratory	O
fitness	O
.	O
Concerning	O
anemia	O
and	O
HbA1c	O
,	O
no	O
clear	O
pattern	O
of	O
association	O
was	O
evident	O
from	O
the	O
univariate	O
analysis	O
.	O
The	O
results	O
from	O
the	O
multivariable	O
linear	O
regression	O
models	O
of	O
the	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
association	O
of	O
single	O
or	O
grouped	O
infections	O
with	O
HbA1c	O
are	O
presented	O
in	O
Table	O
3	O
.	O

We	O
observed	O
a	O
positive	O
association	O
between	O
H	O
.	O
pylori	O
infection	O
and	O
HbA1c	O
,	O
irrespective	O
of	O
adjustments	O
for	O
other	O
infections	O
(	O
β	O
=	O
0	O
.	O
040	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0	O
.	O
006	O
–	O
0	O
.	O
074	O
)	O
.	O
No	O
significant	O
association	O
of	O
HbA1c	O
with	O
any	O
other	O
infectious	O
agent	O
or	O
infection	O
group	O
was	O
observed	O
.	O
Omitting	O
covariates	O
from	O
the	O
multivariable	O
regression	O
models	O
that	O
are	O
potential	O
mediators	O
of	O
infection	O
effects	O
on	O
glycemia	O
(	O
physical	O
activity	O
,	O
physical	O
fitness	O
,	O
weight	O
,	O
BMI	O
,	O
and	O
anemia	O
)	O
or	O
correlated	O
outcomes	O
(	O
blood	O
pressure	O
)	O
did	O
not	O
materially	O
alter	O
the	O
results	O
presented	O
for	O
the	O
fully	O
adjusted	O
models	O
(	O
S5	O
Table	O
)	O
.	O
Excluding	O
children	O
with	O
DM	O
at	O
baseline	O
or	O
at	O
the	O
6	O
-	O
month	O
anthelmintic	O
treatment	O
follow	O
-	O
up	O
did	O
not	O
materially	O
alter	O
the	O
findings	O
(	O
S6	O
Table	O
)	O
.	O
In	O
addition	O
,	O
we	O
were	O
not	O
able	O
to	O
show	O
a	O
statistically	O
significant	O
dose	O
-	O
response	O
relationship	O
between	O
intensity	O
of	O
A	O
.	O
lumbricoides	O
and	O
T	O
.	O
trichiura	O
infection	O
and	O
HbA1c	O
levels	O
,	O
albeit	O
adjusted	O
HbA1c	O
levels	O
were	O
highest	O
in	O
children	O
with	O
most	O
intense	O
infections	O
(	O
S7	O
Table	O
)	O
.	O
Results	O
pertaining	O
to	O
the	O
association	O
between	O
albendazole	O
treatment	O
and	O
change	O
in	O
HbA1c	O
level	O
at	O
the	O
6	O
-	O
month	O
treatment	O
follow	O
-	O
up	O
are	O
presented	O
in	O
Table	O
4	O
.	O
The	O
analysis	O
is	O
restricted	O
to	O
children	O
from	O
schools	O
not	O
subjected	O
to	O
lifestyle	O
interventions	O
given	O
the	O
observed	O
slight	O
decrease	O
in	O
HbA1c	O
in	O
the	O
total	O
study	O
sample	O
.	O
Furthermore	O
,	O
only	O
children	O
with	O
any	O
infection	O
or	O
with	O
nematode	O
infection	O
at	O
baseline	O
,	O
respectively	O
,	O
were	O
included	O
.	O
The	O
regression	O
analyses	O
point	O
to	O
statistically	O
non	O
-	O
significant	O
increases	O
in	O
HbA1c	O
concentrations	O
at	O
the	O
6	O
-	O
month	O
treatment	O
follow	O
-	O
up	O
.	O
The	O
findings	O
from	O
multivariable	O
regression	O
model	O
excluding	O
covariates	O
that	O
could	O
be	O
potential	O
mediators	O
of	O
infection	O
effects	O
on	O
glycemia	O
or	O
correlated	O
outcomes	O
(	O
weight	O
,	O
BMI	O
,	O
anemia	O
,	O
physical	O
activity	O
,	O
physical	O
fitness	O
,	O
and	O
blood	O
pressure	O
)	O
point	O
to	O
generally	O
weaker	O
and	O
still	O
statistically	O
non	O
-	O
significant	O
results	O
(	O
S8	O
Table	O
)	O
.	O
To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
investigation	O
examining	O
the	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
association	O
of	O
a	O
broad	O
spectrum	O
of	O
gastrointestinal	O
tract	O
infections	O
with	O
glycemia	O
in	O
school	O
-	O
aged	O
children	O
and	O
assessing	O
the	O
impact	O
of	O
anthelmintic	O
treatment	O
on	O
the	O
change	O
in	O
HbA1c	O
values	O
.	O

We	O
observed	O
a	O
positive	O
association	O
between	O
H	O
.	O
pylori	O
infection	O
and	O
HbA1c	O
,	O
while	O
no	O
statistically	O
significant	O
relationship	O
was	O
observed	O
with	O
any	O
other	O
type	O
of	O
infection	O
.	O
Some	O
animal	B-methodology
experiments	I-methodology
[	O
28	O
]	O
and	O
human	O
epidemiologic	B-methodology
studies	I-methodology
[	O
10	O
,	O
11	O
,	O
13	O
,	O
15	O
]	O
have	O
shown	O
helminth	O
infections	O
to	O
lower	O
the	O
blood	O
sugar	O
level	O
and	O
inhibit	O
the	O
development	O
of	O
type	O
1	O
DM	O
as	O
well	O
as	O
type	O
2	O
DM	O
.	O
An	O
inverse	O
relationship	O
between	O
lymphatic	O
filariasis	O
and	O
both	O
type	O
1	O
and	O
type	O
2	O
DM	O
was	O
reported	O
from	O
India	O
[	O
10	O
,	O
11	O
]	O
.	O
Having	O
a	O
previous	O
schistosome	O
infection	O
exhibited	O
a	O
strong	O
protective	O
effect	O
against	O
DM	O
in	O
the	O
People	O
’	O
s	O
Republic	O
of	O
China	O
[	O
12	O
]	O
.	O
Strongyloides	O
stercoralis	O
infection	O
seemed	O
to	O
be	O
associated	O
with	O
a	O
reduced	O
risk	O
of	O
type	O
2	O
DM	O
in	O
adult	O
Australians	O
[	O
13	O
]	O
.	O
Soil	O
-	O
transmitted	O
helminth	O
infections	O
were	O
linked	O
with	O
an	O
improvement	O
of	O
insulin	O
sensitivity	O
in	O
Indonesia	O
[	O
15	O
]	O
.	O
Diabetic	O
patients	O
in	O
Turkey	O
were	O
found	O
to	O
have	O
a	O
lower	O
prevalence	O
of	O
parasitic	O
disease	O
than	O
their	O
healthy	O
counterparts	O
[	O
16	O
]	O
.	O
In	O
contrast	O
,	O
a	O
positive	O
association	O
was	O
found	O
between	O
S	O
.	O
stercoralis	O
infection	O
and	O
DM	O
in	O
Brazil	O
,	O
where	O
it	O
was	O
also	O
found	O
that	O
such	O
infections	O
were	O
associated	O
with	O
a	O
high	O
mortality	O
risk	O
among	O
poorly	O
controlled	O
DM	O
patients	O
[	O
14	O
]	O
.	O
A	O
study	O
conducted	O
by	O
Hakim	O
and	O
colleagues	O
reported	O
a	O
high	O
rate	O
of	O
G	O
.	O
intestinalis	O
infection	O
among	O
DM	O
patients	O
[	O
29	O
]	O
.	O
For	O
trematode	O
infections	O
,	O
positive	O
association	O
with	O
HbA1c	O
concentrations	O
were	O
reported	O
from	O
several	O
studies	O
[	O
12	O
,	O
30	O
,	O
31	O
]	O
.	O
The	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
nature	O
of	O
these	O
studies	O
precludes	O
casual	O
inference	O
.	O
H	O
.	O
pylori	O
is	O
one	O
of	O
the	O
most	O
common	O
human	O
pathogens	O
causing	O
gastrointestinal	O
inflammation	O
.	O
Potential	O
underlying	O
mechanisms	O
linking	O
H	O
.	O
pylori	O
infection	O
and	O
HbA1c	O
levels	O
and	O
DM	O
may	O
include	O
a	O
disturbance	O
of	O
glucose	O
and	O
lipid	O
absorption	O
by	O
the	O
inflamed	O
gastrointestinal	O
tissue	O
.	O
H	O
.	O
pylori	O
infections	O
may	O
also	O
alter	O
host	O
metabolic	O
homeostasis	O
by	O
affecting	O
appetite	O
regulation	O
and	O
energy	O
expenditure	O
through	O
altered	O
balance	O
of	O
ghrelin	O
and	O
leptin	O
secretion	O
,	O
leading	O
to	O
over	O
-	O
eating	O
and	O
metabolic	O
syndrome	O
pathogenesis	O
.	O
The	O
mediating	O
role	O
of	O
gut	O
microbiota	O
alterations	O
remains	O
unknown	O
[	O
32	O
]	O
.	O

The	O
reported	O
associations	O
between	O
H	O
.	O
pylori	O
infection	O
and	O
DM	O
remain	O
inconsistent	O
.	O
The	O
positive	O
association	O
reported	O
among	O
school	O
children	O
in	O
the	O
present	O
study	O
corroborates	O
findings	O
from	O
two	O
large	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
national	O
surveys	O
conducted	O
by	O
Chen	O
and	O
Blaser	O
in	O
American	O
population	O
samples	O
(	O
one	O
aged	O
≥18	O
years	O
and	O
one	O
aged	O
≥3	O
years	O
)	O
and	O
a	O
Taiwanese	O
study	O
in	O
adults	O
,	O
which	O
all	O
found	O
that	O
H	O
.	O
pylori	O
infections	O
were	O
associated	O
with	O
higher	O
mean	O
HbA1c	O
levels	O
[	O
33	O
,	O
34	O
]	O
.	O
Several	O
smaller	O
outpatient	O
clinic	O
or	O
hospital	O
based	O
studies	O
in	O
Turkey	O
,	O
Pakistan	O
,	O
and	O
Qatar	O
among	O
adults	O
aged	O
18	O
years	O
and	O
above	O
showed	O
a	O
higher	O
prevalence	O
of	O
H	O
.	O
pylori	O
infection	O
in	O
diabetic	O
patients	O
than	O
non	O
-	O
DM	O
control	O
groups	O
[	O
35	O
–	O
37	O
]	O
.	O
Other	O
studies	O
failed	O
to	O
find	O
a	O
positive	O
association	O
between	O
H	O
.	O
pylori	O
and	O
HbA1c	O
or	O
DM	O
[	O
38	O
–	O
40	O
]	O
.	O
In	O
fact	O
,	O
DM	O
patients	O
were	O
found	O
to	O
have	O
higher	O
rates	O
of	O
H	O
.	O
pylori	O
eradication	O
therapy	O
according	O
to	O
national	O
health	O
insurance	O
data	O
from	O
Taiwan	O
.	O
H	O
.	O
pylori	O
eradication	O
treatment	O
success	O
was	O
found	O
to	O
be	O
lower	O
in	O
DM	O
compared	O
to	O
non	O
-	O
DM	O
patients	O
[	O
41	O
,	O
42	O
]	O
.	O
Future	O
intervention	B-methodology
studies	I-methodology
for	O
the	O
treatment	O
of	O
H	O
.	O
pylori	O
should	O
systematically	O
consider	O
changes	O
in	O
glycemia	O
to	O
shed	O
light	O
on	O
the	O
potential	O
etiologic	O
role	O
of	O
H	O
.	O
pylori	O
in	O
DM	O
development	O
.	O
Some	O
studies	O
indicated	O
an	O
improvement	O
of	O
mean	O
HbA1c	O
and	O
insulin	O
resistance	O
in	O
patients	O
with	O
type	O
2	O
DM	O
after	O
H	O
.	O
pylori	O
treatment	O
[	O
43	O
,	O
44	O
]	O
.	O
We	O
did	O
not	O
observe	O
a	O
statistically	O
significant	O
increase	O
in	O
HbA1c	O
after	O
anthelmintic	O
treatment	O
with	O
albendazole	O
in	O
children	O
harboring	O
nematode	O
infections	O
at	O
baseline	O
,	O
possibly	O
as	O
a	O
result	O
of	O
sample	O
size	O
limitations	O
.	O
The	O
observed	O
direction	O
of	O
the	O
effect	O
is	O
in	O
line	O
with	O
the	O
reported	O
shift	O
towards	O
a	O
Th2	O
response	O
in	O
helminth	O
-	O
infected	O
individuals	O
.	O
A	O
number	O
of	O
clinical	B-methodology
trials	I-methodology
with	O
helminth	O
or	O
helminth	O
antigen	O
therapy	O
have	O
reported	O
promising	O
results	O
in	O
inflammatory	O
bowel	O
diseases	O
[	O
45	O
,	O
46	O
]	O
,	O
multiple	O
sclerosis	O
[	O
47	O
]	O
,	O
rheumatoid	O
arthritis	O
[	O
48	O
]	O
.	O

After	O
deworming	O
,	O
which	O
triggers	O
several	O
hyper	O
-	O
inflammatory	O
processes	O
and	O
shifts	O
immune	O
responses	O
from	O
Th2	O
to	O
Th1	O
,	O
groups	O
of	O
children	O
treated	O
with	O
either	O
albendazole	O
or	O
mebendazole	O
(	O
against	O
soil	O
-	O
transmitted	O
helminthiasis	O
)	O
or	O
praziquantel	O
(	O
against	O
schistosomiasis	O
)	O
had	O
a	O
higher	O
positive	O
response	O
to	O
the	O
skin	O
-	O
prick	O
test	O
and	O
allergy	O
related	O
symptoms	O
[	O
49	O
,	O
50	O
]	O
.	O
Nevertheless	O
,	O
other	O
studies	O
emphasized	O
that	O
anthelmintic	O
treatment	O
did	O
not	O
have	O
an	O
effect	O
on	O
clinical	O
eczema	O
and	O
asthmatic	O
severity	O
scores	O
[	O
51	O
,	O
52	O
]	O
.	O
Given	O
that	O
in	O
our	O
study	O
the	O
highest	O
increase	O
in	O
HbA1c	O
after	O
albendazole	O
treatment	O
was	O
observed	O
in	O
children	O
with	O
non	O
-	O
nematode	O
parasite	O
infection	O
,	O
additional	O
research	O
is	O
needed	O
to	O
understand	O
the	O
effect	O
of	O
the	O
anthelmintic	O
drugs	O
on	O
human	O
glucose	O
metabolism	O
.	O
Yet	O
,	O
our	O
results	O
are	O
aligned	O
with	O
the	O
first	O
publication	O
from	O
a	O
randomized	B-methodology
placebo	I-methodology
-	O
controlled	B-methodology
trial	I-methodology
in	O
Indonesia	O
,	O
which	O
showed	O
no	O
effect	O
of	O
albendazole	O
treatment	O
on	O
insulin	O
resistance	O
[	O
53	O
]	O
.	O
Our	O
study	O
has	O
several	O
strengths	O
.	O
First	O
,	O
the	O
study	O
population	O
exhibited	O
sufficient	O
prevalence	O
range	O
for	O
at	O
least	O
some	O
of	O
the	O
infectious	O
agents	O
investigated	O
to	O
allow	O
for	O
efficient	O
interrogation	O
of	O
the	O
study	O
objective	O
.	O
Second	O
,	O
the	O
detailed	O
characterization	O
of	O
children	O
allowed	O
us	O
to	O
assess	O
independent	O
associations	O
of	O
parasite	O
infections	O
with	O
glycemia	O
and	O
limiting	O
residual	O
confounding	O
.	O
To	O
analyze	O
the	O
SES	O
of	O
study	O
participants	O
,	O
we	O
chose	O
multiple	O
correspondence	O
analysis	O
(	O
MCA	O
)	O
based	O
on	O
household	O
characteristics	O
and	O
assets	O
ownership	O
over	O
more	O
traditional	O
methods	O
thereby	O
minimizing	O
measurement	O
error	O
related	O
to	O
the	O
different	O
calculation	O
methods	O
of	O
income	O
and	O
consumption	O
,	O
recall	O
bias	O
,	O
and	O
seasonal	O
variation	O
of	O
income	O
and	O
expenditure	O
.	O
Third	O
,	O
we	O
used	O
internationally	O
certified	O
HbA1c	O
testing	O
(	O
Alere	O
Technologies	O
)	O
,	O
regularly	O
calibrated	O
with	O
standard	O
control	O
procedure	O
.	O
Ehehalt	O
et	O
al	O
.	O
showed	O
that	O
the	O
measurement	O
of	O
HbA1c	O
was	O
a	O
reliable	O
criterion	O
for	O
children	O
and	O
adolescents	O
to	O
diagnose	O
the	O
onset	O
of	O
childhood	O
type	O
1	O
DM	O
[	O
54	O
]	O
.	O
In	O
addition	O
,	O
the	O
POC	O
HbA1c	O
test	O
is	O
an	O
accepted	O
screening	O
instrument	O
for	O
pre	O
-	O
DM	O
and	O
type	O
2	O
DM	O
[	O
55	O
,	O
56	O
]	O
.	O
We	O
carefully	O
evaluated	O
potential	O
measurement	O
error	O
in	O
HbA1c	O
in	O
the	O
light	O
of	O
the	O
observed	O
high	O
prevalence	O
of	O
pre	O
-	O
DM	O
.	O
We	O
demonstrated	O
the	O
absence	O
of	O
correlations	O
with	O
external	O
temperature	O
,	O
body	O
temperature	O
,	O
and	O
examination	O
date	O
.	O

In	O
addition	O
,	O
all	O
models	O
were	O
adjusted	O
for	O
the	O
concentration	O
of	O
Hb	O
,	O
a	O
potentially	O
important	O
confounder	O
,	O
which	O
was	O
assessed	O
with	O
the	O
widely	O
used	O
HemoCue	O
Hb	O
301	O
system	O
.	O
We	O
also	O
acknowledge	O
some	O
limitations	O
of	O
our	O
study	O
.	O
Reverse	O
causation	O
remains	O
a	O
problem	O
related	O
to	O
the	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
nature	O
of	O
our	O
main	O
analysis	O
.	O
The	O
low	O
prevalence	O
for	O
some	O
infections	O
limited	O
statistical	O
power	O
for	O
the	O
analyses	O
.	O
The	O
association	O
between	O
H	O
.	O
pylori	O
infection	O
and	O
HbA1c	O
is	O
no	O
longer	O
statistically	O
significant	O
if	O
the	O
p	O
-	O
values	O
are	O
adjusted	O
for	O
the	O
number	O
of	O
infections	O
investigated	O
(	O
n	O
=	O
8	O
)	O
.	O
Additionally	O
,	O
the	O
co	O
-	O
infections	O
[	O
3	O
]	O
may	O
in	O
part	O
mask	O
opposite	O
effects	O
of	O
different	O
parasites	O
on	O
HbA1c	O
.	O
Examining	O
only	O
one	O
stool	O
sample	O
has	O
a	O
low	O
diagnostic	O
accuracy	O
due	O
to	O
the	O
day	O
-	O
to	O
-	O
day	O
and	O
intra	O
-	O
specimen	O
variation	O
in	O
helminth	O
egg	O
output	O
.	O
To	O
partially	O
remedy	O
this	O
shortcoming	O
,	O
test	O
specificity	O
was	O
increased	O
by	O
preparing	O
duplicate	O
Kato	O
-	O
Katz	O
thick	O
smears	O
from	O
each	O
stool	O
sample	O
.	O
We	O
observed	O
a	O
very	O
high	O
rate	O
of	O
preDM	O
in	O
the	O
children	O
studied	O
,	O
which	O
may	O
limit	O
the	O
generalizability	O
of	O
the	O
observed	O
associations	O
.	O
Despite	O
the	O
fact	O
that	O
the	O
Alere	O
HbA1c	O
testing	O
is	O
minimally	O
affected	O
by	O
hemoglobinopathies	O
,	O
we	O
cannot	O
assess	O
any	O
influence	O
in	O
the	O
absence	O
of	O
genotyping	O
results	O
.	O
Selection	O
bias	O
related	O
to	O
the	O
complete	B-methodology
case	I-methodology
analysis	I-methodology
approach	O
cannot	O
be	O
excluded	O
but	O
the	O
very	O
high	O
participation	O
rate	O
at	O
baseline	O
and	O
the	O
6	O
-	O
month	O
anthelmintic	O
treatment	O
follow	O
-	O
up	O
(	O
5	O
%	O
drop	O
-	O
out	O
rate	O
)	O
,	O
and	O
the	O
relatively	O
low	O
rate	O
of	O
children	O
not	O
providing	O
stools	O
(	O
15	O
%	O
)	O
are	O
unlikely	O
to	O
have	O
substantially	O
altered	O
the	O
results	O
.	O
In	O
conclusion	O
,	O
the	O
positive	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
association	O
of	O
H	O
.	O
pylori	O
infections	O
with	O
glycemia	O
is	O
consistent	O
with	O
a	O
potential	O
role	O
of	O
this	O
highly	O
prevalent	O
bacterium	O
in	O
DM	O
in	O
LMICs	O
.	O
The	O
direction	O
and	O
causality	O
of	O
the	O
association	O
warrants	O
further	O
scientific	O
inquiry	O
in	O
the	O
context	O
of	O
longitudinal	B-methodology
studies	I-methodology
and	O
biobanks	O
that	O
focus	O
on	O
specific	O
parasites	O
and	O
integrate	O
immunity	O
as	O
well	O
as	O
other	O
biomarkers	O
to	O
improve	O
mechanistic	O
understanding	O
of	O
parasite	O
-	O
glycemia	O
associations	O
and	O
the	O
potential	O
impact	O
of	O
deworming	O
programs	O
on	O
DM	O
prevalence	O
.	O
The	O
authors	O
received	O
no	O
specific	O
funding	O
for	O
this	O
work	O
.	O
All	O
relevant	O
data	O
are	O
within	O
the	O
paper	O
and	O
its	O
Supporting	O
Information	O
files	O
.	O

Traditional	O
Old	O
Dietary	O
Pattern	O
of	O
Castellana	O
Grotte	O
(	O
Apulia	O
)	O
Is	O
Associated	O
with	O
Healthy	O
Outcomes	O
healthy	O
diet	O
indices	O
;	O
food	O
intake	O
;	O
Apulia	O
;	O
MICOL	O
study	O
;	O
greatAGE	O
study	O
;	O
prospective	B-methodology
cohort	I-methodology
study	I-methodology
;	O
mind	O
index	O
;	O
dash	O
index	O
;	O
Meddietscore	O
Background	O
:	O
There	O
is	O
still	O
room	O
for	O
further	O
studies	O
aimed	O
at	O
investigating	O
the	O
most	O
widespread	O
diets	O
in	O
the	O
Mediterranean	O
area	O
.	O
The	O
objective	O
of	O
the	O
study	O
is	O
to	O
analyze	O
the	O
relation	O
of	O
food	O
group	O
intake	O
to	O
clinical	O
chemical	O
indicators	O
of	O
health	O
,	O
and	O
also	O
to	O
compare	O
the	O
food	O
group	O
intake	O
with	O
healthy	O
well	O
-	O
known	O
diet	O
indices	O
.	O
Methods	O
:	O
Lifestyle	O
,	O
dietary	O
,	O
and	O
clinical	O
data	O
collected	O
in	O
2005	O
/	O
2006	O
and	O
2012	O
/	O
2018	O
from	O
Castellana	O
Grotte	O
,	O
located	O
in	O
the	O
rural	O
area	O
of	O
Apulia	O
,	O
were	O
analyzed	O
.	O
The	O
study	O
populations	B-methodology
included	I-methodology
newly	I-methodology
recruited	I-methodology
subjects	I-methodology
at	I-methodology
each	I-methodology
time	I-methodology
period	I-methodology
(	O
n	O
=	O
1870	O
)	O
as	O
well	O
as	O
subjects	O
examined	O
twice	O
and	O
compared	O
over	O
time	O
regarding	O
health	O
indicators	O
(	O
n	O
=	O
734	O
)	O
.	O
Diet	O
was	O
assessed	O
through	O
a	O
validated	O
food	O
frequency	O
questionnaire	O
.	O
Three	O
healthy	O
diet	O
indices	O
were	O
calculated	O
and	O
related	O
to	O
29	O
food	O
groups	O
.	O
We	O
also	O
performed	O
prospective	O
regression	O
of	O
food	O
group	O
consumption	O
with	O
health	O
indicators	O
.	O
Results	O
:	O
The	O
diet	O
over	O
the	O
time	O
period	O
of	O
observation	O
was	O
very	O
stable	O
and	O
consisted	O
of	O
a	O
high	O
proportion	O
of	O
vegetables	O
,	O
fruit	O
and	O
grains	O
.	O
No	O
major	O
changes	O
in	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
and	O
blood	O
pressure	O
were	O
observed	O
.	O
Consumption	O
of	O
low	O
-	O
fat	O
dairy	O
,	O
juices	O
,	O
olive	O
oil	O
,	O
and	O
water	O
were	O
related	O
to	O
reductions	O
in	O
weight	O
gain	O
,	O
systolic	O
blood	O
pressure	O
,	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
-	O
cholesterol	O
and	O
cholesterol	O
(	O
total	O
and	O
HDL	O
)	O
levels	O
,	O
in	O
that	O
order	O
.	O
Over	O
the	O
time	O
periods	O
we	O
observed	O
only	O
a	O
slight	O
decrease	O
of	O
adherence	O
to	O
the	O
Meddietscore	O
.	O
The	O
correlations	O
of	O
the	O
healthy	O
diet	O
indices	O
with	O
food	O
groups	O
revealed	O
some	O
differences	O
among	O
the	O
indices	O
,	O
mostly	O
regarding	O
the	O
intake	O
of	O
fruit	O
and	O
vegetables	O
.	O
Conclusions	O
:	O
The	O
dietary	O
pattern	O
of	O
Apulia	O
is	O
in	O
line	O
with	O
many	O
principles	O
of	O
a	O
healthy	O
diet	O
and	O
the	O
cohort	B-methodology
population	I-methodology
seems	O
to	O
be	O
less	O
liable	O
to	O
undergo	O
a	O
transition	O
to	O
a	O
westernized	O
diet	O
.	O
There	O
is	O
still	O
great	O
interest	O
in	O
the	O
diet	O
practiced	O
around	O
the	O
Mediterranean	O
Sea	O
due	O
to	O
the	O
observation	O
of	O
low	O
disease	O
incidences	O
compared	O
to	O
Northern	O
European	O
countries	O
.	O

A	O
broad	O
search	O
for	O
common	O
dietary	O
practices	O
in	O
this	O
region	O
of	O
the	O
world	O
identified	O
a	O
relatively	O
high	O
proportion	O
of	O
energy	O
gained	O
from	O
cereals	O
,	O
vegetables	O
,	O
and	O
fruits	O
,	O
relatively	O
less	O
meat	O
consumption	O
,	O
and	O
a	O
greater	O
reliance	O
on	O
vegetables	O
than	O
on	O
animal	O
fats	O
compared	O
to	O
Northern	O
Europe	O
[	O
1	O
]	O
.	O
These	O
foods	O
were	O
recently	O
highlighted	O
by	O
the	O
Global	O
Burden	O
of	O
Disease	O
study	O
on	O
diet	O
,	O
which	O
found	O
that	O
dietary	O
factors	O
have	O
a	O
high	O
impact	O
on	O
disability	O
-	O
adjusted	O
life	O
years	O
(	O
DALYs	O
)	O
[	O
2	O
]	O
.	O
However	O
,	O
the	O
amounts	O
and	O
combinations	O
of	O
those	O
foods	O
either	O
promoting	O
or	O
delaying	O
the	O
occurrence	O
of	O
diseases	O
could	O
vary	O
between	O
countries	O
and	O
within	O
countries	O
between	O
regions	O
.	O
Such	O
regional	O
variations	O
within	O
a	O
country	O
were	O
already	O
well	O
documented	O
in	O
The	O
Seven	O
Countries	O
Study	O
from	O
the	O
1960s	O
[	O
3	O
]	O
,	O
taking	O
Italy	O
as	O
example	O
[	O
4	O
]	O
.	O
In	O
that	O
example	O
,	O
diet	O
varied	O
manifold	O
in	O
key	O
food	O
components	O
such	O
as	O
milk	O
and	O
cheese	O
,	O
vegetables	O
,	O
fruits	O
,	O
meat	O
,	O
egg	O
and	O
fish	O
,	O
and	O
even	O
sugar	O
and	O
sweets	O
taking	O
three	O
“	O
Seven	O
Countries	O
Study	O
”	O
areas	O
from	O
North	O
to	O
South	O
.	O
Such	O
regional	O
dietary	O
habits	O
have	O
prevailed	O
up	O
to	O
now	O
and	O
even	O
today	O
understanding	O
the	O
preventive	O
principles	O
associated	O
with	O
regional	O
dietary	O
habits	O
is	O
still	O
a	O
challenge	O
.	O
In	O
this	O
spirit	O
,	O
the	O
publicly	O
funded	O
research	O
hospital	O
IRCCS	O
“	O
S	O
.	O
de	O
Bellis	O
”	O
,	O
located	O
in	O
Castellana	O
Grotte	O
(	O
Apulia	O
,	O
Italy	O
)	O
started	O
in	O
the	O
1980s	O
a	O
population	O
-	O
based	O
cohort	B-methodology
study	I-methodology
,	O
and	O
has	O
been	O
measuring	O
dietary	O
intake	O
in	O
this	O
Mediterranean	O
population	O
since	O
that	O
period	O
[	O
5	O
,	O
6	O
,	O
7	O
]	O
.	O
This	O
interest	O
has	O
recently	O
promoted	O
the	O
recruitment	O
of	O
a	O
new	O
cohort	B-methodology
in	O
order	O
to	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
aging	O
process	O
,	O
particularly	O
related	O
to	O
neurodegeneration	O
and	O
functional	O
decline	O
[	O
8	O
]	O
,	O
with	O
overlaps	O
with	O
the	O
previous	O
study	O
populations	O
.	O
This	O
was	O
seen	O
as	O
opportunity	O
to	O
study	O
diet	O
and	O
its	O
implication	O
not	O
only	O
cross	B-methodology
-	I-methodology
sectionally	I-methodology
but	O
also	O
longitudinally	O
[	O
7	O
]	O
.	O
The	O
aim	O
of	O
the	O
current	O
research	O
was	O
therefore	O
to	O
identify	O
the	O
existing	O
study	O
populations	O
with	O
their	O
overlaps	O
,	O
to	O
describe	O
and	O
analyze	O
the	O
dietary	O
intake	O
over	O
the	O
last	O
two	O
decades	O
,	O
and	O
to	O
link	O
dietary	O
intake	O
longitudinally	O
with	O
a	O
biomarker	O
profile	O
.	O

In	O
the	O
beginning	O
of	O
the	O
1980s	O
,	O
the	O
IRCCS	O
de	O
Bellis	O
participated	O
in	O
the	O
Multicenter	O
Italian	O
study	O
on	O
Cholelithiasis	O
(	O
MICOL	O
)	O
[	O
9	O
]	O
and	O
established	O
,	O
in	O
1985	O
for	O
this	O
purpose	O
,	O
a	O
cohort	B-methodology
study	I-methodology
in	O
Castellana	O
Grotte	O
,	O
Apulia	O
,	O
with	O
the	O
aim	O
of	O
prospectively	O
investigating	O
the	O
role	O
of	O
lifestyle	O
and	O
nutrition	O
in	O
gastrointestinal	O
and	O
other	O
chronic	O
diseases	O
,	O
among	O
them	O
cholelithiasis	O
and	O
other	O
gallbladder	O
diseases	O
.	O
Methodological	O
details	O
of	O
this	O
population	O
-	O
based	O
study	O
have	O
previously	O
been	O
published	O
[	O
6	O
,	O
10	O
]	O
.	O
In	O
brief	O
,	O
in	O
1985	O
a	O
random	O
sample	O
of	O
3500	O
subjects	O
(	O
2000	O
men	O
and	O
1500	O
women	O
)	O
aged	O
≥30	O
years	O
was	O
drawn	O
from	O
the	O
electoral	O
roll	O
of	O
Castellana	O
Grotte	O
(	O
17	O
,	O
334	O
residents	O
at	O
the	O
1981	O
Census	O
)	O
and	O
invited	O
to	O
take	O
part	O
in	O
the	O
study	O
.	O
Among	O
the	O
3500	O
invited	O
subjects	O
,	O
2472	O
(	O
1429	O
men	O
and	O
1043	O
women	O
)	O
agreed	O
(	O
70	O
.	O
6	O
%	O
response	O
rate	O
)	O
.	O
There	O
was	O
no	O
difference	O
in	O
age	O
,	O
sex	O
,	O
or	O
occupation	O
between	O
responders	O
and	O
non	O
-	O
responders	O
;	O
30	O
%	O
of	O
them	O
worked	O
in	O
the	O
agricultural	O
sector	O
.	O
The	O
cohort	B-methodology
was	O
examined	O
several	O
times	O
over	O
the	O
last	O
35	O
years	O
(	O
Figure	O
1	O
)	O
.	O
After	O
the	O
initial	O
examination	O
,	O
the	O
study	O
participants	O
were	O
re	O
-	O
invited	O
in	O
1992	O
–	O
1993	O
for	O
MICOL2	O
(	O
M2	O
;	O
2159	O
participants	O
)	O
,	O
and	O
in	O
2005	O
/	O
2006	O
for	O
MICOL3	O
(	O
MICOL3	O
;	O
1708	O
participants	O
)	O
.	O
M1	O
included	O
questions	O
on	O
the	O
frequency	O
of	O
use	O
of	O
some	O
food	O
items	O
and	O
many	O
other	O
questions	O
on	O
lifestyle	O
habits	O
,	O
M2	O
only	O
some	O
questions	O
on	O
culinary	O
use	O
in	O
addition	O
to	O
the	O
lifestyle	O
questions	O
,	O
and	O
MICOL3	O
included	O
a	O
full	O
dietary	O
assessment	O
(	O
see	O
below	O
in	O
2012	O
,	O
were	O
identified	O
as	O
candidates	O
for	O
a	O
larger	O
population	O
-	O
based	O
study	O
conducted	O
in	O
the	O
same	O
community	O
,	O
the	O
“	O
GreatAGE	O
”	O
Study	O
.	O
The	O
“	O
GreatAGE	O
”	O
Study	O
is	O
an	O
ongoing	O
population	O
-	O
based	O
cohort	B-methodology
focusing	O
,	O
among	O
other	O
aspects	O
,	O
on	O
nutrition	O
,	O
and	O
age	O
-	O
related	O
sensory	O
impairments	O
,	O
frailty	O
,	O
neurodegenerative	O
,	O
and	O
psychiatric	O
diseases	O
in	O
the	O
elderly	O
[	O
11	O
]	O
.	O
In	O
2015	O
,	O
the	O
“	O
GreatAGE	O
”	O
Study	O
was	O
started	O
with	O
an	O
invitation	O
to	O
the	O
previously	O
representative	O
M3	O
participants	O
,	O
and	O
in	O
2016	O
,	O
it	O
became	O
possible	O
to	O
extend	O
the	O
invitation	O
to	O
the	O
whole	O
65	O
+	O
population	O
.	O

The	O
final	O
study	O
population	O
included	O
2522	O
subjects	O
from	O
the	O
4537	O
originally	O
invited	O
.	O
The	O
recruitment	O
of	O
this	O
study	O
ended	O
in	O
2018	O
.	O
All	O
the	O
participants	O
signed	O
an	O
informed	O
consent	O
document	O
,	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
of	O
the	O
National	O
Institute	O
of	O
Gastroenterology	O
and	O
Research	O
Hospital	O
.	O
For	O
this	O
investigation	O
,	O
we	O
concentrated	O
on	O
the	O
M3	O
and	O
“	O
GreatAGE	O
”	O
Study	O
populations	O
with	O
full	O
dietary	O
assessments	O
.	O
We	O
subdivided	O
the	O
M3	O
study	O
population	O
of	O
2005	O
/	O
2006	O
into	O
those	O
who	O
joined	O
the	O
“	O
GreatAGE	O
”	O
Study	O
years	O
later	O
and	O
those	O
who	O
did	O
not	O
or	O
could	O
not	O
join	O
the	O
“	O
GreatAGE	O
”	O
Study	O
,	O
mostly	O
due	O
to	O
age	O
,	O
death	O
,	O
or	O
no	O
interest	O
.	O
We	O
also	O
subdivided	O
the	O
“	O
GreatAGE	O
”	O
Study	O
population	O
of	O
2014	O
/	O
2018	O
into	O
those	O
who	O
had	O
already	O
participated	O
in	O
the	O
M3	O
examination	O
and	O
those	O
who	O
were	O
newly	O
recruited	O
.	O
By	O
subdividing	O
the	O
study	O
population	O
,	O
it	O
was	O
possible	O
to	O
establish	O
a	O
subset	O
of	O
study	O
participants	O
that	O
was	O
examined	O
twice	O
over	O
time	O
and	O
,	O
therefore	O
,	O
could	O
be	O
longitudinally	O
compared	O
(	O
Figure	O
1	O
)	O
.	O
The	O
other	O
study	O
participants	O
at	O
each	O
point	O
in	O
time	O
served	O
as	O
direct	O
comparison	O
groups	O
to	O
the	O
study	O
population	O
examined	O
twice	O
.	O
Education	O
was	O
assessed	O
by	O
a	O
variable	O
having	O
three	O
categories	O
(	O
low	O
,	O
medium	O
,	O
high	O
)	O
.	O
Unfortunately	O
,	O
the	O
variable	O
education	O
had	O
to	O
be	O
constructed	O
differently	O
at	O
each	O
time	O
period	O
of	O
examination	O
.	O
In	O
the	O
MICOL	O
studies	O
,	O
educational	O
level	O
attained	O
was	O
requested	O
in	O
3	O
categories	O
(	O
Primary	O
school	O
,	O
secondary	O
school	O
,	O
under	O
-	O
graduate	O
and	O
graduate	O
studies	O
)	O
.	O
The	O
categories	O
were	O
directly	O
taken	O
and	O
labeled	O
as	O
low	O
,	O
medium	O
,	O
and	O
high	O
education	O
.	O
In	O
the	O
“	O
GreatAGE	O
”	O
Study	O
,	O
the	O
total	O
number	O
of	O
years	O
of	O
schooling	O
(	O
from	O
0	O
to	O
18	O
)	O
was	O
asked	O
.	O
For	O
this	O
study	O
,	O
the	O
latter	O
was	O
cut	O
in	O
3	O
categories	O
(	O
<	O
5	O
years	O
,	O
5	O
–	O
13	O
,	O
>	O
13	O
)	O
that	O
were	O
also	O
labeled	O
as	O
low	O
,	O
medium	O
,	O
and	O
high	O
education	O
.	O
A	O
sphygmomanometer	O
(	O
YTON	O
)	O
and	O
a	O
stethoscope	O
(	O
FARMAC	O
-	O
ZARBAN	O
)	O
were	O
used	O
to	O
measure	O
blood	O
pressure	O
,	O
undertaken	O
by	O
professional	O
nurses	O
with	O
a	O
professional	O
qualification	O
in	O
Italy	O
.	O
Blood	O
pressure	O
was	O
determined	O
in	O
a	O
sitting	O
position	O
after	O
rest	O
.	O
The	O
final	O
values	O
of	O
blood	O
pressure	O
(	O
systolic	O
as	O
well	O
as	O
diastolic	O
blood	O
pressure	O
(	O
SBP	O
,	O
DBP	O
)	O
)	O
were	O
the	O
mean	O
of	O
the	O
last	O
two	O
of	O
three	O
measurements	O
.	O
Height	O
and	O
weight	O
measurements	O
were	O
performed	O
using	O
a	O
Seca	O
220	O
altimeter	O
and	O
a	O
Seca	O
711	O
scale	O
.	O

Blood	O
was	O
collected	O
from	O
the	O
subjects	O
in	O
the	O
morning	O
after	O
an	O
overnight	O
fast	O
and	O
,	O
among	O
other	O
parameters	O
,	O
fasting	O
glucose	O
(	O
GLY	O
)	O
,	O
total	O
cholesterol	O
(	O
TChol	O
)	O
,	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	O
and	O
triglycerides	O
(	O
TG	O
)	O
were	O
measured	O
,	O
using	O
standard	O
automated	O
enzymatic	O
colorimetric	O
methods	O
(	O
AutoMate	O
2550	O
,	O
Beckmann	O
Coulter	O
,	O
Brea	O
,	O
Ca	O
,	O
US	O
)	O
,	O
under	O
strict	O
quality	B-methodology
control	I-methodology
.	O
The	O
prevalence	O
of	O
diabetes	O
was	O
calculated	O
on	O
the	O
basis	O
of	O
a	O
diagnosis	O
of	O
diabetes	O
given	O
at	O
the	O
interview	O
,	O
the	O
use	O
of	O
antidiabetic	O
medications	O
,	O
and	O
fasting	O
blood	O
glucose	O
above	O
126	O
(	O
mg	O
/	O
dL	O
)	O
.	O
During	O
the	O
early	O
1990s	O
,	O
a	O
better	O
assessment	O
of	O
diet	O
was	O
needed	O
because	O
the	O
1985	O
29	O
ad	O
hoc	O
questions	O
provided	O
by	O
the	O
MICOL	O
group	O
on	O
4	O
categories	O
of	O
frequency	O
of	O
intake	O
of	O
specific	O
foods	O
and	O
the	O
use	O
of	O
olive	O
oil	O
and	O
wine	O
[	O
6	O
]	O
were	O
considered	O
too	O
broad	O
.	O
Therefore	O
,	O
the	O
semi	O
-	O
quantitative	O
approach	O
of	O
that	O
time	O
was	O
followed	O
,	O
and	O
a	O
new	O
questionnaire	O
was	O
developed	O
based	O
on	O
foods	O
eaten	O
by	O
the	O
population	O
.	O
For	O
these	O
foods	O
the	O
frequency	O
of	O
intake	O
of	O
a	O
predefined	O
portion	O
over	O
the	O
last	O
year	O
was	O
probed	O
in	O
the	O
questionnaire	O
via	O
a	O
scale	O
of	O
9	O
categories	O
.	O
Each	O
portion	O
was	O
given	O
a	O
weight	O
and	O
thus	O
the	O
quantity	O
of	O
intake	O
was	O
calculated	O
,	O
expressed	O
as	O
mean	O
intake	O
in	O
g	O
per	O
day	O
.	O
The	O
FFQ	O
(	O
Food	O
Frequency	O
Questionnaire	O
)	O
was	O
structured	O
in	O
11	O
sections	O
that	O
partly	O
mirror	O
the	O
sequence	O
of	O
foods	O
during	O
the	O
day	O
and	O
include	O
foods	O
of	O
similar	O
characteristics	O
:	O
grains	O
,	O
meat	O
,	O
fish	O
,	O
milk	O
and	O
dairy	O
products	O
,	O
vegetables	O
,	O
legumes	O
,	O
fruits	O
,	O
miscellaneous	O
foods	O
,	O
water	O
and	O
alcoholic	O
beverages	O
,	O
olive	O
oil	O
and	O
other	O
edible	O
fats	O
,	O
coffee	O
/	O
sugar	O
and	O
salt	O
.	O
In	O
a	O
further	O
step	O
,	O
the	O
FFQ	O
was	O
validated	O
against	O
dietary	O
records	O
and	O
the	O
results	O
were	O
reviewed	O
to	O
make	O
any	O
necessary	O
modification	O
of	O
the	O
questionnaire	O
[	O
12	O
]	O
.	O
In	O
the	O
final	O
questionnaire	O
,	O
85	O
food	O
items	O
were	O
considered	O
to	O
best	O
reflect	O
the	O
regional	O
diet	O
,	O
together	O
with	O
some	O
questions	O
about	O
the	O
use	O
of	O
edible	O
fats	O
.	O
The	O
latter	O
were	O
not	O
quantified	O
,	O
but	O
summarized	O
in	O
a	O
separate	O
food	O
group	O
(	O
19	O
cooking	O
edible	O
fats	O
)	O
.	O
The	O
original	O
FFQ	O
has	O
been	O
included	O
into	O
the	O
section	O
of	O
supplementary	O
material	O
.	O

The	O
85	O
food	O
items	O
of	O
the	O
FFQ	O
and	O
the	O
questions	O
about	O
the	O
use	O
of	O
fat	O
were	O
regrouped	O
and	O
shortened	O
by	O
number	O
and	O
also	O
made	O
concordant	O
with	O
a	O
publication	O
representing	O
a	O
Spanish	O
(	O
Mediterranean	O
)	O
diet	O
(	O
Appendix	O
A	O
(	O
Table	O
A1	O
)	O
)	O
.	O
The	O
publication	O
describing	O
the	O
Spanish	O
study	O
population	O
(	O
controls	O
from	O
a	O
nationwide	O
case	B-methodology
-	I-methodology
control	I-methodology
study	I-methodology
on	O
breast	O
cancer	O
)	O
included	O
26	O
food	O
groups	O
from	O
an	O
original	O
group	O
of	O
117	O
food	O
items	O
[	O
13	O
]	O
.	O
For	O
our	O
FFQ	O
questionnaire	O
,	O
we	O
established	O
29	O
food	O
groups	O
of	O
foods	O
of	O
similar	O
type	O
(	O
Appendix	O
A	O
(	O
Table	O
A1	O
)	O
)	O
;	O
24	O
of	O
them	O
were	O
identical	O
to	O
those	O
in	O
the	O
Spanish	O
publication	O
.	O
One	O
food	O
group	O
(	O
19	O
cooking	O
edible	O
fats	O
)	O
could	O
not	O
be	O
quantified	O
and	O
was	O
not	O
used	O
in	O
this	O
study	O
;	O
these	O
foods	O
did	O
not	O
contribute	O
to	O
nutrient	O
intake	O
.	O
The	O
establishment	O
of	O
28	O
food	O
groups	O
(	O
29	O
minu	O
the	O
1	O
non−quantified	O
food	O
group	O
)	O
was	O
also	O
undertaken	O
to	O
facilitate	O
analyses	O
with	O
less	O
variables	O
for	O
statistical	O
modelling	O
and	O
to	O
allow	O
direct	O
comparisons	O
with	O
other	O
studies	O
from	O
the	O
Mediterranean	O
area	O
.	O
For	O
the	O
study	O
,	O
we	O
selected	O
three	O
commonly	O
used	O
healthy	O
diet	O
indices	O
,	O
the	O
DASH	O
(	O
dietary	O
approaches	O
to	O
stop	O
hypertension	O
)	O
diet	O
index	O
,	O
the	O
Meddietscore	O
,	O
and	O
the	O
MIND	O
(	O
Mediterranean	O
-	O
DASH	O
intervention	O
for	O
neurodegenerative	O
delay	O
)	O
diet	O
index	O
[	O
14	O
]	O
.	O
All	O
indices	O
had	O
been	O
previously	O
shown	O
to	O
be	O
related	O
to	O
a	O
reduced	O
disease	O
risk	O
,	O
focusing	O
on	O
different	O
aspects	O
of	O
the	O
disease	O
spectrum	O
.	O
The	O
final	O
scoring	O
for	O
each	O
index	O
had	O
to	O
be	O
partly	O
adapted	O
to	O
the	O
available	O
data	O
regarding	O
foods	O
,	O
and	O
for	O
the	O
binary	O
score	O
(	O
0	O
or	O
1	O
)	O
,	O
values	O
the	O
median	O
intake	O
of	O
each	O
food	O
in	O
the	O
total	O
group	O
was	O
used	O
.	O
The	O
scoring	O
algorithms	O
are	O
shown	O
in	O
Table	O
1	O
and	O
the	O
relation	O
of	O
the	O
scored	O
foods	O
to	O
the	O
original	O
foods	O
in	O
the	O
questionnaire	O
is	O
shown	O
in	O
Appendix	O
A	O
(	O
Table	O
A2	O
)	O
.	O
The	O
DASH	O
diet	O
index	O
goes	O
back	O
to	O
a	O
successful	O
intervention	B-methodology
study	I-methodology
that	O
reduced	O
hypertension	O
[	O
15	O
,	O
16	O
]	O
.	O
The	O
DASH	O
diet	O
approach	O
was	O
composed	O
of	O
an	O
increased	O
consumption	O
of	O
fruits	O
,	O
vegetables	O
,	O
low	O
-	O
fat	O
dairy	O
,	O
whole	O
grains	O
,	O
poultry	O
,	O
fish	O
,	O
and	O
nuts	O
while	O
limiting	O
the	O
intake	O
of	O
red	O
and	O
processed	O
meat	O
and	O
added	O
sugars	O
.	O
The	O
original	O
DASH	O
diet	O
was	O
relatively	O
low	O
in	O
total	O
fat	O
,	O
saturated	O
fat	O
,	O
and	O
sodium	O
[	O
15	O
]	O
.	O

The	O
scoring	O
of	O
the	O
DASH	O
diet	O
index	O
in	O
our	O
study	O
was	O
based	O
on	O
7	O
food	O
groups	O
and	O
3	O
dietary	O
components	O
(	O
total	O
fat	O
,	O
saturated	O
fat	O
and	O
sodium	O
)	O
.	O
The	O
DASH	O
diet	O
index	O
for	O
each	O
subject	O
could	O
theoretically	O
range	O
from	O
0	O
(	O
lowest	O
)	O
to	O
10	O
(	O
highest	O
concordance	O
)	O
(	O
Table	O
1	O
)	O
.	O
The	O
concordance	O
with	O
the	O
Mediterranean	O
diet	O
was	O
not	O
scored	O
according	O
to	O
the	O
Mediterranean	O
Diet	O
Index	O
established	O
by	O
Trichopoulou	O
et	O
al	O
.	O
[	O
17	O
]	O
but	O
according	O
to	O
the	O
algorithm	O
of	O
the	O
Meddietscore	O
based	O
on	O
the	O
Greek	O
Mediterranean	O
diet	O
pyramid	O
with	O
its	O
food	O
groups	O
,	O
featuring	O
less	O
meat	O
and	O
more	O
carbohydrate	O
-	O
rich	O
foods	O
[	O
18	O
]	O
.	O
The	O
complex	O
scoring	O
with	O
up	O
to	O
5	O
points	O
proposed	O
by	O
this	O
group	O
was	O
not	O
followed	O
but	O
was	O
simplified	O
to	O
a	O
binary	O
score	O
of	O
0	O
and	O
1	O
depending	O
on	O
the	O
quantity	O
of	O
intake	O
(	O
Table	O
1	O
)	O
.	O
The	O
Meddietscore	O
in	O
this	O
study	O
included	O
11	O
dietary	O
components	O
,	O
each	O
scored	O
either	O
as	O
0	O
or	O
1	O
,	O
yielding	O
a	O
score	O
of	O
maximum	O
11	O
points	O
.	O
Details	O
of	O
the	O
dietary	O
components	O
are	O
shown	O
in	O
Table	O
1	O
and	O
the	O
concordance	O
between	O
the	O
original	O
foods	O
and	O
the	O
Med	O
diet	O
components	O
can	O
be	O
found	O
in	O
additional	O
file	O
1	O
(	O
Table	O
A2	O
)	O
.	O
The	O
MIND	O
diet	O
index	O
by	O
Morris	O
et	O
al	O
.	O
[	O
14	O
]	O
is	O
associated	O
with	O
a	O
reduction	O
in	O
cognitive	O
decline	O
.	O
The	O
MIND	O
diet	O
index	O
includes	O
15	O
dietary	O
components	O
,	O
composed	O
of	O
10	O
brain	O
-	O
healthy	O
food	O
groups	O
(	O
green	O
leafy	O
vegetables	O
,	O
other	O
vegetables	O
,	O
nuts	O
,	O
berries	O
,	O
beans	O
,	O
whole	O
grains	O
,	O
fish	O
,	O
poultry	O
,	O
olive	O
oil	O
and	O
wine	O
)	O
and	O
5	O
brain	O
-	O
unhealthy	O
food	O
groups	O
(	O
red	O
meats	O
,	O
butter	O
and	O
margarine	O
,	O
cheese	O
,	O
pastries	O
and	O
sweets	O
,	O
and	O
fried	O
/	O
fast	O
food	O
)	O
.	O
For	O
the	O
diet	O
score	O
components	O
of	O
the	O
MIND	O
diet	O
index	O
,	O
we	O
assigned	O
either	O
a	O
score	O
value	O
of	O
0	O
or	O
1	O
according	O
to	O
the	O
median	O
intake	O
(	O
Table	O
1	O
)	O
.	O
The	O
MIND	O
diet	O
score	O
ranged	O
between	O
0	O
and	O
15	O
(	O
Table	O
1	O
)	O
and	O
the	O
concordance	O
between	O
the	O
original	O
foods	O
in	O
the	O
questionnaire	O
and	O
the	O
Mind	O
-	O
diet	O
components	O
can	O
be	O
found	O
in	O
additional	O
file	O
1	O
(	O
Table	O
A2	O
)	O
.	O
Data	O
were	O
reported	O
as	O
means	O
±	O
standard	O
deviations	O
(	O
X	O
±	O
SD	O
)	O
for	O
continuous	O
measures	O
,	O
and	O
frequency	O
and	O
percentages	O
(	O
%	O
)	O
for	O
all	O
categorical	O
variables	O
,	O
separated	O
according	O
to	O
the	O
study	O
populations	O
(	O
Table	O
2	O
)	O
.	O

For	O
Table	O
3	O
,	O
food	O
intake	O
(	O
g	O
/	O
day	O
)	O
of	O
each	O
study	O
population	O
was	O
standardized	O
to	O
an	O
energy	O
intake	O
of	O
2000	O
Kcal	O
/	O
day	O
for	O
description	O
and	O
comparison	O
purposes	O
.	O
The	O
standardization	O
was	O
done	O
by	O
dividing	O
the	O
total	O
daily	O
individual	O
food	O
quantity	O
in	O
grams	O
/	O
day	O
by	O
Kcal	O
/	O
day	O
,	O
and	O
then	O
multiplying	O
with	O
2000	O
.	O
The	O
relation	O
between	O
food	O
group	O
intake	O
and	O
health	O
indicators	O
was	O
evaluated	O
prospectively	O
.	O
The	O
food	O
group	O
intake	O
at	O
MICOL3	O
was	O
regressed	O
to	O
health	O
indicators	O
at	O
“	O
GreatAGE	O
”	O
(	O
n	O
=	O
734	O
)	O
.	O
For	O
this	O
analysis	O
,	O
specific	O
subgroups	O
were	O
formed	O
,	O
free	O
of	O
impaired	O
health	O
indicators	O
at	O
the	O
MICOL3	O
examination	O
(	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
:	O
subjects	O
with	O
a	O
BMI	O
gain	O
higher	O
than	O
1	O
.	O
5	O
(	O
n	O
=	O
605	O
remained	O
)	O
;	O
SBP	O
:	O
No	O
increased	O
systolic	O
blood	O
pressure	O
(	O
n	O
=	O
373	O
remained	O
)	O
;	O
DBP	O
:	O
No	O
increased	O
diastolic	O
blood	O
pressure	O
(	O
n	O
=	O
373	O
remained	O
)	O
;	O
GLYCEMIA	O
:	O
subjects	O
with	O
a	O
fasting	O
blood	O
glucose	O
above	O
126	O
mg	O
/	O
dL	O
,	O
without	O
a	O
diagnosis	O
of	O
diabetes	O
and	O
use	O
of	O
diabetes	O
medications	O
(	O
n	O
=	O
592	O
remained	O
)	O
;	O
TChol	O
,	O
HDL	O
:	O
subjects	O
without	O
hypercholesterolemia	O
(	O
<	O
200	O
mg	O
)	O
and	O
use	O
of	O
statins	O
(	O
n	O
=	O
310	O
remained	O
)	O
;	O
TG	O
:	O
subjects	O
without	O
hypertriglyceridemia	O
(	O
150	O
mg	O
)	O
and	O
use	O
of	O
statins	O
(	O
n	O
=	O
458	O
remained	O
)	O
.	O
The	O
final	O
numbers	O
were	O
further	O
reduced	O
due	O
to	O
missing	O
information	O
in	O
the	O
covariates	O
(	O
see	O
Table	O
4	O
)	O
)	O
.	O
The	O
prospective	O
relation	O
was	O
investigated	O
via	O
a	O
regression	O
model	O
that	O
included	O
covariates	O
(	O
see	O
legend	O
Table	O
4	O
)	O
.	O
It	O
should	O
be	O
noted	O
that	O
the	O
regression	O
analyses	O
were	O
run	O
with	O
models	O
either	O
including	O
or	O
excluding	O
the	O
other	O
food	O
groups	O
.	O
The	O
fat	O
to	O
carbohydrate	O
ratio	O
included	O
,	O
as	O
the	O
fat	O
component	O
,	O
the	O
intake	O
of	O
lipids	O
taken	O
from	O
the	O
nutrient	O
table	O
and	O
,	O
as	O
the	O
carbohydrate	O
component	O
.	O
A	O
p	O
value	O
<	O
0	O
.	O
05	O
was	O
considered	O
as	O
significant	O
.	O
The	O
characteristics	O
of	O
the	O
study	O
populations	O
are	O
shown	O
in	O
Table	O
2	O
.	O
In	O
2005	O
/	O
2006	O
the	O
MICOL3	O
participants	O
were	O
about	O
65	O
years	O
old	O
,	O
with	O
a	O
slightly	O
smaller	O
percentage	O
of	O
women	O
than	O
men	O
.	O
There	O
were	O
no	O
particular	O
differences	O
between	O
the	O
two	O
study	O
populations	O
of	O
the	O
MICOL3	O
examination	O
in	O
2005	O
/	O
2006	O
.	O

Likewise	O
,	O
the	O
two	O
“	O
GreatAGE	O
”	O
-	O
Study	O
populations	O
,	O
which	O
were	O
aged	O
73	O
.	O
5	O
years	O
on	O
average	O
at	O
study	O
examination	O
in	O
2012	O
/	O
2018	O
,	O
did	O
not	O
show	O
particular	O
differences	O
in	O
regard	O
to	O
anthropometry	O
,	O
and	O
other	O
health	O
indicators	O
.	O
When	O
comparing	O
the	O
two	O
time	O
periods	O
of	O
examination	O
(	O
2005	O
/	O
2006	O
vs	O
.	O
2012	O
/	O
2018	O
)	O
,	O
not	O
much	O
change	O
could	O
be	O
observed	O
.	O
The	O
difference	O
over	O
time	O
seen	O
in	O
the	O
education	O
variable	O
based	O
on	O
methodological	O
differences	O
(	O
see	O
method	O
section	O
)	O
.	O
Of	O
particular	O
interest	O
is	O
the	O
lack	O
of	O
an	O
overall	O
decrease	O
in	O
health	O
conditions	O
referred	O
to	O
the	O
MICOL3	O
/	O
GreatAGE	O
study	O
population	O
as	O
well	O
as	O
the	O
other	O
population	O
groups	O
which	O
served	O
as	O
control	O
samples	O
,	O
not	O
being	O
affected	O
by	O
repeated	O
study	O
participation	O
.	O
Weight	O
gain	O
and	O
a	O
substantial	O
increase	O
in	O
blood	O
pressure	O
did	O
not	O
occur	O
within	O
the	O
time	O
period	O
and	O
indeed	O
,	O
as	O
regards	O
the	O
clinical	O
chemical	O
health	O
indicators	O
,	O
some	O
improvements	O
could	O
actually	O
be	O
observed	O
.	O
This	O
was	O
true	O
in	O
particular	O
of	O
cholesterol	O
in	O
blood	O
.	O
There	O
was	O
also	O
a	O
remarkable	O
stability	O
of	O
energy	O
intake	O
among	O
the	O
study	O
populations	O
and	O
over	O
time	O
,	O
allowing	O
a	O
combined	O
dietary	O
analysis	O
across	O
all	O
study	O
populations	O
.	O
Of	O
importance	O
in	O
the	O
long	O
run	O
could	O
be	O
the	O
observation	O
of	O
an	O
increased	O
fat	O
component	O
compared	O
to	O
the	O
carbohydrate	O
component	O
observable	O
in	O
the	O
fat	O
/	O
carbohydrate	O
ratio	O
,	O
which	O
rose	O
from	O
0	O
.	O
18	O
to	O
0	O
.	O
22	O
.	O
The	O
dietary	O
data	O
,	O
standardized	O
to	O
2000	O
kcal	O
,	O
also	O
showed	O
stability	O
regarding	O
the	O
intake	O
of	O
specific	O
foods	O
such	O
as	O
fruits	O
,	O
and	O
other	O
important	O
foods	O
characterizing	O
the	O
Mediterranean	O
diet	O
(	O
Table	O
3	O
)	O
.	O
Over	O
the	O
two	O
time	O
periods	O
,	O
the	O
mean	O
intake	O
of	O
root	O
and	O
other	O
vegetables	O
increased	O
,	O
as	O
well	O
as	O
of	O
olive	O
oil	O
,	O
and	O
water	O
when	O
taking	O
the	O
mean	O
intake	O
measurements	O
of	O
all	O
4	O
study	B-methodology
groups	I-methodology
and	O
allowing	O
a	O
minimal	O
difference	O
of	O
3	O
g	O
/	O
day	O
between	O
the	O
groups	O
at	O
each	O
point	O
in	O
time	O
(	O
Table	O
3	O
)	O
.	O
Likewise	O
,	O
the	O
intake	O
of	O
grains	O
(	O
pasta	O
and	O
bread	O
)	O
and	O
beer	O
decreased	O
.	O
Red	O
meat	O
was	O
partly	O
replaced	O
by	O
white	O
meat	O
.	O
Next	O
,	O
the	O
role	O
of	O
food	O
intake	O
per	O
health	O
indicators	O
,	O
as	O
shown	O
in	O
Table	O
1	O
,	O
was	O
prospectively	O
investigated	O
.	O
The	O
intake	O
of	O
the	O
29	O
food	O
groups	O
in	O
2005	O
/	O
2006	O
was	O
examined	O
in	O
relation	O
to	O
the	O
health	O
indicators	O
in	O
2012	O
/	O
2018	O
by	O
forming	O
subgroups	O
without	O
impaired	O
health	O
indicators	O
at	O
the	O
2005	O
/	O
2006	O
examination	O
(	O
see	O
method	O
section	O
)	O
.	O
In	O
Table	O
4	O
,	O
the	O
results	O
from	O
the	O
regression	O
models	O
are	O
shown	O
as	O
p	O
-	O
values	O
and	O
the	O
direction	O
of	O
relations	O
.	O

BMI	O
gain	O
(	O
>	O
1	O
.	O
5	O
units	O
)	O
between	O
the	O
two	O
time	O
periods	O
and	O
the	O
values	O
of	O
SBP	O
,	O
DBP	O
,	O
GLY	O
,	O
total	O
and	O
HDL	O
cholesterol	O
,	O
and	O
TG	O
in	O
2012	O
/	O
2018	O
were	O
investigated	O
for	O
their	O
relation	O
with	O
food	O
group	O
intake	O
in	O
2005	O
/	O
2006	O
by	O
calculating	O
two	O
models	O
,	O
one	O
without	O
adjustment	O
for	O
other	O
food	O
groups	O
and	O
one	O
with	O
adjustment	O
for	O
all	O
other	O
food	O
groups	O
.	O
Overall	O
,	O
each	O
regression	O
model	O
with	O
a	O
biomarker	O
as	O
dependent	O
variable	O
at	O
the	O
second	O
examination	O
was	O
adjusted	O
for	O
gender	O
,	O
age	O
,	O
educational	O
score	O
,	O
smoking	O
,	O
BMI	O
,	O
and	O
value	O
of	O
the	O
dependent	O
variable	O
at	O
the	O
first	O
examination	O
,	O
and	O
medication	O
at	O
the	O
second	O
examination	O
(	O
for	O
details	O
of	O
the	O
models	O
see	O
legend	O
Table	O
4	O
)	O
.	O
Ideally	O
,	O
both	O
analyses	O
should	O
come	O
to	O
the	O
same	O
conclusion	O
,	O
which	O
was	O
primarily	O
the	O
case	O
for	O
the	O
many	O
non	O
-	O
significant	O
results	O
.	O
Significant	O
results	O
with	O
agreement	O
between	O
the	O
two	O
models	O
regarded	O
low	O
fat	O
dairy	O
and	O
reduced	O
weight	O
gain	O
,	O
juices	O
and	O
reduced	O
SBP	O
,	O
olive	O
oil	O
and	O
reduced	O
HDL	O
-	O
cholesterol	O
,	O
and	O
water	O
and	O
reduced	O
cholesterol	O
(	O
total	O
and	O
HDL	O
)	O
levels	O
.	O
Next	O
,	O
the	O
significant	O
results	O
without	O
adjustments	O
for	O
other	O
food	O
groups	O
which	O
lost	O
significance	O
after	O
adjustment	O
for	O
other	O
foods	O
are	O
described	O
.	O
We	O
found	O
an	O
inverse	O
relation	O
between	O
seafood	O
/	O
shellfish	O
and	O
total	O
cholesterol	O
and	O
a	O
positive	O
relation	O
between	O
sugary	O
foods	O
and	O
HDL	O
-	O
cholesterol	O
.	O
Finally	O
,	O
we	O
like	O
to	O
mention	O
the	O
relations	O
that	O
became	O
significant	O
after	O
adjustment	O
for	O
other	O
foods	O
.	O
For	O
most	O
health	O
indicators	O
,	O
one	O
or	O
two	O
food	O
groups	O
subsumed	O
all	O
the	O
variance	O
of	O
the	O
food	O
groups	O
and	O
became	O
significant	O
,	O
with	O
the	O
exception	O
of	O
the	O
health	O
indicator	O
DBP	O
.	O
We	O
found	O
a	O
direct	O
relation	O
between	O
leafy	O
vegetables	O
and	O
an	O
inverse	O
relation	O
between	O
other	O
vegetables	O
and	O
SBP	O
,	O
an	O
inverse	O
relation	O
of	O
the	O
same	O
food	O
group	O
with	O
glucose	O
,	O
a	O
direct	O
relation	O
between	O
sugar	O
and	O
an	O
inverse	O
relation	O
between	O
coffee	O
and	O
total	O
cholesterol	O
,	O
and	O
increased	O
triglycerides	O
with	O
eggs	O
and	O
red	O
meat	O
,	O
but	O
decreased	O
triglycerides	O
with	O
ready	O
-	O
to	O
-	O
eat	O
dishes	O
.	O
Next	O
,	O
we	O
investigated	O
the	O
healthy	O
diet	O
indices	O
.	O
The	O
indices	O
were	O
constructed	O
with	O
the	O
medians	O
for	O
the	O
total	O
group	O
,	O
allowing	O
analysis	O
of	O
changes	O
over	O
time	O
and	O
between	O
groups	O
.	O

The	O
DASH	O
diet	O
index	O
score	O
in	O
2005	O
/	O
2006	O
was	O
5	O
.	O
3	O
and	O
5	O
.	O
1	O
,	O
(	O
MICOL3	O
/	O
GreatAGE	O
and	O
MICOL3	O
only	O
)	O
and	O
in	O
2012	O
/	O
2018	O
it	O
was	O
5	O
.	O
1	O
and	O
4	O
.	O
9	O
(	O
MICOL3	O
/	O
GreatAGE	O
and	O
GreatAGE	O
only	O
)	O
;	O
the	O
Meddietscore	O
in	O
2005	O
/	O
2006	O
was	O
5	O
.	O
7	O
and	O
5	O
.	O
5	O
,	O
and	O
in	O
2012	O
/	O
2018	O
it	O
was	O
5	O
.	O
2	O
and	O
5	O
.	O
3	O
;	O
and	O
the	O
MIND	O
diet	O
index	O
in	O
2005	O
/	O
2006	O
was	O
7	O
.	O
4	O
and	O
6	O
.	O
8	O
,	O
and	O
in	O
2012	O
/	O
2018	O
it	O
was	O
6	O
.	O
7	O
and	O
6	O
.	O
6	O
,	O
taking	O
into	O
account	O
the	O
4	O
subgroups	O
.	O
Thus	O
,	O
we	O
could	O
observe	O
a	O
slightly	O
decreased	O
adherence	O
to	O
the	O
Meddietscore	O
between	O
the	O
two	O
time	O
periods	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
also	O
for	O
the	O
MIND	O
diet	O
index	O
.	O
None	O
of	O
the	O
indices	O
showed	O
a	O
significant	O
relation	O
to	O
the	O
health	O
indicators	O
(	O
data	O
not	O
shown	O
)	O
.	O
Finally	O
,	O
in	O
Figure	O
2	O
,	O
Figure	O
3	O
and	O
Figure	O
4	O
,	O
the	O
correlations	O
between	O
the	O
healthy	O
diet	O
indices	O
and	O
the	O
food	O
groups	O
are	O
shown	O
,	O
combined	O
across	O
all	O
the	O
study	O
populations	O
Overall	O
,	O
the	O
correlations	O
between	O
the	O
food	O
groups	O
and	O
the	O
indices	O
were	O
not	O
very	O
strong	O
,	O
but	O
often	O
several	O
food	O
groups	O
stood	O
out	O
.	O
Negative	O
correlations	O
did	O
not	O
reach	O
a	O
value	O
<	O
−0	O
.	O
2	O
.	O
It	O
must	O
be	O
noted	O
that	O
foods	O
could	O
be	O
correlated	O
with	O
the	O
indices	O
without	O
these	O
foods	O
necessarily	O
forming	O
the	O
index	O
.	O
For	O
the	O
DASH	O
-	O
diet	O
index	O
the	O
leading	O
positive	O
correlations	O
(	O
>	O
0	O
.	O
3	O
)	O
were	O
with	O
fruiting	O
vegetables	O
,	O
fruits	O
,	O
and	O
grains	O
.	O
For	O
the	O
Meddietscore	O
the	O
leading	O
positive	O
correlations	O
(	O
>	O
0	O
.	O
3	O
)	O
were	O
with	O
leafy	O
vegetables	O
,	O
fruiting	O
vegetables	O
,	O
other	O
vegetables	O
,	O
legumes	O
,	O
fruit	O
,	O
and	O
borderline	O
potatoes	O
.	O
For	O
the	O
MIND	O
diet	O
index	O
,	O
the	O
leading	O
positive	O
correlations	O
(	O
>	O
0	O
.	O
3	O
)	O
were	O
with	O
leafy	O
vegetables	O
,	O
fruiting	O
vegetables	O
,	O
other	O
vegetables	O
,	O
and	O
borderline	O
legumes	O
.	O
As	O
regards	O
beverages	O
,	O
only	O
the	O
positive	O
relation	O
between	O
wine	O
and	O
the	O
DASH	O
index	O
stood	O
out	O
,	O
whereas	O
the	O
other	O
two	O
indices	O
were	O
not	O
well	O
correlated	O
with	O
beverages	O
.	O
It	O
could	O
also	O
be	O
observed	O
that	O
the	O
diet	O
healthy	O
indices	O
scores	O
were	O
mostly	O
independent	O
of	O
the	O
intake	O
of	O
sweet	O
food	O
groups	O
.	O
In	O
terms	O
of	O
dairy	O
products	O
,	O
weak	O
correlations	O
were	O
found	O
,	O
with	O
the	O
exception	O
of	O
a	O
positive	O
relation	O
between	O
the	O
DASH	O
diet	O
index	O
and	O
low	O
fat	O
dairy	O
.	O

The	O
DASH	O
diet	O
index	O
also	O
differs	O
from	O
the	O
other	O
indices	O
in	O
terms	O
of	O
the	O
slight	O
negative	O
correlations	O
with	O
meat	O
food	O
groups	O
.	O
This	O
study	O
evaluated	O
the	O
dietary	O
intake	O
of	O
the	O
population	O
of	O
Castellana	O
Grotte	O
,	O
located	O
in	O
a	O
rural	O
area	O
in	O
Apulia	O
,	O
at	O
two	O
different	O
time	O
periods	O
and	O
related	O
the	O
dietary	O
intake	O
to	O
health	O
indicators	O
and	O
healthy	O
diet	O
indices	O
.	O
Within	O
the	O
observation	O
period	O
of	O
7	O
years	O
from	O
2005	O
/	O
2006	O
to	O
2012	O
/	O
2018	O
,	O
covering	O
the	O
lifetime	O
age	O
periods	O
between	O
65	O
to	O
73	O
years	O
on	O
average	O
,	O
the	O
source	O
population	O
studied	O
showed	O
a	O
remarkable	O
stability	O
in	O
terms	O
of	O
dietary	O
intake	O
of	O
the	O
29	O
food	O
groups	O
considered	O
,	O
and	O
in	O
terms	O
of	O
health	O
indicators	O
such	O
as	O
anthropometry	O
,	O
blood	O
pressure	O
and	O
clinical	O
biochemistry	O
.	O
Only	O
the	O
intake	O
of	O
bread	O
and	O
pasta	O
(	O
grains	O
)	O
was	O
partly	O
replaced	O
by	O
olive	O
oil	O
,	O
slightly	O
increasing	O
the	O
fat	O
-	O
to	O
-	O
carbohydrate	O
ratio	O
.	O
It	O
could	O
also	O
be	O
seen	O
that	O
dietary	O
intake	O
related	O
prospectively	O
to	O
health	O
indicators	O
,	O
such	O
as	O
olive	O
oil	O
that	O
was	O
inversely	O
correlated	O
to	O
HDL	O
-	O
cholesterol	O
.	O
Three	O
established	O
healthy	O
diet	O
indices	O
were	O
constructed	O
and	O
correlated	O
with	O
food	O
group	O
intake	O
,	O
showing	O
that	O
the	O
DASH	O
-	O
index	O
represents	O
particular	O
fruit	O
and	O
grain	O
intake	O
and	O
the	O
MIND	O
-	O
index	O
vegetable	O
intake	O
.	O
The	O
economy	O
of	O
Castellana	O
Grotte	O
and	O
the	O
surrounding	O
area	O
is	O
based	O
on	O
agricultural	O
production	O
,	O
mainly	O
olives	O
,	O
grapes	O
,	O
cherries	O
,	O
and	O
cattle	O
.	O
The	O
local	O
diet	O
makes	O
use	O
of	O
the	O
existing	O
agricultural	O
infrastructure	O
and	O
,	O
for	O
example	O
,	O
did	O
not	O
include	O
a	O
lot	O
of	O
fish	O
and	O
seafood	O
,	O
available	O
15	O
km	O
away	O
at	O
the	O
coastal	O
sites	O
around	O
Monopoli	O
.	O
The	O
local	O
production	O
of	O
most	O
of	O
the	O
food	O
products	O
eaten	O
,	O
in	O
addition	O
to	O
the	O
dietary	O
tradition	O
of	O
a	O
small	O
town	O
,	O
resulted	O
in	O
a	O
remarkable	O
stability	O
of	O
dietary	O
habits	O
,	O
characterized	O
by	O
high	O
intakes	O
of	O
vegetables	O
,	O
fruit	O
,	O
and	O
local	O
pasta	O
.	O
The	O
slightly	O
lower	O
energy	O
intake	O
of	O
the	O
older	O
subgroups	O
is	O
in	O
line	O
with	O
the	O
biologically	O
reduced	O
energy	O
requirement	O
due	O
to	O
the	O
reduced	O
physical	O
activity	O
and	O
muscle	O
mass	O
[	O
19	O
]	O
.	O
The	O
study	O
also	O
showed	O
that	O
the	O
population	O
with	O
repeated	O
examinations	O
in	O
the	O
study	O
did	O
not	O
differ	O
from	O
the	O
study	O
populations	O
only	O
invited	O
once	O
,	O
indicating	O
a	O
negligible	O
influence	O
of	O
a	O
healthy	O
participant	O
bias	O
in	O
terms	O
of	O
the	O
dietary	O
estimates	O
.	O
Whereas	O
vegetables	O
and	O
fruits	O
are	O
established	O
characteristics	O
of	O
the	O
Mediterranean	O
diet	O
,	O
the	O
Apulian	O
diet	O
differs	O
from	O
that	O
of	O
other	O
regions	O
around	O
the	O
Mediterranean	O
Sea	O
in	O
regard	O
to	O
the	O
type	O
of	O
grain	O
products	O
.	O

Local	O
grain	O
products	O
are	O
based	O
on	O
semolina	O
meal	O
,	O
which	O
is	O
richer	O
in	O
dietary	O
fiber	O
,	O
vitamins	O
of	O
the	O
B	O
-	O
complex	O
,	O
and	O
minerals	O
,	O
as	O
compared	O
to	O
the	O
flours	O
used	O
in	O
industrial	O
products	O
[	O
20	O
]	O
,	O
especially	O
if	O
a	O
brown	O
,	O
non	O
-	O
refined	O
version	O
of	O
Semolina	O
flour	O
has	O
been	O
used	O
.	O
A	O
typical	O
bread	O
is	O
called	O
“	O
Altamura	O
bread	O
”	O
,	O
first	O
made	O
in	O
Altamura	O
,	O
a	O
city	O
near	O
Bari	O
and	O
Castellana	O
.	O
It	O
is	O
obtained	O
from	O
milled	O
durum	O
wheat	O
semolina	O
from	O
the	O
Alta	O
Murgia	O
in	O
the	O
Province	O
of	O
Bari	O
,	O
produced	O
with	O
a	O
natural	O
sourdough	O
.	O
In	O
2003	O
,	O
“	O
Altamura	O
bread	O
”	O
was	O
recognized	O
as	O
DOP	O
(	O
Protected	O
Designation	O
of	O
Origin	O
)	O
by	O
the	O
European	O
Community	O
.	O
Semolina	O
meal	O
is	O
not	O
only	O
used	O
for	O
bread	O
produced	O
locally	O
by	O
small	O
enterprises	O
,	O
or	O
homemade	O
,	O
but	O
more	O
importantly	O
,	O
for	O
fresh	O
pasta	O
(	O
Orecchiette	O
)	O
,	O
which	O
constitutes	O
a	O
traditional	O
typical	O
food	O
product	O
accompanied	O
by	O
vegetable	O
consumption	O
.	O
There	O
is	O
continuous	O
debate	O
as	O
to	O
whether	O
local	O
dietary	O
habits	O
will	O
survive	O
the	O
next	O
decades	O
.	O
The	O
current	O
study	O
results	O
offer	O
a	O
more	O
positive	O
view	O
on	O
this	O
issue	O
.	O
We	O
show	O
that	O
this	O
elderly	O
population	O
has	O
followed	O
stable	O
dietary	O
habits	O
over	O
the	O
last	O
decade	O
.	O
Recently	O
,	O
it	O
was	O
stated	O
that	O
the	O
intake	O
of	O
cereals	O
(	O
including	O
pasta	O
,	O
bread	O
and	O
similar	O
)	O
,	O
whole	O
grain	O
bread	O
,	O
vegetables	O
,	O
legumes	O
and	O
fish	O
significantly	O
increased	O
between	O
1985	O
–	O
1986	O
and	O
2005	O
–	O
2006	O
in	O
this	O
study	O
population	O
,	O
whilst	O
the	O
consumption	O
of	O
fruits	O
,	O
meat	O
,	O
poultry	O
,	O
dairy	O
,	O
olive	O
oil	O
and	O
alcohol	O
significantly	O
decreased	O
[	O
6	O
]	O
.	O
The	O
most	O
dramatic	O
decrease	O
was	O
observed	O
for	O
olive	O
oil	O
,	O
that	O
declined	O
by	O
2	O
.	O
35	O
points	O
in	O
younger	O
people	O
and	O
by	O
0	O
.	O
89	O
in	O
older	O
age	O
groups	O
[	O
6	O
]	O
.	O
These	O
findings	O
between	O
1985	O
and	O
2005	O
/	O
2006	O
are	O
based	O
on	O
a	O
broader	O
type	O
of	O
dietary	O
assessment	O
[	O
7	O
]	O
.	O
Currently	O
,	O
these	O
trends	O
seem	O
to	O
be	O
partially	O
reversed	O
,	O
in	O
particular	O
in	O
regard	O
to	O
olive	O
oil	O
and	O
vegetables	O
.	O
However	O
,	O
our	O
study	O
did	O
not	O
address	O
a	O
younger	O
population	O
,	O
which	O
seems	O
to	O
be	O
more	O
sensitive	O
to	O
dietary	O
changes	O
,	O
as	O
the	O
study	O
by	O
Veronese	O
et	O
al	O
.	O
showed	O
.	O
The	O
decreased	O
intake	O
of	O
red	O
meat	O
is	O
in	O
line	O
with	O
the	O
regional	O
trends	O
of	O
consumption	O
,	O
using	O
data	O
from	O
the	O
National	O
Food	O
Consumption	O
Survey	O
from	O
2005	O
–	O
2006	O
[	O
21	O
]	O
.	O

Our	O
study	O
could	O
confirm	O
the	O
finding	O
by	O
Veronese	O
et	O
al	O
.	O
[	O
6	O
]	O
that	O
over	O
time	O
,	O
adherence	O
to	O
the	O
Mediterranean	O
diet	O
in	O
general	O
is	O
slightly	O
decreasing	O
.	O
However	O
,	O
in	O
terms	O
of	O
dietary	O
change	O
it	O
should	O
be	O
borne	O
in	O
mind	O
that	O
in	O
Southern	O
Italy	O
,	O
adherence	O
to	O
the	O
Mediterranean	O
Diet	O
also	O
depends	O
on	O
the	O
general	O
economic	O
situation	O
,	O
as	O
exemplified	O
by	O
the	O
2007	O
/	O
2010	O
crisis	O
[	O
22	O
]	O
.	O
The	O
stable	O
consumption	O
of	O
vegetables	O
and	O
fruit	O
could	O
be	O
one	O
of	O
the	O
reasons	O
why	O
the	O
study	O
populations	O
as	O
a	O
whole	O
did	O
not	O
show	O
increases	O
in	O
BMI	O
,	O
and	O
also	O
only	O
a	O
small	O
increase	O
in	O
blood	O
pressure	O
within	O
the	O
observation	O
period	O
,	O
despite	O
being	O
in	O
a	O
critical	O
age	O
class	O
for	O
the	O
deterioration	O
of	O
health	O
indicators	O
.	O
Of	O
further	O
note	O
is	O
the	O
slight	O
decrease	O
of	O
basic	O
clinical	O
chemistry	O
parameters	O
,	O
such	O
as	O
cholesterol	O
and	O
fasting	O
glucose	O
,	O
along	O
with	O
weight	O
stability	O
.	O
The	O
laboratory	O
which	O
analyzed	O
the	O
samples	O
is	O
also	O
involved	O
in	O
clinical	B-methodology
practice	I-methodology
and	O
performs	O
continuous	O
quality	B-methodology
control	I-methodology
,	O
which	O
should	O
exclude	O
such	O
a	O
drift	O
due	O
to	O
methodological	O
changes	O
.	O
The	O
only	O
explanation	O
could	O
be	O
the	O
increased	O
use	O
of	O
medication	O
,	O
such	O
as	O
statins	O
,	O
that	O
improve	O
the	O
clinical	O
chemical	O
profile	O
.	O
We	O
found	O
that	O
about	O
one	O
fifth	O
of	O
the	O
subjects	O
were	O
taking	O
this	O
type	O
of	O
medication	O
,	O
confirming	O
the	O
overall	O
trend	O
of	O
high	O
use	O
in	O
Italy	O
[	O
23	O
]	O
.	O
In	O
regard	O
to	O
the	O
prospective	O
relation	O
between	O
food	O
intake	O
and	O
health	O
indicators	O
,	O
we	O
would	O
like	O
firstly	O
to	O
discuss	O
those	O
associations	O
which	O
showed	O
consistency	O
between	O
the	O
statistical	O
models	O
.	O
These	O
regard	O
low	O
fat	O
dairy	O
,	O
juices	O
,	O
olive	O
oil	O
,	O
and	O
water	O
.	O
The	O
finding	O
of	O
a	O
direct	O
association	O
between	O
low	O
-	O
fat	O
dairy	O
products	O
but	O
not	O
high	O
fat	O
dairy	O
consumption	O
and	O
weight	O
gain	O
(	O
BMI	O
>	O
1	O
.	O
5	O
)	O
in	O
about	O
7	O
years	O
is	O
not	O
supported	O
by	O
findings	O
in	O
the	O
literature	O
[	O
24	O
]	O
,	O
and	O
is	O
thus	O
a	O
surprising	O
result	O
.	O
We	O
can	O
only	O
consider	O
the	O
role	O
of	O
fat	O
in	O
the	O
discussion	O
about	O
obesity	O
,	O
and	O
messages	O
to	O
circumvent	O
this	O
relation	O
by	O
eating	O
low	O
-	O
fat	O
products	O
.	O
Thus	O
,	O
our	O
finding	O
could	O
be	O
indicative	O
for	O
populations	O
exposed	O
to	O
such	O
concepts	O
.	O
However	O
,	O
low	O
-	O
fat	O
products	O
are	O
not	O
low	O
energy	O
products	O
,	O
since	O
most	O
of	O
them	O
provide	O
similar	O
energy	O
to	O
dairy	O
products	O
with	O
regular	O
fat	O
,	O
as	O
was	O
recognized	O
more	O
than	O
10	O
years	O
ago	O
[	O
25	O
]	O
.	O
It	O
might	O
not	O
be	O
surprising	O
that	O
subjects	O
concerned	O
about	O
weight	O
gain	O
would	O
start	O
eating	O
low	O
-	O
fat	O
dairies	O
without	O
considering	O
the	O
energy	O
provided	O
by	O
such	O
products	O
.	O

More	O
support	O
from	O
the	O
literature	O
is	O
available	O
for	O
the	O
finding	O
that	O
juices	O
were	O
associated	O
with	O
lower	O
systolic	O
blood	O
pressure	O
.	O
In	O
a	O
recent	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
of	O
observational	B-methodology
studies	I-methodology
,	O
Zheng	O
et	O
al	O
.	O
came	O
to	O
the	O
same	O
conclusion	O
and	O
discussed	O
the	O
biological	O
mechanism	O
underlying	O
this	O
finding	O
[	O
26	O
]	O
.	O
Also	O
the	O
finding	O
regarding	O
olive	O
oil	O
and	O
an	O
inverse	O
association	O
with	O
HDL	O
-	O
cholesterol	O
is	O
supported	O
by	O
a	O
recent	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
of	O
intervention	B-methodology
studies	I-methodology
[	O
27	O
]	O
.	O
The	O
authors	O
of	O
this	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
pointed	O
out	O
that	O
the	O
effect	O
is	O
only	O
seen	O
with	O
virgin	O
olive	O
oil	O
,	O
rich	O
in	O
phenols	O
.	O
The	O
population	O
in	O
Castellana	O
mainly	O
consumes	O
this	O
type	O
of	O
olive	O
oil	O
because	O
it	O
is	O
produced	O
locally	O
.	O
Also	O
,	O
the	O
inverse	O
association	O
between	O
water	O
and	O
total	O
HDL	O
-	O
cholesterol	O
is	O
supported	O
by	O
the	O
only	O
(	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
)	O
intervention	B-methodology
study	I-methodology
in	O
which	O
water	O
with	O
a	O
high	O
content	O
of	O
minerals	O
reduced	O
LDL	O
and	O
HDL	O
-	O
cholesterol	O
[	O
28	O
]	O
.	O
For	O
the	O
other	O
relationships	O
,	O
some	O
doubts	O
arise	O
as	O
to	O
the	O
significance	O
of	O
the	O
statistical	O
behavior	O
.	O
If	O
the	O
initial	O
relation	O
disappears	O
after	O
adjustment	O
,	O
we	O
need	O
to	O
assume	O
that	O
statistical	O
interferences	O
of	O
other	O
foods	O
have	O
taken	O
place	O
.	O
If	O
significance	O
only	O
appeared	O
after	O
adjustment	O
for	O
other	O
foods	O
it	O
is	O
not	O
obvious	O
why	O
.	O
For	O
the	O
statistical	O
findings	O
with	O
no	O
agreements	O
between	O
the	O
models	O
,	O
the	O
interrelations	O
among	O
food	O
intake	O
play	O
an	O
important	O
role	O
firstly	O
attributable	O
to	O
statistical	O
properties	O
and	O
only	O
secondly	O
to	O
biological	O
mechanisms	O
.	O
Therefore	O
,	O
we	O
discuss	O
here	O
only	O
some	O
results	O
from	O
the	O
final	O
regression	O
models	O
adjusted	O
for	O
other	O
foods	O
which	O
are	O
widely	O
discussed	O
in	O
the	O
literature	O
.	O
For	O
triglycerides	O
,	O
we	O
observed	O
a	O
direct	O
relation	O
with	O
eggs	O
and	O
red	O
meat	O
,	O
and	O
an	O
inverse	O
relation	O
with	O
ready	O
-	O
to	O
-	O
eat	O
dishes	O
.	O
The	O
first	O
two	O
findings	O
were	O
not	O
supported	O
by	O
meta	B-methodology
-	I-methodology
analyses	I-methodology
of	O
intervention	B-methodology
studies	I-methodology
[	O
29	O
,	O
30	O
]	O
.	O
The	O
finding	O
regarding	O
eggs	O
is	O
also	O
in	O
contrast	O
to	O
a	O
recent	O
publication	O
from	O
Spain	O
that	O
found	O
the	O
contrary	O
[	O
31	O
]	O
.	O
For	O
the	O
second	O
finding	O
,	O
ready	O
-	O
to	O
-	O
eat	O
dishes	O
could	O
contain	O
fats	O
that	O
decrease	O
triglycerides	O
if	O
eaten	O
at	O
the	O
expense	O
of	O
carbohydrates	O
[	O
32	O
]	O
.	O
Finally	O
,	O
we	O
would	O
like	O
to	O
draw	O
attention	O
to	O
coffee	O
,	O
which	O
is	O
consumed	O
in	O
this	O
area	O
mostly	O
as	O
expresso	O
.	O

The	O
Dutch	O
food	O
-	O
based	O
dietary	O
guidelines	O
recommend	O
not	O
to	O
use	O
unfiltered	O
coffee	O
due	O
to	O
intervention	B-methodology
studies	I-methodology
showing	O
an	O
increase	O
in	O
cholesterol	O
compared	O
to	O
filtered	O
coffee	O
[	O
33	O
]	O
.	O
In	O
Apulia	O
,	O
as	O
in	O
all	O
Italy	O
,	O
coffee	O
is	O
produced	O
by	O
expresso	O
machines	O
which	O
do	O
not	O
use	O
a	O
filter	O
.	O
Fortunately	O
,	O
we	O
did	O
not	O
observe	O
any	O
cholesterol	O
increase	O
with	O
increasing	O
consumption	O
of	O
coffee	O
;	O
indeed	O
,	O
the	O
contrary	O
was	O
observed	O
when	O
considering	O
the	O
fully	O
adjusted	O
model	O
.	O
The	O
correlations	O
between	O
complex	O
healthy	O
diet	O
indices	O
and	O
single	O
food	O
groups	O
could	O
help	O
to	O
understand	O
the	O
significance	O
of	O
the	O
indices	O
themselves	O
in	O
the	O
context	O
of	O
the	O
overall	O
diet	O
and	O
of	O
diet	O
-	O
health	O
associations	O
.	O
Indices	O
are	O
currently	O
widely	O
used	O
in	O
the	O
nutritional	O
epidemiological	O
literature	O
due	O
to	O
the	O
conviction	O
that	O
health	O
effects	O
are	O
best	O
addressed	O
by	O
a	O
number	O
of	O
dietary	O
principles	O
[	O
34	O
,	O
35	O
]	O
.	O
However	O
,	O
indices	O
are	O
based	O
only	O
on	O
a	O
proportion	O
of	O
the	O
dietary	O
information	O
for	O
scoring	O
,	O
and	O
it	O
is	O
of	O
interest	O
to	O
know	O
the	O
whole	O
picture	O
when	O
using	O
such	O
indices	O
in	O
studies	O
.	O
It	O
was	O
not	O
surprising	O
that	O
the	O
indices	O
were	O
correlated	O
with	O
the	O
intake	O
of	O
fruit	O
and	O
vegetables	O
,	O
with	O
some	O
differences	O
in	O
number	O
and	O
type	O
of	O
food	O
group	O
,	O
in	O
accordance	O
with	O
the	O
general	O
principles	O
of	O
a	O
healthy	O
diet	O
.	O
Nevertheless	O
,	O
the	O
correlation	O
analyses	O
show	O
that	O
each	O
of	O
the	O
indices	O
has	O
a	O
slightly	O
different	O
significance	O
in	O
terms	O
of	O
overall	O
food	O
group	O
intake	O
.	O
At	O
this	O
stage	O
of	O
the	O
analysis	O
and	O
in	O
view	O
of	O
the	O
low	O
to	O
moderate	O
correlations	O
,	O
it	O
would	O
be	O
premature	O
to	O
predict	O
the	O
performance	O
of	O
the	O
indices	O
regarding	O
disease	O
outcomes	O
with	O
different	O
dietary	O
hypotheses	O
.	O
However	O
,	O
we	O
can	O
now	O
be	O
sure	O
that	O
the	O
application	O
of	O
the	O
indices	O
in	O
statistical	O
risk	O
analyses	O
is	O
not	O
guided	O
by	O
side	O
effects	O
of	O
other	O
foods	O
,	O
not	O
being	O
part	O
of	O
the	O
scoring	O
algorithm	O
.	O
In	O
this	O
context	O
,	O
the	O
study	O
by	O
Castello	O
et	O
al	O
.	O
[	O
13	O
]	O
in	O
Spain	O
is	O
interesting	O
because	O
they	O
used	O
a	O
similar	O
approach	O
,	O
relating	O
food	O
group	O
intake	O
to	O
dietary	O
health	O
indices	O
.	O
Their	O
results	O
regarding	O
the	O
aMEDindex	O
(	O
Alternative	O
Mediterranean	O
Diet	O
Index	O
)	O
can	O
be	O
directly	O
compared	O
to	O
our	O
results	O
regarding	O
the	O
Meddietscore	O
.	O
There	O
seems	O
to	O
be	O
little	O
difference	O
in	O
the	O
overall	O
profile	O
between	O
their	O
study	O
and	O
ours	O
,	O
demonstrating	O
the	O
validity	O
of	O
the	O
Mediterranean	O
diet	O
concept	O
across	O
regions	O
.	O

The	O
strengths	O
of	O
our	O
investigation	O
are	O
the	O
large	O
number	O
of	O
subjects	O
,	O
the	O
concurrent	O
investigation	O
of	O
a	O
control	B-methodology
group	I-methodology
for	O
the	O
group	O
of	O
subjects	O
with	O
the	O
two	O
measurements	O
,	O
and	O
the	O
use	O
of	O
a	O
validated	O
dietary	O
questionnaire	O
.	O
A	O
further	O
advantage	O
of	O
the	O
study	O
is	O
the	O
high	O
participation	O
rate	O
at	O
the	O
start	O
of	O
the	O
cohort	B-methodology
and	O
at	O
the	O
different	O
subsequent	O
examinations	O
.	O
Despite	O
the	O
losses	O
to	O
follow	O
-	O
up	O
at	O
each	O
examination	O
time	O
,	O
we	O
can	O
assume	O
that	O
the	O
population	O
was	O
still	O
representative	O
of	O
the	O
local	O
population	O
at	O
each	O
time	O
period	O
.	O
The	O
internal	O
validity	O
of	O
the	O
data	O
can	O
,	O
therefore	O
,	O
be	O
considered	O
high	O
,	O
since	O
—	O
at	O
each	O
time	O
period	O
—	O
the	O
subgroups	O
did	O
not	O
show	O
large	O
differences	O
.	O
Nevertheless	O
,	O
we	O
admit	O
that	O
the	O
questionnaire	O
was	O
not	O
designed	O
to	O
capture	O
,	O
in	O
particular	O
,	O
changes	O
of	O
diet	O
.	O
Like	O
many	O
others	O
,	O
we	O
consider	O
the	O
FFQ	O
more	O
as	O
a	O
ranking	O
tool	O
with	O
less	O
focus	O
on	O
the	O
true	O
quantitative	O
intakes	O
,	O
owing	O
to	O
the	O
use	O
of	O
a	O
fixed	O
number	O
of	O
foods	O
and	O
an	O
often	O
arbitrary	O
definition	O
of	O
the	O
portion	O
sizes	O
.	O
In	O
conclusion	O
,	O
the	O
study	O
showed	O
that	O
the	O
Apulian	O
diet	O
includes	O
many	O
aspects	O
of	O
a	O
healthy	O
diet	O
.	O
The	O
dietary	O
intake	O
does	O
not	O
show	O
a	O
rapid	O
transition	O
towards	O
a	O
westernized	O
diet	O
,	O
composed	O
of	O
a	O
high	O
proportion	O
of	O
animal	O
foods	O
including	O
meat	O
and	O
only	O
a	O
small	O
proportion	O
of	O
vegetables	O
and	O
fruit	O
.	O
At	O
first	O
glance	O
,	O
the	O
diet	O
of	O
the	O
Castellana	O
Grotte	O
region	O
seems	O
to	O
be	O
positively	O
associated	O
with	O
health	O
indicators	O
and	O
probably	O
health	O
.	O
However	O
,	O
the	O
analyses	O
also	O
showed	O
that	O
diet	O
is	O
a	O
complex	O
issue	O
,	O
even	O
when	O
condensed	O
to	O
29	O
food	O
groups	O
and	O
three	O
healthy	O
diet	O
indices	O
.	O
We	O
thank	O
the	O
MICOL	O
Study	O
group	O
and	O
the	O
“	O
Salus	O
in	O
Apulia	O
”	O
Research	O
Team	O
.	O
This	O
manuscript	O
is	O
the	O
result	O
of	O
the	O
research	O
work	O
on	O
frailty	O
undertaken	O
by	O
the	O
“	O
Italia	O
Longeva	O
:	O
Research	O
Network	O
on	O
Aging	O
”	O
team	O
,	O
supported	O
by	O
the	O
resources	O
of	O
the	O
Italian	O
Ministry	O
of	O
Health	O
—	O
Research	O
Networks	O
of	O
National	O
Health	O
Institutes	O
.	O

We	O
thank	O
the	O
General	O
Practitioners	O
of	O
Castellana	O
Grotte	O
,	O
for	O
their	O
fundamental	O
role	O
in	O
the	O
recruitment	O
of	O
participants	O
to	O
these	O
studies	O
:	O
Cecilia	O
Olga	O
Maria	O
Campanella	O
,	O
Annamaria	O
Daddabbo	O
,	O
Giosuè	O
Dell	O
’	O
aera	O
,	O
Rosalia	O
Francesca	O
Giustiniano	O
,	O
Massimo	O
Guzzoni	O
Iudice	O
,	O
Savino	O
Lomuscio	O
,	O
Rocco	O
Lucarelli	O
,	O
Antonio	O
Mazzarisi	O
,	O
Mariana	O
Palumbo	O
,	O
Maria	O
Teresa	O
Persio	O
,	O
Rosa	O
Vincenza	O
Pesce	O
,	O
Gabriella	O
Puzzovivo	O
,	O
Pasqua	O
Maria	O
Romano	O
,	O
Cinzia	O
Sgobba	O
,	O
Francesco	O
Simeone	O
,	O
Paola	O
Tartaglia	O
,	O
and	O
Nicola	O
Tauro	O
.	O
The	O
following	O
are	O
available	O
online	O
at	O
https	O
:	O
/	O
/	O
www	O
.	O
mdpi	O
.	O
com	O
/	O
2072	O
-	O
6643	O
/	O
12	O
/	O
10	O
/	O
3097	O
/	O
s1	O
.	O
F	O
.	O
C	O
.	O
and	O
H	O
.	O
B	O
.	O
were	O
involved	O
with	O
study	B-methodology
design	I-methodology
and	O
drafted	O
the	O
manuscript	O
.	O
V	O
.	O
G	O
.	O
and	O
R	O
.	O
D	O
.	O
were	O
involved	O
with	O
study	B-methodology
design	I-methodology
,	O
analyzed	O
and	O
interpreted	O
the	O
data	O
,	O
and	O
edited	O
the	O
manuscript	O
.	O
R	O
.	O
Z	O
.	O
and	O
A	O
.	O
M	O
.	O
C	O
.	O
were	O
involved	O
with	O
study	B-methodology
design	I-methodology
and	O
edited	O
the	O
manuscript	O
.	O
I	O
.	O
B	O
.	O
,	O
L	O
.	O
L	O
.	O
and	O
C	O
.	O
G	O
.	O
were	O
involved	O
with	O
study	B-methodology
design	I-methodology
,	O
analyzed	O
and	O
interpreted	O
the	O
data	O
,	O
and	O
edited	O
the	O
manuscript	O
.	O
G	O
.	O
D	O
.	O
P	O
.	O
,	O
G	O
.	O
G	O
.	O
,	O
R	O
.	O
S	O
.	O
and	O
G	O
.	O
L	O
.	O
were	O
involved	O
with	O
study	B-methodology
design	I-methodology
and	O
edited	O
the	O
manuscript	O
.	O
All	O
authors	O
have	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
This	O
study	O
was	O
funded	O
by	O
the	O
Italian	O
Ministry	O
of	O
Health	O
with	O
“	O
Ricerca	O
Corrente	O
2019	O
”	O
Grant	O
.	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O

Analysis	O
of	O
apoB	O
Concentrations	O
Across	O
Early	O
Adulthood	O
and	O
Predictors	O
for	O
Rates	O
of	O
Change	O
Using	O
CARDIA	O
Study	O
Data	O
apolipoprotein	O
B	O
;	O
epidemiology	O
;	O
change	O
;	O
young	O
adults	O
The	O
cumulative	O
exposure	O
to	O
apolipoprotein	O
B	O
(	O
apoB	O
)	O
-	O
containing	O
lipoproteins	O
in	O
the	O
blood	O
during	O
early	O
adult	O
life	O
is	O
a	O
central	O
determinant	O
of	O
atherosclerotic	O
cardiovascular	O
disease	O
risk	O
.	O
To	O
date	O
,	O
the	O
patterns	O
and	O
rates	O
of	O
change	O
in	O
apoB	O
through	O
early	O
adult	O
life	O
have	O
not	O
been	O
described	O
.	O
Here	O
,	O
we	O
used	O
NMR	O
to	O
measure	O
apoB	O
concentrations	O
in	O
up	O
to	O
3055	O
Coronary	O
Artery	O
Risk	O
Development	O
in	O
Young	O
Adults	O
(	O
CARDIA	O
)	O
Study	O
participants	O
who	O
attended	O
the	O
years	O
2	O
(	O
Y2	O
)	O
,	O
7	O
(	O
Y7	O
)	O
,	O
15	O
(	O
Y15	O
)	O
,	O
20	O
(	O
Y20	O
)	O
,	O
and	O
30	O
(	O
Y30	O
)	O
exams	O
.	O
We	O
examined	O
individual	O
-	O
level	O
spaghetti	O
plots	O
of	O
apoB	O
change	O
,	O
and	O
we	O
calculated	O
average	O
annualized	O
rate	O
of	O
apoB	O
concentration	O
change	O
during	O
follow	O
-	O
up	O
.	O
We	O
used	O
multivariable	O
linear	O
regression	O
models	O
to	O
assess	O
the	O
associations	O
between	O
CARDIA	O
participant	O
characteristics	O
and	O
annualized	O
rates	O
of	O
apoB	O
change	O
.	O
Male	O
sex	O
,	O
higher	O
measures	O
of	O
adiposity	O
,	O
lower	O
HDL	O
-	O
C	O
,	O
lower	O
Healthy	O
Eating	O
Index	O
,	O
and	O
higher	O
blood	O
pressures	O
were	O
observed	O
more	O
commonly	O
in	O
individuals	O
with	O
higher	O
apoB	O
level	O
at	O
Y2	O
and	O
Y20	O
.	O
Inter	O
-	O
and	O
intra	O
-	O
individual	O
variation	O
in	O
apoB	O
concentration	O
over	O
time	O
was	O
substantial	O
—	O
while	O
the	O
mean	O
(	O
SD	O
)	O
rate	O
of	O
change	O
was	O
0	O
.	O
52	O
(	O
1	O
.	O
0	O
)	O
mg	O
/	O
dl	O
/	O
year	O
,	O
the	O
range	O
of	O
annualized	O
rates	O
of	O
change	O
was	O
−6	O
.	O
26	O
to	O
+	O
9	O
.	O
21	O
mg	O
/	O
dl	O
/	O
year	O
.	O
At	O
baseline	O
,	O
lower	O
first	O
apoB	O
measurement	O
,	O
female	O
sex	O
,	O
White	O
race	O
,	O
lower	O
BMI	O
,	O
and	O
current	O
tobacco	O
use	O
were	O
associated	O
with	O
apoB	O
increase	O
.	O
We	O
conclude	O
that	O
the	O
significant	O
variance	O
in	O
apoB	O
level	O
over	O
time	O
and	O
the	O
modest	O
association	O
between	O
baseline	O
measures	O
and	O
rates	O
of	O
apoB	O
change	O
suggest	O
that	O
the	O
ability	O
to	O
predict	O
an	O
individual	O
’	O
s	O
future	O
apoB	O
serum	O
concentrations	O
,	O
and	O
thus	O
their	O
cumulative	O
apoB	O
exposure	O
,	O
after	O
a	O
one	O
-	O
time	O
assessment	O
in	O
young	O
adulthood	O
is	O
low	O
.	O

Apolipoprotein	O
B100	O
(	O
apoB	O
)	O
is	O
the	O
primary	O
structural	O
protein	O
and	O
binding	O
ligand	O
for	O
the	O
atherogenic	O
lipoprotein	O
particles	O
:	O
VLDL	O
,	O
remnant	O
,	O
IDL	O
,	O
LDL	O
,	O
and	O
lipoprotein	O
(	O
a	O
)	O
(	O
Lp	O
(	O
a	O
)	O
)	O
(	O
1	O
,	O
2	O
)	O
.	O
Each	O
atherogenic	O
lipoprotein	O
particle	O
contains	O
one	O
molecule	O
of	O
apoB	O
.	O
Genetic	O
polymorphisms	O
at	O
different	O
loci	O
that	O
mediate	O
lipid	O
metabolism	O
(	O
i	O
.	O
e	O
.	O
,	O
LDLR	O
,	O
LPA	O
,	O
and	O
others	O
)	O
and	O
differences	O
in	O
LDL	O
-	O
receptor	O
density	O
,	O
cholesterol	O
and	O
triglyceride	O
(	O
TG	O
)	O
exchange	O
,	O
insulin	O
resistance	O
,	O
and	O
lifestyle	O
factors	O
result	O
in	O
substantial	O
interindividual	O
differences	O
in	O
the	O
number	O
of	O
apoB	O
-	O
containing	O
particles	O
for	O
a	O
given	O
total	O
mass	O
of	O
cholesterol	O
and	O
TG	O
(	O
3	O
,	O
4	O
)	O
.	O
Thus	O
,	O
measurement	O
of	O
apoB	O
concentration	O
captures	O
the	O
aggregate	O
burden	O
of	O
atherogenic	O
lipoprotein	O
particles	O
present	O
in	O
the	O
blood	O
more	O
precisely	O
than	O
the	O
measurement	O
of	O
the	O
cholesterol	O
concentration	O
in	O
LDL	O
(	O
LDL	O
-	O
C	O
)	O
or	O
non	O
-	O
HDL	O
(	O
non	O
-	O
HDL	O
-	O
C	O
)	O
.	O
The	O
retention	O
of	O
apoB	O
-	O
containing	O
lipoproteins	O
in	O
the	O
subendothelial	O
space	O
,	O
as	O
well	O
as	O
the	O
chronic	O
inflammatory	O
response	O
to	O
these	O
particles	O
,	O
is	O
central	O
to	O
the	O
pathogenesis	O
of	O
atherosclerosis	O
and	O
subsequent	O
atherosclerotic	O
cardiovascular	O
disease	O
(	O
ASCVD	O
)	O
events	O
(	O
5	O
,	O
6	O
)	O
.	O
ApoB	O
blood	O
concentrations	O
have	O
strong	O
associations	O
with	O
subclinical	O
atherosclerosis	O
and	O
incident	O
ASCVD	O
(	O
7	O
)	O
.	O
Because	O
of	O
its	O
ability	O
to	O
quantify	O
the	O
burden	O
of	O
atherogenic	O
lipoprotein	O
particle	O
number	O
more	O
completely	O
and	O
accurately	O
than	O
non	O
-	O
HDL	O
-	O
C	O
,	O
multiple	O
studies	O
suggest	O
that	O
apoB	O
is	O
a	O
superior	O
marker	O
of	O
ASCVD	O
risk	O
,	O
particularly	O
in	O
the	O
8	O
–	O
20	O
%	O
of	O
people	O
who	O
have	O
higher	O
or	O
lower	O
than	O
average	O
apoB	O
levels	O
for	O
a	O
given	O
non	O
-	O
HDL	O
-	O
C	O
level	O
(	O
8	O
)	O
.	O
Nonetheless	O
,	O
other	O
clinical	O
markers	O
of	O
atherogenic	O
lipoprotein	O
burden	O
like	O
non	O
-	O
HDL	O
-	O
C	O
and	O
LDL	O
-	O
C	O
are	O
commonly	O
used	O
in	O
clinical	B-methodology
practice	I-methodology
.	O

Since	O
apoB	O
is	O
a	O
causal	O
determinant	O
of	O
atherosclerosis	O
(	O
9	O
)	O
,	O
and	O
exposure	O
to	O
atherogenic	O
lipoproteins	O
across	O
early	O
adult	O
life	O
is	O
a	O
strong	O
predictor	O
of	O
ASCVD	O
risk	O
(	O
10	O
,	O
11	O
)	O
,	O
it	O
is	O
important	O
to	O
understand	O
normative	O
apoB	O
concentrations	O
in	O
young	O
adults	O
,	O
their	O
patterns	O
and	O
rates	O
of	O
change	O
through	O
midlife	O
,	O
and	O
the	O
predictors	O
of	O
change	O
.	O
Furthermore	O
,	O
understanding	O
how	O
these	O
rates	O
of	O
change	O
compare	O
to	O
other	O
commonly	O
used	O
measures	O
of	O
atherogenic	O
burden	O
may	O
help	O
inform	O
the	O
clinical	O
utility	O
of	O
apoB	O
measurement	O
in	O
young	O
adults	O
,	O
as	O
more	O
stable	O
measures	O
may	O
serve	O
as	O
more	O
reliable	O
markers	O
of	O
an	O
individual	O
patient	O
’	O
s	O
expected	O
future	O
burden	O
of	O
atherogenic	O
lipoproteins	O
,	O
and	O
they	O
may	O
perform	O
better	O
as	O
long	O
-	O
term	O
ASCVD	O
risk	O
markers	O
in	O
young	O
adults	O
.	O
To	O
date	O
,	O
the	O
patterns	O
and	O
rates	O
of	O
change	O
in	O
apoB	O
concentrations	O
within	O
the	O
same	O
individuals	O
across	O
young	O
adulthood	O
have	O
not	O
been	O
described	O
.	O
Here	O
,	O
we	O
report	O
the	O
first	O
descriptions	O
of	O
the	O
rates	O
of	O
intraindividual	O
apoB	O
change	O
,	O
as	O
well	O
as	O
predictors	O
of	O
change	O
,	O
and	O
we	O
compare	O
these	O
rates	O
of	O
change	O
for	O
other	O
commonly	O
used	O
measures	O
of	O
atherogenic	O
lipoprotein	O
burden	O
,	O
across	O
early	O
adult	O
life	O
using	O
unique	O
data	O
from	O
over	O
3	O
,	O
055	O
Coronary	O
Artery	O
Risk	O
Development	O
in	O
Young	O
Adults	O
(	O
CARDIA	O
)	O
study	O
participants	O
.	O
The	O
CARDIA	O
study	O
recruited	O
5	O
,	O
115	O
black	O
and	O
white	O
men	O
and	O
women	O
aged	O
18	O
–	O
30	O
years	O
in	O
1985	O
–	O
1986	O
from	O
four	O
sites	O
across	O
the	O
United	O
States	O
:	O
Birmingham	O
,	O
AL	O
;	O
Chicago	O
,	O
IL	O
;	O
Minneapolis	O
,	O
MN	O
;	O
and	O
Oakland	O
,	O
CA	O
.	O
Participants	O
were	O
sampled	O
to	O
achieve	O
a	O
cohort	B-methodology
balanced	O
by	O
race	O
(	O
52	O
%	O
black	O
and	O
48	O
%	O
white	O
)	O
,	O
sex	O
(	O
55	O
%	O
female	O
and	O
45	O
%	O
male	O
)	O
,	O
education	O
(	O
40	O
%	O
with	O
12	O
years	O
and	O
/	O
or	O
younger	O
,	O
60	O
%	O
with	O
more	O
than	O
12	O
years	O
of	O
education	O
)	O
,	O
and	O
age	O
(	O
45	O
%	O
18	O
–	O
24	O
years	O
and	O
55	O
%	O
25	O
–	O
30	O
years	O
)	O
.	O
CARDIA	O
participants	O
have	O
undergone	O
in	O
-	O
person	O
examinations	O
at	O
baseline	O
(	O
year	O
0	O
:	O
Y0	O
)	O
and	O
at	O
Y2	O
,	O
Y5	O
,	O
Y7	O
,	O
Y10	O
,	O
Y15	O
,	O
Y20	O
,	O
Y25	O
,	O
and	O
Y30	O
(	O
12	O
)	O
.	O
Retention	O
rates	O
among	O
surviving	O
participants	O
at	O
each	O
in	O
-	O
person	O
examination	O
have	O
been	O
high	O
,	O
at	O
91	O
,	O
86	O
,	O
81	O
,	O
79	O
,	O
74	O
,	O
72	O
,	O
72	O
,	O
and	O
71	O
%	O
,	O
respectively	O
.	O

Contact	O
is	O
maintained	O
with	O
participants	O
via	O
telephone	O
,	O
mail	O
,	O
or	O
e	O
-	O
mail	O
every	O
6	O
months	O
,	O
with	O
annual	O
medical	O
history	O
ascertainment	O
between	O
in	O
-	O
person	O
examinations	O
.	O
Over	O
the	O
last	O
5	O
years	O
,	O
>	O
90	O
%	O
of	O
the	O
surviving	O
cohort	B-methodology
members	O
have	O
been	O
directly	O
contacted	O
,	O
and	O
follow	O
up	O
for	O
vital	O
status	O
is	O
virtually	O
complete	O
through	O
related	O
contacts	O
and	O
intermittent	O
National	O
Death	O
Index	O
searches	O
.	O
Since	O
we	O
were	O
interested	O
in	O
understanding	O
the	O
natural	O
history	O
of	O
apoB	O
concentration	O
change	O
across	O
early	O
adulthood	O
,	O
we	O
included	O
samples	O
from	O
participants	O
who	O
had	O
samples	O
available	O
at	O
Y20	O
and	O
at	O
least	O
two	O
of	O
three	O
from	O
Y15	O
,	O
Y7	O
,	O
or	O
Y2	O
(	O
n	O
=	O
3	O
,	O
055	O
)	O
.	O
For	O
patients	O
who	O
met	O
these	O
inclusion	B-methodology
criteria	I-methodology
,	O
we	O
also	O
included	O
data	O
from	O
Y30	O
when	O
it	O
was	O
available	O
(	O
N	O
=	O
2	O
,	O
474	O
)	O
.	O
Of	O
the	O
3	O
,	O
055	O
,	O
we	O
measured	O
apoB	O
in	O
all	O
those	O
with	O
available	O
serum	O
or	O
plasma	O
samples	O
at	O
Y2	O
(	O
N	O
=	O
1	O
,	O
881	O
)	O
,	O
Y7	O
(	O
N	O
=	O
2	O
,	O
582	O
)	O
,	O
Y15	O
(	O
N	O
=	O
2	O
,	O
474	O
)	O
,	O
Y20	O
(	O
N	O
=	O
3	O
,	O
055	O
)	O
,	O
and	O
Y30	O
(	O
N	O
=	O
2	O
,	O
474	O
)	O
.	O
The	O
characteristics	O
of	O
included	O
and	O
excluded	O
participants	O
are	O
presented	O
in	O
supplemental	O
Table	O
S2	O
.	O
Age	O
,	O
race	O
,	O
and	O
sex	O
were	O
determined	O
via	O
self	O
-	O
report	O
.	O
Height	O
,	O
weight	O
,	O
and	O
waist	O
circumference	O
were	O
measured	O
with	O
the	O
participants	O
in	O
light	O
clothing	O
using	O
a	O
standardized	O
stadiometer	O
,	O
tape	O
measure	O
,	O
and	O
calibrated	O
scale	O
;	O
BMI	O
(	O
kg	O
/	O
m2	O
)	O
was	O
calculated	O
.	O
Detailed	O
dietary	O
data	O
are	O
available	O
for	O
Y0	O
,	O
Y7	O
,	O
and	O
Y20	O
.	O
Dietary	O
data	O
obtained	O
at	O
baseline	O
were	O
used	O
to	O
represent	O
Y2	O
dietary	O
patterns	O
.	O
The	O
CARDIA	O
dietary	O
data	O
were	O
obtained	O
via	O
an	O
interview	O
-	O
administered	O
method	O
that	O
included	O
a	O
short	O
questionnaire	O
regarding	O
general	O
dietary	O
practices	O
followed	O
by	O
a	O
comprehensive	O
questionnaire	O
about	O
typical	O
intake	O
of	O
foods	O
(	O
about	O
100	O
header	O
questions	O
such	O
as	O
“	O
do	O
you	O
eat	O
meat	O
,	O
”	O
followed	O
by	O
open	O
-	O
ended	O
responses	O
in	O
answer	O
to	O
that	O
header	O
question	O
)	O
.	O
Detailed	O
data	O
on	O
portion	O
sizes	O
,	O
frequency	O
of	O
consumption	O
,	O
and	O
common	O
additives	O
were	O
conducted	O
on	O
foods	O
that	O
were	O
regularly	O
consumed	O
as	O
well	O
(	O
12	O
,	O
13	O
)	O
.	O
Dietary	O
data	O
were	O
designed	O
to	O
reflect	O
the	O
habitual	O
intake	O
(	O
past	O
month	O
)	O
of	O
CARDIA	O
participants	O
.	O

From	O
these	O
diet	O
history	O
data	O
,	O
the	O
Healthy	O
Eating	O
Index	O
(	O
HEI	O
)	O
at	O
Y2	O
and	O
Y20	O
was	O
calculated	O
and	O
used	O
to	O
represent	O
overall	O
dietary	O
quality	O
(	O
14	O
)	O
.	O
At	O
each	O
CARDIA	O
examination	O
,	O
participants	O
were	O
given	O
the	O
interviewer	O
-	O
administered	O
Physical	O
Activity	O
(	O
PA	O
)	O
History	O
Questionnaire	O
.	O
In	O
brief	O
,	O
participants	O
were	O
asked	O
about	O
self	O
-	O
reported	O
leisure	O
time	O
activity	O
and	O
the	O
frequency	O
of	O
participation	O
in	O
13	O
specific	O
PA	O
categories	O
(	O
eight	O
of	O
vigorous	O
and	O
five	O
of	O
moderate	O
intensity	O
)	O
of	O
recreational	O
sports	O
,	O
structured	O
exercise	O
,	O
home	O
maintenance	O
,	O
and	O
occupational	O
activities	O
during	O
the	O
preceding	O
12	O
months	O
.	O
Intensity	O
of	O
each	O
activity	O
was	O
expressed	O
as	O
metabolic	O
equivalents	O
(	O
15	O
,	O
16	O
)	O
.	O
The	O
PA	O
score	O
summed	O
frequency	O
time	O
intensity	O
over	O
the	O
13	O
activities	O
to	O
get	O
total	O
activity	O
(	O
in	O
exercise	O
units	O
)	O
.	O
Blood	O
pressure	O
was	O
measured	O
after	O
5	O
min	O
of	O
rest	O
in	O
the	O
seated	O
position	O
using	O
a	O
random	O
zero	O
mercury	O
sphygmomanometer	O
,	O
replaced	O
from	O
Y20	O
forward	O
with	O
an	O
Omron	O
oscillometer	O
(	O
calibrated	O
to	O
the	O
random	O
zero	O
)	O
.	O
The	O
means	O
of	O
the	O
second	O
and	O
third	O
systolic	O
and	O
diastolic	O
measurements	O
were	O
used	O
.	O
Alcohol	O
intake	O
,	O
smoking	O
habits	O
,	O
and	O
educational	O
attainment	O
were	O
determined	O
with	O
the	O
use	O
of	O
standardized	O
and	O
validated	O
questionnaires	O
.	O
Blood	O
pressure	O
-	O
and	O
cholesterol	O
-	O
lowering	O
medication	O
use	O
was	O
determined	O
by	O
self	O
-	O
report	O
.	O
After	O
a	O
12	O
-	O
h	O
fast	O
,	O
blood	O
was	O
drawn	O
from	O
a	O
vein	O
in	O
the	O
antecubital	O
fossa	O
into	O
a	O
Vacutainer	O
,	O
coated	O
with	O
EDTA	O
for	O
plasma	O
.	O
Serum	O
and	O
plasma	O
samples	O
were	O
obtained	O
and	O
stored	O
at	O
−80°C	O
for	O
future	O
analysis	O
.	O
Plasma	O
samples	O
were	O
transported	O
on	O
dry	O
ice	O
to	O
the	O
Northwest	O
Lipid	O
Research	O
Center	O
in	O
Seattle	O
,	O
Washington	O
.	O
Plasma	O
concentrations	O
of	O
total	O
cholesterol	O
and	O
TGs	O
were	O
measured	O
using	O
a	O
standard	O
enzymatic	O
assay	O
.	O
HDL	O
-	O
C	O
was	O
quantified	O
after	O
precipitation	O
with	O
dextral	O
sulfate	O
-	O
magnesium	O
chloride	O
on	O
ABA	O
200	O
Biochromatic	O
instrument	O
(	O
Abbott	O
Laboratories	O
,	O
North	O
Chicago	O
,	O
IL	O
)	O
.	O
LDL	O
-	O
C	O
was	O
calculated	O
using	O
the	O
Friedewald	O
equation	O
(	O
17	O
)	O
and	O
non	O
-	O
HDL	O
-	O
C	O
by	O
the	O
difference	O
between	O
total	O
cholesterol	O
and	O
HDL	O
-	O
C	O
.	O

ApoB	O
and	O
LDL	O
particle	O
(	O
LDL	O
-	O
P	O
)	O
were	O
measured	O
from	O
frozen	O
serum	O
(	O
Y2	O
)	O
and	O
EDTA	O
plasma	O
(	O
Y7	O
,	O
Y15	O
,	O
Y20	O
,	O
and	O
Y30	O
)	O
samples	O
by	O
NMR	O
spectroscopy	O
at	O
Labcorp	O
(	O
Morrisville	O
,	O
NC	O
)	O
using	O
the	O
high	O
-	O
throughput	O
Vantera®	O
Clinical	O
NMR	O
Analyzer	O
platform	O
.	O
ApoB	O
was	O
quantified	O
using	O
partial	O
least	O
squares	O
regression	O
modeling	O
of	O
the	O
lipid	O
methyl	O
and	O
methylene	O
spectral	O
region	O
as	O
previously	O
described	O
(	O
18	O
)	O
.	O
ApoB	O
concentrations	O
produced	O
by	O
this	O
assay	O
have	O
been	O
extensively	O
validated	O
as	O
equivalent	O
to	O
those	O
measured	O
by	O
immunoassay	O
(	O
R	O
=	O
0	O
.	O
98	O
)	O
,	O
with	O
precision	O
and	O
accuracy	O
verified	O
quarterly	O
by	O
blinded	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
Lipids	O
Standardization	O
Program	O
proficiency	O
testing	O
(	O
18	O
)	O
.	O
LDL	O
-	O
P	O
was	O
quantified	O
by	O
NMR	O
LipoProfile®	O
analysis	O
using	O
the	O
LP4	O
deconvolution	O
algorithm	O
(	O
18	O
,	O
19	O
)	O
.	O
Only	O
serum	O
was	O
available	O
for	O
the	O
Y2	O
samples	O
.	O
Because	O
of	O
well	O
-	O
described	O
dilution	O
effects	O
that	O
occur	O
in	O
EDTA	O
plasma	O
tubes	O
(	O
20	O
)	O
,	O
we	O
applied	O
a	O
previously	O
derived	O
CARDIA	O
-	O
specific	O
correction	O
factor	O
for	O
total	O
cholesterol	O
of	O
0	O
.	O
9666	O
to	O
the	O
NMR	O
-	O
derived	O
apoB	O
and	O
LDL	O
-	O
P	O
measures	O
that	O
were	O
obtained	O
from	O
the	O
Y2	O
serum	O
separator	O
tubes	O
.	O
To	O
describe	O
the	O
characteristics	O
associated	O
with	O
different	O
apoB	O
concentrations	O
in	O
midlife	O
,	O
we	O
stratified	O
participants	O
into	O
quartiles	O
of	O
apoB	O
concentration	O
at	O
Y20	O
and	O
showed	O
the	O
participant	O
characteristics	O
by	O
Y20	O
quartiles	O
at	O
the	O
Y2	O
,	O
Y7	O
,	O
Y15	O
,	O
Y20	O
,	O
and	O
Y30	O
exams	O
.	O
We	O
compared	O
demographics	O
,	O
anthropometrics	O
,	O
lifestyle	O
behaviors	O
,	O
and	O
traditional	O
risk	O
factor	O
data	O
across	O
quartiles	O
using	O
ANOVA	O
and	O
Chi	O
-	O
square	O
tests	O
as	O
appropriate	O
.	O
To	O
understand	O
the	O
shifts	O
in	O
apoB	O
concentration	O
distribution	O
over	O
time	O
in	O
CARDIA	O
,	O
we	O
generated	O
separate	O
distributions	O
of	O
apoB	O
at	O
exam	O
years	O
2	O
,	O
7	O
,	O
15	O
,	O
20	O
,	O
and	O
30	O
.	O
To	O
visualize	O
individual	O
-	O
level	O
change	O
in	O
apoB	O
,	O
LDL	O
-	O
P	O
,	O
LDL	O
-	O
C	O
,	O
and	O
non	O
-	O
HDL	O
-	O
C	O
concentrations	O
,	O
we	O
generated	O
spaghetti	O
plots	O
of	O
the	O
individual	O
participant	O
’	O
s	O
lipoprotein	O
concentrations	O
across	O
exams	O
.	O

Since	O
the	O
overall	O
pattern	O
of	O
change	O
appeared	O
mostly	O
linear	O
,	O
we	O
calculated	O
annualized	O
rates	O
of	O
lipoprotein	O
change	O
.	O
Individual	O
annualized	O
rates	O
of	O
change	O
were	O
calculated	O
by	O
subtracting	O
the	O
last	O
measured	O
atherogenic	O
lipoprotein	O
measure	O
(	O
Y20	O
or	O
Y30	O
)	O
value	O
by	O
the	O
first	O
measured	O
value	O
.	O
This	O
difference	O
in	O
atherogenic	O
lipoprotein	O
level	O
was	O
then	O
divided	O
by	O
the	O
time	O
between	O
the	O
first	O
and	O
last	O
atherogenic	O
lipoprotein	O
measurement	O
value	O
.	O
We	O
then	O
calculated	O
separate	O
quartiles	O
of	O
atherogenic	O
lipoprotein	O
annualized	O
rate	O
of	O
change	O
,	O
and	O
Y2	O
,	O
Y20	O
,	O
and	O
Y30	O
characteristics	O
were	O
compared	O
across	O
quartiles	O
.	O
We	O
also	O
created	O
a	O
distribution	O
of	O
atherogenic	O
lipoprotein	O
change	O
as	O
well	O
as	O
individual	O
-	O
level	O
waterfall	O
plot	O
of	O
annualized	O
rate	O
of	O
change	O
.	O
To	O
compare	O
intraindividual	O
variability	O
over	O
time	O
,	O
we	O
generated	O
distributions	O
of	O
the	O
percent	O
annual	O
change	O
in	O
each	O
lipid	O
measure	O
.	O
We	O
used	O
linear	O
regression	O
models	O
to	O
assess	O
the	O
associations	O
between	O
characteristics	O
and	O
rates	O
of	O
apoB	O
change	O
.	O
Models	O
were	O
adjusted	O
as	O
follows	O
:	O
model	O
1	O
:	O
first	O
measurement	O
of	O
apoB	O
to	O
account	O
for	O
the	O
level	O
at	O
which	O
the	O
participant	O
’	O
s	O
apoB	O
began	O
;	O
model	O
2	O
:	O
model	O
1	O
+	O
demographics	O
;	O
model	O
3	O
:	O
model	O
2	O
+	O
commonly	O
measured	O
clinical	O
characteristics	O
at	O
baseline	O
(	O
HDL	O
-	O
C	O
,	O
systolic	O
blood	O
pressure	O
,	O
BMI	O
,	O
blood	O
pressure	O
-	O
lowering	O
therapy	O
,	O
diabetes	O
mellitus	O
[	O
DM	O
]	O
status	O
,	O
current	O
tobacco	O
use	O
,	O
PA	O
[	O
exercise	O
units	O
]	O
,	O
serum	O
glucose	O
,	O
and	O
diet	O
[	O
HEI	O
]	O
)	O
;	O
and	O
model	O
4	O
:	O
model	O
2	O
+	O
yearly	O
averages	O
(	O
for	O
characteristics	O
not	O
assessed	O
at	O
each	O
exam	O
)	O
or	O
cumulative	O
values	O
(	O
for	O
those	O
characteristics	O
assessed	O
at	O
all	O
exams	O
)	O
of	O
the	O
commonly	O
measured	O
clinical	O
characteristics	O
used	O
in	O
model	O
3	O
.	O
Multicollinearity	O
was	O
tested	O
between	O
the	O
selected	O
independent	O
variables	O
using	O
the	O
variance	O
inflation	O
factor	O
,	O
and	O
none	O
was	O
found	O
.	O
To	O
assess	O
the	O
association	O
of	O
lipid	O
-	O
lowering	O
therapy	O
during	O
follow	O
-	O
up	O
,	O
we	O
repeated	O
the	O
analyses	O
outlined	O
above	O
after	O
removing	O
all	O
participants	O
(	O
N	O
=	O
717	O
)	O
who	O
reported	O
taking	O
lipid	O
-	O
lowering	O
pharmacotherapy	O
from	O
examination	O
Y2	O
though	O
Y30	O
as	O
a	O
sensitivity	O
analysis	O
.	O
Furthermore	O
,	O
more	O
than	O
2	O
,	O
000	O
participants	O
did	O
not	O
meet	O
NMR	O
analysis	O
criteria	O
and	O
were	O
not	O
included	O
in	O
the	O
primary	O
analysis	O
.	O

To	O
impute	O
the	O
missing	O
factors	O
,	O
we	O
conducted	O
multiple	O
imputation	O
by	O
chained	O
equations	O
with	O
fully	O
conditional	O
specification	O
using	O
the	O
SAS	O
MI	O
package	O
(	O
SAS	O
Institute	O
,	O
Cary	O
,	O
NC	O
)	O
(	O
21	O
)	O
.	O
NMR	O
lipid	O
measurements	O
and	O
related	O
risk	O
factors	O
from	O
all	O
visits	O
were	O
included	O
sequentially	O
in	O
the	O
model	O
specification	O
.	O
We	O
excluded	O
those	O
participants	O
who	O
died	O
prior	O
to	O
exam	O
year	O
7	O
(	O
two	O
exam	O
visits	O
for	O
annualized	O
apoB	O
change	O
calculation	O
)	O
,	O
and	O
finally	O
,	O
5	O
,	O
066	O
participants	O
were	O
included	O
in	O
the	O
imputation	O
model	O
.	O
We	O
created	O
10	O
imputed	O
datasets	O
,	O
and	O
the	O
imputed	O
values	O
were	O
set	O
to	O
missing	O
after	O
participants	O
died	O
.	O
The	O
distribution	O
of	O
covariates	O
between	O
the	O
observed	O
and	O
imputed	O
dataset	O
was	O
similar	O
.	O
Each	O
regression	O
analysis	O
described	O
above	O
was	O
performed	O
separately	O
in	O
each	O
of	O
the	O
imputed	O
datasets	O
,	O
and	O
the	O
results	O
were	O
combined	O
using	O
Rubin	O
’	O
s	O
rules	O
.	O
SAS	O
,	O
version	O
9	O
.	O
4	O
,	O
was	O
used	O
for	O
the	O
analysis	O
(	O
22	O
)	O
.	O
Participant	O
characteristics	O
at	O
Y2	O
and	O
Y20	O
,	O
stratified	O
by	O
quartile	O
of	O
apoB	O
concentration	O
at	O
Y20	O
,	O
are	O
presented	O
in	O
Tables	O
1	O
and	O
2	O
,	O
respectively	O
.	O
The	O
mean	O
(	O
SD	O
)	O
apoB	O
at	O
the	O
Y2	O
exam	O
was	O
85	O
.	O
2	O
(	O
20	O
.	O
2	O
)	O
mg	O
/	O
dl	O
.	O
At	O
the	O
Y2	O
exam	O
,	O
participants	O
in	O
the	O
higher	O
Y20	O
apoB	O
quartiles	O
were	O
more	O
likely	O
to	O
be	O
men	O
,	O
have	O
a	O
higher	O
BMI	O
,	O
greater	O
waist	O
circumference	O
,	O
higher	O
blood	O
pressure	O
,	O
and	O
have	O
lower	O
HEI	O
.	O
Those	O
in	O
the	O
higher	O
Y20	O
apoB	O
strata	O
had	O
lower	O
HDL	O
-	O
C	O
and	O
higher	O
Y2	O
apoB	O
,	O
LDL	O
-	O
C	O
,	O
non	O
-	O
HDL	O
-	O
C	O
,	O
and	O
TG	O
levels	O
as	O
well	O
.	O
Participant	O
characteristics	O
at	O
Y20	O
,	O
stratified	O
by	O
quartile	O
of	O
apoB	O
concentration	O
at	O
Y20	O
,	O
are	O
presented	O
in	O
Table	O
2	O
.	O
The	O
mean	O
(	O
SD	O
)	O
apoB	O
level	O
was	O
95	O
.	O
9	O
(	O
20	O
.	O
5	O
)	O
mg	O
/	O
dl	O
at	O
the	O
year	O
20	O
exam	O
.	O
As	O
was	O
seen	O
for	O
the	O
Y2	O
characteristics	O
,	O
when	O
compared	O
with	O
those	O
in	O
lower	O
quartiles	O
of	O
apoB	O
level	O
,	O
CARDIA	O
participants	O
with	O
higher	O
apoB	O
levels	O
at	O
Y20	O
exam	O
(	O
mean	O
age	O
=	O
45	O
years	O
)	O
were	O
more	O
likely	O
to	O
be	O
men	O
and	O
have	O
higher	O
BMI	O
,	O
waist	O
circumference	O
,	O
and	O
blood	O
pressures	O
.	O

Participants	O
with	O
higher	O
apoB	O
at	O
Y20	O
were	O
also	O
more	O
likely	O
to	O
have	O
lower	O
HDL	O
-	O
C	O
and	O
higher	O
glucose	O
.	O
As	O
expected	O
,	O
the	O
cholesterol	O
and	O
TG	O
concentrations	O
in	O
the	O
apoB	O
lipoproteins	O
were	O
higher	O
as	O
well	O
.	O
There	O
were	O
no	O
significant	O
differences	O
in	O
self	O
-	O
reported	O
saturated	O
fat	O
intake	O
,	O
though	O
the	O
HEI	O
was	O
lower	O
in	O
higher	O
apoB	O
groups	O
.	O
There	O
were	O
no	O
significant	O
differences	O
in	O
self	O
-	O
reported	O
PA	O
level	O
at	O
Y20	O
across	O
apoB	O
quartiles	O
.	O
The	O
characteristics	O
for	O
exam	O
Y7	O
,	O
Y15	O
,	O
and	O
Y30	O
are	O
presented	O
in	O
supplemental	O
Table	O
S1A	O
–	O
C	O
.	O
The	O
associations	O
between	O
characteristics	O
and	O
apoB	O
quartile	O
were	O
similar	O
in	O
Y7	O
,	O
Y15	O
,	O
and	O
Y30	O
when	O
compared	O
with	O
Y20	O
,	O
though	O
the	O
absolute	O
differences	O
in	O
these	O
characteristics	O
at	O
Y7	O
and	O
Y15	O
were	O
smaller	O
than	O
were	O
observed	O
at	O
Y20	O
and	O
Y30	O
.	O
The	O
distributions	O
of	O
apoB	O
stratified	O
by	O
race	O
and	O
sex	O
across	O
exam	O
years	O
2	O
,	O
7	O
,	O
15	O
,	O
20	O
,	O
and	O
30	O
are	O
presented	O
in	O
Fig	O
.	O
1	O
.	O
The	O
mean	O
(	O
SD	O
)	O
apoB	O
concentrations	O
at	O
exam	O
years	O
2	O
,	O
7	O
,	O
15	O
,	O
20	O
,	O
and	O
30	O
were	O
85	O
.	O
2	O
(	O
20	O
.	O
2	O
)	O
,	O
85	O
.	O
8	O
(	O
21	O
.	O
5	O
)	O
,	O
92	O
.	O
7	O
(	O
20	O
.	O
2	O
)	O
,	O
95	O
.	O
9	O
(	O
20	O
.	O
5	O
)	O
,	O
and	O
97	O
.	O
9	O
(	O
20	O
.	O
3	O
)	O
mg	O
/	O
dl	O
,	O
respectively	O
.	O
As	O
expected	O
,	O
the	O
correlation	O
coefficients	O
for	O
apoB	O
and	O
non	O
-	O
HDL	O
-	O
c	O
,	O
LDL	O
-	O
C	O
,	O
and	O
LDL	O
-	O
P	O
measured	O
at	O
the	O
Y20	O
exam	O
are	O
0	O
.	O
89	O
,	O
0	O
.	O
87	O
,	O
and	O
0	O
.	O
94	O
,	O
respectively	O
.	O
The	O
correlations	O
are	O
similar	O
across	O
exam	O
years	O
2	O
,	O
7	O
,	O
15	O
,	O
and	O
30	O
.	O
Spaghetti	O
plots	O
representing	O
individual	O
-	O
level	O
change	O
over	O
time	O
for	O
CARDIA	O
participants	O
,	O
stratified	O
by	O
the	O
decile	O
of	O
their	O
first	O
apoB	O
concentration	O
measurement	O
,	O
are	O
presented	O
in	O
Fig	O
.	O
2	O
.	O
Qualitatively	O
,	O
across	O
all	O
strata	O
of	O
first	O
baseline	O
apoB	O
measurement	O
,	O
the	O
interindividual	O
variance	O
in	O
apoB	O
appears	O
to	O
increase	O
over	O
the	O
early	O
adult	O
life	O
course	O
(	O
i	O
.	O
e	O
.	O
,	O
there	O
is	O
a	O
widening	O
distribution	O
over	O
time	O
among	O
individuals	O
with	O
very	O
similar	O
baseline	O
apoB	O
concentrations	O
)	O
.	O

The	O
pattern	O
of	O
change	O
for	O
most	O
participants	O
appears	O
to	O
be	O
fairly	O
linear	O
,	O
with	O
those	O
in	O
the	O
lower	O
baseline	O
level	O
more	O
likely	O
to	O
increase	O
over	O
time	O
and	O
those	O
in	O
highest	O
strata	O
somewhat	O
more	O
likely	O
to	O
decrease	O
over	O
time	O
.	O
Although	O
several	O
outlier	O
measurements	O
are	O
present	O
for	O
each	O
exam	O
year	O
,	O
on	O
subsequent	O
measurements	O
,	O
the	O
values	O
for	O
those	O
individuals	O
appear	O
more	O
normative	O
.	O
Patterns	O
of	O
change	O
were	O
similar	O
for	O
non	O
-	O
HDL	O
-	O
C	O
,	O
LDL	O
-	O
C	O
,	O
and	O
LDL	O
-	O
P	O
though	O
the	O
absolute	O
ranges	O
of	O
these	O
values	O
at	O
baseline	O
and	O
at	O
Y30	O
were	O
greater	O
(	O
data	O
not	O
shown	O
)	O
.	O
The	O
waterfall	O
plot	O
of	O
individual	O
-	O
level	O
annualized	O
rate	O
of	O
absolute	O
change	O
in	O
apoB	O
is	O
presented	O
in	O
Fig	O
.	O
3	O
.	O
The	O
mean	O
(	O
SD	O
)	O
rate	O
of	O
change	O
was	O
0	O
.	O
52	O
(	O
1	O
.	O
00	O
)	O
mg	O
/	O
dl	O
/	O
year	O
,	O
with	O
a	O
range	O
of	O
−6	O
.	O
2	O
to	O
9	O
.	O
2	O
mg	O
/	O
dl	O
/	O
year	O
from	O
a	O
participant	O
mean	O
age	O
of	O
27	O
through	O
45	O
years	O
.	O
White	O
females	O
had	O
a	O
slightly	O
higher	O
average	O
mean	O
rate	O
of	O
change	O
,	O
at	O
+	O
0	O
.	O
64	O
mg	O
/	O
dl	O
/	O
year	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
57	O
–	O
0	O
.	O
71	O
)	O
,	O
than	O
observed	O
in	O
all	O
other	O
race	O
/	O
sex	O
groups	O
(	O
mean	O
rate	O
and	O
95	O
%	O
CI	O
:	O
black	O
male	O
=	O
+	O
0	O
.	O
40	O
[	O
+	O
0	O
.	O
32	O
to	O
+	O
0	O
.	O
49	O
]	O
,	O
white	O
male	O
=	O
+	O
0	O
.	O
47	O
[	O
+	O
0	O
.	O
40	O
to	O
+	O
0	O
.	O
54	O
]	O
,	O
and	O
black	O
female	O
=	O
+	O
0	O
.	O
50	O
[	O
+	O
0	O
.	O
43	O
to	O
+	O
0	O
.	O
56	O
]	O
mg	O
/	O
dl	O
/	O
year	O
)	O
.	O
The	O
distributions	O
of	O
annualized	O
rates	O
of	O
change	O
in	O
sex	O
and	O
race	O
groups	O
are	O
presented	O
in	O
supplemental	O
Fig	O
.	O
S1	O
.	O
The	O
Y2	O
characteristics	O
of	O
quartiles	O
of	O
annualized	O
rate	O
of	O
change	O
quartiles	O
are	O
presented	O
in	O
Table	O
3	O
.	O
The	O
mean	O
(	O
SD	O
)	O
rates	O
of	O
change	O
in	O
the	O
lowest	O
to	O
the	O
highest	O
quartile	O
of	O
change	O
were	O
−0	O
.	O
7	O
(	O
0	O
.	O
7	O
)	O
,	O
+	O
0	O
.	O
3	O
(	O
0	O
.	O
2	O
)	O
,	O
+	O
0	O
.	O
8	O
(	O
0	O
.	O
2	O
)	O
,	O
and	O
+	O
1	O
.	O
7	O
(	O
0	O
.	O
6	O
)	O
mg	O
/	O
dl	O
/	O
year	O
,	O
respectively	O
.	O

Notably	O
,	O
the	O
quartiles	O
with	O
the	O
lowest	O
rate	O
of	O
increase	O
(	O
−0	O
.	O
7	O
mg	O
/	O
dl	O
/	O
year	O
)	O
had	O
the	O
highest	O
initial	O
apoB	O
concentration	O
of	O
102	O
.	O
7	O
(	O
21	O
.	O
0	O
)	O
mg	O
/	O
dl	O
,	O
and	O
the	O
group	O
with	O
the	O
highest	O
rate	O
of	O
increase	O
(	O
+	O
1	O
.	O
7	O
mg	O
/	O
dl	O
/	O
year	O
)	O
had	O
the	O
lowest	O
starting	O
apoB	O
concentration	O
of	O
76	O
.	O
1	O
(	O
16	O
.	O
1	O
)	O
mg	O
/	O
dl	O
.	O
Participants	O
in	O
the	O
higher	O
rate	O
of	O
increase	O
quartiles	O
were	O
more	O
likely	O
to	O
be	O
women	O
and	O
have	O
lower	O
BMI	O
,	O
waist	O
circumference	O
,	O
glucose	O
,	O
blood	O
pressure	O
,	O
higher	O
PA	O
and	O
HEI	O
,	O
and	O
a	O
lower	O
prevalence	O
of	O
DM	O
than	O
was	O
observed	O
in	O
the	O
lowest	O
rate	O
of	O
change	O
quartile	O
(	O
Table	O
3	O
)	O
.	O
The	O
Y20	O
characteristics	O
of	O
quartiles	O
of	O
annualized	O
rate	O
of	O
change	O
are	O
presented	O
in	O
Table	O
4	O
.	O
The	O
higher	O
rate	O
of	O
change	O
quartiles	O
had	O
a	O
higher	O
HDL	O
-	O
C	O
and	O
higher	O
concentrations	O
of	O
atherogenic	O
cholesterol	O
fractions	O
.	O
Interestingly	O
,	O
the	O
TG	O
concentrations	O
were	O
highest	O
in	O
the	O
lowest	O
and	O
highest	O
apoB	O
change	O
quartiles	O
.	O
Those	O
in	O
the	O
higher	O
rate	O
of	O
change	O
groups	O
had	O
lower	O
Y20	O
systolic	O
blood	O
pressures	O
,	O
lower	O
BMI	O
and	O
waist	O
circumference	O
,	O
and	O
lower	O
serum	O
glucose	O
levels	O
than	O
were	O
observed	O
in	O
the	O
lower	O
rate	O
of	O
change	O
groups	O
.	O
There	O
were	O
higher	O
HEI	O
and	O
PA	O
scores	O
in	O
participants	O
in	O
the	O
highest	O
rate	O
of	O
change	O
quartiles	O
when	O
compared	O
with	O
the	O
lowest	O
rate	O
of	O
change	O
.	O
Regular	O
alcohol	O
use	O
was	O
higher	O
in	O
the	O
higher	O
rate	O
of	O
apoB	O
change	O
quartiles	O
.	O
Spaghetti	O
plots	O
of	O
intraindividual	O
change	O
,	O
stratified	O
by	O
baseline	O
apoB	O
quartile	O
and	O
annualized	O
rate	O
of	O
change	O
quartile	O
,	O
are	O
shown	O
in	O
supplemental	O
Fig	O
.	O
S2	O
.	O
Of	O
those	O
in	O
the	O
lowest	O
quartile	O
of	O
first	O
measured	O
apoB	O
,	O
the	O
mean	O
(	O
SD	O
)	O
rate	O
of	O
change	O
was	O
+	O
1	O
.	O
0	O
(	O
0	O
.	O
69	O
)	O
mg	O
/	O
dl	O
/	O
year	O
.	O
Further	O
decreases	O
in	O
apoB	O
were	O
unusual	O
in	O
this	O
baseline	O
stratum	O
.	O
Of	O
those	O
in	O
the	O
middle	O
two	O
quartiles	O
of	O
baseline	O
apoB	O
measurement	O
,	O
the	O
distribution	O
across	O
strata	O
of	O
change	O
was	O
more	O
balanced	O
than	O
was	O
seen	O
in	O
the	O
highest	O
or	O
lowest	O
baseline	O
strata	O
.	O

In	O
those	O
in	O
the	O
highest	O
baseline	O
stratum	O
of	O
apoB	O
,	O
the	O
mean	O
(	O
SD	O
)	O
rate	O
of	O
change	O
was	O
−0	O
.	O
2	O
(	O
1	O
.	O
1	O
)	O
mg	O
/	O
dl	O
/	O
year	O
.	O
The	O
beta	O
coefficients	O
of	O
linear	O
regression	O
models	O
assessing	O
the	O
participant	O
characteristics	O
that	O
are	O
associated	O
with	O
rates	O
of	O
change	O
in	O
apoB	O
are	O
presented	O
in	O
Table	O
5	O
.	O
In	O
multivariable	O
analysis	O
,	O
lower	O
first	O
measured	O
apoB	O
,	O
female	O
sex	O
,	O
white	O
race	O
,	O
lower	O
BMI	O
,	O
and	O
current	O
tobacco	O
use	O
at	O
the	O
Y2	O
exam	O
were	O
significant	O
predictors	O
of	O
a	O
higher	O
rate	O
of	O
change	O
in	O
apoB	O
across	O
early	O
adulthood	O
.	O
When	O
cumulative	O
participant	O
characteristic	O
levels	O
across	O
follow	O
-	O
up	O
were	O
considered	O
(	O
model	O
4	O
)	O
in	O
multivariable	O
modeling	O
,	O
female	O
sex	O
,	O
white	O
race	O
,	O
lower	O
HDL	O
-	O
C	O
,	O
lower	O
glucose	O
,	O
and	O
alcohol	O
use	O
were	O
associated	O
with	O
an	O
increasing	O
annualized	O
rate	O
of	O
apoB	O
change	O
.	O
The	O
characteristics	O
of	O
those	O
included	O
versus	O
excluded	O
participants	O
are	O
presented	O
in	O
supplemental	O
Table	O
S2	O
.	O
When	O
using	O
an	O
imputed	O
dataset	O
,	O
we	O
observed	O
similar	O
findings	O
regarding	O
to	O
the	O
mean	O
and	O
range	O
of	O
apoB	O
across	O
all	O
exam	O
years	O
,	O
and	O
the	O
average	O
annualized	O
rate	O
of	O
apoB	O
change	O
between	O
first	O
and	O
last	O
measured	O
apoB	O
.	O
In	O
multivariable	O
models	O
,	O
all	O
the	O
predictors	O
as	O
well	O
as	O
their	O
relative	O
strength	O
of	O
association	O
with	O
apoB	O
change	O
were	O
similar	O
to	O
the	O
unimputed	O
dataset	O
.	O
When	O
CARDIA	O
participants	O
who	O
initiated	O
lipid	O
-	O
lowering	O
therapy	O
during	O
follow	O
-	O
up	O
were	O
removed	O
from	O
the	O
analysis	O
dataset	O
,	O
the	O
mean	O
BMI	O
,	O
TG	O
level	O
,	O
glucose	O
,	O
and	O
DM	O
prevalence	O
in	O
the	O
lowest	O
rate	O
of	O
change	O
quartile	O
at	O
Y20	O
were	O
lower	O
than	O
observed	O
in	O
the	O
primary	O
analysis	O
,	O
suggesting	O
that	O
some	O
of	O
the	O
decrease	O
in	O
apoB	O
in	O
that	O
group	O
was	O
due	O
to	O
the	O
use	O
of	O
lipid	O
-	O
lowering	O
therapy	O
in	O
higher	O
risk	O
individuals	O
.	O
However	O
,	O
removal	O
of	O
treated	O
participants	O
resulted	O
in	O
very	O
minor	O
differences	O
in	O
the	O
annualized	O
rates	O
of	O
change	O
and	O
had	O
no	O
effect	O
on	O
multivariable	O
predictors	O
of	O
apoB	O
change	O
over	O
time	O
.	O
The	O
distributions	O
of	O
percent	O
annual	O
change	O
for	O
apoB	O
,	O
non	O
-	O
HDL	O
-	O
C	O
,	O
LDL	O
-	O
C	O
,	O
and	O
LDL	O
-	O
P	O
are	O
shown	O
in	O
Fig	O
.	O
4	O
.	O

The	O
ranges	O
of	O
percent	O
change	O
for	O
LDL	O
-	O
P	O
,	O
LDL	O
-	O
C	O
,	O
and	O
non	O
-	O
HDL	O
-	O
C	O
are	O
larger	O
than	O
the	O
range	O
of	O
percent	O
change	O
for	O
apoB	O
.	O
The	O
SDs	O
of	O
the	O
percent	O
annualized	O
rate	O
of	O
change	O
for	O
apoB	O
,	O
non	O
-	O
HDL	O
-	O
C	O
,	O
LDL	O
-	O
C	O
,	O
and	O
LDL	O
-	O
P	O
were	O
1	O
.	O
2	O
,	O
1	O
.	O
4	O
,	O
1	O
.	O
5	O
,	O
and	O
1	O
.	O
7	O
,	O
respectively	O
.	O
As	O
shown	O
in	O
Fig	O
.	O
4	O
,	O
close	O
to	O
40	O
%	O
of	O
CARDIA	O
participants	O
had	O
a	O
negative	O
annualized	O
percent	O
change	O
in	O
non	O
-	O
HDL	O
-	O
C	O
,	O
LDL	O
-	O
C	O
,	O
and	O
LDL	O
-	O
P	O
during	O
early	O
adult	O
life	O
,	O
whereas	O
approximately	O
20	O
%	O
of	O
CARDIA	O
participants	O
had	O
a	O
negative	O
annualized	O
percent	O
change	O
in	O
apoB	O
.	O
The	O
mean	O
percent	O
change	O
was	O
+	O
0	O
.	O
77	O
,	O
+	O
0	O
.	O
46	O
,	O
+	O
0	O
.	O
20	O
,	O
and	O
+	O
0	O
.	O
62	O
for	O
apoB	O
,	O
non	O
-	O
HDL	O
-	O
C	O
,	O
LDL	O
-	O
C	O
,	O
and	O
LDL	O
-	O
P	O
,	O
respectively	O
.	O
Across	O
all	O
exams	O
,	O
the	O
absolute	O
ranges	O
of	O
non	O
-	O
HDL	O
-	O
C	O
,	O
LDL	O
-	O
C	O
,	O
and	O
LDL	O
-	O
P	O
values	O
are	O
greater	O
than	O
apoB	O
,	O
thus	O
the	O
modest	O
differences	O
in	O
percent	O
change	O
in	O
LDL	O
-	O
C	O
,	O
non	O
-	O
HDL	O
-	O
C	O
,	O
and	O
LDL	O
-	O
P	O
reflect	O
,	O
on	O
average	O
,	O
larger	O
annual	O
changes	O
in	O
absolute	O
value	O
over	O
time	O
in	O
these	O
measures	O
(	O
per	O
percent	O
change	O
)	O
when	O
compared	O
with	O
apoB	O
.	O
Leveraging	O
unique	O
data	O
from	O
a	O
well	O
-	O
phenotyped	O
cohort	B-methodology
of	O
young	O
adults	O
followed	O
for	O
two	O
decades	O
with	O
multiple	O
measures	O
of	O
apoB	O
,	O
we	O
describe	O
distributions	O
of	O
apoB	O
concentrations	O
and	O
demonstrate	O
only	O
modest	O
differences	O
in	O
distributions	O
by	O
sex	O
across	O
young	O
adulthood	O
.	O
We	O
also	O
observed	O
that	O
apoB	O
levels	O
are	O
dynamic	O
across	O
the	O
early	O
adult	O
life	O
course	O
,	O
and	O
intraindividual	O
change	O
in	O
apoB	O
over	O
time	O
tended	O
to	O
be	O
linear	O
.	O
The	O
mean	O
(	O
SD	O
)	O
rate	O
of	O
change	O
was	O
0	O
.	O
52	O
(	O
1	O
.	O
0	O
)	O
mg	O
/	O
dl	O
/	O
year	O
,	O
with	O
a	O
range	O
of	O
−6	O
.	O
26	O
to	O
+	O
9	O
.	O
21	O
mg	O
/	O
dl	O
/	O
year	O
.	O
The	O
baseline	O
apoB	O
concentration	O
was	O
significantly	O
and	O
inversely	O
associated	O
with	O
apoB	O
change	O
,	O
whereas	O
female	O
sex	O
,	O
lower	O
BMI	O
,	O
and	O
higher	O
HDL	O
-	O
C	O
level	O
had	O
more	O
modest	O
associations	O
with	O
increasing	O
apoB	O
during	O
the	O
early	O
adult	O
life	O
course	O
.	O

The	O
substantial	O
interindividual	O
variation	O
in	O
apoB	O
change	O
over	O
time	O
as	O
well	O
as	O
the	O
relatively	O
modest	O
associations	O
between	O
baseline	O
clinical	O
characteristics	O
(	O
other	O
than	O
first	O
apoB	O
measurement	O
)	O
and	O
apoB	O
change	O
suggest	O
that	O
commonly	O
measured	O
clinical	O
characteristics	O
(	O
at	O
least	O
at	O
one	O
time	O
point	O
)	O
are	O
unlikely	O
to	O
predict	O
future	O
apoB	O
levels	O
well	O
.	O
The	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
distributions	O
of	O
apoB	O
that	O
we	O
observed	O
at	O
exam	O
years	O
in	O
CARDIA	O
are	O
consistent	O
with	O
distributions	O
that	O
were	O
reported	O
in	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
NHANES	O
)	O
III	O
study	O
(	O
23	O
)	O
.	O
However	O
,	O
our	O
study	O
is	O
the	O
first	O
description	O
of	O
untreated	O
intraindividual	O
change	O
in	O
apoB	O
concentration	O
across	O
28	O
years	O
of	O
the	O
early	O
adult	O
life	O
course	O
.	O
In	O
NHANES	O
III	O
study	O
,	O
differences	O
in	O
the	O
mean	O
apoB	O
concentration	O
between	O
the	O
20	O
-	O
to	O
30	O
-	O
and	O
40	O
-	O
to	O
50	O
-	O
year	O
-	O
old	O
age	O
groups	O
were	O
21	O
mg	O
/	O
dl	O
for	O
men	O
and	O
8	O
mg	O
/	O
dl	O
for	O
women	O
,	O
which	O
suggested	O
that	O
apoB	O
levels	O
increase	O
with	O
age	O
(	O
23	O
)	O
.	O
However	O
,	O
NHANES	O
III	O
was	O
a	O
serial	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
survey	I-methodology
,	O
and	O
the	O
different	O
age	O
ranges	O
were	O
not	O
derived	O
from	O
a	O
cohort	B-methodology
.	O
Thus	O
,	O
differences	O
in	O
apoB	O
concentration	O
by	O
age	O
group	O
observed	O
in	O
NHANES	O
III	O
study	O
could	O
be	O
due	O
to	O
birth	O
cohort	B-methodology
effects	O
and	O
differences	O
in	O
the	O
sampling	O
of	O
individuals	O
that	O
represented	O
different	O
age	O
groups	O
.	O
Thus	O
,	O
the	O
patterns	O
and	O
rates	O
of	O
change	O
in	O
apoB	O
concentration	O
and	O
their	O
correlates	O
that	O
we	O
report	O
in	O
this	O
article	O
could	O
not	O
have	O
been	O
determined	O
from	O
the	O
NHANES	O
III	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
data	O
alone	O
.	O
ApoB	O
blood	O
concentrations	O
are	O
determined	O
by	O
the	O
rates	O
at	O
which	O
apoB	O
lipoproteins	O
are	O
produced	O
and	O
cleared	O
from	O
the	O
plasma	O
(	O
2	O
,	O
24	O
)	O
.	O
In	O
most	O
individuals	O
,	O
the	O
majority	O
of	O
apoB	O
lipoproteins	O
present	O
in	O
the	O
blood	O
are	O
VLDL	O
and	O
LDL	O
-	O
Ps	O
.	O

Thus	O
,	O
the	O
rates	O
of	O
production	O
and	O
clearance	O
of	O
VLDL	O
and	O
LDL	O
-	O
Ps	O
determine	O
most	O
of	O
the	O
intraindividual	O
and	O
interindividual	O
differences	O
in	O
apoB	O
.	O
Although	O
the	O
mediators	O
of	O
apoB	O
synthetic	O
rate	O
and	O
VLDL	O
particle	O
assembly	O
are	O
not	O
completely	O
understood	O
,	O
feeding	O
and	O
lipid	O
kinetic	O
studies	O
have	O
demonstrated	O
that	O
overnutrition	O
,	O
exogenous	O
intake	O
of	O
saturated	O
fats	O
and	O
simple	O
carbohydrates	O
,	O
and	O
/	O
or	O
insulin	O
resistance	O
causes	O
increases	O
in	O
VLDL	O
particles	O
and	O
therefore	O
increased	O
total	O
apoB	O
(	O
25	O
,	O
26	O
,	O
27	O
)	O
.	O
Thus	O
,	O
chronic	O
excess	O
caloric	O
intake	O
,	O
weight	O
gain	O
,	O
and	O
insulin	O
resistance	O
that	O
occurred	O
during	O
follow	O
-	O
up	O
likely	O
account	O
for	O
some	O
of	O
the	O
apoB	O
increases	O
observed	O
in	O
this	O
analysis	O
.	O
Binding	O
of	O
the	O
apoB	O
molecules	O
present	O
on	O
LDL	O
-	O
Ps	O
to	O
the	O
LDL	O
receptor	O
causes	O
removal	O
of	O
the	O
LDL	O
-	O
P	O
from	O
the	O
serum	O
and	O
downregulation	O
of	O
cholesterol	O
synthesis	O
(	O
28	O
)	O
.	O
Therefore	O
,	O
to	O
the	O
extent	O
that	O
removal	O
of	O
LDL	O
-	O
Ps	O
depends	O
on	O
the	O
activity	O
of	O
the	O
LDL	O
receptor	O
pathway	O
,	O
a	O
decrease	O
in	O
LDL	O
receptor	O
density	O
with	O
age	O
may	O
partially	O
explain	O
the	O
trend	O
to	O
higher	O
levels	O
of	O
apoB	O
seen	O
in	O
many	O
individuals	O
.	O
However	O
,	O
apoB	O
is	O
present	O
on	O
remnant	O
,	O
VLDL	O
,	O
and	O
Lp	O
(	O
a	O
)	O
as	O
well	O
as	O
LDL	O
-	O
Ps	O
.	O
The	O
relative	O
molar	O
concentration	O
of	O
each	O
of	O
these	O
lipoprotein	O
species	O
can	O
vary	O
within	O
and	O
across	O
individuals	O
over	O
time	O
,	O
and	O
some	O
of	O
the	O
non	O
-	O
LDL	O
apoB	O
lipoprotein	O
species	O
are	O
not	O
directly	O
cleared	O
by	O
the	O
LDL	O
receptor	O
(	O
29	O
)	O
.	O
Therefore	O
,	O
change	O
in	O
apoB	O
concentration	O
should	O
not	O
be	O
solely	O
attributed	O
to	O
the	O
LDL	O
receptor	O
density	O
change	O
and	O
alternative	O
exposures	O
,	O
and	O
biologic	O
pathways	O
must	O
contribute	O
to	O
the	O
variation	O
in	O
apoB	O
concentration	O
observed	O
with	O
aging	O
over	O
the	O
early	O
adult	O
life	O
course	O
.	O
Regression	O
to	O
the	O
mean	O
likely	O
contributes	O
to	O
some	O
of	O
the	O
observed	O
patterns	O
of	O
change	O
that	O
we	O
report	O
,	O
as	O
those	O
in	O
the	O
highest	O
and	O
lowest	O
first	O
apoB	O
measurement	O
were	O
more	O
likely	O
,	O
on	O
average	O
,	O
to	O
have	O
repeated	O
values	O
that	O
were	O
closer	O
to	O
normative	O
apoB	O
values	O
.	O
Repeated	O
measures	O
of	O
biological	O
phenomena	O
typically	O
provide	O
a	O
more	O
accurate	O
estimate	O
of	O
an	O
individual	O
’	O
s	O
“	O
usual	O
”	O
values	O
;	O
the	O
extent	O
to	O
which	O
this	O
phenomenon	O
is	O
driven	O
by	O
measurement	O
error	O
versus	O
true	O
biologic	O
variation	O
cannot	O
be	O
determined	O
from	O
this	O
study	O
.	O

Nonetheless	O
,	O
regression	O
to	O
the	O
mean	O
is	O
seen	O
in	O
clinical	B-methodology
practice	I-methodology
when	O
serial	O
lipid	O
testing	O
is	O
performed	O
in	O
individual	O
patients	O
.	O
Thus	O
,	O
our	O
findings	O
are	O
instructive	O
and	O
inform	O
what	O
may	O
be	O
seen	O
in	O
individual	O
patient	O
care	O
.	O
The	O
substantial	O
changes	O
observed	O
over	O
time	O
,	O
as	O
well	O
as	O
the	O
modest	O
associations	O
with	O
baseline	O
predictors	O
reported	O
above	O
,	O
suggest	O
that	O
clinicians	O
will	O
not	O
be	O
able	O
to	O
predict	O
using	O
readily	O
available	O
clinical	O
information	O
what	O
a	O
young	O
adult	O
patient	O
’	O
s	O
apoB	O
level	O
may	O
be	O
5	O
–	O
15	O
years	O
after	O
a	O
one	O
-	O
time	O
measurement	O
.	O
Thus	O
,	O
serial	O
measurement	O
would	O
be	O
needed	O
to	O
monitor	O
a	O
patient	O
’	O
s	O
apoB	O
exposure	O
across	O
early	O
adult	O
life	O
.	O
Nonetheless	O
,	O
the	O
rates	O
of	O
change	O
that	O
we	O
report	O
from	O
CARDIA	O
(	O
mean	O
rate	O
=	O
0	O
.	O
52	O
mg	O
/	O
dl	O
/	O
year	O
)	O
may	O
be	O
useful	O
when	O
serial	O
apoB	O
testing	O
is	O
performed	O
,	O
as	O
clinicians	O
can	O
now	O
have	O
a	O
reference	O
value	O
for	O
the	O
normative	O
,	O
though	O
not	O
necessarily	O
optimal	O
,	O
rates	O
of	O
change	O
in	O
apoB	O
concentration	O
.	O
Although	O
we	O
observed	O
substantial	O
variation	O
in	O
apoB	O
levels	O
across	O
early	O
adult	O
life	O
,	O
the	O
intraindividual	O
variation	O
in	O
apoB	O
level	O
across	O
early	O
adult	O
life	O
was	O
less	O
than	O
that	O
was	O
observed	O
for	O
non	O
-	O
HDL	O
-	O
C	O
,	O
LDL	O
-	O
C	O
,	O
and	O
LDL	O
-	O
P	O
.	O
These	O
observations	O
suggest	O
that	O
of	O
the	O
indices	O
of	O
atherogenic	O
lipoprotein	O
burden	O
,	O
apoB	O
is	O
the	O
most	O
stable	O
during	O
early	O
adult	O
life	O
.	O
Thus	O
,	O
in	O
young	O
adults	O
,	O
one	O
-	O
time	O
measures	O
of	O
aopB	O
may	O
be	O
a	O
better	O
(	O
though	O
still	O
likely	O
inadequate	O
)	O
marker	O
of	O
expected	O
future	O
cumulative	O
atherogenic	O
lipoprotein	O
exposure	O
than	O
non	O
-	O
HDL	O
-	O
C	O
,	O
LDL	O
-	O
C	O
,	O
and	O
LDL	O
-	O
P	O
.	O
However	O
,	O
further	O
research	O
is	O
needed	O
to	O
determine	O
if	O
these	O
differences	O
in	O
stability	O
of	O
these	O
measures	O
of	O
atherogenic	O
lipoprotein	O
burden	O
during	O
early	O
adult	O
life	O
translate	O
into	O
meaningful	O
differences	O
in	O
long	O
-	O
term	O
risk	O
estimation	O
for	O
young	O
adults	O
.	O
Similarly	O
,	O
the	O
lower	O
intrinsic	O
variability	O
in	O
apoB	O
during	O
early	O
adult	O
life	O
—	O
in	O
the	O
context	O
of	O
its	O
well	O
-	O
known	O
mediating	O
effect	O
on	O
ASCVD	O
risk	O
—	O
may	O
indicate	O
that	O
apoB	O
is	O
a	O
better	O
target	O
for	O
lifestyle	O
optimization	O
of	O
lipid	O
-	O
lowering	O
therapy	O
in	O
some	O
.	O
This	O
study	O
has	O
several	O
notable	O
strengths	O
.	O
First	O
,	O
this	O
article	O
represents	O
the	O
first	O
description	O
of	O
rates	O
of	O
change	O
in	O
apoB	O
across	O
the	O
early	O
adult	O
life	O
course	O
using	O
multiple	O
longitudinal	O
measurements	O
in	O
black	O
and	O
white	O
men	O
and	O
women	O
in	O
a	O
community	O
-	O
based	O
sample	O
.	O

Second	O
,	O
in	O
addition	O
to	O
statistics	O
of	O
central	O
tendency	O
(	O
mean	O
,	O
median	O
,	O
SD	O
,	O
etc	O
.	O
)	O
,	O
we	O
show	O
individual	O
-	O
level	O
patterns	O
of	O
change	O
in	O
the	O
spaghetti	O
plots	O
and	O
waterfall	O
plots	O
,	O
which	O
can	O
help	O
contextualize	O
patient	O
-	O
level	O
observations	O
in	O
clinical	B-methodology
practice	I-methodology
.	O
Third	O
,	O
the	O
quality	O
of	O
demographic	O
and	O
behavioral	O
assessment	O
as	O
well	O
as	O
traditional	O
risk	O
factor	O
measurements	O
in	O
the	O
CARDIA	O
study	O
is	O
excellent	O
.	O
Fourth	O
,	O
our	O
observations	O
of	O
apoB	O
are	O
put	O
in	O
context	O
of	O
other	O
commonly	O
used	O
atherogenic	O
lipid	O
measures	O
.	O
Several	O
limitations	O
should	O
be	O
considered	O
as	O
well	O
.	O
First	O
,	O
CARDIA	O
enrolled	O
exclusively	O
self	O
-	O
reported	O
black	O
and	O
white	O
Americans	O
.	O
Thus	O
,	O
it	O
is	O
unclear	O
if	O
the	O
patterns	O
and	O
rates	O
of	O
change	O
that	O
we	O
report	O
are	O
generalizable	O
to	O
other	O
race	O
and	O
ethnicity	O
groups	O
.	O
Second	O
,	O
since	O
our	O
interest	O
was	O
in	O
describing	O
longitudinal	O
patterns	O
of	O
apoB	O
change	O
,	O
we	O
included	O
CARDIA	O
participants	O
who	O
attended	O
the	O
Y20	O
and	O
at	O
least	O
two	O
of	O
the	O
previous	O
exams	O
(	O
Y15	O
,	O
Y7	O
,	O
or	O
Y2	O
)	O
.	O
Thus	O
,	O
participants	O
who	O
were	O
lost	O
to	O
follow	O
-	O
up	O
or	O
died	O
prior	O
to	O
the	O
Y20	O
exam	O
were	O
not	O
included	O
in	O
this	O
analysis	O
,	O
which	O
disproportionally	O
excluded	O
young	O
black	O
men	O
because	O
of	O
lower	O
rates	O
of	O
follow	O
-	O
up	O
in	O
this	O
group	O
(	O
30	O
)	O
.	O
However	O
,	O
sensitivity	O
analyses	O
that	O
imputed	O
missing	O
data	O
did	O
not	O
significantly	O
change	O
our	O
reported	O
results	O
.	O
Our	O
inclusion	B-methodology
criteria	I-methodology
also	O
excluded	O
some	O
participants	O
with	O
chronic	O
diseases	O
(	O
e	O
.	O
g	O
.	O
,	O
HIV	O
)	O
who	O
either	O
died	O
or	O
did	O
not	O
attend	O
the	O
Y20	O
exam	O
.	O
Patterns	O
of	O
apoB	O
change	O
may	O
be	O
different	O
in	O
young	O
individuals	O
with	O
severe	O
chronic	O
illness	O
;	O
thus	O
,	O
our	O
results	O
may	O
not	O
correctly	O
inform	O
the	O
expected	O
apoB	O
rates	O
of	O
change	O
in	O
specific	O
subgroups	O
of	O
patients	O
with	O
chronic	O
illness	O
.	O
Third	O
,	O
NMR	O
does	O
not	O
provide	O
a	O
direct	O
measurement	O
of	O
apoB	O
but	O
a	O
derived	O
value	O
from	O
magnetic	O
resonance	O
decay	O
signals	O
of	O
lipid	O
methyl	O
and	O
methylene	O
groups	O
.	O
However	O
,	O
we	O
are	O
confident	O
in	O
the	O
accuracy	O
and	O
precision	O
of	O
the	O
apoB	O
values	O
provided	O
by	O
NMR	O
as	O
NMR	O
apoB	O
measures	O
have	O
been	O
previously	O
validated	O
against	O
immunonephelometry	O
on	O
standard	O
assays	O
with	O
r2	O
values	O
of	O
0	O
.	O
98	O
(	O
31	O
)	O
.	O
Furthermore	O
,	O
if	O
the	O
accuracy	O
of	O
the	O
NMR	O
apoB	O
measure	O
was	O
poor	O
but	O
consistent	O
,	O
then	O
the	O
patterns	O
and	O
rates	O
of	O
change	O
as	O
well	O
as	O
the	O
variance	O
in	O
these	O
rates	O
that	O
we	O
report	O
would	O
not	O
be	O
affected	O
.	O

On	O
the	O
other	O
hand	O
,	O
if	O
precision	O
of	O
apoB	O
quantification	O
was	O
worse	O
than	O
other	O
atherogenic	O
lipid	O
measures	O
,	O
we	O
would	O
have	O
expected	O
greater	O
variance	O
in	O
apoB	O
change	O
than	O
is	O
observed	O
in	O
LDL	O
-	O
C	O
,	O
non	O
-	O
HDL	O
-	O
C	O
,	O
and	O
LDL	O
-	O
P	O
,	O
but	O
we	O
observed	O
the	O
opposite	O
—	O
apoB	O
had	O
less	O
variance	O
over	O
time	O
than	O
directly	O
measured	O
lipid	O
values	O
.	O
In	O
summary	O
,	O
this	O
article	O
represents	O
the	O
first	O
description	O
of	O
intraindividual	O
apoB	O
concentration	O
change	O
over	O
the	O
early	O
adult	O
life	O
course	O
.	O
ApoB	O
concentrations	O
over	O
time	O
are	O
dynamic	O
,	O
with	O
the	O
average	O
person	O
experiencing	O
a	O
+	O
0	O
.	O
52	O
mg	O
/	O
dl	O
/	O
year	O
increase	O
(	O
[UNK]	O
mg	O
/	O
dl	O
over	O
28	O
years	O
)	O
.	O
Furthermore	O
,	O
the	O
interindividual	O
variation	O
in	O
change	O
over	O
time	O
is	O
substantial	O
as	O
well	O
(	O
range	O
of	O
−6	O
.	O
2	O
to	O
+	O
9	O
.	O
2	O
mg	O
/	O
dl	O
/	O
year	O
)	O
,	O
and	O
the	O
ability	O
to	O
predict	O
an	O
individual	O
’	O
s	O
rate	O
of	O
change	O
using	O
one	O
-	O
time	O
assessment	O
of	O
traditional	O
clinical	O
variables	O
appears	O
modest	O
.	O
However	O
,	O
although	O
absolute	O
variation	O
of	O
apoB	O
blood	O
concentration	O
was	O
significant	O
across	O
early	O
adult	O
life	O
,	O
it	O
was	O
less	O
than	O
was	O
observed	O
for	O
NDHL	O
-	O
C	O
,	O
LDL	O
-	O
C	O
,	O
and	O
LDL	O
-	O
P	O
,	O
suggesting	O
that	O
of	O
these	O
measures	O
,	O
apoB	O
is	O
the	O
most	O
consistent	O
measure	O
of	O
atherogenic	O
lipoprotein	O
burden	O
in	O
young	O
adults	O
.	O
Nonetheless	O
,	O
in	O
total	O
,	O
these	O
observations	O
suggest	O
that	O
serial	O
apoB	O
testing	O
is	O
needed	O
if	O
one	O
aims	O
to	O
quantify	O
the	O
cumulative	O
burden	O
of	O
apoB	O
atherogenic	O
particles	O
across	O
early	O
adult	O
life	O
.	O
Furthermore	O
,	O
an	O
improved	O
understanding	O
of	O
the	O
risks	O
associated	O
with	O
different	O
apoB	O
concentrations	O
,	O
as	O
well	O
as	O
the	O
presence	O
of	O
potentially	O
critical	O
thresholds	O
of	O
exposure	O
or	O
potentially	O
critical	O
periods	O
of	O
exposure	O
during	O
early	O
adult	O
life	O
,	O
is	O
needed	O
to	O
inform	O
testing	O
guidelines	B-methodology
for	O
this	O
central	O
determinant	O
of	O
ASCVD	O
risk	O
.	O
The	O
data	O
that	O
support	O
the	O
findings	O
of	O
this	O
study	O
are	O
available	O
in	O
the	O
CARDIA	O
study	O
by	O
request	O
.	O
This	O
article	O
contains	O
supplemental	O
data	O
.	O
Dr	O
Wilkins	O
reports	O
consulting	O
work	O
for	O
3M	O
.	O
The	O
authors	O
thank	O
the	O
other	O
investigators	O
,	O
staff	O
,	O
and	O
participants	O
of	O
the	O
CARDIA	O
study	O
for	O
their	O
valuable	O
contributions	O
.	O
A	O
full	O
list	O
of	O
participating	O
CARDIA	O
investigators	O
and	O
institutions	O
can	O
be	O
found	O
at	O
https	O
:	O
/	O
/	O
www	O
.	O
cardia	O
.	O
dopm	O
.	O
uab	O
.	O
edu	O
/	O
.	O

The	O
CARDIA	O
study	O
is	O
conducted	O
and	O
supported	O
by	O
the	O
10	O
.	O
13039	O
/	O
100000050National	O
Heart	O
,	O
Lung	O
,	O
and	O
Blood	O
Institute	O
in	O
collaboration	O
with	O
the	O
10	O
.	O
13039	O
/	O
100008333University	O
of	O
Alabama	O
at	O
Birmingham	O
(	O
grant	O
nos	O
.	O
:	O
HHSN268201800005I	O
and	O
HHSN268201800007I	O
)	O
,	O
10	O
.	O
13039	O
/	O
100007059Northwestern	O
University	O
(	O
grant	O
no	O
.	O
:	O
HHSN268201800003I	O
)	O
,	O
10	O
.	O
13039	O
/	O
100007249University	O
of	O
Minnesota	O
(	O
grant	O
no	O
.	O
:	O
HHSN268201800006I	O
)	O
,	O
and	O
10	O
.	O
13039	O
/	O
100007241Kaiser	O
Foundation	O
Research	O
Institute	O
(	O
grant	O
no	O
.	O
:	O
HHSN268201800004I	O
)	O
.	O
This	O
article	O
has	O
been	O
reviewed	O
by	O
CARDIA	O
for	O
scientific	O
content	O
.	O
J	O
.	O
T	O
.	O
W	O
.	O
and	O
A	O
.	O
S	O
.	O
conceptualization	O
;	O
J	O
.	O
T	O
.	O
W	O
.	O
,	O
H	O
.	O
N	O
.	O
,	O
J	O
.	O
O	O
.	O
,	O
D	O
.	O
R	O
.	O
J	O
.	O
,	O
N	O
.	O
A	O
.	O
,	O
and	O
D	O
.	O
M	O
.	O
L	O
.	O
methodology	O
;	O
H	O
.	O
N	O
.	O
,	O
J	O
.	O
O	O
.	O
,	O
D	O
.	O
R	O
.	O
J	O
.	O
,	O
and	O
N	O
.	O
A	O
.	O
formal	O
analysis	O
;	O
J	O
.	O
T	O
.	O
W	O
.	O
writing	O
–	O
original	O
draft	O
;	O
J	O
.	O
T	O
.	O
W	O
.	O
,	O
H	O
.	O
N	O
.	O
,	O
A	O
.	O
S	O
.	O
,	O
N	O
.	O
S	O
.	O
,	O
J	O
.	O
O	O
.	O
,	O
D	O
.	O
R	O
.	O
J	O
.	O
,	O
R	O
.	O
S	O
.	O
,	O
V	O
.	O
L	O
.	O
M	O
.	O
,	O
J	O
.	O
R	O
.	O
,	O
N	O
.	O
A	O
.	O
,	O
and	O
D	O
.	O
M	O
.	O
L	O
.	O
writing	O
–	O
review	O
&	O
editing	O
.	O
This	O
research	O
was	O
supported	O
by	O
the	O
10	O
.	O
13039	O
/	O
100000002National	O
Institutes	O
of	O
Health	O
,	O
under	O
grant	O
R01	O
HL146844	O
(	O
to	O
J	O
.	O
T	O
.	O
W	O
.	O
)	O
.	O
The	O
content	O
is	O
solely	O
the	O
responsibility	O
of	O
the	O
authors	O
and	O
does	O
not	O
necessarily	O
represent	O
the	O
official	O
views	O
of	O
the	O
National	O
Institutes	O
of	O
Health	O
.	O

Environmental	O
Exposure	O
to	O
Dioxins	O
,	O
Dibenzofurans	O
,	O
Bisphenol	O
A	O
,	O
and	O
Phthalates	O
in	O
Children	O
with	O
and	O
without	O
Autism	O
Spectrum	O
Disorder	O
Living	O
near	O
the	O
Gulf	O
of	O
Mexico	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
;	O
dioxins	O
;	O
dibenzofurans	O
;	O
bisphenol	O
A	O
;	O
phthalates	O
;	O
neurodevelopmental	O
disorder	O
;	O
Gulf	O
of	O
Mexico	O
;	O
children	O
Environmental	O
exposure	O
to	O
organic	O
endocrine	O
disrupting	O
chemicals	O
,	O
including	O
dioxins	O
,	O
dibenzofurans	O
,	O
bisphenol	O
A	O
(	O
BPA	O
)	O
,	O
and	O
phthalates	O
has	O
been	O
associated	O
with	O
neurodevelopmental	O
disorders	O
,	O
including	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
.	O
We	O
conducted	O
a	O
pilot	O
monitoring	O
study	O
of	O
30	O
ASD	O
cases	O
and	O
10	O
typically	O
developing	O
(	O
TD	O
)	O
controls	O
ages	O
2	O
–	O
8	O
years	O
from	O
communities	O
along	O
the	O
Gulf	O
of	O
Mexico	O
near	O
Alabama	O
,	O
which	O
houses	O
14	O
Superfund	O
sites	O
,	O
to	O
assess	O
the	O
concentrations	O
of	O
dioxins	O
and	O
dibenzofurans	O
in	O
serum	O
,	O
and	O
BPA	O
and	O
phthalate	O
ester	O
metabolites	O
in	O
urine	O
.	O
Based	O
on	O
General	O
Linear	O
Models	O
,	O
the	O
lipid	O
-	O
or	O
creatinine	O
-	O
adjusted	O
geometric	O
mean	O
concentrations	O
of	O
the	O
aforementioned	O
chemicals	O
did	O
not	O
differ	O
between	O
the	O
ASD	O
case	O
and	O
TD	O
control	O
groups	O
(	O
all	O
p	O
≥	O
0	O
.	O
27	O
)	O
.	O
We	O
compared	O
our	O
findings	O
to	O
the	O
adjusted	O
means	O
as	O
reported	O
by	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
,	O
survey	O
years	O
2011	O
–	O
2012	O
,	O
and	O
found	O
that	O
TD	O
controls	O
in	O
our	O
study	O
had	O
lower	O
BPA	O
(	O
59	O
%	O
)	O
and	O
MEHHP	O
(	O
26	O
%	O
)	O
concentrations	O
,	O
higher	O
MBP	O
(	O
50	O
%	O
)	O
concentration	O
,	O
and	O
comparable	O
(	O
<	O
20	O
%	O
difference	O
)	O
MEP	O
,	O
MBZP	O
,	O
MEOHP	O
,	O
and	O
MCPP	O
concentrations	O
.	O
We	O
also	O
conducted	O
a	O
preliminary	O
investigation	O
of	O
dietary	O
exposures	O
and	O
found	O
that	O
the	O
consumption	O
of	O
certain	O
types	O
of	O
fish	O
may	O
be	O
associated	O
with	O
higher	O
OCDD	O
concentrations	O
,	O
and	O
the	O
consumption	O
of	O
soft	O
drinks	O
and	O
juices	O
may	O
be	O
associated	O
with	O
lower	O
BPA	O
and	O
MEOHP	O
concentrations	O
,	O
respectively	O
.	O

Environmental	O
exposure	O
to	O
organic	O
endocrine	O
disrupting	O
chemicals	O
(	O
EDCs	O
)	O
[	O
1	O
]	O
and	O
persistent	O
organic	O
pollutants	O
[	O
2	O
]	O
,	O
including	O
dioxins	O
[	O
3	O
]	O
,	O
dibenzofurans	O
[	O
4	O
]	O
,	O
bisphenol	O
A	O
(	O
BPA	O
)	O
[	O
5	O
,	O
6	O
]	O
,	O
and	O
phthalates	O
[	O
7	O
,	O
8	O
]	O
,	O
has	O
been	O
associated	O
with	O
neurodevelopmental	O
disorders	O
[	O
9	O
,	O
10	O
,	O
11	O
]	O
.	O
In	O
previous	O
studies	O
,	O
perinatal	O
exposure	O
to	O
dioxins	O
and	O
early	O
postnatal	O
exposure	O
to	O
dibenzofurans	O
as	O
measured	O
in	O
maternal	O
breast	O
milk	O
were	O
associated	O
with	O
poor	O
neurodevelopmental	O
outcomes	O
,	O
including	O
impaired	O
motor	O
coordination	O
and	O
cognitive	O
ability	O
[	O
3	O
]	O
and	O
autistic	O
traits	O
[	O
12	O
]	O
,	O
in	O
children	O
.	O
Children	O
with	O
neurodevelopmental	O
disorders	O
also	O
had	O
higher	O
concentrations	O
of	O
phthalates	O
in	O
serum	O
[	O
11	O
]	O
,	O
and	O
higher	O
concentrations	O
of	O
BPA	O
in	O
serum	O
[	O
11	O
]	O
,	O
urine	O
[	O
13	O
]	O
,	O
and	O
plasma	O
[	O
14	O
]	O
,	O
though	O
these	O
exposures	O
were	O
measured	O
after	O
diagnosis	O
and	O
cannot	O
be	O
used	O
to	O
draw	O
conclusions	O
on	O
the	O
contribution	O
of	O
phthalates	O
and	O
BPA	O
to	O
etiology	O
of	O
neurodevelopmental	O
disorders	O
.	O
Autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
is	O
a	O
neurodevelopmental	O
disorder	O
whose	O
etiology	O
may	O
be	O
associated	O
with	O
the	O
exposure	O
to	O
EDCs	O
[	O
3	O
,	O
8	O
,	O
10	O
,	O
15	O
]	O
,	O
either	O
alone	O
or	O
through	O
gene	O
-	O
environment	O
interactions	O
[	O
16	O
]	O
and	O
epigenetic	O
changes	O
[	O
17	O
]	O
.	O
Epidemiologic	B-methodology
studies	I-methodology
have	O
reported	O
associations	O
between	O
urinary	O
phthalates	O
and	O
phthalate	O
metabolites	O
with	O
increased	O
levels	O
of	O
lipid	O
peroxidation	O
,	O
inflammation	O
,	O
and	O
decreased	O
levels	O
of	O
antioxidants	O
[	O
18	O
,	O
19	O
]	O
,	O
which	O
are	O
markers	O
of	O
oxidative	O
stress	O
.	O
Since	O
oxidative	O
stress	O
is	O
suspected	O
to	O
play	O
a	O
role	O
in	O
ASD	O
etiology	O
[	O
20	O
]	O
,	O
these	O
findings	O
raise	O
questions	O
as	O
to	O
if	O
through	O
a	O
similar	O
mechanism	O
,	O
exposure	O
to	O
dioxins	O
,	O
dibenzofurans	O
,	O
BPA	O
,	O
and	O
phthalates	O
is	O
associated	O
with	O
neurodevelopmental	O
disorders	O
,	O
such	O
as	O
ASD	O
.	O
The	O
level	O
of	O
exposure	O
to	O
dioxins	O
and	O
dibenzofurans	O
in	O
communities	O
along	O
the	O
coast	O
of	O
Alabama	O
is	O
of	O
concern	O
for	O
several	O
reasons	O
.	O

Between	O
2009	O
and	O
2012	O
Alabama	O
houses	O
14	O
Superfund	O
sites	O
,	O
45	O
–	O
46	O
facilities	O
that	O
released	O
dioxin	O
and	O
dioxin	O
-	O
like	O
compounds	O
,	O
and	O
three	O
facilities	O
that	O
released	O
dibenzofurans	O
into	O
the	O
environment	O
,	O
contributing	O
to	O
an	O
81	O
%	O
increase	O
of	O
dioxins	O
and	O
dioxin	O
-	O
like	O
compounds	O
in	O
Alabama	O
by	O
2011	O
[	O
21	O
]	O
.	O
Additionally	O
,	O
Alabama	O
borders	O
the	O
Florida	O
panhandle	O
and	O
its	O
paper	O
mills	O
,	O
which	O
has	O
dioxin	O
and	O
dibenzofuran	O
sediment	O
levels	O
of	O
up	O
to	O
77	O
.	O
51	O
ppt	O
[	O
22	O
]	O
.	O
As	O
a	O
result	O
,	O
dioxin	O
concentrations	O
in	O
sediment	O
and	O
subsequent	O
bioaccumulation	O
in	O
the	O
food	O
chain	O
have	O
been	O
a	O
concern	O
for	O
several	O
years	O
[	O
23	O
]	O
.	O
Furthermore	O
,	O
the	O
BP	O
Deepwater	O
Horizon	O
Oil	O
Spill	O
(	O
DWHOS	O
)	O
in	O
2010	O
released	O
roughly	O
3	O
.	O
19	O
million	O
barrels	O
of	O
oil	O
into	O
the	O
northern	O
Gulf	O
of	O
Mexico	O
[	O
24	O
]	O
.	O
The	O
deliberate	O
oil	O
burns	O
from	O
clean	O
-	O
up	O
efforts	O
created	O
polychlorinated	O
dioxins	O
and	O
dibenzofurans	O
that	O
were	O
distributed	O
to	O
the	O
atmosphere	O
in	O
smoke	O
flumes	O
,	O
potentially	O
affecting	O
air	O
quality	O
[	O
25	O
,	O
26	O
]	O
.	O
The	O
oil	O
spill	O
and	O
cleanup	O
efforts	O
also	O
raised	O
concern	O
about	O
seafood	O
contamination	O
and	O
subsequent	O
risks	O
to	O
health	O
in	O
nearby	O
communities	O
along	O
the	O
Gulf	O
of	O
Mexico	O
[	O
27	O
,	O
28	O
]	O
,	O
particularly	O
since	O
the	O
major	O
route	O
of	O
human	O
exposure	O
to	O
dioxins	O
is	O
via	O
bioaccumulation	O
through	O
the	O
food	O
chain	O
[	O
29	O
]	O
,	O
including	O
meats	O
and	O
fish	O
[	O
4	O
]	O
.	O
The	O
potential	O
health	O
impacts	O
of	O
the	O
DWHOS	O
are	O
of	O
such	O
concern	O
that	O
the	O
National	O
Institute	O
of	O
Environmental	O
Health	O
Sciences	O
(	O
NIEHS	O
)	O
funded	O
a	O
multi	O
-	O
site	O
consortium	O
,	O
the	O
Gulf	O
Coast	O
Health	O
Alliance	O
:	O
Health	O
Risks	O
related	O
to	O
the	O
Macondo	O
Spill	O
(	O
GC	O
-	O
HARMS	O
)	O
,	O
to	O
measure	O
the	O
distribution	O
of	O
hazardous	O
chemicals	O
that	O
remain	O
along	O
the	O
coast	O
by	O
sampling	O
fish	O
and	O
shellfish	O
in	O
the	O
Gulf	O
of	O
Mexico	O
[	O
30	O
]	O
.	O
Chlorinated	O
Dibenzo	O
-	O
p	O
-	O
dioxins	O
(	O
CDDs	O
)	O
[	O
31	O
]	O
are	O
classified	O
into	O
eight	O
groups	O
,	O
according	O
to	O
the	O
number	O
of	O
chlorine	O
atoms	O
[	O
32	O
]	O
.	O

The	O
CDDs	O
that	O
were	O
analyzed	O
in	O
this	O
study	O
belonged	O
to	O
the	O
tetra	O
-	O
chlorinated	O
dioxin	O
(	O
TCDD	O
)	O
,	O
pentachlorinated	O
dioxin	O
(	O
PECDD	O
)	O
,	O
hexa	O
-	O
chlorinated	O
dioxin	O
(	O
HXCDD	O
)	O
,	O
hepta	O
-	O
chlorinated	O
dioxin	O
(	O
HPCDD	O
)	O
,	O
and	O
octa	O
-	O
chlorinated	O
dioxin	O
(	O
OCDD	O
)	O
groups	O
.	O
Dioxins	O
and	O
structurally	O
related	O
dioxin	O
-	O
like	O
chemicals	O
,	O
including	O
polychlorinated	O
dibenzofurans	O
(	O
PCDFs	O
)	O
[	O
33	O
]	O
,	O
are	O
persistent	O
environmental	O
chemicals	O
that	O
are	O
the	O
byproduct	O
of	O
industrial	O
processes	O
,	O
including	O
incineration	O
,	O
chlorine	O
bleaching	O
of	O
paper	O
and	O
pulp	O
,	O
manufacture	O
or	O
disposal	O
of	O
chlorine	O
-	O
containing	O
products	O
,	O
and	O
the	O
manufacture	O
of	O
some	O
pesticides	O
,	O
herbicides	O
,	O
and	O
fungicides	O
,	O
and	O
can	O
also	O
result	O
from	O
natural	O
processes	O
,	O
including	O
forest	O
fires	O
[	O
33	O
,	O
34	O
]	O
.	O
BPA	O
and	O
phthalates	O
are	O
endocrine	O
disrupting	O
chemicals	O
that	O
can	O
impair	O
neurologic	O
processes	O
despite	O
their	O
short	O
half	O
-	O
lives	O
,	O
ranging	O
from	O
hours	O
to	O
days	O
for	O
phthalates	O
and	O
less	O
than	O
one	O
day	O
for	O
BPA	O
[	O
35	O
]	O
.	O
These	O
chemicals	O
are	O
widely	O
used	O
in	O
the	O
production	O
of	O
consumer	O
plastic	O
products	O
,	O
including	O
food	O
and	O
water	O
packaging	O
[	O
36	O
]	O
.	O
In	O
addition	O
to	O
plastic	O
products	O
,	O
humans	O
may	O
be	O
exposed	O
to	O
phthalates	O
through	O
household	O
dust	O
[	O
37	O
]	O
,	O
water	O
,	O
and	O
food	O
[	O
38	O
]	O
.	O
A	O
major	O
dietary	O
route	O
of	O
exposure	O
for	O
children	O
is	O
through	O
fish	O
,	O
meat	O
,	O
and	O
milk	O
[	O
39	O
]	O
.	O
We	O
conducted	O
a	O
pilot	B-methodology
study	I-methodology
to	O
assess	O
the	O
feasibility	O
of	O
conducting	O
a	O
large	O
scale	O
population	O
-	O
based	O
study	O
of	O
communities	O
along	O
the	O
Alabama	O
coast	O
of	O
the	O
Gulf	O
of	O
Mexico	O
to	O
investigate	O
the	O
role	O
of	O
environmental	O
chemical	O
contaminants	O
,	O
such	O
as	O
dioxins	O
,	O
dibenzofurans	O
,	O
BPA	O
,	O
and	O
phthalates	O
,	O
and	O
their	O
interactions	O
with	O
genes	O
that	O
are	O
involved	O
in	O
contaminant	O
metabolism	O
in	O
relation	O
to	O
ASD	O
.	O
This	O
pilot	O
project	O
revealed	O
difficulty	O
in	O
enrolling	O
suitable	O
typically	O
developing	O
(	O
TD	O
)	O
children	O
as	O
controls	O
,	O
and	O
as	O
a	O
result	O
,	O
we	O
have	O
30	O
ASD	O
cases	O
and	O
10	O
TD	O
controls	O
in	O
the	O
present	O
study	O
.	O

The	O
descriptive	O
data	O
provided	O
here	O
will	O
lay	O
the	O
foundation	O
for	O
the	O
first	O
comprehensive	O
epidemiological	B-methodology
study	I-methodology
of	O
the	O
association	O
between	O
the	O
exposure	O
to	O
dioxins	O
,	O
dibenzofurans	O
,	O
BPA	O
,	O
and	O
phthalates	O
and	O
ASD	O
in	O
children	O
living	O
near	O
the	O
Gulf	O
of	O
Mexico	O
.	O
In	O
the	O
present	O
manuscript	O
,	O
we	O
provide	O
hypothesis	O
-	O
generating	O
data	O
on	O
the	O
concentrations	O
of	O
these	O
contaminants	O
in	O
serum	O
or	O
urine	O
samples	O
collected	O
from	O
children	O
with	O
and	O
without	O
ASD	O
in	O
communities	O
in	O
this	O
region	O
,	O
and	O
compare	O
these	O
concentrations	O
to	O
national	O
averages	O
as	O
reported	O
by	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
NHANES	O
)	O
.	O
Since	O
the	O
population	O
along	O
the	O
Gulf	O
of	O
Mexico	O
is	O
expected	O
to	O
be	O
at	O
a	O
higher	O
risk	O
of	O
exposure	O
to	O
EDCs	O
through	O
several	O
sources	O
,	O
particularly	O
through	O
food	O
consumption	O
,	O
we	O
also	O
report	O
preliminary	O
results	O
comparing	O
the	O
mean	O
concentrations	O
of	O
these	O
chemicals	O
in	O
children	O
with	O
various	O
dietary	O
exposures	O
.	O
This	O
pilot	B-methodology
study	I-methodology
was	O
designed	O
as	O
a	O
1	O
:	O
1	O
age	O
-	O
,	O
race	O
-	O
,	O
and	O
sex	O
-	O
matched	O
case	B-methodology
-	I-methodology
control	I-methodology
study	I-methodology
of	O
children	O
with	O
ASD	O
and	O
TD	O
controls	O
aged	O
2	O
–	O
8	O
years	O
.	O
From	O
July	O
2015	O
–	O
Septemeber	O
2016	O
,	O
we	O
enrolled	O
30	O
ASD	O
cases	O
and	O
10	O
TD	O
controls	O
.	O
To	O
be	O
eligible	O
for	O
the	O
present	O
study	O
,	O
all	O
of	O
the	O
children	O
had	O
to	O
have	O
been	O
born	O
along	O
the	O
Gulf	O
of	O
Mexico	O
in	O
or	O
near	O
Alabama	O
(	O
e	O
.	O
g	O
.	O
,	O
Alabama	O
,	O
Florida	O
,	O
or	O
Mississippi	O
)	O
.	O
From	O
July	O
2015	O
–	O
September	O
2016	O
,	O
parents	O
or	O
guardians	O
of	O
children	O
,	O
ages	O
2	O
–	O
8	O
years	O
inclusive	O
,	O
who	O
had	O
previously	O
been	O
diagnosed	O
with	O
ASD	O
based	O
on	O
the	O
Autism	O
Diagnostic	O
Observation	O
Schedule	O
(	O
ADOS	O
)	O
[	O
40	O
]	O
,	O
DSM	O
-	O
5	O
,	O
and	O
clinical	O
expert	O
judgment	O
at	O
the	O
University	O
of	O
South	O
Alabama	O
(	O
USA	O
)	O
Autism	O
Diagnostic	O
Clinic	O
were	O
asked	O
to	O
participate	O
during	O
routine	O
clinic	O
follow	O
-	O
up	O
visits	O
.	O
To	O
confirm	O
that	O
the	O
clinical	O
diagnosis	O
met	O
DSM	O
IV	O
or	O
DSM	O
V	O
criteria	O
at	O
the	O
time	O
of	O
enrollment	O
,	O
we	O
administered	O
both	O
the	O
Autism	O
Diagnostic	O
Interview	O
-	O
Revised	O
(	O
ADI	O
-	O
R	O
)	O
[	O
41	O
]	O
and	O
Autism	O
Diagnostic	O
Observation	O
Schedule	O
-	O
2	O
(	O
ADOS	O
-	O
2	O
)	O
[	O
42	O
]	O
.	O
For	O
cases	O
who	O
had	O
been	O
evaluated	O
using	O
ADOS	O
prior	O
to	O
the	O
release	O
of	O
the	O
revised	O
second	O
edition	O
(	O
ADOS	O
-	O
2	O
)	O
,	O
the	O
original	O
ADOS	O
score	O
was	O
recalculated	O
using	O
the	O
ADOS	O
-	O
2	O
scoring	O
algorithms	O
.	O

TD	O
control	O
children	O
were	O
recruited	O
from	O
the	O
USA	O
General	O
Pediatric	O
clinics	O
and	O
through	O
advertisements	O
on	O
social	O
media	O
(	O
e	O
.	O
g	O
.	O
,	O
Facebook	O
)	O
and	O
in	O
a	O
local	O
newspaper	O
,	O
and	O
were	O
matched	O
to	O
ASD	O
cases	O
based	O
on	O
age	O
(	O
±6	O
months	O
)	O
,	O
race	O
,	O
and	O
sex	O
.	O
The	O
Lifetime	O
and	O
Current	O
forms	O
of	O
the	O
Social	O
Communication	O
Questionnaire	O
(	O
SCQ	O
)	O
[	O
43	O
]	O
were	O
administered	O
to	O
the	O
parents	O
/	O
guardians	O
of	O
TD	O
control	O
children	O
to	O
rule	O
out	O
symptoms	O
of	O
ASD	O
using	O
a	O
cut	O
-	O
off	O
point	O
of	O
6	O
,	O
which	O
is	O
one	O
standard	O
deviation	O
below	O
the	O
mean	O
SCQ	O
score	O
of	O
TD	O
school	O
children	O
[	O
44	O
]	O
.	O
Parental	O
/	O
guardian	O
consent	O
was	O
obtained	O
for	O
all	O
of	O
the	O
children	O
.	O
Children	O
ages	O
7	O
–	O
8	O
also	O
provided	O
written	O
assent	O
when	O
it	O
was	O
deemed	O
appropriate	O
based	O
on	O
the	O
child	O
’	O
s	O
cognitive	O
level	O
.	O
A	O
questionnaire	O
was	O
administered	O
to	O
the	O
parents	O
/	O
guardians	O
of	O
both	O
ASD	O
cases	O
and	O
TD	O
controls	O
to	O
collect	O
demographic	O
and	O
socioeconomic	O
status	O
(	O
SES	O
)	O
,	O
including	O
information	O
about	O
parental	O
age	O
and	O
education	O
levels	O
.	O
In	O
addition	O
,	O
food	O
frequency	O
data	O
representing	O
the	O
typical	O
consumption	O
of	O
food	O
items	O
by	O
children	O
were	O
collected	O
.	O
This	O
included	O
vegetables	O
,	O
fruits	O
,	O
meat	O
,	O
and	O
fresh	O
and	O
canned	O
seafood	O
,	O
with	O
a	O
particular	O
focus	O
on	O
potential	O
exposure	O
to	O
dioxins	O
,	O
dibenzofurans	O
,	O
BPA	O
,	O
and	O
phthalates	O
.	O
In	O
addition	O
,	O
we	O
collected	O
2	O
mL	O
of	O
urine	O
for	O
BPA	O
and	O
phthalate	O
ester	O
metabolite	O
(	O
PEM	O
)	O
analysis	O
,	O
1	O
mL	O
of	O
urine	O
for	O
assessment	O
of	O
creatinine	O
(	O
used	O
to	O
adjust	O
BPA	O
and	O
PEM	O
concentrations	O
by	O
creatinine	O
concentrations	O
)	O
,	O
and	O
15	O
–	O
20	O
mL	O
of	O
whole	O
blood	O
to	O
obtain	O
7	O
–	O
10	O
mL	O
of	O
serum	O
for	O
assessment	O
of	O
dioxins	O
and	O
dibenzofurans	O
from	O
all	O
of	O
the	O
children	O
.	O
Each	O
family	O
was	O
given	O
a	O
$	O
10	O
gift	O
card	O
for	O
their	O
participation	O
.	O
For	O
assessment	O
of	O
creatinine	O
in	O
urine	O
,	O
the	O
urine	O
samples	O
were	O
analyzed	O
at	O
LabCorp	O
Laboratory	O
in	O
Mobile	O
,	O
Alabama	O
immediately	O
after	O
collection	O
.	O
The	O
urine	O
samples	O
for	O
BPA	O
and	O
phthalates	O
were	O
frozen	O
and	O
stored	O
at	O
−10	O
°C	O
and	O
serum	O
samples	O
for	O
dioxins	O
and	O
dibenzofurans	O
were	O
frozen	O
and	O
stored	O
at	O
−30	O
°C	O
until	O
they	O
were	O
transported	O
to	O
SGS	O
AXYS	O
Analytical	O
Services	O
Ltd	O
.	O
,	O
in	O
Sidney	O
,	O
BC	O
,	O
Canada	O
.	O

The	O
samples	O
were	O
analyzed	O
for	O
dioxins	O
and	O
dibenzofurans	O
,	O
BPA	O
,	O
and	O
phthalate	O
concentrations	O
using	O
standard	O
methodology	O
as	O
approved	O
by	O
the	O
Canadian	O
Association	O
for	O
Laboratory	O
Accreditation	O
(	O
CALA	O
)	O
[	O
45	O
]	O
and	O
the	O
National	O
Environmental	O
Laboratory	O
Accreditation	O
Program	O
(	O
NELAP	O
)	O
[	O
46	O
]	O
,	O
and	O
adapted	O
by	O
SGS	O
AXYS	O
Analytical	O
Services	O
Ltd	O
.	O
Institutional	O
Review	O
Boards	O
(	O
IRBs	O
)	O
of	O
the	O
University	O
of	O
Texas	O
Health	O
Science	O
Center	O
at	O
Houston	O
(	O
Project	O
identification	O
code	O
:	O
HSC	O
-	O
GEN	O
-	O
14	O
-	O
0792	O
)	O
and	O
USA	O
(	O
Project	O
identification	O
code	O
:	O
14	O
-	O
344	O
)	O
approved	O
this	O
study	O
.	O
The	O
data	O
presented	O
herein	O
represent	O
analysis	O
of	O
30	O
ASD	O
cases	O
and	O
10	O
TD	O
control	O
children	O
.	O
Prior	O
to	O
analysis	O
a	O
300	O
µL	O
sub	O
-	O
sample	O
was	O
removed	O
and	O
submitted	O
to	O
Quebec	O
Toxicology	O
for	O
total	O
lipid	O
analysis	O
.	O
All	O
of	O
the	O
remaining	O
sera	O
from	O
each	O
participant	O
was	O
analyzed	O
by	O
high	O
resolution	O
gas	O
chromatography	O
with	O
high	O
resolution	O
mass	O
spectrometric	O
detection	O
(	O
HRGC	O
/	O
HRMS	O
)	O
(	O
Micromass	O
Autospec	O
Premier	O
,	O
Waters	O
Corporation	O
,	O
Milford	O
,	O
MA	O
,	O
USA	O
)	O
.	O
Quantification	O
of	O
target	O
analytes	O
was	O
performed	O
by	O
isotope	O
dilution	O
.	O
Results	O
were	O
reported	O
on	O
a	O
mass	O
of	O
analyte	O
per	O
mass	O
of	O
sera	O
basis	O
.	O
Lipid	O
data	O
from	O
each	O
participant	O
was	O
used	O
to	O
adjust	O
sample	O
size	O
from	O
mass	O
of	O
sera	O
to	O
mass	O
of	O
lipid	O
and	O
the	O
results	O
were	O
reported	O
on	O
a	O
mass	O
of	O
analyte	O
per	O
mass	O
of	O
lipid	O
basis	O
.	O
One	O
milliliter	O
of	O
urine	O
from	O
each	O
participant	O
was	O
extracted	O
and	O
analyzed	O
on	O
a	O
high	O
performance	O
liquid	O
chromatograph	O
coupled	O
to	O
a	O
triple	O
quadrupole	O
mass	O
spectrometer	O
LC	O
-	O
MS	O
/	O
MS	O
(	O
Micromass	O
Quattro	O
Ultima	O
,	O
Waters	O
Corporation	O
,	O
Milford	O
,	O
MA	O
,	O
USA	O
)	O
.	O
Quantification	O
was	O
performed	O
by	O
the	O
internal	O
standard	O
/	O
isotope	O
dilution	O
quantification	O
method	O
.	O
Results	O
were	O
reported	O
on	O
a	O
mass	O
of	O
analyte	O
per	O
volume	O
of	O
urine	O
.	O
We	O
conducted	O
descriptive	O
analyses	O
to	O
examine	O
the	O
distributions	O
of	O
various	O
characteristics	O
of	O
the	O
study	O
population	O
,	O
including	O
demographic	O
characteristics	O
and	O
socioeconomic	O
status	O
(	O
SES	O
)	O
,	O
and	O
compared	O
the	O
distribution	O
of	O
these	O
characteristics	O
between	O
ASD	O
cases	O
and	O
TD	O
controls	O
using	O
logistic	O
regression	O
.	O
Children	O
with	O
missing	O
data	O
were	O
excluded	O
from	O
analyses	O
.	O

Due	O
to	O
the	O
limited	O
sample	O
size	O
,	O
we	O
did	O
not	O
adjust	O
for	O
potential	O
confounders	O
in	O
the	O
following	O
analyses	O
in	O
order	O
to	O
avoid	O
unstable	O
estimates	O
.	O
Additionally	O
,	O
we	O
did	O
not	O
account	O
for	O
the	O
potential	O
correlation	O
between	O
paired	O
observations	O
since	O
less	O
than	O
half	O
of	O
the	O
study	O
sample	O
was	O
paired	O
.	O
A	O
sample	O
-	O
specific	O
Limit	O
of	O
Detection	O
(	O
LoD	O
)	O
was	O
reported	O
by	O
SGS	O
AXYS	O
for	O
each	O
serum	O
and	O
urine	O
sample	O
when	O
analyzed	O
for	O
dioxins	O
/	O
dibenzofurans	O
and	O
BPA	O
/	O
phthalates	O
,	O
respectively	O
.	O
Therefore	O
,	O
the	O
LoDs	O
for	O
each	O
analyte	O
are	O
herein	O
reported	O
as	O
a	O
range	O
of	O
the	O
sample	O
-	O
specific	O
LoDs	O
.	O
If	O
the	O
overall	O
percentage	O
of	O
samples	O
with	O
concentrations	O
below	O
their	O
sample	O
-	O
specific	O
LoD	O
was	O
less	O
than	O
20	O
%	O
,	O
then	O
we	O
replaced	O
those	O
non	O
-	O
detectable	O
sample	O
concentrations	O
with	O
the	O
sample	O
-	O
specific	O
LoD	O
divided	O
by	O
the	O
square	O
root	O
of	O
two	O
[	O
47	O
]	O
.	O
This	O
is	O
the	O
same	O
method	O
for	O
imputing	O
observations	O
below	O
LoDs	O
used	O
by	O
NHANES	O
[	O
48	O
]	O
.	O
Since	O
the	O
distributions	O
of	O
serum	O
concentrations	O
of	O
dioxins	O
and	O
dibenzofurans	O
and	O
urine	O
concentrations	O
of	O
BPA	O
and	O
PEMs	O
were	O
skewed	O
,	O
we	O
transformed	O
the	O
data	O
using	O
the	O
natural	O
logarithm	O
(	O
ln	O
)	O
in	O
order	O
to	O
produce	O
a	O
distribution	O
that	O
better	O
approximated	O
a	O
normal	O
distribution	O
.	O
The	O
means	O
that	O
the	O
ln	O
transformed	O
concentrations	O
were	O
transformed	O
to	O
their	O
original	O
scale	O
(	O
i	O
.	O
e	O
.	O
,	O
pg	O
/	O
g	O
for	O
dioxins	O
and	O
dibenzofurans	O
and	O
ng	O
/	O
mL	O
for	O
BPA	O
and	O
PEMs	O
)	O
by	O
applying	O
an	O
exponential	O
function	O
,	O
called	O
the	O
geometric	O
mean	O
(	O
i	O
.	O
e	O
.	O
,	O
exp	O
[	O
Mean	O
(	O
ln	O
OCDD	O
)	O
]	O
=	O
geometric	O
mean	O
OCDD	O
)	O
.	O
All	O
mean	O
analyte	O
concentrations	O
reported	O
herein	O
are	O
in	O
reference	O
to	O
the	O
geometric	O
mean	O
.	O
Additionally	O
,	O
the	O
serum	O
dioxin	O
and	O
dibenzofuran	O
concentrations	O
were	O
adjusted	O
per	O
gram	O
of	O
lipid	O
to	O
account	O
for	O
the	O
lipophilic	O
properties	O
of	O
dioxins	O
and	O
dibenzofurans	O
[	O
49	O
]	O
.	O
Similarly	O
,	O
the	O
urine	O
BPA	O
and	O
PEM	O
concentrations	O
were	O
adjusted	O
per	O
gram	O
of	O
creatinine	O
to	O
account	O
for	O
the	O
variation	O
in	O
dilution	O
of	O
urine	O
samples	O
[	O
50	O
]	O
.	O
General	O
Linear	O
Models	O
(	O
GLMs	O
)	O
were	O
used	O
to	O
test	O
the	O
difference	O
between	O
geometric	O
mean	O
concentrations	O
of	O
dioxins	O
,	O
dibenzofurans	O
,	O
BPA	O
,	O
and	O
PEMs	O
between	O
ASD	O
cases	O
and	O
TD	O
controls	O
.	O

We	O
also	O
compared	O
the	O
lipid	O
-	O
or	O
creatinine	O
-	O
adjusted	O
geometric	O
mean	O
concentrations	O
in	O
our	O
study	O
to	O
those	O
reported	O
by	O
NHANES	O
for	O
children	O
of	O
the	O
most	O
similar	O
age	O
group	O
and	O
the	O
most	O
recent	O
survey	O
year	O
that	O
data	O
are	O
available	O
for	O
each	O
group	O
of	O
chemicals	O
.	O
Furthermore	O
,	O
we	O
used	O
GLM	O
to	O
examine	O
the	O
difference	O
in	O
geometric	O
mean	O
concentration	O
of	O
select	O
analytes	O
between	O
those	O
who	O
had	O
dietary	O
exposures	O
,	O
such	O
as	O
consuming	O
seafood	O
,	O
meat	O
,	O
dairy	O
products	O
,	O
and	O
canned	O
food	O
,	O
and	O
those	O
who	O
did	O
not	O
have	O
these	O
dietary	O
exposures	O
.	O
All	O
statistical	O
testing	O
were	O
conducted	O
at	O
5	O
%	O
level	O
of	O
significance	O
.	O
All	O
of	O
the	O
statistical	O
analyses	O
were	O
conducted	O
using	O
SAS	O
9	O
.	O
4	O
[	O
51	O
]	O
.	O
Among	O
children	O
with	O
ASD	O
and	O
TD	O
children	O
,	O
80	O
%	O
were	O
male	O
.	O
The	O
mean	O
age	O
of	O
children	O
with	O
ASD	O
was	O
78	O
.	O
7	O
months	O
,	O
and	O
the	O
mean	O
age	O
of	O
TD	O
children	O
was	O
70	O
.	O
5	O
months	O
.	O
More	O
than	O
half	O
of	O
children	O
with	O
ASD	O
(	O
56	O
.	O
7	O
%	O
)	O
and	O
TD	O
children	O
(	O
70	O
.	O
0	O
%	O
)	O
were	O
Caucasian	O
,	O
while	O
the	O
remaining	O
children	O
were	O
African	O
American	O
.	O
We	O
also	O
found	O
that	O
50	O
%	O
of	O
parents	O
of	O
children	O
with	O
ASD	O
reported	O
home	O
ownership	O
as	O
compared	O
to	O
70	O
%	O
home	O
ownership	O
among	O
parents	O
of	O
TD	O
children	O
.	O
However	O
,	O
none	O
of	O
the	O
demographic	O
characteristics	O
of	O
children	O
and	O
their	O
parents	O
reported	O
in	O
Table	O
1	O
were	O
significantly	O
associated	O
with	O
ASD	O
status	O
.	O
Of	O
the	O
seven	O
dioxin	O
congeners	O
that	O
were	O
analyzed	O
in	O
this	O
study	O
,	O
only	O
octa	O
-	O
chlorinated	O
dioxin	O
(	O
OCDD	O
)	O
was	O
detected	O
in	O
100	O
%	O
of	O
the	O
serum	O
samples	O
,	O
with	O
lipid	O
-	O
adjusted	O
mean	O
(	O
SD	O
)	O
concentrations	O
of	O
78	O
.	O
51	O
(	O
2	O
.	O
26	O
)	O
pg	O
/	O
g	O
for	O
children	O
with	O
ASD	O
and	O
90	O
.	O
93	O
(	O
1	O
.	O
50	O
)	O
pg	O
/	O
g	O
for	O
TD	O
children	O
(	O
p	O
=	O
0	O
.	O
59	O
)	O
.	O
None	O
of	O
the	O
remaining	O
dioxins	O
or	O
dibenzofurans	O
that	O
were	O
analyzed	O
in	O
this	O
study	O
were	O
detectable	O
in	O
at	O
least	O
70	O
%	O
of	O
serum	O
samples	O
.	O
We	O
compare	O
our	O
results	O
to	O
those	O
most	O
recently	O
reported	O
by	O
NHANES	O
(	O
survey	O
years	O
2003	O
–	O
2004	O
)	O
for	O
the	O
most	O
similar	O
age	O
group	O
(	O
12	O
–	O
19	O
years	O
)	O
[	O
48	O
]	O
.	O
The	O
lipid	O
-	O
adjusted	O
LoD	O
ranges	O
for	O
dioxins	O
and	O
dibenzofurans	O
in	O
this	O
study	O
and	O
NHANES	O
lipid	O
-	O
adjusted	O
means	O
and	O
LoDs	O
are	O
displayed	O
in	O
Table	O
2	O
.	O

BPA	O
was	O
detected	O
in	O
81	O
.	O
8	O
%	O
of	O
urine	O
samples	O
,	O
with	O
creatinine	O
-	O
adjusted	O
mean	O
(	O
SD	O
)	O
concentrations	O
of	O
1	O
.	O
33	O
(	O
2	O
.	O
10	O
)	O
µg	O
/	O
g	O
for	O
children	O
with	O
ASD	O
and	O
0	O
.	O
93	O
(	O
2	O
.	O
43	O
)	O
µg	O
/	O
g	O
for	O
TD	O
children	O
.	O
Of	O
the	O
10	O
PEMs	O
analyzed	O
,	O
two	O
were	O
detected	O
in	O
100	O
%	O
of	O
urine	O
samples	O
:	O
MBP	O
with	O
creatinine	O
-	O
adjusted	O
mean	O
(	O
SD	O
)	O
concentrations	O
of	O
41	O
.	O
82	O
(	O
1	O
.	O
88	O
)	O
µg	O
/	O
g	O
in	O
children	O
with	O
ASD	O
and	O
41	O
.	O
49	O
(	O
2	O
.	O
60	O
)	O
µg	O
/	O
g	O
in	O
TD	O
children	O
;	O
and	O
,	O
MEOHP	O
with	O
creatinine	O
-	O
adjusted	O
mean	O
(	O
SD	O
)	O
concentrations	O
of	O
9	O
.	O
76	O
(	O
2	O
.	O
52	O
)	O
µg	O
/	O
g	O
in	O
children	O
with	O
ASD	O
and	O
8	O
.	O
23	O
(	O
2	O
.	O
13	O
)	O
µg	O
/	O
g	O
in	O
TD	O
children	O
.	O
Additionally	O
,	O
four	O
PEMs	O
were	O
detected	O
in	O
at	O
least	O
70	O
%	O
of	O
urine	O
samples	O
:	O
MEP	O
with	O
creatinine	O
-	O
adjusted	O
mean	O
(	O
SD	O
)	O
concentrations	O
of	O
28	O
.	O
93	O
(	O
1	O
.	O
86	O
)	O
µg	O
/	O
g	O
in	O
children	O
with	O
ASD	O
and	O
37	O
.	O
61	O
(	O
7	O
.	O
58	O
)	O
µg	O
/	O
g	O
in	O
TD	O
children	O
;	O
MBzP	O
with	O
creatinine	O
-	O
adjusted	O
mean	O
(	O
SD	O
)	O
concentrations	O
of	O
19	O
.	O
01	O
(	O
2	O
.	O
38	O
)	O
µg	O
/	O
g	O
in	O
children	O
with	O
ASD	O
and	O
12	O
.	O
55	O
(	O
3	O
.	O
07	O
)	O
µg	O
/	O
g	O
in	O
TD	O
children	O
;	O
MEHHP	O
with	O
creatinine	O
-	O
adjusted	O
mean	O
(	O
SD	O
)	O
concentrations	O
of	O
14	O
.	O
94	O
(	O
2	O
.	O
45	O
)	O
µg	O
/	O
g	O
in	O
children	O
with	O
ASD	O
and	O
11	O
.	O
08	O
(	O
3	O
.	O
22	O
)	O
µg	O
/	O
g	O
in	O
TD	O
children	O
;	O
and	O
,	O
MCPP	O
with	O
creatinine	O
-	O
adjusted	O
mean	O
(	O
SD	O
)	O
concentrations	O
of	O
4	O
.	O
04	O
(	O
1	O
.	O
74	O
)	O
µg	O
/	O
g	O
in	O
children	O
with	O
ASD	O
and	O
4	O
.	O
49	O
(	O
1	O
.	O
75	O
)	O
µg	O
/	O
g	O
in	O
TD	O
children	O
.	O
We	O
compare	O
our	O
results	O
to	O
those	O
most	O
recently	O
reported	O
by	O
NHANES	O
(	O
survey	O
years	O
2011	O
–	O
2012	O
)	O
for	O
the	O
most	O
similar	O
age	O
group	O
(	O
6	O
–	O
11	O
years	O
)	O
.	O
The	O
LoD	O
ranges	O
and	O
detectable	O
mean	O
concentrations	O
for	O
BPA	O
and	O
PEMs	O
in	O
this	O
study	O
and	O
the	O
NHANES	O
creatinine	O
-	O
adjusted	O
means	O
and	O
LoDs	O
are	O
reported	O
in	O
Table	O
3	O
.	O

A	O
comparison	O
of	O
lipid	O
-	O
adjusted	O
mean	O
OCDD	O
concentrations	O
between	O
those	O
with	O
different	O
dietary	O
exposures	O
revealed	O
the	O
following	O
findings	O
.	O
The	O
lipid	O
-	O
adjusted	O
mean	O
OCDD	O
concentration	O
of	O
children	O
who	O
consumed	O
canned	O
sardine	O
or	O
mackerel	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
children	O
who	O
did	O
not	O
consume	O
canned	O
sardine	O
or	O
mackerel	O
(	O
263	O
.	O
75	O
pg	O
/	O
g	O
vs	O
.	O
78	O
.	O
24	O
pg	O
/	O
g	O
,	O
p	O
=	O
0	O
.	O
02	O
)	O
.	O
Similarly	O
,	O
our	O
data	O
showed	O
that	O
lipid	O
-	O
adjusted	O
mean	O
OCDD	O
concentration	O
of	O
children	O
who	O
ate	O
shellfish	O
(	O
lobster	O
,	O
crab	O
,	O
crawfish	O
)	O
was	O
significantly	O
higher	O
when	O
compared	O
to	O
that	O
of	O
children	O
who	O
did	O
not	O
eat	O
shellfish	O
(	O
124	O
.	O
58	O
pg	O
/	O
g	O
vs	O
.	O
69	O
.	O
62	O
pg	O
/	O
g	O
,	O
p	O
=	O
0	O
.	O
02	O
)	O
.	O
Analysis	O
also	O
showed	O
that	O
children	O
who	O
drank	O
milk	O
had	O
significantly	O
lower	O
lipid	O
-	O
adjusted	O
mean	O
OCDD	O
concentrations	O
as	O
compared	O
to	O
children	O
who	O
did	O
not	O
drink	O
milk	O
(	O
76	O
.	O
07	O
pg	O
/	O
g	O
vs	O
.	O
183	O
.	O
76	O
pg	O
/	O
g	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O
There	O
were	O
no	O
significant	O
differences	O
in	O
lipid	O
-	O
adjusted	O
mean	O
OCDD	O
concentrations	O
for	O
children	O
who	O
did	O
and	O
did	O
not	O
consume	O
the	O
remaining	O
food	O
items	O
,	O
as	O
displayed	O
in	O
Table	O
4	O
(	O
all	O
p	O
≥	O
0	O
.	O
09	O
)	O
.	O
Creatinine	O
-	O
adjusted	O
mean	O
BPA	O
concentrations	O
in	O
urine	O
were	O
compared	O
between	O
children	O
that	O
did	O
and	O
did	O
not	O
consume	O
various	O
foods	O
or	O
drink	O
products	O
,	O
such	O
as	O
bottled	O
water	O
,	O
canned	O
fish	O
,	O
bottled	O
juices	O
or	O
soft	O
drinks	O
,	O
and	O
other	O
canned	O
food	O
products	O
.	O
We	O
found	O
that	O
children	O
who	O
drank	O
soft	O
drinks	O
had	O
lower	O
creatinine	O
-	O
adjusted	O
mean	O
BPA	O
concentrations	O
when	O
compared	O
to	O
children	O
who	O
did	O
not	O
drink	O
soft	O
drinks	O
(	O
0	O
.	O
82	O
µg	O
/	O
g	O
vs	O
.	O
1	O
.	O
96	O
µg	O
/	O
g	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O
Our	O
data	O
show	O
that	O
there	O
is	O
no	O
significant	O
difference	O
between	O
the	O
creatinine	O
-	O
adjusted	O
mean	O
BPA	O
concentrations	O
for	O
those	O
who	O
did	O
and	O
did	O
not	O
have	O
other	O
dietary	O
exposures	O
(	O
all	O
p	O
≥	O
0	O
.	O
10	O
)	O
.	O
Comparisons	O
of	O
creatinine	O
-	O
adjusted	O
mean	O
BPA	O
concentrations	O
for	O
dietary	O
exposure	O
variables	O
are	O
displayed	O
in	O
Table	O
5	O
.	O
Similarly	O
,	O
we	O
compared	O
creatinine	O
-	O
adjusted	O
mean	O
MEOHP	O
concentrations	O
in	O
urine	O
between	O
those	O
who	O
did	O
and	O
did	O
not	O
consume	O
bottled	O
water	O
,	O
canned	O
fish	O
,	O
bottled	O
juices	O
/	O
soft	O
drinks	O
,	O
and	O
other	O
canned	O
foods	O
.	O

Children	O
who	O
drank	O
juices	O
(	O
e	O
.	O
g	O
.	O
,	O
orange	O
,	O
tomato	O
,	O
etc	O
.	O
)	O
had	O
lower	O
creatinine	O
-	O
adjusted	O
mean	O
MEOHP	O
concentrations	O
as	O
compared	O
to	O
children	O
who	O
did	O
not	O
drink	O
juices	O
(	O
8	O
.	O
31	O
µg	O
/	O
g	O
vs	O
.	O
17	O
.	O
79	O
µg	O
/	O
g	O
,	O
p	O
=	O
0	O
.	O
05	O
)	O
.	O
However	O
,	O
our	O
data	O
showed	O
that	O
there	O
is	O
no	O
significant	O
difference	O
between	O
the	O
creatinine	O
-	O
adjusted	O
mean	O
MEOHP	O
concentrations	O
of	O
those	O
who	O
did	O
and	O
did	O
not	O
have	O
other	O
dietary	O
exposures	O
,	O
as	O
listed	O
in	O
Table	O
6	O
(	O
all	O
p	O
≥	O
0	O
.	O
15	O
)	O
.	O
Although	O
the	O
sample	O
size	O
was	O
limited	O
in	O
this	O
pilot	B-methodology
study	I-methodology
,	O
we	O
have	O
reported	O
concentrations	O
of	O
7	O
dioxin	O
congeners	O
and	O
10	O
dibenzofurans	O
in	O
serum	O
,	O
and	O
BPA	O
and	O
10	O
phthalate	O
ester	O
metabolite	O
concentrations	O
in	O
urine	O
of	O
children	O
with	O
and	O
without	O
ASD	O
,	O
ages	O
2	O
–	O
8	O
along	O
the	O
Gulf	O
of	O
Mexico	O
as	O
a	O
reference	O
for	O
future	O
studies	O
.	O
However	O
,	O
these	O
results	O
were	O
not	O
adjusted	O
for	O
potential	O
confounders	O
and	O
therefore	O
should	O
be	O
interpreted	O
as	O
exploratory	O
.	O
Additionally	O
,	O
it	O
is	O
important	O
to	O
keep	O
in	O
mind	O
that	O
since	O
we	O
assessed	O
exposure	O
to	O
these	O
chemicals	O
after	O
ASD	O
diagnosis	O
,	O
we	O
cannot	O
make	O
any	O
comments	O
on	O
the	O
contribution	O
of	O
these	O
chemicals	O
to	O
the	O
etiology	O
of	O
ASD	O
,	O
as	O
we	O
only	O
investigated	O
possible	O
associations	O
.	O
We	O
also	O
compared	O
these	O
concentrations	O
to	O
the	O
lipid	O
-	O
or	O
creatinine	O
-	O
adjusted	O
geometric	O
mean	O
concentrations	O
reported	O
by	O
NHANES	O
for	O
children	O
of	O
the	O
most	O
similar	O
age	O
group	O
.	O
In	O
addition	O
,	O
we	O
explored	O
the	O
relationship	O
between	O
dietary	O
exposures	O
and	O
these	O
chemical	O
concentrations	O
.	O
In	O
the	O
following	O
,	O
we	O
will	O
discuss	O
our	O
findings	O
that	O
are	O
related	O
to	O
each	O
of	O
these	O
topics	O
separately	O
for	O
each	O
group	O
of	O
chemicals	O
.	O
Our	O
results	O
showed	O
that	O
the	O
only	O
dioxin	O
with	O
100	O
%	O
of	O
samples	O
above	O
LoD	O
(	O
range	O
=	O
8	O
.	O
41	O
–	O
31	O
.	O
0	O
pg	O
/	O
g	O
)	O
was	O
OCDD	O
,	O
with	O
lipid	O
-	O
adjusted	O
mean	O
concentrations	O
of	O
78	O
.	O
51	O
pg	O
/	O
g	O
of	O
lipid	O
for	O
children	O
with	O
ASD	O
and	O
90	O
.	O
93	O
pg	O
/	O
g	O
of	O
lipid	O
for	O
TD	O
children	O
,	O
however	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

NHANES	O
,	O
which	O
is	O
a	O
population	B-methodology
based	I-methodology
study	I-methodology
in	O
the	O
US	O
,	O
most	O
recently	O
reported	O
that	O
the	O
lipid	O
-	O
adjusted	O
mean	O
concentrations	O
of	O
OCDD	O
in	O
the	O
12	O
–	O
19	O
year	O
age	O
group	O
were	O
unable	O
to	O
be	O
calculated	O
due	O
to	O
a	O
large	O
proportion	O
of	O
results	O
being	O
below	O
LoD	O
(	O
218	O
.	O
0	O
pg	O
/	O
g	O
)	O
in	O
the	O
2003	O
–	O
2004	O
survey	O
years	O
[	O
48	O
]	O
.	O
However	O
,	O
the	O
LoD	O
that	O
was	O
reported	O
in	O
NHANES	O
2003	O
–	O
2004	O
survey	O
years	O
was	O
much	O
higher	O
than	O
the	O
sample	O
-	O
specific	O
LoDs	O
that	O
was	O
reported	O
in	O
our	O
study	O
(	O
218	O
pg	O
/	O
g	O
vs	O
.	O
8	O
.	O
41	O
–	O
31	O
.	O
0	O
pg	O
/	O
g	O
)	O
.	O
Therefore	O
,	O
we	O
are	O
unable	O
to	O
conclude	O
if	O
the	O
lipid	O
-	O
adjusted	O
mean	O
OCDD	O
concentrations	O
in	O
children	O
2	O
–	O
8	O
years	O
living	O
near	O
Gulf	O
of	O
Mexico	O
is	O
similar	O
to	O
that	O
of	O
those	O
ages	O
12	O
–	O
19	O
years	O
as	O
reported	O
by	O
NHANES	O
from	O
2003	O
to	O
2004	O
.	O
Based	O
on	O
Toxic	O
Equivalency	O
Factors	O
(	O
TEFs	O
)	O
,	O
which	O
are	O
used	O
globally	O
to	O
measure	O
toxicities	O
of	O
dioxins	O
[	O
52	O
,	O
53	O
]	O
,	O
OCDD	O
has	O
low	O
toxicity	O
,	O
with	O
a	O
TEF	O
of	O
0	O
.	O
0003	O
[	O
54	O
]	O
.	O
OCDD	O
has	O
been	O
found	O
to	O
have	O
adverse	O
effects	O
on	O
development	O
in	O
animals	O
[	O
32	O
]	O
,	O
however	O
no	O
human	O
deaths	O
have	O
been	O
attributed	O
to	O
exposure	O
to	O
OCDD	O
or	O
any	O
other	O
dioxins	O
[	O
55	O
]	O
.	O
In	O
comparison	O
,	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
TCDD	O
is	O
the	O
most	O
toxic	O
[	O
55	O
]	O
,	O
with	O
a	O
TEF	O
of	O
1	O
[	O
53	O
]	O
.	O
Of	O
all	O
the	O
dioxins	O
and	O
dibenzofurans	O
that	O
are	O
included	O
in	O
this	O
study	O
that	O
were	O
also	O
reported	O
by	O
NHANES	O
for	O
the	O
12	O
–	O
19	O
year	O
age	O
group	O
in	O
survey	O
years	O
2003	O
–	O
2004	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
6	O
,	O
7	O
,	O
8	O
-	O
HpCDD	O
was	O
the	O
only	O
dioxin	O
and	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
6	O
,	O
7	O
,	O
8	O
-	O
HpCDF	O
was	O
the	O
only	O
dibenzofuran	O
with	O
detectable	O
mean	O
concentrations	O
(	O
16	O
.	O
7	O
pg	O
/	O
g	O
and	O
9	O
.	O
36	O
pg	O
/	O
g	O
,	O
respectively	O
)	O
[	O
48	O
]	O
.	O
None	O
of	O
the	O
dibenzofurans	O
analyzed	O
in	O
our	O
study	O
were	O
detectable	O
in	O
at	O
least	O
70	O
%	O
of	O
serum	O
samples	O
.	O

Although	O
there	O
may	O
be	O
some	O
natural	O
sources	O
of	O
dioxins	O
in	O
the	O
environment	O
,	O
such	O
as	O
forest	O
fires	O
,	O
a	O
majority	O
can	O
be	O
contributed	O
to	O
human	O
activity	O
,	O
including	O
the	O
combustion	O
of	O
fossil	O
fuels	O
,	O
industrial	O
waste	O
,	O
bleaching	O
used	O
in	O
paper	O
production	O
,	O
and	O
most	O
importantly	O
,	O
incineration	O
[	O
55	O
]	O
.	O
Dioxins	O
are	O
present	O
globally	O
in	O
soil	O
,	O
water	O
,	O
sediment	O
,	O
plants	O
,	O
and	O
meat	O
.	O
Dioxins	O
in	O
surface	O
waters	O
and	O
sediments	O
can	O
lead	O
to	O
bioaccumulation	O
in	O
the	O
aquatic	O
food	O
chain	O
.	O
However	O
,	O
bioaccumulation	O
factors	O
tend	O
to	O
decrease	O
with	O
dioxins	O
having	O
more	O
than	O
four	O
chlorines	O
[	O
55	O
]	O
.	O
A	O
study	O
conducted	O
in	O
Russia	O
found	O
that	O
a	O
local	O
chemical	O
plant	O
was	O
a	O
source	O
of	O
dioxins	O
detected	O
in	O
air	O
,	O
soil	O
,	O
water	O
,	O
vegetables	O
,	O
and	O
milk	O
,	O
with	O
the	O
most	O
common	O
dioxin	O
being	O
OCDD	O
[	O
56	O
]	O
.	O
Dietary	O
routes	O
of	O
exposure	O
for	O
humans	O
include	O
the	O
consumption	O
of	O
dairy	O
products	O
,	O
meat	O
,	O
pork	O
fat	O
,	O
and	O
fish	O
[	O
56	O
]	O
.	O
In	O
our	O
study	O
,	O
we	O
found	O
detectable	O
concentrations	O
of	O
OCDD	O
in	O
100	O
%	O
of	O
samples	O
,	O
and	O
those	O
who	O
ate	O
shellfish	O
or	O
canned	O
sardine	O
and	O
mackerel	O
had	O
higher	O
lipid	O
-	O
adjusted	O
mean	O
OCDD	O
concentration	O
when	O
compared	O
to	O
those	O
without	O
these	O
dietary	O
exposures	O
.	O
In	O
contrast	O
with	O
what	O
would	O
be	O
expected	O
,	O
those	O
who	O
drank	O
milk	O
had	O
lower	O
lipid	O
-	O
adjusted	O
mean	O
OCDD	O
concentration	O
when	O
compared	O
to	O
those	O
who	O
did	O
not	O
drink	O
milk	O
,	O
although	O
this	O
result	O
may	O
be	O
skewed	O
because	O
one	O
of	O
the	O
few	O
children	O
who	O
did	O
not	O
drink	O
milk	O
had	O
a	O
very	O
high	O
lipid	O
-	O
adjusted	O
OCDD	O
concentration	O
.	O
This	O
extreme	O
observation	O
was	O
verified	O
to	O
be	O
true	O
.	O
Although	O
not	O
statistically	O
significant	O
,	O
in	O
this	O
study	O
the	O
creatinine	O
-	O
adjusted	O
mean	O
BPA	O
concentration	O
was	O
43	O
%	O
greater	O
in	O
children	O
with	O
ASD	O
when	O
compared	O
to	O
TD	O
controls	O
(	O
1	O
.	O
33	O
µg	O
/	O
g	O
vs	O
.	O
0	O
.	O
93	O
µg	O
/	O
g	O
)	O
.	O
Similarly	O
,	O
in	O
a	O
study	O
in	O
New	O
Jersey	O
,	O
USA	O
,	O
Stein	O
et	O
al	O
.	O
reported	O
significantly	O
higher	O
mean	O
BPA	O
urine	O
concentrations	O
in	O
ASD	O
cases	O
as	O
compared	O
to	O
controls	O
after	O
controlling	O
for	O
gender	O
,	O
age	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
and	O
creatinine	O
levels	O
as	O
potential	O
confounders	O
[	O
13	O
]	O
.	O
Kardas	O
et	O
al	O
.	O
also	O
reported	O
significantly	O
higher	O
mean	O
BPA	O
concentrations	O
among	O
ASD	O
cases	O
compared	O
to	O
controls	O
in	O
Turkey	O
[	O
11	O
]	O
.	O

However	O
,	O
results	O
from	O
these	O
studies	O
are	O
not	O
directly	O
comparable	O
to	O
ours	O
due	O
to	O
the	O
different	O
methods	O
that	O
are	O
used	O
for	O
adjusting	O
for	O
creatinine	O
[	O
13	O
]	O
and	O
the	O
measurement	O
of	O
BPA	O
in	O
serum	O
[	O
11	O
]	O
,	O
respectively	O
.	O
The	O
mean	O
BPA	O
concentrations	O
in	O
the	O
present	O
study	O
are	O
lower	O
for	O
both	O
ASD	O
cases	O
(	O
41	O
%	O
)	O
and	O
TD	O
controls	O
(	O
59	O
%	O
)	O
than	O
the	O
creatinine	O
-	O
adjusted	O
mean	O
BPA	O
concentration	O
for	O
the	O
6	O
–	O
11	O
year	O
age	O
group	O
reported	O
by	O
NHANES	O
survey	O
years	O
2011	O
–	O
2012	O
(	O
2	O
.	O
27	O
µg	O
/	O
g	O
)	O
.	O
However	O
,	O
these	O
results	O
are	O
consistent	O
with	O
the	O
decreasing	O
trend	O
in	O
geometric	O
BPA	O
concentrations	O
from	O
NHANES	O
survey	O
years	O
2003	O
–	O
2004	O
to	O
2011	O
–	O
2012	O
[	O
48	O
]	O
.	O
In	O
2013	O
,	O
NHANES	O
conducted	O
a	O
pilot	B-methodology
study	I-methodology
to	O
assess	O
the	O
feasibility	O
of	O
assessing	O
the	O
concentration	O
of	O
BPA	O
and	O
PEMs	O
among	O
American	O
children	O
aged	O
3	O
–	O
5	O
years	O
,	O
which	O
is	O
a	O
more	O
comparable	O
age	O
range	O
to	O
the	O
children	O
included	O
in	O
the	O
present	O
study	O
.	O
This	O
NHANES	O
pilot	B-methodology
study	I-methodology
reported	O
a	O
higher	O
creatinine	O
-	O
adjusted	O
mean	O
BPA	O
concentration	O
(	O
3	O
.	O
0	O
µg	O
/	O
g	O
)	O
among	O
children	O
3	O
–	O
5	O
years	O
than	O
we	O
reported	O
in	O
our	O
study	O
,	O
however	O
the	O
NHANES	O
pilot	B-methodology
study	I-methodology
included	O
a	O
convenience	O
sample	O
of	O
n	O
=	O
122	O
children	O
and	O
was	O
not	O
population	O
-	O
based	O
[	O
57	O
]	O
.	O
Creatinine	O
-	O
adjusted	O
geometric	O
mean	O
concentration	O
for	O
MBzP	O
for	O
children	O
with	O
ASD	O
(	O
19	O
.	O
01	O
µg	O
/	O
g	O
)	O
was	O
about	O
50	O
%	O
higher	O
than	O
the	O
concentration	O
for	O
MBzP	O
for	O
TD	O
children	O
(	O
12	O
.	O
55	O
µg	O
/	O
g	O
)	O
,	O
although	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O
Findings	O
from	O
NHANES	O
(	O
2011	O
–	O
2012	O
)	O
also	O
include	O
the	O
adjusted	O
geometric	O
mean	O
MBzP	O
concentration	O
of	O
12	O
.	O
5	O
µg	O
/	O
g	O
for	O
children	O
age	O
6	O
–	O
11	O
years	O
in	O
the	O
US	O
,	O
which	O
is	O
comparable	O
to	O
the	O
TD	O
group	O
and	O
is	O
52	O
%	O
lower	O
than	O
the	O
ASD	O
group	O
from	O
our	O
study	O
[	O
48	O
]	O
.	O
The	O
NHANES	O
pilot	B-methodology
study	I-methodology
on	O
children	O
3	O
–	O
5	O
years	O
reported	O
an	O
adjusted	O
geometric	O
mean	O
MBzP	O
concentration	O
of	O
13	O
.	O
7	O
µg	O
/	O
g	O
,	O
which	O
is	O
also	O
comparable	O
to	O
our	O
TD	O
group	O
and	O
lower	O
than	O
the	O
ASD	O
group	O
[	O
57	O
]	O
.	O

In	O
our	O
study	O
,	O
we	O
reported	O
the	O
adjusted	O
geometric	O
mean	O
concentration	O
for	O
MBP	O
,	O
which	O
is	O
the	O
sum	O
of	O
MiBP	O
and	O
MnBP	O
,	O
for	O
ASD	O
cases	O
and	O
TD	O
children	O
(	O
41	O
.	O
82	O
and	O
41	O
.	O
49	O
µg	O
/	O
g	O
,	O
respectively	O
)	O
.	O
NHANES	O
did	O
not	O
publish	O
data	O
on	O
MBP	O
concentrations	O
,	O
however	O
they	O
reported	O
creatinine	O
-	O
adjusted	O
geometric	O
mean	O
concentrations	O
for	O
MiBP	O
and	O
MnBP	O
separately	O
for	O
the	O
6	O
–	O
11	O
year	O
age	O
group	O
in	O
the	O
2011	O
–	O
2012	O
survey	O
years	O
.	O
We	O
added	O
the	O
means	O
of	O
MiBP	O
and	O
MnBP	O
as	O
an	O
estimate	O
of	O
the	O
geometric	O
mean	O
concentration	O
of	O
MBP	O
(	O
27	O
.	O
7	O
µg	O
/	O
g	O
)	O
,	O
which	O
was	O
much	O
lower	O
than	O
the	O
results	O
for	O
both	O
the	O
ASD	O
(	O
51	O
%	O
)	O
and	O
TD	O
(	O
50	O
%	O
)	O
groups	O
from	O
our	O
study	O
[	O
48	O
]	O
.	O
Using	O
the	O
same	O
method	O
for	O
estimating	O
the	O
mean	O
concentration	O
of	O
MBP	O
,	O
results	O
from	O
the	O
NHANES	O
pilot	B-methodology
study	I-methodology
on	O
children	O
3	O
–	O
5	O
years	O
for	O
the	O
concentration	O
of	O
MBP	O
(	O
40	O
.	O
0	O
µg	O
/	O
g	O
)	O
is	O
more	O
comparable	O
to	O
our	O
results	O
[	O
57	O
]	O
.	O
Additionally	O
,	O
the	O
creatinine	O
-	O
adjusted	O
geometric	O
mean	O
concentration	O
of	O
MEHHP	O
in	O
our	O
study	O
was	O
about	O
30	O
%	O
higher	O
for	O
children	O
with	O
ASD	O
when	O
compared	O
to	O
TD	O
children	O
(	O
14	O
.	O
94	O
µg	O
/	O
g	O
vs	O
.	O
11	O
.	O
08	O
µg	O
/	O
g	O
)	O
.	O
The	O
geometric	O
mean	O
concentration	O
of	O
14	O
.	O
9	O
µg	O
/	O
g	O
as	O
reported	O
by	O
NHANES	O
(	O
2011	O
–	O
2012	O
)	O
for	O
children	O
ages	O
6	O
–	O
11	O
years	O
is	O
comparable	O
to	O
our	O
findings	O
for	O
children	O
with	O
ASD	O
,	O
but	O
26	O
%	O
higher	O
than	O
TD	O
children	O
[	O
48	O
]	O
.	O
Since	O
the	O
geometric	O
mean	O
MEHHP	O
concentration	O
shows	O
a	O
decreasing	O
trend	O
over	O
NHANES	O
survey	O
years	O
2001	O
–	O
2002	O
to	O
2011	O
–	O
2012	O
,	O
our	O
findings	O
for	O
TD	O
children	O
could	O
possibly	O
be	O
comparable	O
to	O
the	O
current	O
population	O
average	O
,	O
while	O
our	O
findings	O
for	O
ASD	O
children	O
may	O
be	O
elevated	O
as	O
compared	O
to	O
the	O
current	O
population	O
average	O
.	O
In	O
the	O
NHANES	O
pilot	B-methodology
study	I-methodology
on	O
children	O
3	O
–	O
5	O
years	O
,	O
the	O
geometric	O
mean	O
concentration	O
of	O
MEHHP	O
(	O
20	O
.	O
3	O
µg	O
/	O
g	O
)	O
was	O
higher	O
when	O
compared	O
to	O
our	O
results	O
[	O
57	O
]	O
.	O

Creatinine	O
-	O
adjusted	O
geometric	O
mean	O
concentrations	O
of	O
MEP	O
,	O
MEOHP	O
,	O
and	O
MCPP	O
from	O
the	O
children	O
with	O
ASD	O
and	O
the	O
TD	O
children	O
in	O
this	O
study	O
were	O
comparable	O
(	O
<	O
20	O
%	O
difference	O
)	O
with	O
creatinine	O
-	O
adjusted	O
geometric	O
mean	O
concentrations	O
reported	O
by	O
NHANES	O
for	O
survey	O
years	O
2011	O
–	O
2012	O
[	O
48	O
]	O
.	O
Results	O
of	O
the	O
NHANES	O
pilot	B-methodology
study	I-methodology
of	O
children	O
3	O
–	O
5	O
years	O
were	O
higher	O
than	O
our	O
results	O
for	O
MEP	O
(	O
42	O
.	O
6	O
µg	O
/	O
g	O
)	O
and	O
MEOHP	O
(	O
13	O
.	O
2	O
µg	O
/	O
g	O
)	O
,	O
and	O
were	O
comparable	O
to	O
our	O
results	O
for	O
MCPP	O
(	O
3	O
.	O
9	O
µg	O
/	O
g	O
)	O
[	O
57	O
]	O
.	O
According	O
to	O
NHANES	O
data	O
,	O
the	O
mean	O
PEM	O
concentrations	O
in	O
all	O
of	O
the	O
age	O
groups	O
have	O
a	O
decreasing	O
trend	O
across	O
all	O
of	O
the	O
reported	O
survey	O
years	O
[	O
58	O
]	O
.	O
Di	O
-	O
(	O
2	O
-	O
ethylhexyl	O
)	O
phthalate	O
(	O
DEHP	O
)	O
has	O
many	O
metabolites	O
,	O
including	O
MEHHP	O
,	O
MEOHP	O
,	O
and	O
MEHP	O
.	O
While	O
we	O
were	O
unable	O
to	O
report	O
mean	O
concentrations	O
of	O
MEHP	O
due	O
to	O
a	O
large	O
proportion	O
below	O
LoD	O
,	O
Testa	O
et	O
al	O
.	O
reported	O
that	O
among	O
Italian	O
children	O
,	O
ASD	O
cases	O
had	O
significantly	O
higher	O
urine	O
creatinine	O
-	O
adjusted	O
median	O
MEHP	O
concentrations	O
when	O
compared	O
to	O
controls	O
[	O
8	O
]	O
.	O
Stein	O
et	O
al	O
.	O
further	O
separated	O
MEHP	O
into	O
subsequent	O
metabolites	O
and	O
found	O
that	O
ASD	O
cases	O
had	O
a	O
significantly	O
higher	O
mean	O
free	O
MEHP	O
as	O
compared	O
to	O
controls	O
after	O
adjusting	O
for	O
sex	O
,	O
age	O
,	O
BMI	O
,	O
and	O
creatinine	O
.	O
However	O
,	O
they	O
also	O
found	O
that	O
controls	O
had	O
significantly	O
higher	O
mean	O
%	O
bound	O
MEHP	O
when	O
compared	O
to	O
ASD	O
cases	O
after	O
adjusting	O
for	O
the	O
same	O
potential	O
confounders	O
[	O
59	O
]	O
.	O
Kardas	O
et	O
al	O
.	O
also	O
reported	O
higher	O
mean	O
serum	O
MEHP	O
concentration	O
among	O
ASD	O
cases	O
as	O
compared	O
to	O
controls	O
[	O
11	O
]	O
.	O
Phthalates	O
are	O
widely	O
used	O
in	O
manufacturing	O
plastic	O
products	O
but	O
are	O
not	O
covalently	O
bound	O
to	O
them	O
,	O
allowing	O
them	O
to	O
shed	O
and	O
to	O
become	O
ubiquitous	O
in	O
the	O
environment	O
worldwide	O
[	O
60	O
]	O
.	O
Therefore	O
,	O
there	O
are	O
multiple	O
routes	O
of	O
human	O
exposure	O
to	O
phthalates	O
,	O
including	O
plastic	O
containers	O
,	O
household	O
dust	O
[	O
37	O
]	O
,	O
water	O
,	O
dirt	O
,	O
and	O
food	O
products	O
such	O
as	O
meat	O
,	O
dairy	O
,	O
fruits	O
,	O
soft	O
drinks	O
,	O
and	O
fish	O
[	O
38	O
]	O
.	O

Studies	O
have	O
also	O
shown	O
that	O
exposure	O
to	O
phthalates	O
that	O
occur	O
during	O
pregnancy	O
[	O
61	O
]	O
and	O
breastfeeding	O
[	O
62	O
]	O
may	O
have	O
an	O
adverse	O
effect	O
on	O
fetal	O
and	O
infant	O
health	O
.	O
A	O
study	O
conducted	O
in	O
the	O
UK	O
concluded	O
that	O
DEHP	O
and	O
dibutyl	O
phthalate	O
(	O
DBP	O
)	O
(	O
and	O
their	O
respective	O
metabolites	O
,	O
MEHP	O
and	O
MnBP	O
)	O
were	O
found	O
in	O
several	O
animal	O
based	O
food	O
products	O
.	O
DEHP	O
was	O
found	O
in	O
the	O
highest	O
concentrations	O
,	O
and	O
the	O
main	O
route	O
of	O
exposure	O
to	O
young	O
children	O
was	O
through	O
the	O
consumption	O
of	O
fish	O
,	O
meat	O
,	O
and	O
milk	O
[	O
39	O
]	O
.	O
DEHP	O
has	O
been	O
reported	O
to	O
have	O
the	O
highest	O
production	O
volume	O
[	O
60	O
]	O
.	O
In	O
our	O
study	O
,	O
MEHP	O
had	O
about	O
70	O
%	O
of	O
results	O
below	O
the	O
limit	O
of	O
detection	O
.	O
However	O
,	O
we	O
found	O
that	O
creatinine	O
-	O
adjusted	O
concentrations	O
of	O
MEOHP	O
,	O
another	O
metabolite	O
of	O
DEHP	O
,	O
were	O
significantly	O
lower	O
among	O
those	O
who	O
drank	O
juices	O
,	O
such	O
as	O
orange	O
juice	O
and	O
tomato	O
juice	O
,	O
when	O
compared	O
to	O
those	O
who	O
did	O
not	O
drink	O
juice	O
.	O
Phthalate	O
levels	O
in	O
household	O
dust	O
were	O
found	O
to	O
have	O
no	O
association	O
with	O
ASD	O
,	O
however	O
DEHP	O
and	O
Benzylbutylphthalate	O
(	O
BBzP	O
)	O
concentrations	O
in	O
dust	O
were	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
Developmental	O
Disability	O
(	O
DD	O
)	O
and	O
impairments	O
in	O
communication	O
and	O
daily	O
living	O
skills	O
among	O
TD	O
children	O
.	O
Additionally	O
,	O
higher	O
concentrations	O
of	O
DBP	O
and	O
DEP	O
in	O
dust	O
were	O
associated	O
with	O
hyperactivity	O
in	O
boys	O
with	O
ASD	O
or	O
DD	O
[	O
37	O
]	O
.	O
We	O
did	O
not	O
find	O
any	O
statistically	O
significant	O
associations	O
between	O
DEHP	O
and	O
BBzP	O
metabolites	O
or	O
any	O
other	O
PEMs	O
and	O
ASD	O
status	O
of	O
children	O
,	O
however	O
,	O
our	O
study	O
was	O
underpowered	O
due	O
to	O
limited	O
sample	O
size	O
.	O
The	O
association	O
between	O
urine	O
PEM	O
concentrations	O
and	O
ASD	O
status	O
requires	O
further	O
investigation	O
.	O
This	O
was	O
a	O
pilot	B-methodology
study	I-methodology
intended	O
to	O
assess	O
the	O
feasibility	O
of	O
conducting	O
a	O
case	B-methodology
-	I-methodology
control	I-methodology
study	I-methodology
of	O
ASD	O
,	O
and	O
we	O
acknowledge	O
certain	O
limitations	O
.	O
Although	O
the	O
original	O
study	O
was	O
designed	O
as	O
a	O
1	O
:	O
1	O
matched	O
case	B-methodology
-	I-methodology
control	I-methodology
,	O
we	O
encountered	O
difficulty	O
enrolling	O
TD	O
children	O
.	O
We	O
believe	O
that	O
among	O
other	O
factors	O
,	O
this	O
difficulty	O
can	O
largely	O
be	O
attributed	O
to	O
the	O
reluctance	O
of	O
parents	O
to	O
have	O
their	O
TD	O
children	O
participate	O
in	O
a	O
blood	O
draw	O
that	O
would	O
not	O
directly	O
benefit	O
their	O
child	O
.	O

Although	O
several	O
strategies	O
were	O
employed	O
to	O
enroll	O
controls	O
,	O
including	O
advertising	O
in	O
local	O
papers	O
and	O
working	O
with	O
local	O
pediatricians	O
,	O
we	O
only	O
successfully	O
enrolled	O
10	O
TD	O
children	O
.	O
This	O
potentially	O
contributed	O
to	O
selection	O
bias	O
in	O
the	O
controls	O
and	O
decreased	O
the	O
generalizability	O
of	O
our	O
findings	O
.	O
Additionally	O
,	O
due	O
to	O
the	O
limited	O
sample	O
size	O
,	O
we	O
may	O
not	O
have	O
adequate	O
power	O
for	O
testing	O
the	O
statistical	O
significance	O
of	O
differences	O
between	O
comparison	O
groups	O
.	O
As	O
a	O
result	O
of	O
this	O
limitation	O
,	O
we	O
did	O
not	O
adjust	O
for	O
potential	O
confounding	O
variables	O
,	O
such	O
as	O
maternal	O
and	O
paternal	O
age	O
or	O
education	O
,	O
when	O
assessing	O
the	O
associations	O
between	O
analyte	O
concentrations	O
and	O
ASD	O
status	O
to	O
avoid	O
reporting	O
unstable	O
estimates	O
from	O
the	O
regression	O
models	O
.	O
We	O
also	O
acknowledge	O
the	O
potential	O
correlation	O
between	O
ASD	O
cases	O
and	O
TD	O
controls	O
for	O
the	O
nine	O
matched	O
pairs	O
,	O
who	O
were	O
matched	O
on	O
age	O
,	O
race	O
,	O
and	O
gender	O
,	O
and	O
modeling	O
techniques	O
that	O
account	O
for	O
within	O
-	O
pair	O
correlation	O
,	O
such	O
as	O
Generalized	O
Estimating	O
Equations	O
or	O
Mixed	O
Effect	O
Models	O
,	O
may	O
have	O
been	O
more	O
appropriate	O
for	O
the	O
analysis	O
of	O
some	O
analytes	O
.	O
However	O
,	O
due	O
to	O
the	O
limited	O
sample	O
size	O
,	O
we	O
decided	O
to	O
use	O
GLM	O
.	O
Future	O
studies	O
that	O
enroll	O
a	O
larger	O
number	O
of	O
matched	O
ASD	O
cases	O
and	O
TD	O
controls	O
should	O
account	O
for	O
such	O
correlation	O
.	O
Furthermore	O
,	O
we	O
acknowledge	O
that	O
we	O
did	O
not	O
have	O
data	O
on	O
the	O
source	O
of	O
canned	O
and	O
packaged	O
foods	O
.	O
Finally	O
,	O
we	O
did	O
not	O
adjust	O
for	O
multiple	O
comparisons	O
,	O
so	O
it	O
is	O
possible	O
that	O
any	O
statistically	O
significant	O
findings	O
reported	O
in	O
this	O
paper	O
may	O
be	O
due	O
to	O
chance	O
alone	O
.	O
We	O
reported	O
lipid	O
-	O
or	O
creatinine	O
-	O
adjusted	O
mean	O
concentrations	O
of	O
dioxins	O
,	O
dibenzofurans	O
,	O
BPA	O
,	O
and	O
PEMs	O
,	O
in	O
children	O
2	O
–	O
8	O
years	O
of	O
age	O
,	O
with	O
and	O
without	O
ASD	O
along	O
the	O
coast	O
of	O
the	O
Gulf	O
of	O
Mexico	O
near	O
Alabama	O
,	O
which	O
could	O
serve	O
as	O
a	O
reference	O
for	O
future	O
studies	O
.	O
We	O
did	O
not	O
find	O
any	O
significant	O
differences	O
in	O
the	O
adjusted	O
mean	O
concentrations	O
of	O
OCDD	O
,	O
BPA	O
,	O
or	O
PEMs	O
between	O
ASD	O
cases	O
and	O
TD	O
controls	O
.	O
However	O
,	O
these	O
findings	O
are	O
inconclusive	O
and	O
should	O
be	O
interpreted	O
with	O
caution	O
due	O
to	O
the	O
limited	O
sample	O
size	O
.	O
We	O
also	O
compared	O
the	O
concentrations	O
of	O
chemicals	O
that	O
were	O
analyzed	O
in	O
this	O
study	O
with	O
those	O
reported	O
by	O
NHANES	O
.	O
Furthermore	O
,	O
we	O
found	O
that	O
certain	O
dietary	O
exposures	O
,	O
such	O
as	O
fish	O
consumption	O
,	O
may	O
be	O
associated	O
with	O
higher	O
lipid	O
-	O
adjusted	O
mean	O
OCDD	O
concentrations	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
dietary	O
exposures	O
to	O
soft	O
drinks	O
and	O
juices	O
may	O
be	O
associated	O
with	O
lower	O
creatinine	O
-	O
adjusted	O
mean	O
BPA	O
and	O
MEOHP	O
concentrations	O
,	O
respectively	O
.	O
Future	O
studies	O
are	O
required	O
to	O
replicate	O
these	O
findings	O
.	O
This	O
pilot	O
research	O
project	O
is	O
funded	O
by	O
the	O
University	O
of	O
Texas	O
Health	O
Science	O
Center	O
at	O
Houston	O
.	O
We	O
also	O
acknowledge	O
the	O
support	O
provided	O
by	O
the	O
Biostatistics	O
/	O
Epidemiology	O
/	O
Research	B-methodology
Design	I-methodology
(	O
BERD	O
)	O
component	O
of	O
the	O
Center	O
for	O
Clinical	O
and	O
Translational	O
Sciences	O
(	O
CCTS	O
)	O
for	O
this	O
project	O
.	O
CCTS	O
is	O
partly	O
funded	O
by	O
grant	O
UL1	O
TR000371	O
from	O
the	O
National	O
Center	O
for	O
Advancing	O
Translational	O
Sciences	O
(	O
NCATS	O
)	O
,	O
awarded	O
to	O
University	O
of	O
Texas	O
Health	O
Science	O
Center	O
at	O
Houston	O
.	O
The	O
content	O
is	O
solely	O
the	O
responsibility	O
of	O
the	O
authors	O
and	O
does	O
not	O
necessarily	O
represent	O
the	O
official	O
views	O
of	O
the	O
NCATS	O
.	O
Furthermore	O
,	O
we	O
acknowledge	O
that	O
the	O
collection	O
and	O
management	O
of	O
survey	O
data	O
were	O
done	O
using	O
REDCap	O
[	O
63	O
]	O
.	O
Mohammad	O
H	O
.	O
Rahbar	O
and	O
Hanes	O
M	O
.	O
Swingle	O
have	O
made	O
substantial	O
contributions	O
to	O
conception	O
and	O
study	B-methodology
design	I-methodology
;	O
Hanes	O
M	O
.	O
Swingle	O
,	O
Amy	O
Mitchell	O
,	O
and	O
Ryan	O
Krone	O
contributed	O
to	O
acquisition	O
of	O
data	O
;	O
Manouchehr	O
Hessabi	O
,	O
MacKinsey	O
A	O
.	O
Christian	O
,	O
Amy	O
Mitchell	O
,	O
Ryan	O
Krone	O
,	O
Hanes	O
M	O
.	O
Swingle	O
,	O
and	O
Mohammad	O
H	O
.	O
Rahbar	O
have	O
made	O
contributions	O
to	O
data	O
quality	O
assurance	O
procedures	O
;	O
Donald	O
G	O
.	O
Patterson	O
Jr	O
.	O
and	O
Sean	O
Campbell	O
have	O
made	O
contributions	O
to	O
laboratory	O
assessment	O
and	O
data	O
quality	O
of	O
laboratory	O
;	O
Mohammad	O
H	O
.	O
Rahbar	O
,	O
MinJae	O
Lee	O
,	O
MacKinsey	O
A	O
.	O
Christian	O
,	O
and	O
Manouchehr	O
Hessabi	O
conducted	O
data	O
analysis	O
;	O
Mohammad	O
H	O
.	O
Rahbar	O
,	O
Hanes	O
M	O
.	O
Swingle	O
,	O
MacKinsey	O
A	O
.	O
Christian	O
,	O
and	O
Manouchehr	O
Hessabi	O
have	O
contributed	O
to	O
interpretation	O
of	O
data	O
;	O
Mohammad	O
H	O
.	O
Rahbar	O
,	O
Meagan	O
R	O
.	O
Pitcher	O
,	O
MacKinsey	O
A	O
.	O
Christian	O
,	O
and	O
Manouchehr	O
Hessabi	O
significantly	O
contributed	O
to	O
drafting	O
of	O
the	O
manuscript	O
;	O
and	O
Mohammad	O
H	O
.	O
Rahbar	O
,	O
Hanes	O
M	O
.	O
Swingle	O
,	O
Katherine	O
A	O
.	O
Loveland	O
,	O
and	O
Donald	O
G	O
.	O
Patterson	O
Jr	O
.	O
provided	O
critical	O
revision	O
of	O
the	O
manuscript	O
.	O

All	O
authors	O
have	O
read	O
and	O
approved	O
the	O
final	O
version	O
submitted	O
for	O
publication	O
.	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O

Virgin	O
Coconut	O
Oil	O
:	O
A	O
Dietary	B-methodology
Intervention	I-methodology
for	O
Dyslipidaemia	O
in	O
Patients	O
with	O
Diabetes	O
Mellitus	O
virgin	O
coconut	O
oil	O
;	O
nutraceutical	O
;	O
dietary	O
supplements	O
;	O
hyperlipidaemia	O
;	O
diabetes	O
mellitus	O
Hyperlipidaemia	O
is	O
causally	O
related	O
to	O
coronary	O
artery	O
diseases	O
(	O
CAD	O
)	O
and	O
peripheral	O
artery	O
diseases	O
(	O
PAD	O
)	O
in	O
people	O
with	O
Diabetes	O
Mellitus	O
(	O
DM	O
)	O
.	O
An	O
in	B-methodology
vivo	I-methodology
study	I-methodology
confirmed	O
that	O
virgin	O
coconut	O
oil	O
(	O
VCO	O
)	O
could	O
maintain	O
levels	O
of	O
lipids	O
in	O
the	O
blood	O
as	O
effectively	O
as	O
conventional	O
therapy	O
.	O
Therefore	O
,	O
this	O
study	O
aimed	O
to	O
determine	O
the	O
effect	O
of	O
VCO	O
on	O
the	O
lipid	O
profiles	O
and	O
ankle	O
–	O
brachial	O
index	O
(	O
ABI	O
)	O
of	O
patients	O
with	O
DM	O
.	O
In	O
this	O
experimental	B-methodology
study	I-methodology
with	O
pre	O
-	O
and	O
post	O
-	O
test	O
design	O
and	O
a	O
control	B-methodology
group	I-methodology
,	O
the	O
participants	O
were	O
selected	O
purposively	O
.	O
The	O
ABI	O
was	O
evaluated	O
on	O
the	O
first	O
visit	O
.	O
Baseline	O
lipid	O
profile	O
readings	O
were	O
taken	O
.	O
Each	O
participant	O
took	O
1	O
.	O
2	O
mL	O
/	O
kgBW	O
of	O
VCO	O
daily	O
and	O
divided	O
it	O
into	O
three	O
doses	O
.	O
After	O
30	O
days	O
of	O
taking	O
VCO	O
,	O
laboratory	O
examinations	O
and	O
ABI	O
were	O
repeated	O
,	O
and	O
adverse	O
events	O
were	O
evaluated	O
.	O
The	O
dependent	O
t	O
-	O
test	O
and	O
Wilcoxon	O
sign	O
rank	O
test	O
with	O
a	O
significance	O
level	O
of	O
α	O
≤	O
0	O
.	O
05	O
showed	O
a	O
significant	O
decrease	O
in	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
,	O
a	O
significant	O
increase	O
in	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
levels	O
(	O
p	O
=	O
0	O
.	O
031	O
)	O
,	O
a	O
significant	O
decrease	O
in	O
energy	O
intake	O
(	O
p	O
=	O
0	O
.	O
046	O
)	O
and	O
cholesterol	O
intake	O
(	O
p	O
=	O
0	O
.	O
023	O
)	O
at	O
the	O
endpoint	O
in	O
the	O
VCO	O
group	O
.	O
In	O
conclusion	O
,	O
this	O
therapy	O
is	O
beneficial	O
for	O
maintaining	O
lipid	O
profile	O
when	O
combined	O
with	O
dietary	O
therapy	O
.	O
Future	O
studies	O
should	O
investigate	O
the	O
duration	O
and	O
dosage	O
of	O
VCO	O
on	O
patients	O
to	O
maintain	O
lipid	O
-	O
linked	O
protein	O
.	O
Along	O
with	O
the	O
increasing	O
welfare	O
of	O
people	O
in	O
developing	O
countries	O
,	O
the	O
incidence	O
of	O
degenerative	O
diseases	O
is	O
also	O
increasing	O
,	O
one	O
of	O
which	O
is	O
diabetes	O
mellitus	O
(	O
DM	O
)	O
.	O
Globally	O
,	O
increasing	O
DM	O
prevalence	O
requires	O
attention	O
,	O
especially	O
among	O
health	O
practitioners	O
.	O
Without	O
intervention	O
to	O
halt	O
these	O
increases	O
,	O
there	O
will	O
be	O
at	O
least	O
629	O
million	O
people	O
with	O
DM	O
by	O
2045	O
[	O
1	O
]	O
.	O

With	O
the	O
high	O
prevalence	O
of	O
diabetes	O
,	O
the	O
incidence	O
of	O
complications	O
,	O
such	O
as	O
macrovascular	O
and	O
microvascular	O
complications	O
,	O
is	O
increasing	O
.	O
Macrovascular	O
complications	O
often	O
have	O
a	O
poor	O
prognosis	O
and	O
contribute	O
to	O
mortality	O
,	O
whereas	O
higher	O
numbers	O
of	O
death	O
are	O
caused	O
by	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
[	O
2	O
]	O
.	O
Lipid	O
fractions	O
of	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
,	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
and	O
possibly	O
triglyceride	O
(	O
TG	O
)	O
are	O
causally	O
related	O
to	O
CAD	O
in	O
people	O
with	O
DM	O
[	O
3	O
]	O
.	O
Recent	O
study	O
findings	O
identified	O
that	O
LDL	O
elevation	O
and	O
HDL	O
reduction	O
in	O
people	O
with	O
DM	O
are	O
also	O
strongly	O
related	O
to	O
the	O
reduction	O
in	O
the	O
increasing	O
incidence	O
and	O
future	O
risk	O
of	O
peripheral	O
artery	O
diseases	O
(	O
PADs	O
)	O
[	O
4	O
]	O
.	O
North	O
America	O
had	O
the	O
highest	O
reported	O
prevalence	O
of	O
PAD	O
globally	O
,	O
with	O
the	O
major	O
populations	O
being	O
people	O
with	O
type	O
2	O
DM	O
(	O
T2DM	O
)	O
[	O
5	O
]	O
.	O
People	O
with	O
DM	O
with	O
high	O
values	O
of	O
ankle	O
–	O
brachial	O
index	O
(	O
ABI	O
)	O
tend	O
to	O
experience	O
PAD	O
and	O
atherogenic	O
lipid	O
profiles	O
.	O
Furthermore	O
,	O
the	O
characteristic	O
of	O
lipids	O
was	O
associated	O
with	O
ABI	O
[	O
6	O
]	O
.	O
As	O
the	O
characteristic	O
features	O
of	O
diabetic	O
dyslipidaemia	O
are	O
a	O
major	O
risk	O
factor	O
for	O
DM	O
complication	O
[	O
7	O
]	O
,	O
maintaining	O
good	O
lipid	O
profiles	O
can	O
prevent	O
the	O
development	O
and	O
progression	O
of	O
further	O
hyperlipidaemia	O
-	O
related	O
complications	O
among	O
people	O
with	O
DM	O
.	O
Treating	O
the	O
interplay	O
of	O
circulating	O
lipids	O
and	O
the	O
risk	O
of	O
CAD	O
and	O
PAD	O
in	O
people	O
with	O
DM	O
is	O
an	O
emerging	O
and	O
important	O
public	O
health	O
issue	O
.	O
Dyslipidaemia	O
therapy	O
has	O
been	O
demonstrated	O
to	O
provide	O
more	O
benefits	O
to	O
people	O
with	O
DM	O
compared	O
with	O
those	O
without	O
DM	O
,	O
as	O
people	O
with	O
DM	O
responded	O
faster	O
[	O
8	O
]	O
.	O
Virgin	O
coconut	O
oil	O
(	O
VCO	O
)	O
is	O
a	O
dietary	O
supplement	O
that	O
has	O
been	O
shown	O
to	O
improve	O
lipid	O
profiles	O
in	O
dyslipidaemia	O
diabetic	O
rats	O
by	O
decreasing	O
the	O
total	O
cholesterol	O
(	O
TC	O
)	O
and	O
LDL	O
[	O
9	O
]	O
.	O
An	O
in	B-methodology
vivo	I-methodology
study	I-methodology
confirmed	O
that	O
VCO	O
could	O
reduce	O
the	O
TG	O
levels	O
in	O
the	O
blood	O
and	O
be	O
as	O
effective	O
as	O
conventional	O
therapy	O
using	O
simvastatin	O
[	O
10	O
]	O
.	O
In	O
a	O
higher	O
-	O
level	O
study	O
,	O
the	O
intake	O
of	O
30	O
mL	O
of	O
VCO	O
daily	O
increased	O
HDL	O
levels	O
in	O
healthy	O
people	O
[	O
11	O
]	O
.	O

Another	O
clinical	B-methodology
study	I-methodology
showed	O
that	O
VCO	O
taken	O
daily	O
for	O
8	O
weeks	O
reduced	O
TC	O
and	O
TG	O
levels	O
in	O
women	O
with	O
obesity	O
[	O
12	O
]	O
.	O
The	O
biological	O
efficacy	O
of	O
VCO	O
is	O
due	O
to	O
its	O
high	O
polyphenol	O
content	O
such	O
as	O
ferulic	O
acid	O
,	O
vanillic	O
acid	O
,	O
p	O
-	O
coumaric	O
acid	O
,	O
syringic	O
acid	O
,	O
and	O
caffeic	O
acid	O
.	O
These	O
polyphenols	O
are	O
reported	O
to	O
have	O
beneficial	O
effects	O
on	O
lipid	O
parameters	O
by	O
reducing	O
lipogenesis	O
and	O
enhancing	O
the	O
rate	O
of	O
fatty	O
acid	O
catabolism	O
[	O
13	O
]	O
.	O
VCO	O
is	O
also	O
reported	O
to	O
prevent	O
and	O
correct	O
dyslipidaemia	O
through	O
regulating	O
oxidative	O
stress	O
by	O
reducing	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
.	O
The	O
presence	O
of	O
polyphenols	O
in	O
VCO	O
as	O
bioactive	O
molecules	O
might	O
have	O
protected	O
cell	O
constituents	O
against	O
oxidative	O
damage	O
by	O
directly	O
reacting	O
with	O
free	O
radicals	O
in	O
the	O
extracellular	O
environment	O
or	O
by	O
upregulating	O
the	O
cellular	O
antioxidant	O
defence	O
systems	O
[	O
14	O
]	O
.	O
The	O
therapeutic	O
benefits	O
of	O
VCO	O
have	O
been	O
attributed	O
to	O
its	O
high	O
polyphenol	O
contents	O
,	O
such	O
as	O
ferulic	O
acid	O
,	O
quercetin	O
and	O
caffeic	O
acid	O
[	O
15	O
]	O
.	O
The	O
screened	O
secondary	O
metabolites	O
of	O
VCO	O
that	O
contribute	O
to	O
lipid	O
profile	O
maintenance	O
are	O
polyphenols	O
.	O
Polyphenols	O
isolated	O
from	O
VCO	O
were	O
reported	O
to	O
prevent	O
lipid	O
abnormalities	O
in	O
rats	O
by	O
improving	O
the	O
antioxidant	O
defence	O
system	O
[	O
16	O
]	O
.	O
Several	O
studies	O
have	O
identified	O
the	O
pharmacologic	O
effects	O
of	O
VCO	O
in	O
diabetic	O
conditions	O
.	O
VCO	O
demonstrates	O
antidiabetic	O
activity	O
by	O
reducing	O
blood	O
glucose	O
levels	O
,	O
reducing	O
glycated	O
haemoglobin	O
and	O
regenerating	O
damaged	O
islet	O
in	O
diabetic	O
rats	O
[	O
17	O
,	O
18	O
,	O
19	O
]	O
.	O
In	O
addition	O
,	O
VCO	O
was	O
found	O
to	O
maintain	O
lipid	O
profile	O
in	O
diabetic	O
rats	O
by	O
reducing	O
TC	O
,	O
TG	O
and	O
LDL	O
levels	O
and	O
increasing	O
HDL	O
levels	O
[	O
20	O
]	O
.	O
In	O
addition	O
,	O
VCO	O
therapy	O
exerts	O
a	O
probiotic	O
effect	O
on	O
diabetic	O
conditions	O
[	O
21	O
]	O
.	O
To	O
our	O
knowledge	O
,	O
no	O
clinical	B-methodology
studies	I-methodology
have	O
implemented	O
VCO	O
therapy	O
to	O
correct	O
dyslipidaemia	O
among	O
people	O
with	O
DM	O
;	O
thus	O
,	O
studies	O
investigating	O
the	O
beneficial	O
potential	O
of	O
VCO	O
therapy	O
in	O
people	O
with	O
DM	O
and	O
dyslipidaemia	O
are	O
novel	O
.	O

Therefore	O
,	O
this	O
study	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
VCO	O
on	O
serum	O
lipid	O
profiles	O
including	O
TC	O
,	O
LDL	O
,	O
TG	O
and	O
HDL	O
,	O
and	O
on	O
ABI	O
.	O
VCO	O
El	O
Medinah	O
(	O
P	O
-	O
IRT	O
NO	O
.	O
2073402011960	O
-	O
20	O
)	O
was	O
used	O
as	O
a	O
nutraceutical	O
food	O
supplement	O
.	O
TC	O
and	O
TG	O
levels	O
were	O
measured	O
using	O
commercial	O
assay	O
kits	O
(	O
with	O
sensitivity	O
3	O
mg	O
/	O
dL	O
[	O
0	O
.	O
08	O
mmol	O
/	O
L	O
]	O
)	O
(	O
Pars	O
Azmoon	O
Co	O
.	O
,	O
Tehran	O
,	O
Iran	O
)	O
with	O
glycerol	O
oxidation	O
and	O
cholesterol	O
oxidation	O
enzymatic	O
methods	O
by	O
an	O
auto	O
-	O
analyser	O
(	O
Echo	O
plus	O
Company	O
,	O
Italy	O
)	O
.	O
The	O
HDL	O
level	O
was	O
measured	O
after	O
the	O
precipitation	O
of	O
beta	O
-	O
lipoproteins	O
by	O
dextran	O
sulphate	O
and	O
chloride	O
magnesium	O
using	O
the	O
oxidation	O
cholesterol	O
method	O
and	O
an	O
auto	O
-	O
analyser	O
(	O
with	O
sensitivity	O
1	O
mg	O
/	O
dL	O
)	O
.	O
The	O
LDL	O
level	O
was	O
calculated	O
using	O
Friedewald	O
’	O
s	O
formula	O
as	O
seen	O
below	O
[	O
22	O
]	O
:	O
An	O
8	O
MHz	O
Doppler	O
(	O
Parks	O
Medical	O
Elektronics	O
,	O
Inc	O
.	O
,	O
Aloha	O
,	O
OR	O
,	O
USA	O
)	O
was	O
used	O
to	O
detect	O
the	O
ABI	O
values	O
.	O
The	O
participants	O
were	O
recruited	O
on	O
an	O
enrolment	O
basis	O
following	O
the	O
inclusion	B-methodology
criteria	I-methodology
.	O
Participants	O
were	O
diagnosed	O
with	O
DM	O
and	O
dyslipidaemia	O
,	O
aged	O
≥20	O
years	O
,	O
regardless	O
of	O
sex	O
,	O
were	O
visiting	O
the	O
endocrinology	O
clinic	O
on	O
the	O
day	O
of	O
enrolment	O
and	O
had	O
normal	O
body	O
mass	O
index	O
.	O
Patients	O
with	O
a	O
history	O
of	O
routine	O
VCO	O
consumption	O
,	O
cardiovascular	O
and	O
renal	O
diseases	O
,	O
taking	O
statins	O
or	O
any	O
-	O
related	O
medications	O
,	O
not	O
completing	O
VCO	O
therapy	O
at	O
the	O
proposed	O
time	O
,	O
active	O
smokers	O
or	O
experiencing	O
adverse	O
events	O
(	O
e	O
.	O
g	O
.	O
,	O
diarrhoea	O
)	O
were	O
excluded	O
.	O
All	O
eligible	O
patients	O
were	O
asked	O
to	O
provide	O
consent	O
before	O
participating	O
in	O
the	O
study	O
.	O
The	O
calculated	O
sample	O
size	O
was	O
142	O
(	O
71	O
each	O
group	O
)	O
computed	O
based	O
on	O
the	O
following	O
formula	O
[	O
23	O
,	O
24	O
]	O
:	O
n	O
=	O
σ2	O
[	O
Z1−α	O
+	O
Z1−β	O
]	O
2μ0−μa	O
where	O
:	O
n	O
=	O
sample	O
size	O
;	O
µ0	O
=	O
mean	O
from	O
baseline	O
of	O
total	O
cholesterol	O
=	O
4	O
.	O
66	O
;	O
µa	O
=	O
mean	O
from	O
endpoint	O
of	O
total	O
cholesterol	O
=	O
3	O
.	O
94	O
;	O

Z1	O
−	O
α	O
/	O
2	O
=	O
95	O
%	O
confidence	O
interval	O
,	O
alpha	O
0	O
.	O
05	O
this	O
is	O
1	O
.	O
96	O
;	O
Z1	O
−	O
β	O
=	O
This	O
depends	O
on	O
power	O
,	O
for	O
80	O
%	O
this	O
is	O
0	O
.	O
84	O
;	O
σ	O
=	O
standard	O
deviation	O
=	O
2	O
.	O
16	O
.	O
The	O
numbers	O
recruited	O
were	O
147	O
(	O
73	O
in	O
the	O
intervention	B-methodology
group	I-methodology
and	O
72	O
in	O
the	O
control	B-methodology
group	I-methodology
)	O
.	O
The	O
consecutive	O
sampling	O
method	O
was	O
used	O
.	O
Individuals	O
were	O
randomly	B-methodology
allocated	I-methodology
into	O
the	O
intervention	B-methodology
and	I-methodology
control	I-methodology
groups	I-methodology
.	O
The	O
numbers	O
finishing	O
the	O
study	O
were	O
136	O
(	O
68	O
in	O
the	O
intervention	B-methodology
group	I-methodology
and	O
68	O
in	O
the	O
control	B-methodology
group	I-methodology
)	O
.	O
The	O
reasons	O
for	O
leaving	O
the	O
study	O
in	O
the	O
intervention	B-methodology
group	I-methodology
were	O
diarrhoea	O
(	O
n	O
=	O
2	O
)	O
,	O
nauseous	O
(	O
n	O
=	O
1	O
)	O
and	O
taste	O
intolerance	O
(	O
n	O
=	O
2	O
)	O
.	O
Four	O
(	O
4	O
)	O
participants	O
in	O
the	O
control	B-methodology
group	I-methodology
were	O
uncontactable	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O
The	O
study	O
was	O
conducted	O
in	O
Wahidin	O
Sudirohusodo	O
and	O
the	O
teaching	O
hospital	O
of	O
Hasanuddin	O
University	O
in	O
Makassar	O
,	O
Indonesia	O
.	O
This	O
was	O
a	O
quasi	B-methodology
-	I-methodology
experimental	I-methodology
study	I-methodology
using	O
pre	O
-	O
and	O
post	O
-	O
test	O
with	O
a	O
control	B-methodology
group	I-methodology
.	O
After	O
obtaining	O
consent	O
,	O
the	O
demographic	O
data	O
of	O
the	O
participants	O
were	O
collected	O
.	O
Serum	O
TC	O
,	O
TG	O
,	O
LDL	O
and	O
HDL	O
levels	O
and	O
ABI	O
were	O
measured	O
at	O
baseline	O
(	O
day	O
1	O
)	O
and	O
endpoint	O
(	O
day	O
30	O
)	O
.	O
Participants	O
were	O
asked	O
to	O
fill	O
in	O
a	O
dietary	O
sheet	O
daily	O
.	O
The	O
participants	O
were	O
referred	O
to	O
a	O
laboratory	O
for	O
lipid	O
profile	O
assessment	O
.	O
After	O
12	O
h	O
of	O
fasting	O
,	O
5	O
mL	O
of	O
venous	O
blood	O
was	O
taken	O
for	O
serum	O
TC	O
,	O
TG	O
,	O
LDL	O
and	O
HDL	O
measurements	O
.	O
ABI	O
was	O
derived	O
from	O
the	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
measured	O
on	O
the	O
arm	O
and	O
leg	O
after	O
10	O
min	O
of	O
rest	O
in	O
the	O
supine	O
position	O
,	O
with	O
the	O
arms	O
and	O
legs	O
straight	O
and	O
at	O
rest	O
.	O
Manual	O
cuffs	O
were	O
used	O
for	O
all	O
BP	O
measurements	O
,	O
and	O
arm	O
circumference	O
was	O
determined	O
during	O
screening	O
to	O
select	O
the	O
appropriate	O
cuff	O
size	O
.	O
The	O
same	O
cuff	O
size	O
was	O
used	O
for	O
the	O
lower	O
leg	O
,	O
and	O
the	O
straight	O
wrapping	O
technique	O
was	O
employed	O
.	O
Arm	O
BP	O
was	O
measured	O
using	O
a	O
sphygmomanometer	O
and	O
an	O
8	O
MHz	O
Doppler	O
to	O
detect	O
pulses	O
.	O

One	O
measurement	O
was	O
made	O
at	O
each	O
of	O
the	O
six	O
sites	O
in	O
the	O
following	O
order	O
:	O
left	O
arm	O
,	O
left	O
ankle	O
(	O
dorsalis	O
pedis	O
and	O
posterior	O
tibialis	O
)	O
,	O
right	O
arm	O
and	O
right	O
ankle	O
.	O
The	O
right	O
ABI	O
was	O
calculated	O
as	O
the	O
ratio	O
of	O
the	O
higher	O
right	O
ankle	O
pressure	O
(	O
dorsalis	O
pedis	O
or	O
posterior	O
tibialis	O
)	O
divided	O
by	O
the	O
higher	O
brachial	O
pressure	O
(	O
right	O
or	O
left	O
side	O
)	O
.	O
The	O
left	O
ABI	O
was	O
calculated	O
using	O
a	O
similar	O
method	O
.	O
The	O
lower	O
ratio	O
of	O
either	O
side	O
was	O
considered	O
the	O
participant	O
’	O
s	O
ABI	O
[	O
25	O
]	O
.	O
Participants	O
were	O
asked	O
to	O
continue	O
their	O
lifestyle	O
as	O
usual	O
.	O
The	O
VCO	O
dosage	O
was	O
based	O
on	O
the	O
participants	O
’	O
weight	O
.	O
For	O
days	O
1	O
–	O
3	O
,	O
the	O
VCO	O
dosage	O
was	O
0	O
.	O
6	O
mL	O
per	O
kilogram	O
bodyweight	O
(	O
kgBW	O
)	O
and	O
was	O
increased	O
to	O
1	O
.	O
2	O
mL	O
/	O
kgBW	O
for	O
days	O
4	O
–	O
30	O
.	O
The	O
calculated	O
VCO	O
was	O
incorporated	O
into	O
meals	O
at	O
breakfast	O
,	O
lunch	O
and	O
dinner	O
or	O
snacks	O
.	O
This	O
VCO	O
contains	O
lauric	O
acid	O
(	O
47	O
.	O
96	O
%	O
)	O
,	O
myristic	O
acid	O
(	O
20	O
.	O
26	O
%	O
)	O
,	O
palmitic	O
acid	O
(	O
9	O
.	O
08	O
%	O
)	O
,	O
acprylic	O
acid	O
(	O
6	O
.	O
99	O
%	O
)	O
,	O
capric	O
acid	O
(	O
6	O
.	O
49	O
%	O
)	O
,	O
oleic	O
acid	O
(	O
5	O
.	O
18	O
%	O
)	O
,	O
stearic	O
acid	O
(	O
3	O
.	O
11	O
%	O
)	O
and	O
linoleic	O
acid	O
(	O
0	O
.	O
81	O
%	O
)	O
.	O
The	O
researchers	O
conducted	O
telemonitoring	O
to	O
remind	O
and	O
assure	O
VCO	O
consumption	O
schedules	O
.	O
Signs	O
and	O
symptoms	O
were	O
monitored	O
and	O
recorded	O
on	O
a	O
daily	O
basis	O
.	O
NutriSurvey	O
Indonesia	O
version	O
2017	O
was	O
used	O
for	O
the	O
recording	O
of	O
the	O
daily	O
food	O
intake	O
.	O
Statistical	O
analysis	O
was	O
done	O
using	O
IBM	O
SPSS	O
statistics	O
20	O
windows	O
(	O
SPSS	O
Inc	O
.	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O
The	O
results	O
are	O
given	O
in	O
mean	O
±	O
standard	O
deviation	O
and	O
for	O
categorical	O
data	O
as	O
a	O
percentage	O
.	O
The	O
absolute	O
changes	O
from	O
baseline	O
in	O
the	O
lipid	O
parameters	O
and	O
ABI	O
were	O
computed	O
between	O
the	O
two	O
measurements	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
baseline	O
vs	O
.	O
end	O
of	O
the	O
intervention	O
by	O
using	O
paired	O
t	O
-	O
test	O
.	O
The	O
differences	O
were	O
compared	O
between	O
the	O
two	O
groups	O
using	O
the	O
independent	O
t	O
-	O
test	O
.	O

To	O
test	O
the	O
hypothesis	O
,	O
a	O
significance	O
level	O
of	O
0	O
.	O
05	O
was	O
used	O
to	O
determine	O
if	O
the	O
difference	O
between	O
the	O
two	O
groups	O
was	O
statistically	O
significant	O
.	O
The	O
study	O
was	O
conducted	O
according	O
to	O
the	O
guidelines	B-methodology
of	O
the	O
Declarations	O
of	O
Helsinki	O
.	O
The	O
research	O
proposal	O
and	O
all	O
the	O
procedures	O
involving	O
research	B-methodology
study	I-methodology
participants	O
were	O
approved	O
by	O
the	O
ethics	O
committee	O
of	O
the	O
Faculty	O
of	O
Medicine	O
,	O
Hasanuddin	O
University	O
(	O
KE	O
/	O
FK	O
/	O
1213	O
/	O
EC	O
/	O
2019	O
)	O
.	O
A	O
total	O
of	O
136	O
participants	O
finished	O
the	O
study	O
,	O
i	O
.	O
e	O
.	O
,	O
68	O
participants	O
of	O
the	O
VCO	O
group	O
and	O
68	O
participants	O
of	O
the	O
control	B-methodology
group	I-methodology
.	O
As	O
shown	O
in	O
Table	O
1	O
,	O
participants	O
from	O
the	O
VCO	O
group	O
were	O
older	O
than	O
the	O
control	B-methodology
group	I-methodology
and	O
most	O
participants	O
in	O
all	O
groups	O
were	O
male	O
and	O
had	O
a	O
BMI	O
category	O
as	O
overweight	O
.	O
With	O
further	O
analysis	O
,	O
most	O
participants	O
consumed	O
high	O
amounts	O
of	O
carbohydrates	O
(	O
>	O
26	O
%	O
of	O
energy	O
consumption	O
)	O
and	O
cholesterols	O
daily	O
.	O
The	O
carbohydrate	O
requirement	O
per	O
24	O
h	O
in	O
healthy	O
people	O
is	O
30	O
times	O
the	O
body	O
weight	O
(	O
unit	O
calories	O
)	O
,	O
whereas	O
that	O
of	O
patients	O
with	O
DM	O
is	O
60	O
%	O
of	O
the	O
calculated	O
carbohydrate	O
amount	O
in	O
healthy	O
people	O
.	O
Data	O
were	O
obtained	O
by	O
converting	O
grams	O
into	O
calories	O
(	O
1	O
g	O
=	O
4	O
calories	O
)	O
.	O
The	O
biochemistry	O
data	O
,	O
i	O
.	O
e	O
.	O
,	O
total	O
cholesterol	O
(	O
TC	O
)	O
,	O
triglyceride	O
(	O
TG	O
)	O
,	O
HDL	O
,	O
and	O
LDL	O
were	O
not	O
significantly	O
different	O
at	O
baseline	O
between	O
the	O
two	O
groups	O
as	O
well	O
as	O
ABI	O
values	O
.	O
But	O
,	O
the	O
VCO	O
group	O
consumed	O
significantly	O
higher	O
energy	O
intakes	O
than	O
the	O
control	B-methodology
group	I-methodology
at	O
baseline	O
.	O
The	O
mean	O
TC	O
of	O
the	O
participants	O
in	O
the	O
VCO	O
and	O
Control	O
groups	O
at	O
baseline	O
were	O
247	O
.	O
69	O
and	O
231	O
.	O
85	O
mg	O
/	O
dL	O
,	O
respectively	O
(	O
Table	O
1	O
)	O
.	O
After	O
the	O
intervention	O
,	O
there	O
was	O
no	O
significant	O
decrease	O
in	O
the	O
TC	O
of	O
the	O
participants	O
enrolled	O
in	O
both	O
groups	O
(	O
Table	O
2	O
)	O
.	O
However	O
,	O
the	O
range	O
of	O
change	O
from	O
baseline	O
to	O
end	O
point	O
between	O
groups	O
was	O
significantly	O
different	O
(	O
p	O
=	O
0	O
.	O
018	O
)	O
,	O
where	O
the	O
VCO	O
group	O
experienced	O
a	O
decrease	O
in	O
TC	O
at	O
21	O
.	O
08	O
mg	O
/	O
dL	O
while	O
the	O
control	B-methodology
group	I-methodology
experienced	O
an	O
increase	O
in	O
TC	O
at	O
7	O
.	O
99	O
mg	O
/	O
dL	O
(	O
Figure	O
1	O
)	O
.	O

Similarly	O
,	O
The	O
TG	O
of	O
the	O
VCO	O
and	O
control	B-methodology
group	I-methodology
had	O
no	O
significant	O
decrease	O
after	O
the	O
intervention	O
but	O
a	O
significant	O
difference	O
in	O
a	O
range	O
of	O
change	O
between	O
groups	O
was	O
observed	O
(	O
p	O
=	O
0	O
.	O
039	O
)	O
.	O
The	O
VCO	O
group	O
experienced	O
a	O
decrease	O
in	O
TG	O
at	O
9	O
.	O
23	O
mg	O
/	O
dL	O
while	O
the	O
control	B-methodology
group	I-methodology
experienced	O
an	O
increase	O
in	O
TC	O
at	O
7	O
.	O
62	O
mg	O
/	O
dL	O
(	O
Figure	O
1	O
)	O
.	O
The	O
HDL	O
in	O
the	O
VCO	O
group	O
increased	O
significantly	O
after	O
the	O
intervention	O
.	O
The	O
mean	O
difference	O
of	O
HDL	O
was	O
significantly	O
different	O
between	O
groups	O
(	O
p	O
=	O
0	O
.	O
010	O
)	O
as	O
the	O
VCO	O
group	O
experienced	O
an	O
increase	O
in	O
HDL	O
at	O
9	O
.	O
4	O
mg	O
/	O
dL	O
while	O
the	O
control	B-methodology
group	I-methodology
experienced	O
a	O
decrease	O
in	O
HDL	O
at	O
6	O
.	O
15	O
mg	O
/	O
dL	O
(	O
Figure	O
1	O
)	O
.	O
The	O
mean	O
LDL	O
of	O
the	O
VCO	O
and	O
Control	O
groups	O
at	O
baseline	O
were	O
179	O
.	O
62	O
and	O
156	O
.	O
31	O
mg	O
/	O
dL	O
,	O
respectively	O
.	O
After	O
the	O
intervention	O
,	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
VCO	O
group	O
.	O
The	O
mean	O
difference	O
of	O
LDL	O
in	O
the	O
VCO	O
group	O
(	O
38	O
.	O
16	O
mg	O
/	O
dL	O
)	O
was	O
significantly	O
higher	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
than	O
in	O
the	O
Control	B-methodology
group	I-methodology
(	O
3	O
.	O
16	O
mg	O
/	O
dL	O
)	O
(	O
Figure	O
1	O
)	O
.	O
The	O
mean	O
energy	O
intake	O
in	O
the	O
VCO	O
and	O
Control	O
groups	O
were	O
1768	O
kcal	O
/	O
day	O
and	O
1452	O
kcal	O
/	O
day	O
at	O
baseline	O
,	O
respectively	O
.	O
After	O
the	O
intervention	O
,	O
only	O
the	O
VCO	O
group	O
had	O
a	O
significant	O
decrease	O
in	O
energy	O
intake	O
.	O
The	O
mean	O
difference	O
of	O
energy	O
intake	O
in	O
the	O
VCO	O
group	O
(	O
−414	O
kcal	O
/	O
day	O
)	O
was	O
significantly	O
lower	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
than	O
in	O
the	O
control	B-methodology
group	I-methodology
(	O
+	O
26	O
kcal	O
/	O
day	O
)	O
.	O
A	O
significant	O
decrease	O
in	O
cholesterol	O
intake	O
was	O
evident	O
in	O
the	O
intervention	B-methodology
group	I-methodology
towards	O
the	O
end	O
of	O
the	O
intervention	O
(	O
mean	O
difference	O
168	O
.	O
30	O
mg	O
,	O
p	O
=	O
0	O
.	O
023	O
)	O
(	O
Table	O
2	O
)	O
.	O
For	O
the	O
other	O
parameters	O
,	O
no	O
significant	O
difference	O
in	O
the	O
ABI	O
,	O
carbohydrate	O
intake	O
,	O
and	O
IMT	O
was	O
observed	O
.	O
This	O
study	O
is	O
the	O
first	O
study	O
to	O
have	O
evaluated	O
the	O
effect	O
of	O
VCO	O
on	O
people	O
with	O
DM	O
on	O
dyslipidaemia	O
.	O

Overall	O
,	O
the	O
VCO	O
group	O
showed	O
more	O
rapid	O
effects	O
from	O
dyslipidaemia	O
by	O
showing	O
a	O
significantly	O
higher	O
reduction	O
in	O
the	O
mean	O
TC	O
,	O
TG	O
and	O
LDL	O
levels	O
and	O
elevation	O
in	O
the	O
mean	O
HDL	O
level	O
than	O
the	O
control	B-methodology
group	I-methodology
after	O
30	O
days	O
.	O
These	O
observed	O
effects	O
of	O
VCO	O
in	O
the	O
blood	O
levels	O
of	O
the	O
lipid	O
profile	O
in	O
diabetic	O
patients	O
suggested	O
that	O
the	O
extract	O
is	O
effective	O
in	O
ameliorating	O
diabetic	O
complications	O
such	O
as	O
cardiovascular	O
disease	O
,	O
arteriosclerosis	O
,	O
coronary	O
artery	O
disease	O
,	O
etc	O
.	O
,	O
due	O
to	O
its	O
high	O
content	O
of	O
polyphenols	O
which	O
are	O
bioactive	O
components	O
in	O
the	O
extract	O
[	O
26	O
]	O
.	O
Additionally	O
,	O
a	O
decrease	O
in	O
energy	O
intake	O
and	O
cholesterol	O
intake	O
was	O
observed	O
in	O
the	O
VCO	O
group	O
.	O
However	O
,	O
the	O
TC	O
and	O
TG	O
levels	O
in	O
the	O
VCO	O
group	O
decreased	O
with	O
no	O
significant	O
difference	O
.	O
Following	O
the	O
result	O
,	O
VCO	O
has	O
no	O
effect	O
on	O
ABI	O
.	O
In	O
line	O
with	O
the	O
study	O
findings	O
,	O
there	O
was	O
a	O
relationship	O
between	O
TG	O
and	O
ABI	O
in	O
a	O
previous	O
study	O
[	O
27	O
]	O
.	O
A	O
low	O
ABI	O
value	O
reflects	O
atherosclerosis	O
in	O
the	O
vessel	O
wall	O
,	O
resulting	O
in	O
a	O
decrease	O
in	O
perfusion	O
and	O
arterial	O
circulation	O
to	O
the	O
distal	O
extremities	O
.	O
In	O
a	O
recent	O
study	O
,	O
ABI	O
value	O
is	O
associated	O
with	O
different	O
risks	O
of	O
diabetes	O
.	O
Further	O
,	O
there	O
is	O
a	O
relationship	O
between	O
TG	O
and	O
ABI	O
.	O
High	O
amounts	O
of	O
TG	O
affect	O
blood	O
vessel	O
and	O
cause	O
atherosclerosis	O
that	O
contributes	O
to	O
the	O
ABI	O
value	O
[	O
27	O
]	O
.	O
This	O
explanation	O
is	O
in	O
line	O
with	O
our	O
study	O
findings	O
that	O
VCO	O
slightly	O
decreased	O
TG	O
with	O
no	O
significant	O
mean	O
difference	O
.	O
Therefore	O
,	O
a	O
decrease	O
in	O
ABI	O
was	O
not	O
observed	O
.	O
VCO	O
evidently	O
had	O
anti	O
-	O
hyperlipidaemia	O
activities	O
.	O
An	O
in	B-methodology
vivo	I-methodology
study	I-methodology
showed	O
that	O
applying	O
VCO	O
orally	O
could	O
decrease	O
all	O
lipid	O
profiles	O
,	O
including	O
TC	O
,	O
TG	O
,	O
HDL	O
and	O
LDL	O
close	O
to	O
normal	O
levels	O
[	O
14	O
,	O
28	O
]	O
.	O
However	O
,	O
a	O
recent	O
clinical	B-methodology
study	I-methodology
showed	O
that	O
VCO	O
increases	O
HDL	O
without	O
changes	O
in	O
LDL	O
[	O
29	O
]	O
.	O
Different	O
from	O
our	O
study	O
,	O
this	O
study	O
had	O
a	O
population	O
of	O
cardiovascular	O
diseases	O
and	O
long	O
-	O
term	O
VCO	O
taken	O
orally	O
at	O
4	O
g	O
/	O
day	O
without	O
considering	O
patients	O
’	O
weight	O
.	O

In	O
[	O
26	O
]	O
,	O
although	O
the	O
TC	O
and	O
TG	O
levels	O
in	O
the	O
VCO	O
group	O
decreased	O
with	O
no	O
significant	O
difference	O
within	O
the	O
VCO	O
group	O
,	O
VCO	O
improved	O
the	O
lipid	O
profile	O
by	O
significantly	O
decreasing	O
LDL	O
and	O
increasing	O
HDL	O
levels	O
.	O
HDL	O
is	O
a	O
free	O
radical	O
scavenger	O
that	O
can	O
prevent	O
beta	O
-	O
lipoprotein	O
peroxidation	O
.	O
Therefore	O
,	O
lowering	O
the	O
HDL	O
level	O
is	O
considered	O
to	O
prevent	O
heart	O
disease	O
development	O
in	O
people	O
with	O
DM	O
[	O
30	O
]	O
.	O
Epidemiologic	O
evidence	O
shows	O
that	O
when	O
HDL	O
levels	O
are	O
increased	O
by	O
0	O
.	O
025	O
mmol	O
/	O
L	O
,	O
the	O
associated	O
risk	O
of	O
heart	O
disease	O
development	O
is	O
reduced	O
by	O
2	O
–	O
3	O
%	O
[	O
31	O
]	O
.	O
It	O
means	O
that	O
a	O
9	O
.	O
4	O
mg	O
/	O
dL	O
increase	O
in	O
HDL	O
after	O
taking	O
VCO	O
in	O
our	O
study	O
could	O
decrease	O
42	O
–	O
36	O
%	O
of	O
heart	O
disease	O
risk	O
.	O
Showing	O
that	O
there	O
was	O
a	O
significant	O
difference	O
in	O
means	O
between	O
VCO	O
and	O
control	O
groups	O
in	O
all	O
lipid	O
profiles	O
indicates	O
that	O
VCO	O
has	O
the	O
potential	O
to	O
alleviate	O
dyslipidaemia	O
.	O
Future	O
research	O
needs	O
to	O
optimise	O
the	O
dosage	O
and	O
frequency	O
of	O
use	O
to	O
lead	O
to	O
the	O
preeminent	O
effect	O
.	O
Another	O
study	O
found	O
that	O
taking	O
VCO	O
(	O
15	O
mL	O
twice	O
daily	O
)	O
as	O
a	O
supplement	O
for	O
young	O
healthy	O
people	O
increases	O
HDL	O
-	O
C	O
levels	O
and	O
there	O
are	O
no	O
adverse	O
effects	O
,	O
thus	O
its	O
use	O
is	O
recommended	O
to	O
reduce	O
the	O
risk	O
cardiovascular	O
problem	O
[	O
11	O
]	O
.	O
Additionally	O
,	O
coconut	O
,	O
when	O
it	O
is	O
administered	O
in	O
an	O
isoenergetic	O
balanced	O
diet	O
,	O
could	O
raise	O
HDL	O
cholesterol	O
levels	O
and	O
decrease	O
the	O
TC	O
/	O
HDL	O
cholesterol	O
ratio	O
in	O
obese	O
men	O
[	O
32	O
]	O
.	O
VCO	O
is	O
also	O
high	O
in	O
saturated	O
fat	O
(	O
MCFA	O
)	O
,	O
which	O
increases	O
HDL	O
-	O
cholesterol	O
levels	O
compared	O
with	O
other	O
plant	O
-	O
based	O
oils	O
that	O
have	O
polyunsaturated	O
and	O
monounsaturated	O
fats	O
[	O
11	O
]	O
.	O
MCFA	O
upregulates	O
apoA	O
-	O
1	O
,	O
the	O
major	O
protein	O
component	O
of	O
HDL	O
synthesised	O
by	O
the	O
intestinal	O
,	O
which	O
interacts	O
with	O
the	O
ATP	O
-	O
binding	O
cassette	O
transporter	O
A1	O
(	O
ABCA1	O
)	O
.	O
This	O
interaction	O
mediates	O
the	O
efflux	O
of	O
cellular	O
cholesterol	O
to	O
lipid	O
-	O
free	O
apoA	O
-	O
1	O
,	O
thereby	O
inducing	O
reverse	O
cholesterol	O
transport	O
and	O
biogenesis	O
of	O
HDL	O
particles	O
.	O

Therefore	O
,	O
MCFA	O
improves	O
the	O
hepatic	O
mRNA	O
expression	O
of	O
ABCA1	O
,	O
which	O
plays	O
a	O
pivotal	O
role	O
in	O
HDL	O
particle	O
biogenesis	O
[	O
33	O
]	O
.	O
Through	O
another	O
mechanism	O
,	O
VCO	O
polyphenols	O
activate	O
the	O
lecithin	O
cholesterol	O
acyltransferase	O
enzyme	O
in	O
the	O
endogenous	O
pathway	O
.	O
As	O
a	O
result	O
,	O
the	O
bonding	O
process	O
of	O
cholesterol	O
esters	O
–	O
lipoprotein	O
cores	O
improves	O
;	O
thus	O
,	O
low	O
-	O
density	O
lipoprotein	O
(	O
VLDL	O
)	O
catabolism	O
increases	O
.	O
The	O
process	O
means	O
that	O
free	O
cholesterol	O
and	O
phospholipids	O
resulting	O
from	O
VLDL	O
breakdown	O
are	O
transferred	O
to	O
HDLs	O
;	O
thereby	O
,	O
HDL	O
formation	O
increases	O
[	O
34	O
]	O
.	O
The	O
significant	O
decrease	O
in	O
the	O
mean	O
LDL	O
level	O
after	O
VCO	O
supplementation	O
in	O
our	O
study	O
could	O
be	O
due	O
to	O
a	O
greater	O
VLDL	O
lipolysis	O
and	O
uptake	O
rate	O
through	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
(	O
PPAR	O
)	O
activation	O
.	O
PPAR	O
activation	O
increases	O
LPL	O
lipolysis	O
and	O
increases	O
the	O
liver	O
uptake	O
of	O
LDL	O
.	O
The	O
lack	O
of	O
increase	O
in	O
LDL	O
level	O
is	O
also	O
explained	O
as	O
follows	O
:	O
the	O
active	O
chain	O
elongation	O
process	O
might	O
slow	O
the	O
VLDL	O
production	O
and	O
MCFA	O
downregulates	O
the	O
apoB	O
expression	O
.	O
As	O
a	O
result	O
,	O
VLDL	O
production	O
decreased	O
[	O
35	O
]	O
.	O
Other	O
components	O
of	O
VCO	O
that	O
contribute	O
to	O
alleviating	O
dyslipidaemia	O
levels	O
are	O
polyphenols	O
.	O
In	O
a	O
systematic	B-methodology
review	I-methodology
,	O
polyphenols	O
were	O
reported	O
to	O
improve	O
LDL	O
levels	O
by	O
ameliorating	O
25	O
-	O
hydroxycholesterol	O
7	O
-	O
alpha	O
-	O
hydroxylase	O
(	O
CYP7A1	O
)	O
,	O
a	O
protein	O
-	O
coding	O
gene	O
that	O
catalyses	O
many	O
reactions	O
in	O
the	O
synthesis	O
of	O
cholesterol	O
and	O
other	O
lipids	O
.	O
Multiple	O
pathways	O
may	O
be	O
involved	O
in	O
modulating	O
these	O
activities	O
,	O
including	O
regulation	O
through	O
NF	O
-	O
Kβ	O
/	O
ERK	O
and	O
SIRT	O
-	O
RXR	O
-	O
FXR	O
(	O
LXR	O
)	O
signalling	O
pathways	O
,	O
modification	O
of	O
circadian	O
rhythm	O
-	O
associated	O
genes	O
,	O
reversing	O
cholesterol	O
transport	O
and	O
bile	O
salt	O
hydrolysis	O
.	O
Several	O
micro	O
RNAs	O
were	O
also	O
reported	O
to	O
target	O
CYP7A1	O
,	O
and	O
some	O
of	O
these	O
are	O
modulated	O
by	O
polyphenol	O
supplementation	O
[	O
36	O
]	O
.	O

In	O
relation	O
to	O
ABI	O
improvement	O
,	O
VCO	O
reduces	O
LDL	O
levels	O
by	O
dissolving	O
cholesterol	O
.	O
Thus	O
,	O
blood	O
circulation	O
becomes	O
smooth	O
,	O
maintaining	O
the	O
ABI	O
value	O
[	O
34	O
]	O
.	O
The	O
evidence	O
is	O
similar	O
to	O
our	O
finding	O
that	O
the	O
VCO	O
group	O
experienced	O
refinement	O
of	O
the	O
ABI	O
value	O
,	O
whereas	O
the	O
control	B-methodology
group	I-methodology
experienced	O
worsening	O
of	O
the	O
ABI	O
value	O
.	O
Unfortunately	O
,	O
the	O
literature	O
discussing	O
further	O
details	O
of	O
this	O
mechanism	O
is	O
still	O
limited	O
.	O
The	O
trends	O
in	O
a	O
reduction	O
in	O
the	O
levels	O
of	O
TC	O
,	O
TG	O
and	O
ABI	O
,	O
although	O
not	O
significant	O
in	O
the	O
VCO	O
group	O
,	O
are	O
sufficient	O
reasons	O
to	O
claim	O
that	O
VCO	O
exerts	O
a	O
protective	O
effect	O
on	O
DM	O
management	O
in	O
addition	O
to	O
preventing	O
cardiovascular	O
diseases	O
as	O
a	O
DM	O
complication	O
.	O
HDL	O
serves	O
as	O
a	O
‘	O
leader	O
’	O
to	O
other	O
lipids	O
because	O
HDL	O
reverses	O
cholesterol	O
transport	O
from	O
extrahepatic	O
tissues	O
to	O
the	O
liver	O
for	O
onward	O
excretion	O
in	O
bile	O
,	O
thus	O
reducing	O
plasma	O
cholesterol	O
levels	O
[	O
37	O
]	O
.	O
The	O
VCO	O
intervention	O
also	O
has	O
a	O
beneficial	O
effect	O
on	O
diets	O
,	O
i	O
.	O
e	O
.	O
,	O
energy	O
intake	O
and	O
cholesterol	O
intake	O
,	O
but	O
has	O
no	O
effect	O
on	O
carbohydrate	O
intake	O
and	O
BMI	O
.	O
A	O
study	O
revealed	O
that	O
VCO	O
have	O
suppressive	O
effects	O
on	O
hunger	O
and	O
desire	O
to	O
eat	O
in	O
normal	O
-	O
weight	O
men	O
[	O
38	O
]	O
.	O
As	O
most	O
of	O
our	O
participants	O
were	O
overweight	O
men	O
,	O
this	O
result	O
does	O
not	O
match	O
the	O
effect	O
on	O
carbohydrate	O
intake	O
.	O
However	O
,	O
another	O
study	O
reported	O
that	O
after	O
80	O
min	O
of	O
breakfast	O
consumption	O
,	O
carbohydrate	O
oxidation	O
started	O
to	O
reduce	O
,	O
and	O
an	O
increase	O
in	O
fat	O
oxidation	O
after	O
VCO	O
breakfast	O
seemed	O
to	O
occur	O
.	O
The	O
inclusion	O
of	O
carbohydrate	O
sources	O
into	O
breakfasts	O
containing	O
VCO	O
could	O
change	O
substrate	O
oxidation	O
profile	O
,	O
once	O
carbohydrates	O
are	O
preferably	O
oxidised	O
in	O
order	O
to	O
maintain	O
carbohydrate	O
balance	O
.	O
As	O
a	O
consequence	O
,	O
fat	O
oxidation	O
is	O
impaired	O
[	O
39	O
]	O
.	O
In	O
contrast	O
,	O
our	O
study	O
did	O
not	O
identify	O
carbohydrate	O
and	O
fat	O
oxidation	O
.	O
However	O
,	O
although	O
the	O
decrease	O
in	O
carbohydrate	O
intake	O
was	O
not	O
observed	O
in	O
our	O
study	O
,	O
the	O
previous	O
study	O
showing	O
that	O
fat	O
oxidation	O
was	O
impaired	O
after	O
taking	O
VCO	O
explained	O
the	O
evidence	O
of	O
the	O
decrease	O
in	O
profile	O
lipids	O
after	O
taking	O
VCO	O
in	O
our	O
study	O
.	O
The	O
difference	O
of	O
energy	O
intake	O
and	O
cholesterol	O
intake	O
daily	O
among	O
the	O
VCO	O
group	O
before	O
and	O
after	O
its	O
consumption	O
is	O
also	O
shown	O
in	O
the	O
study	O
.	O

After	O
the	O
consumption	O
of	O
VCO	O
,	O
the	O
amount	O
of	O
both	O
energy	O
intake	O
and	O
cholesterol	O
intake	O
considerably	O
declines	O
.	O
This	O
might	O
be	O
caused	O
by	O
the	O
consumption	O
of	O
VCO	O
has	O
led	O
to	O
a	O
decrease	O
in	O
the	O
appetite	O
of	O
the	O
respondents	O
.	O
Even	O
though	O
one	O
study	O
found	O
that	O
VCO	O
which	O
is	O
added	O
to	O
breakfast	O
among	O
women	O
with	O
excess	O
body	O
fat	O
suppressed	O
less	O
the	O
feeling	O
of	O
hunger	O
[	O
39	O
]	O
,	O
another	O
study	O
suggests	O
that	O
VCO	O
consumption	O
may	O
suppress	O
the	O
desire	O
to	O
eat	O
and	O
may	O
affect	O
postprandial	O
Plasma	O
Peptide	O
YY	O
among	O
people	O
with	O
normal	O
weight	O
and	O
especially	O
obese	O
male	O
respondents	O
[	O
38	O
]	O
.	O
This	O
study	O
has	O
several	O
strengths	O
.	O
First	O
,	O
regarding	O
statistics	O
,	O
our	O
participants	O
were	O
homogenous	O
in	O
almost	O
all	O
characteristics	O
including	O
BMI	O
,	O
energy	O
intake	O
,	O
carbohydrate	O
intake	O
,	O
cholesterol	O
intake	O
,	O
ABI	O
and	O
lipid	O
profiles	O
.	O
Second	O
,	O
VCO	O
was	O
provided	O
as	O
a	O
supplement	O
to	O
the	O
daily	O
food	O
intake	O
of	O
each	O
participant	O
.	O
Finally	O
,	O
the	O
participants	O
were	O
asked	O
to	O
maintain	O
their	O
usual	O
habits	O
during	O
the	O
VCO	O
and	O
control	O
periods	O
.	O
Some	O
limitations	O
should	O
also	O
be	O
acknowledged	O
.	O
This	O
study	O
was	O
only	O
conducted	O
with	O
a	O
small	O
sample	O
size	O
because	O
of	O
the	O
dropout	O
rates	O
.	O
Generalising	O
the	O
findings	O
for	O
people	O
outside	O
the	O
age	O
range	O
of	O
adults	O
,	O
particularly	O
those	O
with	O
comorbidities	O
,	O
should	O
be	O
done	O
cautiously	O
.	O
In	O
addition	O
,	O
this	O
study	O
did	O
not	O
control	O
the	O
physical	O
activities	O
of	O
the	O
participants	O
,	O
and	O
this	O
might	O
affect	O
the	O
non	O
-	O
significant	O
results	O
obtained	O
for	O
TC	O
,	O
TG	O
and	O
ABI	O
in	O
the	O
VCO	O
group	O
.	O
An	O
increase	O
in	O
HDL	O
level	O
and	O
a	O
decrease	O
in	O
LDL	O
level	O
were	O
found	O
among	O
people	O
with	O
DM	O
and	O
dyslipidaemia	O
taking	O
1	O
.	O
2	O
mL	O
/	O
kgBW	O
of	O
VCO	O
daily	O
in	O
three	O
divided	O
doses	O
for	O
30	O
days	O
and	O
no	O
harmful	O
side	O
effects	O
were	O
found	O
.	O
Future	O
studies	O
should	O
investigate	O
the	O
duration	O
and	O
dosage	O
of	O
VCO	O
in	O
patients	O
to	O
decrease	O
TG	O
and	O
total	O
TC	O
as	O
well	O
as	O
the	O
mechanism	O
of	O
how	O
the	O
VCO	O
could	O
decrease	O
the	O
lipids	O
.	O
This	O
study	O
acknowledges	O
support	O
from	O
Gerhard	O
Fortwengel	O
(	O
Lecturer	O
of	O
Hochschule	O
Hannover	O
-	O
Germany	O
)	O
in	O
providing	O
language	O
help	O
and	O
writing	O
assistance	O
,	O
and	O
Mochammad	O
Hatta	O
in	O
providing	O
laboratory	O
equipment	O
.	O
This	O
research	O
received	O
no	O
external	O
funding	O
.	O

Disclaimer	O
/	O
Publisher	O
’	O
s	O
Note	O
:	O
The	O
statements	O
,	O
opinions	O
and	O
data	O
contained	O
in	O
all	O
publications	O
are	O
solely	O
those	O
of	O
the	O
individual	O
author	O
(	O
s	O
)	O
and	O
contributor	O
(	O
s	O
)	O
and	O
not	O
of	O
MDPI	O
and	O
/	O
or	O
the	O
editor	O
(	O
s	O
)	O
.	O
MDPI	O
and	O
/	O
or	O
the	O
editor	O
(	O
s	O
)	O
disclaim	O
responsibility	O
for	O
any	O
injury	O
to	O
people	O
or	O
property	O
resulting	O
from	O
any	O
ideas	O
,	O
methods	O
,	O
instructions	O
or	O
products	O
referred	O
to	O
in	O
the	O
content	O
.	O
Conceptualization	O
,	O
A	O
.	O
S	O
.	O
;	O
methodology	O
,	O
A	O
.	O
S	O
.	O
and	O
M	O
.	O
S	O
.	O
S	O
.	O
;	O
software	O
,	O
S	O
.	O
M	O
.	O
and	O
N	O
.	O
J	O
.	O
;	O
formal	O
analysis	O
,	O
A	O
.	O
S	O
.	O
and	O
E	O
.	O
L	O
.	O
S	O
.	O
;	O
investigation	O
,	O
A	O
.	O
S	O
.	O
and	O
S	O
.	O
S	O
.	O
;	O
writing	O
—	O
original	O
draft	O
preparation	O
,	O
A	O
.	O
S	O
.	O
and	O
M	O
.	O
S	O
.	O
S	O
.	O
;	O
writing	O
—	O
review	O
and	O
editing	O
,	O
A	O
.	O
S	O
.	O
,	O
S	O
.	O
M	O
.	O
and	O
N	O
.	O
J	O
.	O
;	O
visualization	O
,	O
A	O
.	O
S	O
.	O
and	O
H	O
.	O
R	O
.	O
;	O
supervision	O
,	O
H	O
.	O
R	O
.	O
All	O
authors	O
have	O
read	O
and	O
agreed	O
to	O
the	O
published	O
version	O
of	O
the	O
manuscript	O
.	O
The	O
study	O
was	O
conducted	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
,	O
and	O
approved	O
by	O
the	O
ethics	O
committee	O
of	O
the	O
Faculty	O
of	O
Medicine	O
,	O
Hasanuddin	O
University	O
(	O
KE	O
/	O
FK	O
/	O
1213	O
/	O
EC	O
/	O
2019	O
)	O
.	O
Up	O
to	O
the	O
28	O
days	O
follow	O
-	O
up	O
,	O
written	B-methodology
informed	I-methodology
consent	I-methodology
was	O
obtained	O
from	O
the	O
participants	O
for	O
their	O
participation	O
and	O
for	O
their	O
information	O
.	O
The	O
raw	O
data	O
and	O
analyses	O
conducted	O
in	O
this	O
study	O
are	O
under	O
restrictions	O
due	O
to	O
the	O
confidentiality	O
requirements	O
by	O
ethical	O
approval	O
committee	O
but	O
can	O
be	O
available	O
upon	O
receiving	O
a	O
plausible	O
request	O
and	O
approval	O
from	O
the	O
ethical	O
committee	O
.	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O

Metabolomic	O
Characteristics	O
of	O
Liver	O
and	O
Cecum	O
Contents	O
in	O
High	O
-	O
Fat	O
-	O
Diet	O
-	O
Induced	O
Obese	O
Mice	O
Intervened	O
with	O
Lactobacillus	O
plantarum	O
FRT10	O
obesity	O
;	O
Lactobacillus	O
plantarumFRT10	O
;	O
UHPLC	O
-	O
QTOF	O
/	O
MS	O
;	O
metabolomics	O
;	O
biomarker	O
;	O
gut	O
–	O
liver	O
axis	O
Obesity	O
has	O
become	O
a	O
major	O
social	O
problem	O
related	O
to	O
health	O
and	O
quality	O
of	O
life	O
.	O
Our	O
previous	O
work	O
demonstrated	O
that	O
Lactobacillus	O
plantarum	O
FRT10	O
alleviated	O
obesity	O
in	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
-	O
fed	O
mice	O
by	O
alleviating	O
gut	O
dysbiosis	O
.	O
However	O
,	O
the	O
underlying	O
functions	O
of	O
FRT10	O
in	O
regulating	O
liver	O
and	O
cecum	O
contents	O
metabolism	O
remain	O
unknown	O
.	O
Liver	O
and	O
cecum	O
contents	O
metabonomics	O
combined	O
with	O
pathway	O
analysis	O
based	O
on	O
ultraperformance	O
liquid	O
chromatography	O
-	O
quadrupole	O
-	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
UHPLC	O
-	O
Q	O
-	O
TOF	O
/	O
MS	O
)	O
were	O
performed	O
to	O
evaluate	O
the	O
alterations	O
of	O
metabolic	O
profiles	O
between	O
obese	O
control	O
mice	O
and	O
obese	O
mice	O
in	O
FRT10	O
-	O
treated	O
groups	O
.	O
The	O
orthogonal	O
partial	O
least	O
squares	O
discriminant	O
analysis	O
(	O
OPLS	O
-	O
DA	O
)	O
score	O
plots	O
showed	O
that	O
there	O
were	O
significant	O
differences	O
in	O
cecum	O
contents	O
and	O
liver	O
markers	O
between	O
experimental	O
groups	O
.	O
In	O
total	O
,	O
26	O
potential	O
biomarkers	O
were	O
identified	O
in	O
the	O
liver	O
and	O
15	O
in	O
cecum	O
contents	O
that	O
could	O
explain	O
the	O
effect	O
of	O
FRT10	O
addition	O
in	O
HFD	O
-	O
fed	O
mice	O
.	O
In	O
addition	O
,	O
gut	O
–	O
liver	O
axis	O
analysis	O
indicated	O
that	O
there	O
was	O
a	O
strong	O
correlation	O
between	O
cecum	O
contents	O
metabolites	O
and	O
hepatic	O
metabolites	O
.	O
The	O
mechanism	O
of	O
FRT10	O
against	O
obesity	O
might	O
be	O
related	O
to	O
the	O
alterations	O
in	O
glycerophospholipid	O
metabolism	O
,	O
primary	O
bile	O
acid	O
biosynthesis	O
,	O
amino	O
metabolism	O
,	O
and	O
purine	O
and	O
pyrimidine	O
metabolism	O
.	O
Studies	O
on	O
these	O
metabolites	O
could	O
help	O
us	O
better	O
understand	O
the	O
role	O
of	O
FRT10	O
in	O
obesity	O
induced	O
by	O
HFD	O
.	O
Obesity	O
caused	O
by	O
diet	O
is	O
considered	O
a	O
serious	O
health	O
problem	O
that	O
increases	O
the	O
risk	O
of	O
many	O
chronic	O
diseases	O
such	O
as	O
cardiovascular	O
diseases	O
,	O
type	O
2	O
diabetes	O
,	O
hypertension	O
,	O
and	O
mental	O
disorders	O
[	O
1	O
]	O
.	O

Obesity	O
is	O
characterized	O
by	O
abnormal	O
or	O
excessive	O
accumulation	O
of	O
fat	O
as	O
a	O
result	O
of	O
a	O
chronic	O
imbalance	O
between	O
energy	O
intake	O
and	O
expenditure	O
[	O
2	O
]	O
.	O
Increasing	O
reports	O
indicate	O
that	O
gut	O
microbiota	O
plays	O
an	O
important	O
role	O
in	O
metabolic	O
disorders	O
associated	O
with	O
obesity	O
and	O
liver	O
diseases	O
[	O
3	O
,	O
4	O
]	O
.	O
It	O
is	O
well	O
known	O
that	O
gut	O
microbiota	O
can	O
improve	O
the	O
host	O
’	O
s	O
energy	O
production	O
from	O
food	O
digestion	O
,	O
alter	O
choline	O
metabolism	O
,	O
and	O
modulate	O
the	O
enterohepatic	O
circulation	O
of	O
bile	O
acids	O
[	O
5	O
]	O
.	O
Similarly	O
,	O
change	O
in	O
the	O
microbiota	O
structure	O
are	O
known	O
to	O
destroy	O
the	O
integrity	O
of	O
the	O
gut	O
barrier	O
,	O
allowing	O
subsequent	O
bacteria	O
metabolites	O
and	O
their	O
components	O
,	O
along	O
with	O
nutrients	O
and	O
other	O
signals	O
,	O
to	O
be	O
transported	O
to	O
the	O
liver	O
through	O
the	O
portal	O
circulation	O
and	O
change	O
gut	O
–	O
liver	O
crosstalk	O
,	O
thereby	O
inducing	O
downstream	O
inflammatory	O
pathways	O
involved	O
in	O
the	O
progression	O
of	O
obesity	O
.	O
The	O
liver	O
plays	O
a	O
key	O
role	O
in	O
defending	O
against	O
substances	O
from	O
the	O
gut	O
,	O
which	O
is	O
defined	O
as	O
the	O
gut	O
–	O
liver	O
axis	O
[	O
6	O
,	O
7	O
]	O
.	O
Recently	O
,	O
the	O
gut	O
microbiota	O
has	O
attracted	O
much	O
attention	O
as	O
a	O
therapeutic	O
approach	O
to	O
combat	O
obesity	O
.	O
The	O
complicated	O
relationship	O
between	O
gut	O
microbiota	O
and	O
obesity	O
opens	O
up	O
an	O
attractive	O
window	O
for	O
finding	O
successful	O
and	O
safe	O
treatments	O
for	O
obesity	O
.	O
Lactobacillus	O
is	O
a	O
significant	O
part	O
of	O
the	O
gut	O
microbiota	O
,	O
which	O
can	O
produce	O
metabolites	O
to	O
inhibit	O
other	O
microorganisms	O
’	O
growth	O
in	O
the	O
intestinal	O
mucosa	O
,	O
strengthen	O
the	O
integrity	O
of	O
the	O
gut	O
barrier	O
,	O
and	O
regulate	O
mucosal	O
homeostasis	O
[	O
8	O
,	O
9	O
]	O
.	O
In	O
addition	O
,	O
Lactobacillus	O
co	O
-	O
exists	O
with	O
intestinal	O
stem	O
cells	O
to	O
regulate	O
epithelium	O
cell	O
regeneration	O
[	O
8	O
,	O
10	O
]	O
,	O
which	O
is	O
essential	O
for	O
maintaining	O
the	O
gut	O
barrier	O
and	O
gut	O
homeostasis	O
.	O
Lactobacillus	O
plantarum	O
is	O
a	O
kind	O
of	O
multifunctional	O
lactic	O
acid	O
bacterium	O
,	O
which	O
carries	O
out	O
many	O
biological	O
activities	O
,	O
including	O
alleviating	O
symptoms	O
of	O
irritable	O
bowel	O
syndrome	O
[	O
11	O
]	O
,	O
reducing	O
total	O
cholesterol	O
[	O
12	O
]	O
,	O
and	O
improving	O
immune	O
function	O
[	O
13	O
]	O
.	O
The	O
treatment	O
of	O
obesity	O
with	O
L	O
.	O
plantarum	O
has	O
been	O
proved	O
to	O
be	O
an	O
efficacious	O
agent	O
for	O
preventing	O
the	O
worsening	O
of	O
obesity	O
[	O
14	O
,	O
15	O
,	O
16	O
]	O
.	O

Although	O
the	O
beneficial	O
effects	O
of	O
L	O
.	O
plantarum	O
have	O
been	O
well	O
documented	O
,	O
the	O
detailed	O
mechanisms	O
by	O
which	O
L	O
.	O
plantarum	O
combat	O
obesity	O
are	O
not	O
fully	O
understood	O
to	O
date	O
.	O
Metabolomics	O
is	O
a	O
comprehensive	O
quantitative	O
and	O
qualitative	O
analysis	O
of	O
metabolite	O
alterations	O
in	O
cells	O
,	O
tissues	O
,	O
or	O
biological	O
fluids	O
to	O
discover	O
potential	O
biomarkers	O
.	O
The	O
approach	O
serves	O
as	O
the	O
endpoint	O
of	O
the	O
‘	O
-	O
omics	O
’	O
cascade	O
after	O
genomics	O
,	O
transcriptomics	O
,	O
and	O
proteomics	O
and	O
plays	O
an	O
increasingly	O
important	O
role	O
in	O
the	O
high	O
-	O
throughput	O
studies	O
of	O
global	O
metabolites	O
that	O
could	O
be	O
used	O
to	O
diagnose	O
and	O
monitor	O
disease	O
progression	O
[	O
17	O
,	O
18	O
]	O
.	O
Previous	O
studies	O
of	O
obesity	O
have	O
intervened	O
with	O
Lactobacillus	O
species	O
and	O
identified	O
a	O
number	O
of	O
biomarkers	O
[	O
14	O
,	O
19	O
,	O
20	O
]	O
,	O
but	O
none	O
have	O
monitored	O
L	O
.	O
plantarum	O
supplementation	O
to	O
produce	O
as	O
many	O
metabolic	O
alterations	O
in	O
a	O
model	O
of	O
obesity	O
.	O
Therefore	O
,	O
understanding	O
the	O
role	O
of	O
L	O
.	O
plantarum	O
in	O
obesity	O
metabolism	O
from	O
a	O
few	O
metabolites	O
is	O
limited	O
.	O
In	O
our	O
previous	O
study	O
,	O
FRT10	O
intervention	O
significantly	O
reduced	O
body	O
weight	O
gain	O
,	O
liver	O
weight	O
,	O
serum	O
TG	O
,	O
hepatic	O
TG	O
,	O
and	O
ALT	O
in	O
high	O
-	O
fat	O
-	O
diet	O
-	O
induced	O
obese	O
mice	O
[	O
11	O
]	O
.	O
FRT10	O
intervention	O
alleviated	O
obesity	O
by	O
modulating	O
the	O
PPARα	O
signal	O
pathway	O
and	O
reshaping	O
gut	O
microbiota	O
composition	O
[	O
11	O
]	O
.	O
In	O
addition	O
,	O
we	O
found	O
that	O
a	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
induced	O
significant	O
metabolomic	O
changes	O
in	O
liver	O
tissue	O
and	O
cecum	O
contents	O
in	O
obese	O
mice	O
[	O
21	O
]	O
.	O
In	O
the	O
present	O
study	O
,	O
a	O
comprehensive	O
analysis	O
was	O
conducted	O
to	O
investigate	O
the	O
possible	O
characteristic	O
metabolites	O
altered	O
by	O
FRT10	O
through	O
cecum	O
contents	O
and	O
liver	O
metabolomics	O
in	O
obese	O
mice	O
.	O
We	O
aimed	O
to	O
better	O
understand	O
the	O
complex	O
correlation	O
between	O
the	O
gut	O
and	O
liver	O
and	O
how	O
it	O
modulates	O
systemic	O
metabolic	O
alterations	O
in	O
HFD	O
-	O
induced	O
obesity	O
.	O
Results	O
from	O
the	O
research	O
will	O
provide	O
a	O
scientific	O
basis	O
for	O
L	O
.	O
plantarum	O
FRT10	O
application	O
in	O
the	O
treatment	O
of	O
obesity	O
.	O
L	O
.	O
plantarum	O
FRT10	O
was	O
isolated	O
and	O
identified	O
from	O
Poland	O
sour	O
dough	O
and	O
deposited	O
in	O
the	O
Chinese	O
General	O
Microorganism	O
Collection	O
Center	O
(	O
accession	O
17956	O
;	O
CGMCC	O
,	O
Beijing	O
,	O
China	O
)	O
.	O

The	O
strain	O
was	O
grown	O
in	O
MRS	O
broth	O
at	O
37	O
°C	O
for	O
24	O
h	O
,	O
centrifuged	O
at	O
4	O
°C	O
,	O
5000×	O
g	O
,	O
10	O
min	O
,	O
and	O
the	O
cells	O
were	O
collected	O
and	O
washed	O
with	O
0	O
.	O
9	O
%	O
saline	O
buffer	O
three	O
times	O
.	O
Then	O
,	O
the	O
strain	O
was	O
adjusted	O
to	O
1	O
×	O
109	O
and	O
1	O
×	O
1010	O
CFU	O
/	O
mL	O
in	O
saline	O
buffer	O
for	O
gavage	B-methodology
,	O
respectively	O
.	O
Twenty	O
-	O
seven	O
7	O
-	O
week	O
-	O
old	O
,	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
female	O
Kunming	O
mice	O
were	O
obtained	O
from	O
Vital	O
River	O
Laboratory	O
Animal	O
Technology	O
Co	O
.	O
,	O
Ltd	O
.	O
(	O
Beijing	O
,	O
China	O
)	O
.	O
After	O
one	O
week	O
of	O
adjustment	O
,	O
as	O
previously	O
reported	O
[	O
22	O
]	O
,	O
the	O
mice	O
were	O
fed	O
with	O
HFD	O
consisting	O
of	O
67	O
%	O
(	O
w	O
/	O
w	O
)	O
normal	O
diet	O
,	O
20	O
%	O
sucrose	O
,	O
10	O
%	O
lard	O
,	O
2	O
.	O
5	O
%	O
cholesterol	O
,	O
and	O
0	O
.	O
5	O
%	O
sodium	O
cholate	O
with	O
minor	O
modifications	O
.	O
After	O
8	O
weeks	O
of	O
dietary	B-methodology
intervention	I-methodology
,	O
HFD	O
mice	O
were	O
randomly	B-methodology
divided	I-methodology
into	O
3	O
subgroups	O
(	O
n	O
=	O
9	O
in	O
each	O
group	O
)	O
according	O
to	O
their	O
body	O
weight	O
with	O
no	O
significant	O
difference	O
and	O
continued	O
to	O
be	O
fed	O
HFD	O
:	O
(	O
1	O
)	O
HF	O
group	O
:	O
high	O
-	O
fat	O
diet	O
group	O
,	O
with	O
gavage	B-methodology
daily	O
0	O
.	O
9	O
%	O
saline	O
as	O
the	O
obese	O
control	O
;	O
(	O
2	O
)	O
HF10L	O
group	O
:	O
HFD	O
plus	O
daily	O
administration	O
of	O
0	O
.	O
2	O
mL	O
of	O
1	O
×	O
109	O
CFU	O
/	O
mL	O
L	O
.	O
plantarum	O
FRT10	O
;	O
and	O
(	O
3	O
)	O
HF10H	O
group	O
:	O
HFD	O
plus	O
daily	O
administration	O
of	O
0	O
.	O
2	O
mL	O
of	O
1	O
×	O
1010	O
CFU	O
/	O
mL	O
L	O
.	O
plantarum	O
FRT10	O
.	O
The	O
gavage	B-methodology
experiment	O
lasted	O
for	O
8	O
weeks	O
.	O
The	O
animal	B-methodology
study	I-methodology
was	O
reviewed	O
and	O
approved	O
by	O
the	O
Laboratory	O
Animal	O
Ethical	O
Committee	O
and	O
its	O
inspection	O
by	O
the	O
Feed	O
Research	O
Institute	O
,	O
Chinese	O
Academy	O
of	O
Agricultural	O
Sciences	O
(	O
Approval	O
No	O
.	O
AEC	O
-	O
CAAS	O
-	O
20090609	O
)	O
.	O
On	O
the	O
last	O
day	O
of	O
the	O
experiment	O
,	O
mice	O
were	O
sacrificed	O
after	O
6	O
h	O
of	O
fasting	O
.	O
Wash	O
liver	O
tissues	O
with	O
ice	O
-	O
cold	O
buffered	O
saline	O
.	O
Then	O
,	O
the	O
liver	O
tissues	O
and	O
cecum	O
contents	O
were	O
collected	O
,	O
weighted	O
,	O
frozen	O
in	O
liquid	O
nitrogen	O
,	O
and	O
stored	O
at	O
−80	O
°C	O
for	O
further	O
analysis	O
.	O

The	O
frozen	O
liver	O
tissues	O
(	O
60	O
mg	O
)	O
were	O
thawed	O
at	O
4	O
°C	O
;	O
800	O
μL	O
of	O
precooled	O
methanol	O
/	O
acetonitrile	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
was	O
added	O
to	O
extract	O
metabolites	O
and	O
then	O
homogenized	O
.	O
Ultrasonic	O
crushing	O
was	O
performed	O
2	O
times	O
on	O
ice	O
for	O
30	O
min	O
and	O
placed	O
at	O
−20	O
°C	O
for	O
1	O
h	O
,	O
and	O
then	O
centrifuged	O
at	O
4	O
°C	O
,	O
14	O
,	O
000×	O
g	O
for	O
20	O
min	O
.	O
The	O
supernatant	O
was	O
freeze	O
-	O
dried	O
and	O
kept	O
at	O
−80	O
°C	O
until	O
further	O
research	O
.	O
Untargeted	O
metabolic	O
profiling	O
analysis	O
was	O
performed	O
using	O
ultraperformance	O
liquid	O
chromatography	O
quadrupole	O
time	O
-	O
of	O
-	O
flight	O
tandem	O
mass	O
spectrometry	O
(	O
UHPLC	O
-	O
Q	O
-	O
TOF	O
/	O
MS	O
)	O
.	O
Agilent	O
1290	O
Infinity	O
LC	O
ultra	O
-	O
high	O
pressure	O
lipid	O
chromatography	O
(	O
UHPLC	O
)	O
system	O
(	O
Agilent	O
,	O
Santa	O
-	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
and	O
AB	O
SCIEX	O
Triple	O
TOF	O
6600	O
System	O
(	O
AB	O
SCIEX	O
,	O
Framingham	O
,	O
MA	O
,	O
USA	O
)	O
were	O
used	O
for	O
LC	O
-	O
MS	O
analysis	O
.	O
LC	O
conditions	O
were	O
set	O
as	O
follows	O
:	O
ACQUITY	O
UPLC	O
HSS	O
T3	O
column	O
(	O
2	O
.	O
1	O
×	O
100	O
nm	O
,	O
1	O
.	O
8	O
μm	O
,	O
Waters	O
MS	O
Technologies	O
,	O
Manchester	O
,	O
UK	O
)	O
.	O
The	O
column	O
was	O
maintained	O
at	O
25	O
°C	O
,	O
and	O
separation	O
was	O
achieved	O
using	O
the	O
following	O
gradient	O
:	O
95	O
%	O
B	O
over	O
0	O
–	O
1	O
.	O
0	O
min	O
,	O
95	O
–	O
65	O
%	O
B	O
over	O
1	O
.	O
0	O
–	O
14	O
.	O
0	O
min	O
,	O
65	O
–	O
40	O
%	O
B	O
over	O
14	O
.	O
0	O
–	O
16	O
.	O
0	O
min	O
,	O
40	O
%	O
B	O
over	O
16	O
.	O
0	O
–	O
18	O
.	O
0	O
min	O
,	O
40	O
–	O
95	O
%	O
B	O
over	O
19	O
.	O
0	O
–	O
18	O
.	O
1	O
min	O
,	O
95	O
%	O
B	O
over	O
18	O
.	O
1	O
–	O
23	O
.	O
0	O
min	O
.	O
The	O
flow	O
rate	O
was	O
300	O
μL	O
/	O
min	O
.	O
A	O
(	O
0	O
.	O
25	O
mM	O
ammonium	O
acetate	O
and	O
25	O
mM	O
ammonium	O
hydroxide	O
in	O
water	O
)	O
and	O
B	O
(	O
acetonitrile	O
)	O
were	O
used	O
as	O
mobile	O
phase	O
.	O
The	O
automatic	O
sampler	O
was	O
maintained	O
at	O
4	O
°C	O
throughout	O
the	O
analysis	O
.	O

The	O
mass	O
spectrometric	O
data	O
were	O
collected	O
using	O
a	O
Triple	O
TOFTM	O
5600	O
system	O
(	O
AB	O
/	O
Sciex	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
equipped	O
with	O
an	O
electrospray	O
ionization	O
(	O
ESI	O
)	O
source	O
operating	O
in	O
either	O
the	O
positive	O
(	O
ESI	O
+	O
)	O
and	O
negative	O
(	O
ESI−	O
)	O
ion	O
mode	O
.	O
The	O
ESI	O
conditions	O
after	O
separation	O
by	O
UHPLC	O
chromatographic	O
were	O
as	O
follows	O
:	O
60	O
psi	O
for	O
ion	O
source	O
gas	O
1	O
(	O
Gas	O
1	O
)	O
,	O
60	O
psi	O
for	O
ion	O
source	O
gas	O
2	O
(	O
Gas	O
2	O
)	O
,	O
30	O
psi	O
for	O
curtain	O
gas	O
(	O
Cur	O
)	O
,	O
600	O
°C	O
for	O
source	O
temperature	O
,	O
and	O
±5500	O
V	O
for	O
ion	O
sapary	O
voltage	O
floating	O
(	O
ISVF	O
)	O
.	O
TOF	O
/	O
MS	O
scan	O
m	O
/	O
z	O
range	O
is	O
from	O
60	O
Da	O
to	O
1000	O
Da	O
,	O
product	O
ion	O
scan	O
m	O
/	O
z	O
range	O
is	O
from	O
25	O
Da	O
to	O
1000	O
Da	O
.	O
TOF	O
MS	O
scan	O
accumulation	O
time	O
is	O
0	O
.	O
20	O
s	O
/	O
spectra	O
,	O
product	O
ion	O
scan	O
accumulation	O
time	O
is	O
0	O
.	O
05	O
s	O
/	O
spectra	O
.	O
Information	O
-	O
dependent	O
acquisition	O
(	O
IDA	O
)	O
with	O
the	O
high	O
-	O
sensitivity	O
modes	O
was	O
used	O
for	O
MS	O
/	O
MS	O
data	O
recording	O
.	O
The	O
IDA	O
parameters	O
were	O
as	O
follows	O
:	O
exclude	O
isotopes	O
within	O
4	O
Da	O
,	O
the	O
number	O
of	O
candidate	O
ions	O
monitored	O
per	O
cycle	O
:	O
6	O
.	O
Monitoring	O
of	O
the	O
system	O
stability	O
and	O
data	O
quality	O
was	O
performed	O
by	O
quality	B-methodology
control	I-methodology
(	O
QC	O
)	O
samples	O
.	O
Cecal	O
contents	O
were	O
freeze	O
-	O
dried	O
and	O
then	O
crushed	O
.	O
Then	O
,	O
1000	O
μL	O
of	O
the	O
extract	O
solution	O
(	O
acetonitrile	O
–	O
methanol	O
–	O
water	O
=	O
2	O
:	O
2	O
:	O
1	O
)	O
and	O
1	O
g	O
/	O
mL	O
internal	O
standard	O
was	O
placed	O
in	O
50	O
mg	O
cecal	O
contents	O
in	O
an	O
EP	O
tube	O
.	O
Homogenate	O
and	O
ultrasonic	O
extraction	O
were	O
performed	O
after	O
vortex	O
-	O
mixing	O
for	O
30	O
s	O
and	O
centrifuged	O
at	O
4	O
°C	O
,	O
12	O
,	O
000×	O
g	O
for	O
15	O
min	O
.	O
The	O
0	O
.	O
22	O
μm	O
nylon	O
filter	O
was	O
used	O
to	O
filter	O
the	O
supernatant	O
,	O
and	O
2	O
μL	O
was	O
injected	O
for	O
analysis	O
.	O
The	O
QC	O
samples	O
were	O
prepared	O
by	O
mixing	O
the	O
supernatants	O
of	O
all	O
samples	O
in	O
equal	O
quantities	O
.	O

The	O
UHPLC	O
system	O
(	O
1290	O
,	O
Agilent	O
Technologies	O
)	O
combined	O
with	O
a	O
UPLC	O
HSS	O
T3	O
column	O
(	O
2	O
.	O
1	O
mm	O
×	O
100	O
mm	O
,	O
1	O
.	O
8	O
μm	O
)	O
and	O
Q	O
Exactive	O
mass	O
spectrometer	O
(	O
Thermo	O
Fisher	O
,	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
was	O
used	O
for	O
chromatographic	O
separation	O
.	O
The	O
flow	O
rate	O
was	O
500	O
μL	O
/	O
min	O
,	O
using	O
a	O
mobile	O
phase	O
of	O
solvent	O
A	O
(	O
0	O
.	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
formic	O
acid	O
)	O
for	O
ESI	O
+	O
mode	O
,	O
5	O
mmol	O
/	O
L	O
ammonium	O
acetate	O
for	O
ESI−	O
mode	O
,	O
and	O
acetonitrile	O
was	O
used	O
for	O
the	O
mobile	O
phase	O
B	O
.	O
The	O
elution	O
gradient	O
was	O
set	O
as	O
follows	O
:	O
1	O
%	O
B	O
over	O
0	O
–	O
1	O
.	O
0	O
min	O
,	O
1	O
–	O
99	O
%	O
B	O
over	O
1	O
.	O
0	O
–	O
8	O
.	O
0	O
min	O
,	O
99	O
%	O
B	O
over	O
8	O
.	O
0	O
–	O
10	O
.	O
0	O
min	O
,	O
99	O
~	O
1	O
%	O
B	O
over	O
10	O
.	O
0	O
–	O
10	O
.	O
1	O
min	O
,	O
1	O
%	O
B	O
over	O
10	O
.	O
1	O
–	O
12	O
min	O
.	O
The	O
MS	O
data	O
were	O
collected	O
from	O
m	O
/	O
z	O
50	O
–	O
1200	O
Da	O
with	O
ESI	O
source	O
,	O
including	O
ESI	O
+	O
and	O
ESI−	O
modes	O
.	O
Xcalibur	O
4	O
.	O
0	O
.	O
27	O
software	O
(	O
Thermo	O
Fisher	O
,	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
based	O
on	O
the	O
IDA	O
function	O
was	O
used	O
for	O
MS	O
spectra	O
acquisition	O
.	O
The	O
ionization	O
source	O
conditions	O
were	O
as	O
follows	O
:	O
45	O
Arb	O
for	O
sheath	O
gas	O
flow	O
rate	O
,	O
15Arb	O
for	O
Aux	O
gas	O
flow	O
rate	O
,	O
400	O
°C	O
for	O
capillary	O
temperature	O
,	O
70	O
,	O
000	O
for	O
full	O
MS	O
resolution	O
,	O
17	O
,	O
500	O
for	O
MS	O
/	O
MS	O
resolution	O
,	O
20	O
/	O
40	O
/	O
60	O
in	O
NCE	O
mode	O
for	O
collision	O
energy	O
,	O
positive	O
mode	O
4000	O
V	O
or	O
negative	O
mode	O
−3600	O
V	O
for	O
spray	O
Voltage	O
.	O
Baseline	O
information	O
analyses	O
were	O
performed	O
as	O
described	O
in	O
our	O
previous	O
report	O
[	O
21	O
]	O
.	O
The	O
original	O
data	O
of	O
UHPLC	O
-	O
Q	O
-	O
TOF	O
/	O
MS	O
were	O
converted	O
to	O
the	O
mzXML	O
format	O
via	O
ProteoWizard	O
before	O
importing	O
the	O
data	O
into	O
the	O
XCMS	O
program	O
for	O
peak	O
detection	O
,	O
extraction	O
,	O
alignment	O
,	O
and	O
integration	O
.	O

The	O
metabolites	O
were	O
then	O
annotated	O
using	O
an	O
in	O
-	O
house	O
MS2	O
database	O
(	O
BiotreeDB	O
)	O
.	O
To	O
identify	O
global	O
differences	O
in	O
metabolic	O
profiles	O
between	O
groups	O
,	O
supervised	O
orthogonal	O
partial	O
least	O
squares	O
discriminant	O
analysis	O
(	O
OPLS	O
-	O
DA	O
)	O
was	O
employed	O
.	O
The	O
robustness	O
of	O
the	O
OPLS	O
-	O
DA	O
model	O
was	O
evaluated	O
by	O
7	O
-	O
fold	O
cross	O
-	O
validation	O
and	O
response	O
200	O
permutation	O
test	O
.	O
By	O
multidimensional	O
analyses	O
of	O
OPLS	O
-	O
DA	O
and	O
Student	O
t	O
-	O
test	O
,	O
the	O
identified	O
metabolites	O
were	O
selected	O
as	O
differentiated	O
metabolites	O
,	O
which	O
all	O
met	O
the	O
variable	O
importance	O
for	O
the	O
projection	O
(	O
VIP	O
)	O
>	O
1	O
and	O
p	O
value	O
<	O
0	O
.	O
05	O
.	O
Then	O
,	O
metabolites	O
with	O
significant	O
differences	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
were	O
analyzed	O
in	O
the	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
(	O
KEGG	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
kegg	O
.	O
jp	O
(	O
accessed	O
on	O
29	O
October	O
2019	O
)	O
)	O
databases	O
.	O
In	O
addition	O
,	O
the	O
metabolic	O
pathways	O
of	O
important	O
identified	O
metabolites	O
were	O
queried	O
against	O
the	O
online	O
KEGG	O
database	O
.	O
Only	O
functional	O
categories	O
and	O
pathways	O
with	O
p	O
<	O
0	O
.	O
05	O
were	O
considered	O
significantly	O
enriched	O
.	O
After	O
8	B-methodology
weeks	I-methodology
of	I-methodology
intervention	I-methodology
,	O
UHPLC	O
-	O
Q	O
-	O
TOF	O
/	O
MS	O
was	O
used	O
to	O
analyze	O
the	O
liver	O
samples	O
from	O
the	O
obese	O
control	B-methodology
group	I-methodology
and	O
FRT10	O
treatment	O
group	O
.	O
The	O
metabolite	O
profiles	O
of	O
the	O
liver	O
were	O
altered	O
in	O
the	O
HF	O
group	O
compared	O
to	O
the	O
normal	O
-	O
chow	O
group	O
in	O
our	O
previous	O
study	O
[	O
21	O
]	O
,	O
while	O
the	O
metabolites	O
after	O
FRT10	O
intervention	O
were	O
distinct	O
from	O
the	O
HF	O
group	O
as	O
observed	O
by	O
OPLA	O
-	O
DA	O
score	O
plots	O
for	O
the	O
positive	O
mode	O
(	O
Figure	O
1	O
)	O
.	O
The	O
parameters	O
of	O
OPLS	O
-	O
DA	O
model	O
showed	O
that	O
the	O
model	O
has	O
an	O
excellent	O
modeling	O
and	O
predictive	O
ability	O
,	O
with	O
R2X	O
=	O
0	O
.	O
797	O
,	O
R2Y	O
=	O
0	O
.	O
994	O
,	O
and	O
Q2	O
=	O
0	O
.	O
507	O
for	O
HF10L	O
vs	O
.	O
HF	O
,	O
and	O
R2X	O
=	O
0	O
.	O
776	O
,	O
R2Y	O
=	O
0	O
.	O
994	O
,	O
and	O
Q2	O
=	O
0	O
.	O
542	O
for	O
HF10H	O
vs	O
.	O
HF	O
.	O
The	O
results	O
showed	O
that	O
the	O
model	O
has	O
no	O
evidence	O
of	O
over	O
-	O
fitting	O
and	O
has	O
high	O
general	O
applicability	O
.	O

To	O
determine	O
the	O
discriminating	O
effect	O
of	O
variables	O
between	O
the	O
two	O
comparison	O
groups	O
,	O
variables	O
with	O
VIP	O
>	O
1	O
and	O
p	O
<	O
0	O
.	O
05	O
was	O
further	O
analyzed	O
by	O
Student	O
’	O
s	O
t	O
-	O
test	O
of	O
OPLS	O
-	O
DA	O
modeling	O
.	O
In	O
total	O
,	O
26	O
metabolites	O
were	O
preliminarily	O
identified	O
as	O
potential	O
biomarkers	O
for	O
the	O
anti	O
-	O
obesity	O
effect	O
of	O
FRT10	O
analyzed	O
in	O
ESI	O
+	O
and	O
ESI−	O
mode	O
(	O
Table	O
1	O
)	O
.	O
The	O
potential	O
biomarkers	O
related	O
to	O
glycerophospholipid	O
metabolism	O
included	O
:	O
choline	O
,	O
glycerophosphocholine	O
,	O
CDP	O
-	O
choline	O
,	O
phosphorylcholine	O
,	O
and	O
sn	O
-	O
glycerol	O
3	O
-	O
phosphoethanolamine	O
.	O
Compared	O
to	O
the	O
HF	O
group	O
,	O
FRT10	O
administration	O
led	O
to	O
a	O
significant	O
decrease	O
in	O
choline	O
and	O
phosphocholine	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
marked	O
decrease	O
in	O
glycerophosphocholine	O
.	O
Taurocholate	O
and	O
cholic	O
acid	O
involved	O
in	O
primary	O
bile	O
acid	O
biosynthesis	O
in	O
HF10L	O
and	O
HF10H	O
groups	O
were	O
reduced	O
0	O
.	O
30	O
and	O
0	O
.	O
45	O
-	O
fold	O
,	O
respectively	O
.	O
After	O
FRT10	O
intervention	O
,	O
eight	O
amino	O
acids	O
related	O
to	O
amino	O
acid	O
metabolism	O
,	O
such	O
as	O
l	O
-	O
phenylalanine	O
,	O
tyramine	O
,	O
l	O
-	O
threonine	O
,	O
d	O
-	O
ornithine	O
,	O
l	O
-	O
asparagine	O
,	O
d	O
-	O
proline	O
,	O
and	O
l	O
-	O
pyrogutamic	O
acid	O
,	O
were	O
significantly	O
enhanced	O
,	O
while	O
L	O
-	O
histidine	O
was	O
markedly	O
increased	O
.	O
Additionally	O
,	O
10	O
potential	O
biomarkers	O
linked	O
to	O
pyrimidine	O
and	O
purine	O
metabolism	O
,	O
including	O
thymidine	O
,	O
uracil	O
,	O
allantoin	O
,	O
inosine	O
,	O
xanthine	O
,	O
xanthosine	O
,	O
and	O
deoxyinosine	O
were	O
significantly	O
increased	O
1	O
.	O
23	O
to	O
4	O
.	O
90	O
-	O
fold	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
while	O
uridine	O
was	O
significantly	O
decreased	O
0	O
.	O
55	O
-	O
fold	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
HF10L	O
group	O
as	O
compared	O
to	O
the	O
HF	O
group	O
.	O
Moreover	O
,	O
FRT10	O
intervention	O
markedly	O
increased	O
thymine	O
and	O
markedly	O
decreased	O
hypoxanthine	O
in	O
HFD	O
-	O
fed	O
obese	O
mice	O
.	O
Through	O
the	O
gut	O
–	O
liver	O
axis	O
,	O
intestinal	O
microbial	O
metabolites	O
reach	O
the	O
liver	O
and	O
affect	O
liver	O
metabolism	O
.	O

The	O
profiles	O
of	O
metabolites	O
identified	O
in	O
the	O
cecal	O
contents	O
were	O
altered	O
in	O
HF	O
group	O
compared	O
to	O
the	O
normal	O
-	O
chow	O
group	O
in	O
our	O
previous	O
study	O
[	O
21	O
]	O
,	O
while	O
the	O
metabolites	O
after	O
FRT10	O
intervention	O
were	O
distinct	O
from	O
the	O
HF	O
group	O
as	O
observed	O
by	O
OPLA	O
-	O
DA	O
score	O
plots	O
for	O
both	O
the	O
positive	O
and	O
negative	O
-	O
ion	O
modes	O
(	O
Figure	O
2	O
)	O
.	O
The	O
parameters	O
of	O
OPLS	O
-	O
DA	O
model	O
were	O
as	O
follows	O
:	O
R2X	O
=	O
0	O
.	O
246	O
,	O
R2Y	O
=	O
0	O
.	O
983	O
,	O
and	O
Q2	O
=	O
0	O
.	O
684	O
in	O
ESI	O
+	O
mode	O
,	O
R2X	O
=	O
0	O
.	O
248	O
,	O
R2Y	O
=	O
0	O
.	O
984	O
,	O
and	O
Q2	O
=	O
0	O
.	O
638	O
in	O
ESI−	O
mode	O
,	O
which	O
indicated	O
the	O
goodness	O
of	O
fit	O
of	O
the	O
data	O
.	O
The	O
candidate	O
metabolites	O
were	O
selected	O
as	O
potential	O
biomarkers	O
according	O
to	O
VIP	O
>	O
1	O
and	O
p	O
<	O
0	O
.	O
05	O
of	O
OPLA	O
-	O
DA	O
models	O
.	O
According	O
to	O
the	O
above	O
criteria	O
,	O
a	O
total	O
of	O
15	O
endogenous	O
metabolites	O
were	O
screened	O
from	O
cecum	O
contents	O
closely	O
involved	O
in	O
the	O
effect	O
of	O
FRT10	O
feeding	O
on	O
HFD	O
-	O
fed	O
mice	O
by	O
UHPLC	O
-	O
Q	O
-	O
TOF	O
/	O
MS	O
(	O
Table	O
2	O
)	O
.	O
Six	O
metabolites	O
were	O
increased	O
,	O
and	O
nine	O
decreased	O
in	O
FRT10	O
-	O
treated	O
mice	O
compared	O
with	O
HFD	O
-	O
fed	O
mice	O
.	O
The	O
levels	O
of	O
PC	O
(	O
O	O
-	O
16	O
:	O
0	O
/	O
2	O
:	O
0	O
)	O
and	O
PC	O
(	O
0	O
:	O
0	O
/	O
20	O
:	O
4	O
(	O
5Z	O
,	O
8Z	O
,	O
11Z	O
,	O
14Z	O
)	O
)	O
were	O
significantly	O
decreased	O
0	O
.	O
65	O
and	O
0	O
.	O
02	O
-	O
fold	O
,	O
while	O
PC	O
(	O
O	O
-	O
8	O
:	O
0	O
/	O
O	O
-	O
8	O
:	O
0	O
)	O
and	O
PC	O
(	O
O	O
-	O
14	O
:	O
1	O
(	O
1E	O
)	O
/	O
0	O
:	O
0	O
)	O
were	O
significantly	O
enhanced	O
1	O
.	O
94	O
and	O
1	O
.	O
64	O
-	O
fold	O
.	O

The	O
levels	O
of	O
LysoPC	O
(	O
18	O
:	O
1	O
(	O
9Z	O
)	O
)	O
,	O
LysoPC	O
(	O
20	O
:	O
3	O
(	O
5Z	O
,	O
8Z	O
,	O
11Z	O
)	O
)	O
,	O
LysoPE	O
(	O
0	O
:	O
0	O
/	O
20	O
:	O
0	O
)	O
,	O
PS	O
(	O
18	O
:	O
2	O
(	O
9Z	O
,	O
12Z	O
)	O
)	O
/	O
22	O
:	O
6	O
(	O
4Z	O
,	O
7Z	O
,	O
10Z	O
,	O
13Z	O
,	O
16Z	O
,	O
19Z	O
)	O
,	O
and	O
1	O
-	O
Palmitoyl	O
-	O
2	O
-	O
linoleoyl	O
PE	O
were	O
significantly	O
reduced	O
,	O
while	O
LysoPE	O
(	O
0	O
:	O
0	O
/	O
20	O
:	O
4	O
(	O
5Z	O
,	O
8Z	O
,	O
11Z	O
,	O
14Z	O
)	O
)	O
and	O
PA	O
(	O
18	O
:	O
0	O
/	O
18	O
:	O
1	O
(	O
9Z	O
)	O
)	O
were	O
significantly	O
increased	O
.	O
Additionally	O
,	O
2	O
-	O
amino	O
-	O
3	O
-	O
(	O
3	O
,	O
4	O
-	O
dihydroxyphenyl	O
)	O
propanoic	O
acid	O
and	O
taurocholic	O
acid	O
were	O
reduced	O
,	O
while	O
cholacalcioic	O
acid	O
and	O
xanthine	O
were	O
significantly	O
enhanced	O
.	O
Glycerophospholipid	O
metabolism	O
,	O
primary	O
bile	O
acid	O
biosynthesis	O
,	O
and	O
purine	O
metabolism	O
were	O
the	O
metabolic	O
pathways	O
in	O
which	O
these	O
metabolites	O
were	O
mainly	O
involved	O
.	O
The	O
gut	O
microbiota	O
produces	O
a	O
variety	O
of	O
compounds	O
that	O
play	O
an	O
important	O
role	O
in	O
modulating	O
distal	O
organ	O
activity	O
,	O
and	O
the	O
liver	O
is	O
located	O
downstream	O
of	O
the	O
intestine	O
,	O
indicating	O
the	O
significance	O
of	O
the	O
gut	O
–	O
liver	O
axis	O
[	O
23	O
]	O
.	O
As	O
a	O
promising	O
anti	O
-	O
obesity	O
candidate	O
,	O
microbiota	O
regulation	O
and	O
its	O
anti	O
-	O
obesity	O
effects	O
on	O
L	O
.	O
plantarum	O
have	O
been	O
elucidated	O
by	O
different	O
researchers	O
[	O
16	O
,	O
24	O
,	O
25	O
]	O
.	O
In	O
our	O
previous	O
study	O
,	O
L	O
.	O
plantarum	O
FRT10	O
intervention	O
reduced	O
the	O
extent	O
and	O
features	O
of	O
obesity	O
in	O
HFD	O
-	O
induced	O
obese	O
mice	O
by	O
modulating	O
the	O
structure	O
of	O
gut	O
microbiota	O
[	O
11	O
]	O
.	O
Meanwhile	O
,	O
metabonomics	O
studies	O
of	O
liver	O
and	O
cecum	O
contents	O
showed	O
that	O
after	O
8	O
weeks	O
of	O
continuous	O
administration	O
of	O
HFD	O
,	O
the	O
obese	O
model	O
of	O
mice	O
was	O
successfully	O
established	O
and	O
developed	O
a	O
metabolic	O
disorder	O
[	O
21	O
]	O
.	O
In	O
this	O
study	O
,	O
UHPLC	O
-	O
Q	O
-	O
TOF	O
MS	O
was	O
used	O
to	O
detect	O
liver	O
,	O
and	O
cecum	O
contents	O
metabolites	O
of	O
HFD	O
-	O
induced	O
obese	O
mice	O
interfered	O
with	O
FRT10	O
,	O
and	O
multivariate	O
statistical	O
analysis	O
comparisons	O
were	O
made	O
.	O

We	O
found	O
that	O
the	O
intake	O
of	O
FRT10	O
altered	O
the	O
metabolic	O
profiles	O
of	O
liver	O
and	O
cecum	O
contents	O
,	O
and	O
these	O
changes	O
were	O
partially	O
associated	O
with	O
lipid	O
metabolism	O
and	O
obesity	O
-	O
related	O
diseases	O
.	O
The	O
results	O
contributed	O
to	O
understanding	O
the	O
mechanism	O
by	O
which	O
L	O
.	O
plantarum	O
alleviated	O
obesity	O
.	O
Since	O
a	O
lower	O
dose	O
of	O
FRT10	O
had	O
a	O
better	O
effect	O
on	O
alleviating	O
obesity	O
[	O
11	O
]	O
,	O
we	O
focus	O
on	O
the	O
HF10L	O
group	O
in	O
the	O
following	O
study	O
.	O
As	O
shown	O
by	O
our	O
study	O
results	O
,	O
26	O
identified	O
liver	O
metabolites	O
and	O
15	O
cecum	O
contents	O
were	O
selected	O
as	O
potential	O
biomarkers	O
for	O
FRT10	O
anti	O
-	O
obesity	O
.	O
Based	O
on	O
identified	O
metabolites	O
,	O
the	O
metabolic	O
pathways	O
of	O
FRT10	O
intervention	O
against	O
obesity	O
and	O
the	O
analysis	O
of	O
the	O
gut	O
–	O
liver	O
axis	O
are	O
shown	O
in	O
Figure	O
3	O
.	O
Dysmetabolism	O
of	O
glycerolphospholipid	O
and	O
fatty	O
acid	O
has	O
been	O
found	O
to	O
be	O
directly	O
associated	O
with	O
the	O
progression	O
of	O
hyperlipidemia	O
.	O
Choline	O
metabolism	O
is	O
disrupted	O
in	O
the	O
context	O
of	O
dysbiosis	O
,	O
and	O
choline	O
deficiency	O
is	O
related	O
to	O
obesity	O
.	O
Choline	O
,	O
synthesized	O
primarily	O
by	O
intestinal	O
biota	O
and	O
completely	O
metabolized	O
in	O
the	O
liver	O
,	O
is	O
an	O
essential	O
nutrient	O
for	O
maintaining	O
the	O
liver	O
function	O
,	O
like	O
phospholipids	O
[	O
26	O
,	O
27	O
]	O
.	O
As	O
shown	O
in	O
Table	O
1	O
,	O
compared	O
to	O
the	O
HF	O
group	O
,	O
choline	O
,	O
and	O
phosphorylcholine	O
in	O
hepatic	O
metabolites	O
were	O
significantly	O
decreased	O
after	O
FRT10	O
intervention	O
.	O
Our	O
previous	O
study	O
showed	O
that	O
excess	O
choline	O
and	O
glycerolphospholipid	O
metabolites	O
were	O
positively	O
correlated	O
with	O
obesity	O
[	O
21	O
]	O
.	O
Increased	O
choline	O
in	O
the	O
liver	O
is	O
related	O
to	O
an	O
increased	O
risk	O
of	O
hepatic	O
steatosis	O
,	O
NASH	O
,	O
and	O
lobular	O
inflammation	O
[	O
28	O
]	O
.	O
The	O
result	O
indicated	O
that	O
FRT10	O
intervention	O
promotes	O
choline	O
metabolism	O
,	O
which	O
is	O
in	O
agreement	O
with	O
the	O
fact	O
that	O
reduced	O
choline	O
bioavailability	O
may	O
lead	O
to	O
NAFLD	O
[	O
29	O
,	O
30	O
]	O
.	O
Choline	O
is	O
an	O
important	O
precursor	O
of	O
phosphatidylcholine	O
(	O
PC	O
)	O
,	O
which	O
is	O
mainly	O
the	O
composition	O
of	O
phospholipid	O
-	O
coated	O
very	O
-	O
low	O
-	O
density	O
lipoprotein	O
(	O
VLDL	O
)	O
particles	O
.	O

Glycerophospholipids	O
are	O
the	O
most	O
abundant	O
lipids	O
and	O
the	O
main	O
components	O
of	O
bile	O
and	O
membrane	O
surfactants	O
except	O
biofilms	O
,	O
which	O
are	O
classified	O
into	O
PC	O
,	O
phosphatidylglycerol	O
(	O
PG	O
)	O
,	O
phosphatidylinositol	O
(	O
PI	O
)	O
,	O
phosphatidic	O
acid	O
(	O
PA	O
)	O
,	O
phosphatidylethanolamine	O
(	O
PE	O
)	O
,	O
and	O
phosphatidylserine	O
(	O
PS	O
)	O
,	O
as	O
well	O
as	O
lyso	O
-	O
PL	O
hydrolyzed	O
according	O
to	O
the	O
fatty	O
acid	O
side	O
chain	O
with	O
different	O
polar	O
heads	O
.	O
In	O
cecum	O
metabolites	O
,	O
PC	O
(	O
O	O
-	O
16	O
:	O
0	O
/	O
2	O
:	O
0	O
)	O
and	O
PC	O
(	O
0	O
:	O
0	O
/	O
20	O
:	O
4	O
(	O
5Z	O
,	O
8Z	O
,	O
11Z	O
,	O
14Z	O
)	O
)	O
were	O
significantly	O
down	O
-	O
regulated	O
,	O
and	O
PC	O
(	O
O	O
-	O
8	O
:	O
0	O
/	O
O	O
-	O
8	O
:	O
0	O
)	O
and	O
PC	O
(	O
O	O
-	O
14	O
:	O
1	O
(	O
1E	O
)	O
/	O
0	O
:	O
0	O
)	O
were	O
significantly	O
up	O
-	O
regulated	O
.	O
PC	O
(	O
O	O
-	O
16	O
:	O
0	O
/	O
2	O
:	O
0	O
)	O
is	O
a	O
neurotoxic	O
lipid	O
species	O
enhanced	O
in	O
Alzheimer	O
’	O
s	O
Disease	O
,	O
which	O
is	O
associated	O
with	O
promoting	O
mitochondrial	O
dysfunction	O
[	O
31	O
]	O
.	O
Altered	O
levels	O
of	O
lysophosphatidylcholines	O
(	O
LysoPCs	O
)	O
have	O
been	O
found	O
to	O
be	O
related	O
to	O
abnormal	O
energy	O
states	O
,	O
such	O
as	O
hyperlipidemia	O
and	O
obesity	O
[	O
32	O
]	O
.	O
LysoPCs	O
are	O
usually	O
produced	O
by	O
hydrolysis	O
of	O
oxidized	O
PC	O
.	O
LysoPC	O
(	O
18	O
:	O
1	O
(	O
9Z	O
)	O
)	O
and	O
LysoPC	O
(	O
20	O
:	O
3	O
(	O
5Z	O
,	O
8Z	O
,	O
11Z	O
)	O
)	O
were	O
significantly	O
reduced	O
in	O
mice	O
fed	O
FRT10	O
.	O
LysoPCs	O
can	O
cause	O
cyclooxygenase	O
expression	O
,	O
inflammation	O
,	O
and	O
autoimmune	O
response	O
,	O
either	O
alone	O
or	O
by	O
activating	O
specific	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
[	O
33	O
]	O
.	O
Studies	O
have	O
linked	O
LysoPCs	O
to	O
a	O
number	O
of	O
diseases	O
,	O
including	O
atherosclerosis	O
,	O
sepsis	O
,	O
diabetes	O
,	O
and	O
cancer	O
[	O
34	O
]	O
.	O

LysoPE	O
(	O
0	O
:	O
0	O
/	O
20	O
:	O
0	O
)	O
was	O
significantly	O
decreased	O
,	O
and	O
LysoPE	O
(	O
0	O
:	O
0	O
/	O
20	O
:	O
4	O
(	O
5Z	O
,	O
8Z	O
,	O
11Z	O
,	O
14Z	O
)	O
)	O
was	O
significantly	O
increased	O
after	O
FRT10	O
intervention	O
,	O
which	O
was	O
partly	O
matched	O
with	O
our	O
previous	O
study	O
that	O
LysoPE	O
(	O
18	O
:	O
1	O
(	O
9Z	O
)	O
)	O
and	O
LysoPE	O
(	O
16	O
:	O
1	O
(	O
9Z	O
)	O
0	O
:	O
0	O
)	O
were	O
positively	O
correlated	O
with	O
obesity	O
,	O
while	O
LysoPE	O
(	O
0	O
:	O
0	O
/	O
20	O
:	O
3	O
(	O
11Z	O
,	O
14Z	O
,	O
17Z	O
)	O
)	O
and	O
LysoPE	O
(	O
20	O
:	O
1	O
(	O
11Z	O
/	O
0	O
:	O
0	O
)	O
)	O
(	O
20	O
:	O
2	O
)	O
were	O
negatively	O
associated	O
with	O
obesity	O
[	O
21	O
]	O
.	O
In	O
addition	O
to	O
PC	O
species	O
,	O
PS	O
(	O
18	O
:	O
2	O
(	O
9Z	O
,	O
12Z	O
)	O
)	O
/	O
22	O
:	O
6	O
(	O
4Z	O
,	O
7Z	O
,	O
10Z	O
,	O
13Z	O
,	O
16Z	O
,	O
19Z	O
)	O
and	O
1	O
-	O
Palmitoyl	O
-	O
2	O
-	O
linoleoyl	O
PE	O
were	O
significantly	O
reduced	O
after	O
FRT10	O
intervention	O
,	O
which	O
is	O
associated	O
with	O
excess	O
PS	O
in	O
obese	O
mice	O
caused	O
by	O
HFD	O
in	O
our	O
previous	O
study	O
[	O
21	O
]	O
.	O
PA	O
is	O
a	O
common	O
phospholipid	O
that	O
is	O
a	O
synthetic	O
precursor	O
for	O
other	O
lipids	O
.	O
It	O
can	O
be	O
synthesized	O
from	O
and	O
converted	O
into	O
a	O
large	O
number	O
of	O
glycerophospholipids	O
,	O
which	O
are	O
involved	O
in	O
membrane	O
formation	O
,	O
cell	O
signaling	O
transduction	O
,	O
lipid	O
storage	O
,	O
etc	O
.	O
[	O
35	O
]	O
.	O
Interestingly	O
,	O
PA	O
(	O
18	O
:	O
0	O
/	O
18	O
:	O
1	O
(	O
9Z	O
)	O
)	O
was	O
increased	O
9	O
.	O
78	O
-	O
fold	O
after	O
FRT10	O
intervention	O
.	O
The	O
result	O
can	O
be	O
interpreted	O
as	O
an	O
attempt	O
by	O
the	O
gut	O
to	O
maintain	O
phospholipid	O
balance	O
by	O
enhancing	O
the	O
PA	O
level	O
.	O
The	O
results	O
suggest	O
that	O
different	O
glycerophospholipids	O
may	O
have	O
different	O
functions	O
,	O
which	O
need	O
to	O
be	O
further	O
studied	O
and	O
clarified	O
.	O
These	O
metabolic	O
alterations	O
of	O
glycerophospholipid	O
metabolites	O
help	O
us	O
further	O
understand	O
the	O
underlying	O
mechanism	O
of	O
FRT10	O
against	O
obesity	O
.	O
Bile	O
acids	O
(	O
BA	O
)	O
are	O
important	O
amphipathic	O
signaling	O
molecules	O
and	O
have	O
important	O
physiological	O
functions	O
,	O
and	O
their	O
homeostasis	O
is	O
regulated	O
by	O
gut	O
microbiota	O
.	O
Disturbed	O
bile	O
acids	O
homeostasis	O
may	O
be	O
caused	O
by	O
impaired	O
liver	O
uptake	O
and	O
elevated	O
basolateral	O
bile	O
acids	O
efflusion	O
[	O
36	O
]	O
.	O

After	O
FRT10	O
intervention	O
,	O
the	O
major	O
bile	O
acid	O
cholic	O
acid	O
(	O
CA	O
)	O
in	O
the	O
liver	O
was	O
significantly	O
decreased	O
by	O
0	O
.	O
45	O
-	O
fold	O
,	O
while	O
CA	O
was	O
significantly	O
increased	O
by	O
1	O
.	O
71	O
-	O
fold	O
in	O
the	O
cecum	O
.	O
Free	O
BA	O
solubilizes	O
intestinal	O
lipids	O
with	O
low	O
reabsorption	O
efficiency	O
,	O
resulting	O
in	O
increased	O
BA	O
excretion	O
in	O
feces	O
and	O
replacement	O
of	O
free	O
BA	O
by	O
bile	O
acids	O
newly	O
synthesized	O
from	O
cholesterol	O
in	O
the	O
liver	O
as	O
a	O
mechanism	O
by	O
which	O
excess	O
cholesterol	O
is	O
excreted	O
through	O
the	O
gut	O
–	O
liver	O
axis	O
.	O
The	O
content	O
of	O
taurocholic	O
acid	O
(	O
TCA	O
)	O
in	O
the	O
liver	O
and	O
cecum	O
decreased	O
by	O
0	O
.	O
30	O
times	O
and	O
0	O
.	O
42	O
times	O
,	O
respectively	O
.	O
TCA	O
is	O
a	O
primary	O
conjugated	O
bile	O
acid	O
synthesized	O
from	O
CA	O
.	O
The	O
result	O
is	O
consistent	O
with	O
a	O
study	O
of	O
higher	O
serum	O
total	O
and	O
conjugated	O
bile	O
acids	O
in	O
patients	O
with	O
liver	O
damage	O
[	O
37	O
]	O
.	O
Our	O
result	O
is	O
consistent	O
with	O
the	O
report	O
that	O
L	O
.	O
plantarum	O
H	O
-	O
87	O
prevented	O
HFD	O
-	O
induced	O
obese	O
mice	O
by	O
regulating	O
bile	O
acid	O
enterohepatic	O
circulation	O
[	O
38	O
]	O
.	O
Amino	O
acids	O
are	O
not	O
only	O
essential	O
nutrients	O
and	O
the	O
source	O
of	O
energy	O
for	O
the	O
human	O
body	O
but	O
also	O
participate	O
in	O
many	O
biochemical	O
processes	O
such	O
as	O
the	O
biosynthesis	O
of	O
purines	O
and	O
the	O
production	O
of	O
uric	O
acid	O
[	O
39	O
]	O
.	O
The	O
primary	O
organ	O
for	O
amino	O
acid	O
metabolism	O
is	O
the	O
liver	O
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
amino	O
acid	O
homeostasis	O
.	O
Abnormal	O
alterations	O
in	O
amino	O
acids	O
have	O
been	O
found	O
to	O
result	O
in	O
dysregulation	O
that	O
may	O
potentially	O
affect	O
fatty	O
acid	O
,	O
protein	O
,	O
and	O
urea	O
synthesis	O
,	O
energy	O
metabolism	O
,	O
proteolysis	O
,	O
and	O
cell	O
signaling	O
[	O
40	O
]	O
.	O
Eight	O
hepatic	O
metabolites	O
related	O
to	O
amino	O
acid	O
metabolism	O
,	O
including	O
l	O
-	O
phenylalanine	O
,	O
tyramine	O
,	O
l	O
-	O
threonine	O
,	O
d	O
-	O
ornithine	O
,	O
l	O
-	O
asparagine	O
,	O
d	O
-	O
proline	O
,	O
and	O
l	O
-	O
pyrogutamic	O
acid	O
,	O
were	O
significantly	O
enhanced	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
while	O
l	O
-	O
histidine	O
was	O
markedly	O
increased	O
after	O
FRT10	O
intervention	O
.	O

These	O
altered	O
amino	O
acids	O
included	O
l	O
-	O
phenylalanine	O
,	O
l	O
-	O
asparagine	O
,	O
and	O
d	O
-	O
proline	O
,	O
which	O
are	O
commonly	O
used	O
as	O
substrates	O
for	O
hepatic	O
glucogenesis	O
[	O
41	O
,	O
42	O
]	O
,	O
and	O
the	O
decrease	O
in	O
hepatic	O
amino	O
acid	O
levels	O
caused	O
by	O
long	O
-	O
term	O
HFD	O
may	O
be	O
related	O
to	O
HFD	O
-	O
induced	O
hepatic	O
abnormal	O
gluconeogenesis	O
[	O
43	O
]	O
.	O
The	O
results	O
of	O
the	O
overall	O
enhancement	O
of	O
amino	O
acids	O
partially	O
matched	O
those	O
of	O
a	O
previous	O
study	O
that	O
Platycodon	O
grandiflorum	O
ameliorated	O
obesity	O
through	O
significantly	O
increasing	O
serine	O
,	O
glycine	O
,	O
threonine	O
,	O
glutamate	O
,	O
methionine	O
,	O
ornithine	O
,	O
phenylalanine	O
,	O
tyrosine	O
,	O
and	O
lysine	O
in	O
the	O
liver	O
of	O
obese	O
mice	O
[	O
44	O
]	O
.	O
The	O
supplementation	O
of	O
Luffa	O
cylindrica	O
could	O
significantly	O
alleviate	O
hepatic	O
steatosis	O
in	O
HFD	O
-	O
induced	O
obese	O
mice	O
by	O
inhibiting	O
lipid	O
synthesis	O
and	O
increasing	O
liver	O
levels	O
of	O
amino	O
acid	O
[	O
45	O
]	O
.	O
Moreover	O
,	O
phenyllactic	O
acid	O
(	O
PLA	O
)	O
,	O
a	O
product	O
of	O
phenylalanine	O
catabolism	O
,	O
was	O
significantly	O
increased	O
in	O
the	O
liver	O
.	O
Manna	O
et	O
al	O
.	O
reported	O
that	O
alcohol	O
-	O
treated	O
Ppara	O
-	O
null	O
mice	O
had	O
elevated	O
levels	O
of	O
PLA	O
in	O
urine	O
[	O
46	O
,	O
47	O
]	O
.	O
PLA	O
is	O
a	O
pharmaceutical	O
component	O
used	O
in	O
the	O
synthesis	O
of	O
the	O
hypoglycemic	O
agent	O
englitazone	O
,	O
a	O
non	O
-	O
protein	O
amino	O
acid	O
statin	O
,	O
and	O
a	O
novel	O
intestinal	O
anthelmintic	O
agent	O
PF1022A	O
[	O
48	O
,	O
49	O
]	O
.	O
PLA	O
was	O
reported	O
to	O
alleviate	O
Samonella	O
Typhimurium	O
-	O
induced	O
colitis	O
[	O
50	O
]	O
.	O
Therefore	O
,	O
it	O
is	O
necessary	O
to	O
further	O
study	O
the	O
relationship	O
between	O
the	O
change	O
in	O
PLA	O
level	O
and	O
anti	O
-	O
obesity	O
effects	O
.	O
We	O
also	O
found	O
some	O
changes	O
in	O
metabolites	O
associated	O
with	O
purine	O
and	O
pyrimidine	O
metabolism	O
.	O

Hepatic	O
metabolites	O
such	O
as	O
inosine	O
,	O
xanthosine	O
,	O
xanthine	O
,	O
deoxyinosine	O
,	O
uracil	O
,	O
allantoin	O
(	O
5	O
-	O
ureidohydantoin	O
or	O
5	O
-	O
ureidoacetolactam	O
)	O
,	O
thymidine	O
,	O
and	O
thymin	O
were	O
significantly	O
increased	O
,	O
while	O
hypoxanthine	O
and	O
urdine	O
were	O
markedly	O
decreased	O
.	O
The	O
data	O
were	O
partially	O
concordant	O
with	O
a	O
previous	O
study	O
that	O
HFD	O
induced	O
a	O
significant	O
decrease	O
in	O
hepatic	O
uracil	O
,	O
uridine	O
,	O
inosine	O
,	O
and	O
hypoxanthine	O
,	O
while	O
Platycodon	O
grandiflorum	O
treatment	O
alleviated	O
HFD	O
-	O
induced	O
obesity	O
by	O
significantly	O
enhancing	O
the	O
contents	O
of	O
uracil	O
and	O
hypoxanthine	O
[	O
44	O
]	O
.	O
Inosine	O
is	O
usually	O
converted	O
from	O
purine	O
nucleoside	O
phosphorylase	O
to	O
hypoxanthine	O
,	O
which	O
is	O
then	O
converted	O
from	O
xanthine	O
oxidase	O
to	O
xanthine	O
.	O
Xanthine	O
is	O
a	O
host	O
–	O
microbial	O
co	O
-	O
metabolite	O
widely	O
present	O
in	O
body	O
tissues	O
,	O
body	O
fluids	O
,	O
and	O
gut	O
microbiota	O
,	O
which	O
can	O
be	O
converted	O
to	O
uric	O
acid	O
in	O
mice	O
.	O
Both	O
xanthine	O
and	O
hypoxanthine	O
are	O
oxypurines	O
and	O
precursors	O
of	O
uric	O
acid	O
,	O
which	O
are	O
oxidized	O
by	O
xanthine	O
oxidoreductase	O
in	O
purine	O
catabolism	O
[	O
51	O
]	O
.	O
Hypoxanthine	O
,	O
an	O
upstream	O
metabolite	O
of	O
xanthine	O
,	O
was	O
markedly	O
decreased	O
in	O
the	O
liver	O
after	O
FRT10	O
intervention	O
,	O
which	O
is	O
consistent	O
with	O
significantly	O
higher	O
plasma	O
hypoxanthine	O
levels	O
in	O
obese	O
participants	O
than	O
in	O
lean	O
participants	O
[	O
52	O
]	O
.	O
The	O
hypoxanthine	O
level	O
in	O
plasma	O
was	O
positively	O
correlated	O
with	O
BMI	O
[	O
53	O
]	O
.	O
However	O
,	O
the	O
result	O
contradicted	O
that	O
topiroxostat	O
suppressed	O
body	O
weight	O
gain	O
by	O
increasing	O
hepatic	O
hypoxanthine	O
in	O
diabetic	O
obese	O
mice	O
[	O
54	O
]	O
.	O
Xanthine	O
was	O
found	O
to	O
be	O
significantly	O
increased	O
both	O
in	O
liver	O
and	O
cecum	O
contents	O
.	O
Gut	O
microbiota	O
mediated	O
-	O
xanthine	O
metabolism	O
correlates	O
with	O
HFD	O
-	O
induced	O
obesity	O
[	O
55	O
]	O
.	O
The	O
results	O
are	O
not	O
in	O
accordance	O
with	O
the	O
report	O
of	O
elevated	O
urine	O
xanthine	O
levels	O
in	O
obese	O
mice	O
[	O
55	O
]	O
.	O

Uridine	O
is	O
a	O
pyrimidine	O
nucleoside	O
that	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
glucose	O
and	O
lipid	O
metabolism	O
.	O
Hepatic	O
uridine	O
was	O
significantly	O
decreased	O
,	O
which	O
contradicted	O
that	O
uridine	O
attenuates	O
obesity	O
and	O
ameliorates	O
hepatic	O
lipid	O
accumulation	O
in	O
HFD	O
-	O
fed	O
mice	O
[	O
56	O
]	O
.	O
Uracil	O
was	O
significantly	O
enhanced	O
,	O
which	O
is	O
in	O
agreement	O
with	O
the	O
fact	O
that	O
uracil	O
and	O
ribose	O
-	O
containing	O
uridine	O
have	O
protective	O
effects	O
on	O
drug	O
-	O
induced	O
hepatotoxicity	O
and	O
mental	O
disorders	O
[	O
57	O
]	O
.	O
Allantoin	O
is	O
a	O
diureide	O
of	O
glyoxylic	O
acid	O
,	O
which	O
has	O
been	O
reported	O
to	O
have	O
antidiabetic	O
effects	O
[	O
58	O
,	O
59	O
]	O
,	O
which	O
was	O
also	O
found	O
to	O
be	O
significantly	O
increased	O
in	O
liver	O
after	O
FRT10	O
intervention	O
.	O
From	O
these	O
results	O
,	O
it	O
appears	O
that	O
FRT10	O
attenuated	O
obesity	O
by	O
enhancing	O
purine	O
and	O
pyrimidine	O
metabolism	O
,	O
resulting	O
in	O
the	O
predisposition	O
of	O
the	O
body	O
toward	O
catabolism	O
in	O
obese	O
mice	O
.	O
These	O
findings	O
suggest	O
that	O
gut	O
microbial	O
-	O
mediated	O
xanthine	O
metabolism	O
is	O
involved	O
in	O
resistance	O
to	O
HFD	O
-	O
induced	O
obesity	O
.	O
This	O
study	O
verified	O
the	O
anti	O
-	O
obesity	O
effect	O
of	O
FRT10	O
by	O
metabonomics	O
.	O
Liver	O
and	O
cecum	O
metabonomic	O
studies	O
based	O
on	O
UPLC	O
-	O
Q	O
-	O
TOF	O
/	O
MS	O
revealed	O
the	O
modulation	O
effects	O
of	O
FRT10	O
on	O
obese	O
mice	O
.	O
Based	O
on	O
identified	O
metabolites	O
,	O
we	O
found	O
that	O
FRT10	O
alleviated	O
obesity	O
via	O
metabolic	O
pathways	O
in	O
glycerophospholipid	O
metabolism	O
,	O
primary	O
bile	O
acid	O
biosynthesis	O
,	O
amino	O
metabolism	O
,	O
and	O
purine	O
and	O
pyrimidine	O
metabolism	O
.	O
FRT10	O
appeared	O
to	O
be	O
a	O
promising	O
candidate	O
for	O
probiotics	O
to	O
combat	O
the	O
increasing	O
incidence	O
of	O
metabolic	O
syndrome	O
and	O
obesity	O
.	O
This	O
research	O
was	O
funded	O
by	O
the	O
National	O
Key	O
Research	O
and	O
Development	O
Program	O
of	O
China	O
,	O
grant	O
number	O
2017YFD0400303	O
,	O
and	O
the	O
National	O
Natural	O
Science	O
Foundation	O
of	O
China	O
,	O
grant	O
number	O
31802081	O
.	O
Publisher	O
’	O
s	O
Note	O
:	O
MDPI	O
stays	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O

Conceptualization	O
,	O
H	O
.	O
C	O
.	O
and	O
P	O
.	O
Y	O
.	O
;	O
Methodology	O
,	O
H	O
.	O
C	O
.	O
,	O
D	O
.	O
L	O
.	O
and	O
Y	O
.	O
H	O
.	O
;	O
Software	O
,	O
D	O
.	O
L	O
.	O
,	O
L	O
.	O
S	O
.	O
and	O
X	O
.	O
X	O
.	O
;	O
Validation	O
,	O
H	O
.	O
C	O
.	O
,	O
X	O
.	O
X	O
.	O
and	O
K	O
.	O
M	O
.	O
;	O
Formal	O
Analysis	O
,	O
D	O
.	O
L	O
.	O
and	O
L	O
.	O
S	O
.	O
;	O
Investigation	O
,	O
H	O
.	O
C	O
.	O
,	O
D	O
.	O
L	O
.	O
and	O
L	O
.	O
S	O
.	O
;	O
Resources	O
,	O
P	O
.	O
Y	O
.	O
;	O
Data	O
Curation	O
,	O
L	O
.	O
S	O
.	O
,	O
X	O
.	O
X	O
.	O
and	O
Y	O
.	O
H	O
.	O
;	O
Writing	O
—	O
Original	O
Draft	O
Preparation	O
,	O
H	O
.	O
C	O
.	O
;	O
Writing	O
—	O
Review	O
and	O
Editing	O
,	O
K	O
.	O
M	O
.	O
and	O
P	O
.	O
Y	O
.	O
;	O
Visualization	O
,	O
D	O
.	O
L	O
.	O
,	O
L	O
.	O
S	O
.	O
and	O
Y	O
.	O
H	O
.	O
;	O
Supervision	O
,	O
K	O
.	O
M	O
.	O
;	O
Project	O
Administration	O
,	O
Z	O
.	O
W	O
.	O
and	O
P	O
.	O
Y	O
.	O
;	O
Funding	O
Acquisition	O
,	O
Z	O
.	O
W	O
.	O
and	O
P	O
.	O
Y	O
.	O
All	O
authors	O
have	O
read	O
and	O
agreed	O
to	O
the	O
published	O
version	O
of	O
the	O
manuscript	O
.	O
The	O
animal	B-methodology
study	I-methodology
protocol	O
was	O
approved	O
by	O
the	O
Laboratory	O
Animal	O
Ethical	O
Committee	O
and	O
its	O
inspection	O
by	O
the	O
Feed	O
Research	O
Institute	O
,	O
Chinese	O
Academy	O
of	O
Agricultural	O
Sciences	O
(	O
Approval	O
No	O
.	O
AEC	O
-	O
CAAS	O
-	O
20090609	O
)	O
.	O
Data	O
is	O
contained	O
within	O
the	O
article	O
.	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O

Arylesterase	O
activity	O
is	O
associated	O
with	O
antioxidant	O
intake	O
and	O
paraoxonase	O
-	O
1	O
(	O
PON1	O
)	O
gene	O
methylation	O
in	O
metabolic	O
syndrome	O
patients	O
following	O
an	O
energy	O
restricted	O
diet	O
DNA	O
methylation	O
;	O
ARE	O
;	O
PON1	O
gene	O
;	O
obesity	O
;	O
metabolic	O
syndrome	O
;	O
energy	O
restriction	O
;	O
antioxidants	O
The	O
arylesterase	O
(	O
ARE	O
)	O
activity	O
linked	O
to	O
the	O
paraoxonase	O
-	O
1	O
(	O
PON1	O
)	O
gene	O
is	O
known	O
to	O
protect	O
lipoproteins	O
from	O
oxidation	O
and	O
provide	O
defense	O
against	O
metabolic	O
syndrome	O
(	O
MetS	O
)	O
and	O
cardiovascular	O
diseases	O
.	O
The	O
epigenetic	O
regulation	O
of	O
enzymatic	O
activities	O
is	O
gaining	O
importance	O
nowadays	O
.	O
This	O
research	O
aimed	O
to	O
assess	O
the	O
potential	O
relationships	O
between	O
the	O
ARE	O
activity	O
with	O
the	O
methylation	O
levels	O
of	O
the	O
PON1	O
gene	O
transcriptional	O
regulatory	O
region	O
,	O
anthropometrics	O
,	O
biochemical	O
markers	O
and	O
antioxidant	O
dietary	O
components	O
.	O
Forty	O
-	O
seven	O
subjects	O
(	O
47	O
±	O
10	O
y	O
.	O
o	O
;	O
BMI	O
36	O
.	O
2	O
±	O
3	O
.	O
8	O
kg	O
/	O
m2	O
;	O
46	O
.	O
8	O
%	O
female	O
)	O
with	O
MetS	O
features	O
,	O
who	O
followed	O
a	O
six	B-methodology
-	I-methodology
month	I-methodology
energy	I-methodology
-	I-methodology
restricted	I-methodology
dietary	I-methodology
weight	I-methodology
-	I-methodology
loss	I-methodology
intervention	I-methodology
,	O
were	O
included	O
in	O
this	O
study	O
(	O
www	O
.	O
clinicaltrials	O
.	O
gov	O
;	O
NCT01087086	O
)	O
.	O
Anthropometric	O
,	O
biochemical	O
,	O
enzymatic	O
and	O
dietary	O
data	O
were	O
assessed	O
using	O
validated	O
procedures	O
.	O
PON1	O
transcriptional	O
regulatory	O
region	O
methylation	O
was	O
analyzed	O
by	O
a	O
microarray	O
technical	O
approach	O
.	O
Volunteers	O
reduced	O
ARE	O
activity	O
in	O
parallel	O
with	O
body	O
weight	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
,	O
BMI	O
(	O
p	O
=	O
0	O
.	O
006	O
)	O
,	O
total	O
fat	O
mass	O
(	O
p	O
=	O
0	O
.	O
020	O
)	O
,	O
diastolic	O
blood	O
pressure	O
(	O
p	O
=	O
0	O
.	O
018	O
)	O
,	O
mean	O
blood	O
pressure	O
(	O
p	O
=	O
0	O
.	O
022	O
)	O
and	O
triglycerides	O
(	O
p	O
=	O
0	O
.	O
014	O
)	O
.	O
Methylation	O
levels	O
of	O
some	O
CpG	O
sites	O
of	O
the	O
PON1	O
gene	O
correlated	O
negatively	O
with	O
ARE	O
activity	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Interestingly	O
,	O
dietary	O
vitamin	O
C	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
,	O
tocopherols	O
(	O
p	O
=	O
0	O
.	O
009	O
)	O
and	O
lycopene	O
(	O
p	O
=	O
0	O
.	O
038	O
)	O
were	O
positively	O
associated	O
with	O
ARE	O
activity	O
and	O
showed	O
an	O
inverse	O
correlation	O
(	O
p	O
=	O
0	O
.	O
004	O
,	O
p	O
=	O
0	O
.	O
029	O
and	O
p	O
=	O
0	O
.	O
021	O
,	O
respectively	O
)	O
with	O
the	O
methylation	O
of	O
some	O
selected	O
CpG	O
sites	O
of	O
the	O
PON1	O
gene	O
.	O
In	O
conclusion	O
,	O
ARE	O
activity	O
decreased	O
in	O
parallel	O
with	O
MetS	O
-	O
related	O
markers	O
associated	O
to	O
the	O
energy	O
restriction	O
,	O
while	O
dietary	O
antioxidants	O
might	O
enhance	O
the	O
ARE	O
activity	O
by	O
lowering	O
the	O
PON1	O
gene	O
methylation	O
in	O
patients	O
with	O
MetS	O
features	O
.	O
Paraoxonase	O
-	O
1	O
(	O
PON1	O
)	O
is	O
a	O
calcium	O
-	O
dependent	O
glycoprotein	O
hepatically	O
synthesized	O
that	O
belongs	O
to	O
the	O
paraoxonase	O
family	O
(	O
Precourt	O
et	O
al	O
.	O
,	O
2011	O
[	O
35	O
]	O
)	O
.	O
This	O
enzyme	O
is	O
related	O
to	O
high	O
density	O
lipoprotein	O
-	O
cholesterol	O
(	O
HDL	O
-	O
c	O
)	O
and	O
has	O
been	O
described	O
to	O
protect	O
lipoproteins	O
,	O
particularly	O
low	O
density	O
lipoprotein	O
-	O
cholesterol	O
(	O
LDL	O
-	O
c	O
)	O
,	O
from	O
oxidation	O
(	O
Kim	O
et	O
al	O
.	O
,	O
2013	O
[	O
18	O
]	O
;	O
Kumar	O
et	O
al	O
.	O
,	O
2013	O
[	O
22	O
]	O
)	O
.	O
Thus	O
,	O
some	O
of	O
the	O
antiatherogenic	O
properties	O
of	O
HDL	O
-	O
c	O
are	O
attributed	O
to	O
PON1	O
functions	O
(	O
Cohen	O
et	O
al	O
.	O
,	O
2012	O
[	O
9	O
]	O
)	O
.	O
The	O
precise	O
mechanisms	O
by	O
which	O
the	O
PON1	O
acts	O
remains	O
unclear	O
,	O
but	O
several	O
in	B-methodology
vitro	I-methodology
activities	O
have	O
been	O
attributed	O
to	O
this	O
enzyme	O
(	O
Nus	O
et	O
al	O
.	O
,	O
2008	O
[	O
32	O
]	O
)	O
:	O
paraoxonase	O
(	O
hydrolysis	O
of	O
organophosphates	O
)	O
,	O
lactonase	O
(	O
hydrolysis	O
of	O
lactones	O
)	O
,	O
and	O
arylesterase	O
or	O
ARE	O
(	O
hydrolysis	O
of	O
aromatic	O
carboxylic	O
acid	O
esters	O
)	O
.	O
Obesity	O
and	O
metabolic	O
syndrome	O
(	O
MetS	O
)	O
features	O
are	O
main	O
risk	O
factors	O
for	O
the	O
development	O
of	O
atherosclerosis	O
and	O
cardiovascular	O
diseases	O
(	O
CVD	O
)	O
onset	O
(	O
Garg	O
et	O
al	O
.	O
,	O
2014	O
[	O
15	O
]	O
)	O
.	O
Due	O
to	O
the	O
increasing	O
prevalence	O
of	O
obese	O
people	O
,	O
these	O
accompanying	O
diseases	O
are	O
considered	O
a	O
major	O
concern	O
for	O
public	O
health	O
authorities	O
and	O
many	O
scientific	O
efforts	O
are	O
being	O
carried	O
out	O
to	O
detect	O
,	O
treat	O
and	O
prevent	O
them	O
.	O

Hypocaloric	O
diets	O
are	O
one	O
of	O
the	O
most	O
common	O
treatments	O
employed	O
to	O
combat	O
MetS	O
and	O
related	O
diseases	O
(	O
Straznicky	O
et	O
al	O
.	O
,	O
2010	O
[	O
39	O
]	O
)	O
.	O
However	O
,	O
more	O
investigation	O
is	O
needed	O
to	O
understand	O
the	O
PON1	O
activity	O
role	O
as	O
part	O
of	O
these	O
nutritional	O
strategies	O
.	O
In	O
this	O
context	O
,	O
some	O
research	O
have	O
been	O
performed	O
focusing	O
on	O
the	O
relationship	O
between	O
the	O
PON1	O
activity	O
levels	O
and	O
the	O
MetS	O
/	O
obesity	O
states	O
(	O
Ferretti	O
et	O
al	O
.	O
,	O
2012	O
[	O
12	O
]	O
;	O
Koncsos	O
et	O
al	O
.	O
,	O
2011	O
[	O
19	O
]	O
;	O
Kota	O
et	O
al	O
.	O
,	O
2013	O
[	O
20	O
]	O
;	O
Tabur	O
et	O
al	O
.	O
,	O
2010	O
[	O
40	O
]	O
)	O
while	O
other	O
authors	O
have	O
investigated	O
the	O
influence	O
of	O
some	O
specific	O
dietary	O
factors	O
on	O
the	O
activity	O
levels	O
of	O
this	O
enzyme	O
(	O
Canales	O
et	O
al	O
.	O
,	O
2011	O
[	O
5	O
]	O
;	O
Jarvik	O
et	O
al	O
.	O
,	O
2002	O
[	O
16	O
]	O
;	O
Vazquez	O
-	O
Velasco	O
et	O
al	O
.	O
,	O
2011	O
[	O
44	O
]	O
)	O
.	O
But	O
the	O
studies	O
carried	O
out	O
are	O
scarce	O
and	O
reported	O
controversial	O
results	O
.	O
Epigenetics	O
is	O
defined	O
as	O
heritable	O
changes	O
in	O
gene	O
expression	O
that	O
cannot	O
be	O
explained	O
by	O
changes	O
in	O
DNA	O
sequence	O
(	O
Christensen	O
et	O
al	O
.	O
,	O
2011	O
[	O
7	O
]	O
)	O
.	O
Among	O
the	O
different	O
possible	O
epigenetic	O
modifications	O
,	O
DNA	O
methylation	O
is	O
probably	O
the	O
most	O
widely	O
studied	O
(	O
Milagro	O
et	O
al	O
.	O
,	O
2011	O
[	O
28	O
]	O
)	O
.	O
In	O
this	O
context	O
,	O
dietary	O
factors	O
,	O
specially	O
antioxidants	O
,	O
have	O
become	O
agents	O
of	O
strong	O
interest	O
in	O
the	O
field	O
of	O
epigenetics	O
due	O
to	O
their	O
prominent	O
role	O
as	O
potent	O
modulators	O
of	O
epigenome	O
-	O
regulated	O
gene	O
expression	O
through	O
regulation	O
of	O
DNA	O
methylation	O
(	O
Bartels	O
,	O
2007	O
[	O
4	O
]	O
;	O
Malireddy	O
et	O
al	O
.	O
,	O
2012	O
[	O
24	O
]	O
;	O
Milagro	O
et	O
al	O
.	O
,	O
2009	O
[	O
29	O
]	O
)	O
.	O
Thus	O
,	O
within	O
this	O
scenario	O
,	O
the	O
current	O
study	O
aimed	O
to	O
assess	O
the	O
potential	O
relationships	O
between	O
the	O
PON1	O
ARE	O
activity	O
and	O
anthropometric	O
and	O
biochemical	O
markers	O
,	O
dietary	O
antioxidants	O
intake	O
,	O
and	O
the	O
cytosine	O
methylation	O
levels	O
of	O
PON1	O
gene	O
transcriptional	O
regulatory	O
region	O
,	O
in	O
volunteers	O
with	O
MetS	O
symptoms	O
after	O
following	O
an	O
energy	O
-	O
restricted	O
dietary	O
program	O
.	O

The	O
current	O
analysis	O
was	O
an	O
ancillary	B-methodology
study	I-methodology
conducted	O
within	O
the	O
RESMENA	O
(	O
Metabolic	O
Syndrome	O
Reduction	O
in	O
Navarra	O
)	O
project	O
,	O
a	O
randomized	B-methodology
controlled	I-methodology
trial	I-methodology
(	O
Zulet	O
et	O
al	O
.	O
,	O
2011	O
[	O
48	O
]	O
)	O
where	O
a	O
subsample	O
of	O
47	O
obese	O
adults	O
(	O
47	O
±	O
10	O
y	O
.	O
o	O
;	O
BMI	O
36	O
.	O
2	O
±	O
3	O
.	O
8	O
kg	O
/	O
m2	O
;	O
46	O
.	O
8	O
%	O
female	O
)	O
who	O
presented	O
MetS	O
features	O
was	O
selected	O
.	O
The	O
study	O
lasted	O
a	O
total	O
of	O
6	O
months	O
divided	O
in	O
two	O
sequential	O
stages	O
:	O
an	O
initial	O
8	O
-	O
week	O
nutritional	O
-	O
learning	O
intervention	B-methodology
period	I-methodology
,	O
during	O
which	O
nutritional	O
assessment	O
was	O
carried	O
out	O
for	O
the	O
participants	O
every	O
15	O
days	O
(	O
Lopez	O
-	O
Legarrea	O
et	O
al	O
.	O
,	O
2013	O
[	O
23	O
]	O
)	O
and	O
a	O
4	O
-	O
month	O
self	O
-	O
control	O
period	O
,	O
during	O
which	O
the	O
participants	O
followed	O
the	O
previously	O
acquired	O
dietary	O
habits	O
(	O
de	O
la	O
Iglesia	O
et	O
al	O
.	O
,	O
2013	O
[	O
11	O
]	O
)	O
.	O
The	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
University	O
of	O
Navarra	O
(	O
065	O
/	O
2009	O
)	O
and	O
appropriately	O
registered	O
at	O
www	O
.	O
clinicaltrials	O
.	O
gov	O
(	O
NCT01087086	O
)	O
.	O
Consequently	O
,	O
all	O
the	O
participants	O
gave	O
written	B-methodology
informed	I-methodology
consent	I-methodology
for	O
participation	O
in	O
agreement	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
.	O
More	O
details	O
about	O
the	O
procedures	O
and	O
protocols	O
have	O
been	O
previously	O
reported	O
(	O
Zulet	O
et	O
al	O
.	O
,	O
2011	O
[	O
48	O
]	O
)	O
.	O
Anthropometric	O
measurements	O
were	O
conducted	O
in	O
fasting	O
conditions	O
according	O
to	O
previously	O
described	O
procedures	O
(	O
Zulet	O
et	O
al	O
.	O
,	O
2011	O
[	O
48	O
]	O
)	O
.	O
Body	O
mass	O
index	O
(	O
BMI	O
)	O
was	O
calculated	O
as	O
the	O
body	O
weight	O
divided	O
by	O
height	O
squared	O
(	O
kg	O
/	O
m2	O
)	O
.	O
Body	O
composition	O
analyses	O
were	O
carried	O
out	O
by	O
Dual	O
Energy	O
X	O
-	O
ray	O
Absorptiometry	O
(	O
DXA	O
)	O
following	O
validated	O
protocols	O
as	O
reported	O
elsewhere	O
(	O
Zulet	O
et	O
al	O
.	O
,	O
2011	O
[	O
48	O
]	O
)	O
.	O
Systolic	O
(	O
SBP	O
)	O
and	O
diastolic	O
(	O
DBP	O
)	O
blood	O
pressures	O
were	O
measured	O
following	O
standardized	O
World	O
Health	O
Organization	O
criteria	O
(	O
Whitworth	O
et	O
al	O
.	O
,	O
2004	O
[	O
45	O
]	O
)	O
.	O
Mean	O
blood	O
pressure	O
(	O
MBP	O
)	O
was	O
calculated	O
as	O
:	O
[	O
(	O
DPB	O
x	O
2	O
)	O
+	O
SBP	O
]	O
/	O
3	O
as	O
advised	O
elsewhere	O
(	O
Shapiro	O
et	O
al	O
.	O
,	O
2010	O
[	O
37	O
]	O
)	O
.	O

Information	O
about	O
dietary	O
intake	O
was	O
collected	O
using	O
a	O
48	O
h	O
weighed	O
food	O
record	O
and	O
analysed	O
using	O
the	O
DIAL	O
(	O
Alce	O
Ingeniería	O
)	O
software	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
alceingenieria	O
.	O
net	O
/	O
nutricion	O
)	O
as	O
previously	O
reported	O
(	O
Perez	O
-	O
Cornago	O
et	O
al	O
.	O
,	O
2013	O
[	O
33	O
]	O
)	O
.	O
Venous	O
blood	O
samples	O
were	O
drawn	O
after	O
a	O
12	O
h	O
overnight	O
fast	O
by	O
venipuncture	O
.	O
The	O
EDTA	O
–	O
plasma	O
and	O
serum	O
samples	O
as	O
well	O
as	O
WBC	O
were	O
separated	O
from	O
whole	O
blood	O
by	O
centrifugation	O
at	O
3	O
,	O
500	O
rpm	O
,	O
5	O
°C	O
,	O
15	O
min	O
(	O
Model	O
5804R	O
,	O
Eppendorf	O
,	O
Germany	O
)	O
,	O
and	O
were	O
frozen	O
immediately	O
at	O
-	O
80	O
°C	O
until	O
assay	O
(	O
WBC	O
in	O
buffy	O
-	O
coat	O
)	O
.	O
Plasma	O
concentrations	O
of	O
triglycerides	O
(	O
TG	O
)	O
,	O
total	O
cholesterol	O
(	O
TC	O
)	O
,	O
HDL	O
-	O
c	O
(	O
Wako	O
Chemicals	O
,	O
GmbH	O
,	O
Nuiss	O
,	O
Germany	O
)	O
and	O
glucose	O
(	O
Horiba	O
ABX	O
Diagnostics	O
,	O
Montpellier	O
,	O
France	O
)	O
were	O
measured	O
by	O
specific	O
colorimetric	O
assays	O
,	O
using	O
an	O
automated	O
analyzer	O
system	O
Pentra	O
C	O
-	O
200	O
(	O
HORIBA	O
ABX	O
,	O
Madrid	O
,	O
Spain	O
)	O
.	O
LDL	O
-	O
c	O
levels	O
were	O
calculated	O
using	O
the	O
Friedewald	O
formula	O
:	O
LDL	O
-	O
c	O
=	O
TC	O
-	O
HDL	O
-	O
c	O
–	O
TG	O
/	O
5	O
(	O
Friedewald	O
et	O
al	O
.	O
,	O
1972	O
[	O
13	O
]	O
)	O
.	O
Apolipoprotein	O
B	O
(	O
Apo	O
B	O
)	O
was	O
measured	O
with	O
a	O
specific	O
kit	O
(	O
Tina	O
-	O
quant	O
Apolipoprotein	O
B	O
ver	O
.	O
2	O
,	O
Mannheim	O
,	O
Germany	O
)	O
using	O
a	O
Model	O
904	O
Modular	O
Roche	O
/	O
Hitachi	O
autoanalyser	O
(	O
Roche	O
Diagnostics	O
,	O
Tokio	O
,	O
Japan	O
)	O
.	O
Plasma	O
concentrations	O
of	O
ARE	O
activity	O
were	O
measured	O
with	O
simulated	O
body	O
fluid	O
(	O
SBF	O
)	O
as	O
buffer	O
and	O
phenylacetate	O
as	O
substrate	O
at	O
pH	O
7	O
.	O
34	O
–	O
7	O
.	O
4	O
and	O
37	O
°C	O
,	O
as	O
published	O
elsewhere	O
(	O
Nus	O
et	O
al	O
.	O
,	O
2006	O
[	O
31	O
]	O
)	O
.	O
Reaction	O
rates	O
of	O
ARE	O
were	O
followed	O
at	O
270	O
nm	O
in	O
thermostatically	O
controlled	O
10	O
-	O
mm	O
Lightpath	O
quartz	O
cuvettes	O
using	O
a	O
Shimadzu	O
UV	O
-	O
2401PC	O
spectrophotometer	O
(	O
Tokio	O
,	O
Japan	O
)	O
.	O

The	O
final	O
reaction	O
volume	O
in	O
the	O
cuvettes	O
was	O
2	O
.	O
0	O
mL	O
,	O
and	O
the	O
total	O
time	O
was	O
3	O
min	O
.	O
One	O
unit	O
of	O
ARE	O
activity	O
was	O
defined	O
as	O
the	O
mmol	O
phenol	O
formed	O
from	O
phenyl	O
acetate	O
per	O
min	O
.	O
Genomic	O
DNA	O
from	O
WBC	O
was	O
extracted	O
using	O
the	O
Master	O
Pure	O
kit	O
(	O
Epicenter	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
,	O
whose	O
quality	O
was	O
assessed	O
with	O
PicoGreen	O
dsDNA	O
Quantitation	O
Reagent	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
.	O
A	O
total	O
of	O
500	O
ng	O
of	O
DNA	O
was	O
modified	O
by	O
using	O
EZ	O
-	O
96	O
DNA	O
Methylation	O
Kit	O
(	O
Zymo	O
Research	O
Corporation	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
,	O
converting	O
thus	O
cytosine	O
into	O
uracil	O
.	O
Array	O
-	O
based	O
specific	O
DNA	O
methylation	O
analysis	O
was	O
performed	O
with	O
the	O
Infinium	O
Human	O
Methylation	O
450K	O
bead	O
chip	O
technology	O
(	O
Illumina	O
,	O
USA	O
)	O
.	O
Bisulfite	O
-	O
treated	O
genomic	O
DNA	O
was	O
whole	O
-	O
genome	O
amplified	O
,	O
hybridized	O
to	O
HumanMethylation450	O
BeadChips	O
(	O
Illumina	O
,	O
USA	O
)	O
and	O
scanned	O
using	O
the	O
Illumina	O
iScanSQ	O
platform	O
(	O
Mansego	O
et	O
al	O
.	O
,	O
2013	O
[	O
25	O
]	O
)	O
.	O
The	O
intensity	O
of	O
the	O
images	O
was	O
extracted	O
with	O
the	O
GenomeStudio	O
Methylation	O
Software	O
Module	O
(	O
v	O
1	O
.	O
9	O
.	O
0	O
,	O
Illumina	O
,	O
USA	O
)	O
.	O
Eight	O
Cytosine	O
-	O
phosphate	O
-	O
guanine	O
(	O
CpG	O
)	O
sites	O
of	O
the	O
PON1	O
gene	O
that	O
codes	O
for	O
the	O
PON1	O
enzyme	O
were	O
selected	O
.	O
CpG	O
sites	O
located	O
in	O
the	O
transcriptional	O
regulatory	O
region	O
(	O
promoter	O
,	O
5	O
’	O
-	O
untranslated	O
region	O
and	O
exon	O
1	O
)	O
were	O
included	O
(	O
Figure	O
1	O
(	O
Fig	O
.	O
1	O
)	O
)	O
.	O
Reference	O
names	O
and	O
characteristics	O
of	O
the	O
selected	O
CpG	O
sites	O
are	O
shown	O
in	O
Table	O
1	O
(	O
Tab	O
.	O
1	O
)	O
.	O
Results	O
are	O
shown	O
as	O
mean	O
value	O
±	O
standard	O
deviation	O
.	O
Variable	O
distribution	O
was	O
determined	O
by	O
the	O
Shapiro	O
-	O
Wilk	O
test	O
and	O
no	O
normal	O
variables	O
(	O
glucose	O
,	O
HDL	O
-	O
c	O
,	O
LDL	O
-	O
c	O
,	O
TG	O
,	O
ARE	O
and	O
ARE	O
/	O
HDL	O
-	O
c	O
)	O
were	O
logarithmically	O
transformed	O
for	O
statistical	O
purposes	O
.	O
Differences	O
between	O
the	O
beginning	O
and	O
the	O
end	O
of	O
the	O
complete	O
study	O
were	O
analyzed	O
by	O
paired	O
Student	O
t	O
-	O
test	O
.	O

Pearson	O
correlations	O
adjusted	O
for	O
age	O
and	O
sex	O
were	O
fitted	O
to	O
evaluate	O
the	O
potential	O
associations	O
of	O
PON1	O
ARE	O
activity	O
and	O
anthropometric	O
,	O
body	O
composition	O
,	O
blood	O
pressure	O
and	O
biochemical	O
variables	O
,	O
and	O
also	O
to	O
assess	O
the	O
relationships	O
between	O
PON1	O
transcriptional	O
regulatory	O
region	O
methylation	O
and	O
ARE	O
activity	O
and	O
specific	O
dietary	O
factors	O
.	O
Pearson	O
correlations	O
adjusted	O
for	O
sex	O
and	O
age	O
were	O
also	O
used	O
to	O
study	O
the	O
association	O
between	O
the	O
ARE	O
activity	O
and	O
the	O
dietary	O
factors	O
intake	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O
Moreover	O
,	O
multiple	O
testing	O
correction	O
(	O
Benjamini	O
–	O
Hochberg	O
)	O
analyses	O
were	O
performed	O
when	O
appropriate	O
.	O
The	O
SPSS	O
19	O
.	O
0	O
software	O
(	O
SPSS	O
Inc	O
.	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
for	O
Windows	O
XP	O
(	O
Microsoft	O
,	O
USA	O
)	O
was	O
used	O
for	O
statistical	O
analyses	O
.	O
Globally	O
,	O
p	O
<	O
0	O
.	O
050	O
was	O
considered	O
as	O
statistically	O
significant	O
.	O
Information	O
about	O
selected	O
anthropometric	O
and	O
biochemical	O
measurements	O
was	O
recorded	O
at	O
baseline	O
and	O
at	O
day	O
180	O
(	O
Table	O
2	O
(	O
Tab	O
.	O
2	O
)	O
)	O
.	O
After	O
the	O
6	O
-	O
month	O
-	O
long	O
trial	O
,	O
participants	O
presented	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
values	O
concerning	O
anthropometric	O
and	O
body	O
composition	O
variables	O
,	O
such	O
as	O
body	O
weight	O
,	O
BMI	O
,	O
waist	O
circumference	O
,	O
WHR	O
,	O
total	O
fat	O
mass	O
and	O
android	O
fat	O
mass	O
.	O
Volunteers	O
also	O
significantly	O
reduced	O
the	O
SBP	O
,	O
DBP	O
and	O
MBP	O
values	O
as	O
well	O
as	O
the	O
plasma	O
glucose	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
Apo	O
B	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
TG	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
LDL	O
-	O
c	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
HDL	O
-	O
c	O
(	O
p	O
=	O
0	O
.	O
011	O
)	O
values	O
were	O
significantly	O
higher	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O
Plasma	O
TC	O
and	O
ARE	O
activity	O
tended	O
to	O
be	O
reduced	O
,	O
although	O
did	O
not	O
reach	O
significance	O
,	O
while	O
the	O
ARE	O
/	O
HDL	O
-	O
c	O
ratio	O
was	O
significantly	O
decreased	O
(	O
p	O
=	O
0	O
.	O
003	O
)	O
.	O
Pearson	O
correlation	O
analyses	O
adjusted	O
for	O
sex	O
and	O
age	O
were	O
performed	O
to	O
assess	O
the	O
possible	O
associations	O
between	O
the	O
PON1	O
ARE	O
activity	O
and	O
the	O
anthropometric	O
,	O
body	O
composition	O
,	O
blood	O
pressure	O
and	O
biochemical	O
variables	O
.	O

The	O
PON1	O
ARE	O
activity	O
levels	O
significantly	O
correlated	O
with	O
TC	O
(	O
r	O
=	O
0	O
.	O
362	O
,	O
p	O
=	O
0	O
.	O
016	O
)	O
,	O
HDL	O
-	O
c	O
(	O
r	O
=	O
0	O
.	O
346	O
,	O
p	O
=	O
0	O
.	O
021	O
)	O
and	O
Apo	O
B	O
(	O
r	O
=	O
0	O
.	O
446	O
,	O
p	O
=	O
0	O
.	O
002	O
)	O
concentrations	O
,	O
at	O
baseline	O
.	O
Moreover	O
,	O
significant	O
positive	O
associations	O
were	O
found	O
between	O
changes	O
in	O
ARE	O
activity	O
and	O
variation	O
of	O
body	O
weight	O
,	O
BMI	O
,	O
total	O
fat	O
mass	O
,	O
DBP	O
,	O
MBP	O
and	O
plasma	O
TG	O
levels	O
(	O
Table	O
3	O
(	O
Tab	O
.	O
3	O
)	O
)	O
.	O
The	O
association	O
with	O
waist	O
circumference	O
and	O
SBP	O
resulted	O
in	O
a	O
trend	O
towards	O
significance	O
.	O
Some	O
of	O
these	O
relationships	O
should	O
be	O
considered	O
as	O
explorative	O
since	O
after	O
applying	O
a	O
multiple	O
comparison	O
correction	O
,	O
the	O
statistical	O
significance	O
was	O
toned	O
down	O
.	O
Interestingly	O
,	O
in	O
the	O
case	O
of	O
BMI	O
variation	O
,	O
which	O
is	O
one	O
of	O
the	O
main	O
variables	O
,	O
remained	O
statistically	O
associated	O
with	O
the	O
change	O
of	O
PON1	O
ARE	O
activity	O
.	O
At	O
the	O
end	O
of	O
the	O
intervention	O
,	O
the	O
PON1	O
ARE	O
activity	O
measurements	O
showed	O
positive	O
correlations	O
with	O
the	O
intake	O
of	O
the	O
selected	O
antioxidants	O
vitamin	O
C	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
,	O
total	O
tocopherols	O
(	O
p	O
=	O
0	O
.	O
009	O
)	O
and	O
lycopene	O
(	O
p	O
=	O
0	O
.	O
038	O
)	O
recorded	O
by	O
the	O
48h	O
weighed	O
food	O
record	O
(	O
Figure	O
2	O
(	O
Fig	O
.	O
2	O
)	O
)	O
.	O
Interestingly	O
,	O
when	O
assessing	O
the	O
association	O
between	O
the	O
selected	O
CpG	O
sites	O
methylation	O
of	O
the	O
PON1	O
gene	O
and	O
the	O
related	O
ARE	O
activity	O
at	O
baseline	O
(	O
Table	O
4	O
(	O
Tab	O
.	O
4	O
)	O
)	O
,	O
a	O
significant	O
inverse	O
correlation	O
was	O
found	O
concerning	O
the	O
PON1	O
CpG	O
1	O
,	O
CpG	O
2	O
,	O
CpG	O
3	O
and	O
CpG	O
4	O
sites	O
with	O
the	O
enzymatic	O
ARE	O
activity	O
.	O
Moreover	O
,	O
these	O
associations	O
remained	O
significant	O
after	O
applying	O
the	O
Benjamini	O
-	O
Hochberg	O
test	O
for	O
multiple	O
comparisons	O
.	O
Finally	O
,	O
the	O
analysis	O
of	O
the	O
possible	O
relationships	O
between	O
the	O
antioxidant	O
dietary	O
intake	O
and	O
the	O
percentage	O
of	O
methylation	O
of	O
the	O
different	O
PON1	O
gene	O
CpG	O
sites	O
,	O
revealed	O
a	O
correlation	O
between	O
the	O
selected	O
antioxidants	O
:	O
vitamin	O
C	O
,	O
total	O
tocopherols	O
and	O
lycopene	O
and	O
the	O
selected	O
CpG	O
sites	O
at	O
baseline	O
(	O
Figure	O
3	O
(	O
Fig	O
.	O
3	O
)	O
)	O
.	O

The	O
assessment	O
of	O
processes	O
associated	O
to	O
weight	O
loss	O
may	O
contribute	O
to	O
a	O
better	O
understanding	O
of	O
the	O
metabolic	O
and	O
genetic	O
machinery	O
,	O
which	O
will	O
benefit	O
the	O
implementation	O
of	O
personalized	O
dietary	O
treatments	O
.	O
Indeed	O
,	O
as	O
reported	O
in	O
other	O
studies	O
concerning	O
hypocaloric	O
diets	O
(	O
Straznicky	O
et	O
al	O
.	O
,	O
2010	O
[	O
39	O
]	O
)	O
,	O
the	O
energy	O
-	O
restricted	O
intervention	O
proved	O
to	O
be	O
effective	O
in	O
improving	O
MetS	O
abnormalities	O
except	O
for	O
LDL	O
-	O
c	O
,	O
which	O
was	O
higher	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O
This	O
outcome	O
agrees	O
with	O
Clifton	O
et	O
al	O
.	O
who	O
described	O
that	O
in	O
some	O
cases	O
,	O
LDL	O
-	O
c	O
may	O
increase	O
despite	O
weight	O
loss	O
(	O
Clifton	O
et	O
al	O
.	O
,	O
2007	O
[	O
8	O
]	O
)	O
.	O
Nevertheless	O
,	O
Apo	O
B	O
,	O
which	O
has	O
been	O
considered	O
a	O
better	O
predictor	O
of	O
CVD	O
onset	O
than	O
any	O
other	O
lipid	O
measurement	O
(	O
McQueen	O
et	O
al	O
.	O
,	O
2008	O
[	O
27	O
]	O
)	O
,	O
evidenced	O
statistically	O
significant	O
decreased	O
levels	O
.	O
Concerning	O
PON1	O
ARE	O
activity	O
,	O
it	O
seems	O
logical	O
the	O
positive	O
correlation	O
found	O
with	O
the	O
HDL	O
-	O
c	O
levels	O
at	O
baseline	O
since	O
it	O
is	O
an	O
HDL	O
-	O
c	O
related	O
enzyme	O
,	O
as	O
other	O
studies	O
have	O
previously	O
reported	O
(	O
Aksoy	O
et	O
al	O
.	O
,	O
2009	O
[	O
2	O
]	O
;	O
Mascarenhas	O
-	O
Melo	O
et	O
al	O
.	O
,	O
2013	O
[	O
26	O
]	O
;	O
Tabur	O
et	O
al	O
.	O
,	O
2010	O
[	O
40	O
]	O
)	O
.	O
The	O
positive	O
correlation	O
with	O
LDL	O
-	O
c	O
and	O
TC	O
also	O
agree	O
with	O
previous	O
studies	O
(	O
Aksoy	O
et	O
al	O
.	O
,	O
2009	O
[	O
2	O
]	O
;	O
Younis	O
et	O
al	O
.	O
,	O
2013	O
[	O
46	O
]	O
)	O
.	O
The	O
PON1	O
ARE	O
activity	O
was	O
reduced	O
in	O
parallel	O
to	O
some	O
anthropometric	O
(	O
body	O
weight	O
,	O
BMI	O
)	O
,	O
body	O
composition	O
(	O
total	O
fat	O
mass	O
)	O
,	O
blood	O
pressure	O
and	O
biochemical	O
biomarkers	O
(	O
TG	O
)	O
related	O
to	O
the	O
MetS	O
.	O
Although	O
there	O
is	O
scarce	O
research	O
about	O
the	O
relationship	O
of	O
PON1	O
activity	O
and	O
obesity	O
or	O
MetS	O
,	O
the	O
studies	O
carried	O
out	O
point	O
to	O
relate	O
obese	O
/	O
MetS	O
status	O
to	O
lower	O
levels	O
of	O
ARE	O
activity	O
(	O
Ferretti	O
et	O
al	O
.	O
,	O
2012	O
[	O
12	O
]	O
;	O
Kota	O
et	O
al	O
.	O
,	O
2013	O
[	O
20	O
]	O
)	O
.	O
Nevertheless	O
,	O
when	O
it	O
comes	O
to	O
clinical	B-methodology
trials	I-methodology
,	O
in	O
accordance	O
to	O
our	O
results	O
,	O
a	O
significant	O
decrease	O
of	O
ARE	O
activity	O
and	O
serum	O
PON1	O
protein	O
levels	O
after	O
a	O
weight	O
loss	O
intervention	O
,	O
as	O
well	O
as	O
a	O
significant	O
association	O
between	O
reduced	O
PON1	O
and	O
reductions	O
in	O
body	O
fat	O
has	O
been	O
reported	O
(	O
Rector	O
et	O
al	O
.	O
,	O
2007	O
[	O
36	O
]	O
)	O
.	O

Similarly	O
,	O
it	O
has	O
been	O
shown	O
that	O
significant	O
depletions	O
of	O
all	O
metabolic	O
outcomes	O
in	O
addition	O
to	O
a	O
significant	O
reduction	O
of	O
PON1	O
activity	O
correlated	O
with	O
BMI	O
reduction	O
,	O
after	O
a	O
low	O
calorie	O
diet	B-methodology
intervention	I-methodology
(	O
Kotani	O
et	O
al	O
.	O
,	O
2009	O
[	O
21	O
]	O
)	O
.	O
In	O
this	O
last	O
study	O
,	O
a	O
significant	O
association	O
of	O
PON1	O
activity	O
changes	O
and	O
LDL	O
-	O
c	O
depletion	O
was	O
also	O
observed	O
;	O
however	O
,	O
no	O
significant	O
relationships	O
were	O
found	O
in	O
the	O
present	O
experimental	B-methodology
trial	I-methodology
.	O
On	O
the	O
other	O
hand	O
,	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
research	O
that	O
has	O
found	O
an	O
association	O
of	O
ARE	O
activity	O
and	O
TG	O
changes	O
after	O
a	O
dietary	B-methodology
intervention	I-methodology
.	O
With	O
regards	O
to	O
the	O
significant	O
association	O
of	O
PON1	O
activity	O
depletion	O
and	O
reduction	O
of	O
blood	O
pressure	O
levels	O
,	O
it	O
has	O
been	O
reported	O
significantly	O
higher	O
ARE	O
levels	O
in	O
hypertensive	O
than	O
in	O
normotensive	O
children	O
(	O
Akis	O
et	O
al	O
.	O
,	O
2009	O
[	O
1	O
]	O
)	O
,	O
while	O
in	O
other	O
studies	O
carried	O
out	O
in	O
different	O
adult	O
populations	O
no	O
association	O
was	O
found	O
(	O
Tabur	O
et	O
al	O
.	O
,	O
2010	O
[	O
40	O
]	O
;	O
Usta	O
et	O
al	O
.	O
,	O
2011	O
[	O
42	O
]	O
)	O
.	O
However	O
,	O
the	O
studies	O
mentioned	O
above	O
were	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
studies	I-methodology
,	O
while	O
the	O
present	O
work	O
is	O
a	O
clinical	B-methodology
intervention	I-methodology
.	O
Taking	O
into	O
account	O
the	O
previous	O
issues	O
and	O
the	O
lack	O
of	O
research	O
in	O
the	O
area	O
,	O
the	O
findings	O
observed	O
in	O
the	O
present	O
study	O
may	O
indicate	O
that	O
reductions	O
on	O
PON1	O
general	O
activity	O
might	O
be	O
indicative	O
of	O
the	O
improvement	O
in	O
the	O
overall	O
MetS	O
/	O
obese	O
related	O
features	O
,	O
in	O
patients	O
with	O
MetS	O
manifestations	O
under	O
an	O
energy	O
-	O
restricted	O
programme	O
.	O
The	O
activity	O
of	O
PON1	O
is	O
under	O
genetic	O
and	O
environmental	O
regulation	O
(	O
Jarvik	O
et	O
al	O
.	O
,	O
2002	O
[	O
16	O
]	O
)	O
.	O
Within	O
the	O
environmental	O
factors	O
that	O
may	O
alter	O
PON1	O
activity	O
,	O
dietary	O
antioxidants	O
are	O
of	O
major	O
importance	O
,	O
since	O
PON1	O
is	O
an	O
oxidative	O
stress	O
related	O
enzyme	O
(	O
de	O
la	O
Iglesia	O
et	O
al	O
.	O
,	O
2014	O
[	O
10	O
]	O
;	O
Kheir	O
-	O
Eldin	O
et	O
al	O
.	O
,	O
2008	O
[	O
17	O
]	O
)	O
.	O
Among	O
the	O
different	O
antioxidants	O
that	O
can	O
be	O
incorporated	O
in	O
the	O
diet	O
,	O
the	O
antioxidant	O
capacity	O
of	O
vitamins	O
C	O
and	O
E	O
and	O
lycopene	O
is	O
well	O
-	O
established	O
(	O
Chen	O
et	O
al	O
.	O
,	O
2013	O
[	O
6	O
]	O
;	O
Mustacich	O
et	O
al	O
.	O
,	O
2007	O
[	O
30	O
]	O
;	O
Story	O
et	O
al	O
.	O
,	O
2010	O
[	O
38	O
]	O
)	O
.	O

The	O
positive	O
relationships	O
between	O
the	O
ARE	O
activity	O
and	O
the	O
selected	O
antioxidant	O
components	O
reported	O
in	O
the	O
present	O
work	O
may	O
be	O
explained	O
by	O
the	O
capacity	O
of	O
the	O
dietary	O
antioxidants	O
to	O
scavenge	O
free	O
-	O
oxygen	O
radical	O
products	O
that	O
may	O
depress	O
PON1	O
activity	O
,	O
as	O
previous	O
studies	O
have	O
suggested	O
(	O
Jarvik	O
et	O
al	O
.	O
,	O
2002	O
[	O
16	O
]	O
;	O
Tsakiris	O
et	O
al	O
.	O
,	O
2009	O
[	O
41	O
]	O
)	O
.	O
DNA	O
methylation	O
is	O
one	O
of	O
the	O
major	O
epigenetic	O
mechanisms	O
considered	O
to	O
regulate	O
gene	O
expression	O
,	O
together	O
with	O
histone	O
modifications	O
and	O
noncoding	O
RNA	O
activity	O
(	O
Portela	O
et	O
al	O
.	O
,	O
2010	O
[	O
34	O
]	O
)	O
.	O
Methylation	O
of	O
the	O
CpG	O
-	O
rich	O
region	O
(	O
CpG	O
island	O
)	O
overlapping	O
a	O
gene	O
’	O
s	O
promoter	O
is	O
a	O
generally	O
accepted	O
mechanism	O
for	O
silencing	O
expression	O
(	O
Vanderkraats	O
et	O
al	O
.	O
,	O
2013	O
[	O
43	O
]	O
)	O
.	O
Our	O
findings	O
confirm	O
this	O
outcome	O
since	O
four	O
CpG	O
sites	O
and	O
the	O
average	O
methylation	O
of	O
all	O
the	O
CpG	O
sites	O
studied	O
inversely	O
correlated	O
with	O
the	O
ARE	O
activity	O
.	O
About	O
the	O
possible	O
mechanisms	O
by	O
which	O
the	O
dietary	O
antioxidants	O
exert	O
their	O
effects	O
,	O
modulation	O
of	O
gene	O
expression	O
through	O
regulation	O
of	O
DNA	O
methylation	O
is	O
one	O
of	O
the	O
main	O
studied	O
mechanisms	O
(	O
Bartels	O
et	O
al	O
.	O
,	O
2007	O
[	O
4	O
]	O
;	O
Malireddy	O
et	O
al	O
.	O
,	O
2012	O
[	O
24	O
]	O
;	O
Milagro	O
et	O
al	O
.	O
,	O
2009	O
[	O
29	O
]	O
)	O
.	O
In	O
the	O
present	O
work	O
,	O
inverse	O
correlations	O
between	O
dietary	O
vitamin	O
C	O
,	O
total	O
tocopherols	O
and	O
lycopene	O
with	O
different	O
CpG	O
sites	O
methylation	O
was	O
observed	O
,	O
which	O
may	O
influence	O
in	O
the	O
ARE	O
activity	O
as	O
other	O
studies	O
have	O
suggested	O
(	O
Jarvik	O
et	O
al	O
.	O
,	O
2002	O
[	O
16	O
]	O
;	O
Tsakiris	O
et	O
al	O
.	O
,	O
2009	O
[	O
41	O
]	O
)	O
.	O
This	O
work	O
has	O
the	O
limitations	O
that	O
we	O
have	O
not	O
determined	O
PON1	O
methylation	O
levels	O
at	O
the	O
end	O
of	O
the	O
intervention	O
and	O
we	O
have	O
not	O
measured	O
expression	O
levels	O
.	O
However	O
,	O
we	O
found	O
that	O
CpG2	O
and	O
CpG7	O
sites	O
match	O
a	O
core	O
-	O
binding	O
consensus	O
motif	O
for	O
the	O
GATA	O
binding	O
protein	O
1	O
(	O
globin	O
transcription	O
factor	O
1	O
)	O
and	O
CpG2	O
site	O
matches	O
for	O
myeloid	O
zinc	O
finger	O
1	O
(	O
MZF1	O
)	O
,	O
which	O
are	O
known	O
transcriptional	O
regulators	O
for	O
several	O
pathways	O
(	O
Gaboli	O
et	O
al	O
.	O
,	O
2001	O
[	O
14	O
]	O
;	O
Zheng	O
et	O
al	O
.	O
,	O
2010	O
[	O
47	O
]	O
)	O
.	O

Furthermore	O
,	O
some	O
statistical	O
associations	O
concerning	O
changes	O
in	O
PON1	O
ARE	O
activity	O
and	O
anthropometric	O
and	O
biochemical	O
measurements	O
variations	O
were	O
lost	O
after	O
the	O
application	O
of	O
a	O
multiple	O
comparison	O
correction	O
test	O
.	O
In	O
conclusion	O
,	O
the	O
present	O
study	O
reports	O
that	O
ARE	O
activity	O
decreased	O
in	O
parallel	O
with	O
MetS	O
-	O
related	O
markers	O
,	O
while	O
dietary	O
antioxidants	O
intake	O
may	O
enhance	O
the	O
ARE	O
activity	O
by	O
lowering	O
the	O
PON1	O
gene	O
methylation	O
in	O
patients	O
with	O
MetS	O
features	O
,	O
under	O
an	O
energy	O
-	O
restricted	O
intervention	O
.	O
These	O
results	O
suggest	O
that	O
further	O
investigations	O
into	O
PON1	O
activity	O
might	O
be	O
a	O
good	O
target	O
to	O
better	O
understand	O
the	O
metabolic	O
effects	O
of	O
the	O
dietary	B-methodology
intervention	I-methodology
studies	I-methodology
,	O
in	O
which	O
epigenetic	O
processes	O
may	O
be	O
involved	O
.	O
We	O
wish	O
to	O
thank	O
the	O
physician	O
Blanca	O
E	O
.	O
Martinez	O
de	O
Morentin	O
,	O
the	O
nurse	O
Salome	O
Perez	O
,	O
the	O
technician	O
Veronica	O
Ciaurriz	O
and	O
the	O
researcher	O
Paloma	O
Celada	O
for	O
excellent	O
technical	O
assistance	O
as	O
well	O
as	O
the	O
volunteers	O
who	O
participated	O
in	O
this	O
study	O
.	O
This	O
work	O
was	O
supported	O
by	O
Health	O
Department	O
of	O
the	O
Government	O
of	O
Navarra	O
(	O
48	O
/	O
2009	O
)	O
and	O
the	O
Linea	O
Especial	O
about	O
Nutrition	O
,	O
Obesity	O
and	O
Health	O
(	O
University	O
of	O
Navarra	O
LE	O
/	O
97	O
)	O
.	O
Also	O
CIBERobn	O
and	O
RETICS	O
schemes	O
from	O
the	O
isciii	O
are	O
gratefully	O
credited	O
.	O
Carlos	O
III	O
Health	O
Institute	O
provided	O
a	O
predoctoral	O
grant	O
to	O
R	O
.	O
de	O
la	O
Iglesia	O
(	O
n°	O
FI10	O
/	O
00587	O
)	O
.	O
M	O
.	O
L	O
.	O
M	O
.	O
holds	O
a	O
Juan	O
de	O
la	O
Cierva	O
fellowship	O
from	O
Spanish	O
Ministry	O
of	O
Economic	O
and	O
Competitiveness	O
.	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
conflict	O
of	O
interest	O
.	O

Effect	O
of	O
a	O
12	O
-	O
Week	O
Almond	O
-	O
Enriched	O
Diet	O
on	O
Biomarkers	O
of	O
Cognitive	O
Performance	O
,	O
Mood	O
,	O
and	O
Cardiometabolic	O
Health	O
in	O
Older	O
Overweight	O
Adults	O
nuts	O
;	O
alertness	O
;	O
cardiometabolic	O
health	O
;	O
overweight	O
;	O
lipids	O
Long	O
term	O
nut	O
consumption	O
is	O
associated	O
with	O
reduced	O
risk	O
of	O
coronary	O
heart	O
disease	O
and	O
better	O
cognitive	O
function	O
.	O
This	O
study	O
examined	O
supplementing	O
habitual	O
diets	O
with	O
almonds	O
or	O
carbohydrate	O
-	O
rich	O
snack	O
foods	O
(	O
providing	O
15	O
%	O
energy	O
)	O
on	O
biomarkers	O
of	O
cardiovascular	O
and	O
metabolic	O
health	O
,	O
mood	O
and	O
cognitive	O
performance	O
.	O
Participants	O
(	O
overweight	O
/	O
obese	O
,	O
50	O
–	O
80	O
years	O
)	O
were	O
randomised	O
to	O
an	O
almond	O
-	O
enriched	O
diet	O
(	O
AED	O
)	O
or	O
isocaloric	O
nut	O
-	O
free	O
diet	O
(	O
NFD	O
)	O
for	O
12	O
weeks	O
.	O
Body	O
weight	O
,	O
blood	O
lipids	O
,	O
glucose	O
,	O
insulin	O
,	O
blood	O
pressure	O
(	O
BP	O
)	O
,	O
arterial	O
stiffness	O
,	O
cell	O
adhesions	O
molecules	O
,	O
C	O
reactive	O
protein	O
(	O
CRP	O
)	O
,	O
mood	O
,	O
and	O
cognitive	O
performance	O
(	O
working	O
memory	O
primary	O
outcome	O
)	O
,	O
dietary	O
profiles	O
and	O
energy	O
intake	O
/	O
expenditure	O
were	O
measured	O
at	O
baseline	O
and	O
Week	O
12	O
in	O
128	O
participants	O
(	O
n	O
=	O
63	O
AED	O
,	O
n	O
=	O
65	O
NFD	O
)	O
.	O
Compared	O
with	O
NFD	O
,	O
AED	O
was	O
associated	O
with	O
altered	O
macro	O
and	O
micronutrient	O
profiles	O
,	O
but	O
no	O
differences	O
in	O
energy	O
intake	O
or	O
expenditure	O
.	O
The	O
AED	O
significantly	O
reduced	O
triglycerides	O
and	O
SBP	O
but	O
there	O
were	O
no	O
other	O
changes	O
in	O
cardiometabolic	O
biomarkers	O
,	O
mood	O
,	O
or	O
cognitive	O
performance	O
.	O
The	O
inclusion	O
of	O
almonds	O
in	O
the	O
diet	O
improves	O
aspects	O
of	O
cardiometabolic	O
health	O
without	O
affecting	O
cognitive	O
performance	O
or	O
mood	O
in	O
overweight	O
/	O
obese	O
adults	O
.	O
Habitual	O
nut	O
intake	O
has	O
long	O
been	O
associated	O
with	O
cardiovascular	O
benefits	O
including	O
reduced	O
risk	O
of	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
[	O
1	O
]	O
,	O
decreased	O
incidence	O
of	O
metabolic	O
syndrome	O
(	O
MetS	O
)	O
[	O
2	O
]	O
,	O
and	O
decreased	O
risk	O
of	O
type	O
II	O
diabetes	O
[	O
3	O
]	O
.	O
Tree	O
nuts	O
are	O
an	O
important	O
source	O
of	O
nutrients	O
,	O
containing	O
phytochemicals	O
,	O
antioxidants	O
,	O
and	O
a	O
healthy	O
lipid	O
profile	O
(	O
rich	O
in	O
mono	O
and	O
polyunsaturated	O
fatty	O
acids	O
)	O
,	O
all	O
of	O
which	O
are	O
thought	O
to	O
mediate	O
the	O
beneficial	O
cardiovascular	O
and	O
metabolic	O
effects	O
through	O
altered	O
lipid	O
metabolism	O
,	O
antioxidant	O
,	O
and	O
anti	O
-	O
inflammatory	O
mechanisms	O
[	O
4	O
]	O
.	O

Components	O
of	O
MetS	O
,	O
e	O
.	O
g	O
.	O
,	O
hypertension	O
,	O
impaired	O
glucose	O
regulation	O
,	O
dyslipidemia	O
,	O
obesity	O
,	O
and	O
inflammation	O
represent	O
modifiable	O
risk	O
factors	O
for	O
cognitive	O
decline	O
[	O
5	O
]	O
and	O
can	O
impair	O
cognitive	O
function	O
[	O
6	O
]	O
.	O
Improvement	O
in	O
these	O
factors	O
,	O
through	O
dietary	O
change	O
,	O
has	O
been	O
shown	O
to	O
modulate	O
cognitive	O
performance	O
[	O
7	O
]	O
.	O
Nut	O
consumption	O
represents	O
one	O
aspect	O
of	O
nutrition	O
with	O
wide	O
ranging	O
benefits	O
that	O
may	O
counteract	O
these	O
negative	O
influences	O
,	O
including	O
reducing	O
oxidative	O
damage	O
and	O
inflammation	O
,	O
and	O
improving	O
vascular	O
responsiveness	O
[	O
8	O
,	O
9	O
,	O
10	O
]	O
.	O
Improvements	O
in	O
vascular	O
function	O
associated	O
with	O
nut	O
intake	O
are	O
proposed	O
to	O
not	O
only	O
improve	O
cardiovascular	O
health	O
but	O
also	O
contribute	O
to	O
improving	O
cognitive	O
function	O
[	O
11	O
]	O
.	O
Clinical	B-methodology
trials	I-methodology
have	O
found	O
improvements	O
in	O
vascular	O
health	O
following	O
consumption	O
of	O
walnuts	O
[	O
12	O
]	O
,	O
hazelnuts	O
[	O
13	O
]	O
,	O
and	O
almonds	O
[	O
14	O
]	O
,	O
but	O
this	O
has	O
not	O
been	O
a	O
consistent	O
finding	O
in	O
all	O
studies	O
,	O
possibly	O
due	O
to	O
differences	O
in	O
methods	O
of	O
assessing	O
vascular	O
health	O
,	O
differences	O
in	O
populations	O
evaluated	O
,	O
dose	O
,	O
or	O
length	O
of	O
the	O
period	O
of	O
consumption	O
[	O
9	O
,	O
10	O
]	O
.	O
Furthermore	O
,	O
there	O
is	O
now	O
emerging	O
literature	O
to	O
support	O
nut	O
consumption	O
being	O
associated	O
with	O
enhanced	O
cognitive	O
function	O
or	O
reduced	O
cognitive	O
decline	O
[	O
15	O
,	O
16	O
]	O
.	O
Key	O
nutrients	O
found	O
in	O
nuts	O
(	O
and	O
almonds	O
in	O
particular	O
)	O
,	O
including	O
monounsaturated	O
fat	O
[	O
17	O
]	O
and	O
vitamin	O
E	O
[	O
18	O
]	O
have	O
been	O
associated	O
with	O
reduced	O
cognitive	O
decline	O
,	O
and	O
it	O
has	O
been	O
proposed	O
that	O
regular	O
nut	O
consumption	O
may	O
prevent	O
or	O
slow	O
the	O
progressing	O
of	O
age	O
-	O
related	O
brain	O
dysfunction	O
[	O
16	O
,	O
19	O
]	O
.	O
Prospective	B-methodology
/	I-methodology
longitudinal	I-methodology
studies	I-methodology
have	O
demonstrated	O
a	O
positive	O
association	O
between	O
nut	O
consumption	O
and	O
cognitive	O
performance	O
[	O
20	O
,	O
21	O
,	O
22	O
]	O
with	O
a	O
greater	O
effect	O
in	O
those	O
with	O
the	O
highest	O
nut	O
consumption	O
[	O
21	O
]	O
.	O
In	O
addition	O
,	O
prospective	B-methodology
cohort	I-methodology
studies	I-methodology
reported	O
improved	O
cognitive	O
performance	O
and	O
a	O
reduced	O
incidence	O
of	O
cognitive	O
decline	O
when	O
the	O
Mediterranean	O
dietary	O
pattern	O
(	O
with	O
nuts	O
as	O
a	O
key	O
component	O
)	O
was	O
adhered	O
to	O
[	O
23	O
,	O
24	O
]	O
.	O
There	O
have	O
been	O
mixed	O
results	O
from	O
randomized	B-methodology
controlled	I-methodology
trials	I-methodology
assessing	O
the	O
effects	O
of	O
nut	O
intake	O
on	O
cognition	O
.	O
A	O
12	O
week	O
weight	O
loss	O
intervention	O
including	O
almonds	O
found	O
improvements	O
in	O
memory	O
and	O
attention	O
but	O
this	O
was	O
due	O
to	O
weight	O
loss	O
and	O
not	O
almonds	O
,	O
but	O
almonds	O
reduced	O
the	O
post	O
-	O
lunch	O
dip	O
in	O
memory	O
[	O
25	O
]	O
.	O

A	O
cross	B-methodology
-	I-methodology
over	I-methodology
study	I-methodology
in	O
University	O
students	O
consuming	O
60	O
g	O
ground	O
walnuts	O
/	O
d	O
or	O
a	O
nut	O
-	O
free	O
diet	O
each	O
for	O
8	O
weeks	O
found	O
no	O
changes	O
in	O
memory	O
,	O
mood	O
or	O
non	O
-	O
verbal	O
reasoning	O
abilities	O
but	O
did	O
find	O
that	O
walnuts	O
may	O
have	O
the	O
ability	O
to	O
increase	O
inferential	O
reasoning	O
[	O
26	O
]	O
.	O
The	O
WAHA	O
study	O
found	O
no	O
effect	O
of	O
global	O
cognitive	O
composite	O
scores	O
in	O
a	O
healthy	O
older	O
population	O
(	O
split	O
across	O
Spain	O
and	O
America	O
)	O
after	O
2	O
years	O
of	O
including	O
~	O
15	O
%	O
energy	O
from	O
walnuts	O
compared	O
with	O
a	O
walnut	O
-	O
free	O
diet	O
.	O
We	O
have	O
previously	O
shown	O
improvements	O
in	O
short	O
-	O
term	O
memory	O
,	O
verbal	O
fluency	O
,	O
and	O
processing	O
speed	O
when	O
middle	O
-	O
aged	O
to	O
older	O
healthy	O
adults	O
consumed	O
Hi	O
-	O
Oleic	O
peanuts	O
(	O
56	O
–	O
84	O
g	O
/	O
day	O
)	O
for	O
12	O
weeks	O
.	O
There	O
has	O
been	O
one	O
pilot	B-methodology
study	I-methodology
with	O
Brazil	O
nuts	O
in	O
older	O
adults	O
with	O
mild	O
cognitive	O
impairment	O
showing	O
an	O
improvement	O
in	O
verbal	O
fluency	O
and	O
constructional	O
praxis	O
after	O
6	O
months	O
of	O
supplementation	O
with	O
one	O
Brazil	O
nut	O
per	O
day	O
[	O
27	O
]	O
.	O
Cross	B-methodology
-	I-methodology
sectional	I-methodology
analyses	O
of	O
cohort	B-methodology
studies	I-methodology
have	O
observed	O
lower	O
depression	O
scores	O
in	O
habitual	O
nut	O
consumers	O
[	O
28	O
,	O
29	O
]	O
,	O
and	O
one	O
study	O
showed	O
that	O
8	O
weeks	O
of	O
walnut	O
consumption	O
in	O
young	O
healthy	O
non	O
-	O
depressed	O
adult	O
males	O
improved	O
total	O
mood	O
disturbance	O
[	O
30	O
]	O
.	O
It	O
has	O
been	O
proposed	O
that	O
the	O
nutrient	O
profile	O
of	O
nuts	O
may	O
be	O
neuroprotective	O
,	O
and	O
a	O
small	O
number	O
of	O
intervention	B-methodology
studies	I-methodology
have	O
compared	O
the	O
effects	O
of	O
consuming	O
nuts	O
on	O
mood	O
.	O
Co	O
-	O
monitoring	O
cardiometabolic	O
measures	O
with	O
mood	O
and	O
cognition	O
may	O
provide	O
insight	O
into	O
the	O
mechanisms	O
underlying	O
any	O
changes	O
in	O
neurocognitive	O
performance	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
,	O
therefore	O
,	O
to	O
compare	O
an	O
almond	O
-	O
enriched	O
diet	O
with	O
a	O
nut	O
-	O
free	O
diet	O
over	O
12	O
weeks	O
on	O
biomarkers	O
of	O
cardiometabolic	O
health	O
,	O
mood	O
and	O
cognitive	O
performance	O
in	O
overweight	O
/	O
obese	O
middle	O
-	O
aged	O
to	O
older	O
adults	O
.	O
The	O
study	O
was	O
a	O
12	O
week	O
,	O
two	B-methodology
-	I-methodology
arm	I-methodology
,	I-methodology
parallel	I-methodology
-	I-methodology
group	I-methodology
randomised	I-methodology
dietary	I-methodology
intervention	I-methodology
conducted	O
at	O
the	O
University	O
of	O
South	O
Australia	O
Clinical	B-methodology
Research	I-methodology
Facility	O
in	O
Adelaide	O
,	O
Australia	O
between	O
January	O
2016	O
and	O
September	O
2017	O
.	O
The	O
study	O
was	O
approved	O
by	O
the	O
University	O
of	O
South	O
Australia	O
Human	B-methodology
Research	I-methodology
Ethics	O
Committee	O
and	O
registered	O
with	O
the	O
Australian	O
and	O
New	O
Zealand	O
Clinical	B-methodology
Trials	I-methodology
Register	O
(	O
ACTRN12615001294549	O
)	O
.	O

The	O
study	O
was	O
explained	O
in	O
detail	O
and	O
written	B-methodology
informed	I-methodology
consent	I-methodology
was	O
obtained	O
from	O
participants	O
prior	O
to	O
commencing	O
,	O
and	O
the	O
study	O
was	O
conducted	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
.	O
Adults	O
aged	O
50	O
–	O
80	O
years	O
(	O
women	O
postmenopausal	O
)	O
,	O
with	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
25	O
–	O
39	O
.	O
9	O
kg	O
/	O
m2	O
were	O
recruited	O
in	O
Adelaide	O
,	O
Australia	O
through	O
advertisements	O
via	O
newspapers	O
,	O
television	O
,	O
social	O
media	O
,	O
medical	O
centres	O
,	O
public	O
noticeboards	O
,	O
and	O
the	O
University	O
of	O
South	O
Australia	O
website	O
.	O
Interested	O
participants	O
were	O
screened	O
for	O
the	O
following	O
exclusion	B-methodology
criteria	I-methodology
:	O
smoking	O
,	O
diagnosis	O
of	O
diabetes	O
,	O
liver	O
,	O
gastrointestinal	O
or	O
CV	O
disease	O
,	O
uncontrolled	O
hypertension	O
(	O
SBP	O
/	O
DBP	O
>	O
160	O
/	O
100	O
mmHg	O
)	O
,	O
neurological	O
disorders	O
or	O
history	O
of	O
inflammatory	O
brain	O
disease	O
,	O
history	O
of	O
depression	O
or	O
anxiety	O
disorders	O
in	O
past	O
2	O
years	O
,	O
cognitive	O
impairment	O
or	O
memory	O
loss	O
(	O
score	O
<	O
18	O
on	O
the	O
Montreal	O
Cognitive	O
Assessment	O
(	O
MOCA	O
)	O
[	O
31	O
]	O
)	O
,	O
regular	O
nut	O
consumption	O
(	O
>	O
30g	O
per	O
day	O
)	O
,	O
known	O
hypersensitivity	O
or	O
allergy	O
to	O
nuts	O
,	O
were	O
a	O
restrained	O
eater	O
(	O
score	O
≥12	O
on	O
the	O
three	O
factor	O
eating	O
questionnaire	O
[	O
32	O
]	O
)	O
,	O
pregnant	O
or	O
breastfeeding	O
,	O
unstable	O
medications	O
in	O
the	O
past	O
3	O
months	O
,	O
taking	O
vitamin	O
supplements	O
,	O
herbal	O
extracts	O
or	O
illicit	O
drugs	O
.	O
Eligible	O
participants	O
were	O
allocated	O
to	O
one	O
of	O
two	O
groups	O
containing	O
either	O
almonds	O
(	O
almond	O
enriched	O
diet	O
,	O
AED	O
)	O
or	O
a	O
nut	O
-	O
free	O
diet	O
(	O
NFD	O
)	O
which	O
provided	O
energy	O
-	O
matched	O
carbohydrate	O
-	O
rich	O
snack	O
foods	O
.	O
Treatment	O
allocation	O
was	O
performed	O
via	O
minimisation	O
[	O
33	O
]	O
based	O
on	O
age	O
;	O
gender	O
and	O
BMI	O
by	O
an	O
investigator	O
who	O
had	O
no	O
participant	O
contact	O
.	O
All	O
staff	O
involved	O
in	O
data	O
collection	O
,	O
analysis	O
,	O
and	O
statistical	O
analysis	O
were	O
blinded	O
to	O
treatment	O
allocation	O
until	O
after	O
completion	O
of	O
statistical	O
analysis	O
.	O
Whole	O
natural	O
raw	O
almonds	O
(	O
Almond	O
Board	O
of	O
California	O
)	O
were	O
provided	O
to	O
those	O
in	O
the	O
AED	O
group	O
.	O
Participants	O
were	O
asked	O
not	O
to	O
chop	O
or	O
grind	O
them	O
prior	O
to	O
consumption	O
as	O
this	O
may	O
influence	O
the	O
effects	O
of	O
almonds	O
on	O
outcome	O
measures	O
[	O
34	O
]	O
.	O

The	O
NFD	O
group	O
were	O
provided	O
with	O
carbohydrate	O
-	O
rich	O
snack	O
foods	O
(	O
The	O
Original	O
Scotch	O
Finger	O
,	O
Arnott	O
’	O
s	O
Biscuits	O
,	O
North	O
Strathfield	O
,	O
Australia	O
and	O
No	O
Added	O
Salt	O
Potato	O
Chips	O
,	O
Freedom	O
Foods	O
,	O
Taren	O
Point	O
,	O
Australia	O
)	O
which	O
were	O
chosen	O
as	O
they	O
were	O
nut	O
-	O
and	O
seed	O
-	O
free	O
and	O
could	O
achieve	O
the	O
15	O
%	O
energy	O
intake	O
with	O
a	O
manageable	O
portion	O
size	O
.	O
In	O
addition	O
,	O
sweet	O
biscuits	O
and	O
potato	O
chips	O
are	O
a	O
common	O
snack	O
in	O
Australia	O
as	O
well	O
as	O
other	O
countries	O
and	O
the	O
same	O
sweet	O
biscuits	O
have	O
previously	O
been	O
used	O
as	O
a	O
comparator	O
food	O
for	O
almonds	O
as	O
a	O
snack	O
in	O
Australia	O
[	O
35	O
]	O
.	O
At	O
the	O
baseline	O
visit	O
,	O
participants	O
commenced	O
their	O
allocated	O
diet	O
under	O
the	O
supervision	O
of	O
a	O
qualified	O
dietitian	O
and	O
registered	O
nutritionist	O
.	O
Individual	O
estimated	O
energy	O
requirements	O
(	O
EER	O
)	O
were	O
calculated	O
using	O
Harris	O
-	O
Benedict	O
Equations	O
based	O
on	O
sex	O
,	O
age	O
,	O
initial	O
body	O
weight	O
and	O
physical	O
activity	O
[	O
36	O
]	O
.	O
Participants	O
were	O
provided	O
with	O
a	O
portion	O
of	O
snack	O
foods	O
equivalent	O
to	O
~	O
15	O
%	O
of	O
their	O
EER	O
.	O
For	O
the	O
AED	O
group	O
this	O
was	O
calculated	O
to	O
the	O
nearest	O
gram	O
and	O
for	O
the	O
NFD	O
group	O
this	O
was	O
to	O
the	O
nearest	O
½	O
biscuit	O
(	O
or	O
grams	O
for	O
potato	O
chips	O
)	O
for	O
practical	O
reasons	O
.	O
Participants	O
were	O
asked	O
to	O
consume	O
their	O
allocated	O
snack	O
food	O
6	O
days	O
per	O
week	O
for	O
12	O
weeks	O
.	O
All	O
participants	O
attended	O
brief	O
appointments	O
every	O
three	O
weeks	O
where	O
they	O
were	O
weighed	O
to	O
check	O
they	O
were	O
weight	O
stable	O
and	O
to	O
confirm	O
that	O
participants	O
were	O
consuming	O
the	O
snack	O
foods	O
(	O
assessed	O
via	O
daily	O
checklists	O
and	O
via	O
multi	O
-	O
pass	O
24	O
h	O
recalls	O
)	O
and	O
to	O
discuss	O
strategies	O
of	O
how	O
to	O
incorporate	O
the	O
snack	O
foods	O
into	O
their	O
habitual	O
diets	O
.	O
In	O
both	O
groups	O
,	O
participants	O
were	O
advised	O
to	O
substitute	O
snack	O
foods	O
for	O
discretionary	O
foods	O
,	O
not	O
to	O
add	O
foods	O
to	O
their	O
usual	O
diet	O
.	O
Participants	O
were	O
required	O
to	O
return	O
any	O
uneaten	O
test	O
foods	O
so	O
they	O
could	O
be	O
weighed	O
,	O
and	O
compliance	O
assessed	O
.	O
Participants	O
were	O
provided	O
with	O
new	O
test	O
foods	O
every	O
three	O
weeks	O
to	O
ensure	O
freshness	O
.	O
Each	O
clinic	O
visit	O
(	O
Week	O
0	O
and	O
Week	O
12	O
)	O
was	O
conducted	O
in	O
the	O
morning	O
following	O
an	O
overnight	O
fast	O
(	O
ab	O
libitum	O
water	O
allowed	O
)	O
and	O
24	O
h	O
free	O
from	O
alcohol	O
and	O
took	O
approximately	O
2	O
.	O
5	O
h	O
to	O
complete	O
.	O
The	O
same	O
order	O
of	O
testing	O
was	O
followed	O
for	O
each	O
participant	O
on	O
each	O
occasion	O
.	O

If	O
participants	O
habitually	O
took	O
medications	O
(	O
stable	O
dose	O
)	O
in	O
the	O
morning	O
this	O
was	O
noted	O
and	O
the	O
same	O
procedure	O
was	O
followed	O
on	O
both	O
testing	O
occasions	O
.	O
Participants	O
were	O
shown	O
how	O
to	O
weigh	O
/	O
measure	O
and	O
record	O
their	O
dietary	O
intake	O
(	O
digital	O
scales	O
were	O
provided	O
)	O
.	O
Dietary	O
intake	O
was	O
assessed	O
based	O
on	O
the	O
analysis	O
of	O
four	O
days	O
(	O
1	O
weekend	O
day	O
)	O
at	O
the	O
beginning	O
and	O
end	O
of	O
the	O
dietary	B-methodology
intervention	I-methodology
.	O
Analysis	O
was	O
performed	O
using	O
a	O
computerised	O
database	O
(	O
FoodWorks®	O
Professional	O
Edition	O
,	O
version	O
8	O
,	O
2012	O
;	O
Xyris	O
Software	O
,	O
Highgate	O
Hill	O
,	O
Australia	O
)	O
which	O
was	O
the	O
most	O
recent	O
version	O
at	O
time	O
of	O
entry	O
and	O
energy	O
,	O
macro	O
and	O
micronutrient	O
data	O
was	O
derived	O
from	O
the	O
Australian	O
Food	O
and	O
Nutrient	O
(	O
AUSNUT	O
)	O
2011	O
-	O
13	O
food	O
composition	O
database	O
[	O
37	O
]	O
.	O
Established	O
cut	O
offs	O
of	O
<	O
4000	O
kJ	O
or	O
>	O
17	O
,	O
000	O
kJ	O
/	O
day	O
were	O
used	O
to	O
exclude	O
participants	O
suspected	O
of	O
under	O
-	O
or	O
over	O
-	O
estimating	O
daily	O
total	O
energy	O
intake	O
[	O
38	O
]	O
.	O
During	O
the	O
intervention	O
,	O
participants	O
were	O
asked	O
to	O
maintain	O
their	O
normal	O
physical	O
activity	O
patterns	O
.	O
Bouchard	O
’	O
s	O
Physical	O
Activity	O
Record	O
[	O
39	O
]	O
was	O
used	O
to	O
capture	O
activity	O
and	O
derive	O
energy	O
expenditure	O
.	O
Data	O
were	O
collected	O
in	O
the	O
week	O
prior	O
to	O
baseline	O
assessments	O
and	O
in	O
the	O
final	O
week	O
on	O
the	O
intervention	O
,	O
reported	O
in	O
15	O
-	O
min	O
intervals	O
and	O
categorised	O
on	O
a	O
scale	O
of	O
increasing	O
metabolic	O
equivalents	O
(	O
1	O
.	O
0	O
to	O
7	O
.	O
8	O
METs	O
)	O
to	O
give	O
an	O
estimate	O
of	O
daily	O
energy	O
expenditure	O
in	O
kilocalories	O
(	O
kcal	O
/	O
day	O
)	O
.	O
Demographic	O
data	O
collected	O
included	O
age	O
,	O
gender	O
,	O
lipid	O
and	O
blood	O
pressure	O
medication	O
usage	O
,	O
education	O
,	O
socio	O
-	O
economic	O
status	O
,	O
race	O
/	O
ethnicity	O
(	O
Classification	O
from	O
Australian	O
Standard	O
Classification	O
of	O
Cultural	O
&	O
Ethnic	O
Groups	O
2016	O
)	O
,	O
employment	O
and	O
marital	O
status	O
All	O
anthropometric	O
assessments	O
were	O
conducted	O
with	O
participants	O
wearing	O
light	O
clothing	O
and	O
barefoot	O
.	O
Body	O
mass	O
and	O
percentage	O
body	O
fat	O
were	O
measured	O
using	O
calibrated	O
electronic	O
scales	O
(	O
Tanita	O
Ultimate	O
Scale	O
2000	O
;	O
Tokyo	O
,	O
Japan	O
)	O
.	O
Measures	O
of	O
height	O
and	O
waist	O
circumference	O
were	O
assessed	O
as	O
described	O
previously	O
[	O
40	O
]	O
.	O
Body	O
mass	O
index	O
(	O
BMI	O
)	O
was	O
calculated	O
using	O
Quetelet	O
’	O
s	O
index	O
:	O
mass	O
(	O
kg	O
)	O
/	O
height	O
(	O
m	O
)	O
2	O
[	O
41	O
]	O
.	O
All	O
assessments	O
were	O
conducted	O
twice	O
with	O
the	O
average	O
value	O
used	O
in	O
analyses	O
.	O

Cognitive	O
function	O
was	O
tested	O
using	O
the	O
Computerised	O
Mental	O
Performance	O
Assessment	O
System	O
(	O
COMPASS	O
)	O
neuropsychological	O
test	O
battery	O
(	O
Northumbria	O
University	O
)	O
,	O
which	O
has	O
previously	O
been	O
shown	O
to	O
be	O
sensitive	O
to	O
nutritional	O
interventions	O
[	O
42	O
]	O
Tasks	O
were	O
presented	O
on	O
a	O
desktop	O
PC	O
and	O
responses	O
were	O
completed	O
using	O
either	O
a	O
four	O
-	O
button	O
response	O
box	O
or	O
the	O
computer	O
mouse	O
and	O
keyboard	O
depending	O
on	O
the	O
task	O
.	O
For	O
word	O
recall	O
,	O
only	O
pen	O
-	O
and	O
-	O
paper	O
were	O
used	O
.	O
The	O
COMPASS	O
battery	O
was	O
designed	O
to	O
measure	O
the	O
cognitive	O
domains	O
attention	O
,	O
episodic	O
memory	O
,	O
and	O
working	O
memory	O
using	O
the	O
following	O
tasks	O
:	O
Immediate	O
Word	O
Recall	O
,	O
Delayed	O
Word	O
Recall	O
,	O
Word	O
Recognition	O
,	O
Simple	O
Reaction	O
Time	O
,	O
Choice	O
Reaction	O
Time	O
,	O
Numeric	O
Working	O
Memory	O
,	O
Corsi	O
Block	O
,	O
N	O
-	O
Back	O
,	O
Picture	O
Recognition	O
,	O
Serial	O
Subtraction	O
(	O
threes	O
and	O
sevens	O
)	O
,	O
Peg	O
and	O
ball	O
,	O
congruent	O
and	O
incongruent	O
Stroop	O
colour	O
-	O
words	O
,	O
and	O
Rapid	O
Visual	O
Information	O
Processing	O
(	O
RVIP	O
)	O
[	O
43	O
]	O
.	O
Participants	O
were	O
familiarised	O
with	O
the	O
computerised	O
cognitive	O
test	O
battery	O
during	O
screening	O
to	O
eliminate	O
learning	O
effects	O
at	O
the	O
subsequent	O
baseline	O
visits	O
and	O
parallel	O
versions	O
of	O
each	O
task	O
were	O
used	O
for	O
the	O
repeated	O
testing	O
sessions	O
.	O
Composite	O
measures	O
for	O
cognitive	O
outcomes	O
were	O
also	O
calculated	O
.	O
The	O
tasks	O
were	O
grouped	O
based	O
on	O
whether	O
they	O
represented	O
a	O
memory	O
task	O
(	O
immediate	O
and	O
delayed	O
word	O
recall	O
,	O
numeric	O
working	O
memory	O
,	O
word	O
recognition	O
,	O
picture	O
recognition	O
,	O
serial	O
threes	O
and	O
sevens	O
)	O
or	O
an	O
attention	O
task	O
(	O
simple	O
reaction	O
time	O
,	O
choice	O
reaction	O
time	O
,	O
N	O
-	O
back	O
,	O
RVIP	O
)	O
.	O
These	O
were	O
then	O
grouped	O
based	O
on	O
whether	O
they	O
measured	O
accuracy	O
(	O
%	O
accuracy	O
)	O
or	O
reaction	O
time	O
(	O
ms	O
)	O
.	O
This	O
created	O
six	O
composite	O
scores	O
:	O
1Composite	O
score	O
for	O
Attention	O
-	O
Reaction	O
Time	O
(	O
RT	O
)	O
=	O
(	O
zSimple	O
RT	O
+	O
zChoice	O
RT	O
+	O
zFour	O
Choice	O
RT	O
+	O
zRapid	O
Visual	O
Information	O
Processing	O
)	O
/	O
4	O
2Composite	O
score	O
for	O
Attention	O
-	O
Accuracy	O
=	O
(	O
zFour	O
Choice	O
RT	O
+	O
zRapid	O
Visual	O
Information	O
Processing	O
+	O
zSerial	O
subtraction	O
3	O
+	O
zSerial	O
subtraction	O
7	O
)	O
/	O
4	O
3Composite	O
score	O
for	O
Working	O
Memory	O
-	O
RT	O
=	O
(	O
zNumeric	O
Working	O
Memory	O
+	O
zN	O
-	O
back	O
+	O
zCorsi	O
blocks	O
+	O
zRapid	O
Visual	O
Information	O
Processing	O
)	O
/	O
4	O

4Composite	O
score	O
for	O
Working	O
Memory	O
-	O
Accuracy	O
=	O
(	O
zNumeric	O
Working	O
Memory	O
+	O
zN	O
-	O
back	O
+	O
zCorsi	O
blocks	O
+	O
zSerial	O
subtraction	O
3	O
+	O
zSerial	O
subtraction	O
7	O
+	O
zRapid	O
Visual	O
Information	O
Processing	O
)	O
/	O
6	O
5Composite	O
score	O
for	O
Long	O
Term	O
Memory	O
=	O
(	O
zDelayed	O
Word	O
Recall	O
+	O
zDelayed	O
Word	O
Recognition	O
+	O
zDelayed	O
Picture	O
Recognition	O
+	O
zVerbal	O
Fluency	O
+	O
zVerbal	O
Fluency	O
Exclusion	O
)	O
/	O
5	O
6Composite	O
score	O
for	O
Executive	O
Function	O
=	O
(	O
zStroop	O
Congruent	O
correct	O
+	O
zStroop	O
Incongruent	O
correct	O
+	O
zVerbal	O
Fluency	O
+	O
zVerbal	O
Fluency	O
Exclusion	O
+	O
zSerial	O
subtraction	O
3	O
+	O
zSerial	O
subtraction	O
7	O
+	O
zPeg	O
and	O
Ball	O
(	O
accuracy	O
=	O
negatively	O
scored	O
errors	O
)	O
)	O
/	O
7	O
Mood	O
state	O
was	O
assessed	O
with	O
a	O
series	O
of	O
Visual	O
Analogue	O
Scales	O
(	O
VAS	O
;	O
a	O
100	O
mm	O
horizontal	O
line	O
displayed	O
on	O
a	O
computer	O
monitor	O
)	O
,	O
with	O
each	O
endpoint	O
labeled	O
with	O
antonyms	O
(	O
e	O
.	O
g	O
.	O
,	O
‘	O
muzzy	O
’	O
and	O
‘	O
clearheaded	O
’	O
;	O
participants	O
responded	O
using	O
a	O
computer	O
mouse	O
cursor	O
.	O
Three	O
dimensions	O
of	O
mood	O
were	O
assessed	O
(	O
alertness	O
,	O
calmness	O
,	O
and	O
contentment	O
)	O
with	O
16	O
separate	O
Bond	O
-	O
Lader	O
VAS	O
items	O
[	O
44	O
]	O
.	O
and	O
mood	O
states	O
were	O
also	O
evaluated	O
using	O
the	O
Profile	O
of	O
Mood	O
States	O
(	O
POMS	O
)	O
scale	O
[	O
45	O
]	O
.	O
Resting	O
Systolic	O
(	O
SBP	O
)	O
and	O
Diastolic	O
blood	O
pressure	O
(	O
DBP	O
)	O
and	O
small	O
(	O
SAC	O
)	O
and	O
large	O
(	O
LAC	O
)	O
arterial	O
compliance	O
were	O
recorded	O
using	O
the	O
Cardiovascular	O
[UNK]	O
(	O
HDI	O
Cardiovascular	O
Profiler	O
CR2000	O
,	O
Hypertension	O
Diagnostics	O
,	O
Eagan	O
,	O
MN	O
,	O
USA	O
)	O
after	O
participants	O
had	O
been	O
lying	O
supine	O
for	O
5	O
–	O
10	O
min	O
with	O
legs	O
uncrossed	O
[	O
46	O
]	O
.	O
Three	O
consecutive	O
readings	O
were	O
recorded	O
at	O
~	O
2	O
min	O
intervals	O
(	O
with	O
the	O
average	O
used	O
for	O
analysis	O
)	O
by	O
automated	O
oscillometry	O
(	O
blood	O
pressure	O
cuff	O
placed	O
over	O
the	O
left	O
brachial	O
artery	O
)	O
and	O
by	O
placing	O
a	O
tonometer	O
over	O
the	O
right	O
radial	O
artery	O
for	O
blood	O
pressure	O
and	O
pulse	O
wave	O
analysis	O
,	O
respectively	O
.	O
Fasting	O
blood	O
samples	O
(	O
10	O
–	O
12	O
h	O
overnight	O
)	O
were	O
obtained	O
through	O
venipuncture	O
of	O
a	O
forearm	O
vein	O
using	O
the	O
Vacuette®	O
blood	O
collection	O
system	O
.	O

EDTA	O
containing	O
tubes	O
were	O
used	O
to	O
collect	O
plasma	O
for	O
assessing	O
triglycerides	O
,	O
total	O
cholesterol	O
,	O
high	O
-	O
density	O
lipoproteins	O
(	O
HDL	O
-	O
C	O
)	O
insulin	O
,	O
C	O
-	O
reactive	O
protein	O
,	O
VCAM	O
,	O
ICAM	O
,	O
alpha	O
tocopherol	O
.	O
Sodium	O
Fluoride	O
containing	O
tubes	O
were	O
used	O
to	O
collect	O
plasma	O
for	O
assessing	O
glucose	O
.	O
Blood	O
samples	O
were	O
centrifuged	O
(	O
4	O
°C	O
,	O
4000	O
rpm	O
,	O
10	O
min	O
)	O
before	O
the	O
plasma	O
was	O
aliquoted	O
and	O
frozen	O
at	O
−20	O
°C	O
then	O
stored	O
at	O
−80	O
°C	O
.	O
Fasting	O
plasma	O
lipids	O
(	O
triglycerides	O
,	O
total	O
cholesterol	O
,	O
HDL	O
)	O
,	O
glucose	O
and	O
high	O
sensitivity	O
C	O
Reactive	O
protein	O
(	O
CRP	O
)	O
concentrations	O
were	O
determined	O
using	O
a	O
commercial	O
assay	O
kit	O
with	O
a	O
Konelab	O
20XT	O
clinical	O
chemistry	O
analyser	O
(	O
Thermo	O
Fisher	O
Scientific	O
,	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
.	O
C	O
Reactive	O
Protein	O
Values	O
for	O
CRP	O
above	O
3	O
mg	O
/	O
L	O
were	O
excluded	O
as	O
they	O
were	O
considered	O
to	O
reflect	O
low	O
-	O
grade	O
inflammation	O
[	O
47	O
]	O
.	O
Low	O
density	O
lipoprotein	O
cholesterol	O
(	O
LDL	O
-	O
C	O
)	O
was	O
calculated	O
using	O
the	O
Friedewald	O
equation	O
[	O
48	O
]	O
.	O
Fasting	O
plasma	O
insulin	O
concentrations	O
were	O
determined	O
by	O
ELISA	O
(	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
)	O
(	O
Mercodia	O
,	O
Uppsala	O
,	O
Sweden	O
)	O
.	O
Reliability	O
for	O
these	O
assays	O
has	O
been	O
described	O
previously	O
[	O
40	O
]	O
.	O
The	O
HOMA	O
2	O
online	O
calculator	O
was	O
used	O
to	O
derive	O
measures	O
of	O
insulin	O
resistance	O
(	O
HOMA2	O
-	O
IR	O
)	O
,	O
insulin	O
sensitivity	O
(	O
HOMA2	O
-	O
%	O
S	O
)	O
and	O
beta	O
cell	O
function	O
(	O
HOMA2	O
-	O
%	O
B	O
)	O
from	O
fasting	O
glucose	O
and	O
insulin	O
values	O
[	O
49	O
]	O
.	O
Endothelial	O
adhesion	O
molecule	O
concentrations	O
of	O
intercellular	O
adhesion	O
molecule	O
1	O
(	O
ICAM	O
1	O
)	O
and	O
vascular	O
cell	O
adhesion	O
molecule	O
1	O
(	O
VCAM	O
-	O
1	O
)	O
were	O
measured	O
by	O
commercially	O
available	O
ELISA	O
kits	O
(	O
Millipore	O
Human	O
Sepsis	O
Panel	O
1	O
analysed	O
on	O
the	O
Luminex	O
MagPix®	O
plate	O
reader	O
)	O
.	O
Plasma	O
α	O
-	O
tocopherol	O
levels	O
were	O
determined	O
by	O
reverse	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatography	O
based	O
on	O
the	O
method	O
of	O
Turner	O
et	O
al	O
.	O
[	O
50	O
]	O
.	O
The	O
primary	O
outcome	O
measure	O
for	O
this	O
trial	O
was	O
the	O
composite	O
score	O
for	O
working	O
memory	O
-	O
reaction	O
time	O
.	O

Power	O
analysis	O
indicated	O
that	O
a	O
total	O
of	O
68	O
participants	O
per	O
group	O
were	O
required	O
to	O
detect	O
a	O
difference	O
in	O
cognitive	O
function	O
between	O
the	O
two	O
groups	O
that	O
equates	O
to	O
a	O
medium	O
effect	O
size	O
(	O
0	O
.	O
5	O
)	O
,	O
at	O
an	O
α	O
-	O
level	O
of	O
0	O
.	O
05	O
with	O
a	O
statistical	O
power	O
of	O
0	O
.	O
80	O
.	O
An	O
additional	O
15	O
(	O
~	O
10	O
%	O
)	O
were	O
recruited	O
to	O
allow	O
for	O
attrition	O
.	O
Non	O
–	O
normally	O
distributed	O
variables	O
were	O
logarithmically	O
transformed	O
before	O
analysis	O
.	O
Where	O
normality	O
was	O
not	O
achieved	O
,	O
nonparametric	O
methods	O
for	O
analysis	O
were	O
used	O
.	O
Baseline	O
characteristics	O
between	O
groups	O
were	O
assessed	O
by	O
independent	O
student	O
t	O
-	O
tests	O
and	O
chi	O
-	O
squared	O
tests	O
for	O
continuous	O
and	O
categorical	O
variables	O
respectively	O
.	O
An	O
intention	B-methodology
to	I-methodology
treat	I-methodology
analysis	I-methodology
was	O
conducted	O
as	O
the	O
main	O
analysis	O
.	O
Changes	O
over	O
time	O
(	O
weeks	O
0	O
–	O
12	O
)	O
between	O
the	O
intervention	B-methodology
groups	I-methodology
were	O
assessed	O
using	O
a	O
linear	O
mixed	O
effects	O
model	O
with	O
treatment	O
as	O
a	O
between	O
-	O
subject	O
factor	O
,	O
and	O
time	O
as	O
the	O
repeated	O
measurement	O
.	O
Age	O
,	O
sex	O
and	O
BMI	O
were	O
controlled	O
for	O
in	O
the	O
mixed	O
models	O
where	O
appropriate	O
.	O
In	O
addition	O
,	O
sleepiness	O
at	O
the	O
time	O
of	O
the	O
cognitive	O
testing	O
was	O
controlled	O
for	O
when	O
assessing	O
Bond	O
-	O
Lader	O
mood	O
scores	O
.	O
Where	O
there	O
was	O
a	O
significant	O
main	O
effect	O
,	O
Bonferroni	O
post	O
hoc	O
comparisons	O
were	O
performed	O
to	O
determine	O
differences	O
between	O
group	O
means	O
.	O
The	O
number	O
of	O
participants	O
who	O
completed	O
the	O
study	O
with	O
data	O
available	O
for	O
each	O
variable	O
are	O
shown	O
in	O
Table	O
S1	O
.	O
Analyses	O
were	O
also	O
conducted	O
for	O
participants	O
who	O
completed	O
the	O
study	O
irrespective	O
of	O
compliance	O
with	O
data	O
shown	O
in	O
Tables	O
S2	O
–	O
S5	O
.	O
Statistical	O
analyses	O
were	O
performed	O
using	O
SPSS	O
version	O
25	O
.	O
0	O
(	O
SPSS	O
In	O
.	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O
A	O
total	O
of	O
363	O
participants	O
were	O
screened	O
,	O
151	O
were	O
randomised	O
,	O
142	O
completed	O
baseline	O
and	O
128	O
(	O
78	O
females	O
,	O
70	O
males	O
)	O
completed	O
the	O
study	O
(	O
Figure	O
1	O
)	O
.	O
The	O
demographics	O
of	O
participants	O
are	O
shown	O
at	O
baseline	O
in	O
Table	O
1	O
and	O
there	O
were	O
no	O
differences	O
between	O
those	O
in	O
the	O
AED	O
or	O
NFD	O
groups	O
.	O
Those	O
who	O
withdrew	O
after	O
baseline	O
(	O
n	O
=	O
14	O
)	O
were	O
heavier	O
but	O
did	O
not	O
differ	O
in	O
BMI	O
or	O
percent	O
body	O
fat	O
and	O
there	O
were	O
no	O
differences	O
in	O
any	O
measures	O
of	O
mood	O
or	O
cognition	O
between	O
the	O
groups	O
at	O
baseline	O
.	O
Overall	O
energy	O
intake	O
did	O
not	O
differ	O
between	O
the	O
AED	O
and	O
NFD	O
groups	O
(	O
Table	O
2	O
)	O
.	O

However	O
,	O
there	O
was	O
a	O
[UNK]	O
%	O
greater	O
fat	O
intake	O
,	O
predominantly	O
monounsaturated	O
,	O
and	O
polyunsaturated	O
fat	O
and	O
a	O
small	O
reduction	O
in	O
saturated	O
fat	O
.	O
The	O
AED	O
group	O
had	O
a	O
lower	O
intake	O
of	O
energy	O
from	O
carbohydrate	O
and	O
the	O
NFD	O
had	O
a	O
lower	O
intake	O
of	O
fibre	O
(	O
Table	O
2	O
)	O
.	O
Intakes	O
of	O
the	O
following	O
micronutrients	O
were	O
higher	O
when	O
almonds	O
were	O
consumed	O
compared	O
with	O
the	O
NFD	O
:	O
alpha	O
-	O
tocopherol	O
,	O
potassium	O
,	O
magnesium	O
,	O
calcium	O
iron	O
,	O
and	O
riboflavin	O
but	O
there	O
were	O
no	O
significant	O
differences	O
in	O
other	O
nutrients	O
There	O
were	O
no	O
differences	O
in	O
total	O
energy	O
expenditure	O
between	O
the	O
dietary	O
phases	O
(	O
Table	O
2	O
)	O
.	O
Cognition	O
and	O
mood	O
data	O
are	O
summarised	O
in	O
Table	O
3	O
and	O
Table	O
4	O
.	O
There	O
were	O
no	O
significant	O
changes	O
in	O
any	O
measures	O
of	O
individual	O
tests	O
of	O
cognitive	O
performance	O
or	O
in	O
the	O
composite	O
scores	O
for	O
cognition	O
.	O
There	O
was	O
a	O
trend	O
for	O
an	O
improvement	O
in	O
alertness	O
in	O
the	O
AED	O
group	O
compared	O
with	O
the	O
NFD	O
group	O
,	O
but	O
no	O
differences	O
in	O
other	O
measures	O
of	O
mood	O
.	O
Cardiometabolic	O
outcomes	O
are	O
summarised	O
in	O
Table	O
5	O
.	O
There	O
were	O
significant	O
reductions	O
in	O
triglycerides	O
and	O
systolic	O
blood	O
pressure	O
following	O
the	O
AED	O
.	O
There	O
were	O
no	O
significant	O
changes	O
other	O
cardiometabolic	O
biomarkers	O
,	O
circulating	O
alpha	O
-	O
tocopherol	O
levels	O
or	O
body	O
composition	O
.	O
Despite	O
long	B-methodology
term	I-methodology
studies	I-methodology
with	O
regular	O
nut	O
consumption	O
suggesting	O
better	O
cognitive	O
performance	O
[	O
20	O
]	O
,	O
the	O
present	O
study	O
failed	O
to	O
find	O
significant	O
changes	O
in	O
any	O
measure	O
of	O
cognitive	O
performance	O
.	O
It	O
has	O
been	O
hypothesised	O
that	O
a	O
regular	O
nut	O
intake	O
may	O
influence	O
cognitive	O
performance	O
by	O
improving	O
systemic	O
vasodilator	O
function	O
and	O
enhancing	O
vasodilator	O
function	O
in	O
the	O
cerebral	O
arteries	O
[	O
11	O
]	O
.	O
We	O
found	O
no	O
significant	O
difference	O
in	O
attention	O
,	O
memory	O
or	O
executive	O
function	O
between	O
groups	O
nor	O
did	O
we	O
see	O
changes	O
in	O
endothelial	O
cell	O
adhesion	O
molecules	O
or	O
arterial	O
stiffness	O
,	O
suggesting	O
that	O
this	O
hypothesis	O
may	O
not	O
be	O
consistent	O
for	O
all	O
nut	O
types	O
or	O
the	O
length	O
of	O
intervention	O
or	O
dose	O
provided	O
in	O
this	O
study	O
was	O
insufficient	O
to	O
elicit	O
this	O
change	O
.	O
Almond	O
consumption	O
resulted	O
in	O
reductions	O
in	O
triglycerides	O
compared	O
with	O
the	O
NFD	O
group	O
.	O
but	O
there	O
were	O
no	O
significant	O
changes	O
in	O
total	O
,	O
LDL	O
or	O
HDL	O
cholesterol	O
.	O
We	O
did	O
not	O
see	O
any	O
changes	O
in	O
fasting	O
glucose	O
,	O
insulin	O
or	O
insulin	O
resistance	O
(	O
HOMA	O
)	O
.	O

These	O
findings	O
are	O
somewhat	O
in	O
line	O
with	O
previous	O
findings	O
,	O
with	O
systematic	B-methodology
reviews	I-methodology
of	O
randomised	B-methodology
controlled	I-methodology
trials	I-methodology
with	O
various	O
nuts	O
having	O
reported	O
improvements	O
in	O
MetS	O
criteria	O
[	O
51	O
]	O
.	O
Systematic	B-methodology
reviews	I-methodology
focused	O
on	O
almonds	O
[	O
52	O
,	O
53	O
]	O
or	O
a	O
range	O
of	O
tree	O
nuts	O
and	O
peanuts	O
have	O
also	O
found	O
improvements	O
in	O
lipids	O
[	O
54	O
]	O
and	O
insulin	O
resistance	O
(	O
HOMA	O
-	O
IR	O
)	O
[	O
55	O
]	O
and	O
some	O
studies	O
have	O
reported	O
improvements	O
in	O
inflammatory	O
biomarkers	O
[	O
56	O
]	O
.	O
Furthermore	O
,	O
there	O
was	O
a	O
significant	O
reduction	O
in	O
systolic	O
blood	O
pressure	O
in	O
the	O
AED	O
group	O
compared	O
with	O
the	O
NFD	O
group	O
.	O
A	O
previous	O
systematic	B-methodology
review	I-methodology
assessing	O
the	O
effects	O
of	O
nut	O
consumption	O
on	O
blood	O
pressure	O
reported	O
that	O
only	O
some	O
studies	O
found	O
significant	O
changes	O
in	O
blood	O
pressure	O
[	O
57	O
]	O
.	O
There	O
were	O
no	O
significant	O
changes	O
in	O
soluble	O
endothelial	O
adhesion	O
molecules	O
(	O
ICAM	O
or	O
VCAM	O
)	O
,	O
nor	O
changes	O
in	O
small	O
or	O
large	O
arterial	O
stiffness	O
(	O
inverse	O
of	O
arterial	O
compliance	O
used	O
in	O
this	O
study	O
)	O
.	O
A	O
previous	O
study	O
by	O
our	O
group	O
in	O
a	O
similar	O
population	O
using	O
the	O
same	O
measure	O
of	O
arterial	O
compliance	O
found	O
a	O
10	O
%	O
reduction	O
in	O
small	O
arterial	O
compliance	O
,	O
but	O
no	O
change	O
in	O
LAC	O
or	O
blood	O
pressure	O
,	O
following	O
regular	O
peanut	O
consumption	O
that	O
provided	O
15	O
%	O
of	O
total	O
energy	O
for	O
12	O
weeks	O
[	O
58	O
]	O
.	O
A	O
recent	O
review	O
comparing	O
the	O
effects	O
of	O
tree	O
nut	O
and	O
peanut	O
consumption	O
on	O
measures	O
of	O
vascular	O
function	O
excluding	O
flow	O
-	O
mediated	O
dilatation	O
,	O
found	O
a	O
lack	O
of	O
consistency	O
in	O
the	O
literature	O
which	O
may	O
reflect	O
differences	O
in	O
techniques	O
,	O
population	O
or	O
ways	O
nuts	O
have	O
been	O
incorporated	O
into	O
the	O
diet	O
[	O
10	O
]	O
.	O
Animal	O
and	O
cell	O
studies	O
have	O
explored	O
other	O
potential	O
mechanisms	O
of	O
how	O
nuts	O
may	O
improve	O
cognitive	O
performance	O
and	O
these	O
studies	O
have	O
been	O
summarised	O
previously	O
[	O
16	O
]	O
.	O
Proposed	O
mechanisms	O
include	O
reduced	O
damage	O
to	O
polyubiquitinated	O
proteins	O
(	O
a	O
hallmark	O
of	O
neurodegenerative	O
disease	O
)	O
and	O
upregulation	O
of	O
autophagy	O
in	O
the	O
hippocampus	O
which	O
is	O
involved	O
in	O
memory	O
and	O
cognitive	O
performance	O
;	O
and	O
the	O
memory	O
-	O
improving	O
activity	O
of	O
almonds	O
may	O
be	O
attributed	O
to	O
their	O
anticholinesterase	O
,	O
procholinergic	O
,	O
and	O
cholesterol	O
-	O
reducing	O
properties	O
.	O
It	O
is	O
important	O
to	O
consider	O
that	O
much	O
of	O
this	O
evidence	O
has	O
come	O
from	O
animal	B-methodology
models	I-methodology
of	O
ageing	O
or	O
dementia	O
and	O
Alzheimer	O
’	O
s	O
disease	O
and	O
it	O
is	O
unclear	O
how	O
long	O
these	O
changes	O
could	O
take	O
in	O
humans	O
or	O
whether	O
they	O
would	O
be	O
observed	O
at	O
all	O
.	O
The	O
lack	O
of	O
change	O
in	O
measures	O
of	O
mood	O
differs	O
from	O
findings	O
in	O
previous	O
studies	O
.	O

Short	O
term	O
walnut	O
consumption	O
has	O
been	O
shown	O
to	O
improve	O
mood	O
in	O
non	O
-	O
depressed	O
healthy	O
young	O
men	O
[	O
30	O
]	O
and	O
a	O
short	O
term	O
cross	B-methodology
-	I-methodology
over	I-methodology
intervention	I-methodology
with	O
a	O
Mediterranean	O
style	O
diet	O
containing	O
nuts	O
also	O
reported	O
improvements	O
in	O
alertness	O
and	O
contentment	O
compared	O
with	O
habitual	O
diet	O
[	O
59	O
]	O
.	O
It	O
has	O
been	O
suggested	O
that	O
improvements	O
in	O
mood	O
may	O
be	O
associated	O
with	O
a	O
higher	O
consumption	O
of	O
magnesium	O
[	O
60	O
]	O
and	O
whilst	O
the	O
AED	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
magnesium	O
intake	O
this	O
did	O
not	O
result	O
in	O
significant	O
changes	O
in	O
alertness	O
.	O
Over	O
the	O
12	B-methodology
week	I-methodology
intervention	I-methodology
both	O
groups	O
remained	O
weight	O
stable	O
and	O
maintained	O
their	O
energy	O
intake	O
and	O
total	O
energy	O
expenditure	O
.	O
However	O
,	O
we	O
acknowledge	O
that	O
the	O
Bouchard	O
Diary	O
likely	O
overestimated	O
energy	O
expenditure	O
as	O
we	O
have	O
seen	O
previously	O
[	O
61	O
]	O
,	O
despite	O
it	O
being	O
a	O
valid	O
tool	O
for	O
capturing	O
change	O
in	O
activity	O
levels	O
[	O
62	O
]	O
.	O
Consistent	O
with	O
the	O
advice	O
to	O
substitute	O
almonds	O
for	O
discretionary	O
foods	O
in	O
the	O
diet	O
,	O
the	O
AED	O
group	O
had	O
significant	O
increase	O
in	O
monounsaturated	O
fat	O
and	O
dietary	O
alpha	O
tocopherol	O
,	O
suggesting	O
that	O
participants	O
were	O
compliant	O
with	O
consuming	O
almonds	O
.	O
While	O
subtle	O
changes	O
in	O
fibre	O
intake	O
were	O
observed	O
in	O
both	O
groups	O
(	O
1g	O
/	O
d	O
increase	O
AED	O
;	O
3g	O
/	O
d	O
decrease	O
NFD	O
)	O
,	O
average	O
fibre	O
intake	O
was	O
consistent	O
with	O
Australian	O
recommendations	O
[	O
63	O
]	O
.	O
Interest	O
in	O
dietary	O
fibre	O
has	O
increased	O
due	O
to	O
its	O
’	O
potential	O
to	O
modulate	O
the	O
gut	O
microbiota	O
[	O
64	O
]	O
,	O
which	O
may	O
have	O
cognitive	O
effects	O
(	O
[	O
65	O
]	O
)	O
.	O
the	O
quantity	O
of	O
almonds	O
incorporated	O
into	O
the	O
diet	O
in	O
the	O
present	O
study	O
may	O
not	O
have	O
been	O
sufficient	O
,	O
or	O
the	O
substitutions	O
that	O
people	O
made	O
to	O
incorporate	O
almonds	O
into	O
their	O
diet	O
may	O
have	O
been	O
too	O
variable	O
,	O
to	O
achieve	O
positive	O
effects	O
on	O
broader	O
cardiometabolic	O
biomarkers	O
and	O
cognitive	O
performance	O
.	O
Whilst	O
the	O
population	O
in	O
this	O
study	O
were	O
free	O
of	O
diagnosed	O
cardiovascular	O
disease	O
and	O
diabetes	O
,	O
several	O
required	O
medications	O
to	O
control	O
lipid	O
and	O
blood	O
pressure	O
,	O
and	O
the	O
improvements	O
in	O
outcomes	O
associated	O
with	O
the	O
altered	O
diet	O
may	O
have	O
been	O
masked	O
as	O
a	O
result	O
.	O

Furthermore	O
,	O
while	O
we	O
selected	O
people	O
with	O
BMIs	O
in	O
the	O
overweight	O
to	O
obese	O
range	O
as	O
elevated	O
BMI	O
has	O
been	O
associated	O
with	O
lower	O
cognitive	O
performance	O
[	O
66	O
]	O
,	O
the	O
participants	O
in	O
this	O
study	O
did	O
not	O
have	O
cognitive	O
impairments	O
and	O
may	O
have	O
required	O
more	O
substantial	O
dietary	O
changes	O
to	O
see	O
an	O
effect	O
,	O
or	O
the	O
dietary	O
changes	O
in	O
this	O
study	O
may	O
have	O
varied	O
too	O
much	O
within	O
the	O
population	O
to	O
detect	O
a	O
significant	O
group	O
effect	O
,	O
or	O
they	O
may	O
take	O
longer	O
to	O
be	O
observed	O
.	O
Whilst	O
improvement	O
in	O
cerebrovascular	O
and	O
cognitive	O
function	O
have	O
previously	O
been	O
demonstrated	O
with	O
peanuts	O
[	O
58	O
]	O
,	O
that	O
study	O
used	O
a	O
crossover	B-methodology
design	I-methodology
that	O
accounted	O
for	O
between	O
-	O
people	O
variation	O
.	O
The	O
parallel	B-methodology
study	I-methodology
design	I-methodology
used	O
in	O
the	O
present	O
study	O
may	O
have	O
introduced	O
additional	O
variation	O
,	O
despite	O
being	O
adequately	O
powered	O
.	O
In	O
addition	O
,	O
the	O
differences	O
between	O
the	O
nutrient	O
profile	O
of	O
almonds	O
and	O
peanuts	O
may	O
alter	O
cognition	O
differently	O
.	O
In	O
conclusion	O
,	O
this	O
study	O
failed	O
to	O
demonstrate	O
,	O
using	O
a	O
randomised	B-methodology
controlled	I-methodology
intervention	I-methodology
trial	I-methodology
study	I-methodology
design	I-methodology
,	O
that	O
inclusion	O
of	O
almonds	O
in	O
the	O
diet	O
of	O
middle	O
aged	O
to	O
older	O
adults	O
with	O
a	O
BMI	O
in	O
the	O
range	O
for	O
overweight	O
or	O
obesity	O
changed	O
measures	O
of	O
cognition	O
.	O
It	O
may	O
be	O
that	O
a	O
longer	O
time	O
-	O
frame	O
is	O
necessary	O
to	O
see	O
changes	O
in	O
cognitive	O
performance	O
,	O
or	O
that	O
populations	O
experiencing	O
cognitive	O
decline	O
may	O
be	O
more	O
sensitive	O
to	O
changes	O
through	O
dietary	O
manipulation	O
.	O
The	O
authors	O
thank	O
the	O
study	O
participants	O
for	O
their	O
willingness	O
to	O
take	O
part	O
in	O
the	O
study	O
.	O
We	O
gratefully	O
acknowledge	O
the	O
following	O
people	O
for	O
their	O
assistance	O
:	O
Louise	O
Massie	O
for	O
assistance	O
and	O
support	O
with	O
the	O
trial	O
;	O
Kirsty	O
Turner	O
,	O
Paul	O
Ruane	O
,	O
Paul	O
Butler	O
,	O
Susan	O
Ward	O
,	O
Mary	O
Cleary	O
,	O
Grainne	O
Quirke	O
,	O
Christine	O
Chern	O
,	O
Daria	O
Mosberger	O
,	O
and	O
Felicia	O
Matulin	O
for	O
assisting	O
with	O
volunteer	O
screening	O
,	O
data	O
collection	O
and	O
/	O
or	O
data	O
entry	O
.	O
The	O
following	O
are	O
available	O
online	O
at	O
https	O
:	O
/	O
/	O
www	O
.	O
mdpi	O
.	O
com	O
/	O
2072	O
-	O
6643	O
/	O
12	O
/	O
4	O
/	O
1180	O
/	O
s1	O
.	O
Table	O
S1	O
:	O
Number	O
of	O
participants	O
with	O
available	O
data	O
for	O
each	O
outcome	O
variable	O
in	O
the	O
Completers	O
analysis	O
;	O
Table	O
S2	O
:	O
Effect	O
of	O
treatment	O
on	O
dietary	O
nutrient	O
intake	O
and	O
energy	O
expenditure	O
as	O
determined	O
weighed	O
food	O
diaries	O
and	O
activity	O
diaries	O
.	O
Completers	O
analysis	O
,	O
Table	O
S3	O
:	O
Effect	O
of	O
Treatment	O
on	O
cognition	O
.	O
Completers	O
analysis	O
,	O
Table	O
S4	O
:	O
Effect	O
of	O
Treatment	O
on	O
mood	O
.	O

Completers	O
analysis	O
,	O
Table	O
S5	O
Effect	O
of	O
Treatment	O
on	O
Cardiometabolic	O
Parameters	O
.	O
Completers	O
analysis	O
.	O
Conceptualisation	O
,	O
A	O
.	O
M	O
.	O
C	O
.	O
,	O
J	O
.	O
D	O
.	O
B	O
.	O
,	O
A	O
.	O
S	O
.	O
,	O
A	O
.	O
M	O
.	O
H	O
.	O
;	O
data	O
curation	O
,	O
A	O
.	O
M	O
.	O
C	O
.	O
,	O
S	O
.	O
M	O
.	O
,	O
C	O
.	O
Y	O
.	O
,	O
A	O
.	O
M	O
.	O
H	O
.	O
;	O
data	O
interpretation	O
,	O
A	O
.	O
M	O
.	O
C	O
.	O
,	O
S	O
.	O
M	O
.	O
,	O
C	O
.	O
Y	O
.	O
,	O
A	O
.	O
S	O
.	O
,	O
J	O
.	O
D	O
.	O
B	O
.	O
,	O
K	O
.	O
A	O
.	O
D	O
.	O
,	O
A	O
.	O
M	O
.	O
H	O
.	O
,	O
formal	O
analysis	O
,	O
A	O
.	O
M	O
.	O
C	O
.	O
,	O
K	O
.	O
A	O
.	O
D	O
.	O
;	O
writing	O
—	O
original	O
draft	O
preparation	O
,	O
A	O
.	O
M	O
.	O
C	O
.	O
;	O
writing	O
—	O
review	O
and	O
editing	O
,	O
S	O
.	O
M	O
.	O
,	O
J	O
.	O
D	O
.	O
B	O
.	O
,	O
A	O
.	O
S	O
.	O
,	O
K	O
.	O
A	O
.	O
D	O
.	O
,	O
A	O
.	O
M	O
.	O
H	O
.	O
;	O
project	O
administration	O
,	O
A	O
.	O
M	O
.	O
C	O
.	O
;	O
funding	O
acquisition	O
,	O
A	O
.	O
M	O
.	O
C	O
.	O
,	O
J	O
.	O
D	O
.	O
B	O
.	O
,	O
A	O
.	O
S	O
.	O
,	O
A	O
.	O
M	O
.	O
H	O
.	O
All	O
authors	O
have	O
read	O
and	O
agreed	O
to	O
the	O
published	O
version	O
of	O
the	O
manuscript	O
.	O
This	O
research	O
was	O
funded	O
by	O
The	O
Almond	O
Board	O
of	O
California	O
(	O
2015	O
-	O
16	O
)	O
AMC	O
has	O
consulted	O
for	O
Nuts	O
for	O
Life	O
(	O
An	O
initiative	O
of	O
the	O
Australian	O
Tree	O
Nut	O
Industry	O
)	O
.	O
The	O
other	O
authors	O
have	O
no	O
conflicts	O
of	O
interest	O
to	O
declare	O
.	O
The	O
funders	O
had	O
no	O
role	O
in	O
the	O
design	O
of	O
the	O
study	O
;	O
in	O
the	O
collection	O
,	O
analyses	O
,	O
or	O
interpretation	O
of	O
data	O
;	O
in	O
the	O
writing	O
of	O
the	O
manuscript	O
,	O
or	O
in	O
the	O
decision	O
to	O
publish	O
the	O
results	O
.	O

Metagenomic	O
Insights	O
Into	O
the	O
Structure	O
and	O
Function	O
of	O
Intestinal	O
Microbiota	O
of	O
the	O
Hadal	O
Amphipods	O
hadal	O
trench	O
;	O
amphipod	O
;	O
gut	O
microbiota	O
;	O
metagenomics	O
;	O
adaptation	O
Hadal	O
trenches	O
are	O
the	O
deepest	O
known	O
areas	O
of	O
the	O
ocean	O
.	O
Amphipods	O
are	O
considered	O
to	O
be	O
the	O
dominant	O
scavengers	O
in	O
the	O
hadal	O
food	O
webs	O
.	O
The	O
studies	O
on	O
the	O
structure	O
and	O
function	O
of	O
the	O
hadal	O
intestinal	O
microbiotas	O
are	O
largely	O
lacking	O
.	O
Here	O
,	O
the	O
intestinal	O
microbiotas	O
of	O
three	O
hadal	O
amphipods	O
,	O
Hirondellea	O
gigas	O
,	O
Scopelocheirus	O
schellenbergi	O
,	O
and	O
Alicella	O
gigantea	O
,	O
from	O
Mariana	O
Trench	O
,	O
Marceau	O
Trench	O
,	O
and	O
New	O
Britain	O
Trench	O
,	O
respectively	O
,	O
were	O
investigated	O
.	O
The	O
taxonomic	O
analysis	O
identified	O
358	O
microbial	O
genera	O
commonly	O
shared	O
within	O
the	O
three	O
amphipods	O
.	O
Different	O
amphipod	O
species	O
possessed	O
their	O
own	O
characteristic	O
dominant	O
microbial	O
component	O
,	O
Psychromonas	O
in	O
H	O
.	O
gigas	O
and	O
Candidatus	O
Hepatoplasma	O
in	O
A	O
.	O
gigantea	O
and	O
S	O
.	O
schellenbergi	O
.	O
Functional	O
composition	O
analysis	O
showed	O
that	O
“	O
Carbohydrate	O
Metabolism	O
,	O
”	O
“	O
Lipid	O
Metabolism	O
,	O
”	O
“	O
Cell	O
Motility	O
,	O
”	O
“	O
Replication	O
and	O
Repair	O
,	O
”	O
and	O
“	O
Membrane	O
Transport	O
”	O
were	O
among	O
the	O
most	O
represented	O
Gene	O
Ontology	O
(	O
GO	O
)	O
Categories	O
in	O
the	O
gut	O
microbiotas	O
.	O
To	O
test	O
the	O
possible	O
functions	O
of	O
“	O
Bacterial	O
Chemotaxis	O
”	O
within	O
the	O
“	O
Cell	O
Motility	O
”	O
category	O
,	O
the	O
methyl	O
-	O
accepting	O
chemotaxis	O
protein	O
(	O
MCP	O
)	O
gene	O
involved	O
in	O
the	O
“	O
Bacterial	O
Chemotaxis	O
”	O
pathway	O
was	O
obtained	O
and	O
used	O
for	O
swarming	O
motility	O
assays	O
.	O
Results	O
showed	O
that	O
bacteria	O
transformed	O
with	O
the	O
gut	O
bacterial	O
MCP	O
gene	O
showed	O
significantly	O
faster	O
growths	O
compared	O
with	O
the	O
control	B-methodology
group	I-methodology
,	O
suggesting	O
MCP	O
promoted	O
the	O
bacterial	O
swimming	O
capability	O
and	O
nutrient	O
utilization	O
ability	O
.	O
This	O
result	O
suggested	O
that	O
hadal	O
gut	O
microbes	O
could	O
promote	O
their	O
survival	O
in	O
poor	O
nutrient	O
conditions	O
by	O
enhancing	O
chemotaxis	O
and	O
motility	O
.	O

In	O
addition	O
,	O
large	O
quantities	O
of	O
probiotic	O
genera	O
were	O
detected	O
in	O
the	O
hadal	O
amphipod	O
gut	O
microbiotas	O
,	O
which	O
indicated	O
that	O
those	O
probiotics	O
would	O
be	O
possible	O
contributors	O
for	O
promoting	O
the	O
host	O
’	O
s	O
growth	O
and	O
development	O
,	O
which	O
could	O
facilitate	O
adaptation	O
of	O
hadal	O
amphipods	O
to	O
the	O
extreme	O
environment	O
.	O
The	O
hadal	O
zone	O
is	O
the	O
deepest	O
area	O
extending	O
from	O
6	O
,	O
000	O
to	O
11	O
,	O
000	O
m	O
depth	O
from	O
the	O
ocean	O
surface	O
.	O
It	O
breaks	O
the	O
continuity	O
of	O
the	O
abyssal	O
plains	O
and	O
forms	O
long	O
but	O
narrow	O
topographic	O
V	O
-	O
shaped	O
ultra	O
-	O
deep	O
habitats	O
that	O
occupy	O
more	O
than	O
45	O
%	O
of	O
the	O
total	O
vertical	O
depth	O
of	O
the	O
marine	O
environment	O
(	O
Lauro	O
and	O
Bartlett	O
,	O
2008	O
;	O
Jamieson	O
et	O
al	O
.	O
,	O
2009	O
;	O
Jamieson	O
,	O
2015	O
)	O
.	O
In	O
general	O
,	O
the	O
hadal	O
zone	O
is	O
an	O
extreme	O
environment	O
characterized	O
by	O
low	O
temperature	O
,	O
poor	O
food	O
resources	O
,	O
and	O
high	O
hydrostatic	O
pressure	O
(	O
Bartlett	O
,	O
1992	O
)	O
.	O
On	O
the	O
basis	O
of	O
extensive	O
deep	O
-	O
sea	O
sampling	O
records	O
,	O
a	O
wide	O
range	O
of	O
organisms	O
was	O
found	O
populating	O
this	O
extreme	O
environment	O
(	O
Danovaro	O
et	O
al	O
.	O
,	O
2002	O
;	O
Nunoura	O
et	O
al	O
.	O
,	O
2015	O
;	O
Tarn	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
The	O
organisms	O
endemic	O
to	O
hadal	O
zones	O
attract	O
wide	O
interest	O
in	O
the	O
specific	O
types	O
of	O
physiological	O
and	O
biochemical	O
adaptations	O
necessary	O
for	O
growth	O
and	O
survival	O
in	O
the	O
hadal	O
habitats	O
(	O
Wolff	O
,	O
1970	O
;	O
Marquis	O
,	O
1982	O
;	O
Jannasch	O
and	O
Taylor	O
,	O
1984	O
;	O
Wang	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O
However	O
,	O
the	O
survival	O
mechanisms	O
of	O
the	O
hadal	O
organisms	O
are	O
so	O
far	O
poorly	O
understood	O
.	O
With	O
increasing	O
sampling	O
efforts	O
over	O
extensive	O
bathymetric	O
ranges	O
,	O
amphipods	O
(	O
Arthropoda	O
:	O
Crustacea	O
:	O
Amphipoda	O
)	O
are	O
being	O
found	O
to	O
have	O
cosmopolitan	O
distributions	O
and	O
are	O
considered	O
to	O
be	O
the	O
dominant	O
scavengers	O
in	O
the	O
hadal	O
food	O
webs	O
(	O
Eustace	O
et	O
al	O
.	O
,	O
2013	O
;	O
Lacey	O
et	O
al	O
.	O
,	O
2016	O
;	O
Linley	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
The	O
large	O
numbers	O
and	O
wide	O
distributions	O
of	O
amphipods	O
reflect	O
their	O
success	O
in	O
adapting	O
to	O
extreme	O
hadal	O
environments	O
.	O
Hadal	O
amphipods	O
have	O
therefore	O
become	O
the	O
main	O
subjects	O
of	O
hadal	O
environmental	O
adaptation	O
studies	O
in	O
recent	O
years	O
(	O
Ritchie	O
et	O
al	O
.	O
,	O
2015	O
;	O
Eustace	O
et	O
al	O
.	O
,	O
2016	O
;	O
Ritchie	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O

The	O
hadal	O
amphipods	O
have	O
proven	O
to	O
have	O
special	O
mandibles	O
and	O
capacious	O
guts	O
,	O
which	O
are	O
considered	O
to	O
enable	O
them	O
to	O
improve	O
the	O
utilization	O
of	O
sporadic	O
food	O
falls	O
and	O
to	O
be	O
adapted	O
for	O
bursts	O
of	O
feeding	O
activity	O
followed	O
by	O
prolonged	O
periods	O
of	O
digestion	O
and	O
fasting	O
(	O
Ingram	O
and	O
Hessler	O
,	O
1983	O
;	O
Saint	O
-	O
Marie	O
,	O
1992	O
)	O
.	O
This	O
lifestyle	O
is	O
thought	O
to	O
serve	O
as	O
an	O
energy	O
storage	O
mechanism	O
in	O
hadal	O
amphipods	O
and	O
has	O
been	O
speculated	O
to	O
resist	O
long	O
periods	O
of	O
food	O
deprivation	O
in	O
the	O
hadal	O
environment	O
(	O
Buhring	O
and	O
Christiansen	O
,	O
2001	O
)	O
.	O
The	O
gut	O
microbiota	O
has	O
been	O
shown	O
to	O
be	O
involved	O
with	O
a	O
number	O
of	O
aspects	O
of	O
host	O
physiology	O
,	O
such	O
as	O
upgrading	O
the	O
nutrient	O
status	O
,	O
developing	O
of	O
host	O
immune	O
system	O
,	O
and	O
enhancing	O
the	O
ability	O
of	O
environmental	O
adaptation	O
in	O
various	O
organisms	O
(	O
Gil	O
et	O
al	O
.	O
,	O
2004	O
;	O
Dugas	O
et	O
al	O
.	O
,	O
2016	O
;	O
Zhang	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Specifically	O
,	O
the	O
presence	O
of	O
various	O
bacteria	O
in	O
the	O
guts	O
of	O
hadal	O
invertebrates	O
was	O
proven	O
to	O
enhance	O
the	O
digestion	O
of	O
refractory	O
organic	O
compounds	O
,	O
which	O
presumably	O
provided	O
another	O
source	O
of	O
energy	O
for	O
amphipod	O
individuals	O
(	O
Fang	O
et	O
al	O
.	O
,	O
2000	O
,	O
2003	O
)	O
.	O
Microorganisms	O
,	O
besides	O
providing	O
continuous	O
energy	O
for	O
the	O
hadal	O
host	O
,	O
can	O
also	O
contribute	O
specific	O
essential	O
nutrients	O
,	O
such	O
as	O
large	O
quantities	O
of	O
essential	O
fatty	O
acids	O
,	O
essential	O
amino	O
acids	O
,	O
and	O
important	O
secondary	O
metabolites	O
(	O
Phillips	O
,	O
1984	O
;	O
Monica	O
et	O
al	O
.	O
,	O
2008	O
;	O
Shulse	O
and	O
Allen	O
,	O
2011	O
)	O
.	O
Psychrophilic	O
and	O
piezophilic	O
bacteria	O
have	O
been	O
reported	O
to	O
be	O
isolated	O
from	O
the	O
guts	O
of	O
deep	O
-	O
sea	O
invertebrates	O
in	O
recent	O
researches	O
(	O
Forget	O
and	O
Juniper	O
,	O
2013	O
;	O
Goffredi	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O
For	O
example	O
,	O
Hepatoplasma	O
spp	O
.	O
,	O
as	O
a	O
vast	O
genus	O
of	O
deep	O
-	O
sea	O
bacteria	O
,	O
has	O
been	O
proven	O
to	O
improve	O
host	O
survival	O
under	O
low	O
nutrient	O
conditions	O
in	O
hadal	O
zones	O
(	O
Fraune	O
and	O
Zimmer	O
,	O
2008	O
)	O
.	O

In	O
studies	O
on	O
biological	O
mechanisms	O
of	O
adaptation	O
to	O
extreme	O
conditions	O
,	O
some	O
microorganisms	O
,	O
especially	O
deep	O
-	O
sea	O
bacteria	O
such	O
as	O
Shewanella	O
,	O
Photobacterium	O
,	O
Colwellia	O
,	O
Vibrio	O
,	O
and	O
Psychromonas	O
,	O
have	O
been	O
shown	O
to	O
produce	O
polyunsaturated	O
fatty	O
acids	O
,	O
which	O
might	O
play	O
a	O
vital	O
role	O
in	O
low	O
-	O
temperature	O
and	O
high	O
-	O
pressure	O
environments	O
by	O
resulting	O
increase	O
in	O
membrane	O
fluidity	O
(	O
DeLong	O
and	O
Yayanos	O
,	O
1986	O
;	O
Fang	O
et	O
al	O
.	O
,	O
2004	O
;	O
Nogi	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O
Metagenomics	O
is	O
the	O
study	O
of	O
the	O
collective	O
genomes	O
of	O
microorganisms	O
present	O
in	O
an	O
environment	O
.	O
Under	O
recent	O
advances	O
in	O
high	O
throughput	O
sequencing	O
,	O
metagenomic	O
analysis	O
has	O
become	O
a	O
more	O
feasible	O
technology	O
to	O
broaden	O
and	O
advance	O
our	O
ability	O
to	O
understand	O
complex	O
microbial	O
communities	O
and	O
the	O
association	O
between	O
microbial	O
communities	O
and	O
specific	O
environmental	O
factors	O
(	O
Gurgui	O
and	O
Piel	O
,	O
2010	O
;	O
Burke	O
et	O
al	O
.	O
,	O
2011	O
;	O
Nemergut	O
et	O
al	O
.	O
,	O
2013	O
;	O
Louca	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Not	O
much	O
is	O
known	O
about	O
the	O
ecology	O
and	O
evolution	O
of	O
these	O
hadal	O
bacteria	O
,	O
and	O
information	O
about	O
the	O
structure	O
and	O
function	O
of	O
the	O
hadal	O
macro	O
-	O
organisms	O
’	O
intestinal	O
microbiotas	O
are	O
lacking	O
.	O
The	O
main	O
objectives	O
of	O
this	O
study	O
were	O
to	O
explore	O
the	O
total	O
bacterial	O
community	O
and	O
functional	O
diversity	O
associated	O
with	O
the	O
guts	O
of	O
three	O
different	O
hadal	O
amphipods	O
by	O
using	O
the	O
Illumina	O
NovaSeq	O
platform	O
,	O
aiming	O
to	O
provide	O
supporting	O
evidence	O
of	O
adaptive	O
functions	O
of	O
the	O
gut	O
microbiota	O
in	O
hadal	O
amphipods	O
.	O
Three	O
species	O
of	O
amphipods	O
,	O
Hirondellea	O
gigas	O
,	O
Scopelocheirus	O
schellenbergi	O
,	O
and	O
Alicella	O
gigantea	O
,	O
were	O
collected	O
from	O
the	O
Mariana	O
Trench	O
,	O
Marceau	O
Trench	O
,	O
and	O
New	O
Britain	O
Trench	O
,	O
respectively	O
(	O
Figure	O
1	O
)	O
.	O
The	O
autonomous	O
deep	O
-	O
ocean	O
lander	O
vehicle	O
was	O
equipped	O
with	O
two	O
cage	O
traps	O
baited	O
with	O
a	O
suitable	O
amount	O
of	O
mackerels	O
.	O
The	O
lander	O
vehicle	O
was	O
launched	O
from	O
the	O
“	O
Zhang	O
Jian	O
”	O
research	O
vessel	O
and	O
deployed	O
to	O
the	O
seafloor	O
for	O
up	O
to	O
10	O
h	O
.	O
The	O
detailed	O
information	O
about	O
the	O
lander	O
vehicle	O
and	O
sampling	O
was	O
described	O
in	O
Chan	O
et	O
al	O
.	O
(	O
2020	O
)	O
.	O
Upon	O
recovery	O
of	O
the	O
lander	O
,	O
amphipods	O
were	O
preserved	O
immediately	O
at	O
–	O
80°C	O
until	O
processed	O
for	O
analysis	O
.	O

DNA	O
for	O
metagenomics	O
was	O
extracted	O
from	O
nine	O
amphipods	O
intestinal	O
mucous	O
samples	O
(	O
three	O
individuals	O
of	O
each	O
amphipod	O
species	O
)	O
by	O
using	O
the	O
FastDNA®	O
SPIN	O
Kit	O
for	O
Feces	O
(	O
MP	O
Biomedicals	O
,	O
Santa	O
Ana	O
,	O
CA	O
,	O
United	O
States	O
)	O
according	O
to	O
manufacturer	O
’	O
s	O
protocols	O
.	O
Concentration	O
and	O
purity	O
were	O
quantified	O
with	O
TBS	O
-	O
380	O
and	O
NanoDrop2000	O
,	O
respectively	O
.	O
DNA	O
quality	O
was	O
detected	O
by	O
a	O
1	O
%	O
agarose	O
gel	O
electrophoresis	O
system	O
to	O
ensure	O
no	O
degradation	O
of	O
genome	O
DNA	O
.	O
DNA	O
extracts	O
were	O
fragmented	O
to	O
an	O
average	O
size	O
of	O
approximately	O
300	O
bp	O
using	O
Covaris	O
M220	O
(	O
Gene	O
Company	O
Limited	O
,	O
China	O
)	O
for	O
paired	O
-	O
end	O
library	O
construction	O
.	O
A	O
paired	O
-	O
end	O
library	O
was	O
constructed	O
using	O
NEXTFLEX®	O
Rapid	O
DNA	O
-	O
Seq	O
(	O
Bioo	O
Scientific	O
,	O
Austin	O
,	O
TX	O
,	O
United	O
States	O
)	O
.	O
Adapters	O
containing	O
the	O
full	O
complement	O
of	O
sequencing	O
primer	O
hybridization	O
sites	O
were	O
ligated	O
to	O
the	O
blunt	O
-	O
end	O
of	O
fragments	O
.	O
Paired	O
-	O
end	O
sequencing	O
was	O
performed	O
on	O
Illumina	O
NovaSeq	O
(	O
Illumina	O
Inc	O
.	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
United	O
States	O
)	O
at	O
Majorbio	O
Bio	O
-	O
Pharm	O
Technology	O
Co	O
.	O
,	O
Ltd	O
.	O
,	O
(	O
Shanghai	O
,	O
China	O
)	O
using	O
NovaSeq	O
Reagent	O
Kits	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions1	O
.	O
Sequence	O
data	O
associated	O
with	O
this	O
project	O
have	O
been	O
deposited	O
in	O
the	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
(	O
NCBI	O
)	O
Sequence	O
Read	O
Archive	O
(	O
SRA	O
)	O
database	O
(	O
BioProject	O
accession	O
number	O
:	O
PRJNA648173	O
;	O
SRA	O
accession	O
number	O
:	O
SRR12315170	O
-	O
SRR12315178	O
)	O
.	O
Adapter	O
sequences	O
were	O
stripped	O
from	O
the	O
3	O
′	O
and	O
5	O
′	O
end	O
of	O
paired	O
-	O
end	O
Illumina	O
reads	O
using	O
SeqPrep2	O
.	O
Low	O
-	O
quality	O
reads	O
(	O
reads	O
with	O
N	O
bases	O
,	O
a	O
minimum	O
length	O
threshold	O
of	O
50	O
bp	O
,	O
and	O
a	O
minimum	O
quality	O
threshold	O
of	O
20	O
)	O
were	O
removed	O
by	O
Sickle3	O
.	O
Reads	O
were	O
aligned	O
to	O
an	O
available	O
amphipod	O
(	O
Hyalella	O
Azteca	O
)	O
genome4	O
by	O
BWA	O
(	O
Li	O
and	O
Durbin	O
,	O
2009	O
)	O
(	O
5	O
,	O
version	O
0	O
.	O
7	O
.	O
9a	O
)	O
,	O
and	O
any	O
hit	O
associated	O
with	O
the	O
reads	O
and	O
their	O
mated	O
reads	O
were	O
removed	O
.	O

Succinct	O
de	O
bruijn	O
-	O
graph	O
-	O
based	O
assembler	O
MEGAHIT	O
(	O
Li	O
et	O
al	O
.	O
,	O
2015	O
)	O
(	O
6	O
,	O
Version	O
1	O
.	O
1	O
.	O
2	O
)	O
(	O
parameters	O
:	O
kmer	O
_	O
min	O
=	O
47	O
,	O
kmer	O
_	O
max	O
=	O
97	O
,	O
step	O
=	O
10	O
)	O
was	O
used	O
to	O
assemble	O
short	O
reads	O
at	O
different	O
sequencing	O
depths	O
.	O
K	O
-	O
mers	O
,	O
using	O
iterations	O
of	O
reads	O
47	O
to	O
97	O
bp	O
in	O
length	O
,	O
were	O
tested	O
for	O
each	O
sample	O
.	O
Scaffolds	O
with	O
a	O
length	O
of	O
more	O
than	O
500	O
bp	O
were	O
retained	O
for	O
statistical	O
tests	O
.	O
We	O
evaluated	O
the	O
quality	O
and	O
quantity	O
of	O
scaffolds	O
generated	O
by	O
each	O
assembly	O
and	O
finally	O
chose	O
the	O
best	O
K	O
-	O
mer	O
that	O
yielded	O
the	O
minimum	O
scaffold	O
number	O
and	O
the	O
maximum	O
value	O
of	O
N50	O
and	O
N90	O
.	O
Then	O
,	O
scaffolds	O
with	O
a	O
length	O
of	O
more	O
than	O
500	O
bp	O
were	O
extracted	O
and	O
broken	O
into	O
contigs	O
without	O
gaps	O
.	O
Contigs	O
were	O
used	O
for	O
further	O
gene	O
prediction	O
and	O
annotation	O
.	O
Open	O
reading	O
frames	O
(	O
ORFs	O
)	O
from	O
the	O
assembled	O
contigs	O
were	O
predicted	O
using	O
MetaGene	O
(	O
Noguchi	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O
Genes	O
with	O
nucleic	O
acid	O
length	O
≥	O
100	O
bp	O
were	O
selected	O
and	O
translated	O
into	O
an	O
amino	O
acid	O
sequence	O
to	O
obtain	O
the	O
gene	O
prediction	O
results	O
of	O
each	O
sample	O
by	O
using	O
the	O
NCBI	O
translation	O
table7	O
.	O
All	O
predicted	O
genes	O
with	O
a	O
95	O
%	O
sequence	O
identity	O
(	O
90	O
%	O
coverage	O
)	O
were	O
clustered	O
using	O
CD	O
-	O
HIT	O
(	O
Fu	O
et	O
al	O
.	O
,	O
2012	O
)	O
(	O
8	O
,	O
version	O
4	O
.	O
6	O
.	O
1	O
)	O
.	O
The	O
longest	O
sequences	O
from	O
each	O
cluster	O
were	O
selected	O
as	O
representative	O
sequences	O
to	O
construct	O
a	O
non	O
-	O
redundant	O
gene	O
catalog	O
.	O
Reads	O
after	O
quality	B-methodology
control	I-methodology
(	O
length	O
threshold	O
is	O
greater	O
than	O
50	O
bp	O
and	O
quality	O
threshold	O
is	O
greater	O
than	O
20	O
)	O
were	O
mapped	O
to	O
the	O
representative	O
sequences	O
with	O
95	O
%	O
identity	O
using	O
SOAPaligner	O
(	O
Li	O
et	O
al	O
.	O
,	O
2008	O
)	O
(	O
version	O
2	O
.	O
21	O
)	O
,	O
and	O
gene	O
abundance	O
for	O
each	O
sample	O
was	O
evaluated	O
.	O
Read	O
counts	O
were	O
normalized	O
by	O
the	O
method	O
of	O
reads	O
per	O
kilobase	O
per	O
million	O
mapped	O
reads	O
.	O
Representative	O
sequences	O
of	O
non	O
-	O
redundant	O
gene	O
catalog	O
were	O
aligned	O
to	O
NCBI	O
NR	O
database	O
with	O
an	O
e	O
-	O
value	O
cutoff	O
of	O
1e	O
-	O
5	O
using	O
BlastP	O
(	O
9	O
,	O
version	O
2	O
.	O
2	O
.	O
28	O
+	O
)	O
(	O
Altschul	O
et	O
al	O
.	O
,	O
1997	O
)	O
for	O
taxonomic	O
annotations	O
.	O

The	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
(	O
KEGG	O
)	O
and	O
probiotics	O
annotation	O
were	O
conducted	O
using	O
BlastP	O
against	O
the	O
KEGG	O
database	O
(	O
Xie	O
et	O
al	O
.	O
,	O
2011	O
)	O
(	O
10	O
,	O
version	O
96	O
.	O
0	O
)	O
and	O
Probio	O
database	O
with	O
an	O
e	O
-	O
value	O
cutoff	O
of	O
1e	O
-	O
5	O
,	O
respectively	O
.	O
Methyl	O
-	O
accepting	O
chemotaxis	O
protein	O
(	O
MCP	O
)	O
complete	O
sequences	O
of	O
the	O
microorganisms	O
were	O
obtained	O
in	O
NCBI	O
databases	O
by	O
blasting	O
,	O
and	O
16	O
related	O
sequences	O
were	O
downloaded	O
.	O
Sequence	O
alignments	O
were	O
generated	O
using	O
Clustal	O
W	O
and	O
then	O
imported	O
into	O
MEGA	O
X	O
software	O
for	O
phylogenetic	O
analysis	O
using	O
the	O
maximum	O
likelihood	O
method	O
with	O
a	O
bootstrap	O
replication	O
number	O
of	O
1	O
,	O
000	O
.	O
Protein	O
sequences	O
of	O
these	O
MCPs	O
were	O
downloaded	O
from	O
NCBI	O
and	O
compared	O
using	O
the	O
Clustal	O
W	O
program	O
.	O
Simple	O
Modular	O
Architecture	O
Research	O
Tool11	O
was	O
used	O
to	O
predict	O
protein	O
domains	O
.	O
The	O
MCP	O
with	O
perfect	O
ORF	O
was	O
obtained	O
from	O
the	O
predicted	O
ORFs	O
of	O
our	O
metagenomic	O
dataset	O
and	O
was	O
subsequently	O
used	O
in	O
swarming	O
motility	O
assays	O
.	O
The	O
sequence	O
of	O
the	O
MCP	O
gene	O
has	O
been	O
deposited	O
into	O
the	O
NCBI	O
with	O
GenBank	O
accession	O
number	O
:	O
MT792534	O
.	O
The	O
MCP	O
recombinant	O
expression	O
plasmids	O
were	O
constructed	O
using	O
pET	O
-	O
32a	O
vector	O
(	O
TIANGEN	O
,	O
China	O
)	O
with	O
restriction	O
endonucleases	O
EcoR	O
I	O
and	O
Not	O
I	O
(	O
TAKARA	O
,	O
Japan	O
)	O
and	O
then	O
checked	O
by	O
DNA	O
sequencing	O
and	O
restriction	O
enzyme	O
digestion	O
.	O
For	O
the	O
expression	O
of	O
the	O
MCP	O
proteins	O
,	O
the	O
recombinant	O
expression	O
plasmids	O
were	O
transformed	O
into	O
Escherichia	O
coli	O
BL21	O
(	O
DE3	O
)	O
competent	O
cells	O
(	O
TIANGEN	O
,	O
China	O
)	O
.	O
Positive	O
transformants	O
were	O
picked	O
from	O
single	O
colonies	O
on	O
Luria	O
–	O
Bertani	O
(	O
LB	O
)	O
plates	O
and	O
grown	O
overnight	O
at	O
37°C	O
in	O
15	O
ml	O
of	O
LB	O
medium	O
with	O
30	O
μg	O
/	O
ml	O
kanamycin	O
.	O

The	O
cultured	O
cells	O
were	O
then	O
inoculated	O
to	O
20	O
-	O
ml	O
fresh	O
LB	O
medium	O
(	O
1	O
:	O
50	O
dilution	O
)	O
containing	O
50	O
μg	O
/	O
ml	O
of	O
kanamycin	O
at	O
37°C	O
until	O
the	O
optical	O
density	O
of	O
the	O
sample	O
measured	O
at	O
a	O
wavelength	O
of	O
600	O
nm	O
values	O
reached	O
0	O
.	O
6	O
,	O
followed	O
by	O
the	O
addition	O
of	O
isopropyl	O
-	O
β	O
-	O
D	O
-	O
1	O
-	O
thiogalactopyranoside	O
(	O
IPTG	O
)	O
(	O
TIANGEN	O
,	O
China	O
)	O
to	O
the	O
final	O
concentration	O
of	O
1	O
mM	O
to	O
induce	O
the	O
expression	O
of	O
MCP	O
proteins	O
.	O
Recombinant	O
MCP	O
expressions	O
were	O
tested	O
by	O
western	O
blot	O
analysis	O
using	O
anti	O
-	O
6	O
×	O
His	O
tag	O
(	O
1	O
:	O
3	O
,	O
000	O
,	O
BBI	O
Biotech	O
,	O
Germany	O
)	O
.	O
Swarming	O
motility	O
assays	O
were	O
carried	O
out	O
with	O
soft	O
agar	O
plates	O
(	O
Sarand	O
et	O
al	O
.	O
,	O
2008	O
)	O
with	O
soft	O
agar	O
plates	O
containing	O
0	O
.	O
5	O
%	O
agarose	O
,	O
1	O
%	O
sodium	O
chloride	O
,	O
50	O
μg	O
/	O
ml	O
kanamycin	O
,	O
and	O
1	O
-	O
mM	O
IPTG	O
in	O
gradient	O
nutrient	O
mediums	O
.	O
Mediums	O
with	O
five	O
different	O
nutrient	O
concentrations	O
were	O
used	O
in	O
current	O
assays	O
,	O
which	O
were	O
100	O
%	O
(	O
contains	O
1	O
%	O
peptone	O
,	O
0	O
.	O
5	O
%	O
yeast	O
extract	O
)	O
,	O
80	O
%	O
(	O
contains	O
0	O
.	O
8	O
%	O
peptone	O
,	O
0	O
.	O
4	O
%	O
yeast	O
extract	O
)	O
,	O
60	O
%	O
(	O
contains	O
0	O
.	O
6	O
%	O
peptone	O
,	O
0	O
.	O
3	O
%	O
yeast	O
extract	O
)	O
,	O
40	O
%	O
(	O
contains	O
0	O
.	O
4	O
%	O
peptone	O
,	O
0	O
.	O
2	O
%	O
yeast	O
extract	O
)	O
,	O
and	O
20	O
%	O
(	O
contains	O
0	O
.	O
2	O
%	O
peptone	O
,	O
0	O
.	O
1	O
%	O
yeast	O
extract	O
)	O
.	O
Bacterial	O
cells	O
induced	O
by	O
IPTG	O
from	O
LB	O
cultures	O
were	O
inoculated	O
into	O
the	O
solidified	O
agar	O
and	O
incubated	O
at	O
26°C	O
for	O
20	O
h	O
,	O
followed	O
by	O
image	O
collection	O
.	O
Nine	O
DNA	O
samples	O
extracted	O
from	O
the	O
intestinal	O
mucous	O
of	O
three	O
species	O
of	O
amphipod	O
H	O
.	O
gigas	O
,	O
S	O
.	O
schellenbergi	O
,	O
and	O
A	O
.	O
gigantea	O
were	O
used	O
to	O
sequence	O
the	O
gut	O
microbiota	O
,	O
generating	O
metagenomic	O
data	O
sets	O
totaling	O
78	O
.	O
23	O
Gb	O
.	O
Read	O
numbers	O
,	O
quality	O
filtering	O
,	O
and	O
the	O
assemblies	O
of	O
Illumina	O
sequencing	O
were	O
summarized	O
in	O
Supplementary	O
Tables	O
1	O
,	O
2	O
.	O

The	O
host	O
(	O
amphipod	O
)	O
derived	O
reads	O
have	O
been	O
removed	O
before	O
analysis	O
,	O
and	O
the	O
relevant	O
information	O
is	O
shown	O
in	O
the	O
optimized	O
reads	O
in	O
Supplementary	O
Table	O
1	O
.	O
De	O
novo	O
assembly	O
of	O
effective	O
reads	O
resulted	O
in	O
32	O
,	O
648	O
non	O
-	O
redundant	O
catalog	O
genes	O
,	O
which	O
were	O
used	O
for	O
subsequent	O
analysis	O
.	O
Taxonomic	O
classification	O
based	O
on	O
non	O
-	O
redundant	O
catalog	O
genes	O
revealed	O
a	O
total	O
eight	O
phyla	O
(	O
with	O
>	O
1	O
%	O
relative	O
abundance	O
of	O
the	O
total	O
microorganisms	O
)	O
from	O
the	O
gut	O
microbial	O
communities	O
.	O
Taxonomic	O
profiling	O
indicated	O
that	O
the	O
hadal	O
amphipods	O
’	O
gut	O
microbiota	O
was	O
dominated	O
by	O
Proteobacteria	O
,	O
followed	O
by	O
Tenericutes	O
and	O
Firmicutes	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
Actinobacteria	O
,	O
Bacteroidetes	O
,	O
Spirochaetes	O
,	O
and	O
Candidatus	O
Tectomicrobia	O
(	O
Figure	O
2	O
)	O
.	O
At	O
the	O
genus	O
level	O
,	O
a	O
total	O
of	O
1	O
,	O
081	O
genera	O
were	O
identified	O
,	O
of	O
which	O
358	O
were	O
shared	O
by	O
the	O
three	O
amphipod	O
species	O
(	O
Figure	O
3A	O
)	O
.	O
Overall	O
,	O
Candidatus	O
Hepatoplasma	O
was	O
the	O
most	O
abundant	O
genus	O
in	O
the	O
gut	O
microbiota	O
of	O
both	O
the	O
New	O
Britain	O
Trench	O
A	O
.	O
gigantea	O
and	O
the	O
Marceau	O
Trench	O
S	O
.	O
schellenbergi	O
individuals	O
,	O
whereas	O
Psychromonas	O
was	O
more	O
abundant	O
in	O
the	O
Mariana	O
Trench	O
H	O
.	O
gigas	O
individuals	O
(	O
Figures	O
2	O
,	O
3B	O
)	O
.	O
The	O
gene	O
functions	O
annotated	O
by	O
KEGG	O
pathway	O
hierarchical	O
level	O
1	O
(	O
SEED	O
1	O
)	O
that	O
indicate	O
“	O
Metabolisms	O
”	O
were	O
the	O
predominant	O
function	O
in	O
the	O
total	O
non	O
-	O
redundant	O
protein	O
-	O
coding	O
genes	O
(	O
SEED1	O
in	O
Figure	O
4A	O
)	O
,	O
followed	O
by	O
“	O
Genetic	O
Information	O
Processing	O
,	O
”	O
“	O
Cellular	O
Processes	O
,	O
”	O
and	O
“	O
Environmental	O
Information	O
Processing	O
”	O
(	O
Figure	O
4A	O
)	O
.	O

“	O
Carbohydrate	O
Metabolism	O
”	O
(	O
13	O
.	O
29	O
,	O
14	O
.	O
92	O
,	O
and	O
14	O
.	O
22	O
%	O
of	O
the	O
total	O
KO	O
function	O
in	O
gut	O
microbiota	O
of	O
the	O
H	O
.	O
gigas	O
,	O
A	O
.	O
gigantea	O
,	O
and	O
S	O
.	O
schellenbergi	O
,	O
respectively	O
)	O
,	O
“	O
Replication	O
and	O
Repair	O
”	O
(	O
8	O
.	O
13	O
,	O
6	O
.	O
72	O
,	O
and	O
6	O
.	O
08	O
%	O
for	O
H	O
.	O
gigas	O
,	O
A	O
.	O
gigantea	O
,	O
and	O
S	O
.	O
schellenbergi	O
,	O
respectively	O
)	O
,	O
“	O
Cell	O
Motility	O
”	O
(	O
5	O
.	O
08	O
,	O
2	O
.	O
68	O
,	O
and	O
3	O
.	O
17	O
%	O
for	O
H	O
.	O
gigas	O
,	O
A	O
.	O
gigantea	O
,	O
and	O
S	O
.	O
schellenbergi	O
,	O
respectively	O
)	O
,	O
and	O
“	O
Membrane	O
Transport	O
”	O
(	O
9	O
.	O
42	O
,	O
7	O
.	O
87	O
,	O
and	O
7	O
.	O
62	O
%	O
for	O
H	O
.	O
gigas	O
,	O
A	O
.	O
gigantea	O
,	O
and	O
S	O
.	O
schellenbergi	O
,	O
respectively	O
)	O
were	O
detected	O
as	O
the	O
most	O
presented	O
KEGG	O
pathway	O
hierarchical	O
level	O
2	O
(	O
SEED	O
2	O
)	O
types	O
among	O
the	O
four	O
SEED1	O
categories	O
(	O
Figure	O
4A	O
)	O
.	O
The	O
top	O
3	O
–	O
10	O
abundant	O
KEGG	O
pathway	O
hierarchical	O
level	O
3	O
(	O
SEED3	O
)	O
for	O
the	O
four	O
SEED2	O
categories	O
(	O
“	O
Carbohydrate	O
Metabolism	O
,	O
”	O
“	O
Replication	O
and	O
Repair	O
,	O
”	O
“	O
Cell	O
Motility	O
,	O
”	O
and	O
“	O
Membrane	O
Transport	O
”	O
)	O
were	O
shown	O
separately	O
(	O
Figures	O
4B	O
–	O
D	O
)	O
,	O
in	O
which	O
“	O
Glycolysis	O
/	O
Gluconeogenesis	O
”	O
was	O
detected	O
as	O
the	O
most	O
abundant	O
category	O
in	O
“	O
Carbohydrate	O
Metabolism	O
”	O
(	O
22	O
.	O
46	O
,	O
25	O
.	O
40	O
,	O
and	O
23	O
.	O
83	O
%	O
of	O
the	O
total	O
“	O
Carbohydrate	O
Metabolisms	O
”	O
functional	O
activities	O
in	O
the	O
gut	O
microbiota	O
of	O
the	O
H	O
.	O
gigas	O
,	O
A	O
.	O
gigantea	O
,	O
and	O
S	O
.	O
schellenbergi	O
,	O
respectively	O
,	O
see	O
Figure	O
4B	O
)	O
.	O
“	O
Homologous	O
Recombination	O
”	O
was	O
the	O
main	O
pathway	O
in	O
“	O
Replication	O
and	O
Repair	O
,	O
”	O
among	O
which	O
26	O
.	O
02	O
,	O
34	O
.	O
98	O
,	O
and	O
28	O
.	O
31	O
%	O
of	O
the	O
total	O
“	O
Replication	O
and	O
Repair	O
”	O
functional	O
activities	O
were	O
in	O
the	O
gut	O
microbiota	O
of	O
the	O
H	O
.	O
gigas	O
,	O
A	O
.	O
gigantea	O
,	O
and	O
S	O
.	O
schellenbergi	O
,	O
respectively	O
(	O
Figure	O
4C	O
)	O
.	O

Moreover	O
,	O
the	O
“	O
Bacterial	O
Chemotaxis	O
”	O
and	O
“	O
Phosphotransferase	O
System	O
”	O
(	O
PTS	O
)	O
were	O
acted	O
as	O
the	O
most	O
presented	O
categories	O
of	O
“	O
Cell	O
Motility	O
”	O
and	O
“	O
Membrane	O
Transport	O
,	O
”	O
respectively	O
(	O
Figures	O
4D	O
,	O
E	O
)	O
.	O
It	O
should	O
be	O
noted	O
that	O
the	O
genes	O
involved	O
in	O
“	O
Flagellar	O
Assembly	O
”	O
were	O
the	O
second	O
most	O
abundant	O
category	O
in	O
the	O
“	O
Cell	O
Motility	O
,	O
”	O
ranging	O
from	O
39	O
.	O
97	O
to	O
46	O
.	O
78	O
%	O
of	O
the	O
total	O
“	O
Cell	O
Motility	O
”	O
functional	O
activities	O
in	O
the	O
gut	O
microbiota	O
of	O
three	O
hadal	O
amphipod	O
samples	O
(	O
Figure	O
4E	O
)	O
.	O
In	O
addition	O
,	O
the	O
categories	O
of	O
“	O
Metabolic	O
and	O
Cellular	O
Processes	O
,	O
”	O
“	O
Cell	O
,	O
”	O
“	O
Cell	O
Part	O
,	O
”	O
and	O
“	O
Membrane	O
and	O
Membrane	O
Part	O
”	O
were	O
also	O
identified	O
in	O
the	O
Gene	O
Ontology	O
(	O
GO	O
)	O
classification	O
based	O
on	O
the	O
read	O
sets	O
of	O
three	O
hadal	O
amphipod	O
species	O
(	O
Supplementary	O
Figures	O
1	O
,	O
2	O
)	O
.	O
To	O
measure	O
the	O
difference	O
between	O
the	O
microbiota	O
functions	O
of	O
the	O
three	O
hadal	O
amphipod	O
groups	O
,	O
we	O
analyzed	O
their	O
diverse	O
functional	O
compositions	O
based	O
on	O
the	O
Kruskal	O
–	O
Wallis	O
and	O
post	O
-	O
hoc	O
tests	O
.	O
The	O
results	O
of	O
a	O
comparative	O
analysis	O
of	O
the	O
compositions	O
and	O
relative	O
abundances	O
of	O
KEGG	O
pathways	O
in	O
the	O
three	O
hadal	O
amphipod	O
gut	O
microflora	O
showed	O
that	O
except	O
for	O
“	O
Translation	O
”	O
and	O
“	O
Transcription	O
”	O
(	O
P	O
-	O
value	O
>	O
0	O
.	O
05	O
,	O
Figure	O
4A	O
)	O
,	O
there	O
were	O
no	O
significant	O
functional	O
differences	O
detected	O
in	O
all	O
the	O
SEED2	O
functional	O
compositions	O
(	O
Figure	O
4A	O
)	O
.	O
Similar	O
results	O
were	O
also	O
found	O
in	O
the	O
SEED3	O
functional	O
compositions	O
of	O
“	O
Carbohydrate	O
Metabolism	O
,	O
”	O
“	O
Replication	O
and	O
Repair	O
,	O
”	O
“	O
Cell	O
Motility	O
,	O
”	O
and	O
“	O
Membrane	O
Transport	O
”	O
(	O
P	O
-	O
value	O
>	O
0	O
.	O
05	O
;	O
Figures	O
4B	O
–	O
E	O
)	O
.	O
Moreover	O
,	O
consistent	O
with	O
the	O
results	O
of	O
KEGG	O
functional	O
composition	O
comparisons	O
,	O
there	O
were	O
no	O
differences	O
detected	O
in	O
the	O
GO	O
functional	O
composition	O
among	O
the	O
three	O
groups	O
of	O
gut	O
microbes	O
(	O
P	O
-	O
value	O
>	O
0	O
.	O
05	O
;	O
Supplementary	O
Figure	O
2	O
)	O
.	O
Correlation	O
analysis	O
of	O
the	O
species	O
and	O
functional	O
contribution	O
relative	O
abundances	O
was	O
performed	O
in	O
the	O
samples	O
from	O
the	O
three	O
localities	O
.	O

In	O
the	O
species	O
functional	O
contribution	O
analysis	O
based	O
on	O
the	O
four	O
most	O
presented	O
KEGG	O
terms	O
,	O
“	O
Cell	O
Motility	O
,	O
”	O
“	O
Phosphotransferase	O
System	O
(	O
PTS	O
)	O
,	O
”	O
“	O
Replication	O
and	O
Repair	O
,	O
”	O
and	O
“	O
Glycolysis	O
/	O
Gluconeogenesis	O
,	O
”	O
we	O
annotated	O
the	O
“	O
Cell	O
Motility	O
”	O
functional	O
categories	O
and	O
found	O
it	O
was	O
mainly	O
contributed	O
by	O
Psychromonas	O
in	O
H	O
.	O
gigas	O
and	O
A	O
.	O
gigantea	O
groups	O
,	O
whereas	O
Moritella	O
and	O
Vibrio	O
were	O
detected	O
to	O
be	O
the	O
major	O
contributors	O
in	O
the	O
S	O
.	O
schellenbergi	O
group	O
(	O
Figure	O
4F	O
)	O
.	O
In	O
comparison	O
,	O
the	O
main	O
KEGG	O
functional	O
pathways	O
of	O
“	O
Phosphotransferase	O
System	O
(	O
PTS	O
)	O
,	O
”	O
“	O
Replication	O
and	O
Repair	O
,	O
”	O
and	O
“	O
Glycolysis	O
/	O
Gluconeogenesis	O
”	O
were	O
detected	O
to	O
be	O
mainly	O
contributed	O
by	O
Candidatus	O
Hepatoplasma	O
,	O
followed	O
by	O
Mycoplasma	O
in	O
all	O
the	O
three	O
hadal	O
amphipod	O
groups	O
(	O
Figure	O
4F	O
)	O
.	O
These	O
different	O
functional	O
contributions	O
suggested	O
that	O
the	O
diverse	O
composition	O
of	O
bacteria	O
species	O
possibly	O
realized	O
the	O
hadal	O
environmental	O
adaptability	O
of	O
gut	O
microbiomes	O
from	O
different	O
hadal	O
amphipods	O
.	O
To	O
gain	O
more	O
insight	O
into	O
possible	O
functions	O
of	O
the	O
“	O
Cell	O
Motility	O
”	O
category	O
,	O
the	O
KEGG	O
database	O
was	O
used	O
for	O
read	O
-	O
based	O
alignments	O
.	O
For	O
the	O
hadal	O
amphipod	O
samples	O
,	O
a	O
large	O
number	O
of	O
genes	O
related	O
to	O
“	O
Cell	O
Motility	O
”	O
were	O
associated	O
with	O
KEGG	O
level	O
3	O
pathways	O
and	O
specifically	O
the	O
“	O
Bacterial	O
Chemotaxis	O
”	O
and	O
“	O
Flagellar	O
Assembly	O
”	O
(	O
Figure	O
5A	O
)	O
.	O
Within	O
the	O
“	O
Bacterial	O
Chemotaxis	O
”	O
pathway	O
,	O
a	O
macromolecular	O
complex	O
known	O
as	O
chemosensory	O
arrays	O
and	O
assembled	O
from	O
the	O
MCP	O
,	O
redox	O
receptor	O
Aer	O
,	O
histidine	O
kinase	O
CheA	O
,	O
and	O
adaptor	O
protein	O
CheW	O
was	O
highly	O
presented	O
(	O
Figure	O
5A	O
marked	O
in	O
red	O
,	O
Supplementary	O
Table	O
3	O
)	O
.	O
In	O
addition	O
,	O
the	O
gene	O
encoding	O
the	O
CheY	O
protein	O
,	O
which	O
acts	O
as	O
a	O
“	O
Response	O
Regulator	O
”	O
during	O
signaling	O
to	O
the	O
flagellum	O
,	O
was	O
also	O
detected	O
to	O
be	O
highly	O
presented	O
(	O
Figure	O
5A	O
and	O
Supplementary	O
Table	O
3	O
)	O
.	O

Similarly	O
,	O
within	O
the	O
“	O
Flagellar	O
Assembly	O
”	O
pathway	O
,	O
almost	O
all	O
genes	O
involved	O
in	O
this	O
pathway	O
were	O
highly	O
presented	O
(	O
see	O
Supplementary	O
Table	O
3	O
)	O
,	O
including	O
MotA	O
,	O
MotB	O
,	O
FliG	O
,	O
FliM	O
,	O
and	O
FliN	O
genes	O
(	O
Figure	O
5A	O
,	O
marked	O
in	O
red	O
,	O
Supplementary	O
Table	O
3	O
)	O
,	O
which	O
are	O
considered	O
important	O
factors	O
of	O
the	O
non	O
-	O
rotating	O
part	O
of	O
the	O
flagellum	O
-	O
motor	O
complex	O
controlling	O
flagellar	O
rotation	O
.	O
“	O
Bacterial	O
Chemotaxis	O
”	O
is	O
the	O
KEGG	O
pathway	O
associates	O
with	O
the	O
microbes	O
’	O
ability	O
to	O
control	O
motility	O
in	O
responding	O
to	O
chemical	O
environments	O
,	O
allowing	O
bacteria	O
to	O
move	O
toward	O
a	O
more	O
favorable	O
location	O
and	O
maintain	O
a	O
steady	O
-	O
state	O
despite	O
ambient	O
conditions	O
.	O
To	O
test	O
the	O
possible	O
hadal	O
adaptation	O
functions	O
of	O
the	O
“	O
Bacterial	O
Chemotaxis	O
”	O
pathway	O
,	O
the	O
MCP	O
gene	O
within	O
the	O
“	O
Bacterial	O
Chemotaxis	O
”	O
pathway	O
(	O
Figure	O
5A	O
)	O
was	O
obtained	O
from	O
the	O
current	O
metagenomic	O
dataset	O
.	O
With	O
respect	O
to	O
the	O
phylogenetic	O
tree	O
,	O
the	O
sequence	O
for	O
MCP	O
from	O
the	O
hadal	O
amphipod	O
was	O
formed	O
a	O
sister	O
clade	O
approximate	O
to	O
the	O
different	O
microorganisms	O
of	O
the	O
same	O
genus	O
in	O
hadal	O
amphipods	O
(	O
e	O
.	O
g	O
.	O
,	O
Moritella	O
,	O
Shewanella	O
,	O
Vibrio	O
,	O
Photobacterium	O
,	O
and	O
Pseudoalteromonas	O
)	O
.	O
The	O
hadal	O
amphipod	O
MCP	O
was	O
also	O
separated	O
from	O
those	O
associated	O
with	O
other	O
species	O
in	O
the	O
tree	O
,	O
such	O
as	O
the	O
microorganism	O
previously	O
isolated	O
from	O
terrestrial	O
and	O
shallow	O
water	O
(	O
Supplementary	O
Figure	O
3	O
)	O
.	O
Moreover	O
,	O
based	O
on	O
protein	O
domain	O
prediction	O
,	O
the	O
specific	O
3C8C	O
|	O
B	O
domain	O
was	O
detected	O
in	O
the	O
MCP	O
from	O
hadal	O
amphipod	O
(	O
Supplementary	O
Figure	O
3	O
)	O
and	O
which	O
was	O
obviously	O
different	O
from	O
other	O
species	O
in	O
the	O
tree	O
.	O
Finally	O
,	O
the	O
MCP	O
recombinant	O
expression	O
plasmids	O
were	O
constructed	O
and	O
subsequently	O
introduced	O
into	O
E	O
.	O
coli	O
.	O
E	O
.	O
coli	O
clones	O
stably	O
expressing	O
the	O
hadal	O
bacterial	O
MCP	O
were	O
found	O
to	O
be	O
significantly	O
enhanced	O
in	O
mobility	O
activity	O
and	O
faster	O
growth	O
compared	O
with	O
the	O
control	B-methodology
group	I-methodology
(	O
Figures	O
5B	O
,	O
C	O
)	O
.	O
The	O
result	O
suggested	O
a	O
contribution	O
by	O
MCP	O
to	O
motility	O
and	O
growth	O
of	O
the	O
gut	O
microbiota	O
in	O
the	O
hadal	O
amphipods	O
where	O
nutrients	O
are	O
poor	O
.	O

The	O
intestine	O
is	O
colonized	O
by	O
a	O
wide	O
variety	O
of	O
microbes	O
that	O
comprise	O
the	O
“	O
gut	O
microbiota	O
,	O
”	O
a	O
complex	O
microbial	O
community	O
that	O
has	O
co	O
-	O
evolved	O
with	O
the	O
host	O
to	O
form	O
a	O
mutually	O
beneficial	O
relationship	O
via	O
a	O
dynamic	O
balance	O
of	O
symbiosis	O
and	O
competition	O
.	O
Accumulating	O
evidence	O
indicates	O
that	O
the	O
gut	O
microbiota	O
can	O
participate	O
in	O
various	O
life	O
activities	O
of	O
the	O
host	O
,	O
such	O
as	O
promoting	O
the	O
absorption	O
of	O
nutrients	O
and	O
energy	O
storage	O
,	O
while	O
also	O
playing	O
many	O
complex	O
roles	O
in	O
the	O
immune	O
function	O
and	O
environmental	O
adaptability	O
in	O
the	O
host	O
(	O
Belkaid	O
and	O
Hand	O
,	O
2014	O
;	O
Ayres	O
,	O
2016	O
)	O
.	O
Therefore	O
,	O
to	O
explore	O
the	O
effects	O
of	O
gut	O
microbiota	O
on	O
the	O
hadal	O
amphipods	O
’	O
adaptations	O
to	O
the	O
extreme	O
environment	O
,	O
the	O
Probio	O
database	O
was	O
used	O
for	O
read	O
-	O
based	O
alignments	O
using	O
the	O
BLAST	O
algorithm	O
with	O
a	O
significant	O
e	O
-	O
value	O
threshold	O
of	O
1e	O
-	O
5	O
.	O
According	O
to	O
the	O
identifications	O
of	O
probiotics	O
against	O
predicted	O
ORFs	O
from	O
our	O
metagenome	O
dataset	O
,	O
a	O
series	O
of	O
probiotics	O
genera	O
such	O
as	O
Lactobacillus	O
,	O
Bacillus	O
,	O
Lactococcus	O
,	O
Burkholderia	O
,	O
Leuconostoc	O
,	O
Bifidobacterium	O
,	O
and	O
Bdellovibrio	O
were	O
detected	O
in	O
large	O
quantities	O
in	O
the	O
hadal	O
amphipod	O
gut	O
microbe	O
samples	O
(	O
Figure	O
6A	O
)	O
.	O
Functional	O
annotation	O
showed	O
that	O
the	O
main	O
functions	O
of	O
these	O
probiotic	O
-	O
related	O
genes	O
were	O
associated	O
with	O
“	O
Animal	O
Survival	O
,	O
”	O
“	O
Animal	O
Growth	O
,	O
”	O
“	O
Immune	O
-	O
protection	O
,	O
”	O
and	O
“	O
Food	O
Digestion	O
”	O
(	O
Figure	O
6B	O
)	O
,	O
which	O
indicated	O
that	O
those	O
probiotics	O
among	O
the	O
hadal	O
amphipod	O
gut	O
microbiota	O
could	O
be	O
contributors	O
of	O
host	O
’	O
s	O
growth	O
and	O
development	O
.	O
In	O
addition	O
,	O
the	O
functional	O
interaction	O
analysis	O
between	O
probiotics	O
and	O
the	O
host	O
further	O
showed	O
the	O
correlations	O
between	O
probiotic	O
effects	O
and	O
categories	O
of	O
predicted	O
gene	O
functions	O
in	O
hadal	O
amphipods	O
,	O
which	O
indicated	O
that	O
they	O
might	O
play	O
important	O
roles	O
in	O
multiple	O
functional	O
pathways	O
in	O
the	O
hadal	O
amphipods	O
,	O
such	O
as	O
“	O
Cell	O
and	O
Membrane	O
Processes	O
,	O
”	O
“	O
Metabolism	O
Processes	O
,	O
”	O
“	O
Cellular	O
Processes	O
,	O
”	O
“	O
Localization	O
and	O
Binding	O
,	O
”	O
and	O
so	O
on	O
(	O
Supplementary	O
Figure	O
4	O
)	O
.	O
The	O
hadal	O
zone	O
is	O
the	O
deepest	O
habitat	O
on	O
Earth	O
,	O
characterized	O
by	O
the	O
near	O
-	O
freezing	O
temperature	O
,	O
scarcity	O
of	O
food	O
and	O
nutrition	O
,	O
and	O
elevated	O
hydrostatic	O
pressure	O
(	O
Lauro	O
and	O
Bartlett	O
,	O
2008	O
;	O
Jamieson	O
et	O
al	O
.	O
,	O
2010	O
)	O
.	O

These	O
physically	O
uniform	O
environmental	O
factors	O
are	O
believed	O
to	O
have	O
contributed	O
to	O
the	O
evolution	O
and	O
persistence	O
of	O
a	O
variety	O
of	O
metazoan	O
organisms	O
(	O
such	O
as	O
fish	O
,	O
polychaetes	O
,	O
and	O
amphipods	O
)	O
and	O
microorganisms	O
,	O
mainly	O
consisting	O
of	O
psychrophilic	O
and	O
piezophilic	O
bacteria	O
,	O
either	O
free	O
-	O
living	O
or	O
host	O
-	O
associated	O
(	O
Sogin	O
et	O
al	O
.	O
,	O
2006	O
;	O
Glud	O
et	O
al	O
.	O
,	O
2013	O
;	O
Ichino	O
et	O
al	O
.	O
,	O
2015	O
;	O
Lacey	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
In	O
the	O
previous	O
studies	O
of	O
microbial	O
communities	O
of	O
trans	O
-	O
trench	O
sediments	O
/	O
water	O
,	O
the	O
vertically	O
distinct	O
microbial	O
community	O
structures	O
were	O
detected	O
between	O
abyssal	O
and	O
hadal	O
sediments	O
/	O
water	O
and	O
which	O
indicated	O
that	O
hadal	O
trenches	O
contained	O
unique	O
microbial	O
biodiversity	O
(	O
Peoples	O
et	O
al	O
.	O
,	O
2018	O
;	O
Hiraoka	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Moreover	O
,	O
the	O
widespread	O
distribution	O
of	O
amphipods	O
in	O
the	O
hadal	O
trenches	O
reflects	O
their	O
successful	O
adaptation	O
to	O
the	O
hadal	O
environments	O
,	O
which	O
may	O
also	O
indicate	O
that	O
unique	O
hadal	O
environmental	O
factors	O
may	O
be	O
responsible	O
for	O
the	O
evolution	O
and	O
presence	O
of	O
specific	O
microbial	O
species	O
in	O
the	O
hadal	O
amphipod	O
gut	O
.	O
Although	O
the	O
well	O
-	O
recognized	O
importance	O
of	O
microbes	O
with	O
regard	O
to	O
their	O
biogeochemical	O
roles	O
in	O
hadal	O
zones	O
,	O
their	O
adaptive	O
strategies	O
and	O
the	O
functional	O
potential	O
of	O
animal	O
association	O
remain	O
poorly	O
studied	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
revealed	O
the	O
composition	O
and	O
function	O
of	O
gut	O
microbiota	O
of	O
three	O
amphipod	O
species	O
by	O
a	O
metagenomics	O
approach	O
.	O
Our	O
results	O
unfolded	O
the	O
universal	O
similarity	O
between	O
the	O
three	O
hadal	O
amphipod	O
populations	O
,	O
as	O
determined	O
by	O
alpha	O
and	O
beta	O
diversity	O
analyses	O
of	O
the	O
taxonomic	O
compositions	O
.	O
Simultaneously	O
,	O
the	O
analyses	O
of	O
the	O
functional	O
potentials	O
revealed	O
the	O
preliminary	O
environmental	O
adaptation	O
strategies	O
for	O
gut	O
microbiota	O
and	O
the	O
potential	O
interactions	O
between	O
the	O
host	O
and	O
gut	O
microbiota	O
in	O
the	O
process	O
of	O
adapting	O
amphipods	O
to	O
hadal	O
environments	O
.	O
As	O
we	O
know	O
,	O
intestinal	O
contents	O
have	O
been	O
widely	O
used	O
for	O
metagenomic	O
analysis	O
in	O
several	O
animal	O
species	O
(	O
Suo	O
et	O
al	O
.	O
,	O
2017	O
;	O
Zhao	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
In	O
our	O
study	O
,	O
based	O
on	O
the	O
composition	O
of	O
the	O
gut	O
microbial	O
communityfrom	O
three	O
hadal	O
amphipod	O
species	O
,	O
the	O
common	O
dominant	O
taxa	O
at	O
phylum	O
and	O
genus	O
levels	O
were	O
detected	O
(	O
Figures	O
2	O
,	O
3	O
)	O
,	O
which	O
suggested	O
that	O
the	O
gut	O
microbial	O
compositions	O
of	O
the	O
co	O
-	O
dwelling	O
hadal	O
amphipods	O
were	O
relatively	O
constant	O
inter	O
-	O
species	O
.	O

We	O
noted	O
that	O
the	O
dominant	O
bacterial	O
taxa	O
at	O
the	O
genus	O
level	O
,	O
such	O
as	O
Candidatus	O
Hepatoplasma	O
and	O
Burkholderia	O
,	O
have	O
been	O
reported	O
to	O
be	O
abundant	O
in	O
different	O
populations	O
of	O
hadal	O
amphipod	O
species	O
(	O
Zhang	O
et	O
al	O
.	O
,	O
2018	O
,	O
2019	O
;	O
Cheng	O
et	O
al	O
.	O
,	O
2019	O
)	O
and	O
also	O
been	O
reported	O
to	O
be	O
symbionts	O
of	O
bean	O
bugs	O
(	O
Kim	O
et	O
al	O
.	O
,	O
2015	O
)	O
and	O
terrestrial	O
isopods	O
(	O
Wang	O
et	O
al	O
.	O
,	O
2004	O
)	O
.	O
Candidatus	O
Hepatoplasma	O
,	O
identified	O
as	O
a	O
Mycoplasma	O
-	O
like	O
symbiont	O
abundant	O
in	O
terrestrial	O
isopods	O
,	O
showed	O
a	O
positive	O
correlation	O
between	O
the	O
host	O
and	O
survivorship	O
on	O
low	O
-	O
quality	O
food	O
(	O
Sebastian	O
and	O
Martin	O
,	O
2008	O
)	O
.	O
In	O
the	O
studies	O
of	O
Wang	O
et	O
al	O
.	O
(	O
2004	O
)	O
and	O
Fraune	O
and	O
Zimmer	O
(	O
2008	O
)	O
,	O
Candidatus	O
Hepatoplasma	O
was	O
reported	O
as	O
a	O
symbiont	O
in	O
the	O
midgut	O
glands	O
of	O
terrestrial	O
isopods	O
,	O
with	O
the	O
results	O
suggesting	O
functions	O
to	O
be	O
related	O
to	O
cellulase	O
production	O
for	O
leaf	O
litter	O
degradation	O
.	O
This	O
is	O
a	O
beneficial	O
relationship	O
for	O
the	O
host	O
in	O
low	O
-	O
nutrient	O
conditions	O
.	O
Moreover	O
,	O
in	O
the	O
study	O
of	O
Sebastian	O
and	O
Martin	O
(	O
2008	O
)	O
,	O
most	O
isopods	O
that	O
survived	O
feeding	O
on	O
a	O
cellulose	O
-	O
based	O
low	O
-	O
quality	O
diet	O
for	O
90	O
days	O
harbored	O
Candidatus	O
Hepatoplasma	O
in	O
their	O
midgut	O
glands	O
,	O
whereas	O
those	O
that	O
died	O
within	O
90	O
days	O
mostly	O
either	O
harbored	O
no	O
or	O
other	O
bacterial	O
symbionts	O
.	O
The	O
presence	O
of	O
these	O
microbial	O
groups	O
,	O
therefore	O
,	O
suggests	O
a	O
close	O
relationship	O
between	O
the	O
gut	O
microbiota	O
and	O
the	O
hadal	O
amphipod	O
host	O
.	O
In	O
addition	O
,	O
members	O
of	O
Psychromonas	O
and	O
Pseudoalteromonas	O
genera	O
were	O
also	O
detected	O
to	O
be	O
highly	O
represented	O
in	O
the	O
gut	O
microbiota	O
of	O
hadal	O
amphipods	O
in	O
our	O
study	O
,	O
especially	O
Psychromonas	O
,	O
which	O
has	O
been	O
shown	O
to	O
contain	O
a	O
variety	O
of	O
piezophilic	O
and	O
psychrophilic	O
species	O
that	O
are	O
widely	O
distributed	O
in	O
marine	O
environments	O
,	O
including	O
hadal	O
zones	O
(	O
Groudieva	O
et	O
al	O
.	O
,	O
2003	O
;	O
Miyazaki	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O

Members	O
of	O
these	O
two	O
genera	O
are	O
thought	O
to	O
share	O
common	O
features	O
,	O
such	O
as	O
synthesis	O
of	O
polyunsaturated	O
fatty	O
acids	O
and	O
/	O
or	O
expression	O
of	O
related	O
genes	O
to	O
enhance	O
membrane	O
fluidity	O
(	O
Casanueva	O
et	O
al	O
.	O
,	O
2010	O
)	O
,	O
which	O
likely	O
facilitates	O
cold	O
and	O
pressure	O
adaptation	O
and	O
survival	O
of	O
the	O
hadal	O
amphipods	O
.	O
However	O
,	O
differences	O
in	O
gut	O
microbial	O
composition	O
were	O
also	O
detected	O
among	O
the	O
three	O
geographically	O
isolated	O
amphipod	O
species	O
(	O
Figure	O
3	O
)	O
,	O
which	O
could	O
be	O
explained	O
by	O
multiple	O
factors	O
such	O
as	O
the	O
host	O
genetic	O
background	O
,	O
environmental	O
location	O
,	O
and	O
food	O
support	O
(	O
Miyake	O
et	O
al	O
.	O
,	O
2005	O
;	O
Wong	O
and	O
Rawls	O
,	O
2012	O
;	O
Liu	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
For	O
instance	O
,	O
Candidatus	O
Hepatoplasma	O
was	O
detected	O
as	O
the	O
dominant	O
bacterium	O
in	O
the	O
gut	O
of	O
the	O
S	O
.	O
schellenbergi	O
and	O
A	O
.	O
gigantea	O
,	O
whereas	O
relative	O
absence	O
in	O
the	O
H	O
.	O
gigas	O
.	O
Given	O
that	O
the	O
New	O
Britain	O
Trench	O
is	O
closest	O
to	O
the	O
coast	O
followed	O
by	O
the	O
Marceau	O
Trench	O
,	O
and	O
finally	O
the	O
Mariana	O
Trench	O
,	O
the	O
decaying	O
plant	O
material	O
content	O
in	O
these	O
trenches	O
should	O
show	O
a	O
decreasing	O
trend	O
,	O
which	O
may	O
be	O
the	O
reason	O
for	O
the	O
difference	O
in	O
the	O
abundance	O
of	O
Candidatus	O
Hepatoplasma	O
in	O
the	O
gut	O
of	O
different	O
amphipod	O
species	O
,	O
and	O
similar	O
conclusions	O
have	O
been	O
mentioned	O
in	O
previous	O
studies	O
(	O
Zhang	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Moreover	O
,	O
the	O
difference	O
in	O
the	O
abundance	O
of	O
Psychromonas	O
of	O
gut	O
microbial	O
composition	O
was	O
also	O
detected	O
among	O
the	O
three	O
geographically	O
isolated	O
amphipod	O
species	O
,	O
especially	O
the	O
almost	O
absence	O
of	O
Psychromonas	O
in	O
the	O
S	O
.	O
schellenbergi	O
and	O
A	O
.	O
gigantea	O
,	O
which	O
suggested	O
that	O
their	O
function	O
is	O
dispensable	O
or	O
their	O
counterparts	O
have	O
emerged	O
in	O
the	O
guts	O
of	O
these	O
amphipods	O
,	O
as	O
Zhang	O
et	O
al	O
.	O
(	O
2019	O
)	O
mentioned	O
in	O
the	O
previous	O
study	O
.	O
To	O
further	O
understand	O
the	O
environmental	O
adaptations	O
of	O
gut	O
microbes	O
in	O
the	O
hadal	O
trench	O
,	O
functional	O
analyses	O
were	O
carried	O
out	O
.	O
From	O
the	O
KEGG	O
and	O
GO	O
annotation	O
and	O
classification	O
analyses	O
,	O
it	O
was	O
obvious	O
that	O
non	O
-	O
differentiated	O
functional	O
components	O
(	O
except	O
for	O
“	O
Translation	O
”	O
and	O
“	O
Transcription	O
”	O
in	O
SEED2	O
functional	O
composition	O
)	O
could	O
be	O
observed	O
from	O
the	O
three	O
geographically	O
isolated	O
amphipod	O
samples	O
in	O
our	O
study	O
(	O
Figure	O
4	O
and	O
Supplementary	O
Figure	O
2	O
)	O
.	O

In	O
detail	O
,	O
the	O
functional	O
pathways	O
of	O
PTS	O
,	O
Glycolysis	O
/	O
Gluconeogenesis	O
,	O
Homologous	O
Recombination	O
,	O
Bacterial	O
Chemotaxis	O
,	O
and	O
Flagellar	O
Assembly	O
were	O
detected	O
as	O
the	O
common	O
functional	O
types	O
in	O
all	O
the	O
amphipod	O
gut	O
samples	O
,	O
suggesting	O
that	O
the	O
existence	O
of	O
a	O
set	O
of	O
similar	O
functional	O
components	O
in	O
gut	O
microbes	O
of	O
the	O
hadal	O
amphipod	O
species	O
(	O
Figure	O
4	O
and	O
Supplementary	O
Figures	O
1	O
,	O
2	O
)	O
.	O
However	O
,	O
the	O
previous	O
study	O
on	O
the	O
H	O
.	O
gigas	O
from	O
Mariana	O
Trench	O
and	O
Japan	O
Trench	O
have	O
shown	O
that	O
different	O
geographical	O
locations	O
lead	O
to	O
functional	O
differentiation	O
of	O
their	O
gut	O
microbes	O
(	O
Zhang	O
et	O
al	O
.	O
,	O
2019	O
)	O
and	O
which	O
was	O
inconsistent	O
with	O
the	O
results	O
of	O
the	O
present	O
study	O
.	O
This	O
difference	O
may	O
result	O
from	O
a	O
combination	O
of	O
selection	O
factors	O
,	O
such	O
as	O
habitat	O
environment	O
,	O
microbial	O
interaction	O
,	O
and	O
host	O
genetic	O
background	O
,	O
and	O
the	O
details	O
remain	O
to	O
be	O
analyzed	O
.	O
The	O
PTS	O
is	O
a	O
complex	O
group	O
translocation	O
system	O
used	O
by	O
bacteria	O
for	O
transporting	O
carbohydrates	O
from	O
cytoplasm	O
to	O
cytoplasm	O
with	O
the	O
least	O
energy	O
-	O
consuming	O
and	O
the	O
most	O
efficient	O
way	O
(	O
Gosset	O
,	O
2005	O
)	O
,	O
which	O
can	O
also	O
play	O
key	O
roles	O
in	O
“	O
Metabolism	O
and	O
Regulation	O
”	O
and	O
provide	O
the	O
initial	O
substrate	O
for	O
glycolysis	O
,	O
and	O
by	O
which	O
bacteria	O
can	O
integrate	O
their	O
nutritional	O
status	O
with	O
diverse	O
environmental	O
stimuli	O
(	O
Snyder	O
et	O
al	O
.	O
,	O
2014	O
;	O
Hayes	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
Meanwhile	O
,	O
the	O
function	O
of	O
the	O
PTS	O
is	O
also	O
inhibited	O
by	O
high	O
concentrations	O
of	O
several	O
metabolizable	O
PTS	O
sugars	O
(	O
Ye	O
and	O
Saier	O
,	O
1996	O
)	O
.	O
Thus	O
,	O
the	O
high	O
presence	O
of	O
“	O
PTS	O
”	O
and	O
“	O
Glycolysis	O
/	O
Gluconeogenesis	O
”	O
in	O
the	O
gut	O
microbiota	O
of	O
the	O
hadal	O
amphipods	O
pointed	O
to	O
the	O
low	O
carbon	O
content	O
in	O
the	O
three	O
hadal	O
trenches	O
,	O
consistent	O
with	O
a	O
previous	O
study	O
by	O
Zhang	O
et	O
al	O
.	O
(	O
2019	O
)	O
,	O
which	O
suggested	O
that	O
the	O
gut	O
microbes	O
mainly	O
generate	O
large	O
amounts	O
of	O
energy	O
to	O
maintain	O
their	O
normal	O
life	O
activities	O
in	O
a	O
hadal	O
environment	O
with	O
the	O
extreme	O
scarcity	O
of	O
food	O
supply	O
through	O
enhancing	O
the	O
PTS	O
and	O
Glycolysis	O
/	O
Gluconeogenesis	O
functional	O
pathways	O
.	O

Motility	O
is	O
another	O
important	O
adaptation	O
for	O
marine	O
bacteria	O
,	O
in	O
particular	O
to	O
avoiding	O
grazing	O
and	O
for	O
the	O
continuous	O
quest	O
for	O
nutrients	O
,	O
which	O
is	O
arguably	O
the	O
most	O
pressure	O
-	O
sensitive	O
cellular	O
process	O
in	O
the	O
surface	O
-	O
water	O
prokaryotes	O
(	O
Grossart	O
et	O
al	O
.	O
,	O
2001	O
;	O
Bartlett	O
,	O
2002	O
)	O
.	O
In	O
a	O
hadal	O
environment	O
,	O
the	O
hunt	O
for	O
dissolved	O
and	O
particulate	O
organic	O
matter	O
might	O
explain	O
a	O
large	O
number	O
of	O
MCPs	O
present	O
in	O
the	O
genomes	O
of	O
all	O
the	O
deep	O
bath	O
types	O
(	O
Azam	O
and	O
Long	O
,	O
2001	O
;	O
Kiorboe	O
and	O
Jackson	O
,	O
2001	O
)	O
,	O
including	O
the	O
hadal	O
amphipods	O
in	O
the	O
present	O
study	O
.	O
MCPs	O
are	O
signal	O
-	O
transducing	O
proteins	O
that	O
respond	O
to	O
gradients	O
of	O
chemicals	O
in	O
the	O
environment	O
,	O
relaying	O
a	O
signal	O
for	O
directional	O
swimming	O
to	O
the	O
flagellar	O
motor	O
.	O
These	O
sensory	O
systems	O
must	O
be	O
able	O
to	O
detect	O
miniscule	O
changes	O
in	O
the	O
surrounding	O
chemistry	O
to	O
enable	O
the	O
cells	O
to	O
maximize	O
their	O
productivity	O
and	O
growth	O
in	O
environments	O
of	O
small	O
amounts	O
of	O
spatially	O
and	O
temporally	O
distributed	O
food	O
supplies	O
(	O
Wirsen	O
and	O
Molyneaux	O
,	O
1999	O
)	O
.	O
Therefore	O
,	O
to	O
clarify	O
the	O
role	O
of	O
chemotaxis	O
in	O
bacteria	O
motility	O
,	O
the	O
motility	O
of	O
the	O
stably	O
MCP	O
recombinant	O
expression	O
clones	O
was	O
assessed	O
with	O
soft	O
agar	O
plate	O
motility	O
assays	O
(	O
Figures	O
5B	O
,	O
C	O
)	O
.	O
Larger	O
areas	O
of	O
plaque	O
were	O
observed	O
in	O
MCP	O
transfected	O
cells	O
in	O
our	O
study	O
(	O
Figures	O
5B	O
,	O
C	O
)	O
,	O
which	O
provided	O
evidence	O
that	O
MCP	O
promotes	O
the	O
swimming	O
capability	O
and	O
their	O
nutrients	O
utilization	O
efficiency	O
of	O
the	O
E	O
.	O
coli	O
and	O
also	O
proved	O
that	O
hadal	O
amphipods	O
gut	O
microbes	O
could	O
promote	O
their	O
survival	O
in	O
the	O
nutrient	O
-	O
poor	O
conditions	O
of	O
hadal	O
trenches	O
by	O
enhancing	O
chemotaxis	O
and	O
motility	O
.	O
In	O
addition	O
,	O
the	O
specific	O
3C8C	O
|	O
B	O
domain	O
was	O
only	O
detected	O
in	O
the	O
hadal	O
amphipod	O
MCP	O
in	O
our	O
study	O
(	O
Supplementary	O
Figure	O
3	O
)	O
and	O
which	O
belongs	O
to	O
the	O
periplasmic	O
sensor	O
-	O
like	O
domain	O
superfamily	O
and	O
is	O
a	O
compound	O
structure	O
of	O
the	O
double	O
cache	O
domain	O
that	O
have	O
been	O
predicted	O
to	O
have	O
a	O
role	O
in	O
small	O
-	O
molecule	O
recognition	O
in	O
a	O
wide	O
range	O
of	O
proteins	O
(	O
Anantharaman	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

Although	O
the	O
functionality	O
of	O
3C8C	O
|	O
B	O
is	O
as	O
yet	O
unknown	O
,	O
it	O
probably	O
makes	O
the	O
MCP	O
gene	O
specialized	O
to	O
the	O
hadal	O
microbes	O
,	O
however	O
,	O
which	O
needs	O
to	O
be	O
verified	O
by	O
substantive	O
validation	O
in	O
the	O
further	O
functional	O
experiments	O
.	O
Intestinal	O
microbiomes	O
are	O
complex	O
ecosystems	O
,	O
which	O
act	O
as	O
the	O
“	O
extra	O
organ	O
”	O
playing	O
an	O
important	O
role	O
in	O
maintaining	O
the	O
host	O
’	O
s	O
health	O
(	O
Heintz	O
-	O
Buschart	O
and	O
Wilmes	O
,	O
2018	O
)	O
.	O
Numerous	O
recent	O
studies	O
have	O
shown	O
that	O
several	O
intestinal	O
functions	O
are	O
achieved	O
through	O
bacterial	O
metabolism	O
,	O
which	O
may	O
benefit	O
the	O
host	O
by	O
improving	O
pathogen	O
defense	O
,	O
nutrient	O
absorption	O
,	O
homeostasis	O
maintenance	O
,	O
and	O
immune	O
response	O
(	O
Hooper	O
and	O
Macpherson	O
,	O
2010	O
;	O
Iwase	O
et	O
al	O
.	O
,	O
2010	O
;	O
Ridaura	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O
Probiotics	O
are	O
an	O
important	O
part	O
of	O
intestinal	O
microbiomes	O
and	O
are	O
defined	O
as	O
live	O
microorganisms	O
that	O
confer	O
a	O
benefit	O
on	O
the	O
host	O
and	O
which	O
could	O
contribute	O
to	O
inhibit	O
pathogenic	O
microorganisms	O
,	O
increase	O
the	O
immune	O
response	O
,	O
enzymatic	O
digestion	O
,	O
and	O
promote	O
growth	O
factors	O
of	O
organisms	O
(	O
Krummenauer	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O
Our	O
study	O
revealed	O
that	O
Lactobacillus	O
,	O
Bacillus	O
,	O
Lactococcus	O
,	O
Burkholderia	O
,	O
and	O
Leuconostoc	O
were	O
the	O
predominant	O
probiotic	O
genera	O
in	O
the	O
intestine	O
of	O
the	O
hadal	O
amphipods	O
(	O
Figure	O
6A	O
)	O
,	O
in	O
which	O
the	O
genera	O
Lactobacillus	O
,	O
Lactococcus	O
,	O
and	O
Leuconostoc	O
are	O
included	O
being	O
representatives	O
in	O
the	O
group	O
of	O
lactic	O
acid	O
bacteria	O
.	O
As	O
has	O
been	O
described	O
before	O
,	O
lactic	O
acid	O
bacteria	O
are	O
considered	O
to	O
be	O
very	O
important	O
,	O
as	O
they	O
could	O
produce	O
several	O
antimicrobial	O
substances	O
(	O
lactic	O
acid	O
,	O
H2O2	O
,	O
bacteriocins	O
,	O
etc	O
.	O
)	O
,	O
digestive	O
enzymes	O
(	O
amylase	O
,	O
lipase	O
,	O
protease	O
,	O
etc	O
.	O
)	O
,	O
and	O
coenzymes	O
(	O
folate	O
and	O
cobalamin	O
)	O
(	O
Carina	O
et	O
al	O
.	O
,	O
2011	O
;	O
LeBlanc	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Similarly	O
,	O
Bacillus	O
and	O
Burkholderia	O
have	O
also	O
been	O
shown	O
to	O
have	O
the	O
ability	O
to	O
produce	O
a	O
variety	O
of	O
digestive	O
enzymes	O
(	O
amylase	O
,	O
lipase	O
,	O
protease	O
,	O
etc	O
.	O
)	O
and	O
antimicrobial	O
substances	O
(	O
siderophores	O
,	O
pyrrolnitrin	O
,	O
monoterpenoid	O
alkaloids	O
,	O
etc	O
.	O
)	O
(	O
Aly	O
et	O
al	O
.	O
,	O
2008	O
;	O
Korkea	O
-	O
Aho	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O
In	O
addition	O
,	O
the	O
genus	O
Vibrio	O
was	O
the	O
most	O
dominant	O
probiotic	O
detected	O
in	O
this	O
study	O
.	O
Although	O
some	O
Vibrio	O
species	O
,	O
such	O
as	O
V	O
.	O
anguillarum	O
,	O
V	O
.	O
coralliilyticus	O
,	O
and	O
V	O
.	O
shiloi	O
,	O
are	O
considered	O
as	O
the	O
pathogens	O
of	O
aquatic	O
organisms	O
(	O
Austin	O
and	O
Zhang	O
,	O
2006	O
;	O
Frans	O
et	O
al	O
.	O
,	O
2011	O
)	O
,	O
most	O
species	O
from	O
this	O
genus	O
are	O
benign	O
,	O
such	O
as	O
V	O
.	O
alginolyticus	O
,	O
V	O
.	O
campbellii	O
,	O
and	O
V	O
.	O
fluvialis	O
detected	O
in	O
the	O
present	O
study	O
,	O
which	O
has	O
been	O
reported	O
to	O
increase	O
the	O
non	O
-	O
specific	O
immune	O
level	O
of	O
the	O
host	O
and	O
enhance	O
resistance	O
to	O
disease	O
(	O
Thompson	O
and	O
Polz	O
,	O
2006	O
;	O
Thompson	O
and	O
Swings	O
,	O
2006	O
)	O
.	O
Moreover	O
,	O
based	O
on	O
the	O
functional	O
analysis	O
of	O
probiotics	O
(	O
Figure	O
6B	O
)	O
and	O
the	O
functional	O
interaction	O
analysis	O
between	O
probiotics	O
and	O
the	O
host	O
(	O
Supplementary	O
Figure	O
4	O
)	O
,	O
we	O
also	O
preliminarily	O
confirm	O
the	O
interactions	O
between	O
intestinal	O
microorganisms	O
and	O
the	O
hadal	O
amphipods	O
.	O
Therefore	O
,	O
the	O
predominance	O
of	O
these	O
probiotics	O
in	O
the	O
hadal	O
amphipod	O
gut	O
would	O
be	O
considered	O
as	O
possible	O
contributors	O
for	O
promoting	O
host	O
biological	O
control	O
,	O
bioremediation	O
,	O
growth	O
,	O
and	O
development	O
and	O
may	O
greatly	O
facilitate	O
the	O
adaptation	O
of	O
hadal	O
amphipods	O
to	O
extreme	O
environments	O
.	O
Metagenomic	O
sequencing	O
overcomes	O
the	O
hurdles	O
of	O
amplicon	O
analysis	O
because	O
it	O
analyzes	O
total	O
DNA	O
extracted	O
from	O
samples	O
and	O
does	O
not	O
depend	O
on	O
target	O
-	O
specific	O
primers	O
.	O
However	O
,	O
for	O
the	O
analysis	O
of	O
host	O
-	O
derived	O
samples	O
,	O
this	O
advantage	O
of	O
metagenomic	O
sequencing	O
is	O
also	O
vulnerable	O
.	O
Because	O
the	O
host	O
genome	O
is	O
roughly	O
a	O
thousand	O
times	O
larger	O
than	O
an	O
average	O
bacterial	O
genome	O
,	O
host	O
DNA	O
can	O
quickly	O
drown	O
out	O
microbial	O
reads	O
in	O
samples	O
containing	O
even	O
a	O
relatively	O
small	O
number	O
of	O
host	O
cells	O
.	O

In	O
addition	O
,	O
the	O
proportion	O
of	O
host	O
cells	O
to	O
microbial	O
cells	O
varies	O
widely	O
by	O
sampling	O
site	O
;	O
for	O
instance	O
,	O
fecal	O
samples	O
from	O
healthy	O
controls	O
typically	O
yield	O
<	O
10	O
%	O
host	O
genome	O
-	O
aligned	O
reads	O
,	O
but	O
the	O
skin	O
sample	O
routinely	O
contains	O
>	O
90	O
%	O
(	O
Marotz	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
hadal	O
amphipod	O
mucosa	O
samples	O
were	O
used	O
for	O
metagenomic	O
sequencing	O
.	O
Because	O
there	O
was	O
no	O
available	O
reference	O
genome	O
of	O
hadal	O
amphipods	O
,	O
we	O
can	O
only	O
perform	O
the	O
host	O
removal	O
analysis	O
using	O
the	O
reference	O
genome	O
from	O
an	O
available	O
amphipod	O
(	O
H	O
.	O
Azteca	O
)	O
in	O
combination	O
with	O
the	O
strict	O
parameters	O
of	O
BWA	O
.	O
Despite	O
the	O
efforts	O
to	O
align	O
to	O
a	O
distant	O
relative	O
,	O
it	O
is	O
likely	O
that	O
there	O
is	O
still	O
host	O
contamination	O
present	O
in	O
the	O
reads	O
and	O
which	O
requires	O
further	O
improvements	O
,	O
such	O
as	O
improvements	O
to	O
sequencing	O
methods	O
(	O
Marotz	O
et	O
al	O
.	O
,	O
2018	O
)	O
and	O
DNA	O
extraction	O
methods	O
(	O
Feehery	O
et	O
al	O
.	O
,	O
2013	O
;	O
Fiedorová	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
All	O
sequencing	O
data	O
associated	O
with	O
this	O
project	O
were	O
deposited	O
in	O
the	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
(	O
NCBI	O
)	O
Sequence	O
Read	O
Archive	O
database	O
(	O
BioProject	O
Accession	O
Number	O
:	O
PRJNA648173	O
;	O
SRA	O
Accession	O
Number	O
:	O
SRR12315170	O
-	O
SRR12315178	O
.	O
Experimental	B-methodology
protocols	I-methodology
involved	O
dead	O
animals	O
in	O
this	O
study	O
.	O
QX	O
conceived	O
the	O
experiments	O
,	O
led	O
the	O
whole	O
project	O
,	O
and	O
contributed	O
to	O
edits	O
to	O
the	O
manuscript	O
.	O
JC	O
analyzed	O
the	O
data	O
and	O
performed	O
the	O
biological	O
experiments	O
.	O
BP	O
designed	O
the	O
lander	O
vehicle	O
for	O
sample	O
collection	O
.	O
DG	O
extracted	O
the	O
DNA	O
.	O
JC	O
,	O
DG	O
,	O
BP	O
,	O
and	O
QZ	O
collected	O
the	O
samples	O
.	O
JC	O
and	O
QX	O
wrote	O
the	O
manuscript	O
.	O
All	O
authors	O
contributed	O
to	O
the	O
article	O
and	O
approved	O
the	O
submitted	O
version	O
.	O
QZ	O
was	O
employed	O
by	O
the	O
company	O
Shanghai	O
Rainbowfish	O
Ocean	O
Technology	O
Co	O
.	O
,	O
Ltd	O
.	O
The	O
remaining	O
authors	O
declare	O
that	O
the	O
research	O
was	O
conducted	O
in	O
the	O
absence	O
of	O
any	O
commercial	O
or	O
financial	O
relationships	O
that	O
could	O
be	O
construed	O
as	O
a	O
potential	O
conflict	O
of	O
interest	O
.	O
Funding	O
.	O

This	O
work	O
was	O
supported	O
in	O
part	O
by	O
the	O
National	O
Key	O
R	O
&	O
D	O
Program	O
of	O
China	O
(	O
2018YFC0310600	O
and	O
2018YFD0900601	O
)	O
,	O
the	O
National	O
Natural	O
Science	O
Foundation	O
of	O
China	O
(	O
31772826	O
)	O
,	O
and	O
the	O
Major	O
Science	O
Innovation	O
Grant	O
(	O
2017	O
-	O
01	O
-	O
07	O
-	O
00	O
-	O
10	O
-	O
E00060	O
)	O
from	O
the	O
Shanghai	O
Education	O
Committee	O
.	O

Does	O
Japan	O
’	O
s	O
national	O
nutrient	O
-	O
based	O
dietary	O
guideline	B-methodology
improve	O
lifestyle	O
-	O
related	O
disease	O
outcomes	O
?	O
A	O
retrospective	O
observational	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
study	I-methodology
The	O
Japanese	O
government	O
has	O
developed	O
and	O
promoted	O
a	O
national	O
nutrient	O
-	O
based	O
dietary	O
guideline	B-methodology
for	O
preventing	O
lifestyle	O
-	O
related	O
chronic	O
disease	O
.	O
However	O
,	O
its	O
impact	O
in	O
a	O
real	O
-	O
life	O
setting	O
has	O
never	O
been	O
evaluated	O
.	O
We	O
performed	O
a	O
critical	O
appraisal	O
of	O
the	O
guideline	B-methodology
by	O
examining	O
the	O
association	O
between	O
adherence	O
to	O
the	O
guideline	B-methodology
and	O
lifestyle	O
-	O
related	O
outcome	O
indicators	O
.	O
This	O
is	O
a	O
retrospective	O
observational	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
study	I-methodology
using	O
nationally	O
representative	O
data	O
on	O
health	O
and	O
nutrition	O
characteristics	O
from	O
the	O
2016	O
National	O
Health	O
and	O
Nutrition	O
Survey	O
of	O
Japan	O
.	O
We	O
considered	O
3	O
,	O
861	O
participants	O
aged	O
≥20	O
years	O
,	O
with	O
evidence	O
of	O
low	O
health	O
risks	O
of	O
diabetes	O
,	O
hypertension	O
,	O
hyperlipidemia	O
,	O
and	O
obesity	O
.	O
Five	O
health	O
outcome	O
indicators	O
(	O
hemoglobin	O
A1c	O
(	O
HbA1c	O
)	O
,	O
systolic	O
blood	O
pressure	O
,	O
diastolic	O
blood	O
pressure	O
,	O
high	O
-	O
density	O
lipoprotein	O
cholesterol	O
,	O
and	O
body	O
mass	O
index	O
)	O
,	O
were	O
employed	O
.	O
A	O
summary	O
score	O
was	O
developed	O
to	O
reflect	O
adherence	O
to	O
the	O
recommended	O
intake	O
of	O
seven	O
nutrients	O
defined	O
by	O
the	O
guideline	B-methodology
,	O
including	O
proteins	O
,	O
fat	O
,	O
saturated	O
fatty	O
acid	O
,	O
carbohydrate	O
,	O
dietary	O
fiber	O
,	O
sodium	O
,	O
and	O
potassium	O
.	O
Multivariate	O
quartile	O
regression	O
approaches	O
were	O
employed	O
to	O
examine	O
the	O
association	O
between	O
the	O
adherence	O
score	O
and	O
the	O
health	O
outcome	O
indicators	O
,	O
adjusting	O
for	O
the	O
covariates	O
.	O
Overall	O
,	O
the	O
proportion	O
of	O
those	O
who	O
adhered	O
to	O
the	O
guideline	B-methodology
(	O
adherence	O
rate	O
)	O
for	O
all	O
seven	O
nutrients	O
was	O
only	O
0	O
.	O
3	O
%	O
.	O
There	O
was	O
considerable	O
variation	O
in	O
the	O
adherence	O
rate	O
between	O
the	O
different	O
nutrients	O
,	O
from	O
24	O
.	O
2	O
%	O
to	O
61	O
.	O
8	O
%	O
.	O
After	O
adjustment	O
for	O
covariates	O
,	O
in	O
most	O
health	O
outcome	O
indicators	O
,	O
regardless	O
of	O
age	O
category	O
and	O
quartile	O
,	O
there	O
was	O
no	O
clear	O
association	O
between	O
the	O
guideline	B-methodology
adherence	O
score	O
and	O
indicators	O
.	O
There	O
is	O
plenty	O
of	O
scope	O
for	O
improving	O
the	O
guideline	B-methodology
.	O
Nutrient	O
impact	O
on	O
health	O
may	O
not	O
necessarily	O
depend	O
on	O
the	O
amount	O
of	O
each	O
nutrient	O
in	O
the	O
diet	O
.	O
The	O
significance	O
and	O
contribution	O
of	O
synergies	O
between	O
nutrients	O
and	O
complex	O
interactions	O
within	O
foods	O
to	O
health	O
outcomes	O
need	O
to	O
be	O
explored	O
in	O
future	O
guideline	B-methodology
updates	O
.	O

Japan	O
is	O
one	O
of	O
the	O
most	O
successful	O
countries	O
in	O
the	O
world	O
on	O
account	O
of	O
excellent	O
health	O
outcomes	O
[	O
1	O
]	O
.	O
The	O
decline	O
in	O
disease	O
burden	O
in	O
Japan	O
in	O
the	O
last	O
decades	O
is	O
largely	O
due	O
to	O
a	O
substantial	O
decline	O
in	O
the	O
incidence	O
of	O
major	O
lifestyle	O
diseases	O
(	O
e	O
.	O
g	O
.	O
cerebrovascular	O
diseases	O
,	O
ischemic	O
heart	O
diseases	O
,	O
and	O
some	O
cancers	O
)	O
[	O
2	O
]	O
.	O
However	O
,	O
today	O
,	O
these	O
diseases	O
still	O
remain	O
top	O
causes	O
of	O
mortality	O
and	O
morbidity	O
,	O
and	O
the	O
progress	O
in	O
population	O
health	O
has	O
slowed	O
down	O
primarily	O
due	O
to	O
the	O
levelling	O
off	O
of	O
the	O
decline	O
in	O
disease	O
burden	O
.	O
More	O
efforts	O
are	O
therefore	O
needed	O
,	O
to	O
tackle	O
major	O
risk	O
factor	O
[	O
2	O
]	O
.	O
According	O
to	O
Nomura	O
and	O
colleagues	O
(	O
2017	O
)	O
,	O
behavioral	O
risk	O
factors	O
made	O
a	O
greater	O
contribution	O
to	O
the	O
overall	O
disease	O
burden	O
,	O
which	O
included	O
mortality	O
and	O
morbidity	O
(	O
25	O
.	O
2	O
%	O
)	O
in	O
2015	O
than	O
metabolic	O
risks	O
(	O
16	O
.	O
4	O
%	O
)	O
,	O
or	O
environmental	O
and	O
occupational	O
risks	O
(	O
4	O
.	O
4	O
%	O
)	O
[	O
2	O
]	O
.	O
Unhealthy	O
diets	O
(	O
high	O
in	O
sodium	O
or	O
low	O
in	O
whole	O
grains	O
,	O
fruits	O
,	O
vegetables	O
,	O
and	O
nuts	O
and	O
seeds	O
)	O
are	O
an	O
important	O
modifiable	O
behavioral	O
risk	O
factor	O
of	O
many	O
health	O
conditions	O
in	O
both	O
men	O
and	O
women	O
in	O
Japan	O
,	O
accounting	O
for	O
,	O
respectively	O
,	O
13	O
.	O
8	O
%	O
and	O
9	O
.	O
3	O
%	O
of	O
disease	O
burden	O
in	O
2015	O
[	O
2	O
]	O
.	O
A	O
recent	O
rising	O
tide	O
of	O
evidence	O
and	O
growing	O
interest	O
in	O
healthy	O
diet	O
,	O
driven	O
by	O
the	O
commercialization	O
of	O
healthy	O
foods	O
and	O
food	O
ingredients	O
,	O
highlights	O
the	O
substantial	O
opportunities	O
for	O
a	O
healthier	O
population	O
in	O
Japan	O
through	O
healthy	O
diet	O
[	O
2	O
–	O
4	O
]	O
.	O
The	O
Japan	O
Ministry	O
of	O
Health	O
,	O
Labour	O
and	O
Welfare	O
(	O
MHLW	O
)	O
established	O
the	O
Dietary	O
Reference	O
Intakes	O
(	O
DRIs	O
)	O
for	O
Japan	O
in	O
2005	O
and	O
revised	O
it	O
in	O
2010	O
and	O
2015	O
[	O
5	O
]	O
,	O
which	O
is	O
expected	O
to	O
be	O
revised	O
again	O
in	O
2020	O
.	O
The	O
DRIs	O
is	O
a	O
unique	O
national	O
nutrient	O
-	O
based	O
dietary	O
guideline	B-methodology
in	O
Japan	O
,	O
developed	O
on	O
the	O
basis	O
of	O
the	O
Health	O
Promotion	O
Act	O
and	O
promoted	O
by	O
the	O
government	O
.	O
The	O
guideline	B-methodology
promotes	O
healthy	O
diet	O
by	O
avoiding	O
adverse	O
health	O
effects	O
due	O
to	O
inadequacy	O
and	O
excessive	O
nutrient	O
intakes	O
,	O
and	O
for	O
preventing	O
lifestyle	O
-	O
related	O
chronic	O
disease	O
.	O
DRIs	O
include	O
tentative	O
dietary	O
goals	O
(	O
TDGs	O
)	O
,	O
defined	O
as	O
the	O
intake	O
range	O
for	O
seven	O
nutrients	O
that	O
Japanese	O
people	O
should	O
aim	O
for	O
,	O
to	O
reduce	O
the	O
risk	O
of	O
lifestyle	O
-	O
related	O
chronic	O
diseases	O
(	O
details	O
are	O
presented	O
below	O
)	O
.	O

Consumption	O
that	O
is	O
in	O
excess	O
or	O
falls	O
short	O
of	O
the	O
TDGs	O
potentially	O
confers	O
an	O
increased	O
risk	O
of	O
chronic	O
diseases	O
.	O
The	O
DRIs	O
/	O
TDGs	O
guidelines	B-methodology
are	O
widely	O
applied	O
in	O
practice	O
,	O
including	O
in	O
commercial	O
food	O
production	O
and	O
nutritional	O
education	O
[	O
6	O
,	O
7	O
]	O
.	O
For	O
example	O
,	O
the	O
Japanese	O
Food	O
Guide	O
Spinning	O
Top	O
was	O
developed	O
based	O
on	O
DRIs	O
,	O
which	O
is	O
a	O
chart	O
designed	O
for	O
the	O
general	O
public	O
,	O
indicating	O
with	O
illustrations	O
,	O
the	O
recommended	O
daily	O
servings	O
for	O
some	O
food	O
group	O
[	O
8	O
,	O
9	O
]	O
.	O
However	O
,	O
despite	O
convincing	O
evidence	O
that	O
nutrients	O
are	O
essential	O
for	O
human	O
health	O
,	O
to	O
our	O
knowledge	O
,	O
the	O
impact	O
of	O
TDGs	O
on	O
health	O
outcomes	O
has	O
never	O
been	O
evaluated	O
using	O
nationally	O
representative	O
data	O
.	O
The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
association	O
in	O
terms	O
of	O
direction	O
,	O
magnitude	O
,	O
and	O
significance	O
between	O
the	O
adherence	O
to	O
the	O
TDGs	O
and	O
health	O
outcomes	O
(	O
determined	O
based	O
on	O
the	O
availability	O
of	O
J	O
-	O
NHNS	O
data	O
)	O
using	O
the	O
National	O
Health	O
and	O
Nutrition	O
Survey	O
of	O
Japan	O
(	O
J	O
-	O
NHNS	O
)	O
.	O
We	O
used	O
data	O
from	O
the	O
National	O
Health	O
and	O
Nutrition	O
Survey	O
of	O
Japan	O
(	O
J	O
-	O
NHNS	O
)	O
performed	O
in	O
2016	O
.	O
J	O
-	O
NHNS	O
is	O
a	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
household	O
survey	O
,	O
carried	O
out	O
once	O
a	O
year	O
in	O
November	O
by	O
the	O
MHLW	O
[	O
10	O
,	O
11	O
]	O
.	O
The	O
objective	O
of	O
the	O
annual	O
J	O
-	O
NHNS	O
is	O
to	O
assess	O
the	O
physical	O
status	O
,	O
nutritional	O
intake	O
,	O
and	O
lifestyle	O
of	O
the	O
Japanese	O
people	O
,	O
for	O
comprehensive	O
promotion	O
of	O
the	O
population	O
health	O
.	O
The	O
J	O
-	O
NHNS	O
comprises	O
of	O
the	O
following	O
three	O
parts	O
:	O
1	O
)	O
physical	O
examination	O
including	O
a	O
blood	O
test	O
,	O
performed	O
by	O
physicians	O
at	O
designated	O
community	O
centers	O
;	O
2	O
)	O
an	O
in	O
-	O
person	O
dietary	O
survey	O
of	O
a	O
weighted	O
single	O
-	O
day	O
dietary	O
record	O
of	O
households	O
,	O
with	O
proportional	O
distribution	O
(	O
of	O
the	O
meal	O
pattern	O
,	O
food	O
items	O
,	O
etc	O
.	O
)	O
within	O
the	O
house	O
,	O
conducted	O
by	O
registered	O
dietitians	O
who	O
visits	O
each	O
household	O
and	O
checks	O
the	O
completeness	O
of	O
recording	O
forms	O
;	O
and	O
3	O
)	O
a	O
self	O
-	O
reported	O
lifestyle	O
questionnaire	O
(	O
including	O
occupation	O
,	O
smoking	O
,	O
and	O
alcohol	O
consumption	O
)	O
,	O
administered	O
along	O
with	O
the	O
dietary	O
survey	O
.	O
The	O
intake	O
of	O
energy	O
and	O
nutrients	O
were	O
estimated	O
(	O
as	O
part	O
of	O
J	O
-	O
NHNS	O
)	O
based	O
on	O
the	O
dietary	O
record	O
and	O
the	O
corresponding	O
food	O
composition	O
list	O
in	O
the	O
Standard	O
Tables	O
of	O
Food	O
Composition	O
in	O
Japan	O
(	O
sixth	O
revised	O
edition	O
as	O
at	O
2016	O
)	O
[	O
12	O
]	O
.	O
Other	O
data	O
included	O
age	O
(	O
as	O
of	O
1	O
November	O
2016	O
)	O
and	O
sex	O
.	O

In	O
the	O
2016	O
J	O
-	O
NHNS	O
,	O
using	O
a	O
stratified	O
single	O
-	O
stage	O
cluster	O
sample	O
design	O
,	O
census	O
enumeration	O
areas	O
were	O
drawn	O
from	O
each	O
prefecture	O
(	O
the	O
country	O
'	O
s	O
first	O
-	O
order	O
administrative	O
division	O
)	O
to	O
obtain	O
a	O
nationally	O
representative	O
sample	O
of	O
the	O
non	O
-	O
institutionalized	O
Japanese	O
population	O
.	O
A	O
total	O
of	O
24	O
,	O
187	O
households	O
from	O
475	O
randomly	O
selected	O
census	O
enumeration	O
areas	O
were	O
eligible	O
for	O
the	O
survey	O
.	O
The	O
response	O
rate	O
of	O
households	O
was	O
44	O
.	O
4	O
%	O
(	O
10	O
,	O
745	O
households	O
;	O
26	O
,	O
354	O
individuals	O
aged	O
1	O
year	O
and	O
older	O
)	O
[	O
13	O
]	O
.	O
Given	O
the	O
availability	O
of	O
J	O
-	O
NHNS	O
data	O
,	O
we	O
considered	O
the	O
following	O
five	O
health	O
outcome	O
indicators	O
related	O
to	O
nutrients	O
:	O
hemoglobin	O
A1c	O
(	O
HbA1c	O
)	O
,	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
,	O
diastolic	O
blood	O
pressure	O
(	O
DBP	O
)	O
,	O
high	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
HDL	O
-	O
C	O
)	O
,	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
.	O
They	O
are	O
known	O
to	O
be	O
associated	O
with	O
lifestyle	O
-	O
related	O
chronic	O
diseases	O
(	O
diabetes	O
,	O
high	O
blood	O
pressure	O
,	O
hyperlipidemia	O
,	O
obesity	O
,	O
etc	O
.	O
)	O
;	O
with	O
higher	O
values	O
indicating	O
a	O
greater	O
risk	O
of	O
the	O
diseases	O
(	O
except	O
for	O
HDL	O
-	O
C	O
,	O
where	O
the	O
lower	O
the	O
value	O
,	O
the	O
greater	O
the	O
risk	O
of	O
diseases	O
)	O
.	O
HbA1c	O
was	O
measured	O
in	O
National	O
Glycohemoglobin	O
Standardization	O
Program	O
(	O
NGSP	O
)	O
units	O
.	O
Given	O
the	O
nature	O
of	O
the	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
study	I-methodology
design	O
of	O
J	O
-	O
NHNS	O
,	O
reverse	O
causation	O
(	O
also	O
called	O
reverse	O
causality	O
)	O
is	O
possible	O
and	O
cannot	O
be	O
ruled	O
out	O
(	O
discussed	O
in	O
the	O
Discussion	O
section	O
)	O
[	O
14	O
,	O
15	O
]	O
.	O
Thus	O
,	O
to	O
minimize	O
the	O
likelihood	O
of	O
reverse	O
causation	O
as	O
much	O
as	O
possible	O
using	O
the	O
available	O
J	O
-	O
NHNS	O
data	O
,	O
we	O
excluded	O
those	O
who	O
might	O
be	O
aware	O
(	O
or	O
ought	O
to	O
be	O
aware	O
)	O
of	O
their	O
health	O
risks	O
including	O
:	O
those	O
with	O
a	O
HbA1c	O
of	O
≥6	O
.	O
5	O
%	O
or	O
taking	O
antihyperglycemic	O
agents	O
for	O
diabetes	O
;	O
those	O
with	O
an	O
LDL	O
-	O
C	O
of	O
≥140	O
mg	O
/	O
dL	O
or	O
HDL	O
-	O
C	O
of	O
≤40	O
mg	O
/	O
dL	O
,	O
or	O
taking	O
antihyperlipidemic	O
agents	O
;	O
those	O
with	O
a	O
SBP	O
of	O
≥140	O
mmHg	O
or	O
DBP	O
of	O
≥90	O
mmHg	O
,	O
or	O
taking	O
antihypertensive	O
agents	O
;	O
and	O
those	O
with	O
a	O
BMI	O
of	O
≥25	O
.	O

Furthermore	O
,	O
since	O
the	O
blood	O
test	O
and	O
lifestyle	O
questionnaire	O
were	O
not	O
administered	O
to	O
children	O
and	O
the	O
younger	O
population	O
aged	O
less	O
than	O
20	O
years	O
,	O
only	O
those	O
aged	O
20	O
years	O
or	O
older	O
were	O
considered	O
.	O
Because	O
of	O
the	O
unique	O
nutritional	O
needs	O
of	O
pregnant	O
women	O
,	O
we	O
also	O
excluded	O
them	O
from	O
the	O
analysis	O
.	O
DRIs	O
proposes	O
a	O
desirable	O
intake	O
of	O
energy	O
and	O
nutrients	O
for	O
Japanese	O
people	O
to	O
maintain	O
and	O
promote	O
their	O
health	O
[	O
5	O
]	O
.	O
Applicable	O
populations	O
are	O
healthy	O
individuals	O
.	O
TDGs	O
—	O
one	O
of	O
the	O
nutritional	O
indices	O
included	O
in	O
DRIs	O
with	O
emphasis	O
on	O
lifestyle	O
-	O
related	O
diseases	O
,	O
are	O
highlighted	O
among	O
others	O
:	O
e	O
.	O
g	O
.	O
recommended	O
dietary	O
allowance	O
,	O
adequate	O
intake	O
,	O
and	O
tolerable	O
upper	O
intake	O
level	O
.	O
This	O
is	O
because	O
—	O
as	O
the	O
DRIs	O
claims	O
—	O
it	O
is	O
based	O
on	O
a	O
sufficient	O
scientific	O
evidence	O
to	O
support	O
the	O
desired	O
intake	O
.	O
In	O
2015	O
,	O
DRIs	O
reported	O
TDGs	O
for	O
seven	O
nutrients	O
(	O
proteins	O
,	O
fat	O
,	O
saturated	O
fatty	O
acid	O
,	O
carbohydrates	O
[	O
excluding	O
sugar	O
]	O
,	O
dietary	O
fiber	O
,	O
sodium	O
,	O
and	O
potassium	O
)	O
by	O
age	O
category	O
(	O
18	O
–	O
69	O
and	O
≥70	O
years	O
old	O
)	O
and	O
sex	O
(	O
Table	O
1	O
)	O
,	O
where	O
there	O
was	O
sufficient	O
evidence	O
;	O
these	O
were	O
considered	O
in	O
this	O
study	O
(	O
i	O
.	O
e	O
.	O
target	O
nutrients	O
of	O
interest	O
)	O
.	O
TDGs	O
of	O
proteins	O
,	O
fat	O
,	O
saturated	O
fatty	O
acid	O
,	O
and	O
carbohydrate	O
are	O
expressed	O
as	O
a	O
percentage	O
of	O
the	O
total	O
energy	O
intake	O
.	O
This	O
is	O
because	O
its	O
goals	O
,	O
in	O
reality	O
,	O
are	O
not	O
independent	O
of	O
other	O
energy	O
sources	O
or	O
of	O
the	O
total	O
energy	O
goals	O
for	O
the	O
individual	O
.	O
Details	O
,	O
including	O
calculation	O
methods	O
of	O
TDGs	O
for	O
each	O
nutrient	O
,	O
are	O
described	O
elsewhere	O
[	O
5	O
]	O
.	O
Globally	O
there	O
are	O
more	O
than	O
25	O
indices	O
measuring	O
overall	O
diet	O
quality	O
and	O
/	O
or	O
variety	O
that	O
mostly	O
assesses	O
adherence	O
to	O
particular	O
dietary	O
recommendations	O
or	O
guidelines	B-methodology
,	O
specific	O
to	O
the	O
country	O
where	O
the	O
indices	O
were	O
developed	O
[	O
16	O
]	O
.	O
In	O
Japan	O
,	O
Oba	O
et	O
al	O
.	O
(	O
2009	O
)	O
developed	O
a	O
dietary	O
adherence	O
index	O
for	O
the	O
Japanese	O
population	O
[	O
9	O
]	O
,	O
and	O
identified	O
,	O
using	O
the	O
index	O
,	O
significant	O
(	O
for	O
women	O
)	O
and	O
non	O
-	O
significant	O
(	O
for	O
men	O
)	O
associations	O
of	O
higher	O
adherence	O
to	O
the	O
Japanese	O
Food	O
Guide	O
Spinning	O
Top	O
(	O
consisting	O
of	O
five	O
basic	O
food	O
[	O
not	O
nutrition	O
]	O
categories	O
)	O
with	O
lower	O
all	O
-	O
cause	O
mortality	O
[	O
9	O
]	O
.	O

According	O
to	O
their	O
methodology	O
,	O
we	O
calculated	O
a	O
summary	O
score	O
,	O
which	O
reflects	O
adherence	O
to	O
TDGs	O
from	O
a	O
maximum	O
of	O
10	O
to	O
a	O
minimum	O
of	O
0	O
for	O
each	O
nutrient	O
and	O
each	O
individual	O
;	O
with	O
a	O
higher	O
score	O
indicating	O
closer	O
adherence	O
and	O
thus	O
better	O
diet	O
.	O
If	O
individuals	O
consumed	O
the	O
TDGs	O
of	O
a	O
nutrient	O
of	O
interest	O
,	O
10	O
points	O
were	O
given	O
.	O
If	O
individuals	O
exceeded	O
or	O
fell	O
short	O
of	O
the	O
TDGs	O
,	O
the	O
score	O
was	O
calculated	O
proportionately	O
between	O
0	O
and	O
10	O
:	O
if	O
an	O
individual	O
consumed	O
less	O
than	O
the	O
TDGs	O
,	O
the	O
score	O
was	O
calculated	O
with	O
the	O
following	O
formula	O
:	O
10×amountofnutritionintakelowerlimitofTDGs	O
while	O
if	O
an	O
individual	O
consumed	O
more	O
than	O
the	O
TDGs	O
,	O
the	O
score	O
was	O
calculated	O
with	O
the	O
following	O
formula	O
:	O
10−10×amountofnutritionintake−upperlimitofTDGsupperlimitofTDGs	O
Scores	O
for	O
seven	O
nutrients	O
of	O
interest	O
were	O
summed	O
to	O
obtain	O
a	O
total	O
score	O
ranging	O
from	O
0	O
(	O
the	O
lowest	O
adherence	O
)	O
to	O
70	O
(	O
the	O
highest	O
adherence	O
)	O
.	O
Unless	O
indicated	O
otherwise	O
,	O
we	O
present	O
adherence	O
score	O
in	O
terms	O
of	O
the	O
total	O
score	O
for	O
the	O
seven	O
nutrients	O
.	O
Differences	O
in	O
values	O
between	O
the	O
stratified	O
groups	O
(	O
according	O
to	O
adherence	O
score	O
quantile	O
or	O
BMI	O
)	O
were	O
tested	O
using	O
Chi	O
-	O
squared	O
,	O
Fisher	O
’	O
s	O
exact	O
,	O
or	O
ANOVA	O
tests	O
depending	O
on	O
the	O
nature	O
of	O
the	O
data	O
.	O
Then	O
the	O
analysis	O
proceeded	O
by	O
age	O
category	O
(	O
20	O
–	O
39	O
,	O
40	O
–	O
59	O
,	O
or	O
≥60	O
years	O
old	O
)	O
using	O
multivariate	O
regression	O
approaches	O
to	O
quantify	O
the	O
association	O
of	O
adherence	O
score	O
with	O
the	O
health	O
outcome	O
indicators	O
,	O
adjusting	O
for	O
the	O
following	O
covariates	O
:	O
sex	O
,	O
occupation	O
(	O
engaged	O
in	O
primary	O
,	O
secondary	O
,	O
tertiary	O
,	O
or	O
other	O
industries	O
)	O
,	O
smoking	O
status	O
(	O
current	O
,	O
former	O
,	O
or	O
never	O
smoke	O
)	O
,	O
and	O
alcohol	O
consumption	O
status	O
(	O
frequently	O
[	O
≥3	O
days	O
/	O
week	O
]	O
,	O
sometimes	O
[	O
≤3	O
days	O
/	O
week	O
]	O
,	O
former	O
,	O
or	O
never	O
drink	O
)	O
.	O
To	O
adjust	O
for	O
possible	O
non	O
-	O
linearity	O
of	O
associations	O
between	O
outcome	O
indicators	O
and	O
total	O
energy	O
intake	O
,	O
we	O
considered	O
restricted	O
cubic	O
spline	O
with	O
three	O
knots	O
placed	O
at	O
the	O
25th	O
,	O
50th	O
,	O
and	O
75th	O
percentiles	O
of	O
total	O
energy	O
intake	O
as	O
a	O
covariate	O
in	O
the	O
following	O
regression	O
models	O
.	O
Two	O
regression	O
models	O
were	O
used	O
in	O
this	O
study	O
:	O
(	O
1	O
)	O
a	O
conventional	O
linear	O
regression	O
,	O
and	O
(	O
2	O
)	O
a	O
linear	O
quantitative	O
regression	O
.	O

First	O
,	O
to	O
estimate	O
the	O
conditional	O
mean	O
of	O
the	O
health	O
outcome	O
indicators	O
as	O
a	O
function	O
of	O
the	O
adherence	O
score	O
with	O
adjustment	O
for	O
covariates	O
,	O
we	O
applied	O
a	O
conventional	O
linear	O
mixed	O
effect	O
regression	O
approach	O
,	O
which	O
included	O
a	O
random	O
intercept	O
for	O
the	O
household	O
,	O
to	O
control	O
for	O
correlation	O
in	O
the	O
data	O
of	O
individuals	O
residing	O
in	O
the	O
same	O
household	O
.	O
Second	O
,	O
a	O
linear	O
quantile	O
regression	O
approach	O
with	O
the	O
random	O
intercept	O
for	O
the	O
household	O
effect	O
was	O
employed	O
to	O
estimate	O
the	O
conditional	O
quantile	O
function	O
of	O
the	O
adherence	O
score	O
,	O
adjusting	O
for	O
covariates	O
.	O
A	O
quantile	O
regression	O
,	O
a	O
statistical	O
tool	O
,	O
extends	O
the	O
conventional	O
mean	O
regression	O
method	O
beyond	O
its	O
application	O
to	O
characterize	O
the	O
entire	O
conditional	O
distribution	O
of	O
the	O
outcome	O
variable	O
(	O
i	O
.	O
e	O
.	O
health	O
outcome	O
indicators	O
)	O
.	O
It	O
also	O
provides	O
more	O
robust	O
results	O
with	O
deviations	O
from	O
normality	O
of	O
the	O
residual	O
[	O
17	O
]	O
.	O
Therefore	O
,	O
a	O
quantile	O
regression	O
allows	O
for	O
the	O
examination	O
of	O
any	O
distribution	O
of	O
the	O
outcome	O
variable	O
,	O
and	O
modelling	O
all	O
the	O
parameters	O
(	O
location	O
,	O
scale	O
,	O
and	O
shape	O
)	O
of	O
the	O
distribution	O
,	O
as	O
functions	O
of	O
the	O
explanatory	O
variables	O
(	O
i	O
.	O
e	O
.	O
adherence	O
score	O
)	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
estimation	O
was	O
performed	O
independently	O
for	O
each	O
quartile	O
(	O
25th	O
,	O
50th	O
,	O
and	O
75th	O
percentiles	O
)	O
.	O
The	O
optimization	O
algorithm	O
for	O
regression	O
estimation	O
relies	O
on	O
the	O
asymptotic	O
Laplace	O
-	O
based	O
likelihood	O
approximation	O
using	O
Gauss	O
-	O
Hermite	O
quadrature	O
with	O
seven	O
knots	O
[	O
18	O
]	O
.	O
It	O
should	O
be	O
noted	O
that	O
BMI	O
is	O
a	O
key	O
physiological	O
predictor	O
of	O
total	O
energy	O
intake	O
while	O
the	O
TDGs	O
of	O
proteins	O
,	O
fat	O
,	O
saturated	O
fatty	O
acids	O
,	O
and	O
carbohydrates	O
are	O
not	O
mutually	O
exclusive	O
,	O
because	O
they	O
are	O
expressed	O
as	O
a	O
percentage	O
of	O
the	O
total	O
energy	O
intake	O
.	O
Therefore	O
,	O
with	O
the	O
sensitivity	O
analyses	O
,	O
the	O
regression	O
models	O
were	O
also	O
estimated	O
by	O
the	O
two	O
different	O
BMI	O
categories	O
to	O
determine	O
differences	O
in	O
the	O
function	O
of	O
the	O
adherence	O
score	O
at	O
different	O
BMI	O
levels	O
.	O
According	O
to	O
the	O
DRIs	O
,	O
the	O
recommended	O
healthy	O
BMI	O
ranges	O
were	O
18	O
.	O
5	O
to	O
25	O
.	O
0	O
(	O
18	O
–	O
49	O
years	O
old	O
)	O
,	O
20	O
.	O
0	O
to	O
25	O
.	O
0	O
(	O
50	O
–	O
69	O
years	O
old	O
)	O
,	O
and	O
21	O
.	O
5	O
to	O
25	O
.	O
0	O
(	O
70	O
years	O
old	O
or	O
older	O
)	O
for	O
both	O
sexes	O
;	O
which	O
were	O
therefore	O
regarded	O
as	O
appropriate	O
categories	O
.	O
BMI	O
,	O
which	O
falls	O
below	O
these	O
ranges	O
were	O
considered	O
as	O
a	O
‘	O
poor	O
’	O
category	O
while	O
the	O
remaining	O
were	O
classed	O
as	O
the	O
‘	O
proper	O
’	O
category	O
.	O

Finally	O
,	O
other	O
sensitivity	O
analyses	O
included	O
the	O
regression	O
models	O
with	O
no	O
eligibility	O
criteria	O
for	O
participants	O
.	O
We	O
considered	O
p	O
-	O
values	O
less	O
than	O
0	O
.	O
05	O
as	O
statistically	O
significant	O
.	O
Ethical	O
approval	O
for	O
the	O
study	O
was	O
granted	O
by	O
the	O
ethics	O
committee	O
of	O
The	O
University	O
of	O
Tokyo	O
(	O
11964	O
)	O
.	O
Written	B-methodology
informed	I-methodology
consent	I-methodology
was	O
not	O
required	O
,	O
as	O
this	O
study	O
was	O
a	O
secondary	O
analysis	O
of	O
anonymized	O
data	O
that	O
is	O
collected	O
routinely	O
by	O
the	O
MHLW	O
.	O
A	O
total	O
of	O
3	O
,	O
861	O
participants	O
were	O
eligible	O
and	O
their	O
data	O
were	O
analyzed	O
in	O
this	O
study	O
.	O
Overall	O
,	O
the	O
proportion	O
of	O
those	O
who	O
adhered	O
to	O
guideline	B-methodology
(	O
adherence	O
rate	O
to	O
TDGs	O
)	O
for	O
all	O
seven	O
nutrients	O
was	O
only	O
0	O
.	O
3	O
%	O
,	O
while	O
the	O
highest	O
adherence	O
rate	O
was	O
observed	O
with	O
proteins	O
(	O
64	O
.	O
8	O
%	O
)	O
,	O
followed	O
by	O
carbohydrate	O
(	O
61	O
.	O
8	O
%	O
)	O
,	O
fat	O
(	O
50	O
.	O
0	O
%	O
)	O
,	O
saturated	O
fatty	O
acid	O
(	O
46	O
.	O
3	O
%	O
)	O
,	O
sodium	O
(	O
27	O
.	O
6	O
%	O
)	O
,	O
potassium	O
(	O
27	O
.	O
5	O
%	O
)	O
,	O
and	O
dietary	O
fiber	O
(	O
24	O
.	O
2	O
%	O
)	O
.	O
The	O
mean	O
and	O
median	O
adherence	O
scores	O
to	O
TDGs	O
were	O
60	O
.	O
03	O
(	O
standard	O
deviation	O
[	O
SD	O
]	O
6	O
.	O
37	O
)	O
and	O
60	O
.	O
70	O
(	O
interquartile	O
range	O
[	O
IQR	O
]	O
56	O
.	O
30	O
–	O
64	O
.	O
90	O
)	O
.	O
Scores	O
ranged	O
from	O
24	O
.	O
9	O
to	O
70	O
.	O
0	O
.	O
Compared	O
to	O
those	O
with	O
a	O
lower	O
adherence	O
score	O
,	O
those	O
with	O
a	O
higher	O
score	O
were	O
older	O
and	O
more	O
likely	O
to	O
be	O
women	O
,	O
be	O
engaged	O
in	O
primary	O
industry	O
,	O
and	O
have	O
a	O
higher	O
total	O
energy	O
intake	O
;	O
and	O
were	O
less	O
likely	O
to	O
be	O
current	O
smokers	O
or	O
to	O
drink	O
alcohol	O
frequently	O
(	O
≥3	O
days	O
/	O
week	O
)	O
(	O
Table	O
2	O
)	O
.	O
Intakes	O
of	O
the	O
seven	O
nutrients	O
among	O
the	O
study	O
population	O
are	O
presented	O
by	O
quantile	O
adherence	O
scores	O
in	O
Table	O
3	O
.	O
The	O
groups	O
with	O
higher	O
adherence	O
scores	O
had	O
a	O
greater	O
adherence	O
rate	O
for	O
each	O
nutrient	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
except	O
for	O
sodium	O
,	O
with	O
an	O
opposing	O
trend	O
;	O
the	O
greater	O
adherence	O
rate	O
was	O
observed	O
in	O
the	O
group	O
with	O
a	O
smaller	O
adherence	O
score	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
Intakes	O
of	O
the	O
seven	O
nutrients	O
by	O
BMI	O
category	O
are	O
shown	O
in	O
Table	O
4	O
.	O
The	O
proper	O
BMI	O
category	O
did	O
not	O
necessarily	O
have	O
a	O
higher	O
adherence	O
rate	O
for	O
each	O
nutrient	O
,	O
although	O
it	O
had	O
the	O
lowest	O
total	O
energy	O
(	O
<	O
0	O
.	O
001	O
)	O
.	O

Table	O
5	O
shows	O
the	O
estimated	O
regression	O
coefficient	O
of	O
the	O
adherence	O
score	O
to	O
the	O
health	O
outcome	O
indicators	O
using	O
linear	O
mixed	O
effect	O
conventional	O
and	O
quantile	O
regressions	O
.	O
After	O
adjustment	O
for	O
covariates	O
(	O
sex	O
,	O
occupation	O
,	O
smoking	O
status	O
,	O
alcohol	O
consumption	O
status	O
,	O
and	O
total	O
energy	O
intake	O
as	O
restricted	O
cubic	O
spline	O
)	O
,	O
the	O
null	O
(	O
non	O
-	O
significant	O
)	O
results	O
were	O
found	O
for	O
most	O
outcome	O
indicators	O
regardless	O
of	O
age	O
category	O
and	O
quartile	O
.	O
Thus	O
,	O
this	O
indicates	O
no	O
clear	O
association	O
of	O
TDGs	O
adherence	O
score	O
(	O
comprising	O
the	O
seven	O
nutrients	O
)	O
with	O
the	O
health	O
outcome	O
indicators	O
,	O
considered	O
in	O
this	O
study	O
.	O
SBP	O
,	O
among	O
a	O
group	O
of	O
20	O
–	O
30	O
and	O
40	O
–	O
59	O
-	O
year	O
-	O
old	O
participants	O
,	O
demonstrated	O
significant	O
results	O
with	O
positive	O
regression	O
coefficients	O
for	O
every	O
quantile	O
.	O
Importantly	O
,	O
a	O
positive	O
coefficient	O
means	O
that	O
the	O
higher	O
the	O
adherence	O
score	O
,	O
the	O
greater	O
the	O
SBP	O
,	O
while	O
better	O
(	O
lower	O
)	O
SBP	O
levels	O
indicate	O
better	O
overall	O
control	O
and	O
a	O
lesser	O
risk	O
of	O
hypertension	O
.	O
At	O
the	O
first	O
quantile	O
for	O
HDL	O
-	O
C	O
among	O
a	O
group	O
of	O
20	O
–	O
39	O
and	O
40	O
–	O
59	O
-	O
year	O
–	O
old	O
participants	O
,	O
a	O
significantly	O
negative	O
coefficient	O
was	O
estimated	O
.	O
This	O
implies	O
that	O
the	O
higher	O
the	O
adherence	O
score	O
,	O
the	O
lower	O
the	O
HDL	O
-	O
C	O
,	O
and	O
an	O
increased	O
risk	O
of	O
hyperlipidemia	O
.	O
With	O
the	O
sensitivity	O
analyses	O
,	O
the	O
regression	O
coefficients	O
of	O
adherence	O
score	O
to	O
the	O
health	O
outcome	O
indicators	O
were	O
also	O
estimated	O
by	O
two	O
different	O
BMI	O
categories	O
(	O
S1	O
and	O
S2	O
Tables	O
for	O
the	O
poor	O
and	O
proper	O
categories	O
,	O
respectively	O
)	O
,	O
which	O
yielded	O
similar	O
null	O
results	O
for	O
most	O
outcome	O
indicators	O
regardless	O
of	O
the	O
age	O
category	O
and	O
quartile	O
,	O
after	O
adjusting	O
for	O
covariates	O
.	O
Other	O
sensitivity	O
analyses	O
also	O
resulted	O
in	O
similar	O
results	O
(	O
S3	O
Table	O
)	O
in	O
terms	O
of	O
direction	O
,	O
magnitude	O
,	O
and	O
significance	O
,	O
except	O
for	O
SBP	O
in	O
25th	O
and	O
50th	O
quantiles	O
.	O
To	O
our	O
knowledge	O
,	O
the	O
present	O
study	O
is	O
the	O
first	O
to	O
perform	O
a	O
critical	O
appraisal	O
of	O
the	O
DRIs	O
by	O
examining	O
the	O
association	O
between	O
adherence	O
to	O
the	O
TDGs	O
and	O
lifestyle	O
-	O
related	O
chronic	O
outcome	O
indicators	O
.	O
Overall	O
,	O
only	O
0	O
.	O
3	O
%	O
of	O
the	O
study	O
population	O
adhered	O
to	O
TDGs	O
for	O
all	O
seven	O
nutrients	O
studied	O
;	O
and	O
there	O
was	O
a	O
large	O
range	O
in	O
the	O
adherence	O
rate	O
between	O
the	O
different	O
nutrients	O
from	O
24	O
.	O
2	O
%	O
to	O
61	O
.	O
8	O
%	O
.	O
We	O
found	O
that	O
a	O
higher	O
adherence	O
score	O
was	O
related	O
to	O
older	O
age	O
and	O
female	O
gender	O
(	O
Table	O
2	O
)	O
.	O

A	O
similar	O
age	O
and	O
gender	O
tendency	O
with	O
regard	O
to	O
dietary	O
guideline	B-methodology
adherence	O
was	O
observed	O
in	O
the	O
U	O
.	O
S	O
.	O
population	O
[	O
19	O
]	O
.	O
These	O
findings	O
indicate	O
the	O
difficulty	O
among	O
most	O
Japanese	O
,	O
especially	O
the	O
younger	O
male	O
population	O
,	O
in	O
meeting	O
the	O
TDGs	O
for	O
the	O
nutrients	O
in	O
their	O
daily	O
diet	O
.	O
While	O
there	O
was	O
a	O
clear	O
tendency	O
that	O
a	O
group	O
with	O
higher	O
adherence	O
score	O
had	O
the	O
greater	O
adherence	O
rate	O
for	O
each	O
nutrient	O
,	O
a	O
poor	O
adherence	O
rate	O
for	O
sodium	O
was	O
observed	O
in	O
a	O
group	O
with	O
higher	O
adherence	O
score	O
(	O
Table	O
3	O
)	O
.	O
Furthermore	O
,	O
that	O
some	O
stratified	O
groups	O
showed	O
significant	O
associations	O
between	O
a	O
higher	O
adherence	O
score	O
and	O
greater	O
SBP	O
and	O
DBP	O
levels	O
(	O
Table	O
5	O
)	O
,	O
could	O
be	O
attributed	O
to	O
higher	O
salt	O
intake	O
.	O
One	O
possible	O
mechanism	O
for	O
this	O
finding	O
includes	O
the	O
fact	O
that	O
adding	O
more	O
vegetables	O
,	O
fruits	O
and	O
/	O
or	O
fish	O
to	O
meals	O
,	O
which	O
is	O
widely	O
acknowledged	O
to	O
be	O
a	O
part	O
of	O
a	O
well	O
-	O
balanced	O
diet	O
,	O
may	O
actually	O
increase	O
the	O
amount	O
of	O
seasoning	O
,	O
which	O
then	O
results	O
in	O
greater	O
sodium	O
intake	O
.	O
In	O
fact	O
,	O
the	O
annual	O
report	O
of	O
the	O
2016	O
J	O
-	O
NHNS	O
reported	O
that	O
older	O
people	O
(	O
who	O
were	O
found	O
to	O
have	O
a	O
higher	O
adherence	O
score	O
in	O
this	O
study	O
)	O
,	O
are	O
more	O
likely	O
not	O
only	O
to	O
eat	O
vegetables	O
and	O
fish	O
,	O
but	O
were	O
also	O
more	O
likely	O
to	O
have	O
higher	O
salt	O
intake	O
[	O
13	O
]	O
.	O
The	O
daily	O
salt	O
intake	O
of	O
Japanese	O
is	O
known	O
to	O
be	O
approximately	O
9	O
.	O
2	O
gram	O
for	O
women	O
and	O
10	O
.	O
8	O
gram	O
for	O
men	O
in	O
2016	O
[	O
13	O
]	O
,	O
and	O
most	O
of	O
it	O
may	O
derive	O
from	O
seasonings	O
(	O
soy	O
sauce	O
,	O
table	O
salt	O
,	O
and	O
miso	O
)	O
,	O
bread	O
,	O
noodles	O
,	O
and	O
other	O
processed	O
foods	O
[	O
20	O
,	O
21	O
]	O
.	O
According	O
to	O
a	O
2018	O
study	O
conducted	O
by	O
Takimoto	O
et	O
al	O
.	O
,	O
using	O
the	O
data	O
of	O
the	O
2012	O
J	O
-	O
NHNS	O
[	O
22	O
]	O
,	O
82	O
.	O
1	O
%	O
of	O
the	O
Japanese	O
consumed	O
soy	O
sauce	O
on	O
the	O
day	O
the	O
survey	O
was	O
conducted	O
,	O
which	O
was	O
equivalent	O
to	O
an	O
average	O
intake	O
of	O
2	O
.	O
2	O
gram	O
of	O
salt	O
.	O
Also	O
,	O
many	O
Japanese	O
used	O
table	O
salt	O
and	O
miso	O
(	O
81	O
.	O
4	O
%	O
and	O
47	O
.	O
1	O
%	O
,	O
respectively	O
)	O
,	O
which	O
were	O
equivalent	O
to	O
1	O
.	O
6	O
gram	O
and	O
1	O
.	O
9	O
gram	O
of	O
salt	O
intake	O
on	O
average	O
,	O
respectively	O
[	O
22	O
]	O
.	O
In	O
addition	O
to	O
these	O
seasonings	O
,	O
about	O
1	O
–	O
3	O
%	O
of	O
the	O
people	O
consumed	O
processed	O
seafood	O
(	O
depending	O
on	O
the	O
product	O
)	O
,	O
which	O
corresponded	O
to	O
about	O
1	O
gram	O
of	O
salt	O
intake	O
[	O
22	O
]	O
.	O

About	O
1	O
.	O
0	O
%	O
of	O
the	O
people	O
ate	O
instant	O
Chinese	O
noodles	O
(	O
dried	O
by	O
frying	O
,	O
seasoned	O
)	O
,	O
which	O
was	O
equivalent	O
to	O
2	O
.	O
2	O
gram	O
of	O
salt	O
intake	O
[	O
22	O
]	O
.	O
These	O
results	O
imply	O
that	O
it	O
is	O
not	O
the	O
food	O
itself	O
but	O
the	O
way	O
in	O
which	O
it	O
is	O
cooked	O
or	O
seasoned	O
that	O
ultimately	O
influences	O
sodium	O
levels	O
in	O
the	O
body	O
.	O
The	O
source	O
of	O
sodium	O
should	O
be	O
clearly	O
considered	O
when	O
addressing	O
sodium	O
intake	O
reduction	O
.	O
Importantly	O
,	O
the	O
findings	O
of	O
the	O
multivariate	O
regression	O
analyses	O
imply	O
that	O
TDG	O
adherence	O
based	O
on	O
the	O
seven	O
nutrients	O
has	O
limited	O
beneficial	O
impact	O
(	O
and	O
an	O
adverse	O
effect	O
on	O
some	O
stratified	O
groups	O
)	O
on	O
the	O
indicators	O
,	O
after	O
adjusting	O
for	O
covariates	O
.	O
These	O
findings	O
support	O
existing	O
nutrition	O
science	O
understandings	O
that	O
the	O
level	O
of	O
each	O
nutrient	O
,	O
independent	O
of	O
the	O
source	O
of	O
the	O
nutrients	O
,	O
may	O
not	O
necessarily	O
explain	O
healthy	O
diet	O
[	O
23	O
,	O
24	O
]	O
.	O
Nutrition	O
science	O
is	O
evolving	O
today	O
and	O
experiencing	O
a	O
paradigm	O
shift	O
from	O
focusing	O
on	O
isolated	O
nutrients	O
,	O
deficiency	O
diseases	O
,	O
and	O
their	O
prevention	O
,	O
towards	O
foods	O
,	O
chronic	O
diseases	O
,	O
and	O
overall	O
diet	O
patterns	O
[	O
24	O
]	O
.	O
Such	O
a	O
scientific	O
shift	O
has	O
been	O
driven	O
by	O
emerging	O
recognition	O
of	O
the	O
diverse	O
,	O
complex	O
health	O
effects	O
of	O
different	O
foods	O
and	O
dietary	O
patterns	O
beyond	O
individual	O
nutrients	O
[	O
25	O
]	O
.	O
There	O
are	O
increasing	O
numbers	O
of	O
food	O
-	O
based	O
dietary	O
guidelines	O
aimed	O
at	O
preventing	O
lifestyle	O
-	O
related	O
chronic	O
diseases	O
[	O
24	O
]	O
,	O
which	O
commonly	O
recommend	O
that	O
people	O
eat	O
more	O
minimally	O
processed	O
,	O
bioactive	O
rich	O
foods	O
(	O
e	O
.	O
g	O
.	O
grains	O
,	O
fruits	O
,	O
and	O
vegetables	O
)	O
and	O
avoid	O
ultra	O
-	O
processed	O
foods	O
rich	O
in	O
ingredients	O
such	O
as	O
sugars	O
,	O
fats	O
,	O
and	O
industrial	O
additives	O
such	O
as	O
trans	O
-	O
fat	O
and	O
sodium	O
[	O
25	O
]	O
.	O
Many	O
studies	O
reported	O
that	O
a	O
quality	O
diet	O
with	O
greater	O
adherence	O
to	O
the	O
food	O
guidelines	B-methodology
led	O
to	O
a	O
lower	O
risk	O
of	O
mortality	O
and	O
morbidity	O
[	O
8	O
,	O
9	O
,	O
26	O
–	O
28	O
]	O
.	O
Our	O
study	O
findings	O
highlight	O
that	O
the	O
scope	O
for	O
improving	O
the	O
DRIs	O
/	O
TDGs	O
is	O
wide	O
.	O
As	O
Jacobs	O
et	O
al	O
.	O
(	O
2009	O
)	O
have	O
reported	O
,	O
foods	O
are	O
more	O
than	O
just	O
a	O
collection	O
of	O
nutrients	O
they	O
contain	O
[	O
23	O
]	O
.	O
There	O
are	O
synergies	O
between	O
nutrients	O
and	O
complex	O
interactions	O
within	O
foods	O
that	O
help	O
explain	O
associations	O
with	O
health	O
outcomes	O
[	O
23	O
,	O
29	O
,	O
30	O
]	O
.	O
This	O
is	O
referred	O
to	O
as	O
the	O
'	O
food	O
matrix	O
[	O
23	O
]	O
.	O
Therefore	O
,	O
the	O
significance	O
and	O
contribution	O
of	O
nutrient	O
interactions	O
in	O
a	O
food	O
matrix	O
to	O
health	O
outcomes	O
also	O
need	O
to	O
be	O
explored	O
in	O
future	O
guideline	B-methodology
updates	O
[	O
31	O
,	O
32	O
]	O
.	O

The	O
aforementioned	O
are	O
also	O
our	O
next	O
research	O
subject	O
.	O
In	O
addition	O
,	O
while	O
TDGs	O
for	O
proteins	O
,	O
fat	O
,	O
and	O
carbohydrates	O
were	O
expressed	O
as	O
a	O
percentage	O
of	O
total	O
energy	O
intake	O
,	O
a	O
desirable	O
energy	O
requirement	O
was	O
not	O
considered	O
in	O
a	O
TDG	O
context	O
.	O
In	O
other	O
words	O
,	O
for	O
example	O
,	O
a	O
high	O
intake	O
of	O
carbohydrates	O
was	O
not	O
considered	O
a	O
concern	O
.	O
Therefore	O
,	O
the	O
reference	O
intake	O
for	O
total	O
energy	O
that	O
could	O
maintain	O
or	O
achieve	O
a	O
proper	O
BMI	O
level	O
should	O
be	O
determined	O
while	O
taking	O
into	O
account	O
energy	O
consumption	O
(	O
i	O
.	O
e	O
.	O
energy	O
balance	O
)	O
,	O
although	O
this	O
is	O
difficult	O
due	O
to	O
the	O
possibility	O
of	O
a	O
high	O
variability	O
between	O
individuals	O
.	O
Our	O
analyses	O
are	O
subject	O
to	O
similar	O
limitations	O
as	O
are	O
described	O
for	O
other	O
studies	O
concerning	O
dietary	O
adherence	O
[	O
8	O
,	O
9	O
]	O
.	O
First	O
,	O
dietary	O
intake	O
was	O
based	O
on	O
a	O
weighted	O
single	O
-	O
day	O
dietary	O
record	O
,	O
which	O
might	O
not	O
represent	O
reproducibility	O
of	O
dietary	O
patterns	O
in	O
the	O
long	O
term	O
.	O
Also	O
,	O
the	O
single	O
-	O
day	O
data	O
does	O
not	O
reflect	O
seasonal	O
variations	O
in	O
dietary	O
patterns	O
.	O
Also	O
,	O
self	O
-	O
reporting	O
in	O
the	O
dietary	O
survey	O
and	O
lifestyle	O
questionnaire	O
renders	O
the	O
participants	O
susceptible	O
to	O
social	O
desirability	O
response	O
bias	O
and	O
recall	O
bias	O
due	O
to	O
subjectivity	O
and	O
poor	O
memory	O
.	O
Unfortunately	O
,	O
there	O
are	O
no	O
data	O
available	O
for	O
testing	O
the	O
validity	O
of	O
their	O
responses	O
.	O
In	O
addition	O
,	O
relying	O
on	O
household	O
representatives	O
to	O
record	O
dietary	O
intake	O
on	O
the	O
survey	O
may	O
lead	O
to	O
biased	O
estimates	O
of	O
the	O
dietary	O
intake	O
of	O
individual	O
respondents	O
,	O
particularly	O
for	O
those	O
who	O
work	O
and	O
have	O
lunch	O
outside	O
the	O
home	O
on	O
weekdays	O
[	O
11	O
]	O
.	O
However	O
,	O
it	O
should	O
be	O
noted	O
that	O
monitoring	O
the	O
daily	O
dietary	O
intake	O
of	O
individuals	O
is	O
challenging	O
owing	O
to	O
the	O
technical	O
,	O
financial	O
,	O
and	O
practical	O
difficulties	O
,	O
as	O
well	O
as	O
barriers	O
involving	O
privacy	O
issues	O
that	O
make	O
people	O
reluctant	O
to	O
participate	O
in	O
such	O
monitoring	O
exercises	O
.	O
In	O
this	O
context	O
,	O
we	O
would	O
like	O
to	O
emphasize	O
that	O
the	O
nationally	O
representative	O
,	O
large	O
-	O
scale	O
data	O
from	O
J	O
-	O
NHNS	O
offered	O
a	O
unique	O
and	O
valuable	O
opportunity	O
for	O
us	O
to	O
perform	O
this	O
study	O
with	O
sufficient	O
quality	O
dietary	O
data	O
in	O
order	O
to	O
better	O
understand	O
associations	O
of	O
adherence	O
to	O
TDGs	O
with	O
chronic	O
diseases	O
indicators	O
.	O
Second	O
,	O
we	O
could	O
not	O
rule	O
out	O
the	O
confounding	O
effects	O
of	O
unmeasured	O
predictors	O
of	O
negative	O
health	O
outcomes	O
,	O
such	O
as	O
low	O
physical	O
activity	O
and	O
functional	O
decline	O
including	O
frailty	O
and	O
sarcopenia	O
among	O
older	O
adults	O
[	O
33	O
]	O
.	O

Although	O
J	O
-	O
NHNS	O
recording	O
forms	O
include	O
physical	O
activity	O
levels	O
,	O
most	O
participants	O
did	O
not	O
report	O
it	O
;	O
thus	O
,	O
we	O
were	O
not	O
able	O
to	O
adjust	O
for	O
potentially	O
different	O
physical	O
activity	O
levels	O
among	O
the	O
study	O
population	O
in	O
the	O
analyses	O
.	O
Other	O
social	O
determinants	O
of	O
health	O
including	O
social	O
,	O
economic	O
,	O
and	O
environmental	O
conditions	O
were	O
also	O
not	O
considered	O
in	O
the	O
study	O
.	O
There	O
is	O
the	O
possibility	O
that	O
the	O
effects	O
of	O
these	O
unmeasured	O
factors	O
might	O
conceal	O
those	O
of	O
TDG	O
adherence	O
on	O
the	O
health	O
outcome	O
indicators	O
.	O
Third	O
,	O
the	O
different	O
nutrients	O
have	O
not	O
been	O
weighted	O
for	O
adherence	O
score	O
calculation	O
.	O
Adherence	O
to	O
TDGs	O
for	O
each	O
nutrient	O
was	O
scored	O
from	O
a	O
maximum	O
of	O
10	O
to	O
a	O
minimum	O
of	O
0	O
for	O
each	O
individual	O
,	O
and	O
scores	O
for	O
the	O
seven	O
nutrients	O
were	O
simply	O
summed	O
up	O
to	O
obtain	O
the	O
total	O
score	O
ranging	O
from	O
0	O
(	O
the	O
lowest	O
adherence	O
)	O
to	O
70	O
(	O
the	O
highest	O
adherence	O
)	O
.	O
How	O
the	O
"	O
best	O
"	O
adherence	O
score	O
(	O
that	O
is	O
,	O
the	O
"	O
best	O
"	O
weighting	O
scheme	O
)	O
is	O
actually	O
defined	O
requires	O
a	O
clear	O
understanding	O
of	O
what	O
the	O
optimal	O
weight	O
is	O
and	O
how	O
it	O
could	O
be	O
optimized	O
.	O
This	O
is	O
a	O
large	O
study	O
subject	O
in	O
itself	O
[	O
34	O
,	O
35	O
]	O
,	O
and	O
was	O
beyond	O
the	O
scope	O
of	O
this	O
study	O
,	O
so	O
it	O
shall	O
be	O
considered	O
as	O
the	O
next	O
research	O
subject	O
.	O
Fourth	O
,	O
the	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
nature	O
of	O
this	O
study	O
limits	O
the	O
drawing	O
of	O
inferences	O
about	O
causation	O
.	O
Importantly	O
,	O
the	O
potential	O
for	O
reverse	O
causation	O
(	O
also	O
called	O
reverse	O
causality	O
)	O
,	O
which	O
refers	O
to	O
a	O
direction	O
of	O
cause	O
-	O
and	O
-	O
effect	O
that	O
is	O
the	O
opposite	O
of	O
the	O
expected	O
outcome	O
,	O
could	O
be	O
a	O
challenge	O
in	O
determining	O
a	O
causal	O
relationship	O
between	O
dietary	O
patterns	O
and	O
health	O
outcome	O
indicators	O
.	O
This	O
tends	O
to	O
be	O
inevitable	O
in	O
observational	B-methodology
studies	I-methodology
[	O
15	O
]	O
.	O
In	O
this	O
study	O
,	O
a	O
possible	O
direction	O
of	O
causation	O
would	O
include	O
that	O
closer	O
adherence	O
to	O
TDGs	O
results	O
in	O
better	O
health	O
outcome	O
indicators	O
.	O
On	O
the	O
other	O
hand	O
,	O
reverse	O
causality	O
may	O
occur	O
with	O
changes	O
in	O
peoples	O
’	O
dietary	O
patterns	O
following	O
disease	O
occurrence	O
.	O
For	O
example	O
,	O
people	O
become	O
concerned	O
about	O
being	O
at	O
high	O
risk	O
of	O
having	O
diabetes	O
after	O
being	O
told	O
of	O
such	O
by	O
their	O
general	O
practitioner	O
;	O
thus	O
,	O
they	O
are	O
more	O
likely	O
than	O
the	O
healthier	O
,	O
low	O
-	O
risk	O
population	O
to	O
reduce	O
their	O
intake	O
of	O
foods	O
high	O
in	O
saturated	O
fat	O
and	O
carbohydrates	O
.	O
Thus	O
,	O
although	O
their	O
current	O
diets	O
are	O
now	O
lower	O
in	O
saturated	O
fat	O
and	O
carbohydrates	O
,	O
their	O
risk	O
of	O
developing	O
diabetes	O
may	O
still	O
be	O
high	O
.	O

Thus	O
,	O
to	O
minimize	O
the	O
likelihood	O
of	O
reverse	O
causation	O
as	O
much	O
as	O
possible	O
using	O
the	O
available	O
J	O
-	O
NHNS	O
data	O
,	O
we	O
excluded	O
those	O
who	O
might	O
be	O
aware	O
(	O
or	O
ought	O
to	O
be	O
aware	O
)	O
of	O
their	O
health	O
risks	O
(	O
see	O
the	O
methods	O
section	O
)	O
.	O
Other	O
underlying	O
diseases	O
known	O
to	O
be	O
associated	O
with	O
dietary	O
risks	O
(	O
e	O
.	O
g	O
.	O
liver	O
disease	O
,	O
chronic	O
kidney	O
disease	O
,	O
and	O
gastrointestinal	O
disease	O
)	O
,	O
may	O
still	O
cause	O
reverse	O
causality	O
.	O
Fifth	O
,	O
we	O
made	O
a	O
number	O
of	O
comparisons	O
,	O
and	O
some	O
statistically	O
significant	O
associations	O
may	O
have	O
occurred	O
owing	O
to	O
chance	O
events	O
.	O
In	O
this	O
study	O
,	O
the	O
regression	O
approach	O
theoretically	O
assumed	O
the	O
independence	O
of	O
the	O
set	O
of	O
participants	O
between	O
regression	O
models	O
(	O
for	O
the	O
different	O
outcomes	O
)	O
.	O
Of	O
course	O
,	O
these	O
models	O
were	O
built	O
with	O
identical	O
participants	O
and	O
hence	O
,	O
this	O
assumption	O
was	O
not	O
fully	O
met	O
.	O
Therefore	O
,	O
the	O
inflation	O
of	O
the	O
alpha	O
error	O
by	O
multiple	O
comparisons	O
can	O
actually	O
be	O
a	O
problem	O
.	O
For	O
example	O
,	O
we	O
observed	O
increased	O
levels	O
of	O
HbA1c	O
among	O
those	O
the	O
20	O
–	O
39	O
and	O
40	O
–	O
59	O
years	O
age	O
categories	O
who	O
had	O
a	O
higher	O
adherence	O
score	O
(	O
Table	O
5	O
)	O
.	O
This	O
was	O
not	O
concordant	O
with	O
our	O
expected	O
direction	O
of	O
association	O
.	O
A	O
two	O
-	O
way	O
ANOVA	O
could	O
be	O
an	O
alternative	O
analysis	O
approach	O
.	O
However	O
,	O
this	O
approach	O
has	O
a	O
different	O
type	O
of	O
problems	O
.	O
While	O
it	O
models	O
the	O
‘	O
mean	O
’	O
variance	O
structure	O
of	O
factors	O
(	O
i	O
.	O
e	O
.	O
,	O
independent	O
variables	O
)	O
,	O
we	O
would	O
like	O
to	O
focus	O
on	O
1	O
)	O
the	O
local	O
structure	O
around	O
the	O
quantiles	O
of	O
the	O
adherence	O
score	O
distribution	O
conditioned	O
by	O
the	O
random	O
intercept	O
for	O
the	O
household	O
,	O
and	O
2	O
)	O
the	O
estimated	O
coefficients	O
of	O
the	O
score	O
on	O
the	O
outcomes	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
direction	O
,	O
magnitude	O
,	O
and	O
significance	O
of	O
the	O
score	O
)	O
.	O
A	O
two	O
-	O
way	O
ANOVA	O
cannot	O
explicitly	O
model	O
these	O
two	O
points	O
.	O
Therefore	O
,	O
we	O
decided	O
to	O
use	O
a	O
quantile	O
regression	O
approach	O
instead	O
of	O
two	O
-	O
way	O
ANOVA	O
.	O
Sixth	O
,	O
the	O
decision	O
to	O
choose	O
HbA1c	O
,	O
SBP	O
,	O
DBP	O
,	O
HDL	O
-	O
C	O
,	O
and	O
BMI	O
as	O
health	O
outcome	O
indicators	O
(	O
the	O
dependent	O
variables	O
)	O
was	O
based	O
on	O
data	O
availability	O
.	O
Future	O
studies	O
should	O
explore	O
outcomes	O
as	O
a	O
whole	O
to	O
attempt	O
to	O
comprehensively	O
evaluate	O
the	O
health	O
impact	O
of	O
TDGs	O
.	O
Finally	O
,	O
as	O
a	O
consequence	O
of	O
this	O
exclusion	O
of	O
people	O
who	O
have	O
disease	O
risks	O
,	O
the	O
potential	O
impact	O
of	O
poor	O
TDGs	O
adherence	O
on	O
the	O
health	O
outcome	O
indicators	O
might	O
be	O
reduced	O
or	O
eliminated	O
because	O
of	O
a	O
healthier	O
population	O
.	O

However	O
,	O
our	O
sensitivity	O
analyses	O
,	O
i	O
.	O
e	O
.	O
the	O
regression	O
analyses	O
of	O
those	O
who	O
failed	O
to	O
meet	O
the	O
eligibility	O
criteria	O
,	O
demonstrated	O
similar	O
results	O
,	O
indicating	O
that	O
the	O
influence	O
of	O
this	O
limitation	O
may	O
be	O
marginal	O
.	O
This	O
manuscript	O
is	O
an	O
original	O
work	O
that	O
has	O
not	O
been	O
submitted	O
for	O
consideration	O
or	O
published	O
elsewhere	O
.	O
This	O
study	O
is	O
partially	O
supported	O
by	O
a	O
joint	O
research	O
grant	O
from	O
Ajinomoto	O
Co	O
.	O
,	O
Inc	O
.	O
,	O
and	O
Grants	O
-	O
in	O
-	O
Aid	O
for	O
Scientific	O
Research	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Culture	O
,	O
Sports	O
,	O
Science	O
and	O
Technology	O
of	O
Japan	O
(	O
MEXT	O
)	O
.	O
KN	O
,	O
HU	O
,	O
and	O
NH	O
are	O
employed	O
by	O
the	O
commercial	O
founder	O
,	O
Ajinomoto	O
Co	O
.	O
,	O
Inc	O
.	O
The	O
commercial	O
funder	O
provided	O
support	O
in	O
the	O
form	O
of	O
salaries	O
for	O
KN	O
,	O
HU	O
,	O
and	O
NH	O
,	O
but	O
did	O
not	O
have	O
any	O
additional	O
role	O
in	O
the	O
study	B-methodology
design	I-methodology
,	O
data	O
collection	O
and	O
analysis	O
,	O
decision	O
to	O
publish	O
,	O
or	O
preparation	O
of	O
the	O
manuscript	O
.	O
The	O
specific	O
roles	O
of	O
these	O
authors	O
are	O
articulated	O
in	O
the	O
‘	O
author	O
contributions	O
’	O
section	O
.	O
The	O
other	O
funder	O
(	O
MEXT	O
)	O
had	O
also	O
no	O
role	O
in	O
the	O
study	B-methodology
design	I-methodology
,	O
data	O
collection	O
and	O
analysis	O
,	O
decision	O
to	O
publish	O
,	O
or	O
preparation	O
of	O
the	O
manuscript	O
.	O
Data	O
used	O
in	O
this	O
study	O
(	O
from	O
the	O
National	O
Health	O
and	O
Nutrition	O
Survey	O
of	O
Japan	O
performed	O
in	O
2016	O
)	O
are	O
accessible	O
via	O
a	O
request	O
to	O
Ministry	O
of	O
Health	O
,	O
Labour	O
and	O
Welfare	O
(	O
MHLW	O
)	O
based	O
on	O
Article	O
33	O
of	O
the	O
Statistics	O
Act	O
(	O
Act	O
No	O
.	O
53	O
in	O
2007	O
)	O
,	O
and	O
the	O
initial	O
contact	O
address	O
for	O
the	O
data	O
request	O
is	O
Office	O
of	O
Director	O
-	O
General	O
for	O
Policy	O
Planning	O
on	O
Statistical	O
Standards	O
,	O
Ministry	O
of	O
Internal	O
Affairs	O
and	O
Communications	O
(	O
MIC	O
)	O
:	O
TEL	O
03	O
-	O
5273	O
-	O
1019	O
FAX	O
;	O
03	O
-	O
5273	O
-	O
1181	O
MAIL	O
;	O
s	O
-	O
2jiriyou	O
@	O
soumu	O
.	O
go	O
.	O
jp	O
.	O

Targeting	O
on	O
Gut	O
Microbiota	O
-	O
Derived	O
Metabolite	O
Trimethylamine	O
to	O
Protect	O
Adult	O
Male	O
Rat	O
Offspring	O
against	O
Hypertension	O
Programmed	O
by	O
Combined	O
Maternal	O
High	O
-	O
Fructose	O
Intake	O
and	O
Dioxin	O
Exposure	O
developmental	O
origins	O
of	O
health	O
and	O
disease	O
(	O
DOHaD	O
)	O
;	O
fructose	O
;	O
gut	O
microbiota	O
;	O
hypertension	O
;	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
(	O
TCDD	O
)	O
;	O
trimethylamine	O
;	O
trimethylamine	O
N	O
-	O
oxide	O
(	O
TMAO	O
)	O
Gut	O
microbiota	O
-	O
dependent	O
metabolites	O
,	O
in	O
particular	O
trimethylamine	O
(	O
TMA	O
)	O
,	O
are	O
linked	O
to	O
hypertension	O
.	O
Maternal	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
(	O
TCDD	O
)	O
exposure	O
or	O
consumption	O
of	O
food	O
high	O
in	O
fructose	O
(	O
HFR	O
)	O
can	O
induce	O
hypertension	O
in	O
adult	O
offspring	O
.	O
We	O
examined	O
whether	O
3	O
,	O
3	O
-	O
maternal	O
dimethyl	O
-	O
1	O
-	O
butanol	O
(	O
DMB	O
,	O
an	O
inhibitor	O
of	O
TMA	O
formation	O
)	O
therapy	O
can	O
protect	O
adult	O
offspring	O
against	O
hypertension	O
arising	O
from	O
combined	O
HFR	O
and	O
TCDD	O
exposure	O
.	O
Pregnant	O
Sprague	O
–	O
Dawley	O
rats	O
received	O
regular	O
chow	O
or	O
chow	O
supplemented	O
with	O
fructose	O
(	O
60	O
%	O
diet	O
by	O
weight	O
)	O
throughout	O
pregnancy	O
and	O
lactation	O
.	O
Additionally	O
,	O
the	O
pregnant	O
dams	O
received	O
TCDD	O
(	O
200	O
ng	O
/	O
kg	O
BW	O
orally	O
)	O
or	O
a	O
corn	O
oil	O
vehicle	O
on	O
days	O
14	O
and	O
21	O
of	O
gestation	O
,	O
and	O
days	O
7	O
and	O
14	O
after	O
birth	O
.	O
Some	O
mother	O
rats	O
received	O
1	O
%	O
DMB	O
in	O
their	O
drinking	O
water	O
throughout	O
pregnancy	O
and	O
lactation	O
.	O
Six	O
groups	O
of	O
male	O
offspring	O
were	O
studied	O
(	O
n	O
=	O
8	O
for	O
each	O
group	O
)	O
:	O
regular	O
chow	O
(	O
CV	O
)	O
,	O
high	O
-	O
fructose	O
diet	O
(	O
HFR	O
)	O
,	O
regular	O
diet	O
+	O
TCDD	O
exposure	O
(	O
CT	O
)	O
,	O
HFR	O
+	O
TCDD	O
exposure	O
(	O
HRT	O
)	O
,	O
high	O
-	O
fructose	O
diet	O
+	O
DMB	O
treatment	O
(	O
HRD	O
)	O
,	O
and	O
HFR	O
+	O
TCDD	O
+	O
DMB	O
treatment	O
(	O
HRTD	O
)	O
.	O
Our	O
data	O
showed	O
that	O
TCDD	O
exacerbates	O
HFR	O
-	O
induced	O
elevation	O
of	O
blood	O
pressure	O
in	O
male	O
adult	O
offspring	O
,	O
which	O
was	O
prevented	O
by	O
maternal	O
DMB	O
administration	O
.	O
We	O
observed	O
that	O
different	O
maternal	O
insults	O
induced	O
distinct	O
enterotypes	O
in	O
adult	O
offspring	O
.	O

The	O
beneficial	O
effects	O
of	O
DMB	O
are	O
related	O
to	O
alterations	O
of	O
gut	O
microbiota	O
,	O
the	O
increase	O
in	O
nitric	O
oxide	O
(	O
NO	O
)	O
bioavailability	O
,	O
the	O
balance	O
of	O
the	O
renin	O
-	O
angiotensin	O
system	O
,	O
and	O
antagonization	O
of	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AHR	O
)	O
signaling	O
.	O
Our	O
findings	O
cast	O
new	O
light	O
on	O
the	O
role	O
of	O
early	O
intervention	O
targeting	O
of	O
the	O
gut	O
microbiota	O
-	O
dependent	O
metabolite	O
TMA	O
,	O
which	O
may	O
allow	O
us	O
to	O
prevent	O
the	O
development	O
of	O
hypertension	O
programmed	O
by	O
maternal	O
excessive	O
fructose	O
intake	O
and	O
environmental	O
dioxin	O
exposure	O
.	O
The	O
global	O
consumption	O
of	O
fructose	O
per	O
capita	O
has	O
grown	O
exponentially	O
during	O
the	O
past	O
few	O
decades	O
[	O
1	O
]	O
.	O
A	O
diet	O
high	O
in	O
fructose	O
consumed	O
during	O
pregnancy	O
not	O
only	O
induces	O
adverse	O
effects	O
for	O
mothers	O
,	O
but	O
also	O
for	O
their	O
adult	O
offspring	O
[	O
2	O
,	O
3	O
]	O
.	O
The	O
origins	O
of	O
many	O
adult	O
diseases	O
can	O
be	O
traced	O
to	O
negative	O
experiences	O
early	O
in	O
life	O
.	O
This	O
notion	O
is	O
termed	O
the	O
developmental	O
origins	O
of	O
health	O
and	O
disease	O
(	O
DOHaD	O
)	O
[	O
4	O
]	O
.	O
Our	O
previous	O
study	O
reported	O
that	O
offspring	O
exposed	O
to	O
maternal	O
high	O
-	O
fructose	O
diets	O
developed	O
hypertension	O
in	O
adulthood	O
[	O
5	O
]	O
.	O
Progression	O
of	O
normotensive	O
children	O
to	O
hypertensive	O
adults	O
can	O
occur	O
synergistically	O
with	O
multiple	O
adverse	O
environmental	O
conditions	O
[	O
5	O
]	O
.	O
Exposure	O
to	O
environmental	O
chemicals	O
,	O
such	O
as	O
dioxins	O
,	O
can	O
increase	O
the	O
risk	O
of	O
hypertension	O
[	O
6	O
]	O
.	O
Specifically	O
,	O
maternal	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
(	O
TCDD	O
)	O
exposure	O
has	O
been	O
reported	O
to	O
exacerbate	O
hypertension	O
in	O
adult	O
male	O
offspring	O
in	O
various	O
models	O
of	O
developmental	O
programming	O
[	O
7	O
,	O
8	O
]	O
.	O
Several	O
mechanisms	O
have	O
been	O
proposed	O
as	O
underlying	O
the	O
pathogenesis	O
of	O
hypertension	O
and	O
kidney	O
disease	O
of	O
developmental	O
origin	O
[	O
9	O
]	O
,	O
such	O
as	O
nitric	O
oxide	O
(	O
NO	O
)	O
deficiency	O
,	O
gut	O
microbiota	O
dysbiosis	O
,	O
and	O
dysregulation	O
of	O
the	O
renin	O
-	O
angiotensin	O
system	O
(	O
RAS	O
)	O
.	O
Gut	O
microbiota	O
dysbiosis	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
hypertension	O
[	O
10	O
]	O
.	O

Cumulative	O
evidence	O
in	O
several	O
animal	B-methodology
models	I-methodology
of	O
hypertension	O
supports	O
the	O
idea	O
that	O
the	O
development	O
of	O
hypertension	O
is	O
interrelated	O
with	O
gut	O
microbiota	O
dysbiosis	O
[	O
10	O
,	O
11	O
]	O
,	O
including	O
the	O
high	O
-	O
fructose	O
(	O
HFR	O
)	O
model	O
[	O
12	O
]	O
.	O
Certain	O
microbiota	O
-	O
generated	O
metabolites	O
have	O
been	O
found	O
to	O
be	O
linked	O
with	O
hypertension	O
,	O
like	O
trimethylamine	O
N	O
-	O
oxide	O
(	O
TMAO	O
)	O
and	O
trimethylamine	O
(	O
TMA	O
)	O
[	O
13	O
]	O
.	O
Gut	O
bacteria	O
metabolize	O
dietary	O
components	O
such	O
as	O
choline	O
and	O
carnitine	O
to	O
TMA	O
,	O
which	O
is	O
subsequently	O
oxidized	O
to	O
TMAO	O
by	O
hepatic	O
enzyme	O
flavin	O
-	O
containing	O
monooxygenases	O
(	O
FMOs	O
)	O
[	O
13	O
]	O
.	O
Our	O
previous	O
study	O
demonstrated	O
that	O
maternal	O
HFR	O
-	O
induced	O
hypertension	O
in	O
adult	O
offspring	O
is	O
relevant	O
to	O
increases	O
in	O
plasma	O
TMA	O
[	O
12	O
]	O
.	O
Additionally	O
,	O
TCDD	O
,	O
an	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AHR	O
)	O
ligand	O
,	O
has	O
been	O
linked	O
with	O
hypertension	O
[	O
14	O
]	O
.	O
Our	O
objective	O
in	O
this	O
study	O
was	O
first	O
to	O
determine	O
whether	O
TCDD	O
exposure	O
exacerbates	O
HFR	O
-	O
induced	O
hypertension	O
via	O
mediation	O
of	O
the	O
gut	O
microbiota	O
-	O
dependent	O
TMA	O
-	O
TMAO	O
metabolic	O
pathway	O
,	O
AHR	O
signaling	O
,	O
RAS	O
,	O
and	O
the	O
NO	O
pathway	O
.	O
Despite	O
probiotics	O
being	O
reported	O
to	O
prevent	O
HFR	O
-	O
induced	O
hypertension	O
[	O
15	O
]	O
,	O
little	O
is	O
known	O
about	O
whether	O
targeting	O
the	O
gut	O
microbiota	O
-	O
derived	O
metabolite	O
TMA	O
can	O
prevent	O
combined	O
HFR	O
and	O
TCDD	O
exposure	O
-	O
induced	O
hypertension	O
in	O
adult	O
offspring	O
.	O
3	O
,	O
3	O
-	O
Dimethyl	O
-	O
1	O
-	O
butanol	O
(	O
DMB	O
)	O
,	O
a	O
structural	O
analog	O
of	O
choline	O
,	O
has	O
been	O
shown	O
to	O
inhibit	O
distinct	O
microbial	O
TMA	O
lyases	O
and	O
reduce	O
plasma	O
TMAO	O
levels	O
[	O
16	O
]	O
.	O
Additionally	O
,	O
we	O
recently	O
reported	O
that	O
maternal	O
DMB	O
treatment	O
protected	O
adult	O
offspring	O
against	O
HFR	O
-	O
induced	O
hypertension	O
,	O
which	O
was	O
associated	O
with	O
reduced	O
plasma	O
levels	O
of	O
TMA	O
and	O
TMAO	O
in	O
the	O
adult	O
offspring	O
[	O
12	O
]	O
.	O
Therefore	O
,	O
the	O
second	O
aim	O
of	O
our	O
study	O
was	O
to	O
examine	O
whether	O
DMB	O
(	O
an	O
inhibitor	O
for	O
TMA	O
formation	O
)	O
treatment	O
can	O
prevent	O
combined	O
HFR	O
plus	O
TCDD	O
exposure	O
-	O
induced	O
hypertension	O
.	O
Figure	O
1	O
illustrates	O
the	O
experimental	O
protocol	O
.	O

We	O
studied	O
six	O
groups	O
of	O
male	O
offspring	O
,	O
including	O
rats	O
that	O
received	O
a	O
regular	O
diet	O
and	O
vehicle	O
(	O
CV	O
)	O
;	O
rats	O
that	O
received	O
a	O
high	O
-	O
fructose	O
diet	O
(	O
HFR	O
)	O
;	O
rats	O
that	O
received	O
a	O
regular	O
diet	O
and	O
TCDD	O
exposure	O
(	O
CT	O
)	O
;	O
rats	O
that	O
received	O
a	O
high	O
-	O
fructose	O
diet	O
and	O
TCDD	O
exposure	O
(	O
HRT	O
)	O
;	O
rats	O
that	O
received	O
a	O
high	O
-	O
fructose	O
diet	O
and	O
DMB	O
treatment	O
(	O
HRD	O
)	O
;	O
and	O
rats	O
that	O
received	O
a	O
high	O
-	O
fructose	O
diet	O
,	O
TCDD	O
+	O
exposure	O
,	O
and	O
DMB	O
treatment	O
(	O
HRTD	O
)	O
.	O
Table	O
1	O
shows	O
no	O
dead	O
pups	O
in	O
any	O
group	O
.	O
The	O
body	O
weight	O
(	O
BW	O
)	O
did	O
not	O
differ	O
among	O
most	O
groups	O
,	O
except	O
the	O
HRD	O
group	O
had	O
a	O
higher	O
BW	O
than	O
the	O
HFR	O
group	O
(	O
Table	O
1	O
)	O
.	O
Combined	O
HFR	O
and	O
TCDD	O
exposure	O
caused	O
a	O
higher	O
kidney	O
weight	O
than	O
HFR	O
alone	O
,	O
while	O
the	O
kidney	O
weight	O
-	O
to	O
-	O
BW	O
ratio	O
was	O
comparable	O
.	O
Figure	O
2	O
shows	O
that	O
the	O
HFR	O
,	O
CT	O
,	O
and	O
HRT	O
groups	O
had	O
a	O
significantly	O
higher	O
systolic	O
BP	O
compared	O
to	O
the	O
CV	O
group	O
from	O
8	O
to	O
12	O
weeks	O
of	O
age	O
.	O
In	O
week	O
12	O
,	O
the	O
elevated	O
SBP	O
was	O
exacerbated	O
more	O
by	O
TCDD	O
exposure	O
in	O
the	O
HRT	O
group	O
than	O
among	O
those	O
in	O
the	O
CV	O
,	O
HFR	O
,	O
and	O
CT	O
groups	O
.	O
A	O
significant	O
reduction	O
in	O
SBP	O
(	O
~	O
16	O
mmHg	O
)	O
was	O
measured	O
in	O
the	O
HRTD	O
group	O
versus	O
the	O
HRT	O
group	O
.	O
Additionally	O
,	O
DMB	O
treatment	O
caused	O
a	O
reduction	O
in	O
the	O
SBP	O
(	O
~	O
7	O
mmHg	O
)	O
in	O
the	O
HRD	O
group	O
,	O
compared	O
to	O
the	O
HFR	O
group	O
.	O
Our	O
data	O
indicated	O
the	O
synergistic	O
interaction	O
between	O
HFR	O
and	O
TCDD	O
influencing	O
the	O
elevation	O
of	O
the	O
BP	O
,	O
which	O
was	O
attenuated	O
by	O
DMB	O
treatment	O
.	O
The	O
HFR	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
,	O
and	O
the	O
CT	O
group	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
had	O
a	O
higher	O
creatinine	O
(	O
Cr	O
)	O
level	O
compared	O
with	O
the	O
CV	O
group	O
,	O
while	O
the	O
Cr	O
levels	O
in	O
the	O
HRT	O
,	O
HRD	O
,	O
and	O
HRTD	O
group	O
were	O
similar	O
to	O
the	O
CV	O
group	O
.	O

We	O
first	O
determined	O
the	O
plasma	O
levels	O
of	O
TMA	O
,	O
TMAO	O
,	O
and	O
dimethylamine	O
(	O
DMA	O
,	O
the	O
metabolite	O
of	O
TMAO	O
and	O
TMA	O
)	O
(	O
Table	O
2	O
)	O
.	O
Maternal	O
high	O
-	O
fructose	O
intake	O
significantly	O
increased	O
plasma	O
TMA	O
levels	O
(	O
HFR	O
vs	O
.	O
CV	O
group	O
,	O
p	O
=	O
0	O
.	O
045	O
)	O
,	O
while	O
TCDD	O
exposure	O
had	O
no	O
effect	O
on	O
the	O
levels	O
.	O
The	O
plasma	O
TMAO	O
level	O
was	O
higher	O
in	O
the	O
HRD	O
group	O
compared	O
to	O
the	O
HRT	O
group	O
(	O
p	O
=	O
0	O
.	O
027	O
)	O
.	O
The	O
CT	O
(	O
p	O
=	O
0	O
.	O
011	O
)	O
,	O
HRT	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
,	O
and	O
HRD	O
group	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
had	O
lower	O
plasma	O
DMA	O
levels	O
compared	O
with	O
the	O
HFR	O
group	O
.	O
As	O
shown	O
in	O
Table	O
2	O
,	O
the	O
plasma	O
levels	O
of	O
asymmetric	O
and	O
symmetric	O
dimethylarginine	O
(	O
ADMA	O
and	O
SDMA	O
,	O
endogenous	O
inhibitors	O
of	O
nitric	O
oxide	O
synthase	O
)	O
were	O
higher	O
,	O
but	O
the	O
L	O
-	O
arginine	O
-	O
to	O
-	O
ADMA	O
ratios	O
were	O
lower	O
in	O
the	O
HRF	O
and	O
CT	O
groups	O
compared	O
to	O
the	O
controls	O
(	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
DMB	O
treatment	O
caused	O
decreases	O
in	O
the	O
ADMA	O
(	O
p	O
=	O
0	O
.	O
003	O
)	O
and	O
SDMA	O
(	O
p	O
=	O
0	O
.	O
003	O
)	O
levels	O
in	O
the	O
HRD	O
group	O
vs	O
.	O
the	O
HFR	O
group	O
.	O
Additionally	O
,	O
a	O
high	O
-	O
fructose	O
diet	O
significantly	O
reduced	O
the	O
L	O
-	O
arginine	O
-	O
to	O
-	O
ADMA	O
ratio	O
in	O
the	O
HFR	O
group	O
compared	O
to	O
the	O
controls	O
(	O
p	O
=	O
0	O
.	O
022	O
)	O
.	O
The	O
decrease	O
in	O
this	O
ratio	O
was	O
restored	O
by	O
DMB	O
treatment	O
in	O
the	O
HRD	O
group	O
.	O
However	O
,	O
NO	O
-	O
related	O
metabolites	O
were	O
comparable	O
between	O
the	O
HRT	O
and	O
HRTD	O
group	O
.	O
In	O
addition	O
to	O
NO	O
,	O
dysregulation	O
of	O
the	O
RAS	O
is	O
a	O
key	O
mechanism	O
involved	O
in	O
programmed	O
hypertension	O
.	O
We	O
analyzed	O
protein	O
levels	O
of	O
RAS	O
components	O
in	O
offspring	O
kidneys	O
.	O
We	O
observed	O
there	O
was	O
a	O
significant	O
increase	O
in	O
the	O
protein	O
level	O
of	O
angiotensin	O
II	O
type	O
1	O
receptor	O
(	O
AT1R	O
)	O
in	O
the	O
CT	O
and	O
HRT	O
groups	O
vs	O
.	O
controls	O
,	O
which	O
DMB	O
therapy	O
prevented	O
(	O
Figure	O
3	O
)	O
.	O

Conversely	O
,	O
the	O
renal	O
protein	O
level	O
of	O
angiotensin	O
II	O
type	O
2	O
receptor	O
(	O
AT2R	O
)	O
was	O
lower	O
in	O
the	O
HRT	O
group	O
compared	O
to	O
the	O
controls	O
.	O
DMB	O
therapy	O
restored	O
the	O
decreased	O
AT2R	O
protein	O
abundance	O
in	O
the	O
HRT	O
group	O
(	O
Figure	O
3B	O
)	O
.	O
We	O
next	O
determined	O
AHR	O
and	O
its	O
target	O
genes	O
in	O
offspring	O
kidneys	O
.	O
Figure	O
3C	O
shows	O
that	O
there	O
was	O
no	O
difference	O
in	O
renal	O
AHR	O
protein	O
level	O
among	O
the	O
six	O
groups	O
.	O
Renal	O
mRNA	O
expression	O
of	O
Ahrr	O
was	O
higher	O
in	O
the	O
CT	O
,	O
HRT	O
,	O
and	O
HRD	O
groups	O
compared	O
to	O
the	O
controls	O
(	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
Additionally	O
,	O
TCDD	O
caused	O
a	O
reduction	O
in	O
Arnt	O
and	O
Tiparp	O
expression	O
.	O
We	O
found	O
that	O
these	O
gene	O
changes	O
in	O
the	O
AHR	O
signaling	O
pathway	O
were	O
recovered	O
by	O
DMB	O
therapy	O
(	O
both	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
We	O
examined	O
the	O
ileal	O
level	O
of	O
tight	O
junction	O
proteins	O
to	O
determine	O
gut	O
permeability	O
.	O
Ileal	O
clausin	O
-	O
1	O
and	O
-	O
2	O
expression	O
significantly	O
decreased	O
in	O
the	O
CT	O
and	O
HRT	O
groups	O
’	O
kidneys	O
,	O
and	O
was	O
restored	O
by	O
DMB	O
therapy	O
(	O
Figure	O
3D	O
)	O
.	O
The	O
occludin	O
protein	O
level	O
was	O
decreased	O
in	O
the	O
HRT	O
group	O
,	O
and	O
was	O
restored	O
by	O
DMB	O
treatment	O
.	O
We	O
further	O
analyzed	O
the	O
composition	O
of	O
the	O
gut	O
microbiota	O
in	O
offspring	O
at	O
3	O
and	O
12	O
weeks	O
of	O
age	O
.	O
Microbiome	O
diversity	O
is	O
typically	O
defined	O
in	O
terms	O
of	O
within	O
(	O
i	O
.	O
e	O
.	O
,	O
α	O
-	O
diversity	O
)	O
and	O
between	O
(	O
i	O
.	O
e	O
.	O
,	O
β	O
-	O
diversity	O
)	O
microbial	O
community	O
diversities	O
[	O
17	O
,	O
18	O
]	O
.	O
The	O
Shannon	O
diversity	O
index	O
is	O
a	O
commonly	O
used	O
α	O
-	O
diversity	O
measure	O
to	O
determine	O
how	O
evenly	O
the	O
microbes	O
are	O
distributed	O
in	O
a	O
community	O
/	O
sample	O
[	O
19	O
]	O
.	O
We	O
found	O
that	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
Shannon	O
index	O
among	O
the	O
six	O
groups	O
at	O
3	O
weeks	O
of	O
age	O
(	O
Figure	O
4A	O
)	O
.	O
We	O
used	O
two	O
different	O
β	O
-	O
diversity	O
analysis	O
techniques	O
,	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
and	O
analysis	O
of	O
similarities	O
(	O
ANOSIM	O
)	O
,	O
to	O
compare	O
the	O
bacterial	O
community	O
similarities	O
[	O
17	O
,	O
18	O
]	O
.	O
PCA	O
can	O
reduce	O
the	O
dimensionality	O
of	O
microbiome	O
data	O
sets	O
so	O
that	O
a	O
summary	O
of	O
the	O
beta	O
diversity	O
relationships	O
can	O
be	O
visualized	O
in	O
two	O
-	O
dimensional	O
scatterplots	O
[	O
18	O
]	O
.	O
ANOSIM	O
was	O
used	O
to	O
compare	O
the	O
differences	O
among	O
the	O
groups	O
of	O
samples	O
[	O
20	O
]	O
.	O

The	O
scatterplots	O
of	O
PCA	O
showed	O
that	O
some	O
(	O
e	O
.	O
g	O
.	O
,	O
HRT	O
vs	O
.	O
HRTD	O
)	O
,	O
but	O
not	O
all	O
,	O
groups	O
were	O
well	O
-	O
separated	O
(	O
Figure	O
4B	O
)	O
,	O
while	O
ANOSIM	O
analysis	O
showed	O
there	O
to	O
be	O
a	O
significant	O
difference	O
between	O
the	O
five	O
groups	O
(	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
except	O
between	O
the	O
HRD	O
and	O
HRT	O
groups	O
(	O
p	O
=	O
0	O
.	O
095	O
)	O
.	O
These	O
findings	O
suggest	O
that	O
most	O
groups	O
are	O
distinct	O
.	O
At	O
3	O
weeks	O
of	O
age	O
,	O
we	O
observed	O
that	O
the	O
main	O
phyla	O
were	O
Bacteroidetes	O
,	O
Firmicutes	O
,	O
Verrucomicrobia	O
,	O
Proteobacteria	O
,	O
and	O
Actinobacteria	O
(	O
Figure	O
4C	O
)	O
.	O
The	O
abundance	O
of	O
the	O
phyla	O
Firmicutes	O
(	O
p	O
=	O
0	O
.	O
038	O
)	O
and	O
Proteobacteria	O
(	O
p	O
=	O
0	O
.	O
035	O
)	O
was	O
increased	O
in	O
the	O
HRT	O
group	O
,	O
which	O
DMB	O
treatment	O
prevented	O
(	O
p	O
=	O
0	O
.	O
033	O
and	O
p	O
<	O
0	O
.	O
001	O
,	O
respectively	O
)	O
(	O
Figure	O
4E	O
,	O
F	O
)	O
.	O
The	O
Firmicutes	O
to	O
Bacteroidetes	O
ratio	O
was	O
comparable	O
between	O
groups	O
.	O
At	O
the	O
family	O
level	O
,	O
HFR	O
,	O
TCDD	O
,	O
and	O
DMB	O
resulted	O
in	O
differential	O
changes	O
in	O
the	O
abundance	O
of	O
gut	O
microbes	O
(	O
Figure	O
4D	O
)	O
.	O
We	O
observed	O
that	O
the	O
abundance	O
of	O
the	O
family	O
Enterobacteriaceae	O
(	O
p	O
=	O
0	O
.	O
014	O
)	O
was	O
higher	O
in	O
the	O
HRT	O
group	O
vs	O
.	O
the	O
control	O
CV	O
group	O
(	O
Figure	O
4G	O
)	O
,	O
which	O
DMB	O
treatment	O
prevented	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
In	O
contrast	O
,	O
the	O
HRT	O
group	O
had	O
a	O
significantly	O
decreased	O
abundance	O
of	O
the	O
family	O
Deferribacteraceae	O
(	O
Figure	O
4H	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
The	O
abundance	O
of	O
the	O
family	O
Prevotellaceae	O
was	O
significantly	O
increased	O
in	O
the	O
HRTD	O
group	O
compared	O
to	O
other	O
groups	O
(	O
Figure	O
4I	O
)	O
.	O
Additionally	O
,	O
we	O
found	O
that	O
the	O
abundance	O
of	O
the	O
genus	O
Holdemania	O
was	O
lower	O
in	O
the	O
HRT	O
group	O
compared	O
to	O
the	O
control	O
(	O
Figure	O
4J	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
which	O
was	O
prevented	O
by	O
DMB	O
treatment	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
As	O
in	O
week	O
3	O
,	O
the	O
α	O
-	O
diversity	O
was	O
not	O
different	O
among	O
the	O
six	O
groups	O
in	O
week	O
12	O
(	O
Figure	O
5A	O
)	O
.	O

However	O
,	O
the	O
PCA	O
plots	O
demonstrated	O
that	O
the	O
composition	O
of	O
microbial	O
communities	O
of	O
some	O
groups	O
(	O
e	O
.	O
g	O
.	O
,	O
CV	O
vs	O
.	O
HRTD	O
)	O
are	O
well	O
separated	O
,	O
while	O
others	O
overlap	O
(	O
e	O
.	O
g	O
.	O
,	O
CT	O
vs	O
.	O
HRTD	O
)	O
.	O
ANOSIM	O
showed	O
that	O
most	O
groups	O
were	O
significantly	O
different	O
(	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
except	O
the	O
difference	O
between	O
the	O
HRT	O
and	O
HRTD	O
groups	O
did	O
not	O
reach	O
significance	O
(	O
Figure	O
5B	O
)	O
(	O
ANOSIM	O
,	O
p	O
=	O
0	O
.	O
111	O
)	O
.	O
Figure	O
5C	O
shows	O
that	O
the	O
major	O
phyla	O
in	O
week	O
12	O
were	O
like	O
those	O
in	O
week	O
3	O
.	O
At	O
the	O
family	O
level	O
,	O
the	O
effects	O
of	O
HFR	O
,	O
TCDD	O
,	O
and	O
DMB	O
on	O
gut	O
microbes	O
are	O
different	O
between	O
3	O
and	O
12	O
weeks	O
of	O
age	O
(	O
Figure	O
5D	O
)	O
.	O
Compared	O
to	O
controls	O
,	O
the	O
abundance	O
of	O
the	O
phyla	O
Actinobacteria	O
(	O
p	O
=	O
0	O
.	O
007	O
)	O
and	O
Proteobacteria	O
(	O
p	O
=	O
0	O
.	O
031	O
)	O
was	O
significantly	O
increased	O
in	O
the	O
HRT	O
group	O
and	O
HRTD	O
group	O
,	O
respectively	O
(	O
Figure	O
5E	O
,	O
F	O
)	O
.	O
We	O
observed	O
that	O
TCDD	O
exposure	O
increased	O
the	O
abundance	O
of	O
the	O
genera	O
Sellimonas	O
and	O
Collinsella	O
in	O
the	O
CT	O
group	O
vs	O
.	O
other	O
groups	O
(	O
Figure	O
5G	O
,	O
H	O
)	O
.	O
Additionally	O
,	O
combined	O
HFR	O
plus	O
TCDD	O
exposure	O
significantly	O
increased	O
the	O
abundance	O
of	O
the	O
genus	O
Gordonibacter	O
compared	O
to	O
other	O
groups	O
(	O
Figure	O
5I	O
)	O
.	O
Moreover	O
,	O
the	O
HRTD	O
group	O
had	O
the	O
highest	O
abundance	O
of	O
genus	O
Butyrivibrio	O
among	O
the	O
six	O
groups	O
(	O
Figure	O
5J	O
)	O
.	O
This	O
is	O
the	O
first	O
study	O
to	O
describe	O
how	O
DMB	O
protects	O
against	O
TCDD	O
plus	O
HFR	O
-	O
induced	O
hypertension	O
,	O
and	O
makes	O
special	O
emphasis	O
on	O
the	O
AHR	O
signaling	O
,	O
gut	O
microbiota	O
,	O
the	O
RAS	O
,	O
and	O
the	O
NO	O
pathway	O
.	O

The	O
main	O
findings	O
of	O
this	O
research	O
were	O
:	O
(	O
1	O
)	O
TCDD	O
exacerbates	O
HFR	O
-	O
induced	O
hypertension	O
in	O
male	O
adult	O
offspring	O
,	O
which	O
can	O
be	O
attenuated	O
by	O
DMB	O
therapy	O
during	O
gestation	O
and	O
lactation	O
;	O
(	O
2	O
)	O
both	O
HFR	O
and	O
TCDD	O
exposure	O
-	O
induced	O
programmed	O
hypertension	O
are	O
associated	O
with	O
increased	O
ADMA	O
and	O
SDMA	O
,	O
but	O
a	O
decreased	O
L	O
-	O
arginine	O
-	O
to	O
-	O
ADMA	O
ratio	O
;	O
(	O
3	O
)	O
HFR	O
plus	O
TCDD	O
-	O
induced	O
hypertension	O
is	O
associated	O
with	O
increased	O
AT1R	O
and	O
decreased	O
AT2R	O
,	O
which	O
DMB	O
prevents	O
;	O
(	O
4	O
)	O
TCDD	O
-	O
induced	O
elevation	O
of	O
BP	O
is	O
combined	O
with	O
increased	O
AT1R	O
,	O
activation	O
of	O
AHR	O
signaling	O
,	O
and	O
increased	O
gut	O
permeability	O
;	O
(	O
5	O
)	O
different	O
maternal	O
exposures	O
induced	O
gut	O
microbiota	O
dysbiosis	O
and	O
distinct	O
enterotypes	O
;	O
and	O
(	O
6	O
)	O
DMB	O
therapy	O
affected	O
several	O
gut	O
microbes	O
related	O
to	O
TMA	O
-	O
TMAO	O
metabolism	O
,	O
including	O
the	O
phyla	O
Firmicutes	O
and	O
Proteobacteria	O
,	O
families	O
Enterobacteriaceae	O
and	O
Deferribacteraceae	O
,	O
and	O
genus	O
Holdemania	O
.	O
Our	O
results	O
reconfirm	O
the	O
results	O
of	O
previous	O
studies	O
demonstrating	O
that	O
excessive	O
consumption	O
of	O
fructose	O
or	O
dioxin	O
exposure	O
by	O
pregnant	O
mother	O
rats	O
increases	O
the	O
risk	O
of	O
adult	O
male	O
offspring	O
developing	O
hypertension	O
and	O
kidney	O
damage	O
[	O
3	O
,	O
8	O
]	O
.	O
Most	O
human	O
exposure	O
to	O
dioxins	O
is	O
through	O
food	O
,	O
mainly	O
animal	O
fats	O
.	O
Although	O
animal	O
fats	O
and	O
fructose	O
are	O
commonly	O
consumed	O
as	O
part	O
of	O
human	O
Western	O
diets	O
,	O
no	O
study	O
to	O
date	O
has	O
examined	O
how	O
early	O
combined	O
exposure	O
to	O
HFR	O
and	O
TCDD	O
increases	O
the	O
risk	O
of	O
developing	O
hypertension	O
and	O
kidney	O
disease	O
in	O
later	O
life	O
.	O
Since	O
pregnant	O
women	O
are	O
increasingly	O
exposed	O
to	O
multiple	O
adverse	O
environmental	O
insults	O
and	O
chemical	O
hazards	O
in	O
modern	O
society	O
,	O
our	O
study	O
casts	O
new	O
light	O
on	O
early	O
microbiome	O
-	O
based	O
metabolite	O
treatments	O
which	O
could	O
be	O
used	O
to	O
prevent	O
hypertension	O
programmed	O
by	O
two	O
-	O
hit	O
insults	O
in	O
later	O
life	O
.	O
Our	O
current	O
study	O
identified	O
certain	O
mechanisms	O
underlying	O
the	O
protective	O
effects	O
of	O
DMB	O
against	O
programmed	O
hypertension	O
,	O
such	O
as	O
the	O
increase	O
in	O
NO	O
bioavailability	O
,	O
the	O
balance	O
of	O
RAS	O
,	O
the	O
abrogation	O
of	O
AHR	O
activation	O
,	O
and	O
the	O
restoration	O
of	O
gut	O
microbiota	O
.	O
First	O
,	O
we	O
observed	O
that	O
both	O
HFR	O
and	O
TCDD	O
affect	O
the	O
NO	O
pathway	O
.	O

The	O
index	O
of	O
NO	O
bioavailability	O
,	O
the	O
L	O
-	O
arginine	O
-	O
to	O
-	O
ADMA	O
ratio	O
,	O
was	O
recovered	O
by	O
DMB	O
therapy	O
in	O
the	O
HFD	O
vs	O
.	O
HFR	O
group	O
.	O
Additionally	O
,	O
DMB	O
caused	O
a	O
reduction	O
in	O
the	O
BP	O
and	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
the	O
NOS	O
inhibitors	O
ADMA	O
and	O
SDMA	O
,	O
which	O
were	O
induced	O
by	O
HFR	O
intake	O
.	O
Our	O
results	O
suggest	O
a	O
link	O
between	O
the	O
TMA	O
-	O
TMAO	O
and	O
ADMA	O
-	O
NO	O
pathways	O
,	O
which	O
concurs	O
with	O
previous	O
studies	O
showing	O
their	O
impacts	O
in	O
hypertension	O
[	O
12	O
,	O
21	O
]	O
.	O
Second	O
,	O
our	O
data	O
showed	O
that	O
DMB	O
therapy	O
restored	O
the	O
combined	O
HFR	O
+	O
TCDD	O
-	O
induced	O
increased	O
AT1R	O
and	O
decreased	O
AT2R	O
protein	O
abundance	O
in	O
the	O
HRTD	O
group	O
.	O
It	O
is	O
well	O
-	O
established	O
that	O
AT2R	O
appears	O
to	O
represent	O
an	O
endogenous	O
counter	O
-	O
regulatory	O
pathway	O
within	O
the	O
RAS	O
,	O
the	O
actions	O
of	O
which	O
are	O
in	O
opposition	O
to	O
the	O
vasoconstrictor	O
Ang	O
II	O
/	O
ACE	O
/	O
AT1R	O
arm	O
[	O
22	O
]	O
.	O
A	O
previous	O
study	O
showed	O
that	O
TMAO	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
angiotensin	O
II	O
-	O
induced	O
hypertension	O
[	O
23	O
]	O
.	O
Although	O
DMB	O
protecting	O
the	O
HRTD	O
group	O
against	O
hypertension	O
is	O
independent	O
of	O
TMA	O
-	O
TMAO	O
formation	O
,	O
our	O
data	O
suggested	O
that	O
the	O
protective	O
mechanism	O
of	O
DMB	O
against	O
hypertension	O
,	O
at	O
least	O
in	O
part	O
,	O
is	O
related	O
to	O
the	O
restoration	O
of	O
the	O
RAS	O
balance	O
in	O
the	O
kidneys	O
.	O
Since	O
DMB	O
therapy	O
affected	O
several	O
gut	O
microbes	O
related	O
to	O
TMA	O
-	O
TMAO	O
metabolism	O
,	O
it	O
is	O
presumable	O
that	O
its	O
beneficial	O
effect	O
on	O
BP	O
is	O
related	O
to	O
the	O
regulation	O
of	O
other	O
microbiota	O
-	O
derived	O
metabolites	O
.	O
Given	O
that	O
microbiota	O
metabolite	O
short	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
could	O
affect	O
BP	O
[	O
11	O
]	O
,	O
and	O
that	O
DMB	O
therapy	O
was	O
reported	O
to	O
regulate	O
SCFAs	O
[	O
12	O
]	O
,	O
whether	O
DMB	O
therapy	O
protected	O
against	O
hypertension	O
is	O
via	O
SCFAs	O
awaits	O
further	O
clarification	O
.	O
Another	O
beneficial	O
effect	O
of	O
DMB	O
therapy	O
could	O
be	O
due	O
to	O
antagonizing	O
AHR	O
-	O
mediated	O
gene	O
transcription	O
.	O
It	O
has	O
been	O
reported	O
that	O
TCDD	O
induces	O
a	O
high	O
BP	O
,	O
and	O
AHR	O
target	O
genes	O
might	O
be	O
involved	O
in	O
this	O
process	O
[	O
8	O
,	O
14	O
]	O
.	O

The	O
AHRR	O
is	O
an	O
AHR	O
target	O
gene	O
that	O
competes	O
with	O
AHR	O
to	O
bind	O
with	O
ARNT	O
[	O
14	O
]	O
.	O
Our	O
results	O
demonstrate	O
that	O
DMB	O
restored	O
TCDD	O
-	O
induced	O
increased	O
Ahrr	O
but	O
decreased	O
Arnt	O
mRNA	O
expression	O
in	O
the	O
kidneys	O
of	O
the	O
offspring	O
.	O
Our	O
data	O
support	O
the	O
hypothesis	O
that	O
TCDD	O
activates	O
the	O
AHR	O
signaling	O
pathway	O
,	O
which	O
appears	O
correlated	O
with	O
the	O
rise	O
in	O
BP	O
.	O
Since	O
the	O
activation	O
of	O
the	O
AHR	O
/	O
ARNT	O
/	O
CYP	O
axis	O
has	O
been	O
reported	O
to	O
induce	O
vasoconstriction	O
[	O
24	O
]	O
,	O
this	O
notion	O
is	O
supported	O
by	O
our	O
findings	O
.	O
However	O
,	O
we	O
observed	O
that	O
cyp1a1	O
expression	O
was	O
not	O
altered	O
;	O
other	O
CYP	O
enzymes	O
await	O
further	O
evaluation	O
.	O
Although	O
our	O
data	O
demonstrated	O
no	O
differences	O
in	O
AHR	O
protein	O
levels	O
among	O
the	O
six	O
groups	O
,	O
mRNA	O
expressions	O
of	O
AHR	O
target	O
genes	O
were	O
changed	O
in	O
some	O
groups	O
.	O
This	O
discrepancy	O
is	O
due	O
to	O
that	O
fact	O
that	O
protein	O
abundance	O
of	O
a	O
transcription	O
factor	O
does	O
not	O
necessarily	O
result	O
in	O
its	O
transcriptional	O
activity	O
.	O
AHR	O
can	O
be	O
sequestered	O
away	O
from	O
nuclear	O
DNA	O
target	O
genes	O
when	O
not	O
actively	O
transcribing	O
target	O
genes	O
[	O
25	O
]	O
.	O
Thus	O
,	O
whether	O
DMB	O
differentially	O
regulates	O
the	O
transcriptional	O
activity	O
of	O
AHR	O
resulting	O
in	O
different	O
expression	O
of	O
AHR	O
target	O
gene	O
warrants	O
further	O
investigation	O
.	O
Moreover	O
,	O
data	O
from	O
the	O
present	O
study	O
indicate	O
that	O
HFR	O
,	O
TCDD	O
,	O
and	O
DMB	O
are	O
associated	O
with	O
distinct	O
enterotypes	O
,	O
represented	O
by	O
β	O
-	O
diversity	O
changes	O
.	O
In	O
week	O
3	O
,	O
TCDD	O
has	O
little	O
effect	O
on	O
the	O
microbiota	O
as	O
compared	O
with	O
HFR	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
abundance	O
of	O
Firmicutes	O
and	O
Proteobacteria	O
,	O
the	O
two	O
main	O
phyla	O
in	O
the	O
TMA	O
-	O
producing	O
community	O
[	O
26	O
]	O
,	O
were	O
higher	O
in	O
the	O
HRT	O
group	O
in	O
week	O
3	O
,	O
while	O
their	O
increases	O
were	O
suppressed	O
by	O
DMB	O
therapy	O
.	O
There	O
was	O
no	O
difference	O
in	O
the	O
Firmicutes	O
to	O
Bacteroidetes	O
ratio	O
among	O
the	O
six	O
groups	O
,	O
despite	O
this	O
ratio	O
being	O
considered	O
a	O
microbial	O
marker	O
for	O
hypertension	O
[	O
10	O
]	O
.	O
According	O
to	O
our	O
data	O
,	O
the	O
HRT	O
group	O
showed	O
an	O
increase	O
in	O
the	O
family	O
Enterobacteriaceae	O
but	O
a	O
decreased	O
abundance	O
of	O
the	O
family	O
Deferribacteraceae	O
and	O
genus	O
Holdemania	O
.	O
These	O
changes	O
were	O
restored	O
by	O
DMB	O
therapy	O
.	O

At	O
the	O
family	O
level	O
,	O
Enterobacteriaceae	O
made	O
the	O
greatest	O
contribution	O
to	O
the	O
conversion	O
of	O
TMAO	O
to	O
TMA	O
[	O
27	O
]	O
,	O
whereas	O
Deferribacteraceae	O
was	O
involved	O
in	O
TMA	O
production	O
[	O
28	O
]	O
.	O
Overall	O
,	O
these	O
observations	O
indicate	O
that	O
certain	O
bacteria	O
populations	O
involved	O
in	O
TMA	O
metabolism	O
were	O
affected	O
by	O
DMB	O
therapy	O
at	O
week	O
3	O
.	O
It	O
is	O
possible	O
that	O
the	O
changes	O
in	O
specific	O
microbial	O
abundance	O
contributed	O
to	O
the	O
balance	O
of	O
the	O
TMA	O
-	O
TMAO	O
pathway	O
,	O
and	O
the	O
beneficial	O
effects	O
this	O
had	O
on	O
hypertension	O
in	O
week	O
12	O
.	O
At	O
12	O
weeks	O
of	O
age	O
,	O
hypertension	O
programmed	O
by	O
TCDD	O
exposure	O
was	O
related	O
to	O
an	O
increased	O
abundance	O
of	O
the	O
genus	O
Collinsella	O
,	O
which	O
was	O
in	O
line	O
with	O
the	O
finding	O
that	O
Collinsella	O
abundance	O
is	O
higher	O
in	O
atherosclerosis	O
patients	O
[	O
29	O
]	O
.	O
In	O
contrast	O
,	O
the	O
reduction	O
in	O
BP	O
in	O
the	O
HRTD	O
group	O
was	O
associated	O
with	O
a	O
high	O
abundance	O
of	O
the	O
genus	O
Butyrivibrio	O
.	O
Our	O
finding	O
ties	O
in	O
well	O
with	O
a	O
previous	O
report	O
linking	O
reduced	O
Butyrivibrio	O
abundance	O
to	O
hypertensive	O
populations	O
[	O
30	O
]	O
.	O
One	O
limitation	O
of	O
this	O
study	O
is	O
a	O
lack	O
of	O
the	O
control	O
+	O
DMB	O
and	O
TCDD	O
+	O
DMB	O
group	O
.	O
One	O
reason	O
for	O
this	O
is	O
because	O
a	O
previous	O
study	O
showed	O
a	O
good	O
safety	O
profile	O
of	O
DMB	O
administration	O
in	O
controls	O
[	O
31	O
]	O
.	O
Another	O
reason	O
is	O
due	O
to	O
the	O
fact	O
that	O
we	O
mainly	O
focused	O
on	O
studying	O
the	O
reprogramming	O
effect	O
of	O
DMB	O
on	O
the	O
two	O
-	O
hit	O
model	O
,	O
instead	O
of	O
the	O
one	O
-	O
hit	O
model	O
.	O
Nevertheless	O
,	O
whether	O
DMB	O
administration	O
in	O
pregnancy	O
and	O
lactation	O
might	O
cause	O
long	O
-	O
term	O
effects	O
in	O
offspring	O
prenatally	O
exposed	O
to	O
TCDD	O
or	O
in	O
normal	O
controls	O
remains	O
to	O
be	O
clarified	O
.	O
Secondly	O
,	O
we	O
only	O
analyzed	O
gut	O
microbiota	O
in	O
offspring	O
,	O
but	O
not	O
in	O
dams	O
.	O
Whether	O
different	O
insults	O
experienced	O
by	O
mothers	O
could	O
regulate	O
the	O
gut	O
microbiota	O
in	O
both	O
dams	O
and	O
offspring	O
,	O
and	O
whether	O
maternal	O
gut	O
microbiota	O
is	O
related	O
to	O
offspring	O
outcome	O
,	O
both	O
require	O
further	O
evaluation	O
.	O
Thirdly	O
,	O
we	O
are	O
well	O
aware	O
that	O
the	O
mechanisms	O
analyzed	O
in	O
the	O
present	O
study	O
might	O
not	O
represent	O
the	O
whole	O
picture	O
of	O
the	O
protective	O
role	O
of	O
DMB	O
therapy	O
.	O

Since	O
maternal	O
HFR	O
-	O
induced	O
hypertension	O
is	O
related	O
to	O
epigenetic	O
regulation	O
and	O
nutrient	O
-	O
sensing	O
signals	O
[	O
5	O
,	O
32	O
]	O
,	O
additional	O
studies	O
are	O
needed	O
to	O
elucidate	O
whether	O
these	O
mechanisms	O
are	O
also	O
associated	O
with	O
the	O
protective	O
effects	O
of	O
DMB	O
.	O
Lastly	O
,	O
we	O
mainly	O
focused	O
on	O
the	O
kidneys	O
in	O
the	O
present	O
study	O
.	O
Accordingly	O
,	O
we	O
know	O
very	O
little	O
about	O
what	O
role	O
other	O
organs	O
play	O
in	O
the	O
BP	O
-	O
lowering	O
effect	O
of	O
DMB	O
.	O
Virgin	O
Sprague	O
–	O
Dawley	O
(	O
SD	O
)	O
rats	O
(	O
BioLASCO	O
Taiwan	O
Co	O
.	O
,	O
Ltd	O
.	O
,	O
Taipei	O
,	O
Taiwan	O
)	O
were	O
housed	O
in	O
a	O
facility	O
accredited	O
by	O
the	O
Association	O
for	O
Assessment	O
and	O
Accreditation	O
of	O
Laboratory	O
Animal	O
Care	O
International	O
.	O
The	O
rats	O
were	O
housed	O
under	O
12	O
h	O
light	O
/	O
12	O
h	O
dark	O
conditions	O
.	O
This	O
study	O
was	O
conducted	O
under	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
protocol	O
approved	O
(	O
Permit	O
number	O
:	O
2019011001	O
;	O
approval	O
date	O
:	O
31	O
January	O
2019	O
)	O
by	O
the	O
Kaohsiung	O
Chang	O
Gung	O
Memorial	O
Hospital	O
,	O
and	O
complies	O
with	O
the	O
National	O
Institutes	O
of	O
Health	O
’	O
s	O
Guide	O
for	O
the	O
Care	O
and	O
Use	O
of	O
Laboratory	O
Animals	O
.	O
Mating	O
was	O
achieved	O
by	O
placing	O
one	O
female	O
and	O
one	O
male	O
in	O
a	O
cage	O
overnight	O
,	O
and	O
successful	O
mating	O
was	O
confirmed	O
by	O
observation	O
of	O
a	O
vaginal	O
plug	O
.	O
To	O
construct	O
a	O
maternal	O
HFR	O
model	O
,	O
pregnant	O
dams	O
fed	O
with	O
high	O
-	O
fructose	O
(	O
60	O
%	O
fructose	O
)	O
diet	O
throughout	O
pregnancy	O
and	O
lactation	O
[	O
5	O
]	O
.	O
Additionally	O
,	O
pregnant	O
rats	O
exposed	O
to	O
an	O
oral	O
dose	O
of	O
TCDD	O
at	O
200	O
ng	O
/	O
kg	O
body	O
weight	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
or	O
an	O
oral	O
dose	O
of	O
corn	O
oil	O
vehicle	O
at	O
4	O
mL	O
/	O
kg	O
BW	O
on	O
gestational	O
day	O
14	O
and	O
21	O
,	O
and	O
days	O
7	O
and	O
14	O
after	O
birth	O
,	O
to	O
provide	O
both	O
in	O
utero	O
and	O
lactation	O
exposure	O
.	O
Because	O
TCDD	O
has	O
a	O
long	O
half	O
-	O
life	O
of	O
~	O
3	O
weeks	O
in	O
rats	O
,	O
TCDD	O
was	O
used	O
at	O
weekly	O
doses	O
based	O
on	O
previous	O
studies	O
[	O
8	O
,	O
33	O
]	O
.	O
One	O
group	O
of	O
mother	O
rats	O
exposed	O
to	O
HFR	O
or	O
HFR	O
+	O
TCDD	O
received	O
1	O
%	O
DMB	O
in	O
the	O
drinking	O
water	O
during	O
the	O
pregnancy	O
and	O
lactation	O
period	O
.	O
The	O
dose	O
of	O
DMB	O
used	O
here	O
was	O
based	O
on	O
findings	O
of	O
previous	O
studies	O
[	O
12	O
,	O
16	O
]	O
.	O

To	O
standardize	O
the	O
received	O
quantity	O
of	O
milk	O
and	O
maternal	O
pup	O
care	O
,	O
the	O
litters	O
were	O
culled	O
to	O
a	O
total	O
of	O
eight	O
pups	O
after	O
birth	O
.	O
Cardiovascular	O
events	O
occur	O
at	O
an	O
earlier	O
age	O
in	O
males	O
than	O
females	O
[	O
34	O
]	O
.	O
We	O
,	O
therefore	O
,	O
only	O
selected	O
male	O
offspring	O
at	O
random	O
from	O
each	O
litter	O
for	O
subsequent	O
experiments	O
.	O
Male	O
offspring	O
were	O
assigned	O
to	O
six	O
groups	O
(	O
n	O
=	O
8	O
for	O
each	O
group	O
)	O
:	O
regular	O
diet	O
(	O
CV	O
)	O
,	O
high	O
-	O
fructose	O
diet	O
(	O
HFR	O
)	O
,	O
regular	O
diet	O
+	O
TCDD	O
exposure	O
(	O
CT	O
)	O
,	O
HFR	O
+	O
TCDD	O
exposure	O
(	O
HRT	O
)	O
,	O
high	O
-	O
fructose	O
diet	O
+	O
DMB	O
treatment	O
(	O
HRD	O
)	O
,	O
and	O
HFR	O
+	O
TCDD	O
+	O
DMB	O
treatment	O
(	O
HRTD	O
)	O
.	O
At	O
3	O
weeks	O
of	O
age	O
,	O
male	O
offspring	O
were	O
weaned	O
and	O
placed	O
onto	O
the	O
regular	O
chow	O
ad	O
libitum	O
from	O
weaning	O
to	O
12	O
weeks	O
of	O
age	O
.	O
We	O
used	O
the	O
BP	O
-	O
2000	O
Blood	O
Pressure	O
Analysis	O
system	O
(	O
BP	O
-	O
2000	O
,	O
Visitech	O
Systems	O
,	O
Inc	O
.	O
,	O
Apex	O
,	O
NC	O
,	O
USA	O
)	O
to	O
measure	O
the	O
BP	O
in	O
conscious	O
rats	O
at	O
intervals	O
of	O
four	O
weeks	O
,	O
beginning	O
from	O
4	O
weeks	O
and	O
through	O
to	O
12	O
weeks	O
of	O
age	O
.	O
This	O
device	O
used	O
the	O
tail	O
-	O
cuff	O
method	O
.	O
To	O
ensure	O
accuracy	O
and	O
reproducibility	O
,	O
the	O
rats	O
were	O
acclimated	O
to	O
restraint	O
and	O
tail	O
-	O
cuff	O
inflation	O
for	O
1	O
week	O
prior	O
to	O
the	O
measurement	O
[	O
5	O
]	O
.	O
Fresh	O
feces	O
samples	O
were	O
collected	O
at	O
3	O
and	O
12	O
weeks	O
of	O
age	O
,	O
frozen	O
,	O
and	O
placed	O
in	O
a	O
−80	O
°C	O
freezer	O
for	O
further	O
analysis	O
.	O
At	O
12	O
weeks	O
of	O
age	O
,	O
all	O
rats	O
were	O
killed	O
.	O
Blood	O
samples	O
were	O
collected	O
in	O
heparinized	O
tubes	O
.	O
The	O
kidneys	O
were	O
harvested	O
and	O
placed	O
in	O
a	O
−80	O
°C	O
freezer	O
until	O
analysis	O
.	O
Plasma	O
creatinine	O
levels	O
were	O
analyzed	O
by	O
HPLC	O
according	O
to	O
our	O
previous	O
protocol	O
[	O
12	O
]	O
.	O
Plasma	O
levels	O
of	O
TMA	O
,	O
TMAO	O
,	O
and	O
DMA	O
were	O
determined	O
by	O
LC	O
–	O
MS	O
/	O
MS	O
analysis	O
.	O
The	O
detection	O
was	O
performed	O
by	O
an	O
Agilent	O
6410	O
Series	O
Triple	O
Quadrupole	O
mass	O
spectrometer	O
(	O
Agilent	O
Technologies	O
,	O
Wilmington	O
,	O
DE	O
,	O
USA	O
)	O
with	O
an	O
electrospray	O
ionization	O
source	O
,	O
as	O
described	O
previously	O
[	O
12	O
]	O
.	O

The	O
mass	O
spectrometric	O
determination	O
was	O
carried	O
out	O
using	O
multiple	O
reaction	O
monitoring	O
mode	O
.	O
The	O
precursor	O
to	O
product	O
ion	O
transitions	O
of	O
m	O
/	O
z	O
60	O
.	O
1→44	O
.	O
1	O
,	O
m	O
/	O
z	O
76	O
.	O
1→58	O
.	O
1	O
,	O
and	O
m	O
/	O
z	O
46	O
.	O
1→30	O
were	O
selected	O
for	O
the	O
quantification	O
of	O
TMA	O
,	O
TMAO	O
and	O
DMA	O
,	O
respectively	O
.	O
Diethylamine	O
was	O
used	O
as	O
an	O
internal	O
standard	O
.	O
Plasma	O
levels	O
of	O
NO	O
-	O
related	O
metabolites	O
,	O
including	O
L	O
-	O
citrulline	O
(	O
the	O
precursor	O
of	O
L	O
-	O
arginine	O
)	O
,	O
L	O
-	O
arginine	O
(	O
substrate	O
for	O
NO	O
synthesis	O
)	O
,	O
SDMA	O
,	O
and	O
SDMA	O
were	O
measured	O
using	O
HPLC	O
(	O
HP	O
series	O
1100	O
;	O
Agilent	O
Technologies	O
Inc	O
.	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
.	O
O	O
-	O
phthalaldehyde	O
/	O
3	O
-	O
mercaptopropionic	O
acid	O
(	O
OPA	O
/	O
3MPA	O
)	O
was	O
used	O
as	O
the	O
derivative	O
reagent	O
[	O
5	O
]	O
.	O
Homoarginine	O
(	O
Sigma	O
)	O
was	O
used	O
as	O
the	O
internal	O
standard	O
.	O
Frozen	O
fecal	O
samples	O
were	O
analyzed	O
with	O
metagenomics	O
focused	O
on	O
the	O
V3	O
–	O
V4	O
of	O
the	O
16S	O
DNA	O
gene	O
.	O
As	O
described	O
previously	O
[	O
12	O
]	O
,	O
all	O
polymerase	O
chain	O
-	O
reaction	O
amplicons	O
were	O
mixed	O
and	O
sent	O
to	O
the	O
Biotools	O
Co	O
.	O
,	O
Ltd	O
.	O
(	O
Taipei	O
,	O
Taiwan	O
)	O
.	O
Libraries	O
were	O
sequenced	O
with	O
Illumina	O
MiSeq	O
platform	O
(	O
Illumina	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O
Illumina	O
sequence	O
data	O
were	O
processed	O
using	O
QIIME	O
version	O
1	O
.	O
9	O
.	O
1	O
.	O
A	O
median	O
of	O
99	O
,	O
198	O
raw	O
sequencing	O
reads	O
and	O
80	O
,	O
622	O
effective	O
tag	O
sequences	O
per	O
sample	O
was	O
obtained	O
,	O
respectively	O
.	O
The	O
sequences	O
were	O
clustered	O
into	O
operational	O
taxonomic	O
units	O
(	O
OTUs	O
)	O
at	O
97	O
%	O
similarity	O
using	O
the	O
USEARCH	O
algorithm	O
.	O
The	O
phylogenetic	O
structure	O
analysis	O
was	O
constructed	O
with	O
Fast	O
-	O
Tree	O
.	O
We	O
compared	O
the	O
patterns	O
of	O
α	O
-	O
and	O
β	O
-	O
diversity	O
for	O
microbial	O
communities	O
[	O
17	O
,	O
18	O
]	O
.	O
The	O
α	O
-	O
diversity	O
analysis	O
,	O
accounting	O
for	O
both	O
the	O
abundance	O
and	O
evenness	O
of	O
the	O
taxa	O
present	O
,	O
was	O
calculated	O
using	O
the	O
Shannon	O
index	O
in	O
QIIME	O
1	O
.	O
9	O
.	O
1	O
[	O
19	O
]	O
.	O

We	O
evaluated	O
the	O
β	O
-	O
diversity	O
changes	O
in	O
gut	O
microbiota	O
across	O
groups	O
using	O
PCA	O
and	O
ANOSIM	O
[	O
20	O
]	O
.	O
RNA	O
was	O
extracted	O
from	O
the	O
kidney	O
cortex	O
[	O
8	O
]	O
.	O
Two	O
-	O
step	O
quantitative	O
real	O
-	O
time	O
PCR	O
(	O
qPCR	O
)	O
was	O
conducted	O
using	O
Quantitect	O
SYBR	O
Green	O
PCR	O
Reagents	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
,	O
USA	O
)	O
on	O
an	O
iCycler	O
iQ	O
Multi	O
-	O
Color	O
Real	O
-	O
Time	O
PCR	O
Detection	O
System	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
)	O
.	O
Four	O
AHR	O
target	O
genes	O
were	O
analyzed	O
,	O
including	O
Ahrr	O
(	O
encoding	O
for	O
the	O
aryl	O
hydrocarbon	O
receptor	O
repressor	O
)	O
,	O
Cyp1a1	O
(	O
Cytochrome	O
P450	O
CYP1A1	O
)	O
,	O
Arnt	O
(	O
encoding	O
for	O
the	O
aryl	O
hydrocarbon	O
receptor	O
nuclear	O
translocator	O
)	O
,	O
and	O
Tiparp	O
(	O
encoding	O
for	O
TCDD	O
-	O
inducible	O
poly	O
-	O
ADP	O
-	O
ribose	O
polymerase	O
)	O
.	O
Rn18s	O
was	O
used	O
as	O
a	O
reference	O
in	O
all	O
analyses	O
.	O
The	O
sequences	O
of	O
the	O
primers	O
used	O
in	O
this	O
study	O
are	O
provided	O
in	O
Table	O
3	O
.	O
All	O
samples	O
were	O
run	O
in	O
duplicate	O
.	O
The	O
comparative	O
threshold	O
cycle	O
(	O
CT	O
)	O
method	O
was	O
used	O
for	O
the	O
relative	O
quantification	O
of	O
gene	O
expression	O
.	O
The	O
averaged	O
CT	O
was	O
subtracted	O
from	O
the	O
corresponding	O
averaged	O
Rn18s	O
value	O
for	O
each	O
sample	O
,	O
resulting	O
in	O
the	O
ΔCT	O
.	O
ΔΔCT	O
was	O
achieved	O
by	O
subtracting	O
the	O
average	O
control	O
ΔCT	O
value	O
from	O
the	O
average	O
experimental	O
ΔCT	O
.	O
The	O
fold	O
change	O
was	O
2−ΔΔCT	O
.	O
The	O
Western	O
blot	O
analysis	O
was	O
performed	O
on	O
the	O
kidney	O
cortex	O
or	O
ileal	O
homogenate	O
,	O
as	O
previously	O
described	O
[	O
5	O
]	O
.	O
We	O
used	O
10	O
–	O
15	O
%	O
polyacrylamide	O
gels	O
and	O
separated	O
by	O
electrophoresis	O
(	O
200	O
V	O
,	O
90	O
min	O
)	O
,	O
then	O
transferred	O
onto	O
polyvinylidene	O
difluoride	O
membranes	O
.	O
Following	O
transfer	O
,	O
the	O
membrane	O
was	O
stained	O
with	O
Ponceau	O
S	O
red	O
(	O
PonS	O
)	O
stain	O
solution	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
to	O
verify	O
equal	O
loading	O
.	O

We	O
analyzed	O
the	O
renal	O
protein	O
abundance	O
of	O
components	O
in	O
the	O
RAS	O
,	O
including	O
AT1R	O
and	O
AT2R	O
.	O
Additionally	O
,	O
we	O
determined	O
the	O
expressions	O
of	O
AHR	O
in	O
the	O
kidney	O
,	O
as	O
well	O
as	O
in	O
the	O
tight	O
junction	O
proteins	O
(	O
occludin	O
,	O
claudin	O
-	O
1	O
,	O
and	O
-	O
2	O
)	O
in	O
the	O
ileal	O
segment	O
.	O
A	O
list	O
of	O
antibodies	O
used	O
for	O
Western	O
blotting	O
is	O
shown	O
in	O
Table	O
4	O
.	O
The	O
Western	O
blots	O
were	O
visualized	O
using	O
a	O
SuperSignal	O
West	O
Pico	O
reagent	O
(	O
Pierce	O
;	O
Rockford	O
,	O
IL	O
,	O
USA	O
)	O
.	O
Densitometry	O
analysis	O
was	O
provided	O
for	O
each	O
band	O
,	O
and	O
was	O
quantified	O
as	O
the	O
integrated	O
optical	O
density	O
(	O
IOD	O
)	O
normalized	O
to	O
PonS	O
staining	O
.	O
Data	O
are	O
expressed	O
as	O
the	O
mean	O
±	O
standard	O
error	O
of	O
the	O
mean	O
.	O
A	O
p	O
-	O
value	O
less	O
than	O
0	O
.	O
05	O
is	O
considered	O
statistically	O
significant	O
for	O
all	O
tests	O
.	O
Two	O
-	O
way	O
repeated	O
-	O
measures	O
ANOVA	O
and	O
Tukey	O
’	O
s	O
post	O
hoc	O
tests	O
were	O
used	O
for	O
BP	O
analysis	O
.	O
Statistical	O
analysis	O
was	O
undertaken	O
using	O
one	O
-	O
way	O
ANOVAs	O
with	O
post	O
hoc	O
Tukey	O
’	O
s	O
test	O
for	O
multiple	O
comparisons	O
.	O
All	O
analyses	O
were	O
performed	O
using	O
the	O
Statistical	O
Package	O
for	O
the	O
Social	O
Sciences	O
(	O
SPSS	O
)	O
15	O
.	O
0	O
statistics	O
software	O
(	O
SPSS	O
Inc	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O
In	O
conclusion	O
,	O
the	O
addition	O
of	O
TCDD	O
exposure	O
exacerbates	O
hypertension	O
programmed	O
by	O
maternal	O
HFR	O
exposure	O
in	O
adult	O
male	O
offspring	O
.	O
There	O
are	O
several	O
protective	O
mechanisms	O
by	O
which	O
maternal	O
DMB	O
therapy	O
moderates	O
hypertension	O
programmed	O
by	O
combined	O
HFR	O
+	O
TCDD	O
exposure	O
,	O
such	O
as	O
increasing	O
NO	O
bioavailability	O
,	O
balancing	O
the	O
RAS	O
,	O
antagonizing	O
AHR	O
signaling	O
,	O
and	O
restoring	O
the	O
gut	O
microbiota	O
.	O
Our	O
findings	O
cast	O
new	O
light	O
on	O
early	O
interventions	O
targeting	O
microbiome	O
-	O
dependent	O
metabolite	O
TMA	O
,	O
which	O
may	O
aid	O
in	O
developing	O
an	O
ideal	O
strategy	O
to	O
protect	O
pregnant	O
women	O
and	O
their	O
children	O
against	O
hypertension	O
programmed	O
by	O
excessive	O
fructose	O
consumption	O
and	O
dioxin	O
exposure	O
.	O
We	O
would	O
like	O
to	O
thank	O
the	O
Super	O
Micro	O
Mass	O
Research	O
and	O
Technology	O
Center	O
and	O
the	O
Center	O
for	O
Environmental	O
Toxin	O
and	O
Emerging	O
-	O
Contaminant	O
Research	O
,	O
Cheng	O
Shiu	O
University	O
,	O
Kaohsiung	O
,	O
for	O
technical	O
support	O
.	O

C	O
.	O
-	O
N	O
.	O
H	O
.	O
:	O
contributed	O
to	O
concept	O
generation	O
,	O
data	O
interpretation	O
,	O
drafting	O
of	O
the	O
manuscript	O
,	O
critical	O
revision	O
of	O
the	O
manuscript	O
,	O
and	O
approval	O
of	O
the	O
article	O
;	O
J	O
.	O
Y	O
.	O
H	O
.	O
C	O
.	O
:	O
contributed	O
to	O
data	O
interpretation	O
,	O
critical	O
revision	O
of	O
the	O
manuscript	O
,	O
and	O
approval	O
of	O
the	O
article	O
;	O
H	O
.	O
-	O
R	O
.	O
Y	O
.	O
:	O
contributed	O
to	O
methodology	O
,	O
critical	O
revision	O
of	O
the	O
manuscript	O
,	O
and	O
approval	O
of	O
the	O
article	O
;	O
K	O
.	O
L	O
.	O
H	O
.	O
W	O
.	O
:	O
contributed	O
to	O
methodology	O
and	O
approval	O
of	O
the	O
article	O
;	O
W	O
.	O
-	O
C	O
.	O
L	O
.	O
:	O
contributed	O
to	O
methodology	O
,	O
critical	O
revision	O
of	O
the	O
manuscript	O
,	O
and	O
approval	O
of	O
the	O
article	O
;	O
G	O
.	O
-	O
P	O
.	O
C	O
.	O
-	O
C	O
.	O
:	O
contributed	O
to	O
methodology	O
and	O
approval	O
of	O
the	O
article	O
;	O
S	O
.	O
L	O
.	O
:	O
contributed	O
to	O
methodology	O
and	O
approval	O
of	O
the	O
article	O
;	O
C	O
.	O
-	O
Y	O
.	O
H	O
.	O
:	O
contributed	O
to	O
methodology	O
and	O
approval	O
of	O
the	O
article	O
;	O
P	O
.	O
-	O
C	O
.	O
L	O
.	O
:	O
contributed	O
to	O
methodology	O
and	O
approval	O
of	O
the	O
article	O
;	O
Y	O
.	O
-	O
L	O
.	O
T	O
.	O
:	O
contributed	O
to	O
concept	O
generation	O
,	O
data	O
interpretation	O
,	O
drafting	O
of	O
the	O
manuscript	O
,	O
critical	O
revision	O
of	O
the	O
manuscript	O
,	O
and	O
approval	O
of	O
the	O
article	O
.	O
All	O
authors	O
have	O
read	O
and	O
agreed	O
to	O
the	O
published	O
version	O
of	O
the	O
manuscript	O
.	O
This	O
work	O
was	O
supported	O
by	O
Grants	O
CMRPG8J0251	O
and	O
CMRPG8J0252	O
from	O
Chang	O
Gung	O
Memorial	O
Hospital	O
,	O
Kaohsiung	O
,	O
Taiwan	O
,	O
and	O
Grant	O
MOST	O
107	O
-	O
2314	O
-	O
B	O
-	O
182	O
-	O
045	O
-	O
MY3	O
from	O
the	O
Ministry	O
of	O
Science	O
and	O
Technology	O
,	O
Taiwan	O
.	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O

Leptin	O
Receptor	O
Blockade	O
Attenuates	O
Hypertension	O
,	O
but	O
Does	O
Not	O
Affect	O
Ventilatory	O
Response	O
to	O
Hypoxia	O
in	O
a	O
Model	O
of	O
Polygenic	O
Obesity	O
leptin	O
;	O
obesity	O
;	O
blood	O
pressure	O
;	O
hypoxic	O
ventilatory	O
response	O
;	O
sleep	O
-	O
disordered	O
breathing	O
;	O
leptin	O
receptor	O
blocker	O
Obesity	O
can	O
cause	O
hypertension	O
and	O
exacerbates	O
sleep	O
-	O
disordered	O
breathing	O
(	O
SDB	O
)	O
.	O
Leptin	O
is	O
an	O
adipocyte	O
-	O
produced	O
hormone	O
,	O
which	O
increases	O
metabolic	O
rate	O
,	O
suppresses	O
appetite	O
,	O
modulates	O
control	O
of	O
breathing	O
,	O
and	O
increases	O
blood	O
pressure	O
.	O
Obese	O
individuals	O
with	O
high	O
circulating	O
levels	O
of	O
leptin	O
are	O
resistant	O
to	O
metabolic	O
and	O
respiratory	O
effects	O
of	O
leptin	O
,	O
but	O
they	O
appear	O
to	O
be	O
sensitive	O
to	O
hypertensive	O
effects	O
of	O
this	O
hormone	O
.	O
Obesity	O
-	O
induced	O
hypertension	O
has	O
been	O
associated	O
with	O
hyperleptinemia	O
.	O
New	O
Zealand	O
obese	O
(	O
NZO	O
)	O
mice	O
,	O
a	O
model	O
of	O
polygenic	O
obesity	O
,	O
have	O
high	O
levels	O
of	O
circulating	O
leptin	O
and	O
hypertension	O
,	O
and	O
are	O
prone	O
to	O
develop	O
SDB	O
,	O
similarly	O
to	O
human	O
obesity	O
.	O
We	O
hypothesize	O
that	O
systemic	O
leptin	O
receptor	O
blocker	O
Allo	O
-	O
aca	O
will	O
treat	O
hypertension	O
in	O
NZO	O
mice	O
without	O
any	O
effect	O
on	O
body	O
weight	O
,	O
food	O
intake	O
,	O
or	O
breathing	O
.	O
Male	O
NZO	O
mice	O
,	O
12	O
–	O
13	O
weeks	O
of	O
age	O
,	O
were	O
treated	O
with	O
Allo	O
-	O
aca	O
(	O
n	O
=	O
6	O
)	O
or	O
a	O
control	O
peptide	O
Gly11	O
(	O
n	O
=	O
12	O
)	O
for	O
8	O
consecutive	O
days	O
.	O
Doses	O
of	O
0	O
.	O
2	O
mg	O
/	O
kg	O
were	O
administered	O
subcutaneously	O
2×	O
/	O
day	O
,	O
at	O
10	O
AM	O
and	O
6	O
PM	O
.	O
Blood	O
pressure	O
was	O
measured	O
by	O
telemetry	O
for	O
48	O
h	O
before	O
and	O
during	O
peptide	O
infusion	O
.	O
Ventilation	O
was	O
assessed	O
by	O
whole	O
-	O
body	O
barometric	O
plethysmography	O
,	O
control	O
of	O
breathing	O
was	O
examined	O
by	O
assessing	O
the	O
hypoxic	O
ventilatory	O
response	O
(	O
HVR	O
)	O
,	O
and	O
polysomnography	O
was	O
performed	O
during	O
light	O
-	O
phase	O
at	O
baseline	O
and	O
during	O
treatment	O
.	O
Heart	O
rate	O
variability	O
analyses	O
were	O
performed	O
to	O
estimate	O
the	O
cardiac	O
autonomic	O
balance	O
.	O
Systemic	O
leptin	O
receptor	O
blockade	O
with	O
Allo	O
-	O
aca	O
did	O
not	O
affect	O
body	O
weight	O
,	O
body	O
temperature	O
,	O
and	O
food	O
intake	O
in	O
NZO	O
mice	O
.	O

Plasma	O
levels	O
of	O
leptin	O
did	O
not	O
change	O
after	O
the	O
treatment	O
with	O
either	O
Allo	O
-	O
aca	O
or	O
the	O
control	O
peptide	O
Gy11	O
.	O
NZO	O
mice	O
were	O
hypertensive	O
at	O
baseline	O
and	O
leptin	O
receptor	O
blocker	O
Allo	O
-	O
aca	O
significantly	O
reduced	O
the	O
mean	O
arterial	O
pressure	O
from	O
134	O
.	O
9	O
±	O
3	O
.	O
1	O
to	O
124	O
.	O
9	O
±	O
5	O
.	O
7	O
mmHg	O
during	O
the	O
light	O
phase	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
whereas	O
the	O
control	O
peptide	O
had	O
no	O
effect	O
.	O
Leptin	O
receptor	O
blockade	O
did	O
not	O
change	O
the	O
heart	O
rate	O
or	O
cardiac	O
autonomic	O
balance	O
.	O
Allo	O
-	O
aca	O
did	O
not	O
affect	O
minute	O
ventilation	O
under	O
normoxic	O
or	O
hypoxic	O
conditions	O
and	O
HVR	O
.	O
Ventilation	O
,	O
apnea	O
index	O
,	O
and	O
oxygen	O
desaturation	O
during	O
NREM	O
and	O
REM	O
sleep	O
did	O
not	O
change	O
with	O
leptin	O
receptor	O
blockade	O
.	O
Systemic	O
leptin	O
receptor	O
blockade	O
attenuates	O
hypertension	O
in	O
NZO	O
mice	O
,	O
but	O
does	O
not	O
exacerbate	O
obesity	O
and	O
SDB	O
.	O
Thus	O
,	O
leptin	O
receptor	O
blockade	O
represents	O
a	O
potential	O
pharmacotherapy	O
for	O
obesity	O
-	O
associated	O
hypertension	O
.	O
Obesity	O
is	O
a	O
major	O
public	O
health	O
problem	O
affecting	O
35	O
%	O
of	O
United	O
States	O
adults	O
(	O
Flegal	O
et	O
al	O
.	O
,	O
2010	O
)	O
.	O
Obesity	O
increases	O
cardiovascular	O
morbidity	O
and	O
mortality	O
(	O
Hubert	O
et	O
al	O
.	O
,	O
1983	O
;	O
Hall	O
et	O
al	O
.	O
,	O
2001	O
;	O
Rahmouni	O
et	O
al	O
.	O
,	O
2005a	O
;	O
Adams	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O
Hypertension	O
is	O
observed	O
in	O
74	O
%	O
of	O
obese	O
individuals	O
and	O
the	O
risk	O
of	O
resistant	O
hypertension	O
is	O
fivefold	O
higher	O
in	O
obesity	O
compared	O
to	O
normal	O
weight	O
patients	O
(	O
Bramlage	O
et	O
al	O
.	O
,	O
2004	O
)	O
.	O
Obesity	O
also	O
causes	O
sleep	O
-	O
disordered	O
breathing	O
(	O
SDB	O
)	O
,	O
which	O
contributes	O
to	O
hypertension	O
(	O
Peppard	O
et	O
al	O
.	O
,	O
2000	O
;	O
Young	O
et	O
al	O
.	O
,	O
2002	O
;	O
Wolk	O
et	O
al	O
.	O
,	O
2003	O
)	O
.	O
Multiple	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
obesity	O
-	O
induced	O
hypertension	O
,	O
one	O
of	O
which	O
is	O
related	O
to	O
high	O
circulating	O
levels	O
of	O
leptin	O
(	O
Rausch	O
et	O
al	O
.	O
,	O
1991	O
;	O
Hall	O
et	O
al	O
.	O
,	O
2001	O
,	O
2010	O
;	O
Rahmouni	O
et	O
al	O
.	O
,	O
2005a	O
,	O
b	O
;	O
Friedman	O
,	O
2009	O
;	O
Bell	O
and	O
Rahmouni	O
,	O
2016	O
)	O
.	O

Leptin	O
,	O
an	O
adipocyte	O
-	O
produced	O
hormone	O
,	O
plays	O
an	O
important	O
role	O
in	O
obesity	O
and	O
its	O
sequelae	O
.	O
Leptin	O
exerts	O
beneficial	O
effects	O
on	O
metabolism	O
by	O
suppressing	O
appetite	O
and	O
increasing	O
the	O
metabolic	O
rate	O
(	O
Halaas	O
et	O
al	O
.	O
,	O
1995	O
;	O
Spiegelman	O
and	O
Flier	O
,	O
2001	O
;	O
Friedman	O
,	O
2009	O
)	O
,	O
mitigating	O
obesity	O
.	O
Leptin	O
has	O
a	O
profound	O
effect	O
on	O
control	O
of	O
breathing	O
,	O
stimulating	O
ventilation	O
(	O
O	O
’	O
Donnell	O
et	O
al	O
.	O
,	O
1999	O
;	O
Pho	O
et	O
al	O
.	O
,	O
2016	O
,	O
2021	O
;	O
Yao	O
et	O
al	O
.	O
,	O
2016	O
)	O
and	O
mitigating	O
SDB	O
.	O
On	O
the	O
other	O
hand	O
,	O
leptin	O
activates	O
the	O
sympathetic	O
nervous	O
system	O
and	O
increases	O
blood	O
pressure	O
(	O
Asferg	O
et	O
al	O
.	O
,	O
2010	O
;	O
Shankar	O
and	O
Xiao	O
,	O
2010	O
;	O
Kshatriya	O
et	O
al	O
.	O
,	O
2011	O
;	O
Bell	O
and	O
Rahmouni	O
,	O
2016	O
;	O
Shin	O
et	O
al	O
.	O
,	O
2019a	O
,	O
2021	O
)	O
,	O
predisposing	O
to	O
hypertension	O
.	O
Obese	O
individuals	O
are	O
resistant	O
to	O
the	O
metabolic	O
and	O
respiratory	O
effects	O
of	O
leptin	O
,	O
but	O
are	O
sensitive	O
to	O
the	O
hypertensive	O
effects	O
of	O
this	O
hormone	O
(	O
Maffei	O
et	O
al	O
.	O
,	O
1995	O
;	O
Considine	O
et	O
al	O
.	O
,	O
1996	O
;	O
Ip	O
et	O
al	O
.	O
,	O
2000	O
;	O
Phipps	O
et	O
al	O
.	O
,	O
2002	O
;	O
Rahmouni	O
et	O
al	O
.	O
,	O
2005b	O
;	O
Yee	O
et	O
al	O
.	O
,	O
2006	O
;	O
Simonds	O
et	O
al	O
.	O
,	O
2014	O
;	O
Fleury	O
Curado	O
et	O
al	O
.	O
,	O
2018	O
;	O
Berger	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Although	O
precise	O
molecular	O
mechanisms	O
of	O
this	O
dichotomy	O
remain	O
poorly	O
understood	O
,	O
limited	O
permeability	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
to	O
leptin	O
could	O
be	O
involved	O
in	O
the	O
process	O
(	O
Schwartz	O
et	O
al	O
.	O
,	O
1996	O
;	O
Banks	O
et	O
al	O
.	O
,	O
1999	O
;	O
Morris	O
and	O
Rui	O
,	O
2009	O
;	O
Scarpace	O
and	O
Zhang	O
,	O
2009	O
;	O
Wauman	O
and	O
Tavernier	O
,	O
2011	O
)	O
.	O
Under	O
these	O
circumstances	O
,	O
the	O
blockade	O
of	O
leptin	O
signaling	O
in	O
leptin	O
resistant	O
obesity	O
would	O
treat	O
hypertension	O
,	O
but	O
would	O
not	O
affect	O
metabolism	O
or	O
respiratory	O
control	O
.	O
Here	O
,	O
we	O
propose	O
to	O
address	O
this	O
hypothesis	O
using	O
an	O
animal	O
model	O
of	O
obesity	O
-	O
induced	O
hypertension	O
and	O
hyperleptinemia	O
,	O
which	O
mimics	O
human	O
obesity	O
.	O

New	O
Zealand	O
obese	O
(	O
NZO	O
)	O
mice	O
are	O
an	O
inbred	O
strain	O
representing	O
polygenic	O
-	O
spontaneous	O
obesity	O
(	O
Bielschowsky	O
and	O
Goodall	O
,	O
1970	O
;	O
Haskell	O
et	O
al	O
.	O
,	O
2002	O
;	O
Joost	O
and	O
Schürmann	O
,	O
2014	O
)	O
.	O
NZO	O
mice	O
naturally	O
develop	O
hypertension	O
,	O
insulin	O
resistance	O
,	O
and	O
glucose	O
intolerance	O
(	O
Ortlepp	O
et	O
al	O
.	O
,	O
2000	O
;	O
Koza	O
et	O
al	O
.	O
,	O
2004	O
;	O
Joost	O
and	O
Schürmann	O
,	O
2014	O
)	O
.	O
NZO	O
mice	O
have	O
altered	O
upper	O
airway	O
anatomy	O
characterized	O
by	O
increased	O
volume	O
of	O
pharyngeal	O
soft	O
tissues	O
and	O
fat	O
deposits	O
in	O
the	O
tongue	O
(	O
Brennick	O
et	O
al	O
.	O
,	O
2009	O
)	O
,	O
which	O
predispose	O
to	O
SDB	O
(	O
Hernandez	O
et	O
al	O
.	O
,	O
2012	O
;	O
Baum	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
Hyperleptinemia	O
and	O
leptin	O
resistance	O
are	O
also	O
key	O
traits	O
of	O
NZO	O
mice	O
(	O
Halaas	O
et	O
al	O
.	O
,	O
1995	O
;	O
Igel	O
et	O
al	O
.	O
,	O
1997	O
;	O
Wator	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O
However	O
,	O
it	O
is	O
still	O
unknown	O
whether	O
leptin	O
plays	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
obesity	O
-	O
induced	O
hypertension	O
and	O
SDB	O
in	O
NZO	O
mice	O
.	O
We	O
used	O
a	O
systemic	O
leptin	O
receptor	O
blocker	O
,	O
Allo	O
-	O
aca	O
,	O
to	O
evaluate	O
the	O
effects	O
of	O
leptin	O
on	O
blood	O
pressure	O
and	O
breathing	O
of	O
NZO	O
mice	O
.	O
We	O
hypothesized	O
that	O
systemic	O
blockade	O
of	O
leptin	O
signaling	O
will	O
treat	O
hypertension	O
in	O
NZO	O
mice	O
without	O
exacerbating	O
obesity	O
and	O
SDB	O
.	O
In	O
total	O
,	O
18	O
male	O
NZO	O
mice	O
,	O
12	O
–	O
13	O
weeks	O
of	O
age	O
,	O
from	O
Jackson	O
Laboratory	O
(	O
Bar	O
Harbor	O
,	O
ME	O
,	O
United	O
States	O
,	O
Stock	O
#	O
002105	O
)	O
were	O
used	O
in	O
our	O
experiments	O
.	O
They	O
were	O
housed	O
in	O
individual	O
cages	O
with	O
water	O
and	O
chow	O
diet	O
ad	O
libitum	O
.	O
Animals	O
were	O
maintained	O
at	O
22°C	O
and	O
at	O
a	O
12	O
h	O
-	O
light	O
/	O
dark	O
cycle	O
with	O
lights	O
on	O
at	O
9	O
AM	O
.	O
Body	O
weight	O
,	O
body	O
temperature	O
,	O
and	O
food	O
consumption	O
were	O
monitored	O
throughout	O
the	O
experiments	O
.	O
The	O
study	O
was	O
approved	O
by	O
the	O
Johns	O
Hopkins	O
University	O
Animal	O
Care	O
and	O
Use	O
Committee	O
(	O
ACUC	O
)	O
under	O
the	O
protocol	O
number	O
#	O
MO18M211	O
.	O
All	O
the	O
surgical	O
procedures	O
were	O
performed	O
under	O
sterile	O
,	O
aseptic	O
conditions	O
.	O

Animals	O
were	O
anesthetized	O
using	O
1	O
–	O
2	O
%	O
isoflurane	O
administered	O
through	O
a	O
facemask	O
.	O
The	O
adequacy	O
of	O
anesthesia	O
was	O
assessed	O
by	O
the	O
breathing	O
frequency	O
and	O
the	O
absence	O
of	O
forelimb	O
or	O
hindlimb	O
pedal	O
withdrawal	O
reflex	O
.	O
Body	O
temperature	O
was	O
kept	O
around	O
37°C	O
with	O
a	O
heating	O
pad	O
during	O
the	O
surgery	O
.	O
Surgical	O
sites	O
were	O
washed	O
with	O
betadyne	O
scrub	O
solution	O
.	O
Sterile	O
ophthalmic	O
ointment	O
was	O
used	O
for	O
lubrication	O
of	O
the	O
eyes	O
.	O
Immediately	O
after	O
the	O
surgeries	O
,	O
all	O
mice	O
received	O
0	O
.	O
05	O
mg	O
/	O
kg	O
of	O
Buprenorphine	O
intraperitoneally	O
and	O
were	O
housed	O
in	O
a	O
recovery	O
chamber	O
under	O
a	O
heating	O
lamp	O
.	O
Mice	O
were	O
monitored	O
and	O
received	O
additional	O
0	O
.	O
05	O
mg	O
/	O
kg	O
of	O
Buprenorphine	O
for	O
the	O
next	O
3	O
days	O
or	O
until	O
no	O
signs	O
of	O
distress	O
or	O
pain	O
were	O
observed	O
.	O
Initially	O
,	O
the	O
NZO	O
mice	O
underwent	O
a	O
telemetry	O
implantation	O
for	O
blood	O
pressure	O
recording	O
as	O
previously	O
described	O
by	O
our	O
group	O
(	O
Jun	O
et	O
al	O
.	O
,	O
2014	O
;	O
Shin	O
et	O
al	O
.	O
,	O
2019a	O
,	O
2021	O
)	O
.	O
Mice	O
were	O
implanted	O
with	O
PA	O
-	O
C10	O
telemeters	O
(	O
Data	O
Sciences	O
International	O
,	O
St	O
.	O
Paul	O
,	O
MN	O
,	O
United	O
States	O
)	O
into	O
the	O
left	O
femoral	O
artery	O
.	O
Mice	O
were	O
allowed	O
to	O
recover	O
for	O
7	O
–	O
10	O
days	O
.	O
After	O
mice	O
fully	O
recovered	O
,	O
they	O
were	O
implanted	O
with	O
EEG	O
/	O
EMG	O
electrodes	O
using	O
an	O
EEG	O
/	O
EMG	O
headmount	O
(	O
Pinnacle	O
Technology	O
,	O
Lawrence	O
,	O
KS	O
,	O
United	O
States	O
)	O
as	O
previously	O
described	O
(	O
Hernandez	O
et	O
al	O
.	O
,	O
2012	O
;	O
Pho	O
et	O
al	O
.	O
,	O
2016	O
,	O
2021	O
;	O
Yao	O
et	O
al	O
.	O
,	O
2016	O
;	O
Fleury	O
Curado	O
et	O
al	O
.	O
,	O
2018	O
;	O
Berger	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Briefly	O
,	O
animals	O
were	O
placed	O
in	O
a	O
stereotaxic	O
frame	O
and	O
a	O
longitudinal	O
midline	O
incision	O
was	O
performed	O
on	O
their	O
skull	O
under	O
aseptic	O
conditions	O
.	O
The	O
underlying	O
fascia	O
was	O
gently	O
removed	O
and	O
the	O
headmount	O
was	O
glued	O
above	O
the	O
bregma	O
.	O
Two	O
pairs	O
of	O
silver	O
electrodes	O
were	O
screwed	O
to	O
the	O
headmount	O
with	O
silver	O
conductive	O
epoxy	O
in	O
frontal	O
and	O
parietal	O
regions	O
bilaterally	O
.	O
Insulated	O
EMG	O
leads	O
were	O
placed	O
over	O
the	O
nuchal	O
muscles	O
.	O

The	O
incision	O
was	O
sutured	O
with	O
6	O
-	O
0	O
silk	O
suture	O
and	O
the	O
area	O
around	O
the	O
headmount	O
was	O
closed	O
with	O
dental	O
acrylic	O
.	O
Mice	O
recovered	O
for	O
at	O
least	O
7	O
days	O
prior	O
to	O
the	O
baseline	O
measurements	O
.	O
Six	O
NZO	O
mice	O
were	O
treated	O
with	O
a	O
designer	O
leptin	O
receptor	O
antagonist	O
,	O
Allo	O
-	O
aca	O
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
)	O
,	O
which	O
was	O
administered	O
2×	O
/	O
day	O
at	O
10	O
AM	O
and	O
6	O
PM	O
via	O
subcutaneous	O
injections	O
for	O
8	O
consecutive	O
days	O
.	O
Injections	O
were	O
performed	O
during	O
light	O
-	O
phase	O
when	O
the	O
animals	O
are	O
more	O
likely	O
to	O
sleep	O
.	O
Allo	O
-	O
aca	O
is	O
a	O
9	O
-	O
residue	O
peptidomimetic	O
(	O
H	O
-	O
alloThr	O
-	O
Glu	O
-	O
Nva	O
-	O
Val	O
-	O
Ala	O
-	O
Leu	O
-	O
Ser	O
-	O
Arg	O
-	O
Aca	O
-	O
NH2	O
)	O
based	O
on	O
the	O
C	O
-	O
terminal	O
site	O
III	O
of	O
leptin	O
with	O
a	O
putative	O
mechanism	O
of	O
action	O
by	O
binding	O
to	O
circulating	O
leptin	O
receptor	O
(	O
Peelman	O
et	O
al	O
.	O
,	O
2004	O
;	O
Otvos	O
et	O
al	O
.	O
,	O
2011a	O
,	O
b	O
)	O
.	O
To	O
date	O
,	O
Allo	O
-	O
aca	O
appears	O
to	O
be	O
the	O
most	O
active	O
leptin	O
receptor	O
antagonist	O
within	O
a	O
wide	O
pharmaceutically	O
acceptable	O
concentration	O
range	O
in	B-methodology
vitro	I-methodology
and	O
effectively	O
produces	O
weight	O
gain	O
and	O
decreases	O
blood	O
pressure	O
in	B-methodology
vivo	I-methodology
(	O
Otvos	O
et	O
al	O
.	O
,	O
2008	O
,	O
2011a	O
,	O
2011b	O
,	O
2014	O
;	O
Huby	O
et	O
al	O
.	O
,	O
2016	O
;	O
You	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Allo	O
-	O
aca	O
shows	O
ObR	O
antagonist	O
properties	O
at	O
0	O
.	O
1	O
and	O
1	O
mg	O
/	O
kg	O
daily	O
doses	O
with	O
little	O
dose	O
-	O
dependence	O
.	O
Receptor	O
binding	O
data	O
have	O
shown	O
that	O
the	O
Allo	O
-	O
aca	O
-	O
ObR	O
interaction	O
half	O
-	O
time	O
is	O
2	O
h	O
and	O
the	O
peptide	O
deactivates	O
the	O
receptor	O
for	O
6	O
–	O
8	O
h	O
(	O
Otvos	O
et	O
al	O
.	O
,	O
2008	O
,	O
2011a	O
,	O
2011b	O
,	O
2014	O
)	O
.	O
Moreover	O
,	O
Allo	O
-	O
aca	O
temporarily	O
crosses	O
the	O
BBB	O
,	O
promoting	O
a	O
blockade	O
of	O
leptin	O
receptors	O
both	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
and	O
in	O
the	O
periphery	O
(	O
Otvos	O
et	O
al	O
.	O
,	O
2011b	O
)	O
.	O
Another	O
group	O
of	O
12	O
NZO	O
mice	O
received	O
a	O
control	O
peptide	O
Gly11	O
at	O
the	O
same	O
dose	O
and	O
according	O
to	O
the	O
same	O
administration	O
protocol	O
as	O
the	O
Allo	O
-	O
aca	O
group	O
.	O

Gly11	O
[	O
(	O
H	O
-	O
Chex	O
-	O
Arg	O
-	O
Pro	O
-	O
Asp	O
-	O
Lys	O
-	O
Pro	O
-	O
Arg	O
-	O
Pro	O
-	O
Tyr	O
-	O
Leu	O
-	O
Gly	O
-	O
Arg	O
-	O
Pro	O
-	O
Arg	O
-	O
Pro	O
-	O
Pro	O
-	O
Arg	O
-	O
Pro	O
-	O
Val	O
-	O
Arg	O
)	O
2	O
-	O
Dab	O
-	O
NH2	O
]	O
is	O
an	O
antimicrobial	O
peptide	O
derivative	O
that	O
was	O
successfully	O
used	O
as	O
a	O
negative	O
control	O
of	O
leptin	O
receptor	O
blockade	O
in	O
previous	O
reports	O
(	O
Otvos	O
et	O
al	O
.	O
,	O
2011a	O
,	O
2018	O
)	O
.	O
Blood	O
pressure	O
and	O
heart	O
rate	O
were	O
recorded	O
at	O
baseline	O
and	O
from	O
day	O
5	O
to	O
day	O
7	O
of	O
treatment	O
with	O
either	O
Allo	O
-	O
aca	O
(	O
n	O
=	O
5	O
)	O
or	O
Gly11	O
(	O
n	O
=	O
8	O
)	O
.	O
Recordings	O
were	O
performed	O
by	O
telemetry	O
as	O
previously	O
described	O
(	O
Jun	O
et	O
al	O
.	O
,	O
2014	O
;	O
Shin	O
et	O
al	O
.	O
,	O
2019a	O
,	O
2021	O
)	O
.	O
Signals	O
were	O
obtained	O
and	O
processed	O
using	O
PowerLabs	O
16	O
/	O
35	O
interfaced	O
with	O
LabChart	O
7	O
Pro	O
software	O
(	O
version	O
7	O
.	O
2	O
)	O
from	O
ADInstruments	O
(	O
Colorado	O
Springs	O
,	O
CO	O
,	O
United	O
States	O
)	O
.	O
Signals	O
were	O
sampled	O
at	O
400	O
Hz	O
per	O
second	O
.	O
Systolic	O
(	O
SBP	O
)	O
and	O
diastolic	O
blood	O
pressure	O
(	O
DBP	O
)	O
were	O
averaged	O
every	O
1	O
h	O
and	O
used	O
to	O
calculate	O
the	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
during	O
light	O
and	O
dark	O
-	O
phase	O
.	O
Heart	O
rate	O
variability	O
was	O
analyzed	O
to	O
estimate	O
the	O
sympathetic	O
and	O
parasympathetic	O
activities	O
,	O
and	O
the	O
cardiac	O
autonomic	O
balance	O
,	O
as	O
previously	O
reported	O
(	O
Malliani	O
et	O
al	O
.	O
,	O
1991	O
;	O
Zoccal	O
et	O
al	O
.	O
,	O
2009	O
;	O
Moraes	O
et	O
al	O
.	O
,	O
2014	O
)	O
,	O
at	O
baseline	O
and	O
after	O
the	O
treatment	O
with	O
either	O
Allo	O
-	O
aca	O
(	O
n	O
=	O
4	O
)	O
or	O
control	O
peptide	O
(	O
n	O
=	O
7	O
)	O
.	O
Frequency	O
components	O
of	O
heart	O
rate	O
could	O
not	O
be	O
extracted	O
from	O
two	O
mice	O
due	O
to	O
technical	O
problems	O
in	O
the	O
data	O
processing	O
.	O
The	O
heart	O
rate	O
recordings	O
were	O
sampled	O
at	O
400	O
Hz	O
.	O
To	O
remove	O
artifacts	O
,	O
we	O
excluded	O
heart	O
rate	O
readings	O
<	O
200	O
or	O
>	O
800	O
bpm	O
,	O
and	O
imputed	O
values	O
with	O
linear	O
interpolation	O
.	O
The	O
reciprocal	O
of	O
the	O
heart	O
rate	O
was	O
then	O
used	O
to	O
estimate	O
the	O
beat	O
-	O
to	O
-	O
beat	O
interval	O
.	O
These	O
recordings	O
were	O
then	O
windowed	O
into	O
2	O
-	O
min	O
segments	O
,	O
which	O
overlapped	O
by	O
1	O
min	O
,	O
with	O
a	O
Hamming	O
window	O
.	O

A	O
fast	O
Fourier	O
transform	O
was	O
applied	O
to	O
each	O
segment	O
to	O
calculate	O
the	O
power	O
spectral	O
density	O
with	O
a	O
frequency	O
resolution	O
of	O
0	O
.	O
1	O
Hz	O
.	O
Low	O
frequency	O
power	O
(	O
LF	O
)	O
was	O
defined	O
as	O
the	O
sum	O
of	O
the	O
power	O
in	O
the	O
0	O
.	O
4	O
–	O
1	O
.	O
5	O
Hz	O
range	O
,	O
representing	O
the	O
cardiac	O
sympathetic	O
activity	O
.	O
High	O
frequency	O
power	O
(	O
HF	O
)	O
was	O
defined	O
as	O
the	O
sum	O
of	O
the	O
power	O
in	O
the	O
1	O
.	O
6	O
–	O
4	O
.	O
0	O
Hz	O
range	O
,	O
as	O
a	O
representative	O
of	O
cardiac	O
parasympathetic	O
activity	O
.	O
The	O
ratio	O
of	O
the	O
LF	O
to	O
HF	O
power	O
was	O
also	O
calculated	O
(	O
LF	O
/	O
HF	O
)	O
to	O
estimate	O
the	O
cardiac	O
autonomic	O
balance	O
.	O
The	O
data	O
were	O
further	O
reduced	O
by	O
averaging	O
each	O
2	O
min	O
segment	O
for	O
each	O
mouse	O
in	O
the	O
baseline	O
and	O
treatment	O
conditions	O
.	O
The	O
analyses	O
were	O
performed	O
in	O
MATLAB	O
software	O
(	O
The	O
MathWorks	O
,	O
Natick	O
,	O
MA	O
,	O
United	O
States	O
)	O
.	O
The	O
hypoxic	O
ventilatory	O
response	O
(	O
HVR	O
)	O
was	O
measured	O
at	O
baseline	O
and	O
at	O
day	O
7	O
of	O
treatment	O
with	O
either	O
Allo	O
-	O
aca	O
(	O
n	O
=	O
6	O
)	O
or	O
Gly11	O
(	O
n	O
=	O
8	O
)	O
as	O
previously	O
described	O
(	O
Caballero	O
-	O
Eraso	O
et	O
al	O
.	O
,	O
2019	O
;	O
Shin	O
et	O
al	O
.	O
,	O
2019b	O
)	O
.	O
Briefly	O
,	O
HVR	O
measurements	O
were	O
performed	O
in	O
a	O
whole	O
-	O
body	O
barometric	O
plethysmography	O
(	O
WBP	O
)	O
chamber	O
(	O
Buxco	O
,	O
Wilmington	O
,	O
NC	O
,	O
United	O
States	O
)	O
combined	O
with	O
a	O
pulse	O
oximetry	O
system	O
(	O
STARR	O
Life	O
Sciences	O
Corp	O
.	O
,	O
PA	O
,	O
United	O
States	O
)	O
(	O
Hernandez	O
et	O
al	O
.	O
,	O
2012	O
;	O
Pho	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
All	O
mice	O
were	O
acclimated	O
to	O
the	O
WBP	O
chamber	O
and	O
to	O
the	O
pulse	O
oximeter	O
collar	O
for	O
at	O
least	O
3	O
days	O
before	O
the	O
baseline	O
recording	O
.	O
HVR	O
was	O
measured	O
during	O
quiet	O
wakefulness	O
.	O
Animals	O
were	O
exposed	O
to	O
2	O
–	O
3	O
cycles	O
of	O
normoxia	O
/	O
hypoxia	O
per	O
day	O
separated	O
by	O
at	O
least	O
30	O
min	O
during	O
the	O
light	O
-	O
phase	O
(	O
between	O
10	O
AM	O
and	O
5	O
PM	O
)	O
.	O
All	O
measurements	O
occurred	O
under	O
thermoneutral	O
conditions	O
(	O
[UNK]	O
)	O
in	O
a	O
neonatal	O
incubator	O
(	O
Ohio	O
Medical	O
,	O
IL	O
,	O
United	O
States	O
)	O
.	O

Ventilation	O
was	O
recorded	O
under	O
normoxic	O
conditions	O
(	O
at	O
20	O
.	O
9	O
%	O
FiO2	O
and	O
0	O
.	O
4	O
%	O
CO2	O
)	O
over	O
20	O
min	O
followed	O
by	O
5	O
min	O
of	O
hypoxia	O
in	O
which	O
the	O
animals	O
were	O
exposed	O
to	O
a	O
gas	O
mixture	O
of	O
10	O
%	O
O2	O
+	O
3	O
%	O
CO2	O
balanced	O
in	O
N2	O
.	O
We	O
have	O
previously	O
shown	O
that	O
a	O
fixed	O
3	O
%	O
CO2	O
tension	O
circumvents	O
the	O
hyperventilation	O
-	O
induced	O
hypocapnia	O
during	O
poikilocapnic	O
hypoxia	O
,	O
maintaining	O
similar	O
partial	O
pressure	O
of	O
CO2	O
(	O
PaCO2	O
)	O
at	O
normoxic	O
and	O
hypoxic	O
conditions	O
in	O
mice	O
(	O
Caballero	O
-	O
Eraso	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
The	O
FiO2	O
was	O
decreased	O
rapidly	O
to	O
10	O
%	O
within	O
the	O
first	O
30	O
s	O
.	O
Minute	O
ventilation	O
(	O
VE	O
)	O
and	O
oxyhemoglobin	O
saturation	O
(	O
SpO2	O
)	O
during	O
hypoxia	O
were	O
measured	O
based	O
on	O
a	O
90	O
s	O
period	O
(	O
from	O
the	O
first	O
30	O
s	O
of	O
hypoxia	O
exposition	O
until	O
2	O
min	O
)	O
.	O
The	O
first	O
2	O
min	O
of	O
acute	O
hypoxia	O
are	O
characterized	O
by	O
an	O
augmented	O
ventilation	O
mainly	O
governed	O
by	O
peripheral	O
chemoreflex	O
(	O
Duffin	O
,	O
2007	O
;	O
Powell	O
,	O
2007	O
;	O
Teppema	O
and	O
Dahan	O
,	O
2010	O
)	O
.	O
HVR	O
was	O
calculated	O
by	O
the	O
slope	O
of	O
the	O
relationship	O
between	O
VE	O
and	O
SpO2	O
at	O
normoxic	O
and	O
hypoxic	O
conditions	O
via	O
a	O
linear	O
least	O
-	O
squares	O
regression	O
analysis	O
as	O
previously	O
described	O
(	O
Polotsky	O
et	O
al	O
.	O
,	O
2004	O
;	O
Caballero	O
-	O
Eraso	O
et	O
al	O
.	O
,	O
2019	O
;	O
Shin	O
et	O
al	O
.	O
,	O
2019b	O
)	O
.	O
Both	O
VE	O
in	O
normoxia	O
and	O
hypoxia	O
,	O
and	O
HVR	O
were	O
normalized	O
by	O
body	O
weight	O
.	O
All	O
signals	O
were	O
sampled	O
at	O
1000	O
Hz	O
(	O
sampling	O
frequency	O
per	O
channel	O
)	O
and	O
recorded	O
in	O
LabChart	O
7	O
Pro	O
(	O
version	O
7	O
.	O
2	O
)	O
.	O
Sleep	O
architecture	O
and	O
ventilation	O
during	O
sleep	O
were	O
examined	O
by	O
full	O
-	O
polysomnography	O
using	O
a	O
WBP	O
chamber	O
at	O
baseline	O
and	O
at	O
day	O
8	O
of	O
treatment	O
with	O
either	O
Allo	O
-	O
aca	O
(	O
n	O
=	O
6	O
)	O
or	O
Gly11	O
(	O
n	O
=	O
7	O
)	O
as	O
previously	O
published	O
by	O
our	O
group	O
(	O
Hernandez	O
et	O
al	O
.	O
,	O
2012	O
;	O
Pho	O
et	O
al	O
.	O
,	O
2016	O
,	O
2021	O
;	O
Yao	O
et	O
al	O
.	O
,	O
2016	O
;	O
Fleury	O
Curado	O
et	O
al	O
.	O
,	O
2018	O
;	O
Berger	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O

All	O
mice	O
were	O
acclimated	O
to	O
the	O
WBP	O
chamber	O
and	O
to	O
the	O
SpO2	O
collar	O
as	O
described	O
above	O
Sleep	O
studies	O
were	O
conducted	O
under	O
constant	O
temperature	O
of	O
[UNK]	O
and	O
[UNK]	O
%	O
humidity	O
.	O
Mice	O
were	O
recorded	O
for	O
6	O
h	O
from	O
10	O
AM	O
to	O
4	O
PM	O
.	O
Signals	O
were	O
processed	O
at	O
1000	O
Hz	O
(	O
sampling	O
frequency	O
per	O
channel	O
)	O
and	O
recorded	O
in	O
LabChart	O
7	O
Pro	O
(	O
version	O
7	O
.	O
2	O
)	O
.	O
Sleep	O
was	O
visually	O
scored	O
in	O
10	O
-	O
s	O
epochs	O
based	O
on	O
EEG	O
and	O
EMG	O
activity	O
as	O
previously	O
described	O
(	O
Hernandez	O
et	O
al	O
.	O
,	O
2012	O
;	O
Pho	O
et	O
al	O
.	O
,	O
2016	O
,	O
2021	O
;	O
Yao	O
et	O
al	O
.	O
,	O
2016	O
;	O
Fleury	O
Curado	O
et	O
al	O
.	O
,	O
2018	O
;	O
Berger	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Epochs	O
with	O
high	O
EEG	O
amplitude	O
in	O
the	O
low	O
-	O
frequency	O
band	O
(	O
[UNK]	O
–	O
5	O
Hz	O
)	O
and	O
low	O
EMG	O
tonus	O
were	O
classified	O
as	O
NREM	O
sleep	O
.	O
Epochs	O
with	O
low	O
-	O
amplitude	O
and	O
mixed	O
frequencies	O
in	O
the	O
EEG	O
(	O
[UNK]	O
–	O
10	O
Hz	O
)	O
and	O
muscle	O
atonia	O
were	O
scored	O
as	O
REM	O
sleep	O
.	O
Ventilation	O
was	O
analyzed	O
during	O
all	O
REM	O
sleep	O
epochs	O
(	O
[UNK]	O
min	O
in	O
6	O
-	O
h	O
recording	O
;	O
see	O
Table	O
1	O
)	O
and	O
in	O
20	O
-	O
s	O
subsamples	O
from	O
NREM	O
sleep	O
.	O
Each	O
NREM	O
subsample	O
was	O
manually	O
selected	O
once	O
per	O
30	O
min	O
of	O
recording	O
.	O
Each	O
breath	O
was	O
further	O
analyzed	O
to	O
determine	O
the	O
maximal	O
inspiratory	O
airflow	O
(	O
VImax	O
)	O
,	O
tidal	O
volume	O
(	O
VT	O
)	O
,	O
respiratory	O
rate	O
(	O
RR	O
)	O
,	O
mean	O
inspiratory	O
flow	O
rate	O
(	O
MIFR	O
)	O
,	O
and	O
inspiratory	O
duty	O
cycle	O
(	O
DC	O
)	O
.	O
VE	O
was	O
normalized	O
to	O
body	O
weight	O
.	O
Inspiratory	O
flow	O
limitation	O
(	O
IFL	O
)	O
was	O
defined	O
as	O
an	O
early	O
inspiratory	O
plateau	O
in	O
airflow	O
associated	O
with	O
increasing	O
respiratory	O
effort	O
as	O
previously	O
reported	O
by	O
our	O
group	O
(	O
Hernandez	O
et	O
al	O
.	O
,	O
2012	O
;	O
Pho	O
et	O
al	O
.	O
,	O
2016	O
,	O
2021	O
)	O
.	O
Apneas	O
were	O
defined	O
as	O
reductions	O
of	O
≥90	O
%	O
in	O
airflow	O
during	O
sleep	O
for	O
at	O
least	O
two	O
breath	O
cycles	O
or	O
≥0	O
.	O
7	O
s	O
(	O
Freire	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Apnea	O
index	O
was	O
calculated	O
by	O
dividing	O
the	O
number	O
of	O
apneas	O
by	O
the	O
total	O
sleep	O
time	O
.	O
Mean	O
SpO2	O
was	O
calculated	O
during	O
both	O
NREM	O
and	O
REM	O
sleep	O
.	O

Oxygen	O
desaturation	O
index	O
(	O
ODI	O
)	O
was	O
defined	O
as	O
the	O
number	O
of	O
≥5	O
%	O
oxyhemoglobin	O
desaturations	O
from	O
baseline	O
divided	O
by	O
the	O
total	O
sleep	O
time	O
as	O
previously	O
described	O
(	O
Yao	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Blood	O
was	O
collected	O
from	O
mice	O
at	O
baseline	O
and	O
on	O
the	O
last	O
day	O
of	O
treatment	O
of	O
either	O
Allo	O
-	O
aca	O
(	O
n	O
=	O
6	O
)	O
or	O
Gly11	O
(	O
n	O
=	O
7	O
)	O
.	O
Blood	O
collection	O
was	O
performed	O
immediately	O
after	O
the	O
sleep	O
studies	O
,	O
while	O
the	O
mice	O
were	O
food	O
and	O
water	O
deprived	O
for	O
6	O
h	O
.	O
Blood	O
samples	O
were	O
centrifuged	O
at	O
3500	O
rpm	O
for	O
15	O
min	O
at	O
4°C	O
.	O
Leptin	O
levels	O
were	O
measured	O
in	O
the	O
plasma	O
using	O
a	O
mouse	O
leptin	O
ELISA	O
kit	O
(	O
#	O
EZML82K	O
,	O
Millipore	O
,	O
MA	O
,	O
United	O
States	O
)	O
.	O
The	O
main	O
outcomes	O
were	O
MAP	O
,	O
HVR	O
,	O
and	O
VE	O
during	O
sleep	O
.	O
Blood	O
pressure	O
analyses	O
were	O
stratified	O
by	O
light	O
vs	O
.	O
dark	O
phase	O
to	O
account	O
for	O
diurnal	O
variations	O
.	O
For	O
each	O
outcome	O
,	O
mixed	O
effects	O
linear	O
regression	O
models	O
were	O
developed	O
to	O
test	O
the	O
independent	O
effects	O
of	O
Allo	O
-	O
aca	O
or	O
Gly11	O
treatments	O
and	O
evaluate	O
the	O
differences	O
within	O
-	O
subjects	O
compared	O
to	O
baseline	O
.	O
The	O
goodness	O
-	O
of	O
-	O
fit	O
of	O
each	O
model	O
was	O
assessed	O
by	O
verifying	O
the	O
normality	O
of	O
the	O
residuals	O
.	O
Considering	O
the	O
reduced	O
sample	O
size	O
,	O
the	O
comparisons	O
from	O
mixed	O
effects	O
regression	O
models	O
were	O
also	O
performed	O
with	O
additional	O
non	O
-	O
parametric	O
tests	O
as	O
a	O
confirmatory	O
method	O
.	O
Mann	O
–	O
Whitney	O
U	O
test	O
and	O
Wilcoxon	O
signed	O
-	O
rank	O
test	O
were	O
used	O
to	O
analyze	O
differences	O
between	O
the	O
groups	O
and	O
within	O
-	O
subjects	O
,	O
respectively	O
.	O
Post	O
hoc	O
power	O
analysis	O
was	O
performed	O
considering	O
the	O
mean	O
differences	O
in	O
MAP	O
between	O
groups	O
.	O
Given	O
our	O
sample	O
size	O
,	O
we	O
had	O
the	O
ability	O
to	O
detect	O
9	O
mmHg	O
difference	O
in	O
MAP	O
between	O
treated	O
and	O
control	B-methodology
animals	I-methodology
(	O
Cohen	O
’	O
s	O
d	O
:	O
1	O
.	O
1	O
)	O
with	O
a	O
power	O
of	O
>	O
90	O
%	O
and	O
significance	O
level	O
α	O
<	O
0	O
.	O
05	O
.	O
LF	O
,	O
HF	O
,	O
and	O
LF	O
/	O
HF	O
ratio	O
of	O
heart	O
rate	O
were	O
compared	O
between	O
groups	O
and	O
to	O
baseline	O
using	O
non	O
-	O
parametric	O
tests	O
due	O
to	O
the	O
reduced	O
sample	O
size	O
.	O
The	O
data	O
are	O
represented	O
as	O
mean	O
±	O
SEM	O
and	O
statistical	O
significance	O
was	O
considered	O
at	O
a	O
level	O
of	O
P	O
<	O
0	O
.	O
05	O
.	O

All	O
statistical	O
analyses	O
were	O
performed	O
using	O
SPSS	O
software	O
version	O
20	O
.	O
0	O
(	O
IBM	O
SPSS	O
Inc	O
.	O
,	O
Chicago	O
,	O
IL	O
,	O
United	O
States	O
)	O
.	O
Graphs	O
were	O
plotted	O
using	O
GraphPad	O
Prism	O
6	O
.	O
0	O
(	O
GraphPad	O
Software	O
,	O
La	O
Jolla	O
,	O
CA	O
,	O
United	O
States	O
)	O
.	O
At	O
baseline	O
,	O
both	O
groups	O
were	O
obese	O
,	O
showing	O
similar	O
body	O
weights	O
(	O
mean	O
±	O
SE	O
of	O
45	O
.	O
6	O
±	O
0	O
.	O
6	O
g	O
in	O
Gly11	O
vs	O
.	O
42	O
.	O
4	O
±	O
1	O
.	O
7	O
g	O
in	O
Allo	O
-	O
aca	O
,	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O
Significant	O
increases	O
in	O
body	O
weight	O
from	O
baseline	O
were	O
observed	O
until	O
day	O
5	O
of	O
treatment	O
with	O
either	O
Allo	O
-	O
aca	O
or	O
control	O
peptide	O
(	O
Figure	O
1A	O
)	O
,	O
suggesting	O
no	O
exacerbation	O
of	O
obesity	O
with	O
the	O
leptin	O
receptor	O
blockade	O
.	O
Body	O
temperature	O
and	O
food	O
consumption	O
before	O
and	O
after	O
the	O
treatment	O
were	O
also	O
similar	O
between	O
the	O
groups	O
(	O
Figures	O
1B	O
,	O
C	O
)	O
.	O
Leptin	O
levels	O
were	O
slightly	O
higher	O
in	O
the	O
controls	O
(	O
14	O
.	O
9	O
±	O
1	O
.	O
5	O
ng	O
/	O
ml	O
)	O
compared	O
to	O
the	O
Allo	O
-	O
aca	O
group	O
(	O
10	O
.	O
4	O
±	O
1	O
.	O
7	O
ng	O
/	O
mL	O
)	O
at	O
baseline	O
,	O
but	O
this	O
difference	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
Figure	O
1D	O
)	O
.	O
Treatment	O
with	O
Allo	O
-	O
aca	O
and	O
control	O
peptide	O
did	O
not	O
affect	O
plasma	O
leptin	O
levels	O
.	O
Figure	O
2A	O
shows	O
a	O
representative	O
trace	O
of	O
blood	O
pressure	O
and	O
heart	O
rate	O
recordings	O
during	O
light	O
-	O
phase	O
at	O
baseline	O
and	O
after	O
the	O
treatment	O
with	O
Allo	O
-	O
aca	O
and	O
control	O
peptide	O
.	O
All	O
NZO	O
mice	O
were	O
hypertensive	O
at	O
baseline	O
(	O
Figure	O
2	O
)	O
.	O
Allo	O
-	O
aca	O
effectively	O
reduced	O
the	O
MAP	O
during	O
light	O
-	O
phase	O
from	O
134	O
.	O
9	O
±	O
3	O
.	O
1	O
to	O
124	O
.	O
9	O
±	O
5	O
.	O
7	O
mmHg	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
whereas	O
the	O
negative	O
control	O
peptide	O
had	O
no	O
effect	O
(	O
Figures	O
2A	O
,	O
B	O
)	O
.	O
Leptin	O
receptor	O
blockade	O
induced	O
a	O
smaller	O
reduction	O
in	O
MAP	O
during	O
dark	O
-	O
phase	O
,	O
which	O
was	O
not	O
significantly	O
different	O
compared	O
to	O
baseline	O
,	O
but	O
it	O
was	O
lower	O
than	O
controls	O
(	O
127	O
.	O
9	O
±	O
5	O
.	O
5	O
vs	O
.	O
137	O
.	O
5	O
±	O
3	O
.	O
0	O
mmHg	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Figures	O
2A	O
,	O
B	O
)	O
.	O

The	O
effects	O
of	O
Allo	O
-	O
aca	O
treatment	O
on	O
MAP	O
during	O
dark	O
-	O
phase	O
were	O
not	O
statistically	O
significant	O
when	O
mixed	O
-	O
effects	O
models	O
were	O
utilized	O
to	O
account	O
for	O
baseline	O
differences	O
in	O
MAP	O
between	O
individual	O
animals	O
.	O
Mice	O
treated	O
with	O
Allo	O
-	O
aca	O
exhibited	O
a	O
significant	O
decrease	O
in	O
SBP	O
during	O
both	O
light	O
and	O
dark	O
-	O
phases	O
(	O
Figure	O
2C	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
DBP	O
was	O
not	O
significantly	O
affected	O
(	O
Figure	O
2D	O
)	O
.	O
Heart	O
rate	O
was	O
similar	O
between	O
the	O
groups	O
at	O
baseline	O
and	O
was	O
not	O
affected	O
by	O
either	O
Allo	O
-	O
aca	O
or	O
Gly11	O
(	O
Figure	O
2E	O
)	O
.	O
Heart	O
rate	O
variability	O
is	O
shown	O
in	O
Figure	O
3	O
.	O
At	O
baseline	O
,	O
LF	O
and	O
HF	O
components	O
of	O
heart	O
rate	O
were	O
lower	O
in	O
Allo	O
-	O
aca	O
group	O
compared	O
to	O
controls	O
(	O
Figures	O
3A	O
,	O
B	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
However	O
,	O
no	O
significant	O
effects	O
of	O
the	O
treatment	O
with	O
either	O
Allo	O
-	O
aca	O
or	O
control	O
peptide	O
were	O
observed	O
on	O
LF	O
and	O
HF	O
.	O
LF	O
/	O
HF	O
ratio	O
was	O
similar	O
between	O
groups	O
and	O
remained	O
unchanged	O
after	O
treatment	O
(	O
Figure	O
3C	O
)	O
,	O
suggesting	O
that	O
the	O
cardiac	O
autonomic	O
balance	O
was	O
not	O
affected	O
.	O
Normalized	O
VE	O
during	O
normoxia	O
(	O
1	O
.	O
2	O
±	O
0	O
.	O
1	O
mL	O
/	O
min	O
/	O
g	O
in	O
both	O
groups	O
)	O
and	O
hypoxia	O
(	O
Gly11	O
2	O
.	O
9	O
±	O
0	O
.	O
2	O
mL	O
/	O
min	O
/	O
g	O
vs	O
.	O
Allo	O
-	O
aca	O
3	O
.	O
0	O
±	O
0	O
.	O
1	O
mL	O
/	O
min	O
/	O
g	O
)	O
were	O
similar	O
at	O
baseline	O
in	O
both	O
groups	O
(	O
Figures	O
4A	O
,	O
B	O
)	O
.	O
Allo	O
-	O
aca	O
and	O
Gly11	O
did	O
not	O
change	O
ventilation	O
at	O
21	O
%	O
and	O
10	O
%	O
FiO2	O
(	O
Figures	O
4A	O
,	O
B	O
)	O
.	O
Consequently	O
,	O
leptin	O
receptor	O
blockade	O
did	O
not	O
affect	O
HVR	O
(	O
baseline	O
0	O
.	O
05	O
±	O
0	O
.	O
0	O
mL	O
/	O
min	O
/	O
g	O
/	O
%	O
vs	O
.	O
Allo	O
-	O
aca	O
0	O
.	O
04	O
±	O
0	O
.	O
0	O
mL	O
/	O
min	O
/	O
g	O
/	O
%	O
)	O
(	O
Figure	O
4C	O
)	O
.	O
Allo	O
-	O
aca	O
and	O
Gly11	O
had	O
no	O
significant	O
effects	O
on	O
sleep	O
architecture	O
and	O
both	O
groups	O
had	O
similar	O
total	O
sleep	O
time	O
,	O
sleep	O
efficiency	O
,	O
and	O
duration	O
of	O
NREM	O
and	O
REM	O
sleep	O
(	O
Table	O
1	O
)	O
.	O

Leptin	O
receptor	O
blockade	O
did	O
not	O
affect	O
ventilation	O
during	O
sleep	O
as	O
represented	O
in	O
Figure	O
5A	O
.	O
Normalized	O
VE	O
during	O
NREM	O
was	O
similar	O
between	O
groups	O
at	O
baseline	O
and	O
remained	O
unchanged	O
after	O
the	O
treatment	O
with	O
Allo	O
-	O
aca	O
and	O
control	O
peptide	O
(	O
Figure	O
5B	O
)	O
.	O
A	O
slight	O
decrease	O
in	O
VE	O
during	O
REM	O
sleep	O
was	O
observed	O
in	O
Allo	O
-	O
aca	O
group	O
,	O
but	O
it	O
was	O
not	O
significantly	O
different	O
compared	O
to	O
baseline	O
and	O
to	O
controls	O
(	O
Figure	O
5C	O
)	O
.	O
VT	O
,	O
RR	O
,	O
VImax	O
,	O
MIFR	O
,	O
and	O
inspiratory	O
DC	O
remained	O
unchanged	O
with	O
both	O
Allo	O
-	O
aca	O
and	O
control	O
peptide	O
(	O
Table	O
2	O
)	O
.	O
The	O
systemic	O
blockade	O
of	O
leptin	O
receptors	O
did	O
not	O
exacerbate	O
SDB	O
in	O
NZO	O
mice	O
,	O
indicated	O
by	O
no	O
significant	O
changes	O
in	O
the	O
frequency	O
of	O
IFL	O
breaths	O
,	O
apnea	O
index	O
,	O
and	O
ODI	O
(	O
Table	O
2	O
)	O
.	O
Taken	O
together	O
,	O
systemic	O
blockade	O
of	O
leptin	O
receptors	O
attenuated	O
hypertension	O
without	O
exacerbating	O
obesity	O
or	O
SDB	O
in	O
NZO	O
mice	O
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
to	O
suggest	O
that	O
obesity	O
-	O
related	O
hypertension	O
in	O
NZO	O
mice	O
is	O
,	O
at	O
least	O
in	O
part	O
,	O
related	O
to	O
leptin	O
signaling	O
.	O
We	O
showed	O
that	O
hypertensive	O
NZO	O
mice	O
treated	O
with	O
leptin	O
receptor	O
blocker	O
Allo	O
-	O
aca	O
had	O
significant	O
reduction	O
in	O
blood	O
pressure	O
with	O
no	O
changes	O
in	O
cardiac	O
autonomic	O
balance	O
.	O
These	O
effects	O
were	O
most	O
pronounced	O
during	O
the	O
light	O
-	O
phase	O
when	O
mice	O
were	O
more	O
likely	O
to	O
sleep	O
.	O
Our	O
data	O
also	O
suggest	O
that	O
leptin	O
receptor	O
blockade	O
did	O
not	O
exacerbate	O
obesity	O
and	O
obesity	O
-	O
induced	O
SDB	O
in	O
NZO	O
mice	O
.	O
First	O
,	O
NZO	O
mice	O
treated	O
with	O
leptin	O
receptor	O
blocker	O
Allo	O
-	O
aca	O
did	O
not	O
show	O
changes	O
in	O
body	O
weight	O
and	O
food	O
consumption	O
.	O
Second	O
,	O
Allo	O
-	O
aca	O
did	O
not	O
affect	O
ventilation	O
during	O
hypoxia	O
.	O
Third	O
,	O
leptin	O
receptor	O
blockade	O
in	O
NZO	O
mice	O
did	O
not	O
alter	O
ventilation	O
,	O
oxygen	O
saturation	O
,	O
and	O
the	O
apnea	O
rate	O
during	O
NREM	O
and	O
REM	O
sleep	O
.	O
It	O
is	O
well	O
known	O
that	O
leptin	O
plays	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	O
of	O
obesity	O
-	O
induced	O
hypertension	O
.	O

Leptin	O
activates	O
the	O
sympathetic	O
nervous	O
system	O
and	O
elevates	O
blood	O
pressure	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Haynes	O
et	O
al	O
.	O
,	O
1997a	O
;	O
Rahmouni	O
et	O
al	O
.	O
,	O
2005a	O
;	O
Asferg	O
et	O
al	O
.	O
,	O
2010	O
;	O
Shankar	O
and	O
Xiao	O
,	O
2010	O
;	O
Machleidt	O
et	O
al	O
.	O
,	O
2013	O
;	O
Shin	O
et	O
al	O
.	O
,	O
2019a	O
,	O
2021	O
)	O
.	O
Systemic	O
blockade	O
of	O
leptin	O
receptors	O
abolishes	O
hypertension	O
in	O
murine	O
models	O
of	O
obesity	O
and	O
hyperleptinemia	O
(	O
Huby	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Here	O
,	O
we	O
used	O
NZO	O
mice	O
to	O
analyze	O
the	O
role	O
of	O
leptin	O
receptor	O
blockade	O
on	O
blood	O
pressure	O
.	O
NZO	O
mice	O
develop	O
hypertension	O
at	O
early	O
age	O
and	O
the	O
weight	O
gain	O
is	O
accompanied	O
by	O
the	O
rise	O
in	O
blood	O
pressure	O
(	O
Ortlepp	O
et	O
al	O
.	O
,	O
2000	O
;	O
Marchesi	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O
However	O
,	O
the	O
mechanisms	O
underlying	O
the	O
development	O
of	O
obesity	O
-	O
related	O
hypertension	O
in	O
NZO	O
mice	O
remain	O
unknown	O
.	O
Polymorphism	O
in	O
leptin	O
receptors	O
has	O
been	O
identified	O
in	O
these	O
animals	O
(	O
Igel	O
et	O
al	O
.	O
,	O
1997	O
;	O
Kluge	O
et	O
al	O
.	O
,	O
2000	O
;	O
Joost	O
and	O
Schürmann	O
,	O
2014	O
)	O
.	O
Similar	O
polymorphism	O
is	O
observed	O
in	O
New	O
Zealand	O
Black	O
(	O
NZB	O
)	O
mice	O
(	O
Igel	O
et	O
al	O
.	O
,	O
1997	O
)	O
,	O
a	O
strain	O
that	O
shares	O
a	O
common	O
origin	O
with	O
NZO	O
mice	O
and	O
develops	O
high	O
blood	O
pressure	O
despite	O
the	O
lack	O
of	O
obesity	O
(	O
Ortlepp	O
et	O
al	O
.	O
,	O
2000	O
;	O
Marchesi	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O
This	O
evidence	O
may	O
implicate	O
leptin	O
signaling	O
in	O
the	O
pathogenesis	O
of	O
hypertension	O
in	O
NZO	O
mice	O
.	O
Our	O
present	O
study	O
adds	O
to	O
this	O
body	O
of	O
knowledge	O
by	O
demonstrating	O
that	O
hypertension	O
in	O
NZO	O
mice	O
is	O
significantly	O
attenuated	O
by	O
the	O
systemic	O
blockade	O
of	O
leptin	O
receptors	O
.	O
Additionally	O
,	O
our	O
findings	O
suggest	O
that	O
the	O
systemic	O
blockade	O
of	O
leptin	O
receptors	O
did	O
not	O
change	O
cardiac	O
autonomic	O
balance	O
.	O
In	O
part	O
,	O
the	O
small	O
sample	O
size	O
and	O
large	O
variability	O
among	O
the	O
mice	O
could	O
have	O
accounted	O
for	O
the	O
different	O
sympathetic	O
and	O
parasympathetic	O
activities	O
at	O
baseline	O
between	O
groups	O
.	O
Leptin	O
is	O
a	O
potent	O
stimulator	O
of	O
breathing	O
.	O

Systemic	O
replacement	O
of	O
leptin	O
in	O
leptin	O
-	O
deficient	O
ob	O
/	O
ob	O
mice	O
normalizes	O
breathing	O
and	O
the	O
hypercapnic	O
ventilatory	O
response	O
(	O
O	O
’	O
Donnell	O
et	O
al	O
.	O
,	O
1999	O
;	O
Pho	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Leptin	O
infusions	O
augment	O
VE	O
under	O
normoxic	O
and	O
hypoxic	O
conditions	O
,	O
and	O
increase	O
HVR	O
in	O
lean	O
rodents	O
(	O
Yuan	O
et	O
al	O
.	O
,	O
2018	O
;	O
Caballero	O
-	O
Eraso	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
In	O
rats	O
,	O
the	O
effects	O
of	O
leptin	O
on	O
ventilation	O
are	O
blunted	O
with	O
the	O
increase	O
in	O
leptin	O
levels	O
induced	O
by	O
high	O
-	O
fat	O
diet	O
,	O
suggesting	O
a	O
compromised	O
ventilatory	O
adaptation	O
possibly	O
induced	O
by	O
the	O
development	O
of	O
leptin	O
resistance	O
in	O
obesity	O
(	O
Ribeiro	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
Our	O
study	O
was	O
the	O
first	O
to	O
analyze	O
ventilation	O
in	O
NZO	O
mice	O
.	O
Compared	O
to	O
our	O
previous	O
study	O
,	O
NZO	O
mice	O
showed	O
lower	O
levels	O
of	O
VE	O
and	O
a	O
lower	O
HVR	O
than	O
lean	O
C57BL	O
/	O
6J	O
mice	O
(	O
[UNK]	O
.	O
6	O
mL	O
/	O
min	O
/	O
g	O
)	O
,	O
but	O
similar	O
ventilatory	O
responses	O
to	O
hypoxia	O
to	O
leptin	O
receptor	O
-	O
deficient	O
db	O
/	O
db	O
mice	O
(	O
HVR	O
:	O
2	O
.	O
8	O
mL	O
/	O
min	O
/	O
g	O
)	O
(	O
Caballero	O
-	O
Eraso	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
The	O
blockade	O
of	O
leptin	O
signaling	O
did	O
not	O
affect	O
HVR	O
and	O
ventilation	O
during	O
sleep	O
in	O
NZO	O
mice	O
,	O
which	O
could	O
have	O
two	O
alternative	O
explanations	O
:	O
(	O
1	O
)	O
a	O
floor	O
effect	O
of	O
leptin	O
on	O
breathing	O
in	O
already	O
hypoventilating	O
NZO	O
mice	O
or	O
(	O
2	O
)	O
relatively	O
modest	O
elevations	O
of	O
leptin	O
levels	O
may	O
not	O
be	O
sufficient	O
to	O
affect	O
the	O
ventilatory	O
control	O
in	O
this	O
strain	O
.	O
In	O
our	O
previous	O
study	O
,	O
leptin	O
infusion	O
promoted	O
a	O
[UNK]	O
-	O
fold	O
increase	O
in	O
leptin	O
levels	O
in	O
lean	O
C57BL	O
/	O
6J	O
mice	O
(	O
from	O
undetectable	O
to	O
34	O
.	O
9	O
±	O
4	O
.	O
3	O
ng	O
/	O
mL	O
)	O
and	O
this	O
massive	O
increase	O
in	O
leptin	O
levels	O
lead	O
to	O
changes	O
in	O
breathing	O
(	O
Caballero	O
-	O
Eraso	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O

Leptin	O
regulates	O
the	O
metabolism	O
and	O
stimulates	O
breathing	O
acting	O
on	O
leptin	O
receptors	O
in	O
the	O
hypothalamus	O
and	O
medulla	O
(	O
Halaas	O
et	O
al	O
.	O
,	O
1995	O
;	O
O	O
’	O
Donnell	O
et	O
al	O
.	O
,	O
1999	O
;	O
Spiegelman	O
and	O
Flier	O
,	O
2001	O
;	O
Friedman	O
,	O
2009	O
;	O
Pho	O
et	O
al	O
.	O
,	O
2016	O
;	O
Yao	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Respiratory	O
sites	O
of	O
leptin	O
have	O
been	O
localized	O
to	O
the	O
nucleus	O
tractus	O
solitarius	O
(	O
NTS	O
)	O
(	O
Inyushkina	O
et	O
al	O
.	O
,	O
2010	O
;	O
Yao	O
et	O
al	O
.	O
,	O
2016	O
;	O
Do	O
et	O
al	O
.	O
,	O
2020	O
)	O
,	O
retrotrapezoid	O
nucleus	O
/	O
parafacial	O
respiratory	O
group	O
(	O
Bassi	O
et	O
al	O
.	O
,	O
2014	O
)	O
,	O
and	O
dorsomedial	O
hypothalamus	O
(	O
Pho	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
In	O
contrast	O
,	O
the	O
sites	O
of	O
hypertensive	O
effects	O
of	O
leptin	O
have	O
not	O
been	O
determined	O
.	O
Earlier	O
studies	O
have	O
suggested	O
that	O
the	O
central	O
regulation	O
of	O
blood	O
pressure	O
by	O
leptin	O
is	O
localized	O
to	O
the	O
dorsomedial	O
hypothalamus	O
(	O
Simonds	O
et	O
al	O
.	O
,	O
2014	O
;	O
Gruber	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
Here	O
,	O
we	O
showed	O
that	O
the	O
systemic	O
blockade	O
of	O
leptin	O
receptors	O
in	O
NZO	O
mice	O
reduced	O
blood	O
pressure	O
,	O
but	O
did	O
not	O
affect	O
ventilation	O
and	O
metabolism	O
,	O
since	O
food	O
intake	O
remained	O
unchanged	O
.	O
Although	O
Allo	O
-	O
aca	O
initially	O
induced	O
weight	O
gain	O
,	O
this	O
effect	O
was	O
transient	O
suggesting	O
the	O
progression	O
of	O
leptin	O
resistance	O
.	O
Our	O
current	O
data	O
are	O
consistent	O
with	O
an	O
established	O
paradigm	O
that	O
obese	O
humans	O
and	O
rodents	O
are	O
resistant	O
to	O
beneficial	O
metabolic	O
and	O
respiratory	O
effects	O
of	O
leptin	O
,	O
but	O
sensitive	O
to	O
detrimental	O
hypertensive	O
effects	O
of	O
this	O
hormone	O
(	O
Maffei	O
et	O
al	O
.	O
,	O
1995	O
;	O
Considine	O
et	O
al	O
.	O
,	O
1996	O
;	O
Ip	O
et	O
al	O
.	O
,	O
2000	O
;	O
Phipps	O
et	O
al	O
.	O
,	O
2002	O
;	O
Yee	O
et	O
al	O
.	O
,	O
2006	O
;	O
Fleury	O
Curado	O
et	O
al	O
.	O
,	O
2018	O
;	O
Berger	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O

Leptin	O
resistance	O
in	O
NZO	O
mice	O
has	O
been	O
attributed	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
an	O
inadequate	O
transport	O
of	O
leptin	O
to	O
the	O
CNS	O
(	O
Halaas	O
et	O
al	O
.	O
,	O
1995	O
;	O
Igel	O
et	O
al	O
.	O
,	O
1997	O
)	O
,	O
while	O
leptin	O
receptor	O
signaling	O
in	O
the	O
CNS	O
remained	O
intact	O
(	O
Igel	O
et	O
al	O
.	O
,	O
1997	O
;	O
Rizk	O
et	O
al	O
.	O
,	O
1998	O
;	O
Hileman	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O
Although	O
Allo	O
-	O
aca	O
penetrates	O
the	O
BBB	O
(	O
Otvos	O
et	O
al	O
.	O
,	O
2011b	O
)	O
,	O
the	O
dichotomy	O
between	O
the	O
absence	O
of	O
central	O
metabolic	O
and	O
respiratory	O
effects	O
of	O
this	O
leptin	O
receptor	O
blocker	O
and	O
the	O
presence	O
of	O
hypotensive	O
effects	O
suggest	O
that	O
leptin	O
may	O
act	O
peripherally	O
to	O
induce	O
hypertension	O
.	O
Peripheral	O
sites	O
,	O
outside	O
the	O
BBB	O
,	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
blood	O
pressure	O
and	O
/	O
or	O
control	O
of	O
breathing	O
,	O
such	O
as	O
the	O
carotid	O
bodies	O
.	O
The	O
carotid	O
bodies	O
are	O
the	O
main	O
peripheral	O
sensors	O
of	O
blood	O
gases	O
and	O
pH	O
located	O
bilaterally	O
at	O
the	O
bifurcation	O
of	O
the	O
common	O
carotid	O
arteries	O
(	O
Ortega	O
-	O
Sáenz	O
and	O
López	O
-	O
Barneo	O
,	O
2020	O
)	O
.	O
The	O
denervation	O
or	O
resection	O
of	O
the	O
carotid	O
bodies	O
effectively	O
reduce	O
blood	O
pressure	O
and	O
HVR	O
(	O
Olson	O
et	O
al	O
.	O
,	O
1988	O
;	O
Fletcher	O
et	O
al	O
.	O
,	O
1992	O
;	O
McBryde	O
et	O
al	O
.	O
,	O
2013	O
;	O
Fudim	O
et	O
al	O
.	O
,	O
2015	O
;	O
Del	O
Rio	O
et	O
al	O
.	O
,	O
2016	O
;	O
Caballero	O
-	O
Eraso	O
et	O
al	O
.	O
,	O
2019	O
;	O
Shin	O
et	O
al	O
.	O
,	O
2019a	O
)	O
.	O
Our	O
group	O
has	O
shown	O
that	O
leptin	O
acts	O
in	O
the	O
leptin	O
receptors	O
in	O
the	O
carotid	O
bodies	O
to	O
induce	O
hypertension	O
and	O
to	O
stimulate	O
breathing	O
and	O
HVR	O
(	O
Caballero	O
-	O
Eraso	O
et	O
al	O
.	O
,	O
2019	O
;	O
Shin	O
et	O
al	O
.	O
,	O
2019a	O
)	O
.	O
These	O
effects	O
are	O
mediated	O
through	O
the	O
activation	O
of	O
transient	O
receptor	O
potential	O
melastatin	O
7	O
(	O
TRPM7	O
)	O
channel	O
and	O
the	O
blockade	O
of	O
TRPM7	O
channels	O
abolishes	O
the	O
leptin	O
-	O
induced	O
hypertension	O
(	O
Shin	O
et	O
al	O
.	O
,	O
2019a	O
,	O
2021	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
reduction	O
in	O
blood	O
pressure	O
of	O
NZO	O
mice	O
with	O
Allo	O
-	O
aca	O
could	O
be	O
attributed	O
to	O
the	O
peripheral	O
blockade	O
of	O
leptin	O
receptors	O
in	O
the	O
carotid	O
bodies	O
,	O
inhibiting	O
the	O
leptin	O
-	O
TRPM7	O
axis	O
.	O
Other	O
peripheral	O
sites	O
could	O
also	O
be	O
involved	O
,	O
including	O
the	O
blockade	O
of	O
leptin	O
receptors	O
in	O
adrenal	O
medulla	O
(	O
Haynes	O
et	O
al	O
.	O
,	O
1997b	O
;	O
Huby	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
However	O
,	O
the	O
blockade	O
of	O
leptin	O
receptors	O
in	O
the	O
current	O
study	O
did	O
not	O
affect	O
the	O
HVR	O
,	O
which	O
may	O
suggest	O
that	O
either	O
the	O
carotid	O
bodies	O
do	O
not	O
play	O
a	O
main	O
role	O
in	O
the	O
regulation	O
of	O
breathing	O
or	O
the	O
peripheral	O
control	O
of	O
breathing	O
is	O
mediated	O
by	O
other	O
molecular	O
mechanisms	O
in	O
NZO	O
mice	O
.	O
Previous	O
studies	O
have	O
suggested	O
the	O
role	O
of	O
protein	O
tyrosine	O
phosphatase	O
1b	O
(	O
Ptp1b	O
)	O
,	O
a	O
negative	O
regulator	O
of	O
leptin	O
and	O
insulin	O
signaling	O
,	O
in	O
the	O
regulation	O
of	O
blood	O
pressure	O
(	O
Belin	O
de	O
Chantemèle	O
et	O
al	O
.	O
,	O
2009	O
;	O
Huby	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Ptp1b	O
knockout	O
mice	O
have	O
increased	O
leptin	O
sensitivity	O
despite	O
the	O
lack	O
of	O
obesity	O
(	O
Belin	O
de	O
Chantemèle	O
et	O
al	O
.	O
,	O
2009	O
;	O
Huby	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
The	O
treatment	O
with	O
Allo	O
-	O
aca	O
in	O
Ptp1b	O
knockout	O
mice	O
treated	O
endothelial	O
dysfunction	O
and	O
hypertension	O
,	O
but	O
its	O
effects	O
on	O
ventilation	O
remain	O
unclear	O
(	O
Huby	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Our	O
study	O
had	O
several	O
limitations	O
.	O
First	O
,	O
we	O
used	O
systemic	O
blockade	O
of	O
leptin	O
receptor	O
in	O
NZO	O
mice	O
and	O
therefore	O
we	O
were	O
unable	O
to	O
distinguish	O
between	O
peripheral	O
and	O
central	O
effects	O
of	O
leptin	O
and	O
to	O
localize	O
the	O
sites	O
of	O
leptin	O
action	O
on	O
blood	O
pressure	O
.	O
Additional	O
techniques	O
to	O
block	O
leptin	O
signaling	O
,	O
such	O
as	O
intracerebroventricular	O
injections	O
of	O
leptin	O
receptor	O
blockers	O
,	O
virus	O
-	O
induced	O
gene	O
silencing	O
at	O
the	O
particular	O
sites	O
or	O
the	O
treatment	O
with	O
leptin	O
antibodies	O
,	O
which	O
do	O
not	O
penetrate	O
BBB	O
,	O
are	O
necessary	O
to	O
confirm	O
our	O
findings	O
.	O
Second	O
,	O
we	O
had	O
a	O
relatively	O
small	O
sample	O
size	O
to	O
analyze	O
the	O
effects	O
of	O
Allo	O
-	O
aca	O
.	O
However	O
,	O
even	O
with	O
a	O
reduced	O
number	O
of	O
animals	O
,	O
our	O
effect	O
sizes	O
were	O
relatively	O
large	O
enabling	O
us	O
to	O
detect	O
the	O
statistical	O
differences	O
in	O
blood	O
pressure	O
.	O
Third	O
,	O
we	O
treated	O
NZO	O
mice	O
acutely	O
with	O
Allo	O
-	O
aca	O
.	O

Chronic	O
protocols	O
could	O
show	O
more	O
long	O
-	O
term	O
beneficial	O
effects	O
of	O
leptin	O
receptor	O
blockade	O
on	O
blood	O
pressure	O
and	O
/	O
or	O
highlight	O
the	O
detrimental	O
effects	O
of	O
leptin	O
inhibition	O
on	O
obesity	O
and	O
SDB	O
.	O
Fourth	O
,	O
blood	O
samples	O
were	O
obtained	O
after	O
a	O
period	O
of	O
6	O
h	O
of	O
food	O
deprivation	O
for	O
sleep	O
studies	O
,	O
which	O
could	O
have	O
accounted	O
for	O
the	O
modest	O
hyperleptinemia	O
observed	O
in	O
our	O
NZO	O
mice	O
(	O
[UNK]	O
–	O
17	O
ng	O
/	O
mL	O
)	O
.	O
Finally	O
,	O
our	O
therapeutic	O
regimen	O
for	O
Allo	O
-	O
aca	O
could	O
explain	O
the	O
more	O
pronounced	O
hypotensive	O
effects	O
of	O
leptin	O
receptor	O
blockade	O
during	O
light	O
-	O
phase	O
.	O
Our	O
protocol	O
also	O
did	O
not	O
allow	O
us	O
to	O
estimate	O
the	O
onset	O
of	O
hypotensive	O
effects	O
of	O
Allo	O
-	O
aca	O
throughout	O
the	O
8	O
days	O
of	O
treatment	O
.	O
In	O
conclusion	O
,	O
systemic	O
leptin	O
receptor	O
blockade	O
attenuates	O
hypertension	O
in	O
NZO	O
mice	O
without	O
exacerbating	O
obesity	O
and	O
SDB	O
.	O
These	O
findings	O
support	O
that	O
leptin	O
is	O
a	O
key	O
regulator	O
of	O
blood	O
pressure	O
and	O
highlight	O
the	O
potential	O
applicability	O
of	O
pharmacological	O
blockade	O
of	O
leptin	O
signaling	O
as	O
a	O
therapy	O
for	O
patients	O
with	O
obesity	O
-	O
induced	O
hypertension	O
.	O
The	O
raw	O
data	O
supporting	O
the	O
conclusions	O
of	O
this	O
article	O
will	O
be	O
made	O
available	O
by	O
the	O
authors	O
,	O
without	O
undue	O
reservation	O
.	O
The	O
animal	B-methodology
study	I-methodology
was	O
reviewed	O
and	O
approved	O
by	O
the	O
Johns	O
Hopkins	O
University	O
Animal	O
Care	O
and	O
Use	O
Committee	O
(	O
ACUC	O
)	O
.	O
LK	O
,	O
LO	O
,	O
and	O
VP	O
:	O
conceived	O
and	O
designed	O
the	O
study	O
.	O
LK	O
,	O
MKS	O
,	O
and	O
HP	O
:	O
data	O
collection	O
.	O
LK	O
,	O
MKS	O
,	O
HP	O
,	O
LO	O
,	O
LP	O
,	O
and	O
VP	O
:	O
data	O
analyses	O
and	O
interpretation	O
.	O
LK	O
,	O
LP	O
,	O
and	O
VP	O
:	O
drafting	O
the	O
manuscript	O
.	O
LK	O
,	O
MKS	O
,	O
HP	O
,	O
LO	O
,	O
MA	O
,	O
ST	O
,	O
LP	O
,	O
and	O
VP	O
:	O
critical	O
revision	O
of	O
the	O
manuscript	O
.	O
All	O
authors	O
contributed	O
to	O
the	O
article	O
and	O
approved	O
the	O
submitted	O
version	O
.	O
LO	O
was	O
employed	O
by	O
the	O
company	O
Arrevus	O
Inc	O
.	O
and	O
OLPE	O
LLC	O
.	O
The	O
remaining	O
authors	O
declare	O
that	O
the	O
research	O
was	O
conducted	O
in	O
the	O
absence	O
of	O
any	O
commercial	O
or	O
financial	O
relationships	O
that	O
could	O
be	O
construed	O
as	O
a	O
potential	O
conflict	O
of	O
interest	O
.	O
Funding	O
.	O

This	O
study	O
was	O
supported	O
by	O
the	O
grants	O
from	O
the	O
National	O
Institutes	O
of	O
Health	O
R01	O
HL128970	O
,	O
R01	O
HL133100	O
,	O
and	O
R01	O
HL13892	O
,	O
American	O
Heart	O
Association	O
(	O
AHA	O
)	O
Postdoctoral	O
Fellowship	O
Award	O
#	O
828142	O
,	O
AHA	O
Career	O
Development	O
Award	O
19CDA34700025	O
,	O
and	O
Associação	O
Fundo	O
de	O
Incentivo	O
à	O
Pesquisa	O
(	O
AFIP	O
)	O
,	O
Brazil	O
.	O

Negative	O
Association	O
between	O
Acrylamide	O
Exposure	O
and	O
Metabolic	O
Syndrome	O
Markers	O
in	O
Adult	O
Population	O
acrylamide	O
;	O
glycidamide	O
;	O
metabolic	O
syndrome	O
;	O
NHANES	O
Metabolic	O
syndrome	O
encompasses	O
multiple	O
conditions	O
that	O
increase	O
the	O
risk	O
of	O
cardiovascular	O
disease	O
,	O
and	O
exposure	O
to	O
environmental	O
chemicals	O
can	O
cause	O
metabolic	O
syndrome	O
.	O
This	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
study	I-methodology
analyzed	O
data	O
from	O
the	O
US	B-methodology
National	I-methodology
Health	I-methodology
and	I-methodology
Nutrition	I-methodology
Examination	I-methodology
Survey	I-methodology
(	O
2003	O
–	O
2006	O
)	O
on	O
4318	O
adult	O
participants	O
to	O
assess	O
the	O
association	O
between	O
acrylamide	O
(	O
AA	O
)	O
exposure	O
and	O
metabolic	O
syndrome	O
.	O
Concentrations	O
of	O
hemoglobin	O
-	O
adducted	O
AA	O
(	O
HbAA	O
)	O
and	O
hemoglobin	O
-	O
adducted	O
glycidamide	O
(	O
HbGA	O
)	O
were	O
evaluated	O
.	O
Metabolic	O
syndrome	O
markers	O
related	O
to	O
HbAA	O
and	O
HbGA	O
and	O
the	O
effect	O
of	O
exposure	O
to	O
AA	O
and	O
GA	O
on	O
the	O
prevalence	O
of	O
metabolic	O
syndrome	O
were	O
studied	O
by	O
ANOVA	O
and	O
multivariate	O
logistic	O
regression	O
analyses	O
,	O
respectively	O
.	O
HbAA	O
concentration	O
inversely	O
correlated	O
with	O
the	O
number	O
of	O
metabolic	O
syndrome	O
markers	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
An	O
increased	O
HbAA	O
concentration	O
was	O
noted	O
with	O
reduced	O
high	O
triglyceride	O
and	O
low	O
high	O
-	O
density	O
lipoprotein	O
cholesterol	O
levels	O
in	O
the	O
adjusted	O
model	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
High	O
fasting	O
plasma	O
glucose	O
level	O
significantly	O
correlated	O
with	O
HbGA	O
concentration	O
in	O
the	O
adjusted	O
model	O
.	O
In	O
conclusion	O
,	O
AA	O
exposure	O
alters	O
metabolic	O
syndrome	O
markers	O
in	O
adults	O
.	O
Additional	O
clinical	O
and	O
animal	B-methodology
studies	I-methodology
will	O
clarify	O
the	O
role	O
of	O
AA	O
exposure	O
at	O
different	O
stages	O
in	O
the	O
progression	O
of	O
metabolic	O
syndrome	O
-	O
related	O
diseases	O
.	O
Acrylamide	O
(	O
AA	O
)	O
is	O
used	O
to	O
synthesize	O
the	O
well	O
-	O
known	O
polymer	O
polyacrylamide	O
and	O
to	O
treat	O
effluents	O
from	O
water	O
treatment	O
plants	O
and	O
industrial	O
processes	O
.	O
AA	O
exposure	O
was	O
first	O
linked	O
to	O
neurotoxicity	O
in	O
1997	O
in	O
Sweden	O
due	O
to	O
a	O
serious	O
event	O
of	O
environmental	O
pollution	O
by	O
the	O
leakage	O
of	O
a	O
sealant	O
during	O
a	O
tunneling	O
project	O
[	O
1	O
,	O
2	O
,	O
3	O
]	O
.	O
The	O
Swedish	O
National	O
Food	O
Administration	O
and	O
researchers	O
from	O
Stockholm	O
University	O
later	O
announced	O
in	O
2002	O
that	O
acrylamide	O
,	O
a	O
toxic	O
and	O
potential	O
carcinogen	O
,	O
is	O
produced	O
in	O
many	O
types	O
of	O
foods	O
prepared	O
or	O
cooked	O
at	O
high	O
temperatures	O
[	O
4	O
]	O
.	O
AA	O
is	O
classified	O
as	O
a	O
Group	O
2A	O
carcinogen	O
by	O
the	O
International	O
Agency	O
for	O
Research	O
on	O
Cancer	O
[	O
5	O
]	O
.	O

High	O
exposure	O
to	O
AA	O
can	O
affect	O
the	O
nervous	O
system	O
,	O
resulting	O
in	O
muscle	O
weakness	O
,	O
numbness	O
of	O
the	O
extremities	O
,	O
sweating	O
,	O
unsteadiness	O
,	O
etc	O
.	O
[	O
6	O
]	O
.	O
Moreover	O
,	O
animal	B-methodology
studies	I-methodology
have	O
reported	O
its	O
reproductive	O
toxicity	O
[	O
7	O
]	O
.	O
One	O
of	O
its	O
metabolites	O
,	O
glycidamide	O
(	O
GA	O
)	O
,	O
is	O
more	O
cytotoxic	O
than	O
AA	O
[	O
8	O
,	O
9	O
]	O
.	O
The	O
health	O
hazards	O
of	O
AA	O
are	O
well	O
-	O
known	O
in	O
environmental	O
medicine	O
.	O
Metabolic	O
syndrome	O
encompasses	O
several	O
metabolic	O
abnormalities	O
that	O
include	O
central	O
obesity	O
,	O
insulin	O
resistance	O
,	O
hypertension	O
,	O
dyslipidemia	O
,	O
high	O
triglycerides	O
(	O
TG	O
)	O
,	O
and	O
low	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	O
and	O
is	O
strongly	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
diabetes	O
,	O
stroke	O
,	O
and	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
[	O
10	O
]	O
.	O
Metabolic	O
syndrome	O
is	O
primarily	O
characterized	O
by	O
insulin	O
resistance	O
,	O
visceral	O
adiposity	O
,	O
atherogenic	O
dyslipidemia	O
,	O
and	O
endothelial	O
dysfunction	O
[	O
11	O
]	O
.	O
Various	O
diagnostic	O
criteria	O
have	O
been	O
proposed	O
by	O
different	O
organizations	O
over	O
the	O
past	O
decade	O
[	O
12	O
]	O
.	O
The	O
present	O
study	O
adhered	O
to	O
criteria	O
set	O
by	O
the	O
National	O
Institute	O
of	O
Health	O
guidelines	B-methodology
as	O
having	O
three	O
or	O
more	O
of	O
the	O
above	O
traits	O
,	O
including	O
those	O
that	O
are	O
controlled	O
by	O
medications	O
[	O
13	O
]	O
.	O
The	O
prevalence	O
of	O
metabolic	O
syndrome	O
increases	O
with	O
age	O
,	O
degree	O
of	O
obesity	O
,	O
and	O
propensity	O
to	O
type	O
2	O
diabetes	O
.	O
The	O
exact	O
cause	O
is	O
not	O
known	O
,	O
and	O
multiple	O
factors	O
are	O
known	O
to	O
be	O
involved	O
.	O
Exposure	O
to	O
hazardous	O
materials	O
can	O
cause	O
various	O
physiological	O
disturbances	O
,	O
resulting	O
in	O
damage	O
to	O
various	O
organ	O
systems	O
,	O
including	O
those	O
involved	O
in	O
metabolism	O
[	O
14	O
]	O
.	O
AA	O
exposure	O
reduces	O
blood	O
insulin	O
levels	O
and	O
causes	O
insulin	O
resistance	O
[	O
15	O
]	O
.	O
Exposure	O
of	O
the	O
general	O
adult	O
population	O
to	O
AA	O
was	O
associated	O
with	O
elevated	O
fasting	O
plasma	O
glucose	O
(	O
FPG	O
)	O
levels	O
,	O
oxidative	O
DNA	O
damage	O
,	O
and	O
lipid	O
peroxidation	O
[	O
16	O
]	O
.	O
Thus	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
relationship	O
between	O
exposure	O
to	O
AA	O
and	O
its	O
metabolite	O
GA	O
and	O
metabolic	O
syndrome	O
.	O
The	O
US	B-methodology
National	I-methodology
Health	I-methodology
and	I-methodology
Nutrition	I-methodology
Examination	I-methodology
Survey	I-methodology
(	O
NHANES	O
)	O
is	O
a	O
nationally	O
representative	O
,	O
complex	O
sampling	O
survey	O
that	O
combines	O
interviews	O
and	O
results	O
of	O
physical	O
examinations	O
.	O
All	O
data	O
were	O
acquired	O
from	O
the	O
NHANES	O
website	O
.	O

Use	O
of	O
the	O
NHANES	O
data	O
was	O
approved	O
by	O
the	O
NCHS	O
Research	O
Ethics	O
Review	O
Board	O
,	O
and	O
all	O
participants	O
had	O
provided	O
written	B-methodology
informed	I-methodology
consent	I-methodology
.	O
We	O
included	O
participants	O
aged	O
≥18	O
years	O
old	O
in	O
the	O
NHANES	O
dataset	O
from	O
2003	O
–	O
2006	O
and	O
excluded	O
persons	O
with	O
missing	O
data	O
.	O
Ultimately	O
,	O
4813	O
participants	O
were	O
included	O
.	O
Participants	O
were	O
divided	O
into	O
two	O
groups	O
based	O
on	O
the	O
presence	O
or	O
absence	O
of	O
metabolic	O
syndrome	O
.	O
The	O
clinical	O
definition	O
of	O
metabolic	O
syndrome	O
was	O
provided	O
by	O
the	O
National	O
Cholesterol	O
Education	O
Program	O
’	O
s	O
Adult	O
Treatment	O
Panel	O
III	O
(	O
ATP	O
III	O
)	O
[	O
17	O
]	O
(	O
Table	O
1	O
)	O
.	O
Blood	O
samples	O
were	O
obtained	O
by	O
the	O
laboratory	O
at	O
NHANES	O
,	O
National	O
Center	O
for	O
Health	O
Statistics	O
,	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
.	O
The	O
blood	O
specimens	O
were	O
collecting	O
in	O
the	O
of	O
whole	O
blood	O
and	O
separated	O
to	O
different	O
vessels	O
for	O
examination	O
.	O
Specimens	O
for	O
acrylamide	O
-	O
and	O
glycidamide	O
hemoglobin	O
adducts	O
analysis	O
may	O
be	O
fresh	O
or	O
frozen	O
erythrocytes	O
or	O
EDTA	O
-	O
whole	O
blood	O
.	O
The	O
sample	O
solutions	O
used	O
for	O
HbAA	O
and	O
HbGA	O
measurements	O
were	O
subjected	O
to	O
the	O
modified	O
Edman	O
reaction	O
,	O
and	O
the	O
Edman	O
products	O
were	O
isolated	O
and	O
analyzed	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
coupled	O
with	O
tandem	O
mass	O
spectrometry	O
(	O
HPLC	O
/	O
MS	O
/	O
MS	O
)	O
.	O
This	O
method	O
is	O
linear	O
for	O
HbAA	O
and	O
HbGA	O
in	O
the	O
range	O
1	O
.	O
25	O
–	O
80	O
nmol	O
/	O
L	O
.	O
The	O
bench	O
quality	B-methodology
control	I-methodology
(	O
QC	O
)	O
pools	O
used	O
in	O
this	O
method	O
comprised	O
three	O
concentration	O
levels	O
(	O
low	O
,	O
medium	O
,	O
and	O
high	O
QC	O
pools	O
)	O
,	O
and	O
the	O
results	O
were	O
checked	O
in	O
triplicate	O
after	O
each	O
run	O
[	O
18	O
]	O
.	O
Ethnicity	O
was	O
categorized	O
as	O
“	O
Mexican	O
American	O
,	O
”	O
“	O
Other	O
Hispanic	O
,	O
”	O
“	O
non	O
-	O
Hispanic	O
white	O
”	O
,	O
“	O
non	O
-	O
Hispanic	O
black	O
”	O
or	O
“	O
Other	O
Race	O
”	O
.	O
Plasma	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
,	O
creatinine	O
(	O
Cr	O
)	O
,	O
cholesterol	O
,	O
and	O
glucose	O
levels	O
constituted	O
the	O
routine	O
biochemistry	O
profile	O
.	O
Analyses	O
were	O
performed	O
with	O
a	O
Beckman	O
Synchron	O
LX20	O
.	O
Smoking	O
status	O
was	O
determined	O
by	O
participants	O
’	O
answers	O
to	O
the	O
question	O
“	O
Do	O
you	O
currently	O
smoke	O
cigarettes	O
?	O
”	O
The	O
physical	O
condition	O
interview	O
data	O
provided	O
the	O
health	O
status	O
and	O
medical	O
history	O
as	O
reported	O
by	O
the	O
individual	O
and	O
the	O
agent	O
,	O
including	O
emphysema	O
and	O
angina	O
/	O
angina	O
pectoris	O
.	O

All	O
data	O
analyses	O
were	O
performed	O
using	O
SPSS	O
(	O
Version	O
18	O
.	O
0	O
for	O
Windows	O
,	O
SPSS	O
,	O
Inc	O
.	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O
We	O
applied	O
the	O
Kolmogorov	O
-	O
Smirnov	O
test	O
for	O
normal	O
distribution	O
.	O
The	O
Chi	O
-	O
square	O
test	O
was	O
used	O
to	O
analyze	O
categorical	O
data	O
,	O
the	O
t	O
-	O
test	O
was	O
used	O
to	O
analyze	O
continuous	O
data	O
.	O
The	O
Mann	O
-	O
Whitney	O
U	O
test	O
was	O
used	O
to	O
analyze	O
HbAA	O
and	O
HbGA	O
concentrations	O
.	O
ANOVA	O
was	O
used	O
to	O
analyze	O
the	O
markers	O
for	O
metabolic	O
syndrome	O
related	O
to	O
HbAA	O
and	O
HbGA	O
concentrations	O
.	O
The	O
extended	O
model	O
was	O
used	O
to	O
adjust	O
for	O
covariates	O
.	O
Values	O
of	O
HbAA	O
and	O
HbGA	O
were	O
log	O
-	O
transformed	O
.	O
Multivariate	O
logistic	O
regression	O
models	O
were	O
used	O
to	O
analyze	O
the	O
effect	O
of	O
exposure	O
to	O
AA	O
and	O
GA	O
on	O
the	O
markers	O
for	O
metabolic	O
syndrome	O
.	O
Multi	O
-	O
variant	O
linear	O
regression	O
analysis	O
was	O
used	O
for	O
HbAA	O
and	O
HbGA	O
concentrations	O
and	O
continuous	O
variables	O
for	O
each	O
marker	O
(	O
waist	O
circumference	O
,	O
blood	O
pressure	O
,	O
and	O
glucose	O
and	O
lipid	O
profiles	O
)	O
.	O
Model	O
1	O
was	O
unadjusted	O
,	O
whereas	O
Model	O
2	O
was	O
adjusted	O
for	O
age	O
,	O
gender	O
,	O
ethnicity	O
,	O
serum	O
AST	O
,	O
serum	O
creatinine	O
,	O
emphysema	O
,	O
angina	O
/	O
angina	O
pectoris	O
,	O
and	O
smoking	O
status	O
.	O
Quartile	O
-	O
based	O
analysis	O
was	O
performed	O
to	O
evaluate	O
the	O
trends	O
in	O
HbAA	O
and	O
HbGA	O
concentrations	O
and	O
the	O
association	O
of	O
prevalence	O
of	O
metabolic	O
syndrome	O
.	O
p	O
<	O
0	O
.	O
05	O
indicates	O
a	O
statistically	O
significant	O
difference	O
.	O
After	O
screening	O
for	O
eligible	O
participants	O
(	O
N	O
=	O
20470	O
)	O
and	O
accounting	O
for	O
those	O
not	O
attending	O
baseline	O
data	O
collection	O
sessions	O
,	O
4813	O
participants	O
were	O
finally	O
available	O
for	O
analysis	O
in	O
this	O
study	O
.	O
The	O
participants	O
were	O
divided	O
into	O
the	O
metabolic	O
syndrome	O
group	O
(	O
N	O
=	O
1064	O
)	O
and	O
the	O
non	O
-	O
metabolic	O
syndrome	O
group	O
(	O
N	O
=	O
3749	O
)	O
(	O
Table	O
2	O
)	O
.	O
The	O
mean	O
age	O
of	O
the	O
non	O
-	O
metabolic	O
syndrome	O
group	O
was	O
lesser	O
than	O
that	O
of	O
the	O
metabolic	O
syndrome	O
group	O
(	O
mean	O
±	O
SD	O
:	O
33	O
.	O
97	O
±	O
20	O
.	O
86	O
vs	O
.	O
53	O
.	O
54	O
±	O
19	O
.	O
20	O
years	O
)	O
.	O
Higher	O
HbAA	O
and	O
HbGA	O
concentrations	O
were	O
noted	O
in	O
the	O
non	O
-	O
metabolic	O
syndrome	O
group	O
.	O
The	O
mean	O
values	O
of	O
all	O
baseline	O
parameters	O
were	O
higher	O
in	O
the	O
metabolic	O
syndrome	O
group	O
than	O
the	O
non	O
-	O
metabolic	O
syndrome	O
group	O
.	O

Table	O
3	O
provides	O
HbAA	O
and	O
HbGA	O
concentrations	O
and	O
the	O
number	O
of	O
metabolic	O
syndrome	O
markers	O
.	O
In	O
the	O
adjusted	O
model	O
,	O
log	O
-	O
transformed	O
HbAA	O
concentration	O
inversely	O
correlated	O
with	O
the	O
number	O
of	O
metabolic	O
syndrome	O
markers	O
(	O
3	O
:	O
β	O
coefficient	O
=	O
−0	O
.	O
051	O
;	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
=	O
−0	O
.	O
141	O
,	O
−0	O
.	O
040	O
;	O
p	O
=	O
0	O
.	O
275	O
and	O
4	O
–	O
5	O
:	O
β	O
coefficient	O
=	O
−0	O
.	O
127	O
;	O
95	O
%	O
CI	O
=	O
−0	O
.	O
229	O
,	O
−0	O
.	O
025	O
;	O
p	O
=	O
0	O
.	O
015	O
)	O
.	O
Most	O
results	O
for	O
correlation	O
with	O
log	O
-	O
transformed	O
HbGA	O
were	O
not	O
significant	O
in	O
the	O
adjusted	O
model	O
,	O
except	O
for	O
high	O
glucose	O
level	O
(	O
β	O
coefficient	O
=	O
−0	O
.	O
072	O
;	O
95	O
%	O
CI	O
=	O
−0	O
.	O
135	O
,	O
−0	O
.	O
008	O
;	O
p	O
=	O
0	O
.	O
027	O
)	O
.	O
Increased	O
concentrations	O
of	O
HbAA	O
were	O
noted	O
with	O
high	O
triglycerides	O
and	O
low	O
HDL	O
cholesterol	O
in	O
the	O
adjusted	O
model	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
(	O
Figure	O
1	O
)	O
.	O
High	O
blood	O
pressure	O
negatively	O
correlated	O
with	O
the	O
concentration	O
of	O
HbAA	O
in	O
Model	O
1	O
but	O
was	O
insignificant	O
after	O
multivariate	O
model	O
adjustment	O
(	O
Model	O
2	O
)	O
.	O
In	O
Table	O
4	O
,	O
the	O
presence	O
of	O
metabolic	O
syndrome	O
was	O
statistically	O
significantly	O
associated	O
with	O
concentrations	O
of	O
HbAA	O
based	O
on	O
quartile	O
analysis	O
in	O
Model	O
2	O
(	O
Q2	O
vs	O
.	O
Q1	O
:	O
OR	O
=	O
0	O
.	O
604	O
;	O
95	O
%	O
CI	O
=	O
0	O
.	O
424	O
,	O
0	O
.	O
860	O
;	O
Q3	O
vs	O
.	O
Q1	O
:	O
OR	O
=	O
0	O
.	O
579	O
;	O
95	O
%	O
CI	O
=	O
0	O
.	O
410	O
,	O
0	O
.	O
817	O
;	O
Q4	O
vs	O
.	O
Q1	O
:	O
OR	O
=	O
0	O
.	O
595	O
;	O
95	O
%	O
CI	O
=	O
0	O
.	O
404	O
,	O
0	O
.	O
876	O
;	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
The	O
association	O
between	O
concentrations	O
of	O
HbGA	O
and	O
metabolic	O
syndrome	O
was	O
not	O
significant	O
.	O
This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
the	O
correlation	O
between	O
metabolic	O
syndrome	O
and	O
HbAA	O
and	O
HbGA	O
levels	O
,	O
which	O
indicate	O
exposure	O
to	O
harmful	O
substances	O
caused	O
by	O
smoking	O
,	O
dietary	O
habits	O
,	O
and	O
occupation	O
.	O
The	O
results	O
revealed	O
a	O
significant	O
negative	O
correlation	O
between	O
metabolic	O
syndrome	O
and	O
HbAA	O
and	O
HbGA	O
concentration	O
.	O
There	O
were	O
no	O
apparent	O
correlations	O
in	O
adjusted	O
model	O
.	O

However	O
,	O
among	O
the	O
metabolic	O
syndrome	O
markers	O
,	O
negative	O
associations	O
with	O
HbAA	O
were	O
observed	O
for	O
high	O
TG	O
and	O
low	O
HDL	O
cholesterol	O
,	O
and	O
negative	O
association	O
with	O
HbGA	O
was	O
observed	O
for	O
high	O
glucose	O
.	O
The	O
toxicological	O
health	O
hazards	O
of	O
AA	O
exposure	O
are	O
well	O
-	O
known	O
.	O
The	O
main	O
sources	O
of	O
AA	O
in	O
the	O
human	O
body	O
are	O
diet	O
,	O
especially	O
Western	O
-	O
style	O
foods	O
,	O
and	O
occupation	O
.	O
AA	O
has	O
been	O
identified	O
as	O
a	O
carcinogen	O
and	O
is	O
shown	O
to	O
exhibit	O
neurotoxicity	O
,	O
genotoxicity	O
,	O
and	O
deleterious	O
reproductive	O
effects	O
.	O
One	O
of	O
its	O
metabolites	O
,	O
GA	O
,	O
is	O
considered	O
to	O
exhibit	O
even	O
stronger	O
cytotoxicity	O
[	O
7	O
,	O
8	O
]	O
.	O
However	O
,	O
the	O
risk	O
assessment	O
for	O
dietary	O
AA	O
exposure	O
is	O
still	O
under	O
debate	O
.	O
For	O
instance	O
,	O
a	O
negative	O
association	O
of	O
AA	O
exposure	O
with	O
insulin	O
resistance	O
was	O
reported	O
previously	O
[	O
15	O
]	O
,	O
and	O
the	O
results	O
from	O
the	O
present	O
study	O
supported	O
this	O
hypothesis	O
.	O
Insulin	O
resistance	O
is	O
central	O
to	O
the	O
development	O
of	O
metabolic	O
syndrome	O
.	O
Increased	O
intracellular	O
fatty	O
acid	O
metabolites	O
contribute	O
to	O
insulin	O
resistance	O
by	O
impairing	O
insulin	O
-	O
signaling	O
pathways	O
.	O
Smoking	O
is	O
a	O
major	O
source	O
of	O
AA	O
exposure	O
,	O
and	O
chronic	O
smoking	O
is	O
associated	O
with	O
high	O
age	O
-	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
-	O
adjusted	O
plasma	O
insulin	O
levels	O
that	O
are	O
independent	O
of	O
other	O
factors	O
known	O
to	O
influence	O
insulin	O
sensitivity	O
[	O
18	O
]	O
.	O
In	O
a	O
study	O
on	O
female	O
rats	O
[	O
19	O
]	O
,	O
exposure	O
to	O
AA	O
significantly	O
increased	O
the	O
FPG	O
level	O
,	O
reduced	O
hepatic	O
glycogen	O
content	O
,	O
and	O
impaired	O
glucose	O
tolerance	O
(	O
i	O
.	O
e	O
.	O
,	O
AA	O
exposure	O
significantly	O
promoted	O
gluconeogenesis	O
and	O
glycogenolysis	O
and	O
decreased	O
glycolysis	O
)	O
,	O
and	O
damaged	O
islets	O
were	O
also	O
observed	O
.	O
Urinary	O
AA	O
metabolites	O
were	O
positively	O
associated	O
with	O
FPG	O
in	O
a	O
study	O
on	O
the	O
general	O
Asian	O
urban	O
adult	O
population	O
[	O
16	O
]	O
,	O
and	O
the	O
results	O
of	O
that	O
study	O
indicated	O
that	O
AA	O
exposure	O
is	O
associated	O
with	O
FPG	O
elevation	O
and	O
increased	O
oxidative	O
DNA	O
damage	O
and	O
lipid	O
peroxidation	O
.	O
In	O
a	O
study	O
on	O
the	O
American	O
adult	O
population	O
[	O
15	O
]	O
,	O
AA	O
was	O
found	O
to	O
be	O
associated	O
with	O
reduced	O
serum	O
insulin	O
levels	O
and	O
homeostasis	O
model	O
assessment	O
of	O
insulin	O
resistance	O
.	O
Meanwhile	O
,	O
it	O
has	O
been	O
suggested	O
that	O
the	O
continual	O
intake	O
of	O
trace	O
AA	O
amounts	O
induces	O
characteristically	O
low	O
serum	O
insulin	O
levels	O
in	O
rats	O
[	O
20	O
]	O
.	O

Exposure	O
to	O
endocrine	O
-	O
disrupting	O
chemicals	O
can	O
accelerate	O
T1DM	O
development	O
by	O
several	O
mechanism	O
of	O
action	O
on	O
known	O
type	O
1	O
diabetes	O
mellitus	O
triggers	O
,	O
such	O
as	O
immunomodulation	O
,	O
gut	O
microbiota	O
,	O
and	O
vitamin	O
D	O
pathway	O
[	O
21	O
,	O
22	O
,	O
23	O
]	O
.	O
Currently	O
,	O
whether	O
AA	O
exposure	O
could	O
triggered	O
type	O
1	O
diabetes	O
mellitus	O
was	O
still	O
lacking	O
of	O
evidence	O
.	O
Insulin	O
resistance	O
can	O
alter	O
systemic	O
lipid	O
metabolism	O
,	O
which	O
then	O
leads	O
to	O
the	O
development	O
of	O
dyslipidemia	O
and	O
includes	O
high	O
levels	O
of	O
plasma	O
TG	O
and	O
LDL	O
and	O
low	O
levels	O
of	O
HDL	O
cholesterol	O
[	O
24	O
]	O
.	O
Lowering	O
of	O
blood	O
lipid	O
levels	O
,	O
whether	O
by	O
diet	O
or	O
medication	O
,	O
can	O
therefore	O
be	O
regarded	O
as	O
an	O
anti	O
-	O
inflammatory	O
and	O
plaque	O
-	O
stabilizing	O
therapy	O
.	O
The	O
TG	O
fraction	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
the	O
HDL	O
level	O
can	O
vary	O
considerably	O
depending	O
on	O
the	O
fasting	O
status	O
of	O
the	O
patient	O
[	O
25	O
]	O
.	O
AA	O
exposure	O
promotes	O
adipocyte	O
differentiation	O
and	O
intracellular	O
lipid	O
accumulation	O
in	O
mice	O
,	O
and	O
the	O
effects	O
of	O
AA	O
on	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPKs	O
)	O
and	O
5	O
′	O
AMP	O
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
-	O
acetyl	O
-	O
CoA	O
carboxylase	O
activation	O
have	O
also	O
been	O
investigated	O
.	O
Exposure	O
of	O
AA	O
to	O
high	O
-	O
fat	O
diet	O
-	O
fed	O
mice	O
significantly	O
increased	O
their	O
body	O
weight	O
,	O
organ	O
weight	O
,	O
and	O
fat	O
mass	O
[	O
26	O
]	O
.	O
TG	O
molecules	O
represent	O
the	O
major	O
form	O
of	O
storage	O
and	O
transport	O
of	O
fatty	O
acids	O
within	O
cells	O
and	O
in	O
the	O
plasma	O
[	O
27	O
]	O
.	O
AA	O
affects	O
lipoprotein	O
metabolism	O
,	O
which	O
can	O
result	O
in	O
the	O
deterioration	O
of	O
atherosclerosis	O
.	O
Exposure	O
to	O
AA	O
can	O
cause	O
acute	O
inflammatory	O
death	O
,	O
accompanied	O
by	O
hyperlipidemia	O
in	O
zebrafish	O
[	O
28	O
]	O
.	O
The	O
liver	O
is	O
one	O
of	O
the	O
major	O
sites	O
of	O
endogenous	O
cholesterol	O
synthesis	O
.	O
Significant	O
downregulation	O
of	O
genes	O
involved	O
in	O
lipid	O
metabolism	O
could	O
cause	O
lipotoxicity	O
in	O
mice	O
[	O
9	O
]	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
determined	O
negative	O
correlations	O
between	O
HbAA	O
concentration	O
and	O
high	O
TG	O
and	O
low	O
HDL	O
levels	O
.	O
Studies	O
on	O
rodents	O
have	O
shown	O
that	O
maternal	O
AA	O
exposure	O
during	O
pregnancy	O
is	O
related	O
to	O
the	O
weight	O
loss	O
of	O
offspring	O
[	O
29	O
]	O
.	O

In	O
subpopulations	O
from	O
the	O
European	O
Prospective	O
Investigation	O
into	O
Cancer	O
and	O
Nutrition	O
(	O
EPIC	O
)	O
study	O
,	O
HbAA	O
was	O
inversely	O
associated	O
with	O
BMI	O
in	O
smokers	O
without	O
adjustment	O
for	O
potential	O
confounders	O
[	O
30	O
]	O
.	O
Cigarette	O
smoking	O
has	O
been	O
associated	O
with	O
increased	O
waist	O
circumference	O
in	O
women	O
younger	O
than	O
40	O
years	O
[	O
31	O
]	O
.	O
In	O
a	O
study	O
on	O
chick	O
embryos	O
,	O
low	O
doses	O
of	O
AA	O
significantly	O
increased	O
the	O
total	O
body	O
weight	O
,	O
whereas	O
high	O
doses	O
of	O
AA	O
induced	O
a	O
loss	O
of	O
body	O
weight	O
[	O
32	O
]	O
.	O
Dietary	O
exposure	O
to	O
AA	O
has	O
also	O
been	O
associated	O
with	O
reduced	O
birth	O
weight	O
and	O
head	O
circumference	O
[	O
33	O
]	O
.	O
The	O
mean	O
AA	O
exposure	O
in	O
Europe	O
is	O
estimated	O
to	O
be	O
in	O
the	O
range	O
of	O
0	O
.	O
31	O
–	O
1	O
.	O
1	O
µg	O
/	O
kg	O
body	O
weight	O
/	O
day	O
for	O
adults	O
(	O
>	O
18	O
years	O
old	O
)	O
,	O
and	O
the	O
major	O
contributors	O
to	O
the	O
exposure	O
in	O
adults	O
are	O
fried	O
potatoes	O
,	O
coffee	O
,	O
and	O
soft	O
bread	O
,	O
whereas	O
in	O
adolescents	O
and	O
children	O
,	O
the	O
major	O
sources	O
of	O
exposure	O
are	O
fried	O
potatoes	O
,	O
soft	O
bread	O
,	O
potato	O
crisps	O
,	O
and	O
biscuits	O
[	O
34	O
]	O
.	O
The	O
results	O
of	O
a	O
previous	O
study	O
involving	O
the	O
US	O
general	O
population	O
indicated	O
that	O
higher	O
concentrations	O
of	O
HbAA	O
are	O
associated	O
with	O
a	O
decrease	O
in	O
body	O
weight	O
[	O
35	O
]	O
.	O
The	O
results	O
of	O
the	O
present	O
study	O
indicate	O
that	O
HbAA	O
is	O
inversely	O
associated	O
with	O
BMI	O
in	O
the	O
adjusted	O
model	O
.	O
AA	O
hemoglobin	O
biomarkers	O
are	O
inversely	O
associated	O
with	O
CVD	O
,	O
including	O
congestive	O
heart	O
failure	O
,	O
coronary	O
heart	O
disease	O
,	O
angina	O
pectoris	O
,	O
heart	O
attacks	O
,	O
and	O
strokes	O
,	O
in	O
people	O
exposed	O
to	O
environmental	O
tobacco	O
smoke	O
and	O
in	O
active	O
smokers	O
.	O
However	O
,	O
there	O
is	O
no	O
significant	O
correlation	O
between	O
hypertension	O
and	O
AA	O
exposure	O
in	O
the	O
risk	O
of	O
CVD	O
[	O
36	O
]	O
.	O
In	O
the	O
mechanism	O
of	O
hypertension	O
,	O
the	O
blood	O
pressure	O
is	O
determined	O
by	O
two	O
components	O
:	O
cardiac	O
output	O
and	O
peripheral	O
resistance	O
.	O
Cardiac	O
output	O
has	O
two	O
determinants	O
:	O
stroke	O
volume	O
and	O
heart	O
rate	O
while	O
peripheral	O
resistance	O
is	O
determined	O
by	O
the	O
vascular	O
structure	O
and	O
function	O
.	O
The	O
neural	O
,	O
endocrine	O
/	O
paracrine	O
,	O
and	O
vascular	O
mechanisms	O
can	O
potentially	O
increase	O
arterial	O
pressure	O
[	O
36	O
,	O
37	O
,	O
38	O
]	O
,	O
and	O
the	O
toxic	O
effects	O
of	O
AA	O
on	O
neuron	O
regulation	O
also	O
include	O
sympathetic	O
autonomic	O
neuropathy	O
[	O
6	O
,	O
39	O
]	O
.	O

AA	O
exposure	O
can	O
result	O
in	O
oxidative	O
stress	O
featured	O
by	O
a	O
significant	O
increase	O
in	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
and	O
malondialdehyde	O
(	O
MDA	O
)	O
levels	O
and	O
consumption	O
of	O
glutathione	O
(	O
GSH	O
)	O
[	O
40	O
]	O
.	O
ROS	O
are	O
involved	O
in	O
inflammation	O
;	O
endothelial	O
dysfunction	O
;	O
cell	O
proliferation	O
,	O
migration	O
,	O
and	O
activation	O
;	O
extracellular	O
matrix	O
deposition	O
;	O
fibrosis	O
;	O
angiogenesis	O
;	O
and	O
vascular	O
remodeling	O
[	O
37	O
]	O
.	O
ROS	O
generation	O
by	O
adipocytes	O
is	O
mediated	O
through	O
the	O
expression	O
and	O
secretion	O
of	O
inflammatory	O
adipokines	O
that	O
impair	O
the	O
regulation	O
of	O
energy	O
homeostasis	O
and	O
vascular	O
function	O
[	O
41	O
,	O
42	O
]	O
.	O
AA	O
exposure	O
disrupts	O
the	O
nitric	O
oxide	O
(	O
NO	O
)	O
signaling	O
pathway	O
,	O
which	O
causes	O
a	O
rostrocaudal	O
difference	O
in	O
the	O
differential	O
expression	O
of	O
nitric	O
oxide	O
synthase	O
(	O
NOS	O
)	O
isoforms	O
nNOS	O
and	O
iNOS	O
in	O
the	O
neocortex	O
and	O
the	O
striatum	O
[	O
43	O
]	O
.	O
In	O
a	O
pediatric	O
chronic	O
kidney	O
disease	O
population	O
,	O
NO	O
-	O
related	O
parameters	O
correlated	O
with	O
blood	O
pressure	O
abnormalities	O
and	O
CVD	O
risk	O
markers	O
,	O
and	O
a	O
positive	O
association	O
between	O
AA	O
metabolites	O
and	O
CVD	O
risk	O
was	O
observed	O
[	O
44	O
]	O
.	O
Although	O
no	O
significant	O
association	O
was	O
found	O
between	O
AA	O
exposure	O
and	O
hypertension	O
,	O
further	O
research	O
is	O
required	O
to	O
assess	O
the	O
potential	O
link	O
between	O
AA	O
exposure	O
and	O
hypertension	O
.	O
A	O
pro	O
-	O
inflammatory	O
state	O
is	O
considered	O
a	O
marker	O
for	O
metabolic	O
syndrome	O
.	O
As	O
mentioned	O
earlier	O
,	O
AA	O
exposure	O
results	O
in	O
oxidative	O
stress	O
featured	O
by	O
increasing	O
ROS	O
and	O
MDA	O
levels	O
and	O
GSH	O
consumption	O
.	O
Moreover	O
,	O
AA	O
activates	O
the	O
nuclear	O
factor	O
erythroid	O
2	O
-	O
related	O
factor	O
2	O
(	O
Nrf2	O
)	O
and	O
nuclear	O
factor	O
-	O
κB	O
(	O
NF	O
-	O
κB	O
)	O
pathways	O
that	O
are	O
regulated	O
by	O
MAPKs	O
[	O
40	O
]	O
.	O
In	O
the	O
activation	O
of	O
the	O
NF	O
-	O
κB	O
pathway	O
,	O
transcription	O
factor	O
Nrf2	O
,	O
a	O
major	O
regulator	O
of	O
antioxidant	O
and	O
cytoprotective	O
genes	O
,	O
is	O
primarily	O
activated	O
in	O
response	O
to	O
oxidative	O
stress	O
.	O

After	O
NF	O
-	O
κB	O
activation	O
,	O
related	O
cytokines	O
,	O
including	O
interleukin	O
(	O
IL	O
)	O
-	O
6	O
,	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
α	O
,	O
granulocyte	O
-	O
colony	O
-	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
,	O
and	O
IL	O
-	O
1β	O
,	O
are	O
released	O
and	O
cell	O
viability	O
decreases	O
[	O
45	O
]	O
.	O
The	O
inflammatory	O
response	O
is	O
determined	O
by	O
concentration	O
-	O
dependent	O
increases	O
in	O
the	O
levels	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
TNF	O
-	O
α	O
and	O
IL	O
-	O
6	O
,	O
which	O
can	O
cause	O
insulin	O
resistance	O
in	O
adipose	O
tissue	O
,	O
skeletal	O
muscle	O
,	O
and	O
the	O
liver	O
by	O
inhibiting	O
insulin	O
signal	O
transduction	O
[	O
46	O
]	O
.	O
It	O
is	O
logical	O
to	O
assume	O
that	O
AA	O
exposure	O
might	O
induce	O
inflammation	O
because	O
recent	O
studies	O
have	O
demonstrated	O
the	O
cytotoxicity	O
and	O
genotoxicity	O
of	O
AA	O
.	O
Although	O
the	O
relationship	O
between	O
metabolic	O
syndrome	O
and	O
AA	O
exposure	O
was	O
hypothesized	O
as	O
a	O
positive	O
association	O
,	O
the	O
results	O
of	O
this	O
study	O
revealed	O
a	O
negative	O
correlation	O
,	O
as	O
have	O
studies	O
in	O
both	O
animals	O
and	O
humans	O
.	O
Thus	O
,	O
a	O
longitudinal	B-methodology
study	I-methodology
is	O
required	O
to	O
further	O
determine	O
the	O
outcome	O
of	O
AA	O
exposure	O
and	O
associated	O
health	O
hazards	O
.	O
First	O
,	O
this	O
was	O
a	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
study	I-methodology
based	I-methodology
on	I-methodology
observational	I-methodology
and	I-methodology
retrospective	I-methodology
analyses	I-methodology
of	O
existing	O
data	O
from	O
a	O
single	O
period	O
rather	O
than	O
on	O
long	O
-	O
term	O
repeated	O
observations	O
with	O
limited	O
causal	O
inference	O
.	O
Second	O
,	O
the	O
information	O
comes	O
directly	O
from	O
participants	O
’	O
self	O
-	O
reports	O
,	O
and	O
other	O
data	O
confirming	O
the	O
diagnosis	O
or	O
following	O
dietary	O
habits	O
are	O
limited	O
because	O
AA	O
consumption	O
is	O
one	O
of	O
the	O
main	O
sources	O
of	O
AA	O
exposure	O
.	O
Third	O
,	O
metabolic	O
syndrome	O
is	O
multifactorial	O
,	O
and	O
the	O
incidence	O
of	O
insulin	O
resistance	O
in	O
men	O
and	O
women	O
increases	O
with	O
age	O
and	O
hormone	O
changes	O
,	O
and	O
these	O
variants	O
cannot	O
be	O
adjusted	O
for	O
due	O
to	O
restricted	O
data	O
access	O
.	O
The	O
mean	O
age	O
difference	O
was	O
found	O
in	O
two	O
groups	O
of	O
our	O
study	O
participants	O
.	O
Similar	O
age	O
cohorts	B-methodology
studies	O
are	O
required	O
for	O
further	O
evaluation	O
.	O
Fourth	O
,	O
exposure	O
to	O
acrylamide	O
may	O
also	O
be	O
an	O
indicator	O
of	O
exposure	O
to	O
multiple	O
chemicals	O
,	O
including	O
other	O
endocrine	O
-	O
disrupting	O
chemicals	O
,	O
which	O
is	O
hard	O
for	O
covariates	O
adjustment	O
in	O
this	O
study	O
.	O
Fifth	O
,	O
liver	O
genes	O
and	O
enzymes	O
affect	O
the	O
differences	O
in	O
the	O
metabolism	O
of	O
AA	O
exposure	O
in	O
human	O
.	O
Among	O
the	O
components	O
of	O
metabolic	O
syndrome	O
,	O
liver	O
enzymes	O
are	O
also	O
closely	O
related	O
to	O
lipid	O
metabolism	O
and	O
sugar	O
metabolism	O
.	O
In	O
this	O
study	O
,	O
we	O
could	O
not	O
assess	O
the	O
impact	O
of	O
genetic	O
differences	O
between	O
ethnic	O
groups	O
.	O

The	O
findings	O
of	O
this	O
study	O
indicate	O
that	O
Hb	O
-	O
adducted	O
AA	O
,	O
the	O
biomarker	O
of	O
exposure	O
to	O
AA	O
is	O
negatively	O
associated	O
with	O
high	O
triglycerides	O
,	O
low	O
HDL	O
cholesterol	O
,	O
markers	O
of	O
metabolic	O
syndrome	O
.	O
Hb	O
-	O
adducted	O
GA	O
,	O
the	O
metabolite	O
of	O
AA	O
in	O
human	O
,	O
is	O
negatively	O
associated	O
with	O
high	O
glucose	O
.	O
As	O
exposure	O
to	O
AA	O
from	O
smoke	O
and	O
food	O
has	O
become	O
a	O
worldwide	O
concern	O
,	O
the	O
findings	O
of	O
this	O
study	O
provide	O
an	O
epidemiological	O
data	O
of	O
AA	O
exposure	O
.	O
The	O
toxic	O
effects	O
of	O
AA	O
include	O
neurotoxicity	O
,	O
reproductive	O
toxicity	O
,	O
genotoxicity	O
,	O
and	O
carcinogenicity	O
.	O
The	O
results	O
of	O
the	O
study	O
indicate	O
that	O
AA	O
could	O
play	O
a	O
role	O
in	O
different	O
stages	O
of	O
progression	O
of	O
metabolic	O
syndrome	O
-	O
related	O
diseases	O
.	O
In	O
the	O
future	O
,	O
the	O
association	O
between	O
long	O
-	O
term	O
exposure	O
and	O
disease	O
progression	O
in	O
different	O
ethnic	O
groups	O
(	O
including	O
dietary	O
habits	O
and	O
smoking	O
status	O
)	O
needs	O
further	O
research	O
to	O
clarify	O
the	O
effects	O
of	O
AA	O
on	O
human	O
health	O
.	O
Publisher	O
’	O
s	O
Note	O
:	O
MDPI	O
stays	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O
Conceptualization	O
,	O
W	O
.	O
-	O
H	O
.	O
F	O
.	O
;	O
Data	O
curation	O
,	O
W	O
.	O
-	O
L	O
.	O
C	O
.	O
;	O
Formal	O
analysis	O
,	O
W	O
.	O
-	O
L	O
.	O
C	O
.	O
;	O
Investigation	O
,	O
W	O
.	O
-	O
L	O
.	O
C	O
.	O
;	O
Methodology	O
,	O
W	O
.	O
-	O
L	O
.	O
C	O
.	O
;	O
Project	O
administration	O
,	O
W	O
.	O
-	O
H	O
.	O
F	O
.	O
;	O
Resources	O
,	O
W	O
.	O
-	O
H	O
.	O
F	O
.	O
;	O
Software	O
,	O
Y	O
.	O
-	O
W	O
.	O
C	O
.	O
;	O
Validation	O
,	O
W	O
.	O
-	O
L	O
.	O
C	O
.	O
and	O
W	O
.	O
-	O
H	O
.	O
F	O
.	O
;	O
Visualization	O
,	O
Y	O
.	O
-	O
W	O
.	O
C	O
.	O
;	O
Writing	O
—	O
original	O
draft	O
,	O
C	O
.	O
-	O
C	O
.	O
H	O
.	O
;	O
Writing	O
—	O
review	O
&	O
editing	O
,	O
W	O
.	O
-	O
H	O
.	O
F	O
.	O
All	O
authors	O
have	O
read	O
and	O
agreed	O
to	O
the	O
published	O
version	O
of	O
the	O
manuscript	O
.	O
This	O
research	O
did	O
not	O
receive	O
any	O
specific	O
grant	O
from	O
funding	O
agencies	O
in	O
the	O
public	O
,	O
commercial	O
,	O
or	O
not	O
-	O
for	O
-	O
profit	O
sectors	O
.	O
Ethical	O
approval	O
and	O
review	O
were	O
not	O
sought	O
or	O
obtained	O
for	O
this	O
study	O
given	O
that	O
it	O
was	O
a	O
secondary	O
analysis	O
of	O
publicly	O
available	O
,	O
de	O
-	O
identified	O
data	O
.	O
Not	O
applicable	O
.	O
NHANES	O
data	O
are	O
publicly	O
available	O
at	O
https	O
:	O
/	O
/	O
wwwn	O
.	O
cdc	O
.	O
gov	O
/	O
nchs	O
/	O
nhanes	O
/	O
Default	O
.	O
aspx	O
(	O
accessed	O
on	O
27	O
October	O
2021	O
)	O
.	O

The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O

Self	O
-	O
Care	O
by	O
Muslim	O
Women	O
during	O
Ramadan	O
Fasting	O
to	O
Protect	O
Nutritional	O
and	O
Cardiovascular	O
Health	O
Ramadan	O
;	O
obesity	O
;	O
bioimpedance	O
;	O
anthropometry	O
;	O
eating	O
habits	O
The	O
practice	O
of	O
Ramadan	O
involves	O
a	O
series	O
of	O
changes	O
in	O
lifestyle	O
,	O
mainly	O
in	O
eating	O
habits	O
.	O
The	O
research	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
prevalence	O
of	O
overweight	O
-	O
obesity	O
,	O
the	O
degree	O
of	O
compliance	O
with	O
dietary	O
recommendations	O
and	O
the	O
effects	O
of	O
religious	O
fasting	O
on	O
cardiovascular	O
health	O
among	O
a	O
population	O
of	O
Muslim	O
women	O
living	O
in	O
Melilla	O
,	O
a	O
Spanish	O
city	O
in	O
North	O
Africa	O
.	O
A	O
follow	O
-	O
up	O
cohort	B-methodology
study	I-methodology
was	O
conducted	O
on	O
62	O
healthy	O
adult	O
women	O
(	O
33	O
.	O
6	O
±	O
12	O
.	O
7	O
years	O
)	O
.	O
Anthropometric	O
and	O
body	O
composition	O
parameters	O
were	O
obtained	O
using	O
bioimpedance	O
and	O
dietary	O
records	O
.	O
All	O
of	O
the	O
participants	O
were	O
overweight	O
or	O
obese	O
,	O
especially	O
due	O
to	O
the	O
non	O
-	O
compliance	O
with	O
dietary	O
recommendations	O
;	O
however	O
,	O
more	O
than	O
60	O
%	O
considered	O
their	O
weight	O
was	O
appropriate	O
or	O
even	O
low	O
.	O
By	O
the	O
end	O
of	O
Ramadan	O
,	O
the	O
women	O
’	O
s	O
body	O
mass	O
index	O
and	O
fat	O
component	O
values	O
had	O
fallen	O
significantly	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
this	O
loss	O
was	O
later	O
recovered	O
.	O
Dietary	O
records	O
revealed	O
an	O
excessive	O
consumption	O
of	O
lipids	O
and	O
sodium	O
,	O
and	O
the	O
presence	O
of	O
a	O
high	O
waist	O
-	O
to	O
-	O
hip	O
ratio	O
.	O
All	O
of	O
these	O
factors	O
are	O
related	O
to	O
cardiovascular	O
risk	O
.	O
In	O
conclusion	O
,	O
promoting	O
nutritional	O
health	O
and	O
encouraging	O
year	O
-	O
round	O
self	O
-	O
care	O
among	O
adult	O
Muslim	O
women	O
is	O
necessary	O
in	O
order	O
to	O
ensure	O
healthy	O
fasting	O
during	O
Ramadan	O
.	O
During	O
the	O
month	O
of	O
Ramadan	O
,	O
Muslims	O
are	O
required	O
to	O
abstain	O
from	O
smoking	O
,	O
sexual	O
intercourse	O
,	O
eating	O
and	O
drinking	O
,	O
from	O
dawn	O
until	O
nightfall	O
.	O
The	O
average	O
duration	O
of	O
the	O
daytime	O
fast	O
depends	O
on	O
the	O
date	O
and	O
the	O
place	O
of	O
residence	O
[	O
1	O
]	O
,	O
since	O
the	O
Muslim	O
calendar	O
follows	O
the	O
lunar	O
system	O
and	O
each	O
month	O
moves	O
through	O
the	O
solar	O
seasons	O
.	O
Some	O
researchers	O
consider	O
this	O
practice	O
a	O
model	O
of	O
intermittent	O
fasting	O
,	O
characterised	O
by	O
the	O
sudden	O
introduction	O
of	O
modifications	O
in	O
dietary	O
habits	O
[	O
2	O
]	O
.	O
In	O
general	O
,	O
Muslims	O
have	O
two	O
meals	O
during	O
the	O
night	O
,	O
one	O
when	O
the	O
fast	O
is	O
broken	O
,	O
shortly	O
after	O
sunset	O
,	O
and	O
the	O
other	O
just	O
before	O
sunrise	O
.	O
This	O
change	O
in	O
eating	O
schedules	O
also	O
affects	O
other	O
activities	O
of	O
daily	O
life	O
[	O
3	O
]	O
.	O

The	O
effects	O
of	O
Ramadan	O
on	O
nutritional	O
health	O
have	O
been	O
widely	O
studied	O
in	O
countries	O
with	O
a	O
Muslim	O
majority	O
,	O
but	O
few	O
such	O
studies	O
have	O
been	O
undertaken	O
with	O
respect	O
to	O
women	O
in	O
a	O
Western	O
context	O
,	O
although	O
in	O
these	O
settings	O
,	O
too	O
,	O
it	O
is	O
women	O
who	O
are	O
mainly	O
responsible	O
for	O
family	O
care	O
[	O
4	O
]	O
.	O
Moreover	O
,	O
women	O
are	O
usually	O
more	O
vulnerable	O
to	O
certain	O
pathologies	O
,	O
especially	O
those	O
related	O
to	O
nutrition	O
[	O
5	O
]	O
.	O
For	O
many	O
years	O
,	O
obesity	O
has	O
been	O
a	O
major	O
problem	O
worldwide	O
,	O
even	O
in	O
European	O
countries	O
where	O
the	O
Mediterranean	O
diet	O
is	O
deeply	O
rooted	O
.	O
For	O
example	O
,	O
in	O
Spain	O
,	O
levels	O
of	O
obesity	O
have	O
risen	O
throughout	O
the	O
population	O
,	O
but	O
especially	O
among	O
adult	O
women	O
[	O
6	O
]	O
.	O
In	O
view	O
of	O
these	O
considerations	O
,	O
together	O
with	O
forecasts	O
of	O
continuing	O
rises	O
in	O
overweight	O
-	O
obesity	O
[	O
7	O
]	O
and	O
taking	O
into	O
account	O
the	O
known	O
association	O
between	O
visceral	O
adipose	O
tissue	O
and	O
cardiovascular	O
health	O
[	O
8	O
]	O
,	O
the	O
present	O
community	O
-	O
bases	O
nursing	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
prevalence	O
of	O
overweight	O
and	O
obesity	O
in	O
a	O
group	O
of	O
Muslim	O
women	O
living	O
in	O
a	O
Western	O
society	O
.	O
The	O
study	O
consists	O
of	O
an	O
analysis	O
of	O
nutritional	O
habits	O
,	O
of	O
compliance	O
with	O
recommendations	O
for	O
micronutrient	O
and	O
macronutrient	O
intake	O
,	O
and	O
of	O
whether	O
the	O
observance	O
of	O
Ramadan	O
strictures	O
is	O
associated	O
with	O
variables	O
related	O
to	O
cardiovascular	O
risk	O
.	O
This	O
follow	O
-	O
up	O
cohort	B-methodology
study	I-methodology
was	O
conducted	O
on	O
a	O
female	O
Muslim	O
population	O
resident	O
in	O
Melilla	O
,	O
a	O
Spanish	O
city	O
on	O
the	O
coast	O
of	O
North	O
Africa	O
.	O
The	O
sample	O
initially	O
consisted	O
of	O
62	O
women	O
,	O
aged	O
18	O
–	O
61	O
years	O
.	O
All	O
participants	O
were	O
Muslim	O
women	O
,	O
of	O
legal	O
age	O
,	O
who	O
voluntarily	O
observed	O
the	O
Ramadan	O
precepts	O
.	O
Women	O
with	O
a	O
chronic	O
or	O
acute	O
disease	O
,	O
or	O
who	O
were	O
pregnant	O
or	O
had	O
a	O
metal	O
prosthesis	O
were	O
excluded	O
.	O
Figure	O
1	O
shows	O
the	O
flow	O
chart	O
for	O
the	O
sessions	O
conducted	O
.	O
In	O
accordance	O
with	O
the	O
calendar	O
for	O
Ramadan	O
during	O
the	O
study	O
period	O
,	O
the	O
first	O
session	O
took	O
place	O
one	O
month	O
before	O
the	O
start	O
of	O
the	O
fast	O
.	O
The	O
second	O
session	O
was	O
held	O
one	O
week	O
before	O
the	O
start	O
of	O
Ramadan	O
,	O
the	O
third	O
in	O
the	O
last	O
week	O
of	O
Ramadan	O
and	O
the	O
final	O
one	O
,	O
three	O
months	O
after	O
Ramadan	O
had	O
ended	O
.	O
In	O
Session	O
1	O
,	O
each	O
participant	O
was	O
given	O
a	O
dietary	O
record	O
to	O
be	O
completed	O
before	O
the	O
start	O
of	O
Ramadan	O
,	O
and	O
anthropometric	O
and	O
body	O
composition	O
parameters	O
were	O
measured	O
and	O
recorded	O
.	O

In	O
Session	O
2	O
,	O
these	O
dietary	O
questionnaires	O
were	O
collected	O
,	O
those	O
to	O
be	O
completed	O
during	O
Ramadan	O
were	O
handed	O
out	O
,	O
and	O
the	O
second	O
measurement	O
and	O
recording	O
of	O
anthropometric	O
and	O
body	O
composition	O
parameters	O
was	O
performed	O
.	O
This	O
process	O
was	O
repeated	O
in	O
Session	O
3	O
,	O
and	O
in	O
the	O
final	O
session	O
,	O
the	O
last	O
measurement	O
and	O
recording	O
of	O
anthropometric	O
and	O
body	O
composition	O
parameters	O
was	O
carried	O
out	O
.	O
Of	O
the	O
62	O
women	O
who	O
were	O
given	O
the	O
dietary	O
record	O
to	O
be	O
completed	O
during	O
the	O
corresponding	O
moments	O
of	O
the	O
study	O
,	O
only	O
45	O
delivered	O
the	O
two	O
records	O
completed	O
in	O
full	O
.	O
Thus	O
,	O
the	O
loss	O
to	O
study	O
was	O
27	O
.	O
4	O
%	O
.	O
However	O
,	O
there	O
is	O
no	O
evidence	O
that	O
the	O
loss	O
of	O
these	O
data	O
was	O
related	O
to	O
the	O
nutritional	O
status	O
of	O
the	O
participants	O
.	O
We	O
suggest	O
that	O
this	O
reluctance	O
to	O
participate	O
might	O
have	O
arisen	O
from	O
the	O
study	B-methodology
design	I-methodology
and	O
/	O
or	O
the	O
characteristics	O
of	O
the	O
religious	O
precepts	O
studied	O
.	O
This	O
study	O
was	O
conducted	O
in	O
full	O
accordance	O
with	O
the	O
guidelines	B-methodology
and	O
ethical	O
principles	O
for	O
medical	O
research	O
in	O
human	O
beings	O
established	O
by	O
the	O
World	O
Medical	O
Association	O
in	O
the	O
Declaration	O
of	O
Helsinki	O
(	O
Finland	O
,	O
1994	O
)	O
,	O
and	O
as	O
reviewed	O
in	O
successive	O
assemblies	O
,	O
the	O
most	O
recent	O
of	O
which	O
was	O
the	O
64th	O
General	O
Assembly	O
,	O
held	O
in	O
Fortaleza	O
(	O
Brazil	O
)	O
in	O
October	O
2013	O
.	O
All	O
participants	O
were	O
informed	O
in	O
detail	O
about	O
the	O
study	O
goals	O
and	O
characteristics	O
,	O
and	O
gave	O
signed	O
informed	O
consent	O
to	O
take	O
part	O
.	O
Furthermore	O
,	O
in	O
accordance	O
with	O
the	O
General	O
Regulations	O
on	O
Data	O
Protection	O
and	O
with	O
Organic	O
Law	O
3	O
/	O
2018	O
,	O
of	O
5	O
December	O
,	O
on	O
the	O
protection	O
of	O
personal	O
data	O
and	O
digital	O
rights	O
,	O
data	O
confidentiality	O
was	O
assured	O
;	O
the	O
participants	O
’	O
anonymity	O
was	O
protected	O
by	O
the	O
use	O
of	O
codes	O
.	O
Moreover	O
,	O
these	O
data	O
were	O
used	O
solely	O
for	O
the	O
scientific	O
purposes	O
presented	O
.	O
Anthropometric	O
variables	O
were	O
measured	O
following	O
the	O
protocol	O
of	O
the	O
International	O
Society	O
for	O
the	O
Advancement	O
of	O
Kinanthropometry	O
[	O
9	O
]	O
.	O
All	O
variables	O
were	O
measured	O
at	O
the	O
same	O
time	O
of	O
day	O
,	O
between	O
9	O
a	O
.	O
m	O
.	O
and	O
12	O
noon	O
,	O
and	O
by	O
the	O
same	O
person	O
.	O
The	O
participants	O
were	O
asked	O
to	O
attend	O
without	O
having	O
eaten	O
beforehand	O
,	O
wearing	O
comfortable	O
clothes	O
,	O
with	O
no	O
metal	O
objects	O
in	O
direct	O
contact	O
with	O
the	O
skin	O
,	O
with	O
an	O
empty	O
urinary	O
bladder	O
and	O
without	O
having	O
practiced	O
intense	O
physical	O
exercise	O
in	O
the	O
previous	O
twelve	O
hours	O
.	O

The	O
following	O
anthropometric	O
variables	O
were	O
studied	O
:	O
total	O
body	O
weight	O
(	O
BW	O
)	O
,	O
height	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
waist	O
circumference	O
(	O
WC	O
)	O
,	O
waist	O
/	O
hip	O
ratio	O
(	O
W	O
/	O
Hp	O
)	O
and	O
waist	O
/	O
height	O
ratio	O
(	O
W	O
/	O
Ht	O
)	O
.	O
Waist	O
and	O
hip	O
circumferences	O
were	O
measured	O
with	O
a	O
flexible	O
,	O
non	O
-	O
extensible	O
Seca®	O
tape	O
measure	O
,	O
with	O
an	O
accuracy	O
of	O
1	O
mm	O
.	O
The	O
waist	O
circumference	O
was	O
measured	O
at	O
the	O
midpoint	O
between	O
the	O
lower	O
rib	O
margin	O
and	O
the	O
iliac	O
crest	O
,	O
with	O
the	O
abdomen	O
relaxed	O
.	O
The	O
hip	O
circumference	O
was	O
measured	O
at	O
the	O
level	O
of	O
maximum	O
circumference	O
of	O
the	O
buttocks	O
.	O
Each	O
perimeter	O
was	O
measured	O
in	O
triplicate	O
by	O
the	O
same	O
observer	O
,	O
and	O
the	O
mean	O
value	O
was	O
taken	O
.	O
The	O
W	O
/	O
Hp	O
ratio	O
was	O
calculated	O
by	O
dividing	O
the	O
waist	O
circumference	O
(	O
cm	O
)	O
by	O
the	O
hip	O
circumference	O
(	O
cm	O
)	O
.	O
For	O
this	O
ratio	O
,	O
a	O
score	O
<	O
0	O
.	O
8	O
was	O
considered	O
within	O
the	O
range	O
of	O
normal	O
values	O
.	O
The	O
W	O
/	O
Ht	O
ratio	O
was	O
calculated	O
by	O
dividing	O
the	O
waist	O
circumference	O
(	O
cm	O
)	O
by	O
the	O
height	O
(	O
cm	O
)	O
.	O
For	O
this	O
ratio	O
,	O
a	O
score	O
of	O
0	O
.	O
4	O
–	O
0	O
.	O
5	O
was	O
considered	O
normal	O
.	O
Height	O
was	O
measured	O
using	O
a	O
portable	O
TANITA®	O
stadiometer	O
,	O
with	O
the	O
participant	O
standing	O
upright	O
,	O
with	O
her	O
head	O
oriented	O
according	O
to	O
the	O
Frankfort	O
plane	O
and	O
with	O
the	O
trunk	O
and	O
pelvis	O
in	O
continuous	O
contact	O
with	O
the	O
vertical	O
branch	O
of	O
the	O
stadiometer	O
.	O
The	O
horizontal	O
branch	O
was	O
then	O
applied	O
to	O
the	O
top	O
of	O
the	O
head	O
.	O
From	O
these	O
weight	O
and	O
height	O
measurements	O
,	O
the	O
BMI	O
was	O
calculated	O
to	O
categorise	O
the	O
participant	O
as	O
normoweight	O
,	O
overweight	O
or	O
obese	O
in	O
accordance	O
with	O
the	O
criteria	O
established	O
by	O
the	O
World	O
Health	O
Organisation	O
(	O
WHO	O
)	O
[	O
10	O
]	O
.	O
In	O
addition	O
to	O
the	O
above	O
,	O
a	O
body	O
composition	O
study	O
was	O
conducted	O
using	O
a	O
TANITA®	O
SC	O
-	O
330	O
body	O
composition	O
analyser	O
,	O
which	O
is	O
self	O
-	O
calibrating	O
and	O
has	O
an	O
accuracy	O
of	O
±100	O
g	O
.	O
This	O
apparatus	O
was	O
also	O
used	O
for	O
weight	O
estimation	O
.	O
The	O
following	O
body	O
composition	O
variables	O
were	O
determined	O
:	O
percentage	O
of	O
fat	O
mass	O
,	O
total	O
fat	O
mass	O
,	O
lean	O
mass	O
,	O
muscle	O
mass	O
,	O
percentage	O
of	O
water	O
content	O
,	O
total	O
water	O
content	O
,	O
visceral	O
fat	O
and	O
bone	O
mass	O
.	O

Dietary	O
intake	O
was	O
determined	O
using	O
a	O
72	O
-	O
h	O
dietary	O
record	O
,	O
in	O
which	O
the	O
participants	O
noted	O
the	O
types	O
and	O
amounts	O
of	O
food	O
consumed	O
,	O
and	O
the	O
procedure	O
used	O
for	O
food	O
preparation	O
.	O
To	O
maximise	O
the	O
precision	O
of	O
the	O
quantities	O
recorded	O
,	O
each	O
participant	O
was	O
given	O
an	O
information	O
sheet	O
with	O
equivalents	O
and	O
other	O
practical	O
indications	O
for	O
use	O
in	O
the	O
home	O
.	O
The	O
dietary	O
recommendations	O
proposed	O
by	O
the	O
Spanish	O
Society	O
of	O
Community	O
Nutrition	O
(	O
SENC	O
)	O
in	O
2011	O
[	O
11	O
]	O
and	O
the	O
WHO	O
in	O
2008	O
[	O
12	O
]	O
were	O
used	O
to	O
assess	O
the	O
compliance	O
with	O
recommendations	O
for	O
micronutrient	O
and	O
macronutrient	O
intake	O
of	O
Muslim	O
women	O
in	O
each	O
session	O
.	O
All	O
statistical	O
analyses	O
were	O
performed	O
using	O
IBM	O
SPSS	O
software	O
v	O
.	O
24	O
(	O
SPSS	O
Inc	O
.	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O
For	O
the	O
descriptive	O
analysis	O
,	O
the	O
mean	O
and	O
standard	O
deviation	O
were	O
calculated	O
for	O
each	O
quantitative	O
variable	O
,	O
while	O
the	O
qualitative	O
variables	O
were	O
described	O
by	O
proportions	O
.	O
All	O
variables	O
were	O
assessed	O
in	O
each	O
of	O
the	O
four	O
study	O
sessions	O
,	O
which	O
were	O
compared	O
by	O
a	O
one	O
-	O
way	O
ANOVA	O
.	O
Student	O
’	O
s	O
t	O
-	O
test	O
(	O
with	O
Levene	O
’	O
s	O
test	O
for	O
the	O
equality	O
of	O
variances	O
)	O
was	O
applied	O
for	O
the	O
variables	O
that	O
presented	O
a	O
normal	O
distribution	O
,	O
and	O
,	O
otherwise	O
,	O
the	O
Wilcoxon	O
test	O
was	O
used	O
.	O
The	O
normality	O
of	O
the	O
distributions	O
was	O
verified	O
using	O
the	O
Shapiro	O
-	O
Wilk	O
test	O
.	O
The	O
effect	O
of	O
fasting	O
during	O
Ramadan	O
(	O
Sessions	O
2	O
and	O
3	O
)	O
was	O
observed	O
using	O
the	O
Wilcoxon	O
test	O
for	O
paired	O
samples	O
.	O
As	O
some	O
values	O
were	O
highly	O
dispersed	O
,	O
an	O
analysis	O
of	O
the	O
medians	O
of	O
the	O
variables	O
was	O
also	O
conducted	O
,	O
before	O
and	O
during	O
Ramadan	O
.	O
Finally	O
,	O
to	O
determine	O
the	O
possible	O
influence	O
of	O
fasting	O
on	O
cardiovascular	O
risk	O
,	O
an	O
analysis	O
of	O
odds	O
ratios	O
,	O
with	O
95	O
%	O
confidence	O
intervals	O
,	O
was	O
carried	O
out	O
,	O
using	O
a	O
logistic	O
regression	O
model	O
adjusted	O
for	O
the	O
present	O
age	O
and	O
for	O
earliest	O
age	O
on	O
starting	O
observance	O
of	O
Ramadan	O
.	O
In	O
every	O
case	O
,	O
the	O
level	O
of	O
significance	O
assumed	O
was	O
p	O
<	O
0	O
.	O
05	O
.	O
Table	O
1	O
shows	O
that	O
slightly	O
over	O
half	O
of	O
the	O
participants	O
were	O
single	O
,	O
while	O
nearly	O
34	O
%	O
were	O
married	O
(	O
33	O
.	O
9	O
%	O
)	O
;	O
the	O
women	O
’	O
s	O
mean	O
age	O
was	O
33	O
.	O
6	O
±	O
12	O
.	O
7	O
years	O
.	O
In	O
terms	O
of	O
education	O
background	O
,	O
the	O
sample	O
was	O
divided	O
into	O
the	O
women	O
who	O
had	O
completed	O
basic	O
,	O
secondary	O
or	O
higher	O
education	O
and	O
also	O
those	O
who	O
had	O
no	O
formal	O
education	O
.	O

Table	O
2	O
shows	O
that	O
the	O
mean	O
BMI	O
values	O
obtained	O
,	O
at	O
each	O
of	O
the	O
moments	O
studied	O
,	O
represent	O
overweight	O
or	O
obese	O
.	O
However	O
,	O
the	O
value	O
recorded	O
for	O
Session	O
2	O
was	O
significantly	O
higher	O
than	O
the	O
recorded	O
for	O
Session	O
3	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
Moreover	O
,	O
it	O
can	O
be	O
observed	O
a	O
decrease	O
of	O
obesity	O
prevalence	O
and	O
an	O
increase	O
of	O
overweight	O
prevalence	O
in	O
Session	O
3	O
,	O
in	O
comparison	O
to	O
Session	O
2	O
.	O
Similar	O
differences	O
between	O
these	O
two	O
moments	O
were	O
observed	O
in	O
the	O
mean	O
values	O
obtained	O
by	O
bioimpedance	O
for	O
the	O
percentage	O
of	O
fat	O
mass	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
visceral	O
fat	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
.	O
Among	O
the	O
anthropometric	O
values	O
related	O
to	O
central	O
adiposity	O
,	O
the	O
only	O
significant	O
differences	O
found	O
were	O
for	O
hip	O
circumference	O
(	O
p	O
=	O
0	O
.	O
008	O
)	O
,	O
between	O
Sessions	O
2	O
and	O
Session	O
3	O
.	O
Notably	O
,	O
the	O
mean	O
values	O
for	O
waist	O
circumference	O
and	O
W	O
/	O
Hp	O
were	O
above	O
normal	O
values	O
at	O
all	O
times	O
during	O
the	O
study	O
.	O
Table	O
3	O
shows	O
that	O
some	O
macronutrients	O
,	O
such	O
as	O
vitamin	O
D	O
and	O
calcium	O
,	O
do	O
not	O
undergo	O
significant	O
changes	O
during	O
fasting	O
(	O
p	O
=	O
0	O
.	O
843	O
and	O
p	O
=	O
0	O
.	O
200	O
,	O
respectively	O
)	O
.	O
However	O
,	O
a	O
significant	O
increase	O
was	O
observed	O
in	O
the	O
intake	O
of	O
phosphorus	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
,	O
cholesterol	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
trans	O
-	O
fatty	O
acids	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
,	O
vegetable	O
fibre	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
all	O
macronutrients	O
.	O
Figure	O
2	O
illustrates	O
the	O
imbalance	O
in	O
the	O
caloric	O
and	O
lipid	O
profiles	O
recorded	O
,	O
before	O
and	O
during	O
the	O
final	O
week	O
of	O
Ramadan	O
.	O
Table	O
4	O
shows	O
the	O
influence	O
of	O
the	O
fasting	O
state	O
(	O
before	O
and	O
during	O
Ramadan	O
)	O
on	O
the	O
variables	O
related	O
to	O
cardiovascular	O
risk	O
.	O
The	O
variables	O
related	O
to	O
central	O
adiposity	O
most	O
strongly	O
associated	O
with	O
the	O
observance	O
of	O
Ramadan	O
were	O
W	O
/	O
Hp	O
ratio	O
and	O
visceral	O
fat	O
,	O
with	O
an	O
adjusted	O
OR	O
of	O
1	O
.	O
62	O
and	O
of	O
1	O
.	O
61	O
respectively	O
.	O
Regarding	O
the	O
variables	O
derived	O
from	O
the	O
dietary	O
record	O
,	O
the	O
change	O
in	O
fasting	O
status	O
only	O
affected	O
potassium	O
(	O
OR	O
2	O
.	O
10	O
,	O
95	O
%	O
CI	O
[	O
1	O
.	O
01	O
,	O
4	O
.	O
35	O
]	O
)	O
,	O
which	O
became	O
abnormally	O
elevated	O
during	O
Ramadan	O
.	O

By	O
contrast	O
,	O
below	O
-	O
normal	O
values	O
were	O
obtained	O
during	O
Ramadan	O
for	O
monounsaturated	O
fatty	O
acids	O
(	O
OR	O
0	O
.	O
36	O
,	O
95	O
%	O
CI	O
[	O
0	O
.	O
17	O
,	O
0	O
.	O
78	O
]	O
)	O
and	O
total	O
cholesterol	O
(	O
OR	O
0	O
.	O
16	O
,	O
95	O
%	O
CI	O
[	O
0	O
.	O
06	O
,	O
0	O
.	O
39	O
]	O
)	O
.	O
The	O
BMI	O
is	O
the	O
most	O
widely	O
-	O
used	O
parameter	O
to	O
define	O
and	O
classify	O
people	O
as	O
overweight	O
and	O
obese	O
.	O
However	O
,	O
body	O
composition	O
techniques	O
provide	O
a	O
more	O
realistic	O
approximation	O
of	O
these	O
concepts	O
[	O
13	O
]	O
.	O
Accordingly	O
,	O
the	O
present	O
study	O
also	O
includes	O
bioimpedance	O
analysis	O
.	O
In	O
addition	O
,	O
measures	O
of	O
central	O
adiposity	O
are	O
obtained	O
,	O
to	O
evaluate	O
the	O
possible	O
effects	O
of	O
Ramadan	O
on	O
cardiovascular	O
health	O
.	O
Our	O
results	O
show	O
that	O
BMI	O
values	O
fell	O
during	O
Ramadan	O
,	O
which	O
corroborates	O
previous	O
research	O
in	O
this	O
area	O
,	O
conducted	O
in	O
different	O
countries	O
[	O
14	O
,	O
15	O
,	O
16	O
,	O
17	O
]	O
.	O
The	O
prevalence	O
of	O
obese	O
women	O
during	O
the	O
final	O
week	O
of	O
Ramadan	O
also	O
fell	O
,	O
which	O
is	O
in	O
consonance	O
with	O
the	O
decrease	O
of	O
the	O
percentage	O
of	O
body	O
fat	O
and	O
visceral	O
fat	O
also	O
observed	O
during	O
the	O
final	O
week	O
of	O
Ramadan	O
.	O
Despite	O
this	O
slight	O
decrease	O
of	O
obesity	O
prevalence	O
,	O
the	O
values	O
of	O
W	O
/	O
Hp	O
and	O
W	O
/	O
Ht	O
did	O
not	O
suffer	O
any	O
change	O
,	O
and	O
the	O
levels	O
were	O
above	O
the	O
normal	O
values	O
.	O
In	O
relation	O
to	O
the	O
changes	O
in	O
body	O
fat	O
that	O
are	O
associated	O
with	O
fasting	O
,	O
some	O
authors	O
have	O
affirmed	O
that	O
a	O
loss	O
of	O
body	O
weight	O
is	O
always	O
accompanied	O
by	O
a	O
corresponding	O
reduction	O
in	O
body	O
fat	O
.	O
Thus	O
,	O
in	O
a	O
study	O
carried	O
out	O
in	O
Sanliurfa	O
(	O
Turkey	O
)	O
,	O
a	O
significant	O
reduction	O
was	O
observed	O
in	O
the	O
percentage	O
of	O
body	O
fat	O
and	O
visceral	O
fat	O
,	O
according	O
to	O
bioimpedance	O
results	O
and	O
the	O
waist	O
/	O
hip	O
ratio	O
[	O
18	O
]	O
.	O
Another	O
investigation	O
,	O
in	O
Indonesia	O
,	O
also	O
measured	O
a	O
loss	O
of	O
body	O
fat	O
.	O
In	O
this	O
case	O
,	O
however	O
,	O
the	O
reduced	O
W	O
/	O
Hp	O
at	O
the	O
end	O
of	O
the	O
fasting	O
period	O
was	O
not	O
significant	O
[	O
19	O
]	O
.	O
In	O
the	O
present	O
investigation	O
,	O
a	O
significant	O
decrease	O
was	O
observed	O
in	O
the	O
percentage	O
of	O
body	O
fat	O
and	O
visceral	O
fat	O
obtained	O
by	O
bioimpedance	O
,	O
but	O
not	O
in	O
the	O
anthropometric	O
measurement	O
of	O
central	O
adiposity	O
.	O
Moreover	O
,	O
unlike	O
the	O
above	O
-	O
mentioned	O
studies	O
,	O
in	O
our	O
participants	O
the	O
W	O
/	O
Hp	O
and	O
W	O
/	O
Ht	O
ratios	O
were	O
always	O
above	O
the	O
recommended	O
values	O
.	O

In	O
addition	O
to	O
dietary	O
factors	O
,	O
the	O
participants	O
’	O
smoking	O
and	O
physical	O
activity	O
habits	O
were	O
considered	O
.	O
In	O
this	O
respect	O
,	O
none	O
of	O
the	O
women	O
in	O
our	O
study	O
were	O
smokers	O
,	O
and	O
all	O
claimed	O
to	O
have	O
maintained	O
the	O
same	O
level	O
of	O
physical	O
activity	O
during	O
Ramadan	O
as	O
in	O
the	O
rest	O
of	O
the	O
year	O
.	O
The	O
dietary	O
records	O
obtained	O
in	O
Sessions	O
2	O
and	O
3	O
revealed	O
a	O
certain	O
imbalance	O
in	O
the	O
intake	O
of	O
micronutrients	O
and	O
macronutrients	O
.	O
In	O
relation	O
to	O
the	O
intake	O
of	O
micronutrients	O
,	O
a	O
notable	O
finding	O
is	O
the	O
deficit	O
of	O
two	O
vitamins	O
that	O
are	O
essential	O
for	O
adults	O
(	O
according	O
to	O
a	O
study	O
of	O
nutritional	O
objectives	O
for	O
the	O
Spanish	O
population	O
)	O
[	O
11	O
]	O
,	O
namely	O
folic	O
acid	O
and	O
vitamin	O
D	O
.	O
Although	O
by	O
the	O
end	O
of	O
Ramadan	O
mean	O
levels	O
of	O
folic	O
acid	O
had	O
increased	O
significantly	O
,	O
the	O
dietary	O
record	O
obtained	O
in	O
Session	O
2	O
indicates	O
a	O
daily	O
intake	O
below	O
the	O
recommended	O
400	O
μg	O
/	O
day	O
for	O
women	O
aged	O
14	O
–	O
70	O
years	O
[	O
11	O
,	O
12	O
]	O
.	O
Similarly	O
,	O
the	O
intake	O
of	O
vitamin	O
D	O
was	O
well	O
below	O
the	O
recommended	O
10	O
µg	O
/	O
day	O
throughout	O
the	O
study	O
[	O
11	O
,	O
12	O
]	O
.	O
In	O
this	O
respect	O
,	O
the	O
increasing	O
presence	O
of	O
obesity	O
in	O
the	O
population	O
,	O
the	O
use	O
of	O
sunscreen	O
and	O
the	O
decreased	O
consumption	O
of	O
dairy	O
foods	O
all	O
tend	O
to	O
provoke	O
vitamin	O
D	O
deficiency	O
,	O
despite	O
the	O
many	O
hours	O
of	O
sunshine	O
received	O
in	O
this	O
part	O
of	O
Spain	O
[	O
20	O
]	O
.	O
Regarding	O
the	O
minerals	O
related	O
to	O
bone	O
health	O
,	O
the	O
participants	O
’	O
dietary	O
intake	O
of	O
phosphorus	O
was	O
high	O
,	O
both	O
in	O
Session	O
2	O
and	O
in	O
Session	O
3	O
.	O
Significantly	O
,	O
a	O
high	O
intake	O
of	O
phosphorus	O
and	O
a	O
low	O
intake	O
of	O
calcium	O
are	O
both	O
risk	O
factors	O
for	O
inadequate	O
bone	O
mineralisation	O
.	O
For	O
this	O
reason	O
,	O
it	O
is	O
normally	O
recommended	O
to	O
limit	O
the	O
consumption	O
of	O
processed	O
foods	O
,	O
which	O
are	O
the	O
main	O
source	O
of	O
inorganic	O
phosphates	O
[	O
21	O
]	O
.	O
In	O
addition	O
,	O
hyperphosphataemia	O
is	O
reported	O
to	O
have	O
a	O
negative	O
impact	O
on	O
cardiovascular	O
health	O
[	O
22	O
]	O
.	O
Another	O
mineral	O
that	O
presented	O
levels	O
of	O
dietary	O
intake	O
higher	O
than	O
the	O
dietary	O
recommendations	O
[	O
11	O
,	O
12	O
]	O
,	O
especially	O
during	O
Ramadan	O
,	O
was	O
potassium	O
.	O
This	O
may	O
be	O
due	O
to	O
the	O
substitution	O
of	O
salt	O
by	O
potassium	O
chloride	O
,	O
which	O
is	O
a	O
widespread	O
practice	O
in	O
the	O
preparation	O
of	O
processed	O
foods	O
,	O
as	O
a	O
means	O
of	O
preventing	O
arterial	O
hypertension	O
.	O
However	O
,	O
high	O
levels	O
of	O
sodium	O
intake	O
were	O
also	O
recorded	O
in	O
Sessions	O
2	O
and	O
3	O
.	O

The	O
excessive	O
consumption	O
of	O
salt	O
(	O
sodium	O
chloride	O
)	O
,	O
in	O
addition	O
to	O
its	O
widely	O
known	O
prejudicial	O
effects	O
,	O
favours	O
microvascular	O
endothelial	O
inflammation	O
,	O
anatomical	O
remodelling	O
and	O
other	O
functional	O
abnormalities	O
,	O
even	O
in	O
persons	O
with	O
normal	O
blood	O
pressure	O
[	O
23	O
]	O
.	O
Regarding	O
the	O
intake	O
of	O
macronutrients	O
,	O
the	O
dietary	O
records	O
reveal	O
an	O
imbalance	O
in	O
the	O
caloric	O
profile	O
in	O
Sessions	O
2	O
and	O
3	O
,	O
with	O
lipids	O
constituting	O
the	O
main	O
source	O
of	O
energy	O
,	O
to	O
the	O
detriment	O
of	O
carbohydrates	O
,	O
especially	O
during	O
the	O
final	O
week	O
of	O
Ramadan	O
.	O
These	O
data	O
differ	O
significantly	O
from	O
the	O
recommendations	O
by	O
the	O
SENC	O
[	O
11	O
]	O
.	O
In	O
our	O
study	O
,	O
the	O
intake	O
of	O
vegetable	O
fibre	O
was	O
significantly	O
augmented	O
during	O
Ramadan	O
,	O
and	O
the	O
levels	O
were	O
above	O
the	O
dietary	O
recommendations	O
[	O
11	O
,	O
12	O
]	O
.	O
The	O
decreased	O
intake	O
of	O
total	O
cholesterol	O
recorded	O
at	O
the	O
end	O
of	O
Ramadan	O
is	O
a	O
positive	O
trend	O
.	O
Nevertheless	O
,	O
the	O
mean	O
values	O
recorded	O
remained	O
above	O
the	O
recommended	O
level	O
[	O
11	O
,	O
12	O
]	O
.	O
These	O
findings	O
are	O
consistent	O
with	O
previous	O
dietary	O
research	O
carried	O
out	O
in	O
Spain	O
,	O
such	O
as	O
the	O
ENIDE	O
study	O
[	O
24	O
]	O
and	O
the	O
Food	O
Consumption	O
Panel	O
[	O
25	O
]	O
.	O
Similar	O
results	O
were	O
reported	O
by	O
the	O
ANIBES	O
study	O
,	O
which	O
recorded	O
a	O
dietary	O
imbalance	O
in	O
women	O
of	O
all	O
age	O
groups	O
,	O
but	O
especially	O
among	O
older	O
women	O
[	O
5	O
]	O
.	O
However	O
,	O
in	O
none	O
of	O
these	O
previous	O
studies	O
was	O
the	O
participants	O
’	O
religion	O
taken	O
into	O
consideration	O
.	O
On	O
the	O
other	O
hand	O
,	O
and	O
despite	O
the	O
influence	O
that	O
religion	O
may	O
exert	O
on	O
nutritional	O
habits	O
,	O
a	O
relevant	O
consideration	O
is	O
that	O
the	O
Muslim	O
women	O
in	O
our	O
study	O
reside	O
in	O
a	O
Western	O
European	O
context	O
.	O
The	O
study	O
results	O
we	O
report	O
highlight	O
the	O
presence	O
of	O
various	O
cardiovascular	O
risk	O
factors	O
among	O
the	O
participants	O
,	O
chiefly	O
overweight	O
/	O
obesity	O
and	O
high	O
waist	O
/	O
hip	O
and	O
waist	O
/	O
height	O
ratios	O
,	O
throughout	O
the	O
study	O
period	O
.	O
Moreover	O
,	O
the	O
weight	O
loss	O
observed	O
during	O
Ramadan	O
is	O
not	O
a	O
protective	O
factor	O
,	O
since	O
this	O
loss	O
is	O
fully	O
recovered	O
three	O
months	O
later	O
.	O
These	O
findings	O
are	O
in	O
line	O
with	O
previous	O
reports	O
,	O
according	O
to	O
which	O
the	O
average	O
weight	O
loss	O
during	O
Ramadan	O
is	O
just	O
over	O
one	O
kilogram	O
,	O
which	O
is	O
subsequently	O
recovered	O
or	O
even	O
increased	O
[	O
26	O
,	O
27	O
]	O
.	O
Another	O
study	O
concluded	O
that	O
Ramadan	O
observance	O
had	O
a	O
neutral	O
effect	O
on	O
health	O
,	O
in	O
view	O
of	O
the	O
ephemeral	O
nature	O
of	O
the	O
changes	O
recorded	O
[	O
28	O
]	O
.	O

In	O
addition	O
,	O
we	O
report	O
an	O
association	O
among	O
the	O
observance	O
of	O
Ramadan	O
and	O
the	O
presence	O
of	O
elevated	O
W	O
/	O
Hp	O
ratio	O
and	O
visceral	O
fat	O
,	O
variables	O
which	O
have	O
been	O
shown	O
to	O
be	O
associated	O
with	O
cardiometabolic	O
risk	O
factors	O
[	O
29	O
]	O
.	O
These	O
results	O
are	O
not	O
in	O
agreement	O
with	O
those	O
of	O
Silveira	O
et	O
al	O
.	O
[	O
30	O
]	O
and	O
Yang	O
et	O
al	O
.	O
[	O
31	O
]	O
,	O
who	O
reported	O
that	O
intermittent	O
fasting	O
had	O
positive	O
effects	O
on	O
reducing	O
cardiovascular	O
risk	O
factors	O
in	O
obese	O
women	O
.	O
These	O
differences	O
are	O
probably	O
due	O
to	O
the	O
non	O
-	O
compliance	O
with	O
dietary	O
recommendations	O
by	O
the	O
participants	O
of	O
our	O
study	O
,	O
which	O
have	O
been	O
previously	O
discussed	O
.	O
Regarding	O
the	O
dietary	O
habits	O
observed	O
,	O
only	O
the	O
increased	O
potassium	O
intake	O
represents	O
a	O
special	O
health	O
risk	O
during	O
Ramadan	O
.	O
However	O
,	O
it	O
is	O
unknown	O
whether	O
the	O
elevated	O
potassium	O
levels	O
associated	O
with	O
increased	O
dietary	O
intake	O
have	O
adverse	O
effects	O
among	O
the	O
general	O
population	O
since	O
,	O
to	O
date	O
,	O
the	O
only	O
studies	O
conducted	O
in	O
this	O
respect	O
have	O
focused	O
on	O
adults	O
with	O
normal	O
renal	O
function	O
[	O
32	O
]	O
.	O
Nevertheless	O
,	O
our	O
findings	O
regarding	O
the	O
dietary	O
habits	O
of	O
the	O
participants	O
corroborate	O
the	O
generalised	O
trend	O
away	O
from	O
the	O
Mediterranean	O
diet	O
in	O
many	O
European	O
countries	O
,	O
despite	O
the	O
evidence	O
of	O
its	O
importance	O
in	O
preventing	O
cardiovascular	O
risks	O
[	O
33	O
]	O
.	O
A	O
relevant	O
consideration	O
is	O
the	O
geographic	O
context	O
of	O
the	O
city	O
of	O
Melilla	O
,	O
which	O
is	O
subject	O
to	O
the	O
cultural	O
influence	O
of	O
neighbouring	O
countries	O
in	O
the	O
Middle	O
East	O
and	O
North	O
Africa	O
.	O
In	O
these	O
regions	O
,	O
it	O
is	O
socially	O
acceptable	O
,	O
or	O
even	O
desirable	O
,	O
for	O
women	O
to	O
be	O
overweight	O
[	O
34	O
]	O
.	O
The	O
possible	O
influence	O
of	O
Arab	O
culture	O
might	O
be	O
apparent	O
in	O
the	O
fact	O
that	O
more	O
than	O
half	O
of	O
the	O
women	O
in	O
our	O
study	O
perceived	O
themselves	O
as	O
having	O
normal	O
weight	O
,	O
despite	O
the	O
objectively	O
high	O
values	O
recorded	O
.	O
In	O
summary	O
,	O
all	O
of	O
the	O
participants	O
were	O
overweight	O
or	O
obese	O
.	O
Although	O
their	O
BMI	O
values	O
decreased	O
during	O
Ramadan	O
,	O
they	O
had	O
returned	O
to	O
baseline	O
three	O
months	O
later	O
.	O
At	O
no	O
stage	O
of	O
the	O
study	O
did	O
the	O
participants	O
comply	O
with	O
the	O
recommendations	O
for	O
the	O
intake	O
of	O
macronutrients	O
and	O
micronutrients	O
,	O
but	O
the	O
imbalance	O
was	O
heightened	O
during	O
Ramadan	O
.	O
For	O
this	O
reason	O
,	O
it	O
is	O
necessary	O
to	O
ensure	O
healthy	O
fasting	O
during	O
Ramadan	O
by	O
promoting	O
a	O
balanced	O
intake	O
of	O
macronutrients	O
and	O
micronutrients	O
.	O

Among	O
the	O
strengths	O
of	O
our	O
study	O
,	O
to	O
our	O
knowledge	O
it	O
is	O
pioneering	O
in	O
the	O
sense	O
that	O
no	O
previous	O
investigation	O
has	O
been	O
made	O
of	O
the	O
dietary	O
impact	O
of	O
fasting	O
,	O
as	O
a	O
feature	O
of	O
religious	O
observance	O
by	O
Muslim	O
women	O
before	O
,	O
during	O
and	O
after	O
Ramadan	O
.	O
Among	O
its	O
limitations	O
,	O
it	O
was	O
not	O
possible	O
to	O
analyse	O
the	O
participants	O
’	O
lipid	O
profile	O
during	O
Ramadan	O
,	O
as	O
almost	O
all	O
of	O
them	O
stated	O
that	O
drawing	O
a	O
blood	O
sample	O
might	O
invalidate	O
their	O
fast	O
.	O
Another	O
limitation	O
was	O
that	O
the	O
sample	O
size	O
of	O
our	O
study	O
is	O
low	O
.	O
The	O
BMI	O
values	O
of	O
our	O
participants	O
decreased	O
during	O
Ramadan	O
,	O
but	O
they	O
had	O
returned	O
to	O
baseline	O
three	O
months	O
later	O
.	O
Moreover	O
,	O
the	O
participants	O
did	O
not	O
comply	O
with	O
the	O
recommendations	O
for	O
the	O
intake	O
of	O
macronutrients	O
and	O
micronutrients	O
throughout	O
the	O
study	O
,	O
with	O
a	O
higher	O
imbalance	O
during	O
Ramadan	O
.	O
Despite	O
the	O
association	O
observed	O
between	O
the	O
observance	O
of	O
Ramadan	O
and	O
the	O
visceral	O
fat	O
and	O
W	O
/	O
Hp	O
ratio	O
,	O
it	O
cannot	O
be	O
concluded	O
that	O
Ramadan	O
observance	O
has	O
a	O
direct	O
impact	O
on	O
cardiovascular	O
health	O
.	O
To	O
clarify	O
these	O
questions	O
,	O
further	O
study	O
is	O
necessary	O
,	O
in	O
a	O
Western	O
European	O
context	O
,	O
such	O
as	O
the	O
one	O
we	O
describe	O
,	O
including	O
,	O
in	O
addition	O
,	O
Muslim	O
women	O
of	O
normal	O
weight	O
.	O
For	O
the	O
present	O
,	O
however	O
,	O
we	O
consider	O
it	O
necessary	O
to	O
put	O
into	O
practice	O
policies	O
and	O
actions	O
aimed	O
at	O
promoting	O
nutritional	O
health	O
and	O
encouraging	O
year	O
-	O
round	O
self	O
-	O
care	O
among	O
adult	O
Muslim	O
women	O
,	O
since	O
only	O
the	O
establishment	O
of	O
appropriate	O
lifestyle	O
habits	O
will	O
ensure	O
healthy	O
fasting	O
during	O
the	O
observance	O
of	O
religious	O
precepts	O
.	O
The	O
authors	O
thank	O
all	O
the	O
Muslim	O
women	O
who	O
participated	O
in	O
this	O
study	O
and	O
made	O
this	O
work	O
possible	O
.	O
They	O
also	O
thank	O
the	O
Regional	O
Hospital	O
of	O
Melilla	O
and	O
Casa	O
de	O
la	O
Juventud	O
in	O
the	O
same	O
city	O
for	O
enabling	O
the	O
use	O
of	O
their	O
facilities	O
.	O
Publisher	O
’	O
s	O
Note	O
:	O
MDPI	O
stays	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O

Conceptualisation	O
,	O
E	O
.	O
G	O
.	O
-	O
J	O
.	O
and	O
J	O
.	O
S	O
.	O
-	O
R	O
.	O
;	O
methodology	O
,	O
E	O
.	O
G	O
.	O
-	O
J	O
.	O
and	O
J	O
.	O
S	O
.	O
-	O
R	O
.	O
;	O
validation	O
,	O
E	O
.	O
G	O
.	O
-	O
J	O
.	O
,	O
J	O
.	O
S	O
.	O
-	O
R	O
.	O
and	O
M	O
.	O
L	O
.	O
-	O
B	O
.	O
;	O
formal	O
analysis	O
,	O
M	O
.	O
Á	O
.	O
M	O
.	O
-	O
A	O
.	O
;	O
investigation	O
,	O
E	O
.	O
G	O
.	O
-	O
J	O
.	O
,	O
J	O
.	O
S	O
.	O
-	O
R	O
.	O
and	O
M	O
.	O
L	O
.	O
-	O
B	O
.	O
;	O
resources	O
,	O
M	O
.	O
L	O
.	O
-	O
B	O
.	O
;	O
data	O
curation	O
,	O
M	O
.	O
L	O
.	O
-	O
B	O
.	O
and	O
Á	O
.	O
F	O
.	O
-	O
A	O
.	O
;	O
writing	O
—	O
original	O
draft	O
preparation	O
,	O
M	O
.	O
L	O
.	O
-	O
B	O
.	O
and	O
Á	O
.	O
F	O
.	O
-	O
A	O
.	O
;	O
writing	O
—	O
review	O
and	O
editing	O
,	O
E	O
.	O
G	O
.	O
-	O
J	O
.	O
and	O
J	O
.	O
S	O
.	O
-	O
R	O
.	O
;	O
visualisation	O
,	O
Á	O
.	O
F	O
.	O
-	O
A	O
.	O
;	O
supervision	O
,	O
J	O
.	O
S	O
.	O
-	O
R	O
.	O
;	O
project	O
administration	O
,	O
E	O
.	O
G	O
.	O
-	O
J	O
.	O
All	O
authors	O
have	O
read	O
and	O
agreed	O
to	O
the	O
published	O
version	O
of	O
the	O
manuscript	O
.	O
This	O
research	O
received	O
no	O
external	O
funding	O
.	O
The	O
study	O
was	O
conducted	O
according	O
to	O
the	O
guidelines	B-methodology
of	O
the	O
Declaration	O
of	O
Helsinki	O
,	O
and	O
approved	O
by	O
the	O
Regional	O
Hospital	O
of	O
Melilla	O
(	O
protocol	O
code	O
201600500010163	O
and	O
date	O
of	O
approval	O
:	O
24	O
October	O
2016	O
)	O
.	O
Informed	O
consent	O
was	O
obtained	O
from	O
all	O
subjects	O
involved	O
in	O
the	O
study	O
.	O
The	O
data	O
presented	O
in	O
this	O
study	O
are	O
available	O
on	O
request	O
from	O
the	O
corresponding	O
author	O
.	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O

Effect	O
of	O
Long	O
-	O
Term	O
and	O
Short	O
-	O
Term	O
Imbalanced	O
Zn	O
Manipulation	O
on	O
Gut	O
Microbiota	O
and	O
Screening	O
for	O
Microbial	O
Markers	O
Sensitive	O
to	O
Zinc	O
Status	O
dietary	O
zinc	O
;	O
intestinal	O
microbiome	O
;	O
short	O
-	O
chain	O
fatty	O
acids	O
;	O
zinc	O
biomarker	O
Zinc	O
(	O
Zn	O
)	O
imbalance	O
is	O
a	O
common	O
single	O
-	O
nutrient	O
disorder	O
worldwide	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
short	O
-	O
term	O
and	O
long	O
-	O
term	O
effects	O
of	O
imbalanced	O
dietary	O
zinc	O
in	O
the	O
intestinal	O
microbiome	O
.	O
Here	O
,	O
3	O
-	O
week	O
-	O
old	O
C57BL	O
/	O
6	O
mice	O
were	O
fed	O
diets	O
supplemented	O
with	O
Zn	O
at	O
the	O
doses	O
of	O
0	O
(	O
low	O
Zn	O
)	O
,	O
30	O
(	O
control	O
Zn	O
)	O
,	O
150	O
(	O
high	O
Zn	O
)	O
,	O
and	O
600	O
mg	O
/	O
kg	O
of	O
body	O
weight	O
(	O
excess	O
Zn	O
)	O
for	O
4	O
weeks	O
(	O
short	O
term	O
)	O
and	O
8	O
weeks	O
(	O
long	O
term	O
)	O
.	O
The	O
gut	O
bacterial	O
composition	O
at	O
the	O
phyla	O
,	O
genus	O
,	O
and	O
species	O
levels	O
were	O
changed	O
as	O
the	O
result	O
of	O
the	O
imbalanced	O
Zn	O
diet	O
(	O
e	O
.	O
g	O
.	O
,	O
Lactobacillus	O
reuteri	O
and	O
Akkermansia	O
muciniphila	O
)	O
.	O
Moreover	O
,	O
pathways	O
including	O
carbohydrate	O
,	O
glycan	O
,	O
and	O
nucleotide	O
metabolism	O
were	O
decreased	O
by	O
a	O
short	O
-	O
term	O
low	O
-	O
Zn	O
diet	O
.	O
Valeriate	O
production	O
was	O
suppressed	O
by	O
a	O
long	O
-	O
term	O
low	O
-	O
Zn	O
diet	O
.	O
Pathways	O
such	O
as	O
drug	O
resistance	O
and	O
infectious	O
diseases	O
were	O
upregulated	O
in	O
high	O
-	O
and	O
excess	O
-	O
Zn	O
diets	O
over	O
4	O
-	O
week	O
and	O
8	O
-	O
week	O
intervals	O
.	O
Long	O
-	O
term	O
zinc	O
fortification	O
doses	O
,	O
especially	O
at	O
the	O
high	O
-	O
Zn	O
level	O
,	O
suppressed	O
the	O
abundance	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
-	O
producing	O
genera	O
as	O
well	O
as	O
the	O
concentrations	O
of	O
metabolites	O
.	O
Finally	O
,	O
Melainabacteria	O
(	O
phylum	O
)	O
and	O
Desulfovibrio	O
sp	O
.	O
strain	O
ABHU2SB	O
(	O
species	O
)	O
were	O
identified	O
to	O
be	O
potential	O
markers	O
for	O
Zn	O
status	O
with	O
high	O
accuracy	O
(	O
area	O
under	O
the	O
curve	O
[	O
AUC	O
]	O
,	O
>	O
0	O
.	O
8	O
)	O
.	O
Collectively	O
,	O
this	O
study	O
identified	O
significant	O
changes	O
in	O
gut	O
microbial	O
composition	O
and	O
its	O
metabolite	O
concentration	O
in	O
altered	O
Zn	O
-	O
fed	O
mice	O
and	O
the	O
relevant	O
microbial	O
markers	O
for	O
Zn	O
status	O
.	O
IMPORTANCE	O
Zn	O
insufficiency	O
is	O
an	O
essential	O
health	O
problem	O
in	O
developing	O
countries	O
.	O

To	O
prevent	O
the	O
occurrence	O
of	O
zinc	O
deficit	O
,	O
zinc	O
fortification	O
and	O
supplementation	O
are	O
widely	O
used	O
.	O
However	O
,	O
in	O
developed	O
countries	O
,	O
the	O
amounts	O
of	O
Zn	O
consumed	O
often	O
exceed	O
the	O
tolerable	O
upper	O
intake	O
limit	O
.	O
Our	O
results	O
demonstrated	O
that	O
dietary	O
Zn	O
is	O
an	O
essential	O
mediator	O
of	O
microbial	O
community	O
structure	O
and	O
that	O
both	O
Zn	O
deficiency	O
and	O
Zn	O
overdose	O
can	O
generate	O
a	O
dysbiosis	O
in	O
the	O
gut	O
microbiota	O
.	O
Moreover	O
,	O
specific	O
microbial	O
biomarkers	O
of	O
Zn	O
status	O
were	O
identified	O
and	O
correlated	O
with	O
serum	O
Zn	O
level	O
.	O
Our	O
study	O
found	O
that	O
a	O
short	O
-	O
term	O
low	O
-	O
Zn	O
diet	O
(	O
0	O
mg	O
/	O
kg	O
)	O
and	O
a	O
long	O
-	O
term	O
high	O
-	O
zinc	O
diet	O
(	O
150	O
mg	O
/	O
kg	O
)	O
had	O
obvious	O
negative	O
effects	O
in	O
a	O
mouse	B-methodology
model	I-methodology
.	O
Thus	O
,	O
these	O
results	O
indicate	O
that	O
the	O
provision	O
and	O
duration	O
of	O
supplemental	O
Zn	O
should	O
be	O
approached	O
with	O
caution	O
.	O
Zinc	O
is	O
an	O
essential	O
nutrient	O
for	O
nearly	O
all	O
organisms	O
(	O
1	O
)	O
.	O
The	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
reported	O
that	O
at	O
least	O
30	O
%	O
of	O
the	O
world	O
population	O
is	O
affected	O
by	O
inadequate	O
zinc	O
,	O
especially	O
for	O
children	O
in	O
developing	O
countries	O
(	O
2	O
)	O
.	O
Zn	O
deficiency	O
may	O
induce	O
growth	O
retardation	O
,	O
hypogonadism	O
(	O
3	O
)	O
,	O
diarrhea	O
(	O
4	O
)	O
,	O
or	O
acrodermatitis	O
enteropathica	O
(	O
AE	O
)	O
(	O
5	O
)	O
.	O
Hence	O
,	O
additional	O
zinc	O
is	O
often	O
given	O
to	O
children	O
in	O
foods	O
,	O
drinks	O
,	O
and	O
nutritional	O
supplements	O
to	O
ensure	O
that	O
they	O
meet	O
their	O
physiological	O
requirements	O
for	O
growth	O
(	O
6	O
)	O
.	O
Nevertheless	O
,	O
the	O
amounts	O
of	O
Zn	O
consumed	O
often	O
exceed	O
well	O
-	O
established	O
nutritional	O
requirements	O
(	O
7	O
–	O
9	O
)	O
.	O
Recent	O
studies	O
reported	O
that	O
Zn	O
overdose	O
exposure	O
can	O
have	O
deleterious	O
consequences	O
,	O
such	O
as	O
decreasing	O
immune	O
function	O
,	O
altering	O
intestinal	O
absorptive	O
and	O
secretory	O
capacity	O
,	O
or	O
increasing	O
visceral	O
adiposity	O
(	O
10	O
–	O
12	O
)	O
.	O
The	O
human	O
gut	O
microbiome	O
has	O
emerged	O
as	O
a	O
major	O
component	O
in	O
host	O
health	O
status	O
over	O
the	O
past	O
decade	O
(	O
13	O
)	O
.	O
It	O
serves	O
several	O
important	O
functions	O
,	O
such	O
as	O
enhancement	O
of	O
immunity	O
and	O
prevention	O
of	O
allergens	O
and	O
generation	O
of	O
SCFAs	O
(	O
14	O
)	O
.	O
Alterations	O
in	O
dietary	O
zinc	O
intake	O
may	O
play	O
a	O
major	O
role	O
in	O
community	O
dynamics	O
and	O
interspecies	O
competition	O
in	O
the	O
intestine	O
.	O

Zn	O
deficiency	O
may	O
increase	O
susceptibility	O
to	O
bacterial	O
infection	O
,	O
such	O
as	O
Brucella	O
abortus	O
,	O
Salmonella	O
enterica	O
,	O
and	O
Campylobacter	O
jejuni	O
(	O
15	O
–	O
17	O
)	O
.	O
Little	O
is	O
known	O
about	O
how	O
Zn	O
overdose	O
affects	O
the	O
intestinal	O
flora	O
.	O
Zackular	O
et	O
al	O
.	O
have	O
shown	O
that	O
in	O
the	O
mouse	B-methodology
model	I-methodology
of	O
C	O
.	O
difficile	O
infection	O
,	O
excess	O
dietary	O
Zn	O
alters	O
the	O
gut	O
microbiota	O
and	O
decreases	O
resistance	O
to	O
C	O
.	O
difficile	O
infection	O
(	O
CDI	O
)	O
(	O
18	O
)	O
.	O
So	O
far	O
,	O
little	O
is	O
known	O
about	O
the	O
short	O
-	O
term	O
or	O
long	O
-	O
term	O
efficacy	O
of	O
imbalanced	O
dietary	O
zinc	O
in	O
the	O
intestinal	O
microbiome	O
in	O
young	O
animals	O
and	O
children	O
.	O
Currently	O
,	O
the	O
lack	O
of	O
a	O
reliable	O
,	O
responsive	O
,	O
and	O
specific	O
zinc	O
biomarker	O
has	O
made	O
the	O
quantification	O
and	O
characterization	O
of	O
Zn	O
imbalance	O
difficult	O
(	O
19	O
)	O
.	O
Lowe	O
and	O
coworkers	O
suggested	O
that	O
serum	O
,	O
plasma	O
,	O
hair	O
,	O
and	O
urinary	O
zinc	O
were	O
the	O
most	O
reliable	O
predictors	O
out	O
of	O
32	O
potential	O
biomarkers	O
in	O
humans	O
(	O
20	O
)	O
.	O
However	O
,	O
accurate	O
assessment	O
of	O
zinc	O
status	O
,	O
especially	O
in	O
marginal	O
imbalance	O
,	O
is	O
difficult	O
,	O
as	O
studies	O
have	O
shown	O
contradictory	O
and	O
inconsistent	O
results	O
.	O
To	O
solve	O
this	O
problem	O
,	O
the	O
WHO	O
and	O
the	O
International	O
Zinc	O
Nutrition	O
Consultative	O
Group	O
(	O
IZiNCG	O
)	O
have	O
put	O
forward	O
a	O
major	O
initiative	O
to	O
promote	O
the	O
development	O
of	O
reliable	O
Zn	O
biomarkers	O
(	O
21	O
)	O
.	O
Host	O
lifestyle	O
and	O
behaviors	O
can	O
be	O
reflected	O
by	O
human	O
gut	O
microbiome	O
variation	O
(	O
22	O
)	O
.	O
Moreover	O
,	O
dietary	O
metal	O
intake	O
is	O
one	O
of	O
the	O
most	O
critical	O
factors	O
affecting	O
the	O
composition	O
of	O
the	O
microbiome	O
(	O
23	O
)	O
.	O
Previous	O
findings	O
based	O
on	O
the	O
human	O
gut	O
have	O
enabled	O
the	O
tentative	O
prediction	O
of	O
urinary	O
arsenic	O
,	O
coronavirus	O
disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
,	O
and	O
adiposity	O
(	O
24	O
–	O
26	O
)	O
.	O
In	O
order	O
to	O
clarify	O
the	O
relationship	O
between	O
dietary	O
zinc	O
and	O
intestinal	O
microflora	O
,	O
we	O
fed	O
different	O
zinc	O
levels	O
to	O
mice	O
from	O
weaning	O
to	O
puberty	O
or	O
maturity	O
to	O
explore	O
the	O
effects	O
of	O
zinc	O
imbalance	O
on	O
intestinal	O
microflora	O
and	O
their	O
metabolites	O
(	O
SCFAs	O
)	O
and	O
screened	O
the	O
microbial	O
markers	O
sensitive	O
to	O
zinc	O
status	O
.	O

To	O
determine	O
the	O
effect	O
of	O
imbalanced	O
dietary	O
Zn	O
and	O
the	O
intervention	O
duration	O
on	O
weaning	O
mice	O
,	O
growth	O
parameters	O
were	O
monitored	O
during	O
the	O
experiment	O
.	O
During	O
the	O
4	O
-	O
week	O
Zn	O
intervention	O
(	O
short	O
-	O
term	O
zinc	O
intervention	O
)	O
,	O
the	O
average	O
daily	O
gain	O
and	O
feed	O
intake	O
were	O
significantly	O
decreased	O
with	O
a	O
low	O
-	O
Zn	O
diet	O
(	O
0	O
mg	O
of	O
Zn	O
/	O
kg	O
of	O
body	O
weight	O
)	O
(	O
Fig	O
.	O
1A	O
and	O
B	O
)	O
.	O
During	O
the	O
8	O
-	O
week	O
Zn	O
intervention	O
(	O
long	O
-	O
term	O
zinc	O
intervention	O
)	O
,	O
the	O
results	O
for	O
the	O
average	O
daily	O
gain	O
were	O
similar	O
among	O
the	O
four	O
groups	O
(	O
Fig	O
.	O
1C	O
)	O
.	O
In	O
comparison	O
with	O
the	O
control	O
-	O
Zn	O
group	O
(	O
30	O
mg	O
/	O
kg	O
)	O
,	O
a	O
marked	O
decrease	O
in	O
the	O
feed	O
intake	O
was	O
observed	O
in	O
both	O
the	O
low	O
-	O
Zn	O
and	O
high	O
-	O
Zn	O
(	O
150	O
mg	O
/	O
kg	O
)	O
groups	O
(	O
Fig	O
.	O
1D	O
)	O
.	O
Distal	O
colon	O
samples	O
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
(	O
H	O
&	O
E	O
)	O
to	O
examine	O
morphological	O
changes	O
due	O
to	O
Zn	O
levels	O
and	O
life	O
stage	O
.	O
A	O
slight	O
shedding	O
of	O
colon	O
villus	O
was	O
observed	O
in	O
the	O
4	O
-	O
week	O
low	O
-	O
Zn	O
group	O
(	O
Fig	O
.	O
1E	O
)	O
,	O
and	O
a	O
partial	O
colon	O
inflammatory	O
cell	O
infiltration	O
was	O
observed	O
in	O
the	O
8	O
-	O
week	O
high	O
-	O
Zn	O
group	O
(	O
Fig	O
.	O
1F	O
)	O
.	O
Mice	O
fed	O
with	O
altered	O
-	O
Zn	O
diets	O
for	O
4	O
weeks	O
or	O
8	O
weeks	O
both	O
showed	O
a	O
marked	O
shift	O
in	O
microbial	O
community	O
structure	O
compared	O
to	O
that	O
in	O
control	O
-	O
Zn	O
-	O
fed	O
mice	O
(	O
Fig	O
.	O
2A	O
and	O
B	O
and	O
Table	O
S1	O
in	O
the	O
supplemental	O
material	O
)	O
.	O
In	O
the	O
short	O
-	O
term	O
zinc	O
intervention	O
,	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
observed	O
species	O
for	O
the	O
excess	O
-	O
Zn	O
-	O
fed	O
mice	O
(	O
600	O
mg	O
/	O
kg	O
)	O
compared	O
with	O
that	O
of	O
the	O
low	O
-	O
Zn	O
-	O
fed	O
mice	O
,	O
whereas	O
no	O
clear	O
differences	O
were	O
observed	O
in	O
the	O
Shannon	O
index	O
(	O
Fig	O
.	O
2C	O
and	O
E	O
)	O
.	O
In	O
the	O
long	O
-	O
term	O
zinc	O
intervention	O
,	O
the	O
observed	O
species	O
were	O
similar	O
among	O
the	O
four	O
groups	O
.	O
A	O
higher	O
Shannon	O
index	O
was	O
generally	O
observed	O
in	O
the	O
low	O
-	O
Zn	O
group	O
and	O
control	O
-	O
Zn	O
group	O
,	O
whereas	O
the	O
high	O
-	O
Zn	O
group	O
showed	O
the	O
lowest	O
Shannon	O
index	O
(	O
Fig	O
.	O
2D	O
and	O
F	O
)	O
.	O

Changes	O
in	O
the	O
relative	O
abundance	O
of	O
phylum	O
populations	O
explained	O
the	O
differences	O
in	O
community	O
structure	O
between	O
the	O
short	O
-	O
term	O
and	O
long	O
-	O
term	O
Zn	O
interventions	O
(	O
low	O
-	O
Zn	O
diet	O
,	O
control	O
-	O
Zn	O
diet	O
,	O
high	O
-	O
Zn	O
diet	O
,	O
and	O
excess	O
-	O
Zn	O
diet	O
,	O
respectively	O
)	O
.	O
Firmicutes	O
(	O
65	O
.	O
7	O
,	O
72	O
.	O
4	O
,	O
69	O
.	O
7	O
,	O
and	O
71	O
.	O
9	O
%	O
)	O
,	O
Actinobacteria	O
(	O
13	O
.	O
9	O
,	O
13	O
.	O
9	O
,	O
10	O
.	O
7	O
,	O
and	O
9	O
%	O
)	O
,	O
Verrucomicrobia	O
(	O
0	O
.	O
2	O
,	O
0	O
.	O
3	O
,	O
10	O
.	O
2	O
,	O
and	O
5	O
.	O
4	O
%	O
)	O
,	O
Proteobacteria	O
(	O
7	O
.	O
8	O
,	O
2	O
.	O
8	O
,	O
2	O
.	O
1	O
,	O
and	O
8	O
.	O
2	O
%	O
)	O
,	O
and	O
Bacteroidetes	O
(	O
11	O
.	O
3	O
9	O
.	O
3	O
,	O
5	O
.	O
2	O
,	O
and	O
4	O
.	O
7	O
%	O
)	O
were	O
the	O
most	O
predominant	O
phyla	O
in	O
the	O
cecum	O
of	O
mice	O
that	O
were	O
fed	O
with	O
altered	O
zinc	O
diets	O
for	O
4	O
weeks	O
,	O
accounting	O
for	O
more	O
than	O
97	O
.	O
9	O
%	O
of	O
the	O
total	O
sequences	O
(	O
Fig	O
.	O
3A	O
)	O
.	O
Minor	O
members	O
of	O
the	O
community	O
were	O
affiliated	O
with	O
the	O
Deferribacteres	O
(	O
0	O
.	O
26	O
,	O
0	O
.	O
1	O
,	O
0	O
.	O
14	O
,	O
and	O
0	O
.	O
03	O
%	O
)	O
,	O
the	O
Tenericutes	O
(	O
0	O
.	O
049	O
,	O
0	O
.	O
005	O
,	O
0	O
.	O
003	O
,	O
and	O
0	O
.	O
002	O
%	O
)	O
,	O
the	O
Cyanobacteria	O
(	O
0	O
.	O
002	O
,	O
0	O
.	O
007	O
,	O
0	O
,	O
and	O
0	O
.	O
002	O
%	O
)	O
,	O
and	O
the	O
Acidobacteria	O
(	O
0	O
.	O
003	O
,	O
0	O
.	O
0008	O
,	O
0	O
.	O
004	O
,	O
and	O
0	O
.	O
002	O
%	O
)	O
.	O
The	O
high	O
-	O
Zn	O
diet	O
and	O
excess	O
-	O
Zn	O
diet	O
substantially	O
enhanced	O
the	O
abundance	O
of	O
the	O
Verrucomicrobia	O
among	O
the	O
four	O
groups	O
(	O
Fig	O
.	O
3B	O
)	O
,	O
and	O
the	O
proportion	O
of	O
the	O
Proteobacteria	O
was	O
significantly	O
higher	O
in	O
the	O
low	O
-	O
Zn	O
diet	O
and	O
excess	O
-	O
Zn	O
diet	O
than	O
in	O
the	O
control	O
and	O
high	O
-	O
Zn	O
diets	O
(	O
Fig	O
.	O
3C	O
)	O
.	O
The	O
decrease	O
in	O
the	O
ratio	O
of	O
Bacteroidetes	O
:	O
Firmicutes	O
was	O
accompanied	O
by	O
the	O
increase	O
of	O
Zn	O
dosage	O
(	O
Fig	O
.	O
3D	O
)	O
.	O
Additionally	O
,	O
the	O
ratio	O
of	O
Bacteroidetes	O
:	O
Firmicutes	O
was	O
inversely	O
correlated	O
with	O
body	O
weight	O
(	O
Fig	O
.	O
3E	O
)	O
.	O

In	O
8	O
-	O
week	O
samples	O
,	O
Firmicutes	O
(	O
65	O
.	O
5	O
,	O
60	O
.	O
2	O
,	O
55	O
,	O
and	O
71	O
.	O
2	O
%	O
)	O
,	O
Actinobacteria	O
(	O
4	O
.	O
5	O
,	O
4	O
.	O
7	O
,	O
21	O
.	O
6	O
,	O
and	O
4	O
.	O
9	O
%	O
)	O
,	O
Bacteroidetes	O
(	O
20	O
.	O
1	O
,	O
20	O
.	O
9	O
,	O
16	O
.	O
6	O
,	O
and	O
17	O
.	O
5	O
%	O
)	O
,	O
Proteobacteria	O
(	O
3	O
.	O
6	O
,	O
4	O
.	O
5	O
,	O
2	O
.	O
8	O
,	O
and	O
3	O
%	O
)	O
,	O
and	O
Verrucomicrobia	O
(	O
2	O
.	O
1	O
,	O
1	O
.	O
7	O
,	O
0	O
.	O
56	O
,	O
and	O
0	O
.	O
96	O
%	O
)	O
occupied	O
more	O
than	O
92	O
.	O
4	O
%	O
of	O
the	O
total	O
sequences	O
(	O
Fig	O
.	O
3F	O
)	O
.	O
Minor	O
members	O
of	O
the	O
community	O
were	O
Deferribacteres	O
(	O
0	O
.	O
7	O
,	O
0	O
.	O
58	O
,	O
0	O
.	O
32	O
,	O
and	O
0	O
.	O
22	O
%	O
)	O
,	O
Synergistetes	O
(	O
0	O
.	O
012	O
,	O
0	O
.	O
08	O
,	O
0	O
.	O
07	O
,	O
and	O
0	O
.	O
08	O
%	O
)	O
,	O
Euryarchaeota	O
(	O
0	O
.	O
03	O
,	O
0	O
.	O
06	O
,	O
0	O
.	O
09	O
,	O
and	O
0	O
.	O
0745	O
%	O
)	O
,	O
and	O
Tenericutes	O
(	O
0	O
.	O
005	O
,	O
0	O
.	O
016	O
,	O
0	O
.	O
05	O
,	O
and	O
0	O
.	O
004	O
%	O
)	O
.	O
The	O
highest	O
abundance	O
of	O
Actinobacteria	O
was	O
observed	O
in	O
mice	O
fed	O
high	O
-	O
Zn	O
diets	O
(	O
Fig	O
.	O
3G	O
)	O
.	O
In	O
contrast	O
to	O
the	O
result	O
of	O
short	O
-	O
term	O
Zn	O
supplementation	O
,	O
the	O
proportion	O
of	O
Verrucomicrobia	O
was	O
increased	O
in	O
the	O
low	O
-	O
Zn	O
group	O
and	O
was	O
decreased	O
in	O
the	O
high	O
-	O
Zn	O
group	O
(	O
Fig	O
.	O
3H	O
)	O
.	O
The	O
ratio	O
of	O
Bacteroidetes	O
:	O
Firmicutes	O
showed	O
insignificant	O
differences	O
among	O
the	O
four	O
groups	O
and	O
was	O
not	O
significantly	O
correlated	O
with	O
the	O
body	O
weight	O
(	O
Fig	O
.	O
3I	O
and	O
J	O
)	O
.	O
Analysis	O
of	O
the	O
relative	O
abundance	O
of	O
the	O
dominant	O
genera	O
(	O
top	O
30	O
)	O
revealed	O
the	O
clear	O
and	O
distinct	O
clustering	O
of	O
cecal	O
microbiota	O
in	O
altered	O
Zn	O
diets	O
in	O
short	O
-	O
term	O
and	O
long	O
-	O
term	O
Zn	O
intervention	O
(	O
Fig	O
.	O
S1	O
)	O
.	O

During	O
the	O
short	O
-	O
term	O
Zn	O
intervention	O
,	O
the	O
cecal	O
contents	O
of	O
mice	O
fed	O
the	O
low	O
-	O
Zn	O
diet	O
were	O
characterized	O
by	O
an	O
increase	O
in	O
the	O
relative	O
abundance	O
of	O
Desulfovibrio	O
,	O
Enterorhabdus	O
,	O
Flavonifractor	O
,	O
Parasutterella	O
,	O
Mucispirillum	O
,	O
“	O
Candidatus	O
Saccharimonas	O
,	O
”	O
Alistipes	O
,	O
Odoribacter	O
,	O
and	O
Anaerotruncus	O
,	O
and	O
a	O
decrease	O
in	O
the	O
relative	O
abundance	O
of	O
Sphingomonas	O
,	O
compared	O
with	O
the	O
other	O
dietary	O
treatments	O
(	O
Fig	O
.	O
S1A	O
)	O
.	O
The	O
relative	O
abundance	O
of	O
unidentified	O
Lachnospiraceae	O
,	O
Lachnoclostridium	O
,	O
and	O
Bifidobacterium	O
in	O
the	O
control	O
-	O
Zn	O
group	O
was	O
higher	O
than	O
that	O
in	O
the	O
high	O
-	O
and	O
excess	O
-	O
Zn	O
groups	O
.	O
The	O
high	O
-	O
Zn	O
diet	O
was	O
associated	O
with	O
enrichment	O
of	O
Akkermansia	O
,	O
Faecalibaculum	O
,	O
Helicobacter	O
,	O
and	O
Ileibacterium	O
compared	O
to	O
other	O
diets	O
.	O
Mice	O
fed	O
the	O
600	O
mg	O
/	O
kg	O
Zn	O
diet	O
showed	O
a	O
higher	O
abundance	O
of	O
Dubosiella	O
,	O
Caulobacter	O
,	O
and	O
Bradyrhizobium	O
and	O
a	O
lower	O
proportion	O
of	O
Romboutsia	O
,	O
Bacteroides	O
,	O
Lactobacillus	O
,	O
and	O
Bifidobacterium	O
.	O
Long	O
-	O
term	O
Zn	O
alteration	O
reversed	O
the	O
distribution	O
of	O
some	O
bacterial	O
genera	O
compared	O
with	O
short	O
-	O
term	O
Zn	O
intervention	O
(	O
Fig	O
.	O
S1B	O
)	O
.	O
Under	O
low	O
-	O
Zn	O
conditions	O
,	O
an	O
increase	O
in	O
the	O
relative	O
abundance	O
of	O
Akkermansia	O
,	O
Blautia	O
,	O
Alloprevotella	O
,	O
and	O
Ruminiclostridium	O
and	O
a	O
decrease	O
in	O
Thermovirga	O
were	O
found	O
in	O
cecum	O
of	O
mice	O
.	O
The	O
relative	O
abundance	O
of	O
Parasutterella	O
,	O
Helicobacter	O
,	O
Odoribacter	O
,	O
and	O
Ileibacterium	O
in	O
the	O
control	O
-	O
Zn	O
group	O
was	O
higher	O
and	O
the	O
proportion	O
of	O
Dubosiella	O
,	O
Faecalibaculum	O
,	O
and	O
Bifidobacterium	O
was	O
lower	O
than	O
in	O
the	O
other	O
groups	O
.	O
For	O
the	O
high	O
-	O
Zn	O
-	O
diet	O
group	O
,	O
most	O
genera	O
were	O
decreased	O
compared	O
with	O
the	O
other	O
dietary	O
treatments	O
,	O
except	O
for	O
Bifidobacterium	O
and	O
Anaeroplasma	O
,	O
which	O
were	O
increased	O
.	O

Mice	O
fed	O
the	O
excess	O
-	O
Zn	O
diet	O
showed	O
increases	O
in	O
the	O
level	O
of	O
Bacteroides	O
and	O
Intestinimonas	O
and	O
decreases	O
in	O
Lactobacillus	O
.	O
We	O
further	O
assessed	O
differences	O
in	O
the	O
bacterial	O
community	O
at	O
the	O
species	O
level	O
(	O
potential	O
probiotics	O
and	O
pathobionts	O
among	O
top	O
the	O
20	O
species	O
)	O
(	O
Fig	O
.	O
4A	O
and	O
G	O
)	O
.	O
In	O
the	O
4	O
-	O
week	O
samples	O
,	O
the	O
abundance	O
of	O
Lactobacillus	O
reuteri	O
and	O
Firmicutes	O
bacterium	O
ASF500	O
was	O
significantly	O
increased	O
in	O
the	O
control	O
-	O
Zn	O
diet	O
compared	O
with	O
other	O
diets	O
,	O
and	O
the	O
relative	O
abundance	O
of	O
Bacteroides	O
acidifaciens	O
was	O
decreased	O
in	O
excess	O
-	O
Zn	O
-	O
diet	O
fed	O
mice	O
compared	O
to	O
control	O
-	O
Zn	O
-	O
fed	O
mice	O
(	O
Fig	O
.	O
4B	O
to	O
D	O
)	O
.	O
High	O
-	O
and	O
excess	O
-	O
Zn	O
supplementation	O
substantially	O
enhanced	O
the	O
abundance	O
of	O
Akkermansia	O
muciniphila	O
in	O
the	O
cecum	O
of	O
mice	O
(	O
Fig	O
.	O
4E	O
)	O
.	O
The	O
low	O
-	O
Zn	O
diet	O
showed	O
the	O
enrichment	O
of	O
Helicobacter	O
hepaticus	O
compared	O
with	O
the	O
other	O
dietary	O
treatments	O
(	O
Fig	O
.	O
4F	O
)	O
.	O
In	O
the	O
8	O
-	O
week	O
samples	O
,	O
the	O
highest	O
abundance	O
of	O
Lactobacillus	O
reuteri	O
was	O
observed	O
in	O
the	O
control	O
-	O
Zn	O
diet	O
,	O
whereas	O
the	O
abundance	O
of	O
Bacteroides	O
acidifaciens	O
was	O
similar	O
among	O
the	O
four	O
groups	O
(	O
Fig	O
.	O
4H	O
and	O
I	O
)	O
.	O
The	O
low	O
-	O
Zn	O
diet	O
and	O
excess	O
-	O
Zn	O
diet	O
were	O
both	O
associated	O
with	O
the	O
enrichment	O
of	O
Firmicutes	O
bacterium	O
ASF500	O
(	O
Fig	O
.	O
4J	O
)	O
.	O
The	O
abundance	O
of	O
Helicobacter	O
hepaticus	O
was	O
higher	O
in	O
the	O
high	O
-	O
Zn	O
group	O
than	O
in	O
the	O
other	O
groups	O
(	O
Fig	O
.	O
4K	O
)	O
.	O
Analysis	O
of	O
functional	O
capacity	O
based	O
on	O
the	O
KEGG	O
pathways	O
“	O
human	O
diseases	O
”	O
and	O
“	O
metabolism	O
”	O
showed	O
significant	O
differences	O
in	O
altered	O
dietary	O
Zn	O
groups	O
(	O
Fig	O
.	O
5	O
)	O
.	O
During	O
the	O
short	O
-	O
term	O
Zn	O
intervention	O
,	O
genes	O
related	O
to	O
human	O
diseases	O
showed	O
a	O
significantly	O
higher	O
abundance	O
in	O
the	O
high	O
-	O
Zn	O
group	O
and	O
a	O
remarkably	O
lower	O
abundance	O
in	O
the	O
control	O
-	O
Zn	O
group	O
for	O
a	O
high	O
number	O
of	O
genes	O
involved	O
,	O
i	O
.	O
e	O
.	O
,	O
in	O
cancers	O
,	O
drug	O
resistance	O
,	O
infection	O
disease	O
,	O
and	O
neurodegenerative	O
diseases	O
(	O
Fig	O
.	O
5A	O
)	O
.	O

Of	O
note	O
,	O
a	O
pathway	O
involved	O
in	O
substance	O
dependence	O
was	O
increased	O
in	O
the	O
low	O
-	O
Zn	O
group	O
and	O
the	O
excess	O
-	O
Zn	O
group	O
,	O
while	O
it	O
was	O
decreased	O
in	O
the	O
high	O
-	O
Zn	O
group	O
.	O
Among	O
all	O
the	O
metabolism	O
pathways	O
analyzed	O
,	O
the	O
level	O
of	O
carbohydrate	O
metabolism	O
,	O
glycan	O
biosynthesis	O
and	O
metabolism	O
,	O
metabolism	O
of	O
other	O
amino	O
acids	O
,	O
metabolism	O
of	O
terpenoids	O
and	O
polyketides	O
,	O
and	O
nucleotide	O
metabolism	O
were	O
suppressed	O
in	O
the	O
low	O
-	O
Zn	O
diet	O
and	O
promoted	O
in	O
the	O
high	O
-	O
Zn	O
diet	O
(	O
Fig	O
.	O
5B	O
)	O
.	O
A	O
higher	O
proportion	O
of	O
genes	O
related	O
to	O
xenobiotic	O
biodegradation	O
and	O
metabolism	O
was	O
observed	O
in	O
both	O
the	O
low	O
-	O
Zn	O
group	O
and	O
the	O
control	O
-	O
Zn	O
group	O
than	O
in	O
the	O
other	O
two	O
higher	O
-	O
Zn	O
-	O
fed	O
groups	O
.	O
During	O
the	O
long	O
-	O
term	O
Zn	O
intervention	O
,	O
the	O
high	O
-	O
Zn	O
-	O
fed	O
mice	O
were	O
enriched	O
in	O
human	O
disease	O
pathways	O
involved	O
in	O
cancers	O
,	O
drug	O
resistance	O
,	O
endocrine	O
and	O
metabolic	O
diseases	O
,	O
and	O
infectious	O
diseases	O
and	O
were	O
depleted	O
in	O
the	O
gene	O
related	O
to	O
substance	O
dependence	O
(	O
Fig	O
.	O
5C	O
)	O
.	O
Genes	O
related	O
to	O
cardiovascular	O
diseases	O
showed	O
a	O
significantly	O
higher	O
abundance	O
in	O
the	O
low	O
-	O
Zn	O
group	O
and	O
a	O
lower	O
abundance	O
in	O
the	O
excess	O
-	O
Zn	O
group	O
.	O
In	O
terms	O
of	O
metabolism	O
pathways	O
,	O
the	O
relative	O
abundances	O
of	O
amino	O
acid	O
metabolism	O
and	O
biosynthesis	O
of	O
other	O
secondary	O
metabolites	O
were	O
dramatically	O
increased	O
in	O
the	O
low	O
-	O
Zn	O
group	O
and	O
decreased	O
in	O
the	O
excess	O
-	O
Zn	O
group	O
(	O
Fig	O
.	O
5D	O
)	O
.	O
Mice	O
fed	O
the	O
high	O
-	O
Zn	O
diet	O
had	O
increased	O
genes	O
related	O
to	O
carbohydrate	O
metabolism	O
,	O
energy	O
metabolism	O
,	O
and	O
nucleotide	O
metabolism	O
and	O
decreased	O
genes	O
involved	O
in	O
enzyme	O
families	O
,	O
lipid	O
metabolism	O
,	O
metabolism	O
of	O
cofactors	O
and	O
vitamins	O
,	O
and	O
metabolism	O
of	O
terpenoids	O
and	O
polyketides	O
.	O
The	O
higher	O
proportions	O
of	O
the	O
gene	O
for	O
xenobiotic	O
biodegradation	O
and	O
metabolism	O
were	O
observed	O
with	O
the	O
control	O
-	O
Zn	O
diet	O
.	O
Analysis	O
of	O
the	O
total	O
and	O
individual	O
metabolites	O
revealed	O
significant	O
differences	O
between	O
dietary	O
groups	O
.	O
During	O
the	O
short	O
-	O
term	O
Zn	O
intervention	O
,	O
the	O
lowest	O
levels	O
of	O
total	O
metabolites	O
were	O
determined	O
in	O
the	O
excess	O
-	O
Zn	O
group	O
,	O
followed	O
by	O
the	O
control	O
-	O
Zn	O
group	O
,	O
high	O
-	O
Zn	O
group	O
,	O
and	O
low	O
-	O
Zn	O
group	O
in	O
that	O
order	O
.	O

Interestingly	O
,	O
a	O
highly	O
similar	O
pattern	O
was	O
also	O
observed	O
for	O
total	O
SCFAs	O
,	O
acetic	O
acid	O
,	O
butyric	O
acid	O
,	O
isobutyric	O
acid	O
,	O
isovaleric	O
acid	O
,	O
and	O
propionic	O
acid	O
(	O
Fig	O
.	O
6A	O
)	O
.	O
During	O
the	O
long	O
-	O
term	O
Zn	O
intervention	O
,	O
high	O
-	O
Zn	O
diet	O
resulted	O
in	O
a	O
marked	O
loss	O
of	O
cecal	O
levels	O
of	O
total	O
metabolites	O
compared	O
with	O
the	O
low	O
-	O
Zn	O
diet	O
and	O
control	O
-	O
Zn	O
diet	O
,	O
as	O
well	O
as	O
total	O
SCFAs	O
,	O
butyric	O
acid	O
,	O
acetic	O
acid	O
,	O
isovaleric	O
acid	O
,	O
isobutyric	O
acid	O
,	O
and	O
propionic	O
acid	O
.	O
The	O
highest	O
concentration	O
of	O
valeric	O
acid	O
was	O
observed	O
with	O
the	O
control	O
-	O
Zn	O
diet	O
,	O
followed	O
by	O
the	O
high	O
-	O
Zn	O
and	O
excess	O
-	O
Zn	O
diets	O
,	O
while	O
the	O
low	O
-	O
Zn	O
diet	O
showed	O
the	O
lowest	O
proportion	O
(	O
Fig	O
.	O
6B	O
)	O
.	O
On	O
the	O
basis	O
of	O
the	O
data	O
for	O
Zn	O
-	O
treated	O
mice	O
,	O
we	O
hypothesized	O
that	O
SCFAs	O
were	O
markedly	O
influenced	O
by	O
microbiota	O
alterations	O
.	O
Enterorhabdus	O
,	O
Alistipes	O
,	O
Odoribacter	O
,	O
Anaerotruncus	O
,	O
Alloprevotella	O
,	O
Bacteroides	O
,	O
and	O
Parabacteroides	O
were	O
changed	O
both	O
in	O
4	O
-	O
week	O
and	O
8	O
-	O
week	O
courses	O
of	O
Zn	O
manipulation	O
,	O
and	O
all	O
of	O
them	O
belong	O
to	O
short	O
-	O
chain	O
fatty	O
acid	O
-	O
producing	O
genera	O
(	O
27	O
–	O
29	O
)	O
.	O
Therefore	O
,	O
correlation	O
analyses	O
between	O
the	O
dominant	O
genera	O
and	O
SCFAs	O
,	O
primarily	O
acetate	O
,	O
propionate	O
,	O
and	O
butyrate	O
,	O
were	O
conducted	O
by	O
Spearman	O
correlation	O
analysis	O
(	O
Fig	O
.	O
6C	O
and	O
D	O
)	O
.	O
Notably	O
,	O
cecal	O
SCFAs	O
production	O
showed	O
remarkable	O
correlation	O
with	O
the	O
relative	O
abundances	O
of	O
Bacteroides	O
,	O
Alistipes	O
,	O
and	O
Parabacteroides	O
,	O
which	O
indicates	O
that	O
these	O
three	O
genera	O
mainly	O
contributed	O
to	O
SCFAs	O
production	O
in	O
this	O
study	O
.	O
To	O
document	O
the	O
impact	O
of	O
imbalanced	O
Zn	O
exposure	O
on	O
the	O
composition	O
of	O
gut	O
microbiota	O
,	O
we	O
performed	O
linear	O
discriminant	O
analysis	O
effect	O
size	O
(	O
LEfSe	O
)	O
analyses	O
using	O
the	O
relative	O
abundance	O
data	O
to	O
identify	O
the	O
bacteria	O
differentially	O
represented	O
among	O
different	O
dietary	O
Zn	O
manipulations	O
.	O
There	O
were	O
55	O
differential	O
bacterial	O
taxa	O
in	O
the	O
short	O
-	O
term	O
Zn	O
intervention	O
samples	O
and	O
79	O
differential	O
bacterial	O
taxa	O
in	O
the	O
long	O
-	O
term	O
treatment	O
samples	O
(	O
Fig	O
.	O
7A	O
and	O
B	O
)	O
.	O

At	O
the	O
phylum	O
level	O
,	O
LEfSe	O
analysis	O
identified	O
Melainabacteria	O
as	O
a	O
strongly	O
discriminative	O
taxon	O
for	O
both	O
short	O
-	O
term	O
and	O
long	O
-	O
term	O
dietary	O
Zn	O
intervention	O
(	O
Fig	O
.	O
7A	O
to	O
D	O
)	O
.	O
Next	O
,	O
correlation	O
analysis	O
between	O
Melainabacteria	O
and	O
serum	O
Zn	O
were	O
conducted	O
by	O
Pearson	O
correlation	O
analysis	O
(	O
Fig	O
.	O
7E	O
and	O
F	O
)	O
.	O
As	O
expected	O
,	O
the	O
serum	O
Zn	O
levels	O
were	O
negatively	O
correlated	O
with	O
the	O
relative	O
abundance	O
of	O
Melainabacteria	O
at	O
both	O
4	O
and	O
8	O
weeks	O
(	O
P	O
=	O
0	O
.	O
0002	O
and	O
P	O
=	O
0	O
.	O
0001	O
,	O
respectively	O
)	O
.	O
Receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
implied	O
that	O
the	O
level	O
of	O
Melainabacteria	O
could	O
potentially	O
be	O
applied	O
to	O
differentiate	O
Zn	O
levels	O
with	O
high	O
accuracy	O
(	O
AUC	O
,	O
>	O
0	O
.	O
85	O
,	O
Fig	O
.	O
7G	O
and	O
H	O
)	O
.	O
In	O
terms	O
of	O
genus	O
level	O
,	O
Lactobacillus	O
was	O
more	O
abundant	O
in	O
the	O
low	O
-	O
Zn	O
group	O
over	O
the	O
4	O
-	O
and	O
8	O
-	O
week	O
intervals	O
.	O
Lactobacillus	O
attained	O
good	O
diagnostic	O
accuracy	O
to	O
distinguish	O
Zn	O
deficiency	O
and	O
Zn	O
overdose	O
over	O
the	O
4	O
-	O
week	O
interval	O
(	O
AUC	O
,	O
>	O
0	O
.	O
84	O
)	O
.	O
However	O
,	O
in	O
8	O
weeks	O
,	O
this	O
genus	O
was	O
not	O
significantly	O
correlated	O
with	O
the	O
serum	O
Zn	O
,	O
and	O
the	O
AUC	O
was	O
only	O
0	O
.	O
69	O
(	O
Fig	O
.	O
S2A	O
-	O
F	O
)	O
.	O
Our	O
LEfSe	O
analysis	O
also	O
identified	O
a	O
species	O
-	O
level	O
bacterium	O
(	O
Desulfovibrio	O
sp	O
.	O
strain	O
ABHU2SB	O
)	O
that	O
was	O
specific	O
for	O
different	O
dietary	O
Zn	O
levels	O
(	O
Fig	O
.	O
7I	O
and	O
J	O
)	O
.	O
According	O
to	O
the	O
Pearson	O
correlation	O
analysis	O
and	O
ROC	O
curve	O
,	O
the	O
serum	O
Zn	O
levels	O
are	O
highly	O
correlated	O
with	O
the	O
relative	O
abundance	O
of	O
Desulfovibrio	O
sp	O
.	O
ABHU2SB	O
over	O
the	O
4	O
-	O
and	O
8	O
-	O
week	O
intervals	O
(	O
P	O
=	O
0	O
.	O
0037	O
and	O
P	O
=	O
0	O
.	O
0004	O
,	O
respectively	O
)	O
,	O
with	O
a	O
ROC	O
plot	O
AUC	O
value	O
of	O
0	O
.	O
8	O
to	O
0	O
.	O
91	O
(	O
Fig	O
.	O
7K	O
to	O
N	O
)	O
.	O
The	O
analysis	O
of	O
the	O
microbial	O
communities	O
has	O
revealed	O
the	O
dramatic	O
alteration	O
of	O
the	O
gut	O
microbiota	O
in	O
conditions	O
of	O
imbalanced	O
dietary	O
Zn	O
.	O

The	O
low	O
-	O
Zn	O
diet	O
did	O
not	O
decrease	O
the	O
intestinal	O
species	O
richness	O
,	O
which	O
is	O
in	O
line	O
with	O
the	O
previous	O
finding	O
in	O
mice	O
(	O
18	O
)	O
.	O
Intriguingly	O
,	O
Zn	O
starvation	O
showed	O
statistically	O
significant	O
decreased	O
microbial	O
diversity	O
in	O
broilers	O
and	O
piglets	O
(	O
30	O
,	O
31	O
)	O
.	O
A	O
possible	O
explanation	O
for	O
this	O
difference	O
is	O
the	O
animal	O
model	O
used	O
.	O
In	O
livestock	O
production	O
,	O
Zn	O
-	O
supplemented	O
diets	O
are	O
regularly	O
utilized	O
to	O
administer	O
drugs	O
,	O
provide	O
nutrients	O
and	O
prevent	O
deficiencies	O
,	O
and	O
increase	O
the	O
size	O
and	O
output	O
of	O
animals	O
(	O
32	O
)	O
.	O
We	O
speculated	O
that	O
livestock	O
was	O
more	O
sensitive	O
to	O
Zn	O
-	O
limited	O
condition	O
than	O
mice	O
.	O
Therefore	O
,	O
Zn	O
starvation	O
might	O
be	O
insufficient	O
for	O
any	O
significant	O
decrease	O
in	O
the	O
microbial	O
diversity	O
in	O
mice	O
.	O
The	O
shift	O
in	O
community	O
composition	O
after	O
Zn	O
addition	O
was	O
accompanied	O
by	O
a	O
reduction	O
in	O
alpha	O
diversities	O
over	O
the	O
4	O
-	O
and	O
8	O
-	O
week	O
intervals	O
,	O
supporting	O
the	O
previous	O
finding	O
in	O
mice	O
(	O
18	O
)	O
.	O
Furthermore	O
,	O
pharmacological	O
intakes	O
of	O
ZnO	O
(	O
2500	O
mg	O
Zn	O
/	O
kg	O
)	O
have	O
been	O
also	O
been	O
shown	O
to	O
affect	O
the	O
regulation	O
of	O
the	O
microbial	O
communities	O
by	O
reducing	O
the	O
microbial	O
richness	O
in	O
the	O
jejunum	O
and	O
feces	O
(	O
33	O
)	O
or	O
the	O
ileal	O
digesta	O
of	O
weaned	O
piglets	O
(	O
34	O
)	O
.	O
The	O
altered	O
-	O
Zn	O
-	O
diet	B-methodology
intervention	I-methodology
resulted	O
in	O
notable	O
changes	O
in	O
the	O
bacterial	O
composition	O
at	O
the	O
phylum	O
,	O
genus	O
,	O
and	O
species	O
levels	O
.	O
An	O
increased	O
prevalence	O
of	O
Proteobacteria	O
is	O
a	O
potential	O
diagnostic	O
signature	O
for	O
dysbiosis	O
or	O
risk	O
of	O
disease	O
(	O
35	O
)	O
.	O
During	O
a	O
feeding	O
period	O
of	O
4	O
weeks	O
,	O
mice	O
on	O
low	O
-	O
Zn	O
and	O
excess	O
-	O
Zn	O
diets	O
showed	O
a	O
remarkable	O
increase	O
in	O
the	O
phylum	O
Proteobacteria	O
,	O
as	O
well	O
as	O
the	O
genus	O
Desulfovibrio	O
,	O
a	O
potential	O
biomarker	O
in	O
inflammatory	O
bowel	O
diseases	O
(	O
36	O
)	O
.	O
The	O
zinc	O
repressor	O
ZUR	O
,	O
which	O
regulates	O
high	O
-	O
affinity	O
zinc	O
transporters	O
znuABC	O
,	O
has	O
been	O
found	O
in	O
Desulfovibrio	O
species	O
(	O
37	O
)	O
.	O
Therefore	O
,	O
a	O
lack	O
of	O
sufficient	O
dietary	O
Zn	O
in	O
the	O
cecum	O
may	O
modulate	O
the	O
level	O
of	O
Desulfovibrio	O
by	O
enabling	O
colonization	O
and	O
outgrowth	O
of	O
Zn	O
-	O
competing	O
bacteria	O
.	O

Furthermore	O
,	O
a	O
heavy	O
metal	O
resistance	O
gene	O
(	O
tetQ	O
)	O
was	O
found	O
to	O
be	O
affiliated	O
with	O
Proteobacteria	O
(	O
38	O
)	O
,	O
it	O
is	O
likely	O
that	O
this	O
phylum	O
possesses	O
certain	O
mechanisms	O
to	O
counteract	O
the	O
high	O
dietary	O
zinc	O
.	O
Therefore	O
,	O
the	O
phylum	O
Proteobacteria	O
was	O
determined	O
to	O
possess	O
a	O
good	O
adaptive	O
capacity	O
under	O
imbalanced	O
zinc	O
conditions	O
.	O
However	O
,	O
dietary	O
Zn	O
alteration	O
did	O
not	O
significantly	O
affect	O
the	O
level	O
of	O
Proteobacteria	O
in	O
the	O
8	O
-	O
week	O
intervention	O
.	O
This	O
could	O
be	O
rationalized	O
by	O
the	O
fact	O
that	O
the	O
intestinal	O
flora	O
of	O
mice	O
would	O
stabilize	O
gradually	O
with	O
age	O
(	O
39	O
)	O
,	O
which	O
makes	O
it	O
easier	O
to	O
prevent	O
the	O
colonization	O
of	O
potential	O
pathogens	O
.	O
Akkermansia	O
muciniphila	O
,	O
a	O
member	O
of	O
the	O
Verrucomicrobia	O
,	O
is	O
an	O
important	O
gut	O
symbiont	O
for	O
the	O
maintenance	O
of	O
metabolic	O
homeostasis	O
and	O
is	O
associated	O
with	O
low	O
inflammation	O
and	O
normal	O
lipid	O
and	O
carbohydrate	O
metabolism	O
(	O
40	O
)	O
.	O
In	O
our	O
study	O
,	O
the	O
proportion	O
of	O
Verrucomicrobia	O
was	O
increased	O
in	O
mice	O
that	O
were	O
fed	O
high	O
-	O
and	O
excess	O
-	O
Zn	O
diets	O
and	O
was	O
decreased	O
in	O
Zn	O
-	O
starvation	O
mice	O
over	O
the	O
4	O
-	O
week	O
interval	O
.	O
Statistically	O
significant	O
differences	O
also	O
were	O
noted	O
at	O
the	O
genus	O
(	O
Akkermansia	O
)	O
and	O
species	O
(	O
Akkermansia	O
muciniphila	O
)	O
levels	O
.	O
This	O
is	O
in	O
agreement	O
with	O
the	O
previous	O
studies	O
showing	O
that	O
zinc	O
deficiency	O
is	O
correlated	O
with	O
low	O
relative	O
abundances	O
of	O
Verrucomicrobia	O
(	O
41	O
,	O
42	O
)	O
.	O
Furthermore	O
,	O
the	O
percentages	O
of	O
Verrucomicrobia	O
was	O
significantly	O
higher	O
in	O
the	O
3	O
,	O
000	O
mg	O
/	O
kg	O
ZnO	O
group	O
of	O
weaning	O
piglets	O
(	O
43	O
)	O
.	O
In	O
the	O
8	O
-	O
week	O
Zn	O
intervention	O
,	O
Verrucomicrobia	O
was	O
found	O
at	O
higher	O
abundance	O
in	O
the	O
low	O
-	O
Zn	O
group	O
and	O
lower	O
abundance	O
in	O
the	O
high	O
-	O
Zn	O
group	O
.	O
This	O
phenomenon	O
revealed	O
that	O
a	O
high	O
dose	O
of	O
Zn	O
has	O
a	O
profound	O
effect	O
on	O
Verrucomicrobia	O
;	O
whether	O
it	O
is	O
positive	O
or	O
negative	O
depends	O
on	O
the	O
exposure	O
duration	O
.	O
We	O
hypothesized	O
that	O
long	O
-	O
term	O
Zn	O
accumulation	O
could	O
be	O
highly	O
toxic	O
to	O
Verrucomicrobia	O
,	O
which	O
may	O
occur	O
through	O
intermetal	O
competition	O
,	O
mis	O
-	O
metallation	O
of	O
metalloprotein	O
,	O
or	O
redox	O
activity	O
(	O
44	O
)	O
.	O

More	O
in	B-methodology
vitro	I-methodology
and	I-methodology
in	I-methodology
vivo	I-methodology
studies	I-methodology
are	O
needed	O
to	O
determine	O
how	O
zinc	O
may	O
affect	O
the	O
growth	O
of	O
Verrucomicrobia	O
(	O
A	O
.	O
muciniphila	O
)	O
,	O
and	O
how	O
they	O
may	O
interact	O
in	O
the	O
process	O
.	O
Lower	O
Bacteroidetes	O
:	O
Firmicutes	O
ratios	O
have	O
been	O
associated	O
with	O
several	O
disorders	O
,	O
such	O
as	O
human	O
obesity	O
(	O
45	O
)	O
,	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
;	O
46	O
)	O
,	O
and	O
type	O
2	O
diabetes	O
(	O
47	O
)	O
.	O
In	O
our	O
study	O
,	O
during	O
the	O
short	O
-	O
term	O
interventions	O
,	O
the	O
ratio	O
of	O
Bacteroidetes	O
:	O
Firmicutes	O
was	O
negatively	O
related	O
to	O
the	O
Zn	O
dosage	O
.	O
In	O
agreement	O
with	O
previous	O
literature	O
,	O
a	O
significantly	O
greater	O
abundance	O
of	O
Bacteroidetes	O
and	O
a	O
significantly	O
lower	O
abundance	O
of	O
Firmicutes	O
was	O
observed	O
in	O
the	O
Zn	O
-	O
deficient	O
group	O
(	O
30	O
)	O
.	O
In	O
addition	O
,	O
the	O
phylum	O
Firmicutes	O
thrived	O
under	O
low	O
-	O
zinc	O
conditions	O
in	O
pregnant	O
mice	O
(	O
48	O
)	O
.	O
However	O
,	O
long	O
-	O
term	O
Zn	O
intervention	O
did	O
not	O
significantly	O
influence	O
the	O
ratio	O
of	O
Bacteroidetes	O
:	O
Firmicutes	O
.	O
It	O
was	O
assumed	O
that	O
the	O
relative	O
proportional	O
representation	O
of	O
the	O
Firmicutes	O
and	O
Bacteroidetes	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
body	O
weight	O
gain	O
(	O
49	O
)	O
.	O
Consistent	O
with	O
the	O
ratio	O
of	O
Bacteroidetes	O
/	O
Firmicutes	O
,	O
there	O
is	O
no	O
significant	O
alteration	O
of	O
body	O
weight	O
gain	O
among	O
different	O
levels	O
of	O
Zn	O
diets	O
in	O
8	O
weeks	O
.	O
We	O
reasoned	O
that	O
this	O
substantial	O
difference	O
(	O
Bacteroidetes	O
:	O
Firmicutes	O
)	O
in	O
long	O
-	O
term	O
and	O
short	O
-	O
term	O
Zn	O
manipulation	O
may	O
be	O
linked	O
not	O
only	O
to	O
intestinal	O
Zn	O
accumulation	O
duration	O
but	O
also	O
to	O
the	O
operation	O
of	O
age	O
,	O
as	O
Mariat	O
and	O
coworkers	O
demonstrated	O
that	O
the	O
ratio	O
of	O
Firmicutes	O
to	O
Bacteroidetes	O
evolves	O
during	O
different	O
life	O
stages	O
(	O
50	O
)	O
.	O
Analysis	O
of	O
total	O
and	O
individual	O
SCFAs	O
revealed	O
significant	O
differences	O
between	O
the	O
dietary	O
Zn	O
groups	O
.	O
There	O
are	O
conflicting	O
data	O
on	O
low	O
-	O
Zn	O
-	O
related	O
changes	O
affect	O
the	O
SCFAs	O
concentration	O
in	O
different	O
animal	B-methodology
models	I-methodology
.	O
Reed	O
et	O
al	O
.	O
observed	O
a	O
significant	O
decrease	O
in	O
the	O
concentration	O
of	O
SCFAs	O
in	O
the	O
Zn	O
deficiency	O
group	O
in	O
chicks	O
(	O
30	O
)	O
,	O
while	O
Pieper	O
et	O
al	O
.	O
found	O
the	O
opposite	O
results	O
in	O
pigs	O
(	O
51	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
during	O
the	O
short	O
-	O
term	O
intervention	O
,	O
higher	O
bacterial	O
metabolites	O
were	O
found	O
in	O
the	O
low	O
-	O
Zn	O
-	O
diet	O
animals	O
,	O
especially	O
acetic	O
acid	O
.	O
In	O
terms	O
of	O
genus	O
levels	O
,	O
the	O
short	O
-	O
term	O
inadequate	O
-	O
zinc	O
diet	O
has	O
remarkable	O
positive	O
correlations	O
with	O
various	O
groups	O
of	O
acetate	O
-	O
,	O
propionate	O
-	O
,	O
and	O
butyrate	O
-	O
producing	O
bacteria	O
(	O
Flavonifractor	O
,	O
Alistipes	O
,	O
Odoribacter	O
,	O
Anaerotruncus	O
,	O
Alloprevotella	O
,	O
Bacteroides	O
,	O
and	O
Parabacteroides	O
)	O
.	O
Previous	O
work	O
showed	O
that	O
cecal	O
SCFAs	O
concentrations	O
,	O
particularly	O
acetate	O
and	O
butyrate	O
,	O
were	O
correlated	O
with	O
cecal	O
pH	O
(	O
52	O
)	O
.	O
Therefore	O
,	O
alterations	O
in	O
the	O
cecal	O
environment	O
,	O
such	O
as	O
a	O
reduction	O
in	O
pH	O
through	O
an	O
increased	O
SCFAs	O
level	O
,	O
can	O
result	O
in	O
a	O
notable	O
increase	O
in	O
the	O
Zn	O
bioavailability	O
and	O
uptake	O
(	O
53	O
,	O
54	O
)	O
.	O
Our	O
data	O
suggested	O
that	O
changes	O
in	O
the	O
gut	O
microbiota	O
composition	O
of	O
the	O
Zn	O
-	O
deficient	O
group	O
can	O
increase	O
Zn	O
availability	O
to	O
combat	O
the	O
Zn	O
-	O
limited	O
conditions	O
.	O
However	O
,	O
it	O
is	O
known	O
that	O
high	O
-	O
dose	O
acetate	O
can	O
cross	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
reach	O
the	O
hypothalamus	O
,	O
decreasing	O
appetite	O
and	O
nutrition	O
intake	O
(	O
55	O
)	O
.	O
For	O
growth	O
parameters	O
,	O
feed	O
intake	O
was	O
suppressed	O
in	O
the	O
Zn	O
-	O
starvation	O
mice	O
,	O
which	O
indicated	O
that	O
the	O
increase	O
in	O
acetic	O
acid	O
production	O
is	O
one	O
of	O
the	O
reasons	O
for	O
feed	O
intake	O
reduction	O
.	O
Also	O
,	O
the	O
negative	O
effects	O
of	O
excess	O
Zn	O
level	O
on	O
SCFAs	O
concentration	O
are	O
in	O
line	O
with	O
the	O
previous	O
findings	O
on	O
piglets	O
(	O
56	O
,	O
57	O
)	O
.	O
Surprisingly	O
,	O
during	O
the	O
long	O
-	O
term	O
intervention	O
,	O
high	O
-	O
Zn	O
-	O
fed	O
mice	O
showed	O
the	O
lowest	O
concentration	O
of	O
SCFAs	O
,	O
except	O
valeric	O
acid	O
and	O
hexanoic	O
acid	O
.	O
Combined	O
with	O
the	O
genus	O
,	O
although	O
the	O
long	O
-	O
term	O
150	O
-	O
mg	O
/	O
kg	O
Zn	O
diet	O
showed	O
the	O
highest	O
abundance	O
of	O
Bifidobacterium	O
,	O
which	O
indirectly	O
contributes	O
to	O
the	O
production	O
of	O
SCFAs	O
(	O
58	O
)	O
,	O
it	O
inhibited	O
the	O
enrichment	O
of	O
SCFA	O
-	O
producing	O
bacteria	O
more	O
than	O
the	O
overdosed	O
diet	O
(	O
600	O
mg	O
/	O
kg	O
)	O
.	O
Consistent	O
with	O
the	O
result	O
for	O
SCFAs	O
,	O
the	O
KEGG	O
pathway	O
“	O
lipid	O
metabolism	O
”	O
was	O
also	O
significantly	O
decreased	O
in	O
the	O
high	O
-	O
Zn	O
-	O
fed	O
mice	O
.	O

In	O
addition	O
,	O
cecal	O
SCFAs	O
production	O
decreases	O
along	O
the	O
colon	O
as	O
a	O
function	O
of	O
distance	O
from	O
the	O
cecum	O
due	O
to	O
absorption	O
by	O
colonocytes	O
for	O
energy	O
or	O
for	O
use	O
in	O
cholesterol	O
,	O
fat	O
,	O
and	O
sugar	O
metabolism	O
(	O
59	O
)	O
.	O
Moreover	O
,	O
SCFAs	O
were	O
found	O
to	O
play	O
essential	O
roles	O
in	O
inflammation	O
suppression	O
,	O
thus	O
promoting	O
the	O
integrity	O
of	O
the	O
intestinal	O
epithelium	O
(	O
60	O
)	O
.	O
The	O
fractional	O
colon	O
inflammatory	O
cell	O
infiltration	O
was	O
partially	O
shown	O
in	O
the	O
8	O
-	O
week	O
high	O
-	O
Zn	O
-	O
fed	O
mice	O
.	O
We	O
speculated	O
that	O
long	O
-	O
term	O
exposure	O
to	O
a	O
high	O
Zn	O
level	O
increases	O
susceptibility	O
to	O
colitis	O
by	O
reducing	O
short	O
-	O
chain	O
fatty	O
acids	O
and	O
decreasing	O
microbial	O
diversity	O
.	O
Depressed	O
levels	O
of	O
SCFAs	O
and	O
decreased	O
α	O
-	O
diversity	O
have	O
been	O
described	O
in	O
the	O
stool	O
of	O
IBD	O
patients	O
(	O
61	O
,	O
62	O
)	O
.	O
In	O
addition	O
,	O
the	O
long	O
-	O
term	O
excess	O
-	O
Zn	O
diet	O
showed	O
a	O
dramatic	O
decrease	O
in	O
valerate	O
production	O
.	O
As	O
previously	O
described	O
,	O
valerate	O
significantly	O
decreased	O
C	O
.	O
difficile	O
growth	O
in	O
an	O
interventional	O
mouse	B-methodology
model	I-methodology
of	O
CDI	O
(	O
63	O
,	O
64	O
)	O
.	O
Our	O
data	O
could	O
further	O
support	O
the	O
research	O
by	O
Zackular	O
et	O
al	O
.	O
showing	O
that	O
excess	O
dietary	O
zinc	O
decreases	O
resistance	O
to	O
CDI	O
(	O
18	O
,	O
65	O
)	O
.	O
With	O
respect	O
to	O
human	O
disease	O
pathways	O
,	O
the	O
individual	O
KEGG	O
terms	O
“	O
drug	O
resistance	O
”	O
and	O
“	O
infection	O
disease	O
”	O
had	O
the	O
highest	O
abundance	O
in	O
the	O
high	O
-	O
Zn	O
-	O
diet	O
group	O
and	O
the	O
lowest	O
abundance	O
in	O
the	O
low	O
-	O
Zn	O
-	O
diet	O
group	O
.	O
It	O
was	O
observed	O
that	O
150	O
mg	O
/	O
kg	O
Zn	O
contributes	O
to	O
an	O
enrichment	O
of	O
the	O
potential	O
pathobiont	O
with	O
drug	O
resistance	O
genes	O
.	O
In	O
agreement	O
with	O
the	O
literature	O
,	O
subinhibitory	O
levels	O
(	O
below	O
the	O
MICs	O
)	O
of	O
heavy	O
metals	O
(	O
Cu	O
,	O
Ag	O
,	O
Cr	O
,	O
and	O
Zn	O
)	O
increased	O
antibiotic	O
-	O
resistant	O
bacteria	O
and	O
antibiotic	O
resistance	O
genes	O
(	O
ARGs	O
)	O
,	O
which	O
in	O
turn	O
contribute	O
to	O
the	O
resistance	O
phenomena	O
via	O
facilitating	O
the	O
horizontal	O
transfer	O
of	O
ARGs	O
(	O
66	O
)	O
.	O
To	O
further	O
discusses	O
the	O
effect	O
of	O
intestinal	O
zinc	O
on	O
human	O
diseases	O
,	O
we	O
assessed	O
differences	O
in	O
probiotics	O
and	O
,	O
potentially	O
,	O
pathobionts	O
among	O
the	O
top	O
20	O
species	O
.	O

Lactobacillus	O
reuteri	O
is	O
a	O
well	O
-	O
studied	O
probiotic	O
bacterium	O
(	O
67	O
)	O
;	O
the	O
decrease	O
in	O
the	O
abundance	O
of	O
L	O
.	O
reuteri	O
in	O
humans	O
in	O
the	O
past	O
decades	O
is	O
correlated	O
with	O
an	O
increase	O
in	O
the	O
incidences	O
of	O
inflammatory	O
diseases	O
over	O
the	O
same	O
period	O
(	O
68	O
)	O
.	O
In	O
our	O
study	O
,	O
L	O
.	O
reuteri	O
was	O
substantially	O
influenced	O
by	O
imbalanced	O
Zn	O
diets	O
,	O
where	O
the	O
excessive	O
Zn	O
diet	O
groups	O
had	O
the	O
lowest	O
proportion	O
of	O
L	O
.	O
reuteri	O
in	O
the	O
4	O
-	O
and	O
8	O
-	O
week	O
interventions	O
.	O
In	O
contrast	O
,	O
it	O
has	O
also	O
been	O
reported	O
that	O
L	O
.	O
reuteri	O
was	O
less	O
affected	O
by	O
pharmacological	O
doses	O
of	O
ZnO	O
(	O
2	O
,	O
425	O
mg	O
/	O
kg	O
)	O
in	O
pigs	O
(	O
56	O
)	O
.	O
This	O
could	O
be	O
due	O
to	O
the	O
ZnO	O
therapy	O
for	O
weaned	O
piglets	O
decades	O
ago	O
,	O
which	O
promoted	O
zinc	O
resistance	O
in	O
intestinal	O
bacteria	O
(	O
69	O
)	O
.	O
The	O
above	O
-	O
described	O
findings	O
would	O
support	O
a	O
forward	O
selection	O
of	O
L	O
.	O
reuteri	O
in	O
pigs	O
with	O
the	O
specific	O
evolutionary	O
adaptation	O
through	O
dietary	O
zinc	O
amounts	O
.	O
Helicobacter	O
hepaticus	O
is	O
the	O
enteric	O
or	O
enterohepatic	O
Helicobacter	O
species	O
(	O
70	O
)	O
;	O
outgrowth	O
of	O
H	O
.	O
hepaticus	O
is	O
related	O
to	O
chronic	O
hepatitis	O
,	O
IBD	O
,	O
colitis	O
,	O
and	O
gallstones	O
(	O
71	O
)	O
.	O
A	O
high	O
proportion	O
of	O
H	O
.	O
hepaticus	O
was	O
observed	O
in	O
the	O
short	O
-	O
term	O
low	O
-	O
Zn	O
diet	O
and	O
long	O
-	O
term	O
high	O
-	O
Zn	O
diet	O
groups	O
.	O
Very	O
little	O
is	O
known	O
about	O
the	O
relationship	O
between	O
the	O
dietary	O
Zn	O
levels	O
and	O
the	O
abundance	O
of	O
H	O
.	O
hepaticus	O
.	O
A	O
previous	O
study	O
showed	O
that	O
Helicobacter	O
pylori	O
infection	O
has	O
no	O
significant	O
effect	O
on	O
serum	O
zinc	O
levels	O
among	O
children	O
(	O
the	O
gastric	O
Helicobacter	O
species	O
)	O
(	O
72	O
)	O
.	O
However	O
,	O
Tran	O
et	O
al	O
.	O
found	O
that	O
short	O
-	O
term	O
zinc	O
supplementation	O
(	O
Zn	O
acetate	O
,	O
1	O
mg	O
/	O
ml	O
;	O
ZnSO4	O
,	O
5	O
mg	O
/	O
ml	O
)	O
attenuated	O
Helicobacter	O
felis	O
-	O
induced	O
gastritis	O
in	O
mice	O
(	O
the	O
gastric	O
Helicobacter	O
species	O
)	O
(	O
73	O
)	O
.	O
Therefore	O
,	O
the	O
correlation	O
between	O
Helicobacter	O
species	O
and	O
the	O
Zn	O
level	O
needs	O
further	O
research	O
.	O

Previous	O
studies	O
tended	O
to	O
utilize	O
serum	O
Zn	O
,	O
nail	O
Zn	O
,	O
and	O
Zn	O
-	O
related	O
genes	O
/	O
proteins	O
(	O
enzymes	O
,	O
inflammatory	O
cytokines	O
,	O
transporters	O
,	O
and	O
binding	O
proteins	O
)	O
to	O
reflect	O
dietary	O
Zn	O
intake	O
(	O
74	O
–	O
76	O
)	O
,	O
whereas	O
in	O
our	O
research	O
,	O
the	O
relative	O
abundance	O
of	O
Melainabacteria	O
(	O
phylum	O
)	O
and	O
Desulfovibrio	O
sp	O
.	O
ABHU2SB	O
(	O
species	O
)	O
appears	O
to	O
be	O
efficacious	O
in	O
differentiating	O
the	O
deficient	O
,	O
normal	O
,	O
or	O
high	O
/	O
excess	O
Zn	O
status	O
in	O
mice	O
.	O
Regarding	O
the	O
Zn	O
-	O
related	O
gene	O
/	O
protein	O
expression	O
,	O
these	O
biomarkers	O
may	O
not	O
be	O
sensitive	O
enough	O
to	O
reveal	O
differences	O
in	O
zinc	O
status	O
in	O
a	O
relatively	O
short	O
-	O
term	O
Zn	O
intervention	O
and	O
could	O
not	O
distinguish	O
between	O
Zn	O
deficiency	O
and	O
Zn	O
excess	O
(	O
77	O
)	O
.	O
Although	O
serum	O
Zn	O
is	O
currently	O
the	O
most	O
reliable	O
predictor	O
,	O
the	O
inherent	O
problems	O
of	O
its	O
measurement	O
and	O
interpretation	O
may	O
disrupt	O
the	O
sensitivity	O
and	O
specificity	O
of	O
serum	O
zinc	O
(	O
20	O
)	O
.	O
The	O
development	O
of	O
sequencing	O
techniques	O
and	O
modeling	O
algorithms	O
facilitates	O
the	O
predictions	O
of	O
the	O
risk	O
of	O
malnutrition	O
and	O
disease	O
outbreaks	O
by	O
microbiota	O
,	O
which	O
is	O
one	O
of	O
the	O
goals	O
of	O
microbiome	O
research	O
(	O
78	O
)	O
.	O
Specifically	O
,	O
intestinal	O
microbial	O
organisms	O
are	O
directly	O
exposed	O
to	O
dietary	O
Zn	O
and	O
easily	O
affected	O
by	O
altered	O
Zn	O
intake	O
(	O
41	O
,	O
79	O
)	O
.	O
Spenser	O
and	O
coworkers	O
found	O
that	O
Clostridium	O
indolis	O
and	O
unclassified	O
Bacteroidales	O
were	O
inversely	O
correlated	O
with	O
the	O
final	O
body	O
weight	O
and	O
the	O
dietary	O
Zn	O
adequacy	O
in	O
chickens	O
,	O
which	O
provided	O
evidence	O
for	O
the	O
potential	O
effectors	O
of	O
the	O
chronic	O
Zn	O
-	O
deficient	O
phenotype	O
(	O
30	O
)	O
.	O
However	O
,	O
the	O
relative	O
abundance	O
of	O
Clostridium	O
species	O
(	O
Clostridium	O
sp	O
.	O
ASF502	O
,	O
Clostridium	O
leptum	O
,	O
etc	O
.	O
)	O
was	O
less	O
dependent	O
on	O
the	O
dietary	O
Zn	O
over	O
the	O
4	O
-	O
week	O
and	O
8	O
-	O
week	O
intervals	O
in	O
mice	O
.	O
Our	O
results	O
showed	O
that	O
Melainabacteria	O
(	O
phyla	O
)	O
and	O
Desulfovibrio	O
sp	O
.	O
ABHU2SB	O
(	O
species	O
)	O
were	O
markedly	O
correlated	O
with	O
serum	O
Zn	O
levels	O
in	O
both	O
the	O
short	O
-	O
term	O
and	O
long	O
-	O
term	O
interventions	O
and	O
responded	O
to	O
Zn	O
imbalance	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

Melainabacteria	O
,	O
a	O
sibling	O
phylum	O
identified	O
in	O
2013	O
,	O
is	O
identified	O
in	O
groundwater	O
,	O
wastewater	O
treatment	O
plants	O
,	O
and	O
herbivorous	O
mammal	O
and	O
human	O
guts	O
and	O
is	O
also	O
known	O
to	O
synthesize	O
vitamins	O
B	O
and	O
K	O
,	O
which	O
suggests	O
they	O
are	O
beneficial	O
bacteria	O
to	O
their	O
hosts	O
(	O
80	O
)	O
.	O
ROC	O
analysis	O
showed	O
that	O
the	O
AUCs	O
of	O
Melainabacteria	O
for	O
distinguishing	O
low	O
Zn	O
levels	O
and	O
high	O
/	O
excess	O
Zn	O
levels	O
were	O
both	O
higher	O
than	O
0	O
.	O
85	O
.	O
A	O
recent	O
study	O
reported	O
that	O
Melainabacteria	O
was	O
ranked	O
the	O
second	O
in	O
abundance	O
in	O
fresh	O
tap	O
water	O
(	O
no	O
Zn	O
detected	O
)	O
yet	O
declined	O
in	O
rank	O
in	O
poststagnation	O
water	O
samples	O
(	O
Zn	O
detected	O
)	O
,	O
which	O
is	O
in	O
line	O
with	O
our	O
study	O
of	O
mice	O
(	O
81	O
)	O
.	O
With	O
regard	O
to	O
Desulfovibrio	O
sp	O
.	O
ABHU2SB	O
,	O
the	O
predicted	O
accuracy	O
was	O
higher	O
than	O
0	O
.	O
85	O
for	O
Zn	O
deficiency	O
status	O
and	O
higher	O
than	O
0	O
.	O
8	O
for	O
Zn	O
excess	O
status	O
.	O
However	O
,	O
the	O
function	O
of	O
Desulfovibrio	O
sp	O
.	O
ABHU2SB	O
and	O
the	O
influence	O
of	O
Zn	O
on	O
Desulfovibrio	O
sp	O
.	O
ABHU2SB	O
have	O
not	O
been	O
well	O
studied	O
.	O
Recent	O
studies	O
reported	O
that	O
the	O
species	O
Desulfovibrio	O
sp	O
.	O
ABHU2SB	O
thrives	O
in	O
experimental	O
autoimmune	O
uveitis	O
rat	O
and	O
type	O
2	O
diabetes	O
animal	O
model	O
KKAy	O
mice	O
(	O
82	O
,	O
83	O
)	O
.	O
Future	O
studies	O
are	O
needed	O
to	O
investigate	O
the	O
mechanism	O
of	O
dietary	O
Zn	O
level	O
on	O
the	O
modulation	O
of	O
these	O
potential	O
microbial	O
markers	O
in	O
order	O
to	O
elucidate	O
new	O
roles	O
for	O
this	O
specific	O
microbe	O
in	O
the	O
etiology	O
and	O
/	O
or	O
progression	O
of	O
Zn	O
imbalance	O
.	O
Collectively	O
,	O
these	O
data	O
revealed	O
that	O
dietary	O
Zn	O
is	O
an	O
essential	O
mediator	O
of	O
microbial	O
community	O
structure	O
and	O
that	O
both	O
Zn	O
deficiency	O
and	O
Zn	O
overdose	O
could	O
generate	O
a	O
dysbiosis	O
in	O
gut	O
microbiota	O
.	O
Moreover	O
,	O
specific	O
microbial	O
biomarkers	O
of	O
Zn	O
status	O
were	O
identified	O
and	O
correlated	O
with	O
serum	O
Zn	O
level	O
.	O
Our	O
study	O
found	O
that	O
a	O
short	O
-	O
term	O
low	O
-	O
Zn	O
diet	O
(	O
0	O
mg	O
/	O
kg	O
)	O
and	O
a	O
long	O
-	O
term	O
high	O
-	O
zinc	O
diet	O
(	O
150	O
mg	O
/	O
kg	O
)	O
had	O
obvious	O
negative	O
effects	O
in	O
a	O
mouse	B-methodology
model	I-methodology
.	O
Thus	O
,	O
these	O
results	O
indicated	O
that	O
the	O
provision	O
and	O
duration	O
of	O
supplemental	O
Zn	O
should	O
be	O
approached	O
with	O
caution	O
.	O

All	O
experimental	B-methodology
protocols	I-methodology
of	O
this	O
study	O
were	O
approved	O
by	O
the	O
Animal	O
Ethics	O
Committee	O
of	O
Zhejiang	O
University	O
in	O
accordance	O
with	O
the	O
relevant	O
regulations	O
and	O
laws	O
.	O
Studies	O
were	O
conducted	O
on	O
3	O
-	O
week	O
-	O
old	O
male	O
C57BL	O
/	O
6	O
mice	O
that	O
were	O
maintained	O
on	O
a	O
12	O
-	O
h	O
light	O
/	O
dark	O
cycle	O
under	O
a	O
temperature	O
-	O
maintained	O
room	O
(	O
20	O
±	O
3°C	O
)	O
and	O
caged	O
in	O
stainless	O
steel	O
cages	O
with	O
free	O
access	O
to	O
deionized	O
water	O
.	O
Diets	O
containing	O
altered	O
Zn	O
levels	O
were	O
synthesized	O
by	O
SLAC	O
Experimental	O
Animals	O
LLC	O
(	O
Data	O
set	O
S1	O
)	O
.	O
Zn	O
was	O
added	O
as	O
carbonate	O
salts	O
,	O
using	O
the	O
AIN	O
-	O
93M	O
standardized	O
diet	O
(	O
84	O
)	O
.	O
We	O
aimed	O
to	O
model	O
the	O
relative	O
amount	O
of	O
imbalance	O
Zn	O
supplement	O
the	O
children	O
intestine	O
might	O
be	O
exposed	O
to	O
based	O
on	O
the	O
amount	O
of	O
Zn	O
that	O
human	O
infants	O
are	O
exposed	O
to	O
.	O
The	O
low	O
-	O
Zn	O
diet	O
had	O
0	O
mg	O
/	O
kg	O
Zn	O
added	O
back	O
to	O
the	O
base	O
diet	O
,	O
which	O
was	O
intended	O
to	O
model	O
Zn	O
starvation	O
in	O
infants	O
.	O
The	O
control	O
-	O
Zn	O
diet	O
,	O
supplemented	O
with	O
30	O
mg	O
/	O
kg	O
Zn	O
,	O
met	O
the	O
recommended	O
value	O
of	O
dietary	O
zinc	O
for	O
mice	O
.	O
The	O
high	O
-	O
Zn	O
diet	O
contained	O
150	O
mg	O
/	O
kg	O
Zn	O
,	O
which	O
is	O
5	O
-	O
fold	O
the	O
amount	O
of	O
Zn	O
in	O
standard	O
mouse	O
chow	O
.	O
It	O
was	O
designed	O
to	O
model	O
the	O
Zinc	O
consumption	O
of	O
many	O
infants	O
,	O
which	O
normally	O
ranges	O
from	O
4	O
to	O
12	O
times	O
their	O
adequate	O
intake	O
(	O
7	O
–	O
9	O
)	O
.	O
The	O
excess	O
-	O
Zn	O
diet	O
,	O
with	O
600	O
mg	O
/	O
kg	O
Zn	O
added	O
,	O
was	O
designed	O
to	O
model	O
Zn	O
-	O
overload	O
intake	O
.	O
A	O
total	O
of	O
64	O
mice	O
were	O
fed	O
altered	O
Zn	O
diets	O
starting	O
at	O
3	O
weeks	O
of	O
age	O
,	O
and	O
diets	O
were	O
maintained	O
for	O
4	O
weeks	O
(	O
short	O
-	O
term	O
zinc	O
intervention	O
)	O
or	O
8	O
weeks	O
(	O
long	O
-	O
term	O
zinc	O
intervention	O
)	O
to	O
model	O
children	O
from	O
weaning	O
to	O
puberty	O
and	O
maturity	O
(	O
n	O
=	O
8	O
)	O
.	O
During	O
the	O
treatment	O
period	O
,	O
the	O
body	O
weights	O
,	O
feed	O
intake	O
,	O
and	O
water	O
intake	O
of	O
the	O
animals	O
were	O
monitored	O
regularly	O
.	O
At	O
the	O
end	O
of	O
the	O
study	O
,	O
mice	O
were	O
fasted	O
for	O
8	O
h	O
before	O
being	O
euthanized	O
with	O
chloral	O
hydrate	O
followed	O
by	O
cervical	O
dislocation	O
,	O
and	O
blood	O
was	O
collected	O
from	O
sedated	O
mice	O
by	O
retro	O
-	O
orbital	O
plexus	O
before	O
sacrifice	O
.	O
Fresh	O
cecal	O
chymus	O
samples	O
from	O
mice	O
were	O
snap	O
-	O
frozen	O
in	O
liquid	O
nitrogen	O
and	O
stored	O
at	O
−80°C	O
until	O
analysis	O
.	O

Briefly	O
,	O
the	O
colon	O
was	O
collected	O
and	O
fixed	O
in	O
10	O
%	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
-	O
buffered	O
formalin	O
and	O
embedded	O
in	O
paraffin	O
.	O
The	O
0	O
.	O
2	O
-	O
mm	O
paraffin	O
sections	O
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
(	O
H	O
&	O
E	O
)	O
.	O
Photomicrographs	O
were	O
obtained	O
using	O
an	O
inverted	O
microscope	O
(	O
Olympus	O
CKX41	O
,	O
Japan	O
)	O
.	O
Serum	O
Zn	O
levels	O
was	O
assessed	O
with	O
a	O
zinc	O
assay	O
kit	O
(	O
E011	O
-	O
1	O
-	O
1	O
;	O
Jiancheng	O
Bioengineering	O
Institute	O
,	O
Nanjing	O
,	O
China	O
)	O
;	O
serum	O
Zn	O
forms	O
a	O
colored	O
complex	O
with	O
5	O
-	O
Br	O
-	O
PAPS	O
in	O
the	O
reagent	O
at	O
room	O
temperature	O
,	O
and	O
the	O
depth	O
of	O
the	O
color	O
is	O
proportional	O
to	O
the	O
zinc	O
ion	O
concentration	O
.	O
The	O
serum	O
Zn	O
levels	O
were	O
positively	O
correlated	O
with	O
dietary	O
Zn	O
in	O
both	O
the	O
4	O
-	O
and	O
8	O
-	O
week	O
intervention	B-methodology
groups	I-methodology
(	O
Fig	O
.	O
S3	O
)	O
.	O
Total	O
genome	O
DNA	O
from	O
samples	O
was	O
extracted	O
using	O
the	O
cetyltrimethylammonium	O
bromide	O
(	O
CTAB	O
)	O
/	O
SDS	O
method	O
.	O
Illumina	O
MiSeq	O
sequencing	O
and	O
general	O
data	O
analysis	O
were	O
performed	O
by	O
a	O
commercial	O
company	O
(	O
Novogene	O
,	O
Beijing	O
,	O
China	O
)	O
.	O
The	O
16S	O
rRNA	O
gene	O
sequence	O
data	O
have	O
been	O
deposited	O
in	O
the	O
NCBI	O
SRA	O
under	O
no	O
.	O
PRJNA749497	O
.	O
Microbial	O
metabolite	O
analysis	O
was	O
performed	O
for	O
randomly	O
selected	O
mice	O
(	O
n	O
=	O
6	O
/	O
group	O
)	O
representing	O
both	O
sets	O
of	O
cages	O
in	O
each	O
diet	O
group	O
.	O
Samples	O
were	O
treated	O
as	O
follows	O
:	O
30	O
mg	O
of	O
cecal	O
chymus	O
was	O
put	O
in	O
a	O
2	O
-	O
ml	O
glass	O
centrifuge	O
tube	O
,	O
900	O
μl	O
0	O
.	O
5	O
%	O
phosphoric	O
acid	O
was	O
added	O
,	O
and	O
the	O
tube	O
was	O
shaken	O
for	O
2	O
min	O
and	O
then	O
centrifuged	O
at	O
14	O
000	O
×	O
g	O
for	O
10	O
min	O
.	O
Then	O
,	O
800	O
μl	O
of	O
the	O
supernatant	O
was	O
extracted	O
,	O
and	O
the	O
same	O
amount	O
of	O
ethyl	O
acetate	O
was	O
added	O
to	O
the	O
extract	O
.	O
Next	O
,	O
600	O
μl	O
supernatant	O
of	O
the	O
extract	O
was	O
mixed	O
with	O
500	O
μM	O
(	O
final	O
concentration	O
)	O
of	O
internal	O
standard	O
(	O
4	O
-	O
methylpentanoic	O
acid	O
)	O
before	O
injection	O
.	O

The	O
samples	O
were	O
separated	O
on	O
an	O
Agilent	O
DB	O
-	O
WAX	O
capillary	O
column	O
(	O
30	O
m	O
×	O
0	O
.	O
25	O
mm	O
ID	O
×	O
0	O
.	O
25	O
μm	O
)	O
gas	O
chromatography	O
system	O
.	O
The	O
temperature	O
programming	O
was	O
as	O
follows	O
:	O
the	O
initial	O
temperature	O
was	O
90°C	O
and	O
remained	O
as	O
such	O
for	O
3	O
min	O
.	O
The	O
temperature	O
increased	O
at	O
10°C	O
/	O
min	O
up	O
to	O
120°C	O
and	O
then	O
increased	O
at	O
25°C	O
/	O
min	O
up	O
to	O
250°C	O
and	O
remained	O
there	O
for	O
20	O
min	O
.	O
The	O
carrier	O
gas	O
was	O
helium	O
,	O
and	O
the	O
carrier	O
gas	O
velocity	O
was	O
1	O
.	O
0	O
ml	O
/	O
min	O
.	O
A	O
quality	B-methodology
control	I-methodology
(	O
QC	O
)	O
sample	O
was	O
used	O
for	O
testing	O
and	O
evaluating	O
the	O
stability	O
and	O
repeatability	O
of	O
the	O
system	O
.	O
An	O
Agilent	O
7890A	O
/	O
5975C	O
gas	O
chromatography	O
-	O
mass	O
spectrometer	O
was	O
used	O
for	O
analysis	O
.	O
The	O
temperatures	O
of	O
the	O
injection	O
port	O
and	O
transmission	O
line	O
were	O
250°C	O
and	O
230°C	O
,	O
respectively	O
.	O
The	O
electron	O
bombardment	O
ionization	O
(	O
EI	O
)	O
source	O
,	O
selected	O
ion	O
monitoring	O
(	O
SIM	O
)	O
scanning	O
mode	O
,	O
and	O
electron	O
energy	O
were	O
70	O
eV	O
.	O
The	O
MSD	O
ChemStation	O
software	O
was	O
used	O
to	O
extract	O
chromatographic	O
peak	O
area	O
and	O
retention	O
time	O
.	O
The	O
content	O
of	O
medium	O
-	O
and	O
long	O
-	O
chain	O
fatty	O
acids	O
in	O
the	O
sample	O
was	O
calculated	O
by	O
plotting	O
the	O
curve	O
.	O
The	O
quality	B-methodology
control	I-methodology
samples	O
were	O
processed	O
together	O
with	O
the	O
biological	O
samples	O
.	O
The	O
detected	O
metabolites	O
in	O
pooled	O
samples	O
with	O
a	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
less	O
than	O
30	O
%	O
were	O
denoted	O
reproducible	O
measurements	O
.	O
The	O
reads	O
of	O
the	O
paired	O
ends	O
were	O
assigned	O
to	O
the	O
samples	O
based	O
on	O
their	O
unique	O
barcodes	O
and	O
truncated	O
by	O
cutting	O
off	O
the	O
barcode	O
and	O
primer	O
sequence	O
.	O
Paired	O
-	O
end	O
reads	O
were	O
merged	O
with	O
FLASH	O
v1	O
.	O
2	O
.	O
7	O
(	O
85	O
)	O
.	O
According	O
to	O
the	O
quality	O
-	O
controlled	O
process	O
of	O
QIIME	O
v1	O
.	O
9	O
.	O
1	O
(	O
86	O
)	O
,	O
the	O
raw	O
labels	O
were	O
quality	O
filtered	O
under	O
specific	O
filtering	O
conditions	O
in	O
order	O
to	O
obtain	O
high	O
-	O
quality	O
clean	O
tags	O
(	O
87	O
)	O
.	O
By	O
detecting	O
chimeric	O
sequences	O
using	O
the	O
UCHIME	O
algorithm	O
(	O
88	O
)	O
,	O
the	O
tags	O
were	O
compared	O
with	O
a	O
reference	O
database	O
(	O
Silva	O
database	O
)	O
,	O
and	O
finally	O
,	O
valid	O
tags	O
were	O
obtained	O
and	O
then	O
the	O
chimeric	O
sequences	O
were	O
removed	O
(	O
89	O
)	O
.	O
Sequences	O
analysis	O
was	O
performed	O
with	O
UPARSE	O
v7	O
.	O
0	O
.	O
1001	O
(	O
90	O
)	O
.	O

Sequences	O
with	O
similarity	O
of	O
≥97	O
%	O
were	O
assigned	O
to	O
the	O
same	O
operational	O
taxonomic	O
units	O
(	O
OTUs	O
)	O
.	O
The	O
representative	O
sequence	O
of	O
each	O
OTU	O
was	O
screened	O
for	O
further	O
annotation	O
.	O
Subsequently	O
,	O
the	O
alpha	O
diversity	O
and	O
beta	O
diversity	O
were	O
analyzed	O
based	O
on	O
this	O
standardized	O
output	O
data	O
.	O
For	O
biomarker	O
identification	O
,	O
linear	O
discriminant	O
analysis	O
effect	O
size	O
(	O
LEfSe	O
)	O
analysis	O
(	O
http	O
:	O
/	O
/	O
huttenhower	O
.	O
sph	O
.	O
harvard	O
.	O
edu	O
/	O
galaxy	O
/	O
)	O
was	O
used	O
to	O
determine	O
differences	O
in	O
categorical	O
component	O
classification	O
between	O
the	O
4	O
cohort	B-methodology
groups	O
.	O
Candidate	O
biomarkers	O
with	O
linear	O
discriminant	O
analysis	O
(	O
>	O
3	O
)	O
were	O
selected	O
as	O
the	O
effective	O
biomarkers	O
.	O
The	O
discriminatory	O
power	O
of	O
the	O
biomarkers	O
was	O
assessed	O
by	O
plotting	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curves	O
and	O
calculating	O
the	O
area	O
under	O
the	O
ROC	O
curve	O
using	O
Prism	O
8	O
.	O
To	O
further	O
understand	O
the	O
specific	O
functions	O
of	O
each	O
group	O
of	O
bacteria	O
,	O
16S	O
high	O
-	O
throughput	O
sequencing	O
data	O
were	O
used	O
to	O
classify	O
the	O
OTUs	O
through	O
the	O
SILVAngs	O
platform	O
based	O
on	O
the	O
SILVA	O
database	O
.	O
The	O
16S	O
copy	O
number	O
was	O
then	O
standardized	O
according	O
to	O
the	O
National	O
Center	O
of	O
Biotechnology	O
Information	O
genome	O
annotation	O
.	O
Finally	O
,	O
the	O
prediction	O
of	O
the	O
microbial	O
community	O
function	O
was	O
realized	O
by	O
constructing	O
a	O
linear	O
relationship	O
between	O
the	O
SILVA	O
classification	O
and	O
pronuclear	O
classification	O
in	O
the	O
KEGG	O
database	O
.	O
The	O
statistical	O
analysis	O
was	O
carried	O
out	O
using	O
SPSS	O
v22	O
.	O
0	O
(	O
IBM	O
,	O
Inc	O
.	O
)	O
.	O
All	O
values	O
were	O
expressed	O
as	O
the	O
mean	O
±	O
standard	O
deviation	O
(	O
SD	O
)	O
.	O
Comparisons	O
between	O
multiple	O
groups	O
were	O
analyzed	O
by	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
with	O
a	O
post	O
hoc	O
Bonferroni	O
test	O
.	O
P	O
values	O
of	O
<	O
0	O
.	O
05	O
were	O
considered	O
to	O
be	O
a	O
significant	O
difference	O
.	O
For	O
correlation	O
analysis	O
,	O
Spearman	O
and	O
Pearson	O
analyses	O
were	O
performed	O
.	O
We	O
are	O
grateful	O
for	O
the	O
financial	O
support	O
of	O
the	O
Natural	O
Science	O
Foundation	O
of	O
China	O
(	O
No	O
.	O
31972998	O
)	O
and	O
the	O
Zhejiang	O
Provincial	O
Key	O
Research	O
and	O
Development	O
Program	O
(	O
2019C02051	O
)	O
.	O
Supplemental	O
material	O
is	O
available	O
online	O
only	O
.	O
10	O
.	O
1128	O
/	O
Spectrum	O
.	O
00483	O
-	O
21	O
.	O
1SUPPLEMENTAL	O
FILE	O
1Supplemental	O
material	O
.	O
Download	O

Effect	O
of	O
a	O
probiotic	O
on	O
blood	O
pressure	O
in	O
grade	O
1	O
hypertension	O
(	O
HYPRO	O
)	O
:	O
protocol	O
of	O
a	O
randomized	B-methodology
controlled	I-methodology
study	I-methodology
Hypertension	O
;	O
Probiotic	O
;	O
Vivomixx®	O
;	O
Blood	O
pressure	O
;	O
Microbiome	O
;	O
Metabolome	O
;	O
Immune	O
cell	O
phenotype	O
;	O
Glucose	O
variability	O
;	O
Randomized	B-methodology
controlled	I-methodology
trial	I-methodology
Arterial	O
hypertension	O
is	O
a	O
major	O
risk	O
factor	O
for	O
cardiovascular	O
disease	O
and	O
leads	O
to	O
target	O
organ	O
damage	O
including	O
stroke	O
,	O
heart	O
failure	O
,	O
and	O
kidney	O
disease	O
.	O
About	O
1	O
.	O
5	O
billion	O
people	O
worldwide	O
have	O
hypertension	O
,	O
and	O
it	O
is	O
estimated	O
that	O
it	O
causes	O
about	O
8	O
million	O
deaths	O
each	O
year	O
.	O
Although	O
there	O
are	O
several	O
drugs	O
available	O
to	O
lower	O
blood	O
pressure	O
(	O
BP	O
)	O
,	O
a	O
great	O
proportion	O
of	O
treated	O
patients	O
does	O
not	O
reach	O
recommended	O
treatment	O
targets	O
.	O
Typical	O
antihypertensive	O
drugs	O
target	O
the	O
vessels	O
,	O
the	O
kidneys	O
,	O
and	O
the	O
heart	O
.	O
However	O
,	O
our	O
gut	O
microbiota	O
also	O
influences	O
cardiovascular	O
health	O
,	O
and	O
gut	O
dysbiosis	O
is	O
associated	O
with	O
hypertension	O
.	O
In	O
this	O
study	B-methodology
protocol	I-methodology
,	O
we	O
investigate	O
the	O
potential	O
BP	O
-	O
lowering	O
effect	O
of	O
a	O
probiotic	O
in	O
patients	O
with	O
grade	O
1	O
hypertension	O
.	O
This	O
study	O
is	O
an	O
exploratory	O
,	O
randomized	O
,	O
double	B-methodology
-	I-methodology
blind	I-methodology
,	I-methodology
placebo	I-methodology
-	O
controlled	O
,	O
parallel	B-methodology
-	I-methodology
group	I-methodology
study	I-methodology
.	O
One	O
hundred	O
ten	O
patients	O
with	O
grade	O
1	O
hypertension	O
(	O
treated	O
or	O
untreated	O
)	O
will	O
be	O
randomized	O
to	O
either	O
the	O
probiotic	O
Vivomixx®	O
or	O
placebo	B-methodology
.	O
The	O
primary	O
endpoint	O
is	O
the	O
nocturnal	O
systolic	O
BP	O
measured	O
by	O
ambulatory	O
blood	O
pressure	O
monitoring	O
after	O
8	O
weeks	O
adjusted	O
for	O
the	O
baseline	O
value	O
.	O
The	O
secondary	O
endpoints	O
are	O
changes	O
from	O
baseline	O
in	O
nocturnal	O
diastolic	O
BP	O
,	O
antihypertensive	O
medication	O
,	O
fecal	O
microbiome	O
composition	O
,	O
fecal	O
and	O
serum	O
metabolome	O
,	O
immune	O
cell	O
phenotypes	O
,	O
glucose	O
variability	O
after	O
three	O
standardized	O
breakfasts	O
,	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
PROMIS	O
-	O
29	O
)	O
.	O
We	O
also	O
assess	O
the	O
safety	O
profile	O
of	O
the	O
intervention	O
.	O
We	O
postulate	O
that	O
various	O
administrated	O
bacteria	O
(	O
Lactobacilli	O
,	O
Bifidobacteria	O
,	O
and	O
Streptococcus	O
thermophilus	O
)	O
convert	O
dietary	O
components	O
into	O
active	O
metabolites	O
that	O
positively	O
affect	O
immune	O
cell	O
function	O
.	O
A	O
reduction	O
of	O
pro	O
-	O
inflammatory	O
immune	O
cell	O
function	O
could	O
promote	O
a	O
BP	O
-	O
lowering	O
effect	O
.	O

ClinicalTrials	O
.	O
gov	O
NCT03906578	O
.	O
Registered	O
on	O
08	O
April	O
2019	O
The	O
online	O
version	O
contains	O
supplementary	O
material	O
available	O
at	O
10	O
.	O
1186	O
/	O
s13063	O
-	O
020	O
-	O
04973	O
-	O
0	O
.	O
Arterial	O
hypertension	O
is	O
one	O
of	O
the	O
major	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
,	O
including	O
ischemic	O
heart	O
disease	O
,	O
heart	O
failure	O
,	O
kidney	O
disease	O
,	O
and	O
stroke	O
.	O
About	O
1	O
.	O
5	O
billion	O
people	O
worldwide	O
develop	O
arterial	O
hypertension	O
[	O
1	O
]	O
to	O
which	O
about	O
8	O
million	O
premature	O
deaths	O
per	O
year	O
are	O
attributable	O
[	O
2	O
]	O
.	O
The	O
Global	O
Burden	O
of	O
Disease	O
Study	O
2013	O
revealed	O
that	O
—	O
after	O
dietary	O
risks	O
—	O
high	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
was	O
the	O
second	O
most	O
important	O
risk	O
factor	O
for	O
morbidity	O
and	O
mortality	O
globally	O
,	O
exceeding	O
the	O
risks	O
of	O
tobacco	O
smoke	O
,	O
high	O
body	O
mass	O
index	O
,	O
high	O
fasting	O
plasma	O
glucose	O
,	O
and	O
high	O
total	O
cholesterol	O
[	O
3	O
]	O
.	O
In	O
2017	O
,	O
15	O
%	O
of	O
women	O
and	O
25	O
%	O
of	O
men	O
in	O
Germany	O
had	O
elevated	O
BP	O
[	O
4	O
]	O
.	O
Commonly	O
used	O
antihypertensive	O
drugs	O
typically	O
target	O
different	O
hormone	O
systems	O
(	O
e	O
.	O
g	O
.	O
,	O
renin	O
-	O
angiotensin	O
system	O
)	O
and	O
the	O
production	O
of	O
endogenous	O
vasoactive	O
substances	O
,	O
aiming	O
to	O
protect	O
the	O
blood	O
vessels	O
,	O
heart	O
,	O
and	O
kidney	O
.	O
However	O
,	O
despite	O
the	O
fact	O
that	O
there	O
are	O
several	O
drugs	O
available	O
to	O
lower	O
BP	O
,	O
a	O
large	O
proportion	O
of	O
treated	O
patients	O
do	O
not	O
reach	O
the	O
BP	O
targets	O
recommended	O
by	O
current	O
guidelines	B-methodology
[	O
5	O
]	O
.	O
Non	O
-	O
pharmacological	O
approaches	O
to	O
prevent	O
and	O
treat	O
hypertension	O
are	O
lifestyle	O
modifications	O
,	O
such	O
as	O
increased	O
physical	O
activity	O
,	O
reduced	O
salt	O
and	O
alcohol	O
intake	O
,	O
weight	O
loss	O
,	O
and	O
a	O
healthy	O
diet	O
[	O
6	O
]	O
.	O
Another	O
non	O
-	O
pharmacological	O
approach	O
to	O
lower	O
BP	O
is	O
the	O
use	O
of	O
probiotics	O
.	O
Research	O
efforts	O
in	O
this	O
field	O
first	O
focused	O
on	O
milk	O
fermented	O
with	O
Lactobacillus	O
helveticus	O
,	O
which	O
contains	O
two	O
tripeptides	O
that	O
inhibit	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
[	O
7	O
]	O
.	O
Since	O
1996	O
,	O
a	O
number	O
of	O
clinical	B-methodology
studies	I-methodology
that	O
investigated	O
the	O
BP	O
-	O
lowering	O
effects	O
of	O
fermented	O
dairy	O
products	O
in	O
hypertensive	O
subjects	O
were	O
published	O
,	O
and	O
the	O
majority	O
of	O
them	O
showed	O
BP	O
-	O
lowering	O
effects	O
.	O

However	O
,	O
a	O
Cochrane	O
review	O
in	O
2012	O
evaluated	O
these	O
studies	O
and	O
concluded	O
that	O
the	O
effect	O
on	O
systolic	O
BP	O
was	O
too	O
modest	O
to	O
recommend	O
a	O
general	O
use	O
in	O
the	O
treatment	O
of	O
hypertension	O
[	O
8	O
]	O
.	O
Two	O
years	O
later	O
,	O
a	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
of	O
9	O
studies	O
,	O
which	O
investigated	O
the	O
effect	O
of	O
various	O
probiotics	O
,	O
found	O
a	O
modest	O
but	O
clinically	O
meaningful	O
BP	O
reduction	O
[	O
9	O
]	O
.	O
This	O
was	O
confirmed	O
by	O
a	O
very	O
recent	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
of	O
14	O
studies	O
published	O
between	O
2002	O
and	O
2019	O
[	O
10	O
]	O
.	O
Here	O
,	O
we	O
use	O
a	O
probiotic	O
formulation	O
with	O
a	O
high	O
concentration	O
of	O
eight	O
different	O
live	O
bacterial	O
strains	O
.	O
Our	O
proposed	O
mode	O
of	O
action	O
is	O
not	O
through	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibition	O
but	O
through	O
the	O
modulation	O
of	O
the	O
microbiota	O
-	O
immune	O
interaction	O
.	O
The	O
gut	O
microbiota	O
is	O
thought	O
to	O
be	O
relevant	O
for	O
cardiovascular	O
health	O
[	O
11	O
]	O
,	O
and	O
microbial	O
imbalance	O
is	O
linked	O
to	O
experimental	O
and	O
human	O
hypertension	O
[	O
12	O
,	O
13	O
]	O
.	O
This	O
is	O
supported	O
by	O
recent	O
epidemiological	O
evidence	O
showing	O
that	O
higher	O
total	O
yogurt	O
intake	O
lowers	O
the	O
risk	O
of	O
incident	O
high	O
BP	O
in	O
middle	O
-	O
aged	O
and	O
older	O
adults	O
[	O
14	O
]	O
.	O
Furthermore	O
,	O
hypertensive	O
subjects	O
with	O
a	O
high	O
yogurt	O
intake	O
had	O
a	O
lower	O
risk	O
of	O
developing	O
cardiovascular	O
disease	O
[	O
15	O
]	O
.	O
Microbial	O
metabolites	O
are	O
resorbed	O
from	O
the	O
intestinal	O
lumen	O
and	O
affect	O
various	O
functions	O
of	O
the	O
host	O
.	O
Their	O
effects	O
are	O
not	O
restricted	O
to	O
the	O
intestine	O
but	O
also	O
affect	O
the	O
immune	O
system	O
,	O
the	O
vasculature	O
,	O
and	O
the	O
kidney	O
.	O
Hypertensive	O
organ	O
damage	O
seems	O
to	O
be	O
largely	O
mediated	O
by	O
immune	O
cells	O
like	O
effector	O
memory	O
T	O
cells	O
[	O
16	O
]	O
and	O
T	O
cells	O
producing	O
interleukin	O
-	O
17	O
(	O
Th17	O
cells	O
)	O
[	O
17	O
]	O
.	O
Recently	O
,	O
we	O
demonstrated	O
that	O
a	O
high	O
-	O
salt	O
diet	O
affected	O
fecal	O
Lactobacillus	O
abundance	O
in	O
mice	O
and	O
humans	O
alongside	O
increased	O
BP	O
and	O
Th17	O
abundance	O
.	O
A	O
probiotic	O
Lactobacillus	O
treatment	O
reduced	O
the	O
salt	O
-	O
induced	O
increase	O
in	O
BP	O
and	O
Th17	O
[	O
18	O
]	O
.	O
In	O
an	O
exploratory	B-methodology
study	I-methodology
,	O
we	O
found	O
that	O
Vivomixx®	O
prevented	O
a	O
high	O
salt	O
-	O
induced	O
increase	O
in	O
BP	O
in	O
healthy	O
men	O
(	O
unpublished	O
data	O
,	O
NCT02971787	O
)	O
.	O

In	O
subjects	O
eating	O
a	O
synbiotic	O
yogurt	O
for	O
90	O
days	O
,	O
we	O
found	O
that	O
an	O
increased	O
capacity	O
for	O
intestinal	O
short	O
-	O
chain	O
fatty	O
acid	O
production	O
was	O
correlated	O
with	O
diastolic	O
BP	O
reduction	O
[	O
19	O
]	O
.	O
Here	O
,	O
we	O
present	O
the	O
protocol	O
of	O
a	O
randomized	O
,	O
double	B-methodology
-	I-methodology
blind	I-methodology
,	I-methodology
placebo	I-methodology
-	O
controlled	B-methodology
study	I-methodology
investigating	O
the	O
effects	O
of	O
a	O
probiotic	O
in	O
patients	O
with	O
grade	O
1	O
hypertension	O
.	O
We	O
hypothesize	O
that	O
the	O
probiotic	O
is	O
superior	O
to	O
placebo	B-methodology
in	O
lowering	O
BP	O
.	O
Secondary	O
endpoints	O
are	O
changes	O
in	O
antihypertensive	O
medication	O
,	O
fecal	O
microbiome	O
composition	O
,	O
fecal	O
and	O
serum	O
metabolome	O
,	O
immune	O
cell	O
phenotypes	O
,	O
glucose	O
variability	O
after	O
three	O
standardized	O
breakfasts	O
,	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
.	O
This	O
is	O
an	O
exploratory	O
,	O
randomized	O
,	O
double	B-methodology
-	I-methodology
blind	I-methodology
,	I-methodology
placebo	I-methodology
-	O
controlled	O
,	O
parallel	B-methodology
-	I-methodology
group	I-methodology
study	I-methodology
conducted	O
at	O
the	O
Experimental	O
and	O
Clinical	B-methodology
Research	I-methodology
Center	O
of	O
Charité	O
-	O
Universitätsmedizin	O
Berlin	O
,	O
Germany	O
.	O
Recruitment	O
started	O
in	O
August	O
2019	O
(	O
ClinicalTrials	O
.	O
gov	O
identifier	O
:	O
NCT03906578	O
)	O
.	O
Patients	O
are	O
recruited	O
from	O
greater	O
Berlin	O
,	O
Germany	O
.	O
Recruitment	O
is	O
performed	O
via	O
the	O
hypertension	O
outpatient	O
clinic	O
at	O
Helios	O
Klinikum	O
Berlin	O
-	O
Buch	O
,	O
study	O
flyers	O
in	O
medical	O
practices	O
,	O
and	O
advertisements	O
in	O
a	O
broad	O
range	O
of	O
media	O
relevant	O
to	O
the	O
study	O
population	O
.	O
We	O
intend	O
to	O
randomize	O
110	O
patients	O
with	O
grade	O
1	O
hypertension	O
to	O
either	O
8	O
weeks	O
of	O
Vivomixx®	O
or	O
placebo	B-methodology
.	O
The	O
intervention	O
is	O
followed	O
by	O
a	O
4	O
-	O
week	O
recovery	O
period	O
.	O
This	O
study	B-methodology
protocol	I-methodology
was	O
approved	O
by	O
the	O
institutional	O
review	O
board	O
of	O
Charité	O
-	O
Universitätsmedizin	O
Berlin	O
,	O
and	O
we	O
obtain	O
written	B-methodology
informed	I-methodology
consent	I-methodology
from	O
all	O
participants	O
before	O
study	O
entry	O
(	O
Additional	O
files	O
1	O
and	O
2	O
)	O
.	O
The	O
study	O
is	O
conducted	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
in	O
its	O
currently	O
applicable	O
version	O
,	O
the	O
guidelines	B-methodology
of	O
the	O
International	O
Conference	O
on	O
Harmonization	O
of	O
Good	O
Clinical	B-methodology
Practice	I-methodology
(	O
ICH	O
-	O
GCP	O
)	O
,	O
and	O
applicable	O
German	O
laws	O
.	O
Information	O
and	O
informed	O
consent	O
forms	O
have	O
been	O
prepared	O
in	O
accordance	O
with	O
the	O
guidelines	B-methodology
of	O
the	O
institutional	O
review	O
board	O
of	O
Charité	O
-	O
Universitätsmedizin	O
Berlin	O
.	O
Potential	O
participants	O
receive	O
both	O
forms	O
at	O
least	O
1	O
day	O
before	O
their	O
screening	O
visit	O
.	O

During	O
this	O
visit	O
,	O
a	O
study	O
physician	O
explains	O
all	O
study	O
procedures	O
,	O
and	O
written	B-methodology
informed	I-methodology
consent	I-methodology
is	O
only	O
given	O
after	O
participants	O
had	O
adequate	O
time	O
to	O
ask	O
questions	O
.	O
We	O
include	O
men	O
and	O
postmenopausal	O
women	O
with	O
grade	O
1	O
hypertension	O
in	O
this	O
study	O
.	O
Men	O
and	O
postmenopausal	O
women	O
(	O
ratio	O
1	O
:	O
1	O
)	O
50	O
–	O
75	O
years	O
of	O
age	O
Grade	O
1	O
hypertension	O
,	O
defined	O
as	O
resting	O
office	O
blood	O
pressure	O
of	O
140	O
–	O
159	O
and	O
/	O
or	O
90	O
–	O
99	O
mmHg	O
according	O
to	O
the	O
European	O
Societies	O
of	O
Cardiology	O
and	O
Hypertension	O
(	O
ESC	O
/	O
ESH	O
)	O
guidelines	B-methodology
[	O
20	O
]	O
Hypertension	O
can	O
be	O
treated	O
or	O
untreated	O
Body	O
mass	O
index	O
between	O
18	O
.	O
5	O
and	O
34	O
.	O
9	O
kg	O
/	O
m2	O
Secondary	O
causes	O
of	O
hypertension	O
Known	O
target	O
organ	O
damage	O
Pharmacological	O
BP	O
treatment	O
which	O
has	O
been	O
initiated	O
recently	O
(	O
<	O
1	O
month	O
)	O
and	O
is	O
still	O
in	O
the	O
optimization	O
phase	O
Ten	O
-	O
year	O
cardiovascular	O
risk	O
score	O
>	O
5	O
%	O
according	O
to	O
the	O
2017	O
ACC	O
/	O
AHA	O
guideline	B-methodology
Clinically	O
relevant	O
metabolic	O
,	O
autoimmune	O
,	O
chronic	O
,	O
progressive	O
,	O
or	O
malignant	O
diseases	O
Postoperative	O
phase	O
Current	O
or	O
chronic	O
infections	O
Use	O
of	O
antibiotics	O
within	O
3	O
months	O
before	O
the	O
study	O
Regular	O
use	O
of	O
probiotics	O
and	O
dietary	O
supplements	O
Special	O
diet	O
for	O
medical	O
reasons	O
Food	O
intolerances	O
and	O
food	O
allergies	O
Vegan	O
diet	O
Weight	O
loss	O
diet	O
or	O
loss	O
of	O
more	O
than	O
2	O
kg	O
within	O
1	O
month	O
before	O
the	O
study	O
Inability	O
to	O
fully	O
understand	O
the	O
significance	O
,	O
procedures	O
,	O
and	O
scope	O
of	O
this	O
study	O
Known	O
alcohol	O
or	O
drug	O
abuse	O
Participation	O
in	O
another	O
interventional	B-methodology
study	I-methodology
The	O
discontinuation	O
criteria	O
are	O
withdrawal	O
of	O
consent	O
,	O
subsequent	O
occurrence	O
of	O
an	O
exclusion	O
criterion	O
(	O
e	O
.	O
g	O
.	O
,	O
change	O
of	O
BP	O
medication	O
)	O
,	O
lack	O
of	O
compliance	O
,	O
and	O
other	O
medical	O
reasons	O
for	O
stopping	O
the	O
intervention	O
.	O
An	O
advantage	O
in	O
terms	O
of	O
compliance	O
is	O
the	O
fact	O
that	O
patients	O
only	O
have	O
to	O
take	O
a	O
single	O
dose	O
of	O
the	O
probiotic	O
or	O
placebo	B-methodology
for	O
a	O
relatively	O
short	O
period	O
.	O
A	O
potential	O
disadvantage	O
is	O
the	O
fact	O
that	O
they	O
only	O
suffer	O
from	O
a	O
mild	O
form	O
of	O
hypertension	O
,	O
which	O
might	O
decrease	O
compliance	O
.	O

To	O
improve	O
and	O
/	O
or	O
ensure	O
compliance	O
,	O
we	O
ask	O
patients	O
before	O
inclusion	O
if	O
they	O
intend	O
to	O
be	O
compliant	O
,	O
establish	O
a	O
good	O
relationship	O
,	O
give	O
simple	O
and	O
precise	O
verbal	O
and	O
written	O
instructions	O
,	O
and	O
directly	O
question	O
patients	O
for	O
regular	O
probiotics	O
/	O
placebo	B-methodology
intake	O
and	O
estimate	O
compliance	O
by	O
counting	O
unused	O
sachets	O
.	O
These	O
efforts	O
also	O
improve	O
the	O
retention	O
of	O
patients	O
in	O
the	O
study	O
.	O
In	O
addition	O
,	O
we	O
will	O
detect	O
probiotic	O
bacterial	O
strains	O
in	O
stool	O
samples	O
.	O
However	O
,	O
these	O
bacteria	O
are	O
thought	O
to	O
transiently	O
colonize	O
the	O
intestine	O
.	O
Thus	O
,	O
their	O
detection	O
in	O
stool	O
samples	O
after	O
8	B-methodology
weeks	I-methodology
of	I-methodology
intervention	I-methodology
does	O
not	O
necessarily	O
confirm	O
rigorous	O
compliance	O
.	O
Eligible	O
patients	O
are	O
included	O
after	O
the	O
successful	O
screening	O
.	O
Randomization	O
is	O
done	O
by	O
the	O
supplier	O
(	O
see	O
below	O
)	O
based	O
on	O
the	O
lists	O
generated	O
with	O
an	O
ad	O
hoc	O
SAS®	O
program	O
(	O
sex	O
stratification	O
,	O
randomly	O
varying	O
block	O
sizes	O
)	O
.	O
Based	O
on	O
these	O
lists	O
,	O
the	O
supplier	O
delivers	O
sequentially	O
numbered	O
boxes	O
containing	O
sachets	O
to	O
the	O
study	O
center	O
without	O
any	O
information	O
on	O
group	O
allocation	O
.	O
Thus	O
,	O
strictly	O
concealed	O
allocation	O
and	O
complete	O
blinding	O
are	O
ensured	O
.	O
A	O
person	O
of	O
trust	O
from	O
the	O
study	O
center	O
not	O
involved	O
in	O
the	O
study	O
has	O
access	O
to	O
sealed	O
envelopes	O
for	O
each	O
participant	O
,	O
thereby	O
enabling	O
disclosure	O
of	O
group	O
allocation	O
if	O
necessary	O
.	O
Vivomixx®	O
is	O
a	O
microbiotic	O
food	O
supplement	O
.	O
It	O
contains	O
eight	O
strains	O
of	O
live	O
bacteria	O
(	O
Lactobacilli	O
paracasei	O
,	O
plantarum	O
,	O
acidophilus	O
,	O
and	O
delbrueckii	O
;	O
Bifidobacteria	O
longum	O
,	O
infantis	O
,	O
and	O
breve	O
;	O
Streptococcus	O
thermophilus	O
)	O
in	O
a	O
concentration	O
of	O
450	O
billion	O
bacteria	O
per	O
sachet	O
.	O
Patients	O
take	O
the	O
content	O
of	O
two	O
sachets	O
dissolved	O
in	O
water	O
in	O
the	O
evening	O
(	O
approx	O
.	O
every	O
24	O
h	O
,	O
either	O
30	O
min	O
before	O
or	O
2	O
h	O
after	O
dinner	O
)	O
.	O
Two	O
sachets	O
yield	O
a	O
daily	O
dose	O
of	O
9	O
×	O
1011	O
colony	O
-	O
forming	O
units	O
(	O
CFU	O
)	O
.	O
The	O
placebo	B-methodology
group	I-methodology
takes	O
sachets	O
with	O
an	O
identically	O
appearing	O
powder	O
without	O
any	O
bacteria	O
.	O
Both	O
interventional	O
products	O
are	O
provided	O
by	O
the	O
supplier	O
Mendes	O
S	O
.	O
A	O
,	O
Lugano	O
,	O
Switzerland	O
.	O
Vivomixx®	O
has	O
been	O
safely	O
used	O
in	O
other	O
studies	O
and	O
was	O
well	O
tolerated	O
,	O
even	O
in	O
patients	O
with	O
irritable	O
bowel	O
syndrome	O
[	O
21	O
]	O
.	O
Minor	O
adverse	O
events	O
of	O
probiotics	O
can	O
be	O
increased	O
gas	O
,	O
bloating	O
,	O
and	O
stool	O
frequency	O
.	O

These	O
side	O
effects	O
are	O
mild	O
and	O
transient	O
.	O
Nevertheless	O
,	O
we	O
question	O
all	O
patients	O
at	O
each	O
visit	O
for	O
related	O
or	O
unrelated	O
health	O
issues	O
and	O
record	O
all	O
adverse	O
events	O
.	O
Serious	O
adverse	O
events	O
due	O
to	O
this	O
probiotic	O
are	O
not	O
to	O
be	O
expected	O
.	O
All	O
outcomes	O
are	O
assessed	O
at	O
three	O
time	O
points	O
—	O
at	O
baseline	O
,	O
after	O
8	O
weeks	O
of	O
intervention	O
,	O
and	O
4	O
weeks	O
after	O
discontinuation	O
(	O
recovery	O
)	O
.	O
Our	O
primary	O
hypothesis	O
is	O
that	O
a	O
probiotic	O
containing	O
eight	O
different	O
strains	O
of	O
live	O
bacteria	O
reduces	O
BP	O
in	O
grade	O
1	O
hypertension	O
.	O
Accordingly	O
,	O
our	O
primary	O
endpoint	O
is	O
the	O
mean	O
nocturnal	O
systolic	O
BP	O
after	O
8	O
weeks	O
of	O
probiotic	O
intake	O
compared	O
to	O
placebo	B-methodology
and	O
adjusted	O
for	O
the	O
baseline	O
value	O
.	O
We	O
already	O
used	O
this	O
outcome	O
to	O
attain	O
a	O
maximally	O
standardized	O
way	O
of	O
BP	O
measurement	O
[	O
18	O
]	O
.	O
Other	O
established	O
outcomes	O
in	O
hypertension	O
research	O
like	O
office	O
BP	O
and	O
ambulatory	O
24	O
-	O
h	O
BP	O
will	O
be	O
included	O
as	O
important	O
secondary	O
outcomes	O
.	O
Further	O
secondary	O
endpoints	O
are	O
change	O
of	O
antihypertensive	O
medication	O
,	O
fecal	O
microbiome	O
composition	O
,	O
fecal	O
and	O
serum	O
metabolome	O
,	O
immune	O
cell	O
phenotypes	O
,	O
glucose	O
variability	O
after	O
three	O
standardized	O
breakfasts	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
from	O
baseline	O
.	O
We	O
perform	O
a	O
4	O
-	O
week	O
follow	O
-	O
up	O
after	O
the	O
intervention	O
,	O
in	O
which	O
procedures	O
will	O
be	O
repeated	O
to	O
investigate	O
any	O
prolonged	O
treatment	O
effects	O
.	O
We	O
will	O
also	O
control	O
for	O
BP	O
-	O
reducing	O
lifestyle	O
factors	O
such	O
as	O
weight	O
reduction	O
(	O
anthropometry	O
)	O
and	O
dietary	O
habits	O
including	O
salt	O
intake	O
(	O
food	O
records	O
)	O
before	O
and	O
after	O
the	O
intervention	O
.	O
Body	O
composition	O
is	O
measured	O
by	O
air	O
-	O
displacement	O
plethysmography	O
,	O
and	O
the	O
blood	O
is	O
sampled	O
for	O
routine	O
and	O
research	O
measurements	O
as	O
well	O
as	O
peripheral	O
blood	O
mononuclear	O
cell	O
(	O
PBMC	O
)	O
isolation	O
.	O
In	O
addition	O
,	O
patients	O
rate	O
their	O
health	O
-	O
related	O
quality	O
of	O
life	O
with	O
the	O
PROMIS	O
-	O
29	O
questionnaire	O
.	O
Glucose	O
variability	O
is	O
measured	O
by	O
continuous	O
glucose	O
monitoring	O
(	O
FreeStyle	O
Libre	O
Pro	O
,	O
Abbott	O
)	O
.	O
For	O
this	O
,	O
a	O
sensor	O
is	O
placed	O
in	O
the	O
adipose	O
tissue	O
(	O
triceps	O
region	O
)	O
where	O
it	O
measures	O
the	O
interstitial	O
glucose	O
concentration	O
every	O
15	O
min	O
for	O
7	O
days	O
.	O
To	O
study	O
possible	O
changes	O
in	O
postprandial	O
glucose	O
concentrations	O
,	O
patients	O
are	O
asked	O
to	O
eat	O
three	O
standardized	O
breakfasts	O
on	O
three	O
consecutive	O
mornings	O
while	O
wearing	O
the	O
sensor	O
.	O
These	O
breakfasts	O
are	O
prepared	O
in	O
the	O
study	O
center	O
and	O
handed	O
out	O
to	O
patients	O
to	O
eat	O
at	O
home	O
.	O

Breakfasts	O
are	O
similar	O
in	O
calorie	O
and	O
carbohydrate	O
content	O
but	O
differ	O
in	O
glycemic	O
index	O
(	O
high	O
,	O
medium	O
,	O
low	O
)	O
.	O
To	O
evaluate	O
and	O
control	O
for	O
dietary	O
intake	O
,	O
patients	O
record	O
food	O
and	O
beverage	O
consumption	O
in	O
4	O
-	O
day	O
food	O
records	O
while	O
wearing	O
the	O
sensor	O
.	O
Although	O
food	O
records	O
over	O
the	O
whole	O
7	O
days	O
might	O
have	O
been	O
preferable	O
,	O
4	O
-	O
day	O
records	O
are	O
considered	O
to	O
yield	O
sufficient	O
results	O
,	O
are	O
less	O
demanding	O
on	O
patients	O
and	O
investigators	O
,	O
and	O
reduce	O
the	O
time	O
in	O
which	O
dietary	O
habits	O
might	O
change	O
due	O
to	O
recording	O
,	O
e	O
.	O
g	O
.	O
,	O
undereating	O
.	O
Records	O
will	O
be	O
analyzed	O
for	O
macro	O
-	O
and	O
micronutrient	O
content	O
using	O
OptiDiet	O
Plus	O
(	O
V6	O
.	O
0	O
,	O
GOE	O
,	O
Linden	O
,	O
Germany	O
)	O
.	O
This	O
professional	O
analysis	O
software	O
uses	O
the	O
nutrient	O
content	O
of	O
12	O
,	O
000	O
foods	O
provided	O
by	O
the	O
German	O
Nutrient	O
Database	O
.	O
From	O
stool	O
samples	O
,	O
bacterial	O
DNA	O
will	O
be	O
sequenced	O
,	O
and	O
fecal	O
and	O
serum	O
metabolites	O
will	O
be	O
measured	O
by	O
mass	O
spectrometry	O
.	O
We	O
will	O
explore	O
metabolites	O
with	O
–	O
omics	O
-	O
based	O
methods	O
.	O
We	O
hypothesize	O
that	O
changes	O
in	O
the	O
gut	O
microbiota	O
affect	O
the	O
ratio	O
of	O
certain	O
tryptophan	O
metabolites	O
and	O
levels	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
,	O
which	O
in	O
turn	O
affect	O
immune	O
responses	O
and	O
blood	O
pressure	O
.	O
However	O
,	O
we	O
will	O
also	O
design	O
more	O
experiments	O
that	O
address	O
the	O
biological	O
question	O
of	O
this	O
study	O
.	O
The	O
obtained	O
results	O
will	O
enable	O
the	O
construction	O
of	O
rigorous	O
scientific	O
hypotheses	O
which	O
can	O
be	O
tested	O
later	O
using	O
-	O
omic	O
or	O
non	O
-	O
omic	O
methods	O
.	O
Table	O
1	O
provides	O
a	O
detailed	O
overview	O
of	O
assessments	O
and	O
endpoints	O
.	O
Based	O
on	O
the	O
above	O
mentioned	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
[	O
9	O
]	O
and	O
on	O
our	O
own	O
unpublished	O
data	O
(	O
NCT02509962	O
,	O
NCT02971787	O
)	O
,	O
we	O
estimate	O
a	O
mean	O
decrease	O
in	O
systolic	O
BP	O
of	O
3	O
.	O
8	O
mmHg	O
with	O
a	O
standard	O
deviation	O
of	O
5	O
.	O
0	O
mmHg	O
in	O
the	O
probiotic	O
group	O
.	O
In	O
addition	O
,	O
we	O
assume	O
that	O
the	O
placebo	B-methodology
group	I-methodology
will	O
have	O
the	O
same	O
systolic	O
BP	O
baseline	O
value	O
and	O
a	O
small	O
decrease	O
in	O
the	O
mean	O
systolic	O
BP	O
of	O
0	O
.	O
2	O
mmHg	O
with	O
the	O
same	O
standard	O
deviation	O
.	O
That	O
leads	O
to	O
a	O
standardized	O
effect	O
size	O
between	O
groups	O
of	O
(	O
3	O
.	O
8	O
−	O
0	O
.	O
2	O
)	O
/	O
(	O
√2	O
×	O
5	O
.	O
0	O
)	O
≈	O
0	O
.	O
51	O
.	O

The	O
required	O
sample	O
size	O
to	O
find	O
a	O
significant	O
effect	O
with	O
a	O
power	O
of	O
0	O
.	O
8	O
at	O
a	O
two	O
-	O
sided	O
significance	O
level	O
of	O
0	O
.	O
1	O
is	O
given	O
by	O
98	O
patients	O
(	O
49	O
per	O
treatment	O
arm	O
,	O
calculated	O
with	O
ADDPLAN	O
,	O
version	O
6	O
.	O
1	O
)	O
.	O
To	O
account	O
for	O
approximately	O
10	O
%	O
dropout	O
,	O
the	O
total	O
number	O
of	O
patients	O
to	O
be	O
recruited	O
is	O
110	O
(	O
98	O
/	O
110	O
≈	O
0	O
.	O
9	O
)	O
.	O
To	O
protect	O
participant	O
’	O
s	O
confidentiality	O
,	O
only	O
pseudonyms	O
are	O
used	O
for	O
all	O
data	O
documentation	O
,	O
sample	O
markings	O
,	O
and	O
communication	O
with	O
third	O
parties	O
(	O
e	O
.	O
g	O
.	O
,	O
laboratories	O
,	O
collaboration	O
partners	O
)	O
.	O
Clinical	O
data	O
are	O
collected	O
in	O
source	O
documents	O
and	O
electronic	O
case	B-methodology
report	I-methodology
forms	O
(	O
Research	O
Electronic	O
Data	O
Capture	O
database	O
)	O
.	O
Database	O
entries	O
are	O
automatically	O
checked	O
for	O
data	O
format	O
and	O
appropriate	O
range	O
.	O
We	O
do	O
not	O
rely	O
on	O
an	O
additional	O
independent	O
monitoring	O
for	O
this	O
is	O
a	O
single	B-methodology
-	I-methodology
center	I-methodology
,	O
exploratory	B-methodology
study	I-methodology
.	O
Due	O
to	O
the	O
minimal	O
risks	O
of	O
the	O
probiotic	O
intervention	O
,	O
a	O
data	O
monitoring	O
committee	O
is	O
deemed	O
unnecessary	O
.	O
We	O
will	O
submit	O
modifications	O
to	O
this	O
protocol	O
to	O
the	O
institutional	O
review	O
board	O
,	O
participants	O
,	O
and	O
investigators	O
.	O
After	O
completion	O
of	O
the	O
study	O
,	O
data	O
will	O
be	O
stored	O
for	O
10	O
years	O
and	O
then	O
be	O
deleted	O
.	O
We	O
do	O
not	O
ask	O
participants	O
for	O
broad	O
consent	O
.	O
Thus	O
,	O
we	O
will	O
only	O
use	O
data	O
and	O
samples	O
for	O
the	O
hypotheses	O
stated	O
in	O
this	O
protocol	O
and	O
will	O
not	O
provide	O
them	O
for	O
ancillary	O
studies	O
.	O
After	O
completion	O
of	O
this	O
study	O
,	O
the	O
results	O
will	O
be	O
expounded	O
to	O
participants	O
,	O
presented	O
on	O
scientific	O
conferences	O
,	O
published	O
in	O
peer	O
-	O
reviewed	O
journals	O
,	O
and	O
circulated	O
to	O
physicians	O
and	O
the	O
medical	O
laity	O
.	O
We	O
will	O
comply	O
with	O
the	O
official	O
eligibility	O
guidelines	B-methodology
for	O
authorship	O
for	O
all	O
publications	O
and	O
do	O
not	O
intend	O
to	O
use	O
professional	O
writers	O
.	O
A	O
confirmatory	O
analysis	O
will	O
be	O
conducted	O
based	O
on	O
the	O
intention	O
-	O
to	O
-	O
treat	O
(	O
ITT	O
)	O
population	O
,	O
defined	O
by	O
the	O
ITT	O
principle	O
.	O
We	O
want	O
to	O
show	O
that	O
the	O
intervention	B-methodology
group	I-methodology
is	O
superior	O
to	O
the	O
control	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
mean	O
nocturnal	O
systolic	O
BP	O
at	O
8	O
weeks	O
after	O
the	O
start	O
of	O
treatment	O
adjusted	O
for	O
the	O
baseline	O
value	O
is	O
lower	O
in	O
the	O
intervention	B-methodology
group	I-methodology
than	O
in	O
the	O
control	B-methodology
group	I-methodology
.	O
An	O
analysis	O
of	O
covariance	O
(	O
ANCOVA	O
)	O
adjusted	O
for	O
baseline	O
systolic	O
BP	O
values	O
using	O
group	O
allocation	O
as	O
a	O
factor	O
will	O
be	O
applied	O
.	O
The	O
global	O
two	O
-	O
sided	O
significance	O
level	O
is	O
0	O
.	O
1	O
.	O
Missing	O
values	O
will	O
be	O
replaced	O
using	O
multiple	O
imputation	O
[	O
22	O
]	O
.	O

A	O
sensitivity	O
analysis	O
to	O
the	O
primary	O
efficacy	O
ANCOVA	O
model	O
will	O
be	O
applied	O
with	O
additional	O
covariates	O
/	O
factors	O
given	O
by	O
age	O
and	O
sex	O
.	O
Subgroup	O
analysis	O
is	O
planned	O
for	O
sex	O
.	O
Descriptive	O
methods	O
will	O
be	O
used	O
for	O
the	O
analysis	O
of	O
all	O
clinical	O
,	O
demographic	O
,	O
and	O
safety	O
parameters	O
,	O
including	O
the	O
calculation	O
of	O
appropriate	O
summary	O
measures	O
of	O
the	O
empirical	O
distribution	O
as	O
well	O
as	O
95	O
%	O
confidence	O
intervals	O
and	O
calculation	O
of	O
descriptive	O
two	O
-	O
sided	O
p	O
values	O
.	O
A	O
safety	O
analysis	O
of	O
frequencies	O
and	O
rates	O
of	O
adverse	O
events	O
will	O
be	O
performed	O
.	O
Additionally	O
,	O
sensitivity	O
analyses	O
will	O
be	O
conducted	O
for	O
different	O
populations	O
(	O
per	O
-	O
protocol	O
population	O
,	O
patients	O
with	O
complete	O
cases	O
)	O
.	O
Interim	O
analyses	O
are	O
not	O
included	O
in	O
our	O
analysis	O
plan	O
.	O
All	O
analyses	O
will	O
be	O
done	O
using	O
validated	O
statistical	O
software	O
.	O
With	O
this	O
study	O
,	O
we	O
want	O
to	O
close	O
the	O
gap	O
between	O
the	O
existing	O
epidemiological	O
,	O
experimental	O
,	O
and	O
our	O
own	O
clinical	O
data	O
in	O
healthy	O
volunteers	O
.	O
We	O
will	O
do	O
this	O
by	O
thoroughly	O
investigating	O
the	O
effects	O
of	O
a	O
probiotic	O
that	O
has	O
not	O
been	O
used	O
in	O
hypertensive	O
patients	O
before	O
.	O
However	O
,	O
we	O
do	O
not	O
only	O
aim	O
at	O
alleviating	O
hypertension	O
,	O
we	O
will	O
also	O
use	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
omics	O
systems	O
approaches	O
to	O
understand	O
the	O
impact	O
of	O
probiotics	O
on	O
the	O
gut	O
microbiome	O
,	O
immunome	O
,	O
metabolome	O
,	O
and	O
vascular	O
phenotypes	O
in	O
these	O
patients	O
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
that	O
comprehensively	O
investigates	O
all	O
of	O
these	O
levels	O
in	O
human	O
hypertension	O
.	O
We	O
hypothesize	O
that	O
targeting	O
the	O
intestinal	O
microbial	O
community	O
with	O
live	O
bacteria	O
will	O
improve	O
hypertension	O
along	O
with	O
an	O
improved	O
immune	O
cell	O
homeostasis	O
.	O
This	O
mode	O
of	O
action	O
could	O
also	O
be	O
effective	O
in	O
treated	O
hypertensive	O
patients	O
who	O
do	O
not	O
reach	O
the	O
desired	O
treatment	O
targets	O
.	O
An	O
improved	O
immune	O
homeostasis	O
could	O
not	O
only	O
lead	O
to	O
lower	O
BP	O
but	O
also	O
to	O
better	O
target	O
organ	O
protection	O
,	O
since	O
immune	O
cells	O
are	O
known	O
to	O
migrate	O
into	O
target	O
organs	O
thereby	O
promoting	O
organ	O
dysfunction	O
.	O
Further	O
,	O
probiotic	O
strains	O
might	O
stably	O
colonize	O
the	O
gut	O
and	O
might	O
evoke	O
—	O
in	O
contrast	O
to	O
classical	O
pharmacological	O
therapy	O
—	O
a	O
long	O
-	O
lasting	O
antihypertensive	O
benefit	O
after	O
discontinuation	O
of	O
treatment	O
.	O
This	O
will	O
be	O
tested	O
in	O
our	O
follow	O
-	O
up	O
phase	O
.	O
Moreover	O
,	O
probiotics	O
are	O
generally	O
well	O
tolerated	O
and	O
have	O
little	O
side	O
effects	O
.	O

Thus	O
,	O
compliance	O
in	O
hypertensive	O
patients	O
,	O
who	O
are	O
skeptical	O
of	O
classical	O
pharmacotherapy	O
,	O
might	O
be	O
improved	O
.	O
We	O
include	O
either	O
untreated	O
grade	O
1	O
hypertensive	O
patients	O
in	O
whom	O
pharmacological	O
treatment	O
can	O
be	O
postponed	O
for	O
a	O
limited	O
time	O
in	O
favor	O
of	O
lifestyle	O
modifications	O
or	O
treated	O
patients	O
who	O
are	O
not	O
on	O
goal	O
despite	O
adequate	O
pharmacotherapy	O
.	O
Included	O
patients	O
have	O
no	O
clinical	O
signs	O
of	O
target	O
organ	O
damage	O
,	O
serious	O
concomitant	O
diseases	O
,	O
or	O
secondary	O
causes	O
of	O
hypertension	O
.	O
From	O
our	O
point	O
of	O
view	O
,	O
these	O
mildly	O
hypertensive	O
patients	O
would	O
benefit	O
most	O
from	O
a	O
probiotic	O
intervention	O
.	O
Furthermore	O
,	O
according	O
to	O
applicable	O
guidelines	B-methodology
,	O
it	O
is	O
possible	O
to	O
delay	O
the	O
start	O
or	O
change	O
of	O
pharmacotherapy	O
for	O
the	O
12	O
-	O
week	O
study	O
duration	O
at	O
this	O
stage	O
of	O
the	O
disease	O
.	O
This	O
choice	O
will	O
limit	O
the	O
extrapolation	O
of	O
our	O
results	O
to	O
other	O
hypertension	O
grades	O
,	O
such	O
as	O
patients	O
with	O
resistant	O
hypertension	O
.	O
However	O
,	O
these	O
patients	O
have	O
a	O
higher	O
risk	O
for	O
cardiovascular	O
events	O
,	O
and	O
necessary	O
therapeutic	O
changes	O
cannot	O
be	O
postponed	O
.	O
Interventional	O
considerations	O
were	O
based	O
on	O
a	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
that	O
suggested	O
an	O
intervention	B-methodology
period	I-methodology
of	O
≥	O
8	O
weeks	O
with	O
≥	O
1011	O
CFU	O
/	O
day	O
of	O
a	O
multi	O
-	O
strain	O
probiotic	O
to	O
effectively	O
lower	O
BP	O
[	O
9	O
]	O
.	O
We	O
chose	O
nocturnal	O
BP	O
instead	O
of	O
office	O
BP	O
or	O
24	O
-	O
h	O
ambulatory	O
BP	O
measurement	O
to	O
achieve	O
a	O
highly	O
standardized	O
measurement	O
in	O
the	O
patient	O
’	O
s	O
natural	O
environment	O
.	O
This	O
standardized	O
measurement	O
,	O
which	O
excludes	O
variations	O
due	O
to	O
physical	O
activity	O
during	O
the	O
day	O
,	O
allows	O
to	O
conduct	O
this	O
study	O
with	O
a	O
medium	O
sample	O
size	O
.	O
Although	O
there	O
is	O
a	O
high	O
level	O
of	O
interest	O
among	O
eligible	O
patients	O
,	O
recruitment	O
turned	O
out	O
to	O
be	O
rather	O
challenging	O
.	O
This	O
is	O
mainly	O
due	O
to	O
the	O
fact	O
that	O
BP	O
is	O
highly	O
variable	O
within	O
subjects	O
.	O
About	O
8	O
of	O
10	O
candidates	O
fail	O
our	O
pre	B-methodology
-	I-methodology
screening	I-methodology
,	O
because	O
they	O
cannot	O
be	O
classified	O
as	O
grade	O
1	O
hypertensive	O
.	O
Recruitment	O
is	O
additionally	O
impeded	O
by	O
common	O
comorbidities	O
,	O
such	O
as	O
insulin	O
-	O
dependent	O
type	O
2	O
diabetes	O
or	O
severe	O
obesity	O
.	O
Nevertheless	O
,	O
due	O
to	O
our	O
medium	O
sample	O
size	O
,	O
it	O
is	O
important	O
that	O
demographic	O
,	O
cardiovascular	O
,	O
and	O
metabolic	O
characteristics	O
are	O
well	O
-	O
defined	O
and	O
as	O
narrow	O
as	O
possible	O
.	O
All	O
biomaterials	O
,	O
in	O
particular	O
,	O
stool	O
samples	O
,	O
are	O
collected	O
with	O
the	O
highest	O
scientific	O
standards	O
to	O
allow	O
for	O
high	O
-	O
quality	O
microbiome	O
analyses	O
[	O
23	O
]	O
.	O

In	O
conclusion	O
,	O
probiotic	O
treatment	O
of	O
patients	O
with	O
grade	O
1	O
hypertension	O
has	O
the	O
potential	O
to	O
lower	O
BP	O
.	O
Due	O
to	O
its	O
innovative	O
mode	O
of	O
action	O
,	O
probiotic	O
treatments	O
could	O
be	O
considered	O
for	O
prevention	O
,	O
might	O
delay	O
pharmacotherapy	O
,	O
and	O
enable	O
dose	O
reduction	O
of	O
antihypertensive	O
drugs	O
,	O
and	O
thereby	O
contribute	O
to	O
target	O
organ	O
protection	O
and	O
the	O
reduction	O
of	O
cardiovascular	O
events	O
.	O
This	O
article	O
is	O
based	O
on	O
the	O
study	B-methodology
protocol	I-methodology
version	O
1	O
.	O
4	O
of	O
2	O
July	O
2019	O
.	O
Recruitment	O
started	O
on	O
28	O
August	O
2019	O
and	O
will	O
probably	O
continue	O
until	O
March	O
2022	O
.	O
We	O
thank	O
Sein	O
Schmidt	O
,	O
Knut	O
Mai	O
,	O
Nicole	O
Stobäus	O
,	O
Verena	O
Benz	O
,	O
and	O
Andreas	O
Hetey	O
for	O
their	O
scientific	O
collaboration	O
with	O
glucose	O
monitoring	O
,	O
PROMIS	O
-	O
29	O
questionnaire	O
,	O
and	O
IT	O
support	O
for	O
our	O
RedCap	O
database	O
(	O
all	O
Berlin	O
Institute	O
of	O
Health	O
,	O
Charité	O
-	O
Universitätsmedizin	O
Berlin	O
)	O
.	O
Charité	O
-	O
Universitätsmedizin	O
Berlin	O
Prof	O
.	O
Dr	O
.	O
Dominik	O
Müller	O
(	O
principle	O
investigator	O
)	O
Lindenberger	O
Weg	O
80	O
,	O
13125	O
Berlin	O
,	O
Germany	O
dominik	O
.	O
mueller	O
@	O
mdc	O
-	O
berlin	O
.	O
de	O
0049	O
30	O
450	O
540	O
286	O
Publisher	O
’	O
s	O
NoteSpringer	O
Nature	O
remains	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O
AM	O
,	O
NW	O
,	O
GR	O
,	O
RD	O
,	O
and	O
DNM	O
designed	O
the	O
study	O
and	O
drafted	O
the	O
study	B-methodology
protocol	I-methodology
.	O
AM	O
and	O
DNM	O
procured	O
funding	O
.	O
GR	O
performed	O
the	O
statistical	O
planning	O
and	O
sample	O
size	O
calculation	O
.	O
AM	O
drafted	O
the	O
manuscript	O
.	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
version	O
.	O
This	O
study	O
is	O
supported	O
by	O
a	O
grant	O
from	O
the	O
Berlin	O
Institute	O
of	O
Health	O
,	O
Berlin	O
.	O
Vivomixx®	O
and	O
placebo	B-methodology
for	O
this	O
study	O
will	O
be	O
supplied	O
by	O
the	O
company	O
Mendes	O
S	O
.	O
A	O
.	O
free	O
of	O
charge	O
.	O
Open	O
Access	O
funding	O
enabled	O
and	O
organized	O
by	O
Projekt	O
DEAL	O
.	O
Not	O
applicable	O
.	O
This	O
study	O
was	O
approved	O
by	O
the	O
institutional	O
review	O
board	O
of	O
Charité	O
-	O
Universitätsmedizin	O
Berlin	O
,	O
and	O
written	B-methodology
informed	I-methodology
consent	I-methodology
is	O
obtained	O
from	O
all	O
study	O
participants	O
before	O
study	O
entry	O
.	O
The	O
authors	O
declare	O
no	O
competing	O
interests	O
.	O
The	O
final	O
trial	O
dataset	O
will	O
be	O
available	O
to	O
the	O
investigators	O
.	O

The	O
funders	O
of	O
the	O
study	O
are	O
neither	O
involved	O
in	O
the	O
study	B-methodology
design	I-methodology
nor	O
the	O
interpretation	O
of	O
the	O
data	O
or	O
the	O
publishing	O
of	O
the	O
results	O
.	O

Relationship	O
between	O
salivary	O
/	O
pancreatic	O
amylase	O
and	O
body	O
mass	O
index	O
:	O
a	O
systems	O
biology	O
approach	O
AMY1A	O
/	O
AMY2A	O
;	O
Body	O
mass	O
index	O
;	O
Copy	O
number	O
variant	O
;	O
Mendelian	O
randomization	O
;	O
Metabonomics	O
;	O
Obesity	O
;	O
Salivary	O
/	O
Pancreatic	O
amylase	O
;	O
Starch	O
Salivary	O
(	O
AMY1	O
)	O
and	O
pancreatic	O
(	O
AMY2	O
)	O
amylases	O
hydrolyze	O
starch	O
.	O
Copy	O
number	O
of	O
AMY1A	O
(	O
encoding	O
AMY1	O
)	O
was	O
reported	O
to	O
be	O
higher	O
in	O
populations	O
with	O
a	O
high	O
-	O
starch	O
diet	O
and	O
reduced	O
in	O
obese	O
people	O
.	O
These	O
results	O
based	O
on	O
quantitative	O
PCR	O
have	O
been	O
challenged	O
recently	O
.	O
We	O
aimed	O
to	O
re	O
-	O
assess	O
the	O
relationship	O
between	O
amylase	O
and	O
adiposity	O
using	O
a	O
systems	O
biology	O
approach	O
.	O
We	O
assessed	O
the	O
association	O
between	O
plasma	O
enzymatic	O
activity	O
of	O
AMY1	O
or	O
AMY2	O
,	O
and	O
several	O
metabolic	O
traits	O
in	O
almost	O
4000	O
French	O
individuals	O
from	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
longitudinal	B-methodology
study	I-methodology
.	O
The	O
effect	O
of	O
the	O
number	O
of	O
copies	O
of	O
AMY1A	O
(	O
encoding	O
AMY1	O
)	O
or	O
AMY2A	O
(	O
encoding	O
AMY2	O
)	O
measured	O
through	O
droplet	O
digital	O
PCR	O
was	O
then	O
analyzed	O
on	O
the	O
same	O
parameters	O
in	O
the	O
same	O
study	O
.	O
A	O
Mendelian	O
randomization	O
analysis	O
was	O
also	O
performed	O
.	O
We	O
subsequently	O
assessed	O
the	O
association	O
between	O
AMY1A	O
copy	O
number	O
and	O
obesity	O
risk	O
in	O
two	O
case	B-methodology
-	I-methodology
control	I-methodology
studies	I-methodology
(	O
5000	O
samples	O
in	O
total	O
)	O
.	O
Finally	O
,	O
we	O
assessed	O
the	O
association	O
between	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
-	O
related	O
plasma	O
metabolites	O
and	O
AMY1	O
or	O
AMY2	O
activity	O
.	O
We	O
evidenced	O
strong	O
associations	O
between	O
AMY1	O
or	O
AMY2	O
activity	O
and	O
lower	O
BMI	O
.	O
However	O
,	O
we	O
found	O
a	O
modest	O
contribution	O
of	O
AMY1A	O
copy	O
number	O
to	O
lower	O
BMI	O
.	O
Mendelian	O
randomization	O
identified	O
a	O
causal	O
negative	O
effect	O
of	O
BMI	O
on	O
AMY1	O
and	O
AMY2	O
activities	O
.	O
Yet	O
,	O
we	O
also	O
found	O
a	O
significant	O
negative	O
contribution	O
of	O
AMY1	O
activity	O
at	O
baseline	O
to	O
the	O
change	O
in	O
BMI	O
during	O
the	O
9	O
-	O
year	O
follow	O
-	O
up	O
,	O
and	O
a	O
significant	O
contribution	O
of	O
AMY1A	O
copy	O
number	O
to	O
lower	O
obesity	O
risk	O
in	O
children	O
,	O
suggesting	O
a	O
bidirectional	O
relationship	O
between	O
AMY1	O
activity	O
and	O
adiposity	O
.	O

Metabonomics	O
identified	O
a	O
BMI	O
-	O
independent	O
association	O
between	O
AMY1	O
activity	O
and	O
lactate	O
,	O
a	O
product	O
of	O
complex	O
carbohydrate	O
fermentation	O
.	O
These	O
findings	O
provide	O
new	O
insights	O
into	O
the	O
involvement	O
of	O
amylase	O
in	O
adiposity	O
and	O
starch	O
metabolism	O
.	O
The	O
online	O
version	O
of	O
this	O
article	O
(	O
doi	O
:	O
10	O
.	O
1186	O
/	O
s12916	O
-	O
017	O
-	O
0784	O
-	O
x	O
)	O
contains	O
supplementary	O
material	O
,	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O
Amylase	O
is	O
responsible	O
for	O
starch	O
hydrolysis	O
,	O
initiating	O
carbohydrate	O
digestion	O
in	O
the	O
oral	O
cavity	O
and	O
later	O
in	O
the	O
gut	O
.	O
In	O
humans	O
,	O
approximately	O
half	O
of	O
the	O
amylase	O
activity	O
found	O
in	O
serum	O
is	O
produced	O
by	O
the	O
salivary	O
glands	O
and	O
the	O
remaining	O
part	O
by	O
the	O
exocrine	O
pancreas	O
[	O
1	O
]	O
from	O
different	O
genes	O
located	O
in	O
the	O
same	O
complex	O
chromosome	O
1	O
locus	O
.	O
A	O
well	O
-	O
known	O
multi	O
-	O
allelic	O
copy	O
number	O
variant	O
at	O
salivary	O
amylase	O
gene	O
(	O
AMY1A	O
;	O
diploid	O
copy	O
number	O
ranging	O
from	O
one	O
to	O
roughly	O
20	O
)	O
evolved	O
as	O
an	O
adaptation	O
to	O
dietary	O
habits	O
[	O
2	O
]	O
.	O
Populations	O
with	O
high	O
starch	O
consumption	O
carry	O
larger	O
number	O
of	O
copies	O
than	O
others	O
that	O
have	O
maintained	O
an	O
ancestral	O
pre	O
-	O
agricultural	O
way	O
of	O
life	O
[	O
2	O
]	O
.	O
Previously	O
,	O
we	O
reported	O
that	O
AMY1A	O
copy	O
number	O
estimated	O
by	O
quantitative	O
RT	O
-	O
PCR	O
(	O
qPCR	O
)	O
is	O
associated	O
with	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
in	O
North	O
European	O
and	O
South	O
Asian	O
adult	O
populations	O
[	O
3	O
]	O
.	O
It	O
provided	O
a	O
putative	O
genetic	O
link	O
between	O
complex	O
carbohydrate	O
metabolism	O
in	O
the	O
gut	O
and	O
obesity	O
.	O
This	O
association	O
was	O
replicated	O
in	O
early	O
-	O
onset	O
obese	O
females	O
from	O
Finland	O
[	O
4	O
]	O
and	O
in	O
prepubertal	O
boys	O
in	O
Italy	O
[	O
5	O
]	O
,	O
and	O
an	O
association	O
with	O
insulin	O
resistance	O
was	O
reported	O
in	O
adult	O
Korean	O
men	O
[	O
6	O
]	O
,	O
where	O
AMY1A	O
copy	O
number	O
was	O
also	O
estimated	O
by	O
qPCR	O
.	O
On	O
the	O
other	O
hand	O
,	O
using	O
digital	O
PCR	O
,	O
two	O
studies	O
failed	O
to	O
reproduce	O
these	O
findings	O
[	O
7	O
,	O
8	O
]	O
.	O
Usher	O
et	O
al	O
.	O
[	O
7	O
]	O
suggested	O
that	O
the	O
discrepancy	O
with	O
the	O
previously	O
reported	O
observations	O
likely	O
comes	O
from	O
their	O
higher	O
-	O
resolution	O
approaches	O
for	O
both	O
molecular	O
and	O
computational	O
analyses	O
.	O

Recently	O
,	O
however	O
,	O
using	O
digital	O
PCR	O
,	O
we	O
have	O
found	O
that	O
,	O
in	O
Mexican	O
children	O
with	O
high	O
-	O
starch	O
diet	O
,	O
high	O
number	O
of	O
AMY1A	O
copies	O
significantly	O
protects	O
against	O
obesity	O
in	O
this	O
population	O
[	O
9	O
]	O
.	O
Finally	O
,	O
a	O
study	O
that	O
used	O
fiber	O
-	O
FISH	O
suggested	O
a	O
role	O
for	O
copy	O
number	O
of	O
pancreatic	O
amylase	O
genes	O
(	O
AMY2A	O
and	O
AMY2B	O
)	O
in	O
the	O
observed	O
functional	O
associations	O
[	O
10	O
]	O
.	O
This	O
debate	O
is	O
important	O
for	O
several	O
reasons	O
.	O
First	O
,	O
chromosome	O
structural	O
variants	O
are	O
increasingly	O
recognized	O
to	O
highly	O
contribute	O
to	O
disease	O
development	O
[	O
11	O
]	O
,	O
and	O
thus	O
the	O
correct	O
genotyping	O
of	O
multi	O
-	O
allelic	O
copy	O
number	O
variant	O
is	O
mandatory	O
[	O
12	O
]	O
.	O
Second	O
,	O
it	O
was	O
shown	O
that	O
non	O
-	O
obese	O
adults	O
with	O
high	O
salivary	O
amylase	O
activity	O
(	O
and	O
putatively	O
high	O
AMY1A	O
copy	O
number	O
)	O
present	O
with	O
improved	O
glucose	O
tolerance	O
following	O
liquid	O
starch	O
ingestion	O
[	O
13	O
]	O
.	O
Furthermore	O
,	O
high	O
serum	O
amylase	O
activity	O
was	O
shown	O
to	O
be	O
associated	O
with	O
decreased	O
risk	O
of	O
metabolic	O
syndrome	O
and	O
type	O
2	O
diabetes	O
in	O
a	O
Japanese	O
asymptomatic	O
population	O
[	O
14	O
]	O
.	O
Finally	O
,	O
in	O
more	O
than	O
100	O
different	O
strains	O
of	O
mice	O
fed	O
a	O
high	O
-	O
fat	O
,	O
high	O
-	O
sucrose	O
diet	O
,	O
the	O
Amy1	O
locus	O
was	O
reported	O
to	O
be	O
significantly	O
associated	O
with	O
weight	O
gain	O
variation	O
and	O
with	O
an	O
enrichment	O
of	O
obesity	O
-	O
associated	O
bacteria	O
of	O
gut	O
microbiota	O
[	O
15	O
]	O
.	O
Therefore	O
,	O
it	O
is	O
crucial	O
to	O
robustly	O
determine	O
if	O
amylase	O
activities	O
(	O
and	O
amylase	O
gene	O
copy	O
number	O
)	O
impact	O
energy	O
and	O
glucose	O
homeostasis	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
employed	O
a	O
systems	O
biology	O
approach	O
,	O
using	O
genetics	O
,	O
protein	O
activity	O
and	O
metabonomics	O
analyses	O
,	O
to	O
decipher	O
the	O
putative	O
interaction	O
between	O
amylase	O
genes	O
and	O
adiposity	O
in	O
human	O
population	O
.	O
We	O
first	O
assessed	O
the	O
association	O
between	O
plasma	O
enzymatic	O
activity	O
of	O
salivary	O
(	O
AMY1	O
)	O
or	O
pancreatic	O
(	O
AMY2	O
)	O
amylase	O
,	O
and	O
several	O
metabolic	O
traits	O
,	O
including	O
BMI	O
.	O
We	O
then	O
analyzed	O
the	O
effect	O
of	O
AMY1A	O
or	O
AMY2A	O
copy	O
number	O
on	O
the	O
same	O
parameters	O
.	O

A	O
Mendelian	O
randomization	O
analysis	O
was	O
subsequently	O
performed	O
to	O
assess	O
causality	O
effects	O
explaining	O
the	O
complex	O
relationship	O
between	O
BMI	O
and	O
AMY1	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
,	O
and	O
actually	O
suggested	O
a	O
bidirectional	O
causal	O
negative	O
effect	O
in	O
the	O
relationship	O
between	O
BMI	O
and	O
AMY1	O
plasma	O
enzymatic	O
activity	O
.	O
We	O
subsequently	O
confirmed	O
an	O
association	O
between	O
AMY1A	O
copy	O
number	O
and	O
reduced	O
obesity	O
risk	O
in	O
children	O
.	O
Finally	O
,	O
we	O
assessed	O
the	O
association	O
between	O
BMI	O
-	O
related	O
plasma	O
metabolites	O
and	O
AMY1	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
.	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
is	O
a	O
9	O
-	O
year	O
longitudinal	B-methodology
study	I-methodology
in	O
a	O
French	O
general	O
population	O
,	O
fully	O
described	O
elsewhere	O
[	O
16	O
]	O
.	O
A	O
total	O
of	O
4834	O
unrelated	O
individuals	O
who	O
were	O
successfully	O
genotyped	O
through	O
iSelect	O
Metabochip	O
DNA	O
microarrays	O
(	O
Illumina	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
was	O
included	O
in	O
the	O
present	O
study	O
.	O
AMY1A	O
copy	O
number	O
and	O
AMY2A	O
copy	O
number	O
were	O
successfully	O
genotyped	O
in	O
3607	O
and	O
3657	O
participants	O
,	O
respectively	O
.	O
At	O
baseline	O
,	O
we	O
had	O
access	O
to	O
AMY1	O
plasma	O
enzymatic	O
activity	O
for	O
3744	O
participants	O
.	O
Among	O
them	O
,	O
we	O
had	O
access	O
to	O
AMY1	O
plasma	O
enzymatic	O
activity	O
after	O
9	O
years	O
of	O
follow	O
-	O
up	O
for	O
679	O
individuals	O
,	O
to	O
BMI	O
after	O
9	O
years	O
of	O
follow	O
-	O
up	O
for	O
2796	O
individuals	O
,	O
and	O
to	O
the	O
levels	O
of	O
BMI	O
-	O
associated	O
plasma	O
metabolites	O
at	O
baseline	O
for	O
718	O
individuals	O
.	O
Moreover	O
,	O
we	O
had	O
access	O
to	O
AMY2	O
plasma	O
enzymatic	O
activity	O
at	O
baseline	O
for	O
3980	O
participants	O
.	O
Among	O
them	O
,	O
we	O
had	O
access	O
to	O
AMY2	O
plasma	O
enzymatic	O
activity	O
after	O
9	O
years	O
of	O
follow	O
-	O
up	O
for	O
705	O
individuals	O
,	O
to	O
BMI	O
after	O
9	O
years	O
of	O
follow	O
-	O
up	O
for	O
2970	O
individuals	O
,	O
and	O
to	O
the	O
levels	O
of	O
BMI	O
-	O
associated	O
plasma	O
metabolites	O
at	O
baseline	O
for	O
718	O
individuals	O
.	O
Additional	O
file	O
1	O
recapitulates	O
all	O
these	O
numbers	O
.	O
Non	O
-	O
diabetic	O
participants	O
did	O
not	O
use	O
glucose	O
lowering	O
medication	O
,	O
and	O
presented	O
with	O
fasting	O
plasma	O
glucose	O
less	O
than	O
7	O
mmol	O
/	O
L	O
and	O
glycated	O
hemoglobin	O
A1c	O
less	O
than	O
6	O
.	O
5	O
%	O
[	O
17	O
]	O
.	O

ABOS	O
is	O
a	O
cohort	B-methodology
study	I-methodology
(	O
ClinicalGov	O
NCT01129297	O
)	O
from	O
the	O
University	O
Hospital	O
of	O
Lille	O
,	O
France	O
,	O
fully	O
described	O
elsewhere	O
[	O
18	O
]	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
measured	O
plasma	O
enzymatic	O
activity	O
of	O
AMY1	O
and	O
AMY2	O
in	O
488	O
participants	O
who	O
were	O
also	O
genotyped	O
through	O
Metabochip	O
DNA	O
microarrays	O
(	O
Illumina	O
)	O
.	O
Clinical	O
characteristics	O
of	O
study	O
participants	O
are	O
shown	O
in	O
Additional	O
file	O
2	O
.	O
The	O
first	O
case	B-methodology
-	I-methodology
control	I-methodology
study	I-methodology
included	O
2220	O
normal	O
-	O
weight	O
adults	O
(	O
with	O
a	O
BMI	O
<	O
25	O
kg	O
/	O
m2	O
)	O
and	O
1179	O
adults	O
presenting	O
with	O
obesity	O
(	O
with	O
a	O
BMI	O
≥	O
30	O
kg	O
/	O
m2	O
)	O
.	O
These	O
adults	O
were	O
from	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
or	O
were	O
recruited	O
either	O
by	O
the	O
CNRS	O
UMR8199	O
(	O
Lille	O
,	O
France	O
)	O
,	O
by	O
the	O
Department	O
of	O
Nutrition	O
of	O
Hotel	O
-	O
Dieu	O
Hospital	O
(	O
Paris	O
,	O
France	O
)	O
,	O
or	O
by	O
the	O
Centre	O
d	O
'	O
Etude	O
du	O
Polymorphisme	O
Humain	O
(	O
CEPH	O
,	O
Saint	O
-	O
Louis	O
hospital	O
,	O
Paris	O
,	O
France	O
)	O
.	O
The	O
second	O
case	B-methodology
-	I-methodology
control	I-methodology
study	I-methodology
included	O
712	O
normal	O
-	O
weight	O
children	O
or	O
adolescents	O
(	O
with	O
a	O
BMI	O
-	O
for	O
-	O
age	O
<	O
85th	O
percentile	O
)	O
and	O
785	O
children	O
or	O
adolescents	O
presenting	O
with	O
obesity	O
(	O
with	O
a	O
BMI	O
-	O
for	O
-	O
age	O
≥	O
99th	O
percentile	O
)	O
.	O
These	O
children	O
or	O
adolescents	O
were	O
from	O
the	O
French	O
Haguenau	O
regional	O
cohort	B-methodology
study	I-methodology
[	O
19	O
]	O
or	O
from	O
the	O
French	O
Fleurbaix	O
-	O
Laventie	O
Ville	O
Santé	O
study	O
[	O
20	O
]	O
,	O
or	O
they	O
were	O
recruited	O
by	O
the	O
CNRS	O
UMR8199	O
(	O
Lille	O
,	O
France	O
)	O
.	O
Copy	O
number	O
of	O
AMY1A	O
and	O
AMY2A	O
was	O
estimated	O
using	O
the	O
QX200	O
droplet	O
digital	O
PCR	O
(	O
ddPCR	O
)	O
system	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
)	O
,	O
following	O
the	O
manufacturer	O
’	O
s	O
recommendations	O
.	O
Concentration	O
of	O
DNA	O
samples	O
was	O
measured	O
using	O
the	O
Qubit	O
ds	O
DNA	O
Assay	O
HS	O
kit	O
(	O
Life	O
Technologies	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
.	O
Dilutions	O
were	O
performed	O
with	O
20×	O
GE	O
Sample	O
Loading	O
Reagent	O
(	O
Fluidigm	O
,	O
South	O
San	O
Francisco	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Each	O
40	O
μL	O
reaction	O
included	O
11	O
μL	O
ddPCR	O
SuperMix	O
for	O
Probes	O
no	O
dUTP	O
(	O
Bio	O
-	O
Rad	O
)	O
,	O
24	O
ng	O
DNA	O
(	O
for	O
AMY1A	O
copy	O
number	O
estimation	O
)	O
or	O
32	O
ng	O
DNA	O
(	O
for	O
AMY2A	O
copy	O
number	O
estimation	O
)	O
,	O
1	O
.	O
1	O
μL	O
of	O
TaqMan	O
assay	O
targeting	O
AMY1A	O
or	O
AMY2A	O
(	O
Hs07226362	O
_	O
cn	O
or	O
Hs04204136	O
_	O
cn	O
,	O
respectively	O
;	O
Life	O
Technologies	O
)	O
,	O
1	O
.	O
1	O
μL	O
of	O
TaqMan	O
assay	O
targeting	O
the	O
reference	O
RNase	O
P	O
assay	O
(	O
Human	O
RNase	O
P	O
#	O
4403328	O
;	O
Life	O
Technologies	O
)	O
,	O
and	O
0	O
.	O
5	O
U	O
HindIII	O
(	O
High	O
Fidelity	O
;	O
New	O
England	O
Biolabs	O
,	O
Ipswich	O
,	O
MA	O
,	O
USA	O
)	O
.	O
Of	O
note	O
,	O
both	O
AMY1A	O
and	O
AMY2A	O
target	O
assays	O
utilized	O
FAM	O
-	O
labeled	O
probes	O
,	O
while	O
RNase	O
P	O
assay	O
was	O
labeled	O
in	O
VIC	O
.	O
Enzymatic	O
digestion	O
was	O
done	O
for	O
5	O
minutes	O
at	O
20	O
°C	O
.	O
Subsequently	O
,	O
the	O
reaction	O
was	O
emulsified	O
with	O
Droplet	O
Generator	O
Oil	O
(	O
Bio	O
-	O
Rad	O
)	O
using	O
the	O
QX200	O
Droplet	O
Generator	O
(	O
Bio	O
-	O
Rad	O
)	O
,	O
following	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O
The	O
droplets	O
were	O
then	O
transferred	O
to	O
a	O
96	O
-	O
well	O
reaction	O
plate	O
(	O
Eppendorf	O
)	O
and	O
PCR	O
amplification	O
was	O
performed	O
using	O
a	O
Veriti	O
Thermal	O
Cycler	O
(	O
Life	O
Technologies	O
)	O
.	O
After	O
amplification	O
,	O
droplets	O
were	O
read	O
using	O
a	O
QX200	O
Droplet	O
Reader	O
(	O
Bio	O
-	O
Rad	O
)	O
.	O
Fluorescence	O
data	O
were	O
analyzed	O
using	O
QuantaSoft	O
software	O
(	O
version	O
1	O
.	O
7	O
.	O
4	O
,	O
Bio	O
-	O
Rad	O
)	O
.	O
Only	O
samples	O
with	O
at	O
least	O
7000	O
droplets	O
were	O
kept	O
for	O
further	O
analyses	O
.	O
Plasma	O
enzymatic	O
activities	O
of	O
total	O
amylase	O
and	O
AMY2	O
were	O
estimated	O
by	O
an	O
enzymatic	O
colorimetric	O
assay	O
with	O
an	O
autoanalyzer	O
(	O
CoBAS	O
Icobas	O
8000	O
modular	O
analyzer	O
series	O
;	O
kits	O
#	O
AMY	O
-	O
P	O
-	O
20766623322	O
and	O
#	O
AMYL2	O
-	O
03183742122	O
;	O
Hoffman	O
-	O
La	O
Roche	O
,	O
Basel	O
,	O
Switzerland	O
)	O
.	O

The	O
plasma	O
enzymatic	O
activity	O
of	O
AMY1	O
was	O
calculated	O
by	O
subtracting	O
the	O
activity	O
of	O
AMY2	O
from	O
the	O
activity	O
of	O
total	O
amylase	O
.	O
Normal	O
ranges	O
of	O
the	O
plasma	O
enzymatic	O
activities	O
of	O
AMY2	O
and	O
total	O
amylase	O
were	O
13	O
–	O
53	O
U	O
/	O
L	O
and	O
29	O
–	O
99	O
U	O
/	O
L	O
,	O
respectively	O
.	O
Only	O
individuals	O
presenting	O
with	O
these	O
normal	O
ranges	O
were	O
analyzed	O
.	O
Fasting	O
plasma	O
samples	O
were	O
processed	O
by	O
the	O
Metabolon	O
(	O
Durham	O
,	O
NC	O
,	O
USA	O
)	O
platform	O
using	O
gas	O
chromatography	O
mass	O
spectrometry	O
and	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometry	O
,	O
as	O
previously	O
described	O
[	O
21	O
,	O
22	O
]	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
only	O
analyzed	O
36	O
metabolites	O
previously	O
shown	O
to	O
be	O
associated	O
with	O
BMI	O
[	O
23	O
]	O
,	O
including	O
1	O
,	O
5	O
-	O
anhydroglucitol	O
,	O
1	O
-	O
oleoylglycerophosphocholine	O
(	O
18	O
:	O
1	O
)	O
,	O
2	O
-	O
hydroxybutyrate	O
,	O
2	O
-	O
linoleoylglycerophosphocholine	O
,	O
3	O
-	O
(	O
4	O
-	O
hydroxyphenyl	O
)	O
lactate	O
,	O
3	O
-	O
hydroxyisobutyrate	O
,	O
3	O
-	O
methyl	O
-	O
2	O
-	O
oxobutyrate	O
,	O
3	O
-	O
methyl	O
-	O
2	O
-	O
oxovalerate	O
,	O
4	O
-	O
methyl	O
-	O
2	O
-	O
oxopentanoate	O
,	O
7	O
-	O
alpha	O
-	O
hydroxy	O
-	O
3	O
-	O
oxo	O
-	O
4	O
-	O
cholestenoate	O
,	O
alpha	O
-	O
hydroxyisovalerate	O
,	O
andro	O
steroid	O
monosulfate	O
2	O
,	O
asparagine	O
,	O
benzoate	O
,	O
butyrylcarnitine	O
,	O
carnitine	O
,	O
gamma	O
-	O
glutamylisoleucine	O
,	O
gamma	O
-	O
glutamyltyrosine	O
,	O
glutamate	O
,	O
glycerol	O
,	O
glycine	O
,	O
hexanoylcarnitine	O
,	O
histidine	O
,	O
isoleucine	O
,	O
isovalerylcarnitine	O
,	O
kynurenine	O
,	O
lactate	O
,	O
lathosterol	O
,	O
leucine	O
,	O
mannose	O
,	O
N	O
-	O
acetylglycine	O
,	O
palmitoyl	O
sphingomyelin	O
,	O
phenylalanine	O
,	O
propionylcarnitine	O
,	O
tyrosine	O
,	O
and	O
valine	O
.	O
These	O
metabolites	O
presented	O
with	O
a	O
missing	O
value	O
rate	O
of	O
less	O
than	O
5	O
%	O
.	O
The	O
missing	O
values	O
were	O
imputed	O
with	O
the	O
smallest	O
detected	O
value	O
.	O

We	O
were	O
unable	O
to	O
analyze	O
the	O
BMI	O
-	O
associated	O
metabolite	O
1	O
-	O
eicosadienoylglycerophosphocholine	O
[	O
23	O
]	O
,	O
as	O
it	O
was	O
undetectable	O
in	O
the	O
present	O
study	B-methodology
cohort	I-methodology
.	O
Ethnic	O
characterization	O
of	O
each	O
participant	O
was	O
assessed	O
using	O
the	O
iSelect	O
Metabochip	O
DNA	O
microarrays	O
(	O
Illumina	O
)	O
,	O
as	O
previously	O
described	O
[	O
24	O
]	O
.	O
The	O
associations	O
between	O
metabolic	O
quantitative	O
traits	O
(	O
except	O
BMI	O
)	O
and	O
enzymatic	O
activity	O
of	O
AMY1	O
/	O
AMY2	O
or	O
AMY1A	O
/	O
AMY2A	O
copy	O
number	O
were	O
assessed	O
through	O
linear	O
regression	O
models	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
BMI	O
,	O
daily	O
alcohol	O
consumption	O
,	O
smoking	O
status	O
,	O
and	O
the	O
first	O
two	O
principal	O
components	O
for	O
ethnicity	O
as	O
previously	O
described	O
[	O
24	O
]	O
.	O
We	O
used	O
the	O
same	O
models	O
for	O
the	O
analysis	O
of	O
plasma	O
metabolites	O
,	O
with	O
the	O
same	O
adjustments	O
(	O
including	O
or	O
not	O
BMI	O
)	O
.	O
The	O
analysis	O
of	O
BMI	O
was	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
daily	O
alcohol	O
consumption	O
,	O
smoking	O
status	O
,	O
and	O
the	O
first	O
two	O
principal	O
components	O
for	O
ethnicity	O
.	O
The	O
effect	O
of	O
AMY1	O
or	O
AMY2	O
activity	O
at	O
baseline	O
on	O
the	O
change	O
in	O
BMI	O
during	O
the	O
9	O
-	O
year	O
follow	O
-	O
up	O
was	O
assessed	O
through	O
a	O
linear	O
regression	O
model	O
adjusted	O
for	O
age	O
at	O
baseline	O
,	O
sex	O
,	O
BMI	O
at	O
baseline	O
,	O
daily	O
alcohol	O
consumption	O
,	O
smoking	O
status	O
,	O
and	O
the	O
first	O
two	O
principal	O
components	O
for	O
ethnicity	O
.	O
The	O
effect	O
of	O
BMI	O
at	O
baseline	O
on	O
the	O
change	O
in	O
AMY1	O
or	O
AMY2	O
activity	O
during	O
the	O
9	O
-	O
year	O
follow	O
-	O
up	O
was	O
assessed	O
through	O
a	O
linear	O
regression	O
model	O
adjusted	O
for	O
age	O
at	O
baseline	O
,	O
sex	O
,	O
AMY1	O
or	O
AMY2	O
activity	O
at	O
baseline	O
,	O
daily	O
alcohol	O
consumption	O
,	O
smoking	O
status	O
,	O
and	O
the	O
first	O
two	O
principal	O
components	O
for	O
ethnicity	O
.	O
Of	O
note	O
,	O
BMI	O
,	O
aspartate	O
aminotransferase	O
,	O
fasting	O
insulin	O
,	O
triglyceride	O
levels	O
,	O
and	O
the	O
homeostasis	O
model	O
assessment	O
of	O
beta	O
-	O
cell	O
function	O
(	O
HOMA	O
-	O
2B	O
)	O
and	O
of	O
insulin	O
resistance	O
(	O
HOMA	O
-	O
2IR	O
)	O
were	O
logarithmically	O
transformed	O
before	O
statistical	O
analysis	O
.	O
Association	O
analyses	O
of	O
glucose	O
-	O
related	O
traits	O
were	O
performed	O
in	O
non	O
-	O
diabetic	O
individuals	O
only	O
.	O
Association	O
analyses	O
of	O
lipid	O
traits	O
were	O
performed	O
in	O
participants	O
who	O
did	O
not	O
use	O
any	O
lipid	O
-	O
lowering	O
drugs	O
at	O
baseline	O
.	O
Association	O
analyses	O
of	O
blood	O
pressure	O
were	O
performed	O
in	O
participants	O
who	O
did	O
not	O
use	O
any	O
drugs	O
against	O
hypertension	O
at	O
baseline	O
.	O

HOMA	O
-	O
2B	O
and	O
HOMA	O
-	O
2IR	O
were	O
calculated	O
in	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
participants	O
as	O
previously	O
described	O
[	O
24	O
]	O
.	O
In	O
each	O
regression	O
model	O
,	O
traits	O
were	O
analyzed	O
as	O
dependent	O
variables	O
whilst	O
copy	O
number	O
and	O
enzymatic	O
activities	O
were	O
used	O
as	O
covariates	O
.	O
The	O
causal	O
effect	O
between	O
BMI	O
and	O
AMY1	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
was	O
estimated	O
using	O
a	O
Mendelian	O
randomization	O
approach	O
[	O
25	O
,	O
26	O
]	O
.	O
We	O
used	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
previously	O
found	O
to	O
be	O
genome	O
-	O
wide	O
significantly	O
associated	O
with	O
BMI	O
[	O
27	O
]	O
as	O
genetic	O
instruments	O
for	O
this	O
analysis	O
.	O
We	O
excluded	O
14	O
SNPs	O
with	O
known	O
pleiotropic	O
effects	O
on	O
non	O
-	O
anthropometric	O
traits	O
(	O
Additional	O
file	O
3	O
)	O
.	O
Among	O
the	O
remaining	O
83	O
SNPs	O
,	O
four	O
were	O
not	O
testable	O
through	O
the	O
Illumina	O
Metabochip	O
DNA	O
microarray	O
(	O
rs12016871	O
within	O
MTIF3	O
locus	O
,	O
rs16851483	O
within	O
RASA2	O
locus	O
,	O
rs17001654	O
within	O
SCARB2	O
locus	O
,	O
and	O
rs9641123	O
within	O
CALCR	O
locus	O
)	O
and	O
one	O
SNP	O
did	O
not	O
pass	O
the	O
quality	B-methodology
control	I-methodology
(	O
rs12566985	O
within	O
the	O
FPGT	O
locus	O
)	O
.	O
These	O
five	O
SNPs	O
were	O
replaced	O
with	O
proxies	O
(	O
R2	O
≥	O
0	O
.	O
64	O
;	O
Additional	O
file	O
3	O
)	O
.	O
For	O
each	O
of	O
the	O
83	O
instrumental	O
genetic	O
variables	O
,	O
we	O
estimated	O
causal	O
effects	O
of	O
BMI	O
on	O
AMY1	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
as	O
ratios	O
between	O
the	O
SNP	O
effect	O
sizes	O
on	O
plasma	O
AMY1	O
or	O
AMY2	O
enzymatic	O
activity	O
(	O
measured	O
in	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
)	O
over	O
the	O
SNP	O
effect	O
size	O
on	O
BMI	O
(	O
obtained	O
from	O
Locke	O
et	O
al	O
.	O
[	O
27	O
]	O
)	O
.	O
Standard	O
errors	O
for	O
these	O
causal	O
estimates	O
were	O
derived	O
by	O
replacing	O
in	O
the	O
former	O
calculations	O
each	O
SNP	O
effect	O
size	O
on	O
AMY1	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
with	O
its	O
corresponding	O
standard	O
error	O
estimated	O
within	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
The	O
83	O
values	O
of	O
causal	O
effects	O
of	O
BMI	O
on	O
AMY1	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
were	O
collapsed	O
into	O
single	O
estimates	O
(	O
one	O
for	O
each	O
enzymatic	O
activity	O
)	O
using	O
inverse	O
-	O
variance	O
weighting	O
[	O
25	O
]	O
.	O

Since	O
no	O
published	O
genome	B-methodology
-	I-methodology
wide	I-methodology
association	I-methodology
studies	I-methodology
on	O
amylase	O
activities	O
were	O
available	O
,	O
we	O
used	O
as	O
an	O
alternative	O
approach	O
,	O
the	O
two	O
-	O
stage	O
least	O
-	O
squares	O
(	O
TSLS	O
)	O
regression	O
to	O
estimate	O
the	O
causal	O
effect	O
of	O
BMI	O
on	O
AMY1	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
using	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
data	O
.	O
This	O
analysis	O
used	O
as	O
the	O
instrumental	O
variable	O
the	O
genetic	O
risk	O
score	O
,	O
calculated	O
as	O
the	O
sum	O
of	O
alleles	O
increasing	O
BMI	O
over	O
the	O
83	O
selected	O
SNPs	O
.	O
We	O
did	O
not	O
observe	O
any	O
residual	O
effect	O
of	O
BMI	O
-	O
associated	O
SNPs	O
on	O
amylase	O
activities	O
(	O
P	O
>	O
0	O
.	O
2	O
)	O
.	O
To	O
ensure	O
that	O
cryptic	O
pleiotropic	O
effects	O
among	O
the	O
83	O
SNPs	O
were	O
not	O
influencing	O
our	O
estimates	O
of	O
causal	O
effect	O
of	O
BMI	O
on	O
AMY1	O
and	O
AMY2	O
plasma	O
enzymatic	O
activities	O
,	O
we	O
used	O
Egger	O
regression	O
to	O
test	O
for	O
the	O
significance	O
of	O
the	O
intercept	O
[	O
28	O
]	O
.	O
We	O
found	O
no	O
significant	O
effect	O
of	O
pleiotropy	O
(	O
P	O
=	O
0	O
.	O
41	O
for	O
AMY1	O
activity	O
,	O
and	O
P	O
=	O
0	O
.	O
49	O
for	O
AMY2	O
activity	O
)	O
.	O
We	O
were	O
unable	O
to	O
use	O
AMY1A	O
or	O
AMY2A	O
copy	O
number	O
as	O
instrumental	O
variables	O
to	O
assess	O
the	O
inverse	O
causation	O
between	O
AMY1	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
and	O
BMI	O
as	O
they	O
both	O
showed	O
a	O
residual	O
association	O
with	O
BMI	O
after	O
adjusting	O
for	O
the	O
corresponding	O
plasma	O
enzymatic	O
activity	O
(	O
P	O
<	O
0	O
.	O
001	O
;	O
Additional	O
file	O
4	O
)	O
.	O
We	O
therefore	O
looked	O
for	O
other	O
instruments	O
by	O
testing	O
the	O
association	O
between	O
SNP	O
genotyped	O
on	O
the	O
Metabochip	O
DNA	O
microarray	O
(	O
Illumina	O
)	O
and	O
AMY1	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
in	O
the	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
participants	O
.	O
This	O
association	O
was	O
assessed	O
using	O
linear	O
regression	O
of	O
AMY1	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
on	O
genotyped	O
SNP	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
BMI	O
,	O
and	O
the	O
first	O
two	O
principal	O
components	O
for	O
ethnicity	O
.	O

Subsequently	O
,	O
the	O
significant	O
associations	O
between	O
SNPs	O
and	O
AMY1	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
(	O
after	O
Bonferroni	O
correction	O
:	O
P	O
<	O
4	O
×	O
10−7	O
=	O
0	O
.	O
05÷124	O
,	O
571	O
tested	O
SNPs	O
)	O
were	O
confirmed	O
in	O
ABOS	O
.	O
The	O
combined	O
analyses	O
were	O
performed	O
using	O
a	O
weighted	O
inverse	O
normal	O
method	O
via	O
the	O
function	O
“	O
metagen	O
”	O
,	O
with	O
a	O
fixed	O
effect	O
,	O
in	O
the	O
“	O
META	O
”	O
R	O
package	O
.	O
No	O
heterogeneity	O
was	O
observed	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O
A	O
good	O
instrument	O
was	O
consequently	O
defined	O
as	O
a	O
SNP	O
significantly	O
associated	O
(	O
P	O
<	O
4	O
×	O
10−7	O
)	O
with	O
AMY1	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
,	O
without	O
showing	O
any	O
residual	O
association	O
with	O
BMI	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O
Given	O
these	O
instruments	O
,	O
the	O
causal	O
effect	O
of	O
AMY1	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
on	O
BMI	O
was	O
estimated	O
using	O
TSLS	O
regression	O
as	O
implemented	O
in	O
the	O
R	O
package	O
ivpack	O
(	O
R	O
function	O
ivreg	O
)	O
.	O
The	O
association	O
between	O
obesity	O
and	O
AMY1A	O
copy	O
number	O
was	O
assessed	O
by	O
a	O
logistic	O
regression	O
model	O
adjusted	O
for	O
age	O
and	O
sex	O
in	O
the	O
two	O
case	B-methodology
-	I-methodology
control	I-methodology
studies	I-methodology
.	O
The	O
combined	O
analysis	O
was	O
performed	O
using	O
a	O
weighted	O
inverse	O
normal	O
method	O
via	O
the	O
function	O
“	O
metagen	O
”	O
,	O
with	O
a	O
fixed	O
effect	O
,	O
in	O
the	O
“	O
META	O
”	O
R	O
package	O
.	O
No	O
heterogeneity	O
was	O
observed	O
for	O
this	O
combined	O
analysis	O
(	O
P	O
=	O
0	O
.	O
14	O
)	O
.	O
All	O
genetic	O
analyses	O
were	O
performed	O
under	O
an	O
additive	O
model	O
.	O
All	O
statistical	O
analyses	O
were	O
performed	O
using	O
IBM	O
SPSS	O
(	O
version	O
14	O
.	O
0	O
)	O
or	O
R	O
(	O
version	O
3	O
.	O
0	O
)	O
.	O
After	O
adjustment	O
for	O
clinical	O
and	O
ethnic	O
confounders	O
,	O
a	O
significant	O
association	O
was	O
found	O
between	O
plasma	O
enzymatic	O
activity	O
of	O
AMY1	O
or	O
AMY2	O
and	O
lower	O
BMI	O
in	O
the	O
French	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
participants	O
(	O
β	O
=	O
–	O
0	O
.	O
0013	O
±	O
0	O
.	O
0002	O
kg	O
/	O
m2	O
,	O
P	O
=	O
2	O
.	O
4	O
×	O
10−13	O
;	O
β	O
=	O
–	O
0	O
.	O
0024	O
±	O
0	O
.	O
0003	O
kg	O
/	O
m2	O
,	O
P	O
=	O
2	O
.	O
4	O
×	O
10−13	O
,	O
respectively	O
;	O
Table	O
1	O
)	O
.	O

Importantly	O
,	O
the	O
effects	O
of	O
AMY1	O
and	O
AMY2	O
activities	O
seemed	O
partly	O
independent	O
as	O
they	O
remained	O
significant	O
when	O
both	O
AMY1	O
and	O
AMY2	O
activities	O
were	O
added	O
in	O
the	O
same	O
regression	O
model	O
(	O
β	O
=	O
–	O
0	O
.	O
0012	O
±	O
0	O
.	O
0002	O
kg	O
/	O
m2	O
,	O
P	O
=	O
2	O
.	O
8	O
×	O
10−12	O
;	O
β	O
=	O
–	O
0	O
.	O
0021	O
±	O
0	O
.	O
0003	O
kg	O
/	O
m2	O
,	O
P	O
=	O
4	O
.	O
2	O
×	O
10−12	O
,	O
respectively	O
)	O
.	O
Furthermore	O
,	O
in	O
non	O
-	O
diabetic	O
participants	O
,	O
we	O
identified	O
a	O
significant	O
association	O
between	O
AMY1	O
or	O
AMY2	O
activity	O
and	O
lower	O
fasting	O
plasma	O
glucose	O
levels	O
(	O
β	O
=	O
–	O
0	O
.	O
0019	O
±	O
0	O
.	O
0006	O
mmol	O
/	O
L	O
,	O
P	O
=	O
1	O
.	O
4	O
×	O
10−3	O
;	O
β	O
=	O
–	O
0	O
.	O
0026	O
±	O
0	O
.	O
0010	O
mmol	O
/	O
L	O
,	O
P	O
=	O
9	O
.	O
2	O
×	O
10−3	O
,	O
respectively	O
;	O
Table	O
1	O
)	O
,	O
as	O
well	O
as	O
higher	O
beta	O
-	O
cell	O
function	O
modeled	O
by	O
HOMA	O
-	O
2B	O
(	O
β	O
=	O
0	O
.	O
0010	O
±	O
0	O
.	O
0004	O
,	O
P	O
=	O
9	O
.	O
0	O
×	O
10−3	O
;	O
β	O
=	O
0	O
.	O
0017	O
±	O
0	O
.	O
0006	O
,	O
P	O
=	O
4	O
.	O
6	O
×	O
10−3	O
,	O
respectively	O
;	O
Table	O
1	O
)	O
.	O
These	O
associations	O
remained	O
significant	O
after	O
the	O
inclusion	O
of	O
AMY1	O
and	O
AMY2	O
activities	O
in	O
the	O
same	O
regression	O
model	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
We	O
also	O
found	O
that	O
AMY2	O
activity	O
was	O
associated	O
with	O
higher	O
fasting	O
serum	O
insulin	O
levels	O
(	O
β	O
=	O
0	O
.	O
0025	O
±	O
0	O
.	O
0009	O
pmol	O
/	O
L	O
,	O
P	O
=	O
7	O
.	O
5	O
×	O
10−3	O
;	O
Table	O
1	O
)	O
.	O
However	O
,	O
neither	O
AMY2	O
activity	O
nor	O
AMY1	O
activity	O
were	O
found	O
to	O
be	O
associated	O
with	O
insulin	O
resistance	O
(	O
modeled	O
by	O
HOMA	O
-	O
2IR	O
;	O
P	O
>	O
0	O
.	O
05	O
;	O
Table	O
1	O
)	O
.	O
Regarding	O
lipid	O
traits	O
,	O
we	O
found	O
that	O
AMY1	O
activity	O
was	O
associated	O
with	O
higher	O
high	O
-	O
density	O
lipoprotein	O
cholesterol	O
levels	O
(	O
β	O
=	O
0	O
.	O
0015	O
±	O
0	O
.	O
0005	O
mmol	O
/	O
L	O
,	O
P	O
=	O
2	O
.	O
1	O
×	O
10−3	O
;	O
Table	O
1	O
)	O
,	O
as	O
well	O
as	O
higher	O
apolipoprotein	O
A1	O
levels	O
(	O
β	O
=	O
0	O
.	O
0008	O
±	O
0	O
.	O
0003	O
g	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
016	O
;	O
Table	O
1	O
)	O
.	O

Furthermore	O
,	O
we	O
identified	O
a	O
significant	O
association	O
between	O
AMY1	O
activity	O
and	O
higher	O
aspartate	O
aminotransferase	O
levels	O
(	O
β	O
=	O
0	O
.	O
0017	O
±	O
0	O
.	O
0004	O
IU	O
/	O
I	O
,	O
P	O
=	O
4	O
.	O
1	O
×	O
10−5	O
;	O
Table	O
1	O
)	O
,	O
and	O
AMY2	O
activity	O
was	O
found	O
to	O
be	O
modestly	O
associated	O
with	O
lower	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
;	O
β	O
=	O
-	O
0	O
.	O
067	O
±	O
0	O
.	O
029	O
mm	O
Hg	O
,	O
P	O
=	O
0	O
.	O
020	O
;	O
Table	O
1	O
)	O
.	O
When	O
analyzing	O
copy	O
number	O
of	O
AMY1A	O
and	O
AMY2A	O
in	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
participants	O
through	O
ddPCR	O
(	O
Additional	O
files	O
5	O
and	O
6	O
)	O
,	O
we	O
confirmed	O
that	O
even	O
AMY1A	O
copy	O
numbers	O
were	O
more	O
frequent	O
than	O
odd	O
AMY1A	O
copy	O
numbers	O
(	O
Additional	O
files	O
5	O
and	O
6	O
)	O
,	O
as	O
shown	O
by	O
Usher	O
et	O
al	O
.	O
[	O
7	O
]	O
.	O
Furthermore	O
,	O
we	O
confirmed	O
that	O
the	O
copy	O
numbers	O
of	O
AMY1A	O
and	O
AMY2A	O
were	O
nearly	O
always	O
both	O
even	O
or	O
both	O
odd	O
(	O
Additional	O
file	O
6	O
)	O
[	O
7	O
,	O
8	O
,	O
10	O
]	O
.	O
Although	O
AMY1A	O
or	O
AMY2A	O
copy	O
number	O
was	O
significantly	O
correlated	O
with	O
AMY1	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
,	O
respectively	O
(	O
Spearman	O
test	O
:	O
R2	O
=	O
0	O
.	O
34	O
,	O
P	O
<	O
2	O
.	O
2	O
×	O
10−16	O
;	O
R2	O
=	O
0	O
.	O
12	O
,	O
P	O
<	O
2	O
.	O
2	O
×	O
10−16	O
,	O
respectively	O
;	O
Fig	O
.	O
1a	O
and	O
b	O
)	O
,	O
we	O
only	O
found	O
a	O
nominal	O
association	O
between	O
AMY1A	O
copy	O
number	O
and	O
lower	O
BMI	O
(	O
β	O
=	O
–	O
0	O
.	O
0018	O
±	O
0	O
.	O
0009	O
kg	O
/	O
m2	O
per	O
AMY1A	O
copy	O
,	O
P	O
=	O
0	O
.	O
044	O
;	O
Additional	O
file	O
7	O
)	O
.	O
Of	O
note	O
,	O
we	O
found	O
that	O
ddPCR	O
-	O
estimated	O
AMY1A	O
copy	O
number	O
is	O
highly	O
correlated	O
with	O
AMY1A	O
copy	O
number	O
previously	O
estimated	O
by	O
qPCR	O
(	O
Spearman	O
test	O
:	O
R2	O
=	O
0	O
.	O
86	O
,	O
P	O
<	O
2	O
.	O
2	O
×	O
10−16	O
;	O
Additional	O
file	O
8	O
)	O
in	O
2137	O
participants	O
from	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
[	O
3	O
]	O
.	O

Furthermore	O
,	O
among	O
these	O
2137	O
samples	O
previously	O
assessed	O
,	O
we	O
confirmed	O
a	O
highly	O
significant	O
association	O
between	O
ddPCR	O
-	O
estimated	O
AMY1A	O
copy	O
number	O
and	O
lower	O
BMI	O
(	O
β	O
=	O
–	O
0	O
.	O
0043	O
±	O
0	O
.	O
0011	O
kg	O
/	O
m2	O
per	O
AMY1A	O
copy	O
,	O
P	O
=	O
1	O
.	O
7	O
×	O
10−4	O
;	O
Additional	O
files	O
9	O
and	O
10	O
)	O
.	O
However	O
,	O
as	O
tackled	O
above	O
,	O
the	O
association	O
between	O
AMY1A	O
copy	O
number	O
and	O
lower	O
BMI	O
was	O
only	O
nominal	O
when	O
we	O
analyzed	O
the	O
whole	O
sample	O
set	O
from	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
(	O
Additional	O
files	O
7	O
,	O
9	O
and	O
10	O
)	O
.	O
We	O
did	O
not	O
find	O
other	O
significant	O
associations	O
between	O
AMY1A	O
or	O
AMY2A	O
copy	O
number	O
and	O
metabolic	O
traits	O
(	O
P	O
>	O
0	O
.	O
05	O
;	O
Additional	O
file	O
7	O
)	O
.	O
A	O
Mendelian	O
randomization	O
analysis	O
was	O
subsequently	O
performed	O
to	O
assess	O
causal	O
effects	O
explaining	O
the	O
complex	O
relationship	O
between	O
BMI	O
and	O
AMY1	O
or	O
AMY2	O
activity	O
.	O
We	O
found	O
evidence	O
of	O
a	O
causal	O
negative	O
effect	O
of	O
BMI	O
on	O
both	O
AMY1	O
(	O
βcausal	O
=	O
–	O
4	O
.	O
15	O
±	O
1	O
.	O
66	O
IU	O
/	O
L	O
per	O
kg	O
/	O
m2	O
,	O
P	O
=	O
0	O
.	O
012	O
;	O
Table	O
2	O
)	O
and	O
AMY2	O
(	O
βcausal	O
=	O
–	O
2	O
.	O
53	O
±	O
0	O
.	O
94	O
IU	O
/	O
L	O
per	O
kg	O
/	O
m2	O
,	O
P	O
=	O
7	O
.	O
1	O
×	O
10−3	O
;	O
Table	O
2	O
)	O
plasma	O
enzymatic	O
activities	O
.	O
These	O
significant	O
effects	O
were	O
confirmed	O
using	O
the	O
TSLS	O
regression	O
(	O
Table	O
2	O
)	O
.	O
Assessing	O
the	O
inverse	O
relationship	O
(	O
AMY1	O
/	O
AMY2	O
→	O
BMI	O
)	O
turned	O
out	O
to	O
be	O
challenging	O
as	O
we	O
could	O
use	O
neither	O
AMY1A	O
nor	O
AMY2A	O
copy	O
numbers	O
as	O
genetic	O
instruments	O
.	O
Indeed	O
,	O
we	O
found	O
a	O
significant	O
residual	O
association	O
between	O
AMY1A	O
or	O
AMY2A	O
copy	O
number	O
and	O
BMI	O
when	O
adjusting	O
for	O
the	O
corresponding	O
plasma	O
enzymatic	O
activity	O
(	O
P	O
<	O
0	O
.	O
001	O
,	O
Additional	O
file	O
4	O
)	O
.	O
As	O
no	O
genome	B-methodology
-	I-methodology
wide	I-methodology
association	I-methodology
study	I-methodology
for	O
AMY1	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
has	O
been	O
performed	O
thus	O
far	O
,	O
we	O
assessed	O
the	O
association	O
between	O
124	O
,	O
571	O
SNPs	O
genotyped	O
through	O
the	O
Metabochip	O
DNA	O
microarray	O
and	O
AMY1	O
or	O
AMY2	O
activity	O
in	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
participants	O
,	O
and	O
confirmed	O
the	O
identified	O
associations	O
in	O
another	O
French	B-methodology
cohort	I-methodology
study	I-methodology
(	O
ABOS	O
)	O
in	O
order	O
to	O
find	O
valid	O
genetic	O
instruments	O
.	O

We	O
found	O
one	O
SNP	O
strongly	O
associated	O
with	O
AMY1	O
activity	O
(	O
PRH1	O
-	O
PRR4	O
rs10492100	O
:	O
P	O
=	O
3	O
.	O
3	O
×	O
10−11	O
;	O
Table	O
3	O
)	O
and	O
two	O
SNPs	O
strongly	O
associated	O
with	O
AMY2	O
activity	O
(	O
AMY2B	O
rs12075225	O
:	O
P	O
=	O
2	O
.	O
0	O
×	O
10−71	O
;	O
ABO	O
rs507666	O
:	O
P	O
=	O
1	O
.	O
3	O
×	O
10−8	O
;	O
Table	O
3	O
)	O
.	O
SNP	O
rs12075225	O
could	O
not	O
be	O
considered	O
as	O
instruments	O
into	O
the	O
Mendelian	O
randomization	O
analysis	O
as	O
we	O
found	O
a	O
residual	O
association	O
between	O
rs12075225	O
and	O
BMI	O
when	O
adjusting	O
for	O
AMY2	O
activity	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
However	O
,	O
we	O
were	O
able	O
to	O
use	O
rs10492100	O
and	O
rs507666	O
as	O
instruments	O
to	O
assess	O
the	O
causal	O
effect	O
of	O
AMY1	O
and	O
AMY2	O
activities	O
,	O
respectively	O
,	O
on	O
BMI	O
.	O
When	O
using	O
TSLS	O
regression	O
with	O
these	O
instruments	O
,	O
we	O
did	O
not	O
find	O
a	O
significant	O
causal	O
relationship	O
of	O
AMY1	O
or	O
AMY2	O
activity	O
on	O
BMI	O
(	O
P	O
>	O
0	O
.	O
05	O
;	O
Table	O
2	O
)	O
.	O
Next	O
,	O
we	O
took	O
advantage	O
of	O
the	O
prospective	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
study	B-methodology
design	I-methodology
with	O
measured	O
AMY1	O
(	O
n	O
=	O
679	O
)	O
or	O
AMY2	O
(	O
n	O
=	O
705	O
)	O
plasma	O
enzymatic	O
activity	O
after	O
9	O
years	O
of	O
follow	O
-	O
up	O
(	O
Additional	O
file	O
1	O
)	O
.	O
Indeed	O
,	O
although	O
confounding	O
can	O
still	O
be	O
present	O
in	O
prospective	B-methodology
studies	I-methodology
,	O
having	O
consistent	O
results	O
between	O
baseline	O
and	O
follow	O
-	O
up	O
data	O
reinforces	O
the	O
significance	O
of	O
the	O
causal	O
effect	O
estimated	O
besides	O
using	O
Mendelian	O
randomization	O
tools	O
.	O
We	O
found	O
a	O
significant	O
negative	O
effect	O
of	O
BMI	O
at	O
baseline	O
on	O
the	O
change	O
in	O
AMY1	O
activity	O
(	O
β	O
=	O
–	O
0	O
.	O
20	O
±	O
0	O
.	O
08	O
IU	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
014	O
)	O
or	O
AMY2	O
activity	O
(	O
β	O
=	O
–	O
0	O
.	O
18	O
±	O
0	O
.	O
06	O
IU	O
/	O
L	O
,	O
P	O
=	O
3	O
.	O
0	O
×	O
10−3	O
)	O
during	O
the	O
9	O
-	O
year	O
follow	O
-	O
up	O
,	O
which	O
is	O
in	O
line	O
with	O
the	O
results	O
of	O
the	O
Mendelian	O
randomization	O
analyses	O
showing	O
that	O
BMI	O
negatively	O
impacts	O
amylase	O
activity	O
.	O

Nonetheless	O
,	O
we	O
also	O
identified	O
a	O
significant	O
negative	O
contribution	O
of	O
AMY1	O
activity	O
at	O
baseline	O
to	O
the	O
change	O
in	O
BMI	O
during	O
the	O
9	O
-	O
year	O
follow	O
-	O
up	O
(	O
n	O
=	O
2796	O
;	O
β	O
=	O
–	O
0	O
.	O
0062	O
±	O
0	O
.	O
0027	O
kg	O
/	O
m2	O
,	O
P	O
=	O
0	O
.	O
022	O
)	O
,	O
which	O
would	O
imply	O
a	O
bidirectional	O
causal	O
negative	O
effect	O
in	O
the	O
relationship	O
between	O
BMI	O
and	O
AMY1	O
plasma	O
enzymatic	O
activity	O
.	O
The	O
association	O
between	O
AMY2	O
activity	O
at	O
baseline	O
and	O
the	O
change	O
in	O
BMI	O
during	O
the	O
9	O
-	O
year	O
follow	O
-	O
up	O
was	O
not	O
significant	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O
The	O
uncertainty	O
about	O
the	O
causal	O
effect	O
of	O
lower	O
AMY1A	O
copy	O
number	O
(	O
or	O
AMY1	O
activity	O
)	O
to	O
higher	O
BMI	O
prompted	O
us	O
to	O
assess	O
the	O
association	O
between	O
AMY1A	O
copy	O
number	O
and	O
obesity	O
risk	O
in	O
two	O
French	O
case	B-methodology
-	I-methodology
control	I-methodology
studies	I-methodology
,	O
one	O
including	O
1179	O
obese	O
adults	O
and	O
2220	O
controls	O
,	O
and	O
the	O
other	O
one	O
including	O
785	O
obese	O
children	O
/	O
adolescents	O
and	O
712	O
controls	O
(	O
Additional	O
file	O
2	O
;	O
Additional	O
files	O
11	O
and	O
12	O
)	O
.	O
In	O
the	O
French	O
adults	O
,	O
we	O
found	O
that	O
the	O
mean	O
number	O
of	O
AMY1A	O
copies	O
was	O
lower	O
in	O
obese	O
subjects	O
(	O
6	O
.	O
8	O
±	O
2	O
.	O
5	O
;	O
Table	O
4	O
)	O
than	O
in	O
controls	O
(	O
7	O
.	O
0	O
±	O
2	O
.	O
6	O
;	O
Table	O
4	O
)	O
,	O
although	O
this	O
difference	O
was	O
not	O
significant	O
when	O
we	O
adjusted	O
the	O
logistic	O
regression	O
model	O
for	O
both	O
age	O
and	O
sex	O
(	O
P	O
=	O
0	O
.	O
13	O
;	O
Table	O
4	O
)	O
.	O
In	O
contrast	O
,	O
in	O
the	O
French	O
children	O
/	O
adolescents	O
,	O
we	O
found	O
a	O
significant	O
association	O
between	O
AMY1A	O
copy	O
number	O
and	O
lower	O
obesity	O
risk	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
per	O
estimated	O
copy	O
0	O
.	O
94	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
0	O
.	O
90	O
–	O
0	O
.	O
98	O
;	O
P	O
=	O
7	O
.	O
1	O
×	O
10−3	O
;	O
Table	O
4	O
)	O
.	O
When	O
we	O
combined	O
the	O
two	O
case	B-methodology
-	I-methodology
control	I-methodology
studies	I-methodology
in	O
adults	O
and	O
youths	O
,	O
we	O
identified	O
a	O
significant	O
contribution	O
of	O
AMY1A	O
copy	O
number	O
to	O
lower	O
obesity	O
risk	O
(	O
OR	O
per	O
estimated	O
copy	O
0	O
.	O
97	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
94	O
–	O
0	O
.	O
99	O
;	O
P	O
=	O
6	O
.	O
8	O
×	O
10−3	O
;	O
heterogeneity	O
:	O
P	O
=	O
0	O
.	O
14	O
;	O
Table	O
4	O
)	O
.	O

Finally	O
,	O
we	O
aimed	O
to	O
assess	O
the	O
association	O
between	O
36	O
plasma	O
metabolites	O
known	O
to	O
be	O
associated	O
with	O
BMI	O
[	O
23	O
]	O
and	O
AMY1	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
in	O
718	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
participants	O
.	O
First	O
,	O
we	O
confirmed	O
a	O
significant	O
association	O
between	O
these	O
metabolites	O
and	O
BMI	O
in	O
these	O
participants	O
,	O
except	O
for	O
palmitoyl	O
sphingomyelin	O
,	O
which	O
was	O
found	O
to	O
be	O
only	O
metabolite	O
nominally	O
associated	O
with	O
BMI	O
(	O
P	O
=	O
0	O
.	O
07	O
)	O
,	O
although	O
with	O
the	O
same	O
published	O
effect	O
size	O
direction	O
(	O
β	O
<	O
0	O
)	O
[	O
23	O
]	O
.	O
Then	O
,	O
we	O
identified	O
significant	O
associations	O
between	O
several	O
metabolites	O
,	O
including	O
branched	O
-	O
chain	O
amino	O
acids	O
(	O
isoleucine	O
,	O
isovalerylcarnitine	O
,	O
and	O
leucine	O
)	O
,	O
and	O
AMY1	O
and	O
/	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
(	O
Additional	O
file	O
13	O
)	O
,	O
with	O
an	O
effect	O
size	O
direction	O
opposite	O
to	O
the	O
one	O
of	O
BMI	O
effect	O
on	O
the	O
same	O
metabolites	O
(	O
Additional	O
file	O
13	O
)	O
.	O
Interestingly	O
,	O
lactate	O
was	O
significantly	O
associated	O
with	O
higher	O
AMY1	O
activity	O
,	O
when	O
the	O
regression	O
model	O
was	O
adjusted	O
or	O
not	O
for	O
BMI	O
(	O
β	O
=	O
0	O
.	O
050	O
±	O
0	O
.	O
020	O
,	O
P	O
=	O
5	O
.	O
8	O
×	O
10−3	O
;	O
BMI	O
-	O
adjusted	O
:	O
β	O
=	O
0	O
.	O
058	O
±	O
0	O
.	O
020	O
,	O
P	O
=	O
1	O
.	O
6	O
×	O
10−3	O
;	O
Additional	O
file	O
13	O
)	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
plasma	O
enzymatic	O
activities	O
of	O
both	O
AMY1	O
and	O
AMY2	O
were	O
markedly	O
associated	O
with	O
lower	O
BMI	O
and	O
some	O
other	O
related	O
metabolic	O
traits	O
,	O
including	O
lower	O
fasting	O
plasma	O
glucose	O
levels	O
,	O
higher	O
pancreatic	O
beta	O
-	O
cell	O
function	O
,	O
and	O
better	O
lipid	O
profiles	O
,	O
linking	O
starch	O
hydrolysis	O
and	O
metabolism	O
in	O
humans	O
.	O
Although	O
AMY1	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
was	O
significantly	O
correlated	O
with	O
the	O
number	O
of	O
copies	O
of	O
AMY1A	O
or	O
AMY2A	O
,	O
respectively	O
(	O
Fig	O
.	O
1a	O
and	O
b	O
)	O
,	O
we	O
found	O
a	O
nominal	O
association	O
between	O
AMY1A	O
copy	O
number	O
and	O
lower	O
BMI	O
in	O
middle	O
-	O
aged	O
French	O
adults	O
.	O
However	O
,	O
we	O
identified	O
a	O
significant	O
association	O
between	O
AMY1A	O
copy	O
number	O
and	O
lower	O
risk	O
of	O
obesity	O
in	O
French	O
children	O
,	O
which	O
is	O
in	O
line	O
with	O
our	O
previous	O
study	O
performed	O
in	O
Mexican	O
children	O
[	O
9	O
]	O
.	O

The	O
present	O
study	O
also	O
assessed	O
the	O
hypothesis	O
that	O
pancreatic	O
amylase	O
genes	O
(	O
instead	O
of	O
salivary	O
amylase	O
gene	O
)	O
could	O
actually	O
drive	O
the	O
association	O
with	O
BMI	O
[	O
10	O
]	O
.	O
However	O
,	O
we	O
did	O
not	O
find	O
any	O
significant	O
marginal	O
association	O
between	O
AMY2A	O
copy	O
number	O
and	O
BMI	O
,	O
which	O
makes	O
unlikely	O
a	O
major	O
role	O
for	O
pancreatic	O
amylase	O
gene	O
.	O
Yet	O
,	O
we	O
only	O
genotyped	O
AMY2A	O
copy	O
number	O
and	O
not	O
AMY2B	O
copy	O
number	O
,	O
which	O
is	O
a	O
limitation	O
of	O
our	O
study	O
,	O
even	O
if	O
Usher	O
et	O
al	O
.	O
[	O
7	O
]	O
showed	O
that	O
AMY2A	O
copy	O
number	O
was	O
similar	O
to	O
AMY2B	O
copy	O
number	O
in	O
approximately	O
95	O
%	O
of	O
haploid	O
genotypes	O
.	O
Through	O
a	O
Mendelian	O
randomization	O
analysis	O
,	O
we	O
identified	O
a	O
causal	O
negative	O
effect	O
of	O
BMI	O
on	O
plasma	O
enzymatic	O
activities	O
of	O
both	O
AMY1	O
and	O
AMY2	O
.	O
In	O
contrast	O
,	O
we	O
failed	O
to	O
find	O
any	O
causal	O
effect	O
of	O
AMY1	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
on	O
BMI	O
,	O
although	O
this	O
specific	O
analysis	O
likely	O
lacked	O
sufficient	O
statistical	O
power	O
.	O
Indeed	O
,	O
since	O
we	O
could	O
use	O
neither	O
AMY1A	O
nor	O
AMY2A	O
copy	O
number	O
as	O
a	O
genetic	O
instrument	O
for	O
the	O
analysis	O
,	O
we	O
were	O
deprived	O
of	O
the	O
possibility	O
to	O
utilize	O
some	O
of	O
the	O
strongest	O
potential	O
instruments	O
available	O
.	O
Despite	O
this	O
limitation	O
,	O
we	O
were	O
able	O
to	O
find	O
surrogate	O
instruments	O
that	O
were	O
,	O
however	O
,	O
poorly	O
associated	O
with	O
plasma	O
enzymatic	O
activities	O
of	O
AMY1	O
and	O
AMY2	O
compared	O
to	O
their	O
corresponding	O
gene	O
copy	O
number	O
.	O
In	O
addition	O
,	O
since	O
no	O
large	O
genome	B-methodology
-	I-methodology
wide	I-methodology
association	I-methodology
study	I-methodology
for	O
AMY1	O
or	O
AMY2	O
plasma	O
enzymatic	O
activity	O
has	O
been	O
performed	O
so	O
far	O
,	O
we	O
were	O
left	O
with	O
a	O
very	O
limited	O
number	O
of	O
useable	O
instruments	O
.	O
The	O
prospective	O
data	O
available	O
in	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
further	O
supported	O
the	O
negative	O
effect	O
of	O
BMI	O
on	O
AMY1	O
and	O
AMY2	O
activities	O
.	O
However	O
,	O
we	O
also	O
found	O
a	O
significant	O
negative	O
contribution	O
of	O
AMY1	O
activity	O
at	O
baseline	O
to	O
the	O
change	O
in	O
BMI	O
during	O
the	O
9	O
years	O
of	O
follow	O
-	O
up	O
,	O
which	O
implies	O
a	O
possibly	O
causative	O
impact	O
of	O
AMY1	O
activity	O
on	O
decreased	O
adiposity	O
.	O
This	O
was	O
supported	O
by	O
the	O
present	O
results	O
obtained	O
from	O
our	O
obesity	O
case	B-methodology
-	I-methodology
control	I-methodology
study	I-methodology
,	O
showing	O
a	O
significant	O
contribution	O
of	O
AMY1A	O
copy	O
number	O
to	O
decreased	O
obesity	O
risk	O
in	O
French	O
children	O
.	O

The	O
impact	O
of	O
AMY1	O
activity	O
and	O
AMY1A	O
copy	O
number	O
on	O
adiposity	O
is	O
therefore	O
complex	O
and	O
it	O
seems	O
to	O
interact	O
with	O
the	O
metabolic	O
effect	O
of	O
complex	O
carbohydrate	O
digestion	O
by	O
the	O
gut	O
microflora	O
.	O
Our	O
recent	O
independent	O
digital	O
PCR	O
analyses	O
of	O
AMY1A	O
copy	O
number	O
in	O
Mexican	O
children	O
[	O
9	O
]	O
and	O
our	O
present	O
results	O
in	O
French	O
youths	O
found	O
strong	O
evidence	O
that	O
high	O
AMY1A	O
copy	O
numbers	O
protect	O
against	O
childhood	O
obesity	O
in	O
this	O
high	O
-	O
starch	O
diet	O
populations	O
.	O
In	O
contrast	O
,	O
in	O
French	O
middle	O
-	O
aged	O
adults	O
from	O
the	O
general	O
population	O
,	O
we	O
failed	O
to	O
reproduce	O
these	O
findings	O
.	O
The	O
difference	O
between	O
adults	O
and	O
children	O
may	O
be	O
due	O
to	O
the	O
fact	O
that	O
the	O
heritability	O
of	O
BMI	O
is	O
higher	O
in	O
childhood	O
than	O
in	O
adulthood	O
[	O
29	O
,	O
30	O
]	O
,	O
optimizing	O
the	O
identification	O
of	O
significant	O
associations	O
between	O
genetic	O
events	O
and	O
obesity	O
risk	O
.	O
Furthermore	O
,	O
this	O
difference	O
may	O
be	O
due	O
to	O
different	O
gene	O
–	O
environment	O
interactions	O
depending	O
on	O
age	O
[	O
29	O
,	O
30	O
]	O
.	O
For	O
instance	O
,	O
youths	O
may	O
eat	O
more	O
carbohydrates	O
than	O
adults	O
(	O
as	O
the	O
energy	O
requirements	O
of	O
youths	O
have	O
been	O
shown	O
to	O
parallel	O
their	O
growth	O
rate	O
)	O
[	O
31	O
]	O
.	O
In	O
rodents	O
,	O
it	O
was	O
shown	O
that	O
the	O
SNP	O
at	O
Amy1	O
locus	O
strongly	O
predicts	O
weight	O
gain	O
after	O
8	O
weeks	O
on	O
a	O
high	O
-	O
fat	O
,	O
high	O
-	O
sucrose	O
diet	O
,	O
with	O
an	O
associated	O
enrichment	O
in	O
gut	O
bacteria	O
observed	O
in	O
obesity	O
states	O
,	O
which	O
may	O
mediate	O
the	O
metabolic	O
effect	O
of	O
Amy1	O
expression	O
variation	O
[	O
15	O
]	O
.	O
In	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
,	O
we	O
found	O
that	O
AMY1	O
plasma	O
enzymatic	O
activity	O
was	O
significantly	O
associated	O
with	O
higher	O
plasma	O
lactate	O
levels	O
independently	O
of	O
BMI	O
.	O
Lactate	O
is	O
a	O
well	O
-	O
known	O
product	O
of	O
complex	O
carbohydrate	O
fermentation	O
by	O
the	O
gut	O
microbiota	O
[	O
32	O
]	O
.	O
It	O
has	O
been	O
proposed	O
that	O
decrease	O
in	O
the	O
lactate	O
/	O
butyrate	O
ratio	O
can	O
generate	O
an	O
extra	O
20	O
calories	O
/	O
day	O
,	O
which	O
may	O
lead	O
to	O
an	O
extra	O
kilogram	O
for	O
weight	O
over	O
a	O
year	O
[	O
32	O
]	O
.	O
Therefore	O
,	O
we	O
suggest	O
that	O
amylase	O
activity	O
,	O
which	O
is	O
associated	O
with	O
higher	O
lactate	O
production	O
,	O
may	O
protect	O
against	O
obesity	O
,	O
especially	O
in	O
individuals	O
with	O
a	O
high	O
-	O
starch	O
diet	O
.	O

In	O
conclusion	O
,	O
our	O
systems	O
biology	O
study	O
performed	O
in	O
a	O
prospectively	O
followed	O
population	O
-	O
based	O
European	O
cohort	B-methodology
suggests	O
a	O
bidirectional	O
relationship	O
between	O
AMY1	O
plasma	O
enzymatic	O
activity	O
and	O
adiposity	O
.	O
Altogether	O
,	O
low	O
AMY1	O
activity	O
due	O
to	O
both	O
genetic	O
and	O
environmental	O
events	O
may	O
modulate	O
human	O
colonic	O
microbiota	O
fermentation	O
of	O
oligosaccharides	O
into	O
short	O
-	O
chain	O
fatty	O
acids	O
via	O
lactate	O
regulation	O
[	O
32	O
]	O
,	O
which	O
may	O
have	O
a	O
negative	O
impact	O
on	O
energy	O
harvest	O
,	O
and	O
therefore	O
may	O
aggravate	O
obesity	O
.	O
Further	O
studies	O
are	O
warranted	O
to	O
assess	O
the	O
validity	O
of	O
this	O
hypothesis	O
that	O
,	O
if	O
confirmed	O
,	O
may	O
have	O
clinical	O
implications	O
in	O
obesity	O
treatment	O
[	O
33	O
]	O
.	O
This	O
work	O
was	O
supported	O
by	O
grants	O
from	O
the	O
French	O
National	O
Research	O
Agency	O
(	O
ANR	O
-	O
10	O
-	O
LABX	O
-	O
46	O
[	O
European	O
Genomics	O
Institute	O
for	O
Diabetes	O
]	O
and	O
ANR	O
-	O
10	O
-	O
EQPX	O
-	O
07	O
-	O
01	O
[	O
LIGAN	O
-	O
PM	O
]	O
,	O
to	O
PF	O
)	O
,	O
from	O
the	O
European	O
Research	O
Council	O
(	O
ERC	O
GEPIDIAB	O
–	O
294785	O
,	O
to	O
PF	O
)	O
,	O
from	O
FEDER	O
,	O
from	O
Qatar	O
Foundation	O
,	O
and	O
from	O
the	O
‘	O
Région	O
Nord	O
Pas	O
-	O
de	O
-	O
Calais	O
’	O
.	O
AB	O
was	O
supported	O
by	O
Inserm	O
.	O
The	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
study	O
was	O
supported	O
by	O
Inserm	O
contracts	O
with	O
CNAMTS	O
,	O
Lilly	O
,	O
Novartis	O
Pharma	O
,	O
and	O
Sanofi	O
-	O
Aventis	O
,	O
and	O
by	O
Inserm	O
(	O
Réseaux	O
en	O
Santé	O
Publique	O
,	O
Interactions	O
entre	O
les	O
déterminants	O
de	O
la	O
santé	O
,	O
Cohortes	O
Santé	O
TGIR	O
2008	O
)	O
,	O
the	O
Association	O
Diabète	O
Risque	O
Vasculaire	O
,	O
the	O
Fédération	O
Française	O
de	O
Cardiologie	O
,	O
La	O
Fondation	O
de	O
France	O
,	O
Société	O
Francophone	O
du	O
Diabète	O
,	O
ONIVINS	O
,	O
Ardix	O
Medical	O
,	O
Bayer	O
Diagnostics	O
,	O
Becton	O
Dickinson	O
,	O
Cardionics	O
,	O
Merck	O
Santé	O
,	O
Novo	O
Nordisk	O
,	O
Pierre	O
Fabre	O
,	O
Roche	O
,	O
and	O
Topcon	O
.	O

Clinical	O
,	O
metabolic	O
,	O
and	O
genetic	O
data	O
are	O
available	O
according	O
to	O
the	O
rules	O
of	O
each	O
individual	O
cohort	B-methodology
and	O
can	O
be	O
requested	O
from	O
the	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
cohort	B-methodology
(	O
Kremlin	O
Bicêtre	O
,	O
France	O
)	O
,	O
the	O
ABOS	O
study	O
(	O
Lille	O
,	O
France	O
)	O
,	O
the	O
CNRS	O
UMR8199	O
unit	O
(	O
Lille	O
,	O
France	O
)	O
,	O
the	O
Haguenau	O
study	O
(	O
Paris	O
,	O
France	O
)	O
,	O
and	O
the	O
Fleurbaix	O
-	O
Laventie	O
Ville	O
Santé	O
study	O
(	O
Lille	O
,	O
France	O
)	O
.	O
Writing	O
–	O
Original	O
Draft	O
,	O
AB	O
,	O
LY	O
,	O
PF	O
;	O
Writing	O
–	O
Review	O
&	O
Editing	O
,	O
BB	O
,	O
FP	O
,	O
TB	O
;	O
Investigation	O
:	O
AD	O
,	O
MCas	O
,	O
ER	O
,	O
FA	O
;	O
Formal	O
Analysis	O
,	O
AB	O
,	O
LY	O
,	O
MCan	O
;	O
Resources	O
,	O
RC	O
,	O
VR	O
,	O
MP	O
,	O
AA	O
,	O
J	O
-	O
MB	O
,	O
CL	O
-	O
M	O
,	O
JW	O
,	O
RR	O
,	O
BB	O
,	O
MM	O
,	O
FP	O
,	O
TB	O
,	O
PF	O
;	O
Conceptualization	O
,	O
AB	O
,	O
LY	O
,	O
PF	O
;	O
Supervision	O
,	O
AB	O
,	O
PF	O
.	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O
Not	O
applicable	O
.	O
Ethical	O
approval	O
was	O
obtained	O
from	O
each	O
of	O
the	O
following	O
committees	O
:	O
Bicêtre	O
Hospital	O
(	O
Kremlin	O
Bicêtre	O
,	O
France	O
)	O
,	O
Comité	O
Consultatif	O
de	O
Protection	O
des	O
Personnes	O
se	O
prêtant	O
à	O
des	O
Recherches	O
Biomédicales	O
(	O
CPPRB	O
)	O
of	O
Lille	O
-	O
Lille	O
Hospital	O
(	O
Lille	O
,	O
France	O
)	O
,	O
and	O
Paris	O
St	O
Louis	O
University	O
(	O
Paris	O
,	O
France	O
)	O
.	O
Informed	O
consent	O
was	O
obtained	O
from	O
each	O
subject	O
before	O
participation	O
in	O
the	O
study	O
,	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
principles	O
.	O
For	O
children	O
or	O
adolescents	O
younger	O
than	O
18	O
years	O
,	O
oral	O
consent	O
was	O
obtained	O
,	O
and	O
parents	O
provided	O
written	B-methodology
informed	I-methodology
consent	I-methodology
.	O

Neurobeachin	O
,	O
a	O
Regulator	O
of	O
Synaptic	O
Protein	O
Targeting	O
,	O
Is	O
Associated	O
with	O
Body	O
Fat	O
Mass	O
and	O
Feeding	O
Behavior	O
in	O
Mice	O
and	O
Body	O
-	O
Mass	O
Index	O
in	O
Humans	O
Neurobeachin	O
(	O
Nbea	O
)	O
regulates	O
neuronal	O
membrane	O
protein	O
trafficking	O
and	O
is	O
required	O
for	O
the	O
development	O
and	O
functioning	O
of	O
central	O
and	O
neuromuscular	O
synapses	O
.	O
In	O
homozygous	O
knockout	O
(	O
KO	O
)	O
mice	O
,	O
Nbea	O
deficiency	O
causes	O
perinatal	O
death	O
.	O
Here	O
,	O
we	O
report	O
that	O
heterozygous	O
KO	O
mice	O
haploinsufficient	O
for	O
Nbea	O
have	O
higher	O
body	O
weight	O
due	O
to	O
increased	O
adipose	O
tissue	O
mass	O
.	O
In	O
several	O
feeding	O
paradigms	O
,	O
heterozygous	O
KO	O
mice	O
consumed	O
more	O
food	O
than	O
wild	O
-	O
type	O
(	O
WT	O
)	O
controls	O
,	O
and	O
this	O
consumption	O
was	O
primarily	O
driven	O
by	O
calories	O
rather	O
than	O
palatability	O
.	O
Expression	O
analysis	O
of	O
feeding	O
-	O
related	O
genes	O
in	O
the	O
hypothalamus	O
and	O
brainstem	O
with	O
real	O
-	O
time	O
PCR	O
showed	O
differential	O
expression	O
of	O
a	O
subset	O
of	O
neuropeptide	O
or	O
neuropeptide	O
receptor	O
mRNAs	O
between	O
WT	O
and	O
Nbea	O
+	O
/	O
−	O
mice	O
in	O
the	O
sated	O
state	O
and	O
in	O
response	O
to	O
food	O
deprivation	O
,	O
but	O
not	O
to	O
feeding	O
reward	O
.	O
In	O
humans	O
,	O
we	O
identified	O
two	O
intronic	O
NBEA	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
that	O
are	O
significantly	O
associated	O
with	O
body	O
-	O
mass	O
index	O
(	O
BMI	O
)	O
in	O
adult	O
and	O
juvenile	O
cohorts	B-methodology
.	O
Overall	O
,	O
data	O
obtained	O
in	O
mice	O
and	O
humans	O
suggest	O
that	O
variation	O
of	O
Nbea	O
abundance	O
or	O
activity	O
critically	O
affects	O
body	O
weight	O
,	O
presumably	O
by	O
influencing	O
the	O
activity	O
of	O
feeding	O
-	O
related	O
neural	O
circuits	O
.	O
Our	O
study	O
emphasizes	O
the	O
importance	O
of	O
neural	O
mechanisms	O
in	O
body	O
weight	O
control	O
and	O
points	O
out	O
NBEA	O
as	O
a	O
potential	O
risk	O
gene	O
in	O
human	O
obesity	O
.	O
Body	O
weight	O
and	O
energy	O
balance	O
are	O
under	O
very	O
complex	O
neural	O
,	O
endocrine	O
,	O
and	O
metabolic	O
control	O
.	O
Correspondingly	O
,	O
recent	O
research	O
suggests	O
that	O
hundreds	O
of	O
genes	O
contribute	O
to	O
human	O
obesity	O
and	O
that	O
only	O
a	O
small	O
proportion	O
of	O
them	O
have	O
as	O
yet	O
been	O
identified	O
.	O
Neurobeachin	O
(	O
Nbea	O
)	O
is	O
a	O
protein	O
specifically	O
expressed	O
in	O
nerve	O
and	O
endocrine	O
cells	O
and	O
is	O
important	O
for	O
neurotransmission	O
,	O
apparently	O
by	O
influencing	O
the	O
synaptic	O
targeting	O
of	O
membrane	O
proteins	O
.	O

Here	O
,	O
we	O
show	O
that	O
heterozygous	O
knockout	O
mice	O
,	O
expressing	O
Nbea	O
at	O
50	O
%	O
of	O
normal	O
levels	O
,	O
display	O
increased	O
adipose	O
tissue	O
mass	O
,	O
abnormal	O
feeding	O
behavior	O
,	O
and	O
modified	O
expression	O
of	O
specific	O
genes	O
in	O
the	O
brainstem	O
and	O
hypothalamus	O
known	O
to	O
be	O
important	O
for	O
body	O
weight	O
control	O
.	O
Moreover	O
,	O
we	O
find	O
that	O
NBEA	O
gene	O
polymorphisms	O
are	O
associated	O
with	O
body	O
-	O
mass	O
index	O
in	O
adult	B-methodology
and	I-methodology
juvenile	I-methodology
human	I-methodology
cohorts	I-methodology
.	O
Our	O
results	O
demonstrate	O
that	O
variation	O
of	O
Nbea	O
activity	O
critically	O
affects	O
body	O
weight	O
,	O
presumably	O
by	O
influencing	O
the	O
activity	O
of	O
feeding	O
-	O
related	O
neural	O
circuits	O
.	O
They	O
emphasize	O
the	O
importance	O
of	O
neural	O
mechanisms	O
in	O
body	O
weight	O
control	O
,	O
and	O
they	O
identify	O
NBEA	O
as	O
a	O
potential	O
genetic	O
risk	O
factor	O
in	O
human	O
obesity	O
.	O
The	O
BEACH	O
(	O
beige	O
and	O
Chediak	O
-	O
Higashi	O
)	O
domain	O
protein	O
family	O
is	O
implicated	O
in	O
the	O
intracellular	O
targeting	O
of	O
membrane	O
proteins	O
.	O
Its	O
members	O
have	O
been	O
found	O
in	O
yeasts	O
,	O
amoebas	O
,	O
plants	O
and	O
animals	O
,	O
suggesting	O
involvement	O
in	O
fundamental	O
cellular	O
functions	O
.	O
Mutations	O
in	O
BEACH	O
domain	O
proteins	O
result	O
in	O
complex	O
defects	O
of	O
cellular	O
membrane	O
dynamics	O
and	O
membrane	O
protein	O
targeting	O
[	O
1	O
]	O
–	O
[	O
5	O
]	O
.	O
One	O
of	O
the	O
eight	O
mammalian	O
BEACH	O
proteins	O
[	O
5	O
]	O
is	O
Neurobeachin	O
(	O
Nbea	O
)	O
,	O
a	O
327	O
-	O
kDa	O
molecule	O
expressed	O
in	O
neurons	O
and	O
endocrine	O
cells	O
.	O
Nbea	O
contains	O
a	O
high	O
-	O
affinity	O
binding	O
site	O
for	O
the	O
type	O
II	O
regulatory	O
subunit	O
of	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
[	O
6	O
]	O
,	O
which	O
classifies	O
it	O
as	O
an	O
A	O
-	O
kinase	O
anchor	O
protein	O
(	O
AKAP	O
)	O
.	O
AKAPs	O
anchor	O
and	O
concentrate	O
the	O
PKA	O
holoenzyme	O
at	O
defined	O
subcellular	O
locations	O
,	O
enhancing	O
the	O
efficiency	O
and	O
specificity	O
of	O
the	O
interaction	O
of	O
PKA	O
with	O
selected	O
subsets	O
of	O
its	O
target	O
proteins	O
[	O
7	O
]	O
.	O
Nbea	O
is	O
associated	O
with	O
polymorphic	O
vesiculo	O
-	O
tubulo	O
-	O
cisternal	O
endomembranes	O
and	O
postsynaptic	O
plasma	O
membranes	O
,	O
and	O
it	O
is	O
found	O
at	O
high	O
concentrations	O
near	O
the	O
trans	O
side	O
of	O
Golgi	O
stacks	O
.	O
Therefore	O
,	O
a	O
role	O
of	O
Nbea	O
in	O
the	O
post	O
-	O
Golgi	O
sorting	O
or	O
targeting	O
of	O
membrane	O
proteins	O
was	O
proposed	O
[	O
6	O
]	O
.	O

Nbea	O
is	O
essential	O
for	O
synaptic	O
neurotransmission	O
at	O
neuromuscular	O
junctions	O
(	O
NMJ	O
)	O
:	O
Nbea	O
-	O
null	O
mice	O
generated	O
via	O
coincidental	O
insertion	O
mutagenesis	O
die	O
immediately	O
after	O
birth	O
due	O
to	O
breathing	O
paralysis	O
caused	O
by	O
a	O
complete	O
block	O
of	O
evoked	O
transmission	O
at	O
NMJs	O
[	O
8	O
]	O
.	O
In	O
independently	O
derived	O
Nbea	O
KO	O
mice	O
,	O
central	O
neurons	O
showed	O
impaired	O
neurotransmission	O
at	O
both	O
excitatory	O
and	O
inhibitory	O
synapses	O
,	O
lower	O
synapse	O
density	O
and	O
altered	O
synaptic	O
protein	O
composition	O
while	O
the	O
lethal	O
NMJ	O
phenotype	O
was	O
also	O
confirmed	O
.	O
The	O
electrophysiological	O
phenomena	O
at	O
central	O
synapses	O
suggested	O
defects	O
of	O
both	O
presynaptic	O
neurotransmitter	O
release	O
and	O
postsynaptic	O
response	O
,	O
e	O
.	O
g	O
.	O
,	O
through	O
reduced	O
neurotransmitter	O
receptor	O
density	O
[	O
9	O
]	O
.	O
Human	O
data	O
on	O
NBEA	O
are	O
very	O
limited	O
,	O
but	O
heterozygous	O
disruptions	O
in	O
the	O
NBEA	O
gene	O
have	O
been	O
linked	O
with	O
autism	O
and	O
multiple	O
myeloma	O
.	O
A	O
de	O
novo	O
translocation	O
in	O
the	O
NBEA	O
gene	O
was	O
detected	O
in	O
an	O
autistic	O
patient	O
[	O
10	O
]	O
,	O
and	O
additional	O
evidence	O
linking	O
deletions	O
of	O
the	O
chromosomal	O
region	O
containing	O
NBEA	O
to	O
autism	O
has	O
been	O
found	O
(	O
[	O
11	O
]	O
;	O
OMIM	O
608049	O
)	O
.	O
Heterozygous	O
deletions	O
involving	O
NBEA	O
were	O
found	O
in	O
a	O
subgroup	O
of	O
multiple	O
myeloma	O
patients	O
[	O
12	O
]	O
,	O
and	O
NBEA	O
was	O
shown	O
to	O
harbor	O
a	O
region	O
of	O
enhanced	O
chromosomal	O
fragility	O
[	O
11	O
]	O
,	O
[	O
13	O
]	O
.	O
Homozygous	O
inactivation	O
of	O
the	O
Nbea	O
gene	O
in	O
mice	O
results	O
in	O
perinatal	O
death	O
,	O
whereas	O
heterozygous	O
Nbea	O
KO	O
mice	O
are	O
viable	O
and	O
fertile	O
and	O
do	O
not	O
display	O
obvious	O
abnormalities	O
.	O
The	O
association	O
of	O
heterozygous	O
human	O
NBEA	O
mutations	O
with	O
autism	O
and	O
cancer	O
suggested	O
that	O
NBEA	O
haploinsufficiency	O
may	O
produce	O
related	O
phenotypes	O
in	O
mice	O
,	O
and	O
we	O
therefore	O
investigated	O
Nbea	O
+	O
/	O
−	O
mice	O
in	O
the	O
phenotyping	O
screen	O
of	O
the	O
German	O
Mouse	O
Clinic	O
(	O
GMC	O
)	O
.	O

While	O
the	O
possible	O
involvement	O
of	O
Nbea	O
in	O
autism	O
and	O
cancer	O
requires	O
further	O
study	O
,	O
we	O
unexpectedly	O
found	O
phenotypic	O
features	O
of	O
these	O
mice	O
implicating	O
Nbea	O
in	O
energy	O
balance	O
regulation	O
:	O
significantly	O
greater	O
body	O
weight	O
and	O
adipose	O
tissue	O
mass	O
and	O
an	O
elevated	O
energy	O
surplus	O
during	O
early	O
life	O
.	O
Subsequently	O
,	O
we	O
detected	O
alterations	O
in	O
feeding	O
behavior	O
of	O
Nbea	O
+	O
/	O
−	O
mice	O
in	O
several	O
functional	O
tests	O
investigating	O
the	O
effects	O
of	O
high	O
caloric	O
and	O
highly	O
palatable	O
diets	O
,	O
and	O
in	O
the	O
expression	O
of	O
feeding	O
-	O
related	O
genes	O
in	O
the	O
hypothalamus	O
.	O
Finally	O
,	O
we	O
detected	O
the	O
association	O
of	O
two	O
intronic	O
NBEA	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
with	O
weight	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
in	O
humans	O
,	O
suggesting	O
that	O
variability	O
within	O
the	O
NBEA	O
gene	O
may	O
be	O
a	O
genetic	O
risk	O
factor	O
in	O
human	O
obesity	O
.	O
The	O
Nbea	O
gene	O
-	O
trap	O
KO	O
allele	O
has	O
been	O
described	O
[	O
9	O
]	O
.	O
Mice	O
heterozygous	O
for	O
this	O
allele	O
are	O
viable	O
and	O
fertile	O
and	O
display	O
no	O
obvious	O
abnormalities	O
in	O
observation	O
up	O
to	O
an	O
age	O
of	O
2	O
years	O
.	O
We	O
did	O
not	O
observe	O
the	O
dwarfism	O
described	O
by	O
Su	O
et	O
al	O
.	O
[	O
8	O
]	O
for	O
their	O
Nbea	O
+	O
/	O
−	O
mice	O
.	O
This	O
phenotypic	O
aspect	O
of	O
the	O
mutants	O
of	O
Su	O
et	O
al	O
.	O
may	O
be	O
due	O
to	O
the	O
specific	O
nature	O
of	O
their	O
mutation	O
(	O
antisense	O
-	O
oriented	O
insertion	O
of	O
a	O
growth	O
hormone	O
minigene	O
)	O
.	O
Immunoblot	O
analysis	O
of	O
brain	O
homogenates	O
showed	O
that	O
Nbea	O
protein	O
expression	O
in	O
Nbea	O
+	O
/	O
−	O
mice	O
was	O
[UNK]	O
%	O
of	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
(	O
42±6	O
%	O
[	O
mean±SEM	O
]	O
,	O
n	O
=	O
12	O
)	O
whereas	O
the	O
expression	O
level	O
of	O
the	O
Nbea	O
isoform	O
,	O
Lrba	O
,	O
was	O
unaffected	O
(	O
Figure	O
1A	O
)	O
.	O
Nbea	O
+	O
/	O
−	O
mice	O
were	O
systematically	O
analyzed	O
for	O
genotype	O
effects	O
in	O
the	O
primary	O
phenotyping	O
screen	O
at	O
the	O
GMC	O
.	O
Mutant	O
and	O
control	O
mice	O
entered	O
the	O
screen	O
at	O
an	O
age	O
of	O
9	O
weeks	O
and	O
were	O
consecutively	O
investigated	O
in	O
the	O
behavior	O
,	O
neurology	O
,	O
dysmorphology	O
,	O
clinical	O
chemistry	O
and	O
energy	O
metabolism	O
screen	O
,	O
among	O
others	O
[	O
14	O
]	O
–	O
[	O
15	O
]	O
.	O
Both	O
male	O
and	O
female	O
mutant	O
mice	O
were	O
slightly	O
but	O
significantly	O
heavier	O
than	O
controls	O
.	O

Dual	O
-	O
energy	O
X	O
-	O
ray	O
absorptiometry	O
(	O
DXA	O
)	O
performed	O
on	O
16	O
weeks	O
old	O
WT	O
and	O
Nbea	O
+	O
/	O
−	O
mice	O
revealed	O
that	O
the	O
difference	O
in	O
body	O
weight	O
was	O
due	O
to	O
increased	O
body	O
fat	O
content	O
(	O
Table	O
1	O
)	O
.	O
This	O
increased	O
adiposity	O
was	O
apparent	O
in	O
both	O
females	O
and	O
males	O
.	O
As	O
part	O
of	O
the	O
first	O
-	O
line	O
phenotyping	O
screen	O
we	O
then	O
determined	O
food	O
intake	O
and	O
efficiency	O
of	O
energy	O
extraction	O
from	O
the	O
diet	O
in	O
cohorts	B-methodology
of	O
7	O
mice	O
over	O
5	O
days	O
at	O
the	O
age	O
of	O
18	O
–	O
20	O
weeks	O
,	O
with	O
ad	O
libitum	O
access	O
to	O
standard	O
chow	O
(	O
Table	O
1	O
)	O
.	O
At	O
this	O
stage	O
food	O
intake	O
was	O
higher	O
in	O
Nbea	O
+	O
/	O
−	O
mice	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
but	O
proportional	O
to	O
body	O
mass	O
;	O
if	O
initial	O
body	O
mass	O
was	O
included	O
as	O
a	O
covariate	O
,	O
the	O
statistical	O
analysis	O
detected	O
no	O
genotype	O
effect	O
on	O
food	O
intake	O
.	O
The	O
overall	O
efficiency	O
of	O
energy	O
extraction	O
from	O
food	O
(	O
food	O
assimilation	O
coefficient	O
)	O
did	O
not	O
differ	O
between	O
genotypes	O
.	O
Daily	O
metabolized	O
energy	O
intake	O
was	O
indistinguishable	O
between	O
the	O
two	O
genotypes	O
when	O
adjusted	O
for	O
body	O
weight	O
.	O
Behavioral	O
analysis	O
of	O
spontaneous	O
activity	O
in	O
a	O
novel	O
environment	O
,	O
measured	O
by	O
the	O
modified	O
Hole	O
Board	O
test	O
at	O
age	O
8	O
–	O
9	O
weeks	O
,	O
and	O
neurological	O
analysis	O
according	O
to	O
a	O
modified	O
SHIRPA	O
protocol	O
at	O
age	O
9	O
–	O
10	O
weeks	O
,	O
did	O
not	O
indicate	O
reduced	O
spontaneous	O
activity	O
that	O
could	O
cause	O
lower	O
energy	O
expense	O
of	O
the	O
Nbea	O
+	O
/	O
−	O
mice	O
.	O
In	O
particular	O
,	O
no	O
reductions	O
of	O
motor	O
activity	O
parameters	O
(	O
e	O
.	O
g	O
.	O
,	O
total	O
distance	O
moved	O
)	O
were	O
detected	O
.	O
The	O
only	O
genotype	O
-	O
related	O
abnormality	O
was	O
a	O
slight	O
increase	O
of	O
mean	O
locomotion	O
velocity	O
in	O
both	O
sexes	O
by	O
an	O
average	O
6	O
.	O
5	O
%	O
(	O
genotype	O
effect	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
which	O
may	O
indicate	O
a	O
minor	O
perturbation	O
of	O
the	O
locomotor	O
rhythm	O
generator	O
and	O
would	O
,	O
if	O
at	O
all	O
,	O
cause	O
an	O
increased	O
energy	O
expense	O
.	O
Blood	O
chemical	O
parameters	O
determined	O
at	O
the	O
ages	O
of	O
12	O
–	O
13	O
and	O
17	O
–	O
18	O
weeks	O
yielded	O
a	O
slightly	O
increased	O
α	O
-	O
amylase	O
activity	O
in	O
both	O
sexes	O
by	O
an	O
average	O
8	O
%	O
as	O
the	O
only	O
parameter	O
significantly	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
reproducibly	O
abnormal	O
in	O
the	O
mutants	O
(	O
age	O
12	O
–	O
13	O
weeks	O
:	O
males	O
,	O
WT	O
2640±90	O
vs	O
.	O
Nbea	O
+	O
/	O
−2790±60	O
;	O
females	O
,	O
WT	O
1940±50	O
vs	O
.	O

Nbea	O
+	O
/	O
−	O
2130±40	O
;	O
in	O
U	O
/	O
L±SEM	O
)	O
.	O
Sodium	O
,	O
potassium	O
,	O
calcium	O
,	O
chloride	O
,	O
inorganic	O
phosphate	O
,	O
creatinine	O
,	O
triglycerides	O
,	O
cholesterol	O
,	O
urea	O
,	O
uric	O
acid	O
,	O
glucose	O
,	O
total	O
protein	O
,	O
creatine	O
kinase	O
,	O
alanine	O
aminotransferase	O
,	O
aspartate	O
aminotransferase	O
,	O
alkaline	O
phosphatase	O
,	O
ferritin	O
,	O
transferrin	O
and	O
lipase	O
were	O
unaffected	O
by	O
genotype	O
.	O
In	O
a	O
second	O
cohort	B-methodology
of	O
mice	O
we	O
monitored	O
body	O
mass	O
and	O
body	O
composition	O
weekly	O
during	O
early	O
lifetime	O
.	O
We	O
could	O
confirm	O
the	O
development	O
of	O
mild	O
obesity	O
both	O
in	O
Nbea	O
+	O
/	O
−	O
males	O
and	O
females	O
(	O
Figure	O
1B	O
–	O
1D	O
)	O
.	O
To	O
evaluate	O
daily	O
energy	O
balance	O
,	O
we	O
monitored	O
both	O
sides	O
of	O
the	O
energy	O
balance	O
equation	O
,	O
i	O
.	O
e	O
.	O
food	O
intake	O
and	O
energy	O
assimilation	O
and	O
energy	O
expenditure	O
,	O
by	O
gas	O
exchange	O
measurements	O
over	O
24	O
hours	O
at	O
eight	O
weeks	O
of	O
age	O
.	O
Indirect	O
calorimetry	O
did	O
not	O
reveal	O
statistically	O
significant	O
differences	O
in	O
daily	O
energy	O
expenditure	O
(	O
Table	O
2	O
)	O
.	O
Monitoring	O
of	O
food	O
intake	O
and	O
bomb	O
calorimetry	O
of	O
feces	O
and	O
diet	O
samples	O
to	O
determine	O
caloric	O
uptake	O
and	O
the	O
amount	O
of	O
metabolizable	O
energy	O
indicated	O
that	O
energy	O
uptake	O
was	O
slightly	O
increased	O
in	O
mutant	O
animals	O
but	O
the	O
difference	O
did	O
not	O
reach	O
statistical	O
significance	O
when	O
analyzed	O
by	O
a	O
linear	O
regression	O
model	O
including	O
genotype	O
,	O
sex	O
and	O
body	O
mass	O
(	O
Table	O
2	O
)	O
.	O
Calculating	O
the	O
difference	O
between	O
daily	O
metabolizable	O
energy	O
and	O
daily	O
energy	O
expenditure	O
showed	O
that	O
both	O
WT	O
and	O
Nbea	O
+	O
/	O
−	O
mice	O
were	O
in	O
a	O
positive	O
energy	O
balance	O
at	O
8	O
weeks	O
of	O
age	O
(	O
Table	O
2	O
and	O
Figure	O
1E	O
)	O
.	O
In	O
WT	O
mice	O
this	O
surplus	O
of	O
energy	O
,	O
expressed	O
as	O
in	O
-	O
out	O
difference	O
in	O
Table	O
2	O
,	O
was	O
in	O
the	O
range	O
of	O
[UNK]	O
kJ	O
per	O
day	O
reflecting	O
the	O
normal	O
energy	O
demand	O
for	O
growth	O
in	O
8	O
weeks	O
old	O
mice	O
.	O
Notably	O
,	O
the	O
surplus	O
of	O
energy	O
in	O
Nbea	O
+	O
/	O
−	O
mice	O
was	O
slightly	O
higher	O
with	O
[UNK]	O
kJ	O
per	O
day	O
.	O
When	O
compared	O
to	O
WT	O
mice	O
,	O
Nbea	O
+	O
/	O
−	O
mice	O
had	O
3	O
.	O
2	O
kJ	O
(	O
females	O
)	O
and	O
3	O
.	O
4	O
kJ	O
(	O
males	O
)	O
excess	O
energy	O
available	O
on	O
a	O
per	O
day	O
basis	O
(	O
Table	O
2	O
)	O
.	O
This	O
effect	O
of	O
genotype	O
was	O
significant	O
when	O
body	O
mass	O
changes	O
during	O
the	O
indirect	O
calorimetry	O
trial	O
were	O
included	O
in	O
the	O
linear	O
regression	O
model	O
.	O

Continuous	O
monitoring	O
of	O
spontaneous	O
motor	O
activity	O
(	O
distance	O
traveled	O
,	O
rearing	O
)	O
and	O
determination	O
of	O
body	O
temperatures	O
again	O
ruled	O
out	O
both	O
parameters	O
as	O
explanations	O
for	O
the	O
increased	O
fat	O
mass	O
and	O
positive	O
energy	O
balance	O
of	O
Nbea	O
+	O
/	O
−	O
mice	O
(	O
Table	O
2	O
)	O
.	O
Plasma	O
insulin	O
(	O
males	O
+	O
146	O
%	O
,	O
females	O
+	O
29	O
%	O
,	O
genotype	O
p	O
=	O
0	O
.	O
013	O
)	O
and	O
leptin	O
levels	O
(	O
males	O
+	O
122	O
%	O
,	O
females	O
+	O
131	O
%	O
,	O
genotype	O
p	O
=	O
0	O
.	O
002	O
)	O
,	O
determined	O
at	O
22	O
weeks	O
of	O
age	O
,	O
were	O
significantly	O
increased	O
in	O
Nbea	O
+	O
/	O
−	O
mice	O
(	O
Figure	O
1F	O
,	O
1G	O
)	O
.	O
When	O
adjusted	O
for	O
body	O
fat	O
content	O
,	O
however	O
,	O
no	O
difference	O
in	O
leptin	O
levels	O
could	O
be	O
detected	O
.	O
Resistin	O
and	O
PAI	O
-	O
1	O
were	O
not	O
different	O
between	O
genotypes	O
.	O
Several	O
mouse	B-methodology
models	I-methodology
for	O
obesity	O
exhibit	O
normal	O
or	O
only	O
slightly	O
increased	O
body	O
weight	O
on	O
standard	O
diets	O
but	O
develop	O
increased	O
adiposity	O
in	O
response	O
to	O
high	O
-	O
fat	O
(	O
HF	O
)	O
diet	O
intake	O
[	O
16	O
]	O
.	O
Therefore	O
,	O
Nbea	O
+	O
/	O
−	O
and	O
WT	O
mice	O
were	O
fed	O
a	O
HF	O
diet	O
(	O
60	O
energy	O
%	O
fat	O
)	O
from	O
the	O
age	O
of	O
14	O
weeks	O
.	O
In	O
this	O
third	O
cohort	B-methodology
of	O
mice	O
,	O
Nbea	O
+	O
/	O
−	O
males	O
and	O
females	O
weighed	O
,	O
respectively	O
,	O
2	O
.	O
0	O
g	O
and	O
3	O
.	O
6	O
g	O
more	O
than	O
WT	O
mice	O
at	O
the	O
onset	O
of	O
HF	O
feeding	O
,	O
again	O
confirming	O
the	O
body	O
mass	O
phenotype	O
.	O
In	O
response	O
to	O
HF	O
feeding	O
,	O
Nbea	O
+	O
/	O
−	O
females	O
,	O
in	O
particular	O
,	O
exhibited	O
increased	O
susceptibility	O
to	O
diet	O
-	O
induced	O
obesity	O
.	O
After	O
7	O
weeks	O
of	O
HF	O
feeding	O
Nbea	O
+	O
/	O
−	O
females	O
gained	O
substantially	O
more	O
weight	O
than	O
WT	O
(	O
4	O
.	O
1	O
g	O
)	O
,	O
whereas	O
the	O
differential	O
weight	O
gain	O
of	O
Nbea	O
+	O
/	O
−	O
males	O
in	O
excess	O
of	O
WT	O
was	O
marginal	O
(	O
0	O
.	O
6	O
g	O
)	O
(	O
Figure	O
1H	O
,	O
1I	O
)	O
.	O
A	O
glucose	O
tolerance	O
test	O
after	O
22	O
weeks	O
revealed	O
no	O
genotype	O
effects	O
on	O
baseline	O
glucose	O
level	O
or	O
glucose	O
response	O
,	O
in	O
males	O
or	O
females	O
(	O
not	O
shown	O
)	O
.	O
As	O
the	O
previous	O
experiments	O
detected	O
mild	O
differences	O
in	O
gross	O
energy	O
balance	O
between	O
Nbea	O
+	O
/	O
−	O
and	O
WT	O
mice	O
,	O
we	O
tested	O
for	O
more	O
subtle	O
modifications	O
of	O
feeding	O
behavior	O
in	O
episodic	O
feeding	O
paradigms	O
.	O
During	O
these	O
tests	O
,	O
male	O
mice	O
were	O
between	O
the	O
8th	O
and	O
10th	O
week	O
of	O
age	O
,	O
before	O
the	O
emergence	O
of	O
a	O
statistically	O
significant	O
body	O
weight	O
difference	O
between	O
the	O
genotypes	O
.	O

Although	O
,	O
at	O
this	O
age	O
,	O
Nbea	O
+	O
/	O
−	O
mice	O
did	O
not	O
consume	O
detectably	O
more	O
standard	O
chow	O
when	O
fed	O
ad	O
libitum	O
(	O
Nbea	O
+	O
/	O
−	O
:	O
174	O
.	O
8±1	O
.	O
0	O
g	O
/	O
kg	O
body	O
weight	O
;	O
WT	O
:	O
177±2	O
.	O
3	O
g	O
/	O
kg	O
body	O
weight	O
)	O
,	O
the	O
combined	O
incentive	O
of	O
high	O
calorie	O
content	O
and	O
palatability	O
of	O
a	O
high	O
-	O
fat	O
/	O
high	O
-	O
sugar	O
(	O
HFHS	O
)	O
diet	O
stimulated	O
them	O
to	O
eat	O
significantly	O
more	O
than	O
WT	O
controls	O
(	O
Figure	O
2A	O
)	O
.	O
When	O
refed	O
after	O
overnight	O
food	O
deprivation	O
,	O
Nbea	O
+	O
/	O
−	O
mice	O
ingested	O
more	O
also	O
of	O
the	O
standard	O
chow	O
(	O
Figure	O
2B	O
)	O
.	O
Similarly	O
,	O
daily	O
consumption	O
of	O
caloric	O
palatable	O
fluids	O
(	O
Intralipid	O
fat	O
emulsion	O
,	O
sucrose	O
,	O
glucose	O
,	O
fructose	O
)	O
was	O
higher	O
in	O
Nbea	O
+	O
/	O
−	O
than	O
in	O
WT	O
mice	O
(	O
Figure	O
2C	O
)	O
.	O
In	O
contrast	O
,	O
non	O
-	O
caloric	O
yet	O
palatable	O
tastants	O
(	O
saline	O
,	O
saccharin	O
,	O
sucralose	O
)	O
were	O
not	O
overconsumed	O
by	O
the	O
Nbea	O
+	O
/	O
−	O
animals	O
(	O
Figure	O
2D	O
)	O
.	O
Obesity	O
may	O
be	O
caused	O
by	O
leptin	O
resistance	O
.	O
Resistant	O
animals	O
injected	O
with	O
leptin	O
prior	O
to	O
a	O
meal	O
do	O
not	O
reduce	O
food	O
consumption	O
.	O
When	O
we	O
treated	O
overnight	O
-	O
deprived	O
Nbea	O
+	O
/	O
−	O
mice	O
with	O
leptin	O
at	O
the	O
time	O
of	O
chow	O
refeeding	O
,	O
they	O
ate	O
significantly	O
less	O
food	O
than	O
control	B-methodology
animals	I-methodology
receiving	O
only	O
saline	O
injection	O
(	O
Figure	O
2E	O
)	O
,	O
indicating	O
that	O
leptin	O
resistance	O
is	O
unlikely	O
to	O
explain	O
the	O
obesity	O
of	O
Nbea	O
+	O
/	O
−	O
mice	O
.	O
Resistance	O
to	O
leptin	O
is	O
also	O
marked	O
by	O
the	O
lack	O
of	O
responsiveness	O
of	O
hypothalamic	O
neurons	O
,	O
which	O
relay	O
the	O
effects	O
of	O
leptin	O
at	O
the	O
central	O
level	O
,	O
to	O
hormone	O
infusion	O
.	O
A	O
preliminary	O
c	O
-	O
Fos	O
induction	O
experiment	O
(	O
Figure	O
S1	O
)	O
showed	O
that	O
leptin	O
infusion	O
increased	O
the	O
density	O
of	O
Fos	O
-	O
immunopositive	O
,	O
activated	O
neurons	O
in	O
the	O
arcuate	O
nucleus	O
(	O
ARC	O
)	O
of	O
an	O
Nbea	O
+	O
/	O
−	O
and	O
a	O
WT	O
mouse	O
alike	O
,	O
confirming	O
that	O
the	O
mutant	O
mice	O
are	O
sensitive	O
to	O
leptin	O
.	O

An	O
anorexigenic	O
dose	O
of	O
the	O
opioid	O
receptor	O
antagonist	O
,	O
naltrexone	O
(	O
NTX	O
)	O
,	O
administered	O
peripherally	O
to	O
overnight	O
-	O
deprived	O
mice	O
just	O
prior	O
to	O
chow	O
refeeding	O
,	O
caused	O
a	O
[UNK]	O
%	O
reduction	O
in	O
food	O
intake	O
in	O
WT	O
animals	O
.	O
Nbea	O
+	O
/	O
−	O
mice	O
consumed	O
[UNK]	O
%	O
less	O
food	O
than	O
saline	O
controls	O
(	O
Figure	O
2F	O
)	O
,	O
showing	O
that	O
they	O
are	O
responsive	O
to	O
NTX	O
,	O
indeed	O
even	O
hyperresponsive	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
.	O
Following	O
the	O
identification	O
of	O
altered	O
feeding	O
behavior	O
described	O
above	O
,	O
we	O
hypothesized	O
that	O
reduced	O
Nbea	O
expression	O
may	O
alter	O
the	O
activity	O
of	O
neuronal	O
networks	O
involved	O
in	O
energy	O
balance	O
control	O
.	O
We	O
investigated	O
whether	O
expression	O
of	O
feeding	O
-	O
related	O
genes	O
differs	O
between	O
the	O
Nbea	O
+	O
/	O
−	O
and	O
WT	O
genotypes	O
in	O
response	O
to	O
different	O
food	O
availability	O
/	O
quality	O
regimens	O
:	O
in	O
ad	O
libitum	O
feeding	O
of	O
standard	O
chow	O
,	O
following	O
food	O
deprivation	O
,	O
and	O
when	O
a	O
palatable	O
diet	O
is	O
offered	O
.	O
Ad	O
libitum	O
-	O
fed	O
Nbea	O
+	O
/	O
−	O
mice	O
expressed	O
a	O
higher	O
level	O
of	O
orexigenic	O
dynorphin	O
(	O
DYN	O
)	O
mRNA	O
compared	O
to	O
WT	O
controls	O
in	O
the	O
hypothalamus	O
(	O
Figure	O
3A	O
)	O
.	O
Moderate	O
-	O
length	O
(	O
16	O
h	O
)	O
food	O
deprivation	O
led	O
to	O
higher	O
mRNA	O
expression	O
of	O
four	O
hypothalamic	O
genes	O
in	O
Nbea	O
+	O
/	O
−	O
vs	O
.	O
WT	O
mice	O
.	O
Three	O
of	O
them	O
:	O
DYN	O
,	O
proopiomelanocortin	O
(	O
POMC	O
)	O
and	O
opioid	O
-	O
like	O
receptor	O
-	O
1	O
(	O
ORL1	O
)	O
,	O
are	O
linked	O
with	O
orexigenic	O
responses	O
(	O
POMC	O
gives	O
rise	O
to	O
orexigenic	O
beta	O
-	O
endorphin	O
,	O
but	O
also	O
to	O
hypophagic	O
melanocortins	O
(	O
MC	O
)	O
)	O
,	O
whereas	O
corticotropin	O
releasing	O
hormone	O
(	O
CRH	O
)	O
is	O
involved	O
in	O
the	O
HPA	O
axial	O
activity	O
and	O
satiety	O
signaling	O
.	O
In	O
the	O
brainstem	O
,	O
only	O
the	O
MC3	O
receptor	O
mRNA	O
level	O
was	O
lower	O
in	O
Nbea	O
+	O
/	O
−	O
than	O
in	O
WT	O
mice	O
in	O
the	O
ad	O
libitum	O
paradigm	O
,	O
and	O
none	O
of	O
the	O
markers	O
were	O
differentially	O
affected	O
by	O
food	O
deprivation	O
(	O
Figure	O
3B	O
)	O
.	O

Animals	O
exposed	O
to	O
the	O
palatable	O
diet	O
did	O
not	O
show	O
any	O
difference	O
between	O
genotypes	O
in	O
their	O
gene	O
expression	O
response	O
in	O
the	O
hypothalamus	O
(	O
Figure	O
3C	O
)	O
.	O
We	O
then	O
examined	O
whether	O
the	O
link	O
between	O
Nbea	O
and	O
body	O
weight	O
control	O
identified	O
in	O
the	O
mouse	B-methodology
model	I-methodology
can	O
be	O
extended	O
to	O
humans	O
.	O
We	O
studied	O
the	O
association	O
of	O
two	O
relatively	O
common	O
SNPs	O
with	O
body	O
weight	O
and	O
BMI	O
.	O
Two	O
intronic	O
SNPs	O
in	O
NBEA	O
,	O
rs17775456	O
and	O
rs7990537	O
(	O
r2	O
=	O
0	O
.	O
12	O
)	O
,	O
were	O
genotyped	O
in	O
two	O
cohorts	B-methodology
:	O
one	O
comprising	O
adult	O
men	O
from	O
the	O
ULSAM	O
cohort	B-methodology
and	O
one	O
case	B-methodology
-	I-methodology
control	I-methodology
cohort	I-methodology
of	O
children	O
and	O
adolescents	O
.	O
Table	O
3	O
shows	O
anthropometric	O
characteristics	O
in	O
the	O
two	O
cohorts	B-methodology
according	O
to	O
NBEA	O
rs17775456	O
and	O
rs7990537	O
genotype	O
and	O
weight	O
status	O
.	O
None	O
of	O
the	O
two	O
SNPs	O
caused	O
deviation	O
from	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
in	O
any	O
of	O
the	O
studied	O
cohorts	B-methodology
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O
We	O
analyzed	O
the	O
subjects	O
for	O
associations	O
with	O
overweight	O
and	O
obesity	O
depending	O
on	O
NBEA	O
genotypes	O
(	O
Table	O
4	O
)	O
as	O
well	O
as	O
BMI	O
and	O
weight	O
as	O
continuous	O
traits	O
(	O
Table	O
5	O
)	O
.	O
We	O
found	O
a	O
significant	O
association	O
for	O
rs17775456	O
and	O
rs7990537	O
with	O
BMI	O
as	O
a	O
continuous	O
trait	O
(	O
rs17775456	O
:	O
p	O
=	O
0	O
.	O
001	O
and	O
rs7990537	O
:	O
p	O
=	O
0	O
.	O
006	O
)	O
and	O
trends	O
for	O
weight	O
(	O
rs17775456	O
:	O
p	O
=	O
0	O
.	O
022	O
and	O
rs7990537	O
:	O
p	O
=	O
0	O
.	O
025	O
)	O
among	O
the	O
overweight	O
adult	O
men	O
.	O
Carriers	O
of	O
the	O
minor	O
allele	O
were	O
heavier	O
and	O
had	O
higher	O
BMI	O
than	O
non	O
-	O
carriers	O
.	O
Among	O
children	O
and	O
adolescents	O
,	O
we	O
found	O
that	O
rs7990537	O
was	O
significantly	O
associated	O
with	O
BMI	O
in	O
the	O
normal	O
-	O
weight	O
children	O
,	O
the	O
carriers	O
of	O
the	O
minor	O
allele	O
again	O
having	O
higher	O
BMI	O
standard	O
deviation	O
scores	O
(	O
SDS	O
)	O
.	O
For	O
years	O
,	O
obesity	O
research	O
focused	O
primarily	O
on	O
ligand	O
-	O
receptor	O
interactions	O
as	O
the	O
basis	O
of	O
feeding	O
and	O
metabolic	O
responses	O
.	O
Consequently	O
,	O
improper	O
functioning	O
of	O
the	O
ligand	O
-	O
receptor	O
system	O
was	O
considered	O
a	O
causative	O
factor	O
underlying	O
dysregulation	O
of	O
body	O
weight	O
.	O

While	O
this	O
holds	O
true	O
for	O
many	O
such	O
systems	O
,	O
including	O
melanocortins	O
,	O
leptin	O
,	O
ghrelin	O
and	O
neuropeptide	O
Y	O
[	O
17	O
]	O
–	O
[	O
20	O
]	O
,	O
it	O
has	O
become	O
clear	O
that	O
molecules	O
which	O
are	O
not	O
directly	O
involved	O
in	O
communication	O
at	O
the	O
cell	O
surface	O
,	O
but	O
are	O
part	O
of	O
intracellular	O
mechanisms	O
,	O
e	O
.	O
g	O
.	O
,	O
the	O
nucleic	O
acid	O
demethylase	O
Fto	O
,	O
also	O
play	O
a	O
crucial	O
role	O
in	O
the	O
control	O
of	O
energy	O
homeostasis	O
[	O
21	O
]	O
.	O
Here	O
,	O
we	O
report	O
a	O
combination	O
of	O
mouse	O
and	O
human	O
data	O
pertaining	O
to	O
Nbea	O
,	O
a	O
regulator	O
of	O
membrane	O
protein	O
trafficking	O
,	O
showing	O
that	O
mice	O
heterozygous	O
for	O
the	O
Nbea	O
KO	O
allele	O
develop	O
an	O
obese	O
phenotype	O
and	O
that	O
two	O
intronic	O
NBEA	O
SNPs	O
are	O
associated	O
with	O
weight	O
and	O
BMI	O
in	O
humans	O
.	O
Nbea	O
is	O
one	O
of	O
a	O
growing	O
number	O
of	O
proteins	O
important	O
for	O
synaptic	O
development	O
and	O
function	O
that	O
is	O
also	O
associated	O
with	O
obesity	O
.	O
Changes	O
in	O
the	O
Nbea	O
status	O
appear	O
to	O
affect	O
select	O
metabolic	O
and	O
feeding	O
-	O
related	O
parameters	O
.	O
Nbea	O
+	O
/	O
−	O
mice	O
develop	O
moderately	O
elevated	O
body	O
weight	O
during	O
early	O
adulthood	O
.	O
Body	O
composition	O
analyses	O
show	O
that	O
this	O
higher	O
body	O
weight	O
stems	O
from	O
increased	O
adipose	O
tissue	O
mass	O
.	O
Lean	O
mass	O
is	O
virtually	O
unaffected	O
(	O
slightly	O
lower	O
in	O
the	O
experiment	O
of	O
Table	O
1	O
,	O
slightly	O
higher	O
in	O
the	O
experiment	O
of	O
Figure	O
1D	O
)	O
,	O
suggesting	O
altered	O
partitioning	O
of	O
energy	O
in	O
these	O
animals	O
in	O
favor	O
of	O
energy	O
preservation	O
and	O
storage	O
.	O
Therefore	O
,	O
the	O
phenotype	O
of	O
the	O
Nbea	O
+	O
/	O
−	O
mouse	O
can	O
be	O
defined	O
as	O
mildly	O
obese	O
.	O
Increased	O
insulin	O
levels	O
are	O
consistent	O
with	O
this	O
phenotype	O
.	O
Clinical	O
chemistry	O
parameters	O
were	O
otherwise	O
unremarkable	O
,	O
except	O
for	O
a	O
small	O
increase	O
of	O
α	O
-	O
amylase	O
activity	O
in	O
plasma	O
.	O
Leptin	O
levels	O
in	O
Nbea	O
+	O
/	O
−	O
mice	O
were	O
increased	O
only	O
in	O
proportion	O
to	O
the	O
higher	O
body	O
fat	O
content	O
,	O
and	O
these	O
animals	O
were	O
not	O
leptin	O
-	O
resistant	O
just	O
prior	O
to	O
the	O
onset	O
of	O
the	O
overweight	O
phenotype	O
,	O
as	O
demonstrated	O
by	O
their	O
hypophagia	O
and	O
c	O
-	O
Fos	O
induction	O
in	O
response	O
to	O
leptin	O
administration	O
.	O
At	O
the	O
age	O
of	O
16	O
to	O
18	O
weeks	O
Nbea	O
+	O
/	O
−	O
mice	O
fed	O
ad	O
libitum	O
consumed	O
standard	O
chow	O
in	O
greater	O
quantities	O
and	O
exhibited	O
higher	O
daily	O
metabolizable	O
energy	O
intake	O
as	O
compared	O
to	O
WT	O
mice	O
(	O
Table	O
1	O
)	O
,	O
but	O
only	O
in	O
proportion	O
to	O
body	O
mass	O
[	O
22	O
]	O
.	O

Reduced	O
locomotor	O
activity	O
or	O
body	O
temperature	O
as	O
possible	O
explanations	O
of	O
weight	O
gain	O
could	O
not	O
be	O
detected	O
,	O
neither	O
in	O
the	O
primary	O
phenotyping	O
(	O
Table	O
1	O
)	O
nor	O
in	O
the	O
experiment	O
of	O
Table	O
2	O
.	O
Rather	O
,	O
also	O
in	O
additional	O
measurements	O
,	O
body	O
temperature	O
always	O
tended	O
to	O
be	O
increased	O
.	O
Taken	O
together	O
,	O
our	O
primary	O
screen	O
data	O
did	O
not	O
reveal	O
an	O
explanation	O
for	O
the	O
development	O
of	O
mild	O
obesity	O
in	O
Nbea	O
+	O
/	O
−	O
mice	O
.	O
Metabolic	O
abnormalities	O
in	O
mildly	O
obese	O
mice	O
,	O
such	O
as	O
Nbea	O
+	O
/	O
−	O
,	O
are	O
very	O
small	O
and	O
difficult	O
to	O
detect	O
in	O
whole	O
body	O
energy	O
balance	O
studies	O
.	O
It	O
has	O
been	O
pointed	O
out	O
that	O
the	O
statistical	O
power	O
required	O
to	O
detect	O
a	O
slight	O
but	O
relevant	O
imbalance	O
between	O
energy	O
intake	O
and	O
expenditure	O
is	O
usually	O
not	O
attained	O
with	O
the	O
small	O
cohort	B-methodology
sizes	O
used	O
in	O
most	O
animal	B-methodology
experimentation	I-methodology
[	O
23	O
]	O
.	O
We	O
therefore	O
conducted	O
a	O
second	O
,	O
more	O
detailed	O
analysis	O
of	O
whole	O
body	O
energy	O
balance	O
in	O
a	O
new	O
cohort	B-methodology
of	O
mice	O
just	O
before	O
the	O
emergence	O
of	O
increased	O
body	O
fat	O
accumulation	O
.	O
Energy	O
assimilation	O
and	O
energy	O
expenditure	O
were	O
monitored	O
in	O
parallel	O
,	O
but	O
neither	O
parameter	O
as	O
such	O
was	O
significantly	O
altered	O
.	O
However	O
,	O
we	O
found	O
a	O
small	O
but	O
significant	O
elevation	O
of	O
the	O
in	O
-	O
out	O
difference	O
of	O
both	O
parameters	O
in	O
Nbea	O
+	O
/	O
−	O
as	O
compared	O
to	O
WT	O
mice	O
.	O
In	O
terms	O
of	O
absolute	O
surplus	O
energy	O
gain	O
the	O
higher	O
in	O
-	O
out	O
-	O
difference	O
of	O
about	O
3	O
kJ	O
per	O
day	O
in	O
Nbea	O
+	O
/	O
−	O
mice	O
is	O
sufficient	O
to	O
build	O
up	O
excess	O
fat	O
stores	O
of	O
about	O
1	O
g	O
over	O
less	O
than	O
two	O
weeks	O
[	O
23	O
]	O
.	O
Notably	O
,	O
an	O
increased	O
drive	O
to	O
consume	O
food	O
was	O
revealed	O
in	O
the	O
Nbea	O
+	O
/	O
−	O
mice	O
by	O
presenting	O
them	O
with	O
a	O
defined	O
meal	O
of	O
standard	O
chow	O
following	O
a	O
single	O
period	O
of	O
mild	O
food	O
deprivation	O
.	O
Nbea	O
+	O
/	O
−	O
animals	O
ingested	O
significantly	O
more	O
calories	O
than	O
WTs	O
even	O
though	O
no	O
detectable	O
difference	O
in	O
body	O
weight	O
between	O
the	O
mutant	O
and	O
WT	O
animals	O
had	O
as	O
yet	O
developed	O
.	O
Therefore	O
heterozygotes	O
have	O
a	O
higher	O
baseline	O
consumption	O
reflecting	O
their	O
elevated	O
body	O
weight	O
and	O
additionally	O
,	O
under	O
certain	O
food	O
availability	O
conditions	O
,	O
they	O
are	O
more	O
prone	O
to	O
episodic	O
overeating	O
that	O
exceeds	O
the	O
body	O
weight	O
-	O
adjusted	O
control	O
values	O
.	O

In	O
line	O
with	O
this	O
,	O
our	O
data	O
on	O
liquid	O
diet	O
intakes	O
indicate	O
that	O
Nbea	O
+	O
/	O
−	O
animals	O
,	O
regardless	O
of	O
their	O
energy	O
status	O
(	O
i	O
.	O
e	O
.	O
,	O
hungry	O
or	O
sated	O
)	O
,	O
episodically	O
overconsume	O
tastants	O
providing	O
energy	O
,	O
as	O
evidenced	O
by	O
our	O
finding	O
that	O
non	O
-	O
deprived	O
heterozygotes	O
ingest	O
more	O
calorie	O
-	O
containing	O
solutions	O
of	O
sucrose	O
,	O
glucose	O
,	O
fructose	O
or	O
a	O
lipid	O
emulsion	O
(	O
Intralipid	O
)	O
than	O
WTs	O
.	O
An	O
increase	O
is	O
also	O
observed	O
upon	O
ad	O
libitum	O
exposure	O
to	O
high	O
-	O
fat	O
high	O
-	O
sugar	O
chow	O
.	O
It	O
is	O
important	O
to	O
note	O
that	O
this	O
elevated	O
intake	O
of	O
solid	O
and	O
liquid	O
diets	O
does	O
not	O
appear	O
to	O
be	O
primarily	O
driven	O
by	O
an	O
increased	O
response	O
to	O
food	O
reward	O
.	O
While	O
palatability	O
serves	O
as	O
a	O
co	O
-	O
stimulus	O
to	O
ingest	O
food	O
,	O
the	O
absence	O
of	O
calories	O
prevents	O
heterozygotes	O
from	O
consuming	O
more	O
than	O
WTs	O
even	O
when	O
the	O
level	O
of	O
feeding	O
reward	O
is	O
high	O
,	O
as	O
Nbea	O
+	O
/	O
−	O
and	O
WT	O
mice	O
did	O
not	O
differ	O
in	O
the	O
amount	O
of	O
ingested	O
non	O
-	O
caloric	O
tastants	O
,	O
including	O
palatable	O
saccharin	O
,	O
sucralose	O
and	O
saline	O
.	O
As	O
Nbea	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
development	O
of	O
and	O
neurotransmission	O
within	O
brain	O
networks	O
[	O
9	O
]	O
,	O
we	O
investigated	O
the	O
potential	O
influence	O
of	O
Nbea	O
haploinsufficiency	O
on	O
brain	O
mechanisms	O
pertaining	O
to	O
energy	O
balance	O
.	O
Our	O
gene	O
expression	O
data	O
suggest	O
changes	O
in	O
the	O
activity	O
of	O
the	O
circuitry	O
governing	O
energy	O
homeostasis	O
.	O
Sated	O
Nbea	O
+	O
/	O
−	O
animals	O
overexpress	O
orexigenic	O
DYN	O
in	O
the	O
hypothalamus	O
.	O
This	O
may	O
predispose	O
them	O
to	O
eating	O
more	O
upon	O
exposure	O
to	O
caloric	O
foods	O
of	O
desirable	O
characteristics	O
(	O
e	O
.	O
g	O
.	O
,	O
palatability	O
,	O
texture	O
)	O
.	O
An	O
increased	O
sensitivity	O
of	O
Nbea	O
+	O
/	O
−	O
mice	O
to	O
naltrexone	O
in	O
the	O
feeding	O
model	O
strengthens	O
the	O
link	O
between	O
the	O
opioid	O
system	O
and	O
dysregulation	O
of	O
energy	O
balance	O
in	O
Nbea	O
haplosufficiency	O
.	O
DYN	O
,	O
which	O
mediates	O
maintenance	O
of	O
feeding	O
as	O
well	O
as	O
reward	O
[	O
24	O
]	O
,	O
[	O
25	O
]	O
,	O
is	O
a	O
plausible	O
candidate	O
for	O
such	O
a	O
function	O
.	O
Negative	O
energy	O
balance	O
induced	O
by	O
food	O
deprivation	O
led	O
to	O
increased	O
expression	O
of	O
as	O
many	O
as	O
four	O
hypothalamic	O
genes	O
in	O
Nbea	O
+	O
/	O
−	O
compared	O
to	O
WT	O
mice	O
.	O

Two	O
of	O
them	O
,	O
DYN	O
and	O
ORL1	O
,	O
encode	O
orexigens	O
[	O
24	O
]	O
,	O
[	O
26	O
]	O
,	O
[	O
27	O
]	O
.	O
This	O
suggests	O
an	O
enhanced	O
sensitivity	O
of	O
the	O
hypothalamic	O
feeding	O
circuitry	O
to	O
calorie	O
deprivation	O
in	O
Nbea	O
+	O
/	O
−	O
mice	O
,	O
associated	O
with	O
upregulated	O
expression	O
of	O
neuropeptides	O
which	O
stimulate	O
feeding	O
.	O
Since	O
POMC	O
codes	O
for	O
anorexigenic	O
melanocyte	O
stimulating	O
hormone	O
,	O
changes	O
in	O
its	O
expression	O
may	O
also	O
reflect	O
a	O
compensatory	O
mechanism	O
in	O
response	O
to	O
a	O
positive	O
energy	O
balance	O
in	O
the	O
mutant	O
.	O
In	O
contrast	O
to	O
the	O
findings	O
in	O
the	O
deprived	O
and	O
sated	O
state	O
,	O
exposing	O
animals	O
to	O
the	O
palatable	O
diet	O
did	O
not	O
cause	O
differential	O
expression	O
of	O
any	O
gene	O
between	O
Nbea	O
+	O
/	O
−	O
and	O
WT	O
mice	O
in	O
the	O
hypothalamus	O
.	O
We	O
searched	O
HapMap	O
(	O
www	O
.	O
hapmap	O
.	O
org	O
)	O
for	O
SNPs	O
in	O
the	O
human	O
NBEA	O
gene	O
with	O
the	O
aim	O
to	O
genotype	O
a	O
frequent	O
SNP	O
as	O
well	O
as	O
a	O
rare	O
SNP	O
that	O
could	O
have	O
a	O
higher	O
penetrance	O
than	O
a	O
common	O
SNP	O
.	O
NBEA	O
is	O
a	O
large	O
gene	O
,	O
[UNK]	O
kb	O
,	O
and	O
based	O
on	O
HapMap	O
data	O
the	O
gene	O
contains	O
over	O
30	O
haplotype	O
blocks	O
.	O
The	O
two	O
SNPs	O
we	O
selected	O
,	O
rs17775456	O
and	O
rs7990537	O
,	O
are	O
part	O
of	O
two	O
separate	O
haplotype	O
blocks	O
spanning	O
around	O
261	O
and	O
54	O
kb	O
,	O
respectively	O
.	O
These	O
SNPs	O
were	O
genotyped	O
in	O
two	O
cohorts	B-methodology
:	O
one	O
consisting	O
of	O
severely	O
obese	O
Swedish	O
children	O
and	O
adolescents	O
(	O
mean	O
age	O
12	O
.	O
6±3	O
.	O
3	O
years	O
and	O
mean	O
BMI	O
SDS	O
6	O
.	O
2±1	O
.	O
4	O
)	O
and	O
their	O
age	O
-	O
matched	O
normal	O
-	O
weight	O
controls	O
,	O
and	O
another	O
one	O
of	O
Swedish	O
men	O
born	O
1920	O
–	O
1924	O
,	O
thus	O
reaching	O
adulthood	O
prior	O
to	O
the	O
appearance	O
of	O
today	O
'	O
s	O
obesogenic	O
environment	O
.	O
Individuals	O
in	O
both	O
cohorts	B-methodology
showed	O
a	O
significant	O
association	O
of	O
NBEA	O
polymorphism	O
with	O
BMI	O
.	O
We	O
found	O
associations	O
for	O
both	O
,	O
rs17775456	O
and	O
rs7990537	O
,	O
with	O
both	O
body	O
weight	O
and	O
BMI	O
in	O
overweight	O
adult	O
men	O
,	O
while	O
one	O
of	O
the	O
SNPs	O
showed	O
association	O
with	O
BMI	O
in	O
the	O
normal	O
-	O
weight	O
children	O
.	O

In	O
both	O
cohorts	B-methodology
,	O
the	O
same	O
allele	O
was	O
associated	O
with	O
high	O
BMI	O
.	O
No	O
genetic	O
variants	O
in	O
NBEA	O
have	O
previously	O
been	O
reported	O
to	O
be	O
associated	O
with	O
obesity	O
.	O
However	O
,	O
one	O
of	O
the	O
latest	O
papers	O
on	O
novel	O
loci	O
for	O
BMI	O
[	O
28	O
]	O
estimates	O
that	O
there	O
are	O
at	O
least	O
an	O
additional	O
300	O
undiscovered	O
variants	O
that	O
can	O
be	O
linked	O
to	O
obesity	O
.	O
In	O
addition	O
,	O
according	O
to	O
data	O
on	O
1479	O
subjects	O
from	O
the	O
British	O
58	O
Birth	O
Cohort	B-methodology
(	O
www	O
.	O
b58cgene	O
.	O
sgul	O
.	O
ac	O
.	O
uk	O
/	O
index	O
.	O
php	O
)	O
six	O
SNPs	O
in	O
the	O
two	O
haplotype	O
blocks	O
harboring	O
our	O
SNPs	O
are	O
nominal	O
associated	O
with	O
BMI	O
at	O
the	O
age	O
of	O
44	O
–	O
45	O
with	O
the	O
same	O
effect	O
direction	O
.	O
This	O
suggests	O
that	O
NBEA	O
may	O
be	O
linked	O
to	O
a	O
moderately	O
adipogenic	O
activity	O
which	O
,	O
in	O
children	O
,	O
is	O
better	O
detectable	O
in	O
a	O
normal	O
-	O
weight	O
than	O
in	O
a	O
severely	O
obese	O
background	O
,	O
and	O
only	O
manifests	O
as	O
overweight	O
at	O
an	O
adult	O
age	O
.	O
We	O
conclude	O
that	O
neural	O
circuitries	O
involved	O
in	O
food	O
intake	O
and	O
body	O
weight	O
control	O
are	O
sensitive	O
to	O
moderate	O
variation	O
of	O
Nbea	O
activity	O
such	O
as	O
haploinsufficiency	O
.	O
Morphological	O
and	O
electrophysiological	O
abnormalities	O
of	O
cortical	O
neurons	O
have	O
indeed	O
been	O
detected	O
in	O
Nbea	O
+	O
/	O
−	O
mice	O
[	O
29	O
]	O
.	O
The	O
reduction	O
of	O
Nbea	O
expression	O
by	O
only	O
50	O
%	O
suffices	O
to	O
cause	O
monogenic	O
adiposity	O
,	O
at	O
least	O
in	O
the	O
mouse	B-methodology
model	I-methodology
and	O
the	O
C57BL	O
/	O
6N	O
genetic	O
background	O
.	O
This	O
points	O
out	O
human	O
NBEA	O
as	O
a	O
potential	O
genetic	O
factor	O
in	O
common	O
,	O
polygenic	O
obesity	O
in	O
collusion	O
with	O
additional	O
genes	O
.	O
Even	O
more	O
subtle	O
variations	O
of	O
NBEA	O
expression	O
,	O
activity	O
or	O
regulation	O
may	O
contribute	O
to	O
polygenic	O
obesity	O
,	O
as	O
a	O
risk	O
or	O
protective	O
factor	O
.	O
The	O
NBEA	O
gene	O
is	O
very	O
large	O
(	O
730	O
kb	O
,	O
58	O
exons	O
)	O
and	O
recombination	O
-	O
prone	O
[	O
13	O
]	O
,	O
offering	O
extensive	O
mutation	O
potential	O
.	O
Recent	O
genome	B-methodology
-	I-methodology
wide	I-methodology
association	I-methodology
studies	I-methodology
emphasize	O
the	O
high	O
proportion	O
of	O
neuronally	O
expressed	O
genes	O
implicated	O
in	O
obesity	O
.	O
Indeed	O
,	O
human	O
obesity	O
has	O
been	O
characterized	O
as	O
“	O
a	O
heritable	O
neurobehavioral	O
disorder	O
that	O
is	O
highly	O
sensitive	O
to	O
environmental	O
conditions	O
”	O
[	O
30	O
]	O
.	O
Our	O
characterization	O
of	O
the	O
obese	O
Nbea	O
+	O
/	O
−	O
phenotype	O
is	O
a	O
case	O
in	O
point	O
for	O
both	O
parts	O
of	O
this	O
statement	O
.	O

Nbea	O
is	O
expressed	O
in	O
apparently	O
all	O
neuronal	O
and	O
endocrine	O
cell	O
types	O
[	O
6	O
]	O
and	O
probably	O
has	O
a	O
broad	O
importance	O
for	O
nervous	O
system	O
development	O
and	O
function	O
[	O
9	O
]	O
.	O
In	O
spite	O
of	O
this	O
pleiotropy	O
,	O
the	O
first	O
macroscopic	O
manifestation	O
of	O
Nbea	O
haploinsufficiency	O
to	O
be	O
detected	O
in	O
mice	O
is	O
an	O
impact	O
on	O
body	O
weight	O
,	O
reflecting	O
the	O
subtlety	O
and	O
vulnerability	O
of	O
the	O
neural	O
control	O
of	O
energy	O
balance	O
.	O
Moreover	O
,	O
our	O
findings	O
that	O
the	O
Nbea	O
+	O
/	O
−	O
mice	O
are	O
more	O
prone	O
than	O
WT	O
mice	O
to	O
respond	O
to	O
episodic	O
feeding	O
paradigms	O
by	O
overconsuming	O
can	O
be	O
seen	O
as	O
a	O
perturbed	O
ability	O
to	O
handle	O
nutritional	O
challenges	O
,	O
an	O
important	O
factor	O
also	O
in	O
human	O
obesity	O
.	O
It	O
is	O
intriguing	O
that	O
heterozygous	O
perturbations	O
of	O
the	O
NBEA	O
gene	O
have	O
been	O
linked	O
to	O
three	O
dissimilar	O
medical	O
conditions	O
:	O
autism	O
,	O
multiple	O
myeloma	O
,	O
and	O
now	O
obesity	O
.	O
Whereas	O
involvements	O
in	O
autism	O
and	O
obesity	O
may	O
be	O
explained	O
by	O
impacts	O
of	O
NBEA	O
underexpression	O
on	O
the	O
development	O
or	O
functioning	O
of	O
different	O
neuronal	O
circuitries	O
,	O
the	O
association	O
with	O
cancer	O
may	O
be	O
due	O
to	O
functional	O
overlap	O
with	O
its	O
ubiquitous	O
isoform	O
,	O
LRBA	O
[	O
31	O
]	O
.	O
It	O
seems	O
to	O
be	O
a	O
common	O
feature	O
of	O
BEACH	O
proteins	O
that	O
they	O
are	O
involved	O
in	O
the	O
targeting	O
of	O
multiple	O
membrane	O
proteins	O
,	O
and	O
that	O
their	O
KOs	O
therefore	O
generate	O
pleiotropic	O
but	O
partial	O
defects	O
[	O
9	O
]	O
.	O
Autism	O
,	O
cancer	O
and	O
obesity	O
all	O
are	O
typical	O
polygenic	O
disorders	O
,	O
and	O
in	O
combination	O
with	O
different	O
sets	O
of	O
additional	O
risk	O
genes	O
,	O
NBEA	O
misexpression	O
may	O
contribute	O
to	O
different	O
manifestations	O
.	O
Construction	O
and	O
genotyping	O
of	O
the	O
Nbea	O
gene	O
-	O
trap	O
KO	O
mice	O
has	O
been	O
described	O
[	O
9	O
]	O
.	O
Analyses	O
described	O
here	O
were	O
performed	O
with	O
animals	O
after	O
backcrossing	O
into	O
the	O
C57Bl	O
/	O
6N	O
background	O
for	O
5	O
generations	O
or	O
more	O
.	O
Animal	B-methodology
experiments	I-methodology
were	O
performed	O
at	O
the	O
animal	O
facilities	O
of	O
Uppsala	O
University	O
or	O
the	O
GMC	O
at	O
the	O
Helmholtz	O
Zentrum	O
München	O
,	O
Germany	O
.	O
All	O
studies	O
received	O
prior	O
approval	O
from	O
the	O
local	O
animal	O
ethics	O
committees	O
and	O
adhered	O
to	O
the	O
German	O
,	O
Swedish	O
and	O
EU	O
laws	O
pertaining	O
to	O
the	O
protection	O
of	O
animals	O
.	O

Immunoblots	O
of	O
5	O
%	O
SDS	O
-	O
polyacrylamide	O
gels	O
were	O
sequentially	O
probed	O
with	O
affinity	O
-	O
purified	O
rabbit	O
sera	O
directed	O
against	O
isoform	O
-	O
specific	O
sequences	O
of	O
mouse	O
Nbea	O
and	O
mouse	O
Lrba	O
generated	O
in	O
our	O
laboratory	O
(	O
S	O
.	O
S	O
.	O
&	O
M	O
.	O
W	O
.	O
K	O
.	O
)	O
,	O
and	O
with	O
an	O
anti	O
-	O
pan	O
-	O
cadherin	O
mAb	O
(	O
Sigma	O
C1821	O
)	O
.	O
Chemiluminescence	O
-	O
exposed	O
X	O
-	O
ray	O
films	O
were	O
analyzed	O
by	O
densitometry	O
.	O
Whole	O
-	O
brain	O
homogenates	O
were	O
prepared	O
from	O
four	O
animals	O
of	O
each	O
genotype	O
(	O
aged	O
6	O
months	O
)	O
,	O
adjusted	O
for	O
equal	O
protein	O
concentrations	O
,	O
and	O
dilution	O
series	O
of	O
all	O
four	O
sample	O
sets	O
were	O
analyzed	O
twice	O
by	O
Western	O
blotting	O
and	O
densitometry	O
.	O
Nbea	O
and	O
Lrba	O
signals	O
of	O
each	O
lane	O
were	O
normalized	O
on	O
the	O
respective	O
cadherin	O
control	O
signal	O
.	O
Metabolic	O
functions	O
of	O
WT	O
and	O
Nbea	O
+	O
/	O
−	O
mice	O
were	O
characterized	O
in	O
a	O
comprehensive	O
systemic	O
phenotyping	O
screen	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
.	O
In	O
total	O
,	O
140	O
mice	O
entered	O
the	O
GMC	O
in	O
three	O
cohorts	B-methodology
.	O
The	O
primary	O
screen	O
was	O
conducted	O
using	O
the	O
first	O
cohort	B-methodology
of	O
60	O
mice	O
(	O
n	O
=	O
15	O
per	O
sex	O
and	O
genotype	O
for	O
clinical	O
chemistry	O
[	O
tested	O
at	O
12	O
–	O
13	O
and	O
17	O
–	O
18	O
weeks	O
]	O
and	O
DXA	O
[	O
age	O
,	O
16	O
–	O
18	O
weeks	O
]	O
;	O
a	O
subsample	O
of	O
n	O
=	O
7	O
mice	O
per	O
sex	O
and	O
genotype	O
in	O
the	O
energy	O
metabolism	O
screen	O
)	O
.	O
Groups	O
of	O
up	O
to	O
four	O
mice	O
per	O
cage	O
were	O
housed	O
on	O
a	O
12	O
-	O
h	O
light	O
/	O
dark	O
cycle	O
,	O
had	O
ad	O
libitum	O
access	O
to	O
regular	O
laboratory	O
chow	O
(	O
Altromin1324	O
;	O
Altromin	O
,	O
Lage	O
,	O
Germany	O
)	O
,	O
and	O
were	O
provided	O
with	O
UV	O
-	O
irradiated	O
and	O
micro	O
-	O
filtered	O
tap	O
water	O
.	O
For	O
energy	O
assimilation	O
monitoring	O
(	O
age	O
18	O
–	O
20	O
weeks	O
)	O
,	O
mice	O
were	O
single	O
-	O
caged	O
on	O
grid	O
panels	O
(	O
0	O
.	O
5	O
-	O
cm	O
grid	O
hole	O
diameter	O
)	O
allowing	O
the	O
collection	O
of	O
feces	O
and	O
spilled	O
food	O
of	O
individual	O
mice	O
.	O
Body	O
weight	O
,	O
food	O
consumption	O
,	O
mean	O
rectal	O
body	O
temperature	O
of	O
five	O
consecutive	O
measurements	O
conducted	O
at	O
10	O
a	O
.	O
m	O
.	O

every	O
day	O
,	O
daily	O
feces	O
production	O
calculated	O
from	O
a	O
five	O
-	O
day	O
pooled	O
sample	O
,	O
energy	O
uptake	O
,	O
energy	O
content	O
of	O
the	O
feces	O
,	O
metabolizable	O
energy	O
and	O
the	O
food	O
assimilation	O
coefficient	O
were	O
determined	O
.	O
Samples	O
of	O
the	O
lab	O
chow	O
and	O
feces	O
(	O
[UNK]	O
g	O
)	O
were	O
dried	O
at	O
60°C	O
for	O
two	O
days	O
,	O
homogenized	O
in	O
a	O
grinder	O
and	O
squeezed	O
to	O
a	O
pill	O
for	O
determination	O
of	O
energy	O
content	O
in	O
a	O
bomb	O
calorimeter	O
(	O
IKA	O
Calorimeter	O
C7000	O
)	O
.	O
Energy	O
uptake	O
was	O
determined	O
as	O
the	O
product	O
of	O
food	O
consumed	O
and	O
the	O
caloric	O
value	O
of	O
the	O
food	O
.	O
To	O
obtain	O
metabolizable	O
energy	O
,	O
the	O
energy	O
content	O
of	O
feces	O
and	O
urine	O
(	O
2	O
%	O
of	O
energy	O
uptake	O
)	O
was	O
subtracted	O
from	O
energy	O
uptake	O
.	O
Two	O
-	O
way	O
ANOVA	O
(	O
SigmaStat	O
,	O
Jandel	O
Scientific	O
)	O
was	O
used	O
to	O
test	O
for	O
effects	O
of	O
the	O
factors	O
,	O
genotype	O
and	O
sex	O
.	O
To	O
adjust	O
for	O
body	O
mass	O
differences	O
in	O
energy	O
metabolism	O
parameters	O
,	O
a	O
linear	O
regression	O
model	O
was	O
applied	O
including	O
body	O
mass	O
as	O
a	O
co	O
-	O
variate	O
(	O
TIBCO	O
Spotfire	O
S	O
+	O
8	O
.	O
1	O
for	O
Windows	O
)	O
.	O
A	O
pDEXA	O
Sabre	O
X	O
-	O
ray	O
Bone	O
Densitometer	O
(	O
Norland	O
Medical	O
Systems	O
Inc	O
.	O
,	O
Basingstoke	O
,	O
Hampshire	O
,	O
UK	O
)	O
was	O
used	O
for	O
dual	O
-	O
energy	O
X	O
-	O
ray	O
absorptiometry	O
(	O
DXA	O
)	O
.	O
The	O
entire	O
body	O
area	O
including	O
and	O
excluding	O
the	O
skull	O
was	O
assayed	O
with	O
a	O
0	O
.	O
02	O
-	O
g	O
/	O
cm2	O
Histogram	O
Averaging	O
Width	O
(	O
HAW	O
)	O
setting	O
.	O
In	O
the	O
second	O
cohort	B-methodology
of	O
mice	O
(	O
n	O
=	O
10	O
per	O
sex	O
and	O
genotype	O
)	O
,	O
body	O
composition	O
was	O
followed	O
up	O
by	O
non	O
-	O
invasive	O
qNMR	O
scans	O
(	O
MiniSpec	O
LF60	O
,	O
Bruker	O
Optics	O
,	O
Germany	O
)	O
.	O
For	O
the	O
evaluation	O
of	O
energy	O
balance	O
,	O
single	O
mice	O
were	O
kept	O
in	O
respirometry	O
cages	O
(	O
Phenomaster	O
System	O
,	O
TSE	O
Systems	O
,	O
Germany	O
)	O
including	O
the	O
monitoring	O
of	O
gas	O
exchange	O
,	O
food	O
and	O
water	O
uptake	O
,	O
and	O
locomotor	O
activity	O
.	O
To	O
convert	O
food	O
consumption	O
into	O
caloric	O
uptake	O
,	O
energy	O
extraction	O
efficiency	O
of	O
individual	O
mice	O
was	O
determined	O
as	O
described	O
above	O
.	O

Li	O
-	O
heparin	O
plasma	O
samples	O
for	O
clinical	O
chemistry	O
analyses	O
were	O
obtained	O
by	O
blood	O
collection	O
from	O
the	O
retroorbital	O
vein	O
plexus	O
of	O
ether	O
-	O
(	O
first	O
cohort	B-methodology
)	O
or	O
isoflurane	O
-	O
anesthetized	O
mice	O
into	O
heparinized	O
tubes	O
.	O
Samples	O
were	O
mixed	O
thoroughly	O
and	O
stored	O
for	O
2	O
h	O
at	O
room	O
temperature	O
before	O
being	O
separated	O
from	O
blood	O
cells	O
by	O
centrifugation	O
(	O
4656×	O
g	O
;	O
10	O
min	O
)	O
.	O
Plasma	O
samples	O
were	O
stored	O
at	O
4°C	O
and	O
analyzed	O
within	O
24	O
h	O
using	O
an	O
AU400	O
autoanalyzer	O
(	O
Olympus	O
,	O
Hamburg	O
,	O
Germany	O
)	O
and	O
adapted	O
test	O
kits	O
from	O
Olympus	O
.	O
Adipokine	O
determinations	O
were	O
performed	O
with	O
the	O
LINCOplex	O
mouse	O
serum	O
adipokine	O
multiplex	O
immunoassay	O
kit	O
MADPK	O
-	O
71K	O
-	O
07	O
.	O
Two	O
-	O
way	O
ANOVA	O
(	O
SigmaStat	O
,	O
Jandel	O
Scientific	O
)	O
was	O
used	O
to	O
test	O
for	O
effects	O
of	O
genotype	O
and	O
sex	O
,	O
and	O
significance	O
of	O
mean	O
differences	O
between	O
genotypes	O
within	O
each	O
sex	O
was	O
tested	O
using	O
the	O
Welsh	O
t	O
-	O
test	O
(	O
Excel	O
,	O
Microsoft	O
)	O
.	O
Beginning	O
at	O
the	O
age	O
of	O
14	O
weeks	O
,	O
a	O
third	O
cohort	B-methodology
of	O
mice	O
(	O
n	O
=	O
10	O
per	O
sex	O
and	O
genotype	O
)	O
were	O
fed	O
a	O
HF	O
diet	O
(	O
D12492	O
,	O
Research	O
Diets	O
,	O
New	O
Brunswick	O
NJ	O
,	O
USA	O
)	O
for	O
further	O
24	O
weeks	O
.	O
60	O
%	O
of	O
the	O
total	O
energy	O
content	O
(	O
23	O
.	O
2	O
kJ	O
g−1	O
)	O
was	O
due	O
to	O
fat	O
(	O
lard	O
and	O
soybean	O
oil	O
)	O
.	O
Mice	O
were	O
weighed	O
every	O
week	O
.	O
After	O
22	O
weeks	O
,	O
an	O
intraperitoneal	O
glucose	O
tolerance	O
test	O
was	O
conducted	O
after	O
overnight	O
fasting	O
according	O
to	O
the	O
EMPReSSslim	O
protocol	O
(	O
www	O
.	O
eumodic	O
.	O
eu	O
)	O
.	O
Blood	O
samples	O
were	O
taken	O
from	O
the	O
tail	O
vein	O
prior	O
,	O
15	O
,	O
30	O
,	O
60	O
,	O
90	O
,	O
and	O
120	O
minutes	O
after	O
intraperitoneal	O
injection	O
of	O
the	O
2	O
mg	O
per	O
g	O
body	O
mass	O
glucose	O
bolus	O
.	O
Animals	O
were	O
housed	O
individually	O
in	O
a	O
temperature	O
-	O
(	O
21	O
–	O
23°C	O
)	O
and	O
humidity	O
-	O
controlled	O
facility	O
with	O
a	O
12	O
:	O
12	O
LD	O
cycle	O
(	O
lights	O
on	O
at	O
06	O
:	O
00	O
)	O
.	O
Age	O
-	O
matched	O
(	O
±2	O
days	O
)	O
males	O
were	O
used	O
simultaneously	O
.	O

Tap	O
water	O
and	O
standard	O
chow	O
(	O
Lactamin	O
,	O
Lidköping	O
,	O
Sweden	O
)	O
were	O
available	O
ad	O
libitum	O
unless	O
specified	O
otherwise	O
.	O
Sixteen	O
age	O
-	O
matched	O
animals	O
of	O
each	O
genotype	O
were	O
used	O
in	O
Experiments	O
1	O
,	O
2	O
and	O
3	O
,	O
whereas	O
11	O
mice	O
per	O
genotype	O
were	O
included	O
in	O
Experiment	O
4	O
.	O
Mice	O
were	O
between	O
the	O
8th	O
and	O
10th	O
week	O
of	O
age	O
,	O
before	O
the	O
emergence	O
of	O
a	O
statistically	O
significant	O
difference	O
in	O
body	O
weight	O
between	O
the	O
genotypes	O
:	O
18	O
.	O
0±0	O
.	O
4	O
g	O
in	O
heterozygotes	O
and	O
17	O
.	O
5±0	O
.	O
3	O
g	O
in	O
WT	O
controls	O
.	O
Standard	O
chow	O
was	O
removed	O
from	O
cages	O
at	O
09	O
:	O
00	O
and	O
it	O
was	O
replaced	O
with	O
the	O
palatable	O
HFHS	O
pellets	O
(	O
Research	O
Diets	O
)	O
.	O
During	O
the	O
first	O
24	O
h	O
of	O
exposure	O
to	O
the	O
HFHS	O
food	O
,	O
the	O
animals	O
were	O
allowed	O
to	O
get	O
accustomed	O
to	O
the	O
new	O
diet	O
.	O
Then	O
the	O
amount	O
of	O
ingested	O
food	O
(	O
corrected	O
for	O
spillage	O
)	O
was	O
measured	O
for	O
the	O
period	O
of	O
24	O
–	O
72	O
h	O
.	O
Standard	O
chow	O
was	O
removed	O
just	O
before	O
the	O
onset	O
of	O
darkness	O
and	O
it	O
was	O
returned	O
at	O
10	O
:	O
00	O
on	O
the	O
subsequent	O
day	O
.	O
The	O
amount	O
of	O
ingested	O
food	O
(	O
corrected	O
for	O
spillage	O
)	O
was	O
measured	O
2	O
h	O
later	O
when	O
the	O
major	O
consummatory	O
activity	O
had	O
subsided	O
.	O
Mice	O
were	O
given	O
a	O
bottle	O
of	O
10	O
%	O
sucrose	O
,	O
4	O
.	O
1	O
%	O
Intralipid	O
,	O
10	O
%	O
glucose	O
or	O
10	O
%	O
fructose	O
in	O
addition	O
to	O
chow	O
for	O
48	O
h	O
.	O
Intralipid	O
(	O
Fresenius	O
,	O
Sweden	O
)	O
,	O
a	O
palatable	O
lipid	O
emulsion	O
of	O
soybean	O
oil	O
,	O
glycerol	O
and	O
egg	O
yolk	O
phospholipids	O
,	O
has	O
been	O
used	O
in	O
experiments	O
utilizing	O
liquid	O
diets	O
[	O
32	O
]	O
.	O
Sucrose	O
,	O
glucose	O
,	O
fructose	O
and	O
Intralipid	O
were	O
isocaloric	O
(	O
0	O
.	O
4	O
kcal	O
/	O
g	O
)	O
,	O
whereas	O
the	O
energy	O
content	O
of	O
chow	O
was	O
3	O
.	O
6	O
kcal	O
/	O
g	O
.	O
During	O
the	O
first	O
24	O
h	O
of	O
exposure	O
to	O
the	O
liquids	O
,	O
the	O
animals	O
were	O
allowed	O
to	O
get	O
accustomed	O
to	O
the	O
new	O
tastants	O
.	O
Uptake	O
was	O
measured	O
during	O
the	O
following	O
24	O
h	O
.	O
Mice	O
were	O
given	O
a	O
bottle	O
of	O
0	O
.	O
1	O
%	O
saccharin	O
,	O
0	O
.	O
05	O
%	O
sucralose	O
or	O
saline	O
in	O
addition	O
to	O
chow	O
for	O
48	O
h	O
.	O

Total	O
caloric	O
intake	O
per	O
mouse	O
in	O
the	O
saccharin	O
paradigm	O
in	O
heterozygotes	O
was	O
12	O
.	O
53±0	O
.	O
7	O
kcal	O
and	O
in	O
WTs	O
,	O
13	O
.	O
39±0	O
.	O
5	O
kcal	O
;	O
in	O
the	O
sucralose	O
paradigm	O
,	O
heterozygotes	O
ingested	O
14	O
.	O
89±0	O
.	O
7	O
kcal	O
and	O
WTs	O
,	O
14	O
.	O
53±0	O
.	O
5	O
kcal	O
;	O
in	O
the	O
saline	O
paradigm	O
,	O
heterozygotes	O
ingested	O
13	O
.	O
19±0	O
.	O
4	O
kcal	O
and	O
WTs	O
,	O
13	O
.	O
25±0	O
.	O
5	O
kcal	O
.	O
During	O
the	O
first	O
24	O
h	O
of	O
exposure	O
to	O
the	O
liquids	O
,	O
the	O
animals	O
were	O
allowed	O
to	O
get	O
accustomed	O
to	O
the	O
new	O
tastants	O
.	O
Chow	O
was	O
removed	O
from	O
the	O
hoppers	O
of	O
Nbea	O
+	O
/	O
−	O
mice	O
before	O
the	O
onset	O
of	O
darkness	O
.	O
On	O
the	O
next	O
day	O
,	O
at	O
11	O
:	O
00	O
,	O
the	O
animals	O
were	O
injected	O
i	O
.	O
p	O
.	O
with	O
10	O
µg	O
leptin	O
or	O
vehicle	O
(	O
n	O
=	O
5	O
/	O
group	O
)	O
and	O
the	O
pre	O
-	O
weighed	O
food	O
pellets	O
were	O
returned	O
to	O
the	O
hopper	O
.	O
Food	O
intake	O
was	O
measured	O
3	O
h	O
post	O
-	O
injections	O
and	O
corrected	O
for	O
spillage	O
.	O
Chow	O
was	O
removed	O
from	O
the	O
hoppers	O
of	O
Nbea	O
+	O
/	O
−	O
and	O
WT	O
mice	O
before	O
the	O
onset	O
of	O
darkness	O
.	O
On	O
the	O
next	O
day	O
,	O
at	O
11	O
:	O
00	O
,	O
the	O
animals	O
were	O
injected	O
i	O
.	O
p	O
.	O
with	O
3	O
mg	O
/	O
kg	O
NTX	O
or	O
vehicle	O
(	O
n	O
=	O
5	O
–	O
7	O
/	O
group	O
)	O
and	O
the	O
pre	O
-	O
weighed	O
food	O
pellets	O
were	O
returned	O
to	O
the	O
hopper	O
.	O
Food	O
intake	O
was	O
measured	O
3	O
h	O
post	O
-	O
injections	O
and	O
corrected	O
for	O
spillage	O
.	O
Standard	O
chow	O
was	O
removed	O
just	O
before	O
the	O
onset	O
of	O
darkness	O
and	O
mice	O
(	O
n	O
=	O
8	O
/	O
genotype	O
)	O
were	O
decapitated	O
between	O
10	O
:	O
00	O
and	O
11	O
:	O
00	O
on	O
the	O
next	O
day	O
.	O
The	O
fed	O
controls	O
(	O
n	O
=	O
8	O
/	O
genotype	O
)	O
had	O
food	O
ad	O
libitum	O
and	O
were	O
decapitated	O
between	O
09	O
:	O
00	O
and	O
10	O
:	O
00	O
.	O
mRNA	O
expression	O
in	O
the	O
hypothalamus	O
and	O
brainstem	O
was	O
studied	O
with	O
real	O
-	O
time	O
PCR	O
.	O
Mice	O
that	O
had	O
been	O
pre	O
-	O
exposed	O
5	O
days	O
earlier	O
to	O
the	O
HFHS	O
food	O
(	O
Research	O
Diets	O
)	O
for	O
1	O
day	O
were	O
given	O
this	O
diet	O
again	O
for	O
48	O
h	O
;	O
controls	O
(	O
n	O
=	O
8	O
/	O
genotype	O
)	O
had	O
standard	O
chow	O
only	O
.	O

Mice	O
were	O
decapitated	O
after	O
48	O
h	O
(	O
between	O
10	O
:	O
00	O
and	O
11	O
:	O
00	O
)	O
.	O
mRNA	O
expression	O
in	O
the	O
hypothalamus	O
was	O
studied	O
with	O
real	O
-	O
time	O
PCR	O
.	O
Brains	O
were	O
excised	O
,	O
anatomical	O
regions	O
of	O
interest	O
dissected	O
,	O
immersed	O
in	O
RNAlater	O
(	O
Ambion	O
,	O
USA	O
)	O
,	O
kept	O
at	O
room	O
temperature	O
for	O
2	O
h	O
and	O
,	O
thereafter	O
,	O
stored	O
at	O
−80°C	O
until	O
further	O
processed	O
.	O
Samples	O
were	O
homogenized	O
and	O
RNA	O
prepared	O
as	O
previously	O
described	O
[	O
33	O
]	O
.	O
Relative	O
expression	O
levels	O
of	O
seven	O
housekeeping	O
genes	O
(	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
-	O
dehydrogenase	O
,	O
β	O
-	O
tubulin	O
,	O
ribosomal	O
protein	O
19	O
,	O
histone	O
H3	O
,	O
cyclophilin	O
,	O
β	O
-	O
actin	O
,	O
and	O
succinate	O
dehydrogenase	O
complex	O
subunit	O
B	O
)	O
and	O
of	O
the	O
genes	O
of	O
interest	O
were	O
determined	O
with	O
quantitative	O
rtPCR	O
.	O
Each	O
reaction	O
,	O
with	O
a	O
total	O
volume	O
of	O
20	O
µl	O
,	O
contained	O
20	O
mM	O
Tris	O
/	O
HCl	O
pH	O
9	O
.	O
0	O
,	O
50	O
mM	O
KCl	O
,	O
4	O
mM	O
MgCl2	O
,	O
0	O
.	O
2	O
mM	O
dNTP	O
,	O
DMSO	O
(	O
[UNK]	O
)	O
and	O
SYBR	O
Green	O
(	O
[UNK]	O
)	O
.	O
Template	O
concentration	O
was	O
5	O
ng	O
/	O
µl	O
and	O
the	O
concentration	O
of	O
each	O
primer	O
was	O
2	O
pmol	O
/	O
µl	O
.	O
Primers	O
were	O
designed	O
with	O
Beacon	O
Designer	O
(	O
Premier	O
Biosoft	O
)	O
using	O
the	O
SYBR	O
Green	O
settings	O
.	O
All	O
rtPCR	O
experiments	O
were	O
performed	O
in	O
duplicates	O
;	O
for	O
each	O
primer	O
pair	O
a	O
negative	O
control	O
with	O
water	O
and	O
a	O
positive	O
control	O
with	O
5	O
ng	O
/	O
µl	O
of	O
genomic	O
DNA	O
were	O
included	O
on	O
each	O
plate	O
.	O
Amplifications	O
were	O
performed	O
with	O
0	O
.	O
02	O
µg	O
/	O
ml	O
Taq	O
DNA	O
polymerase	O
(	O
Biotools	O
,	O
Sweden	O
)	O
under	O
the	O
following	O
conditions	O
:	O
initial	O
denaturation	O
at	O
95°C	O
for	O
3	O
min	O
,	O
50	O
cycles	O
of	O
denaturing	O
at	O
95°C	O
for	O
15	O
sec	O
,	O
annealing	O
at	O
52	O
.	O
8	O
–	O
60	O
.	O
1°C	O
for	O
15	O
sec	O
and	O
extension	O
at	O
72°C	O
for	O
30	O
sec	O
.	O
Analysis	O
of	O
rtPCR	O
data	O
was	O
performed	O
as	O
previously	O
reported	O
[	O
34	O
]	O
.	O
MyIQ	O
1	O
.	O
0	O
software	O
(	O
Bio	O
-	O
Rad	O
)	O
was	O
used	O
.	O

Primer	O
efficiencies	O
were	O
calculated	O
using	O
LinRegPCR	O
[	O
35	O
]	O
and	O
samples	O
were	O
corrected	O
for	O
differences	O
in	O
primer	O
efficiencies	O
.	O
The	O
GeNorm	O
protocol	O
described	O
by	O
Vandesompele	O
et	O
al	O
.	O
[	O
36	O
]	O
was	O
used	O
to	O
calculate	O
normalization	O
factors	O
from	O
the	O
expression	O
levels	O
of	O
the	O
housekeeping	O
genes	O
.	O
Grubbs	O
'	O
test	O
was	O
used	O
to	O
remove	O
outliers	O
.	O
Differences	O
in	O
gene	O
expression	O
between	O
groups	O
were	O
analyzed	O
with	O
ANOVA	O
followed	O
by	O
Fisher	O
'	O
s	O
PLSD	O
test	O
where	O
appropriate	O
.	O
P	O
<	O
0	O
.	O
05	O
was	O
used	O
as	O
the	O
criterion	O
of	O
statistical	O
significance	O
.	O
We	O
genotyped	O
1152	O
men	O
from	O
the	O
Uppsala	O
Longitudinal	B-methodology
Study	I-methodology
of	O
Adult	O
Men	O
(	O
ULSAM	O
)	O
,	O
described	O
previously	O
[	O
37	O
]	O
–	O
[	O
38	O
]	O
.	O
The	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
Department	O
of	O
Medicine	O
,	O
Uppsala	O
University	O
.	O
All	O
participants	O
gave	O
their	O
written	B-methodology
informed	I-methodology
consent	I-methodology
.	O
We	O
further	O
genotyped	O
1027	O
children	O
and	O
adolescents	O
comprising	O
one	O
group	O
of	O
obese	O
children	O
and	O
adolescents	O
and	O
one	O
group	O
of	O
normal	O
-	O
weight	O
adolescents	O
,	O
as	O
described	O
earlier	O
[	O
39	O
]	O
.	O
The	O
study	O
was	O
approved	O
by	O
the	O
Regional	O
Ethics	O
Committee	O
in	O
Stockholm	O
.	O
For	O
the	O
men	O
,	O
height	O
was	O
measured	O
to	O
the	O
nearest	O
whole	O
centimeter	O
and	O
weight	O
to	O
the	O
nearest	O
whole	O
kilogram	O
at	O
age	O
50	O
years	O
.	O
BMI	O
was	O
calculated	O
as	O
weight	O
divided	O
by	O
height	O
squared	O
(	O
kg	O
/	O
m2	O
)	O
.	O
For	O
the	O
children	O
and	O
adolescents	O
,	O
body	O
weight	O
and	O
height	O
were	O
measured	O
to	O
the	O
nearest	O
0	O
.	O
1	O
kg	O
and	O
1	O
cm	O
,	O
respectively	O
.	O
BMI	O
standard	O
deviation	O
score	O
(	O
BMI	O
SDS	O
)	O
was	O
calculated	O
from	O
weight	O
and	O
height	O
and	O
standardized	O
for	O
age	O
and	O
sex	O
[	O
40	O
]	O
.	O
Genotyping	O
of	O
NBEA	O
rs7990537	O
and	O
rs17775456	O
variants	O
in	O
the	O
ULSAM	O
cohort	B-methodology
was	O
carried	O
out	O
at	O
the	O
SNP	O
technology	O
platform	O
at	O
Uppsala	O
University	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
genotyping	O
.	O
SE	O
/	O
)	O
using	O
an	O
Illumina	O
Golden	O
Gate	O
Assay	O
[	O
41	O
]	O
.	O
The	O
SNP	O
genotype	O
call	O
rate	O
in	O
the	O
samples	O
was	O
96	O
.	O
8	O
%	O
.	O
For	O
the	O
children	O
and	O
adolescents	O
,	O
genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
using	O
QiaGen	O
Maxiprep	O
kit	O
(	O
Qiagen	O
,	O
Hilden	O
,	O
Germany	O
)	O
.	O

Genotyping	O
was	O
performed	O
with	O
pre	O
-	O
designed	O
Taqman	O
single	O
-	O
nucleotide	O
polymorphism	O
genotyping	O
assay	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
USA	O
)	O
and	O
an	O
ABI7900	O
genetic	O
analyzer	O
with	O
SDS	O
2	O
.	O
2	O
software	O
.	O
In	O
order	O
to	O
test	O
for	O
deviation	O
from	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
,	O
the	O
Person	O
'	O
s	O
χ2	O
-	O
test	O
(	O
1	O
d	O
.	O
f	O
)	O
was	O
applied	O
.	O
Association	O
analysis	O
of	O
rs17775456	O
and	O
rs7990537	O
with	O
obesity	O
measurements	O
was	O
performed	O
using	O
BMI	O
and	O
body	O
weight	O
as	O
continuous	O
traits	O
.	O
The	O
adult	O
men	O
were	O
categorized	O
as	O
overweight	O
(	O
BMI≥25	O
kg	O
/	O
m2	O
)	O
or	O
normal	O
-	O
weight	O
(	O
BMI	O
<	O
25	O
kg	O
/	O
m2	O
)	O
before	O
the	O
analysis	O
.	O
Skewed	O
variables	O
were	O
log	O
-	O
transformed	O
and	O
analyzed	O
with	O
linear	O
regression	O
,	O
assuming	O
an	O
additive	O
model	O
.	O
Covariates	O
such	O
as	O
height	O
,	O
age	O
and	O
sex	O
were	O
tested	O
for	O
dependence	O
on	O
the	O
response	O
variables	O
and	O
included	O
in	O
the	O
model	O
if	O
significant	O
.	O
In	O
order	O
to	O
correct	O
for	O
multiple	O
comparisons	O
Bonferroni	O
correction	O
was	O
applied	O
and	O
a	O
p	O
-	O
value≤0	O
.	O
006	O
was	O
considered	O
statistically	O
significant	O
.	O
All	O
the	O
analyses	O
were	O
performed	O
using	O
PLINK	O
(	O
http	O
:	O
/	O
/	O
pngu	O
.	O
mgh	O
.	O
harvard	O
.	O
edu	O
/	O
purcell	O
/	O
plink	O
/	O
)	O
[	O
42	O
]	O
.	O
Power	O
calculation	O
was	O
carried	O
out	O
with	O
the	O
CaTS	O
power	O
calculator	O
(	O
www	O
.	O
sph	O
.	O
umich	O
.	O
edu	O
/	O
csg	O
/	O
abecasis	O
/	O
CaTS	O
/	O
index	O
.	O
html	O
)	O
[	O
43	O
]	O
and	O
Power	O
and	O
Sample	O
Size	O
Calculation	O
(	O
biostat	O
.	O
mc	O
.	O
vanderbilt	O
.	O
edu	O
/	O
wiki	O
/	O
Main	O
/	O
PowerSampleSize	O
)	O
[	O
44	O
]	O
.	O
For	O
rs17775456	O
we	O
had	O
80	O
%	O
power	O
to	O
detect	O
association	O
with	O
overweight	O
and	O
obesity	O
,	O
with	O
a	O
relative	O
risk	O
of	O
1	O
.	O
2	O
.	O
For	O
rs7990537	O
we	O
had	O
80	O
%	O
power	O
to	O
detect	O
association	O
with	O
overweight	O
and	O
obesity	O
with	O
a	O
relative	O
risk	O
of	O
1	O
.	O
4	O
.	O

The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O
The	O
studies	O
were	O
supported	O
by	O
grants	O
of	O
the	O
Deutsche	O
Forschungsgemeinschaft	O
(	O
Ki	O
324	O
/	O
15	O
)	O
to	O
MWK	O
,	O
the	O
Swedish	O
Research	O
Council	O
(	O
VR	O
-	O
Medicine	O
)	O
to	O
HBS	O
and	O
MWK	O
,	O
the	O
Novo	O
Nordisk	O
Foundation	O
to	O
HBS	O
,	O
the	O
German	O
Federal	O
Ministry	O
of	O
Education	O
and	O
Research	O
to	O
the	O
German	O
Center	O
for	O
Diabetes	O
Research	O
(	O
DZD	O
e	O
.	O
V	O
.	O
)	O
,	O
by	O
NGFNplus	O
grants	O
to	O
MK	O
(	O
01GS0822	O
)	O
and	O
to	O
the	O
German	O
Mouse	O
Clinic	O
(	O
GMC	O
)	O
(	O
01GS0850	O
,	O
01GS0851	O
,	O
01GS0869	O
)	O
,	O
as	O
well	O
as	O
by	O
EU	O
grants	O
to	O
the	O
GMC	O
(	O
EUMODIC	O
LSHG	O
-	O
2006	O
-	O
037188	O
and	O
PhenoScale	O
grant	O
agreement	O
number	O
223263	O
)	O
.	O
It	O
was	O
also	O
supported	O
by	O
the	O
Initiative	O
and	O
Networking	O
Fund	O
of	O
the	O
Helmholtz	O
Association	O
in	O
the	O
framework	O
of	O
the	O
Helmholtz	O
Alliance	O
for	O
Mental	O
Research	O
in	O
an	O
Ageing	O
Society	O
T	O
(	O
HA	O
-	O
215	O
)	O
.	O
The	O
SNP	O
genotyping	O
was	O
performed	O
by	O
the	O
SNP	O
Technology	O
Platform	O
,	O
Uppsala	O
,	O
Sweden	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
genotyping	O
.	O
se	O
)	O
with	O
support	O
from	O
Uppsala	O
University	O
and	O
the	O
Knut	O
and	O
Alice	O
Wallenberg	O
foundation	O
,	O
and	O
at	O
the	O
Uppsala	O
Genome	O
Centre	O
.	O
The	O
funders	O
had	O
no	O
role	O
in	O
study	B-methodology
design	I-methodology
,	O
data	O
collection	O
and	O
analysis	O
,	O
decision	O
to	O
publish	O
,	O
or	O
preparation	O
of	O
the	O
manuscript	O
.	O

Ketogenic	O
diet	O
enhances	O
neurovascular	O
function	O
with	O
altered	O
gut	O
microbiome	O
in	O
young	O
healthy	O
mice	O
Neurovascular	O
integrity	O
,	O
including	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
and	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
function	O
,	O
plays	O
a	O
major	O
role	O
in	O
determining	O
cognitive	O
capability	O
.	O
Recent	O
studies	O
suggest	O
that	O
neurovascular	O
integrity	O
could	O
be	O
regulated	O
by	O
the	O
gut	O
microbiome	O
.	O
The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
identify	O
if	O
ketogenic	O
diet	O
(	O
KD	O
)	O
intervention	O
would	O
alter	O
gut	O
microbiome	O
and	O
enhance	O
neurovascular	O
functions	O
,	O
and	O
thus	O
reduce	O
risk	O
for	O
neurodegeneration	O
in	O
young	O
healthy	O
mice	O
(	O
12	O
–	O
14	O
weeks	O
old	O
)	O
.	O
Here	O
we	O
show	O
that	O
with	O
16	O
weeks	O
of	O
KD	O
,	O
mice	O
had	O
significant	O
increases	O
in	O
CBF	O
and	O
P	O
-	O
glycoprotein	O
transports	O
on	O
BBB	O
to	O
facilitate	O
clearance	O
of	O
amyloid	O
-	O
beta	O
,	O
a	O
hallmark	O
of	O
Alzheimer	O
’	O
s	O
disease	O
(	O
AD	O
)	O
.	O
These	O
neurovascular	O
enhancements	O
were	O
associated	O
with	O
reduced	O
mechanistic	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
and	O
increased	O
endothelial	O
nitric	O
oxide	O
synthase	O
(	O
eNOS	O
)	O
protein	O
expressions	O
.	O
KD	O
also	O
increased	O
the	O
relative	O
abundance	O
of	O
putatively	O
beneficial	O
gut	O
microbiota	O
(	O
Akkermansia	O
muciniphila	O
and	O
Lactobacillus	O
)	O
,	O
and	O
reduced	O
that	O
of	O
putatively	O
pro	O
-	O
inflammatory	O
taxa	O
(	O
Desulfovibrio	O
and	O
Turicibacter	O
)	O
.	O
We	O
also	O
observed	O
that	O
KD	O
reduced	O
blood	O
glucose	O
levels	O
and	O
body	O
weight	O
,	O
and	O
increased	O
blood	O
ketone	O
levels	O
,	O
which	O
might	O
be	O
associated	O
with	O
gut	O
microbiome	O
alteration	O
.	O
Our	O
findings	O
suggest	O
that	O
KD	O
intervention	O
started	O
in	O
the	O
early	O
stage	O
may	O
enhance	O
brain	O
vascular	O
function	O
,	O
increase	O
beneficial	O
gut	O
microbiota	O
,	O
improve	O
metabolic	O
profile	O
,	O
and	O
reduce	O
risk	O
for	O
AD	O
.	O
Neurovascular	O
functions	O
play	O
a	O
critical	O
role	O
in	O
determining	O
cognitive	O
capability	O
and	O
mental	O
health1	O
.	O
Studies	O
have	O
shown	O
that	O
neurovascular	O
risk	O
is	O
highly	O
associated	O
with	O
accelerated	O
decline	O
in	O
language	O
ability	O
,	O
verbal	O
memory	O
,	O
attention	O
and	O
visuospatial	O
abilities2	O
,	O
3	O
.	O
Specifically	O
,	O
reduced	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
is	O
linked	O
to	O
increased	O
risk	O
for	O
anxiety	O
,	O
depression	O
,	O
and	O
dementia3	O
–	O
5	O
,	O
while	O
impaired	O
blood	O
-	O
brain	O
-	O
barrier	O
(	O
BBB	O
)	O
function	O
is	O
associated	O
with	O
neuroinflammation	O
,	O
synaptic	O
dysfunction	O
,	O
and	O
psychiatric	O
disorders6	O
,	O
7	O
.	O

Emerging	O
evidence	O
suggests	O
that	O
gut	O
microbiota	O
play	O
an	O
important	O
role	O
in	O
determining	O
brain	O
vascular	O
integrity	O
.	O
Braniste	O
et	O
al	O
.	O
recently	O
showed	O
that	O
BBB	O
permeability	O
is	O
increased	O
in	O
germ	O
-	O
free	O
mice	O
due	O
to	O
lack	O
of	O
butyrate	O
,	O
a	O
short	O
chain	O
fatty	O
acid	O
(	O
SCFA	O
)	O
produced	O
by	O
microorganisms	O
such	O
as	O
Clostridium	O
tyrobutyricum8	O
.	O
Similarly	O
,	O
Akkermansia	O
muciniphila	O
can	O
produce	O
SCFAs	O
such	O
as	O
acetate	O
and	O
propionate9	O
,	O
and	O
the	O
lack	O
of	O
A	O
.	O
muciniphila	O
can	O
alter	O
the	O
microbial	O
ecology	O
of	O
the	O
mucus	O
layer10	O
and	O
lead	O
to	O
damage	O
of	O
tight	O
junctions	O
of	O
BBB	O
and	O
the	O
gut7	O
,	O
11	O
.	O
BBB	O
dysfunction	O
further	O
leads	O
to	O
reduced	O
CBF	O
and	O
impaired	O
clearance	O
of	O
amyloid	O
-	O
beta	O
(	O
Aβ	O
)	O
plaques	O
,	O
a	O
hallmark	O
of	O
Alzheimer	O
’	O
s	O
disease	O
(	O
AD	O
)	O
1	O
,	O
6	O
.	O
Interventions	O
that	O
maintain	O
gut	O
microbiome	O
and	O
neurovascular	O
integrity	O
may	O
be	O
thus	O
crucial	O
for	O
impeding	O
neurological	O
disorders	O
.	O
Ketogenic	O
diet	O
(	O
KD	O
)	O
,	O
a	O
high	O
fat	O
and	O
low	O
carbohydrate	O
diet	O
,	O
has	O
been	O
an	O
effective	O
therapeutic	O
for	O
a	O
wide	O
range	O
of	O
neurological	O
disorders12	O
.	O
Clinically	O
,	O
KD	O
has	O
been	O
used	O
to	O
treat	O
epilepsy12	O
,	O
13	O
,	O
Parkinson	O
’	O
s	O
disease14	O
,	O
and	O
autism15	O
.	O
Furthermore	O
,	O
significant	O
evidence	O
for	O
KD	O
as	O
a	O
therapeutic	O
for	O
a	O
broader	O
range	O
of	O
conditions	O
can	O
be	O
found	O
in	O
preclinical	B-methodology
studies	I-methodology
where	O
KD	O
has	O
been	O
shown	O
to	O
protect	O
brain	O
function	O
in	O
Alzheimer	O
’	O
s	O
disease16	O
,	O
traumatic	O
brain	O
injury17	O
,	O
and	O
ischemic	O
stroke18	O
.	O
A	O
recent	O
study	O
showed	O
that	O
KD	O
significantly	O
increased	O
regional	O
CBF	O
in	O
a	O
mouse	B-methodology
model	I-methodology
with	O
ischemic	O
stroke19	O
.	O
In	O
another	O
study	O
with	O
an	O
autism	O
mouse	B-methodology
model	I-methodology
,	O
KD	O
mitigated	O
neurological	O
symptoms	O
potentially	O
through	O
changes	O
in	O
the	O
gut	O
microbiome20	O
.	O
Collectively	O
,	O
KD	O
may	O
be	O
protective	O
against	O
various	O
neurological	O
disorders	O
,	O
possibly	O
through	O
the	O
restoration	O
of	O
neurovascular	O
function	O
and	O
by	O
maintaining	O
healthy	O
gut	O
microbiome	O
.	O
While	O
KD	O
has	O
beneficial	O
effects	O
in	O
disease	O
systems	O
,	O
it	O
is	O
unclear	O
if	O
similar	O
impacts	O
persist	O
in	O
healthy	O
conditions	O
.	O

Therefore	O
,	O
the	O
goal	O
of	O
the	O
study	O
was	O
to	O
identify	O
whether	O
administration	O
of	O
KD	O
to	O
young	O
healthy	O
mice	O
would	O
also	O
benefit	O
their	O
neurovascular	O
functions	O
and	O
gut	O
microbiome	O
composition	O
,	O
and	O
whether	O
these	O
changes	O
could	O
contribute	O
to	O
lowering	O
risk	O
for	O
AD	O
,	O
the	O
most	O
common	O
form	O
of	O
dementia	O
.	O
We	O
were	O
also	O
interested	O
in	O
identifying	O
potential	O
signaling	O
pathways	O
in	O
association	O
with	O
vascular	O
changes	O
induced	O
by	O
KD	O
.	O
We	O
hypothesized	O
that	O
KD	O
would	O
increase	O
neuroprotection	O
for	O
young	O
healthy	O
mice	O
,	O
and	O
reduce	O
their	O
risk	O
for	O
neurodegeneration	O
,	O
by	O
enhancing	O
their	O
neurovascular	O
functions	O
and	O
increasing	O
the	O
abundance	O
of	O
beneficial	O
gut	O
microbiota	O
.	O
We	O
used	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
to	O
measure	O
CBF	O
and	O
confocal	O
microscopy	O
to	O
determine	O
BBB	O
function	O
.	O
Figure	O
1a	O
shows	O
representative	O
CBF	O
maps	O
superimposed	O
on	O
structural	O
brain	O
images	O
.	O
The	O
color	O
code	O
indicates	O
the	O
level	O
of	O
CBF	O
in	O
a	O
linear	O
scale	O
.	O
We	O
found	O
that	O
KD	O
-	O
fed	O
mice	O
had	O
significantly	O
elevated	O
CBF	O
globally	O
and	O
regionally	O
,	O
particularly	O
in	O
ventromedial	O
hypothalamus	O
(	O
VMH	O
)	O
(	O
11	O
.	O
82	O
%	O
;	O
p	O
<	O
0	O
.	O
0001	O
;	O
Fig	O
.	O
1b	O
)	O
.	O
We	O
previously	O
reported	O
that	O
inhibiting	O
mechanistic	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
signaling	O
increases	O
neurovascular	O
function	O
by	O
activating	O
endothelial	O
nitric	O
oxide	O
synthase	O
(	O
eNOS	O
)	O
21	O
,	O
22	O
.	O
In	O
this	O
study	O
,	O
we	O
also	O
found	O
that	O
mTOR	O
protein	O
expression	O
was	O
reduced	O
(	O
−29	O
.	O
9	O
%	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
while	O
eNOS	O
levels	O
were	O
increased	O
(	O
111	O
.	O
5	O
%	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
mice	O
fed	O
with	O
KD	O
,	O
compared	O
to	O
control	O
mice	O
(	O
Fig	O
.	O
1c	O
)	O
.	O
In	O
addition	O
,	O
protein	O
expression	O
levels	O
of	O
P	O
-	O
glycoprotein	O
(	O
P	O
-	O
gp	O
)	O
,	O
which	O
transports	O
Aβ	O
across	O
at	O
the	O
BBB	O
,	O
were	O
also	O
significantly	O
elevated	O
in	O
KD	O
-	O
fed	O
mice	O
(	O
50	O
.	O
5	O
%	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
The	O
Western	O
blots	O
are	O
shown	O
in	O
Fig	O
.	O
1c	O
and	O
the	O
corresponding	O
values	O
are	O
shown	O
in	O
Fig	O
.	O
1d	O
.	O
We	O
further	O
used	O
confocal	O
microscope	O
imaging	O
to	O
assess	O
P	O
-	O
gp	O
transport	O
activity23	O
.	O

This	O
assay	O
measures	O
accumulation	O
of	O
[	O
N	O
-	O
ε	O
(	O
4	O
-	O
nitro	O
-	O
benzofurazan	O
-	O
7	O
-	O
yl	O
)	O
-	O
DLys	O
(	O
8	O
)	O
]	O
-	O
cyclosporin	O
A	O
(	O
NBD	O
-	O
CSA	O
)	O
,	O
a	O
fluorescent	O
P	O
-	O
gp	O
substrate	O
in	O
the	O
capillary	O
lumen	O
.	O
Figure	O
1e	O
(	O
top	O
)	O
shows	O
representative	O
confocal	O
images	O
of	O
capillaries	O
incubated	O
to	O
steady	O
state	O
in	O
a	O
medium	O
containing	O
2	O
µM	O
NBD	O
-	O
CSA	O
;	O
the	O
intensity	O
of	O
fluorescence	O
in	O
the	O
capillary	O
lumen	O
reflects	O
the	O
amount	O
of	O
NBD	O
-	O
CSA	O
transported	O
by	O
P	O
-	O
gp	O
.	O
The	O
corresponding	O
quantitative	O
results	O
are	O
shown	O
in	O
Fig	O
.	O
1e	O
(	O
bottom	O
)	O
–	O
KD	O
mice	O
had	O
significantly	O
enhanced	O
P	O
-	O
gp	O
transport	O
activity	O
(	O
185	O
.	O
38	O
%	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
capillaries	O
compared	O
to	O
capillaries	O
isolated	O
from	O
control	O
mice	O
.	O
Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
KD	O
enhanced	O
neurovascular	O
function	O
and	O
increased	O
Aβ	O
clearance	O
.	O
Figure	O
2a	O
shows	O
Shannon	O
index	O
(	O
H	O
)	O
for	O
alpha	O
diversity	O
,	O
which	O
is	O
measure	O
of	O
within	O
-	O
sample	O
diversity	O
and	O
is	O
a	O
synthesis	O
of	O
both	O
the	O
richness	O
and	O
evenness	O
of	O
the	O
microbial	O
community	O
in	O
a	O
particular	O
sample	O
.	O
Shannon	O
indices	O
calculated	O
based	O
on	O
rarefied	O
datasets	O
(	O
10	O
,	O
000	O
sequences	O
/	O
sample	O
)	O
were	O
significantly	O
different	O
between	O
control	O
and	O
KD	O
mice	O
(	O
Mann	O
-	O
Whitney	O
U	O
test	O
;	O
p	O
=	O
0	O
.	O
018	O
)	O
,	O
with	O
the	O
fecal	O
microbiomes	O
of	O
KD	O
mice	O
having	O
lower	O
diversity	O
.	O
Figure	O
2b	O
shows	O
a	O
genus	O
-	O
level	O
metric	O
multi	O
-	O
dimensional	O
scaling	O
(	O
mMDS	O
)	O
plot	O
of	O
16s	O
rRNA	O
gene	O
amplicon	O
microbiome	O
data	O
generated	O
from	O
a	O
Bray	O
-	O
Curtis	O
resemblance	O
matrix	O
.	O
The	O
fecal	O
microbiomes	O
of	O
control	O
and	O
KD	O
mice	O
were	O
significantly	O
different	O
as	O
assessed	O
by	O
analysis	O
of	O
similarity	O
(	O
ANOSIM	O
;	O
R	O
=	O
0	O
.	O
473	O
,	O
p	O
=	O
0	O
.	O
0002	O
)	O
.	O
These	O
results	O
indicate	O
that	O
KD	O
significantly	O
altered	O
fecal	O
microbial	O
composition	O
,	O
and	O
the	O
effects	O
included	O
both	O
a	O
significant	O
decrease	O
in	O
microbial	O
diversity	O
and	O
a	O
significant	O
shift	O
in	O
microbial	O
community	O
composition	O
.	O
We	O
used	O
a	O
group	O
significance	O
test	O
(	O
Kruskal	O
-	O
Wallis	O
test	O
)	O
24	O
to	O
identify	O
specific	O
microbial	O
taxa	O
,	O
which	O
differed	O
in	O
relative	O
abundance	O
between	O
fecal	O
samples	O
of	O
KD	O
and	O
control	O
mice	O
.	O

Table	O
1	O
shows	O
the	O
genera	O
and	O
species	O
that	O
were	O
significantly	O
different	O
between	O
control	O
and	O
KD	O
mice	O
(	O
Kruskal	O
-	O
Wallis	O
test	O
,	O
with	O
Benjamini	O
-	O
Hochberg	O
false	O
discovery	O
rate	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
We	O
found	O
that	O
KD	O
mice	O
had	O
significant	O
increases	O
in	O
the	O
relative	O
abundance	O
of	O
A	O
.	O
muciniphila	O
and	O
Lactobacillus	O
(	O
approximately	O
2	O
.	O
5	O
and	O
3	O
.	O
2	O
-	O
fold	O
increases	O
,	O
respectively	O
)	O
.	O
Both	O
taxa	O
have	O
members	O
that	O
are	O
capable	O
of	O
producing	O
SCFAs25	O
,	O
26	O
and	O
members	O
of	O
the	O
genus	O
Lactobacillus	O
have	O
been	O
used	O
elsewhere	O
as	O
probiotics27	O
.	O
Two	O
low	O
abundance	O
genera	O
of	O
putative	O
acetate	O
producers	O
(	O
<	O
0	O
.	O
3	O
%	O
relative	O
abundance	O
)	O
within	O
the	O
order	O
Clostridiales	O
,	O
Clostridium	O
and	O
Dorea28	O
,	O
were	O
significantly	O
lower	O
in	O
KD	O
mice	O
.	O
The	O
relative	O
abundance	O
of	O
bacteria	O
from	O
the	O
genera	O
Desulfovibrio	O
and	O
Turicibacter	O
was	O
significantly	O
and	O
substantially	O
lower	O
in	O
KD	O
mice	O
.	O
Desulfovibrio	O
sequences	O
were	O
not	O
detected	O
in	O
KD	O
mice	O
but	O
present	O
at	O
an	O
average	O
relative	O
abundance	O
of	O
0	O
.	O
53	O
%	O
in	O
control	B-methodology
animals	I-methodology
,	O
while	O
Turicibacter	O
relative	O
abundance	O
was	O
nearly	O
two	O
orders	O
of	O
magnitude	O
higher	O
in	O
the	O
fecal	O
samples	O
of	O
control	O
mice	O
relative	O
to	O
KD	O
mice	O
.	O
Desulfovibrio	O
are	O
sulfate	O
-	O
reducing	O
bacteria	O
associated	O
with	O
inflammatory	O
bowel	O
disease29	O
,	O
while	O
members	O
of	O
the	O
genus	O
Turicibacter	O
were	O
shown	O
to	O
increase	O
with	O
diet	O
-	O
induced	O
obesity30	O
.	O
Collectively	O
,	O
KD	O
increased	O
the	O
relative	O
abundance	O
of	O
microbiota	O
that	O
are	O
putatively	O
able	O
to	O
protect	O
neurovascular	O
integrity	O
,	O
as	O
well	O
as	O
reduced	O
those	O
which	O
may	O
induce	O
inflammation	O
.	O
A	O
.	O
muciniphila	O
can	O
increase	O
insulin	O
sensitivity31	O
,	O
and	O
exhibits	O
a	O
negative	O
correlation	O
with	O
body	O
-	O
mass	O
index32	O
.	O
Consistent	O
with	O
our	O
gut	O
microbiome	O
findings	O
,	O
we	O
observed	O
a	O
significant	O
decrease	O
in	O
blood	O
glucose	O
level	O
in	O
the	O
KD	O
mice	O
(	O
Fig	O
.	O
3a	O
;	O
−19	O
.	O
97	O
%	O
;	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O
With	O
KD	O
feeding	O
,	O
mice	O
exhibited	O
significantly	O
higher	O
ketone	O
concentration	O
when	O
compared	O
to	O
the	O
control	B-methodology
group	I-methodology
(	O
Fig	O
.	O
3b	O
;	O
43	O
.	O
48	O
%	O
;	O
p	O
=	O
0	O
.	O
0004	O
)	O
.	O
Interestingly	O
,	O
there	O
was	O
a	O
significant	O
inverse	O
correlation	O
between	O
ketone	O
level	O
and	O
blood	O
glucose	O
measurements	O
(	O
Fig	O
.	O

3c	O
;	O
Pearson	O
’	O
s	O
r	O
=	O
−	O
0	O
.	O
58	O
;	O
r2	O
=	O
0	O
.	O
33	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O
Another	O
interesting	O
aspect	O
of	O
the	O
present	O
study	O
is	O
that	O
KD	O
mice	O
lost	O
body	O
weight	O
despite	O
having	O
higher	O
energy	O
intake	O
(	O
7	O
.	O
24	O
kcal	O
/	O
gm	O
)	O
compared	O
to	O
the	O
control	O
mice	O
(	O
3	O
.	O
79	O
kcal	O
/	O
gm	O
)	O
.	O
KD	O
mice	O
exhibited	O
reduced	O
body	O
weight	O
by	O
week	O
3	O
(	O
Fig	O
.	O
3d	O
;	O
−15	O
.	O
50	O
%	O
;	O
p	O
=	O
0	O
.	O
0096	O
)	O
,	O
and	O
this	O
trend	O
continued	O
for	O
the	O
remainder	O
of	O
the	O
study	O
.	O
At	O
the	O
time	O
of	O
the	O
final	O
measurement	O
,	O
the	O
KD	O
mice	O
maintained	O
significantly	O
lower	O
weights	O
than	O
the	O
control	O
mice	O
(	O
−14	O
.	O
58	O
%	O
;	O
p	O
=	O
0	O
.	O
0042	O
)	O
.	O
Our	O
findings	O
are	O
consistent	O
with	O
literature	O
that	O
KD	O
reduces	O
blood	O
glucose	O
levels33	O
and	O
body	O
weight34	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
KD	O
enhanced	O
neurovascular	O
functions	O
and	O
increased	O
beneficial	O
gut	O
microbiota	O
in	O
young	O
healthy	O
mice	O
.	O
In	O
particular	O
,	O
KD	O
enhanced	O
BBB	O
function	O
by	O
increasing	O
protein	O
expression	O
and	O
transport	O
activity	O
of	O
the	O
Aβ	O
transporter	O
P	O
-	O
gp	O
,	O
increased	O
CBF	O
in	O
VMH	O
,	O
and	O
reduced	O
mTOR	O
with	O
increased	O
eNOS	O
protein	O
expressions	O
.	O
In	O
addition	O
,	O
KD	O
increased	O
potentially	O
beneficial	O
gut	O
microorganisms	O
,	O
including	O
A	O
.	O
muciniphila	O
and	O
bacteria	O
from	O
the	O
genus	O
Lactobacillus	O
.	O
KD	O
also	O
reduced	O
potentially	O
pro	O
-	O
inflammatory	O
taxa	O
,	O
including	O
bacteria	O
from	O
the	O
genera	O
Desulfovibrio	O
and	O
Turicibacter	O
.	O
We	O
also	O
found	O
that	O
mice	O
fed	O
with	O
KD	O
had	O
reduced	O
blood	O
glucose	O
levels	O
and	O
body	O
weight	O
,	O
and	O
increased	O
blood	O
ketone	O
body	O
levels	O
;	O
there	O
was	O
an	O
inverse	O
correlation	O
between	O
blood	O
glucose	O
and	O
ketone	O
bodies	O
levels	O
.	O
Collectively	O
,	O
KD	O
showed	O
multifactorial	O
benefits	O
for	O
mice	O
even	O
under	O
healthy	O
conditions	O
.	O
The	O
enhancements	O
of	O
CBF	O
,	O
BBB	O
transporter	O
activities	O
,	O
and	O
potentially	O
increased	O
Aβ	O
clearance	O
suggest	O
that	O
mice	O
with	O
KD	O
may	O
have	O
lower	O
risk	O
to	O
develop	O
age	O
-	O
related	O
neurodegenerative	O
disorders	O
,	O
including	O
AD	O
.	O
This	O
is	O
consistent	O
with	O
literature	O
that	O
KD	O
reduces	O
Aβ	O
toxicity	O
and	O
restores	O
memory	O
in	O
animal	B-methodology
models	I-methodology
that	O
develop	O
AD	O
-	O
like	O
symptoms35	O
–	O
38	O
.	O

This	O
also	O
agrees	O
with	O
our	O
previous	O
findings	O
showing	O
that	O
preserving	O
CBF	O
and	O
BBB	O
integrity	O
is	O
critical	O
in	O
preventing	O
AD	O
development	O
in	O
a	O
mouse	B-methodology
model	I-methodology
with	O
human	O
APOE4	O
gene	O
,	O
the	O
strongest	O
genetic	O
risk	O
factor	O
for	O
AD39	O
;	O
and	O
restoring	O
CBF	O
improves	O
memory	O
in	O
a	O
symptomatic	O
AD	O
mouse	O
model21	O
.	O
Our	O
findings	O
are	O
consistent	O
with	O
literature	O
showing	O
that	O
an	O
acute	O
increase	O
in	O
ketone	O
body	O
levels	O
elevated	O
CBF	O
in	O
rats37	O
and	O
humans36	O
.	O
We	O
further	O
demonstrate	O
that	O
mTOR	O
inhibition	O
may	O
play	O
an	O
important	O
role	O
in	O
neurovascular	O
enhancements	O
.	O
mTOR	O
is	O
a	O
nutrient	O
sensor	O
and	O
its	O
activity	O
can	O
be	O
down	O
-	O
regulated	O
when	O
glucose	O
availability	O
is	O
reduced	O
or	O
ketogenesis	O
is	O
increased40	O
.	O
Similar	O
to	O
caloric	O
restriction	O
,	O
mTOR	O
inhibition	O
can	O
preserve	O
brain	O
metabolism	O
with	O
age41	O
,	O
potentially	O
due	O
to	O
the	O
shift	O
from	O
glucose	O
to	O
ketone	O
body	O
utilization42	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
KD	O
mice	O
exhibited	O
significantly	O
lower	O
expression	O
of	O
mTOR	O
,	O
but	O
significantly	O
increased	O
expression	O
of	O
eNOS	O
.	O
This	O
is	O
consistent	O
with	O
our	O
previous	O
study	O
using	O
rapamycin	O
,	O
showing	O
that	O
mTOR	O
inhibition	O
can	O
activate	O
eNOS	O
,	O
which	O
causes	O
the	O
release	O
of	O
nitric	O
oxide	O
,	O
a	O
vessel	O
dilator	O
,	O
and	O
consequently	O
elevates	O
CBF21	O
,	O
23	O
.	O
This	O
is	O
also	O
consistent	O
with	O
studies	O
showing	O
that	O
down	O
-	O
regulation	O
of	O
mTOR	O
is	O
associated	O
with	O
elevated	O
P	O
-	O
gp	O
expression23	O
.	O
The	O
neurovascular	O
enhancements	O
by	O
mTOR	O
inhibition	O
were	O
associated	O
with	O
preserved	O
white	O
matter	O
integrity	O
and	O
long	O
-	O
term	O
memory	O
,	O
and	O
reduced	O
anxiety	O
in	O
aging	O
mice23	O
,	O
43	O
.	O
Gut	O
microbiome	O
alterations	O
induced	O
by	O
KD	O
may	O
also	O
contribute	O
to	O
the	O
neurovascular	O
enhancements	O
.	O
We	O
found	O
that	O
KD	O
significantly	O
increased	O
the	O
relative	O
abundance	O
of	O
A	O
.	O
muciniphila	O
and	O
Lactobacillus	O
,	O
known	O
to	O
produce	O
SCFAs25	O
–	O
27	O
.	O
SCFAs	O
are	O
transported	O
by	O
monocarboxylate	O
transporters	O
expressed	O
at	O
the	O
BBB44	O
,	O
45	O
.	O
Lack	O
of	O
SCFAs	O
can	O
cause	O
higher	O
BBB	O
permeability7	O
,	O
8	O
,	O
11	O
.	O
On	O
the	O
other	O
hand	O
,	O
we	O
found	O
that	O
Desulfovibrio	O
was	O
absent	O
in	O
KD	O
mice	O
.	O
This	O
is	O
consistent	O
with	O
a	O
prior	O
study	O
showing	O
that	O
KD	O
significantly	O
decreases	O
the	O
abundance	O
of	O
Desulfovibrio	O
in	O
Glucose	O
Transporter	O
1	O
Deficiency	O
Syndrome29	O
.	O

Members	O
of	O
the	O
genus	O
Desulfovibrio	O
are	O
capable	O
of	O
respiring	O
sulfate	O
and	O
producing	O
hydrogen	O
sulfide	O
,	O
which	O
is	O
known	O
to	O
induce	O
gut	O
barrier	O
impairment46	O
.	O
Consequently	O
,	O
reducing	O
the	O
abundance	O
of	O
Desulfovibrio	O
may	O
also	O
facilitate	O
BBB	O
and	O
neurovascular	O
enhancements	O
.	O
Together	O
,	O
changes	O
in	O
relative	O
abundance	O
of	O
A	O
.	O
muciniphila	O
,	O
Lactobacillus	O
,	O
and	O
Desulfovibrio	O
may	O
contribute	O
to	O
protection	O
of	O
neurovascular	O
functions	O
.	O
We	O
found	O
that	O
KD	O
decreased	O
overall	O
microbial	O
diversity	O
.	O
This	O
is	O
likely	O
a	O
result	O
of	O
reduced	O
carbohydrate	O
intake	O
,	O
which	O
decreases	O
the	O
polysaccharide	O
content	O
that	O
many	O
gut	O
bacteria	O
derive	O
energy	O
from47	O
.	O
Although	O
other	O
studies	O
suggested	O
that	O
reduced	O
microbiome	O
diversity	O
may	O
be	O
associated	O
with	O
disease	O
progression48	O
,	O
we	O
found	O
that	O
levels	O
of	O
several	O
beneficial	O
microbiota	O
were	O
increased	O
,	O
even	O
though	O
the	O
overall	O
diversity	O
was	O
reduced	O
by	O
KD	O
.	O
In	O
part	O
,	O
the	O
decrease	O
in	O
diversity	O
(	O
Shannon	O
index	O
)	O
can	O
be	O
attributed	O
to	O
the	O
substantially	O
higher	O
relative	O
abundance	O
of	O
A	O
.	O
muciniphila	O
in	O
KD	O
mice	O
,	O
reaching	O
nearly	O
20	O
%	O
of	O
the	O
observed	O
microbial	O
community	O
.	O
Future	O
studies	O
are	O
needed	O
to	O
further	O
identify	O
the	O
different	O
contributions	O
between	O
overall	O
diversity	O
and	O
underlying	O
taxonomy	O
for	O
health	O
and	O
diseases	O
.	O
In	O
addition	O
,	O
shotgun	O
metagenome	O
and	O
metatranscriptome	O
sequencing	O
efforts	O
will	O
be	O
required	O
to	O
associate	O
specific	O
metabolic	O
capabilities	O
(	O
e	O
.	O
g	O
.	O
,	O
SCFAs	O
production	O
)	O
with	O
identified	O
taxa	O
,	O
and	O
to	O
demonstrate	O
where	O
and	O
when	O
these	O
genes	O
are	O
expressed	O
in	O
situ	O
in	O
the	O
gastrointestinal	O
tract	O
.	O
We	O
confirmed	O
that	O
KD	O
is	O
able	O
to	O
reduce	O
body	O
weight34	O
and	O
lower	O
blood	O
glucose	O
level33	O
.	O
This	O
could	O
be	O
due	O
to	O
increased	O
relative	O
abundance	O
of	O
A	O
.	O
muciniphila	O
and	O
Lactobacillus	O
spp	O
.	O
The	O
relative	O
abundance	O
of	O
A	O
.	O
muciniphila	O
also	O
increases	O
when	O
type	O
2	O
diabetic	O
patients	O
are	O
given	O
metformin49	O
,	O
a	O
prescribed	O
medication	O
to	O
increase	O
glucose	O
utilization	O
and	O
reduce	O
body	O
weight	O
by	O
activating	O
AMP	O
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
pathway50	O
.	O
Accordingly	O
,	O
A	O
.	O
muciniphila	O
is	O
associated	O
with	O
increased	O
insulin	O
sensitivity31	O
and	O
reduced	O
body	O
weight32	O
.	O
Similar	O
results	O
could	O
be	O
elicited	O
by	O
Lactobacillus	O
through	O
SCFAs	O
production	O
.	O

In	O
line	O
with	O
this	O
,	O
Lactobacillus	O
has	O
been	O
shown	O
in	O
several	O
studies	O
to	O
decrease	O
body	O
weight	O
and	O
fat51	O
.	O
Being	O
able	O
to	O
maintain	O
proper	O
body	O
weight	O
and	O
blood	O
glucose	O
level	O
is	O
crucial	O
for	O
reducing	O
risk	O
for	O
AD	O
,	O
which	O
is	O
known	O
as	O
type	O
3	O
diabetes	O
with	O
increased	O
glucose	O
intolerance	O
in	O
the	O
brain52	O
.	O
In	O
fact	O
,	O
diabetes	O
or	O
obesity	O
is	O
highly	O
associated	O
with	O
glucose	O
intolerance	O
,	O
insulin	O
insensitivity	O
,	O
and	O
increased	O
risk	O
for	O
AD53	O
.	O
Recent	O
advances	O
indicate	O
that	O
excessive	O
white	O
fat	O
increases	O
secretion	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
from	O
adipocytes	O
,	O
which	O
could	O
consequently	O
lead	O
to	O
neuroinflammation	O
,	O
Aβ	O
retention	O
,	O
brain	O
cell	O
death	O
,	O
and	O
dementia54	O
.	O
In	O
a	O
study	O
with	O
obese	O
rats	O
,	O
KD	O
reduced	O
their	O
body	O
weight	O
and	O
improved	O
their	O
lipid	O
profile55	O
.	O
In	O
addition	O
,	O
KD	O
decreases	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
e	O
.	O
g	O
.	O
,	O
TNF	O
-	O
α	O
)	O
,	O
down	O
-	O
regulates	O
brain	O
amyloid	O
protein	O
precursor	O
,	O
and	O
improves	O
brain	O
oxidative	O
stress	O
of	O
the	O
obese	O
rats	O
.	O
Furthermore	O
,	O
KD	O
improves	O
hippocampal	O
glycolytic	O
and	O
tricarboxylic	O
acid	O
cycle	O
intermediates	O
and	O
amino	O
acid	O
in	O
a	O
3xTgAD	O
mouse	O
model56	O
,	O
suggesting	O
that	O
KD	O
may	O
also	O
improve	O
insulin	O
sensitivity	O
in	O
the	O
brain57	O
.	O
It	O
indicates	O
that	O
KD	O
-	O
induced	O
body	O
weight	O
loss	O
may	O
evoke	O
metabolic	O
and	O
immune	O
function	O
changes	O
that	O
potentially	O
lead	O
to	O
neuroprotective	O
effects	O
.	O
This	O
is	O
consistent	O
with	O
a	O
human	B-methodology
study	I-methodology
that	O
diet	O
-	O
induced	O
weight	O
loss	O
improves	O
functional	O
brain	O
responses	O
during	O
an	O
episodic	O
memory	O
task58	O
.	O
Although	O
KD	O
mice	O
had	O
higher	O
energy	O
intake	O
per	O
gram	O
of	O
the	O
food	O
(	O
due	O
to	O
high	O
fat	O
content	O
)	O
compared	O
to	O
the	O
control	O
mice	O
,	O
they	O
still	O
showed	O
lower	O
body	O
weight	O
.	O
As	O
ketone	O
bodies	O
could	O
enhance	O
fatty	O
acid	O
metabolism	O
,	O
we	O
speculate	O
that	O
KD	O
would	O
switch	O
from	O
burning	O
carbohydrate	O
to	O
fat	O
and	O
thus	O
facilitate	O
fat	O
utilization	O
more	O
effectively	O
in	O
the	O
body59	O
.	O
This	O
is	O
consistent	O
with	O
a	O
clinical	B-methodology
study	I-methodology
that	O
people	O
with	O
obesity	O
lost	O
three	O
times	O
more	O
visceral	O
adipose	O
tissue	O
with	O
KD60	O
.	O
There	O
were	O
several	O
limitations	O
in	O
the	O
present	O
study	O
.	O

We	O
did	O
not	O
measure	O
levels	O
of	O
SCFAs	O
,	O
and	O
tight	O
junction	O
protein	O
in	O
the	O
intestinal	O
barrier	O
and	O
BBB	O
.	O
Therefore	O
,	O
we	O
could	O
not	O
identify	O
further	O
linkages	O
between	O
the	O
gut	O
microbiome	O
changes	O
and	O
brain	O
vascular	O
protection	O
.	O
In	O
addition	O
,	O
we	O
used	O
DNA	O
-	O
based	O
amplicon	O
profiling	O
of	O
the	O
microbial	O
community	O
in	O
fecal	O
samples	O
to	O
determine	O
the	O
diversity	O
and	O
taxonomy	O
of	O
gut	O
microbiota	O
.	O
We	O
acknowledge	O
that	O
the	O
various	O
compartments	O
of	O
the	O
gastrointestinal	O
(	O
GI	O
)	O
tract	O
harbor	O
different	O
bacterial	O
populations61	O
;	O
therefore	O
,	O
future	O
studies	O
will	O
need	O
to	O
include	O
different	O
parts	O
of	O
the	O
GI	O
tracts	O
for	O
gut	O
microbiome	O
analysis	O
,	O
and	O
to	O
incorporate	O
shotgun	O
sequencing	O
approaches	O
to	O
the	O
community	O
profiling	O
to	O
improve	O
taxonomic	O
resolution	O
and	O
to	O
measure	O
gene	O
expression	O
activity	O
.	O
In	O
conclusion	O
,	O
we	O
have	O
demonstrated	O
that	O
KD	O
enhanced	O
neurovascular	O
functions	O
,	O
which	O
might	O
be	O
associated	O
with	O
the	O
diet	O
-	O
induced	O
changes	O
in	O
gut	O
microbiome	O
.	O
Our	O
results	O
indicate	O
that	O
KD	O
may	O
not	O
only	O
be	O
beneficial	O
in	O
disease	O
states	O
,	O
but	O
also	O
in	O
healthy	O
condition	O
.	O
These	O
findings	O
imply	O
that	O
dietary	B-methodology
intervention	I-methodology
started	O
in	O
early	O
stages	O
may	O
evoke	O
neuroprotective	O
effects	O
via	O
neurovascular	O
and	O
gut	O
microbiome	O
changes	O
.	O
Future	O
studies	O
will	O
be	O
needed	O
to	O
further	O
identify	O
the	O
mechanism	O
linking	O
brain	O
and	O
gut	O
interactions	O
for	O
KD	O
-	O
induced	O
neuroprotective	O
effects	O
in	O
both	O
healthy	O
and	O
disease	O
states	O
.	O
Understanding	O
nutritional	O
effects	O
on	O
central	O
and	O
enteric	O
nervous	O
systems	O
,	O
and	O
their	O
interactions	O
,	O
has	O
profound	O
implications	O
for	O
neuroprotection	O
in	O
humans	O
.	O
We	O
used	O
C57BL	O
/	O
6	O
male	O
mice	O
(	O
12	O
–	O
14	O
weeks	O
of	O
age	O
)	O
obtained	O
from	O
the	O
National	O
Institutes	O
of	O
Health	O
.	O
We	O
determined	O
the	O
sample	O
size	O
with	O
the	O
power	O
that	O
could	O
perform	O
the	O
comparison	O
at	O
a	O
0	O
.	O
05	O
level	O
of	O
significance	O
,	O
with	O
a	O
90	O
%	O
chance	O
of	O
detecting	O
a	O
true	O
difference	O
of	O
all	O
the	O
measurements	O
between	O
the	O
two	O
groups	O
;	O
N	O
=	O
9	O
–	O
10	O
per	O
group	O
were	O
used	O
in	O
the	O
study	O
.	O
After	O
arriving	O
at	O
our	O
facilities	O
,	O
each	O
mouse	O
was	O
given	O
its	O
own	O
cage	O
housed	O
in	O
a	O
specific	O
pathogen	O
-	O
free	O
facility	O
to	O
avoid	O
microbiome	O
transfer62	O
.	O
The	O
control	O
regimen	O
(	O
type	O
F1515	O
)	O
consisted	O
of	O
3	O
.	O
79	O
kcal	O
/	O
gm	O
pellets	O
composed	O
of	O
65	O
.	O
2	O
%	O
carbohydrates	O
,	O
18	O
.	O
1	O
%	O
protein	O
,	O
5	O
.	O
1	O
%	O
fat	O
,	O
4	O
.	O
8	O
%	O
fiber	O
,	O
2	O
.	O
9	O
%	O
ash	O
,	O
and	O
less	O
than	O
10	O
%	O
moisture	O
.	O

The	O
KD	O
regimen	O
(	O
type	O
F3666	O
)	O
,	O
in	O
the	O
form	O
of	O
a	O
7	O
.	O
24	O
kcal	O
/	O
gm	O
paste	O
,	O
consisted	O
of	O
75	O
.	O
1	O
%	O
fat	O
(	O
composed	O
of	O
saturated	O
,	O
monounsaturated	O
,	O
and	O
polyunsaturated	O
fatty	O
acids	O
)	O
,	O
8	O
.	O
6	O
%	O
protein	O
,	O
4	O
.	O
8	O
%	O
fiber	O
,	O
3	O
.	O
2	O
%	O
carbohydrates	O
,	O
3	O
.	O
0	O
%	O
ash	O
,	O
and	O
less	O
than	O
10	O
%	O
moisture	O
.	O
Both	O
diets	O
were	O
obtained	O
from	O
Bio	O
-	O
Serv	O
.	O
All	O
mice	O
were	O
fed	O
ad	O
libitum	O
for	O
16	O
weeks	O
,	O
and	O
body	O
weight	O
was	O
measured	O
once	O
a	O
week	O
.	O
The	O
amount	O
of	O
remaining	O
diet	O
was	O
weighted	O
each	O
week	O
to	O
determine	O
the	O
food	O
intake	O
of	O
the	O
mice	O
.	O
We	O
did	O
not	O
find	O
a	O
significant	O
difference	O
in	O
food	O
intake	O
between	O
the	O
control	O
(	O
46	O
±	O
3	O
g	O
/	O
mouse	O
/	O
week	O
)	O
and	O
KD	O
mice	O
(	O
47	O
±	O
2	O
g	O
/	O
mouse	O
/	O
week	O
;	O
p	O
>	O
0	O
.	O
5	O
)	O
.	O
All	O
experimental	O
procedures	O
were	O
approved	O
by	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
(	O
IACUC	O
)	O
at	O
the	O
University	O
of	O
Kentucky	O
(	O
UK	O
)	O
and	O
in	O
compliance	O
with	O
the	O
ARRIVE	O
guidelines63	O
.	O
We	O
measured	O
CBF	O
using	O
MRI	O
-	O
based	O
arterial	O
spin	O
labeling	O
techniques	O
.	O
Details	O
have	O
been	O
described	O
in	O
a	O
previous	O
study23	O
.	O
Briefly	O
,	O
MRI	O
experiments	O
were	O
performed	O
on	O
a	O
7T	O
MR	O
scanner	O
(	O
Clinscan	O
,	O
Bruker	O
BioSpin	O
,	O
Germany	O
)	O
at	O
the	O
Magnetic	O
Resonance	O
Imaging	O
&	O
Spectroscopy	O
Center	O
of	O
the	O
University	O
of	O
Kentucky	O
.	O
Mice	O
were	O
anesthetized	O
with	O
4	O
.	O
0	O
%	O
isoflurane	O
for	O
induction	O
and	O
then	O
maintained	O
in	O
a	O
1	O
.	O
2	O
%	O
isoflurane	O
and	O
air	O
mixture	O
using	O
a	O
nose	O
cone	O
.	O
Heart	O
rate	O
(	O
90	O
–	O
110	O
bpm	O
)	O
,	O
respiration	O
rate	O
(	O
50	O
–	O
80	O
breaths	O
/	O
min	O
)	O
,	O
and	O
rectal	O
temperature	O
(	O
37	O
±	O
1	O
°C	O
)	O
was	O
continuously	O
monitored	O
and	O
maintained	O
.	O
A	O
water	O
bath	O
with	O
circulating	O
water	O
at	O
45	O
–	O
50	O
°C	O
was	O
used	O
to	O
maintain	O
the	O
body	O
temperature	O
.	O
A	O
whole	O
-	O
body	O
volume	O
coil	O
was	O
used	O
for	O
transmission	O
and	O
a	O
mouse	O
brain	O
surface	O
coil	O
was	O
placed	O
on	O
top	O
of	O
the	O
head	O
for	O
receiving	O
.	O
We	O
measured	O
CBF	O
using	O
MRI	O
-	O
based	O
pseudo	O
-	O
continuous	O
arterial	O
spin	O
labeling	O
(	O
pCASL	O
)	O
techniques23	O
.	O

Paired	O
control	O
and	O
label	O
images	O
were	O
acquired	O
in	O
an	O
interleaved	O
fashion	O
with	O
a	O
train	O
of	O
Hanning	O
window	O
-	O
shaped	O
radiofrequency	O
pulses	O
of	O
duration	O
/	O
spacing	O
=	O
200	O
/	O
200	O
μs	O
,	O
flip	O
angle	O
=	O
25°	O
and	O
slice	O
-	O
selective	O
gradient	O
=	O
9	O
mT	O
/	O
m	O
,	O
and	O
a	O
labeling	O
duration	O
=	O
2100	O
ms	O
.	O
The	O
images	O
were	O
acquired	O
by	O
2D	O
multi	O
-	O
slice	O
spin	O
-	O
echo	O
echo	O
planner	O
imaging	O
with	O
FOV	O
=	O
18	O
×	O
18	O
mm2	O
,	O
matrix	O
=	O
128	O
×	O
128	O
,	O
slice	O
thickness	O
=	O
1	O
mm	O
,	O
10	O
slices	O
,	O
TR	O
=	O
4	O
,	O
000	O
ms	O
,	O
TE	O
=	O
35	O
ms	O
,	O
and	O
120	O
repetitions	O
.	O
pCASL	O
images	O
were	O
analyzed	O
with	O
in	O
-	O
house	O
written	O
codes	O
in	O
MATLAB	O
(	O
MathWorks	O
,	O
Natick	O
,	O
MA	O
)	O
to	O
obtain	O
quantitative	O
CBF	O
(	O
with	O
units	O
of	O
mL	O
/	O
g	O
per	O
minute	O
)	O
.	O
Brain	O
structural	O
T2	O
-	O
weighted	O
images	O
were	O
acquired	O
with	O
field	O
of	O
view	O
(	O
FOV	O
)	O
=	O
18	O
×	O
18	O
mm2	O
,	O
matrix	O
=	O
256	O
×	O
256	O
;	O
slice	O
thickness	O
=	O
1	O
mm	O
,	O
10	O
slices	O
,	O
repetition	O
time	O
(	O
TR	O
)	O
=	O
1500	O
ms	O
,	O
and	O
echo	O
time	O
(	O
TE	O
)	O
=	O
35	O
ms	O
.	O
The	O
CBF	O
images	O
were	O
then	O
superimposed	O
to	O
the	O
corresponding	O
structural	O
images	O
using	O
Multi	O
-	O
Image	O
Analysis	O
GUI	O
(	O
Mango	O
)	O
software	O
(	O
http	O
:	O
/	O
/	O
rii	O
.	O
uthscsa	O
.	O
edu	O
/	O
mango	O
/	O
)	O
.	O
The	O
experimental	O
protocol	O
has	O
been	O
described	O
in	O
a	O
previous	O
study64	O
.	O
Fecal	O
samples	O
were	O
collected	O
from	O
control	O
and	O
KD	O
mice	O
and	O
frozen	O
at	O
−80	O
°C	O
until	O
further	O
use	O
.	O
The	O
PowerSoil	O
DNA	O
Isolation	O
Kit	O
(	O
MO	O
BIO	O
Laboratories	O
,	O
Inc	O
.	O
)	O
was	O
used	O
for	O
fecal	O
DNA	O
extraction	O
,	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
protocol	O
.	O
Genomic	O
DNA	O
was	O
PCR	O
amplified	O
with	O
primers	O
515	O
F	O
modified	O
and	O
926R65	O
targeting	O
the	O
V4	O
-	O
V5	O
regions	O
of	O
microbial	O
16S	O
rRNA	O
genes	O
using	O
a	O
two	O
-	O
stage	O
“	O
targeted	O
amplicon	O
sequencing	O
(	O
TAS	O
)	O
”	O
protocol66	O
.	O
The	O
primers	O
contained	O
5	O
′	O
common	O
sequence	O
tags	O
(	O
known	O
as	O
common	O
sequence	O
1	O
and	O
2	O
,	O
CS1	O
and	O
CS2	O
)	O
as	O
described	O
previously67	O
.	O

First	O
stage	O
amplifications	O
were	O
performed	O
with	O
the	O
following	O
thermocycling	O
conditions	O
:	O
95	O
°C	O
for	O
3	O
mins	O
,	O
28	O
cycles	O
of	O
95	O
°C	O
for	O
45	O
sec	O
,	O
50	O
°C	O
for	O
45	O
sec	O
,	O
72	O
°C	O
for	O
1	O
:	O
30	O
minutes	O
and	O
final	O
elongation	O
at	O
72	O
°C	O
for	O
10	O
minutes	O
.	O
The	O
PCR	O
master	O
mix	O
was	O
made	O
in	O
a	O
total	O
volume	O
of	O
25	O
µl	O
of	O
reaction	O
mixture	O
containing	O
4	O
µl	O
(	O
100	O
ng	O
)	O
of	O
DNA	O
template	O
,	O
0	O
.	O
5	O
µl	O
(	O
20	O
µM	O
)	O
of	O
each	O
forward	O
and	O
reverse	O
primers	O
,	O
12	O
.	O
5	O
µl	O
of	O
PCR	O
ready	O
-	O
to	O
-	O
use	O
mixture	O
(	O
MyTaq	O
HS	O
Mix	O
2x	O
,	O
Bioline	O
,	O
London	O
,	O
UK	O
)	O
and	O
7	O
.	O
5	O
µl	O
of	O
distilled	O
water	O
.	O
Subsequently	O
,	O
a	O
second	O
PCR	O
amplification	O
was	O
performed	O
in	O
10	O
microliter	O
reactions	O
in	O
96	O
-	O
well	O
plates	O
.	O
A	O
mastermix	O
for	O
the	O
entire	O
plate	O
was	O
made	O
using	O
the	O
MyTaq	O
HS	O
2X	O
mastermix	O
.	O
Each	O
well	O
received	O
a	O
separate	O
primer	O
pair	O
with	O
a	O
unique	O
10	O
-	O
base	O
barcode	O
,	O
obtained	O
from	O
the	O
Access	O
Array	O
Barcode	O
Library	O
for	O
Illumina	O
(	O
Fluidigm	O
,	O
South	O
San	O
Francisco	O
,	O
CA	O
;	O
Item	O
#	O
100	O
-	O
4876	O
)	O
.	O
These	O
Access	O
Array	O
primers	O
contained	O
the	O
CS1	O
and	O
CS2	O
linkers	O
at	O
the	O
3	O
′	O
ends	O
of	O
the	O
oligonucleotides	O
.	O
Cycling	O
conditions	O
were	O
as	O
follows	O
:	O
95	O
°C	O
for	O
5	O
minutes	O
,	O
followed	O
by	O
8	O
cycles	O
of	O
95	O
°C	O
for	O
30	O
”	O
,	O
60	O
°C	O
for	O
30	O
”	O
and	O
72	O
°C	O
for	O
30	O
”	O
.	O
A	O
final	O
,	O
7	O
-	O
minute	O
elongation	O
step	O
was	O
performed	O
at	O
72	O
°C	O
.	O
PCR	O
products	O
were	O
purified	O
using	O
SequalPrep	O
plates	O
(	O
Life	O
Technologies	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O
Subsequently	O
,	O
these	O
PCR	O
products	O
were	O
quantified	O
using	O
a	O
Quant	O
-	O
iT	O
PicoGreen	O
dsDNA	O
Assay	O
Kit	O
(	O
Thermo	O
Fisher	O
)	O
,	O
implemented	O
on	O
a	O
Genios	O
Pro	O
Fluorescence	O
microplate	O
reader	O
(	O
Tecan	O
)	O
.	O
PCR	O
products	O
were	O
then	O
pooled	O
using	O
PicoGreen	O
quantification	O
results	O
,	O
using	O
an	O
epMotion5075	O
liquid	O
handling	O
workstation	O
(	O
Eppendorf	O
)	O
.	O

The	O
pooled	O
libraries	O
,	O
with	O
a	O
15	O
%	O
phiX	O
spike	O
-	O
in	O
,	O
were	O
loaded	O
on	O
to	O
a	O
MiSeq	O
v3	O
flow	O
cell	O
,	O
and	O
sequenced	O
using	O
an	O
Illumina	O
MiSeq	O
sequencer	O
,	O
with	O
paired	O
-	O
end	O
300	O
base	O
reads	O
.	O
Fluidigm	O
sequencing	O
primers	O
,	O
targeting	O
the	O
CS1	O
and	O
CS2	O
linker	O
regions	O
,	O
were	O
used	O
to	O
initiate	O
sequencing	O
.	O
De	O
-	O
multiplexing	O
of	O
reads	O
was	O
performed	O
on	O
instrument	O
.	O
Second	O
stage	O
PCR	O
amplification	O
and	O
library	O
pooling	O
was	O
performed	O
at	O
the	O
DNA	O
Services	O
(	O
DNAS	O
)	O
facility	O
,	O
Research	O
Resources	O
Center	O
(	O
RRC	O
)	O
,	O
University	O
of	O
Illinois	O
at	O
Chicago	O
(	O
UIC	O
)	O
.	O
Sequencing	O
was	O
performed	O
at	O
the	O
W	O
.	O
M	O
.	O
Keck	O
Center	O
for	O
Comparative	O
and	O
Functional	O
Genomics	O
at	O
the	O
University	O
of	O
Illinois	O
at	O
Urbana	O
-	O
Champaign	O
(	O
UIUC	O
)	O
.	O
Forward	O
and	O
reverse	O
reads	O
were	O
merged	O
using	O
PEAR68	O
.	O
Primer	O
sequences	O
were	O
identified	O
using	O
Smith	O
-	O
Watermann	O
alignment	O
and	O
trimmed	O
from	O
the	O
sequence	O
.	O
Reads	O
that	O
lacked	O
either	O
primer	O
sequence	O
were	O
discarded	O
.	O
Sequences	O
were	O
then	O
trimmed	O
based	O
on	O
quality	O
scores	O
using	O
a	O
modified	O
Mott	O
algorithm	O
with	O
PHRED	O
quality	O
threshold	O
of	O
p	O
=	O
0	O
.	O
01	O
,	O
and	O
sequences	O
shorter	O
than	O
300	O
bases	O
after	O
trimming	O
were	O
discarded	O
.	O
QIIME	O
v1	O
.	O
8	O
was	O
used	O
to	O
generate	O
OTU	O
tables	O
and	O
taxonomic	O
summaries24	O
.	O
Briefly	O
,	O
the	O
resulting	O
sequence	O
files	O
were	O
merged	O
with	O
sample	O
information	O
.	O
OTU	O
clusters	O
were	O
generated	O
in	O
a	O
de	O
novo	O
manner	O
using	O
the	O
UCLUST	O
algorithm	O
with	O
a	O
97	O
%	O
similarity	O
threshold69	O
.	O
Chimeric	O
sequences	O
were	O
identified	O
using	O
the	O
USEARCH61	O
algorithm	O
with	O
the	O
GreenGenes	O
13	O
_	O
8	O
reference	O
sequences70	O
.	O
Taxonomic	O
annotations	O
for	O
each	O
OTU	O
were	O
using	O
the	O
UCLUST	O
algorithm	O
and	O
GreenGenes	O
13	O
_	O
8	O
reference	O
with	O
a	O
minimum	O
similarity	O
threshold	O
of	O
90	O
%	O
69	O
,	O
70	O
.	O
Taxonomic	O
and	O
OTU	O
abundance	O
data	O
were	O
merged	O
into	O
a	O
single	O
OTU	O
table	O
and	O
summaries	O
of	O
absolute	O
abundances	O
of	O
taxa	O
were	O
generated	O
for	O
all	O
phyla	O
,	O
classes	O
,	O
orders	O
,	O
families	O
,	O
genera	O
,	O
and	O
species	O
present	O
in	O
the	O
dataset	O
.	O
The	O
taxonomic	O
summary	O
tables	O
were	O
then	O
rarefied	O
to	O
a	O
depth	O
of	O
10	O
,	O
000	O
counts	O
per	O
sample	O
.	O

Shannon	O
and	O
Bray	O
-	O
Curtis	O
indices	O
were	O
calculated	O
with	O
default	O
parameters	O
in	O
software	O
package	O
Primer771	O
.	O
The	O
rarefied	O
species	O
data	O
,	O
taxonomic	O
level	O
6	O
,	O
were	O
used	O
to	O
calculate	O
both	O
indices	O
.	O
Significant	O
difference	O
among	O
tested	O
groups	O
was	O
determined	O
using	O
the	O
Kruskal	O
-	O
Wallis	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
.	O
The	O
group	O
significance	O
tests	O
were	O
performed	O
on	O
the	O
rarefied	O
species	O
data	O
using	O
the	O
group	O
_	O
significance	O
.	O
py	O
script	O
within	O
the	O
QIIME	O
v1	O
.	O
8	O
package	O
.	O
The	O
gene	O
amplicon	O
sequence	O
data	O
generated	O
as	O
part	O
of	O
this	O
study	O
have	O
been	O
submitted	O
to	O
the	O
NCBI	O
BioProject	O
database	O
(	O
PRJNA401034	O
)	O
.	O
Details	O
of	O
the	O
experiments	O
have	O
been	O
described	O
in	O
previous	O
studies23	O
,	O
64	O
.	O
Brain	O
capillaries	O
were	O
isolated	O
from	O
mice	O
according	O
to	O
a	O
previously	O
described	O
protocol23	O
.	O
Briefly	O
,	O
mice	O
were	O
euthanized	O
by	O
CO2	O
inhalation	O
and	O
decapitated	O
;	O
brains	O
were	O
immediately	O
harvested	O
and	O
collected	O
in	O
ice	O
-	O
cold	O
DPBS	O
buffer	O
supplemented	O
with	O
5	O
mM	O
D	O
-	O
glucose	O
and	O
1	O
mM	O
Na	O
-	O
pyruvate	O
,	O
pH	O
7	O
.	O
4	O
.	O
Brains	O
were	O
dissected	O
by	O
removing	O
meninges	O
,	O
choroid	O
plexus	O
and	O
white	O
matter	O
,	O
and	O
homogenized	O
in	O
DPBS	O
.	O
The	O
brain	O
homogenate	O
was	O
mixed	O
with	O
Ficoll®	O
and	O
centrifuged	O
at	O
5	O
,	O
800	O
g	O
for	O
15	O
min	O
at	O
4	O
°C	O
.	O
The	O
capillary	O
pellet	O
was	O
resuspended	O
in	O
1	O
%	O
BSA	O
buffer	O
and	O
first	O
passed	O
through	O
a	O
300	O
µm	O
nylon	O
mesh	O
followed	O
by	O
filtration	O
through	O
a	O
27	O
µm	O
nylon	O
mesh	O
.	O
Capillaries	O
retained	O
by	O
the	O
27	O
µm	O
nylon	O
mesh	O
were	O
collected	O
and	O
washed	O
with	O
DPBS	O
buffer	O
,	O
and	O
used	O
for	O
experiments	O
.	O
Isolated	O
brain	O
capillaries	O
were	O
incubated	O
for	O
1	O
h	O
at	O
room	O
temperature	O
with	O
2	O
μM	O
NBD	O
-	O
CSA	O
(	O
custom	O
-	O
synthesized	O
by	O
R	O
.	O
Wenger	O
,	O
Basel	O
,	O
Switzerland	O
)	O
in	O
DPBS	O
buffer	O
.	O
Per	O
treatment	O
group	O
,	O
10	O
capillary	O
images	O
were	O
acquired	O
by	O
confocal	O
microscopy	O
(	O
Leica	O
TSP	O
SP5	O
Confocal	O
Microscope	O
with	O
Environmental	O
Chamber	O
,	O
63	O
×	O
D	O
-	O
Water	O
UV	O
objective	O
,	O
numerical	O
aperture	O
1	O
.	O
2	O
,	O
488	O
-	O
nm	O
line	O
of	O
an	O
argon	O
laser	O
,	O
Leica	O
Microsystems	O
)	O
.	O

Confocal	O
images	O
were	O
analyzed	O
by	O
quantitating	O
luminal	O
NBD	O
-	O
CSA	O
fluorescence	O
with	O
Image	O
J	O
software	O
(	O
v	O
.	O
1	O
.	O
45	O
s	O
;	O
Wayne	O
Rasband	O
,	O
NIH	O
)	O
.	O
Specific	O
,	O
luminal	O
NBD	O
-	O
CSA	O
fluorescence	O
was	O
taken	O
as	O
the	O
difference	O
between	O
total	O
luminal	O
fluorescence	O
and	O
fluorescence	O
in	O
the	O
presence	O
of	O
the	O
P	O
-	O
glycoprotein	O
specific	O
inhibitor	O
PSC833	O
(	O
5	O
μM	O
,	O
Novartis	O
,	O
Basel	O
,	O
Switzerland	O
)	O
.	O
To	O
determine	O
protein	O
expression	O
,	O
isolated	O
brain	O
capillaries	O
were	O
homogenized	O
in	O
tissue	O
lysis	O
buffer	O
containing	O
protease	O
inhibitor	O
cocktail	O
.	O
Homogenized	O
brain	O
capillary	O
samples	O
were	O
centrifuged	O
at	O
10	O
,	O
000	O
g	O
for	O
15	O
min	O
at	O
4	O
°C	O
,	O
followed	O
by	O
centrifugation	O
of	O
the	O
denucleated	O
supernatants	O
at	O
100	O
,	O
000	O
g	O
for	O
90	O
min	O
at	O
4	O
°C	O
.	O
Pellets	O
(	O
crude	O
brain	O
capillary	O
plasma	O
membranes	O
)	O
were	O
resuspended	O
and	O
protein	O
concentrations	O
were	O
determined	O
using	O
the	O
Bradford	O
protein	O
assay	O
.	O
Western	O
blots	O
were	O
performed	O
using	O
the	O
[UNK]	O
electrophoresis	O
and	O
blotting	O
system	O
from	O
Invitrogen	O
(	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
.	O
Blotting	O
membranes	O
were	O
incubated	O
overnight	O
with	O
antibody	O
to	O
P	O
-	O
gp	O
(	O
C219	O
;	O
MA1	O
-	O
26528	O
,	O
ThermoFisher	O
,	O
1	O
μg	O
/	O
ml	O
)	O
,	O
mTOR	O
(	O
ab134903	O
,	O
Abcam	O
,	O
1	O
μg	O
/	O
ml	O
)	O
,	O
GLUT1	O
(	O
ab652	O
,	O
Abcam	O
,	O
1	O
μg	O
/	O
ml	O
)	O
,	O
and	O
β	O
-	O
actin	O
(	O
ab8226	O
from	O
Abcam	O
,	O
1	O
:	O
1000	O
,	O
1	O
μg	O
/	O
ml	O
)	O
.	O
Proteins	O
were	O
detected	O
using	O
SuperSignal®	O
West	O
Pico	O
Chemoluminescent	O
substrate	O
(	O
Pierce	O
,	O
Rockford	O
,	O
IL	O
,	O
USA	O
)	O
and	O
protein	O
bands	O
were	O
visualized	O
with	O
a	O
BioRad	O
Gel	O
[UNK]	O
XRS	O
imaging	O
system	O
.	O
Image	O
Lab	O
5	O
.	O
0	O
software	O
from	O
Bio	O
-	O
Rad	O
Laboratories	O
was	O
used	O
for	O
densitometric	O
analyses	O
of	O
band	O
intensities	O
and	O
digital	O
molecular	O
weight	O
analyses	O
;	O
the	O
molecular	O
weight	O
marker	O
was	O
RPN800E	O
(	O
GE	O
Healthcare	O
,	O
Chalfont	O
St	O
.	O
Giles	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
.	O

Linear	O
adjustments	O
of	O
contrast	O
and	O
brightness	O
were	O
applied	O
to	O
entire	O
Western	O
blot	O
images	O
.	O
None	O
of	O
the	O
Western	O
blots	O
shown	O
were	O
modified	O
by	O
nonlinear	O
adjustments	O
.	O
The	O
procedure	O
has	O
been	O
described	O
in	O
a	O
previous	O
study43	O
.	O
When	O
the	O
mice	O
were	O
sacrificed	O
,	O
blood	O
samples	O
were	O
collected	O
in	O
500	O
μl	O
lithium	O
heparin	O
12	O
.	O
5	O
IU	O
Terumo	O
Capiject	O
Capillary	O
blood	O
collection	O
tubes	O
(	O
Vacutainer	O
K2	O
EDTA	O
)	O
to	O
avoid	O
blood	O
coagulation	O
.	O
A	O
total	O
of	O
1	O
–	O
2	O
μl	O
of	O
blood	O
sample	O
were	O
used	O
to	O
measure	O
blood	O
glucose	O
level	O
using	O
a	O
blood	O
glucose	O
meter	O
and	O
a	O
test	O
strip	O
(	O
Clarity	O
Plus	O
,	O
Boca	O
Raton	O
,	O
FL	O
,	O
USA	O
)	O
.	O
Another	O
10	O
μl	O
of	O
blood	O
sample	O
was	O
used	O
for	O
ketone	O
bodies	O
level	O
measurement	O
using	O
a	O
STAT	O
-	O
Site	O
M	O
(	O
β	O
-	O
Hydroxybutyrate	O
)	O
meter	O
and	O
a	O
test	O
strip	O
(	O
Standbio	O
Ketosite	O
STAT	O
-	O
Site	O
M	O
-	O
β	O
HB	O
,	O
Boerne	O
,	O
TX	O
,	O
USA	O
)	O
.	O
Statistical	O
analyses	O
were	O
performed	O
using	O
GraphPad	O
Prism	O
7	O
(	O
GraphPad	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O
One	O
-	O
tailed	O
Student	O
’	O
s	O
t	O
-	O
test	O
was	O
performed	O
for	O
determination	O
of	O
differences	O
between	O
the	O
two	O
groups	O
.	O
Values	O
of	O
p	O
<	O
0	O
.	O
05	O
were	O
considered	O
statistically	O
significant	O
.	O
This	O
research	O
was	O
supported	O
by	O
NIH	O
/	O
NIA	O
grants	O
R01AG054459	O
and	O
K01AG040164	O
,	O
NIH	O
/	O
CTSA	O
grant	O
UL1TR000117	O
,	O
and	O
American	O
Federation	O
for	O
Aging	O
Research	O
Grant	O
#	O
A12474	O
to	O
A	O
-	O
LL	O
,	O
NIH	O
/	O
NIA	O
grant	O
R01AG039621	O
to	O
AMSH	O
,	O
NIH	O
/	O
NINDS	O
grant	O
R01NS079507	O
to	O
BB	O
,	O
and	O
NIH	O
/	O
NIDDK	O
Training	O
Grant	O
T32DK007778	O
to	O
JDH	O
.	O
The	O
content	O
is	O
solely	O
the	O
responsibility	O
of	O
the	O
authors	O
and	O
does	O
not	O
necessarily	O
represent	O
the	O
official	O
views	O
of	O
the	O
National	O
Institute	O
on	O
Aging	O
or	O
the	O
National	O
Institutes	O
of	O
Health	O
.	O
The	O
MRI	O
imaging	O
and	O
data	O
were	O
processed	O
using	O
MANGO	O
software	O
developed	O
by	O
the	O
Research	O
Imaging	O
Institute	O
of	O
the	O
University	O
of	O
Texas	O
Health	O
Science	O
Center	O
at	O
San	O
Antonio	O
.	O
The	O
7	O
T	O
ClinScan	O
small	O
animal	O
MRI	O
scanner	O
of	O
UK	O
was	O
funded	O
by	O
the	O
S10	O
NIH	O
Shared	O
Instrumentation	O
Program	O
Grant	O
(	O
1S10RR029541	O
-	O
01	O
)	O
.	O

We	O
thank	O
Vikas	O
Bakshi	O
,	O
Janet	O
Guo	O
,	O
Max	O
Baker	O
,	O
Stephanie	O
Edelmann	O
,	O
and	O
Ralf	O
Rempe	O
of	O
the	O
University	O
of	O
Kentucky	O
for	O
assisting	O
the	O
experiments	O
.	O
Publisher	O
'	O
s	O
note	O
:	O
Springer	O
Nature	O
remains	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O
D	O
.	O
M	O
.	O
,	O
A	O
.	O
C	O
.	O
W	O
.	O
,	O
I	O
.	O
P	O
.	O
,	O
and	O
A	O
.	O
-	O
L	O
.	O
L	O
.	O
contributed	O
to	O
the	O
major	O
design	O
,	O
acquisition	O
,	O
analysis	O
and	O
interpretation	O
of	O
data	O
for	O
the	O
work	O
.	O
S	O
.	O
J	O
.	O
G	O
.	O
,	O
G	O
.	O
C	O
.	O
,	O
and	O
I	O
.	O
P	O
.	O
contributed	O
to	O
the	O
gut	O
microbiome	O
analysis	O
.	O
B	O
.	O
S	O
.	O
S	O
.	O
,	O
A	O
.	O
M	O
.	O
S	O
.	O
H	O
.	O
and	O
B	O
.	O
B	O
.	O
contributed	O
to	O
data	O
acquisition	O
and	O
analysis	O
related	O
to	O
blood	O
-	O
brain	O
barrier	O
functions	O
.	O
D	O
.	O
M	O
.	O
,	O
A	O
.	O
C	O
.	O
W	O
.	O
,	O
I	O
.	O
P	O
.	O
,	O
J	O
.	O
D	O
.	O
H	O
.	O
,	O
S	O
.	O
J	O
.	O
G	O
.	O
,	O
G	O
.	O
C	O
.	O
,	O
M	O
.	O
P	O
.	O
M	O
.	O
,	O
B	O
.	O
S	O
.	O
S	O
.	O
,	O
B	O
.	O
B	O
.	O
,	O
A	O
.	O
M	O
.	O
S	O
.	O
H	O
.	O
,	O
and	O
A	O
.	O
-	O
L	O
.	O
L	O
.	O
drafted	O
and	O
revised	O
the	O
work	O
for	O
important	O
intellectual	O
content	O
.	O
D	O
.	O
M	O
.	O
,	O
A	O
.	O
C	O
.	O
W	O
.	O
,	O
I	O
.	O
P	O
.	O
,	O
J	O
.	O
D	O
.	O
H	O
.	O
,	O
S	O
.	O
J	O
.	O
G	O
.	O
,	O
G	O
.	O
C	O
.	O
,	O
M	O
.	O
P	O
.	O
M	O
.	O
,	O
B	O
.	O
S	O
.	O
S	O
.	O
,	O
B	O
.	O
B	O
.	O
,	O
A	O
.	O
M	O
.	O
S	O
.	O
H	O
.	O
,	O
and	O
A	O
.	O
-	O
L	O
.	O
L	O
.	O
approved	O
of	O
the	O
final	O
version	O
and	O
agreed	O
to	O
be	O
accountable	O
for	O
all	O
aspects	O
of	O
the	O
work	O
in	O
ensuring	O
that	O
questions	O
related	O
to	O
the	O
accuracy	O
or	O
integrity	O
of	O
any	O
part	O
of	O
the	O
work	O
are	O
appropriately	O
investigated	O
and	O
resolved	O
.	O
The	O
authors	O
declare	O
no	O
competing	O
interests	O
.	O

Association	O
Between	O
Adherence	O
To	O
The	O
French	O
Dietary	B-methodology
Guidelines	I-methodology
And	O
Lower	O
Resting	O
Heart	O
Rate	O
,	O
Longer	O
Diastole	O
Duration	O
,	O
And	O
Lower	O
Myocardial	O
Oxygen	O
Consumption	O
.	O
The	O
NUTRIVASC	O
Study	O
French	O
Health	O
and	O
Nutrition	O
Program	O
;	O
PNNS	O
;	O
heart	O
rate	O
;	O
arterial	O
stiffness	O
;	O
cutaneous	O
blood	O
flow	O
;	O
endothelial	O
function	O
;	O
heart	O
rate	O
variability	O
To	O
investigate	O
whether	O
chronic	O
adherence	O
to	O
the	O
French	O
Nutrition	O
and	O
Health	O
Program	O
(	O
PNNS	O
)	O
guidelines	B-methodology
was	O
associated	O
with	O
better	O
cardiovascular	O
health	O
.	O
A	O
study	O
nested	O
within	O
the	O
SU	O
.	O
VI	O
.	O
MAX2	O
cohort	B-methodology
was	O
conducted	O
on	O
participants	O
without	O
cardiovascular	O
risk	O
factors	O
.	O
Long	O
-	O
term	O
adherence	O
to	O
the	O
PNNS	O
guidelines	B-methodology
was	O
estimated	O
using	O
validated	O
dietary	O
scores	O
from	O
2007	O
and	O
2012	O
.	O
Individuals	O
who	O
did	O
(	O
PNNS	O
+	O
)	O
and	O
did	O
not	O
(	O
PNNS−	O
)	O
continuously	O
adhere	O
to	O
the	O
PNNS	O
guidelines	B-methodology
were	O
included	O
.	O
Applanation	O
tonometry	O
,	O
impedance	O
cardiography	O
,	O
laser	O
doppler	O
flowmetry	O
,	O
heart	O
rate	O
,	O
heart	O
rate	O
variability	O
,	O
endothelial	O
function	O
was	O
used	O
for	O
the	O
assessment	O
of	O
cardiovascular	O
health	O
.	O
A	O
total	O
of	O
49	O
subjects	O
(	O
mean	O
age	O
65	O
.	O
4	O
±	O
5	O
.	O
6	O
years	O
,	O
75	O
.	O
5	O
%	O
women	O
)	O
had	O
been	O
included	O
.	O
Those	O
in	O
the	O
PNNS	O
+	O
group	O
(	O
n	O
=	O
26	O
)	O
were	O
older	O
,	O
had	O
a	O
higher	O
BMI	O
and	O
fat	O
mass	O
than	O
those	O
in	O
the	O
PNNS−	O
group	O
,	O
both	O
groups	O
had	O
similar	O
metabolic	O
parameters	O
.	O
After	O
adjusting	O
for	O
sex	O
,	O
age	O
,	O
and	O
BMI	O
,	O
PNNS	O
+	O
subjects	O
were	O
found	O
to	O
have	O
a	O
lower	O
heart	O
rate	O
(	O
60	O
.	O
2	O
±	O
8	O
.	O
0	O
vs	O
64	O
.	O
3	O
±	O
8	O
.	O
4	O
beats	O
/	O
min	O
,	O
p	O
=	O
0	O
.	O
042	O
)	O
,	O
a	O
lower	O
heart	O
rate	O
×	O
systolic	O
blood	O
pressure	O
product	O
(	O
7166	O
±	O
1323	O
vs	O
7788	O
±	O
1680	O
beats×	O
mmHg	O
/	O
min	O
,	O
p	O
=	O
0	O
.	O
009	O
)	O
,	O
a	O
longer	O
diastole	O
duration	O
(	O
66	O
.	O
7	O
±	O
3	O
.	O
1	O
%	O
vs	O
64	O
.	O
6	O
±	O
4	O
.	O
1	O
%	O
of	O
the	O
cardiac	O
cycle	O
duration	O
,	O
p	O
=	O
0	O
.	O
049	O
)	O
,	O
and	O
a	O
shorter	O
tension	O
–	O
time	O
index	O
(	O
2145	O
±	O
489	O
vs	O
2307	O
±	O
428	O
ms	O
*	O
mmHg	O
,	O
p	O
=	O
0	O
.	O
018	O
)	O
compared	O
to	O
the	O
PNNS−	O
group	O
.	O

Long	O
-	O
term	O
adherence	O
to	O
the	O
PNNS	O
guidelines	B-methodology
had	O
a	O
favorable	O
impact	O
on	O
heart	O
rate	O
,	O
diastole	O
duration	O
,	O
and	O
myocardial	O
oxygen	O
consumption	O
.	O
NCT01579409	O
.	O
Cardiac	O
vago	O
-	O
sympathetic	O
activity	O
,	O
arterial	O
stiffness	O
,	O
and	O
endothelial	O
function	O
have	O
been	O
considered	O
as	O
integrators	O
of	O
cardiovascular	O
risk	O
factors	O
given	O
that	O
they	O
reflect	O
the	O
duration	O
and	O
intensity	O
of	O
exposure	O
to	O
such	O
factors	O
.	O
Cardiac	O
vago	O
-	O
sympathetic	O
activity	O
is	O
altered	O
in	O
diabetes	O
,	O
obesity	O
,	O
and	O
hypertension	O
.	O
1	O
Nutritional	O
factors	O
can	O
acutely	O
activate	O
the	O
autonomous	O
nervous	O
system	O
during	O
food	O
intake	O
through	O
afferent	O
vagal	O
nerve	O
fibers	O
via	O
the	O
release	O
of	O
neuro	O
-	O
endocrine	O
hormones	O
.	O
2	O
Accordingly	O
,	O
peripheral	O
sympathetic	O
or	O
parasympathetic	O
nervous	O
system	O
activity	O
regulates	O
the	O
function	O
of	O
organs	O
(	O
such	O
as	O
the	O
liver	O
)	O
,	O
white	O
and	O
brown	O
fat	O
,	O
muscles	O
,	O
and	O
alpha	O
and	O
beta	O
cells	O
of	O
pancreatic	O
islets	O
,	O
thereby	O
controlling	O
metabolism	O
and	O
energy	O
expenditure	O
and	O
storage	O
.	O
3	O
Daily	O
dietary	O
habits	O
,	O
such	O
as	O
drinking	O
coffee	O
,	O
have	O
been	O
known	O
to	O
increase	O
vagal	O
nerve	O
activity	O
,	O
4	O
whereas	O
mixing	O
energy	O
drinks	O
with	O
alcohol	O
can	O
provoke	O
reduced	O
parasympathetic	O
tone	O
.	O
5	O
Energy	O
expenditure	O
is	O
closely	O
associated	O
with	O
both	O
heart	O
rate	O
(	O
HR	O
)	O
6	O
and	O
blood	O
pressure	O
(	O
BP	O
)	O
.	O
7	O
Notably	O
,	O
a	O
higher	O
HR	O
has	O
been	O
shown	O
to	O
predict	O
worse	O
cardiovascular	O
outcomes8	O
–	O
10	O
whereas	O
lower	O
HR	O
has	O
been	O
associated	O
with	O
lower	O
mortality	O
.	O
11	O
Arterial	O
stiffness	O
is	O
influenced	O
by	O
several	O
modifiable	O
determinants	O
that	O
represent	O
current	O
therapeutic	O
targets	O
:	O
obesity	O
,	O
glucose	O
intolerance	O
,	O
type	O
1	O
and	O
2	O
diabetes	O
,	O
dyslipidemia	O
,	O
metabolic	O
syndrome	O
,	O
12	O
and	O
smoking	O
.	O
13	O
The	O
endothelium	O
plays	O
a	O
major	O
role	O
in	O
vascular	O
tone	O
regulation	O
and	O
atherosclerosis	O
development	O
.	O
14	O
,	O
15	O
Apart	O
from	O
gender	O
and	O
age	O
,	O
16	O
components	O
of	O
the	O
metabolic	O
syndrome	O
,	O
such	O
as	O
diabetes	O
,	O
17	O
hypertension	O
,	O
dyslipidemia	O
,	O
and	O
obesity	O
,	O
have	O
also	O
been	O
associated	O
with	O
endothelial	O
dysfunction	O
.	O
12	O

Intervention	B-methodology
studies	I-methodology
involving	O
both	O
primary	O
and	O
secondary	O
prevention	O
have	O
shown	O
the	O
beneficial	O
effect	O
of	O
a	O
Mediterranean	O
diet	O
in	O
reducing	O
the	O
occurrence	O
of	O
major	O
cardiovascular	O
events	O
.	O
18	O
Nutrition	O
can	O
influence	O
arterial	O
stiffness	O
by	O
as	O
early	O
as	O
age	O
10	O
,	O
19	O
while	O
the	O
introduction	O
of	O
healthy	O
nutritional	O
habits	O
early	O
in	O
life	O
can	O
reduce	O
arterial	O
stiffness	O
later	O
during	O
adult	O
life	O
.	O
20	O
Although	O
impaired	O
endothelial	O
function	O
has	O
been	O
observed	O
with	O
a	O
high	O
-	O
fat	O
diet	O
,	O
improvements	O
therein	O
have	O
been	O
found	O
with	O
the	O
Mediterranean	O
diet	O
.	O
21	O
The	O
protective	O
effect	O
of	O
antioxidant	O
vitamins	O
against	O
endothelial	O
dysfunction	O
suggests	O
oxidative	O
stress	O
as	O
a	O
potential	O
mechanism	O
.	O
22	O
Currently	O
,	O
a	O
discrepancy	O
exists	O
between	O
results	O
from	O
short	O
-	O
and	O
long	O
-	O
term	O
intervention	B-methodology
studies	I-methodology
involving	O
antioxidant	O
treatment	O
for	O
arterial	O
stiffness	O
and	O
oxidative	O
stress	O
markers	O
.	O
23	O
A	O
study	O
conducted	O
on	O
a	O
sample	O
of	O
over	O
1000	O
subjects	O
included	O
in	O
the	O
SU	O
.	O
VI	O
.	O
MAX	O
(	O
Supplémentation	O
en	O
Vitamines	O
et	O
Minéraux	O
Antioxydants	O
)	O
cohort	B-methodology
revealed	O
that	O
long	O
-	O
term	O
supplementation	O
with	O
antioxidant	O
vitamins	O
and	O
minerals	O
had	O
no	O
beneficial	O
effect	O
on	O
carotid	O
atherosclerosis	O
and	O
arterial	O
stiffness	O
.	O
24	O
However	O
,	O
only	O
a	O
few	O
studies	O
compared	O
cardiovascular	O
parameters	O
according	O
to	O
dietary	O
patterns	O
and	O
attempted	O
to	O
determine	O
the	O
mechanisms	O
involved	O
.	O
Most	O
studies	O
presented	O
relatively	O
short	O
-	O
term	O
results	O
in	O
populations	O
that	O
had	O
confounding	O
factors	O
,	O
like	O
cardiovascular	O
risk	O
factors	O
.	O
The	O
French	O
Health	O
and	O
Nutrition	O
Program	O
[	O
Programme	O
National	O
Nutrition	O
Santé	O
(	O
PNNS	O
)	O
]	O
,	O
launched	O
in	O
2001	O
,	O
has	O
developed	O
nutritional	O
guidelines	B-methodology
with	O
the	O
objective	O
of	O
preventing	O
chronic	O
diseases	O
(	O
cardiovascular	O
diseases	O
,	O
cancer	O
,	O
and	O
obesity	O
)	O
through	O
diet	O
and	O
lifestyle	O
counseling	O
.	O
The	O
main	O
objective	O
of	O
the	O
NUTRIVASC	O
study	O
was	O
to	O
investigate	O
the	O
protective	O
mechanisms	O
of	O
nutrition	O
provided	O
by	O
the	O
long	O
-	O
term	O
adherence	O
to	O
the	O
PNNS	O
guidelines	B-methodology
in	O
subjects	O
who	O
have	O
stable	O
dietary	O
habits	O
and	O
no	O
cardiovascular	O
risk	O
factors	O
.	O
We	O
hypothesized	O
that	O
subjects	O
who	O
did	O
not	O
continuously	O
adhere	O
to	O
the	O
PNNS	O
recommendations	O
would	O
have	O
worse	O
cardiovascular	O
health	O
,	O
higher	O
heart	O
rate	O
,	O
greater	O
sympathetic	O
nervous	O
system	O
activity	O
,	O
higher	O
arterial	O
stiffness	O
,	O
and	O
worse	O
endothelial	O
dysfunction	O
compared	O
to	O
those	O
who	O
did	O
.	O

The	O
longitudinal	O
,	O
randomized	O
,	O
double	B-methodology
-	I-methodology
blind	I-methodology
study	O
SU	O
.	O
VI	O
.	O
MAX	O
was	O
conducted	O
between	O
1994	O
and	O
2002	O
.	O
25	O
Moreover	O
,	O
a	O
total	O
of	O
6850	O
agreed	O
to	O
participate	O
in	O
SU	O
.	O
VI	O
.	O
MAX2	O
,	O
a	O
prospective	B-methodology
cohort	I-methodology
study	I-methodology
.	O
Subjects	O
aging	O
45	O
to	O
70	O
years	O
were	O
evaluated	O
from	O
2007	O
to	O
2009	O
according	O
to	O
their	O
anthropometric	O
and	O
metabolic	O
criteria	O
and	O
responses	O
to	O
validated	O
food	O
frequency	O
questionnaires	O
.	O
26	O
The	O
NUTRIVASC	O
study	O
was	O
a	O
registered	O
study	O
nested	O
within	O
the	O
SU	O
.	O
VI	O
.	O
MAX2	O
cohort	B-methodology
(	O
NCT	O
01579409	O
,	O
French	O
Agency	O
for	O
the	O
Security	O
of	O
Health	O
Products	O
,	O
registration	O
number	O
Afssaps	O
:	O
B111351	O
-	O
70	O
,	O
08	O
/	O
11	O
/	O
2011	O
and	O
CNIL	O
:	O
1552838	O
,	O
15	O
/	O
12	O
/	O
2011	O
)	O
.	O
The	O
study	O
was	O
conducted	O
according	O
to	O
the	O
Declaration	O
of	O
Helsinki	O
of	O
1975	O
as	O
revised	O
in	O
1983	O
,	O
and	O
written	B-methodology
informed	I-methodology
consent	I-methodology
was	O
obtained	O
from	O
all	O
subjects	O
prior	O
to	O
inclusion	O
.	O
Data	O
collection	O
had	O
been	O
completed	O
by	O
August	O
2016	O
.	O
Among	O
the	O
participants	O
included	O
in	O
the	O
SU	O
.	O
VI	O
.	O
MAX2	O
cohort	B-methodology
,	O
those	O
who	O
had	O
filled	O
out	O
the	O
validated	O
food	O
frequency	O
questionnaire	O
from	O
2007	O
to	O
2009	O
were	O
50	O
to	O
75	O
years	O
old	O
and	O
were	O
living	O
within	O
the	O
Paris	O
area	O
were	O
screened	O
.	O
The	O
exclusion	B-methodology
criteria	I-methodology
included	O
a	O
history	O
of	O
cancer	O
,	O
a	O
history	O
of	O
cardiovascular	O
disease	O
(	O
stroke	O
,	O
myocardial	O
infarction	O
,	O
or	O
amputation	O
)	O
,	O
hypertension	O
[	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
≥	O
140	O
mmHg	O
,	O
diastolic	O
blood	O
pressure	O
(	O
DBP	O
)	O
≥	O
90	O
mmHg	O
,	O
or	O
anti	O
-	O
hypertensive	O
treatment	O
]	O
.	O
dyslipidemia	O
(	O
LDL	O
cholesterol	O
>	O
4	O
.	O
9	O
mmol	O
/	O
L	O
or	O
lipid	O
-	O
lowering	O
treatment	O
)	O
,	O
active	O
smoking	O
or	O
smoking	O
cessation	O
within	O
the	O
last	O
3	O
years	O
,	O
known	O
diabetes	O
before	O
inclusion	O
(	O
fasting	O
glycemia	O
≥	O
126	O
mg	O
/	O
dL	O
or	O
anti	O
-	O
diabetic	O
therapy	O
)	O
,	O
fasting	O
hyperglycemia	O
(	O
fasting	O
glycemia	O
≥	O
110	O
mg	O
/	O
dL	O
)	O
,	O
and	O
the	O
presence	O
of	O
a	O
pacemaker	O
.	O
The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
subjects	O
who	O
adhered	O
to	O
the	O
PNNS	O
recommendations	O
with	O
those	O
who	O
did	O
not	O
.	O
Screening	O
was	O
performed	O
using	O
the	O
2007	O
–	O
2009	O
database	O
.	O

Accordingly	O
,	O
the	O
PNNS	O
guideline	B-methodology
scores	O
were	O
used	O
after	O
removing	O
the	O
physical	O
activity	O
component	O
in	O
2007	O
and	O
2012	O
(	O
mPNNS	O
-	O
GS	O
)	O
,	O
a	O
method	O
that	O
has	O
been	O
previously	O
validated	O
.	O
27	O
Nutritional	O
quality	O
scores	O
have	O
been	O
often	O
shown	O
to	O
positively	O
correlate	O
with	O
energy	O
intake	O
.	O
28	O
Therefore	O
,	O
the	O
probability	O
of	O
adhering	O
to	O
the	O
recommendations	O
increases	O
with	O
high	O
-	O
energy	O
intake	O
,	O
i	O
.	O
e	O
.	O
,	O
by	O
eating	O
large	O
quantities	O
of	O
food	O
.	O
To	O
avoid	O
this	O
potential	O
bias	O
,	O
a	O
penalty	O
system	O
had	O
been	O
developed	O
.	O
Energy	O
requirements	O
were	O
calculated	O
using	O
the	O
Schofield	O
equations	O
,	O
which	O
include	O
age	O
,	O
sex	O
,	O
size	O
,	O
and	O
bodyweight	O
of	O
the	O
subject	O
,	O
adjusted	O
for	O
a	O
coefficient	O
of	O
physical	O
activity	O
.	O
29	O
If	O
the	O
estimated	O
energy	O
intake	O
determined	O
from	O
the	O
food	O
questionnaire	O
was	O
at	O
least	O
5	O
%	O
higher	O
than	O
that	O
determined	O
from	O
theoretical	O
calculations	O
using	O
the	O
Schofield	O
equation	O
,	O
then	O
the	O
score	O
was	O
penalized	O
as	O
previously	O
detailed	O
.	O
27	O
The	O
penalized	O
score	O
was	O
an	O
important	O
predictor	O
of	O
weight	O
change	O
within	O
the	O
SU	O
.	O
VI	O
.	O
MAX	O
cohort	B-methodology
.	O
30	O
Accordingly	O
,	O
28	O
%	O
of	O
the	O
SU	O
.	O
VI	O
.	O
MAX2	O
cohort	B-methodology
had	O
a	O
penalized	O
score	O
.	O
We	O
preselected	O
subjects	O
who	O
had	O
a	O
2007	O
–	O
2009	O
mPNNS	O
-	O
GS	O
that	O
fell	O
between	O
the	O
1st	O
and	O
40th	O
(	O
lower	O
adherence	O
to	O
PNNS	O
recommendations	O
)	O
and	O
between	O
the	O
60th	O
and	O
100th	O
(	O
higher	O
adherence	O
to	O
PNNS	O
recommendations	O
)	O
percentile	O
.	O
In	O
2012	O
,	O
an	O
information	O
leaflet	O
detailing	O
the	O
protocol	O
,	O
a	O
questionnaire	O
aiming	O
to	O
confirm	O
eligibility	O
(	O
screening	O
criteria	O
)	O
,	O
a	O
participation	O
request	O
form	O
,	O
and	O
a	O
new	O
food	O
frequency	O
questionnaire	O
were	O
mailed	O
to	O
the	O
preselected	O
subjects	O
.	O
The	O
2012	O
mPNNS	O
-	O
GS	O
was	O
then	O
calculated	O
for	O
patients	O
who	O
satisfied	O
the	O
inclusion	O
and	O
non	O
-	O
inclusion	B-methodology
criteria	I-methodology
(	O
Figure	O
1	O
)	O
.	O
Finally	O
,	O
individuals	O
who	O
did	O
(	O
exposed	O
)	O
and	O
did	O
not	O
(	O
non	O
-	O
exposed	O
)	O
continuously	O
adhere	O
to	O
the	O
PNNS	O
guidelines	B-methodology
were	O
identified	O
.	O
Those	O
who	O
did	O
not	O
adhere	O
to	O
the	O
guidelines	B-methodology
(	O
PNNS−	O
)	O
had	O
a	O
2007	O
mPNNS	O
-	O
GS	O
between	O
the	O
1st	O
and	O
40th	O
percentile	O
and	O
a	O
2012	O
mPNNS	O
-	O
GS	O
below	O
the	O
first	O
quartile	O
.	O
Meanwhile	O
,	O
those	O
who	O
adhered	O
to	O
the	O
guidelines	B-methodology
(	O
PNNS	O
+	O
)	O
had	O
a	O
2007	O
mPNNS	O
-	O
GS	O
between	O
the	O
60th	O
and	O
100th	O
percentile	O
and	O
a	O
2012	O
mPNNS	O
-	O
GS	O
at	O
the	O
4th	O
quartile	O
.	O

Once	O
selected	O
subjects	O
were	O
prospectively	O
included	O
in	O
the	O
study	O
.	O
Physical	O
activity	O
in	O
2007	O
was	O
also	O
assessed	O
using	O
a	O
validated	O
questionnaire	O
.	O
The	O
questionnaire	O
included	O
questions	O
regarding	O
physical	O
activity	O
and	O
duration	O
during	O
leisure	O
and	O
working	O
hours	O
or	O
at	O
home	O
according	O
to	O
intensity	O
(	O
weak	O
,	O
medium	O
,	O
or	O
high	O
)	O
,	O
as	O
well	O
as	O
sedentary	O
behavior	O
and	O
duration	O
.	O
31	O
Tests	O
were	O
performed	O
between	O
September	O
2012	O
and	O
December	O
2013	O
at	O
the	O
Department	O
of	O
Endocrinology	O
-	O
Diabetology	O
-	O
Nutrition	O
,	O
Jean	O
Verdier	O
Hospital	O
,	O
Bondy	O
,	O
France	O
.	O
The	O
investigator	O
(	O
M	O
.	O
F	O
)	O
was	O
blinded	O
for	O
the	O
group	O
of	O
participants	O
.	O
Participants	O
arrived	O
at	O
07	O
:	O
30	O
in	O
the	O
morning	O
after	O
an	O
overnight	O
fast	O
and	O
were	O
instructed	O
to	O
abstain	O
from	O
drinking	O
alcoholic	O
beverages	O
,	O
coffee	O
,	O
or	O
tea	O
on	O
the	O
morning	O
prior	O
to	O
the	O
study	O
and	O
to	O
empty	O
their	O
bladder	O
.	O
Approximately	O
20	O
min	O
after	O
catheter	O
insertion	O
on	O
the	O
right	O
arm	O
for	O
drawing	O
blood	O
,	O
measurements	O
were	O
conducted	O
at	O
an	O
ambient	O
temperature	O
of	O
22	O
°C	O
to	O
24	O
°C	O
in	O
a	O
room	O
where	O
noise	O
and	O
light	O
were	O
kept	O
to	O
a	O
minimum	O
.	O
Participants	O
remained	O
at	O
rest	O
in	O
the	O
supine	O
position	O
throughout	O
the	O
tests	O
.	O
All	O
cardiovascular	O
tests	O
were	O
non	O
-	O
invasive	O
and	O
lasted	O
for	O
approximately	O
2	O
hrs	O
(	O
Figure	O
S1	O
)	O
.	O
The	O
following	O
tests	O
had	O
been	O
performed	O
.	O
Finger	O
arterial	O
BP	O
and	O
HR	O
were	O
recorded	O
continuously	O
in	O
the	O
supine	O
position	O
for	O
6	O
min	O
at	O
a	O
paced	O
breathing	O
rate	O
of	O
12	O
breaths	O
/	O
min	O
using	O
photoplethysmographic	O
sensors	O
and	O
synchronous	O
6	O
-	O
lead	O
ECG	O
recordings	O
(	O
Task	O
force	O
monitor®	O
,	O
CNSystems	O
Medizintechnik	O
,	O
Austria	O
)	O
.	O
Cardiac	O
autonomic	O
nervous	O
system	O
activity	O
was	O
assessed	O
using	O
spectral	O
analysis	O
of	O
HR	O
and	O
SBP	O
variations	O
.	O
1	O
The	O
opposite	O
brachial	O
artery	O
was	O
used	O
to	O
calibrate	O
digital	O
arterial	O
BP	O
measurements	O
.	O

Cardiac	O
autonomic	O
activity	O
was	O
expressed	O
as	O
normalized	O
spectral	O
HR	O
variability	O
:	O
i	O
)	O
normalized	O
spectral	O
index	O
[	O
i	O
.	O
e	O
.	O
,	O
the	O
percentage	O
of	O
the	O
high	O
-	O
frequency	O
band	O
(	O
HF	O
:	O
0	O
.	O
15	O
–	O
0	O
.	O
40	O
Hz	O
/	O
total	O
spectrum	O
)	O
of	O
HR	O
variations	O
(	O
HF	O
-	O
HR	O
:	O
vagal	O
function	O
)	O
;	O
ii	O
)	O
the	O
ratio	O
between	O
low	O
frequency	O
(	O
LF	O
:	O
0	O
.	O
03	O
–	O
0	O
.	O
15	O
Hz	O
/	O
total	O
spectrum	O
)	O
and	O
HF	O
bands	O
of	O
HR	O
variations	O
(	O
LF	O
/	O
HF	O
-	O
HR	O
:	O
sympathetic	O
–	O
parasympathetic	O
balance	O
)	O
,	O
and	O
iii	O
)	O
LF	O
band	O
of	O
the	O
SBP	O
spectrum	O
(	O
LF	O
-	O
SBP	O
:	O
0	O
.	O
075	O
–	O
0	O
.	O
15	O
Hz	O
;	O
vascular	O
sympathetic	O
activity	O
)	O
.	O
Transthoracic	O
bioimpedance	O
cardiography	O
(	O
Task	O
Force	O
Monitor®	O
,	O
CNSystems	O
Medizintechnik	O
,	O
Austria	O
)	O
was	O
used	O
for	O
the	O
measurement	O
of	O
the	O
following	O
hemodynamic	O
parameters	O
:	O
stroke	O
volume	O
,	O
cardiac	O
output	O
,	O
total	O
peripheral	O
resistance	O
,	O
ventricular	O
ejection	O
time	O
,	O
left	O
ventricular	O
work	O
index	O
,	O
and	O
thoracic	O
fluid	O
content	O
.	O
The	O
pulse	O
wave	O
velocity	O
(	O
PWV	O
)	O
was	O
measured	O
as	O
previously	O
described	O
,	O
in	O
the	O
supine	O
position	O
.	O
32	O
BP	O
was	O
measured	O
just	O
before	O
PWV	O
measurements	O
with	O
an	O
Omron	O
750	O
IT	O
BP	O
device	O
.	O
Briefly	O
,	O
PWV	O
was	O
measured	O
as	O
the	O
arterial	O
distance	O
divided	O
by	O
the	O
transit	O
time	O
from	O
the	O
carotid	O
to	O
the	O
femoral	O
artery	O
.	O
The	O
arterial	O
distance	O
was	O
assessed	O
from	O
surface	O
measurements	O
subtracting	O
the	O
sternal	O
notch	O
femoral	O
distance	O
to	O
the	O
carotid	O
-	O
sternal	O
notch	O
distance	O
.	O
Transit	O
time	O
was	O
automatically	O
calculated	O
from	O
the	O
foot	O
of	O
carotid	O
and	O
femoral	O
pulses	O
measured	O
successively	O
by	O
applanation	O
tonometry	O
using	O
R	O
-	O
wave	O
of	O
an	O
ECG	O
as	O
a	O
timing	O
reference	O
.	O
Only	O
measurements	O
with	O
a	O
beat	O
to	O
beat	O
transit	O
time	O
standard	O
deviation	O
below	O
5	O
%	O
were	O
considered	O
of	O
good	O
quality	O
and	O
used	O
in	O
the	O
study	O
.	O

Using	O
applanation	O
tonometry	O
on	O
the	O
radial	O
artery	O
(	O
Sphygmocor®	O
,	O
Atcor	O
Medical	O
,	O
Australia	O
)	O
,	O
the	O
following	O
measurements	O
had	O
been	O
obtained	O
:	O
(	O
i	O
)	O
radial	O
and	O
central	O
BPs	O
,	O
pulse	O
pressures	O
(	O
PP	O
=	O
SBP	O
−	O
DBP	O
)	O
,	O
and	O
PP	O
augmentation	O
ratio	O
;	O
(	O
ii	O
)	O
two	O
arterial	O
stiffness	O
indices	O
[	O
carotid	O
-	O
to	O
-	O
femoral	O
PWV	O
and	O
augmentation	O
index	O
adjusted	O
for	O
a	O
HR	O
of	O
75	O
beats	O
/	O
min	O
(	O
AIx	O
@	O
75	O
)	O
]	O
;	O
and	O
(	O
iii	O
)	O
cardiac	O
cycle	O
,	O
systole	O
,	O
and	O
diastole	O
durations	O
based	O
on	O
the	O
BP	O
curve	O
.	O
Myocardial	O
oxygen	O
demand	O
was	O
determined	O
by	O
calculating	O
the	O
double	O
product	O
(	O
HR	O
×	O
central	O
SBP	O
)	O
and	O
the	O
tension	O
–	O
time	O
index	O
(	O
systolic	O
pressure	O
–	O
time	O
integral	O
×	O
HR	O
)	O
,	O
whereas	O
myocardial	O
perfusion	O
were	O
determined	O
by	O
calculating	O
the	O
subendocardial	O
viability	O
ratio	O
(	O
diastolic	O
time	O
index	O
/	O
tension	O
–	O
time	O
index	O
)	O
.	O
33	O
Arterial	O
endothelial	O
function	O
and	O
HR	O
were	O
assessed	O
in	O
one	O
of	O
the	O
digital	O
arteries	O
by	O
recording	O
finger	O
arterial	O
pulsatile	O
volume	O
changes	O
for	O
15	O
min	O
using	O
the	O
Endopat2000®	O
system	O
(	O
Itamar	O
Medical	O
,	O
Israel	O
)	O
,	O
which	O
makes	O
use	O
of	O
plethysmographic	O
biosensors	O
.	O
Reactive	O
hyperhemia	O
was	O
measured	O
after	O
occluding	O
brachial	O
artery	O
blood	O
flow	O
for	O
5	O
min	O
.	O
The	O
reactive	O
hyperhemia	O
index	O
represents	O
the	O
post	O
-	O
to	O
-	O
pre	O
occlusion	O
signal	O
ratio	O
on	O
the	O
occluded	O
side	O
normalized	O
to	O
the	O
control	O
side	O
.	O
Cutaneous	O
blood	O
flow	O
(	O
CBF	O
)	O
at	O
rest	O
and	O
during	O
1	O
min	O
of	O
paced	O
breathing	O
(	O
6	O
breaths	O
/	O
min	O
)	O
was	O
measured	O
for	O
6	O
min	O
in	O
the	O
forearm	O
using	O
laser	O
Doppler	O
flowmetry	O
(	O
Periflux	O
System	O
5000®	O
PERIMED	O
,	O
Sweden	O
)	O
.	O
CBF	O
fluctuations	O
during	O
the	O
1	O
min	O
of	O
paced	O
breathing	O
reflect	O
microvascular	O
autonomic	O
activity	O
.	O
Moreover	O
,	O
CBF	O
decreases	O
during	O
inhalation	O
due	O
to	O
sympathetic	O
nervous	O
system	O
activation	O
.	O
The	O
percentage	O
decrease	O
in	O
the	O
signal	O
wavelet	O
from	O
the	O
zenith	O
to	O
nadir	O
was	O
calculated	O
,	O
and	O
the	O
mean	O
decrease	O
during	O
the	O
three	O
last	O
breaths	O
was	O
used	O
as	O
the	O
index	O
of	O
microvascular	O
sympathetic	O
activity	O
.	O

Changes	O
in	O
CBF	O
after	O
transcutaneous	O
administration	O
of	O
acetylcholine	O
(	O
Ach	O
)	O
(	O
Miochol	O
-	O
E®	O
,	O
20	O
mg	O
of	O
Ach	O
chloride	O
/	O
vial	O
;	O
CHAUVIN®	O
,	O
topical	O
application	O
of	O
4	O
mg	O
)	O
through	O
iontophoresis	O
were	O
also	O
measured	O
to	O
explore	O
endothelial	O
function	O
.	O
Ach	O
chloride	O
was	O
diluted	O
in	O
1	O
mL	O
of	O
sterile	O
water	O
,	O
after	O
which	O
200	O
µL	O
of	O
this	O
solution	O
was	O
placed	O
into	O
a	O
special	O
chamber	O
of	O
a	O
sponge	O
that	O
was	O
used	O
for	O
skin	O
application	O
.	O
After	O
Ach	O
administration	O
,	O
we	O
measured	O
i	O
)	O
maximal	O
CBF	O
,	O
ii	O
)	O
CBF	O
incremental	O
area	O
under	O
the	O
curve	O
3	O
min	O
after	O
Ach	O
administration	O
,	O
which	O
is	O
considered	O
an	O
integrator	O
of	O
microvascular	O
endothelial	O
function	O
,	O
iii	O
)	O
delay	O
from	O
Ach	O
administration	O
to	O
maximal	O
CBF	O
(	O
peak	O
delay	O
)	O
,	O
iv	O
)	O
peak	O
tangent	O
from	O
basal	O
to	O
maximal	O
CBF	O
(	O
tangent	O
increase	O
represents	O
acceleration	O
in	O
tissue	O
perfusion	O
)	O
,	O
and	O
v	O
)	O
vasodilation	O
duration	O
from	O
Ach	O
administration	O
until	O
return	O
to	O
levels	O
at	O
least	O
20	O
%	O
higher	O
than	O
those	O
for	O
basal	O
CBF	O
.	O
34	O
Body	O
composition	O
(	O
lean	O
and	O
fat	O
mass	O
)	O
was	O
determined	O
using	O
bioelectrical	O
impedance	O
(	O
Bodystat®	O
Quadscan	O
,	O
EuroMedix	O
,	O
Germany	O
)	O
.	O
Blood	O
samples	O
were	O
collected	O
from	O
fasted	O
subjects	O
upon	O
arrival	O
and	O
were	O
stored	O
at	O
−80	O
°C	O
at	O
the	O
CRB	O
(	O
liver	O
disease	O
biobank	O
)	O
,	O
Groupe	O
Hospitalier	O
Paris	O
Seine	O
-	O
Saint	O
-	O
Denis	O
BB	O
-	O
0033	O
-	O
00027	O
.	O
Glucose	O
levels	O
in	O
venous	O
plasma	O
were	O
measured	O
through	O
colorimetry	O
using	O
the	O
glucose	O
oxidase	O
method	O
(	O
Kone	O
Optima	O
,	O
Thermolab	O
System	O
,	O
France	O
)	O
.	O
HbA1c	O
measurements	O
were	O
based	O
on	O
the	O
turbidimetric	O
inhibition	O
immunoassay	O
principle	O
(	O
Dimension®	O
technology	O
,	O
Siemens	O
Healthcare	O
Diagnosis	O
Inc	O
.	O
,	O
Newark	O
,	O
NJ	O
,	O
USA	O
)	O
,	O
while	O
HbA1c	O
levels	O
were	O
standardized	O
according	O
to	O
the	O
Diabetes	O
Control	O
and	O
Complications	O
Trial	O
.	O
Serum	O
fructosamine	O
was	O
measured	O
using	O
the	O
nitroblue	O
tetrazolium	O
colorimetric	O
procedure	O
(	O
COBAS	O
;	O
Roche	O
Diagnostics	O
GmBH	O
,	O
Penzberg	O
,	O
Germany	O
)	O
.	O

Total	O
cholesterol	O
,	O
HDL	O
cholesterol	O
,	O
and	O
triglycerides	O
were	O
measured	O
using	O
enzymatic	O
colorimetry	O
(	O
Hitachi	O
912	O
,	O
Roche	O
Diagnostic	O
,	O
France	O
)	O
,	O
whereas	O
LDL	O
cholesterol	O
was	O
calculated	O
using	O
the	O
Friedwald	O
formula	O
.	O
None	O
of	O
the	O
participants	O
had	O
triglyceride	O
concentrations	O
greater	O
than	O
400	O
mg	O
/	O
dL	O
.	O
Laser	O
immunonephelometry	O
(	O
BN100	O
;	O
Dade	O
-	O
Behring	O
)	O
was	O
used	O
to	O
measure	O
the	O
urinary	O
albumin	O
excretion	O
rate	O
from	O
urine	O
specimens	O
.	O
To	O
obtain	O
80	O
%	O
power	O
to	O
detect	O
a	O
1	O
m	O
/	O
s	O
difference	O
in	O
PWV	O
and	O
a	O
1	O
.	O
7	O
m	O
/	O
s	O
standard	O
deviation	O
between	O
the	O
two	O
groups	O
using	O
Student	O
’	O
s	O
t	O
-	O
test	O
,	O
the	O
number	O
of	O
participants	O
per	O
group	O
was	O
set	O
at	O
47	O
.	O
Alpha	O
(	O
α	O
)	O
was	O
set	O
at	O
5	O
%	O
,	O
while	O
,	O
for	O
all	O
other	O
parameters	O
,	O
the	O
sample	O
size	O
yielded	O
80	O
%	O
power	O
to	O
detect	O
a	O
difference	O
between	O
groups	O
at	O
an	O
effect	O
size	O
(	O
Δ	O
/	O
σ	O
)	O
of	O
about	O
0	O
.	O
6	O
.	O
Differences	O
in	O
PWV	O
were	O
interpreted	O
according	O
to	O
results	O
from	O
a	O
Finnish	O
study	O
on	O
the	O
consumption	O
of	O
fruits	O
and	O
vegetables	O
during	O
childhood	O
and	O
adolescence	O
in	O
young	O
healthy	O
subjects	O
(	O
age	O
range	O
:	O
40	O
–	O
45	O
years	O
)	O
.	O
PWV	O
was	O
0	O
.	O
47	O
m	O
/	O
s	O
lower	O
among	O
those	O
who	O
consumed	O
fruits	O
and	O
vegetables	O
.	O
20	O
The	O
non	O
-	O
adherence	O
to	O
the	O
PNNS	O
guidelines	B-methodology
had	O
been	O
considered	O
to	O
cause	O
a	O
1	O
m	O
/	O
s	O
difference	O
in	O
PWV	O
between	O
both	O
groups	O
.	O
The	O
clinical	O
relevance	O
of	O
this	O
difference	O
in	O
PWV	O
was	O
demonstrated	O
by	O
Blacher	O
et	O
al35	O
in	O
a	O
population	O
with	O
a	O
very	O
high	O
cardiovascular	O
risk	O
who	O
found	O
that	O
a	O
1	O
m	O
/	O
s	O
increase	O
in	O
PWV	O
was	O
consistent	O
with	O
a	O
14	O
%	O
increase	O
in	O
cardiovascular	O
and	O
total	O
mortality	O
.	O
All	O
quantitative	O
parameters	O
were	O
summarized	O
according	O
to	O
group	O
and	O
time	O
collected	O
.	O
Descriptive	O
statistics	O
,	O
which	O
included	O
means	O
and	O
standard	O
deviations	O
,	O
was	O
used	O
to	O
describe	O
all	O
quantitative	O
parameters	O
at	O
each	O
time	O
.	O
Qualitative	O
parameters	O
have	O
been	O
presented	O
as	O
frequency	O
distributions	O
.	O
The	O
level	O
of	O
significance	O
was	O
set	O
at	O
5	O
%	O
for	O
all	O
statistical	O
analyses	O
conducted	O
between	O
both	O
groups	O
.	O
Relationships	O
between	O
parameters	O
were	O
measured	O
during	O
a	O
fasted	O
state	O
.	O
Analysis	O
of	O
covariance	O
(	O
ANCOVA	O
)	O
was	O
used	O
to	O
compare	O
quantitative	O
parameters	O
between	O
the	O
PNNS	O
+	O
and	O
PNNS−	O
groups	O
according	O
to	O
their	O
status	O
.	O

Age	O
,	O
BMI	O
,	O
and	O
waist	O
circumference	O
were	O
considered	O
as	O
covariates	O
,	O
with	O
the	O
first	O
model	O
including	O
age	O
and	O
BMI	O
(	O
model	O
1	O
)	O
,	O
the	O
second	O
one	O
including	O
age	O
and	O
waist	O
circumference	O
(	O
model	O
2	O
)	O
,	O
and	O
the	O
third	O
one	O
gender	O
,	O
age	O
,	O
and	O
BMI	O
(	O
model	O
3	O
)	O
.	O
Figure	O
1	O
shows	O
the	O
flow	O
chart	O
of	O
the	O
study	O
.	O
A	O
total	O
of	O
49	O
subjects	O
were	O
ultimately	O
included	O
,	O
37	O
of	O
whom	O
were	O
women	O
.	O
Subject	O
characteristics	O
and	O
a	O
comparison	O
between	O
those	O
who	O
did	O
(	O
PNNS	O
+	O
:	O
n	O
=	O
26	O
)	O
and	O
did	O
not	O
(	O
PNNS−	O
:	O
n	O
=	O
23	O
)	O
adhere	O
to	O
the	O
PNNS	O
guidelines	B-methodology
are	O
shown	O
in	O
Table	O
1	O
.	O
Compared	O
to	O
those	O
in	O
the	O
PNNS−	O
group	O
,	O
those	O
in	O
the	O
PNNS	O
+	O
group	O
were	O
older	O
,	O
had	O
a	O
higher	O
BMI	O
,	O
had	O
greater	O
waist	O
and	O
hip	O
circumferences	O
,	O
and	O
had	O
more	O
fat	O
mass	O
.	O
Other	O
characteristics	O
were	O
similar	O
,	O
including	O
physical	O
activity	O
(	O
evaluated	O
in	O
2007	O
)	O
and	O
biological	O
parameters	O
(	O
Table	O
1	O
)	O
.	O
Age	O
correlated	O
to	O
heart	O
rate	O
(	O
p	O
=	O
0	O
.	O
014	O
)	O
,	O
BMI	O
was	O
not	O
correlated	O
neither	O
with	O
age	O
nor	O
with	O
heart	O
rate	O
(	O
data	O
not	O
shown	O
)	O
.	O
Weight	O
change	O
between	O
2007	O
and	O
2012	O
was	O
similar	O
in	O
the	O
PNNS−	O
and	O
PNNS	O
+	O
groups	O
(	O
0	O
.	O
4	O
±	O
3	O
.	O
3	O
vs	O
−0	O
.	O
2	O
±	O
3	O
.	O
3	O
kg	O
,	O
p	O
=	O
0	O
.	O
529	O
)	O
.	O
Energy	O
and	O
nutrient	O
intake	O
in	O
2007	O
and	O
2012	O
are	O
shown	O
in	O
Tables	O
S1	O
(	O
for	O
all	O
participants	O
)	O
and	O
S2	O
(	O
for	O
each	O
group	O
)	O
.	O
Individuals	O
in	O
the	O
PNNS	O
+	O
group	O
had	O
declared	O
lesser	O
intake	O
of	O
calories	O
,	O
added	O
sugars	O
,	O
and	O
saturated	O
fat	O
and	O
higher	O
intake	O
of	O
vegetable	O
proteins	O
than	O
those	O
in	O
the	O
PNNS−	O
group	O
.	O
HR	O
was	O
lower	O
after	O
adjustment	O
in	O
the	O
PNNS	O
+	O
group	O
when	O
measured	O
with	O
applanation	O
tonometry	O
on	O
the	O
radial	O
,	O
carotid	O
,	O
and	O
femoral	O
arteries	O
.	O
HR	O
after	O
adjustment	O
was	O
also	O
lower	O
in	O
the	O
PNNS	O
+	O
group	O
during	O
an	O
average	O
15	O
min	O
recording	O
with	O
finger	O
plethysmography	O
(	O
Table	O
2	O
)	O
.	O
No	O
significant	O
difference	O
in	O
any	O
of	O
the	O
cardiovascular	O
autonomic	O
activity	O
indices	O
and	O
parameters	O
provided	O
by	O
cardiac	O
impedancemetry	O
were	O
found	O
between	O
the	O
PNNS−	O
and	O
PNNS	O
+	O
groups	O
(	O
Table	O
3	O
)	O
.	O
Table	O
4	O
shows	O
a	O
comparison	O
of	O
parameters	O
obtained	O
using	O
applanation	O
tonometry	O
.	O

After	O
adjusting	O
for	O
age	O
,	O
BMI	O
and	O
gender	O
(	O
model	O
3	O
)	O
,	O
subjects	O
in	O
the	O
PNNS−	O
group	O
had	O
greater	O
double	O
product	O
,	O
higher	O
tension	O
–	O
time	O
index	O
,	O
lesser	O
percent	O
diastole	O
duration	O
(	O
diastole	O
duration	O
as	O
a	O
percentage	O
of	O
the	O
cardiac	O
cycle	O
)	O
,	O
and	O
a	O
trend	O
toward	O
lower	O
subendocardial	O
viability	O
ratio	O
compared	O
to	O
those	O
in	O
PNNS	O
+	O
group	O
.	O
Measured	O
PWV	O
values	O
were	O
similar	O
in	O
both	O
groups	O
(	O
p	O
=	O
0	O
.	O
522	O
)	O
.	O
Age	O
-	O
predicted	O
PWV	O
values	O
in	O
all	O
participants	O
were	O
also	O
analyzed	O
.	O
Given	O
the	O
higher	O
age	O
of	O
our	O
subjects	O
(	O
60	O
–	O
65	O
years	O
)	O
and	O
the	O
increase	O
in	O
PWV	O
with	O
age	O
,	O
the	O
full	O
quadratic	O
equation	O
would	O
provide	O
better	O
R2	O
values	O
than	O
a	O
linear	O
fit	O
(	O
0	O
.	O
000	O
×	O
age	O
+	O
0	O
.	O
83	O
×	O
10	O
–	O
3	O
×	O
age2	O
+	O
5	O
.	O
55	O
)	O
.	O
36	O
Measured	O
values	O
were	O
significantly	O
lower	O
than	O
age	O
-	O
predicted	O
values	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
with	O
mean	O
predicted	O
values	O
being	O
9	O
.	O
3	O
±	O
0	O
.	O
6	O
and	O
8	O
.	O
9	O
±	O
0	O
.	O
6	O
m	O
/	O
s	O
for	O
the	O
PNNS	O
+	O
and	O
PNNS−	O
groups	O
,	O
respectively	O
(	O
PNNS−	O
vs	O
PNNS	O
+	O
,	O
p	O
=	O
0	O
.	O
306	O
)	O
(	O
Figure	O
S2	O
)	O
.	O
We	O
also	O
compared	O
predicted	O
PWV	O
values	O
with	O
the	O
direct	O
path	O
length	O
measurements	O
according	O
to	O
the	O
equation	O
from	O
the	O
paper	O
that	O
established	O
the	O
reference	O
values36	O
and	O
the	O
results	O
remained	O
the	O
same	O
(	O
Table	O
S3	O
)	O
.	O
After	O
adjusting	O
for	O
HR	O
,	O
cardiac	O
cycle	O
duration	O
(	O
p	O
=	O
0	O
.	O
352	O
)	O
,	O
diastole	O
duration	O
(	O
p	O
=	O
0	O
.	O
370	O
)	O
,	O
percent	O
diastole	O
duration	O
(	O
p	O
=	O
0	O
.	O
966	O
)	O
and	O
SEVR	O
(	O
p	O
=	O
0	O
.	O
945	O
)	O
were	O
similar	O
in	O
both	O
groups	O
.	O
Endothelial	O
function	O
in	O
small	O
arteries	O
(	O
reactive	O
hyperhemia	O
index	O
)	O
and	O
cutaneous	O
microcirculation	O
(	O
CBF	O
after	O
Ach	O
administration	O
)	O
,	O
CBF	O
,	O
and	O
sympathetic	O
microvascular	O
activity	O
were	O
all	O
similar	O
between	O
both	O
groups	O
(	O
Table	O
5	O
)	O
.	O
The	O
NUTRIVASC	O
study	O
has	O
been	O
the	O
first	O
to	O
extensively	O
examine	O
the	O
effect	O
of	O
long	O
-	O
term	O
adherence	O
to	O
the	O
French	O
nutritional	O
guidelines	B-methodology
on	O
cardiovascular	O
risk	O
integrators	O
in	O
patients	O
without	O
cardiovascular	O
risk	O
factors	O
.	O
Compared	O
to	O
participants	O
who	O
did	O
not	O
adhere	O
to	O
the	O
nutritional	O
guidelines	B-methodology
,	O
those	O
who	O
did	O
adhere	O
were	O
found	O
to	O
have	O
higher	O
intake	O
of	O
vegetable	O
protein	O
and	O
lesser	O
intake	O
of	O
calories	O
,	O
saturated	O
fat	O
,	O
and	O
added	O
sugar	O
.	O

Despite	O
sharing	O
similar	O
physical	O
activity	O
and	O
metabolic	O
profiles	O
,	O
those	O
who	O
adhered	O
to	O
the	O
guidelines	B-methodology
were	O
older	O
and	O
presented	O
worse	O
anthropometric	O
characteristics	O
(	O
i	O
.	O
e	O
.	O
,	O
higher	O
BMI	O
,	O
higher	O
waist	O
circumference	O
and	O
higher	O
fat	O
mass	O
)	O
compared	O
to	O
those	O
who	O
did	O
not	O
.	O
After	O
adjustment	O
for	O
these	O
differences	O
,	O
subjects	O
in	O
the	O
PNNS	O
+	O
group	O
had	O
a	O
lower	O
HR	O
,	O
longer	O
diastole	O
duration	O
,	O
lower	O
HR	O
×	O
BP	O
product	O
,	O
and	O
lower	O
tension	O
–	O
time	O
index	O
.	O
Both	O
groups	O
had	O
similar	O
SBP	O
,	O
arterial	O
stiffness	O
,	O
endothelial	O
function	O
,	O
and	O
vago	O
-	O
sympathetic	O
cardiac	O
activity	O
.	O
These	O
results	O
suggest	O
that	O
aside	O
from	O
the	O
favorable	O
effect	O
on	O
myocardial	O
oxygen	O
consumption	O
as	O
suggested	O
by	O
lower	O
HR	O
x	O
BP	O
product	O
,	O
nutritional	O
adequacy	O
in	O
terms	O
of	O
adherence	O
to	O
the	O
PNNS	O
guidelines	B-methodology
could	O
prevent	O
deterioration	O
in	O
cardiovascular	O
risk	O
integrators	O
with	O
age	O
.	O
Arterial	O
stiffness	O
indices	O
,	O
like	O
the	O
carotid	O
to	O
femoral	O
PWV	O
and	O
digital	O
,	O
radial	O
and	O
aortic	O
AIx	O
,	O
were	O
not	O
affected	O
.	O
AIx	O
measurements	O
remained	O
similar	O
despite	O
differences	O
in	O
age	O
,	O
even	O
after	O
adjusting	O
for	O
a	O
HR	O
of	O
75	O
beats	O
/	O
min	O
(	O
AIx	O
@	O
75	O
)	O
.	O
A	O
diet	O
favoring	O
meat	O
,	O
alcohol	O
and	O
low	O
micronutrient	O
intake	O
has	O
been	O
associated	O
with	O
increased	O
arterial	O
stiffness	O
.	O
37	O
On	O
the	O
contrary	O
,	O
a	O
meal	O
rich	O
in	O
ω	O
-	O
3	O
polyunsaturated	O
fatty	O
acids	O
has	O
been	O
found	O
to	O
acutely	O
reduce	O
arterial	O
stiffness	O
in	O
healthy	O
subjects	O
.	O
38	O
Nutrient	O
quality	O
,	O
especially	O
in	O
low	O
-	O
glycemic	O
-	O
index	O
diets	O
,	O
have	O
been	O
shown	O
to	O
lower	O
insulin	O
secretion	O
in	O
healthy	O
subjects	O
,	O
while	O
the	O
preventive	O
properties	O
of	O
this	O
type	O
of	O
diet	O
in	O
large	O
cohort	B-methodology
studies	I-methodology
have	O
shown	O
to	O
decrease	O
the	O
risk	O
of	O
developing	O
diabetes	O
and	O
cardiovascular	O
diseases	O
.	O
39	O
Notably	O
,	O
the	O
mean	O
measured	O
PWV	O
values	O
in	O
both	O
PNNS	O
+	O
and	O
PNNS−	O
groups	O
were	O
less	O
than	O
the	O
10th	O
percentile	O
of	O
reference	O
values	O
(	O
7	O
.	O
9	O
m	O
/	O
s	O
)	O
obtained	O
from	O
a	O
group	O
of	O
subjects	O
from	O
the	O
general	O
population	O
who	O
had	O
the	O
same	O
age	O
category	O
,	O
optimal	O
or	O
normal	O
BP	O
,	O
and	O
no	O
additional	O
CV	O
risk	O
factors	O
.	O
36	O
Although	O
the	O
study	O
was	O
designed	O
based	O
on	O
the	O
assumption	O
that	O
adherence	O
to	O
the	O
PNNS	O
guidelines	B-methodology
could	O
lead	O
to	O
a	O
1	O
m	O
/	O
s	O
difference	O
in	O
PWV	O
between	O
both	O
groups	O
,	O
the	O
actual	O
difference	O
was	O
only	O
0	O
.	O
36	O
m	O
/	O
s	O
.	O

Measured	O
PWV	O
values	O
were	O
lower	O
than	O
age	O
predicted	O
ones	O
for	O
both	O
groups	O
(	O
mean	O
PWV	O
difference	O
of	O
1	O
.	O
8	O
m	O
/	O
s	O
)	O
,	O
probably	O
because	O
we	O
selected	O
patients	O
without	O
any	O
cardiovascular	O
risk	O
factor	O
.	O
This	O
may	O
have	O
attenuated	O
differences	O
in	O
arterial	O
stiffness	O
.	O
One	O
of	O
the	O
major	O
findings	O
of	O
the	O
present	O
study	O
was	O
that	O
participants	O
who	O
adhered	O
to	O
the	O
PNNS	O
guidelines	B-methodology
had	O
lower	O
HR	O
independent	O
of	O
age	O
,	O
with	O
vago	O
-	O
sympathetic	O
cardiac	O
activity	O
and	O
sympathetic	O
vascular	O
activity	O
being	O
similar	O
.	O
Lower	O
HR	O
was	O
confirmed	O
using	O
two	O
different	O
methods	O
,	O
the	O
first	O
of	O
which	O
was	O
applanation	O
tonometry	O
of	O
the	O
radial	O
,	O
carotid	O
and	O
femoral	O
arteries	O
during	O
AIx	O
and	O
PWV	O
measurements	O
.	O
The	O
second	O
method	O
utilized	O
finger	O
plethysmography	O
(	O
average	O
HR	O
recording	O
of	O
15	O
min	O
)	O
,	O
which	O
evaluated	O
arterial	O
endothelial	O
function	O
.	O
It	O
is	O
important	O
to	O
note	O
that	O
Mediterranean	O
Diet	O
Scores	O
and	O
PNNS	O
-	O
GS	O
scores	O
predicted	O
obesity	O
risk	O
equally	O
well	O
among	O
French	O
adults	O
and	O
that	O
strong	O
adherence	O
to	O
the	O
PNNS	O
guidelines	B-methodology
was	O
protective	O
against	O
weight	O
gain	O
and	O
obesity	O
.	O
30	O
The	O
current	O
results	O
are	O
in	O
line	O
with	O
those	O
of	O
previous	O
studies	O
that	O
reported	O
lower	O
HRs	O
with	O
adherence	O
to	O
the	O
Mediterranean	O
diet	O
.	O
40	O
However	O
,	O
although	O
the	O
aforementioned	O
trial	O
had	O
used	O
a	O
semi	O
-	O
automatic	O
oscillometer	O
during	O
HR	O
assessment	O
,	O
such	O
a	O
finding	O
has	O
yet	O
to	O
be	O
confirmed	O
in	O
a	O
prospective	O
5	O
-	O
year	O
diet	B-methodology
intervention	I-methodology
.	O
41	O
A	O
resting	O
HR	O
between	O
50	O
and	O
70	O
beats	O
/	O
min	O
has	O
been	O
associated	O
with	O
lower	O
rates	O
of	O
mortality	O
among	O
the	O
general	O
population	O
.	O
11	O
However	O
,	O
obtaining	O
the	O
same	O
HR	O
using	O
a	O
β	O
-	O
blocker	O
doubled	O
the	O
mortality	O
,	O
42	O
suggesting	O
that	O
a	O
naturally	O
occurring	O
slow	O
resting	O
HR	O
was	O
indicative	O
of	O
good	O
overall	O
health	O
.	O
The	O
present	O
study	O
selected	O
subjects	O
who	O
had	O
no	O
confounding	O
factors	O
,	O
like	O
hypertension	O
and	O
anti	O
-	O
hypertensive	O
therapy	O
.	O
Higher	O
resting	O
HR	O
has	O
been	O
independently	O
associated	O
with	O
arterial	O
stiffness	O
.	O
Accordingly	O
,	O
HR	O
reduction	O
could	O
also	O
slow	O
accelerated	O
age	O
-	O
related	O
endothelial	O
dysfunction	O
through	O
two	O
potential	O
mechanisms	O
:	O
reduction	O
in	O
mechanical	O
stress	O
and	O
prolongation	O
of	O
the	O
period	O
of	O
steady	O
laminar	O
flow	O
.	O
43	O
In	O
the	O
current	O
study	O
,	O
subjects	O
who	O
adhered	O
to	O
the	O
nutritional	O
guidelines	B-methodology
had	O
a	O
longer	O
diastole	O
,	O
which	O
was	O
associated	O
with	O
better	O
myocardial	O
perfusion	O
as	O
suggested	O
by	O
SEVR	O
measurements	O
.	O

This	O
positive	O
association	O
was	O
HR	O
-	O
dependent	O
given	O
that	O
differences	O
between	O
the	O
two	O
groups	O
were	O
no	O
longer	O
significant	O
after	O
adjusting	O
for	O
HR	O
.	O
Another	O
important	O
finding	O
was	O
that	O
the	O
HR	O
×	O
SBP	O
double	O
product44	O
and	O
the	O
tension	O
–	O
time	O
index	O
,	O
both	O
hemodynamic	O
determinants	O
of	O
myocardial	O
oxygen	O
demand	O
,	O
were	O
also	O
lower	O
in	O
the	O
PNNS	O
+	O
group	O
than	O
in	O
the	O
PNNS−	O
group	O
.	O
The	O
presence	O
of	O
similar	O
stroke	O
volume	O
,	O
preload	O
,	O
afterload	O
,	O
and	O
contractility	O
with	O
a	O
lower	O
HR	O
suggested	O
a	O
more	O
efficient	O
myocardial	O
metabolism	O
for	O
achieving	O
similar	O
cardiac	O
workload	O
.	O
These	O
results	O
could	O
not	O
have	O
been	O
attributed	O
to	O
physical	O
activity	O
considering	O
that	O
no	O
difference	O
in	O
physical	O
activity	O
existed	O
between	O
those	O
who	O
did	O
and	O
did	O
not	O
adhere	O
to	O
the	O
PNNS	O
recommendations	O
.	O
Nutritional	O
factors	O
,	O
which	O
could	O
account	O
for	O
the	O
lower	O
HR	O
,	O
remain	O
to	O
be	O
determined	O
.	O
A	O
study	O
on	O
cultured	O
myocardial	O
cells	O
suggested	O
that	O
enrichment	O
with	O
n−3	O
fatty	O
acids	O
,	O
like	O
docosahexaenoic	O
acid	O
,	O
had	O
a	O
positive	O
influence	O
on	O
β	O
-	O
adrenergic	O
transduction	O
.	O
45	O
Intrinsic	O
dietary	O
effects	O
on	O
the	O
myocardium	O
have	O
been	O
described	O
to	O
be	O
independent	O
from	O
dietary	O
effects	O
on	O
circulating	O
hormone	O
or	O
substrate	O
levels	O
in	O
murine	O
models	O
.	O
46	O
In	O
the	O
current	O
study	O
,	O
although	O
no	O
difference	O
had	O
been	O
found	O
between	O
the	O
PNNS	O
+	O
and	O
PNNS−	O
groups	O
in	O
terms	O
of	O
estimated	O
docosahexaenoic	O
acid	O
intake	O
,	O
the	O
PNNS	O
+	O
group	O
had	O
a	O
lower	O
saturated	O
fat	O
intake	O
(	O
Table	O
S2	O
)	O
.	O
Dietary	O
patterns	O
,	O
such	O
as	O
the	O
Mediterranean	O
diet	O
or	O
the	O
Dietary	O
Approach	O
to	O
Stop	O
Hypertension	O
(	O
DASH	O
)	O
diet	O
have	O
shown	O
greater	O
benefits	O
.	O
Potential	O
health	O
benefits	O
of	O
fruits	O
and	O
vegetables	O
,	O
olive	O
oil	O
,	O
nuts	O
,	O
wine	O
and	O
fiber	O
have	O
been	O
shown	O
by	O
many	O
epidemiological	B-methodology
studies	I-methodology
.	O
A	O
recent	O
meta	O
-	O
analysis47	O
showed	O
that	O
a	O
higher	O
intake	O
of	O
fruits	O
or	O
vegetables	O
was	O
inversely	O
associated	O
with	O
the	O
levels	O
of	O
inflammatory	O
biomarkers	O
.	O
Recently	O
,	O
icosapent	O
ethyl	O
,	O
an	O
omega	O
-	O
3	O
fatty	O
acid	O
found	O
in	O
fish	O
oil	O
,	O
decreased	O
ischemic	O
events	O
and	O
cardiovascular	O
death	O
compared	O
to	O
placebo	B-methodology
despite	O
the	O
use	O
of	O
statins	O
.	O
48	O
Other	O
substances	O
like	O
lycopene	O
,	O
phytosterols	O
and	O
polyphenols	O
have	O
also	O
antioxidant	O
actions	O
.	O
49	O
Nonetheless	O
,	O
the	O
effects	O
of	O
docosahexaenoic	O
acid	O
intake	O
on	O
HR	O
merit	O
further	O
investigation	O
.	O

The	O
hemodynamic	O
profile	O
of	O
both	O
groups	O
,	O
which	O
included	O
stroke	O
volume	O
,	O
peripheral	O
resistance	O
,	O
myocardial	O
contractility	O
,	O
left	O
ventricular	O
ejection	O
time	O
and	O
venous	O
return	O
,	O
was	O
also	O
similar	O
.	O
Previous	O
studies	O
have	O
shown	O
that	O
the	O
consumption	O
of	O
high	O
-	O
fat	O
meals	O
with	O
high	O
levels	O
of	O
saturated	O
fat	O
over	O
the	O
course	O
of	O
several	O
weeks	O
may	O
lead	O
to	O
higher	O
total	O
peripheral	O
resistance	O
compared	O
to	O
the	O
consumption	O
low	O
-	O
fat	O
meals	O
.	O
50	O
BP	O
was	O
measured	O
on	O
the	O
radial	O
artery	O
,	O
while	O
central	O
BP	O
was	O
derived	O
from	O
the	O
generalized	O
transfer	O
function	O
.	O
DBP	O
has	O
been	O
known	O
to	O
decrease	O
during	O
the	O
sixth	O
decade	O
,	O
whereas	O
SBP	O
increases	O
with	O
age	O
,	O
usually	O
leading	O
to	O
increased	O
PP	O
.	O
Moreover	O
,	O
a	O
decrease	O
in	O
PP	O
amplification	O
with	O
age	O
has	O
been	O
due	O
to	O
large	O
artery	O
stiffening	O
.	O
51	O
The	O
absence	O
of	O
a	O
difference	O
in	O
endothelial	O
function	O
indices	O
,	O
measured	O
either	O
at	O
the	O
digital	O
artery	O
level	O
or	O
using	O
CBF	O
at	O
rest	O
and	O
after	O
Ach	O
iontophoresis	O
,	O
is	O
also	O
worth	O
considering	O
.	O
The	O
role	O
of	O
nutrients	O
in	O
endothelial	O
function	O
has	O
been	O
thoroughly	O
studied	O
:	O
intra	O
-	O
arterial	O
glucose	O
infusion	O
impairs	O
endothelium	O
-	O
dependent	O
vasodilation	O
in	O
healthy	O
humans	O
in	B-methodology
vivo	I-methodology
,	O
52	O
transient	O
hypertriglyceridemia	O
decreases	O
brachial	O
artery	O
reactivity	O
,	O
presumably	O
through	O
both	O
endothelium	O
-	O
dependent	O
and	O
endothelium	O
-	O
independent	O
mechanisms	O
,	O
53	O
while	O
intravenous	O
infusion	O
of	O
l	O
-	O
arginine	O
improved	O
endothelial	O
function	O
.	O
54	O
The	O
similarity	O
in	O
hemodynamic	O
profile	O
and	O
endothelial	O
function	O
in	O
the	O
present	O
study	O
was	O
probably	O
due	O
to	O
the	O
good	O
nutritional	O
habits	O
and	O
adequate	O
caloric	O
intake	O
among	O
those	O
that	O
did	O
not	O
follow	O
the	O
PNNS	O
recommendations	O
given	O
that	O
their	O
mean	O
BMI	O
was	O
less	O
than	O
25	O
kg	O
/	O
m2	O
with	O
practically	O
no	O
weight	O
change	O
during	O
a	O
5	O
-	O
year	O
period	O
.	O
These	O
results	O
could	O
not	O
have	O
been	O
related	O
to	O
antioxidant	O
supplementation	O
considering	O
that	O
none	O
of	O
the	O
patients	O
received	O
any	O
antioxidants	O
since	O
2002	O
.	O
Moreover	O
,	O
recent	O
meta	B-methodology
-	I-methodology
analyses	I-methodology
have	O
confirmed	O
that	O
diet	O
,	O
and	O
not	O
antioxidant	O
supplementation	O
,	O
seems	O
to	O
have	O
been	O
the	O
optimal	O
source	O
of	O
antioxidants	O
in	O
subjects	O
with	O
no	O
nutritional	O
deficits	O
.	O
55	O
Our	O
study	O
has	O
limitations	O
and	O
strengths	O
.	O
We	O
included	O
a	O
smaller	O
sample	O
size	O
than	O
initially	O
designed	O
which	O
resulted	O
in	O
a	O
loss	O
of	O
statistical	O
power	O
.	O
One	O
of	O
the	O
limitations	O
of	O
questionnaires	O
is	O
that	O
unanswered	O
answers	O
were	O
not	O
assessed	O
and	O
the	O
inevitable	O
of	O
forgetfulness	O
by	O
interviewed	O
subjects	O
.	O

The	O
strengths	O
of	O
the	O
present	O
study	O
were	O
that	O
participants	O
were	O
tested	O
for	O
their	O
adherence	O
to	O
nutritional	O
guidelines	B-methodology
at	O
two	O
time	O
points	O
over	O
a	O
5	O
-	O
year	O
period	O
and	O
were	O
selected	O
because	O
their	O
evaluations	O
were	O
concordant	O
throughout	O
the	O
study	O
period	O
.	O
Moreover	O
,	O
to	O
avoid	O
high	O
-	O
energy	O
intake	O
bias	O
,	O
a	O
penalty	O
system	O
was	O
used	O
when	O
both	O
groups	O
were	O
selected	O
.	O
Both	O
groups	O
had	O
no	O
cardiovascular	O
confounders	O
given	O
that	O
they	O
were	O
free	O
of	O
cardiovascular	O
risk	O
factors	O
and	O
did	O
not	O
take	O
any	O
drug	O
that	O
could	O
modify	O
cardiovascular	O
measurements	O
.	O
After	O
considering	O
anthropometric	O
measurements	O
and	O
metabolic	O
profiles	O
,	O
both	O
groups	O
were	O
found	O
to	O
have	O
probably	O
shared	O
a	O
healthy	O
way	O
of	O
living	O
prior	O
to	O
study	O
participation	O
,	O
thus	O
increasing	O
selection	O
accuracy	O
based	O
on	O
the	O
mPNNS	O
-	O
GS	O
.	O
Finally	O
,	O
a	O
follow	O
-	O
up	O
evaluation	O
of	O
physical	O
activity	O
level	O
in	O
2012	O
would	O
have	O
been	O
useful	O
.	O
Pronounced	O
changes	O
in	O
physical	O
activity	O
would	O
have	O
been	O
unlikely	O
considering	O
that	O
practically	O
no	O
weight	O
change	O
had	O
been	O
observed	O
over	O
a	O
5	O
-	O
year	O
period	O
.	O
However	O
,	O
it	O
is	O
known	O
that	O
prolonged	O
modest	O
changes	O
in	O
physical	O
fitness	O
in	O
individuals	O
can	O
have	O
important	O
effects	O
on	O
cardiovascular	O
health	O
not	O
mediated	O
by	O
changes	O
in	O
BMI	O
.	O
We	O
also	O
compared	O
the	O
indices	O
for	O
physical	O
activity	O
from	O
2001	O
to	O
2007	O
(	O
data	O
not	O
shown	O
)	O
during	O
leisure	O
(	O
p	O
=	O
0	O
.	O
510	O
)	O
,	O
working	O
hours	O
(	O
p	O
=	O
0	O
.	O
059	O
,	O
tendency	O
to	O
decrease	O
)	O
and	O
at	O
home	O
(	O
p	O
=	O
0	O
.	O
250	O
)	O
.	O
Our	O
subjects	O
had	O
a	O
mean	O
age	O
of	O
65	O
.	O
4	O
±	O
5	O
.	O
6	O
years	O
,	O
and	O
at	O
this	O
age	O
were	O
less	O
likely	O
to	O
start	O
a	O
physical	O
activity	O
and	O
more	O
likely	O
to	O
decrease	O
their	O
physical	O
activity	O
.	O
56	O
We	O
also	O
observed	O
that	O
the	O
weight	O
change	O
(	O
data	O
not	O
shown	O
)	O
from	O
2001	O
to	O
2012	O
was	O
not	O
significant	O
(	O
0	O
.	O
655	O
±	O
3	O
.	O
9	O
kg	O
,	O
p	O
=	O
0	O
.	O
256	O
)	O
.	O
In	O
conclusion	O
the	O
NUTRIVASC	O
study	O
suggests	O
that	O
adherence	O
to	O
the	O
French	O
nutritional	O
guidelines	B-methodology
has	O
a	O
positive	O
impact	O
on	O
resting	O
HR	O
and	O
myocardial	O
perfusion	O
indices	O
.	O
Beneficial	O
effects	O
of	O
adhering	O
to	O
nutritional	O
guidelines	B-methodology
also	O
encompass	O
delayed	O
vascular	O
aging	O
and	O
decreased	O
myocardial	O
oxygen	O
consumption	O
.	O
Molecular	O
pathways	O
of	O
nutritional	B-methodology
intervention	I-methodology
need	O
to	O
be	O
studied	O
,	O
since	O
information	O
about	O
possible	O
mechanisms	O
implicated	O
in	O
the	O
cardioprotective	O
effect	O
of	O
diet	O
patterns	O
,	O
nutrients	O
or	O
bioactive	O
compounds	O
is	O
lacking	O
.	O

These	O
results	O
not	O
only	O
describe	O
a	O
mechanism	O
whereby	O
nutrition	O
protects	O
against	O
cardiovascular	O
diseases	O
but	O
also	O
underline	O
the	O
importance	O
of	O
programs	O
geared	O
toward	O
preventing	O
cardiovascular	O
diseases	O
as	O
recommended	O
in	O
the	O
PNNS	O
.	O
Future	O
randomized	B-methodology
controlled	I-methodology
studies	I-methodology
in	O
order	O
to	O
confirm	O
the	O
results	O
of	O
the	O
current	O
study	O
are	O
necessary	O
.	O
We	O
would	O
like	O
to	O
thank	O
INSERM	O
(	O
Institut	O
national	O
de	O
la	O
santé	O
et	O
de	O
la	O
recherché	O
médicale	O
)	O
for	O
promoting	O
this	O
work	O
.	O
We	O
would	O
also	O
like	O
to	O
thank	O
for	O
the	O
storage	O
of	O
our	O
samples	O
CRB	O
(	O
CRB	O
(	O
liver	O
disease	O
biobank	O
)	O
,	O
Groupe	O
Hospitalier	O
Paris	O
Seine	O
-	O
Saint	O
-	O
Denis	O
BB	O
-	O
0033	O
-	O
00027	O
)	O
.	O
We	O
would	O
like	O
to	O
thank	O
the	O
University	O
of	O
Paris	O
13	O
for	O
a	O
research	O
grant	O
(	O
Bonus	O
Qualité	O
Recherche	O
,	O
faculty	O
decision	O
-	O
26	O
/	O
01	O
/	O
2010	O
)	O
.	O
Research	O
grant	O
from	O
the	O
University	O
of	O
Paris	O
13	O
(	O
Bonus	O
Qualité	O
Recherche	O
,	O
faculty	O
decision	O
of	O
26	O
/	O
01	O
/	O
2010	O
)	O
.	O

Dietary	O
fibers	O
inhibit	O
obesity	O
in	O
mice	O
,	O
but	O
host	O
responses	O
in	O
the	O
cecum	O
and	O
liver	O
appear	O
unrelated	O
to	O
fiber	O
-	O
specific	O
changes	O
in	O
cecal	O
bacterial	O
taxonomic	O
composition	O
Dietary	O
fibers	O
(	O
DF	O
)	O
can	O
prevent	O
obesity	O
in	O
rodents	O
fed	O
a	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
.	O
Their	O
mode	O
of	O
action	O
is	O
not	O
fully	O
elucidated	O
,	O
but	O
the	O
gut	O
microbiota	O
have	O
been	O
implicated	O
.	O
This	O
study	O
aimed	O
to	O
identify	O
the	O
effects	O
of	O
seven	O
dietary	O
fibers	O
(	O
barley	O
beta	O
-	O
glucan	O
,	O
apple	O
pectin	O
,	O
inulin	O
,	O
inulin	O
acetate	O
ester	O
,	O
inulin	O
propionate	O
ester	O
,	O
inulin	O
butyrate	O
ester	O
or	O
a	O
combination	O
of	O
inulin	O
propionate	O
ester	O
and	O
inulin	O
butyrate	O
ester	O
)	O
effective	O
in	O
preventing	O
diet	O
-	O
induced	O
obesity	O
and	O
links	O
to	O
differences	O
in	O
cecal	O
bacteria	O
and	O
host	O
gene	O
expression	O
.	O
Mice	O
(	O
n	O
=	O
12	O
)	O
were	O
fed	O
either	O
a	O
low	O
-	O
fat	O
diet	O
(	O
LFD	O
)	O
,	O
HFD	O
or	O
a	O
HFD	O
supplemented	O
with	O
the	O
DFs	O
,	O
barley	O
beta	O
-	O
glucan	O
,	O
apple	O
pectin	O
,	O
inulin	O
,	O
inulin	O
acetate	O
ester	O
,	O
inulin	O
propionate	O
ester	O
,	O
inulin	O
butyrate	O
ester	O
or	O
a	O
combination	O
of	O
inulin	O
propionate	O
ester	O
and	O
inulin	O
butyrate	O
ester	O
for	O
8	O
weeks	O
.	O
Cecal	O
bacteria	O
were	O
determined	O
by	O
Illumina	O
MiSeq	O
sequencing	O
of	O
16S	O
rRNA	O
gene	O
amplicons	O
.	O
Host	O
responses	O
,	O
body	O
composition	O
,	O
metabolic	O
markers	O
and	O
gene	O
transcription	O
(	O
cecum	O
and	O
liver	O
)	O
were	O
assessed	O
post	O
intervention	O
.	O
HFD	O
mice	O
showed	O
increased	O
adiposity	O
,	O
while	O
all	O
of	O
the	O
DFs	O
prevented	O
weight	O
gain	O
.	O
DF	O
specific	O
differences	O
in	O
cecal	O
bacteria	O
were	O
observed	O
.	O
Results	O
indicate	O
that	O
diverse	O
DFs	O
prevent	O
weight	O
gain	O
on	O
a	O
HFD	O
,	O
despite	O
giving	O
rise	O
to	O
different	O
cecal	O
bacteria	O
profiles	O
.	O
Conversely	O
,	O
common	O
host	O
responses	O
to	O
dietary	O
fiber	O
observed	O
are	O
predicted	O
to	O
be	O
important	O
in	O
improving	O
barrier	O
function	O
and	O
genome	O
stability	O
in	O
the	O
gut	O
,	O
maintaining	O
energy	O
homeostasis	O
and	O
reducing	O
HFD	O
induced	O
inflammatory	O
responses	O
in	O
the	O
liver	O
.	O
The	O
intestinal	O
microbiota	O
interacts	O
with	O
host	O
physiology	O
via	O
numerous	O
putative	O
metabolic	O
and	O
regulatory	O
routes	O
to	O
impact	O
health	O
and	O
disease1	O
,	O
2	O
.	O
The	O
microbiota	O
is	O
implicated	O
in	O
the	O
development	O
of	O
diet	O
-	O
induced	O
obesity	O
,	O
but	O
the	O
underlying	O
mechanisms	O
are	O
not	O
fully	O
elucidated3	O
,	O
4	O
.	O

Dietary	O
fibers	O
are	O
protective	O
against	O
the	O
development	O
of	O
diet	O
–	O
induced	O
obesity5	O
–	O
7	O
.	O
The	O
effects	O
of	O
dietary	O
fibers	O
are	O
largely	O
attributed	O
to	O
their	O
fermentation	O
by	O
gut	O
bacteria	O
and	O
the	O
uptake	O
of	O
metabolites	O
,	O
such	O
as	O
short	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
,	O
by	O
the	O
colon	O
epithelium	O
,	O
splanchnic	O
tissues	O
and	O
peripheral	O
organs	O
.	O
For	O
example	O
,	O
butyrate	O
stimulates	O
intestinal	O
gluconeogenesis	O
from	O
propionate	O
and	O
SCFA	O
metabolism	O
in	O
the	O
liver	O
regulates	O
glucose	O
and	O
lipid	O
metabolism	O
and	O
energy	O
homeostasis8	O
,	O
9	O
.	O
Dietary	O
fiber	O
and	O
SCFAs	O
are	O
reported	O
to	O
limit	O
body	O
weight	O
gain	O
due	O
to	O
a	O
reduction	O
in	O
food	O
intake	O
in	O
rodents10	O
–	O
12	O
and	O
are	O
inversely	O
associated	O
with	O
body	O
weight	O
gain	O
in	O
humans13	O
–	O
15	O
.	O
Dietary	O
fibers	O
are	O
diverse	O
polysaccharides	O
and	O
oligosaccharides	O
of	O
plant	O
origin	O
.	O
Gut	O
bacteria	O
vary	O
in	O
their	O
ability	O
to	O
degrade	O
and	O
utilize	O
dietary	O
fiber	O
and	O
consequently	O
different	O
dietary	O
dietary	O
fibers	O
profoundly	O
alter	O
the	O
composition	O
of	O
the	O
gut	O
microbiota16	O
.	O
Our	O
study	O
aimed	O
to	O
firstly	O
establish	O
whether	O
seven	O
different	O
dietary	O
fibers	O
(	O
barley	O
beta	O
-	O
glucan	O
,	O
apple	O
pectin	O
,	O
inulin	O
,	O
inulin	O
acetate	O
ester	O
,	O
inulin	O
propionate	O
ester	O
,	O
inulin	O
butyrate	O
ester	O
or	O
a	O
combination	O
of	O
inulin	O
propionate	O
ester	O
and	O
inulin	O
butyrate	O
ester	O
)	O
,	O
selected	O
following	O
in	B-methodology
vitro	I-methodology
fermentation	O
studies17	O
,	O
were	O
all	O
equally	O
protective	O
in	O
preventing	O
diet	O
-	O
induced	O
obesity	O
in	O
mice	O
and	O
whether	O
this	O
is	O
related	O
to	O
specific	O
cecal	O
bacterial	O
profiles	O
.	O
Since	O
one	O
potential	O
mechanism	O
for	O
the	O
action	O
of	O
dietary	O
fibers	O
is	O
via	O
SCFA	O
production	O
we	O
also	O
included	O
inulin	O
SCFA	O
esters	O
to	O
assess	O
the	O
role	O
of	O
individual	O
SCFA18	O
,	O
19	O
.	O
A	O
second	O
aim	O
was	O
to	O
determine	O
associated	O
dietary	O
fiber	O
altered	O
regulation	O
of	O
gene	O
expression	O
in	O
the	O
cecum	O
,	O
the	O
first	O
organ	O
impacted	O
by	O
differences	O
in	O
the	O
cecal	O
bacteria	O
,	O
and	O
the	O
liver	O
,	O
the	O
gatekeeper	O
organ	O
between	O
the	O
gut	O
and	O
the	O
systemic	O
circulation	O
and	O
whether	O
this	O
could	O
be	O
linked	O
to	O
cecal	O
bacterial	O
profiles	O
.	O
To	O
do	O
this	O
we	O
used	O
a	O
well	O
-	O
defined	O
model	O
of	O
diet	O
-	O
induced	O
obesity	O
.	O

We	O
have	O
previously	O
shown	O
that	O
12	O
week	O
old	O
(	O
24	O
–	O
25	O
grams	O
body	O
weight	O
)	O
C57Bl	O
/	O
6J	O
male	O
mice	O
rapidly	O
and	O
predictably	O
gain	O
bodyweight	O
,	O
adiposity	O
and	O
liver	O
lipid	O
content	O
when	O
fed	O
a	O
HFD20	O
.	O
Using	O
this	O
model	O
for	O
the	O
current	O
study	O
we	O
manipulated	O
dietary	O
carbohydrate	O
to	O
replace	O
a	O
proportion	O
of	O
corn	O
starch	O
and	O
cellulose	O
in	O
the	O
HFD	O
with	O
different	O
fermentable	O
dietary	O
fibers	O
(	O
barley	O
beta	O
-	O
glucan	O
,	O
apple	O
pectin	O
,	O
inulin	O
,	O
inulin	O
acetate	O
ester	O
,	O
inulin	O
propionate	O
ester	O
,	O
inulin	O
butyrate	O
ester	O
or	O
a	O
combination	O
of	O
inulin	O
propionate	O
ester	O
and	O
inulin	O
butyrate	O
ester	O
)	O
.	O
We	O
measured	O
food	O
intake	O
and	O
adiposity	O
at	O
the	O
same	O
time	O
as	O
analysing	O
post	O
-	O
intervention	O
profiles	O
of	O
bacteria	O
collected	O
from	O
the	O
cecal	O
contents	O
using	O
Illumina	O
MiSeq	O
sequencing	O
and	O
associated	O
host	O
gene	O
expression	O
in	O
the	O
cecum	O
and	O
liver	O
.	O
Body	O
composition	O
and	O
food	O
intake	O
of	O
male	O
C57BL	O
/	O
6	O
mice	O
fed	O
either	O
HFD	O
(	O
high	O
fat	O
diet	O
)	O
(	O
45	O
%	O
of	O
energy	O
from	O
fat	O
)	O
(	O
D12451	O
)	O
,	O
LFD	O
(	O
low	O
fat	O
diet	O
)	O
(	O
10	O
%	O
fat	O
by	O
energy	O
)	O
(	O
D12450B	O
)	O
,	O
or	O
the	O
HFD	O
where	O
10	O
%	O
of	O
the	O
carbohydrate	O
by	O
weight	O
(	O
5	O
%	O
corn	O
starch	O
,	O
5	O
%	O
cellulose	O
)	O
was	O
replaced	O
by	O
the	O
following	O
dietary	O
fibers	O
:	O
beta	O
glucan	O
(	O
HFD	O
+	O
bglucan	O
)	O
(	O
Glucagel	O
,	O
DKSH	O
,	O
Milan	O
Italy	O
)	O
,	O
pectin	O
(	O
HFD	O
+	O
pectin	O
)	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
Gillingham	O
,	O
UK	O
)	O
,	O
inulin	O
(	O
Beneo	O
Orafti®	O
HP	O
,	O
DKSH	O
,	O
London	O
UK	O
)	O
,	O
inulin	O
acetate	O
ester	O
(	O
HFD	O
+	O
inul	O
A	O
)	O
,	O
inulin	O
propionate	O
ester	O
(	O
HFD	O
+	O
inul	O
P	O
)	O
,	O
inulin	O
butyrate	O
ester	O
(	O
HFD	O
+	O
inul	O
B	O
)	O
or	O
5	O
%	O
each	O
of	O
inulin	O
propionate	O
and	O
inulin	O
butyrate	O
ester	O
(	O
HFD	O
+	O
inul	O
PB	O
)	O
(	O
details	O
of	O
diets	O
are	O
provided	O
in	O
Supplementary	O
File	O
S1	O
)	O
for	O
8	O
weeks	O
was	O
assessed	O
.	O

HFD	O
fed	O
mice	O
were	O
heavier	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
after	O
1	O
week	O
(	O
26	O
.	O
96	O
±	O
0	O
.	O
32	O
g	O
)	O
compared	O
to	O
LFD	O
(	O
25	O
.	O
01	O
±	O
0	O
.	O
29	O
g	O
)	O
and	O
HFD	O
+	O
DFs	O
.	O
HFD	O
mice	O
remained	O
heavier	O
compared	O
to	O
other	O
diet	O
groups	O
throughout	O
the	O
experiment	O
(	O
Fig	O
.	O
1A	O
,	O
B	O
)	O
.	O
HFD	O
mice	O
had	O
a	O
greater	O
fat	O
mass	O
at	O
8	O
weeks	O
(	O
Fig	O
.	O
1C	O
)	O
.	O
There	O
were	O
no	O
differences	O
in	O
lean	O
mass	O
in	O
any	O
of	O
the	O
diet	O
groups	O
(	O
Fig	O
.	O
1C	O
)	O
.	O
Colon	O
length	O
,	O
weight	O
/	O
cm	O
ratios	O
and	O
liver	O
weights	O
were	O
measured	O
and	O
were	O
not	O
found	O
to	O
be	O
significantly	O
different	O
(	O
data	O
not	O
shown	O
)	O
.	O
Food	O
intake	O
was	O
not	O
different	O
in	O
mice	O
fed	O
HFD	O
(	O
138	O
.	O
22	O
±	O
3	O
.	O
54	O
g	O
)	O
or	O
HFD	O
+	O
DF	O
(	O
Fig	O
.	O
1D	O
)	O
.	O
LFD	O
fed	O
mice	O
had	O
a	O
higher	O
food	O
intake	O
by	O
weight	O
compared	O
to	O
other	O
diets	O
(	O
153	O
.	O
36	O
±	O
2	O
.	O
18	O
g	O
)	O
(	O
Fig	O
.	O
1D	O
)	O
.	O
Total	O
liver	O
lipid	O
was	O
lower	O
in	O
mice	O
fed	O
LFD	O
and	O
all	O
HFD	O
+	O
DFs	O
(	O
Fig	O
.	O
1E	O
)	O
,	O
but	O
did	O
not	O
reach	O
significance	O
for	O
HFD	O
+	O
bglucan	O
and	O
HFD	O
+	O
inul	O
B	O
vs	O
.	O
HFD	O
(	O
Fig	O
.	O
1E	O
)	O
.	O
Cecum	O
content	O
weight	O
varied	O
with	O
diet	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
(	O
Fig	O
.	O
1F	O
)	O
.	O
HFD	O
fed	O
mice	O
had	O
the	O
lowest	O
cecal	O
content	O
weight	O
(	O
110	O
.	O
0	O
±	O
5	O
.	O
4	O
mg	O
)	O
(	O
Fig	O
.	O
1F	O
)	O
,	O
while	O
HFD	O
+	O
inulin	O
yielded	O
the	O
highest	O
weight	O
(	O
Fig	O
.	O
1F	O
)	O
.	O
Circulating	O
leptin	O
,	O
resistin	O
and	O
insulin	O
levels	O
measured	O
in	O
plasma	O
from	O
cardiac	O
puncture	O
were	O
lower	O
in	O
HFD	O
+	O
DFs	O
and	O
LFD	O
mice	O
(	O
Fig	O
.	O
2A	O
–	O
C	O
)	O
.	O
Gut	O
hormones	O
,	O
PYY	O
,	O
GIP	O
and	O
ghrelin	O
were	O
measured	O
in	O
hepatic	O
portal	O
vein	O
.	O
Plasma	O
PYY	O
(	O
p	O
=	O
0	O
.	O
041	O
)	O
was	O
higher	O
in	O
HFD	O
+	O
bglucan	O
,	O
HFD	O
+	O
inulin	O
and	O
HFD	O
+	O
inul	O
B	O
ester	O
vs	O
.	O

HFD	O
mice	O
(	O
Fig	O
.	O
2D	O
)	O
.	O
There	O
were	O
no	O
differences	O
in	O
GIP	O
or	O
ghrelin	O
(	O
data	O
not	O
shown	O
)	O
.	O
GLP	O
-	O
1	O
was	O
undetectable	O
.	O
Illumina	O
MiSeq	O
sequencing	O
of	O
16S	O
rRNA	O
gene	O
amplicons	O
derived	O
from	O
cecal	O
contents	O
revealed	O
a	O
strong	O
influence	O
of	O
dietary	O
fiber	O
supplementation	O
on	O
bacterial	O
composition	O
.	O
Phylum	O
-	O
level	O
analysis	O
showed	O
that	O
Firmicutes	O
were	O
dominant	O
in	O
HFD	O
+	O
bglucan	O
,	O
HFD	O
+	O
inul	O
B	O
,	O
HFD	O
+	O
inul	O
PB	O
,	O
HFD	O
and	O
LFD	O
groups	O
,	O
whereas	O
Bacteroidetes	O
were	O
the	O
most	O
proportionally	O
abundant	O
phylum	O
in	O
the	O
HFD	O
+	O
pectin	O
,	O
HFD	O
+	O
inul	O
A	O
and	O
HFD	O
+	O
inul	O
P	O
groups	O
(	O
Fig	O
.	O
3A	O
)	O
.	O
HFD	O
+	O
inulin	O
had	O
equal	O
proportions	O
of	O
each	O
of	O
the	O
two	O
phyla	O
(	O
Fig	O
.	O
3A	O
)	O
.	O
HFD	O
+	O
pectin	O
and	O
HFD	O
+	O
inulin	O
had	O
the	O
highest	O
percentage	O
levels	O
of	O
Proteobacteria	O
(	O
mostly	O
Deltaproteobacteria	O
)	O
,	O
but	O
there	O
was	O
large	O
individual	O
variation	O
(	O
Fig	O
.	O
3A	O
)	O
.	O
Mice	O
fed	O
the	O
LFD	O
had	O
higher	O
proportions	O
of	O
Actinobacteria	O
belonging	O
to	O
the	O
Bifidobacteriaceae	O
family	O
relative	O
to	O
those	O
fed	O
HFD	O
diets	O
with	O
or	O
without	O
added	O
dietary	O
fibers	O
(	O
Fig	O
.	O
3A	O
,	O
B	O
)	O
.	O
Large	O
differences	O
were	O
also	O
observed	O
at	O
family	O
(	O
Fig	O
.	O
3B	O
,	O
Supplementary	O
File	O
S3	O
)	O
and	O
Operational	O
Taxonomic	O
Unit	O
(	O
OTU	O
)	O
level	O
(	O
Fig	O
.	O
3C	O
,	O
Supplementary	O
File	O
S4	O
)	O
between	O
different	O
groups	O
,	O
some	O
of	O
which	O
were	O
associated	O
with	O
specific	O
diets	O
(	O
Supplementary	O
File	O
S4	O
)	O
,	O
including	O
Ruminococcaceae	O
and	O
Lachnospiraceae	O
in	O
the	O
HFD	O
group	O
,	O
Bacteroidaceae	O
in	O
the	O
HFD	O
+	O
pectin	O
group	O
and	O
Porphyromonadaceae	O
in	O
the	O
HFD	O
+	O
inulin	O
acetate	O
ester	O
group	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

The	O
38	O
most	O
abundant	O
OTUs	O
(	O
≥0	O
.	O
5	O
%	O
of	O
total	O
sequences	O
;	O
data	O
for	O
all	O
OTUs	O
are	O
given	O
in	O
Supplementary	O
File	O
S4	O
)	O
are	O
shown	O
in	O
the	O
heat	O
map	O
of	O
relative	O
abundance	O
(	O
expressed	O
as	O
average	O
percentage	O
to	O
total	O
sequences	O
per	O
diet	O
)	O
(	O
Fig	O
.	O
3C	O
)	O
.	O
Cecum	O
bacterial	O
profiles	O
clustered	O
separately	O
from	O
one	O
another	O
based	O
upon	O
diet	O
for	O
most	O
animals	O
.	O
LFD	O
and	O
HFD	O
with	O
no	O
added	O
fiber	O
clustered	O
together	O
,	O
indicating	O
that	O
presence	O
of	O
fiber	O
is	O
a	O
major	O
driver	O
of	O
overall	O
community	O
composition	O
.	O
Metastats	O
and	O
LEfSe	O
(	O
Linear	O
discriminant	O
analysis	O
effect	O
size	O
)	O
analyses	O
confirmed	O
that	O
there	O
were	O
a	O
large	O
number	O
of	O
significant	O
differences	O
in	O
constituent	O
taxa	O
between	O
these	O
two	O
groups	O
and	O
all	O
the	O
fiber	O
-	O
containing	O
groups	O
together	O
(	O
Supplementary	O
File	O
S4	O
)	O
.	O
In	O
contrast	O
,	O
the	O
two	O
dietary	O
groups	O
with	O
no	O
added	O
fibers	O
(	O
LFD	O
and	O
HFD	O
)	O
showed	O
fewer	O
significant	O
differences	O
between	O
them	O
(	O
Supplementary	O
File	O
S5	O
)	O
.	O
We	O
also	O
observed	O
that	O
the	O
four	O
inulin	O
esters	O
separated	O
into	O
two	O
clear	O
groups	O
,	O
with	O
HFD	O
+	O
inul	O
A	O
/	O
HFD	O
+	O
inul	O
P	O
and	O
HFD	O
+	O
inul	O
B	O
/	O
HFD	O
+	O
inul	O
PB	O
clustering	O
together	O
(	O
Fig	O
.	O
3B	O
,	O
Supplementary	O
File	O
S3	O
)	O
.	O
Two	O
different	O
clustering	O
methods	O
,	O
(	O
Jaccard	O
,	O
which	O
incorporates	O
only	O
presence	O
/	O
absence	O
of	O
OTUs	O
,	O
and	O
Bray	O
Curtis	O
,	O
which	O
also	O
incorporates	O
proportional	O
abundances	O
of	O
each	O
OTU	O
when	O
comparing	O
dissimilarities	O
)	O
revealed	O
a	O
highly	O
significant	O
effect	O
of	O
diet	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
Pairwise	O
comparison	O
of	O
all	O
dietary	O
groups	O
showed	O
that	O
clustering	O
in	O
both	O
trees	O
was	O
significant	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
with	O
the	O
exception	O
of	O
HFD	O
+	O
inul	O
A	O
compared	O
to	O
HFD	O
+	O
inul	O
P	O
(	O
P	O
=	O
0	O
.	O
018	O
Jaccard	O
;	O
P	O
=	O
0	O
.	O
071	O
Bray	O
Curtis	O
)	O
and	O
HFD	O
+	O
inul	O
B	O
compared	O
to	O
HFD	O
+	O
inul	O
PB	O
(	O
not	O
significant	O
)	O
.	O
AMOVA	O
analysis	O
essentially	O
resulted	O
in	O
the	O
same	O
outcome	O
(	O
HFD	O
+	O
inul	O
A	O
compared	O
to	O
HFD	O
+	O
inul	O
P	O
P	O
<	O
0	O
.	O
001	O
Jaccard	O
;	O
P	O
=	O
0	O
.	O
058	O
Bray	O
Curtis	O
;	O
HFD	O
+	O
inul	O
B	O
compared	O
to	O
HFD	O
+	O
inul	O
PB	O
not	O
significant	O
;	O
all	O
other	O
comparisons	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

LEfSe	O
analysis	O
including	O
all	O
individual	O
dietary	O
groups	O
revealed	O
the	O
highest	O
number	O
of	O
significant	O
associations	O
for	O
the	O
HFD	O
fed	O
group	O
,	O
followed	O
by	O
HFD	O
+	O
pectin	O
(	O
Supplementary	O
File	O
S4	O
)	O
.	O
Thus	O
there	O
were	O
no	O
consistent	O
changes	O
in	O
phylogenetic	O
(	O
16S	O
rRNA	O
-	O
based	O
)	O
community	O
composition	O
with	O
weight	O
gain	O
and	O
fiber	O
intake	O
on	O
the	O
HFD	O
diets	O
,	O
despite	O
the	O
significant	O
impacts	O
of	O
individual	O
fibers	O
on	O
bacterial	O
composition	O
when	O
incorporated	O
in	O
the	O
HFD	O
.	O
However	O
,	O
the	O
possibility	O
of	O
common	O
changes	O
in	O
some	O
functional	O
microbial	O
group	O
/	O
groups	O
that	O
impact	O
on	O
weight	O
gain	O
,	O
or	O
in	O
some	O
low	O
-	O
abundance	O
taxon	O
that	O
has	O
a	O
major	O
effect	O
on	O
physiology	O
cannot	O
be	O
ruled	O
out	O
.	O
Bacterial	O
diversity	O
was	O
higher	O
in	O
HFD	O
fed	O
mice	O
compared	O
to	O
mice	O
on	O
all	O
other	O
diets	O
and	O
there	O
were	O
also	O
significant	O
differences	O
in	O
diversity	O
indices	O
between	O
different	O
diets	O
incorporating	O
different	O
dietary	O
fibers	O
that	O
were	O
consistent	O
with	O
the	O
Bray	O
-	O
Curtis	O
clustering	O
(	O
Supplementary	O
File	O
S5	O
)	O
.	O
All	O
diets	O
containing	O
dietary	O
fibers	O
had	O
higher	O
total	O
bacterial	O
16S	O
rRNA	O
gene	O
copies	O
compared	O
to	O
either	O
HFD	O
or	O
LFD	O
,	O
indicating	O
greater	O
bacterial	O
numbers	O
per	O
g	O
of	O
cecal	O
contents	O
.	O
HFD	O
fed	O
mice	O
had	O
the	O
lowest	O
bacterial	O
abundance	O
(	O
Fig	O
.	O
3D	O
)	O
.	O
Global	O
microarray	O
analysis	O
was	O
conducted	O
on	O
liver	O
and	O
cecum	O
of	O
mice	O
(	O
n	O
=	O
6	O
)	O
from	O
HFD	O
,	O
LFD	O
,	O
HFD	O
+	O
inul	O
and	O
HFD	O
+	O
inul	O
PB	O
groups	O
.	O
The	O
HFD	O
+	O
inul	O
PB	O
were	O
chosen	O
as	O
the	O
lowest	O
weight	O
gain	O
and	O
analysis	O
of	O
the	O
HFD	O
+	O
inulin	O
group	O
allowed	O
identification	O
of	O
any	O
inulin	O
vs	O
.	O
inulin	O
ester	O
effects	O
.	O
Comparison	O
with	O
HFD	O
and	O
LFD	O
mice	O
distinguished	O
the	O
effects	O
of	O
dietary	O
fibers	O
from	O
body	O
weight	O
/	O
adiposity	O
effects	O
.	O
Principal	O
component	O
analysis	O
(	O
PCA	O
)	O
of	O
normalised	O
microarray	O
data	O
indicated	O
diet	O
associated	O
cecum	O
and	O
liver	O
gene	O
expression	O
,	O
explaining	O
22	O
.	O
99	O
%	O
and	O
19	O
.	O
22	O
%	O
of	O
the	O
variation	O
in	O
the	O
data	O
respectively	O
(	O
Supplementary	O
File	O
S6	O
Fig	O
.	O
S2A	O
,	O
B	O
)	O
.	O
PCA	O
analysis	O
of	O
cecal	O
gene	O
expression	O
indicated	O
a	O
tendency	O
for	O
the	O
HFD	O
+	O
inul	O
and	O
HFD	O
+	O
inul	O
PB	O
fed	O
mice	O
to	O
cluster	O
together	O
distinct	O
from	O
the	O
HFD	O
and	O
LFD	O
fed	O
mice	O
(	O
Supplementary	O
File	O
S6	O
Fig	O
.	O
S2A	O
)	O
.	O

However	O
,	O
PCA	O
analysis	O
of	O
liver	O
gene	O
expression	O
profiles	O
did	O
not	O
reveal	O
distinct	O
clusters	O
(	O
Supplementary	O
File	O
S6	O
Fig	O
.	O
S2B	O
)	O
.	O
Subsequent	O
analysis	O
was	O
applied	O
to	O
identify	O
probe	O
IDs	O
indicating	O
a	O
>	O
1	O
.	O
5	O
fold	O
difference	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
in	O
gene	O
expression	O
when	O
compared	O
to	O
HFD	O
mice	O
.	O
Using	O
the	O
cut	O
off	O
set	O
at	O
>	O
1	O
.	O
5	O
fold	O
difference	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
741	O
probe	O
IDs	O
in	O
HFD	O
+	O
inulin	O
,	O
1614	O
in	O
HFD	O
+	O
inul	O
PB	O
ester	O
and	O
151	O
in	O
LFD	O
fed	O
mice	O
showed	O
differences	O
in	O
expression	O
levels	O
compared	O
to	O
HFD	O
fed	O
mice	O
(	O
Supplementary	O
File	O
S6	O
Fig	O
.	O
S2C	O
–	O
E	O
,	O
GEO	O
Accession	O
no	O
.	O
GSE106375	O
)	O
.	O
In	O
liver	O
,	O
there	O
were	O
68	O
probe	O
IDs	O
in	O
HFD	O
+	O
inulin	O
,	O
53	O
in	O
HFD	O
+	O
inul	O
PB	O
and	O
196	O
in	O
LFD	O
mice	O
(	O
GEO	O
Accession	O
no	O
.	O
GSE106375	O
)	O
showing	O
differences	O
in	O
gene	O
expression	O
compared	O
to	O
HFD	O
mice	O
.	O
Greater	O
numbers	O
of	O
probe	O
IDs	O
were	O
identified	O
in	O
the	O
cecum	O
of	O
mice	O
consuming	O
HFD	O
+	O
DFs	O
compared	O
to	O
LFD	O
,	O
indicating	O
that	O
differences	O
in	O
gene	O
expression	O
are	O
greater	O
with	O
DF	O
supplementation	O
,	O
rather	O
than	O
simply	O
altered	O
in	O
association	O
with	O
body	O
weight	O
/	O
adiposity	O
.	O
The	O
same	O
selection	O
criteria	O
identified	O
a	O
greater	O
number	O
of	O
differences	O
in	O
gene	O
expression	O
regulated	O
by	O
LFD	O
in	O
liver	O
compared	O
to	O
HFD	O
supplemented	O
with	O
DFs	O
.	O
Validation	O
of	O
microarray	O
data	O
was	O
conducted	O
to	O
confirm	O
altered	O
regulation	O
of	O
selected	O
gene	O
targets	O
in	O
response	O
to	O
HFD	O
+	O
inulin	O
and	O
HFD	O
+	O
inul	O
PB	O
.	O
Comparison	O
of	O
the	O
selected	O
gene	O
targets	O
was	O
assessed	O
in	O
the	O
microarrayed	O
samples	O
and	O
also	O
in	O
response	O
to	O
the	O
other	O
diet	B-methodology
interventions	I-methodology
using	O
a	O
custom	O
designed	O
RT	O
Profiler	O
PCR	O
Array	O
of	O
cecum	O
and	O
Taqman	O
assays	O
of	O
cecum	O
and	O
liver	O
.	O
Genes	O
were	O
selected	O
on	O
the	O
basis	O
of	O
large	O
differences	O
in	O
response	O
to	O
consumption	O
of	O
HFD	O
+	O
inulin	O
or	O
HFD	O
+	O
inul	O
PB	O
ester	O
diets	O
,	O
and	O
involvement	O
in	O
gut	O
barrier	O
function	O
in	O
the	O
case	O
of	O
cecum	O
microarray	O
targets	O
.	O

RT	O
Profiler	O
PCR	O
Array	O
confirmed	O
that	O
cecal	O
genes	O
were	O
associated	O
with	O
dietary	O
fiber	O
supplementation	O
rather	O
than	O
adiposity	O
,	O
with	O
no	O
differences	O
observed	O
in	O
target	O
gene	O
expression	O
in	O
LFD	O
fed	O
mice	O
(	O
Fig	O
.	O
4A	O
)	O
.	O
Selected	O
gene	O
targets	O
were	O
regulated	O
similarly	O
in	O
response	O
to	O
all	O
HFD	O
+	O
DF	O
diets	O
,	O
including	O
higher	O
levels	O
of	O
cecal	O
Tex19	O
.	O
1	O
(	O
Testis	O
expressed	O
19	O
.	O
1	O
)	O
(	O
Fig	O
.	O
4A	O
)	O
and	O
Muc16	O
(	O
Mucin	O
16	O
)	O
,	O
except	O
HFD	O
+	O
inul	O
A	O
and	O
HFD	O
+	O
inul	O
B	O
(	O
Fig	O
.	O
4A	O
)	O
.	O
Higher	O
Cldn23	O
(	O
Claudin	O
23	O
)	O
expression	O
was	O
not	O
confirmed	O
by	O
RT	O
Profiler	O
PCR	O
.	O
Significant	O
reduced	O
levels	O
of	O
cecal	O
Cldn4	O
(	O
Claudin	O
4	O
)	O
and	O
Muc2	O
(	O
Mucin	O
2	O
)	O
were	O
confirmed	O
for	O
all	O
HFD	O
+	O
DFs	O
(	O
Fig	O
.	O
4A	O
)	O
,	O
while	O
Cfd	O
(	O
Complement	O
Factor	O
D	O
)	O
down	O
regulation	O
observed	O
in	O
the	O
majority	O
of	O
HFD	O
+	O
DFs	O
failed	O
to	O
reach	O
significance	O
(	O
Fig	O
.	O
4A	O
)	O
.	O
Lower	O
Cldn5	O
(	O
Claudin	O
5	O
)	O
expression	O
was	O
observed	O
in	O
HFD	O
+	O
pectin	O
,	O
HFD	O
+	O
inulin	O
,	O
HFD	O
+	O
inul	O
B	O
and	O
HFD	O
+	O
inul	O
PB	O
(	O
Fig	O
.	O
4A	O
)	O
.	O
Tff3	O
(	O
Trefoil	O
Factor	O
3	O
)	O
was	O
lower	O
in	O
HFD	O
+	O
pectin	O
,	O
HFD	O
+	O
inul	O
P	O
,	O
HFD	O
+	O
inul	O
B	O
and	O
HFD	O
+	O
inul	O
PB	O
(	O
Fig	O
.	O
4A	O
)	O
.	O
In	O
summary	O
,	O
the	O
majority	O
of	O
microarray	O
identified	O
genes	O
were	O
similarly	O
regulated	O
by	O
all	O
diets	O
containing	O
dietary	O
fibers	O
(	O
Fig	O
.	O
4A	O
)	O
.	O
Microarray	O
analysis	O
revealed	O
increased	O
Enho	O
(	O
Energy	O
Homesostasis	O
Associated	O
)	O
expression	O
in	O
liver	O
for	O
all	O
HFD	O
+	O
DF	O
diets	O
relative	O
to	O
the	O
HFD	O
diet	O
,	O
with	O
the	O
greatest	O
levels	O
observed	O
in	O
response	O
to	O
HFD	O
+	O
inul	O
PB	O
.	O
Enho	O
expression	O
in	O
LFD	O
mice	O
compared	O
to	O
HFD	O
fed	O
mice	O
was	O
not	O
altered	O
(	O
Fig	O
.	O
4B	O
)	O
and	O
levels	O
of	O
adropin	O
,	O
encoded	O
by	O
Enho	O
,	O
were	O
not	O
increased	O
in	O
liver	O
(	O
Fig	O
.	O
4C	O
)	O
.	O

The	O
validation	O
of	O
gene	O
expression	O
using	O
RT	O
Profiler	O
PCR	O
Array	O
and	O
Taqman	O
assays	O
revealed	O
common	O
responses	O
to	O
dietary	O
fiber	O
consumption	O
in	O
cecum	O
(	O
Fig	O
.	O
4A	O
)	O
and	O
liver	O
(	O
Fig	O
.	O
4B	O
)	O
irrespective	O
of	O
the	O
type	O
of	O
dietary	O
fiber	O
or	O
dietary	O
fiber	O
specific	O
differences	O
in	O
cecal	O
bacterial	O
composition	O
(	O
Fig	O
.	O
3	O
)	O
.	O
Pathway	O
analysis	O
was	O
carried	O
out	O
on	O
a	O
sub	O
-	O
set	O
of	O
normalised	O
microarray	O
gene	O
expression	O
data	O
of	O
known	O
genes	O
(	O
predicted	O
genes	O
and	O
unnamed	O
transcripts	O
were	O
excluded	O
)	O
that	O
showed	O
>	O
1	O
.	O
5	O
fold	O
differences	O
P	O
≤	O
0	O
.	O
01	O
in	O
gene	O
expression	O
compared	O
to	O
HFD	O
in	O
cecum	O
and	O
liver	O
in	O
response	O
to	O
HFD	O
+	O
inul	O
and	O
HFD	O
+	O
inul	O
PB	O
,	O
but	O
not	O
LFD	O
.	O
This	O
gene	O
sub	O
-	O
set	O
consisted	O
of	O
168	O
genes	O
with	O
higher	O
and	O
102	O
with	O
lower	O
levels	O
of	O
gene	O
expression	O
in	O
cecum	O
and	O
2	O
with	O
higher	O
and	O
6	O
with	O
lower	O
levels	O
of	O
gene	O
expression	O
in	O
liver	O
(	O
Supplementary	O
Files	O
S7	O
and	O
S8	O
)	O
when	O
compared	O
to	O
HFD	O
fed	O
mice	O
.	O
Common	O
transcriptional	O
responses	O
to	O
HFD	O
+	O
inul	O
and	O
HFD	O
+	O
inul	O
PB	O
are	O
shown	O
(	O
Fig	O
.	O
5A	O
)	O
.	O
A	O
Cytoscape	O
network	O
of	O
genes	O
showing	O
common	O
transcriptional	O
responses	O
to	O
HFD	O
+	O
inul	O
and	O
HFD	O
+	O
inul	O
PB	O
illustrates	O
the	O
categories	O
these	O
genes	O
fall	O
into	O
,	O
including	O
anion	O
transport	O
,	O
lipid	O
,	O
small	O
molecule	O
,	O
single	O
-	O
organism	O
,	O
long	O
-	O
chain	O
fatty	O
acid	O
,	O
cellular	O
lipid	O
,	O
monocarboxylic	O
,	O
arachidonic	O
,	O
icosanoid	O
and	O
fatty	O
acid	O
metabolic	O
processes	O
being	O
upregulated	O
(	O
Fig	O
.	O
5A	O
)	O
,	O
while	O
sulphur	O
compound	O
metabolic	O
process	O
epithelium	O
,	O
gland	O
and	O
tissue	O
development	O
were	O
downregulated	O
in	O
the	O
cecum	O
(	O
Fig	O
.	O
5B	O
)	O
.	O
GO	O
(	O
Gene	O
Ontology	O
)	O
terms	O
enriched	O
in	O
liver	O
in	O
response	O
to	O
HFD	O
+	O
inul	O
and	O
HFD	O
+	O
inul	O
PB	O
were	O
localisation	O
,	O
locomotion	O
,	O
immune	O
system	O
,	O
metabolic	O
and	O
single	O
-	O
organism	O
processes	O
(	O
Fig	O
.	O
5C	O
)	O
.	O

The	O
Cytoscape	O
network	O
revealed	O
SAA1	O
(	O
Serum	O
Amyloid	O
A1	O
)	O
and	O
SAA2	O
(	O
Serum	O
Amyloid	O
A2	O
)	O
,	O
involved	O
in	O
inflammatory	O
responses	O
,	O
differed	O
in	O
response	O
to	O
consumption	O
of	O
HFD	O
+	O
inul	O
and	O
HFD	O
+	O
inul	O
PB	O
esters	O
in	O
both	O
cecum	O
(	O
higher	O
)	O
and	O
liver	O
(	O
lower	O
)	O
(	O
Fig	O
.	O
5E	O
)	O
compared	O
to	O
HFD	O
.	O
The	O
differences	O
in	O
gene	O
expression	O
were	O
confirmed	O
by	O
real	O
-	O
time	O
PCR	O
(	O
Fig	O
.	O
6	O
)	O
.	O
However	O
,	O
higher	O
SAA1	O
levels	O
in	O
cecum	O
failed	O
to	O
reach	O
significance	O
for	O
HFD	O
+	O
pectin	O
and	O
HFD	O
+	O
inul	O
P	O
,	O
as	O
did	O
SAA2	O
for	O
HFD	O
+	O
inul	O
P	O
(	O
Fig	O
.	O
6A	O
,	O
B	O
)	O
.	O
Lower	O
levels	O
of	O
SAA1	O
in	O
liver	O
were	O
observed	O
in	O
response	O
to	O
consumption	O
of	O
HFD	O
+	O
DFs	O
,	O
reaching	O
significance	O
in	O
HFD	O
+	O
bglucan	O
and	O
HFD	O
+	O
inulin	O
fed	O
mice	O
.	O
While	O
the	O
lower	O
level	O
of	O
SAA2	O
in	O
liver	O
was	O
significant	O
for	O
all	O
HFD	O
+	O
DFs	O
,	O
except	O
from	O
HFD	O
+	O
pectin	O
and	O
HFD	O
+	O
inul	O
P	O
.	O
LFD	O
mice	O
also	O
showed	O
comparable	O
differences	O
in	O
SAA1	O
and	O
SAA2	O
in	O
cecum	O
and	O
liver	O
measured	O
using	O
real	O
time	O
PCR	O
(	O
these	O
differences	O
were	O
noted	O
in	O
microarray	O
analysis	O
,	O
but	O
had	O
failed	O
to	O
meet	O
the	O
significance	O
cut	O
off	O
)	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Fig	O
.	O
6	O
)	O
.	O
This	O
study	O
reports	O
comprehensive	O
analysis	O
of	O
seven	O
dietary	O
fibers	O
combined	O
with	O
HFD	O
on	O
cecal	O
bacterial	O
profiles	O
and	O
host	O
gene	O
expression	O
in	O
the	O
cecum	O
and	O
liver	O
of	O
mice	O
.	O
While	O
there	O
were	O
fiber	O
-	O
specific	O
differences	O
in	O
cecal	O
bacterial	O
composition	O
,	O
all	O
dietary	O
fibers	O
tested	O
prevented	O
obesity	O
and	O
yielded	O
similar	O
responses	O
in	O
body	O
composition	O
and	O
host	O
gene	O
expression	O
in	O
cecum	O
and	O
liver	O
of	O
a	O
number	O
of	O
gene	O
targets	O
identified	O
by	O
microarray	O
.	O
The	O
responses	O
to	O
dietary	O
fiber	O
of	O
the	O
gene	O
targets	O
selected	O
for	O
further	O
analysis	O
confirmed	O
a	O
similar	O
outcome	O
,	O
implying	O
that	O
while	O
cecal	O
bacterial	O
profiles	O
differ	O
specific	O
to	O
each	O
dietary	O
fiber	O
,	O
this	O
results	O
in	O
collective	O
outcomes	O
in	O
the	O
expression	O
of	O
certain	O
host	O
genes	O
.	O

Despite	O
the	O
differences	O
in	O
bacterial	O
profiles	O
associated	O
with	O
specific	O
fibers	O
we	O
established	O
common	O
gene	O
expression	O
differences	O
in	O
the	O
host	O
irrespective	O
of	O
which	O
fiber	O
was	O
incorporated	O
in	O
the	O
HFD	O
.	O
This	O
finding	O
was	O
a	O
significant	O
outcome	O
of	O
our	O
study	O
and	O
implies	O
that	O
bacterial	O
composition	O
per	O
se	O
may	O
not	O
be	O
causal	O
in	O
protecting	O
against	O
HFD	O
-	O
induced	O
weight	O
gain	O
.	O
However	O
,	O
there	O
is	O
a	O
possibility	O
that	O
common	O
changes	O
in	O
microbial	O
groups	O
producing	O
particular	O
metabolites	O
or	O
signalling	O
molecules	O
,	O
or	O
a	O
low	O
-	O
abundance	O
taxon	O
that	O
induces	O
major	O
effects	O
on	O
physiology	O
,	O
could	O
be	O
contributing	O
to	O
the	O
observed	O
effects	O
on	O
weight	O
gain	O
and	O
metabolism	O
.	O
Nonetheless	O
,	O
replacement	O
of	O
dietary	O
starch	O
by	O
dietary	O
fibers	O
in	O
these	O
defined	O
diets	O
was	O
predicted	O
to	O
decrease	O
the	O
supply	O
of	O
carbohydrate	O
-	O
derived	O
calories	O
in	O
the	O
upper	O
GI	O
tract	O
by	O
12	O
.	O
4	O
%	O
.	O
Calories	O
arising	O
from	O
bacterial	O
fermentation	O
of	O
dietary	O
fibers	O
cannot	O
be	O
calculated	O
exactly	O
,	O
but	O
iso	O
-	O
caloric	O
replacement	O
is	O
based	O
on	O
the	O
assumption	O
that	O
dietary	O
fibers	O
provide	O
50	O
%	O
of	O
the	O
calorific	O
value	O
of	O
digestible	O
carbohydrates21	O
.	O
The	O
cellulose	O
incorporated	O
in	O
the	O
diets	O
(	O
International	O
Fiber	O
Corporation	O
)	O
has	O
no	O
calorific	O
value	O
for	O
the	O
host	O
and	O
was	O
replaced	O
with	O
dietary	O
fibers	O
in	O
the	O
HFD	O
+	O
DF	O
diets	O
.	O
Given	O
that	O
there	O
was	O
no	O
detectable	O
change	O
in	O
cumulative	O
food	O
intake	O
(	O
Fig	O
.	O
1D	O
)	O
between	O
the	O
HFD	O
and	O
the	O
HFD	O
diets	O
incorporating	O
dietary	O
fiber	O
,	O
together	O
with	O
protection	O
against	O
diet	O
-	O
induced	O
obesity	O
(	O
Fig	O
.	O
1A	O
–	O
C	O
)	O
,	O
our	O
results	O
indicate	O
that	O
the	O
net	O
calorie	O
gain	O
may	O
have	O
been	O
lower	O
than	O
this	O
.	O
While	O
composition	O
of	O
the	O
cecal	O
bacteria	O
were	O
different	O
between	O
the	O
different	O
dietary	O
fibers	O
,	O
numbers	O
of	O
cecal	O
bacteria	O
per	O
g	O
cecal	O
contents	O
were	O
enhanced	O
by	O
all	O
dietary	O
fibers	O
.	O
It	O
is	O
known	O
that	O
gut	O
bacterial	O
composition	O
is	O
affected	O
by	O
the	O
addition	O
of	O
dietary	O
fibers	O
to	O
the	O
diet16	O
,	O
17	O
,	O
22	O
,	O
but	O
also	O
by	O
dietary	O
fat	O
and	O
protein23	O
,	O
by	O
gut	O
turnover	O
/	O
transit	O
time	O
and	O
the	O
gut	O
environment	O
(	O
e	O
.	O
g	O
.	O
pH	O
)	O
2	O
.	O

In	O
contrast	O
to	O
earlier	O
reports24	O
,	O
25	O
we	O
found	O
little	O
difference	O
between	O
the	O
HFD	O
and	O
LFD	O
diets	O
in	O
the	O
representation	O
of	O
Bacteroidetes	O
and	O
Firmicutes	O
phyla	O
,	O
but	O
Actinobacteria	O
were	O
proportionally	O
less	O
abundant	O
in	O
HFD	O
mice	O
,	O
except	O
for	O
HFD	O
+	O
pectin	O
and	O
HFD	O
+	O
inulin	O
.	O
Major	O
differences	O
in	O
cecal	O
Bacteroidetes	O
and	O
Firmicutes	O
proportions	O
were	O
seen	O
between	O
the	O
HFD	O
+	O
DFs	O
.	O
For	O
the	O
three	O
non	O
-	O
esterified	O
dietary	O
fiber	O
diets	O
,	O
Bacteroidetes	O
were	O
proportionally	O
favoured	O
on	O
HFD	O
+	O
pectin	O
and	O
Firmicutes	O
on	O
HFD	O
+	O
bglucan	O
,	O
while	O
the	O
two	O
phyla	O
were	O
approximately	O
equally	O
represented	O
on	O
HFD	O
+	O
inulin	O
.	O
These	O
differences	O
appear	O
largely	O
due	O
to	O
dietary	O
fiber	O
specific	O
responses	O
at	O
the	O
OTU	O
level	O
(	O
Supplementary	O
File	O
S4	O
)	O
16	O
.	O
There	O
were	O
also	O
major	O
differences	O
in	O
the	O
proportions	O
of	O
these	O
two	O
phyla	O
and	O
at	O
the	O
OTU	O
level	O
with	O
the	O
four	O
esterified	O
inulin	O
substrates	O
.	O
It	O
has	O
been	O
reported	O
that	O
SCFA	O
differentially	O
affect	O
the	O
growth	O
of	O
members	O
of	O
these	O
two	O
phyla	O
through	O
pH	O
-	O
dependent	O
stress26	O
.	O
However	O
,	O
there	O
is	O
no	O
evidence	O
that	O
these	O
major	O
differences	O
in	O
cecal	O
bacterial	O
composition	O
differentially	O
affect	O
adiposity	O
apart	O
from	O
decreased	O
weight	O
gain	O
on	O
HFD	O
.	O
There	O
was	O
no	O
significant	O
impact	O
of	O
dietary	O
fibers	O
in	O
GIP	O
or	O
ghrelin	O
(	O
GLP	O
-	O
1	O
levels	O
were	O
undetectable	O
)	O
.	O
However	O
,	O
levels	O
of	O
PYY	O
,	O
leptin	O
,	O
insulin	O
and	O
resistin	O
differed	O
in	O
HFD	O
+	O
DF	O
compared	O
to	O
HFD	O
fed	O
mice	O
.	O
There	O
were	O
no	O
consistent	O
patterns	O
observed	O
in	O
observed	O
significant	O
differences	O
with	O
consumption	O
of	O
the	O
different	O
fibers	O
.	O
Leptin	O
levels	O
were	O
significantly	O
higher	O
in	O
mice	O
fed	O
HFD	O
+	O
inulinA	O
compared	O
to	O
HFD	O
+	O
bglucan	O
only	O
.	O
While	O
there	O
was	O
some	O
indication	O
that	O
HFD	O
+	O
bglucan	O
had	O
significantly	O
higher	O
levels	O
of	O
PYY	O
compared	O
to	O
HFD	O
+	O
inulinA	O
and	O
HFD	O
+	O
inulinP	O
.	O
However	O
,	O
notably	O
PYY	O
plasma	O
levels	O
were	O
observed	O
to	O
be	O
variable	O
in	O
mice	O
.	O

While	O
there	O
was	O
a	O
tendency	O
for	O
increased	O
PYY	O
this	O
was	O
only	O
significantly	O
increased	O
in	O
HFD	O
+	O
bglucan	O
,	O
HFD	O
+	O
inul	O
and	O
HFD	O
+	O
inulin	O
B	O
fed	O
mice	O
(	O
Fig	O
.	O
2D	O
)	O
.	O
This	O
is	O
in	O
contrast	O
to	O
reports	O
which	O
have	O
reported	O
SCFA	O
upregulation	O
of	O
PYY4	O
.	O
However	O
,	O
there	O
were	O
no	O
differences	O
in	O
cumulative	O
food	O
intake	O
between	O
HFD	O
and	O
HFD	O
+	O
DF	O
mice	O
(	O
Fig	O
.	O
1D	O
)	O
.	O
Likewise	O
there	O
was	O
no	O
transcriptional	O
response	O
of	O
FFAR3	O
in	O
cecum	O
(	O
measured	O
by	O
microarray	O
analysis	O
)	O
in	O
response	O
to	O
dietary	O
fibers	O
(	O
GEO	O
Accession	O
no	O
.	O
GSE106375	O
)	O
,	O
while	O
FFAR2	O
was	O
only	O
down	O
-	O
regulated	O
in	O
HFD	O
+	O
inul	O
+	O
PB	O
mice	O
.	O
This	O
is	O
not	O
definitive	O
evidence	O
,	O
but	O
may	O
indicate	O
that	O
these	O
pathways	O
are	O
not	O
a	O
major	O
influence	O
on	O
the	O
effects	O
of	O
dietary	O
fiber	O
on	O
adiposity	O
.	O
Levels	O
of	O
leptin	O
,	O
insulin	O
and	O
resistin	O
are	O
directly	O
associated	O
with	O
adiposity	O
and	O
HFD	O
+	O
DF	O
mice	O
with	O
lower	O
adiposity	O
consequently	O
have	O
lower	O
levels	O
of	O
these	O
hormones	O
.	O
In	O
contrast	O
to	O
the	O
diet	O
specific	O
differences	O
in	O
cecal	O
bacterial	O
profiles	O
,	O
the	O
transcriptional	O
responses	O
in	O
cecum	O
and	O
liver	O
are	O
similar	O
.	O
Nonetheless	O
,	O
there	O
were	O
instances	O
of	O
differences	O
in	O
expression	O
of	O
selected	O
gene	O
targets	O
associated	O
with	O
individual	O
fiber	O
diets	O
,	O
but	O
these	O
did	O
not	O
show	O
any	O
consistent	O
pattern	O
that	O
would	O
permit	O
speculation	O
on	O
potential	O
physiological	O
outcomes	O
.	O
Microarray	O
analysis	O
indicated	O
that	O
many	O
genes	O
and	O
pathways	O
modulated	O
in	O
response	O
to	O
dietary	O
fibers	O
are	O
epithelial	O
,	O
with	O
a	O
number	O
involved	O
in	O
gut	O
barrier	O
function	O
(	O
Fig	O
.	O
5	O
)	O
.	O
The	O
gut	O
barrier	O
protects	O
against	O
ingress	O
of	O
harmful	O
agents	O
while	O
allowing	O
nutrient	O
absorption	O
.	O
The	O
myriad	O
genes	O
generating	O
the	O
proteins	O
required	O
to	O
maintain	O
healthy	O
gut	O
barrier	O
function	O
is	O
still	O
not	O
fully	O
understood	O
.	O
However	O
,	O
there	O
are	O
indications	O
that	O
the	O
observed	O
changes	O
in	O
gut	O
barrier	O
gene	O
expression	O
in	O
the	O
current	O
study	O
are	O
favourable	O
to	O
improved	O
barrier	O
function	O
.	O
The	O
altered	O
expression	O
of	O
claudins	O
have	O
potential	O
to	O
alter	O
trans	O
-	O
epithelial	O
and	O
strand	O
tightness	O
of	O
tight	O
junctions27	O
.	O

Mucins	O
are	O
another	O
complex	O
group	O
of	O
molecules	O
known	O
to	O
be	O
important	O
components	O
of	O
the	O
gut	O
barrier	O
with	O
Muc2	O
deficiency	O
,	O
consistently	O
expressed	O
at	O
lower	O
levels	O
in	O
fiber	O
fed	O
mice	O
in	O
our	O
study	O
,	O
reported	O
to	O
protect	O
mice	O
from	O
diet	O
-	O
induced	O
fatty	O
liver	O
disease	O
and	O
obesity28	O
.	O
GO	O
also	O
indicated	O
higher	O
levels	O
of	O
anion	O
transport	O
genes	O
,	O
including	O
SLC	O
transporters	O
which	O
are	O
widely	O
expressed	O
in	O
epithelia	O
,	O
particularly	O
associated	O
with	O
barrier	O
function29	O
.	O
Both	O
SLC5A8	O
and	O
SLC26A3	O
,	O
were	O
elevated	O
in	O
cecum	O
(	O
Fig	O
.	O
5	O
/	O
Supplementary	O
File	O
S7	O
,	O
GEO	O
Accession	O
no	O
.	O
GSE106375	O
)	O
in	O
response	O
to	O
HFD	O
+	O
inul	O
and	O
HFD	O
+	O
inul	O
PB	O
,	O
and	O
are	O
tumour	O
suppressors30	O
,	O
31	O
with	O
SLC5A8	O
also	O
linked	O
to	O
butyrate	O
and	O
propionate	O
uptake32	O
.	O
These	O
results	O
,	O
together	O
with	O
the	O
associated	O
evidence	O
of	O
reduced	O
inflammation	O
in	O
the	O
liver	O
,	O
leads	O
us	O
to	O
conclude	O
that	O
observed	O
changes	O
in	O
gut	O
epithelial	O
genes	O
favour	O
an	O
improvement	O
in	O
gut	O
barrier	O
function	O
.	O
SAA1	O
and	O
SAA2	O
,	O
the	O
main	O
acute	O
phase	O
isoforms	O
of	O
serum	O
amyloid	O
A	O
,	O
are	O
expressed	O
by	O
the	O
lumenal	O
surface	O
epithelium	O
lining	O
the	O
colon32	O
and	O
are	O
thought	O
to	O
provide	O
an	O
anti	O
-	O
bacterial	O
role	O
,	O
assisting	O
in	O
maintenance	O
of	O
epithelial	O
immune	O
homeostasis32	O
.	O
The	O
encoded	O
proteins	O
are	O
secreted	O
into	O
the	O
lumen	O
,	O
play	O
a	O
role	O
in	O
innate	O
recognition	O
of	O
Gram	O
-	O
negative	O
bacteria	O
,	O
reduce	O
bacterial	O
viability32	O
,	O
33	O
and	O
are	O
linked	O
to	O
reduced	O
risk	O
of	O
inflammatory	O
bowel	O
disease32	O
.	O
SAA1	O
and	O
SAA2	O
were	O
downregulated	O
in	O
liver	O
in	O
response	O
to	O
HFD	O
+	O
DF	O
.	O
HFD	O
increases	O
the	O
inflammatory	O
response	O
in	O
liver	O
with	O
an	O
increase	O
in	O
circulating	O
SAA20	O
.	O
The	O
reduced	O
inflammatory	O
response	O
in	O
liver	O
is	O
evidenced	O
by	O
lower	O
levels	O
of	O
SAA1	O
and	O
SAA2	O
.	O
Studies	O
have	O
shown	O
that	O
damaged	O
gut	O
epithelium	O
results	O
in	O
elevated	O
levels	O
of	O
circulating	O
SAA	O
most	O
likely	O
derived	O
from	O
liver34	O
.	O
Thus	O
,	O
the	O
opposing	O
effects	O
of	O
dietary	O
fibers	O
on	O
SAA1	O
and	O
SAA2	O
in	O
cecum	O
and	O
liver	O
may	O
be	O
linked	O
(	O
Fig	O
.	O
5E	O
)	O
.	O

Dietary	O
fibers	O
upregulate	O
Tex19	O
.	O
1	O
which	O
has	O
restricted	O
expression	O
in	O
pluripotent	O
stem	O
cells35	O
and	O
inhibits	O
retrotransposons36	O
.	O
Tex19	O
.	O
1	O
potentially	O
stabilises	O
the	O
gut	O
stem	O
cell	O
genome	O
during	O
replication	O
and	O
renewal	O
of	O
the	O
gut	O
epithelium	O
,	O
linking	O
dietary	O
fiber	O
intake	O
to	O
anticancer	O
effects	O
.	O
There	O
was	O
a	O
smaller	O
subset	O
of	O
gene	O
changes	O
in	O
common	O
in	O
the	O
response	O
to	O
consumption	O
of	O
dietary	O
fibers	O
in	O
the	O
liver	O
compared	O
to	O
those	O
identified	O
in	O
the	O
cecum	O
measured	O
by	O
microarray	O
analysis	O
.	O
Enho	O
was	O
chosen	O
for	O
further	O
analysis	O
following	O
reports	O
that	O
its	O
encoded	O
protein	O
,	O
adropin	O
,	O
is	O
a	O
hormone	O
involved	O
in	O
energy	O
homeostasis	O
and	O
lipid	O
metabolism	O
,	O
with	O
adropin	O
deficiency	O
associated	O
with	O
obesity	O
and	O
insulin	O
resistance36	O
.	O
The	O
higher	O
level	O
of	O
Enho	O
expression	O
in	O
liver	O
is	O
seen	O
with	O
all	O
dietary	O
fibers	O
tested	O
and	O
may	O
be	O
an	O
important	O
factor	O
in	O
reducing	O
adiposity	O
.	O
Nonetheless	O
,	O
this	O
was	O
not	O
reflected	O
in	O
higher	O
levels	O
of	O
liver	O
adropin	O
,	O
the	O
protein	O
encoded	O
by	O
Enho	O
.	O
It	O
has	O
been	O
reported	O
that	O
Enho	O
expression	O
in	O
liver	O
results	O
in	O
increased	O
circulating	O
adropin37	O
and	O
it	O
may	O
be	O
that	O
the	O
elevated	O
Enho	O
expression	O
in	O
the	O
liver	O
may	O
produce	O
increased	O
adropin	O
secretion	O
while	O
liver	O
adropin	O
levels	O
remain	O
stable	O
(	O
Fig	O
.	O
4C	O
)	O
.	O
Adropin	O
is	O
involved	O
in	O
energy	O
homeostasis	O
and	O
lipid	O
metabolism	O
,	O
with	O
deficiency	O
associated	O
with	O
obesity	O
and	O
insulin	O
resistance36	O
.	O
Treatment	O
with	O
synthetic	O
adropin	O
reduces	O
weight	O
gain36	O
,	O
38	O
in	O
agreement	O
with	O
prevention	O
of	O
weight	O
gain	O
in	O
HFD	O
+	O
DF	O
mice	O
showing	O
higher	O
levels	O
of	O
liver	O
Enho	O
when	O
compared	O
to	O
HFD	O
fed	O
mice	O
.	O
However	O
,	O
Enho	O
gene	O
expression	O
was	O
not	O
altered	O
in	O
HFD	O
compared	O
to	O
LFD	O
mice	O
,	O
indicating	O
that	O
the	O
response	O
was	O
a	O
consequence	O
of	O
dietary	O
fiber	O
intake	O
.	O
Supporting	O
our	O
findings	O
,	O
LFD	O
mice	O
were	O
reported	O
to	O
have	O
reduced	O
levels	O
of	O
adropin	O
compared	O
to	O
mice	O
fed	O
chow	O
,	O
which	O
is	O
a	O
rich	O
source	O
of	O
fiber36	O
.	O
The	O
consequences	O
of	O
increased	O
Enho	O
expression	O
specifically	O
in	O
the	O
liver	O
may	O
form	O
the	O
basis	O
for	O
explaining	O
the	O
beneficial	O
effects	O
of	O
dietary	O
fibers	O
on	O
metabolic	O
health	O
.	O
Despite	O
high	O
levels	O
of	O
Enho	O
expression	O
in	O
cecum	O
(	O
detected	O
by	O
microarray	O
)	O
it	O
is	O
not	O
differentially	O
expressed	O
in	O
response	O
to	O
the	O
supplementation	O
of	O
the	O
HFD	O
with	O
dietary	O
fibers	O
.	O

It	O
was	O
noted	O
that	O
changes	O
in	O
other	O
liver	O
targets	O
,	O
such	O
as	O
Lcn2	O
(	O
Lipocalin	O
2	O
)	O
and	O
Itagx	O
(	O
integrin	O
subunit	O
alpha	O
X	O
)	O
,	O
which	O
are	O
expressed	O
at	O
lower	O
levels	O
in	O
the	O
microarray	O
analysis	O
of	O
HFD	O
+	O
inulin	O
and	O
HFD	O
+	O
inulPB	O
compared	O
to	O
HFD	O
provide	O
further	O
support	O
for	O
the	O
protective	O
effect	O
of	O
dietary	O
fibers	O
on	O
liver	O
.	O
Lcn2	O
and	O
Itagx	O
are	O
reported	O
to	O
be	O
key	O
inflammatory	O
markers	O
with	O
activation	O
of	O
these	O
markers	O
indicative	O
of	O
metabolic	O
and	O
inflammatory	O
stress	O
in	O
the	O
liver39	O
–	O
41	O
.	O
This	O
also	O
further	O
substantiates	O
our	O
contention	O
that	O
dietary	O
fibers	O
may	O
improve	O
barrier	O
function	O
and	O
protect	O
the	O
liver	O
from	O
the	O
inflammatory	O
effects	O
of	O
consuming	O
a	O
HFD	O
.	O
Our	O
study	O
provides	O
a	O
novel	O
insight	O
on	O
the	O
impact	O
of	O
dietary	O
fiber	O
on	O
the	O
cecal	O
bacteria	O
and	O
host	O
responses	O
to	O
diet	O
-	O
induced	O
obesity	O
,	O
revealing	O
that	O
of	O
the	O
seven	O
dietary	O
fibers	O
tested	O
,	O
all	O
exert	O
a	O
similar	O
effect	O
on	O
reducing	O
adiposity	O
and	O
cecum	O
and	O
liver	O
expression	O
of	O
the	O
selected	O
gene	O
targets	O
.	O
It	O
should	O
be	O
noted	O
however	O
,	O
that	O
consumption	O
of	O
fibers	O
of	O
different	O
particle	O
size	O
have	O
been	O
shown	O
to	O
differentially	O
affect	O
metabolic	O
and	O
inflammatory	O
responses	O
in	O
mice42	O
.	O
Dietary	O
fiber	O
-	O
induced	O
resistance	O
to	O
diet	O
-	O
induced	O
obesity	O
in	O
this	O
study	O
is	O
potentially	O
mediated	O
by	O
the	O
hormone	O
adropin	O
,	O
as	O
indicated	O
by	O
the	O
liver	O
specific	O
increased	O
levels	O
of	O
Enho	O
.	O
Additionally	O
,	O
improved	O
gut	O
barrier	O
function	O
,	O
characterised	O
by	O
regulation	O
of	O
Tex19	O
.	O
1	O
and	O
altered	O
mucins	O
,	O
claudins	O
and	O
epithelial	O
solute	O
transporters	O
is	O
associated	O
with	O
reduced	O
expression	O
of	O
markers	O
of	O
inflammation	O
and	O
accumulation	O
of	O
fat	O
in	O
liver	O
.	O
The	O
studies	O
reported	O
in	O
the	O
present	O
paper	O
were	O
conducted	O
in	O
mice	O
with	O
further	O
studies	O
in	O
humans	O
needed	O
to	O
determine	O
the	O
effects	O
of	O
dietary	O
fibers	O
on	O
modulating	O
obesity	O
.	O
The	O
already	O
known	O
associations	O
of	O
adropin	O
and	O
human	O
health	O
provide	O
a	O
useful	O
focus	O
for	O
further	O
study	O
of	O
translational	O
potential	O
to	O
humans	O
.	O
In	O
conclusion	O
the	O
effects	O
of	O
fiber	O
consumption	O
on	O
a	O
high	O
fat	O
diet	O
has	O
potential	O
implications	O
for	O
health	O
that	O
are	O
apparently	O
not	O
directly	O
related	O
to	O
cecal	O
bacterial	O
community	O
composition	O
,	O
although	O
we	O
cannot	O
exclude	O
the	O
possibility	O
that	O
they	O
may	O
be	O
related	O
to	O
total	O
microbial	O
populations	O
and	O
,	O
or	O
their	O
overall	O
metabolic	O
activity	O
.	O

The	O
animal	B-methodology
studies	I-methodology
were	O
licensed	O
under	O
the	O
Animal	O
(	O
Scientific	O
Procedures	O
)	O
Act	O
of	O
1986	O
and	O
in	O
accordance	O
with	O
the	O
European	O
Directive	O
on	O
the	O
Protection	O
of	O
Animals	O
used	O
for	O
Scientific	O
Purposes	O
2010	O
/	O
63	O
/	O
E	O
following	O
ARRIVE	B-methodology
guidelines	I-methodology
and	O
received	O
approval	O
from	O
the	O
Rowett	O
Institute	O
’	O
s	O
Ethical	O
Review	O
Committee	O
.	O
Male	O
C57BL	O
/	O
6	O
mice	O
,	O
12	O
weeks	O
of	O
age	O
and	O
24	O
–	O
25	O
g	O
in	O
weight	O
(	O
Harlan	O
,	O
Bicester	O
,	O
UK	O
)	O
,	O
were	O
randomly	B-methodology
assigned	I-methodology
to	O
one	O
of	O
nine	O
dietary	O
groups	O
(	O
n	O
=	O
12	O
)	O
and	O
fed	O
,	O
either	O
:	O
1	O
.	O
HFD	O
(	O
high	O
fat	O
diet	O
)	O
(	O
45	O
%	O
of	O
energy	O
from	O
fat	O
)	O
(	O
D12451	O
)	O
2	O
.	O
LFD	O
(	O
low	O
fat	O
diet	O
)	O
(	O
10	O
%	O
fat	O
by	O
energy	O
)	O
(	O
D12450B	O
)	O
,	O
or	O
the	O
HFD	O
where	O
10	O
%	O
of	O
the	O
carbohydrate	O
by	O
weight	O
(	O
5	O
%	O
corn	O
starch	O
,	O
5	O
%	O
cellulose	O
)	O
was	O
replaced	O
by	O
the	O
following	O
dietary	O
fibers	O
:	O
3	O
.	O
beta	O
glucan	O
(	O
HFD	O
+	O
bglucan	O
)	O
(	O
Glucagel	O
,	O
DKSH	O
,	O
Milan	O
Italy	O
)	O
4	O
.	O
pectin	O
(	O
HFD	O
+	O
pectin	O
)	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
Gillingham	O
,	O
UK	O
)	O
5	O
.	O
inulin	O
(	O
Beneo	O
Orafti®	O
HP	O
,	O
DKSH	O
,	O
London	O
UK	O
)	O
6	O
.	O
inulin	O
acetate	O
ester	O
(	O
HFD	O
+	O
inul	O
A	O
)	O
7	O
.	O
inulin	O
propionate	O
ester	O
(	O
HFD	O
+	O
inul	O
P	O
)	O
8	O
.	O
inulin	O
butyrate	O
ester	O
(	O
HFD	O
+	O
inul	O
B	O
)	O
9	O
.	O
5	O
%	O
each	O
of	O
inulin	O
propionate	O
and	O
inulin	O
butyrate	O
ester	O
(	O
HFD	O
+	O
inul	O
PB	O
)	O
(	O
details	O
of	O
diets	O
are	O
provided	O
in	O
Supplementary	O
File	O
S1	O
)	O
for	O
8	O
weeks	O
.	O
The	O
cellulose	O
used	O
in	O
the	O
diets	O
contributes	O
zero	O
calories	O
.	O
Further	O
details	O
of	O
animals	O
,	O
dietary	B-methodology
intervention	I-methodology
and	O
sample	O
collection	O
are	O
provided	O
in	O
Supplementary	O
File	O
S2	O
.	O
Genomic	O
DNA	O
(	O
gDNA	O
)	O
was	O
extracted	O
from	O
the	O
cecum	O
contents	O
using	O
the	O
FastDNA®	O
SPIN	O
Kit	O
for	O
Soil	O
(	O
MP	O
Biomedicals	O
,	O
Illkirch	O
,	O
France	O
)	O
.	O

Total	O
cecal	O
bacterial	O
abundance	O
was	O
estimated	O
following	O
the	O
dietary	B-methodology
interventions	I-methodology
by	O
quantitative	O
PCR	O
and	O
the	O
V3	O
-	O
V4	O
region	O
of	O
bacterial	O
16S	O
rRNA	O
genes	O
were	O
sequenced	O
on	O
the	O
Illumina	O
MiSeq	O
using	O
a	O
v3	O
flow	O
cell	O
with	O
2	O
×	O
300	O
bp	O
paired	O
end	O
reads	O
(	O
full	O
details	O
of	O
the	O
subsequent	O
analysis	O
steps	O
used	O
are	O
available	O
in	O
Supplementary	O
File	O
S2	O
)	O
.	O
Sequencing	O
data	O
generated	O
during	O
this	O
study	O
are	O
available	O
in	O
the	O
SRA	O
database	O
under	O
SRA	O
accession	O
SRP117745	O
(	O
accessible	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
sra	O
/	O
SRP117745	O
)	O
.	O
Hormones	O
were	O
measured	O
in	O
plasma	O
from	O
cardiac	O
puncture	O
(	O
CP	O
)	O
or	O
from	O
hepatic	O
portal	O
vein	O
(	O
HPV	O
)	O
(	O
n	O
=	O
4	O
–	O
8	O
)	O
collected	O
with	O
incorporation	O
of	O
Protease	O
Inhibitor	O
Cocktail	O
for	O
General	O
Use	O
(	O
Sigma	O
cat	O
#	O
P2714	O
)	O
using	O
Millipore	O
’	O
s	O
MILLIPLEX	O
MAP	O
Mouse	O
Metabolic	O
Hormone	O
Magnetic	O
Bead	O
panel	O
(	O
Merck	O
Millipore	O
,	O
Feltham	O
,	O
UK	O
)	O
.	O
Total	O
fat	O
was	O
extracted	O
from	O
left	O
liver	O
lobes	O
based	O
on	O
the	O
method	O
by	O
Folch	O
et	O
al	O
.	O
43	O
and	O
weight	O
of	O
fat	O
per	O
microgram	O
of	O
liver	O
tissue	O
calculated	O
.	O
Total	O
RNA	O
extracted	O
from	O
liver	O
and	O
cecum	O
using	O
an	O
RNeasy	O
Mini	O
Kit	O
(	O
Qiagen	O
,	O
Crawley	O
,	O
UK	O
)	O
was	O
microarrayed	O
with	O
SurePrint	O
G3	O
Mouse	O
GE	O
8	O
×	O
60	O
K	O
Microarray	O
G4852A	O
(	O
Agilent	O
Technologies	O
,	O
UK	O
)	O
(	O
Supplementary	O
File	O
S2	O
)	O
.	O
Data	O
are	O
deposited	O
in	O
NCBI	O
’	O
s	O
Gene	O
Expression	O
Omnibus44	O
and	O
are	O
accessible	O
through	O
GEO	O
Series	O
accession	O
number	O
GSE106375	O
(	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
geo	O
/	O
query	O
/	O
acc	O
.	O
cgi	O
?	O
acc	O
=	O
GSE106375	O
)	O
.	O
Details	O
of	O
statistical	O
analysis	O
of	O
microarray	O
data	O
is	O
provided	O
in	O
Supplementary	O
File	O
S2	O
.	O
Genes	O
showing	O
altered	O
responses	O
to	O
HFD	O
+	O
inulin	O
or	O
HFD	O
+	O
inul	O
PB	O
esters	O
in	O
cecum	O
were	O
identified	O
from	O
microarray	O
analysis	O
and	O
validated	O
using	O
a	O
custom	O
designed	O
RT	O
Profiler	O
PCR	O
Array	O
(	O
Qiagen	O
)	O
(	O
Supplementary	O
File	O
S2	O
)	O
.	O

Complementary	O
cDNA	O
templates	O
for	O
real	O
-	O
time	O
PCR	O
assays	O
were	O
prepared	O
from	O
Superscript	O
II	O
(	O
Invitrogen	O
)	O
reverse	O
transcribed	O
total	O
RNA	O
and	O
Taqman	O
assays	O
were	O
conducted	O
with	O
duplex	O
target	O
and	O
reference	O
gene	O
UBE2D2	O
.	O
(	O
Supplementary	O
File	O
S2	O
)	O
.	O
An	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
kit	O
(	O
Cusabio	O
USA	O
)	O
was	O
used	O
to	O
measure	O
adropin	O
in	O
accordance	O
with	O
manufacturer	O
’	O
s	O
instructions	O
.	O
(	O
Supplementary	O
File	O
S2	O
)	O
.	O
Details	O
of	O
statistical	O
analysis	O
of	O
cecal	O
microbiota	O
sequencing	O
,	O
cecum	O
and	O
liver	O
microarray	O
data	O
can	O
be	O
found	O
in	O
Supplementary	O
File	O
S2	O
.	O
Other	O
data	O
are	O
presented	O
as	O
mean	O
±	O
SEM	O
and	O
analysed	O
using	O
GenStat	O
(	O
Gen	O
Stat®13th	O
Edition	O
(	O
VSN	O
International	O
,	O
Ltd	O
.	O
,	O
Hemel	O
Hempstead	O
,	O
UK	O
)	O
apart	O
from	O
the	O
RT	O
-	O
PCR	O
data	O
which	O
were	O
analysed	O
on	O
a	O
logarithmic	O
(	O
delta	O
CT	O
)	O
scale	O
but	O
presented	O
as	O
fold	O
-	O
changes	O
(	O
anti	O
-	O
logged	O
differences	O
)	O
without	O
standard	O
errors	O
.	O
Comparison	O
of	O
a	O
diet	O
group	O
with	O
the	O
high	O
fat	O
fed	O
group	O
were	O
conducted	O
using	O
t	O
tests	O
.	O
The	O
influence	O
of	O
a	O
single	O
factor	O
and	O
comparisons	O
between	O
the	O
diet	O
groups	O
was	O
tested	O
using	O
one	O
-	O
way	O
ANOVA	O
.	O
Multiple	O
comparisons	O
were	O
tested	O
using	O
either	O
Fisher	O
’	O
s	O
protected	O
or	O
unprotected	O
LSD	O
test	O
.	O
Skewed	O
data	O
was	O
log	O
transformed	O
prior	O
to	O
statistical	O
analysis	O
.	O
This	O
work	O
was	O
supported	O
by	O
a	O
Scottish	O
Government	O
Rural	O
and	O
Environment	O
Science	O
and	O
Analytical	O
Services	O
Division	O
Strategic	O
Partnership	O
.	O
We	O
also	O
acknowledge	O
the	O
support	O
of	O
the	O
Maxwell	O
compute	O
cluster	O
funded	O
by	O
the	O
University	O
of	O
Aberdeen	O
.	O
We	O
thank	O
Gill	O
Campbell	O
for	O
conducting	O
the	O
microarray	O
analysis	O
,	O
Donna	O
Henderson	O
for	O
liver	O
fat	O
analysis	O
(	O
Rowett	O
Institute	O
,	O
University	O
of	O
Aberdeen	O
)	O
and	O
Pete	O
Hedley	O
(	O
James	O
Hutton	O
Institute	O
,	O
Dundee	O
)	O
,	O
for	O
scanning	O
the	O
Agilent	O
arrays	O
.	O
Publisher	O
’	O
s	O
note	O
:	O
Springer	O
Nature	O
remains	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O
J	O
.	O
E	O
.	O
D	O
.	O
,	O
L	O
.	O
M	O
.	O
W	O
.	O
,	O
C	O
.	O
-	O
D	O
.	O
M	O
.	O
,	O
G	O
.	O
M	O
.	O
,	O
D	O
.	O
M	O
.	O
,	O
T	O
.	O
P	O
.	O
,	O
H	O
.	O
J	O
.	O
F	O
.	O
and	O
P	O
.	O
L	O
.	O
participated	O
in	O
study	B-methodology
design	I-methodology
.	O

J	O
.	O
E	O
.	O
D	O
.	O
L	O
.	O
M	O
.	O
W	O
.	O
,	O
C	O
.	O
-	O
D	O
.	O
M	O
.	O
,	O
A	O
.	O
W	O
.	O
,	O
H	O
.	O
J	O
.	O
F	O
.	O
and	O
P	O
.	O
L	O
.	O
wrote	O
the	O
main	O
manuscript	O
text	O
.	O
N	O
.	O
R	O
.	O
,	O
A	O
.	O
J	O
.	O
F	O
.	O
,	O
F	O
.	O
F	O
.	O
conducted	O
experimental	O
procedures	O
,	O
sample	O
and	O
data	O
collection	O
and	O
processing	O
.	O
J	O
.	O
E	O
.	O
D	O
.	O
,	O
C	O
.	O
-	O
D	O
.	O
M	O
.	O
,	O
A	O
.	O
W	O
.	O
,	O
P	O
.	O
L	O
.	O
,	O
S	O
.	O
K	O
.	O
,	O
A	O
.	O
J	O
.	O
F	O
.	O
conducted	O
data	O
analysis	O
and	O
prepared	O
figures	O
and	O
tables	O
.	O
All	O
authors	O
reviewed	O
the	O
manuscript	O
.	O
D	O
.	O
M	O
.	O
and	O
T	O
.	O
P	O
.	O
are	O
named	O
inventors	O
on	O
the	O
patent	O
WO2014020344	O
A1	O

Nutritional	O
Status	O
and	O
Selected	O
Adipokines	O
in	O
Children	O
with	O
Irritable	O
Bowel	O
Syndrome	O
irritable	O
bowel	O
syndrome	O
;	O
leptin	O
;	O
adiponectin	O
;	O
chemerin	O
;	O
omentin	O
-	O
1	O
;	O
children	O
Background	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
nutritional	O
status	O
and	O
serum	O
concentrations	O
of	O
adipokines	O
in	O
children	O
with	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
and	O
healthy	O
controls	O
.	O
We	O
also	O
sought	O
to	O
evaluate	O
their	O
relation	O
to	O
metabolic	O
parameters	O
.	O
Methods	O
:	O
We	O
studied	O
33	O
IBS	O
patients	O
(	O
11	O
girls	O
,	O
22	O
boys	O
)	O
aged	O
5	O
–	O
17	O
years	O
and	O
30	O
healthy	O
age	O
-	O
matched	O
controls	O
(	O
11	O
girls	O
,	O
19	O
boys	O
)	O
.	O
The	O
analysis	O
included	O
anthropometric	O
measurements	O
,	O
body	O
composition	O
parameter	O
measurements	O
using	O
bioimpedance	O
,	O
and	O
biochemical	O
tests	O
and	O
measurements	O
of	O
serum	O
concentrations	O
of	O
leptin	O
,	O
adiponectin	O
,	O
chemerin	O
,	O
and	O
omentin	O
-	O
1	O
.	O
Results	O
:	O
The	O
results	O
of	O
the	O
anthropometric	O
measurements	O
were	O
comparable	O
between	O
the	O
patients	O
and	O
the	O
controls	O
.	O
The	O
patients	O
had	O
higher	O
triglycerides	O
,	O
HOMA	O
-	O
IRs	O
,	O
and	O
chemerin	O
concentrations	O
than	O
the	O
healthy	O
subjects	O
.	O
The	O
HDL	O
cholesterol	O
and	O
omentin	O
-	O
1	O
levels	O
were	O
lower	O
than	O
in	O
the	O
controls	O
.	O
Leptin	O
and	O
adiponectin	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
groups	O
.	O
An	O
analysis	O
of	O
the	O
receiver	O
operator	O
curves	O
(	O
ROCs	O
)	O
showed	O
that	O
serum	O
concentrations	O
of	O
chemerin	O
≥	O
232	O
.	O
8	O
ng	O
/	O
mL	O
had	O
30	O
%	O
sensitivity	O
and	O
87	O
%	O
specificity	O
when	O
they	O
were	O
used	O
to	O
differentiate	O
between	O
children	O
with	O
IBS	O
and	O
healthy	O
subjects	O
.	O
In	O
the	O
case	O
of	O
serum	O
omentin	O
-	O
1	O
concentrations	O
≤	O
279	O
.	O
4	O
ng	O
/	O
mL	O
,	O
the	O
sensitivity	O
and	O
specificity	O
were	O
60	O
%	O
and	O
80	O
%	O
,	O
respectively	O
.	O
Conclusions	O
:	O
The	O
nutritional	O
status	O
of	O
children	O
with	O
IBS	O
did	O
not	O
differ	O
from	O
that	O
of	O
the	O
healthy	O
controls	O
.	O
We	O
found	O
significant	O
differences	O
in	O
serum	O
chemerin	O
and	O
omentin	O
-	O
1	O
concentrations	O
between	O
IBS	O
patients	O
and	O
healthy	O
children	O
.	O
These	O
adipokines	O
could	O
be	O
used	O
as	O
IBS	O
biomarkers	O
as	O
they	O
demonstrate	O
good	O
specificity	O
and	O
moderate	O
sensitivity	O
.	O
The	O
serum	O
concentrations	O
of	O
chemerin	O
and	O
omentin	O
-	O
1	O
in	O
IBS	O
patients	O
were	O
related	O
to	O
nutritional	O
status	O
and	O
insulin	O
resistance	O
.	O

Irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
is	O
one	O
of	O
the	O
most	O
common	O
functional	O
disorders	O
of	O
the	O
gastrointestinal	O
tract	O
(	O
GI	O
)	O
,	O
and	O
it	O
is	O
accompanied	O
by	O
abdominal	O
pain	O
and	O
defecation	O
disorders	O
,	O
with	O
no	O
accompanying	O
organic	O
changes	O
[	O
1	O
,	O
2	O
]	O
.	O
Its	O
prevalence	O
is	O
increasing	O
worldwide	O
and	O
is	O
now	O
estimated	O
to	O
range	O
from	O
9	O
to	O
23	O
%	O
in	O
the	O
general	O
population	O
[	O
3	O
]	O
.	O
The	O
etiopathogenesis	O
of	O
this	O
condition	O
remains	O
unclear	O
,	O
but	O
factors	O
taken	O
into	O
consideration	O
include	O
motoric	O
disorders	O
of	O
the	O
GI	O
tract	O
,	O
visceral	O
hypersensitivity	O
,	O
disorders	O
of	O
the	O
gut	O
–	O
brain	O
axis	O
,	O
genetics	O
,	O
immunology	O
,	O
diet	O
,	O
and	O
changes	O
in	O
the	O
microbiome	O
[	O
4	O
]	O
.	O
Among	O
the	O
above	O
-	O
mentioned	O
factors	O
,	O
food	O
and	O
nutritional	O
status	O
are	O
associated	O
with	O
symptom	O
onset	O
or	O
exacerbation	O
in	O
a	O
significant	O
proportion	O
of	O
patients	O
;	O
however	O
,	O
the	O
role	O
of	O
diet	O
in	O
the	O
pathogenesis	O
of	O
functional	O
gastrointestinal	O
disorders	O
(	O
FGID	O
)	O
is	O
poorly	O
understood	O
[	O
5	O
]	O
.	O
Most	O
clinical	B-methodology
studies	I-methodology
have	O
demonstrated	O
that	O
excessive	O
body	O
weight	O
and	O
excessive	O
fatness	O
are	O
common	O
in	O
children	O
with	O
IBS	O
[	O
6	O
,	O
7	O
,	O
8	O
]	O
,	O
and	O
obesity	O
is	O
a	O
predictor	O
of	O
poor	O
outcomes	O
and	O
disability	O
at	O
long	O
-	O
term	O
follow	O
-	O
up	O
in	O
children	O
with	O
abdominal	O
pain	O
-	O
related	O
FGIDs	O
[	O
9	O
]	O
.	O
However	O
,	O
recent	O
data	O
from	O
a	O
community	O
-	O
based	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
study	I-methodology
did	O
not	O
confirm	O
these	O
observations	O
[	O
10	O
]	O
.	O
One	O
of	O
the	O
most	O
intensively	O
studied	O
hypotheses	O
is	O
that	O
visceral	O
hypersensitivity	O
is	O
related	O
to	O
immune	O
system	O
activation	O
and	O
low	O
-	O
grade	O
inflammation	O
in	O
the	O
walls	O
of	O
the	O
intestine	O
[	O
2	O
,	O
11	O
]	O
.	O
Although	O
IBS	O
and	O
IBD	O
are	O
considered	O
to	O
be	O
two	O
different	O
conditions	O
,	O
some	O
processes	O
may	O
be	O
common	O
in	O
both	O
of	O
them	O
.	O
Recently	O
,	O
studies	O
have	O
investigated	O
the	O
participation	O
of	O
hormones	O
of	O
adipose	O
tissue	O
in	O
the	O
pathogenesis	O
of	O
IBD	O
.	O
Changes	O
in	O
the	O
expression	O
of	O
adipokines	O
by	O
the	O
mesenteric	O
adipose	O
tissue	O
and	O
their	O
serum	O
concentrations	O
may	O
impact	O
the	O
immunological	O
,	O
neuroendocrine	O
,	O
and	O
lymphatic	O
systems	O
,	O
as	O
well	O
as	O
the	O
mucosal	O
barrier	O
[	O
12	O
,	O
13	O
]	O
.	O
In	O
contrast	O
to	O
IBD	O
,	O
research	O
concerning	O
adipokines	O
in	O
IBS	O
is	O
sparse	O
and	O
has	O
only	O
examined	O
adults	O
.	O

There	O
are	O
conflicting	O
results	O
in	O
related	O
studies	O
,	O
most	O
of	O
which	O
have	O
investigated	O
leptin	O
and	O
adiponectin	O
[	O
14	O
,	O
15	O
,	O
16	O
,	O
17	O
,	O
18	O
,	O
19	O
,	O
20	O
]	O
.	O
Considering	O
the	O
suggested	O
relation	O
of	O
IBS	O
with	O
low	O
-	O
grade	O
inflammation	O
of	O
the	O
intestinal	O
walls	O
,	O
disorders	O
in	O
adipokine	O
expression	O
and	O
secretion	O
may	O
also	O
occur	O
in	O
this	O
condition	O
[	O
11	O
,	O
21	O
]	O
.	O
Altered	O
adipokine	O
concentrations	O
in	O
IBS	O
patients	O
may	O
also	O
be	O
related	O
to	O
diet	O
and	O
nutritional	O
status	O
[	O
22	O
,	O
23	O
,	O
24	O
,	O
25	O
]	O
.	O
Since	O
no	O
specific	O
markers	O
to	O
help	O
diagnose	O
IBS	O
have	O
been	O
determined	O
thus	O
far	O
,	O
adipokines	O
may	O
potentially	O
serve	O
this	O
purpose	O
[	O
4	O
,	O
20	O
]	O
.	O
For	O
this	O
study	O
,	O
four	O
adipokines	O
were	O
selected	O
according	O
to	O
their	O
origin	O
and	O
activity	O
:	O
leptin	O
,	O
adiponectin	O
,	O
chemerin	O
,	O
and	O
omentin	O
-	O
1	O
.	O
Leptin	O
is	O
a	O
pleiotropic	O
adipokine	O
produced	O
mainly	O
in	O
white	O
adipose	O
tissue	O
(	O
predominantly	O
subcutaneously	O
)	O
but	O
also	O
in	O
low	O
quantities	O
by	O
the	O
placenta	O
,	O
skeletal	O
muscle	O
,	O
brain	O
,	O
P	O
/	O
D1	O
cells	O
in	O
the	O
stomach	O
,	O
and	O
T	O
cells	O
[	O
26	O
,	O
27	O
]	O
.	O
Apart	O
from	O
influencing	O
lipid	O
and	O
carbohydrate	O
homeostasis	O
,	O
this	O
cytokine	O
influences	O
immune	O
reactions	O
.	O
It	O
stimulates	O
B	O
lymphocytes	O
to	O
produce	O
C	O
-	O
reactive	O
protein	O
and	O
interferon	O
γ	O
[	O
12	O
,	O
26	O
,	O
27	O
,	O
28	O
,	O
29	O
,	O
30	O
,	O
31	O
,	O
32	O
]	O
.	O
Higher	O
leptin	O
concentrations	O
are	O
associated	O
with	O
increased	O
risk	O
of	O
inflammatory	O
and	O
autoimmune	O
diseases	O
[	O
28	O
,	O
30	O
]	O
.	O
More	O
recent	O
data	O
on	O
its	O
anti	O
-	O
inflammatory	O
effects	O
suggest	O
that	O
leptin	O
is	O
an	O
important	O
immune	O
modulator	O
with	O
a	O
wide	O
range	O
of	O
functions	O
,	O
playing	O
a	O
critical	O
role	O
in	O
the	O
pathophysiology	O
of	O
multiple	O
obesity	O
-	O
associated	O
diseases	O
and	O
infections	O
[	O
32	O
]	O
.	O
Adiponectin	O
is	O
a	O
224	O
amino	O
acid	O
protein	O
that	O
is	O
produced	O
by	O
adipocytes	O
of	O
white	O
and	O
brown	O
adipose	O
tissues	O
.	O
The	O
biological	O
role	O
of	O
this	O
adipokine	O
is	O
multifaceted	O
and	O
dependent	O
on	O
its	O
isoform	O
.	O

There	O
are	O
three	O
forms	O
of	O
adiponectin	O
with	O
different	O
molecular	O
weights	O
:	O
a	O
low	O
-	O
molecular	O
-	O
weight	O
complex	O
(	O
LMW	O
)	O
composed	O
of	O
12	O
–	O
18	O
polymer	O
molecules	O
,	O
a	O
middle	O
-	O
molecular	O
-	O
weight	O
complex	O
(	O
MMW	O
)	O
,	O
and	O
a	O
high	O
-	O
molecular	O
-	O
weight	O
complex	O
(	O
HMW	O
)	O
[	O
23	O
,	O
33	O
,	O
34	O
]	O
.	O
The	O
polymeric	O
forms	O
(	O
HMW	O
)	O
are	O
associated	O
with	O
metabolic	O
processes	O
,	O
strongly	O
interacting	O
in	O
the	O
regulation	O
of	O
tissue	O
sensitivity	O
to	O
insulin	O
,	O
glucose	O
uptake	O
,	O
and	O
lipid	O
metabolism	O
.	O
This	O
form	O
of	O
adiponectin	O
exerts	O
anti	O
-	O
diabetic	O
and	O
anti	O
-	O
atherosclerotic	O
effects	O
.	O
HMW	O
complexes	O
seem	O
to	O
activate	O
both	O
anti	O
-	O
inflammatory	O
and	O
pro	O
-	O
inflammatory	O
signaling	O
pathways	O
.	O
LMW	O
complexes	O
have	O
potent	O
anti	O
-	O
inflammatory	O
bioactivity	O
.	O
They	O
stimulate	O
the	O
production	O
of	O
anti	O
-	O
inflammatory	O
cytokines	O
(	O
interleukin	O
10	O
,	O
interleukin	O
-	O
1	O
receptor	O
antagonist	O
)	O
and	O
inhibit	O
the	O
secretion	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
macrophage	O
inflammatory	O
proteins	O
1γ	O
and	O
1β	O
(	O
MIP	O
-	O
1γ	O
and	O
-	O
1β	O
)	O
,	O
MCP	O
-	O
1	O
,	O
and	O
tissue	O
inhibitors	O
of	O
metalloproteinases	O
1	O
and	O
2	O
(	O
TIMP	O
-	O
1	O
and	O
-	O
2	O
)	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
globular	O
adiponectin	O
may	O
have	O
pro	O
-	O
inflammatory	O
effects	O
[	O
29	O
,	O
33	O
,	O
34	O
,	O
35	O
,	O
36	O
,	O
37	O
]	O
.	O
Decreased	O
adiponectin	O
concentrations	O
have	O
been	O
found	O
in	O
various	O
conditions	O
,	O
such	O
as	O
type	O
2	O
diabetes	O
,	O
obesity	O
,	O
and	O
metabolic	O
syndrome	O
,	O
while	O
they	O
are	O
increased	O
in	O
chronic	O
kidney	O
disease	O
,	O
type	O
1	O
diabetes	O
,	O
lipodystrophy	O
,	O
anorexia	O
nervosa	O
,	O
IBD	O
,	O
rheumatoid	O
arthritis	O
,	O
and	O
other	O
conditions	O
[	O
34	O
,	O
35	O
,	O
36	O
]	O
.	O
Adiponectin	O
and	O
leptin	O
levels	O
are	O
independently	O
associated	O
with	O
the	O
development	O
of	O
metabolic	O
syndrome	O
,	O
diabetes	O
mellitus	O
type	O
II	O
,	O
and	O
cardiovascular	O
diseases	O
.	O
However	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
adiponectin	O
/	O
leptin	O
ratio	O
(	O
A	O
/	O
L	O
)	O
is	O
more	O
strongly	O
correlated	O
with	O
insulin	O
resistance	O
,	O
metabolic	O
syndrome	O
,	O
carotid	O
intima	O
-	O
media	O
thickness	O
,	O
and	O
an	O
“	O
at	O
-	O
risk	O
phenotype	O
”	O
than	O
individual	O
hormones	O
.	O

The	O
A	O
/	O
L	O
ratio	O
can	O
be	O
considered	O
a	O
practical	O
marker	O
of	O
adipose	O
tissue	O
dysfunction	O
when	O
identifying	O
persons	O
at	O
increased	O
risk	O
of	O
cardiometabolic	O
diseases	O
[	O
38	O
]	O
.	O
Chemerin	O
is	O
produced	O
by	O
adipocytes	O
and	O
stroma	O
cells	O
in	O
adipose	O
tissue	O
,	O
and	O
it	O
generally	O
shows	O
pro	O
-	O
inflammatory	O
activity	O
[	O
39	O
,	O
40	O
,	O
41	O
,	O
42	O
,	O
43	O
]	O
.	O
However	O
,	O
in	O
certain	O
circumstances	O
,	O
it	O
inhibits	O
inflammation	O
by	O
stimulating	O
adiponectin	O
production	O
and	O
decreasing	O
the	O
secretion	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
[	O
40	O
,	O
41	O
]	O
.	O
Elevated	O
chemerin	O
concentrations	O
are	O
present	O
in	O
chronic	O
inflammatory	O
diseases	O
and	O
in	O
states	O
of	O
insulin	O
resistance	O
,	O
as	O
this	O
adipokine	O
has	O
a	O
negative	O
impact	O
on	O
carbohydrate	O
metabolism	O
[	O
40	O
,	O
41	O
,	O
42	O
]	O
.	O
Omentin	O
-	O
1	O
is	O
secreted	O
by	O
the	O
stromal	O
cells	O
of	O
visceral	O
adipose	O
tissue	O
and	O
endothelial	O
cells	O
[	O
44	O
,	O
45	O
]	O
.	O
Although	O
its	O
biological	O
activity	O
is	O
still	O
not	O
fully	O
understood	O
,	O
it	O
has	O
been	O
shown	O
to	O
increase	O
the	O
insulin	O
sensitivity	O
of	O
tissues	O
[	O
46	O
]	O
and	O
have	O
anti	O
-	O
inflammatory	O
effects	O
[	O
45	O
,	O
47	O
]	O
.	O
Decreased	O
omentin	O
-	O
1	O
levels	O
have	O
been	O
found	O
in	O
chronic	O
inflammatory	O
diseases	O
and	O
in	O
states	O
of	O
insulin	O
resistance	O
[	O
45	O
,	O
48	O
,	O
49	O
]	O
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
assess	O
the	O
nutritional	O
status	O
and	O
concentrations	O
of	O
leptin	O
,	O
adiponectin	O
,	O
omentin	O
-	O
1	O
,	O
and	O
chemerin	O
in	O
children	O
with	O
IBS	O
.	O
The	O
results	O
were	O
compared	O
to	O
those	O
of	O
a	O
healthy	O
control	B-methodology
group	I-methodology
.	O
The	O
association	O
with	O
clinical	O
and	O
laboratory	O
parameters	O
was	O
also	O
investigated	O
.	O
This	O
investigation	O
was	O
approved	O
by	O
the	O
Bioethical	O
Committee	O
of	O
the	O
Medical	O
University	O
of	O
Silesia	O
in	O
Katowice	O
,	O
Poland	O
(	O
KNW	O
/	O
0022	O
/	O
KB1	O
/	O
69	O
/	O
13	O
dated	O
25	O
June	O
2013	O
)	O
.	O
Written	O
consent	O
was	O
obtained	O
from	O
all	O
caregivers	O
of	O
the	O
participants	O
and	O
all	O
children	O
aged	O
16	O
years	O
or	O
older	O
.	O
For	O
the	O
study	O
group	O
,	O
we	O
enrolled	O
33	O
children	O
(	O
11	O
girls	O
and	O
22	O
boys	O
)	O
aged	O
5	O
–	O
18	O
years	O
who	O
were	O
diagnosed	O
with	O
IBS	O
based	O
on	O
the	O
Rome	O
III	O
Criteria	O
that	O
were	O
in	O
force	O
at	O
the	O
time	O
when	O
the	O
study	O
was	O
conducted	O
.	O
Chronic	O
diseases	O
were	O
ruled	O
out	O
in	O
these	O
individuals	O
based	O
on	O
their	O
medical	O
history	O
and	O
clinical	O
and	O
laboratory	O
findings	O
.	O

They	O
had	O
no	O
alarming	O
symptoms	O
affecting	O
the	O
gastrointestinal	O
tract	O
(	O
weight	O
loss	O
,	O
fever	O
of	O
an	O
unknown	O
cause	O
,	O
GI	O
bleeding	O
,	O
night	O
-	O
time	O
symptoms	O
,	O
perianal	O
changes	O
,	O
prolonged	O
vomiting	O
,	O
dysphagia	O
,	O
arthritis	O
,	O
growth	O
or	O
sexual	O
maturation	O
retardation	O
,	O
positive	O
family	O
history	O
of	O
cancer	O
or	O
IBD	O
,	O
organic	O
disease	O
of	O
the	O
GI	O
tract	O
)	O
.	O
They	O
had	O
no	O
acute	O
infections	O
within	O
14	O
days	O
prior	O
to	O
the	O
study	O
and	O
took	O
no	O
medication	O
or	O
diet	O
supplements	O
either	O
chronically	O
or	O
incidentally	O
during	O
the	O
month	O
prior	O
to	O
the	O
study	O
.	O
Pregnancy	O
was	O
also	O
an	O
exclusion	O
criterion	O
.	O
These	O
criteria	O
were	O
met	O
by	O
33	O
patients	O
(	O
11	O
girls	O
;	O
22	O
boys	O
)	O
,	O
of	O
whom	O
26	O
(	O
78	O
.	O
8	O
%	O
)	O
had	O
IBS	O
with	O
diarrhea	O
(	O
IBS	O
-	O
D	O
)	O
,	O
4	O
(	O
12	O
.	O
1	O
%	O
)	O
had	O
constipation	O
(	O
IBS	O
-	O
C	O
)	O
,	O
and	O
3	O
(	O
9	O
.	O
1	O
%	O
)	O
had	O
alternating	O
diarrhea	O
and	O
constipation	O
(	O
IBS	O
-	O
DC	O
)	O
.	O
The	O
general	O
characteristics	O
of	O
the	O
group	O
of	O
IBS	O
patients	O
are	O
shown	O
in	O
Table	O
1	O
.	O
The	O
control	B-methodology
group	I-methodology
consisted	O
of	O
30	O
healthy	O
children	O
(	O
11	O
girls	O
;	O
19	O
,	O
boys	O
)	O
aged	O
5	O
–	O
17	O
years	O
who	O
were	O
recruited	O
from	O
patients	O
attending	O
the	O
Pediatric	O
Surgical	O
Out	O
-	O
patient	O
Clinic	O
in	O
Clinical	O
Hospital	O
No	O
1	O
in	O
Zabrze	O
,	O
Poland	O
.	O
These	O
individuals	O
were	O
seen	O
for	O
control	O
visits	O
after	O
the	O
treatment	O
of	O
minor	O
traumas	O
,	O
such	O
as	O
joint	O
dislocations	O
,	O
bruises	O
,	O
and	O
superficial	O
wounds	O
.	O
The	O
exclusion	B-methodology
criteria	I-methodology
were	O
the	O
following	O
:	O
any	O
chronic	O
diseases	O
,	O
acute	O
infection	O
in	O
the	O
14	O
days	O
before	O
the	O
study	O
,	O
medication	O
or	O
ingestion	O
of	O
diet	O
supplements	O
chronically	O
or	O
incidentally	O
one	O
month	O
before	O
the	O
study	O
,	O
and	O
pregnancy	O
.	O
Data	O
describing	O
the	O
control	B-methodology
group	I-methodology
are	O
presented	O
in	O
Table	O
1	O
.	O
The	O
patient	O
and	O
control	O
groups	O
were	O
physically	O
examined	O
,	O
and	O
detailed	O
medical	O
history	O
was	O
recorded	O
.	O
Anthropometric	O
measurements	O
were	O
conducted	O
in	O
the	O
morning	O
after	O
fasting	O
and	O
urinating	O
in	O
a	O
well	O
-	O
lit	O
and	O
heated	O
room	O
by	O
the	O
same	O
person	O
.	O
The	O
mean	O
of	O
three	O
measurements	O
was	O
calculated	O
for	O
each	O
parameter	O
.	O
Height	O
was	O
measured	O
using	O
an	O
anthropometer	O
(	O
GPM	O
,	O
Switzerland	O
)	O
in	O
a	O
relaxed	O
standing	O
position	O
,	O
without	O
excessive	O
straightening	O
and	O
with	O
the	O
subject	O
’	O
s	O
head	O
positioned	O
in	O
the	O
ocular	O
-	O
auricular	O
plane	O
(	O
Frankfurt	O
)	O
.	O

Weight	O
was	O
measured	O
using	O
a	O
medical	O
scale	O
and	O
used	O
to	O
calculate	O
body	O
mass	O
index	O
(	O
BMI	O
=	O
(	O
body	O
weight	O
(	O
kg	O
)	O
)	O
/	O
(	O
height	O
(	O
m	O
)	O
2	O
)	O
)	O
.	O
Weight	O
,	O
height	O
,	O
and	O
BMI	O
were	O
expressed	O
as	O
standard	O
deviation	O
scores	O
(	O
SDSs	O
)	O
for	O
age	O
and	O
gender	O
,	O
which	O
were	O
calculated	O
using	O
reference	O
data	O
published	O
by	O
Palczewska	O
et	O
al	O
.	O
[	O
50	O
]	O
.	O
Waist	O
and	O
hip	O
circumferences	O
were	O
measured	O
in	O
a	O
relaxed	O
standing	O
position	O
using	O
a	O
meter	O
after	O
emptying	O
the	O
bladder	O
.	O
The	O
data	O
were	O
used	O
to	O
calculate	O
the	O
waist	O
-	O
to	O
-	O
hip	O
ratio	O
(	O
WHR	O
=	O
waist	O
circumference	O
(	O
cm	O
)	O
/	O
hip	O
circumference	O
(	O
cm	O
)	O
)	O
[	O
51	O
]	O
.	O
Blood	O
was	O
drawn	O
for	O
laboratory	O
testing	O
between	O
8	O
and	O
9	O
a	O
.	O
m	O
.	O
after	O
12	O
h	O
of	O
fasting	O
.	O
Serum	O
samples	O
were	O
obtained	O
after	O
centrifugation	O
(	O
15	O
min	O
,	O
1000×	O
g	O
,	O
in	O
+	O
4	O
°C	O
)	O
and	O
stored	O
at	O
−70	O
°C	O
until	O
analysis	O
.	O
In	O
the	O
case	O
of	O
menstruating	O
girls	O
,	O
blood	O
was	O
drawn	O
in	O
the	O
follicular	O
phase	O
of	O
the	O
menstrual	O
cycle	O
.	O
Concentrations	O
of	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
,	O
glucose	O
,	O
lipids	O
,	O
alanine	O
and	O
aspartate	O
aminotransferases	O
(	O
ALT	O
and	O
AST	O
)	O
,	O
and	O
insulin	O
were	O
measured	O
in	O
the	O
Central	O
Laboratory	O
of	O
Clinical	O
Hospital	O
No	O
1	O
in	O
Zabrze	O
using	O
a	O
Cobas	O
6000	O
analyzer	O
(	O
Cobas	O
c	O
501	O
module	O
;	O
Roche	O
Diagnostics	O
,	O
Basel	O
,	O
Switzerland	O
)	O
.	O
Enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
(	O
ELISAs	O
)	O
were	O
carried	O
out	O
in	O
the	O
same	O
laboratory	O
using	O
commercial	O
tests	O
(	O
BioVendor	O
(	O
Brno	O
,	O
Czech	O
Republic	O
)	O
)	O
to	O
assess	O
leptin	O
,	O
adiponectin	O
,	O
omentin	O
-	O
1	O
,	O
and	O
chemerin	O
concentrations	O
.	O

The	O
limits	O
of	O
detection	O
(	O
LD	O
)	O
and	O
the	O
intra	O
-	O
and	O
inter	O
-	O
assay	O
coefficients	O
of	O
variability	O
(	O
intra	O
-	O
CV	O
and	O
inter	O
-	O
CV	O
)	O
for	O
the	O
sets	O
were	O
as	O
follows	O
:	O
leptin	O
(	O
LD	O
0	O
.	O
2	O
ng	O
/	O
mL	O
,	O
intra	O
-	O
CV	O
7	O
.	O
6	O
%	O
,	O
inter	O
-	O
CV	O
6	O
.	O
7	O
%	O
)	O
,	O
adiponectin	O
(	O
LD	O
0	O
.	O
47	O
ng	O
/	O
mL	O
,	O
intra	O
-	O
CV	O
4	O
.	O
4	O
%	O
,	O
inter	O
-	O
CV	O
6	O
.	O
2	O
%	O
)	O
,	O
omentin	O
-	O
1	O
(	O
LD	O
0	O
.	O
5	O
ng	O
/	O
mL	O
,	O
intra	O
-	O
CV	O
4	O
.	O
1	O
%	O
,	O
inter	O
-	O
CV	O
4	O
.	O
8	O
%	O
)	O
,	O
and	O
chemerin	O
(	O
LD	O
0	O
.	O
1	O
ng	O
/	O
mL	O
,	O
intra	O
-	O
CV	O
7	O
.	O
0	O
%	O
,	O
inter	O
-	O
CV	O
8	O
.	O
3	O
%	O
)	O
.	O
The	O
homeostasis	O
assessment	O
model	O
—	O
insulin	O
resistance	O
(	O
HOMA	O
-	O
IR	O
)	O
was	O
used	O
as	O
the	O
insulin	O
resistance	O
index	O
and	O
calculated	O
based	O
on	O
the	O
glucose	O
and	O
insulin	O
concentrations	O
as	O
HOMA	O
-	O
IR	O
=	O
(	O
insulin	O
(	O
μIU	O
/	O
mL	O
)	O
×	O
glucose	O
(	O
mmol	O
/	O
L	O
)	O
)	O
/	O
22	O
.	O
5	O
.	O
Statistical	O
analyses	O
were	O
performed	O
using	O
Statistica	O
10	O
.	O
0	O
(	O
StatSoft	O
Inc	O
.	O
,	O
Tulsa	O
,	O
OK	O
,	O
USA	O
)	O
.	O
Descriptive	O
statistics	O
for	O
all	O
the	O
variables	O
were	O
calculated	O
,	O
and	O
adequate	O
figures	O
were	O
generated	O
.	O
The	O
Kołmogorow	O
–	O
Smirnow	O
test	O
was	O
used	O
to	O
check	O
the	O
normality	O
of	O
distributions	O
,	O
and	O
Levene	O
’	O
s	O
test	O
was	O
used	O
to	O
verify	O
the	O
variance	O
homogeneity	O
of	O
the	O
variables	O
.	O
Normally	O
distributed	O
variables	O
were	O
comparatively	O
analyzed	O
using	O
a	O
Student	O
’	O
s	O
t	O
-	O
test	O
,	O
ANOVA	O
,	O
and	O
post	O
hoc	O
Tukey	O
’	O
s	O
test	O
.	O
In	O
cases	O
without	O
a	O
distribution	O
and	O
a	O
lack	O
of	O
variance	O
homogeneity	O
,	O
the	O
U	O
Mann	O
–	O
Whitney	O
or	O
Kruskal	O
–	O
Wallis	O
ANOVA	O
was	O
applied	O
.	O
The	O
chi2	O
test	O
with	O
Yates	O
correction	O
was	O
used	O
to	O
analyze	O
the	O
frequency	O
of	O
improper	O
laboratory	O
results	O
.	O
Associations	O
between	O
two	O
variables	O
were	O
estimated	O
using	O
Pearson	O
’	O
s	O
or	O
Spearman	O
’	O
s	O
correlation	O
coefficients	O
depending	O
on	O
the	O
distribution	O
of	O
the	O
continuous	O
variables	O
.	O
Values	O
of	O
adipokine	O
concentrations	O
were	O
corrected	O
using	O
an	O
analysis	O
of	O
covariance	O
(	O
ANCOVA	O
)	O
against	O
clinical	O
parameters	O
that	O
significantly	O
differed	O
between	O
groups	O
.	O

The	O
diagnostic	O
value	O
of	O
adipokine	O
concentrations	O
was	O
determined	O
using	O
the	O
receiver	O
operator	O
curves	O
(	O
ROCs	O
)	O
.	O
The	O
sensitivity	O
,	O
specificity	O
,	O
and	O
efficiency	O
were	O
calculated	O
.	O
The	O
parameter	O
limit	O
values	O
corresponding	O
to	O
the	O
maximum	O
test	O
efficiency	O
were	O
determined	O
for	O
the	O
point	O
where	O
sensitivity	O
and	O
specificity	O
were	O
equal	O
.	O
The	O
results	O
were	O
considered	O
significant	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O
The	O
patients	O
and	O
controls	O
did	O
not	O
differ	O
in	O
terms	O
of	O
age	O
and	O
anthropometric	O
parameters	O
(	O
Table	O
1	O
)	O
.	O
Obesity	O
(	O
BMI	O
SDS	O
>	O
2	O
.	O
0	O
)	O
was	O
similarly	O
common	O
in	O
both	O
groups	O
(	O
15	O
%	O
vs	O
.	O
10	O
%	O
;	O
p	O
=	O
0	O
.	O
87	O
)	O
.	O
There	O
were	O
significant	O
differences	O
in	O
lipid	O
concentrations	O
.	O
Children	O
with	O
IBS	O
had	O
lower	O
mean	O
HDL	O
cholesterol	O
(	O
1	O
.	O
26	O
±	O
0	O
.	O
31	O
mmol	O
/	O
L	O
vs	O
.	O
1	O
.	O
49	O
±	O
0	O
.	O
36	O
mmol	O
/	O
L	O
,	O
p	O
=	O
0	O
.	O
009	O
)	O
and	O
higher	O
triglyceride	O
(	O
TG	O
)	O
(	O
1	O
.	O
05	O
±	O
0	O
.	O
49	O
mmol	O
/	O
L	O
vs	O
.	O
0	O
.	O
68	O
±	O
0	O
.	O
2	O
mmol	O
/	O
L	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
HOMA	O
-	O
IR	O
(	O
2	O
.	O
21	O
±	O
1	O
.	O
5	O
vs	O
.	O
1	O
.	O
57	O
±	O
0	O
.	O
81	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
levels	O
.	O
The	O
mean	O
CRP	O
,	O
glucose	O
,	O
insulin	O
,	O
and	O
total	O
cholesterol	O
concentrations	O
and	O
transaminase	O
activity	O
did	O
not	O
differ	O
between	O
the	O
study	O
and	O
control	O
groups	O
(	O
Table	O
1	O
)	O
.	O
There	O
were	O
no	O
differences	O
in	O
the	O
frequency	O
of	O
metabolic	O
syndrome	O
indicators	O
between	O
groups	O
:	O
CRP	O
>	O
5	O
mg	O
/	O
L	O
(	O
3	O
%	O
vs	O
.	O
3	O
.	O
3	O
%	O
,	O
p	O
=	O
0	O
.	O
51	O
)	O
,	O
glucose	O
≥	O
100	O
mg	O
/	O
dL	O
(	O
3	O
%	O
vs	O
.	O
6	O
.	O
7	O
%	O
,	O
p	O
=	O
0	O
.	O
96	O
)	O
,	O
total	O
cholesterol	O
>	O
5	O
.	O
2	O
mmol	O
/	O
L	O
(	O
9	O
%	O
vs	O
.	O
0	O
%	O
,	O
p	O
=	O
0	O
.	O
54	O
)	O
,	O
HDL	O
cholesterol	O
≤	O
1	O
.	O
02	O
mmol	O
/	O
L	O
(	O
24	O
.	O
2	O
%	O
vs	O
.	O
6	O
.	O
7	O
%	O
,	O
p	O
=	O
0	O
.	O
20	O
)	O
,	O
and	O
TG	O
>	O
1	O
.	O
69	O
(	O
9	O
%	O
vs	O
.	O
3	O
.	O
3	O
%	O
,	O
p	O
=	O
0	O
.	O
72	O
)	O
.	O
Serum	O
leptin	O
(	O
Figure	O
1	O
)	O
and	O
adiponectin	O
(	O
Figure	O
2	O
)	O
levels	O
did	O
not	O
differ	O
significantly	O
between	O
IBS	O
patients	O
and	O
the	O
controls	O
.	O

These	O
results	O
did	O
not	O
change	O
after	O
adjusting	O
for	O
gender	O
,	O
TG	O
,	O
HDL	O
,	O
and	O
HOMA	O
-	O
IR	O
.	O
The	O
L	O
/	O
A	O
ratio	O
was	O
similar	O
(	O
p	O
=	O
0	O
.	O
37	O
)	O
in	O
IBS	O
patients	O
and	O
the	O
control	B-methodology
group	I-methodology
(	O
0	O
.	O
82	O
±	O
1	O
.	O
17	O
vs	O
.	O
0	O
.	O
57	O
±	O
0	O
.	O
80	O
,	O
respectively	O
)	O
.	O
The	O
mean	O
chemerin	O
concentrations	O
were	O
significantly	O
higher	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
in	O
IBS	O
patients	O
(	O
Figure	O
3	O
)	O
;	O
this	O
was	O
also	O
found	O
after	O
adjusting	O
for	O
gender	O
,	O
TG	O
,	O
HDL	O
,	O
and	O
HOMA	O
-	O
IR	O
.	O
In	O
contrast	O
,	O
omentin	O
-	O
1	O
serum	O
concentrations	O
in	O
IBS	O
patients	O
were	O
significantly	O
lower	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
than	O
in	O
healthy	O
children	O
(	O
Figure	O
4	O
)	O
,	O
even	O
after	O
adjusting	O
for	O
gender	O
,	O
TG	O
,	O
HDL	O
,	O
and	O
HOMA	O
-	O
IR	O
.	O
Among	O
IBS	O
patients	O
,	O
leptin	O
levels	O
were	O
positively	O
correlated	O
with	O
chemerin	O
concentrations	O
(	O
r	O
=	O
0	O
.	O
62	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
inversely	O
correlated	O
with	O
serum	O
omentin	O
-	O
1	O
(	O
r	O
=	O
−0	O
.	O
60	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
In	O
the	O
control	B-methodology
group	I-methodology
,	O
concentrations	O
of	O
adipokines	O
showed	O
no	O
significant	O
associations	O
with	O
each	O
other	O
.	O
Age	O
was	O
not	O
related	O
to	O
the	O
concentration	O
of	O
the	O
studied	O
adipokines	O
in	O
either	O
of	O
the	O
investigated	O
groups	O
,	O
apart	O
from	O
a	O
negative	O
association	O
with	O
serum	O
adiponectin	O
among	O
healthy	O
controls	O
(	O
r	O
=	O
−0	O
.	O
47	O
,	O
p	O
=	O
0	O
.	O
009	O
)	O
.	O
In	O
children	O
with	O
IBS	O
,	O
leptin	O
concentrations	O
were	O
positively	O
related	O
to	O
weight	O
SDS	O
(	O
r	O
=	O
0	O
.	O
56	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
BMI	O
SDS	O
(	O
r	O
=	O
0	O
.	O
63	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
waist	O
circumference	O
SDS	O
(	O
r	O
=	O
0	O
.	O
54	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
,	O
and	O
WHR	O
(	O
r	O
=	O
0	O
.	O
33	O
,	O
p	O
=	O
0	O
.	O
004	O
)	O
.	O
In	O
healthy	O
controls	O
,	O
leptin	O
concentrations	O
had	O
a	O
positive	O
correlation	O
only	O
with	O
BMI	O
SDS	O
(	O
r	O
=	O
0	O
.	O
40	O
,	O
p	O
=	O
0	O
.	O
03	O
)	O
(	O
Table	O
2	O
)	O
.	O
Adiponectin	O
concentrations	O
were	O
not	O
significantly	O
associated	O
with	O
the	O
analyzed	O
anthropometric	O
parameters	O
in	O
either	O
of	O
the	O
groups	O
.	O
Statistically	O
significant	O
correlations	O
of	O
serum	O
chemerin	O
were	O
found	O
only	O
among	O
IBS	O
patients	O
.	O

The	O
concentration	O
of	O
these	O
adipokines	O
rose	O
with	O
weight	O
SDS	O
(	O
r	O
=	O
0	O
.	O
39	O
,	O
p	O
=	O
0	O
.	O
03	O
)	O
,	O
BMI	O
SDS	O
(	O
r	O
=	O
0	O
.	O
48	O
,	O
p	O
=	O
0	O
.	O
007	O
)	O
,	O
and	O
waist	O
circumference	O
SDS	O
(	O
r	O
=	O
0	O
.	O
45	O
,	O
p	O
=	O
0	O
.	O
007	O
)	O
.	O
In	O
children	O
with	O
IBS	O
,	O
omentin	O
-	O
1	O
concentrations	O
were	O
negatively	O
related	O
to	O
all	O
anthropometric	O
parameters	O
:	O
weight	O
SDS	O
(	O
r	O
=	O
−0	O
.	O
43	O
,	O
p	O
=	O
0	O
.	O
02	O
)	O
,	O
BMI	O
SDS	O
(	O
r	O
=	O
−0	O
.	O
44	O
,	O
p	O
=	O
0	O
.	O
02	O
)	O
,	O
waist	O
circumference	O
SDS	O
(	O
r	O
=	O
−0	O
.	O
44	O
,	O
p	O
=	O
0	O
.	O
009	O
)	O
,	O
and	O
WHR	O
(	O
r	O
=	O
−0	O
.	O
42	O
,	O
p	O
=	O
0	O
.	O
02	O
)	O
.	O
In	O
healthy	O
children	O
,	O
only	O
weight	O
SDS	O
(	O
r	O
=	O
−0	O
.	O
36	O
,	O
p	O
=	O
0	O
.	O
049	O
)	O
and	O
BMI	O
SDS	O
(	O
r	O
=	O
−0	O
.	O
45	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
were	O
inversely	O
associated	O
with	O
serum	O
omentin	O
-	O
1	O
(	O
Table	O
2	O
)	O
.	O
Significant	O
associations	O
were	O
found	O
between	O
biochemical	O
parameters	O
and	O
adipokine	O
concentrations	O
,	O
predominantly	O
observed	O
in	O
IBS	O
patients	O
.	O
Serum	O
leptin	O
levels	O
in	O
patients	O
and	O
controls	O
were	O
positively	O
associated	O
with	O
insulin	O
concentration	O
(	O
r	O
=	O
0	O
.	O
53	O
,	O
p	O
=	O
0	O
.	O
001	O
and	O
r	O
=	O
0	O
.	O
48	O
,	O
p	O
=	O
0	O
.	O
007	O
,	O
respectively	O
)	O
and	O
HOMA	O
-	O
IR	O
(	O
r	O
=	O
0	O
,	O
61	O
,	O
p	O
<	O
0	O
.	O
001	O
and	O
r	O
=	O
0	O
.	O
39	O
,	O
p	O
=	O
0	O
.	O
04	O
,	O
respectively	O
)	O
.	O
Moreover	O
,	O
in	O
the	O
IBS	O
group	O
,	O
leptin	O
was	O
positively	O
related	O
to	O
CRP	O
values	O
(	O
r	O
=	O
0	O
.	O
44	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
and	O
TG	O
(	O
r	O
=	O
0	O
.	O
36	O
,	O
p	O
=	O
0	O
.	O
04	O
)	O
(	O
Table	O
3	O
)	O
.	O
In	O
both	O
groups	O
,	O
adiponectin	O
was	O
negatively	O
correlated	O
with	O
HOMA	O
-	O
IR	O
values	O
(	O
IBS	O
patients	O
:	O
r	O
=	O
−0	O
.	O
37	O
,	O
p	O
=	O
0	O
.	O
04	O
,	O
controls	O
:	O
r	O
=	O
−0	O
.	O
44	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O
Additionally	O
,	O
in	O
controls	O
,	O
adiponectin	O
was	O
positively	O
related	O
to	O
HDL	O
cholesterol	O
levels	O
(	O
r	O
=	O
0	O
.	O
39	O
,	O
p	O
=	O
0	O
.	O
03	O
)	O
and	O
negatively	O
related	O
to	O
insulin	O
concentration	O
(	O
r	O
=	O
−0	O
.	O
47	O
,	O
p	O
=	O
0	O
.	O
009	O
)	O
.	O

Chemerin	O
and	O
omentin	O
-	O
1	O
were	O
significantly	O
associated	O
with	O
biochemical	O
parameters	O
only	O
in	O
IBS	O
patients	O
.	O
Positive	O
correlations	O
were	O
found	O
between	O
serum	O
chemerin	O
and	O
total	O
cholesterol	O
(	O
r	O
=	O
0	O
.	O
45	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
,	O
LDL	O
cholesterol	O
(	O
r	O
=	O
0	O
.	O
4	O
,	O
p	O
=	O
0	O
.	O
006	O
)	O
,	O
TG	O
(	O
r	O
=	O
0	O
.	O
4	O
,	O
p	O
=	O
0	O
.	O
02	O
)	O
,	O
insulin	O
(	O
r	O
=	O
0	O
.	O
5	O
,	O
p	O
=	O
0	O
.	O
003	O
)	O
,	O
and	O
HOMA	O
-	O
IR	O
values	O
(	O
r	O
=	O
0	O
.	O
5	O
,	O
p	O
=	O
0	O
.	O
004	O
)	O
.	O
Omentin	O
-	O
1	O
was	O
inversely	O
associated	O
with	O
CRP	O
(	O
r	O
=	O
−0	O
.	O
36	O
,	O
p	O
=	O
0	O
.	O
04	O
)	O
,	O
insulin	O
(	O
r	O
=	O
−0	O
.	O
5	O
,	O
p	O
=	O
0	O
.	O
005	O
)	O
,	O
TG	O
(	O
r	O
=	O
−0	O
.	O
3	O
,	O
p	O
=	O
0	O
.	O
04	O
)	O
,	O
and	O
HOMA	O
-	O
IR	O
values	O
(	O
r	O
=	O
−0	O
.	O
40	O
,	O
p	O
=	O
0	O
.	O
006	O
)	O
and	O
positively	O
associated	O
with	O
HDL	O
cholesterol	O
levels	O
only	O
(	O
r	O
=	O
0	O
.	O
38	O
,	O
p	O
=	O
0	O
.	O
04	O
)	O
(	O
Table	O
3	O
)	O
.	O
There	O
were	O
significant	O
differences	O
in	O
chemerin	O
and	O
omentin	O
-	O
1	O
between	O
IBS	O
patients	O
and	O
controls	O
.	O
ROC	O
plots	O
were	O
used	O
to	O
determine	O
cut	O
-	O
off	O
points	O
for	O
the	O
serum	O
levels	O
of	O
these	O
two	O
adipokines	O
in	O
IBS	O
.	O
Chemerin	O
concentrations	O
≥	O
232	O
.	O
8	O
ng	O
/	O
mL	O
showed	O
quite	O
low	O
sensitivity	O
(	O
39	O
%	O
)	O
,	O
but	O
good	O
specificity	O
(	O
87	O
%	O
)	O
in	O
differentiating	O
patients	O
with	O
IBS	O
from	O
health	O
controls	O
(	O
Figure	O
5	O
)	O
.	O
Omentin	O
-	O
1	O
levels	O
≤	O
279	O
.	O
4	O
ng	O
/	O
mL	O
had	O
60	O
%	O
sensitivity	O
and	O
80	O
%	O
specificity	O
(	O
Figure	O
6	O
)	O
.	O
The	O
most	O
important	O
findings	O
of	O
the	O
present	O
study	O
were	O
the	O
significantly	O
higher	O
chemerin	O
and	O
loweromentin	O
-	O
1	O
concentrations	O
in	O
children	O
with	O
IBS	O
compared	O
to	O
controls	O
,	O
as	O
well	O
as	O
the	O
lack	O
of	O
differences	O
in	O
adiponectin	O
and	O
leptin	O
levels	O
between	O
these	O
two	O
groups	O
.	O
As	O
of	O
the	O
time	O
of	O
writing	O
,	O
there	O
are	O
no	O
published	O
data	O
on	O
the	O
hormonal	O
activity	O
of	O
adipose	O
tissue	O
in	O
children	O
with	O
IBS	O
,	O
and	O
not	O
much	O
research	O
has	O
been	O
conducted	O
in	O
adults	O
.	O
Moreover	O
,	O
the	O
results	O
of	O
the	O
sparse	O
studies	O
available	O
are	O
conflicting	O
[	O
14	O
,	O
15	O
,	O
16	O
,	O
17	O
,	O
18	O
,	O
19	O
,	O
20	O
]	O
.	O

To	O
our	O
knowledge	O
,	O
there	O
are	O
no	O
published	O
data	O
on	O
the	O
use	O
of	O
adipokines	O
as	O
markers	O
of	O
IBS	O
.	O
Our	O
results	O
might	O
point	O
to	O
a	O
new	O
path	O
in	O
the	O
search	O
for	O
laboratory	O
parameters	O
for	O
IBS	O
diagnostics	O
using	O
adipose	O
tissue	O
hormones	O
.	O
Leptin	O
concentrations	O
did	O
not	O
differ	O
between	O
children	O
with	O
IBS	O
and	O
healthy	O
controls	O
.	O
We	O
demonstrated	O
their	O
positive	O
correlation	O
with	O
BMI	O
,	O
weight	O
,	O
and	O
waist	O
circumference	O
,	O
as	O
well	O
as	O
the	O
metabolic	O
parameters	O
HOMA	O
-	O
IR	O
,	O
CRP	O
,	O
TG	O
,	O
and	O
insulin	O
levels	O
.	O
One	O
study	O
conducted	O
in	O
adults	O
with	O
IBS	O
revealed	O
significantly	O
higher	O
leptin	O
concentrations	O
compared	O
to	O
healthy	O
control	O
subjects	O
[	O
14	O
]	O
,	O
while	O
another	O
study	O
found	O
lower	O
levels	O
[	O
15	O
]	O
.	O
The	O
findings	O
of	O
most	O
authors	O
[	O
16	O
,	O
18	O
,	O
19	O
]	O
are	O
in	O
accordance	O
with	O
our	O
results	O
.	O
The	O
studies	O
mentioned	O
[	O
14	O
,	O
15	O
,	O
18	O
,	O
19	O
]	O
confirmed	O
the	O
well	O
-	O
known	O
association	O
between	O
leptin	O
and	O
weight	O
/	O
BMI	O
[	O
14	O
,	O
27	O
,	O
52	O
]	O
,	O
but	O
metabolic	O
parameters	O
were	O
generally	O
not	O
assessed	O
,	O
except	O
in	O
the	O
research	O
by	O
Weaver	O
et	O
al	O
.	O
[	O
18	O
]	O
,	O
who	O
demonstrated	O
a	O
positive	O
correlation	O
between	O
leptin	O
and	O
total	O
cholesterol	O
in	O
females	O
.	O
Although	O
Russo	O
et	O
al	O
.	O
[	O
16	O
]	O
did	O
not	O
find	O
any	O
significant	O
differences	O
in	O
leptin	O
levels	O
between	O
patients	O
with	O
diarrhea	O
-	O
predominant	O
IBS	O
(	O
IBS	O
-	O
D	O
)	O
and	O
healthy	O
controls	O
,	O
their	O
more	O
thorough	O
research	O
demonstrated	O
significantly	O
higher	O
leptin	O
concentrations	O
only	O
in	O
the	O
IBS	O
-	O
D	O
subgroup	O
with	O
altered	O
small	O
-	O
intestinal	O
permeability	O
[	O
17	O
]	O
.	O
Additionally	O
,	O
sex	O
hormones	O
may	O
modulate	O
leptin	O
secretion	O
directly	O
and	O
indirectly	O
by	O
impacting	O
the	O
distribution	O
of	O
adipose	O
tissue	O
in	O
the	O
body	O
[	O
53	O
]	O
.	O
Interestingly	O
,	O
Weaver	O
et	O
al	O
.	O
[	O
18	O
]	O
postulate	O
that	O
disturbances	O
in	O
the	O
functioning	O
of	O
normal	O
feedback	O
mechanisms	O
along	O
the	O
hypothalamic	O
–	O
pituitary	O
–	O
gonadal	O
axis	O
observed	O
in	O
women	O
with	O
IBS	O
may	O
be	O
involved	O
in	O
the	O
exacerbation	O
of	O
symptoms	O
.	O
In	O
our	O
study	O
,	O
there	O
were	O
also	O
no	O
differences	O
in	O
adiponectin	O
concentrations	O
between	O
the	O
groups	O
.	O
There	O
are	O
no	O
data	O
on	O
serum	O
adiponectin	O
levels	O
in	O
children	O
with	O
IBS	O
,	O
and	O
studies	O
involving	O
adult	O
patients	O
have	O
yielded	O
contradictory	O
findings	O
[	O
16	O
,	O
17	O
,	O
20	O
]	O
.	O

In	O
the	O
two	O
publications	O
by	O
Russo	O
et	O
al	O
.	O
[	O
16	O
,	O
17	O
]	O
,	O
serum	O
adiponectin	O
levels	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
IBS	O
-	O
D	O
(	O
especially	O
with	O
normal	O
small	O
-	O
intestinal	O
permeability	O
)	O
in	O
comparison	O
to	O
healthy	O
controls	O
,	O
whereas	O
Baram	O
et	O
al	O
.	O
[	O
20	O
]	O
reported	O
the	O
opposite	O
results	O
in	O
a	O
group	O
including	O
patients	O
with	O
all	O
types	O
of	O
IBS	O
.	O
Unfortunately	O
,	O
correlations	O
between	O
adiponectin	O
and	O
anthropometric	O
and	O
metabolic	O
parameters	O
were	O
not	O
assessed	O
in	O
these	O
studies	O
,	O
and	O
the	O
clinical	O
characteristics	O
of	O
the	O
examined	O
groups	O
only	O
involved	O
BMI	O
[	O
16	O
,	O
17	O
,	O
20	O
]	O
and	O
body	O
fat	O
percentage	O
[	O
20	O
]	O
,	O
which	O
were	O
not	O
different	O
between	O
patients	O
and	O
healthy	O
controls	O
.	O
Similarly	O
to	O
Baram	O
et	O
al	O
.	O
[	O
20	O
]	O
,	O
we	O
found	O
significantly	O
higher	O
chemerin	O
concentrations	O
in	O
IBS	O
patients	O
than	O
in	O
controls	O
.	O
They	O
also	O
demonstrated	O
that	O
an	O
increase	O
in	O
pro	O
-	O
inflammatory	O
adipokine	O
levels	O
is	O
associated	O
with	O
an	O
increase	O
in	O
the	O
severity	O
of	O
symptoms	O
[	O
20	O
]	O
.	O
Interestingly	O
,	O
in	O
our	O
study	O
,	O
correlations	O
between	O
chemerin	O
,	O
anthropometric	O
,	O
and	O
biochemical	O
parameters	O
and	O
concentrations	O
of	O
other	O
adipokines	O
were	O
present	O
only	O
among	O
children	O
with	O
IBS	O
who	O
had	O
higher	O
chemerin	O
levels	O
than	O
the	O
controls	O
.	O
This	O
might	O
suggest	O
that	O
such	O
relations	O
develop	O
in	O
non	O
-	O
physiological	O
states	O
.	O
Similar	O
results	O
were	O
shown	O
in	O
a	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
concerning	O
metabolic	O
syndrome	O
[	O
54	O
]	O
.	O
Such	O
observations	O
were	O
also	O
noted	O
in	O
children	O
with	O
obesity	O
[	O
55	O
]	O
.	O
In	O
addition	O
,	O
an	O
association	O
between	O
chemerin	O
and	O
insulin	O
resistance	O
has	O
been	O
found	O
in	O
various	O
studies	O
on	O
children	O
and	O
adults	O
who	O
are	O
healthy	O
,	O
obese	O
,	O
or	O
have	O
type	O
2	O
diabetes	O
[	O
40	O
,	O
56	O
,	O
57	O
,	O
58	O
,	O
59	O
]	O
.	O
Therefore	O
,	O
higher	O
chemerin	O
levels	O
in	O
the	O
IBS	O
group	O
should	O
be	O
considered	O
as	O
an	O
adverse	O
factor	O
that	O
may	O
be	O
related	O
to	O
the	O
metabolic	O
disorders	O
observed	O
in	O
this	O
group	O
.	O
Higher	O
chemerin	O
was	O
also	O
found	O
in	O
adults	O
with	O
IBD	O
than	O
in	O
healthy	O
controls	O
,	O
especially	O
in	O
men	O
[	O
60	O
,	O
61	O
]	O
;	O
animal	B-methodology
studies	I-methodology
have	O
indicated	O
that	O
it	O
may	O
take	O
part	O
in	O
the	O
development	O
of	O
bowel	O
inflammation	O
and	O
could	O
also	O
experimentally	O
induce	O
it	O
.	O
Thus	O
,	O
chemerin	O
is	O
suggested	O
as	O
a	O
biomarker	O
of	O
the	O
inflammation	O
severity	O
in	O
IBD	O
and	O
a	O
potential	O
therapeutic	O
target	O
[	O
62	O
]	O
.	O

In	O
our	O
group	O
of	O
children	O
with	O
IBS	O
,	O
omentin	O
-	O
1	O
levels	O
were	O
significantly	O
lower	O
than	O
in	O
healthy	O
controls	O
,	O
and	O
they	O
correlated	O
negatively	O
with	O
anthropometric	O
and	O
biochemical	O
parameters	O
.	O
Unfortunately	O
,	O
no	O
data	O
on	O
serum	O
omentin	O
-	O
1	O
in	O
patients	O
with	O
IBS	O
have	O
been	O
published	O
so	O
far	O
.	O
We	O
can	O
only	O
speculate	O
that	O
,	O
due	O
to	O
omentin	O
-	O
1	O
′	O
s	O
anti	O
-	O
inflammatory	O
activity	O
,	O
omentin	O
-	O
1	O
concentrations	O
may	O
inversely	O
reflect	O
the	O
severity	O
of	O
low	O
-	O
grade	O
inflammation	O
.	O
It	O
may	O
also	O
be	O
suggested	O
that	O
decreased	O
serum	O
omentin	O
-	O
1	O
in	O
IBS	O
patients	O
could	O
be	O
involved	O
in	O
the	O
metabolic	O
disorders	O
observed	O
in	O
this	O
group	O
,	O
as	O
this	O
adipokine	O
has	O
been	O
proven	O
to	O
have	O
a	O
positive	O
impact	O
on	O
insulin	O
sensitivity	O
and	O
the	O
concentrations	O
of	O
adiponectin	O
and	O
HDL	O
[	O
63	O
,	O
64	O
,	O
65	O
]	O
.	O
The	O
varying	O
conclusions	O
concerning	O
adipokine	O
concentration	O
in	O
IBS	O
patients	O
may	O
result	O
from	O
several	O
factors	O
that	O
influence	O
the	O
secretion	O
of	O
these	O
hormones	O
,	O
such	O
as	O
the	O
mass	O
of	O
fat	O
tissue	O
and	O
its	O
distribution	O
,	O
age	O
,	O
insulin	O
sensitivity	O
,	O
IBS	O
type	O
and	O
duration	O
,	O
medication	O
,	O
sex	O
hormones	O
,	O
stress	O
,	O
and	O
the	O
presence	O
of	O
low	O
-	O
grade	O
inflammation	O
[	O
4	O
,	O
12	O
,	O
21	O
,	O
29	O
]	O
.	O
The	O
latter	O
component	O
is	O
a	O
relevant	O
issue	O
in	O
the	O
pathophysiology	O
of	O
IBS	O
[	O
4	O
]	O
.	O
Briefly	O
,	O
the	O
greater	O
magnitude	O
of	O
gut	O
microbiota	O
dysbiosis	O
in	O
patients	O
with	O
IBS	O
demonstrated	O
in	O
many	O
studies	O
may	O
contribute	O
to	O
increased	O
intestinal	O
permeability	O
and	O
consequent	O
barrier	O
dysfunction	O
that	O
allows	O
the	O
permeation	O
of	O
pathogenic	O
microorganisms	O
and	O
their	O
products	O
.	O
Furthermore	O
,	O
these	O
infections	O
lead	O
to	O
the	O
increment	O
of	O
various	O
immune	O
-	O
related	O
cells	O
,	O
such	O
as	O
macrophages	O
,	O
mast	O
cells	O
,	O
T	O
-	O
lymphocytes	O
,	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
TNF	O
-	O
α	O
,	O
IFN	O
-	O
γ	O
,	O
IL	O
-	O
3	O
,	O
IL	O
-	O
4	O
,	O
IL	O
-	O
5	O
,	O
and	O
IL	O
-	O
6	O
)	O
,	O
resulting	O
in	O
low	O
-	O
grade	O
inflammation	O
that	O
has	O
a	O
notable	O
effect	O
on	O
vascular	O
permeability	O
,	O
gastrointestinal	O
motility	O
,	O
secretion	O
,	O
and	O
visceral	O
hypersensitivity	O
,	O
as	O
these	O
play	O
key	O
roles	O
in	O
the	O
development	O
of	O
IBS	O
symptoms	O
[	O
4	O
,	O
66	O
]	O
.	O
Low	O
-	O
grade	O
inflammation	O
in	O
visceral	O
adipose	O
tissue	O
may	O
also	O
potentially	O
result	O
in	O
alterations	O
in	O
adipokine	O
secretion	O
[	O
29	O
]	O
.	O

Therefore	O
,	O
it	O
could	O
be	O
speculated	O
that	O
higher	O
chemerin	O
—	O
taking	O
part	O
in	O
the	O
generation	O
and	O
maintenance	O
of	O
inflammation	O
and	O
lower	O
anti	O
-	O
inflammatory	O
omentin	O
-	O
1	O
levels	O
—	O
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
IBS	O
.	O
These	O
specific	O
adipokines	O
were	O
also	O
found	O
to	O
be	O
specific	O
markers	O
for	O
differentiating	O
IBS	O
from	O
healthy	O
children	O
,	O
although	O
their	O
sensitivity	O
was	O
low	O
or	O
moderate	O
.	O
Since	O
IBS	O
symptoms	O
also	O
occur	O
in	O
many	O
other	O
diseases	O
,	O
a	O
specific	O
and	O
sensitive	O
marker	O
for	O
IBS	O
would	O
certainly	O
make	O
the	O
diagnosis	O
easier	O
and	O
more	O
cost	O
effective	O
[	O
67	O
,	O
68	O
]	O
.	O
An	O
interesting	O
aspect	O
of	O
our	O
study	O
is	O
metabolic	O
disorders	O
in	O
children	O
with	O
IBS	O
.	O
Our	O
results	O
may	O
indicate	O
an	O
increased	O
risk	O
for	O
developing	O
metabolic	O
syndrome	O
in	O
IBS	O
patients	O
,	O
which	O
has	O
been	O
suggested	O
in	O
other	O
publications	O
[	O
69	O
,	O
70	O
]	O
.	O
Indicators	O
of	O
metabolic	O
syndrome	O
,	O
such	O
as	O
higher	O
triglycerides	O
and	O
HOMA	O
-	O
IR	O
,	O
as	O
well	O
as	O
lower	O
HDL	O
cholesterol	O
,	O
were	O
revealed	O
in	O
children	O
with	O
IBS	O
,	O
despite	O
a	O
lack	O
of	O
differences	O
in	O
anthropometric	O
measurements	O
.	O
However	O
,	O
one	O
should	O
be	O
aware	O
that	O
anthropometric	O
parameters	O
are	O
not	O
sensitive	O
enough	O
in	O
the	O
early	O
diagnosis	O
of	O
metabolic	O
disorders	O
.	O
The	O
adverse	O
changes	O
in	O
gut	O
microbiome	O
,	O
intestinal	O
low	O
-	O
grade	O
inflammation	O
,	O
and	O
oxidative	O
stress	O
in	O
IBS	O
may	O
lead	O
to	O
visceral	O
adipose	O
tissue	O
dysfunction	O
manifested	O
by	O
an	O
imbalance	O
between	O
pro	O
-	O
inflammatory	O
(	O
e	O
.	O
g	O
.	O
,	O
chemerin	O
)	O
and	O
anti	O
-	O
inflammatory	O
(	O
e	O
.	O
g	O
.	O
,	O
omentin	O
-	O
1	O
)	O
adipokines	O
.	O
Impaired	O
function	O
of	O
adipose	O
tissue	O
and	O
increased	O
triglyceride	O
absorption	O
in	O
IBS	O
may	O
promote	O
ectopic	O
lipid	O
accumulation	O
in	O
the	O
liver	O
,	O
skeletal	O
muscle	O
tissue	O
,	O
and	O
around	O
the	O
heart	O
.	O
Such	O
abnormal	O
fat	O
content	O
can	O
be	O
visualized	O
on	O
an	O
MRI	O
long	O
before	O
obvious	O
physical	O
changes	O
appear	O
[	O
70	O
]	O
.	O
Adipose	O
tissue	O
may	O
also	O
accumulate	O
around	O
small	O
mesenteric	O
lymphatic	O
and	O
blood	O
vessels	O
due	O
to	O
their	O
increased	O
permeability	O
caused	O
by	O
low	O
-	O
grade	O
inflammation	O
[	O
71	O
]	O
.	O
Our	O
observations	O
are	O
consistent	O
with	O
this	O
theory	O
since	O
only	O
adipokines	O
produced	O
by	O
the	O
adipose	O
tissue	O
stroma	O
differed	O
significantly	O
between	O
children	O
with	O
IBS	O
and	O
controls	O
.	O
Deposition	O
of	O
fat	O
in	O
non	O
-	O
adipose	O
tissue	O
may	O
be	O
associated	O
with	O
insulin	O
resistance	O
and	O
metabolic	O
complications	O
of	O
obesity	O
(	O
lipotoxicity	O
)	O
.	O

Whether	O
insulin	O
resistance	O
is	O
a	O
cause	O
or	O
consequence	O
of	O
metabolic	O
inflexibility	O
—	O
i	O
.	O
e	O
.	O
,	O
the	O
impaired	O
ability	O
of	O
the	O
body	O
to	O
switch	O
from	O
fat	O
to	O
carbohydrate	O
oxidation	O
—	O
remains	O
unresolved	O
[	O
72	O
]	O
.	O
The	O
metabolically	O
“	O
inflexible	O
”	O
state	O
is	O
typically	O
characterized	O
by	O
decreased	O
fat	O
oxidation	O
during	O
fasting	O
and	O
a	O
reduced	O
ability	O
to	O
upregulate	O
carbohydrate	O
oxidation	O
during	O
feeding	O
[	O
73	O
]	O
.	O
This	O
impaired	O
fuel	O
switching	O
in	O
mitochondria	O
may	O
result	O
from	O
the	O
continuous	O
influx	O
of	O
fuel	O
sources	O
due	O
to	O
overnutrition	O
,	O
as	O
well	O
as	O
physical	O
inactivity	O
and	O
sedentary	O
behaviors	O
[	O
72	O
,	O
73	O
]	O
.	O
We	O
did	O
not	O
assess	O
the	O
subjects	O
’	O
physical	O
activity	O
and	O
fitness	O
levels	O
;	O
however	O
,	O
possible	O
sedentary	O
lifestyle	O
and	O
avoiding	O
exercises	O
due	O
to	O
somatic	O
(	O
abdominal	O
pain	O
,	O
diarrhea	O
)	O
and	O
mental	O
(	O
anxiety	O
and	O
mood	O
disorders	O
)	O
stresses	O
caused	O
by	O
IBS	O
may	O
have	O
potentially	O
affected	O
the	O
obtained	O
results	O
.	O
In	O
endurance	O
-	O
trained	O
subjects	O
,	O
there	O
are	O
many	O
structural	O
and	O
functional	O
changes	O
in	O
muscle	O
fibers	O
affecting	O
intramyocellular	O
triacylglycerol	O
depletion	O
and	O
storage	O
.	O
Such	O
muscle	O
,	O
despite	O
having	O
elevated	O
lipid	O
content	O
,	O
remains	O
markedly	O
insulin	O
-	O
sensitive	O
[	O
72	O
]	O
.	O
Recent	O
data	O
confirm	O
that	O
the	O
most	O
active	O
children	O
have	O
better	O
anthropometric	O
,	O
metabolic	O
,	O
and	O
inflammatory	O
profiles	O
,	O
which	O
may	O
lead	O
to	O
a	O
better	O
cardiometabolic	O
status	O
[	O
74	O
]	O
.	O
Physical	O
activity	O
can	O
also	O
stimulate	O
variations	O
in	O
the	O
gut	O
microbiota	O
through	O
numerous	O
mechanisms	O
,	O
such	O
as	O
myokine	O
release	O
,	O
increased	O
intestinal	O
transit	O
,	O
or	O
the	O
secretion	O
of	O
neurotransmitters	O
and	O
hormones	O
,	O
and	O
it	O
can	O
potentially	O
modify	O
the	O
IBS	O
course	O
[	O
75	O
]	O
.	O
Therefore	O
,	O
further	O
research	O
on	O
adipokine	O
levels	O
in	O
IBS	O
patients	O
should	O
also	O
include	O
physical	O
activity	O
.	O
This	O
investigation	O
has	O
some	O
limitations	O
,	O
such	O
as	O
its	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
design	O
and	O
relatively	O
small	O
study	B-methodology
groups	I-methodology
.	O
We	O
did	O
not	O
analyze	O
the	O
socioeconomic	O
status	O
of	O
the	O
subjects	O
,	O
which	O
may	O
have	O
affected	O
their	O
nutrition	O
and	O
their	O
physical	O
activity	O
and	O
fitness	O
levels	O
.	O
Nonetheless	O
,	O
our	O
research	O
is	O
original	O
and	O
there	O
are	O
very	O
little	O
data	O
concerning	O
adipokines	O
in	O
IBS	O
,	O
especially	O
for	O
chemerin	O
and	O
omentin	O
-	O
1	O
.	O
Thus	O
,	O
the	O
presented	O
results	O
could	O
lead	O
to	O
new	O
hypotheses	O
and	O
starting	O
points	O
for	O
further	O
investigations	O
.	O

The	O
concentrations	O
of	O
adipokines	O
secreted	O
by	O
stromal	O
cells	O
of	O
visceral	O
adipose	O
tissue	O
(	O
chemerin	O
and	O
omentin	O
-	O
1	O
)	O
showed	O
significant	O
differences	O
in	O
children	O
with	O
IBS	O
in	O
comparison	O
to	O
healthy	O
subjects	O
.	O
At	O
the	O
same	O
time	O
,	O
there	O
was	O
no	O
discrepancy	O
in	O
serum	O
levels	O
of	O
hormones	O
mainly	O
produced	O
by	O
adipocytes	O
.	O
The	O
observed	O
changes	O
indirectly	O
suggest	O
the	O
potential	O
participation	O
of	O
visceral	O
adipose	O
tissue	O
in	O
the	O
pathogenesis	O
of	O
IBS	O
.	O
The	O
adipokine	O
concentrations	O
in	O
the	O
investigated	O
children	O
were	O
related	O
to	O
nutritional	O
status	O
and	O
,	O
in	O
the	O
case	O
of	O
chemerin	O
and	O
omentin	O
-	O
1	O
,	O
also	O
to	O
insulin	O
resistance	O
.	O
Therefore	O
,	O
their	O
altered	O
concentrations	O
may	O
contribute	O
to	O
the	O
development	O
of	O
metabolic	O
disorders	O
in	O
IBS	O
patients	O
.	O
Chemerin	O
and	O
omentin	O
-	O
1	O
might	O
be	O
considered	O
as	O
IBS	O
biomarkers	O
with	O
good	O
specificity	O
and	O
moderate	O
sensitivity	O
.	O
The	O
study	O
was	O
supported	O
by	O
the	O
Medical	O
University	O
of	O
Silesia	O
in	O
Katowice	O
(	O
grant	O
no	O
KNW	O
-	O
1	O
-	O
094	O
/	O
N	O
/	O
6	O
/	O
K	O
)	O
.	O
Publisher	O
’	O
s	O
Note	O
:	O
MDPI	O
stays	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O
Conceptualization	O
,	O
W	O
.	O
R	O
.	O
,	O
A	O
.	O
S	O
.	O
and	O
J	O
.	O
O	O
.	O
;	O
Data	O
curation	O
,	O
A	O
.	O
S	O
.	O
and	O
M	O
.	O
S	O
.	O
;	O
Formal	O
analysis	O
,	O
W	O
.	O
R	O
.	O
and	O
J	O
.	O
O	O
.	O
;	O
Funding	O
acquisition	O
,	O
J	O
.	O
O	O
.	O
;	O
Investigation	O
,	O
A	O
.	O
S	O
.	O
,	O
M	O
.	O
S	O
.	O
and	O
B	O
.	O
M	O
.	O
;	O
Methodology	O
,	O
J	O
.	O
O	O
.	O
and	O
W	O
.	O
R	O
.	O
;	O
Project	O
administration	O
,	O
J	O
.	O
O	O
.	O
;	O
Resources	O
,	O
A	O
.	O
S	O
.	O
and	O
W	O
.	O
R	O
.	O
;	O
Software	O
,	O
W	O
.	O
R	O
.	O
;	O
Supervision	O
,	O
J	O
.	O
O	O
.	O
and	O
A	O
.	O
C	O
.	O
;	O
Writing	O
—	O
original	O
draft	O
,	O
A	O
.	O
S	O
.	O
and	O
W	O
.	O
R	O
.	O
;	O
Writing	O
—	O
review	O
and	O
editing	O
,	O
J	O
.	O
O	O
.	O
and	O
A	O
.	O
C	O
.	O
All	O
authors	O
have	O
read	O
and	O
agreed	O
to	O
the	O
published	O
version	O
of	O
the	O
manuscript	O
.	O
The	O
study	O
was	O
conducted	O
according	O
to	O
the	O
guidelines	B-methodology
of	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
Medical	O
University	O
of	O
Silesia	O
(	O
approved	O
on	O
25	O
June	O
2013	O
,	O
approval	O
no	O
.	O
KNW	O
/	O
0022	O
/	O
KB1	O
/	O
69	O
/	O
13	O
)	O
.	O
The	O
local	O
ethics	O
committee	O
at	O
the	O
Medical	O
University	O
of	O
Silesia	O
in	O
Katowice	O
provided	O
permission	O
for	O
this	O
study	O
(	O
approval	O
no	O
.	O

KNW	O
/	O
0022	O
/	O
KB1	O
/	O
69	O
/	O
13	O
of	O
25	O
June	O
2013	O
)	O
.	O
Informed	O
consent	O
was	O
obtained	O
from	O
all	O
the	O
subjects	O
and	O
their	O
parents	O
/	O
representatives	O
involved	O
in	O
the	O
study	O
.	O
All	O
patients	O
and	O
their	O
parents	O
/	O
representatives	O
provided	O
their	O
informed	O
consent	O
prior	O
to	O
their	O
inclusion	O
in	O
the	O
study	O
.	O
The	O
data	O
presented	O
in	O
this	O
study	O
are	O
available	O
on	O
request	O
from	O
the	O
corresponding	O
author	O
.	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O

Bilirubin	O
Prevents	O
Atherosclerotic	O
Lesion	O
Formation	O
in	O
Low	O
‐	O
Density	O
Lipoprotein	O
Receptor	O
‐	O
Deficient	O
Mice	O
by	O
Inhibiting	O
Endothelial	O
VCAM	O
‐	O
1	O
and	O
ICAM	O
‐	O
1	O
Signaling	O
adhesion	O
molecule	O
;	O
atherosclerosis	O
;	O
bilirubin	O
;	O
intercellular	O
adhesion	O
molecule	O
1	O
;	O
monocyte	O
;	O
vascular	O
cell	O
adhesion	O
molecule	O
1	O
;	O
vascular	O
endothelium	O
Endothelium	O
/	O
Vascular	O
Type	O
/	O
Nitric	O
Oxide	O
;	O
Vascular	O
Biology	O
;	O
Atherosclerosis	O
Numerous	O
epidemiological	B-methodology
studies	I-methodology
support	O
an	O
inverse	O
association	O
between	O
serum	O
bilirubin	O
levels	O
and	O
the	O
incidence	O
of	O
cardiovascular	O
disease	O
;	O
however	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
bilirubin	O
may	O
protect	O
against	O
atherosclerosis	O
is	O
undefined	O
.	O
The	O
goals	O
of	O
the	O
present	O
investigations	O
were	O
to	O
assess	O
the	O
ability	O
of	O
bilirubin	O
to	O
prevent	O
atherosclerotic	O
plaque	O
formation	O
in	O
low	O
‐	O
density	O
lipoprotein	O
receptor	O
‐	O
deficient	O
(	O
Ldlr	O
−	O
/	O
−	O
)	O
mice	O
and	O
elucidate	O
the	O
molecular	O
processes	O
underlying	O
this	O
effect	O
.	O
Bilirubin	O
,	O
at	O
physiological	O
concentrations	O
(	O
≤20	O
μmol	O
/	O
L	O
)	O
,	O
dose	O
‐	O
dependently	O
inhibits	O
THP	O
‐	O
1	O
monocyte	O
migration	O
across	O
tumor	O
necrosis	O
factor	O
α	O
–	O
activated	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
monolayers	O
without	O
altering	O
leukocyte	O
binding	O
or	O
cytokine	O
production	O
.	O
A	O
potent	O
antioxidant	O
,	O
bilirubin	O
effectively	O
blocks	O
the	O
generation	O
of	O
cellular	O
reactive	O
oxygen	O
species	O
induced	O
by	O
the	O
cross	O
‐	O
linking	O
of	O
endothelial	O
vascular	O
cell	O
adhesion	O
molecule	O
1	O
(	O
VCAM	O
‐	O
1	O
)	O
or	O
intercellular	O
adhesion	O
molecule	O
1	O
(	O
ICAM	O
‐	O
1	O
)	O
.	O
These	O
findings	O
were	O
validated	O
by	O
treating	O
cells	O
with	O
blocking	O
antibodies	O
or	O
with	O
specific	O
inhibitors	O
of	O
VCAM	O
‐	O
1	O
and	O
ICAM	O
‐	O
1	O
signaling	O
.	O
When	O
administered	O
to	O
Ldlr	O
−	O
/	O
−	O
mice	O
on	O
a	O
Western	O
diet	O
,	O
bilirubin	O
(	O
30	O
mg	O
/	O
kg	O
intraperitoneally	O
)	O
prevents	O
atherosclerotic	O
plaque	O
formation	O
,	O
but	O
does	O
not	O
alter	O
circulating	O
cholesterol	O
or	O
chemokine	O
levels	O
.	O

Aortic	O
roots	O
from	O
bilirubin	O
‐	O
treated	O
animals	O
exhibit	O
reduced	O
lipid	O
and	O
collagen	O
deposition	O
,	O
decreased	O
infiltration	O
of	O
monocytes	O
and	O
lymphocytes	O
,	O
fewer	O
smooth	O
muscle	O
cells	O
,	O
and	O
diminished	O
levels	O
of	O
chlorotyrosine	O
and	O
nitrotyrosine	O
,	O
without	O
changes	O
in	O
VCAM	O
‐	O
1	O
or	O
ICAM	O
‐	O
1	O
expression	O
.	O
Bilirubin	O
suppresses	O
atherosclerotic	O
plaque	O
formation	O
in	O
Ldlr	O
−	O
/	O
−	O
mice	O
by	O
disrupting	O
endothelial	O
VCAM	O
‐	O
1	O
‐	O
and	O
ICAM	O
‐	O
1	O
‐	O
mediated	O
leukocyte	O
migration	O
through	O
the	O
scavenging	O
of	O
reactive	O
oxygen	O
species	O
signaling	O
intermediaries	O
.	O
These	O
findings	O
suggest	O
a	O
potential	O
mechanism	O
for	O
the	O
apparent	O
cardioprotective	O
effects	O
of	O
bilirubin	O
.	O
Bilirubin	O
is	O
formed	O
during	O
the	O
normal	O
physiological	O
degradation	O
of	O
heme	O
.	O
An	O
inverse	O
association	O
between	O
serum	O
bilirubin	O
concentrations	O
and	O
incidence	O
of	O
coronary	O
artery	O
disease	O
was	O
first	O
described	O
by	O
Schwertner	O
et	O
al	O
in	O
1994	O
.	O
1	O
Since	O
this	O
initial	O
report	O
,	O
a	O
number	O
of	O
epidemiological	O
analyses	O
have	O
provided	O
corroborating	O
evidence	O
that	O
individuals	O
with	O
a	O
higher	O
serum	O
bilirubin	O
level	O
exhibit	O
a	O
lower	O
risk	O
of	O
cardiovascular	O
events	O
.	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
Notably	O
,	O
heme	O
oxygenase	O
(	O
HO	O
)	O
,	O
the	O
rate	O
‐	O
limiting	O
enzyme	O
in	O
bilirubin	O
synthesis	O
,	O
has	O
an	O
inducible	O
isoform	O
(	O
HO	O
‐	O
1	O
)	O
that	O
plays	O
an	O
important	O
role	O
in	O
attenuating	O
inflammation	O
,	O
6	O
including	O
processes	O
that	O
can	O
lead	O
to	O
atherogenesis	O
.	O
HO	O
‐	O
1	O
induction	O
has	O
been	O
shown	O
to	O
suppress	O
venular	O
leukocyte	O
adhesion	O
,	O
an	O
effect	O
that	O
is	O
abolished	O
by	O
HO	O
inhibitors	O
and	O
reconstituted	O
by	O
bilirubin	O
,	O
7	O
,	O
8	O
whereas	O
knockdown	O
of	O
HO	O
‐	O
1	O
accelerates	O
plaque	O
formation	O
in	O
apolipoprotein	O
E	O
(	O
apoE	O
)	O
‐	O
deficient	O
mice	O
.	O
9	O
However	O
,	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
the	O
products	O
of	O
the	O
HO	O
‐	O
1	O
enzyme	O
act	O
to	O
prevent	O
atherosclerosis	O
have	O
yet	O
to	O
be	O
delineated	O
.	O

Vascular	O
cell	O
adhesion	O
molecule	O
1	O
(	O
VCAM	O
‐	O
1	O
)	O
is	O
localized	O
on	O
the	O
surface	O
of	O
activated	O
endothelial	O
cells	O
and	O
has	O
been	O
implicated	O
as	O
a	O
key	O
mediator	O
of	O
atherosclerosis	O
.	O
10	O
It	O
selectively	O
binds	O
to	O
α4	O
‐	O
containing	O
integrins	O
(	O
α4β1	O
,	O
α4β7	O
)	O
expressed	O
by	O
T	O
lymphocytes	O
and	O
monocytes11	O
and	O
facilitates	O
leukocyte	O
migration	O
into	O
the	O
vascular	O
intima	O
,	O
an	O
early	O
and	O
critical	O
event	O
in	O
plaque	O
formation	O
.	O
12	O
,	O
13	O
VCAM	O
‐	O
1	O
is	O
detected	O
primarily	O
at	O
atherosclerosis	O
‐	O
prone	O
sites	O
,	O
14	O
and	O
targeted	O
disruption	O
of	O
this	O
adhesion	O
molecule	O
inhibits	O
early	O
plaque	O
formation	O
in	O
low	O
‐	O
density	O
lipoprotein	O
receptor	O
‐	O
deficient	O
(	O
Ldlr	O
−	O
/	O
−	O
)	O
mice	O
.	O
10	O
Integrin	O
binding	O
to	O
VCAM	O
‐	O
1	O
triggers	O
a	O
signaling	O
cascade	O
within	O
the	O
endothelial	O
cell	O
that	O
results	O
in	O
the	O
generation	O
of	O
superoxide	O
(	O
[UNK]	O
)	O
through	O
activation	O
of	O
NAPDH	O
oxidase	O
(	O
Nox	O
)	O
.	O
15	O
The	O
increase	O
in	O
intracellular	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
induces	O
actin	O
restructuring	O
,	O
leading	O
to	O
disruption	O
of	O
endothelial	O
tight	O
junctions	O
and	O
enabling	O
leukocyte	O
transmigration	O
from	O
the	O
vessel	O
lumen	O
to	O
the	O
intima	O
.	O
15	O
,	O
16	O
Bilirubin	O
is	O
a	O
potent	O
chain	O
‐	O
breaking	O
antioxidant17	O
that	O
uniquely	O
undergoes	O
intracellular	O
redox	O
cycling	O
,	O
18	O
facilitating	O
the	O
efficient	O
consumption	O
of	O
ROS	O
.	O
Our	O
group	O
has	O
shown	O
that	O
bilirubin	O
inhibits	O
the	O
transendothelial	O
migration	O
of	O
murine	O
lymphocytes	O
in	O
vitro19	O
and	O
also	O
attenuates	O
tissue	O
injury	O
in	O
mouse	B-methodology
models	I-methodology
of	O
VCAM	O
‐	O
1	O
‐	O
dependent	O
inflammation	O
.	O
19	O
,	O
20	O
Based	O
on	O
these	O
findings	O
,	O
we	O
postulate	O
that	O
bilirubin	O
'	O
s	O
cardioprotective	O
effect	O
is	O
derived	O
from	O
its	O
ability	O
to	O
disrupt	O
VCAM	O
‐	O
1	O
‐	O
mediated	O
leukocyte	O
migration	O
by	O
scavenging	O
Nox	O
‐	O
derived	O
ROS	O
.	O
19	O
,	O
20	O
,	O
21	O

Intercellular	O
adhesion	O
molecule	O
1	O
(	O
ICAM	O
‐	O
1	O
)	O
is	O
another	O
endothelial	O
adhesion	O
molecule	O
that	O
is	O
upregulated	O
at	O
sites	O
of	O
atherosclerosis	O
.	O
22	O
Studies	O
have	O
shown	O
that	O
levels	O
of	O
soluble	O
ICAM	O
‐	O
1	O
correlate	O
with	O
the	O
extent	O
of	O
atherosclerosis	O
in	O
humans	O
,	O
23	O
and	O
that	O
ICAM	O
‐	O
1	O
knockdown	O
is	O
associated	O
with	O
a	O
reduction	O
in	O
the	O
size	O
of	O
vascular	O
lesions	O
in	O
apoE	O
‐	O
deficient	O
mice	O
.	O
24	O
The	O
selective	O
binding	O
of	O
αLβ2	O
integrin	O
,	O
which	O
is	O
expressed	O
by	O
lymphocytes	O
,	O
monocytes	O
,	O
and	O
neutrophils	O
,	O
25	O
,	O
26	O
to	O
ICAM	O
‐	O
1	O
activates	O
xanthine	O
oxidase	O
(	O
XO	O
)	O
and	O
generates	O
[UNK]	O
and	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
within	O
the	O
endothelial	O
cell	O
.	O
27	O
,	O
28	O
While	O
the	O
effect	O
of	O
bilirubin	O
on	O
ICAM	O
‐	O
1	O
signaling	O
has	O
not	O
previously	O
been	O
studied	O
,	O
we	O
speculate	O
that	O
it	O
scavenges	O
ICAM	O
‐	O
1	O
‐	O
dependent	O
intracellular	O
ROS	O
in	O
a	O
manner	O
analogous	O
to	O
what	O
we	O
have	O
proposed	O
for	O
VCAM	O
‐	O
1	O
,	O
thereby	O
augmenting	O
its	O
ability	O
to	O
inhibit	O
atherosclerosis	O
.	O
Monocytes	O
represent	O
one	O
of	O
the	O
principal	O
inflammatory	O
cell	O
types	O
in	O
early	O
atherosclerotic	O
plaques	O
and	O
are	O
believed	O
to	O
play	O
an	O
important	O
role	O
in	O
lesion	O
progression	O
.	O
13	O
T	O
lymphocytes	O
also	O
contribute	O
to	O
atherogenesis	O
by	O
producing	O
cytokines	O
and	O
chemokines	O
that	O
induce	O
adhesion	O
molecule	O
expression	O
and	O
recruit	O
inflammatory	O
cells	O
to	O
sites	O
of	O
vascular	O
injury	O
.	O
29	O
Given	O
that	O
both	O
monocytes	O
and	O
T	O
cells	O
express	O
integrins	O
that	O
mediate	O
binding	O
to	O
VCAM	O
‐	O
1	O
and	O
ICAM	O
‐	O
1	O
,	O
22	O
we	O
postulate	O
that	O
bilirubin	O
impedes	O
atherogenesis	O
by	O
disrupting	O
the	O
trafficking	O
of	O
these	O
leukocytes	O
to	O
the	O
vascular	O
intima	O
.	O
To	O
test	O
this	O
hypothesis	O
,	O
we	O
investigated	O
the	O
modulatory	O
effect	O
of	O
bilirubin	O
on	O
VCAM	O
‐	O
1	O
‐	O
and	O
ICAM	O
‐	O
1	O
‐	O
dependent	O
monocyte	O
migration	O
in	B-methodology
vitro	I-methodology
and	O
validated	O
our	O
findings	O
by	O
assessing	O
the	O
influence	O
of	O
bilirubin	O
on	O
the	O
development	O
of	O
early	O
atherosclerotic	O
lesions	O
in	O
Ldlr	O
−	O
/	O
−	O
mice	O
.	O

Our	O
data	O
indicate	O
that	O
bilirubin	O
impedes	O
the	O
migration	O
of	O
monocytes	O
and	O
lymphocytes	O
to	O
the	O
vascular	O
intima	O
by	O
scavenging	O
ROS	O
that	O
mediate	O
endothelial	O
VCAM	O
‐	O
1	O
and	O
ICAM	O
‐	O
1	O
signaling	O
,	O
suggesting	O
a	O
potential	O
mechanism	O
for	O
the	O
cardioprotective	O
effects	O
of	O
bilirubin	O
.	O
Unconjugated	O
bilirubin	O
(	O
bilirubin	O
IXα	O
)	O
was	O
obtained	O
from	O
Porphyrin	O
Products	O
(	O
Logan	O
,	O
UT	O
)	O
and	O
further	O
purified	O
according	O
to	O
the	O
method	O
of	O
McDonagh	O
and	O
Assisi30	O
to	O
eliminate	O
potential	O
lipid	O
contaminants	O
.	O
Unless	O
otherwise	O
indicated	O
,	O
bilirubin	O
was	O
freshly	O
prepared	O
in	O
0	O
.	O
1	O
mol	O
/	O
L	O
of	O
potassium	O
phosphate	O
(	O
pH	O
12	O
)	O
,	O
as	O
previously	O
described	O
by	O
our	O
group	O
.	O
19	O
The	O
addition	O
of	O
a	O
small	O
aliquot	O
(	O
≤0	O
.	O
4	O
%	O
vol	O
/	O
vol	O
)	O
of	O
this	O
vehicle	O
solution	O
had	O
no	O
effect	O
on	O
the	O
pH	O
of	O
the	O
culture	O
medium	O
or	O
on	O
cell	O
viability	O
.	O
31	O
Recombinant	O
human	O
tumor	O
necrosis	O
factor	O
α	O
(	O
TNF	O
‐	O
α	O
)	O
was	O
purchased	O
from	O
PeproTech	O
(	O
Rocky	O
Hill	O
,	O
NJ	O
)	O
and	O
solubilized	O
in	O
DMSO	O
.	O
Allopurinol	O
(	O
AP	O
)	O
was	O
purchased	O
from	O
MP	O
Biomedicals	O
(	O
Santa	O
Ana	O
,	O
CA	O
)	O
.	O
ML171	O
(	O
2	O
‐	O
acetylphenothiazine	O
)	O
and	O
mouse	O
immunoglobulin	O
G	O
(	O
IgG	O
)	O
were	O
purchased	O
from	O
Calbiochem	O
(	O
San	O
Diego	O
,	O
CA	O
)	O
.	O
Mouse	O
anti	O
‐	O
human	O
CD18	O
(	O
β2	O
;	O
ab8220	O
)	O
and	O
mouse	O
anti	O
‐	O
human	O
CD49d	O
(	O
α4	O
;	O
clone	O
2B4	O
)	O
were	O
purchased	O
from	O
Abcam	O
(	O
Paris	O
,	O
France	O
)	O
and	O
R	O
&	O
D	O
Systems	O
(	O
Minneapolis	O
,	O
MN	O
)	O
,	O
respectively	O
.	O
Mouse	O
anti	O
‐	O
human	O
VCAM	O
‐	O
1	O
(	O
clone	O
P3C4	O
)	O
and	O
mouse	O
anti	O
‐	O
human	O
ICAM	O
‐	O
1	O
(	O
clone	O
P2A4	O
)	O
were	O
purchased	O
from	O
Millipore	O
(	O
Temecula	O
,	O
CA	O
)	O
.	O
CellTrace	O
Far	O
Red	O
,	O
dihydrorhodamine	O
123	O
,	O
Texas	O
Red	O
‐	O
dextran	O
10	O
000	O
molecular	O
weight	O
,	O
and	O
rhodamine	O
6G	O
were	O
obtained	O
from	O
Molecular	O
Probes	O
(	O
Eugene	O
,	O
OR	O
)	O
.	O
Human	O
serum	O
albumin	O
was	O
purchased	O
from	O
Sigma	O
‐	O
Aldrich	O
(	O
St	O
.	O

Louis	O
,	O
MO	O
)	O
.	O
Human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
were	O
isolated	O
from	O
umbilical	O
cords	O
using	O
type	O
I	O
collagenase	O
.	O
32	O
Cells	O
were	O
grown	O
in	O
F	O
‐	O
12K	O
supplemented	O
with	O
10	O
%	O
FCS	O
,	O
endothelial	O
cell	O
growth	O
supplement	O
(	O
Corning	O
,	O
Bedford	O
,	O
MA	O
)	O
,	O
0	O
.	O
1	O
mg	O
/	O
mL	O
of	O
heparin	O
(	O
Sigma	O
‐	O
Aldrich	O
)	O
,	O
100	O
IU	O
of	O
penicillin	O
,	O
and	O
100	O
μg	O
/	O
mL	O
of	O
streptomycin	O
(	O
Corning	O
,	O
Manassas	O
,	O
VA	O
)	O
.	O
All	O
experiments	O
were	O
performed	O
using	O
cells	O
pooled	O
from	O
multiple	O
donors	O
,	O
passages	O
3	O
to	O
7	O
.	O
The	O
human	O
acute	O
monocyte	O
leukemia	O
cell	O
line	O
,	O
THP	O
‐	O
1	O
(	O
ATCC	O
,	O
Manassas	O
,	O
VA	O
)	O
,	O
was	O
cultured	O
in	O
RPMI	O
1640	O
(	O
Hyclone	O
,	O
Logan	O
,	O
UT	O
)	O
supplemented	O
with	O
10	O
%	O
FCS	O
,	O
1	O
mmol	O
/	O
L	O
of	O
l	O
‐	O
glutamine	O
,	O
100	O
IU	O
of	O
penicillin	O
,	O
and	O
100	O
μg	O
/	O
mL	O
of	O
streptomycin	O
.	O
Whole	O
‐	O
cell	O
lysates	O
were	O
prepared	O
in	O
modified	O
RIPA	O
buffer	O
(	O
50	O
mmol	O
/	O
L	O
of	O
HEPES	O
,	O
20	O
mmol	O
/	O
L	O
of	O
pyrophosphate	O
,	O
25	O
mmol	O
/	O
L	O
of	O
β	O
‐	O
glycerophosphate	O
,	O
50	O
mmol	O
/	O
L	O
of	O
NaF	O
,	O
5	O
mmol	O
/	O
L	O
of	O
Na2MoO4	O
,	O
5	O
mmol	O
/	O
L	O
of	O
EDTA	O
,	O
150	O
mmol	O
/	O
L	O
of	O
orthophenanthrol	O
,	O
1	O
%	O
NP	O
‐	O
40	O
,	O
2	O
%	O
deoxycholate	O
,	O
and	O
1	O
%	O
Triton	O
X	O
‐	O
100	O
)	O
in	O
the	O
presence	O
of	O
protease	O
and	O
phosphatase	O
inhibitors	O
.	O
Protein	O
concentrations	O
were	O
quantified	O
using	O
the	O
Pierce	O
BCA	O
Protein	O
Assay	O
(	O
Thermo	O
Scientific	O
,	O
Waltham	O
,	O
MA	O
)	O
.	O
Samples	O
(	O
25	O
μg	O
protein	O
)	O
were	O
denatured	O
,	O
resolved	O
on	O
an	O
8	O
%	O
SDS	O
‐	O
polyacrylamide	O
gel	O
,	O
and	O
then	O
transferred	O
to	O
an	O
Immuno	O
‐	O
blot	O
PVDF	O
membrane	O
(	O
Amersham	O
Biosciences	O
,	O
Piscataway	O
,	O
NJ	O
)	O
.	O

Incubation	O
with	O
primary	O
antibodies	O
(	O
rabbit	O
anti	O
‐	O
VCAM	O
‐	O
1	O
,	O
mouse	O
anti	O
‐	O
ICAM	O
‐	O
1	O
,	O
rabbit	O
anti	O
‐	O
E	O
‐	O
Selectin	O
,	O
and	O
mouse	O
anti	O
‐	O
GAPDH	O
;	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
)	O
was	O
performed	O
for	O
2	O
hours	O
,	O
followed	O
by	O
HRP	O
‐	O
linked	O
anti	O
‐	O
rabbit	O
IgG	O
or	O
anti	O
‐	O
mouse	O
IgG	O
(	O
Bio	O
‐	O
Rad	O
,	O
Hercules	O
,	O
CA	O
)	O
secondary	O
antibodies	O
for	O
40	O
minutes	O
at	O
room	O
temperature	O
.	O
Immunoreactive	O
bands	O
were	O
visualized	O
by	O
chemiluminescence	O
using	O
an	O
Amersham	O
ECL	O
Prime	O
Western	O
Blotting	O
Detection	O
Kit	O
(	O
GE	O
Healthcare	O
,	O
Pittsburgh	O
,	O
PA	O
)	O
.	O
Densitometry	O
was	O
performed	O
using	O
ChemiDoc	O
MP	O
System	O
software	O
(	O
Bio	O
‐	O
Rad	O
)	O
.	O
Total	O
cellular	O
RNA	O
was	O
extracted	O
and	O
quantitative	O
reverse	O
‐	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
‐	O
PCR	O
)	O
was	O
performed	O
with	O
a	O
MX300P	O
system	O
(	O
Stratagene	O
,	O
Cedar	O
Creek	O
,	O
TX	O
)	O
using	O
SYBR	O
Green	O
QPRC	O
Master	O
Mix	O
(	O
AB	O
‐	O
4166	O
;	O
Thermo	O
Scientific	O
)	O
.	O

Primers	O
for	O
human	O
VCAM	O
‐	O
1	O
(	O
sense	O
:	O
5	O
′	O
‐	O
caggctgtgagtccccatt	O
‐	O
3	O
′	O
;	O
antisense	O
:	O
5	O
′	O
‐	O
ttgactgtgatcggcttcc	O
‐	O
3	O
′	O
)	O
,	O
ICAM	O
‐	O
1	O
(	O
sense	O
:	O
5	O
′	O
‐	O
accatctacagctttccggc	O
‐	O
3	O
′	O
;	O
antisense	O
:	O
5	O
′	O
‐	O
tttctggccacgtccagttt	O
‐	O
3	O
′	O
)	O
,	O
E	O
‐	O
Selectin	O
(	O
sense	O
:	O
5	O
′	O
‐	O
ggcagttccgggaaagatca	O
‐	O
3	O
′	O
;	O
antisense	O
:	O
5	O
′	O
‐	O
gtgggagcttcacaggtagg	O
‐	O
3	O
′	O
)	O
,	O
P	O
‐	O
Selectin	O
(	O
sense	O
:	O
5	O
′	O
‐	O
cgaggaaacatgacctgcct	O
‐	O
3	O
′	O
;	O
antisense	O
:	O
5	O
′	O
‐	O
tagcctcacaggttggcaag	O
‐	O
3	O
′	O
)	O
,	O
and	O
platelet	O
‐	O
endothelial	O
cell	O
adhesion	O
molecule	O
1	O
(	O
PECAM	O
‐	O
1	O
;	O
sense	O
:	O
5	O
′	O
‐	O
gctaactgaacccactcccc	O
‐	O
3	O
′	O
;	O
antisense	O
:	O
5	O
′	O
‐	O
gacagctgccatgtgactct	O
‐	O
3	O
′	O
)	O
were	O
utilized	O
for	O
assessment	O
of	O
adhesion	O
molecule	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
expression	O
.	O
Human	O
β	O
‐	O
2	O
‐	O
microglobulin	O
(	O
sense	O
:	O
5	O
′	O
‐	O
ggcattcctgaagctgac	O
‐	O
3	O
′	O
;	O
antisense	O
:	O
5	O
′	O
‐	O
gaatctttggagtacgctgg	O
‐	O
3	O
′	O
)	O
was	O
used	O
as	O
a	O
control	O
for	O
amplification	O
.	O
HUVECs	O
were	O
seeded	O
at	O
a	O
density	O
of	O
0	O
.	O
8×105	O
cells	O
per	O
well	O
and	O
grown	O
to	O
confluence	O
in	O
24	O
‐	O
well	O
plates	O
(	O
Corning	O
)	O
.	O

Cytokine	O
(	O
interleukin	O
[	O
IL	O
]	O
‐	O
6	O
,	O
IL	O
‐	O
1β	O
,	O
IL	O
‐	O
8	O
,	O
macrophage	O
colony	O
stimulating	O
factor	O
[	O
M	O
‐	O
CSF	O
]	O
,	O
monocyte	O
chemoattractant	O
protein	O
‐	O
1	O
[	O
MCP	O
‐	O
1	O
;	O
chemokine	O
ligand	O
{	O
CCL	O
}	O
2	O
]	O
,	O
and	O
regulated	O
on	O
activation	O
,	O
normal	O
T	O
cell	O
expressed	O
and	O
secreted	O
[	O
RANTES	O
;	O
CCL	O
‐	O
5	O
]	O
)	O
levels	O
in	O
cell	O
‐	O
culture	O
medium	O
were	O
determined	O
24	O
hours	O
following	O
the	O
addition	O
of	O
the	O
indicated	O
treatments	O
using	O
a	O
human	O
Magnetic	O
Luminex	O
Assay	O
Kit	O
(	O
R	O
&	O
D	O
Systems	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
,	O
and	O
quantified	O
by	O
a	O
Luminex	O
multiplexing	O
suspension	O
array	O
system	O
(	O
Millipore	O
,	O
Sigma	O
‐	O
Aldrich	O
)	O
.	O
33	O
HUVECs	O
were	O
seeded	O
at	O
a	O
density	O
of	O
4×105	O
cells	O
per	O
insert	O
and	O
grown	O
to	O
confluence	O
on	O
the	O
upper	O
chamber	O
of	O
24	O
‐	O
well	O
transwells	O
with	O
8	O
‐	O
μm	O
pores	O
(	O
Costar	O
,	O
Cambridge	O
,	O
MA	O
)	O
that	O
were	O
precoated	O
with	O
collagen	O
(	O
0	O
.	O
4	O
mg	O
/	O
cm2	O
)	O
and	O
fibronectin	O
(	O
2	O
μg	O
/	O
cm2	O
)	O
.	O
Monolayer	O
integrity	O
was	O
validated	O
by	O
overlaying	O
Texas	O
Red	O
dextran	O
10	O
kDa	O
(	O
20	O
μg	O
/	O
mL	O
)	O
and	O
measuring	O
fluorescence	O
intensity	O
(	O
excitation	O
,	O
595	O
nm	O
;	O
emission	O
,	O
625	O
nm	O
)	O
in	O
the	O
lower	O
chamber	O
.	O
HUVEC	O
monolayers	O
were	O
stimulated	O
with	O
5	O
ng	O
/	O
mL	O
of	O
TNF	O
‐	O
α	O
for	O
24	O
hours	O
before	O
performing	O
migration	O
studies	O
in	O
order	O
to	O
induce	O
adhesion	O
molecule	O
expression	O
.	O
34	O
THP	O
‐	O
1	O
cells	O
were	O
incubated	O
in	O
the	O
presence	O
of	O
25	O
μmol	O
/	O
L	O
of	O
CellTrace	O
Far	O
Red	O
for	O
45	O
minutes	O
at	O
37°C	O
,	O
washed	O
,	O
and	O
migration	O
initiated	O
by	O
the	O
addition	O
of	O
these	O
fluorescently	O
‐	O
labeled	O
cells	O
(	O
1×105	O
cells	O
per	O
insert	O
)	O
to	O
the	O
upper	O
chamber	O
of	O
the	O
transwell	O
.	O
Studies	O
were	O
performed	O
in	O
the	O
presence	O
of	O
bilirubin	O
(	O
0	O
–	O
20	O
μmol	O
/	O
L	O
)	O
or	O
vehicle	O
,	O
which	O
was	O
added	O
to	O
the	O
medium	O
(	O
F	O
‐	O
12K	O
plus	O
0	O
.	O
1	O
%	O
human	O
serum	O
albumin	O
)	O
in	O
both	O
the	O
upper	O
and	O
lower	O
chambers	O
.	O

Transendothelial	O
migration	O
was	O
quantified	O
by	O
measuring	O
CellTrace	O
fluorescence	O
intensity	O
(	O
excitation	O
,	O
625	O
nm	O
;	O
emission	O
,	O
670	O
nm	O
)	O
in	O
the	O
lower	O
chamber	O
of	O
the	O
transwell	O
at	O
the	O
indicated	O
time	O
intervals	O
using	O
a	O
Biotek	O
Synergy	O
H1	O
reader	O
.	O
35	O
The	O
accuracy	O
of	O
the	O
measurements	O
was	O
validated	O
by	O
direct	O
cell	O
count	O
.	O
Migration	O
studies	O
also	O
were	O
conducted	O
in	O
the	O
presence	O
of	O
maximally	O
effective	O
concentrations	O
of	O
blocking	O
antibodies	O
to	O
VCAM	O
‐	O
1	O
(	O
10	O
μg	O
/	O
mL	O
)	O
,	O
ICAM	O
‐	O
1	O
(	O
10	O
μg	O
/	O
mL	O
)	O
,	O
α4	O
(	O
20	O
μg	O
/	O
mL	O
)	O
,	O
and	O
/	O
or	O
β2	O
(	O
5	O
μg	O
/	O
mL	O
)	O
,	O
which	O
were	O
added	O
to	O
the	O
upper	O
chamber	O
of	O
the	O
transwell	O
.	O
As	O
control	O
,	O
isotype	O
antibody	O
was	O
found	O
to	O
have	O
no	O
effect	O
on	O
THP	O
‐	O
1	O
migration	O
.	O
In	O
experiments	O
using	O
maximally	O
effective	O
concentrations	O
of	O
the	O
Nox	O
inhibitor	O
,	O
ML171	O
(	O
10	O
μmol	O
/	O
L	O
)	O
,	O
and	O
/	O
or	O
the	O
XO	O
inhibitor	O
,	O
allopurinol	O
(	O
40	O
μmol	O
/	O
L	O
)	O
,	O
reagents	O
were	O
solubilized	O
in	O
DMSO	O
and	O
added	O
to	O
both	O
the	O
upper	O
and	O
lower	O
chambers	O
(	O
final	O
DMSO	O
concentration	O
,	O
0	O
.	O
05	O
%	O
)	O
.	O
HUVECs	O
were	O
seeded	O
on	O
96	O
‐	O
well	O
plates	O
(	O
Thermo	O
Scientific	O
)	O
at	O
a	O
density	O
of	O
1×104	O
cells	O
per	O
well	O
and	O
grown	O
to	O
confluence	O
.	O
Monolayers	O
were	O
stimulated	O
with	O
5	O
ng	O
/	O
mL	O
of	O
TNF	O
‐	O
α	O
for	O
24	O
hours	O
in	O
the	O
presence	O
of	O
bilirubin	O
or	O
vehicle	O
,	O
after	O
which	O
THP	O
‐	O
1	O
monocytes	O
(	O
1×105	O
cells	O
per	O
well	O
)	O
labeled	O
with	O
25	O
μmol	O
/	O
L	O
of	O
CellTrace	O
Far	O
Red	O
were	O
added	O
.	O
Following	O
a	O
30	O
‐	O
minute	O
incubation	O
at	O
37°C	O
,	O
nonadherent	O
monocytes	O
were	O
removed	O
by	O
gently	O
vortexing	O
and	O
aspirating	O
the	O
supernatant	O
3	O
sequential	O
times	O
,	O
as	O
previously	O
described	O
.	O
15	O
,	O
19	O
Monolayers	O
were	O
then	O
overlaid	O
with	O
100	O
μL	O
of	O
PBS	O
and	O
adherence	O
was	O
quantified	O
by	O
measuring	O
CellTrace	O
fluorescence	O
intensity	O
.	O
36	O
HUVECs	O
were	O
grown	O
on	O
35	O
‐	O
mm	O
glass	O
‐	O
bottomed	O
culture	O
dishes	O
(	O
Ibidi	O
,	O
Munich	O
,	O
Germany	O
)	O
and	O
stimulated	O
with	O
5	O
ng	O
/	O
mL	O
of	O
TNF	O
‐	O
α	O
for	O
24	O
hours	O
to	O
induce	O
adhesion	O
molecule	O
expression	O
.	O

Monolayers	O
were	O
subsequently	O
washed	O
and	O
incubated	O
in	O
the	O
presence	O
or	O
absence	O
of	O
10	O
μg	O
/	O
mL	O
of	O
anti	O
‐	O
VCAM	O
‐	O
1	O
or	O
anti	O
‐	O
ICAM	O
‐	O
1	O
antibody	O
for	O
30	O
minutes	O
at	O
37°C	O
.	O
Cells	O
were	O
then	O
washed	O
,	O
loaded	O
with	O
1	O
μmol	O
/	O
L	O
dihydrorhodamine	O
,	O
and	O
incubated	O
in	O
the	O
presence	O
of	O
20	O
μmol	O
/	O
L	O
of	O
bilirubin	O
or	O
vehicle	O
in	O
Phenol	O
Red	O
–	O
free	O
medium	O
for	O
15	O
minutes	O
.	O
Additional	O
studies	O
were	O
conducted	O
in	O
the	O
presence	O
of	O
ML171	O
(	O
10	O
μmol	O
/	O
L	O
)	O
or	O
AP	O
(	O
40	O
μmol	O
/	O
L	O
)	O
.	O
Adhesion	O
molecule	O
activation	O
was	O
triggered	O
by	O
the	O
addition	O
of	O
cross	O
‐	O
linking	O
goat	O
anti	O
‐	O
mouse	O
(	O
1	O
:	O
100	O
)	O
secondary	O
antibodies	O
(	O
Pierce	O
,	O
Rockford	O
,	O
IL	O
)	O
and	O
the	O
subsequent	O
time	O
‐	O
dependent	O
changes	O
in	O
dihydrorhodamine	O
fluorescence	O
intensity	O
(	O
excitation	O
,	O
485	O
nm	O
;	O
emission	O
,	O
525	O
nm	O
)	O
were	O
quantified	O
by	O
confocal	O
microscopy	O
(	O
Zeiss	O
7	O
LIVE	O
;	O
Carl	O
Zeiss	O
,	O
Jena	O
,	O
Germany	O
)	O
,	O
as	O
previously	O
described	O
.	O
19	O
XO	O
activity	O
was	O
determined	O
by	O
colorimetric	O
assay	O
using	O
an	O
Amplex	O
Red	O
Xanthine	O
/	O
Xanthine	O
Oxidase	O
Assay	O
Kit	O
(	O
Molecular	O
Probes	O
)	O
,	O
according	O
to	O
the	O
[UNK]	O
instructions	O
.	O
H2O2	O
production	O
was	O
quantified	O
by	O
measuring	O
absorbance	O
at	O
571	O
nm	O
.	O
All	O
reactions	O
were	O
conducted	O
at	O
room	O
temperature	O
for	O
15	O
minutes	O
.	O
Bilirubin	O
and	O
the	O
XO	O
inhibitors	O
AP	O
and	O
2	O
‐	O
chloro	O
‐	O
6	O
(	O
methylamino	O
)	O
purine	O
(	O
CMAP	O
)	O
,	O
were	O
solubilized	O
in	O
DMSO	O
.	O
Ldlr	O
−	O
/	O
−	O
mice	O
on	O
a	O
C57BL	O
/	O
6	O
background	O
were	O
a	O
generous	O
gift	O
from	O
Dr	O
David	O
Hui	O
(	O
University	O
of	O
Cincinnati	O
,	O
Cincinnati	O
,	O
OH	O
)	O
.	O
Animals	O
were	O
maintained	O
in	O
a	O
pathogen	O
‐	O
free	O
environment	O
on	O
a	O
12	O
‐	O
hour	O
light	O
/	O
dark	O
cycle	O
.	O

Beginning	O
at	O
12	O
weeks	O
of	O
age	O
,	O
male	O
mice	O
were	O
fed	O
a	O
Western	O
(	O
D12108C	O
;	O
20	O
%	O
fat	O
,	O
1	O
.	O
25	O
%	O
cholesterol	O
;	O
Research	O
Diets	O
,	O
Inc	O
,	O
New	O
Brunswick	O
,	O
NJ	O
)	O
diet	O
ad	O
libitum	O
while	O
simultaneously	O
receiving	O
daily	O
intraperitoneal	O
injections	O
of	O
vehicle	O
(	O
50	O
mmol	O
/	O
L	O
of	O
K3PO4	O
plus	O
10	O
%	O
serum	O
;	O
n	O
=	O
4	O
)	O
,	O
bilirubin	O
(	O
30	O
mg	O
/	O
kg	O
body	O
weight	O
in	O
vehicle	O
;	O
n	O
=	O
7	O
)	O
,	O
or	O
sham	O
(	O
n	O
=	O
7	O
)	O
for	O
8	O
weeks	O
.	O
Body	O
weight	O
was	O
monitored	O
weekly	O
.	O
Because	O
the	O
marked	O
lipemia	O
in	O
Western	O
diet	O
–	O
fed	O
Ldlr	O
−	O
/	O
−	O
mice	O
impedes	O
the	O
serological	O
assay	O
for	O
bilirubin	O
,	O
37	O
,	O
38	O
steady	O
‐	O
state	O
bilirubin	O
levels	O
were	O
determined	O
in	O
chow	O
‐	O
fed	O
congenic	O
C57BL	O
/	O
6J	O
(	O
The	O
Jackson	O
Laboratory	O
,	O
Bar	O
Harbor	O
,	O
ME	O
)	O
mice	O
.	O
All	O
studies	O
were	O
reviewed	O
and	O
approved	O
by	O
the	O
University	O
of	O
Cincinnati	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
(	O
protocol	O
#	O
14	O
‐	O
03	O
‐	O
03	O
‐	O
01	O
)	O
.	O
The	O
heart	O
and	O
aorta	O
were	O
removed	O
and	O
prepared	O
as	O
previously	O
described	O
.	O
39	O
,	O
40	O
Briefly	O
,	O
hearts	O
were	O
embedded	O
in	O
optimal	O
cutting	O
temperature	O
compound	O
(	O
Tissue	O
‐	O
Tek	O
)	O
,	O
frozen	O
,	O
and	O
7	O
‐	O
μm	O
sections	O
obtained	O
with	O
a	O
cryostat	O
(	O
Leica	O
Biosystems	O
,	O
Wetzlar	O
,	O
Germany	O
)	O
,	O
commencing	O
at	O
the	O
valve	O
nubs	O
and	O
appearance	O
of	O
the	O
coronary	O
artery	O
and	O
continuing	O
through	O
the	O
aortic	O
sinus	O
until	O
the	O
valve	O
separates	O
at	O
the	O
base	O
.	O
40	O
Serial	O
aortic	O
root	O
sections	O
were	O
stained	O
with	O
Oil	O
Red	O
O	O
to	O
assess	O
for	O
neutral	O
lipid	O
accumulation	O
and	O
with	O
Sirius	O
Red	O
to	O
identify	O
collagen	O
deposition	O
.	O
12	O
Immunohistochemical	O
staining	O
for	O
α	O
‐	O
smooth	O
muscle	O
(	O
α	O
‐	O
SM	O
)	O
actin	O
(	O
prediluted	O
;	O
Roche	O
,	O
Indianapolis	O
,	O
IN	O
)	O
to	O
detect	O
smooth	O
muscle	O
cells41	O
was	O
conducted	O
using	O
an	O
OmniMap	O
detection	O
kit	O
(	O
Roche	O
)	O
.	O

Immunofluorescence	O
for	O
VCAM	O
‐	O
1	O
(	O
1	O
:	O
500	O
;	O
Biorbyt	O
Ltd	O
,	O
Cambridge	O
,	O
UK	O
)	O
,	O
ICAM	O
‐	O
1	O
(	O
1	O
:	O
75	O
;	O
Abcam	O
,	O
Cambridge	O
,	O
MA	O
)	O
,	O
CD68	O
(	O
macrophages	O
;	O
1	O
:	O
25	O
;	O
Abcam	O
)	O
,	O
CD3	O
(	O
T	O
lymphocytes	O
;	O
prediluted	O
;	O
Ventana	O
Medical	O
Systems	O
,	O
Oro	O
Valley	O
,	O
AZ	O
)	O
,	O
chlorinated	O
tyrosines	O
(	O
ROS	O
;	O
1	O
:	O
100	O
;	O
Hycult	O
Biotech	O
,	O
Uden	O
,	O
The	O
Netherlands	O
)	O
,	O
and	O
nitrosylated	O
tyrosines	O
(	O
reactive	O
nitrogen	O
species	O
;	O
1	O
:	O
100	O
;	O
Life	O
Technologies	O
,	O
Invitrogen	O
,	O
CA	O
)	O
was	O
assessed	O
using	O
anti	O
‐	O
rabbit	O
secondary	O
antibodies	O
conjugated	O
to	O
Alexa488	O
(	O
1	O
:	O
100	O
;	O
Life	O
Technologies	O
)	O
and	O
4	O
,	O
6	O
‐	O
diamidino	O
‐	O
2	O
‐	O
phenylindole	O
(	O
DAPI	O
)	O
counterstaining	O
.	O
Images	O
were	O
obtained	O
using	O
an	O
Olympus	O
BX61	O
microscope	O
(	O
Olympus	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O
Quantitative	O
analyses	O
of	O
the	O
lesion	O
area	O
were	O
performed	O
on	O
digitalized	O
images	O
using	O
ImageJ	O
software	O
(	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
MD	O
)	O
and	O
expressed	O
as	O
ratios	O
of	O
lesion	O
area	O
to	O
total	O
valve	O
area	O
or	O
as	O
ratios	O
of	O
compositional	O
area	O
to	O
total	O
lesion	O
area	O
,	O
as	O
previously	O
described	O
.	O
39	O
,	O
42	O
Blood	O
samples	O
were	O
collected	O
at	O
the	O
time	O
of	O
euthanasia	O
.	O
Serum	O
bilirubin	O
levels	O
were	O
determined	O
using	O
the	O
Sigma	O
Diagnostics	O
Total	O
Bilirubin	O
Assay	O
Kit	O
(	O
Sigma	O
Chemical	O
)	O
,	O
as	O
previously	O
described	O
.	O
31	O
Serum	O
chemokines	O
(	O
MCP	O
‐	O
1	O
,	O
MIP	O
‐	O
1α	O
,	O
and	O
RANTES	O
)	O
were	O
detected	O
using	O
an	O
Immunology	O
Multiplex	O
Assay	O
Kit	O
(	O
EMD	O
Millipore	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
,	O
and	O
quantified	O
by	O
Luminex	O
.	O
33	O
Serum	O
total	O
cholesterol	O
and	O
triglyceride	O
levels	O
were	O
determined	O
using	O
Cholesterol	O
Fluorometric	O
Assay	O
and	O
Triglyceride	O
Colorimetric	O
Assay	O
Kits	O
,	O
respectively	O
(	O
Cayman	O
Chemical	O
Co	O
,	O
Ann	O
Arbor	O
,	O
MI	O
)	O
.	O

Serum	O
malondialdehyde	O
(	O
MDA	O
)	O
concentration	O
,	O
a	O
marker	O
of	O
lipid	O
peroxidation	O
,	O
was	O
quantified	O
using	O
a	O
Lipid	O
Peroxidation	O
(	O
MDA	O
)	O
Fluorometric	O
Assay	O
Kit	O
(	O
Abcam	O
)	O
.	O
Data	O
were	O
analyzed	O
using	O
a	O
computer	O
‐	O
based	O
statistical	O
package	O
(	O
SSI	O
SigmaStat	O
;	O
Systat	O
Software	O
Inc	O
,	O
San	O
Jose	O
,	O
CA	O
)	O
with	O
differences	O
between	O
mean	O
values	O
assessed	O
for	O
statistical	O
significance	O
.	O
For	O
normally	O
distributed	O
data	O
,	O
one	O
‐	O
way	O
ANOVA	O
with	O
Holm	O
–	O
Sidak	O
post	O
‐	O
hoc	O
analysis	O
was	O
used	O
to	O
correct	O
for	O
multiple	O
hypothesis	O
testing	O
.	O
For	O
data	O
that	O
were	O
not	O
normally	O
distributed	O
,	O
a	O
nonparametric	O
Kruskal	O
–	O
Wallis	O
test	O
was	O
performed	O
.	O
Curve	O
‐	O
fit	O
analyses	O
were	O
conducted	O
utilizing	O
a	O
mixed	O
model	O
with	O
random	O
effects	O
as	O
implemented	O
in	O
SAS	O
PROC	O
MIXED	O
.	O
Experiment	O
ID	O
was	O
included	O
as	O
a	O
random	O
effect	O
to	O
define	O
non	O
‐	O
independent	O
observations	O
,	O
with	O
treatment	O
,	O
time	O
,	O
and	O
a	O
treatment×time	O
interaction	O
term	O
included	O
in	O
the	O
model	O
.	O
Identical	O
results	O
were	O
obtained	O
when	O
the	O
“	O
repeated	O
”	O
statement	O
was	O
used	O
.	O
To	O
facilitate	O
investigation	O
of	O
the	O
effect	O
of	O
bilirubin	O
on	O
VCAM	O
‐	O
1	O
‐	O
and	O
ICAM	O
‐	O
1	O
‐	O
mediated	O
leukocyte	O
migration	O
in	B-methodology
vitro	I-methodology
,	O
we	O
first	O
identified	O
conditions	O
that	O
optimized	O
expression	O
of	O
these	O
2	O
adhesion	O
molecules	O
.	O
HUVEC	O
monolayers	O
were	O
incubated	O
in	O
the	O
presence	O
of	O
TNF	O
‐	O
α	O
,	O
and	O
cellular	O
mRNA	O
and	O
protein	O
levels	O
for	O
VCAM	O
‐	O
1	O
and	O
ICAM	O
‐	O
1	O
were	O
quantified	O
by	O
qRT	O
‐	O
PCR	O
and	O
Western	O
blotting	O
.	O
We	O
simultaneously	O
assessed	O
for	O
expression	O
of	O
PECAM	O
‐	O
1	O
,	O
which	O
also	O
facilitates	O
leukocyte	O
transmigration	O
,	O
43	O
and	O
E	O
‐	O
Selectin	O
and	O
P	O
‐	O
Selectin	O
,	O
which	O
mediate	O
leukocyte	O
rolling	O
.	O
44	O
Consistent	O
with	O
previous	O
reports	O
,	O
45	O
TNF	O
‐	O
α	O
induced	O
a	O
marked	O
increase	O
in	O
mRNA	O
for	O
E	O
‐	O
Selectin	O
,	O
VCAM	O
‐	O
1	O
,	O
and	O
ICAM	O
‐	O
1	O
at	O
4	O
hours	O
,	O
while	O
expression	O
of	O
P	O
‐	O
Selectin	O
and	O
PECAM	O
‐	O
1	O
was	O
unchanged	O
(	O
Figure	O
1A	O
and	O
1B	O
)	O
.	O

Concordantly	O
,	O
protein	O
levels	O
of	O
E	O
‐	O
Selectin	O
,	O
VCAM	O
‐	O
1	O
,	O
and	O
ICAM	O
‐	O
1	O
(	O
Figure	O
1C	O
and	O
1D	O
)	O
were	O
significantly	O
elevated	O
after	O
4	O
hours	O
of	O
TNF	O
‐	O
α	O
treatment	O
,	O
but	O
only	O
VCAM	O
‐	O
1	O
and	O
ICAM	O
‐	O
1	O
exhibited	O
sustained	O
expression	O
out	O
to	O
24	O
hours	O
.	O
46	O
To	O
specifically	O
facilitate	O
an	O
analysis	O
of	O
the	O
effect	O
of	O
bilirubin	O
on	O
these	O
2	O
adhesion	O
molecules	O
,	O
all	O
subsequent	O
experiments	O
used	O
a	O
24	O
‐	O
hour	O
incubation	O
period	O
.	O
To	O
determine	O
whether	O
bilirubin	O
modulates	O
human	O
monocyte	O
migration	O
,	O
HUVECs	O
were	O
seeded	O
and	O
grown	O
in	O
the	O
upper	O
chamber	O
of	O
a	O
transwell	O
system	O
.	O
CellTrace	O
Far	O
Red	O
–	O
labeled	O
THP	O
‐	O
1	O
monocytes	O
were	O
overlaid	O
onto	O
confluent	O
HUVEC	O
monolayers	O
and	O
the	O
time	O
course	O
for	O
transmigration	O
was	O
assessed	O
by	O
measuring	O
fluorescence	O
intensity	O
in	O
the	O
lower	O
chamber	O
.	O
Expression	O
of	O
VCAM	O
‐	O
1	O
and	O
ICAM	O
‐	O
1	O
was	O
stimulated	O
by	O
incubating	O
HUVECs	O
in	O
the	O
presence	O
of	O
TNF	O
‐	O
α	O
,	O
which	O
induced	O
a	O
significant	O
increase	O
in	O
THP	O
‐	O
1	O
cell	O
migration	O
(	O
Figure	O
2A	O
)	O
.	O
Bilirubin	O
blocked	O
TNF	O
‐	O
α	O
‐	O
stimulated	O
monocyte	O
migration	O
in	O
a	O
dose	O
‐	O
dependent	O
manner	O
(	O
Figure	O
2B	O
)	O
,	O
with	O
maximal	O
inhibition	O
achieved	O
by	O
bilirubin	O
concentrations	O
within	O
the	O
upper	O
‐	O
normal	O
physiological	O
range	O
(	O
20	O
μmol	O
/	O
L	O
≈1	O
.	O
2	O
mg	O
/	O
dL	O
)	O
.	O
Release	O
of	O
cytokines	O
and	O
chemokines	O
by	O
activated	O
endothelia	O
fosters	O
the	O
recruitment	O
of	O
inflammatory	O
cells	O
that	O
promote	O
atherogenesis	O
.	O
47	O
To	O
determine	O
whether	O
bilirubin	O
modulates	O
endothelial	O
cell	O
production	O
of	O
cytokines	O
relevant	O
to	O
leukocyte	O
trafficking	O
,	O
we	O
examined	O
its	O
effect	O
on	O
interleukin	O
(	O
IL	O
)	O
‐	O
6	O
,	O
IL	O
‐	O
1β	O
,	O
IL	O
‐	O
8	O
,	O
MCP	O
‐	O
1	O
,	O
M	O
‐	O
CSF	O
,	O
and	O
RANTES	O
release	O
into	O
the	O
culture	O
medium	O
of	O
TNF	O
‐	O
α	O
‐	O
activated	O
HUVECs	O
.	O
As	O
shown	O
in	O
Figure	O
3	O
,	O
bilirubin	O
did	O
not	O
alter	O
the	O
cellular	O
generation	O
of	O
any	O
of	O
these	O
cytokines	O
,	O
suggesting	O
that	O
it	O
does	O
not	O
act	O
by	O
regulating	O
inflammatory	O
or	O
chemotactic	O
stimuli	O
.	O

Further	O
support	O
for	O
this	O
conclusion	O
is	O
provided	O
by	O
our	O
finding	O
that	O
addition	O
of	O
MCP	O
‐	O
1	O
to	O
the	O
lower	O
chamber	O
of	O
the	O
transwell	O
did	O
not	O
augment	O
bilirubin	O
‐	O
inhibited	O
THP	O
‐	O
1	O
cell	O
transmigration	O
(	O
data	O
not	O
shown	O
)	O
.	O
Because	O
transendothelial	O
migration	O
is	O
predicated	O
upon	O
binding	O
of	O
leukocyte	O
integrins	O
to	O
endothelial	O
cell	O
adhesion	O
molecules	O
,	O
we	O
investigated	O
the	O
influence	O
of	O
bilirubin	O
on	O
adhesion	O
molecule	O
expression	O
.	O
As	O
shown	O
in	O
Figure	O
4	O
,	O
incubation	O
of	O
HUVECs	O
in	O
the	O
presence	O
of	O
bilirubin	O
did	O
not	O
alter	O
basal	O
or	O
TNF	O
‐	O
α	O
‐	O
stimulated	O
mRNA	O
or	O
protein	O
levels	O
of	O
VCAM	O
‐	O
1	O
,	O
ICAM	O
‐	O
1	O
,	O
PECAM	O
‐	O
1	O
,	O
E	O
‐	O
Selectin	O
,	O
or	O
P	O
‐	O
Selectin	O
.	O
Consistent	O
with	O
these	O
findings	O
,	O
no	O
effect	O
of	O
bilirubin	O
on	O
monocyte	O
adhesion	O
to	O
untreated	O
or	O
TNF	O
‐	O
α	O
‐	O
stimulated	O
HUVECs	O
was	O
observed	O
(	O
Figure	O
4A	O
,	O
lower	O
right	O
panel	O
)	O
,	O
indicating	O
that	O
bilirubin	O
does	O
not	O
prevent	O
monocyte	O
migration	O
by	O
disrupting	O
adhesion	O
molecule	O
expression	O
or	O
binding	O
to	O
leukocyte	O
integrins	O
.	O
Because	O
bilirubin	O
is	O
a	O
potent	O
antioxidant	O
,	O
17	O
we	O
assessed	O
whether	O
it	O
is	O
able	O
to	O
inhibit	O
the	O
generation	O
of	O
ROS	O
(	O
ie	O
,	O
[UNK]	O
,	O
H2O2	O
)	O
that	O
mediate	O
endothelial	O
cell	O
signaling	O
through	O
VCAM	O
‐	O
1	O
(	O
by	O
activation	O
of	O
Nox	O
)	O
and	O
/	O
or	O
ICAM	O
‐	O
1	O
(	O
by	O
activation	O
of	O
XO	O
)	O
.	O
15	O
,	O
27	O
,	O
28	O
To	O
directly	O
examine	O
the	O
influence	O
of	O
bilirubin	O
on	O
endothelial	O
ROS	O
signaling	O
,	O
TNF	O
‐	O
α	O
‐	O
activated	O
HUVECs	O
were	O
incubated	O
with	O
anti	O
‐	O
VCAM	O
‐	O
1	O
or	O
anti	O
‐	O
ICAM	O
‐	O
1	O
antibodies	O
and	O
then	O
loaded	O
with	O
the	O
redox	O
‐	O
sensitive	O
fluorophore	O
,	O
dihydrorhodamine	O
.	O
Adhesion	O
molecule	O
activation	O
was	O
triggered	O
by	O
the	O
addition	O
of	O
cross	O
‐	O
linking	O
antibodies	O
,	O
15	O
,	O
19	O
and	O
fluorescence	O
intensity	O
was	O
quantified	O
by	O
confocal	O
microscopy	O
.	O

As	O
expected	O
,	O
activation	O
of	O
VCAM	O
‐	O
1	O
(	O
Figure	O
5	O
,	O
left	O
panels	O
)	O
or	O
ICAM	O
‐	O
1	O
(	O
Figure	O
5	O
,	O
right	O
panels	O
)	O
produced	O
a	O
robust	O
time	O
‐	O
dependent	O
increase	O
in	O
cellular	O
fluorescence	O
(	O
indicative	O
of	O
ROS	O
generation	O
)	O
that	O
was	O
markedly	O
attenuated	O
by	O
bilirubin	O
(	O
Figure	O
5	O
,	O
lower	O
panels	O
)	O
.	O
To	O
validate	O
these	O
findings	O
,	O
we	O
utilized	O
ML171	O
,	O
which	O
specifically	O
blocks	O
Nox	O
activity	O
by	O
interfering	O
with	O
the	O
catalytic	O
subunit	O
(	O
but	O
without	O
affecting	O
other	O
cellular	O
ROS	O
‐	O
producing	O
enzymes	O
)	O
,	O
48	O
and	O
AP	O
,	O
a	O
purine	O
analog	O
that	O
competitively	O
inhibits	O
XO	O
.	O
49	O
As	O
anticipated	O
,	O
treatment	O
with	O
ML171	O
completely	O
suppressed	O
cellular	O
ROS	O
production	O
in	O
response	O
to	O
activation	O
of	O
VCAM	O
‐	O
1	O
(	O
Figure	O
6A	O
)	O
while	O
exerting	O
no	O
effect	O
on	O
ICAM	O
‐	O
1	O
‐	O
generated	O
ROS	O
(	O
Figure	O
6B	O
)	O
,	O
whereas	O
AP	O
significantly	O
abrogated	O
ICAM	O
‐	O
1	O
‐	O
dependent	O
ROS	O
generation	O
(	O
Figure	O
6B	O
)	O
without	O
altering	O
VCAM	O
‐	O
1	O
‐	O
generated	O
ROS	O
(	O
Figure	O
6A	O
)	O
.	O
To	O
confirm	O
that	O
inhibition	O
of	O
VCAM	O
‐	O
1	O
or	O
ICAM	O
‐	O
1	O
signaling	O
disrupts	O
monocyte	O
transendothelial	O
migration	O
,	O
and	O
to	O
delineate	O
the	O
relative	O
contributions	O
of	O
VCAM	O
‐	O
1	O
and	O
ICAM	O
‐	O
1	O
to	O
this	O
process	O
,	O
the	O
effect	O
of	O
ML171	O
and	O
/	O
or	O
AP	O
on	O
the	O
movement	O
of	O
THP	O
‐	O
1	O
cells	O
across	O
HUVEC	O
monolayers	O
was	O
assessed	O
using	O
a	O
transwell	O
system	O
.	O
As	O
shown	O
in	O
Figure	O
6C	O
,	O
treatment	O
of	O
HUVECs	O
with	O
maximal	O
inhibitory	O
concentrations	O
of	O
the	O
Nox	O
inhibitor	O
,	O
ML171	O
,	O
was	O
associated	O
with	O
a	O
substantial	O
reduction	O
in	O
TNF	O
‐	O
α	O
‐	O
stimulated	O
monocyte	O
migration	O
,	O
whereas	O
the	O
XO	O
inhibitor	O
,	O
AP	O
,	O
had	O
minimal	O
effect	O
,	O
supporting	O
a	O
primary	O
role	O
for	O
VCAM	O
‐	O
1	O
in	O
monocyte	O
transmigration	O
.	O
Consistent	O
with	O
these	O
findings	O
,	O
incubation	O
of	O
HUVEC	O
monolayers	O
with	O
anti	O
‐	O
VCAM	O
‐	O
1	O
,	O
but	O
not	O
anti	O
‐	O
ICAM	O
‐	O
1	O
,	O
caused	O
significant	O
inhibition	O
of	O
THP	O
‐	O
1	O
cell	O
migration	O
,	O
with	O
modest	O
synergy	O
when	O
both	O
antibodies	O
were	O
combined	O
(	O
Figure	O
6D	O
)	O
.	O
These	O
data	O
were	O
further	O
validated	O
using	O
antibodies	O
that	O
specifically	O
block	O
leukocyte	O
integrin	O
binding	O
to	O
VCAM	O
‐	O
1	O
(	O
anti	O
‐	O
α4	O
)	O
or	O
ICAM	O
‐	O
1	O
(	O
anti	O
‐	O
β2	O
;	O
Figure	O
6E	O
)	O
.	O

While	O
bilirubin	O
has	O
been	O
shown	O
to	O
suppress	O
Nox	O
‐	O
mediated	O
ROS	O
production	O
in	B-methodology
vitro	I-methodology
,	O
21	O
data	O
regarding	O
its	O
effect	O
on	O
XO	O
are	O
lacking	O
.	O
Using	O
an	O
Amplex	O
Red	O
assay	O
system	O
,	O
we	O
studied	O
the	O
XO	O
‐	O
catalyzed	O
generation	O
of	O
H2O2	O
.	O
Reciprocal	O
plots	O
(	O
Figure	O
6F	O
)	O
demonstrate	O
that	O
bilirubin	O
inhibits	O
XO	O
‐	O
catalyzed	O
H2O2	O
production	O
in	O
a	O
competitive	O
manner	O
,	O
with	O
potency	O
nearly	O
twice	O
that	O
of	O
AP	O
.	O
Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
VCAM	O
‐	O
1	O
constitutes	O
the	O
principal	O
adhesion	O
molecule	O
mediating	O
TNF	O
‐	O
α	O
‐	O
induced	O
monocyte	O
migration	O
,	O
and	O
support	O
the	O
hypothesis	O
that	O
bilirubin	O
inhibits	O
monocyte	O
transmigration	O
by	O
disrupting	O
adhesion	O
molecule	O
‐	O
dependent	O
ROS	O
signaling	O
.	O
To	O
determine	O
whether	O
bilirubin	O
prevents	O
atherogenesis	O
in	B-methodology
vivo	I-methodology
,	O
we	O
used	O
a	O
murine	B-methodology
model	I-methodology
in	O
which	O
Ldlr	O
−	O
/	O
−	O
mice	O
were	O
fed	O
a	O
Western	O
(	O
high	O
‐	O
fat	O
)	O
diet	O
.	O
We	O
administered	O
a	O
once	O
‐	O
daily	O
dose	O
of	O
bilirubin	O
(	O
30	O
mg	O
/	O
kg	O
)	O
,	O
which	O
produced	O
a	O
3	O
‐	O
fold	O
increase	O
(	O
1	O
.	O
7	O
mg	O
/	O
dL≈28	O
.	O
9	O
μmol	O
/	O
L	O
)	O
in	O
steady	O
‐	O
state	O
serum	O
levels	O
(	O
Figure	O
7A	O
)	O
.	O
Mice	O
received	O
intraperitoneal	O
bilirubin	O
(	O
n	O
=	O
7	O
)	O
,	O
vehicle	O
(	O
n	O
=	O
4	O
)	O
,	O
or	O
sham	O
(	O
n	O
=	O
7	O
)	O
once	O
‐	O
daily	O
for	O
a	O
total	O
of	O
8	O
weeks	O
.	O
All	O
animals	O
appeared	O
outwardly	O
healthy	O
throughout	O
the	O
course	O
of	O
the	O
study	O
.	O
There	O
were	O
no	O
significant	O
differences	O
in	O
body	O
weight	O
(	O
Figure	O
7B	O
)	O
,	O
serum	O
triglycerides	O
(	O
Figure	O
7C	O
)	O
,	O
or	O
serum	O
cholesterol	O
(	O
Figure	O
7D	O
)	O
between	O
the	O
treatment	O
groups	O
,	O
although	O
there	O
was	O
a	O
strong	O
trend	O
toward	O
reduced	O
triglyceride	O
levels	O
in	O
mice	O
that	O
received	O
bilirubin	O
.	O
At	O
the	O
end	O
of	O
treatment	O
,	O
cross	O
‐	O
sectional	O
analysis	O
of	O
Oil	O
Red	O
O	O
–	O
stained	O
aortic	O
root	O
specimens	O
from	O
sham	O
‐	O
and	O
vehicle	O
‐	O
treated	O
mice	O
demonstrated	O
large	O
,	O
well	O
‐	O
established	O
atherosclerotic	O
plaques	O
(	O
Figure	O
8A	O
)	O
,	O
while	O
bilirubin	O
‐	O
treated	O
animals	O
had	O
significantly	O
smaller	O
lesions	O
(	O
Figure	O
8A	O
)	O
with	O
reduced	O
deposition	O
of	O
extracellular	O
matrix	O
and	O
diminished	O
numbers	O
of	O
smooth	O
muscle	O
cells	O
(	O
Figure	O
8B	O
and	O
8C	O
)	O
.	O

Mice	O
that	O
received	O
bilirubin	O
also	O
had	O
fewer	O
CD68	O
‐	O
(	O
Figure	O
9A	O
)	O
and	O
CD3	O
‐	O
positive	O
(	O
Figure	O
9B	O
)	O
positive	O
leukocytes	O
in	O
aortic	O
root	O
lesions	O
,	O
despite	O
unchanged	O
expression	O
of	O
VCAM	O
‐	O
1	O
and	O
ICAM	O
‐	O
1	O
(	O
Figure	O
10	O
)	O
and	O
no	O
differences	O
in	O
serum	O
levels	O
of	O
the	O
principal	O
leukocyte	O
chemoattractants	O
,	O
50	O
MCP	O
‐	O
1	O
,	O
MIP	O
‐	O
1α	O
,	O
or	O
RANTES	O
(	O
Figure	O
11A	O
through	O
11C	O
)	O
.	O
These	O
data	O
suggest	O
that	O
bilirubin	O
impedes	O
infiltration	O
of	O
monocytes	O
and	O
lymphocytes	O
into	O
the	O
aortic	O
root	O
in	O
spite	O
of	O
adequate	O
adhesion	O
molecule	O
expression	O
and	O
chemotactic	O
stimuli	O
.	O
Bilirubin	O
‐	O
treated	O
animals	O
also	O
manifested	O
significantly	O
(	O
albeit	O
modestly	O
)	O
reduced	O
serum	O
indicators	O
of	O
lipid	O
peroxidation	O
(	O
Figure	O
11D	O
)	O
,	O
and	O
aortic	O
root	O
lesions	O
from	O
these	O
mice	O
exhibited	O
substantially	O
reduced	O
immunoreactivity	O
to	O
chlorotyrosine	O
and	O
nitrotyrosine	O
(	O
Figure	O
9C	O
and	O
9D	O
)	O
,	O
markers	O
of	O
tissue	O
oxidation	O
.	O
39	O
These	O
observations	O
support	O
a	O
mitigating	O
effect	O
of	O
bilirubin	O
on	O
oxidative	O
and	O
nitrosative	O
stress	O
and	O
,	O
when	O
taken	O
in	O
conjunction	O
with	O
our	O
finding	O
that	O
bilirubin	O
suppresses	O
VCAM	O
‐	O
1	O
‐	O
and	O
ICAM	O
‐	O
1	O
‐	O
stimulated	O
endothelial	O
ROS	O
production	O
(	O
Figure	O
5	O
)	O
,	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
bilirubin	O
prevents	O
atherosclerotic	O
plaque	O
formation	O
by	O
inhibiting	O
leukocyte	O
migration	O
through	O
scavenging	O
of	O
ROS	O
signaling	O
intermediaries	O
.	O
Although	O
numerous	O
epidemiological	B-methodology
studies	I-methodology
have	O
identified	O
an	O
inverse	O
association	O
between	O
serum	O
bilirubin	O
levels	O
and	O
incidence	O
of	O
cardiovascular	O
disease	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
it	O
has	O
not	O
previously	O
been	O
shown	O
that	O
bilirubin	O
is	O
able	O
to	O
prevent	O
atherosclerosis	O
.	O

In	O
the	O
present	O
studies	O
,	O
we	O
demonstrate	O
that	O
administration	O
of	O
bilirubin	O
to	O
Ldlr	O
−	O
/	O
−	O
mice	O
impedes	O
plaque	O
formation	O
and	O
significantly	O
reduces	O
the	O
infiltration	O
of	O
monocytes	O
and	O
lymphocytes	O
into	O
aortic	O
root	O
lesions	O
,	O
processes	O
that	O
are	O
VCAM	O
‐	O
1	O
‐	O
and	O
ICAM	O
‐	O
1	O
‐	O
dependent	O
.	O
12	O
,	O
15	O
,	O
51	O
,	O
52	O
We	O
further	O
show	O
that	O
bilirubin	O
effectively	O
blocks	O
VCAM	O
‐	O
1	O
‐	O
and	O
ICAM	O
‐	O
1	O
‐	O
mediated	O
migration	O
of	O
monocytes	O
across	O
activated	O
endothelial	O
monolayers	O
at	O
bilirubin	O
concentrations	O
(	O
≤20	O
μmol	O
/	O
L	O
)	O
that	O
are	O
within	O
the	O
normal	O
physiological	O
range	O
(	O
women	O
,	O
3	O
–	O
20	O
μmol	O
/	O
L	O
;	O
men	O
,	O
5	O
–	O
29	O
μmol	O
/	O
L	O
)	O
.	O
53	O
These	O
findings	O
correlate	O
well	O
with	O
epidemiological	O
data	O
demonstrating	O
that	O
patients	O
in	O
the	O
highest	O
quartile	O
of	O
serum	O
bilirubin	O
(	O
>	O
12	O
–	O
17	O
μmol	O
/	O
L	O
)	O
exhibit	O
a	O
decreased	O
incidence	O
of	O
coronary1	O
,	O
2	O
,	O
4	O
and	O
carotid54	O
artery	O
disease	O
,	O
as	O
compared	O
with	O
those	O
in	O
the	O
lowest	O
quartile	O
(	O
<	O
7	O
–	O
10	O
μmol	O
/	O
L	O
)	O
.	O
Concordantly	O
,	O
individuals	O
possessing	O
the	O
prevalent	O
Gilbert	O
'	O
s	O
polymorphism	O
,	O
which	O
is	O
associated	O
with	O
mildly	O
elevated	O
serum	O
bilirubin	O
levels	O
as	O
a	O
consequence	O
of	O
reduced	O
expression	O
of	O
the	O
bilirubin	O
‐	O
specific	O
1A1	O
isoform	O
of	O
UDP	O
‐	O
glucuronosyltransferase	O
,	O
55	O
have	O
been	O
found	O
to	O
develop	O
ischemic	O
heart	O
disease	O
at	O
significantly	O
lower	O
rates	O
than	O
the	O
general	O
population	O
.	O
5	O
,	O
56	O
Given	O
that	O
the	O
recruitment	O
and	O
subendothelial	O
accumulation	O
of	O
leukocytes	O
are	O
key	O
initiating	O
events	O
in	O
the	O
formation	O
of	O
atherosclerotic	O
plaques	O
,	O
13	O
,	O
29	O
our	O
findings	O
suggest	O
a	O
potential	O
mechanism	O
as	O
to	O
how	O
bilirubin	O
exerts	O
a	O
cardioprotective	O
effect	O
.	O

Binding	O
of	O
leukocyte	O
integrins	O
to	O
VCAM	O
‐	O
1	O
or	O
ICAM	O
‐	O
1	O
has	O
been	O
shown	O
to	O
trigger	O
signaling	O
cascades	O
that	O
lead	O
to	O
production	O
of	O
superoxide	O
and	O
hydrogen	O
peroxide	O
within	O
the	O
endothelial	O
cell	O
.	O
28	O
,	O
57	O
These	O
ROS	O
induce	O
downstream	O
alterations	O
in	O
the	O
endothelial	O
junctional	O
structure	O
that	O
facilitate	O
the	O
transmigration	O
of	O
leukocytes	O
.	O
20	O
Given	O
that	O
bilirubin	O
is	O
a	O
potent	O
,	O
chain	O
‐	O
breaking	O
antioxidant	O
,	O
17	O
we	O
postulated	O
that	O
it	O
would	O
disrupt	O
the	O
endothelial	O
response	O
to	O
adhesion	O
molecule	O
activation	O
by	O
scavenging	O
superoxide	O
and	O
hydrogen	O
peroxide	O
signaling	O
intermediaries	O
(	O
Figure	O
12	O
)	O
.	O
Our	O
demonstration	O
that	O
bilirubin	O
attenuates	O
ROS	O
generation	O
by	O
activated	O
HUVECs	O
in	O
response	O
to	O
VCAM	O
‐	O
1	O
or	O
ICAM	O
‐	O
1	O
cross	O
‐	O
linking	O
and	O
inhibits	O
H2O2	O
production	O
by	O
isolated	O
XO	O
enzyme	O
supports	O
this	O
hypothesis	O
.	O
These	O
findings	O
are	O
in	O
line	O
with	O
previous	O
studies	O
in	O
which	O
bilirubin	O
has	O
been	O
shown	O
to	O
suppress	O
VCAM	O
‐	O
1	O
‐	O
dependent	O
ROS	O
generation	O
by	O
murine	O
high	O
endothelial	O
cells19	O
and	O
scavenge	O
Nox	O
‐	O
derived	O
[UNK]	O
and	O
H2O2	O
in	O
murine	O
macrophages	O
.	O
21	O
That	O
these	O
mechanisms	O
are	O
relevant	O
primarily	O
at	O
the	O
tissue	O
level	O
in	B-methodology
vivo	I-methodology
are	O
supported	O
by	O
the	O
more	O
pronounced	O
inhibition	O
by	O
bilirubin	O
of	O
chlorinated	O
and	O
nitrosylated	O
tyrosine	O
formation	O
in	O
the	O
aortic	O
root	O
,	O
as	O
compared	O
with	O
its	O
modest	O
effect	O
on	O
serum	O
markers	O
of	O
lipid	O
peroxidation	O
.	O
Our	O
data	O
demonstrating	O
that	O
bilirubin	O
does	O
not	O
alter	O
IL	O
‐	O
6	O
,	O
IL	O
‐	O
1β	O
,	O
or	O
IL	O
‐	O
8	O
production	O
by	O
HUVECs	O
,	O
and	O
does	O
not	O
affect	O
VCAM	O
‐	O
1	O
or	O
ICAM	O
‐	O
1	O
expression	O
in	B-methodology
vitro	I-methodology
or	O
in	B-methodology
vivo	I-methodology
,	O
suggest	O
that	O
bilirubin	O
does	O
not	O
modulate	O
endothelial	O
activation	O
.	O

These	O
findings	O
are	O
concordant	O
with	O
our	O
previous	O
work	O
showing	O
no	O
impact	O
of	O
bilirubin	O
on	O
VCAM	O
‐	O
1	O
expression	O
by	O
isolated	O
murine19	O
or	O
human	O
endothelial	O
cells	O
,	O
20	O
or	O
in	O
the	O
pulmonary	O
vasculature	O
of	O
mice	O
with	O
allergen	O
‐	O
induced	O
asthma	O
.	O
19	O
Although	O
we	O
are	O
unable	O
to	O
explain	O
conflicting	O
reports	O
that	O
bilirubin	O
inhibits	O
endothelial	O
VCAM	O
‐	O
1	O
and	O
ICAM	O
‐	O
1	O
expression	O
in	B-methodology
vitro	I-methodology
,	O
58	O
,	O
59	O
,	O
60	O
our	O
demonstration	O
that	O
bilirubin	O
has	O
no	O
influence	O
on	O
monocyte	O
adhesion	O
to	O
TNF	O
‐	O
α	O
‐	O
activated	O
HUVEC	O
monolayers	O
under	O
conditions	O
where	O
transmigration	O
is	O
maximally	O
inhibited	O
supports	O
an	O
effect	O
exerted	O
beyond	O
the	O
step	O
of	O
integrin	O
‐	O
adhesion	O
molecule	O
interaction	O
.	O
Our	O
observations	O
that	O
bilirubin	O
also	O
does	O
not	O
modulate	O
the	O
production	O
of	O
the	O
chemoattractants	O
,	O
MCP	O
‐	O
1	O
,	O
M	O
‐	O
CSF	O
,	O
and	O
RANTES	O
,	O
by	O
activated	O
HUVECs	O
,	O
or	O
circulating	O
levels	O
of	O
MCP	O
‐	O
1	O
,	O
MIP	O
‐	O
1α	O
,	O
and	O
RANTES	O
in	O
Ldlr	O
−	O
/	O
−	O
mice	O
,	O
are	O
consistent	O
with	O
previous	O
reports19	O
and	O
suggest	O
that	O
bilirubin	O
does	O
not	O
inhibit	O
leukocyte	O
recruitment	O
by	O
regulating	O
chemotactic	O
stimuli	O
.	O
61	O
As	O
atherosclerotic	O
lesions	O
mature	O
,	O
smooth	O
muscle	O
cells	O
infiltrate	O
the	O
intima	O
,	O
where	O
they	O
proliferate	O
and	O
produce	O
extracellular	O
matrix	O
proteins	O
(	O
eg	O
,	O
collagen	O
)	O
.	O
62	O
We	O
found	O
that	O
bilirubin	O
treatment	O
was	O
associated	O
with	O
a	O
marked	O
reduction	O
in	O
collagen	O
deposition	O
and	O
in	O
the	O
number	O
of	O
smooth	O
muscle	O
cells	O
in	O
aortic	O
root	O
lesions	O
,	O
suggesting	O
that	O
bilirubin	O
impedes	O
plaque	O
progression	O
.	O
While	O
our	O
data	O
do	O
not	O
elucidate	O
whether	O
the	O
decrease	O
in	O
plaque	O
‐	O
associated	O
smooth	O
muscle	O
cells	O
results	O
from	O
impaired	O
migration	O
,	O
induced	O
apoptosis	O
,	O
or	O
reduced	O
proliferation	O
,	O
our	O
findings	O
are	O
consistent	O
with	O
previous	O
reports	O
that	O
bilirubin	O
directly	O
inhibits	O
smooth	O
muscle	O
cell	O
proliferation	O
in	B-methodology
vitro	I-methodology
and	O
in	O
response	O
to	O
balloon	O
injury	O
in	B-methodology
vivo	I-methodology
.	O
63	O
Since	O
it	O
also	O
has	O
been	O
shown	O
that	O
chlorotyrosine	O
promotes	O
aortic	O
smooth	O
muscle	O
cell	O
migration	O
,	O
64	O
our	O
demonstration	O
that	O
bilirubin	O
reduces	O
the	O
formation	O
of	O
this	O
oxidative	O
by	O
‐	O
product	O
suggests	O
an	O
additional	O
mechanism	O
by	O
which	O
bilirubin	O
may	O
prevent	O
plaque	O
maturation	O
.	O

We	O
note	O
that	O
Ldlr	O
−	O
/	O
−	O
mice	O
treated	O
with	O
bilirubin	O
manifested	O
a	O
strong	O
trend	O
toward	O
reduced	O
serum	O
triglyceride	O
concentrations	O
.	O
This	O
finding	O
is	O
consistent	O
with	O
previous	O
reports	O
describing	O
lower	O
total	O
triglyceride	O
levels	O
in	O
congenitally	O
hyperbilirubinemic	O
rats	O
,	O
as	O
well	O
as	O
in	O
humans	O
with	O
elevated	O
bilirubin	O
levels	O
.	O
65	O
Although	O
a	O
number	O
of	O
explanations	O
as	O
to	O
how	O
bilirubin	O
may	O
modulate	O
lipid	O
metabolism	O
have	O
been	O
proposed	O
,	O
65	O
data	O
in	O
support	O
of	O
these	O
hypotheses	O
remain	O
scant	O
.	O
In	O
summary	O
,	O
we	O
show	O
that	O
bilirubin	O
inhibits	O
monocyte	O
migration	O
across	O
activated	O
human	O
endothelial	O
cells	O
by	O
disrupting	O
VCAM	O
‐	O
1	O
and	O
ICAM	O
‐	O
1	O
signaling	O
through	O
scavenging	O
of	O
Nox	O
‐	O
and	O
XO	O
‐	O
generated	O
ROS	O
,	O
findings	O
that	O
were	O
recapitulated	O
using	O
specific	O
enzyme	O
inhibitors	O
and	O
blocking	O
antibodies	O
.	O
We	O
propose	O
that	O
this	O
effect	O
of	O
bilirubin	O
underlies	O
the	O
inverse	O
association	O
between	O
serum	O
bilirubin	O
levels	O
and	O
cardiovascular	O
disease	O
,	O
and	O
have	O
validated	O
this	O
hypothesis	O
in	O
a	O
murine	B-methodology
model	I-methodology
of	O
atherosclerosis	O
,	O
in	O
which	O
we	O
show	O
that	O
treatment	O
with	O
bilirubin	O
diminishes	O
the	O
number	O
of	O
monocytes	O
,	O
lymphocytes	O
,	O
and	O
smooth	O
muscle	O
cells	O
,	O
decreases	O
collagen	O
deposition	O
,	O
and	O
reduces	O
oxidative	O
stress	O
in	O
aortic	O
root	O
lesions	O
,	O
without	O
altering	O
adhesion	O
molecule	O
expression	O
or	O
circulating	O
chemokine	O
levels	O
.	O

While	O
other	O
antioxidants	O
,	O
such	O
as	O
tocopherols	O
,	O
66	O
have	O
the	O
potential	O
to	O
exert	O
similar	O
effects	O
,	O
bilirubin	O
is	O
unique	O
in	O
its	O
ability	O
to	O
readily	O
diffuse	O
into	O
cells67	O
and	O
to	O
be	O
continuously	O
regenerated	O
by	O
intracellular	O
redox	O
cycling	O
through	O
the	O
action	O
of	O
the	O
ubiquitous	O
biliverdin	O
reductase	O
enzyme	O
.	O
18	O
It	O
is	O
notable	O
that	O
endothelial	O
adhesion	O
molecules	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
a	O
number	O
of	O
inflammatory	O
disorders	O
,	O
10	O
,	O
20	O
,	O
68	O
,	O
69	O
,	O
70	O
,	O
71	O
,	O
72	O
and	O
bilirubin	O
has	O
been	O
shown	O
to	O
ameliorate	O
animal	B-methodology
models	I-methodology
of	O
VCAM	O
‐	O
1	O
‐	O
and	O
ICAM	O
‐	O
1	O
‐	O
mediated	O
inflammation	O
,	O
including	O
colitis	O
,	O
20	O
allergic	O
pneumonitis	O
,	O
19	O
and	O
encephalomyelitis	O
.	O
73	O
Given	O
that	O
the	O
inducible	O
isoform	O
of	O
HO	O
‐	O
1	O
,	O
which	O
catalyzes	O
the	O
rate	O
‐	O
limiting	O
step	O
in	O
bilirubin	O
synthesis	O
,	O
appears	O
to	O
play	O
a	O
key	O
role	O
in	O
attenuating	O
inflammation	O
,	O
74	O
we	O
speculate	O
that	O
HO	O
‐	O
1	O
‐	O
generated	O
bilirubin	O
may	O
serve	O
a	O
fundamental	O
physiological	O
function	O
with	O
regard	O
to	O
regulation	O
of	O
inflammatory	O
responses	O
.	O
This	O
study	O
was	O
supported	O
by	O
a	O
National	O
Institutes	O
of	O
Health	O
research	O
grant	O
DK	O
071125	O
(	O
Zucker	O
)	O
and	O
by	O
a	O
University	O
of	O
Cincinnati	O
:	O
Department	O
of	O
Internal	O
Medicine	O
Rehn	O
Family	O
Research	O
Award	O
(	O
Vogel	O
)	O
.	O
None	O
.	O
The	O
authors	O
gratefully	O
acknowledge	O
David	O
Hui	O
,	O
PhD	O
,	O
for	O
his	O
guidance	O
and	O
assistance	O
with	O
aortic	O
root	O
analyses	O
.	O
We	O
also	O
wish	O
to	O
thank	O
Alex	O
Lentsch	O
,	O
PhD	O
,	O
George	O
Deepe	O
,	O
MD	O
,	O
and	O
Florence	O
Rothenberg	O
,	O
MD	O
,	O
for	O
their	O
helpful	O
suggestions	O
and	O
insights	O
.	O
Additionally	O
,	O
the	O
authors	O
gratefully	O
acknowledge	O
Alyssa	O
Sproles	O
,	O
Betsy	O
A	O
.	O
DiPasquale	O
,	O
and	O
Chet	O
Closson	O
for	O
their	O
kind	O
assistance	O
and	O
guidance	O
.	O

Cyanidin	O
-	O
3	O
-	O
O	O
-	O
β	O
-	O
Glucoside	O
and	O
Protocatechuic	O
Acid	O
Exert	O
Insulin	O
-	O
Like	O
Effects	O
by	O
Upregulating	O
PPARγ	O
Activity	O
in	O
Human	O
Omental	O
Adipocytes	O
Insulin	O
resistance	O
(	O
IR	O
)	O
represents	O
an	O
independent	O
risk	O
factor	O
for	O
metabolic	O
,	O
cardiovascular	O
,	O
and	O
neoplastic	O
disorders	O
.	O
Preventing	O
/	O
attenuating	O
IR	O
is	O
a	O
major	O
objective	O
to	O
be	O
reached	O
to	O
preserve	O
population	O
health	O
.	O
Because	O
many	O
insulin	O
-	O
sensitizing	O
drugs	O
have	O
shown	O
unwanted	O
side	O
effects	O
,	O
active	O
harmless	O
compounds	O
are	O
sought	O
after	O
.	O
Dietary	O
anthocyanins	O
have	O
been	O
demonstrated	O
to	O
ameliorate	O
hyperglycemia	O
and	O
insulin	O
sensitivity	O
.	O
This	O
study	O
aimed	O
at	O
investigating	O
whether	O
cyanidin	O
-	O
3	O
-	O
O	O
-	O
β	O
-	O
glucoside	O
(	O
C3G	O
)	O
and	O
its	O
metabolite	O
protocatechuic	O
acid	O
(	O
PCA	O
)	O
might	O
have	O
a	O
role	O
in	O
glucose	O
transport	O
activation	O
in	O
human	O
omental	O
adipocytes	O
and	O
3T3	O
-	O
L1	O
cells	O
.	O
In	O
cells	O
treated	O
with	O
50	O
µmol	O
/	O
L	O
C3G	O
and	O
100	O
µmol	O
/	O
L	O
PCA	O
,	O
[	O
3H	O
]	O
-	O
2	O
-	O
deoxyglucose	O
uptake	O
,	O
GLUT4	O
translocation	O
by	O
immunoblotting	O
,	O
adiponectin	O
secretion	O
,	O
and	O
peroxisome	O
proliferator	O
–	O
activated	O
receptor	O
-	O
γ	O
(	O
PPARγ	O
)	O
activation	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
kits	O
were	O
evaluated	O
.	O
Parallel	B-methodology
experiments	I-methodology
were	O
carried	O
out	O
in	O
murine	O
adipocyte	O
3T3	O
-	O
L1	O
.	O
To	O
define	O
the	O
role	O
of	O
PPARγ	O
in	O
modulating	O
polyphenol	O
effects	O
,	O
small	O
interfering	O
RNA	O
technique	O
and	O
PPARγ	O
antagonist	O
were	O
used	O
to	O
inhibit	O
transcription	O
factor	O
activity	O
.	O
C3G	O
and	O
PCA	O
increased	O
adipocyte	O
glucose	O
uptake	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
GLUT4	O
membrane	O
translocation	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
Significant	O
increases	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
nuclear	O
PPARγ	O
activity	O
,	O
as	O
well	O
as	O
in	O
adiponectin	O
and	O
GLUT4	O
expressions	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
were	O
also	O
shown	O
.	O
It	O
is	O
interesting	O
that	O
PPARγ	O
inhibition	O
counteracted	O
the	O
polyphenol	O
-	O
induced	O
adiponectin	O
and	O
GLUT4	O
upregulations	O
,	O
suggesting	O
a	O
direct	O
involvement	O
of	O
PPARγ	O
in	O
this	O
process	O
.	O

Our	O
study	O
provides	O
evidence	O
that	O
C3G	O
and	O
PCA	O
might	O
exert	O
insulin	O
-	O
like	O
activities	O
by	O
PPARγ	O
activation	O
,	O
evidencing	O
a	O
causal	O
relationship	O
between	O
this	O
transcription	O
factor	O
and	O
adiponectin	O
and	O
GLUT4	O
upregulation	O
.	O
Dietary	O
polyphenols	O
could	O
be	O
included	O
in	O
the	O
preventive	O
/	O
therapeutic	O
armory	O
against	O
pathological	O
conditions	O
associated	O
with	O
IR	O
.	O
The	O
prevalence	O
of	O
type	O
2	O
diabetes	O
is	O
estimated	O
to	O
reach	O
>	O
300	O
million	O
cases	O
by	O
year	O
2030	O
(	O
1	O
)	O
.	O
Metabolic	O
syndrome	O
,	O
which	O
is	O
often	O
a	O
precursor	O
to	O
diabetes	O
and	O
cardiovascular	O
diseases	O
,	O
is	O
characterized	O
by	O
insulin	O
resistance	O
(	O
IR	O
)	O
,	O
increased	O
fasting	O
glucose	O
,	O
decreased	O
HDL	O
,	O
hypertension	O
,	O
and	O
obesity	O
(	O
specifically	O
,	O
visceral	O
obesity	O
)	O
(	O
2	O
)	O
.	O
Furthermore	O
,	O
metabolic	O
syndrome	O
as	O
well	O
as	O
atherosclerosis	O
,	O
type	O
2	O
diabetes	O
,	O
and	O
obesity	O
is	O
associated	O
with	O
increased	O
circulating	O
oxidized	O
LDL	O
(	O
oxLDL	O
)	O
(	O
3	O
–	O
6	O
)	O
.	O
In	O
cultured	O
cells	O
,	O
oxLDLs	O
have	O
been	O
demonstrated	O
to	O
lower	O
insulin	O
sensitivity	O
(	O
7	O
)	O
and	O
to	O
impair	O
the	O
insulin	O
-	O
dependent	O
GLUT4	O
-	O
mediated	O
uptake	O
of	O
glucose	O
(	O
8	O
–	O
10	O
)	O
.	O
Many	O
studies	O
have	O
shown	O
that	O
adipocytes	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
obesity	O
-	O
associated	O
pathologies	O
and	O
IR	O
,	O
mostly	O
by	O
synthesizing	O
and	O
secreting	O
biologically	O
active	O
molecules	O
called	O
adipocytokines	O
(	O
11	O
)	O
,	O
such	O
as	O
adiponectin	O
,	O
which	O
is	O
able	O
to	O
improve	O
insulin	O
sensitivity	O
of	O
target	O
cells	O
(	O
12	O
)	O
.	O
Serum	O
levels	O
of	O
adiponectin	O
protein	O
correlate	O
with	O
systemic	O
insulin	O
sensitivity	O
(	O
13	O
)	O
and	O
are	O
decreased	O
in	O
insulin	O
-	O
resistant	O
,	O
diabetic	O
,	O
and	O
obese	O
subjects	O
(	O
14	O
)	O
.	O
Adiponectin	O
is	O
regulated	O
by	O
peroxisome	O
proliferator	O
–	O
activated	O
receptor	O
-	O
γ	O
(	O
PPARγ	O
)	O
(	O
15	O
)	O
.	O
PPARγ	O
is	O
a	O
ligand	O
-	O
activated	O
nuclear	O
hormone	O
receptor	O
that	O
controls	O
glucose	O
and	O
lipid	O
metabolism	O
(	O
16	O
,	O
17	O
)	O
,	O
as	O
well	O
as	O
the	O
transcription	O
of	O
proteins	O
involved	O
in	O
glucose	O
and	O
fatty	O
acid	O
cellular	O
uptake	O
.	O
For	O
these	O
reasons	O
,	O
it	O
represents	O
a	O
main	O
target	O
for	O
antidiabetic	O
drugs	O
,	O
such	O
as	O
thiazolidinediones	O
(	O
TZDs	O
)	O
(	O
18	O
)	O
.	O

In	O
addition	O
to	O
their	O
insulin	O
-	O
sensitizing	O
effects	O
,	O
TZDs	O
have	O
a	O
number	O
of	O
side	O
effects	O
,	O
such	O
as	O
promoting	O
adipogenesis	O
,	O
causing	O
body	O
weight	O
gain	O
,	O
and	O
increasing	O
risk	O
for	O
bone	O
fracture	O
and	O
cardiovascular	O
diseases	O
.	O
Hence	O
,	O
ligands	O
for	O
PPARγ	O
that	O
do	O
not	O
procure	O
these	O
unwanted	O
side	O
effects	O
are	O
being	O
sought	O
.	O
Recently	O
,	O
great	O
interest	O
has	O
arisen	O
regarding	O
evidence	O
that	O
the	O
consumption	O
of	O
a	O
diet	O
rich	O
in	O
vegetables	O
and	O
fruit	O
can	O
exert	O
beneficial	O
healthy	O
effects	O
,	O
likely	O
because	O
of	O
the	O
high	O
content	O
in	O
fiber	O
,	O
mineral	O
salts	O
,	O
vitamins	O
,	O
and	O
polyphenols	O
(	O
19	O
–	O
22	O
)	O
.	O
Among	O
polyphenols	O
,	O
anthocyanins	O
(	O
ACNs	O
)	O
are	O
flavonoids	O
of	O
great	O
nutritional	O
interest	O
because	O
their	O
daily	O
intake	O
(	O
180	O
–	O
250	O
mg	O
/	O
day	O
)	O
is	O
much	O
higher	O
than	O
that	O
of	O
other	O
polyphenols	O
(	O
23	O
)	O
.	O
ACNs	O
are	O
absorbed	O
in	O
animals	O
and	O
humans	O
(	O
24	O
–	O
26	O
)	O
and	O
rapidly	O
metabolized	O
,	O
ultimately	O
leading	O
to	O
the	O
formation	O
of	O
phenolic	O
acids	O
and	O
aldehydes	O
(	O
27	O
)	O
.	O
In	O
particular	O
,	O
at	O
physiological	O
pH	O
(	O
such	O
as	O
in	O
the	O
bloodstream	O
)	O
,	O
ACNs	O
easily	O
convert	O
to	O
protocatechuic	O
acid	O
(	O
PCA	O
)	O
,	O
which	O
is	O
also	O
abundantly	O
formed	O
and	O
absorbed	O
in	O
the	O
large	O
intestine	O
after	O
microbial	O
metabolization	O
(	O
28	O
)	O
.	O
Owing	O
to	O
the	O
potential	O
benefits	O
for	O
human	O
health	O
(	O
29	O
)	O
,	O
many	O
studies	O
have	O
focused	O
on	O
cyanidin	O
-	O
3	O
-	O
O	O
-	O
β	O
-	O
glucoside	O
(	O
C3G	O
)	O
,	O
the	O
best	O
known	O
and	O
most	O
investigated	O
ACN	O
,	O
highlighting	O
its	O
potential	O
activities	O
in	O
free	O
radical	O
scavenging	O
and	O
prevention	O
of	O
oxLDL	O
generation	O
,	O
exerting	O
beneficial	O
effects	O
on	O
cardiovascular	O
diseases	O
,	O
obesity	O
,	O
and	O
inflammation	O
(	O
30	O
–	O
32	O
)	O
.	O
Some	O
compelling	O
studies	O
have	O
reported	O
that	O
ACNs	O
improve	O
insulin	O
sensitivity	O
and	O
glucose	O
uptake	O
in	O
diabetic	O
rats	O
(	O
33	O
)	O
and	O
effectively	O
upregulate	O
the	O
signaling	O
pathway	O
of	O
PPARγ	O
in	O
mouse	O
peritoneal	O
macrophages	O
(	O
34	O
)	O
,	O
strongly	O
suggesting	O
that	O
they	O
could	O
be	O
successfully	O
used	O
as	O
insulin	O
-	O
sensitizing	O
agents	O
.	O
However	O
,	O
the	O
molecular	O
mechanism	O
of	O
action	O
and	O
the	O
effectiveness	O
of	O
C3G	O
and	O
PCA	O
in	O
exerting	O
protective	O
effects	O
against	O
IR	O
are	O
still	O
poorly	O
understood	O
.	O

Finally	O
,	O
most	O
of	O
the	O
research	O
on	O
adipocytes	O
has	O
been	O
conducted	O
on	O
the	O
murine	O
cell	O
line	O
3T3	O
-	O
L1	O
,	O
which	O
is	O
considered	O
a	O
suitable	O
model	O
for	O
studying	O
the	O
pathophysiology	O
of	O
adipocytes	O
and	O
,	O
in	O
particular	O
,	O
for	O
assessing	O
the	O
response	O
to	O
insulin	O
(	O
10	O
)	O
.	O
Conversely	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
only	O
a	O
few	O
studies	O
have	O
been	O
specifically	O
carried	O
out	O
on	O
human	O
omental	O
adipocytes	O
.	O
This	O
study	O
investigated	O
the	O
effects	O
of	O
C3G	O
and	O
PCA	O
on	O
glucose	O
uptake	O
machinery	O
in	O
adipocytes	O
by	O
evaluating	O
their	O
ability	O
to	O
reverse	O
the	O
oxLDL	O
-	O
induced	O
impairment	O
of	O
adipocyte	O
response	O
to	O
insulin	O
and	O
the	O
molecular	O
events	O
underlying	O
their	O
effects	O
.	O
Specifically	O
,	O
we	O
demonstrated	O
that	O
C3G	O
and	O
PCA	O
enhanced	O
glucose	O
uptake	O
and	O
GLUT4	O
translocation	O
in	O
both	O
insulin	O
-	O
stimulated	O
human	O
omental	O
adipocytes	O
and	O
3T3	O
-	O
L1	O
cells	O
.	O
Notably	O
,	O
the	O
polyphenols	O
elicited	O
the	O
same	O
response	O
in	O
the	O
absence	O
of	O
insulin	O
,	O
showing	O
insulin	O
-	O
like	O
activity	O
;	O
specifically	O
,	O
they	O
upregulated	O
PPARγ	O
activity	O
and	O
the	O
expression	O
and	O
secretion	O
of	O
its	O
target	O
gene	O
adiponectin	O
.	O
These	O
findings	O
support	O
the	O
hypothesis	O
that	O
C3G	O
,	O
and	O
its	O
main	O
metabolite	O
PCA	O
,	O
might	O
play	O
a	O
role	O
in	O
the	O
therapeutic	O
armory	O
against	O
disease	O
states	O
associated	O
with	O
IR	O
,	O
such	O
as	O
type	O
2	O
diabetes	O
and	O
obesity	O
.	O
LDLs	O
(	O
1	O
.	O
019	O
–	O
1	O
.	O
063	O
g	O
/	O
mL	O
)	O
were	O
isolated	O
by	O
density	O
gradient	O
ultracentrifugation	O
from	O
fresh	O
pooled	O
plasma	O
of	O
healthy	O
volunteers	O
as	O
described	O
elsewhere	O
(	O
35	O
)	O
.	O
The	O
protein	O
content	O
was	O
measured	O
by	O
Lowry	O
method	O
(	O
8	O
)	O
.	O
Native	O
LDLs	O
(	O
nLDLs	O
)	O
were	O
oxidized	O
as	O
previously	O
described	O
(	O
10	O
)	O
.	O
Human	O
omental	O
adipocytes	O
were	O
collected	O
from	O
anesthetized	O
individuals	O
undergoing	O
abdominal	O
surgery	O
or	O
laparoscopy	O
for	O
benign	O
conditions	O
(	O
i	O
.	O
e	O
.	O
,	O
gallbladder	O
disease	O
without	O
icterus	O
,	O
umbilical	O
hernia	O
,	O
or	O
uterine	O
fibromatosis	O
)	O
(	O
11	O
females	O
and	O
9	O
males	O
,	O
age	O
50	O
–	O
70	O
years	O
,	O
BMI	O
20	O
.	O
0	O
–	O
26	O
.	O
9	O
,	O
waist	O
circumference	O
≤107	O
for	O
males	O
and	O
≤92	O
for	O
females	O
)	O
.	O

Exclusion	B-methodology
criteria	I-methodology
were	O
steroidal	O
and	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
therapies	O
,	O
hormonal	O
substitutive	O
or	O
contraceptive	O
therapy	O
,	O
hormonal	O
therapy	O
for	O
any	O
thyroid	O
dysfunctions	O
,	O
drug	O
or	O
alcohol	O
abuse	O
,	O
diabetes	O
,	O
chronic	O
renal	O
failure	O
,	O
cancer	O
,	O
pregnancy	O
,	O
and	O
mental	O
disability	O
.	O
The	O
omental	O
sampling	O
was	O
performed	O
at	O
the	O
same	O
site	O
(	O
great	O
omentum	O
)	O
with	O
the	O
patient	O
in	O
anti	O
-	O
Trendelenburg	O
position	O
(	O
25°	O
head	O
up	O
)	O
with	O
the	O
surgeon	O
standing	O
between	O
the	O
legs	O
.	O
The	O
biopsies	O
were	O
obtained	O
by	O
monopolar	O
electrocautery	O
or	O
harmonic	O
scalpel	O
.	O
The	O
standard	O
sampling	O
was	O
considered	O
2	O
×	O
2	O
cm	O
,	O
avoiding	O
bleeding	O
and	O
other	O
possible	O
contamination	O
.	O
The	O
omentum	O
was	O
collected	O
into	O
an	O
endobag	O
and	O
extracted	O
through	O
the	O
umbilical	O
trocar	O
to	O
avoid	O
crash	O
and	O
contamination	O
.	O
The	O
study	B-methodology
protocol	I-methodology
has	O
been	O
approved	O
by	O
the	O
ethics	O
committee	O
of	O
the	O
La	O
Sapienza	O
University	O
.	O
All	O
the	O
subjects	O
were	O
volunteers	O
and	O
gave	O
their	O
informed	O
consent	O
according	O
to	O
the	O
Italian	O
law	O
on	O
this	O
matter	O
(	O
Legislative	O
Decree	O
of	O
the	O
Italian	O
Ministry	O
of	O
Health	O
,	O
25	O
January	O
2001	O
,	O
published	O
in	O
the	O
Official	O
Gazette	O
of	O
3	O
April	O
2001	O
)	O
.	O
From	O
5	O
to	O
10	O
grams	O
of	O
omental	O
biopsies	O
were	O
microdissected	O
,	O
rinsed	O
several	O
times	O
in	O
0	O
.	O
9	O
%	O
NaCl	O
,	O
and	O
digested	O
with	O
5	O
mL	O
of	O
Krebs	O
-	O
Ringer	O
solution	O
(	O
0	O
.	O
12	O
mol	O
/	O
L	O
NaCl	O
,	O
4	O
.	O
7	O
mol	O
/	O
L	O
KCl	O
,	O
2	O
.	O
5	O
mmol	O
/	O
L	O
CaCl2	O
,	O
1	O
.	O
2	O
mmol	O
/	O
L	O
MgSO4	O
,	O
and	O
1	O
.	O
2	O
mmol	O
/	O
L	O
KH2PO4	O
)	O
containing	O
20	O
mmol	O
/	O
L	O
HEPES	O
pH	O
7	O
.	O
4	O
,	O
3	O
.	O
5	O
%	O
fatty	O
acid	O
–	O
free	O
BSA	O
,	O
200	O
nmol	O
/	O
L	O
adenosine	O
,	O
2	O
mmol	O
/	O
L	O
glucose	O
,	O
and	O
collagenase	O
(	O
type	O
1	O
)	O
for	O
1	O
h	O
(	O
1	O
mg	O
/	O
g	O
adipose	O
tissue	O
)	O
at	O
37°C	O
in	O
shaking	O
water	O
bath	O
(	O
36	O
)	O
.	O
After	O
collagenase	O
digestion	O
,	O
the	O
adipocytes	O
were	O
separated	O
from	O
tissue	O
debris	O
by	O
filtering	O
through	O
sterile	O
nylon	O
mesh	O
(	O
250	O
μm	O
)	O
.	O

Cells	O
were	O
then	O
washed	O
three	O
times	O
with	O
Krebs	O
-	O
Ringer	O
solution	O
containing	O
20	O
mmol	O
/	O
L	O
HEPES	O
,	O
pH	O
7	O
.	O
4	O
,	O
1	O
%	O
fatty	O
acid	O
–	O
free	O
BSA	O
,	O
200	O
nmol	O
/	O
L	O
adenosine	O
,	O
and	O
2	O
mmol	O
/	O
L	O
glucose	O
and	O
resuspended	O
in	O
199	O
-	O
medium	O
containing	O
1	O
%	O
fatty	O
acid	O
–	O
free	O
BSA	O
and	O
25	O
mmol	O
/	O
L	O
HEPES	O
.	O
Floating	O
fraction	O
of	O
isolated	O
omental	O
adipocytes	O
from	O
different	O
individuals	O
was	O
used	O
for	O
the	O
experiments	O
described	O
below	O
.	O
3T3	O
-	O
L1	O
preadipocytes	O
(	O
American	O
Type	O
Culture	O
Collection	O
)	O
were	O
induced	O
to	O
differentiate	O
according	O
to	O
Masella	O
et	O
al	O
.	O
(	O
8	O
)	O
.	O
The	O
cells	O
were	O
used	O
for	O
the	O
experiments	O
on	O
day	O
14	O
,	O
when	O
>	O
90	O
%	O
of	O
cells	O
presented	O
the	O
adipocyte	O
phenotype	O
(	O
8	O
)	O
.	O
Different	O
oxLDL	O
concentrations	O
(	O
25	O
–	O
200	O
mg	O
protein	O
/	O
L	O
)	O
were	O
used	O
to	O
test	O
both	O
oxLDL	O
cytotoxicity	O
and	O
their	O
effects	O
on	O
glucose	O
uptake	O
to	O
determine	O
the	O
best	O
concentration	O
.	O
The	O
100	O
mg	O
/	O
L	O
concentration	O
was	O
chosen	O
because	O
it	O
effectively	O
reduces	O
the	O
glucose	O
uptake	O
by	O
50	O
%	O
in	O
human	O
and	O
murine	O
adipocytes	O
without	O
showing	O
any	O
sign	O
of	O
cytotoxicity	O
,	O
as	O
assessed	O
by	O
Neutral	O
Red	O
assay	O
,	O
or	O
affecting	O
the	O
morphology	O
or	O
the	O
metabolism	O
of	O
adipocytes	O
,	O
as	O
determined	O
by	O
the	O
expression	O
of	O
leptin	O
and	O
adipocyte	O
protein	O
2	O
(	O
aP2	O
)	O
and	O
by	O
the	O
incorporation	O
of	O
[	O
3H	O
]	O
Uridine	O
,	O
which	O
were	O
both	O
comparable	O
to	O
the	O
controls	O
(	O
data	O
not	O
shown	O
)	O
.	O
Under	O
all	O
the	O
experimental	O
conditions	O
described	O
below	O
,	O
adipocytes	O
,	O
untreated	O
and	O
treated	O
with	O
nLDL	O
(	O
100	O
mg	O
/	O
L	O
)	O
,	O
were	O
used	O
as	O
controls	O
.	O
Because	O
we	O
obtained	O
wholly	O
overlapping	O
results	O
,	O
we	O
report	O
data	O
for	O
untreated	O
cells	O
only	O
.	O
Adipocytes	O
were	O
incubated	O
with	O
C3G	O
(	O
Polyphenols	O
Laboratories	O
AS	O
,	O
Sandnes	O
,	O
Norway	O
)	O
or	O
PCA	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
at	O
concentrations	O
of	O
50	O
and	O
100	O
μmol	O
/	O
L	O
,	O
respectively	O
,	O
for	O
human	O
omental	O
adipocytes	O
and	O
10	O
and	O
100	O
μmol	O
/	O
L	O
,	O
respectively	O
,	O
for	O
3T3	O
-	O
L1	O
18	O
h	O
before	O
the	O
addition	O
of	O
nLDL	O
or	O
oxLDL	O
for	O
4	O
or	O
18	O
h	O
.	O

To	O
define	O
the	O
experimental	O
conditions	O
,	O
we	O
carried	O
out	O
preliminary	B-methodology
trials	I-methodology
,	O
incubating	O
the	O
cells	O
with	O
different	O
concentrations	O
of	O
the	O
polyphenols	O
(	O
1	O
–	O
150	O
μmol	O
/	O
L	O
)	O
for	O
different	O
times	O
before	O
oxLDL	O
addition	O
and	O
determining	O
the	O
percentage	O
of	O
glucose	O
internalized	O
in	O
the	O
cells	O
after	O
insulin	O
stimulation	O
.	O
On	O
the	O
basis	O
of	O
the	O
data	O
obtained	O
(	O
not	O
shown	O
)	O
,	O
the	O
time	O
and	O
the	O
lowest	O
concentration	O
of	O
the	O
two	O
polyphenols	O
able	O
to	O
provide	O
a	O
50	O
%	O
recovery	O
of	O
glucose	O
uptake	O
in	O
oxLDL	O
-	O
treated	O
cells	O
were	O
used	O
in	O
all	O
the	O
experiments	O
.	O
To	O
define	O
the	O
effect	O
of	O
the	O
polyphenols	O
on	O
PPARγ	O
,	O
we	O
assessed	O
the	O
mRNA	O
expression	O
and	O
activity	O
of	O
the	O
transcription	O
factor	O
in	O
cells	O
incubated	O
for	O
2	O
or	O
18	O
h	O
with	O
C3G	O
or	O
PCA	O
.	O
In	O
the	O
experiments	O
intended	O
to	O
evaluate	O
the	O
specific	O
involvement	O
of	O
PPARγ	O
in	O
the	O
activation	O
of	O
its	O
target	O
genes	O
,	O
the	O
cells	O
were	O
treated	O
with	O
10	O
μmol	O
/	O
L	O
GW9662	O
,	O
a	O
PPARγ	O
antagonist	O
,	O
30	O
min	O
before	O
the	O
treatment	O
with	O
polyphenols	O
.	O
Glucose	O
transport	O
was	O
measured	O
as	O
described	O
elsewhere	O
(	O
37	O
)	O
.	O
Briefly	O
,	O
human	O
and	O
3T3	O
-	O
L1	O
adipocytes	O
,	O
plated	O
in	O
low	O
-	O
glucose	O
Dulbecco	O
’	O
s	O
modified	O
Eagle	O
’	O
s	O
medium	O
(	O
1	O
,	O
000	O
mg	O
/	O
L	O
d	O
-	O
(	O
+	O
)	O
-	O
glucose	O
)	O
,	O
were	O
serum	O
starved	O
for	O
18	O
h	O
and	O
stimulated	O
with	O
20	O
nmol	O
/	O
L	O
insulin	O
for	O
15	O
min	O
.	O
[	O
3H	O
]	O
-	O
2	O
-	O
DG	O
(	O
2	O
-	O
deoxyglucose	O
)	O
(	O
1	O
μCi	O
/	O
well	O
)	O
was	O
added	O
to	O
the	O
cells	O
,	O
and	O
45	O
min	O
was	O
allowed	O
for	O
its	O
uptake	O
by	O
the	O
cells	O
.	O
The	O
reaction	O
was	O
stopped	O
by	O
ice	O
-	O
cold	O
PBS	O
in	O
3T3	O
-	O
L1	O
cells	O
and	O
by	O
rapid	O
centrifugation	O
at	O
8	O
,	O
000	O
rpm	O
for	O
5	O
min	O
through	O
300	O
μL	O
cushion	O
of	O
silicon	O
oil	O
in	O
human	O
omental	O
adipocytes	O
.	O
The	O
total	O
incorporated	O
radioactivity	O
was	O
determined	O
in	O
a	O
liquid	O
scintillation	O
counter	O
.	O
The	O
results	O
were	O
corrected	O
for	O
aspecific	O
absorption	O
(	O
37	O
)	O
.	O
Aspecific	O
absorption	O
was	O
always	O
<	O
10	O
%	O
of	O
total	O
uptake	O
.	O
Results	O
were	O
normalized	O
for	O
protein	O
content	O
.	O

To	O
evaluate	O
GLUT4	O
in	O
plasma	O
membranes	O
(	O
PM	O
)	O
and	O
in	O
low	O
-	O
density	O
microsome	O
(	O
LDM	O
)	O
fractions	O
enriched	O
in	O
the	O
intracellular	O
GLUT4	O
storage	O
vesicles	O
(	O
38	O
)	O
,	O
the	O
cells	O
were	O
fractionated	O
according	O
to	O
McKeel	O
and	O
Jarett	O
(	O
39	O
)	O
.	O
Whole	O
-	O
cell	O
extracts	O
were	O
prepared	O
from	O
cells	O
as	O
previously	O
described	O
(	O
8	O
)	O
.	O
Nuclear	O
protein	O
extracts	O
were	O
prepared	O
by	O
the	O
Nuclear	O
/	O
Cytosol	O
Fractionation	O
Kit	O
(	O
Medical	O
&	O
Biological	O
Laboratories	O
,	O
Watertown	O
,	O
LA	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O
Immunoblotting	O
analyses	O
were	O
carried	O
out	O
using	O
specific	O
antibodies	O
for	O
PPARγ	O
and	O
GLUT4	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
)	O
.	O
Blots	O
were	O
treated	O
with	O
appropriate	O
secondary	O
antibodies	O
conjugated	O
with	O
horseradish	O
peroxidase	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
followed	O
by	O
enhanced	O
chemiluminescence	O
detection	O
(	O
Amersham	O
Bio	O
-	O
sciences	O
,	O
Buckinghamshire	O
,	O
U	O
.	O
K	O
.	O
)	O
.	O
Equal	O
loading	O
of	O
proteins	O
was	O
verified	O
by	O
immunoblotting	O
with	O
a	O
goat	O
anti	O
–	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
antibody	O
.	O
Densitometric	O
analysis	O
was	O
performed	O
using	O
a	O
molecular	O
imager	O
FX	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
CA	O
)	O
.	O
Total	O
RNA	O
was	O
isolated	O
with	O
TRIZOL	O
reagent	O
(	O
Invitrogen	O
-	O
Life	O
Technologies	O
,	O
Carlsbad	O
,	O
CA	O
)	O
as	O
reported	O
elsewhere	O
(	O
8	O
)	O
.	O
Quantitative	O
real	O
-	O
time	O
PCR	O
(	O
RTq	O
-	O
PCR	O
)	O
was	O
carried	O
out	O
with	O
gene	O
-	O
specific	O
TaqMan	O
MGB	O
probes	O
and	O
primers	O
(	O
Applied	O
Biosystems	O
,	O
Carlsbad	O
,	O
CA	O
)	O
in	O
an	O
ABI	O
7700	O
sequence	O
detector	O
(	O
Applied	O
Biosystems	O
)	O
.	O
PPARγ	O
,	O
GLUT4	O
,	O
adiponectin	O
,	O
and	O
endogenous	O
controls	O
TATA	O
-	O
box	O
binding	O
protein	O
(	O
TBP	O
)	O
and	O
GAPDH	O
were	O
purchased	O
from	O
Applied	O
Biosystems	O
as	O
predesigned	O
assays	O
.	O
All	O
gene	O
expression	O
assays	O
have	O
a	O
FAM	O
reporter	O
dye	O
at	O
5	O
′	O
end	O
of	O
TaqMan	O
MGB	O
probe	O
and	O
a	O
nonfluorescent	O
quencher	O
at	O
3	O
′	O
end	O
of	O
the	O
probe	O
.	O

Expression	O
of	O
PPARγ	O
,	O
GLUT4	O
,	O
and	O
adiponectin	O
genes	O
were	O
determined	O
as	O
the	O
amount	O
of	O
individual	O
mRNA	O
relative	O
to	O
mRNA	O
for	O
TBP	O
(	O
murine	O
adipocytes	O
)	O
or	O
GAPDH	O
(	O
human	O
adipocytes	O
)	O
using	O
the	O
comparative	O
CT	O
method	O
described	O
in	O
the	O
ABI	O
7700	O
sequence	O
detection	O
system	O
,	O
user	O
bulletin	O
number	O
two	O
.	O
PPARγ	O
activity	O
was	O
determined	O
in	O
nuclear	O
extracts	O
with	O
the	O
TransAM	O
ELISA	O
Kit	O
(	O
Active	O
Motif	O
Europe	O
,	O
Rixensart	O
,	O
Belgium	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O
The	O
release	O
of	O
adiponectin	O
was	O
evaluated	O
in	O
the	O
culture	O
media	O
by	O
ELISA	O
Kit	O
(	O
R	O
&	O
D	O
Systems	O
Inc	O
.	O
,	O
Minneapolis	O
,	O
MN	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O
PPARγ	O
expression	O
was	O
inhibited	O
with	O
specific	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
reagents	O
(	O
mouse	O
PPARγ	O
siGENOME	O
SMARTpool	O
siRNA	O
;	O
Dharmacon	O
,	O
Lafayette	O
,	O
CO	O
)	O
as	O
previously	O
described	O
(	O
8	O
)	O
.	O
Scrambled	O
nontargeting	O
siRNA	O
was	O
used	O
as	O
negative	O
control	O
.	O
At	O
selected	O
time	O
points	O
after	O
transfection	O
,	O
mRNA	O
and	O
protein	O
were	O
extracted	O
to	O
assess	O
PPARγ	O
,	O
GLUT4	O
,	O
and	O
adiponectin	O
mRNA	O
expressions	O
and	O
GLUT4	O
protein	O
in	O
PM	O
.	O
The	O
results	O
are	O
expressed	O
as	O
means	O
±	O
SEM	O
of	O
at	O
least	O
four	O
independent	B-methodology
experiments	I-methodology
performed	O
in	O
duplicate	O
.	O
In	O
the	O
human	B-methodology
studies	I-methodology
,	O
depending	O
on	O
the	O
amount	O
of	O
adipocytes	O
isolated	O
from	O
each	O
subject	O
,	O
each	O
experiment	O
was	O
performed	O
in	O
at	O
least	O
4	O
different	O
individuals	O
(	O
men	O
-	O
to	O
-	O
women	O
1	O
:	O
1	O
)	O
randomly	O
chosen	O
from	O
the	O
20	O
recruited	O
subjects	O
.	O
Comparisons	O
between	O
two	O
groups	O
were	O
carried	O
out	O
by	O
Student	O
t	O
test	O
.	O
ANOVA	O
followed	O
by	O
Student	O
-	O
Newman	O
-	O
Keuls	O
multiple	O
comparison	O
test	O
were	O
used	O
when	O
>	O
2	O
groups	O
were	O
compared	O
.	O
Differences	O
were	O
considered	O
significant	O
when	O
P	O
<	O
0	O
.	O
05	O
.	O
We	O
have	O
previously	O
demonstrated	O
that	O
oxLDLs	O
are	O
able	O
to	O
affect	O
cell	O
sensitivity	O
toward	O
insulin	O
,	O
inhibiting	O
glucose	O
uptake	O
by	O
interfering	O
with	O
the	O
cell	O
response	O
to	O
insulin	O
in	O
3T3	O
-	O
L1	O
adipocytes	O
(	O
10	O
)	O
.	O
Similar	O
results	O
were	O
obtained	O
in	O
insulin	O
-	O
stimulated	O
human	O
omental	O
adipocytes	O
treated	O
with	O
oxLDL	O
(	O
100	O
mg	O
/	O
L	O
)	O
.	O

Indeed	O
,	O
these	O
cells	O
showed	O
a	O
strong	O
decrease	O
(	O
−40	O
%	O
)	O
in	O
glucose	O
uptake	O
and	O
a	O
concomitant	O
reduction	O
of	O
GLUT4	O
protein	O
(	O
−60	O
%	O
)	O
in	O
the	O
PMs	O
after	O
oxLDL	O
treatment	O
(	O
Fig	O
.	O
1A	O
and	O
B	O
)	O
.	O
In	O
the	O
present	O
article	O
,	O
we	O
evaluated	O
whether	O
polyphenols	O
,	O
specifically	O
PCA	O
and	O
C3G	O
,	O
could	O
counteract	O
the	O
detrimental	O
effects	O
induced	O
by	O
oxLDL	O
in	O
adipocyte	O
cell	O
models	O
.	O
To	O
this	O
end	O
,	O
glucose	O
uptake	O
was	O
evaluated	O
in	O
oxLDL	O
-	O
treated	O
adipocytes	O
,	O
previously	O
incubated	O
with	O
each	O
polyphenol	O
for	O
18	O
h	O
,	O
as	O
described	O
in	O
research	B-methodology
design	I-methodology
and	O
methods	O
.	O
Our	O
results	O
evidenced	O
that	O
both	O
the	O
polyphenols	O
were	O
able	O
to	O
counteract	O
the	O
drop	O
in	O
glucose	O
uptake	O
of	O
human	O
as	O
well	O
as	O
murine	O
insulin	O
-	O
treated	O
adipocytes	O
(	O
Fig	O
.	O
1A	O
and	O
C	O
,	O
respectively	O
)	O
.	O
In	O
addition	O
,	O
they	O
reversed	O
the	O
impairment	O
of	O
GLUT4	O
translocation	O
(	O
Fig	O
.	O
1B	O
and	O
D	O
)	O
induced	O
by	O
oxLDL	O
.	O
Notably	O
,	O
the	O
levels	O
of	O
both	O
glucose	O
uptake	O
and	O
GLUT4	O
translocation	O
were	O
increased	O
in	O
insulin	O
-	O
stimulated	O
adipocytes	O
treated	O
with	O
polyphenols	O
with	O
respect	O
to	O
those	O
treated	O
with	O
insulin	O
alone	O
(	O
up	O
to	O
40	O
%	O
at	O
50	O
μmol	O
/	O
L	O
and	O
100	O
μmol	O
/	O
L	O
of	O
C3G	O
and	O
PCA	O
,	O
respectively	O
)	O
.	O
This	O
increase	O
might	O
be	O
the	O
result	O
of	O
an	O
enhancement	O
of	O
cell	O
sensibility	O
to	O
insulin	O
as	O
well	O
as	O
to	O
an	O
additive	O
effect	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
polyphenols	O
could	O
improve	O
glucose	O
uptake	O
and	O
GLUT4	O
translocation	O
by	O
activating	O
other	O
factors	O
than	O
those	O
specifically	O
involved	O
in	O
insulin	O
pathways	O
)	O
.	O
However	O
,	O
we	O
have	O
no	O
evidence	O
to	O
support	O
any	O
hypothesis	O
.	O
To	O
better	O
define	O
the	O
possible	O
effects	O
of	O
oxLDL	O
on	O
the	O
basal	O
uptake	O
of	O
glucose	O
,	O
we	O
determined	O
glucose	O
uptake	O
and	O
GLUT4	O
translocation	O
in	O
unstimulated	O
human	O
omental	O
adipocytes	O
after	O
4	O
and	O
18	O
h	O
of	O
incubation	O
with	O
oxLDL	O
alone	O
and	O
in	O
the	O
presence	O
of	O
polyphenols	O
.	O
The	O
glucose	O
transport	O
machinery	O
appeared	O
not	O
to	O
be	O
affected	O
by	O
4	O
-	O
h	O
oxLDL	O
treatment	O
,	O
whereas	O
18	O
-	O
h	O
treatment	O
caused	O
the	O
lowering	O
of	O
glucose	O
uptake	O
and	O
GLUT4	O
translocation	O
.	O

Both	O
the	O
polyphenols	O
were	O
able	O
to	O
counteract	O
such	O
decrease	O
(	O
Fig	O
.	O
2A	O
and	O
B	O
)	O
.	O
On	O
the	O
basis	O
of	O
this	O
finding	O
,	O
we	O
carried	O
out	O
an	O
in	O
-	O
depth	O
study	O
to	O
define	O
the	O
effects	O
of	O
the	O
polyphenols	O
on	O
the	O
efficiency	O
of	O
the	O
glucose	O
transport	O
mechanism	O
.	O
Thus	O
,	O
human	O
omental	O
adipocytes	O
and	O
3T3	O
-	O
L1	O
were	O
incubated	O
with	O
different	O
concentrations	O
of	O
C3G	O
(	O
1	O
–	O
100	O
μmol	O
/	O
L	O
)	O
or	O
PCA	O
(	O
1	O
–	O
150	O
μmol	O
/	O
L	O
)	O
for	O
18	O
h	O
.	O
Then	O
,	O
2	O
-	O
deoxy	O
-	O
d	O
-	O
[	O
3H	O
]	O
glucose	O
transport	O
was	O
assessed	O
in	O
either	O
insulin	O
-	O
stimulated	O
or	O
unstimulated	O
cells	O
.	O
The	O
results	O
indicate	O
that	O
C3G	O
and	O
PCA	O
treatments	O
were	O
associated	O
with	O
an	O
enhancement	O
of	O
glucose	O
uptake	O
in	O
the	O
adipocytes	O
not	O
only	O
in	O
the	O
insulin	O
-	O
stimulated	O
cells	O
but	O
also	O
in	O
the	O
unstimulated	O
cells	O
(	O
Fig	O
.	O
3	O
)	O
.	O
It	O
is	O
worth	O
noting	O
that	O
the	O
glucose	O
uptake	O
in	O
adipocytes	O
not	O
stimulated	O
with	O
insulin	O
increased	O
by	O
up	O
to	O
60	O
and	O
40	O
%	O
with	O
50	O
μmol	O
/	O
L	O
C3G	O
or	O
100	O
μmol	O
/	O
L	O
PCA	O
,	O
respectively	O
(	O
Fig	O
.	O
3A	O
and	O
B	O
)	O
.	O
A	O
similar	O
trend	O
was	O
also	O
observed	O
in	O
3T3	O
-	O
L1	O
cells	O
in	O
which	O
glucose	O
uptake	O
increased	O
by	O
up	O
to	O
60	O
%	O
with	O
10	O
μmol	O
/	O
L	O
C3G	O
or	O
100	O
μmol	O
/	O
L	O
PCA	O
(	O
Fig	O
.	O
3C	O
and	O
D	O
)	O
.	O
Thus	O
,	O
the	O
polyphenols	O
exhibited	O
a	O
significant	O
insulin	O
-	O
like	O
activity	O
.	O
To	O
elucidate	O
the	O
mechanism	O
responsible	O
for	O
the	O
insulin	O
-	O
like	O
activity	O
of	O
the	O
polyphenols	O
,	O
we	O
evaluated	O
whether	O
C3G	O
and	O
PCA	O
exhibited	O
a	O
direct	O
effect	O
on	O
the	O
glucose	O
transporter	O
GLUT4	O
.	O
In	O
particular	O
,	O
we	O
determined	O
its	O
expression	O
,	O
as	O
protein	O
and	O
mRNA	O
,	O
in	O
adipocytes	O
treated	O
with	O
each	O
polyphenol	O
.	O
As	O
shown	O
in	O
Fig	O
.	O
4A	O
,	O
in	O
human	O
omental	O
adipocytes	O
,	O
C3G	O
and	O
PCA	O
were	O
able	O
to	O
upregulate	O
GLUT4	O
mRNA	O
,	O
as	O
also	O
demonstrated	O
in	O
3T3	O
-	O
L1	O
adipocytes	O
(	O
Fig	O
.	O
4C	O
)	O
.	O
In	O
parallel	O
,	O
we	O
assessed	O
GLUT4	O
protein	O
levels	O
in	O
whole	O
-	O
cell	O
lysates	O
and	O
PMs	O
.	O

We	O
found	O
that	O
in	O
human	O
omental	O
adipocytes	O
,	O
as	O
well	O
as	O
in	O
3T3	O
-	O
L1	O
,	O
GLUT4	O
was	O
upregulated	O
in	O
whole	O
-	O
cell	O
lysates	O
(	O
[UNK]	O
%	O
in	O
both	O
human	O
and	O
murine	O
cells	O
)	O
but	O
especially	O
in	O
PMs	O
(	O
up	O
to	O
170	O
and	O
50	O
%	O
in	O
human	O
and	O
murine	O
adipocytes	O
,	O
respectively	O
)	O
(	O
Fig	O
.	O
4B	O
and	O
D	O
)	O
.	O
Notably	O
,	O
in	O
human	O
omental	O
adipocytes	O
,	O
we	O
also	O
determined	O
GLUT4	O
in	O
the	O
storage	O
vesicles	O
(	O
LDM	O
)	O
,	O
showing	O
that	O
the	O
upregulation	O
of	O
GLUT4	O
in	O
the	O
PMs	O
was	O
accompanied	O
by	O
a	O
significant	O
decrease	O
in	O
the	O
LDM	O
fractions	O
(	O
Fig	O
.	O
4B	O
)	O
.	O
These	O
findings	O
indicated	O
that	O
polyphenols	O
increased	O
glucose	O
uptake	O
by	O
significantly	O
inducing	O
GLUT4	O
expression	O
and	O
mostly	O
,	O
GLUT4	O
translocation	O
.	O
Adiponectin	O
has	O
been	O
shown	O
to	O
have	O
some	O
insulin	O
-	O
sensitizing	O
properties	O
(	O
13	O
,	O
40	O
)	O
and	O
to	O
be	O
decreased	O
in	O
serum	O
of	O
insulin	O
-	O
resistant	O
,	O
diabetic	O
,	O
and	O
obese	O
subjects	O
(	O
14	O
)	O
.	O
Thus	O
,	O
we	O
hypothesized	O
that	O
oxLDL	O
could	O
affect	O
adiponectin	O
production	O
/	O
secretion	O
and	O
that	O
the	O
polyphenols	O
could	O
counteract	O
this	O
effect	O
.	O
To	O
verify	O
our	O
hypothesis	O
,	O
human	O
omental	O
adipocytes	O
were	O
incubated	O
for	O
4	O
and	O
18	O
h	O
with	O
oxLDL	O
alone	O
or	O
in	O
the	O
presence	O
of	O
the	O
phenolic	O
compounds	O
.	O
After	O
4	O
h	O
of	O
oxLDL	O
treatment	O
,	O
both	O
in	O
presence	O
or	O
absence	O
of	O
polyphenols	O
,	O
the	O
levels	O
of	O
adiponectin	O
expression	O
and	O
secretion	O
were	O
not	O
substantially	O
changed	O
(	O
Fig	O
.	O
2C	O
and	O
D	O
)	O
.	O
On	O
the	O
contrary	O
,	O
at	O
18	O
h	O
,	O
oxLDL	O
reduced	O
adiponectin	O
mRNA	O
levels	O
by	O
50	O
%	O
(	O
Fig	O
.	O
2C	O
)	O
and	O
adiponectin	O
secretion	O
by	O
30	O
%	O
(	O
Fig	O
.	O
2D	O
)	O
,	O
whereas	O
both	O
polyphenols	O
prevented	O
such	O
reductions	O
.	O
Worthy	O
of	O
note	O
is	O
the	O
finding	O
that	O
polyphenols	O
were	O
able	O
to	O
upregulate	O
both	O
mRNA	O
expression	O
and	O
secretion	O
of	O
adiponectin	O
by	O
themselves	O
(	O
Fig	O
.	O
5A	O
and	O
B	O
)	O
.	O

A	O
similar	O
increase	O
in	O
adiponectin	O
expression	O
and	O
secretion	O
was	O
also	O
demonstrated	O
in	O
3T3	O
-	O
L1	O
cells	O
after	O
polyphenol	O
treatment	O
(	O
Fig	O
.	O
5C	O
and	O
D	O
)	O
.	O
To	O
identify	O
a	O
possible	O
mechanism	O
responsible	O
for	O
the	O
different	O
modulation	O
of	O
GLUT4	O
and	O
adiponectin	O
observed	O
in	O
oxLDL	O
-	O
or	O
polyphenol	O
-	O
treated	O
adipocytes	O
,	O
we	O
assessed	O
whether	O
PPARγ	O
,	O
the	O
master	O
regulator	O
of	O
mature	O
adipocyte	O
genes	O
(	O
15	O
)	O
,	O
could	O
be	O
involved	O
.	O
For	O
this	O
purpose	O
,	O
we	O
carried	O
out	O
experiments	O
to	O
determine	O
PPARγ	O
mRNA	O
after	O
treatment	O
with	O
oxLDL	O
and	O
/	O
or	O
polyphenols	O
.	O
RTq	O
-	O
PCR	O
analysis	O
showed	O
a	O
significant	O
decrease	O
in	O
PPARγ	O
mRNA	O
expression	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
human	O
omental	O
adipocytes	O
within	O
18	O
h	O
of	O
treatment	O
with	O
oxLDL	O
that	O
was	O
counteracted	O
by	O
polyphenols	O
(	O
Fig	O
.	O
2E	O
)	O
.	O
Furthermore	O
,	O
we	O
determined	O
the	O
activation	O
status	O
of	O
PPARγ	O
in	O
nuclear	O
extracts	O
of	O
cells	O
treated	O
with	O
oxLDL	O
and	O
/	O
or	O
polyphenols	O
,	O
further	O
demonstrating	O
that	O
oxLDL	O
negatively	O
affected	O
PPARγ	O
activation	O
,	O
whereas	O
C3G	O
and	O
PCA	O
were	O
able	O
to	O
counteract	O
the	O
oxLDL	O
-	O
induced	O
detrimental	O
action	O
(	O
Fig	O
.	O
2F	O
)	O
.	O
It	O
is	O
interesting	O
that	O
the	O
polyphenols	O
elicited	O
per	O
se	O
both	O
the	O
rise	O
of	O
PPARγ	O
gene	O
transcription	O
(	O
Fig	O
.	O
6A	O
)	O
and	O
an	O
early	O
and	O
prolonged	O
increase	O
in	O
PPARγ	O
activity	O
(	O
Fig	O
.	O
6B	O
)	O
.	O
In	O
3T3	O
-	O
L1	O
cells	O
,	O
C3G	O
and	O
PCA	O
also	O
upregulated	O
PPARγ	O
gene	O
expression	O
and	O
activity	O
(	O
Fig	O
.	O
6C	O
and	O
D	O
)	O
.	O
To	O
further	O
demonstrate	O
the	O
involvement	O
of	O
PPARγ	O
in	O
the	O
insulin	O
-	O
like	O
activity	O
exerted	O
by	O
C3G	O
and	O
PCA	O
,	O
we	O
silenced	O
PPARγ	O
expression	O
in	O
3T3	O
-	O
L1	O
by	O
using	O
the	O
small	O
interfering	O
mRNA	O
technique	O
and	O
the	O
PPARγ	O
antagonist	O
GW9662	O
.	O

In	O
the	O
transfected	O
cells	O
,	O
as	O
well	O
as	O
in	O
the	O
PPARγ	O
inhibitor	O
–	O
treated	O
cells	O
,	O
we	O
found	O
that	O
the	O
significant	O
upregulation	O
of	O
adiponectin	O
and	O
GLUT4	O
mRNAs	O
induced	O
by	O
polyphenols	O
were	O
counteracted	O
(	O
Fig	O
.	O
7A	O
and	O
B	O
)	O
,	O
providing	O
additional	O
evidence	O
for	O
the	O
causal	O
relationship	O
between	O
PPARγ	O
activation	O
and	O
polyphenol	O
-	O
induced	O
upregulation	O
of	O
adiponectin	O
and	O
GLUT4	O
.	O
We	O
also	O
demonstrated	O
that	O
in	O
the	O
absence	O
of	O
PPARγ	O
activity	O
,	O
GLUT4	O
translocation	O
to	O
the	O
PM	O
did	O
not	O
occur	O
(	O
Fig	O
.	O
7C	O
)	O
.	O
This	O
was	O
a	O
conclusive	O
demonstration	O
of	O
the	O
direct	O
involvement	O
of	O
PPARγ	O
in	O
the	O
regulation	O
of	O
the	O
glucose	O
transport	O
mechanism	O
by	O
C3G	O
and	O
PCA	O
.	O
In	O
the	O
current	O
study	O
,	O
we	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
C3G	O
and	O
its	O
main	O
metabolite	O
PCA	O
were	O
able	O
to	O
completely	O
counteract	O
the	O
oxLDL	O
-	O
induced	O
impairment	O
of	O
glucose	O
transport	O
mechanism	O
in	O
human	O
omental	O
and	O
murine	O
adipocytes	O
.	O
More	O
important	O
,	O
we	O
provided	O
evidence	O
for	O
an	O
insulin	O
-	O
like	O
activity	O
of	O
the	O
polyphenols	O
that	O
were	O
able	O
to	O
regulate	O
the	O
internalization	O
of	O
glucose	O
.	O
Maintenance	O
of	O
glucose	O
homeostasis	O
by	O
strict	O
hormonal	O
control	O
is	O
of	O
utmost	O
importance	O
to	O
human	O
physiology	O
.	O
Failure	O
of	O
this	O
control	O
,	O
with	O
defects	O
in	O
both	O
insulin	O
action	O
and	O
insulin	O
secretion	O
,	O
can	O
result	O
in	O
metabolic	O
syndrome	O
,	O
a	O
multisymptom	O
disorder	O
of	O
energy	O
homeostasis	O
.	O
The	O
disturbance	O
of	O
glucose	O
metabolism	O
is	O
often	O
related	O
to	O
the	O
increase	O
of	O
fat	O
mass	O
,	O
especially	O
in	O
the	O
abdominal	O
area	O
,	O
which	O
in	O
turn	O
results	O
in	O
inflammation	O
,	O
exacerbated	O
oxidative	O
stress	O
at	O
the	O
whole	O
body	O
level	O
with	O
increased	O
circulating	O
oxLDL	O
levels	O
,	O
and	O
malfunction	O
in	O
several	O
organs	O
,	O
including	O
adipose	O
tissue	O
(	O
3	O
)	O
.	O
IR	O
seems	O
to	O
underlie	O
the	O
early	O
stages	O
of	O
development	O
of	O
metabolic	O
syndrome	O
and	O
,	O
thus	O
,	O
approaches	O
to	O
improve	O
insulin	O
action	O
have	O
been	O
and	O
remain	O
key	O
targets	O
for	O
potentially	O
slowing	O
or	O
ultimately	O
preventing	O
type	O
2	O
diabetes	O
(	O
41	O
,	O
42	O
)	O
.	O
The	O
potential	O
of	O
polyphenols	O
in	O
controlling	O
glycemia	O
is	O
currently	O
under	O
intensive	O
study	O
.	O
However	O
,	O
although	O
indications	O
for	O
positive	O
effects	O
of	O
ACNs	O
on	O
glucose	O
homeostasis	O
have	O
been	O
obtained	O
in	B-methodology
vitro	I-methodology
and	O
in	O
animal	B-methodology
studies	I-methodology
(	O
43	O
–	O
45	O
)	O
,	O
definitive	O
conclusions	O
in	O
humans	O
,	O
especially	O
at	O
the	O
molecular	O
mechanistic	O
level	O
,	O
are	O
still	O
lacking	O
.	O

Furthermore	O
,	O
the	O
biological	O
properties	O
of	O
ACNs	O
have	O
nearly	O
always	O
been	O
studied	O
in	B-methodology
vitro	I-methodology
by	O
using	O
their	O
native	O
form	O
,	O
which	O
appears	O
quite	O
inappropriate	O
because	O
of	O
their	O
in	B-methodology
vivo	I-methodology
extensive	O
and	O
rapid	O
biotransformation	O
after	O
ingestion	O
(	O
28	O
)	O
.	O
Indeed	O
,	O
the	O
native	O
forms	O
of	O
ACN	O
are	O
poorly	O
present	O
in	O
the	O
bloodstream	O
(	O
28	O
)	O
,	O
and	O
they	O
might	O
be	O
metabolites	O
such	O
as	O
PCA	O
,	O
which	O
likely	O
reach	O
tissues	O
and	O
may	O
exert	O
biological	O
effects	O
.	O
So	O
far	O
,	O
PCA	O
has	O
been	O
poorly	O
investigated	O
because	O
of	O
its	O
low	O
concentration	O
in	O
foods	O
.	O
However	O
,	O
in	O
our	O
opinion	O
,	O
it	O
deserves	O
great	O
nutritional	O
interest	O
as	O
the	O
main	O
human	O
metabolite	O
of	O
C3G	O
,	O
which	O
is	O
in	O
turn	O
the	O
most	O
representative	O
dietary	O
ACN	O
.	O
In	O
this	O
regard	O
,	O
our	O
study	O
represents	O
a	O
novel	O
approach	O
in	O
this	O
field	O
of	O
research	O
because	O
for	O
the	O
first	O
time	O
,	O
the	O
properties	O
of	O
both	O
C3G	O
and	O
PCA	O
were	O
evaluated	O
in	O
an	O
innovative	O
ex	B-methodology
vivo	I-methodology
model	O
of	O
human	O
omental	O
adipocytes	O
.	O
Actually	O
,	O
few	O
studies	O
have	O
specifically	O
investigated	O
ACN	O
and	O
phenolic	O
acid	O
bioavailability	O
in	O
humans	O
(	O
28	O
,	O
46	O
,	O
47	O
)	O
.	O
PCA	O
was	O
first	O
identified	O
as	O
human	O
C3G	O
metabolite	O
by	O
Vitaglione	O
et	O
al	O
.	O
(	O
28	O
)	O
,	O
accounting	O
for	O
almost	O
73	O
%	O
of	O
ingested	O
C3G	O
.	O
Details	O
of	O
the	O
study	O
show	O
that	O
after	O
ingestion	O
of	O
1	O
L	O
of	O
blood	O
orange	O
juice	O
containing	O
71	O
mg	O
C3G	O
,	O
the	O
serum	O
maximal	O
concentrations	O
of	O
C3G	O
and	O
PCA	O
were	O
1	O
.	O
9	O
nmol	O
/	O
L	O
and	O
492	O
nmol	O
/	O
L	O
,	O
respectively	O
.	O
However	O
,	O
it	O
should	O
be	O
considered	O
that	O
bioavailability	O
can	O
be	O
affected	O
by	O
“	O
chronic	O
”	O
exposure	O
to	O
the	O
polyphenols	O
,	O
as	O
that	O
achievable	O
by	O
daily	O
consumption	O
of	O
ACN	O
-	O
rich	O
food	O
.	O
Furthermore	O
,	O
the	O
polyphenols	O
might	O
concentrate	O
at	O
cellular	O
level	O
in	O
the	O
tissue	O
microenvironment	O
.	O
From	O
this	O
point	O
of	O
view	O
,	O
the	O
polyphenol	O
concentrations	O
tested	O
in	O
our	O
experiments	O
,	O
although	O
higher	O
than	O
that	O
reported	O
after	O
ingestion	O
of	O
food	O
rich	O
in	O
ACN	O
,	O
can	O
provide	O
significant	O
information	O
.	O
Besides	O
,	O
from	O
a	O
pharmacological	O
point	O
of	O
view	O
,	O
our	O
study	O
offers	O
a	O
new	O
clue	O
to	O
the	O
possible	O
use	O
of	O
PCA	O
as	O
a	O
hypoglycemic	O
agent	O
.	O
Finally	O
,	O
this	O
study	O
provides	O
strong	O
evidence	O
of	O
the	O
molecular	O
mechanism	O
that	O
enabled	O
the	O
two	O
polyphenols	O
to	O
exert	O
some	O
insulin	O
-	O
like	O
effects	O
.	O

It	O
is	O
worth	O
noting	O
that	O
C3G	O
and	O
PCA	O
were	O
able	O
to	O
positively	O
modulate	O
adipocyte	O
glucose	O
uptake	O
largely	O
by	O
inducing	O
GLUT4	O
translocation	O
as	O
demonstrated	O
by	O
the	O
increase	O
of	O
GLUT4	O
level	O
in	O
PMs	O
and	O
the	O
concomitant	O
decrease	O
in	O
the	O
storage	O
vesicles	O
.	O
Adiponectin	O
has	O
been	O
described	O
as	O
a	O
principal	O
player	O
in	O
modulating	O
both	O
glucose	O
and	O
lipid	O
metabolism	O
in	O
skeletal	O
muscle	O
and	O
liver	O
by	O
acting	O
as	O
an	O
insulin	O
sensitizer	O
(	O
13	O
)	O
.	O
Low	O
levels	O
of	O
plasma	O
adiponectin	O
are	O
associated	O
with	O
several	O
pathological	O
conditions	O
that	O
represent	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
(	O
13	O
,	O
48	O
)	O
.	O
It	O
is	O
worthy	O
of	O
note	O
that	O
oxLDL	O
determined	O
a	O
significant	O
decrease	O
in	O
adiponectin	O
in	O
human	O
omental	O
adipocytes	O
.	O
Because	O
adiponectin	O
has	O
often	O
been	O
considered	O
a	O
good	O
target	O
for	O
developing	O
therapeutic	O
strategies	O
(	O
12	O
)	O
,	O
our	O
finding	O
that	O
both	O
C3G	O
and	O
PCA	O
were	O
able	O
not	O
only	O
to	O
counteract	O
the	O
adiponectin	O
decrease	O
induced	O
by	O
oxLDL	O
but	O
also	O
to	O
significantly	O
stimulate	O
the	O
expression	O
and	O
secretion	O
of	O
adiponectin	O
by	O
adipocytes	O
is	O
therefore	O
of	O
particular	O
interest	O
.	O
Furthermore	O
,	O
the	O
significant	O
increase	O
in	O
adiponectin	O
mRNA	O
expression	O
induced	O
by	O
C3G	O
was	O
consistent	O
with	O
the	O
previous	O
data	O
obtained	O
by	O
Tsuda	O
et	O
al	O
.	O
in	O
rat	O
(	O
49	O
)	O
and	O
human	O
adipocytes	O
(	O
50	O
)	O
.	O
PPARγ	O
is	O
the	O
most	O
extensively	O
studied	O
and	O
clinically	O
validated	O
gene	O
for	O
therapeutic	O
utility	O
in	O
type	O
2	O
diabetes	O
(	O
18	O
)	O
because	O
it	O
is	O
a	O
main	O
metabolic	O
regulator	O
of	O
peripheral	O
organs	O
and	O
tissues	O
,	O
such	O
as	O
adipose	O
tissue	O
(	O
17	O
)	O
.	O
Upregulation	O
of	O
PPARγ	O
expression	O
/	O
activity	O
by	O
TZDs	O
(	O
16	O
)	O
and	O
ACNs	O
has	O
been	O
reported	O
to	O
improve	O
insulin	O
sensitivity	O
and	O
glucose	O
uptake	O
in	O
human	O
adipocytes	O
(	O
50	O
)	O
and	O
in	O
animal	B-methodology
models	I-methodology
of	O
diabetes	O
(	O
33	O
)	O
.	O
We	O
hypothesized	O
that	O
oxLDL	O
and	O
polyphenols	O
could	O
affect	O
GLUT4	O
and	O
adiponectin	O
expressions	O
by	O
differently	O
modulating	O
PPARγ	O
.	O
Our	O
results	O
allowed	O
us	O
to	O
strongly	O
support	O
this	O
hypothesis	O
.	O
Indeed	O
,	O
oxLDL	O
significantly	O
reduced	O
the	O
expression	O
and	O
activity	O
of	O
PPARγ	O
in	O
human	O
omental	O
adipocytes	O
,	O
as	O
already	O
reported	O
in	O
3T3	O
-	O
L1	O
(	O
10	O
)	O
,	O
whereas	O
the	O
polyphenols	O
were	O
able	O
to	O
counteract	O
such	O
decrease	O
.	O

It	O
is	O
interesting	O
that	O
in	O
untreated	O
cells	O
,	O
both	O
C3G	O
and	O
PCA	O
significantly	O
increased	O
the	O
expression	O
of	O
PPARγ	O
gene	O
and	O
especially	O
its	O
activity	O
with	O
respect	O
to	O
basal	O
values	O
.	O
PPARγ	O
activity	O
remained	O
higher	O
during	O
the	O
entire	O
experimental	O
period	O
,	O
likely	O
through	O
the	O
promotion	O
of	O
its	O
binding	O
to	O
the	O
oligonucleotide	O
at	O
its	O
consensus	O
binding	O
site	O
.	O
Finally	O
,	O
our	O
data	O
strongly	O
suggest	O
that	O
PPARγ	O
plays	O
a	O
key	O
role	O
in	O
the	O
activation	O
of	O
its	O
target	O
genes	O
by	O
C3G	O
and	O
PCA	O
.	O
In	O
fact	O
,	O
the	O
silencing	O
of	O
PPARγ	O
overrode	O
the	O
increase	O
in	O
GLUT4	O
and	O
adiponectin	O
and	O
the	O
translocation	O
of	O
GLUT4	O
on	O
the	O
PM	O
induced	O
by	O
the	O
two	O
polyphenols	O
.	O
In	O
conclusion	O
,	O
we	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
C3G	O
and	O
PCA	O
exert	O
insulin	O
-	O
like	O
activity	O
in	O
human	O
omental	O
adipocytes	O
.	O
The	O
increase	O
in	O
glucose	O
uptake	O
was	O
associated	O
with	O
enhanced	O
GLUT4	O
translocation	O
and	O
adiponectin	O
secretion	O
,	O
which	O
were	O
probably	O
caused	O
by	O
the	O
increased	O
activity	O
of	O
PPARγ	O
induced	O
by	O
the	O
polyphenols	O
.	O
We	O
also	O
confirmed	O
that	O
the	O
3T3	O
-	O
L1	O
cell	O
line	O
represents	O
a	O
suitable	O
model	O
for	O
the	O
study	O
of	O
human	O
adipocyte	O
biology	O
because	O
they	O
showed	O
the	O
same	O
response	O
to	O
polyphenol	O
treatment	O
as	O
human	O
adipocytes	O
.	O
Altogether	O
,	O
our	O
data	O
provide	O
new	O
evidence	O
on	O
the	O
biological	O
activity	O
of	O
C3G	O
and	O
PCA	O
,	O
supporting	O
a	O
possible	O
use	O
of	O
these	O
polyphenols	O
as	O
dietary	O
bioactive	O
compounds	O
against	O
the	O
IR	O
condition	O
linked	O
to	O
the	O
occurrence	O
of	O
metabolic	O
syndrome	O
.	O
This	O
study	O
was	O
partially	O
supported	O
by	O
the	O
Provincia	O
Regionale	O
di	O
Catania	O
through	O
the	O
Antioxidant	O
Properties	O
of	O
Sicilian	O
Pigmented	O
Oranges	O
Project	O
.	O
No	O
potential	O
conflicts	O
of	O
interest	O
relevant	O
to	O
this	O
article	O
were	O
reported	O
.	O
B	O
.	O
S	O
.	O
provided	O
research	O
data	O
,	O
contributed	O
to	O
discussion	O
,	O
and	O
wrote	O
the	O
manuscript	O
.	O
R	O
.	O
V	O
.	O
contributed	O
to	O
research	O
data	O
and	O
discussion	O
.	O
C	O
.	O
F	O
.	O
contributed	O
to	O
research	O
data	O
.	O
M	O
.	O
D	O
.	O
,	O
C	O
.	O
S	O
.	O
,	O
and	O
C	O
.	O
G	O
.	O
contributed	O
to	O
discussion	O
and	O
reviewed	O
the	O
manuscript	O
.	O
A	O
.	O
I	O
.	O
and	O
G	O
.	O
S	O
.	O
provided	O
the	O
human	O
biopsies	O
and	O
reviewed	O
the	O
manuscript	O
.	O
G	O
.	O
L	O
.	O
V	O
.	O
and	O
F	O
.	O
G	O
.	O
contributed	O
to	O
discussion	O
and	O
reviewed	O
the	O
manuscript	O
.	O
R	O
.	O
M	O
.	O
contributed	O
to	O
discussion	O
and	O
wrote	O
the	O
manuscript	O
.	O

The	O
authors	O
wish	O
to	O
thank	O
Professor	O
Gabriella	O
Girelli	O
,	O
Director	O
of	O
Centro	O
Trasfusionale	O
,	O
University	O
of	O
Rome	O
La	O
Sapienza	O
,	O
for	O
providing	O
human	O
plasma	O
and	O
Antonietta	O
Pucciarmati	O
,	O
Department	O
of	O
Veterinary	O
Public	O
Health	O
and	O
Food	O
Safety	O
,	O
Italian	O
National	O
Institute	O
of	O
Health	O
,	O
for	O
technical	O
assistance	O
.	O

Effects	O
of	O
Whole	O
Milk	O
Supplementation	O
on	O
Gut	O
Microbiota	O
and	O
Cardiometabolic	O
Biomarkers	O
in	O
Subjects	O
with	O
and	O
without	O
Lactose	O
Malabsorption	O
lactose	O
malabsorption	O
;	O
milk	O
;	O
gut	O
microbiota	O
;	O
Bifidobacterium	O
;	O
short	O
-	O
chain	O
fatty	O
acids	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
impact	O
of	O
whole	O
milk	O
supplementation	O
on	O
gut	O
microbiota	O
and	O
cardiometabolic	O
biomarkers	O
between	O
lactose	O
malabsorbers	O
(	O
LM	O
)	O
and	O
absorbers	O
(	O
LA	O
)	O
.	O
We	O
performed	O
a	O
pair	O
-	O
wise	O
intervention	B-methodology
study	I-methodology
of	O
31	O
LM	O
and	O
31	O
LA	O
,	O
1	O
:	O
1	O
matched	O
by	O
age	O
,	O
sex	O
,	O
body	O
mass	O
index	O
,	O
and	O
daily	O
dairy	O
intake	O
.	O
Subjects	O
were	O
required	O
to	O
add	O
250	O
mL	O
/	O
day	O
whole	O
milk	O
for	O
four	O
weeks	O
in	O
their	O
routine	O
diet	O
.	O
At	O
the	O
beginning	O
and	O
the	O
end	O
of	O
the	O
intervention	B-methodology
period	I-methodology
,	O
we	O
collected	O
data	O
on	O
gut	O
microbiota	O
and	O
cardiometabolic	O
biomarkers	O
.	O
Whole	O
milk	O
supplementation	O
significantly	O
increased	O
Actinobacteria	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
Bifidobacterium	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
Anaerostipe	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
Blautia	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
,	O
and	O
decreased	O
Megamonas	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
in	O
LM	O
,	O
but	O
not	O
LA	O
.	O
Microbial	O
richness	O
and	O
diversity	O
were	O
not	O
affected	O
.	O
The	O
fecal	O
levels	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
remained	O
stable	O
throughout	O
the	O
study	O
.	O
Body	O
fat	O
mass	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
body	O
fat	O
percentage	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
reduced	O
in	O
both	O
groups	O
,	O
but	O
the	O
changes	O
did	O
not	O
differ	O
between	O
groups	O
.	O
No	O
significant	O
differences	O
in	O
other	O
cardiometabolic	O
markers	O
were	O
found	O
between	O
LM	O
and	O
LA	O
.	O
When	O
compared	O
with	O
LA	O
,	O
whole	O
milk	O
supplementation	O
could	O
alter	O
the	O
intestinal	O
microbiota	O
composition	O
in	O
LM	O
,	O
without	O
significant	O
changes	O
in	O
fecal	O
SCFAs	O
and	O
cardiometabolic	O
biomarkers	O
.	O
Milk	O
has	O
been	O
commonly	O
regarded	O
as	O
an	O
essential	O
component	O
of	O
a	O
balanced	O
diet	O
,	O
since	O
it	O
is	O
rich	O
in	O
high	O
-	O
quality	O
protein	O
,	O
calcium	O
,	O
as	O
well	O
as	O
plenty	O
of	O
health	O
-	O
promoting	O
bioactive	O
components	O
,	O
such	O
as	O
whey	O
peptides	O
,	O
conjugated	O
linoleum	O
acid	O
,	O
oligosaccharides	O
,	O
and	O
immunoglobulin	O
[	O
1	O
]	O
.	O

Previous	O
prospective	B-methodology
studies	I-methodology
suggested	O
that	O
milk	O
consumption	O
was	O
significantly	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
obesity	O
[	O
2	O
]	O
,	O
hypertension	O
[	O
3	O
]	O
,	O
type	O
2	O
diabetes	O
[	O
4	O
]	O
,	O
and	O
cardiovascular	O
disease	O
[	O
5	O
]	O
.	O
In	O
humans	O
,	O
the	O
ability	O
to	O
digest	O
lactose	O
,	O
which	O
is	O
the	O
main	O
carbohydrate	O
present	O
in	O
milk	O
,	O
depends	O
on	O
the	O
levels	O
of	O
the	O
enzyme	O
lactase	O
-	O
phlorizin	O
hydrolase	O
(	O
LPH	O
)	O
in	O
the	O
small	O
intestine	O
,	O
which	O
decline	O
rapidly	O
after	O
weaning	O
in	O
a	O
majority	O
of	O
humans	O
.	O
Lactose	O
malabsorption	O
occurs	O
when	O
there	O
are	O
not	O
enough	O
LPH	O
to	O
hydrolyze	O
ingested	O
lactose	O
in	O
them	O
.	O
Under	O
this	O
condition	O
,	O
undigested	O
lactose	O
is	O
generally	O
fermented	O
by	O
colonic	O
microbiota	O
into	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
and	O
gases	O
(	O
CO2	O
,	O
H2	O
,	O
and	O
CH4	O
)	O
,	O
which	O
could	O
lead	O
to	O
abdominal	O
bloating	O
,	O
abdominal	O
pain	O
,	O
diarrhea	O
,	O
and	O
other	O
uncomfortable	O
symptoms	O
[	O
6	O
]	O
.	O
Although	O
previous	O
evidence	O
suggested	O
that	O
even	O
the	O
severe	O
lactose	O
malabsorbers	O
(	O
LM	O
)	O
could	O
tolerate	O
the	O
lactose	O
in	O
240	O
mL	O
milk	O
per	O
day	O
[	O
7	O
]	O
,	O
lactose	O
malabsorption	O
was	O
proposed	O
to	O
account	O
for	O
low	O
dairy	O
intake	O
in	O
many	O
populations	O
[	O
8	O
,	O
9	O
]	O
.	O
For	O
instance	O
,	O
the	O
prevalence	O
rate	O
of	O
lactose	O
malabsorption	O
is	O
up	O
to	O
80	O
%	O
in	O
the	O
Chinese	O
population	O
[	O
10	O
]	O
.	O
According	O
to	O
the	O
results	O
of	O
the	O
2010	O
–	O
2013	O
China	O
Nutrition	O
and	O
Health	O
Surveillance	O
,	O
the	O
average	O
dairy	O
consumption	O
was	O
only	O
24	O
.	O
7	O
g	O
/	O
day	O
in	O
Chinese	O
adults	O
[	O
11	O
]	O
,	O
which	O
is	O
much	O
lower	O
than	O
the	O
recommendation	O
of	O
300	O
g	O
/	O
day	O
[	O
12	O
]	O
.	O
In	O
lactose	O
malabsorbers	O
,	O
the	O
undigested	O
lactose	O
and	O
products	O
derived	O
from	O
its	O
fermentation	O
in	O
the	O
colon	O
could	O
be	O
energy	O
sources	O
of	O
some	O
gut	O
bacterial	O
species	O
and	O
alter	O
the	O
gut	O
microbiota	O
composition	O
,	O
so	O
the	O
impact	O
of	O
milk	O
intake	O
on	O
the	O
gut	O
microbiota	O
composition	O
may	O
be	O
different	O
in	O
subjects	O
with	O
and	O
without	O
lactose	O
malabsorption	O
.	O
Lactose	O
was	O
demonstrated	O
to	O
have	O
the	O
capacity	O
to	O
stimulate	O
the	O
growth	O
of	O
putatively	O
beneficial	O
genera	O
,	O
such	O
as	O
Bifidobacterium	O
in	O
LM	O
,	O
but	O
not	O
in	O
lactose	O
absorbers	O
(	O
LA	O
)	O
[	O
13	O
]	O
.	O

However	O
,	O
intervention	B-methodology
studies	I-methodology
are	O
sparse	O
to	O
examine	O
the	O
board	O
-	O
spectrum	O
response	O
of	O
microbiota	O
community	O
to	O
lactose	O
/	O
milk	O
stimulation	O
,	O
including	O
both	O
expected	O
cross	O
-	O
feeding	O
interaction	O
and	O
changes	O
in	O
the	O
gut	O
environment	O
[	O
14	O
]	O
.	O
Additionally	O
,	O
accumulating	O
evidence	O
has	O
suggested	O
that	O
alternations	O
in	O
gut	O
microbiota	O
composition	O
could	O
affect	O
host	O
lipid	O
and	O
glucose	O
metabolism	O
via	O
SCFAs	O
production	O
through	O
carbohydrate	O
fermentation	O
,	O
and	O
then	O
contribute	O
to	O
metabolic	O
disease	O
[	O
15	O
,	O
16	O
]	O
.	O
Consequently	O
,	O
milk	O
intake	O
may	O
lead	O
to	O
changes	O
in	O
the	O
cardiometabolic	O
profiles	O
through	O
the	O
alternations	O
in	O
gut	O
microbiota	O
in	O
LM	O
.	O
However	O
,	O
to	O
our	O
best	O
knowledge	O
,	O
no	O
previous	O
study	O
has	O
comprehensively	O
investigated	O
the	O
effects	O
of	O
milk	O
intervention	O
on	O
the	O
gut	O
microbiota	O
composition	O
and	O
cardiometabolic	O
health	O
,	O
according	O
to	O
lactose	O
absorption	O
status	O
.	O
Therefore	O
,	O
in	O
the	O
current	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
potentially	O
differential	O
effects	O
of	O
whole	O
milk	O
supplementation	O
on	O
the	O
gut	O
microbiome	O
and	O
cardiometabolic	O
biomarkers	O
in	O
LM	O
and	O
LA	O
.	O
Prior	O
to	O
initiating	O
the	O
study	O
,	O
the	O
study	B-methodology
design	I-methodology
and	O
consent	O
form	O
were	O
reviewed	O
and	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
School	O
of	O
Public	O
Health	O
,	O
Tongji	O
Medical	O
College	O
,	O
Huazhong	O
University	O
of	O
Science	O
and	O
Technology	O
(	O
approval	O
No	O
.	O
12012015	O
)	O
.	O
The	O
study	O
was	O
registered	O
at	O
clinicaltrials	O
.	O
gov	O
(	O
NCT02798718	O
)	O
.	O
This	O
study	O
was	O
a	O
1	O
:	O
1	O
pair	O
-	O
wise	O
matching	O
intervention	B-methodology
study	I-methodology
in	O
lactose	O
absorbers	O
and	O
malabsorbers	O
.	O
At	O
the	O
beginning	O
,	O
233	O
participants	O
were	O
voluntarily	O
recruited	O
from	O
Tongji	O
Medical	O
College	O
of	O
Huazhong	O
University	O
of	O
Science	O
and	O
Technology	O
.	O
The	O
inclusion	B-methodology
criteria	I-methodology
included	O
healthy	O
volunteers	O
aged	O
≥18	O
years	O
,	O
Han	O
population	O
,	O
and	O
average	O
dairy	O
intake	O
less	O
than	O
one	O
serving	O
during	O
the	O
past	O
year	O
.	O
We	O
then	O
excluded	O
the	O
participants	O
with	O
a	O
history	O
of	O
acute	O
or	O
chronic	O
gastrointestinal	O
disorders	O
,	O
any	O
known	O
metabolic	O
disease	O
(	O
diagnosed	O
diabetes	O
,	O
hypertension	O
,	O
or	O
cardiovascular	O
disease	O
)	O
,	O
consumption	O
of	O
antibiotics	O
or	O
probiotics	O
within	O
the	O
preceding	O
month	O
,	O
use	O
of	O
medications	O
or	O
dietary	O
supplements	O
that	O
could	O
influence	O
glucose	O
or	O
lipids	O
metabolism	O
,	O
pregnancy	O
or	O
lactation	O
,	O
excessive	O
alcohol	O
consumption	O
,	O
significant	O
body	O
weight	O
variation	O
in	O
the	O
past	O
three	O
months	O
,	O
or	O
a	O
known	O
allergy	O
to	O
milk	O
.	O

Then	O
,	O
227	O
eligible	O
participants	O
underwent	O
a	O
hydrogen	O
breath	O
test	O
after	O
lactose	O
administration	O
to	O
examine	O
the	O
presence	O
of	O
lactose	O
malabsorption	O
.	O
Written	B-methodology
informed	I-methodology
consent	I-methodology
was	O
obtained	O
from	O
all	O
the	O
participants	O
before	O
participating	O
.	O
This	O
test	O
was	O
performed	O
with	O
a	O
hydrogen	O
breath	O
test	O
analyzer	O
(	O
Shenzhen	O
Zhonghe	O
Headway	O
Bio	O
-	O
Sci	O
&	O
Tech	O
Co	O
.	O
,	O
Ltd	O
.	O
,	O
Shenzhen	O
,	O
China	O
)	O
.	O
Briefly	O
,	O
after	O
a	O
standardized	O
low	O
-	O
carbohydrate	O
dinner	O
and	O
a	O
12	O
-	O
h	O
fast	O
,	O
the	O
end	O
-	O
expiratory	O
breath	O
H2	O
was	O
determined	O
before	O
and	O
at	O
30	O
-	O
min	O
intervals	O
after	O
a	O
25	O
-	O
g	O
lactose	O
load	O
for	O
the	O
ensuing	O
3	O
h	O
.	O
Eating	O
,	O
smoking	O
,	O
and	O
exercising	O
were	O
not	O
allowed	O
throughout	O
the	O
test	O
.	O
A	O
rise	O
of	O
20	O
ppm	O
in	O
breath	O
H2	O
over	O
basal	O
values	O
was	O
considered	O
as	O
an	O
indication	O
of	O
lactose	O
malabsorption	O
[	O
17	O
]	O
.	O
Finally	O
,	O
31	O
LA	O
and	O
31	O
LM	O
were	O
recruited	O
by	O
1	O
:	O
1	O
pair	O
-	O
wise	O
matching	O
with	O
age	O
(	O
±3	O
years	O
)	O
,	O
sex	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
(	O
±10	O
%	O
)	O
,	O
and	O
the	O
average	O
dairy	O
intake	O
(	O
<	O
125	O
g	O
/	O
day	O
,	O
125	O
–	O
250	O
g	O
/	O
day	O
)	O
for	O
the	O
intervention	B-methodology
study	I-methodology
.	O
The	O
details	O
of	O
participant	O
recruitment	O
are	O
shown	O
in	O
Supplementary	O
Figure	O
S1	O
.	O
In	O
one	O
-	O
week	O
run	O
-	O
in	O
phase	O
,	O
all	O
of	O
the	O
participants	O
were	O
required	O
to	O
maintain	O
their	O
initial	O
diet	O
.	O
In	O
the	O
following	O
four	O
-	O
week	O
intervention	O
,	O
they	O
were	O
further	O
instructed	O
to	O
add	O
extra	O
one	O
box	O
of	O
250	O
mL	O
whole	O
milk	O
(	O
Mengniu	O
Dairy	O
(	O
Group	O
)	O
Co	O
.	O
,	O
Ltd	O
.	O
,	O
Hohhot	O
,	O
China	O
)	O
in	O
their	O
routine	O
diet	O
per	O
day	O
.	O
All	O
of	O
the	O
subjects	O
were	O
instructed	O
to	O
maintain	O
their	O
usual	O
physical	O
activity	O
throughout	O
the	O
entire	O
study	O
.	O
The	O
participants	O
were	O
asked	O
to	O
return	O
the	O
empty	O
milk	O
package	O
to	O
assure	O
compliance	O
.	O
To	O
quantify	O
macronutrient	O
composition	O
,	O
individuals	O
were	O
instructed	O
to	O
complete	O
a	O
three	O
-	O
day	O
food	O
record	O
(	O
including	O
two	O
weekdays	O
and	O
one	O
weekend	O
day	O
)	O
at	O
the	O
end	O
of	O
run	O
-	O
in	O
and	O
intervention	B-methodology
periods	I-methodology
.	O
Before	O
start	O
of	O
the	O
study	O
,	O
the	O
participants	O
were	O
instructed	O
by	O
investigators	O
how	O
to	O
weigh	O
and	O
record	O
their	O
food	O
intake	O
.	O
The	O
dietary	O
records	O
were	O
checked	O
,	O
in	O
the	O
case	O
of	O
missing	O
data	O
,	O
and	O
analyzed	O
by	O
the	O
investigators	O
.	O
Energy	O
and	O
nutrient	O
intake	O
were	O
calculated	O
according	O
to	O
the	O
“	O
Chinese	O
Food	O
Composition	O
Tables	O
”	O
[	O
18	O
]	O
.	O

Anthropometric	O
and	O
biochemical	O
measurements	O
were	O
conducted	O
at	O
the	O
beginning	O
and	O
end	O
of	O
the	O
intervention	B-methodology
period	I-methodology
.	O
Body	O
composition	O
was	O
measured	O
by	O
bioelectric	O
impedance	O
analysis	O
using	O
Inbody	O
720	O
(	O
BIOSPACE	O
CHINA	O
Inc	O
.	O
,	O
Shanghai	O
,	O
China	O
)	O
.	O
Body	O
weight	O
(	O
kg	O
)	O
and	O
body	O
height	O
(	O
cm	O
)	O
,	O
were	O
measured	O
with	O
standardized	O
techniques	O
.	O
BMI	O
(	O
kg	O
/	O
m2	O
)	O
was	O
calculated	O
as	O
body	O
weight	O
divided	O
by	O
the	O
square	O
of	O
height	O
.	O
Waist	O
circumference	O
,	O
hip	O
circumference	O
,	O
and	O
blood	O
pressure	O
were	O
measured	O
with	O
standardized	O
techniques	O
.	O
Fasting	O
blood	O
samples	O
were	O
drawn	O
from	O
an	O
antecubital	O
vein	O
into	O
heparinized	O
tubes	O
in	O
the	O
morning	O
after	O
a	O
12	O
-	O
h	O
fast	O
.	O
Plasma	O
was	O
separated	O
in	O
a	O
4	O
°C	O
centrifuge	O
and	O
stored	O
at	O
−80	O
°C	O
until	O
analysis	O
.	O
Fasting	O
plasma	O
glucose	O
(	O
FPG	O
)	O
,	O
total	O
cholesterol	O
(	O
TC	O
)	O
,	O
triglycerides	O
(	O
TG	O
)	O
,	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
LDL	O
-	O
C	O
)	O
,	O
and	O
high	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
HDL	O
-	O
C	O
)	O
were	O
analyzed	O
by	O
colorimetric	O
enzymatic	O
methods	O
using	O
commercial	O
kits	O
(	O
BioSino	O
Bio	O
-	O
Technology	O
&	O
Science	O
Inc	O
.	O
,	O
Beijing	O
,	O
China	O
)	O
.	O
Fasting	O
plasma	O
insulin	O
(	O
FPI	O
)	O
and	O
C	O
-	O
peptide	O
were	O
analyzed	O
with	O
ELISA	O
kits	O
(	O
Mercodia	O
AB	O
,	O
Uppsala	O
,	O
Sweden	O
)	O
.	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
was	O
determined	O
with	O
ELISA	O
kits	O
(	O
R	O
&	O
D	O
Systems	O
,	O
Inc	O
.	O
,	O
Minneapolis	O
,	O
MN	O
,	O
USA	O
)	O
.	O
Malondialdehyde	O
(	O
MDA	O
)	O
was	O
measured	O
according	O
to	O
the	O
thiobarbituric	O
acid	O
method	O
with	O
commercial	O
kits	O
(	O
Jiancheng	O
Bioengineering	O
Institute	O
,	O
Nanjing	O
,	O
China	O
)	O
.	O
Intraassay	O
variation	O
for	O
FPG	O
,	O
TC	O
,	O
TG	O
,	O
LDL	O
-	O
C	O
,	O
HDL	O
-	O
C	O
,	O
FPI	O
,	O
C	O
-	O
peptide	O
,	O
CRP	O
,	O
and	O
MDA	O
ranged	O
from	O
0	O
.	O
9	O
%	O
to	O
5	O
.	O
5	O
%	O
and	O
interassay	O
variation	O
ranged	O
from	O
1	O
.	O
2	O
%	O
to	O
6	O
.	O
5	O
%	O
.	O

Homeostasis	O
model	O
assessment	O
of	O
insulin	O
resistance	O
(	O
HOMA	O
-	O
IR	O
)	O
was	O
calculated	O
from	O
fasting	O
glucose	O
and	O
insulin	O
while	O
using	O
the	O
following	O
formula	O
[	O
19	O
]	O
:	O
HOM	O
-	O
IR	O
=	O
[	O
FPI	O
(	O
mU	O
/	O
L	O
)	O
×	O
FPG	O
(	O
mmol	O
/	O
L	O
)	O
]	O
÷	O
22	O
.	O
5	O
(	O
1	O
)	O
Participants	O
were	O
instructed	O
to	O
collect	O
their	O
stool	O
using	O
aseptic	O
swabs	O
and	O
were	O
sealed	O
dung	O
cup	O
before	O
and	O
after	O
the	O
intervention	B-methodology
study	I-methodology
.	O
Uncontaminated	O
samples	O
were	O
collected	O
and	O
immediately	O
stored	O
in	O
a	O
provided	O
cooler	O
,	O
then	O
frozen	O
at	O
−80	O
°C	O
within	O
30	O
min	O
.	O
DNA	O
extraction	O
was	O
performed	O
using	O
a	O
QIAamp	O
Fast	O
DNA	O
Stool	O
Mini	O
Kit	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
,	O
USA	O
)	O
.	O
The	O
concentration	O
of	O
bacterial	O
DNA	O
was	O
measured	O
using	O
Nanodrop	O
2000	O
(	O
Thermo	O
Scientific	O
,	O
Wilmington	O
,	O
NC	O
,	O
USA	O
)	O
.	O
The	O
V3	O
-	O
V4	O
region	O
of	O
the	O
bacteria	O
’	O
s	O
16S	O
ribosomal	O
RNA	O
(	O
rRNA	O
)	O
gene	O
was	O
amplified	O
with	O
barcode	O
-	O
indexed	O
primers	O
(	O
338F	O
and	O
806R	O
)	O
by	O
thermocycler	O
Polymerase	O
Chain	O
Reaction	O
(	O
PCR	O
system	O
(	O
GeneAmp	O
9700	O
,	O
ABI	O
,	O
Hampton	O
,	O
NH	O
,	O
USA	O
)	O
using	O
FastPfu	O
Polymerase	O
.	O
Amplicons	O
were	O
purified	O
using	O
AxyPrep	O
DNA	O
GelExtraction	O
Kit	O
(	O
Axygen	O
Biosciences	O
,	O
Union	O
City	O
,	O
CA	O
,	O
USA	O
)	O
,	O
then	O
quantified	O
using	O
QuantiFluor	O
-	O
ST	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
.	O
Sequencing	O
was	O
performed	O
using	O
the	O
Illumina	O
MiSeq	O
platform	O
(	O
Illumina	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O
The	O
16S	O
rRNA	O
sequencing	O
data	O
were	O
processed	O
using	O
the	O
Quantitative	O
Insights	O
Into	O
Microbial	O
Ecology	O
platform	O
(	O
QIIME	O
,	O
Boulder	O
,	O
CO	O
,	O
USA	O
,	O
V	O
.	O
1	O
.	O
7	O
.	O
1	O
)	O
[	O
20	O
]	O
.	O
Raw	O
sequencing	O
reads	O
were	O
demultiplexed	O
and	O
filtered	O
.	O
Chimeras	O
were	O
removed	O
and	O
the	O
operational	O
taxonomic	O
units	O
(	O
OTUs	O
)	O
were	O
with	O
97	O
%	O
homology	O
were	O
generated	O
using	O
USEARCH	O
[	O
21	O
]	O
.	O
The	O
identified	O
taxonomy	O
was	O
aligned	O
with	O
Ribosomal	O
Database	O
Project	O
Classifier	O
[	O
22	O
]	O
and	O
Greengenes	O
reference	O
database	O
(	O
V	O
.	O
13	O
.	O
8	O
)	O
.	O

To	O
ensure	O
an	O
even	O
sampling	O
depth	O
,	O
all	O
of	O
the	O
samples	O
were	O
rarefied	O
to	O
the	O
lowest	O
read	O
number	O
.	O
Alpha	O
and	O
beta	O
diversity	O
metrics	O
were	O
calculated	O
in	O
QIIME	O
using	O
the	O
rarefied	O
OTU	O
table	O
.	O
Beta	O
diversity	O
was	O
estimated	O
using	O
weighted	O
and	O
unweighted	O
UniFrac	O
distances	O
between	O
samples	O
and	O
was	O
visualized	O
with	O
principal	O
coordinate	O
analysis	O
(	O
PCoA	O
)	O
.	O
Fecal	O
samples	O
(	O
0	O
.	O
5	O
g	O
)	O
were	O
homogenized	O
after	O
addition	O
of	O
5	O
mL	O
of	O
ultrapure	O
water	O
and	O
centrifuged	O
at	O
4000	O
rpm	O
for	O
10	O
min	O
at	O
4	O
°C	O
.	O
The	O
supernatant	O
fluid	O
(	O
600	O
μL	O
)	O
was	O
mixed	O
with	O
120	O
μL	O
25	O
%	O
phosphoric	O
acid	O
,	O
homogenized	O
and	O
centrifuged	O
at	O
12	O
,	O
000	O
rpm	O
for	O
10	O
min	O
at	O
4	O
°C	O
.	O
Then	O
,	O
the	O
supernatant	O
was	O
filtered	O
through	O
a	O
Millex	O
-	O
GS	O
0	O
.	O
22	O
-	O
mm	O
syringe	O
filter	O
unit	O
(	O
Millipore	O
,	O
Burlington	O
,	O
MA	O
,	O
USA	O
)	O
.	O
The	O
filtrate	O
was	O
mixed	O
with	O
2	O
-	O
ethylbutyrate	O
(	O
DRE	O
,	O
Altshausen	O
,	O
Germany	O
)	O
as	O
the	O
internal	O
standard	O
with	O
1	O
mM	O
.	O
A	O
mixed	O
-	O
SCFA	O
standard	O
solution	O
was	O
prepared	O
by	O
using	O
analytical	O
quality	O
(	O
>	O
99	O
%	O
purity	O
)	O
reagents	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
Bornem	O
,	O
Belgium	O
)	O
.	O
SCFAs	O
were	O
quantified	O
with	O
an	O
Agilent	O
6890N	O
gas	O
chromatograph	O
coupled	O
with	O
an	O
Agilent	O
5975B	O
mass	O
spectrometer	O
(	O
Agilent	O
Technologies	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
.	O
The	O
capillary	O
GC	O
column	O
was	O
an	O
Agilent	O
HP	O
-	O
INNOWAX	O
30	O
m	O
×	O
0	O
.	O
25	O
mm	O
,	O
0	O
.	O
25	O
μm	O
film	O
thickness	O
,	O
with	O
helium	O
as	O
the	O
carrier	O
gas	O
at	O
a	O
constant	O
flow	O
rate	O
of	O
2	O
.	O
8	O
mL	O
/	O
min	O
.	O
The	O
GC	O
oven	O
temperature	O
program	O
was	O
as	O
follows	O
:	O
initial	O
temperature	O
72	O
°C	O
,	O
then	O
to	O
170	O
°C	O
at	O
13	O
°C	O
/	O
min	O
,	O
to	O
a	O
final	O
temperature	O
230	O
°C	O
,	O
where	O
it	O
was	O
held	O
for	O
5	O
min	O
,	O
at	O
30	O
°C	O
/	O
min	O
.	O
The	O
temperatures	O
of	O
the	O
injector	O
,	O
transfer	O
line	O
,	O
and	O
detector	O
were	O
set	O
at	O
200	O
°C	O
,	O
280	O
°C	O
,	O
and	O
220	O
°C	O
,	O
respectively	O
.	O
The	O
total	O
run	O
time	O
was	O
14	O
.	O
54	O
min	O
.	O

Acetate	O
,	O
propionate	O
,	O
and	O
butyrate	O
were	O
quantified	O
with	O
appropriate	O
calibration	O
curves	O
obtained	O
using	O
internal	O
standard	O
quantitation	O
.	O
The	O
Varian	O
MS	O
workstation	O
software	O
(	O
version	O
6	O
.	O
6	O
)	O
was	O
used	O
for	O
data	O
acquisition	O
and	O
processing	O
.	O
The	O
interday	O
and	O
intraday	O
coefficient	O
of	O
variances	O
ranged	O
from	O
4	O
.	O
6	O
%	O
to	O
8	O
.	O
7	O
%	O
.	O
PCR	O
amplification	O
and	O
detection	O
were	O
conducted	O
in	O
96	O
-	O
well	O
plates	O
with	O
PrimeScriptTM	O
RT	O
reagent	O
kit	O
(	O
TAKARA	O
BIO	O
INC	O
.	O
,	O
Dalian	O
,	O
China	O
)	O
on	O
a	O
DNA	O
Engine	O
Opticon	O
2	O
fluorescence	O
detection	O
system	O
(	O
BIO	O
-	O
RID	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
)	O
.	O
Samples	O
were	O
run	O
with	O
a	O
final	O
volume	O
of	O
25	O
μL	O
,	O
containing	O
0	O
.	O
4	O
μM	O
of	O
each	O
primer	O
and	O
2	O
μL	O
of	O
the	O
respective	O
template	O
DNA	O
.	O
The	O
specific	O
primers	O
for	O
Bifidobacterium	O
forward	O
CTCCTGGAAACGGGTGG	O
and	O
reverse	O
GGTGTTCTTCCCGATATCTACA	O
[	O
23	O
]	O
.	O
Amplifications	O
were	O
done	O
with	O
the	O
following	O
temperature	O
profiles	O
:	O
one	O
cycle	O
at	O
95	O
°C	O
(	O
30	O
s	O
)	O
,	O
40	O
cycles	O
of	O
denaturation	O
at	O
95	O
°C	O
(	O
5	O
s	O
)	O
,	O
61	O
°C	O
(	O
30	O
s	O
)	O
,	O
and	O
72	O
°C	O
(	O
45	O
s	O
)	O
,	O
and	O
a	O
final	O
one	O
cycle	O
of	O
94	O
°C	O
(	O
5	O
min	O
)	O
.	O
Quantification	O
was	O
done	O
by	O
using	O
standard	O
curves	O
made	O
from	O
know	O
concentrations	O
of	O
plasmid	O
DNA	O
,	O
which	O
was	O
prepared	O
according	O
to	O
Sabine	O
et	O
al	O
.	O
[	O
24	O
]	O
.	O
All	O
the	O
data	O
were	O
expressed	O
as	O
the	O
mean	O
±	O
standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
)	O
.	O
Dietary	O
energy	O
and	O
nutrients	O
intake	O
were	O
analyzed	O
using	O
Student	O
’	O
s	O
paired	O
t	O
-	O
test	O
.	O
For	O
cardiometabolic	O
biomarkers	O
,	O
baseline	O
differences	O
were	O
evaluated	O
using	O
a	O
Student	O
’	O
s	O
unpaired	O
t	O
-	O
test	O
.	O
Between	O
-	O
group	O
differences	O
were	O
analyzed	O
using	O
a	O
two	O
-	O
factor	O
repeated	O
measures	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
with	O
time	O
(	O
pre	O
,	O
post	O
)	O
and	O
group	O
(	O
LM	O
,	O
LA	O
)	O
as	O
the	O
factors	O
.	O
In	O
the	O
case	O
of	O
a	O
significant	O
time	O
effect	O
being	O
shown	O
,	O
post	O
-	O
hoc	O
analyses	O
with	O
Bonferroni	O
correction	O
were	O
applied	O
to	O
identify	O
significant	O
within	O
-	O
group	O
differences	O
.	O
The	O
Kolomogorov	O
-	O
Smirnov	O
test	O
was	O
performed	O
to	O
test	O
the	O
normality	O
of	O
distribution	O
.	O

If	O
skewed	O
distribution	O
,	O
data	O
was	O
logarithmically	O
transformed	O
.	O
Statistics	O
were	O
performed	O
with	O
SPSS	O
24	O
.	O
0	O
(	O
IBM	O
,	O
Brussels	O
,	O
Belgium	O
)	O
.	O
For	O
phylum	O
-	O
or	O
genus	O
-	O
level	O
microbiota	O
groups	O
,	O
comparisons	O
between	O
two	O
groups	O
were	O
evaluated	O
with	O
Mann	O
-	O
Whitney	O
tests	O
,	O
within	O
-	O
group	O
differences	O
were	O
analyzed	O
using	O
Wilcoxon	O
signed	O
-	O
rank	O
tests	O
,	O
between	O
-	O
group	O
differences	O
were	O
evaluated	O
using	O
a	O
linear	O
mixed	O
model	O
with	O
package	O
“	O
lme4	O
”	O
taking	O
into	O
account	O
of	O
repeated	O
measurements	O
,	O
group	O
,	O
gender	O
,	O
and	O
BMI	O
.	O
Data	O
of	O
qPCR	O
were	O
expressed	O
as	O
logarithmically	O
transformed	O
.	O
ANOVA	O
with	O
Turkey	O
post	O
-	O
hoc	O
analysis	O
was	O
applied	O
to	O
compare	O
the	O
alpha	O
diversity	O
between	O
and	O
within	O
groups	O
.	O
Beta	O
diversity	O
was	O
assessed	O
based	O
on	O
unweighted	O
and	O
weighted	O
UniFrac	O
distances	O
and	O
its	O
significance	O
was	O
determined	O
using	O
permutation	O
-	O
based	O
ANOVA	O
with	O
the	O
use	O
of	O
the	O
Adonis	O
function	O
in	O
the	O
“	O
vegan	O
”	O
package	O
.	O
P	O
values	O
were	O
corrected	O
for	O
multiple	O
comparisons	O
using	O
the	O
Benjamini	O
-	O
Hochberg	O
procedure	O
.	O
Enterotyping	O
on	O
the	O
basis	O
of	O
Partitioning	O
Around	O
Medoids	O
with	O
Jensen	O
-	O
Shannon	O
divergence	O
was	O
conducted	O
on	O
a	O
combined	O
genus	O
-	O
abundance	O
matrix	O
of	O
all	O
samples	O
[	O
25	O
]	O
.	O
Besides	O
,	O
the	O
optimal	O
number	O
of	O
cluster	O
was	O
determined	O
by	O
the	O
Calinski	O
–	O
Harabasz	O
Index	O
.	O
Statistics	O
were	O
performed	O
using	O
R	O
version	O
3	O
.	O
3	O
.	O
3	O
.	O
A	O
two	O
-	O
tailed	O
P	O
<	O
0	O
.	O
05	O
was	O
considered	O
to	O
be	O
statistically	O
significant	O
.	O
A	O
corrected	O
false	O
discovery	O
rate	O
(	O
FDR	O
)	O
<	O
0	O
.	O
2	O
was	O
considered	O
as	O
significant	O
[	O
26	O
]	O
.	O
A	O
total	O
of	O
62	O
subjects	O
,	O
31	O
LA	O
and	O
31	O
LM	O
,	O
participated	O
in	O
the	O
intervention	B-methodology
study	I-methodology
.	O
There	O
were	O
44	O
men	O
and	O
18	O
women	O
with	O
an	O
average	O
age	O
of	O
24	O
.	O
7	O
±	O
0	O
.	O
3	O
years	O
and	O
an	O
average	O
body	O
mass	O
index	O
of	O
22	O
.	O
0	O
±	O
0	O
.	O
4	O
kg	O
/	O
m2	O
.	O
No	O
subjects	O
dropped	O
out	O
of	O
the	O
study	O
during	O
the	O
intervention	B-methodology
period	I-methodology
(	O
See	O
Supplementary	O
Figure	O
S1	O
)	O
.	O
No	O
significant	O
differences	O
were	O
found	O
between	O
LA	O
and	O
LM	O
at	O
the	O
baseline	O
(	O
Table	O
1	O
)	O
.	O
No	O
adverse	O
events	O
and	O
gastrointestinal	O
discomforts	O
were	O
reported	O
during	O
the	O
entire	O
study	O
.	O

Energy	O
and	O
macronutrient	O
intake	O
,	O
as	O
assessed	O
by	O
self	O
-	O
reported	O
three	O
-	O
day	O
food	O
records	O
,	O
remained	O
stable	O
throughout	O
the	O
study	O
,	O
but	O
calcium	O
intake	O
significantly	O
increased	O
in	O
all	O
of	O
the	O
participants	O
following	O
the	O
whole	O
milk	O
intervention	O
(	O
See	O
Supplementary	O
Table	O
S1	O
)	O
.	O
At	O
baseline	O
,	O
the	O
microbiota	O
composition	O
at	O
the	O
phylum	O
and	O
genus	O
level	O
(	O
See	O
Supplementary	O
Table	O
S2	O
)	O
did	O
not	O
differ	O
between	O
LM	O
and	O
LA	O
.	O
Four	O
-	O
week	O
whole	O
milk	O
supplementation	O
induced	O
significant	O
alternations	O
in	O
microbiota	O
composition	O
of	O
LM	O
,	O
but	O
not	O
that	O
of	O
LA	O
(	O
Figure	O
1	O
)	O
.	O
At	O
the	O
phylum	O
level	O
,	O
Actinobacteria	O
dramatically	O
increased	O
in	O
LM	O
(	O
1	O
.	O
86	O
±	O
0	O
.	O
67	O
%	O
,	O
P	O
<	O
0	O
.	O
01	O
,	O
FDR	O
<	O
0	O
.	O
01	O
)	O
.	O
At	O
the	O
genus	O
level	O
,	O
Bifidobacterium	O
determined	O
by	O
Illumina	O
16S	O
rRNA	O
gene	O
sequencing	O
steep	O
increased	O
in	O
LM	O
(	O
1	O
.	O
72	O
±	O
0	O
.	O
62	O
%	O
,	O
P	O
<	O
0	O
.	O
01	O
,	O
FDR	O
<	O
0	O
.	O
01	O
)	O
,	O
which	O
was	O
mirrored	O
by	O
qPCR	O
analysis	O
.	O
Besides	O
,	O
there	O
were	O
a	O
significant	O
increase	O
in	O
Anaerostipe	O
(	O
0	O
.	O
77	O
±	O
0	O
.	O
19	O
%	O
,	O
P	O
<	O
0	O
.	O
01	O
,	O
FDR	O
<	O
0	O
.	O
01	O
)	O
and	O
Blautia	O
(	O
0	O
.	O
90	O
±	O
0	O
.	O
48	O
%	O
,	O
P	O
=	O
0	O
.	O
04	O
,	O
FDR	O
=	O
0	O
.	O
11	O
)	O
,	O
and	O
a	O
significant	O
decrease	O
in	O
Megamonas	O
(	O
4	O
.	O
11	O
±	O
2	O
.	O
02	O
%	O
,	O
P	O
=	O
0	O
.	O
04	O
,	O
FDR	O
=	O
0	O
.	O
11	O
)	O
in	O
LM	O
.	O
Between	O
-	O
group	O
analysis	O
highlighted	O
the	O
significant	O
interaction	O
of	O
lactose	O
absorption	O
status	O
and	O
whole	O
milk	O
supplementation	O
on	O
Actinobacteria	O
(	O
P	O
for	O
interaction	O
=	O
0	O
.	O
02	O
)	O
,	O
Bifidobacterium	O
(	O
P	O
for	O
interaction	O
=	O
0	O
.	O
03	O
)	O
,	O
Anaerostipe	O
(	O
P	O
for	O
interaction	O
=	O
0	O
.	O
02	O
)	O
,	O
Blautia	O
(	O
P	O
for	O
interaction	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
Megamonas	O
(	O
P	O
for	O
interaction	O
<	O
0	O
.	O
01	O
)	O
.	O
No	O
significant	O
variations	O
in	O
microbiota	O
diversity	O
were	O
found	O
within	O
and	O
between	O
the	O
groups	O
throughout	O
the	O
entire	O
study	O
(	O
Figure	O
2	O
)	O
.	O
Fecal	O
communities	O
were	O
then	O
clustered	O
into	O
Bacteroides	O
and	O
Prevotella	O
enterotypes	O
(	O
Figure	O
3	O
)	O
.	O

Although	O
the	O
sample	O
distribution	O
over	O
enterotypes	O
was	O
not	O
affected	O
by	O
he	O
lactose	O
malabsorption	O
status	O
(	O
P	O
=	O
0	O
.	O
43	O
)	O
or	O
whole	O
milk	O
supplementation	O
(	O
P	O
=	O
0	O
.	O
84	O
)	O
,	O
shifts	O
in	O
the	O
gut	O
microbiota	O
composition	O
differed	O
between	O
enterotypes	O
(	O
Figure	O
3	O
)	O
.	O
At	O
the	O
phylum	O
level	O
,	O
Actinobacteria	O
merely	O
increased	O
in	O
LM	O
with	O
Bacteroides	O
enterotype	O
(	O
1	O
.	O
66	O
±	O
0	O
.	O
69	O
%	O
,	O
P	O
=	O
0	O
.	O
02	O
,	O
FDR	O
=	O
0	O
.	O
02	O
)	O
,	O
but	O
not	O
in	O
LM	O
with	O
Prevotella	O
enterotype	O
.	O
Similarly	O
,	O
at	O
the	O
genus	O
level	O
,	O
a	O
similar	O
trend	O
was	O
observed	O
in	O
Bifidobacterium	O
(	O
1	O
.	O
56	O
±	O
0	O
.	O
65	O
%	O
,	O
P	O
<	O
0	O
.	O
01	O
,	O
FDR	O
=	O
0	O
.	O
07	O
)	O
.	O
Fecal	O
acetate	O
,	O
propionate	O
,	O
and	O
butyrate	O
concentration	O
did	O
not	O
significantly	O
differ	O
within	O
and	O
between	O
the	O
groups	O
(	O
Figure	O
4	O
)	O
.	O
Although	O
body	O
weight	O
and	O
BMI	O
remained	O
unchanged	O
during	O
the	O
intervention	B-methodology
study	I-methodology
,	O
body	O
fat	O
mass	O
(	O
P	O
=	O
0	O
.	O
03	O
for	O
LM	O
;	O
P	O
<	O
0	O
.	O
01	O
for	O
LA	O
)	O
and	O
the	O
proportion	O
of	O
body	O
fat	O
(	O
P	O
=	O
0	O
.	O
02	O
for	O
LM	O
;	O
P	O
<	O
0	O
.	O
01	O
for	O
LA	O
)	O
significantly	O
decreased	O
in	O
both	O
groups	O
(	O
Table	O
2	O
)	O
.	O
Changes	O
in	O
body	O
composition	O
did	O
not	O
differ	O
between	O
LM	O
and	O
LA	O
.	O
No	O
significant	O
within	O
-	O
or	O
between	O
-	O
group	O
differences	O
were	O
observed	O
in	O
blood	O
pressure	O
,	O
FPG	O
,	O
FPI	O
,	O
C	O
-	O
peptide	O
,	O
TG	O
,	O
TC	O
,	O
LDL	O
-	O
C	O
,	O
HDL	O
-	O
C	O
,	O
CRP	O
,	O
and	O
MDA	O
.	O
Change	O
in	O
LDL	O
-	O
C	O
was	O
inversely	O
associated	O
with	O
a	O
change	O
in	O
Blautia	O
abundances	O
among	O
LM	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
but	O
no	O
shifts	O
in	O
the	O
cardiometabolic	O
biomarkers	O
were	O
associated	O
with	O
alternations	O
in	O
the	O
relative	O
abundance	O
of	O
Bifidobacterium	O
,	O
Anaerostipes	O
,	O
and	O
Megamonas	O
(	O
See	O
Supplementary	O
Tables	O
S3	O
–	O
S6	O
)	O
.	O
In	O
the	O
present	O
study	O
,	O
as	O
compared	O
with	O
LA	O
,	O
four	O
-	O
week	O
250	O
mL	O
/	O
day	O
whole	O
milk	O
supplementation	O
selectively	O
altered	O
gut	O
microbiota	O
composition	O
in	O
LM	O
,	O
especially	O
in	O
those	O
with	O
Bacteroides	O
enterotype	O
,	O
without	O
significant	O
effects	O
on	O
the	O
overall	O
microbiota	O
richness	O
and	O
diversity	O
.	O

Additionally	O
,	O
no	O
significant	O
differences	O
were	O
found	O
in	O
alternations	O
in	O
fecal	O
SCFAs	O
or	O
cardiometabolic	O
biomarkers	O
between	O
LM	O
and	O
LA	O
.	O
We	O
observed	O
that	O
four	O
-	O
week	O
whole	O
milk	O
supplementation	O
significantly	O
increased	O
the	O
relative	O
abundances	O
of	O
Bifidobacterium	O
in	O
LM	O
,	O
which	O
was	O
mainly	O
consistent	O
with	O
a	O
previous	O
study	O
,	O
showing	O
the	O
bifidogenic	O
effects	O
of	O
lactose	O
in	O
healthy	O
LM	O
in	O
western	O
population	O
[	O
13	O
]	O
.	O
Bifidobacterium	O
could	O
utilize	O
lactose	O
as	O
a	O
preferable	O
energy	O
source	O
rather	O
than	O
glucose	O
[	O
27	O
]	O
,	O
and	O
thus	O
the	O
abundance	O
of	O
Bifidobacterium	O
could	O
increase	O
with	O
higher	O
lactose	O
intake	O
derived	O
from	O
milk	O
supplementation	O
[	O
28	O
]	O
.	O
Bifidobacteria	O
is	O
believed	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
gut	O
microbiota	O
homeostasis	O
and	O
human	O
health	O
[	O
29	O
]	O
.	O
Several	O
strains	O
in	O
bifidobacteria	O
have	O
been	O
widely	O
used	O
as	O
probiotics	O
because	O
of	O
both	O
direct	O
and	O
indirect	O
influences	O
on	O
enhancing	O
immunity	O
,	O
inhibiting	O
the	O
growth	O
of	O
pathogenic	O
bacteria	O
,	O
and	O
treating	O
inflammatory	O
disease	O
[	O
30	O
]	O
.	O
In	O
our	O
study	O
,	O
the	O
abundance	O
of	O
Anaerostipes	O
and	O
Blautia	O
also	O
increased	O
with	O
whole	O
milk	O
supplementation	O
in	O
LM	O
.	O
Anaerostipes	O
was	O
a	O
butyrate	O
-	O
production	O
bacteria	O
,	O
and	O
the	O
cross	O
-	O
feeding	O
relationship	O
between	O
Anaerostipes	O
and	O
Bifidobacterium	O
might	O
account	O
for	O
its	O
alteration	O
[	O
31	O
]	O
.	O
Blautia	O
was	O
acetogenic	O
and	O
might	O
benefit	O
from	O
the	O
production	O
of	O
hydrogen	O
,	O
a	O
production	O
from	O
lactose	O
fermentation	O
by	O
Bifidobacterium	O
[	O
32	O
]	O
.	O
Additionally	O
,	O
our	O
results	O
indicated	O
that	O
whole	O
milk	O
supplementation	O
induced	O
different	O
alternations	O
in	O
microbiota	O
composition	O
across	O
different	O
enterotypes	O
,	O
which	O
was	O
in	O
line	O
with	O
previous	O
findings	O
that	O
individuals	O
with	O
distinct	O
enterotypes	O
differed	O
in	O
responses	O
to	O
the	O
same	O
diet	B-methodology
intervention	I-methodology
[	O
33	O
,	O
34	O
]	O
.	O
There	O
were	O
no	O
significant	O
changes	O
in	O
the	O
fecal	O
levels	O
of	O
SCFAs	O
following	O
four	O
-	O
week	O
supplementation	O
of	O
whole	O
milk	O
,	O
despite	O
the	O
significant	O
changes	O
in	O
several	O
SCFA	O
-	O
producing	O
microbiota	O
taxa	O
.	O
One	O
potential	O
explanation	O
for	O
this	O
might	O
be	O
conversion	O
among	O
SCFAs	O
through	O
microbial	O
cross	O
-	O
feeding	O
,	O
in	O
particular	O
,	O
from	O
acetate	O
to	O
butyrate	O
[	O
35	O
]	O
,	O
which	O
was	O
mainly	O
metabolized	O
in	O
the	O
colon	O
to	O
supply	O
energy	O
for	O
colonocytes	O
[	O
36	O
]	O
.	O

But	O
,	O
some	O
studies	O
suggested	O
that	O
fecal	O
butyrate	O
significantly	O
increased	O
following	O
8	O
-	O
week	O
intervention	O
of	O
undigested	O
carbohydrate	O
intervention	O
,	O
but	O
did	O
not	O
following	O
four	O
-	O
week	O
intervention	O
[	O
15	O
]	O
.	O
Therefore	O
,	O
relative	O
short	O
intervention	O
duration	O
might	O
be	O
another	O
reason	O
accounting	O
for	O
the	O
unchanged	O
fecal	O
concentrations	O
of	O
SCFAs	O
in	O
this	O
study	O
,	O
and	O
long	O
-	O
term	O
studies	O
are	O
needed	O
to	O
further	O
verify	O
this	O
finding	O
in	O
the	O
future	O
.	O
In	O
this	O
study	O
,	O
whole	O
milk	O
supplementation	O
did	O
not	O
significantly	O
affect	O
the	O
cardiometabolic	O
biomarkers	O
,	O
except	O
slight	O
decreases	O
of	O
body	O
fat	O
mass	O
and	O
body	O
fat	O
percentage	O
in	O
LM	O
and	O
LA	O
.	O
Several	O
intervention	B-methodology
studies	I-methodology
suggested	O
that	O
consumption	O
of	O
dairy	O
products	O
might	O
have	O
a	O
beneficial	O
effect	O
on	O
cardiometabolic	O
factors	O
[	O
37	O
,	O
38	O
,	O
39	O
,	O
40	O
]	O
.	O
A	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
of	I-methodology
randomized	I-methodology
controlled	I-methodology
trial	I-methodology
elucidated	O
that	O
dairy	O
products	O
reduced	O
body	O
fat	O
mass	O
in	O
short	O
-	O
term	O
intervention	B-methodology
studies	I-methodology
,	O
but	O
not	O
in	O
long	O
-	O
term	O
[	O
37	O
]	O
,	O
which	O
well	O
supported	O
the	O
results	O
of	O
our	O
study	O
.	O
A	O
possible	O
explanation	O
might	O
be	O
the	O
differential	O
compliance	O
with	O
the	O
intervention	O
protocol	O
between	O
short	O
and	O
long	O
trials	O
[	O
41	O
]	O
.	O
In	O
our	O
study	O
,	O
the	O
marked	O
microbial	O
changes	O
in	O
LM	O
did	O
not	O
affect	O
carbiometabolic	O
biomarkers	O
.	O
Previous	O
studies	O
showed	O
that	O
Bifidobacteria	O
improved	O
diabetes	O
induced	O
by	O
high	O
-	O
fat	O
diet	O
[	O
29	O
,	O
42	O
]	O
but	O
we	O
did	O
not	O
observe	O
any	O
association	O
between	O
Bifidobacterium	O
and	O
carbiometabolic	O
biomarkers	O
.	O
When	O
compared	O
the	O
Bifidobacterium	O
of	O
our	O
study	O
population	O
with	O
that	O
of	O
other	O
population	O
,	O
we	O
found	O
the	O
baseline	O
abundance	O
of	O
Bifidobacterium	O
was	O
markedly	O
lower	O
in	O
our	O
study	O
population	O
,	O
but	O
it	O
reached	O
slightly	O
higher	O
abundance	O
after	O
whole	O
milk	O
population	O
as	O
compared	O
to	O
this	O
healthy	O
,	O
untreated	O
population	O
[	O
26	O
,	O
43	O
]	O
.	O
Therefore	O
,	O
one	O
reason	O
for	O
lack	O
of	O
effects	O
on	O
the	O
cardiometabolic	O
biomarkers	O
in	O
LM	O
may	O
be	O
the	O
significant	O
but	O
small	O
increase	O
as	O
well	O
as	O
inconsistent	O
pattern	O
of	O
increase	O
.	O
Our	O
observations	O
indicated	O
that	O
moderate	O
whole	O
milk	O
supplementation	O
(	O
250	O
mL	O
/	O
day	O
)	O
had	O
no	O
adverse	O
cardiometabolic	O
effect	O
in	O
LM	O
,	O
compared	O
with	O
LA	O
.	O
Accordingly	O
,	O
it	O
is	O
possibly	O
acceptable	O
for	O
LM	O
to	O
consume	O
moderate	O
whole	O
milk	O
per	O
day	O
for	O
health	O
promotion	O
,	O
which	O
would	O
draw	O
more	O
attention	O
in	O
the	O
countries	O
of	O
high	O
prevalence	O
of	O
lactose	O
malabsorption	O
.	O
There	O
are	O
several	O
strengths	O
of	O
the	O
current	O
study	O
.	O

To	O
our	O
best	O
knowledge	O
,	O
no	O
previous	O
study	O
has	O
comprehensively	O
compared	O
the	O
effects	O
of	O
whole	O
milk	O
supplementation	O
on	O
the	O
gut	O
microbiota	O
composition	O
and	O
its	O
crucial	O
metabolites	O
(	O
SCFAs	O
)	O
and	O
cardiometabolic	O
biomarkers	O
in	O
LM	O
and	O
LA	O
.	O
We	O
also	O
investigated	O
the	O
possible	O
different	O
responses	O
to	O
whole	O
milk	O
in	O
subjects	O
with	O
different	O
enterotypes	O
.	O
Our	O
study	O
also	O
has	O
certain	O
limitations	O
.	O
Firstly	O
,	O
we	O
did	O
not	O
include	O
a	O
group	O
without	O
whole	O
milk	O
intervention	O
,	O
so	O
the	O
potential	O
effects	O
of	O
non	O
-	O
treatment	O
factors	O
could	O
not	O
be	O
excluded	O
.	O
However	O
,	O
the	O
1	O
:	O
1	O
pair	O
-	O
wise	O
design	O
allowed	O
us	O
to	O
evaluate	O
the	O
different	O
effects	O
of	O
whole	O
milk	O
supplementation	O
between	O
LM	O
and	O
LA	O
.	O
Secondly	O
,	O
we	O
did	O
not	O
control	O
the	O
diet	O
of	O
the	O
participants	O
,	O
but	O
added	O
whole	O
milk	O
to	O
the	O
initial	O
diet	O
.	O
However	O
,	O
total	O
energy	O
and	O
macronutrients	O
intake	O
was	O
not	O
different	O
between	O
two	O
groups	O
,	O
and	O
the	O
effects	O
of	O
changes	O
in	O
diet	O
could	O
be	O
excluded	O
.	O
Thirdly	O
,	O
four	O
weeks	O
may	O
be	O
relative	O
short	O
to	O
observe	O
changes	O
in	O
cardiometabolic	O
biomarkers	O
of	O
healthy	O
adults	O
aged	O
from	O
20	O
–	O
30	O
in	O
this	O
study	O
,	O
whose	O
cardiometabolic	O
biomarkers	O
maintain	O
a	O
relatively	O
steady	O
state	O
.	O
Long	O
-	O
term	O
studies	O
or	O
studies	O
in	O
the	O
participants	O
of	O
different	O
metabolic	O
statuses	O
are	O
needed	O
to	O
replicate	O
our	O
findings	O
and	O
precisely	O
assess	O
the	O
effect	O
of	O
milk	O
on	O
cardiometabolic	O
outcomes	O
.	O
In	O
conclusion	O
,	O
when	O
compared	O
with	O
LA	O
,	O
250	O
mL	O
/	O
day	O
whole	O
milk	O
supplementation	O
could	O
alter	O
the	O
intestinal	O
microbiota	O
composition	O
in	O
LM	O
,	O
without	O
alternations	O
in	O
fecal	O
SCFAs	O
and	O
metabolic	O
biomarkers	O
.	O
It	O
may	O
be	O
acceptable	O
to	O
include	O
moderate	O
milk	O
as	O
a	O
part	O
of	O
the	O
routine	O
diet	O
of	O
LM	O
,	O
as	O
a	O
suggestion	O
to	O
personalize	O
milk	O
consumption	O
,	O
and	O
thereby	O
enhance	O
the	O
levels	O
of	O
dietary	O
calcium	O
intake	O
and	O
improve	O
health	O
.	O
Further	O
studies	O
are	O
warranted	O
to	O
confirm	O
our	O
findings	O
and	O
clarify	O
the	O
underlying	O
mechanisms	O
.	O
We	O
would	O
like	O
to	O
thank	O
all	O
study	O
participants	O
for	O
their	O
participation	O
.	O

The	O
following	O
are	O
available	O
online	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
mdpi	O
.	O
com	O
/	O
2072	O
-	O
6643	O
/	O
10	O
/	O
10	O
/	O
1403	O
/	O
s1	O
,	O
Figure	O
S1	O
:	O
Flow	O
chart	O
of	O
the	O
participant	O
recruitment	O
and	O
withdraw	O
,	O
Table	O
S1	O
:	O
Dietary	O
energy	O
and	O
nutrients	O
intake	O
based	O
on	O
a	O
three	O
-	O
day	O
food	O
records	O
at	O
baseline	O
and	O
following	O
4	O
-	O
week	O
supplementation	O
of	O
whole	O
milk	O
,	O
Table	O
S2	O
:	O
Comparison	O
of	O
gut	O
microbiota	O
composition	O
at	O
the	O
phylum	O
and	O
genus	O
level	O
betweem	O
lactose	O
malabsorbers	O
(	O
LM	O
)	O
and	O
absorbers	O
(	O
LA	O
)	O
,	O
Table	O
S3	O
:	O
Comparison	O
of	O
changes	O
in	O
cardiometabolic	O
biomarkers	O
between	O
groups	O
based	O
on	O
changes	O
in	O
Bifidobacterium	O
abundance	O
among	O
lactose	O
malabsorbers	O
,	O
Table	O
S4	O
:	O
Comparison	O
of	O
changes	O
in	O
cardiometabolic	O
biomarkers	O
between	O
groups	O
based	O
on	O
changes	O
in	O
Anaerostipes	O
abundance	O
among	O
lactose	O
malabsorbers	O
,	O
Table	O
S5	O
:	O
Comparison	O
of	O
changes	O
in	O
cardiometabolic	O
biomarkers	O
between	O
groups	O
based	O
on	O
changes	O
in	O
Blautia	O
abundance	O
among	O
lactose	O
malabsorbers	O
,	O
Table	O
S6	O
:	O
Comparison	O
of	O
changes	O
in	O
cardiometabolic	O
biomarkers	O
between	O
groups	O
based	O
on	O
changes	O
in	O
Megamonas	O
abundance	O
among	O
lactose	O
malaborbers	O
.	O
Conceptualization	O
,	O
X	O
.	O
L	O
.	O
,	O
Z	O
.	O
S	O
.	O
and	O
L	O
.	O
L	O
.	O
;	O
Data	O
curation	O
,	O
X	O
.	O
L	O
.	O
;	O
Formal	O
analysis	O
,	O
X	O
.	O
L	O
.	O
,	O
J	O
.	O
Y	O
.	O
and	O
Y	O
.	O
Z	O
.	O
;	O
Funding	O
acquisition	O
,	O
L	O
.	O
L	O
.	O
;	O
Investigation	O
,	O
X	O
.	O
L	O
.	O
,	O
J	O
.	O
Y	O
.	O
,	O
Y	O
.	O
Z	O
.	O
,	O
X	O
.	O
W	O
.	O
,	O
X	O
.	O
H	O
.	O
,	O
Y	O
.	O
H	O
.	O
,	O
L	O
.	O
C	O
.	O
,	O
S	O
.	O
C	O
.	O
and	O
W	O
.	O
Y	O
.	O
;	O
Methodology	O
,	O
X	O
.	O
L	O
.	O
,	O
J	O
.	O
Y	O
.	O
and	O
Y	O
.	O
Z	O
.	O
;	O
Project	O
administration	O
,	O
X	O
.	O
L	O
.	O
and	O
Z	O
.	O
S	O
.	O
;	O
Software	O
,	O
X	O
.	O
L	O
.	O
;	O
Supervision	O
,	O
L	O
.	O
L	O
.	O
;	O
Visualization	O
,	O
X	O
.	O
L	O
.	O
;	O
Writing	O
–	O
original	O
draft	O
,	O
X	O
.	O
L	O
.	O
;	O
Writing	O
–	O
review	O
&	O
editing	O
,	O
W	O
.	O
B	O
.	O
and	O
Z	O
.	O
S	O
.	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

This	O
research	O
was	O
funded	O
by	O
Chinese	O
Nutrition	O
Society	O
Research	O
Fund	O
,	O
grant	O
number	O
CNS	O
-	O
2015	O
;	O
the	O
National	O
Key	O
Research	O
and	O
Development	O
Program	O
of	O
China	O
,	O
grant	O
number	O
2017YFC1600500	O
;	O
and	O
the	O
National	O
Natural	O
Science	O
Foundation	O
of	O
China	O
,	O
grant	O
number	O
81703214	O
.	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O
The	O
funders	O
had	O
no	O
role	O
in	O
the	O
design	O
of	O
the	O
study	O
;	O
in	O
the	O
collection	O
,	O
analyses	O
,	O
or	O
interpretation	O
of	O
data	O
;	O
in	O
the	O
writing	O
of	O
the	O
manuscript	O
,	O
or	O
in	O
the	O
decision	O
to	O
publish	O
the	O
results	O
.	O

Archive	O
for	O
Research	O
in	O
Child	O
Health	O
(	O
ARCH	O
)	O
and	O
Baby	O
Gut	O
:	O
Study	B-methodology
Protocol	I-methodology
for	O
a	O
Remote	O
,	O
Prospective	O
,	O
Longitudinal	O
Pregnancy	O
and	O
Birth	O
Cohort	B-methodology
to	O
Address	O
Microbiota	O
Development	O
and	O
Child	O
Health	O
gut	O
microbiome	O
;	O
pregnancy	O
;	O
human	O
milk	O
exposure	O
;	O
child	O
development	O
;	O
infancy	O
;	O
microbiota	O
;	O
cohort	B-methodology
The	O
infant	O
gut	O
microbiome	O
is	O
shaped	O
by	O
numerous	O
factors	O
such	O
as	O
diet	O
and	O
the	O
maternal	O
microbiota	O
and	O
is	O
also	O
associated	O
with	O
later	O
atopy	O
and	O
obesity	O
.	O
The	O
Archive	O
for	O
Research	O
in	O
Child	O
Health	O
and	O
Baby	O
Gut	O
(	O
ARCHBG	O
)	O
cohort	B-methodology
was	O
established	O
in	O
2015	O
to	O
(	O
1	O
)	O
understand	O
how	O
the	O
development	O
of	O
the	O
infant	O
gut	O
microbiota	O
is	O
associated	O
with	O
atopy	O
,	O
obesity	O
,	O
and	O
gastrointestinal	O
disease	O
and	O
(	O
2	O
)	O
characterize	O
the	O
associations	O
of	O
maternal	O
pre	O
-	O
pregnancy	O
BMI	O
and	O
infant	O
diet	O
with	O
the	O
development	O
of	O
the	O
gut	O
microbiota	O
.	O
Study	O
participants	O
for	O
ARCHBG	O
are	O
convenience	O
samples	O
recruited	O
through	O
two	O
pipelines	O
in	O
Lansing	O
and	O
Traverse	O
City	O
,	O
Michigan	O
:	O
(	O
1	O
)	O
Archive	O
for	O
Research	O
in	O
Child	O
Health	O
(	O
ARCHGUT	O
)	O
and	O
(	O
2	O
)	O
BABYGUT	O
.	O
A	O
total	O
of	O
(	O
n	O
=	O
51	O
)	O
mother	O
–	O
infant	O
dyads	O
have	O
been	O
enrolled	O
to	O
date	O
.	O
This	O
prospective	B-methodology
cohort	I-methodology
study	I-methodology
collects	O
maternal	O
pre	O
-	O
pregnancy	O
fecal	O
samples	O
,	O
maternal	O
data	O
,	O
child	O
fecal	O
samples	O
at	O
four	O
timepoints	O
(	O
one	O
week	O
,	O
six	O
months	O
,	O
12	O
months	O
,	O
and	O
24	O
months	O
)	O
,	O
and	O
child	O
data	O
up	O
to	O
five	O
years	O
of	O
age	O
.	O
All	O
samples	O
and	O
data	O
are	O
collected	O
remotely	O
by	O
mail	O
,	O
phone	O
,	O
or	O
drop	O
-	O
off	O
at	O
select	O
locations	O
.	O
Of	O
all	O
participants	O
enrolled	O
,	O
76	O
.	O
5	O
%	O
(	O
n	O
=	O
39	O
)	O
of	O
infants	O
have	O
a	O
complete	O
record	O
of	O
stool	O
samples	O
.	O
At	O
least	O
88	O
.	O
2	O
%	O
(	O
n	O
=	O
45	O
)	O
of	O
fecal	O
samples	O
were	O
submitted	O
at	O
each	O
timepoint	O
.	O
ARCHBG	O
will	O
allow	O
for	O
a	O
nuanced	O
understanding	O
of	O
the	O
temporal	O
development	O
of	O
the	O
infant	O
gut	O
microbiome	O
and	O
numerous	O
child	O
health	O
outcomes	O
.	O
The	O
human	O
gut	O
microbiota	O
is	O
a	O
key	O
factor	O
in	O
perinatal	O
research	O
that	O
is	O
associated	O
with	O
numerous	O
pregnancy	O
and	O
infant	O
factors	O
such	O
as	O
mode	O
of	O
delivery	O
,	O
diet	O
,	O
antibiotic	O
use	O
,	O
adiposity	O
,	O
and	O
human	O
milk	O
exposure	O
[	O
1	O
,	O
2	O
]	O
.	O
In	O
spite	O
of	O
this	O
,	O
logistic	O
and	O
pragmatic	O
ethical	O
considerations	O
often	O
prevent	O
adequate	O
experimental	O
analysis	O
to	O
determine	O
causal	O
ties	O
between	O
the	O
gut	O
microbiome	O
and	O
numerous	O
human	O
health	O
outcomes	O
[	O
3	O
]	O
.	O

Hence	O
,	O
prospective	O
,	O
longitudinal	O
,	O
cohort	B-methodology
studies	I-methodology
are	O
valuable	O
tools	O
to	O
ascertain	O
the	O
directionality	O
of	O
the	O
relationships	O
and	O
associations	O
of	O
the	O
gut	O
microbiome	O
in	O
pregnant	O
women	O
and	O
their	O
infants	O
to	O
child	O
health	O
outcomes	O
.	O
Recently	O
,	O
the	O
gut	O
microbiome	O
has	O
also	O
been	O
demonstrated	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
diseases	O
from	O
infancy	O
into	O
childhood	O
[	O
4	O
]	O
.	O
With	O
a	O
lifetime	O
asthma	O
prevalence	O
of	O
12	O
.	O
7	O
%	O
in	O
Americans	O
[	O
5	O
]	O
,	O
and	O
with	O
the	O
significant	O
increase	O
in	O
the	O
incidence	O
of	O
allergies	O
[	O
6	O
]	O
,	O
it	O
is	O
imperative	O
to	O
develop	O
a	O
nuanced	O
understanding	O
of	O
the	O
corollary	O
pathogenesis	O
associated	O
with	O
altered	O
gut	O
microbial	O
conditions	O
in	O
infancy	O
,	O
a	O
time	O
when	O
the	O
immune	O
system	O
is	O
still	O
developing	O
.	O
For	O
example	O
,	O
antibiotic	O
-	O
induced	O
dysbiosis	O
of	O
the	O
infant	O
gut	O
microbiome	O
has	O
been	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
later	O
developing	O
asthma	O
,	O
obesity	O
,	O
and	O
intestinal	O
bowel	O
disease	O
[	O
7	O
,	O
8	O
,	O
9	O
]	O
.	O
Further	O
research	O
is	O
needed	O
to	O
identify	O
the	O
pathways	O
for	O
these	O
associations	O
in	O
light	O
of	O
the	O
numerous	O
confounding	O
variables	O
involved	O
in	O
infant	O
growth	O
and	O
health	O
.	O
The	O
ARCHGUT	O
/	O
BABYGUT	O
(	O
ARCHBG	O
)	O
study	O
is	O
a	O
convenience	O
sample	O
of	O
mother	O
/	O
infant	O
dyads	O
from	O
the	O
Lansing	O
and	O
Traverse	O
City	O
areas	O
of	O
Michigan	O
.	O
This	O
prospective	O
,	O
longitudinal	O
pregnancy	O
and	O
birth	B-methodology
cohort	I-methodology
study	I-methodology
began	O
in	O
2015	O
,	O
and	O
recruitment	O
into	O
the	O
BABYGUT	O
cohort	B-methodology
arm	O
is	O
ongoing	O
.	O
The	O
design	O
of	O
the	O
research	O
methodologies	O
used	O
for	O
this	O
cohort	B-methodology
serve	O
as	O
an	O
important	O
template	O
for	O
the	O
research	O
community	O
to	O
conduct	O
remote	O
sample	O
collection	O
and	O
maintain	O
participant	O
engagement	O
through	O
incentivized	O
follow	O
-	O
up	O
participation	O
.	O
Both	O
of	O
these	O
design	O
factors	O
are	O
relevant	O
not	O
only	O
to	O
the	O
pandemic	O
of	O
today	O
,	O
but	O
also	O
to	O
busy	O
families	O
during	O
any	O
moment	O
in	O
time	O
as	O
well	O
as	O
to	O
the	O
continued	O
efforts	O
of	O
implementing	O
cost	O
-	O
effective	O
strategies	O
to	O
conduct	O
the	O
research	O
of	O
tomorrow	O
.	O
Primarily	O
,	O
the	O
objective	O
of	O
the	O
ARCHBG	O
cohort	B-methodology
study	I-methodology
is	O
to	O
comprehend	O
how	O
the	O
long	O
-	O
term	O
development	O
of	O
the	O
gut	O
microbiota	O
within	O
infants	O
through	O
preadolescence	O
is	O
associated	O
with	O
food	O
allergies	O
,	O
asthma	O
,	O
and	O
other	O
atopic	O
diseases	O
,	O
in	O
addition	O
to	O
obesity	O
.	O
Secondary	O
objectives	O
include	O
characterization	O
of	O
maternal	O
pre	O
-	O
pregnancy	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
and	O
infant	O
dietary	O
associations	O
with	O
the	O
gut	O
microbiota	O
and	O
the	O
development	O
of	O
gastrointestinal	O
(	O
GI	O
)	O
diseases	O
.	O

Recently	O
,	O
it	O
has	O
been	O
suggested	O
that	O
the	O
initial	O
seeding	O
of	O
the	O
infant	O
microbiome	O
may	O
occur	O
in	O
utero	O
,	O
but	O
that	O
the	O
major	O
event	O
of	O
microbial	O
colonization	O
of	O
the	O
infant	O
is	O
during	O
birth	O
[	O
10	O
]	O
.	O
Indeed	O
,	O
infants	O
born	O
vaginally	O
exhibit	O
distinct	O
gut	O
microbiomes	O
from	O
those	O
born	O
by	O
C	O
-	O
section	O
,	O
and	O
exhibit	O
less	O
risk	O
for	O
developing	O
asthma	O
and	O
obesity	O
in	O
later	O
life	O
[	O
11	O
]	O
.	O
The	O
longitudinal	O
data	O
that	O
has	O
been	O
collected	O
and	O
continues	O
to	O
be	O
collected	O
from	O
ARCHBG	O
will	O
aid	O
efforts	O
by	O
researchers	O
to	O
characterize	O
the	O
complex	O
gut	O
microbial	O
relationships	O
corresponding	O
to	O
the	O
development	O
of	O
atopy	O
,	O
obesity	O
,	O
and	O
gastrointestinal	O
disease	O
,	O
and	O
the	O
impact	O
of	O
results	O
from	O
this	O
cohort	B-methodology
can	O
be	O
expanded	O
through	O
merging	O
data	O
with	O
other	O
cohort	B-methodology
studies	I-methodology
of	O
sufficiently	O
similar	O
design	O
.	O
Study	O
participants	O
for	O
ARCHBG	O
are	O
convenience	O
samples	O
recruited	O
through	O
two	O
separate	O
pipelines	O
.	O
The	O
first	O
,	O
ARCHGUT	O
,	O
enrolled	O
pregnant	O
women	O
as	O
a	O
subgroup	O
of	O
the	O
Archive	O
for	O
Research	O
in	O
Child	O
Health	O
(	O
ARCH	O
)	O
pregnancy	O
cohort	B-methodology
[	O
12	O
]	O
.	O
ARCH	O
is	O
designed	O
to	O
be	O
low	O
-	O
cost	O
,	O
with	O
medical	O
records	O
,	O
birth	O
certificates	O
,	O
newborn	O
blood	O
spots	O
,	O
blood	O
samples	O
,	O
and	O
urine	O
samples	O
all	O
collected	O
at	O
the	O
time	O
of	O
routine	O
clinical	O
check	O
-	O
ups	O
,	O
with	O
no	O
extra	O
burden	O
on	O
participants	O
.	O
ARCHGUT	O
was	O
an	O
optional	O
extension	O
of	O
ARCH	O
focused	O
on	O
collecting	O
questionnaire	O
responses	O
and	O
fecal	O
samples	O
(	O
maternal	O
third	O
trimester	O
of	O
pregnancy	O
;	O
infant	O
at	O
one	O
week	O
,	O
six	O
months	O
,	O
12	O
months	O
,	O
and	O
24	O
months	O
)	O
from	O
participants	O
who	O
provided	O
written	O
,	O
informed	O
consent	O
.	O
ARCHGUT	O
enrollment	O
occurred	O
between	O
2015	O
–	O
2017	O
in	O
a	O
clinic	O
in	O
Lansing	O
,	O
Michigan	O
and	O
another	O
in	O
Traverse	O
City	O
,	O
Michigan	O
,	O
with	O
n	O
=	O
29	O
mothers	O
enrolling	O
at	O
the	O
time	O
of	O
pregnancy	O
.	O
The	O
BABYGUT	O
arm	O
was	O
developed	O
as	O
a	O
supplement	O
to	O
ARCHGUT	O
.	O
Using	O
the	O
same	O
overall	O
methods	O
,	O
participants	O
were	O
recruited	O
at	O
several	O
clinics	O
in	O
Lansing	O
,	O
Michigan	O
.	O
The	O
clinics	O
were	O
afforded	O
pamphlets	O
describing	O
the	O
study	O
.	O
Incentives	O
included	O
personal	O
(	O
monetary	O
)	O
and	O
societal	O
(	O
understanding	O
atopy	O
,	O
obesity	O
and	O
gastrointestinal	O
disease	O
)	O
benefits	O
to	O
participating	O
in	O
the	O
study	O
.	O
Prospective	O
participants	O
interested	O
in	O
enrolling	O
called	O
the	O
phone	O
number	O
provided	O
in	O
the	O
pamphlet	O
,	O
and	O
after	O
providing	O
written	O
,	O
informed	O
consent	O
,	O
were	O
successfully	O
enrolled	O
in	O
the	O
study	O
.	O
BABYGUT	O
commenced	O
in	O
2016	O
and	O
is	O
ongoing	O
,	O
with	O
n	O
=	O
22	O
participants	O
successfully	O
enrolled	O
to	O
date	O
.	O

ARCHBG	O
is	O
open	O
to	O
all	O
English	O
-	O
speaking	O
,	O
18	O
+	O
pregnant	O
women	O
and	O
their	O
infants	O
.	O
As	O
of	O
August	O
2020	O
,	O
the	O
total	O
enrolled	O
population	O
of	O
ARCHBG	O
is	O
N	O
=	O
51	O
,	O
with	O
potential	O
for	O
continued	O
growth	O
and	O
a	O
target	O
sample	O
of	O
n	O
=	O
100	O
.	O
The	O
study	O
collects	O
information	O
from	O
both	O
the	O
mother	O
and	O
infant	O
that	O
allows	O
for	O
gut	O
microbial	O
analysis	O
in	O
light	O
of	O
numerous	O
health	O
exposures	O
,	O
such	O
as	O
diet	O
and	O
maternal	O
pre	O
-	O
pregnancy	O
BMI	O
,	O
and	O
outcomes	O
such	O
as	O
the	O
development	O
of	O
atopy	O
,	O
obesity	O
,	O
or	O
GI	O
diseases	O
(	O
Figure	O
1	O
)	O
.	O
The	O
longitudinal	O
nature	O
of	O
this	O
cohort	B-methodology
study	I-methodology
allows	O
for	O
a	O
temporal	O
analysis	O
of	O
the	O
onset	O
of	O
atopy	O
or	O
obesity	O
and	O
the	O
development	O
of	O
the	O
gut	O
microbiome	O
over	O
time	O
.	O
ARCHBG	O
is	O
an	O
ongoing	O
cohort	B-methodology
study	I-methodology
,	O
and	O
apart	O
from	O
initial	O
enrollment	O
,	O
which	O
may	O
be	O
done	O
via	O
mail	O
or	O
in	O
person	O
,	O
participant	O
data	O
and	O
samples	O
are	O
collected	O
remotely	O
through	O
the	O
use	O
of	O
telephones	O
,	O
postal	O
service	O
,	O
or	O
drop	O
-	O
off	O
at	O
select	O
locations	O
.	O
Both	O
ARCHGUT	O
and	O
BABYGUT	O
were	O
approved	O
by	O
the	O
Michigan	O
State	O
University	O
Human	B-methodology
Research	I-methodology
Protection	O
Program	O
(	O
IRB	O
C07	O
-	O
1201	O
(	O
ARCH	O
)	O
,	O
15	O
–	O
1240	O
(	O
BABYGUT	O
)	O
and	O
14	O
–	O
170M	O
(	O
ARCHGUT	O
)	O
)	O
.	O
After	O
participants	O
are	O
successfully	O
enrolled	O
in	O
ARCHBG	O
,	O
they	O
complete	O
an	O
enrollment	O
questionnaire	O
and	O
provide	O
fecal	O
samples	O
during	O
their	O
third	O
trimester	O
of	O
pregnancy	O
(	O
Table	O
1	O
)	O
.	O
The	O
enrollment	O
questionnaire	O
surveys	O
the	O
parents	O
’	O
health	O
statuses	O
and	O
any	O
suspected	O
/	O
diagnosed	O
allergies	O
they	O
may	O
have	O
[	O
13	O
]	O
.	O
It	O
also	O
asks	O
about	O
body	O
weight	O
,	O
height	O
,	O
antibiotic	O
use	O
,	O
smoking	O
,	O
age	O
,	O
intention	O
to	O
breastfeed	O
,	O
size	O
of	O
family	O
household	O
,	O
and	O
various	O
demographic	O
factors	O
(	O
race	O
,	O
ethnicity	O
,	O
education	O
,	O
marriage	O
,	O
and	O
income	O
/	O
assets	O
)	O
.	O
Along	O
with	O
the	O
fecal	O
sample	O
at	O
the	O
third	O
trimester	O
of	O
pregnancy	O
,	O
participants	O
also	O
complete	O
a	O
sample	O
questionnaire	O
which	O
requests	O
additional	O
information	O
about	O
proximal	O
probiotic	O
/	O
prebiotic	O
/	O
antibiotic	O
use	O
,	O
whether	O
the	O
mother	O
is	O
currently	O
sick	O
,	O
water	O
source	O
,	O
and	O
a	O
recall	O
of	O
food	O
/	O
drink	O
consumed	O
in	O
the	O
past	O
24	O
h	O
.	O
Upon	O
return	O
of	O
the	O
maternal	O
fecal	O
sample	O
,	O
participants	O
are	O
rewarded	O
with	O
either	O
a	O
baby	O
box	O
(	O
containing	O
diapers	O
,	O
a	O
mattress	O
,	O
a	O
onesie	O
,	O
a	O
sleeper	O
,	O
a	O
blanket	O
,	O
a	O
hat	O
,	O
and	O
mittens	O
)	O
or	O
a	O
$	O
25	O
gift	O
card	O
for	O
a	O
local	O
store	O
.	O

Mothers	O
are	O
also	O
expected	O
to	O
return	O
infant	O
fecal	O
samples	O
at	O
one	O
week	O
,	O
six	O
months	O
,	O
12	O
months	O
,	O
and	O
24	O
months	O
post	O
-	O
partum	O
.	O
At	O
each	O
of	O
these	O
timepoints	O
and	O
until	O
five	O
years	O
(	O
with	O
potential	O
for	O
up	O
to	O
12	O
years	O
follow	O
-	O
up	O
upon	O
provision	O
of	O
consent	O
)	O
,	O
questionnaires	O
are	O
administered	O
regarding	O
various	O
health	O
parameters	O
(	O
Table	O
2	O
)	O
.	O
At	O
one	O
week	O
and	O
six	O
months	O
,	O
questionnaires	O
collect	O
data	O
about	O
infant	O
medicinal	O
use	O
,	O
mother	O
’	O
s	O
medicinal	O
use	O
,	O
whether	O
the	O
infant	O
is	O
sick	O
,	O
human	O
milk	O
exposure	O
at	O
the	O
breast	O
in	O
the	O
past	O
24	O
h	O
,	O
human	O
milk	O
fed	O
from	O
a	O
bottle	O
in	O
the	O
past	O
24	O
h	O
,	O
formula	O
exposure	O
in	O
past	O
24	O
h	O
,	O
formula	O
name	O
/	O
brand	O
,	O
other	O
foods	O
ingested	O
,	O
prebiotic	O
/	O
probiotic	O
use	O
,	O
infant	O
weight	O
,	O
infant	O
length	O
,	O
mode	O
of	O
delivery	O
,	O
infant	O
sex	O
,	O
and	O
whether	O
the	O
infant	O
attends	O
a	O
care	O
center	O
or	O
is	O
cared	O
for	O
outside	O
of	O
the	O
home	O
.	O
Starting	O
at	O
six	O
months	O
,	O
questionnaires	O
also	O
assess	O
all	O
food	O
/	O
drink	O
consumed	O
in	O
past	O
24	O
h	O
.	O
From	O
12	O
months	O
onward	O
,	O
the	O
questionnaire	O
expands	O
to	O
account	O
for	O
suspected	O
allergies	O
,	O
diagnosed	O
medical	O
conditions	O
,	O
and	O
breastfeeding	O
continuation	O
/	O
cessation	O
in	O
addition	O
to	O
child	O
height	O
/	O
weight	O
,	O
childcare	O
in	O
home	O
or	O
outside	O
home	O
,	O
and	O
antibiotic	O
use	O
in	O
the	O
past	O
year	O
.	O
Questionnaire	O
data	O
is	O
collected	O
either	O
by	O
mail	O
or	O
by	O
phone	O
call	O
according	O
to	O
the	O
participant	O
’	O
s	O
preference	O
,	O
ensuring	O
a	O
streamlined	O
,	O
low	O
-	O
burden	O
process	O
.	O
Recently	O
,	O
questionnaires	O
administered	O
through	O
a	O
web	O
-	O
based	O
survey	O
software	O
(	O
Qualtrics	O
,	O
Provo	O
,	O
UT	O
)	O
have	O
also	O
been	O
offered	O
for	O
the	O
three	O
-	O
,	O
four	O
-	O
,	O
and	O
five	O
-	O
year	O
follow	O
-	O
up	O
periods	O
.	O
All	O
fecal	O
samples	O
are	O
collected	O
by	O
the	O
participants	O
themselves	O
with	O
Para	O
Pak	O
collection	O
tubes	O
(	O
Meridian	O
Biosciences	O
,	O
Cincinnati	O
,	O
OH	O
,	O
USA	O
)	O
.	O
At	O
each	O
collection	O
timepoint	O
,	O
participants	O
are	O
sent	O
kits	O
containing	O
handouts	O
on	O
proper	O
collection	O
procedures	O
for	O
both	O
the	O
maternal	O
(	O
third	O
trimester	O
)	O
and	O
infant	O
fecal	O
samples	O
.	O
Overall	O
,	O
the	O
maternal	O
kit	O
contains	O
a	O
stool	O
hat	O
,	O
a	O
Para	O
Pak	O
collection	O
tube	O
,	O
gloves	O
,	O
a	O
small	O
zip	O
-	O
locking	O
bag	O
,	O
paper	O
towels	O
,	O
a	O
water	O
/	O
tear	O
-	O
resistant	O
envelope	O
,	O
a	O
stamped	O
return	O
box	O
,	O
and	O
the	O
sample	O
info	O
questionnaire	O
(	O
Figure	O
S1a	O
)	O
.	O
Baby	O
sample	O
kits	O
contain	O
diapers	O
in	O
place	O
of	O
the	O
stool	O
hat	O
(	O
Figure	O
S1b	O
)	O
.	O

Fecal	O
samples	O
are	O
mailed	O
to	O
the	O
lab	O
or	O
picked	O
up	O
from	O
a	O
participant	O
-	O
designated	O
location	O
,	O
aliquoted	O
in	O
the	O
lab	O
,	O
and	O
stored	O
in	O
a	O
−80	O
°C	O
freezer	O
until	O
further	O
processing	O
.	O
For	O
each	O
infant	O
fecal	O
sample	O
returned	O
,	O
participants	O
are	O
given	O
a	O
$	O
10	O
gift	O
card	O
for	O
a	O
local	O
store	O
.	O
From	O
the	O
one	O
-	O
year	O
timepoint	O
on	O
,	O
participants	O
are	O
mailed	O
a	O
children	O
’	O
s	O
book	O
each	O
year	O
that	O
they	O
respond	O
to	O
the	O
data	O
questionnaire	O
.	O
Participants	O
also	O
receive	O
a	O
$	O
10	O
gift	O
card	O
to	O
a	O
local	O
store	O
for	O
completion	O
of	O
the	O
4	O
-	O
and	O
5	O
-	O
year	O
questionnaires	O
.	O
Aims	O
of	O
the	O
statistical	O
analyses	O
for	O
ARCHBG	O
are	O
to	O
(	O
1	O
)	O
observe	O
the	O
development	O
and	O
exposures	O
associated	O
with	O
gastrointestinal	O
pathologies	O
,	O
obesity	O
,	O
and	O
atopy	O
and	O
(	O
2	O
)	O
determine	O
gut	O
microbial	O
differences	O
between	O
participants	O
and	O
identify	O
the	O
underlying	O
,	O
associated	O
exposures	O
.	O
The	O
exact	O
statistical	O
methods	O
and	O
processes	O
will	O
vary	O
according	O
to	O
the	O
project	O
and	O
its	O
specifications	O
,	O
but	O
there	O
are	O
commonalities	O
to	O
the	O
approach	O
.	O
Demographic	O
differences	O
between	O
populations	O
that	O
differ	O
by	O
a	O
variable	O
of	O
interest	O
will	O
be	O
compared	O
using	O
t	O
-	O
tests	O
for	O
parametric	O
and	O
Wilcoxon	O
rank	O
-	O
sum	O
tests	O
for	O
nonparametric	O
continuous	O
data	O
.	O
Categorical	O
variables	O
are	O
typically	O
compared	O
using	O
chi	O
-	O
squared	O
tests	O
.	O
BMI	O
and	O
human	O
milk	O
exposure	O
measures	O
are	O
grouped	O
into	O
categorical	O
units	O
to	O
ensure	O
adequate	O
statistical	O
power	O
.	O
Measures	O
of	O
microbial	O
diversity	O
are	O
calculated	O
in	O
R	O
[	O
14	O
]	O
.	O
Alpha	O
diversity	O
,	O
or	O
within	O
-	O
sample	O
variation	O
in	O
number	O
of	O
individual	O
taxa	O
and	O
their	O
respective	O
abundances	O
(	O
richness	O
and	O
evenness	O
)	O
,	O
is	O
measured	O
using	O
Chao1	O
,	O
Shannon	O
,	O
and	O
Inverse	O
Simpson	O
indices	O
through	O
the	O
vegan	O
package	O
[	O
15	O
]	O
.	O
Significant	O
differences	O
between	O
alpha	O
diversity	O
indices	O
are	O
assessed	O
with	O
ANOVA	O
for	O
parametric	O
data	O
,	O
with	O
normality	O
confirmed	O
using	O
the	O
Shapiro	O
–	O
Wilk	O
test	O
.	O
If	O
nonparametric	O
,	O
alpha	O
diversity	O
indices	O
are	O
assessed	O
with	O
the	O
Wilcoxon	O
rank	O
-	O
sum	O
test	O
or	O
Kruskal	O
–	O
Wallis	O
test	O
depending	O
on	O
number	O
of	O
groups	O
being	O
compared	O
.	O
Power	O
calculations	O
for	O
alpha	O
diversity	O
are	O
conducted	O
using	O
G	O
*	O
power	O
version	O
3	O
.	O
1	O
.	O
9	O
.	O
2	O
[	O
16	O
]	O
.	O
Beta	O
diversity	O
,	O
or	O
differences	O
in	O
microbial	O
community	O
structure	O
and	O
composition	O
between	O
samples	O
,	O
is	O
visualized	O
using	O
principal	O
coordinates	O
analysis	O
(	O
PCoA	O
)	O
for	O
Sorensen	O
or	O
Bray	O
–	O
Curtis	O
dissimilarity	O
scores	O
.	O

Significant	O
differences	O
between	O
group	O
means	O
and	O
variances	O
are	O
tested	O
using	O
permutational	O
multivariate	O
analysis	O
of	O
variance	O
(	O
PERMANOVA	O
)	O
and	O
permutation	O
of	O
dispersion	O
(	O
PERMDISP	O
)	O
from	O
the	O
adonis	O
and	O
betadisper	O
functions	O
,	O
respectively	O
,	O
in	O
the	O
vegan	O
package	O
.	O
Power	O
calculations	O
for	O
beta	O
diversity	O
are	O
conducted	O
using	O
the	O
micropower	O
package	O
[	O
17	O
]	O
.	O
Taxa	O
that	O
differ	O
significantly	O
between	O
groups	O
are	O
tested	O
using	O
a	O
negative	O
binomial	O
model	O
from	O
the	O
MASS	O
package	O
[	O
18	O
]	O
.	O
p	O
-	O
values	O
less	O
than	O
0	O
.	O
05	O
are	O
considered	O
significant	O
,	O
with	O
the	O
Benjamini	O
–	O
Hochberg	O
procedure	O
applied	O
for	O
false	O
discovery	O
rate	O
correction	O
.	O
From	O
the	O
overarching	O
ARCH	O
study	O
,	O
n	O
=	O
39	O
prospective	O
mothers	O
initially	O
expressed	O
interest	O
in	O
participating	O
in	O
ARCHGUT	O
.	O
Of	O
these	O
,	O
n	O
=	O
29	O
provided	O
written	O
,	O
informed	O
consent	O
and	O
completed	O
an	O
enrollment	O
form	O
.	O
One	O
participant	O
dropped	O
out	O
,	O
leaving	O
n	O
=	O
28	O
total	O
participants	O
.	O
One	O
mother	O
had	O
twins	O
,	O
accounting	O
for	O
a	O
total	O
of	O
n	O
=	O
29	O
mother	O
–	O
infant	O
dyads	O
from	O
the	O
ARCHGUT	O
recruitment	O
branch	O
.	O
For	O
BABYGUT	O
,	O
n	O
=	O
23	O
prospective	O
mothers	O
expressed	O
initial	O
interest	O
,	O
with	O
n	O
=	O
20	O
enrolling	O
.	O
Of	O
these	O
,	O
n	O
=	O
2	O
mothers	O
enrolled	O
two	O
infants	O
in	O
the	O
study	O
,	O
accounting	O
for	O
n	O
=	O
22	O
mother	O
–	O
infant	O
dyads	O
from	O
BABYGUT	O
.	O
This	O
leaves	O
a	O
total	O
of	O
n	O
=	O
51	O
participants	O
who	O
have	O
enrolled	O
in	O
ARCHBG	O
to	O
date	O
.	O
Of	O
these	O
,	O
n	O
=	O
39	O
infants	O
have	O
a	O
complete	O
record	O
of	O
stool	O
samples	O
,	O
with	O
at	O
least	O
n	O
=	O
45	O
(	O
88	O
.	O
2	O
%	O
)	O
fecal	O
samples	O
at	O
each	O
timepoint	O
(	O
Figure	O
2	O
)	O
.	O
The	O
ARCHGUT	O
and	O
BABYGUT	O
cohorts	B-methodology
did	O
not	O
statistically	O
differ	O
except	O
in	O
stock	O
/	O
bond	O
ownership	O
(	O
Table	O
3	O
)	O
.	O
There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
participants	O
who	O
submitted	O
all	O
fecal	O
samples	O
versus	O
those	O
who	O
missed	O
at	O
least	O
one	O
infant	O
/	O
maternal	O
fecal	O
sample	O
(	O
Table	O
S1	O
)	O
.	O
Analysis	O
of	O
maternal	O
pre	O
-	O
pregnancy	O
BMI	O
with	O
the	O
maternal	O
fecal	O
microbiome	O
in	O
the	O
third	O
trimester	O
of	O
pregnancy	O
revealed	O
lower	O
gut	O
microbial	O
diversity	O
among	O
overweight	O
mothers	O
compared	O
to	O
normal	O
or	O
obese	O
mothers	O
(	O
Chao1	O
,	O
p	O
=	O
0	O
.	O
02	O
;	O
Inverse	O
Simpson	O
,	O
p	O
=	O
0	O
.	O
05	O
;	O
Shannon	O
,	O
p	O
=	O
0	O
.	O
02	O
)	O
.	O

However	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
alpha	O
diversity	O
among	O
one	O
-	O
week	O
infant	O
fecal	O
samples	O
after	O
stratifying	O
groups	O
based	O
on	O
maternal	O
BMI	O
(	O
Chao1	O
,	O
p	O
=	O
0	O
.	O
58	O
;	O
Inverse	O
Simpson	O
,	O
p	O
=	O
0	O
.	O
49	O
;	O
Shannon	O
,	O
p	O
=	O
0	O
.	O
51	O
)	O
.	O
Univariate	O
analysis	O
revealed	O
significant	O
differences	O
in	O
infant	O
beta	O
diversity	O
community	O
composition	O
(	O
Sorensen	O
)	O
arising	O
from	O
breastmilk	O
exposure	O
(	O
p	O
=	O
0	O
.	O
008	O
)	O
and	O
mode	O
of	O
delivery	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O
Infants	O
consuming	O
breastmilk	O
exclusively	O
were	O
significantly	O
enriched	O
in	O
Escherichia	O
–	O
Shigella	O
and	O
Staphylococcus	O
and	O
lacking	O
in	O
Akkermansia	O
and	O
Acidaminococcus	O
when	O
compared	O
to	O
infants	O
consuming	O
a	O
mixed	O
diet	O
(	O
formula	O
and	O
breast	O
milk	O
)	O
.	O
Additionally	O
,	O
infants	O
with	O
obese	O
mothers	O
were	O
significantly	O
enriched	O
in	O
Akkermansia	O
and	O
Acidaminococcus	O
compared	O
to	O
infants	O
with	O
either	O
overweight	O
or	O
normal	O
-	O
weight	O
mothers	O
.	O
These	O
results	O
delineate	O
associations	O
of	O
maternal	O
pre	O
-	O
pregnancy	O
BMI	O
with	O
both	O
maternal	O
and	O
early	O
infant	O
gut	O
microbial	O
parameters	O
[	O
19	O
]	O
.	O
At	O
six	O
months	O
[	O
20	O
]	O
,	O
human	O
milk	O
exposure	O
(	O
categorized	O
into	O
100	O
%	O
,	O
80	O
%	O
,	O
50	O
–	O
80	O
%	O
,	O
and	O
<	O
20	O
%	O
groups	O
based	O
on	O
estimated	O
fraction	O
in	O
infant	O
diet	O
)	O
within	O
the	O
last	O
24	O
h	O
was	O
significantly	O
different	O
for	O
infants	O
based	O
on	O
their	O
mother	O
’	O
s	O
pre	O
-	O
pregnancy	O
BMI	O
category	O
(	O
Chi	O
-	O
Square	O
,	O
p	O
=	O
0	O
.	O
02	O
)	O
,	O
with	O
all	O
normal	O
weight	O
mothers	O
exposing	O
their	O
infants	O
to	O
50	O
%	O
+	O
human	O
milk	O
in	O
their	O
diets	O
compared	O
to	O
approximately	O
one	O
-	O
third	O
of	O
overweight	O
mothers	O
and	O
two	O
-	O
thirds	O
of	O
obese	O
mothers	O
exposing	O
their	O
infants	O
to	O
less	O
than	O
20	O
%	O
human	O
milk	O
in	O
their	O
diets	O
.	O
Infants	O
consuming	O
less	O
than	O
20	O
%	O
human	O
milk	O
in	O
their	O
diets	O
had	O
significantly	O
higher	O
alpha	O
diversity	O
in	O
comparison	O
to	O
all	O
other	O
human	O
milk	O
exposure	O
groups	O
(	O
Chao1	O
,	O
p	O
=	O
0	O
.	O
01	O
;	O
Inverse	O
Simpson	O
,	O
p	O
<	O
0	O
.	O
001	O
;	O
Shannon	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
a	O
finding	O
which	O
is	O
corroborated	O
by	O
existing	O
literature	O
[	O
21	O
]	O
.	O

Infant	O
gut	O
microbial	O
community	O
structures	O
(	O
Bray	O
–	O
Curtis	O
)	O
differed	O
significantly	O
between	O
individuals	O
in	O
different	O
human	O
milk	O
exposure	O
categories	O
(	O
Genus	O
:	O
p	O
=	O
0	O
.	O
01	O
;	O
Phylum	O
:	O
p	O
=	O
0	O
.	O
005	O
)	O
and	O
by	O
maternal	O
BMI	O
category	O
(	O
Genus	O
:	O
p	O
=	O
0	O
.	O
03	O
;	O
Phylum	O
:	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O
Multivariable	O
linear	O
regression	O
models	O
accounting	O
for	O
human	O
milk	O
exposure	O
,	O
maternal	O
BMI	O
category	O
,	O
sample	O
shipping	O
time	O
,	O
age	O
,	O
sex	O
,	O
delivery	O
mode	O
,	O
and	O
cohort	B-methodology
demonstrated	O
that	O
human	O
milk	O
exposure	O
consistently	O
and	O
significantly	O
accounted	O
for	O
the	O
most	O
variance	O
in	O
beta	O
diversity	O
genus	O
richness	O
(	O
Sorensen	O
)	O
with	O
p	O
≤	O
0	O
.	O
002	O
and	O
R2	O
~	O
0	O
.	O
1	O
for	O
all	O
models	O
.	O
Megasphaera	O
,	O
unclassified	O
Lachnospiraceae	O
,	O
and	O
Blautia	O
were	O
all	O
significantly	O
lower	O
for	O
infants	O
consuming	O
100	O
%	O
breast	O
milk	O
at	O
six	O
months	O
of	O
age	O
.	O
After	O
screening	O
321	O
antibiotic	O
resistance	O
genes	O
(	O
ARG	O
)	O
and	O
53	O
mobile	O
genetic	O
elements	O
(	O
MGE	O
)	O
in	O
maternal	O
(	O
pregnancy	O
)	O
and	O
six	O
-	O
month	O
infant	O
fecal	O
samples	O
,	O
133	O
genes	O
were	O
found	O
in	O
at	O
least	O
one	O
sample	O
and	O
therefore	O
used	O
in	O
the	O
analysis	O
.	O
Genes	O
conferring	O
resistance	O
to	O
tetracycline	O
and	O
the	O
related	O
transposon	O
sequences	O
were	O
most	O
abundant	O
among	O
all	O
samples	O
.	O
Tetracycline	O
resistance	O
genes	O
were	O
also	O
the	O
genes	O
most	O
commonly	O
shared	O
between	O
mother	O
–	O
infant	O
dyads	O
,	O
with	O
50	O
%	O
sharing	O
the	O
same	O
ARG	O
.	O
On	O
average	O
,	O
29	O
%	O
of	O
ARG	O
and	O
24	O
%	O
of	O
MGE	O
in	O
the	O
fecal	O
samples	O
were	O
shared	O
between	O
mothers	O
and	O
their	O
infants	O
,	O
but	O
infant	O
MGE	O
compositions	O
were	O
more	O
similar	O
between	O
unrelated	O
infants	O
than	O
between	O
each	O
infant	O
and	O
their	O
own	O
mother	O
(	O
Sorensen	O
;	O
p	O
=	O
0	O
.	O
014	O
)	O
.	O
Infant	O
fecal	O
samples	O
also	O
had	O
more	O
MGE	O
but	O
no	O
significant	O
differences	O
in	O
the	O
number	O
of	O
ARGs	O
in	O
comparison	O
to	O
the	O
pregnancy	O
samples	O
.	O
The	O
diversity	O
of	O
ARGs	O
and	O
MGEs	O
was	O
significantly	O
higher	O
in	O
infants	O
than	O
in	O
the	O
mothers	O
(	O
ARG	O
,	O
p	O
=	O
0	O
.	O
016	O
;	O
MGE	O
,	O
p	O
=	O
0	O
.	O
0036	O
)	O
.	O

The	O
multi	O
-	O
drug	O
resistance	O
,	O
sulfonamide	O
,	O
and	O
fluoroquinolone	O
ARGs	O
were	O
all	O
significantly	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
enriched	O
in	O
infant	O
samples	O
compared	O
to	O
pregnancy	O
samples	O
,	O
which	O
were	O
significantly	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
enriched	O
in	O
the	O
aminoglycoside	O
,	O
vancomycin	O
,	O
and	O
macrolide	O
-	O
lincosamide	O
-	O
streptogramin	O
B	O
ARGs	O
.	O
ARG	O
patterns	O
for	O
those	O
consuming	O
>	O
50	O
%	O
breastmilk	O
were	O
significantly	O
different	O
compared	O
to	O
those	O
consuming	O
less	O
(	O
Bray	O
–	O
Curtis	O
,	O
p	O
=	O
0	O
.	O
043	O
)	O
.	O
Overall	O
abundance	O
patterns	O
of	O
ARGs	O
and	O
gut	O
microbial	O
taxa	O
were	O
associated	O
(	O
Procrustes	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O
However	O
,	O
there	O
were	O
no	O
significant	O
associations	O
between	O
the	O
infant	O
fecal	O
resistome	O
and	O
antibiotic	O
exposure	O
in	O
pregnancy	O
or	O
postpartum	O
[	O
22	O
]	O
.	O
Human	O
milk	O
exposure	O
at	O
six	O
and	O
12	O
months	O
of	O
infant	O
age	O
differed	O
significantly	O
by	O
pre	O
-	O
pregnancy	O
maternal	O
BMI	O
category	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O
All	O
infants	O
with	O
mothers	O
in	O
the	O
normal	O
BMI	O
range	O
had	O
some	O
proximal	O
human	O
milk	O
exposure	O
,	O
but	O
36	O
.	O
4	O
%	O
of	O
infants	O
with	O
overweight	O
mothers	O
and	O
66	O
.	O
7	O
%	O
of	O
infants	O
with	O
obese	O
mothers	O
were	O
reported	O
to	O
have	O
no	O
proximal	O
exposure	O
to	O
human	O
milk	O
at	O
the	O
time	O
of	O
fecal	O
sampling	O
when	O
six	O
or	O
12	O
months	O
of	O
age	O
.	O
Infants	O
exposed	O
to	O
human	O
milk	O
had	O
significantly	O
lower	O
gut	O
microbial	O
richness	O
than	O
infants	O
who	O
were	O
not	O
exposed	O
(	O
Chao1	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O
Although	O
maternal	O
pre	O
-	O
pregnancy	O
BMI	O
was	O
associated	O
with	O
significantly	O
greater	O
infant	O
gut	O
microbial	O
diversity	O
(	O
Chao1	O
,	O
p	O
=	O
0	O
.	O
01	O
;	O
Shannon	O
,	O
p	O
=	O
0	O
.	O
04	O
)	O
,	O
a	O
bivariate	O
analysis	O
revealed	O
that	O
human	O
milk	O
exposure	O
was	O
the	O
likely	O
driver	O
of	O
this	O
observed	O
association	O
(	O
Chao1	O
,	O
p	O
=	O
0	O
.	O
03	O
;	O
Shannon	O
,	O
p	O
=	O
0	O
.	O
07	O
)	O
,	O
and	O
not	O
maternal	O
BMI	O
(	O
Chao1	O
,	O
p	O
=	O
0	O
.	O
49	O
;	O
Shannon	O
,	O
p	O
=	O
0	O
.	O
54	O
)	O
.	O

At	O
12	O
months	O
of	O
age	O
,	O
infant	O
BMI	O
-	O
for	O
-	O
age	O
z	O
-	O
scores	O
were	O
only	O
significantly	O
related	O
to	O
maternal	O
pre	O
-	O
pregnancy	O
BMI	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
,	O
and	O
not	O
human	O
milk	O
exposure	O
(	O
p	O
=	O
0	O
.	O
53	O
)	O
or	O
the	O
infant	O
gut	O
microbiota	O
(	O
Chao1	O
,	O
p	O
=	O
0	O
.	O
95	O
;	O
Shannon	O
,	O
p	O
=	O
0	O
.	O
10	O
;	O
Bray	O
–	O
Curtis	O
,	O
p	O
=	O
0	O
.	O
90	O
;	O
Sorensen	O
,	O
p	O
=	O
1	O
)	O
[	O
23	O
]	O
.	O
ARCHBG	O
is	O
a	O
pregnancy	O
cohort	B-methodology
that	O
allows	O
for	O
continued	O
remote	O
follow	O
-	O
up	O
and	O
the	O
collection	O
of	O
fecal	O
samples	O
from	O
birth	O
until	O
two	O
years	O
of	O
age	O
and	O
data	O
throughout	O
the	O
growth	O
of	O
an	O
infant	O
until	O
a	O
maximum	O
of	O
12	O
years	O
.	O
This	O
cohort	B-methodology
provides	O
the	O
opportunity	O
to	O
study	O
gut	O
microbial	O
associations	O
with	O
various	O
developmental	O
milestones	O
,	O
such	O
as	O
growth	O
,	O
dietary	O
transitions	O
,	O
and	O
,	O
notably	O
,	O
the	O
development	O
of	O
various	O
gastrointestinal	O
and	O
atopic	O
maladies	O
.	O
The	O
data	O
that	O
has	O
been	O
collected	O
starting	O
in	O
2015	O
has	O
allowed	O
for	O
several	O
analyses	O
delineating	O
associative	O
factors	O
with	O
the	O
maternal	O
gut	O
microbiome	O
,	O
the	O
early	O
infant	O
gut	O
microbiome	O
,	O
antibiotic	O
resistance	O
,	O
human	O
milk	O
exposure	O
,	O
and	O
infant	O
growth	O
.	O
The	O
lack	O
of	O
significant	O
differences	O
between	O
the	O
ARCHGUT	O
and	O
BABYGUT	O
cohorts	B-methodology
,	O
save	O
for	O
stock	O
/	O
bond	O
ownership	O
,	O
justifies	O
combining	O
these	O
two	O
foundational	O
cohorts	B-methodology
to	O
form	O
the	O
overall	O
ARCHBG	O
cohort	B-methodology
(	O
Table	O
3	O
)	O
.	O
The	O
median	O
shipping	O
time	O
was	O
four	O
days	O
at	O
each	O
sample	O
collection	O
time	O
point	O
,	O
and	O
the	O
high	O
rate	O
of	O
infant	O
fecal	O
sample	O
collection	O
at	O
each	O
timepoint	O
indicates	O
a	O
high	O
rate	O
of	O
retention	O
of	O
our	O
participants	O
,	O
with	O
n	O
=	O
39	O
(	O
76	O
.	O
5	O
%	O
)	O
submitting	O
all	O
four	O
infant	O
fecal	O
samples	O
and	O
a	O
minimum	O
submission	O
rate	O
of	O
n	O
=	O
45	O
(	O
88	O
.	O
2	O
%	O
)	O
at	O
each	O
timepoint	O
(	O
Figure	O
2	O
)	O
.	O
Although	O
this	O
is	O
a	O
high	O
rate	O
of	O
response	O
and	O
retention	O
,	O
it	O
serves	O
to	O
emphasize	O
the	O
quintessential	O
issue	O
of	O
participant	O
attrition	O
in	O
longitudinal	O
cohorts	O
.	O
Especially	O
in	O
the	O
age	O
of	O
COVID	O
-	O
19	O
,	O
studies	O
requiring	O
high	O
-	O
levels	O
of	O
participatory	O
involvement	O
are	O
increasingly	O
difficult	O
to	O
conduct	O
due	O
to	O
social	O
reluctance	O
and	O
legislative	O
restrictions	O
on	O
in	O
-	O
person	O
gatherings	O
aimed	O
at	O
slowing	O
the	O
spread	O
of	O
the	O
disease	O
[	O
24	O
]	O
.	O

These	O
obstacles	O
add	O
to	O
an	O
already	O
difficult	O
domain	O
of	O
data	O
collection	O
and	O
longitudinal	O
engagement	O
in	O
perinatal	O
research	O
,	O
leading	O
to	O
the	O
requisite	O
consideration	O
of	O
novel	O
research	O
methods	O
to	O
overcome	O
these	O
barriers	O
[	O
25	O
]	O
.	O
As	O
a	O
prospective	B-methodology
cohort	I-methodology
study	I-methodology
,	O
ARCHBG	O
has	O
the	O
potential	O
to	O
provide	O
quality	O
data	O
regarding	O
the	O
temporal	O
progression	O
of	O
various	O
conditions	O
in	O
conjunction	O
with	O
the	O
development	O
of	O
the	O
gut	O
microbiome	O
.	O
The	O
collection	O
of	O
both	O
maternal	O
(	O
pregnancy	O
)	O
and	O
four	O
infant	O
fecal	O
samples	O
at	O
different	O
timepoints	O
allows	O
for	O
the	O
examination	O
of	O
familial	O
versus	O
environmental	O
associations	O
,	O
and	O
can	O
prevent	O
recall	O
bias	O
for	O
confounders	O
arising	O
from	O
pregnancy	O
,	O
a	O
common	O
issue	O
in	O
cohort	B-methodology
studies	I-methodology
[	O
26	O
]	O
.	O
This	O
is	O
especially	O
important	O
in	O
light	O
of	O
emerging	O
evidence	O
that	O
the	O
pregnancy	O
gut	O
microbiome	O
is	O
involved	O
in	O
fetal	O
development	O
and	O
health	O
outcomes	O
[	O
27	O
]	O
.	O
Many	O
cohort	B-methodology
studies	I-methodology
do	O
not	O
collect	O
maternal	O
fecal	O
samples	O
[	O
27	O
,	O
28	O
,	O
29	O
,	O
30	O
,	O
31	O
,	O
32	O
,	O
33	O
,	O
34	O
,	O
35	O
,	O
36	O
,	O
37	O
,	O
38	O
,	O
39	O
]	O
.	O
For	O
those	O
that	O
do	O
,	O
maternal	O
fecal	O
samples	O
are	O
usually	O
collected	O
at	O
birth	O
or	O
post	O
-	O
partum	O
[	O
40	O
,	O
41	O
,	O
42	O
,	O
43	O
,	O
44	O
,	O
45	O
,	O
46	O
,	O
47	O
,	O
48	O
]	O
,	O
with	O
very	O
few	O
cohorts	B-methodology
collecting	O
fecal	O
samples	O
during	O
gestation	O
[	O
49	O
]	O
.	O
Additionally	O
,	O
the	O
ARCHBG	O
questionnaires	O
recorded	O
both	O
maternal	O
and	O
paternal	O
health	O
history	O
and	O
conditions	O
,	O
which	O
provides	O
a	O
more	O
complete	O
picture	O
than	O
maternal	O
data	O
alone	O
on	O
the	O
potential	O
etiology	O
of	O
future	O
conditions	O
within	O
the	O
growing	O
infant	O
[	O
50	O
]	O
.	O
The	O
salient	O
strength	O
of	O
the	O
design	O
of	O
ARCHBG	O
is	O
the	O
remote	O
methodology	O
utilized	O
for	O
the	O
collection	O
of	O
samples	O
and	O
data	O
.	O
The	O
only	O
potential	O
physical	O
contact	O
between	O
the	O
mother	O
and	O
researchers	O
is	O
at	O
enrollment	O
,	O
with	O
all	O
later	O
interaction	O
occurring	O
by	O
mail	O
,	O
telephone	O
,	O
or	O
pick	O
-	O
up	O
from	O
a	O
designated	O
location	O
.	O
Due	O
to	O
the	O
current	O
COVID	O
-	O
19	O
pandemic	O
,	O
the	O
study	B-methodology
design	I-methodology
of	O
ARCHBG	O
is	O
especially	O
relevant	O
as	O
it	O
provides	O
a	O
template	O
for	O
future	O
research	O
that	O
addresses	O
the	O
common	O
challenges	O
associated	O
with	O
perinatal	O
research	O
that	O
have	O
been	O
compounded	O
amidst	O
a	O
global	O
health	O
crisis	O
,	O
especially	O
among	O
vulnerable	O
populations	O
[	O
51	O
]	O
.	O
These	O
challenges	O
include	O
participant	O
attrition	O
,	O
labor	O
-	O
dependence	O
for	O
interviewer	O
-	O
administered	O
questionnaires	O
and	O
sample	O
collection	O
,	O
high	O
costs	O
,	O
and	O
logistical	O
obstacles	O
for	O
the	O
participation	O
of	O
mothers	O
and	O
their	O
infants	O
[	O
50	O
,	O
52	O
,	O
53	O
]	O
.	O

Although	O
recruitment	O
occurred	O
at	O
a	O
health	O
clinic	O
,	O
the	O
ability	O
to	O
remotely	O
engage	O
in	O
the	O
research	O
may	O
encourage	O
women	O
who	O
would	O
otherwise	O
have	O
been	O
lost	O
to	O
follow	O
-	O
up	O
due	O
to	O
missed	O
appointments	O
,	O
transportation	O
issues	O
,	O
or	O
relocation	O
to	O
a	O
new	O
city	O
.	O
Furthermore	O
,	O
it	O
may	O
appease	O
those	O
families	O
with	O
skepticism	O
of	O
modern	O
healthcare	O
,	O
and	O
it	O
provides	O
the	O
ability	O
for	O
women	O
to	O
discuss	O
with	O
their	O
partners	O
before	O
choosing	O
to	O
participate	O
[	O
25	O
]	O
.	O
Although	O
collecting	O
questionnaires	O
and	O
fecal	O
samples	O
by	O
mail	O
is	O
a	O
technique	O
that	O
has	O
been	O
around	O
for	O
several	O
decades	O
,	O
the	O
postal	O
questionnaires	O
used	O
in	O
this	O
study	O
were	O
designed	O
with	O
best	O
practice	O
recommendations	O
in	O
mind	O
,	O
ensuring	O
financial	O
incentives	O
for	O
fecal	O
samples	O
,	O
a	O
concise	O
,	O
personal	O
questionnaire	O
,	O
providing	O
stamped	O
return	O
envelopes	O
,	O
and	O
following	O
-	O
up	O
with	O
participants	O
post	O
-	O
contact	O
[	O
54	O
]	O
.	O
This	O
likely	O
contributed	O
to	O
the	O
relatively	O
low	O
attrition	O
rates	O
for	O
a	O
pregnancy	O
cohort	B-methodology
requiring	O
repeated	O
engagement	O
.	O
Considering	O
that	O
the	O
US	O
median	O
household	O
income	O
was	O
$	O
68	O
,	O
703	O
in	O
2019	O
[	O
55	O
]	O
and	O
that	O
n	O
=	O
20	O
(	O
43	O
.	O
5	O
%	O
)	O
of	O
our	O
cohort	B-methodology
report	O
earning	O
a	O
household	O
income	O
of	O
less	O
than	O
$	O
50	O
,	O
000	O
annually	O
(	O
Table	O
3	O
)	O
,	O
ARCHBG	O
is	O
also	O
more	O
representative	O
of	O
the	O
national	O
spectrum	O
of	O
socioeconomic	O
statuses	O
than	O
other	O
cohorts	B-methodology
,	O
which	O
are	O
often	O
skewed	O
towards	O
families	O
with	O
higher	O
incomes	O
[	O
29	O
]	O
.	O
The	O
pivotal	O
limitation	O
thus	O
far	O
to	O
ARCHBG	O
is	O
the	O
recruitment	O
of	O
participants	O
which	O
has	O
fallen	O
below	O
anticipated	O
levels	O
.	O
This	O
presents	O
issues	O
in	O
the	O
generalizability	O
of	O
the	O
data	O
due	O
to	O
low	O
power	O
for	O
some	O
associations	O
with	O
small	O
effects	O
and	O
limited	O
sample	O
size	O
.	O
As	O
a	O
convenience	O
sample	O
of	O
volunteers	O
,	O
costs	O
associated	O
with	O
recruitment	O
have	O
been	O
kept	O
to	O
a	O
minimum	O
.	O
However	O
,	O
a	O
more	O
involved	O
,	O
provider	O
-	O
based	O
sampling	O
model	O
,	O
while	O
clearly	O
more	O
expensive	O
and	O
resource	O
-	O
intensive	O
,	O
may	O
be	O
worth	O
exploring	O
in	O
future	O
studies	O
due	O
to	O
its	O
ability	O
to	O
enroll	O
a	O
high	O
percentage	O
of	O
eligible	O
and	O
geographically	O
-	O
representative	O
women	O
[	O
56	O
]	O
.	O
Participant	O
recruitment	O
is	O
also	O
limited	O
to	O
Traverse	O
City	O
and	O
Lansing	O
,	O
MI	O
.	O
In	O
the	O
future	O
,	O
expanding	O
the	O
overall	O
recruitment	O
zones	O
for	O
ARCHBG	O
may	O
provide	O
a	O
more	O
comprehensive	O
view	O
of	O
gut	O
microbial	O
development	O
in	O
Michigan	O
infants	O
.	O
Additionally	O
,	O
the	O
vast	O
majority	O
of	O
participants	O
elected	O
to	O
complete	O
the	O
questionnaires	O
on	O
paper	O
and	O
return	O
by	O
mail	O
.	O

However	O
,	O
we	O
do	O
not	O
collect	O
information	O
on	O
perceived	O
burden	O
of	O
each	O
mode	O
of	O
questionnaire	O
collection	O
(	O
mail	O
,	O
phone	O
,	O
internet	O
)	O
,	O
so	O
it	O
is	O
difficult	O
to	O
ascertain	O
which	O
mode	O
is	O
most	O
efficient	O
for	O
participants	O
.	O
Though	O
the	O
mailing	O
of	O
fecal	O
samples	O
eases	O
participatory	O
burdens	O
and	O
research	O
-	O
associated	O
costs	O
,	O
it	O
also	O
can	O
affect	O
the	O
quality	O
of	O
microbial	O
data	O
,	O
as	O
the	O
sample	O
is	O
subjected	O
to	O
less	O
-	O
than	O
-	O
ideal	O
conditions	O
during	O
the	O
mailing	O
period	O
.	O
Although	O
this	O
results	O
in	O
changes	O
to	O
the	O
microbial	O
data	O
compared	O
to	O
samples	O
that	O
are	O
immediately	O
frozen	O
[	O
57	O
]	O
,	O
gut	O
microbial	O
differences	O
between	O
samples	O
are	O
preserved	O
in	O
spite	O
of	O
short	O
-	O
term	O
storage	O
at	O
room	O
temperature	O
,	O
conserving	O
result	O
validity	O
[	O
58	O
]	O
.	O
In	O
addition	O
,	O
the	O
ARCHBG	O
protocol	O
only	O
includes	O
16S	O
rRNA	O
amplicon	O
metagenomics	O
.	O
In	O
the	O
future	O
,	O
studies	O
may	O
benefit	O
from	O
applying	O
other	O
‘	O
omics	O
’	O
analyses	O
to	O
the	O
fecal	O
samples	O
to	O
obtain	O
a	O
greater	O
depth	O
and	O
breadth	O
of	O
information	O
.	O
Furthermore	O
,	O
the	O
remote	O
nature	O
of	O
ARCHBG	O
calls	O
for	O
self	O
-	O
reported	O
measurements	O
for	O
parameters	O
such	O
as	O
breastmilk	O
exposure	O
and	O
growth	O
metrics	O
,	O
but	O
these	O
have	O
also	O
been	O
demonstrated	O
to	O
be	O
valid	O
among	O
maternal	O
populations	O
[	O
59	O
,	O
60	O
]	O
.	O
Finally	O
,	O
despite	O
relatively	O
low	O
attrition	O
rates	O
among	O
participants	O
(	O
Figure	O
2	O
)	O
and	O
no	O
significant	O
differences	O
between	O
those	O
who	O
submitted	O
all	O
fecal	O
samples	O
versus	O
those	O
who	O
missed	O
at	O
least	O
one	O
(	O
Table	O
S1	O
)	O
,	O
there	O
is	O
always	O
room	O
to	O
further	O
improve	O
non	O
-	O
response	O
and	O
dropout	O
rates	O
to	O
limit	O
potential	O
selection	O
bias	O
.	O
Attrition	O
may	O
be	O
reduced	O
in	O
the	O
future	O
by	O
incorporating	O
web	O
-	O
based	O
questionnaires	O
,	O
which	O
has	O
been	O
shown	O
in	O
a	O
randomized	B-methodology
intervention	I-methodology
follow	O
-	O
up	O
to	O
be	O
effective	O
in	O
garnering	O
a	O
high	O
level	O
of	O
data	O
retention	O
(	O
~	O
89	O
%	O
)	O
alongside	O
time	O
-	O
dependent	O
bonus	O
incentives	O
[	O
61	O
]	O
.	O
Internet	O
-	O
based	O
methodologies	O
will	O
also	O
further	O
reduce	O
costs	O
and	O
may	O
be	O
no	O
more	O
prone	O
to	O
selection	O
bias	O
than	O
traditional	O
follow	O
-	O
up	O
methodologies	O
[	O
62	O
]	O
.	O
Considering	O
the	O
reach	O
and	O
cost	O
-	O
effectiveness	O
of	O
web	O
-	O
based	O
strategies	O
,	O
future	O
pregnancy	O
cohorts	B-methodology
may	O
be	O
well	O
-	O
advised	O
to	O
complement	O
both	O
their	O
recruitment	O
and	O
follow	O
-	O
up	O
methodologies	O
with	O
online	O
options	O
.	O
The	O
design	O
of	O
ARCHBG	O
provides	O
a	O
valuable	O
template	O
for	O
future	O
research	O
that	O
examines	O
the	O
gut	O
microbiome	O
or	O
seeks	O
to	O
remotely	O
engage	O
participants	O
over	O
an	O
extended	O
period	O
of	O
time	O
.	O

Despite	O
the	O
low	O
number	O
of	O
participants	O
in	O
the	O
initial	O
analyses	O
,	O
the	O
preliminary	O
results	O
provide	O
insight	O
into	O
important	O
factors	O
associated	O
with	O
the	O
infant	O
gut	O
microbiome	O
,	O
be	O
they	O
maternal	O
BMI	O
,	O
infant	O
diet	O
,	O
or	O
infant	O
growth	O
,	O
that	O
merit	O
further	O
examination	O
as	O
more	O
participants	O
are	O
recruited	O
and	O
enrolled	O
.	O
ARCHBG	O
welcomes	O
collaboration	O
with	O
other	O
qualified	O
research	O
teams	O
seeking	O
to	O
examine	O
covariates	O
within	O
the	O
dataset	O
or	O
to	O
combine	O
data	O
with	O
that	O
of	O
a	O
similar	O
pregnancy	O
cohort	B-methodology
for	O
more	O
robust	O
analysis	O
.	O
Apart	O
from	O
the	O
current	O
research	O
directions	O
and	O
preliminary	O
findings	O
,	O
ARCHBG	O
is	O
anticipated	O
to	O
contribute	O
to	O
the	O
growing	O
body	O
of	O
knowledge	O
centering	O
on	O
maternal	O
–	O
infant	O
wellbeing	O
,	O
with	O
implications	O
for	O
policy	O
and	O
practical	O
life	O
.	O
Thank	O
you	O
to	O
the	O
cohort	B-methodology
investigators	O
,	O
some	O
of	O
whom	O
were	O
not	O
directly	O
involved	O
in	O
this	O
project	O
,	O
but	O
without	O
your	O
efforts	O
this	O
project	O
could	O
not	O
have	O
been	O
completed	O
.	O
Figure	O
1	O
was	O
created	O
with	O
BioRender	O
.	O
com	O
.	O
Special	O
thanks	O
to	O
the	O
MSU	O
Faculty	O
Clinic	O
at	O
Sparrow	O
in	O
Lansing	O
and	O
Munson	O
in	O
Traverse	O
City	O
,	O
Michigan	O
,	O
where	O
participant	B-methodology
enrollment	I-methodology
occurred	O
as	O
part	O
of	O
ARCH	O
.	O
Publisher	O
’	O
s	O
Note	O
:	O
MDPI	O
stays	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O
The	O
following	O
are	O
available	O
online	O
at	O
https	O
:	O
/	O
/	O
www	O
.	O
mdpi	O
.	O
com	O
/	O
article	O
/	O
10	O
.	O
3390	O
/	O
mps4030052	O
/	O
s1	O
,	O
Figure	O
S1	O
,	O
Photo	O
of	O
(	O
a	O
)	O
maternal	O
fecal	O
sample	O
collection	O
kit	O
and	O
(	O
b	O
)	O
infant	O
fecal	O
sample	O
collection	O
kit	O
.	O
,	O
Table	O
S1	O
,	O
Comparison	O
of	O
sociodemographic	O
information	O
and	O
sample	O
shipping	O
time	O
for	O
ARCHBG	O
participants	O
who	O
submitted	O
all	O
fecal	O
samples	O
versus	O
those	O
that	O
missed	O
at	O
least	O
one	O
fecal	O
sample	O
.	O

Conceptualization	O
,	O
S	O
.	O
S	O
.	O
C	O
.	O
;	O
methodology	O
,	O
S	O
.	O
S	O
.	O
C	O
.	O
;	O
software	O
,	O
S	O
.	O
S	O
.	O
C	O
.	O
and	O
E	O
.	O
N	O
.	O
H	O
.	O
;	O
validation	O
,	O
S	O
.	O
S	O
.	O
C	O
.	O
and	O
E	O
.	O
N	O
.	O
H	O
.	O
;	O
formal	O
analysis	O
,	O
E	O
.	O
N	O
.	O
H	O
.	O
;	O
investigation	O
,	O
S	O
.	O
S	O
.	O
C	O
.	O
;	O
resources	O
,	O
S	O
.	O
S	O
.	O
C	O
.	O
;	O
data	O
curation	O
,	O
S	O
.	O
S	O
.	O
C	O
.	O
and	O
E	O
.	O
N	O
.	O
H	O
.	O
;	O
writing	O
—	O
original	O
draft	O
preparation	O
,	O
E	O
.	O
N	O
.	O
H	O
.	O
;	O
writing	O
—	O
review	O
and	O
editing	O
,	O
S	O
.	O
S	O
.	O
C	O
.	O
and	O
E	O
.	O
N	O
.	O
H	O
.	O
;	O
visualization	O
,	O
E	O
.	O
N	O
.	O
H	O
.	O
;	O
supervision	O
,	O
S	O
.	O
S	O
.	O
C	O
.	O
;	O
project	O
administration	O
,	O
S	O
.	O
S	O
.	O
C	O
.	O
;	O
funding	O
acquisition	O
,	O
S	O
.	O
S	O
.	O
C	O
.	O
All	O
authors	O
have	O
read	O
and	O
agreed	O
to	O
the	O
published	O
version	O
of	O
the	O
manuscript	O
.	O
This	O
research	O
was	O
financially	O
supported	O
by	O
funds	O
provided	O
to	O
S	O
.	O
S	O
.	O
C	O
.	O
by	O
Michigan	O
State	O
AgBioResearch	O
as	O
well	O
as	O
an	O
investigator	O
grant	O
from	O
the	O
Offices	O
of	O
Vice	O
Presidents	O
for	O
Research	O
from	O
three	O
universities	O
(	O
Michigan	O
State	O
University	O
,	O
the	O
University	O
of	O
Michigan	O
,	O
and	O
Wayne	O
State	O
University	O
)	O
within	O
the	O
Child	O
Health	O
Advances	O
from	O
Research	O
with	O
Mothers	O
Coalition	O
(	O
CHARM	O
)	O
.	O
The	O
study	O
was	O
conducted	O
according	O
to	O
the	O
guidelines	B-methodology
of	O
the	O
Declaration	O
of	O
Helsinki	O
,	O
and	O
both	O
ARCHGUT	O
and	O
BABYGUT	O
were	O
approved	O
by	O
the	O
Michigan	O
State	O
University	O
Human	B-methodology
Research	I-methodology
Protection	O
Program	O
(	O
IRB	O
C07	O
-	O
1201	O
(	O
ARCH	O
)	O
,	O
15	O
-	O
1240	O
(	O
BABYGUT	O
)	O
and	O
14	O
-	O
170M	O
(	O
ARCHGUT	O
)	O
)	O
.	O
Informed	O
consent	O
was	O
obtained	O
from	O
all	O
subjects	O
involved	O
in	O
the	O
study	O
.	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O

Distribution	O
of	O
lipid	O
levels	O
and	O
prevalence	O
of	O
hyperlipidemia	O
:	O
data	O
from	O
the	O
NHANES	O
2007	O
–	O
2018	O
Hyperlipidemia	O
;	O
Lipid	O
levels	O
;	O
Age	O
;	O
Sex	O
;	O
Race	O
;	O
Smoking	O
status	O
;	O
NHANES	O
database	O
Lipid	O
-	O
lowering	O
therapy	O
is	O
important	O
,	O
and	O
the	O
distribution	O
of	O
lipid	O
levels	O
and	O
the	O
incidence	O
of	O
hyperlipidemia	O
may	O
vary	O
in	O
different	O
subgroups	O
of	O
the	O
population	O
.	O
We	O
aimed	O
to	O
explore	O
the	O
distribution	O
of	O
lipid	O
levels	O
and	O
the	O
prevalence	O
of	O
hyperlipidemia	O
in	O
subpopulations	O
with	O
subgroup	O
factors	O
,	O
including	O
age	O
,	O
sex	O
,	O
race	O
,	O
and	O
smoking	O
status	O
.	O
Our	O
study	O
used	O
data	O
from	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
NHANES	O
)	O
from	O
2007	O
to	O
2018	O
,	O
ultimately	O
enrolling	O
and	O
analyzing	O
15	O
,	O
499	O
participants	O
.	O
A	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
analysis	I-methodology
was	O
performed	O
to	O
assess	O
the	O
distribution	O
of	O
lipids	O
and	O
prevalence	O
of	O
hyperlipidemia	O
in	O
subpopulations	O
,	O
and	O
multifactorial	O
logistic	O
regression	O
analyses	O
were	O
performed	O
for	O
the	O
prevalence	O
of	O
hyperlipidemia	O
,	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
race	O
and	O
smoking	O
status	O
.	O
Blacks	O
had	O
significantly	O
lower	O
mean	O
serum	O
total	O
cholesterol	O
and	O
triglycerides	O
and	O
higher	O
serum	O
high	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
HDL	O
-	O
C	O
)	O
than	O
whites	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
In	O
contrast	O
,	O
Mexican	O
Americans	O
had	O
markedly	O
higher	O
mean	O
serum	O
triglycerides	O
and	O
lower	O
serum	O
HDL	O
-	O
C	O
than	O
whites	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
Furthermore	O
,	O
the	O
prevalence	O
of	O
hypercholesterolemia	O
and	O
hypertriglyceridemia	O
was	O
lower	O
in	O
blacks	O
than	O
in	O
whites	O
(	O
P	O
=	O
0	O
.	O
003	O
and	O
P	O
<	O
0	O
.	O
001	O
,	O
respectively	O
)	O
,	O
while	O
the	O
prevalence	O
of	O
hypertriglyceridemia	O
was	O
significantly	O
higher	O
in	O
Mexican	O
Americans	O
than	O
in	O
whites	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O
In	O
addition	O
,	O
total	O
cholesterol	O
and	O
triglyceride	O
levels	O
were	O
significantly	O
higher	O
in	O
women	O
aged	O
65	O
years	O
or	O
older	O
and	O
markedly	O
higher	O
than	O
in	O
men	O
in	O
the	O
same	O
age	O
group	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
addition	O
,	O
overall	O
mean	O
total	O
cholesterol	O
,	O
triglyceride	O
,	O
and	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
LDL	O
-	O
C	O
)	O
levels	O
were	O
higher	O
in	O
smokers	O
than	O
in	O
nonsmokers	O
(	O
P	O
=	O
0	O
.	O
01	O
,	O
P	O
<	O
0	O
.	O
001	O
,	O
and	O
P	O
=	O
0	O
.	O
005	O
,	O
respectively	O
)	O
.	O
Based	O
on	O
NHANES	O
data	O
,	O
the	O
mean	O
lipid	O
levels	O
and	O
prevalence	O
of	O
hyperlipidemia	O
differed	O
by	O
sex	O
,	O
age	O
,	O
race	O
,	O
and	O
smoking	O
status	O
.	O
Hyperlipidemia	O
is	O
defined	O
as	O
a	O
higher	O
-	O
than	O
-	O
normal	O
level	O
of	O
one	O
or	O
more	O
lipids	O
in	O
plasma	O
,	O
which	O
is	O
clinically	O
classified	O
as	O
hypercholesterolemia	O
,	O
hypertriglyceridemia	O
,	O
mixed	O
hyperlipidemia	O
,	O
and	O
high	O
-	O
density	O
lipoproteinemia	O
in	O
the	O
clinic	O
[	O
1	O
,	O
2	O
]	O
.	O
Epidemiological	B-methodology
studies	I-methodology
and	O
clinical	B-methodology
trials	I-methodology
have	O
confirmed	O
that	O
elevated	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
LDL	O
-	O
C	O
)	O
,	O
cholesterol	O
,	O
or	O
triglycerides	O
are	O
the	O
major	O
contributors	O
to	O
atherosclerotic	O
cardiovascular	O
disease	O
[	O
3	O
,	O
4	O
]	O
.	O
Generally	O
,	O
the	O
risk	O
of	O
atherosclerotic	O
events	O
increased	O
significantly	O
when	O
plasma	O
total	O
cholesterol	O
levels	O
exceeded	O
240	O
mg	O
/	O
dl	O
or	O
triglyceride	O
levels	O
exceeded	O
200	O
mg	O
/	O
dl	O
[	O
5	O
,	O
6	O
]	O
.	O
Furthermore	O
,	O
hyperlipidemia	O
-	O
induced	O
atherosclerosis	O
increases	O
morbidity	O
and	O
mortality	O
in	O
a	O
quiet	O
modality	O
,	O
including	O
myocardial	O
infarction	O
,	O
cerebral	O
infarction	O
,	O
and	O
peripheral	O
vascular	O
disease	O
[	O
4	O
]	O
.	O
In	O
patients	O
with	O
hyperlipidemia	O
,	O
the	O
incidence	O
of	O
cardiovascular	O
events	O
remains	O
high	O
even	O
when	O
treated	O
with	O
secondary	O
or	O
primary	O
prevention	O
therapy	O
,	O
such	O
as	O
statins	O
,	O
where	O
elevated	O
triglyceride	O
levels	O
can	O
serve	O
as	O
an	O
independent	O
marker	O
of	O
increased	O
risk	O
of	O
ischemic	O
events	O
[	O
7	O
]	O
.	O
In	O
the	O
United	O
States	O
(	O
US	O
)	O
,	O
Canadian	O
and	O
European	O
guidelines	B-methodology
for	O
the	O
management	O
of	O
hypercholesterolemia	O
,	O
LDL	O
-	O
C	O
is	O
the	O
primary	O
target	O
for	O
lipid	O
-	O
lowering	O
therapy	O
,	O
based	O
on	O
which	O
hypercholesterolemia	O
is	O
the	O
most	O
important	O
pathogenic	O
factor	O
in	O
atherosclerotic	O
cardiovascular	O
disease	O
[	O
8	O
]	O
.	O

The	O
American	O
Heart	O
Association	O
Task	O
Force	O
on	O
Clinical	B-methodology
Practice	I-methodology
Guidelines	I-methodology
proposed	O
individualized	O
management	O
and	O
lifestyle	O
interventions	O
that	O
consider	O
risk	O
factors	O
while	O
lowering	O
LDL	O
-	O
C	O
with	O
high	O
-	O
intensity	O
statins	O
with	O
reference	O
LDL	O
-	O
C	O
thresholds	O
,	O
including	O
70	O
mg	O
/	O
dL	O
(	O
1	O
.	O
8	O
mmol	O
/	O
L	O
)	O
and	O
100	O
mg	O
/	O
dL	O
(	O
2	O
.	O
6	O
mmol	O
/	O
L	O
)	O
,	O
and	O
age	O
points	O
of	O
40	O
and	O
75	O
years	O
[	O
9	O
]	O
.	O
The	O
guidelines	B-methodology
related	O
to	O
hyperlipidemia	O
are	O
graded	O
as	O
low	O
risk	O
,	O
moderate	O
risk	O
,	O
moderate	O
-	O
high	O
risk	O
,	O
and	O
high	O
risk	O
in	O
that	O
order	O
based	O
on	O
a	O
comprehensive	O
assessment	O
of	O
risk	O
factors	O
(	O
e	O
.	O
g	O
.	O
,	O
sex	O
,	O
age	O
,	O
smoking	O
,	O
hypertension	O
,	O
coronary	O
heart	O
disease	O
,	O
etc	O
.	O
)	O
,	O
cholesterol	O
and	O
triglyceride	O
levels	O
[	O
9	O
,	O
10	O
]	O
.	O
In	O
addition	O
,	O
the	O
corresponding	O
treatment	O
is	O
administered	O
according	O
to	O
the	O
risk	O
level	O
after	O
hyperlipidemia	O
assessment	O
to	O
reduce	O
the	O
occurrence	O
of	O
cardiovascular	O
events	O
and	O
other	O
complications	O
[	O
11	O
,	O
12	O
]	O
.	O
However	O
,	O
race	O
/	O
ethnicity	O
can	O
influence	O
the	O
estimation	O
of	O
atherosclerotic	O
cardiovascular	O
disease	O
risk	O
,	O
treatment	O
intensity	O
,	O
and	O
even	O
the	O
use	O
of	O
lipid	O
-	O
lowering	O
drugs	O
,	O
such	O
as	O
the	O
higher	O
risk	O
of	O
atherosclerotic	O
cardiovascular	O
disease	O
in	O
South	O
Asians	O
,	O
greater	O
statin	O
sensitivity	O
in	O
East	O
Asians	O
,	O
and	O
higher	O
prevalence	O
of	O
hypertension	O
in	O
blacks	O
[	O
13	O
]	O
.	O
Therefore	O
,	O
the	O
specific	O
distribution	O
of	O
blood	O
lipid	O
levels	O
by	O
race	O
,	O
sex	O
,	O
and	O
age	O
is	O
still	O
unclear	O
,	O
and	O
current	O
treatments	O
based	O
on	O
risk	O
stratification	O
of	O
lipids	O
also	O
do	O
not	O
consider	O
differences	O
in	O
those	O
factors	O
[	O
14	O
,	O
15	O
]	O
.	O
The	O
objective	O
of	O
our	O
study	O
was	O
to	O
investigate	O
the	O
distribution	O
of	O
blood	O
lipid	O
levels	O
by	O
race	O
,	O
sex	O
,	O
age	O
,	O
and	O
smoking	O
status	O
in	O
the	O
population	O
based	O
on	O
data	O
from	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
NHANES	O
)	O
:	O
2007	O
–	O
2018	O
.	O
These	O
data	O
will	O
refine	O
lipid	O
-	O
related	O
information	O
for	O
different	O
subpopulations	O
and	O
provide	O
a	O
reference	O
for	O
more	O
accurate	O
cardiovascular	O
event	O
prevention	O
treatment	O
in	O
different	O
populations	O
.	O
NHANES	O
is	O
a	O
representative	O
series	O
of	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
studies	I-methodology
designed	O
to	O
monitor	O
the	O
health	O
status	O
of	O
the	O
US	O
population	O
.	O
NHANES	O
data	O
consist	O
of	O
interviews	O
,	O
examinations	O
,	O
and	O
laboratory	O
data	O
collected	O
from	O
a	O
complex	O
,	O
multistage	O
,	O
stratified	O
,	O
aggregated	O
probability	O
sample	O
of	O
civilians	O
and	O
nonhospital	O
personnel	O
[	O
16	O
]	O
.	O

The	O
institutional	O
Review	O
Board	O
of	O
the	O
National	O
Center	O
for	O
Health	O
Statistics	O
(	O
NCHS	O
)	O
approved	O
the	O
study	B-methodology
protocol	I-methodology
,	O
and	O
all	O
participants	O
provided	O
written	B-methodology
informed	I-methodology
consent	I-methodology
.	O
In	O
NHANES	O
from	O
1999	O
to	O
2018	O
,	O
participation	O
in	O
-	O
home	O
interviews	O
was	O
52	O
–	O
84	O
%	O
,	O
and	O
the	O
percentage	O
in	O
mobile	O
medical	O
examinations	O
was	O
49	O
–	O
80	O
%	O
.	O
Our	O
study	O
included	O
adult	O
participants	O
aged	O
18	O
years	O
or	O
older	O
in	O
NHANES	O
from	O
2007	O
to	O
2018	O
.	O
The	O
exclusion	B-methodology
criteria	I-methodology
included	O
the	O
following	O
:	O
(	O
1	O
)	O
participants	O
under	O
the	O
age	O
of	O
18	O
;	O
(	O
2	O
)	O
participants	O
who	O
did	O
not	O
attend	O
screening	O
centers	O
;	O
and	O
(	O
3	O
)	O
participants	O
with	O
missing	O
lipid	O
values	O
.	O
Participants	O
reported	O
age	O
,	O
sex	O
(	O
male	O
or	O
female	O
)	O
,	O
race	O
(	O
white	O
,	O
black	O
,	O
Mexican	O
-	O
American	O
)	O
,	O
and	O
smoking	O
status	O
(	O
smoker	O
or	O
nonsmoker	O
)	O
.	O
NHANES	O
organizers	O
collected	O
3	O
ml	O
or	O
5	O
ml	O
of	O
K3	O
EDTA	O
anticoagulant	O
whole	O
blood	O
from	O
all	O
participants	O
18	O
years	O
of	O
age	O
or	O
older	O
using	O
established	O
venipuncture	O
protocols	O
and	O
procedures	O
.	O
Total	O
cholesterol	O
,	O
triglycerides	O
,	O
LDL	O
-	O
C	O
,	O
and	O
serum	O
high	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
HDL	O
-	O
C	O
)	O
values	O
were	O
measured	O
enzymatically	O
.	O
Hypercholesterolemia	O
was	O
defined	O
as	O
fasting	O
total	O
cholesterol	O
values	O
≥	O
240	O
mg	O
/	O
dl	O
.	O
High	O
triglycerides	O
were	O
defined	O
as	O
fasting	O
triglyceride	O
values	O
≥	O
200	O
ng	O
/	O
dl	O
.	O
Smokers	O
were	O
defined	O
as	O
smoking	O
more	O
than	O
100	O
cigarettes	O
in	O
life	O
and	O
smoking	O
some	O
days	O
or	O
every	O
day	O
,	O
while	O
nonsmokers	O
smoked	O
less	O
than	O
100	O
cigarettes	O
in	O
life	O
.	O
Our	O
analyses	O
used	O
a	O
weighted	O
sample	O
and	O
took	O
into	O
account	O
stratification	O
and	O
clustering	O
designed	O
to	O
derive	O
estimates	O
of	O
the	O
U	O
.	O
S	O
.	O
population	O
[	O
17	O
]	O
.	O
All	O
statistical	O
analyses	O
were	O
carried	O
out	O
using	O
R	O
software	O
(	O
version	O
4	O
.	O
1	O
.	O
0	O
;	O
http	O
:	O
/	O
/	O
www	O
.	O
R	O
-	O
project	O
.	O
org	O
,	O
R	O
Foundation	O
for	O
Statistical	O
Computing	O
,	O
Vienna	O
,	O
Austria	O
)	O
.	O
The	O
unadjusted	O
frequency	O
distribution	O
of	O
blood	O
lipid	O
values	O
and	O
unadjusted	O
prevalence	O
of	O
hyperlipidemia	O
associated	O
with	O
age	O
,	O
sex	O
,	O
race	O
,	O
and	O
smoking	O
status	O
were	O
identified	O
.	O
We	O
used	O
linear	O
regression	O
to	O
obtain	O
mean	O
values	O
and	O
comparisons	O
of	O
age	O
-	O
adjusted	O
and	O
sex	O
-	O
adjusted	O
blood	O
lipids	O
,	O
where	O
age	O
was	O
modeled	O
as	O
a	O
continuous	O
variable	O
.	O

We	O
also	O
compared	O
the	O
adjusted	O
mean	O
blood	O
lipids	O
of	O
smokers	O
and	O
nonsmokers	O
.	O
Multivariate	O
logistic	O
regression	O
analysis	O
was	O
performed	O
for	O
the	O
prevalence	O
of	O
hypercholesterolemia	O
and	O
hyperlipidemia	O
,	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
and	O
ethnic	O
groups	O
.	O
More	O
complex	O
models	O
including	O
ethnicity	O
and	O
sex	O
were	O
also	O
tested	O
,	O
and	O
different	O
age	O
classifications	O
were	O
considered	O
.	O
Of	O
the	O
36	O
,	O
580	O
participants	O
aged	O
18	O
or	O
older	O
who	O
were	O
asked	O
to	O
attend	O
the	O
mobile	O
examination	O
center	O
,	O
1	O
,	O
418	O
did	O
not	O
come	O
to	O
the	O
screening	O
center	O
,	O
and	O
19	O
,	O
663	O
had	O
missing	O
blood	O
lipid	O
values	O
.	O
A	O
total	O
of	O
15	O
,	O
499	O
NHANES	O
participants	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
which	O
represented	O
104	O
.	O
4	O
million	O
United	O
States	O
residents	O
.	O
We	O
used	O
linear	O
regression	O
to	O
compare	O
age	O
-	O
adjusted	O
and	O
sex	O
-	O
adjusted	O
mean	O
blood	O
lipid	O
values	O
across	O
the	O
major	O
races	O
.	O
Relative	O
to	O
white	O
participants	O
,	O
black	O
participants	O
had	O
lower	O
mean	O
total	O
cholesterol	O
levels	O
(	O
mean	O
difference	O
,	O
4	O
.	O
0	O
mg	O
/	O
dl	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
lower	O
triglyceride	O
levels	O
(	O
24	O
.	O
7	O
mg	O
/	O
dl	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
higher	O
HDL	O
-	O
C	O
levels	O
(	O
2	O
.	O
2	O
mg	O
/	O
dl	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
similar	O
LDL	O
-	O
C	O
levels	O
(	O
1	O
.	O
3	O
mg	O
/	O
dl	O
;	O
P	O
=	O
0	O
.	O
19	O
)	O
.	O
Mexican	O
-	O
American	O
participants	O
had	O
similar	O
mean	O
total	O
cholesterol	O
levels	O
(	O
0	O
.	O
9	O
mg	O
/	O
dl	O
;	O
P	O
=	O
0	O
.	O
47	O
)	O
,	O
higher	O
triglyceride	O
levels	O
(	O
11	O
.	O
9	O
mg	O
/	O
dl	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
lower	O
HDL	O
-	O
C	O
levels	O
(	O
3	O
.	O
0	O
mg	O
/	O
dl	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
similar	O
LDL	O
-	O
C	O
levels	O
(	O
1	O
.	O
5	O
mg	O
/	O
dl	O
;	O
P	O
=	O
0	O
.	O
21	O
)	O
compared	O
with	O
white	O
participants	O
(	O
Table	O
1	O
)	O
.	O
Total	O
cholesterol	O
,	O
triglyceride	O
and	O
HDL	O
-	O
C	O
levels	O
in	O
females	O
aged	O
65	O
years	O
or	O
older	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
females	O
aged	O
less	O
than	O
65	O
years	O
,	O
while	O
the	O
opposite	O
trend	O
was	O
observed	O
in	O
males	O
except	O
HDL	O
-	O
C	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
in	O
the	O
population	O
aged	O
65	O
years	O
or	O
older	O
,	O
females	O
had	O
higher	O
cholesterol	O
,	O
triglyceride	O
,	O
HDL	O
-	O
C	O
and	O
LDL	O
-	O
C	O
levels	O
than	O
males	O
,	O
except	O
Mexican	O
-	O
American	O
participants	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
In	O
addition	O
,	O
the	O
triglyceride	O
levels	O
of	O
females	O
were	O
lower	O
than	O
those	O
of	O
males	O
in	O
the	O
population	O
aged	O
less	O
than	O
65	O
years	O
,	O
while	O
the	O
trend	O
was	O
the	O
opposite	O
for	O
LDL	O
-	O
C	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
.	O
1	O
;	O
Table	O
2	O
)	O
.	O
We	O
compared	O
mean	O
age	O
-	O
adjusted	O
and	O
sex	O
-	O
adjusted	O
blood	O
lipid	O
levels	O
between	O
smokers	O
and	O
nonsmokers	O
(	O
Table	O
3	O
)	O
.	O
Smokers	O
had	O
higher	O
overall	O
mean	O
total	O
cholesterol	O
,	O
triglycerides	O
,	O
and	O
LDL	O
-	O
C	O
levels	O
than	O
nonsmokers	O
(	O
P	O
=	O
0	O
.	O
01	O
,	O
P	O
<	O
0	O
.	O
001	O
,	O
P	O
=	O
0	O
.	O
005	O
,	O
respectively	O
)	O
.	O
However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
total	O
cholesterol	O
levels	O
among	O
ethnic	O
groups	O
whether	O
they	O
smoked	O
or	O
not	O
(	O
P	O
=	O
0	O
.	O
06	O
for	O
whites	O
,	O
P	O
=	O
0	O
.	O
32	O
for	O
blacks	O
,	O
and	O
P	O
=	O
0	O
.	O
17	O
for	O
Mexican	O
-	O
Americans	O
)	O
.	O
We	O
also	O
found	O
that	O
smokers	O
had	O
lower	O
overall	O
mean	O
HDL	O
-	O
C	O
levels	O
than	O
nonsmokers	O
,	O
which	O
was	O
consistent	O
in	O
white	O
participants	O
(	O
all	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
Smoking	O
had	O
the	O
greatest	O
effect	O
on	O
the	O
increase	O
in	O
triglyceride	O
levels	O
among	O
Mexican	O
-	O
Americans	O
(	O
17	O
.	O
2	O
mg	O
/	O
dL	O
)	O
,	O
the	O
smaller	O
effect	O
in	O
white	O
participants	O
(	O
14	O
.	O
7	O
mg	O
/	O
dL	O
)	O
,	O
and	O
the	O
smallest	O
effect	O
in	O
black	O
participants	O
(	O
12	O
.	O
8	O
mg	O
/	O
dL	O
)	O
.	O
Hypercholesterolemia	O
(	O
total	O
cholesterol	O
values	O
≥	O
240	O
mg	O
/	O
dl	O
)	O
and	O
hypertriglyceridemia	O
(	O
triglyceride	O
levels	O
≥	O
200	O
mg	O
/	O
dl	O
)	O
differed	O
by	O
sex	O
,	O
age	O
,	O
and	O
ethnic	O
group	O
(	O
Fig	O
.	O
2	O
;	O
Table	O
4	O
)	O
.	O

A	O
total	O
of	O
1	O
,	O
715	O
and	O
1	O
,	O
616	O
participants	O
had	O
hypercholesterolemia	O
and	O
hypertriglyceridemia	O
,	O
with	O
a	O
weighted	O
prevalence	O
of	O
11	O
.	O
5	O
%	O
(	O
95	O
%	O
CI	O
,	O
10	O
.	O
6	O
–	O
12	O
.	O
5	O
%	O
)	O
and	O
10	O
.	O
4	O
%	O
(	O
CI	O
,	O
9	O
.	O
4	O
–	O
11	O
.	O
4	O
%	O
)	O
,	O
representing	O
an	O
estimated	O
12	O
.	O
05	O
million	O
and	O
10	O
.	O
84	O
million	O
Americans	O
,	O
respectively	O
.	O
Hypercholesterolemia	O
and	O
hypertriglyceridemia	O
were	O
present	O
in	O
12	O
.	O
2	O
%	O
(	O
CI	O
,	O
11	O
.	O
3	O
–	O
13	O
.	O
1	O
%	O
)	O
and	O
10	O
.	O
9	O
%	O
(	O
CI	O
,	O
9	O
.	O
8	O
–	O
11	O
.	O
9	O
%	O
)	O
of	O
white	O
participants	O
,	O
9	O
.	O
4	O
%	O
(	O
CI	O
,	O
8	O
.	O
3	O
–	O
10	O
.	O
4	O
%	O
)	O
and	O
4	O
.	O
4	O
%	O
(	O
5	O
.	O
1	O
%	O
CI	O
,	O
3	O
.	O
7	O
%	O
)	O
of	O
black	O
participants	O
,	O
and	O
10	O
.	O
1	O
%	O
(	O
CI	O
,	O
8	O
.	O
5	O
–	O
11	O
.	O
7	O
%	O
)	O
and	O
13	O
.	O
2	O
%	O
(	O
CI	O
,	O
11	O
.	O
5	O
–	O
14	O
.	O
5	O
%	O
)	O
of	O
Mexican	O
-	O
American	O
participants	O
(	O
Table	O
4	O
)	O
.	O
Among	O
ethnic	O
groups	O
,	O
males	O
were	O
more	O
likely	O
to	O
have	O
hypertriglyceridemia	O
:	O
white	O
males	O
13	O
.	O
0	O
%	O
versus	O
white	O
females	O
8	O
.	O
9	O
%	O
,	O
black	O
males	O
6	O
.	O
9	O
%	O
versus	O
black	O
females	O
2	O
.	O
5	O
%	O
,	O
Mexicans	O
-	O
American	O
males	O
14	O
.	O
3	O
%	O
versus	O
Mexicans	O
-	O
American	O
females	O
9	O
.	O
2	O
%	O
.	O
Nevertheless	O
,	O
the	O
proportion	O
of	O
females	O
with	O
hypercholesterolemia	O
was	O
higher	O
than	O
that	O
of	O
males	O
.	O
In	O
every	O
age	O
and	O
sex	O
category	O
,	O
black	O
participants	O
were	O
less	O
likely	O
to	O
have	O
hypertriglyceridemia	O
than	O
white	O
participants	O
,	O
and	O
hypertriglyceridemia	O
was	O
more	O
common	O
among	O
Mexican	O
-	O
American	O
participants	O
than	O
among	O
white	O
participants	O
.	O
Multivariate	O
logistic	O
regression	O
analysis	O
was	O
performed	O
for	O
the	O
prevalence	O
of	O
hyperlipidemia	O
,	O
adjusted	O
for	O
sex	O
,	O
age	O
,	O
and	O
race	O
(	O
Table	O
4	O
)	O
.	O
Black	O
participants	O
were	O
less	O
likely	O
to	O
have	O
hypercholesterolemia	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
or	O
hypertriglyceridemia	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
than	O
white	O
participants	O
.	O

Mexican	O
-	O
Americans	O
had	O
no	O
significant	O
difference	O
in	O
the	O
prevalence	O
of	O
hypercholesterolemia	O
(	O
P	O
=	O
0	O
.	O
70	O
)	O
but	O
had	O
a	O
significantly	O
higher	O
prevalence	O
of	O
hypertriglyceridemia	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
than	O
white	O
participants	O
.	O
Males	O
had	O
less	O
hypercholesterolemia	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
but	O
more	O
hypertriglyceridemia	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
than	O
females	O
.	O
The	O
prevalence	O
of	O
hyperlipidemia	O
peaked	O
from	O
the	O
age	O
of	O
35	O
to	O
65	O
years	O
and	O
generally	O
decreased	O
after	O
the	O
age	O
of	O
65	O
years	O
.	O
In	O
independent	O
logistic	O
regression	O
analysis	O
adjusted	O
for	O
sex	O
,	O
age	O
,	O
and	O
race	O
,	O
smokers	O
had	O
significantly	O
higher	O
percentages	O
of	O
hypercholesterolemia	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
and	O
hypertriglyceridemia	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
than	O
nonsmokers	O
.	O
In	O
this	O
analysis	O
of	O
nationally	O
representative	O
data	O
,	O
the	O
mean	O
lipid	O
levels	O
and	O
prevalence	O
of	O
hyperlipidemia	O
were	O
different	O
among	O
sex	O
,	O
age	O
,	O
smoking	O
status	O
,	O
and	O
ethnic	O
group	O
.	O
The	O
mean	O
values	O
of	O
serum	O
total	O
cholesterol	O
and	O
triglycerides	O
in	O
black	O
participants	O
were	O
significantly	O
lower	O
than	O
those	O
in	O
white	O
participants	O
,	O
and	O
serum	O
HDL	O
-	O
C	O
was	O
higher	O
than	O
in	O
white	O
participants	O
.	O
Mexicans	O
-	O
American	O
participants	O
had	O
considerably	O
higher	O
average	O
serum	O
triglycerides	O
and	O
lower	O
serum	O
HDL	O
-	O
C	O
than	O
white	O
participants	O
.	O
Black	O
participants	O
had	O
a	O
notably	O
lower	O
prevalence	O
of	O
hypercholesterolemia	O
or	O
hypertriglyceridemia	O
than	O
white	O
participants	O
,	O
and	O
Mexican	O
-	O
American	O
participants	O
had	O
a	O
significantly	O
higher	O
prevalence	O
of	O
hypertriglyceridemia	O
than	O
white	O
participants	O
.	O
Similarly	O
,	O
a	O
CARDIA	O
study	O
of	O
long	O
-	O
term	O
trends	O
in	O
lipid	O
levels	O
in	O
whites	O
and	O
blacks	O
,	O
men	O
and	O
women	O
in	O
four	O
U	O
.	O
S	O
.	O
communities	O
followed	O
by	O
a	O
multifactorial	O
regression	O
stratified	O
by	O
race	O
and	O
sex	O
analysis	O
found	O
that	O
LHD	O
-	O
C	O
increased	O
with	O
age	O
,	O
except	O
for	O
black	O
women	O
who	O
consistently	O
maintained	O
lower	O
LHD	O
-	O
C	O
levels	O
,	O
while	O
triglycerides	O
showed	O
an	O
unfavorable	O
long	O
-	O
term	O
upward	O
trend	O
in	O
white	O
women	O
[	O
18	O
]	O
.	O

Studies	O
on	O
the	O
association	O
between	O
age	O
and	O
lipid	O
levels	O
are	O
still	O
controversial	O
,	O
for	O
example	O
,	O
in	O
Spain	O
,	O
France	O
,	O
Finland	O
,	O
and	O
Australia	O
,	O
showing	O
a	O
decreasing	O
trend	O
in	O
total	O
cholesterol	O
and	O
/	O
or	O
LHD	O
-	O
C	O
with	O
increasing	O
age	O
and	O
use	O
of	O
lipid	O
-	O
lowering	O
drugs	O
[	O
19	O
–	O
22	O
]	O
.	O
However	O
,	O
investigations	O
in	O
countries	O
such	O
as	O
Japan	O
and	O
India	O
have	O
shown	O
an	O
increasing	O
trend	O
in	O
age	O
-	O
adjusted	O
mean	O
total	O
cholesterol	O
and	O
triglycerides	O
over	O
the	O
same	O
period	O
,	O
despite	O
an	O
increase	O
in	O
the	O
use	O
of	O
lipid	O
-	O
lowering	O
drugs	O
[	O
23	O
,	O
24	O
]	O
.	O
In	O
our	O
study	O
,	O
females	O
had	O
higher	O
cholesterol	O
and	O
triglyceride	O
levels	O
than	O
males	O
in	O
the	O
population	O
aged	O
65	O
years	O
and	O
older	O
,	O
regardless	O
of	O
other	O
factors	O
.	O
Compared	O
to	O
females	O
,	O
males	O
had	O
less	O
hypercholesterolemia	O
but	O
more	O
hypertriglyceridemia	O
,	O
with	O
this	O
difference	O
using	O
age	O
65	O
as	O
the	O
cutoff	O
.	O
In	O
addition	O
,	O
smokers	O
had	O
higher	O
total	O
cholesterol	O
,	O
triglyceride	O
,	O
and	O
LDL	O
-	O
C	O
levels	O
and	O
lower	O
HDL	O
-	O
C	O
levels	O
than	O
nonsmokers	O
.	O
The	O
prevalence	O
of	O
hypercholesterolemia	O
and	O
hypertriglyceridemia	O
was	O
significantly	O
higher	O
in	O
smokers	O
than	O
in	O
nonsmokers	O
.	O
Among	O
them	O
,	O
smoking	O
had	O
the	O
greatest	O
effect	O
on	O
elevated	O
triglyceride	O
levels	O
in	O
Mexican	O
-	O
American	O
participants	O
,	O
with	O
a	O
smaller	O
effect	O
in	O
white	O
participants	O
and	O
the	O
least	O
effect	O
in	O
black	O
participants	O
.	O
Many	O
projects	O
have	O
researched	O
the	O
incidence	O
and	O
prevalence	O
of	O
hyperlipidemia	O
,	O
which	O
is	O
associated	O
with	O
many	O
metabolic	O
disorders	O
in	O
the	O
clinic	O
.	O
Sparkar	O
et	O
al	O
.	O
suggested	O
that	O
hyperlipidemia	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
nonalcoholic	O
fatty	O
liver	O
disease	O
in	O
blacks	O
and	O
whites	O
,	O
affecting	O
black	O
adults	O
in	O
particular	O
[	O
25	O
]	O
.	O
Among	O
women	O
with	O
early	O
breast	O
cancer	O
,	O
hyperlipidemia	O
was	O
more	O
prevalent	O
in	O
black	O
women	O
than	O
in	O
white	O
women	O
(	O
28	O
%	O
versus	O
18	O
%	O
;	O
P	O
=	O
0	O
.	O
02	O
)	O
[	O
26	O
]	O
.	O
However	O
,	O
a	O
national	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
study	I-methodology
in	O
South	O
Africa	O
showed	O
that	O
black	O
African	O
men	O
(	O
0	O
.	O
64	O
,	O
0	O
.	O
49	O
–	O
0	O
.	O
84	O
)	O
and	O
women	O
(	O
0	O
.	O
52	O
,	O
0	O
.	O
43	O
–	O
0	O
.	O
62	O
)	O
had	O
significantly	O
lower	O
odds	O
of	O
hypercholesterolemia	O
than	O
white	O
men	O
and	O
women	O
,	O
respectively	O
[	O
27	O
]	O
.	O

Similarly	O
,	O
hypercholesterolemia	O
was	O
significantly	O
higher	O
in	O
white	O
patients	O
with	O
non	O
-	O
ST	O
-	O
segment	O
elevation	O
myocardial	O
infarction	O
than	O
in	O
patients	O
of	O
color	O
(	O
49	O
%	O
versus	O
34	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
including	O
black	O
,	O
Asian	O
,	O
and	O
ethnic	O
minority	O
patients	O
[	O
28	O
]	O
.	O
In	O
addition	O
,	O
among	O
South	O
African	O
children	O
and	O
adolescents	O
,	O
other	O
ethnic	O
groups	O
were	O
more	O
likely	O
to	O
have	O
hypertriglyceridemia	O
(	O
1	O
.	O
94	O
,	O
0	O
.	O
99	O
–	O
3	O
.	O
78	O
)	O
and	O
low	O
HDL	O
-	O
C	O
(	O
3	O
.	O
65	O
,	O
2	O
.	O
33	O
–	O
5	O
.	O
72	O
)	O
than	O
whites	O
and	O
blacks	O
[	O
29	O
]	O
.	O
In	O
another	O
study	O
,	O
the	O
prevalence	O
of	O
hypertriglyceridemia	O
was	O
found	O
to	O
be	O
significantly	O
lower	O
in	O
non	O
-	O
Hispanic	O
black	O
women	O
than	O
in	O
non	O
-	O
Hispanic	O
whites	O
and	O
Hispanics	O
(	O
5	O
.	O
1	O
versus	O
28	O
.	O
3	O
versus	O
30	O
.	O
5	O
%	O
,	O
P	O
<	O
0	O
.	O
01	O
,	O
respectively	O
)	O
[	O
30	O
]	O
.	O
The	O
findings	O
of	O
the	O
current	O
studies	O
are	O
contradictory	O
,	O
and	O
there	O
is	O
not	O
a	O
relatively	O
consistent	O
conclusion	O
.	O
Moreover	O
,	O
the	O
current	O
studies	O
are	O
limited	O
to	O
a	O
specific	O
population	O
,	O
and	O
there	O
is	O
no	O
analysis	O
of	O
racial	O
differences	O
in	O
blood	O
lipids	O
in	O
the	O
general	O
population	O
.	O
However	O
,	O
one	O
thing	O
is	O
certain	O
is	O
that	O
there	O
are	O
differences	O
in	O
the	O
distribution	O
of	O
lipid	O
levels	O
in	O
different	O
subpopulations	O
.	O
Our	O
study	O
suggests	O
that	O
lipid	O
levels	O
vary	O
by	O
race	O
,	O
sex	O
,	O
age	O
,	O
smoking	O
,	O
etc	O
.	O
In	O
general	O
,	O
blacks	O
have	O
significantly	O
lower	O
lipid	O
levels	O
than	O
other	O
populations	O
,	O
and	O
smokers	O
have	O
significantly	O
higher	O
lipids	O
than	O
nonsmokers	O
.	O
In	O
addition	O
,	O
age	O
also	O
affects	O
lipid	O
levels	O
,	O
especially	O
hormonal	O
changes	O
in	O
women	O
after	O
menopause	O
.	O
Therefore	O
,	O
the	O
diagnosis	O
and	O
treatment	O
of	O
hyperlipidemia	O
should	O
be	O
done	O
concerning	O
the	O
lipid	O
levels	O
of	O
subpopulations	O
,	O
not	O
the	O
general	O
population	O
.	O
Our	O
study	O
is	O
the	O
first	O
to	O
describe	O
the	O
distribution	O
of	O
blood	O
lipids	O
across	O
ethnic	O
,	O
gender	O
,	O
and	O
age	O
groups	O
.	O
Besides	O
,	O
the	O
prevalence	O
of	O
hypercholesteremia	O
and	O
hypertriglyceridemia	O
across	O
different	O
ethnic	O
,	O
gender	O
,	O
and	O
age	O
were	O
also	O
explored	O
.	O
However	O
,	O
there	O
were	O
several	O
limitations	O
about	O
this	O
study	O
.	O
Our	O
study	O
did	O
not	O
include	O
diet	O
and	O
medication	O
use	O
in	O
the	O
comparative	O
analysis	O
,	O
and	O
they	O
may	O
have	O
influenced	O
the	O
lipid	O
and	O
study	O
results	O
.	O

In	O
addition	O
,	O
the	O
data	O
in	O
this	O
study	O
were	O
surveyed	O
for	O
the	O
US	O
population	O
,	O
and	O
geographic	O
characteristics	O
such	O
as	O
climate	O
and	O
economy	O
may	O
have	O
affected	O
the	O
results	O
accordingly	O
,	O
so	O
we	O
may	O
consider	O
adding	O
relevant	O
lipid	O
data	O
from	O
other	O
geographic	O
populations	O
in	O
the	O
future	O
to	O
improve	O
the	O
accuracy	O
of	O
the	O
data	O
analysis	O
.	O
Distribution	O
of	O
population	O
lipid	O
levels	O
and	O
prevalence	O
of	O
hyperlipidemia	O
based	O
on	O
differences	O
in	O
age	O
,	O
sex	O
,	O
race	O
,	O
and	O
smoking	O
status	O
.	O
Therefore	O
,	O
our	O
analysis	O
suggested	O
a	O
new	O
view	O
that	O
the	O
diagnosis	O
and	O
treatment	O
of	O
hyperlipidemia	O
should	O
be	O
more	O
accurate	O
by	O
referring	O
to	O
the	O
lipid	O
levels	O
of	O
subpopulations	O
rather	O
than	O
those	O
of	O
the	O
general	O
population	O
.	O
None	O
.	O
Publisher	O
’	O
s	O
noteSpringer	O
Nature	O
remains	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O
Jun	O
Qian	O
,	O
Zhongpei	O
Chen	O
and	O
Xuebo	O
Liu	O
contributed	O
equally	O
and	O
share	O
the	O
corresponding	O
author	O
.	O
Conceptualization	O
,	O
Jun	O
Qian	O
and	O
Zhenhan	O
Li	O
;	O
methodology	O
,	O
Guoqi	O
Zhu	O
;	O
software	O
,	O
Jun	O
Qian	O
.	O
;	O
validation	O
,	O
Zhongpei	O
Chen	O
and	O
Xuebo	O
Liu	O
;	O
data	O
curation	O
,	O
Guo	O
Chen	O
and	O
Mei	O
Luo	O
;	O
writing	O
—	O
original	O
draft	O
preparation	O
,	O
Zhenhan	O
Li	O
.	O
;	O
writing	O
—	O
review	O
and	O
editing	O
,	O
Zhenhan	O
Li	O
and	O
Jun	O
Qian	O
;	O
supervision	O
,	O
Zhongpei	O
Chen	O
and	O
Xuebo	O
Liu	O
.	O
;	O
project	O
administration	O
,	O
Jun	O
Qian	O
.	O
All	O
authors	O
have	O
read	O
and	O
agreed	O
to	O
the	O
published	O
version	O
of	O
the	O
manuscript	O
.	O
The	O
data	O
that	O
support	O
the	O
findings	O
of	O
this	O
study	O
are	O
openly	O
available	O
in	O
[	O
NHANES	O
]	O
at	O
[	O
https	O
:	O
/	O
/	O
www	O
.	O
cdc	O
.	O
gov	O
/	O
nchs	O
/	O
nhanes	O
/	O
index	O
.	O
htm	O
]	O
.	O
The	O
NHANES	O
protocol	O
was	O
approved	O
by	O
the	O
NCHS	O
Research	O
Ethics	O
Review	O
Board	O
,	O
and	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
participants	O
.	O
Not	O
applicable	O
.	O
The	O
authors	O
declare	O
that	O
the	O
research	O
was	O
conducted	O
in	O
the	O
absence	O
of	O
any	O
commercial	O
or	O
financial	O
relationships	O
that	O
could	O
be	O
construed	O
as	O
a	O
potential	O
conflict	O
of	O
interest	O
.	O

The	O
plasma	O
lipidome	O
of	O
the	O
Quaker	O
parrot	O
(	O
Myiopsitta	O
monachus	O
)	O
Dyslipidemias	O
and	O
lipid	O
-	O
accumulation	O
disorders	O
are	O
common	O
in	O
captive	O
parrots	O
,	O
in	O
particular	O
in	O
Quaker	O
parrots	O
.	O
Currently	O
available	O
diagnostic	O
tests	O
only	O
measure	O
a	O
fraction	O
of	O
blood	O
lipids	O
and	O
have	O
overall	O
problematic	O
cross	O
-	O
species	O
applicability	O
.	O
Comprehensively	O
analyzing	O
lipids	O
in	O
the	O
plasma	O
of	O
parrots	O
is	O
the	O
first	O
step	O
to	O
better	O
understand	O
their	O
lipid	O
metabolism	O
in	O
health	O
and	O
disease	O
,	O
as	O
well	O
as	O
to	O
explore	O
new	O
lipid	O
biomarkers	O
.	O
The	O
plasma	O
lipidome	O
of	O
12	O
Quaker	O
parrots	O
was	O
investigated	O
using	O
UHPLC	O
-	O
MS	O
/	O
MS	O
with	O
both	O
targeted	O
and	O
untargeted	O
methods	O
.	O
Targeted	O
methods	O
on	O
6	O
replicates	O
measured	O
432	O
lipids	O
comprised	O
of	O
sterol	O
,	O
cholesterol	O
ester	O
,	O
bile	O
acid	O
,	O
fatty	O
acid	O
,	O
acylcarnitine	O
,	O
glycerolipid	O
,	O
glycerophospholipid	O
,	O
and	O
sphingolipid	O
panels	O
.	O
For	O
untargeted	O
lipidomics	O
,	O
precursor	O
ion	O
mass	O
-	O
to	O
-	O
charge	O
ratios	O
were	O
matched	O
to	O
corresponding	O
lipids	O
using	O
the	O
LIPIDMAPS	O
structure	O
database	O
and	O
LipidBlast	O
at	O
the	O
sum	O
composition	O
or	O
acyl	O
species	O
level	O
of	O
information	O
.	O
Sterol	O
lipids	O
and	O
glycerophospholipids	O
constituted	O
the	O
majority	O
of	O
plasma	O
lipids	O
on	O
a	O
molar	O
basis	O
.	O
The	O
most	O
common	O
lipids	O
detected	O
with	O
the	O
targeted	O
methods	O
included	O
free	O
cholesterol	O
,	O
CE	O
(	O
18	O
:	O
2	O
)	O
,	O
CE	O
(	O
20	O
:	O
4	O
)	O
for	O
sterol	O
lipids	O
;	O
PC	O
(	O
36	O
:	O
2	O
)	O
,	O
PC	O
(	O
34	O
:	O
2	O
)	O
,	O
PC	O
(	O
34	O
:	O
1	O
)	O
for	O
glycerophospholipids	O
;	O
TG	O
(	O
52	O
:	O
3	O
)	O
,	O
TG	O
(	O
54	O
:	O
4	O
)	O
,	O
TG	O
(	O
54	O
:	O
5	O
)	O
,	O
TG	O
(	O
52	O
:	O
2	O
)	O
for	O
glycerolipids	O
;	O
SM	O
(	O
d18	O
:	O
1	O
/	O
16	O
:	O
0	O
)	O
for	O
sphingolipids	O
;	O
and	O
palmitic	O
acid	O
for	O
fatty	O
acyls	O
.	O
Over	O
a	O
thousand	O
different	O
lipid	O
species	O
were	O
detected	O
by	O
untargeted	O
lipidomics	O
.	O
Sex	O
differences	O
in	O
the	O
plasma	O
lipidome	O
were	O
observed	O
using	O
heatmaps	O
,	O
principal	O
component	O
analysis	O
,	O
and	O
discriminant	O
analysis	O
.	O

This	O
report	O
presents	O
the	O
first	O
comprehensive	O
database	O
of	O
plasma	O
lipid	O
species	O
in	O
psittacine	O
birds	O
and	O
paves	O
the	O
way	O
for	O
further	O
research	O
into	O
blood	O
lipid	O
diagnostics	O
and	O
the	O
impact	O
of	O
diet	O
,	O
diseases	O
,	O
and	O
drugs	O
on	O
the	O
parrot	O
plasma	O
lipidome	O
.	O
Dyslipidemias	O
and	O
lipid	O
-	O
accumulation	O
disorders	O
,	O
such	O
as	O
atherosclerosis	O
,	O
hepatic	O
lipidosis	O
,	O
fatty	O
tumors	O
and	O
obesity	O
,	O
are	O
extremely	O
common	O
in	O
captive	O
Psittaciformes	O
[	O
1	O
–	O
4	O
]	O
.	O
The	O
prevalence	O
of	O
severe	O
atherosclerotic	O
lesions	O
in	O
the	O
general	O
parrot	O
population	O
is	O
approximatively	O
7	O
%	O
,	O
but	O
can	O
be	O
as	O
high	O
as	O
50	O
%	O
in	O
older	O
parrots	O
[	O
3	O
]	O
.	O
Hepatic	O
lipidosis	O
is	O
also	O
prevalent	O
and	O
one	O
of	O
the	O
major	O
liver	O
diseases	O
in	O
parrots	O
with	O
an	O
estimated	O
overall	O
prevalence	O
of	O
6	O
%	O
,	O
but	O
susceptible	O
species	O
such	O
as	O
Quaker	O
parrots	O
have	O
an	O
estimated	O
prevalence	O
of	O
20	O
%	O
[	O
2	O
]	O
.	O
The	O
prevalence	O
of	O
female	O
parrot	O
reproductive	O
disorders	O
associated	O
with	O
upregulated	O
vitellogenesis	O
(	O
hepatic	O
lipid	O
synthesis	O
and	O
lipid	O
transport	O
to	O
eggs	O
)	O
is	O
unknown	O
,	O
but	O
is	O
suspected	O
to	O
be	O
enormous	O
based	O
on	O
clinical	O
experience	O
.	O
Taken	O
together	O
,	O
lipid	O
-	O
related	O
disorders	O
are	O
likely	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
non	O
-	O
infectious	O
diseases	O
in	O
captive	O
parrots	O
.	O
However	O
,	O
despite	O
the	O
frequency	O
of	O
these	O
diseases	O
,	O
there	O
is	O
a	O
vast	O
gap	O
of	O
knowledge	O
in	O
regards	O
to	O
the	O
pathophysiology	O
of	O
most	O
of	O
these	O
diseases	O
as	O
well	O
as	O
diagnostic	O
tests	O
,	O
biomarkers	O
,	O
treatment	O
,	O
and	O
therapeutic	O
targets	O
.	O
As	O
dyslipidemic	O
changes	O
are	O
frequently	O
concurrent	O
and	O
comorbid	O
to	O
lipid	O
-	O
accumulation	O
disorders	O
as	O
well	O
as	O
important	O
risk	O
factors	O
,	O
blood	O
lipid	O
analysis	O
can	O
be	O
used	O
for	O
the	O
diagnosis	O
,	O
screening	O
,	O
and	O
monitoring	O
of	O
a	O
variety	O
of	O
diseases	O
associated	O
with	O
lipid	O
dysmetabolism	O
[	O
1	O
,	O
5	O
–	O
7	O
]	O
.	O
Lipids	O
are	O
the	O
main	O
biomolecular	O
constituents	O
of	O
plasma	O
[	O
8	O
]	O
and	O
are	O
transported	O
in	O
the	O
form	O
of	O
macromolecular	O
aggregates	O
of	O
mixed	O
lipid	O
species	O
and	O
proteins	O
(	O
lipoproteins	O
)	O
.	O
Traditionally	O
,	O
dyslipidemias	O
in	O
mammals	O
have	O
been	O
understood	O
as	O
primarily	O
associated	O
with	O
elevated	O
total	O
cholesterol	O
,	O
triglycerides	O
and	O
changes	O
in	O
cholesterol	O
lipoprotein	O
fractions	O
[	O
9	O
,	O
10	O
]	O
.	O

While	O
psittacine	O
lipoproteins	O
have	O
been	O
measured	O
in	O
plasma	O
using	O
reference	O
methods	O
[	O
11	O
–	O
13	O
]	O
,	O
routine	O
laboratory	O
methods	O
have	O
not	O
been	O
validated	O
in	O
parrots	O
and	O
are	O
likely	O
to	O
perform	O
poorly	O
due	O
to	O
the	O
marked	O
differences	O
between	O
avian	O
and	O
mammalian	O
lipoprotein	O
structure	O
and	O
metabolism	O
[	O
14	O
,	O
15	O
]	O
.	O
For	O
these	O
reasons	O
,	O
lipoprotein	O
testing	O
has	O
not	O
been	O
widely	O
applied	O
to	O
parrots	O
with	O
dyslipidemia	O
or	O
lipid	O
-	O
related	O
disorders	O
and	O
the	O
lipoprotein	O
profiles	O
of	O
psittacine	O
spontaneously	O
-	O
occurring	O
dyslipidemia	O
have	O
not	O
been	O
characterized	O
.	O
In	O
order	O
to	O
elucidate	O
the	O
pathophysiology	O
of	O
the	O
many	O
common	O
lipid	O
-	O
related	O
diseases	O
in	O
parrots	O
as	O
well	O
as	O
to	O
provide	O
new	O
tools	O
for	O
biomarkers	O
discovery	O
,	O
a	O
more	O
comprehensive	O
analysis	O
of	O
their	O
lipid	O
metabolism	O
in	O
health	O
and	O
disease	O
is	O
required	O
.	O
Comprehensive	O
lipid	O
analysis	O
by	O
mass	O
spectrometry	O
is	O
known	O
as	O
lipidomics	O
.	O
This	O
approach	O
is	O
revolutionizing	O
the	O
way	O
lipid	O
metabolic	O
disorders	O
are	O
investigated	O
as	O
a	O
results	O
of	O
the	O
vast	O
amount	O
of	O
data	O
generated	O
when	O
blood	O
lipids	O
are	O
analyzed	O
using	O
lipidomics	O
[	O
16	O
–	O
20	O
]	O
.	O
Further	O
,	O
in	O
the	O
context	O
of	O
dyslipidemia	O
,	O
specific	O
lipid	O
species	O
of	O
complex	O
lipids	O
may	O
be	O
better	O
targets	O
or	O
biomarkers	O
than	O
crude	O
measurements	O
of	O
a	O
single	O
lipid	O
molecule	O
such	O
as	O
cholesterol	O
(	O
the	O
cholesterol	O
test	O
measures	O
both	O
free	O
cholesterol	O
and	O
the	O
cholesterol	O
moiety	O
of	O
a	O
variety	O
of	O
cholesteryl	O
esters	O
)	O
and	O
triglycerides	O
(	O
the	O
triglyceride	O
test	O
only	O
measures	O
the	O
glycerol	O
backbone	O
of	O
the	O
molecule	O
)	O
.	O
Lipidomics	O
allows	O
for	O
the	O
measurement	O
of	O
each	O
lipid	O
in	O
their	O
native	O
biological	O
form	O
.	O
Therefore	O
,	O
thousands	O
of	O
species	O
of	O
fatty	O
acyls	O
,	O
triglycerides	O
,	O
phospholipids	O
,	O
sphingolipids	O
,	O
and	O
cholesteryl	O
esters	O
with	O
a	O
variety	O
of	O
saturated	O
and	O
unsaturated	O
fatty	O
acid	O
chains	O
can	O
be	O
measured	O
in	O
plasma	O
.	O
In	O
humans	O
,	O
lipidomics	O
has	O
been	O
used	O
to	O
study	O
the	O
lipidome	O
[	O
8	O
,	O
21	O
]	O
,	O
dyslipidemia	O
[	O
22	O
,	O
23	O
]	O
,	O
various	O
clinical	O
lipid	O
-	O
accumulation	O
disorders	O
[	O
17	O
,	O
19	O
,	O
20	O
]	O
,	O
and	O
statin	O
pharmacology	O
[	O
24	O
,	O
25	O
]	O
.	O

However	O
,	O
this	O
powerful	O
analytical	O
technique	O
has	O
not	O
been	O
applied	O
to	O
psittacine	O
birds	O
or	O
used	O
in	O
avian	O
health	O
research	O
as	O
far	O
as	O
the	O
authors	O
know	O
.	O
Plasma	O
lipidomic	O
profiling	O
in	O
psittacine	O
birds	O
may	O
not	O
only	O
provide	O
a	O
clearer	O
picture	O
of	O
ongoing	O
lipid	O
abnormalities	O
,	O
but	O
also	O
lead	O
to	O
innovation	O
in	O
lipid	O
biomarkers	O
and	O
therapeutic	O
targets	O
beyond	O
cholesterol	O
for	O
a	O
variety	O
of	O
lipid	O
-	O
related	O
diseases	O
.	O
The	O
first	O
step	O
in	O
applying	O
clinical	O
lipidomics	O
in	O
psittacine	O
medicine	O
is	O
to	O
report	O
the	O
plasma	O
lipidome	O
as	O
blood	O
is	O
the	O
most	O
accessible	O
tissue	O
and	O
plasma	O
biomarkers	O
are	O
the	O
most	O
practical	O
to	O
develop	O
.	O
Knowing	O
the	O
normal	O
lipidome	O
may	O
also	O
allow	O
to	O
detect	O
specific	O
lipidomic	O
signatures	O
of	O
lipid	O
-	O
related	O
diseases	O
in	O
birds	O
.	O
The	O
Quaker	O
parrot	O
(	O
Myiopsitta	O
monachus	O
)	O
has	O
been	O
used	O
as	O
an	O
experimental	O
model	O
of	O
lipid	O
disorders	O
in	O
Psittaciformes	O
for	O
dyslipidemia	O
and	O
atherosclerosis	O
[	O
11	O
,	O
12	O
,	O
26	O
,	O
27	O
]	O
.	O
Quaker	O
parrots	O
are	O
also	O
extremely	O
prone	O
to	O
spontaneously	O
-	O
occurring	O
dyslipidemia	O
and	O
lipid	O
-	O
accumulation	O
disorders	O
,	O
more	O
than	O
other	O
psittacine	O
species	O
[	O
2	O
,	O
4	O
]	O
.	O
It	O
is	O
therefore	O
logical	O
to	O
first	O
use	O
this	O
species	O
to	O
report	O
the	O
psittacine	O
plasma	O
lipidome	O
.	O
The	O
objective	O
of	O
this	O
observational	B-methodology
study	I-methodology
was	O
to	O
comprehensively	O
report	O
the	O
plasma	O
lipidome	O
of	O
young	O
male	O
and	O
female	O
healthy	O
Quaker	O
parrots	O
using	O
a	O
variety	O
of	O
quantitative	O
(	O
targeted	O
lipidomics	O
)	O
and	O
semi	O
-	O
quantitative	O
(	O
untargeted	O
lipidomics	O
)	O
methods	O
.	O
Twelve	O
approximately	O
1	O
-	O
year	O
-	O
old	O
Quaker	O
parrots	O
(	O
Myiopsitta	O
monachus	O
)	O
were	O
used	O
for	O
this	O
study	O
.	O
The	O
parrots	O
were	O
captive	O
-	O
bred	O
and	O
hand	O
raised	O
at	O
the	O
Hagen	O
Avicultural	O
Research	O
Institute	O
(	O
QC	O
,	O
Canada	O
)	O
.	O
The	O
parrots	O
included	O
6	O
males	O
and	O
6	O
females	O
;	O
sex	O
was	O
confirmed	O
by	O
DNA	O
testing	O
on	O
blood	O
.	O
The	O
parrots	O
were	O
housed	O
together	O
at	O
the	O
University	O
of	O
Guelph	O
–	O
Central	O
Animal	O
Facility	O
in	O
a	O
large	O
stainless	O
-	O
steel	O
aviary	O
with	O
food	O
and	O
water	O
provided	O
ad	O
libitum	O
,	O
and	O
fed	O
a	O
pelletized	O
diet	O
(	O
Tropican	O
2mm	O
pellet	O
,	O
Hagen	O
Inc	O
.	O
,	O
Baie	O
d	O
’	O
Urfee	O
,	O
QC	O
,	O
Canada	O
)	O
.	O

They	O
were	O
considered	O
healthy	O
and	O
free	O
of	O
dyslipidemia	O
based	O
on	O
a	O
recent	O
physical	O
examination	O
,	O
CBC	O
,	O
plasma	O
biochemistry	O
,	O
lipoprotein	O
panel	O
,	O
and	O
avian	O
chlamydiosis	O
PCR	O
testing	O
.	O
Animal	O
utilization	O
protocols	O
(	O
AUP	O
)	O
were	O
approved	O
for	O
this	O
research	O
by	O
the	O
University	O
of	O
Guelph	O
—	O
Animal	O
Care	O
Committee	O
(	O
AUP	O
#	O
3875	O
and	O
AUP	O
#	O
4035	O
)	O
.	O
The	O
parrots	O
were	O
fasted	O
overnight	O
prior	O
to	O
sample	O
collection	O
.	O
Blood	O
was	O
collected	O
and	O
stored	O
according	O
to	O
guidelines	B-methodology
for	O
plasma	O
lipidomics	O
[	O
28	O
]	O
.	O
To	O
minimize	O
stress	O
and	O
exertion	O
,	O
birds	O
were	O
captured	O
in	O
the	O
dark	O
and	O
blood	O
was	O
collected	O
within	O
2	O
–	O
5	O
minutes	O
following	O
capture	O
.	O
A	O
1	O
mL	O
blood	O
sample	O
was	O
collected	O
from	O
each	O
parrot	O
from	O
the	O
right	O
jugular	O
vein	O
under	O
manual	O
restraint	O
using	O
a	O
3mL	O
syringe	O
connected	O
to	O
a	O
26g	O
needle	O
.	O
Blood	O
was	O
transferred	O
to	O
a	O
heparinized	O
tube	O
without	O
a	O
serum	O
separator	O
(	O
BD	O
Microtainer	O
,	O
Becton	O
and	O
Dickinson	O
,	O
Mississauga	O
,	O
ON	O
,	O
Canada	O
)	O
.	O
Tubes	O
were	O
inverted	O
a	O
minimum	O
of	O
5	O
times	O
and	O
placed	O
on	O
ice	O
.	O
Blood	O
was	O
centrifuged	O
for	O
10	O
minutes	O
at	O
1500g	O
and	O
approximately	O
0	O
.	O
5	O
mL	O
plasma	O
harvested	O
and	O
aliquoted	O
in	O
cryovials	O
.	O
The	O
plasma	O
was	O
stored	O
at	O
-	O
80C	O
until	O
shipping	O
on	O
dry	O
ice	O
to	O
the	O
various	O
analytical	O
laboratories	O
.	O
All	O
samples	O
were	O
analyzed	O
by	O
The	O
Metabolomics	O
Innovation	O
Centre	O
(	O
co	O
-	O
located	O
at	O
the	O
University	O
of	O
Alberta	O
and	O
University	O
of	O
Victoria	O
,	O
Canada	O
)	O
.	O
Six	O
samples	O
(	O
3	O
females	O
,	O
3	O
males	O
)	O
were	O
submitted	O
to	O
the	O
University	O
of	O
Victoria	O
Genome	O
BC	O
Proteomics	O
Centre	O
for	O
untargeted	O
lipidomics	O
and	O
targeted	O
panels	O
for	O
bile	O
acids	O
,	O
sterols	O
,	O
non	O
-	O
esterified	O
fatty	O
acids	O
,	O
acyl	O
carnitines	O
,	O
and	O
sphingolipids	O
.	O
Another	O
six	O
samples	O
(	O
3	O
females	O
,	O
3	O
males	O
)	O
were	O
submitted	O
to	O
the	O
University	O
of	O
Alberta	O
for	O
the	O
targeted	O
panels	O
using	O
a	O
metabolomics	O
kit	O
for	O
glycerolipids	O
,	O
glycerophosphocholines	O
and	O
cholesteryl	O
esters	O
at	O
the	O
University	O
of	O
Alberta	O
.	O
A	O
100g	O
sample	O
of	O
the	O
pelleted	O
parrot	O
diet	O
was	O
submitted	O
to	O
an	O
independent	O
laboratory	O
(	O
SGS	O
Canada	O
Inc	O
.	O

Agriculture	O
and	O
Food	O
,	O
Mississauga	O
,	O
ON	O
,	O
Canada	O
)	O
for	O
nutritional	O
analysis	O
.	O
Total	O
fat	O
was	O
analyzed	O
by	O
an	O
acid	O
hydrolysis	O
method	O
(	O
SGS	O
-	O
Canada	O
,	O
test	O
QAM	O
-	O
105	O
)	O
and	O
fatty	O
acid	O
composition	O
was	O
obtained	O
using	O
gas	O
chromatographic	O
methods	O
[	O
Association	O
of	O
Official	O
Analytical	O
Collaboration	O
(	O
AOAC	O
)	O
International	O
991	O
.	O
39	O
,	O
AOAC	O
963	O
.	O
2	O
]	O
.	O
All	O
lipid	O
species	O
were	O
analyzed	O
at	O
the	O
brutto	O
(	O
sum	O
composition	O
)	O
or	O
medio	O
(	O
fatty	O
acyl	O
chain	O
)	O
level	O
of	O
identification	O
[	O
29	O
]	O
.	O
For	O
analysis	O
of	O
bile	O
acids	O
,	O
sterols	O
,	O
steroids	O
,	O
fatty	O
acids	O
,	O
carnitines	O
,	O
and	O
sphingolipids	O
,	O
an	O
Agilent	O
1290	O
UHPLC	O
system	O
coupled	O
to	O
an	O
Agilent	O
6495	O
QQQ	O
(	O
Agilent	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
or	O
a	O
Sciex	O
4000	O
QTRAP	O
(	O
Sciex	O
,	O
Framingham	O
,	O
MA	O
,	O
USA	O
)	O
mass	O
spectrometer	O
equipped	O
with	O
an	O
electrospray	O
ion	O
(	O
ESI	O
)	O
source	O
was	O
used	O
.	O
The	O
MS	O
instruments	O
were	O
operated	O
in	O
multiple	O
-	O
reaction	O
monitoring	O
(	O
MRM	O
)	O
with	O
negative	O
-	O
ion	O
(	O
-	O
)	O
detection	O
for	O
analysis	O
of	O
fatty	O
acids	O
and	O
bile	O
acids	O
,	O
and	O
with	O
positive	O
-	O
ion	O
(	O
+	O
)	O
detection	O
for	O
analysis	O
of	O
carnitines	O
,	O
sphingolipids	O
,	O
sterols	O
and	O
steroids	O
.	O
Bile	O
acids	O
was	O
quantitated	O
by	O
UPLC	O
-	O
MRM	O
/	O
MS	O
on	O
an	O
Agilent	O
1290	O
UHPLC	O
system	O
coupled	O
to	O
an	O
Agilent	O
6495	O
QQQ	O
mass	O
spectrometer	O
(	O
Agilent	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
,	O
according	O
to	O
a	O
previously	O
published	O
procedure	O
by	O
the	O
University	O
of	O
Victoria	O
Genome	O
BC	O
Proteomics	O
Centre	O
[	O
30	O
,	O
31	O
]	O
.	O
A	O
mixed	O
standard	O
solution	O
containing	O
reference	O
substances	O
of	O
62	O
bile	O
acids	O
,	O
which	O
were	O
detailed	O
in	O
the	O
same	O
studies	O
[	O
30	O
,	O
31	O
]	O
,	O
was	O
prepared	O
in	O
50	O
%	O
methanol	O
at	O
10	O
nmol	O
/	O
mL	O
for	O
each	O
compound	O
and	O
was	O
used	O
as	O
standard	O
solution	O
S1	O
.	O
This	O
solution	O
was	O
further	O
diluted	O
step	O
by	O
step	O
at	O
a	O
dilution	O
ratio	O
of	O
1	O
to	O
4	O
(	O
v	O
/	O
v	O
)	O
to	O
have	O
standard	O
solutions	O
of	O
S2	O
to	O
S10	O
.	O

Fifty	O
μL	O
of	O
S1	O
to	O
S10	O
was	O
mixed	O
with	O
50	O
μL	O
of	O
a	O
solution	O
containing	O
14	O
D	O
-	O
labeled	O
bile	O
acids	O
as	O
internal	O
standard	O
.	O
Twenty	O
μL	O
of	O
each	O
solution	O
was	O
injected	O
to	O
run	O
UPLC	O
-	O
(	O
-	O
)	O
ESI	O
-	O
MRM	O
/	O
MS	O
.	O
Linear	O
-	O
regression	O
calibration	O
curves	O
were	O
constructed	O
using	O
analyte	O
-	O
to	O
-	O
internal	O
standard	O
peak	O
area	O
ratios	O
(	O
As	O
/	O
Ai	O
)	O
versus	O
molar	O
concentrations	O
(	O
nmol	O
/	O
mL	O
)	O
of	O
each	O
bile	O
acid	O
.	O
For	O
the	O
bile	O
acids	O
without	O
isotope	O
-	O
labeled	O
analogues	O
as	O
internal	O
standard	O
,	O
glycodeoxycholic	O
acid	O
-	O
D4	O
was	O
used	O
as	O
a	O
common	O
internal	O
standard	O
.	O
For	O
sample	O
preparation	O
,	O
50	O
μL	O
of	O
plasma	O
was	O
mixed	O
with	O
50	O
μL	O
of	O
the	O
internal	O
standard	O
solution	O
and	O
400	O
μL	O
of	O
methanol	O
in	O
an	O
Eppendorf	O
tube	O
.	O
After	O
vortex	O
mixing	O
for	O
15	O
s	O
and	O
sonication	O
for	O
2	O
min	O
in	O
an	O
ice	O
-	O
water	O
bath	O
,	O
the	O
tube	O
was	O
centrifuged	O
at	O
15	O
,	O
000	O
rpm	O
for	O
15	O
min	O
in	O
an	O
Eppendorf	O
5420R	O
centrifuge	O
to	O
pellet	O
proteins	O
.	O
The	O
supernatant	O
was	O
taken	O
out	O
and	O
dried	O
in	O
a	O
nitrogen	O
evaporator	O
under	O
a	O
gentle	O
nitrogen	O
gas	O
flow	O
.	O
The	O
residue	O
was	O
dissolved	O
in	O
100	O
μL	O
of	O
50	O
%	O
methanol	O
.	O
After	O
centrifugal	O
clarification	O
,	O
20	O
μL	O
was	O
injected	O
for	O
detection	O
and	O
quantitation	O
of	O
bile	O
acids	O
by	O
UPLC	O
-	O
MRM	O
/	O
MS	O
.	O
Concentrations	O
of	O
bile	O
acids	O
in	O
each	O
sample	O
were	O
calculated	O
from	O
the	O
standard	O
curves	O
of	O
the	O
individual	O
analytes	O
.	O
A	O
mixed	O
standard	O
solution	O
containing	O
reference	O
substances	O
of	O
10	O
sterols	O
(	O
lanosterol	O
,	O
zymosterol	O
,	O
7	O
-	O
dehydrodesmosterol	O
,	O
desmosterol	O
,	O
dihydrolanosterol	O
,	O
zymostenol	O
,	O
lathosterol	O
,	O
7	O
-	O
dehydrocholesterol	O
,	O
dihydrolathosterol	O
and	O
cholesterol	O
)	O
which	O
were	O
obtained	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
Oakville	O
,	O
ON	O
,	O
Canada	O
)	O
or	O
Steraloids	O
Inc	O
.	O
(	O
Newport	O
,	O
RI	O
,	O
USA	O
)	O
was	O
prepared	O
in	O
acetonitrile	O
at	O
10	O
nmol	O
/	O
mL	O
for	O
each	O
compound	O
,	O
and	O
was	O
used	O
as	O
standard	O
solution	O
S1	O
.	O

This	O
solution	O
was	O
further	O
diluted	O
step	O
by	O
step	O
at	O
a	O
dilution	O
ratio	O
of	O
1	O
to	O
4	O
(	O
v	O
/	O
v	O
)	O
to	O
have	O
standard	O
solutions	O
of	O
S1	O
to	O
S10	O
.	O
Ten	O
μL	O
of	O
plasma	O
was	O
mixed	O
with	O
90	O
μL	O
of	O
methanol	O
.	O
After	O
vortex	O
mixing	O
for	O
15	O
s	O
and	O
sonication	O
for	O
2	O
min	O
in	O
an	O
ice	O
-	O
water	O
bath	O
,	O
the	O
tube	O
was	O
centrifuged	O
at	O
15	O
,	O
000	O
rpm	O
for	O
15	O
min	O
in	O
an	O
Eppendorf	O
5420R	O
centrifuge	O
.	O
The	O
supernatant	O
was	O
taken	O
out	O
and	O
dried	O
in	O
a	O
nitrogen	O
evaporator	O
under	O
a	O
gentle	O
nitrogen	O
gas	O
flow	O
.	O
50	O
μL	O
of	O
acetonitrile	O
was	O
added	O
to	O
resuspend	O
the	O
residue	O
.	O
Each	O
sample	O
solution	O
or	O
50	O
μL	O
of	O
each	O
standard	O
solution	O
,	O
was	O
mixed	O
with	O
20	O
μL	O
of	O
an	O
internal	O
standard	O
solution	O
containing	O
13C3	O
-	O
cholesterol	O
.	O
The	O
mixture	O
was	O
subjected	O
to	O
chemical	O
derivatization	O
with	O
20	O
mM	O
of	O
dansyl	O
chloride	O
in	O
the	O
presence	O
of	O
100	O
mM	O
4	O
-	O
(	O
dimethylamino	O
)	O
-	O
pyridine	O
(	O
DMAP	O
)	O
as	O
a	O
catalyst	O
at	O
50	O
°C	O
for	O
60	O
min	O
,	O
according	O
to	O
a	O
previously	O
published	O
procedure	O
with	O
necessary	O
modifications	O
[	O
32	O
]	O
.	O
After	O
derivatization	O
,	O
20	O
μL	O
of	O
each	O
resultant	O
solution	O
was	O
injected	O
to	O
run	O
UPLC	O
-	O
(	O
+	O
)	O
ESI	O
-	O
MRM	O
/	O
MS	O
on	O
a	O
C18	O
UPLC	O
column	O
(	O
2	O
.	O
1	O
x	O
50	O
mm	O
,	O
1	O
.	O
7	O
μm	O
)	O
with	O
0	O
.	O
1	O
%	O
formic	O
acid	O
and	O
isopropanol	O
/	O
acetonitrile	O
(	O
1	O
:	O
2	O
)	O
as	O
the	O
mobile	O
phase	O
for	O
binary	O
-	O
solvent	O
gradient	O
elution	O
,	O
at	O
a	O
flow	O
of	O
0	O
.	O
4	O
mL	O
/	O
min	O
and	O
60	O
°C	O
.	O
Linear	O
-	O
regression	O
calibration	O
curves	O
were	O
constructed	O
using	O
analyte	O
-	O
to	O
-	O
internal	O
standard	O
peak	O
area	O
ratios	O
(	O
As	O
/	O
Ai	O
)	O
versus	O
molar	O
concentrations	O
(	O
nmol	O
/	O
mL	O
)	O
of	O
the	O
standard	O
solutions	O
for	O
each	O
sterol	O
with	O
13C3	O
-	O
cholesterol	O
as	O
a	O
common	O
internal	O
standard	O
.	O
Concentrations	O
of	O
sterols	O
detected	O
in	O
each	O
sample	O
were	O
calculated	O
from	O
the	O
standard	O
curves	O
of	O
the	O
individual	O
analytes	O
.	O
A	O
mixed	O
standard	O
solution	O
containing	O
reference	O
substances	O
of	O
cortisol	O
,	O
aldosterone	O
and	O
androstenedione	O
(	O
Steraloids	O
Inc	O
.	O
,	O
Newport	O
,	O
RI	O
)	O
was	O
prepared	O
in	O
methanol	O
at	O
10	O
nmol	O
/	O
mL	O
for	O
each	O
compound	O
.	O

This	O
solution	O
was	O
further	O
diluted	O
step	O
by	O
step	O
at	O
a	O
dilution	O
ratio	O
of	O
1	O
to	O
4	O
(	O
v	O
/	O
v	O
)	O
with	O
the	O
same	O
solvent	O
to	O
have	O
standard	O
solutions	O
of	O
S1	O
to	O
S9	O
.	O
Fifty	O
μL	O
of	O
plasma	O
was	O
mixed	O
with	O
425	O
μL	O
of	O
125	O
mM	O
sodium	O
acetate	O
buffer	O
(	O
pH	O
=	O
5	O
.	O
5	O
)	O
and	O
25	O
μL	O
of	O
an	O
internal	O
standard	O
solution	O
containing	O
cortisol	O
-	O
D4	O
and	O
6β	O
-	O
OH	O
cortisol	O
-	O
D4	O
.	O
After	O
vortex	O
-	O
mixing	O
,	O
1	O
mL	O
of	O
ethyl	O
acetate	O
was	O
added	O
and	O
the	O
mixture	O
was	O
vortex	O
-	O
mixed	O
for	O
30	O
s	O
followed	O
by	O
centrifugal	O
clarification	O
.	O
The	O
clear	O
supernatant	O
was	O
taken	O
out	O
and	O
dried	O
in	O
a	O
nitrogen	O
evaporator	O
.	O
The	O
residue	O
was	O
reconstituted	O
in	O
50	O
μL	O
of	O
methanol	O
.	O
Ten	O
μL	O
was	O
injected	O
to	O
run	O
UPLC	O
-	O
(	O
+	O
)	O
ESI	O
-	O
MRM	O
/	O
MS	O
on	O
a	O
C18	O
UPLC	O
column	O
(	O
2	O
.	O
1	O
x	O
100	O
mm	O
,	O
1	O
.	O
7	O
μm	O
)	O
with	O
0	O
.	O
1	O
%	O
formic	O
acid	O
and	O
acetonitrile	O
as	O
the	O
mobile	O
phase	O
for	O
binary	O
-	O
solvent	O
gradient	O
elution	O
,	O
at	O
0	O
.	O
3	O
mL	O
/	O
min	O
and	O
50	O
°C	O
.	O
Linear	O
-	O
regression	O
calibration	O
curves	O
were	O
constructed	O
using	O
analyte	O
-	O
to	O
-	O
internal	O
standard	O
peak	O
area	O
ratios	O
(	O
As	O
/	O
Ai	O
)	O
versus	O
molar	O
concentrations	O
(	O
nmol	O
/	O
mL	O
)	O
of	O
the	O
standard	O
solutions	O
.	O
Concentrations	O
of	O
steroids	O
detected	O
in	O
each	O
sample	O
were	O
calculated	O
from	O
the	O
standard	O
curves	O
of	O
the	O
individual	O
analytes	O
,	O
with	O
internal	O
calibration	O
.	O
Quantitation	O
of	O
fatty	O
acids	O
was	O
performed	O
using	O
3	O
-	O
nitrophenylhydrazine	O
(	O
3	O
-	O
NPH	O
)	O
derivatization	O
–	O
UPLC	O
-	O
MRM	O
/	O
MS	O
,	O
adapted	O
from	O
a	O
published	O
procedure	O
from	O
Han	O
et	O
al	O
.	O
[	O
33	O
]	O

A	O
mixed	O
standard	O
solution	O
containing	O
reference	O
substances	O
of	O
46	O
C2	O
to	O
C24	O
saturated	O
and	O
unsaturated	O
fatty	O
acids	O
(	O
as	O
listed	O
in	O
Tables	O
5	O
–	O
7	O
)	O
and	O
9	O
organic	O
acids	O
of	O
the	O
tri	O
-	O
carboxylic	O
acid	O
cycle	O
(	O
glycolic	O
,	O
lactic	O
,	O
malic	O
,	O
succinic	O
,	O
fumaric	O
,	O
citric	O
,	O
isocitric	O
,	O
pyruvic	O
and	O
α	O
-	O
ketoglutaric	O
acid	O
)	O
,	O
which	O
were	O
obtained	O
from	O
Sigma	O
-	O
Aldrich	O
or	O
from	O
Cayman	O
Chemical	O
(	O
Arbor	O
,	O
Michigan	O
,	O
USA	O
)	O
,	O
all	O
the	O
targeted	O
organic	O
acids	O
was	O
prepared	O
in	O
methanol	O
at	O
200	O
nmol	O
/	O
mL	O
for	O
each	O
compound	O
.	O
This	O
solution	O
was	O
further	O
diluted	O
step	O
by	O
step	O
at	O
a	O
dilution	O
ratio	O
of	O
1	O
to	O
5	O
(	O
v	O
/	O
v	O
)	O
to	O
have	O
standard	O
solutions	O
of	O
S1	O
to	O
S10	O
.	O
Ten	O
μL	O
of	O
each	O
plasma	O
was	O
mixed	O
with	O
90	O
μL	O
of	O
methanol	O
.	O
After	O
vortex	O
-	O
mixing	O
for	O
15	O
s	O
,	O
3	O
-	O
min	O
sonication	O
and	O
centrifugal	O
clarification	O
for	O
15	O
min	O
,	O
50	O
μL	O
of	O
the	O
supernatant	O
,	O
or	O
50	O
μL	O
of	O
each	O
standard	O
solution	O
was	O
mixed	O
with	O
20	O
μL	O
of	O
a	O
solution	O
containing	O
deuterium	O
-	O
labeled	O
analogues	O
of	O
C8	O
to	O
C24	O
even	O
-	O
carbon	O
saturated	O
fatty	O
acids	O
as	O
internal	O
standard	O
,	O
25	O
μL	O
of	O
200	O
-	O
mM	O
3	O
-	O
NPH	O
solution	O
and	O
2	O
μL	O
of	O
150	O
-	O
mM	O
EDC	O
solution	O
.	O
The	O
mixture	O
was	O
allowed	O
to	O
react	O
at	O
35	O
°C	O
for	O
60	O
min	O
in	O
a	O
thermomixer	O
at	O
a	O
shaking	O
frequency	O
of	O
900	O
rpm	O
.	O
After	O
the	O
reaction	O
,	O
10	O
μL	O
was	O
injected	O
onto	O
a	O
C8	O
UPLC	O
column	O
(	O
2	O
.	O
1	O
mm	O
I	O
.	O
D	O
.	O
x	O
100	O
mm	O
,	O
1	O
.	O
7	O
μm	O
)	O
for	O
LC	O
separation	O
with	O
a	O
mobile	O
phase	O
composed	O
of	O
1	O
mM	O
ammonium	O
fluoride	O
in	O
water	O
and	O
isopropanol	O
-	O
acetonitrile	O
for	O
binary	O
-	O
solvent	O
gradient	O
elution	O
at	O
0	O
.	O
4	O
mL	O
/	O
min	O
and	O
55	O
°C	O
.	O
The	O
efficient	O
gradient	O
was	O
10	O
%	O
to	O
100	O
%	O
in	O
14	O
min	O
.	O
Linear	O
-	O
regression	O
calibration	O
curves	O
were	O
constructed	O
using	O
analyte	O
-	O
to	O
-	O
internal	O
standard	O
peak	O
area	O
ratios	O
(	O
As	O
/	O
Ai	O
)	O
versus	O
molar	O
concentrations	O
(	O
nmol	O
/	O
mL	O
)	O
of	O
the	O
standard	O
solutions	O
for	O
each	O
compound	O
.	O

Concentrations	O
of	O
organic	O
acids	O
detected	O
in	O
each	O
sample	O
were	O
calculated	O
from	O
the	O
standard	O
curves	O
of	O
the	O
individual	O
analytes	O
with	O
internal	O
calibration	O
.	O
Quantitation	O
of	O
carnitines	O
was	O
carried	O
out	O
according	O
to	O
a	O
previously	O
published	O
method	O
by	O
Han	O
et	O
al	O
[	O
34	O
]	O
.	O
A	O
mixed	O
standard	O
solution	O
containing	O
reference	O
substances	O
of	O
28	O
free	O
and	O
acyl	O
carnitines	O
,	O
as	O
previously	O
described	O
[	O
34	O
]	O
,	O
was	O
prepared	O
in	O
methanol	O
at	O
10	O
nmol	O
/	O
mL	O
for	O
each	O
compound	O
.	O
This	O
solution	O
was	O
further	O
diluted	O
step	O
by	O
step	O
at	O
a	O
dilution	O
ratio	O
of	O
1	O
to	O
4	O
(	O
v	O
/	O
v	O
)	O
to	O
have	O
standard	O
solutions	O
of	O
S1	O
to	O
S9	O
.	O
Fifteen	O
μL	O
of	O
each	O
plasma	O
was	O
mixed	O
with	O
85	O
μL	O
of	O
methanol	O
.	O
After	O
vortex	O
-	O
mixing	O
for	O
30	O
s	O
and	O
sonication	O
for	O
3	O
min	O
,	O
followed	O
by	O
centrifugal	O
clarification	O
at	O
15	O
,	O
000	O
rpm	O
for	O
15	O
min	O
,	O
50	O
μL	O
of	O
the	O
supernatant	O
was	O
mixed	O
with	O
50	O
μL	O
of	O
100	O
mM	O
of	O
3	O
-	O
NPH	O
solution	O
and	O
50	O
μL	O
of	O
a	O
mixed	O
solution	O
containing	O
100	O
mM	O
of	O
EDC	O
,	O
HCl	O
and	O
3	O
%	O
pyridine	O
,	O
all	O
in	O
75	O
%	O
aqueous	O
methanol	O
.	O
The	O
mixture	O
was	O
allowed	O
to	O
react	O
at	O
30	O
°C	O
for	O
30	O
min	O
in	O
a	O
thermomixer	O
at	O
a	O
shaking	O
frequency	O
of	O
900	O
rpm	O
.	O
After	O
the	O
reaction	O
,	O
50	O
μL	O
of	O
13C6	O
-	O
3NPH	O
derivatives	O
of	O
all	O
the	O
targeted	O
carnitines	O
,	O
which	O
was	O
in	O
advance	O
prepared	O
in	O
a	O
“	O
one	O
-	O
pot	O
”	O
reaction	O
was	O
added	O
.	O
After	O
mixing	O
,	O
20	O
μL	O
of	O
each	O
solution	O
was	O
injected	O
for	O
quantitation	O
of	O
free	O
and	O
acyl	O
carnitines	O
in	O
the	O
samples	O
by	O
UPLC	O
-	O
MRM	O
/	O
MS	O
with	O
positive	O
-	O
ion	O
detection	O
using	O
the	O
previously	O
described	O
method	O
[	O
34	O
]	O
.	O
A	O
C8	O
UPLC	O
column	O
(	O
2	O
.	O
1	O
x	O
100	O
mm	O
,	O
1	O
.	O
8	O
μm	O
)	O
was	O
used	O
for	O
LC	O
separation	O
with	O
water	O
-	O
0	O
.	O
1	O
%	O
formic	O
acid	O
and	O
acetonitrile	O
as	O
the	O
mobile	O
phase	O
for	O
binary	O
gradient	O
elution	O
.	O
Linear	O
-	O
regression	O
calibration	O
curves	O
were	O
constructed	O
using	O
analyte	O
-	O
to	O
-	O
internal	O
standard	O
peak	O
area	O
ratios	O
(	O
As	O
/	O
Ai	O
)	O
versus	O
molar	O
concentrations	O
(	O
nmol	O
/	O
mL	O
)	O
of	O
the	O
standard	O
solutions	O
for	O
each	O
bile	O
acid	O
.	O

Concentrations	O
of	O
carnitines	O
in	O
each	O
sample	O
were	O
calculated	O
from	O
the	O
calibration	O
curves	O
of	O
the	O
individual	O
carnitines	O
.	O
Concentrations	O
of	O
organic	O
acids	O
detected	O
in	O
each	O
sample	O
were	O
calculated	O
from	O
the	O
standard	O
curves	O
of	O
the	O
individual	O
analytes	O
with	O
internal	O
calibration	O
.	O
A	O
mixed	O
standard	O
solution	O
containing	O
reference	O
substances	O
of	O
60	O
sphingolipids	O
(	O
from	O
Avantis	O
Polar	O
Lipids	O
,	O
Alabaster	O
,	O
AL	O
,	O
USA	O
;	O
or	O
Cayman	O
chemical	O
)	O
was	O
dissolved	O
in	O
methanol	O
at	O
50	O
nmol	O
/	O
mL	O
for	O
each	O
compound	O
.	O
This	O
solution	O
was	O
further	O
diluted	O
step	O
by	O
step	O
at	O
a	O
dilution	O
ratio	O
of	O
1	O
to	O
4	O
(	O
v	O
/	O
v	O
)	O
to	O
have	O
standard	O
solutions	O
of	O
S1	O
to	O
S10	O
.	O
20	O
μL	O
of	O
plasma	O
was	O
mixed	O
with	O
180	O
μL	O
of	O
methanol	O
-	O
chloroform	O
(	O
1	O
:	O
1	O
)	O
.	O
After	O
vortex	O
-	O
mixing	O
for	O
30	O
s	O
and	O
sonication	O
for	O
15	O
min	O
at	O
15000	O
rpm	O
.	O
The	O
supernatant	O
was	O
taken	O
out	O
and	O
dried	O
down	O
in	O
a	O
nitrogen	O
evaporator	O
.	O
The	O
residue	O
was	O
resuspended	O
in	O
50	O
μL	O
of	O
methanol	O
.	O
10	O
μL	O
of	O
each	O
standard	O
solution	O
or	O
each	O
sample	O
solution	O
was	O
injected	O
onto	O
a	O
C8	O
UPLC	O
column	O
(	O
2	O
.	O
1	O
x	O
50	O
mm	O
,	O
1	O
.	O
7	O
μm	O
)	O
for	O
UPLC	O
-	O
MRM	O
/	O
MS	O
with	O
positive	O
-	O
ion	O
detection	O
,	O
with	O
0	O
.	O
1	O
%	O
formic	O
acid	O
in	O
water	O
(	O
A	O
)	O
and	O
acetonitrile	O
-	O
isopropanol	O
(	O
1	O
:	O
1	O
)	O
(	O
B	O
)	O
as	O
the	O
mobile	O
phase	O
for	O
binary	O
gradient	O
elution	O
,	O
at	O
0	O
.	O
4	O
mL	O
/	O
min	O
and	O
55	O
°C	O
.	O
The	O
efficient	O
gradient	O
is	O
50	O
%	O
to	O
100	O
%	O
B	O
in	O
15	O
min	O
.	O
Linear	O
-	O
regression	O
calibration	O
curves	O
were	O
constructed	O
using	O
peak	O
areas	O
versus	O
molar	O
concentrations	O
(	O
nmol	O
/	O
mL	O
)	O
of	O
the	O
standard	O
solutions	O
for	O
each	O
sphingolipid	O
.	O
Concentrations	O
of	O
each	O
detected	O
lipid	O
were	O
calculated	O
from	O
the	O
calibration	O
curves	O
with	O
peak	O
areas	O
.	O
For	O
those	O
sphingolipids	O
detected	O
but	O
without	O
the	O
standard	O
substances	O
available	O
,	O
their	O
concentrations	O
were	O
estimated	O
using	O
the	O
calibration	O
curves	O
from	O
one	O
of	O
the	O
homologues	O
in	O
each	O
sphingolipid	O
class	O
with	O
the	O
closest	O
carbon	O
number	O
of	O
their	O
acyl	O
chains	O
.	O

For	O
these	O
analytes	O
,	O
a	O
metabolomics	O
kit	O
(	O
Absolute	O
IDQ	O
p400	O
HR	O
kit	O
,	O
Biocrates	O
Life	O
Sciences	O
AG	O
,	O
Innsbruck	O
,	O
Austria	O
)	O
was	O
used	O
according	O
to	O
the	O
manufacturer	O
standard	O
operating	O
procedure	O
using	O
UHPLC	O
with	O
a	O
C18	O
column	O
coupled	O
to	O
a	O
QExactive	O
HF	O
OrbiTrap	O
mass	O
spectrometer	O
(	O
Thermo	O
Fisher	O
Scientific	O
,	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
with	O
protocols	O
previously	O
published	O
by	O
the	O
University	O
of	O
Alberta	O
—	O
The	O
Metabolomics	O
Innovation	O
Centre	O
[	O
35	O
,	O
36	O
]	O
.	O
Only	O
lipid	O
metabolites	O
were	O
reported	O
.	O
The	O
kit	O
panel	O
overlapped	O
with	O
the	O
other	O
targeted	O
panels	O
for	O
carnitines	O
and	O
some	O
sphingolipids	O
.	O
Only	O
the	O
analytes	O
not	O
measured	O
by	O
other	O
targeted	O
techniques	O
were	O
reported	O
.	O
A	O
Dionex	O
Ultimate	O
3000	O
UHPLC	O
system	O
coupled	O
to	O
a	O
Thermo	O
Scientific	O
LTQ	O
-	O
Orbitrap	O
Velos	O
Pro	O
mass	O
spectrometer	O
equipped	O
with	O
an	O
electrospray	O
ionization	O
(	O
ESI	O
)	O
source	O
was	O
used	O
.	O
Fifty	O
μL	O
of	O
plasma	O
was	O
aliquoted	O
to	O
a	O
1	O
.	O
5	O
-	O
mL	O
Eppendorf	O
safe	O
-	O
lock	O
tube	O
.	O
250	O
μL	O
of	O
mixed	O
methanol	O
/	O
chloroform	O
(	O
3	O
:	O
1	O
)	O
was	O
added	O
.	O
The	O
tube	O
was	O
vortex	O
mixed	O
for	O
20	O
s	O
at	O
3000	O
rpm	O
,	O
sonicated	O
in	O
an	O
ice	O
-	O
water	O
bath	O
for	O
3	O
min	O
and	O
then	O
centrifuged	O
at	O
15000	O
rpm	O
for	O
20	O
min	O
.	O
The	O
clear	O
supernatant	O
was	O
taken	O
out	O
and	O
transferred	O
to	O
an	O
LC	O
injection	O
micro	O
-	O
vial	O
.	O
10	O
-	O
μL	O
aliquot	O
were	O
injected	O
to	O
run	O
reversed	O
-	O
phase	O
LC	O
-	O
MS	O
for	O
detection	O
and	O
relative	O
quantitation	O
of	O
lipids	O
,	O
in	O
(	O
+	O
)	O
and	O
(	O
-	O
)	O
ion	O
modes	O
,	O
respectively	O
,	O
with	O
two	O
rounds	O
of	O
LC	O
-	O
MS	O
runs	O
.	O
UHPLC	O
-	O
MS	O
/	O
MS	O
runs	O
were	O
carried	O
out	O
for	O
analysis	O
of	O
various	O
lipids	O
with	O
the	O
use	O
of	O
a	O
C8	O
UHPLC	O
column	O
(	O
2	O
.	O
1	O
x	O
50	O
mm	O
,	O
1	O
.	O
7	O
μm	O
)	O
for	O
chromatographic	O
separation	O
.	O
The	O
mobile	O
phase	O
was	O
(	O
A	O
)	O
0	O
.	O
02	O
%	O
formic	O
acid	O
in	O
water	O
and	O
(	O
B	O
)	O
0	O
.	O
02	O
%	O
formic	O
acid	O
in	O
acetonitrile	O
-	O
isopropanol	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
.	O

The	O
efficient	O
gradient	O
was	O
5	O
%	O
to	O
50	O
%	O
B	O
in	O
5	O
min	O
;	O
50	O
%	O
to	O
100	O
%	O
B	O
in	O
15	O
min	O
and	O
100	O
%	O
B	O
for	O
2	O
.	O
5	O
min	O
before	O
the	O
column	O
was	O
equilibrated	O
for	O
4	O
min	O
at	O
5	O
%	O
B	O
between	O
injections	O
.	O
The	O
column	O
flow	O
was	O
400	O
μL	O
/	O
min	O
and	O
the	O
column	O
temperature	O
was	O
maintained	O
at	O
55	O
°C	O
.	O
The	O
MS	O
instrument	O
was	O
operated	O
in	O
the	O
survey	O
-	O
scan	O
mode	O
with	O
full	O
-	O
mass	O
and	O
high	O
-	O
resolution	O
Fourier	O
transform	O
MS	O
detection	O
at	O
a	O
mass	O
resolution	O
of	O
60	O
,	O
000	O
FWHM	O
@	O
m	O
/	O
z	O
200	O
.	O
The	O
mass	O
scan	O
range	O
was	O
m	O
/	O
z	O
70	O
to	O
1800	O
for	O
both	O
positive	O
-	O
ion	O
and	O
negative	O
-	O
ion	O
detection	O
.	O
Along	O
with	O
the	O
MS	O
data	O
,	O
MS	O
/	O
MS	O
data	O
was	O
also	O
acquired	O
using	O
collision	O
induced	O
dissociation	O
(	O
CID	O
)	O
with	O
top	O
6	O
acquisitions	O
.	O
Two	O
MS	O
full	O
-	O
mass	O
detection	O
datasets	O
were	O
acquired	O
.	O
To	O
process	O
these	O
MS	O
datasets	O
,	O
the	O
raw	O
data	O
files	O
were	O
converted	O
to	O
a	O
common	O
data	O
format	O
and	O
were	O
processed	O
with	O
XCMS	O
(	O
https	O
:	O
/	O
/	O
xcmsonline	O
.	O
scripps	O
.	O
edu	O
/	O
)	O
in	O
R	O
for	O
peak	O
detection	O
,	O
retention	O
time	O
shift	O
corrections	O
,	O
peak	O
grouping	O
and	O
peak	O
alignment	O
.	O
Mass	O
de	O
-	O
isotoping	O
and	O
removal	O
of	O
chemical	O
background	O
noise	O
peaks	O
were	O
performed	O
,	O
with	O
partial	O
manual	O
interventions	O
based	O
on	O
several	O
rules	O
in	O
chemistry	O
and	O
mass	O
spectrometry	O
.	O
Lipid	O
annotations	O
were	O
performed	O
manually	O
using	O
the	O
LIPIDMAPS	O
structural	O
database	O
(	O
LMSD	O
)	O
bulk	O
structures	O
[	O
37	O
]	O
and	O
LipidBlast	O
software	O
(	O
Lipidblast	O
-	O
mz	O
-	O
lookup	O
-	O
v49	O
module	O
)	O
[	O
38	O
]	O
for	O
positive	O
mode	O
[	O
(	O
M	O
+	O
H	O
)	O
+	O
and	O
(	O
M	O
+	O
Na	O
)	O
+	O
ions	O
]	O
and	O
for	O
negative	O
mode	O
[	O
(	O
M	O
-	O
H	O
)	O
-	O
ions	O
]	O
.	O
A	O
m	O
/	O
z	O
error	O
of	O
5ppm	O
(	O
Lipidmaps	O
)	O
or	O
0	O
.	O
008	O
Da	O
(	O
Lipidblast	O
)	O
was	O
used	O
.	O
Only	O
biologically	O
relevant	O
species	O
were	O
included	O
in	O
the	O
search	O
.	O
LipidBlast	O
was	O
used	O
to	O
query	O
glycerolipids	O
(	O
DG	O
,	O
TG	O
)	O
,	O
glycerophospholipids	O
(	O
PC	O
,	O
PE	O
,	O
PS	O
,	O
PG	O
,	O
PI	O
,	O
PA	O
)	O
and	O
sphingolipids	O
(	O
SM	O
,	O
gangliosides	O
,	O
ceramides	O
)	O
.	O

LMSD	O
was	O
used	O
to	O
additionally	O
query	O
MG	O
,	O
cholesteryl	O
esters	O
(	O
CE	O
)	O
,	O
and	O
fatty	O
acyls	O
(	O
search	O
restricted	O
to	O
fatty	O
acids	O
and	O
acyl	O
-	O
carnitines	O
)	O
.	O
Duplicate	O
hits	O
were	O
removed	O
manually	O
.	O
The	O
LIPIDMAPS	O
nomenclature	O
was	O
used	O
for	O
lipid	O
names	O
,	O
category	O
names	O
,	O
and	O
abbreviations	O
.	O
Lipid	O
species	O
were	O
reported	O
at	O
the	O
brutto	O
level	O
of	O
information	O
[	O
29	O
]	O
.	O
Targeted	O
lipidomics	O
data	O
were	O
reported	O
with	O
their	O
median	O
,	O
interquartile	O
range	O
(	O
IQR	O
)	O
,	O
minimum	O
,	O
and	O
maximum	O
for	O
each	O
lipid	O
group	O
and	O
relative	O
percentage	O
for	O
some	O
lipid	O
groups	O
.	O
A	O
global	O
barplot	O
on	O
polar	O
coordinate	O
was	O
performed	O
with	O
all	O
targeted	O
panels	O
to	O
have	O
a	O
graphical	O
representation	O
of	O
the	O
whole	O
lipidome	O
.	O
For	O
untargeted	O
lipidomics	O
data	O
,	O
only	O
the	O
main	O
lipid	O
species	O
per	O
lipid	O
groups	O
were	O
reported	O
with	O
the	O
most	O
common	O
lipid	O
species	O
based	O
on	O
peak	O
intensity	O
.	O
For	O
differences	O
between	O
sexes	O
,	O
targeted	O
lipidomics	O
data	O
were	O
pre	O
-	O
processed	O
using	O
auto	O
scaling	O
(	O
mean	O
centered	O
and	O
divided	O
by	O
standard	O
deviation	O
)	O
for	O
multivariate	O
analysis	O
.	O
Metabolites	O
below	O
the	O
limits	O
of	O
detection	O
were	O
removed	O
from	O
the	O
analysis	O
.	O
Differences	O
in	O
individual	O
lipid	O
metabolites	O
between	O
sexes	O
were	O
then	O
assessed	O
using	O
serial	O
t	O
-	O
tests	O
with	O
a	O
false	O
discovery	O
rate	O
of	O
5	O
%	O
.	O
The	O
lipidome	O
was	O
explored	O
using	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
to	O
detect	O
sex	O
lipidomics	O
signatures	O
using	O
an	O
unsupervised	O
technique	O
.	O
Lipid	O
analytes	O
contribution	O
to	O
respective	O
principal	O
components	O
was	O
assessed	O
by	O
evaluation	O
of	O
the	O
PCA	O
biplots	O
.	O
Differences	O
between	O
sexes	O
were	O
further	O
explored	O
using	O
a	O
supervised	O
classifying	O
multivariate	O
tool	O
:	O
partial	O
least	O
squares	O
—	O
linear	O
discriminant	O
analysis	O
(	O
PLS	O
-	O
DA	O
)	O
.	O
Loading	O
plots	O
were	O
also	O
inspected	O
for	O
important	O
features	O
as	O
well	O
as	O
the	O
variable	O
importance	O
in	O
projection	O
(	O
VIP	O
)	O
scores	O
.	O
A	O
heatmap	O
with	O
hierarchical	O
clustering	O
was	O
also	O
generated	O
for	O
data	O
exploration	O
using	O
the	O
50	O
most	O
important	O
analytes	O
based	O
on	O
t	O
-	O
test	O
p	O
-	O
values	O
on	O
normalized	O
data	O
.	O
R	O
(	O
version	O
4	O
.	O
0	O
.	O
0	O
,	O
R	O
foundation	O
for	O
statistical	O
computing	O
,	O
Vienna	O
,	O
Austria	O
)	O
was	O
used	O
for	O
descriptive	O
statistical	O
analysis	O
,	O
ggplot2	O
for	O
bar	O
plots	O
[	O
39	O
]	O
,	O
and	O
MetaboAnalyst	O
4	O
.	O
0	O
for	O
multivariate	O
analysis	O
and	O
graphs	O
[	O
40	O
]	O
.	O

The	O
parrot	O
pelleted	O
diet	O
contained	O
11	O
.	O
5	O
%	O
total	O
fat	O
including	O
1	O
.	O
6	O
%	O
of	O
saturated	O
fatty	O
acids	O
,	O
4	O
.	O
8	O
%	O
of	O
monounsaturated	O
fatty	O
acids	O
,	O
and	O
5	O
.	O
1	O
%	O
of	O
polyunsaturated	O
fatty	O
acids	O
.	O
The	O
fatty	O
acid	O
profile	O
included	O
palmitic	O
acid	O
(	O
FA	O
16	O
:	O
0	O
)	O
as	O
the	O
preponderant	O
saturated	O
fatty	O
acid	O
,	O
oleic	O
acid	O
(	O
FA	O
18	O
:	O
1	O
)	O
as	O
the	O
preponderant	O
monounsaturated	O
fatty	O
acid	O
,	O
and	O
linoleic	O
acid	O
(	O
FA	O
18	O
:	O
2	O
)	O
as	O
the	O
preponderant	O
polyunsaturated	O
fatty	O
acid	O
.	O
The	O
combination	O
of	O
linoleic	O
acid	O
and	O
oleic	O
acid	O
represented	O
more	O
than	O
80	O
%	O
of	O
total	O
dietary	O
fatty	O
acids	O
.	O
The	O
complete	O
fatty	O
acid	O
profile	O
is	O
reported	O
in	O
Table	O
1	O
.	O
The	O
number	O
of	O
lipid	O
species	O
(	O
not	O
accounting	O
for	O
isomeric	O
species	O
,	O
which	O
are	O
numerous	O
for	O
triacylglycerols	O
and	O
diaryl	O
lipids	O
)	O
quantified	O
by	O
targeted	O
lipidomics	O
panels	O
are	O
reported	O
in	O
Table	O
2	O
and	O
included	O
432	O
lipids	O
.	O
The	O
highest	O
number	O
of	O
lipids	O
analyzed	O
were	O
for	O
glycerophospholipids	O
,	O
but	O
only	O
included	O
glycerophosphocholines	O
.	O
A	O
global	O
representation	O
of	O
the	O
targeted	O
lipidomics	O
panel	O
is	O
also	O
presented	O
in	O
Fig	O
1	O
.	O
The	O
Quaker	O
parrot	O
plasma	O
lipidome	O
,	O
as	O
assessed	O
using	O
these	O
incomplete	O
panels	O
,	O
was	O
dominated	O
by	O
sterol	O
lipids	O
and	O
glycerophospholipids	O
on	O
a	O
molar	O
basis	O
followed	O
by	O
glycerolipids	O
(	O
Fig	O
1	O
and	O
Table	O
3	O
)	O
.	O
Cholesterol	O
and	O
its	O
esters	O
were	O
the	O
most	O
abundant	O
lipid	O
species	O
by	O
far	O
especially	O
for	O
free	O
cholesterol	O
and	O
cholesteryl	O
linoleate	O
[	O
CE	O
(	O
18	O
:	O
2	O
)	O
]	O
.	O
Untargeted	O
lipidomics	O
results	O
yielded	O
a	O
high	O
number	O
of	O
lipid	O
species	O
(	O
Table	O
4	O
)	O
.	O
They	O
included	O
lipid	O
categories	O
and	O
species	O
not	O
represented	O
or	O
measured	O
in	O
the	O
targeted	O
lipidomics	O
panels	O
.	O
The	O
most	O
diverse	O
lipid	O
category	O
was	O
the	O
glycerophospholipids	O
,	O
which	O
was	O
dominated	O
by	O
glycerophosphoethanolamines	O
(	O
PE	O
)	O
and	O
glycerophosphocholines	O
(	O
PC	O
)	O
species	O
.	O
Of	O
those	O
,	O
only	O
PCs	O
were	O
quantified	O
using	O
targeted	O
methods	O
.	O

Identified	O
abundant	O
species	O
did	O
not	O
necessarily	O
correspond	O
to	O
lipid	O
found	O
to	O
be	O
abundant	O
on	O
targeted	O
panels	O
.	O
Raw	O
data	O
for	O
untargeted	O
lipidomics	O
prior	O
to	O
lipid	O
identification	O
and	O
results	O
of	O
the	O
targeted	O
panels	O
were	O
published	O
in	O
the	O
public	O
domain	O
in	O
a	O
permanent	O
scientific	O
data	O
repository	O
(	O
Beaufrère	O
H	O
,	O
2020	O
,	O
The	O
plasma	O
lipidome	O
of	O
the	O
Quaker	O
parrot	O
(	O
Myiopsitta	O
monachus	O
)	O
,	O
https	O
:	O
/	O
/	O
doi	O
.	O
org	O
/	O
10	O
.	O
5683	O
/	O
SP2	O
/	O
XUW31U	O
,	O
Scholars	O
Portal	O
Dataverse	O
,	O
V1	O
)	O
.	O
Measured	O
free	O
fatty	O
acids	O
included	O
non	O
-	O
esterified	O
saturated	O
fatty	O
acids	O
(	O
Table	O
5	O
)	O
,	O
unsaturated	O
fatty	O
acids	O
(	O
Table	O
6	O
)	O
of	O
short	O
,	O
medium	O
,	O
long	O
,	O
and	O
very	O
-	O
long	O
chains	O
as	O
well	O
as	O
one	O
hydroxy	O
-	O
fatty	O
acid	O
(	O
Table	O
7	O
)	O
.	O
Non	O
-	O
esterified	O
fatty	O
acids	O
correspond	O
to	O
only	O
a	O
small	O
proportion	O
of	O
all	O
fatty	O
acids	O
in	O
the	O
plasma	O
as	O
most	O
are	O
esterified	O
to	O
various	O
head	O
groups	O
.	O
Palmitic	O
acid	O
was	O
the	O
most	O
abundant	O
free	O
fatty	O
acid	O
in	O
the	O
plasma	O
by	O
far	O
followed	O
by	O
stearic	O
acid	O
,	O
oleic	O
acid	O
,	O
linoleic	O
acid	O
,	O
and	O
arachidonic	O
acid	O
(	O
Fig	O
1	O
)	O
.	O
It	O
was	O
also	O
the	O
most	O
abundant	O
free	O
saturated	O
fatty	O
acid	O
representing	O
more	O
than	O
68	O
%	O
of	O
all	O
plasmatic	O
free	O
saturated	O
fatty	O
acids	O
.	O
Palmitic	O
and	O
stearic	O
acids	O
represented	O
93	O
%	O
of	O
all	O
saturated	O
fatty	O
acids	O
.	O
Oleic	O
acid	O
was	O
the	O
most	O
common	O
monounsaturated	O
fatty	O
acid	O
,	O
but	O
also	O
the	O
most	O
common	O
unsaturated	O
fatty	O
acid	O
.	O
Linoleic	O
acid	O
was	O
the	O
most	O
abundant	O
polyunsaturated	O
fatty	O
acid	O
and	O
omega	O
-	O
6	O
fatty	O
acid	O
and	O
docosahexaenoic	O
acid	O
(	O
DHA	O
)	O
the	O
most	O
common	O
omega	O
-	O
3	O
fatty	O
acid	O
.	O
Acyl	O
-	O
carnitines	O
were	O
also	O
measured	O
(	O
Table	O
8	O
)	O
.	O
They	O
are	O
activated	O
fatty	O
acids	O
that	O
can	O
be	O
transported	O
across	O
mitochondrial	O
membranes	O
for	O
beta	O
-	O
oxidation	O
to	O
produce	O
energy	O
.	O
Unsurprisingly	O
,	O
acetyl	O
carnitine	O
was	O
the	O
most	O
common	O
acyl	O
carnitines	O
as	O
it	O
facilitates	O
the	O
movement	O
of	O
acetyl	O
-	O
CoA	O
as	O
end	O
-	O
products	O
of	O
mitochondrial	O
fatty	O
acid	O
oxidation	O
.	O
Oleyl	O
-	O
carnitine	O
and	O
linoleyl	O
-	O
carnitine	O
were	O
the	O
most	O
abundant	O
long	O
-	O
chain	O
fatty	O
acyl	O
carnitines	O
.	O

Fatty	O
acyls	O
also	O
include	O
a	O
large	O
number	O
of	O
lipid	O
mediators	O
,	O
which	O
were	O
also	O
measured	O
in	O
these	O
parrots	O
,	O
but	O
as	O
part	O
of	O
a	O
different	O
study	O
on	O
the	O
plasma	O
mediator	O
lipidome	O
.	O
The	O
most	O
abundant	O
glycerolipids	O
were	O
triacylglycerols	O
(	O
Table	O
9	O
)	O
.	O
They	O
were	O
quantified	O
based	O
on	O
identification	O
at	O
the	O
sum	O
composition	O
.	O
The	O
most	O
common	O
species	O
were	O
TGs	O
in	O
C52	O
or	O
C54	O
with	O
2	O
to	O
6	O
double	O
bonds	O
.	O
The	O
four	O
most	O
common	O
TG	O
species	O
represented	O
more	O
than	O
half	O
(	O
57	O
.	O
3	O
%	O
)	O
of	O
all	O
TGs	O
on	O
a	O
molar	O
basis	O
.	O
Untargeted	O
lipidomics	O
also	O
identified	O
these	O
TGs	O
as	O
common	O
.	O
While	O
only	O
the	O
sum	O
composition	O
was	O
used	O
,	O
based	O
on	O
typical	O
stereospecific	O
structures	O
of	O
biological	O
TGs	O
in	O
animals	O
and	O
common	O
plasma	O
free	O
fatty	O
acids	O
from	O
Tables	O
5	O
and	O
6	O
,	O
they	O
likely	O
contained	O
a	O
high	O
proportion	O
of	O
palmitic	O
acid	O
,	O
and	O
C18	O
fatty	O
acids	O
such	O
as	O
stearic	O
,	O
oleic	O
,	O
linoleic	O
,	O
and	O
alpha	O
-	O
linolenic	O
acids	O
and	O
arachidonic	O
acid	O
as	O
a	O
highly	O
unsaturated	O
fatty	O
acid	O
.	O
Diacylglycerols	O
(	O
Table	O
10	O
)	O
and	O
some	O
ether	O
-	O
linked	O
diarylglycerols	O
(	O
Table	O
11	O
)	O
were	O
quantified	O
and	O
were	O
present	O
at	O
substantially	O
lower	O
concentrations	O
than	O
TGs	O
.	O
They	O
are	O
metabolic	O
intermediates	O
and	O
metabolites	O
of	O
TGs	O
and	O
glycerophospholipids	O
.	O
DGs	O
in	O
C36	O
were	O
the	O
most	O
common	O
,	O
likely	O
containing	O
either	O
a	O
combination	O
of	O
C18	O
fatty	O
acids	O
(	O
stearic	O
,	O
oleic	O
,	O
linoleic	O
,	O
linolenic	O
)	O
or	O
a	O
combination	O
of	O
palmitic	O
acid	O
and	O
arachidonic	O
acid	O
.	O
DGs	O
were	O
identified	O
at	O
the	O
sum	O
composition	O
level	O
of	O
information	O
and	O
it	O
is	O
unknown	O
whether	O
they	O
were	O
1	O
,	O
2	O
DG	O
or	O
1	O
,	O
3	O
DG	O
.	O
They	O
were	O
not	O
detected	O
through	O
untargeted	O
lipidomics	O
.	O
Monoacylglycerols	O
were	O
not	O
quantified	O
by	O
targeted	O
techniques	O
,	O
but	O
untargeted	O
methods	O
tentatively	O
identified	O
MG	O
(	O
18	O
:	O
1	O
)	O
and	O
MG	O
(	O
18	O
:	O
2	O
)	O
as	O
common	O
plasmatic	O
species	O
.	O
Only	O
glycerophosphocholines	O
were	O
quantified	O
as	O
part	O
of	O
targeted	O
lipidomics	O
panels	O
,	O
but	O
untargeted	O
methods	O
detected	O
a	O
large	O
number	O
of	O
other	O
glycerophospholipids	O
(	O
Table	O
4	O
)	O
.	O

Glycerophosphocholines	O
(	O
PCs	O
)	O
was	O
one	O
of	O
the	O
most	O
diverse	O
lipid	O
categories	O
and	O
also	O
included	O
the	O
highest	O
number	O
of	O
lipid	O
species	O
quantified	O
by	O
targeted	O
panels	O
(	O
Tables	O
12	O
–	O
14	O
)	O
.	O
Phosphatidylcholines	O
were	O
the	O
most	O
common	O
PCs	O
especially	O
the	O
species	O
in	O
C34	O
,	O
C36	O
and	O
C38	O
.	O
As	O
they	O
only	O
contain	O
2	O
fatty	O
acid	O
chains	O
,	O
the	O
most	O
likely	O
components	O
were	O
palmitic	O
acid	O
,	O
stearic	O
acid	O
,	O
linoleic	O
acid	O
,	O
linolenic	O
acid	O
,	O
and	O
arachidonic	O
acid	O
.	O
Based	O
on	O
untargeted	O
lipidomics	O
,	O
PE	O
are	O
also	O
common	O
and	O
abundant	O
species	O
in	O
parrot	O
plasma	O
with	O
PE	O
(	O
36	O
:	O
2	O
)	O
common	O
[	O
as	O
for	O
PC	O
(	O
36	O
:	O
2	O
)	O
]	O
,	O
but	O
those	O
could	O
not	O
be	O
confirmed	O
and	O
further	O
quantified	O
by	O
targeted	O
techniques	O
.	O
Ether	O
-	O
linked	O
PCs	O
(	O
PC	O
-	O
O	O
)	O
were	O
also	O
common	O
and	O
quantified	O
(	O
Table	O
13	O
)	O
.	O
Lysophophatidylcholines	O
(	O
LPCs	O
)	O
are	O
reported	O
in	O
Table	O
4	O
along	O
with	O
LPC	O
-	O
O	O
and	O
are	O
metabolites	O
of	O
PCs	O
.	O
LPCs	O
in	O
C18	O
and	O
with	O
palmitic	O
acid	O
were	O
the	O
most	O
abundant	O
.	O
Most	O
sphingolipids	O
had	O
sphingosine	O
(	O
d18	O
:	O
1	O
)	O
as	O
the	O
sphingoid	O
base	O
;	O
however	O
only	O
sphingolipids	O
with	O
sphingosine	O
or	O
sphinganine	O
(	O
d18	O
:	O
0	O
)	O
were	O
quantified	O
by	O
targeted	O
methods	O
and	O
only	O
the	O
sum	O
composition	O
was	O
obtained	O
for	O
untargeted	O
methods	O
.	O
Sphingosine	O
was	O
also	O
the	O
most	O
abundant	O
non	O
-	O
esterified	O
sphingoid	O
base	O
in	O
the	O
plasma	O
at	O
87	O
.	O
2	O
%	O
(	O
Table	O
15	O
)	O
.	O
Sphingomyelins	O
(	O
SM	O
)	O
were	O
the	O
most	O
abundant	O
plasma	O
sphingolipids	O
and	O
sphingomyelin	O
with	O
long	O
-	O
chain	O
saturated	O
fatty	O
acids	O
were	O
the	O
preponderant	O
species	O
such	O
as	O
the	O
most	O
common	O
,	O
palmitoyl	O
sphingomyelin	O
[	O
SM	O
(	O
d18	O
:	O
1	O
/	O
16	O
:	O
0	O
)	O
]	O
.	O
Saturated	O
fatty	O
acid	O
sphingomyelins	O
accounted	O
for	O
81	O
.	O
8	O
%	O
of	O
all	O
SMs	O
(	O
Table	O
16	O
)	O
.	O
Ceramides	O
and	O
dihydroceramides	O
were	O
in	O
much	O
lower	O
concentrations	O
in	O
the	O
plasma	O
than	O
SMs	O
at	O
about	O
3	O
%	O
of	O
all	O
measured	O
sphingolipids	O
.	O

There	O
was	O
a	O
tendency	O
for	O
these	O
lipids	O
to	O
have	O
very	O
long	O
chain	O
fatty	O
acids	O
(	O
>	O
C22	O
)	O
as	O
esterified	O
fatty	O
acids	O
.	O
The	O
most	O
common	O
ceramide	O
included	O
nervonic	O
acid	O
[	O
Cer	O
(	O
d18	O
:	O
1	O
/	O
24	O
:	O
1	O
)	O
]	O
(	O
Table	O
17	O
)	O
.	O
Dihydroceramides	O
were	O
in	O
minute	O
concentrations	O
when	O
compared	O
to	O
ceramides	O
(	O
Table	O
18	O
)	O
.	O
A	O
few	O
cerebrosides	O
(	O
monoglycosylceramides	O
)	O
and	O
globosides	O
(	O
polyglycosylceramides	O
)	O
were	O
quantified	O
(	O
Table	O
19	O
)	O
.	O
Like	O
ceramides	O
and	O
dihydroceramides	O
,	O
they	O
had	O
very	O
long	O
chain	O
fatty	O
acids	O
.	O
As	O
mentioned	O
above	O
,	O
sterol	O
lipids	O
,	O
in	O
particular	O
free	O
cholesterol	O
and	O
CE	O
(	O
18	O
:	O
2	O
)	O
dominate	O
the	O
plasma	O
lipidome	O
of	O
the	O
Quaker	O
parrot	O
.	O
Cholesteryl	O
esters	O
(	O
CE	O
)	O
(	O
Table	O
20	O
)	O
compose	O
about	O
2	O
/	O
3	O
of	O
plasma	O
cholesterol	O
with	O
the	O
remaining	O
1	O
/	O
3	O
being	O
free	O
cholesterol	O
(	O
Table	O
21	O
)	O
.	O
Most	O
important	O
CE	O
had	O
polyunsaturated	O
fatty	O
acids	O
such	O
as	O
linoleic	O
acid	O
,	O
linolenic	O
acid	O
,	O
arachidonic	O
acid	O
,	O
and	O
DHA	O
.	O
While	O
free	O
cholesterol	O
was	O
the	O
main	O
non	O
-	O
esterified	O
sterol	O
,	O
other	O
species	O
were	O
quantified	O
as	O
well	O
as	O
some	O
steroids	O
,	O
which	O
are	O
synthesized	O
from	O
cholesterol	O
(	O
Table	O
21	O
)	O
.	O
Corticosterone	O
,	O
the	O
most	O
important	O
steroid	O
of	O
birds	O
,	O
was	O
not	O
part	O
of	O
this	O
targeted	O
steroid	O
panel	O
.	O
A	O
comprehensive	O
bile	O
acid	O
panel	O
was	O
also	O
performed	O
on	O
the	O
plasma	O
of	O
these	O
parrots	O
(	O
Table	O
22	O
)	O
.	O
By	O
far	O
,	O
the	O
most	O
common	O
plasma	O
bile	O
acid	O
of	O
birds	O
was	O
taurochenodeoxycholic	O
acid	O
.	O
Taurocholic	O
acid	O
was	O
the	O
second	O
most	O
common	O
plasma	O
bile	O
acid	O
and	O
together	O
with	O
taurochenodeoxycholic	O
acid	O
represented	O
87	O
.	O
4	O
%	O
of	O
all	O
bile	O
acids	O
.	O
Other	O
metabolites	O
associated	O
with	O
lipid	O
metabolism	O
were	O
quantified	O
as	O
part	O
of	O
the	O
targeted	O
lipidomics	O
panels	O
.	O

These	O
included	O
dicarboxylic	O
acids	O
important	O
in	O
the	O
TCA	O
cycle	O
(	O
which	O
provides	O
substrates	O
for	O
fatty	O
acid	O
and	O
cholesterol	O
biosynthesis	O
)	O
,	O
free	O
carnitine	O
and	O
other	O
lipid	O
-	O
like	O
metabolites	O
(	O
Table	O
23	O
)	O
.	O
On	O
serial	O
t	O
-	O
tests	O
for	O
targeted	O
results	O
on	O
lipid	O
concentrations	O
,	O
only	O
2	O
lipid	O
species	O
,	O
both	O
minor	O
PCs	O
(	O
see	O
Tables	O
12	O
and	O
13	O
)	O
,	O
were	O
found	O
to	O
be	O
significantly	O
different	O
between	O
sexes	O
,	O
PC	O
(	O
42	O
:	O
4	O
)	O
(	O
q	O
=	O
0	O
.	O
024	O
)	O
and	O
PC	O
-	O
O	O
(	O
34	O
:	O
3	O
)	O
(	O
q	O
=	O
0	O
.	O
024	O
)	O
.	O
The	O
sexes	O
were	O
well	O
clustered	O
on	O
PCA	O
and	O
PLS	O
-	O
DA	O
plots	O
without	O
overlap	O
(	O
Fig	O
2	O
)	O
.	O
The	O
PCA	O
biplot	O
was	O
difficult	O
to	O
interpret	O
because	O
of	O
the	O
number	O
of	O
variables	O
.	O
Using	O
VIP	O
scores	O
,	O
the	O
most	O
important	O
discriminating	O
variables	O
between	O
sexes	O
on	O
PLS	O
-	O
DA	O
were	O
mainly	O
PCs	O
[	O
PC	O
(	O
42	O
:	O
4	O
)	O
and	O
PC	O
-	O
O	O
(	O
34	O
:	O
3	O
)	O
being	O
the	O
most	O
important	O
]	O
,	O
acyl	O
-	O
carnitines	O
(	O
C12	O
:	O
1	O
,	O
C14	O
:	O
0	O
,	O
and	O
C12	O
:	O
0	O
being	O
the	O
most	O
important	O
)	O
,	O
and	O
TG	O
(	O
56	O
:	O
7	O
)	O
for	O
females	O
,	O
and	O
Cer	O
(	O
d18	O
:	O
1	O
/	O
18	O
:	O
0	O
)	O
for	O
males	O
.	O
The	O
PCA	O
model	O
explained	O
57	O
.	O
4	O
%	O
of	O
the	O
variance	O
and	O
the	O
PLS	O
-	O
DA	O
model	O
explained	O
54	O
.	O
7	O
%	O
of	O
the	O
variance	O
.	O
The	O
heatmap	O
also	O
suggested	O
different	O
lipidome	O
profiles	O
between	O
sexes	O
(	O
Fig	O
3	O
)	O
.	O
Most	O
lipids	O
were	O
in	O
higher	O
plasma	O
concentrations	O
in	O
female	O
parrots	O
,	O
in	O
particular	O
glycerophospholipids	O
,	O
acyl	O
-	O
carnitines	O
,	O
and	O
some	O
TGs	O
and	O
CEs	O
.	O
A	O
few	O
lipid	O
species	O
were	O
higher	O
in	O
males	O
,	O
all	O
being	O
sphingolipids	O
.	O
This	O
report	O
presents	O
the	O
first	O
comprehensive	O
database	O
of	O
plasma	O
lipid	O
species	O
in	O
a	O
psittacine	O
bird	O
.	O
The	O
plasma	O
lipidome	O
of	O
animals	O
is	O
astoundingly	O
diverse	O
and	O
several	O
quantitative	O
or	O
semi	O
-	O
quantitative	O
mass	O
spectrometric	O
methods	O
are	O
typically	O
needed	O
to	O
grasp	O
a	O
portion	O
of	O
this	O
diversity	O
due	O
to	O
the	O
various	O
molecular	O
structures	O
and	O
abundance	O
of	O
the	O
different	O
lipid	O
categories	O
[	O
21	O
,	O
41	O
,	O
42	O
]	O
.	O

While	O
the	O
targeted	O
lipidomics	O
panels	O
used	O
here	O
give	O
a	O
good	O
overview	O
of	O
the	O
plasma	O
lipidome	O
of	O
the	O
Quaker	O
parrot	O
,	O
only	O
a	O
fraction	O
of	O
the	O
plasma	O
lipids	O
were	O
quantified	O
.	O
As	O
some	O
lipids	O
are	O
structurally	O
complex	O
,	O
we	O
only	O
reported	O
individual	O
lipid	O
species	O
or	O
group	O
of	O
species	O
at	O
the	O
brutto	O
level	O
(	O
sum	O
composition	O
of	O
carbons	O
and	O
carbon	O
-	O
carbon	O
double	O
bonds	O
)	O
for	O
most	O
complex	O
lipids	O
such	O
as	O
glycerolipids	O
and	O
glycerophospholipids	O
or	O
medio	O
level	O
(	O
with	O
added	O
knowledge	O
of	O
fatty	O
acyl	O
chains	O
)	O
for	O
sphingolipids	O
[	O
29	O
]	O
.	O
For	O
complex	O
lipids	O
with	O
many	O
possible	O
combination	O
of	O
fatty	O
acids	O
such	O
as	O
TG	O
,	O
a	O
single	O
reported	O
species	O
such	O
as	O
displayed	O
in	O
Table	O
9	O
may	O
encompass	O
several	O
dozen	O
TG	O
isomeric	O
species	O
(	O
same	O
elemental	O
composition	O
,	O
but	O
different	O
lipids	O
)	O
,	O
so	O
this	O
is	O
a	O
limitation	O
of	O
the	O
present	O
study	O
and	O
MS	O
/	O
MS	O
characterization	O
of	O
TG	O
and	O
glycerophospholipids	O
should	O
be	O
considered	O
in	O
the	O
future	O
.	O
However	O
,	O
most	O
likely	O
TG	O
candidates	O
can	O
reasonably	O
be	O
predicted	O
based	O
on	O
known	O
stereochemical	O
structures	O
of	O
these	O
lipids	O
as	O
well	O
as	O
the	O
most	O
common	O
fatty	O
acyl	O
chains	O
present	O
in	O
animals	O
and	O
given	O
that	O
the	O
fatty	O
acid	O
composition	O
of	O
the	O
diet	O
was	O
determined	O
.	O
The	O
impact	O
of	O
diet	O
on	O
the	O
fatty	O
acid	O
composition	O
of	O
plasma	O
TG	O
of	O
several	O
parrot	O
species	O
has	O
been	O
determined	O
[	O
43	O
]	O
.	O
For	O
monoacyl	O
lipids	O
such	O
as	O
non	O
-	O
esterified	O
fatty	O
acids	O
,	O
cholesteryl	O
esters	O
,	O
lyso	O
-	O
PC	O
,	O
the	O
sum	O
composition	O
obviously	O
gives	O
the	O
type	O
of	O
fatty	O
acid	O
.	O
But	O
even	O
then	O
,	O
the	O
position	O
of	O
the	O
double	O
bonds	O
along	O
the	O
fatty	O
acyl	O
chain	O
,	O
the	O
stereochemical	O
positions	O
of	O
the	O
different	O
fatty	O
acyl	O
chains	O
(	O
esterified	O
positions	O
on	O
the	O
glycerol	O
molecule	O
or	O
other	O
head	O
groups	O
)	O
,	O
and	O
the	O
configuration	O
of	O
the	O
carbon	O
-	O
carbon	O
double	O
bonds	O
(	O
cis	O
/	O
trans	O
isomers	O
)	O
are	O
unknown	O
and	O
several	O
lipid	O
species	O
are	O
still	O
represented	O
.	O
In	O
some	O
cases	O
,	O
such	O
as	O
for	O
omega	O
-	O
3	O
or	O
omega	O
-	O
6	O
fatty	O
acids	O
,	O
the	O
position	O
of	O
these	O
double	O
bonds	O
is	O
clinically	O
relevant	O
.	O
Untargeted	O
lipidomics	O
is	O
semi	O
-	O
quantitative	O
(	O
peak	O
intensity	O
)	O
and	O
is	O
typically	O
used	O
more	O
for	O
exploratory	O
analysis	O
and	O
discovery	O
work	O
as	O
the	O
analysis	O
is	O
unbiased	O
and	O
not	O
restricted	O
to	O
predetermined	O
panels	O
[	O
44	O
]	O
.	O

Identified	O
lipid	O
species	O
must	O
ideally	O
be	O
confirmed	O
and	O
quantified	O
by	O
targeted	O
methods	O
[	O
44	O
]	O
.	O
For	O
each	O
match	O
with	O
lipid	O
databases	O
,	O
many	O
isobaric	O
species	O
(	O
same	O
or	O
nearly	O
same	O
mass	O
,	O
but	O
different	O
lipids	O
)	O
are	O
also	O
possible	O
,	O
so	O
lipid	O
identification	O
is	O
less	O
certain	O
.	O
Nevertheless	O
,	O
it	O
was	O
used	O
here	O
to	O
complement	O
the	O
targeted	O
panels	O
and	O
give	O
a	O
glimpse	O
of	O
the	O
diversity	O
of	O
other	O
lipids	O
present	O
in	O
Quaker	O
parrot	O
plasma	O
and	O
to	O
highlight	O
which	O
lipid	O
groups	O
and	O
species	O
are	O
important	O
.	O
In	O
addition	O
to	O
the	O
incomplete	O
information	O
on	O
individual	O
lipid	O
species	O
,	O
our	O
investigation	O
of	O
the	O
Quaker	O
parrot	O
lipidome	O
was	O
limited	O
to	O
available	O
targeted	O
panels	O
.	O
In	O
particular	O
,	O
the	O
prenol	O
lipids	O
were	O
not	O
investigated	O
,	O
a	O
group	O
including	O
dolichols	O
,	O
ubiquinones	O
,	O
some	O
fat	O
-	O
soluble	O
vitamins	O
(	O
K	O
and	O
E	O
)	O
,	O
and	O
carotenoids	O
.	O
Within	O
investigated	O
lipid	O
categories	O
,	O
some	O
important	O
lipids	O
were	O
also	O
not	O
measured	O
such	O
as	O
most	O
glycerophospholipids	O
other	O
than	O
PC	O
,	O
MGs	O
,	O
and	O
cardiolipins	O
.	O
Several	O
bioactive	O
lipids	O
were	O
reported	O
here	O
,	O
mainly	O
steroid	O
hormones	O
,	O
but	O
the	O
mediator	O
lipidome	O
including	O
fatty	O
acid	O
derivatives	O
was	O
not	O
reported	O
as	O
it	O
was	O
considered	O
outside	O
of	O
the	O
scope	O
of	O
this	O
report	O
,	O
which	O
focused	O
on	O
the	O
high	O
abundance	O
lipid	O
(	O
macrolipidomics	O
)	O
.	O
Nevertheless	O
,	O
a	O
complete	O
characterization	O
of	O
the	O
parrot	O
lipidome	O
at	O
a	O
high	O
level	O
of	O
molecular	O
information	O
would	O
require	O
considerable	O
resources	O
and	O
extensive	O
analysis	O
and	O
we	O
believe	O
the	O
snapshot	O
of	O
the	O
lipidome	O
reported	O
here	O
gives	O
a	O
reasonable	O
overview	O
of	O
what	O
could	O
be	O
of	O
relevance	O
for	O
potential	O
clinical	B-methodology
research	I-methodology
applications	O
.	O
The	O
reported	O
lipidome	O
of	O
other	O
species	O
,	O
mainly	O
mammals	O
,	O
is	O
typically	O
of	O
comparable	O
breadth	O
and	O
details	O
[	O
21	O
,	O
45	O
,	O
46	O
]	O
As	O
the	O
plasma	O
lipidome	O
of	O
other	O
avian	O
species	O
including	O
chickens	O
has	O
not	O
been	O
reported	O
,	O
comparisons	O
can	O
only	O
be	O
made	O
with	O
mammals	O
,	O
in	O
particular	O
humans	O
in	O
which	O
it	O
has	O
been	O
well	O
characterized	O
and	O
quantitative	O
data	O
are	O
available	O
[	O
21	O
,	O
45	O
–	O
47	O
]	O
.	O
However	O
,	O
methodologies	O
in	O
these	O
other	O
studies	O
were	O
different	O
,	O
thus	O
comparisons	O
were	O
mainly	O
made	O
based	O
on	O
large	O
magnitude	O
of	O
concentration	O
differences	O
and	O
on	O
relative	O
abundance	O
within	O
lipid	O
classes	O
.	O

In	O
addition	O
,	O
the	O
plasma	O
lipidome	O
is	O
heavily	O
influenced	O
by	O
the	O
diet	O
,	O
in	O
particular	O
its	O
fatty	O
acid	O
profile	O
,	O
and	O
the	O
reported	O
lipidome	O
should	O
be	O
interpreted	O
in	O
the	O
context	O
of	O
the	O
diet	O
consumed	O
as	O
humans	O
are	O
omnivorous	O
and	O
Quaker	O
parrots	O
are	O
frugivorous	O
/	O
granivorous	O
.	O
For	O
this	O
reason	O
,	O
the	O
parrot	O
diet	O
was	O
also	O
analyzed	O
.	O
Surprisingly	O
,	O
the	O
Quaker	O
parrot	O
lipidome	O
had	O
many	O
similarities	O
to	O
reported	O
mammalian	O
lipidomes	O
,	O
but	O
also	O
some	O
unique	O
differences	O
.	O
The	O
relative	O
importance	O
of	O
the	O
different	O
lipid	O
categories	O
was	O
similar	O
in	O
parrots	O
and	O
humans	O
on	O
a	O
molar	O
basis	O
(	O
sterols	O
>	O
glycerolipids	O
>	O
glycerophospholipids	O
)	O
;	O
however	O
,	O
most	O
lipid	O
group	O
concentrations	O
were	O
much	O
higher	O
in	O
the	O
parrots	O
than	O
in	O
humans	O
[	O
21	O
]	O
.	O
Several	O
very	O
abundant	O
lipids	O
in	O
the	O
human	O
plasma	O
lipidome	O
were	O
also	O
found	O
to	O
be	O
abundant	O
in	O
parrots	O
.	O
The	O
parrot	O
plasma	O
lipidome	O
was	O
dominated	O
by	O
free	O
cholesterol	O
and	O
cholesteryl	O
linoleate	O
[	O
CE	O
(	O
18	O
:	O
2	O
)	O
]	O
on	O
a	O
molar	O
basis	O
,	O
which	O
is	O
also	O
the	O
case	O
in	O
humans	O
.	O
However	O
,	O
CE	O
(	O
18	O
:	O
2	O
)	O
represents	O
only	O
50	O
%	O
of	O
all	O
CE	O
in	O
humans	O
compared	O
to	O
more	O
than	O
70	O
%	O
in	O
parrots	O
,	O
but	O
the	O
same	O
number	O
of	O
CE	O
species	O
weren	O
’	O
t	O
analyzed	O
.	O
Free	O
cholesterol	O
and	O
all	O
CE	O
concentrations	O
were	O
also	O
much	O
higher	O
than	O
in	O
humans	O
.	O
However	O
,	O
lathosterol	O
,	O
a	O
marker	O
of	O
cholesterol	O
synthesis	O
,	O
was	O
much	O
lower	O
in	O
Quaker	O
parrots	O
.	O
For	O
glycerophospholipids	O
,	O
PC	O
(	O
36	O
:	O
2	O
)	O
,	O
PC	O
(	O
34	O
:	O
2	O
)	O
,	O
and	O
PC	O
(	O
38	O
:	O
4	O
)	O
were	O
some	O
of	O
the	O
most	O
common	O
PCs	O
in	O
both	O
species	O
.	O
PC	O
species	O
identified	O
as	O
abundant	O
on	O
untargeted	O
techniques	O
were	O
also	O
common	O
species	O
in	O
human	O
plasma	O
.	O
Common	O
LPCs	O
in	O
Quaker	O
parrots	O
were	O
also	O
common	O
in	O
humans	O
.	O
For	O
glycerolipids	O
,	O
a	O
similar	O
TG	O
profile	O
was	O
also	O
observed	O
with	O
TG	O
(	O
52	O
:	O
3	O
)	O
being	O
the	O
most	O
common	O
plasma	O
TG	O
in	O
both	O
species	O
followed	O
by	O
TGs	O
in	O
C52	O
or	O
C54	O
.	O
The	O
DG	O
profiles	O
were	O
also	O
similar	O
with	O
DG	O
in	O
C36	O
being	O
the	O
most	O
common	O
.	O

For	O
sphingolipids	O
,	O
sphingosine	O
was	O
the	O
most	O
common	O
sphingoid	O
base	O
in	O
Quaker	O
parrot	O
as	O
it	O
is	O
the	O
case	O
in	O
humans	O
and	O
mammals	O
in	O
general	O
.	O
SM	O
(	O
d18	O
:	O
1	O
/	O
16	O
:	O
0	O
)	O
was	O
the	O
most	O
common	O
sphingomyelin	O
by	O
far	O
representing	O
about	O
1	O
/	O
3	O
of	O
all	O
SM	O
in	O
both	O
species	O
.	O
It	O
is	O
also	O
the	O
most	O
common	O
SM	O
in	O
a	O
number	O
of	O
other	O
mammals	O
[	O
48	O
]	O
.	O
As	O
in	O
humans	O
,	O
the	O
fatty	O
acid	O
distribution	O
in	O
ceramides	O
was	O
quite	O
different	O
from	O
SM	O
with	O
palmitic	O
acid	O
contributing	O
very	O
little	O
compared	O
to	O
very	O
-	O
long	O
chain	O
fatty	O
acids	O
.	O
As	O
in	O
humans	O
and	O
other	O
mammals	O
plasma	O
,	O
ceramides	O
containing	O
C24	O
:	O
1	O
and	O
C24	O
:	O
0	O
were	O
the	O
most	O
abundant	O
ceramides	O
in	O
Quaker	O
parrot	O
plasma	O
representing	O
more	O
than	O
60	O
%	O
of	O
all	O
ceramides	O
[	O
48	O
]	O
.	O
Ceramides	O
are	O
clinically	O
important	O
metabolites	O
and	O
lipid	O
precursors	O
and	O
can	O
also	O
act	O
as	O
bioactive	O
lipids	O
.	O
They	O
have	O
frequently	O
been	O
identified	O
as	O
potential	O
biomarkers	O
for	O
a	O
variety	O
of	O
diseases	O
in	O
humans	O
and	O
mammalian	O
models	O
[	O
20	O
,	O
49	O
,	O
50	O
]	O
.	O
Therefore	O
,	O
these	O
similarities	O
in	O
parrots	O
may	O
translate	O
into	O
similar	O
ceramide	O
profiles	O
for	O
lipid	O
-	O
related	O
diseases	O
.	O
Likewise	O
,	O
glycosphingolipids	O
had	O
similar	O
fatty	O
acid	O
compositions	O
than	O
in	O
humans	O
with	O
very	O
-	O
long	O
chain	O
fatty	O
acids	O
predominating	O
.	O
A	O
difference	O
observed	O
between	O
humans	O
and	O
Quaker	O
parrots	O
pertain	O
to	O
their	O
non	O
-	O
esterified	O
fatty	O
acid	O
profile	O
.	O
In	O
Quaker	O
parrots	O
,	O
palmitic	O
acid	O
was	O
the	O
most	O
common	O
free	O
fatty	O
acid	O
in	O
plasma	O
by	O
far	O
despite	O
these	O
parrots	O
having	O
a	O
dietary	O
fatty	O
acid	O
profile	O
dominated	O
by	O
oleic	O
acid	O
.	O
Free	O
palmitic	O
acid	O
is	O
a	O
potent	O
mediator	O
of	O
lipotoxicity	O
and	O
high	O
levels	O
in	O
Quaker	O
parrots	O
are	O
noteworthy	O
considering	O
their	O
high	O
susceptibility	O
to	O
hepatic	O
lipidosis	O
[	O
2	O
,	O
51	O
]	O
.	O
By	O
comparison	O
,	O
oleic	O
acid	O
is	O
the	O
main	O
free	O
fatty	O
acid	O
in	O
human	O
plasma	O
.	O
In	O
addition	O
,	O
all	O
concentrations	O
of	O
free	O
fatty	O
acids	O
were	O
far	O
higher	O
to	O
reported	O
concentrations	O
in	O
humans	O
.	O

However	O
,	O
palmitic	O
,	O
stearic	O
,	O
and	O
oleic	O
acids	O
still	O
represented	O
the	O
vast	O
majority	O
of	O
free	O
fatty	O
acids	O
in	O
both	O
species	O
and	O
arachidonic	O
acid	O
and	O
linoleic	O
acids	O
were	O
also	O
the	O
most	O
common	O
PUFAs	O
in	O
both	O
species	O
.	O
Another	O
marked	O
difference	O
was	O
in	O
the	O
plasma	O
bile	O
acid	O
profile	O
.	O
In	O
parrots	O
,	O
the	O
two	O
major	O
bile	O
acids	O
representing	O
close	O
to	O
90	O
%	O
of	O
all	O
bile	O
acids	O
were	O
the	O
taurine	O
-	O
conjugated	O
bile	O
acids	O
taurochenodeoxycholic	O
acid	O
and	O
taurocholic	O
acid	O
.	O
The	O
same	O
bile	O
acids	O
also	O
predominate	O
in	O
chickens	O
and	O
turkeys	O
[	O
52	O
]	O
.	O
In	O
humans	O
,	O
these	O
2	O
bile	O
acids	O
are	O
also	O
common	O
in	O
plasma	O
but	O
glycine	O
-	O
conjugated	O
bile	O
acids	O
are	O
equally	O
or	O
more	O
common	O
[	O
53	O
,	O
54	O
]	O
whereas	O
they	O
were	O
at	O
very	O
low	O
to	O
undetectable	O
concentrations	O
in	O
Quaker	O
parrot	O
plasma	O
.	O
Different	O
lipidomic	O
profiles	O
were	O
detected	O
in	O
female	O
and	O
male	O
Quaker	O
parrots	O
in	O
this	O
study	O
.	O
Although	O
our	O
analysis	O
lacked	O
statistical	O
power	O
to	O
find	O
significant	O
differences	O
between	O
sexes	O
among	O
the	O
individual	O
lipids	O
species	O
,	O
most	O
lipids	O
still	O
appear	O
to	O
be	O
more	O
abundant	O
in	O
females	O
,	O
especially	O
glycerophospholipids	O
and	O
some	O
acyl	O
-	O
carnitines	O
,	O
TGs	O
,	O
and	O
CEs	O
whereas	O
a	O
number	O
of	O
sphingolipids	O
were	O
more	O
abundant	O
in	O
males	O
.	O
These	O
differences	O
are	O
likely	O
explained	O
by	O
the	O
specific	O
female	O
lipid	O
metabolism	O
associated	O
with	O
egg	O
laying	O
(	O
vitellogenesis	O
)	O
.	O
Vitellogenesis	O
is	O
typically	O
associated	O
with	O
increased	O
plasma	O
TG	O
and	O
Glycerophospholipids	O
[	O
55	O
]	O
.	O
The	O
lipids	O
found	O
in	O
eggs	O
are	O
mainly	O
composed	O
of	O
TGs	O
and	O
glycerophospholipids	O
with	O
a	O
lower	O
proportion	O
of	O
cholesterol	O
and	O
cholesteryl	O
esters	O
as	O
shown	O
by	O
published	O
lipidomic	O
analysis	O
of	O
chicken	O
egg	O
yolk	O
[	O
56	O
]	O
.	O
Males	O
also	O
had	O
more	O
Cer	O
(	O
d18	O
:	O
1	O
/	O
18	O
:	O
0	O
)	O
,	O
which	O
was	O
identified	O
on	O
both	O
PLS	O
-	O
DA	O
and	O
heatmaps	O
and	O
also	O
more	O
of	O
other	O
long	O
-	O
chain	O
fatty	O
acid	O
sphingolipid	O
species	O
than	O
females	O
.	O
In	O
humans	O
,	O
a	O
number	O
of	O
plasmatic	O
sphingolipids	O
are	O
increased	O
in	O
association	O
with	O
steatohepatitis	O
and	O
fatty	O
liver	O
disease	O
[	O
20	O
]	O
.	O

It	O
is	O
interesting	O
as	O
male	O
Quaker	O
parrots	O
have	O
more	O
than	O
3	O
times	O
the	O
prevalence	O
of	O
hepatic	O
lipidosis	O
than	O
female	O
Quaker	O
parrots	O
so	O
this	O
association	O
could	O
also	O
prove	O
to	O
be	O
important	O
in	O
this	O
species	O
[	O
2	O
]	O
.	O
The	O
Quaker	O
parrots	O
in	O
this	O
study	O
were	O
young	O
but	O
either	O
close	O
to	O
sexual	O
maturity	O
or	O
had	O
just	O
reached	O
sexual	O
maturity	O
at	O
time	O
of	O
sampling	O
as	O
some	O
females	O
laid	O
eggs	O
just	O
a	O
few	O
months	O
after	O
the	O
study	O
(	O
sexual	O
maturity	O
is	O
reported	O
to	O
be	O
at	O
1	O
–	O
2	O
years	O
of	O
age	O
in	O
this	O
species	O
)	O
.	O
Only	O
12	O
Quaker	O
parrots	O
were	O
used	O
in	O
this	O
study	O
with	O
6	O
replicates	O
per	O
panel	O
.	O
While	O
this	O
seems	O
like	O
a	O
small	O
sample	O
size	O
,	O
5	O
–	O
6	O
animals	O
are	O
typically	O
used	O
for	O
discovery	O
studies	O
on	O
previously	O
uncharacterized	O
plasma	O
lipidomes	O
due	O
to	O
the	O
number	O
of	O
panels	O
and	O
the	O
associated	O
high	O
cost	O
of	O
lipidomic	O
analysis	O
[	O
45	O
–	O
47	O
,	O
57	O
]	O
.	O
Some	O
of	O
the	O
reported	O
animal	O
plasma	O
lipidomes	O
were	O
also	O
only	O
determined	O
using	O
untargeted	O
techniques	O
.	O
The	O
parrots	O
in	O
this	O
study	O
were	O
relatively	O
young	O
and	O
from	O
a	O
homogeneous	O
colony	O
,	O
therefore	O
the	O
reported	O
lipidome	O
may	O
not	O
capture	O
the	O
variability	O
that	O
is	O
present	O
in	O
different	O
demographic	O
groups	O
and	O
in	O
older	O
parrots	O
.	O
Another	O
limitation	O
of	O
our	O
study	O
is	O
the	O
accuracy	O
of	O
reported	O
lipid	O
concentrations	O
.	O
While	O
targeted	O
lipidomics	O
is	O
quantitative	O
,	O
it	O
still	O
suffers	O
from	O
accuracy	O
and	O
precision	O
issues	O
.	O
This	O
is	O
due	O
in	O
part	O
to	O
the	O
lack	O
of	O
suitable	O
internal	O
standards	O
for	O
every	O
lipid	O
species	O
,	O
differing	O
ion	O
suppression	O
,	O
collision	O
energy	O
,	O
and	O
ionization	O
efficiency	O
between	O
lipid	O
and	O
fatty	O
acid	O
types	O
,	O
and	O
the	O
lack	O
of	O
standardization	O
of	O
lipidomics	O
techniques	O
[	O
41	O
,	O
44	O
,	O
58	O
–	O
60	O
]	O
.	O
Therefore	O
,	O
reported	O
concentrations	O
should	O
be	O
considered	O
as	O
semiquantitative	O
estimates	O
of	O
the	O
true	O
concentrations	O
and	O
comparisons	O
between	O
lipids	O
should	O
only	O
be	O
made	O
within	O
the	O
same	O
lipid	O
classes	O
and	O
using	O
the	O
reported	O
relative	O
values	O
(	O
%	O
in	O
tables	O
or	O
fold	O
changes	O
)	O
.	O
Studies	O
have	O
shown	O
up	O
to	O
30	O
–	O
80	O
%	O
variability	O
/	O
imprecision	O
with	O
various	O
methodology	O
settings	O
and	O
depending	O
on	O
lipid	O
classes	O
[	O
35	O
,	O
58	O
,	O
60	O
]	O
.	O
The	O
accuracy	O
of	O
the	O
Biocrates	O
Absolute	O
IDQ	O
p400	O
HR	O
kit	O
used	O
in	O
our	O
study	O
has	O
specifically	O
been	O
investigated	O
across	O
laboratories	O
and	O
showed	O
some	O
inaccuracies	O
with	O
biases	O
of	O
about	O
50	O
%	O
for	O
most	O
analytes	O
[	O
35	O
]	O
.	O

In	O
this	O
kit	O
,	O
TGs	O
and	O
CEs	O
had	O
the	O
largest	O
biases	O
up	O
to	O
100	O
–	O
200	O
%	O
in	O
overestimation	O
[	O
35	O
]	O
.	O
This	O
was	O
definitely	O
observed	O
in	O
this	O
study	O
as	O
total	O
cholesterol	O
compounds	O
(	O
free	O
cholesterol	O
+	O
CEs	O
)	O
and	O
total	O
glycerides	O
(	O
TGs	O
+	O
DGs	O
)	O
were	O
largely	O
overestimated	O
compared	O
to	O
known	O
plasma	O
values	O
in	O
this	O
colony	O
of	O
Quaker	O
parrots	O
as	O
measured	O
using	O
conventional	O
techniques	O
[	O
12	O
]	O
.	O
TGs	O
and	O
CEs	O
are	O
neutral	O
lipids	O
,	O
which	O
present	O
specific	O
challenges	O
for	O
absolute	O
quantification	O
using	O
MS	O
-	O
based	O
lipidomics	O
[	O
61	O
]	O
.	O
In	O
conclusion	O
,	O
this	O
study	O
lays	O
the	O
necessary	O
groundwork	O
for	O
further	O
research	O
on	O
the	O
pathophysiology	O
,	O
biomarkers	O
discovery	O
,	O
and	O
pharmacologic	O
intervention	O
of	O
lipid	O
-	O
related	O
diseases	O
in	O
parrots	O
such	O
as	O
atherosclerosis	O
and	O
hepatic	O
lipidosis	O
,	O
which	O
are	O
exceedingly	O
common	O
in	O
captivity	O
.	O
Lipid	O
biomarkers	O
of	O
lipid	O
-	O
related	O
diseases	O
in	O
humans	O
are	O
often	O
lipid	O
mediators	O
such	O
as	O
those	O
derived	O
from	O
polyunsaturated	O
fatty	O
acids	O
(	O
arachidonic	O
acid	O
,	O
ALA	O
,	O
DHA	O
,	O
EPA	O
)	O
as	O
part	O
of	O
the	O
microlipidome	O
or	O
glycerophospholipids	O
such	O
as	O
PCs	O
,	O
PEs	O
,	O
and	O
PIs	O
or	O
metabolite	O
intermediates	O
and	O
precursors	O
of	O
structural	O
lipids	O
such	O
as	O
non	O
-	O
esterified	O
fatty	O
acids	O
,	O
ceramides	O
,	O
LPCs	O
,	O
LPC	O
-	O
Os	O
,	O
DGs	O
,	O
and	O
a	O
variety	O
of	O
small	O
lipid	O
molecules	O
[	O
20	O
,	O
22	O
,	O
41	O
,	O
49	O
,	O
62	O
,	O
63	O
]	O
.	O
In	O
Quaker	O
parrots	O
,	O
some	O
of	O
the	O
relative	O
abundance	O
and	O
importance	O
of	O
these	O
lipids	O
is	O
very	O
similar	O
to	O
humans	O
such	O
as	O
for	O
most	O
PCs	O
and	O
DGs	O
while	O
it	O
is	O
very	O
different	O
for	O
others	O
such	O
as	O
non	O
-	O
esterified	O
fatty	O
acids	O
and	O
ceramides	O
.	O
Future	O
research	O
exploring	O
these	O
lipid	O
biomarkers	O
is	O
therefore	O
likely	O
to	O
find	O
both	O
conserved	O
biomarkers	O
across	O
species	O
and	O
species	O
-	O
specific	O
biomarkers	O
.	O
In	O
addition	O
,	O
specific	O
lipidomic	O
signatures	O
of	O
the	O
various	O
psittacine	O
lipid	O
disorders	O
could	O
be	O
investigated	O
as	O
well	O
as	O
lipidomic	O
profiling	O
of	O
parrot	O
plasma	O
with	O
various	O
nutritional	O
and	O
pharmacological	O
interventions	O
for	O
lipid	O
disorders	O
.	O

Finally	O
,	O
lipidomic	O
fingerprinting	O
between	O
various	O
species	O
of	O
parrots	O
is	O
another	O
area	O
that	O
may	O
help	O
to	O
elucidate	O
species	O
predisposition	O
to	O
certain	O
lipid	O
disorders	O
.	O
HB	O
:	O
D19ZO	O
-	O
301	O
,	O
Morris	O
Animal	O
Foundation	O
,	O
https	O
:	O
/	O
/	O
www	O
.	O
morrisanimalfoundation	O
.	O
org	O
This	O
publication	O
has	O
not	O
been	O
reviewed	O
or	O
endorsed	O
by	O
the	O
Morris	O
Animal	O
Foundation	O
and	O
the	O
views	O
expressed	O
do	O
not	O
necessarily	O
reflect	O
the	O
views	O
of	O
the	O
Foundation	O
,	O
its	O
officers	O
,	O
directors	O
,	O
affiliates	O
or	O
agents	O
.	O
HB	O
:	O
054209	O
,	O
OVC	O
Pet	O
Trust	O
,	O
https	O
:	O
/	O
/	O
ovc	O
.	O
uoguelph	O
.	O
ca	O
/	O
pettrust	O
/	O
help	O
-	O
pets	O
-	O
we	O
-	O
love	O
-	O
live	O
-	O
longer	O
-	O
healthier	O
-	O
lives	O
The	O
funders	O
had	O
no	O
role	O
in	O
study	B-methodology
design	I-methodology
,	O
data	O
collection	O
and	O
analysis	O
,	O
decision	O
to	O
publish	O
,	O
or	O
preparation	O
of	O
the	O
manuscript	O
.	O
Data	O
are	O
available	O
in	O
the	O
Scholars	O
Portal	O
Dataverse	O
(	O
doi	O
:	O
10	O
.	O
5683	O
/	O
SP2	O
/	O
XUW31U	O
)	O
.	O

Extensive	O
Study	O
of	O
Breast	O
Milk	O
and	O
Infant	O
Growth	O
:	O
Protocol	O
of	O
the	O
Cambridge	O
Baby	O
Growth	O
and	O
Breastfeeding	O
Study	O
(	O
CBGS	O
-	O
BF	O
)	O
infant	O
growth	O
;	O
breast	O
milk	O
;	O
early	O
life	O
;	O
cohort	B-methodology
profile	O
;	O
infant	O
nutrition	O
;	O
breast	O
milk	O
nutrients	O
;	O
human	O
milk	O
oligosaccharides	O
;	O
breastfeeding	O
;	O
childhood	O
obesity	O
;	O
prevention	O
Growth	O
and	O
nutrition	O
during	O
early	O
life	O
have	O
been	O
strongly	O
linked	O
to	O
future	O
health	O
and	O
metabolic	O
risks	O
.	O
The	O
Cambridge	O
Baby	O
Growth	O
Study	O
(	O
CBGS	O
)	O
,	O
a	O
longitudinal	B-methodology
birth	I-methodology
cohort	I-methodology
of	O
2229	O
mother	O
–	O
infant	O
pairs	O
,	O
was	O
set	O
up	O
in	O
2001	O
to	O
investigate	O
early	O
life	O
determinant	O
factors	O
of	O
infant	O
growth	O
and	O
body	O
composition	O
in	O
the	O
UK	O
setting	O
.	O
To	O
carry	O
out	O
extensive	O
profiling	O
of	O
breastmilk	O
intakes	O
and	O
composition	O
in	O
relation	O
to	O
infancy	O
growth	O
,	O
the	O
Cambridge	O
Baby	O
Growth	O
and	O
Breastfeeding	O
Study	O
(	O
CBGS	O
-	O
BF	O
)	O
was	O
established	O
upon	O
the	O
original	O
CBGS	O
.	O
The	O
strict	O
inclusion	B-methodology
criteria	I-methodology
were	O
applied	O
,	O
focusing	O
on	O
a	O
normal	O
birth	O
weight	O
vaginally	O
delivered	O
infant	O
cohort	B-methodology
born	O
of	O
healthy	O
and	O
non	O
-	O
obese	O
mothers	O
.	O
Crucially	O
,	O
only	O
infants	O
who	O
were	O
exclusively	O
breastfed	O
for	O
the	O
first	O
6	O
weeks	O
of	O
life	O
were	O
retained	O
in	O
the	O
analysed	O
study	O
sample	O
.	O
At	O
each	O
visit	O
from	O
birth	O
,	O
2	O
weeks	O
,	O
6	O
weeks	O
,	O
and	O
then	O
at	O
3	O
,	O
6	O
,	O
12	O
,	O
24	O
,	O
and	O
36	O
months	O
,	O
longitudinal	O
anthropometric	O
measurements	O
and	O
blood	O
spot	O
collections	O
were	O
conducted	O
.	O
Infant	O
body	O
composition	O
was	O
assessed	O
using	O
air	O
displacement	O
plethysmography	O
(	O
ADP	O
)	O
at	O
6	O
weeks	O
and	O
3	O
months	O
of	O
age	O
.	O
Breast	O
milk	O
was	O
collected	O
for	O
macronutrients	O
and	O
human	O
milk	O
oligosaccharides	O
(	O
HMO	O
)	O
measurements	O
.	O
Breast	O
milk	O
intake	O
volume	O
was	O
also	O
estimated	O
,	O
as	O
well	O
as	O
sterile	O
breastmilk	O
and	O
infant	O
stool	O
collection	O
for	O
microbiome	O
study	O
.	O
The	O
original	O
Cambridge	O
Baby	O
Growth	O
Study	O
(	O
CBGS	O
)	O
was	O
set	O
up	O
in	O
2001	O
,	O
historically	O
to	O
investigate	O
the	O
effect	O
of	O
environmental	O
factors	O
on	O
male	O
reproductive	O
development	O
but	O
then	O
the	O
entire	O
birth	O
cohort	B-methodology
(	O
males	O
and	O
females	O
)	O
were	O
included	O
to	O
examine	O
the	O
ante	O
-	O
and	O
postnatal	O
determinants	O
of	O
infant	O
growth	O
and	O
body	O
composition	O
,	O
including	O
genetic	O
and	O
environmental	O
factors	O
[	O
1	O
]	O
.	O
The	O
recruitment	O
took	O
place	O
until	O
2009	O
among	O
pregnant	O
mothers	O
from	O
a	O
single	O
maternity	O
hospital	O
in	O
Cambridge	O
.	O

The	O
study	O
visits	O
were	O
conducted	O
twice	O
during	O
pregnancy	O
and	O
four	O
times	O
postnatally	O
at	O
3	O
,	O
12	O
,	O
18	O
,	O
and	O
24	O
months	O
.	O
The	O
original	O
CBGS	O
has	O
provided	O
valuable	O
insights	O
into	O
the	O
maternal	O
-	O
foetal	O
communication	O
and	O
pregnancy	O
comorbidities	O
[	O
2	O
,	O
3	O
]	O
,	O
infant	O
growth	O
and	O
nutrition	O
[	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
]	O
and	O
its	O
association	O
to	O
later	O
childhood	O
outcomes	O
[	O
8	O
]	O
,	O
as	O
well	O
as	O
growth	O
and	O
adiposity	O
development	O
of	O
infants	O
at	O
risk	O
[	O
9	O
]	O
.	O
The	O
original	O
CBGS	O
and	O
other	O
studies	O
have	O
associated	O
breastfeeding	O
with	O
slower	O
subsequent	O
growth	O
and	O
adiposity	O
gains	O
in	O
infancy	O
and	O
childhood	O
compared	O
to	O
formula	O
feeding	O
[	O
4	O
,	O
10	O
,	O
11	O
,	O
12	O
]	O
,	O
and	O
thus	O
support	O
breastfeeding	O
as	O
a	O
potential	O
component	O
in	O
the	O
early	O
prevention	O
against	O
later	O
obesity	O
.	O
It	O
is	O
conjectured	O
that	O
this	O
difference	O
in	O
early	O
growth	O
rates	O
may	O
be	O
due	O
to	O
the	O
nutrient	O
contents	O
in	O
human	O
breast	O
milk	O
(	O
BM	O
)	O
.	O
Accordingly	O
,	O
triglycerides	O
,	O
lactose	O
,	O
protein	O
,	O
and	O
SCFA	O
contents	O
in	O
BM	O
have	O
been	O
considered	O
important	O
for	O
subsequent	O
infants	O
’	O
weight	O
and	O
adiposity	O
gains	O
[	O
4	O
,	O
5	O
,	O
13	O
]	O
.	O
However	O
,	O
BM	O
nutrient	O
concentrations	O
do	O
not	O
necessarily	O
reflect	O
the	O
amount	O
consumed	O
by	O
infants	O
.	O
The	O
measurement	O
of	O
infant	O
’	O
s	O
nutritional	O
intake	O
from	O
BM	O
could	O
provide	O
a	O
better	O
mechanistic	O
link	O
between	O
breastfeeding	O
and	O
infancy	O
growth	O
and	O
adiposity	O
.	O
Additionally	O
several	O
studies	O
have	O
reported	O
that	O
the	O
establishment	O
of	O
infant	O
gut	O
microbiota	O
,	O
which	O
is	O
associated	O
with	O
the	O
BM	O
microbiome	O
and	O
potentially	O
with	O
BM	O
oligosaccharide	O
composition	O
,	O
may	O
influence	O
childhood	O
weight	O
gain	O
trajectories	O
,	O
early	O
metabolic	O
programming	O
,	O
and	O
hence	O
later	O
obesity	O
risk	O
[	O
14	O
,	O
15	O
]	O
.	O
Therefore	O
,	O
the	O
CBGS	O
-	O
Breastfeeding	O
Study	O
(	O
CBGS	O
-	O
BF	O
)	O
was	O
established	O
in	O
2015	O
in	O
collaboration	O
with	O
the	O
research	O
division	O
of	O
Mead	O
Johnson	O
Nutrition	O
,	O
with	O
the	O
particular	O
aim	O
to	O
identify	O
factors	O
in	O
BM	O
that	O
are	O
associated	O
with	O
infant	O
growth	O
and	O
might	O
reduce	O
obesity	O
risk	O
later	O
in	O
life	O
.	O
In	O
this	O
study	O
,	O
parameters	O
of	O
BM	O
intake	O
and	O
composition	O
were	O
studied	O
more	O
extensively	O
,	O
including	O
BM	O
intake	O
volume	O
using	O
a	O
deuterium	O
-	O
labelled	O
water	O
technique	O
,	O
longitudinal	O
BM	O
collection	O
and	O
a	O
more	O
detailed	O
BM	O
composition	O
including	O
macronutrients	O
,	O
butyrate	O
and	O
human	O
milk	O
oligosaccharides	O
(	O
HMOs	O
)	O
,	O
and	O
explorative	O
analyses	O
of	O
microbiota	O
in	O
BM	O
and	O
infant	O
gut	O
.	O

This	O
study	O
has	O
been	O
funded	O
by	O
Mead	O
Johnson	O
Nutrition	O
with	O
additional	O
support	O
from	O
MRC	O
Epidemiology	O
Unit	O
,	O
NIHR	O
Clinical	B-methodology
Research	I-methodology
Network	O
,	O
NIHR	O
Cambridge	O
Biomedical	O
Research	O
Centre	O
,	O
Newlife	O
,	O
and	O
Mothercare	O
.	O
Mother	O
–	O
infant	O
pairs	O
were	O
recruited	O
at	O
birth	O
from	O
the	O
same	O
single	O
centre	O
as	O
the	O
original	O
CBGS	O
,	O
the	O
Rosie	O
Maternity	O
Hospital	O
,	O
Cambridge	O
(	O
UK	O
)	O
.	O
Inclusion	B-methodology
criteria	I-methodology
were	O
:	O
healthy	O
term	O
vaginally	O
delivered	O
singletons	O
of	O
normal	O
birthweight	O
(	O
defined	O
as	O
greater	O
than	O
−1	O
.	O
5	O
SDS	O
for	O
gestational	O
age	O
,	O
using	O
British	O
1990	O
growth	O
reference	O
)	O
and	O
if	O
the	O
family	O
intended	O
to	O
continue	O
exclusive	O
breastfeeding	O
from	O
birth	O
until	O
at	O
least	O
age	O
6	O
weeks	O
.	O
To	O
allow	O
for	O
standardised	O
microbiota	O
sampling	O
,	O
further	O
exclusion	B-methodology
criteria	I-methodology
were	O
:	O
maternal	O
pre	O
-	O
pregnancy	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
>	O
30	O
kg	O
/	O
m2	O
)	O
,	O
any	O
significant	O
maternal	O
illness	O
or	O
pregnancy	O
comorbidity	O
,	O
use	O
of	O
antibiotics	O
or	O
steroids	O
in	O
30	O
days	O
before	O
delivery	O
,	O
and	O
regular	O
consumption	O
of	O
probiotics	O
.	O
In	O
total	O
,	O
150	O
mother	O
–	O
infant	O
pairs	O
were	O
recruited	O
,	O
of	O
whom	O
94	O
were	O
exclusively	O
breastfed	O
for	O
at	O
least	O
6	O
weeks	O
and	O
were	O
thus	O
eligible	O
for	O
retention	O
in	O
the	O
study	O
.	O
During	O
that	O
exclusive	O
breastfeeding	O
period	O
,	O
as	O
defined	O
by	O
the	O
WHO	O
,	O
infants	O
received	O
solely	O
BM	O
and	O
no	O
other	O
liquid	O
or	O
solid	O
food	O
was	O
given	O
,	O
except	O
drops	O
of	O
multivitamin	O
/	O
mineral	O
supplements	O
or	O
medicines	O
if	O
indicated	O
[	O
16	O
]	O
.	O
The	O
CBGS	O
-	O
BF	O
was	O
approved	O
by	O
the	O
National	O
Research	O
Ethics	O
Service	O
Cambridgeshire	O
2	O
Research	O
Ethics	O
Committee	O
,	O
and	O
all	O
mothers	O
gave	O
informed	O
written	O
consent	O
.	O
This	O
study	O
built	O
on	O
the	O
same	O
design	O
and	O
protocol	O
as	O
the	O
original	O
CBGS	O
[	O
1	O
]	O
with	O
extra	O
visits	O
and	O
biological	O
sample	O
collections	O
,	O
including	O
infant	O
stool	O
,	O
dried	O
milk	O
spot	O
(	O
DMS	O
)	O
,	O
and	O
both	O
maternal	O
and	O
infant	O
urine	O
for	O
BM	O
intake	O
volume	O
measurement	O
(	O
Table	O
1	O
,	O
Figure	O
1	O
)	O
.	O
There	O
was	O
also	O
an	O
addition	O
to	O
body	O
composition	O
measurement	O
by	O
estimating	O
infant	O
total	O
body	O
fat	O
-	O
and	O
fat	O
-	O
free	O
mass	O
.	O
This	O
was	O
conducted	O
using	O
air	O
-	O
displacement	O
plethysmography	O
(	O
ADP	O
)	O
,	O
Pea	O
Pod	O
system	O
(	O
Life	O
measurement	O
Inc	O
.	O
,	O
Concord	O
,	O
CA	O
,	O
USA	O
)	O
.	O
All	O
anthropometry	O
and	O
body	O
composition	O
measurements	O
were	O
performed	O
by	O
three	O
trained	O
paediatric	O
research	O
nurses	O
.	O
Birthweight	O
was	O
taken	O
from	O
routine	O
medical	O
records	O
of	O
measurements	O
by	O
health	O
professionals	O
at	O
delivery	O
.	O

Other	O
birth	O
measurements	O
(	O
Table	O
1	O
)	O
were	O
conducted	O
by	O
the	O
research	O
team	O
in	O
the	O
first	O
8	O
days	O
of	O
life	O
.	O
At	O
all	O
subsequent	O
visits	O
,	O
weight	O
,	O
length	O
,	O
subcutaneous	O
skinfolds	O
,	O
head	O
circumference	O
,	O
and	O
waist	O
circumference	O
were	O
measured	O
by	O
the	O
research	O
team	O
(	O
Figure	O
1	O
,	O
Table	O
1	O
)	O
.	O
All	O
of	O
these	O
measurements	O
were	O
done	O
in	O
triplicate	O
and	O
averaged	O
.	O
A	O
Seca	O
757	O
electronic	O
baby	O
scale	O
(	O
Seca	O
Ltd	O
.	O
,	O
Hamburg	O
,	O
Germany	O
)	O
was	O
used	O
to	O
measure	O
infant	O
weight	O
to	O
the	O
nearest	O
1	O
g	O
.	O
Infants	O
were	O
weighed	O
before	O
feeding	O
,	O
naked	O
without	O
diapers	O
,	O
or	O
alternatively	O
the	O
weight	O
of	O
the	O
diaper	O
was	O
subtracted	O
from	O
the	O
measured	O
weight	O
.	O
A	O
Seca	O
416	O
infantometer	O
was	O
used	O
to	O
measure	O
supine	O
length	O
to	O
the	O
nearest	O
0	O
.	O
1	O
cm	O
.	O
Weight	O
and	O
length	O
measurements	O
were	O
used	O
to	O
calculate	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
and	O
ponderal	O
index	O
(	O
PI	O
)	O
,	O
a	O
more	O
accurate	O
adiposity	O
parameter	O
during	O
infancy	O
,	O
by	O
dividing	O
weight	O
(	O
kg	O
)	O
by	O
length	O
cubed	O
(	O
kg	O
/	O
m3	O
)	O
.	O
To	O
measure	O
head	O
circumference	O
(	O
HC	O
)	O
,	O
a	O
Seca	O
212	O
measuring	O
tape	O
was	O
circled	O
around	O
the	O
largest	O
circumference	O
of	O
the	O
head	O
,	O
i	O
.	O
e	O
.	O
,	O
from	O
above	O
the	O
eyebrows	O
and	O
around	O
the	O
back	O
of	O
the	O
head	O
.	O
Adiposity	O
measurements	O
included	O
subcutaneous	O
skinfolds	O
thicknesses	O
,	O
waist	O
circumference	O
(	O
WC	O
)	O
and	O
abdominal	O
fat	O
thickness	O
(	O
U	O
/	O
S	O
)	O
,	O
and	O
accurate	O
body	O
composition	O
estimation	O
using	O
air	O
-	O
displacement	O
plethysmography	O
(	O
ADP	O
)	O
-	O
Pea	O
Pod	O
.	O
Skinfold	O
thicknesses	O
were	O
measured	O
at	O
four	O
sites	O
,	O
triceps	O
,	O
subscapular	O
,	O
flank	O
,	O
and	O
quadriceps	O
,	O
using	O
a	O
Holtain	O
Tanner	O
/	O
Whitehouse	O
Skinfold	O
Caliper	O
(	O
Holtain	O
Ltd	O
.	O
,	O
Crymych	O
,	O
Wales	O
,	O
UK	O
)	O
.	O
Triceps	O
skinfold	O
was	O
measured	O
at	O
the	O
posterior	O
surface	O
of	O
the	O
arm	O
,	O
halfway	O
between	O
the	O
acromial	O
process	O
(	O
shoulder	O
)	O
and	O
the	O
olecranon	O
(	O
elbow	O
)	O
;	O
subscapular	O
skinfold	O
at	O
the	O
oblique	O
angle	O
below	O
the	O
scapula	O
(	O
upper	O
back	O
)	O
;	O
flank	O
skinfold	O
in	O
the	O
posterior	O
axillary	O
line	O
immediately	O
posterior	O
to	O
the	O
iliac	O
crest	O
,	O
and	O
quadriceps	O
skinfold	O
in	O
the	O
midline	O
and	O
halfway	O
between	O
the	O
top	O
of	O
the	O
patella	O
and	O
the	O
inguinal	O
crease	O
.	O

WC	O
was	O
measured	O
using	O
a	O
Seca	O
201	O
ergonomic	O
circumference	O
measuring	O
tape	O
.	O
WC	O
was	O
taken	O
at	O
the	O
end	O
of	O
a	O
normal	O
expiration	O
midway	O
between	O
the	O
lowest	O
rib	O
and	O
the	O
iliac	O
crest	O
as	O
the	O
minimum	O
diameter	O
,	O
preferably	O
before	O
feeding	O
.	O
A	O
standard	O
ultrasound	O
machine	O
(	O
Logiq	O
Book	O
XP	O
ultrasound	O
with	O
3C	O
MHZ	O
-	O
RS	O
abdominal	O
curved	O
array	O
transducer	O
,	O
GE	O
Healthcare	O
,	O
Bedford	O
,	O
UK	O
)	O
was	O
used	O
to	O
assess	O
abdominal	O
intra	O
-	O
abdominal	O
(	O
visceral	O
/	O
medial	O
)	O
and	O
subcutaneous	O
fat	O
depth	O
as	O
parameters	O
of	O
abdominal	O
fat	O
deposition	O
[	O
17	O
]	O
.	O
The	O
infants	O
were	O
lying	O
in	O
the	O
supine	O
position	O
on	O
a	O
flat	O
surface	O
and	O
the	O
ultrasound	O
probe	O
was	O
placed	O
at	O
a	O
point	O
where	O
the	O
midline	O
of	O
the	O
transverse	O
plane	O
used	O
for	O
WC	O
measurement	O
intercepts	O
with	O
the	O
xiphoid	O
line	O
.	O
To	O
measure	O
visceral	O
depth	O
,	O
the	O
probe	O
was	O
placed	O
on	O
the	O
longitudinal	O
plane	O
with	O
a	O
probe	O
depth	O
of	O
6	O
or	O
7	O
cm	O
,	O
and	O
was	O
defined	O
as	O
the	O
distance	O
between	O
the	O
peritoneal	O
boundary	O
and	O
the	O
lumbar	O
vertebrae	O
.	O
Subcutaneous	O
abdominal	O
fat	O
depth	O
was	O
measured	O
with	O
the	O
probe	O
on	O
the	O
transverse	O
plane	O
with	O
a	O
probe	O
depth	O
of	O
4	O
or	O
5	O
cm	O
,	O
and	O
defined	O
as	O
the	O
distance	O
between	O
the	O
bottom	O
of	O
the	O
cutaneous	O
layer	O
and	O
the	O
linea	O
alba	O
,	O
the	O
fibrous	O
sheath	O
lining	O
the	O
anterior	O
abdominal	O
wall	O
.	O
To	O
assess	O
infant	O
total	O
body	O
fat	O
-	O
and	O
fat	O
-	O
free	O
mass	O
,	O
ADP	O
using	O
the	O
Pea	O
Pod	O
system	O
(	O
Life	O
measurement	O
Inc	O
.	O
,	O
Concord	O
,	O
CA	O
,	O
USA	O
)	O
was	O
performed	O
at	O
6	O
weeks	O
and	O
3	O
months	O
.	O
ADP	O
Pea	O
Pod	O
is	O
a	O
safe	O
and	O
non	O
-	O
invasive	O
procedure	O
and	O
infants	O
were	O
lain	O
supine	O
and	O
naked	O
inside	O
the	O
enclosed	O
chamber	O
(	O
Figure	O
2	O
)	O
.	O
ADP	O
Pea	O
Pod	O
assumes	O
a	O
two	O
-	O
component	O
model	O
of	O
body	O
composition	O
(	O
fat	O
-	O
and	O
fat	O
-	O
free	O
components	O
)	O
and	O
is	O
considered	O
to	O
be	O
a	O
criterion	O
method	O
for	O
measuring	O
infant	O
body	O
composition	O
[	O
18	O
]	O
.	O
Dried	O
blood	O
spots	O
(	O
DBS	O
)	O
and	O
a	O
small	O
amount	O
of	O
blood	O
for	O
extraction	O
of	O
plasma	O
were	O
sampled	O
from	O
heel	O
prick	O
at	O
all	O
research	O
visits	O
.	O
Stool	O
samples	O
were	O
collected	O
at	O
each	O
visit	O
from	O
2	O
weeks	O
until	O
12	O
months	O
(	O
in	O
total	O
5	O
visits	O
)	O
for	O
microbiota	O
analysis	O
.	O

To	O
allow	O
consideration	O
of	O
modifiers	O
of	O
microbiota	O
composition	O
,	O
detailed	O
data	O
were	O
gathered	O
via	O
structured	O
questionnaires	O
on	O
exposures	O
to	O
pro	O
/	O
prebiotics	O
,	O
antibiotics	O
,	O
antifungals	O
,	O
and	O
steroids	O
in	O
the	O
14	O
days	O
before	O
each	O
stool	O
sample	O
.	O
Liquid	O
hindmilk	O
was	O
collected	O
at	O
each	O
visit	O
from	O
birth	O
until	O
12	O
months	O
of	O
age	O
if	O
the	O
mothers	O
were	O
still	O
breastfeeding	O
.	O
Milk	O
was	O
hand	O
-	O
or	O
pump	O
-	O
expressed	O
after	O
feeding	O
the	O
baby	O
during	O
the	O
actual	O
research	O
visit	O
,	O
or	O
in	O
7	O
days	O
prior	O
or	O
after	O
visit	O
.	O
To	O
collect	O
liquid	O
BM	O
for	O
microbiota	O
analysis	O
at	O
6	O
weeks	O
of	O
the	O
infant	O
’	O
s	O
age	O
,	O
complete	O
milk	O
expression	O
was	O
taken	O
place	O
from	O
one	O
breast	O
,	O
using	O
a	O
breast	O
pump	O
and	O
sterile	O
milk	O
collection	O
unit	O
provided	O
by	O
the	O
research	O
team	O
.	O
To	O
ensure	O
the	O
sterile	O
procedure	O
,	O
the	O
breast	O
was	O
first	O
cleaned	O
using	O
antiseptic	O
soap	O
and	O
dried	O
with	O
sterile	O
paper	O
towels	O
.	O
Analysis	O
of	O
non	O
-	O
sterile	O
collected	O
BM	O
composition	O
included	O
macronutrients	O
(	O
carbohydrate	O
,	O
fat	O
,	O
protein	O
)	O
,	O
butyrate	O
,	O
and	O
human	O
milk	O
oligosaccharides	O
(	O
HMOs	O
)	O
.	O
Dried	O
milk	O
spots	O
(	O
DMS	O
)	O
were	O
also	O
collected	O
for	O
lipidomics	O
analyses	O
in	O
each	O
visit	O
until	O
mothers	O
stopped	O
breastfeeding	O
.	O
To	O
measure	O
the	O
amount	O
of	O
BM	O
consumed	O
by	O
infants	O
between	O
4	O
–	O
6	O
weeks	O
of	O
age	O
,	O
mother	O
–	O
infant	O
deuterium	O
-	O
oxide	O
(	O
2H2O	O
)	O
turnover	O
technique	O
was	O
employed	O
[	O
19	O
,	O
20	O
]	O
.	O
Baseline	O
urine	O
samples	O
from	O
both	O
mother	O
and	O
infant	O
were	O
collected	O
on	O
day	O
0	O
,	O
after	O
which	O
the	O
mother	O
received	O
an	O
oral	O
dose	O
of	O
50	O
g	O
of	O
this	O
‘	O
heavy	O
’	O
water	O
.	O
Further	O
daily	O
urine	O
samples	O
from	O
mother	O
and	O
baby	O
were	O
collected	O
over	O
a	O
14	O
-	O
day	O
period	O
.	O
The	O
volume	O
of	O
BM	O
intake	O
was	O
then	O
determined	O
by	O
measuring	O
transfer	O
of	O
isotope	O
enrichment	O
from	O
mother	O
to	O
her	O
baby	O
.	O
After	O
being	O
administered	O
,	O
the	O
deuterium	O
-	O
enriched	O
tracer	O
water	O
was	O
incorporated	O
into	O
the	O
mother	O
’	O
s	O
total	O
body	O
water	O
(	O
TBW	O
)	O
pool	O
and	O
passed	O
onto	O
her	O
baby	O
as	O
BM	O
.	O
The	O
amount	O
of	O
BM	O
consumed	O
by	O
the	O
baby	O
could	O
be	O
calculated	O
by	O
analysing	O
the	O
rate	O
of	O
deuterium	O
(	O
2H	O
)	O
appearance	O
in	O
the	O
baby	O
’	O
s	O
urine	O
and	O
disappearance	O
from	O
the	O
mothers	O
urine	O
(	O
Figure	O
3	O
)	O
.	O
2H	O
enrichment	O
in	O
the	O
urine	O
samples	O
was	O
measured	O
by	O
isotope	O
ratio	O
mass	O
spectrometry	O
.	O

The	O
formulas	O
and	O
assumptions	O
used	O
for	O
calculating	O
BM	O
intake	O
were	O
following	O
those	O
of	O
Haisma	O
et	O
al	O
.	O
[	O
20	O
]	O
.	O
The	O
experiment	O
was	O
conducted	O
in	O
a	O
collaboration	O
with	O
the	O
MRC	O
Elsie	O
Widdowson	O
Laboratory	O
and	O
the	O
results	O
were	O
displayed	O
in	O
L	O
/	O
day	O
.	O
Macronutrients	O
and	O
butyrate	O
were	O
analysed	O
following	O
the	O
same	O
protocol	O
as	O
used	O
in	O
the	O
original	O
CBGS	O
[	O
4	O
,	O
5	O
]	O
.	O
Defrosted	O
and	O
homogenised	O
liquid	O
BM	O
samples	O
were	O
mixed	O
with	O
CDC13	O
solvent	O
with	O
1	O
:	O
1	O
ratio	O
.	O
The	O
resulting	O
polar	O
fraction	O
was	O
then	O
used	O
to	O
measure	O
butyrate	O
concentration	O
while	O
the	O
non	O
-	O
polar	O
fraction	O
was	O
used	O
to	O
measure	O
lipid	O
concentrations	O
using	O
1H	O
-	O
Nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
spectra	O
.	O
Triglyceride	O
(	O
TG	O
)	O
served	O
as	O
a	O
surrogate	O
for	O
total	O
fat	O
content	O
since	O
it	O
contributes	O
95	O
–	O
98	O
%	O
of	O
total	O
BM	O
lipid	O
content	O
.	O
Meanwhile	O
,	O
the	O
polar	O
fraction	O
of	O
the	O
BM	O
sample	O
was	O
used	O
to	O
measure	O
lactose	O
,	O
the	O
most	O
abundant	O
BM	O
carbohydrate	O
,	O
using	O
1H	O
1D	O
nuclear	O
Overhauser	O
effect	O
spectroscopy	O
(	O
NOESY	O
)	O
.	O
For	O
protein	O
,	O
total	O
nitrogen	O
level	O
was	O
measured	O
by	O
the	O
DUMAS	O
method	O
,	O
and	O
the	O
protein	O
factor	O
conversion	O
of	O
6	O
.	O
25	O
was	O
used	O
to	O
calculate	O
crude	O
protein	O
content	O
.	O
Atwater	O
conversion	O
factors	O
were	O
used	O
to	O
calculate	O
the	O
total	O
metabolisable	O
calorie	O
content	O
(	O
TCC	O
)	O
of	O
BM	O
,	O
taking	O
energy	O
contents	O
of	O
4	O
,	O
9	O
,	O
and	O
4	O
kcal	O
/	O
g	O
for	O
lactose	O
,	O
fat	O
,	O
and	O
protein	O
,	O
respectively	O
,	O
and	O
was	O
expressed	O
in	O
kcal	O
/	O
100	O
mL	O
.	O
BM	O
nutrient	O
density	O
was	O
calculated	O
as	O
macronutrient	O
content	O
as	O
%	O
of	O
TCC	O
,	O
i	O
.	O
e	O
.	O
,	O
%	O
carbohydrate	O
,	O
%	O
fat	O
,	O
%	O
protein	O
.	O
Human	O
milk	O
oligosaccharides	O
(	O
HMOs	O
)	O
were	O
quantified	O
from	O
liquid	O
BM	O
samples	O
obtained	O
from	O
2	O
weeks	O
to	O
12	O
months	O
of	O
age	O
.	O
Briefly	O
,	O
each	O
milk	O
sample	O
was	O
diluted	O
and	O
filtered	O
,	O
and	O
its	O
oligosaccharides	O
were	O
quantified	O
by	O
high	O
-	O
pH	O
anion	O
-	O
exchange	O
chromatography	O
using	O
a	O
Thermo	O
Scientific	O
Dionex	O
ICS	O
-	O
5000	O
+	O
system	O
with	O
a	O
pulsed	O
amperometric	O
detector	O
(	O
HPAEC	O
-	O
PAD	O
)	O
[	O
21	O
]	O
.	O

A	O
selection	O
of	O
the	O
most	O
abundant	O
and	O
represented	O
HMOs	O
was	O
chosen	O
,	O
consisting	O
of	O
2	O
′	O
-	O
fucosyllactose	O
(	O
2	O
′	O
-	O
FL	O
)	O
,	O
3	O
-	O
fucosyllactose	O
(	O
3	O
-	O
FL	O
)	O
,	O
lacto	O
-	O
N	O
-	O
fucopentaose	O
I	O
(	O
LNFP	O
I	O
)	O
,	O
lacto	O
-	O
N	O
-	O
tetraose	O
(	O
LNT	O
)	O
,	O
and	O
lacto	O
-	O
N	O
-	O
neotetraose	O
(	O
LNnT	O
)	O
as	O
neutral	O
HMOs	O
,	O
and	O
3	O
′	O
-	O
sialyllactose	O
(	O
3	O
′	O
-	O
SL	O
)	O
and	O
6	O
′	O
-	O
sialyllactose	O
(	O
6	O
′	O
-	O
SL	O
)	O
as	O
acidic	O
HMOs	O
.	O
In	O
brief	O
,	O
each	O
sample	O
was	O
prepared	O
using	O
the	O
“	O
dilute	O
-	O
and	O
-	O
shoot	O
”	O
method	O
and	O
analysed	O
using	O
HPAEC	O
-	O
PAD	O
in	O
duplicates	O
.	O
During	O
sample	O
dilution	O
,	O
five	O
concentrations	O
of	O
the	O
standards	O
of	O
each	O
of	O
the	O
7	O
HMO	O
species	O
being	O
studied	O
were	O
spiked	O
into	O
a	O
6	O
-	O
week	O
milk	O
sample	O
.	O
Recovery	O
was	O
determined	O
by	O
calculating	O
the	O
ratio	O
between	O
the	O
measured	O
and	O
theoretical	O
spiked	O
quantities	O
.	O
To	O
assess	O
repeatability	O
,	O
the	O
same	O
samples	O
were	O
injected	O
5	O
times	O
and	O
the	O
coefficient	O
of	O
variation	O
was	O
calculated	O
.	O
For	O
each	O
HMO	O
species	O
,	O
the	O
limit	O
of	O
detection	O
and	O
the	O
limit	O
of	O
quantification	O
were	O
empirically	O
decided	O
if	O
the	O
resulting	O
concentration	O
could	O
produce	O
a	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
of	O
3	O
:	O
1	O
and	O
6	O
:	O
1	O
,	O
respectively	O
[	O
21	O
]	O
.	O
Fucosyltransferase	O
2	O
(	O
FUT2	O
)	O
genotyping	O
study	O
was	O
performed	O
on	O
maternal	O
and	O
infant	O
saliva	O
.	O
The	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
target	O
used	O
in	O
this	O
study	O
was	O
rs516246	O
and	O
the	O
secretor	O
phenotype	O
was	O
defined	O
by	O
homozygous	O
G	O
/	O
G	O
or	O
heterozygous	O
A	O
/	O
G	O
genotypes	O
,	O
whereas	O
homozygous	O
A	O
/	O
A	O
indicated	O
the	O
non	O
-	O
secretor	O
phenotype	O
[	O
22	O
]	O
.	O
Bacterial	O
composition	O
in	O
maternal	O
BM	O
and	O
infant	O
stool	O
was	O
analysed	O
by	O
sequencing	O
of	O
the	O
16S	O
ribosomal	O
RNA	O
(	O
rRNA	O
)	O
genes	O
.	O

All	O
procedures	O
,	O
including	O
DNA	O
extraction	O
,	O
PCR	O
amplification	O
,	O
library	O
preparation	O
,	O
and	O
sequencing	O
of	O
the	O
V3	O
–	O
V4	O
region	O
of	O
the	O
16S	O
rRNA	O
genes	O
on	O
a	O
MiSeq	O
sequencer	O
(	O
Illumina	O
Inc	O
.	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
,	O
were	O
performed	O
using	O
a	O
standard	O
protocol	O
with	O
established	O
quality	B-methodology
control	I-methodology
[	O
23	O
]	O
.	O
This	O
study	O
recruited	O
119	O
infants	O
at	O
birth	O
in	O
total	O
,	O
of	O
whom	O
94	O
were	O
eligible	O
for	O
follow	O
-	O
up	O
as	O
receiving	O
solely	O
BM	O
in	O
the	O
first	O
6	O
weeks	O
of	O
life	O
.	O
Of	O
these	O
,	O
14	O
infants	O
were	O
introduced	O
to	O
mixed	O
-	O
feeding	O
between	O
6	O
and	O
12	O
weeks	O
,	O
52	O
between	O
3	O
and	O
6	O
months	O
,	O
and	O
the	O
remaining	O
28	O
continued	O
exclusive	O
breastfeeding	O
for	O
at	O
least	O
6	O
months	O
.	O
Up	O
to	O
date	O
,	O
all	O
infants	O
have	O
completed	O
follow	O
-	O
up	O
to	O
12	O
months	O
.	O
The	O
24	O
-	O
and	O
36	O
months	O
visits	O
are	O
ongoing	O
.	O
The	O
overall	O
aim	O
of	O
the	O
study	O
is	O
to	O
assess	O
the	O
associations	O
between	O
human	O
milk	O
components	O
and	O
their	O
intakes	O
,	O
with	O
infant	O
growth	O
,	O
weight	O
gain	O
,	O
and	O
changes	O
in	O
body	O
composition	O
.	O
The	O
primary	O
outcomes	O
are	O
changes	O
in	O
age	O
-	O
and	O
sex	O
-	O
standardised	O
scores	O
for	O
infant	O
length	O
,	O
weight	O
,	O
fat	O
mass	O
and	O
fat	O
-	O
free	O
mass	O
between	O
birth	O
to	O
age	O
12	O
months	O
.	O
We	O
highlight	O
below	O
some	O
of	O
the	O
key	O
questions	O
to	O
be	O
addressed	O
.	O
We	O
hypothesize	O
that	O
there	O
is	O
a	O
bidirectional	O
relationship	O
between	O
exclusive	O
breastfeeding	O
and	O
infant	O
growth	O
.	O
In	O
this	O
study	O
,	O
growth	O
assessments	O
and	O
BM	O
intake	O
volumes	O
were	O
measured	O
at	O
age	O
6	O
weeks	O
,	O
while	O
all	O
infants	O
were	O
still	O
exclusively	O
breastfed	O
.	O
We	O
conjecture	O
that	O
slower	O
weight	O
between	O
birth	O
and	O
6	O
weeks	O
and	O
lower	O
BM	O
intake	O
volumes	O
at	O
6	O
weeks	O
will	O
predict	O
subsequent	O
earlier	O
introduction	O
of	O
infant	O
formula	O
and	O
/	O
or	O
complementary	O
foods	O
.	O
Conversely	O
,	O
we	O
expect	O
that	O
earlier	O
introduction	O
of	O
infant	O
formula	O
will	O
predict	O
subsequent	O
faster	O
weight	O
gain	O
.	O
Few	O
other	O
infant	B-methodology
cohort	I-methodology
studies	I-methodology
have	O
collected	O
sufficiently	O
repeated	O
assessments	O
of	O
growth	O
and	O
feeding	O
to	O
address	O
such	O
questions	O
.	O
In	O
line	O
with	O
the	O
above	O
findings	O
,	O
we	O
speculate	O
negative	O
associations	O
between	O
BM	O
intake	O
volumes	O
at	O
age	O
6	O
weeks	O
and	O
subsequent	O
infant	O
growth	O
and	O
adiposity	O
gains	O
,	O
that	O
could	O
persist	O
until	O
36	O
months	O
.	O
We	O
will	O
also	O
explore	O
specific	O
BM	O
nutrient	O
intakes	O
as	O
potential	O
regulators	O
of	O
infant	O
weight	O
gain	O
.	O

To	O
do	O
this	O
,	O
associations	O
between	O
each	O
BM	O
macronutrient	O
and	O
BM	O
intake	O
volume	O
will	O
be	O
investigated	O
to	O
highlight	O
the	O
importance	O
of	O
considering	O
BM	O
nutrient	O
intakes	O
when	O
examining	O
infant	O
weight	O
gain	O
nutritional	O
drivers	O
,	O
as	O
opposed	O
to	O
simply	O
BM	O
nutrient	O
contents	O
.	O
Our	O
previous	O
publication	O
and	O
other	O
studies	O
have	O
reported	O
positive	O
associations	O
bet	O
-	O
ween	O
BM	O
lactose	O
(	O
representing	O
carbohydrate	O
)	O
and	O
protein	O
with	O
infant	O
weight	O
gain	O
and	O
adiposity	O
[	O
4	O
,	O
13	O
,	O
24	O
,	O
25	O
,	O
26	O
]	O
.	O
BM	O
fat	O
intakes	O
were	O
also	O
inversely	O
associated	O
with	O
those	O
growth	O
para	O
-	O
meters	O
in	O
the	O
original	O
CBGS	O
[	O
4	O
]	O
.	O
We	O
are	O
inclined	O
to	O
reproduce	O
the	O
same	O
examinations	O
in	O
the	O
CBGS	O
-	O
BF	O
,	O
supplemented	O
by	O
BM	O
nutrient	O
intakes	O
analyses	O
.	O
We	O
predict	O
similar	O
results	O
for	O
lactose	O
and	O
protein	O
in	O
this	O
study	O
,	O
but	O
not	O
with	O
fat	O
as	O
we	O
collected	O
hind	O
-	O
milk	O
samples	O
that	O
might	O
reduce	O
interindividual	O
BM	O
fat	O
content	O
variations	O
.	O
By	O
acting	O
as	O
act	O
as	O
soluble	O
prebiotics	O
and	O
contributing	O
to	O
the	O
establishment	O
of	O
desirable	O
infant	O
gut	O
microbiota	O
,	O
HMOs	O
have	O
been	O
evidence	O
to	O
promote	O
overall	O
infant	O
health	O
and	O
growth	O
via	O
protection	O
from	O
infections	O
and	O
obesity	O
[	O
27	O
,	O
28	O
]	O
.	O
However	O
,	O
the	O
evidence	O
of	O
HMOs	O
determinant	O
factors	O
as	O
well	O
as	O
their	O
effects	O
during	O
infancy	O
is	O
still	O
scarce	O
,	O
inconclusive	O
,	O
and	O
confounded	O
by	O
many	O
factors	O
,	O
especially	O
the	O
amount	O
of	O
intake	O
by	O
infants	O
.	O
Maternal	O
FUT2	O
polymorphism	O
is	O
reported	O
to	O
be	O
the	O
major	O
determining	O
factor	O
in	O
HMOs	O
diversity	O
and	O
abundance	O
.	O
FUT2	O
secretor	O
and	O
non	O
-	O
secretor	O
mothers	O
have	O
distinct	O
HMO	O
profiles	O
,	O
with	O
predominant	O
2	O
′	O
fucosyllactose	O
(	O
2	O
′	O
FL	O
)	O
and	O
lacto	O
-	O
N	O
-	O
fucopentaose	O
I	O
(	O
LNFPI	O
)	O
among	O
secretors	O
[	O
27	O
,	O
29	O
]	O
.	O
In	O
this	O
study	O
,	O
we	O
attempt	O
to	O
examine	O
the	O
pre	O
-	O
,	O
ante	O
-	O
,	O
and	O
postnatal	O
influencing	O
factors	O
of	O
HMOs	O
and	O
the	O
association	O
of	O
HMOs	O
intake	O
and	O
infant	O
growth	O
in	O
the	O
first	O
year	O
of	O
life	O
.	O
We	O
are	O
planning	O
to	O
observe	O
the	O
diversity	O
and	O
development	O
of	O
infant	O
gut	O
microbiota	O
over	O
time	O
,	O
especially	O
in	O
relation	O
to	O
BM	O
microbiota	O
,	O
breastfeeding	O
duration	O
,	O
and	O
HMOs	O
.	O

We	O
hypothesize	O
that	O
exclusive	O
breastfeeding	O
duration	O
and	O
HMOs	O
intakes	O
influence	O
bacterial	O
abundance	O
and	O
diversity	O
in	O
infant	O
gut	O
microbiota	O
,	O
providing	O
important	O
insights	O
into	O
the	O
relationship	O
between	O
mother	O
’	O
s	O
milk	O
and	O
infant	O
gut	O
microbiome	O
.	O
Although	O
data	O
collection	O
and	O
sample	O
analyses	O
in	O
the	O
CBGS	O
-	O
BF	O
are	O
still	O
ongoing	O
,	O
several	O
findings	O
have	O
already	O
emerged	O
.	O
First	O
,	O
HMO	O
abundances	O
were	O
prominently	O
affected	O
by	O
stages	O
of	O
lactation	O
and	O
maternal	O
genotype	O
.	O
Two	O
HMO	O
species	O
,	O
3	O
-	O
FL	O
and	O
3	O
′	O
-	O
SL	O
,	O
increased	O
in	O
concentration	O
as	O
the	O
lactation	O
progressed	O
while	O
the	O
others	O
,	O
including	O
2	O
′	O
-	O
FL	O
,	O
LNFP	O
I	O
,	O
LNT	O
,	O
LNnT	O
,	O
and	O
6	O
′	O
-	O
SL	O
decreased	O
with	O
time	O
.	O
Maternal	O
FUT2	O
genotype	O
predicted	O
the	O
profile	O
of	O
oligosaccharides	O
secreted	O
in	O
BM	O
,	O
with	O
marked	O
differences	O
in	O
BM	O
concentrations	O
of	O
2	O
′	O
-	O
FL	O
,	O
3	O
-	O
FL	O
,	O
LNFP	O
I	O
and	O
LNT	O
between	O
secretors	O
and	O
non	O
-	O
secretors	O
[	O
21	O
]	O
.	O
Second	O
,	O
the	O
use	O
of	O
ADP	O
-	O
PEA	O
Pod	O
in	O
the	O
study	O
has	O
enabled	O
the	O
derivation	O
of	O
new	O
prediction	O
equations	O
to	O
estimate	O
body	O
composition	O
during	O
infancy	O
.	O
Infant	O
sex	O
,	O
postnatal	O
age	O
at	O
measurement	O
,	O
weight	O
,	O
length	O
,	O
and	O
skinfold	O
thicknesses	O
were	O
modelled	O
to	O
develop	O
infant	O
fat	O
-	O
and	O
fat	O
-	O
free	O
mass	O
prediction	O
equations	O
against	O
ADP	O
-	O
PEA	O
Pod	O
as	O
the	O
criterion	O
.	O
Recently	O
,	O
these	O
have	O
been	O
validated	O
in	O
an	O
independent	O
study	O
.	O
The	O
new	O
prediction	O
equations	O
resulted	O
in	O
better	O
validity	O
and	O
smaller	O
bias	O
compared	O
to	O
previously	O
available	O
equations	O
that	O
were	O
based	O
on	O
measurements	O
made	O
only	O
at	O
birth	O
[	O
30	O
]	O
.	O
The	O
main	O
strength	O
of	O
the	O
study	O
is	O
the	O
design	O
of	O
CBGS	O
-	O
BF	O
that	O
involves	O
comprehensive	O
and	O
longitudinal	O
data	O
collection	O
,	O
including	O
prenatal	O
questionnaires	O
and	O
food	O
diaries	O
,	O
diverse	O
biological	O
sample	O
collection	O
,	O
and	O
thorough	O
anthropometry	O
and	O
body	O
composition	O
measurements	O
.	O
Measurements	O
of	O
BM	O
intake	O
volume	O
using	O
deuterium	O
-	O
labelled	O
water	O
,	O
detailed	O
assessment	O
of	O
BM	O
composition	O
including	O
oligosaccharides	O
and	O
other	O
components	O
,	O
and	O
BM	O
and	O
infant	O
gut	O
microbiota	O
profiles	O
allow	O
a	O
unique	O
depth	O
of	O
investigation	O
into	O
the	O
mechanisms	O
that	O
link	O
breastfeeding	O
to	O
healthy	O
patterns	O
of	O
infant	O
growth	O
and	O
weight	O
gain	O
.	O
Limitations	O
of	O
the	O
study	O
include	O
the	O
use	O
of	O
a	O
single	O
site	O
with	O
predominant	O
White	O
Caucasian	O
population	O
,	O
which	O
could	O
limit	O
the	O
applicability	O
of	O
the	O
results	O
to	O
more	O
diverse	O
populations	O
.	O

The	O
application	O
of	O
stringent	O
recruitment	O
criteria	O
as	O
well	O
as	O
exclusion	O
of	O
infant	O
-	O
mother	O
pairs	O
who	O
did	O
not	O
exclusively	O
breastfeed	O
for	O
at	O
least	O
6	O
weeks	O
has	O
advantages	O
and	O
disadvantages	O
.	O
While	O
this	O
focussed	O
study	O
sample	O
minimises	O
the	O
confounding	O
effects	O
of	O
many	O
environmental	O
factors	O
,	O
it	O
limited	O
the	O
number	O
of	O
subjects	O
eligible	O
for	O
inclusion	O
.	O
The	O
CBGS	O
-	O
BF	O
aimed	O
primarily	O
to	O
carry	O
out	O
extensive	O
profiling	O
of	O
breastmilk	O
intakes	O
and	O
composition	O
in	O
relation	O
to	O
infancy	O
growth	O
.	O
Anonymised	O
data	O
can	O
be	O
made	O
available	O
to	O
other	O
researchers	O
through	O
collaborative	O
agreements	O
.	O
The	O
CBGS	O
-	O
BF	O
investigators	O
welcome	O
formal	O
or	O
informal	O
proposals	O
and	O
will	O
consider	O
these	O
at	O
their	O
quarterly	O
meetings	O
.	O
Prof	O
Ken	O
Ong	O
(	O
Ken	O
.	O
Ong	O
@	O
mrc	O
-	O
epid	O
.	O
cam	O
.	O
ac	O
.	O
uk	O
)	O
.	O
The	O
authors	O
acknowledge	O
the	O
CBGS	O
research	O
nurses	O
Suzanne	O
Smith	O
,	O
Anne	O
-	O
Marie	O
Wardell	O
,	O
and	O
Karen	O
Forbes	O
,	O
all	O
the	O
families	O
who	O
contributed	O
to	O
the	O
study	O
,	O
the	O
staff	O
at	O
the	O
National	O
Institute	O
for	O
Health	O
Research	O
(	O
NIHR	O
)	O
Cambridge	O
/	O
Wellcome	O
Trust	O
Clinical	B-methodology
Research	I-methodology
Facility	O
,	O
the	O
NIHR	O
Cambridge	O
Comprehensive	O
Biomedical	O
Research	O
Centre	O
,	O
and	O
the	O
midwives	O
at	O
the	O
Rosie	O
Maternity	O
Hospital	O
,	O
Cambridge	O
,	O
UK	O
.	O
The	O
authors	O
also	O
thank	O
Priya	O
Singh	O
and	O
Michelle	O
Venables	O
(	O
MRC	O
Elsie	O
Widdowson	O
Laboratory	O
)	O
for	O
measuring	O
breastmilk	O
intake	O
volume	O
;	O
Guus	O
Kortman	O
(	O
NIZO	O
Food	O
Research	O
)	O
for	O
microbiome	O
study	O
;	O
Daniela	O
Barile	O
,	O
Sierra	O
Durham	O
,	O
and	O
Russell	O
Robinson	O
(	O
Department	O
of	O
Food	O
Science	O
and	O
Technology	O
,	O
University	O
of	O
California	O
,	O
Davis	O
)	O
for	O
executing	O
HMO	O
analyses	O
.	O
We	O
would	O
also	O
like	O
to	O
thank	O
EAF	O
van	O
Tol	O
,	O
MH	O
Schoemaker	O
,	O
and	O
SS	O
Wu	O
(	O
all	O
employees	O
of	O
Mead	O
Johnson	O
Nutrition	O
at	O
that	O
time	O
)	O
,	O
as	O
well	O
as	O
Harro	O
Timmerman	O
(	O
employee	O
of	O
NIZO	O
Food	O
Research	O
at	O
that	O
time	O
)	O
for	O
their	O
involvement	O
during	O
initiation	O
of	O
the	O
study	O
.	O
Publisher	O
’	O
s	O
Note	O
:	O
MDPI	O
stays	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O

D	O
.	O
B	O
.	O
D	O
.	O
,	O
K	O
.	O
K	O
.	O
O	O
.	O
,	O
I	O
.	O
A	O
.	O
H	O
.	O
,	O
and	O
P	O
.	O
M	O
.	O
P	O
.	O
were	O
involved	O
in	O
the	O
conduction	O
of	O
both	O
original	O
CBGS	O
and	O
CBGS	O
-	O
BF	O
.	O
L	O
.	O
O	O
.	O
was	O
responsible	O
for	O
infant	O
recruitment	O
,	O
clinic	O
visit	O
,	O
and	O
blood	O
sampling	O
in	O
the	O
CBGS	O
-	O
BF	O
.	O
L	O
.	O
O	O
.	O
drafted	O
the	O
manuscript	O
.	O
C	O
.	O
J	O
.	O
P	O
.	O
,	O
J	O
.	O
A	O
.	O
v	O
.	O
D	O
.	O
,	O
G	O
.	O
G	O
.	O
,	O
M	O
.	O
C	O
.	O
,	O
I	O
.	O
A	O
.	O
H	O
.	O
,	O
K	O
.	O
K	O
.	O
O	O
.	O
,	O
and	O
D	O
.	O
B	O
.	O
D	O
.	O
critically	O
revised	O
the	O
manuscript	O
.	O
J	O
.	O
V	O
.	O
,	O
J	O
.	O
B	O
.	O
,	O
J	O
.	O
A	O
.	O
v	O
.	O
D	O
.	O
,	O
G	O
.	O
G	O
.	O
,	O
and	O
M	O
.	O
C	O
.	O
were	O
involved	O
in	O
the	O
collaborative	O
work	O
of	O
CBGS	O
-	O
BF	O
since	O
the	O
conduction	O
of	O
the	O
study	O
and	O
J	O
.	O
V	O
.	O
and	O
J	O
.	O
B	O
.	O
were	O
responsible	O
for	O
macronutrient	O
measurements	O
and	O
microbiota	O
analysis	O
,	O
respectively	O
.	O
All	O
authors	O
have	O
read	O
and	O
agreed	O
to	O
the	O
published	O
version	O
of	O
the	O
manuscript	O
.	O
This	O
study	O
has	O
been	O
supported	O
by	O
Reckitt	O
/	O
Mead	O
Johnson	O
Nutrition	O
Institute	O
.	O
This	O
research	O
was	O
also	O
supported	O
by	O
the	O
National	O
Institute	O
for	O
Health	O
Research	O
/	O
Wellcome	O
Trust	O
Clinical	B-methodology
Research	I-methodology
Facility	O
at	O
Cambridge	O
University	O
Hospitals	O
NHS	O
Foundation	O
Trust	O
and	O
the	O
NIHR	O
Cambridge	O
Comprehensive	O
Biomedical	O
Research	O
Centre	O
.	O
KKO	O
is	O
supported	O
by	O
the	O
Medical	O
Research	O
Council	O
(	O
Unit	O
programmes	O
:	O
MC	O
_	O
UU	O
_	O
12015	O
/	O
2	O
and	O
MC	O
_	O
UU	O
_	O
00006	O
/	O
2	O
)	O
.	O
The	O
original	O
CBGS	O
had	O
also	O
been	O
supported	O
by	O
the	O
Medical	O
Research	O
Council	O
(	O
7500001180	O
)	O
,	O
European	O
Union	O
639	O
Framework	O
5	O
(	O
QLK4	O
-	O
1999	O
-	O
01422	O
)	O
,	O
the	O
Mothercare	O
Charitable	O
Foundation	O
(	O
RG54608	O
)	O
,	O
Newlife	O
640	O
Foundation	O
for	O
Disabled	O
Children	O
(	O
07	O
/	O
20	O
)	O
,	O
and	O
the	O
World	O
Cancer	O
Research	O
Fund	O
International	O
641	O
(	O
2004	O
/	O
03	O
)	O
.	O
The	O
study	O
was	O
conducted	O
according	O
to	O
the	O
guidelines	B-methodology
of	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
approved	O
by	O
the	O
National	O
Research	O
Ethics	O
Service	O
Cambridgeshire	O
2	O
Research	O
Ethics	O
Committee	O
(	O
IRAS	O
No	O
67546	O
,	O
REC	O
No	O
11	O
/	O
EE	O
/	O
0068	O
)	O
.	O
Informed	O
consent	O
was	O
obtained	O
from	O
all	O
mothers	O
involved	O
in	O
the	O
study	O
.	O
Anonymised	O
data	O
can	O
be	O
made	O
available	O
to	O
other	O
researchers	O
through	O
collaborative	O
agreements	O
.	O

Please	O
contact	O
Prof	O
Ken	O
Ong	O
(	O
Ken	O
.	O
Ong	O
@	O
mrc	O
-	O
epid	O
.	O
cam	O
.	O
ac	O
.	O
uk	O
)	O
.	O
This	O
study	O
has	O
been	O
supported	O
by	O
Reckitt	O
/	O
Mead	O
Johnson	O
Nutrition	O
Institute	O
.	O
JA	O
van	O
Diepen	O
,	O
M	O
Chichlowski	O
and	O
G	O
Gross	O
are	O
employees	O
of	O
Reckitt	O
/	O
Mead	O
Johnson	O
Nutrition	O
Institute	O
.	O
No	O
other	O
authors	O
declare	O
a	O
conflict	O
of	O
interest	O
.	O

Caffeine	O
ameliorates	O
the	O
metabolic	O
syndrome	O
in	O
diet	O
-	O
induced	O
obese	O
mice	O
through	O
regulating	O
the	O
gut	O
microbiota	O
and	O
serum	O
metabolism	O
Caffeine	O
;	O
Gut	O
microbiota	O
;	O
Serum	O
metabolism	O
;	O
Metabolic	O
syndrome	O
Obesity	O
is	O
associated	O
with	O
gut	O
microbiota	O
disorders	O
,	O
which	O
has	O
been	O
related	O
to	O
developing	O
metabolic	O
syndromes	O
.	O
The	O
research	O
aims	O
to	O
investigate	O
the	O
effects	O
of	O
caffeine	O
treatment	O
on	O
insulin	O
resistance	O
,	O
intestinal	O
microbiota	O
composition	O
and	O
serum	O
metabolomic	O
changes	O
in	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
-	O
induced	O
obesity	O
mice	O
.	O
Eight	O
-	O
week	O
-	O
old	O
male	O
C57BL	O
/	O
6	O
J	O
mice	O
were	O
fed	O
a	O
normal	O
chow	O
diet	O
(	O
NCD	O
)	O
or	O
HFD	O
with	O
or	O
without	O
different	O
concentrations	O
of	O
caffeine	O
.	O
After	O
12	O
weeks	O
of	O
treatment	O
,	O
body	O
weight	O
,	O
insulin	O
resistance	O
,	O
serum	O
lipid	O
profiles	O
,	O
gut	O
microbiota	O
and	O
serum	O
metabolomic	O
profiles	O
were	O
assessed	O
.	O
Caffeine	B-methodology
intervention	I-methodology
improved	O
the	O
metabolic	O
syndrome	O
in	O
HFD	O
-	O
fed	O
mice	O
,	O
such	O
as	O
serum	O
lipid	O
disorders	O
and	O
insulin	O
resistance	O
.	O
16S	O
rRNA	O
Sequencing	O
analysis	O
revealed	O
that	O
caffeine	O
increased	O
the	O
relative	O
abundance	O
of	O
Dubosiella	O
,	O
Bifidobacterium	O
and	O
Desulfovibrio	O
and	O
decreased	O
that	O
of	O
Bacteroides	O
,	O
Lactobacillus	O
and	O
Lactococcus	O
to	O
reverse	O
HFD	O
-	O
fed	O
obesity	O
in	O
mice	O
.	O
Additionally	O
,	O
Caffeine	O
Supplementation	O
also	O
altered	O
serum	O
metabolomics	O
,	O
mainly	O
focusing	O
on	O
lipid	O
metabolism	O
,	O
bile	O
acid	O
metabolism	O
and	O
energy	O
metabolism	O
.	O
Caffeine	O
increased	O
its	O
metabolite	O
1	O
,	O
7	O
-	O
Dimethylxanthine	O
,	O
which	O
was	O
positively	O
correlated	O
with	O
Dubosiella	O
.	O
Caffeine	O
exerts	O
a	O
beneficial	O
effect	O
on	O
insulin	O
resistance	O
in	O
HFD	O
-	O
mice	O
,	O
and	O
the	O
underlying	O
mechanism	O
may	O
be	O
partly	O
related	O
to	O
altered	O
gut	O
microbiota	O
and	O
bile	O
acid	O
metabolism	O
.	O
Obesity	O
is	O
a	O
serious	O
issue	O
worldwide	O
,	O
and	O
its	O
prevalence	O
continues	O
to	O
rise	O
in	O
most	O
countries	O
[	O
1	O
]	O
.	O
Obesity	O
can	O
be	O
simply	O
summarized	O
as	O
the	O
imbalance	O
between	O
energy	O
intake	O
and	O
expenditure	O
resulting	O
in	O
the	O
accumulation	O
of	O
excess	O
energy	O
in	O
the	O
body	O
,	O
leading	O
to	O
metabolic	O
disorders	O
in	O
the	O
organism	O
[	O
2	O
]	O
.	O
Many	O
kinds	O
of	O
research	O
show	O
it	O
is	O
closely	O
related	O
to	O
type	O
2	O
diabetes	O
,	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
,	O
and	O
heart	O
diseases	O
[	O
3	O
,	O
4	O
]	O
.	O
Moreover	O
,	O
Insulin	O
resistance	O
(	O
IR	O
)	O
has	O
long	O
been	O
a	O
problem	O
carried	O
by	O
obesity	O
itself	O
.	O

Although	O
taking	O
diet	O
pills	O
is	O
currently	O
the	O
most	O
popular	O
way	O
to	O
lose	O
weight	O
,	O
they	O
still	O
have	O
some	O
side	O
effects	O
and	O
may	O
improve	O
insulin	O
resistance	O
to	O
a	O
limited	O
extent	O
.	O
For	O
example	O
,	O
Metformin	O
can	O
cause	O
adverse	O
gastrointestinal	O
reactions	O
(	O
5	O
)	O
.	O
This	O
is	O
why	O
an	O
urgent	O
search	O
for	O
a	O
functional	O
food	O
that	O
fights	O
obesity	O
while	O
improving	O
insulin	O
resistance	O
is	O
critical	O
.	O
Coffee	O
and	O
tea	O
are	O
the	O
food	O
products	O
most	O
consumed	O
worldwide	O
[	O
6	O
,	O
7	O
]	O
.	O
Long	O
-	O
term	O
consumption	O
of	O
tea	O
or	O
coffee	O
has	O
a	O
wide	O
range	O
of	O
health	O
-	O
promoting	O
effects	O
,	O
including	O
anti	O
-	O
obesity	O
[	O
8	O
]	O
,	O
prevention	O
of	O
Type	O
II	O
Diabetes	O
[	O
9	O
]	O
,	O
as	O
well	O
as	O
inhibition	O
of	O
the	O
development	O
of	O
diabetic	O
complications	O
[	O
10	O
]	O
.	O
Caffeine	O
is	O
the	O
main	O
active	O
ingredient	O
of	O
tea	O
and	O
coffee	O
.	O
A	O
study	O
of	O
green	O
tea	O
containing	O
caffeine	O
suggests	O
that	O
caffeine	O
may	O
be	O
its	O
main	O
anti	O
-	O
obesity	O
ingredient	O
[	O
11	O
]	O
.	O
The	O
beneficial	O
metabolic	O
effects	O
of	O
caffeine	O
on	O
obesity	O
include	O
the	O
downregulation	O
of	O
inflammatory	O
factors	O
expression	O
in	O
the	O
circulation	O
and	O
various	O
tissues	O
,	O
the	O
upregulation	O
of	O
adipocyte	O
lipolysis	O
,	O
the	O
inhibition	O
of	O
lipid	O
synthesis	O
and	O
hepatic	O
steatosis	O
,	O
a	O
reduction	O
in	O
fat	O
mass	O
and	O
the	O
improvement	O
of	O
fatty	O
liver	O
,	O
hepatic	O
/	O
systemic	O
insulin	O
resistance	O
,	O
which	O
have	O
been	O
reported	O
in	O
both	O
humans	O
and	O
animals	O
[	O
12	O
–	O
15	O
]	O
.	O
In	O
addition	O
,	O
in	O
nonobese	O
research	B-methodology
models	I-methodology
,	O
caffeine	O
was	O
also	O
found	O
to	O
inhibit	O
neonatal	O
cord	O
blood	O
mononuclear	O
cells	O
from	O
releasing	O
TNF	O
-	O
α	O
,	O
improving	O
fructose	O
-	O
induced	O
insulin	O
resistance	O
in	O
mice	O
by	O
enhancing	O
central	O
insulin	O
signaling	O
and	O
Glut4	O
expression	O
in	O
skeletal	O
muscle	O
to	O
reverse	O
rat	O
ageing	O
-	O
induced	O
insulin	O
resistance	O
[	O
16	O
–	O
18	O
]	O
.	O
Many	O
reports	O
show	O
the	O
gut	O
microbiota	O
has	O
been	O
linked	O
to	O
inflammatory	O
bowel	O
disease	O
[	O
19	O
]	O
,	O
obesity	O
[	O
20	O
]	O
,	O
autism	O
spectrum	O
disorders	O
[	O
21	O
]	O
and	O
immune	O
system	O
disorders	O
[	O
22	O
]	O
among	O
others	O
.	O
Some	O
components	O
of	O
coffee	O
might	O
have	O
affected	O
the	O
gut	O
microbiota	O
[	O
23	O
–	O
25	O
]	O
.	O
A	O
recent	O
study	O
has	O
shown	O
that	O
EGCG	O
and	O
caffeine	O
,	O
the	O
main	O
component	O
of	O
green	O
tea	O
,	O
can	O
modulate	O
the	O
gut	O
microbiome	O
to	O
fight	O
obesity	O
[	O
26	O
]	O
.	O

Fubrick	O
tea	O
has	O
been	O
confirmed	O
to	O
improve	O
metabolic	O
disorders	O
by	O
regulating	O
intestinal	O
microbiome	O
and	O
caffeine	O
metabolism	O
[	O
27	O
]	O
,	O
and	O
the	O
close	O
relationship	O
between	O
gut	O
microbiome	O
and	O
metabolomics	O
suggests	O
that	O
caffeine	O
may	O
affect	O
gut	O
microbiome	O
.	O
What	O
'	O
s	O
more	O
,	O
it	O
has	O
been	O
shown	O
that	O
caffeine	O
-	O
induced	O
sleep	O
restriction	O
alters	O
the	O
gut	O
microbiome	O
in	O
mice	O
[	O
28	O
]	O
.	O
However	O
,	O
the	O
relationship	O
between	O
how	O
caffeine	O
affects	O
the	O
gut	O
microbes	O
and	O
its	O
improvement	O
in	O
metabolic	O
syndrome	O
has	O
not	O
been	O
reported	O
.	O
Metabolomics	O
has	O
been	O
widely	O
used	O
because	O
of	O
its	O
potential	O
to	O
help	O
researchers	O
identify	O
the	O
involvement	O
of	O
different	O
biomarkers	O
.	O
Therefore	O
,	O
we	O
focus	O
on	O
investigating	O
whether	O
caffeine	O
,	O
a	O
main	O
component	O
of	O
coffee	O
,	O
ameliorates	O
insulin	O
resistance	O
in	O
diet	O
-	O
induced	O
obesity	O
mice	O
in	O
association	O
with	O
gut	O
microbiota	O
alterations	O
and	O
explores	O
its	O
underlying	O
mechanism	O
through	O
plasma	O
metabolites	O
.	O
Caffeine	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
C0750	O
)	O
was	O
respectively	O
dissolved	O
in	O
sterile	O
water	O
to	O
get	O
a	O
concentration	O
of	O
low	O
-	O
dose	O
caffeine	O
solution	O
(	O
0	O
.	O
5	O
g	O
/	O
L	O
)	O
and	O
high	O
-	O
dose	O
caffeine	O
solution	O
(	O
1	O
g	O
/	O
L	O
)	O
for	O
feeding	O
to	O
high	O
-	O
fat	O
mice	O
until	O
mice	O
were	O
sacrificed	O
.	O
Forty	O
male	O
C57BL	O
/	O
6	O
J	O
mice	O
(	O
Charles	O
River	O
)	O
weighing	O
20	O
–	O
25	O
g	O
were	O
bred	O
at	O
Shantou	O
University	O
Medical	O
College	O
(	O
Shantou	O
,	O
China	O
)	O
.	O
All	O
animals	O
lived	O
in	O
a	O
specific	O
pathogen	O
-	O
free	O
environment	O
with	O
free	O
access	O
to	O
food	O
and	O
water	O
.	O
After	O
all	O
,	O
mice	O
were	O
acclimatized	O
to	O
the	O
research	O
environment	O
for	O
one	O
week	O
;	O
ten	O
mice	O
were	O
randomly	O
fed	O
with	O
a	O
normal	O
chow	O
diet	O
(	O
NCD	O
group	O
)	O
.	O
In	O
contrast	O
,	O
the	O
remaining	O
30	O
mice	O
were	O
fed	O
with	O
a	O
60	O
%	O
high	O
-	O
fat	O
diet	O
(	O
ResearchDiet	O
,	O
D12492	O
)	O
and	O
randomly	B-methodology
divided	I-methodology
into	O
three	O
groups	O
to	O
fed	O
with	O
the	O
sterile	O
water	O
(	O
HFD	O
group	O
)	O
,	O
low	O
-	O
dose	O
caffeine	O
solution	O
(	O
caffeine	O
low	O
-	O
dose	O
group	O
)	O
and	O
high	O
-	O
dose	O
caffeine	O
solution	O
(	O
caffeine	O
high	O
-	O
dose	O
group	O
)	O
at	O
the	O
same	O
time	O
.	O
The	O
ten	O
mice	O
in	O
the	O
same	O
group	O
were	O
randomly	O
labelled	O
and	O
housed	O
in	O
two	O
standard	O
cages	O
(	O
five	O
mice	O
per	O
cage	O
)	O
.	O
The	O
body	O
weight	O
of	O
mice	O
and	O
the	O
amount	O
of	O
food	O
intake	O
were	O
measured	O
weekly	O
.	O

At	O
the	O
end	O
of	O
the	O
experiment	O
,	O
all	O
mice	O
were	O
anaesthetized	O
with	O
sodium	O
pentobarbital	O
(	O
50	O
mg	O
/	O
kg	O
)	O
intraperitoneally	O
.	O
The	O
eyes	O
were	O
removed	O
to	O
collect	O
the	O
blood	O
samples	O
in	O
5	O
mL	O
Vacutainer	O
tubes	O
containing	O
the	O
chelating	O
agent	O
ethylene	O
diamine	O
tetraacetic	O
acid	O
(	O
EDTA	O
)	O
.	O
The	O
samples	O
were	O
centrifuged	O
at	O
4	O
[UNK]	O
for	O
15	O
min	O
,	O
and	O
plasma	O
samples	O
were	O
collected	O
and	O
stored	O
at	O
−	O
80	O
°C	O
.	O
Serum	O
random	O
blood	O
glucose	O
and	O
lipid	O
profiles	O
such	O
as	O
Total	O
cholesterol	O
(	O
TC	O
)	O
,	O
total	O
triglycerides	O
(	O
TG	O
)	O
,	O
High	O
-	O
density	O
lipoproteins	O
(	O
HDL	O
)	O
and	O
Low	O
-	O
density	O
lipoproteins	O
(	O
LDL	O
)	O
were	O
measured	O
with	O
an	O
Abbott	O
Architect	O
c16000	O
instrument	O
(	O
The	O
First	O
Affiliated	O
Hospital	O
of	O
Shantou	O
University	O
Medical	O
College	O
)	O
.	O
After	O
12	O
weeks	O
of	O
caffeine	B-methodology
intervention	I-methodology
,	O
all	O
mice	O
fasted	O
for	O
8	O
h	O
.	O
Using	O
blood	O
glucose	O
test	O
strips	O
,	O
measured	O
the	O
blood	O
glucose	O
level	O
at	O
0	O
min	O
.	O
Immediately	O
after	O
that	O
,	O
all	O
animals	O
were	O
intraperitoneally	O
injected	O
with	O
20	O
%	O
glucose	O
solution	O
(	O
1	O
g	O
/	O
kg	O
)	O
.	O
Subsequently	O
,	O
blood	O
glucose	O
values	O
were	O
respectively	O
measured	O
at	O
30	O
,	O
60	O
,	O
90	O
,	O
and	O
120	O
min	O
.	O
Plot	O
the	O
blood	O
glucose	O
-	O
time	O
curve	O
and	O
computer	O
the	O
area	O
under	O
the	O
IPGTT	O
curve	O
(	O
AUC	O
)	O
.	O
The	O
blood	O
glucose	O
values	O
of	O
each	O
animal	O
given	O
adequate	O
diet	O
and	O
water	O
were	O
measured	O
as	O
the	O
blood	O
glucose	O
values	O
at	O
0	O
min	O
.	O
Afterwards	O
,	O
blood	O
glucose	O
levels	O
were	O
measured	O
at	O
30	O
,	O
60	O
,	O
90	O
and	O
120	O
min	O
after	O
giving	O
each	O
mouse	O
an	O
intraperitoneal	O
injection	O
of	O
0	O
.	O
75U	O
/	O
kg	O
of	O
insulin	O
with	O
fasting	O
without	O
water	O
.	O
The	O
blood	O
glucose	O
-	O
time	O
curve	O
and	O
the	O
AUC	O
of	O
IPITT	O
are	O
similar	O
to	O
that	O
described	O
above	O
.	O
Total	O
genomic	O
DNA	O
from	O
39	O
samples	O
was	O
obtained	O
by	O
hexadecyl	O
trimethyl	O
ammonium	O
bromide	O
(	O
CTAB	O
)	O
/	O
sodium	O
dodecyl	O
sulfate	O
(	O
SDS	O
)	O
method	O
,	O
and	O
the	O
concentration	O
and	O
purity	O
of	O
DNA	O
were	O
detected	O
by	O
1	O
%	O
agarosegels	O
.	O
The	O
DNA	O
was	O
diluted	O
to	O
1	O
ng	O
/	O
μl	O
with	O
sterile	O
water	O
.	O
16S	O
rRNA	O
was	O
amplified	O
using	O
barcode	O
-	O
containing	O
specific	O
primers	O
341F	O
-	O
806R	O
(	O
V3	O
-	O
V4	O
)	O
.	O

After	O
quantifying	O
and	O
identifying	O
PCR	O
products	O
using	O
1X	O
loading	O
buffer	O
(	O
containing	O
SYBR	O
green	O
)	O
and	O
2	O
%	O
agarose	O
gel	O
,	O
the	O
mixed	O
PCR	O
products	O
were	O
purified	O
using	O
the	O
AxyPrepDNA	O
Gel	O
Extraction	O
Kit	O
(	O
AXYGEN	O
)	O
.	O
Sequencing	O
libraries	O
were	O
generated	O
using	O
the	O
NEB	O
Next®	O
[UNK]	O
DNA	O
Library	O
Prep	O
Kit	O
for	O
Illumina	O
(	O
NEB	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
recommendations	O
with	O
index	O
codes	O
added	O
.	O
Library	O
quality	O
was	O
evaluated	O
on	O
a	O
Qubit	O
@	O
2	O
.	O
0	O
Fluorometer	O
(	O
Thermo	O
Scientific	O
)	O
and	O
an	O
Agilent	O
Bioanalyzer	O
2100	O
system	O
.	O
Finally	O
,	O
the	O
library	O
was	O
sequenced	O
on	O
the	O
Illumina	O
Miseq	O
/	O
HiSeq2500	O
platform	O
to	O
obtain	O
250	O
bp	O
/	O
300	O
bp	O
paired	O
-	O
end	O
reads	O
.	O
Paired	O
-	O
end	O
reads	O
from	O
raw	O
DNA	O
fragments	O
were	O
merged	O
using	O
FLASH	O
and	O
assigned	O
to	O
each	O
sample	O
based	O
on	O
a	O
unique	O
barcode	O
.	O
Sequence	O
analysis	O
was	O
performed	O
by	O
the	O
UPARSE	O
software	O
package	O
using	O
the	O
UPARSE	O
-	O
OTU	O
and	O
UPARSE	O
-	O
OTUref	O
algorithms	O
.	O
Sequences	O
with	O
≥	O
97	O
%	O
similarity	O
were	O
assigned	O
to	O
the	O
same	O
OTU	O
.	O
We	O
select	O
a	O
representative	O
sequence	O
for	O
each	O
OTU	O
and	O
use	O
the	O
RDP	O
classifier	O
to	O
annotate	O
the	O
taxonomic	O
information	O
of	O
each	O
representative	O
sequence	O
.	O
Histograms	O
of	O
the	O
relative	O
abundance	O
of	O
species	O
at	O
the	O
phylum	O
and	O
genus	O
levels	O
show	O
the	O
community	O
structure	O
of	O
each	O
grouping	O
at	O
different	O
taxonomic	O
levels	O
.	O
Alpha	O
Diversity	O
metrics	O
such	O
as	O
ace	O
and	O
chao1	O
were	O
used	O
to	O
Analyze	O
Microbiota	O
evenness	O
and	O
diversity	O
.	O
To	O
confirm	O
differences	O
in	O
the	O
taxonomic	O
abundance	O
of	O
individuals	O
between	O
the	O
two	O
groups	O
,	O
STAMP	O
software	O
was	O
used	O
.	O
LEfSe	O
was	O
used	O
to	O
quantify	O
biomarkers	O
within	O
different	O
groups	O
.	O
Plasma	O
samples	O
collected	O
as	O
above	O
were	O
thawed	O
at	O
4	O
°C	O
.	O
An	O
appropriate	O
amount	O
of	O
sample	O
and	O
pre	O
-	O
cooled	O
methanol	O
/	O
acetonitrile	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
were	O
mixed	O
and	O
centrifuged	O
for	O
20	O
min	O
(	O
14000	O
g	O
,	O
4	O
[UNK]	O
)	O
.	O
The	O
supernatant	O
was	O
used	O
for	O
LC	O
-	O
MS	O
/	O
MS	O
Analysis	O
.	O
The	O
serum	O
samples	O
were	O
detected	O
by	O
a	O
UHPLC	O
(	O
1290	O
Infinity	O
LC	O
,	O
Agilent	O
Technologies	O
)	O
.	O

The	O
column	O
temperature	O
,	O
flow	O
rate	O
and	O
injection	O
volume	O
were	O
25	O
°C	O
,	O
0	O
.	O
5	O
mL	O
/	O
min	O
and	O
2	O
μL	O
.	O
The	O
mobile	O
phase	O
consisted	O
of	O
A	O
(	O
water	O
+	O
25	O
mM	O
ammonium	O
acetate	O
+	O
25	O
mM	O
ammonia	O
)	O
and	O
B	O
(	O
acetonitrile	O
)	O
.	O
The	O
gradient	O
elution	O
program	O
was	O
as	O
follows	O
:	O
0	O
–	O
0	O
.	O
5	O
min	O
95	O
%	O
B	O
;	O
0	O
.	O
5	O
–	O
7	O
min	O
,	O
B	O
linearly	O
change	O
from	O
95	O
to	O
65	O
%	O
;	O
7	O
–	O
8	O
min	O
,	O
B	O
from	O
65	O
%	O
linear	O
change	O
to	O
40	O
%	O
;	O
8	O
–	O
9	O
min	O
,	O
B	O
maintained	O
at	O
40	O
%	O
;	O
9	O
–	O
9	O
.	O
1	O
min	O
,	O
B	O
linear	O
change	O
from	O
40	O
to	O
95	O
%	O
;	O
9	O
.	O
1	O
–	O
12	O
min	O
,	O
B	O
maintained	O
at	O
95	O
%	O
.	O
Samples	O
are	O
analyzed	O
randomly	O
and	O
continuously	O
to	O
reduce	O
errors	O
caused	O
by	O
fluctuations	O
in	O
the	O
instrument	O
detection	O
signals	O
.	O
The	O
separated	O
samples	O
were	O
analyzed	O
using	O
a	O
quadrupole	O
time	O
-	O
of	O
-	O
flight	O
(	O
AB	O
Sciex	O
TripleTOF	O
6600	O
)	O
with	O
electrospray	O
ionization	O
in	O
positive	O
and	O
negative	O
ion	O
modes	O
,	O
as	O
described	O
in	O
a	O
previous	O
study	O
[	O
29	O
]	O
.	O
The	O
raw	O
data	O
was	O
converted	O
to	O
.	O
mzXML	O
format	O
by	O
ProteoWizard	O
,	O
and	O
imported	O
into	O
the	O
XCMS	O
software	O
for	O
peak	O
alignment	O
,	O
retention	O
time	O
correction	O
and	O
peak	O
area	O
extraction	O
.	O
Subsequently	O
,	O
the	O
data	O
extracted	O
by	O
XCMS	O
were	O
subjected	O
to	O
metabolite	O
structure	O
identification	O
,	O
data	O
pre	O
-	O
processing	O
,	O
data	O
quality	O
evaluation	O
and	O
finally	O
,	O
data	O
analysis	O
.	O
The	O
data	O
acquired	O
were	O
sample	O
normalized	O
,	O
log	O
-	O
transformed	O
(	O
base	O
10	O
)	O
and	O
auto	O
-	O
scaled	O
on	O
MetaboAnalyst	O
5	O
.	O
0	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
metaboanalyst	O
.	O
ca	O
/	O
MetaboA	O
-	O
alyst	O
/	O
ModuleView	O
.	O
xhtml	O
)	O
.	O
Partial	O
Least	O
Squares	O
—	O
Discriminant	O
Analysis	O
(	O
PLS	O
-	O
DA	O
)	O
and	O
Orthogonal	O
Partial	O
Least	O
Squares	O
Discriminant	O
Analysis	O
(	O
OPLS	O
-	O
DA	O
)	O
are	O
used	O
to	O
perform	O
multivariate	O
statistical	O
analyses	O
.	O
The	O
variable	O
importance	O
in	O
projection	O
(	O
VIP	O
)	O
values	O
showing	O
the	O
contribution	O
of	O
each	O
variable	O
to	O
the	O
classification	O
were	O
measured	O
and	O
counted	O
in	O
the	O
OPLS	O
-	O
DA	O
model	O
.	O
The	O
student	O
'	O
s	O
t	O
-	O
test	O
P	O
values	O
lower	O
than	O
0	O
.	O
05	O
indicated	O
statistically	O
significant	O
differences	O
.	O
Volcano	O
plots	O
further	O
revealed	O
changes	O
in	O
metabolites	O
,	O
with	O
FC	O
>	O
1	O
.	O
2	O
being	O
upregulation	O
and	O
FC	O
<	O
0	O
.	O
8	O
being	O
downregulation	O
.	O

Lastly	O
,	O
we	O
selected	O
important	O
differential	O
metabolites	O
for	O
metabolite	O
pathway	O
studies	O
in	O
the	O
KEGG	O
(	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
kegg	O
.	O
jp	O
/	O
)	O
database	O
.	O
The	O
relationships	O
between	O
different	O
bacterial	O
lineages	O
and	O
metabolites	O
were	O
obtained	O
by	O
correlation	O
analysis	O
using	O
Spearman	O
’	O
s	O
correlation	O
method	O
for	O
the	O
critical	O
differential	O
metabolites	O
screened	O
by	O
metabolomics	O
and	O
Intestinal	O
microbes	O
that	O
differed	O
significantly	O
at	O
the	O
genus	O
level	O
by	O
16S	O
sequencing	O
.	O
Correlation	O
heatmap	O
and	O
hierarchical	O
clustering	O
analysis	O
were	O
performed	O
on	O
R	O
language	O
(	O
4	O
.	O
1	O
.	O
2	O
)	O
software	O
.	O
All	O
data	O
are	O
expressed	O
as	O
mean	O
±	O
SEM	O
.	O
Statistical	O
analysis	O
between	O
the	O
control	O
and	O
experiment	O
groups	O
was	O
performed	O
using	O
One	O
-	O
way	O
ANOVA	O
on	O
SPSS	O
25	O
software	O
.	O
The	O
Bonferroni	O
post	O
hoc	O
test	O
and	O
the	O
Dunnett	O
T3	O
post	O
hoc	O
were	O
respectively	O
used	O
for	O
conformity	O
to	O
chi	O
-	O
square	O
and	O
non	O
-	O
conformity	O
chi	O
-	O
square	O
.	O
P	O
-	O
value	O
<	O
0	O
.	O
05	O
was	O
considered	O
statistically	O
significant	O
.	O
Graphs	O
were	O
made	O
using	O
GraphPad	O
Prism	O
8	O
software	O
.	O
Metabolic	O
syndrome	O
is	O
characterized	O
by	O
obesity	O
,	O
diabetes	O
,	O
impaired	O
glucose	O
regulation	O
,	O
and	O
dyslipidemia	O
.	O
As	O
shown	O
in	O
Fig	O
.	O
1A	O
,	O
B	O
,	O
body	O
weight	O
gain	O
and	O
liver	O
weight	O
were	O
increased	O
in	O
HFD	O
mice	O
in	O
comparison	O
with	O
NCD	O
mice	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
while	O
caffeine	O
high	O
-	O
dose	O
treatment	O
significantly	O
reduced	O
these	O
indices	O
in	O
comparison	O
with	O
HFD	O
mice	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O
Compared	O
with	O
the	O
NCD	O
mice	O
,	O
serum	O
triglyceride	O
(	O
TG	O
)	O
,	O
total	O
cholesterol	O
(	O
TC	O
)	O
and	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
LDL	O
-	O
C	O
)	O
levels	O
were	O
elevated	O
.	O
However	O
,	O
the	O
high	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
HDL	O
-	O
C	O
)	O
level	O
was	O
also	O
increased	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
Consequently	O
,	O
caffeine	O
high	O
-	O
dose	O
significantly	O
downregulated	O
TC	O
and	O
LDL	O
-	O
C	O
levels	O
and	O
upregulated	O
HDL	O
-	O
C	O
levels	O
(	O
Fig	O
.	O
1C	O
,	O
p	O
<	O
0	O
.	O
01	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
Similarly	O
,	O
caffeine	O
high	O
-	O
dose	O
reduced	O
plasma	O
random	O
blood	O
glucose	O
in	O
HFD	O
mice	O
(	O
Fig	O
.	O

1B	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
IPGTT	O
and	O
IPITT	O
tested	O
insulin	O
resistance	O
.	O
Our	O
results	O
indicated	O
that	O
supplementation	O
with	O
high	O
caffeine	O
dose	O
rather	O
than	O
a	O
low	O
dose	O
decreased	O
the	O
AUC	O
of	O
GTT	O
and	O
ITT	O
curve	O
,	O
increasing	O
HFD	O
in	O
mice	O
(	O
Fig	O
.	O
2	O
;	O
p	O
<	O
0	O
.	O
001	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
Overall	O
,	O
caffeine	O
high	O
-	O
dose	O
improved	O
the	O
metabolic	O
disorders	O
associated	O
with	O
high	O
-	O
fat	O
diet	O
-	O
induced	O
obesity	O
.	O
Growing	O
evidence	O
indicates	O
Gut	O
microbiota	O
dysbiosis	O
has	O
been	O
repeatedly	O
seen	O
in	O
insulin	O
resistance	O
.	O
To	O
investigate	O
whether	O
caffeine	O
affects	O
the	O
gut	O
microbiota	O
,	O
we	O
collected	O
faeces	O
at	O
12	O
weeks	O
of	O
NCD	O
,	O
HFD	O
and	O
caffeine	O
high	O
-	O
dose	O
+	O
HFD	O
mice	O
and	O
then	O
profiled	O
the	O
microbiota	O
composition	O
by	O
16S	O
rRNA	O
gene	O
sequencing	O
.	O
We	O
performed	O
Splicing	O
,	O
filtering	O
,	O
and	O
chimaera	O
removal	O
on	O
100897	O
raw	O
tags	O
from	O
29	O
faecal	O
samples	O
to	O
get	O
83789	O
clean	O
sequences	O
clustered	O
into	O
1821	O
operational	O
taxonomic	O
units	O
(	O
OTUs	O
)	O
with	O
consistently	O
higher	O
than	O
97	O
%	O
for	O
further	O
analysis	O
.	O
As	O
observed	O
on	O
a	O
Venn	O
diagram	O
(	O
Fig	O
.	O
3A	O
)	O
,	O
767	O
OUT	O
were	O
shared	O
among	O
the	O
three	O
groups	O
,	O
and	O
each	O
group	O
had	O
unique	O
OTUs	O
.	O
Ace	O
and	O
chao1	O
,	O
representative	O
Alpha	O
analyses	O
indices	O
(	O
Fig	O
.	O
3B	O
)	O
,	O
showed	O
HFD	O
decreased	O
microbiota	O
species	O
richness	O
and	O
diversity	O
,	O
while	O
caffeine	O
seemed	O
to	O
reverse	O
this	O
change	O
(	O
with	O
no	O
statistical	O
significance	O
)	O
.	O
As	O
expected	O
,	O
Firmicutes	O
was	O
the	O
most	O
abundant	O
phylum	O
of	O
all	O
samples	O
;	O
however	O
,	O
caffeine	O
seems	O
not	O
to	O
affect	O
Firmicutes	O
.	O
We	O
observed	O
caffeine	O
decreased	O
further	O
Bacteroidetes	O
,	O
which	O
may	O
be	O
associated	O
with	O
a	O
reduction	O
in	O
Bacteroides	O
at	O
the	O
genus	O
level	O
(	O
Fig	O
.	O
4	O
)	O
.	O
Among	O
the	O
significant	O
microbial	O
communities	O
at	O
the	O
genus	O
level	O
,	O
the	O
relative	O
abundance	O
of	O
Dubosiella	O
and	O
Desulfovibrio	O
was	O
decreased	O
by	O
HFD	O
mice	O
compared	O
with	O
the	O
NCD	O
mice	O
,	O
while	O
caffeine	O
increased	O
these	O
two	O
microbiotas	O
.	O
Moreover	O
,	O
it	O
also	O
raised	O
Faecalibaculum	O
and	O
Blautia	O
.	O

At	O
the	O
same	O
time	O
,	O
caffeine	O
decreased	O
the	O
relative	O
abundance	O
of	O
Lactobacillus	O
,	O
Romboutsia	O
,	O
Lactococcus	O
and	O
Erysipelatoclostridium	O
increased	O
by	O
HFD	O
mice	O
(	O
Fig	O
.	O
4	O
)	O
.	O
We	O
did	O
a	O
Welch	O
t	O
-	O
test	O
with	O
an	O
abundance	O
index	O
for	O
the	O
HFD	O
and	O
caffeine	O
high	O
-	O
dose	O
groups	O
to	O
further	O
explore	O
whether	O
caffeine	O
affected	O
the	O
faecal	O
microbiota	O
.	O
We	O
found	O
19	O
OTUs	O
significantly	O
different	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
As	O
shown	O
in	O
Fig	O
.	O
5	O
,	O
we	O
found	O
the	O
differences	O
between	O
Dubosiella	O
,	O
Desulfovibrio	O
and	O
Lactobacillus	O
were	O
statistically	O
significant	O
.	O
Furthermore	O
,	O
caffeine	O
elevated	O
Ruminococcaceae	O
UCG	O
-	O
004	O
,	O
Bifidobacterium	O
,	O
[	O
Eubacterium	O
]	O
brachy	O
group	O
,	O
Ruminococcaceae	O
UGC	O
-	O
014	O
,	O
Enterococcus	O
,	O
Alkanindiges	O
,	O
Haliangium	O
,	O
Holdemania	O
and	O
Ruminococcaceae	O
UCG	O
-	O
009	O
and	O
decreased	O
Gemella	O
,	O
Allobaculum	O
,	O
Helicobacter	O
,	O
Geothermobacter	O
,	O
Tyzzerella	O
,	O
[	O
Eubacterium	O
]	O
no	O
datum	O
group	O
and	O
Aerococcus	O
.	O
Similarly	O
,	O
we	O
used	O
LDA	O
Effect	O
Size	O
(	O
LEfSe	O
)	O
analysis	O
to	O
identify	O
communities	O
or	O
species	O
that	O
significantly	O
impacted	O
the	O
sample	O
delineation	O
shown	O
in	O
Fig	O
.	O
6	O
.	O
Species	O
with	O
LDA	O
values	O
greater	O
than	O
4	O
were	O
set	O
as	O
statistically	O
different	O
markers	O
between	O
groups	O
(	O
Fig	O
.	O
7	O
)	O
.	O
PCA	O
is	O
a	O
statistical	O
method	O
that	O
can	O
predict	O
the	O
species	O
with	O
the	O
most	O
enormous	O
difference	O
between	O
groups	O
,	O
which	O
is	O
an	O
unsupervised	O
model	O
;	O
while	O
PLS	O
-	O
DA	O
is	O
a	O
supervised	O
model	O
,	O
which	O
can	O
maximize	O
the	O
difference	O
between	O
groups	O
according	O
to	O
a	O
predefined	O
classification	O
,	O
which	O
has	O
better	O
separation	O
than	O
PCA	O
.	O
The	O
PLS	O
-	O
DA	O
plot	O
showed	O
that	O
there	O
was	O
a	O
clear	O
separation	O
between	O
NCD	O
and	O
HFD	O
and	O
caffeine	O
high	O
-	O
dose	O
groups	O
(	O
Fig	O
.	O
8	O
)	O
.	O
To	O
identify	O
differential	O
metabolites	O
,	O
the	O
OPLS	O
-	O
DA	O
and	O
its	O
corresponding	O
variable	O
importance	O
of	O
projection	O
(	O
VIP	O
)	O
were	O
applied	O
.	O

Consistent	O
with	O
the	O
PLS	O
-	O
DA	O
results	O
,	O
the	O
OPLS	O
-	O
DA	O
model	O
also	O
showed	O
NCD	O
group	O
could	O
be	O
well	O
distinguished	O
from	O
the	O
HFD	O
group	O
,	O
and	O
significant	O
distinctions	O
were	O
observed	O
between	O
HFD	O
and	O
caffeine	O
high	O
-	O
dose	O
group	O
(	O
Figs	O
.	O
9	O
,	O
10	O
)	O
.	O
In	O
addition	O
,	O
compared	O
to	O
the	O
NCD	O
group	O
,	O
the	O
volcano	O
plot	O
showed	O
that	O
168	O
metabolites	O
were	O
downregulated	O
and	O
383	O
metabolites	O
were	O
upregulated	O
under	O
high	O
-	O
fat	O
diet	O
induction	O
;	O
caffeine	O
high	O
-	O
dose	O
in	O
obese	O
mice	O
resulted	O
in	O
24	O
metabolites	O
downregulated	O
and	O
53	O
metabolites	O
upregulated	O
in	O
serum	O
(	O
Figs	O
.	O
11	O
,	O
12	O
)	O
.	O
Next	O
,	O
we	O
used	O
differential	O
metabolites	O
(	O
FC	O
>	O
1	O
.	O
2	O
or	O
FC	O
<	O
0	O
.	O
8	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
VIP	O
>	O
1	O
.	O
0	O
)	O
for	O
metabolic	O
pathway	O
screening	O
.	O
Compared	O
with	O
the	O
NCD	O
group	O
,	O
the	O
top	O
8	O
KEGG	O
pathways	O
that	O
changed	O
in	O
the	O
HFD	O
group	O
mainly	O
included	O
Starch	O
and	O
sucrose	O
metabolism	O
,	O
Fructose	O
and	O
mannose	O
metabolism	O
,	O
Pentose	O
phosphate	O
pathway	O
,	O
Glycerophospholipid	O
metabolism	O
and	O
caffeine	O
metabolism	O
,	O
which	O
focuses	O
on	O
energy	O
metabolism	O
(	O
Fig	O
.	O
13	O
)	O
;	O
while	O
the	O
pathways	O
changed	O
by	O
caffeine	O
high	O
-	O
dose	O
mainly	O
included	O
Linoleic	O
acid	O
metabolism	O
,	O
Sulfur	O
metabolism	O
,	O
Primary	O
bile	O
acid	O
biosynthesis	O
,	O
Caffeine	O
metabolism	O
,	O
Histidine	O
metabolism	O
,	O
Purine	O
metabolism	O
,	O
Pyruvate	O
metabolism	O
,	O
Glycine	O
,	O
serine	O
and	O
threonine	O
metabolism	O
,	O
Biosynthesis	O
of	O
unsaturated	O
fatty	O
acids	O
and	O
Steroid	O
hormone	O
biosynthesis	O
could	O
be	O
seen	O
(	O
Fig	O
.	O
14	O
)	O
.	O
The	O
Specific	O
trends	O
of	O
variation	O
of	O
differential	O
metabolites	O
contained	O
in	O
metabolic	O
pathways	O
are	O
shown	O
in	O
Table	O
1	O
.	O
Correlation	O
analysis	O
of	O
serum	O
untargeted	O
metabolites	O
and	O
gut	O
microbiota	O
at	O
genus	O
level	O
in	O
the	O
NCD	O
,	O
HFD	O
and	O
caffeine	O
high	O
-	O
dose	O
groups	O
was	O
presented	O
by	O
correlation	O
heatmap	O
.	O
As	O
shown	O
in	O
Fig	O
.	O
15	O
,	O
caffeine	O
metabolomics	O
such	O
as	O
1	O
,	O
7	O
-	O
Dimethylxanthine	O
showed	O
positive	O
correlations	O
with	O
Dubosiella	O
,	O
Alkaninndiges	O
and	O
Faecalibaculum	O
.	O
Pyruvaldehype	O
was	O
positive	O
correlations	O
with	O
Allobaculum	O
.	O

In	O
addition	O
,	O
Desulfovibrio	O
,	O
Dubosiella	O
,	O
and	O
Alkaninndiges	O
correlated	O
positively	O
with	O
most	O
of	O
the	O
metabolites	O
.	O
N	O
-	O
methylhistamine	O
and	O
Cholic	O
acid	O
showed	O
negative	O
correlations	O
with	O
some	O
gut	O
microbiota	O
.	O
In	O
addition	O
,	O
Bifidobacterium	O
,	O
Desulfovibrio	O
and	O
Ruminococcaceae	O
showed	O
negative	O
correlations	O
with	O
and	O
Lactobacillus	O
,	O
Lactococcus	O
,	O
Faecalibaculum	O
,	O
and	O
Allobaculum	O
showed	O
positive	O
correlations	O
with	O
physiological	O
data	O
and	O
insulin	O
resistance	O
indicators	O
(	O
Figs	O
.	O
16	O
,	O
17	O
)	O
.	O
In	O
our	O
study	O
,	O
we	O
found	O
that	O
caffeine	O
high	O
-	O
dose	O
could	O
reduce	O
body	O
weight	O
and	O
liver	O
weight	O
,	O
and	O
improve	O
hyperlipidemia	O
and	O
insulin	O
resistance	O
in	O
the	O
HFD	O
mice	O
,	O
demonstrating	O
caffeine	O
has	O
a	O
therapeutic	O
effect	O
on	O
metabolic	O
syndromes	O
,	O
which	O
is	O
consistent	O
with	O
previous	O
studies	O
[	O
15	O
–	O
17	O
]	O
.	O
Moreover	O
,	O
we	O
elucidate	O
the	O
mechanism	O
of	O
this	O
anti	O
-	O
metabolic	O
syndrome	O
,	O
which	O
may	O
involve	O
gut	O
microbiota	O
,	O
bile	O
acid	O
metabolism	O
,	O
lipid	O
metabolism	O
,	O
and	O
energy	O
metabolism	O
.	O
The	O
nature	O
of	O
the	O
intestinal	O
microbiome	O
has	O
been	O
shown	O
to	O
be	O
closely	O
related	O
to	O
IR	O
in	O
several	O
human	O
and	O
animal	O
model	O
studies	O
[	O
30	O
,	O
31	O
]	O
.	O
16S	O
rRNA	O
sequencing	O
was	O
used	O
to	O
investigate	O
how	O
caffeine	O
affects	O
the	O
composition	O
of	O
the	O
gut	O
microbiome	O
.	O
Compared	O
to	O
the	O
NCD	O
group	O
,	O
HFD	O
mice	O
have	O
a	O
substantial	O
reduction	O
in	O
the	O
abundance	O
of	O
Bacteroidetes	O
and	O
a	O
proportional	O
increase	O
in	O
Firmicutes	O
,	O
similar	O
to	O
previous	O
studies	O
[	O
20	O
]	O
.	O
However	O
,	O
caffeine	O
further	O
reduced	O
Bacteroidetes	O
,	O
which	O
seems	O
likely	O
that	O
caffeine	O
has	O
its	O
unique	O
effect	O
on	O
the	O
intestinal	O
microbiome	O
.	O
Bacteroidetes	O
is	O
a	O
Gram	O
-	O
negative	O
bacterium	O
containing	O
LPS	O
,	O
a	O
potent	O
activator	O
of	O
toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
)	O
,	O
which	O
causes	O
inflammatory	O
responses	O
and	O
cytokine	O
expression	O
and	O
secretion	O
.	O
In	O
addition	O
,	O
Lower	O
Bacteroidetes	O
may	O
be	O
associated	O
with	O
lower	O
Bacteroides	O
at	O
the	O
genus	O
level	O
.	O
Bacteroides	O
,	O
Lactobacillus	O
and	O
Lactococcus	O
containing	O
bile	O
salt	O
hydrolase	O
(	O
BSH	O
)	O
can	O
hydrolyze	O
conjugated	O
bile	O
acids	O
into	O
unconjugated	O
bile	O
acids	O
[	O
37	O
]	O
.	O

It	O
has	O
been	O
reported	O
that	O
conjugated	O
bile	O
acid	O
is	O
a	O
nuclear	O
farnesoid	O
X	O
receptor	O
(	O
FXR	O
)	O
antagonist	O
[	O
33	O
]	O
.	O
Decreased	O
BSH	O
leads	O
to	O
increased	O
conjugated	O
bile	O
acids	O
,	O
which	O
increases	O
the	O
conversion	O
of	O
cholesterol	O
to	O
bile	O
acids	O
and	O
reduces	O
lipid	O
accumulation	O
.	O
Likewise	O
,	O
in	O
our	O
plasma	O
data	O
,	O
cholic	O
acid	O
,	O
which	O
was	O
elevated	O
in	O
insulin	O
-	O
resistant	O
mice	O
and	O
humans	O
[	O
9	O
,	O
34	O
]	O
,	O
was	O
decreased	O
by	O
caffeine	O
,	O
while	O
glycocholic	O
acid	O
was	O
increased	O
.	O
This	O
may	O
suggest	O
that	O
the	O
improvement	O
of	O
dyslipidemia	O
by	O
caffeine	O
may	O
be	O
related	O
to	O
bile	O
acid	O
metabolism	O
.	O
Bifidobacterium	O
is	O
a	O
probiotic	O
.	O
In	O
a	O
human	O
report	O
,	O
16	O
healthy	O
subjects	O
drank	O
a	O
daily	O
dose	O
of	O
3	O
cups	O
of	O
coffee	O
for	O
three	O
weeks	O
,	O
which	O
raised	O
the	O
number	O
of	O
Bifidobacterium	O
compared	O
with	O
human	O
faeces	O
before	O
coffee	O
consumption	O
[	O
35	O
]	O
.	O
This	O
bifidogenic	O
effect	O
of	O
coffee	O
was	O
also	O
discovered	O
in	O
animal	B-methodology
models	I-methodology
[	O
32	O
]	O
.	O
Meanwhile	O
,	O
caffeine	O
also	O
increased	O
this	O
probiotic	O
in	O
the	O
NAFLD	O
patients	O
[	O
36	O
]	O
.	O
In	O
accordance	O
with	O
our	O
results	O
,	O
which	O
hint	O
the	O
bifidogenic	O
effect	O
of	O
coffee	O
may	O
be	O
related	O
to	O
caffeine	O
.	O
Moreover	O
,	O
Bifidobacterium	O
and	O
Ruminococcaceae	O
are	O
short	O
-	O
chain	O
fatty	O
acid	O
(	O
SCFAs	O
)	O
-	O
producing	O
bacteria	O
;	O
SCFAs	O
have	O
been	O
shown	O
to	O
increase	O
gut	O
barrier	O
function	O
[	O
37	O
]	O
and	O
stimulate	O
pancreatic	O
islet	O
beta	O
-	O
cell	O
growth	O
and	O
proliferation	O
,	O
regulate	O
the	O
body	O
'	O
s	O
insulin	O
sensitivity	O
[	O
38	O
]	O
.	O
Desulfovibrio	O
,	O
significantly	O
elevated	O
by	O
caffeine	O
,	O
was	O
shown	O
to	O
produce	O
acetic	O
acid	O
and	O
regulate	O
liver	O
lipid	O
metabolism	O
in	O
mice	O
to	O
alleviate	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
[	O
39	O
]	O
;	O
to	O
produce	O
H2S	O
,	O
which	O
maintains	O
lipid	O
metabolism	O
balance	O
[	O
40	O
]	O
and	O
reduces	O
systemic	O
inflammation	O
[	O
41	O
]	O
.	O
In	O
addition	O
,	O
the	O
present	O
study	O
also	O
shown	O
Bifidobacterium	O
,	O
Ruminococcaceae	O
and	O
Desulfovibrio	O
were	O
negatively	O
associated	O
with	O
obesity	O
indicators	O
.	O
Serum	O
metabolomics	O
showed	O
that	O
the	O
serum	O
metabolites	O
of	O
the	O
three	O
groups	O
were	O
separated	O
from	O
each	O
other	O
.	O

However	O
,	O
caffeine	O
did	O
not	O
move	O
the	O
plasma	O
metabolites	O
of	O
HFD	O
mice	O
closer	O
to	O
that	O
of	O
NCD	O
mice	O
,	O
which	O
may	O
be	O
the	O
effect	O
of	O
caffeine	O
as	O
a	O
foreign	O
substance	O
in	O
the	O
metabolism	O
.	O
Elevations	O
of	O
caffeine	O
metabolites	O
such	O
as	O
1	O
,	O
7	O
-	O
Dimethylxanthine	O
in	O
plasma	O
may	O
illustrate	O
this	O
point	O
.	O
In	O
our	O
data	O
,	O
1	O
,	O
7	O
-	O
Dimethylxanthine	O
was	O
positively	O
correlated	O
with	O
Dubosiella	O
,	O
Alkaninndiges	O
and	O
Faecalibaculum	O
,	O
possibly	O
indicating	O
that	O
changes	O
in	O
the	O
intestinal	O
microbiome	O
are	O
associated	O
with	O
caffeine	O
metabolism	O
.	O
Dubosiella	O
significantly	O
elevated	O
in	O
response	O
to	O
caffeine	O
,	O
is	O
not	O
yet	O
well	O
studied	O
.	O
Still	O
,	O
this	O
bacterium	O
was	O
negatively	O
correlated	O
with	O
most	O
inflammatory	O
factors	O
and	O
indicators	O
of	O
obesity	O
and	O
positively	O
associated	O
with	O
butyric	O
acid	O
[	O
42	O
,	O
43	O
]	O
.	O
Moreover	O
,	O
Dubosiella	O
is	O
positively	O
correlated	O
with	O
Adenosine	O
5	O
'	O
-	O
monophosphate	O
(	O
AMP	O
)	O
and	O
Linoleic	O
acid	O
,	O
which	O
Implies	O
the	O
relationship	O
between	O
Dubosiella	O
and	O
energy	O
metabolism	O
.	O
Metabolic	O
pathway	O
enrichment	O
analysis	O
showed	O
that	O
caffeine	O
could	O
regulate	O
Steroid	O
hormone	O
biosynthesis	O
,	O
Primary	O
bile	O
acid	O
biosynthesis	O
,	O
Biosynthesis	O
of	O
unsaturated	O
fatty	O
acids	O
,	O
Glycine	O
,	O
serine	O
and	O
threonine	O
metabolism	O
,	O
Linoleic	O
acid	O
metabolism	O
,	O
Pyruvate	O
metabolism	O
and	O
so	O
on	O
.	O
The	O
Biosynthesis	O
of	O
steroid	O
hormones	O
,	O
the	O
Biosynthesis	O
of	O
primary	O
bile	O
acids	O
and	O
the	O
Biosynthesis	O
of	O
unsaturated	O
fatty	O
acids	O
are	O
closely	O
related	O
to	O
lipid	O
metabolism	O
.	O
Disturbances	O
in	O
lipid	O
metabolism	O
often	O
accompany	O
insulin	O
resistance	O
.	O
In	O
a	O
study	O
of	O
the	O
activity	O
and	O
function	O
of	O
the	O
cytochrome	O
P450	O
side	O
-	O
chain	O
cleavage	O
enzyme	O
(	O
CYP11A1	O
)	O
,	O
the	O
rate	O
-	O
limiting	O
enzyme	O
for	O
the	O
conversion	O
of	O
cholesterol	O
to	O
pregnenolone	O
,	O
it	O
was	O
found	O
that	O
incubation	O
of	O
isolated	O
mitochondria	O
with	O
the	O
cholesterol	O
analogue	O
22R	O
-	O
hydroxycholesterol	O
resulted	O
in	O
the	O
efficient	O
formation	O
of	O
pregnenolone	O
,	O
the	O
direct	O
precursor	O
for	O
the	O
synthesis	O
of	O
all	O
steroid	O
hormones	O
[	O
44	O
]	O
.	O
Estrogen	O
has	O
been	O
reported	O
to	O
increase	O
insulin	O
sensitivity	O
[	O
45	O
]	O
.	O

Similarly	O
,	O
22R	O
-	O
hydroxycholesterol	O
is	O
a	O
natural	O
ligand	O
for	O
the	O
liver	O
X	O
receptor	O
[	O
LXR	O
]	O
,	O
and	O
activation	O
of	O
LXR	O
improves	O
TNFα	O
-	O
induced	O
insulin	O
resistance	O
in	O
brown	O
adipocytes	O
[	O
46	O
]	O
.	O
All	O
of	O
the	O
above	O
suggests	O
that	O
the	O
improvement	O
of	O
insulin	O
resistance	O
by	O
caffeine	O
may	O
be	O
related	O
to	O
steroid	O
hormone	O
synthesis	O
.	O
Glycine	O
,	O
serine	O
,	O
threonine	O
,	O
linoleic	O
acid	O
and	O
pyruvate	O
acid	O
ultimately	O
produce	O
energy	O
metabolism	O
through	O
the	O
tricarboxylic	O
acid	O
cycle	O
.	O
Caffeine	O
is	O
known	O
to	O
activate	O
beta	O
receptors	O
,	O
increase	O
plasma	O
cAMP	O
concentrations	O
and	O
promote	O
lipolysis	O
and	O
beta	O
-	O
oxidation	O
[	O
47	O
]	O
.	O
This	O
study	O
illustrates	O
the	O
ameliorative	O
effect	O
of	O
caffeine	O
on	O
diet	O
-	O
induced	O
obesity	O
mice	O
by	O
combining	O
16S	O
rRNA	O
Sequencing	O
and	O
plasma	O
metabolomics	O
.	O
Caffeine	O
modulates	O
plasma	O
lipid	O
metabolism	O
disorders	O
,	O
ameliorates	O
insulin	O
resistance	O
,	O
and	O
may	O
change	O
the	O
gut	O
microbial	O
composition	O
by	O
promoting	O
beneficial	O
bacteria	O
and	O
reducing	O
harmful	O
bacteria	O
.	O
In	O
addition	O
,	O
serum	O
metabolomics	O
suggests	O
that	O
caffeine	O
may	O
act	O
by	O
regulating	O
bile	O
acid	O
metabolism	O
,	O
lipid	O
metabolism	O
and	O
energy	O
metabolism	O
.	O
The	O
present	O
study	O
is	O
the	O
first	O
article	O
that	O
caffeine	O
can	O
affect	O
the	O
gut	O
microbiota	O
and	O
provides	O
a	O
possible	O
mechanism	O
of	O
intestinal	O
microbiota	O
to	O
account	O
for	O
the	O
effect	O
of	O
caffeine	O
on	O
insulin	O
resistance	O
.	O
Not	O
applicable	O
.	O
Publisher	O
'	O
s	O
NoteSpringer	O
Nature	O
remains	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O
Li	O
Chen	O
and	O
Xian	O
-	O
jun	O
Wang	O
contributed	O
equally	O
to	O
this	O
work	O
LC	O
Mouse	O
experiment	O
;	O
XJW	O
Article	O
conception	O
,	O
Treatment	O
and	O
analysis	O
of	O
data	O
,	O
Drafting	O
of	O
the	O
manuscript	O
;	O
JXC	O
Critical	O
revision	O
;	O
JCY	O
Data	O
processing	O
and	O
analysis	O
;	O
LL	O
Research	B-methodology
design	I-methodology
;	O
XBC	O
and	O
YSC	O
Research	O
conception	O
and	O
design	O
,	O
Critical	O
revision	O
.	O
All	O
authors	O
reviewed	O
the	O
manuscript	O
.	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

This	O
work	O
was	O
supported	O
by	O
General	O
Program	O
of	O
the	O
Natural	O
Science	O
Foundation	O
of	O
Guangdong	O
Province	O
,	O
China	O
[	O
General	O
Number	O
2019A1515010917	O
]	O
,	O
Science	O
and	O
Technology	O
Planning	O
Project	O
of	O
Shantou	O
City	O
[	O
Grant	O
Number	O
190430145264400	O
]	O
,	O
Grant	O
for	O
Key	O
Disciplinary	O
Project	O
of	O
Clinical	O
Medicine	O
under	O
the	O
Guangdong	O
High	O
-	O
level	O
University	O
Development	O
Program	O
[	O
Grant	O
Number	O
002	O
-	O
18119101	O
]	O
.	O
Data	O
are	O
available	O
upon	O
reasonable	O
request	O
.	O
The	O
Medical	O
Animal	O
Care	O
&	O
Welfare	O
Committee	O
of	O
Shantou	O
University	O
Medical	O
College	O
agrees	O
with	O
the	O
research	B-methodology
design	I-methodology
of	O
this	O
animal	B-methodology
experiment	I-methodology
(	O
SUMC2019	O
-	O
413	O
)	O
which	O
follows	O
the	O
National	O
Guidelines	B-methodology
for	O
laboratory	O
Animals	O
.	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Cardiovascular	O
-	O
Related	O
Outcomes	O
in	O
U	O
.	O
S	O
.	O
Adults	O
Exposed	O
to	O
Lead	O
cardiovascular	O
;	O
lead	O
exposure	O
;	O
occupational	O
;	O
clinical	O
markers	O
;	O
blood	O
pressure	O
;	O
lipid	O
profile	O
Cardiovascular	O
-	O
related	O
clinical	O
markers	O
were	O
evaluated	O
in	O
this	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
study	I-methodology
of	O
United	O
States	O
adults	O
(	O
aged	O
≥	O
20	O
)	O
exposed	O
to	O
lead	O
via	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
2007	O
–	O
2008	O
and	O
the	O
2009	O
–	O
2010	O
datasets	O
.	O
In	O
four	O
quartiles	O
of	O
exposure	O
—	O
0	O
–	O
2	O
μg	O
/	O
dL	O
,	O
2	O
–	O
5	O
μg	O
/	O
dL	O
,	O
5	O
–	O
10	O
μg	O
/	O
dL	O
,	O
and	O
10	O
μg	O
/	O
dL	O
and	O
over	O
,	O
clinical	O
and	O
anthropometric	O
markers	O
were	O
evaluated	O
—	O
to	O
examine	O
how	O
the	O
markers	O
manifested	O
in	O
the	O
quartiles	O
.	O
Associations	O
were	O
determined	O
via	O
linear	O
regression	O
.	O
Finally	O
,	O
clinical	O
makers	O
,	O
and	O
how	O
they	O
manifested	O
between	O
exposed	O
and	O
less	O
-	O
exposed	O
occupations	O
,	O
were	O
explored	O
in	O
addition	O
to	O
how	O
duration	O
of	O
exposure	O
altered	O
these	O
clinical	O
markers	O
.	O
In	O
regression	O
analysis	O
,	O
Diastolic	O
Blood	O
Pressure	O
(	O
DBP	O
)	O
and	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	O
,	O
were	O
significantly	O
associated	O
with	O
blood	O
lead	O
level	O
(	O
BLL	O
)	O
.	O
In	O
the	O
occupational	O
analysis	O
,	O
Systolic	O
Blood	O
Pressure	O
(	O
SBP	O
)	O
,	O
DBP	O
,	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
,	O
triglycerides	O
,	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
cholesterol	O
,	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	O
,	O
showed	O
differences	O
between	O
populations	O
in	O
the	O
exposed	O
and	O
less	O
-	O
exposed	O
occupations	O
.	O
Regarding	O
Agriculture	O
,	O
Forestry	O
&	O
Fishing	O
,	O
the	O
duration	O
of	O
exposure	O
altered	O
SBP	O
,	O
CRP	O
,	O
and	O
LDL	O
cholesterol	O
.	O
With	O
mining	O
,	O
the	O
duration	O
of	O
exposure	O
altered	O
SBP	O
,	O
DBP	O
,	O
triglycerides	O
,	O
and	O
HDL	O
cholesterol	O
,	O
whereas	O
in	O
construction	O
,	O
the	O
duration	O
in	O
occupation	O
altered	O
SBP	O
,	O
triglycerides	O
,	O
and	O
CRP	O
.	O
In	O
conclusion	O
,	O
lead	O
exposure	O
has	O
a	O
profound	O
effect	O
on	O
the	O
cardiovascular	O
system	O
,	O
with	O
potentially	O
adverse	O
outcomes	O
existing	O
at	O
all	O
exposure	O
levels	O
.	O
Cardiovascular	O
diseases	O
are	O
the	O
leading	O
cause	O
of	O
mortality	O
both	O
in	O
the	O
United	O
States	O
and	O
around	O
the	O
world	O
[	O
1	O
]	O
.	O

Exposure	O
to	O
lead	O
potentially	O
accelerates	O
the	O
development	O
of	O
several	O
cardiovascular	O
diseases	O
or	O
disorders	O
such	O
as	O
coronary	O
heart	O
disease	O
,	O
peripheral	O
arterial	O
disease	O
,	O
left	O
ventricular	O
hypertrophy	O
,	O
and	O
cardiac	O
arrhythmias	O
in	O
acute	O
and	O
chronic	O
exposure	O
[	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
]	O
.	O
Indeed	O
,	O
lead	O
is	O
a	O
risk	O
factor	O
for	O
hypertension	O
in	O
adults	O
,	O
and	O
a	O
positive	O
association	O
of	O
lead	O
exposure	O
with	O
elevated	O
blood	O
pressure	O
has	O
also	O
been	O
identified	O
in	O
the	O
literature	O
[	O
3	O
,	O
4	O
]	O
.	O
Lead	O
exposure	O
can	O
be	O
either	O
acute	O
or	O
chronic	O
.	O
Whereas	O
acute	O
lead	O
exposure	O
occurs	O
over	O
a	O
short	O
period	O
and	O
can	O
be	O
of	O
any	O
dose	O
,	O
chronic	O
exposure	O
occurs	O
over	O
a	O
longer	O
period	O
of	O
time	O
and	O
can	O
also	O
be	O
of	O
any	O
dose	O
.	O
Many	O
epidemiologic	B-methodology
studies	I-methodology
have	O
shown	O
an	O
association	O
between	O
chronic	O
low	O
-	O
level	O
lead	O
exposure	O
and	O
hypertension	O
[	O
6	O
,	O
7	O
]	O
.	O
Navas	O
-	O
Acien	O
and	O
co	O
-	O
authors	O
,	O
in	O
a	O
systemic	O
review	O
of	O
lead	O
exposure	O
,	O
identified	O
a	O
link	O
between	O
the	O
effects	O
of	O
chronic	O
low	O
-	O
level	O
lead	O
exposure	O
and	O
cardiovascular	O
health	O
[	O
3	O
]	O
.	O
The	O
authors	O
pointed	O
out	O
,	O
in	O
a	O
review	O
studies	O
involving	O
animals	O
,	O
that	O
,	O
chronic	O
exposure	O
to	O
low	O
lead	O
levels	O
resulted	O
in	O
arterial	O
hypertension	O
that	O
persists	O
long	O
after	O
the	O
cessation	O
of	O
lead	O
exposure	O
.	O
Indeed	O
studies	O
have	O
found	O
that	O
a	O
2	O
-	O
fold	O
increase	O
in	O
BLLs	O
(	O
i	O
.	O
e	O
.	O
,	O
5	O
to	O
10	O
ug	O
/	O
dL	O
)	O
increases	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
between	O
0	O
.	O
6	O
and	O
1	O
.	O
25	O
mmHg	O
[	O
3	O
]	O
.	O
Hertz	O
-	O
Picciotto	O
and	O
co	O
-	O
authors	O
also	O
found	O
that	O
lead	O
exposure	O
is	O
strongly	O
associated	O
with	O
a	O
causal	O
increase	O
SBP	O
,	O
DBP	O
,	O
and	O
hypertension	O
[	O
8	O
]	O
.	O
Other	O
studies	O
such	O
as	O
that	O
by	O
Schwartz	O
in	O
a	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
also	O
bolster	O
the	O
above	O
-	O
mentioned	O
finding	O
by	O
discovering	O
a	O
strong	O
causal	O
association	O
in	O
BLLs	O
and	O
an	O
elevation	O
of	O
SBP	O
in	O
men	O
[	O
9	O
]	O
.	O
In	O
another	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
,	O
Nawrot	O
and	O
co	O
-	O
authors	O
found	O
an	O
association	O
,	O
albeit	O
a	O
weak	O
one	O
,	O
between	O
elevated	O
SBP	O
,	O
DBP	O
,	O
and	O
BLLs	O
[	O
10	O
]	O
.	O

According	O
to	O
the	O
review	O
findings	O
,	O
even	O
though	O
the	O
mechanism	O
behind	O
lead	O
exposure	O
and	O
hypertension	O
is	O
still	O
under	O
investigation	O
,	O
it	O
is	O
speculated	O
that	O
such	O
a	O
mechanism	O
may	O
be	O
related	O
to	O
the	O
kidney	O
and	O
glomerular	O
filtration	O
rate	O
,	O
oxidative	O
stress	O
,	O
lead	O
’	O
s	O
effects	O
on	O
the	O
renin	O
-	O
angiotensin	O
-	O
aldosterone	O
system	O
,	O
nitric	O
oxide	O
,	O
or	O
soluble	O
guanylate	O
cyclase	O
.	O
Indeed	O
according	O
to	O
Babiker	O
and	O
co	O
-	O
authors	O
in	O
a	O
study	O
of	O
rats	O
,	O
lead	O
exposure	O
induces	O
oxidative	O
stress	O
,	O
apoptosis	O
in	O
addition	O
to	O
promoting	O
ischemic	O
-	O
reperfusion	O
injury	O
[	O
11	O
]	O
.	O
The	O
role	O
lead	O
plays	O
in	O
systemic	O
inflammation	O
as	O
measured	O
by	O
the	O
biomarker	O
CRP	O
has	O
been	O
varied	O
in	O
the	O
literature	O
.	O
Khan	O
and	O
co	O
-	O
authors	O
in	O
an	O
occupational	O
study	O
found	O
a	O
significant	O
association	O
between	O
lead	O
exposure	O
and	O
CRP	O
[	O
12	O
]	O
.	O
In	O
contrast	O
,	O
a	O
large	O
population	O
-	O
based	O
study	O
that	O
examined	O
9145	O
individuals	O
who	O
were	O
≥40	O
years	O
of	O
age	O
from	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
1999	O
–	O
2004	O
did	O
not	O
find	O
a	O
dose	O
-	O
dependent	O
relationship	O
between	O
BLL	O
and	O
CRP	O
after	O
adjusting	O
for	O
a	O
broad	O
array	O
of	O
potential	O
confounders	O
leading	O
the	O
researchers	O
to	O
conclude	O
that	O
inflammation	O
did	O
not	O
appear	O
to	O
be	O
an	O
important	O
mediator	O
of	O
lead	O
toxicity	O
[	O
13	O
]	O
.	O
Lead	O
may	O
play	O
a	O
role	O
in	O
altering	O
the	O
enzymes	O
involved	O
in	O
cholesterol	O
synthesis	O
.	O
This	O
has	O
been	O
manifested	O
in	O
the	O
literature	O
with	O
a	O
study	O
by	O
Kojima	O
and	O
co	O
-	O
authors	O
which	O
demonstrated	O
that	O
lead	O
nitrate	O
-	O
mediated	O
induction	O
of	O
hepatic	O
hypercholesterolemia	O
involved	O
the	O
activation	O
of	O
cholesterol	O
biosynthetic	O
enzymes	O
such	O
as	O
3	O
-	O
hydroxy3methyglutaryl	O
-	O
CoA	O
reductase	O
,	O
farnesyl	O
diphosphate	O
synthase	O
,	O
squalene	O
synthase	O
,	O
and	O
lanosterol	O
14a	O
-	O
demethylase	O
CYP51	O
,	O
a	O
vital	O
enzyme	O
for	O
cholesterol	O
biosynthesis	O
,	O
in	O
addition	O
to	O
the	O
concurrent	O
suppression	O
of	O
cholesterol	O
-	O
catabolic	O
enzymes	O
such	O
as	O
7α	O
-	O
hydroxylase	O
[	O
14	O
]	O
.	O

A	O
study	O
by	O
Kristal	O
-	O
Boneh	O
and	O
co	O
-	O
authors	O
[	O
15	O
]	O
looking	O
at	O
BLL	O
,	O
serum	O
total	O
cholesterol	O
,	O
and	O
other	O
cardiovascular	O
-	O
related	O
outcomes	O
in	O
56	O
lead	O
-	O
exposed	O
male	O
industrial	O
employees	O
compared	O
with	O
87	O
unexposed	O
employees	O
sought	O
to	O
ascertain	O
potential	O
associations	O
between	O
BLL	O
and	O
serum	O
cholesterol	O
in	O
subjects	O
occupationally	O
exposed	O
to	O
lead	O
.	O
The	O
researchers	O
found	O
that	O
mean	O
BLLs	O
were	O
42	O
.	O
3	O
(	O
+	O
/	O
−14	O
.	O
9	O
)	O
µg	O
/	O
dL	O
in	O
the	O
exposed	O
workers	O
and	O
2	O
.	O
7	O
(	O
+	O
/	O
−3	O
.	O
6	O
)	O
µg	O
/	O
dL	O
in	O
the	O
less	O
-	O
exposed	O
with	O
the	O
exposed	O
subjects	O
having	O
elevated	O
mean	O
levels	O
of	O
total	O
cholesterol	O
.	O
Ademuyiwa	O
and	O
co	O
-	O
authors	O
[	O
16	O
]	O
investigated	O
the	O
effects	O
of	O
lead	O
exposure	O
on	O
risk	O
of	O
cardiovascular	O
disease	O
in	O
those	O
occupationally	O
exposed	O
as	O
compared	O
to	O
those	O
non	O
-	O
exposed	O
in	O
Abeokuta	O
,	O
Nigeria	O
.	O
In	O
the	O
study	O
,	O
they	O
found	O
that	O
increased	O
risk	O
of	O
cardiovascular	O
disease	O
was	O
observed	O
in	O
the	O
occupationally	O
exposed	O
because	O
total	O
cholesterol	O
in	O
artisans	O
was	O
between	O
1	O
.	O
5	O
and	O
2	O
.	O
0	O
times	O
higher	O
than	O
in	O
controls	O
.	O
In	O
the	O
same	O
study	O
they	O
found	O
no	O
significant	O
difference	O
in	O
the	O
mean	O
concentration	O
of	O
triglycerides	O
in	O
occupationally	O
lead	O
-	O
exposed	O
workers	O
as	O
compared	O
to	O
controls	O
[	O
16	O
]	O
.	O
For	O
their	O
part	O
,	O
Kristal	O
-	O
Boneh	O
and	O
co	O
-	O
authors	O
also	O
found	O
no	O
significant	O
difference	O
between	O
the	O
mean	O
triglycerides	O
of	O
those	O
occupationally	O
exposed	O
to	O
lead	O
as	O
compared	O
to	O
the	O
less	O
-	O
exposed	O
[	O
15	O
]	O
.	O
Our	O
study	O
sought	O
to	O
examine	O
the	O
effects	O
of	O
lead	O
on	O
the	O
cardiovascular	O
system	O
in	O
the	O
US	O
general	O
adult	O
population	O
by	O
looking	O
at	O
cardiovascular	O
-	O
related	O
clinical	O
markers	O
of	O
interest	O
and	O
how	O
they	O
manifested	O
in	O
exposed	O
adults	O
.	O
In	O
this	O
study	O
it	O
was	O
hypothesized	O
that	O
exposure	O
to	O
lead	O
adversely	O
affects	O
cardiovascular	O
function	O
via	O
adversely	O
affecting	O
blood	O
pressure	O
,	O
inflammation	O
,	O
and	O
lipid	O
profiles	O
in	O
the	O
study	O
participants	O
.	O
In	O
testing	O
the	O
above	O
hypothesis	O
the	O
following	O
objective	O
was	O
put	O
forward	O
,	O
namely	O
:	O
To	O
investigate	O
the	O
effects	O
of	O
lead	O
exposure	O
on	O
the	O
studied	O
participants	O
by	O
analyzing	O
their	O
SBP	O
,	O
DBP	O
,	O
CRP	O
,	O
triglycerides	O
,	O
total	O
cholesterol	O
,	O
LDL	O
cholesterol	O
,	O
and	O
HDL	O
cholesterol	O
levels	O
.	O
The	O
analysis	O
of	O
BLLs	O
and	O
clinical	O
markers	O
within	O
a	O
sample	O
of	O
United	O
States	O
adults	O
determined	O
the	O
extent	O
to	O
which	O
exposure	O
to	O
lead	O
potentially	O
altered	O
these	O
markers	O
.	O

Lead	O
’	O
s	O
impact	O
on	O
occupation	O
was	O
explored	O
to	O
determine	O
its	O
effects	O
on	O
the	O
clinical	O
makers	O
of	O
interest	O
among	O
those	O
occupationally	O
exposed	O
to	O
lead	O
.	O
Potential	O
mechanisms	O
of	O
disease	O
pathology	O
were	O
hypothesized	O
as	O
follows	O
:	O
exposure	O
to	O
lead	O
brings	O
about	O
inflammation	O
which	O
through	O
various	O
intermediary	O
steps	O
,	O
eventually	O
leads	O
to	O
elevation	O
of	O
blood	O
pressure	O
and	O
alterations	O
in	O
lipid	O
metabolism	O
.	O
The	O
sociodemographic	O
,	O
behavioral	O
and	O
anthropometric	O
covariates	O
made	O
it	O
possible	O
to	O
statistically	O
control	O
for	O
factors	O
associated	O
with	O
adverse	O
cardiovascular	O
outcomes	O
.	O
It	O
also	O
made	O
it	O
possible	O
to	O
make	O
estimations	O
about	O
the	O
contribution	O
of	O
lead	O
to	O
studied	O
participants	O
’	O
cardiovascular	O
-	O
related	O
markers	O
.	O
In	O
all	O
,	O
it	O
was	O
hypothesized	O
that	O
being	O
exposed	O
to	O
lead	O
would	O
be	O
associated	O
with	O
elevated	O
SBP	O
,	O
DBP	O
,	O
CRP	O
,	O
triglycerides	O
,	O
and	O
cholesterol	O
(	O
LDL	O
and	O
Total	O
)	O
with	O
a	O
reduction	O
in	O
HDL	O
Cholesterol	O
.	O
Data	O
from	O
NHANES	O
2007	O
–	O
2010	O
were	O
used	O
to	O
examine	O
the	O
association	O
between	O
lead	O
and	O
cardiovascular	O
-	O
related	O
markers	O
—	O
SBP	O
,	O
DBP	O
,	O
CRP	O
,	O
total	O
cholesterol	O
,	O
LDL	O
cholesterol	O
,	O
HDL	O
cholesterol	O
,	O
and	O
triglycerides	O
—	O
in	O
the	O
general	O
United	O
States	O
population	O
.	O
The	O
2007	O
–	O
2008	O
and	O
the	O
2009	O
–	O
2010	O
data	O
sets	O
were	O
pooled	O
together	O
using	O
NHANES	O
web	O
tutorial	O
[	O
17	O
]	O
.	O
The	O
NHANES	O
2007	O
–	O
2010	O
survey	O
was	O
conducted	O
by	O
the	O
CDC	O
using	O
a	O
representative	O
sample	O
of	O
the	O
U	O
.	O
S	O
.	O
noninstitutionalized	O
civilian	O
population	O
.	O
Altogether	O
,	O
12	O
,	O
153	O
adult	O
subjects	O
≥20	O
years	O
were	O
included	O
in	O
this	O
complex	O
multistage	O
,	O
stratified	O
cluster	O
survey	O
in	O
2007	O
through	O
2010	O
representing	O
217	O
,	O
057	O
,	O
187	O
people	O
.	O
Of	O
the	O
12	O
,	O
153	O
participants	O
,	O
blood	O
lead	O
was	O
measured	O
in	O
9781	O
adult	O
subjects	O
representing	O
an	O
estimated	O
182	O
,	O
052	O
,	O
299	O
people	O
.	O
Blood	O
pressure	O
value	O
levels	O
were	O
measured	O
in	O
10	O
,	O
316	O
adult	O
subjects	O
,	O
which	O
represented	O
an	O
estimated	O
192	O
,	O
473	O
,	O
335	O
people	O
in	O
the	O
population	O
.	O
CRP	O
values	O
levels	O
were	O
measured	O
in	O
11	O
,	O
071	O
adult	O
subjects	O
which	O
represented	O
an	O
estimated	O
205	O
,	O
722	O
,	O
599	O
people	O
in	O
the	O
population	O
.	O
Triglycerides	O
was	O
measured	O
for	O
5375	O
,	O
which	O
represented	O
an	O
estimated	O
215	O
,	O
374	O
,	O
827	O
people	O
.	O

Regarding	O
total	O
cholesterol	O
,	O
value	O
levels	O
measured	O
were	O
11	O
,	O
028	O
,	O
representing	O
an	O
estimated	O
204	O
,	O
918	O
,	O
352	O
people	O
,	O
whereas	O
HDL	O
cholesterol	O
data	O
was	O
measured	O
for	O
11	O
,	O
028	O
representing	O
204	O
,	O
918	O
,	O
352	O
people	O
.	O
For	O
LDL	O
,	O
cholesterol	O
values	O
were	O
measured	O
for	O
5263	O
people	O
which	O
represented	O
211	O
,	O
686	O
,	O
405	O
people	O
.	O
The	O
biochemistry	O
biomarkers	O
were	O
measured	O
using	O
a	O
Beckman	O
Synchron	O
LX20	O
,	O
Beckman	O
UniCel®	O
DxC800	O
Synchron	O
at	O
Collaborative	O
Laboratory	O
Services	O
(	O
Brea	O
,	O
CA	O
,	O
USA	O
)	O
and	O
the	O
Roche	O
Modular	O
P	O
chemistry	O
analyzer	O
(	O
University	O
of	O
Minnesota	O
,	O
Minneapolis	O
,	O
MN	O
,	O
USA	O
)	O
.	O
LDL	O
cholesterol	O
was	O
calculated	O
using	O
the	O
Friedewald	O
equation	O
.	O
CRP	O
was	O
measured	O
on	O
a	O
Behring	O
Nephelometer	O
(	O
University	O
of	O
Washington	O
,	O
Seattle	O
,	O
WA	O
,	O
USA	O
)	O
.	O
Metal	O
assays	O
in	O
whole	O
blood	O
samples	O
were	O
conducted	O
in	O
the	O
NHANES	O
2007	O
–	O
2010	O
at	O
the	O
Division	O
of	O
Laboratory	O
Sciences	O
,	O
National	O
Center	O
for	O
Environmental	O
Health	O
(	O
NCEH	O
)	O
of	O
the	O
CDC	O
.	O
Blood	O
lead	O
was	O
determined	O
by	O
inductively	O
coupled	O
plasma	O
mass	O
spectrometry	O
(	O
ICP	O
-	O
MS	O
;	O
CDC	O
method	O
No	O
.	O
ITB0001A	O
)	O
.	O
Data	O
management	O
was	O
done	O
in	O
accordance	O
with	O
the	O
NHANES	O
analytical	O
guidelines	B-methodology
relating	O
to	O
survey	O
design	O
and	O
weighting	O
.	O
The	O
software	O
Stata	O
SE	O
/	O
15	O
.	O
0	O
(	O
StataCorp	O
,	O
College	O
Station	O
,	O
TX	O
,	O
USA	O
)	O
was	O
used	O
for	O
data	O
management	O
.	O
This	O
study	O
analyzed	O
results	O
from	O
adults	O
aged	O
20	O
and	O
older	O
.	O
In	O
portions	O
of	O
the	O
study	O
,	O
analysis	O
was	O
performed	O
on	O
those	O
experiencing	O
various	O
degrees	O
of	O
exposure	O
represented	O
by	O
BLLs	O
in	O
four	O
quartiles	O
;	O
0	O
–	O
2	O
µg	O
/	O
dL	O
,	O
2	O
–	O
5	O
µg	O
/	O
dL	O
,	O
5	O
–	O
10	O
µg	O
/	O
dL	O
,	O
10	O
+	O
µg	O
/	O
dL	O
presented	O
in	O
this	O
study	O
as	O
quartile	O
1	O
,	O
quartile	O
2	O
,	O
quartile	O
3	O
,	O
and	O
quartile	O
4	O
respectively	O
,	O
which	O
represent	O
thresholds	O
typically	O
and	O
historically	O
used	O
in	O
the	O
literature	O
to	O
represent	O
elevated	O
exposure	O
.	O
Association	O
between	O
lead	O
and	O
cardiovascular	O
outcomes	O
were	O
explored	O
using	O
linear	O
regression	O
.	O
Since	O
the	O
variables	O
of	O
interest	O
were	O
not	O
normally	O
distributed	O
,	O
natural	O
log	O
transformation	O
was	O
used	O
for	O
dependent	O
and	O
independent	O
variables	O
in	O
regression	O
analysis	O
.	O

For	O
linear	O
regression	O
,	O
all	O
independent	O
variables	O
were	O
analyzed	O
as	O
continuous	O
variables	O
.	O
The	O
covariates	O
of	O
interest	O
(	O
gender	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
ethnicity	O
,	O
and	O
age	O
)	O
,	O
as	O
well	O
as	O
“	O
taking	O
a	O
prescription	O
”	O
for	O
hypertension	O
(	O
for	O
SBP	O
and	O
DBP	O
)	O
,	O
and	O
consumption	O
of	O
alcohol	O
(	O
those	O
who	O
had	O
taken	O
at	O
least	O
12	O
alcoholic	O
drinks	O
in	O
the	O
past	O
year	O
)	O
,	O
smoking	O
habits	O
,	O
and	O
taking	O
prescription	O
medication	O
for	O
cholesterol	O
for	O
(	O
total	O
cholesterol	O
,	O
HDL	O
,	O
LDL	O
,	O
and	O
triglycerides	O
)	O
were	O
adjusted	O
for	O
to	O
determine	O
leads	O
impact	O
on	O
the	O
clinical	O
markers	O
of	O
interest	O
.	O
Statistical	O
analyses	O
were	O
performed	O
using	O
Stata	O
SE	O
/	O
15	O
.	O
0	O
,	O
as	O
the	O
software	O
allowed	O
for	O
adjustment	O
for	O
clusters	O
and	O
strata	O
of	O
the	O
complex	O
sample	O
in	O
addition	O
to	O
incorporating	O
the	O
sample	O
weight	O
in	O
order	O
to	O
generate	O
estimates	O
for	O
the	O
total	O
noninstitutionalized	O
civilian	O
population	O
of	O
the	O
United	O
States	O
.	O
Occupational	O
exposure	O
to	O
lead	O
was	O
explored	O
by	O
determining	O
three	O
occupations	O
which	O
had	O
the	O
highest	O
and	O
lowest	O
BLLs	O
at	O
the	O
occupation	O
of	O
longest	O
duration	O
(	O
the	O
occupation	O
they	O
had	O
spent	O
most	O
of	O
their	O
career	O
in	O
)	O
.	O
This	O
was	O
done	O
to	O
examine	O
how	O
the	O
clinical	O
makers	O
manifested	O
in	O
high	O
exposure	O
occupations	O
when	O
compared	O
to	O
low	O
exposure	O
occupations	O
.	O
In	O
addition	O
,	O
duration	O
in	O
occupation	O
was	O
examined	O
for	O
time	O
intervals	O
of	O
0	O
–	O
5	O
years	O
,	O
5	O
–	O
10	O
years	O
,	O
and	O
over	O
10	O
years	O
to	O
see	O
how	O
length	O
of	O
time	O
at	O
a	O
lead	O
exposed	O
job	O
may	O
alter	O
clinical	O
markers	O
of	O
interest	O
.	O
A	O
p	O
-	O
value	O
of	O
<	O
0	O
.	O
05	O
was	O
considered	O
significant	O
while	O
a	O
value	O
of	O
<	O
0	O
.	O
10	O
was	O
considered	O
moderately	O
significant	O
.	O
Excel	O
2016	O
was	O
used	O
to	O
generate	O
charts	O
/	O
figures	O
.	O
Information	O
on	O
age	O
and	O
BMI	O
and	O
clinical	O
makers	O
by	O
degree	O
of	O
exposure	O
are	O
presented	O
in	O
Table	O
1	O
.	O
Associations	O
of	O
BLL	O
were	O
examined	O
with	O
each	O
of	O
the	O
cardiovascular	O
related	O
variables	O
(	O
which	O
included	O
CRP	O
,	O
SBP	O
,	O
DBP	O
,	O
triglycerides	O
,	O
total	O
cholesterol	O
,	O
LDL	O
Cholesterol	O
,	O
and	O
HDL	O
Cholesterol	O
variables	O
)	O
using	O
separate	O
regression	O
models	O
for	O
each	O
exposure	O
-	O
outcome	O
association	O
.	O
All	O
variables	O
were	O
adjusted	O
for	O
age	O
,	O
gender	O
,	O
race	O
/	O
ethnicity	O
,	O
BMI	O
,	O
alcohol	O
consumption	O
and	O
smoking	O
.	O
In	O
addition	O
,	O
SBP	O
,	O
DBP	O
were	O
adjusted	O
for	O
taking	O
prescription	O
medications	O
for	O
hypertension	O
with	O
triglycerides	O
,	O
total	O
cholesterol	O
,	O
LDL	O
,	O
and	O
HDL	O
adjusted	O
for	O
taking	O
medications	O
for	O
cholesterol	O
.	O

The	O
associations	O
of	O
BLL	O
and	O
the	O
cardiovascular	O
-	O
related	O
variables	O
are	O
presented	O
in	O
Table	O
2	O
below	O
.	O
The	O
occupations	O
providing	O
a	O
high	O
level	O
of	O
exposure	O
as	O
measured	O
by	O
mean	O
BLLs	O
were	O
:	O
(	O
a	O
)	O
Agriculture	O
,	O
Forestry	O
&	O
Fishing	O
2	O
.	O
19	O
µg	O
/	O
dL	O
(	O
SE	O
=	O
0	O
.	O
12	O
)	O
;	O
(	O
b	O
)	O
Mining	O
2	O
.	O
33	O
µg	O
/	O
dL	O
(	O
SE	O
=	O
0	O
.	O
34	O
)	O
;	O
and	O
(	O
c	O
)	O
Construction	O
2	O
.	O
39	O
µg	O
/	O
dL	O
(	O
SE	O
=	O
0	O
.	O
12	O
)	O
.	O
The	O
occupation	O
providing	O
the	O
lowest	O
levels	O
of	O
exposure	O
as	O
measured	O
by	O
mean	O
BLLs	O
were	O
:	O
(	O
a	O
)	O
Professional	O
,	O
Scientific	O
,	O
Technical	O
Services	O
1	O
.	O
35	O
µg	O
/	O
dL	O
(	O
SE	O
=	O
0	O
.	O
05	O
)	O
;	O
(	O
b	O
)	O
Private	O
Household	O
1	O
.	O
35	O
µg	O
/	O
dL	O
(	O
SE	O
=	O
0	O
.	O
11	O
)	O
;	O
and	O
(	O
c	O
)	O
Arts	O
,	O
Entertainment	O
,	O
Recreation	O
1	O
.	O
33	O
µg	O
/	O
dL	O
(	O
SE	O
=	O
0	O
.	O
11	O
)	O
.	O
Figure	O
1	O
below	O
illustrates	O
the	O
findings	O
.	O
The	O
mean	O
cholesterol	O
levels	O
in	O
the	O
occupations	O
of	O
interest	O
are	O
shown	O
in	O
Figure	O
2	O
below	O
.	O
For	O
the	O
high	O
exposure	O
occupations	O
,	O
the	O
mean	O
cholesterol	O
level	O
for	O
Agriculture	O
,	O
Forestry	O
&	O
Fishing	O
was	O
193	O
.	O
95	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
3	O
.	O
48	O
)	O
.	O
For	O
Mining	O
and	O
Construction	O
,	O
the	O
mean	O
cholesterol	O
levels	O
were	O
188	O
.	O
41	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
4	O
.	O
02	O
)	O
and	O
195	O
.	O
02	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
2	O
.	O
66	O
)	O
respectively	O
.	O
For	O
the	O
low	O
exposure	O
occupations	O
,	O
the	O
mean	O
cholesterol	O
levels	O
were	O
:	O
Professional	O
Scientific	O
,	O
Technical	O
Services	O
198	O
.	O
72	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
4	O
.	O
33	O
)	O
;	O
Private	O
Household	O
212	O
.	O
42	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
5	O
.	O
00	O
)	O
;	O
and	O
Arts	O
Entertainment	O
,	O
Recreation	O
187	O
.	O
30	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
5	O
.	O
13	O
)	O
.	O
Blood	O
pressure	O
in	O
these	O
occupations	O
was	O
also	O
explored	O
.	O
Figure	O
3a	O
,	O
b	O
shows	O
the	O
SBP	O
and	O
DBP	O
levels	O
based	O
on	O
the	O
longest	O
served	O
occupation	O
.	O
For	O
the	O
high	O
exposure	O
occupations	O
,	O
the	O
mean	O
SBP	O
level	O
regarding	O
Agriculture	O
,	O
Forestry	O
&	O
Fishing	O
was	O
126	O
.	O
53	O
.	O
58	O
mmHg	O
(	O
SE	O
=	O
1	O
.	O
42	O
)	O
;	O
for	O
Mining	O
it	O
was	O
127	O
.	O
26	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
2	O
.	O
88	O
)	O
.	O
For	O
Construction	O
,	O
SBP	O
level	O
was	O
123	O
.	O
03	O
mmHg	O
(	O
SE	O
=	O
0	O
.	O
85	O
)	O
.	O

For	O
the	O
low	O
exposure	O
occupations	O
,	O
the	O
mean	O
SBP	O
levels	O
were	O
:	O
Professional	O
Scientific	O
,	O
Technical	O
Services	O
120	O
.	O
51	O
mmHg	O
(	O
SE	O
=	O
1	O
.	O
41	O
)	O
;	O
Private	O
Household	O
122	O
.	O
95	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
2	O
.	O
15	O
)	O
;	O
and	O
Arts	O
,	O
Entertainment	O
,	O
Recreation	O
118	O
.	O
15	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
1	O
.	O
63	O
)	O
.	O
See	O
Figure	O
3a	O
.	O
The	O
results	O
for	O
DBP	O
levels	O
for	O
the	O
high	O
exposure	O
occupations	O
were	O
as	O
follows	O
:	O
Agriculture	O
,	O
Forestry	O
&	O
Fishing	O
,	O
67	O
.	O
68	O
mmHg	O
(	O
SE	O
=	O
1	O
.	O
10	O
)	O
;	O
Mining	O
,	O
71	O
.	O
72	O
mmHg	O
(	O
SE	O
=	O
2	O
.	O
92	O
)	O
;	O
and	O
Construction	O
,	O
71	O
.	O
04	O
mmHg	O
(	O
SE	O
=	O
0	O
.	O
77	O
)	O
.	O
For	O
the	O
low	O
exposure	O
occupations	O
,	O
the	O
mean	O
DBP	O
levels	O
were	O
:	O
Professional	O
Scientific	O
,	O
Technical	O
Services	O
,	O
68	O
.	O
38	O
mmHg	O
(	O
SE	O
=	O
1	O
.	O
10	O
)	O
;	O
Private	O
Household	O
,	O
68	O
.	O
42	O
mmHg	O
(	O
SE	O
=	O
4	O
.	O
01	O
)	O
;	O
and	O
Arts	O
Entertainment	O
,	O
Recreation	O
,	O
69	O
.	O
86	O
mmHg	O
(	O
SE	O
=	O
2	O
.	O
99	O
)	O
.	O
Figure	O
3a	O
,	O
b	O
represents	O
the	O
mean	O
SBP	O
and	O
DBP	O
mean	O
levels	O
in	O
the	O
longest	O
served	O
(	O
duration	O
)	O
occupations	O
.	O
Results	O
of	O
the	O
mean	O
C	O
-	O
reactive	O
protein	O
by	O
occupation	O
are	O
shown	O
Figure	O
4	O
below	O
.	O
For	O
the	O
high	O
exposure	O
occupations	O
,	O
the	O
mean	O
CRP	O
in	O
Agriculture	O
,	O
Forestry	O
&	O
Fishing	O
was	O
0	O
.	O
31	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
0	O
.	O
03	O
)	O
;	O
that	O
for	O
Mining	O
was	O
0	O
.	O
58	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
0	O
.	O
3	O
)	O
whereas	O
that	O
for	O
Construction	O
was	O
0	O
.	O
44	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
0	O
.	O
047	O
)	O
.	O
For	O
the	O
low	O
exposure	O
occupations	O
,	O
the	O
mean	O
C	O
-	O
reactive	O
protein	O
levels	O
were	O
:	O
Professional	O
,	O
Scientific	O
,	O
Technical	O
Services	O
,	O
0	O
.	O
30	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
0	O
.	O
028	O
)	O
;	O
Private	O
Household	O
,	O
0	O
.	O
45	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
0	O
.	O
038	O
)	O
;	O
and	O
Arts	O
,	O
Entertainment	O
,	O
Recreation	O
,	O
0	O
.	O
22	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
0	O
.	O
024	O
)	O
.	O
Results	O
of	O
the	O
mean	O
triglyceride	O
levels	O
are	O
shown	O
in	O
Figure	O
5	O
below	O
.	O
For	O
the	O
high	O
exposure	O
occupations	O
,	O
the	O
following	O
results	O
were	O
obtained	O
.	O
The	O
mean	O
triglyceride	O
level	O
for	O
Agriculture	O
,	O
Forestry	O
&	O
Fishing	O
was	O
141	O
.	O
50	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
17	O
.	O
91	O
)	O
.	O

For	O
Mining	O
,	O
the	O
level	O
was	O
133	O
.	O
50	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
11	O
.	O
60	O
)	O
and	O
that	O
for	O
Construction	O
was	O
134	O
.	O
94	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
7	O
.	O
79	O
)	O
.	O
For	O
the	O
low	O
exposure	O
occupations	O
,	O
the	O
mean	O
triglyceride	O
level	O
levels	O
were	O
:	O
Professional	O
,	O
Scientific	O
,	O
Technical	O
Services	O
,	O
103	O
.	O
59	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
6	O
.	O
85	O
)	O
;	O
Private	O
Household	O
,	O
187	O
.	O
48	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
48	O
.	O
95	O
)	O
;	O
and	O
Arts	O
Entertainment	O
,	O
Recreation	O
,	O
105	O
.	O
17	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
12	O
.	O
93	O
)	O
.	O
The	O
mean	O
LDL	O
cholesterol	O
levels	O
are	O
shown	O
in	O
Figure	O
6	O
below	O
.	O
For	O
the	O
high	O
exposure	O
occupations	O
,	O
the	O
following	O
cholesterol	O
levels	O
were	O
obtained	O
:	O
Agriculture	O
,	O
Forestry	O
&	O
Fishing	O
,	O
117	O
.	O
82	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
6	O
.	O
58	O
)	O
;	O
Mining	O
,	O
108	O
.	O
72	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
3	O
.	O
89	O
)	O
;	O
and	O
Construction	O
,	O
119	O
.	O
45	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
3	O
.	O
45	O
)	O
.	O
For	O
the	O
low	O
exposure	O
occupations	O
,	O
the	O
mean	O
LDL	O
levels	O
were	O
:	O
Professional	O
Scientific	O
,	O
Technical	O
Services	O
,	O
115	O
.	O
97	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
4	O
.	O
02	O
)	O
;	O
Private	O
Household	O
,	O
117	O
.	O
43	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
6	O
.	O
17	O
)	O
;	O
and	O
Arts	O
Entertainment	O
&	O
Recreation	O
,	O
106	O
.	O
58	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
5	O
.	O
98	O
)	O
.	O
The	O
mean	O
HDL	O
cholesterol	O
levels	O
are	O
shown	O
in	O
Figure	O
7	O
below	O
.	O
For	O
the	O
high	O
exposure	O
occupations	O
,	O
results	O
of	O
the	O
mean	O
HDL	O
cholesterol	O
levels	O
were	O
as	O
follows	O
:	O
Agriculture	O
,	O
Forestry	O
&	O
Fishing	O
,	O
46	O
.	O
93	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
1	O
.	O
51	O
)	O
;	O
Mining	O
,	O
46	O
.	O
79	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
2	O
.	O
41	O
)	O
;	O
and	O
Construction	O
,	O
48	O
.	O
3	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
0	O
.	O
79	O
)	O
.	O
For	O
the	O
low	O
exposure	O
occupations	O
,	O
the	O
mean	O
HDL	O
levels	O
were	O
:	O
Professional	O
,	O
Scientific	O
,	O
Technical	O
Services	O
,	O
55	O
.	O
27	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
1	O
.	O
58	O
)	O
;	O
Private	O
Household	O
,	O
53	O
.	O
93	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
2	O
.	O
59	O
)	O
;	O
and	O
Arts	O
Entertainment	O
&	O
Recreation	O
,	O
56	O
.	O
63	O
mg	O
/	O
dL	O
(	O
SE	O
=	O
1	O
.	O
3	O
)	O
.	O
The	O
effects	O
of	O
duration	O
of	O
exposure	O
on	O
the	O
clinical	O
markers	O
of	O
interest	O
are	O
shown	O
in	O
Table	O
3	O
below	O
.	O
The	O
values	O
represent	O
mean	O
levels	O
for	O
the	O
clinical	O
makers	O
of	O
interest	O
during	O
that	O
listed	O
time	O
interval	O
.	O

This	O
study	O
sought	O
to	O
determine	O
the	O
associations	O
of	O
cardiovascular	O
-	O
related	O
markers	O
with	O
BLL	O
in	O
US	O
adults	O
in	O
addition	O
to	O
predicting	O
the	O
likelihood	O
of	O
elevated	O
BLL	O
at	O
different	O
exposure	O
levels	O
.	O
Finally	O
it	O
sought	O
to	O
understand	O
how	O
lead	O
exposure	O
manifested	O
in	O
high	O
-	O
and	O
low	O
-	O
lead	O
exposed	O
occupations	O
cognizant	O
of	O
the	O
fact	O
that	O
lead	O
exposure	O
in	O
adults	O
most	O
commonly	O
occurs	O
in	O
the	O
workplace	O
and	O
industries	O
such	O
as	O
the	O
construction	O
industry	O
have	O
historically	O
been	O
a	O
source	O
of	O
lead	O
exposure	O
among	O
adults	O
[	O
18	O
,	O
19	O
]	O
.	O
It	O
was	O
determined	O
that	O
the	O
occupations	O
providing	O
the	O
most	O
exposure	O
,	O
as	O
measured	O
by	O
BLLs	O
in	O
adults	O
were	O
the	O
Construction	O
industry	O
;	O
Agriculture	O
Forestry	O
&	O
Fishing	O
;	O
and	O
Mining	O
.	O
This	O
is	O
in	O
line	O
with	O
research	O
that	O
has	O
demonstrated	O
that	O
jobs	O
such	O
as	O
those	O
within	O
the	O
construction	O
industry	O
are	O
potential	O
sources	O
of	O
lead	O
exposure	O
[	O
20	O
]	O
.	O
Agriculture	O
Forestry	O
&	O
Fishing	O
,	O
in	O
addition	O
to	O
Mining	O
also	O
provide	O
avenues	O
to	O
keep	O
workers	O
exposed	O
to	O
toxicants	O
such	O
as	O
lead	O
[	O
21	O
,	O
22	O
]	O
.	O
The	O
occupations	O
with	O
the	O
least	O
exposed	O
population	O
were	O
:	O
Professional	O
,	O
Scientific	O
,	O
and	O
Technical	O
Services	O
;	O
Private	O
Household	O
;	O
and	O
Arts	O
,	O
Entertainment	O
,	O
and	O
Recreation	O
.	O
These	O
industries	O
were	O
examined	O
to	O
see	O
their	O
how	O
the	O
clinical	O
markers	O
of	O
interest	O
varied	O
between	O
the	O
high	O
exposure	O
occupations	O
and	O
the	O
lower	O
exposure	O
occupations	O
.	O
In	O
comparing	O
high	O
exposure	O
occupations	O
to	O
low	O
exposure	O
occupations	O
,	O
the	O
mean	O
BLLs	O
were	O
significantly	O
higher	O
when	O
comparing	O
the	O
three	O
high	O
exposure	O
occupations	O
to	O
the	O
three	O
low	O
exposure	O
occupations	O
.	O
Even	O
though	O
BLL	O
is	O
a	O
marker	O
of	O
acute	O
exposure	O
this	O
potentially	O
hints	O
at	O
chronic	O
low	O
-	O
level	O
lead	O
exposure	O
among	O
the	O
highly	O
exposed	O
occupations	O
as	O
the	O
BLL	O
levels	O
in	O
these	O
occupations	O
were	O
below	O
the	O
Occupational	O
Safety	O
and	O
Health	O
Administration	O
’	O
s	O
(	O
OSHA	O
)	O
lead	O
standards	O
which	O
require	O
that	O
workers	O
be	O
removed	O
from	O
lead	O
exposure	O
sources	O
when	O
BLLs	O
are	O
≥50	O
μg	O
/	O
dL	O
in	O
the	O
construction	O
industry	O
or	O
60	O
μg	O
/	O
dL	O
in	O
general	O
industry	O
[	O
23	O
]	O
.	O
Mean	O
SBP	O
was	O
significantly	O
elevated	O
when	O
comparing	O
the	O
Agriculture	O
,	O
Forestry	O
&	O
Fishing	O
industries	O
to	O
Professional	O
Scientific	O
,	O
Technical	O
Services	O
,	O
and	O
Arts	O
,	O
Entertainment	O
,	O
and	O
Recreation	O
.	O
This	O
may	O
be	O
due	O
to	O
lead	O
contaminated	O
soils	O
[	O
24	O
]	O
which	O
owing	O
to	O
leads	O
persistent	O
nature	O
may	O
continue	O
to	O
expose	O
workers	O
in	O
this	O
industry	O
.	O
In	O
Mining	O
,	O
mean	O
SBP	O
was	O
significantly	O
elevated	O
when	O
compared	O
to	O
Arts	O
,	O
Entertainment	O
,	O
and	O
Recreation	O
,	O
while	O
it	O
was	O
moderately	O
significantly	O
elevated	O
for	O
mining	O
when	O
compared	O
to	O
Professional	O
,	O
Scientific	O
&	O
Technical	O
services	O
.	O
Living	O
by	O
mining	O
areas	O
exposes	O
populations	O
to	O
heavy	O
metals	O
such	O
as	O
lead	O
[	O
25	O
]	O
,	O
with	O
a	O
resulting	O
health	O
outcome	O
from	O
the	O
exposure	O
potentially	O
being	O
hypertension	O
[	O
3	O
]	O
.	O

Studies	O
on	O
blood	O
pressure	O
in	O
construction	O
workers	O
have	O
varied	O
,	O
with	O
some	O
studies	O
finding	O
no	O
association	O
between	O
SBP	O
and	O
DBP	O
in	O
this	O
occupation	O
[	O
26	O
]	O
,	O
and	O
others	O
finding	O
construction	O
workers	O
to	O
have	O
elevated	O
SBP	O
and	O
DBP	O
.	O
In	O
this	O
study	O
,	O
those	O
in	O
the	O
Construction	O
industry	O
had	O
significantly	O
elevated	O
blood	O
pressure	O
as	O
compared	O
to	O
those	O
in	O
the	O
less	O
-	O
exposed	O
occupations	O
such	O
as	O
Education	O
.	O
Regarding	O
DBP	O
,	O
the	O
mean	O
levels	O
were	O
significantly	O
elevated	O
when	O
comparing	O
Construction	O
to	O
Professional	O
,	O
Scientific	O
,	O
and	O
Technical	O
services	O
.	O
For	O
CRP	O
,	O
Agriculture	O
,	O
Forestry	O
,	O
&	O
Fishing	O
was	O
significantly	O
elevated	O
when	O
compared	O
to	O
Arts	O
,	O
Entertainment	O
,	O
&	O
Recreation	O
.	O
There	O
was	O
also	O
a	O
significant	O
elevation	O
between	O
Construction	O
and	O
Professional	O
Scientific	O
and	O
Technical	O
services	O
,	O
and	O
a	O
moderately	O
significant	O
difference	O
between	O
Construction	O
and	O
Arts	O
,	O
and	O
Entertainment	O
&	O
Recreation	O
.	O
This	O
potentially	O
speaks	O
to	O
the	O
degree	O
of	O
systemic	O
inflammation	O
that	O
comes	O
from	O
performing	O
these	O
lead	O
exposed	O
jobs	O
with	O
CRP	O
and	O
other	O
markers	O
,	O
indicating	O
that	O
the	O
cardiovascular	O
system	O
may	O
bear	O
a	O
significant	O
portion	O
of	O
this	O
inflammation	O
.	O
Elevated	O
CRP	O
has	O
been	O
associated	O
with	O
lead	O
exposure	O
[	O
27	O
]	O
in	O
community	O
-	O
based	O
studies	O
as	O
well	O
as	O
occupational	O
studies	O
;	O
thus	O
systemic	O
inflammation	O
may	O
serve	O
as	O
a	O
mediator	O
for	O
other	O
biological	O
mechanisms	O
such	O
as	O
oxidative	O
stress	O
in	O
those	O
exposed	O
to	O
lead	O
.	O
These	O
two	O
mechanisms	O
potentially	O
serve	O
as	O
the	O
genesis	O
of	O
many	O
of	O
the	O
cardiovascular	O
pathologies	O
that	O
comes	O
about	O
from	O
lead	O
exposure	O
.	O
Regarding	O
triglycerides	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
the	O
means	O
between	O
Mining	O
and	O
Professional	O
,	O
and	O
Scientific	O
&	O
Technical	O
Services	O
.	O
In	O
Construction	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
the	O
mean	O
levels	O
for	O
mining	O
when	O
compared	O
to	O
Professional	O
and	O
Scientific	O
&	O
Technical	O
Services	O
.	O
There	O
was	O
also	O
a	O
moderately	O
significant	O
difference	O
between	O
Agriculture	O
and	O
Forestry	O
&	O
Fishing	O
when	O
compared	O
to	O
Professional	O
,	O
Scientific	O
,	O
&	O
Technical	O
Services	O
,	O
and	O
between	O
Construction	O
and	O
Arts	O
,	O
and	O
Entertainment	O
&	O
Recreation	O
.	O
Triglyceride	O
levels	O
may	O
potentially	O
be	O
altered	O
by	O
occupation	O
;	O
with	O
working	O
in	O
lead	O
-	O
exposed	O
occupations	O
seeming	O
to	O
worsen	O
triglyceride	O
levels	O
in	O
adults	O
.	O
What	O
is	O
unclear	O
is	O
the	O
degree	O
to	O
which	O
lead	O
alters	O
triglyceride	O
levels	O
.	O
For	O
LDL	O
cholesterol	O
,	O
there	O
was	O
a	O
moderately	O
significant	O
elevation	O
in	O
those	O
in	O
Construction	O
as	O
compared	O
to	O
those	O
in	O
Arts	O
,	O
Entertainment	O
,	O
&	O
Recreation	O
whereas	O
for	O
HDL	O
,	O
the	O
less	O
-	O
exposed	O
occupations	O
were	O
significantly	O
elevated	O
compared	O
to	O
the	O
high	O
exposure	O
occupations	O
.	O
Lead	O
potentially	O
promoting	O
LDL	O
and	O
diminishing	O
HDL	O
in	O
the	O
occupational	O
analysis	O
largely	O
supports	O
the	O
results	O
of	O
similar	O
occupational	O
studies	O
[	O
16	O
]	O
.	O

Finally	O
,	O
in	O
longest	O
held	O
occupation	O
,	O
a	O
marker	O
of	O
long	O
term	O
exposure	O
,	O
results	O
for	O
Construction	O
demonstrated	O
that	O
mean	O
BLLs	O
were	O
significantly	O
elevated	O
from	O
the	O
0	O
–	O
5	O
-	O
year	O
working	O
period	O
when	O
compared	O
to	O
the	O
10	O
plus	O
year	O
working	O
period	O
;	O
while	O
it	O
was	O
moderately	O
elevated	O
from	O
the	O
0	O
–	O
5	O
to	O
5	O
–	O
10	O
-	O
year	O
period	O
.	O
In	O
Mining	O
BLLs	O
were	O
significantly	O
elevated	O
from	O
the	O
0	O
–	O
5	O
-	O
year	O
to	O
the	O
10	O
+	O
year	O
period	O
and	O
from	O
the	O
0	O
–	O
5	O
-	O
year	O
period	O
to	O
the	O
5	O
–	O
10	O
-	O
year	O
period	O
.	O
Mean	O
SBP	O
was	O
elevated	O
significantly	O
from	O
the	O
0	O
–	O
5	O
-	O
year	O
working	O
period	O
when	O
compared	O
to	O
the	O
10	O
plus	O
year	O
working	O
period	O
in	O
Agriculture	O
and	O
Mining	O
,	O
&	O
Construction	O
,	O
while	O
it	O
was	O
also	O
significantly	O
elevated	O
from	O
the	O
0	O
–	O
5	O
-	O
year	O
period	O
to	O
the	O
5	O
–	O
10	O
-	O
year	O
period	O
in	O
Construction	O
.	O
DBP	O
was	O
significantly	O
elevated	O
from	O
the	O
0	O
–	O
5	O
-	O
year	O
period	O
to	O
the	O
5	O
–	O
10	O
-	O
year	O
period	O
in	O
Mining	O
.	O
This	O
potentially	O
indicates	O
that	O
the	O
time	O
spent	O
in	O
a	O
job	O
in	O
which	O
lead	O
exposure	O
exists	O
may	O
alter	O
blood	O
pressure	O
,	O
with	O
outcomes	O
possibly	O
being	O
time	O
-	O
dependent	O
.	O
The	O
time	O
interval	O
in	O
which	O
the	O
more	O
severe	O
pathology	O
happens	O
is	O
debatable	O
and	O
is	O
likely	O
related	O
to	O
several	O
factors	O
including	O
,	O
genetic	O
[	O
28	O
]	O
and	O
behavioral	O
factors	O
.	O
CRP	O
was	O
significantly	O
elevated	O
from	O
the	O
0	O
–	O
5	O
to	O
5	O
–	O
10	O
-	O
year	O
period	O
in	O
Agriculture	O
and	O
Forestry	O
&	O
Fishing	O
,	O
and	O
moderately	O
elevated	O
form	O
the	O
0	O
–	O
5	O
to	O
10	O
+	O
year	O
period	O
in	O
Construction	O
,	O
indicating	O
that	O
lead	O
exposure	O
in	O
these	O
occupations	O
may	O
promote	O
systemic	O
inflammation	O
over	O
time	O
,	O
which	O
could	O
potentially	O
lead	O
to	O
cardiovascular	O
pathology	O
over	O
an	O
extended	O
period	O
of	O
time	O
.	O
An	O
observation	O
of	O
the	O
data	O
also	O
showed	O
that	O
Triglycerides	O
levels	O
were	O
elevated	O
from	O
the	O
5	O
–	O
10	O
to	O
10	O
+	O
year	O
period	O
in	O
Mining	O
and	O
Construction	O
;	O
and	O
also	O
elevated	O
from	O
the	O
0	O
–	O
5	O
to	O
5	O
–	O
10	O
-	O
year	O
period	O
in	O
Construction	O
.	O
LDL	O
cholesterol	O
was	O
elevated	O
from	O
the	O
0	O
–	O
5	O
to	O
the	O
5	O
–	O
10	O
-	O
year	O
period	O
,	O
and	O
0	O
–	O
5	O
to	O
10	O
+	O
year	O
period	O
.	O
HDL	O
cholesterol	O
level	O
was	O
elevated	O
from	O
the	O
5	O
–	O
10	O
to	O
10	O
+	O
year	O
period	O
in	O
Mining	O
,	O
and	O
moderately	O
decreased	O
in	O
the	O
5	O
–	O
10	O
to	O
the	O
10	O
+	O
year	O
period	O
in	O
Construction	O
.	O
Lead	O
’	O
s	O
potential	O
action	O
on	O
these	O
clinical	O
markers	O
indicates	O
more	O
work	O
must	O
be	O
done	O
to	O
understand	O
its	O
effects	O
over	O
longer	O
and	O
shorter	O
periods	O
of	O
time	O
.	O

This	O
will	O
give	O
insight	O
into	O
how	O
to	O
properly	O
mitigate	O
lead	O
exposure	O
for	O
those	O
exposed	O
to	O
different	O
occupations	O
,	O
which	O
may	O
present	O
different	O
exposure	O
conditions	O
,	O
and	O
potentially	O
induce	O
or	O
promote	O
disease	O
to	O
manifest	O
in	O
different	O
ways	O
.	O
According	O
to	O
Lanphear	O
and	O
co	O
-	O
authors	O
,	O
low	O
-	O
level	O
environmental	O
lead	O
exposure	O
substantially	O
affects	O
cardiovascular	O
health	O
[	O
29	O
]	O
.	O
In	O
the	O
United	O
States	O
,	O
owing	O
to	O
the	O
legacy	O
of	O
lead	O
contamination	O
such	O
exposure	O
is	O
common	O
.	O
Among	O
adults	O
in	O
the	O
United	O
States	O
,	O
the	O
primary	O
avenue	O
by	O
which	O
exposure	O
to	O
lead	O
occurs	O
is	O
in	O
the	O
workplace	O
[	O
30	O
]	O
.	O
With	O
respect	O
to	O
BLL	O
and	O
cardiovascular	O
-	O
related	O
markers	O
in	O
all	O
adults	O
,	O
significant	O
associations	O
between	O
BLL	O
,	O
DBP	O
,	O
and	O
HDL	O
cholesterol	O
was	O
found	O
in	O
this	O
study	O
.	O
In	O
examining	O
the	O
clinical	O
markers	O
by	O
quartile	O
of	O
exposure	O
,	O
for	O
SBP	O
there	O
was	O
a	O
significant	O
elevation	O
from	O
quartile	O
1	O
to	O
quartiles	O
2	O
and	O
3	O
.	O
This	O
indicates	O
a	O
potential	O
relationship	O
,	O
with	O
higher	O
exposure	O
to	O
lead	O
increasing	O
SBP	O
.	O
For	O
DBP	O
,	O
there	O
was	O
a	O
significant	O
elevation	O
from	O
quartile	O
1	O
when	O
compared	O
to	O
quartile	O
4	O
.	O
For	O
CRP	O
there	O
was	O
a	O
significant	O
elevation	O
from	O
quartile	O
1	O
to	O
quartile	O
3	O
.	O
This	O
indicates	O
that	O
systemic	O
inflammation	O
potentially	O
increases	O
with	O
increasing	O
dose	O
of	O
lead	O
,	O
but	O
it	O
should	O
be	O
noted	O
that	O
there	O
was	O
not	O
a	O
significant	O
association	O
in	O
regression	O
analysis	O
,	O
which	O
may	O
partly	O
be	O
due	O
to	O
how	O
the	O
data	O
is	O
more	O
skewed	O
toward	O
the	O
lower	O
BLLs	O
.	O
Larger	O
databases	O
or	O
studies	O
with	O
larger	O
groups	O
of	O
significantly	O
exposed	O
individuals	O
may	O
yield	O
different	O
results	O
.	O
For	O
triglycerides	O
,	O
there	O
was	O
a	O
significant	O
elevation	O
from	O
quartile	O
1	O
when	O
compared	O
to	O
quartiles	O
2	O
and	O
4	O
;	O
and	O
for	O
total	O
cholesterol	O
,	O
there	O
was	O
a	O
significant	O
elevation	O
from	O
quartile	O
1	O
to	O
quartiles	O
2	O
and	O
3	O
.	O
With	O
respect	O
to	O
mean	O
LDL	O
cholesterol	O
level	O
,	O
there	O
was	O
a	O
significant	O
elevation	O
from	O
quartile	O
1	O
to	O
quartiles	O
2	O
and	O
4	O
,	O
whereas	O
for	O
mean	O
HDL	O
cholesterol	O
level	O
,	O
there	O
was	O
a	O
significant	O
elevation	O
from	O
quartile	O
1	O
and	O
2	O
;	O
quartile	O
4	O
had	O
the	O
lowest	O
mean	O
HDL	O
cholesterol	O
level	O
.	O
All	O
of	O
this	O
indicates	O
that	O
lead	O
potentially	O
accelerates	O
the	O
formation	O
of	O
LDL	O
and	O
total	O
cholesterol	O
,	O
and	O
hinders	O
the	O
production	O
of	O
HDL	O
,	O
but	O
the	O
dosage	O
at	O
which	O
that	O
starts	O
is	O
unclear	O
.	O

As	O
demonstrated	O
in	O
the	O
literature	O
,	O
lead	O
has	O
been	O
associated	O
with	O
increases	O
in	O
both	O
SBP	O
and	O
DBP	O
.	O
Research	O
has	O
consistently	O
found	O
an	O
association	O
between	O
BLL	O
and	O
SBP	O
and	O
DBP	O
with	O
Harlan	O
and	O
co	O
-	O
authors	O
,	O
using	O
data	O
from	O
the	O
second	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
,	O
to	O
demonstrate	O
a	O
direct	O
relationship	O
between	O
BLL	O
and	O
SBP	O
and	O
DBPs	O
for	O
men	O
and	O
women	O
,	O
and	O
for	O
white	O
and	O
black	O
persons	O
aged	O
12	O
to	O
74	O
[	O
31	O
]	O
.	O
For	O
their	O
part	O
,	O
Nawrot	O
and	O
co	O
-	O
authors	O
found	O
,	O
in	O
a	O
study	O
including	O
both	O
men	O
and	O
women	O
,	O
that	O
two	O
-	O
fold	O
increase	O
in	O
blood	O
lead	O
concentration	O
was	O
associated	O
with	O
a	O
1	O
.	O
0	O
mm	O
Hg	O
rise	O
in	O
the	O
SBP	O
(	O
95	O
%	O
CI	O
+	O
0	O
.	O
5	O
to	O
+	O
1	O
.	O
4	O
mm	O
Hg	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
with	O
a	O
0	O
.	O
6	O
mm	O
Hg	O
increase	O
in	O
the	O
DBP	O
(	O
95	O
%	O
CI	O
+	O
0	O
.	O
4	O
to	O
+	O
0	O
.	O
8	O
mm	O
Hg	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
[	O
10	O
]	O
.	O
A	O
comparison	O
of	O
the	O
results	O
of	O
my	O
study	O
with	O
those	O
in	O
the	O
literature	O
points	O
to	O
the	O
fact	O
that	O
the	O
results	O
of	O
my	O
study	O
,	O
to	O
a	O
large	O
extent	O
,	O
bolster	O
what	O
obtains	O
in	O
the	O
literature	O
regarding	O
the	O
positive	O
association	O
.	O
The	O
results	O
of	O
lead	O
and	O
its	O
effects	O
on	O
lipoproteins	O
have	O
been	O
varied	O
.	O
Research	O
by	O
Cocco	O
and	O
co	O
-	O
authors	O
found	O
that	O
lead	O
-	O
exposed	O
patients	O
had	O
decreased	O
cholesterol	O
levels	O
[	O
32	O
]	O
.	O
Meanwhile	O
,	O
Ademuyiwa	O
and	O
co	O
-	O
authors	O
reported	O
a	O
significant	O
elevation	O
in	O
total	O
cholesterol	O
for	O
subjects	O
exposed	O
to	O
lead	O
,	O
compared	O
to	O
controls	O
in	O
addition	O
to	O
finding	O
a	O
strong	O
positive	O
association	O
between	O
BLL	O
and	O
total	O
and	O
LDL	O
cholesterol	O
,	O
but	O
not	O
HDL	O
or	O
triglycerides	O
[	O
16	O
]	O
.	O
Kristal	O
-	O
Boneh	O
and	O
co	O
-	O
authors	O
,	O
in	O
a	O
study	O
of	O
the	O
association	O
between	O
occupational	O
lead	O
exposure	O
and	O
serum	O
cholesterol	O
and	O
lipoproteins	O
found	O
a	O
significant	O
elevation	O
in	O
the	O
HDL	O
and	O
total	O
cholesterol	O
levels	O
between	O
the	O
less	O
exposed	O
and	O
exposed	O
,	O
which	O
bolster	O
the	O
results	O
of	O
this	O
study	O
,	O
but	O
their	O
study	O
did	O
not	O
find	O
a	O
significant	O
elevation	O
of	O
LDL	O
cholesterol	O
between	O
the	O
less	O
exposed	O
and	O
exposed	O
[	O
15	O
]	O
.	O
The	O
positive	O
association	O
of	O
BLL	O
with	O
HDL	O
cholesterol	O
is	O
paradoxical	O
.	O
This	O
may	O
be	O
explained	O
by	O
the	O
data	O
being	O
skewed	O
toward	O
lower	O
exposure	O
.	O

The	O
analysis	O
of	O
mean	O
values	O
indicated	O
that	O
the	O
mean	O
HDL	O
cholesterol	O
values	O
were	O
higher	O
for	O
higher	O
exposure	O
levels	O
as	O
compared	O
to	O
lower	O
exposure	O
levels	O
,	O
but	O
these	O
differences	O
were	O
not	O
significant	O
.	O
Overall	O
,	O
a	O
larger	O
dataset	O
may	O
have	O
yielded	O
different	O
results	O
,	O
and	O
lead	O
’	O
s	O
diminishing	O
effects	O
on	O
HDL	O
may	O
be	O
at	O
higher	O
doses	O
.	O
In	O
the	O
literature	O
,	O
findings	O
for	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
have	O
varied	O
.	O
As	O
noted	O
earlier	O
,	O
Khan	O
and	O
co	O
-	O
authors	O
in	O
an	O
occupational	O
study	O
found	O
a	O
significant	O
association	O
between	O
lead	O
exposure	O
and	O
CRP	O
[	O
12	O
]	O
.	O
On	O
the	O
other	O
hand	O
,	O
Songdej	O
and	O
co	O
-	O
authors	O
,	O
in	O
a	O
population	O
-	O
based	O
study	O
,	O
did	O
not	O
find	O
a	O
consistent	O
association	O
[	O
13	O
]	O
.	O
Measurement	O
of	O
BLLs	O
does	O
not	O
indicate	O
longer	O
-	O
term	O
exposure	O
;	O
rather	O
,	O
it	O
is	O
indicative	O
of	O
recent	O
lead	O
exposure	O
as	O
well	O
as	O
lead	O
that	O
has	O
been	O
mobilized	O
from	O
bone	O
or	O
other	O
tissue	O
sources	O
with	O
no	O
ability	O
to	O
distinguish	O
between	O
both	O
.	O
Measurement	O
of	O
bone	O
lead	O
levels	O
,	O
particularly	O
tibia	O
lead	O
level	O
,	O
via	O
K	O
-	O
Shell	O
X	O
-	O
ray	O
Fluorescence	O
(	O
KSXF	O
)	O
would	O
have	O
provided	O
more	O
information	O
on	O
length	O
of	O
exposure	O
,	O
as	O
bone	O
lead	O
levels	O
are	O
indicative	O
of	O
long	O
-	O
term	O
cumulative	O
exposure	O
to	O
lead	O
.	O
Both	O
the	O
BLLs	O
and	O
bone	O
lead	O
levels	O
taken	O
together	O
would	O
have	O
provided	O
the	O
best	O
and	O
most	O
comprehensive	O
view	O
of	O
the	O
participant	O
’	O
s	O
exposure	O
[	O
33	O
]	O
.	O
In	O
attempting	O
to	O
overcome	O
the	O
limitation	O
of	O
long	O
-	O
term	O
exposure	O
,	O
the	O
length	O
of	O
time	O
at	O
occupation	O
was	O
analyzed	O
,	O
and	O
seeing	O
the	O
differences	O
in	O
health	O
outcomes	O
overtime	O
helped	O
to	O
give	O
hints	O
on	O
the	O
manifestations	O
of	O
long	O
term	O
exposure	O
.	O
Finally	O
,	O
owing	O
to	O
the	O
inability	O
to	O
adjust	O
for	O
covariates	O
in	O
the	O
occupational	O
analysis	O
,	O
and	O
the	O
inability	O
to	O
perform	O
regression	O
analysis	O
on	O
lead	O
exposed	O
occupations	O
due	O
to	O
inadequate	O
data	O
in	O
all	O
strata	O
for	O
any	O
of	O
exposed	O
occupations	O
,	O
future	O
work	O
should	O
look	O
at	O
larger	O
occupational	O
databases	O
.	O
This	O
will	O
enable	O
us	O
to	O
evaluate	O
the	O
significances	O
found	O
here	O
in	O
adjusted	O
models	O
for	O
lead	O
-	O
exposed	O
occupations	O
.	O
Lead	O
exposure	O
was	O
significantly	O
associated	O
with	O
adverse	O
cardiovascular	O
-	O
related	O
outcomes	O
,	O
with	O
elevated	O
exposure	O
resulting	O
in	O
poorer	O
outcomes	O
.	O
Looking	O
at	O
various	O
degrees	O
of	O
exposure	O
,	O
exposure	O
to	O
lead	O
increased	O
the	O
odds	O
of	O
adverse	O
cardiovascular	O
-	O
related	O
and	O
inflammatory	O
clinical	O
markers	O
.	O
Lastly	O
,	O
occupational	O
exposure	O
potentially	O
plays	O
a	O
role	O
in	O
these	O
outcomes	O
.	O
The	O
findings	O
in	O
this	O
study	O
add	O
to	O
the	O
extensive	O
research	O
that	O
has	O
demonstrated	O
that	O
lead	O
exposure	O
may	O
be	O
an	O
important	O
risk	O
factor	O
for	O
cardiovascular	O
-	O
related	O
dysfunction	O
in	O
populations	O
experiencing	O
various	O
degrees	O
of	O
exposure	O
.	O

Based	O
on	O
this	O
study	O
,	O
it	O
is	O
suggested	O
that	O
a	O
critical	O
need	O
exists	O
to	O
test	O
novel	O
interventions	O
capable	O
of	O
mitigating	O
and	O
subsequently	O
eliminating	O
the	O
impact	O
of	O
lead	O
on	O
cardiovascular	O
health	O
.	O
Studies	B-methodology
aimed	I-methodology
at	I-methodology
interventions	I-methodology
that	O
mitigate	O
and	O
/	O
or	O
eliminate	O
the	O
harmful	O
effects	O
of	O
lead	O
on	O
the	O
environment	O
and	O
on	O
human	O
health	O
are	O
still	O
required	O
for	O
successful	O
optimal	O
health	O
management	O
.	O
We	O
acknowledge	O
the	O
National	O
Center	O
for	O
Health	O
Statistics	O
of	O
the	O
U	O
.	O
S	O
.	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
)	O
for	O
its	O
invaluable	O
work	O
conducting	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
,	O
and	O
the	O
researchers	O
at	O
the	O
Division	O
of	O
Laboratory	O
Sciences	O
,	O
National	O
Center	O
for	O
Environmental	O
Health	O
of	O
the	O
CDC	O
.	O
Emmanuel	O
Obeng	O
-	O
Gyasi	O
conceived	O
the	O
idea	O
for	O
the	O
paper	O
,	O
wrote	O
the	O
paper	O
,	O
and	O
did	O
the	O
analysis	O
.	O
Rodrigo	O
X	O
.	O
Armijos	O
edited	O
the	O
paper	O
and	O
contributed	O
to	O
the	O
analysis	O
of	O
the	O
data	O
.	O
M	O
.	O
Margaret	O
Weigel	O
edited	O
the	O
paper	O
and	O
provided	O
analytical	O
evaluation	O
.	O
Gabriel	O
M	O
.	O
Filippelli	O
provided	O
analytical	O
guidance	O
for	O
the	O
paper	O
.	O
M	O
.	O
Aaron	O
Sayegh	O
provided	O
analytical	O
guidance	O
for	O
the	O
paper	O
.	O
The	O
authors	O
declare	O
no	O
conflicts	O
of	O
interest	O
.	O

Association	O
of	O
Maternal	O
Diet	O
during	O
Pregnancy	O
and	O
Metabolite	O
Profile	O
in	O
Cord	O
Blood	O
targeted	O
metabolomics	O
;	O
maternal	O
diet	O
;	O
dietary	O
patterns	O
;	O
pregnancy	O
;	O
cord	O
blood	O
;	O
early	O
programming	O
;	O
epidemiology	O
Cord	O
blood	O
metabolites	O
can	O
be	O
predictive	O
of	O
long	O
-	O
term	O
disease	O
risk	O
,	O
but	O
how	O
levels	O
of	O
different	O
metabolites	O
might	O
vary	O
with	O
respect	O
to	O
maternal	O
diet	O
is	O
not	O
well	O
understood	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
associations	O
of	O
different	O
dietary	O
patterns	O
during	O
pregnancy	O
with	O
cord	O
blood	O
metabolites	O
(	O
including	O
glycerophospholipid	O
fatty	O
acids	O
,	O
polar	O
lipids	O
,	O
non	O
-	O
esterified	O
fatty	O
acids	O
,	O
amino	O
acids	O
,	O
and	O
the	O
sum	O
of	O
hexoses	O
)	O
.	O
Participants	O
from	O
the	O
German	O
LISA	O
birth	B-methodology
cohort	I-methodology
study	I-methodology
,	O
with	O
available	O
data	O
on	O
targeted	O
cord	O
blood	O
metabolomics	O
and	O
maternal	O
diet	O
,	O
were	O
included	O
(	O
n	O
=	O
739	O
)	O
.	O
Maternal	O
diet	O
during	O
the	O
last	O
4	O
weeks	O
of	O
pregnancy	O
was	O
assessed	O
by	O
a	O
non	O
-	O
quantitative	O
food	O
-	O
frequency	O
questionnaire	O
.	O
Using	O
factor	O
analysis	O
,	O
ten	O
dietary	O
patterns	O
were	O
identified	O
,	O
which	O
were	O
used	O
in	O
linear	O
regression	O
models	O
exploring	O
associations	O
with	O
cord	O
blood	O
metabolites	O
.	O
After	O
correction	O
for	O
multiple	O
hypothesis	O
testing	O
and	O
adjustment	O
for	O
basic	O
covariates	O
,	O
“	O
fish	O
and	O
shellfish	O
”	O
was	O
associated	O
with	O
higher	O
glycerophospholipid	O
fatty	O
acid	O
C20	O
:	O
5	O
n3	O
and	O
lower	O
C22	O
:	O
5	O
n6	O
,	O
whereas	O
the	O
“	O
meat	O
and	O
potato	O
”	O
pattern	O
was	O
directly	O
associated	O
with	O
propionylcarnitine	O
(	O
C3	O
:	O
0	O
)	O
.	O
The	O
observed	O
associations	O
highlight	O
potential	O
metabolic	O
pathways	O
involved	O
in	O
the	O
early	O
programming	O
of	O
health	O
and	O
disease	O
through	O
maternal	O
diet	O
,	O
as	O
well	O
as	O
the	O
potential	O
for	O
establishing	O
quantitative	O
biomarkers	O
for	O
dietary	O
patterns	O
of	O
pregnant	O
women	O
.	O
Maternal	O
diet	O
during	O
pregnancy	O
contributes	O
to	O
fetal	O
growth	O
and	O
development	O
,	O
playing	O
a	O
crucial	O
role	O
in	O
the	O
short	O
-	O
and	O
long	O
-	O
term	O
health	O
of	O
the	O
offspring	O
.	O
It	O
is	O
well	O
established	O
that	O
certain	O
key	O
nutrient	O
deficiencies	O
in	O
the	O
mother	O
can	O
lead	O
to	O
health	O
problems	O
in	O
the	O
offspring	O
,	O
manifesting	O
as	O
impaired	O
physical	O
and	O
/	O
or	O
mental	O
capacities	O
[	O
1	O
,	O
2	O
,	O
3	O
]	O
.	O
Furthermore	O
,	O
it	O
is	O
now	O
widely	O
accepted	O
that	O
many	O
adult	O
-	O
onset	O
chronic	O
diseases	O
may	O
have	O
their	O
origins	O
before	O
birth	O
,	O
with	O
maternal	O
diet	O
hypothesized	O
as	O
a	O
primary	O
programming	O
stimulus	O
[	O
4	O
,	O
5	O
]	O
.	O
For	O
example	O
,	O
reduced	O
birth	O
size	O
resulting	O
from	O
insufficient	O
fetal	O
nutrient	O
supply	O
is	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
chronic	O
diseases	O
in	O
adulthood	O
[	O
6	O
,	O
7	O
,	O
8	O
]	O
.	O

Low	O
birth	O
weight	O
is	O
often	O
followed	O
by	O
increased	O
postnatal	O
weight	O
gain	O
,	O
which	O
in	O
turn	O
has	O
been	O
linked	O
to	O
asthma	O
[	O
9	O
]	O
and	O
reduced	O
lung	O
function	O
in	O
adolescence	O
[	O
10	O
]	O
.	O
In	O
contrast	O
,	O
excessive	O
maternal	O
energy	O
intake	O
increases	O
the	O
risk	O
for	O
high	O
birth	O
weight	O
,	O
leading	O
to	O
increased	O
risk	O
of	O
overweight	O
in	O
later	O
childhood	O
[	O
11	O
,	O
12	O
,	O
13	O
]	O
.	O
Growing	O
evidence	O
also	O
highlights	O
the	O
importance	O
of	O
diet	O
composition	O
to	O
ensure	O
optimal	O
health	O
of	O
the	O
offspring	O
[	O
14	O
]	O
.	O
The	O
human	O
diet	O
typically	O
involves	O
combinations	O
of	O
different	O
foods	O
and	O
nutrients	O
,	O
and	O
thus	O
,	O
their	O
roles	O
must	O
be	O
interpreted	O
in	O
the	O
context	O
of	O
possible	O
correlations	O
and	O
interactions	O
among	O
them	O
.	O
For	O
this	O
,	O
the	O
study	O
of	O
dietary	O
patterns	O
can	O
be	O
highly	O
informative	O
[	O
15	O
]	O
.	O
A	O
number	O
of	O
studies	O
on	O
maternal	O
dietary	O
patterns	O
have	O
observed	O
significant	O
associations	O
with	O
birth	O
outcomes	O
,	O
most	O
often	O
reporting	O
protective	O
effects	O
of	O
vegetables	O
,	O
fruit	O
,	O
whole	O
grains	O
,	O
and	O
fish	O
[	O
16	O
,	O
17	O
,	O
18	O
]	O
,	O
and	O
negative	O
effects	O
of	O
diets	O
high	O
in	O
fat	O
,	O
sugars	O
,	O
and	O
processed	O
foods	O
[	O
19	O
,	O
20	O
,	O
21	O
]	O
.	O
Nevertheless	O
,	O
the	O
metabolic	O
pathways	O
through	O
which	O
different	O
dietary	O
patterns	O
may	O
influence	O
fetal	O
development	O
and	O
future	O
chronic	O
diseases	O
are	O
poorly	O
understood	O
.	O
We	O
assume	O
that	O
the	O
maternal	O
diet	O
affects	O
metabolism	O
,	O
and	O
consequently	O
the	O
intrauterine	O
milieu	O
,	O
hence	O
determining	O
metabolic	O
adaptations	O
in	O
the	O
neonate	O
.	O
The	O
cord	O
blood	O
metabolome	O
provides	O
information	O
on	O
the	O
intrauterine	O
environment	O
,	O
which	O
involves	O
the	O
complex	O
interaction	O
of	O
maternal	O
metabolism	O
,	O
placental	O
nutrient	O
transfer	O
,	O
and	O
fetal	O
metabolism	O
[	O
22	O
]	O
.	O
Studies	O
have	O
shown	O
significant	O
associations	O
between	O
maternal	O
metabolic	O
status	O
,	O
such	O
as	O
BMI	O
or	O
dysglycemia	O
,	O
and	O
cord	O
blood	O
metabolites	O
[	O
23	O
,	O
24	O
,	O
25	O
,	O
26	O
]	O
.	O
Others	O
have	O
identified	O
metabolic	O
profiles	O
associated	O
with	O
unfavorable	O
birth	O
outcomes	O
[	O
27	O
,	O
28	O
,	O
29	O
,	O
30	O
]	O
.	O
However	O
,	O
there	O
is	O
limited	O
evidence	O
on	O
the	O
impact	O
of	O
maternal	O
diet	O
on	O
cord	O
blood	O
metabolites	O
[	O
31	O
]	O
.	O
Thus	O
,	O
in	O
the	O
present	O
study	O
,	O
we	O
applied	O
targeted	O
metabolomics	O
in	O
order	O
to	O
investigate	O
the	O
association	O
of	O
maternal	O
dietary	O
patterns	O
during	O
pregnancy	O
with	O
cord	O
blood	O
metabolites	O
.	O
We	O
demonstrated	O
associations	O
with	O
specific	O
metabolites	O
with	O
known	O
roles	O
in	O
lipid	O
signaling	O
,	O
beta	O
-	O
oxidation	O
,	O
and	O
branched	O
-	O
chain	O
amino	O
acid	O
degradation	O
.	O
Ultimately	O
,	O
if	O
confirmed	O
in	O
future	O
studies	O
,	O
these	O
findings	O
could	O
contribute	O
to	O
a	O
better	O
understanding	O
of	O
early	O
disease	O
etiology	O
.	O

Data	O
obtained	O
from	O
participants	O
of	O
the	O
LISA	O
(	O
Influence	O
of	O
Life	O
-	O
Style	O
Factors	O
on	O
the	O
Development	O
of	O
the	O
Immune	O
System	O
and	O
Allergies	O
in	O
East	O
and	O
West	O
Germany	O
)	O
study	O
were	O
used	O
for	O
the	O
present	O
analyses	O
[	O
32	O
]	O
.	O
In	O
summary	O
,	O
3097	O
healthy	O
full	O
-	O
term	O
newborns	O
(	O
of	O
which	O
3	O
later	O
withdrew	O
consent	O
)	O
were	O
recruited	O
from	O
November	O
1997	O
to	O
January	O
1999	O
from	O
four	O
regions	O
of	O
Germany	O
(	O
Munich	O
,	O
Leipzig	O
,	O
Wesel	O
,	O
and	O
Bad	O
Honnef	O
)	O
.	O
At	O
birth	O
,	O
4	O
mL	O
of	O
venous	O
cord	O
blood	O
was	O
collected	O
and	O
centrifuged	O
at	O
1400×	O
g	O
for	O
10	O
min	O
.	O
The	O
resulting	O
serum	O
was	O
deep	O
-	O
frozen	O
at	O
−80	O
°C	O
until	O
metabolomics	O
analysis	O
.	O
Information	O
on	O
maternal	O
diet	O
during	O
the	O
last	O
four	O
weeks	O
of	O
pregnancy	O
was	O
obtained	O
by	O
means	O
of	O
a	O
non	O
-	O
quantitative	O
food	O
-	O
frequency	O
questionnaire	O
,	O
administered	O
to	O
the	O
mothers	O
after	O
birth	O
.	O
Dietary	O
assessment	O
and	O
metabolomics	O
analysis	O
are	O
described	O
in	O
more	O
detail	O
below	O
.	O
Additional	O
information	O
was	O
collected	O
after	O
birth	O
through	O
questionnaires	O
,	O
including	O
gestational	O
age	O
at	O
birth	O
(	O
weeks	O
)	O
,	O
smoking	O
during	O
the	O
3rd	O
trimester	O
of	O
pregnancy	O
(	O
yes	O
;	O
no	O
)	O
,	O
maternal	O
education	O
(	O
low	O
:	O
<	O
10	O
years	O
of	O
education	O
;	O
medium	O
:	O
10	O
years	O
;	O
high	O
:	O
>	O
10	O
years	O
)	O
,	O
maternal	O
age	O
(	O
years	O
)	O
,	O
maternal	O
pre	O
-	O
pregnancy	O
BMI	O
(	O
kg	O
/	O
m2	O
,	O
categorized	O
as	O
underweight	O
:	O
<	O
18	O
.	O
5	O
;	O
normal	O
weight	O
:	O
≥18	O
.	O
5	O
and	O
<	O
25	O
;	O
and	O
overweight	O
:	O
≥25	O
,	O
according	O
to	O
WHO	O
classification	O
[	O
29	O
]	O
)	O
,	O
gestational	O
weight	O
gain	O
(	O
kg	O
/	O
month	O
)	O
,	O
and	O
birth	O
weight	O
of	O
the	O
neonate	O
(	O
kg	O
)	O
.	O
Approval	O
by	O
the	O
local	O
ethics	O
committees	O
(	O
Bavarian	O
Board	O
of	O
Physicians	O
,	O
Board	O
of	O
Physicians	O
of	O
North	O
-	O
Rhine	O
-	O
Westphalia	O
)	O
and	O
written	O
consent	O
from	O
the	O
parents	O
were	O
obtained	O
.	O

Glycerophospholipid	O
fatty	O
acids	O
(	O
GPL	O
-	O
FA	O
)	O
,	O
acylcarnitines	O
(	O
AC	O
)	O
,	O
diacyl	O
-	O
phosphatidylcholines	O
(	O
PCa	O
)	O
,	O
acyl	O
-	O
alkyl	O
-	O
phosphatidylcholines	O
(	O
PCe	O
)	O
,	O
sphingomyelins	O
(	O
SM	O
)	O
,	O
acyl	O
-	O
lysophosphatidylcholines	O
(	O
LPCa	O
)	O
,	O
alkyl	O
-	O
lysophosphatidylcholines	O
(	O
LPCe	O
)	O
,	O
non	O
-	O
esterified	O
fatty	O
acids	O
(	O
NEFA	O
)	O
,	O
amino	O
acids	O
,	O
and	O
the	O
sum	O
of	O
hexoses	O
(	O
H1	O
)	O
,	O
were	O
measured	O
in	O
750	O
samples	O
of	O
cord	O
blood	O
serum	O
.	O
Measurements	O
were	O
performed	O
at	O
the	O
laboratory	O
of	O
the	O
Division	O
of	O
Metabolic	O
and	O
Nutritional	O
Medicine	O
,	O
Dr	O
.	O
von	O
Hauner	O
Children	O
’	O
s	O
Hospital	O
,	O
Ludwig	O
-	O
Maximilians	O
-	O
Universität	O
München	O
.	O
Analysis	O
of	O
GPL	O
-	O
FA	O
was	O
performed	O
by	O
transesterification	O
of	O
GPL	O
-	O
FA	O
into	O
methyl	O
esters	O
and	O
their	O
gas	O
chromatographic	O
separation	O
,	O
flame	O
ionization	O
detection	O
(	O
Agilent	O
7890A	O
,	O
Agilent	O
Technologies	O
,	O
Waldbronn	O
,	O
Germany	O
)	O
,	O
and	O
quantification	O
as	O
previously	O
described	O
[	O
33	O
]	O
.	O
AC	O
,	O
PC	O
,	O
SM	O
,	O
LPC	O
,	O
and	O
the	O
sum	O
of	O
hexoses	O
were	O
analyzed	O
by	O
flow	O
-	O
injection	O
analysis	O
tandem	O
mass	O
spectrometry	O
as	O
previously	O
reported	O
[	O
31	O
]	O
.	O
Briefly	O
,	O
10	O
μL	O
of	O
samples	O
were	O
diluted	O
with	O
methanol	O
for	O
protein	O
precipitation	O
,	O
containing	O
internal	O
standards	O
for	O
different	O
lipid	O
groups	O
(	O
D3	O
-	O
carnitine	O
C2	O
,	O
D3	O
-	O
carnitine	O
C8	O
,	O
D3	O
-	O
carnitine	O
C16	O
,	O
13C6	O
-	O
D	O
-	O
glucose	O
(	O
all	O
Cambridge	O
Isotope	O
Laboratories	O
,	O
Tewksbury	O
,	O
MA	O
,	O
USA	O
)	O
,	O
acyl	O
-	O
lysophosphatidylcholine	O
C13	O
:	O
0	O
,	O
and	O
diacyl	O
-	O
phosphatidylcholine	O
C28	O
:	O
0	O
(	O
both	O
Avanti	O
Polar	O
Lipids	O
,	O
Alabaster	O
,	O
AL	O
,	O
USA	O
)	O
)	O
and	O
ammonium	O
acetate	O
.	O

After	O
centrifugation	O
,	O
supernatants	O
were	O
injected	O
into	O
a	O
high	O
-	O
performance	O
liquid	O
chromatography	O
system	O
(	O
1200	O
,	O
Agilent	O
,	O
Waldbronn	O
,	O
Germany	O
)	O
coupled	O
to	O
a	O
triple	O
quadrupole	O
mass	O
spectrometer	O
(	O
QTRAP4000	O
,	O
Sciex	O
,	O
Darmstadt	O
,	O
Germany	O
)	O
with	O
an	O
electrospray	O
ionization	O
source	O
.	O
The	O
system	O
was	O
run	O
in	O
multiple	O
reaction	O
monitoring	O
(	O
MRM	O
)	O
mode	O
.	O
NEFA	O
were	O
analyzed	O
as	O
previously	O
described	O
[	O
34	O
]	O
.	O
Briefly	O
,	O
10	O
μL	O
of	O
the	O
samples	O
was	O
mixed	O
with	O
200	O
µL	O
isopropanol	O
containing	O
internal	O
standard	O
(	O
uniformly	O
labeled	O
palmitic	O
acid	O
U	O
-	O
13C16	O
,	O
98	O
%	O
,	O
Euriso	O
-	O
Top	O
)	O
for	O
protein	O
precipitation	O
.	O
After	O
centrifugation	O
,	O
an	O
aliquot	O
of	O
the	O
supernatant	O
was	O
injected	O
into	O
a	O
high	O
-	O
performance	O
liquid	O
chromatography	O
system	O
(	O
1200	O
,	O
Agilent	O
,	O
Waldbronn	O
,	O
Germany	O
)	O
coupled	O
to	O
a	O
triple	O
quadrupole	O
mass	O
spectrometer	O
(	O
QTRAP4000	O
,	O
Sciex	O
,	O
Darmstadt	O
,	O
Germany	O
)	O
operating	O
in	O
multiple	O
reaction	O
monitoring	O
mode	O
after	O
negative	O
electrospray	O
ionization	O
.	O
Unlike	O
for	O
GPL	O
-	O
FA	O
,	O
the	O
analytical	O
technique	O
applied	O
for	O
AC	O
,	O
PC	O
,	O
SM	O
,	O
LPC	O
,	O
and	O
NEFA	O
is	O
not	O
capable	O
of	O
determining	O
the	O
position	O
of	O
the	O
double	O
bonds	O
and	O
the	O
distribution	O
of	O
carbon	O
atoms	O
between	O
fatty	O
acid	O
side	O
chains	O
.	O
Therefore	O
,	O
these	O
were	O
separated	O
according	O
to	O
chain	O
length	O
and	O
number	O
of	O
double	O
bonds	O
,	O
but	O
not	O
according	O
to	O
the	O
position	O
of	O
double	O
bonds	O
.	O
In	O
the	O
applied	O
nomenclature	O
for	O
these	O
metabolites	O
,	O
CX	O
:	O
Y	O
,	O
X	O
is	O
the	O
length	O
of	O
the	O
carbon	O
chain	O
,	O
and	O
Y	O
is	O
the	O
number	O
of	O
double	O
bonds	O
.	O
‘	O
a	O
’	O
indicates	O
that	O
the	O
acyl	O
chain	O
is	O
bound	O
via	O
an	O
ester	O
bond	O
to	O
the	O
backbone	O
,	O
while	O
‘	O
e	O
’	O
indicates	O
binding	O
by	O
an	O
ether	O
bond	O
.	O
Finally	O
,	O
amino	O
acid	O
(	O
AA	O
)	O
analysis	O
was	O
performed	O
as	O
previously	O
reported	O
[	O
35	O
]	O
.	O
Briefly	O
,	O
10	O
μL	O
of	O
samples	O
was	O
diluted	O
with	O
the	O
corresponding	O
internal	O
standard	O
reagent	O
.	O

A	O
labeled	O
AA	O
standards	O
set	O
(	O
set	O
A	O
)	O
was	O
mixed	O
with	O
15N2	O
-	O
L	O
-	O
asparagine	O
,	O
and	O
indole	O
-	O
D5	O
-	O
L	O
-	O
tryptophan	O
(	O
all	O
Cambridge	O
Isotope	O
Laboratories	O
,	O
Tewksbury	O
,	O
MA	O
,	O
USA	O
)	O
and	O
added	O
to	O
the	O
precipitation	O
reagent	O
for	O
internal	O
standardization	O
.	O
After	O
centrifugation	O
,	O
AA	O
were	O
derivatized	O
to	O
AA	O
butyl	O
esters	O
and	O
determined	O
by	O
ion	O
-	O
pair	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
1100	O
,	O
Agilent	O
,	O
Waldbronn	O
,	O
Germany	O
)	O
coupled	O
to	O
a	O
triple	O
quadrupole	O
mass	O
spectrometer	O
(	O
API	O
2000	O
,	O
Applied	O
Biosystems	O
,	O
Darmstadt	O
,	O
Germany	O
)	O
with	O
an	O
atmospheric	O
pressure	O
chemical	O
ionization	O
source	O
operating	O
in	O
positive	O
ionization	O
mode	O
and	O
multiple	O
reaction	O
monitoring	O
.	O
Six	O
plasma	O
quality	B-methodology
control	I-methodology
samples	O
were	O
measured	O
twice	O
,	O
along	O
with	O
the	O
samples	O
per	O
batch	O
.	O
The	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
was	O
calculated	O
for	O
each	O
single	O
batch	O
(	O
intra	O
-	O
batch	O
)	O
and	O
for	O
all	O
batches	O
(	O
inter	O
-	O
batch	O
)	O
.	O
Regarding	O
intra	O
-	O
batch	O
precision	O
,	O
batches	O
with	O
a	O
CV	O
larger	O
than	O
30	O
%	O
were	O
excluded	O
for	O
single	O
metabolite	O
measurements	O
,	O
and	O
complete	O
metabolite	O
measurements	O
with	O
an	O
inter	O
-	O
batch	O
CV	O
>	O
30	O
%	O
were	O
excluded	O
.	O
We	O
report	O
all	O
metabolite	O
concentrations	O
in	O
μmol	O
/	O
L	O
cord	O
blood	O
serum	O
.	O
Maternal	O
dietary	O
intake	O
during	O
the	O
last	O
4	O
weeks	O
of	O
pregnancy	O
was	O
assessed	O
by	O
means	O
of	O
a	O
non	O
-	O
quantitative	O
food	O
-	O
frequency	O
questionnaire	O
(	O
FFQ	O
)	O
,	O
administered	O
shortly	O
after	O
childbirth	O
[	O
36	O
]	O
.	O
For	O
the	O
45	O
food	O
items	O
included	O
in	O
the	O
FFQ	O
,	O
mothers	O
were	O
asked	O
to	O
report	O
their	O
average	O
consumption	O
frequency	O
over	O
the	O
last	O
4	O
weeks	O
.	O
For	O
all	O
food	O
items	O
except	O
milk	O
and	O
yoghurt	O
,	O
this	O
was	O
done	O
by	O
selecting	O
from	O
a	O
choice	O
of	O
five	O
frequency	O
categories	O
,	O
namely	O
:	O
“	O
never	O
or	O
less	O
than	O
2	O
times	O
per	O
month	O
”	O
,	O
“	O
2	O
–	O
3	O
times	O
per	O
month	O
”	O
,	O
“	O
1	O
–	O
2	O
times	O
per	O
week	O
”	O
,	O
“	O
3	O
–	O
4	O
times	O
per	O
week	O
”	O
,	O
and	O
“	O
more	O
than	O
4	O
times	O
per	O
week	O
”	O
.	O

Milk	O
and	O
yoghurt	O
intakes	O
were	O
quantified	O
according	O
to	O
four	O
categories	O
,	O
defined	O
for	O
milk	O
as	O
“	O
never	O
”	O
,	O
“	O
sometimes	O
”	O
,	O
“	O
up	O
to	O
0	O
.	O
5	O
L	O
per	O
day	O
”	O
,	O
and	O
“	O
more	O
than	O
0	O
.	O
5	O
L	O
per	O
day	O
”	O
,	O
and	O
for	O
yoghurt	O
as	O
“	O
never	O
”	O
,	O
“	O
sometimes	O
”	O
,	O
“	O
up	O
to	O
200	O
g	O
per	O
day	O
”	O
,	O
and	O
“	O
more	O
than	O
200	O
g	O
per	O
day	O
”	O
.	O
Subjects	O
were	O
excluded	O
(	O
78	O
of	O
3094	O
)	O
if	O
they	O
had	O
missing	O
responses	O
to	O
more	O
than	O
9	O
food	O
items	O
,	O
which	O
amounted	O
to	O
20	O
%	O
of	O
the	O
FFQ	O
.	O
In	O
accordance	O
with	O
recommendations	O
by	O
Willett	O
for	O
data	O
cleaning	O
in	O
nutritional	O
epidemiology	O
[	O
37	O
]	O
,	O
sporadic	O
blanks	O
in	O
an	O
otherwise	O
carefully	O
completed	O
FFQ	O
were	O
considered	O
as	O
no	O
consumption	O
of	O
that	O
particular	O
food	O
item	O
,	O
defined	O
as	O
“	O
never	O
or	O
less	O
than	O
2	O
times	O
per	O
month	O
”	O
and	O
as	O
“	O
0	O
L	O
/	O
day	O
”	O
or	O
“	O
0	O
g	O
/	O
day	O
”	O
for	O
milk	O
and	O
yoghurt	O
,	O
respectively	O
.	O
All	O
statistical	O
analyses	O
were	O
performed	O
using	O
R	O
version	O
3	O
.	O
4	O
.	O
2	O
(	O
R	O
Foundation	O
for	O
Statistical	O
Computing	O
,	O
Vienna	O
,	O
Austria	O
.	O
URL	O
https	O
:	O
/	O
/	O
www	O
.	O
R	O
-	O
project	O
.	O
org	O
/	O
,	O
first	O
accessed	O
on	O
1	O
October	O
2017	O
)	O
[	O
38	O
]	O
.	O
As	O
a	O
first	O
step	O
,	O
we	O
conducted	O
an	O
exploratory	O
factor	O
analysis	O
to	O
identify	O
maternal	O
dietary	O
patterns	O
,	O
which	O
would	O
then	O
be	O
used	O
in	O
association	O
analysis	O
with	O
cord	O
blood	O
metabolites	O
.	O
Factor	O
analysis	O
seeks	O
to	O
compress	O
several	O
variables	O
into	O
a	O
few	O
underlying	O
factors	O
,	O
based	O
on	O
the	O
degree	O
to	O
which	O
they	O
are	O
correlated	O
with	O
one	O
another	O
.	O
It	O
is	O
hence	O
a	O
useful	O
tool	O
for	O
investigating	O
complex	O
exposures	O
such	O
as	O
habitual	O
diet	O
,	O
going	O
beyond	O
single	O
foods	O
and	O
nutrients	O
,	O
which	O
facilitates	O
interpretation	O
and	O
accounts	O
for	O
possible	O
correlations	O
between	O
foods	O
that	O
are	O
commonly	O
consumed	O
together	O
[	O
39	O
]	O
.	O
Additionally	O
,	O
the	O
method	O
reduces	O
the	O
number	O
of	O
tests	O
to	O
be	O
carried	O
out	O
,	O
limiting	O
the	O
occurrence	O
of	O
chance	O
findings	O
.	O
Firstly	O
,	O
the	O
45	O
reported	O
food	O
items	O
were	O
presented	O
in	O
a	O
correlation	O
matrix	O
and	O
the	O
eigenvalues	O
of	O
the	O
matrix	O
calculated	O
for	O
the	O
extraction	O
of	O
factors	O
.	O
The	O
optimal	O
number	O
of	O
factors	O
was	O
decided	O
based	O
on	O
the	O
Kaiser	O
–	O
Guttman	O
rule	O
that	O
states	O
that	O
factors	O
with	O
an	O
eigenvalue	O
greater	O
than	O
1	O
should	O
be	O
used	O
[	O
40	O
,	O
41	O
]	O
.	O

The	O
number	O
of	O
factors	O
to	O
retain	O
following	O
this	O
rule	O
was	O
defined	O
by	O
a	O
Non	O
-	O
Graphical	O
Cattell	O
’	O
s	O
Scree	O
test	O
,	O
using	O
the	O
nScree	O
function	O
in	O
the	O
package	O
“	O
nFactors	O
”	O
[	O
42	O
]	O
.	O
We	O
then	O
performed	O
a	O
posteriori	O
determination	O
of	O
dietary	O
patterns	O
by	O
maximum	O
likelihood	O
factor	O
analysis	O
with	O
varimax	O
rotation	O
,	O
using	O
the	O
factanal	O
function	O
in	O
the	O
package	O
“	O
stats	O
”	O
[	O
38	O
]	O
.	O
Varimax	O
rotation	O
is	O
an	O
orthogonal	O
rotation	O
of	O
the	O
factor	O
axes	O
that	O
maximizes	O
variance	O
of	O
the	O
squared	O
loadings	O
of	O
a	O
factor	O
on	O
all	O
the	O
variables	O
in	O
a	O
factor	O
matrix	O
,	O
which	O
effectively	O
differentiates	O
the	O
original	O
variables	O
by	O
extracted	O
factor	O
.	O
Factor	O
loadings	O
show	O
an	O
increasing	O
difference	O
between	O
lower	O
weights	O
,	O
centering	O
them	O
closer	O
to	O
zero	O
,	O
and	O
higher	O
weights	O
,	O
converging	O
them	O
to	O
one	O
,	O
therefore	O
allowing	O
an	O
easier	O
interpretation	O
of	O
the	O
results	O
.	O
In	O
this	O
study	O
,	O
food	O
items	O
with	O
factor	O
loadings	O
of	O
≥	O
|	O
0	O
.	O
3	O
|	O
were	O
considered	O
influential	O
and	O
were	O
used	O
to	O
define	O
a	O
descriptive	O
‘	O
pattern	O
’	O
of	O
the	O
diet	O
associated	O
with	O
the	O
factor	O
.	O
Factor	O
scores	O
for	O
each	O
subject	O
were	O
obtained	O
by	O
the	O
regression	O
method	O
of	O
Thomson	O
1951	O
[	O
43	O
]	O
.	O
Their	O
associations	O
with	O
potential	O
covariates	O
were	O
tested	O
using	O
Pearson	O
correlation	O
for	O
numeric	O
variables	O
and	O
t	O
-	O
test	O
or	O
ANOVA	O
for	O
categorical	O
variables	O
.	O
Following	O
checks	O
to	O
confirm	O
that	O
the	O
metabolomics	O
data	O
met	O
the	O
corresponding	O
assumptions	O
,	O
associations	O
between	O
the	O
identified	O
maternal	O
dietary	O
patterns	O
and	O
metabolite	O
concentrations	O
in	O
cord	O
blood	O
were	O
analyzed	O
using	O
linear	O
regression	O
,	O
in	O
four	O
differently	O
adjusted	O
models	O
.	O
The	O
first	O
model	O
was	O
a	O
“	O
crude	O
model	O
”	O
,	O
minimally	O
adjusted	O
for	O
potential	O
batch	O
effects	O
in	O
the	O
metabolite	O
measurements	O
.	O
The	O
“	O
main	O
model	O
”	O
included	O
further	O
adjustment	O
for	O
city	O
,	O
sex	O
,	O
gestational	O
age	O
,	O
smoking	O
during	O
the	O
3rd	O
trimester	O
,	O
maternal	O
education	O
,	O
and	O
maternal	O
age	O
.	O
Additional	O
models	O
were	O
run	O
,	O
adjusting	O
for	O
covariates	O
of	O
the	O
main	O
model	O
plus	O
maternal	O
pre	O
-	O
pregnancy	O
BMI	O
and	O
gestational	O
weight	O
gain	O
(	O
“	O
main	O
model	O
+	O
”	O
)	O
,	O
and	O
finally	O
adjusting	O
for	O
all	O
above	O
-	O
mentioned	O
covariates	O
as	O
well	O
as	O
child	O
’	O
s	O
birth	O
weight	O
(	O
“	O
main	O
model	O
+	O
+	O
”	O
)	O
.	O

The	O
main	O
model	O
is	O
considered	O
the	O
most	O
important	O
model	O
for	O
interpretation	O
as	O
maternal	O
BMI	O
,	O
gestational	O
weight	O
gain	O
,	O
and	O
child	O
’	O
s	O
birth	O
weight	O
may	O
lie	O
in	O
the	O
causal	O
pathway	O
(	O
being	O
potentially	O
affected	O
by	O
diet	O
and	O
in	O
turn	O
altering	O
metabolic	O
processes	O
)	O
,	O
and	O
hence	O
models	O
with	O
these	O
covariates	O
could	O
be	O
over	O
-	O
adjusted	O
.	O
Correction	O
for	O
multiple	O
hypothesis	O
testing	O
via	O
false	O
discovery	O
rate	O
(	O
FDR	O
)	O
was	O
applied	O
to	O
all	O
models	O
to	O
determine	O
significant	O
associations	O
.	O
The	O
present	O
analysis	O
comprises	O
739	O
participants	O
from	O
the	O
Munich	O
(	O
77	O
%	O
)	O
and	O
Bad	O
Honnef	O
(	O
23	O
%	O
)	O
LISA	B-methodology
study	I-methodology
centers	O
,	O
for	O
whom	O
complete	O
information	O
on	O
maternal	O
diet	O
and	O
cord	O
blood	O
metabolites	O
was	O
available	O
(	O
representing	O
39	O
%	O
and	O
18	O
%	O
of	O
newborns	O
initially	O
recruited	O
from	O
Munich	O
and	O
Bad	O
Honnef	O
,	O
respectively	O
)	O
.	O
Basic	O
characteristics	O
of	O
the	O
study	O
population	O
are	O
described	O
in	O
Table	O
1	O
with	O
means	O
(	O
standard	O
deviation	O
)	O
for	O
numeric	O
variables	O
and	O
frequencies	O
(	O
%	O
)	O
for	O
categorical	O
variables	O
.	O
The	O
average	O
age	O
of	O
the	O
mothers	O
was	O
32	O
.	O
0	O
±	O
4	O
.	O
0	O
years	O
,	O
and	O
~	O
75	O
%	O
of	O
them	O
had	O
a	O
normal	O
BMI	O
.	O
Among	O
the	O
remaining	O
25	O
%	O
,	O
124	O
were	O
overweight	O
and	O
43	O
underweight	O
,	O
all	O
together	O
presenting	O
a	O
mean	O
maternal	O
BMI	O
of	O
22	O
.	O
6	O
±	O
4	O
.	O
1	O
.	O
On	O
average	O
,	O
~	O
90	O
%	O
of	O
the	O
mothers	O
reported	O
to	O
be	O
non	O
-	O
smokers	O
during	O
the	O
last	O
trimester	O
of	O
pregnancy	O
.	O
Gestational	O
weight	O
gain	O
averaged	O
0	O
.	O
3	O
±	O
0	O
.	O
1	O
kg	O
per	O
month	O
over	O
approximately	O
40	O
.	O
0	O
±	O
1	O
.	O
2	O
weeks	O
.	O
The	O
offspring	O
had	O
a	O
mean	O
birth	O
weight	O
of	O
3	O
.	O
5	O
±	O
0	O
.	O
4	O
kg	O
.	O
Following	O
factor	O
analysis	O
,	O
ten	O
dietary	O
patterns	O
were	O
retained	O
,	O
explaining	O
28	O
%	O
of	O
the	O
total	O
variance	O
of	O
maternal	O
diet	O
.	O
This	O
level	O
of	O
total	O
explained	O
variance	O
is	O
expected	O
for	O
food	O
-	O
frequency	O
questionnaires	O
,	O
including	O
a	O
large	O
number	O
of	O
items	O
,	O
given	O
the	O
multidimensionality	O
of	O
diet	O
,	O
and	O
is	O
comparable	O
in	O
magnitude	O
to	O
that	O
observed	O
in	O
other	O
studies	O
[	O
44	O
,	O
45	O
]	O
.	O
The	O
dietary	O
patterns	O
were	O
labeled	O
based	O
on	O
the	O
most	O
relevant	O
food	O
items	O
as	O
indicated	O
by	O
the	O
highest	O
factor	O
loadings	O
.	O
The	O
chosen	O
labels	O
were	O
hence	O
data	O
-	O
dependent	O
and	O
entirely	O
arbitrarily	O
defined	O
:	O
Factor	O
1	O
=	O
“	O
vegetables	O
”	O
,	O
Factor	O
2	O
=	O
“	O
fruits	O
”	O
,	O
Factor	O
3	O
=	O
“	O
summer	O
vegetables	O
”	O
,	O
Factor	O
4	O
=	O
“	O
salad	O
and	O
dressings	O
”	O
,	O
Factor	O
5	O
=	O
“	O
cereal	O
,	O
seeds	O
,	O
nuts	O
,	O
yoghurt	O
,	O
cheese	O
”	O
,	O
Factor	O
6	O
=	O
“	O
butter	O
vs	O
.	O

margarine	O
”	O
,	O
Factor	O
7	O
=	O
“	O
meat	O
and	O
potato	O
”	O
,	O
Factor	O
8	O
=	O
“	O
sweets	O
”	O
,	O
Factor	O
9	O
=	O
“	O
fish	O
and	O
shellfish	O
”	O
,	O
and	O
Factor	O
10	O
=	O
“	O
seasonal	O
”	O
.	O
For	O
the	O
ten	O
dietary	O
patterns	O
(	O
factors	O
1	O
–	O
10	O
)	O
,	O
the	O
factor	O
loadings	O
for	O
each	O
food	O
item	O
and	O
the	O
percentage	O
of	O
variance	O
explained	O
are	O
presented	O
in	O
Table	O
2	O
.	O
The	O
foods	O
with	O
factor	O
loadings	O
of	O
≥	O
|	O
0	O
.	O
3	O
|	O
,	O
which	O
were	O
used	O
to	O
label	O
each	O
dietary	O
pattern	O
,	O
are	O
marked	O
with	O
an	O
asterisk	O
,	O
as	O
well	O
as	O
separately	O
listed	O
in	O
Supplementary	O
Table	O
S1	O
.	O
The	O
dietary	O
patterns	O
indicated	O
the	O
tendency	O
for	O
mothers	O
to	O
have	O
specific	O
eating	O
behaviors	O
characterized	O
by	O
more	O
(	O
or	O
less	O
)	O
of	O
certain	O
foods	O
.	O
Some	O
of	O
the	O
covariates	O
presented	O
significant	O
associations	O
with	O
the	O
resulting	O
dietary	O
patterns	O
(	O
Supplementary	O
Table	O
S2	O
)	O
.	O
In	O
Bad	O
Honnef	O
,	O
there	O
was	O
a	O
higher	O
maternal	O
consumption	O
of	O
the	O
“	O
vegetables	O
”	O
and	O
“	O
meat	O
and	O
potato	O
”	O
patterns	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
,	O
in	O
contrast	O
,	O
lower	O
intakes	O
of	O
“	O
fruits	O
”	O
,	O
“	O
summer	O
vegetables	O
”	O
and	O
“	O
butter	O
vs	O
.	O
margarine	O
”	O
patterns	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
Mothers	O
who	O
smoked	O
during	O
the	O
last	O
trimester	O
of	O
pregnancy	O
also	O
showed	O
a	O
difference	O
in	O
their	O
diet	O
.	O
Non	O
-	O
smokers	O
indicated	O
a	O
preference	O
for	O
the	O
“	O
cereal	O
,	O
nut	O
,	O
seeds	O
,	O
yoghurt	O
,	O
cheese	O
”	O
and	O
the	O
“	O
butter	O
vs	O
.	O
margarine	O
”	O
patterns	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
whereas	O
the	O
smokers	O
had	O
higher	O
intakes	O
of	O
the	O
“	O
meat	O
and	O
potato	O
”	O
dietary	O
pattern	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
High	O
maternal	O
education	O
was	O
associated	O
with	O
a	O
higher	O
consumption	O
of	O
“	O
fruits	O
”	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
“	O
cereal	O
,	O
nut	O
,	O
seeds	O
,	O
yoghurt	O
,	O
cheese	O
”	O
and	O
“	O
butter	O
vs	O
.	O
margarine	O
”	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
patterns	O
,	O
with	O
significantly	O
less	O
intakes	O
of	O
“	O
meat	O
and	O
potato	O
”	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
;	O
the	O
opposite	O
was	O
the	O
case	O
for	O
the	O
lowest	O
educated	O
mothers	O
.	O
An	O
increase	O
in	O
“	O
cereal	O
,	O
nut	O
,	O
seeds	O
,	O
yoghurt	O
,	O
cheese	O
”	O
,	O
“	O
butter	O
vs	O
.	O
margarine	O
”	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
“	O
fish	O
and	O
shellfish	O
”	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
was	O
also	O
observed	O
with	O
increasing	O
maternal	O
age	O
.	O

Since	O
the	O
many	O
linear	O
regression	O
associations	O
tested	O
cannot	O
be	O
displayed	O
in	O
a	O
single	O
table	O
,	O
only	O
associations	O
with	O
p	O
<	O
0	O
.	O
005	O
in	O
at	O
least	O
one	O
model	O
are	O
presented	O
in	O
Table	O
3	O
.	O
Associations	O
that	O
were	O
significant	O
following	O
correction	O
for	O
multiple	O
hypothesis	O
testing	O
are	O
shown	O
in	O
bold	O
and	O
marked	O
with	O
an	O
asterisk	O
.	O
The	O
full	O
list	O
of	O
all	O
associations	O
is	O
provided	O
in	O
Supplementary	O
Table	O
S3	O
.	O
Generally	O
,	O
a	O
positive	O
beta	O
coefficient	O
indicates	O
that	O
a	O
dietary	O
pattern	O
is	O
proportionately	O
influencing	O
the	O
level	O
of	O
a	O
metabolite	O
,	O
and	O
a	O
negative	O
beta	O
would	O
imply	O
that	O
metabolite	O
levels	O
are	O
inversely	O
associated	O
with	O
the	O
dietary	O
pattern	O
.	O
A	O
significant	O
positive	O
association	O
was	O
seen	O
for	O
the	O
“	O
cereal	O
,	O
nut	O
,	O
seeds	O
,	O
yoghurt	O
,	O
cheese	O
”	O
pattern	O
with	O
SM	O
C30	O
:	O
1	O
in	O
the	O
crude	O
model	O
,	O
which	O
was	O
also	O
significant	O
in	O
model	O
+	O
+	O
.	O
For	O
this	O
dietary	O
pattern	O
,	O
an	O
association	O
with	O
SM	O
C43	O
:	O
2	O
was	O
also	O
observed	O
in	O
the	O
crude	O
model	O
,	O
but	O
this	O
association	O
was	O
not	O
statistically	O
significant	O
in	O
any	O
of	O
the	O
further	O
-	O
adjusted	O
models	O
.	O
For	O
the	O
“	O
butter	O
vs	O
.	O
margarine	O
”	O
pattern	O
,	O
the	O
crude	O
model	O
resulted	O
in	O
eight	O
significant	O
associations	O
,	O
including	O
positive	O
associations	O
with	O
SM	O
C39	O
:	O
1	O
,	O
SM	O
C43	O
:	O
2	O
,	O
LPCe	O
C18	O
:	O
0	O
,	O
LPCe	O
C16	O
:	O
0	O
,	O
and	O
NEFA	O
C15	O
:	O
0	O
and	O
C17	O
:	O
0	O
,	O
and	O
inverse	O
associations	O
with	O
LPCa	O
C18	O
:	O
3	O
and	O
AC	O
C8	O
:	O
1	O
.	O
After	O
adjustment	O
for	O
covariates	O
,	O
none	O
of	O
these	O
associations	O
were	O
statistically	O
significant	O
;	O
however	O
,	O
effect	O
sizes	O
remained	O
stable	O
for	O
AC	O
C8	O
:	O
1	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
,	O
SM	O
C39	O
:	O
1	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
SM	O
C43	O
:	O
2	O
(	O
p	O
=	O
0	O
.	O
003	O
)	O
after	O
adjustment	O
in	O
the	O
main	O
model	O
.	O
A	O
significant	O
,	O
direct	O
association	O
with	O
AC	O
C3	O
:	O
0	O
was	O
observed	O
for	O
the	O
“	O
meat	O
and	O
potato	O
”	O
pattern	O
across	O
all	O
models	O
.	O
“	O
Fish	O
and	O
shellfish	O
”	O
presented	O
an	O
inverse	O
association	O
with	O
n	O
-	O
6	O
osbond	O
acid	O
(	O
C22	O
:	O
5	O
n6	O
)	O
across	O
all	O
models	O
except	O
model	O
+	O
+	O
.	O
Further	O
,	O
this	O
pattern	O
had	O
a	O
direct	O
association	O
with	O
n	O
-	O
3	O
eicosapentaenoic	O
acid	O
(	O
EPA	O
,	O
C20	O
:	O
5	O
n3	O
)	O
in	O
the	O
crude	O
model	O
,	O
which	O
approached	O
significance	O
in	O
all	O
further	O
-	O
adjusted	O
models	O
(	O
with	O
p	O
-	O
value	O
=	O
0	O
.	O
001	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
association	O
of	O
maternal	O
diet	O
with	O
a	O
range	O
of	O
chemically	O
characterized	O
cord	O
blood	O
metabolites	O
.	O
Using	O
factor	O
analysis	O
,	O
we	O
identified	O
ten	O
dietary	O
patterns	O
describing	O
the	O
eating	O
behaviors	O
of	O
mothers	O
during	O
the	O
last	O
four	O
weeks	O
of	O
pregnancy	O
.	O
Dietary	O
patterns	O
presenting	O
robust	O
associations	O
with	O
metabolites	O
across	O
differently	O
adjusted	O
models	O
were	O
“	O
fish	O
and	O
shellfish	O
”	O
and	O
“	O
meat	O
and	O
potato	O
”	O
.	O
For	O
the	O
dietary	O
patterns	O
“	O
cereals	O
,	O
seeds	O
,	O
nuts	O
,	O
yoghurt	O
,	O
cheese	O
”	O
and	O
“	O
butter	O
vs	O
.	O
margarine	O
”	O
,	O
associations	O
were	O
observed	O
which	O
were	O
stable	O
across	O
all	O
models	O
in	O
terms	O
of	O
effect	O
size	O
,	O
but	O
which	O
were	O
not	O
statistically	O
significant	O
beyond	O
the	O
crude	O
model	O
.	O
For	O
“	O
fish	O
and	O
shellfish	O
”	O
,	O
an	O
inverse	O
association	O
was	O
observed	O
with	O
osbond	O
acid	O
,	O
and	O
a	O
positive	O
association	O
was	O
observed	O
with	O
EPA	O
(	O
although	O
the	O
latter	O
was	O
only	O
significant	O
in	O
the	O
crude	O
model	O
,	O
the	O
effect	O
size	O
was	O
barely	O
reduced	O
in	O
all	O
further	O
-	O
adjusted	O
models	O
,	O
and	O
these	O
all	O
had	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O
In	O
particular	O
,	O
oily	O
fish	O
and	O
seafood	O
are	O
rich	O
sources	O
of	O
EPA	O
and	O
docosahexaenoic	O
acid	O
(	O
DHA	O
,	O
C22	O
:	O
6	O
n3	O
)	O
[	O
46	O
]	O
,	O
thus	O
a	O
positive	O
association	O
with	O
EPA	O
is	O
to	O
be	O
expected	O
.	O
A	O
significant	O
positive	O
association	O
with	O
DHA	O
was	O
however	O
not	O
observed	O
in	O
our	O
analyses	O
.	O
Incorporation	O
of	O
DHA	O
in	O
membranes	O
is	O
reported	O
to	O
be	O
slower	O
and	O
more	O
erratic	O
than	O
that	O
of	O
EPA	O
[	O
47	O
]	O
.	O
Some	O
[	O
48	O
,	O
49	O
]	O
but	O
not	O
all	O
[	O
50	O
,	O
51	O
]	O
studies	O
have	O
reported	O
increased	O
cord	O
blood	O
DHA	O
levels	O
with	O
DHA	O
supplementation	O
during	O
pregnancy	O
.	O
The	O
importance	O
of	O
DHA	O
for	O
optimal	O
neurodevelopment	O
of	O
the	O
fetus	O
is	O
now	O
widely	O
recognized	O
[	O
52	O
,	O
53	O
]	O
;	O
however	O
,	O
research	O
on	O
DHA	O
during	O
pregnancy	O
was	O
at	O
very	O
early	O
stages	O
during	O
the	O
time	O
of	O
dietary	O
assessment	O
(	O
1995	O
–	O
1998	O
)	O
[	O
48	O
]	O
,	O
and	O
so	O
residual	O
confounding	O
due	O
to	O
DHA	O
supplementation	O
is	O
unlikely	O
.	O
It	O
has	O
been	O
previously	O
highlighted	O
that	O
only	O
a	O
small	O
proportion	O
of	O
the	O
variation	O
in	O
cord	O
blood	O
DHA	O
levels	O
is	O
explained	O
by	O
maternal	O
DHA	O
intake	O
[	O
54	O
]	O
.	O
It	O
is	O
postulated	O
that	O
in	O
the	O
last	O
trimester	O
of	O
pregnancy	O
there	O
is	O
a	O
preferential	O
transfer	O
of	O
DHA	O
from	O
the	O
mother	O
to	O
the	O
fetus	O
,	O
leading	O
to	O
a	O
depletion	O
of	O
maternal	O
stores	O
[	O
50	O
]	O
.	O

Differences	O
in	O
dietary	O
intake	O
at	O
this	O
stage	O
may	O
hence	O
have	O
a	O
more	O
appreciable	O
effect	O
on	O
maternal	O
DHA	O
status	O
than	O
on	O
cord	O
blood	O
levels	O
.	O
In	O
line	O
with	O
our	O
results	O
,	O
a	O
study	O
of	O
maternal	O
diet	O
in	O
coastal	O
and	O
inland	O
China	O
reported	O
higher	O
EPA	O
levels	O
in	O
cord	O
blood	O
in	O
the	O
coastal	O
population	O
,	O
but	O
no	O
significant	O
differences	O
in	O
DHA	O
[	O
55	O
]	O
.	O
Finally	O
,	O
osbond	O
acid	O
is	O
synthesized	O
when	O
there	O
is	O
a	O
lack	O
of	O
DHA	O
,	O
and	O
is	O
hence	O
considered	O
a	O
marker	O
of	O
DHA	O
functional	O
shortage	O
[	O
56	O
]	O
.	O
The	O
observed	O
lower	O
osbond	O
acid	O
related	O
to	O
“	O
fish	O
and	O
shellfish	O
”	O
intake	O
may	O
thus	O
provide	O
a	O
better	O
indication	O
of	O
diet	O
-	O
induced	O
changes	O
to	O
cord	O
blood	O
DHA	O
status	O
than	O
DHA	O
itself	O
.	O
The	O
dietary	O
pattern	O
“	O
meat	O
and	O
potato	O
”	O
was	O
significantly	O
and	O
consistently	O
positively	O
associated	O
with	O
AC	O
C3	O
:	O
0	O
across	O
all	O
models	O
.	O
In	O
preliminary	O
descriptive	O
analyses	O
,	O
this	O
dietary	O
pattern	O
was	O
correlated	O
with	O
maternal	O
education	O
and	O
smoking	O
during	O
the	O
third	O
trimester	O
(	O
Table	O
S2	O
)	O
.	O
However	O
,	O
adjusting	O
for	O
such	O
variables	O
in	O
the	O
main	O
model	O
did	O
not	O
reduce	O
the	O
magnitude	O
of	O
effect	O
.	O
The	O
short	O
-	O
chain	O
AC	O
C3	O
:	O
0	O
is	O
a	O
by	O
-	O
product	O
of	O
branched	O
-	O
chain	O
amino	O
acid	O
(	O
BCAA	O
)	O
catabolism	O
[	O
57	O
]	O
.	O
In	O
line	O
with	O
our	O
findings	O
,	O
observational	B-methodology
studies	I-methodology
in	O
adults	O
have	O
shown	O
this	O
metabolite	O
to	O
be	O
associated	O
with	O
higher	O
meat	O
intakes	O
[	O
58	O
,	O
59	O
]	O
,	O
and	O
increased	O
levels	O
were	O
observed	O
in	O
infants	O
provided	O
with	O
high	O
-	O
protein	O
formula	O
milk	O
[	O
60	O
]	O
.	O
Short	O
-	O
chain	O
ACs	O
have	O
been	O
associated	O
with	O
high	O
birth	O
weight	O
[	O
61	O
]	O
,	O
as	O
well	O
as	O
with	O
obesity	O
and	O
metabolic	O
syndrome	O
in	O
adults	O
[	O
62	O
]	O
.	O
Considering	O
that	O
meat	O
is	O
the	O
richest	O
dietary	O
source	O
of	O
BCAA	O
[	O
63	O
]	O
,	O
these	O
results	O
add	O
to	O
the	O
evidence	O
suggesting	O
an	O
involvement	O
of	O
the	O
BCAA	O
degradation	O
pathway	O
in	O
linking	O
maternal	O
diets	O
high	O
in	O
red	O
and	O
processed	O
meat	O
to	O
metabolic	O
disturbances	O
in	O
the	O
offspring	O
[	O
64	O
,	O
65	O
]	O
.	O
We	O
did	O
not	O
observe	O
differences	O
in	O
levels	O
of	O
BCAA	O
;	O
however	O
,	O
the	O
aromatic	O
amino	O
acid	O
tryptophan	O
was	O
slightly	O
increased	O
in	O
association	O
with	O
this	O
dietary	O
pattern	O
(	O
p	O
=	O
0	O
.	O
002	O
in	O
the	O
main	O
model	O
)	O
.	O
BCAA	O
are	O
known	O
to	O
elevate	O
aromatic	O
amino	O
acid	O
concentrations	O
,	O
suggested	O
to	O
be	O
the	O
most	O
potent	O
promoters	O
of	O
IGF	O
-	O
1	O
secretion	O
[	O
66	O
]	O
,	O
thereby	O
enhancing	O
infant	O
weight	O
gain	O
according	O
to	O
the	O
early	O
protein	O
hypothesis	O
[	O
67	O
]	O
.	O

Finally	O
,	O
the	O
observed	O
inverse	O
association	O
with	O
palmitoleate	O
(	O
C16	O
:	O
1n7	O
)	O
,	O
which	O
was	O
not	O
significant	O
but	O
consistent	O
across	O
all	O
models	O
at	O
p	O
≤	O
0	O
.	O
002	O
,	O
may	O
reflect	O
reduced	O
adipocyte	O
de	O
novo	O
lipogenesis	O
[	O
68	O
]	O
.	O
Palmitoleate	O
from	O
adipose	O
tissue	O
is	O
suggested	O
to	O
promote	O
insulin	O
sensitivity	O
[	O
69	O
,	O
70	O
]	O
,	O
and	O
lower	O
levels	O
could	O
reflect	O
unfavorable	O
fetal	O
metabolism	O
.	O
Indeed	O
,	O
the	O
same	O
opposing	O
associations	O
of	O
AC	O
C3	O
:	O
0	O
and	O
palmitoleate	O
have	O
been	O
previously	O
reported	O
in	O
relation	O
to	O
type	O
2	O
diabetes	O
mellitus	O
and	O
fasting	O
glucose	O
sensitivity	O
[	O
71	O
]	O
.	O
It	O
is	O
suggested	O
that	O
chronic	O
elevations	O
in	O
BCAA	O
and	O
related	O
metabolites	O
synergize	O
with	O
a	O
rise	O
in	O
circulating	O
fatty	O
acids	O
to	O
drive	O
a	O
state	O
of	O
chronic	O
hyperinsulinemia	O
and	O
metabolic	O
disease	O
[	O
72	O
]	O
.	O
Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
a	O
maternal	O
diet	O
high	O
in	O
meat	O
might	O
already	O
promote	O
such	O
metabolic	O
disruptions	O
in	O
the	O
offspring	O
in	O
utero	O
.	O
In	O
relation	O
to	O
the	O
“	O
butter	O
vs	O
.	O
margarine	O
”	O
pattern	O
,	O
an	O
inverse	O
association	O
with	O
AC	O
C8	O
:	O
1	O
and	O
positive	O
associations	O
with	O
SM	O
C39	O
:	O
1	O
and	O
SM	O
C43	O
:	O
2	O
were	O
observed	O
in	O
the	O
crude	O
model	O
,	O
and	O
although	O
not	O
statistically	O
significant	O
(	O
p	O
≤	O
0	O
.	O
003	O
)	O
,	O
the	O
magnitude	O
of	O
these	O
effects	O
remained	O
stable	O
following	O
further	O
adjustment	O
in	O
the	O
main	O
model	O
.	O
The	O
inverse	O
association	O
observed	O
with	O
AC	O
C8	O
:	O
1	O
could	O
be	O
an	O
indication	O
of	O
better	O
mitochondrial	O
function	O
,	O
as	O
medium	O
-	O
chain	O
ACs	O
are	O
suggested	O
to	O
result	O
from	O
a	O
mismatch	O
between	O
beta	O
-	O
oxidation	O
and	O
tricarboxylic	O
acid	O
(	O
TCA	O
)	O
cycle	O
capacity	O
[	O
73	O
]	O
and	O
have	O
also	O
been	O
associated	O
with	O
gestational	O
diabetes	O
[	O
74	O
]	O
.	O
Indeed	O
,	O
this	O
specific	O
metabolite	O
has	O
been	O
associated	O
with	O
increased	O
body	O
fat	O
[	O
75	O
]	O
and	O
pre	O
-	O
diabetic	O
conditions	O
[	O
76	O
]	O
,	O
so	O
lower	O
levels	O
would	O
suggest	O
a	O
beneficial	O
effect	O
in	O
the	O
offspring	O
by	O
consuming	O
butter	O
at	O
the	O
expense	O
of	O
margarine	O
during	O
pregnancy	O
.	O
A	O
similar	O
dietary	O
pattern	O
was	O
described	O
by	O
Floegel	O
et	O
al	O
.	O
in	O
adults	O
,	O
for	O
which	O
an	O
inverse	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
association	O
with	O
AC	O
C8	O
:	O
1	O
was	O
also	O
observed	O
[	O
77	O
]	O
.	O
The	O
positive	O
associations	O
of	O
butter	O
with	O
SM	O
C39	O
:	O
1	O
and	O
43	O
:	O
2	O
have	O
to	O
our	O
knowledge	O
not	O
been	O
previously	O
reported	O
.	O

Dairy	O
products	O
are	O
important	O
dietary	O
sources	O
of	O
SM	O
;	O
however	O
,	O
during	O
butter	O
manufacture	O
,	O
the	O
milk	O
fat	O
globule	O
membrane	O
that	O
contains	O
the	O
SM	O
is	O
separated	O
from	O
the	O
triglyceride	O
-	O
rich	O
core	O
and	O
removed	O
[	O
78	O
]	O
.	O
The	O
associated	O
metabolites	O
are	O
therefore	O
more	O
likely	O
to	O
be	O
the	O
result	O
of	O
the	O
endogenous	O
combination	O
of	O
ceramides	O
and	O
sphingomyelins	O
with	O
very	O
long	O
-	O
chain	O
saturated	O
and	O
monounsaturated	O
fatty	O
acids	O
derived	O
from	O
fatty	O
acid	O
elongation	O
[	O
79	O
,	O
80	O
]	O
.	O
Most	O
saturated	O
and	O
monounsaturated	O
very	O
long	O
-	O
chain	O
fatty	O
acids	O
are	O
sphingolipid	O
components	O
and	O
thus	O
play	O
important	O
roles	O
in	O
skin	O
barrier	O
formation	O
and	O
neural	O
functions	O
[	O
81	O
]	O
.	O
Higher	O
SM	O
C39	O
:	O
1	O
has	O
been	O
observed	O
within	O
LDL	O
in	O
pregnant	O
women	O
[	O
82	O
]	O
,	O
and	O
cholesterol	O
levels	O
are	O
known	O
to	O
increase	O
during	O
pregnancy	O
[	O
83	O
]	O
.	O
LDL	O
receptors	O
in	O
the	O
placenta	O
allow	O
the	O
uptake	O
of	O
LDL	O
,	O
providing	O
important	O
cholesterol	O
and	O
fatty	O
acids	O
for	O
fetal	O
development	O
[	O
84	O
]	O
.	O
The	O
direct	O
associations	O
observed	O
in	O
our	O
study	O
suggest	O
a	O
specific	O
relevance	O
of	O
these	O
metabolites	O
for	O
the	O
fetus	O
.	O
Indeed	O
,	O
SM	O
with	O
saturated	O
acyl	O
chains	O
are	O
the	O
main	O
constituents	O
of	O
lipid	O
rafts	O
,	O
and	O
are	O
important	O
for	O
membrane	O
function	O
and	O
in	O
the	O
regulation	O
of	O
cell	O
signaling	O
pathways	O
,	O
especially	O
in	O
the	O
brain	O
[	O
85	O
]	O
.	O
The	O
biological	O
importance	O
of	O
SM	O
for	O
brain	O
development	O
has	O
been	O
shown	O
in	O
a	O
trial	O
that	O
reported	O
neurobehavioral	O
benefits	O
in	O
preterm	O
infants	O
given	O
formula	O
enriched	O
with	O
SM	O
[	O
86	O
]	O
.	O
The	O
association	O
of	O
“	O
cereals	O
,	O
seeds	O
,	O
nuts	O
,	O
yoghurt	O
,	O
cheese	O
”	O
with	O
SM	O
C30	O
:	O
1	O
could	O
be	O
explained	O
by	O
the	O
high	O
intakes	O
of	O
dairy	O
that	O
characterize	O
this	O
dietary	O
pattern	O
.	O
We	O
expect	O
that	O
the	O
fatty	O
acyl	O
chain	O
in	O
SM	O
C30	O
:	O
1	O
is	O
a	O
medium	O
-	O
chain	O
saturated	O
fatty	O
acid	O
(	O
MCFA	O
,	O
C12	O
:	O
0	O
)	O
,	O
assuming	O
a	O
sphingosine	O
backbone	O
(	O
C18	O
:	O
1	O
)	O
.	O
Although	O
most	O
common	O
in	O
coconut	O
milk	O
,	O
this	O
fatty	O
acid	O
can	O
also	O
be	O
found	O
in	O
bovine	O
milk	O
and	O
is	O
suggested	O
to	O
have	O
antibacterial	O
properties	O
[	O
87	O
]	O
,	O
as	O
well	O
as	O
modulating	O
cellular	O
signaling	O
and	O
regulating	O
key	O
glucose	O
and	O
lipid	O
metabolism	O
[	O
88	O
]	O
.	O

Saturated	O
MCFA	O
are	O
used	O
in	O
mitochondrial	O
energy	O
production	O
independent	O
of	O
the	O
carnitine	O
transport	O
system	O
,	O
thus	O
allowing	O
valuable	O
ATP	O
molecules	O
to	O
be	O
saved	O
for	O
other	O
cellular	O
processes	O
in	O
the	O
developing	O
fetus	O
[	O
89	O
]	O
.	O
Indeed	O
,	O
a	O
study	O
observed	O
lower	O
levels	O
of	O
MCFA	O
in	O
the	O
diet	O
of	O
women	O
giving	O
birth	O
to	O
preterm	O
and	O
small	O
for	O
gestational	O
age	O
infants	O
[	O
90	O
]	O
,	O
highlighting	O
their	O
value	O
for	O
fetal	O
development	O
.	O
From	O
the	O
present	O
findings	O
,	O
it	O
seems	O
that	O
effects	O
of	O
maternal	O
diet	O
are	O
overruled	O
in	O
some	O
cases	O
by	O
the	O
corresponding	O
placental	O
transfer	O
mechanisms	O
.	O
In	O
general	O
,	O
given	O
the	O
predominance	O
of	O
significant	O
associations	O
with	O
phospholipids	O
,	O
our	O
findings	O
suggest	O
that	O
facilitated	O
diffusion	O
is	O
of	O
greater	O
importance	O
for	O
these	O
than	O
for	O
amino	O
acids	O
.	O
Diffusion	O
leads	O
to	O
proportional	O
concentrations	O
,	O
whereas	O
the	O
active	O
transport	O
of	O
amino	O
acids	O
works	O
against	O
the	O
proportionality	O
of	O
maternal	O
and	O
cord	O
blood	O
concentrations	O
(	O
higher	O
amino	O
acid	O
concentrations	O
in	O
fetal	O
than	O
in	O
maternal	O
circulation	O
)	O
[	O
91	O
]	O
,	O
and	O
may	O
explain	O
why	O
maternal	O
diet	O
was	O
reflected	O
to	O
a	O
lesser	O
extent	O
in	O
cord	O
blood	O
amino	O
acids	O
.	O
In	O
line	O
with	O
this	O
principle	O
is	O
the	O
lack	O
of	O
association	O
for	O
fish	O
intake	O
with	O
DHA	O
,	O
which	O
could	O
be	O
explained	O
by	O
the	O
selective	O
maternal	O
–	O
fetal	O
transfer	O
of	O
DHA	O
being	O
more	O
reliant	O
on	O
existing	O
maternal	O
stores	O
than	O
on	O
dietary	O
DHA	O
intake	O
[	O
54	O
]	O
.	O
Additionally	O
,	O
an	O
unexpected	O
observation	O
is	O
that	O
associations	O
between	O
fish	O
and	O
long	O
-	O
chain	O
PUFA	O
were	O
seen	O
for	O
GPL	O
-	O
FA	O
but	O
not	O
for	O
PC	O
species	O
.	O
This	O
could	O
signify	O
insufficient	O
choline	O
availability	O
and	O
thus	O
limited	O
phosphatidylethanolamine	O
-	O
N	O
-	O
methyltransferase	O
activity	O
,	O
reducing	O
placental	O
transport	O
of	O
PCs	O
carrying	O
long	O
-	O
chain	O
PUFA	O
[	O
92	O
]	O
.	O
A	O
major	O
strength	O
of	O
this	O
study	O
is	O
the	O
cord	O
blood	O
metabolomics	O
data	O
available	O
in	O
a	O
large	O
sample	O
of	O
739	O
participants	O
,	O
which	O
entails	O
a	O
tremendous	O
effort	O
and	O
is	O
highly	O
unusual	O
.	O
Our	O
study	O
provides	O
a	O
data	O
-	O
driven	O
description	O
of	O
dietary	O
patterns	O
,	O
defined	O
on	O
the	O
basis	O
of	O
foods	O
most	O
commonly	O
associated	O
with	O
one	O
another	O
(	O
consumed	O
together	O
or	O
at	O
the	O
expense	O
of	O
each	O
other	O
)	O
.	O
This	O
takes	O
into	O
account	O
the	O
complexities	O
of	O
habitual	O
diet	O
,	O
such	O
as	O
potential	O
interactions	O
or	O
synergistic	O
effects	O
within	O
the	O
food	O
complex	O
or	O
correlations	O
among	O
different	O
foods	O
and	O
nutrients	O
,	O
the	O
individual	O
effects	O
of	O
which	O
are	O
often	O
difficult	O
to	O
disentangle	O
.	O

This	O
method	O
also	O
ensures	O
enough	O
power	O
in	O
the	O
analysis	O
of	O
associations	O
with	O
a	O
large	O
number	O
of	O
metabolites	O
,	O
whereas	O
a	O
focus	O
on	O
individual	O
foods	O
would	O
signify	O
a	O
much	O
larger	O
number	O
of	O
tests	O
and	O
an	O
increased	O
potential	O
for	O
chance	O
findings	O
.	O
Total	O
explained	O
variance	O
by	O
the	O
different	O
factors	O
was	O
indeed	O
low	O
;	O
however	O
,	O
this	O
is	O
not	O
uncommon	O
for	O
factor	O
analysis	O
of	O
dietary	O
data	O
given	O
its	O
multidimensionality	O
,	O
and	O
is	O
comparable	O
to	O
that	O
observed	O
in	O
other	O
studies	O
[	O
44	O
]	O
.	O
The	O
applied	O
method	O
for	O
dietary	O
assessment	O
entails	O
some	O
limitations	O
.	O
A	O
non	O
-	O
quantitative	O
FFQ	O
was	O
used	O
,	O
which	O
was	O
part	O
of	O
the	O
main	O
questionnaire	O
completed	O
upon	O
recruitment	O
,	O
and	O
was	O
not	O
previously	O
validated	O
.	O
The	O
lack	O
of	O
more	O
detailed	O
portion	O
size	O
information	O
limits	O
our	O
ability	O
to	O
precisely	O
estimate	O
associations	O
of	O
metabolites	O
with	O
intake	O
levels	O
of	O
individual	O
foods	O
.	O
Thus	O
,	O
with	O
the	O
available	O
data	O
,	O
we	O
cannot	O
show	O
which	O
specific	O
food	O
items	O
and	O
intake	O
levels	O
within	O
the	O
derived	O
dietary	O
patterns	O
underlie	O
the	O
observed	O
associations	O
.	O
The	O
FFQ	O
was	O
however	O
not	O
intended	O
for	O
an	O
estimation	O
of	O
exact	O
quantities	O
,	O
or	O
nutrient	O
content	O
of	O
the	O
reported	O
diet	O
.	O
Rather	O
,	O
the	O
aim	O
was	O
to	O
provide	O
a	O
general	O
estimation	O
of	O
dietary	O
intakes	O
of	O
common	O
foods	O
to	O
allow	O
the	O
ranking	O
of	O
individual	O
intakes	O
with	O
respect	O
to	O
the	O
overall	O
study	O
population	O
,	O
for	O
which	O
frequency	O
alone	O
should	O
provide	O
sufficient	O
information	O
[	O
93	O
]	O
.	O
Potential	O
reporting	O
errors	O
common	O
to	O
all	O
dietary	O
assessment	O
methods	O
may	O
however	O
limit	O
the	O
accuracy	O
of	O
the	O
collected	O
dietary	O
data	O
.	O
On	O
the	O
other	O
hand	O
,	O
we	O
cannot	O
know	O
to	O
what	O
extent	O
reports	O
of	O
diet	O
during	O
the	O
last	O
four	O
weeks	O
of	O
pregnancy	O
are	O
representative	O
of	O
usual	O
diet	O
.	O
Despite	O
this	O
,	O
we	O
observed	O
plausible	O
and	O
robust	O
associations	O
between	O
dietary	O
patterns	O
and	O
a	O
select	O
few	O
metabolites	O
.	O
Nonetheless	O
,	O
residual	O
confounding	O
cannot	O
be	O
ruled	O
out	O
and	O
given	O
the	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
nature	O
of	O
the	O
study	O
,	O
a	O
causal	O
effect	O
of	O
diet	O
cannot	O
be	O
assumed	O
.	O
We	O
also	O
cannot	O
exclude	O
possible	O
variation	O
arising	O
due	O
to	O
the	O
length	O
of	O
time	O
until	O
storage	O
of	O
samples	O
or	O
the	O
duration	O
of	O
storage	O
[	O
29	O
]	O
.	O
This	O
study	O
demonstrated	O
clear	O
associations	O
between	O
maternal	O
dietary	O
patterns	O
consumed	O
during	O
pregnancy	O
and	O
cord	O
blood	O
metabolites	O
.	O
Significant	O
associations	O
were	O
observed	O
specifically	O
in	O
relation	O
to	O
a	O
pattern	O
high	O
in	O
fish	O
and	O
shellfish	O
and	O
to	O
a	O
pattern	O
high	O
in	O
meat	O
and	O
potatoes	O
.	O
The	O
identified	O
associated	O
metabolites	O
highlight	O
possible	O
mechanisms	O
through	O
which	O
consuming	O
certain	O
types	O
of	O
dietary	O
patterns	O
during	O
pregnancy	O
may	O
influence	O
both	O
short	O
-	O
and	O
long	O
-	O
term	O
health	O
of	O
the	O
offspring	O
.	O

In	O
this	O
context	O
,	O
the	O
relevance	O
of	O
lipid	O
signaling	O
,	O
beta	O
-	O
oxidation	O
,	O
and	O
branched	O
-	O
chain	O
amino	O
acid	O
degradation	O
are	O
discussed	O
.	O
This	O
study	O
provides	O
novel	O
findings	O
that	O
,	O
if	O
confirmed	O
in	O
further	O
studies	O
,	O
could	O
greatly	O
aid	O
our	O
understanding	O
of	O
the	O
role	O
of	O
diet	O
during	O
pregnancy	O
and	O
hence	O
improve	O
dietary	O
recommendations	O
.	O
Our	O
findings	O
also	O
indicate	O
the	O
great	O
potential	O
for	O
establishing	O
biomarkers	O
for	O
dietary	O
patterns	O
of	O
pregnant	O
women	O
,	O
which	O
could	O
overcome	O
the	O
inherent	O
imprecision	O
of	O
current	O
available	O
methods	O
of	O
assessing	O
dietary	O
intakes	O
.	O
We	O
thank	O
Stefanie	O
Winterstetter	O
and	O
Stefan	O
Stromer	O
(	O
Division	O
of	O
Metabolic	O
and	O
Nutritional	O
Medicine	O
,	O
von	O
Hauner	O
Children	O
’	O
s	O
Hospital	O
,	O
Ludwigs	O
-	O
Maximilians	O
-	O
Universität	O
München	O
)	O
,	O
who	O
prepared	O
the	O
plasma	O
samples	O
for	O
GC	O
and	O
LC	O
-	O
MS	O
/	O
MS	O
analysis	O
.	O
Furthermore	O
,	O
we	O
thank	O
all	O
members	O
of	O
the	O
LISA	B-methodology
Study	I-methodology
Group	O
for	O
their	O
excellent	O
work	O
.	O
The	O
LISA	B-methodology
Study	I-methodology
group	O
consists	O
of	O
the	O
following	O
:	O
Helmholtz	O
Zentrum	O
München	O
,	O
German	O
Research	O
Center	O
for	O
Environmental	O
Health	O
,	O
Institute	O
of	O
Epidemiology	O
,	O
Munich	O
(	O
Heinrich	O
J	O
,	O
Schnappinger	O
M	O
,	O
Brüske	O
I	O
,	O
Ferland	O
M	O
,	O
Schulz	O
H	O
,	O
Zeller	O
C	O
,	O
Standl	O
M	O
,	O
Thiering	O
E	O
,	O
Tiesler	O
C	O
,	O
Flexeder	O
C	O
)	O
;	O
Department	O
of	O
Pediatrics	O
,	O
Municipal	O
Hospital	O
“	O
St	O
.	O

Georg	O
”	O
,	O
Leipzig	O
(	O
Borte	O
M	O
,	O
Diez	O
U	O
,	O
Dorn	O
C	O
,	O
Braun	O
E	O
)	O
;	O
Marien	O
Hospital	O
Wesel	O
,	O
Department	O
of	O
Pediatrics	O
,	O
Wesel	O
(	O
von	O
Berg	O
A	O
,	O
Berdel	O
D	O
,	O
Stiers	O
G	O
,	O
Maas	O
B	O
)	O
;	O
Pediatric	O
Practice	O
,	O
Bad	O
Honnef	O
(	O
Schaaf	O
B	O
)	O
;	O
Helmholtz	O
Centre	O
of	O
Environmental	O
Research	O
—	O
UFZ	O
,	O
Department	O
of	O
Environmental	O
Immunology	O
/	O
Core	O
Facility	O
Studies	O
,	O
Leipzig	O
(	O
Lehmann	O
I	O
,	O
Bauer	O
M	O
,	O
Röder	O
S	O
,	O
Schilde	O
M	O
,	O
Nowak	O
M	O
,	O
Herberth	O
G	O
,	O
Müller	O
J	O
)	O
;	O
Technical	O
University	O
Munich	O
,	O
Department	O
of	O
Pediatrics	O
,	O
Munich	O
(	O
Hoffmann	O
U	O
,	O
Paschke	O
M	O
,	O
Marra	O
S	O
)	O
;	O
Clinical	B-methodology
Research	I-methodology
Group	O
Molecular	O
Dermatology	O
,	O
Department	O
of	O
Dermatology	O
and	O
Allergy	O
,	O
Technische	O
Universität	O
München	O
(	O
TUM	O
)	O
,	O
Munich	O
(	O
Ollert	O
M	O
,	O
J	O
.	O
Grosch	O
)	O
.	O
The	O
LISA	B-methodology
study	I-methodology
was	O
mainly	O
supported	O
by	O
grants	O
from	O
the	O
Federal	O
Ministry	O
for	O
Education	O
,	O
Science	O
,	O
Research	O
and	O
Technology	O
and	O
in	O
addition	O
from	O
Helmholtz	O
Zentrum	O
Munich	O
(	O
former	O
GSF	O
)	O
,	O
Helmholtz	O
Centre	O
for	O
Environmental	O
Research	O
—	O
UFZ	O
,	O
Leipzig	O
,	O
Research	O
Institute	O
at	O
Marien	O
-	O
Hospital	O
Wesel	O
,	O
Pediatric	O
Practice	O
,	O
Bad	O
Honnef	O
for	O
the	O
first	O
2	O
years	O
.	O
The	O
4	O
year	O
,	O
6	O
year	O
,	O
10	O
year	O
and	O
15	O
year	O
follow	O
-	O
up	O
examinations	O
of	O
the	O
LISA	B-methodology
study	I-methodology
were	O
covered	O
from	O
the	O
respective	O
budgets	O
of	O
the	O
involved	O
partners	O
(	O
Helmholtz	O
Zentrum	O
Munich	O
(	O
former	O
GSF	O
)	O
,	O
Helmholtz	O
Centre	O
for	O
Environmental	O
Research	O
—	O
UFZ	O
,	O
Leipzig	O
,	O
Research	O
Institute	O
at	O
Marien	O
-	O
Hospital	O
Wesel	O
,	O
Pediatric	O
Practice	O
,	O
Bad	O
Honnef	O
,	O
IUF	O
—	O
Leibniz	O
-	O
Research	O
Institute	O
for	O
Environmental	O
Medicine	O
at	O
the	O
University	O
of	O
Düsseldorf	O
)	O
and	O
in	O
addition	O
by	O
a	O
grant	O
from	O
the	O
Federal	O
Ministry	O
for	O
Environment	O
(	O
IUF	O
Düsseldorf	O
,	O
FKZ	O
20462296	O
)	O
.	O
Further	O
,	O
the	O
15	O
-	O
year	O
follow	O
-	O
up	O
examination	O
of	O
the	O
LISA	B-methodology
study	I-methodology
was	O
supported	O
by	O
the	O
Commission	O
of	O
the	O
European	O
Communities	O
,	O
the	O
7th	O
Framework	O
Program	O
:	O
MeDALL	O
project	O
.	O

The	O
metabolomics	O
analyses	O
were	O
financially	O
supported	O
in	O
part	O
by	O
the	O
Commission	O
of	O
the	O
European	O
Communities	O
7th	O
Framework	O
Programme	O
,	O
contract	O
FP7	O
–	O
289346	O
-	O
EARLY	O
NUTRITION	O
,	O
the	O
European	O
Research	O
Council	O
Advanced	O
Grant	O
ERC	O
-	O
2012	O
-	O
AdG	O
—	O
No	O
.	O
322605	O
META	O
-	O
GROWTH	O
and	O
German	O
Research	O
Council	O
/	O
Deutsche	O
Forschungsgemeinschaft	O
(	O
INST	O
409	O
/	O
224	O
-	O
1	O
FUGG	O
)	O
.	O
BK	O
is	O
the	O
Else	O
Kröner	O
Seniorprofessor	O
of	O
Paediatrics	O
at	O
LMU	O
—	O
University	O
of	O
Munich	O
,	O
financially	O
supported	O
by	O
Else	O
Kröner	O
-	O
Fresenius	O
-	O
Foundation	O
,	O
LMU	O
Medical	O
Faculty	O
and	O
LMU	O
University	O
Hospitals	O
.	O
This	O
paper	O
does	O
not	O
necessarily	O
reflect	O
the	O
views	O
of	O
the	O
European	O
Commission	O
and	O
in	O
no	O
way	O
anticipates	O
the	O
future	O
policy	O
in	O
this	O
area	O
.	O
The	O
APC	O
was	O
funded	O
by	O
MDPI	O
Biomolecules	O
(	O
invitation	O
to	O
contribute	O
a	O
featured	O
paper	O
)	O
.	O
Publisher	O
’	O
s	O
Note	O
:	O
MDPI	O
stays	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O
The	O
following	O
supporting	O
information	O
can	O
be	O
downloaded	O
at	O
:	O
https	O
:	O
/	O
/	O
www	O
.	O
mdpi	O
.	O
com	O
/	O
article	O
/	O
10	O
.	O
3390	O
/	O
biom12101333	O
/	O
s1	O
,	O
Table	O
S1	O
:	O
List	O
of	O
foods	O
with	O
factor	O
loadings	O
of	O
≥	O
|	O
0	O
.	O
3	O
|	O
used	O
to	O
label	O
dietary	O
patterns	O
;	O
Table	O
S2	O
:	O
Association	O
between	O
dietary	O
patterns	O
and	O
covariates	O
;	O
Table	O
S3	O
:	O
Association	O
of	O
dietary	O
patterns	O
with	O
cord	O
blood	O
metabolites	O
(	O
all	O
results	O
)	O
.	O
Conceptualization	O
,	O
J	O
.	O
H	O
.	O
,	O
M	O
.	O
S	O
.	O
,	O
and	O
E	O
.	O
T	O
.	O
;	O
Formal	O
analysis	O
,	O
C	O
.	O
R	O
.	O
and	O
E	O
.	O
T	O
.	O
;	O
Methodology	O
,	O
O	O
.	O
U	O
.	O
,	O
H	O
.	O
D	O
.	O
and	O
B	O
.	O
K	O
.	O
;	O
Supervision	O
,	O
E	O
.	O
T	O
.	O
;	O
Writing	O
—	O
original	O
draft	O
preparation	O
,	O
C	O
.	O
P	O
.	O
H	O
.	O
;	O
Writing	O
—	O
review	O
and	O
editing	O
,	O
C	O
.	O
P	O
.	O
H	O
.	O
,	O
O	O
.	O
U	O
.	O
,	O
H	O
.	O
D	O
.	O
,	O
J	O
.	O
H	O
.	O
,	O
B	O
.	O
K	O
.	O
,	O
M	O
.	O
S	O
.	O
,	O
and	O
E	O
.	O
T	O
.	O
All	O
authors	O
have	O
read	O
and	O
agreed	O
to	O
the	O
published	O
version	O
of	O
the	O
manuscript	O
.	O
The	O
study	O
was	O
conducted	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
,	O
and	O
approved	O
by	O
the	O
local	O
ethics	O
committees	O
(	O
Bavarian	O
Board	O
of	O
Physicians	O
,	O
Board	O
of	O
Physicians	O
of	O
North	O
-	O
Rhine	O
-	O
Westphalia	O
)	O
.	O

Informed	O
consent	O
was	O
obtained	O
from	O
all	O
subjects	O
involved	O
in	O
the	O
study	O
.	O
Restrictions	O
apply	O
to	O
the	O
availability	O
of	O
these	O
data	O
.	O
The	O
datasets	O
generated	O
and	O
/	O
or	O
analyzed	O
during	O
the	O
current	O
study	O
are	O
not	O
publicly	O
available	O
due	O
data	O
protection	O
but	O
are	O
available	O
from	O
the	O
corresponding	O
author	O
on	O
reasonable	O
request	O
and	O
acceptance	O
of	O
a	O
data	O
transfer	O
agreement	O
from	O
the	O
legal	O
department	O
of	O
the	O
Helmholtz	O
Zentrum	O
München	O
.	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O

Short	O
-	O
Term	O
Physiological	O
Effects	O
of	O
a	O
Very	O
Low	O
-	O
Calorie	O
Ketogenic	O
Diet	O
:	O
Effects	O
on	O
Adiponectin	O
Levels	O
and	O
Inflammatory	O
States	O
very	O
low	O
-	O
calorie	O
ketogenic	O
diet	O
(	O
VLCKD	O
)	O
;	O
adipose	O
tissue	O
(	O
AT	O
)	O
;	O
adiponectin	O
;	O
cytokines	O
;	O
inflammatory	O
diseases	O
;	O
visceral	O
adipose	O
tissue	O
(	O
VAT	O
)	O
;	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
;	O
lipid	O
profile	O
Adipose	O
tissue	O
is	O
a	O
multifunctional	O
organ	O
involved	O
in	O
many	O
physiological	O
and	O
metabolic	O
processes	O
through	O
the	O
production	O
of	O
adipokines	O
and	O
,	O
in	O
particular	O
,	O
adiponectin	O
.	O
Caloric	O
restriction	O
is	O
one	O
of	O
the	O
most	O
important	O
strategies	O
against	O
obesity	O
today	O
.	O
The	O
very	O
low	O
-	O
calorie	O
ketogenic	O
diet	O
(	O
VLCKD	O
)	O
represents	O
a	O
type	O
of	O
caloric	O
restriction	O
with	O
very	O
or	O
extremely	O
low	O
daily	O
food	O
energy	O
consumption	O
.	O
This	O
study	O
aimed	O
to	O
investigate	O
the	O
physiological	O
effects	O
of	O
a	O
VLCKD	O
on	O
anthropometric	O
and	O
biochemical	O
parameters	O
such	O
as	O
adiponectin	O
levels	O
,	O
as	O
well	O
as	O
analyzing	O
oligomeric	O
profiles	O
and	O
cytokine	O
serum	O
levels	O
in	O
obese	O
subjects	O
before	O
and	O
after	O
a	O
VLCKD	O
.	O
Twenty	O
obese	O
subjects	O
were	O
enrolled	O
.	O
At	O
baseline	O
and	O
after	O
eight	B-methodology
weeks	I-methodology
of	I-methodology
intervention	I-methodology
,	O
anthropometric	O
and	O
biochemical	O
parameters	O
,	O
such	O
as	O
adiponectin	O
levels	O
,	O
were	O
recorded	O
.	O
Our	O
findings	O
showed	O
a	O
significant	O
change	O
in	O
the	O
anthropometric	O
and	O
biochemical	O
parameters	O
of	O
these	O
obese	O
subjects	O
before	O
and	O
after	O
a	O
VLCKD	O
.	O
We	O
found	O
a	O
negative	O
correlation	O
between	O
adiponectin	O
and	O
lipid	O
profile	O
,	O
visceral	O
adipose	O
tissue	O
(	O
VAT	O
)	O
,	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
,	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
tumor	O
necrosis	O
factor	O
-	O
α	O
(	O
TNF	O
-	O
α	O
)	O
,	O
which	O
confirmed	O
the	O
important	O
involvement	O
of	O
adiponectin	O
in	O
metabolic	O
and	O
inflammatory	O
diseases	O
.	O
We	O
demonstrated	O
the	O
beneficial	O
short	O
-	O
term	O
effects	O
of	O
a	O
VLCKD	O
not	O
only	O
in	O
the	O
treatment	O
of	O
obesity	O
but	O
also	O
in	O
the	O
establishment	O
of	O
obesity	O
-	O
correlated	O
diseases	O
.	O
Adipose	O
tissue	O
(	O
AT	O
)	O
is	O
a	O
multifunctional	O
organ	O
involved	O
in	O
many	O
physiological	O
and	O
metabolic	O
processes	O
.	O

It	O
is	O
not	O
only	O
a	O
site	O
for	O
energy	O
storage	O
but	O
also	O
an	O
endocrine	O
organ	O
,	O
composed	O
of	O
adipocytes	O
,	O
and	O
it	O
is	O
also	O
populated	O
by	O
several	O
immune	O
cells	O
such	O
as	O
T	O
lymphocytes	O
and	O
macrophages	O
.	O
As	O
a	O
result	O
of	O
excessive	O
expansion	O
of	O
AT	O
mass	O
,	O
a	O
high	O
-	O
fat	O
diet	O
,	O
lipolysis	O
activation	O
,	O
and	O
non	O
-	O
shivering	O
thermogenesis	O
recruit	O
and	O
activate	O
numerous	O
immune	O
cells	O
.	O
Through	O
the	O
production	O
of	O
adipokines	O
and	O
,	O
in	O
particular	O
,	O
adiponectin	O
,	O
AT	O
is	O
involved	O
in	O
many	O
metabolic	O
and	O
inflammatory	O
functions	O
,	O
as	O
well	O
as	O
thermoregulation	O
.	O
Moreover	O
,	O
literature	O
data	O
demonstrate	O
that	O
obese	O
people	O
have	O
a	O
higher	O
incidence	O
of	O
immune	O
and	O
autoimmune	O
diseases	O
[	O
1	O
,	O
2	O
]	O
.	O
In	O
the	O
obese	O
condition	O
,	O
there	O
is	O
an	O
accumulation	O
of	O
visceral	O
adipose	O
tissue	O
(	O
VAT	O
)	O
in	O
the	O
abdominal	O
area	O
of	O
the	O
body	O
,	O
which	O
is	O
extremely	O
dangerous	O
for	O
health	O
.	O
Furthermore	O
,	O
white	O
visceral	O
fat	O
adipocytes	O
are	O
particularly	O
active	O
in	O
the	O
release	O
of	O
adipokines	O
,	O
hormones	O
involved	O
in	O
several	O
metabolic	O
and	O
inflammatory	O
processes	O
,	O
as	O
well	O
as	O
in	O
the	O
normal	O
homeostasis	O
of	O
many	O
organs	O
and	O
tissues	O
.	O
Among	O
these	O
,	O
adiponectin	O
is	O
the	O
most	O
abundant	O
product	O
from	O
AT	O
.	O
It	O
constitutes	O
about	O
0	O
.	O
1	O
%	O
of	O
total	O
serum	O
proteins	O
.	O
Adiponectin	O
circulates	O
as	O
oligomers	O
of	O
different	O
molecular	O
weight	O
,	O
low	O
molecular	O
weight	O
(	O
LMW	O
)	O
,	O
medium	O
molecular	O
weight	O
(	O
MMW	O
)	O
,	O
and	O
high	O
molecular	O
weight	O
(	O
HMW	O
)	O
,	O
which	O
are	O
the	O
most	O
biologically	O
active	O
.	O
Through	O
the	O
direct	O
or	O
indirect	O
release	O
of	O
this	O
adipocytokine	O
,	O
visceral	O
fat	O
controls	O
appetite	O
and	O
energy	O
balance	O
,	O
immunity	O
,	O
angiogenesis	O
,	O
insulin	O
sensitivity	O
,	O
and	O
lipid	O
metabolism	O
[	O
3	O
]	O
.	O
Adiponectin	O
has	O
pleiotropic	O
functions	O
on	O
different	O
target	O
tissues	O
through	O
the	O
presence	O
of	O
its	O
receptors	O
,	O
AdipoR1	O
,	O
AdipoR2	O
,	O
and	O
T	O
-	O
cadherin	O
in	O
liver	O
,	O
muscle	O
,	O
and	O
adipose	O
tissue	O
,	O
where	O
it	O
positively	O
affects	O
homeostasis	O
and	O
metabolism	O
of	O
glucose	O
and	O
fatty	O
acids	O
[	O
4	O
,	O
5	O
]	O
.	O
As	O
reported	O
by	O
Yamauchi	O
et	O
al	O
.	O
,	O
the	O
expression	O
of	O
AdipoR1	O
/	O
R2	O
mediates	O
increased	O
AMP	O
kinase	O
and	O
PPARα	O
ligand	O
activities	O
,	O
as	O
well	O
as	O
fatty	O
-	O
acid	O
oxidation	O
and	O
glucose	O
uptake	O
by	O
adiponectin	O
[	O
5	O
]	O
.	O

Adiponectin	O
increases	O
insulin	O
sensitivity	O
and	O
reduces	O
hepatic	O
neo	O
-	O
glucogenesis	O
.	O
Furthermore	O
,	O
many	O
studies	O
reported	O
that	O
adiponectin	O
could	O
be	O
an	O
early	O
marker	O
assisting	O
in	O
the	O
evaluation	O
of	O
the	O
initial	O
stages	O
of	O
a	O
worsening	O
glucose	O
metabolism	O
.	O
The	O
measurement	O
of	O
adiponectin	O
concentration	O
would	O
aid	O
in	O
the	O
identification	O
of	O
high	O
-	O
risk	O
individuals	O
with	O
glycated	O
hemoglobin	O
(	O
HbA1c	O
)	O
concentrations	O
above	O
a	O
particular	O
threshold	O
,	O
independently	O
of	O
serum	O
glucose	O
concentration	O
.	O
It	O
is	O
well	O
known	O
that	O
glycated	O
hemoglobin	O
is	O
a	O
long	O
-	O
term	O
marker	O
of	O
glucose	O
metabolism	O
;	O
for	O
these	O
reasons	O
,	O
these	O
two	O
factors	O
may	O
be	O
useful	O
in	O
the	O
prevention	O
of	O
the	O
initial	O
stage	O
of	O
diabetes	O
[	O
6	O
]	O
.	O
Among	O
the	O
inflammation	O
markers	O
,	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
is	O
an	O
acute	O
phase	O
reactant	O
marker	O
of	O
inflammation	O
correlated	O
with	O
cardiac	O
injury	O
;	O
in	O
addition	O
,	O
it	O
is	O
strongly	O
related	O
to	O
adiposity	O
and	O
insulin	O
sensitivity	O
.	O
Literature	O
data	O
report	O
that	O
adiponectin	O
and	O
CRP	O
serum	O
levels	O
are	O
negatively	O
correlated	O
in	O
type	O
2	O
diabetes	O
and	O
obesity	O
[	O
6	O
]	O
.	O
Moreover	O
,	O
numerous	O
studies	O
,	O
both	O
in	B-methodology
vitro	I-methodology
and	O
in	B-methodology
vivo	I-methodology
,	O
also	O
characterized	O
the	O
anti	O
-	O
inflammatory	O
,	O
anti	O
-	O
atherogenic	O
,	O
and	O
anti	O
-	O
angiogenic	O
effects	O
of	O
adiponectin	O
[	O
7	O
,	O
8	O
,	O
9	O
]	O
.	O
The	O
anti	O
-	O
inflammatory	O
effects	O
of	O
adiponectin	O
include	O
both	O
the	O
suppression	O
of	O
pro	O
-	O
inflammatory	O
cytokine	O
production	O
,	O
such	O
as	O
TNF	O
-	O
α	O
and	O
IL	O
-	O
6	O
,	O
C	O
protein	O
,	O
and	O
growth	O
factors	O
,	O
and	O
modulation	O
of	O
the	O
expression	O
of	O
anti	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
IL	O
-	O
10	O
in	O
monocytes	O
and	O
macrophages	O
.	O
On	O
the	O
other	O
hand	O
,	O
TNF	O
-	O
α	O
and	O
other	O
inflammatory	O
markers	O
(	O
IL	O
-	O
6	O
,	O
C	O
-	O
reactive	O
protein	O
,	O
SAA	O
,	O
tPA	O
,	O
MCP	O
-	O
1	O
)	O
and	O
glucocorticoids	O
suppress	O
adiponectin	O
production	O
and	O
regulate	O
its	O
levels	O
.	O
The	O
anti	O
-	O
inflammatory	O
cytokines	O
,	O
such	O
as	O
IL	O
-	O
10	O
,	O
positively	O
correlate	O
to	O
adiponectin	O
levels	O
,	O
and	O
the	O
production	O
of	O
this	O
cytokine	O
is	O
stimulated	O
by	O
adiponectin	O
[	O
3	O
,	O
7	O
]	O
.	O
Furthermore	O
,	O
this	O
adipokine	O
is	O
involved	O
in	O
obesity	O
outcome	O
;	O
in	O
particular	O
,	O
it	O
is	O
strongly	O
reduced	O
in	O
the	O
serum	O
of	O
obese	O
subjects	O
.	O

Moreover	O
,	O
it	O
improves	O
the	O
oxidation	O
of	O
free	O
fatty	O
acids	O
in	O
muscle	O
,	O
preventing	O
the	O
growth	O
of	O
free	O
fatty	O
acids	O
and	O
triglycerides	O
as	O
a	O
result	O
of	O
a	O
high	O
-	O
fat	O
diet	O
.	O
Numerous	O
studies	O
,	O
both	O
in	B-methodology
vitro	I-methodology
and	O
in	B-methodology
vivo	I-methodology
,	O
also	O
characterized	O
the	O
anti	O
-	O
atherogenic	O
and	O
anti	O
-	O
angiogenic	O
effects	O
of	O
this	O
protein	O
[	O
7	O
,	O
8	O
,	O
9	O
]	O
.	O
Furthermore	O
,	O
it	O
is	O
well	O
known	O
that	O
adiponectin	O
levels	O
are	O
strongly	O
modified	O
by	O
diets	O
such	O
as	O
the	O
Mediterranean	O
diet	O
or	O
the	O
DASH	O
diet	O
[	O
10	O
]	O
.	O
In	O
this	O
scenario	O
,	O
caloric	O
restriction	O
represents	O
one	O
of	O
the	O
most	O
important	O
strategies	O
against	O
obesity	O
.	O
Caloric	O
restriction	O
reduces	O
or	O
slows	O
the	O
onset	O
of	O
diseases	O
related	O
to	O
obesity	O
,	O
inducing	O
a	O
considerable	O
weight	O
loss	O
and	O
having	O
beneficial	O
and	O
anti	O
-	O
inflammatory	O
effects	O
,	O
reducing	O
the	O
production	O
of	O
free	O
radicals	O
,	O
and	O
favoring	O
higher	O
resistance	O
to	O
stress	O
and	O
prolonging	O
lifespan	O
.	O
A	O
very	O
low	O
-	O
calorie	O
ketogenic	O
diet	O
(	O
VLCKD	O
)	O
represents	O
a	O
type	O
of	O
caloric	O
restriction	O
with	O
very	O
or	O
extremely	O
low	O
daily	O
food	O
energy	O
consumption	O
(	O
800	O
kilocalories	O
per	O
day	O
or	O
less	O
)	O
.	O
The	O
VLCKD	O
is	O
a	O
dietetic	O
regimen	O
that	O
mimics	O
fasting	O
by	O
restricting	O
carbohydrates	O
with	O
a	O
moderate	O
increase	O
in	O
protein	O
intake	O
,	O
which	O
is	O
proposed	O
to	O
achieve	O
rapid	O
weight	O
loss	O
.	O
This	O
diet	O
is	O
a	O
particular	O
ketogenic	O
diet	O
that	O
was	O
shown	O
to	O
be	O
effective	O
,	O
at	O
least	O
in	O
the	O
short	O
to	O
medium	O
term	O
,	O
as	O
a	O
tool	O
to	O
fight	O
obesity	O
[	O
11	O
]	O
.	O
This	O
diet	O
has	O
various	O
beneficial	O
effects	O
on	O
numerous	O
organs	O
and	O
tissues	O
,	O
inducing	O
weight	O
loss	O
,	O
reducing	O
blood	O
insulin	O
levels	O
,	O
and	O
cardiovascular	O
risk	O
factors	O
,	O
increasing	O
mitochondriogenesis	O
,	O
and	O
modulating	O
neurotransmitter	O
activity	O
,	O
as	O
well	O
as	O
improving	O
vascular	O
density	O
in	O
the	O
brain	O
.	O
The	O
ketogenic	O
diet	O
also	O
has	O
an	O
important	O
role	O
as	O
a	O
signaling	O
mediator	O
,	O
driver	O
of	O
protein	O
post	O
-	O
translational	O
modification	O
,	O
and	O
modulator	O
of	O
inflammation	O
and	O
oxidative	O
stress	O
.	O
Several	O
studies	O
reported	O
that	O
VLCKD	O
in	O
the	O
short	O
term	O
is	O
able	O
to	O
reduce	O
visceral	O
adipose	O
tissue	O
and	O
ameliorate	O
lipid	O
profile	O
,	O
in	O
addition	O
to	O
reducing	O
cardiovascular	O
risk	O
factors	O
.	O
[	O
12	O
,	O
13	O
]	O
.	O

The	O
VLCKD	O
is	O
more	O
effective	O
in	O
inducing	O
weight	O
loss	O
compared	O
with	O
a	O
standard	O
low	O
-	O
calorie	O
diet	O
,	O
presenting	O
higher	O
patient	O
compliance	O
;	O
in	O
fact	O
,	O
the	O
ketone	O
bodies	O
increase	O
satiety	O
.	O
The	O
mechanism	O
on	O
which	O
this	O
satiety	O
effect	O
is	O
based	O
is	O
complex	O
and	O
depends	O
on	O
the	O
relationship	O
that	O
is	O
established	O
with	O
several	O
hormones	O
and	O
metabolites	O
,	O
mainly	O
on	O
a	O
peripheral	O
level	O
[	O
14	O
]	O
.	O
The	O
production	O
of	O
ketone	O
bodies	O
activates	O
the	O
ventromedial	O
nucleus	O
of	O
the	O
hypothalamus	O
,	O
which	O
is	O
directly	O
related	O
to	O
satiety	O
,	O
and	O
which	O
varies	O
throughout	O
the	O
day	O
according	O
to	O
the	O
intake	O
of	O
fats	O
.	O
As	O
a	O
consequence	O
of	O
this	O
satiating	O
effect	O
,	O
changes	O
in	O
body	O
composition	O
characterized	O
by	O
weight	O
loss	O
are	O
produced	O
,	O
related	O
to	O
lower	O
resistance	O
to	O
insulin	O
and	O
a	O
low	O
atherogenic	O
lipid	O
panel	O
.	O
Meanwhile	O
,	O
an	O
increase	O
in	O
lean	O
mass	O
is	O
shown	O
;	O
therefore	O
,	O
weight	O
loss	O
would	O
be	O
mainly	O
based	O
on	O
a	O
lower	O
amount	O
of	O
body	O
fat	O
[	O
14	O
]	O
.	O
In	O
light	O
of	O
these	O
literature	O
data	O
,	O
this	O
study	O
aimed	O
to	O
investigate	O
the	O
physiological	O
effects	O
of	O
a	O
VLCKD	O
on	O
anthropometric	O
and	O
biochemical	O
parameters	O
such	O
as	O
pro	O
-	O
inflammatory	O
and	O
anti	O
-	O
inflammatory	O
cytokines	O
,	O
as	O
well	O
as	O
on	O
total	O
adiponectin	O
levels	O
and	O
its	O
oligomeric	O
profile	O
.	O
Monitoring	O
was	O
performed	O
before	O
and	O
after	O
eight	O
weeks	O
of	O
VLCKD	O
.	O
The	O
anthropometric	O
and	O
biochemical	O
parameters	O
of	O
the	O
VLCKD	O
obese	O
participants	O
before	O
and	O
after	O
eight	O
weeks	O
of	O
nutritional	B-methodology
intervention	I-methodology
are	O
reported	O
in	O
Table	O
1	O
weight	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
fat	O
mass	O
(	O
FM	O
)	O
,	O
and	O
visceral	O
adipose	O
tissue	O
(	O
VAT	O
)	O
were	O
statistically	O
reduced	O
in	O
obese	O
participants	O
after	O
the	O
VLCKD	O
.	O
Moreover	O
,	O
biochemical	O
parameters	O
such	O
as	O
glycemic	O
and	O
lipid	O
profiles	O
were	O
strongly	O
ameliorated	O
in	O
these	O
participants	O
after	O
the	O
diet	O
.	O
Interestingly	O
,	O
the	O
adiponectin	O
levels	O
in	O
participants	O
statistically	O
increased	O
after	O
the	O
diet	O
,	O
while	O
CRP	O
levels	O
strongly	O
decreased	O
.	O
As	O
widely	O
demonstrated	O
,	O
we	O
found	O
a	O
sexual	O
dimorphism	O
in	O
our	O
study	O
population	O
.	O
In	O
particular	O
,	O
in	O
VLCKD	O
female	O
obese	O
participants	O
,	O
adiponectin	O
levels	O
were	O
higher	O
compared	O
to	O
male	O
VLCKD	O
obese	O
participants	O
both	O
before	O
and	O
after	O
the	O
diet	B-methodology
intervention	I-methodology
(	O
Table	O
2	O
)	O
.	O

For	O
both	O
males	O
and	O
females	O
,	O
we	O
registered	O
a	O
strong	O
increase	O
in	O
adiponectin	O
levels	O
after	O
eight	O
weeks	O
of	O
the	O
VLCKD	O
.	O
Furthermore	O
,	O
adiponectin	O
negatively	O
correlated	O
with	O
VAT	O
,	O
with	O
CRP	O
(	O
Figure	O
1	O
)	O
,	O
and	O
with	O
glycated	O
hemoglobin	O
and	O
lipidic	O
profile	O
,	O
but	O
positively	O
correlated	O
with	O
HDL	O
-	O
cholesterol	O
(	O
Figure	O
2	O
)	O
.	O
In	O
addition	O
,	O
we	O
found	O
a	O
strong	O
reduction	O
of	O
TNF	O
-	O
α	O
serum	O
levels	O
in	O
participants	O
after	O
the	O
VLCKD	O
;	O
on	O
the	O
contrary	O
,	O
IL	O
-	O
10	O
serum	O
levels	O
were	O
statistically	O
increased	O
after	O
the	O
diet	B-methodology
intervention	I-methodology
.	O
With	O
regard	O
to	O
IL	O
-	O
6	O
serum	O
levels	O
,	O
we	O
found	O
no	O
strong	O
differences	O
between	O
the	O
two	O
groups	O
of	O
participants	O
(	O
Table	O
1	O
)	O
.	O
TNF	O
-	O
α	O
and	O
IL	O
-	O
10	O
strongly	O
correlated	O
to	O
adiponectin	O
serum	O
levels	O
in	O
participants	O
before	O
and	O
after	O
VLCKD	O
(	O
Figure	O
3	O
)	O
.	O
All	O
these	O
results	O
showed	O
that	O
there	O
is	O
an	O
improvement	O
in	O
anthropometric	O
and	O
biochemical	O
parameters	O
in	O
a	O
short	O
period	O
of	O
diet	B-methodology
intervention	I-methodology
.	O
The	O
distribution	O
of	O
serum	O
adiponectin	O
in	O
our	O
VLCKD	O
participants	O
was	O
analyzed	O
by	O
western	O
blotting	O
ting	O
analysis	O
(	O
Figure	O
4	O
)	O
.	O
Three	O
bands	O
corresponding	O
to	O
HMW	O
(	O
≥250	O
kDa	O
)	O
,	O
MMW	O
(	O
180	O
kDa	O
)	O
,	O
and	O
LMW	O
(	O
70	O
kDa	O
)	O
oligomers	O
were	O
evident	O
in	O
the	O
serum	O
from	O
our	O
participants	O
;	O
Figure	O
2A	O
shows	O
a	O
representative	O
blot	O
of	O
the	O
different	O
oligomers	O
(	O
HMW	O
,	O
MMW	O
,	O
and	O
LMW	O
)	O
present	O
in	O
the	O
serum	O
of	O
two	O
VLCKD	O
participants	O
at	O
baseline	O
(	O
T0	O
)	O
and	O
after	O
eight	O
weeks	O
of	O
VLCKD	O
(	O
T1	O
)	O
.	O
The	O
densitometric	O
evaluation	O
of	O
the	O
adiponectin	O
oligomers	O
in	O
serum	O
from	O
all	O
participants	O
compared	O
before	O
and	O
after	O
eight	O
weeks	O
of	O
nutritional	B-methodology
intervention	I-methodology
confirmed	O
that	O
HMW	O
,	O
MMW	O
,	O
and	O
LMW	O
oligomers	O
increased	O
after	O
the	O
dietary	B-methodology
intervention	I-methodology
(	O
Figure	O
2B	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
In	O
particular	O
,	O
HMW	O
adiponectin	O
oligomers	O
,	O
which	O
are	O
the	O
most	O
biologically	O
active	O
,	O
were	O
statistically	O
increased	O
in	O
VLCKD	O
participants	O
after	O
the	O
period	O
of	O
diet	B-methodology
intervention	I-methodology
.	O
The	O
VLCKD	O
is	O
increasingly	O
promoted	O
as	O
a	O
strategy	O
to	O
fight	O
obesity	O
.	O

Although	O
the	O
VLCKD	O
is	O
effective	O
for	O
weight	O
loss	O
and	O
weight	O
control	O
,	O
a	O
comprehensive	O
determination	O
of	O
its	O
relationship	O
with	O
biochemical	O
and	O
physiological	O
changes	O
,	O
in	O
particular	O
with	O
the	O
adipokines	O
produced	O
by	O
AT	O
,	O
is	O
still	O
largely	O
unexplored	O
.	O
This	O
is	O
the	O
first	O
study	O
that	O
evaluated	O
total	O
adiponectin	O
serum	O
levels	O
using	O
an	O
ELISA	O
test	O
and	O
its	O
oligomeric	O
profile	O
using	O
Western	O
blotting	O
analysis	O
.	O
Furthermore	O
,	O
the	O
Western	O
blotting	O
analysis	O
is	O
a	O
semi	O
-	O
quantitative	O
method	O
to	O
support	O
the	O
previous	O
results	O
obtained	O
by	O
the	O
ELISA	O
test	O
.	O
The	O
main	O
differences	O
between	O
low	O
-	O
calorie	O
and	O
ketogenic	O
diets	O
regard	O
macronutrient	O
composition	O
.	O
A	O
low	O
-	O
calorie	O
diet	O
is	O
a	O
balanced	O
diet	O
characterized	O
by	O
45	O
–	O
55	O
%	O
carbohydrates	O
,	O
15	O
–	O
25	O
%	O
proteins	O
,	O
and	O
25	O
–	O
35	O
%	O
fat	O
,	O
with	O
the	O
additional	O
dose	O
of	O
30	O
g	O
of	O
fiber	O
in	O
the	O
form	O
of	O
fruit	O
and	O
vegetables	O
[	O
15	O
]	O
.	O
On	O
the	O
contrary	O
,	O
the	O
ketogenic	O
diet	O
is	O
low	O
in	O
carbohydrates	O
(	O
<	O
50	O
g	O
daily	O
from	O
vegetables	O
)	O
and	O
lipids	O
(	O
only	O
10	O
g	O
of	O
olive	O
oil	O
per	O
day	O
)	O
[	O
16	O
]	O
.	O
In	O
this	O
study	O
,	O
anthropometric	O
and	O
biochemical	O
parameters	O
in	O
VLCKD	O
participants	O
before	O
and	O
after	O
eight	O
weeks	O
of	O
diet	B-methodology
intervention	I-methodology
were	O
investigated	O
,	O
focusing	O
on	O
the	O
effects	O
of	O
this	O
diet	O
on	O
total	O
adiponectin	O
and	O
its	O
oligomeric	O
profile	O
.	O
The	O
results	O
of	O
the	O
present	O
study	O
showed	O
that	O
the	O
eight	O
-	O
week	O
intervention	O
with	O
the	O
VLCKD	O
produced	O
significant	O
weight	O
loss	O
in	O
our	O
participants	O
,	O
decreasing	O
pro	O
-	O
inflammatory	O
cytokine	O
production	O
,	O
increasing	O
adiponectin	O
serum	O
levels	O
,	O
and	O
improving	O
metabolic	O
profile	O
.	O
To	O
support	O
our	O
results	O
,	O
several	O
studies	O
reported	O
beneficial	O
effects	O
of	O
a	O
ketogenic	O
diet	O
[	O
17	O
,	O
18	O
,	O
19	O
,	O
20	O
]	O
.	O
In	O
addition	O
,	O
VLCKD	O
is	O
advantageous	O
in	O
increasing	O
satiety	O
despite	O
a	O
negative	O
energy	O
balance	O
,	O
and	O
sustaining	O
basal	O
energy	O
expenditure	O
despite	O
body	O
weight	O
loss	O
due	O
to	O
a	O
sparing	O
of	O
fat	O
mass	O
[	O
20	O
,	O
21	O
,	O
22	O
]	O
.	O
Interestingly	O
,	O
as	O
reported	O
by	O
Zhang	O
et	O
al	O
.	O
,	O
a	O
ketogenic	O
diet	O
in	O
combination	O
with	O
exercise	O
reduced	O
PPARγ	O
and	O
lipid	O
synthetic	O
genes	O
,	O
as	O
well	O
as	O
enhancing	O
the	O
PPARα	O
and	O
lipid	O
β	O
-	O
oxidation	O
gene	O
program	O
in	O
the	O
liver	O
compared	O
to	O
those	O
in	O
a	O
ketogenic	O
diet	O
without	O
exercise	O
[	O
23	O
]	O
.	O

On	O
the	O
contrary	O
,	O
some	O
studies	O
reported	O
that	O
any	O
beneficial	O
effects	O
are	O
only	O
transient	O
[	O
24	O
]	O
.	O
In	O
addition	O
,	O
Ellenbroek	O
et	O
al	O
.	O
supported	O
that	O
a	O
long	O
-	O
term	O
ketogenic	O
diet	O
(	O
22	O
weeks	O
)	O
caused	O
dyslipidemia	O
,	O
a	O
pro	O
-	O
inflammatory	O
state	O
,	O
signs	O
of	O
hepatic	O
steatosis	O
,	O
glucose	O
intolerance	O
,	O
and	O
a	O
reduction	O
in	O
beta	O
and	O
alpha	O
cell	O
mass	O
,	O
without	O
weight	O
loss	O
in	O
mice	O
;	O
however	O
,	O
the	O
induction	O
of	O
ketosis	O
and	O
the	O
response	O
to	O
ketosis	O
in	O
man	O
and	O
mouse	O
are	O
quite	O
different	O
,	O
and	O
22	O
weeks	O
is	O
a	O
very	O
long	O
period	O
for	O
a	O
mouse	O
that	O
could	O
be	O
compared	O
to	O
several	O
years	O
in	O
human	O
beings	O
[	O
23	O
,	O
25	O
]	O
.	O
The	O
strength	O
of	O
this	O
study	O
is	O
that	O
,	O
in	O
a	O
short	O
period	O
,	O
the	O
VLCKD	O
changed	O
the	O
anthropometric	O
and	O
metabolic	O
profile	O
of	O
our	O
participants	O
in	O
a	O
statistically	O
significant	O
manner	O
.	O
It	O
is	O
well	O
known	O
that	O
VAT	O
is	O
dangerous	O
to	O
health	O
,	O
generating	O
chronic	O
low	O
inflammation	O
and	O
leading	O
to	O
an	O
imbalance	O
in	O
the	O
function	O
of	O
adipose	O
tissue	O
;	O
for	O
these	O
reasons	O
,	O
the	O
inverse	O
correlation	O
between	O
adiponectin	O
and	O
VAT	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
TNF	O
-	O
α	O
is	O
very	O
important	O
[	O
26	O
,	O
27	O
,	O
28	O
]	O
.	O
Gustafson	O
and	O
colleagues	O
reported	O
that	O
,	O
among	O
the	O
fat	O
storage	O
compartments	O
in	O
the	O
body	O
,	O
VAT	O
was	O
found	O
to	O
be	O
an	O
important	O
source	O
of	O
pro	O
-	O
inflammatory	O
adipokines	O
such	O
as	O
TNF	O
-	O
α	O
and	O
IL	O
-	O
6	O
,	O
and	O
it	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
atherosclerosis	O
,	O
more	O
so	O
than	O
subcutaneous	O
fat	O
[	O
27	O
]	O
.	O
Moreover	O
,	O
significant	O
changes	O
in	O
VAT	O
,	O
as	O
well	O
as	O
in	O
inflammatory	O
and	O
adipose	O
tissue	O
activity	O
biomarkers	O
,	O
were	O
reported	O
,	O
suggesting	O
that	O
the	O
VLCKD	O
,	O
in	O
the	O
short	O
term	O
,	O
can	O
be	O
considered	O
very	O
important	O
in	O
the	O
deregulation	O
of	O
the	O
balance	O
between	O
abdominal	O
fat	O
and	O
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
.	O
We	O
also	O
tested	O
adiponectin	O
,	O
whose	O
expression	O
is	O
strongly	O
increased	O
after	O
eight	O
weeks	O
of	O
VLCKD	O
.	O
Adiponectin	O
is	O
the	O
most	O
abundant	O
circulating	O
adipokine	O
,	O
and	O
plasmatic	O
levels	O
,	O
together	O
with	O
free	O
fatty	O
acids	O
(	O
FFA	O
)	O
,	O
are	O
statistically	O
inversely	O
related	O
to	O
body	O
fat	O
,	O
abdominal	O
visceral	O
fat	O
,	O
and	O
glucose	O
and	O
lipid	O
metabolism	O
.	O

This	O
adipokine	O
,	O
through	O
its	O
HMW	O
oligomers	O
,	O
which	O
are	O
the	O
most	O
biologically	O
active	O
,	O
strongly	O
increased	O
in	O
our	O
participants	O
after	O
the	O
diet	B-methodology
intervention	I-methodology
.	O
Adiponectin	O
exerts	O
an	O
anti	O
-	O
inflammatory	O
effect	O
and	O
modulates	O
insulin	O
sensitivity	O
by	O
stimulating	O
glucose	O
utilization	O
and	O
fatty	O
acid	O
oxidation	O
.	O
On	O
the	O
contrary	O
,	O
elevated	O
FFA	O
was	O
linked	O
with	O
the	O
development	O
of	O
insulin	O
resistance	O
,	O
defects	O
in	O
insulin	O
secretion	O
,	O
nonalcoholic	O
fatty	O
liver	O
disease	O
,	O
and	O
metabolic	O
syndrome	O
[	O
28	O
]	O
.	O
As	O
reported	O
by	O
Nigro	O
et	O
al	O
.	O
,	O
serum	O
adiponectin	O
levels	O
are	O
reduced	O
in	O
obese	O
and	O
diabetic	O
subjects	O
and	O
are	O
considered	O
as	O
a	O
marker	O
of	O
various	O
metabolic	O
diseases	O
,	O
as	O
well	O
as	O
of	O
improvement	O
of	O
metabolic	O
activity	O
[	O
29	O
]	O
.	O
Furthermore	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
show	O
a	O
negative	O
correlation	O
between	O
adiponectin	O
and	O
glycated	O
hemoglobin	O
;	O
these	O
findings	O
,	O
in	O
agreement	O
with	O
Okoro	O
et	O
al	O
.	O
,	O
confirm	O
the	O
strong	O
involvement	O
of	O
adiponectin	O
in	O
metabolic	O
syndrome	O
and	O
in	O
the	O
establishment	O
of	O
type	O
2	O
diabetes	O
[	O
29	O
,	O
30	O
,	O
31	O
]	O
.	O
However	O
,	O
the	O
molecular	O
mechanism	O
underlying	O
the	O
cause	O
-	O
and	O
-	O
effect	O
relationship	O
between	O
hypoadiponectinemia	O
and	O
insulin	O
resistance	O
is	O
not	O
yet	O
fully	O
clear	O
[	O
32	O
]	O
.	O
Indeed	O
,	O
in	B-methodology
vivo	I-methodology
and	O
in	B-methodology
vitro	I-methodology
studies	I-methodology
suggested	O
that	O
adiponectin	O
has	O
an	O
antidiabetic	O
and	O
hypoglycemic	O
effect	O
[	O
33	O
]	O
,	O
activating	O
hepatic	O
insulin	O
receptor	O
and	O
promoting	O
pancreatic	O
beta	O
-	O
cell	O
function	O
[	O
33	O
,	O
34	O
,	O
35	O
]	O
.	O
Data	O
in	O
the	O
literature	O
confirmed	O
that	O
the	O
ketogenic	O
diet	O
is	O
associated	O
with	O
increases	O
in	O
adiponectin	O
in	O
obese	O
subjects	O
[	O
31	O
,	O
35	O
]	O
.	O
Sherrier	O
et	O
al	O
.	O
hypothesized	O
that	O
the	O
level	O
of	O
nutritional	O
ketosis	O
may	O
be	O
an	O
important	O
factor	O
in	O
the	O
regulation	O
of	O
adiponectin	O
expression	O
,	O
since	O
ketones	O
influence	O
AMPK	O
activity	O
through	O
adiponectin	O
[	O
36	O
]	O
.	O
Furthermore	O
,	O
it	O
is	O
worth	O
mentioning	O
that	O
adipose	O
tissue	O
is	O
the	O
target	O
of	O
many	O
metabolically	O
active	O
factors	O
,	O
many	O
of	O
which	O
induce	O
the	O
secretion	O
of	O
adiponectin	O
.	O
[	O
36	O
]	O
.	O

On	O
the	O
contrary	O
,	O
Garaulet	O
et	O
al	O
.	O
reported	O
that	O
adiponectin	O
is	O
related	O
to	O
protection	O
against	O
the	O
metabolic	O
syndrome	O
but	O
is	O
not	O
involved	O
in	O
the	O
regulation	O
of	O
VLCD	O
-	O
induced	O
improvement	O
of	O
insulin	O
sensitivity	O
[	O
37	O
]	O
.	O
In	O
a	O
chronic	O
inflammatory	O
state	O
,	O
such	O
as	O
obesity	O
,	O
the	O
physiologic	O
status	O
of	O
the	O
cells	O
presents	O
changes	O
in	O
adipose	O
tissue	O
altering	O
the	O
production	O
of	O
adipokines	O
[	O
35	O
]	O
.	O
In	O
this	O
scenario	O
,	O
another	O
essential	O
function	O
of	O
adiponectin	O
and	O
its	O
HMW	O
oligomers	O
is	O
their	O
role	O
in	O
inflammatory	O
and	O
immune	O
responses	O
.	O
We	O
found	O
a	O
negative	O
correlation	O
between	O
adiponectin	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
TNF	O
-	O
α	O
;	O
in	O
fact	O
,	O
adiponectin	O
is	O
able	O
to	O
suppress	O
nucleus	O
NF	O
-	O
κB	O
translocation	O
and	O
pro	O
-	O
inflammatory	O
cytokine	O
expression	O
,	O
including	O
TNF	O
-	O
α	O
,	O
IL	O
-	O
1b	O
,	O
and	O
IL	O
-	O
6	O
[	O
38	O
,	O
39	O
,	O
40	O
]	O
.	O
In	O
addition	O
,	O
as	O
we	O
demonstrated	O
,	O
adiponectin	O
positively	O
correlates	O
with	O
IL	O
-	O
10	O
serum	O
levels	O
;	O
in	O
fact	O
,	O
it	O
increases	O
the	O
expression	O
of	O
anti	O
-	O
inflammatory	O
mediators	O
,	O
such	O
as	O
IL	O
-	O
10	O
,	O
and	O
induces	O
the	O
polarization	O
of	O
anti	O
-	O
inflammatory	O
M2	O
macrophages	O
[	O
41	O
,	O
42	O
]	O
.	O
Furthermore	O
,	O
adiponectin	O
enhances	O
cold	O
-	O
induced	O
browning	O
of	O
subcutaneous	O
adipose	O
tissue	O
through	O
M2	O
macrophage	O
proliferation	O
and	O
promotes	O
cell	O
proliferation	O
via	O
the	O
activation	O
of	O
serine	O
/	O
threonine	O
-	O
specific	O
protein	O
kinase	O
Akt	O
,	O
consequently	O
leading	O
to	O
beige	O
cell	O
activation	O
[	O
43	O
,	O
44	O
,	O
45	O
]	O
.	O
Moreover	O
,	O
Tsuchida	O
et	O
al	O
.	O
suggested	O
that	O
adiponectin	O
,	O
through	O
innate	O
immune	O
response	O
-	O
dependent	O
mechanisms	O
,	O
can	O
regulate	O
insulin	O
sensitivity	O
and	O
energy	O
expenditure	O
.	O
On	O
the	O
other	O
hand	O
,	O
adiponectin	O
and	O
its	O
HMW	O
oligomers	O
are	O
strongly	O
involved	O
not	O
only	O
in	O
metabolic	O
processes	O
but	O
also	O
in	O
inflammatory	O
and	O
immune	O
responses	O
[	O
45	O
]	O
.	O

In	O
light	O
of	O
this	O
evidence	O
,	O
the	O
negative	O
correlations	O
that	O
we	O
found	O
between	O
adiponectin	O
and	O
lipid	O
profile	O
,	O
VAT	O
,	O
CPR	O
,	O
and	O
TNF	O
-	O
α	O
confirmed	O
the	O
profound	O
involvement	O
of	O
adiponectin	O
in	O
many	O
metabolic	O
and	O
inflammatory	O
diseases	O
and	O
,	O
in	O
parallel	O
,	O
also	O
confirmed	O
the	O
beneficial	O
short	O
-	O
term	O
effects	O
of	O
VLCKD	O
intervention	O
not	O
only	O
in	O
the	O
treatment	O
of	O
obesity	O
but	O
also	O
in	O
the	O
establishment	O
of	O
obesity	O
-	O
correlated	O
diseases	O
.	O
Indeed	O
,	O
for	O
its	O
anti	O
-	O
inflammatory	O
properties	O
,	O
the	O
ketogenic	O
diet	O
is	O
used	O
as	O
an	O
adjuvant	O
treatment	O
in	O
the	O
cancer	O
therapy	O
.	O
As	O
suggested	O
by	O
Weber	O
et	O
al	O
.	O
,	O
a	O
ketogenic	O
diet	O
creates	O
an	O
unfavorable	O
metabolic	O
environment	O
for	O
cancer	O
cells	O
and	O
,	O
thus	O
,	O
can	O
be	O
regarded	O
as	O
a	O
promising	O
adjuvant	O
as	O
a	O
patient	O
-	O
specific	O
multifactorial	O
therapy	O
[	O
15	O
]	O
.	O
The	O
main	O
limitation	O
of	O
this	O
study	O
is	O
related	O
to	O
the	O
small	O
number	O
of	O
participants	O
;	O
contrariwise	O
,	O
the	O
short	O
time	O
of	O
the	O
observation	O
period	O
can	O
represent	O
a	O
strong	O
point	O
of	O
the	O
study	O
.	O
Indeed	O
,	O
the	O
short	O
period	O
of	O
VLCKD	O
intervention	O
has	O
beneficial	O
effects	O
not	O
only	O
on	O
metabolic	O
rate	O
but	O
also	O
on	O
the	O
inflammatory	O
state	O
,	O
improving	O
adiponectin	O
and	O
IL	O
-	O
10	O
levels	O
,	O
as	O
well	O
as	O
reducing	O
both	O
TNF	O
-	O
α	O
and	O
IL	O
-	O
6	O
levels	O
.	O
Twenty	O
obese	O
subjects	O
(	O
10	O
females	O
,	O
10	O
males	O
)	O
,	O
aged	O
between	O
20	O
and	O
60	O
years	O
(	O
mean	O
48	O
±	O
10	O
years	O
)	O
,	O
were	O
enrolled	O
.	O
The	O
study	O
took	O
place	O
at	O
the	O
Laboratory	O
of	O
Physiology	O
,	O
Department	O
of	O
Clinical	O
and	O
Experimental	O
Medicine	O
,	O
University	O
of	O
Foggia	O
.	O
This	O
study	O
was	O
performed	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
approved	O
by	O
the	O
local	O
ethics	O
committee	O
on	O
22	O
May	O
2018	O
,	O
n°440	O
/	O
DS	O
.	O
According	O
to	O
the	O
current	O
legislation	O
in	O
Italy	O
,	O
informed	O
consent	O
was	O
signed	O
by	O
all	O
participants	O
,	O
who	O
were	O
free	O
to	O
leave	O
the	O
study	O
at	O
any	O
moment	O
.	O
Exclusion	B-methodology
criteria	I-methodology
were	O
as	O
follows	O
:	O
medical	O
history	O
positive	O
for	O
renal	O
insufficiency	O
,	O
hyperuricemia	O
,	O
severe	O
hepatic	O
insufficiency	O
,	O
type	O
1	O
–	O
2	O
diabetes	O
mellitus	O
treated	O
with	O
insulin	O
,	O
atrioventricular	O
block	O
,	O
heart	O
failure	O
,	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
,	O
unbalanced	O
hypokalemia	O
,	O
hypo	O
-	O
hyperthyroidism	O
,	O
chronic	O
treatment	O
with	O
corticosteroid	O
drugs	O
,	O
severe	O
mental	O
disorders	O
,	O
neoplasms	O
,	O
pregnancy	O
,	O
and	O
lactation	O
.	O

All	O
participants	O
were	O
highly	O
motivated	O
and	O
none	O
of	O
them	O
had	O
any	O
previous	O
experience	O
with	O
low	O
-	O
carbohydrate	O
or	O
ketogenic	O
diets	O
.	O
As	O
previously	O
reported	O
,	O
all	O
participants	O
underwent	O
a	O
general	O
medical	O
examination	O
.	O
We	O
recorded	O
age	O
,	O
height	O
,	O
weight	O
,	O
blood	O
pressure	O
,	O
and	O
laboratory	O
tests	O
,	O
at	O
baseline	O
and	O
after	O
eight	O
weeks	O
[	O
46	O
,	O
47	O
]	O
.	O
During	O
the	O
study	O
,	O
dietary	O
adherence	O
was	O
measured	O
daily	O
,	O
between	O
2	O
:	O
00	O
and	O
4	O
:	O
00	O
p	O
.	O
m	O
.	O
,	O
by	O
capillary	O
blood	O
ketone	O
assessment	O
,	O
(	O
GD40	O
Delta	O
test	O
strips	O
,	O
TaiDoc	O
Technology	O
Co	O
.	O
,	O
Taiwan	O
)	O
.	O
Nutritional	O
ketosis	O
was	O
defined	O
as	O
a	O
blood	O
ketone	O
(	O
b	O
-	O
hydroxybutyrate	O
)	O
level	O
>	O
0	O
.	O
5	O
mmol	O
/	O
L	O
.	O
Body	O
weight	O
was	O
recorded	O
at	O
the	O
same	O
time	O
of	O
the	O
day	O
,	O
to	O
the	O
nearest	O
0	O
.	O
1	O
kg	O
(	O
SECA	O
711	O
,	O
Hamburg	O
,	O
Germany	O
)	O
with	O
the	O
participants	O
wearing	O
light	O
clothing	O
,	O
and	O
height	O
was	O
recorded	O
to	O
the	O
nearest	O
0	O
.	O
1	O
cm	O
(	O
SECA	O
213	O
,	O
Hamburg	O
,	O
Germany	O
)	O
.	O
Fasting	O
(	O
12	O
h	O
)	O
blood	O
samples	O
were	O
collected	O
at	O
8	O
:	O
00	O
a	O
.	O
m	O
.	O
,	O
and	O
blood	O
samples	O
were	O
centrifuged	O
with	O
the	O
resultant	O
serum	O
stored	O
at	O
−80	O
°C	O
until	O
use	O
[	O
47	O
]	O
.	O
Height	O
,	O
weight	O
,	O
BMI	O
,	O
and	O
waist	O
circumference	O
of	O
the	O
20	O
obese	O
participants	O
were	O
recorded	O
.	O
Body	O
weight	O
was	O
measured	O
in	O
a	O
fasting	O
state	O
in	O
the	O
morning	O
with	O
a	O
mechanical	O
balance	O
(	O
±0	O
.	O
1	O
kg	O
,	O
SECA	O
700	O
,	O
Hamburg	O
,	O
Germany	O
)	O
.	O
BMI	O
was	O
calculated	O
as	O
body	O
weight	O
divided	O
by	O
height	O
squared	O
(	O
kg	O
/	O
m2	O
)	O
with	O
categories	O
in	O
accordance	O
with	O
the	O
World	O
Health	O
Organization	O
guidelines	B-methodology
.	O
To	O
define	O
participants	O
with	O
alterations	O
in	O
BMI	O
and	O
circumferences	O
,	O
the	O
reference	O
intervals	O
normalized	O
to	O
the	O
age	O
of	O
each	O
participant	O
were	O
applied	O
[	O
47	O
]	O
.	O
Body	O
composition	O
was	O
estimated	O
by	O
DXA	O
(	O
Lunar	O
Prodigy	O
DXA	O
,	O
GE	O
Healthcare	O
,	O
USA	O
)	O
,	O
via	O
whole	O
-	O
body	O
scan	O
.	O
VAT	O
was	O
quantified	O
by	O
subtracting	O
subcutaneous	O
fat	O
from	O
total	O
abdominal	O
fat	O
,	O
reported	O
in	O
grams	O
,	O
using	O
the	O
CoreScan	O
software	O
(	O
GE	O
Healthcare	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
[	O
48	O
]	O
.	O

Blood	O
human	O
samples	O
were	O
taken	O
after	O
obtaining	O
the	O
informed	O
consent	O
from	O
the	O
patients	O
or	O
control	O
subjects	O
in	O
accordance	O
with	O
the	O
tenets	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
.	O
The	O
samples	O
were	O
collected	O
after	O
an	O
overnight	O
fast	O
(	O
12	O
h	O
)	O
,	O
and	O
serum	O
samples	O
were	O
collected	O
.	O
Serum	O
albumin	O
,	O
insulin	O
,	O
C	O
-	O
reactive	O
protein	O
,	O
glucose	O
,	O
total	O
cholesterol	O
,	O
HDL	O
and	O
LDL	O
cholesterol	O
,	O
and	O
triglycerides	O
were	O
measured	O
.	O
Concentrations	O
of	O
total	O
adiponectin	O
in	O
serum	O
were	O
measured	O
via	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
using	O
a	O
commercial	O
kit	O
(	O
Elabscience	O
,	O
Houston	O
,	O
Texas	O
,	O
USA	O
)	O
.	O
Furthermore	O
,	O
we	O
analyzed	O
TNF	O
-	O
α	O
,	O
IL	O
-	O
10	O
,	O
and	O
IL	O
-	O
6	O
serum	O
levels	O
via	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
using	O
a	O
commercial	O
kit	O
(	O
BD	O
Opt	O
EIA	O
for	O
human	O
TNF	O
-	O
α	O
,	O
IL	O
-	O
10	O
,	O
IL	O
-	O
6	O
)	O
.	O
All	O
ELISA	O
tests	O
were	O
performed	O
in	O
triplicate	O
,	O
and	O
the	O
protocols	O
followed	O
were	O
according	O
to	O
the	O
manufacturers	O
’	O
instructions	O
.	O
Serum	O
samples	O
from	O
all	O
participants	O
were	O
quantified	O
for	O
total	O
proteins	O
by	O
the	O
Bradford	O
assay	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
)	O
,	O
and	O
10	O
μg	O
of	O
total	O
protein	O
was	O
heated	O
in	O
1×	O
Laemmli	O
buffer	O
at	O
95	O
°C	O
for	O
10	O
min	O
and	O
loaded	O
onto	O
10	O
%	O
SDS	O
-	O
PAGE	O
gels	O
as	O
previously	O
described	O
[	O
49	O
]	O
.	O
The	O
immunoblots	O
were	O
developed	O
by	O
ECL	O
(	O
Amersham	O
Biosciences	O
,	O
Piscataway	O
,	O
NJ	O
,	O
USA	O
)	O
with	O
the	O
use	O
of	O
Kodak	O
BioMax	O
Light	O
film	O
,	O
digitalized	O
with	O
a	O
scanner	O
(	O
1200	O
dpi	O
)	O
,	O
and	O
analyzed	O
by	O
densitometry	O
with	O
ImageJ	O
software	O
(	O
https	O
:	O
/	O
/	O
imagej	O
.	O
nih	O
.	O
gov	O
/	O
ij	O
/	O
)	O
.	O
Each	O
sample	O
was	O
tested	O
three	O
times	O
in	O
duplicate	O
.	O
The	O
participants	O
followed	O
the	O
VLCKD	O
according	O
to	O
a	O
commercial	O
weight	O
loss	O
program	O
(	O
Lignaform	O
,	O
Therascience	O
,	O
3	O
,	O
rue	O
de	O
l	O
’	O
Industrie	O
,	O
98000	O
Principato	O
di	O
Monaco	O
)	O
,	O
previously	O
reported	O
in	O
our	O
published	O
paper	O
[	O
47	O
]	O
.	O
The	O
characteristics	O
of	O
this	O
diet	O
are	O
reported	O
in	O
Table	O
3	O
.	O

Statistical	O
analyses	O
were	O
performed	O
using	O
the	O
StatView	O
software	O
5	O
.	O
0	O
.	O
1	O
.	O
0	O
(	O
SAS	O
Institute	O
,	O
Cary	O
,	O
NC	O
,	O
USA	O
)	O
.	O
All	O
data	O
are	O
presented	O
as	O
means	O
±	O
SD	O
.	O
A	O
p	O
-	O
value	O
≤0	O
.	O
05	O
was	O
used	O
for	O
statistical	O
significance	O
.	O
Adiponectin	O
,	O
VAT	O
,	O
and	O
CRP	O
serum	O
concentrations	O
were	O
correlated	O
by	O
Pearson	O
’	O
s	O
or	O
Spearman	O
’	O
s	O
rho	O
tests	O
,	O
according	O
to	O
data	O
distribution	O
.	O
A	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
was	O
considered	O
statistically	O
significant	O
.	O
Multiple	O
comparisons	O
on	O
Western	O
blotting	O
ting	O
experiments	O
were	O
performed	O
.	O
We	O
wish	O
to	O
thank	O
the	O
Scientific	O
Bureau	O
of	O
the	O
University	O
of	O
Catania	O
for	O
language	O
support	O
.	O
We	O
wish	O
to	O
thank	O
Antonietta	O
Messina	O
,	O
Ines	O
Villano	O
,	O
Marco	O
Carotenuto	O
,	O
Fiorenzo	O
Moscatelli	O
,	O
Girolamo	O
Di	O
Maio	O
,	O
Aurora	O
Daniele	O
,	O
and	O
Marcellino	O
Monda	O
of	O
University	O
of	O
Campania	O
,	O
Luigi	O
Vanvitelli	O
for	O
their	O
support	O
.	O
Conceptualization	O
,	O
V	O
.	O
M	O
.	O
,	O
R	O
.	O
P	O
.	O
,	O
G	O
.	O
C	O
.	O
(	O
Giuseppe	O
Cibelli	O
)	O
,	O
and	O
G	O
.	O
M	O
.	O
;	O
methodology	O
,	O
V	O
.	O
M	O
.	O
and	O
R	O
.	O
P	O
.	O
;	O
validation	O
,	O
G	O
.	O
C	O
.	O
(	O
Giuseppe	O
Cibelli	O
)	O
and	O
G	O
.	O
M	O
.	O
;	O
formal	O
analysis	O
,	O
A	O
.	O
V	O
.	O
,	O
F	O
.	O
S	O
.	O
,	O
E	O
.	O
N	O
.	O
,	O
A	O
.	O
L	O
.	O
,	O
and	O
A	O
.	O
A	O
.	O
;	O
data	O
curation	O
A	O
.	O
F	O
.	O
and	O
N	O
.	O
D	O
.	O
N	O
.	O
;	O
writing	O
—	O
original	O
draft	O
preparation	O
,	O
V	O
.	O
M	O
.	O
,	O
R	O
.	O
P	O
.	O
,	O
G	O
.	O
C	O
.	O
(	O
Gaetano	O
Corso	O
)	O
,	O
and	O
G	O
.	O
M	O
.	O
;	O
writing	O
—	O
review	O
and	O
editing	O
,	O
G	O
.	O
C	O
.	O
(	O
Giuseppe	O
Cibelli	O
)	O
,	O
and	O
G	O
.	O
M	O
.	O
;	O
visualization	O
,	O
G	O
.	O
C	O
.	O
(	O
Giuseppe	O
Cibelli	O
)	O
and	O
G	O
.	O
M	O
.	O
All	O
authors	O
have	O
read	O
and	O
agreed	O
to	O
the	O
published	O
version	O
of	O
the	O
manuscript	O
.	O
This	O
research	O
was	O
funded	O
by	O
Therascience	O
(	O
Monaco	O
)	O
,	O
free	O
of	O
charge	O
to	O
the	O
participants	O
.	O
The	O
funding	O
source	O
had	O
no	O
involvement	O
in	O
the	O
study	B-methodology
design	I-methodology
,	O
recruitment	O
of	O
participants	O
,	O
study	O
interventions	O
,	O
data	O
collection	O
,	O
or	O
interpretation	O
of	O
the	O
results	O
.	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O

Mediterranean	O
Diet	O
Combined	O
With	O
a	O
Low	O
-	O
Carbohydrate	O
Dietary	O
Pattern	O
in	O
the	O
Treatment	O
of	O
Overweight	O
Polycystic	O
Ovary	O
Syndrome	O
Patients	O
mediterranean	O
diet	O
;	O
low	O
-	O
carbohydrate	O
diet	O
;	O
polycystic	O
ovary	O
syndrome	O
;	O
overweight	O
mediterranean	O
diet	O
;	O
overweight	O
To	O
determine	O
the	O
therapeutic	O
effect	O
of	O
a	O
Mediterranean	O
diet	O
(	O
MED	O
)	O
combined	O
with	O
a	O
low	O
-	O
carbohydrate	O
(	O
LC	O
)	O
dietary	O
model	O
in	O
overweight	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
patients	O
.	O
In	O
this	O
12	O
-	O
week	O
randomized	B-methodology
controlled	I-methodology
clinical	I-methodology
trial	I-methodology
,	O
72	O
overweight	O
patients	O
with	O
PCOS	O
were	O
randomly	B-methodology
assigned	I-methodology
to	O
one	O
of	O
two	O
energy	O
-	O
restricted	O
dietary	O
models	O
:	O
the	O
MED	O
/	O
LC	O
diet	O
or	O
the	O
Low	O
fat	O
(	O
LF	O
)	O
diet	O
.	O
After	O
the	O
intervention	O
,	O
the	O
number	O
of	O
the	O
two	O
groups	O
returned	O
to	O
normal	O
menstruation	O
was	O
counted	O
.	O
Body	O
weight	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
waist	O
circumference	O
,	O
waist	O
-	O
hip	O
ratio	O
(	O
WHR	O
)	O
,	O
body	O
fat	O
percentage	O
(	O
BF	O
%	O
)	O
,	O
serum	O
fasting	O
insulin	O
(	O
FINS	O
)	O
,	O
fasting	O
plasma	O
glucose	O
(	O
FPG	O
)	O
,	O
insulin	O
resistance	O
index	O
(	O
HOMA	O
-	O
IR	O
)	O
,	O
quantitative	O
insulin	O
sensitivity	O
index	O
(	O
QUIKI	O
)	O
,	O
total	O
cholesterol	O
(	O
TC	O
)	O
and	O
high	O
density	O
lipoprotein	O
cholesterol	O
(	O
HDL	O
-	O
C	O
)	O
,	O
low	O
density	O
lipoprotein	O
cholesterol	O
(	O
LDL	O
-	O
C	O
)	O
,	O
triglyceride	O
(	O
TG	O
)	O
,	O
total	O
testosterone	O
(	O
TT	O
)	O
,	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
,	O
follicle	O
-	O
stimulating	O
hormone	O
(	O
FSH	O
)	O
,	O
and	O
prolactin	O
(	O
PRL	O
)	O
were	O
compared	O
between	O
2	O
groups	O
before	O
and	O
after	O
intervention	O
.	O

MED	O
/	O
LC	O
group	O
had	O
more	O
significant	O
reduction	O
trend	O
in	O
weight	O
(	O
−6	O
.	O
10	O
±	O
1	O
.	O
52	O
kg	O
vs	O
−4	O
.	O
79	O
±	O
0	O
.	O
97	O
kg	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
BMI	O
(	O
−2	O
.	O
12	O
±	O
0	O
.	O
57	O
kg	O
/	O
m2	O
vs	O
−1	O
.	O
78	O
±	O
0	O
.	O
36	O
kg	O
/	O
m2	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
WC	O
(	O
−6	O
.	O
12	O
±	O
5	O
.	O
95	O
cm	O
vs	O
−3	O
.	O
90	O
±	O
1	O
.	O
58	O
cm	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
WHR	O
(	O
−0	O
.	O
06	O
±	O
0	O
.	O
02	O
vs	O
−0	O
.	O
03	O
±	O
0	O
.	O
02	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
BF	O
%	O
(	O
−2	O
.	O
97	O
%	O
±	O
1	O
.	O
78	O
%	O
vs	O
−1	O
.	O
19	O
%	O
±	O
0	O
.	O
91	O
%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
TT	O
(	O
−0	O
.	O
20	O
±	O
0	O
.	O
24	O
ng	O
/	O
mL	O
vs	O
0	O
.	O
08	O
±	O
0	O
.	O
11	O
ng	O
/	O
Ml	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
LH	O
(	O
−5	O
.	O
28	O
±	O
3	O
.	O
31	O
mIU	O
/	O
mL	O
vs	O
−3	O
.	O
39	O
±	O
3	O
.	O
64	O
mIU	O
/	O
mL	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
LH	O
/	O
FSH	O
(	O
−1	O
.	O
18	O
±	O
0	O
.	O
75	O
vs	O
-	O
0	O
.	O
66	O
±	O
1	O
.	O
05	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
compared	O
with	O
the	O
LF	O
group	O
.	O
In	O
addition	O
,	O
FPG	O
(	O
0	O
.	O
05	O
±	O
0	O
.	O
38	O
mmol	O
/	O
mL	O
vs	O
-	O
0	O
.	O
50	O
±	O
1	O
.	O
01	O
mmol	O
/	O
mL	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
FINS	O
(	O
−4	O
.	O
88	O
±	O
6	O
.	O
11	O
μU	O
/	O
mL	O
vs	O
−8	O
.	O
53	O
±	O
5	O
.	O
61	O
μU	O
/	O
mL	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
HOMA	O
-	O
IR	O
index	O
(	O
−1	O
.	O
11	O
±	O
1	O
.	O
51	O
vs	O
−2	O
.	O
23	O
±	O
0	O
.	O
25	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
QUIKI	O
index	O
(	O
0	O
.	O
014	O
±	O
0	O
.	O
016	O
vs	O
0	O
.	O
028	O
±	O
0	O
.	O
019	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
decreased	O
significantly	O
in	O
the	O
MED	O
/	O
LC	O
group	O
compared	O
with	O
the	O
LF	O
group	O
.	O

Comparing	O
the	O
changes	O
in	O
lipid	O
parameters	O
between	O
the	O
two	O
groups	O
(	O
LF	O
vs	O
MED	O
/	O
LC	O
)	O
,	O
significant	O
differences	O
in	O
TG	O
(	O
−0	O
.	O
33	O
±	O
0	O
.	O
32	O
mmol	O
vs	O
−0	O
.	O
76	O
±	O
0	O
.	O
97	O
mmol	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
TC	O
(	O
−0	O
.	O
40	O
±	O
1	O
.	O
00	O
mmol	O
vs	O
−1	O
.	O
45	O
±	O
2	O
.	O
00	O
mmol	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
LDL	O
-	O
C	O
(	O
−0	O
.	O
41	O
±	O
1	O
.	O
05	O
mmol	O
vs	O
−0	O
.	O
73	O
±	O
0	O
.	O
76	O
mmol	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
observed	O
.	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
MED	O
/	O
LC	O
diet	O
model	O
is	O
a	O
good	O
treatment	O
for	O
overweight	O
PCOS	O
patients	O
,	O
significantly	O
restoring	O
their	O
menstrual	O
cycle	O
,	O
improving	O
their	O
anthropometric	O
parameters	O
and	O
correcting	O
their	O
disturbed	O
endocrine	O
levels	O
,	O
and	O
its	O
overall	O
effectiveness	O
is	O
significantly	O
better	O
than	O
the	O
LF	O
diet	O
model	O
.	O
Therefore	O
,	O
this	O
study	O
recommends	O
that	O
the	O
MED	O
/	O
LC	O
diet	O
model	O
can	O
be	O
used	O
in	O
the	O
clinical	O
treatment	O
of	O
patients	O
with	O
overweight	O
PCOS	O
.	O
Polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
is	O
a	O
common	O
group	O
of	O
endocrine	O
metabolic	O
disorders	O
in	O
women	O
of	O
reproductive	O
age	O
,	O
characterised	O
by	O
polycystic	O
ovarian	O
changes	O
,	O
sporadic	O
ovulation	O
and	O
menstrual	O
disorders	O
(	O
1	O
)	O
.	O
Based	O
on	O
conservative	O
estimates	O
,	O
the	O
prevalence	O
of	O
PCOS	O
in	O
women	O
of	O
reproductive	O
age	O
is	O
6	O
–	O
15	O
%	O
,	O
whereas	O
insulin	O
resistance	O
(	O
IR	O
)	O
is	O
present	O
in	O
50	O
–	O
70	O
%	O
of	O
patients	O
with	O
PCOS	O
,	O
with	O
obese	O
PCOS	O
patients	O
accounting	O
for	O
approximately	O
75	O
%	O
of	O
IR	O
patients	O
(	O
2	O
)	O
.	O
PCOS	O
causes	O
reproductive	O
endocrine	O
disorders	O
in	O
the	O
near	O
term	O
,	O
which	O
can	O
lead	O
to	O
metabolic	O
syndromes	O
in	O
the	O
long	O
term	O
,	O
such	O
as	O
fatty	O
liver	O
,	O
type	O
2	O
diabetes	O
,	O
cardiovascular	O
risk	O
,	O
and	O
increased	O
risk	O
of	O
endometrial	O
cancer	O
(	O
3	O
)	O
.	O
Amongst	O
these	O
disorders	O
,	O
IR	O
is	O
an	O
important	O
mechanism	O
causing	O
abnormal	O
glucolipid	O
metabolism	O
and	O
reproductive	O
dysfunction	O
(	O
4	O
)	O
,	O
whereas	O
obesity	O
increases	O
IR	O
and	O
compensatory	O
hyperinsulinemia	O
(	O
HI	O
)	O
,	O
which	O
in	O
turn	O
increases	O
adipogenesis	O
and	O
decreases	O
lipolysis	O
,	O
promotes	O
ovarian	O
androgen	O
production	O
and	O
exacerbates	O
ovarian	O
androgen	O
hypersecretion	O
disorder	O
,	O
thereby	O
further	O
amplifying	O
reproductive	O
endocrine	O
disorders	O
and	O
metabolic	O
problems	O
in	O
patients	O
with	O
PCOS	O
(	O
5	O
)	O
.	O

Pharmacological	O
treatment	O
;	O
lifestyle	O
management	O
such	O
as	O
diet	O
and	O
exercise	O
and	O
psychological	O
modification	O
have	O
been	O
recommended	O
as	O
the	O
first	O
line	O
of	O
treatment	O
for	O
PCOS	O
at	O
all	O
times	O
(	O
6	O
)	O
,	O
with	O
dietary	O
modification	O
playing	O
an	O
important	O
role	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
PCOS	O
patients	O
.	O
Based	O
on	O
previous	O
reports	O
,	O
the	O
diet	O
of	O
patients	O
with	O
PCOS	O
tends	O
to	O
be	O
high	O
in	O
carbohydrates	O
and	O
fat	O
,	O
which	O
to	O
a	O
certain	O
extent	O
increases	O
the	O
IR	O
and	O
lipid	O
inflammatory	O
environment	O
of	O
patients	O
(	O
7	O
)	O
and	O
promotes	O
the	O
progression	O
of	O
the	O
disease	O
.	O
Therefore	O
,	O
calorie	O
-	O
restricted	O
dietary	O
regimens	O
have	O
been	O
recognised	O
as	O
important	O
dietary	O
options	O
for	O
patients	O
with	O
PCOS	O
(	O
8	O
)	O
,	O
and	O
corresponding	O
studies	O
on	O
the	O
effects	O
of	O
dietary	O
modification	O
on	O
PCOS	O
are	O
found	O
,	O
such	O
as	O
low	O
-	O
fat	O
(	O
LF	O
)	O
diet	O
,	O
low	O
-	O
carbohydrate	O
(	O
LC	O
)	O
diet	O
,	O
top	O
hypertension	O
diet	O
,	O
pulse	O
-	O
based	O
diet	O
,	O
high	O
-	O
protein	O
diet	O
,	O
ketogenic	O
diet	O
and	O
other	O
dietary	O
models	O
(	O
9	O
–	O
11	O
)	O
.	O
At	O
present	O
,	O
considerable	O
research	O
has	O
been	O
conducted	O
to	O
demonstrate	O
that	O
LF	O
diets	O
can	O
effectively	O
reduce	O
central	O
obesity	O
in	O
patients	O
by	O
affecting	O
their	O
insulin	O
levels	O
and	O
lipid	O
metabolism	O
(	O
12	O
,	O
13	O
)	O
.	O
LC	O
diet	O
has	O
also	O
been	O
shown	O
to	O
improve	O
insulin	O
sensitivity	O
and	O
promote	O
normal	O
lipid	O
metabolism	O
(	O
14	O
)	O
,	O
however	O
,	O
effective	O
comparisons	O
of	O
dietary	O
regimens	O
and	O
strategies	O
for	O
optimal	O
dietary	O
combinations	O
are	O
not	O
yet	O
well	O
researched	O
.	O
The	O
Mediterranean	O
diet	O
(	O
MED	O
)	O
model	O
has	O
been	O
studied	O
and	O
discussed	O
in	O
many	O
fields	O
in	O
recent	O
years	O
as	O
a	O
respected	O
dietary	O
structure	O
(	O
15	O
,	O
16	O
)	O
.	O
Its	O
nutritional	O
structure	O
is	O
modelled	O
by	O
emphasising	O
a	O
high	O
intake	O
of	O
vegetables	O
,	O
fruits	O
,	O
fish	O
,	O
seafood	O
,	O
legumes	O
,	O
and	O
nuts	O
,	O
with	O
whole	O
grains	O
generally	O
recommended	O
as	O
staple	O
foods	O
,	O
and	O
cooking	O
with	O
vegetable	O
oils	O
(	O
containing	O
unsaturated	O
fatty	O
acids	O
)	O
instead	O
of	O
animal	O
oils	O
(	O
containing	O
saturated	O
fatty	O
acids	O
)	O
,	O
with	O
olive	O
oil	O
being	O
particularly	O
advocated	O
.	O
This	O
diet	O
is	O
more	O
liberal	O
with	O
regard	O
to	O
fat	O
intake	O
,	O
and	O
cereals	O
have	O
a	O
moderating	O
effect	O
on	O
IR	O
as	O
good	O
-	O
quality	O
carbohydrates	O
(	O
17	O
)	O
.	O

Based	O
on	O
previous	O
studies	O
,	O
the	O
MED	O
model	O
can	O
reduce	O
the	O
secretion	O
of	O
pro	O
-	O
inflammatory	O
adipocytokines	O
by	O
reducing	O
visceral	O
fat	O
,	O
with	O
a	O
diet	O
structure	O
based	O
on	O
plant	O
-	O
based	O
food	O
intake	O
,	O
and	O
phenolic	O
compounds	O
of	O
plant	O
origin	O
can	O
modulate	O
insulin	O
action	O
and	O
metabolism	O
in	O
insulin	O
-	O
sensitive	O
tissues	O
,	O
with	O
potential	O
preventive	O
or	O
therapeutic	O
effects	O
on	O
IR	O
and	O
IR	O
-	O
related	O
diseases	O
.	O
The	O
increased	O
intake	O
of	O
seafood	O
suggested	O
in	O
the	O
protocol	O
can	O
remarkably	O
increase	O
the	O
levels	O
of	O
n	O
-	O
3	O
long	O
-	O
chain	O
polyunsaturated	O
fatty	O
acids	O
in	O
human	O
and	O
the	O
circulating	O
levels	O
of	O
insulin	O
-	O
sensitive	O
hormone	O
lipocalin	O
to	O
a	O
certain	O
extent	O
,	O
and	O
the	O
regular	O
intake	O
of	O
seafood	O
can	O
reduce	O
energy	O
intake	O
by	O
4	O
–	O
9	O
%	O
compared	O
with	O
the	O
regular	O
intake	O
of	O
terrestrial	O
meat	O
,	O
which	O
could	O
be	O
effective	O
in	O
preventing	O
obesity	O
and	O
maintaining	O
energy	O
balance	O
(	O
18	O
,	O
19	O
)	O
.	O
By	O
contrast	O
,	O
the	O
extent	O
to	O
which	O
the	O
MED	O
model	O
is	O
effective	O
has	O
not	O
been	O
supported	O
by	O
additional	O
data	O
in	O
studies	O
of	O
dietary	O
models	O
of	O
PCOS	O
.	O
Thus	O
,	O
this	O
study	O
aimed	O
to	O
combine	O
the	O
MED	O
model	O
with	O
a	O
LC	O
dietary	O
model	O
based	O
on	O
energy	O
restriction	O
,	O
compared	O
with	O
a	O
LF	O
dietary	O
model	O
,	O
investigate	O
whether	O
this	O
novel	O
dietary	O
model	O
could	O
provide	O
significant	O
improvements	O
in	O
reproductive	O
endocrine	O
and	O
metabolic	O
levels	O
in	O
overweight	O
patients	O
with	O
PCOS	O
through	O
a	O
12	O
-	O
week	O
strict	O
dietary	B-methodology
intervention	I-methodology
and	O
provide	O
better	O
supplements	O
and	O
recommendations	O
for	O
the	O
behavioural	O
treatment	O
of	O
PCOS	O
in	O
clinical	B-methodology
practice	I-methodology
.	O
This	O
study	O
is	O
an	O
open	O
-	O
label	O
,	O
parallel	B-methodology
-	I-methodology
group	I-methodology
randomised	I-methodology
controlled	I-methodology
trial	I-methodology
design	O
for	O
a	O
12	O
-	O
week	O
intervention	O
with	O
a	O
4	O
-	O
week	O
follow	O
-	O
up	O
.	O
The	O
study	B-methodology
protocol	I-methodology
was	O
approved	O
by	O
the	O
by	O
the	O
Ethics	O
Committee	O
of	O
Changhai	O
Hospital	O
of	O
PLA	O
Military	O
Medical	O
University	O
.	O
The	O
study	B-methodology
protocol	I-methodology
was	O
in	O
accordance	O
with	O
all	O
the	O
principles	O
of	O
the	O
World	O
Medical	O
Association	O
Declaration	O
of	O
Helsinki	O
.	O
Written	B-methodology
informed	I-methodology
consent	I-methodology
was	O
signed	O
by	O
participants	O
prior	O
to	O
their	O
inclusion	O
in	O
the	O
study	O
.	O
The	O
trial	O
was	O
registered	O
at	O
https	O
:	O
/	O
/	O
ClinicalTrials	O
.	O
gov	O
/	O
,	O
No	O
.	O
CHiECRCT	O
-	O
20160050	O
.	O
Participants	O
had	O
basic	O
information	O
collected	O
through	O
a	O
questionnaire	O
at	O
the	O
beginning	O
of	O
the	O
study	O
,	O
including	O
age	O
,	O
height	O
,	O
weight	O
,	O
medical	O
history	O
,	O
blood	O
pressure	O
,	O
and	O
heart	O
rate	O
.	O

They	O
were	O
randomly	B-methodology
assigned	I-methodology
to	O
one	O
of	O
two	O
calorie	O
-	O
restricted	O
diets	O
throughout	O
the	O
study	O
period	O
:	O
a	O
LF	O
diet	O
or	O
a	O
Mediterranean	O
/	O
low	O
-	O
carbohydrate	O
(	O
MED	O
/	O
LC	O
)	O
diet	O
.	O
Items	O
collected	O
before	O
and	O
after	O
the	O
intervention	O
included	O
fasting	O
weight	O
on	O
the	O
day	O
of	O
collection	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
waist	O
circumference	O
(	O
WC	O
)	O
,	O
hip	O
circumference	O
(	O
HC	O
)	O
,	O
body	O
fat	O
percentage	O
(	O
BF	O
%	O
)	O
,	O
fasting	O
plasma	O
glucose	O
(	O
FPG	O
)	O
,	O
fasting	O
insulin	O
(	O
FINS	O
)	O
,	O
total	O
testosterone	O
(	O
TT	O
)	O
,	O
luteinising	O
hormone	O
(	O
LH	O
)	O
,	O
follicle	O
-	O
stimulating	O
hormone	O
(	O
FSH	O
)	O
,	O
oestradiol	O
(	O
E2	O
)	O
,	O
prolactin	O
(	O
PRL	O
)	O
,	O
progesterone	O
(	O
P	O
)	O
,	O
triglycerides	O
(	O
TG	O
)	O
,	O
total	O
cholesterol	O
(	O
TC	O
)	O
,	O
high	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
HDL	O
-	O
C	O
)	O
,	O
and	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
LDL	O
-	O
C	O
)	O
.	O
The	O
72	O
participants	O
in	O
this	O
study	O
were	O
successively	O
drawn	O
from	O
patients	O
with	O
PCOS	O
,	O
who	O
were	O
attending	O
the	O
Department	O
of	O
Traditional	O
Chinese	O
Medicine	O
and	O
Gynecology	O
at	O
the	O
Changhai	O
Hospital	O
of	O
PLA	O
Military	O
Medical	O
University	O
from	O
2018	O
to	O
2020	O
,	O
with	O
all	O
data	O
collection	O
completed	O
in	O
February	O
2021	O
.	O
The	O
inclusion	B-methodology
criteria	I-methodology
were	O
as	O
follows	O
:	O
(	O
a	O
)	O
diagnosis	O
of	O
PCOS	O
according	O
to	O
the	O
Rotterdam	O
criteria	O
(	O
20	O
)	O
,	O
(	O
b	O
)	O
age	O
16	O
–	O
45	O
years	O
,	O
and	O
(	O
c	O
)	O
BMI	O
consistent	O
with	O
an	O
overweight	O
diagnosis	O
of	O
BMI	O
≥24	O
.	O
0	O
kg	O
/	O
m2	O
.	O

The	O
exclusion	B-methodology
criteria	I-methodology
were	O
as	O
follows	O
:	O
(	O
a	O
)	O
combination	O
of	O
other	O
endocrine	O
etiological	O
disorders	O
(	O
congenital	O
adrenal	O
hyperplasia	O
,	O
Cushing	O
’	O
s	O
syndrome	O
,	O
androgen	O
-	O
secreting	O
tumours	O
,	O
hyperprolactinemia	O
,	O
diabetes	O
mellitus	O
,	O
thyroid	O
,	O
adrenal	O
,	O
and	O
other	O
endocrine	O
disorders	O
)	O
according	O
to	O
the	O
Rotterdam	O
criteria	O
;	O
(	O
b	O
)	O
combination	O
of	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
,	O
haematological	O
disorders	O
,	O
hepatic	O
and	O
renal	O
insufficiency	O
,	O
and	O
other	O
serious	O
diseases	O
;	O
(	O
c	O
)	O
pregnant	O
women	O
,	O
breastfeeding	O
women	O
,	O
and	O
pregnancy	O
preparation	O
or	O
no	O
contraception	O
during	O
the	O
intervention	B-methodology
period	I-methodology
;	O
(	O
d	O
)	O
suffering	O
from	O
mental	O
illness	O
or	O
cancer	O
;	O
and	O
(	O
e	O
)	O
have	O
taken	O
non	O
-	O
progesterone	O
hormonal	O
medication	O
or	O
insulin	O
sensitisers	O
or	O
medication	O
affecting	O
lipid	O
metabolism	O
(	O
fish	O
oil	O
,	O
etc	O
.	O
)	O
within	O
3	O
months	O
.	O
The	O
exclusion	O
and	O
detachment	O
criteria	O
were	O
as	O
follows	O
:	O
(	O
a	O
)	O
poor	O
compliance	O
during	O
the	O
intervention	O
and	O
non	O
-	O
cooperation	O
with	O
treatment	O
and	O
(	O
b	O
)	O
incomplete	O
observation	O
case	O
information	O
.	O
Participant	O
groupings	O
were	O
randomly	B-methodology
assigned	I-methodology
by	O
an	O
associate	O
in	O
the	O
department	O
based	O
on	O
a	O
computer	O
-	O
generated	O
random	O
number	O
table	O
.	O
Both	O
diets	O
aimed	O
at	O
moderate	O
long	O
-	O
term	O
metabolic	O
improvement	O
and	O
restricted	O
the	O
intake	O
of	O
sweets	O
and	O
foods	O
containing	O
trans	O
fatty	O
acids	O
.	O
The	O
participants	O
were	O
divided	O
into	O
two	O
groups	O
,	O
and	O
they	O
joined	O
separate	O
diet	O
management	O
groups	O
,	O
where	O
a	O
professional	O
dietitian	O
recommended	O
7	O
-	O
day	O
recipes	O
.	O
The	O
LF	O
group	O
had	O
less	O
than	O
30	O
%	O
of	O
total	O
dietary	O
calories	O
from	O
fat	O
,	O
less	O
than	O
40	O
g	O
of	O
fat	O
intake	O
throughout	O
the	O
day	O
and	O
up	O
to	O
10	O
%	O
saturated	O
fat	O
(	O
21	O
)	O
.	O
They	O
do	O
not	O
consume	O
fatty	O
foods	O
such	O
as	O
fatty	O
meats	O
,	O
butter	O
,	O
offal	O
,	O
fried	O
foods	O
,	O
preserved	O
foods	O
,	O
poultry	O
skin	O
,	O
fish	O
roe	O
,	O
shrimp	O
roe	O
,	O
and	O
crabmeat	O
,	O
and	O
they	O
increased	O
the	O
intake	O
of	O
cereals	O
,	O
vegetables	O
,	O
and	O
fruits	O
as	O
appropriate	O
(	O
Supplementary	O
Table	O
1	O
)	O
.	O
In	O
the	O
MED	O
/	O
LC	O
group	O
,	O
which	O
is	O
a	O
combination	O
of	O
MED	O
and	O
LC	O
diet	O
,	O
according	O
to	O
the	O
definition	O
of	O
a	O
LC	O
diet	O
(	O
22	O
)	O
,	O
the	O
participants	O
had	O
a	O
maximum	O
carbohydrate	O
intake	O
of	O
less	O
than	O
20	O
%	O
,	O
a	O
maximum	O
carbohydrate	O
intake	O
of	O
100	O
g	O
throughout	O
the	O
day	O
and	O
an	O
increased	O
intake	O
of	O
protein	O
and	O
fat	O
.	O

In	O
combination	O
with	O
the	O
MED	O
group	O
,	O
participants	O
were	O
advised	O
to	O
consume	O
whole	O
grain	O
as	O
a	O
staple	O
food	O
,	O
a	O
high	O
intake	O
of	O
extra	O
virgin	O
olive	O
oil	O
,	O
vegetables	O
(	O
including	O
green	O
leafy	O
vegetables	O
,	O
fruit	O
,	O
cereals	O
,	O
nuts	O
,	O
and	O
legumes	O
)	O
,	O
moderate	O
intake	O
of	O
fish	O
and	O
other	O
meat	O
,	O
dairy	O
products	O
,	O
and	O
a	O
low	O
intake	O
of	O
eggs	O
(	O
23	O
)	O
(	O
Supplementary	O
Table	O
2	O
)	O
.	O
The	O
average	O
daily	O
total	O
calorie	O
baseline	O
was	O
maintained	O
for	O
both	O
dietary	O
groups	O
.	O
Participants	O
were	O
provided	O
with	O
a	O
daily	O
food	O
recommendation	O
every	O
7	O
days	O
via	O
the	O
Chinese	O
social	O
networking	O
software	O
WeChat	O
and	O
were	O
instructed	O
to	O
record	O
their	O
daily	O
food	O
intake	O
from	O
the	O
beginning	O
to	O
the	O
end	O
of	O
the	O
dietary	B-methodology
intervention	I-methodology
period	O
using	O
the	O
Chinese	O
dietary	O
app	O
Boohee	O
software	O
to	O
calculate	O
the	O
corresponding	O
calories	O
.	O
Participants	O
were	O
asked	O
to	O
perform	O
only	O
daily	O
basal	O
activity	O
during	O
the	O
intervention	B-methodology
period	I-methodology
and	O
were	O
prohibited	O
from	O
taking	O
any	O
other	O
nutritional	O
supplements	O
.	O
Participants	O
were	O
contacted	O
via	O
WeChat	O
at	O
the	O
end	O
of	O
each	O
week	O
to	O
review	O
the	O
programme	O
,	O
monitor	O
for	O
adverse	O
events	O
and	O
provide	O
counselling	O
support	O
to	O
facilitate	O
the	O
effectiveness	O
of	O
the	O
intervention	O
.	O
All	O
outcome	O
assessments	O
were	O
performed	O
at	O
week	O
12	O
,	O
and	O
data	O
were	O
collected	O
when	O
normal	O
menstrual	O
cycles	O
returned	O
.	O
The	O
height	O
of	O
each	O
participant	O
was	O
measured	O
using	O
an	O
ultrasonic	O
height	O
-	O
measuring	O
device	O
with	O
an	O
accuracy	O
of	O
1	O
cm	O
(	O
BXT	O
-	O
15A	O
,	O
BAXIT	O
,	O
Germany	O
)	O
,	O
and	O
the	O
weight	O
and	O
BF	O
%	O
were	O
measured	O
using	O
a	O
body	O
composition	O
analyser	O
with	O
an	O
accuracy	O
of	O
0	O
.	O
1	O
kg	O
(	O
T6100A	O
,	O
TEZEWA	O
,	O
United	O
States	O
)	O
.	O
In	O
addition	O
,	O
the	O
BMI	O
was	O
automatically	O
read	O
by	O
an	O
app	O
connected	O
to	O
the	O
instrument	O
(	O
kg	O
/	O
m2	O
)	O
.	O
WC	O
and	O
HC	O
were	O
measured	O
by	O
a	O
fixed	O
researcher	O
using	O
a	O
soft	O
ruler	O
with	O
an	O
accuracy	O
of	O
1	O
mm	O
.	O
WC	O
was	O
measured	O
as	O
the	O
midpoint	O
of	O
the	O
line	O
between	O
the	O
lowest	O
point	O
of	O
the	O
rib	O
and	O
the	O
upper	O
edge	O
of	O
the	O
iliac	O
crest	O
,	O
and	O
HC	O
was	O
measured	O
as	O
the	O
horizontal	O
circumference	O
of	O
the	O
most	O
prominent	O
part	O
of	O
the	O
hip	O
towards	O
the	O
back	O
.	O
The	O
waist	O
-	O
to	O
-	O
hip	O
ratio	O
(	O
WHR	O
)	O
was	O
calculated	O
as	O
WC	O
(	O
cm	O
)	O
/	O
HC	O
(	O
cm	O
)	O
.	O
Fasting	O
blood	O
samples	O
were	O
obtained	O
in	O
the	O
morning	O
at	O
2	O
–	O
5	O
days	O
of	O
the	O
menstrual	O
cycle	O
(	O
or	O
progesterone	O
withdrawal	O
bleeding	O
)	O
from	O
the	O
median	O
cubital	O
vein	O
,	O
and	O
the	O
hormonal	O
and	O
glucose	O
parameters	O
were	O
detected	O
.	O

Blood	O
samples	O
were	O
collected	O
in	O
BD	O
vacutainers	O
tubes	O
(	O
SSTTM	O
II	O
Advance	O
,	O
REF	O
367958	O
)	O
and	O
centrifuged	O
at	O
3	O
,	O
500	O
rpm	O
for	O
15	O
min	O
at	O
4°C	O
,	O
and	O
then	O
serum	O
and	O
plasma	O
were	O
frozen	O
at	O
−80°C	O
.	O
FINS	O
,	O
FSH	O
,	O
LH	O
,	O
E2	O
,	O
TT	O
,	O
PRL	O
,	O
and	O
P	O
were	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
Elisa	O
Kit	O
,	O
CUSABIO	O
,	O
Wuhan	O
,	O
China	O
)	O
.	O
FPG	O
,	O
TC	O
,	O
TG	O
,	O
HDL	O
-	O
C	O
,	O
and	O
LDL	O
-	O
C	O
were	O
measured	O
by	O
coupled	O
enzyme	O
assay	O
(	O
Sigma	O
,	O
United	O
States	O
)	O
.	O
The	O
HOMA	O
-	O
IR	O
index	O
was	O
calculated	O
as	O
FINS	O
(	O
μU	O
/	O
mL	O
)	O
×FPG	O
(	O
mmol	O
/	O
L	O
)	O
/	O
22	O
.	O
5	O
,	O
and	O
the	O
QUIKI	O
index	O
was	O
calculated	O
as	O
1	O
/	O
(	O
log	O
(	O
FINS	O
(	O
μU	O
/	O
mL	O
)	O
)	O
+	O
log	O
(	O
FPG	O
(	O
mg	O
/	O
dL	O
)	O
)	O
)	O
.	O
The	O
Shapiro	O
–	O
Wilk	O
test	O
was	O
used	O
to	O
test	O
whether	O
the	O
data	O
conformed	O
to	O
a	O
normal	O
distribution	O
.	O
Data	O
that	O
conformed	O
to	O
a	O
normal	O
distribution	O
were	O
expressed	O
as	O
mean	O
±	O
standard	O
deviation	O
(	O
mean	O
±	O
SD	O
)	O
,	O
and	O
data	O
before	O
and	O
after	O
the	O
intervention	O
were	O
counted	O
using	O
paired	O
t	O
-	O
tests	O
and	O
between	O
two	O
groups	O
using	O
independent	O
sample	O
t	O
-	O
tests	O
.	O
Data	O
that	O
did	O
not	O
conform	O
to	O
a	O
normal	O
distribution	O
were	O
presented	O
as	O
median	O
(	O
25th	O
–	O
75th	O
percentile	O
)	O
and	O
analysed	O
using	O
the	O
Mann	O
–	O
Whitney	O
U	O
test	O
to	O
compare	O
the	O
parameters	O
before	O
and	O
after	O
12	O
weeks	O
.	O
All	O
data	O
analyses	O
were	O
performed	O
using	O
SPSS	O
,	O
version	O
26	O
(	O
SPSS	O
Inc	O
.	O
,	O
Chicago	O
,	O
IL	O
,	O
United	O
States	O
)	O
.	O
All	O
data	O
graphs	O
were	O
produced	O
and	O
analysed	O
using	O
GraphPad	O
Prism	O
(	O
version	O
9	O
.	O
0	O
.	O
0	O
)	O
.	O
Differences	O
were	O
considered	O
statistically	O
significant	O
when	O
P	O
<	O
0	O
.	O
05	O
.	O
For	O
the	O
treatment	O
of	O
missing	O
values	O
,	O
these	O
values	O
were	O
not	O
included	O
in	O
this	O
analysis	O
.	O
Figure	O
1	O
shows	O
a	O
flow	O
chart	O
of	O
participants	O
’	O
progress	O
through	O
the	O
various	O
stages	O
of	O
the	O
study	O
.	O
We	O
recruited	O
a	O
total	O
of	O
104	O
patients	O
,	O
of	O
whom	O
16	O
were	O
taking	O
hormone	O
medication	O
five	O
had	O
abnormal	O
liver	O
function	O
,	O
two	O
were	O
on	O
insulin	O
sensitisers	O
,	O
six	O
were	O
preparing	O
for	O
pregnancy	O
and	O
three	O
were	O
resistant	O
to	O
diet	O
modification	O
.	O

We	O
included	O
72	O
patients	O
in	O
the	O
study	O
programme	O
,	O
of	O
which	O
some	O
patients	O
in	O
both	O
groups	O
did	O
not	O
complete	O
the	O
study	O
cycle	O
because	O
they	O
were	O
unable	O
to	O
adhere	O
to	O
the	O
diet	O
programme	O
or	O
for	O
personal	O
reasons	O
(	O
change	O
of	O
pregnancy	O
plans	O
or	O
outright	O
discontinuation	O
of	O
the	O
study	O
programme	O
)	O
,	O
resulting	O
in	O
29	O
final	O
completers	O
in	O
the	O
LF	O
diet	O
group	O
and	O
30	O
final	O
completers	O
in	O
the	O
MED	O
/	O
LC	O
diet	O
group	O
.	O
No	O
side	O
effects	O
were	O
observed	O
during	O
the	O
dietary	B-methodology
intervention	I-methodology
in	O
patients	O
with	O
PCOS	O
throughout	O
the	O
study	O
.	O
Based	O
on	O
the	O
initial	O
randomisation	O
,	O
no	O
differences	O
were	O
observed	O
between	O
the	O
LF	O
and	O
MED	O
/	O
LC	O
groups	O
at	O
baseline	O
with	O
regard	O
to	O
age	O
,	O
anthropometrics	O
,	O
sex	O
hormone	O
levels	O
,	O
and	O
blood	O
biochemistry	O
(	O
Table	O
1	O
)	O
.	O
Differences	O
in	O
total	O
nutrient	O
intake	O
were	O
calculated	O
on	O
three	O
randomly	O
selected	O
days	O
based	O
on	O
participants	O
’	O
dietary	O
records	O
throughout	O
the	O
intervention	O
(	O
Figure	O
2	O
)	O
.	O
No	O
statistically	O
significant	O
differences	O
were	O
found	O
between	O
the	O
two	O
groups	O
with	O
regard	O
to	O
total	O
energy	O
and	O
cholesterol	O
intake	O
.	O
The	O
MED	O
/	O
LC	O
group	O
had	O
a	O
relatively	O
lower	O
carbohydrate	O
intake	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
a	O
relatively	O
higher	O
total	O
protein	O
and	O
fat	O
intake	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
a	O
significant	O
difference	O
in	O
saturated	O
fatty	O
acid	O
intake	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
compared	O
with	O
the	O
LF	O
group	O
(	O
Table	O
2	O
)	O
.	O
At	O
the	O
end	O
of	O
the	O
study	O
,	O
the	O
number	O
of	O
patients	O
who	O
returned	O
to	O
normal	O
menstruation	O
in	O
the	O
two	O
groups	O
was	O
counted	O
.	O
72	O
.	O
4	O
%	O
(	O
21	O
/	O
29	O
)	O
of	O
patients	O
in	O
the	O
LF	O
group	O
returned	O
to	O
normal	O
menstrual	O
cycles	O
,	O
whereas	O
86	O
.	O
7	O
%	O
(	O
26	O
/	O
30	O
)	O
of	O
patients	O
in	O
the	O
MED	O
/	O
LC	O
group	O
returned	O
to	O
normal	O
menstrual	O
cycles	O
,	O
with	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
(	O
P	O
=	O
0	O
.	O
174	O
>	O
0	O
.	O
05	O
)	O
.	O
Combining	O
the	O
data	O
before	O
and	O
after	O
the	O
dietary	B-methodology
intervention	I-methodology
in	O
both	O
groups	O
,	O
a	O
decrease	O
in	O
weight	O
,	O
BMI	O
,	O
WC	O
,	O
WHR	O
,	O
and	O
BF	O
%	O
in	O
both	O
groups	O
was	O
observed	O
,	O
with	O
statistically	O
significant	O
differences	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
001	O
;	O
Table	O
3	O
)	O
,	O
indicating	O
that	O
both	O
interventions	O
had	O
effective	O
management	O
effects	O
.	O

Figure	O
3	O
shows	O
the	O
data	O
before	O
and	O
after	O
the	O
two	O
groups	O
showed	O
that	O
the	O
MED	O
/	O
LC	O
group	O
had	O
more	O
significant	O
reduction	O
trend	O
in	O
weight	O
(	O
−6	O
.	O
10	O
±	O
1	O
.	O
52	O
kg	O
vs	O
−4	O
.	O
79	O
±	O
0	O
.	O
97	O
kg	O
)	O
,	O
BMI	O
(	O
−2	O
.	O
12	O
±	O
0	O
.	O
57	O
kg	O
/	O
m2	O
vs	O
−1	O
.	O
78	O
±	O
0	O
.	O
36	O
kg	O
/	O
m2	O
)	O
,	O
WC	O
(	O
−6	O
.	O
12	O
±	O
5	O
.	O
95	O
cm	O
vs	O
−3	O
.	O
90	O
±	O
1	O
.	O
58	O
cm	O
)	O
,	O
WHR	O
(	O
−0	O
.	O
06	O
±	O
0	O
.	O
02	O
vs	O
−0	O
.	O
03	O
±	O
0	O
.	O
02	O
)	O
,	O
and	O
BF	O
%	O
(	O
−2	O
.	O
97	O
%	O
±	O
1	O
.	O
78	O
%	O
vs	O
.	O
−1	O
.	O
19	O
%	O
±	O
0	O
.	O
91	O
%	O
)	O
compared	O
with	O
the	O
LF	O
group	O
.	O
With	O
regard	O
to	O
sex	O
hormones	O
(	O
Table	O
4	O
)	O
,	O
significant	O
changes	O
in	O
TT	O
,	O
LH	O
,	O
and	O
LH	O
/	O
FSH	O
were	O
observed	O
before	O
and	O
after	O
the	O
dietary	B-methodology
intervention	I-methodology
in	O
both	O
groups	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
whereas	O
FSH	O
and	O
PRL	O
were	O
basically	O
unchanged	O
compared	O
with	O
baseline	O
values	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O
As	O
shown	O
in	O
Figure	O
4	O
,	O
the	O
trend	O
of	O
hormonal	O
changes	O
in	O
the	O
two	O
groups	O
was	O
compared	O
,	O
and	O
a	O
decrease	O
in	O
TT	O
(	O
−0	O
.	O
20	O
±	O
0	O
.	O
24	O
ng	O
/	O
mL	O
vs	O
.	O
0	O
.	O
08	O
±	O
0	O
.	O
11	O
ng	O
/	O
mL	O
)	O
was	O
found	O
in	O
the	O
MED	O
/	O
LC	O
group	O
compared	O
with	O
the	O
LF	O
group	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
In	O
addition	O
,	O
a	O
decrease	O
in	O
LH	O
(	O
−5	O
.	O
28	O
±	O
3	O
.	O
31	O
mIU	O
/	O
mL	O
vs	O
.	O
−3	O
.	O
39	O
±	O
3	O
.	O
64	O
mIU	O
/	O
mL	O
)	O
and	O
LH	O
/	O
FSH	O
(	O
−1	O
.	O
18	O
±	O
0	O
.	O
75	O
vs	O
−0	O
.	O
66	O
±	O
1	O
.	O
05	O
)	O
was	O
found	O
,	O
and	O
the	O
differences	O
were	O
statistically	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
However	O
,	O
the	O
change	O
in	O
PRL	O
between	O
the	O
two	O
groups	O
was	O
not	O
statistically	O
significant	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O
After	O
the	O
intervention	O
in	O
both	O
groups	O
(	O
Table	O
5	O
)	O
,	O
FINS	O
,	O
HOMA	O
-	O
IR	O
index	O
,	O
QUIKI	O
index	O
and	O
lipid	O
parameters	O
,	O
including	O
TG	O
,	O
TC	O
,	O
and	O
LDL	O
-	O
C	O
,	O
decreased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
HDL	O
-	O
C	O
levels	O
did	O
not	O
change	O
significantly	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
reduction	O
in	O
blood	O
glucose	O
in	O
the	O
MED	O
/	O
LC	O
group	O
after	O
the	O
intervention	O
was	O
statistically	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
In	O
the	O
MED	O
/	O
LC	O
group	O
,	O
FPG	O
(	O
0	O
.	O
05	O
±	O
0	O
.	O
38	O
mmol	O
/	O
mL	O
vs	O
-	O
0	O
.	O
50	O
±	O
1	O
.	O
01	O
mmol	O
/	O
mL	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
FINS	O
(	O
−4	O
.	O
88	O
±	O
6	O
.	O
11	O
μU	O
/	O
mL	O
vs	O
−8	O
.	O
53	O
±	O
5	O
.	O
61	O
μU	O
/	O
mL	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
HOMA	O
-	O
IR	O
index	O
(	O
−1	O
.	O
11	O
±	O
1	O
.	O
51	O
vs	O
−2	O
.	O
23	O
±	O
0	O
.	O
25	O
)	O
,	O
and	O
QUIKI	O
index	O
(	O
0	O
.	O
014	O
±	O
0	O
.	O
016	O
vs	O
0	O
.	O
028	O
±	O
0	O
.	O
019	O
)	O
decreased	O
compared	O
with	O
the	O
LF	O
group	O
(	O
Figure	O
5	O
)	O
,	O
and	O
all	O
differences	O
were	O
statistically	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
Comparing	O
the	O
changes	O
in	O
lipid	O
parameters	O
between	O
the	O
two	O
groups	O
(	O
LF	O
vs	O
MED	O
/	O
LC	O
)	O
,	O
significant	O
differences	O
in	O
TG	O
(	O
−0	O
.	O
33	O
±	O
0	O
.	O
32	O
mmol	O
vs	O
−0	O
.	O
76	O
±	O
0	O
.	O
97	O
mmol	O
)	O
,	O
TC	O
(	O
−0	O
.	O
40	O
±	O
1	O
.	O
00	O
mmol	O
vs	O
−1	O
.	O
45	O
±	O
2	O
.	O
00	O
mmol	O
)	O
,	O
and	O
LDL	O
-	O
C	O
(	O
−0	O
.	O
41	O
±	O
1	O
.	O
05	O
mmol	O
vs	O
−0	O
.	O
73	O
±	O
0	O
.	O
76	O
mmol	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
observed	O
,	O
but	O
no	O
significant	O
difference	O
in	O
HDL	O
-	O
C	O
was	O
found	O
between	O
the	O
two	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O
This	O
study	O
was	O
the	O
first	O
to	O
use	O
the	O
MED	O
combined	O
with	O
a	O
LC	O
diet	O
for	O
12	O
weeks	O
of	O
strict	O
dietary	O
management	O
in	O
overweight	O
patients	O
with	O
PCOS	O
.	O
It	O
also	O
compared	O
the	O
effects	O
of	O
the	O
MED	O
/	O
LC	O
diet	O
and	O
the	O
LF	O
diet	O
on	O
anthropometric	O
indicators	O
,	O
reproductive	O
endocrine	O
levels	O
,	O
degree	O
of	O
IR	O
and	O
lipid	O
metabolism	O
levels	O
in	O
patients	O
with	O
PCOS	O
;	O
recorded	O
the	O
number	O
of	O
people	O
who	O
returned	O
to	O
normal	O
menstrual	O
cycles	O
during	O
management	O
in	O
both	O
groups	O
and	O
investigated	O
the	O
degree	O
of	O
rationality	O
and	O
effectiveness	O
of	O
the	O
two	O
dietary	O
regimens	O
.	O
Polycystic	O
ovary	O
syndrome	O
is	O
a	O
common	O
gynaecological	O
endocrine	O
metabolic	O
disorder	O
in	O
adolescent	O
and	O
fertile	O
women	O
.	O

IR	O
is	O
a	O
metabolic	O
abnormality	O
characteristic	O
of	O
PCOS	O
,	O
and	O
it	O
leads	O
to	O
compensatory	O
elevation	O
of	O
body	O
insulin	O
levels	O
and	O
the	O
development	O
of	O
HI	O
,	O
which	O
exacerbates	O
hyperandrogenaemia	O
,	O
anovulation	O
and	O
polycystic	O
ovary	O
formation	O
(	O
24	O
)	O
.	O
Most	O
patients	O
with	O
PCOS	O
are	O
formally	O
obese	O
,	O
and	O
obesity	O
is	O
an	O
important	O
cause	O
of	O
IR	O
in	O
patients	O
with	O
PCOS	O
.	O
Clinical	O
management	O
of	O
PCOS	O
is	O
still	O
mostly	O
limited	O
to	O
pharmacological	O
treatment	O
.	O
As	O
research	O
into	O
the	O
mechanisms	O
of	O
IR	O
in	O
patients	O
with	O
PCOS	O
progresses	O
,	O
including	O
its	O
effects	O
on	O
glucose	O
and	O
lipid	O
metabolism	O
and	O
the	O
warning	O
of	O
long	O
-	O
term	O
complications	O
such	O
as	O
cardiovascular	O
disease	O
and	O
endometrial	O
cancer	O
,	O
considerable	O
attention	O
should	O
be	O
given	O
to	O
lifestyle	O
interventions	O
as	O
a	O
safe	O
,	O
effective	O
and	O
closely	O
related	O
daily	O
treatment	O
management	O
modality	O
(	O
25	O
)	O
.	O
As	O
the	O
first	O
line	O
of	O
treatment	O
for	O
PCOS	O
,	O
the	O
management	O
of	O
dietary	O
behaviour	O
plays	O
an	O
important	O
role	O
in	O
the	O
efficacy	O
of	O
the	O
disease	O
,	O
and	O
no	O
standardised	O
dietary	O
protocols	O
are	O
available	O
at	O
present	O
.	O
In	O
an	O
earlier	O
clinical	B-methodology
study	I-methodology
,	O
the	O
average	O
daily	O
total	O
energy	O
intake	O
of	O
patients	O
with	O
PCOS	O
was	O
higher	O
than	O
that	O
of	O
the	O
common	O
people	O
,	O
and	O
limiting	O
their	O
total	O
energy	O
intake	O
ameliorated	O
their	O
weight	O
,	O
androgen	O
secretion	O
and	O
insulin	O
index	O
(	O
26	O
)	O
.	O
Subsequently	O
,	O
overweight	O
patients	O
with	O
PCOS	O
have	O
a	O
predominance	O
of	O
visceral	O
adiposity	O
,	O
and	O
they	O
are	O
evidently	O
and	O
centrally	O
obese	O
.	O
In	O
addition	O
,	O
adipose	O
tissue	O
secretes	O
a	O
variety	O
of	O
adipokines	O
,	O
including	O
leptin	O
,	O
lipocalin	O
,	O
resistin	O
and	O
visceral	O
adiponectin	O
to	O
promote	O
the	O
development	O
of	O
PCOS	O
.	O
The	O
formation	O
of	O
obesity	O
is	O
strongly	O
related	O
to	O
the	O
daily	O
preference	O
for	O
high	O
-	O
fat	O
foods	O
(	O
27	O
)	O
.	O
The	O
development	O
of	O
obesity	O
is	O
strongly	O
associated	O
with	O
the	O
daily	O
preference	O
for	O
high	O
-	O
fat	O
foods	O
.	O
Therefore	O
,	O
some	O
researchers	O
have	O
developed	O
a	O
LF	O
diet	O
model	O
with	O
no	O
energy	O
restriction	O
and	O
a	O
low	O
glycaemic	O
index	O
diet	O
model	O
to	O
compare	O
the	O
improvement	O
of	O
obesity	O
and	O
reproductive	O
endocrinology	O
in	O
patients	O
with	O
PCOS	O
and	O
found	O
that	O
both	O
dietary	O
models	O
improved	O
obesity	O
in	O
patients	O
with	O
PCOS	O
but	O
not	O
reproductive	O
endocrinology	O
(	O
28	O
)	O
.	O

In	O
the	O
pathogenesis	O
of	O
PCOS	O
,	O
IR	O
plays	O
a	O
crucial	O
role	O
as	O
a	O
central	O
mechanism	O
for	O
the	O
sensitivity	O
of	O
body	O
’	O
s	O
glucose	O
metabolism	O
,	O
usually	O
manifested	O
by	O
poor	O
glucose	O
tolerance	O
and	O
reduced	O
insulin	O
sensitivity	O
(	O
29	O
)	O
.	O
Therefore	O
,	O
controlling	O
the	O
level	O
of	O
carbohydrate	O
content	O
in	O
the	O
daily	O
dietary	O
intake	O
of	O
patients	O
with	O
PCOS	O
plays	O
an	O
important	O
role	O
.	O
Jafari	O
-	O
Maram	O
et	O
al	O
.	O
found	O
diets	O
lower	O
in	O
carbohydrate	O
and	O
higher	O
in	O
protein	O
and	O
fat	O
were	O
not	O
associated	O
with	O
overweight	O
,	O
obesity	O
and	O
cardiovascular	O
risk	O
factors	O
(	O
30	O
)	O
.	O
In	O
a	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
of	O
intervention	B-methodology
studies	I-methodology
in	O
patients	O
with	O
PCOS	O
using	O
an	O
unrestricted	O
energy	O
LC	O
diet	O
model	O
,	O
LC	O
significantly	O
reduced	O
BMI	O
,	O
androgen	O
and	O
IR	O
levels	O
and	O
improved	O
lipid	O
metabolism	O
in	O
eight	O
relevant	O
RCTs	B-methodology
compared	O
with	O
standard	O
dietary	O
regimens	O
(	O
31	O
)	O
.	O
Thus	O
,	O
a	O
LC	O
diet	O
is	O
recommended	O
.	O
The	O
MED	O
model	O
,	O
a	O
dietary	O
model	O
that	O
has	O
emerged	O
in	O
recent	O
years	O
,	O
is	O
based	O
on	O
a	O
rich	O
variety	O
of	O
plant	O
foods	O
,	O
including	O
a	O
large	O
number	O
of	O
vegetables	O
,	O
fruits	O
,	O
grains	O
and	O
cereals	O
,	O
legumes	O
,	O
nuts	O
and	O
seeds	O
,	O
with	O
fat	O
accounting	O
for	O
up	O
to	O
35	O
%	O
of	O
total	O
dietary	O
energy	O
and	O
less	O
than	O
7	O
–	O
8	O
%	O
of	O
saturated	O
fatty	O
acids	O
.	O
It	O
has	O
a	O
refined	O
broad	O
framework	O
for	O
the	O
composition	O
of	O
the	O
diet	O
,	O
and	O
it	O
is	O
widely	O
used	O
in	O
metabolic	O
and	O
cardiovascular	O
diseases	O
(	O
32	O
)	O
,	O
but	O
its	O
application	O
in	O
PCOS	O
is	O
less	O
common	O
.	O
The	O
MED	O
model	O
can	O
effectively	O
modify	O
IR	O
(	O
33	O
)	O
.	O
Therefore	O
,	O
in	O
this	O
study	O
,	O
we	O
used	O
the	O
MED	O
structural	O
model	O
combined	O
with	O
the	O
LC	O
diet	O
model	O
,	O
which	O
was	O
compared	O
with	O
the	O
LF	O
diet	O
model	O
,	O
to	O
provide	O
a	O
12	B-methodology
-	I-methodology
week	I-methodology
dietary	I-methodology
intervention	I-methodology
for	O
overweight	O
patients	O
with	O
PCOS	O
based	O
on	O
restricted	O
total	O
energy	O
intake	O
,	O
and	O
we	O
found	O
that	O
at	O
the	O
end	O
of	O
the	O
intervention	O
,	O
both	O
dietary	O
models	O
had	O
an	O
effect	O
on	O
the	O
anthropometric	O
indicators	O
of	O
patients	O
with	O
PCOS	O
,	O
reproductive	O
endocrine	O
levels	O
,	O
the	O
degree	O
of	O
IR	O
and	O
lipid	O
metabolism	O
-	O
related	O
indicators	O
.	O
The	O
MED	O
/	O
LC	O
group	O
showed	O
more	O
significant	O
improvements	O
in	O
weight	O
,	O
BMI	O
,	O
WC	O
,	O
WHR	O
,	O
and	O
BF	O
%	O
than	O
the	O
LF	O
diet	O
group	O
.	O

The	O
primary	O
issue	O
for	O
overweight	O
patients	O
with	O
PCOS	O
is	O
weight	O
and	O
body	O
fat	O
loss	O
;	O
therefore	O
,	O
the	O
MED	O
/	O
LC	O
regimen	O
is	O
effective	O
for	O
overweight	O
patients	O
with	O
PCOS	O
,	O
surpassing	O
the	O
LF	O
regimen	O
to	O
a	O
certain	O
extent	O
.	O
With	O
regard	O
to	O
reproductive	O
endocrine	O
levels	O
,	O
TT	O
,	O
LH	O
,	O
and	O
LH	O
/	O
FSH	O
all	O
decreased	O
to	O
a	O
certain	O
extent	O
in	O
the	O
LF	O
group	O
after	O
the	O
intervention	O
,	O
but	O
the	O
decrease	O
was	O
more	O
prominent	O
after	O
the	O
MED	O
/	O
LC	O
intervention	O
.	O
In	O
addition	O
,	O
with	O
regard	O
to	O
FSH	O
and	O
PRL	O
levels	O
,	O
a	O
slight	O
change	O
was	O
observed	O
in	O
both	O
groups	O
.	O
The	O
decrease	O
in	O
these	O
indicators	O
is	O
important	O
for	O
follicular	O
development	O
and	O
the	O
recovery	O
of	O
ovulatory	O
cycles	O
in	O
patients	O
with	O
PCOS	O
.	O
The	O
decline	O
in	O
TT	O
is	O
particularly	O
important	O
.	O
Hyperandrogenaemia	O
,	O
a	O
representative	O
pathological	O
mechanism	O
in	O
PCOS	O
,	O
is	O
a	O
pathological	O
increase	O
in	O
androgens	O
that	O
activates	O
the	O
earliest	O
stages	O
of	O
follicular	O
growth	O
,	O
thereby	O
stimulating	O
the	O
growth	O
of	O
small	O
sinus	O
follicles	O
,	O
leading	O
to	O
the	O
recruitment	O
of	O
small	O
follicles	O
and	O
the	O
formation	O
of	O
polycystic	O
ovaries	O
.	O
Moreover	O
,	O
a	O
high	O
androgen	O
level	O
increases	O
the	O
expression	O
of	O
granulosa	O
cell	O
androgen	O
receptors	O
and	O
FSH	O
receptors	O
,	O
promoting	O
granulosa	O
cell	O
and	O
follicular	O
membrane	O
cell	O
proliferation	O
and	O
cortical	O
thickening	O
,	O
with	O
ovulatory	O
disturbances	O
and	O
secondary	O
menstrual	O
disorders	O
(	O
34	O
)	O
.	O
Therefore	O
,	O
a	O
decrease	O
in	O
androgens	O
would	O
play	O
a	O
direct	O
role	O
in	O
restoring	O
ovulation	O
.	O
In	O
previous	O
studies	O
,	O
the	O
LF	O
diet	O
alone	O
did	O
not	O
significantly	O
improve	O
reproductive	O
endocrine	O
disorders	O
in	O
overweight	O
patients	O
with	O
PCOS	O
(	O
28	O
)	O
,	O
whereas	O
the	O
LF	O
diet	O
model	O
in	O
this	O
study	O
showed	O
good	O
improvement	O
.	O
The	O
present	O
study	O
controlled	O
the	O
total	O
energy	O
intake	O
by	O
setting	O
the	O
LF	O
diet	O
model	O
,	O
which	O
had	O
an	O
important	O
effect	O
on	O
the	O
metabolic	O
level	O
to	O
a	O
certain	O
extent	O
.	O
This	O
result	O
suggests	O
that	O
the	O
restriction	O
of	O
total	O
energy	O
intake	O
is	O
important	O
in	O
the	O
development	O
of	O
dietary	B-methodology
intervention	I-methodology
,	O
regardless	O
of	O
the	O
changes	O
in	O
the	O
composition	O
of	O
the	O
diet	O
.	O
Comparing	O
the	O
number	O
of	O
people	O
who	O
returned	O
to	O
normal	O
menstrual	O
cycles	O
between	O
the	O
two	O
groups	O
,	O
the	O
return	O
to	O
normal	O
menstrual	O
cycles	O
was	O
greater	O
than	O
50	O
%	O
in	O
the	O
LF	O
and	O
MED	O
/	O
LC	O
groups	O
(	O
72	O
.	O
4	O
vs	O
.	O

86	O
.	O
7	O
%	O
)	O
,	O
with	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
,	O
indicating	O
that	O
both	O
dietary	O
regimens	O
were	O
effective	O
in	O
restoring	O
ovulation	O
in	O
overweight	O
patients	O
with	O
PCOS	O
.	O
In	O
the	O
dietary	O
regimen	O
of	O
this	O
study	O
,	O
the	O
LF	O
group	O
was	O
set	O
up	O
with	O
an	O
average	O
daily	O
fat	O
intake	O
of	O
less	O
than	O
40	O
g	O
,	O
thereby	O
significantly	O
increasing	O
the	O
ratio	O
of	O
carbohydrate	O
to	O
protein	O
intake	O
compared	O
with	O
the	O
MED	O
/	O
LC	O
group	O
with	O
regard	O
to	O
dietary	O
structure	O
.	O
When	O
comparing	O
the	O
reduction	O
in	O
the	O
degree	O
of	O
IR	O
,	O
we	O
found	O
that	O
the	O
FPG	O
in	O
the	O
LF	O
group	O
was	O
higher	O
than	O
that	O
before	O
the	O
intervention	O
,	O
which	O
may	O
be	O
related	O
to	O
the	O
higher	O
proportion	O
of	O
carbohydrate	O
intake	O
in	O
this	O
model	O
.	O
Therefore	O
,	O
the	O
total	O
energy	O
intake	O
and	O
the	O
total	O
fat	O
intake	O
were	O
controlled	O
during	O
the	O
12	O
weeks	O
of	O
the	O
protocol	O
,	O
and	O
the	O
FINS	O
,	O
HOMA	O
-	O
IR	O
,	O
and	O
QUIKI	O
indices	O
still	O
showed	O
a	O
decreasing	O
trend	O
to	O
a	O
certain	O
extent	O
,	O
indicating	O
that	O
our	O
LF	O
diet	O
in	O
the	O
presence	O
of	O
calorie	O
restriction	O
can	O
still	O
alleviate	O
the	O
degree	O
of	O
IR	O
,	O
although	O
the	O
carbohydrate	O
intake	O
ratio	O
was	O
correspondingly	O
higher	O
.	O
The	O
results	O
of	O
a	O
previous	O
study	O
found	O
little	O
difference	O
in	O
changes	O
in	O
blood	O
glucose	O
and	O
HI	O
-	O
related	O
indicators	O
after	O
a	O
high	O
-	O
fat	O
diet	O
versus	O
a	O
high	O
-	O
carbohydrate	O
diet	O
,	O
but	O
the	O
metabolic	O
pattern	O
shifted	O
to	O
impaired	O
insulin	O
sensitivity	O
during	O
the	O
high	O
-	O
fat	O
diet	O
(	O
35	O
)	O
.	O
This	O
finding	O
suggests	O
that	O
the	O
intake	O
of	O
fat	O
content	O
has	O
a	O
profound	O
effect	O
on	O
the	O
IR	O
status	O
,	O
which	O
could	O
explain	O
the	O
corresponding	O
improvement	O
in	O
IR	O
in	O
our	O
LF	O
diet	O
model	O
.	O
However	O
,	O
the	O
MED	O
/	O
LC	O
group	O
significantly	O
controlled	O
carbohydrate	O
intake	O
compared	O
with	O
the	O
LF	O
group	O
.	O
Combining	O
the	O
two	O
dietary	O
models	O
,	O
the	O
MED	O
/	O
LC	O
group	O
significantly	O
increased	O
protein	O
intake	O
compared	O
with	O
the	O
LF	O
group	O
,	O
whereas	O
fat	O
intake	O
did	O
not	O
significantly	O
exceed	O
the	O
standard	O
diet	O
(	O
the	O
standard	O
for	O
a	O
LF	O
diet	O
is	O
a	O
total	O
daily	O
intake	O
of	O
<	O
50	O
g	O
,	O
and	O
the	O
fat	O
intake	O
in	O
this	O
study	O
was	O
at	O
57	O
.	O
51	O
±	O
6	O
.	O
56	O
g	O
)	O
.	O
Therefore	O
,	O
the	O
MED	O
/	O
LC	O
diet	O
model	O
in	O
this	O
study	O
is	O
similar	O
to	O
the	O
high	O
-	O
protein	O
(	O
HP	O
)	O
diet	O
model	O
to	O
a	O
certain	O
extent	O
.	O

In	O
an	O
earlier	O
trial	O
of	O
a	O
dietary	B-methodology
intervention	I-methodology
for	O
PCOS	O
,	O
researchers	O
found	O
significant	O
improvements	O
in	O
anthropometric	O
indicators	O
and	O
testosterone	O
levels	O
and	O
a	O
slight	O
difference	O
in	O
lipid	O
levels	O
in	O
patients	O
with	O
PCOS	O
compared	O
with	O
the	O
standard	O
ratio	O
dietary	O
model	O
after	O
intervention	O
with	O
a	O
dietary	O
model	O
that	O
simply	O
increased	O
the	O
protein	O
/	O
carbohydrate	O
ratio	O
(	O
36	O
)	O
.	O
In	O
studies	O
of	O
metabolic	O
-	O
related	O
diseases	O
,	O
calorie	O
-	O
restricted	O
HP	O
diet	O
model	O
can	O
relieve	O
hyperglycaemia	O
and	O
IR	O
status	O
by	O
modifying	O
intestinal	O
flora	O
(	O
37	O
,	O
38	O
)	O
,	O
and	O
the	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
a	O
similar	O
mechanism	O
may	O
exist	O
in	O
the	O
MED	O
/	O
LC	O
model	O
.	O
Comparing	O
the	O
relevant	O
metabolic	O
indices	O
before	O
and	O
after	O
the	O
intervention	O
of	O
the	O
two	O
dietary	O
models	O
in	O
this	O
study	O
,	O
the	O
decrease	O
in	O
IR	O
-	O
related	O
indices	O
(	O
FPG	O
,	O
FINS	O
,	O
HOMA	O
-	O
IR	O
index	O
,	O
and	O
QUIKI	O
index	O
)	O
and	O
lipid	O
profile	O
(	O
TG	O
,	O
TC	O
,	O
and	O
LDL	O
-	O
C	O
)	O
after	O
the	O
MED	O
/	O
LC	O
diet	B-methodology
intervention	I-methodology
was	O
significant	O
compared	O
with	O
the	O
LF	O
group	O
,	O
which	O
indicated	O
that	O
the	O
MED	O
/	O
LC	O
diet	O
model	O
has	O
an	O
advantage	O
over	O
the	O
LF	O
diet	O
model	O
with	O
regard	O
to	O
calorie	O
restriction	O
.	O
The	O
MED	O
/	O
LC	O
group	O
had	O
an	O
advantage	O
over	O
the	O
LF	O
group	O
with	O
regard	O
to	O
improvement	O
in	O
all	O
PCOS	O
-	O
related	O
indicators	O
,	O
which	O
was	O
also	O
related	O
to	O
the	O
difference	O
in	O
the	O
specific	O
refinement	O
of	O
food	O
between	O
the	O
two	O
groups	O
.	O
The	O
MED	O
diet	O
recommends	O
a	O
whole	O
-	O
grain	O
diet	O
as	O
the	O
staple	O
food	O
,	O
and	O
the	O
LF	O
model	O
does	O
not	O
emphasise	O
restricting	O
the	O
type	O
of	O
staple	O
food	O
,	O
which	O
may	O
also	O
have	O
some	O
effect	O
.	O
Based	O
on	O
previous	O
studies	O
,	O
the	O
dietary	O
fibre	O
content	O
of	O
cereals	O
is	O
higher	O
than	O
that	O
of	O
refined	O
carbohydrates	O
(	O
e	O
.	O
g	O
.	O
,	O
rice	O
and	O
noodles	O
)	O
,	O
and	O
the	O
higher	O
the	O
dietary	O
fibre	O
intake	O
,	O
the	O
lower	O
the	O
body	O
weight	O
,	O
glycaemic	O
load	O
and	O
triglyceride	O
and	O
cholesterol	O
levels	O
(	O
39	O
)	O
,	O
which	O
would	O
better	O
explain	O
the	O
advantages	O
of	O
the	O
MED	O
/	O
LC	O
dietary	O
model	O
.	O
The	O
MED	O
/	O
LC	O
group	O
is	O
more	O
finely	O
structured	O
than	O
the	O
LF	O
group	O
and	O
is	O
more	O
useful	O
for	O
clinicians	O
to	O
understand	O
its	O
specific	O
application	O
.	O
The	O
strength	O
of	O
this	O
study	O
lies	O
in	O
the	O
combination	O
of	O
the	O
MED	O
diet	O
model	O
and	O
the	O
LC	O
diet	O
model	O
,	O
with	O
specific	O
dietary	B-methodology
interventions	I-methodology
based	O
on	O
calorie	O
restriction	O
and	O
a	O
comparison	O
with	O
the	O
LF	O
group	O
.	O

Analysis	O
of	O
the	O
results	O
shows	O
that	O
the	O
MED	O
/	O
LC	O
diet	O
model	O
with	O
calorie	O
restriction	O
has	O
a	O
greater	O
advantage	O
in	O
the	O
improvement	O
of	O
all	O
indicators	O
in	O
overweight	O
patients	O
with	O
PCOS	O
,	O
and	O
it	O
provides	O
a	O
better	O
reference	O
for	O
the	O
intervention	O
criteria	O
of	O
the	O
PCOS	O
diet	O
structure	O
.	O
In	O
addition	O
,	O
the	O
MED	O
/	O
LC	O
diet	O
model	O
has	O
a	O
more	O
specific	O
reference	O
for	O
the	O
arrangement	O
of	O
the	O
diet	O
structure	O
,	O
which	O
also	O
facilitates	O
clinical	O
application	O
.	O
Few	O
prospective	O
controlled	B-methodology
studies	I-methodology
have	O
used	O
the	O
MED	O
diet	O
model	O
for	O
the	O
treatment	O
of	O
PCOS	O
.	O
One	O
single	B-methodology
-	I-methodology
arm	I-methodology
study	O
of	O
the	O
MED	O
diet	O
model	O
combined	O
with	O
a	O
ketogenic	O
diet	O
model	O
showed	O
that	O
the	O
combined	O
diet	O
model	O
was	O
effective	O
in	O
improving	O
PCOS	O
anthropometric	O
indicators	O
,	O
reproductive	O
endocrine	O
levels	O
and	O
IR	O
levels	O
(	O
40	O
)	O
.	O
However	O
,	O
the	O
ketogenic	O
diet	O
is	O
not	O
long	O
lasting	O
because	O
of	O
potential	O
negative	O
effects	O
on	O
the	O
kidneys	O
and	O
adverse	O
effects	O
such	O
as	O
decreased	O
insulin	O
sensitivity	O
after	O
withdrawal	O
of	O
ketones	O
(	O
41	O
)	O
,	O
which	O
also	O
has	O
some	O
reference	O
value	O
for	O
our	O
study	O
.	O
Notably	O
,	O
this	O
study	O
still	O
has	O
significant	O
limitations	O
similar	O
to	O
other	O
studies	O
of	O
lifestyle	O
interventions	O
.	O
First	O
,	O
patient	O
adherence	O
to	O
the	O
dietary	B-methodology
intervention	I-methodology
in	O
this	O
study	O
was	O
highly	O
problematic	O
,	O
with	O
PCOS	O
patients	O
having	O
difficulty	O
adhering	O
to	O
a	O
single	O
dietary	O
model	O
for	O
12	O
consecutive	O
weeks	O
.	O
Second	O
,	O
this	O
study	O
was	O
a	O
single	O
-	O
centre	O
trial	O
,	O
and	O
the	O
participants	O
were	O
all	O
Chinese	O
patients	O
.	O
The	O
development	O
of	O
the	O
diet	O
plan	O
considered	O
certain	O
regional	O
characteristics	O
,	O
and	O
the	O
generalised	O
type	O
of	O
diet	O
may	O
have	O
some	O
limitations	O
for	O
various	O
food	O
cultures	O
.	O
Third	O
,	O
the	O
treatment	O
period	O
was	O
only	O
12	O
weeks	O
,	O
without	O
long	O
-	O
term	O
intervention	O
and	O
follow	O
-	O
up	O
,	O
and	O
some	O
statistical	O
biases	O
against	O
long	O
-	O
term	O
effects	O
were	O
found	O
.	O
Therefore	O
,	O
this	O
study	O
could	O
establish	O
a	O
relatively	O
advantageous	O
dietary	O
model	O
as	O
a	O
model	O
reference	O
for	O
clinicians	O
in	O
the	O
treatment	O
of	O
PCOS	O
with	O
regard	O
to	O
dietary	B-methodology
interventions	I-methodology
.	O
This	O
study	O
evaluated	O
the	O
effectiveness	O
of	O
the	O
MED	O
diet	O
model	O
in	O
combination	O
with	O
the	O
LC	O
diet	O
model	O
in	O
the	O
treatment	O
of	O
overweight	O
patients	O
with	O
PCOS	O
,	O
based	O
on	O
restricting	O
total	O
energy	O
intake	O
,	O
compared	O
with	O
the	O
LF	O
diet	O
model	O
.	O

The	O
results	O
of	O
the	O
study	O
showed	O
that	O
the	O
LF	O
and	O
MED	O
/	O
LC	O
dietary	O
models	O
were	O
effective	O
in	O
modifying	O
anthropometric	O
parameters	O
,	O
reproductive	O
endocrine	O
levels	O
,	O
IR	O
levels	O
and	O
lipid	O
levels	O
in	O
patients	O
with	O
PCOS	O
,	O
with	O
the	O
MED	O
/	O
LC	O
dietary	O
model	O
being	O
more	O
effective	O
and	O
the	O
recovery	O
of	O
menstrual	O
cycles	O
being	O
approximately	O
the	O
same	O
in	O
both	O
groups	O
.	O
Therefore	O
,	O
the	O
MED	O
/	O
LC	O
diet	O
model	O
was	O
recommended	O
for	O
the	O
treatment	O
of	O
overweight	O
patients	O
with	O
PCOS	O
.	O
The	O
raw	O
data	O
supporting	O
the	O
conclusions	O
of	O
this	O
article	O
will	O
be	O
made	O
available	O
by	O
the	O
authors	O
,	O
without	O
undue	O
reservation	O
.	O
The	O
studies	O
involving	O
human	O
participants	O
were	O
reviewed	O
and	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
Changhai	O
Hospital	O
of	O
PLA	O
Military	O
Medical	O
University	O
.	O
The	O
patients	O
/	O
participants	O
provided	O
their	O
written	B-methodology
informed	I-methodology
consent	I-methodology
to	O
participate	O
in	O
this	O
study	O
.	O
SM	O
and	O
JD	O
collected	O
the	O
data	O
and	O
thesis	O
writing	O
.	O
KW	O
conducted	O
the	O
statistical	O
analyses	O
.	O
ZN	O
revised	O
the	O
final	O
version	O
.	O
JY	O
proposed	O
the	O
research	O
ideas	O
and	O
designed	O
the	O
research	O
plans	O
.	O
All	O
authors	O
contributed	O
to	O
the	O
article	O
and	O
approved	O
the	O
submitted	O
version	O
.	O
The	O
authors	O
declare	O
that	O
the	O
research	O
was	O
conducted	O
in	O
the	O
absence	O
of	O
any	O
commercial	O
or	O
financial	O
relationships	O
that	O
could	O
be	O
construed	O
as	O
a	O
potential	O
conflict	O
of	O
interest	O
.	O
The	O
reviewer	O
JQ	O
declared	O
a	O
shared	O
affiliation	O
with	O
the	O
author	O
JY	O
to	O
the	O
handling	O
editor	O
at	O
the	O
time	O
of	O
review	O
.	O
All	O
claims	O
expressed	O
in	O
this	O
article	O
are	O
solely	O
those	O
of	O
the	O
authors	O
and	O
do	O
not	O
necessarily	O
represent	O
those	O
of	O
their	O
affiliated	O
organizations	O
,	O
or	O
those	O
of	O
the	O
publisher	O
,	O
the	O
editors	O
and	O
the	O
reviewers	O
.	O
Any	O
product	O
that	O
may	O
be	O
evaluated	O
in	O
this	O
article	O
,	O
or	O
claim	O
that	O
may	O
be	O
made	O
by	O
its	O
manufacturer	O
,	O
is	O
not	O
guaranteed	O
or	O
endorsed	O
by	O
the	O
publisher	O
.	O

Health	O
outcomes	O
of	O
100	O
%	O
orange	O
juice	O
and	O
orange	O
flavored	O
beverage	O
:	O
A	O
comparative	O
analysis	O
of	O
gut	O
microbiota	O
and	O
metabolomics	O
in	O
rats	O
Fruit	O
juice	O
;	O
Fruity	O
beverage	O
;	O
100	O
%	O
orange	O
Juice	O
;	O
Orange	O
flavored	O
beverage	O
;	O
Gut	O
microbiota	O
;	O
Kidney	O
;	O
Metabolic	O
syndrome	O
A	O
high	O
intake	O
of	O
sugar	O
-	O
sweetened	O
fruity	O
beverage	O
(	O
FB	O
)	O
is	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
metabolic	O
syndromes	O
,	O
but	O
the	O
health	O
outcome	O
of	O
100	O
%	O
fruit	O
juice	O
(	O
FJ	O
)	O
intake	O
remains	O
unclear	O
.	O
We	O
aim	O
to	O
reveal	O
health	O
outcomes	O
of	O
diet	B-methodology
intervention	I-methodology
(	O
FJ	O
or	O
FB	O
)	O
with	O
system	O
profiling	O
via	O
interaction	O
of	O
gut	O
microbiota	O
and	O
metabolomics	O
in	O
a	O
rat	O
(	O
Rattus	O
norvegicus	O
)	O
model	O
.	O
Firstly	O
,	O
the	O
glucose	O
,	O
sucrose	O
,	O
fructose	O
,	O
and	O
bioactive	O
metabolites	O
of	O
FJ	O
and	O
FB	O
were	O
analyzed	O
,	O
and	O
FJ	O
possessed	O
higher	O
sucrose	O
and	O
flavonoids	O
,	O
while	O
FB	O
showed	O
higher	O
glucose	O
and	O
fructose	O
.	O
Secondly	O
,	O
C0	O
was	O
set	O
as	O
the	O
control	B-methodology
group	I-methodology
on	O
Day	O
0	O
,	O
and	O
a	O
4	O
-	O
week	O
diet	B-methodology
invention	I-methodology
was	O
performed	O
to	O
control	O
,	O
FJ	O
-	O
intake	O
,	O
and	O
FB	O
-	O
intake	O
groups	O
with	O
normal	O
saline	O
,	O
FJ	O
,	O
and	O
FB	O
,	O
respectively	O
.	O
The	O
results	O
showed	O
that	O
FJ	O
improved	O
alpha	O
diversity	O
and	O
decreased	O
the	O
Firmicutes	O
/	O
Bacteroidota	O
ratio	O
(	O
F	O
/	O
B	O
ratio	O
)	O
of	O
gut	O
microbiota	O
and	O
prevented	O
insulin	O
resistance	O
.	O
However	O
,	O
FB	O
possessed	O
unchanged	O
microbial	O
diversity	O
and	O
enhanced	O
F	O
/	O
B	O
ratio	O
,	O
causing	O
insulin	O
resistance	O
with	O
renal	O
triglyceride	O
accumulation	O
.	O
In	O
summary	O
,	O
FJ	O
,	O
although	O
naturally	O
containing	O
similar	O
amounts	O
of	O
total	O
free	O
sugars	O
as	O
FB	O
,	O
could	O
be	O
a	O
healthier	O
drink	O
choice	O
.	O
•	O
100	O
%	O
orange	O
juice	O
improves	O
microbial	O
diversity	O
and	O
function	O
related	O
to	O
insulin	O
resistance	O
.	O
•	O
Orange	O
flavored	O
beverage	O
alters	O
the	O
microbiome	O
and	O
promotes	O
renal	O
triglyceride	O
accumulation	O
.	O
•	O
100	O
%	O
orange	O
juice	O
containing	O
similar	O
amounts	O
of	O
total	O
free	O
sugars	O
is	O
healthier	O
compared	O
to	O
orange	O
beverage	O
.	O
In	O
2012	O
,	O
the	O
United	O
Nations	O
announced	O
that	O
chronic	O
non	O
-	O
communicable	O
diseases	O
(	O
CNCD	O
)	O
,	O
such	O
as	O
cancer	O
,	O
diabetes	O
,	O
and	O
heart	O
disease	O
,	O
pose	O
a	O
considerable	O
health	O
burden	O
than	O
do	O
infectious	O
diseases	O
.	O
Tobacco	O
,	O
alcohol	O
,	O
and	O
diet	O
were	O
targeted	O
as	O
the	O
central	O
risk	O
factors	O
in	O
CNCD	O
(	O
Ng	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

Both	O
tobacco	O
and	O
alcohol	O
are	O
regulated	O
by	O
governments	O
to	O
protect	O
public	O
health	O
,	O
leaving	O
diet	O
behind	O
health	O
crisis	O
unchecked	O
(	O
Lustig	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O
Globally	O
,	O
many	O
governments	O
have	O
adopted	O
diverse	O
regulatory	O
policies	O
,	O
including	O
nutrition	O
labeling	O
,	O
restrictions	O
on	O
food	O
marketing	O
,	O
and	O
taxation	O
,	O
to	O
curb	O
the	O
epidemic	O
of	O
obesity	O
and	O
CNCD	O
(	O
Lartey	O
et	O
al	O
.	O
,	O
2018	O
;	O
Vandevijvere	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Diet	O
is	O
foods	O
and	O
drinks	O
regularly	O
consumed	O
,	O
and	O
its	O
regulation	O
is	O
complicated	O
.	O
It	O
is	O
necessary	O
to	O
obtain	O
a	O
practical	O
understanding	O
of	O
which	O
foods	O
and	O
drinks	O
contribute	O
to	O
health	O
and	O
well	O
-	O
being	O
and	O
which	O
could	O
be	O
detrimental	O
.	O
As	O
two	O
commonest	O
drinks	O
,	O
fruity	O
beverages	O
(	O
FB	O
)	O
are	O
defined	O
as	O
fruit	O
-	O
flavored	O
drinks	O
,	O
calorie	O
-	O
containing	O
carbonated	O
drinks	O
,	O
vitamin	O
water	O
drinks	O
,	O
energy	O
drinks	O
,	O
and	O
sports	O
drinks	O
(	O
Zheng	O
et	O
al	O
.	O
,	O
2015	O
)	O
,	O
while	O
fruit	O
juice	O
(	O
FJ	O
)	O
is	O
liquid	O
obtained	O
from	O
the	O
edible	O
part	O
of	O
mature	O
and	O
fresh	O
fruit	O
or	O
of	O
fruit	O
maintained	O
in	O
sound	O
condition	O
by	O
suitable	O
means	O
following	O
CODEX	O
STAN	O
247	O
–	O
2005	O
(	O
CODEX	O
STAN	O
,	O
2005	O
)	O
.	O
Clear	O
evidence	O
shows	O
that	O
a	O
high	O
intake	O
of	O
FB	O
is	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
metabolic	O
syndromes	O
,	O
such	O
as	O
for	O
overweight	O
and	O
obesity	O
(	O
Hagele	O
et	O
al	O
.	O
,	O
2018	O
)	O
,	O
hypertension	O
,	O
type	O
2	O
diabetes	O
,	O
cardiovascular	O
disease	O
(	O
Jayalath	O
V	O
H	O
,	O
Souza	O
R	O
J	O
D	O
,	O
&	O
V	O
,	O
2015	O
;	O
Malik	O
et	O
al	O
.	O
,	O
2010	O
;	O
Narain	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
as	O
well	O
as	O
dental	O
caries	O
(	O
Guido	O
JA	O
,	O
Martinez	O
Mier	O
EA	O
,	O
&	O
A	O
,	O
2011	O
)	O
and	O
even	O
poor	O
mental	O
health	O
(	O
Freije	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
Unlike	O
for	O
FB	O
,	O
there	O
is	O
inconsistent	O
evidence	O
that	O
drinking	O
FJ	O
poses	O
a	O
risk	O
to	O
human	O
health	O
,	O
and	O
there	O
is	O
conflict	O
between	O
the	O
findings	O
of	O
observational	B-methodology
studies	I-methodology
,	O
which	O
can	O
be	O
influenced	O
by	O
confounders	O
,	O
and	O
those	O
of	O
randomized	B-methodology
controlled	I-methodology
trials	I-methodology
.	O
Although	O
no	O
effect	O
on	O
weight	O
gain	O
was	O
found	O
in	O
a	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
of	I-methodology
randomized	I-methodology
controlled	I-methodology
trials	I-methodology
(	O
D	O
'	O
Elia	O
et	O
al	O
.	O
,	O
2021	O
)	O
,	O
longitudinal	O
evaluation	O
showed	O
drinking	O
100	O
%	O
fruit	O
juice	O
was	O
related	O
to	O
higher	O
odds	O
of	O
becoming	O
overweight	O
(	O
Shefferly	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O

Moreover	O
,	O
a	O
controlled	B-methodology
clinical	I-methodology
trial	I-methodology
suggested	O
that	O
daily	O
consumption	O
of	O
fruit	O
juice	O
had	O
a	O
positive	O
effect	O
on	O
the	O
intestinal	O
microbiota	O
and	O
metabolic	O
biomarkers	O
of	O
young	O
women	O
(	O
Lima	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Recently	O
,	O
the	O
interplay	O
between	O
host	O
metabolism	O
and	O
associated	O
gut	O
microbiota	O
has	O
been	O
a	O
research	O
hotspot	O
(	O
Laparra	O
and	O
Sanz	O
,	O
2010	O
;	O
Monteiro	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
Notably	O
,	O
their	O
joint	O
characterization	O
is	O
conducive	O
to	O
clarifying	O
the	O
effects	O
of	O
diet	B-methodology
intervention	I-methodology
on	O
health	O
outcomes	O
(	O
Posma	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Certain	O
plant	O
foods	O
that	O
contain	O
bioactive	O
compounds	O
may	O
be	O
more	O
likely	O
to	O
drive	O
microbial	O
changes	O
than	O
others	O
;	O
however	O
,	O
complexity	O
of	O
food	O
can	O
make	O
interpretation	O
difficult	O
(	O
Willis	O
and	O
Slavin	O
,	O
2020	O
)	O
.	O
Higher	O
plant	O
-	O
based	O
diet	O
ratio	O
was	O
significantly	O
associated	O
with	O
a	O
higher	O
relative	O
abundance	O
of	O
Bacteroides	O
and	O
Eubacterium	O
,	O
amino	O
acid	O
biosynthesis	O
pathways	O
,	O
and	O
the	O
pathway	O
of	O
pyruvate	O
fermentation	O
(	O
Y	O
.	O
Li	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
In	O
this	O
work	O
,	O
a	O
4	O
-	O
week	O
drink	O
intervention	B-methodology
study	I-methodology
on	O
rats	O
was	O
conducted	O
to	O
illuminate	O
health	O
outcomes	O
for	O
intake	O
of	O
FJ	O
via	O
interaction	O
of	O
gut	O
microbiota	O
and	O
metabolomics	O
compared	O
with	O
intake	O
of	O
FB	O
.	O
The	O
orange	O
flavor	O
occupies	O
the	O
first	O
position	O
with	O
26	O
.	O
2	O
%	O
of	O
the	O
fruit	O
juice	O
market	O
share	O
(	O
Neves	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Hence	O
,	O
we	O
chose	O
2	O
kinds	O
of	O
popular	O
drinks	O
from	O
the	O
local	O
supermarket	O
as	O
the	O
objects	O
of	O
our	O
study	O
.	O
FB	O
is	O
a	O
kind	O
of	O
orange	O
-	O
flavored	O
beverage	O
,	O
or	O
sugar	O
-	O
sweetened	O
fruity	O
beverage	O
.	O
It	O
contains	O
orange	O
juice	O
from	O
concentrate	O
and	O
its	O
label	O
claims	O
no	O
less	O
than	O
10	O
%	O
orange	O
juice	O
content	O
.	O
The	O
ingredient	O
list	O
shows	O
that	O
FB	O
contains	O
water	O
,	O
high	O
fructose	O
corn	O
syrup	O
,	O
granulated	O
sugar	O
,	O
and	O
food	O
additives	O
(	O
citric	O
acid	O
,	O
sodium	O
citrate	O
,	O
and	O
β	O
-	O
carotene	O
)	O
,	O
essence	O
,	O
and	O
vitamin	O
C	O
.	O
FJ	O
is	O
a	O
kind	O
of	O
100	O
%	O
orange	O
juice	O
not	O
from	O
concentrate	O
,	O
and	O
its	O
label	O
claims	O
100	O
%	O
orange	O
juice	O
content	O
without	O
extra	O
ingredient	O
.	O
All	O
drink	O
samples	O
were	O
sealed	O
in	O
their	O
original	O
packaging	O
,	O
stored	O
at	O
room	O
temperature	O
,	O
and	O
shaken	O
before	O
use	O
.	O
The	O
rats	O
only	O
received	O
one	O
juice	O
product	O
per	O
intervention	B-methodology
group	I-methodology
.	O

The	O
contents	O
of	O
glucose	O
,	O
fructose	O
,	O
and	O
sucrose	O
were	O
determined	O
according	O
to	O
the	O
previous	O
method	O
with	O
some	O
modifications	O
(	O
B	O
.	O
Wang	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
The	O
juice	O
was	O
diluted	O
5000	O
times	O
and	O
filtered	O
using	O
a	O
0	O
.	O
22	O
-	O
μm	O
polytetrafluoroethylene	O
membrane	O
.	O
Ion	O
chromatography	O
(	O
ICS	O
3000	O
+	O
,	O
Thermo	O
Fisher	O
Scientific	O
,	O
USA	O
)	O
system	O
,	O
consisted	O
of	O
(	O
i	O
)	O
an	O
ICS	O
-	O
3000	O
dual	O
pump	O
,	O
(	O
ii	O
)	O
an	O
automated	O
sample	O
injector	O
(	O
Dionex	O
AS	O
autosampler	O
)	O
,	O
(	O
iii	O
)	O
working	O
electrode	O
:	O
Gold	O
(	O
Au	O
)	O
,	O
reference	O
electrode	O
:	O
pH	O
electrode	O
(	O
Dionex	O
,	O
Germany	O
)	O
,	O
(	O
iv	O
)	O
PA20	O
anion	O
analysis	O
column	O
(	O
3	O
mm	O
×	O
150	O
mm	O
)	O
,	O
(	O
vi	O
)	O
PA20	O
guard	O
column	O
(	O
4×50	O
mm	O
)	O
,	O
was	O
used	O
.	O
Mobile	O
phase	O
A	O
was	O
water	O
and	O
B	O
was	O
200	O
mM	O
NaOH	O
.	O
The	O
elution	O
procedure	O
was	O
0	O
–	O
20	O
.	O
00	O
min	O
,	O
5	O
%	O
B	O
;	O
20	O
.	O
00	O
–	O
20	O
.	O
01	O
min	O
,	O
5	O
%	O
–	O
20	O
%	O
B	O
;	O
20	O
.	O
01	O
–	O
30	O
.	O
00	O
min	O
,	O
20	O
%	O
B	O
;	O
30	O
.	O
00	O
–	O
30	O
.	O
01	O
min	O
,	O
20	O
%	O
–	O
100	O
%	O
B	O
;	O
30	O
.	O
01	O
–	O
40	O
.	O
00	O
min	O
,	O
100	O
%	O
B	O
;	O
40	O
.	O
00	O
–	O
40	O
.	O
01	O
min	O
,	O
100	O
%	O
–	O
5	O
%	O
B	O
;	O
40	O
.	O
01	O
–	O
50	O
.	O
00	O
min	O
,	O
5	O
%	O
B	O
.	O
The	O
injection	O
volume	O
,	O
flow	O
rate	O
,	O
and	O
column	O
temperature	O
were	O
10	O
μL	O
,	O
0	O
.	O
400	O
mL	O
/	O
min	O
,	O
and	O
30	O
°C	O
,	O
respectively	O
.	O
All	O
animal	B-methodology
experiments	I-methodology
were	O
performed	O
in	O
the	O
lab	O
of	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
of	O
Beijing	O
Vital	O
River	O
Laboratory	O
Animal	O
Technology	O
Co	O
.	O
,	O
Ltd	O
.	O
All	O
experimental	O
procedures	O
described	O
here	O
were	O
conducted	O
following	O
the	O
National	O
Institutes	O
of	O
Health	O
Guidelines	B-methodology
on	O
the	O
Care	O
and	O
Use	O
of	O
Laboratory	O
Animal	O
of	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
of	O
Beijing	O
Vital	O
River	O
Laboratory	O
Animal	O
Technology	O
Co	O
.	O
,	O
Ltd	O
.	O
The	O
approve	O
code	O
is	O
SCXK	O
-	O
2016	O
–	O
0006	O
.	O
The	O
permission	O
code	O
is	O
P2021032	O
.	O
Six	O
-	O
to	O
eight	O
-	O
week	O
-	O
old	O
SD	O
(	O
Rattus	O
norvegicus	O
)	O
rats	O
(	O
male	O
;	O
SPF	O
;	O
the	O
mean	O
weight	O
of	O
209	O
g	O
)	O
were	O
purchased	O
from	O
Vital	O
River	O
Laboratory	O
Animal	O
Technology	O
Co	O
.	O
Ltd	O
(	O
Beijing	O
,	O
China	O
)	O
.	O

The	O
animal	O
feeds	O
were	O
purchased	O
from	O
Keao	O
Xieli	O
Feed	O
Co	O
.	O
,	O
Ltd	O
(	O
Beijing	O
,	O
China	O
)	O
,	O
and	O
the	O
primary	O
nutrients	O
of	O
animal	O
feed	O
are	O
shown	O
in	O
Table	O
S1	O
.	O
The	O
rats	O
were	O
kept	O
under	O
controlled	O
light	O
conditions	O
(	O
12	O
h	O
light	O
-	O
dark	O
cycle	O
)	O
with	O
free	O
access	O
to	O
feed	O
and	O
water	O
throughout	O
the	O
entire	O
intervention	O
.	O
The	O
design	O
of	O
drink	O
intervention	B-methodology
study	I-methodology
is	O
shown	O
in	O
Fig	O
.	O
1	O
.	O
The	O
rats	O
were	O
acclimatized	O
for	O
7	O
days	O
,	O
and	O
the	O
weight	O
,	O
fasting	O
blood	O
glucose	O
(	O
FBG	O
)	O
,	O
total	O
cholesterols	O
(	O
TC	O
)	O
,	O
total	O
triglycerides	O
(	O
TG	O
)	O
,	O
high	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
HDL	O
-	O
C	O
)	O
,	O
and	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
LDL	O
-	O
C	O
)	O
were	O
recorded	O
on	O
the	O
last	O
day	O
of	O
acclimatization	O
.	O
When	O
the	O
rats	O
were	O
adapted	O
to	O
the	O
experiment	O
condition	O
during	O
the	O
first	O
week	O
,	O
body	O
weight	O
,	O
FBG	O
,	O
TC	O
,	O
TG	O
,	O
HDL	O
-	O
C	O
,	O
and	O
LDL	O
-	O
C	O
were	O
measured	O
to	O
divide	O
these	O
rats	O
into	O
4	O
groups	O
,	O
denoted	O
as	O
C0	O
,	O
control	O
,	O
FJ	O
-	O
intake	O
,	O
and	O
FB	O
-	O
intake	O
,	O
respectively	O
.	O
After	O
grouping	O
,	O
there	O
are	O
no	O
significant	O
differences	O
in	O
these	O
indices	O
among	O
groups	O
(	O
Fig	O
.	O
S1	O
)	O
.	O
For	O
C0	O
,	O
cecum	O
,	O
and	O
serum	O
samples	O
were	O
directly	O
collected	O
after	O
7	O
days	O
of	O
acclimatization	O
and	O
stored	O
at	O
−80	O
°C	O
until	O
analysis	O
.	O
Then	O
,	O
rats	O
were	O
dissected	O
to	O
obtain	O
kidney	O
,	O
brain	O
,	O
liver	O
,	O
fat	O
from	O
subcutaneous	O
and	O
epididymis	O
,	O
colon	O
,	O
intestine	O
,	O
and	O
cecum	O
.	O
The	O
organ	O
mass	O
was	O
recorded	O
and	O
the	O
organs	O
were	O
stored	O
at	O
−80	O
°C	O
until	O
analysis	O
.	O
The	O
control	O
and	O
2	O
intervention	B-methodology
groups	I-methodology
(	O
control	O
,	O
FJ	O
-	O
intake	O
,	O
and	O
FB	O
-	O
intake	O
)	O
proceeded	O
with	O
formal	O
intervention	O
for	O
28	O
days	O
.	O
Under	O
the	O
regular	O
diet	O
,	O
the	O
rats	O
were	O
gavaged	O
with	O
normal	O
saline	O
,	O
FJ	O
,	O
and	O
FB	O
for	O
control	O
,	O
FJ	O
-	O
intake	O
,	O
and	O
FB	O
-	O
intake	O
,	O
respectively	O
(	O
twice	O
per	O
day	O
)	O
at	O
the	O
same	O
time	O
every	O
day	O
.	O
Each	O
rat	O
was	O
given	O
the	O
equivalent	O
of	O
one	O
adult	O
(	O
60	O
kg	O
)	O
drinking	O
300	O
mL	O
of	O
drinks	O
a	O
day	O
.	O

According	O
to	O
previous	O
study	O
,	O
the	O
dose	O
conversion	O
between	O
rat	O
and	O
human	O
is	O
6	O
.	O
2	O
(	O
Nair	O
and	O
Jacob	O
,	O
2016	O
)	O
.	O
If	O
an	O
adult	O
(	O
60	O
kg	O
)	O
consumes	O
300	O
mL	O
of	O
orange	O
juice	O
daily	O
,	O
the	O
equivalent	O
dose	O
for	O
rats	O
is	O
31	O
mL	O
/	O
kg	O
(	O
300	O
mL	O
/	O
60	O
kg	O
*	O
6	O
.	O
2	O
=	O
31	O
mL	O
/	O
kg	O
)	O
.	O
Hence	O
,	O
the	O
specific	O
volume	O
of	O
gavage	B-methodology
was	O
calculated	O
as	O
31	O
times	O
the	O
volume	O
of	O
each	O
rat	O
'	O
s	O
last	O
measured	O
body	O
weight	O
(	O
for	O
example	O
,	O
if	O
the	O
last	O
measured	O
weight	O
of	O
a	O
rat	O
is	O
0	O
.	O
2	O
kg	O
,	O
its	O
gavage	B-methodology
volume	O
is	O
6	O
.	O
2	O
mL	O
per	O
day	O
)	O
.	O
During	O
the	O
28	O
-	O
day	O
diet	O
,	O
the	O
weight	O
,	O
FBG	O
,	O
TC	O
,	O
TG	O
,	O
HDL	O
-	O
C	O
,	O
and	O
LDL	O
-	O
C	O
were	O
recorded	O
once	O
per	O
week	O
.	O
On	O
the	O
last	O
day	O
,	O
samples	O
from	O
the	O
3	O
groups	O
were	O
collected	O
and	O
stored	O
under	O
the	O
same	O
condition	O
as	O
C0	O
.	O
The	O
organ	O
index	O
was	O
calculated	O
based	O
on	O
the	O
ratio	O
of	O
organ	O
mass	O
to	O
body	O
weight	O
.	O
Eight	O
rats	O
were	O
randomly	O
selected	O
from	O
each	O
group	O
for	O
16S	O
rRNA	O
sequencing	O
.	O
The	O
corresponding	O
cecum	O
sample	O
from	O
the	O
chosen	O
rat	O
was	O
snap	O
-	O
frozen	O
with	O
liquid	O
nitrogen	O
following	O
collection	O
and	O
was	O
stored	O
in	O
a	O
−80	O
°C	O
refrigerator	O
.	O
Then	O
,	O
32	O
cecum	O
samples	O
were	O
transported	O
to	O
Majorbio	O
Bio	O
-	O
pharm	O
Technology	O
Co	O
.	O
,	O
Ltd	O
(	O
Shanghai	O
,	O
China	O
)	O
on	O
dry	O
ice	O
.	O
The	O
genomic	O
DNA	O
of	O
cecum	O
samples	O
was	O
extracted	O
using	O
the	O
DNA	O
Extract	O
Kit	O
(	O
Omega	O
Bio	O
-	O
Tek	O
,	O
USA	O
)	O
.	O
The	O
DNA	O
was	O
checked	O
on	O
1	O
%	O
agarose	O
gel	O
,	O
and	O
the	O
concentration	O
and	O
purity	O
of	O
DNA	O
were	O
determined	O
using	O
NanoDrop	O
2000	O
UV	O
–	O
vis	O
spectrophotometer	O
(	O
Thermo	O
Scientific	O
,	O
USA	O
)	O
.	O
The	O
16S	O
rRNA	O
genes	O
of	O
V3	O
–	O
V4	O
regions	O
were	O
amplified	O
with	O
specific	O
primers	O
(	O
338F	O
and	O
806R	O
)	O
using	O
ABI	O
GeneAmp®	O
9700	O
PCR	O
thermocycler	O
(	O
ABI	O
,	O
USA	O
)	O
.	O

After	O
initial	O
denaturation	O
at	O
95	O
°C	O
for	O
3	O
min	O
,	O
30	O
cycles	O
of	O
amplification	O
were	O
performed	O
as	O
follows	O
:	O
95	O
°C	O
for	O
30	O
s	O
,	O
55	O
°C	O
for	O
30	O
s	O
,	O
and	O
72	O
°C	O
for	O
45	O
s	O
followed	O
by	O
a	O
single	O
extension	O
at	O
72	O
°C	O
for	O
10	O
min	O
to	O
amplify	O
the	O
16S	O
rRNA	O
gene	O
.	O
The	O
PCR	O
product	O
was	O
verified	O
on	O
a	O
2	O
%	O
agarose	O
gel	O
and	O
purified	O
using	O
the	O
AxyPrep	O
DNA	O
Gel	O
Extraction	O
Kit	O
(	O
Axygen	O
Biosciences	O
,	O
USA	O
)	O
and	O
quantified	O
using	O
[UNK]	O
Fluorometer	O
(	O
Promega	O
,	O
USA	O
)	O
.	O
Purified	O
amplicons	O
were	O
pooled	O
into	O
equimolar	O
and	O
paired	O
-	O
end	O
sequenced	O
on	O
an	O
Illumina	O
MiSeq	O
PE300	O
platform	O
(	O
Illumina	O
,	O
USA	O
)	O
.	O
The	O
raw	O
16S	O
rRNA	O
gene	O
sequencing	O
reads	O
were	O
demultiplexed	O
,	O
quality	O
-	O
filtered	O
by	O
fastp	O
version	O
0	O
.	O
20	O
.	O
0	O
,	O
and	O
merged	O
by	O
FLASH	O
version	O
1	O
.	O
2	O
.	O
7	O
.	O
Operational	O
taxonomic	O
units	O
(	O
OTUs	O
)	O
with	O
a	O
97	O
%	O
similarity	O
cutoff	O
were	O
clustered	O
using	O
UPARSE	O
version	O
7	O
.	O
1	O
,	O
and	O
chimeric	O
sequences	O
were	O
identified	O
and	O
removed	O
.	O
The	O
taxonomy	O
of	O
each	O
OTU	O
representative	O
sequence	O
was	O
analyzed	O
by	O
RDP	O
Classifier	O
version	O
2	O
.	O
2	O
against	O
the	O
Silva	O
v138	O
16S	O
rRNA	O
database	O
using	O
a	O
confidence	O
threshold	O
of	O
0	O
.	O
7	O
.	O
The	O
metabolite	O
analysis	O
was	O
performed	O
by	O
ultrahigh	O
-	O
pressure	O
liquid	O
chromatography	O
coupled	O
with	O
a	O
quadrupole	O
time	O
-	O
of	O
-	O
flight	O
mass	O
(	O
UHPLC	O
-	O
QTOF	O
MS	O
)	O
.	O
The	O
samples	O
were	O
subjected	O
to	O
a	O
reversed	O
-	O
phase	O
chromatography	O
using	O
an	O
LC	O
system	O
(	O
SCIEX	O
,	O
USA	O
)	O
.	O
Mass	O
spectrometric	O
analysis	O
was	O
performed	O
with	O
a	O
QTOF	O
MS	O
with	O
a	O
DuoSpray	O
ion	O
source	O
(	O
TripleTOF	O
6600	O
,	O
SCIEX	O
,	O
USA	O
)	O
.	O
Quality	B-methodology
control	I-methodology
(	O
QC	O
)	O
samples	O
were	O
made	O
by	O
pooling	O
equal	O
aliquots	O
of	O
each	O
sample	O
together	O
in	O
an	O
analytical	O
run	O
(	O
Johnson	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
The	O
QC	O
sample	O
was	O
injected	O
and	O
analyzed	O
at	O
regular	O
intervals	O
of	O
every	O
6	O
samples	O
in	O
UHPLC	O
-	O
QTOF	O
MS	O
acquisition	O
.	O

These	O
QC	O
sample	O
data	O
were	O
used	O
to	O
monitor	O
the	O
reproducibility	O
and	O
stability	O
of	O
the	O
analytes	O
in	O
samples	O
during	O
the	O
analysis	O
(	O
Theodoridis	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O
The	O
metabolomics	O
was	O
conducted	O
on	O
2	O
drinks	O
according	O
to	O
the	O
previous	O
method	O
with	O
modifications	O
(	O
K	O
.	O
Wang	O
and	O
Xu	O
,	O
2022	O
)	O
.	O
The	O
2	O
drinks	O
were	O
filtered	O
using	O
a	O
0	O
.	O
22	O
-	O
μm	O
polytetrafluoroethylene	O
membrane	O
and	O
2	O
drinks	O
with	O
6	O
replicates	O
each	O
were	O
obtained	O
.	O
The	O
separation	O
column	O
is	O
ACQUITY	O
UPLC	O
HSS	O
T3	O
(	O
1	O
.	O
8	O
μm	O
,	O
2	O
.	O
1×100	O
mm	O
,	O
Waters	O
,	O
USA	O
)	O
,	O
maintained	O
at	O
40	O
°C	O
,	O
and	O
the	O
autosampler	O
was	O
maintained	O
at	O
4	O
°C	O
.	O
The	O
injection	O
volume	O
and	O
flow	O
rate	O
were	O
2	O
μL	O
and	O
0	O
.	O
300	O
mL	O
/	O
min	O
.	O
Mobile	O
phases	O
A	O
and	O
B	O
were	O
0	O
.	O
2	O
%	O
formic	O
acid	O
in	O
water	O
and	O
acetonitrile	O
,	O
respectively	O
.	O
Solvent	O
gradient	O
was	O
as	O
follow	O
:	O
0	O
–	O
11	O
.	O
50	O
min	O
,	O
5	O
%	O
–	O
30	O
%	O
B	O
;	O
11	O
.	O
50	O
–	O
11	O
.	O
51	O
min	O
,	O
30	O
–	O
100	O
%	O
B	O
;	O
11	O
.	O
51	O
–	O
15	O
.	O
00	O
min	O
,	O
100	O
%	O
B	O
;	O
15	O
.	O
00	O
–	O
15	O
.	O
01	O
min	O
,	O
100	O
%	O
–	O
5	O
%	O
B	O
;	O
15	O
.	O
01	O
–	O
18	O
.	O
00	O
min	O
,	O
5	O
%	O
B	O
.	O
The	O
SWATH	O
with	O
a	O
cycle	O
time	O
of	O
545	O
ms	O
was	O
composed	O
of	O
a	O
TOF	O
MS	O
scan	O
(	O
accumulation	O
time	O
,	O
50	O
ms	O
;	O
CE	O
,	O
10	O
eV	O
)	O
and	O
a	O
series	O
of	O
product	O
ion	O
scans	O
(	O
accumulation	O
time	O
,	O
30	O
ms	O
each	O
;	O
CE	O
,	O
35	O
eV	O
,	O
CES	O
15	O
eV	O
)	O
of	O
15	O
Q1	O
windows	O
of	O
60	O
Da	O
from	O
m	O
/	O
z	O
100	O
–	O
1000	O
.	O
The	O
lipidomics	O
was	O
conducted	O
on	O
kidney	O
samples	O
according	O
to	O
previous	O
methods	O
with	O
modifications	O
(	O
Z	O
.	O
Chen	O
et	O
al	O
.	O
,	O
2020	O
;	O
Tu	O
et	O
al	O
.	O
,	O
2017	O
;	O
K	O
.	O
Wang	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
Thirty	O
-	O
mg	O
frozen	O
kidney	O
tissue	O
was	O
weighed	O
and	O
homogenized	O
in	O
600	O
-	O
μL	O
extract	O
(	O
MTBE	O
:	O
MeOH	O
=	O
5	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
using	O
the	O
homogenizer	O
,	O
and	O
1	O
-	O
μL	O
internal	O
standard	O
of	O
Cer	O
-	O
d7	O
(	O
100	O
μg	O
/	O
mL	O
)	O
was	O
added	O
.	O

The	O
solution	O
was	O
vortexed	O
for	O
30	O
s	O
,	O
followed	O
by	O
10	O
min	O
of	O
sonication	O
,	O
and	O
centrifugation	O
at	O
3000	O
rpm	O
for	O
15	O
min	O
.	O
The	O
upper	O
organic	O
layer	O
was	O
collected	O
.	O
An	O
additional	O
600	O
-	O
μL	O
MTBE	O
was	O
added	O
to	O
the	O
bottom	O
layer	O
for	O
re	O
-	O
extraction	O
.	O
The	O
re	O
-	O
extraction	O
was	O
repeated	O
twice	O
.	O
The	O
pooled	O
organic	O
layer	O
was	O
evaporated	O
using	O
a	O
termovap	O
sample	O
concentrator	O
.	O
Before	O
subsequent	O
analysis	O
,	O
the	O
dry	O
extract	O
was	O
reconstituted	O
using	O
100	O
-	O
μL	O
DCM	O
:	O
MeOH	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
.	O
The	O
separation	O
column	O
is	O
Phenomenex	O
Kinetex	O
C18	O
column	O
(	O
1	O
.	O
7	O
μm	O
,	O
2	O
.	O
1×100	O
mm	O
,	O
Waters	O
,	O
USA	O
)	O
,	O
maintained	O
at	O
55	O
°C	O
,	O
and	O
the	O
autosampler	O
was	O
maintained	O
at	O
4	O
°C	O
.	O
The	O
injection	O
volume	O
was	O
2	O
μL	O
and	O
6	O
μL	O
in	O
positive	O
and	O
negative	O
modes	O
,	O
respectively	O
.	O
The	O
mobile	O
phase	O
consisted	O
of	O
A	O
:	O
5	O
mM	O
H3CCOONH4	O
+	O
40	O
%	O
H2O	O
+	O
60	O
%	O
CAN	O
,	O
B	O
:	O
5	O
mM	O
H3COONH4	O
+	O
10	O
%	O
ACN	O
+	O
90	O
%	O
IPA	O
was	O
carried	O
with	O
elution	O
gradient	O
as	O
follows	O
:	O
0	O
min	O
,	O
40	O
%	O
B	O
;	O
12	O
min	O
,	O
100	O
%	O
B	O
;	O
13	O
.	O
5	O
min	O
,	O
100	O
%	O
B	O
;	O
13	O
.	O
7	O
min	O
,	O
40	O
%	O
B	O
;	O
18	O
min	O
,	O
40	O
%	O
B	O
,	O
which	O
was	O
delivered	O
at	O
0	O
.	O
3	O
mL	O
/	O
min	O
.	O
The	O
Triple	O
TOF	O
mass	O
spectrometer	O
was	O
used	O
for	O
its	O
ability	O
to	O
acquire	O
MS	O
/	O
MS	O
spectra	O
on	O
an	O
IDA	O
mode	O
.	O
The	O
acquisition	O
software	O
(	O
Analyst	O
TF	O
1	O
.	O
7	O
,	O
AB	O
SCIEX	O
)	O
continuously	O
evaluates	O
the	O
full	O
scan	O
survey	O
MS	O
data	O
in	O
this	O
mode	O
.	O
It	O
collects	O
and	O
triggers	O
the	O
acquisition	O
of	O
MS	O
/	O
MS	O
spectra	O
depending	O
on	O
preselected	O
criteria	O
.	O
In	O
each	O
cycle	O
,	O
11	O
precursor	O
ions	O
whose	O
intensity	O
greater	O
than	O
100	O
were	O
chosen	O
for	O
fragmentation	O
at	O
collision	O
energy	O
(	O
CE	O
)	O
of	O
35	O
V	O
(	O
15	O
MS	O
/	O
MS	O
events	O
with	O
product	O
ion	O
accumulation	O
time	O
of	O
50	O
ms	O
each	O
)	O
.	O
ESI	O
source	O
conditions	O
were	O
set	O
as	O
follows	O
:	O
Ion	O
source	O
gas	O
1	O
as	O
60	O
,	O
Ion	O
source	O
gas	O
2	O
as	O
60	O
,	O
Curtain	O
gas	O
as	O
30	O
,	O
source	O
temperature	O
550	O
°C	O
,	O
Ion	O
Spray	O
Voltage	O
Floating	O
(	O
ISVF	O
)	O
5500	O
V	O
or	O
−	O
4500	O
V	O
in	O
positive	O
or	O
negative	O
modes	O
,	O
respectively	O
.	O

The	O
cecum	O
content	O
samples	O
were	O
performed	O
according	O
to	O
previous	O
methods	O
with	O
modifications	O
(	O
Tian	O
et	O
al	O
.	O
,	O
2012	O
;	O
Xie	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O
And	O
300	O
-	O
mg	O
of	O
cecum	O
contents	O
was	O
weighed	O
with	O
1	O
.	O
5	O
-	O
mL	O
methanol	O
-	O
water	O
(	O
v	O
:	O
v	O
=	O
1	O
:	O
1	O
,	O
4	O
°C	O
)	O
solution	O
added	O
.	O
The	O
mixture	O
was	O
vibrated	O
for	O
30	O
s	O
,	O
frozen	O
in	O
liquid	O
nitrogen	O
for	O
30	O
s	O
,	O
then	O
thawed	O
in	O
water	O
at	O
room	O
temperature	O
,	O
and	O
repeated	O
3	O
times	O
.	O
After	O
the	O
last	O
thawing	O
,	O
an	O
ultrasound	O
was	O
performed	O
for	O
30	O
s	O
followed	O
by	O
10	O
-	O
s	O
vibration	O
and	O
30	O
-	O
s	O
standing	O
;	O
then	O
,	O
the	O
process	O
was	O
repeated	O
5	O
times	O
.	O
Centrifugation	O
was	O
performed	O
at	O
15000	O
g	O
for	O
5	O
min	O
at	O
4	O
°C	O
.	O
Finally	O
,	O
the	O
supernatant	O
was	O
filtered	O
using	O
a	O
0	O
.	O
22	O
-	O
μm	O
nylon	O
membrane	O
for	O
analysis	O
.	O
The	O
separation	O
column	O
is	O
C18	O
(	O
1	O
.	O
7	O
μm	O
,	O
2	O
.	O
1×100	O
mm	O
,	O
Waters	O
,	O
USA	O
)	O
,	O
maintained	O
at	O
40	O
°C	O
,	O
and	O
the	O
autosampler	O
was	O
maintained	O
at	O
4	O
°C	O
.	O
The	O
injection	O
volume	O
and	O
flow	O
rate	O
were	O
2	O
μL	O
and	O
0	O
.	O
300	O
mL	O
/	O
min	O
.	O
Mobile	O
phases	O
A	O
and	O
B	O
were	O
0	O
.	O
1	O
%	O
formic	O
acid	O
in	O
water	O
,	O
and	O
0	O
.	O
1	O
%	O
formic	O
acid	O
in	O
acetonitrile	O
,	O
respectively	O
.	O
For	O
cecum	O
samples	O
,	O
solvent	O
gradient	O
was	O
as	O
follow	O
:	O
0	O
–	O
0	O
.	O
10	O
min	O
,	O
5	O
%	O
B	O
;	O
0	O
.	O
10	O
–	O
2	O
.	O
00	O
min	O
,	O
5	O
–	O
13	O
%	O
B	O
;	O
2	O
.	O
00	O
–	O
4	O
.	O
00	O
min	O
,	O
13	O
–	O
28	O
%	O
B	O
;	O
4	O
.	O
00	O
–	O
8	O
.	O
50	O
min	O
,	O
28	O
–	O
40	O
%	O
B	O
;	O
11	O
.	O
50	O
–	O
13	O
.	O
00	O
min	O
,	O
40	O
–	O
70	O
%	O
A	O
;	O
13	O
.	O
00	O
–	O
13	O
.	O
50	O
min	O
,	O
73	O
–	O
100	O
%	O
B	O
;	O
13	O
.	O
50	O
–	O
16	O
.	O
00	O
min	O
,	O
100	O
%	O
B	O
;	O
16	O
.	O
00	O
–	O
20	O
min	O
,	O
5	O
%	O
B	O
.	O
The	O
SWATH	O
with	O
a	O
cycle	O
time	O
of	O
550	O
ms	O
was	O
composed	O
of	O
a	O
TOF	O
MS	O
scan	O
(	O
accumulation	O
time	O
,	O
50	O
ms	O
;	O
CE	O
,	O
10	O
eV	O
)	O
and	O
a	O
series	O
of	O
product	O
ion	O
scans	O
(	O
accumulation	O
time	O
,	O
30	O
ms	O
each	O
;	O
CE	O
,	O
35	O
eV	O
,	O
CES	O
15	O
eV	O
)	O
of	O
15	O
Q1	O
windows	O
from	O
m	O
/	O
z	O
50	O
–	O
1200	O
.	O

The	O
serum	O
content	O
samples	O
were	O
performed	O
according	O
to	O
a	O
previous	O
method	O
with	O
modifications	O
(	O
Lin	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O
The	O
serum	O
was	O
thawed	O
in	O
a	O
refrigerator	O
at	O
4	O
°C	O
.	O
After	O
thawing	O
,	O
the	O
serum	O
was	O
rotated	O
for	O
5	O
s	O
.	O
The	O
400	O
-	O
μL	O
methanol	O
was	O
added	O
to	O
200	O
-	O
μL	O
serum	O
,	O
and	O
the	O
mixture	O
was	O
rotated	O
for	O
10	O
s	O
and	O
stood	O
at	O
room	O
temperature	O
for	O
15	O
min	O
.	O
Then	O
,	O
centrifugation	O
was	O
performed	O
at	O
10000	O
g	O
for	O
20	O
min	O
at	O
4	O
°C	O
.	O
Finally	O
,	O
the	O
supernatant	O
was	O
filtered	O
using	O
a	O
0	O
.	O
22	O
-	O
μm	O
nylon	O
membrane	O
for	O
analysis	O
.	O
Totally	O
,	O
120	O
samples	O
of	O
the	O
cecum	O
and	O
serum	O
samples	O
(	O
60	O
samples	O
each	O
)	O
from	O
all	O
the	O
rats	O
were	O
obtained	O
.	O
The	O
separation	O
column	O
is	O
C18	O
(	O
1	O
.	O
7	O
μm	O
,	O
2	O
.	O
1×100	O
mm	O
,	O
Waters	O
,	O
USA	O
)	O
,	O
maintained	O
at	O
40	O
°C	O
,	O
and	O
the	O
autosampler	O
was	O
maintained	O
at	O
4	O
°C	O
.	O
The	O
injection	O
volume	O
and	O
flow	O
rate	O
were	O
2	O
μL	O
and	O
0	O
.	O
300	O
mL	O
/	O
min	O
.	O
Mobile	O
phases	O
A	O
and	O
B	O
were	O
0	O
.	O
1	O
%	O
formic	O
acid	O
in	O
water	O
,	O
and	O
0	O
.	O
1	O
%	O
formic	O
acid	O
in	O
acetonitrile	O
,	O
respectively	O
.	O
For	O
serum	O
samples	O
,	O
solvent	O
gradient	O
was	O
as	O
follow	O
:	O
0	O
–	O
0	O
.	O
10	O
min	O
,	O
5	O
%	O
B	O
;	O
0	O
.	O
10	O
–	O
1	O
.	O
50	O
min	O
,	O
5	O
–	O
13	O
%	O
B	O
;	O
1	O
.	O
50	O
–	O
2	O
.	O
50	O
min	O
,	O
13	O
–	O
28	O
%	O
B	O
;	O
2	O
.	O
50	O
–	O
5	O
.	O
50	O
min	O
,	O
28	O
–	O
40	O
%	O
B	O
;	O
5	O
.	O
50	O
–	O
7	O
.	O
50	O
min	O
,	O
40	O
–	O
70	O
%	O
A	O
;	O
7	O
.	O
50	O
–	O
15	O
.	O
00	O
min	O
,	O
70	O
–	O
90	O
%	O
B	O
;	O
15	O
.	O
00	O
–	O
16	O
.	O
00	O
min	O
,	O
90	O
–	O
100	O
%	O
B	O
;	O
16	O
.	O
00	O
–	O
19	O
.	O
00	O
min	O
,	O
100	O
%	O
B	O
;	O
19	O
.	O
01	O
–	O
22	O
.	O
00	O
min	O
,	O
5	O
%	O
B	O
.	O
The	O
SWATH	O
with	O
a	O
cycle	O
time	O
of	O
550	O
ms	O
was	O
composed	O
of	O
a	O
TOF	O
MS	O
scan	O
(	O
accumulation	O
time	O
,	O
50	O
ms	O
;	O
CE	O
,	O
10	O
eV	O
)	O
and	O
a	O
series	O
of	O
product	O
ion	O
scans	O
(	O
accumulation	O
time	O
,	O
30	O
ms	O
each	O
;	O
CE	O
,	O
35	O
eV	O
,	O
CES	O
15	O
eV	O
)	O
of	O
15	O
Q1	O
windows	O
from	O
m	O
/	O
z	O
50	O
–	O
1200	O
.	O

Mean	O
values	O
with	O
relative	O
standard	O
deviation	O
(	O
RSD	O
)	O
were	O
calculated	O
,	O
and	O
statistical	O
analyses	O
were	O
performed	O
using	O
R	O
4	O
.	O
0	O
.	O
3	O
(	O
Inc	O
.	O
,	O
MA	O
,	O
USA	O
)	O
.	O
To	O
compare	O
glucose	O
,	O
sucrose	O
,	O
fructose	O
contents	O
,	O
and	O
the	O
fructose	O
-	O
to	O
-	O
glucose	O
ratio	O
in	O
2	O
drinks	O
,	O
the	O
student	O
'	O
s	O
t	O
-	O
test	O
was	O
conducted	O
.	O
For	O
comparing	O
food	O
intake	O
,	O
FBG	O
,	O
TC	O
,	O
TG	O
,	O
HDL	O
-	O
C	O
,	O
LDL	O
-	O
C	O
,	O
body	O
weight	O
change	O
,	O
and	O
organ	O
mass	O
index	O
in	O
rats	O
from	O
different	O
groups	O
,	O
ANOVA	O
followed	O
by	O
the	O
Bonferroni	O
test	O
was	O
conducted	O
.	O
For	O
gut	O
microbiota	O
analysis	O
,	O
the	O
alpha	O
diversity	O
(	O
ACE	O
,	O
Chao	O
,	O
and	O
Sobs	O
estimator	O
)	O
and	O
beta	O
diversity	O
of	O
PCoA	O
based	O
on	O
weighted	O
UniFrac	O
distances	O
were	O
analyzed	O
using	O
R	O
4	O
.	O
0	O
.	O
3	O
.	O
To	O
compare	O
alpha	O
diversity	O
,	O
the	O
Kruskal	O
-	O
Wallis	O
rank	O
-	O
sum	O
test	O
followed	O
by	O
Game	O
-	O
Howell	O
was	O
conducted	O
.	O
Linear	O
discriminant	O
analysis	O
effect	O
size	O
(	O
LEfSe	O
)	O
was	O
used	O
to	O
identify	O
the	O
microbial	O
taxa	O
that	O
significantly	O
differed	O
between	O
FJ	O
-	O
intake	O
and	O
FB	O
-	O
intake	O
groups	O
,	O
with	O
a	O
threshold	O
of	O
linear	O
discriminant	O
analysis	O
(	O
LDA	O
)	O
score	O
>	O
2	O
.	O
0	O
.	O
Functional	O
pathway	O
analysis	O
of	O
gut	O
microbiota	O
was	O
performed	O
using	O
the	O
PICRUSt2	O
approach	O
,	O
based	O
on	O
the	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
(	O
KEGG	O
)	O
database	O
with	O
the	O
16S	O
rRNA	O
gene	O
sequencing	O
data	O
(	O
Majorbio	O
Cloud	O
Platform	O
)	O
.	O
Differences	O
in	O
pathways	O
between	O
FJ	O
-	O
intake	O
and	O
FB	O
-	O
intake	O
groups	O
were	O
identified	O
using	O
LEfSe	O
with	O
a	O
threshold	O
LDA	O
score	O
of	O
>	O
2	O
.	O
0	O
.	O
For	O
metabolite	O
analysis	O
,	O
UHPLC	O
-	O
QTOF	O
MS	O
data	O
were	O
processed	O
by	O
MS	O
-	O
DIAL	O
4	O
.	O
60	O
to	O
get	O
the	O
MS1	O
raw	O
peak	O
list	O
and	O
intensity	O
.	O
The	O
parameters	O
were	O
set	O
as	O
follows	O
:	O
MS1	O
and	O
MS2	O
tolerance	O
were	O
0	O
.	O
01	O
Da	O
and	O
0	O
.	O
025	O
Da	O
in	O
peak	O
extraction	O
,	O
and	O
the	O
maximum	O
charge	O
number	O
was	O
2	O
.	O
MS1	O
and	O
MS2	O
tolerance	O
were	O
0	O
.	O
01	O
Da	O
and	O
0	O
.	O
05	O
Da	O
in	O
qualitative	O
extraction	O
,	O
and	O
the	O
retention	O
time	O
deviation	O
in	O
peak	O
alignment	O
was	O
0	O
.	O
2	O
min	O
.	O

The	O
MS1	O
deviation	O
was	O
0	O
.	O
015	O
Da	O
,	O
the	O
detection	O
rate	O
reached	O
80	O
%	O
in	O
at	O
least	O
one	O
group	O
,	O
and	O
the	O
S	O
/	O
N	O
ratio	O
(	O
maximum	O
in	O
the	O
sample	O
/	O
mean	O
in	O
the	O
blank	O
sample	O
)	O
was	O
5	O
.	O
The	O
exported	O
MS1	O
peak	O
list	O
was	O
analyzed	O
by	O
Microsoft	O
Office	O
Excel	O
2020	O
(	O
Microsoft	O
Corporation	O
,	O
USA	O
)	O
to	O
remove	O
the	O
MS1	O
features	O
with	O
a	O
detection	O
rate	O
was	O
<	O
80	O
%	O
or	O
RSD	O
>	O
30	O
%	O
in	O
the	O
QC	O
group	O
(	O
Lachowicz	O
and	O
Oszmianski	O
,	O
2018	O
)	O
.	O
For	O
kidney	O
lipidomics	O
samples	O
,	O
the	O
MS1	O
features	O
with	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
and	O
FC	O
>	O
1	O
.	O
2	O
were	O
selected	O
as	O
characteristic	O
markers	O
for	O
further	O
identification	O
with	O
a	O
built	O
-	O
in	O
lipid	O
database	O
in	O
MS	O
-	O
DIAL	O
(	O
K	O
.	O
Wang	O
et	O
al	O
.	O
,	O
2022	O
)	O
.	O
For	O
drinks	O
,	O
the	O
MS1	O
features	O
with	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
,	O
FC	O
>	O
5	O
,	O
and	O
variable	O
importance	O
for	O
projection	O
(	O
VIP	O
)	O
>	O
1	O
.	O
5	O
based	O
on	O
the	O
orthogonal	O
partial	O
-	O
least	O
squares	O
discriminant	O
analysis	O
(	O
OPLS	O
-	O
DA	O
)	O
model	O
were	O
selected	O
as	O
characteristic	O
markers	O
for	O
further	O
identification	O
.	O
For	O
cecum	O
and	O
serum	O
samples	O
,	O
all	O
the	O
MS1	O
features	O
were	O
further	O
identified	O
.	O
Specifically	O
,	O
the	O
MS1	O
features	O
that	O
met	O
the	O
above	O
conditions	O
were	O
identified	O
by	O
exporting	O
their	O
MS2	O
spectra	O
from	O
MS	O
-	O
DIAL	O
4	O
.	O
60	O
into	O
MS	O
-	O
FINDER	O
3	O
.	O
50	O
for	O
putative	O
annotation	O
by	O
matching	O
the	O
databases	O
,	O
such	O
as	O
MassBank	O
of	O
North	O
America	O
,	O
RIKEN	O
PlaSMA	O
,	O
ReSpect	O
,	O
HMDB	O
,	O
lipid	O
maps	O
,	O
PubChem	O
,	O
and	O
FooDB	O
.	O
The	O
parameters	O
,	O
MS1	O
tolerance	O
,	O
and	O
MS2	O
tolerance	O
were	O
set	O
as	O
10	O
ppm	O
and	O
15	O
ppm	O
,	O
respectively	O
.	O
For	O
correlation	O
analysis	O
,	O
spearman	O
correlations	O
were	O
conducted	O
on	O
GraphPad	O
Prism	O
8	O
(	O
GraphPad	O
Software	O
,	O
USA	O
)	O
.	O
The	O
correlation	O
with	O
coefficient	O
>	O
0	O
.	O
5	O
and	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
was	O
considered	O
a	O
significant	O
correlation	O
and	O
then	O
plotted	O
by	O
Microsoft	O
Office	O
Excel	O
2020	O
or	O
Cytoscape	O
(	O
v3	O
.	O
4	O
.	O
0	O
)	O
.	O

Based	O
on	O
the	O
product	O
'	O
s	O
labels	O
(	O
Table	O
S2	O
)	O
,	O
the	O
energy	O
of	O
FJ	O
(	O
205	O
kJ	O
/	O
100	O
mL	O
)	O
is	O
slightly	O
higher	O
than	O
that	O
of	O
FB	O
(	O
183	O
kJ	O
/	O
100	O
mL	O
)	O
,	O
and	O
the	O
carbohydrate	O
contents	O
in	O
FJ	O
and	O
FB	O
are	O
similar	O
,	O
which	O
are	O
100	O
g	O
and	O
94	O
g	O
per	O
liter	O
,	O
respectively	O
.	O
Moreover	O
,	O
FJ	O
contains	O
13	O
.	O
25	O
g	O
glucose	O
,	O
15	O
.	O
19	O
g	O
fructose	O
,	O
and	O
30	O
.	O
66	O
g	O
sucrose	O
per	O
liter	O
,	O
while	O
FB	O
contains	O
19	O
.	O
37	O
g	O
glucose	O
,	O
28	O
.	O
14	O
g	O
fructose	O
,	O
and	O
17	O
.	O
31	O
g	O
sucrose	O
per	O
liter	O
(	O
Fig	O
.	O
2A	O
)	O
.	O
Glucose	O
and	O
fructose	O
contents	O
in	O
FB	O
are	O
higher	O
than	O
those	O
in	O
FJ	O
,	O
while	O
sucrose	O
content	O
in	O
FJ	O
is	O
significantly	O
higher	O
than	O
that	O
in	O
FB	O
.	O
The	O
increased	O
glucose	O
and	O
fructose	O
contents	O
in	O
FB	O
should	O
come	O
from	O
the	O
added	O
high	O
fructose	O
corn	O
syrup	O
,	O
which	O
was	O
also	O
claimed	O
on	O
the	O
labels	O
.	O
Then	O
,	O
the	O
fructose	O
-	O
to	O
-	O
glucose	O
ratio	O
in	O
FJ	O
is	O
significantly	O
lower	O
than	O
that	O
in	O
FB	O
,	O
which	O
are	O
1	O
.	O
1	O
and	O
1	O
.	O
5	O
,	O
respectively	O
(	O
Fig	O
.	O
2B	O
)	O
.	O
During	O
the	O
formal	O
intervention	O
,	O
no	O
matter	O
what	O
types	O
of	O
drinks	O
they	O
ingested	O
,	O
it	O
would	O
not	O
affect	O
the	O
rats	O
'	O
FBG	O
and	O
blood	O
routine	O
examination	O
indices	O
(	O
Fig	O
.	O
S2	O
[UNK]	O
)	O
.	O
The	O
food	O
intake	O
of	O
all	O
the	O
3	O
groups	O
increased	O
as	O
the	O
rats	O
grew	O
older	O
;	O
specifically	O
,	O
during	O
the	O
first	O
two	O
weeks	O
,	O
the	O
food	O
intake	O
of	O
FB	O
-	O
intake	O
group	O
was	O
significantly	O
lower	O
compared	O
to	O
control	O
and	O
FJ	O
-	O
intake	O
groups	O
(	O
Fig	O
.	O
2C	O
)	O
.	O
However	O
,	O
during	O
the	O
third	O
and	O
fourth	O
weeks	O
,	O
the	O
opposite	O
phenomenon	O
appeared	O
:	O
food	O
intake	O
in	O
FB	O
-	O
intake	O
and	O
control	O
groups	O
was	O
significantly	O
higher	O
than	O
in	O
FJ	O
-	O
intake	O
groups	O
(	O
Fig	O
.	O
2C	O
)	O
.	O
The	O
weight	O
change	O
is	O
generally	O
consistent	O
with	O
the	O
food	O
intake	O
changes	O
(	O
Fig	O
.	O
2D	O
)	O
.	O
It	O
is	O
worth	O
noting	O
that	O
FJ	O
with	O
higher	O
labeled	O
energy	O
led	O
to	O
a	O
lower	O
weight	O
gain	O
than	O
FB	O
.	O
Remarkably	O
,	O
a	O
significant	O
increase	O
of	O
kidney	O
mass	O
index	O
is	O
found	O
in	O
FB	O
-	O
intake	O
group	O
compared	O
with	O
control	O
and	O
FJ	O
-	O
intake	O
groups	O
(	O
Fig	O
.	O
2E	O
)	O
.	O

In	O
contrast	O
,	O
no	O
significant	O
difference	O
in	O
the	O
other	O
organ	O
indices	O
is	O
found	O
(	O
Figs	O
.	O
S2	O
–	O
F	O
)	O
.	O
The	O
increase	O
of	O
kidney	O
mass	O
was	O
statistically	O
associated	O
with	O
the	O
whole	O
injury	O
process	O
of	O
renal	O
disorders	O
(	O
Craig	O
et	O
al	O
.	O
,	O
2015	O
;	O
H	O
.	O
Liu	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
Lipids	O
are	O
attributed	O
to	O
[UNK]	O
%	O
of	O
human	O
renal	O
wet	O
weight	O
.	O
Regardless	O
of	O
whether	O
the	O
injury	O
is	O
acute	O
or	O
chronic	O
,	O
either	O
intrarenal	O
or	O
circulatory	O
lipid	O
disturbances	O
are	O
exhibited	O
in	O
various	O
renal	O
disorders	O
(	O
Su	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
Hence	O
,	O
we	O
highly	O
speculated	O
that	O
the	O
intrarenal	O
lipids	O
were	O
altered	O
and	O
lipidomics	O
analysis	O
of	O
kidney	O
was	O
further	O
conducted	O
to	O
verify	O
the	O
renal	O
disorder	O
in	O
FB	O
-	O
intake	O
group	O
(	O
Fig	O
.	O
S3	O
and	O
Table	O
S3	O
)	O
.	O
According	O
to	O
the	O
above	O
results	O
,	O
control	O
and	O
FJ	O
-	O
intake	O
were	O
combined	O
into	O
the	O
normal	O
group	O
to	O
compare	O
with	O
the	O
abnormal	O
group	O
of	O
FB	O
-	O
intake	O
.	O
The	O
ChemRICH	O
plot	O
illustrates	O
significantly	O
altered	O
lipid	O
classes	O
.	O
Most	O
lipids	O
in	O
triradylglycerols	O
[	O
GL03	O
]	O
,	O
glycerophosphocholines	O
[	O
GP01	O
]	O
,	O
and	O
phosphosphingolipids	O
[	O
SP03	O
]	O
are	O
significantly	O
higher	O
in	O
FB	O
-	O
intake	O
group	O
,	O
while	O
half	O
lipids	O
in	O
ceramides	O
[	O
SP02	O
]	O
are	O
elevated	O
in	O
FB	O
-	O
intake	O
group	O
(	O
Fig	O
.	O
2F	O
)	O
.	O
The	O
altered	O
lipids	O
in	O
the	O
kidney	O
further	O
proved	O
potential	O
chronic	O
renal	O
disorder	O
in	O
FB	O
-	O
intake	O
group	O
.	O
For	O
A	O
and	O
B	O
,	O
the	O
student	O
'	O
s	O
t	O
-	O
test	O
was	O
conducted	O
.	O
For	O
C	O
,	O
D	O
,	O
and	O
E	O
the	O
ANOVA	O
followed	O
by	O
the	O
Bonferroni	O
test	O
was	O
conducted	O
.	O
For	O
F	O
,	O
the	O
size	O
of	O
the	O
cluster	O
indicates	O
the	O
number	O
of	O
metabolites	O
within	O
the	O
class	O
.	O
Red	O
in	O
a	O
cluster	O
is	O
the	O
percentage	O
of	O
rising	O
lipids	O
in	O
the	O
class	O
,	O
and	O
blue	O
in	O
a	O
cluster	O
is	O
the	O
percentage	O
of	O
decreasing	O
lipids	O
in	O
the	O
class	O
.	O
The	O
number	O
shows	O
the	O
quantities	O
of	O
rising	O
and	O
decreasing	O
lipids	O
.	O
The	O
X	O
-	O
axis	O
shows	O
the	O
median	O
of	O
Xlogp	O
,	O
which	O
correlates	O
with	O
the	O
lipophilicity	O
of	O
classes	O
,	O
so	O
polar	O
classes	O
are	O
shown	O
on	O
the	O
right	O
side	O
of	O
the	O
plot	O
.	O

The	O
y	O
-	O
axis	O
shows	O
the	O
negative	O
log	O
of	O
p	O
-	O
value	O
,	O
so	O
significantly	O
important	O
classes	O
are	O
shown	O
at	O
the	O
top	O
of	O
the	O
plot	O
.	O
Different	O
letters	O
of	O
the	O
same	O
index	O
represent	O
significant	O
differences	O
(	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
)	O
.	O
*	O
,	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
*	O
,	O
p	O
-	O
value	O
<	O
0	O
.	O
001	O
.	O
A	O
total	O
of	O
2	O
,	O
361	O
,	O
607	O
sequences	O
are	O
obtained	O
from	O
32	O
cecum	O
content	O
samples	O
,	O
and	O
sequencing	O
quality	O
is	O
assessed	O
using	O
the	O
rarefaction	O
curve	O
and	O
rank	O
abundance	O
curve	O
(	O
Fig	O
.	O
S4	O
)	O
.	O
PCoA	O
analysis	O
based	O
on	O
ANOSIM	O
demonstrates	O
differences	O
between	O
the	O
4	O
groups	O
(	O
p	O
-	O
value	O
=	O
0	O
.	O
012	O
,	O
Fig	O
.	O
3A	O
)	O
.	O
In	O
particular	O
,	O
C0	O
on	O
the	O
left	O
of	O
PCoA	O
was	O
separated	O
from	O
the	O
other	O
three	O
groups	O
,	O
indicating	O
the	O
gut	O
microbiota	O
changes	O
of	O
rats	O
were	O
age	O
-	O
dependent	O
.	O
Compared	O
to	O
control	O
,	O
FJ	O
-	O
intake	O
group	O
possesses	O
higher	O
alpha	O
diversity	O
as	O
measured	O
by	O
Ace	O
,	O
Chao	O
,	O
and	O
Sobs	O
indices	O
,	O
while	O
FB	O
-	O
intake	O
group	O
shows	O
similar	O
alpha	O
diversity	O
(	O
Fig	O
.	O
3B	O
)	O
.	O
Drinking	O
FJ	O
tends	O
to	O
increase	O
alpha	O
diversity	O
over	O
drinking	O
FB	O
,	O
although	O
not	O
significantly	O
.	O
A	O
broad	O
overview	O
of	O
microbial	O
taxonomic	O
data	O
is	O
displayed	O
in	O
Fig	O
.	O
3C	O
,	O
showing	O
the	O
abundance	O
variance	O
of	O
high	O
-	O
abundance	O
microorganisms	O
in	O
different	O
groups	O
.	O
Firmicutes	O
,	O
Bacteroidetes	O
,	O
Actinobacteria	O
,	O
Verrucomicrobiota	O
,	O
and	O
Proteobacteria	O
are	O
the	O
top	O
five	O
phyla	O
.	O
Notably	O
,	O
Firmicutes	O
and	O
Bacteroidota	O
are	O
the	O
dominant	O
phyla	O
in	O
each	O
sample	O
and	O
their	O
total	O
relative	O
abundance	O
reached	O
98	O
.	O
27	O
±	O
1	O
.	O
10	O
%	O
(	O
C0	O
)	O
,	O
98	O
.	O
68	O
±	O
0	O
.	O
54	O
%	O
(	O
control	O
)	O
,	O
98	O
.	O
35	O
±	O
0	O
.	O
77	O
%	O
(	O
FJ	O
-	O
intake	O
)	O
,	O
and	O
97	O
.	O
99	O
±	O
1	O
.	O
19	O
%	O
(	O
FB	O
-	O
intake	O
)	O
.	O
Moreover	O
,	O
a	O
significantly	O
reduced	O
F	O
/	O
B	O
ratio	O
is	O
revealed	O
in	O
FJ	O
-	O
intake	O
group	O
against	O
control	O
and	O
FB	O
-	O
intake	O
groups	O
(	O
Fig	O
.	O
3D	O
)	O
.	O
The	O
reduced	O
F	O
/	O
B	O
ratio	O
in	O
FJ	O
-	O
intake	O
group	O
mainly	O
results	O
from	O
the	O
increase	O
of	O
Bacteroidota	O
(	O
phylum	O
)	O
.	O

Especially	O
,	O
Bacteroidia	O
(	O
class	O
)	O
,	O
Bacteroidales	O
(	O
order	O
)	O
,	O
and	O
Muribaculaceae	O
(	O
family	O
)	O
all	O
come	O
from	O
the	O
same	O
cladogenesis	O
of	O
Bacteroidota	O
(	O
phylum	O
)	O
,	O
and	O
they	O
increase	O
significantly	O
in	O
FJ	O
-	O
intake	O
group	O
against	O
both	O
control	O
and	O
FB	O
-	O
intake	O
groups	O
(	O
Fig	O
.	O
3E	O
)	O
.	O
For	O
B	O
,	O
D	O
,	O
and	O
E	O
,	O
the	O
Kruskal	O
-	O
Wallis	O
rank	O
-	O
sum	O
test	O
followed	O
by	O
Game	O
-	O
Howell	O
was	O
conducted	O
.	O
*	O
,	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
p	O
-	O
value	O
<	O
0	O
.	O
01	O
;	O
*	O
*	O
*	O
,	O
p	O
-	O
value	O
<	O
0	O
.	O
001	O
.	O
To	O
find	O
the	O
constant	O
differential	O
bioactive	O
metabolites	O
,	O
metabolomics	O
was	O
conducted	O
on	O
FJ	O
and	O
FB	O
.	O
Totally	O
,	O
159	O
potential	O
markers	O
are	O
determined	O
via	O
OPLS	O
-	O
DA	O
model	O
and	O
S	O
-	O
plot	O
(	O
Fig	O
.	O
S5	O
)	O
.	O
The	O
potential	O
markers	O
with	O
fold	O
change	O
(	O
FC	O
)	O
value	O
>	O
5	O
are	O
identified	O
,	O
and	O
they	O
are	O
mainly	O
amino	O
acids	O
,	O
sugars	O
,	O
organic	O
acids	O
,	O
and	O
flavonoids	O
(	O
Table	O
S4	O
)	O
.	O
Interestingly	O
,	O
8	O
flavonoids	O
,	O
which	O
are	O
naringenin	O
,	O
quercetin	O
,	O
hesperetin	O
,	O
nobiletin	O
,	O
narirutin	O
,	O
vicenin	O
2	O
,	O
didymin	O
,	O
and	O
hesperidin	O
are	O
significantly	O
higher	O
in	O
FJ	O
,	O
and	O
their	O
FC	O
values	O
between	O
FJ	O
and	O
FB	O
are	O
11	O
.	O
3	O
on	O
average	O
,	O
with	O
quercetin	O
and	O
hesperetin	O
achieving	O
the	O
higher	O
FC	O
value	O
of	O
28	O
.	O
3	O
and	O
26	O
.	O
2	O
(	O
Fig	O
.	O
4	O
and	O
Table	O
S4	O
)	O
.	O
These	O
findings	O
guided	O
multiple	O
correlation	O
analysis	O
between	O
the	O
8	O
flavonoids	O
and	O
markedly	O
altered	O
gut	O
microbiota	O
.	O
The	O
markedly	O
altered	O
gut	O
microbiota	O
is	O
obtained	O
with	O
LDA	O
scores	O
>	O
2	O
through	O
LEfSe	O
analysis	O
(	O
Fig	O
.	O
5A	O
)	O
.	O
Fifteen	O
bacterial	O
taxa	O
from	O
Bacteroidetes	O
and	O
Desulfobacterota	O
significantly	O
increased	O
in	O
the	O
FJ	O
-	O
intake	O
group	O
,	O
while	O
the	O
other	O
15	O
bacterial	O
taxa	O
from	O
Firmicutes	O
and	O
Actinobacteriota	O
markedly	O
increased	O
in	O
the	O
FB	O
-	O
intake	O
group	O
.	O
The	O
correlation	O
analysis	O
illustrates	O
that	O
nobiletin	O
and	O
hesperetin	O
possess	O
the	O
highest	O
number	O
of	O
significant	O
correlations	O
,	O
while	O
vicenin	O
2	O
shows	O
the	O
lowest	O
number	O
of	O
significant	O
correlations	O
(	O
Fig	O
.	O

5B	O
)	O
.	O
In	O
terms	O
of	O
microbiota	O
,	O
bacterial	O
taxa	O
from	O
Bacteroidetes	O
and	O
Firmicutes	O
exhibit	O
the	O
highest	O
number	O
of	O
significant	O
positive	O
and	O
negative	O
correlations	O
with	O
flavonoids	O
,	O
respectively	O
.	O
Similar	O
to	O
bacterial	O
taxa	O
from	O
Bacteroidetes	O
,	O
bacterial	O
taxa	O
from	O
Desulfobacterota	O
are	O
positively	O
correlated	O
with	O
flavonoids	O
as	O
well	O
,	O
while	O
bacterial	O
taxa	O
from	O
Actinobacteriota	O
are	O
the	O
opposite	O
(	O
Fig	O
.	O
5C	O
)	O
.	O
Additionally	O
,	O
it	O
is	O
evident	O
that	O
except	O
for	O
vicenin	O
2	O
,	O
the	O
other	O
7	O
flavonoids	O
show	O
significant	O
negative	O
correlations	O
with	O
the	O
F	O
/	O
B	O
ratio	O
(	O
Fig	O
.	O
5B	O
)	O
.	O
The	O
aforementioned	O
results	O
confirmed	O
that	O
higher	O
flavonoids	O
in	O
FJ	O
were	O
conducive	O
to	O
improving	O
bacterial	O
taxa	O
from	O
Bacteroidetes	O
and	O
Desulfobacterota	O
,	O
while	O
they	O
were	O
detrimental	O
to	O
the	O
growth	O
of	O
bacterial	O
taxa	O
from	O
Firmicutes	O
and	O
Actinobacteriota	O
,	O
hence	O
achieving	O
a	O
decreased	O
F	O
/	O
B	O
ratio	O
.	O
For	O
B	O
,	O
node	O
size	O
is	O
proportional	O
to	O
the	O
number	O
of	O
significant	O
correlations	O
.	O
Nodes	O
are	O
colored	O
according	O
to	O
groups	O
:	O
orange	O
—	O
juice	O
flavonoids	O
and	O
green	O
—	O
gut	O
microbiota	O
.	O
Solid	O
edges	O
—	O
positive	O
correlations	O
,	O
marquee	O
equal	O
dash	O
edges	O
—	O
negative	O
correlations	O
.	O
Only	O
correlations	O
with	O
correlation	O
coefficient	O
>	O
0	O
.	O
5	O
and	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
are	O
displayed	O
in	O
network	O
graphs	O
.	O
For	O
C	O
,	O
bacterial	O
taxa	O
with	O
an	O
LDA	O
score	O
>	O
2	O
.	O
0	O
are	O
written	O
in	O
black	O
,	O
while	O
the	O
others	O
are	O
written	O
in	O
white	O
.	O
To	O
explore	O
the	O
role	O
of	O
gut	O
microbiota	O
in	O
rat	O
response	O
to	O
2	O
drinks	O
,	O
a	O
total	O
of	O
309	O
functional	O
KEGG	O
categories	O
were	O
obtained	O
by	O
PICRUSt2	O
.	O
Among	O
them	O
,	O
17	O
KEGG	O
categories	O
(	O
level	O
3	O
)	O
significantly	O
differ	O
between	O
FJ	O
-	O
intake	O
and	O
FB	O
-	O
intake	O
groups	O
(	O
Fig	O
.	O
6A	O
)	O
.	O
FJ	O
-	O
intake	O
group	O
,	O
which	O
was	O
characterized	O
by	O
bacterial	O
taxa	O
from	O
Bacteroidetes	O
and	O
Desulfobacterota	O
,	O
stimulated	O
the	O
functional	O
pathways	O
of	O
sphingolipid	O
metabolism	O
,	O
alpha	O
-	O
linolenic	O
acid	O
metabolism	O
,	O
and	O
glycosphingolipid	O
biosynthesis	O
,	O
while	O
FB	O
-	O
intake	O
group	O
,	O
which	O
was	O
characterized	O
by	O
bacterial	O
taxa	O
from	O
Firmicutes	O
and	O
Actinobacteriota	O
,	O
stimulated	O
the	O
functional	O
pathways	O
of	O
insulin	O
resistance	O
.	O

Also	O
,	O
about	O
half	O
of	O
the	O
17	O
categories	O
were	O
related	O
to	O
metabolism	O
(	O
KEGG	O
level	O
1	O
)	O
,	O
indicating	O
drinks	O
could	O
primarily	O
alter	O
microbial	O
metabolism	O
.	O
Cecum	O
and	O
serum	O
metabolites	O
are	O
sensitive	O
to	O
drinks	O
and	O
are	O
tightly	O
involved	O
in	O
functional	O
pathways	O
.	O
C17	O
-	O
sphinganine	O
,	O
belonging	O
to	O
sphingolipid	O
,	O
was	O
identified	O
in	O
the	O
serum	O
of	O
rats	O
,	O
and	O
it	O
was	O
higher	O
in	O
FB	O
-	O
intake	O
group	O
compared	O
to	O
FJ	O
-	O
intake	O
group	O
,	O
with	O
an	O
FC	O
value	O
of	O
2	O
.	O
3	O
.	O
Further	O
,	O
it	O
negatively	O
correlates	O
with	O
sphingolipid	O
metabolism	O
(	O
Fig	O
.	O
6B	O
)	O
.	O
C17	O
-	O
sphinganine	O
in	O
serum	O
is	O
a	O
specific	O
biomarker	O
of	O
renal	O
disorder	O
(	O
Lin	O
et	O
al	O
.	O
,	O
2012	O
)	O
,	O
and	O
its	O
enhanced	O
level	O
in	O
FB	O
-	O
intake	O
group	O
might	O
indicate	O
a	O
potential	O
chronic	O
renal	O
disorder	O
.	O
Dimethyl	O
-	O
L	O
-	O
arginine	O
(	O
ADMA	O
)	O
is	O
recognized	O
as	O
an	O
essential	O
biomarker	O
of	O
metabolic	O
syndrome	O
(	O
Etxeberria	O
et	O
al	O
.	O
,	O
2015	O
;	O
Sibal	O
et	O
al	O
.	O
,	O
2010	O
)	O
,	O
which	O
is	O
positively	O
correlated	O
with	O
many	O
insulin	O
-	O
resistant	O
states	O
and	O
thus	O
interferes	O
with	O
insulin	O
signaling	O
(	O
Sydow	O
et	O
al	O
.	O
,	O
2005	O
)	O
,	O
increasing	O
the	O
risk	O
of	O
diabetes	O
,	O
hypertension	O
,	O
and	O
hypercholesterolemia	O
(	O
De	O
Gennaro	O
Colonna	O
,	O
Bianchi	O
,	O
Pascale	O
,	O
Ferrario	O
,	O
Morelli	O
,	O
Pascale	O
,	O
et	O
al	O
.	O
,	O
2009	O
;	O
Siervo	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O
Also	O
,	O
ADMA	O
is	O
generated	O
by	O
catalyzing	O
the	O
transfer	O
of	O
methyl	O
groups	O
from	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
methionine	O
(	O
SAM	O
)	O
to	O
arginine	O
in	O
target	O
proteins	O
(	O
Hong	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O
In	O
this	O
work	O
,	O
ADMA	O
and	O
SAM	O
in	O
cecum	O
show	O
significantly	O
positive	O
and	O
negative	O
correlations	O
with	O
insulin	O
resistance	O
(	O
Fig	O
.	O
6C	O
and	O
D	O
)	O
,	O
displaying	O
the	O
transfer	O
of	O
SAM	O
into	O
ADMA	O
and	O
hence	O
causing	O
insulin	O
resistance	O
.	O
Additionally	O
,	O
the	O
excess	O
fructose	O
in	O
FB	O
may	O
partly	O
be	O
contributed	O
to	O
renal	O
disorder	O
via	O
fast	O
lipid	O
accumulation	O
(	O
Fig	O
.	O
6E	O
)	O
,	O
which	O
is	O
detailed	O
in	O
the	O
discussion	O
.	O

KHK	O
,	O
ketohexokinase	O
;	O
HK	O
,	O
hexokinase	O
;	O
ALDOB	O
,	O
aldolase	O
B	O
;	O
DHAP	O
,	O
dihydroxyacetone	O
phosphate	O
;	O
F1P	O
,	O
fructose	O
-	O
1	O
-	O
phosphate	O
;	O
GA	O
,	O
glyceraldehyde	O
;	O
SM	O
,	O
sphingomyelin	O
;	O
Cer	O
,	O
ceramide	O
;	O
FA	O
,	O
fatty	O
acid	O
;	O
TAG	O
,	O
triacylglycerol	O
;	O
DAG	O
,	O
diacylglycerol	O
;	O
MAG	O
,	O
monoacylglycerols	O
;	O
PC	O
,	O
choline	O
glycerophospholipid	O
;	O
PE	O
,	O
phosphatidylethanolamine	O
;	O
LPC	O
,	O
lysophosphatidylcholine	O
;	O
LPE	O
,	O
lysophosphatidylethanolamine	O
;	O
SAM	O
,	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
methionine	O
;	O
CDP	O
-	O
choline	O
,	O
cytidine	O
diphosphate	O
-	O
choline	O
.	O
The	O
NOVA	O
food	O
classification	O
divides	O
foods	O
into	O
four	O
categories	O
based	O
on	O
food	O
processing	O
degrees	O
.	O
It	O
divides	O
foods	O
into	O
four	O
categories	O
:	O
unprocessed	O
and	O
minimally	O
processed	O
foods	O
,	O
processed	O
culinary	O
ingredients	O
,	O
processed	O
foods	O
,	O
and	O
ultra	O
-	O
processed	O
foods	O
(	O
Monteiro	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
FB	O
and	O
FJ	O
belong	O
to	O
ultra	O
-	O
processed	O
food	O
and	O
minimally	O
processed	O
food	O
,	O
respectively	O
.	O
Although	O
FAO	O
guidelines	B-methodology
appeal	O
to	O
promote	O
the	O
consumption	O
of	O
minimally	O
processed	O
foods	O
and	O
avoid	O
the	O
use	O
of	O
ultra	O
-	O
processed	O
foods	O
,	O
the	O
consequence	O
of	O
food	O
processing	O
degrees	O
on	O
health	O
outcomes	O
was	O
not	O
adequately	O
illustrated	O
(	O
Food	O
and	O
Agriculture	O
Organization	O
of	O
the	O
United	O
Nations	O
,	O
2015	O
)	O
.	O
Metabolic	O
syndrome	O
,	O
an	O
essential	O
part	O
of	O
the	O
epidemiology	O
of	O
CNCD	O
,	O
would	O
raise	O
the	O
risk	O
of	O
individuals	O
developing	O
obesity	O
,	O
diabetes	O
mellitus	O
,	O
insulin	O
resistance	O
,	O
and	O
atherosclerotic	O
cardiovascular	O
disease	O
(	O
Kotlyarov	O
and	O
Bulgakov	O
,	O
2021	O
;	O
Markopoulou	O
et	O
al	O
.	O
,	O
2019	O
;	O
Neergaard	O
et	O
al	O
.	O
,	O
2017	O
;	O
Vega	O
,	O
2004	O
)	O
.	O
It	O
mainly	O
results	O
from	O
a	O
long	O
-	O
term	O
diet	O
imbalance	O
and	O
microbial	O
dysbiosis	O
,	O
affecting	O
collaborative	O
metabolic	O
pathways	O
(	O
Remely	O
and	O
Haslberger	O
,	O
2017	O
)	O
.	O
Insulin	O
resistance	O
is	O
one	O
of	O
the	O
most	O
accepted	O
unifying	O
theories	O
explaining	O
the	O
pathophysiology	O
of	O
metabolic	O
syndrome	O
(	O
Mikhail	O
,	O
2009	O
)	O
.	O

We	O
found	O
that	O
the	O
microbial	O
function	O
indicated	O
an	O
enhanced	O
insulin	O
resistance	O
pathway	O
,	O
which	O
has	O
been	O
identified	O
as	O
a	O
potential	O
contributor	O
to	O
metabolic	O
syndrome	O
in	O
the	O
host	O
(	O
Caricilli	O
and	O
Saad	O
,	O
2013	O
;	O
He	O
and	O
Li	O
,	O
2020	O
)	O
.	O
Moreover	O
,	O
insulin	O
resistance	O
plays	O
an	O
essential	O
role	O
in	O
renal	O
disorder	O
(	O
De	O
Cosmo	O
,	O
Menzaghi	O
,	O
Prudente	O
and	O
Trischitta	O
,	O
2013	O
)	O
.	O
In	O
other	O
words	O
,	O
renal	O
triacylglycerol	O
accumulation	O
,	O
as	O
a	O
marker	O
of	O
lipotoxicity	O
,	O
is	O
associated	O
with	O
insulin	O
resistance	O
(	O
Guebre	O
-	O
Egziabher	O
et	O
al	O
.	O
,	O
2013	O
;	O
Unger	O
and	O
Scherer	O
,	O
2010	O
)	O
.	O
We	O
speculated	O
that	O
the	O
upregulated	O
insulin	O
resistance	O
pathway	O
led	O
to	O
renal	O
triacylglycerol	O
accumulation	O
and	O
increased	O
kidney	O
mass	O
index	O
,	O
which	O
could	O
cause	O
potential	O
chronic	O
renal	O
disorder	O
in	O
FB	O
-	O
intake	O
group	O
.	O
Additionally	O
,	O
insulin	O
plays	O
a	O
dominant	O
role	O
in	O
regulating	O
food	O
intake	O
(	O
Rezek	O
,	O
1976	O
)	O
,	O
and	O
individuals	O
who	O
present	O
with	O
insulin	O
resistance	O
have	O
a	O
higher	O
preference	O
for	O
food	O
,	O
likely	O
due	O
to	O
a	O
reduction	O
in	O
the	O
ability	O
of	O
insulin	O
to	O
inhibit	O
satiety	O
(	O
Tiedemann	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
Glucose	O
and	O
fructose	O
can	O
suppress	O
energy	O
intake	O
,	O
but	O
this	O
effect	O
is	O
mainly	O
in	O
the	O
short	O
term	O
.	O
In	O
young	O
men	O
,	O
either	O
75	O
g	O
(	O
G	O
.	O
Harvey	O
et	O
al	O
.	O
,	O
2002	O
)	O
or	O
50	O
g	O
(	O
Rogers	O
et	O
al	O
.	O
,	O
1988	O
)	O
of	O
glucose	O
in	O
drinks	O
reduced	O
food	O
intake	O
1	O
h	O
later	O
.	O
Consumption	O
of	O
50	O
g	O
fructose	O
in	O
a	O
drink	O
suppresses	O
energy	O
intake	O
to	O
an	O
even	O
greater	O
extent	O
at	O
test	O
meals	O
from	O
38	O
min	O
to	O
2	O
.	O
25	O
h	O
later	O
(	O
Anderson	O
,	O
1995	O
;	O
Anderson	O
and	O
Woodend	O
,	O
2003	O
;	O
A	O
.	O
G	O
.	O
Harvey	O
,	O
Catherine	O
Nicole	O
,	O
Woodend	O
,	O
&	O
Wolever	O
Thomas	O
,	O
2002	O
)	O
.	O
Consistent	O
with	O
our	O
results	O
,	O
FB	O
containing	O
significant	O
higher	O
glucose	O
and	O
fructose	O
contents	O
effectively	O
reduced	O
the	O
food	O
intakes	O
of	O
rats	O
in	O
the	O
early	O
stage	O
,	O
but	O
after	O
2	O
weeks	O
,	O
the	O
food	O
intakes	O
of	O
rats	O
in	O
FB	O
-	O
intake	O
group	O
increased	O
significantly	O
,	O
which	O
was	O
higher	O
than	O
that	O
in	O
control	O
and	O
FJ	O
-	O
intake	O
groups	O
in	O
the	O
long	O
term	O
.	O
Combined	O
with	O
the	O
enhanced	O
insulin	O
resistance	O
pathway	O
,	O
FB	O
-	O
intake	O
group	O
might	O
gradually	O
develop	O
insulin	O
resistance	O
after	O
the	O
2	O
-	O
week	O
intervention	O
,	O
resulting	O
in	O
increased	O
food	O
intake	O
and	O
weight	O
gain	O
.	O

Moreover	O
,	O
the	O
excess	O
fructose	O
in	O
FB	O
may	O
partly	O
be	O
contributed	O
to	O
renal	O
disorder	O
via	O
fast	O
lipid	O
accumulation	O
(	O
Fig	O
.	O
6E	O
)	O
.	O
Fructolysis	O
bypasses	O
glycogen	O
synthase	O
,	O
and	O
the	O
enzymolysis	O
rate	O
of	O
fructose	O
kinase	O
(	O
ketohexokinase	O
,	O
KHK	O
)	O
is	O
much	O
higher	O
than	O
glucose	O
kinase	O
(	O
hexokinase	O
,	O
HK	O
)	O
(	O
Asipu	O
,	O
Hayward	O
,	O
O	O
'	O
Reilly	O
and	O
Bonthron	O
,	O
2003	O
)	O
.	O
Aldolase	O
B	O
(	O
ALDOB	O
)	O
directly	O
splits	O
fructose	O
-	O
1	O
-	O
phosphate	O
into	O
dihydroxyacetone	O
phosphate	O
(	O
DHAP	O
)	O
and	O
glyceraldehyde	O
(	O
GA	O
)	O
without	O
overcoming	O
the	O
rate	O
-	O
limiting	O
phosphofructokinase	O
(	O
PFK	O
)	O
(	O
Bulik	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Hence	O
,	O
fructose	O
is	O
rapidly	O
metabolized	O
,	O
and	O
its	O
metabolites	O
are	O
potent	O
activators	O
of	O
glycolytic	O
enzymes	O
and	O
lipogenic	O
transcription	O
factors	O
,	O
leading	O
to	O
a	O
rapid	O
accumulation	O
of	O
TAG	O
in	O
kidney	O
(	O
Hannou	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
The	O
renal	O
triacylglycerol	O
accumulation	O
was	O
proven	O
by	O
most	O
lipids	O
in	O
GL03	O
increasing	O
in	O
FB	O
-	O
intake	O
group	O
(	O
Fig	O
.	O
2F	O
)	O
.	O
Further	O
,	O
triacylglycerol	O
would	O
be	O
converted	O
to	O
DAG	O
,	O
generating	O
PC	O
,	O
LPC	O
,	O
and	O
SM	O
(	O
Han	O
,	O
2016	O
)	O
,	O
verified	O
by	O
the	O
lipid	O
alteration	O
of	O
GP01	O
,	O
SP02	O
,	O
and	O
SP03	O
in	O
FB	O
-	O
intake	O
group	O
(	O
Fig	O
.	O
2F	O
)	O
.	O
Moreover	O
,	O
excess	O
free	O
fructose	O
(	O
EFF	O
)	O
is	O
defined	O
as	O
fructose	O
-	O
to	O
-	O
glucose	O
ratios	O
that	O
exceed	O
1	O
(	O
Dechristopher	O
,	O
2015	O
)	O
.	O
FB	O
contains	O
more	O
EFF	O
,	O
while	O
FJ	O
nearly	O
does	O
not	O
.	O
Although	O
we	O
have	O
observed	O
higher	O
EFF	O
contents	O
in	O
FB	O
yield	O
renal	O
disorder	O
,	O
subsequent	O
research	O
is	O
required	O
to	O
probe	O
the	O
molecular	O
mechanism	O
of	O
high	O
EFF	O
-	O
induced	O
renal	O
disorder	O
.	O
On	O
the	O
contrary	O
,	O
FJ	O
prevented	O
metabolic	O
syndrome	O
with	O
downregulated	O
insulin	O
resistance	O
.	O

Markers	O
of	O
insulin	O
resistance	O
,	O
poor	O
control	O
of	O
blood	O
glucose	O
levels	O
,	O
and	O
systemic	O
inflammation	O
were	O
associated	O
with	O
lower	O
gut	O
microbiome	O
diversity	O
(	O
Zouiouich	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
Hence	O
,	O
the	O
significantly	O
higher	O
alpha	O
diversity	O
in	O
FJ	O
-	O
intake	O
group	O
would	O
be	O
conducive	O
to	O
downregulated	O
insulin	O
resistance	O
.	O
Moreover	O
,	O
the	O
high	O
F	O
/	O
B	O
ratio	O
association	O
with	O
obesity	O
and	O
metabolic	O
syndrome	O
seems	O
to	O
be	O
a	O
reasonably	O
recurrent	O
finding	O
(	O
Woting	O
and	O
Blaut	O
,	O
2016	O
)	O
,	O
suggesting	O
the	O
lower	O
F	O
/	O
B	O
ratio	O
prevents	O
obesity	O
and	O
metabolic	O
syndrome	O
in	O
FJ	O
-	O
intake	O
group	O
.	O
Furthermore	O
,	O
the	O
low	O
F	O
/	O
B	O
ratio	O
mainly	O
comes	O
from	O
the	O
high	O
abundance	O
of	O
bacterial	O
taxa	O
from	O
Bacteroides	O
,	O
which	O
are	O
Bacterioidia	O
(	O
Class	O
)	O
,	O
Bacteroidales	O
(	O
Order	O
)	O
,	O
Muribaculaceae	O
(	O
Family	O
)	O
,	O
and	O
Prevotella	O
(	O
Genus	O
)	O
,	O
and	O
these	O
above	O
bacterial	O
taxa	O
are	O
negatively	O
correlated	O
with	O
metabolic	O
syndrome	O
.	O
For	O
instance	O
,	O
attenuated	O
metabolic	O
syndrome	O
was	O
related	O
to	O
the	O
increased	O
Bacteroidia	O
(	O
John	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
The	O
enhanced	O
Bacteroidales	O
were	O
positively	O
correlated	O
with	O
the	O
reduced	O
metabolic	O
syndrome	O
of	O
fat	O
accumulation	O
and	O
lipid	O
disorders	O
(	O
Xu	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
As	O
a	O
beneficial	O
composition	O
of	O
gut	O
microbiota	O
,	O
the	O
increased	O
richness	O
of	O
Muribaculaceae	O
was	O
an	O
approach	O
for	O
metabolic	O
syndrome	O
alleviation	O
(	O
J	O
.	O
Chen	O
et	O
al	O
.	O
,	O
2021	O
;	O
Z	O
.	O
-	O
R	O
.	O
Li	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
The	O
flavonoids	O
may	O
be	O
one	O
of	O
the	O
reasons	O
for	O
the	O
health	O
benefit	O
of	O
FJ	O
intake	O
.	O
Flavonoids	O
,	O
such	O
as	O
hesperidin	O
and	O
quercetin	O
,	O
could	O
modulate	O
postprandial	O
glycaemic	O
response	O
(	O
Kerimi	O
et	O
al	O
.	O
,	O
2019	O
)	O
and	O
the	O
gut	O
microbiota	O
structure	O
to	O
prevent	O
metabolic	O
diseases	O
(	O
Estruel	O
-	O
Amades	O
et	O
al	O
.	O
,	O
2019	O
;	O
Porras	O
et	O
al	O
.	O
,	O
2019	O
)	O
,	O
which	O
might	O
explain	O
why	O
100	O
%	O
orange	O
juice	O
has	O
a	O
neutral	O
effect	O
on	O
rats	O
although	O
naturally	O
containing	O
similar	O
amounts	O
of	O
free	O
sugars	O
as	O
sugar	O
-	O
sweetened	O
beverage	O
.	O
Two	O
key	O
factors	O
,	O
the	O
type	O
of	O
flavonoids	O
and	O
dose	O
,	O
are	O
tightly	O
related	O
to	O
the	O
effect	O
of	O
flavonoids	O
on	O
gut	O
microbiota	O
structure	O
.	O

Flavonoids	O
occur	O
as	O
aglycones	O
,	O
glycosides	O
,	O
and	O
methylated	O
derivatives	O
(	O
Kumar	O
and	O
Pandey	O
,	O
2013	O
)	O
.	O
Among	O
the	O
8	O
flavonoids	O
,	O
naringenin	O
,	O
quercetin	O
,	O
hesperetin	O
,	O
and	O
nobiletin	O
belong	O
to	O
aglycones	O
,	O
while	O
narirutin	O
,	O
didymin	O
,	O
hesperidin	O
,	O
and	O
vicenin	O
2	O
belong	O
to	O
glucosides	O
,	O
especially	O
vicenin	O
2	O
containing	O
2	O
glycosides	O
.	O
Although	O
vicenin	O
2	O
is	O
4	O
.	O
9	O
times	O
higher	O
in	O
FJ	O
compared	O
to	O
FB	O
,	O
it	O
shows	O
no	O
significant	O
correlation	O
with	O
the	O
F	O
/	O
B	O
ratio	O
,	O
while	O
the	O
other	O
7	O
flavonoids	O
,	O
especially	O
naringenin	O
and	O
didymin	O
belonging	O
to	O
flavonoid	O
aglycones	O
,	O
with	O
lower	O
FC	O
values	O
of	O
3	O
.	O
3	O
and	O
3	O
.	O
1	O
,	O
are	O
negatively	O
correlated	O
to	O
the	O
F	O
/	O
B	O
ratio	O
.	O
Previous	O
studies	O
with	O
inconsistent	O
results	O
have	O
shown	O
glucosides	O
strongly	O
affect	O
the	O
bioactivity	O
of	O
flavonoids	O
:	O
some	O
studies	O
showed	O
that	O
flavonoid	O
glycosides	O
enhanced	O
more	O
bioactivity	O
than	O
their	O
flavonoid	O
aglycones	O
(	O
Xiao	O
,	O
2017	O
)	O
,	O
while	O
others	O
showed	O
that	O
glycosides	O
showed	O
no	O
bioactivity	O
(	O
Steensma	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O
Essentially	O
,	O
flavonoid	O
glycosides	O
are	O
either	O
hydrolyzed	O
in	O
the	O
small	O
intestine	O
by	O
specific	O
enzymes	O
or	O
metabolized	O
in	O
the	O
large	O
intestine	O
by	O
the	O
action	O
of	O
intestinal	O
microbiota	O
to	O
yield	O
aglycones	O
to	O
exert	O
their	O
biological	O
function	O
(	O
Baky	O
et	O
al	O
.	O
,	O
2022	O
)	O
.	O
Given	O
our	O
study	O
,	O
flavonoid	O
aglycones	O
exhibit	O
more	O
potent	O
regulatory	O
bioactivity	O
for	O
gut	O
microbiota	O
structure	O
,	O
which	O
may	O
be	O
because	O
the	O
bioactivity	O
of	O
flavonoid	O
aglycones	O
is	O
more	O
direct	O
,	O
which	O
reduces	O
the	O
uncertainty	O
of	O
the	O
conversion	O
of	O
glycosides	O
to	O
aglycones	O
.	O
Furthermore	O
,	O
the	O
different	O
effects	O
of	O
flavonoid	O
types	O
and	O
their	O
thresholds	O
on	O
gut	O
microbiota	O
structure	O
are	O
worth	O
exploring	O
thoroughly	O
.	O
However	O
,	O
it	O
is	O
hard	O
to	O
identify	O
all	O
the	O
differential	O
bioactive	O
metabolites	O
due	O
to	O
the	O
limited	O
electronic	O
database	O
.	O

Previous	O
studies	O
have	O
revealed	O
that	O
pectin	O
modulates	O
the	O
digestion	O
and	O
absorption	O
of	O
nutrients	O
,	O
regulates	O
the	O
composition	O
and	O
activity	O
of	O
the	O
gut	O
microbiota	O
,	O
and	O
affects	O
the	O
production	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
J	O
.	O
Liu	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Therefore	O
,	O
exploring	O
the	O
health	O
effects	O
of	O
pectin	O
in	O
drinks	O
,	O
which	O
is	O
a	O
comprehensive	O
system	O
,	O
is	O
very	O
complex	O
,	O
and	O
the	O
contribution	O
of	O
pectin	O
should	O
never	O
be	O
ignored	O
.	O
Disparate	O
trends	O
in	O
the	O
metabolic	O
syndrome	O
of	O
rats	O
were	O
discovered	O
in	O
FJ	O
-	O
intake	O
and	O
FB	O
-	O
intake	O
groups	O
(	O
Fig	O
.	O
7	O
)	O
.	O
FJ	O
improved	O
alpha	O
diversity	O
and	O
decreased	O
F	O
/	O
B	O
ratio	O
of	O
gut	O
microbiota	O
and	O
prevented	O
insulin	O
resistance	O
with	O
the	O
reduced	O
food	O
intake	O
in	O
FJ	O
-	O
intake	O
group	O
.	O
However	O
,	O
FB	O
possessed	O
unchanged	O
microbial	O
diversity	O
and	O
F	O
/	O
B	O
ratio	O
,	O
causing	O
insulin	O
resistance	O
with	O
renal	O
triglyceride	O
accumulation	O
,	O
increased	O
kidney	O
mass	O
index	O
as	O
well	O
as	O
steadily	O
improved	O
weight	O
change	O
in	O
FB	O
-	O
intake	O
group	O
.	O
In	O
summary	O
,	O
the	O
result	O
here	O
provided	O
valid	O
evidence	O
that	O
considering	O
only	O
the	O
sugar	O
content	O
of	O
100	O
%	O
fruit	O
juice	O
is	O
not	O
a	O
balanced	O
approach	O
,	O
and	O
the	O
multi	O
-	O
bioactive	O
metabolites	O
(	O
such	O
as	O
flavonoids	O
)	O
of	O
FJ	O
may	O
positively	O
impact	O
host	O
health	O
compared	O
with	O
FB	O
.	O
The	O
disparate	O
health	O
outcomes	O
of	O
foods	O
with	O
distinct	O
processing	O
degrees	O
were	O
further	O
illuminated	O
that	O
FJ	O
prevented	O
insulin	O
resistance	O
while	O
FB	O
caused	O
insulin	O
resistance	O
through	O
the	O
diet	O
-	O
microbiome	O
-	O
metabolic	O
pathway	O
axis	O
.	O
Our	O
results	O
clearly	O
suggest	O
that	O
FJ	O
with	O
a	O
lower	O
processing	O
degree	O
,	O
although	O
naturally	O
containing	O
similar	O
amounts	O
of	O
free	O
sugars	O
as	O
FB	O
,	O
could	O
be	O
a	O
healthier	O
drink	O
choice	O
.	O
The	O
animal	B-methodology
experiments	I-methodology
were	O
performed	O
in	O
the	O
lab	O
of	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
of	O
Beijing	O
Vital	O
River	O
Laboratory	O
Animal	O
Technology	O
Co	O
.	O
,	O
Ltd	O
.	O
All	O
experimental	O
procedures	O
described	O
here	O
were	O
conducted	O
following	O
the	O
National	O
Institutes	O
of	O
Health	O
Guidelines	B-methodology
on	O
the	O
Care	O
and	O
Use	O
of	O
Laboratory	O
Animal	O
of	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
of	O
Beijing	O
Vital	O
River	O
Laboratory	O
Animal	O
Technology	O
Co	O
.	O
,	O
Ltd	O
.	O
The	O
approve	O
code	O
is	O
SCXK	O
-	O
2016	O
–	O
0006	O
.	O
The	O
permission	O
code	O
is	O
P2021032	O
.	O
Kewen	O
Wang	O
:	O
Formal	O
analysis	O
,	O
Data	O
curation	O
,	O
Writing	O
–	O
original	O
draft	O
.	O
Yang	O
Zhao	O
:	O
Writing	O
–	O
original	O
draft	O
.	O
Lei	O
Xu	O
:	O
Writing	O
–	O
original	O
draft	O
.	O
Xiaojun	O
Liao	O
:	O
Conceptualization	O
,	O
Supervision	O
.	O

Zhenzhen	O
Xu	O
:	O
Conceptualization	O
,	O
Formal	O
analysis	O
,	O
Methodology	O
,	O
Writing	O
–	O
review	O
&	O
editing	O
,	O
Supervision	O
.	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
known	O
competing	O
financial	O
interests	O
or	O
personal	O
relationships	O
that	O
could	O
have	O
appeared	O
to	O
influence	O
the	O
work	O
reported	O
in	O
this	O
paper	O
.	O
This	O
research	O
was	O
funded	O
by	O
10	O
.	O
13039	O
/	O
501100001809National	O
Natural	O
Science	O
Foundation	O
of	O
China	O
(	O
grant	O
number	O
32072234	O
and	O
32222067	O
)	O
,	O
and	O
National	O
Key	O
R	O
&	O
D	O
Program	O
of	O
China	O
(	O
grant	O
number	O
2017YFD0400705	O
)	O
.	O
We	O
thank	O
the	O
Shanghai	O
Luming	O
biological	O
technology	O
co	O
.	O
,	O
LTD	O
(	O
Shanghai	O
,	O
China	O
)	O
for	O
uploading	O
our	O
metabolomics	O
data	O
online	O
.	O
Appendix	O
ASupplementary	O
data	O
to	O
this	O
article	O
can	O
be	O
found	O
online	O
at	O
https	O
:	O
/	O
/	O
doi	O
.	O
org	O
/	O
10	O
.	O
1016	O
/	O
j	O
.	O
crfs	O
.	O
2023	O
.	O
100454	O
.	O

Ketogenic	O
and	O
Low	O
FODMAP	O
Diet	O
in	O
Therapeutic	O
Management	O
of	O
a	O
Young	O
Autistic	O
Patient	O
with	O
Epilepsy	O
and	O
Dysmetabolism	O
Poorly	O
Responsive	O
to	O
Therapies	O
:	O
Clinical	O
Response	O
and	O
Effects	O
of	O
Intestinal	O
Microbiota	O
microbiota	O
;	O
ketogenic	O
diet	O
;	O
FODMAPs	O
;	O
seizures	O
;	O
ASD	O
;	O
ASD	O
-	O
epilepsy	O
;	O
case	B-methodology
report	I-methodology
Autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
is	O
often	O
associated	O
with	O
several	O
intestinal	O
and	O
/	O
or	O
metabolic	O
disorders	O
as	O
well	O
as	O
neurological	O
manifestations	O
such	O
as	O
epilepsy	O
(	O
ASD	O
-	O
E	O
)	O
.	O
Those	O
presenting	O
these	O
neuropathological	O
conditions	O
share	O
common	O
aspects	O
in	O
terms	O
of	O
gut	O
microbiota	O
composition	O
.	O
The	O
use	O
of	O
microbiota	O
intervention	O
strategies	O
may	O
be	O
an	O
approach	O
to	O
consider	O
in	O
the	O
management	O
of	O
these	O
cases	O
.	O
We	O
describe	O
the	O
case	O
of	O
a	O
17	O
-	O
year	O
-	O
old	O
girl	O
affected	O
by	O
ASD	O
,	O
reduced	O
growth	O
,	O
neurological	O
development	O
delay	O
,	O
mutations	O
in	O
the	O
PGM1	O
and	O
EEF1A2	O
genes	O
(	O
in	O
the	O
absence	O
of	O
clinically	O
manifested	O
disease	O
)	O
and	O
,	O
intestinal	O
disorders	O
such	O
as	O
abdominal	O
pain	O
and	O
diarrhea	O
associated	O
with	O
weight	O
loss	O
.	O
As	O
she	O
demonstrated	O
poor	O
responsiveness	O
to	O
the	O
therapies	O
provided	O
,	O
we	O
attempted	O
two	O
specific	O
dietary	O
patterns	O
:	O
a	O
ketogenic	O
diet	O
,	O
followed	O
by	O
a	O
low	O
fermentable	O
oligosaccharides	O
,	O
disaccharides	O
,	O
monosaccharides	O
and	O
polyols	O
(	O
FODMAP	O
)	O
diet	O
,	O
with	O
the	O
aim	O
of	O
improving	O
her	O
neurological	O
,	O
metabolic	O
,	O
and	O
intestinal	O
symptoms	O
through	O
modulation	O
of	O
the	O
gut	O
microbiota	O
’	O
s	O
composition	O
.	O
The	O
ketogenic	O
diet	O
(	O
KD	O
)	O
provided	O
a	O
reduction	O
in	O
Firmicutes	O
,	O
Bacteroidetes	O
,	O
and	O
Proteobacteria	O
.	O
Although	O
her	O
intestinal	O
symptoms	O
improved	O
,	O
KD	O
was	O
poorly	O
tolerated	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
passage	O
to	O
a	O
low	O
FODMAPs	O
diet	O
produced	O
a	O
significant	O
improvement	O
in	O
all	O
neurological	O
,	O
intestinal	O
,	O
and	O
metabolic	O
symptoms	O
and	O
was	O
well	O
-	O
tolerated	O
.	O
The	O
following	O
gut	O
microbiota	O
analysis	O
showed	O
reductions	O
in	O
Actinobacteria	O
,	O
Firmicutes	O
,	O
Lactobacilli	O
,	O
and	O
Bifidobacteria	O
.	O
The	O
alpha	O
biodiversity	O
was	O
consistently	O
increased	O
and	O
the	O
Firmicutes	O
/	O
Bacteroidetes	O
ratio	O
decreased	O
,	O
reducing	O
the	O
extent	O
of	O
fermentative	O
dysbiosis	O
.	O

Gut	O
microbiota	O
could	O
be	O
a	O
therapeutic	O
target	O
to	O
improve	O
ASD	O
-	O
related	O
symptoms	O
.	O
Further	O
studies	O
are	O
needed	O
to	O
better	O
understand	O
the	O
correlation	O
between	O
gut	O
microbiota	O
composition	O
and	O
ASD	O
,	O
and	O
its	O
possible	O
involvement	O
in	O
the	O
physiopathology	O
of	O
ASD	O
.	O
Autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
is	O
a	O
condition	O
that	O
can	O
be	O
associated	O
with	O
other	O
neurological	O
manifestations	O
such	O
as	O
epilepsy	O
,	O
defining	O
a	O
phenotypic	O
manifestation	O
common	O
to	O
various	O
genetic	O
disorders	O
:	O
ASD	O
-	O
epilepsy	O
(	O
ASD	O
-	O
E	O
)	O
[	O
1	O
]	O
.	O
This	O
clinical	O
manifestation	O
can	O
be	O
considerably	O
worsened	O
by	O
associated	O
metabolic	O
disorders	O
,	O
which	O
can	O
make	O
patient	O
management	O
a	O
decidedly	O
complex	O
task	O
,	O
especially	O
when	O
a	O
known	O
clinical	O
–	O
syndromic	O
scenario	O
is	O
not	O
readily	O
recognizable	O
.	O
A	O
low	O
fermentable	O
oligosaccharides	O
,	O
disaccharides	O
,	O
monosaccharides	O
and	O
polyols	O
(	O
FODMAP	O
)	O
diet	O
was	O
proposed	O
by	O
Nogay	O
et	O
al	O
.	O
as	O
a	O
possible	O
intervention	O
for	O
the	O
management	O
of	O
gastrointestinal	O
disorders	O
in	O
children	O
with	O
ASD	O
-	O
E	O
.	O
This	O
diet	O
begins	O
with	O
the	O
assumption	O
that	O
insufficient	O
digestion	O
and	O
absorption	O
of	O
some	O
short	O
-	O
chain	O
carbohydrates	O
can	O
lead	O
to	O
symptoms	O
such	O
as	O
abdominal	O
pain	O
and	O
distension	O
,	O
diarrhea	O
and	O
/	O
or	O
intestinal	O
constipation	O
,	O
which	O
also	O
occur	O
at	O
the	O
microbiota	O
level	O
.	O
In	O
general	O
,	O
the	O
initial	O
benefits	O
are	O
observed	O
after	O
the	O
first	O
week	O
of	O
the	O
diet	O
,	O
and	O
a	O
period	O
of	O
between	O
2	O
and	O
6	O
weeks	O
,	O
at	O
least	O
,	O
is	O
recommended	O
to	O
evaluate	O
the	O
clinical	O
response	O
[	O
2	O
]	O
.	O
The	O
case	O
presentation	O
was	O
redacted	O
according	O
to	O
CARE	O
guidelines	B-methodology
[	O
3	O
]	O
.	O
The	O
aim	O
of	O
this	O
report	O
was	O
to	O
describe	O
how	O
simple	O
interventions	O
such	O
as	O
a	O
low	O
-	O
FODMAP	O
diet	O
,	O
through	O
shaping	O
of	O
the	O
gut	O
microbiota	O
,	O
improved	O
ASD	O
-	O
E	O
-	O
related	O
symptoms	O
along	O
with	O
intestinal	O
and	O
metabolic	O
symptoms	O
in	O
a	O
17	O
-	O
year	O
-	O
old	O
Caucasian	O
girl	O
presenting	O
with	O
a	O
very	O
complex	O
clinical	O
pattern	O
.	O
Here	O
,	O
we	O
describe	O
the	O
case	O
of	O
a	O
17	O
-	O
year	O
-	O
old	O
Caucasian	O
girl	O
with	O
a	O
history	O
of	O
generalized	O
seizures	O
(	O
atypical	O
atonic	O
crises	O
)	O
with	O
an	O
early	O
onset	O
in	O
infancy	O
,	O
associated	O
with	O
neurological	O
development	O
delay	O
corresponding	O
to	O
autism	O
spectrum	O
disorder	O
and	O
reduced	O
growth	O
.	O
The	O
girl	O
also	O
suffered	O
stypsis	O
and	O
frequent	O
episodes	O
of	O
abdominal	O
pain	O
.	O

Genetic	O
examination	O
revealed	O
a	O
mutation	O
in	O
the	O
phosphoglucomutase	O
1	O
(	O
PGM1	O
)	O
gene	O
,	O
which	O
is	O
responsible	O
for	O
a	O
rare	O
congenital	O
genetic	O
disease	O
affecting	O
glycosylation	O
and	O
glycogen	O
storage	O
[	O
4	O
]	O
,	O
and	O
a	O
variant	O
of	O
the	O
eukaryotic	O
translation	O
elongation	O
factor	O
1	O
alpha	O
2	O
(	O
EEF1A2	O
)	O
gene	O
on	O
the	O
long	O
arm	O
of	O
the	O
cr	O
20	O
,	O
which	O
is	O
responsible	O
for	O
unspecified	O
early	O
-	O
onset	O
epileptic	O
encephalopathy	O
and	O
autosomal	O
dominant	O
non	O
-	O
syndromic	O
intellectual	O
disability	O
[	O
5	O
]	O
in	O
the	O
absence	O
of	O
clinically	O
manifested	O
disease	O
.	O
Other	O
chromosomal	O
,	O
genetic	O
,	O
and	O
mitochondrial	O
causes	O
were	O
excluded	O
during	O
thorough	O
examinations	O
in	O
important	O
European	O
pediatric	O
hospitals	O
.	O
Among	O
the	O
different	O
therapeutic	O
approaches	O
to	O
managing	O
epilepsy	O
,	O
vigabatrin	O
,	O
valproic	O
acid	O
and	O
pyridoxine	O
,	O
carbamazepine	O
,	O
clonazepam	O
,	O
and	O
clobazan	O
had	O
been	O
attempted	O
over	O
time	O
,	O
resulting	O
in	O
a	O
limited	O
neurological	O
benefit	O
for	O
a	O
short	O
period	O
of	O
time	O
,	O
especially	O
with	O
valproic	O
acid	O
and	O
pyridoxine	O
and	O
,	O
subsequently	O
,	O
clonazepam	O
;	O
however	O
,	O
her	O
behavior	O
and	O
interaction	O
worsened	O
.	O
Additionally	O
,	O
she	O
had	O
worsened	O
abdominal	O
pain	O
and	O
stool	O
consistency	O
,	O
potentially	O
due	O
to	O
the	O
involvement	O
of	O
the	O
microbiota	O
as	O
reported	O
by	O
Ilhan	O
et	O
al	O
.	O
[	O
6	O
]	O
.	O
Adverse	O
intestinal	O
reactions	O
particularly	O
seemed	O
to	O
occur	O
following	O
the	O
intake	O
of	O
a	O
large	O
number	O
of	O
pharmacological	O
excipients	O
in	O
a	O
similar	O
way	O
to	O
that	O
described	O
for	O
carboxymethylcellulose	O
[	O
7	O
]	O
.	O
However	O
,	O
drugs	O
are	O
rarely	O
available	O
in	O
pharmaceutical	O
form	O
without	O
or	O
with	O
a	O
reduced	O
content	O
of	O
excipients	O
,	O
and	O
resolving	O
these	O
symptoms	O
could	O
prove	O
very	O
complex	O
.	O
Since	O
her	O
first	O
days	O
of	O
life	O
,	O
the	O
patient	O
had	O
suffered	O
from	O
hypoglycemic	O
crises	O
exacerbated	O
by	O
the	O
introduction	O
of	O
fruit	O
and	O
carbohydrates	O
during	O
complementary	O
feeding	O
,	O
and	O
she	O
had	O
been	O
documented	O
with	O
a	O
glycemic	O
holter	O
at	O
the	O
age	O
of	O
22	O
months	O
.	O
The	O
incidence	O
of	O
these	O
events	O
reduced	O
after	O
increasing	O
meal	O
frequency	O
and	O
adding	O
corn	O
derivatives	O
to	O
her	O
diet	O
;	O
a	O
reduction	O
in	O
hypoglycemic	O
episodes	O
was	O
also	O
noted	O
following	O
valproic	O
acid	O
suspension	O
.	O
Hyperinsulinism	O
was	O
excluded	O
by	O
laboratory	O
and	O
radiological	O
exams	O
.	O

Further	O
glycemic	O
stabilization	O
was	O
obtained	O
after	O
introducing	O
acarbose	O
.	O
At	O
the	O
age	O
of	O
15	O
,	O
the	O
recurrence	O
of	O
frequent	O
episodes	O
of	O
generalized	O
seizures	O
required	O
the	O
introduction	O
of	O
clonazepam	O
;	O
a	O
new	O
onset	O
of	O
diarrheic	O
disorder	O
with	O
poorly	O
consistent	O
yellowish	O
and	O
greenish	O
stools	O
was	O
also	O
noted	O
,	O
associated	O
with	O
weight	O
loss	O
.	O
Further	O
laboratory	O
exams	O
showed	O
the	O
absence	O
of	O
Rotavirus	O
,	O
Campylobacter	O
,	O
Shigella	O
,	O
Salmonella	O
,	O
and	O
Yersinia	O
in	O
the	O
stools	O
,	O
while	O
the	O
complete	O
blood	O
count	O
,	O
cholesterol	O
,	O
total	O
proteins	O
,	O
iron	O
,	O
C	O
-	O
reactive	O
protein	O
,	O
and	O
electrolyte	O
exams	O
were	O
normal	O
,	O
virtually	O
excluding	O
malabsorption	O
and	O
/	O
or	O
inflammatory	O
bowel	O
diseases	O
.	O
In	O
March	O
2021	O
,	O
a	O
microbiota	O
analysis	O
was	O
performed	O
according	O
to	O
the	O
method	O
used	O
by	O
Mancabelli	O
and	O
Milani	O
[	O
8	O
]	O
(	O
by	O
MyMicrobiota	O
Lab	O
,	O
Pontenure	O
,	O
PC	O
,	O
Italy	O
)	O
.	O
A	O
fermentative	O
dysbiosis	O
pattern	O
was	O
observed	O
,	O
with	O
Firmicutes	O
dominance	O
,	O
Actinobacteria	O
overgrowth	O
,	O
and	O
high	O
presence	O
of	O
lactate	O
-	O
producing	O
bacteria	O
such	O
as	O
Bifidobacteria	O
,	O
Lactobacillus	O
,	O
and	O
Streptococcus	O
;	O
high	O
lactate	O
production	O
was	O
balanced	O
by	O
the	O
higher	O
presence	O
of	O
Negativicutes	O
.	O
This	O
pattern	O
is	O
not	O
surprising	O
[	O
9	O
]	O
,	O
as	O
it	O
has	O
been	O
observed	O
in	O
similar	O
cases	O
of	O
drug	O
-	O
resistant	O
epilepsy	O
.	O
After	O
these	O
findings	O
,	O
a	O
short	O
treatment	O
with	O
rifaximin	O
was	O
proposed	O
[	O
10	O
]	O
,	O
followed	O
by	O
the	O
administration	O
of	O
a	O
supplement	O
with	O
Streptococcus	O
salivarius	O
K12	O
[	O
11	O
]	O
at	O
1	O
billion	O
UFC	O
(	O
notified	O
to	O
the	O
Italian	O
Ministry	O
of	O
Health	O
as	O
a	O
food	O
supplement	O
by	O
Pharmextracta	O
SpA	O
,	O
Pontenure	O
,	O
PC	O
,	O
Italy	O
,	O
complying	O
with	O
law	O
No	O
.	O

196	O
-	O
2004	O
,	O
notification	O
number	O
:	O
53435	O
;	O
marketed	O
in	O
Italy	O
under	O
the	O
name	O
of	O
Bactoblis	O
)	O
once	O
a	O
day	O
,	O
Berberis	O
vulgaris	O
(	O
255	O
mg	O
)	O
,	O
hydrolyzed	O
Guam	O
gum	O
(	O
750	O
mg	O
)	O
,	O
and	O
melatonin	O
(	O
0	O
.	O
5	O
mg	O
)	O
[	O
12	O
]	O
(	O
notified	O
to	O
the	O
Italian	O
Ministry	O
of	O
Health	O
as	O
a	O
food	O
supplement	O
by	O
Pharmextracta	O
SpA	O
,	O
Pontenure	O
,	O
PC	O
,	O
Italy	O
,	O
complying	O
with	O
law	O
No	O
.	O
196	O
-	O
2004	O
,	O
notification	O
number	O
:	O
12	O
;	O
marketed	O
in	O
Italy	O
under	O
the	O
name	O
of	O
Dibiesse	O
)	O
two	O
times	O
a	O
day	O
,	O
with	O
rapid	O
resolution	O
of	O
diarrhea	O
,	O
mood	O
,	O
weight	O
recovery	O
,	O
and	O
daily	O
activities	O
(	O
with	O
all	O
the	O
limitations	O
of	O
the	O
case	O
)	O
.	O
The	O
decision	O
to	O
administer	O
a	O
nutraceutical	O
specifically	O
formulated	O
for	O
the	O
management	O
of	O
diarrhea	O
[	O
12	O
]	O
was	O
made	O
,	O
in	O
addition	O
to	O
the	O
approach	O
based	O
on	O
rifaximin	O
followed	O
by	O
probiotics	O
(	O
already	O
described	O
in	O
the	O
literature	O
[	O
10	O
]	O
)	O
to	O
provide	O
rapid	O
clinical	O
benefit	O
to	O
the	O
patient	O
,	O
with	O
the	O
aim	O
of	O
improving	O
her	O
quality	O
of	O
life	O
as	O
soon	O
as	O
possible	O
.	O
Following	O
this	O
result	O
,	O
a	O
ketogenic	O
diet	O
approach	O
was	O
administered	O
with	O
the	O
aim	O
of	O
reducing	O
the	O
dominance	O
of	O
Firmicutes	O
reduction	O
,	O
and	O
Bacteroidetes	O
and	O
Proteobacteria	O
growth	O
in	O
accordance	O
with	O
Zhang	O
et	O
al	O
.	O
[	O
13	O
]	O
.	O
In	O
the	O
following	O
months	O
,	O
a	O
ketogenic	O
diet	O
with	O
a	O
1	O
.	O
95	O
–	O
2	O
.	O
30	O
k	O
-	O
ratio	O
was	O
poorly	O
tolerated	O
,	O
as	O
frequent	O
hypoglycemic	O
events	O
occurred	O
.	O
With	O
a	O
progressive	O
k	O
-	O
ratio	O
and	O
ketone	O
reduction	O
,	O
hypoglycemic	O
events	O
improved	O
but	O
notable	O
asthenia	O
was	O
noted	O
.	O
However	O
,	O
a	O
further	O
modest	O
improvement	O
in	O
intestinal	O
symptoms	O
was	O
reported	O
,	O
as	O
expected	O
.	O
Given	O
these	O
results	O
,	O
a	O
low	O
-	O
FODMAP	O
diet	O
was	O
then	O
started	O
[	O
10	O
]	O
;	O
after	O
a	O
few	O
weeks	O
,	O
the	O
patient	O
’	O
s	O
condition	O
improved	O
with	O
glycemic	O
steadiness	O
,	O
a	O
further	O
normalization	O
of	O
bowel	O
dynamics	O
,	O
and	O
less	O
frequent	O
and	O
severe	O
episodes	O
of	O
seizures	O
.	O
In	O
January	O
2022	O
,	O
the	O
microbiota	O
analysis	O
was	O
repeated	O
:	O
the	O
alpha	O
biodiversity	O
was	O
consistently	O
increased	O
.	O
The	O
presence	O
of	O
Firmicutes	O
and	O
Actinobacteria	O
was	O
drastically	O
reduced	O
,	O
with	O
a	O
relevant	O
increase	O
in	O
Bacteroidetes	O
.	O

As	O
a	O
result	O
,	O
the	O
Firmicutes	O
/	O
Bacteroidetes	O
ratio	O
decreased	O
,	O
resulting	O
in	O
a	O
lesser	O
extent	O
of	O
fermentative	O
dysbiosis	O
.	O
Additionally	O
,	O
lactate	O
-	O
producing	O
bacteria	O
such	O
as	O
Lactobacilli	O
and	O
Bifidobacteria	O
were	O
markedly	O
reduced	O
,	O
as	O
shown	O
in	O
Figure	O
1	O
.	O
The	O
management	O
and	O
analysis	O
of	O
this	O
case	O
proved	O
to	O
be	O
very	O
complex	O
,	O
especially	O
considering	O
that	O
it	O
has	O
not	O
yet	O
been	O
possible	O
to	O
identify	O
a	O
single	O
common	O
pathological	O
element	O
or	O
a	O
well	O
-	O
defined	O
syndrome	O
that	O
would	O
allow	O
for	O
the	O
planning	O
of	O
a	O
specific	O
treatment	O
.	O
In	O
the	O
administration	O
of	O
the	O
different	O
treatments	O
,	O
with	O
the	O
aim	O
of	O
clinical	O
management	O
of	O
the	O
symptoms	O
,	O
particular	O
attention	O
was	O
paid	O
to	O
the	O
possibility	O
that	O
elements	O
such	O
as	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
amino	O
acids	O
,	O
endocrine	O
neurotransmitters	O
,	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFA	O
)	O
,	O
free	O
radicals	O
of	O
oxygen	O
(	O
ROS	O
)	O
,	O
and	O
other	O
metabolites	O
produced	O
in	O
the	O
intestine	O
may	O
be	O
basis	O
of	O
neuro	O
-	O
mediated	O
stimuli	O
and	O
alterations	O
in	O
the	O
permeability	O
of	O
the	O
mucosal	O
barrier	O
,	O
acting	O
dysfunctionally	O
at	O
the	O
immune	O
,	O
inflammatory	O
,	O
and	O
blood	O
–	O
brain	O
barrier	O
(	O
BBB	O
)	O
permeability	O
levels	O
.	O
This	O
potentially	O
favors	O
a	O
condition	O
of	O
neuroinflammation	O
,	O
a	O
situation	O
described	O
as	O
potentially	O
being	O
able	O
to	O
further	O
contribute	O
to	O
intestinal	O
dysbiosis	O
in	O
a	O
two	O
-	O
way	O
manner	O
[	O
14	O
]	O
.	O
In	O
this	O
context	O
,	O
increased	O
levels	O
of	O
Firmicutes	O
(	O
at	O
the	O
expense	O
of	O
reduced	O
levels	O
of	O
Bacteroidetes	O
)	O
have	O
been	O
described	O
in	O
epilepsy	O
cases	O
with	O
consequent	O
reduced	O
activity	O
in	O
the	O
threonine	O
,	O
tryptophan	O
,	O
and	O
creatinine	O
pathways	O
.	O

Additionally	O
,	O
high	O
levels	O
of	O
Clostridium	O
and	O
Lactobacillus	O
with	O
an	O
altered	O
Firmicutes	O
/	O
Bacteroidetes	O
ratio	O
have	O
been	O
described	O
in	O
ASD	O
,	O
resulting	O
in	O
alterations	O
in	O
the	O
tricarboxylic	O
pathway	O
(	O
↑	O
succinic	O
acid	O
,	O
[UNK]	O
citric	O
acid	O
)	O
,	O
the	O
kynurenine	O
pathway	O
(	O
↑	O
xanthurenic	O
acid	O
and	O
quinolinic	O
acid	O
,	O
[UNK]	O
kynurenic	O
acid	O
)	O
,	O
and	O
serotonin	O
pathways	O
(	O
[UNK]	O
melatonin	O
)	O
;	O
increases	O
in	O
the	O
bacterial	O
degradation	O
of	O
tryptophan	O
;	O
increases	O
in	O
purine	O
catabolites	O
,	O
glutamate	O
,	O
aspartate	O
,	O
and	O
3	O
-	O
aminoisobutyric	O
and	O
glutaric	O
acid	O
;	O
and	O
decreases	O
in	O
glutathione	O
,	O
creatinine	O
,	O
and	O
isoleucine	O
[	O
13	O
]	O
.	O
In	O
this	O
regard	O
,	O
the	O
ketogenic	O
diet	O
could	O
prove	O
to	O
be	O
a	O
potentially	O
interesting	O
tool	O
:	O
as	O
described	O
by	O
Zhang	O
et	O
al	O
.	O
[	O
13	O
]	O
,	O
following	O
6	O
months	O
of	O
therapy	O
with	O
a	O
ketogenic	O
diet	O
,	O
in	O
one	O
sample	O
,	O
a	O
lower	O
α	O
-	O
diversity	O
was	O
found	O
in	O
epileptic	O
children	O
with	O
a	O
reduction	O
in	O
Firmicutes	O
levels	O
and	O
an	O
increase	O
in	O
Bacteroidetes	O
levels	O
.	O
Furthermore	O
,	O
Xie	O
et	O
al	O
.	O
described	O
how	O
the	O
intestinal	O
microbiota	O
of	O
epileptic	O
infants	O
is	O
significantly	O
more	O
rich	O
in	O
pathogenic	O
bacteria	O
compared	O
with	O
that	O
of	O
healthy	O
controls	O
,	O
showing	O
that	O
significant	O
changes	O
could	O
be	O
observed	O
after	O
a	O
week	O
of	O
following	O
a	O
ketogenic	O
diet	O
[	O
15	O
]	O
.	O
These	O
elements	O
become	O
particularly	O
significant	O
if	O
examined	O
in	O
light	O
of	O
the	O
correlation	O
between	O
elevated	O
levels	O
of	O
Bacteroidetes	O
and	O
cognitive	O
performance	O
[	O
16	O
,	O
17	O
]	O
.	O
The	O
patient	O
did	O
not	O
tolerate	O
a	O
ketogenic	O
diet	O
well	O
,	O
an	O
interesting	O
fact	O
that	O
could	O
be	O
interpreted	O
on	O
the	O
basis	O
of	O
what	O
was	O
reported	O
by	O
Tagliabue	O
et	O
al	O
.	O
[	O
18	O
]	O
.	O
In	O
the	O
microbiota	O
of	O
children	O
with	O
GLUT1	O
deficiency	O
syndrome	O
following	O
a	O
ketogenic	O
diet	O
for	O
3	O
months	O
,	O
a	O
significant	O
increase	O
in	O
Desulfovibrio	O
spp	O
.	O
was	O
reported	O
,	O
similar	O
to	O
in	O
our	O
patient	O
,	O
as	O
this	O
bacterial	O
group	O
is	O
believed	O
to	O
be	O
involved	O
in	O
the	O
exacerbation	O
of	O
the	O
inflammatory	O
condition	O
of	O
the	O
intestinal	O
mucosa	O
.	O
This	O
suggests	O
that	O
the	O
extent	O
of	O
these	O
interventions	O
is	O
still	O
yet	O
to	O
be	O
understood	O
,	O
as	O
the	O
relationship	O
between	O
the	O
effects	O
was	O
also	O
directly	O
related	O
to	O
the	O
ketogenic	O
diet	O
and	O
the	O
changes	O
generated	O
in	O
the	O
intestinal	O
microbiota	O
[	O
19	O
]	O
.	O

It	O
is	O
important	O
to	O
underline	O
what	O
was	O
reported	O
by	O
Roussin	O
et	O
al	O
.	O
According	O
to	O
the	O
literature	B-methodology
review	I-methodology
,	O
Desulfovibrio	O
is	O
present	O
in	O
at	O
least	O
50	O
%	O
of	O
children	O
with	O
ASD	O
;	O
other	O
characteristic	O
aspects	O
described	O
by	O
various	O
authors	O
are	O
the	O
increase	O
in	O
Clostridium	O
,	O
the	O
reduction	O
in	O
Bifidobacterium	O
,	O
and	O
the	O
increase	O
in	O
Faecalibacterium	O
[	O
17	O
]	O
,	O
aspects	O
that	O
were	O
not	O
initially	O
observable	O
in	O
our	O
patient	O
but	O
were	O
outlined	O
following	O
improvements	O
in	O
the	O
dynamics	O
of	O
her	O
bowel	O
habits	O
.	O
The	O
improvement	O
found	O
with	O
the	O
low	O
-	O
FODMAP	O
diet	O
—	O
which	O
,	O
unlike	O
the	O
ketogenic	O
diet	O
,	O
was	O
well	O
-	O
tolerated	O
—	O
could	O
also	O
be	O
analyzed	O
on	O
the	O
basis	O
of	O
what	O
was	O
observed	O
in	O
patients	O
suffering	O
from	O
propionic	O
acidosis	O
.	O
This	O
is	O
a	O
genetic	O
disorder	O
characterized	O
by	O
propionate	O
accumulation	O
,	O
which	O
manifests	O
as	O
a	O
delay	O
in	O
neurological	O
development	O
,	O
a	O
high	O
prevalence	O
of	O
ASD	O
(	O
21	O
%	O
)	O
[	O
20	O
]	O
,	O
and	O
mitochondrial	O
dysfunction	O
associated	O
with	O
significant	O
oxidative	O
stress	O
[	O
21	O
]	O
.	O
It	O
is	O
tempting	O
to	O
say	O
that	O
propionic	O
acid	O
,	O
which	O
is	O
also	O
a	O
product	O
of	O
bacterial	O
metabolism	O
efficiently	O
obtained	O
from	O
fermentable	O
substances	O
such	O
as	O
FODMAPs	O
,	O
could	O
play	O
a	O
very	O
important	O
role	O
in	O
similar	O
neurological	O
and	O
systemic	O
diseases	O
.	O
The	O
success	O
of	O
the	O
low	O
-	O
FODMAP	O
diet	O
could	O
also	O
help	O
explain	O
the	O
adverse	O
intestinal	O
reaction	O
to	O
some	O
drug	O
excipients	O
,	O
which	O
were	O
possibly	O
used	O
as	O
an	O
energy	O
substrate	O
for	O
fermentation	O
processes	O
by	O
intestinal	O
bacteria	O
[	O
7	O
]	O
.	O
Indeed	O
,	O
Vervevier	O
et	O
al	O
.	O
described	O
cases	O
of	O
inflammatory	O
bowel	O
disease	O
(	O
IBS	O
)	O
characterized	O
by	O
a	O
pathogenic	O
gut	O
microbial	O
signature	O
,	O
enriched	O
in	O
Firmicutes	O
and	O
genes	O
for	O
carbohydrate	O
and	O
amino	O
acid	O
metabolism	O
,	O
but	O
depleted	O
in	O
Bacteroidetes	O
species	O
.	O
This	O
microbiota	O
composition	O
switched	O
towards	O
a	O
pattern	O
similar	O
to	O
the	O
control	B-methodology
group	I-methodology
following	O
a	O
low	O
-	O
FODMAP	O
diet	O
[	O
22	O
]	O
,	O
in	O
a	O
very	O
similar	O
way	O
to	O
what	O
was	O
found	O
in	O
our	O
case	O
,	O
where	O
following	O
a	O
low	O
-	O
FODMAP	O
diet	O
and	O
,	O
subsequently	O
,	O
normalization	O
of	O
bowel	O
movements	O
,	O
a	O
microbial	O
pattern	O
much	O
more	O
similar	O
to	O
those	O
described	O
in	O
similar	O
patients	O
emerged	O
.	O
Additionally	O
,	O
what	O
was	O
reported	O
by	O
Lindefeldt	O
et	O
al	O
.	O
should	O
be	O
considered	O
.	O

Analysis	O
of	O
the	O
microbiota	O
of	O
12	O
children	O
with	O
drug	O
-	O
resistant	O
epilepsy	O
who	O
were	O
administered	O
a	O
ketogenic	O
diet	O
,	O
highlighted	O
a	O
reduction	O
in	O
Bifidobacterium	O
and	O
an	O
increase	O
in	O
Escherichia	O
—	O
as	O
in	O
our	O
case	O
—	O
as	O
relevant	O
elements	O
that	O
could	O
induce	O
functional	O
changes	O
[	O
23	O
]	O
while	O
enhancing	O
the	O
effects	O
on	O
the	O
microbiota	O
due	O
to	O
the	O
reduced	O
consumption	O
of	O
fiber	O
,	O
which	O
,	O
in	O
our	O
case	O
and	O
in	O
the	O
work	O
of	O
Vervevier	O
et	O
al	O
.	O
[	O
22	O
]	O
,	O
have	O
been	O
associated	O
with	O
positive	O
effects	O
.	O
To	O
confirm	O
the	O
potential	O
role	O
played	O
by	O
the	O
microbiota	O
in	O
epilepsy	O
,	O
it	O
is	O
interesting	O
to	O
highlight	O
the	O
case	O
described	O
by	O
He	O
et	O
al	O
.	O
involving	O
a	O
patient	O
suffering	O
from	O
Crohn	O
’	O
s	O
disease	O
,	O
epilepsy	O
,	O
and	O
continuous	O
menstrual	O
irregularities	O
who	O
,	O
following	O
a	O
fecal	O
transplant	O
,	O
reported	O
complete	O
clinical	O
remission	O
of	O
epileptic	O
seizures	O
,	O
allowing	O
the	O
suspension	O
of	O
therapy	O
,	O
with	O
remission	O
maintained	O
until	O
the	O
end	O
of	O
the	O
20	O
-	O
month	O
follow	O
-	O
up	O
.	O
The	O
patient	O
showed	O
a	O
continuous	O
improvement	O
in	O
quality	O
of	O
life	O
,	O
she	O
started	O
to	O
work	O
,	O
her	O
menstrual	O
cycle	O
was	O
regularized	O
at	O
6	O
weeks	O
with	O
a	O
normal	O
flow	O
,	O
and	O
she	O
was	O
able	O
to	O
conceive	O
a	O
child	O
with	O
eutocic	O
delivery	O
[	O
24	O
]	O
.	O
These	O
results	O
underline	O
that	O
there	O
are	O
still	O
numerous	O
pathophysiological	O
aspects	O
to	O
be	O
understood	O
in	O
the	O
host	O
–	O
microbiota	O
relationship	O
,	O
even	O
in	O
apparently	O
unrelated	O
complex	O
situations	O
.	O
The	O
analysis	O
of	O
this	O
case	O
shows	O
that	O
there	O
are	O
still	O
many	O
pathophysiological	O
aspects	O
to	O
consider	O
,	O
both	O
in	O
the	O
management	O
of	O
complex	O
cases	O
and	O
possibly	O
also	O
in	O
the	O
management	O
of	O
ordinary	O
cases	O
,	O
integrating	O
the	O
potential	O
of	O
clinical	B-methodology
intervention	I-methodology
with	O
respect	O
to	O
what	O
has	O
been	O
achieved	O
so	O
far	O
.	O
Future	O
studies	O
will	O
be	O
needed	O
to	O
understand	O
whether	O
the	O
benefits	O
deriving	O
from	O
the	O
ketogenic	O
diet	O
(	O
when	O
tolerated	O
)	O
refer	O
exclusively	O
to	O
metabolic	O
aspects	O
,	O
to	O
remodulation	O
of	O
the	O
intestinal	O
microbiota	O
,	O
or	O
both	O
.	O
A	O
great	O
challenge	O
in	O
the	O
coming	O
years	O
will	O
probably	O
be	O
understanding	O
the	O
role	O
of	O
nutrition	O
in	O
the	O
modulation	O
of	O
the	O
microbiota	O
,	O
considering	O
,	O
as	O
in	O
the	O
case	O
described	O
,	O
that	O
foods	O
rich	O
in	O
fiber	O
—	O
generally	O
considered	O
healthy	O
—	O
and	O
bacteria	O
—	O
considered	O
exclusively	O
protective	O
—	O
could	O
also	O
exert	O
a	O
dysfunctional	O
role	O
instead	O
.	O

A	O
low	O
-	O
FODMAP	O
diet	O
combined	O
with	O
appropriate	O
pharmacological	O
,	O
nutraceutical	O
,	O
and	O
bacterial	O
precision	O
therapy	O
derived	O
from	O
an	O
in	O
-	O
depth	O
study	O
of	O
the	O
intestinal	O
microbiota	O
facilitated	O
significant	O
clinical	O
benefits	O
capable	O
of	O
significantly	O
impacting	O
patients	O
’	O
health	O
and	O
quality	O
of	O
life	O
.	O
Expanding	O
this	O
knowledge	O
will	O
probably	O
lead	O
to	O
a	O
review	O
of	O
some	O
concepts	O
,	O
such	O
as	O
that	O
of	O
a	O
healthy	O
diet	O
and	O
protective	O
bacteria	O
,	O
which	O
are	O
taken	O
for	O
granted	O
and	O
consolidated	O
today	O
,	O
leading	O
us	O
to	O
understand	O
how	O
,	O
most	O
likely	O
,	O
there	O
is	O
no	O
diet	O
or	O
“	O
healthy	O
”	O
microbial	O
pattern	O
valid	O
for	O
all	O
situations	O
.	O
Understanding	O
of	O
these	O
factors	O
may	O
clarify	O
,	O
in	O
the	O
future	O
,	O
what	O
role	O
the	O
different	O
techniques	O
available	O
for	O
modulation	O
of	O
the	O
intestinal	O
microbiota	O
may	O
have	O
for	O
better	O
clinical	O
management	O
,	O
even	O
of	O
very	O
complex	O
cases	O
such	O
as	O
the	O
one	O
described	O
.	O
This	O
research	O
received	O
no	O
external	O
funding	O
.	O
Publisher	O
’	O
s	O
Note	O
:	O
MDPI	O
stays	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O
Conceptualization	O
:	O
A	O
.	O
B	O
.	O
,	O
M	O
.	O
C	O
.	O
and	O
M	O
.	O
R	O
.	O
M	O
.	O
;	O
investigation	O
:	O
M	O
.	O
R	O
.	O
M	O
.	O
and	O
F	O
.	O
D	O
.	O
P	O
.	O
;	O
data	O
curation	O
,	O
F	O
.	O
D	O
.	O
P	O
.	O
and	O
A	O
.	O
B	O
.	O
;	O
writing	O
—	O
original	O
draft	O
preparation	O
,	O
A	O
.	O
B	O
.	O
,	O
M	O
.	O
C	O
.	O
and	O
G	O
.	O
B	O
.	O
Z	O
.	O
;	O
review	O
and	O
editing	O
,	O
A	O
.	O
B	O
.	O
,	O
G	O
.	O
B	O
.	O
Z	O
.	O
,	O
M	O
.	O
C	O
.	O
,	O
M	O
.	O
R	O
.	O
M	O
.	O
and	O
A	O
.	O
B	O
.	O
All	O
authors	O
have	O
read	O
and	O
agreed	O
to	O
the	O
published	O
version	O
of	O
the	O
manuscript	O
.	O
The	O
case	B-methodology
report	I-methodology
was	O
redacted	O
according	O
to	O
CARE	O
guidelines	B-methodology
,	O
both	O
legal	O
representatives	O
of	O
the	O
patient	O
authorized	O
the	O
publication	O
of	O
the	O
case	B-methodology
report	I-methodology
.	O
Informed	O
consent	O
was	O
obtained	O
from	O
the	O
legal	O
guardian	O
of	O
the	O
subject	O
involved	O
in	O
the	O
case	B-methodology
report	I-methodology
.	O
Written	B-methodology
informed	I-methodology
consent	I-methodology
has	O
been	O
obtained	O
from	O
the	O
patient	O
’	O
s	O
legal	O
guardian	O
to	O
publish	O
this	O
paper	O
.	O
The	O
data	O
presented	O
in	O
this	O
study	O
are	O
available	O
on	O
request	O
from	O
the	O
corresponding	O
author	O
.	O
A	O
.	O
B	O
.	O
is	O
a	O
Pharmextracta	O
and	O
MyMicrobiota	O
lab	O
consultant	O
.	O
FDP	O
belongs	O
to	O
the	O
Scientific	O
Board	O
of	O
Pharmextracta	O
and	O
MyMicrobiota	O
lab	O
.	O

Cardiometabolic	O
risk	O
factors	O
and	O
mental	O
health	O
status	O
among	O
truck	O
drivers	O
:	O
a	O
systematic	B-methodology
review	I-methodology
epidemiology	O
;	O
occupational	O
&	O
industrial	O
medicine	O
;	O
preventive	O
medicine	O
;	O
public	O
health	O
This	O
study	O
aimed	O
to	O
systematically	O
review	O
and	O
summarise	O
the	O
literature	O
on	O
cardiometabolic	O
risk	O
factors	O
,	O
lifestyle	O
health	O
behaviours	O
and	O
mental	O
health	O
status	O
of	O
truck	O
drivers	O
globally	O
to	O
ascertain	O
the	O
scale	O
of	O
these	O
health	O
concerns	O
.	O
Systematic	B-methodology
review	I-methodology
reported	O
using	O
the	O
Preferred	O
Reporting	O
Items	O
for	O
Systematic	B-methodology
Reviews	I-methodology
and	I-methodology
Meta	I-methodology
-	I-methodology
Analyses	I-methodology
guidelines	I-methodology
.	O
PubMed	O
,	O
Scopus	O
,	O
PsycINFO	O
and	O
Web	O
of	O
Science	O
were	O
searched	O
in	O
January	O
2019	O
and	O
updated	O
in	O
January	O
2020	O
,	O
from	O
the	O
date	O
of	O
inception	O
to	O
16	O
January	O
2020	O
.	O
Papers	O
were	O
included	O
if	O
they	O
(	O
1	O
)	O
reported	O
independent	O
data	O
on	O
truck	O
drivers	O
,	O
(	O
2	O
)	O
included	O
quantitative	O
data	O
on	O
outcomes	O
related	O
to	O
cardiometabolic	O
markers	O
of	O
health	O
,	O
mental	O
health	O
and	O
/	O
or	O
health	O
behaviours	O
,	O
(	O
3	O
)	O
were	O
written	O
in	O
English	O
and	O
(	O
4	O
)	O
were	O
published	O
in	O
a	O
peer	O
-	O
reviewed	O
journal	O
.	O
Grey	O
literature	O
was	O
ineligible	O
for	O
this	O
review	O
.	O
One	O
reviewer	O
independently	O
extracted	O
data	O
and	O
assessed	O
methodological	O
quality	O
using	O
a	O
checklist	O
based	O
on	O
the	O
National	O
Heart	O
,	O
Lung	O
and	O
Blood	O
Institute	O
Quality	O
Assessment	O
tool	O
.	O
20	O
%	O
were	O
independently	O
assessed	O
for	O
eligibility	O
and	O
quality	O
by	O
a	O
second	O
reviewer	O
.	O
Due	O
to	O
heterogeneity	O
of	O
the	O
outcomes	O
,	O
results	O
were	O
narratively	O
presented	O
.	O
3601	O
titles	O
and	O
abstracts	O
were	O
screened	O
.	O
Seventy	O
-	O
three	O
studies	O
met	O
the	O
inclusion	B-methodology
criteria	I-methodology
.	O
Truck	O
driving	O
is	O
associated	O
with	O
enforced	O
sedentarism	O
,	O
long	O
and	O
irregular	O
working	O
hours	O
,	O
lack	O
of	O
healthy	O
foods	O
,	O
social	O
isolation	O
and	O
chronic	O
time	O
pressures	O
.	O
Strong	O
evidence	O
was	O
observed	O
for	O
truck	O
drivers	O
to	O
generally	O
exhibit	O
poor	O
cardiometabolic	O
risk	O
profiles	O
including	O
overweight	O
and	O
obesity	O
,	O
hypertension	O
,	O
hypercholesterolaemia	O
,	O
high	O
blood	O
glucose	O
,	O
poor	O
mental	O
health	O
and	O
cigarette	O
smoking	O
.	O
Improving	O
truck	O
driver	O
health	O
is	O
vital	O
for	O
the	O
longevity	O
of	O
the	O
trucking	O
industry	O
,	O
and	O
for	O
the	O
safety	O
of	O
all	O
road	O
users	O
.	O
The	O
workplace	O
plays	O
a	O
vital	O
role	O
in	O
truck	O
driver	O
health	O
;	O
policies	O
,	O
regulations	O
and	O
procedures	O
are	O
required	O
to	O
address	O
this	O
health	O
crisis	O
.	O
CRD42019124499	O
.	O
Truck	O
driving	O
encompasses	O
an	O
abundance	O
of	O
integral	O
,	O
interlinking	O
health	O
risk	O
factors	O
that	O
create	O
barriers	O
to	O
the	O
adoption	O
of	O
healthy	O
lifestyle	O
behaviours	O
.	O

These	O
include	O
long	O
hours	O
of	O
enforced	O
sedentarism	O
,	O
reducing	O
opportunities	O
for	O
physical	O
activity	O
,	O
limited	O
availability	O
of	O
healthy	O
food	O
,	O
irregular	O
shift	O
patterns	O
and	O
sleep	O
deprivation	O
.	O
1	O
The	O
isolated	O
nature	O
of	O
the	O
work	O
results	O
in	O
a	O
lack	O
of	O
peer	O
social	O
modelling	O
and	O
poor	O
mental	O
health	O
.	O
2	O
This	O
is	O
exacerbated	O
by	O
intense	O
job	O
demands	O
and	O
low	O
levels	O
of	O
perceived	O
job	O
control	O
,	O
resulting	O
in	O
chronic	O
time	O
pressures	O
compounded	O
by	O
tight	O
delivery	O
schedules	O
and	O
traffic	O
conditions	O
.	O
3	O
Truck	O
driving	O
is	O
a	O
male	O
-	O
dominated	O
industry	O
comprising	O
an	O
ageing	O
workforce	O
.	O
4	O
These	O
factors	O
are	O
likely	O
associated	O
with	O
the	O
high	O
prevalence	O
of	O
obesity	O
,	O
chronic	O
diseases	O
,	O
mental	O
ill	O
health	O
and	O
reduced	O
life	O
expectancies	O
seen	O
in	O
truck	O
drivers	O
in	O
comparison	O
to	O
other	O
occupational	O
groups	O
.	O
5	O
–	O
8	O
The	O
health	O
and	O
well	O
-	O
being	O
of	O
professional	O
truck	O
drivers	O
is	O
of	O
public	O
concern	O
given	O
their	O
health	O
impacts	O
the	O
safety	O
of	O
all	O
road	O
users	O
.	O
6	O
For	O
example	O
,	O
truck	O
drivers	O
with	O
obesity	O
,	O
cardiovascular	O
disease	O
,	O
depression	O
,	O
anxiety	O
or	O
with	O
≥3	O
comorbidities	O
have	O
a	O
significantly	O
increased	O
risk	O
of	O
preventable	O
crashes	O
.	O
9	O
–	O
13	O
There	O
is	O
a	O
developing	O
body	O
of	O
evidence	O
relating	O
to	O
the	O
physical	O
and	O
mental	O
health	O
of	O
truck	O
drivers	O
which	O
consist	O
of	O
small	O
-	O
scale	O
independent	O
studies	O
.	O
When	O
efficiently	O
aggregated	O
together	O
,	O
these	O
studies	O
will	O
establish	O
whether	O
the	O
findings	O
are	O
consistent	O
and	O
hence	O
provide	O
greater	O
strength	O
with	O
the	O
ability	O
to	O
establish	O
a	O
better	O
understanding	O
of	O
the	O
international	O
prevalence	O
.	O
This	O
prompts	O
the	O
need	O
for	O
a	O
systematic	B-methodology
review	I-methodology
and	O
appraisal	O
of	O
data	O
to	O
facilitate	O
health	O
promotion	O
interventions	O
for	O
this	O
underserved	O
occupational	O
group	O
.	O
The	O
objective	O
of	O
this	O
paper	O
was	O
to	O
systematically	O
review	O
the	O
literature	O
regarding	O
the	O
cardiometabolic	O
and	O
mental	O
health	O
profile	O
of	O
truck	O
drivers	O
globally	O
.	O
The	O
review	O
protocol	O
was	O
reported	O
using	O
the	O
Preferred	O
Reporting	O
Items	O
for	O
Systematic	B-methodology
Reviews	I-methodology
and	I-methodology
Meta	I-methodology
-	I-methodology
Analyses	I-methodology
(	O
PRISMA	O
,	O
see	O
online	O
supplemental	O
material	O
1	O
and	O
2	O
)	O
.	O
14	O
A	O
literature	O
search	O
for	O
relevant	O
papers	O
was	O
conducted	O
in	O
four	O
electronic	O
bibliographic	O
databases	O
:	O
PubMed	O
,	O
Scopus	O
,	O
PsycINFO	O
and	O
Web	O
of	O
Science	O
.	O
Several	O
synonyms	O
of	O
‘	O
truck	O
driver	O
’	O
were	O
used	O
such	O
as	O
‘	O
HGV	O
’	O
and	O
‘	O
lorry	O
driver	O
’	O
,	O
a	O
truck	O
driver	O
in	O
this	O
paper	O
is	O
defined	O
as	O
somebody	O
who	O
earns	O
a	O
living	O
transporting	O
goods	O
over	O
land	O
by	O
operating	O
a	O
heavy	O
goods	O
vehicle	O
,	O
this	O
means	O
that	O
the	O
criteria	O
would	O
accept	O
lorry	O
drivers	O
but	O
reject	O
bus	O
,	O
coach	O
,	O
van	O
,	O
taxi	O
and	O
train	O
drivers	O
.	O
These	O
were	O
combined	O
with	O
a	O
comprehensive	O
list	O
of	O
forty	O
key	O
terms	O
for	O
risk	O
factors	O
,	O
related	O
health	O
outcomes	O
and	O
lifestyle	O
factors	O
/	O
behaviours	O
to	O
locate	O
potentially	O
relevant	O
studies	O
.	O

Keywords	O
were	O
created	O
with	O
guidance	O
from	O
a	O
research	O
librarian	O
to	O
ensure	O
a	O
thorough	O
scope	O
was	O
reached	O
.	O
An	O
example	O
of	O
the	O
search	O
strategy	O
used	O
for	O
PubMed	O
is	O
provided	O
in	O
online	O
supplemental	O
material	O
3	O
.	O
In	O
addition	O
,	O
manual	O
searches	O
of	O
reference	O
lists	O
of	O
primary	O
studies	O
,	O
reviews	O
and	O
identified	O
articles	O
were	O
conducted	O
.	O
The	O
search	O
strategy	O
was	O
carried	O
out	O
in	O
January	O
2019	O
and	O
updated	O
in	O
January	O
2020	O
.	O
No	O
patient	O
involved	O
.	O
To	O
be	O
included	O
in	O
the	O
review	O
,	O
the	O
studies	O
were	O
required	O
to	O
(	O
1	O
)	O
report	O
independent	O
data	O
on	O
truck	O
drivers	O
,	O
(	O
eg	O
,	O
if	O
data	O
were	O
combined	O
with	O
bus	O
drivers	O
then	O
they	O
were	O
excluded	O
)	O
,	O
(	O
2	O
)	O
include	O
quantitative	O
data	O
on	O
outcomes	O
related	O
to	O
cardiometabolic	O
markers	O
of	O
health	O
,	O
mental	O
health	O
and	O
/	O
or	O
health	O
behaviours	O
,	O
(	O
3	O
)	O
be	O
written	O
in	O
English	O
and	O
(	O
4	O
)	O
be	O
published	O
in	O
a	O
peer	O
-	O
reviewed	O
journal	O
from	O
the	O
date	O
of	O
inception	O
up	O
to	O
the	O
16	O
January	O
2020	O
.	O
All	O
study	B-methodology
designs	I-methodology
were	O
considered	O
for	O
inclusion	O
.	O
The	O
titles	O
and	O
abstracts	O
of	O
identified	O
articles	O
were	O
simultaneously	O
screened	O
for	O
eligibility	O
by	O
one	O
reviewer	O
(	O
AG	O
)	O
,	O
20	O
%	O
of	O
which	O
were	O
randomly	O
selected	O
and	O
verified	O
by	O
a	O
second	O
reviewer	O
to	O
ensure	O
consistency	O
(	O
Y	O
-	O
LC	O
)	O
,	O
which	O
resulted	O
in	O
a	O
96	O
%	O
agreement	O
rate	O
.	O
If	O
abstracts	O
were	O
not	O
available	O
or	O
provided	O
insufficient	O
information	O
,	O
the	O
entire	O
article	O
was	O
retrieved	O
and	O
screened	O
against	O
the	O
inclusion	B-methodology
criteria	I-methodology
.	O
Any	O
discrepancies	O
in	O
identification	O
of	O
relevant	O
studies	O
were	O
discussed	O
.	O
If	O
a	O
decision	O
could	O
not	O
be	O
reached	O
then	O
a	O
third	O
reviewer	O
was	O
consulted	O
(	O
NPe	O
)	O
.	O
Data	O
were	O
extracted	O
from	O
all	O
included	O
papers	O
on	O
standardised	O
Excel	O
spreadsheets	O
by	O
one	O
reviewer	O
(	O
AG	O
)	O
.	O
Extracted	O
data	O
included	O
:	O
study	B-methodology
design	I-methodology
,	O
country	O
,	O
sample	O
size	O
,	O
sociodemographic	O
information	O
,	O
measurement	O
methods	O
,	O
main	O
findings	O
,	O
funding	O
source	O
,	O
markers	O
of	O
health	O
(	O
anthropometric	O
measurements	O
,	O
blood	O
pressure	O
,	O
blood	O
profile	O
,	O
mental	O
health	O
)	O
and	O
lifestyle	O
health	O
behaviours	O
(	O
diet	O
,	O
physical	O
activity	O
,	O
addictive	O
behaviours	O
)	O
.	O
Included	O
studies	O
were	O
evaluated	O
on	O
their	O
methodological	O
quality	O
using	O
a	O
checklist	O
based	O
on	O
the	O
National	O
Heart	O
,	O
Lung	O
and	O
Blood	O
Institute	O
Quality	O
Assessment	O
tool	O
for	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
and	O
cohort	B-methodology
studies	I-methodology
,	O
15	O
though	O
questions	O
were	O
tailored	O
for	O
this	O
review	O
.	O
The	O
questions	O
referred	O
to	O
informativeness	O
(	O
two	O
items	O
)	O
and	O
study	O
methodology	O
(	O
four	O
items	O
)	O
.	O
It	O
was	O
scored	O
as	O
positive	O
(	O
+	O
)	O
,	O
negative	O
(	O
−	O
)	O
or	O
not	O
reported	O
/	O
applicable	O
(	O
?	O
)	O
.	O

The	O
primary	O
author	O
(	O
AG	O
)	O
scored	O
the	O
quality	O
of	O
each	O
article	O
,	O
the	O
second	O
author	O
(	O
Y	O
-	O
LC	O
)	O
independently	O
scored	O
20	O
%	O
.	O
The	O
results	O
of	O
the	O
scoring	O
were	O
compared	O
,	O
and	O
differences	O
were	O
discussed	O
and	O
rectified	O
with	O
the	O
assistance	O
of	O
a	O
third	O
author	O
(	O
NPe	O
)	O
.	O
Papers	O
were	O
deemed	O
good	O
if	O
they	O
met	O
≥5	O
criteria	O
,	O
fair	O
if	O
they	O
met	O
4	O
and	O
poor	O
if	O
they	O
met	O
≤3	O
criteria	O
.	O
The	O
literature	O
search	O
yielded	O
3601	O
potentially	O
relevant	O
papers	O
,	O
of	O
which	O
95	O
were	O
included	O
,	O
representing	O
73	O
studies	O
(	O
figure	O
1	O
)	O
.	O
Online	O
supplemental	O
material	O
4	O
shows	O
the	O
studies	O
which	O
consist	O
of	O
multiple	O
papers	O
.	O
Sample	O
sizes	O
ranged	O
from	O
12	O
to	O
95	O
567	O
.	O
Study	B-methodology
designs	I-methodology
included	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
(	O
53	O
studies	O
,	O
68	O
papers	O
)	O
,	O
repeated	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
(	O
3	O
studies	O
,	O
5	O
papers	O
)	O
,	O
case	O
–	O
control	O
(	O
5	O
studies	O
/	O
papers	O
)	O
,	O
retrospective	O
cohort	B-methodology
(	O
4	O
studies	O
/	O
papers	O
)	O
,	O
prospective	O
cohort	B-methodology
(	O
6	O
studies	O
/	O
papers	O
)	O
and	O
interventions	O
(	O
5	O
studies	O
,	O
7	O
papers	O
)	O
table	O
1	O
.	O
Due	O
to	O
heterogeneity	O
between	O
study	O
methodologies	O
,	O
a	O
qualitative	O
synthesis	O
of	O
the	O
data	O
was	O
deemed	O
most	O
appropriate	O
to	O
draw	O
conclusions	O
about	O
the	O
cardiometabolic	O
and	O
mental	O
health	O
of	O
truck	O
drivers	O
.	O
16	O
See	O
online	O
supplemental	O
material	O
5	O
for	O
the	O
full	O
summary	O
of	O
included	O
papers	O
.	O
A	O
summary	O
of	O
the	O
quality	O
assessment	O
of	O
the	O
included	O
papers	O
is	O
shown	O
in	O
table	O
2	O
.	O
Individual	O
paper	O
quality	O
assessment	O
has	O
been	O
provided	O
in	O
online	O
supplemental	O
material	O
6	O
.	O
Sixty	O
-	O
five	O
studies	O
included	O
information	O
on	O
sex	O
distribution2	O
3	O
5	O
9	O
11	O
–	O
13	O
17	O
–	O
92	O
of	O
which	O
,	O
only	O
15	O
%	O
included	O
<	O
90	O
%	O
males	O
.	O
11	O
23	O
26	O
30	O
32	O
36	O
41	O
55	O
57	O
64	O
69	O
Twenty	O
-	O
eight	O
studies	O
were	O
conducted	O
in	O
North	O
America	O
,	O
12	O
in	O
South	O
America	O
,	O
14	O
in	O
Asia	O
,	O
8	O
in	O
Europe	O
,	O
8	O
in	O
Australia	O
and	O
3	O
in	O
Africa	O
(	O
table	O
1	O
)	O
.	O

Of	O
the	O
studies	O
which	O
reported	O
average	O
age	O
of	O
participants	O
,	O
the	O
means	O
ranged	O
from	O
22	O
.	O
866	O
to	O
56	O
.	O
3	O
years	O
.	O
91	O
Seventy	O
-	O
five	O
per	O
cent	O
of	O
studies	O
reported	O
mean	O
ages	O
over	O
40	O
years	O
.	O
2	O
5	O
11	O
–	O
13	O
17	O
18	O
22	O
25	O
26	O
28	O
30	O
31	O
33	O
35	O
–	O
39	O
41	O
–	O
44	O
47	O
–	O
57	O
59	O
–	O
61	O
64	O
65	O
69	O
–	O
72	O
74	O
75	O
78	O
79	O
81	O
–	O
83	O
85	O
87	O
–	O
89	O
91	O
–	O
98	O
Twenty	O
-	O
four	O
studies	O
reported	O
sample	O
ethnicity	O
,	O
2	O
11	O
25	O
26	O
31	O
33	O
36	O
–	O
41	O
44	O
47	O
49	O
50	O
55	O
57	O
60	O
61	O
63	O
64	O
66	O
67	O
73	O
75	O
84	O
89	O
94	O
97	O
98	O
with	O
all	O
but	O
three	O
including	O
a	O
majority	O
of	O
white	O
participants	O
.	O
33	O
66	O
73	O
Thirty	O
-	O
five	O
studies	O
described	O
participants	O
’	O
education	O
level	O
,	O
2	O
13	O
19	O
20	O
25	O
27	O
33	O
34	O
36	O
40	O
41	O
43	O
–	O
45	O
47	O
–	O
50	O
57	O
58	O
63	O
–	O
69	O
71	O
73	O
75	O
77	O
83	O
86	O
89	O
–	O
91	O
94	O
96	O
97	O
99	O
the	O
percentage	O
of	O
those	O
not	O
completing	O
high	O
/	O
secondary	O
school	O
ranged	O
from	O
11	O
.	O
5	O
%	O
69	O
to	O
96	O
.	O
7	O
%	O
,	O
27	O
though	O
the	O
overall	O
trend	O
was	O
towards	O
most	O
participants	O
having	O
a	O
low	O
level	O
of	O
education	O
,	O
with	O
the	O
majority	O
not	O
completing	O
secondary	O
/	O
high	O
school	O
education	O
.	O
Thirty	O
-	O
six	O
studies	O
reported	O
classifications	O
of	O
truck	O
drivers	O
.	O
Twenty	O
-	O
seven	O
of	O
these	O
were	O
long	O
haul	O
(	O
ie	O
,	O
typically	O
drives	O
>	O
250	O
miles	O
per	O
drop	O
)	O
,	O
9	O
22	O
25	O
27	O
28	O
30	O
33	O
34	O
36	O
–	O
40	O
49	O
–	O
51	O
53	O
55	O
60	O
–	O
65	O
68	O
70	O
73	O
75	O
83	O
85	O
89	O
93	O
–	O
95	O
97	O
100	O
two	O
short	O
haul	O
(	O
ie	O
,	O
typically	O
drives	O
<	O
150	O
miles	O
per	O
drop	O
)	O
48	O
54	O
and	O
six	O
reported	O
a	O
combination	O
of	O
both	O
long	O
and	O
short	O
haul	O
.	O
17	O
32	O
59	O
69	O
72	O
101	O
Two	O
studies	O
compared	O
day	O
shift	O
and	O
irregular	O
shift	O
truck	O
drivers	O
.	O
19	O
–	O
21	O
32	O
Fifty	O
-	O
three	O
studies	O
reported	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
(	O
table	O
1	O
)	O
,	O
63	O
.	O
8	O
%	O
objectively	O
measured	O
height	O
and	O
weight	O
,	O
while	O
36	O
.	O
2	O
%	O
relied	O
on	O
self	O
-	O
reported	O
data	O
.	O
Mean	O
BMI	O
ranged	O
from	O
22	O
.	O
027	O
to	O
39	O
.	O
7	O
kg	O
/	O
m2	O
.	O
28	O
Based	O
on	O
the	O
WHO	O
guidance	O
for	O
BMI	O
thresholds	O
for	O
White	O
European	O
and	O
Asian	O
populations	O
,	O
102	O
only	O
two	O
studies	O
reported	O
an	O
average	O
healthy	O
BMI27	O
103	O
within	O
their	O
samples	O
.	O

Twenty	O
-	O
seven	O
studies	O
reported	O
a	O
sample	O
mean	O
BMI	O
within	O
the	O
overweight	O
category	O
;	O
9	O
19	O
–	O
24	O
29	O
32	O
40	O
43	O
45	O
–	O
48	O
52	O
–	O
54	O
58	O
71	O
–	O
74	O
80	O
–	O
82	O
85	O
–	O
89	O
96	O
97	O
99	O
23	O
studies	O
were	O
within	O
the	O
obese	O
category	O
.	O
2	O
5	O
11	O
12	O
17	O
18	O
25	O
26	O
28	O
30	O
31	O
37	O
–	O
39	O
41	O
42	O
44	O
49	O
–	O
51	O
55	O
–	O
57	O
59	O
69	O
70	O
78	O
79	O
83	O
84	O
94	O
95	O
98	O
100	O
One	O
study	O
reported	O
obesity	O
was	O
twice	O
as	O
prevalent	O
in	O
a	O
sample	O
of	O
US	O
truck	O
drivers	O
than	O
the	O
US	O
adult	O
population	O
.	O
89	O
Sixteen	O
studies	O
included	O
waist	O
circumferences	O
,	O
11	O
17	O
–	O
21	O
26	O
–	O
28	O
30	O
37	O
38	O
40	O
–	O
42	O
47	O
60	O
69	O
73	O
83	O
84	O
87	O
94	O
97	O
with	O
12	O
of	O
these	O
reporting	O
average	O
waist	O
circumferences	O
which	O
indicate	O
increased	O
risk	O
of	O
developing	O
adverse	O
health	O
conditions	O
(	O
>	O
102	O
cm	O
Europids	O
/	O
>	O
90	O
cm	O
South	O
Asians	O
)	O
.	O
11	O
17	O
18	O
26	O
28	O
30	O
37	O
38	O
41	O
42	O
47	O
60	O
69	O
83	O
84	O
87	O
94	O
97	O
104	O
Nineteen	O
studies	O
included	O
blood	O
pressure	O
measurements	O
,	O
5	O
11	O
18	O
21	O
23	O
26	O
28	O
37	O
–	O
39	O
41	O
42	O
47	O
53	O
54	O
60	O
69	O
73	O
79	O
80	O
82	O
83	O
93	O
97	O
98	O
with	O
average	O
blood	O
pressures	O
ranging	O
from	O
116	O
/	O
8023	O
to	O
142	O
/	O
87	O
mmHg	O
.	O
18	O
Twenty	O
-	O
nine	O
studies	O
included	O
prevalence	O
of	O
self	O
-	O
reported	O
or	O
objectively	O
measured	O
hypertension	O
,	O
3	O
5	O
11	O
12	O
17	O
25	O
27	O
33	O
34	O
39	O
–	O
43	O
46	O
49	O
53	O
61	O
–	O
64	O
69	O
70	O
72	O
75	O
78	O
–	O
80	O
82	O
86	O
–	O
89	O
96	O
–	O
98	O
103	O
with	O
thresholds	O
ranging	O
from	O
>	O
140	O
/	O
>	O
90	O
to	O
>	O
165	O
/	O
>	O
95	O
mmHg	O
,	O
though	O
many	O
studies	O
did	O
not	O
report	O
the	O
hypertension	O
thresholds	O
applied	O
.	O
Hypertension	O
prevalence	O
ranged	O
from	O
3	O
%	O
34	O
to	O
63	O
%	O
.	O
17	O
Two	O
studies	O
found	O
truck	O
drivers	O
with	O
obesity	O
had	O
a	O
higher	O
prevalence	O
of	O
hypertension	O
.	O
46	O
88	O
Seventy	O
-	O
seven	O
per	O
cent	O
of	O
studies5	O
11	O
17	O
19	O
27	O
39	O
–	O
42	O
49	O
53	O
62	O
63	O
69	O
75	O
79	O
82	O
86	O
–	O
88	O
97	O
98	O
103	O
indicated	O
that	O
the	O
prevalence	O
of	O
hypertension	O
in	O
truck	O
drivers	O
was	O
higher	O
than	O
the	O
global	O
prevalence	O
(	O
26	O
.	O
4	O
%	O
)	O
.	O
105	O
Twelve	O
studies	O
objectively	O
measured	O
total	O
cholesterol	O
levels	O
.	O
11	O
19	O
21	O
26	O
28	O
37	O
–	O
42	O
47	O
49	O
54	O
61	O
69	O
73	O
88	O
Most	O
measurements	O
were	O
in	O
mg	O
/	O
dL	O
,	O
mean	O
readings	O
ranged	O
from	O
168	O
.	O
2	O
mg	O
/	O
dL37	O
to	O
202	O
.	O
8	O
mg	O
/	O
dL	O
,	O
54	O
though	O
the	O
latter	O
reading	O
was	O
not	O
fasted	O
.	O

Six	O
studies	O
measured	O
the	O
prevalence	O
of	O
high	O
total	O
cholesterol	O
levels	O
.	O
19	O
38	O
–	O
40	O
49	O
69	O
88	O
Thresholds	O
varied	O
from	O
>	O
19019	O
to	O
>	O
240	O
mg	O
/	O
dL	O
,	O
88	O
though	O
the	O
remainder38	O
–	O
40	O
69	O
106	O
reported	O
high	O
total	O
cholesterol	O
based	O
on	O
the	O
Adult	O
Treatment	O
Panel	O
(	O
ATP	O
)	O
III	O
classification	O
of	O
>	O
200	O
mg	O
/	O
dL	O
.	O
107	O
Of	O
those	O
using	O
the	O
>	O
200	O
mg	O
/	O
dL	O
threshold	O
,	O
studies	O
reported	O
prevalence	O
of	O
borderline	O
-	O
high	O
total	O
cholesterol	O
as	O
11	O
.	O
4	O
%	O
,	O
38	O
39	O
33	O
.	O
0	O
%	O
,	O
40	O
38	O
.	O
8	O
%	O
69	O
and	O
45	O
.	O
8	O
%	O
.	O
106	O
Eleven	O
studies	O
reported	O
HDL	O
,	O
11	O
19	O
21	O
26	O
28	O
37	O
–	O
42	O
47	O
54	O
60	O
61	O
69	O
73	O
83	O
most	O
measurements	O
were	O
in	O
mg	O
/	O
dL	O
,	O
mean	O
readings	O
ranged	O
from	O
29	O
.	O
0	O
mg	O
/	O
dL28	O
to	O
52	O
.	O
5	O
mg	O
/	O
dL	O
.	O
54	O
Forty	O
three	O
per	O
cent	O
of	O
studies	O
(	O
n	O
=	O
7	O
studies	O
)	O
reported	O
mean	O
HDL	O
level	O
as	O
low	O
(	O
<	O
40	O
mg	O
/	O
dL	O
)	O
,	O
11	O
28	O
37	O
–	O
39	O
60	O
61	O
69	O
based	O
on	O
the	O
ATP	O
III	O
Classification	O
of	O
HDL	O
cholesterol	O
.	O
107	O
Ten	O
studies	O
measured	O
LDL	O
levels	O
,	O
19	O
21	O
26	O
28	O
37	O
40	O
–	O
42	O
47	O
61	O
69	O
73	O
83	O
most	O
measurements	O
were	O
in	O
mg	O
/	O
dL	O
,	O
mean	O
readings	O
ranged	O
from	O
103	O
.	O
5	O
mg	O
/	O
dL28	O
to	O
150	O
.	O
4	O
mg	O
/	O
dL	O
.	O
83	O
According	O
to	O
ATP	O
III	O
,	O
all	O
mean	O
LDL	O
values	O
reported	O
in	O
mg	O
/	O
dL	O
were	O
above	O
optimal	O
.	O
Cavagioni	O
et	O
al	O
found	O
25	O
.	O
2	O
%	O
of	O
truck	O
drivers	O
had	O
an	O
LDL	O
of	O
>	O
130	O
mg	O
/	O
dL	O
,	O
40	O
which	O
is	O
borderline	O
-	O
high	O
based	O
on	O
the	O
ATP	O
III	O
classification	O
of	O
LDL	O
cholesterol	O
.	O
107	O
This	O
is	O
supported	O
by	O
Lemke	O
et	O
al	O
who	O
found	O
that	O
52	O
.	O
8	O
%	O
of	O
truck	O
drivers	O
had	O
an	O
LDL	O
level	O
of	O
>	O
115	O
mg	O
/	O
dL	O
.	O
61	O
Nine	O
studies	O
reported	O
triglyceride	O
levels	O
,	O
19	O
21	O
26	O
37	O
40	O
–	O
42	O
47	O
60	O
61	O
73	O
83	O
mean	O
readings	O
ranged	O
from	O
158	O
.	O
5	O
mg	O
/	O
dL40	O
to	O
203	O
.	O
1	O
mg	O
/	O
dL	O
.	O
21	O
All	O
reported	O
mean	O
triglyceride	O
levels	O
were	O
>	O
150	O
mg	O
/	O
dL	O
,	O
which	O
based	O
on	O
the	O
ATP	O
III	O
classification	O
of	O
triglycerides	O
is	O
borderline	O
-	O
high	O
.	O
107	O

Seventeen	O
studies	O
measured	O
fasting	O
blood	O
glucose	O
levels	O
,	O
11	O
19	O
21	O
26	O
–	O
28	O
37	O
–	O
42	O
47	O
49	O
53	O
54	O
60	O
69	O
73	O
83	O
87	O
88	O
97	O
most	O
were	O
reported	O
in	O
mg	O
/	O
dL	O
,	O
mean	O
readings	O
ranged	O
from	O
86	O
.	O
3	O
mg	O
/	O
dL37	O
to	O
125	O
.	O
0	O
mg	O
/	O
dL	O
.	O
53	O
Thirty	O
three	O
per	O
cent	O
of	O
reported	O
mean	O
glucose	O
levels	O
were	O
>	O
110	O
mg	O
/	O
dL	O
,	O
11	O
28	O
53	O
69	O
which	O
based	O
on	O
the	O
ATP	O
III	O
classification	O
of	O
fasting	O
glucose	O
,	O
is	O
a	O
risk	O
factor	O
for	O
the	O
metabolic	O
syndrome	O
.	O
107	O
Three	O
studies	O
measured	O
Hemoglobin	O
A1c	O
(	O
HbA1c	O
)	O
,	O
11	O
49	O
54	O
69	O
with	O
means	O
ranging	O
from	O
5	O
.	O
0	O
%	O
69	O
to	O
6	O
.	O
1	O
%	O
,	O
49	O
two	O
studies	O
of	O
which	O
,	O
reported	O
means	O
within	O
the	O
pre	O
-	O
diabetic	O
range	O
of	O
HbA1c	O
level	O
(	O
>	O
5	O
.	O
7	O
%	O
)	O
according	O
to	O
the	O
American	O
Diabetes	O
Association	O
.	O
108	O
While	O
three	O
reported	O
plasma	O
glucose	O
levels41	O
47	O
73	O
which	O
ranged	O
from	O
5	O
.	O
2	O
to	O
5	O
.	O
7	O
mmol	O
/	O
L	O
.	O
Twenty	O
-	O
four	O
studies	O
reported	O
prevalence	O
of	O
type	O
2	O
diabetes	O
.	O
3	O
5	O
11	O
12	O
25	O
27	O
33	O
34	O
37	O
41	O
–	O
43	O
48	O
53	O
61	O
62	O
64	O
69	O
70	O
72	O
73	O
75	O
78	O
79	O
83	O
87	O
–	O
89	O
96	O
–	O
98	O
Self	O
-	O
reported	O
previously	O
diagnosed	O
type	O
2	O
diabetes3	O
5	O
12	O
25	O
33	O
34	O
43	O
48	O
61	O
62	O
64	O
69	O
70	O
72	O
75	O
78	O
79	O
89	O
96	O
98	O
ranged	O
from	O
1	O
.	O
5	O
%	O
34	O
to	O
17	O
%	O
,	O
25	O
while	O
prevalence	O
in	O
those	O
with	O
objectively	O
measured	O
abnormal	O
glucose	O
levels11	O
19	O
27	O
37	O
42	O
53	O
73	O
83	O
87	O
88	O
ranged	O
from	O
3	O
.	O
4	O
%	O
27	O
to	O
18	O
.	O
3	O
%	O
.	O
37	O
Four	O
studies	O
reported	O
metabolic	O
syndrome	O
prevalence	O
.	O
37	O
–	O
39	O
41	O
60	O
83	O
87	O
Apostolopoulos	O
et	O
al	O
found	O
a	O
significantly	O
higher	O
proportion	O
of	O
US	O
truck	O
drivers	O
had	O
metabolic	O
syndrome	O
than	O
a	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
comparative	O
group	O
(	O
73	O
.	O
7	O
%	O
vs	O
33	O
.	O
8	O
%	O
,	O
respectively	O
)	O
,	O
37	O
similar	O
findings	O
have	O
been	O
reported	O
elsewhere	O
.	O
41	O
Ebrahimi	O
et	O
al	O
also	O
found	O
a	O
high	O
prevalence	O
of	O
the	O
metabolic	O
syndrome	O
in	O
Iranian	O
truck	O
drivers	O
of	O
26	O
.	O
1	O
%	O
based	O
on	O
the	O
ATP	O
definition107	O
and	O
32	O
.	O
6	O
%	O
based	O
on	O
the	O
International	O
Diabetes	O
Federation	O
definition	O
of	O
metabolic	O
syndrome	O
.	O
83	O
109	O

Nineteen	O
studies	O
reported	O
depression	O
and	O
depressive	O
symptoms	O
prevalence	O
.	O
2	O
3	O
13	O
22	O
24	O
33	O
35	O
43	O
47	O
62	O
–	O
68	O
73	O
75	O
76	O
90	O
96	O
110	O
There	O
were	O
limited	O
consistent	O
measurements	O
of	O
depression	O
;	O
self	O
-	O
reported	O
questionnaires	O
were	O
the	O
measurement	O
tool	O
used	O
in	O
17	O
studies	O
,	O
2	O
3	O
13	O
22	O
24	O
35	O
47	O
62	O
–	O
68	O
73	O
75	O
76	O
90	O
110	O
one	O
study	O
conducted	O
qualitative	O
interviews	O
,	O
33	O
and	O
one	O
study	O
reported	O
depression	O
medication	O
use	O
as	O
0	O
.	O
6	O
%	O
.	O
43	O
96	O
Self	O
-	O
reported	O
symptoms	O
of	O
depression	O
ranged	O
from	O
6	O
%	O
90	O
to	O
26	O
.	O
9	O
%	O
,	O
2	O
40	O
.	O
8	O
%	O
of	O
a	O
sample	O
of	O
Kenyan	O
truck	O
drivers	O
reported	O
feeling	O
depressed	O
.	O
68	O
In	O
a	O
large	O
sample	O
of	O
US	O
occupational	O
groups	O
,	O
Fan	O
et	O
al	O
found	O
truck	O
drivers	O
had	O
a	O
twofold	O
higher	O
prevalence	O
of	O
depression	O
than	O
the	O
average	O
US	O
worker	O
.	O
76	O
Alavi	O
et	O
al	O
found	O
that	O
depression	O
could	O
increase	O
the	O
likelihood	O
of	O
a	O
road	O
traffic	O
collision	O
in	O
truck	O
drivers	O
(	O
OR	O
2	O
.	O
4	O
)	O
.	O
13	O
Eight	O
studies	O
reported	O
anxiety	O
prevalence	O
.	O
2	O
13	O
22	O
24	O
33	O
43	O
47	O
62	O
67	O
90	O
96	O
Those	O
that	O
compared	O
truck	O
drivers	O
anxiety	O
levels	O
to	O
national	O
averages	O
,	O
found	O
truck	O
drivers	O
had	O
significantly	O
higher	O
values	O
of	O
anxiety	O
.	O
2	O
24	O
47	O
67	O
Anxiety	O
was	O
associated	O
with	O
a	O
fourfold	O
increase	O
in	O
likelihood	O
of	O
crashes	O
.	O
13	O
Though	O
it	O
appeared	O
self	O
-	O
reported	O
medication	O
use	O
for	O
anxiety	O
was	O
low	O
compared	O
with	O
that	O
of	O
the	O
general	O
population	O
.	O
43	O
96	O
111	O
Ten	O
studies	O
reported	O
on	O
psychological	O
stress	O
.	O
7	O
21	O
27	O
62	O
67	O
76	O
90	O
94	O
95	O
99	O
110	O
112	O
Ulhoa	O
et	O
al	O
found	O
cortisol	O
levels	O
30	O
minutes	O
after	O
wakening	O
were	O
higher	O
in	O
irregular	O
shift	O
workers	O
compared	O
with	O
day	O
-	O
shift	O
workers	O
.	O
21	O
Orris	O
et	O
al	O
used	O
a	O
Symptom	O
Checklist	O
90	O
R	O
questionnaire	O
and	O
found	O
US	O
truck	O
drivers	O
were	O
in	O
the	O
91st	O
percentile	O
for	O
psychological	O
distress	O
compared	O
with	O
the	O
US	O
working	O
population	O
.	O
67	O
Similar	O
results	O
were	O
also	O
seen	O
in	O
China	O
.	O
66	O
In	O
a	O
separate	O
study	O
,	O
Ulhoa	O
et	O
al	O
used	O
a	O
Self	O
-	O
Report	O
Questionnaire	O
and	O
found	O
that	O
6	O
.	O
1	O
%	O
of	O
the	O
sample	O
had	O
minor	O
psychiatric	O
disorders	O
,	O
with	O
the	O
most	O
common	O
reported	O
stressors	O
being	O
traffic	O
congestion	O
,	O
strict	O
vehicle	O
tracking	O
control	O
,	O
and	O
extended	O
working	O
hours	O
.	O
Thirty	O
-	O
three	O
per	O
cent	O
reported	O
high	O
job	O
demand	O
and	O
54	O
.	O
9	O
%	O
reported	O
low	O
job	O
control	O
,	O
which	O
were	O
associated	O
with	O
minor	O
psychiatric	O
disorders	O
.	O
45	O
Croon	O
et	O
al	O
conducted	O
a	O
2	O
-	O
year	O
prospective	B-methodology
cohort	I-methodology
study	I-methodology
which	O
found	O
that	O
job	O
movement	O
to	O
any	O
job	O
outside	O
of	O
the	O
trucking	O
industry	O
resulted	O
in	O
a	O
larger	O
strain	O
reduction	O
compared	O
with	O
job	O
movement	O
within	O
the	O
trucking	O
industry	O
.	O
112	O

Four	O
studies	O
reported	O
on	O
isolation	O
.	O
2	O
33	O
45	O
110	O
Ulhôa	O
et	O
al	O
found	O
60	O
.	O
8	O
%	O
of	O
truck	O
driver	O
reported	O
low	O
social	O
support	O
in	O
the	O
workplace	O
.	O
45	O
Hatami	O
et	O
al	O
showed	O
significantly	O
reduced	O
prevalence	O
of	O
depression	O
in	O
truck	O
drivers	O
who	O
have	O
a	O
codriver	O
than	O
solo	O
truck	O
drivers	O
.	O
110	O
Shattell	O
et	O
al	O
reported	O
27	O
.	O
9	O
%	O
of	O
truck	O
drivers	O
mentioned	O
being	O
lonely2	O
and	O
27	O
.	O
1	O
%	O
mentioned	O
they	O
did	O
not	O
have	O
good	O
friendships	O
,	O
with	O
15	O
.	O
3	O
%	O
saying	O
they	O
had	O
no	O
friends	O
.	O
33	O
Seventeen	O
studies	O
reported	O
truck	O
drivers	O
’	O
diet17	O
18	O
20	O
26	O
28	O
30	O
32	O
35	O
42	O
43	O
47	O
48	O
50	O
53	O
56	O
59	O
73	O
86	O
;	O
of	O
which	O
nine	O
studies	O
measured	O
daily	O
fruit	O
and	O
vegetable	O
intake	O
.	O
17	O
18	O
26	O
30	O
42	O
47	O
50	O
56	O
59	O
73	O
This	O
ranged	O
from	O
1	O
.	O
72	O
servings	O
/	O
day30	O
to	O
5	O
servings	O
/	O
day	O
.	O
47	O
It	O
is	O
suggested	O
that	O
at	O
least	O
five	O
portions	O
(	O
>	O
400	O
g	O
)	O
of	O
varied	O
fruits	O
and	O
vegetables	O
should	O
be	O
consumed	O
each	O
day	O
to	O
prevent	O
all	O
-	O
cause	O
mortality	O
,	O
cancers	O
and	O
cardiovascular	O
disease	O
.	O
113	O
Wong	O
et	O
al	O
found	O
that	O
only	O
1	O
.	O
1	O
%	O
of	O
truck	O
drivers	O
from	O
Hong	O
Kong	O
ate	O
≥5	O
portions	O
of	O
fruits	O
/	O
vegetables	O
per	O
day	O
.	O
56	O
Reis	O
et	O
al	O
reported	O
that	O
58	O
.	O
3	O
%	O
of	O
Brazilian	O
long	O
haul	O
truck	O
drivers	O
ate	O
an	O
‘	O
unhealthy	O
diet	O
’	O
,	O
53	O
similar	O
results	O
were	O
also	O
found	O
in	O
Canada	O
(	O
48	O
%	O
)	O
,	O
48	O
though	O
neither	O
study	O
reported	O
how	O
this	O
was	O
defined	O
.	O
Additionally	O
,	O
Olson	O
et	O
al	O
found	O
that	O
36	O
.	O
6	O
%	O
of	O
calories	O
in	O
the	O
diet	O
came	O
from	O
fat	O
,	O
26	O
exceeding	O
the	O
higher	O
threshold	O
of	O
15	O
–	O
30	O
%	O
based	O
on	O
WHO	O
guidelines	B-methodology
.	O
114	O
Korelitz	O
et	O
al	O
reported	O
13	O
.	O
6	O
%	O
of	O
truck	O
drivers	O
ate	O
>	O
3	O
snacks	O
per	O
day	O
,	O
while	O
the	O
majority	O
of	O
participants	O
(	O
51	O
%	O
)	O
ate	O
two	O
meals	O
per	O
day	O
.	O
86	O
Wong	O
et	O
al	O
reported	O
that	O
24	O
.	O
9	O
%	O
of	O
truck	O
drivers	O
from	O
Hong	O
Kong	O
ate	O
at	O
restaurants	O
>	O
10	O
times	O
a	O
week	O
,	O
this	O
was	O
significantly	O
higher	O
than	O
their	O
professional	O
driver	O
counterparts	O
such	O
as	O
taxi	O
and	O
bus	O
drivers	O
.	O
56	O
This	O
is	O
pertinent	O
as	O
the	O
average	O
calorie	O
content	O
in	O
meals	O
from	O
restaurants	O
regularly	O
exceeds	O
that	O
of	O
home	O
cooked	O
meals	O
.	O
115	O

Twenty	O
-	O
six	O
studies	O
observed	O
physical	O
activity	O
levels	O
in	O
truck	O
drivers	O
,	O
11	O
17	O
19	O
20	O
26	O
28	O
30	O
36	O
38	O
–	O
40	O
42	O
44	O
47	O
49	O
53	O
55	O
56	O
58	O
59	O
69	O
73	O
85	O
86	O
89	O
97	O
99	O
103	O
however	O
,	O
only	O
two	O
studies	O
objectively	O
measured	O
physical	O
activity	O
using	O
an	O
accelerometer	O
(	O
GENEActiv	O
)	O
17	O
18	O
and	O
inclinometer	O
(	O
activPAL3	O
)	O
.	O
22	O
47	O
Though	O
measurements	O
of	O
physical	O
activity	O
were	O
heterogenous	O
,	O
overall	O
the	O
vast	O
majority	O
of	O
truck	O
drivers	O
did	O
not	O
reach	O
WHO	O
physical	O
activity	O
guidelines	B-methodology
.	O
116	O
Sangaleti	O
et	O
al	O
found	O
72	O
.	O
8	O
%	O
of	O
Brazilian	O
truck	O
drivers	O
were	O
physically	O
inactive	O
,	O
97	O
this	O
is	O
supported	O
by	O
Marqueze	O
et	O
al	O
who	O
found	O
66	O
.	O
7	O
%	O
of	O
truck	O
drivers	O
completed	O
<	O
10	O
min	O
of	O
physical	O
activity	O
a	O
week	O
.	O
19	O
Similar	O
results	O
were	O
found	O
in	O
USA	O
and	O
Ethiopia	O
,	O
with	O
69	O
.	O
4	O
%	O
and	O
63	O
.	O
8	O
%	O
of	O
truck	O
drivers	O
reporting	O
no	O
regular	O
exercise	O
,	O
respectively	O
.	O
44	O
58	O
The	O
highest	O
self	O
-	O
reported	O
regular	O
exercise	O
was	O
57	O
.	O
7	O
%	O
of	O
truck	O
drivers	O
within	O
a	O
different	O
US	O
sample11	O
69	O
and	O
42	O
.	O
9	O
%	O
of	O
truck	O
drivers	O
in	O
Hong	O
Kong	O
,	O
56	O
however	O
,	O
Korelitz	O
et	O
al	O
found	O
only	O
8	O
%	O
of	O
US	O
truck	O
drivers	O
reported	O
regular	O
physical	O
activity	O
,	O
while	O
49	O
.	O
6	O
%	O
reported	O
never	O
doing	O
physical	O
activity	O
.	O
86	O
Layne	O
et	O
al	O
found	O
minimal	O
differences	O
between	O
male	O
and	O
female	O
truck	O
drivers	O
levels	O
of	O
physical	O
activity	O
.	O
36	O
Seven	O
studies	O
reported	O
sedentary	O
behaviour	O
.	O
11	O
17	O
22	O
38	O
–	O
40	O
47	O
62	O
97	O
99	O
The	O
percentage	O
of	O
waking	O
time	O
spent	O
sedentary	O
in	O
truck	O
drivers	O
varied	O
from	O
39	O
.	O
4	O
%	O
38	O
39	O
to	O
78	O
.	O
1	O
%	O
.	O
53	O
One	O
study	O
objectively	O
measured	O
sitting	O
time	O
in	O
a	O
sample	O
of	O
truck	O
drivers	O
using	O
inclinometers	O
(	O
activPAL3	O
)	O
and	O
observed	O
truck	O
drivers	O
spent	O
13	O
hours	O
/	O
day	O
sitting	O
on	O
work	O
-	O
days	O
,	O
and	O
8	O
hours	O
/	O
day	O
sitting	O
on	O
non	O
-	O
workdays	O
.	O
47	O
Shorter	O
accelerometer	O
-	O
determined	O
sedentary	O
durations	O
of	O
9	O
.	O
1	O
hours	O
/	O
workday	O
were	O
found	O
in	O
an	O
Australian	O
sample	O
.	O
17	O
A	O
sample	O
of	O
truck	O
drivers	O
in	O
the	O
USA	O
also	O
self	O
-	O
reported	O
sitting	O
for	O
an	O
average	O
of	O
4	O
.	O
3	O
hours	O
/	O
day	O
outside	O
of	O
work	O
.	O
11	O

Thirty	O
-	O
eight	O
studies	O
reported	O
on	O
smoking	O
status	O
.	O
3	O
11	O
18	O
–	O
21	O
23	O
27	O
34	O
36	O
38	O
–	O
42	O
46	O
–	O
49	O
53	O
54	O
56	O
63	O
65	O
69	O
70	O
72	O
77	O
80	O
82	O
83	O
86	O
–	O
89	O
91	O
96	O
97	O
103	O
Prevalence	O
of	O
current	O
smokers	O
ranged	O
from	O
10	O
%	O
73	O
to	O
72	O
.	O
9	O
%	O
,	O
83	O
however	O
,	O
categorising	O
‘	O
current	O
smokers	O
’	O
varied	O
between	O
studies	O
and	O
was	O
not	O
defined	O
in	O
some	O
.	O
Jain	O
et	O
al	O
found	O
long	O
haul	O
truck	O
drivers	O
were	O
more	O
likely	O
to	O
smoke	O
than	O
delivery	O
drivers	O
,	O
dock	O
workers	O
,	O
mechanics	O
or	O
clerks	O
.	O
91	O
Mansur	O
et	O
al	O
found	O
that	O
the	O
smoking	O
prevalence	O
in	O
truck	O
drivers	O
has	O
decreased	O
from	O
2006	O
to	O
2011	O
by	O
1	O
.	O
4	O
%	O
,	O
87	O
though	O
Sieber	O
et	O
al	O
showed	O
that	O
compared	O
with	O
the	O
US	O
adult	O
working	O
population	O
,	O
US	O
long	O
haul	O
truck	O
drivers	O
were	O
more	O
than	O
twice	O
as	O
likely	O
to	O
smoke	O
(	O
51	O
%	O
vs	O
19	O
%	O
)	O
.	O
89	O
Moreno	O
et	O
al	O
found	O
that	O
although	O
overall	O
prevalence	O
of	O
smoking	O
was	O
high	O
,	O
those	O
who	O
were	O
obese	O
were	O
less	O
likely	O
to	O
smoke	O
.	O
88	O
77	O
%	O
of	O
studies	O
that	O
reported	O
smoking	O
status	O
,	O
reported	O
higher	O
smoking	O
prevalence	O
rates	O
than	O
the	O
global	O
average	O
of	O
20	O
%	O
.	O
117	O
Thirty	O
-	O
five	O
studies	O
measured	O
alcohol	O
consumption	O
.	O
2	O
3	O
5	O
11	O
18	O
20	O
21	O
23	O
27	O
32	O
–	O
35	O
40	O
43	O
47	O
53	O
54	O
56	O
58	O
62	O
63	O
65	O
68	O
–	O
70	O
72	O
73	O
75	O
80	O
–	O
82	O
85	O
–	O
90	O
97	O
99	O
Alcohol	O
consumption	O
was	O
diversely	O
measured	O
.	O

da	O
Silva	O
-	O
Júnior	O
et	O
al	O
reported	O
48	O
.	O
3	O
%	O
of	O
a	O
sample	O
of	O
Brazilian	O
truck	O
drivers	O
admitted	O
to	O
drinking	O
alcohol	O
during	O
working	O
hours	O
,	O
and	O
88	O
.	O
6	O
%	O
were	O
aware	O
of	O
similar	O
behaviour	O
in	O
colleagues	O
.	O
3	O
Rosso	O
et	O
al	O
also	O
found	O
24	O
.	O
2	O
%	O
of	O
a	O
sample	O
of	O
Italian	O
truck	O
drivers	O
reported	O
drinking	O
during	O
working	O
hours	O
or	O
breaks	O
.	O
43	O
Kartikeyan	O
et	O
al	O
observed	O
that	O
over	O
half	O
of	O
the	O
Indian	O
truck	O
drivers	O
assessed	O
were	O
classified	O
as	O
alcoholics	O
(	O
ie	O
,	O
consuming	O
>	O
75	O
g	O
alcohol	O
/	O
day	O
)	O
,	O
34	O
this	O
is	O
supported	O
by	O
Sharma	O
et	O
al	O
,	O
where	O
57	O
.	O
6	O
%	O
of	O
their	O
Indian	O
truck	O
driving	O
sample	O
were	O
classified	O
as	O
alcoholics	O
.	O
27	O
Rice	O
et	O
al	O
reported	O
that	O
14	O
.	O
2	O
%	O
of	O
Australian	O
truck	O
drivers	O
admit	O
to	O
drinking	O
excessively	O
.	O
35	O
Hilton	O
et	O
al	O
found	O
that	O
using	O
the	O
Alcohol	O
Use	O
Disorders	O
Identification	O
Test	O
questionnaire	O
,	O
26	O
.	O
8	O
%	O
of	O
their	O
sample	O
of	O
Australian	O
truck	O
drivers	O
were	O
considered	O
alcohol	O
dependent	O
.	O
90	O
Mansur	O
found	O
that	O
alcohol	O
consumption	O
in	O
Brazilian	O
truck	O
drivers	O
has	O
decreased	O
from	O
36	O
.	O
6	O
%	O
in	O
2006	O
to	O
23	O
%	O
in	O
2011	O
,	O
however	O
,	O
illicit	O
drug	O
use	O
has	O
nearly	O
doubled	O
from	O
4	O
.	O
1	O
%	O
in	O
2006	O
to	O
8	O
.	O
1	O
%	O
in	O
2011	O
.	O
87	O
Seventeen	O
studies	O
measured	O
illicit	O
substance	O
use	O
.	O
2	O
3	O
12	O
33	O
35	O
40	O
45	O
49	O
63	O
68	O
70	O
72	O
–	O
75	O
87	O
92	O
97	O
Overall	O
self	O
-	O
reported	O
drug	O
use	O
was	O
low	O
.	O
Ulhôa	O
et	O
al	O
reported	O
that	O
0	O
%	O
of	O
Brazilian	O
participants	O
asked	O
used	O
psychotropic	O
drugs	O
,	O
45	O
which	O
is	O
similar	O
to	O
findings	O
from	O
a	O
US	O
study	O
.	O
12	O
However	O
,	O
Shattell	O
et	O
al	O
found	O
a	O
relatively	O
high	O
prevalence	O
of	O
reported	O
use	O
of	O
cannabis	O
(	O
3	O
.	O
4	O
%	O
)	O
,	O
opioids	O
(	O
2	O
.	O
5	O
%	O
)	O
and	O
sedatives	O
(	O
1	O
.	O
8	O
%	O
)	O
in	O
the	O
past	O
month	O
in	O
a	O
sample	O
of	O
US	O
truck	O
drivers	O
.	O
2	O
Riva	O
et	O
al	O
found	O
a	O
higher	O
drug	O
use	O
in	O
a	O
sample	O
of	O
Italian	O
truck	O
drivers	O
where	O
15	O
.	O
6	O
%	O
reported	O
using	O
recreational	O
drugs	O
,	O
and	O
of	O
those	O
,	O
12	O
%	O
reported	O
they	O
were	O
addicted	O
.	O
72	O
7	O
.	O
8	O
%	O
of	O
a	O
sample	O
of	O
Brazilian	O
truck	O
drivers	O
tested	O
positive	O
for	O
psychoactive	O
substances	O
.	O
92	O
Shattell	O
et	O
al	O
interviewed	O
60	O
specially	O
selected	O
long	O
haul	O
truck	O
drivers	O
based	O
on	O
their	O
involvement	O
in	O
illegal	O
/	O
illicit	O
behaviours	O
,	O
they	O
found	O
88	O
.	O
1	O
%	O
admitted	O
to	O
drug	O
use	O
,	O
and	O
of	O
those	O
,	O
81	O
.	O
6	O
%	O
used	O
crack	O
cocaine	O
.	O
33	O
Self	O
-	O
reported	O
stimulant	O
use	O
was	O
high	O
in	O
several	O
studies	O
.	O
3	O
40	O
63	O
97	O

The	O
aim	O
of	O
this	O
review	O
was	O
to	O
systematically	O
summarise	O
the	O
literature	O
regarding	O
cardiometabolic	O
risk	O
factors	O
,	O
lifestyle	O
health	O
behaviours	O
and	O
mental	O
health	O
status	O
of	O
truck	O
drivers	O
globally	O
.	O
Findings	O
suggest	O
truck	O
drivers	O
are	O
an	O
at	O
-	O
risk	O
occupational	O
group	O
,	O
exhibiting	O
unhealthy	O
lifestyle	O
behaviours	O
,	O
such	O
as	O
high	O
levels	O
of	O
physical	O
inactivity	O
and	O
sedentary	O
behaviour	O
,	O
poor	O
dietary	O
choices	O
,	O
high	O
consumption	O
of	O
alcohol	O
and	O
high	O
smoking	O
prevalence	O
.	O
This	O
is	O
reinforced	O
by	O
the	O
reported	O
markers	O
of	O
health	O
such	O
as	O
high	O
obesity	O
levels	O
,	O
adverse	O
blood	O
profiles	O
and	O
mental	O
ill	O
health	O
.	O
Another	O
considerable	O
risk	O
factor	O
for	O
developing	O
cardiometabolic	O
health	O
conditions	O
is	O
age	O
,	O
with	O
truck	O
drivers	O
included	O
in	O
this	O
review	O
typically	O
being	O
middle	O
aged	O
.	O
This	O
is	O
representative	O
of	O
that	O
seen	O
in	O
the	O
real	O
-	O
world	O
setting	O
,	O
where	O
truck	O
drivers	O
are	O
classified	O
as	O
an	O
ageing	O
workforce	O
.	O
118	O
Nevertheless	O
,	O
one	O
repeated	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
study	I-methodology
in	O
the	O
USA	O
found	O
that	O
the	O
average	O
age	O
of	O
truck	O
drivers	O
has	O
dropped	O
between	O
2005	O
and	O
2012	O
,	O
79	O
which	O
is	O
an	O
optimistic	O
trajectory	O
for	O
the	O
future	O
of	O
the	O
road	O
transportation	O
and	O
logistics	O
industry	O
.	O
It	O
is	O
apparent	O
that	O
truck	O
driving	O
is	O
not	O
conducive	O
to	O
health	O
.	O
Predictive	O
factors	O
for	O
obesity	O
were	O
found	O
to	O
be	O
time	O
behind	O
the	O
wheel	O
,	O
96	O
travelling	O
more	O
than	O
40	O
000	O
miles	O
per	O
year96	O
and	O
working	O
>	O
11	O
hours	O
/	O
day	O
.	O
95	O
Interestingly	O
,	O
truck	O
drivers	O
with	O
obesity	O
were	O
significantly	O
more	O
likely	O
to	O
rate	O
the	O
exercise	O
environment	O
as	O
bad	O
,	O
and	O
therefore	O
,	O
had	O
more	O
perceived	O
barriers	O
to	O
exercise	O
.	O
99	O
A	O
repeated	O
cross	B-methodology
-	I-methodology
sectional	I-methodology
study	I-methodology
of	O
USA	O
truck	O
drivers	O
found	O
that	O
BMI	O
has	O
increased	O
significantly	O
from	O
2005	O
to	O
2012	O
.	O
79	O
Similarly	O
,	O
the	O
presence	O
of	O
dyslipidaemia	O
had	O
significantly	O
increased	O
from	O
2006	O
to	O
2011	O
.	O
87	O
The	O
increase	O
in	O
incidence	O
of	O
obesity	O
and	O
cardiometabolic	O
biomarkers	O
is	O
alarming	O
for	O
the	O
future	O
of	O
truck	O
driving	O
,	O
especially	O
considering	O
drivers	O
with	O
obesity	O
have	O
significantly	O
higher	O
crash	O
risks	O
than	O
healthy	O
weight	O
drivers	O
.	O
10	O
44	O
Obesity	O
also	O
has	O
an	O
economic	O
impact	O
to	O
the	O
employer	O
,	O
as	O
truck	O
drivers	O
with	O
overweight	O
and	O
obesity	O
exhibit	O
higher	O
annual	O
healthcare	O
costs	O
than	O
healthy	O
weight	O
truck	O
drivers	O
.	O
98	O
This	O
is	O
particularly	O
pertinent	O
for	O
companies	O
that	O
cover	O
employee	O
health	O
insurance	O
costs	O
.	O
Future	O
research	O
is	O
required	O
to	O
evaluate	O
the	O
health	O
of	O
truck	O
drivers	O
in	O
lesser	O
studied	O
regions	O
to	O
gain	O
a	O
more	O
global	O
understanding	O
of	O
the	O
health	O
and	O
implications	O
of	O
truck	O
driving	O
worldwide	O
.	O
Health	O
and	O
well	O
-	O
being	O
programmes	O
that	O
focus	O
on	O
health	O
education	O
should	O
be	O
implemented	O
and	O
prioritised	O
within	O
the	O
logistics	O
industry	O
.	O

In	O
truck	O
drivers	O
,	O
improved	O
education	O
levels	O
have	O
been	O
associated	O
with	O
increased	O
physical	O
activity	O
,	O
99	O
reduced	O
BMI43	O
and	O
improved	O
mental	O
health	O
status	O
.	O
3	O
Where	O
they	O
exist	O
,	O
health	O
and	O
well	O
-	O
being	O
programmes	O
within	O
this	O
industry	O
have	O
been	O
recognised	O
as	O
having	O
the	O
potential	O
of	O
providing	O
beneficial	O
impact	O
on	O
employee	O
health	O
,	O
morale	O
and	O
employee	O
–	O
employer	O
relations	O
.	O
119	O
This	O
would	O
also	O
directly	O
benefit	O
employers	O
with	O
increased	O
employee	O
retention	O
,	O
reduced	O
healthcare	O
costs	O
,	O
improved	O
safety	O
and	O
job	O
desirability	O
,	O
combatting	O
the	O
global	O
driver	O
shortage	O
.	O
118	O
Despite	O
their	O
potential	O
,	O
limited	O
health	O
promotion	O
programmes	O
currently	O
exist	O
within	O
the	O
logistics	O
industry	O
and	O
most	O
have	O
been	O
minimally	O
effective	O
.	O
6	O
Though	O
primary	O
prevention	O
is	O
vital	O
,	O
interventions	O
should	O
aim	O
to	O
reach	O
a	O
multitude	O
of	O
risk	O
factors	O
by	O
applying	O
multiple	O
components	O
,	O
targeting	O
health	O
literacy	O
and	O
improving	O
workplace	O
opportunities	O
to	O
make	O
healthy	O
lifestyle	O
choices	O
,	O
in	O
order	O
to	O
gain	O
maximum	O
effectiveness	O
.	O
Research	O
should	O
then	O
determine	O
which	O
components	O
are	O
most	O
effective	O
for	O
improving	O
driver	O
health	O
,	O
26	O
and	O
which	O
facilitators	O
and	O
barriers	O
may	O
have	O
affected	O
participant	O
adherence	O
.	O
120	O
All	O
stakeholders	O
including	O
drivers	O
,	O
employers	O
,	O
unions	O
,	O
clinicians	O
,	O
truck	O
stops	O
,	O
regulatory	O
agencies	O
and	O
policy	O
-	O
makers	O
should	O
be	O
engaged	O
to	O
achieve	O
these	O
ambitions	O
.	O
A	O
key	O
strength	O
is	O
the	O
comprehensive	B-methodology
review	I-methodology
itself	O
,	O
encompassing	O
a	O
large	O
range	O
of	O
cardiometabolic	O
risk	O
factors	O
,	O
health	O
-	O
related	O
behaviours	O
and	O
mental	O
health	O
,	O
thus	O
providing	O
a	O
complete	O
scope	O
of	O
the	O
health	O
status	O
of	O
truck	O
drivers	O
.	O
Strengths	O
also	O
include	O
the	O
thorough	O
search	O
strategy	O
;	O
however	O
,	O
it	O
is	O
possible	O
that	O
some	O
relevant	O
papers	O
were	O
missed	O
due	O
to	O
the	O
English	O
-	O
only	O
search	O
criteria	O
.	O
A	O
further	O
strength	O
is	O
the	O
stringent	O
independent	O
scoring	O
of	O
each	O
paper	O
’	O
s	O
methodological	O
quality	O
.	O
One	O
reviewer	O
screened	O
all	O
titles	O
,	O
abstracts	O
,	O
and	O
full	O
texts	O
for	O
inclusion	O
followed	O
by	O
a	O
methodological	O
quality	O
assessment	O
of	O
each	O
included	O
paper	O
.	O
Subsequently	O
,	O
20	O
%	O
were	O
randomly	O
selected	O
for	O
independent	O
verification	O
at	O
each	O
stage	O
by	O
a	O
second	O
reviewer	O
,	O
which	O
is	O
identified	O
as	O
a	O
limitation	O
of	O
this	O
paper	O
based	O
on	O
the	O
PRISMA	B-methodology
guidelines	I-methodology
.	O
Similarly	O
,	O
33	O
%	O
of	O
included	O
papers	O
were	O
scored	O
‘	O
poor	O
’	O
in	O
the	O
quality	O
assessment	O
,	O
and	O
24	O
%	O
included	O
small	O
sample	O
sizes	O
(	O
n	O
=	O
<	O
100	O
)	O
which	O
may	O
impact	O
the	O
confidence	O
within	O
the	O
results	O
.	O
Due	O
to	O
the	O
heterogeneity	O
of	O
measuring	O
and	O
reporting	O
findings	O
from	O
each	O
study	O
,	O
a	O
descriptive	O
synthesis	O
of	O
results	O
appeared	O
most	O
appropriate	O
,	O
though	O
this	O
may	O
have	O
led	O
to	O
inconsistent	O
statistical	O
findings	O
between	O
papers	O
.	O
As	O
a	O
recommendation	O
for	O
future	O
research	O
,	O
authors	O
are	O
encouraged	O
to	O
report	O
and	O
use	O
consistent	O
thresholds	O
for	O
defining	O
the	O
prevalence	O
of	O
certain	O
risk	O
factors	O
to	O
enable	O
a	O
meta	B-methodology
-	I-methodology
analysis	I-methodology
.	O

By	O
presenting	O
all	O
study	O
characteristics	O
and	O
results	O
in	O
online	O
supplemental	O
file	O
4	O
,	O
transparency	O
has	O
been	O
added	O
.	O
A	O
limitation	O
is	O
the	O
unequal	O
geographical	O
distribution	O
of	O
papers	O
(	O
table	O
1	O
)	O
,	O
ethnicity	O
was	O
predominantly	O
White	O
in	O
all	O
but	O
two	O
studies	O
,	O
33	O
66	O
suggesting	O
the	O
review	O
may	O
not	O
provide	O
a	O
complete	O
representation	O
of	O
the	O
global	O
cardiometabolic	O
and	O
mental	O
health	O
status	O
of	O
truck	O
drivers	O
.	O
Truck	O
driving	O
is	O
a	O
very	O
heterogeneous	O
job	O
,	O
there	O
are	O
many	O
varieties	O
of	O
truck	O
drivers	O
,	O
predominantly	O
long	O
haul	O
or	O
short	O
haul	O
.	O
Typically	O
,	O
short	O
haul	O
truck	O
drivers	O
are	O
more	O
physically	O
active	O
as	O
they	O
are	O
often	O
loading	O
and	O
unloading	O
their	O
trucks	O
,	O
the	O
distances	O
they	O
travel	O
are	O
smaller	O
and	O
hence	O
their	O
sedentary	O
time	O
is	O
often	O
broken	O
up	O
.	O
They	O
also	O
tend	O
to	O
return	O
home	O
after	O
most	O
shifts	O
and	O
drive	O
less	O
miles	O
overall	O
,	O
which	O
results	O
in	O
an	O
overall	O
healthier	O
way	O
of	O
life	O
.	O
Only	O
36	O
included	O
studies	O
reported	O
on	O
the	O
type	O
of	O
truck	O
driver	O
,	O
which	O
warrants	O
consideration	O
.	O
Another	O
important	O
factor	O
is	O
the	O
law	O
in	O
many	O
countries	O
requires	O
truck	O
drivers	O
to	O
be	O
of	O
adequate	O
health	O
in	O
order	O
to	O
legally	O
operate	O
commercial	O
vehicles	O
on	O
public	O
roads	O
,	O
and	O
as	O
a	O
result	O
,	O
truck	O
drivers	O
are	O
required	O
to	O
undergo	O
regular	O
medical	O
examinations	O
.	O
Truck	O
drivers	O
may	O
be	O
disqualified	O
for	O
a	O
multitude	O
of	O
health	O
conditions	O
and	O
subsequently	O
leave	O
the	O
industry	O
.	O
Consequently	O
,	O
a	O
substantial	O
healthy	O
worker	O
effect	O
is	O
created	O
,	O
as	O
those	O
who	O
are	O
unfit	O
to	O
work	O
will	O
not	O
be	O
included	O
in	O
studies	O
.	O
121	O
This	O
may	O
lead	O
to	O
the	O
prevalence	O
of	O
diseases	O
being	O
low	O
,	O
while	O
the	O
prevalence	O
of	O
risk	O
factors	O
for	O
chronic	O
disease	O
are	O
substantial	O
.	O
48	O
This	O
reflects	O
the	O
findings	O
from	O
this	O
systematic	B-methodology
review	I-methodology
,	O
where	O
for	O
example	O
,	O
only	O
41	O
%	O
of	O
papers	O
reported	O
a	O
mean	O
higher	O
prevalence	O
of	O
type	O
2	O
diabetes	O
than	O
the	O
global	O
average	O
(	O
9	O
.	O
3	O
%	O
in	O
2019	O
)	O
.	O
122	O
Notably	O
,	O
addictive	O
behaviour	O
such	O
as	O
alcohol	O
and	O
illicit	O
drug	O
consumptions	O
are	O
likely	O
to	O
be	O
underreported	O
due	O
to	O
fears	O
that	O
it	O
may	O
lead	O
to	O
disciplinary	O
action	O
.	O
123	O
Participation	O
bias	O
may	O
also	O
impact	O
these	O
findings	O
,	O
for	O
example	O
,	O
drivers	O
at	O
risk	O
of	O
certain	O
health	O
conditions	O
may	O
choose	O
to	O
not	O
enrol	O
in	O
such	O
studies	O
.	O
This	O
is	O
exacerbated	O
by	O
the	O
certain	O
levels	O
of	O
mistrust	O
frequently	O
seen	O
among	O
truck	O
drivers	O
,	O
often	O
resulting	O
in	O
their	O
reluctance	O
to	O
release	O
personal	O
information	O
,	O
making	O
them	O
a	O
hard	O
-	O
to	O
-	O
reach	O
population	O
.	O
124	O
Similar	O
reviews	O
examining	O
the	O
health	O
of	O
truck	O
drivers	O
have	O
found	O
comparable	O
findings	O
.	O

Abu	O
Dabrh	O
et	O
al	O
found	O
that	O
the	O
average	O
BMI	O
of	O
32	O
combined	O
studies	O
of	O
truck	O
drivers	O
was	O
30	O
.	O
5	O
kg	O
/	O
m2	O
and	O
the	O
prevalence	O
of	O
hypertension	O
was	O
23	O
%	O
(	O
n	O
=	O
1000	O
)	O
.	O
125	O
A	O
systematic	B-methodology
review	I-methodology
which	O
examined	O
the	O
health	O
of	O
truck	O
drivers	O
in	O
North	O
America	O
also	O
found	O
the	O
average	O
BMI	O
for	O
all	O
nine	O
included	O
studies	O
was	O
>	O
30	O
kg	O
/	O
m2	O
.	O
126	O
This	O
is	O
further	O
supported	O
by	O
Prince	O
et	O
al	O
who	O
compared	O
cardiometabolic	O
health	O
variability	O
between	O
occupational	O
groups	O
,	O
and	O
found	O
driving	O
-	O
based	O
workers	O
had	O
a	O
higher	O
BMI	O
and	O
blood	O
pressure	O
than	O
other	O
occupational	O
groups	O
.	O
127	O
Similarly	O
,	O
a	O
literature	B-methodology
review	I-methodology
of	O
truck	O
drivers	O
found	O
hypertension	O
in	O
seven	O
studies	O
ranged	O
from	O
24	O
%	O
to	O
47	O
.	O
9	O
%	O
,	O
the	O
majority	O
were	O
above	O
the	O
global	O
average	O
.	O
105	O
128	O
Based	O
on	O
the	O
results	O
of	O
this	O
review	O
,	O
there	O
is	O
strong	O
evidence	O
to	O
indicate	O
that	O
truck	O
drivers	O
have	O
a	O
detrimental	O
cardiometabolic	O
and	O
mental	O
health	O
profile	O
in	O
comparison	O
to	O
general	O
populations	O
.	O
Obesity	O
levels	O
and	O
other	O
cardiometabolic	O
risk	O
factors	O
in	O
truck	O
drivers	O
are	O
alarming	O
considering	O
it	O
impacts	O
the	O
safety	O
of	O
all	O
road	O
users	O
.	O
Improving	O
truck	O
driver	O
health	O
is	O
vital	O
for	O
the	O
longevity	O
of	O
the	O
trucking	O
industry	O
.	O
It	O
is	O
imperative	O
to	O
understand	O
that	O
the	O
systemic	O
working	O
conditions	O
that	O
truck	O
drivers	O
endure	O
create	O
a	O
fundamental	O
barrier	O
to	O
the	O
adoption	O
of	O
a	O
healthy	O
lifestyle	O
.	O
These	O
unique	O
job	O
demands	O
include	O
the	O
long	O
irregular	O
hours	O
of	O
enforced	O
sedentarism	O
,	O
which	O
suppress	O
the	O
opportunity	O
for	O
physical	O
activity	O
,	O
alongside	O
the	O
lack	O
of	O
healthy	O
food	O
choices	O
at	O
truck	O
stops	O
,	O
which	O
creates	O
an	O
obesogenic	O
working	O
environment	O
.	O
The	O
workplace	O
plays	O
a	O
vital	O
role	O
in	O
truck	O
driver	O
health	O
;	O
policies	O
,	O
regulations	O
and	O
procedures	O
are	O
required	O
to	O
change	O
in	O
order	O
to	O
address	O
this	O
health	O
crisis	O
.	O
Twitter	O
:	O
@	O
StacyClemesContributors	O
:	O
All	O
authors	O
contributed	O
to	O
the	O
conception	O
of	O
the	O
review	O
.	O
AG	O
completed	O
the	O
literature	O
search	O
and	O
quality	O
assessments	O
,	O
Y	O
-	O
LC	O
quality	O
checked	O
20	O
%	O
of	O
papers	O
at	O
titles	O
,	O
abstract	O
,	O
and	O
full	O
text	O
for	O
inclusion	O
and	O
methodological	O
quality	O
assessment	O
.	O
Any	O
discrepancies	O
were	O
resolved	O
by	O
NP	O
.	O
NP	O
,	O
SC	O
,	O
NJP	O
and	O
JAK	O
revised	O
for	O
critically	O
important	O
content	O
.	O
All	O
authors	O
approved	O
the	O
final	O
version	O
of	O
the	O
manuscript	O
.	O
Funding	O
:	O
The	O
first	O
author	O
(	O
AG	O
)	O
has	O
received	O
funding	O
for	O
their	O
PhD	O
Studentship	O
from	O
the	O
Colt	O
Foundation	O
.	O

The	O
Colt	O
Foundation	O
had	O
no	O
role	O
in	O
study	B-methodology
design	I-methodology
;	O
election	O
,	O
synthesis	O
and	O
interpretation	O
of	O
data	O
;	O
writing	O
of	O
the	O
report	O
;	O
or	O
the	O
decision	O
to	O
submit	O
the	O
manuscript	O
for	O
publication	O
.	O
SC	O
and	O
JAK	O
are	O
in	O
receipt	O
of	O
funding	O
from	O
the	O
NIHR	O
Public	O
Health	O
Research	O
Programme	O
(	O
reference	O
:	O
NIHR	O
PHR	O
15	O
/	O
190	O
/	O
42	O
)	O
for	O
the	O
evaluation	O
of	O
a	O
multi	O
-	O
component	O
health	O
behaviour	O
intervention	O
in	O
truck	O
drivers	O
.	O
They	O
are	O
also	O
supported	O
by	O
the	O
NIHR	O
Leicester	O
Biomedical	O
Research	O
Centre	O
–	O
Lifestyle	O
theme	O
.	O
The	O
views	O
expressed	O
are	O
those	O
of	O
the	O
authors	O
and	O
not	O
necessarily	O
those	O
of	O
the	O
NHS	O
,	O
the	O
NIHR	O
or	O
the	O
Department	O
of	O
Health	O
and	O
Social	O
Care	O
.	O
Competing	O
interests	O
:	O
None	O
declared	O
.	O
Patient	O
consent	O
for	O
publication	O
:	O
Not	O
required	O
.	O
Provenance	O
and	O
peer	O
review	O
:	O
Not	O
commissioned	O
;	O
externally	O
peer	O
reviewed	O
.	O
Data	O
availability	O
statement	O
:	O
All	O
data	O
relevant	O
to	O
the	O
study	O
are	O
included	O
in	O
the	O
article	O
or	O
uploaded	O
as	O
online	O
supplemental	O
information	O
.	O
All	O
data	O
generated	O
in	O
this	O
study	O
are	O
included	O
in	O
this	O
published	O
article	O
and	O
its	O
additional	O
files	O
,	O
no	O
additional	O
data	O
are	O
available	O
.	O

Anti	O
-	O
obesity	O
effect	O
of	O
extract	O
from	O
fermented	O
Curcuma	O
longa	O
L	O
.	O
through	O
regulation	O
of	O
adipogenesis	O
and	O
lipolysis	O
pathway	O
in	O
high	O
-	O
fat	O
diet	O
-	O
induced	O
obese	O
rats	O
Curcuma	O
longa	O
;	O
high	O
-	O
fat	O
diet	O
;	O
adipogenesis	O
;	O
lipolysis	O
;	O
anti	O
-	O
obesity	O
Even	O
though	O
Curcuma	O
longa	O
L	O
.	O
possesses	O
various	O
biological	O
activities	O
,	O
it	O
has	O
strong	O
flavor	O
and	O
taste	O
,	O
which	O
decrease	O
consumer	O
palatability	O
and	O
limit	O
industrial	O
applications	O
in	O
food	O
.	O
The	O
present	O
study	O
investigates	O
the	O
effects	O
of	O
C	O
.	O
longa	O
L	O
.	O
fermented	O
with	O
Aspergillus	O
oryzae	O
supplementation	O
in	O
60	O
%	O
high	O
-	O
fat	O
diet	O
-	O
induced	O
obese	O
rats	O
measured	O
by	O
the	O
activation	O
of	O
adipogenesis	O
and	O
lipolysis	O
.	O
Rats	O
were	O
divided	O
into	O
four	O
groups	O
(	O
n	O
=	O
6	O
per	O
group	O
)	O
after	O
1	O
week	O
of	O
acclimatization	O
:	O
a	O
normal	O
diet	O
group	O
comprised	O
rats	O
fed	O
the	O
AIN76A	O
rodent	O
diet	O
;	O
a	O
high	O
-	O
fat	O
diet	O
-	O
induced	O
obese	O
group	O
with	O
rats	O
fed	O
a	O
60	O
%	O
high	O
-	O
fat	O
diet	O
;	O
a	O
Garcinia	O
cambogia	O
treated	O
group	O
(	O
positive	O
control	O
)	O
with	O
rats	O
fed	O
a	O
60	O
%	O
high	O
-	O
fat	O
diet	O
with	O
G	O
.	O
cambogia	O
500	O
g	O
/	O
kg	O
body	O
weight	O
(	O
b	O
.	O
w	O
.	O
)	O
/	O
day	O
;	O
and	O
an	O
fermented	O
C	O
.	O
longa	O
L	O
.	O
50	O
%	O
ethanolic	O
extract	O
treated	O
group	O
(	O
FCE50	O
)	O
with	O
rats	O
fed	O
a	O
60	O
%	O
high	O
-	O
fat	O
diet	O
with	O
FCE50	O
500	O
g	O
/	O
kg	O
b	O
.	O
w	O
.	O
/	O
day	O
.	O
Each	O
group	O
received	O
the	O
appropriate	O
vehicle	O
or	O
sample	O
daily	O
by	O
gastric	O
intubation	O
for	O
12	O
weeks	O
.	O
We	O
found	O
that	O
FCE50	O
administration	O
suppressed	O
b	O
.	O
w	O
.	O
gain	O
and	O
reduced	O
white	O
adipose	O
tissue	O
weight	O
,	O
serum	O
triglyceride	O
(	O
TG	O
)	O
,	O
and	O
cholesterol	O
in	O
high	O
-	O
fat	O
diet	O
-	O
induced	O
obese	O
rats	O
.	O
These	O
results	O
can	O
be	O
associated	O
with	O
the	O
suppression	O
of	O
adipocyte	O
differentiation	O
and	O
lipogenesis	O
with	O
a	O
decrease	O
in	O
the	O
mRNA	O
expressions	O
of	O
fatty	O
acid	O
synthase	O
,	O
acetyl	O
-	O
CoA	O
carboxylase	O
,	O
adipocyte	O
protein	O
2	O
,	O
and	O
lipoprotein	O
lipase	O
induced	O
by	O
FCE50	O
administration	O
.	O

In	O
addition	O
,	O
FCE50	O
increased	O
lipolysis	O
and	O
β	O
-	O
oxidation	O
by	O
up	O
-	O
regulating	O
the	O
expression	O
of	O
lipases	O
such	O
as	O
adipose	O
triglyceride	O
lipase	O
,	O
hormone	O
-	O
sensitive	O
lipase	O
,	O
adiponectin	O
,	O
and	O
AMP	O
-	O
activated	O
protein	O
kinase	O
.	O
These	O
results	O
suggest	O
that	O
FCE50	O
can	O
be	O
a	O
candidate	O
for	O
the	O
prevention	O
of	O
obesity	O
via	O
suppressing	O
adipogenesis	O
and	O
promoting	O
lipolysis	O
.	O
Obesity	O
has	O
become	O
a	O
serious	O
global	O
public	O
health	O
problem	O
in	O
the	O
past	O
few	O
decades	O
.	O
It	O
is	O
defined	O
as	O
a	O
medical	O
condition	O
with	O
an	O
abnormal	O
accumulation	O
of	O
body	O
fat	O
and	O
is	O
associated	O
with	O
excessive	O
growth	O
and	O
expansion	O
of	O
adipose	O
tissue	O
due	O
to	O
an	O
imbalance	O
between	O
energy	O
intake	O
and	O
expenditure	O
(	O
1	O
)	O
.	O
Obesity	O
commonly	O
leads	O
to	O
a	O
risk	O
of	O
developing	O
various	O
life	O
-	O
threatening	O
diseases	O
,	O
including	O
diabetes	O
,	O
cardiovascular	O
disease	O
,	O
hyperlipidemia	O
,	O
hypertension	O
,	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
,	O
and	O
certain	O
cancers	O
(	O
1	O
,	O
2	O
)	O
.	O
Dietary	O
excess	O
and	O
obesity	O
are	O
associated	O
with	O
the	O
expansion	O
of	O
adipose	O
tissue	O
.	O
The	O
expansion	O
of	O
adipose	O
tissue	O
is	O
induced	O
by	O
adipogenesis	O
and	O
the	O
accumulation	O
of	O
triglycerides	O
in	O
adipocytes	O
(	O
3	O
)	O
.	O
Adipogenesis	O
is	O
a	O
differentiation	O
process	O
by	O
which	O
undifferentiated	O
pre	O
-	O
adipocytes	O
are	O
converted	O
to	O
mature	O
adipocytes	O
(	O
3	O
,	O
4	O
)	O
.	O
During	O
adipocyte	O
differentiation	O
,	O
adipogenic	O
transcription	O
factors	O
,	O
such	O
as	O
sterol	O
regulatory	O
element	O
-	O
binding	O
protein	O
-	O
1c	O
(	O
SREBP	O
-	O
1c	O
)	O
,	O
peroxisome	O
proliferators	O
-	O
activator	O
receptor	O
-	O
γ	O
(	O
PPAR	O
-	O
γ	O
)	O
,	O
and	O
CCAAT	O
/	O
enhancer	O
binding	O
protein	O
-	O
α	O
(	O
C	O
/	O
EBPα	O
)	O
,	O
are	O
considered	O
key	O
regulators	O
of	O
adipogenesis	O
(	O
4	O
–	O
6	O
)	O
.	O
SREBP	O
-	O
1c	O
stimulates	O
the	O
expression	O
of	O
C	O
/	O
EBPα	O
,	O
PPAR	O
-	O
γ	O
,	O
and	O
several	O
lipogenic	O
enzyme	O
products	O
including	O
fatty	O
acid	O
synthase	O
(	O
FAS	O
)	O
and	O
acetyl	O
-	O
CoA	O
carboxylase	O
(	O
ACC	O
)	O
.	O
Activation	O
of	O
lipogenic	O
enzymes	O
induces	O
the	O
conversion	O
of	O
acetyl	O
-	O
CoA	O
into	O
fatty	O
acids	O
and	O
triglycerides	O
as	O
well	O
as	O
tissue	O
uptake	O
of	O
plasma	O
triglycerides	O
(	O
4	O
,	O
5	O
)	O
.	O

In	O
addition	O
,	O
mature	O
adipocytes	O
secrete	O
lipoprotein	O
lipase	O
(	O
LPL	O
)	O
,	O
which	O
plays	O
a	O
central	O
role	O
in	O
controlling	O
lipid	O
accumulation	O
by	O
fatty	O
acid	O
uptake	O
into	O
adipose	O
tissue	O
from	O
circulating	O
lipoproteins	O
(	O
7	O
)	O
.	O
Conversely	O
,	O
lipolysis	O
is	O
the	O
process	O
of	O
triglyceride	O
breakdown	O
,	O
which	O
makes	O
it	O
one	O
of	O
the	O
key	O
processes	O
for	O
achieving	O
weight	O
loss	O
(	O
8	O
)	O
.	O
Adipose	O
triglyceride	O
lipase	O
(	O
ATGL	O
)	O
is	O
the	O
rate	O
-	O
limiting	O
enzyme	O
for	O
lipolysis	O
in	O
adipocytes	O
.	O
Another	O
important	O
lipase	O
for	O
catalyzing	O
the	O
process	O
of	O
lipolysis	O
is	O
hormone	O
-	O
sensitive	O
lipase	O
(	O
HSL	O
)	O
,	O
which	O
is	O
implicated	O
in	O
hormonal	O
regulation	O
by	O
insulin	O
(	O
9	O
)	O
.	O
ATGL	O
initiates	O
lipolysis	O
by	O
specifically	O
removing	O
free	O
fatty	O
acids	O
to	O
produce	O
a	O
diacylglycerol	O
,	O
which	O
is	O
then	O
hydrolyzed	O
by	O
HSL	O
(	O
9	O
)	O
.	O
In	O
addition	O
,	O
the	O
phosphorylation	O
of	O
AMP	O
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
activates	O
the	O
β	O
-	O
oxidation	O
of	O
fatty	O
acids	O
and	O
inhibits	O
lipid	O
synthesis	O
pathways	O
,	O
such	O
as	O
FA	O
synthesis	O
,	O
through	O
the	O
suppression	O
of	O
SREBP	O
-	O
1c	O
(	O
9	O
–	O
11	O
)	O
.	O
These	O
lipid	O
metabolisms	O
demonstrate	O
that	O
the	O
inhibition	O
of	O
adipogenesis	O
can	O
prevent	O
obesity	O
and	O
that	O
the	O
activation	O
of	O
lipolysis	O
can	O
cure	O
obesity	O
.	O
Accordingly	O
,	O
there	O
is	O
increasing	O
evidence	O
that	O
some	O
natural	O
plants	O
can	O
induce	O
the	O
inhibition	O
of	O
adipogenesis	O
and	O
lipogenesis	O
or	O
the	O
activation	O
of	O
lipolysis	O
(	O
12	O
)	O
.	O
One	O
such	O
plant	O
is	O
the	O
root	O
of	O
Curcuma	O
longa	O
L	O
.	O
,	O
which	O
is	O
widely	O
cultivated	O
mainly	O
in	O
tropical	O
regions	O
of	O
Asia	O
and	O
Africa	O
.	O
It	O
possesses	O
various	O
biological	O
activities	O
such	O
as	O
anti	O
-	O
obesity	O
,	O
anti	O
-	O
atherosclerosis	O
,	O
anti	O
-	O
diabetes	O
,	O
anti	O
-	O
mutagenesis	O
,	O
anti	O
-	O
cancer	O
,	O
and	O
anti	O
-	O
oxidation	O
effects	O
(	O
13	O
)	O
.	O
These	O
effects	O
might	O
be	O
related	O
to	O
its	O
well	O
-	O
known	O
biologically	O
active	O
compounds	O
,	O
curcuminoids	O
,	O
which	O
include	O
curcumin	O
,	O
demethoxycurcumin	O
,	O
and	O
bisdemethoxycurcumin	O
(	O
14	O
)	O
.	O
Even	O
though	O
C	O
.	O
longa	O
L	O
.	O
has	O
good	O
medicinal	O
efficacy	O
,	O
it	O
has	O
strong	O
flavor	O
and	O
taste	O
,	O
which	O
decrease	O
consumer	O
palatability	O
and	O
limit	O
the	O
industrial	O
applications	O
in	O
food	O
.	O

Consequently	O
,	O
it	O
is	O
necessary	O
to	O
improve	O
its	O
characterization	O
.	O
C	O
.	O
longa	O
L	O
.	O
fermented	O
by	O
Aspergillus	O
oryzae	O
has	O
various	O
properties	O
including	O
reduced	O
bitterness	O
and	O
harsh	O
taste	O
that	O
increase	O
consumer	O
acceptance	O
(	O
15	O
)	O
.	O
In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
C	O
.	O
longa	O
L	O
.	O
50	O
%	O
ethanolic	O
extract	O
supplementation	O
in	O
60	O
%	O
high	O
-	O
fat	O
diet	O
-	O
induced	O
obese	O
rats	O
measured	O
by	O
the	O
activation	O
of	O
adipogenesis	O
and	O
lipolysis	O
.	O
Raw	O
C	O
.	O
longa	O
L	O
.	O
was	O
harvested	O
from	O
Jindo	O
Jeollanam	O
-	O
do	O
,	O
Korea	O
,	O
and	O
prepared	O
as	O
a	O
200	O
-	O
mesh	O
powder	O
by	O
grinding	O
and	O
sieving	O
.	O
The	O
powder	O
was	O
fermented	O
with	O
2	O
%	O
A	O
.	O
oryzae	O
.	O
After	O
fermentation	O
for	O
40	O
h	O
at	O
the	O
temperature	O
of	O
25±2°C	O
and	O
humidity	O
of	O
50±5	O
%	O
,	O
the	O
product	O
was	O
sterilized	O
at	O
121°C	O
for	O
15	O
min	O
and	O
dried	O
at	O
60±5°C	O
.	O
Finally	O
,	O
the	O
dried	O
sample	O
was	O
prepared	O
as	O
a	O
200	O
-	O
mesh	O
powder	O
by	O
grinding	O
and	O
sieving	O
.	O
The	O
powder	O
(	O
1	O
kg	O
)	O
was	O
refluxed	O
with	O
20	O
volumes	O
of	O
50	O
%	O
ethanol	O
at	O
250°C	O
for	O
5	O
h	O
.	O
The	O
extraction	O
solution	O
obtained	O
after	O
filtering	O
was	O
concentrated	O
and	O
lyophilized	O
,	O
yielding	O
50	O
%	O
ethanol	O
extract	O
(	O
FCE50	O
,	O
19	O
%	O
)	O
.	O
It	O
was	O
stored	O
at	O
−20°C	O
until	O
needed	O
.	O
Five	O
-	O
week	O
-	O
old	O
male	O
Sprague	O
–	O
Dawley	O
(	O
SD	O
)	O
rats	O
with	O
a	O
body	O
weight	O
(	O
b	O
.	O
w	O
.	O
)	O
of	O
225±2	O
.	O
5	O
g	O
were	O
purchased	O
from	O
Orient	O
Bio	O
(	O
Seongnam	O
,	O
Korea	O
)	O
and	O
housed	O
in	O
cages	O
under	O
automatically	O
controlled	O
air	O
conditions	O
of	O
temperature	O
(	O
22±2°C	O
)	O
,	O
humidity	O
(	O
about	O
50	O
%	O
)	O
,	O
and	O
lighting	O
(	O
12	O
:	O
12	O
-	O
h	O
light	O
/	O
dark	O
cycle	O
)	O
.	O
The	O
rats	O
in	O
the	O
normal	O
diet	O
control	B-methodology
group	I-methodology
were	O
fed	O
a	O
commercial	O
pelleted	O
chow	O
(	O
AIN	O
-	O
76A	O
rodent	O
purified	O
diet	O
,	O
Orient	O
Bio	O
)	O
and	O
water	O
ad	O
libitum	O
.	O
For	O
the	O
high	O
-	O
fat	O
diet	O
-	O
induced	O
obese	O
group	O
,	O
rats	O
were	O
fed	O
a	O
60	O
%	O
high	O
-	O
fat	O
diet	O
(	O
60	O
%	O
high	O
-	O
fat	O
rodent	O
purified	O
diet	O
,	O
Orient	O
Bio	O
)	O
.	O

The	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
of	O
Chonnam	O
National	O
University	O
approved	O
the	O
protocol	O
(	O
CNU	O
IACUC	O
-	O
YB	O
-	O
2015	O
-	O
35	O
)	O
for	O
the	O
animal	B-methodology
study	I-methodology
,	O
and	O
the	O
animals	O
were	O
cared	O
for	O
in	O
accordance	O
with	O
the	O
‘	O
Guidelines	O
for	O
Animal	O
Experiments	O
’	O
established	O
by	O
the	O
university	O
.	O
Rats	O
were	O
divided	O
into	O
four	O
groups	O
after	O
1	O
week	O
of	O
acclimatization	O
:	O
a	O
normal	O
diet	O
group	O
(	O
ND	O
,	O
n	O
=	O
6	O
)	O
comprised	O
rats	O
fed	O
the	O
AIN76A	O
rodent	O
diet	O
;	O
a	O
high	O
-	O
fat	O
diet	O
-	O
induced	O
obese	O
group	O
(	O
HFD	O
,	O
n	O
=	O
6	O
)	O
comprised	O
rats	O
fed	O
a	O
60	O
%	O
high	O
-	O
fat	O
diet	O
;	O
a	O
Garcinia	O
cambogia	O
treated	O
group	O
(	O
positive	O
control	O
)	O
(	O
GC	O
,	O
n	O
=	O
6	O
)	O
comprised	O
rats	O
fed	O
a	O
60	O
%	O
high	O
-	O
fat	O
diet	O
with	O
G	O
.	O
cambogia	O
500	O
g	O
/	O
kg	O
b	O
.	O
w	O
.	O
/	O
day	O
;	O
and	O
a	O
FCE50	O
treated	O
group	O
(	O
FCE50	O
,	O
n	O
=	O
6	O
)	O
comprised	O
rats	O
fed	O
a	O
60	O
%	O
high	O
-	O
fat	O
diet	O
with	O
FCE50	O
500	O
g	O
/	O
kg	O
b	O
.	O
w	O
.	O
/	O
day	O
.	O
G	O
.	O
cambogia	O
was	O
used	O
for	O
reference	O
.	O
It	O
has	O
been	O
found	O
to	O
contain	O
large	O
amounts	O
of	O
hydroxycitric	O
acid	O
,	O
which	O
is	O
widely	O
used	O
as	O
an	O
anti	O
-	O
obesity	O
herbal	O
supplement	O
(	O
16	O
)	O
.	O
Each	O
group	O
received	O
the	O
appropriate	O
vehicle	O
or	O
sample	O
daily	O
by	O
gastric	O
intubation	O
for	O
12	O
weeks	O
.	O
Body	O
weight	O
was	O
measured	O
at	O
the	O
beginning	O
of	O
the	O
experiment	O
and	O
at	O
1	O
-	O
week	O
intervals	O
for	O
12	O
weeks	O
.	O
The	O
amount	O
of	O
food	O
consumption	O
by	O
each	O
group	O
was	O
recorded	O
two	O
times	O
per	O
week	O
for	O
12	O
weeks	O
.	O
At	O
the	O
end	O
of	O
the	O
experiment	O
,	O
the	O
mice	O
were	O
sacrificed	O
to	O
collect	O
serum	O
and	O
tissues	O
.	O
Serum	O
was	O
separated	O
from	O
blood	O
samples	O
by	O
centrifugation	O
at	O
3	O
,	O
000g	O
for	O
15	O
min	O
.	O
The	O
concentrations	O
of	O
serum	O
triglyceride	O
(	O
TG	O
)	O
,	O
total	O
cholesterol	O
,	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
/	O
very	O
-	O
low	O
-	O
density	O
lipoprotein	O
(	O
VLDL	O
)	O
cholesterol	O
,	O
and	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	O
were	O
evaluated	O
spectrophotometrically	O
,	O
using	O
commercially	O
available	O
diagnostic	O
kits	O
supplied	O
by	O
Asan	O
Pharmaceutical	O
(	O
Seoul	O
,	O
South	O
Korea	O
)	O
.	O
Quantitation	O
of	O
AMPK	O
phosphorylation	O
proteins	O
was	O
carried	O
out	O
by	O
western	O
blot	O
analysis	O
.	O

The	O
white	O
adipose	O
tissues	O
of	O
each	O
rat	O
were	O
homogenized	O
in	O
a	O
[UNK]	O
MT	O
lysis	O
reagent	O
(	O
Sigma	O
–	O
Aldrich	O
,	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
and	O
centrifuged	O
at	O
12	O
,	O
000g	O
for	O
20	O
min	O
at	O
4°C	O
.	O
The	O
protein	O
content	O
of	O
the	O
clear	O
lysates	O
was	O
estimated	O
with	O
the	O
Bradford	O
method	O
using	O
the	O
Protein	O
assay	O
reagent	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
)	O
.	O
Forty	O
micrograms	O
of	O
protein	O
were	O
dissolved	O
in	O
NuPAGE®	O
LDS	O
sample	O
buffer	O
4×	O
(	O
Life	O
Technologies	O
,	O
Gaithersburg	O
,	O
MD	O
,	O
USA	O
)	O
.	O
Membranes	O
were	O
incubated	O
for	O
1	O
h	O
in	O
a	O
blocking	O
solution	O
containing	O
5	O
%	O
non	O
-	O
fat	O
milk	O
in	O
Tris	O
-	O
buffered	O
saline	O
and	O
then	O
incubated	O
for	O
12	O
h	O
at	O
4°C	O
with	O
anti	O
-	O
β	O
-	O
actin	O
(	O
1	O
:	O
1	O
,	O
000	O
,	O
Abcam	O
,	O
Cambridge	O
,	O
England	O
)	O
and	O
anti	O
-	O
phospho	O
-	O
AMPK	O
(	O
1	O
:	O
1	O
,	O
000	O
,	O
Abcam	O
)	O
.	O
After	O
incubation	O
with	O
the	O
primary	O
antibody	O
,	O
membranes	O
were	O
incubated	O
with	O
a	O
secondary	O
antibody	O
(	O
anti	O
-	O
rabbit	O
IgG	O
HRP	O
-	O
linked	O
antibody	O
,	O
1	O
:	O
5	O
,	O
000	O
,	O
Cell	O
Signaling	O
,	O
Beverly	O
,	O
MA	O
,	O
USA	O
)	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O
Proteins	O
were	O
developed	O
using	O
a	O
detection	O
system	O
(	O
Molecular	O
Imager	O
[UNK]	O
+	O
,	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
and	O
visualized	O
with	O
Image	O
[UNK]	O
Software	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
.	O
Total	O
RNA	O
was	O
isolated	O
from	O
epididymal	O
white	O
adipose	O
tissue	O
by	O
Trizol	O
reagent	O
extraction	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
MRC	O
,	O
Montgomery	O
,	O
OH	O
,	O
USA	O
)	O
.	O
Complementary	O
DNA	O
was	O
synthesized	O
from	O
1	O
µL	O
purified	O
total	O
RNA	O
in	O
20	O
µL	O
of	O
reaction	O
buffer	O
using	O
the	O
[UNK]	O
cDNA	O
Synthesis	O
Kit	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
.	O
Real	O
-	O
time	O
PCR	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
was	O
performed	O
on	O
triplicate	O
samples	O
using	O
1	O
µL	O
cDNA	O
with	O
the	O
SYBR	O
Green	O
PCR	O
Master	O
Mix	O
(	O
iQ	O
SYBR	O
Green	O
Supermix	O
,	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
.	O

The	O
cDNA	O
was	O
amplified	O
for	O
40	O
cycles	O
of	O
denaturation	O
(	O
95°C	O
for	O
30	O
sec	O
)	O
,	O
annealing	O
(	O
57°C	O
for	O
40	O
sec	O
)	O
and	O
extension	O
(	O
72°C	O
for	O
40	O
sec	O
)	O
.	O

The	O
sequences	O
of	O
the	O
primers	O
used	O
in	O
the	O
study	O
are	O
as	O
follows	O
:	O
ACC	O
(	O
XM	O
_	O
132282	O
)	O
,	O
F	O
:	O
5	O
′	O
-	O
TCC	O
CCA	O
AGT	O
TCT	O
TCA	O
CGT	O
TCA	O
-	O
3	O
′	O
,	O
R	O
:	O
5	O
′	O
-	O
CAG	O
GCT	O
CCA	O
AGT	O
GGC	O
GAT	O
AA	O
-	O
3	O
′	O
;	O
adiponectin	O
(	O
NM	O
_	O
144744	O
)	O
,	O
F	O
:	O
5	O
′	O
-	O
AAC	O
CCC	O
TGG	O
CAG	O
GAA	O
AGG	O
-	O
3	O
′	O
,	O
R	O
:	O
5	O
′	O
-	O
TGA	O
ACG	O
CTG	O
AGC	O
GAT	O
ACA	O
CAT	O
-	O
3	O
′	O
;	O
aP2	O
(	O
M84651	O
)	O
,	O
F	O
:	O
5	O
′	O
-	O
TCT	O
CTG	O
GCA	O
GGC	O
ATC	O
TGA	O
CA	O
-	O
3	O
′	O
,	O
R	O
:	O
5	O
′	O
-	O
GGC	O
AGC	O
AGA	O
CTG	O
TGA	O
TCA	O
ACT	O
T	O
-	O
3	O
′	O
;	O
ATGL	O
(	O
AY894805	O
)	O
,	O
F	O
:	O
5	O
′	O
-	O
CAT	O
TCT	O
CAG	O
GCG	O
AGA	O
GTG	O
ACA	O
T	O
-	O
3	O
′	O
,	O
R	O
:	O
5	O
′	O
-	O
GAC	O
GCG	O
AAG	O
CTC	O
GTG	O
GAT	O
-	O
3	O
′	O
;	O
C	O
/	O
EBPα	O
(	O
NM	O
_	O
012524	O
)	O
,	O
F	O
:	O
5	O
′	O
-	O
CTG	O
CGA	O
GCA	O
CGA	O
GAC	O
GTC	O
TA	O
-	O
3	O
′	O
,	O
R	O
:	O
5	O
′	O
-	O
GCC	O
AGG	O
AAC	O
TCG	O
TCG	O
TTG	O
AA	O
-	O
3	O
′	O
;	O
CPT1	O
(	O
NM	O
_	O
013495	O
)	O
,	O
F	O
:	O
5	O
′	O
-	O
GTG	O
ACT	O
GGT	O
GGG	O
AGG	O
AAT	O
AC	O
-	O
3	O
′	O
,	O
R	O
:	O
5	O
′	O
-	O
GAG	O
CAT	O
CTC	O
CAT	O
GGC	O
GTA	O
G	O
-	O
3	O
′	O
;	O
PPAR	O
-	O
γ	O
(	O
AB011365	O
)	O
,	O
F	O
:	O
5	O
′	O
-	O
TGA	O
CTT	O
GGC	O
CAT	O
ATT	O
TAT	O
AGC	O
TGT	O
CA	O
-	O
3	O
′	O
,	O
R	O
:	O
5	O
′	O
-	O
CGA	O
TGG	O
GCT	O
TCA	O
CGT	O
TCA	O
G	O
-	O
3	O
′	O
;	O
FAS	O
(	O
X62888	O
)	O
,	O
F	O
:	O
5	O
′	O
-	O
GAC	O
CCT	O
GAC	O
TCC	O
AAG	O
TTA	O
TTC	O
GA	O
-	O
3	O
′	O
,	O
R	O
:	O
5	O
′	O
-	O
CGT	O
CAA	O
GCG	O
GGA	O
GAC	O
AGA	O
CT	O
-	O
3	O
′	O
;	O
HSL	O
(	O
BC021642	O
)	O
,	O
F	O
:	O
5	O
′	O
-	O
CAC	O
TAG	O
TCC	O
CTC	O
CCC	O
CA	O

The	O
real	O
-	O
time	O
PCR	O
results	O
were	O
visualized	O
and	O
the	O
relative	O
quantitation	O
was	O
calculated	O
using	O
the	O
7500	O
System	O
SDS	O
software	O
version	O
1	O
.	O
3	O
.	O
1	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O
All	O
data	O
are	O
presented	O
as	O
mean±SD	O
.	O
The	O
data	O
were	O
statistically	O
evaluated	O
using	O
Duncan	O
'	O
s	O
multiple	O
range	O
tests	O
after	O
one	O
-	O
way	O
ANOVA	O
using	O
SPSS	O
statistical	O
procedures	O
(	O
SPSS	O
PASW	O
Statistic	O
20	O
.	O
0	O
,	O
SPSS	O
,	O
Inc	O
.	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O
Statistical	O
significant	O
differences	O
were	O
considered	O
at	O
the	O
p	O
<	O
0	O
.	O
05	O
level	O
.	O
Table	O
1	O
shows	O
the	O
effects	O
of	O
FCE50	O
on	O
the	O
b	O
.	O
w	O
.	O
gain	O
and	O
white	O
adipose	O
tissue	O
weight	O
of	O
the	O
experimental	O
rats	O
.	O
The	O
b	O
.	O
w	O
.	O
gain	O
and	O
food	O
efficiency	O
rate	O
(	O
FER	O
)	O
increased	O
significantly	O
in	O
the	O
HFD	O
group	O
compared	O
to	O
the	O
ND	O
group	O
.	O
FCE50	O
administration	B-methodology
for	I-methodology
12	I-methodology
weeks	I-methodology
significantly	O
decreased	O
b	O
.	O
w	O
.	O
gain	O
and	O
FER	O
compared	O
to	O
the	O
HFD	O
group	O
.	O
The	O
weights	O
of	O
epididymal	O
and	O
perirenal	O
white	O
adipose	O
tissues	O
were	O
significantly	O
higher	O
in	O
the	O
HFD	O
group	O
compared	O
to	O
the	O
ND	O
group	O
.	O
The	O
epididymal	O
and	O
perirenal	O
white	O
adipose	O
tissue	O
weights	O
of	O
the	O
FCE50	O
group	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
the	O
HFD	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
In	O
the	O
HFD	O
group	O
,	O
the	O
levels	O
of	O
serum	O
TG	O
,	O
total	O
cholesterol	O
,	O
and	O
LDL	O
/	O
VLDL	O
cholesterol	O
increased	O
significantly	O
,	O
whereas	O
the	O
levels	O
of	O
serum	O
HDL	O
cholesterol	O
decreased	O
significantly	O
compared	O
with	O
those	O
of	O
the	O
ND	O
group	O
.	O
The	O
GC	O
and	O
FCE50	O
groups	O
exhibited	O
a	O
significant	O
decrease	O
in	O
the	O
levels	O
of	O
serum	O
TG	O
,	O
total	O
cholesterol	O
,	O
and	O
LDL	O
/	O
VLDL	O
and	O
an	O
increase	O
in	O
the	O
level	O
of	O
serum	O
HDL	O
cholesterol	O
compared	O
with	O
the	O
HFD	O
group	O
.	O
In	O
the	O
HFD	O
group	O
,	O
the	O
atherogenic	O
index	O
(	O
AI	O
)	O
increased	O
significantly	O
whereas	O
the	O
HDL	O
cholesterol	O
/	O
total	O
cholesterol	O
ratio	O
(	O
HTR	O
)	O
decreased	O
significantly	O
compared	O
with	O
the	O
ND	O
group	O
.	O

However	O
,	O
there	O
were	O
significant	O
decreases	O
in	O
the	O
AI	O
and	O
significant	O
increases	O
in	O
the	O
HTR	O
of	O
the	O
GC	O
and	O
FCE50	O
groups	O
compared	O
with	O
the	O
HFD	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
;	O
Table	O
2	O
)	O
.	O
There	O
were	O
significant	O
increases	O
in	O
the	O
mRNA	O
expression	O
of	O
PPAR	O
-	O
γ	O
and	O
C	O
/	O
EBPα	O
in	O
the	O
white	O
adipose	O
tissue	O
of	O
the	O
HFD	O
group	O
(	O
PPAR	O
-	O
γ	O
:	O
1	O
.	O
01±0	O
.	O
09	O
,	O
C	O
/	O
EBPα	O
:	O
1	O
.	O
03±0	O
.	O
16	O
)	O
compared	O
with	O
the	O
ND	O
group	O
(	O
PPAR	O
-	O
γ	O
:	O
0	O
.	O
43±0	O
.	O
06	O
,	O
C	O
/	O
EBPα	O
:	O
0	O
.	O
44±0	O
.	O
18	O
)	O
.	O
In	O
the	O
GC	O
(	O
PPAR	O
-	O
γ	O
:	O
0	O
.	O
23±0	O
.	O
11	O
,	O
C	O
/	O
EBPα	O
:	O
0	O
.	O
68±0	O
.	O
09	O
)	O
and	O
FCE50	O
(	O
PPAR	O
-	O
γ	O
:	O
0	O
.	O
29±0	O
.	O
13	O
,	O
C	O
/	O
EBPα	O
:	O
0	O
.	O
63±0	O
.	O
13	O
)	O
groups	O
,	O
the	O
expression	O
of	O
PPAR	O
-	O
γ	O
and	O
C	O
/	O
EBPα	O
mRNAs	O
in	O
the	O
white	O
adipose	O
tissue	O
was	O
significantly	O
decreased	O
compared	O
with	O
the	O
HFD	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
;	O
Fig	O
.	O
1	O
)	O
.	O
The	O
mRNA	O
expression	O
of	O
the	O
lipogenic	O
enzymes	O
,	O
FAS	O
and	O
ACC	O
,	O
in	O
the	O
white	O
adipose	O
tissue	O
of	O
the	O
HFD	O
group	O
(	O
FAS	O
:	O
1	O
.	O
06±0	O
.	O
13	O
,	O
ACC	O
:	O
1	O
.	O
00±0	O
.	O
13	O
)	O
increased	O
significantly	O
when	O
compared	O
with	O
the	O
ND	O
group	O
(	O
FAS	O
:	O
0	O
.	O
58±0	O
.	O
17	O
,	O
ACC	O
:	O
0	O
.	O
30±0	O
.	O
02	O
)	O
.	O
There	O
were	O
significant	O
decreases	O
in	O
the	O
mRNA	O
expression	O
of	O
lipogenic	O
enzymes	O
in	O
the	O
white	O
adipose	O
tissue	O
of	O
the	O
GC	O
(	O
FAS	O
:	O
0	O
.	O
36±0	O
.	O
12	O
,	O
ACC	O
:	O
0	O
.	O
41±0	O
.	O
13	O
)	O
and	O
FCE50	O
(	O
FAS	O
:	O
0	O
.	O
43±0	O
.	O
09	O
,	O
ACC	O
:	O
0	O
.	O
65±0	O
.	O
07	O
)	O
groups	O
compared	O
with	O
the	O
HFD	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
;	O
Fig	O
.	O
2a	O
)	O
.	O

The	O
mRNA	O
expression	O
of	O
adipocyte	O
protein	O
2	O
(	O
aP2	O
)	O
and	O
LPL	O
in	O
the	O
white	O
adipose	O
tissue	O
of	O
the	O
HFD	O
group	O
(	O
aP2	O
:	O
1	O
.	O
00±	O
0	O
.	O
19	O
,	O
LPL	O
:	O
1	O
.	O
05±0	O
.	O
14	O
)	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
ND	O
group	O
(	O
aP2	O
:	O
0	O
.	O
36±0	O
.	O
10	O
,	O
LPL	O
:	O
0	O
.	O
58±0	O
.	O
17	O
)	O
.	O
The	O
mRNA	O
expression	O
of	O
aP2	O
and	O
LPL	O
in	O
the	O
white	O
adipose	O
tissues	O
of	O
the	O
GC	O
(	O
aP2	O
:	O
0	O
.	O
21±	O
0	O
.	O
12	O
,	O
LPL	O
:	O
0	O
.	O
53±0	O
.	O
02	O
)	O
and	O
FCE50	O
(	O
aP2	O
:	O
0	O
.	O
40±0	O
.	O
07	O
,	O
LPL	O
:	O
0	O
.	O
83±	O
0	O
.	O
04	O
)	O
groups	O
decreased	O
significantly	O
compared	O
with	O
that	O
of	O
the	O
HFD	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
;	O
Fig	O
.	O
2b	O
)	O
.	O
The	O
mRNA	O
expression	O
of	O
enzymes	O
for	O
the	O
lipolysis	O
of	O
triglycerides	O
(	O
HSL	O
and	O
ATGL	O
)	O
in	O
the	O
white	O
adipose	O
tissue	O
of	O
the	O
HFD	O
group	O
(	O
HSL	O
:	O
0	O
.	O
96±0	O
.	O
11	O
,	O
ATGL	O
:	O
1	O
.	O
05±0	O
.	O
06	O
)	O
decreased	O
significantly	O
compared	O
with	O
that	O
of	O
the	O
ND	O
group	O
(	O
HSL	O
:	O
1	O
.	O
40±0	O
.	O
14	O
,	O
ATGL	O
:	O
1	O
.	O
51±0	O
.	O
06	O
)	O
.	O
However	O
,	O
the	O
GC	O
group	O
(	O
HSL	O
:	O
1	O
.	O
93±0	O
.	O
20	O
,	O
ATGL	O
:	O
2	O
.	O
09±0	O
.	O
22	O
)	O
and	O
the	O
FCE50	O
group	O
(	O
HSL	O
:	O
2	O
.	O
11±0	O
.	O
32	O
,	O
ATGL	O
:	O
1	O
.	O
79±0	O
.	O
13	O
)	O
demonstrated	O
significantly	O
increased	O
mRNA	O
expression	O
of	O
HSL	O
and	O
ATGL	O
in	O
the	O
white	O
adipose	O
tissue	O
compared	O
with	O
the	O
ND	O
group	O
as	O
well	O
as	O
the	O
HFD	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
;	O
Fig	O
.	O
3	O
)	O
.	O

There	O
were	O
significant	O
decreases	O
in	O
the	O
mRNA	O
expression	O
of	O
CPT1	O
and	O
adiponectin	O
as	O
well	O
as	O
in	O
the	O
protein	O
expression	O
of	O
AMPK	O
phosphorylation	O
in	O
the	O
white	O
adipose	O
tissue	O
of	O
the	O
HFD	O
group	O
(	O
CPT1	O
:	O
1	O
.	O
00±0	O
.	O
09	O
,	O
adiponectin	O
:	O
1	O
.	O
02±0	O
.	O
06	O
,	O
AMPK	O
phosphorylation	O
:	O
100	O
%	O
)	O
compared	O
with	O
the	O
ND	O
group	O
(	O
CPT1	O
:	O
1	O
.	O
88±0	O
.	O
28	O
,	O
adiponectin	O
:	O
1	O
.	O
52±0	O
.	O
11	O
,	O
AMPK	O
phosphorylation	O
:	O
112	O
.	O
93±7	O
.	O
39	O
%	O
)	O
.	O
The	O
mRNA	O
expression	O
of	O
CPT1	O
and	O
adiponectin	O
and	O
the	O
protein	O
expression	O
of	O
AMPK	O
phosphorylation	O
in	O
the	O
white	O
adipose	O
tissue	O
of	O
the	O
GC	O
(	O
CPT1	O
:	O
2	O
.	O
22±0	O
.	O
14	O
,	O
adiponectin	O
:	O
2	O
.	O
70±0	O
.	O
37	O
,	O
AMPK	O
phosphorylation	O
:	O
118	O
.	O
78±3	O
.	O
71	O
%	O
)	O
and	O
FCE50	O
(	O
CPT1	O
:	O
2	O
.	O
40±0	O
.	O
19	O
,	O
adiponectin	O
:	O
2	O
.	O
15±0	O
.	O
22	O
,	O
AMPK	O
phosphorylation	O
:	O
126	O
.	O
75±11	O
.	O
70	O
%	O
)	O
groups	O
significantly	O
increased	O
compared	O
with	O
the	O
HFD	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
;	O
Fig	O
.	O
4	O
)	O
.	O
Chronic	O
consumption	O
of	O
a	O
high	O
-	O
fat	O
diet	O
has	O
been	O
shown	O
to	O
produce	O
obesity	O
through	O
increases	O
in	O
adipocyte	O
number	O
and	O
size	O
resulting	O
from	O
the	O
high	O
caloric	O
density	O
(	O
17	O
)	O
.	O
A	O
high	O
-	O
fat	O
diet	O
-	O
induced	O
obese	O
animal	O
is	O
pathophysiologically	O
very	O
similar	O
to	O
an	O
obese	O
human	O
.	O
Therefore	O
,	O
it	O
is	O
an	O
appropriate	O
animal	O
model	O
for	O
the	O
evaluation	O
of	O
anti	O
-	O
obesity	O
interventions	O
in	O
an	O
in	B-methodology
vivo	I-methodology
experimental	O
test	O
(	O
18	O
)	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
used	O
a	O
high	O
-	O
fat	O
diet	O
-	O
fed	O
SD	O
rat	B-methodology
model	I-methodology
to	O
investigate	O
the	O
effect	O
of	O
FCE50	O
on	O
obesity	O
.	O
SD	O
rats	O
have	O
been	O
used	O
to	O
study	O
obesity	O
as	O
they	O
readily	O
gain	O
weight	O
on	O
high	O
-	O
fat	O
diets	O
and	O
are	O
useful	O
animals	O
for	O
studying	O
the	O
pathogenesis	O
of	O
high	O
-	O
fat	O
diet	O
-	O
induced	O
obesity	O
(	O
19	O
)	O
.	O

The	O
present	O
study	O
demonstrated	O
significant	O
increases	O
in	O
the	O
weight	O
gain	O
,	O
FER	O
,	O
and	O
white	O
adipose	O
tissue	O
weight	O
in	O
the	O
60	O
%	O
high	O
-	O
fat	O
diet	O
-	O
fed	O
rats	O
compared	O
with	O
the	O
normal	O
diet	O
-	O
fed	O
rats	O
(	O
Table	O
1	O
)	O
.	O
In	O
addition	O
,	O
we	O
found	O
that	O
the	O
60	O
%	O
high	O
-	O
fat	O
diet	O
induced	O
dyslipidemia	O
,	O
which	O
is	O
the	O
elevation	O
of	O
triglycerides	O
,	O
total	O
cholesterol	O
,	O
and	O
LDL	O
/	O
VLDL	O
cholesterol	O
in	O
addition	O
to	O
a	O
low	O
HDL	O
level	O
in	O
the	O
blood	O
(	O
Table	O
2	O
)	O
.	O
Ghibaudi	O
et	O
al	O
.	O
(	O
19	O
)	O
also	O
reported	O
that	O
administration	O
of	O
an	O
increasing	O
amount	O
of	O
dietary	O
fat	O
in	O
rats	O
enhanced	O
weight	O
gain	O
,	O
fat	O
mass	O
,	O
plasma	O
cholesterol	O
,	O
triglycerides	O
,	O
and	O
free	O
fatty	O
acid	O
levels	O
.	O
Chronic	O
consumption	O
of	O
a	O
high	O
-	O
fat	O
diet	O
is	O
regarded	O
as	O
a	O
direct	O
cause	O
in	O
the	O
development	O
of	O
dyslipidemia	O
,	O
which	O
can	O
contribute	O
to	O
the	O
development	O
of	O
abnormal	O
lipid	O
metabolism	O
,	O
atherosclerosis	O
,	O
and	O
obesity	O
(	O
20	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
we	O
found	O
a	O
marked	O
decrease	O
in	O
the	O
weight	O
gain	O
,	O
FER	O
,	O
and	O
white	O
adipose	O
tissue	O
weight	O
as	O
well	O
as	O
improvements	O
in	O
the	O
development	O
of	O
dyslipidemia	O
in	O
the	O
60	O
%	O
high	O
-	O
fat	O
diet	O
-	O
fed	O
rat	O
treated	O
with	O
FCE50	O
(	O
Tables	O
1	O
and	O
2	O
)	O
.	O
The	O
reduction	O
of	O
weight	O
gain	O
and	O
dyslipidemia	O
induced	O
by	O
FCE50	O
administration	O
can	O
be	O
correlated	O
with	O
the	O
inhibition	O
of	O
abnormal	O
fat	O
accumulation	O
in	O
adipose	O
tissue	O
and	O
the	O
development	O
of	O
obesity	O
-	O
related	O
diseases	O
.	O
Adipose	O
tissue	O
has	O
important	O
functions	O
such	O
as	O
helping	O
to	O
reduce	O
heat	O
loss	O
,	O
providing	O
mechanical	O
protection	O
,	O
and	O
energy	O
storage	O
.	O
Although	O
adipose	O
tissue	O
is	O
vitally	O
important	O
for	O
various	O
normal	O
processes	O
,	O
excess	O
adipose	O
tissue	O
can	O
have	O
many	O
negative	O
implications	O
for	O
human	O
disease	O
states	O
with	O
the	O
development	O
of	O
obesity	O
(	O
21	O
)	O
.	O
The	O
mechanism	O
of	O
adipose	O
tissue	O
expansion	O
has	O
been	O
studied	O
for	O
decades	O
to	O
understand	O
how	O
it	O
contributes	O
to	O
the	O
metabolic	O
dysregulation	O
associated	O
with	O
obesity	O
.	O
The	O
expansion	O
of	O
adipose	O
tissue	O
begins	O
when	O
differentiated	O
adipocytes	O
rapidly	O
respond	O
to	O
nutrient	O
excess	O
(	O
22	O
)	O
.	O
When	O
pre	O
-	O
adipocytes	O
differentiate	O
into	O
mature	O
adipocytes	O
,	O
the	O
mature	O
cells	O
can	O
act	O
as	O
lipid	O
-	O
synthesizing	O
and	O
lipid	O
-	O
storing	O
adipocytes	O
(	O
4	O
)	O
.	O

The	O
differentiation	O
of	O
pre	O
-	O
adipocytes	O
is	O
regulated	O
by	O
several	O
transcription	O
factors	O
such	O
as	O
PPAR	O
-	O
γ	O
and	O
C	O
/	O
EBPα	O
that	O
play	O
a	O
central	O
role	O
in	O
the	O
control	O
of	O
adipogenesis	O
(	O
6	O
)	O
.	O
Kadowaki	O
et	O
al	O
.	O
(	O
23	O
)	O
reported	O
that	O
PPAR	O
-	O
γ	O
mediates	O
high	O
-	O
fat	O
-	O
diet	O
-	O
induced	O
adipocyte	O
differentiation	O
and	O
adipocyte	O
hypertrophy	O
to	O
generate	O
large	O
adipocytes	O
and	O
insulin	O
resistance	O
.	O
In	O
addition	O
,	O
the	O
report	O
from	O
Rosen	O
et	O
al	O
.	O
(	O
24	O
)	O
demonstrated	O
that	O
PPAR	O
-	O
γ	O
and	O
C	O
/	O
EBPα	O
participated	O
in	O
a	O
single	O
pathway	O
during	O
the	O
differentiation	O
of	O
pre	O
-	O
adipocytes	O
,	O
with	O
PPAR	O
-	O
γ	O
being	O
the	O
proximal	O
effector	O
of	O
adipogenesis	O
whereas	O
C	O
/	O
EBPα	O
has	O
no	O
ability	O
to	O
promote	O
differentiation	O
in	O
the	O
absence	O
of	O
PPAR	O
-	O
γ	O
.	O
We	O
found	O
in	O
the	O
present	O
study	O
that	O
the	O
60	O
%	O
high	O
-	O
fat	O
diet	O
-	O
fed	O
rats	O
exhibited	O
a	O
significant	O
increase	O
in	O
the	O
mRNA	O
expression	O
of	O
PPAR	O
-	O
γ	O
and	O
C	O
/	O
EBPα	O
in	O
white	O
adipose	O
tissue	O
compared	O
with	O
the	O
normal	O
diet	O
-	O
fed	O
rats	O
(	O
Fig	O
.	O
1	O
)	O
.	O
Moreover	O
,	O
the	O
mRNA	O
expression	O
of	O
FAS	O
,	O
ACC	O
,	O
aP2	O
,	O
and	O
LPL	O
in	O
white	O
adipose	O
tissue	O
was	O
increased	O
by	O
chronic	O
high	O
-	O
fat	O
diet	O
intake	O
(	O
Fig	O
.	O
2	O
)	O
.	O
PPAR	O
-	O
γ	O
and	O
C	O
/	O
EBPα	O
regulate	O
the	O
transcription	O
factors	O
involved	O
in	O
adipose	O
tissue	O
adipogenesis	O
such	O
as	O
FAS	O
,	O
ACC	O
,	O
aP2	O
,	O
and	O
LPL	O
.	O
FAS	O
and	O
ACC	O
are	O
enzymes	O
for	O
the	O
synthesis	O
of	O
fatty	O
acids	O
from	O
acetyl	O
-	O
CoA	O
and	O
malonyl	O
-	O
CoA	O
,	O
which	O
is	O
an	O
important	O
step	O
of	O
the	O
lipogenesis	O
process	O
(	O
25	O
)	O
.	O
When	O
LPL	O
hydrolyzes	O
triglycerides	O
in	O
lipoproteins	O
in	O
the	O
blood	O
to	O
promote	O
cellular	O
uptake	O
of	O
fatty	O
acids	O
and	O
triglyceride	O
,	O
aP2	O
acts	O
as	O
the	O
carrier	O
protein	O
for	O
fatty	O
acids	O
in	O
adipocytes	O
.	O
Thus	O
,	O
LPL	O
and	O
aP2	O
are	O
genes	O
closely	O
associated	O
with	O
fatty	O
acid	O
uptake	O
and	O
triglyceride	O
accumulation	O
(	O
26	O
)	O
.	O

Interestingly	O
,	O
this	O
present	O
study	O
found	O
that	O
FCE50	O
administration	O
induced	O
a	O
statistically	O
significant	O
decrease	O
in	O
the	O
mRNA	O
expressions	O
of	O
FAS	O
,	O
ACC	O
,	O
aP2	O
,	O
and	O
LPL	O
as	O
well	O
as	O
PPAR	O
-	O
γ	O
and	O
C	O
/	O
EBPα	O
(	O
Figs	O
.	O
1	O
and	O
2	O
)	O
.	O
Some	O
studies	O
have	O
reported	O
that	O
C	O
.	O
longa	O
L	O
.	O
and	O
its	O
biologically	O
active	O
compounds	O
such	O
as	O
curcumin	O
have	O
an	O
effect	O
on	O
the	O
inhibition	O
of	O
FAS	O
,	O
differentiation	O
and	O
triglyceride	O
accumulation	O
in	O
adipocytes	O
(	O
13	O
,	O
27	O
,	O
28	O
)	O
.	O
Ejaz	O
et	O
al	O
.	O
(	O
27	O
)	O
found	O
that	O
dietary	O
curcumin	O
caused	O
lower	O
adiposity	O
and	O
weight	O
gain	O
coupled	O
with	O
the	O
suppression	O
of	O
PPAR	O
-	O
γ	O
and	O
C	O
/	O
EBPα	O
expression	O
in	O
high	O
-	O
fat	O
diet	O
-	O
fed	O
mice	O
.	O
A	O
report	O
by	O
Zhao	O
et	O
al	O
.	O
(	O
28	O
)	O
revealed	O
that	O
curcumin	O
works	O
as	O
a	O
FAS	O
inhibitor	O
,	O
suppressing	O
the	O
differentiation	O
of	O
pre	O
-	O
adipocytes	O
and	O
lipid	O
accumulation	O
in	O
adipocytes	O
.	O
According	O
to	O
these	O
reports	O
and	O
our	O
present	O
results	O
,	O
FCE50	O
administration	O
reduces	O
weight	O
gain	O
and	O
fat	O
accumulation	O
by	O
the	O
suppression	O
of	O
adipocyte	O
differentiation	O
and	O
lipogenesis	O
due	O
to	O
the	O
effect	O
of	O
curcumin	O
.	O
In	O
addition	O
,	O
we	O
found	O
that	O
FCE50	O
administration	O
leads	O
to	O
the	O
activation	O
of	O
lipolysis	O
in	O
the	O
adipose	O
tissue	O
of	O
high	O
-	O
fat	O
diet	O
-	O
fed	O
rats	O
(	O
Figs	O
.	O
3	O
and	O
4	O
)	O
.	O
White	O
adipose	O
tissue	O
is	O
metabolic	O
flexible	O
tissue	O
,	O
which	O
is	O
important	O
for	O
energy	O
storage	O
or	O
energy	O
source	O
release	O
in	O
the	O
form	O
of	O
anabolism	O
or	O
catabolism	O
of	O
triglycerides	O
(	O
29	O
)	O
.	O
Catabolism	O
of	O
triglycerides	O
,	O
known	O
as	O
lipolysis	O
,	O
is	O
regulated	O
in	O
consecutive	O
steps	O
that	O
involve	O
at	O
least	O
three	O
different	O
enzymes	O
such	O
as	O
ATGL	O
,	O
HSL	O
,	O
and	O
monoacylglycerol	O
lipase	O
(	O
MGL	O
)	O
,	O
resulting	O
in	O
the	O
release	O
of	O
glycerol	O
and	O
fatty	O
acids	O
(	O
9	O
)	O
.	O
Catabolism	O
of	O
fatty	O
acids	O
,	O
known	O
as	O
β	O
-	O
oxidation	O
,	O
generates	O
acetyl	O
-	O
CoA	O
,	O
which	O
enters	O
the	O
TCA	O
cycle	O
and	O
produces	O
ATP	O
(	O
30	O
)	O
.	O
An	O
imbalance	O
between	O
fatty	O
acid	O
uptake	O
,	O
synthesis	O
,	O
and	O
β	O
-	O
oxidation	O
can	O
be	O
associated	O
with	O
triglyceride	O
accumulation	O
in	O
adipocyte	O
(	O
30	O
)	O
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
phosphorylation	O
of	O
AMPK	O
leads	O
to	O
β	O
-	O
oxidation	O
by	O
inactivating	O
ACC	O
and	O
up	O
-	O
regulating	O
CPT1	O
expression	O
.	O
AMPK	O
is	O
a	O
multisubunit	O
enzyme	O
recognized	O
as	O
a	O
major	O
regulator	O
of	O
lipid	O
biosynthetic	O
pathways	O
due	O
to	O
its	O
role	O
in	O
the	O
phosphorylation	O
and	O
inactivation	O
of	O
key	O
enzymes	O
(	O
9	O
,	O
10	O
,	O
31	O
)	O
.	O
Herms	O
et	O
al	O
.	O
(	O
31	O
)	O
recently	O
reported	O
that	O
lipid	O
droplets	O
that	O
efficiently	O
supply	O
fatty	O
acids	O
were	O
induced	O
by	O
the	O
activation	O
of	O
the	O
energy	O
sensor	O
AMPK	O
for	O
mitochondrial	O
β	O
-	O
oxidation	O
during	O
nutrient	O
starvation	O
.	O
Adiponectin	O
,	O
a	O
novel	O
adipocyte	O
-	O
specific	O
protein	O
,	O
has	O
been	O
shown	O
to	O
increase	O
β	O
-	O
oxidation	O
via	O
the	O
phosphorylation	O
of	O
AMPK	O
and	O
inactivation	O
of	O
ACC	O
(	O
32	O
,	O
33	O
)	O
.	O
It	O
has	O
been	O
reported	O
that	O
adiponectin	O
levels	O
are	O
lower	O
in	O
obese	O
subjects	O
than	O
in	O
lean	O
subjects	O
(	O
34	O
)	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
the	O
expression	O
of	O
adiponectin	O
was	O
suppressed	O
in	O
the	O
white	O
adipose	O
tissue	O
of	O
the	O
high	O
-	O
fat	O
diet	O
-	O
fed	O
rats	O
.	O
In	O
addition	O
,	O
mRNA	O
expression	O
of	O
CPT1	O
and	O
the	O
protein	O
expression	O
of	O
AMPK	O
phosphorylation	O
were	O
decreased	O
in	O
the	O
white	O
adipose	O
tissue	O
of	O
the	O
HFD	O
group	O
compared	O
with	O
the	O
ND	O
group	O
.	O
However	O
,	O
we	O
found	O
that	O
mRNA	O
expression	O
of	O
CPT1	O
and	O
adiponectin	O
as	O
well	O
as	O
the	O
protein	O
expression	O
of	O
AMPK	O
phosphorylation	O
were	O
significantly	O
higher	O
in	O
the	O
FCE50	O
group	O
(	O
Fig	O
.	O
5	O
)	O
.	O
These	O
results	O
indicate	O
that	O
FCE50	O
administration	O
inhibits	O
lipogenesis	O
and	O
enhanced	O
lipolysis	O
through	O
adiponectin	O
and	O
pAMPK	O
expression	O
in	O
the	O
white	O
adipose	O
tissue	O
.	O
In	O
conclusion	O
,	O
we	O
found	O
that	O
FCE50	O
administration	O
suppressed	O
b	O
.	O
w	O
.	O
gain	O
,	O
white	O
adipose	O
tissue	O
weight	O
,	O
serum	O
TG	O
,	O
and	O
cholesterol	O
in	O
high	O
-	O
fat	O
diet	O
-	O
induced	O
obese	O
rats	O
.	O
These	O
results	O
can	O
be	O
associated	O
with	O
the	O
suppression	O
of	O
adipocyte	O
differentiation	O
and	O
lipogenesis	O
with	O
the	O
decrease	O
in	O
the	O
mRNA	O
expressions	O
of	O
FAS	O
,	O
ACC	O
,	O
aP2	O
,	O
and	O
LPL	O
induced	O
by	O
FCE50	O
administration	O
.	O

In	O
addition	O
,	O
FCE50	O
increased	O
lipolysis	O
and	O
β	O
-	O
oxidation	O
by	O
up	O
-	O
regulating	O
the	O
expression	O
of	O
lipases	O
such	O
as	O
ATGL	O
and	O
HSL	O
,	O
adiponectin	O
,	O
and	O
AMPK	O
phosphorylation	O
.	O
The	O
present	O
study	O
demonstrated	O
that	O
FCE50	O
could	O
be	O
a	O
good	O
option	O
for	O
preventing	O
adipogenesis	O
and	O
activating	O
lipolysis	O
.	O

Could	O
Artificial	O
Intelligence	O
/	O
Machine	O
Learning	O
and	O
Inclusion	O
of	O
Diet	O
-	O
Gut	O
Microbiome	O
Interactions	O
Improve	O
Disease	O
Risk	O
Prediction	O
?	O
Case	B-methodology
Study	I-methodology
:	O
Coronary	O
Artery	O
Disease	O
machine	O
learning	O
;	O
diet	O
;	O
gut	O
microbiome	O
;	O
personalized	O
nutrition	O
;	O
coronary	O
artery	O
disease	O
;	O
artificial	O
intelligence	O
;	O
risk	O
prediction	O
Coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
is	O
the	O
most	O
common	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
and	O
the	O
main	O
leading	O
cause	O
of	O
morbidity	O
and	O
mortality	O
worldwide	O
,	O
posing	O
a	O
huge	O
socio	O
-	O
economic	O
burden	O
to	O
the	O
society	O
and	O
health	O
systems	O
.	O
Therefore	O
,	O
timely	O
and	O
precise	O
identification	O
of	O
people	O
at	O
high	O
risk	O
of	O
CAD	O
is	O
urgently	O
required	O
.	O
Most	O
current	O
CAD	O
risk	O
prediction	O
approaches	O
are	O
based	O
on	O
a	O
small	O
number	O
of	O
traditional	O
risk	O
factors	O
(	O
age	O
,	O
sex	O
,	O
diabetes	O
,	O
LDL	O
and	O
HDL	O
cholesterol	O
,	O
smoking	O
,	O
systolic	O
blood	O
pressure	O
)	O
and	O
are	O
incompletely	O
predictive	O
across	O
all	O
patient	O
groups	O
,	O
as	O
CAD	O
is	O
a	O
multi	O
-	O
factorial	O
disease	O
with	O
complex	O
etiology	O
,	O
considered	O
to	O
be	O
driven	O
by	O
both	O
genetic	O
,	O
as	O
well	O
as	O
numerous	O
environmental	O
/	O
lifestyle	O
factors	O
.	O
Diet	O
is	O
one	O
of	O
the	O
modifiable	O
factors	O
for	O
improving	O
lifestyle	O
and	O
disease	O
prevention	O
.	O
However	O
,	O
the	O
current	O
rise	O
in	O
obesity	O
,	O
type	O
2	O
diabetes	O
(	O
T2D	O
)	O
and	O
CVD	O
/	O
CAD	O
indicates	O
that	O
the	O
“	O
one	O
-	O
size	O
-	O
fits	O
-	O
all	O
”	O
approach	O
may	O
not	O
be	O
efficient	O
,	O
due	O
to	O
significant	O
variation	O
in	O
inter	O
-	O
individual	O
responses	O
.	O
Recently	O
,	O
the	O
gut	O
microbiome	O
has	O
emerged	O
as	O
a	O
potential	O
and	O
previously	O
under	O
-	O
explored	O
contributor	O
to	O
these	O
variations	O
.	O
Hence	O
,	O
efficient	O
integration	O
of	O
dietary	O
and	O
gut	O
microbiome	O
information	O
alongside	O
with	O
genetic	O
variations	O
and	O
clinical	O
data	O
holds	O
a	O
great	O
promise	O
to	O
improve	O
CAD	O
risk	O
prediction	O
.	O
Nevertheless	O
,	O
the	O
highly	O
complex	O
nature	O
of	O
meals	O
combined	O
with	O
the	O
huge	O
inter	O
-	O
individual	O
variability	O
of	O
the	O
gut	O
microbiome	O
poses	O
several	O
Big	O
Data	O
analytics	O
challenges	O
in	O
modeling	O
diet	O
-	O
gut	O
microbiota	O
interactions	O
and	O
integrating	O
these	O
within	O
CAD	O
risk	O
prediction	O
approaches	O
for	O
the	O
development	O
of	O
personalized	O
decision	O
support	O
systems	O
(	O
DSS	O
)	O
.	O
In	O
this	O
regard	O
,	O
the	O
recent	O
re	O
-	O
emergence	O
of	O
Artificial	O
Intelligence	O
(	O
AI	O
)	O
/	O
Machine	O
Learning	O
(	O
ML	O
)	O
is	O
opening	O
intriguing	O
perspectives	O
,	O
as	O
these	O
approaches	O
are	O
able	O
to	O
capture	O
large	O
and	O
complex	O
matrices	O
of	O
data	O
,	O
incorporating	O
their	O
interactions	O
and	O
identifying	O
both	O
linear	O
and	O
non	O
-	O
linear	O
relationships	O
.	O

In	O
this	O
Mini	O
-	O
Review	O
,	O
we	O
consider	O
(	O
1	O
)	O
the	O
most	O
used	O
AI	O
/	O
ML	O
approaches	O
and	O
their	O
different	O
use	O
cases	O
for	O
CAD	O
risk	O
prediction	O
(	O
2	O
)	O
modeling	O
of	O
the	O
content	O
,	O
choice	O
and	O
impact	O
of	O
dietary	O
factors	O
on	O
CAD	O
risk	O
;	O
(	O
3	O
)	O
classification	O
of	O
individuals	O
by	O
their	O
gut	O
microbiome	O
composition	O
into	O
CAD	O
cases	O
vs	O
.	O
controls	O
and	O
(	O
4	O
)	O
modeling	O
of	O
the	O
diet	O
-	O
gut	O
microbiome	O
interactions	O
and	O
their	O
impact	O
on	O
CAD	O
risk	O
.	O
Finally	O
,	O
we	O
provide	O
an	O
outlook	O
for	O
putting	O
it	O
all	O
together	O
for	O
improved	O
CAD	O
risk	O
predictions	O
.	O
Coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
is	O
the	O
most	O
common	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
and	O
the	O
main	O
leading	O
cause	O
of	O
morbidity	O
and	O
mortality	O
worldwide	O
,	O
posing	O
a	O
huge	O
socio	O
-	O
economic	O
burden	O
to	O
the	O
society	O
and	O
health	O
systems	O
(	O
Lopez	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O
Currently	O
,	O
our	O
health	O
care	O
system	O
is	O
facing	O
a	O
paradigm	O
shift	O
from	O
a	O
“	O
one	O
size	O
fits	O
all	O
”	O
approach	O
to	O
a	O
more	O
optimized	O
model	O
to	O
identify	O
prevention	O
strategies	O
and	O
treatments	O
tailored	O
to	O
each	O
individual	O
,	O
the	O
so	O
called	O
personalized	O
medicine	O
.	O
Moreover	O
,	O
the	O
vision	O
of	O
prevention	O
has	O
also	O
transformed	O
toward	O
a	O
concept	O
of	O
“	O
positive	O
health	O
”	O
and	O
primordial	O
prevention	O
—	O
the	O
prevention	O
of	O
disease	O
risk	O
factors	O
before	O
they	O
actually	O
occur	O
,	O
i	O
.	O
e	O
.	O
,	O
through	O
targeted	O
modifications	O
of	O
person	O
'	O
s	O
environment	O
/	O
lifestyle	O
(	O
Movsisyan	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Therefore	O
,	O
timely	O
and	O
precise	O
identification	O
of	O
people	O
at	O
high	O
risk	O
of	O
CAD	O
is	O
of	O
utmost	O
importance	O
for	O
the	O
personalized	O
cardiology	O
(	O
Alaa	O
et	O
al	O
.	O
,	O
2019	O
)	O
,	O
as	O
such	O
persons	O
may	O
need	O
more	O
aggressive	O
health	O
promotion	O
strategies	O
,	O
especially	O
the	O
modifiable	O
CAD	O
risk	O
factors	O
could	O
be	O
effectively	O
reduced	O
or	O
even	O
eliminated	O
in	O
this	O
way	O
(	O
Movsisyan	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Over	O
the	O
past	O
two	O
decades	O
,	O
numerous	O
approaches	O
for	O
CAD	O
risk	O
prediction	O
have	O
been	O
developed	O
and	O
several	O
have	O
also	O
entered	O
the	O
clinical	O
routine	O
such	O
as	O
the	O
Framingham	O
Risk	O
Score	O
(	O
FRS	O
)	O
(	O
Wilson	O
et	O
al	O
.	O
,	O
1998	O
)	O
or	O
the	O
Systematic	O
Coronary	O
Risk	O
Evaluation	O
(	O
SCORE	O
)	O
metrics	O
(	O
Conroy	O
et	O
al	O
.	O
,	O
2003	O
)	O
,	O
extensively	O
reviewed	O
elsewhere	O
(	O
Damen	O
et	O
al	O
.	O
,	O
2016	O
;	O
Westerlund	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O

However	O
,	O
these	O
approaches	O
are	O
mostly	O
based	O
on	O
a	O
limited	O
number	O
of	O
predictors	O
—	O
the	O
traditional	O
CAD	O
risk	O
factors	O
(	O
age	O
,	O
sex	O
,	O
diabetes	O
,	O
systolic	O
blood	O
pressure	O
,	O
LDL	O
/	O
HDL	O
cholesterol	O
,	O
smoking	O
)	O
.	O
Hence	O
,	O
incompletely	O
predictive	O
of	O
disease	O
onset	O
,	O
progression	O
and	O
clinical	O
outcome	O
across	O
all	O
patient	O
groups	O
(	O
Alaa	O
et	O
al	O
.	O
,	O
2019	O
)	O
,	O
overestimating	O
the	O
10	O
-	O
year	O
CAD	O
/	O
CVD	O
risk	O
,	O
especially	O
for	O
high	O
-	O
risk	O
individuals	O
and	O
European	O
populations	O
(	O
Damen	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
These	O
models	O
typically	O
do	O
not	O
take	O
into	O
account	O
the	O
fact	O
that	O
the	O
treatment	O
options	O
have	O
improved	O
and	O
that	O
,	O
by	O
modifying	O
the	O
person	O
'	O
s	O
environment	O
/	O
lifestyle	O
,	O
the	O
disease	O
risk	O
can	O
be	O
reduced	O
over	O
time	O
(	O
Westerlund	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
CAD	O
is	O
a	O
multi	O
-	O
factorial	O
disease	O
with	O
complex	O
etiology	O
,	O
considered	O
to	O
be	O
driven	O
by	O
both	O
environment	O
/	O
lifestyle	O
and	O
genetic	O
factors	O
(	O
Davey	O
Smith	O
et	O
al	O
.	O
,	O
2005	O
;	O
Erdmann	O
et	O
al	O
.	O
,	O
2018	O
;	O
Vilne	O
and	O
Schunkert	O
,	O
2018	O
)	O
.	O
Over	O
the	O
last	O
14	O
years	O
,	O
several	O
large	O
-	O
scale	O
genome	B-methodology
-	I-methodology
wide	I-methodology
association	I-methodology
studies	I-methodology
have	O
aimed	O
to	O
identify	O
the	O
genetic	O
factors	O
associated	O
with	O
CAD	O
risk	O
(	O
Samani	O
et	O
al	O
.	O
,	O
2007	O
;	O
Erdmann	O
et	O
al	O
.	O
,	O
2009	O
;	O
Tregouet	O
et	O
al	O
.	O
,	O
2009	O
;	O
Schunkert	O
et	O
al	O
.	O
,	O
2011	O
;	O
Deloukas	O
et	O
al	O
.	O
,	O
2012	O
;	O
Nikpay	O
et	O
al	O
.	O
,	O
2015	O
;	O
Howson	O
et	O
al	O
.	O
,	O
2017	O
;	O
Nelson	O
et	O
al	O
.	O
,	O
2017	O
;	O
Webb	O
et	O
al	O
.	O
,	O
2017	O
;	O
van	O
der	O
Harst	O
and	O
Verweij	O
,	O
2018	O
)	O
and	O
their	O
functional	O
consequences	O
(	O
Brænne	O
et	O
al	O
.	O
,	O
2015	O
;	O
Kessler	O
et	O
al	O
.	O
,	O
2015	O
,	O
2016	O
,	O
2017	O
;	O
Zhao	O
et	O
al	O
.	O
,	O
2016	O
;	O
Aherrahrou	O
et	O
al	O
.	O
,	O
2017	O
;	O
Vilne	O
et	O
al	O
.	O
,	O
2017	O
;	O
Lempiäinen	O
et	O
al	O
.	O
,	O
2018	O
;	O
Schunkert	O
et	O
al	O
.	O
,	O
2018	O
;	O
Neiburga	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
It	O
is	O
currently	O
a	O
matter	O
of	O
intense	O
debate	O
,	O
whether	O
it	O
might	O
be	O
time	O
to	O
implement	O
genetic	O
variations	O
in	O
the	O
clinical	O
routine	O
CAD	O
risk	O
predictions	O
(	O
Inouye	O
et	O
al	O
.	O
,	O
2018	O
;	O
Khera	O
et	O
al	O
.	O
,	O
2018	O
;	O
Cecile	O
et	O
al	O
.	O
,	O
2019	O
;	O
Gola	O
et	O
al	O
.	O
,	O
2020	O
;	O
Lieb	O
and	O
Vasan	O
,	O
2020	O
)	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
contribution	O
of	O
environmental	O
/	O
lifestyle	O
factors	O
,	O
in	O
particular	O
,	O
dietary	O
factors	O
have	O
remained	O
less	O
investigated	O
(	O
Khera	O
et	O
al	O
.	O
,	O
2017	O
;	O
Dimovski	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Diet	O
is	O
one	O
of	O
the	O
modifiable	O
factors	O
for	O
disease	O
prevention	O
and	O
dietary	O
recommendations	O
have	O
been	O
formulated	O
for	O
decades	O
to	O
guide	O
us	O
toward	O
changing	O
our	O
eating	O
habits	O
in	O
favor	O
of	O
healthy	O
choices	O
.	O
For	O
example	O
,	O
the	O
consumption	O
of	O
foods	O
abundant	O
in	O
cholesterol	O
and	O
fats	O
,	O
such	O
as	O
(	O
processed	O
)	O
red	O
meats	O
,	O
have	O
been	O
associated	O
with	O
increased	O
CAD	O
risk	O
and	O
mortality	O
(	O
Bernstein	O
et	O
al	O
.	O
,	O
2010	O
;	O
Micha	O
et	O
al	O
.	O
,	O
2010	O
)	O
.	O
First	O
evidence	O
suggests	O
that	O
even	O
for	O
individuals	O
at	O
high	O
genetic	O
CAD	O
risk	O
and	O
with	O
pre	O
-	O
existing	O
non	O
-	O
modifiable	O
risk	O
factors	O
(	O
age	O
,	O
sex	O
,	O
positive	O
family	O
history	O
)	O
adherence	O
to	O
a	O
healthy	O
lifestyle	O
could	O
be	O
associated	O
with	O
an	O
almost	O
50	O
%	O
lower	O
relative	O
risk	O
of	O
CAD	O
(	O
Khera	O
et	O
al	O
.	O
,	O
2017	O
;	O
Dimovski	O
et	O
al	O
.	O
,	O
2019	O
)	O
,	O
indicating	O
that	O
the	O
inclusion	O
of	O
dietary	O
factors	O
can	O
substantially	O
improve	O
CAD	O
risk	O
prediction	O
,	O
as	O
compared	O
to	O
standard	O
Cox	O
models	O
without	O
these	O
additional	O
variables	O
(	O
Rigdon	O
and	O
Basu	O
,	O
2019	O
;	O
Ho	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
With	O
the	O
advent	O
of	O
biosensors	O
and	O
wearable	O
health	O
technology	O
connected	O
to	O
mobile	O
apps	O
,	O
large	B-methodology
-	I-methodology
scale	I-methodology
longitudinal	I-methodology
food	O
diaries	O
and	O
images	O
of	O
meals	O
consumed	O
are	O
increasingly	O
becoming	O
available	O
and	O
are	O
even	O
being	O
integrated	O
within	O
electronic	O
health	O
records	O
(	O
Verma	O
et	O
al	O
.	O
,	O
2018	O
;	O
Dinh	O
-	O
Le	O
et	O
al	O
.	O
,	O
2019	O
;	O
Moraes	O
Lopes	O
et	O
al	O
.	O
,	O
2020	O
)	O
,	O
whereas	O
further	O
advances	O
in	O
and	O
rapidly	O
decreasing	O
costs	O
of	O
next	O
generation	O
sequencing	O
generate	O
increasing	O
data	O
volumes	O
describing	O
the	O
human	O
gut	O
microbiome	O
qualitative	O
and	O
quantitative	O
composition	O
and	O
function	O
(	O
Eetemadi	O
et	O
al	O
.	O
,	O
2020	O
)	O
,	O
thus	O
providing	O
valuable	O
sources	O
of	O
data	O
for	O
integration	O
in	O
the	O
context	O
of	O
personalized	O
diet	O
recommendation	O
systems	O
(	O
Eetemadi	O
et	O
al	O
.	O
,	O
2020	O
)	O
,	O
which	O
could	O
be	O
further	O
integrated	O
into	O
clinical	O
decision	O
support	O
systems	O
for	O
improved	O
CAD	O
risk	O
predictions	O
.	O

However	O
,	O
the	O
current	O
rise	O
in	O
obesity	O
,	O
type	O
2	O
diabetes	O
(	O
T2D	O
)	O
and	O
CVD	O
/	O
CAD	O
(	O
Pallazola	O
et	O
al	O
.	O
,	O
2019	O
)	O
,	O
indicates	O
that	O
the	O
“	O
one	O
-	O
size	O
-	O
fits	O
-	O
all	O
”	O
approach	O
may	O
not	O
be	O
efficient	O
,	O
due	O
to	O
significant	O
variation	O
in	O
inter	O
-	O
individual	O
responses	O
to	O
diet	O
(	O
Hughes	O
et	O
al	O
.	O
,	O
2019	O
)	O
,	O
and	O
that	O
interactions	O
between	O
diet	O
and	O
other	O
factors	O
need	O
to	O
be	O
considered	O
(	O
Qi	O
,	O
2012	O
)	O
.	O
Recently	O
,	O
the	O
human	O
gut	O
microbiome	O
has	O
emerged	O
as	O
a	O
potential	O
and	O
previously	O
under	O
-	O
explored	O
contributor	O
to	O
these	O
variations	O
(	O
Bashiardes	O
et	O
al	O
.	O
,	O
2018	O
)	O
,	O
as	O
the	O
composition	O
and	O
function	O
of	O
this	O
complex	O
community	O
of	O
trillions	O
of	O
microorganisms	O
(	O
including	O
bacteria	O
,	O
archaea	O
,	O
viruses	O
,	O
and	O
microbial	O
eukaryotes	O
)	O
(	O
Garud	O
and	O
Pollard	O
,	O
2020	O
)	O
is	O
modulated	O
by	O
dietary	O
components	O
,	O
e	O
.	O
g	O
.	O
,	O
the	O
well	O
-	O
known	O
beneficial	O
impact	O
of	O
the	O
so	O
called	O
Mediterranean	O
diet	O
(	O
De	O
Filippis	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
This	O
impact	O
is	O
partly	O
mediated	O
through	O
the	O
metabolization	O
and	O
transformation	O
of	O
different	O
nutrients	O
by	O
the	O
gut	O
microbiome	O
,	O
generating	O
secondary	O
metabolites	O
,	O
with	O
changed	O
retention	O
time	O
,	O
bioactivity	O
and	O
different	O
impact	O
on	O
health	O
outcomes	O
:	O
being	O
either	O
protective	O
,	O
such	O
as	O
the	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFA	O
)	O
or	O
promoting	O
the	O
disease	O
development	O
such	O
as	O
hydrogen	O
sulfite	O
or	O
bile	O
acids	O
(	O
Ni	O
et	O
al	O
.	O
,	O
2015	O
;	O
Hughes	O
et	O
al	O
.	O
,	O
2019	O
;	O
Eetemadi	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Changes	O
in	O
the	O
qualitative	O
and	O
quantitative	O
composition	O
of	O
the	O
gut	O
microbiome	O
have	O
been	O
increasingly	O
linked	O
to	O
a	O
number	O
of	O
diseases	O
,	O
including	O
obesity	O
(	O
Turnbaugh	O
et	O
al	O
.	O
,	O
2009	O
;	O
Maruvada	O
et	O
al	O
.	O
,	O
2017	O
;	O
Miyamoto	O
et	O
al	O
.	O
,	O
2019	O
)	O
and	O
CVD	O
/	O
CAD	O
(	O
Koeth	O
et	O
al	O
.	O
,	O
2013	O
;	O
Miele	O
et	O
al	O
.	O
,	O
2015	O
;	O
Tang	O
et	O
al	O
.	O
,	O
2017	O
;	O
Ascher	O
and	O
Reinhardt	O
,	O
2018	O
)	O
.	O
Hence	O
,	O
efficient	O
integration	O
of	O
dietary	O
factors	O
with	O
the	O
gut	O
microbiome	O
holds	O
a	O
great	O
promise	O
to	O
revolutionize	O
the	O
way	O
diseases	O
are	O
treated	O
,	O
through	O
dietary	O
recommendations	O
and	O
lifestyle	O
changes	O
or	O
even	O
the	O
optimization	O
of	O
our	O
gut	O
microbiome	O
,	O
personalized	O
to	O
each	O
individual	O
and	O
the	O
desired	O
health	O
outcomes	O
(	O
Bashiardes	O
et	O
al	O
.	O
,	O
2018	O
;	O
Eetemadi	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O

Taken	O
together	O
,	O
the	O
multifactorial	O
and	O
complex	O
etiology	O
of	O
CAD	O
(	O
driven	O
by	O
both	O
genetic	O
and	O
environmental	O
/	O
lifestyle	O
factors	O
)	O
,	O
combined	O
with	O
the	O
highly	O
complex	O
nature	O
of	O
meals	O
(	O
containing	O
multiple	O
ingredients	O
and	O
spices	O
)	O
and	O
with	O
the	O
additional	O
complexity	O
and	O
huge	O
inter	O
-	O
individual	O
variability	O
of	O
the	O
gut	O
microbiome	O
(	O
Marcos	O
-	O
Zambrano	O
et	O
al	O
.	O
,	O
2021	O
;	O
Moreno	O
-	O
Indias	O
et	O
al	O
.	O
,	O
2021	O
)	O
,	O
resulting	O
in	O
completely	O
different	O
responses	O
to	O
identical	O
meals	O
(	O
Zeevi	O
et	O
al	O
.	O
,	O
2015	O
)	O
,	O
urgently	O
calling	O
for	O
more	O
advanced	O
problem	O
-	O
solving	O
approaches	O
.	O
Moreover	O
,	O
with	O
the	O
development	O
of	O
high	O
-	O
throughput	O
omic	O
measurement	O
platforms	O
and	O
digitalization	O
of	O
health	O
records	O
,	O
the	O
field	O
is	O
rapidly	O
entering	O
the	O
Big	O
Data	O
era	O
,	O
as	O
the	O
volumes	O
of	O
these	O
data	O
are	O
increasing	O
exponentially	O
(	O
Stephens	O
et	O
al	O
.	O
,	O
2015	O
)	O
and	O
need	O
to	O
be	O
transformed	O
into	O
valuable	O
knowledge	O
.	O
In	O
this	O
regard	O
,	O
the	O
recent	O
re	O
-	O
emergence	O
of	O
advanced	O
computational	O
data	O
-	O
driven	O
technologies	O
such	O
as	O
Artificial	O
Intelligence	O
(	O
AI	O
)	O
/	O
Machine	O
Learning	O
(	O
ML	O
)	O
approaches	O
are	O
opening	O
intriguing	O
perspectivesfor	O
the	O
integration	O
of	O
omics	O
data	O
(	O
genetic	O
variations	O
,	O
gut	O
microbiome	O
)	O
with	O
additional	O
clinical	O
(	O
Reel	O
et	O
al	O
.	O
,	O
2021	O
)	O
and	O
environmental	O
/	O
lifestyle	O
and	O
the	O
development	O
personalized	O
CAD	O
diagnostics	O
tools	O
(	O
Alizadehsani	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
AI	O
/	O
ML	O
represent	O
automated	O
approaches	O
that	O
are	O
adaptive	O
and	O
able	O
to	O
capture	O
large	O
and	O
heterogeneous	O
matrices	O
of	O
data	O
extracting	O
meaningful	O
patterns	O
and	O
identifying	O
both	O
linear	O
and	O
non	O
-	O
linear	O
relationships	O
between	O
these	O
high	O
-	O
dimensional	O
input	O
variables	O
and	O
the	O
outcomes	O
(	O
Alaa	O
et	O
al	O
.	O
,	O
2019	O
;	O
Rigdon	O
and	O
Basu	O
,	O
2019	O
;	O
Bodnar	O
et	O
al	O
.	O
,	O
2020	O
;	O
Moraes	O
Lopes	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Especially	O
,	O
Deep	O
Learning	O
(	O
DL	O
)	O
approaches	O
,	O
hold	O
a	O
great	O
promise	O
for	O
future	O
progress	O
due	O
to	O
its	O
capabilities	O
to	O
learn	O
from	O
input	O
raw	O
data	O
,	O
instead	O
of	O
using	O
hand	O
-	O
crafted	O
features	O
that	O
require	O
domain	O
expertise	O
(	O
Ching	O
et	O
al	O
.	O
,	O
2018	O
;	O
Solares	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
In	O
this	O
Mini	O
Review	O
,	O
we	O
explore	O
,	O
whether	O
the	O
inclusion	O
of	O
dietary	O
factors	O
and	O
/	O
or	O
gut	O
microbiome	O
data	O
in	O
combination	O
with	O
the	O
power	O
of	O
AI	O
/	O
ML	O
could	O
potentially	O
improve	O
CAD	O
risk	O
prediction	O
.	O

In	O
particular	O
,	O
we	O
consider	O
:	O
(	O
1	O
)	O
the	O
most	O
used	O
AI	O
/	O
ML	O
approaches	O
for	O
CAD	O
risk	O
prediction	O
;	O
(	O
2	O
)	O
the	O
use	O
cases	O
of	O
AI	O
/	O
ML	O
approaches	O
to	O
model	O
the	O
content	O
,	O
choice	O
and	O
impact	O
of	O
dietary	O
factors	O
and	O
how	O
this	O
could	O
be	O
used	O
to	O
predict	O
CAD	O
risk	O
;	O
(	O
3	O
)	O
the	O
use	O
cases	O
of	O
AI	O
/	O
ML	O
approaches	O
to	O
classify	O
individuals	O
by	O
their	O
gut	O
microbiome	O
composition	O
into	O
CAD	O
cases	O
vs	O
.	O
controls	O
and	O
to	O
(	O
4	O
)	O
model	O
the	O
diet	O
-	O
gut	O
microbiome	O
interactions	O
and	O
their	O
impact	O
on	O
CAD	O
risk	O
(	O
as	O
illustrated	O
in	O
Figure	O
1	O
and	O
summarized	O
in	O
Table	O
1	O
)	O
.	O
(	O
5	O
)	O
Finally	O
,	O
we	O
provide	O
an	O
outlook	O
for	O
putting	O
it	O
all	O
together	O
into	O
a	O
smart	O
clinical	O
decision	O
support	O
system	O
(	O
DSS	O
)	O
,	O
considering	O
the	O
traditional	O
risk	O
factors	O
in	O
combination	O
with	O
individual	O
'	O
s	O
genetic	O
variations	O
,	O
as	O
well	O
as	O
dietary	O
factors	O
and	O
gut	O
microbiome	O
and	O
discuss	O
the	O
potential	O
of	O
AI	O
/	O
ML	O
based	O
methods	O
vs	O
.	O
conventional	O
approaches	O
for	O
risk	O
predictions	O
.	O
Artificial	O
Intelligence	O
(	O
AI	O
)	O
/	O
Machine	O
Learning	O
(	O
ML	O
)	O
has	O
recently	O
caught	O
the	O
interest	O
of	O
both	O
academia	O
and	O
industry	O
,	O
and	O
the	O
different	O
approaches	O
have	O
been	O
explicitly	O
reviewed	O
elsewhere	O
,	O
e	O
.	O
g	O
.	O
,	O
Cao	O
et	O
al	O
.	O
,	O
2018	O
;	O
Goecks	O
et	O
al	O
.	O
,	O
2020	O
.	O
Hence	O
,	O
we	O
only	O
give	O
a	O
very	O
brief	O
overview	O
,	O
highlighting	O
some	O
of	O
the	O
most	O
popular	O
and	O
widely	O
used	O
approaches	O
and	O
common	O
terminology	O
in	O
the	O
field	O
,	O
to	O
prepare	O
the	O
reader	O
for	O
the	O
sections	O
to	O
follow	O
.	O
In	O
general	O
,	O
AI	O
/	O
ML	O
-	O
based	O
approaches	O
can	O
be	O
considered	O
as	O
a	O
set	O
of	O
methods	O
that	O
can	O
effectively	O
use	O
large	O
and	O
complex	O
data	O
sets	O
to	O
extract	O
meaningful	O
patterns	O
(	O
i	O
.	O
e	O
.	O
,	O
“	O
learn	O
”	O
)	O
in	O
order	O
to	O
use	O
this	O
“	O
knowledge	O
”	O
to	O
make	O
predictions	O
on	O
other	O
data	O
(	O
Vilne	O
et	O
al	O
.	O
,	O
2019	O
)	O
and	O
improve	O
with	O
experience	O
(	O
Libbrecht	O
and	O
Noble	O
,	O
2015	O
)	O
.	O

Moreover	O
AI	O
/	O
ML	O
can	O
be	O
performed	O
either	O
(	O
1	O
)	O
in	O
a	O
unsupervised	O
manner	O
by	O
exploring	O
and	O
detecting	O
what	O
types	O
of	O
labels	O
best	O
explain	O
the	O
data	O
i	O
.	O
e	O
.	O
,	O
using	O
unlabeled	O
data	O
;	O
(	O
2	O
)	O
in	O
a	O
supervised	O
manner	O
by	O
classifying	O
,	O
predicting	O
and	O
explaining	O
the	O
data	O
,	O
requiring	O
labels	O
(	O
Vilne	O
et	O
al	O
.	O
,	O
2019	O
;	O
Eetemadi	O
et	O
al	O
.	O
,	O
2020	O
)	O
,	O
or	O
(	O
3	O
)	O
in	O
a	O
semi	O
-	O
supervised	O
manner	O
,	O
taking	O
advantage	O
of	O
both	O
unlabeled	O
and	O
labeled	O
data	O
,	O
where	O
only	O
a	O
subset	O
of	O
data	O
is	O
labeled	O
(	O
Libbrecht	O
and	O
Noble	O
,	O
2015	O
)	O
.	O
In	O
particular	O
,	O
supervised	O
learning	O
has	O
gained	O
much	O
attention	O
recently	O
(	O
Reel	O
et	O
al	O
.	O
,	O
2021	O
)	O
,	O
as	O
it	O
allows	O
to	O
define	O
certain	O
outputs	O
that	O
can	O
be	O
used	O
for	O
classification	O
of	O
patients	O
,	O
and	O
will	O
be	O
the	O
main	O
focus	O
of	O
this	O
Mini	O
-	O
Review	O
.	O
In	O
this	O
class	O
,	O
one	O
of	O
the	O
most	O
popular	O
is	O
the	O
Random	O
Forest	O
(	O
RF	O
)	O
approach	O
(	O
Breiman	O
,	O
2001	O
)	O
,	O
which	O
randomly	O
selects	O
a	O
subset	O
from	O
the	O
training	O
data	O
to	O
construct	O
an	O
ensemble	O
of	O
Decision	O
Tree	O
(	O
DT	O
)	O
predictors	O
to	O
aggregate	O
the	O
predictions	O
,	O
by	O
this	O
attempting	O
to	O
lower	O
the	O
variance	O
and	O
deal	O
with	O
the	O
issue	O
of	O
overfitting	O
.	O
Decision	O
Tree	O
(	O
DT	O
)	O
approach	O
is	O
also	O
a	O
commonly	O
used	O
classifier	O
,	O
splitting	O
the	O
input	O
data	O
into	O
branch	O
-	O
like	O
segments	O
,	O
according	O
to	O
a	O
certain	O
parameter	O
(	O
Goecks	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Another	O
popular	O
method	O
in	O
the	O
field	O
is	O
the	O
Support	O
Vector	O
Machine	O
(	O
SVM	O
)	O
classifier	O
,	O
representing	O
a	O
pattern	O
classification	O
technique	O
,	O
based	O
on	O
the	O
idea	O
of	O
transforming	O
the	O
original	O
data	O
that	O
is	O
not	O
linearly	O
separable	O
to	O
a	O
higher	O
dimensional	O
space	O
and	O
finding	O
a	O
hyperplane	O
separating	O
the	O
data	O
into	O
classes	O
,	O
based	O
on	O
a	O
priori	O
defined	O
criteria	O
,	O
with	O
the	O
aim	O
to	O
overcome	O
overfitting	O
(	O
Suykens	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O
However	O
,	O
further	O
improvements	O
may	O
be	O
necessary	O
when	O
dealing	O
with	O
omics	O
data	O
(	O
Han	O
and	O
Jiang	O
,	O
2014	O
)	O
.	O
Gradient	O
Boosting	O
(	O
GB	O
)	O
,	O
such	O
as	O
Stochastic	O
Gradient	O
Boosting	O
Regression	O
(	O
Friedman	O
,	O
2001	O
)	O
is	O
a	O
technique	O
that	O
,	O
similar	O
to	O
RF	O
,	O
constructs	O
multiple	O
decision	O
trees	O
by	O
drawing	O
a	O
random	O
samples	O
from	O
the	O
data	O
set	O
(	O
termed	O
bagging	O
)	O
.	O

However	O
,	O
instead	O
of	O
constructing	O
many	O
parallel	O
deep	O
trees	O
,	O
it	O
constructs	O
multiple	O
shallow	O
trees	O
(	O
weak	O
learners	O
)	O
and	O
in	O
a	O
sequential	O
manner	O
(	O
i	O
.	O
e	O
.	O
,	O
one	O
after	O
the	O
other	O
)	O
so	O
that	O
the	O
next	O
tree	O
improves	O
upon	O
the	O
classification	O
of	O
previous	O
trees	O
in	O
an	O
additive	O
manner	O
.	O
GB	O
is	O
known	O
to	O
perform	O
best	O
with	O
fewer	O
input	O
variables	O
of	O
low	O
dimensionality	O
,	O
whereas	O
RF	O
performs	O
better	O
with	O
many	O
input	O
variables	O
or	O
high	O
dimensionality	O
(	O
Hughes	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Finally	O
,	O
Artificial	O
Neural	O
Networks	O
(	O
ANN	O
)	O
,	O
and	O
their	O
extension	O
,	O
Deep	O
Learning	O
(	O
DL	O
)	O
,	O
are	O
graph	O
computing	O
models	O
,	O
which	O
,	O
at	O
least	O
to	O
some	O
extent	O
,	O
should	O
mimic	O
the	O
functioning	O
of	O
the	O
human	O
brain	O
,	O
hence	O
their	O
computing	O
units	O
are	O
called	O
neurons	O
and	O
are	O
interconnected	O
for	O
passing	O
information	O
to	O
each	O
other	O
.	O
Moreover	O
,	O
networks	O
of	O
neurons	O
are	O
additionally	O
organized	O
in	O
layers	O
.	O
The	O
first	O
one	O
is	O
an	O
input	O
layer	O
,	O
receiving	O
the	O
training	O
data	O
.	O
This	O
is	O
followed	O
by	O
several	O
hidden	O
layers	O
.	O
The	O
last	O
one	O
is	O
an	O
output	O
layer	O
,	O
which	O
performs	O
the	O
actual	O
prediction	O
of	O
the	O
class	O
(	O
McCulloch	O
and	O
Pitts	O
,	O
1990	O
)	O
.	O
ANN	O
have	O
been	O
demonstrated	O
to	O
outperform	O
other	O
AI	O
/	O
ML	O
approaches	O
in	O
many	O
areas	O
,	O
especially	O
(	O
medical	O
)	O
image	O
analyses	O
(	O
Eetemadi	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Performance	O
of	O
an	O
AI	O
/	O
ML	O
classifier	O
is	O
often	O
expressed	O
as	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
,	O
where	O
a	O
value	O
of	O
0	O
.	O
5	O
indicates	O
poor	O
performance	O
(	O
equal	O
to	O
a	O
random	O
guess	O
)	O
while	O
higher	O
values	O
(	O
approaching	O
1	O
)	O
indicate	O
better	O
classification	O
performance	O
,	O
allowing	O
an	O
easy	O
comparison	O
of	O
the	O
success	O
of	O
various	O
implementations	O
of	O
AI	O
/	O
ML	O
approaches	O
(	O
Bradley	O
,	O
1997	O
)	O
.	O
However	O
,	O
considering	O
that	O
,	O
in	O
most	O
cases	O
,	O
the	O
users	O
are	O
more	O
interested	O
in	O
positive	O
outputs	O
(	O
i	O
.	O
e	O
.	O
,	O
people	O
at	O
high	O
CAD	O
risk	O
)	O
,	O
some	O
other	O
performance	O
measures	O
would	O
need	O
to	O
be	O
considered	O
as	O
well	O
,	O
such	O
as	O
the	O
Jaccard	O
index	O
(	O
J	O
)	O
or	O
the	O
F1	O
-	O
score	O
,	O
focusing	O
on	O
the	O
fraction	O
of	O
true	O
positives	O
(	O
Jiao	O
and	O
Du	O
,	O
2016	O
)	O
.	O

Moreover	O
,	O
if	O
the	O
input	O
data	O
sets	O
are	O
imbalanced	O
(	O
i	O
.	O
e	O
.	O
,	O
many	O
more	O
controls	O
than	O
CAD	O
patients	O
in	O
the	O
training	O
set	O
)	O
,	O
precision	O
-	O
recall	O
(	O
PR	O
)	O
curve	O
should	O
be	O
considered	O
along	O
the	O
ROC	O
curve	O
and	O
additional	O
performance	O
measures	O
,	O
such	O
as	O
the	O
balanced	O
accuracy	O
(	O
BAcc	O
)	O
and	O
the	O
Matthew	O
'	O
s	O
Correlation	O
Coefficient	O
(	O
MCC	O
)	O
considered	O
(	O
Jiao	O
and	O
Du	O
,	O
2016	O
)	O
.	O
We	O
refer	O
the	O
interested	O
reader	O
to	O
Jiao	O
and	O
Du	O
(	O
2016	O
)	O
for	O
more	O
details	O
.	O
Moreover	O
,	O
if	O
the	O
input	O
data	O
is	O
not	O
normally	O
distributed	O
,	O
maximum	O
likelihood	O
estimation	O
(	O
MLE	O
)	O
should	O
be	O
used	O
to	O
model	O
this	O
data	O
and	O
determine	O
the	O
model	O
parameters	O
for	O
the	O
evaluation	O
metrics	O
(	O
Maximum	O
-	O
likelihood	O
method	O
,	O
2001	O
)	O
.	O
The	O
added	O
value	O
of	O
AI	O
/	O
ML	O
models	O
in	O
CAD	O
diagnostics	O
has	O
been	O
thoroughly	O
reviewed	O
before	O
,	O
examining	O
149	O
relevant	O
studies	O
between	O
1992	O
and	O
2019	O
(	O
Alizadehsani	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Most	O
of	O
this	O
research	O
focused	O
on	O
the	O
usage	O
of	O
clinical	O
data	O
(	O
symptom	O
,	O
examination	O
and	O
echo	O
features	O
)	O
,	O
laboratory	O
measurements	O
and	O
medical	O
images	O
(	O
e	O
.	O
g	O
.	O
,	O
coronary	O
computed	O
tomography	O
angiography	O
,	O
myocardial	O
perfusion	O
imaging	O
or	O
intravascular	O
ultrasound	O
)	O
(	O
Alizadehsani	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
The	O
Authors	O
observed	O
that	O
there	O
were	O
three	O
approaches	O
applied	O
to	O
almost	O
all	O
the	O
datasets	O
—	O
ANN	O
/	O
DL	O
,	O
DT	O
,	O
and	O
SVM	O
—	O
most	O
probably	O
due	O
to	O
their	O
ease	O
of	O
use	O
,	O
low	O
computational	O
burden	O
and	O
encouraging	O
performance	O
(	O
Alizadehsani	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
In	O
particular	O
,	O
studies	O
with	O
best	O
performances	O
(	O
i	O
.	O
e	O
.	O
,	O
with	O
a	O
reported	O
accuracy	O
of	O
>	O
98	O
%	O
)	O
used	O
ANN	O
and	O
SVM	O
as	O
their	O
classifiers	O
,	O
which	O
may	O
be	O
due	O
to	O
the	O
use	O
of	O
non	O
-	O
linear	O
kernel	O
functions	O
(	O
Alizadehsani	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
However	O
,	O
it	O
was	O
concluded	O
that	O
further	O
investigation	O
are	O
needed	O
to	O
determine	O
which	O
approaches	O
are	O
most	O
appropriate	O
for	O
a	O
particular	O
feature	O
category	O
(	O
e	O
.	O
g	O
.	O
,	O
ejection	O
fraction	O
,	O
regional	O
wall	O
motion	O
abnormality	O
,	O
and	O
valvular	O
heart	O
disease	O
extracted	O
from	O
echo	O
)	O
.	O

Of	O
note	O
,	O
however	O
,	O
neither	O
of	O
the	O
data	O
types	O
highlighted	O
above	O
provide	O
any	O
information	O
on	O
the	O
molecular	O
bases	O
of	O
a	O
disease	O
,	O
which	O
could	O
possibly	O
yield	O
a	O
more	O
timely	O
and	O
precise	O
diagnosis	O
,	O
or	O
even	O
risk	O
prediction	O
,	O
allowing	O
for	O
individually	O
tailored	O
treatments	O
(	O
Westerlund	O
et	O
al	O
.	O
,	O
2021	O
)	O
or	O
even	O
prevention	O
strategies	O
,	O
toward	O
the	O
goal	O
of	O
“	O
positive	O
health	O
”	O
,	O
resulting	O
in	O
a	O
significantly	O
improved	O
life	O
-	O
span	O
and	O
quality	O
(	O
Movsisyan	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Genomic	O
data	O
have	O
been	O
used	O
in	O
combination	O
with	O
AI	O
/	O
ML	O
for	O
CAD	O
risk	O
prediction	O
.	O
In	O
particular	O
,	O
(	O
penalized	O
)	O
logistic	O
regression	O
,	O
Naïve	O
Bayes	O
(	O
NB	O
)	O
,	O
RF	O
,	O
SVM	O
,	O
and	O
GB	O
were	O
compared	O
vs	O
.	O
polygenic	O
risk	O
scores	O
(	O
PRS	O
)	O
on	O
a	O
data	O
set	O
of	O
7	O
,	O
736	O
CAD	O
cases	O
vs	O
.	O
6	O
,	O
774	O
controls	O
,	O
testing	O
the	O
final	O
models	O
on	O
an	O
independent	O
data	O
set	O
(	O
527	O
CAD	O
cases	O
vs	O
.	O
473	O
controls	O
)	O
(	O
Gola	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Interestingly	O
,	O
they	O
found	O
that	O
PRS	O
actually	O
outperformed	O
AI	O
/	O
ML	O
-	O
based	O
approaches	O
in	O
predicting	O
CAD	O
status	O
(	O
AUC	O
~	O
0	O
.	O
92	O
vs	O
.	O
~	O
0	O
.	O
81	O
for	O
NB	O
and	O
SVM	O
and	O
AUC	O
~	O
0	O
.	O
75	O
for	O
RF	O
and	O
GB	O
)	O
.	O
The	O
Authors	O
conclude	O
that	O
“	O
there	O
is	O
no	O
need	O
to	O
use	O
a	O
sledge	O
-	O
hammer	O
to	O
crack	O
the	O
nut	O
”	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
assumption	O
of	O
linear	O
additive	O
effects	O
influencing	O
the	O
risk	O
of	O
CAD	O
seems	O
sufficient	O
.	O
On	O
the	O
other	O
hand	O
,	O
PRS	O
may	O
not	O
be	O
a	O
suitable	O
option	O
,	O
if	O
the	O
goal	O
would	O
be	O
to	O
predict	O
the	O
changes	O
in	O
CAD	O
risk	O
over	O
time	O
or	O
the	O
particular	O
molecular	O
basis	O
driving	O
the	O
development	O
and	O
progression	O
CAD	O
(	O
Westerlund	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
This	O
is	O
were	O
additional	O
data	O
layers	O
such	O
dietary	O
factors	O
and	O
gut	O
microbiome	O
,	O
as	O
an	O
integrator	O
of	O
this	O
information	O
(	O
Bashiardes	O
et	O
al	O
.	O
,	O
2018	O
;	O
Eetemadi	O
et	O
al	O
.	O
,	O
2020	O
)	O
,	O
come	O
in	O
.	O

However	O
,	O
only	O
a	O
few	O
studies	O
so	O
far	O
have	O
used	O
dietary	O
factors	O
(	O
Alaa	O
et	O
al	O
.	O
,	O
2019	O
;	O
Rigdon	O
and	O
Basu	O
,	O
2019	O
)	O
or	O
gut	O
microbiome	O
(	O
Zhu	O
et	O
al	O
.	O
,	O
2018	O
;	O
Aryal	O
et	O
al	O
.	O
,	O
2020	O
)	O
,	O
and	O
no	O
studies	O
using	O
both	O
(	O
the	O
closest	O
being	O
Zeevi	O
et	O
al	O
.	O
,	O
2015	O
related	O
to	O
blood	O
glucose	O
levels	O
)	O
,	O
in	O
combination	O
with	O
AI	O
/	O
ML	O
for	O
CAD	O
risk	O
prediction	O
.	O
We	O
further	O
discuss	O
these	O
few	O
studies	O
and	O
also	O
consider	O
closely	O
related	O
research	O
on	O
dietary	O
factors	O
,	O
gut	O
microbiome	O
and	O
combinations	O
of	O
both	O
in	O
other	O
disease	O
settings	O
vs	O
.	O
healthy	O
individuals	O
.	O
Dietary	O
information	O
is	O
mainly	O
collected	O
via	O
questionnaires	O
,	O
either	O
through	O
self	O
-	O
reporting	O
or	O
by	O
a	O
trained	O
interviewer	O
.	O
For	O
self	O
-	O
reporting	O
,	O
a	O
food	O
frequency	O
questionnaire	O
and	O
dietary	O
recall	O
can	O
be	O
used	O
,	O
where	O
participants	O
report	O
their	O
meal	O
intake	O
either	O
every	O
24	O
h	O
or	O
over	O
a	O
longer	O
period	O
through	O
a	O
checklist	O
of	O
food	O
items	O
(	O
Eetemadi	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
At	O
the	O
same	O
time	O
,	O
fitness	O
apps	O
are	O
gaining	O
increased	O
popularity	O
,	O
as	O
food	O
logging	O
can	O
be	O
performed	O
during	O
its	O
consumption	O
or	O
even	O
by	O
capturing	O
an	O
image	O
of	O
the	O
meal	O
,	O
thus	O
the	O
bias	O
related	O
to	O
individual	O
'	O
s	O
memory	O
can	O
be	O
reduced	O
(	O
Weber	O
and	O
Achananuparp	O
,	O
2016	O
;	O
Verma	O
et	O
al	O
.	O
,	O
2018	O
;	O
Eetemadi	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Clearly	O
,	O
such	O
food	O
tracking	O
would	O
be	O
of	O
utmost	O
importance	O
for	O
a	O
more	O
efficient	O
management	O
of	O
patients	O
with	O
obesity	O
,	O
T2D	O
and	O
CVD	O
/	O
CAD	O
(	O
Bernstein	O
et	O
al	O
.	O
,	O
2010	O
;	O
Pallazola	O
et	O
al	O
.	O
,	O
2019	O
)	O
,	O
when	O
successfully	O
coupled	O
with	O
an	O
effective	O
coaching	O
to	O
modulate	O
it	O
toward	O
healthy	O
food	O
choices	O
(	O
Spanakis	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
The	O
AI	O
/	O
ML	O
approaches	O
can	O
be	O
leveraged	O
for	O
such	O
purposes	O
(	O
Verma	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
In	O
this	O
regard	O
,	O
Myers	O
et	O
al	O
.	O
(	O
2015	O
)	O
created	O
a	O
Google	O
app	O
,	O
Im2Calories	O
,	O
to	O
predict	O
the	O
nutritional	O
contents	O
and	O
calories	O
of	O
individual	O
'	O
s	O
meal	O
from	O
its	O
image	O
,	O
using	O
a	O
Convolutional	O
Neural	O
Network	O
/	O
DL	O
-	O
based	O
classifier	O
,	O
which	O
was	O
modified	O
to	O
run	O
on	O
a	O
mobile	O
phone	O
analyzing	O
images	O
taken	O
by	O
users	O
,	O
demonstrating	O
promising	O
first	O
results	O
in	O
this	O
direction	O
.	O

Weber	O
and	O
Achananuparp	O
(	O
2016	O
)	O
used	O
public	O
food	O
diaries	O
of	O
>	O
4	O
,	O
000	O
MyFitnessPal	O
users	O
to	O
train	O
a	O
SVM	O
classifier	O
to	O
distinguish	O
between	O
a	O
successful	O
(	O
“	O
below	O
”	O
a	O
user	O
specified	O
“	O
daily	O
calories	O
goal	O
”	O
)	O
vs	O
.	O
un	O
-	O
successful	O
(	O
“	O
above	O
”	O
the	O
goal	O
)	O
diet	O
and	O
analyzed	O
the	O
different	O
dietary	O
factors	O
influencing	O
these	O
two	O
outcomes	O
.	O
It	O
was	O
observed	O
that	O
“	O
oil	O
”	O
,	O
“	O
butter	O
”	O
,	O
“	O
mcdonalds	O
”	O
,	O
“	O
dessert	O
”	O
or	O
“	O
pork	O
”	O
vs	O
.	O
“	O
poultry	O
”	O
were	O
related	O
to	O
being	O
“	O
above	O
”	O
the	O
calories	O
goal	O
.	O
Moreover	O
,	O
there	O
were	O
less	O
food	O
logging	O
on	O
the	O
weekend	O
and	O
the	O
users	O
were	O
most	O
likely	O
to	O
be	O
“	O
above	O
”	O
the	O
calories	O
goal	O
(	O
Weber	O
and	O
Achananuparp	O
,	O
2016	O
)	O
.	O
Spanakis	O
et	O
al	O
.	O
(	O
2017	O
)	O
made	O
use	O
of	O
data	O
collected	O
from	O
the	O
fitness	O
app	O
ThinkSlim	O
,	O
to	O
link	O
the	O
individual	O
states	O
(	O
like	O
location	O
,	O
activity	O
,	O
emotions	O
-	O
cheerful	O
,	O
relaxed	O
vs	O
.	O
sad	O
,	O
bored	O
,	O
stressed	O
,	O
angry	O
,	O
worried	O
)	O
of	O
healthy	O
-	O
weight	O
vs	O
.	O
overweight	O
individuals	O
to	O
their	O
dietary	O
choices	O
or	O
wishes	O
,	O
using	O
a	O
Decision	O
Tree	O
(	O
DT	O
)	O
-	O
based	O
classifier	O
,	O
modified	O
to	O
use	O
longitudinal	O
real	O
-	O
time	O
data	O
.	O
They	O
derived	O
several	O
groups	O
of	O
individuals	O
with	O
similar	O
eating	O
behavior	O
and	O
used	O
this	O
information	O
to	O
warn	O
the	O
participants	O
before	O
the	O
individual	O
states	O
that	O
may	O
lead	O
to	O
unhealthy	O
eating	O
behavior	O
(	O
Spanakis	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
Mathias	O
et	O
al	O
.	O
(	O
2018	O
)	O
conducted	O
a	O
six	O
-	O
week	O
study	O
to	O
evaluate	O
,	O
how	O
136	O
healthy	O
Brazilian	O
children	O
and	O
teens	O
(	O
9	O
–	O
13	O
years	O
old	O
)	O
responded	O
to	O
multivitamins	O
and	O
minerals	O
,	O
to	O
develop	O
recommendations	O
for	O
optimizing	O
their	O
levels	O
,	O
based	O
on	O
several	O
clinical	O
,	O
anthropometric	O
and	O
food	O
intake	O
parameters	O
.	O
These	O
data	O
were	O
then	O
used	O
to	O
predict	O
each	O
individual	O
'	O
s	O
response	O
to	O
the	O
intervention	O
,	O
based	O
on	O
these	O
measures	O
using	O
an	O
Elastic	O
Net	O
penalized	O
regression	O
model	O
.	O
However	O
,	O
none	O
of	O
the	O
above	O
mentioned	O
studies	O
were	O
directly	O
related	O
to	O
CAD	O
risk	O
prediction	O
.	O
There	O
have	O
been	O
only	O
a	O
few	O
studies	O
considering	O
the	O
dietary	O
factors	O
for	O
CAD	O
risk	O
prediction	O
,	O
so	O
far	O
.	O
Alaa	O
et	O
al	O
.	O
(	O
2019	O
)	O
analyzed	O
423	O
,	O
604	O
UK	O
Biobank	O
participants	O
without	O
CVD	O
at	O
baseline	O
with	O
the	O
aim	O
to	O
predict	O
their	O
future	O
disease	O
risk	O
.	O

They	O
investigated	O
,	O
whether	O
AI	O
/	O
ML	O
-	O
based	O
approaches	O
could	O
possibly	O
improve	O
disease	O
risk	O
prediction	O
,	O
as	O
compared	O
to	O
conventional	O
approaches	O
(	O
such	O
as	O
FRS	O
)	O
and	O
whether	O
considering	O
additional	O
information	O
(	O
i	O
.	O
e	O
.	O
,	O
473	O
variables	O
,	O
including	O
dietary	O
information	O
)	O
could	O
increase	O
the	O
accuracy	O
of	O
their	O
predictions	O
.	O
They	O
used	O
AutoPrognosis	O
,	O
which	O
allows	O
to	O
automatically	O
select	O
and	O
tune	O
the	O
best	O
possible	O
AI	O
/	O
ML	O
approaches	O
,	O
by	O
comprising	O
different	O
imputation	O
strategies	O
,	O
feature	O
selection	O
and	O
processing	O
,	O
as	O
well	O
as	O
classification	O
and	O
calibration	O
approaches	O
.	O
They	O
observed	O
and	O
improvement	O
in	O
comparison	O
to	O
(	O
AUC	O
~	O
0	O
.	O
77	O
vs	O
.	O
~	O
0	O
.	O
72	O
for	O
FRS	O
)	O
conventional	O
approaches	O
(	O
Alaa	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Rigdon	O
and	O
Basu	O
(	O
2019	O
)	O
performed	O
a	O
retrospective	B-methodology
study	I-methodology
using	O
AI	O
/	O
ML	O
exploring	O
whether	O
considering	O
randomly	O
sampled	O
sparse	O
nutrition	O
data	O
could	O
possibly	O
improve	O
CVD	O
mortality	O
risk	O
prediction	O
.	O
They	O
made	O
use	O
of	O
NHANES	O
interview	O
data	O
collected	O
from	O
1999	O
to	O
2011	O
linked	O
to	O
the	O
National	O
Death	O
Index	O
(	O
NDI	O
)	O
in	O
the	O
US	O
,	O
selecting	O
29	O
,	O
390	O
participants	O
as	O
their	O
training	O
set	O
and	O
further	O
12	O
,	O
600	O
participants	O
as	O
their	O
test	O
set	O
.	O
Similarly	O
to	O
Alaa	O
et	O
al	O
.	O
(	O
2019	O
)	O
,	O
they	O
aimed	O
at	O
testing	O
whether	O
AI	O
/	O
ML	O
-	O
based	O
approaches	O
vs	O
.	O
standard	O
(	O
Cox	O
)	O
models	O
and	O
considering	O
additional	O
predictor	O
variables	O
(	O
dietary	O
information	O
)	O
could	O
possibly	O
improve	O
CVD	O
mortality	O
risk	O
prediction	O
.	O
They	O
applied	O
two	O
DT	O
-	O
based	O
AI	O
/	O
ML	O
approaches	O
the	O
Gradient	O
Boosted	O
Machines	O
(	O
GBM	O
)	O
(	O
Chen	O
et	O
al	O
.	O
,	O
2013	O
)	O
and	O
RF	O
(	O
Ishwaran	O
et	O
al	O
.	O
,	O
2008	O
)	O
,	O
tailored	O
to	O
the	O
analyses	O
of	O
survival	O
data	O
to	O
demonstrated	O
that	O
the	O
inclusion	O
of	O
dietary	O
information	O
significantly	O
improved	O
risk	O
prediction	O
,	O
as	O
compared	O
to	O
the	O
standard	O
models	O
and	O
when	O
including	O
only	O
the	O
traditional	O
risk	O
factors	O
.	O
In	O
particular	O
,	O
they	O
found	O
that	O
a	O
standard	O
Cox	O
model	O
without	O
dietary	O
factors	O
overestimated	O
the	O
CVD	O
mortality	O
risk	O
nearly	O
two	O
-	O
fold	O
,	O
whereas	O
AI	O
/	O
ML	O
models	O
in	O
combination	O
with	O
these	O
additional	O
data	O
substantially	O
improved	O
their	O
predictions	O
(	O
AUC	O
~	O
0	O
.	O
87	O
vs	O
.	O
~	O
0	O
.	O
93	O
)	O
.	O
In	O
addition	O
to	O
genetic	O
and	O
environmental	O
/	O
life	O
-	O
style	O
factors	O
,	O
gut	O
microbiota	O
has	O
emerged	O
as	O
a	O
additional	O
factor	O
influencing	O
the	O
CAD	O
risk	O
(	O
Aryal	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O

Clearly	O
,	O
researchers	O
have	O
asked	O
,	O
whether	O
gut	O
microbiome	O
profiling	O
combined	O
with	O
AI	O
/	O
ML	O
approaches	O
could	O
be	O
used	O
for	O
improved	O
CAD	O
/	O
CVD	O
risk	O
prediction	O
.	O
In	O
the	O
last	O
10	O
years	O
,	O
a	O
number	O
of	O
studies	O
have	O
demonstrated	O
that	O
there	O
is	O
a	O
possible	O
relationship	O
between	O
the	O
gut	O
microbiome	O
composition	O
,	O
such	O
as	O
changes	O
in	O
the	O
abundance	O
of	O
Bacteroidetes	O
,	O
Firmicutes	O
,	O
Lactobacillus	O
,	O
Streptococcus	O
,	O
Bifidobacterium	O
,	O
Roseburia	O
,	O
or	O
Escherichia	O
spp	O
.	O
and	O
the	O
development	O
of	O
several	O
diseases	O
,	O
including	O
obesity	O
(	O
Turnbaugh	O
et	O
al	O
.	O
,	O
2009	O
;	O
Maruvada	O
et	O
al	O
.	O
,	O
2017	O
;	O
Miyamoto	O
et	O
al	O
.	O
,	O
2019	O
)	O
hypertension	O
(	O
Karbach	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
and	O
CVD	O
(	O
Karlsson	O
et	O
al	O
.	O
,	O
2012	O
;	O
Koeth	O
et	O
al	O
.	O
,	O
2013	O
;	O
Miele	O
et	O
al	O
.	O
,	O
2015	O
;	O
Kelly	O
et	O
al	O
.	O
,	O
2016	O
;	O
Tang	O
et	O
al	O
.	O
,	O
2017	O
;	O
Ascher	O
and	O
Reinhardt	O
,	O
2018	O
)	O
.	O
Several	O
studies	O
have	O
used	O
AI	O
/	O
ML	O
approaches	O
to	O
classify	O
test	O
subjects	O
into	O
groups	O
(	O
such	O
as	O
healthy	O
vs	O
.	O
disease	O
)	O
based	O
on	O
microbiome	O
data	O
.	O
In	O
most	O
studies	O
,	O
relative	O
abundances	O
of	O
microbiome	O
taxa	O
are	O
used	O
as	O
features	O
,	O
obtained	O
either	O
by	O
amplicon	O
sequencing	O
of	O
the	O
16S	O
rRNA	O
phylogenetic	O
marker	O
gene	O
or	O
by	O
shotgun	O
metagenomic	O
sequencing	O
(	O
Hughes	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
As	O
the	O
costs	O
of	O
shotgun	O
metagenomic	O
sequencing	O
decrease	O
,	O
the	O
functional	O
profiles	O
derived	O
from	O
metagenome	O
sequences	O
can	O
be	O
expected	O
to	O
increasingly	O
be	O
used	O
as	O
input	O
features	O
with	O
AI	O
/	O
ML	O
approaches	O
(	O
Eetemadi	O
et	O
al	O
.	O
,	O
2020	O
;	O
Sanchez	O
-	O
Rodriguez	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Pasolli	O
et	O
al	O
.	O
(	O
2016	O
)	O
utilized	O
2	O
,	O
424	O
shotgun	O
metagenomic	O
samples	O
from	O
eight	O
studies	O
to	O
assess	O
the	O
potential	O
of	O
the	O
(	O
mainly	O
gut	O
)	O
microbiome	O
species	O
-	O
level	O
abundances	O
to	O
be	O
used	O
in	O
order	O
to	O
differentiate	O
healthy	O
vs	O
.	O
unhealthy	O
(	O
including	O
obese	O
and	O
T2D	O
)	O
individuals	O
and	O
compare	O
the	O
prediction	O
accuracy	O
of	O
RF	O
vs	O
.	O
SVM	O
approaches	O
.	O

Interestingly	O
,	O
for	O
T2D	O
and	O
obesity	O
,	O
the	O
models	O
demonstrated	O
lower	O
discrimination	O
ability	O
as	O
compared	O
,	O
for	O
example	O
,	O
to	O
liver	O
cirrhosis	O
(	O
AUC	O
of	O
0	O
.	O
74	O
and	O
0	O
.	O
65	O
vs	O
.	O
0	O
.	O
94	O
,	O
respectively	O
)	O
,	O
suggesting	O
less	O
significant	O
changes	O
in	O
microbiome	O
composition	O
related	O
to	O
T2D	O
and	O
obesity	O
.	O
Comparing	O
the	O
accuracy	O
of	O
RF	O
vs	O
.	O
SVM	O
,	O
in	O
all	O
cases	O
,	O
RF	O
demonstrated	O
similar	O
or	O
even	O
better	O
results	O
than	O
SVM	O
(	O
for	O
T2D	O
:	O
AUC	O
~	O
0	O
.	O
74	O
vs	O
.	O
~	O
0	O
.	O
66	O
,	O
respectively	O
)	O
.	O
However	O
,	O
although	O
the	O
approach	O
of	O
using	O
gut	O
microbiome	O
in	O
combination	O
with	O
AI	O
/	O
ML	O
approaches	O
for	O
disease	O
risk	O
prediction	O
is	O
not	O
novel	O
,	O
it	O
has	O
not	O
been	O
widely	O
applied	O
for	O
CAD	O
,	O
yet	O
(	O
Aryal	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Zhu	O
et	O
al	O
.	O
(	O
2018	O
)	O
compared	O
the	O
composition	O
of	O
the	O
gut	O
microbiome	O
between	O
70	O
CAD	O
patients	O
vs	O
.	O
98	O
healthy	O
controls	O
and	O
used	O
RF	O
to	O
potentially	O
differentiate	O
these	O
two	O
groups	O
of	O
individuals	O
,	O
achieving	O
and	O
AUC	O
of	O
0	O
.	O
67	O
.	O
In	O
addition	O
,	O
the	O
gut	O
microbiome	O
of	O
CAD	O
patients	O
displayed	O
decreased	O
diversity	O
and	O
richness	O
,	O
with	O
decreased	O
abundances	O
of	O
Faecalibacterium	O
,	O
Roseburia	O
,	O
and	O
Eubacterium	O
rectale	O
(	O
the	O
butyrate	O
producers	O
)	O
and	O
increased	O
abundances	O
of	O
Escherichia	O
-	O
Shigella	O
and	O
Enterococcus	O
.	O
More	O
recently	O
,	O
in	O
order	O
to	O
test	O
whether	O
gut	O
microbiome	O
could	O
be	O
potentially	O
used	O
for	O
diagnostic	O
screening	O
of	O
CVD	O
,	O
Aryal	O
et	O
al	O
.	O
(	O
2020	O
)	O
applied	O
five	O
different	O
AI	O
/	O
ML	O
approaches	O
(	O
RF	O
,	O
SVM	O
,	O
DT	O
,	O
Elastic	O
-	O
Net	O
and	O
Neural	O
Networks	O
)	O
to	O
the	O
gut	O
microbiome	O
relative	O
abundances	O
of	O
478	O
CVD	O
patients	O
vs	O
.	O
473	O
healthy	O
controls	O
,	O
collected	O
as	O
part	O
of	O
the	O
American	O
Gut	O
Project	O
[	O
https	O
:	O
/	O
/	O
microsetta	O
.	O
ucsd	O
.	O
edu	O
/	O
american	O
-	O
gut	O
-	O
project	O
/	O
]	O
and	O
profiled	O
using	O
fecal	O
16S	O
ribosomal	O
RNA	O
sequencing	O
.	O

However	O
,	O
when	O
using	O
39	O
differential	O
bacterial	O
taxa	O
as	O
features	O
,	O
the	O
best	O
AUC	O
this	O
study	O
could	O
achieve	O
was	O
AUC	O
~	O
0	O
.	O
58	O
(	O
with	O
Neural	O
Networks	O
)	O
,	O
followed	O
by	O
Elastic	O
-	O
Net	O
(	O
AUC	O
~	O
0	O
.	O
57	O
)	O
,	O
SVM	O
(	O
AUC	O
~	O
0	O
.	O
55	O
)	O
and	O
DT	O
(	O
AUC	O
~	O
0	O
.	O
51	O
)	O
.	O
Interestingly	O
,	O
the	O
performance	O
of	O
RF	O
significantly	O
improved	O
(	O
AUC	O
~	O
0	O
.	O
65	O
)	O
when	O
trained	O
with	O
the	O
top	O
500	O
high	O
-	O
variance	O
OTU	O
features	O
,	O
instead	O
of	O
taxonomic	O
features	O
,	O
whereas	O
the	O
AUC	O
of	O
Neural	O
Networks	O
dropped	O
(	O
AUC	O
~	O
0	O
.	O
48	O
)	O
.	O
Furthermore	O
,	O
highly	O
contributing	O
OTU	O
features	O
(	O
HCOFs	O
)	O
were	O
selected	O
based	O
on	O
their	O
variable	O
importance	O
(	O
0	O
–	O
100	O
,	O
where	O
0	O
:	O
no	O
contribution	O
to	O
the	O
model	O
and	O
100	O
:	O
max	O
contribution	O
to	O
the	O
model	O
)	O
to	O
further	O
reduce	O
the	O
dimensionality	O
of	O
the	O
OTU	O
feature	O
space	O
.	O
The	O
top	O
100	O
HCOFs	O
with	O
the	O
highest	O
scores	O
were	O
selected	O
for	O
training	O
the	O
RF	O
model	O
.	O
As	O
a	O
result	O
,	O
the	O
RF	O
models	O
trained	O
with	O
the	O
top	O
20	O
and	O
top	O
25	O
HCOFs	O
achieved	O
further	O
improved	O
performance	O
(	O
AUC	O
~	O
0	O
.	O
70	O
)	O
.	O
It	O
can	O
be	O
assumed	O
that	O
particular	O
diets	O
,	O
such	O
as	O
those	O
high	O
in	O
fats	O
and	O
/	O
or	O
sugars	O
might	O
lead	O
to	O
variations	O
in	O
the	O
gut	O
microbiome	O
composition	O
and	O
changes	O
in	O
its	O
functional	O
capacity	O
that	O
potentially	O
might	O
facilitate	O
the	O
development	O
of	O
diseases	O
,	O
including	O
metabolic	O
disorders	O
such	O
as	O
obesity	O
,	O
insulin	O
resistance	O
and	O
atherosclerosis	O
/	O
CVD	O
(	O
Sanchez	O
-	O
Rodriguez	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Despite	O
the	O
close	O
link	O
between	O
our	O
diet	O
and	O
gut	O
microbiome	O
,	O
the	O
number	O
of	O
studies	O
collecting	O
and	O
analyzing	O
both	O
types	O
of	O
data	O
is	O
sparse	O
and	O
either	O
not	O
considering	O
the	O
full	O
spectrum	O
of	O
dietary	O
factors	O
(	O
Lu	O
et	O
al	O
.	O
,	O
2017	O
)	O
or	O
not	O
directly	O
addressing	O
the	O
prediction	O
of	O
CVD	O
/	O
CAD	O
risk	O
(	O
Zeevi	O
et	O
al	O
.	O
,	O
2015	O
;	O
Venkataraman	O
et	O
al	O
.	O
,	O
2016	O
;	O
Spector	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O

Zeevi	O
et	O
al	O
.	O
(	O
2015	O
)	O
used	O
a	O
the	O
GB	O
approach	O
to	O
investigate	O
whether	O
individuals	O
'	O
gut	O
microbiome	O
profiles	O
in	O
combination	O
with	O
several	O
other	O
sources	O
of	O
information	O
(	O
blood	O
parameters	O
,	O
anthropometrics	O
,	O
self	O
-	O
reported	O
lifestyle	O
behaviors	O
and	O
physical	O
activity	O
)	O
could	O
predict	O
glucose	O
levels	O
in	O
response	O
to	O
standardized	O
and	O
real	O
-	O
life	O
meals	O
in	O
a	O
cohort	B-methodology
of	O
800	O
overweight	O
or	O
obese	O
non	O
-	O
diabetic	O
individuals	O
,	O
observing	O
high	O
inter	O
-	O
individual	O
variability	O
,	O
even	O
in	O
response	O
to	O
identical	O
meals	O
,	O
suggesting	O
that	O
dietary	O
recommendations	O
need	O
to	O
be	O
personalized	O
.	O
Later	O
,	O
these	O
predictions	O
were	O
validated	O
by	O
Mendes	O
-	O
Soares	O
et	O
al	O
.	O
(	O
2019	O
)	O
in	O
an	O
independent	O
cohort	B-methodology
of	O
327	O
individuals	O
and	O
by	O
Korem	O
et	O
al	O
.	O
(	O
2017	O
)	O
,	O
when	O
focusing	O
on	O
the	O
consumption	O
of	O
sourdough	O
-	O
leavened	O
whole	O
-	O
grain	O
bread	O
vs	O
.	O
industrially	O
made	O
white	O
bread	O
,	O
also	O
using	O
the	O
GB	O
approach	O
.	O
In	O
the	O
latter	O
case	O
,	O
the	O
relative	O
abundances	O
of	O
Coprobacter	O
fastidiosus	O
and	O
Lachnospiraceae	O
bacterium	O
were	O
among	O
the	O
most	O
informative	O
features	O
.	O
Venkataraman	O
et	O
al	O
.	O
(	O
2016	O
)	O
used	O
RF	O
to	O
predict	O
whether	O
the	O
gut	O
microbiome	O
composition	O
of	O
individuals	O
can	O
predict	O
their	O
response	O
to	O
dietary	O
supplementation	O
with	O
resistant	O
starch	O
,	O
as	O
measured	O
using	O
fecal	O
butyrate	O
concentrations	O
.	O
This	O
study	O
could	O
identify	O
three	O
different	O
response	O
groups	O
—	O
enhanced	O
,	O
high	O
and	O
low	O
,	O
and	O
could	O
attribute	O
these	O
differences	O
to	O
the	O
increase	O
of	O
starch	O
-	O
degrading	O
bacteria	O
Bifidobacterium	O
adolescentis	O
and	O
Ruminococcus	O
bromii	O
in	O
the	O
enhanced	O
and	O
high	O
,	O
but	O
not	O
in	O
the	O
low	O
fecal	O
butyrate	O
concentration	O
group	O
.	O
Spector	O
et	O
al	O
.	O
(	O
2019	O
)	O
,	O
as	O
part	O
of	O
the	O
PREDICT	O
study	O
[	O
http	O
:	O
/	O
/	O
www	O
.	O
tim	O
-	O
spector	O
.	O
co	O
.	O
uk	O
/	O
predict	O
/	O
]	O
,	O
is	O
actively	O
working	O
toward	O
personalized	O
nutrition	O
tools	O
by	O
systematically	O
analyzing	O
the	O
diet	O
-	O
induced	O
gut	O
microbiome	O
changes	O
using	O
AI	O
/	O
ML	O
approaches	O
in	O
order	O
to	O
stratify	O
individual	O
responses	O
to	O
dietary	B-methodology
interventions	I-methodology
based	O
on	O
the	O
individual	O
'	O
s	O
gut	O
microbiome	O
and	O
develop	O
standardized	O
protocols	O
for	O
the	O
purpose	O
.	O
Among	O
others	O
,	O
this	O
study	O
has	O
demonstrated	O
that	O
shotgun	O
metagenomic	O
sequencing	O
may	O
be	O
more	O
accurate	O
than	O
16S	O
rRNA	O
amplicon	O
sequencing	O
,	O
as	O
it	O
allows	O
also	O
capturing	O
individual	O
-	O
specific	O
strain	O
-	O
level	O
features	O
,	O
thus	O
improving	O
the	O
stratification	O
.	O

In	O
the	O
context	O
of	O
CVD	O
/	O
CAD	O
risk	O
prediction	O
,	O
most	O
studies	O
have	O
focused	O
on	O
the	O
circulating	O
levels	O
of	O
the	O
diet	O
-	O
and	O
gut	O
microbiota	O
-	O
dependent	O
metabolite	O
trimethylamine	O
-	O
N	O
-	O
oxide	O
(	O
TMAO	O
)	O
(	O
Trøseid	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Lu	O
et	O
al	O
.	O
(	O
2017	O
)	O
used	O
RF	O
and	O
the	O
gut	O
microbiome	O
data	O
to	O
predict	O
changes	O
of	O
TMAO	O
levels	O
after	O
choline	O
intake	O
,	O
as	O
a	O
potential	O
approach	O
for	O
screening	O
population	O
at	O
high	O
risk	O
of	O
CVD	O
and	O
identified	O
the	O
beta	O
(	O
inter	O
-	O
individual	O
)	O
diversity	O
of	O
the	O
gut	O
microbiome	O
as	O
a	O
significant	O
predictor	O
(	O
AUC	O
of	O
0	O
.	O
86	O
)	O
of	O
increased	O
vs	O
.	O
decreased	O
plasma	O
TMAO	O
level	O
.	O
Timely	O
and	O
precise	O
identification	O
of	O
people	O
at	O
high	O
risk	O
of	O
CAD	O
is	O
of	O
utmost	O
importance	O
for	O
the	O
development	O
of	O
personalized	O
treatment	O
strategies	O
(	O
Alaa	O
et	O
al	O
.	O
,	O
2019	O
;	O
Westerlund	O
et	O
al	O
.	O
,	O
2021	O
)	O
,	O
as	O
such	O
persons	O
may	O
need	O
more	O
aggressive	O
health	O
promotion	O
strategies	O
,	O
especially	O
the	O
modifiable	O
CAD	O
risk	O
factors	O
could	O
be	O
effectively	O
reduced	O
or	O
even	O
eliminated	O
in	O
this	O
way	O
(	O
Movsisyan	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Although	O
,	O
numerous	O
algorithms	O
for	O
CAD	O
risk	O
prediction	O
have	O
been	O
developed	O
over	O
the	O
years	O
and	O
several	O
have	O
also	O
entered	O
the	O
clinical	O
routine	O
(	O
FRS	O
Wilson	O
et	O
al	O
.	O
,	O
1998	O
,	O
SCORE	O
Conroy	O
et	O
al	O
.	O
,	O
2003	O
)	O
,	O
these	O
are	O
typically	O
based	O
on	O
a	O
limited	O
number	O
of	O
traditional	O
CAD	O
risk	O
factors	O
(	O
age	O
,	O
sex	O
,	O
diabetes	O
,	O
LDL	O
and	O
HDL	O
cholesterol	O
,	O
smoking	O
,	O
systolic	O
blood	O
pressure	O
)	O
and	O
are	O
not	O
suitable	O
across	O
all	O
patient	O
groups	O
(	O
Alaa	O
et	O
al	O
.	O
,	O
2019	O
)	O
and	O
do	O
not	O
take	O
into	O
account	O
the	O
fact	O
that	O
by	O
modifying	O
the	O
person	O
'	O
s	O
environment	O
/	O
lifestyle	O
the	O
disease	O
risk	O
could	O
be	O
reduced	O
over	O
time	O
(	O
Westerlund	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
The	O
added	O
value	O
of	O
AI	O
/	O
ML	O
approaches	O
in	O
CAD	O
diagnostics	O
has	O
been	O
explored	O
before	O
,	O
however	O
,	O
so	O
far	O
,	O
most	O
of	O
this	O
research	O
has	O
focused	O
on	O
the	O
usage	O
of	O
clinical	O
data	O
and	O
medical	O
images	O
(	O
Alizadehsani	O
et	O
al	O
.	O
,	O
2019	O
)	O
,	O
thus	O
providing	O
no	O
information	O
on	O
the	O
molecular	O
bases	O
of	O
a	O
disease	O
(	O
Westerlund	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
A	O
small	O
number	O
of	O
studies	O
has	O
used	O
genomic	O
data	O
have	O
been	O
used	O
in	O
combination	O
with	O
AI	O
/	O
ML	O
for	O
CAD	O
risk	O
prediction	O
(	O
Gola	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O

However	O
,	O
AI	O
/	O
ML	O
approaches	O
underperformed	O
in	O
comparison	O
to	O
a	O
simple	O
PRS	O
,	O
assuming	O
linear	O
additive	O
effects	O
(	O
Gola	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
This	O
is	O
were	O
additional	O
data	O
layers	O
such	O
dietary	O
factors	O
and	O
gut	O
microbiome	O
,	O
as	O
an	O
integrator	O
of	O
this	O
information	O
(	O
Bashiardes	O
et	O
al	O
.	O
,	O
2018	O
;	O
Eetemadi	O
et	O
al	O
.	O
,	O
2020	O
)	O
,	O
come	O
in	O
.	O
However	O
,	O
only	O
a	O
few	O
studies	O
so	O
far	O
have	O
used	O
dietary	O
factors	O
(	O
Alaa	O
et	O
al	O
.	O
,	O
2019	O
;	O
Rigdon	O
and	O
Basu	O
,	O
2019	O
)	O
or	O
gut	O
microbiome	O
(	O
Zhu	O
et	O
al	O
.	O
,	O
2018	O
;	O
Aryal	O
et	O
al	O
.	O
,	O
2020	O
)	O
,	O
and	O
no	O
studies	O
using	O
both	O
[	O
the	O
closest	O
being	O
(	O
Zeevi	O
et	O
al	O
.	O
,	O
2015	O
)	O
related	O
to	O
blood	O
glucose	O
levels	O
]	O
,	O
in	O
combination	O
with	O
AI	O
/	O
ML	O
for	O
CAD	O
risk	O
prediction	O
.	O
We	O
further	O
discuss	O
these	O
few	O
studies	O
and	O
also	O
consider	O
closely	O
related	O
research	O
on	O
dietary	O
factors	O
,	O
gut	O
micorbiome	O
and	O
combinations	O
of	O
both	O
in	O
other	O
disease	O
settings	O
vs	O
.	O
healthy	O
individuals	O
.	O
With	O
the	O
advent	O
of	O
wearable	O
biosensors	O
connected	O
to	O
mobile	O
applications	O
,	O
large	B-methodology
-	I-methodology
scale	I-methodology
longitudinal	I-methodology
food	O
diaries	O
and	O
images	O
of	O
meals	O
consumed	O
will	O
become	O
increasingly	O
available	O
providing	O
a	O
valuable	O
data	O
source	O
for	O
such	O
investigations	O
(	O
Munos	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
The	O
future	O
vision	O
for	O
personalized	O
nutrition	O
has	O
led	O
to	O
great	O
interest	O
for	O
advancements	O
in	O
the	O
diagnostics	O
and	O
decision	O
support	O
systems	O
(	O
DSS	O
)	O
that	O
would	O
allow	O
continuous	O
assessment	O
of	O
individual	O
'	O
s	O
dietary	O
features	O
,	O
in	O
conjunction	O
with	O
gut	O
microbiome	O
composition	O
and	O
additional	O
information	O
,	O
such	O
as	O
access	O
to	O
the	O
electronic	O
health	O
record	O
(	O
EHR	O
)	O
and	O
lifestyle	O
and	O
environment	O
information	O
,	O
physical	O
activity	O
from	O
the	O
biosensors	O
and	O
wearable	O
health	O
technology	O
.	O
All	O
of	O
it	O
would	O
aid	O
in	O
forming	O
tailored	O
recommendations	O
such	O
as	O
choosing	O
an	O
optimal	O
meal	O
for	O
lowering	O
post	O
-	O
meal	O
glucose	O
levels	O
(	O
as	O
shown	O
by	O
Zeevi	O
et	O
al	O
.	O
,	O
2015	O
)	O
in	O
patients	O
with	O
T2D	O
.	O
Although	O
,	O
the	O
recent	O
re	O
-	O
emergence	O
of	O
AI	O
/	O
ML	O
approaches	O
is	O
opening	O
intriguing	O
perspectives	O
in	O
this	O
direction	O
,	O
it	O
must	O
be	O
remembered	O
that	O
these	O
data	O
-	O
driven	O
technologies	O
and	O
their	O
predictions	O
strongly	O
depend	O
on	O
the	O
quantity	O
and	O
quality	O
of	O
the	O
input	O
data	O
.	O
In	O
this	O
regard	O
,	O
several	O
limitations	O
to	O
the	O
current	O
food	O
intake	O
and	O
composition	O
databases	O
have	O
been	O
observed	O
.	O
Apparently	O
,	O
these	O
databases	O
currently	O
contain	O
only	O
0	O
.	O
5	O
%	O
of	O
the	O
known	O
nutritional	O
compounds	O
(	O
Eetemadi	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O

Another	O
issue	O
is	O
the	O
data	O
standardization	O
,	O
which	O
is	O
challenging	O
as	O
complex	O
dietary	O
patterns	O
need	O
to	O
be	O
captured	O
in	O
an	O
organized	O
manner	O
,	O
translating	O
chemicals	O
constituents	O
of	O
the	O
food	O
into	O
the	O
intake	O
of	O
energy	O
and	O
nutrients	O
(	O
Verma	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
Currently	O
,	O
the	O
most	O
widely	O
applied	O
methods	O
of	O
food	O
intake	O
monitoring	O
include	O
the	O
food	O
diaries	O
,	O
which	O
make	O
it	O
difficult	O
to	O
convert	O
the	O
food	O
descriptions	O
into	O
the	O
energy	O
.	O
Additional	O
challenges	O
arise	O
when	O
the	O
food	O
is	O
collected	O
from	O
different	O
sources	O
,	O
i	O
.	O
e	O
.	O
,	O
individual	O
and	O
/	O
or	O
hospital	O
-	O
based	O
sources	O
.	O
The	O
missing	O
data	O
problem	O
could	O
be	O
partly	O
addressed	O
through	O
improved	O
data	O
imputation	O
techniques	O
,	O
which	O
should	O
be	O
complemented	O
by	O
improved	O
food	O
intake	O
monitoring	O
and	O
data	O
collection	O
methods	O
,	O
creating	O
integrated	O
databases	O
with	O
defined	O
standard	O
formats	O
for	O
annotation	O
and	O
classification	O
,	O
considering	O
the	O
FAIR	O
(	O
Findability	O
,	O
Accessibility	O
,	O
Interoperability	O
,	O
and	O
Reuse	O
)	O
data	O
principles	O
[	O
https	O
:	O
/	O
/	O
www	O
.	O
go	O
-	O
fair	O
.	O
org	O
/	O
fair	O
-	O
principles	O
/	O
]	O
.	O
Initiatives	O
such	O
as	O
the	O
EuroDISH	O
project	O
[	O
https	O
:	O
/	O
/	O
www	O
.	O
eurofir	O
.	O
org	O
/	O
our	O
-	O
resources	O
/	O
past	O
-	O
projects	O
/	O
eurodish	O
/	O
]	O
are	O
already	O
working	O
in	O
this	O
direction	O
.	O
There	O
are	O
a	O
number	O
of	O
challenges	O
and	O
limitations	O
related	O
to	O
the	O
application	O
of	O
AI	O
/	O
ML	O
approaches	O
for	O
microbiome	O
studies	O
,	O
as	O
thoroughly	O
and	O
systematically	O
summarized	O
in	O
several	O
literature	B-methodology
reviews	I-methodology
(	O
Marcos	O
-	O
Zambrano	O
et	O
al	O
.	O
,	O
2021	O
;	O
Moreno	O
-	O
Indias	O
et	O
al	O
.	O
,	O
2021	O
)	O
by	O
the	O
members	O
of	O
the	O
COST	O
Action	O
CA18131	O
“	O
ML4Microbiome	O
”	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
cost	O
.	O
eu	O
/	O
actions	O
/	O
CA18131	O
/	O
)	O
,	O
bringing	O
together	O
AI	O
/	O
ML	O
experts	O
and	O
microbiome	O
researchers	O
.	O
Overall	O
,	O
similar	O
to	O
other	O
high	O
-	O
throughput	O
studies	O
,	O
one	O
of	O
the	O
main	O
limitations	O
in	O
current	O
research	O
has	O
been	O
the	O
usage	O
of	O
inappropriate	O
study	B-methodology
design	I-methodology
,	O
including	O
small	O
datasets	O
and	O
lack	O
of	O
additional	O
data	O
to	O
estimate	O
confounding	O
effects	O
,	O
especially	O
considering	O
the	O
well	O
-	O
known	O
huge	O
variations	O
in	O
microbiome	O
composition	O
across	O
individuals	O
and	O
body	O
sites	O
and	O
their	O
strong	O
dependence	O
on	O
the	O
environment	O
/	O
lifestyle	O
factors	O
such	O
as	O
geographic	O
location	O
,	O
diet	O
and	O
medications	O
(	O
Marcos	O
-	O
Zambrano	O
et	O
al	O
.	O
,	O
2021	O
;	O
Moreno	O
-	O
Indias	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O

In	O
order	O
to	O
identify	O
generalized	O
responses	O
,	O
a	O
much	O
larger	O
number	O
of	O
individuals	O
spanning	O
a	O
range	O
of	O
microbiome	O
types	O
and	O
a	O
careful	O
adjustment	O
for	O
potential	O
confounding	O
effects	O
would	O
be	O
required	O
(	O
Johnson	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
In	O
addition	O
,	O
a	O
number	O
of	O
data	O
processing	O
/	O
statistical	O
and	O
AI	O
/	O
ML	O
challenges	O
have	O
been	O
observed	O
,	O
such	O
as	O
the	O
selection	O
of	O
appropriate	O
normalization	O
methods	O
to	O
address	O
the	O
variability	O
in	O
raw	O
read	O
counts	O
,	O
inappropriate	O
distributional	O
assumptions	O
considering	O
the	O
data	O
sparsity	O
,	O
compositional	O
nature	O
and	O
complex	O
and	O
hierarchical	O
dependency	O
structures	O
,	O
the	O
choice	O
of	O
suitable	O
feature	O
selection	O
approaches	O
,	O
i	O
.	O
e	O
.	O
,	O
requiring	O
customized	O
analytical	O
approaches	O
(	O
Eetemadi	O
et	O
al	O
.	O
,	O
2020	O
;	O
Marcos	O
-	O
Zambrano	O
et	O
al	O
.	O
,	O
2021	O
;	O
Moreno	O
-	O
Indias	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
In	O
fact	O
,	O
successful	O
examples	O
often	O
present	O
a	O
combination	O
of	O
different	O
statistical	O
approaches	O
,	O
specifically	O
tailored	O
to	O
the	O
characteristics	O
of	O
different	O
data	O
types	O
(	O
Marcos	O
-	O
Zambrano	O
et	O
al	O
.	O
,	O
2021	O
;	O
Moreno	O
-	O
Indias	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
On	O
top	O
of	O
that	O
the	O
dependence	O
on	O
the	O
reference	O
databases	O
is	O
a	O
well	O
-	O
known	O
major	O
limitation	O
of	O
the	O
sequence	O
alignment	O
-	O
based	O
approaches	O
,	O
used	O
to	O
assign	O
taxa	O
in	O
sequencing	O
studies	O
(	O
Chaudhary	O
et	O
al	O
.	O
,	O
2015	O
;	O
Vilne	O
et	O
al	O
.	O
,	O
2019	O
)	O
,	O
resulting	O
in	O
large	O
numbers	O
of	O
uncharacterized	O
microbes	O
(	O
the	O
“	O
microbial	O
dark	O
matter	O
”	O
)	O
(	O
Marcos	O
-	O
Zambrano	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
Finally	O
,	O
the	O
field	O
of	O
high	O
-	O
throughput	O
sequencing	O
overall	O
needs	O
a	O
rigorous	O
assessment	O
,	O
benchmarking	O
and	O
standardization	O
of	O
approaches	O
and	O
tools	O
(	O
Vilne	O
et	O
al	O
.	O
,	O
2019	O
)	O
,	O
to	O
allow	O
cross	B-methodology
-	I-methodology
study	I-methodology
comparisons	O
and	O
modeling	O
(	O
Marcos	O
-	O
Zambrano	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
Currently	O
,	O
the	O
integration	O
of	O
microbiome	O
data	O
across	O
several	O
studies	O
is	O
difficult	O
due	O
to	O
the	O
above	O
mentioned	O
factors	O
,	O
as	O
well	O
as	O
the	O
differences	O
in	O
sample	O
collection	O
,	O
storage	O
and	O
processing	O
protocols	O
in	O
the	O
wet	O
-	O
lab	O
,	O
which	O
may	O
introduce	O
biases	O
(	O
Eetemadi	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Hence	O
,	O
all	O
findings	O
should	O
be	O
validated	O
,	O
e	O
.	O
g	O
.	O
,	O
using	O
quantitative	O
PCR	O
(	O
Jian	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O

Finally	O
,	O
also	O
for	O
these	O
data	O
,	O
the	O
above	O
mentioned	O
FAIR	O
data	O
principles	O
should	O
be	O
widely	O
incorporated	O
[	O
https	O
:	O
/	O
/	O
www	O
.	O
go	O
-	O
fair	O
.	O
org	O
/	O
fair	O
-	O
principles	O
/	O
]	O
to	O
facilitate	O
such	O
efforts	O
.	O
For	O
more	O
details	O
we	O
refer	O
the	O
reader	O
to	O
Marcos	O
-	O
Zambrano	O
et	O
al	O
.	O
(	O
2021	O
)	O
;	O
Moreno	O
-	O
Indias	O
et	O
al	O
.	O
(	O
2021	O
)	O
.	O
However	O
,	O
we	O
note	O
that	O
these	O
current	O
limitations	O
related	O
to	O
microbiome	O
studies	O
are	O
posing	O
additional	O
challenges	O
for	O
CAD	O
risk	O
prediction	O
.	O
Moreover	O
,	O
several	O
studies	O
have	O
shown	O
that	O
the	O
inter	O
-	O
individual	O
responses	O
to	O
dietary	O
factors	O
may	O
differ	O
,	O
mostly	O
due	O
to	O
the	O
differences	O
in	O
the	O
gut	O
microbiome	O
composition	O
(	O
Zeevi	O
et	O
al	O
.	O
,	O
2015	O
;	O
Korem	O
et	O
al	O
.	O
,	O
2017	O
;	O
Mendes	O
-	O
Soares	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
However	O
,	O
especially	O
in	O
the	O
context	O
of	O
multi	O
-	O
factorial	O
diseases	O
,	O
such	O
as	O
CAD	O
,	O
the	O
differences	O
in	O
individual	O
genetic	O
predisposition	O
(	O
Nikpay	O
et	O
al	O
.	O
,	O
2015	O
;	O
Nelson	O
et	O
al	O
.	O
,	O
2017	O
)	O
and	O
its	O
down	O
-	O
stream	O
implications	O
(	O
Brænne	O
et	O
al	O
.	O
,	O
2015	O
;	O
Vilne	O
et	O
al	O
.	O
,	O
2017	O
;	O
Lempiäinen	O
et	O
al	O
.	O
,	O
2018	O
;	O
Vilne	O
and	O
Schunkert	O
,	O
2018	O
)	O
in	O
addition	O
to	O
variations	O
in	O
other	O
(	O
besides	O
diet	O
)	O
environmental	O
and	O
lifestyle	O
factors	O
such	O
as	O
physical	O
activity	O
,	O
stress	O
and	O
sleep	O
may	O
play	O
and	O
important	O
role	O
in	O
these	O
responses	O
(	O
Khera	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
Hence	O
,	O
emphasizing	O
the	O
need	O
to	O
collect	O
a	O
wide	O
variety	O
of	O
measures	O
in	O
large	O
populations	O
that	O
would	O
allow	O
for	O
stratification	O
of	O
patients	O
in	O
sub	O
-	O
groups	O
and	O
perform	O
longitudinal	O
sampling	O
to	O
also	O
capture	O
the	O
dynamics	O
of	O
these	O
responses	O
.	O
Endeavors	O
to	O
standardize	O
the	O
study	O
protocols	O
have	O
already	O
started	O
(	O
Spector	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
benchmark	O
investigations	O
have	O
demonstrated	O
that	O
,	O
whether	O
a	O
particular	O
AI	O
/	O
ML	O
approach	O
would	O
actually	O
improve	O
the	O
predictions	O
compared	O
to	O
conventional	O
approaches	O
,	O
may	O
depended	O
on	O
the	O
specific	O
dataset	O
at	O
hand	O
(	O
Westerlund	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
For	O
example	O
,	O
in	O
microbiome	O
studies	O
,	O
DL	O
approaches	O
have	O
been	O
demonstrated	O
to	O
underperform	O
in	O
comparison	O
to	O
GB	O
,	O
possibly	O
due	O
to	O
the	O
potentially	O
large	O
variability	O
in	O
the	O
relative	O
importance	O
of	O
different	O
input	O
features	O
.	O
To	O
overcome	O
this	O
limitation	O
,	O
Ira	O
Shavitt	O
(	O
2018	O
)	O
have	O
proposed	O
an	O
approach	O
called	O
Regularization	O
of	O
Learning	O
Networks	O
(	O
RLN	O
)	O
.	O

They	O
used	O
it	O
to	O
predict	O
a	O
number	O
of	O
traits	O
related	O
to	O
disease	O
risk	O
,	O
such	O
as	O
cholesterol	O
levels	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
from	O
the	O
gut	O
microbiome	O
data	O
of	O
2	O
,	O
574	O
healthy	O
individuals	O
.	O
They	O
evaluated	O
four	O
different	O
AI	O
/	O
ML	O
approaches	O
[	O
RLN	O
,	O
GB	O
,	O
DL	O
,	O
and	O
Linear	O
Models	O
(	O
LM	O
)	O
]	O
and	O
,	O
although	O
,	O
GB	O
still	O
outperformed	O
the	O
other	O
three	O
,	O
RLN	O
performed	O
significantly	O
better	O
than	O
DL	O
(	O
15	O
%	O
vs	O
.	O
ca	O
.	O
2	O
%	O
less	O
explained	O
variance	O
than	O
GB	O
on	O
average	O
)	O
.	O
Currently	O
,	O
the	O
number	O
of	O
studies	O
investigating	O
the	O
potential	O
of	O
gut	O
-	O
microbiome	O
in	O
combination	O
with	O
AI	O
/	O
ML	O
to	O
predict	O
CVD	O
risk	O
is	O
limited	O
(	O
Aryal	O
et	O
al	O
.	O
,	O
2020	O
)	O
an	O
so	O
is	O
the	O
prediction	O
power	O
of	O
these	O
models	O
,	O
with	O
a	O
max	O
AUC	O
of	O
0	O
.	O
70	O
,	O
when	O
training	O
a	O
RF	O
model	O
with	O
the	O
top	O
25	O
highest	O
contributing	O
OTU	O
features	O
(	O
Aryal	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
However	O
,	O
it	O
must	O
be	O
noted	O
that	O
the	O
authors	O
did	O
not	O
normalize	O
the	O
OTU	O
data	O
across	O
all	O
the	O
samples	O
to	O
test	O
the	O
option	O
of	O
classifying	O
new	O
samples	O
without	O
the	O
need	O
for	O
repeated	O
processing	O
(	O
Aryal	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
In	O
addition	O
,	O
this	O
study	O
addressed	O
the	O
prediction	O
of	O
CVD	O
,	O
which	O
,	O
as	O
the	O
authors	O
themselves	O
recognize	O
(	O
Aryal	O
et	O
al	O
.	O
,	O
2020	O
)	O
includes	O
a	O
range	O
of	O
conditions	O
(	O
from	O
hypertension	O
and	O
atherosclerosis	O
to	O
CAD	O
)	O
.	O
Hence	O
,	O
these	O
predictions	O
may	O
improve	O
when	O
stratifying	O
CVD	O
patients	O
into	O
specific	O
disease	O
sub	O
-	O
types	O
.	O
Moreover	O
,	O
another	O
interesting	O
observation	O
from	O
this	O
study	O
is	O
the	O
fact	O
that	O
bacterial	O
taxonomic	O
features	O
achieved	O
a	O
lower	O
(	O
AUC	O
~	O
0	O
.	O
58	O
)	O
AUC	O
,	O
in	O
comparison	O
to	O
high	O
-	O
variance	O
OTU	O
features	O
(	O
AUC	O
~	O
0	O
.	O
65	O
)	O
,	O
and	O
especially	O
when	O
further	O
reducing	O
the	O
dimensionality	O
of	O
the	O
feature	O
space	O
by	O
pre	O
-	O
selecting	O
the	O
top	O
25	O
highest	O
contributing	O
OTU	O
features	O
(	O
AUC	O
~	O
0	O
.	O
70	O
)	O
(	O
Aryal	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
From	O
the	O
usage	O
in	O
clinical	O
routine	O
,	O
focusing	O
on	O
a	O
small	O
number	O
of	O
highly	O
contributing	O
OTUs	O
may	O
be	O
indeed	O
more	O
practical	O
,	O
analogous	O
to	O
the	O
handful	O
of	O
traditional	O
CAD	O
risk	O
factors	O
,	O
however	O
,	O
we	O
will	O
need	O
further	O
studies	O
to	O
arrive	O
replicate	O
these	O
findings	O
and	O
arrive	O
at	O
these	O
gut	O
microbiome	O
biomarkers	O
.	O

Furthermore	O
,	O
their	O
mechanistic	O
implications	O
in	O
CVD	O
need	O
to	O
be	O
further	O
investigated	O
(	O
Aryal	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Gut	O
microbiota	O
as	O
the	O
only	O
type	O
of	O
data	O
used	O
for	O
diagnostic	O
classification	O
of	O
non	O
-	O
CVD	O
vs	O
.	O
CVD	O
may	O
not	O
be	O
sufficient	O
Especially	O
,	O
considering	O
that	O
gut	O
microbiome	O
can	O
be	O
influenced	O
by	O
other	O
features	O
such	O
as	O
diet	O
and	O
medications	O
,	O
hence	O
these	O
data	O
should	O
be	O
always	O
collected	O
in	O
parallel	O
.	O
Clearly	O
,	O
AI	O
/	O
ML	O
(	O
especially	O
DL	O
approaches	O
due	O
to	O
their	O
capabilities	O
to	O
learn	O
from	O
input	O
raw	O
data	O
,	O
instead	O
of	O
using	O
hand	O
-	O
crafted	O
features	O
that	O
require	O
domain	O
expertise	O
,	O
Ching	O
et	O
al	O
.	O
,	O
2018	O
)	O
in	O
combination	O
with	O
timely	O
access	O
to	O
numerous	O
,	O
potentially	O
relevant	O
,	O
data	O
sources	O
[	O
e	O
.	O
g	O
.	O
,	O
gut	O
microbiome	O
and	O
genetic	O
data	O
,	O
in	O
addition	O
to	O
the	O
current	O
7	O
CVD	O
metrics	O
smoking	O
,	O
physical	O
activity	O
,	O
body	O
mass	O
index	O
,	O
blood	O
pressure	O
,	O
cholesterol	O
,	O
glucose	O
and	O
dietary	O
factors	O
(	O
Angell	O
et	O
al	O
.	O
,	O
2020	O
)	O
,	O
combined	O
with	O
longitudinal	O
clinical	O
data	O
from	O
electronic	O
health	O
records	O
(	O
Matlock	O
et	O
al	O
.	O
,	O
2013	O
;	O
Reynolds	O
et	O
al	O
.	O
,	O
2017	O
)	O
]	O
also	O
holds	O
a	O
great	O
promise	O
for	O
the	O
improvements	O
of	O
public	O
health	O
surveillance	O
systems	O
,	O
formulation	O
of	O
policies	O
by	O
forecasting	O
the	O
impact	O
of	O
a	O
factor	O
or	O
intervention	O
on	O
the	O
burden	O
of	O
disease	O
and	O
the	O
cost	O
of	O
care	O
,	O
and	O
to	O
propose	O
recommendations	O
to	O
stakeholders	O
(	O
medical	O
institutions	O
,	O
public	O
health	O
authorities	O
,	O
scientific	O
communities	O
)	O
enabling	O
public	O
health	O
action	O
and	O
measure	O
progress	O
with	O
the	O
aim	O
to	O
reduce	O
the	O
huge	O
socio	O
-	O
economic	O
burden	O
of	O
CVD	O
/	O
CAD	O
and	O
increase	O
healthy	O
life	O
expectancy	O
in	O
future	O
(	O
Angell	O
et	O
al	O
.	O
,	O
2020	O
;	O
Roger	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
The	O
same	O
is	O
true	O
for	O
the	O
implementation	O
of	O
personalized	O
decision	O
support	O
system	O
(	O
DSS	O
)	O
for	O
CAD	O
risk	O
prediction	O
and	O
patient	O
management	O
that	O
would	O
be	O
a	O
great	O
support	O
for	O
clinicians	O
in	O
health	O
care	O
.	O
However	O
,	O
despite	O
the	O
rapid	O
development	O
of	O
several	O
technologies	O
and	O
advancements	O
in	O
Big	O
Data	O
analytics	O
,	O
the	O
implementation	O
of	O
such	O
systems	O
that	O
would	O
integrate	O
comprehensive	O
health	O
and	O
related	O
data	O
(	O
such	O
as	O
genetic	O
variations	O
,	O
dietary	O
factors	O
,	O
gut	O
microbiome	O
)	O
to	O
provide	O
either	O
generalized	O
recommendations	O
for	O
public	O
health	O
surveillance	O
and	O
policy	O
makers	O
or	O
individual	O
recommendations	O
for	O
the	O
routine	O
clinical	B-methodology
practice	I-methodology
,	O
still	O
poses	O
a	O
number	O
of	O
challenges	O
that	O
will	O
need	O
to	O
be	O
overcame	O
first	O
,	O
in	O
order	O
to	O
move	O
toward	O
their	O
implementation	O
and	O
usability	O
in	O
practice	O
.	O

Overall	O
,	O
such	O
systems	O
will	O
need	O
to	O
deal	O
with	O
heterogeneous	O
datasets	O
and	O
we	O
will	O
require	O
a	O
rigorous	O
assessment	O
,	O
benchmarking	O
and	O
standardization	O
of	O
AI	O
/	O
ML	O
-	O
based	O
CVD	O
/	O
CAD	O
risk	O
prediction	O
models	O
,	O
ensuring	O
model	O
availability	O
and	O
extensive	O
multiple	O
external	O
validations	O
and	O
calibration	O
across	O
different	O
disease	O
outcomes	O
,	O
populations	O
(	O
in	O
men	O
and	O
women	O
separately	O
)	O
and	O
geographical	O
regions	O
via	O
head	O
-	O
to	O
-	O
head	O
comparisons	O
across	O
different	O
studies	O
and	O
model	O
impact	O
and	O
performance	O
generalizability	O
assessment	O
and	O
to	O
identify	O
potential	O
sources	O
of	O
heterogeneity	O
(	O
Damen	O
et	O
al	O
.	O
,	O
2016	O
;	O
Marcos	O
-	O
Zambrano	O
et	O
al	O
.	O
,	O
2021	O
;	O
Westerlund	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
Moreover	O
,	O
In	O
April	O
2016	O
,	O
the	O
European	O
Union	O
adopted	O
new	O
rules	O
regarding	O
the	O
use	O
of	O
personal	O
information	O
,	O
the	O
General	O
Data	O
Protection	O
Regulation	O
,	O
which	O
imposes	O
additional	O
legal	O
and	O
privacy	O
constraints	O
when	O
analyzing	O
sensitive	O
health	O
data	O
,	O
hence	O
model	O
training	O
will	O
need	O
to	O
be	O
accomplished	O
within	O
a	O
differential	O
privacy	O
framework	O
without	O
sharing	O
the	O
raw	O
data	O
(	O
e	O
.	O
g	O
.	O
,	O
federated	O
learning	O
)	O
and	O
considering	O
other	O
rules	O
regarding	O
the	O
use	O
of	O
personal	O
information	O
as	O
input	O
for	O
decision	O
-	O
making	O
approaches	O
,	O
such	O
as	O
the	O
‘	O
right	O
to	O
an	O
explanation	O
'	O
,	O
meaning	O
that	O
when	O
using	O
AI	O
/	O
ML	O
,	O
we	O
must	O
be	O
able	O
to	O
explain	O
how	O
a	O
decision	O
was	O
reached	O
,	O
especially	O
if	O
the	O
ground	O
-	O
truth	O
is	O
unknown	O
(	O
Ching	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
This	O
calls	O
for	O
the	O
AI	O
/	O
ML	O
models	O
to	O
be	O
human	O
-	O
interpretable	O
,	O
reliable	O
and	O
explainable	O
to	O
aid	O
the	O
formulation	O
guidelines	B-methodology
or	O
personalized	O
advice	O
on	O
treatment	O
strategy	O
,	O
or	O
even	O
prevention	O
,	O
plans	O
(	O
Ching	O
et	O
al	O
.	O
,	O
2018	O
;	O
Westerlund	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
In	O
any	O
case	O
,	O
the	O
AI	O
/	O
ML	O
tools	O
will	O
not	O
be	O
a	O
replacement	O
for	O
the	O
human	O
experts	O
,	O
who	O
are	O
still	O
an	O
integral	O
part	O
of	O
the	O
knowledge	O
discovery	O
process	O
,	O
hence	O
,	O
managing	O
huge	O
amounts	O
of	O
health	O
data	O
will	O
need	O
to	O
become	O
an	O
integral	O
part	O
of	O
future	O
medical	O
,	O
policy	O
making	O
and	O
research	O
activity	O
,	O
across	O
sub	O
-	O
disciplines	O
(	O
Moreira	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
BV	O
wrote	O
the	O
manuscript	O
.	O
[UNK]	O
,	O
IS	O
,	O
IL	O
,	O
AK	O
,	O
and	O
OV	O
participated	O
in	O
revising	O
and	O
editing	O
the	O
manuscript	O
.	O
All	O
authors	O
have	O
read	O
and	O
approved	O
the	O
final	O
version	O
of	O
the	O
manuscript	O
.	O
This	O
research	O
was	O
funded	O
by	O
the	O
Latvian	O
Council	O
of	O
Science	O
within	O
the	O
project	O
Gut	O
microbiome	O
composition	O
and	O
diversity	O
among	O
health	O
and	O
lifestyle	O
induced	O
dietary	O
regimen	O
,	O
project	O
No	O
.	O

lzp	O
-	O
2018	O
/	O
2	O
-	O
0266	O
.	O
The	O
authors	O
declare	O
that	O
the	O
research	O
was	O
conducted	O
in	O
the	O
absence	O
of	O
any	O
commercial	O
or	O
financial	O
relationships	O
that	O
could	O
be	O
construed	O
as	O
a	O
potential	O
conflict	O
of	O
interest	O
.	O
All	O
claims	O
expressed	O
in	O
this	O
article	O
are	O
solely	O
those	O
of	O
the	O
authors	O
and	O
do	O
not	O
necessarily	O
represent	O
those	O
of	O
their	O
affiliated	O
organizations	O
,	O
or	O
those	O
of	O
the	O
publisher	O
,	O
the	O
editors	O
and	O
the	O
reviewers	O
.	O
Any	O
product	O
that	O
may	O
be	O
evaluated	O
in	O
this	O
article	O
,	O
or	O
claim	O
that	O
may	O
be	O
made	O
by	O
its	O
manufacturer	O
,	O
is	O
not	O
guaranteed	O
or	O
endorsed	O
by	O
the	O
publisher	O
.	O

Integrating	O
omics	O
to	O
characterize	O
eco	O
‐	O
physiological	O
adaptations	O
:	O
How	O
moose	O
diet	O
and	O
metabolism	O
differ	O
across	O
biogeographic	O
zones	O
biomarker	O
;	O
DNA	O
‐	O
metabarcoding	O
;	O
energy	O
metabolism	O
;	O
metabolomics	O
;	O
nutritional	O
ecology	O
;	O
starvation	O
;	O
ungulate	O
With	O
accelerated	O
land	O
conversion	O
and	O
global	O
heating	O
at	O
northern	O
latitudes	O
,	O
it	O
becomes	O
crucial	O
to	O
understand	O
,	O
how	O
life	O
histories	O
of	O
animals	O
in	O
extreme	O
environments	O
adapt	O
to	O
these	O
changes	O
.	O
Animals	O
may	O
either	O
adapt	O
by	O
adjusting	O
foraging	O
behavior	O
or	O
through	O
physiological	O
responses	O
,	O
including	O
adjusting	O
their	O
energy	O
metabolism	O
or	O
both	O
.	O
Until	O
now	O
,	O
it	O
has	O
been	O
difficult	O
to	O
study	O
such	O
adaptations	O
in	O
free	O
‐	O
ranging	O
animals	O
due	O
to	O
methodological	O
constraints	O
that	O
prevent	O
extensive	O
spatiotemporal	O
coverage	O
of	O
ecological	O
and	O
physiological	O
data	O
.	O
Through	O
a	O
novel	O
approach	O
of	O
combining	O
DNA	O
‐	O
metabarcoding	O
and	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
‐	O
based	O
metabolomics	O
,	O
we	O
aim	O
to	O
elucidate	O
the	O
links	O
between	O
diets	O
and	O
metabolism	O
in	O
Scandinavian	O
moose	O
Alces	O
alces	O
over	O
three	O
biogeographic	O
zones	O
using	O
a	O
unique	O
dataset	O
of	O
265	O
marked	O
individuals	O
.	O
Based	O
on	O
17	O
diet	O
items	O
,	O
we	O
identified	O
four	O
different	O
classes	O
of	O
diet	O
types	O
that	O
match	O
browse	O
species	O
availability	O
in	O
respective	O
ecoregions	O
in	O
northern	O
Sweden	O
.	O
Individuals	O
in	O
the	O
boreal	O
zone	O
consumed	O
predominantly	O
pine	O
and	O
had	O
the	O
least	O
diverse	O
diets	O
,	O
while	O
individuals	O
with	O
highest	O
diet	O
diversity	O
occurred	O
in	O
the	O
coastal	O
areas	O
.	O
Males	O
exhibited	O
lower	O
average	O
diet	O
diversity	O
than	O
females	O
.	O
We	O
identified	O
several	O
molecular	O
markers	O
indicating	O
metabolic	O
constraints	O
linked	O
to	O
diet	O
constraints	O
in	O
terms	O
of	O
food	O
availability	O
during	O
winter	O
.	O
While	O
animals	O
consuming	O
pine	O
had	O
higher	O
lipid	O
,	O
phospocholine	O
,	O
and	O
glycerophosphocholine	O
concentrations	O
in	O
their	O
serum	O
than	O
other	O
diet	O
types	O
,	O
birch	O
‐	O
and	O
willow	O
/	O
aspen	O
‐	O
rich	O
diets	O
exhibit	O
elevated	O
concentrations	O
of	O
several	O
amino	O
acids	O
.	O
The	O
individuals	O
with	O
highest	O
diet	O
diversity	O
had	O
increased	O
levels	O
of	O
ketone	O
bodies	O
,	O
indicating	O
extensive	O
periods	O
of	O
starvation	O
for	O
these	O
individuals	O
.	O
Our	O
results	O
show	O
how	O
the	O
adaptive	O
capacity	O
of	O
moose	O
at	O
the	O
eco	O
‐	O
physiological	O
level	O
varies	O
over	O
a	O
large	O
eco	O
‐	O
geographic	O
scale	O
and	O
how	O
it	O
responds	O
to	O
land	O
use	O
pressures	O
.	O
In	O
light	O
of	O
extensive	O
ongoing	O
climate	O
and	O
land	O
use	O
changes	O
,	O
these	O
findings	O
pave	O
the	O
way	O
for	O
future	O
scenario	O
building	O
for	O
animal	O
adaptive	O
capacity	O
.	O
With	O
accelerated	O
land	O
conversion	O
and	O
global	O
heating	O
at	O
northern	O
latitudes	O
,	O
it	O
becomes	O
crucial	O
to	O
understand	O
,	O
how	O
life	O
histories	O
of	O
animals	O
in	O
extreme	O
environments	O
adapt	O
to	O
these	O
changes	O
.	O

By	O
integrating	O
omics	O
,	O
we	O
characterize	O
eco	O
‐	O
physiological	O
adaptations	O
that	O
show	O
how	O
moose	O
diet	O
and	O
metabolism	O
differ	O
across	O
three	O
biogeographic	O
zones	O
.	O
The	O
biomarkers	O
identified	O
in	O
this	O
study	O
pave	O
the	O
way	O
for	O
future	O
scenario	O
building	O
for	O
animal	O
adaptive	O
capacity	O
.	O
Global	O
heating	O
and	O
exploitation	O
of	O
natural	O
resources	O
are	O
affecting	O
ecosystems	O
globally	O
with	O
their	O
impacts	O
particularly	O
accelerated	O
and	O
elevated	O
at	O
high	O
latitudes	O
(	O
Berglöv	O
et	O
al	O
.	O
,	O
2015	O
;	O
Post	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
However	O
,	O
we	O
still	O
know	O
relatively	O
little	O
about	O
how	O
animals	O
in	O
northern	O
ecosystems	O
are	O
adapted	O
to	O
these	O
latitudes	O
and	O
how	O
they	O
may	O
adapt	O
to	O
changes	O
in	O
future	O
.	O
Spatio	O
‐	O
temporal	O
adaptations	O
of	O
animals	O
to	O
temperatures	O
,	O
snow	O
coverage	O
,	O
food	O
type	O
,	O
and	O
food	O
availability	O
may	O
provide	O
clues	O
to	O
how	O
these	O
organisms	O
would	O
react	O
to	O
climate	O
shifts	O
and	O
other	O
environmental	O
changes	O
caused	O
by	O
human	O
activity	O
(	O
Bronson	O
,	O
2009	O
;	O
Neumann	O
et	O
al	O
.	O
,	O
2020	O
;	O
Sheriff	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O
In	O
highly	O
seasonal	O
environments	O
,	O
animals	O
may	O
adapt	O
to	O
seasonal	O
constraints	O
by	O
reducing	O
metabolic	O
expenditure	O
in	O
combination	O
with	O
foraging	O
and	O
starvation	O
bouts	O
when	O
food	O
is	O
limited	O
(	O
McCue	O
,	O
2010	O
)	O
.	O
Starvation	O
and	O
adaptation	O
are	O
reflected	O
at	O
a	O
biochemical	O
level	O
that	O
can	O
be	O
assessed	O
by	O
measuring	O
metabolites	O
in	O
body	O
fluids	O
(	O
Pagano	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
Hence	O
,	O
metabolic	O
profiles	O
can	O
be	O
explored	O
to	O
(	O
a	O
)	O
understand	O
the	O
relationships	O
between	O
physiological	O
responses	O
and	O
environmental	O
factors	O
and	O
(	O
b	O
)	O
to	O
identify	O
specific	O
biomarkers	O
(	O
e	O
.	O
g	O
.	O
,	O
naturally	O
occurring	O
molecules	O
)	O
of	O
distinct	O
environmental	O
responses	O
,	O
and	O
(	O
c	O
)	O
monitor	O
the	O
uptake	O
of	O
trophic	O
biomarkers	O
in	O
individual	O
organisms	O
.	O
These	O
biomarkers	O
can	O
be	O
identified	O
and	O
evaluated	O
on	O
the	O
scale	O
of	O
entire	O
populations	O
or	O
ecosystems	O
(	O
Galloway	O
&	O
Budge	O
,	O
2020	O
)	O
.	O
In	O
recent	O
years	O
,	O
metabolomics	O
has	O
emerged	O
as	O
a	O
powerful	O
approach	O
to	O
understand	O
on	O
a	O
molecular	O
level	O
the	O
organismal	O
response	O
to	O
environmental	O
stress	O
and	O
to	O
identify	O
specific	O
biomarkers	O
for	O
distinct	O
pathologies	O
or	O
physiological	O
responses	O
to	O
environmental	O
change	O
(	O
Chiu	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
Nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
‐	O
based	O
metabolomics	O
has	O
become	O
an	O
ideal	O
method	O
for	O
such	O
studies	O
due	O
to	O
its	O
undiscriminating	O
character	O
which	O
allows	O
identification	O
and	O
quantification	O
of	O
all	O
major	O
metabolites	O
,	O
ease	O
of	O
sample	O
preparation	O
,	O
unmatched	O
cross	O
‐	O
laboratory	O
reproducibility	O
,	O
and	O
lack	O
of	O
sampling	O
bias	O
(	O
Beckonert	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

NMR	O
is	O
ideal	O
to	O
generate	O
hypotheses	O
involving	O
complex	O
environmental	O
stressors	O
for	O
which	O
the	O
mode	O
of	O
actions	O
is	O
still	O
unknown	O
(	O
Lankadurai	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O
The	O
potential	O
of	O
environmental	O
metabolomics	O
on	O
wild	O
free	O
‐	O
ranging	O
vertebrates	O
to	O
identify	O
biomarkers	O
based	O
on	O
demographic	O
variables	O
has	O
previously	O
been	O
demonstrated	O
in	O
Mongolian	O
gerbils	O
Meriones	O
unguiculatus	O
and	O
American	O
black	O
bears	O
Ursus	O
americanus	O
,	O
respectively	O
(	O
Niemuth	O
&	O
Stoskopf	O
,	O
2014	O
;	O
Shi	O
et	O
al	O
.	O
,	O
2015	O
)	O
.	O
The	O
vast	O
majority	O
of	O
animal	O
species	O
still	O
remains	O
unstudied	O
.	O
Metabolic	O
demands	O
and	O
environmental	O
constraints	O
also	O
lead	O
to	O
variation	O
in	O
individual	O
foraging	O
patterns	O
,	O
which	O
can	O
be	O
assessed	O
in	O
their	O
diets	O
.	O
DNA	O
‐	O
based	O
analysis	O
of	O
fecal	O
samples	O
using	O
metabarcoding	O
is	O
another	O
powerful	O
omics	O
approach	O
to	O
understand	O
fine	O
‐	O
scale	O
foraging	O
behavior	O
(	O
Kartzinel	O
et	O
al	O
.	O
,	O
2015	O
;	O
Kowalczyk	O
et	O
al	O
.	O
,	O
2019	O
;	O
Pansu	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
A	O
distinct	O
advantage	O
of	O
the	O
DNA	O
‐	O
metabarcoding	O
approach	O
is	O
its	O
independence	O
from	O
observer	O
bias	O
,	O
accurate	O
identification	O
of	O
species	O
and	O
efficiency	O
when	O
handling	O
large	O
sample	O
sizes	O
.	O
This	O
makes	O
this	O
approach	O
ideal	O
for	O
studying	O
fine	O
‐	O
scale	O
individual	O
variation	O
in	O
diets	O
across	O
large	O
spatial	O
and	O
temporal	O
scales	O
.	O
The	O
coupling	O
of	O
the	O
two	O
omics	O
approaches	O
(	O
DNA	O
‐	O
metabarcoding	O
and	O
NMR	O
‐	O
based	O
metabolomics	O
)	O
covering	O
both	O
high	O
taxonomic	O
diversity	O
as	O
well	O
as	O
high	O
functional	O
diversity	O
is	O
therefore	O
a	O
promising	O
way	O
to	O
determine	O
the	O
degree	O
at	O
which	O
diet	O
and	O
metabolic	O
responses	O
influence	O
each	O
other	O
and	O
to	O
what	O
extent	O
they	O
vary	O
across	O
individual	O
animals	O
(	O
Taberlet	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
These	O
linkages	O
may	O
provide	O
even	O
further	O
important	O
insights	O
on	O
the	O
consequences	O
of	O
foraging	O
and	O
physiological	O
adaptations	O
on	O
animal	O
demography	O
and	O
behavior	O
and	O
ultimately	O
their	O
population	O
persistence	O
.	O
Moose	O
Alces	O
alces	O
is	O
a	O
highly	O
relevant	O
model	O
species	O
to	O
understand	O
the	O
physiological	O
adaptations	O
of	O
an	O
animal	O
species	O
to	O
environmental	O
gradients	O
.	O
Moose	O
are	O
widely	O
distributed	O
across	O
the	O
northern	O
hemisphere	O
and	O
therefore	O
encounter	O
a	O
variety	O
of	O
eco	O
‐	O
geographic	O
zones	O
characterized	O
by	O
differences	O
in	O
climatic	O
conditions	O
,	O
topography	O
as	O
well	O
as	O
forage	O
species	O
(	O
Neumann	O
et	O
al	O
.	O
,	O
2020	O
;	O
Singh	O
et	O
al	O
.	O
,	O
2012	O
;	O
Spitzer	O
,	O
2019	O
)	O
.	O

They	O
experience	O
food	O
limitation	O
during	O
winter	O
due	O
to	O
extensive	O
snow	O
cover	O
(	O
Parikh	O
et	O
al	O
.	O
,	O
2017	O
;	O
Shipley	O
et	O
al	O
.	O
,	O
1998	O
)	O
and	O
hence	O
utilize	O
built	O
up	O
body	O
stores	O
(	O
Moen	O
et	O
al	O
.	O
,	O
1997	O
;	O
Parker	O
et	O
al	O
.	O
,	O
2009	O
)	O
as	O
well	O
as	O
reduce	O
activity	O
and	O
body	O
temperature	O
(	O
Allen	O
,	O
Dorey	O
,	O
et	O
al	O
.	O
,	O
2016	O
;	O
Græsli	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
The	O
energy	O
metabolism	O
of	O
moose	O
is	O
likely	O
influenced	O
by	O
forage	O
availability	O
and	O
local	O
habitat	O
composition	O
(	O
Felton	O
et	O
al	O
.	O
,	O
2020	O
;	O
Spitzer	O
,	O
2019	O
)	O
.	O
However	O
,	O
little	O
is	O
known	O
about	O
the	O
consequences	O
of	O
variation	O
in	O
diets	O
on	O
moose	O
physiology	O
,	O
and	O
the	O
energetic	O
costs	O
and	O
benefits	O
associated	O
with	O
different	O
diet	O
types	O
.	O
The	O
main	O
objective	O
of	O
this	O
study	O
is	O
to	O
characterize	O
the	O
physiological	O
and	O
dietary	O
adaptations	O
of	O
moose	O
across	O
a	O
biogeographic	O
gradient	O
.	O
This	O
crucial	O
bit	O
of	O
knowledge	O
will	O
pave	O
the	O
way	O
toward	O
predictions	O
on	O
the	O
future	O
survival	O
and	O
adaptive	O
capacity	O
of	O
moose	O
and	O
similar	O
,	O
widely	O
distributed	O
,	O
and	O
generalist	O
species	O
.	O
This	O
is	O
especially	O
important	O
in	O
light	O
of	O
climate	O
and	O
land	O
use	O
changes	O
,	O
such	O
as	O
resource	O
extraction	O
,	O
that	O
are	O
occurring	O
across	O
the	O
globe	O
.	O
The	O
study	O
area	O
covers	O
a	O
gradient	O
across	O
the	O
Swedish	O
sub	O
‐	O
Arctic	O
biome	O
(	O
Figure	O
1	O
)	O
,	O
between	O
18	O
.	O
4	O
–	O
24	O
.	O
0ºE	O
and	O
65	O
.	O
6	O
–	O
68	O
.	O
0ºN	O
,	O
and	O
spanning	O
altitudes	O
from	O
3	O
to	O
674	O
m	O
a	O
.	O
s	O
.	O
l	O
.	O
The	O
study	O
area	O
is	O
demarcated	O
into	O
“	O
montane	O
”	O
(	O
tundra	O
)	O
and	O
“	O
boreal	O
”	O
(	O
taiga	O
)	O
based	O
on	O
Ecoregions	O
2017	O
(	O
Dinerstein	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
Moose	O
was	O
captured	O
in	O
these	O
two	O
ecoregions	O
and	O
in	O
an	O
additional	O
area	O
around	O
the	O
archipelago	O
of	O
the	O
Bothnian	O
Bay	O
that	O
was	O
classified	O
as	O
“	O
coastal	O
.	O
”	O
While	O
mining	O
,	O
hydro	O
‐	O
and	O
wind	O
‐	O
power	O
plants	O
,	O
tourism	O
and	O
military	O
activities	O
are	O
among	O
the	O
dominating	O
land	O
use	O
factors	O
,	O
the	O
spatially	O
most	O
extensive	O
extractive	O
land	O
use	O
in	O
the	O
study	O
area	O
is	O
forestry	O
(	O
Fohringer	O
et	O
al	O
.	O
,	O
in	O
review	O
)	O
.	O

Scots	O
pine	O
(	O
Pinus	O
sylvestris	O
)	O
is	O
the	O
dominant	O
commercially	O
important	O
tree	O
species	O
(	O
Swedish	O
Forest	O
Agency	O
,	O
2010	O
)	O
and	O
a	O
predominant	O
winter	O
forage	O
for	O
moose	O
across	O
northern	O
Fennoscandia	O
,	O
especially	O
when	O
growing	O
in	O
young	O
plantation	O
stands	O
(	O
Bergqvist	O
et	O
al	O
.	O
,	O
2018	O
;	O
Milligan	O
&	O
Koricheva	O
,	O
2013	O
)	O
.	O
No	O
forestry	O
is	O
carried	O
out	O
in	O
the	O
montane	O
ecoregion	O
that	O
is	O
characterized	O
by	O
mountain	O
birch	O
Betula	O
pubescens	O
as	O
the	O
dominating	O
tree	O
species	O
.	O
Moreover	O
,	O
most	O
animals	O
in	O
the	O
coastal	O
ecoregion	O
were	O
captured	O
in	O
the	O
archipelago	O
that	O
is	O
partly	O
located	O
in	O
a	O
national	O
park	O
(	O
Haparanda	O
Skärgård	O
)	O
where	O
overall	O
little	O
forest	O
management	O
occurs	O
.	O
The	O
islands	O
in	O
the	O
archipelago	O
offer	O
a	O
mosaic	O
of	O
different	O
forest	O
types	O
,	O
with	O
Scots	O
pine	O
and	O
Norway	O
spruce	O
Picea	O
abies	O
still	O
being	O
the	O
dominating	O
tree	O
species	O
,	O
but	O
generally	O
more	O
open	O
habitat	O
compared	O
to	O
the	O
mainland	O
.	O
Otherwise	O
,	O
all	O
captures	O
were	O
carried	O
out	O
in	O
areas	O
in	O
production	O
/	O
managed	O
forest	O
,	O
dominated	O
by	O
Scots	O
pine	O
and	O
Norway	O
spruce	O
.	O
Generally	O
,	O
land	O
use	O
in	O
our	O
study	O
area	O
intensifies	O
from	O
the	O
montane	O
to	O
the	O
coastal	O
habitat	O
(	O
see	O
Appendix	O
,	O
Figure	O
A1	O
)	O
.	O
This	O
study	O
includes	O
265	O
free	O
‐	O
ranging	O
adult	O
moose	O
captured	O
between	O
the	O
winters	O
of	O
2008	O
and	O
2017	O
(	O
between	O
February	O
14	O
and	O
March	O
31	O
)	O
,	O
and	O
following	O
a	O
standard	O
monitoring	O
procedure	O
.	O
Animals	O
were	O
immobilized	O
from	O
helicopter	O
via	O
dart	O
injection	O
(	O
Kreeger	O
&	O
Arnemo	O
,	O
2018	O
)	O
with	O
a	O
CO2	O
‐	O
powered	O
rifle	O
(	O
Dan	O
‐	O
Inject	O
)	O
with	O
the	O
drug	O
combination	O
of	O
4	O
.	O
5	O
mg	O
etorphine	O
(	O
Captivon®	O
98	O
Etorphine	O
HCl	O
9	O
.	O
8	O
mg	O
/	O
ml	O
,	O
Wildlife	O
Pharmaceuticals	O
(	O
PTY	O
)	O
Ltd	O
.	O
)	O
and	O
50	O
mg	O
xylazine	O
(	O
Xylased®	O
500	O
mg	O
,	O
Bioveta	O
,	O
a	O
.	O
s	O
.	O
)	O
(	O
Evans	O
et	O
al	O
.	O
,	O
2012	O
;	O
Græsli	O
et	O
al	O
.	O
,	O
2020	O
;	O
Lian	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O

Fecal	O
pellets	O
were	O
collected	O
from	O
the	O
rectum	O
into	O
50	O
ml	O
screw	O
cap	O
tubes	O
that	O
were	O
frozen	O
within	O
6	O
hr	O
and	O
stored	O
subsequently	O
at	O
−20ºC	O
.	O
For	O
serum	O
collection	O
,	O
whole	O
blood	O
was	O
drawn	O
from	O
the	O
jugular	O
vein	O
into	O
9	O
ml	O
S	O
‐	O
Monovette®	O
Z	O
‐	O
Gel	O
collection	O
tubes	O
,	O
processed	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
and	O
stored	O
at	O
−20°C	O
.	O
All	O
moose	O
captures	O
are	O
in	O
line	O
with	O
the	O
following	O
proposed	O
ethical	O
permits	O
:	O
A124	O
‐	O
05	O
,	O
A116	O
‐	O
09	O
,	O
A50	O
‐	O
12	O
,	O
and	O
A14	O
‐	O
15	O
,	O
granted	O
by	O
the	O
Swedish	O
Animal	O
Ethics	O
Committee	O
.	O
GPS	O
positions	O
of	O
capture	O
locations	O
and	O
demographic	O
data	O
(	O
sex	O
,	O
pregnancy	O
status	O
,	O
number	O
of	O
calves	O
)	O
were	O
collected	O
during	O
capture	O
and	O
this	O
data	O
was	O
then	O
stored	O
in	O
the	O
Wireless	O
Remote	O
Animal	O
Monitoring	O
database	O
(	O
Dettki	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O
To	O
assess	O
moose	O
winter	O
diet	O
across	O
different	O
landscapes	O
,	O
we	O
identified	O
the	O
plant	O
contents	O
of	O
fecal	O
pellets	O
and	O
metabolites	O
from	O
corresponding	O
serum	O
samples	O
from	O
our	O
study	O
individuals	O
from	O
multiple	O
capture	O
areas	O
across	O
northern	O
Sweden	O
(	O
Figure	O
1	O
)	O
.	O
Animals	O
captured	O
across	O
northern	O
Sweden	O
were	O
shown	O
to	O
be	O
genetically	O
similar	O
(	O
Blåhed	O
et	O
al	O
.	O
,	O
2018	O
;	O
Niedzialkowska	O
et	O
al	O
.	O
,	O
2016	O
;	O
Wennerstrom	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
and	O
genetic	O
admixture	O
is	O
possible	O
due	O
to	O
their	O
high	O
propensity	O
for	O
seasonal	O
migration	O
(	O
Allen	O
,	O
Dorey	O
,	O
et	O
al	O
.	O
,	O
2016	O
;	O
Singh	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O
We	O
focused	O
on	O
the	O
winter	O
period	O
as	O
this	O
is	O
when	O
dietary	O
constraints	O
are	O
highest	O
and	O
this	O
is	O
when	O
the	O
samples	O
were	O
taken	O
.	O
Snow	O
cover	O
lasts	O
typically	O
from	O
25	O
October	O
to	O
5	O
May	O
in	O
the	O
coastal	O
habitat	O
and	O
1	O
October	O
to	O
25	O
May	O
in	O
the	O
montane	O
habitat	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
smhi	O
.	O
se	O
/	O
data	O
/	O
meteorologi	O
/	O
sno	O
,	O
last	O
accessed	O
06	O
/	O
10	O
/	O
2020	O
)	O
.	O
DNA	O
from	O
fecal	O
samples	O
was	O
extracted	O
following	O
Spitzer	O
(	O
2019	O
)	O
and	O
purification	O
was	O
carried	O
out	O
on	O
a	O
QIASymphony	O
SP	O
platform	O
using	O
the	O
DSP	O
DNA	O
minikit	O
(	O
Quiagen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

To	O
determine	O
the	O
diet	O
composition	O
,	O
we	O
used	O
the	O
universal	O
primer	O
pair	O
Sper01	O
_	O
F	O
&	O
Sper01	O
_	O
R	O
(	O
Tab	O
erlet	O
et	O
al	O
.	O
,	O
2018	O
)	O
to	O
amplify	O
the	O
P6	O
‐	O
loop	O
of	O
the	O
trnL	O
intron	O
of	O
chloroplasts	O
.	O
This	O
commonly	O
used	O
metabarcoding	O
marker	O
for	O
plants	O
(	O
e	O
.	O
g	O
.	O
,	O
De	O
Barba	O
et	O
al	O
.	O
(	O
2014	O
)	O
,	O
Tab	O
erlet	O
et	O
al	O
.	O
(	O
2012	O
)	O
,	O
Valentini	O
et	O
al	O
.	O
(	O
2009	O
)	O
)	O
has	O
been	O
well	O
‐	O
established	O
for	O
the	O
study	O
of	O
herbivore	O
diets	O
(	O
Kartzinel	O
et	O
al	O
.	O
,	O
2015	O
;	O
Nichols	O
et	O
al	O
.	O
,	O
2016	O
;	O
Pansu	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
For	O
each	O
fecal	O
sample	O
,	O
PCR	O
reactions	O
were	O
performed	O
using	O
technical	O
triplicates	O
.	O
All	O
experiments	O
included	O
extraction	O
controls	O
,	O
PCR	O
negative	O
and	O
positive	O
controls	O
,	O
and	O
PCR	O
blanks	O
.	O
PCR	O
products	O
were	O
purified	O
using	O
the	O
MinElute	O
PCR	O
purification	O
kit	O
and	O
sequenced	O
on	O
an	O
Illumina	O
HiSeq	O
2	O
,	O
500	O
platform	O
using	O
a	O
paired	O
‐	O
end	O
approach	O
(	O
2	O
x	O
125	O
bp	O
)	O
.	O
Sequence	O
data	O
were	O
then	O
processed	O
using	O
the	O
OBITools	O
software	O
(	O
Boyer	O
et	O
al	O
.	O
,	O
2016	O
)	O
for	O
(	O
a	O
)	O
assembly	O
and	O
dereplication	O
of	O
reads	O
,	O
(	O
b	O
)	O
matching	O
sequences	O
to	O
samples	O
,	O
(	O
c	O
)	O
denoising	O
the	O
data	O
by	O
removing	O
singletons	O
,	O
low	O
‐	O
quality	O
sequences	O
,	O
putative	O
PCR	O
and	O
sequencing	O
artifacts	O
,	O
and	O
(	O
d	O
)	O
taxonomic	O
assignation	O
of	O
the	O
remaining	O
sequences	O
.	O
For	O
the	O
latter	O
,	O
we	O
built	O
a	O
reference	O
library	O
for	O
the	O
local	O
plant	O
species	O
by	O
extracting	O
the	O
relevant	O
parts	O
of	O
the	O
EMBL	O
(	O
European	O
Molecular	O
Biology	O
Laboratory	O
)	O
nucleotide	O
database	O
,	O
the	O
NCBI	O
(	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
)	O
taxonomy	O
,	O
and	O
a	O
database	O
for	O
arcto	O
‐	O
boreal	O
plant	O
species	O
and	O
bryophytes	O
(	O
Soininen	O
et	O
al	O
.	O
,	O
2015	O
;	O
Sønstebø	O
et	O
al	O
.	O
,	O
2010	O
;	O
Willerslev	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O
For	O
further	O
data	O
processing	O
,	O
we	O
used	O
R	O
(	O
R	O
Core	O
Team	O
,	O
2017	O
)	O
.	O
To	O
facilitate	O
data	O
analysis	O
at	O
the	O
ecological	O
level	O
,	O
the	O
final	O
dataset	O
was	O
stored	O
in	O
a	O
relational	O
database	O
using	O
PostgreSQL	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
postgresql	O
.	O
org	O
)	O
.	O

Sequences	O
without	O
a	O
match	O
to	O
a	O
reference	O
sequence	O
and	O
outlying	O
PCR	O
replicates	O
were	O
excluded	O
from	O
further	O
analyses	O
.	O
We	O
retained	O
annotated	O
sequences	O
as	O
molecular	O
operational	O
taxonomic	O
units	O
(	O
MOTUs	O
)	O
and	O
averaged	O
the	O
number	O
of	O
reads	O
for	O
each	O
MOTU	O
across	O
the	O
remaining	O
PCR	O
replicates	O
for	O
each	O
sample	O
.	O
To	O
confer	O
the	O
same	O
weight	O
to	O
each	O
fecal	O
sample	O
,	O
read	O
abundances	O
were	O
converted	O
into	O
relative	O
read	O
abundances	O
(	O
RRA	O
)	O
,	O
representing	O
the	O
proportion	O
of	O
each	O
MOTU	O
in	O
each	O
fecal	O
sample	O
.	O
MOTUs	O
that	O
did	O
not	O
represent	O
at	O
least	O
2	O
.	O
5	O
%	O
in	O
at	O
least	O
one	O
fecal	O
sample	O
were	O
removed	O
from	O
the	O
final	O
dataset	O
(	O
Bison	O
et	O
al	O
.	O
,	O
2015	O
)	O
.	O
RRA	O
is	O
increasingly	O
used	O
as	O
a	O
quantitative	O
measure	O
for	O
diet	O
composition	O
(	O
Craine	O
et	O
al	O
.	O
,	O
2015	O
;	O
Deagle	O
et	O
al	O
.	O
,	O
2019	O
;	O
Kowalczyk	O
et	O
al	O
.	O
,	O
2019	O
;	O
Pansu	O
et	O
al	O
.	O
,	O
2019	O
)	O
and	O
has	O
been	O
shown	O
to	O
yield	O
similar	O
conclusions	O
to	O
those	O
derived	O
from	O
presence	O
/	O
absence	O
data	O
(	O
Kartzinel	O
et	O
al	O
.	O
,	O
2015	O
;	O
Kowalczyk	O
et	O
al	O
.	O
,	O
2019	O
;	O
Willerslev	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O
Because	O
the	O
taxonomic	O
resolution	O
of	O
the	O
trnL	O
P6	O
barcode	O
varies	O
among	O
plant	O
families	O
(	O
Taberlet	O
et	O
al	O
.	O
,	O
2007	O
)	O
,	O
sequences	O
could	O
frequently	O
only	O
be	O
assigned	O
at	O
genus	O
level	O
or	O
higher	O
.	O
To	O
determine	O
diet	O
types	O
,	O
we	O
adopted	O
the	O
approach	O
used	O
by	O
Shipley	O
(	O
2010	O
)	O
who	O
defined	O
moose	O
consuming	O
a	O
“	O
specialist	O
”	O
diet	O
if	O
>	O
60	O
%	O
of	O
the	O
diet	O
consisted	O
of	O
a	O
single	O
plant	O
genus	O
;	O
conversely	O
,	O
a	O
“	O
generalist	O
”	O
moose	O
diet	O
was	O
defined	O
by	O
no	O
plant	O
genus	O
contributing	O
>	O
60	O
%	O
to	O
the	O
diet	O
.	O
Based	O
on	O
the	O
diet	O
composition	O
,	O
we	O
quantified	O
diet	O
diversity	O
as	O
the	O
Shannon	O
entropy	O
(	O
Shannon	O
–	O
Wiener	O
index	O
)	O
using	O
the	O
R	O
package	O
vegan	O
(	O
Oksanen	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
All	O
statistical	O
tests	O
were	O
carried	O
out	O
at	O
a	O
significance	O
level	O
of	O
alpha	O
=	O
0	O
.	O
05	O
.	O
Prior	O
to	O
analysis	O
,	O
serum	O
samples	O
were	O
thawed	O
and	O
300	O
μl	O
were	O
mixed	O
with	O
300	O
μl	O
1	O
.	O
5	O
M	O
deuterated	O
phosphate	O
buffer	O
(	O
NaH2PO4	O
and	O
K2HPO4	O
,	O
including	O
0	O
.	O
1	O
%	O
TSP	O
,	O
pH	O
7	O
.	O
47	O
)	O
and	O
transferred	O
into	O
96	O
‐	O
well	O
plates	O
for	O
NMR	O
spectroscopy	O
using	O
a	O
Gilson	O
robot	O
.	O

Quality	B-methodology
control	I-methodology
samples	O
were	O
prepared	O
by	O
pooling	O
all	O
samples	O
to	O
monitor	O
analytical	O
variability	O
of	O
the	O
metabolic	O
profiling	O
platform	O
.	O
The	O
1H	O
NMR	O
spectra	O
were	O
acquired	O
using	O
a	O
Bruker	O
600	O
MHz	O
AVANCE	O
III	O
spectrometer	O
equipped	O
with	O
a	O
5	O
mm	O
BBO	O
broadband	O
(	O
1H	O
/	O
19F	O
/	O
2D	O
)	O
z	O
‐	O
gradient	O
cryo	O
‐	O
probe	O
at	O
311	O
.	O
0	O
K	O
and	O
an	O
automatic	O
temperature	O
‐	O
controlled	O
high	O
‐	O
throughput	O
sample	O
changer	O
(	O
SampleJet	O
,	O
Bruker	O
)	O
.	O
One	O
‐	O
dimensional	O
(	O
1D	O
)	O
spectra	O
were	O
recorded	O
using	O
Carr	O
‐	O
Purcell	O
‐	O
Meiboom	O
‐	O
Gill	O
(	O
CPMG	O
)	O
sequence	O
with	O
water	O
suppression	O
in	O
order	O
to	O
have	O
enhanced	O
visualization	O
of	O
low	O
molecular	O
weight	O
compounds	O
.	O
The	O
spectrum	O
was	O
acquired	O
with	O
a	O
recycle	O
delay	O
of	O
4	O
s	O
,	O
12	O
‐	O
kHz	O
spectral	O
width	O
,	O
73	O
,	O
728	O
data	O
points	O
,	O
30	O
ms	O
total	O
spin	O
‐	O
echo	O
time	O
,	O
total	O
64	O
scans	O
,	O
and	O
4	O
dummy	O
scans	O
.	O
The	O
acquired	O
NMR	O
spectra	O
were	O
manually	O
corrected	O
for	O
the	O
phase	O
and	O
the	O
baseline	O
with	O
TopSpin	O
2	O
.	O
1	O
(	O
Bruker	O
Biospin	O
)	O
.	O
1H	O
NMR	O
spectra	O
were	O
aligned	O
using	O
icoshift	O
1	O
.	O
2	O
and	O
manual	O
integration	O
of	O
peaks	O
was	O
performed	O
to	O
a	O
linear	O
baseline	O
on	O
all	O
spectra	O
in	O
parallel	O
using	O
an	O
in	O
‐	O
house	O
developed	O
Matlab	O
routine	O
as	O
was	O
applied	O
before	O
(	O
Dudka	O
et	O
al	O
.	O
,	O
2020	O
;	O
Virel	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
The	O
integrated	O
data	O
from	O
serum	O
were	O
normalized	O
to	O
the	O
total	O
sum	O
of	O
the	O
spectrum	O
to	O
give	O
the	O
same	O
total	O
integration	O
value	O
for	O
each	O
spectrum	O
.	O
Identification	O
of	O
the	O
metabolites	O
was	O
achieved	O
by	O
assigning	O
their	O
specific	O
resonances	O
according	O
to	O
the	O
chemical	O
shift	O
values	O
and	O
multiplicities	O
using	O
the	O
Chenomx	O
NMR	O
suite	O
professional	O
(	O
version	O
7	O
.	O
72	O
,	O
Chenomx	O
,	O
Inc	O
.	O
)	O
and	O
the	O
Human	O
Metabolome	O
Database	O
(	O
Wishart	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
Normalized	O
NMR	O
data	O
were	O
UV	O
‐	O
scaled	O
prior	O
to	O
multivariate	O
analysis	O
.	O
Multivariate	O
data	O
analysis	O
methods	O
,	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
,	O
and	O
orthogonal	O
partial	O
least	O
squares	O
discriminant	O
analysis	O
(	O
OPLS	O
‐	O
DA	O
)	O
were	O
used	O
to	O
reduce	O
the	O
dimensionality	O
and	O
to	O
enable	O
the	O
visualization	O
of	O
the	O
separation	O
of	O
diet	O
types	O
(	O
SIMCA	O
14	O
.	O
0	O
,	O
Umetrics	O
)	O
.	O

An	O
unsupervised	O
PCA	O
was	O
performed	O
to	O
obtain	O
a	O
trend	O
of	O
separation	O
of	O
samples	O
according	O
to	O
groups	O
(	O
e	O
.	O
g	O
.	O
,	O
sex	O
,	O
diet	O
type	O
,	O
and	O
pregnancy	O
status	O
)	O
and	O
identified	O
possible	O
outliers	O
.	O
To	O
maximize	O
the	O
sample	O
group	O
separation	O
and	O
identify	O
discriminating	O
metabolites	O
,	O
OPLS	O
‐	O
DA	O
analysis	O
was	O
carried	O
out	O
.	O
This	O
supervised	O
approach	O
removes	O
the	O
variation	O
that	O
is	O
orthogonal	O
to	O
predefined	O
variables	O
from	O
the	O
models	O
that	O
were	O
calculated	O
for	O
each	O
two	O
‐	O
group	O
comparison	O
,	O
making	O
them	O
easier	O
to	O
interpret	O
and	O
thus	O
more	O
informative	O
.	O
All	O
OPLS	O
‐	O
DA	O
models	O
were	O
described	O
by	O
the	O
number	O
of	O
principal	O
components	O
,	O
the	O
amount	O
of	O
variation	O
in	O
X	O
explained	O
by	O
the	O
model	O
(	O
R2X	O
)	O
,	O
the	O
amount	O
of	O
variation	O
in	O
Y	O
explained	O
by	O
the	O
model	O
(	O
R2Y	O
)	O
,	O
the	O
amount	O
of	O
variation	O
in	O
Y	O
predicted	O
by	O
the	O
model	O
(	O
Q2	O
)	O
.	O
To	O
assess	O
the	O
predictive	O
ability	O
of	O
the	O
models	O
,	O
a	O
sevenfold	O
cross	O
‐	O
validation	O
was	O
used	O
.	O
Further	O
validation	O
of	O
the	O
models	O
was	O
carried	O
out	O
by	O
using	O
cross	O
‐	O
validation	O
ANOVA	O
(	O
CV	O
‐	O
ANOVA	O
)	O
and	O
inspection	O
of	O
corresponding	O
permutations	O
plots	O
.	O
Important	O
metabolites	O
differentiating	O
selected	O
groups	O
were	O
selected	O
based	O
on	O
model	O
covariance	O
loadings	O
(	O
|	O
w	O
*	O
|	O
≥	O
0	O
.	O
15	O
)	O
from	O
respective	O
OPLS	O
‐	O
DA	O
model	O
and	O
results	O
of	O
univariate	O
analysis	O
using	O
t	O
test	O
with	O
Benjamini	O
–	O
Hochberg	O
correction	O
(	O
p	O
≤	O
0	O
.	O
05	O
)	O
were	O
used	O
to	O
determine	O
significantly	O
altered	O
metabolites	O
.	O
Simplified	O
representation	O
of	O
metabolic	O
pathways	O
was	O
based	O
on	O
KEGG	O
Pathway	O
Database	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
genome	O
.	O
jp	O
/	O
kegg	O
/	O
pathway	O
.	O
html	O
)	O
.	O
Our	O
DNA	O
‐	O
metabarcoding	O
approach	O
resulted	O
in	O
the	O
detection	O
of	O
17	O
molecular	O
operational	O
taxonomic	O
units	O
(	O
MOTUs	O
)	O
in	O
moose	O
winter	O
diet	O
(	O
Appendix	O
,	O
Table	O
A1	O
)	O
.	O
The	O
number	O
of	O
MOTUs	O
detected	O
per	O
individual	O
sample	O
ranged	O
from	O
1	O
to	O
12	O
.	O
One	O
of	O
265	O
fecal	O
samples	O
did	O
not	O
pass	O
the	O
filtering	O
criteria	O
in	O
the	O
metabarcoding	O
process	O
and	O
was	O
excluded	O
from	O
subsequent	O
analyses	O
.	O
The	O
60	O
%	O
‐	O
threshold	O
to	O
differentiate	O
“	O
specialist	O
”	O
from	O
“	O
generalist	O
”	O
diets	O
,	O
resulted	O
in	O
four	O
categories	O
of	O
diet	O
types	O
(	O
Figure	O
1	O
)	O
.	O

The	O
majority	O
of	O
moose	O
exhibited	O
a	O
“	O
specialist	O
”	O
diet	O
,	O
with	O
194	O
individuals	O
having	O
a	O
pine	O
‐	O
rich	O
(	O
Pinus	O
)	O
diet	O
,	O
while	O
32	O
individuals	O
had	O
diets	O
dominated	O
by	O
birch	O
(	O
Betula	O
)	O
and	O
10	O
that	O
were	O
dominated	O
by	O
Saliceae	O
,	O
that	O
is	O
,	O
.	O
willow	O
and	O
aspen	O
.	O
A	O
“	O
generalist	O
”	O
diet	O
type	O
was	O
found	O
in	O
28	O
individuals	O
(	O
11	O
%	O
)	O
.	O
Pine	O
‐	O
rich	O
diets	O
were	O
least	O
diverse	O
,	O
while	O
“	O
generalist	O
”	O
diets	O
were	O
most	O
diverse	O
(	O
Figure	O
2	O
)	O
.	O
Diet	O
types	O
reflect	O
ecozonation	O
and	O
further	O
,	O
the	O
land	O
use	O
intensity	O
of	O
moose	O
winter	O
range	O
(	O
Figure	O
1	O
;	O
Appendix	O
,	O
Figures	O
A1	O
and	O
A2	O
)	O
,	O
thereby	O
representing	O
the	O
availability	O
of	O
tree	O
species	O
during	O
the	O
dormant	O
season	O
.	O
Half	O
(	O
52	O
%	O
)	O
of	O
the	O
generalist	O
moose	O
diets	O
occurred	O
in	O
the	O
coastal	O
ecoregion	O
,	O
whereas	O
diets	O
of	O
animals	O
captured	O
in	O
the	O
montane	O
region	O
were	O
dominated	O
by	O
birch	O
(	O
61	O
%	O
)	O
.	O
While	O
96	O
%	O
of	O
diets	O
from	O
the	O
boreal	O
region	O
consumed	O
pine	O
‐	O
rich	O
diets	O
,	O
this	O
diet	O
type	O
accounts	O
for	O
41	O
%	O
in	O
the	O
coastal	O
and	O
only	O
approximately	O
6	O
%	O
in	O
the	O
montane	O
region	O
,	O
respectively	O
.	O
The	O
proportions	O
of	O
generalist	O
and	O
willow	O
/	O
aspen	O
‐	O
rich	O
diet	O
in	O
the	O
montane	O
are	O
at	O
an	O
equal	O
16	O
%	O
.	O
A	O
nonparametric	O
two	O
‐	O
samples	O
Wilcoxon	O
rank	O
test	O
determined	O
a	O
significant	O
difference	O
(	O
p	O
=	O
0	O
.	O
004	O
)	O
of	O
diet	O
diversity	O
between	O
sexes	O
(	O
Appendix	O
,	O
Figure	O
A3	O
)	O
.	O
Females	O
exhibited	O
a	O
higher	O
(	O
and	O
more	O
variable	O
)	O
diet	O
diversity	O
and	O
consumed	O
proportionally	O
less	O
pine	O
than	O
males	O
.	O
This	O
difference	O
was	O
neither	O
explained	O
by	O
pregnancy	O
state	O
nor	O
by	O
the	O
number	O
of	O
offspring	O
accompanying	O
the	O
mothers	O
.	O
Nontargeted	O
metabolomics	O
analysis	O
with	O
application	O
of	O
1H	O
NMR	O
spectroscopy	O
was	O
performed	O
for	O
260	O
serum	O
samples	O
.	O
Four	O
serum	O
samples	O
did	O
not	O
pass	O
the	O
quality	O
criteria	O
required	O
for	O
1H	O
NMR	O
analysis	O
and	O
were	O
therefore	O
removed	O
from	O
subsequent	O
analysis	O
.	O
A	O
representative	O
600	O
MHz	O
1H	O
CPMG	O
NMR	O
spectrum	O
of	O
a	O
serum	O
sample	O
is	O
presented	O
in	O
Appendix	O
,	O
Figure	O
A4	O
.	O
Due	O
to	O
the	O
well	O
resolved	O
individual	O
NMR	O
resonances	O
,	O
a	O
wide	O
variety	O
of	O
metabolites	O
can	O
be	O
differentiated	O
and	O
putatively	O
identified	O
.	O
In	O
total	O
,	O
55	O
metabolites	O
were	O
putatively	O
identified	O
and	O
quantified	O
(	O
complete	O
list	O
of	O
identified	O
metabolites	O
is	O
shown	O
in	O
Appendix	O
,	O
Table	O
S2	O
)	O
.	O

The	O
most	O
predominant	O
metabolites	O
were	O
as	O
follows	O
:	O
BCAA	O
(	O
branched	O
‐	O
chain	O
amino	O
acids	O
)	O
,	O
alanine	O
,	O
lactate	O
,	O
lysine	O
,	O
acetate	O
,	O
glutamate	O
,	O
glutamine	O
,	O
pyruvate	O
,	O
citrate	O
,	O
creatinine	O
,	O
glycerophosphocholine	O
,	O
phosphocholine	O
,	O
glycine	O
,	O
urea	O
,	O
tyrosine	O
,	O
phenylalanine	O
,	O
1	O
‐	O
methylhistidine	O
,	O
formate	O
,	O
and	O
numerous	O
lipid	O
species	O
.	O
Metabolomic	O
profiles	O
were	O
different	O
between	O
sexes	O
as	O
illustrated	O
in	O
an	O
OPLS	O
‐	O
DA	O
score	O
plot	O
(	O
Appendix	O
,	O
Figure	O
A5	O
)	O
.	O
Goodness	O
of	O
fit	O
values	O
and	O
predictive	O
ability	O
values	O
were	O
obtained	O
(	O
R2X	O
=	O
0	O
.	O
529	O
,	O
R2Y	O
=	O
0	O
.	O
443	O
,	O
Q2	O
=	O
0	O
.	O
29	O
)	O
indicating	O
that	O
the	O
model	O
had	O
a	O
reasonably	O
good	O
fit	O
and	O
predictive	O
power	O
.	O
A	O
CV	O
‐	O
ANOVA	O
showed	O
highly	O
significant	O
variation	O
related	O
to	O
the	O
separation	O
of	O
groups	O
,	O
p	O
‐	O
value	O
<	O
0	O
.	O
01	O
.	O
Based	O
on	O
the	O
|	O
w	O
*	O
|	O
‐	O
vales	O
from	O
the	O
OPLS	O
‐	O
DA	O
model	O
we	O
selected	O
ten	O
metabolites	O
differing	O
between	O
sexes	O
.	O
However	O
,	O
only	O
creatinine	O
and	O
albumin	O
lysyl	O
were	O
statistically	O
significant	O
(	O
t	O
test	O
p	O
‐	O
value	O
≤	O
0	O
.	O
05	O
)	O
and	O
males	O
exhibited	O
decreased	O
concentrations	O
of	O
both	O
(	O
Appendix	O
,	O
Table	O
A3	O
)	O
.	O
Metabolomic	O
patterns	O
did	O
not	O
differ	O
between	O
pregnant	O
and	O
nonpregnant	O
females	O
or	O
between	O
females	O
with	O
and	O
without	O
accompanying	O
offspring	O
.	O
To	O
investigate	O
the	O
metabolic	O
variations	O
correlated	O
with	O
four	O
diet	O
types	O
,	O
we	O
conducted	O
a	O
two	O
‐	O
way	O
comparison	O
of	O
each	O
diet	O
type	O
,	O
obtaining	O
six	O
comparisons	O
in	O
total	O
.	O
First	O
,	O
PCA	O
plots	O
were	O
investigated	O
,	O
presenting	O
an	O
unclear	O
separation	O
of	O
diet	O
‐	O
groups	O
(	O
Appendix	O
,	O
Figure	O
A6	O
)	O
.	O
Second	O
,	O
OPLS	O
‐	O
DA	O
models	O
were	O
established	O
for	O
each	O
of	O
comparison	O
to	O
clearly	O
discriminate	O
and	O
identify	O
metabolites	O
based	O
on	O
diet	O
types	O
(	O
Figure	O
3	O
)	O
.	O
Detailed	O
characterization	O
of	O
two	O
‐	O
class	O
OPLS	O
‐	O
DA	O
models	O
obtained	O
based	O
on	O
1H	O
NMR	O
metabolomic	O
data	O
distinguished	O
by	O
moose	O
winter	O
diet	O
types	O
is	O
summarized	O
in	O
Appendix	O
,	O
Table	O
A4	O
.	O
The	O
permutation	O
tests	O
confirmed	O
the	O
robustness	O
of	O
all	O
OPLS	O
‐	O
DA	O
models	O
(	O
Appendix	O
,	O
Figure	O
A7	O
)	O
.	O

Linking	O
metabolic	O
profiles	O
with	O
diet	O
types	O
resulted	O
in	O
the	O
identification	O
of	O
29	O
metabolites	O
that	O
significantly	O
drove	O
the	O
separation	O
of	O
1H	O
NMR	O
metabolomic	O
profiles	O
among	O
four	O
diet	O
types	O
(	O
as	O
seen	O
in	O
Figure	O
3	O
)	O
.	O
A	O
pathway	O
network	O
map	O
of	O
significantly	O
altered	O
metabolites	O
,	O
including	O
box	O
plots	O
of	O
metabolites	O
for	O
four	O
different	O
diet	O
types	O
,	O
summarizes	O
the	O
key	O
significant	O
metabolites	O
that	O
are	O
major	O
intermediates	O
of	O
pathways	O
involving	O
amino	O
acid	O
,	O
lipid	O
,	O
and	O
gut	O
microbiota	O
metabolism	O
.	O
The	O
following	O
pattern	O
of	O
decreased	O
levels	O
of	O
lipids	O
(	O
specifically	O
the	O
fatty	O
acids	O
‐	O
CH3	O
(	O
HDL	O
)	O
,	O
CH3	O
(	O
CH2	O
)	O
n	O
,	O
CH2	O
‐	O
C	O
=	O
C	O
,	O
‐	O
CH	O
=	O
CH	O
‐	O
)	O
,	O
glycerophosphocholine	O
,	O
and	O
phosphocholine	O
in	O
animals	O
with	O
a	O
birch	O
‐	O
(	O
Betula	O
)	O
and	O
willow	O
/	O
aspen	O
‐	O
rich	O
diet	O
(	O
Saliceae	O
)	O
(	O
that	O
dominate	O
the	O
montane	O
and	O
coastal	O
ecoregion	O
,	O
respectively	O
)	O
compared	O
to	O
pine	O
‐	O
rich	O
(	O
Pinus	O
)	O
diets	O
was	O
observed	O
.	O
The	O
reverse	O
trend	O
was	O
observed	O
for	O
amino	O
acids	O
,	O
such	O
as	O
glutathione	O
,	O
threonine	O
,	O
proline	O
,	O
phenylalanine	O
,	O
tyrosine	O
,	O
glycine	O
,	O
histidine	O
,	O
and	O
ornithine	O
.	O
They	O
all	O
were	O
decreased	O
in	O
pine	O
‐	O
rich	O
diets	O
(	O
Pinus	O
)	O
with	O
respect	O
to	O
all	O
other	O
types	O
of	O
diet	O
(	O
Betula	O
,	O
Saliceae	O
,	O
and	O
Generalist	O
)	O
.	O
Moreover	O
,	O
differences	O
in	O
gut	O
microbiota	O
were	O
directly	O
reflected	O
by	O
a	O
significant	O
increase	O
of	O
dimethyl	O
sulfone	O
in	O
moose	O
with	O
pine	O
‐	O
rich	O
diets	O
(	O
Pinus	O
)	O
compared	O
to	O
all	O
other	O
types	O
of	O
diet	O
(	O
Betula	O
,	O
Saliceae	O
,	O
and	O
Generalist	O
)	O
.	O
Additionally	O
,	O
we	O
observed	O
significant	O
differences	O
in	O
the	O
levels	O
of	O
two	O
metabolites	O
related	O
to	O
energy	O
metabolism	O
.	O
Acetoacetate	O
was	O
significantly	O
elevated	O
in	O
individuals	O
that	O
consumed	O
a	O
generalist	O
diet	O
compared	O
to	O
a	O
pine	O
‐	O
rich	O
diet	O
,	O
whereas	O
animals	O
that	O
exhibit	O
a	O
generalist	O
and	O
birch	O
‐	O
rich	O
diet	O
compared	O
with	O
pine	O
‐	O
rich	O
diet	O
exhibited	O
elevated	O
levels	O
of	O
2	O
‐	O
Hydroxybutyrate	O
(	O
Table	O
1	O
;	O
Figure	O
4	O
)	O
.	O
We	O
attempted	O
additional	O
validation	O
of	O
our	O
results	O
by	O
analyzing	O
diet	O
type	O
classification	O
within	O
the	O
montane	O
region	O
since	O
all	O
four	O
diet	O
types	O
were	O
present	O
in	O
this	O
ecoregion	O
via	O
OPLS	O
‐	O
DA	O
score	O
plots	O
of	O
two	O
‐	O
way	O
comparison	O
(	O
Appendix	O
,	O
Figure	O
A8	O
)	O
.	O

A	O
Betula	O
versus	O
Pinus	O
model	O
could	O
not	O
be	O
obtained	O
for	O
a	O
comparison	O
.	O
The	O
resulting	O
classification	O
for	O
the	O
montane	O
ecoregion	O
did	O
not	O
perform	O
as	O
well	O
as	O
for	O
models	O
including	O
all	O
regions	O
with	O
higher	O
number	O
of	O
samples	O
.	O
However	O
,	O
grouping	O
of	O
specific	O
diet	O
types	O
could	O
still	O
be	O
observed	O
.	O
Our	O
results	O
provide	O
important	O
baseline	O
physiological	O
information	O
on	O
a	O
large	O
herbivore	O
species	O
that	O
is	O
widely	O
distributed	O
and	O
is	O
adapted	O
to	O
diverse	O
habitat	O
conditions	O
across	O
a	O
large	O
latitudinal	O
gradient	O
in	O
the	O
northern	O
hemisphere	O
.	O
We	O
demonstrate	O
the	O
adaptive	O
flexibility	O
of	O
moose	O
in	O
terms	O
of	O
dietary	O
use	O
and	O
we	O
identified	O
important	O
biomarkers	O
that	O
provide	O
vital	O
hints	O
on	O
linkages	O
between	O
its	O
diet	O
and	O
the	O
potential	O
to	O
adapt	O
physiologically	O
to	O
extreme	O
and	O
wide	O
variety	O
of	O
climatic	O
and	O
land	O
use	O
conditions	O
.	O
Using	O
a	O
1H	O
NMR	O
approach	O
,	O
we	O
were	O
able	O
to	O
show	O
that	O
serum	O
metabolomic	O
profiles	O
of	O
moose	O
varied	O
among	O
the	O
four	O
different	O
diet	O
types	O
.	O
These	O
diet	O
types	O
clearly	O
mirrored	O
the	O
ecozonation	O
and	O
were	O
further	O
characterized	O
by	O
the	O
land	O
use	O
(	O
see	O
Figure	O
1	O
)	O
,	O
adding	O
to	O
evidence	O
of	O
a	O
high	O
degree	O
of	O
flexibility	O
that	O
moose	O
exhibit	O
(	O
Hoy	O
et	O
al	O
.	O
,	O
2019	O
;	O
Vivas	O
and	O
Saether	O
,	O
1987	O
;	O
Parikh	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
We	O
confirm	O
that	O
moose	O
unavoidably	O
experience	O
a	O
nutritional	O
deficit	O
due	O
to	O
limiting	O
forage	O
availability	O
during	O
winter	O
.	O
However	O
,	O
the	O
degree	O
of	O
this	O
nutritional	O
deficit	O
seems	O
to	O
be	O
highly	O
variable	O
between	O
areas	O
,	O
as	O
we	O
show	O
by	O
identifying	O
biomarkers	O
of	O
starvation	O
in	O
moose	O
blood	O
.	O
We	O
broadly	O
identified	O
four	O
diet	O
types	O
in	O
moose	O
winter	O
diet	O
as	O
“	O
specialist	O
”	O
pine	O
‐	O
rich	O
,	O
birch	O
‐	O
rich	O
,	O
Saliceae	O
‐	O
rich	O
and	O
a	O
more	O
diverse	O
“	O
generalist	O
”	O
diet	O
.	O
These	O
diet	O
types	O
not	O
only	O
reflect	O
the	O
ecozonation	O
of	O
moose	O
winter	O
range	O
but	O
also	O
correspond	O
to	O
the	O
dominant	O
type	O
of	O
land	O
uses	O
in	O
the	O
area	O
,	O
which	O
influences	O
the	O
vegetation	O
and	O
the	O
forage	O
availability	O
.	O
The	O
major	O
land	O
use	O
in	O
Northern	O
areas	O
of	O
Sweden	O
is	O
forestry	O
and	O
other	O
types	O
of	O
extractive	O
industry	O
such	O
as	O
mining	O
(	O
Fohringer	O
et	O
al	O
.	O
in	O
review	O
)	O
.	O
Even	O
though	O
our	O
samples	O
reflect	O
the	O
climatic	O
coast	O
to	O
mountain	O
gradient	O
,	O
they	O
also	O
are	O
affected	O
by	O
intensive	O
forestry	O
practices	O
manipulating	O
the	O
supply	O
of	O
forage	O
species	O
to	O
moose	O
,	O
especially	O
the	O
quantity	O
of	O
Scots	O
pine	O
which	O
is	O
the	O
major	O
timber	O
species	O
.	O

The	O
quantity	O
of	O
pine	O
varies	O
across	O
our	O
sampling	O
gradient	O
with	O
minimum	O
abundance	O
in	O
the	O
montane	O
region	O
(	O
hence	O
,	O
a	O
birch	O
‐	O
rich	O
diet	O
in	O
moose	O
in	O
this	O
area	O
)	O
and	O
the	O
coastal	O
protected	O
area	O
region	O
(	O
more	O
diverse	O
or	O
generalist	O
diet	O
)	O
and	O
highest	O
in	O
the	O
boreal	O
zone	O
(	O
evident	O
from	O
the	O
pine	O
‐	O
rich	O
diet	O
in	O
moose	O
from	O
this	O
area	O
)	O
.	O
There	O
are	O
other	O
mechanisms	O
such	O
as	O
disturbance	O
and	O
habitat	O
loss	O
potentially	O
triggered	O
by	O
mining	O
,	O
tourism	O
,	O
and	O
interference	O
that	O
may	O
indirectly	O
affect	O
moose	O
habitat	O
choice	O
and	O
their	O
metabolic	O
expenditure	O
as	O
well	O
(	O
Fohringer	O
et	O
al	O
.	O
,	O
in	O
review	O
)	O
.	O
We	O
found	O
differences	O
in	O
diet	O
diversity	O
across	O
sexes	O
.	O
However	O
,	O
among	O
females	O
,	O
we	O
found	O
no	O
effect	O
of	O
pregnancy	O
status	O
or	O
the	O
presence	O
of	O
offspring	O
on	O
diet	O
diversity	O
(	O
Appendix	O
,	O
Figure	O
A3	O
)	O
.	O
The	O
differences	O
between	O
the	O
sexes	O
can	O
be	O
attributed	O
to	O
a	O
higher	O
mean	O
proportion	O
of	O
Pinus	O
consumed	O
by	O
males	O
,	O
as	O
range	O
use	O
in	O
our	O
study	O
area	O
is	O
not	O
significantly	O
different	O
between	O
the	O
sexes	O
(	O
see	O
Allen	O
,	O
Dorey	O
,	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
This	O
difference	O
follows	O
the	O
Jarman	O
‐	O
Bell	O
principle	O
(	O
Geist	O
,	O
1974	O
)	O
enabling	O
the	O
generally	O
larger	O
sized	O
males	O
to	O
rely	O
less	O
on	O
quality	O
but	O
rather	O
on	O
abundant	O
diet	O
items	O
during	O
winter	O
.	O
Moose	O
males	O
generally	O
enter	O
winter	O
with	O
lower	O
energy	O
reserves	O
as	O
they	O
spend	O
less	O
time	O
foraging	O
during	O
the	O
rutting	O
period	O
(	O
late	O
September	O
to	O
mid	O
‐	O
October	O
)	O
compared	O
to	O
females	O
.	O
Hence	O
,	O
males	O
should	O
typically	O
maximize	O
their	O
instantaneous	O
rate	O
of	O
food	O
intake	O
to	O
sustain	O
them	O
through	O
the	O
winter	O
(	O
Du	O
Toit	O
,	O
2006	O
)	O
.	O
Similar	O
to	O
the	O
separation	O
in	O
diet	O
types	O
,	O
and	O
perhaps	O
also	O
driven	O
by	O
this	O
,	O
we	O
found	O
differences	O
in	O
energy	O
metabolism	O
of	O
individuals	O
based	O
on	O
the	O
biomarkers	O
observed	O
across	O
ecoregions	O
.	O
Pine	O
‐	O
rich	O
diets	O
had	O
more	O
lipids	O
in	O
moose	O
serum	O
than	O
the	O
other	O
diets	O
whereas	O
amino	O
acids	O
and	O
ketone	O
bodies	O
were	O
higher	O
in	O
the	O
birch	O
and	O
willow	O
diets	O
than	O
in	O
the	O
pine	O
diets	O
.	O
The	O
generalist	O
diets	O
were	O
elevated	O
in	O
ketone	O
bodies	O
relative	O
to	O
the	O
other	O
diets	O
.	O
The	O
elevated	O
concentrations	O
of	O
lipids	O
indicate	O
short	O
periods	O
of	O
starvation	O
,	O
whereas	O
increased	O
concentrations	O
of	O
amino	O
acids	O
and	O
ketone	O
bodies	O
indicate	O
prolonged	O
starvation	O
.	O
Again	O
,	O
this	O
points	O
to	O
the	O
fact	O
that	O
climatic	O
and	O
land	O
use	O
patterns	O
may	O
affect	O
animal	O
physiology	O
through	O
the	O
manipulation	O
of	O
forage	O
species	O
and	O
thereby	O
affecting	O
diet	O
choice	O
(	O
Allen	O
,	O
Månsson	O
,	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O

Metabolic	O
shifts	O
are	O
unlikely	O
attributed	O
to	O
genetic	O
differences	O
among	O
animals	O
,	O
since	O
individuals	O
included	O
in	O
our	O
study	O
area	O
were	O
found	O
to	O
be	O
genetically	O
similar	O
(	O
Blåhed	O
et	O
al	O
.	O
,	O
2018	O
;	O
Niedzialkowska	O
et	O
al	O
.	O
,	O
2016	O
;	O
Wennerstrom	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
When	O
animals	O
experience	O
food	O
deprivation	O
,	O
they	O
respond	O
by	O
mobilizing	O
internal	O
energy	O
stores	O
,	O
triggering	O
a	O
starvation	O
response	O
.	O
In	O
early	O
starvation	O
of	O
vertebrates	O
,	O
stores	O
of	O
glycogen	O
and	O
triglyceride	O
provide	O
most	O
of	O
the	O
metabolic	O
needs	O
of	O
tissues	O
.	O
Fatty	O
acids	O
are	O
being	O
released	O
from	O
liver	O
and	O
adipose	O
for	O
use	O
in	O
other	O
tissues	O
.	O
After	O
prolonged	O
starvation	O
,	O
glycogen	O
reserves	O
are	O
depleted	O
and	O
ketone	O
bodies	O
are	O
produced	O
from	O
fatty	O
acids	O
from	O
adipose	O
and	O
liver	O
,	O
as	O
well	O
as	O
some	O
amino	O
acids	O
derived	O
from	O
muscle	O
proteolysis	O
(	O
Moyes	O
&	O
Schulte	O
,	O
2008	O
)	O
.	O
Another	O
important	O
set	O
of	O
biomarkers	O
,	O
we	O
found	O
were	O
serum	O
creatinine	O
and	O
albumin	O
lysyl	O
which	O
are	O
known	O
to	O
be	O
associated	O
with	O
muscle	O
mass	O
and	O
nutritional	O
restriction	O
,	O
respectively	O
,	O
especially	O
from	O
studies	O
in	O
humans	O
(	O
Lee	O
et	O
al	O
.	O
,	O
2015	O
;	O
Schutte	O
et	O
al	O
.	O
,	O
1981	O
)	O
.	O
We	O
found	O
the	O
concentrations	O
of	O
these	O
to	O
be	O
different	O
between	O
the	O
sexes	O
(	O
lower	O
in	O
males	O
)	O
,	O
potentially	O
indicating	O
differences	O
in	O
the	O
ecology	O
of	O
the	O
sexes	O
,	O
when	O
males	O
lose	O
more	O
muscle	O
mass	O
during	O
rut	O
than	O
the	O
females	O
and	O
simultaneously	O
compromising	O
on	O
nutritional	O
gains	O
by	O
feeding	O
less	O
(	O
Miquelle	O
,	O
1990	O
;	O
Mysterud	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O
Therefore	O
,	O
one	O
would	O
expect	O
that	O
these	O
differences	O
would	O
not	O
persist	O
across	O
ecoregions	O
or	O
across	O
land	O
use	O
pressures	O
unless	O
these	O
disrupt	O
the	O
reproductive	O
ecology	O
of	O
the	O
species	O
locally	O
.	O
Rather	O
,	O
changes	O
in	O
sex	O
ratio	O
as	O
well	O
as	O
density	O
dependence	O
may	O
bring	O
about	O
differences	O
across	O
regions	O
or	O
in	O
time	O
,	O
linked	O
to	O
reproductive	O
collapse	O
through	O
hunting	O
(	O
e	O
.	O
g	O
.	O
,	O
Milner	O
‐	O
Gulland	O
et	O
al	O
.	O
,	O
2003	O
)	O
.	O
Nevertheless	O
,	O
we	O
only	O
present	O
spatial	O
trends	O
and	O
not	O
temporal	O
,	O
in	O
this	O
study	O
.	O
Animals	O
consuming	O
predominantly	O
Pinus	O
exhibit	O
significantly	O
higher	O
dimethyl	O
sulfone	O
concentrations	O
compared	O
with	O
all	O
other	O
diet	O
types	O
.	O
This	O
compound	O
is	O
derived	O
from	O
dietary	O
sources	O
,	O
intestinal	O
bacterial	O
metabolism	O
,	O
and	O
the	O
body	O
'	O
s	O
endogenous	O
methanethiol	O
metabolism	O
(	O
He	O
&	O
Slupsky	O
,	O
2014	O
)	O
.	O

The	O
presence	O
of	O
dimethyl	O
sulfone	O
in	O
human	O
biofluids	O
has	O
been	O
shown	O
to	O
be	O
highly	O
influenced	O
by	O
diet	O
and	O
a	O
high	O
content	O
thereof	O
is	O
suggested	O
to	O
explain	O
enhanced	O
intestinal	O
fermentation	O
activity	O
due	O
to	O
fiber	O
consumption	O
(	O
He	O
&	O
Slupsky	O
,	O
2014	O
)	O
.	O
In	O
ruminants	O
,	O
several	O
studies	O
have	O
attributed	O
increased	O
levels	O
of	O
dimethyl	O
sulfone	O
to	O
increased	O
levels	O
of	O
dietary	O
crude	O
protein	O
(	O
Coppa	O
et	O
al	O
.	O
,	O
2011	O
;	O
O	O
’	O
Callaghan	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
This	O
hints	O
toward	O
the	O
fact	O
that	O
even	O
though	O
moose	O
in	O
pine	O
‐	O
dominated	O
areas	O
are	O
limited	O
in	O
diet	O
diversity	O
,	O
they	O
may	O
still	O
be	O
able	O
to	O
cope	O
well	O
due	O
to	O
high	O
dimethyl	O
sulfone	O
promoting	O
fermentation	O
.	O
This	O
redirects	O
back	O
to	O
the	O
observations	O
that	O
moose	O
being	O
large	O
and	O
bulk	O
feeders	O
may	O
be	O
able	O
to	O
survive	O
on	O
abundant	O
,	O
relatively	O
low	O
quality	O
,	O
forage	O
(	O
pine	O
being	O
the	O
most	O
abundant	O
browse	O
species	O
in	O
Fennoscandia	O
)	O
instead	O
of	O
depending	O
on	O
high	O
‐	O
quality	O
forage	O
,	O
especially	O
in	O
lean	O
winter	O
months	O
(	O
Felton	O
et	O
al	O
.	O
,	O
2020	O
;	O
Månsson	O
et	O
al	O
.	O
,	O
2007	O
;	O
Pfeffer	O
et	O
al	O
.	O
,	O
2021	O
)	O
.	O
Conversely	O
,	O
animals	O
that	O
have	O
not	O
consumed	O
this	O
bulk	O
diet	O
item	O
extensively	O
—	O
most	O
likely	O
due	O
to	O
restricted	O
availability	O
—	O
may	O
not	O
be	O
able	O
to	O
provide	O
their	O
fermentative	O
bacteria	O
with	O
sufficient	O
cellulose	O
,	O
thus	O
,	O
reducing	O
microbial	O
activity	O
in	O
the	O
rumen	O
which	O
is	O
reflected	O
in	O
significantly	O
lower	O
concentrations	O
of	O
dimethyl	O
sulfone	O
in	O
their	O
serum	O
.	O
Animals	O
in	O
such	O
regions	O
are	O
likely	O
to	O
perform	O
worse	O
in	O
the	O
winters	O
which	O
would	O
be	O
reflected	O
in	O
the	O
variable	O
concentrations	O
of	O
other	O
metabolites	O
such	O
as	O
lipids	O
that	O
may	O
indicate	O
starvation	O
.	O
Higher	O
diet	O
diversity	O
is	O
suggested	O
to	O
be	O
beneficial	O
for	O
moose	O
to	O
reduce	O
the	O
risk	O
of	O
overconsumption	O
of	O
secondary	O
plant	O
metabolites	O
(	O
Felton	O
et	O
al	O
.	O
,	O
2020	O
;	O
Parikh	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
It	O
is	O
difficult	O
to	O
conclude	O
,	O
at	O
what	O
level	O
does	O
the	O
diet	O
diversity	O
becomes	O
crucial	O
,	O
and	O
what	O
is	O
the	O
tolerance	O
boundary	O
for	O
moose	O
for	O
that	O
.	O
We	O
may	O
conclude	O
though	O
,	O
that	O
pine	O
may	O
serve	O
as	O
a	O
bulk	O
item	O
that	O
is	O
“	O
good	O
enough	O
,	O
”	O
providing	O
endosymbiotic	O
bacteria	O
with	O
sufficient	O
amounts	O
of	O
cellulose	O
to	O
keep	O
beneficial	O
dimethyl	O
sulfone	O
at	O
a	O
comparatively	O
higher	O
level	O
.	O

Increased	O
concentrations	O
of	O
ketone	O
bodies	O
,	O
such	O
as	O
acetoacetate	O
,	O
present	O
in	O
individuals	O
that	O
consumed	O
a	O
generalist	O
diet	O
compared	O
with	O
a	O
pine	O
‐	O
rich	O
diet	O
,	O
indicate	O
late	O
starvation	O
or	O
prolonged	O
physical	O
exertion	O
as	O
part	O
of	O
gluconeogenesis	O
(	O
Hogan	O
&	O
Philips	O
,	O
2016	O
;	O
Leng	O
,	O
1970	O
)	O
.	O
We	O
found	O
increased	O
2	O
‐	O
hydroxybutyrate	O
for	O
animals	O
that	O
exhibit	O
a	O
generalist	O
and	O
birch	O
‐	O
rich	O
diet	O
compared	O
with	O
those	O
that	O
had	O
a	O
pine	O
‐	O
rich	O
diet	O
.	O
This	O
metabolite	O
generally	O
appears	O
at	O
high	O
concentrations	O
in	O
situations	O
related	O
to	O
impeded	O
energy	O
metabolism	O
and	O
was	O
suggested	O
to	O
be	O
an	O
early	O
marker	O
indicating	O
impaired	O
glucose	O
regulation	O
that	O
appears	O
to	O
arise	O
due	O
to	O
increased	O
lipid	O
oxidation	O
and	O
oxidative	O
stress	O
in	O
humans	O
(	O
Gall	O
et	O
al	O
.	O
,	O
2010	O
)	O
.	O
If	O
this	O
also	O
applies	O
in	O
moose	O
,	O
the	O
identification	O
of	O
such	O
biomarkers	O
of	O
stress	O
becomes	O
an	O
important	O
finding	O
.	O
This	O
is	O
especially	O
applicable	O
in	O
the	O
context	O
of	O
environmental	O
stress	O
related	O
to	O
climate	O
and	O
land	O
use	O
changes	O
,	O
since	O
moose	O
in	O
montane	O
regions	O
facing	O
extreme	O
snow	O
conditions	O
along	O
with	O
extensive	O
starvation	O
bouts	O
and	O
those	O
in	O
coastal	O
areas	O
facing	O
human	O
land	O
use	O
pressure	O
reducing	O
access	O
to	O
certain	O
key	O
forage	O
species	O
,	O
may	O
experience	O
oxidative	O
stress	O
beyond	O
baseline	O
conditions	O
.	O
Conversely	O
,	O
extensive	O
forest	O
management	O
in	O
the	O
boreal	O
region	O
creates	O
abundant	O
supply	O
of	O
pine	O
,	O
a	O
staple	O
food	O
source	O
for	O
moose	O
,	O
thereby	O
decreasing	O
stress	O
and	O
starvation	O
.	O
We	O
have	O
identified	O
and	O
linked	O
several	O
important	O
biomarkers	O
in	O
this	O
study	O
(	O
Figure	O
4	O
)	O
and	O
there	O
are	O
yet	O
numerous	O
more	O
which	O
we	O
have	O
found	O
but	O
not	O
discussed	O
(	O
Appendix	O
,	O
Table	O
A2	O
)	O
.	O
These	O
warrant	O
careful	O
considerations	O
and	O
analyses	O
,	O
and	O
here	O
,	O
we	O
provide	O
a	O
blueprint	O
on	O
how	O
one	O
can	O
go	O
about	O
exploring	O
these	O
further	O
and	O
linking	O
to	O
various	O
other	O
aspects	O
of	O
animal	O
physiology	O
and	O
ecology	O
.	O
A	O
caveat	O
of	O
our	O
study	O
is	O
the	O
potential	O
confounding	O
effect	O
of	O
ecoregion	O
,	O
which	O
encompasses	O
both	O
climate	O
and	O
vegetation	O
,	O
hence	O
,	O
representing	O
forage	O
availability	O
and	O
thermal	O
environment	O
for	O
an	O
animal	O
.	O
Diet	O
composition	O
on	O
the	O
other	O
hand	O
represents	O
habitat	O
selection	O
of	O
an	O
animal	O
which	O
is	O
in	O
this	O
case	O
,	O
again	O
influenced	O
by	O
the	O
ecoregion	O
.	O
After	O
conducting	O
multivariate	O
analysis	O
within	O
the	O
only	O
ecoregion	O
where	O
all	O
four	O
diet	O
types	O
were	O
present	O
,	O
clustering	O
of	O
diet	O
types	O
remained	O
but	O
was	O
less	O
striking	O
compared	O
to	O
the	O
same	O
analysis	O
across	O
all	O
ecoregions	O
.	O

Despite	O
,	O
ruling	O
out	O
potential	O
population	O
effects	O
,	O
we	O
can	O
therefore	O
not	O
rule	O
out	O
that	O
other	O
environmental	O
factors	O
encompassed	O
by	O
ecoregions	O
(	O
beyond	O
diet	O
)	O
also	O
influence	O
metabolic	O
profiles	O
.	O
Moreover	O
,	O
we	O
may	O
have	O
missed	O
to	O
identify	O
biomarkers	O
of	O
animal	O
health	O
,	O
behavior	O
and	O
fitness	O
,	O
and	O
mechanisms	O
driving	O
these	O
due	O
to	O
the	O
absence	O
of	O
relevant	O
ancillary	O
information	O
to	O
test	O
for	O
these	O
parameters	O
.	O
Calls	O
have	O
been	O
made	O
by	O
recent	O
reviews	O
for	O
the	O
high	O
potential	O
of	O
the	O
integration	O
of	O
multi	O
‐	O
omics	O
approaches	O
to	O
facilitate	O
a	O
more	O
holistic	O
understanding	O
of	O
how	O
organisms	O
respond	O
to	O
different	O
stressors	O
(	O
Gooseens	O
et	O
al	O
.	O
,	O
2020	O
;	O
Schwartz	O
,	O
2020	O
)	O
.	O
We	O
show	O
how	O
NMR	O
‐	O
based	O
metabolomics	O
can	O
be	O
used	O
to	O
identify	O
molecules	O
that	O
give	O
novel	O
insights	O
on	O
species	O
ecophysiology	O
.	O
Our	O
study	O
exemplifies	O
that	O
the	O
integration	O
of	O
omics	O
approaches	O
into	O
routinely	O
used	O
monitoring	O
protocols	O
is	O
not	O
only	O
feasible	O
but	O
also	O
combinable	O
,	O
even	O
in	O
nonexperimental	O
nonclinical	O
set	O
‐	O
ups	O
such	O
as	O
the	O
one	O
examined	O
.	O
Most	O
other	O
studies	O
on	O
free	O
‐	O
ranging	O
vertebrates	O
have	O
evaluated	O
feasibility	O
and	O
have	O
not	O
gone	O
as	O
far	O
as	O
to	O
make	O
functional	O
linkages	O
between	O
physiology	O
and	O
diet	O
at	O
this	O
resolution	O
.	O
Integrative	O
approaches	O
bridging	O
biomolecular	O
methods	O
with	O
animal	O
demographics	O
and	O
environmental	O
variables	O
to	O
elucidate	O
the	O
effects	O
of	O
diet	O
on	O
organismal	O
metabolism	O
and	O
vice	O
versa	O
are	O
essential	O
to	O
understand	O
diet	O
choices	O
and	O
shifts	O
and	O
corresponding	O
physiological	O
responses	O
across	O
the	O
species	O
range	O
.	O
We	O
see	O
a	O
great	O
potential	O
for	O
the	O
application	O
of	O
our	O
combined	O
omics	O
approach	O
for	O
longitudinal	B-methodology
studies	I-methodology
to	O
detect	O
seasonal	O
and	O
annual	O
shifts	O
in	O
metabolism	O
and	O
diet	O
in	O
association	O
with	O
movement	O
characteristics	O
,	O
fitness	O
proxies	O
,	O
and	O
environmental	O
data	O
.	O
In	O
addition	O
to	O
nonlethal	O
serum	O
sampling	O
,	O
alternative	O
bioliquids	O
,	O
such	O
as	O
rumen	O
fluid	O
or	O
liquefied	O
feces	O
can	O
be	O
analyzed	O
in	O
future	O
environmental	O
omics	O
studies	O
to	O
attain	O
even	O
deeper	O
insight	O
into	O
metabolic	O
consequences	O
of	O
environmental	O
change	O
.	O
The	O
biomarkers	O
(	O
metabolites	O
)	O
identified	O
by	O
our	O
approach	O
are	O
intended	O
to	O
encourage	O
subsequent	O
monitoring	O
by	O
means	O
of	O
additional	O
diagnostics	O
assays	O
(	O
e	O
.	O
g	O
.	O
,	O
lipidomics	O
,	O
proteomics	O
,	O
metallomics	O
,	O
stable	O
isotope	O
analysis	O
,	O
or	O
hormone	O
assays	O
)	O
that	O
can	O
then	O
be	O
associated	O
with	O
animal	O
diets	O
,	O
their	O
microbiome	O
,	O
physiology	O
,	O
and	O
energy	O
metabolism	O
in	O
further	O
detail	O
.	O
None	O
declared	O
.	O

Christian	O
Fohringer	O
:	O
Conceptualization	O
(	O
lead	O
)	O
;	O
Data	O
curation	O
(	O
equal	O
)	O
;	O
Funding	O
acquisition	O
(	O
equal	O
)	O
;	O
Methodology	O
(	O
equal	O
)	O
;	O
Validation	O
(	O
lead	O
)	O
;	O
Visualization	O
(	O
lead	O
)	O
;	O
Writing	O
‐	O
original	O
draft	O
(	O
lead	O
)	O
;	O
Writing	O
‐	O
review	O
&	O
editing	O
(	O
lead	O
)	O
.	O
Ilona	O
Dudka	O
:	O
Conceptualization	O
(	O
equal	O
)	O
;	O
Data	O
curation	O
(	O
equal	O
)	O
;	O
Formal	O
analysis	O
(	O
equal	O
)	O
;	O
Methodology	O
(	O
equal	O
)	O
;	O
Software	O
(	O
equal	O
)	O
;	O
Validation	O
(	O
equal	O
)	O
;	O
Visualization	O
(	O
equal	O
)	O
;	O
Writing	O
‐	O
original	O
draft	O
(	O
equal	O
)	O
;	O
Writing	O
‐	O
review	O
&	O
editing	O
(	O
equal	O
)	O
.	O
Robert	O
Spitzer	O
:	O
Data	O
curation	O
(	O
supporting	O
)	O
;	O
Methodology	O
(	O
equal	O
)	O
;	O
Validation	O
(	O
equal	O
)	O
;	O
Writing	O
‐	O
review	O
&	O
editing	O
(	O
equal	O
)	O
.	O
Fredrik	O
Stenbacka	O
:	O
Methodology	O
(	O
equal	O
)	O
;	O
Validation	O
(	O
supporting	O
)	O
;	O
Writing	O
‐	O
review	O
&	O
editing	O
(	O
equal	O
)	O
.	O
Olena	O
Rzhepishevska	O
:	O
Conceptualization	O
(	O
equal	O
)	O
;	O
Writing	O
‐	O
review	O
&	O
editing	O
(	O
equal	O
)	O
.	O
Joris	O
P	O
.	O
G	O
.	O
M	O
.	O
Cromsigt	O
:	O
Funding	O
acquisition	O
(	O
equal	O
)	O
;	O
Writing	O
‐	O
review	O
&	O
editing	O
(	O
equal	O
)	O
.	O
Gerhard	O
Gröbner	O
:	O
Methodology	O
(	O
supporting	O
)	O
;	O
Writing	O
‐	O
review	O
&	O
editing	O
(	O
equal	O
)	O
.	O
Göran	O
Ericsson	O
:	O
Supervision	O
(	O
supporting	O
)	O
;	O
Writing	O
‐	O
review	O
&	O
editing	O
(	O
equal	O
)	O
.	O
Navinder	O
Singh	O
:	O
Conceptualization	O
(	O
equal	O
)	O
;	O
Supervision	O
(	O
equal	O
)	O
;	O
Writing	O
‐	O
original	O
draft	O
(	O
equal	O
)	O
;	O
Writing	O
‐	O
review	O
&	O
editing	O
(	O
equal	O
)	O
.	O
This	O
study	O
was	O
financed	O
by	O
the	O
project	O
“	O
Resource	O
Extraction	O
and	O
Sustainable	O
Arctic	O
Communities	O
(	O
REXSAC	O
)	O
,	O
which	O
is	O
funded	O
by	O
Nordforsk	O
—	O
a	O
“	O
Nordic	O
Centre	O
of	O
Excellence	O
”	O
—	O
(	O
project	O
number	O
76938	O
)	O
.	O
This	O
work	O
was	O
supported	O
by	O
the	O
Knut	O
and	O
Alice	O
Wallenberg	O
foundation	O
(	O
“	O
NMR	O
for	O
Life	O
”	O
Programme	O
;	O
KAW2014	O
.	O
0280	O
)	O
,	O
the	O
Kempe	O
Foundation	O
(	O
I	O
.	O
D	O
.	O
)	O
,	O
the	O
SciLifeLab	O
and	O
SLU	O
.	O
The	O
Swedish	O
NMR	O
centre	O
at	O
Umeå	O
University	O
is	O
acknowledged	O
for	O
support	O
.	O
Consumables	O
and	O
running	O
costs	O
for	O
metabolomics	O
analysis	O
were	O
partly	O
covered	O
by	O
a	O
grant	O
from	O
the	O
Helge	O
Ax	O
:	O
son	O
Johnsons	O
stiftelse	O
(	O
grant	O
number	O
F18	O
‐	O
0363	O
)	O
.	O

The	O
dietary	O
part	O
of	O
this	O
study	O
formed	O
part	O
of	O
the	O
research	O
program	O
“	O
Beyond	O
Moose	O
”	O
and	O
was	O
financially	O
supported	O
by	O
the	O
Swedish	O
Environmental	O
Protection	O
Agency	O
(	O
NV	O
‐	O
01337	O
‐	O
15	O
/	O
NV	O
‐	O
03047	O
‐	O
16	O
/	O
NV	O
‐	O
08503	O
‐	O
18	O
)	O
,	O
Kempe	O
Foundation	O
(	O
JCK	O
‐	O
1514	O
)	O
,	O
the	O
Swedish	O
Association	O
for	O
Hunting	O
and	O
Wildlife	O
Management	O
(	O
grant	O
number	O
5855	O
/	O
2015	O
)	O
,	O
and	O
Västerbotten	O
County	O
'	O
s	O
Älgvårdsfonden	O
(	O
no	O
.	O
218	O
‐	O
9314	O
‐	O
15	O
)	O
.	O
We	O
thank	O
Pierre	O
Taberlet	O
and	O
Delphine	O
Rioux	O
at	O
the	O
Laboratoire	O
d	O
'	O
Ecologie	O
Alpine	O
(	O
LECA	O
)	O
in	O
Grenoble	O
,	O
France	O
for	O
their	O
assistance	O
with	O
PCR	O
and	O
purification	O
.	O
Eric	O
Coissac	O
and	O
Frédéric	O
Boyer	O
(	O
LECA	O
,	O
CNRS	O
&	O
University	O
Grenoble	O
‐	O
Alpes	O
)	O
helped	O
with	O
data	O
processing	O
and	O
bioinformatics	O
.	O
Appendix	O
1	O

